Mammalian Phenotype Ontology Annotations

Mammalian Phenotype Ontology Annotations
Query Results - Summary

16320 genotypes with 53096 annotations displayed of selected term and subterms
Searched Term: immune system phenotype
Allelic Composition (Genetic Background)	Annotated Term	Reference
1700016L21Rik^{Tg(Itgax-HBEGF/EGFP)57Lan}/0 (C.FVB-1700016L21Rik^{Tg(Itgax-HBEGF/EGFP)57Lan})	abnormal CD8-positive, alpha-beta T cell differentiation	J:93488
	abnormal T cell activation	J:93488
	decreased CD8-positive, alpha-beta T cell number	J:93488
	decreased cytotoxic T cell cytolysis	J:93488
	decreased dendritic cell number	J:93488
	increased neutrophil cell number	J:194800
1700016L21Rik^{Tg(Itgax-HBEGF/EGFP)57Lan}/0 (B6.FVB-1700016L21Rik^{Tg(Itgax-HBEGF/EGFP)57Lan}/J)	abnormal NK cell physiology	J:96123
	abnormal NK T cell physiology	J:96123
	decreased circulating interferon-gamma level	J:96123
	decreased circulating interleukin-12 level	J:96123
	decreased dendritic cell number	J:100867, J:113232, J:96123
	decreased interferon-gamma secretion	J:96123
	decreased interleukin-4 secretion	J:96123
	decreased interleukin-12b secretion	J:125611
	immune system phenotype	J:122114, J:96123
	impaired natural killer cell mediated cytotoxicity	J:125611
	sepsis	J:113232
1700016L21Rik^{Tg(Itgax-HBEGF/EGFP)57Lan}/0 (C.FVB-1700016L21Rik^{Tg(Itgax-HBEGF/EGFP)57Lan}/J)	abnormal NK cell physiology	J:96123
	decreased circulating interferon-gamma level	J:96123
	decreased circulating interleukin-12 level	J:96123
	decreased dendritic cell number	J:96123
	decreased interferon-gamma secretion	J:96123
	immune system phenotype	J:96123
1700016L21Rik^{Tg(Itgax-HBEGF/EGFP)57Lan}/0 (involves: C57BL/6 * FVB/N)	abnormal alveolar macrophage morphology	J:137452
	decreased dendritic cell number	J:137452
	decreased interferon-gamma secretion	J:137452
	increased susceptibility to Orthomyxoviridae infection	J:137452
1700016L21Rik^{Tg(Itgax-HBEGF/EGFP)57Lan}/0 (NOD.FVB-1700016L21Rik^{Tg(Itgax-HBEGF/EGFP)57Lan}/Jdk)	abnormal professional antigen presenting cell physiology	J:137009
	decreased dendritic cell number	J:137009
	decreased macrophage cell number	J:137009
	decreased NK T cell number	J:137009
	decreased susceptibility to autoimmune diabetes	J:137009
	increased interferon-gamma secretion	J:137009
	increased tumor necrosis factor secretion	J:137009
	insulitis	J:137009
1700016L21Rik^{Tg(Itgax-HBEGF/EGFP)57Lan}/0 (involves: FVB/N)	abnormal response to infection	J:189122
	decreased gamma-delta T cell number	J:193548
	decreased interleukin-17 secretion	J:193548
	decreased leukocyte cell number	J:193548
	decreased neutrophil cell number	J:193548
	decreased susceptibility to bacterial infection	J:210086
	decreased T cell number	J:193548
1700016L21Rik^{Tg(Itgax-HBEGF/EGFP)57Lan}/0 (B6.FVB-1700016L21Rik^{Tg(Itgax-HBEGF/EGFP)57Lan})	abnormal circulating cytokine level	J:194800
	abnormal susceptibility to infection	J:194800
	decreased dendritic cell number	J:194800
	decreased neutrophil cell number	J:194800
	impaired neutrophil recruitment	J:194800
	increased monocyte cell number	J:194800
	increased neutrophil cell number	J:194800
	increased susceptibility to bacterial infection	J:194800
1700019D03Rik^{tm1.1(NCOM)Mfgc}/1700019D03Rik^{tm1.1(NCOM)Mfgc} (C57BL/6N-1700019D03Rik^{tm1.1(NCOM)Mfgc}/Tcp)	enlarged lymph nodes	J:211773
1700025G04Rik^em1(IMPC)Mbp/1700025G04Rik^em1(IMPC)Mbp (C57BL/6NCrl-1700025G04Rik^em1(IMPC)Mbp/Mmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
1700034E13Rik^em1(IMPC)Mbp/1700034E13Rik^em1(IMPC)Mbp (C57BL/6NCrl-1700034E13Rik^em1(IMPC)Mbp/Mmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
1700067K01Rik^{tm2a(KOMP)Wtsi}/1700067K01Rik^{tm2a(KOMP)Wtsi} (C57BL/6N-1700067K01Rik^{tm2a(KOMP)Wtsi}/Wtsi)	blood in lymph vessels	J:239583
1700069L16Rik^em1(IMPC)Mbp/1700069L16Rik^em1(IMPC)Mbp (C57BL/6NCrl-1700069L16Rik^em1(IMPC)Mbp/Mmucd)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
2310022B05Rik^{tm1a(EUCOMM)Hmgu}/2310022B05Rik^{tm1a(EUCOMM)Hmgu} (C57BL/6N-2310022B05Rik^{tm1a(EUCOMM)Hmgu}/H)	increased B cell number	J:165965
	increased leukocyte cell number	J:165965
2810408A11Rik^{tm1a(EUCOMM)Wtsi}/2810408A11Rik^{tm1a(EUCOMM)Wtsi} (C57BL/6N-2810408A11Rik^{tm1a(EUCOMM)Wtsi}/H)	decreased NK cell number	J:165965
	increased CD4-positive, alpha-beta T cell number	J:165965
	increased NK cell number	J:165965
3425401B19Rik^{em2(IMPC)Ccpcz}/3425401B19Rik^{em2(IMPC)Ccpcz} (C57BL/6NCrl-3425401B19Rik^{em2(IMPC)Ccpcz}/Ph)	increased effector memory T-helper cell number	J:211773
	increased eosinophil cell number	J:211773
4930444P10Rik^em1(IMPC)Tcp/4930444P10Rik⁺ (C57BL/6NCrl-4930444P10Rik^em1(IMPC)Tcp/Cmmr)	decreased eosinophil cell number	J:211773
4931422A03Rik^{tm1b(EUCOMM)Wtsi}/4931422A03Rik^{tm1b(EUCOMM)Wtsi} (C57BL/6N-4931422A03Rik^{tm1b(EUCOMM)Wtsi}/Bay)	decreased leukocyte cell number	J:211773
4933434E20Rik^{tm1a(EUCOMM)Wtsi}/4933434E20Rik^{tm1a(EUCOMM)Wtsi} (C57BL/6N-4933434E20Rik^{tm1a(EUCOMM)Wtsi}/Wtsi)	blood in lymph vessels	J:239583
	enlarged lymphatic vessel	J:239583
5730403I07Rik^em8Gpt/5730403I07Rik^em8Gpt (involves: C57BL/6JGpt)	abnormal regulatory T cell physiology	J:329871
	abnormal T cell number	J:329871
	abnormal T cell physiology	J:329871
	increased inflammatory response	J:329871
	increased interferon-gamma secretion	J:329871
6430548M08Rik^em1(IMPC)Mbp/6430548M08Rik^em1(IMPC)Mbp (C57BL/6N-6430548M08Rik^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
9030622O22Rik^em1Eem/9030622O22Rik⁺ Foxa2^tm1.1Khk/Foxa2⁺ (involves: 129P2/OlaHsd * C57BL/6 * CD-1)	respiratory system inflammation	J:284174
9030622O22Rik^em1Eem/9030622O22Rik^em1Eem (involves: C57BL/6 * CD-1)	lung inflammation	J:284174
9430015G10Rik^tm1Lex/9430015G10Rik^tm1Lex (B6;129S5-9430015G10Rik^tm1Lex/Mmucd)	decreased CD4-positive, alpha-beta T cell number	J:171883
	increased B cell number	J:171883
A1cf^{Tg(Myh6-cre/Esr1)1Jmk}/A1cf⁺ Tg(Myh6-2A)#Know/0 (involves: BALB/c C57BL/6 * FVB/N)	heart inflammation	J:128060
A2ml1^em1(IMPC)Tcp/A2ml1⁺ (C57BL/6N-A2ml1^em1(IMPC)Tcp/Tcp)	abnormal spleen morphology	J:211773
A2ml1^em1(IMPC)Tcp/A2ml1^em1(IMPC)Tcp (C57BL/6N-A2ml1^em1(IMPC)Tcp/Tcp)	abnormal spleen morphology	J:211773
A3galt2^tm1.1Hjg/A3galt2^tm1.1Hjg (involves: 129P2/OlaHsd * BALB/cJ)	immune system phenotype	J:120323
A4galt^tm1.1Poru/A4galt^tm1.1Poru Gla^tm1Kul/Gla^tm1Kul (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)	immune system phenotype	J:189359
A4gnt^tm1Jnaka/A4gnt^tm1Jnaka (B6.129S6-A4gnt^tm1Jnaka)	stomach inflammation	J:184485
A930024E05Rik^em2Zfa/A930024E05Rik^em2Zfa Commd10^{Tg(Vav1-icre)A2Kio}/Commd10⁺ (involves: C57BL/6 * C57BL/10 * CBA/Ca)	immune system phenotype	J:259392
A930024E05Rik^em2Zfa/A930024E05Rik^em2Zfa Satb1^em1Zfa/Satb1^em1Zfa Tg(Rorc-cre)1Litt/0 (involves: C57BL/6 * FVB)	increased susceptibility to bacterial infection	J:259392
	increased susceptibility to bacterial infection induced morbidity/mortality	J:259392
A930024E05Rik^em2Zfa/A930024E05Rik^em2Zfa Tg(Rorc-cre)1Litt/0 (involves: C57BL/6 * FVB)	abnormal interleukin secretion	J:259392
	increased susceptibility to bacterial infection	J:259392
	increased susceptibility to bacterial infection induced morbidity/mortality	J:259392
A^tm1Brd/A^tm1Brd Ypel4^{tm1a(EUCOMM)Wtsi}/Ypel4^{tm1a(EUCOMM)Wtsi} (C57BL/6N-A^tm1Brd Ypel4^{tm1a(EUCOMM)Wtsi}/WtsiIeg)	immune system phenotype	J:313842
A^y/a Apoe^tm1Unc/Apoe^tm1Unc (involves: 129P2/OlaHsd * C57BL/6J * KK/TaJcl)	abnormal inflammatory response	J:177084
	increased monocyte cell number	J:177084
AA467197^em1Nyam/AA467197^em1Nyam (C57BL/6J-AA467197^em1Nyam)	abnormal thymus cortex morphology	J:347271
	abnormal thymus medulla morphology	J:347271
	decreased CD4-positive, alpha-beta T cell number	J:347271
	increased IgG level	J:347271
	kidney inflammation	J:347271
	liver inflammation	J:347271
	lung inflammation	J:347271
AA467197^em1Nyam/AA467197^em1Nyam (C.B6-AA467197^em1Nyam)	increased susceptibility to autoimmune disorder	J:347271
Aabpr^NZB/Slc/? (involves: NZB/Slc * NZW/Slc)	increased B cell proliferation	J:87690
Aadac^em1(IMPC)Mbp/Aadac^em1(IMPC)Mbp (C57BL/6NCrl-Aadac^em1(IMPC)Mbp/Mmucd)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	small thymus	J:211773
Aadacl4^{em1(IMPC)Ccpcz}/Aadacl4^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Aadacl4^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Aars2^{tm1(KOMP)Wtsi}/Aars2⁺ (C57BL/6N-Aars2^{tm1(KOMP)Wtsi}/Nju)	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
	increased neutrophil cell number	J:211773
Aass^em1(IMPC)Tcp/Aass^em1(IMPC)Tcp (C57BL/6NCrl-Aass^em1(IMPC)Tcp/Cmmr)	enlarged lymph nodes	J:211773
Abat^{tm1c(EUCOMM)Hmgu}/Abat^{tm1c(EUCOMM)Hmgu} Tg(Cd4-cre)1Cwi/0 (involves: 129S4/SvJaeSor * C57BL/6 * C57BL/6N * DBA/2)	abnormal CD4-positive T cell differentiation	J:333883
	abnormal CD4-positive, CD25-positive, alpha-beta regulatory T cell morphology	J:333883
	abnormal T-helper 1 cell differentiation	J:333883
	abnormal T-helper 17 cell differentiation	J:333883
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:333883
	decreased T cell proliferation	J:333883
	immune system phenotype	J:333883
Abca1^tm1Jdm/Abca1^tm1Jdm (DBA/1LacJ-Abca1^tm1Jdm)	enlarged spleen	J:60210
Abca1^tm1Jdm/Abca1^tm1Jdm (DBA/1LacJ-Abca1^tm1Jdm)	impaired macrophage phagocytosis	J:63265
Abca1^tm1Jdm/Abca1^tm1Jdm (involves: C57BL/6 * DBA/1LacJ)	abnormal thymus morphology	J:132254
Abca1^tm1Jdm/Abca1^tm1Jdm (involves: C57BL/6 * DBA/1LacJ)	impaired macrophage phagocytosis	J:132254
Abca1^tm1Jdm/Abca1^tm1Jdm Abcg1^tm1Dgen/Abcg1^tm1Dgen (involves: 129P2/OlaHsd * C57BL/6 * DBA/1LacJ)	abnormal chemokine secretion	J:130777
	abnormal cytokine secretion	J:130777
Abca1^tm1Jdm/Abca1^tm1Jdm Abcg1^tm1Dgen/Abcg1^tm1Dgen (involves: 129P2/OlaHsd * C57BL/6 * DBA * DBA/1LacJ)	decreased monocyte cell number	J:190966
	increased monocyte cell number	J:190966
	increased neutrophil cell number	J:190966
Abca1^tm1Jdm/Abca1^tm1Jdm Tgm2^tm1Gml/Tgm2^tm1Gml (involves: C57BL/6 * DBA/1LacJ)	abnormal thymus morphology	J:132254
	impaired macrophage phagocytosis	J:132254
Abca1^tm1Jp/Abca1^tm1Jp Abcg1^tm1Tall/Abcg1^tm1Tall Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6)	increased interleukin-17 secretion	J:190966
	increased interleukin-23 secretion	J:190966
Abca1^tm1Jp/Abca1^tm1Jp Abcg1^tm1Tall/Abcg1^tm1Tall Tg(Itgax-cre,-EGFP)4097Ach/0 (involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J)	increased interleukin-17 secretion	J:190966
	increased interleukin-23 secretion	J:190966
Abca1^tm1Wpfl/Abca1^tm1Wpfl (involves: 129P2/OlaHsd * C57BL/6J)	abnormal thymus morphology	J:64390
	glomerulonephritis	J:64390
	uterus inflammation	J:64390
Abca5^{em1(IMPC)Ccpcz}/Abca5^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Abca5^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Abcb1a^mds/Abcb1a^mds (involves: CF-1)	increased eosinophil cell number	J:64725
Abcb1a^tm1Bor/Abcb1a^tm1Bor (FVBTac.129P2-Abcb1a^tm1Bor)	abnormal CD8 positive, alpha-beta intraepithelial T cell morphology	J:102640
Abcb1a^tm1Bor/Abcb1a^tm1Bor (FVBTac.129P2-Abcb1a^tm1Bor)	decreased gamma-delta intraepithelial T cell number	J:102640
Abcb1a^tm1Bor/Abcb1a^tm1Bor (FVB.129P2-Abcb1a^tm1Bor/TacImx)	abnormal lymphocyte physiology	J:51190
	colitis	J:51190
	increased IgA level	J:51190
	increased IgE level	J:51190
	increased IgG1 level	J:51190
	increased IgG2 level	J:51190
	increased IgG2a level	J:51190
	increased IgG2b level	J:51190
	increased IgG3 level	J:51190
	increased IgM level	J:51190
	increased immunoglobulin level	J:51190
	large intestinal inflammation	J:51190
Abcb1a^tm1Bor/Abcb1a^tm1Bor Abcb1b^tm1Bor/Abcb1b^tm1Bor (FVBTac.129P2-Abcb1b^tm1Bor Abcb1a^tm1Bor)	abnormal CD8 positive, alpha-beta intraepithelial T cell morphology	J:102640
	abnormal T cell physiology	J:102640
	decreased gamma-delta intraepithelial T cell number	J:102640
	increased double-positive T cell number	J:102640
	increased interferon-gamma secretion	J:102640
	increased interleukin-2 secretion	J:102640
Abcb4^em1(IMPC)H/Abcb4^em1(IMPC)H (C57BL/6NTac-Abcb4^em1(IMPC)H/H)	increased basophil cell number	J:211773
	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
	increased spleen weight	J:211773
Abcb4^tm1Bor/Abcb4^tm1Bor (either: (involves: 129P2/OlaHsd) or (involves: 129P2/OlaHsd * FVB/N))	bile duct inflammation	J:15531, J:21232
	liver inflammation	J:15531
Abcb4^tm1Bor/Abcb4^tm1Bor (involves: 129P2/OlaHsd * FVB/N)	bile duct inflammation	J:175015
Abcb4^tm1Bor/Abcb4^tm1Bor (involves: 129P2/OlaHsd * FVB/N)	liver inflammation	J:175015
Abcb4^tm1Bor/Abcb4^tm1Bor (FVB.129P2-Abcb4^tm1Bor/J)	bile duct inflammation	J:105357
Abcb4^tm1Bor/Abcb4^tm1Bor (FVB.129P2-Abcb4^tm1Bor/J)	enlarged spleen	J:217802
Abcb4^tm1Bor/Abcb4^tm1Bor (involves: 129P2/OlaHsd * BALB/c)	bile duct inflammation	J:168123
Abcb4^tm1Bor/Abcb4^tm1Bor (CAnNCrl.12P2(FVB)-Abcb4^tm1Bor)	enlarged spleen	J:217802
Abcb9^{tm1b(KOMP)Wtsi}/Abcb9^{tm1b(KOMP)Wtsi} (C57BL/6N-Abcb9^{tm1b(KOMP)Wtsi}/Tcp)	enlarged lymph nodes	J:211773
Abcc1^tm1Bor/Abcc1^tm1Bor (involves: 129P2/OlaHsd * FVB)	abnormal mast cell physiology	J:44110
Abcc1^tm1Bor/Abcc1^tm1Bor (involves: 129P2/OlaHsd * FVB)	decreased inflammatory response	J:44110
Abcc1^tm1Bor/Abcc1^tm1Bor Tg(Thy1-APPSw,Thy1-PSEN1L166P)21Jckr/0 (FVB.Cg-Abcc1^tm1Bor Tg(Thy1-APPSw,Thy1-PSEN1L166P)21Jckr)	microgliosis	J:178230
Abcc2^{tm2b(KOMP)Wtsi}/Abcc2^{tm2b(KOMP)Wtsi} (C57BL/6N-Abcc2^{tm2b(KOMP)Wtsi}/H)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Abcc4^tm1Kruh/Abcc4^tm1Kruh (B6.129-Abcc4^tm1Kruh)	abnormal spleen B cell follicle morphology	J:117326
	abnormal spleen red pulp morphology	J:117326
	decreased spleen B cell follicle number	J:117326
	decreased spleen B cell follicle size	J:117326
	increased susceptibility to induced colitis	J:117326
	intestinal inflammation	J:117326
	small intestinal inflammation	J:117326
	small spleen	J:117326
	thymus cortex hypoplasia	J:117326
Abcc5^em1(IMPC)H/Abcc5^em1(IMPC)H (C57BL/6N-Abcc5^em1(IMPC)H/H)	decreased eosinophil cell number	J:211773
	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
Abcc9^em1(IMPC)H/Abcc9⁺ (C57BL/6N-Abcc9^em1(IMPC)H/H)	decreased lymphocyte cell number	J:211773
Abcc9^em1(IMPC)H/Abcc9⁺ (C57BL/6N-Abcc9^em1(IMPC)H/H)	increased monocyte cell number	J:211773
Abcc10^tm1Eah/Abcc10^tm1Eah (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal spleen red pulp morphology	J:172648
	decreased leukocyte cell number	J:172648
	decreased spleen germinal center number	J:172648
	decreased spleen germinal center size	J:172648
	decreased spleen white pulp amount	J:172648
	small spleen	J:172648
	thymus cortex hypoplasia	J:172648
Abcd1^tm1Kds/Y (involves: 129S4/SvJae * C57BL/6J)	abnormal microglial cell morphology	J:94583
Abcd1^tm1Kds/Y Abcd2^tm1Apuj/Abcd2^tm1Apuj (involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6J)	abnormal microglial cell morphology	J:94583
	increased inflammatory response	J:94583
Abcd2^tm1Apuj/Abcd2^tm1Apuj (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	abnormal microglial cell morphology	J:94583
Abce1^{tm1.1(KOMP)Vlcg}/Abce1⁺ (C57BL/6N-Abce1^{tm1.1(KOMP)Vlcg}/Tcp)	enlarged lymph nodes	J:211773
	increased neutrophil cell number	J:211773
Abce1^{tm1b(EUCOMM)Hmgu}/Abce1⁺ (C57BL/6N-Abce1^{tm1b(EUCOMM)Hmgu}/H)	increased large unstained cell number	J:211773
Abcg1^tm1Dgen/Abcg1^tm1Dgen (B6.129P2-Abcg1^tm1Dgen)	abnormal macrophage physiology	J:117028
Abcg1^tm1Dgen/Abcg1^tm1Dgen (B6.129P2-Abcg1^tm1Dgen)	increased macrophage derived foam cell number	J:117028
Abcg1^tm1Dgen/Abcg1^tm1Dgen (involves: 129P2/OlaHsd * C57BL/6)	abnormal chemokine secretion	J:130777
	abnormal cytokine secretion	J:130777
	abnormal leukocyte morphology	J:132952
	abnormal macrophage morphology	J:132952
	abnormal monocyte differentiation	J:132952
	increased B cell number	J:132952
	increased CD4-positive, alpha-beta T cell number	J:132952
	increased CD8-positive, alpha-beta T cell number	J:132952
	increased dendritic cell number	J:132952
	increased eosinophil cell number	J:132952
	increased monocyte cell number	J:132952
	increased neutrophil cell number	J:132952
	lung inflammation	J:132952
Abcg2^tm1.1Ssf/Abcg2^tm1.1Ssf (involves: 129 * C57BL/6 * FVB)	liver inflammation	J:201884
Abcg5^trac/Abcg5^trac (A/J-Abcg5^trac)	abnormal neutrophil morphology	J:157223
Abcg5^trac/Abcg5^trac (A/J-Abcg5^trac)	decreased leukocyte cell number	J:157223
Abcg8^{tm1b(KOMP)Wtsi}/Abcg8^{tm1b(KOMP)Wtsi} (C57BL/6N-Abcg8^{tm1b(KOMP)Wtsi}/Ccpcz)	abnormal spleen morphology	J:211773
	decreased B-2 B cell number	J:211773
	decreased CD4-negative NK T cell number	J:211773
	decreased CD4-positive, alpha-beta T cell number	J:211773
	decreased CD8-positive, alpha-beta T cell number	J:211773
	decreased memory-marker CD4-negative NK T cell number	J:211773
	decreased NK T cell number	J:211773
	decreased T cell number	J:211773
	enlarged spleen	J:211773
	immune system phenotype	J:211773
Abhd5^tm1.1Lqyu/Abhd5^tm1.1Lqyu Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺ (involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6 * DBA)	liver inflammation	J:199570
Abhd5^tm1.1Rze/Abhd5^tm1.1Rze (involves: 129P2/OlaHsd * C57BL/6)	abnormal granulocyte morphology	J:160725
Abhd10^em1(IMPC)Mbp/Abhd10^em1(IMPC)Mbp (C57BL/6NCrl-Abhd10^em1(IMPC)Mbp/Mmucd)	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
Abhd12^tm1Crv/Abhd12^tm1Crv (involves: C57BL/6)	microgliosis	J:193716
Abhd13^em1(IMPC)Mbp/Abhd13^em1(IMPC)Mbp (C57BL/6NCrl-Abhd13^em1(IMPC)Mbp/Mmucd)	decreased spleen weight	J:211773
Abhd16a^{tm1a(EUCOMM)Wtsi}/Abhd16a^{tm1a(EUCOMM)Wtsi} (involves: C57BL/6N * C57BL/6NTac)	abnormal macrophage physiology	J:232688
	decreased interleukin-1 beta secretion	J:232688
	decreased interleukin-6 secretion	J:232688
	decreased macrophage cytokine production	J:232688
	decreased tumor necrosis factor secretion	J:232688
Abhd17c^em1(IMPC)Mbp/Abhd17c^em1(IMPC)Mbp (C57BL/6N-Abhd17c^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Abi1^tm1Pen/Abi1⁺ Abi2^tm1Pen/Abi2^tm1Pen (Not Specified)	decreased interleukin-2 secretion	J:104623
	decreased T cell proliferation	J:104623
	immune system phenotype	J:104623
Abl1^m1/Abl1^m1 (either: 129S/SvEv-Abl1^m1 or (involves: 129S/SvEv * CD-1) or (involves: 129S/SvEv * C57BL/6 * DBA/2))	abnormal B cell differentiation	J:14644
	abnormal immune system cell morphology	J:14644
	abnormal immune system organ morphology	J:14644
	abnormal spleen germinal center morphology	J:14644
	abnormal spleen morphology	J:14644
	abnormal spleen white pulp morphology	J:14644
	abnormal T cell number	J:14644
	abnormal thymus morphology	J:14644
	decreased immature B cell number	J:14644
	decreased pre-B cell number	J:14644
	decreased pro-B cell number	J:14644
	decreased single-positive T cell number	J:14644
	decreased thymocyte number	J:14644
	increased single-positive T cell number	J:14644
	increased susceptibility to infection	J:14644
	spleen hypoplasia	J:14644
	thymus cortex hypoplasia	J:14644
	thymus hypoplasia	J:14644
Abl1^m1/Abl1^m1 (involves: 129S/SvEv)	abnormal B cell differentiation	J:28795
	abnormal immune system cell morphology	J:34903
	abnormal splenocyte physiology	J:34903
	decreased mature B cell number	J:28795
	decreased pre-B cell number	J:28795
	decreased pro-B cell number	J:28795
Abl1^m1/Abl1^m1 (involves: 129S/SvEv * C57BL/6)	abnormal B cell calcium ion homeostasis	J:148105
	abnormal lymphopoiesis	J:148105
	decreased pro-B cell number	J:148105
Abl1^tm1Mlg/Abl1^tm1Mlg (involves: 129S/SvEv * C57BL/6J)	decreased B cell number	J:72875
	decreased lymphocyte cell number	J:72875
	decreased T cell number	J:72875
	decreased thymocyte number	J:72875
	lung inflammation	J:72875
	spleen atrophy	J:72875
	thymus atrophy	J:72875
Abl1^tm1Mlg/Abl1^tm1Mlg (involves: 129S/SvEv * C57BL/6J * CBA)	abnormal spleen morphology	J:34643
	increased susceptibility to infection	J:34643
Abl1^tm1Mlg/Abl1^tm1Mlg Tg(ACTB-Abl1K290R)1Spg/0 (involves: 129S/SvEv C57BL/6J * CBA)	abnormal spleen morphology	J:34643
	increased susceptibility to infection	J:34643
Abl1^tm2.2Goff/Abl1^tm2.2Goff (involves: 129P2/OlaHsd * C57BL/6J * FVB/N)	spleen atrophy	J:166211
	thymus atrophy	J:166211
Ablim3^em1(IMPC)Tcp/Ablim3^em1(IMPC)Tcp (C57BL/6N-Ablim3^em1(IMPC)Tcp/Tcp)	decreased basophil cell number	J:211773
	enlarged lymph nodes	J:211773
	increased lymphocyte cell number	J:211773
Abmm^DBA/2J/? (involves: BALB/cByJ * DBA/2J)	myocarditis	J:52296
Abraxas2^tm1.2Bwng/Abraxas2⁺ (involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NCrl)	enlarged spleen	J:245949
Abraxas2^tm1.2Bwng/Abraxas2^tm1.2Bwng (involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NCrl)	enlarged spleen	J:245949
	increased inflammatory response	J:245949
Abtb1^{em1(IMPC)Ccpcz}/Abtb1^{em1(IMPC)Ccpcz} (C57BL/6N-Abtb1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Abtb2^{tm1a(KOMP)Wtsi}/Abtb2^{tm1a(KOMP)Wtsi} (C57BL/6N-A^tm1Brd Abtb2^{tm1a(KOMP)Wtsi}/WtsiH)	decreased leukocyte cell number	J:211773
Acaca^tm1Dejs/Acaca^tm1Dejs Tg(Cd4-cre)1Cwi/? (involves: C57BL/6 * DBA/2)	abnormal T cell physiology	J:209886
	decreased memory T cell number	J:209886
	decreased T cell number	J:209886
	immune system phenotype	J:209886
Acaca^tm1Dejs/Acaca^tm1Dejs Tg(Cd4-cre)1Cwi/? Tg(TcraTcrb)1100Mjb/? (involves: C57BL/6 * DBA/2)	increased T cell proliferation	J:209886
Acad10^em1(IMPC)Tcp/Acad10^em1(IMPC)Tcp (C57BL/6N-Acad10^em1(IMPC)Tcp/Tcp)	abnormal spleen morphology	J:211773
Acan^{tm1b(EUCOMM)Hmgu}/Acan⁺ (C57BL/6N-Acan^{tm1b(EUCOMM)Hmgu}/H)	increased basophil cell number	J:211773
Acan^tm2Afos/Acan^tm2Afos (involves: C57BL/6)	decreased susceptibility to induced arthritis	J:122102
Acbd5^{tm1a(EUCOMM)Wtsi}/Acbd5^{tm1a(EUCOMM)Wtsi} (C57BL/6N-A^tm1Brd Acbd5^{tm1a(EUCOMM)Wtsi}/WtsiCnbc)	abnormal microglial cell morphology	J:299448
	brain inflammation	J:299448
Ace2^{em1(ACE2)Yowa}/Ace2^{em1(ACE2)Yowa} (C57BL/6-Ace2^{em1(ACE2)Yowa})	abnormal circulating cytokine level	J:288243
	increased circulating interferon-gamma level	J:288243
	increased circulating interleukin-9 level	J:288243
	increased susceptibility to Coronaviridae infection	J:288243
	interstitial pneumonia	J:288243
Ace2^{em1(IMPC)Ccpcz}/Y (C57BL/6NCrl-Ace2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Ace2^{em1(IMPC)Ccpcz}/Ace2^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Ace2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Ace2^em1Cya/Y (C57BL/6J-Ace2^em1Cya/Cya)	increased susceptibility to induced colitis	J:299383
Ace2^em1Cya/Y (C57BL/6J-Ace2^em1Cya/Cya)	intestinal inflammation	J:299383
Ace2^em2(ACE2)Gpt/Y (C57BL/6JGpt-Ace2^em2(ACE2)Gpt/Gpt)	increased susceptibility to Coronaviridae infection	J:302150
Ace2^em2(ACE2)Gpt/Y (C57BL/6JGpt-Ace2^em2(ACE2)Gpt/Gpt)	lung inflammation	J:302150
Ace2^em#Yngh/Y (involves: Kunming)	increased susceptibility to induced colitis	J:221616
Ace2^{tm1a(KOMP)Wtsi}/Y Tg(FOXJ1-cre)F26Htzm/0 (involves: C57BL/6N * C57BL/6NTac)	increased neutrophil cell number	J:282139
	increased susceptibility to bacterial infection	J:282139
	increased susceptibility to bacterial infection induced morbidity/mortality	J:282139
	lung inflammation	J:282139
Ace2^{tm1a(KOMP)Wtsi}/Ace2^{tm1a(KOMP)Wtsi} Tg(FOXJ1-cre)F26Htzm/0 (involves: C57BL/6N * C57BL/6NTac)	increased neutrophil cell number	J:282139
	increased susceptibility to bacterial infection	J:282139
	increased susceptibility to bacterial infection induced morbidity/mortality	J:282139
	lung inflammation	J:282139
Ace2^tm1Cof/Ace2^tm1Cof (involves: 129S6/SvEvTac * C57BL/6)	increased incidence of corneal inflammation	J:289503
Ace2^tm1Lex/Ace2^tm1Lex (B6;129S5-Ace2^tm1Lex/Mmucd)	lung inflammation	J:264991
Ace2^tm1Pngr/Y (involves: 129P2/OlaHsd * C57BL/6)	abnormal cytokine level	J:124548
Ace2^tm1Pngr/Y (involves: 129P2/OlaHsd * C57BL/6)	heart inflammation	J:124548
Ace2^tm1Pngr/Y (B6.129P2-Ace2^tm1Pngr/J)	decreased susceptibility to Coronaviridae infection	J:286299
Ace2^tm1Pngr/Y (involves: 129P2/OlaHsd)	increased neutrophil cell number	J:282139
	increased susceptibility to bacterial infection	J:282139
	increased susceptibility to bacterial infection induced morbidity/mortality	J:282139
	lung inflammation	J:282139, J:100334
Ace2^tm1Pngr/Y (involves: 129P2/OlaHsd * C57BL/6J)	increased susceptibility to Orthomyxoviridae infection	J:277074
	increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:277074
	lung inflammation	J:277074
Ace2^tm1Pngr/Ace2^tm1Pngr (involves: 129P2/OlaHsd)	increased neutrophil cell number	J:282139
	increased susceptibility to bacterial infection	J:282139
	increased susceptibility to bacterial infection induced morbidity/mortality	J:282139
	lung inflammation	J:282139, J:100334
Ace2^tm1Pngr/Ace2^tm1Pngr (involves: 129P2/OlaHsd * C57BL/6J)	increased susceptibility to Orthomyxoviridae infection	J:277074
	increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:277074
	lung inflammation	J:277074
Ace2^tm1Pngr/Ace2^tm1Pngr (B6.129P2-Ace2^tm1Pngr/J)	decreased susceptibility to Coronaviridae infection	J:286299
Ace^{tm1.1(KOMP)Vlcg}/Ace⁺ (C57BL/6N-Ace^{tm1.1(KOMP)Vlcg}/MbpMmucd)	increased basophil cell number	J:211773
Ace^tm1Keb/Ace^tm1Keb (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	kidney inflammation	J:33018
Ace^tm1Mcf/Ace^tm1Mcf (Not Specified)	kidney inflammation	J:32114
Ace^tm1Mcf/Ace^tm1Mcf (Not Specified)	tubulointerstitial nephritis	J:32114
Ace^tm1Unc/Ace^tm1Unc (involves: 129P2/OlaHsd * C57BL/6J)	kidney inflammation	J:25284
Ace^tm6Keb/Ace^tm6Keb (involves: 129 * C57BL/6)	abnormal interleukin level	J:122178
Ace^tm6Keb/Ace^tm6Keb (involves: 129 * C57BL/6)	increased T cell number	J:122178
Ace^tm9Keb/Ace^tm9Keb (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	kidney inflammation	J:185888
Acer1^{tm1a(EUCOMM)Wtsi}/Acer1^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Acer1^{tm1a(EUCOMM)Wtsi})	increased eosinophil cell number	J:235775
	skin inflammation	J:235775
Ache^em1(IMPC)Mbp/Ache⁺ (C57BL/6N-Ache^em1(IMPC)Mbp/MbpMmucd)	increased neutrophil cell number	J:211773
Ackr1^tm1Scp/Ackr1^tm1Scp (involves: 129P2/OlaHsd * C57BL/6)	increased inflammatory response	J:64222
Ackr1^tm1Scp/Ackr1^tm1Scp (involves: 129P2/OlaHsd)	abnormal circulating chemokine level	J:162629
Ackr1^tm1Skmz/Ackr1^tm1Skmz (involves: 129P2/OlaHsd * C57BL/6J)	abnormal chemokine level	J:82938
Ackr2^tm1Gjg/Ackr2^tm1Gjg (involves: 129/Sv * C57BL/6)	dermatitis	J:97607
Ackr2^tm1Gjg/Ackr2^tm1Gjg (involves: 129/Sv * C57BL/6)	increased inflammatory response	J:97806
Ackr3^tm1.1Fma/Ackr3^tm1.1Fma (involves: BALB/cJ * C57BL/6)	decreased marginal zone B cell number	J:124878
Ackr3^tm1.1Rodb/Ackr3^tm1.1Rodb (involves: 129S6/SvEvTac * BALB/cJ * C57BL/6)	immune system phenotype	J:165184
Ackr3^tm1Jgo/Ackr3⁺ (involves: 129S/SvEvBrd * C57BL/6)	lung inflammation	J:136246
Ackr3^tm1Jgo/Ackr3^tm1Jgo (involves: 129S/SvEvBrd * C57BL/6)	lung inflammation	J:136246
Ackr4^tm1.1Rjbn/Ackr4^tm1.1Rjbn (B6.129S6-Ackr4^tm1.1Rjbn)	abnormal CD4-positive, alpha-beta T cell number	J:166490
	abnormal CD4-positive, alpha-beta T cell physiology	J:166490
	abnormal chemokine level	J:166490
	abnormal circulating chemokine level	J:166490
	abnormal T-helper 17 cell differentiation	J:166490
	decreased T cell proliferation	J:166490
	increased interleukin-23 secretion	J:166490
	increased susceptibility to experimental autoimmune encephalomyelitis	J:166490
	increased T-helper 17 cell number	J:166490
	spleen hyperplasia	J:166490
Acla1^BXSB/Slc/Acla1^BXSB/Slc (involves: BXSB/Slc * NZW/Slc)	increased autoantibody level	J:49899
Acla1^NZW/Slc/Acla1^BXSB/Slc (involves: BXSB/Slc * NZW/Slc)	increased autoantibody level	J:49899
Acla2^BXSB/Slc/Acla2^BXSB/Slc (involves: BXSB/Slc * NZW/Slc)	increased autoantibody level	J:49899
Acla2^NZW/Slc/Acla2^BXSB/Slc (involves: BXSB/Slc * NZW/Slc)	increased autoantibody level	J:49899
Acod1^{tm1a(KOMP)Wtsi}/Acod1^{tm1a(KOMP)Wtsi} (involves: C57BL/6N)	abnormal macrophage physiology	J:235002
Acot11^tm1Deco/Acot11^tm1Deco (involves: 129S6/SvEvTac * C57BL/6)	decreased inflammatory response	J:182660
Acox1^lampe1/Acox1^lampe1 (involves: C57BL/6J)	liver inflammation	J:174942
Acox2^em1Jynz/Acox2^em1Jynz (involves: C57BL/6N)	liver inflammation	J:323193
Acoxl^em1(IMPC)Mbp/Acoxl^em1(IMPC)Mbp (C57BL/6NCrl-Acoxl^em1(IMPC)Mbp/Mmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	decreased lymphocyte cell number	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	increased neutrophil cell number	J:211773
Acp1^tm1Lex/Acp1^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6J)	increased interleukin-6 secretion	J:171883
Acp2^{tm1a(EUCOMM)Wtsi}/Acp2^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Acp2^{tm1a(EUCOMM)Wtsi}/H)	decreased CD4-positive, alpha-beta T cell number	J:165965
	decreased CD8-positive, alpha-beta T cell number	J:165965
	decreased T cell number	J:165965
	increased B cell number	J:165965
Acp2^tm1Psa/Acp2^tm1Psa (involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6J)	abnormal microglial cell morphology	J:41986
Acp5^tm1Ahdm/Acp5^tm1Ahdm (involves: 129S/SvEv)	abnormal osteoclast physiology	J:36232
Acsl3^{Gt(OST148301)Lex}/Acsl3^{Gt(OST148301)Lex} (B6;129S5-Acsl3^{Gt(OST148301)Lex}/Orl)	abnormal humoral immune response	J:82809
	decreased B cell number	J:82809
	increased CD4-positive, alpha-beta T cell number	J:82809
Acsl5^{tm1.1(KOMP)Vlcg}/Acsl5^{tm1.1(KOMP)Vlcg} (C57BL/6N-Acsl5^{tm1.1(KOMP)Vlcg}/Ucd)	increased spleen weight	J:211773
Acsl6^tm1.1Jeme/Acsl6^tm1.1Jeme (involves: BALB/cJ * C57BL/6)	abnormal microglial cell activation	J:267563
Acsm1^{em1(IMPC)Mhzh}/Acsm1^{em1(IMPC)Mhzh} (C57BL/6N-Acsm1^{em1(IMPC)Mhzh}/Mhzh)	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
Acsns1^A/J/Acsns1^A/J (involves: A/J * SM/J)	decreased susceptibility to parasitic infection	J:75549
Acsns2^SM/J/Acsns2^SM/J (involves: A/J * SM/J)	increased susceptibility to parasitic infection	J:75549
Acsns2^SM/J/Acsns2^SM/J Acsns3^SM/J/Acsns3^SM/J (involves: A/J * SM/J)	increased susceptibility to parasitic infection	J:75549
Acsns3^SM/J/Acsns3^SM/J (involves: A/J * SM/J)	increased susceptibility to parasitic infection	J:75549
Acss2^em22Gpt/Acss2^em22Gpt (C57BL/6JGpt-Acss2^em22Gpt/Gpt)	decreased interleukin-1 beta secretion	J:346990
Acss2^em22Gpt/Acss2^em22Gpt (C57BL/6JGpt-Acss2^em22Gpt/Gpt)	decreased susceptibility to endotoxin shock	J:346990
Acss3^{em1(IMPC)Ccpcz}/Acss3^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Acss3^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
	increased effector memory T-helper cell number	J:211773
Acta2^em1(IMPC)H/Acta2^em1(IMPC)H (C57BL/6NTac-Acta2^em1(IMPC)H/H)	decreased basophil cell number	J:211773
	decreased lymphocyte cell number	J:211773
Actb^{tm4(cre/ERT2)Npa}/Actb⁺ Sgpl1^tm1.1Npa/Sgpl1^tm1.1Npa (involves: BALB/cJ * C57BL/6)	abnormal lymph node morphology	J:199525
	abnormal regulatory T cell number	J:199525
	abnormal type IV hypersensitivity reaction	J:199525
	decreased follicular B cell number	J:199525
	decreased marginal zone B cell number	J:199525
	decreased single-positive T cell number	J:199525
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:199525
	increased thymocyte number	J:199525
	spleen hypoplasia	J:199525
Actl6a^tm1.1Grc/Actl6a⁺ Tg(Mx1-cre)1Cgn/0 (involves: 129S6/SvEvTac * C57BL/6J * CBA)	decreased granulocyte number	J:192124
	decreased macrophage cell number	J:192124
Actl6a^tm1.1Grc/Actl6a^tm1.1Grc Tg(Mx1-cre)1Cgn/0 (involves: 129S6/SvEvTac * C57BL/6J * CBA)	decreased B cell number	J:192124
	decreased granulocyte number	J:192124
	decreased leukocyte cell number	J:192124
	decreased lymphocyte cell number	J:192124
	decreased macrophage cell number	J:192124
	decreased monocyte cell number	J:192124
Actn4^{tm1a(EUCOMM)Wtsi}/Actn4^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Actn4^{tm1a(EUCOMM)Wtsi}/Wtsi)	blood in lymph vessels	J:239583
Actn4^tm1Mrpk/Actn4^tm1Mrpk (involves: 129 * C57BL/6)	abnormal lymphocyte chemotaxis	J:83911
Acvr1^tm1Emsh/Acvr1⁺ (chimera involves: BALB/c * C57BL/6 * CD-1)	increased inflammatory response	J:194134
Acvr1b^{tm1.1(KOMP)Vlcg}/Acvr1b⁺ (C57BL/6N-Acvr1b^{tm1.1(KOMP)Vlcg}/Ucd)	enlarged lymph nodes	J:211773
Acvr2a^{tm1.1(KOMP)Vlcg}/Acvr2a⁺ (C57BL/6N-Acvr2a^{tm1.1(KOMP)Vlcg}/Ucd)	decreased eosinophil cell number	J:211773
	decreased neutrophil cell number	J:211773
Acvr2b^tm1Enl/Acvr2b^tm1Enl (either: (involves: 129S4/SvJae) or (involves: 129S4/SvJae * C57BL/6J))	abnormal spleen morphology	J:42018
	small spleen	J:42018
Ada^tm1Mw/Ada^tm1Mw (involves: 129S7/SvEvBrd * C57BL/6)	decreased T cell number	J:25085
Ada^tm1Mw/Ada^tm1Mw (involves: 129S7/SvEvBrd)	abnormal dendritic cell physiology	J:138722
Ada^tm1Mw/Ada^tm1Mw (involves: 129S7/SvEvBrd)	increased dendritic cell number	J:138722
Ada^tm1Mw/Ada^tm1Mw Tg(PLADA)4118Rkmb/0 (involves: 129S7/SvEvBrd * C57BL/6)	abnormal spleen red pulp morphology	J:73418
	abnormal thymus corticomedullary boundary morphology	J:73418
	decreased double-positive T cell number	J:73418
	decreased immunoglobulin level	J:73418
	decreased leukocyte cell number	J:73418
	increased double-negative T cell number	J:73418
	increased eosinophil cell number	J:73418
	increased granulocyte number	J:73418
	increased macrophage cell number	J:73418
	lung inflammation	J:73418
	small spleen	J:73418
	small thymus	J:73418
	spleen hypoplasia	J:73418
Adam7^tm1Tigm/Adam7^tm1Tigm (involves: C57BL/6)	spermatic granuloma	J:226260
Adam8^tm1.1Mdz/Adam8^tm1.1Mdz (DBA/1LacJ-Adam8^tm1.1Mdz)	decreased susceptibility to induced arthritis	J:155243
Adam8^tm1.1Mdz/Adam8^tm1.1Mdz (DBA/1LacJ-Adam8^tm1.1Mdz)	immune system phenotype	J:155243
Adam8^tm1.1Rood/Adam8^tm1.1Rood (involves: 129/Sv * C57BL/6 * FVB/N)	abnormal osteoclast differentiation	J:172936
Adam10^tm1.1Dhc/Adam10^tm1.1Dhc Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J * SJL)	abnormal B cell differentiation	J:158127
	absent marginal zone B cells	J:158127
	decreased transitional stage T2 B cell number	J:158127
	increased follicular B cell number	J:158127
	increased transitional stage T1 B cell number	J:158127
Adam10^tm1.1Khr/Adam10^tm1.1Khr Csf3r^tm1Link/Csf3r^tm1Link Tg(Mx1-cre)1Cgn/0 (involves: 129S6/SvEvTac * 129X1/SvJ * C57BL/6 * C57BL/6N)	abnormal granulocyte differentiation	J:179060
	enlarged spleen	J:179060
	myeloid hyperplasia	J:179060
	spleen hyperplasia	J:179060
Adam10^tm1.1Khr/Adam10^tm1.1Khr Tg(Mx1-cre)1Cgn/0 (involves: 129S6/SvEvTac * C57BL/6 * C57BL/6N)	abnormal granulocyte differentiation	J:179060
	abnormal spleen morphology	J:179060
	abnormal T cell differentiation	J:179060
	decreased CD4-positive, alpha-beta T cell number	J:179060
	decreased CD8-positive, alpha-beta T cell number	J:179060
	decreased double-positive T cell number	J:179060
	decreased T cell number	J:179060
	enlarged spleen	J:179060
	increased leukocyte cell number	J:179060
	increased neutrophil cell number	J:179060
	increased spleen red pulp amount	J:179060
	increased spleen weight	J:179060
	myeloid hyperplasia	J:179060
	small thymus	J:179060
	spleen hyperplasia	J:179060
	thymus hypoplasia	J:179060
Adam10^tm1Zhu/Adam10^tm1.1Zhu Tg(Lck-cre)#Zhu/0 (involves: 129S6/SvEvTac * C57BL/6 * SJL * SJL/J)	abnormal T cell differentiation	J:139042
	decreased CD4-positive, alpha-beta T cell number	J:139042
	decreased double-positive T cell number	J:139042
	thymus hypoplasia	J:139042
Adam10^tm1Zhu/Adam10^tm1Zhu Tg(Lck-cre)#Zhu/0 (involves: 129S6/SvEvTac * C57BL/6 * SJL/J)	abnormal T cell differentiation	J:139042
	decreased CD4-positive, alpha-beta T cell number	J:139042
	decreased double-positive T cell number	J:139042
	thymus hypoplasia	J:139042
Adam17^m1Btlr/Adam17^m1Btlr (C57BL/6J-Adam17^m1Btlr)	decreased circulating tumor necrosis factor level	J:166602
Adam17^m1Btlr/Adam17^m1Btlr (C57BL/6J-Adam17^m1Btlr)	increased susceptibility to induced colitis	J:166602
Adam17^tm1.1Srj/Adam17^tm1.1Srj (involves: 129S/SvEv * C57BL/6 * SJL)	abnormal chemokine level	J:163380
	abnormal interleukin secretion	J:163380
	increased interleukin-10 secretion	J:163380
	increased susceptibility to induced colitis	J:163380
	skin inflammation	J:163380
Adam17^tm1.2Bbl/Adam17^tm1.2Bbl Il17a^tm1Yiw/Il17a^tm1Yiw Sox9^tm3(cre)Crm/Sox9⁺ (involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * SJL)	dermatitis	J:229771
Adam17^tm1.2Bbl/Adam17^tm1.2Bbl Il23a^tm1Dnax/Il23a^tm1Dnax Sox9^tm3(cre)Crm/Sox9⁺ (involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * SJL)	dermatitis	J:229771
Adam17^tm1.2Bbl/Adam17^tm1.2Bbl Sox9^tm3(cre)Crm/Sox9⁺ (involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6)	abnormal spleen morphology	J:144795
	decreased B cell number	J:144795
	decreased lymphocyte cell number	J:144795
	decreased T cell number	J:144795
	enlarged spleen	J:144795
	increased circulating interleukin-17 level	J:144795
	increased interleukin-17 secretion	J:144795
	increased leukocyte cell number	J:144795
	increased macrophage cell number	J:144795
	increased neutrophil cell number	J:144795
	increased spleen red pulp amount	J:144795
Adam17^tm1.2Bbl/Adam17^tm1.2Bbl Sox9^tm3(cre)Crm/Sox9⁺ (B6.129(SJL)-Sox9^tm3(cre)Crm Adam17^tm1.2Bbl)	abnormal circulating chemokine level	J:229771
	dermatitis	J:229771
	increased IgE level	J:229771
	increased T-helper 1 cell number	J:229771
	increased T-helper 2 cell number	J:229771
	increased T-helper 17 cell number	J:229771
Adam17^{tm1a(EUCOMM)Wtsi}/Adam17⁺ (involves: C57BL/6 * C57BL/6N)	myeloid hyperplasia	J:213427
Adam17^tm1Bbl/Adam17^tm1Bbl Lyz2^tm1(cre)Ifo/0 (involves: 129P2/OlaHsd)	abnormal macrophage physiology	J:139846
	decreased circulating tumor necrosis factor level	J:139846
	decreased susceptibility to endotoxin shock	J:139846
Adam17^tm1Bbl/Adam17^tm1Bbl Tg(Mx1-cre)1Cgn/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA)	decreased circulating tumor necrosis factor level	J:139846
	decreased susceptibility to endotoxin shock	J:139846
Adam17^tm1Ckww/Adam17^tm1Ckww (Not Specified)	abnormal dendritic cell physiology	J:138782
Adam17^tm1Imx/Adam17^tm1Imx (involves: 129 * C57BL/6)	increased incidence of corneal inflammation	J:51053
Adam17^tm1Imx/Adam17^tm1Imx (B6.129-Adam17^tm1Imx)	enhanced leukocyte tethering or rolling	J:174865
Adam17^tm1Rain/Adam17^tm1Rain (involves: C57BL/6)	enhanced leukocyte tethering or rolling	J:174865
Adam17^woe/Adam17^woe (C57BL/6-Adam17^woe)	dermatitis	J:160781
Adam17^woe/Adam17^woe (C57BL/6-Adam17^woe)	increased incidence of corneal inflammation	J:160781
Adam28^tm1.2Dica/Adam28^tm1.2Dica (B6JRj.129-Adam28^tm1.2Dica)	abnormal alpha-beta T cell morphology	J:298188
	abnormal lymphocyte morphology	J:298188
	decreased CD8-positive, alpha-beta T cell number	J:298188
Adam28^tm1.2Dica/Adam28^tm1.2Dica (CJRj.129-Adam28^tm1.2Dica)	decreased CD8-positive, alpha-beta T cell number	J:298188
Adam29^em1Otin/Adam29^em1Otin (C57BL/6-Adam29^em1Otin)	increased inflammatory response	J:353244
Adamdec1^tm1Dgen/Adamdec1⁺ (B6.129P2-Adamdec1^tm1Dgen)	increased susceptibility to induced colitis	J:301741
Adamdec1^tm1Dgen/Adamdec1^tm1Dgen (B6.129P2-Adamdec1^tm1Dgen)	decreased circulating interleukin-10 level	J:301741
	increased circulating interleukin-1 beta level	J:301741
	increased circulating interleukin-6 level	J:301741
	increased neutrophil cell number	J:301741
	increased susceptibility to bacterial infection	J:301741
	increased susceptibility to bacterial infection induced morbidity/mortality	J:301741
	increased susceptibility to colitis induced morbidity/mortality	J:301741
	increased susceptibility to induced colitis	J:301741
	intestinal inflammation	J:301741
Adamts1^em1(IMPC)Mbp/Adamts1⁺ (C57BL/6N-Adamts1^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Adamts2^tm1Prc/Adamts2^tm1Prc (involves: 129 * 129S1/Sv * 129X1/SvJ * C57BL/6)	increased interferon-gamma secretion	J:271185
Adamts3^tm1.2Itl/Adamts3^tm1.2Itl (involves: BALB/cJ * C57BL/6NTac * SJL)	abnormal lymphangiogenesis	J:245044
	absent lymphatic vessels	J:245044
Adamts5^tm1.1Eam/Adamts5⁺ (involves: 129S5/SvEvBrd)	decreased susceptibility to induced arthritis	J:97590
Adamts5^tm1.1Eam/Adamts5^tm1.1Eam (involves: 129S5/SvEvBrd)	decreased susceptibility to induced arthritis	J:97590
Adamts5^tm1Lex/Adamts5^tm1Lex Tg(CMV-cre)1Cgn/0 (involves: 129S5/SvEvBrd * BALB/cJ)	osteoarthritis	J:105138
Adamts5^tm2.2Lex/Adamts5^tm2.2Lex (B6.129S5-Adamts5^tm2.2Lex)	decreased susceptibility to induced arthritis	J:175366
Adamts6^b2b1879.1Clo/Adamts6^b2b1879.1Clo (C57BL/6J-Adamts6^b2b1879.1Clo)	thymus hypoplasia	J:175213
Adamts6^b2b2029Clo/Adamts6^b2b2029Clo (C57BL/6J-Adamts6^b2b2029Clo)	thymus hypoplasia	J:175213
Adamts6^b2b2182Clo/Adamts6^b2b2182Clo (C57BL/6J-Adamts6^b2b2182Clo)	thymus hypoplasia	J:175213
Adamts6^b2b2187.1Clo/Adamts6^b2b2187.1Clo (C57BL/6J-Adamts6^b2b2187.1Clo)	thymus hypoplasia	J:175213
Adamts6^b2b2228Clo/Adamts6^b2b2228Clo (C57BL/6J-Adamts6^b2b2228Clo)	thymus hypoplasia	J:175213
Adamts6^b2b2405Clo/Adamts6^b2b2405Clo (C57BL/6J-Adamts6^b2b2405Clo)	thymus hypoplasia	J:175213
Adamts6^b2b2407Clo/Adamts6^b2b2407Clo (C57BL/6J-Adamts6^b2b2407Clo)	thymus hypoplasia	J:175213
Adamts6^b2b2744Clo/Adamts6^b2b2744Clo (C57BL/6J-Adamts6^b2b2744Clo)	thymus hypoplasia	J:175213
Adamts6^b2b2966.2Clo/Adamts6^b2b2966.2Clo (C57BL/6J-Adamts6^b2b2966.2Clo)	thymus hypoplasia	J:175213
Adamts9^{tm1b(KOMP)Wtsi}/Adamts9⁺ (C57BL/6N-Adamts9^{tm1b(KOMP)Wtsi}/MbpMmucd)	abnormal lymph node morphology	J:211773
Adamts13^tm1Dgi/Adamts13^tm1Dgi (involves: 129X1/SvJ * C57BL/6J * CASA/Rk)	immune system phenotype	J:101752
	increased susceptibility to bacterial infection	J:101752
Adamts14^{Gt(511E11)Cmhd}/Adamts14^{Gt(511E11)Cmhd} (involves: 129 * 129S1/Sv * 129X1/SvJ * C57BL/6)	increased interferon-gamma secretion	J:271185
	increased interleukin-2 secretion	J:271185
Adamts14^{Gt(511E11)Cmhd}/Adamts14^{Gt(511E11)Cmhd} Adamts2^tm1Prc/Adamts2^tm1Prc (involves: 129 * 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal T cell activation	J:271185
	cutaneous mastocytosis	J:271185
	decreased B cell number	J:271185
	decreased CD8-positive, alpha-beta T cell number	J:271185
	dermatitis	J:271185
	increased CD4-positive, alpha-beta T cell number	J:271185
	increased interferon-gamma secretion	J:271185
	increased interleukin-2 secretion	J:271185
	increased T cell proliferation	J:271185
Adamts16^em1(IMPC)H/Adamts16^em1(IMPC)H (C57BL/6N-Adamts16^em1(IMPC)H/H)	decreased eosinophil cell number	J:211773
	decreased neutrophil cell number	J:211773
Adamts18^tm1.1Wzha/Adamts18^tm1.1Wzha (involves: 129 * C57BL/6)	increased acute inflammation	J:258487
	increased susceptibility to induced colitis	J:258487
Adamtsl3^em1(IMPC)Tcp/Adamtsl3^em1(IMPC)Tcp (C57BL/6N-Adamtsl3^em1(IMPC)Tcp/Cmmr)	enlarged lymph nodes	J:211773
	small spleen	J:211773
Adap1^{tm1a(EUCOMM)Wtsi}/Adap1^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Adap1^{tm1a(EUCOMM)Wtsi}/Wtsi)	decreased memory-marker NK cell number	J:211773
	increased NK cell number	J:211773
Adar^em1Stsn/Adar^tm1Olds (involves: 129S/SvEv * C57BL/6J)	abnormal spleen morphology	J:308678
Adar^em2Qwan/Adar^em2Qwan (Not Specified)	immune system phenotype	J:325221
Adar^em3Qwan/Adar^em3Qwan (Not Specified)	abnormal chemokine level	J:325221
	immune system phenotype	J:325221
	increased circulating interleukin-1 level	J:325221
	increased circulating interleukin-6 level	J:325221
	increased circulating interleukin-17 level	J:325221
	increased CXCL10 level	J:325221
Adar^tm1Olds/Adar^tm1Olds (involves: 129S/SvEv * C57BL/6J)	increased susceptibility to Orthomyxoviridae infection	J:169014
Adar^tm1Olds/Adar^tm1Olds (involves: 129S/SvEv * C57BL/6J)	increased susceptibility to Paramyxoviridae infection	J:169014
Adar^tm2Phs/Adar^tm2Phs (B6.Cg-Adar^tm2Phs)	abnormal circulating interferon-beta level	J:142338
Adar^tm2Phs/Adar^tm2Phs (B6.Cg-Adar^tm2Phs)	increased circulating interferon-alpha level	J:142338
Adarb2^em1(IMPC)Tcp/Adarb2^em1(IMPC)Tcp (C57BL/6NCrl-Adarb2^em1(IMPC)Tcp/Tcp)	abnormal spleen morphology	J:211773
Adaz1^NZM2328/J/Adaz1^NZM2328/J (involves: C57L/J * NZM2328/J)	increased anti-double stranded DNA antibody level	J:71397
Adck1^em2(IMPC)Tcp/Adck1^em2(IMPC)Tcp (C57BL/6NCrl-Adck1^em2(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Adcy1^{tm1b(EUCOMM)Wtsi}/Adcy1^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Adcy1^{tm1b(EUCOMM)Wtsi}/H)	increased leukocyte cell number	J:211773
Adcy7^tm1.1Pcst/Adcy7^tm1.1Pcst Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6J)	increased tumor necrosis factor secretion	J:191067
	peritoneal inflammation	J:191067
Adcy9^{Gt(OST193739)Lex}/Adcy9^{Gt(OST193739)Lex} (involves: 129S5/SvEvBrd * C57BL/6J)	increased IgG1 level	J:103485
Adcy9^{tm1b(EUCOMM)Wtsi}/Adcy9^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Adcy9^{tm1b(EUCOMM)Wtsi}/Wtsi)	blood in lymph vessels	J:239583
Adcyap1^tm1Clw/Adcyap1^tm1Clw (B6.129S4-Adcyap1^tm1Clw)	abnormal regulatory T cell physiology	J:194151
	abnormal T cell activation	J:194151
	increased microglial cell activation	J:194151
	increased T-helper 17 cell number	J:194151
Adcyap1r1^tm1Bbt/Adcyap1r1^tm1Bbt (involves: 129 * C57BL/6J)	increased susceptibility to bacterial infection	J:73990
Add2^tm1Feb/Add2^tm1Feb (B6.129-Add2^tm1Feb)	increased spleen weight	J:63047
Add2^tm1Llp/Add2^tm1Llp (involves: 129S4/SvJae * C57BL/6J)	enlarged spleen	J:71029
Add2^tm1Llp/Add2^tm1Llp (involves: 129S4/SvJae * C57BL/6J)	increased spleen iron level	J:71029
Adgb^em1(IMPC)Mbp/Adgb⁺ (C57BL/6NCrl-Adgb^em1(IMPC)Mbp/Mmucd)	increased eosinophil cell number	J:211773
Adgrb1^{tm2a(EUCOMM)Wtsi}/Adgrb1⁺ (C57BL/6N-Adgrb1^{tm2a(EUCOMM)Wtsi}/Wtsi)	decreased leukocyte cell number	J:211773
Adgrd1^{tm1b(EUCOMM)Wtsi}/Adgrd1^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Adgrd1^{tm1b(EUCOMM)Wtsi}/Wtsi)	increased anti-nuclear antigen antibody level	J:211773
Adgre1^m1Btlr/Adgre1^m1Btlr (C57BL/6J-Adgre1^m1Btlr)	immune system phenotype	J:135219
Adgre1^m2Btlr/Adgre1^m2Btlr (C57BL/6J-Adgre1^m2Btlr)	abnormal macrophage physiology	J:195410
Adgre1^m2Btlr/Adgre1^m2Btlr (C57BL/6J-Adgre1^m2Btlr)	decreased macrophage cell number	J:195410
Adgre1^m3Btlr/Adgre1^m3Btlr (C57BL/6J-Adgre1^m3Btlr)	abnormal macrophage physiology	J:234244
Adgre1^m3Btlr/Adgre1^m3Btlr (C57BL/6J-Adgre1^m3Btlr)	decreased macrophage cell number	J:234244
Adgre1^M4Btlr/Adgre1⁺ (C57BL/6J-Adgre1^M4Btlr)	decreased macrophage cell number	J:255001
Adgre1^M4Btlr/Adgre1^M4Btlr (C57BL/6J-Adgre1^M4Btlr)	decreased macrophage cell number	J:255001
Adgre1^tm1Stst/Adgre1^tm1Stst (B6.129S1-Emr1^tm1Stst)	abnormal immune tolerance	J:99213
Adgre1^tm1Stst/Adgre1^tm1Stst (B6.129S1-Emr1^tm1Stst)	abnormal regulatory T cell physiology	J:99213
Adgre5^tm1.1Joha/Adgre5^tm1.1Joha (involves: 129P2/OlaHsd * C57BL/6J * FVB/N)	immune system phenotype	J:140713
	increased granulocyte number	J:140713
Adgre5^tm1Kake/Adgre5^tm1Kake (B6.129S6-Adgre5^tm1Kake)	decreased susceptibility to bacterial infection	J:118705
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:118705
	immune system phenotype	J:118705
	increased granulocyte number	J:118705
Adgrf1^{em1(IMPC)Ccpcz}/Adgrf1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Adgrf1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Adgrf5^tm1.2Bstc/Adgrf5^tm1.2Bstc (involves: 129S4/SvJae * C57BL/6J)	increased macrophage derived foam cell number	J:196943
Adgrf5^tm1.2Jpbs/Adgrf5^tm1.2Jpbs (BALB/c-Adgrf5^tm1.2Jpbs)	abnormal alveolar macrophage morphology	J:221769
Adgrf5^{tm1b(KOMP)Wtsi}/Adgrf5^{tm1b(KOMP)Wtsi} (C57BL/6N-Adgrf5^{tm1b(KOMP)Wtsi}/Tcp)	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
	decreased monocyte cell number	J:211773
Adgrf5^tm1Shiro/Adgrf5^tm1Shiro (B6.Cg-Adgrf5^tm1Shiro)	abnormal alveolar macrophage morphology	J:204701
Adgrf5^tm1Shiro/Adgrf5^tm1Shiro (B6.Cg-Adgrf5^tm1Shiro)	increased macrophage cell number	J:204701
Adgrg3^tm1Fwa/Adgrg3^tm1Fwa (129S4/SvJae-Adgrg3^tm1Fwa)	immune system phenotype	J:62512
Adgrg3^tm1Zgwg/Adgrg3^tm1Zgwg (involves: 129 * C57BL/6)	abnormal B cell morphology	J:222670
	abnormal IgG1 level	J:222670
	abnormal IgG2 level	J:222670
	abnormal IgG level	J:222670
	abnormal immune system morphology	J:222670
	abnormal immune system physiology	J:222670
	abnormal immunoglobulin level	J:222670
	abnormal spleen B cell follicle morphology	J:222670
	abnormal spleen B cell follicle shape	J:222670
	abnormal spleen marginal zone morphology	J:222670
	abnormal spleen morphology	J:222670
	decreased follicular B cell number	J:222670
	decreased IgA level	J:222670
	decreased IgG1 level	J:222670
	decreased IgG2b level	J:222670
	decreased IgG3 level	J:222670
	decreased IgM level	J:222670
	decreased mature B cell number	J:222670
	decreased transitional stage T1 B cell number	J:222670
	immune system phenotype	J:222670
	increased B cell apoptosis	J:222670
	increased IgG1 level	J:222670
	increased IgG2a level	J:222670
	increased marginal zone B cell number	J:222670
	increased transitional stage T2 B cell number	J:222670
Adgrl4^em1(IMPC)Mbp/Adgrl4^em1(IMPC)Mbp (C57BL/6N-Adgrl4^em1(IMPC)Mbp/MbpMmucd)	increased neutrophil cell number	J:211773
Adh5^tm1.1Llli/Adh5^tm1.1Llli Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺ (B6.Cg-Adh5^tm1.1Llli Speer6-ps1^{Tg(Alb-cre)21Mgn})	increased susceptibility to bacterial infection induced morbidity/mortality	J:173666
Adh5^tm1Stam/Adh5^tm1Stam (B6.129-Adh5^tm1Stam)	increased susceptibility to bacterial infection	J:88337
Adh5^tm1Stam/Adh5^tm1Stam (B6.129-Adh5^tm1Stam)	increased susceptibility to bacterial infection induced morbidity/mortality	J:88337
Adip1^LG/J/? Capn10^tm1Chev/Capn10⁺ ((B6.129-Capn10^tm1Chev x LG/J)F1)	increased spleen weight	J:153477
Adipoq^tm1Chan/Adipoq⁺ (B6.129-Adipoq^tm1Chan)	abnormal leukocyte physiology	J:122020
Adipoq^tm1Chan/Adipoq⁺ (B6.129-Adipoq^tm1Chan)	increased leukocyte cell number	J:122020
Adipoq^tm1Chan/Adipoq^tm1Chan (B6.129-Adipoq^tm1Chan)	abnormal leukocyte physiology	J:122020
Adipoq^tm1Chan/Adipoq^tm1Chan (B6.129-Adipoq^tm1Chan)	increased leukocyte cell number	J:122020
Adipoq^tm1Ish/Adipoq^tm1Ish (involves: 129S7/SvEvBrd * C57BL/6J)	abnormal osteoclast morphology	J:199264
Adipor1^{tm1b(EUCOMM)Hmgu}/Adipor1^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Adipor1^{tm1b(EUCOMM)Hmgu}/H)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Adipor2^{tm1b(EUCOMM)Hmgu}/Adipor2^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Adipor2^{tm1b(EUCOMM)Hmgu}/H)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Adk^{em1(IMPC)Ccpcz}/Adk⁺ (C57BL/6N-Adk^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Adm2^em1Zhan/Adm2^em1Zhan (Not Specified)	increased inflammatory response	J:266495
	increased Ly6C high monocyte number	J:266495
	increased susceptibility to infection	J:266495
	liver inflammation	J:266495
Adm^tm1Kmca/Adm^tm1Kmca (B6.129P2-Adm^tm1Kmca)	increased uterine NK cell number	J:201446
Adm^tm1Tfjt/Adm⁺ (involves: C57BL/6 * CBA)	blood vessel inflammation	J:102946
Adm^tm1Unc/Adm^tm1Unc (involves: 129S6/SvEvTac)	decreased uterine NK cell number	J:201446
Adm^tm1Unc/Adm^tm1Unc (129S6/SvEvTac-Adm^tm1Unc)	abnormal lymph organ development	J:130930
Adnp2^em3(IMPC)Tcp/Adnp2⁺ (C57BL/6NCrl-Adnp2^em3(IMPC)Tcp/Tcp)	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	small spleen	J:211773
Adora2a^em1(IMPC)H/Adora2a^em1(IMPC)H (C57BL/6N-Adora2a^em1(IMPC)H/H)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Adora2a^tm1Map/Adora2a^tm1Map (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	decreased interleukin-10 secretion	J:147023
Adora2b^tm1.1Msit/Adora2b^tm1.1Msit (either: (involves: C57BL/6) or (involves: C57BL/6 * CD-1 * ICR))	abnormal macrophage physiology	J:169155
	increased interleukin-6 secretion	J:169155
	increased tumor necrosis factor secretion	J:169155
Adora2b^tm1Dgen/Adora2b^tm1Dgen (B6.129P2-Adora2b^tm1Dgen)	abnormal dendritic cell physiology	J:138722
Adora2b^tm1Dgen/Adora2b^tm1Dgen (B6.129P2-Adora2b^tm1Dgen)	decreased interleukin-10 secretion	J:147023
Adora2b^tm1Kra/Adora2b^tm1Kra (involves: 129 * C57BL/6J)	abnormal cytokine level	J:111715
	abnormal inflammatory response	J:111715
	abnormal interleukin level	J:111715
	abnormal leukocyte adhesion	J:111715
	abnormal leukocyte migration	J:111715
	abnormal tumor necrosis factor level	J:111715
	decreased interleukin-10 secretion	J:111715
	enhanced leukocyte tethering or rolling	J:111715
	increased circulating interleukin-6 level	J:111715
Adora2b^tm1Till/Adora2b^tm1Till (B6.129P2-Adora2b^tm1Till)	abnormal cellular extravasation	J:125297
	increased interleukin-6 secretion	J:125297
	increased susceptibility to type I hypersensitivity reaction	J:125297
Adora3^{tm1(ADORA3)Msth}/Adora3^{tm1(ADORA3)Msth} (involves: 129S7/SvEvBrd * C57BL/6J)	abnormal mast cell physiology	J:104494
	decreased mast cell degranulation	J:104494
Adora3^tm1Jbsn/Adora3^tm1Jbsn (either: (involves: 129P2/OlaHsd * C57BL/6 * DBA/2) or (involves: 129P2/OlaHsd * C57BL/6))	abnormal mast cell physiology	J:60293
	decreased tumor necrosis factor secretion	J:60293
Adora3^tm1Jbsn/Adora3^tm1Jbsn (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	decreased acute inflammation	J:120442
Adora3^tm1Jbsn/Adora3^tm1Jbsn (B6.129P2-Adora3^tm1Jbsn)	abnormal mast cell degranulation	J:123463
Adora3^tm1Jbsn/Adora3^tm1Jbsn (B6.129P2-Adora3^tm1Jbsn)	impaired neutrophil recruitment	J:123463
Adprh^tm1Jlms/Adprh^tm1Jlms (involves: 129X1/SvJ * C57BL/6J)	increased susceptibility to infection	J:123619
Adrb2^em1(IMPC)Mbp/Adrb2^em1(IMPC)Mbp (C57BL/6N-Adrb2^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Adrb2^tm1Bkk/Adrb2⁺ (involves: 129S1/Sv * 129X1/SvJ)	abnormal osteoclast differentiation	J:97566
Adrb2^tm1Bkk/Adrb2^tm1Bkk (involves: 129S1/Sv * 129X1/SvJ)	abnormal osteoclast differentiation	J:97566
	abnormal osteoclast morphology	J:97566
	abnormal osteoclast physiology	J:97566
Adrb2^tm1Bkk/Adrb2^tm1Bkk (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * DBA/2 * FVB/N)	increased tumor necrosis factor secretion	J:204379
Adrb3^em1(IMPC)Krb/Adrb3^em1(IMPC)Krb (C57BL/6NTac-Adrb3^em1(IMPC)Krb/Krb)	increased CD4-negative, CD25-positive NK T cell number	J:211773
Adrm1^{Gt(OST128063)Lex}/Adrm1^{Gt(OST128063)Lex} (involves: 129S5/SvEvBrd * C57BL/6J)	abnormal single-positive T cell number	J:166694
	enlarged thymus	J:166694
	immune system phenotype	J:166694
	increased CD4-positive, alpha-beta T cell number	J:166694
	increased CD8-positive, alpha-beta T cell number	J:166694
	thymus hyperplasia	J:166694
Ads1^NZB/Ads1^NZB (involves: NZB * NZW)	increased anti-double stranded DNA antibody level	J:7239, J:7111
Ads1^NZB/Ads1^NZB (involves: NZB * NZW)	increased susceptibility to autoimmune disorder	J:7111
Ads1^NZB/Ads1^NZW (involves: NZB * NZW)	increased anti-double stranded DNA antibody level	J:7111
Ads1^NZB/Ads1^NZW (involves: NZB * NZW)	increased susceptibility to autoimmune disorder	J:7111
Ads2^NZB/Ads2^NZB (involves: NZB * NZW)	increased anti-double stranded DNA antibody level	J:7111
Ads2^NZB/Ads2^NZB (involves: NZB * NZW)	increased susceptibility to autoimmune disorder	J:7111
Ads2^NZB/Ads2^NZW (involves: NZB * NZW)	increased anti-double stranded DNA antibody level	J:7111
Ads2^NZB/Ads2^NZW (involves: NZB * NZW)	increased susceptibility to autoimmune disorder	J:7111
Ads3^NZB/Ads3^NZW (involves: NZB * NZW)	abnormal immunoglobulin level	J:7111
Ads3^NZB/Ads3^NZW (involves: NZB * NZW)	increased susceptibility to autoimmune disorder	J:7111
Ads3^NZW/Ads3^NZW (involves: NZB * NZW)	abnormal immunoglobulin level	J:7111
	increased anti-double stranded DNA antibody level	J:7239
	increased susceptibility to autoimmune disorder	J:7111
Ads4^NZB/Ads4^NZB (involves: NZB * NZW)	decreased anti-double stranded DNA antibody level	J:11074
Ads4^NZB/Ads4^NZW (involves: NZB * NZW)	abnormal immunoglobulin level	J:7111
Ads4^NZB/Ads4^NZW (involves: NZB * NZW)	increased susceptibility to autoimmune disorder	J:7111
Ads4^NZW/Ads4^NZW (involves: NZB * NZW)	abnormal immunoglobulin level	J:7111
Ads4^NZW/Ads4^NZW (involves: NZB * NZW)	increased susceptibility to autoimmune disorder	J:7111
Adss2^{tm1b(EUCOMM)Wtsi}/Adss2⁺ (C57BL/6N-Adss2^{tm1b(EUCOMM)Wtsi}/Bay)	decreased eosinophil cell number	J:211773
Adtrp^tm1.1Clu/Adtrp^tm1.1Clu (involves: 129S4/SvJaeSor * C57BL/6)	increased inflammatory response	J:295059
	increased mast cell number	J:295059
Aec1^NOD/Uf/Aec1^NOD/Uf Aec2^NOD/Uf/Aec2^NOD/Uf (B6.NOD-Aec2^NOD/Uf Aec1^NOD/Uf)	increased anti-nuclear antigen antibody level	J:129282
	increased susceptibility to autoimmune disorder	J:128900
	lacrimal gland inflammation	J:129282
	salivary gland inflammation	J:129282
Aem1^C57BL/6/Aem1^NZB (involves: C57BL/6 * NZB)	decreased autoantibody level	J:7191
Aem2^C57BL/6/Aem2^C57BL/6 (involves: C57BL/6 * NZB)	decreased autoantibody level	J:59427
Aem2^C57BL/6/Aem2^NZB (involves: C57BL/6 * NZB)	decreased autoantibody level	J:59427
Aem2^C57BL/6/Aem2^NZB Aem3^C57BL/6/Aem3^NZB (involves: C57BL/6 * NZB)	decreased autoantibody level	J:59427
Aem3^C57BL/6/? (involves: C57BL/6 * NZB)	abnormal immune system physiology	J:59427
Afap1l2^{tm1b(KOMP)Wtsi}/Afap1l2^{tm1b(KOMP)Wtsi} (C57BL/6N-Afap1l2^{tm1b(KOMP)Wtsi}/Ucd)	abnormal spleen morphology	J:211773
	increased neutrophil cell number	J:211773
Afdn^em1(IMPC)Mbp/Afdn⁺ (C57BL/6N-Afdn^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	decreased lymphocyte cell number	J:211773
	decreased spleen weight	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	small spleen	J:211773
Aff1^Rob/Aff1⁺ (involves: BALB/cAnNCrl * C3H/HeN)	abnormal double-negative T cell morphology	J:82265
	decreased thymus weight	J:82265
	thymus hypoplasia	J:82265
Aff1^tm1Cim/Aff1^tm1Cim (involves: 129P2/OlaHsd * BALB/c)	abnormal immune system cell morphology	J:63253
	abnormal immune system organ morphology	J:63253
	abnormal T cell differentiation	J:63253
	decreased B cell number	J:63253
	decreased double-positive T cell number	J:63253
	decreased mature B cell number	J:63253
	decreased pre-B cell number	J:63253
	decreased single-positive T cell number	J:63253
	thymus hypoplasia	J:63253
Afg2b^em1(IMPC)Bay/Afg2b⁺ (C57BL/6N-Afg2b^em1(IMPC)Bay/BayMmucd)	enlarged lymph nodes	J:211773
Afg3l1^tm1.1Arte/Afg3l1^tm1.1Arte Afg3l2^tm1Arte/Afg3l2^tm1Arte Tg(Plp1-cre/ERT)3Pop/0 (involves: C57BL/6J * C57BL/6N)	microgliosis	J:237410
Afg3l2^tm1Arte/Afg3l2^tm1Arte Tg(Pcp2-cre)2Mpin/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	microgliosis	J:193564
Agbl1^em1Zfa/Agbl1^em1Zfa (Not Specified)	immune system phenotype	J:231311
Agbl2^em1Zfa/Agbl2^em1Zfa (Not Specified)	immune system phenotype	J:231311
Agbl3^em1Zfa/Agbl3^em1Zfa (Not Specified)	immune system phenotype	J:231311
Agbl4^em1(IMPC)Mbp/Agbl4^em1(IMPC)Mbp (C57BL/6NCrl-Agbl4^em1(IMPC)Mbp/Mmucd)	increased monocyte cell number	J:211773
Agbl4^{Tn(pb-Act-RFP)1.080115015-HRAZhu}/Agbl4^{Tn(pb-Act-RFP)1.080115015-HRAZhu} (involves: FVB/N)	abnormal spleen morphology	J:233744
	increased spleen weight	J:233744
	increased susceptibility to Herpesvirales infection	J:231311
	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:231311
	increased susceptibility to Poxviridae infection	J:231311
	increased susceptibility to Poxviridae infection induced morbidity/mortality	J:231311
Agbl5^em1Zfa/Agbl5^em1Zfa (Not Specified)	increased susceptibility to Herpesvirales infection	J:231311
	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:231311
	increased susceptibility to Poxviridae infection	J:231311
	increased susceptibility to Poxviridae infection induced morbidity/mortality	J:231311
Ager^tm1.1Arnd/Ager^tm1.1Arnd (B6.129P2-Ager^tm1.1Arnd)	decreased circulating interleukin-6 level	J:104998
Ager^tm1.1Arnd/Ager^tm1.1Arnd (B6.129P2-Ager^tm1.1Arnd)	decreased osteoclast cell number	J:104998
Ager^tm1.1Arnd/Ager^tm1.1Arnd (involves: 129P2/OlaHsd)	abnormal immune system physiology	J:113376
Ager^tm1Arnd/Ager⁺ Tg(Itgax-EGFP,-cre,-HBEGF,-luc)2Gjh/0 (involves: 129P2/OlaHsd * C57BL/6)	decreased dendritic cell number	J:194800
	decreased plasmacytoid dendritic cell number	J:194800
Agk^em1Qiz/Agk^em1Qiz (involves: C57BL/6 * DBA/2)	abnormal CD8-positive, alpha beta T cell morphology	J:282052
	abnormal CD8-positive, alpha-beta T cell physiology	J:282052
	decreased effector memory CD8-positive, alpha-beta T cell number	J:282052
Agk^tm1.1Smoc/Agk^tm1.1Smoc (Not Specified)	decreased effector memory CD8-positive, alpha-beta T cell number	J:282052
Agk^tm1.1Smoc/Agk^tm1.1Smoc (Not Specified)	immune system phenotype	J:282052
Aglna/? (C57BL/6-Aglna/Anu)	abnormal spleen marginal zone morphology	J:169366
Aglna/? (C57BL/6-Aglna/Anu)	increased activated T cell number	J:169366
Agnm1^MRL/MpJ/Agnm1^MRL/MpJ (involves: C3H/HeJ-Fas^lpr * MRL/MpJ-Fas^lpr)	glomerulonephritis	J:97786
	increased susceptibility to systemic lupus erythematosus	J:97786
Agnm2^C3H/HeJ/Agnm2^MRL/MpJ (involves: C3H/HeJ-Fas^lpr * MRL/MpJ-Fas^lpr)	glomerulonephritis	J:97786
	increased susceptibility to systemic lupus erythematosus	J:97786
Agnm2^MRL/MpJ/Agnm2^MRL/MpJ (involves: C3H/HeJ-Fas^lpr * MRL/MpJ-Fas^lpr)	glomerulonephritis	J:97786
	increased susceptibility to systemic lupus erythematosus	J:97786
Agnm3^C3H/HeJ/Agnm3^MRL/MpJ (involves: C3H/HeJ-Fas^lpr * MRL/MpJ-Fas^lpr)	glomerulonephritis	J:97786
	increased susceptibility to systemic lupus erythematosus	J:97786
Agnm3^MRL/MpJ/Agnm3^MRL/MpJ (involves: C3H/HeJ-Fas^lpr * MRL/MpJ-Fas^lpr)	glomerulonephritis	J:97786
	increased susceptibility to systemic lupus erythematosus	J:97786
Ago2^tm1.1Tara/Ago2^tm1.1Tara Tg(Mx1-cre)1Cgn/0 (involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6 * CBA)	enlarged spleen	J:165967
Agp1^NZB/Agp1^NZB (involves: NZB * NZW)	increased susceptibility to type III hypersensitivity reaction	J:6920
Agp1^NZB/Agp1^NZW (involves: NZB * NZW)	increased susceptibility to type III hypersensitivity reaction	J:6920
Agp2^NZB/Agp2^NZW (involves: NZB * NZW)	increased susceptibility to type III hypersensitivity reaction	J:6920
Agp2^NZW/Agp2^NZW (involves: NZB * NZW)	increased susceptibility to type III hypersensitivity reaction	J:6920
Agpat2^{em1(IMPC)Ccpcz}/Agpat2⁺ (C57BL/6NCrl-Agpat2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Agpat2^{Gt(OST438470)Lex}/Agpat2^{Gt(OST438470)Lex} (involves: 129S5/SvEvBrd * C57BL/6)	brown adipose tissue inflammation	J:186035
	granulomatous inflammation	J:186035
	liver inflammation	J:186035
Agpat2^tm1Garg/Agpat2^tm1Garg (involves: 129S6/SvEvTac)	increased spleen weight	J:146649
Agpat5^{em1(IMPC)Ccpcz}/Agpat5^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Agpat5^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Agr2^tm1.1Lpkn/Agr2^tm1.1Lpkn Gt(ROSA)26Sor^{tm1(cre/ERT)Nat}/Gt(ROSA)26Sor⁺ (involves: 129 * 129S6/SvEvTac * C57BL/6)	colitis	J:156704
Agr2^tm1.2Erle/Agr2^tm1.2Erle (involves: 129S4/SvJae * FVB/N)	increased mast cell number	J:148339
	increased susceptibility to induced colitis	J:148339
Agr2^tm1.2Lpkn/Agr2^tm1.2Lpkn (involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6)	abnormal Peyer's patch follicle morphology	J:156704
	colitis	J:156704
	ileum inflammation	J:156704
Agt^tm1Afu/Agt^tm1Afu (involves: C57BL/6 * CBA)	tubulointerstitial nephritis	J:46506
Agt^tm1Unc/Agt^tm1Unc (involves: 129P2/OlaHsd * C57BL/6J)	tubulointerstitial nephritis	J:24156
Agtpbp1^atms/Agtpbp1^atms (MRL/Mp-Agtpbp1^atms Fas^lpr)	decreased spleen weight	J:103944
Agtpbp1^atms/Agtpbp1^atms (MRL/Mp-Agtpbp1^atms)	abnormal lymphocyte cell number	J:103944
	abnormal spleen morphology	J:103944
	abnormal T cell differentiation	J:103944
	abnormal T cell physiology	J:103944
	abnormal T cell subpopulation ratio	J:103944
	decreased B cell number	J:103944
	decreased spleen weight	J:103944
	increased CD4-positive, alpha-beta T cell number	J:103944
	increased CD8-positive, alpha-beta T cell number	J:103944
	spleen hypoplasia	J:103944
Agtpbp1^atms/Agtpbp1^atms Fas^lpr/Fas^lpr (MRL/Mp-Agtpbp1^atms Fas^lpr)	enlarged lymph nodes	J:103944
	enlarged spleen	J:103944
Agtpbp1^pcd-3J/Agtpbp1^pcd-3J (involves: BALB/cByJ)	immune system phenotype	J:231311
Agtr1a^{em1(IMPC)Rbrc}/Agtr1a^{em1(IMPC)Rbrc} (C57BL/6NJcl-Agtr1a^{em1(IMPC)Rbrc}/Rbrc)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	increased spleen weight	J:211773
Agtr1a^tm1Unc/Agtr1a^tm1Unc Agtr1b^tm1Cof/Agtr1b^tm1Cof (involves: 129P2/OlaHsd * C57BL/6)	kidney inflammation	J:137944
Agtrap^em1(IMPC)Mbp/Agtrap^em1(IMPC)Mbp (C57BL/6NCrl-Agtrap^em1(IMPC)Mbp/MbpMmucd)	increased basophil cell number	J:211773
	increased neutrophil cell number	J:211773
Agtrap^tm1Tamk/Agtrap^tm1Tamk (involves: C57BL/6N)	abnormal macrophage morphology	J:263253
Ahcy^{tm1b(EUCOMM)Hmgu}/Ahcy⁺ (C57BL/6N-Ahcy^{tm1b(EUCOMM)Hmgu}/Tcp)	increased basophil cell number	J:211773
Ahi1^tm1Jgg/Ahi1^tm1Jgg Tg(TCF/Lef1-lacZ)34Efu/0 (involves: 129S1/Sv * 129X1/SvJ)	kidney inflammation	J:154321
Ahnak^{tm1b(KOMP)Mbp}/Ahnak⁺ (C57BL/6N-Ahnak^{tm1b(KOMP)Mbp}/H)	increased large unstained cell number	J:211773
	increased monocyte cell number	J:211773
Ahnak^tm1Vtm/Ahnak^tm1Vtm (involves: 129S1/Sv * C57BL/6)	abnormal T cell activation	J:131148
	abnormal T-helper 1 physiology	J:131148
	decreased interferon-gamma secretion	J:131148
	decreased interleukin-2 secretion	J:131148
	decreased T cell proliferation	J:131148
	increased interleukin-4 secretion	J:131148
	increased susceptibility to parasitic infection	J:131148
Ahr^b-1/Ahr^b-1 (C57BL/6J)	increased inflammatory response	J:5244, J:5387
Ahr^b-1/Ahr^b-1 (involves: C57BL/6J * DBA/2J)	abnormal immune system physiology	J:5387
Ahr^tm1Bra/Ahr^tm1Bra (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal cytokine secretion	J:148870
	abnormal Langerhans cell morphology	J:148870
	abnormal Langerhans cell physiology	J:148870
	decreased spleen germinal center size	J:33827
	decreased susceptibility to type IV hypersensitivity reaction	J:148870
	enlarged spleen	J:33827
Ahr^tm1Bra/Ahr^tm1Bra (B6.129-Ahr^tm1Bra/J)	abnormal chemokine level	J:118646
	abnormal cytokine level	J:118646
	abnormal interleukin level	J:118646
	abnormal macrophage physiology	J:118646
	abnormal tumor necrosis factor level	J:118646
	increased susceptibility to bacterial infection	J:118646
	lung inflammation	J:118646, J:100359
Ahr^tm1Gonz/Ahr^tm1Gonz (involves: 129S4/SvJae * C57BL/6N)	abnormal spleen morphology	J:44690
	abnormal spleen red pulp morphology	J:44690
	bile duct inflammation	J:25048
	colitis	J:44690
	decreased spleen white pulp amount	J:44690
	enlarged spleen	J:44690
	folliculitis	J:44690
	heart inflammation	J:44690
	increased inflammatory response	J:25048
	small spleen	J:25048
	spleen hypoplasia	J:25048
Ahr^tm1Yfk/Ahr^tm1Yfk (involves: 129S/SvEv * C57BL/6J)	urinary bladder inflammation	J:179919
Ahr^tm2Bra/Ahr^tm2Bra (involves: 129/Sv * C57BL/6)	increased spleen weight	J:83597
Ahr^tm4.1Bra/Ahr^tm4.1Bra (involves: 129/Sv * C57BL/6)	enlarged spleen	J:141978
Ahsp^tm1.1Mjwe/Ahsp^tm1.1Mjwe (involves: 129S6/SvEvTac * C57BL/6)	enlarged spleen	J:94421
Ahsp^tm1Mjwe/Ahsp^tm1Mjwe (involves: 129S6/SvEvTac * C57BL/6)	enlarged spleen	J:94421
Aia1^NZB/Omr/Aia1^NZB/Omr (involves: NZB/Omr * NZC/Omr)	increased susceptibility to autoimmune hemolytic anemia	J:6517
Aia1^NZB/Omr/Aia1^NZC/Omr (involves: NZB/Omr * NZC/Omr)	increased susceptibility to autoimmune hemolytic anemia	J:6517
Aicda^em1Jaych/Aicda^em1Jaych (involves: C57BL/6J)	abnormal class switch recombination	J:305843
	abnormal lymph node cell ratio	J:305843
	abnormal Peyer's patch germinal center morphology	J:305843
	abnormal splenic cell ratio	J:305843
	increased IgM level	J:305843
Aicda^m1Btlr/Aicda^m1Btlr (C57BL/6J-Aicda^m1Btlr)	abnormal humoral immune response	J:265155
	decreased IgE level	J:265155
	increased IgM level	J:265155
Aicda^m2Btlr/Aicda^m2Btlr (C57BL/6J-Aicda^m2Btlr)	abnormal humoral immune response	J:265156
	decreased IgE level	J:265156
	increased IgM level	J:265156
Aicda^tm1(cre)Mnz/Aicda⁺ Gt(ROSA)26Sor^{tm2(sb11)Njen}/Gt(ROSA)26Sor⁺ TgTn(sb-T2/Onc2)6070Njen/0 (involves: 129 * 129P2/OlaHsd * C57BL/6 * C57BL/6J)	increased T cell derived lymphoma incidence	J:153656
Aicda^tm1(cre)Mnz/Aicda⁺ Igh^tm3Mnz/Igh⁺ Myc^tm37Mnz/Myc⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell physiology	J:145691
Aicda^tm1(cre)Mnz/Aicda⁺ Igh^tm3Mnz/Igh⁺ Myc^tm39Mnz/Myc⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell physiology	J:145691
Aicda^tm1.1Fwa/Aicda^tm1.1Fwa (involves: 129S6/SvEvTac)	abnormal class switch recombination	J:209271
	abnormal somatic hypermutation frequency	J:209271
	immune system phenotype	J:209271
Aicda^{tm1b(EUCOMM)Hmgu}/Aicda^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Aicda^{tm1b(EUCOMM)Hmgu}/Wtsi)	decreased follicular B cell number	J:211773
	decreased late germinal center B cell number	J:211773
	increased early germinal center B cell number	J:211773
	increased germinal center B cell number	J:211773
	increased leukocyte cell number	J:211773
Aicda^tm1Hon/Aicda⁺ (involves: C57BL/6 * CBA)	abnormal class switch recombination	J:136224, J:141427
	abnormal somatic hypermutation frequency	J:141427
	immune system phenotype	J:136224
Aicda^tm1Hon/Aicda^tm1.1Fwa (involves: 129S/SvEv * C57BL/6NCrlj * CBA/JNCrlj)	abnormal class switch recombination	J:209271
	immune system phenotype	J:209271
Aicda^tm1Hon/Aicda^tm1Hon (involves: C57BL/6 * CBA)	abnormal class switch recombination	J:141427, J:73659, J:120658
	abnormal somatic hypermutation frequency	J:136224, J:141427
	decreased IgA level	J:169227
	decreased IgG1 level	J:169227, J:73659
	decreased IgG2a level	J:73659
	decreased IgG2b level	J:169227
	decreased IgG3 level	J:169227
	decreased IgG level	J:169227
	increased germinal center B cell number	J:169227
	increased IgM level	J:169227, J:73659
	increased susceptibility to bacterial infection induced morbidity/mortality	J:169227
Aicda^tm1Hon/Aicda^tm1Hon Bcl6^tm1.1Jwan/Bcl6^tm1.1Jwan (involves: 129S6/SvEvTac * C57BL/6NCrlj * CBA/JNCrlj)	abnormal somatic hypermutation frequency	J:190534
Aicda^tm1Hon/Aicda^tm1Hon Blm^tm3Brd/Blm^tm3Brd Igh^tm4.1Mnz/Igh⁺ Trp53bp1^tm1Jc/Trp53bp1^tm1Jc (involves: 129S7/SvEvBrd * C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj)	immune system phenotype	J:194603
Aicda^tm1Hon/Aicda^tm1Hon Exo1^tm1Wed/Exo1^tm1Wed Igh^tm4.1Mnz/Igh⁺ (involves: C57BL/6 * CBA/JNCrlj * SJL)	abnormal immunoglobulin heavy chain V(D)J recombination	J:194603
Aicda^tm1Hon/Aicda^tm1Hon Exo1^tm1Wed/Exo1^tm1Wed Igh^tm4.1Mnz/Igh⁺ Trp53bp1^tm1Jc/Trp53bp1^tm1Jc (involves: 129 * C57BL/6 * CBA/JNCrlj * SJL)	abnormal immunoglobulin heavy chain V(D)J recombination	J:194603
Aicda^tm1Hon/Aicda^tm1Hon Igh^tm3Mnz/Igh^tm4.1Mnz Trp53bp1^tm1Jc/Trp53bp1^tm1Jc (involves: 129 * C57BL/6 * CBA)	abnormal class switch recombination	J:159173
Aicda^tm1Hon/Aicda^tm1Hon Igh^tm4.1Mnz/Igh⁺ (involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj)	abnormal immunoglobulin heavy chain V(D)J recombination	J:194603
Aicda^tm1Hon/Aicda^tm1Hon Igh^tm4.1Mnz/Igh⁺ Trp53bp1^tm1Jc/Trp53bp1^tm1Jc (involves: 129 * C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj)	abnormal immunoglobulin heavy chain V(D)J recombination	J:194603
Aicda^tm1Hon/Aicda^tm1Hon Ighm^{tm1.1(IGH-2)Cog}/Ighm⁺ (involves: 129P2/OlaHsd * C57BL/6 * CBA * FVB/N)	abnormal B cell physiology	J:157575
Aicda^tm1Hon/Aicda^tm1Hon Tg(Igkv3-5-MYC)#Plbe/0 (involves: C57BL/6 C57BL/6NCrlj * CBA/JNCrlj)	immune system phenotype	J:131912
Aicda^tm1Hon/Aicda^tm2Mnz (involves: C57BL/6 * CBA)	immune system phenotype	J:136224
Aicda^tm1Hon/Aicda^tm3Mnz (involves: C57BL/6 * CBA)	abnormal class switch recombination	J:141427
Aicda^tm1Hon/Aicda^tm3Mnz (involves: C57BL/6 * CBA)	abnormal somatic hypermutation frequency	J:141427
Aicda^tm1Hon/Aicda^tm4Mnz (involves: C57BL/6 * CBA)	abnormal class switch recombination	J:141427
Aicda^tm1Hon/Aicda^tm4Mnz (involves: C57BL/6 * CBA)	abnormal somatic hypermutation frequency	J:141427
Aicda^tm2.1Hon/Aicda^tm2.1Hon (C57BL/6-Aicda^tm2.1Hon)	abnormal somatic hypermutation frequency	J:169227
	decreased IgG1 level	J:169227
	immune system phenotype	J:169227
	increased germinal center B cell number	J:169227
	increased susceptibility to bacterial infection	J:169227
	increased susceptibility to bacterial infection induced morbidity/mortality	J:169227
Aicda^tm2.1Hon/Aicda^tm2.1Hon (involves: BALB/c * C57BL/6)	increased germinal center B cell number	J:169227
Aicda^tm2Mnz/Aicda^tm2Mnz (B6.Cg-Aicda^tm2Mnz)	immune system phenotype	J:136224
Aicda^tm3.1Mnz/Aicda^tm3.1Mnz (involves: C57BL/6)	abnormal class switch recombination	J:147109
Aicda^tm3.1Mnz/Aicda^tm3.1Mnz (involves: C57BL/6)	abnormal somatic hypermutation frequency	J:147109
Aicda^tm3Mnz/Aicda⁺ (involves: C57BL/6 * CBA)	abnormal class switch recombination	J:141427
Aicda^tm3Mnz/Aicda⁺ (involves: C57BL/6 * CBA)	abnormal somatic hypermutation frequency	J:141427
Aicda^tm4.1Mnz/Aicda^tm4.1Mnz (involves: C57BL/6)	abnormal class switch recombination	J:147109
Aicda^tm4.1Mnz/Aicda^tm4.1Mnz (involves: C57BL/6)	abnormal somatic hypermutation frequency	J:147109
Aicda^tm4Mnz/Aicda⁺ (involves: C57BL/6 * CBA)	abnormal class switch recombination	J:141427
Aicda^tm4Mnz/Aicda⁺ (involves: C57BL/6 * CBA)	abnormal somatic hypermutation frequency	J:141427
Aif1^tm1Nsib/Aif1^tm1Nsib (involves: 129S/SvEv * C57BL/6)	decreased spleen weight	J:204462
Aif1^tm1Nsib/Aif1^tm1Nsib (involves: 129S/SvEv * C57BL/6)	decreased susceptibility to induced arthritis	J:204462
Aif1l^{tm1b(EUCOMM)Wtsi}/Aif1l^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Aif1l^{tm1b(EUCOMM)Wtsi}/Bay)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	increased spleen weight	J:211773
	small thymus	J:211773
Aim2^{em1(IMPC)Ccpcz}/Aim2^{em1(IMPC)Ccpcz} (C57BL/6N-Aim2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Aim2^{Gt(CSG445)Byg}/Aim2^{Gt(CSG445)Byg} (involves: 129P2/OlaHsd * C57BL/6)	abnormal macrophage physiology	J:158969
	decreased circulating interleukin-18 level	J:158969
	decreased interleukin-1 beta secretion	J:158969
	decreased interleukin-18 secretion	J:158969
	decreased NK cell number	J:158969
	increased interferon-beta secretion	J:158969
	increased susceptibility to bacterial infection	J:158969
	increased susceptibility to Herpesvirales infection	J:158969
	increased susceptibility to Poxviridae infection	J:158969
Aim2^{Gt(CSG445)Byg}/Aim2^{Gt(CSG445)Byg} (involves: 129P2/OlaHsd)	immune system phenotype	J:173245
Aim2^{Gt(CSG445)Byg}/Aim2^{Gt(CSG445)Byg} (B6.129P2-Aim2^{Gt(CSG445)Byg}/J)	abnormal interferon secretion	J:234263
	decreased interleukin-1 beta secretion	J:234263
	decreased macrophage apoptosis	J:234263
Aim2^tm1.1Vmd/Aim2^tm1.1Vmd (C57BL/6-Aim2^tm1.1Vmd)	abnormal cytokine secretion	J:160545
	abnormal macrophage physiology	J:160545
	decreased interleukin-1 beta secretion	J:160545
	decreased interleukin-18 secretion	J:160545
	increased interferon-beta secretion	J:160545
	increased susceptibility to bacterial infection	J:160545
	increased tumor necrosis factor secretion	J:160545
Aim2^tm1.2Arte/Aim2^tm1.2Arte Dnase2a^tm1Osa/Dnase2a^tm1Osa Ifnar1^tm1Agt/Ifnar1^tm1Agt (involves: 129 * BALB/c * C57BL/6 * C57BL/6J)	abnormal spleen morphology	J:238323
	enlarged spleen	J:238323
	increased autoantibody level	J:238323
	increased circulating interleukin-10 level	J:238323
	increased circulating tumor necrosis factor level	J:238323
	increased spleen weight	J:238323
	rheumatoid arthritis	J:238323
Aim2^tm1Ktak/Aim2^tm1Ktak (involves: 129S4/SvJae * C57BL/6)	decreased circulating interleukin-18 level	J:188013
	decreased interferon-gamma secretion	J:188013
	decreased interleukin-1 beta secretion	J:188013
	decreased interleukin-18 secretion	J:188013
	increased susceptibility to bacterial infection	J:188013
	increased susceptibility to bacterial infection induced morbidity/mortality	J:188013
Aimp1^em1(IMPC)Tcp/Aimp1^em1(IMPC)Tcp (C57BL/6NCrl-Aimp1^em1(IMPC)Tcp/Tcp)	enlarged spleen	J:211773
Aimp1^{Gt(OST58507)Lex}/Aimp1^{Gt(OST58507)Lex} (involves: 129S5/SvEvBrd * C57BL/6)	decreased inflammatory response	J:95974
Aire^{tm1.1(cre)Ghr}/Aire^{tm1.1(cre)Ghr} (Not Specified)	decreased dendritic cell number	J:176844
	decreased regulatory T cell number	J:176844
	increased dendritic cell number	J:176844
Aire^{tm1.1(NCOM)Mfgc}/Aire^{tm1.1(NCOM)Mfgc} (C57BL/6N-Aire^{tm1.1(NCOM)Mfgc}/Tcp)	increased monocyte cell number	J:211773
Aire^tm1.1Doi/Aire^tm1.1Doi (involves: 129S2/SvPas * C57BL/6)	abnormal thymus medulla morphology	J:83422
	increased autoantibody level	J:119475
	increased susceptibility to autoimmune disorder	J:83422
	increased T cell number	J:83422
	stomach inflammation	J:119475
Aire^tm1.1Doi/Aire^tm1.1Doi (B6.129S2-Aire^tm1.1Doi/Doi)	increased autoantibody level	J:107432
	increased incidence of corneal inflammation	J:107432
	lung inflammation	J:107432
	salivary gland inflammation	J:107432
	stomach inflammation	J:107432
Aire^tm1.1Doi/Aire^tm1.1Doi (NOD.129S2(B6)-Aire^tm1.1Doi/Doi)	increased autoantibody level	J:107432
	increased incidence of corneal inflammation	J:107432
	liver inflammation	J:107432
	lung inflammation	J:107432
	ovary inflammation	J:107432
	pancreas inflammation	J:107432
	prostate gland inflammation	J:107432
	salivary gland inflammation	J:107432
	stomach inflammation	J:107432
	thyroid gland inflammation	J:107432
Aire^tm1.1Doi/Aire^tm1.1Doi (C.129S2-Aire^tm1.1Doi/Doi)	increased autoantibody level	J:107432
	increased incidence of corneal inflammation	J:107432
	liver inflammation	J:107432
	lung inflammation	J:107432
	ovary inflammation	J:107432
	prostate gland inflammation	J:107432
	salivary gland inflammation	J:107432
	stomach inflammation	J:107432
Aire^tm1.1Doi/Aire^tm1.1Doi (SJL.129S2-Aire^tm1.1Doi/Doi)	increased autoantibody level	J:107432
	liver inflammation	J:107432
	lung inflammation	J:107432
	ovary inflammation	J:107432
	pancreas inflammation	J:107432
	prostate gland inflammation	J:107432
	salivary gland inflammation	J:107432
	stomach inflammation	J:107432
Aire^tm1.1Doi/Aire^tm1.1Doi (involves: 129S2/SvPas * C57BL/6 * NOD)	liver inflammation	J:107432
	lung inflammation	J:107432
	pancreas inflammation	J:107432
	salivary gland inflammation	J:107432
	stomach inflammation	J:107432
Aire^tm1.1Doi/Aire^tm1.1Doi (NOD.129S2-Aire^tm1.1Doi)	abnormal CD4-positive, alpha-beta T cell physiology	J:135154
	chronic pancreas inflammation	J:135154
	insulitis	J:135154
	lacrimal gland inflammation	J:135154
	lung inflammation	J:135154
	salivary gland inflammation	J:135154
	stomach inflammation	J:135154
	thyroid gland inflammation	J:135154
	uveitis	J:135154
Aire^tm1.1Doi/Aire^tm1.1Doi H2^b/H2^b (NOD.Cg-Aire^tm1.1Doi H2^b/Doi)	stomach inflammation	J:107432
Aire^tm1.1Doi/Aire^tm1.1Doi Idd3^C57BL/6/Idd3^C57BL/6 Idd5^C57BL/10SnJ/Idd5^C57BL/10SnJ (NOD.Cg-Idd3^C57BL/6 Idd5^C57BL/10SnJ Aire^tm1.1Doi/Doi)	stomach inflammation	J:107432
Aire^tm1.1Doi/Aire^tm1.1Doi Il1r1^tm1Imx/Il1r1⁺ (involves: 129S2/SvPas * 129S7/SvEvBrd * NOD)	keratoconjunctivitis	J:163691
	lacrimal gland inflammation	J:163691
Aire^tm1.1Doi/Aire^tm1.1Doi Il1r1^tm1Imx/Il1r1^tm1Imx (involves: 129S2/SvPas * 129S7/SvEvBrd * NOD)	keratoconjunctivitis	J:163691
	lacrimal gland inflammation	J:163691
Aire^tm1.1Doi/Aire^tm1.1Doi Tg(Ins2-TFRC/OVA)296Wehi/0 Tg(TcraTcrb)425Cbn/0 (involves: 129P2/OlaHsd * C57BL/6)	abnormal T cell differentiation	J:135154
	decreased CD4-positive, alpha-beta T cell number	J:135154
Aire^tm1Mand/Aire⁺ (involves: 129P2/OlaHsd * C57BL/6)	lacrimal gland inflammation	J:135154
Aire^tm1Mand/Aire⁺ (involves: 129P2/OlaHsd * C57BL/6)	salivary gland inflammation	J:135154
Aire^tm1Mand/Aire⁺ (NOD.129P2-Aire^tm1Mand)	abnormal CD4-positive, alpha-beta T cell physiology	J:135154, J:188686
	abnormal chemokine level	J:188686
	chronic pancreas inflammation	J:135154
	CNS inflammation	J:135154
	increased autoantibody level	J:188686
	increased CXCL10 level	J:188686
	increased inflammatory response	J:188686
	increased susceptibility to autoimmune diabetes	J:135154, J:188686
	insulitis	J:135154
	lacrimal gland inflammation	J:135154
	salivary gland inflammation	J:135154
	thyroid gland inflammation	J:135154
Aire^tm1Mand/Aire⁺ Tg(Ins2-TFRC/OVA)296Wehi/0 Tg(TcraTcrb)425Cbn/0 (involves: 129P2/OlaHsd * C57BL/6)	abnormal T cell differentiation	J:135154
Aire^tm1Mand/Aire^tm1.1Doi (NOD.129-Aire^tm1Mand/Aire^tm1.1Doi)	abnormal CD4-positive, alpha-beta T cell physiology	J:135154
	chronic pancreas inflammation	J:135154
	insulitis	J:135154
	lacrimal gland inflammation	J:135154
	lung inflammation	J:135154
	salivary gland inflammation	J:135154
	stomach inflammation	J:135154
	thyroid gland inflammation	J:135154
	uveitis	J:135154
Aire^tm1Mand/Aire^tm1Mand (involves: 129P2/OlaHsd * C57BL/6)	eye inflammation	J:135154
	lacrimal gland inflammation	J:135154
	salivary gland inflammation	J:135154
Aire^tm1Mmat/Aire^tm1Mmat (involves: C57BL/6 * CBA)	autoimmune response	J:96580
	lacrimal gland inflammation	J:96580
	pancreas inflammation	J:96580
	parotid gland inflammation	J:96580
	stomach inflammation	J:96580
	submandibular gland inflammation	J:96580
Aire^tm1Mmat/Aire^tm1Mmat (C.Cg-Aire^tm1Mmat)	increased autoantibody level	J:96580
Aire^tm1Mmat/Aire^tm1Mmat (C.Cg-Aire^tm1Mmat)	stomach inflammation	J:96580
Aire^tm1Mmat/Aire^tm1Mmat (B6.Cg-Aire^tm1Mmat)	autoimmune response	J:96580
Aire^tm1Mmat/Aire^tm1Mmat (B6.Cg-Aire^tm1Mmat)	salivary gland inflammation	J:96580
Aire^tm1Mmat/Aire^tm2Mmat (involves: C57BL/6 * CBA)	abnormal thymus morphology	J:141379
Aire^tm1Mmat/Aire^tm2Mmat (involves: C57BL/6 * CBA)	autoimmune response	J:141379
Aire^tm1Mmat/Aire^tm2Mmat Tg(TcraTcrb)425Cbn/? (involves: BALB/c * C57BL/6 * CBA)	abnormal thymus morphology	J:141379
	immune system phenotype	J:141379
Aire^tm1Pltn/Aire^tm1Pltn (involves: 129S4/SvJae * C57BL/6)	abnormal T cell morphology	J:77873
	increased autoantibody level	J:77873
	increased T cell proliferation	J:77873
	liver inflammation	J:77873
	thymus atrophy	J:77873
Aire^tm1Pltn/Aire^tm1Pltn (B6.129S4-Aire^tm1Pltn)	abnormal metallophilic macrophage morphology	J:115076
	abnormal myelopoiesis	J:115076
	abnormal spleen marginal zone morphology	J:115076
	decreased follicular B cell number	J:115076
	enlarged spleen	J:115076
	immune system phenotype	J:115076
	increased B cell number	J:115076
	increased marginal zone B cell number	J:115076
	increased monocyte cell number	J:115076
	increased spleen weight	J:115076
	liver inflammation	J:115076
Aire^tm1Ptsn/Aire^tm1Ptsn (C57BL/6-Aire^tm1Ptsn)	abnormal T cell activation	J:145910
	abnormal thymus medulla morphology	J:145910
	increased autoantibody level	J:145910
	parotid gland inflammation	J:145910
	sublingual gland inflammation	J:145910
	uveitis	J:145910
	vitreous body inflammation	J:145910
Aire^tm1Ptsn/Aire^tm1Ptsn (C.B6-Aire^tm1Ptsn)	abnormal adaptive immunity	J:174653
	abnormal cytokine level	J:174653
	abnormal regulatory T cell physiology	J:174653
	abnormal T-helper 1 physiology	J:174653
	abnormal T-helper 17 cell physiology	J:174653
	decreased susceptibility to fungal infection	J:174653
	increased interleukin-6 secretion	J:174653
	increased interleukin-12 secretion	J:174653
	increased interleukin-23 secretion	J:174653
	increased susceptibility to autoimmune disorder	J:174653
	increased susceptibility to fungal infection	J:174653
	increased tumor necrosis factor secretion	J:174653
	stomach inflammation	J:174653
Aire^tm2Mmat/Aire^tm2Mmat (involves: C57BL/6 * CBA)	abnormal thymus morphology	J:141379
	abnormal thymus physiology	J:141379
	absent Hassall's corpuscle	J:141379
	autoimmune response	J:141379
Ajuba^em1(IMPC)H/Ajuba^em1(IMPC)H (C57BL/6N-Ajuba^em1(IMPC)H/H)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
	increased spleen weight	J:211773
Ak7^{em1(IMPC)Ccpcz}/Ak7⁺ (C57BL/6NCrl-Ak7^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Ak7^{Gt(OST434404)Lex}/Ak7^{Gt(OST434404)Lex} (involves: 129S5/SvEvBrd * C57BL/6J)	rhinosinusitis	J:185566
Ak7^{Tg(tetO-Hmox1)67Sami}/Ak7^{Tg(tetO-Hmox1)67Sami} (FVB/N-Ak7^{Tg(tetO-Hmox1)67Sami})	respiratory system inflammation	J:186062
	rhinitis	J:186062
Akap9^{tm1a(KOMP)Wtsi}/Akap9⁺ (involves: C57BL/6 * C57BL/6N)	decreased B cell number	J:213427
	decreased mature B cell number	J:213427
	increased CD4-positive, alpha-beta T cell number	J:213427
	increased CD8-positive, alpha-beta T cell number	J:213427
	increased T cell number	J:213427
Akap11^{tm1b(EUCOMM)Hmgu}/Akap11^{tm1b(EUCOMM)Hmgu} (B6N(Cg)-Akap11^{tm1b(EUCOMM)Hmgu}/J)	decreased leukocyte cell number	J:211773
Akap12^tm1Ihg/Akap12^tm1Ihg (involves: 129S4/SvJae * C57BL/6)	increased spleen red pulp amount	J:138882
	liver inflammation	J:138882
Akap13^em1(IMPC)Mbp/Akap13^em1(IMPC)Mbp (C57BL/6N-Akap13^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
Akap13^tm1Segj/Akap13⁺ (involves: 129)	abnormal lymphocyte physiology	J:111574
	abnormal splenocyte physiology	J:181088
	decreased B cell number	J:181088
	decreased IgG1 level	J:181088
	decreased spleen B cell follicle size	J:181088
	decreased spleen weight	J:181088
	decreased splenocyte number	J:181088
	decreased transitional stage T2 B cell number	J:181088
	increased transitional stage T1 B cell number	J:181088
	small spleen	J:181088
	spleen hypoplasia	J:181088
Akip1^em1Cya/Akip1^em1Cya (C57BL/6N-Akip1^em1Cya)	decreased susceptibility to endotoxin shock	J:326919
Akip1^em1Cya/Akip1^em1Cya (C57BL/6N-Akip1^em1Cya)	decreased susceptibility to viral infection	J:326919
Akna^tm1Mak/Akna^tm1Mak (B6.129P2-Akna^tm1Mak)	alveolitis	J:233952
	increased acute inflammation	J:233952
	increased neutrophil cell number	J:233952
	increased susceptibility to fungal infection	J:233952
	lung inflammation	J:233952
Akna^tm2Mak/Akna^tm2Mak (B6.129-Akna^tm2Mak)	increased susceptibility to fungal infection	J:233952
Akr1a1^{Gt(OST222400)Lex}/Akr1a1^{Gt(OST222400)Lex} (B6.129S5-Akr1a1^{Gt(OST222400)Lex})	abnormal osteoclast physiology	J:164548
	increased osteoclast cell number	J:164548
Akr1b8^tm1Dgen/Akr1b8^tm1Dgen (Not Specified)	abnormal interferon level	J:301852
	abnormal interleukin level	J:301852
	increased susceptibility to induced colitis	J:301852
Akr1c21^em1Wany/Akr1c21^em1Wany (involves: C57BL/6)	increased acute inflammation	J:322353
	increased interleukin level	J:322353
	lung inflammation	J:322353
Akt1^tm1Nhy/Akt1^tm1Nhy (involves: 129/Sv * C57BL/6)	abnormal thymus morphology	J:71404
Akt1^tm1Pnt/Akt1^tm1Pnt Akt2^tm1.1Mbb/Akt2^tm1.1Mbb Akt3^tm1Mbb/Akt3^tm1Mbb Tg(Lck-cre)1Cwi/0 (involves: 129P2/OlaHsd)	arrested T cell differentiation	J:135903
	decreased double-positive T cell number	J:135903
	increased double-negative T cell number	J:135903
	increased T cell apoptosis	J:135903
	thymus hypoplasia	J:135903
Akt1^tm1Pnt/Akt1^tm1Pnt Akt2^tm1.1Mbb/Akt2^tm1.1Mbb Tg(Lck-cre)1Cwi/0 (involves: 129P2/OlaHsd)	arrested T cell differentiation	J:135903
	decreased double-positive T cell number	J:135903
	increased double-negative T cell number	J:135903
	increased T cell apoptosis	J:135903
	thymus hypoplasia	J:135903
Akt1^tm1Pnt/Akt1^tm1Pnt Akt3^tm1Mbb/Akt3^tm1Mbb Tg(Lck-cre)1Cwi/0 (Not Specified)	decreased double-positive T cell number	J:135903
	thymus hypoplasia	J:135903
Akt2^tm1.1Mbb/Akt2^tm1.1Mbb (involves: 129P2/OlaHsd)	immune system phenotype	J:135903
Akt3^tm1Mbb/Akt3^tm1Mbb (Not Specified)	immune system phenotype	J:135903
Aktip^{tm1a(EUCOMM)Hmgu}/Aktip^{tm1a(EUCOMM)Hmgu} Trp53^tm1Tyj/Trp53^tm1Tyj (involves: 129S2/SvPas * C57BL/6N)	kidney inflammation	J:276210
	liver inflammation	J:276210
	lung inflammation	J:276210
	peritoneal inflammation	J:276210
Alad^em1(IMPC)Tcp/Alad⁺ (C57BL/6NCrl-Alad^em1(IMPC)Tcp/Cmmr)	enlarged lymph nodes	J:211773
	enlarged thymus	J:211773
Alan2^B10.O20/Dem/Alan2^B10.O20/Dem (involves: B10.O20/Dem * O20/A)	abnormal immune system physiology	J:67657
Alan2^B10.O20/Dem/Alan2^O20/A (involves: B10.O20/Dem * O20/A)	abnormal immune system physiology	J:67657
Aldh1a2^tm1Dll/Aldh1a2^tm1Ipc (involves: CD-1)	athymia	J:81969
Aldh1a2^tm1Dll/Aldh1a2^tm1Ipc (involves: CD-1)	thymus hypoplasia	J:81969
Aldh1l2^{em1(IMPC)Kmpc}/Aldh1l2^{em1(IMPC)Kmpc} (C57BL/6NTac-Aldh1l2^{em1(IMPC)Kmpc}/Kmpc)	increased B-1a cell number	J:211773
	increased CD8-positive, CD25-positive alpha-beta T cell number	J:211773
Aldh1l2^{tm2e(KOMP)Wtsi}/Aldh1l2^{tm2e(KOMP)Wtsi} (involves: C57BL/6 * C57BL/6N)	immune system phenotype	J:299012
Aldh2^tm1.1Mak/Aldh2⁺ (involves: 129S6/SvEvTac * C57BL/6J)	decreased leukocyte cell number	J:223796
Aldh2^tm1.1Mak/Aldh2^tm1.1Mak (involves: 129S6/SvEvTac * C57BL/6J)	decreased leukocyte cell number	J:223796
Aldh2^{tm1a(EUCOMM)Wtsi}/Aldh2^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Aldh2^{tm1a(EUCOMM)Wtsi}/Ieg)	decreased CD4-positive, alpha-beta T cell number	J:165965
	decreased CD8-positive, alpha-beta T cell number	J:165965
	decreased T cell number	J:165965
Aldh2^{tm1a(EUCOMM)Wtsi}/Aldh2^{tm1a(EUCOMM)Wtsi} Fancd2^tm1Hou/Fancd2^tm1Hou (involves: 129S4/SvJae * C57BL/6J * C57BL/6N)	abnormal lymphopoiesis	J:193232
	abnormal spleen morphology	J:188123
	abnormal thymus morphology	J:188123
	decreased leukocyte cell number	J:188123
	enlarged spleen	J:193232
	increased CD8-positive, alpha-beta T cell number	J:193232
	increased double-positive T cell number	J:193232
	increased T cell derived lymphoma incidence	J:193232
Aldh18a1^{tm1a(KOMP)Wtsi}/Aldh18a1⁺ (C57BL/6N-Aldh18a1^{tm1a(KOMP)Wtsi}/Wtsi)	skin inflammation	J:232539
Aldoa^{tm1.1(KOMP)Wtsi}/Aldoa⁺ (C57BL/6N-Aldoa^{tm1.1(KOMP)Wtsi}/Bay)	decreased leukocyte cell number	J:211773
Aldob^{tm1(KOMP)Vlcg}/Aldob^{tm1(KOMP)Vlcg} (C57BL/6NTac-Aldob^{tm1(KOMP)Vlcg})	liver inflammation	J:220330
Alg1^{tm1b(KOMP)Wtsi}/Alg1⁺ (C57BL/6N-Alg1^{tm1b(KOMP)Wtsi}/Nju)	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
Alg6^em1(IMPC)Tcp/Alg6⁺ (C57BL/6N-Alg6^em1(IMPC)Tcp/Cmmr)	enlarged lymph nodes	J:211773
Alg13^{tm1a(KOMP)Wtsi}/Alg13^{tm1a(KOMP)Wtsi} (C57BL/6N-Alg13^{tm1a(KOMP)Wtsi}/Wtsi)	increased leukocyte cell number	J:211773
Alkbh1^{tm1b(EUCOMM)Hmgu}/Alkbh1⁺ (C57BL/6N-Alkbh1^{tm1b(EUCOMM)Hmgu}/Ieg)	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
Alms1^Gt(XH152)Byg/Alms1^Gt(XH152)Byg (involves: 129P2/OlaHsd * C57BL/6J)	tubulointerstitial nephritis	J:100403
Alo1/Alo1 (involves: C3H/HeJ * C57BL/6J)	abnormal lymph node morphology	J:109802
	enlarged lymph nodes	J:109802
	enlarged spleen	J:109802
	lymph node necrosis	J:109802
Alo1/Alo1⁺ (involves: C3H/HeJ * C57BL/6J)	abnormal lymph node morphology	J:109802
	enlarged lymph nodes	J:109802
	enlarged spleen	J:109802
	lymph node necrosis	J:109802
Alo2/Alo2 (involves: C3H/HeJ * C57BL/6J)	abnormal lymph node morphology	J:109802
	enlarged lymph nodes	J:109802
	enlarged spleen	J:109802
	lymph node necrosis	J:109802
Alo2/Alo2⁺ (involves: C3H/HeJ * C57BL/6J)	abnormal lymph node morphology	J:109802
	enlarged lymph nodes	J:109802
	enlarged spleen	J:109802
	lymph node necrosis	J:109802
Alox5^{em1(IMPC)Ccpcz}/Alox5^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Alox5^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Alox5^tm1Bhk/Alox5^tm1Bhk (either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129P2/OlaHsd * C57BL/6 * DBA/2))	abnormal inflammatory response	J:68714
	abnormal neutrophil physiology	J:68714
	decreased acute inflammation	J:68714
	decreased susceptibility to type I hypersensitivity reaction	J:68714
	impaired neutrophil chemotaxis	J:68714
	impaired neutrophil recruitment	J:68714
Alox5^tm1Fun/Alox5^tm1Fun (involves: 129S2/SvPas * C57BL/6)	abnormal immune system physiology	J:21372
	decreased inflammatory response	J:21372, J:75371
	immune system phenotype	J:21372
	small spleen	J:21372
Alox5^tm1Fun/Alox5^tm1Fun (B6.129S2-Alox5^tm1Fun)	immune system phenotype	J:89268
Alox5^tm1Fun/Alox5^tm1Fun (B6.129S2-Alox5^tm1Fun/J)	decreased susceptibility to experimental autoimmune uveoretinitis	J:108446
Alox5ap^tm1Bhk/Alox5ap^tm1Bhk (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	decreased susceptibility to type I hypersensitivity reaction	J:39229
Alox5ap^tm1Bhk/Alox5ap^tm1Bhk (involves: 129P2/OlaHsd * 129S/SvEv)	decreased acute inflammation	J:39229
	impaired neutrophil recruitment	J:39229
Alox5ap^tm1Jdm/Alox5ap⁺ (DBA/1LacJ-Alox5ap^tm1Jdm)	decreased susceptibility to induced arthritis	J:100736
Alox5ap^tm1Jdm/Alox5ap⁺ (DBA/1LacJ-Alox5ap^tm1Jdm)	immune system phenotype	J:100736
Alox5ap^tm1Jdm/Alox5ap^tm1Jdm (DBA/1LacJ-Alox5ap^tm1Jdm)	decreased inflammatory response	J:100736
	decreased susceptibility to induced arthritis	J:100736
	immune system phenotype	J:100736
Alox8^{tm1a(KOMP)Wtsi}/Alox8^{tm1a(KOMP)Wtsi} (C57BL/6N-Alox8^{tm1a(KOMP)Wtsi}/MbpMmucd)	abnormal susceptibility to Orthomyxoviridae infection	J:277623
	increased interleukin-6 secretion	J:277623
	lung inflammation	J:277623
Alox12^tm1Fun/Alox12^tm1Fun (involves: 129S2/SvPas * C57BL/6)	immune system phenotype	J:55741
Alox15^tm1Fun/Alox15^tm1Fun (involves: 129/Sv * C57BL/6)	abnormal immune system physiology	J:44778
Alox15^tm1Fun/Alox15^tm1Fun (B6.129S2-Alox15^tm1Fun/J)	abnormal lymph node morphology	J:119405
	abnormal myelopoiesis	J:119405
	abnormal spleen red pulp morphology	J:119405
	abnormal spleen white pulp morphology	J:119405
	decreased spleen B cell follicle number	J:119405
	dermatitis	J:119405
	increased basophil cell number	J:119405
	increased leukocyte cell number	J:119405
	increased spleen weight	J:119405
	intermingled spleen red and white pulp	J:119405
Alox15^tm1Fun/Alox15^tm1Fun (B6.129S2-Alox15^tm1Fun)	immune system phenotype	J:197334
Aloxe3^em1(IMPC)Mbp/Aloxe3⁺ (C57BL/6N-Aloxe3^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	small spleen	J:211773
Alpk1^em1Dlka/Alpk1^em1Dlka Crb1^rd8/Crb1^rd8 (involves: C57BL/6N)	abnormal circulating chemokine level	J:344848
	immune system phenotype	J:344848
	increased circulating CXCL10 level	J:344848
Alpl^{em1(IMPC)Ccpcz}/Alpl⁺ (C57BL/6NCrl-Alpl^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
Alpl^tm1Jlm/Alpl^tm1Jlm (either: (involves: 129S2/SvPas) or (involves: 129S2/SvPas * C57BL/6J))	abnormal spleen morphology	J:39015
	abnormal thymus cortex morphology	J:39015
	decreased leukocyte cell number	J:39015
	pale spleen	J:39015
	small spleen	J:39015
Als2^tm1Jei/Als2^tm1Jei (involves: 129P2/OlaHsd * C57BL/6J)	CNS inflammation	J:104446
Altre^tm1.1Hbgl/Altre^tm1.1Hbgl Foxp3^{tm4(YFP/icre)Ayr}/Y (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	abnormal regulatory T cell physiology	J:342907
	decreased regulatory T cell number	J:342907
	decreased T cell number	J:342907
	increased CD8-positive, alpha-beta T cell number	J:342907
	increased interleukin-17 secretion	J:342907
	increased memory T cell number	J:342907
	increased regulatory T cell apoptosis	J:342907
amd^A/J/amd^A/J (involves: A/J * C57BL/6J)	myocarditis	J:2843, J:11025
amd^DBA/2J/amd^DBA/2J (B10.D2-H8^b/(57N)SnJ)	myocarditis	J:11025
Amdhd1^{tm2b(EUCOMM)Hmgu}/Amdhd1^{tm2b(EUCOMM)Hmgu} (C57BL/6N-Amdhd1^{tm2b(EUCOMM)Hmgu}/BayMmucd)	increased lymphocyte cell number	J:211773
Amelx^{em1(IMPC)Ccpcz}/Y (C57BL/6N-Amelx^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
	small spleen	J:211773
Amelx^{em1(IMPC)Ccpcz}/Amelx⁺ (C57BL/6N-Amelx^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	decreased lymphocyte cell number	J:211773
	enlarged lymph nodes	J:211773
	increased eosinophil cell number	J:211773
Amelx^{em1(IMPC)Ccpcz}/Amelx^{em1(IMPC)Ccpcz} (C57BL/6N-Amelx^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Amer1^tm1.2Nbar/Y (involves: 129S4/SvJae * C57BL/6 * CD-1 * SJL)	spleen hypoplasia	J:173242
Amfr^{Gt(IST12797A11)Tigm}/Amfr^{Gt(IST12797A11)Tigm} (C57BL/6-Amfr^{Gt(IST12797A11)Tigm})	liver inflammation	J:221247
Amhr2^tm3(cre)Bhr/Amhr2⁺ Pten^tm1Hwu/Pten^tm1Hwu (involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6)	decreased uterine NK cell number	J:170203
Amotl2^em1(IMPC)Mbp/Amotl2^em1(IMPC)Mbp (C57BL/6NCrl-Amotl2^em1(IMPC)Mbp/MbpMmucd)	increased monocyte cell number	J:211773
Ampd1^{tm1b(KOMP)Wtsi}/Ampd1⁺ (C57BL/6N-Ampd1^{tm1b(KOMP)Wtsi}/Ucd)	decreased neutrophil cell number	J:211773
Ampd1^{tm1b(KOMP)Wtsi}/Ampd1^{tm1b(KOMP)Wtsi} (C57BL/6N-Ampd1^{tm1b(KOMP)Wtsi}/Ucd)	enlarged lymph nodes	J:211773
Ampd2^tm1Tm/Ampd2^tm1Tm (involves: 129S2/SvPas)	immune system phenotype	J:201211
Ampd3^tm1Tm/Ampd3^tm1Tm (Not Specified)	lung inflammation	J:201211
Ampd3^tm1Tm/Ampd3^tm1Tm Pklr^slc/Pklr^slc (involves: CBA/NSlc)	enlarged spleen	J:203909
Ampd3^{tm2a(KOMP)Wtsi}/Ampd3^{tm2a(KOMP)Wtsi} (B6JTyr;B6N-Ampd3^{tm2a(KOMP)Wtsi}/Wtsi)	increased leukocyte cell number	J:165965
Amt^em1(IMPC)Tcp/Amt⁺ (C57BL/6N-Amt^em1(IMPC)Tcp/Cmmr)	decreased lymphocyte cell number	J:211773
Amtn^em1(IMPC)Mbp/Amtn^em1(IMPC)Mbp (C57BL/6N-Amtn^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	small spleen	J:211773
anan/anan (involves: C57BL/6 * C57BL/10Sg * C57BR/c)	increased anti-nuclear antigen antibody level	J:169366
anan/anan⁺ (involves: C57BL/6 * C57BL/10Sg * C57BR/c)	increased anti-nuclear antigen antibody level	J:169366
anaya/anaya (involves: C57BL/6 * C57BL/10Sg * C57BR/c)	increased anti-nuclear antigen antibody level	J:169366
andra/andra (involves: C57BL/6 * C57BL/10Sg * C57BR/c)	increased anti-nuclear antigen antibody level	J:169366
anem/anem (BALB/c-anem)	increased leukocyte cell number	J:227974
Ang^{tm1.1(KOMP)Vlcg}/Ang^{tm1.1(KOMP)Vlcg} (C57BL/6N-Ang^{tm1.1(KOMP)Vlcg}/Ucd)	increased eosinophil cell number	J:211773
Ang^tm1Dats/Ang^tm1Dats (Not Specified)	decreased leukocyte cell number	J:236081
Ang^tm1Dats/Ang^tm1Dats (Not Specified)	increased lymphocyte cell number	J:236081
Angpt1^tm1.1Seq/Angpt1^tm1.1Seq Angpt2^{tm1c(KOMP)Seq}/Angpt2^{tm1c(KOMP)Seq} Gt(ROSA)26Sor^{tm1(rtTA,EGFP)Nagy}/? Tg(tetO-cre)1Jaw/0 (involves: 129 * C57BL/6NCr)	abnormal lymphatic vessel morphology	J:217296
Angpt2^em1(IMPC)Mbp/Angpt2⁺ (C57BL/6NCrl-Angpt2^em1(IMPC)Mbp/Mmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
Angpt2^em1(IMPC)Mbp/Angpt2^em1(IMPC)Mbp (C57BL/6NCrl-Angpt2^em1(IMPC)Mbp/Mmucd)	abnormal lymph node morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	small thymus	J:211773
Angpt2^tm1Gdy/Angpt2^tm1Gdy (involves: 129P2/OlaHsd * C57BL/6)	abnormal lymphatic vessel morphology	J:89618
Angpt2^{tm2(Angpt1)Gdy}/Angpt2^{tm2(Angpt1)Gdy} (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:89618
Angptl2^tm1Yo/Angptl2^tm1Yo (B6.Cg-Angptl2^tm1Yo)	impaired macrophage chemotaxis	J:152387
Angptl3^{tm2b(KOMP)Wtsi}/Angptl3^{tm2b(KOMP)Wtsi} (C57BL/6N-Angptl3^{tm2b(KOMP)Wtsi}/Ccpcz)	enlarged lymph nodes	J:211773
Angptl4^{Gt(OST352973)Lex}/Angptl4^{Gt(OST352973)Lex} (involves: 129S5/SvEvBrd * C57BL/6)	abnormal lymphatic vessel morphology	J:122968
	abnormal mesenteric lymph node morphology	J:122968
Angptl4^tm1Lex/Angptl4^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6)	abnormal lymphatic vessel morphology	J:122968
	abnormal mesenteric lymph node morphology	J:122968
Ank1^ity16/Ank1⁺ (involves: 129S1/Sv * 129X1/SvJ * DBA/2J)	increased susceptibility to bacterial infection	J:199427
Ank1^ity16/Ank1⁺ (involves: 129S1/Sv * 129X1/SvJ * DBA/2J)	increased susceptibility to bacterial infection induced morbidity/mortality	J:199427
Ank1^ity16/Ank1^ity16 (involves: 129S1/Sv * 129X1/SvJ * DBA/2J)	decreased spleen iron level	J:199427
	enlarged spleen	J:199427
	glomerulonephritis	J:199427
	increased leukocyte cell number	J:199427
	increased lymphocyte cell number	J:199427
	increased neutrophil cell number	J:199427
	increased susceptibility to bacterial infection	J:199427
	increased susceptibility to bacterial infection induced morbidity/mortality	J:199427
Ank1^M1Btlr/Ank1^M1Btlr (C57BL/6J-Ank1^m1Btlr)	abnormal spleen morphology	J:203831
	enlarged spleen	J:203831
	increased spleen iron level	J:203831
Ank1^M1Wlst/Ank1⁺ (involves: 129S1/SvImJ * C3H/HeJ * C57BL/6)	enlarged spleen	J:170562
Ank1^M1Wlst/Ank1^M1Wlst (involves: C3H/HeJ * C57BL/6)	abnormal leukocyte cell number	J:170562
Ank1^M1Wlst/Ank1^M1Wlst (involves: 129S1/SvImJ * C3H/HeJ * C57BL/6)	abnormal myelopoiesis	J:170562
	enlarged spleen	J:170562
Ank1^MRI23420/Ank1⁺ (SJL/J-Ank1^MRI23420)	abnormal spleen morphology	J:187820
	decreased susceptibility to parasitic infection	J:187820
	decreased susceptibility to parasitic infection induced morbidity/mortality	J:187820
	enlarged spleen	J:187820
	increased spleen iron level	J:187820
	increased spleen weight	J:187820
Ank1^MRI23420/Ank1^MRI23420 (SJL/J-Ank1^MRI23420)	enlarged spleen	J:187820
Ank1^MRI23420/Ank1^MRI23420 (SJL/J-Ank1^MRI23420)	increased spleen weight	J:187820
Ank1^nb/Ank1⁺ (involves: C57BL/6J * WB/Re)	decreased susceptibility to parasitic infection	J:111131
Ank1^nb/Ank1^nb (either: (involves: non-inbred stock) or (involves: C57BL/6) or (involves: WB/Re))	abnormal thymus development	J:30699
	enlarged lymph nodes	J:30699
	enlarged spleen	J:30699
	increased leukocyte cell number	J:30699
Ank1^nb/Ank1^nb (involves: C57BL/6J * WB/Re)	decreased susceptibility to parasitic infection	J:111131
Ank1^nb/Ank1^nb ((WB.Cg-Ank1^nb/BrkJ x B6.Cg-Ank1^nb/BrkJ)F1)	enlarged spleen	J:162532
Ank1^Rbc2/Ank1⁺ (involves: 129S1/Sv * BALB/c)	decreased susceptibility to parasitic infection	J:148127
Ank1^Rbc2/Ank1^Rbc2 (involves: 129S1/Sv * BALB/c)	enlarged spleen	J:148127
Ank^ank/Ank^ank (involves: C3HeB/FeJ * C57BL/6J * JGBF/LeJ)	autoimmune arthritis	J:63420
Ank^tm1.1Ejr/Ank⁺ (B6.129-Ank^tm1.1Ejr)	abnormal osteoclast differentiation	J:168526
Ank^tm1.1Ejr/Ank^tm1.1Ejr (B6.129-Ank^tm1.1Ejr)	abnormal osteoclast differentiation	J:168526
Ankfy1^{tm1b(KOMP)Mbp}/Ankfy1⁺ (C57BL/6N-Ankfy1^{tm1b(KOMP)Mbp}/Tcp)	increased monocyte cell number	J:211773
Ankrd2^tm1Krc/Ankrd2^tm1Krc (involves: 129 * Black Swiss)	abnormal inflammatory response	J:214867
Ankrd11^{tm1c(EUCOMM)Wtsi}/Ankrd11^{tm1c(EUCOMM)Wtsi} E2f1^{Tg(Wnt1-cre)2Sor}/E2f1⁺ (involves: C3H * C57BL/6 * C57BL/6N)	decreased osteoclast cell number	J:306391
Ankrd11^Yod/Ankrd11⁺ (involves: BALB/cAnNCrl * C3H/HeH)	decreased osteoclast cell number	J:136455
Ankrd31^{em1(IMPC)Hmgu}/Ankrd31^{em1(IMPC)Hmgu} (C57BL/6NCrl-Ankrd31^{em1(IMPC)Hmgu}/Ieg)	abnormal spleen morphology	J:211773
Ankrd46^em1(IMPC)Mbp/Ankrd46^em1(IMPC)Mbp (C57BL/6NCrl-Ankrd46^em1(IMPC)Mbp/MbpMmucd)	increased monocyte cell number	J:211773
Ankrd49^em1(IMPC)Tcp/Ankrd49⁺ (C57BL/6NCrl-Ankrd49^em1(IMPC)Tcp/Cmmr)	enlarged lymph nodes	J:211773
	enlarged thymus	J:211773
Ankrd52^em1(IMPC)J/Ankrd52⁺ (C57BL/6NJ-Ankrd52^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
Ankrd60^em1(IMPC)J/Ankrd60^em1(IMPC)J (C57BL/6NJ-Ankrd60^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
Ano2^{em1(IMPC)Ccpcz}/Ano2^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Ano2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged thymus	J:211773
Ano5^em1Huyi/Ano5^em1Huyi (C57BL/6N-Ano5^em1Huyi)	periodontium inflammation	J:294237
Ano5^em2Huyi/Ano5^em2Huyi (C57BL/6-Ano5^em2Huyi)	abnormal osteoclast physiology	J:336715
	decreased osteoclast cell number	J:336715
	osteomyelitis	J:336715
Ano6^em3(IMPC)Tcp/Ano6⁺ (C57BL/6NCrl-Ano6^em3(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Anpep^tm1.1Lsha/Anpep^tm1.1Lsha (B6.Cg-Anpep^tm1.1Lsha)	abnormal macrophage physiology	J:163945
	immune system phenotype	J:163945
	increased CD4-positive, alpha-beta T cell number	J:163945
Anta/Anta⁺ (involves: C57BL/6 * C57BL/10 * C57BR/cd)	glomerulonephritis	J:169366
Anta/Anta⁺ (involves: C57BL/6 * C57BL/10 * C57BR/cd)	increased anti-nuclear antigen antibody level	J:169366
Anth2^CBA/J/? (involves: A/J * CBA/J)	decreased susceptibility to bacterial infection	J:9501
Anth^C3H/HeNCrj/Anth^C3H/HeNCrj (involves: C3H/HeNCrj * C57BL/6NCrj)	decreased susceptibility to bacterial infection	J:11149
Anth^C3H/HeNCrj/Anth^C57BL/6NCrj (involves: C3H/HeNCrj * C57BL/6NCrj)	decreased susceptibility to bacterial infection	J:11149
Antxr1^tm1.2Lepp/Antxr1^tm1.2Lepp (involves: 129 * C57BL/6)	immune system phenotype	J:150952
Antxr2^tm1.1Jkit/Antxr2^tm1.1Jkit (involves: 129 * C57BL/6)	lymphangiectasis	J:187210
Antxr2^tm1.2Lepp/Antxr2^tm1.2Lepp (involves: C57BL/6)	decreased susceptibility to bacterial infection induced morbidity/mortality	J:150952
anx/anx (B6C3Fe a/a-anx/J)	abnormal inflammatory response	J:103396
	decreased spleen weight	J:7689
	increased thymus weight	J:7689
	pale spleen	J:7689
	small spleen	J:7689
anx/anx (involves: DW/J * M. m. domesticus poschiavinus * Swiss)	abnormal spleen morphology	J:13936
	small spleen	J:13936
Anxa1^{em1(IMPC)Ccpcz}/Anxa1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Anxa1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
	small spleen	J:211773
Anxa1^tm1Rjf/Anxa1⁺ (Not Specified)	increased inflammatory response	J:81498
Anxa1^tm1Rjf/Anxa1^tm1Rjf (Not Specified)	abnormal leukocyte physiology	J:81498
	impaired macrophage phagocytosis	J:81498
	increased inflammatory response	J:81498
Anxa1^tm1Rjf/Anxa1^tm1Rjf (involves: BALB/c)	increased susceptibility to induced colitis	J:142735
Anxa5^tm1Epo/Anxa5^tm1Epo (involves: 129P2/OlaHsd * C57BL/6)	abnormal cytokine secretion	J:117249
	abnormal inflammatory response	J:117249
	decreased susceptibility to type IV hypersensitivity reaction	J:117249
Anxa5^tm1Epo/Anxa5^tm1Epo Anxa6^tm1Moss/Anxa6^tm1Moss (involves: 129P2/OlaHsd * C57BL/6)	decreased dendritic cell number	J:193886
	increased B cell number	J:193886
Anxa5^tm1Epo/Anxa5^tm1Epo Anxa6^tm1Moss/Anxa6^tm1Moss Col10a1^tm1Ksec/Col10a1^tm1Ksec (involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6)	decreased dendritic cell number	J:193886
	increased B cell number	J:193886
	increased T-helper cell number	J:193886
Anxa6^tm1Moss/Anxa6^tm1Moss (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:58609
Anxa7^tm1Pll/Anxa7⁺ (Not Specified)	pancreas inflammation	J:58572
Anxa8^tm1Resc/Anxa8^tm1Resc Tg(Pgk1-cre)1Lni/0 (involves: 129 * C57BL/6J * BALB/c)	impaired leukocyte tethering or rolling	J:225224
Aoah^tm1Rsm/Aoah^tm1Rsm (involves: 129S6/SvEvTac)	abnormal humoral immune response	J:90493
Aoc3^tm1Salm/Aoc3^tm1Salm (involves: 129S6/SvEvTac * 129S7/SvEvBrd)	abnormal cellular extravasation	J:95656
	abnormal leukocyte adhesion	J:95656
	abnormal leukocyte migration	J:95656
	decreased inflammatory response	J:95656
	impaired leukocyte tethering or rolling	J:95656
Aod1a^A/J/? (involves: A/J * C57BL/6J)	ovary inflammation	J:83714
Aod1b^C57BL/6J/? (involves: A/J * C57BL/6J)	ovary inflammation	J:83714
Aod3^A/J/? (A/J)	ovary inflammation	J:78005
aol/aol (involves: C3H * C57BL/6)	osteoarthritis	J:115238
Ap1b1^b2b1660Clo/Ap1b1^b2b1660Clo (C57BL/6J-Ap1b1^b2b1660Clo)	absent spleen	J:175213
	spleen hypoplasia	J:175213
Ap1g1^tm1Schu/Ap1g1⁺ (either: (involves: 129P2/OlaHsd * 129X1/SvJ) or (involves: 129P2/OlaHsd * C57BL/6J))	decreased CD4-positive, alpha-beta T cell number	J:53252
Ap2b1^b2b2321Clo/Ap2b1^b2b2321Clo (C57BL/6J-Ap2b1^b2b2321Clo)	thymus hypoplasia	J:175213
Ap3b1^m1Btlr/Ap3b1^m1Btlr (C57BL/6J-Ap3b1^m1Btlr)	increased susceptibility to Herpesvirales infection	J:132673
Ap3b1^pe/Ap3b1^pe Hps1^ep/Hps1^ep (involves: C3H/He * C3HeB/FeJ * C57BL/6J)	abnormal monocyte morphology	J:85431
	lung inflammation	J:85431
Ap4e1^{tm1b(KOMP)Wtsi}/Ap4e1^{tm1b(KOMP)Wtsi} (C57BL/6N-Ap4e1^{tm1b(KOMP)Wtsi}/Bay)	abnormal spleen morphology	J:211773
Ap4e1^{tm1b(KOMP)Wtsi}/Ap4e1^{tm1b(KOMP)Wtsi} (C57BL/6N-Ap4e1^{tm1b(KOMP)Wtsi}/Ucd)	enlarged lymph nodes	J:211773
Ap4e1^{tm1b(KOMP)Wtsi}/Ap4e1^{tm1b(KOMP)Wtsi} (C57BL/6N-Ap4e1^{tm1b(KOMP)Wtsi}/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Ap4m1^{tm1b(EUCOMM)Wtsi}/Ap4m1^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Ap4m1^{tm1b(EUCOMM)Wtsi}/Wtsi)	increased leukocyte cell number	J:211773
Ap5m1^em1(IMPC)Mbp/Ap5m1^em1(IMPC)Mbp (C57BL/6N-Ap5m1^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
Apaf1^tm1Mak/Apaf1^tm1Mak (either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129P2/OlaHsd * CD-1))	immune system phenotype	J:49841
Apba3^tm1.1Ski/Apba3^tm1.1Ski Lyz2^tm1(cre)Ifo/Lyz2⁺ (B6.129-Apba3^tm1.1Ski Lyz2^tm1(cre)Ifo)	decreased susceptibility to endotoxin shock	J:176742
Apba3^tm1.2Ski/Apba3^tm1.2Ski (B6.129-Apba3^tm1.2Ski)	abnormal macrophage physiology	J:176742
	decreased circulating interleukin-12 level	J:176742
	decreased circulating tumor necrosis factor level	J:176742
	decreased interleukin-12 secretion	J:176742
	decreased susceptibility to endotoxin shock	J:176742
	decreased tumor necrosis factor secretion	J:176742
Apbb1ip^{em1(IMPC)Ccpcz}/Apbb1ip^{em1(IMPC)Ccpcz} (C57BL/6N-Apbb1ip^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	decreased CD8-positive, alpha-beta T cell number	J:211773
	decreased CD8-positive, naive alpha-beta T cell number	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
	increased eosinophil cell number	J:211773
	increased leukocyte cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
	increased spleen weight	J:211773
Apc^Min/Apc⁺ (C57BL/6J-Apc^Min)	decreased macrophage cell number	J:85142
Apc^Min/Apc⁺ (involves: 129 * C57BL/6)	decreased NK cell number	J:156864
	decreased splenocyte number	J:156864
	decreased T cell number	J:156864
Apc^Min/Apc⁺ (C57BL/6J-Apc^Min/J)	abnormal interleukin secretion	J:305794
Apc^Min/Apc⁺ Elp3^tm1.1Tac/Elp3^tm1.1Tac Tg(Vil1-cre)997Gum/0 (involves: C57BL/6 * C57BL/6J * C57BL/6NTac * SJL)	immune system phenotype	J:227334
Apc^Min/Apc⁺ Esr2^tm1Mma/Esr2^tm1Mma (involves: 129S2/SvPas * C57BL/6J)	colitis	J:118600
Apc^Min/Apc⁺ Mapkapk2^tm1.2Gkl/Mapkapk2^tm1.2Gkl (involves: BALB/cJ * C57BL/6J)	abnormal chemokine secretion	J:262876
	decreased interleukin-6 secretion	J:262876
Apc^Min/Apc⁺ Tg(Rorc-EGFP)1Ebe/? (involves: C57BL/6)	abnormal effector T cell morphology	J:137020
	enlarged mesenteric lymph nodes	J:137020
	lymph node hyperplasia	J:137020
Apc^tm1Kk/Apc^tm1Kk Tg(Lck-cre)1Cwi/? (involves: 129S6/SvEvTac * C57BL/6 * DBA/2)	abnormal T cell differentiation	J:100461
	arrested T cell differentiation	J:100461
	increased circulating tumor necrosis factor level	J:128606
	increased double-negative T cell number	J:100461
	increased mast cell number	J:128606
	small thymus	J:100461
	thymus hypoplasia	J:100461
Apc^tm1Rak/Apc⁺ Smad4^E6sad/Smad4⁺ (B6.129P2-Apc^tm1Rak Smad4^E6sad/+ +)	enlarged spleen	J:107273
Apc^tm1Tno/Apc⁺ Pten^tm2Mak/Pten^tm2Mak Tg(Cyp1a1-cre/ERT)1Dwi/0 (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * CBA)	peritoneal inflammation	J:143082
Apc^tm2.1Cip/Apc⁺ Atg7^tm1Tchi/Atg7^tm1Tchi Tg(Vil1-cre/ERT2)23Syr/0 (involves: 129P2/OlaHsd * C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj * DBA/2)	abnormal immune system physiology	J:227287
	increased CD8-positive, alpha-beta T cell number	J:227287
	increased CD103-positive CD11b-low dendritic cell number	J:227287
	increased interleukin-1 beta secretion	J:227287
	increased interleukin-10 secretion	J:227287
	increased regulatory T cell number	J:227287
Apc^tm2.1Cip/Apc^tm2.1Cip Lect2^tm1Ymg/Lect2^tm1Ymg Tg(Ttr-cre/Esr1)1Vco/0 (B6.Cg-Lect2^tm1Ymg Apc^tm2.1Cip Tg(Ttr-cre/Esr1)1Vco)	abnormal chemokine level	J:184496
	abnormal neutrophil physiology	J:184496
	abnormal NK T cell physiology	J:184496
	decreased interferon-gamma secretion	J:184496
	increased interleukin-4 secretion	J:184496
	increased NK T cell number	J:184496
	liver inflammation	J:184496
Apc^tm2.1Cip/Apc^tm2.1Cip Tg(Ttr-cre/Esr1)1Vco/0 (B6.Cg-Apc^tm2.1Cip Tg(Ttr-cre/Esr1)1Vco)	abnormal NK T cell physiology	J:184496
	decreased NK T cell number	J:184496
	increased interferon-gamma secretion	J:184496
	increased interleukin-4 secretion	J:184496
	liver inflammation	J:184496
Apc^tm2Rak/Apc⁺ Trp53^tm1Brn/Trp53^tm1Brn Tg(Pdx1-cre)6Tuv/0 (involves: 129/Sv * 129P2/OlaHsd * C57BL/6J * FVB/N * SJL)	abnormal cytokine level	J:234310
Apc^tm2Rak/Apc^tm2Rak Tg(KRT14-cre)8Brn/0 (involves: 129/Sv * C57BL/6J * FVB/N * SJL)	abnormal Hassall's corpuscle morphology	J:114152
	abnormal thymus morphology	J:114152
	decreased thymocyte number	J:114152
	small thymus	J:114152
Apcs^tm1Mpe/Apcs⁺ (B6.Cg-Apcs^tm1Mpe)	abnormal spleen red pulp morphology	J:90502
	abnormal spleen white pulp morphology	J:90502
	glomerulonephritis	J:90502
	increased autoantibody level	J:90502
	increased spleen white pulp amount	J:90502
Apcs^tm1Mpe/Apcs^tm1Mpe (B6.Cg-Apcs^tm1Mpe)	abnormal spleen morphology	J:90502
	abnormal spleen red pulp morphology	J:90502
	abnormal spleen white pulp morphology	J:90502
	decreased susceptibility to bacterial infection	J:125473
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:125473
	glomerulonephritis	J:90502
	increased autoantibody level	J:90502
	increased spleen white pulp amount	J:90502
	increased susceptibility to bacterial infection induced morbidity/mortality	J:125473
Apcs^tm1Mpe/Apcs^tm1Mpe (129.Cg-Apcs^tm1Mpe)	decreased susceptibility to bacterial infection induced morbidity/mortality	J:125473
	glomerulonephritis	J:90502
	immune system phenotype	J:90502
	increased susceptibility to bacterial infection induced morbidity/mortality	J:125473
Apcs^tm1Smae/Apcs^tm1Smae (involves: 129S/SvEv * C57BL/6)	decreased susceptibility to endotoxin shock	J:71194
Apcs^tm1Smae/Apcs^tm1Smae (involves: 129S/SvEv * C57BL/6)	increased autoantibody level	J:71194
Apex1^tm1Cur/Apex1⁺ (involves: 129S1/Sv)	increased circulating interleukin-1 alpha level	J:119957
Apex1^tm1Cur/Apex1⁺ (involves: 129S1/Sv)	increased circulating interleukin-10 level	J:119957
Apex1^tm1Ecf/Apex1⁺ (either: (involves: 129/Sv) or (involves: 129/Sv * C57BL/6))	heart inflammation	J:70397
	myocarditis	J:70397
	pericarditis	J:70397
Apex2^em1(IMPC)H/Apex2^em1(IMPC)H (C57BL/6NTac-Apex2^em1(IMPC)H/H)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Apex2^tm1Yun/Y (B6.129S-Apex2^tm1Yun)	decreased B cell number	J:95267
	decreased leukocyte cell number	J:95267
	decreased splenocyte proliferation	J:95267
	decreased T cell number	J:95267
	decreased thymocyte number	J:95267
	thymus atrophy	J:95267
Aplf^{Gt(RRF189)Byg}/Aplf^{Gt(RRF189)Byg} (involves: 129P2/OlaHsd * C57BL/6J)	abnormal class switch recombination	J:168260
Apoa4^tm1Bres/Apoa4^tm1Bres (B6.129S4-Apoa4^tm1Bres)	increased susceptibility to induced colitis	J:91357
Apob^tm2Sgy/Apob^tm2Sgy Ldlr^tm1Her/Ldlr^tm1Her Tg(Ins-Igf2)1Fbos/? (involves: 129S7/SvEvBrd * C57BL/6 * C57BL/6J * SJL)	aortitis	J:227165
Apobec1^{em1(IMPC)Ccpcz}/Apobec1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Apobec1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
	small spleen	J:211773
Apobec3^Gt(XN450)Byg/Apobec3^Gt(XN450)Byg (B6.Cg-Apobec3^Gt(XN450)Byg)	increased susceptibility to Retroviridae infection	J:118597
Apobec3^Gt(XN450)Byg/Apobec3^Gt(XN450)Byg (B6.129P2-Apobec3^Gt(XN450)Byg)	abnormal immunoglobulin level	J:138778
	increased susceptibility to Retroviridae infection	J:138778
Apobec3^Gt(XN450)Byg/Apobec3^Gt(XN450)Byg (129P2/OlaHsd-Apobec3^Gt(XN450)Byg)	abnormal immunoglobulin level	J:138778
	increased susceptibility to Retroviridae infection	J:138778
Apobec3^Gt(XN450)Byg/Apobec3^Rfv3-s H2^b/H2^b (involves: A.BY * C57BL/6)	abnormal immunoglobulin level	J:138778
Apobec3^Gt(XN450)Byg/Apobec3^Rfv3-s H2^b/H2^d (involves: BALB/c * C57BL/6)	abnormal immunoglobulin level	J:138778
	increased susceptibility to Retroviridae infection	J:138778
	increased susceptibility to Retroviridae infection induced morbidity/mortality	J:138778
Apobec3^Rfv3-r/Apobec3⁺ ((B10.A x A)F1)	decreased susceptibility to Retroviridae infection	J:6147
Apobec3^Rfv3-r/Apobec3⁺ ((B10.A x A)F1)	immune system phenotype	J:41946, J:6261, J:6147
Apoc4^{tm1.1(KOMP)Mbp}/Apoc4^{tm1.1(KOMP)Mbp} (C57BL/6N-Apoc4^{tm1.1(KOMP)Mbp}/Ieg)	increased leukocyte cell number	J:211773
Apoe^tm1.1Mae/Apoe^tm1.1Mae Tg(Fabp4-cre)1Rev/0 (B6.Cg-Apoe^tm1.1Mae Tg(Fabp4-cre)1Rev)	decreased macrophage cell number	J:219838
	increased macrophage cell number	J:219838
Apoe^tm1Bres/Apoe^tm1Bres Bcl2^tm1Irt/Bcl2^tm1Irt Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6)	increased macrophage apoptosis	J:144243
Apoe^tm1Bres/Apoe^tm1Bres Cx3cr1^tm1Ifc/Cx3cr1^tm1Ifc (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)	impaired macrophage chemotaxis	J:81822
Apoe^tm1Bres/Apoe^tm1Bres Mapk9^tm1Flv/Mapk9^tm1Flv (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)	abnormal macrophage morphology	J:94044
	abnormal macrophage physiology	J:94044
	increased macrophage derived foam cell number	J:94044
Apoe^tm1Khw/Apoe^tm1Khw Tg(Mx1-cre)29-4Her/0 (B6.Cg-Apoe^tm1Khw Tg(Mx1-cre)29-4Her)	immune system phenotype	J:196923
Apoe^tm1Rraf/Apoe^tm1Rraf Tg(Mx1-cre)29-4Her/0 (B6.Cg-Apoe^tm1Rraf Tg(Mx1-cre)29-4Her)	immune system phenotype	J:196923
Apoe^tm1Unc/Apoe^tm1Unc (B6.129P2-Apoe^tm1Unc/J)	abnormal B cell activation	J:133606
	abnormal CD4-positive, alpha-beta T cell number	J:108154, J:47027
	abnormal immune serum protein physiology	J:61564
	abnormal immune system morphology	J:47027
	abnormal immune system physiology	J:61564
	abnormal T cell number	J:47027
	blood vessel inflammation	J:91058
	decreased follicular B cell number	J:133606
	decreased interferon-gamma secretion	J:47027
	decreased marginal zone B cell number	J:133606
	decreased susceptibility to type IV hypersensitivity reaction	J:61564
	increased anti-double stranded DNA antibody level	J:133606
	increased anti-nuclear antigen antibody level	J:133606
	increased autoantibody level	J:133606
	increased B cell number	J:133606
	increased IgM level	J:61564
	increased immunoglobulin level	J:133606
	increased marginal zone B cell number	J:133606
	increased spleen weight	J:61564
	increased susceptibility to systemic lupus erythematosus	J:133606
	increased T-helper 2 cell number	J:47027
Apoe^tm1Unc/Apoe^tm1Unc (involves: 129P2/OlaHsd * C57BL/6)	lung inflammation	J:83615
Apoe^tm1Unc/Apoe^tm1Unc (B6.129P2-Apoe^tm1Unc)	abnormal cell-mediated immunity	J:125366
	abnormal dendritic cell physiology	J:125366
	increased CD4-positive, alpha-beta T cell number	J:125366
	increased susceptibility to parasitic infection	J:125366
Apoe^tm1Unc/Apoe^tm1Unc (B6.Cg-Apoe^tm1Unc Fas^lpr)	increased anti-double stranded DNA antibody level	J:133606
	increased anti-nuclear antigen antibody level	J:133606
	increased immunoglobulin level	J:133606
	increased susceptibility to systemic lupus erythematosus	J:133606
Apoe^tm1Unc/Apoe^tm1Unc Cbs^tm1Unc/Cbs^tm1Unc Tg(Mt1-CBS)25Waku/0 (involves: 129P2/OlaHsd * C3H * C57BL/6)	increased circulating tumor necrosis factor level	J:168131
	increased Ly6C high monocyte number	J:168131
	increased monocyte cell number	J:168131
Apoe^tm1Unc/Apoe^tm1Unc Ccr1^tm1Gao/Ccr1^tm1Gao (involves: 129P2/OlaHsd * 129S4/SvJae)	increased interferon-gamma secretion	J:128063
Apoe^tm1Unc/Apoe^tm1Unc Ccr2^tm1Ifc/Ccr2^tm1Ifc (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)	impaired macrophage chemotaxis	J:111471
Apoe^tm1Unc/Apoe^tm1Unc Ccr2^tm1Ifc/Ccr2^tm1Ifc (B6.Cg-Apoe^tm1Unc Ccr2^tm1Ifc)	decreased monocyte cell number	J:153310
Apoe^tm1Unc/Apoe^tm1Unc Ccr2^tm1Ifc/Ccr2^tm1Ifc Cx3cl1^tm1Lira/Cx3cl1^tm1Lira (B6.Cg-Apoe^tm1Unc Cx3cl1^tm1Lira Ccr2^tm1Ifc)	decreased monocyte cell number	J:153310
Apoe^tm1Unc/Apoe^tm1Unc Ccr5^tm1Blck/Ccr5^tm1Blck (involves: 129P2/OlaHsd * C57BL/6)	abnormal cytokine secretion	J:128063
	abnormal lymphocyte physiology	J:128063
	abnormal mononuclear phagocyte morphology	J:128063
	decreased interferon-gamma secretion	J:128063
	decreased T cell number	J:128063
	increased interleukin-10 secretion	J:128063
Apoe^tm1Unc/Apoe^tm1Unc Ccr5^tm1Kuz/Ccr5^tm1Kuz (involves: 129P2/OlaHsd * C57BL/6)	abnormal cytokine secretion	J:128063
	abnormal lymphocyte physiology	J:128063
	abnormal mononuclear phagocyte morphology	J:128063
	decreased interferon-gamma secretion	J:128063
	decreased T cell number	J:128063
	increased interleukin-10 secretion	J:128063
Apoe^tm1Unc/Apoe^tm1Unc Cd36^tm1Mfe/Cd36^tm1Mfe (involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6)	abnormal macrophage derived foam cell morphology	J:61672
	abnormal macrophage physiology	J:61672
Apoe^tm1Unc/Apoe^tm1Unc Cx3cl1^tm1Sgs/Cx3cl1^tm1Sgs (B6.129-Apoe^tm1Unc Cx3cl1^tm1Sgs)	impaired macrophage chemotaxis	J:95279
	increased macrophage derived foam cell number	J:95279
Apoe^tm1Unc/Apoe^tm1Unc Cxcl10^tm1Adl/Cxcl10^tm1Adl (B6.129-Cxcl10^tm1Adl Apoe^tm1Unc)	decreased CD4-positive, alpha-beta T cell number	J:166204
	impaired macrophage chemotaxis	J:166204
Apoe^tm1Unc/Apoe^tm1Unc Cyp4f13^{Gt(OST14770)Lex}/Cyp4f13^{Gt(OST14770)Lex} (involves: 129P2/OlaHsd * 129S5/SvEvBrd * C57BL/6)	abnormal macrophage chemotaxis	J:289999
Apoe^tm1Unc/Apoe^tm1Unc Cyp19a1^tm1Esi/Cyp19a1^tm1Esi (involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6)	increased circulating C-reactive protein level	J:184647
	increased circulating interleukin-6 level	J:184647
	increased circulating tumor necrosis factor level	J:184647
Apoe^tm1Unc/Apoe^tm1Unc Fas^lpr/Fas^lpr (MRL.Cg-Apoe^tm1Unc Fas^lpr)	increased anti-double stranded DNA antibody level	J:133606
	increased anti-nuclear antigen antibody level	J:133606
	increased autoantibody level	J:133606
	increased immunoglobulin level	J:133606
	increased susceptibility to systemic lupus erythematosus	J:133606
Apoe^tm1Unc/Apoe^tm1Unc Fas^lpr/Fas^lpr (B6.Cg-Apoe^tm1Unc Fas^lpr)	decreased autoantibody level	J:121671
	decreased CD4-positive, alpha-beta T cell number	J:121671
	decreased CD8-positive, alpha-beta T cell number	J:121671
	enlarged lymph nodes	J:121671
	enlarged spleen	J:121671
	enlarged thymus	J:121671
	glomerulonephritis	J:121671
	increased anti-double stranded DNA antibody level	J:121671
	increased autoantibody level	J:121671
	increased IgG level	J:121671
Apoe^tm1Unc/Apoe^tm1Unc Fasl^gld/Fasl^gld (B6.Cg-Fasl^gld Apoe^tm1Unc)	abnormal lymph node morphology	J:91058
	blood vessel inflammation	J:91058
	enlarged lymph nodes	J:200141, J:91058
	enlarged spleen	J:91058
	impaired macrophage phagocytosis	J:91058
	increased anti-nuclear antigen antibody level	J:200141, J:91058
	increased autoantibody level	J:91058
	increased IgG level	J:91058
	increased spleen weight	J:200141, J:91058
	increased T cell number	J:91058
	kidney inflammation	J:200141
Apoe^tm1Unc/Apoe^tm1Unc Gja5^tm1Mchn/Gja5^tm1Mchn Tg(TIE2-lacZ)182Sato/0 (involves: 129P2/OlaHsd * BALB/c * C57BL/6)	abnormal neutrophil physiology	J:162224
	alveolitis	J:162224
Apoe^tm1Unc/Apoe^tm1Unc Glg1^{Gt(RST092)Byg}/Glg1⁺ (B6J.129P2-Apoe^tm1Unc Glg1^{Gt(RST092)Byg})	decreased macrophage cell number	J:226586
	impaired macrophage chemotaxis	J:226586
Apoe^tm1Unc/Apoe^tm1Unc Hp^tm1Alev/Hp^tm1Alev (involves: 129)	abnormal macrophage chemotaxis	J:134942
Apoe^tm1Unc/Apoe^tm1Unc Hsd11b1^tm1Lex/Hsd11b1^tm1Lex (B6.129-Hsd11b1^tm1Lex Apoe^tm1Unc)	abnormal cytokine secretion	J:199430
	abnormal macrophage derived foam cell morphology	J:199430
	decreased macrophage cell number	J:199430
	decreased tumor necrosis factor secretion	J:199430
	immune system phenotype	J:199430
Apoe^tm1Unc/Apoe^tm1Unc Il1r1^tm1Imx/Il1r1^tm1Imx (B6.129-Il1r1^tm1Imx Apoe^tm1Unc)	decreased circulating interleukin-6 level	J:148173
Apoe^tm1Unc/Apoe^tm1Unc Il1rn^tm1Dih/Il1rn^tm1Dih (involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6)	abnormal macrophage chemotaxis	J:132570
Apoe^tm1Unc/Apoe^tm1Unc Il10^tm1Cgn/Il10^tm1Cgn (involves: 129P2/OlaHsd * C57BL/6)	abnormal circulating cytokine level	J:105858
	increased circulating interferon-gamma level	J:105858
	increased circulating interleukin-12 level	J:105858
Apoe^tm1Unc/Apoe^tm1Unc Itgb3^tm1Hyn/Itgb3^tm1Hyn (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)	lung inflammation	J:83615
Apoe^tm1Unc/Apoe^tm1Unc Klf15^tm2Jain/Klf15^tm2Jain Tg(Tagln-cre)1Jjl/0 (involves: 129P2/OlaHsd * FVB/N)	blood vessel inflammation	J:203920
	increased macrophage cell number	J:203920
Apoe^tm1Unc/Apoe^tm1Unc Mmp9^tm1Tvu/Mmp9^tm1Tvu (involves: 129P2/OlaHsd * 129S6/SvEvTac)	decreased macrophage cell number	J:110044
Apoe^tm1Unc/Apoe^tm1Unc Ncf1^tm1Shl/Ncf1^tm1Shl (involves: 129P2/OlaHsd * 129S2/SvPas)	decreased acute inflammation	J:123854
Apoe^tm1Unc/Apoe^tm1Unc Nck1^tm1Paw/Nck1^tm1Paw Nck2^tm3Paw/Nck2^tm3Paw Tg(Cdh5-cre/ERT2)1Rha/0 (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6)	decreased inflammatory response	J:326659
Apoe^tm1Unc/Apoe^tm1Unc Nfe2l2^tm1Mym/Nfe2l2^tm1Mym (involves: 129P2/OlaHsd * C57BL/6J)	abnormal macrophage physiology	J:143903
Apoe^tm1Unc/Apoe^tm1Unc Pla2g15^tm1Ytan/Pla2g15^tm1Ytan (involves: 129S/SvEv * B6.129P2-Apoe^tm1Unc/J)	abnormal macrophage morphology	J:97471
Apoe^tm1Unc/Apoe^tm1Unc Soat1^tm1Far/Soat1^tm1Far (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6J)	skin inflammation	J:61147
Apoe^tm1Unc/Apoe^tm1Unc Spp1^tm1Blh/Spp1^tm1Blh (involves: 129P2/OlaHsd * 129S6/SvEvTac * Black Swiss * C57BL/6J)	abnormal macrophage physiology	J:86531
Apoe^tm1Unc/Apoe^tm1Unc Tg(CAG-IL1RN)1Cga/? (involves: 129P2/OlaHsd * C57BL/6 * DBA/1 * FVB)	decreased circulating serum amyloid protein level	J:132570
Apoe^tm1Unc/Apoe^tm1Unc Tg(CAG-IL1RN)2Cga/? (involves: 129P2/OlaHsd * C57BL/6 * DBA/1 * FVB)	decreased circulating serum amyloid protein level	J:132570
Apoe^tm1Unc/Apoe^tm1Unc Tg(MSR1-Plau)1Ddi/0 (involves: 129P2/OlaHsd * C57BL/6 * SJL)	heart inflammation	J:101486
Apoe^tm1Unc/Apoe^tm1Unc Thbs4^tm1Olsa/Thbs4^tm1Olsa (involves: 129P2/OlaHsd * C57BL/6J)	increased chemokine level	J:345752
	increased circulating interleukin-10 level	J:345752
	increased circulating tumor necrosis factor level	J:345752
	increased macrophage cell number	J:345752
Apoe^{tm2(APOE3)Mae}/Apoe^{tm2(APOE3)Mae} (involves: 129P2/OlaHsd * C57BL/6J)	decreased interleukin-6 secretion	J:86768
	decreased tumor necrosis factor secretion	J:86768
Apoe^{tm2(APOE3)Mae}/Apoe^{tm2(APOE3)Mae} Tg(Thy1-APPSwDutIowa)BWevn/? (involves: 129P2/OlaHsd * C57BL/6)	abnormal microglial cell morphology	J:136318
Apoe^{tm3(APOE4)Mae}/Apoe^{tm3(APOE4)Mae} (involves: 129P2/OlaHsd * C57BL/6)	abnormal response to infection	J:138241
	increased interleukin-6 secretion	J:86768
	increased tumor necrosis factor secretion	J:86768
Apoe^{tm3(APOE4)Mae}/Apoe^{tm3(APOE4)Mae} Tg(Thy1-APPSwDutIowa)BWevn/? (involves: 129P2/OlaHsd * C57BL/6)	abnormal microglial cell morphology	J:136318
Apof^{tm1.1(KOMP)Vlcg}/Apof^{tm1.1(KOMP)Vlcg} (C57BL/6N-Apof^{tm1.1(KOMP)Vlcg}/Ucd)	increased basophil cell number	J:211773
Apol6^em1Hsul/Apol6^em1Hsul (Not Specified)	decreased inflammatory response	J:344362
Apol7c^em4Gpt/Apol7c^em4Gpt (C57BL/6JGpt-Apol7c^em4Gpt/Gpt)	abnormal dendritic cell antigen presentation	J:362930
Apol7c^em4Gpt/Apol7c^em4Gpt (C57BL/6JGpt-Apol7c^em4Gpt/Gpt)	abnormal dendritic cell physiology	J:362930
App^{tm1b(KOMP)Wtsi}/App⁺ (C57BL/6N-App^{tm1b(KOMP)Wtsi}/Ics)	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
App^tm1Ck/App^tm1Ck Tg(PDGFB-PSEN1M146L)2Jhd/0 (involves: 129 * Black Swiss * C57BL/6 * DBA/2 * SW)	abnormal microglial cell morphology	J:102542
App^tm2.1Ldad/App^tm2.1Ldad (involves: 129 * C57BL/6J)	myositis	J:166989
App^tm2.1Tcs/App^tm2.1Tcs (involves: C57BL/6)	microgliosis	J:212758
App^tm2.1Tcs/App^tm2.1Tcs Cast^tm1Tcs/Cast^tm1Tcs (involves: 129P2/OlaHsd * C57BL/6)	microgliosis	J:212758
App^tm3.1Tcs/App^tm3.1Tcs (involves: C57BL/6)	microgliosis	J:212758
App^tm3.1Tcs/App^tm3.1Tcs Mapt^{tm1.1(MAPT)Tcs}/Mapt^{tm1.1(MAPT)Tcs} (involves: 129S/SvEv * C57BL/6)	CNS inflammation	J:278451
Appl1^Gt(XM073)Byg/Appl1^Gt(XM073)Byg (B6.129P2-Appl1^Gt(XM073)Byg)	immune system phenotype	J:164696
	increased T cell proliferation	J:164696
Appl1^tm1.2Test/Appl1^tm1.2Test (involves: 129X1/SvJ)	increased T cell proliferation	J:164696
Aprt^tm1Dwm/Aprt^tm1Dwm (129P2/OlaHsd-Aprt^tm1Dwm)	pyelonephritis	J:38450
Aprt^tm1Jat/Aprt^tm1Jat (involves: 129S2/SvPas * Black Swiss)	kidney inflammation	J:33255
Aprt^tm1Jat/Aprt^tm1Jat (involves: 129S2/SvPas * C57BL/6J)	kidney inflammation	J:33255
Aprt^tm1Vri/Aprt^tm1Vri (involves: 129P2/OlaHsd * C57BL/6)	kidney inflammation	J:50874
Aptx^tm1Pmc/Aptx^tm1Pmc Atm^tm2.1Mfgc/Atm^tm2.1Mfgc (involves: 129 * C57BL/6)	abnormal CD4-positive helper T cell morphology	J:316365
	abnormal T cell differentiation	J:316365
	decreased T cell number	J:316365
	increased CD8-positive, alpha-beta T cell number	J:316365
Aqp1^{tm1b(EUCOMM)Wtsi}/Aqp1^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Aqp1^{tm1b(EUCOMM)Wtsi}/H)	increased neutrophil cell number	J:211773
Aqp3^m1Btlr/Aqp3^m1Btlr (C57BL/6J-Aqp3^m1Btlr)	abnormal gut-associated lymphoid tissue morphology	J:153279
Aqp3^m1Btlr/Aqp3^m1Btlr (C57BL/6J-Aqp3^m1Btlr)	increased susceptibility to induced colitis	J:153279
Aqp4^tm1.1Lmno/Aqp4^tm1.1Lmno (B6.Cg-Aqp4^tm1.1Lmno)	increased susceptibility to parasitic infection	J:193622
Aqp4^tm1.1Lmno/Aqp4^tm1.1Lmno (B6.Cg-Aqp4^tm1.1Lmno)	increased susceptibility to parasitic infection induced morbidity/mortality	J:193622
Aqp4^tm1.1Mysi/Aqp4^tm1.1Mysi (involves: C57BL/6JJcl * C57BL/6NCrlj * CBA/JNCrlj)	abnormal microglial cell physiology	J:214906
Aqp9^tm1Nlsn/Aqp9^tm1Nlsn (involves: 129S1/Sv)	decreased susceptibility to parasitic infection	J:123305
Aqp11^{tm1.1(KOMP)Vlcg}/Aqp11⁺ (B6N(Cg)-Aqp11^{tm1.1(KOMP)Vlcg}/J)	decreased leukocyte cell number	J:211773
Aqp12^tm1Rai/Aqp12^tm1Rai (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	increased susceptibility to induced pancreatitis	J:155920
Ar^Tfm/Y (involves: STOCK Eda^Ta Atp7a^Mo-blo)	abnormal myeloid leukocyte morphology	J:110923
Ar^Tfm/Y (involves: STOCK Eda^Ta Atp7a^Mo-blo)	increased immature B cell number	J:110923
Ar^tm1Chc/Y Tmem163^{Tg(ACTB-cre)2Mrt}/0 (involves: 129S/SvEv * C57BL/6J * FVB/N)	increased osteoclast cell number	J:81789
Ar^tm1Chc/Ar^tm1.1Chc Tmem163^{Tg(ACTB-cre)2Mrt}/0 (involves: 129S/SvEv * C57BL/6J * FVB/N)	enlarged thymus	J:87193
Ar^tm1Verh/Y Rnase10^tm1(cre)Hht/Rnase10⁺ (involves: 129S7/SvEvBrd * C57BL/6)	testis inflammation	J:173897
Araf^tm1Mmc/Y (involves: 129P2/OlaHsd * C57BL/6)	small thymus	J:33951
Araf^tm1Mmc/Araf^tm1Mmc (involves: 129P2/OlaHsd * C57BL/6)	small thymus	J:33951
Arb2a^{em2(IMPC)Ccpcz}/Arb2a^{em2(IMPC)Ccpcz} (C57BL/6NCrl-Arb2a^{em2(IMPC)Ccpcz}/Ph)	abnormal thymus morphology	J:211773
	decreased Ly6C-positive NK T cell number	J:211773
	enlarged thymus	J:211773
Arb2a^{Tg(Tyr)TpNpln}/Arb2a^{Tg(Tyr)TpNpln} (involves: FVB/N)	thymus hypoplasia	J:260599
Areg^tm1Dle/Areg^tm1Dle Egf^tm1Dle/Egf^tm1Dle Tgfa^tm1Unc/Tgfa^tm1Unc (involves: 129P2/OlaHsd * C57BL/6)	dermatitis	J:54980
Areg^{tm2c(EUCOMM)Hmgu}/Areg^{tm2c(EUCOMM)Hmgu} Foxp3^{tm4(YFP/icre)Ayr}/Foxp3⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6N)	immune system phenotype	J:224904
	increased susceptibility to Orthomyxoviridae infection	J:224904
Areg^{tm2c(EUCOMM)Hmgu}/Areg^{tm2c(EUCOMM)Hmgu} Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * C57BL/6N * DBA/2)	immune system phenotype	J:224904
	increased susceptibility to Orthomyxoviridae infection	J:224904
Arel1^em1Bbc/Arel1⁺ (C57BL/6J-Arel1^em1Bbc)	decreased acute inflammation	J:280563
Arel1^em1Bbc/Arel1⁺ (C57BL/6J-Arel1^em1Bbc)	decreased response to antigen	J:280563
Arel1^em1Bbc/Arel1^em1Bbc (C57BL/6J-Arel1^em1Bbc)	decreased acute inflammation	J:280563
Arel1^em1Bbc/Arel1^em1Bbc (C57BL/6J-Arel1^em1Bbc)	decreased response to antigen	J:280563
Arf4^{tm1b(KOMP)Wtsi}/Arf4⁺ (C57BL/6N-Arf4^{tm1b(KOMP)Wtsi}/Ucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	increased spleen weight	J:211773
Arfgap2^{tm1c(EUCOMM)Hmgu}/Arfgap2^{tm1c(EUCOMM)Hmgu} Commd10^{Tg(Vav1-icre)A2Kio}/Commd10⁺ (involves: 129S4/SvJae * C57BL/6J * C57BL/6N * C57BL/10 * CBA/Ca)	immune system phenotype	J:363611
Arfgap2^{tm1c(EUCOMM)Hmgu}/Arfgap2^{tm1c(EUCOMM)Hmgu} Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6J * C57BL/6N)	immune system phenotype	J:363611
Arfgap2^{tm1c(EUCOMM)Hmgu}/Arfgap2^{tm1c(EUCOMM)Hmgu} Sting1^em1Jmin/Sting1^em1Jmin Commd10^{Tg(Vav1-icre)A2Kio}/Commd10⁺ (Not Specified)	abnormal splenic cell ratio	J:363611
	decreased CD8-positive, alpha-beta T cell number	J:363611
	decreased effector memory CD4-positive, alpha-beta T cell number	J:363611
	decreased interferon-gamma secretion	J:363611
	decreased interleukin-1 beta secretion	J:363611
	decreased susceptibility to autoimmune disorder	J:363611
	increased CD4-positive, alpha-beta memory T cell number	J:363611
	increased CD4-positive, alpha-beta T cell number	J:363611
	increased regulatory T cell number	J:363611
Arfgap2^{tm1c(EUCOMM)Hmgu}/Arfgap2^{tm1c(EUCOMM)Hmgu} Tg(CAG-cre/Esr1)5Amc/0 (involves: 129S4/SvJae C57BL/6J * C57BL/6N)	abnormal macrophage activation involved in immune response	J:363611
	decreased interferon-beta secretion	J:363611
	decreased interleukin-6 secretion	J:363611
	decreased level of surface class I molecules	J:363611
	decreased level of surface class II molecules	J:363611
	decreased macrophage cytokine production	J:363611
	immune system phenotype	J:363611
Arfgap2^{tm1c(EUCOMM)Hmgu}/Arfgap2^{tm1c(EUCOMM)Hmgu} Tg(Cd4-cre)1Cwi/0 (involves: 129S4/SvJae * C57BL/6J * C57BL/6N)	immune system phenotype	J:363611
Arfip1^em1(IMPC)Mbp/Arfip1^em1(IMPC)Mbp (C57BL/6N-Arfip1^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
Arg1^tm1.1Lky/Arg1⁺ Tg(Sftpc-Chia)#Lky/0 (involves: 129S4/SvJae * BALB/c * C57BL/6 * DBA/2)	decreased macrophage cell number	J:122735
Arg1^tm1.1Pmu/Arg1^tm1.1Pmu (involves: C57BL/6 * NZB)	increased macrophage nitric oxide production	J:143229
Arg1^tm1Ekoe/Arg1^tm1Ekoe (involves: 129P2/OlaHsd)	abnormal macrophage physiology	J:183882
Arg1^tm1Pmu/Arg1^tm1Pmu Lyz2^tm1(cre)Ifo/? (B6.Cg-Arg1^tm1Pmu Lyz2^tm1(cre)Ifo)	decreased susceptibility to parasitic infection	J:143229
Arg1^tm1Pmu/Arg1^tm1Pmu Tg(Tek-cre)1Ywa/? (B6.Cg-Tg(Tek-cre)1Ywa Arg1^tm1Pmu)	abnormal macrophage physiology	J:143229
	decreased susceptibility to bacterial infection	J:143229
	increased macrophage nitric oxide production	J:143229
Arg2^{em1(IMPC)Ccpcz}/Arg2^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Arg2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
	small spleen	J:211773
Arhgap1^tm1Yizh/Arhgap1^tm1Yizh (involves: 129S6/SvEvTac)	spleen hypoplasia	J:101418
Arhgap1^tm1Yizh/Arhgap1^tm1Yizh (involves: 129S6/SvEvTac)	thymus hypoplasia	J:101418
Arhgap1^tm1Yizh/Arhgap1^tm1Yizh (involves: 129S6/SvEvTac * C57BL/6)	decreased spleen white pulp amount	J:119516
	spleen hypoplasia	J:119516
Arhgap5^tm1Jset/Arhgap5^tm1Jset (involves: 129S2/SvPas * C57BL/6J)	small thymus	J:76484
Arhgap10^em1(IMPC)Tcp/Arhgap10^em1(IMPC)Tcp (C57BL/6NCrl-Arhgap10^em1(IMPC)Tcp/Cmmr)	enlarged lymph nodes	J:211773
Arhgap15^tm1Ehi/Arhgap15^tm1Ehi (B6.129-Arhgap15^tm1Ehi)	abnormal leukocyte cell number	J:174896
	abnormal leukocyte morphology	J:174896
	abnormal macrophage morphology	J:174896
	abnormal neutrophil physiology	J:174896
	decreased lymphocyte cell number	J:174896
	decreased macrophage cell number	J:174896
	decreased monocyte cell number	J:174896
	decreased neutrophil cell number	J:174896
	decreased susceptibility to bacterial infection	J:174896
	immune system phenotype	J:174896
Arhgap17^{Gt(RRN062)Byg}/Arhgap17^{Gt(RRN062)Byg} (B6.129P2-Arhgap17^{Gt(RRN062)Byg})	increased susceptibility to induced colitis	J:277297
	increased tumor necrosis factor secretion	J:277297
Arhgap17^{tm1b(EUCOMM)Wtsi}/Arhgap17^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Arhgap17^{tm1b(EUCOMM)Wtsi}/Wtsi)	decreased B-1a cell number	J:211773
	decreased follicular B cell number	J:211773
	decreased mature B cell number	J:211773
	increased transitional stage T1 B cell number	J:211773
Arhgap21^{Gt(RRR629)Byg}/Arhgap21⁺ (B6.129P2-Arhgap21^{Gt(RRR629)Byg})	increased leukocyte cell number	J:262703
	increased neutrophil cell number	J:262703
Arhgap25^{tm1a(KOMP)Wtsi}/Arhgap25^{tm1a(KOMP)Wtsi} (involves: C57BL/6N)	abnormal cellular extravasation	J:240521
	abnormal neutrophil physiology	J:240521
	enhanced leukocyte migration	J:240521
	enhanced leukocyte tethering or rolling	J:240521
	increased acute inflammation	J:240521
	increased neutrophil cell number	J:240521
Arhgap26^{tm1b(EUCOMM)Hmgu}/Arhgap26^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Arhgap26^{tm1b(EUCOMM)Hmgu}/Ieg)	increased leukocyte cell number	J:211773
Arhgap28^em1(IMPC)Mbp/Arhgap28^em1(IMPC)Mbp (C57BL/6NCrl-Arhgap28^em1(IMPC)Mbp/Mmucd)	abnormal spleen morphology	J:211773
Arhgap30^{tm1a(EUCOMM)Wtsi}/Arhgap30^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Arhgap30^{tm1a(EUCOMM)Wtsi}/Wtsi)	decreased leukocyte cell number	J:211773
Arhgap45^em1Ciphe/Arhgap45^em1Ciphe (C57BL/6-Arhgap45^em1Ciphe)	decreased B cell number	J:309971
	decreased CD4-positive, alpha-beta T cell number	J:309971
	decreased CD8-positive, alpha-beta T cell number	J:309971
	decreased CD8-positive, naive alpha-beta T cell number	J:309971
	decreased DN1 thymic pro-T cell number	J:309971
	decreased lymphocyte chemotaxis	J:309971
	decreased naive B cell number	J:309971
	decreased T cell number	J:309971
	immune system phenotype	J:309971
	lymph node hypoplasia	J:309971
Arhgdia^tm1Ytk/Arhgdia^tm1Ytk (involves: 129S/SvEv * C57BL/6 * DBA)	decreased T cell number	J:140671
	tubulointerstitial nephritis	J:57995
Arhgdia^tm1Ytk/Arhgdia^tm1Ytk Arhgdib^tm1Miyo/Arhgdib^tm1Miyo (involves: 129S/SvEv)	abnormal leukocyte cell number	J:140671
	abnormal lymph node B cell domain morphology	J:140671
	abnormal mesenteric lymph node morphology	J:140671
	abnormal T cell physiology	J:140671
	abnormal thymus medulla morphology	J:140671
	decreased double-positive T cell number	J:140671
	decreased follicular B cell number	J:140671
	decreased immature B cell number	J:140671
	decreased marginal zone B cell number	J:140671
	decreased mature B cell number	J:140671
	decreased pre-B cell number	J:140671
	decreased T cell number	J:140671
	decreased T cell proliferation	J:140671
	decreased transitional stage B cell number	J:140671
	disorganized spleen B cell follicle	J:140671
	enhanced B cell migration	J:140671
	increased B cell proliferation	J:140671
	increased circulating interleukin-5 level	J:140671
	increased eosinophil cell number	J:140671
	increased single-positive T cell number	J:140671
	spleen hypoplasia	J:140671
Arhgdib^tm1Len/Arhgdib^tm1Len (involves: 129S4/SvJae * C57BL/6)	immune system phenotype	J:42604
	increased B cell proliferation	J:42604
Arhgdib^tm1Miyo/Arhgdib^tm1Miyo (involves: 129S/SvEv)	decreased B cell number	J:140671
Arhgdib^tm1Miyo/Arhgdib^tm1Miyo (involves: 129S/SvEv)	decreased T cell number	J:140671
Arhgef1^tm1.1Rmt/Arhgef1^tm1.1Rmt (C57BL/6-Arhgef1^tm1.1Rmt)	abnormal marginal zone B cell physiology	J:113295
	decreased B cell number	J:113295
	decreased B-1 B cell number	J:113295
	decreased follicular B cell number	J:113295
	decreased IgM level	J:113295
	decreased marginal zone B cell number	J:113295
Arhgef1^{tm1a(EUCOMM)Wtsi}/Arhgef1^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Arhgef1^{tm1a(EUCOMM)Wtsi}/Wtsi)	decreased CD8-positive, alpha-beta T cell number	J:211773
	decreased dendritic cell number	J:211773
	decreased immature NK cell number	J:211773
	decreased Ly6C-positive immature NK cell number	J:211773
	decreased marginal zone B cell number	J:211773
	decreased memory-marker CD4-positive NK T cell number	J:211773
	decreased memory-marker gamma-delta T cell number	J:211773
	increased CD4-positive, alpha-beta memory T cell number	J:211773
	increased CD4-positive, alpha-beta T cell number	J:211773
	increased CD8-positive, alpha-beta memory T cell number	J:211773
	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
	increased gamma-delta T cell number	J:211773
	increased KLRG1-positive CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	increased KLRG1-positive NK cell number	J:211773
	increased Ly6C low monocyte number	J:211773
	increased Ly6C-positive NK T cell number	J:211773
	increased mature NK cell number	J:211773
	increased monocyte cell number	J:211773
	increased plasmacytoid dendritic cell number	J:211773
Arhgef1^tm1Djle/Arhgef1^tm1Djle (involves: 129S4/SvJae * C57BL/6)	abnormal neutrophil physiology	J:129331
	enlarged spleen	J:129331
	increased leukocyte cell number	J:129331
Arhgef1^tm1Djle/Arhgef1^tm1Djle (involves: 129S4/SvJae)	increased germinal center B cell number	J:174313
Arhgef1^tm1Kdf/Arhgef1^tm1Kdf (involves: 129S1/Sv * 129X1/SvJ)	abnormal humoral immune response	J:99463
	abnormal lymphocyte cell number	J:99463
	abnormal lymphocyte physiology	J:99463
	decreased B cell number	J:99463
	decreased B cell proliferation	J:99463
	decreased IgG level	J:99463
	decreased IgM level	J:99463
	decreased marginal zone B cell number	J:99463
	increased T cell proliferation	J:99463
Arhgef2^em1(IMPC)Mbp/Arhgef2^em1(IMPC)Mbp (C57BL/6N-Arhgef2^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	small spleen	J:211773
Arhgef2^{Gt(IST13976A8)Tigm}/Arhgef2^{Gt(IST13976A8)Tigm} (involves: C57BL/6N)	abnormal macrophage physiology	J:209086
	decreased interferon-beta secretion	J:209086
	immune system phenotype	J:209086
	increased susceptibility to Orthomyxoviridae infection	J:209086
Arhgef4^{tm1a(KOMP)Wtsi}/Arhgef4^{tm1a(KOMP)Wtsi} (C57BL/6N-Arhgef4^{tm1a(KOMP)Wtsi}/Wtsi)	decreased IgE level	J:165965
	decreased IgG1 level	J:165965
	decreased T cell number	J:165965
	increased mature B cell number	J:165965
Arhgef5^tm1.1Dwu/Arhgef5^tm1.1Dwu (involves: 129S1/Sv * 129S6/SvEvTac)	abnormal CD4-positive, alpha-beta T cell physiology	J:157812
	abnormal dendritic cell physiology	J:157812
	decreased eosinophil cell number	J:157812
	decreased interleukin-4 secretion	J:157812
	immune system phenotype	J:157812
Arhgef6^tm1Kdf/Arhgef6^tm1Kdf (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell number	J:137269
	abnormal humoral immune response	J:137269
	abnormal T cell physiology	J:137269
	decreased B cell proliferation	J:137269
	decreased CD4-positive, alpha-beta T cell number	J:137269
	decreased CD8-positive, alpha-beta T cell number	J:137269
	decreased interleukin-2 secretion	J:137269
	decreased lymphocyte cell number	J:137269
	decreased mature B cell number	J:137269
	decreased T cell proliferation	J:137269
	enhanced B cell migration	J:137269
Arhgef6^{tm2e.1(EUCOMM)Wtsi}/Y (C57BL/6N-Arhgef6^{tm2e.1(EUCOMM)Wtsi}/Tcp)	enlarged lymph nodes	J:211773
Arhgef6^{tm2e.1(EUCOMM)Wtsi}/Arhgef6^{tm2e.1(EUCOMM)Wtsi} (C57BL/6N-Arhgef6^{tm2e.1(EUCOMM)Wtsi}/Tcp)	decreased lymphocyte cell number	J:211773
Arhgef12^tm1.1Wet/Arhgef12^tm1.1Wet Tg(Lck-cre)548Jxm/0 (involves: 129 * C57BL/6 * CBA)	abnormal T cell proliferation	J:149560
Arhgef16^em1(IMPC)Mbp/Arhgef16^em1(IMPC)Mbp (C57BL/6NCrl-Arhgef16^em1(IMPC)Mbp/Mmucd)	increased monocyte cell number	J:211773
Arid1a^tm1.1Mag/Arid1a^tm1.1Mag Gt(ROSA)26Sor^{tm1(Pik3caH1047R)Egan}/Gt(ROSA)26Sor⁺ (involves: 129S6/SvEvTac CD-1)	increased interleukin-6 secretion	J:219794
Arid1b^em1(IMPC)Tcp/Arid1b⁺ (C57BL/6NCrl-Arid1b^em1(IMPC)Tcp/Tcp)	abnormal spleen morphology	J:211773
Arid2^{tm1a(EUCOMM)Wtsi}/Arid2^{tm1a(EUCOMM)Wtsi} (involves: C57BL/6J * C57BL/6N)	immune system phenotype	J:223458
Arid3a^tm1Pwt/Arid3a^tm1Pwt (involves: 129S6/SvEvTac * C57BL/6)	abnormal B cell differentiation	J:169178
	abnormal class switch recombination	J:169178
	decreased B cell number	J:169178
	decreased B-1 B cell number	J:169178
	decreased B-1a cell number	J:169178
	decreased B-2 B cell number	J:169178
	decreased IgG1 level	J:169178
	decreased IgM level	J:169178
	decreased marginal zone B cell number	J:169178
	decreased pre-B cell number	J:169178
	decreased pro-B cell number	J:169178
	decreased transitional stage B cell number	J:169178
	decreased transitional stage T1 B cell number	J:169178
	decreased transitional stage T2 B cell number	J:169178
Arid3b^{tm1c(KOMP)Wtsi}/Arid3b^{tm1c(KOMP)Wtsi} Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6J * C57BL/6N * SJL)	abnormal B cell differentiation	J:236980
	decreased B cell number	J:236980
	decreased B-1b cell number	J:236980
	decreased CD4-positive, alpha-beta T cell number	J:236980
	decreased immature B cell number	J:236980
	decreased pre-B cell number	J:236980
	decreased pre-pro B cell number	J:236980
	decreased pro-B cell number	J:236980
	decreased transitional stage B cell number	J:236980
	increased B-1a cell number	J:236980
	increased follicular B cell number	J:236980
Arid3c^em1(IMPC)J/Arid3c^em1(IMPC)J (C57BL/6NJ-Arid3c^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
Arid4a^tm1Alb/Arid4a^tm1Alb (involves: 129S7/SvEvBrd)	abnormal mononuclear cell differentiation	J:141004
	decreased B cell number	J:141004
	decreased leukocyte cell number	J:141004
	decreased lymphocyte cell number	J:141004
	decreased monocyte cell number	J:141004
	decreased neutrophil cell number	J:141004
	decreased T cell number	J:141004
	enlarged spleen	J:141004
	increased leukocyte cell number	J:141004
	increased T cell number	J:141004
Arid4a^tm1Alb/Arid4a^tm1Alb Arid4b^tm1Alb/Arid4b⁺ (involves: 129S7/SvEvBrd)	abnormal leukopoiesis	J:141004
	decreased B cell number	J:141004
	decreased lymphocyte cell number	J:141004
	decreased T cell number	J:141004
	enlarged spleen	J:141004
	hemophagocytosis	J:141004
	increased leukocyte cell number	J:141004
	increased monocyte cell number	J:141004
	increased neutrophil cell number	J:141004
	increased T cell number	J:141004
Arid5a^tm1Rnis/Arid5a^tm1Rnis (B6.Cg-Arid5a^tm1Rnis)	decreased circulating interleukin-6 level	J:197418
	decreased circulating tumor necrosis factor level	J:197418
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:197418
	decreased T-helper 17 cell number	J:197418
	increased T cell number	J:197418
Arid5b^{Gt(ROSA)75Sor}/Arid5b^{Gt(ROSA)75Sor} (involves: 129S4/SvJaeSor)	kidney inflammation	J:117491
Arid5b^tm1Pjh/Arid5b^tm1Pjh (involves: 129S4/SvJae * BALB/c)	abnormal immune system organ morphology	J:70658
	abnormal lymphopoiesis	J:70658
	decreased double-positive T cell number	J:70658
	decreased pro-B cell number	J:70658
	increased single-positive T cell number	J:70658
	spleen hypoplasia	J:70658
	thymus cortex hypoplasia	J:70658
	thymus hypoplasia	J:70658
Arigg1^NZB/BlNJ/? (involves: BALB/cByJ * NZB/BlNJ)	increased anti-erythrocyte antigen antibody level	J:93737
Arigg2^NZB/BlNJ/? (involves: BALB/cByJ * NZB/BlNJ)	increased anti-erythrocyte antigen antibody level	J:93737
Arigg3^NZB/BlNJ/? (involves: BALB/cByJ * NZB/BlNJ)	increased anti-erythrocyte antigen antibody level	J:93737
Arigg4^NZB/BlNJ/? (involves: BALB/cByJ * NZB/BlNJ)	increased anti-erythrocyte antigen antibody level	J:93737
Arigg5^NZB/BlNJ/? (involves: BALB/cByJ * NZB/BlNJ)	increased anti-erythrocyte antigen antibody level	J:93737
Arigg6^NZB/BlNJ/? (involves: BALB/cByJ * NZB/BlNJ)	increased anti-erythrocyte antigen antibody level	J:93737
Arigg7^NZB/BlNJ/? (involves: BALB/cByJ * NZB/BlNJ)	increased anti-erythrocyte antigen antibody level	J:93737
Arigg8^BALB/cByJ/? (involves: BALB/cByJ * NZB/BlNJ)	increased anti-erythrocyte antigen antibody level	J:93737
Arigg9^NZB/BlNJ/? (involves: BALB/cByJ * NZB/BlNJ)	increased anti-erythrocyte antigen antibody level	J:93737
Arigg10^BALB/cByJ/? (involves: BALB/cByJ * NZB/BlNJ)	increased anti-erythrocyte antigen antibody level	J:93737
Arigm1^BALB/cByJ/? (involves: BALB/cByJ * NZB/BlNJ)	increased IgM level	J:93737
Arigm2^NZB/BlNJ/? (involves: BALB/cByJ * NZB/BlNJ)	increased IgM level	J:93737
Arigm3^NZB/BlNJ/? (involves: BALB/cByJ * NZB/BlNJ)	increased IgM level	J:93737
Arigm4^NZB/BlNJ/? (involves: BALB/cByJ * NZB/BlNJ)	increased IgM level	J:93737
Arigm5^NZB/BlNJ/? (involves: BALB/cByJ * NZB/BlNJ)	increased IgM level	J:93737
Arigm6^NZB/BlNJ/? (involves: BALB/cByJ * NZB/BlNJ)	increased IgM level	J:93737
Arigm7^NZB/BlNJ/? (involves: BALB/cByJ * NZB/BlNJ)	increased IgM level	J:93737
Arih1^em3Gpt/Arih1^em3Gpt Gt(ROSA)26Sor^{tm1(cre/ERT2)Tyj}/Gt(ROSA)26Sor⁺ (involves: 129S4/SvJae * C57BL/6JGpt)	decreased interferon-beta secretion	J:330879
	decreased interleukin-6 secretion	J:330879
	increased susceptibility to Herpesvirales infection	J:330879
	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:330879
Arih1^em3Gpt/Arih1^em3Gpt Lyz2^em1(icre)Gpt/Lyz2⁺ (C57BL/6JGpt-Arih1^em3Gpt Lyz2^em1(icre)Gpt)	decreased circulating interferon-beta level	J:330879
	decreased circulating interleukin-6 level	J:330879
	decreased interferon-beta secretion	J:330879
	decreased interleukin-6 secretion	J:330879
	immune system phenotype	J:330879
	increased susceptibility to Herpesvirales infection	J:330879
	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:330879
Arih1^em3Gpt/Arih1^em3Gpt Lyz2^em1(icre)Gpt/Lyz2⁺ Trex1^em1Gpt/Trex1^em1Gpt (C57BL/6JGpt-Arih1^em3Gpt Trex1^em1Gpt Lyz2^em1(icre)Gpt)	immune system phenotype	J:330879
Arih2^tm1Mak/Arih2^tm1Mak (involves: 129P2/OlaHsd * C57BL/6)	dermatitis	J:191066
	heart inflammation	J:191066
	increased inflammatory response	J:191066
	liver inflammation	J:191066
	lung inflammation	J:191066
Arih2^tm1Mak/Arih2^tm1Mak (B6.129P2-Arih2^tm1Mak)	abnormal dendritic cell physiology	J:191066
Arih2^tm1Mak/Arih2^tm1Mak (B6.129P2-Arih2^tm1Mak)	increased inflammatory response	J:191066
Arl3^{Gt(OST263303)Lex}/Arl3^{Gt(OST263303)Lex} (involves: 129S5/SvEvBrd)	bile duct inflammation	J:107331
Arl6ip5^tm1.2Jwzh/Arl6ip5^tm1.2Jwzh (B6.129X1-Arl6ip5^tm1.2Jwzh)	abnormal immune system organ morphology	J:187133
Arl16^{em1(IMPC)Ccpcz}/Arl16^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Arl16^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
	small spleen	J:211773
Arln^em1(IMPC)Mbp/Arln^em1(IMPC)Mbp (C57BL/6NCrl-Arln^em1(IMPC)Mbp/MbpMmucd)	increased basophil cell number	J:211773
Armc2^{tm1b(EUCOMM)Hmgu}/Armc2⁺ (C57BL/6N-Armc2^{tm1b(EUCOMM)Hmgu}/H)	increased neutrophil cell number	J:211773
Armcx1^em1(IMPC)Mbp/Y (C57BL/6N-Armcx1^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
Armh4^em1(IMPC)H/Armh4^em1(IMPC)H (C57BL/6N-Armh4^em1(IMPC)H/H)	enlarged spleen	J:211773
Arnt^tm1.1Gonz/Arnt^tm1.2Gonz Tg(Lck-cre)I57Jxm/0 (involves: 129X1/SvJ * ICR)	abnormal immune system physiology	J:85934
Arp^BALB/c/Arp^BALB/c (involves: B10.D2 * BALB/c)	abnormal lymph node morphology	J:7273
	abnormal Peyer's patch morphology	J:6549
	lymph node hypoplasia	J:6549
	spleen hyperplasia	J:6549
	thymus hyperplasia	J:6549
Arp^BALB/c/Arp^BALB/c Lus^C57BL/10/Lus^C57BL/10 (involves: B10.D2 * BALB/c)	abnormal lymph node morphology	J:7273
Arpc1b^{tm1a(EUCOMM)Wtsi}/Arpc1b^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Arpc1b^{tm1a(EUCOMM)Wtsi}/Wtsi)	decreased CD4-positive, alpha-beta T cell number	J:211773
	decreased KLRG1-positive NK cell number	J:211773
	decreased Ly6C-positive mature NK cell number	J:211773
	decreased macrophage cell number	J:211773
	decreased marginal zone precursor B cell number	J:211773
	decreased mature NK cell number	J:211773
	decreased NK cell number	J:211773
	decreased transitional stage T2 B cell number	J:211773
	increased CD4-positive, alpha-beta memory T cell number	J:211773
	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	increased CD103-positive CD11b-low dendritic cell number	J:211773
	increased effector memory T-helper cell number	J:211773
	increased immature NK cell number	J:211773
	increased KLRG1+ CD4 alpha-beta T cell number	J:211773
	increased KLRG1-positive CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	increased KLRG1-positive T-helper cell number	J:211773
	increased leukocyte cell number	J:211773
	increased memory CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	increased memory-marker CD4-negative NK T cell number	J:211773
	increased memory-marker NK cell number	J:211773
	increased plasma cell number	J:211773
Arpc4^{tm1a(EUCOMM)Wtsi}/Arpc4⁺ (B6JTyr;B6N-Arpc4^{tm1a(EUCOMM)Wtsi}/Wtsi)	increased leukocyte cell number	J:165965
Arpc4^{tm1c(EUCOMM)Wtsi}/Arpc4^{tm1c(EUCOMM)Wtsi} Krt14^tm1(cre)Wbm/Krt14⁺ (B6.Cg-Arpc4^{tm1c(EUCOMM)Wtsi} Krt14^tm1(cre)Wbm)	dermatitis	J:253986
Arrb2^tm1Rjl/Arrb2^tm1Rjl (involves: 129X1/SvJ * C57BL/6)	abnormal circulating tumor necrosis factor level	J:112607
	abnormal lymphocyte physiology	J:76872
	increased acute inflammation	J:112607
	increased circulating interleukin-6 level	J:112607
	increased interleukin-6 secretion	J:112607
	increased interleukin-12b secretion	J:112607
	increased susceptibility to endotoxin shock	J:112607
	increased tumor necrosis factor secretion	J:112607
Arrdc4^em1(IMPC)Tcp/Arrdc4^em1(IMPC)Tcp (C57BL/6NCrl-Arrdc4^em1(IMPC)Tcp/Cmmr)	enlarged lymph nodes	J:211773
	increased monocyte cell number	J:211773
Arsa^tm1Gie/Arsa^tm1Gie (involves: 129P2/OlaHsd * C57BL/6J)	abnormal microglial cell morphology	J:37978
Arsg^tm1Tdi/Arsg^tm1Tdi (involves: 129S2/SvPas * C57BL/6)	abnormal macrophage morphology	J:185592
	abnormal microglial cell morphology	J:185592
	abnormal perivascular macrophage morphology	J:185592
	microgliosis	J:185592, J:254592
Art1^{tm1b(EUCOMM)Wtsi}/Art1^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Art1^{tm1b(EUCOMM)Wtsi}/Tcp)	enlarged lymph nodes	J:211773
	increased basophil cell number	J:211773
Art2a^tm1Fkn/Art2a^tm1Fkn Art2b^tm1Fkn/Art2b^tm1Fkn (NOD.129S4(B6)-Art2a^tm1Fkn Art2b^tm1Fkn/Lt)	decreased T cell apoptosis	J:108097
Art2a^tm1Fkn/Art2a^tm1Fkn Art2b^tm1Fkn/Art2b^tm1Fkn Cd38^tm1Lnd/Cd38^tm1Lnd (NOD.129(B6)-Cd38^tm1Lnd Art2a^tm1Fkn Art2b^tm1Fkn/Lt)	decreased susceptibility to autoimmune diabetes	J:108097
Arti1^C57BL/6J/Arti1^C57BL/6J Arti2^C57BL/6J/Arti2^C57BL/6J (involves: C57BL/6J * DBA/2J)	abnormal thymus involution	J:85261
Arti1^DBA/2J/Arti1^DBA/2J Arti2^DBA/2J/Arti2^DBA/2J (involves: C57BL/6J * DBA/2J)	abnormal thymus involution	J:85261
Arvm2^MRL/MpJ/Arvm2^MRL/MpJ (involves: C3H/HeJ-Fas^lpr * MRL/MpJ-Fas^lpr)	abnormal immune system physiology	J:63511
asa/asa (either: A/J or BALB/c or DBA/2J)	increased autoantibody level	J:2843
asa/asa (either: A/J or BALB/c or DBA/2J)	myocarditis	J:2843
Asah1^tm1.2Geno/Asah1^tm1.2Geno (involves: C57BL/6)	abnormal circulating cytokine level	J:285931
	abnormal lymph node morphology	J:285931
	abnormal thymus morphology	J:285931
	decreased B cell number	J:285931
	decreased CD4-positive, alpha-beta T cell number	J:285931
	decreased CD8-positive, alpha-beta T cell number	J:285931
	decreased double-positive T cell number	J:285931
	decreased leukocyte cell number	J:285931
	decreased lymphocyte cell number	J:285931
	decreased splenocyte number	J:285931
	decreased T cell number	J:285931
	enlarged spleen	J:285931
	increased circulating CXCL10 level	J:285931
	increased granulocyte number	J:285931
	increased macrophage cell number	J:285931
	increased macrophage derived foam cell number	J:285931
	increased monocyte cell number	J:285931
	lung inflammation	J:285931
Asah1^tm1Medin/Asah1^tm1Medin (involves: 129S6/SvEvTac * CD-1)	abnormal chemokine secretion	J:232306
	abnormal circulating chemokine level	J:232306
	enlarged lymph nodes	J:232306
	enlarged spleen	J:232306
	enlarged thymus	J:232306
	increased circulating interleukin-12b level	J:232306
	increased eosinophil cell number	J:232306
	increased leukocyte cell number	J:232306
	increased macrophage derived foam cell number	J:232306
	increased monocyte cell number	J:232306
	increased neutrophil cell number	J:232306
	increased spleen weight	J:232306
	pale spleen	J:232306
Asb1^{em1(IMPC)Ccpcz}/Asb1^{em1(IMPC)Ccpcz} (C57BL/6N-Asb1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Asb1^tm1Wehi/Asb1^tm1Wehi (involves: C57BL/6)	small spleen	J:71266
Asb1^tm1Wehi/Asb1^tm1Wehi (involves: C57BL/6)	spleen hypoplasia	J:71266
Asb2^tm1.1Lutz/Asb2^tm1.1Lutz Tg(Mx1-cre)1Cgn/0 (involves: 129S2/SvPas * C57BL/6 * CBA)	abnormal dendritic cell physiology	J:200966
Asb2^{tm2b(KOMP)Wtsi}/Asb2⁺ (C57BL/6N-Asb2^{tm2b(KOMP)Wtsi}/Kmpc)	decreased Ly6C-positive immature NK cell number	J:211773
	increased Ly6C-positive immature NK cell number	J:211773
	increased T cell number	J:211773
Asb4^{em1(IMPC)Ccpcz}/Asb4^{em1(IMPC)Ccpcz} (C57BL/6N-Asb4^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
Asb5^{em1(IMPC)Ccpcz}/Asb5^{em1(IMPC)Ccpcz} (C57BL/6N-Asb5^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Asb7^{em1(IMPC)Ccpcz}/Asb7^{em1(IMPC)Ccpcz} (C57BL/6N-Asb7^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	decreased CD8-positive, alpha-beta T cell number	J:211773
	enlarged spleen	J:211773
	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
Asb16^{em1(IMPC)Ccpcz}/Asb16^{em1(IMPC)Ccpcz} (C57BL/6N-Asb16^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Asbb1^BALB/c/Asbb1^BALB/c (involves: BALB/c * C57BL/6J)	increased susceptibility to systemic lupus erythematosus	J:76486
Asbb2^BALB/c/Asbb2^C57BL/6J (involves: BALB/c * C57BL/6J)	increased susceptibility to systemic lupus erythematosus	J:76486
Asbb2^C57BL/6J/Asbb2^C57BL/6J (involves: BALB/c * C57BL/6J)	increased susceptibility to systemic lupus erythematosus	J:76486
Asbb3^C57BL/6J/Asbb3^C57BL/6J (involves: BALB/c * C57BL/6J)	increased susceptibility to systemic lupus erythematosus	J:76486
Ascc2^{tm1a(EUCOMM)Wtsi}/Ascc2⁺ (C57BL/6N-Ascc2^{tm1a(EUCOMM)Wtsi}/Bay)	enlarged spleen	J:211773
Ascl4^em1(IMPC)J/Ascl4^em1(IMPC)J (C57BL/6NJ-Ascl4^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
Ascl5^{em1(IMPC)Ccpcz}/Ascl5^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Ascl5^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Asf1b^m1Btlr/Asf1b^m1Btlr (C57BL/6J-Asf1b^m1Btlr)	increased IgE level	J:267479
Asgr1^tm1Sau/Asgr1^tm1Sau (B6.129S4-Asgr1^tm1Sau)	increased susceptibility to bacterial infection	J:136946
Asgr2^tm1Her/Asgr2^tm1Her (B6.129S7-Asgr2^tm1Her)	increased susceptibility to bacterial infection	J:136946
Ash1l^{Gt(AL0395)Wtsi}/Ash1l^{Gt(AL0395)Wtsi} (involves: 129P2/OlaHsd * C57BL/6J)	blepharitis	J:227516
Ash1l^{tm2b(EUCOMM)Hmgu}/Ash1l⁺ (C57BL/6N-Ash1l^{tm2b(EUCOMM)Hmgu}/Nju)	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
Ash1l^{Tn(pb-Act-RFP)1.AF0-180T25Zhu}/Ash1l^{Tn(pb-Act-RFP)1.AF0-180T25Zhu} (B6.FVB-Ash1l^{Tn(pb-Act-RFP)1.AF0-180T25Zhu})	glomerulonephritis	J:208213
	immune system phenotype	J:208213
	increased autoantibody level	J:208213
	increased circulating interleukin-6 level	J:208213
	increased circulating tumor necrosis factor level	J:208213
	increased IgA level	J:208213
	increased IgG1 level	J:208213
	increased IgG2a level	J:208213
	increased IgG2b level	J:208213
	increased IgM level	J:208213
	increased interleukin-6 secretion	J:208213
	increased susceptibility to autoimmune disorder	J:208213
	increased susceptibility to bacterial infection	J:208213
	increased susceptibility to bacterial infection induced morbidity/mortality	J:208213
	increased susceptibility to endotoxin shock	J:208213
	increased susceptibility to induced arthritis	J:208213
	increased tumor necrosis factor secretion	J:208213
Ash1l^{Tn(pb-Act-RFP)1.AF0-180T25Zhu}/Ash1l^{Tn(pb-Act-RFP)1.AF0-180T25Zhu} Il6^tm1Kopf/Il6^tm1Kopf (B6.Cg-Ash1l^{Tn(pb-Act-RFP)1.AF0-180T25Zhu} Il6^tm1Kopf)	abnormal inflammatory response	J:208213
	increased susceptibility to induced arthritis	J:208213
Asic2^em1(IMPC)Mbp/Asic2^em1(IMPC)Mbp (C57BL/6N-Asic2^em1(IMPC)Mbp/MbpMmucd)	small spleen	J:211773
Asic3^em1(IMPC)Mbp/Asic3^em1(IMPC)Mbp (C57BL/6NCrl-Asic3^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Asl^tm1Brle/Asl^tm1Brle (involves: 129S7/SvEvBrd)	decreased lymphocyte cell number	J:180208
	decreased spleen germinal center number	J:180208
	increased macrophage cell number	J:180208
	increased spleen red pulp amount	J:180208
	thymus cortex hypoplasia	J:180208
Asm1^MRL/MpJ/? (involves: C3H/HeJ-Fas^lpr * MRL/MpJ-Fas^lpr)	abnormal immune system physiology	J:66459
Asm2^MRL/MpJ/? (involves: C3H/HeJ-Fas^lpr * MRL/MpJ-Fas^lpr)	salivary gland inflammation	J:66459
Asphd1^{em1(IMPC)Ccpcz}/Asphd1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Asphd1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Aspscr1^em1(IMPC)Tcp/Aspscr1^em1(IMPC)Tcp (C57BL/6NCrl-Aspscr1^em1(IMPC)Tcp/Tcp)	decreased neutrophil cell number	J:211773
	enlarged lymph nodes	J:211773
	increased lymphocyte cell number	J:211773
Asq1^IQI/Asq1^IQI (involves: IQI * C57BL/6CrSlc)	salivary gland inflammation	J:127310
Ass1^tm1.1Ekoe/Ass1^tm1.1Ekoe Tg(Vil1-cre)997Gum/0 (involves: 129P2/OlaHsd * C57BL/6 * SJL)	immune system phenotype	J:203474
Aste1^{tm1a(KOMP)Wtsi}/Aste1^{tm1a(KOMP)Wtsi} (B6JTyr;B6N-Aste1^{tm1a(KOMP)Wtsi}/Wtsi)	decreased leukocyte cell number	J:175295
Asxl1^tm1.1Iaai/Asxl1^tm1.1Iaai Tet2^tm1.1Iaai/Tet2^tm1.1Iaai Tg(Mx1-cre)1Cgn/0 (involves: 129S/SvEv * C57BL/6 * CBA)	abnormal myelopoiesis	J:208092
Asxl1^tm1.1Iaai/Asxl1^tm1.1Iaai Tg(Mx1-cre)1Cgn/0 (involves: 129S/SvEv * C57BL/6 * CBA)	abnormal myelopoiesis	J:208092
	decreased leukocyte cell number	J:208092
	decreased mature B cell number	J:208092
	decreased monocyte cell number	J:208092
	decreased neutrophil cell number	J:208092
Asxl1^tm1.1Iaai/Asxl1^tm1.1Iaai Tg(VAV1-cre)1Graf/0 (involves: 129S/SvEv * C57BL/6)	abnormal myelopoiesis	J:208092
	decreased leukocyte cell number	J:208092
	decreased mature B cell number	J:208092
	decreased monocyte cell number	J:208092
	decreased neutrophil cell number	J:208092
	decreased splenocyte number	J:208092
Asxl1^tm1.1Mjxu/Asxl1⁺ (involves: 129 * C57BL/6)	abnormal leukocyte morphology	J:208085
	abnormal myelopoiesis	J:208085
	abnormal neutrophil morphology	J:208085
	abnormal neutrophil physiology	J:208085
	abnormal spleen morphology	J:208085
	decreased B cell number	J:208085
	decreased leukocyte cell number	J:208085
	decreased neutrophil cell number	J:208085
	enlarged spleen	J:208085
	increased leukocyte cell number	J:208085
	increased monocyte cell number	J:208085
Asxl1^tm1.1Mjxu/Asxl1^tm1.1Mjxu (involves: 129 * C57BL/6)	abnormal leukocyte morphology	J:208085
	abnormal neutrophil morphology	J:208085
	abnormal spleen white pulp morphology	J:208085
	decreased B cell number	J:208085
	decreased leukocyte cell number	J:208085
	decreased lymphocyte cell number	J:208085
	decreased spleen red pulp amount	J:208085
	decreased spleen weight	J:208085
	increased monocyte cell number	J:208085
	increased single-positive T cell number	J:208085
	myeloid hyperplasia	J:208085
	small spleen	J:208085
	spleen atrophy	J:208085
Asxl1^{tm1a(EUCOMM)Wtsi}/Asxl1⁺ (B6Dnk;B6Brd;B6N-Asxl1^{tm1a(EUCOMM)Wtsi} Tyr^c-Brd/WtsiH)	decreased leukocyte cell number	J:175295
Asxl1^{tm1a(EUCOMM)Wtsi}/Asxl1⁺ (C57BL/6N-Asxl1^{tm1a(EUCOMM)Wtsi}/Cnrm)	decreased B cell number	J:165965
Asxl1^tm1Bc/Asxl1^tm1Bc (involves: 129P2/OlaHsd * C57BL/6J)	abnormal immune system cell morphology	J:155898
	abnormal immune system organ morphology	J:155898
	abnormal lymphopoiesis	J:155898
	abnormal thymus morphology	J:155898
	decreased B cell number	J:155898
	decreased CD4-positive, alpha-beta T cell number	J:155898
	decreased pre-B cell number	J:155898
	decreased T cell number	J:155898
	increased double-negative T cell number	J:155898
	spleen hyperplasia	J:155898
Atad2b^{tm1b(EUCOMM)Hmgu}/Atad2b^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Atad2b^{tm1b(EUCOMM)Hmgu}/Ics)	decreased NK T cell number	J:211773
Atad5^{Gt(RRF055)Byg}/Atad5⁺ (involves: 129P2/OlaHsd)	increased T cell derived lymphoma incidence	J:176672
Atcay^ji/Atcay^ji (Not Specified)	abnormal thymus cortex morphology	J:14903
	abnormal thymus medulla morphology	J:14903
	abnormal thymus morphology	J:14903
Atf1^tm1.1Arte/Atf1^tm1.1Arte (involves: C57BL/6)	immune system phenotype	J:191723
Atf2^{Tg(Gzma-Klra1)7Wum}/Atf2⁺ (involves: C57BL/6)	abnormal NK cell physiology	J:61178
	decreased circulating interferon-gamma level	J:61178
	decreased NK cell number	J:61178
	decreased NK T cell number	J:61178
	immune system phenotype	J:61178
Atf2^{tm1b(EUCOMM)Hmgu}/Atf2⁺ (C57BL/6N-Atf2^{tm1b(EUCOMM)Hmgu}/Ccpcz)	abnormal spleen morphology	J:211773
Atf2^tm1Glm/Atf2^tm1Glm (involves: 129S2/SvPas)	eye inflammation	J:30611
Atf2^tm1Glm/Atf2^tm1Glm (involves: 129S2/SvPas)	increased susceptibility to bacterial infection	J:30611
Atf2^tm1Glm/Atf2^tm1Glm (C.Cg-Atf2^tm1Glm)	abnormal cytokine secretion	J:67176
	immune system phenotype	J:67176
	increased susceptibility to endotoxin shock	J:67176
	increased susceptibility to Herpesvirales infection	J:67176
	increased susceptibility to Picornaviridae infection	J:67176
Atf3^tm1Dron/Atf3^tm1Dron (involves: 129X1/SvJ * C57BL/6)	abnormal T-helper 2 physiology	J:140112
	decreased IgG2a level	J:140112
	increased interleukin-4 secretion	J:140112
	increased interleukin-5 secretion	J:140112
	increased interleukin-13 secretion	J:140112
	lung inflammation	J:140112
Atf4^tm1(KOMP)Mbp/Atf4⁺ (C57BL/6NCrl-Atf4^tm1(KOMP)Mbp/MbpMmucd)	decreased monocyte cell number	J:211773
Atg3^tm1.1Ywh/Atg3^tm1.1Ywh Fnip1^m1Btlr/Fnip1^m1Btlr Gt(ROSA)26Sor^{tm1(cre/ERT)Nat}/Gt(ROSA)26Sor⁺ (involves: 129S/SvEv * 129S1/Sv * 129X1/SvJ * C57BL/6J)	absent B cells	J:234285
Atg3^tm1.1Ywh/Atg3^tm1.1Ywh Gt(ROSA)26Sor^{tm1(cre/ERT)Brn}/Gt(ROSA)26Sor⁺ (involves: 129P2/OlaHsd * 129S/SvEv * 129S4/SvJaeSor * C57BL/6)	abnormal T cell morphology	J:172749
	increased T cell apoptosis	J:172749
Atg3^tm1.1Ywh/Atg3^tm1.1Ywh Tg(Lck-cre)548Jxm/0 (involves: 129S/SvEv * 129S4/SvJaeSor * C57BL/6 * CBA)	abnormal T cell morphology	J:172749
	decreased CD4-positive, alpha-beta T cell number	J:172749
	decreased CD8-positive, alpha-beta T cell number	J:172749
	decreased T cell proliferation	J:172749
	increased T cell apoptosis	J:172749
	spleen hypoplasia	J:172749
	thymus hypoplasia	J:172749
Atg4b^{tm1b(EUCOMM)Hmgu}/Atg4b^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Atg4b^{tm1b(EUCOMM)Hmgu}/H)	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
Atg5^tm1Myok/Atg5^tm1Myok Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * 129S/SvEv)	abnormal circulating chemokine level	J:235399
	abnormal macrophage physiology	J:235399
	decreased circulating interleukin-10 level	J:235399
	glomerulonephritis	J:235399
	increased anti-double stranded DNA antibody level	J:235399
	increased anti-nuclear antigen antibody level	J:235399
	increased autoantibody level	J:235399
	increased circulating interleukin-1 beta level	J:235399
	increased circulating interleukin-6 level	J:235399
	increased circulating interleukin-12b level	J:235399
	increased IgG level	J:235399
	increased lymphocyte cell number	J:235399
	increased monocyte cell number	J:235399
	increased neutrophil cell number	J:235399
	increased susceptibility to systemic lupus erythematosus	J:235399
Atg5^tm1Nmz/Atg5^tm1Nmz (involves: 129 * BALB/c * C57BL/6)	abnormal thymus cortex morphology	J:140583
Atg5^tm1Nmz/Atg5^tm1Nmz Tg(CAG-EGFP/Map1lc3b)53Nmz/? (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal thymus morphology	J:140583
	abnormal thymus physiology	J:140583
Atg5^tm1Nmz/Atg5^tm1Nmz Tg(Cd4-cre)1Cwi/? (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)	abnormal T cell morphology	J:211733
	abnormal T cell physiology	J:211733
	abnormal T cell subpopulation ratio	J:211733
	decreased CD4-positive, alpha-beta T cell number	J:211733
	decreased CD8-positive, alpha-beta T cell number	J:211733
	decreased T cell number	J:211733
	decreased T cell proliferation	J:211733
Atg7^tm1Tchi/Atg7^tm1Tchi Commd10^{Tg(Vav1-icre)A2Kio}/Commd10⁺ (involves: C57BL/6NCrlj * C57BL/10 * CBA/Ca * CBA/JNCrlj)	abnormal leukocyte morphology	J:176843
	decreased B cell number	J:176843
	decreased leukocyte cell number	J:176843
	decreased NK cell number	J:176843
	decreased T cell number	J:176843
Atg7^tm1Tchi/Atg7^tm1Tchi Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6NCrlj * CBA/JNCrlj)	abnormal circulating chemokine level	J:235399
	abnormal macrophage physiology	J:235399
	decreased circulating interleukin-10 level	J:235399
	glomerulonephritis	J:235399
	increased anti-double stranded DNA antibody level	J:235399
	increased anti-nuclear antigen antibody level	J:235399
	increased autoantibody level	J:235399
	increased circulating interleukin-1 beta level	J:235399
	increased circulating interleukin-6 level	J:235399
	increased circulating interleukin-12b level	J:235399
	increased IgG level	J:235399
	increased lymphocyte cell number	J:235399
	increased monocyte cell number	J:235399
	increased neutrophil cell number	J:235399
	increased susceptibility to systemic lupus erythematosus	J:235399
Atg7^tm1Tchi/Atg7^tm1Tchi Lyz2^tm1(cre)Ifo/Lyz2⁺ Tg(CAG-EGFP/Map1lc3b)53Nmz/0 (involves: 129P2/OlaHsd * C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj * DBA/2)	abnormal circulating chemokine level	J:235399
	abnormal macrophage physiology	J:235399
	decreased circulating interleukin-10 level	J:235399
	increased circulating interleukin-1 beta level	J:235399
	increased circulating interleukin-6 level	J:235399
Atg7^tm1Tchi/Atg7^tm1Tchi Xbp1^tm2Glm/Xbp1^tm2Glm Tg(Defa6-icre)1Rsb/0 (involves: 129S6/SvEvTac * C57BL/6 * CBA)	small intestinal inflammation	J:206084
Atg7^tm1Tchi/Atg7^tm1Tchi Xbp1^tm2Glm/Xbp1^tm2Glm Tg(Vil1-cre)997Gum/0 (involves: 129S6/SvEvTac * C57BL/6 * CBA * SJL)	ileum inflammation	J:206084
	intestinal inflammation	J:206084
Atg9a^tm1Aki/Atg9a^tm1Aki (involves: 129/Sv * C57BL/6)	abnormal innate immunity	J:155552
	increased interferon-beta secretion	J:155552
	increased interleukin-6 secretion	J:155552
Atg16l1^tm1.1Mvlc/Atg16l1^tm1.1Mvlc (C57BL/6-Atg16l1^tm1.1Mvlc)	abnormal macrophage physiology	J:206931
	immune system phenotype	J:206931
	increased circulating interleukin-1 beta level	J:206931
	increased macrophage cytokine production	J:206931
	increased susceptibility to bacterial infection	J:206931
Atg16l1^{tm1a(EUCOMM)Wtsi}/Atg16l1^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Atg16l1^{tm1a(EUCOMM)Wtsi}/Wtsi)	abnormal thymus topology	J:239583
	absent connection between subcutaneous lymph vessels and lymph sac	J:239583
	blood in lymph vessels	J:239583
Atg16l1^tm1Aki/Atg16l1^tm1Aki (involves: 129/Sv * C57BL/6)	abnormal macrophage physiology	J:141420
	increased interleukin-1 beta secretion	J:141420
	increased interleukin-18 secretion	J:141420
	increased susceptibility to induced colitis	J:141420
Atg16l1^{tm1c(EUCOMM)Wtsi}/Atg16l1^{tm1c(EUCOMM)Wtsi} Tcrd^tm1Mom/Tcrd^tm1Mom Tg(Vil1-cre)997Gum/0 (involves: 129P2/OlaHsd * C57BL/6J * C57BL/6N * SJL)	abnormal cytokine level	J:340266
	increased susceptibility to colitis induced morbidity/mortality	J:340266
Atg16l1^{tm1c(EUCOMM)Wtsi}/Atg16l1^{tm1c(EUCOMM)Wtsi} Tg(Defa6-icre)1Rsb/0 (involves: C57BL/6)	increased susceptibility to colitis induced morbidity/mortality	J:340266
	increased susceptibility to induced colitis	J:340266
Atg16l1^{tm1c(EUCOMM)Wtsi}/Atg16l1^{tm1c(EUCOMM)Wtsi} Tg(Itgax-cre)1-1Reiz/? (involves: C57BL/6 * C57BL/6N * CBA)	immune system phenotype	J:221019
Atg16l1^{tm1c(EUCOMM)Wtsi}/Atg16l1^{tm1c(EUCOMM)Wtsi} Tg(Vil1-cre)997Gum/? (involves: C57BL/6J * C57BL/6N * SJL)	abnormal chemokine level	J:221019
	abnormal circulating interleukin level	J:221019
	abnormal cytokine level	J:221019
	cecum inflammation	J:221019
	increased circulating interleukin-1 beta level	J:221019
	increased circulating interleukin-6 level	J:221019
	increased macrophage cell number	J:221019
	increased susceptibility to bacterial infection	J:221019
Atg16l1^tm1Kuv/Atg16l1^tm1Kuv Tg(Vil1-cre)997Gum/0 (B6.Cg-Atg16l1^tm1Kuv Tg(Vil1-cre)997Gum)	increased susceptibility to induced colitis	J:269933
	small intestinal inflammation	J:269933
Atg16l1^tm1Kuv/Atg16l1^tm1Kuv Tg(Vil1-cre)997Gum/0 Xbp1^tm2Glm/Xbp1^tm2Glm (B6.Cg-Atg16l1^tm1Kuv Xbp1^tm2Glm Tg(Vil1-cre)997Gum)	small intestinal inflammation	J:269933
Atg16l1^tm1Kuv/Atg16l1^tm1Kuv Xbp1^tm2Glm/Xbp1^tm2Glm Tg(Vil1-cre)997Gum/0 (involves: 129S6/SvEvTac * C57BL/6 * SJL)	ileum inflammation	J:206084
	intestinal inflammation	J:206084
Atg16l2^m1Anu/Atg16l2^m1Anu (C57BL/6NCrl-Atg16l2^m1Anu/Anu)	decreased lymphocyte cell number	J:104190
Atl1^tm1.2Cbla/Atl1^tm1.2Cbla Reep1^{Gt(OST398247)Lex}/Reep1^{Gt(OST398247)Lex} (B6.Cg-Reep1^{Gt(OST398247)Lex} Atl1^tm1.2Cbla)	increased susceptibility to otitis media	J:334532
Atl2^{tm2b(EUCOMM)Hmgu}/Atl2⁺ (C57BL/6N-Atl2^{tm2b(EUCOMM)Hmgu}/H)	decreased neutrophil cell number	J:211773
	decreased spleen weight	J:211773
	increased lymphocyte cell number	J:211773
Atl3^em1(IMPC)Tcp/Atl3^em1(IMPC)Tcp (C57BL/6N-Atl3^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Atm^m1Btlr/Atm^m1Btlr (C57BL/6J-Atm^m1Btlr)	decreased CD4-positive, alpha-beta T cell number	J:265252
	decreased CD8-positive, alpha-beta T cell number	J:265252
	decreased response to antigen	J:265252
	decreased single-positive T cell number	J:265252
	decreased T cell number	J:265252
	impaired humoral immune response	J:265252
	increased IgM level	J:265252
Atm^m2Btlr/Atm^m2Btlr (C57BL/6J-Atm^m2Btlr)	decreased CD4-positive, alpha-beta T cell number	J:265253
	decreased CD8-positive, naive alpha-beta T cell number	J:265253
	decreased single-positive T cell number	J:265253
	increased central memory CD8 positive, alpha-beta T cell number	J:265253
	increased effector memory CD4-positive, alpha-beta T cell number	J:265253
Atm^m3Btlr/Atm^m3Btlr (C57BL/6J-Atm^m3Btlr)	increased B-1a cell number	J:272820
Atm^m3Btlr/Atm^m3Btlr (C57BL/6J-Atm^m3Btlr)	increased macrophage cell number	J:272820
Atm^M4Btlr/Atm^M4Btlr (C57BL/6J-Atm^M4Btlr)	abnormal CD8-positive, alpha-beta T cell differentiation	J:272821
Atm^m5Btlr/Atm^m5Btlr (C57BL/6J-Atm^m5Btlr)	abnormal lymphocyte morphology	J:272824
	decreased interleukin-1 beta secretion	J:272824
	impaired macrophage phagocytosis	J:272824
	increased B-1 B cell number	J:272824
Atm^m6Btlr/Atm^m6Btlr (C57BL/6J-Atm^m6Btlr)	abnormal CD4-positive T cell differentiation	J:274964
	abnormal CD8-positive, alpha-beta T cell differentiation	J:274964
	abnormal T cell differentiation	J:274964
	decreased CD4-positive, alpha-beta T cell number	J:274964
	decreased CD8-positive, naive alpha-beta T cell number	J:274964
	decreased T cell number	J:274964
	increased CD8-positive, alpha-beta memory T cell number	J:274964
	increased central memory CD4-positive, alpha-beta T cell number	J:274964
	increased central memory CD8 positive, alpha-beta T cell number	J:274964
	increased effector memory CD4-positive, alpha-beta T cell number	J:274964
Atm^tm1.1Mmpl/Atm^tm1.1Mmpl (involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6J)	decreased T cell number	J:226414
	increased B cell number	J:226414
	increased T cell derived lymphoma incidence	J:226414
Atm^tm1Awb/Atm⁺ Rad50^tm2Jpt/Rad50^tm2Jpt (involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6)	decreased macrophage cell number	J:103922
Atm^tm1Awb/Atm^tm1Awb (either: 129S6/SvEvTac-Atm^tm1Awb or (involves: 129S6/SvEvTac * NIH Black Swiss))	decreased activated T cell number	J:34193
	decreased double-positive T cell number	J:34193
	decreased T cell number	J:34193
	immune system phenotype	J:34193
	increased double-positive T cell number	J:34193
	increased T cell derived lymphoma incidence	J:34193
Atm^tm1Awb/Atm^tm1Awb (involves: 129S6/SvEvTac * C57BL/6)	increased T cell derived lymphoma incidence	J:103922
Atm^tm1Awb/Atm^tm1Awb (involves: 129S6/SvEvTac)	abnormal class switch recombination	J:150435
	decreased CD4-positive, alpha-beta T cell number	J:90941
	decreased CD8-positive, alpha-beta T cell number	J:90941
	immune system phenotype	J:126920
	increased T cell derived lymphoma incidence	J:90941
Atm^tm1Awb/Atm^tm1Awb (CByJ.129S6-Atm^tm1Awb)	increased T cell derived lymphoma incidence	J:208539
Atm^tm1Awb/Atm^tm1Awb (129S6/SvEvTac-Atm^tm1Awb)	increased T cell derived lymphoma incidence	J:208539
Atm^tm1Awb/Atm^tm1Awb (either: (129S6/SvEvTac-Atm^tm1Awb x B6.129S6-Atm^tm1Awb)F1 or (B6.129S6-Atm^tm1Awb x 129S6/SvEvTac-Atm^tm1Awb)F1)	increased T cell derived lymphoma incidence	J:208539
Atm^tm1Awb/Atm^tm1Awb (either: (129S6/SvEvTac-Atm^tm1Awb x A.129S6-Atm^tm1Awb)F1 or (A.129S6-Atm^tm1Awb x 129S6/SvEvTac-Atm^tm1Awb)F1)	increased T cell derived lymphoma incidence	J:208539
Atm^tm1Awb/Atm^tm1Awb (129S6/SvEvTac-Atm^tm1Awb/J)	decreased single-positive T cell number	J:226414
	decreased T cell number	J:226414
	increased B cell number	J:226414
	increased double-positive T cell number	J:226414
	increased T cell derived lymphoma incidence	J:226414
Atm^tm1Awb/Atm^tm1Awb Paxx^em1Spj/Paxx^em1Spj (involves: A/J * C57BL/6NTac)	abnormal class switch recombination	J:236776
	decreased B cell number	J:236776
	decreased splenocyte number	J:236776
	decreased T cell number	J:236776
Atm^tm1Awb/Atm^tm1Awb Rad52^tm1Aps/Rad52^tm1Aps (involves: 129P2/OlaHsd * 129S6/SvEvTac)	decreased CD4-positive, alpha-beta T cell number	J:90941
	decreased CD8-positive, alpha-beta T cell number	J:90941
	increased T cell derived lymphoma incidence	J:90941
Atm^tm1Bal/Atm^tm1Bal (involves: 129S4/SvJae)	abnormal microglial cell physiology	J:44190
	abnormal T cell physiology	J:35914
	decreased IgG2a level	J:35914
	decreased IgG2b level	J:35914
	decreased IgG3 level	J:35914
	decreased IgG level	J:35914
	decreased pre-B cell number	J:35914
	decreased thymocyte number	J:35914
	increased T cell derived lymphoma incidence	J:35914
	small thymus	J:35914
Atm^tm1Fwa/Atm^tm1Fwa (involves: 129S4/SvJae * C57BL/6)	decreased immature B cell number	J:61201
	decreased lymphocyte cell number	J:61201
	decreased pre-B cell number	J:61201
	decreased splenocyte number	J:61201
	decreased T cell number	J:61201
	decreased thymocyte number	J:61201
	increased T cell derived lymphoma incidence	J:61201
Atm^tm1Fwa/Atm^tm1Fwa (involves: 129S4/SvJae)	abnormal class switch recombination	J:191288
Atm^tm1Led/Atm^tm1Led (involves: 129S6/SvEvTac * Black Swiss)	abnormal T cell differentiation	J:36561
	decreased CD4-positive, alpha-beta T cell number	J:36561
	increased double-positive T cell number	J:36561
	increased T cell derived lymphoma incidence	J:69726
	small thymus	J:36561
	thymus cortex hypoplasia	J:36561
Atm^tm1Mfl/Atm^tm1Mfl (involves: 129T2/SvEms * C57BL/6J)	abnormal immune system cell morphology	J:69726
	abnormal immune system organ morphology	J:69726
	abnormal T cell differentiation	J:69726
	decreased thymocyte number	J:69726
	enlarged spleen	J:69726
	increased double-negative T cell number	J:69726
	increased single-positive T cell number	J:69726
	increased T cell derived lymphoma incidence	J:69726
	small lymph nodes	J:69726
	small spleen	J:69726
	small thymus	J:69726
Atm^tm1Pmc/Atm^tm1Pmc Trp73^tm2Mak/Trp73^tm2Mak (involves: 129P2/OlaHsd * C57BL/6J)	decreased thymocyte apoptosis	J:157905
Atm^tm1Shzh/Atm^tm2.1Fwa Gt(ROSA)26Sor^{tm1(cre/ERT2)Thl}/Gt(ROSA)26Sor⁺ (involves: 129 * 129S6/SvEvTac)	abnormal class switch recombination	J:191288
Atm^tm2.1Fwa/Atm^tm2.1Fwa Tg(VAV1-cre)1Graf/0 (involves: 129S6/SvEvTac)	decreased B cell number	J:277750
	decreased T cell number	J:277750
	decreased thymocyte number	J:277750
	increased T cell derived lymphoma incidence	J:277750
Atm^tm2.1Mfgc/Atm^tm2.1Mfgc (C57BL/6-Atm^tm2.1Mfgc)	abnormal T cell differentiation	J:316365
Atm^tm2.1Mfgc/Atm^tm2.1Mfgc (C57BL/6-Atm^tm2.1Mfgc)	decreased T cell number	J:316365
Atmin^tm1.1Jhh/Atmin^tm1.1Jhh (C57BL/6-Atmin^tm1.1Jhh)	thymus hypoplasia	J:167544
Atmin^tm1.1Jhh/Atmin^tm1.1Jhh Cd79a^tm1(cre)Reth/Cd79a⁺ (B6.Cg-Cd79a^tm1(Cre)Reth Atmin^tm1.1Jhh)	decreased B cell number	J:230105
	decreased IgG1 level	J:230105
	decreased immature B cell number	J:230105
	increased B cell apoptosis	J:230105
Atmin^tm1.1Jhh/Atmin^tm1.1Jhh Cd79a^tm1(cre)Reth/Cd79a⁺ Tg(IghMyc)22Bri/0 (B6.Cg-Cd79a^tm1(Cre)Reth Atmin^tm1.1Jhh Tg(IghMyc)22Bri)	decreased B cell number	J:230105
	decreased immature B cell number	J:230105
	increased B cell apoptosis	J:230105
Atmin^tm1.2Jhh/Atmin^tm1.2Jhh Bcl2l11^tm1.1Ast/Bcl2l11^tm1.1Ast Cd79a^tm1(cre)Reth/Cd79a⁺ (involves: 129S1/Sv * BALB/c * C57BL/6)	enlarged spleen	J:191832
	immune system phenotype	J:191832
	increased B cell number	J:191832
	increased immature B cell number	J:191832
	increased pre-B cell number	J:191832
	increased spleen weight	J:191832
Atmin^tm1.2Jhh/Atmin^tm1.2Jhh Cd79a^tm1(cre)Reth/Cd79a⁺ (involves: BALB/c * C57BL/6)	abnormal B cell differentiation	J:191832
	abnormal B cell physiology	J:191832
	decreased immature B cell number	J:191832
	decreased mature B cell number	J:191832
	decreased pre-B cell number	J:191832
	decreased spleen weight	J:191832
	small spleen	J:191832
Atmin^tm1.2Jhh/Atmin^tm1.2Jhh Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA)	decreased B cell number	J:191832
	decreased lymphocyte cell number	J:191832
	decreased mature B cell number	J:191832
	decreased pre-B cell number	J:191832
	immune system phenotype	J:191832
Atmin^tm1.2Jhh/Atmin^tm1.2Jhh Trp53^tm1Brn/Trp53^tm1Brn Cd79a^tm1(cre)Reth/Cd79a⁺ (involves: 129P2/OlaHsd * BALB/c * C57BL/6)	decreased B cell number	J:191832
	decreased immature B cell number	J:191832
Atn1^{tm1b(EUCOMM)Wtsi}/Atn1^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Atn1^{tm1b(EUCOMM)Wtsi}/Cnrm)	decreased lymphocyte cell number	J:211773
	decreased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Atp1a1^{em1(IMPC)Ccpcz}/Atp1a1⁺ (C57BL/6NCrl-Atp1a1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged thymus	J:211773
Atp1a3^Myk/Atp1a3⁺ (involves: 129S1/SvImJ * C57BL/6J * C57BL/6NCr * FVB/NCr)	microgliosis	J:151948
Atp2a2^tm1Ges/Atp2a2⁺ (involves: 129X1/SvJ)	abnormal osteoclast differentiation	J:198051
Atp2b4^tm1Ges/Atp2b4^tm1Ges (involves: 129X1/SvJ * Black Swiss)	enlarged submandibular lymph nodes	J:91844
Atp2c2^em1(IMPC)Tcp/Atp2c2^em1(IMPC)Tcp (C57BL/6NCrl-Atp2c2^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Atp4a^m1Btlr/Atp4a^m1Btlr (involves: C57BL/6J)	abnormal spleen morphology	J:179090
Atp4a^m1Btlr/Atp4a^m1Btlr (involves: C57BL/6J)	enlarged spleen	J:179090
Atp5if1^em1Jpy/Atp5if1^em1Jpy (C57BL/6J-Atp5if1^em1Jpy)	decreased neutrophil cell number	J:312819
Atp5if1^em1Jpy/Atp5if1^em1Jpy (C57BL/6J-Atp5if1^em1Jpy)	decreased susceptibility to colitis induced morbidity/mortality	J:312819
Atp5mg^{tm1b(EUCOMM)Hmgu}/Atp5mg⁺ (C57BL/6N-Atp5mg^{tm1b(EUCOMM)Hmgu}/H)	decreased eosinophil cell number	J:211773
	enlarged spleen	J:211773
Atp5mk^{tm1b(EUCOMM)Wtsi}/Atp5mk^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Atp5mk^{tm1b(EUCOMM)Wtsi}/H)	increased leukocyte cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Atp6v0a2^tm1Kdb/Atp6v0a2^tm1Kdb Commd10^{Tg(Vav1-icre)A2Kio}/Commd10⁺ (involves: C57BL/6 * C57BL/10 * CBA/Ca)	abnormal CD8-positive, alpha-beta cytotoxic T cell morphology	J:274048
	decreased alpha-beta T cell number	J:274048
	decreased CD4-positive, alpha-beta T cell number	J:274048
	decreased T cell number	J:274048
Atp6v0d1^{tm1b(EUCOMM)Hmgu}/Atp6v0d1⁺ (C57BL/6N-Atp6v0d1^{tm1b(EUCOMM)Hmgu}/Tcp)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Atp6v0d2^tm1Ywc/Atp6v0d2^tm1Ywc (involves: 129P2/OlaHsd * C57BL/6)	abnormal osteoclast differentiation	J:117744
	abnormal osteoclast morphology	J:117744
Atp6v1b2^{tm1b(KOMP)Wtsi}/Atp6v1b2⁺ (C57BL/6N-Atp6v1b2^{tm1b(KOMP)Wtsi}/Tcp)	small lymph nodes	J:211773
Atp6v1c1^{tm1b(NCOM)Mfgc}/Atp6v1c1⁺ (C57BL/6N-Atp6v1c1^{tm1b(NCOM)Mfgc}/Tcp)	increased leukocyte cell number	J:211773
Atp6v1h^em1Xhd/Atp6v1h⁺ (involves: C57BL/6)	abnormal osteoclast differentiation	J:239439
Atp6v1h^em1Xhd/Atp6v1h⁺ (involves: C57BL/6)	abnormal osteoclast physiology	J:239439
Atp7a^Mo-3Btlr/Y (C57BL/6J-Atp7a^Mo-3Btlr)	decreased susceptibility to prion infection	J:188598
Atp7a^Mo-blo/Y (B6.Cg-Atp7a^Mo-blo/J)	osteoarthritis	J:36378
Atp7a^Mo-ml/Y (involves: C3Hf/He)	decreased spleen weight	J:12745
Atp7b^tx-J/Atp7b^tx-J (C3H/HeJ-Atp7b^tx-J/J)	increased eosinophil cell number	J:24233
Atp8b1^em1(IMPC)Tcp/Atp8b1^em1(IMPC)Tcp (C57BL/6NCrl-Atp8b1^em1(IMPC)Tcp/Tcp)	enlarged spleen	J:211773
	increased leukocyte cell number	J:211773
Atp10a^m1Anu/Atp10a^m1Anu (C57BL/6NCrl-Atp10a^m1Anu)	immune system phenotype	J:104190
Atp11a^{tm1a(KOMP)Wtsi}/Atp11a^{tm1a(KOMP)Wtsi} (C57BL/6N-Atp11a^{tm1a(KOMP)Wtsi}/Wtsi)	abnormal thymus morphology	J:239583
Atp11c^ambr/Y (C57BL/6-Atp11c^ambr)	abnormal B cell differentiation	J:171924
	abnormal humoral immune response	J:171924
	decreased B cell number	J:171924
	decreased B-1 B cell number	J:171924
	decreased B-1a cell number	J:171924
	decreased B-1b cell number	J:171924
	decreased B-2 B cell number	J:171924
	decreased follicular B cell number	J:171924
	decreased immature B cell number	J:171924
	decreased leukocyte cell number	J:171924
	decreased lymphocyte cell number	J:171924
	decreased mature B cell number	J:171924
	decreased pre-B cell number	J:171924
	decreased pro-B cell number	J:171924
	decreased T cell number	J:171924
Atp11c^ambr/Y Tg(H2-Ea-Il7)10Rhdr/0 (involves: C57BL/6 * C57BL/6JApb * DBA/2)	decreased B cell number	J:171924
Atp11c^ambr/Y Tg(IghelMD4)4Ccg/0 (involves: C57BL/6 * C57BL/6JApb)	decreased immature B cell number	J:171924
	decreased pro-B cell number	J:171924
Atp11c^ambr/Y Tg(Vav-BCL2)69Jad/0 (involves: C57BL/6 * C57BL/6J * C57BL/6JApb)	decreased B cell number	J:171924
	decreased immature B cell number	J:171924
	decreased pre-B cell number	J:171924
Atp11c^em1(IMPC)J/Y (C57BL/6NJ-Atp11c^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
Atp11c^em1(IMPC)J/Atp11c^em1(IMPC)J (C57BL/6NJ-Atp11c^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
Atp11c^m1Btlr/Y (involves: C57BL/6J)	absent follicular B cells	J:171925
	arrested B cell differentiation	J:171925
	decreased B cell number	J:185495, J:171925
	decreased B-1 B cell number	J:171925
	decreased B-2 B cell number	J:171925
	decreased IgA level	J:171925
	decreased IgG1 level	J:171925
	decreased IgM level	J:171925
	decreased immature B cell number	J:171925
	decreased transitional stage B cell number	J:171925
	decreased transitional stage T1 B cell number	J:171925
	decreased transitional stage T2 B cell number	J:171925
	decreased transitional stage T3 B cell number	J:171925
	immune system phenotype	J:185495, J:171925
Atp11c^m1Btlr/Y Tg(BCL2)22Wehi/0 (involves: C57BL/6J * C57BL/6JWehi * SJL/Wehi)	decreased B cell number	J:171925
	decreased follicular B cell number	J:171925
	decreased mature B cell number	J:171925
	increased marginal zone B cell number	J:171925
Atp11c^m1Btlr/Y Tg(IghmHyHEL10,IgkHyHEL10)4Ccg/0 (involves: C57BL/6 * C57BL/6J * C57BL/6JSfdAnu)	decreased B cell number	J:171925
Atp11c^m1Btlr/Atp11c^m1Btlr (involves: C57BL/6J)	decreased B cell number	J:185495
Atp11c^m1Btlr/Atp11c^m1Btlr (involves: C57BL/6J)	immune system phenotype	J:185495, J:171925
Atp11c^m1Btlr/Atp11c^m2Btlr (involves: C57BL/6J)	decreased B cell number	J:171925
Atp11c^m2Anu/Y (C57BL/6JAnu-Atp11c^m2Anu/AnuApb)	decreased B cell number	J:171924
Atp11c^m2Btlr/Y (involves: C57BL/6J)	decreased B cell number	J:185495, J:171925
Atp11c^m2Btlr/Y (involves: C57BL/6J)	immune system phenotype	J:185495
Atp11c^m2Btlr/Atp11c^m2Btlr (involves: C57BL/6J)	decreased B cell number	J:185495
Atp11c^m2Btlr/Atp11c^m2Btlr (involves: C57BL/6J)	immune system phenotype	J:185495
Atp13a3^em1(IMPC)J/Atp13a3^em1(IMPC)J (C57BL/6NJ-Atp13a3^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
Atp13a5^tm1Lex/Atp13a5^tm1Lex (B6;129S5-Atp13a5^tm1Lex/Mmucd)	decreased NK cell number	J:171883
Atr^tm1Bal/Atr^tm2Bal Ndor1^{Tg(UBC-cre/ERT2)1Ejb}/0 (involves: 129S/SvEv * 129S2/SvPas * C57BL/6)	abnormal thymus involution	J:123200
	decreased thymocyte number	J:123200
	kidney inflammation	J:123200
Atr^tm1Ofc/Atr^tm1Ofc (Not Specified)	decreased spleen weight	J:151542
Atr^tm1Ofc/Atr^tm1Ofc (Not Specified)	decreased thymus weight	J:151542
Atxn3^{tm1a(KOMP)Wtsi}/Atxn3^{tm1a(KOMP)Wtsi} (C57BL/6N-Atxn3^{tm1a(KOMP)Wtsi}/Wtsi)	increased anti-nuclear antigen antibody level	J:211773
AU040320^em1Janc/AU040320^em2Janc (FVB/N-AU040320^em1Janc AU040320^em2Janc)	decreased susceptibility to Parvoviridae infection	J:229089
Auh^em1(IMPC)Tcp/Auh^em1(IMPC)Tcp (C57BL/6NCrl-Auh^em1(IMPC)Tcp/Tcp)	increased eosinophil cell number	J:211773
Aurka^{tm1b(EUCOMM)Hmgu}/Aurka⁺ (B6N(Cg)-Aurka^{tm1b(EUCOMM)Hmgu}/J)	decreased leukocyte cell number	J:211773
Avil^tm2(cre)Fawa/Avil^tm2(cre)Fawa (B6J.129P2-Avil^tm2(cre)Fawa)	increased susceptibility to experimental autoimmune encephalomyelitis	J:265529
Avp^{tm1b(EUCOMM)Wtsi}/Avp⁺ (C57BL/6N-Avp^{tm1b(EUCOMM)Wtsi}/H)	decreased large unstained cell number	J:211773
	decreased neutrophil cell number	J:211773
	increased lymphocyte cell number	J:211773
Avpr1a^tm1Sbhu/Avpr1a^tm1Sbhu (involves: C57BL/6)	abnormal B cell differentiation	J:105892
	abnormal immunoglobulin level	J:105892
	decreased IgG2b level	J:105892
	increased B-1a cell number	J:105892
	increased IgG2a level	J:105892
AW112010^em2Flv/AW112010^em2Flv (involves: C57BL/6N)	decreased circulating interleukin-6 level	J:267975
	decreased circulating interleukin-12b level	J:267975
	decreased interleukin-6 secretion	J:267975
	decreased interleukin-12b secretion	J:267975
	decreased susceptibility to induced colitis	J:267975
	increased susceptibility to bacterial infection	J:267975
	increased susceptibility to bacterial infection induced morbidity/mortality	J:267975
Awat2^em1(IMPC)Mbp/Y (C57BL/6NCrl-Awat2^em1(IMPC)Mbp/Mmucd)	abnormal lymph node morphology	J:211773
Awat2^tm1.2Golc/Y (involves: 129 * C57BL/6 * C57BL/6J)	abnormal lymphangiogenesis	J:308387
	blepharitis	J:308387
	eye inflammation	J:308387
Awat2^tm1.2Golc/Awat2^tm1.2Golc (involves: 129 * C57BL/6 * C57BL/6J)	abnormal lymphangiogenesis	J:308387
	blepharitis	J:308387
	eye inflammation	J:308387
awg^{Tg(GBts1env)832Pkw}/awg^{Tg(GBts1env)832Pkw} (involves: C57BL/6J * SJL)	thymus atrophy	J:43273
Axl^tm1Grl/Axl^tm1Grl Mertk^tm1Grl/Mertk^tm1Grl (involves: C57BL/6J)	increased anti-double stranded DNA antibody level	J:70420
Axl^tm1Grl/Axl^tm1Grl Mertk^tm1Grl/Mertk^tm1Grl Tyro3^tm1Grl/Tyro3^tm1Grl (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	abnormal B cell activation	J:70420
	abnormal macrophage physiology	J:70420
	abnormal professional antigen presenting cell physiology	J:70420
	abnormal susceptibility to autoimmune disorder	J:70420
	abnormal T cell activation	J:70420
	enlarged lymph nodes	J:70420
	enlarged spleen	J:54681, J:70420
	increased anti-double stranded DNA antibody level	J:70420
	increased autoantibody level	J:70420
	increased B cell proliferation	J:70420
	increased circulating tumor necrosis factor level	J:70420
	increased lymphocyte cell number	J:70420
	increased splenocyte apoptosis	J:54681
	increased T cell proliferation	J:70420
	joint inflammation	J:70420
Axl^tm1Grl/Axl^tm1Grl Tyro3^tm1Grl/Tyro3^tm1Grl (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	increased anti-double stranded DNA antibody level	J:70420
Azgp1^tm1.1Sbah/Azgp1^tm1.1Sbah (involves: 129P2/OlaHsd * C57BL/6)	enlarged spleen	J:118213
Azi2^tm1Aki/Azi2^tm1Aki (Not Specified)	abnormal dendritic cell differentiation	J:204786
	abnormal dendritic cell physiology	J:204786
	decreased interferon-alpha secretion	J:204786
	decreased interleukin-6 secretion	J:204786
	decreased tumor necrosis factor secretion	J:204786
	immune system phenotype	J:204786
Azi2^tm1Aki/Azi2^tm1Aki Tbkbp1^tm1Aki/Tbkbp1^tm1Aki (Not Specified)	abnormal dendritic cell physiology	J:204786
	decreased interferon-alpha secretion	J:204786
	decreased interleukin-6 secretion	J:204786
	decreased tumor necrosis factor secretion	J:204786
	immune system phenotype	J:204786
b2b227Clo/b2b227Clo (C57BL/6J-b2b227Clo)	spleen hypoplasia	J:175213
b2b386.1Clo/b2b386.1Clo (C57BL/6J-b2b386.1Clo)	absent spleen	J:175213
b2b386Clo/b2b386Clo (C57BL/6J-b2b386Clo)	absent spleen	J:175213
b2b954Clo/b2b954Clo (C57BL/6J-b2b954Clo)	thymus hypoplasia	J:175213
b2b1249Clo/b2b1249Clo (C57BL/6J-b2b1249Clo)	thymus hypoplasia	J:175213
b2b1702Clo/b2b1702Clo (C57BL/6J-b2b1702Clo)	spleen hypoplasia	J:175213
b2b1702Clo/b2b1702Clo (C57BL/6J-b2b1702Clo)	thymus hypoplasia	J:175213
b2b1941Clo/b2b1941Clo (C57BL/6J-b2b1941Clo)	athymia	J:175213
b2b2025Clo/b2b2025Clo (C57BL/6J-b2b2025Clo)	absent spleen	J:175213
b2b2025Clo/b2b2025Clo (C57BL/6J-b2b2025Clo)	spleen hypoplasia	J:175213
b2b2059Clo/b2b2059Clo (C57BL/6J-b2b2059Clo)	spleen hypoplasia	J:175213
b2b2140Clo/b2b2140Clo (C57BL/6J-b2b2140Clo)	spleen hypoplasia	J:175213
b2b2187Clo/b2b2187Clo (C57BL/6J-b2b2187Clo)	thymus hypoplasia	J:175213
b2b2463Clo/b2b2463Clo (C57BL/6J-b2b2463Clo)	thymus hypoplasia	J:175213
b2b2588Clo/b2b2588Clo (C57BL/6J-b2b2588Clo)	thymus hypoplasia	J:175213
b2b2696.1Clo/b2b2696.1Clo (C57BL/6J-b2b2696.1Clo)	absent spleen	J:175213
b2b2696.2Clo/b2b2696.2Clo (C57BL/6J-b2b2696.2Clo)	thymus hypoplasia	J:175213
b2b2696Clo/b2b2696Clo (C57BL/6J-b2b2696Clo)	absent spleen	J:175213
b2b2736.2Clo/b2b2736.2Clo (C57BL/6J-b2b2736.2Clo)	thymus hypoplasia	J:175213
b2b2736Clo/b2b2736Clo (C57BL/6J-b2b2736Clo)	accessory spleen	J:175213
	spleen hypoplasia	J:175213
	thymus hypoplasia	J:175213
b2b2821Clo/b2b2821Clo (C57BL/6J-b2b2821Clo)	thymus hypoplasia	J:175213
b2b2966Clo/b2b2966Clo (C57BL/6J-b2b2966Clo)	thymus hypoplasia	J:175213
b2b3077.2Clo/b2b3077.2Clo (C57BL/6J-b2b3077.2Clo)	thymus hypoplasia	J:175213
b2b3077Clo/b2b3077Clo (C57BL/6J-b2b3077Clo)	thymus hypoplasia	J:175213
b2b3121Clo/b2b3121Clo (C57BL/6J-b2b3121Clo)	thymus hypoplasia	J:175213
b2b3260.2Clo/b2b3260.2Clo (C57BL/6J-b2b3260.2Clo)	abnormal thymus morphology	J:175213
b2b3260.2Clo/b2b3260.2Clo (C57BL/6J-b2b3260.2Clo)	thymus hypoplasia	J:175213
b2b3260Clo/b2b3260Clo (C57BL/6J-b2b3260Clo)	abnormal thymus morphology	J:175213
b2b3260Clo/b2b3260Clo (C57BL/6J-b2b3260Clo)	thymus hypoplasia	J:175213
B2m^tm1Jae/B2m^tm1Jae (involves: 129S2/SvPas * C57BL/6J)	abnormal CD8-positive, alpha-beta cytotoxic T cell morphology	J:80910
	abnormal cytotoxic T cell physiology	J:80910
	decreased CD8-positive, alpha-beta T cell number	J:80910, J:744
	increased gamma-delta intraepithelial T cell number	J:744
	increased gamma-delta T cell number	J:744
B2m^tm1Jae/B2m^tm1Jae (involves: 129S2/SvPas)	decreased CD8-positive, alpha-beta T cell number	J:166104
B2m^tm1Jae/B2m^tm1Jae (B6.129S2-B2m^tm1Jae)	decreased interleukin-4 secretion	J:64283
	decreased susceptibility to parasitic infection	J:64283
	increased interleukin-3 secretion	J:64283
	increased tumor necrosis factor secretion	J:64283
B2m^tm1Jae/B2m^tm1Jae Cd4^tm1Jrp/Cd4^tm1Jrp (involves: 129S2/SvPas * C57BL/6)	increased CD8-positive, alpha-beta T cell number	J:45168
B2m^tm1Jae/B2m^tm1Jae Foxp3^sf Otc^spf/Y (involves: 129/Rl * 129S2/SvPas)	abnormal immune system organ morphology	J:20865
	abnormal interleukin level	J:20865
	abnormal lymph node morphology	J:20865
	abnormal tumor necrosis factor level	J:20865
	dermatitis	J:20865
	enlarged lymph nodes	J:20865
	enlarged spleen	J:20865
	increased CD4-positive, alpha-beta T cell number	J:20865
	increased IgG level	J:20865
	increased IgM level	J:20865
	increased immunoglobulin level	J:20865
	increased plasma cell number	J:20865
B2m^tm1Jae/B2m^tm1Jae Rr94^tm3.2Litt/Rr94^tm3.2Litt (involves: 129P2/OlaHsd * 129S2/SvPas * FVB/N)	abnormal T cell differentiation	J:158962
	abnormal T cell subpopulation ratio	J:158962
	decreased CD4-positive, alpha-beta T cell number	J:158962
	increased CD8-positive, alpha-beta T cell number	J:158962
	increased T cell proliferation	J:158962
B2m^tm1Jae/B2m^tm1Jae Rr96^tm1.1Yzo/Rr96^tm1.1Yzo (involves: 129P2/OlaHsd * 129S2/SvPas)	abnormal T cell differentiation	J:130559
B2m^tm1Jae/B2m^tm1Jae Tg(H2-K-Cd86)27All/0 (involves: 129S2/SvPas * C57BL/6 * CBA)	absent B cells	J:112475
B2m^tm1Jae/B2m^tm1Jae Tg(LckNotch1)9Erob/? (involves: 129S2/SvPas * C57BL/6 * CBA)	increased CD8-positive, alpha-beta T cell number	J:93005
	lymph node hypoplasia	J:93005
B2m^tm1Jae/B2m^tm1Jae Themis^tm1Lov/Themis^tm1Lov (involves: 129)	abnormal CD8-positive, alpha-beta T cell differentiation	J:151075
B2m^tm1Jae/B2m^tm1Jae Tnf^tm2Gkl/Tnf⁺ (involves: 129S/SvEv * 129S2/SvPas * C57BL/6J)	small intestinal inflammation	J:108572
B2m^tm1Jae/B2m^tm1Jae Tox^tm1.1Kay/Tox^tm1.1Kay (involves: 129S6/SvEvTac * 129S2/SvPas)	abnormal CD8-positive, alpha-beta T cell number	J:131287
B2m^tm1Jae/B2m^tm1Jae Zbtb7b^tm1Litt/Zbtb7b^tm1.2Litt (involves: 129S2/SvPas * C57BL/6)	abnormal CD8-positive, alpha-beta T cell differentiation	J:141144
	abnormal double-positive T cell morphology	J:141144
B2m^tm1Unc/B2m⁺ (involves: 129P2/OlaHsd * C57BL/6)	decreased CD8-positive, alpha-beta T cell number	J:64451
B2m^tm1Unc/B2m⁺ (involves: 129P2/OlaHsd * C57BL/6)	decreased level of surface class I molecules	J:64451
B2m^tm1Unc/B2m^tm1Unc (involves: 129P2/OlaHsd * C57BL/6)	abnormal T cell number	J:113083
	absent CD8-positive, alpha-beta T cells	J:64451
	decreased level of surface class I molecules	J:64451
B2m^tm1Unc/B2m^tm1Unc (NOD.129P2-B2m^tm1Unc)	absent CD8-positive, alpha-beta T cells	J:121685
B2m^tm1Unc/B2m^tm1Unc (NOD.129P2-B2m^tm1Unc)	decreased susceptibility to autoimmune diabetes	J:121685, J:17000
B2m^tm1Unc/B2m^tm1Unc (involves: 129P2/OlaHsd * NOD/Lt)	insulitis	J:93557
B2m^tm1Unc/B2m^tm1Unc (B6.129P2-B2m^tm1Unc/DcrJ)	abnormal interleukin level	J:123934
	abnormal tumor necrosis factor level	J:123934
	decreased CD8-positive, alpha-beta T cell number	J:123934
	decreased IgG level	J:110885
	decreased susceptibility to autoimmune diabetes	J:135214
	decreased susceptibility to bacterial infection	J:123934
	increased IgM level	J:110885
	increased susceptibility to infection induced morbidity/mortality	J:123934
	increased T-helper 1 cell number	J:123934
B2m^tm1Unc/B2m^tm1Unc Cd4^tm1Mak/Cd4^tm1Mak Cd8a^{tm2.1(Cd4)Asin}/Cd8a^{tm2.1(Cd4)Asin} (involves: 129 * C57BL/6)	abnormal T cell physiology	J:180236
B2m^tm1Unc/B2m^tm1Unc Ciita^tm1Ccum/Ciita^tm1Ccum (NOD.Cg-B2m^tm1Unc Ciita^tm1Ccum)	decreased single-positive T cell number	J:107051
	decreased susceptibility to autoimmune diabetes	J:107051
B2m^tm1Unc/B2m^tm1Unc Emv30^b/Emv30^b Prkdc^scid/Prkdc^scid Tg(B2M)55Hpl/? Mcph1^{Tg(HLA-A2.1)1Enge}/? (NOD.Cg-B2m^tm1Unc Mcph1^{Tg(HLA-A2.1)1Enge} Emv30^b Prkdc^scid Tg(B2M)55Hpl/Dvs)	decreased susceptibility to autoimmune diabetes	J:109851
B2m^tm1Unc/B2m^tm1Unc H2-Ab1^b-tm1Doi/H2-Ab1^b-tm1Doi Lat^tm1.1Mal/Lat^tm1.1Mal (involves: 129P2/OlaHsd * 129S2/SvPas)	absent CD4-positive, alpha-beta T cells	J:77098
	absent CD8-positive, alpha-beta T cells	J:77098
	immune system phenotype	J:77098
B2m^tm1Unc/B2m^tm1Unc H2-D1^b-tm1Bpe/H2-D1^b-tm1Bpe (involves: 129P2/OlaHsd * C57BL/6)	decreased CD8-positive, alpha-beta T cell number	J:41077
B2m^tm1Unc/B2m^tm1Unc Il2^tm1Hor/Il2^tm1Hor (involves: 129 * C57BL/6)	abnormal CD4-positive T cell differentiation	J:39981
	abnormal CD4-positive, alpha-beta T cell physiology	J:51450
	abnormal CD8 positive, alpha-beta intraepithelial T cell morphology	J:39981
	abnormal CD8-positive, alpha beta T cell morphology	J:51450
	abnormal CD8-positive, alpha-beta cytotoxic T cell morphology	J:39981
	colitis	J:39981, J:51450
B2m^tm1Unc/B2m^tm1Unc Il2rg^tm1.1Asin/Il2rg^tm1Wjl Tg(Cd8a-cre)B8Asin/0 (involves: 129P2/OlaHsd 129S4/SvJae * C57BL/6)	decreased CD8-positive, alpha-beta T cell number	J:190889
B2m^tm1Unc/B2m^tm1Unc Il7r^tm1.1Asin/Il7r^tm1Imx Tg(Cd8a-cre)B8Asin/0 (involves: 129P2/OlaHsd 129S7/SvEvBrd * C57BL/6)	decreased CD8-positive, alpha-beta T cell number	J:190889
B2m^tm1Unc/B2m^tm1Unc Lat^tm1.1Mal/Lat^tm1.1Mal (involves: 129P2/OlaHsd * 129S2/SvPas)	abnormal immune system morphology	J:77098
B2m^tm1Unc/B2m^tm1Unc Prkdc^scid/Prkdc^scid (NOD.Cg-B2m^tm1Unc Prkdc^scid)	abnormal NK cell physiology	J:102141
	abnormal response to transplant	J:102141
	absent lymphocyte	J:102141
	arrested B cell differentiation	J:102141
	arrested T cell differentiation	J:102141
	decreased level of surface class I molecules	J:102141
	increased macrophage cell number	J:102141
	increased T cell derived lymphoma incidence	J:102141
B2m^tm1Unc/B2m^tm1Unc Rr381^em2Kap/Rr381^em2Kap (involves: 129P2/OlaHsd * C57BL/6)	absent CD8-positive, alpha-beta T cells	J:333471
B2m^tm1Unc/B2m^tm1Unc Tespa1^tm1Smoc/Tespa1^tm1Smoc (involves: 129 * 129P2/OlaHsd * C57BL/6)	abnormal CD8-positive, alpha beta T cell morphology	J:186446
B2m^tm1Unc/B2m^tm1Unc Tg(B2M)55Hpl/0 (NOD.Cg-B2m^tm1Unc Tg(B2M)55Hpl/Dvs)	decreased susceptibility to autoimmune diabetes	J:71837
	immune system phenotype	J:71837
B2m^tm1Unc/B2m^tm1Unc Tg(B2M)55Hpl/Tg(B2M)55Hpl Mcph1^{Tg(HLA-A2.1)1Enge}/Mcph1^{Tg(HLA-A2.1)1Enge} (NOD.Cg-B2m^tm1Unc Mcph1^{Tg(HLA-A2.1)1Enge} Tg(B2M)55Hpl)	increased susceptibility to autoimmune diabetes	J:109851
B2m^tm1Unc/B2m^tm1Unc Tg(GFAP-B2m)9Mdos/? (involves: 129P2/OlaHsd * C57BL/6 * NOD/ShiLtJ)	absent CD8-positive, alpha-beta T cells	J:135214
	decreased susceptibility to autoimmune diabetes	J:135214
B2m^tm1Unc/B2m^tm1Unc Tg(GFAP-B2m)#Mdos/? (involves: 129P2/OlaHsd * C57BL/6 * NOD/ShiLtJ)	absent CD8-positive, alpha-beta T cells	J:135214
	decreased susceptibility to autoimmune diabetes	J:135214
B2m^tm1Unc/B2m^tm1Unc Tg(HLA-A/H2-D/B2M)1Dvs/0 (NOD.Cg-B2m^tm1Unc Tg(HLA-A/H2-D/B2M)1Dvs)	abnormal CD8-positive, alpha-beta T cell physiology	J:121685
	abnormal cell-mediated immunity	J:121685
	abnormal cytotoxic T cell physiology	J:121685
	decreased CD8-positive, alpha-beta T cell number	J:121685
	increased susceptibility to autoimmune diabetes	J:121685
B2m^tm1Unc/B2m^tm1Unc Tg(TcraAI4)1Dvs/0 Tg(TcrbAI4)1Dvs/0 (NOD.Cg-B2m^tm1Unc Tg(TcraAI4)1Dvs Tg(TcrbAI4)1Dvs)	abnormal CD8-positive, alpha beta T cell morphology	J:93553
	decreased susceptibility to autoimmune diabetes	J:93553
B2m^tm1Unc/B2m^tm1Unc X/Yaa (BXSB.129P2(B6)-B2m^tm1Unc/Dcr)	increased anti-nuclear antigen antibody level	J:179430
B2m^tm1Unc/B2m^tm1Unc X/Yaa (BXSB.129P2(B6)-B2m^tm1Unc/Dcr)	increased susceptibility to systemic lupus erythematosus	J:179430
B2m^tm1Unc/B2m^tm1Unc Zbtb7b^tm4.1Itan/Zbtb7b^tm4.1Itan (involves: 129P2/OlaHsd)	increased CD8-positive, alpha-beta T cell number	J:193321
B3galt2^{tm1.1(KOMP)Vlcg}/B3galt2⁺ (C57BL/6N-B3galt2^{tm1.1(KOMP)Vlcg}/Tcp)	decreased lymphocyte cell number	J:211773
B3gnt2^{Gt(OST237555)Lex}/B3gnt2^{Gt(OST237555)Lex} (involves: 129S5/SvEvBrd * C57BL/6N)	abnormal macrophage physiology	J:125556
	increased interleukin-1 beta secretion	J:125556
	increased interleukin-6 secretion	J:125556
	increased T cell proliferation	J:125556
	increased tumor necrosis factor secretion	J:125556
B3gnt5^tm1Big/B3gnt5^tm1Big (C57BL/6-B3gnt5^tm1Big)	abnormal spleen germinal center morphology	J:166763
	abnormal spleen morphology	J:166763
	absent spleen marginal zone	J:166763
	decreased B cell number	J:166763
	enlarged lymph nodes	J:166763
	enlarged spleen	J:166763
	increased spleen white pulp amount	J:166763
	intermingled spleen red and white pulp	J:166763
B3gnt5^tm1Nari/B3gnt5^tm1Nari (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell morphology	J:161366
	increased IgG2a level	J:161366
	increased IgG2b level	J:161366
	increased IgG level	J:161366
B3gnt5^tm2.1Big/B3gnt5^tm2.1Big (involves: 129/Sv * C57BL/6 * FVB/N)	abnormal spleen germinal center morphology	J:166763
	abnormal spleen morphology	J:166763
	absent spleen marginal zone	J:166763
	decreased B cell number	J:166763
	enlarged lymph nodes	J:166763
	enlarged spleen	J:166763
	increased spleen white pulp amount	J:166763
	intermingled spleen red and white pulp	J:166763
B3gnt6^tm1Lx/B3gnt6^tm1Lx (involves: 129S1/Sv * C57BL/6J)	increased interferon-gamma secretion	J:123826
	increased interleukin-2 secretion	J:123826
	increased macrophage cell number	J:123826
	increased monocyte cell number	J:123826
	increased susceptibility to induced colitis	J:123826
	increased T cell number	J:123826
	increased tumor necrosis factor secretion	J:123826
B3gnt6^tm1Lx/B3gnt6^tm1Lx C1galt1^tm1.1Rpmc/C1galt1^tm1.1Rpmc Tg(Vil1-cre)997Gum/0 (involves: 129S1/Sv * C57BL/6J * SJL)	small intestinal inflammation	J:239765
B3gnt7^{tm1e.1(KOMP)Wtsi}/B3gnt7^{tm1e.1(KOMP)Wtsi} (C57BL/6N-B3gnt7^{tm1e.1(KOMP)Wtsi}/Ucd)	enlarged spleen	J:211773
B4galnt1^tm1Rlp/B4galnt1^tm1Rlp Hexb^tm1Rlp/Hexb^tm1Rlp (involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6)	abnormal macrophage morphology	J:53080
B4galnt2^tm1Jbl/B4galnt2^tm1Jbl (involves: 129S1/Sv)	abnormal B cell number	J:217719
B4galnt2^tm1Jbl/B4galnt2^tm1Jbl (involves: 129S1/Sv)	increased neutrophil cell number	J:217719
B4galnt3^{tm1a(EUCOMM)Wtsi}/B4galnt3^{tm1a(EUCOMM)Wtsi} (C57BL/6N-B4galnt3^{tm1a(EUCOMM)Wtsi}/Ics)	increased CD8-positive, alpha-beta T cell number	J:165965
B4galt1^tm1Yiw/B4galt1^tm1Yiw (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	abnormal leukocyte physiology	J:106669
	abnormal neutrophil physiology	J:106669
	decreased acute inflammation	J:106669
	decreased susceptibility to type IV hypersensitivity reaction	J:106669
	enlarged spleen	J:106669
	impaired macrophage chemotaxis	J:89125
	impaired neutrophil recruitment	J:89125
	increased leukocyte cell number	J:106669
	increased lymphocyte cell number	J:106669
	increased neutrophil cell number	J:106669
B4galt1^tm1Yiw/B4galt1^tm1Yiw (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal IgM level	J:117891
	glomerulonephritis	J:117891
	increased IgA level	J:117891
B4galt3^em1Masn/B4galt3^em1Masn (C57BL/6-B4galt3^em1Masn)	abnormal CD8-positive, alpha-beta cytotoxic T cell morphology	J:343168
	decreased regulatory T cell number	J:343168
	increased CD8-positive, alpha-beta T cell number	J:343168
B4galt4^em1(IMPC)J/B4galt4^em1(IMPC)J (C57BL/6NJ-B4galt4^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
B4galt5^em1(IMPC)Tcp/B4galt5⁺ (C57BL/6NCrl-B4galt5^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
B4gat1^tm1Mifu/B4gat1^tm1Mifu (B6.Cg-B4gat1^tm1Mifu)	abnormal lymph node cell ratio	J:120722
	immune system phenotype	J:120722
	impaired leukocyte tethering or rolling	J:120722
B4gat1^tm1Mifu/B4gat1^tm1Mifu Gcnt1^tm1Jxm/Gcnt1^tm1Jxm (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal leukocyte migration	J:120722
	abnormal lymph node cell ratio	J:120722
	decreased susceptibility to type IV hypersensitivity reaction	J:120722
	impaired leukocyte tethering or rolling	J:120722
B9d2/Tgfb1^tm1Flv/B9d2/Tgfb1^tm1Flv Tg(Cd4-cre)1Cwi/0 (involves: 129S6/SvEvTac * C57BL/6 * SJL)	abnormal regulatory T cell physiology	J:204761
B9d2/Tgfb1^tm1Flv/B9d2/Tgfb1^tm1Flv Tg(CD207-cre)1Dhka/? (involves: 129S6/SvEvTac * C57BL/6J * SJL/J)	decreased Langerhans cell number	J:126147
B9d2/Tgfb1^tm1Flv/Tgfb1^tm2Flv Foxp3^{tm4(YFP/icre)Ayr}/Foxp3⁺ (involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ)	immune system phenotype	J:169839
	increased regulatory T cell number	J:169839
B9d2/Tgfb1^tm1Flv/Tgfb1^tm2Flv Tg(Cd4-cre)1Cwi/0 (involves: 129S6/SvEvTac * C57BL/6 * DBA/2)	abnormal inflammatory response	J:123547
	abnormal interferon level	J:123547
	abnormal interleukin level	J:123547
	abnormal T cell activation	J:123547
	abnormal T cell differentiation	J:123547
	abnormal T-helper 17 cell differentiation	J:169839
	colitis	J:123547
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:123547
	increased anti-double stranded DNA antibody level	J:123547
	increased anti-nuclear antigen antibody level	J:123547
	increased T cell proliferation	J:123547
B9d2/Tgfb1^tm1Flv/Tgfb1^tm2Flv Tnfrsf4^tm2(cre)Nik/Tnfrsf4⁺ (involves: 129S6/SvEvTac * 129X1/SvJ)	abnormal T cell differentiation	J:169839
	colitis	J:169839
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:169839
	decreased T-helper 17 cell number	J:169839
	increased regulatory T cell number	J:169839
	increased T-helper 1 cell number	J:169839
	liver inflammation	J:169839
	lung inflammation	J:169839
B9d2/Tgfb1^tm1Flv/B9d2/Tgfb1^tm1Flv Tg(Cd4-cre)1Cwi/? (involves: 129S6/SvEvTac * C57BL/6 * DBA/2)	abnormal inflammatory response	J:123547
B9d2/Tgfb1^tm1Flv/B9d2/Tgfb1^tm1Flv Tg(Cd4-cre)1Cwi/0 (involves: 129S6/SvEvTac * C57BL/6 * SJL)	abnormal regulatory T cell physiology	J:204761
B9d2/Tgfb1^tm1Flv/B9d2/Tgfb1^tm1Flv Tg(CD207-cre)1Dhka/? (involves: 129S6/SvEvTac * C57BL/6J * SJL/J)	decreased Langerhans cell number	J:126147
B9d2/Tgfb1^tm1Flv/B9d2⁺ Foxp3^{tm4(YFP/icre)Ayr}/Foxp3⁺ (involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ)	immune system phenotype	J:169839
	increased regulatory T cell number	J:169839
B9d2/Tgfb1^tm1Flv/B9d2⁺ Tg(Cd4-cre)1Cwi/0 (involves: 129S6/SvEvTac * C57BL/6 * DBA/2)	abnormal T-helper 17 cell differentiation	J:169839
B9d2/Tgfb1^tm1Flv/B9d2⁺ Tg(CD207-cre)1Dhka/? (involves: 129S6/SvEvTac * C57BL/6J * SJL/J)	decreased Langerhans cell number	J:126147
B9d2/Tgfb1^tm1Flv/B9d2⁺ Tnfrsf4^tm2(cre)Nik/Tnfrsf4⁺ (involves: 129S6/SvEvTac * 129X1/SvJ)	abnormal T cell differentiation	J:169839
	colitis	J:169839
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:169839
	decreased T-helper 17 cell number	J:169839
	increased regulatory T cell number	J:169839
	increased T-helper 1 cell number	J:169839
	liver inflammation	J:169839
	lung inflammation	J:169839
B9d2^{tm1a(EUCOMM)Wtsi}/B9d2^{tm1a(EUCOMM)Wtsi} (C57BL/6N-B9d2^{tm1a(EUCOMM)Wtsi}/Wtsi)	abnormal thymus topology	J:239583
	accessory spleen	J:239583
	blood in lymph vessels	J:239583
	enlarged lymphatic vessel	J:239583
	small spleen	J:239583
Baa1^BALB/cJ/Baa1^NZW/LacJ (involves: BALB/cJ * NZW/LacJ)	increased IgM level	J:35434
Baa2^BALB/cJ/Baa2^NZW/LacJ (involves: BALB/cJ * NZW/LacJ)	increased IgM level	J:35434
Baat^em1(IMPC)Mbp/Baat^em1(IMPC)Mbp (C57BL/6NCrl-Baat^em1(IMPC)Mbp/Mmucd)	abnormal lymph node morphology	J:211773
Babam1^{em1(IMPC)Ccpcz}/Babam1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Babam1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	decreased NK T cell number	J:211773
	enlarged thymus	J:211773
	increased eosinophil cell number	J:211773
Bach2^M1Btlr/Bach2^M1Btlr (C57BL/6J-Bach2^M1Btlr)	decreased CD4-positive, alpha-beta T cell number	J:272023
Bach2^M1Btlr/Bach2^M1Btlr (C57BL/6J-Bach2^M1Btlr)	increased B-1 B cell number	J:272023
Bach2^m1Ccg/Bach2^m1Ccg (C57BL/6-Bach2^m1Ccg)	decreased B cell number	J:94077
	decreased marginal zone B cell number	J:94077
	myeloid hyperplasia	J:94077
Bach2^m2Anu/Bach2^m2Anu (C57BL/6NCrl-Bach2^m2Anu)	decreased mature B cell number	J:104190
	increased IgM level	J:104190
	increased immature B cell number	J:104190
Bach2^{tm1a(EUCOMM)Wtsi}/Bach2^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Bach2^{tm1a(EUCOMM)Wtsi}/Wtsi)	decreased B cell number	J:211773
	decreased CD8-positive, naive alpha-beta T cell number	J:211773
	decreased CD11b-high dendritic cell number	J:211773
	decreased effector memory CD8-positive, alpha-beta T cell number	J:211773
	decreased follicular B cell number	J:211773
	decreased mature B cell number	J:211773
	decreased memory-marker NK cell number	J:211773
	decreased regulatory T cell number	J:211773
	increased CD4-positive, alpha-beta memory T cell number	J:211773
	increased CD8-positive, alpha-beta memory T cell number	J:211773
	increased CD11b-low dendritic cell number	J:211773
	increased CD103-positive CD11b-low dendritic cell number	J:211773
	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
	increased effector memory T-helper cell number	J:211773
	increased eosinophil cell number	J:211773
	increased immature B cell number	J:211773
	increased KLRG1+ CD4 alpha-beta T cell number	J:211773
	increased KLRG1+ CD8 alpha-beta T cell number	J:211773
	increased KLRG1-positive CD4-negative NK T cell number	J:211773
	increased KLRG1-positive CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	increased KLRG1-positive gamma-delta T cell number	J:211773
	increased KLRG1-positive NK cell number	J:211773
	increased Ly6C high monocyte number	J:211773
	increased Ly6C low monocyte number	J:211773
	increased macrophage cell number	J:211773
	increased memory CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	increased memory-marker CD4-negative NK T cell number	J:211773
	increased memory-marker NK cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
	increased NK cell number	J:211773
Bach2^{tm1b(EUCOMM)Wtsi}/Bach2^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Bach2^{tm1b(EUCOMM)Wtsi}/Ieg)	decreased B cell number	J:211773
	decreased B-1a cell number	J:211773
	decreased B-2 B cell number	J:211773
	decreased CD4-negative NK T cell number	J:211773
	decreased CD8-positive, naive alpha-beta T cell number	J:211773
	decreased CD11b-high dendritic cell number	J:211773
	decreased follicular B cell number	J:211773
	decreased Ly6C-positive immature NK cell number	J:211773
	decreased Ly6C-positive mature NK cell number	J:211773
	decreased marginal zone B cell number	J:211773
	decreased memory-marker CD4-negative NK T cell number	J:211773
	decreased NK cell number	J:211773
	decreased NK T cell number	J:211773
	decreased transitional stage B cell number	J:211773
	immune system phenotype	J:211773
	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
	increased eosinophil cell number	J:211773
	increased granulocyte number	J:211773
	increased memory-marker CD4-negative NK T cell number	J:211773
	increased monocyte cell number	J:211773
	increased NK T cell number	J:211773
Bach2^tm1Igar/Bach2^tm1Igar (involves: 129P2/OlaHsd * C57BL/6J)	abnormal B cell differentiation	J:91110
	abnormal B cell physiology	J:91110
	abnormal class switch recombination	J:91110
	abnormal somatic hypermutation frequency	J:91110
	absent germinal center B cells	J:91110
	decreased B cell number	J:91110
	decreased IgA level	J:91110
	decreased IgG1 level	J:91110
	decreased IgG2a level	J:91110
	decreased IgG2b level	J:91110
	decreased IgG3 level	J:91110
	decreased IgG level	J:91110
	decreased mature B cell number	J:91110
	increased IgM level	J:91110
	spleen hypoplasia	J:91110
Bad^tm1Meg/Bad^tm1Meg (involves: 129S4/SvJae)	abnormal B cell differentiation	J:88139
	abnormal T cell differentiation	J:88139
	decreased mature B cell number	J:88139
	decreased pro-B cell number	J:88139
	decreased thymus weight	J:88139
	small thymus	J:88139
	thymus hypoplasia	J:88139
Bad^tm1Sjk/Bad^tm1Sjk (either: 129X1/SvJ or (involves: 129X1/SvJ * C57BL/6))	abnormal B cell physiology	J:84987
	abnormal immune system cell morphology	J:84987
	abnormal T cell physiology	J:84987
Bad^tm1Sjk/Bad^tm1Sjk (involves: 129X1/SvJ)	immune system phenotype	J:132819
Bag3^tm1.1Jhl/Bag3^tm1.1Jhl (B6.129S2-Bag3^tm1.1Jhl)	decreased leukocyte cell number	J:144416
	decreased lymphocyte cell number	J:144416
	decreased neutrophil cell number	J:144416
	decreased spleen weight	J:144416
	decreased thymus weight	J:144416
	spleen hypoplasia	J:144416
	thymus hypoplasia	J:144416
Bag4^tm1Yeh/Bag4^tm1Yeh (involves: 129P2/OlaHsd * C57BL/6)	abnormal macrophage physiology	J:83559
	increased circulating interleukin-6 level	J:83559
	increased inflammatory response	J:83559
	increased interleukin-6 secretion	J:83559
	spleen hypoplasia	J:83559
	thymus hypoplasia	J:83559
Bahd1^tm1.1Ics/Bahd1⁺ (involves: C57BL/6)	decreased susceptibility to bacterial infection	J:169470
Bahd1^{tm2b(KOMP)Wtsi}/Bahd1⁺ (C57BL/6N-Bahd1^{tm2b(KOMP)Wtsi}/Ics)	decreased effector memory CD8-positive, alpha-beta T cell number	J:211773
	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
	increased CD4-negative NK T cell number	J:211773
	increased memory-marker CD4-negative NK T cell number	J:211773
	increased neutrophil cell number	J:211773
	increased NK cell number	J:211773
	increased NK T cell number	J:211773
	increased T cell number	J:211773
Bak1^tm1Thsn/Bak1^tm1Thsn Bax^tm1Sjk/Bax^tm1Sjk (involves: 129S1/Sv * 129S1/SvImJ * 129X1/SvJ * C57BL/6)	abnormal B cell morphology	J:66872
	abnormal splenocyte physiology	J:66872
	abnormal T cell morphology	J:66872
	enlarged lymph nodes	J:66872
	enlarged spleen	J:66872
	increased leukocyte cell number	J:66872
	increased lymphocyte cell number	J:66872
	increased spleen red pulp amount	J:66872
	increased spleen white pulp amount	J:66872
Bak1^tm1Thsn/Bak1^tm1Thsn Bax^tm1Sjk/Bax^tm2Sjk Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ)	abnormal B cell number	J:100463
	abnormal B cell physiology	J:100463
	decreased marginal zone B cell number	J:100463
	increased B cell number	J:100463
	increased B-2 B cell number	J:100463
	increased follicular B cell number	J:100463
	increased IgA level	J:100463
	increased IgG level	J:100463
	increased IgM level	J:100463
	increased immunoglobulin level	J:100463
	increased pre-B cell number	J:100463
	increased pro-B cell number	J:100463
	increased transitional stage B cell number	J:100463
Bak1^tm1Thsn/Bak1^tm1Thsn Bax^tm1Sjk/Bax^tm2Sjk Tg(Mx1-cre)1Cgn/0 (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)	abnormal T cell differentiation	J:100463
	autoimmune arthritis	J:100463
	glomerulonephritis	J:100463
	increased anti-double stranded DNA antibody level	J:100463
	increased B cell number	J:100463
	increased leukocyte cell number	J:100463
	increased lymphocyte cell number	J:100463
	increased susceptibility to autoimmune disorder	J:100463
Bak1^tm1Thsn/Bak1^tm1Thsn Bax^tm2Sjk/Bax^tm2Sjk Tg(Lck-cre)1Cwi/? (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)	decreased thymocyte apoptosis	J:220951
Bak1^tm1Thsn/Bak1^tm1Thsn Bax^tm2Sjk/Bax^tm2Sjk Tg(Lck-cre)548Jxm/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)	increased regulatory T cell number	J:208318
Bank1^tm1Kuro/Bank1^tm1Kuro (Not Specified)	abnormal B cell physiology	J:113321
	abnormal lymphocyte physiology	J:113321
	abnormal spleen germinal center morphology	J:113321
	abnormal splenic cell ratio	J:113321
	increased B cell proliferation	J:113321
	increased B-1a cell number	J:113321
	increased IgG2a level	J:113321
	increased IgM level	J:113321
	increased mature B cell number	J:113321
	increased spleen germinal center number	J:113321
	increased spleen germinal center size	J:113321
Bank1^tm1Kuro/Bank1^tm1Kuro Cd40^tm1Kik/Cd40^tm1Kik (involves: 129P2/OlaHsd)	immune system phenotype	J:113321
Bap1^tm1.1Geno/Bap1^tm1.1Geno Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte}/Gt(ROSA)26Sor⁺ (involves: C57BL/6 * C57BL/6NTac)	abnormal granulocyte morphology	J:187380
	abnormal myelopoiesis	J:187380
	abnormal neutrophil morphology	J:187380
	enlarged spleen	J:187380
	heart inflammation	J:187380
	increased leukocyte cell number	J:187380
	increased monocyte cell number	J:187380
	increased neutrophil cell number	J:187380
	myeloid hyperplasia	J:187380
Batf2^tm1Kmm/Batf2^tm1Kmm (129S6/SvEvTac-Batf2^tm1Kmm)	increased susceptibility to parasitic infection induced morbidity/mortality	J:101977
Batf3^tm1Kmm/Batf3^tm1Kmm (involves: 129S6/SvEvTac * BALB/cJ)	abnormal cytotoxic T cell physiology	J:141064
	abnormal dendritic cell antigen presentation	J:141064
	abnormal dendritic cell differentiation	J:141064
	abnormal dendritic cell physiology	J:141064
	abnormal immune system physiology	J:141064
	decreased cytotoxic T cell cytolysis	J:141064
	decreased memory T cell number	J:141064
	decreased myeloid dendritic cell number	J:141064
Batf3^tm1Kmm/Batf3^tm1Kmm (involves: 129S6/SvEvTac)	abnormal cytotoxic T cell physiology	J:181366
	abnormal dendritic cell antigen presentation	J:362930
	immune system phenotype	J:181366
Batf3^tm1Kmm/Batf3^tm1Kmm Id2^tm1Gtbz/Id2^tm1Gtbz (B6.Cg-Batf3^tm1Kmm Id2^tm1Gtbz)	abnormal dendritic cell physiology	J:194760
Batf^tm1.1Ejt/Batf^tm1.1Ejt (involves: 129S/Sv * C57BL/6 * FVB/N)	abnormal class switch recombination	J:160935
	abnormal T-helper 2 cell differentiation	J:160935
	absent germinal center B cells	J:160935
	decreased CD4-positive, alpha-beta T cell number	J:160935
	decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:160935
	decreased IgA level	J:160935
	decreased IgE level	J:160935
	decreased IgG1 level	J:160935
	decreased IgG2c level	J:160935
	decreased IgM level	J:160935
	decreased interleukin-4 secretion	J:160935
	decreased interleukin-17 secretion	J:160935
	decreased T follicular helper cell number	J:160935
	decreased T-helper 17 cell number	J:160935
Batf^tm1.1Kmm/Batf^tm1.1Kmm (129S6/SvEvTac-Batf^tm1.1Kmm)	abnormal CD4-positive T cell differentiation	J:150643
	decreased interleukin-17 secretion	J:150643
	decreased interleukin-21 secretion	J:150643
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:150643
Bax^tm1Sjk/Bax^tm1Sjk (involves: 129X1/SvJ)	enlarged spleen	J:29253
	increased B cell number	J:29253
	increased thymocyte number	J:29253
Baz2a^em1(IMPC)Tcp/Baz2a^em1(IMPC)Tcp (C57BL/6NCrl-Baz2a^em1(IMPC)Tcp/Tcp)	abnormal spleen morphology	J:211773
Baz2b^{em1(IMPC)Wtsi}/Baz2b^{em1(IMPC)Wtsi} (C57BL/6N-Baz2b^{em1(IMPC)Wtsi}/Wtsi)	increased leukocyte cell number	J:211773
Bbaa1^C3H/HeNCr/Bbaa1^C3H/HeNCr (involves: C3H/HeNCr * C57BL/6NCr)	abnormal inflammatory response	J:52017
Bbaa1^C3H/HeNCr/Bbaa1^C57BL/6NCr (involves: C3H/HeNCr * C57BL/6NCr)	abnormal inflammatory response	J:52017
Bbaa2^C3H/HeNCr/Bbaa2^C3H/HeNCr (involves: C3H/HeNCr * C57BL/6NCr)	abnormal immune system physiology	J:52017
Bbaa3^C3H/HeNCr/Bbaa3^C3H/HeNCr (involves: C3H/HeNCr * C57BL/6NCr)	abnormal inflammatory response	J:73060
Bbaa3^C3H/HeNCr/Bbaa3^C57BL/6NCr (involves: C3H/HeNCr * C57BL/6NCr)	abnormal inflammatory response	J:52017
Bbaa5^C57BL/6NCr/Bbaa5^C57BL/6NCr (involves: C3H/HeNCr * C57BL/6NCr)	increased IgM level	J:52017
Bbaa9^C57BL/6NCr/Bbaa9^C3H/HeNCr (involves: C3H/HeNCr * C57BL/6NCr)	abnormal immunoglobulin level	J:52017
Bbaa9^C57BL/6NCr/Bbaa9^C57BL/6NCr (involves: C3H/HeNCr * C57BL/6NCr)	abnormal immunoglobulin level	J:52017
Bbaa10^C3H/HeN/? (involves: C3H/HeN * C57BL/6N)	increased inflammatory response	J:73060
Bbaa11^C3H/HeN/? (involves: C3H/HeN * C57BL/6N)	increased inflammatory response	J:73060
Bbaa12^C3H/HeN/? (involves: C3H/HeN * C57BL/6N)	increased inflammatory response	J:73060
Bbaa13^C3H/HeN/? (involves: C3H/HeN * C57BL/6N)	increased inflammatory response	J:73060
Bbaa14^C3H/HeJ/? (involves: C3H/HeN * C57BL/6N)	increased IgG level	J:73060
Bbaa14^C3H/HeJ/? (involves: C3H/HeN * C57BL/6N)	increased inflammatory response	J:73060
Bbaa15^C3H/HeN/? (involves: C3H/HeN * C57BL/6N)	increased IgG level	J:73060
Bbaa16^C3H/HeN/? (involves: C3H/HeN * C57BL/6N)	increased inflammatory response	J:73060
Bbaa17^C3H/HeN/? (involves: C3H/HeN * C57BL/6N)	increased inflammatory response	J:73060
Bbaa18^C3H/HeN/? (involves: C3H/HeN * C57BL/6N)	increased inflammatory response	J:73060
Bbaa19^C3H/HeN/? (involves: C3H/HeN * C57BL/6N)	increased IgG level	J:73060
Bbaa20^C3H/HeJ/? (involves: C3H/HeN * C57BL/6N)	increased inflammatory response	J:73060
Bbaa21^C3H/HeN/? (involves: C3H/HeN * C57BL/6N)	increased susceptibility to bacterial infection	J:73060
Bbaa22^C3H/HeN/? (involves: C3H/HeN * C57BL/6N)	increased inflammatory response	J:73060
Bbaa23^C3H/HeN/? (involves: C3H/HeN * C57BL/6N)	increased inflammatory response	J:73060
Bbc3^tm1Ast/Bbc3^tm1Ast (involves: C57BL/6 * NZB)	abnormal CD8-positive, alpha-beta T cell physiology	J:132819
	abnormal splenic cell ratio	J:132819
	immune system phenotype	J:132819
	increased CD8-positive, alpha-beta T cell number	J:132819
	increased leukocyte cell number	J:132819
Bbc3^tm1Gpz/Bbc3^tm1Gpz Trp53^tm1Brd/Trp53^tm8Xu (involves: 129P2/OlaHsd * 129S7/SvEvBrd)	decreased thymocyte number	J:170216
Bbln^{tm1(KOMP)Wtsi}/Bbln⁺ (involves: C57BL/6N)	abnormal osteoclast differentiation	J:296689
Bbln^{tm1(KOMP)Wtsi}/Bbln^{tm1(KOMP)Wtsi} (involves: C57BL/6N)	abnormal osteoclast differentiation	J:296689
	increased osteoclast cell number	J:296689
Bbs4^Gt1Nk/Bbs4^Gt1Nk (involves: 129S7/SvEvBrd)	increased immunoglobulin level	J:134093
Bbs5^{tm1b(EUCOMM)Wtsi}/Bbs5^{tm1b(EUCOMM)Wtsi} (C57BL/6NTac-Bbs5^{tm1b(EUCOMM)Wtsi}/H)	decreased spleen weight	J:211773
	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
	increased monocyte cell number	J:211773
Bbs9^em1(IMPC)Bay/Bbs9⁺ (C57BL/6N-Bbs9^em1(IMPC)Bay/Bay)	increased leukocyte cell number	J:211773
Bbs12^{em1(IMPC)Ccpcz}/Bbs12⁺ (C57BL/6NCrl-Bbs12^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Bbs12^tm1.1Vmar/Bbs12^tm1.1Vmar (involves: 129S6/SvEvTac * C57BL/6)	decreased circulating interleukin-6 level	J:189019
	decreased circulating tumor necrosis factor level	J:189019
	decreased inflammatory response	J:189019
Bbx^{tm1a(EUCOMM)Wtsi}/Bbx^{tm1a(EUCOMM)Wtsi} (involves: C57BL/6 * C57BL/6N)	increased IgA level	J:213427
Bcap31^tm1.1Bwang/Bcap31^tm1.1Bwang Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6)	increased inflammatory response	J:292505
	increased interleukin-1 beta secretion	J:292505
	increased microglial cell activation	J:292505
	increased tumor necrosis factor secretion	J:292505
Bcap31^tm1.1Bwang/Bcap31^tm1.1Bwang Tg(Lck-cre)548Jxm/0 (involves: C57BL/6 * CBA)	abnormal T cell activation	J:274469
	decreased CD8-positive, naive alpha-beta T cell number	J:274469
	decreased interferon-gamma secretion	J:274469
	decreased interleukin-2 secretion	J:274469
	decreased single-positive T cell number	J:274469
	decreased T cell proliferation	J:274469
	decreased thymocyte number	J:274469
	decreased thymus weight	J:274469
	increased effector memory T-helper cell number	J:274469
	increased thymocyte apoptosis	J:274469
	small thymus	J:274469
	thymus hypoplasia	J:274469
Bcar3^em1(IMPC)Mbp/Bcar3^em1(IMPC)Mbp (C57BL/6N-Bcar3^em1(IMPC)Mbp/MbpMmucd)	increased basophil cell number	J:211773
Bcas1^tm1Himo/Bcas1^tm1Himo (C57BL/6-Bcas1^tm1Himo)	brain inflammation	J:242041
Bcat1^tm1.2Eaa/Bcat1^tm1.2Eaa (involves: C57BL/6)	abnormal T cell physiology	J:216027
Bckdha^em1(IMPC)Tcp/Bckdha⁺ (C57BL/6NCrl-Bckdha^em1(IMPC)Tcp/Tcp)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Bcl2^tm1Dlo/Bcl2^tm1Dlo (involves: 129P2/OlaHsd * C57BL/6)	abnormal T cell differentiation	J:73660
	decreased CD8-positive, alpha-beta T cell number	J:73660
	decreased lymphocyte cell number	J:73660
	decreased mature B cell number	J:73660
	decreased pre-B cell number	J:73660
	decreased thymocyte number	J:73660
Bcl2^tm1Dlo/Bcl2^tm1Dlo (B6.129P2-Bcl2^tm1Dlo)	abnormal leukopoiesis	J:73316
	abnormal lymphocyte physiology	J:104487, J:73316
	decreased spleen weight	J:153846
	decreased spleen white pulp amount	J:153846
	increased B cell apoptosis	J:73316
	increased splenocyte apoptosis	J:153846
	increased T cell apoptosis	J:73316
	spleen atrophy	J:153846
Bcl2^tm1Dlo/Bcl2^tm1Dlo Bcl2l11^tm1.1Ast/Bcl2l11⁺ (B6.129-Bcl2^tm1Dlo Bcl2l11^tm1.1Ast)	abnormal lymphocyte physiology	J:73316
	increased T cell apoptosis	J:73316
Bcl2^tm1Dlo/Bcl2^tm1Dlo Bcl2l11^tm1.1Ast/Bcl2l11⁺ (B6.Cg-Bcl2^tm1Dlo Bcl2l11^tm1.1Ast)	increased leukocyte cell number	J:153846
	increased spleen weight	J:153846
Bcl2^tm1Dlo/Bcl2^tm1Dlo Bcl2l11^tm1.1Ast/Bcl2l11^tm1.1Ast (B6.129-Bcl2^tm1Dlo Bcl2l11^tm1.1Ast)	abnormal leukopoiesis	J:73316
	abnormal lymphocyte physiology	J:73316
	decreased B cell apoptosis	J:73316
	increased T cell apoptosis	J:73316
Bcl2^tm1Dlo/Bcl2^tm1Dlo Bcl2l11^tm1.1Ast/Bcl2l11^tm1.1Ast (B6.Cg-Bcl2^tm1Dlo Bcl2l11^tm1.1Ast)	increased leukocyte cell number	J:153846
	increased spleen weight	J:153846
Bcl2^tm1Dlo/Bcl2^tm1Dlo Bcl2l11^tm1.1Boui/Bcl2l11^tm1.1Boui (B6.Cg-Bcl2^tm1Dlo Bcl2l11^tm1.1Boui)	immune system phenotype	J:153846
Bcl2^tm1Dlo/Bcl2^tm1Dlo Bcl2l11^tm1.1Boui/Bcl2l11^tm2.1Boui (B6.Cg-Bcl2^tm1Dlo Bcl2l11^tm1.1Boui/Bcl2l11^tm2.1Boui)	immune system phenotype	J:153846
	increased leukocyte cell number	J:153846
	increased spleen weight	J:153846
Bcl2^tm1Dlo/Bcl2^tm1Dlo Bcl2l11^tm2.1Boui/Bcl2l11^tm2.1Boui (B6.Cg-Bcl2^tm1Dlo Bcl2l11^tm2.1Boui)	immune system phenotype	J:153846
Bcl2^tm1Dlo/Bcl2^tm1Dlo Bcl2l11^tm3.1Boui/Bcl2l11^tm3.1Boui (B6.Cg-Bcl2^tm1Dlo Bcl2l11^tm3.1Boui)	decreased splenocyte apoptosis	J:153846
	immune system phenotype	J:153846
	increased leukocyte cell number	J:153846
	increased spleen weight	J:153846
Bcl2^tm1Dlo/Bcl2^tm1Dlo Bik^tm1Ast/Bik^tm1Ast (B6.Cg-Bcl2^tm1Dlo Bik^tm1Ast)	abnormal lymphocyte physiology	J:104487
Bcl2^tm1Irt/Bcl2^tm1Irt Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6)	increased macrophage apoptosis	J:144243
Bcl2^tm1Lbox/Bcl2^tm1Lbox (involves: 129S1/Sv * 129X1/SvJ * FVB/N)	abnormal B cell activation	J:114637
	abnormal B cell differentiation	J:114637
	decreased B cell number	J:114637
	decreased B cell proliferation	J:114637
	decreased immature B cell number	J:114637
	decreased mature B cell number	J:114637
	decreased pre-B cell number	J:114637
	increased B cell apoptosis	J:114637
Bcl2^tm1Sjk/Bcl2^tm1Sjk (involves: 129S2/SvPas * C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:15224
	abnormal CD8-positive, alpha beta T cell morphology	J:15224
	abnormal immune system organ morphology	J:15224
	abnormal spleen morphology	J:15224
	abnormal spleen red pulp morphology	J:15224
	abnormal spleen white pulp morphology	J:15224
	abnormal thymus involution	J:15224
	abnormal thymus morphology	J:15224
	decreased B cell number	J:15224
	decreased double-positive T cell number	J:15224
	decreased lymphocyte cell number	J:15224
	decreased T cell number	J:15224
	increased double-negative T cell number	J:15224
	increased T cell apoptosis	J:15224
	small spleen	J:15224
	small thymus	J:15224
Bcl2^tm1Tsu/Bcl2^tm1Tsu (involves: 129P2/OlaHsd * ICR)	abnormal lymphocyte morphology	J:22391
	abnormal T cell physiology	J:22391
	small spleen	J:22391
	small thymus	J:22391
	spleen atrophy	J:22391
	thymus atrophy	J:22391
Bcl2^tm2.1Lbox/Bcl2⁺ (involves: 129S1/Sv * 129X1/SvJ * FVB/N)	abnormal B cell physiology	J:175730
	enlarged lymph nodes	J:175730
	enlarged spleen	J:175730
	increased B cell number	J:175730
	increased immature B cell number	J:175730
	increased mature B cell number	J:175730
	increased pre-B cell number	J:175730
Bcl2^tm2.1Lbox/Bcl2^tm2.1Lbox (involves: 129S1/Sv * 129X1/SvJ * FVB/N)	abnormal B cell physiology	J:175730
	enlarged lymph nodes	J:175730
	enlarged spleen	J:175730
	increased B cell number	J:175730
	increased immature B cell number	J:175730
	increased mature B cell number	J:175730
	increased pre-B cell number	J:175730
Bcl2a1a^tm1.1Tac/Bcl2a1a^tm1.1Tac Bcl2a1b^tm1.1Tac/Bcl2a1b^tm1.1Tac Bcl2a1d^tm1.1Tac/Bcl2a1d^tm1.1Tac (involves: BALB/cJ * C57BL/6NTac)	abnormal dendritic cell physiology	J:258915
	decreased CD4-positive, alpha-beta memory T cell number	J:258915
	decreased central memory CD4-positive, alpha-beta T cell number	J:258915
	decreased dendritic cell number	J:258915
	decreased effector memory CD4-positive, alpha-beta T cell number	J:258915
	decreased gamma-delta T cell number	J:258915
	decreased regulatory T cell number	J:258915
	immune system phenotype	J:258915
Bcl2a1a^tm1Prys/Bcl2a1a^tm1Prys (involves: 129/Sv * C57BL/6J * SJL)	abnormal neutrophil physiology	J:74478
	decreased inflammatory response	J:74478
	decreased susceptibility to parasitic infection	J:74478
Bcl2a1a^tm1Sen/Bcl2a1a^tm1Sen (involves: 129P2/OlaHsd * C57BL/6)	abnormal neutrophil physiology	J:52127
Bcl2l1^tm1Cant/Bcl2l1^tm1Cant (involves: 129S6/SvEvTac)	abnormal memory T cell physiology	J:77507
	abnormal T cell physiology	J:77507
	decreased interleukin-2 secretion	J:77507
	decreased memory T cell number	J:77507
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:77507
	decreased T cell proliferation	J:77507
Bcl2l1^tm1Dlo/Bcl2l1^tm1.1Mam Tg(Aicda-cre)9Mbu/0 (B6.Cg-Bcl2l1^tm1Dlo/Bcl2l1^tm1.1Mam Tg(Aicda-cre)9Mbu)	decreased IgG1 level	J:166069
	immune system phenotype	J:166069
Bcl2l1^tm1Ywh/Bcl2l1^tm1Ywh Mcl1^tm1Ywh/Mcl1^tm1Ywh Tg(Cd4-cre)1Cwi/0 (involves: 129S6/SvEvTac * C57BL/6 * DBA/2)	absent CD4-positive, alpha-beta T cells	J:137400
	absent CD8-positive, alpha-beta T cells	J:137400
	decreased double-positive T cell number	J:137400
Bcl2l1^tm1Ywh/Bcl2l1^tm1Ywh Tg(Lck-cre)548Jxm/? (involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6 * CBA)	decreased double-positive T cell number	J:99012
	decreased thymocyte number	J:99012
Bcl2l11^em1(IMPC)H/Bcl2l11^em1(IMPC)H (C57BL/6NTac-Bcl2l11^em1(IMPC)H/H)	increased large unstained cell number	J:211773
	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
	increased spleen weight	J:211773
Bcl2l11^em1Flv/Bcl2l11⁺ Morrbid⁺/Morrbid^em1Flv (C57BL/6N-Bcl2l11^em1Flv +/+ Morrbid^em1Flv)	decreased eosinophil cell number	J:236609
	decreased Ly6C high monocyte number	J:236609
	decreased neutrophil cell number	J:236609
Bcl2l11^em1Flv/Bcl2l11⁺ Morrbid^em1Flv/Morrbid⁺ (C57BL/6N-Bcl2l11^em1Flv Morrbid^em1Flv /+ +)	immune system phenotype	J:236609
Bcl2l11^tm1.1Ast/Bcl2l11⁺ (involves: 129S1/Sv * C57BL/6)	abnormal lymphocyte physiology	J:58641
	glomerulonephritis	J:58641
	increased IgA level	J:58641
	increased IgG level	J:58641
	increased IgM level	J:58641
	increased susceptibility to autoimmune disorder	J:58641
Bcl2l11^tm1.1Ast/Bcl2l11⁺ (B6.129S1-Bcl2l11^tm1.1Ast)	immune system phenotype	J:153846
	increased leukocyte cell number	J:153846
	increased spleen weight	J:153846
Bcl2l11^tm1.1Ast/Bcl2l11⁺ Pten^tm1Hwu/Pten⁺ Tg(CD2-icre)4Kio/0 (involves: 129S1/Sv * 129S4/SvJae * C57BL/10 * CBA/Ca)	abnormal T cell number	J:133215
	increased germinal center B cell number	J:133215
Bcl2l11^tm1.1Ast/Bcl2l11^tm1.1Ast (involves: 129S1/Sv * C57BL/6)	abnormal B cell proliferation	J:90963
	abnormal lymphocyte physiology	J:58641
	abnormal plasma cell morphology	J:58641
	abnormal spleen morphology	J:58641
	abnormal splenic cell ratio	J:132217
	decreased B cell apoptosis	J:90963
	decreased double-positive T cell number	J:58641
	enlarged spleen	J:58641
	glomerulonephritis	J:58641
	increased anti-double stranded DNA antibody level	J:132217
	increased anti-histone antibody level	J:132217
	increased anti-nuclear antigen antibody level	J:132217
	increased anti-single stranded DNA antibody level	J:132217
	increased autoantibody level	J:132217
	increased B cell number	J:58641
	increased CD4-positive, alpha-beta T cell number	J:58641
	increased CD8-positive, alpha-beta T cell number	J:58641
	increased double-negative T cell number	J:58641
	increased follicular B cell number	J:132217
	increased granulocyte number	J:58641
	increased IgA level	J:58641
	increased IgG level	J:58641
	increased IgM level	J:58641
	increased immature B cell number	J:132217
	increased inflammatory response	J:58641
	increased leukocyte cell number	J:58641
	increased marginal zone B cell number	J:132217
	increased monocyte cell number	J:58641
	increased splenocyte number	J:132217
	increased susceptibility to autoimmune disorder	J:58641
	increased T cell number	J:58641
	increased transitional stage B cell number	J:132217
	spleen hyperplasia	J:58641
Bcl2l11^tm1.1Ast/Bcl2l11^tm1.1Ast (B6.129S1-Bcl2l11^tm1.1Ast)	abnormal B cell morphology	J:133084
	abnormal leukopoiesis	J:73316
	abnormal lymphocyte physiology	J:73316
	abnormal NK cell morphology	J:123409
	abnormal response to infection	J:123409
	decreased B cell apoptosis	J:73316
	decreased T cell apoptosis	J:73316, J:133084
	immune system phenotype	J:153846
	increased immature B cell number	J:133084
	increased leukocyte cell number	J:153846
	increased mature B cell number	J:133084
	increased NK cell number	J:123409
	increased regulatory T cell number	J:208318
	increased spleen weight	J:153846
	increased transitional stage B cell number	J:133084
Bcl2l11^tm1.1Ast/Bcl2l11^tm1.1Ast (B6.129-Bcl2l11^tm1.1Ast/J)	decreased lymphocyte cell number	J:137609
Bcl2l11^tm1.1Ast/Bcl2l11^tm1.1Ast (involves: 129S1/Sv)	abnormal CD4-positive, alpha-beta T cell number	J:132819
	abnormal CD8-positive, alpha-beta T cell physiology	J:132819
	abnormal splenic cell ratio	J:132819
	decreased splenocyte apoptosis	J:266833
	decreased thymocyte apoptosis	J:266833
	increased B cell number	J:132819
Bcl2l11^tm1.1Ast/Bcl2l11^tm1.1Ast (B6.129S1-Bcl2l11^tm1.1Ast/J)	decreased T cell apoptosis	J:153652
	increased B cell number	J:153652
	increased CD4-positive, alpha-beta T cell number	J:153652
	increased CD8-positive, alpha-beta T cell number	J:153652
	increased splenocyte number	J:153652
Bcl2l11^tm1.1Ast/Bcl2l11^tm1.1Ast Bik^tm1Ast/Bik^tm1Ast (B6.Cg-Bcl2l11^tm1.1Ast Bik^tm1Ast)	abnormal B cell differentiation	J:103605
	abnormal lymphocyte physiology	J:103605
	abnormal T cell differentiation	J:103605
	decreased immature B cell number	J:103605
	decreased pre-B cell number	J:103605
	decreased pro-B cell number	J:103605
	enlarged spleen	J:103605
	increased B cell number	J:103605
	increased granulocyte number	J:103605
	increased mature B cell number	J:103605
	increased monocyte cell number	J:103605
	increased T cell number	J:103605
Bcl2l11^tm1.1Ast/Bcl2l11^tm1.1Ast Bmf^tm1Rjd/Bmf^tm1Rjd (B6.129S-Bcl2l11^tm1.1Ast Bmf^tm1Rjd)	decreased T cell apoptosis	J:153652
	increased B cell number	J:153652
	increased CD4-positive, alpha-beta T cell number	J:153652
	increased CD8-positive, alpha-beta T cell number	J:153652
	increased splenocyte number	J:153652
	increased thymocyte number	J:153652
Bcl2l11^tm1.1Ast/Bcl2l11^tm1.1Ast Bmf^tm2.1Rjd/Bmf^tm2.1Rjd (B6.129S-Bcl2l11^tm1.1Ast Bmf^tm2.1Rjd)	increased B cell number	J:153652
	increased CD4-positive, alpha-beta T cell number	J:153652
	increased CD8-positive, alpha-beta T cell number	J:153652
	increased splenocyte number	J:153652
Bcl2l11^tm1.1Ast/Bcl2l11^tm1.1Ast Bnip3l^{Gt(XT0573)Wtsi}/Bnip3l^{Gt(XT0573)Wtsi} (involves: 129S1/Sv * C57BL/6)	decreased lymphocyte cell number	J:137609
Bcl2l11^tm1.1Ast/Bcl2l11^tm1.1Ast Dicer1^tm1Mmk/Dicer1^tm1Mmk Cd79a^tm1(cre)Reth/Cd79a⁺ (involves: 129S1/Sv * BALB/c)	decreased B cell number	J:135783
	decreased mature B cell number	J:135783
Bcl2l11^tm1.1Ast/Bcl2l11^tm1.1Ast Fas^lpr/Fas^lpr (B6.Cg-Bcl2l11^tm1.1Ast Fas^lpr)	abnormal effector T cell morphology	J:132217
	abnormal lymph node cell ratio	J:132217
	abnormal splenic cell ratio	J:132217
	abnormal T cell number	J:132217
	abnormal T cell subpopulation ratio	J:132217
	decreased B cell number	J:132217
	decreased spleen red pulp amount	J:132217
	enlarged lymph nodes	J:132217
	enlarged spleen	J:132217
	increased anti-double stranded DNA antibody level	J:132217
	increased anti-histone antibody level	J:132217
	increased anti-nuclear antigen antibody level	J:132217
	increased anti-single stranded DNA antibody level	J:132217
	increased autoantibody level	J:132217
	increased dendritic cell number	J:132217
	increased follicular B cell number	J:132217
	increased immature B cell number	J:132217
	increased leukocyte cell number	J:132217
	increased macrophage cell number	J:132217
	increased marginal zone B cell number	J:132217
	increased memory T cell number	J:132217
	increased spleen white pulp amount	J:132217
	increased susceptibility to autoimmune disorder	J:132217
	increased transitional stage B cell number	J:132217
	lymph node hyperplasia	J:132217
	spleen hyperplasia	J:132217
Bcl2l11^tm1.1Ast/Bcl2l11^tm1.1Ast Il15^tm1Imx/Il15^tm1Imx (involves: C57BL/6)	immune system phenotype	J:208318
Bcl2l11^tm1.1Ast/Bcl2l11^tm1.1Ast Mirc14^tm1.2Flv/Mirc14^tm1.2Flv (involves: 129S1/Sv * C57BL/6 * C57BL/6N * FVB/N * SJL)	decreased NK T cell number	J:203157
Bcl2l11^tm1.1Ast/Bcl2l11^tm1.1Ast Mlf1^tm1Swm/Mlf1^tm1Swm (involves: 129S1/Sv * C57BL/6)	decreased splenocyte apoptosis	J:266833
	decreased thymocyte apoptosis	J:266833
Bcl2l11^tm1.1Ast/Bcl2l11^tm1.1Ast Pmaip1^tm1Ast/Pmaip1^tm1Ast (involves: 129S1/Sv * C57BL/6)	abnormal NK cell morphology	J:123409
Bcl2l11^tm1.1Ast/Bcl2l11^tm1.1Ast Zbtb1^m1Btlr/Zbtb1^m1Btlr (involves: 129S1/Sv * C3H/HeN * C57BL/6 * C57BL/6J)	absent T cells	J:178820
Bcl2l11^tm1.1Boui/Bcl2l11⁺ Tg(IghMyc)22Bri/0 (involves: C57BL/6 * SJL)	increased leukocyte cell number	J:186117
	increased T cell derived lymphoma incidence	J:186117
Bcl2l11^tm1.1Boui/Bcl2l11^tm1.1Boui (C57BL/6-Bcl2l11^tm1.1Boui)	immune system phenotype	J:153846
	increased leukocyte cell number	J:153846
	increased spleen weight	J:153846
Bcl2l11^tm1.1Boui/Bcl2l11^tm1.1Boui Tg(IghMyc)22Bri/0 (involves: C57BL/6 * SJL)	increased leukocyte cell number	J:186117
Bcl2l11^tm1.1Boui/Bcl2l11^tm2.1Boui (C57BL/6-Bcl2l11^tm1.1Boui/Bcl2l11^tm2.1Boui)	immune system phenotype	J:153846
	increased leukocyte cell number	J:153846
	increased spleen weight	J:153846
Bcl2l11^tm1Ast/Bcl2l11^tm1Ast Dicer1^tm1Bdh/Dicer1^tm1Bdh Aicda^tm1(cre)Njen/Aicda⁺ (involves: 129S1/Sv * C57BL/6)	abnormal B cell differentiation	J:181782
	decreased germinal center B cell number	J:181782
	decreased plasma cell number	J:181782
Bcl2l11^tm1Sjk/Bcl2l11^tm1Sjk (involves: 129X1/SvJ)	abnormal B cell physiology	J:100463
	abnormal spleen marginal zone morphology	J:100463
	increased B cell number	J:100463
	increased B-2 B cell number	J:100463
	increased follicular B cell number	J:100463
	increased immunoglobulin level	J:100463
	increased transitional stage B cell number	J:100463
Bcl2l11^tm2.1Boui/Bcl2l11⁺ Tg(IghMyc)22Bri/0 (involves: C57BL/6 * SJL)	increased leukocyte cell number	J:186117
Bcl2l11^tm2.1Boui/Bcl2l11^tm2.1Boui (C57BL/6-Bcl2l11^tm2.1Boui)	immune system phenotype	J:153846
	increased leukocyte cell number	J:153846
	increased spleen weight	J:153846
Bcl2l11^tm2.1Boui/Bcl2l11^tm2.1Boui Tg(IghMyc)22Bri/0 (involves: C57BL/6 * SJL)	increased leukocyte cell number	J:186117
Bcl2l11^tm3.1Boui/Bcl2l11^tm3.1Boui (C57BL/6-Bcl2l11^tm3.1Boui)	immune system phenotype	J:153846
	increased leukocyte cell number	J:153846
	increased spleen weight	J:153846
Bcl2l11^tm3Rjd/Bcl2l11^tm3Rjd (B6.129S6-Bcl2l11^tm3Rjd)	decreased thymocyte apoptosis	J:137061
	increased B cell number	J:153652
	increased CD4-positive, alpha-beta T cell number	J:153652
	increased CD8-positive, alpha-beta T cell number	J:153652
	increased splenocyte number	J:153652
Bcl2l11^tm3Rjd/Bcl2l11^tm3Rjd Bmf^tm3.1Rjd/Bmf^tm3.1Rjd (B6.129S6-Bcl2l11^tm3Rjd Bmf^tm3.1Rjd)	increased B cell number	J:153652
	increased CD4-positive, alpha-beta T cell number	J:153652
	increased CD8-positive, alpha-beta T cell number	J:153652
	increased splenocyte number	J:153652
Bcl2l11^tm4Boul/Bcl2l11^tm4Boul (involves: C57BL/6)	immune system phenotype	J:203181
Bcl2l11^tm4Rjd/Bcl2l11^tm4Rjd (involves: 129S6/SvEvTac * C57BL/6)	immune system phenotype	J:203181
Bcl2l11^tm5Boul/Bcl2l11^tm5Boul (involves: C57BL/6)	immune system phenotype	J:203181
Bcl2l11^tm6.1Boui/Bcl2l11^tm6.1Boui Foxp3^{tm4(YFP/icre)Ayr}/Foxp3⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)	increased regulatory T cell number	J:208318
Bcl2l12^{tm1.1(KOMP)Vlcg}/Bcl2l12^{tm1.1(KOMP)Vlcg} (C57BL/6N-Bcl2l12^{tm1.1(KOMP)Vlcg}/Ucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	increased spleen weight	J:211773
Bcl2l14^tm1.1Boui/Bcl2l14^tm1.1Boui (involves: C57BL/6)	abnormal susceptibility to induced colitis	J:296081
Bcl3^m1Btlr/Bcl3⁺ (C57BL/6J-Bcl3^m1Btlr)	decreased B cell number	J:255184
	decreased B-1b cell number	J:255184
	increased CD8-positive, alpha-beta T cell number	J:255184
	increased macrophage cell number	J:255184
Bcl3^m1Btlr/Bcl3^m1Btlr (C57BL/6J-Bcl3^m1Btlr)	abnormal humoral immune response	J:255184
	decreased B cell number	J:255184
	decreased B-1b cell number	J:255184
	decreased IgE level	J:255184
	decreased IgG level	J:255184
	increased B-1 B cell number	J:255184
	increased CD8-positive, alpha-beta T cell number	J:255184
	increased central memory CD4-positive, alpha-beta T cell number	J:255184
	increased macrophage cell number	J:255184
Bcl3^m2Btlr/Bcl3^m2Btlr (C57BL/6J-Bcl3^m2Btlr)	decreased CD4-positive, alpha-beta T cell number	J:264818
	decreased IgD level	J:264818
	increased B-1 B cell number	J:264818
	increased CD8-positive, alpha-beta memory T cell number	J:264818
	increased IgM level	J:264818
Bcl3^m3Btlr/Bcl3^m3Btlr (C57BL/6J-Bcl3^m3Btlr)	decreased central memory CD8 positive, alpha-beta T cell number	J:274858
Bcl3^{tm1b(EUCOMM)Wtsi}/Bcl3^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Bcl3^{tm1b(EUCOMM)Wtsi}/H)	increased spleen weight	J:211773
Bcl3^tm1Rie/Bcl3^tm1Rie (involves: 129)	abnormal dendritic cell number	J:77049
	abnormal follicular dendritic cell morphology	J:77049
	abnormal myeloid dendritic cell morphology	J:77049
	abnormal Peyer's patch follicle morphology	J:77049
	abnormal Peyer's patch germinal center morphology	J:77049
	abnormal Peyer's patch morphology	J:77049
	abnormal Peyer's patch T cell area morphology	J:77049
	decreased B cell number	J:77049
	decreased Peyer's patch number	J:77049
	increased plasmacytoid dendritic cell number	J:77049
	small Peyer's patches	J:77049
Bcl3^tm1Rsch/Bcl3^tm1Rsch (involves: 129P2/OlaHsd * CD-1)	abnormal cytokine secretion	J:116724
	abnormal innate immunity	J:116724
	increased susceptibility to bacterial infection	J:116724
Bcl3^tm1Rsch/Bcl3^tm1Rsch (B6.Cg-Bcl3^tm1Rsch)	abnormal cytokine secretion	J:116724
Bcl3^tm1Rsch/Bcl3^tm1Rsch (B6.Cg-Bcl3^tm1Rsch)	abnormal macrophage physiology	J:116724
Bcl3^tm1Sbn/Bcl3^tm1Sbn (involves: 129S4/SvJae * C57BL/6)	abnormal B cell differentiation	J:39747
	abnormal class switch recombination	J:39747
	abnormal cytotoxic T cell physiology	J:39747
	abnormal lymph node B cell domain morphology	J:39747
	abnormal lymphocyte morphology	J:39747
	abnormal metallophilic macrophage morphology	J:39747
	abnormal spleen marginal zone macrophage morphology	J:39747
	absent spleen germinal center	J:39747
	decreased B cell number	J:39747
	decreased IgG2a level	J:39747
	decreased interferon-gamma secretion	J:39747
	decreased interleukin-12 secretion	J:39747
	decreased macrophage cell number	J:39747
	decreased spleen germinal center size	J:39747
	disorganized spleen B cell follicle	J:39747
	increased susceptibility to parasitic infection	J:39747
	intermingled spleen red and white pulp	J:39747
	lymph node hypoplasia	J:39747
Bcl3^tm1Sbn/Bcl3^tm1Sbn (involves: 129S4/SvJae)	abnormal B cell physiology	J:207111
	decreased B cell proliferation	J:207111
	decreased follicular B cell number	J:207111
	decreased transitional stage T1 B cell number	J:207111
	decreased transitional stage T2 B cell number	J:207111
	increased B cell proliferation	J:207111
	increased marginal zone B cell number	J:207111
Bcl3^tm1Ver/Bcl3^tm1Ver (involves: 129P2/OlaHsd * FVB/NJ)	abnormal humoral immune response	J:38092
	absent spleen germinal center	J:38092
	immune system phenotype	J:38092
	increased susceptibility to bacterial infection	J:38092
Bcl6^tm1.1Dent/Bcl6^tm1.1Dent Tg(Cd4-cre)1Cwi/0 (involves: 129S/SvEv * C57BL/6 * DBA/2 * FVB/N)	abnormal T follicular helper cell differentiation	J:202372
	decreased germinal center B cell number	J:202372
	decreased IgG level	J:202372
	decreased interleukin-4 secretion	J:202372
	decreased T follicular helper cell number	J:202372
	increased interleukin-10 secretion	J:202372
Bcl6^tm1.1Jwan/Bcl6^tm1.1Jwan (involves: 129S6/SvEvTac)	abnormal somatic hypermutation frequency	J:190534
Bcl6^tm1.1Jwan/Bcl6^tm1.1Jwan (involves: 129S6/SvEvTac)	immune system phenotype	J:190534
Bcl6^tm1.1Meln/Bcl6^tm1.1Meln (involves: 129 * C57BL/6 * FVB/N)	abnormal adaptive immunity	J:194821
	abnormal germinal center B cell physiology	J:194821
	abnormal immune system organ morphology	J:194821
	abnormal Peyer's patch germinal center morphology	J:194821
	abnormal professional antigen presenting cell physiology	J:194821
	abnormal spleen germinal center morphology	J:194821
	decreased IgG1 level	J:194821
	decreased IgG2a level	J:194821
	decreased IgG level	J:194821
	decreased spleen germinal center number	J:194821
	decreased T follicular helper cell number	J:194821
	immune system phenotype	J:194821
Bcl6^tm1.1Mtto/Bcl6^tm1.1Mtto Cd79a^tm1(cre)Reth/Cd79a⁺ (involves: BALB/c * C57BL/6 * C57BL/6JJcl)	abnormal humoral immune response	J:190943
	abnormal memory B cell morphology	J:190943
	abnormal memory B cell physiology	J:190943
	abnormal somatic hypermutation frequency	J:190943
	decreased germinal center B cell number	J:190943
Bcl6^tm1.1Mtto/Bcl6^tm1.1Mtto Cd79a^tm1(cre)Reth/Cd79a⁺ Tg(Cd4-cre)1Cwi/0 (involves: BALB/c * C57BL/6 * C57BL/6JJcl * DBA/2)	decreased germinal center B cell number	J:190943
	immune system phenotype	J:190943
Bcl6^tm1.1Mtto/Bcl6^tm1.1Mtto Ighg1^tm1(cre)Cgn/Ighg1⁺ (involves: 129P2/OlaHsd * C57BL/6 * C57BL/6JJcl)	decreased germinal center B cell number	J:190943
	immune system phenotype	J:190943
Bcl6^tm1.1Mtto/Bcl6^tm1.1Mtto Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * C57BL/6JJcl * DBA/2)	abnormal humoral immune response	J:190943
	abnormal somatic hypermutation frequency	J:190943
	absent germinal center B cells	J:190943
	decreased germinal center B cell number	J:190943
	decreased T follicular helper cell number	J:190943
Bcl6^tm1.1Toka/Bcl6⁺ Tg(TcraTcrb)425Cbn/0 (involves: BALB/c * C57BL/6 * NZB)	decreased T cell proliferation	J:174014
Bcl6^tm1.1Toka/Bcl6^tm1.1Toka (involves: C57BL/6 * NZB)	abnormal Peyer's patch morphology	J:174014
	decreased germinal center B cell number	J:174014
	decreased T follicular helper cell number	J:174014
	immune system phenotype	J:174014
Bcl6^tm1.1Toka/Bcl6^tm1.1Toka Tg(IghelMD4)4Ccg/0 (involves: C57BL/6 * NZB)	abnormal germinal center B cell physiology	J:174014
	increased activation-induced B cell apoptosis	J:174014
Bcl6^tm1Gdba/Bcl6^tm1Gdba Tg(Adipoq-cre)1Evdr/0 (involves: C57BL/6 * FVB/NJ)	white adipose tissue inflammation	J:271078
Bcl6^tm1Htno/Bcl6^tm1Htno (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal spleen morphology	J:55952
	lung inflammation	J:55952
	myocarditis	J:55952
Bcl6^tm1Rdf/Bcl6^tm1Rdf (involves: 129S1/Sv)	abnormal B cell physiology	J:40769
	abnormal humoral immune response	J:40769
	abnormal immune system morphology	J:40769
	abnormal immune system physiology	J:40769
	abnormal Peyer's patch germinal center morphology	J:40769
	abnormal T-helper 2 physiology	J:40769
	absent lymph node germinal center	J:40769
	absent spleen germinal center	J:40769
	decreased IgG level	J:40769
	decreased IgM level	J:40769
	heart inflammation	J:40769
	increased eosinophil cell number	J:40769
	increased inflammatory response	J:40769
	increased susceptibility to bacterial infection	J:40769
	liver inflammation	J:40769
	lung inflammation	J:40769
	small thymus	J:40769
	spleen hyperplasia	J:40769
Bcl6^tm1Sdt/Bcl6^tm1Sdt (involves: 129/Sv * C57BL/6)	abnormal chemokine level	J:123621
	abnormal immune system physiology	J:123621
	spleen hypoplasia	J:123621
Bcl6^tm1Sdt/Bcl6^tm1Sdt Bcl6b^tm2Dent/Bcl6b^tm2Dent (involves: 129/Sv * C57BL/6)	abnormal immune system physiology	J:123621
Bcl6^tm2Rdf/Bcl6^tm2Rdf (involves: 129S1/Sv)	abnormal B cell physiology	J:40769
	abnormal humoral immune response	J:40769
	abnormal immune system morphology	J:40769
	abnormal immune system physiology	J:40769
	abnormal Peyer's patch germinal center morphology	J:40769
	abnormal T-helper 2 physiology	J:40769
	absent lymph node germinal center	J:40769
	absent spleen germinal center	J:40769
	decreased B cell proliferation	J:40769
	decreased IgG level	J:40769
	decreased IgM level	J:40769
	heart inflammation	J:40769
	increased eosinophil cell number	J:40769
	increased inflammatory response	J:40769
	increased susceptibility to bacterial infection	J:40769
	liver inflammation	J:40769
	lung inflammation	J:40769
	small thymus	J:40769
	spleen hyperplasia	J:40769
Bcl6^tm2Rdf/Bcl6^tm2Rdf Ighm^tm1(Bcl6)Rdf/? (involves: 129/Sv * 129S1/Sv * C57BL/6)	abnormal immune system morphology	J:98937
	abnormal spleen germinal center morphology	J:98937
Bcl6b^tm1Dtf/Bcl6b^tm1Dtf (involves: 129P2/OlaHsd)	abnormal response to infection	J:99818
	decreased memory T cell number	J:99818
	decreased T cell proliferation	J:99818
Bcl6b^tm1Tto/Bcl6b^tm1Tto (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:93656
	abnormal CD8-positive, alpha beta T cell morphology	J:93656
Bcl6b^tm2Dent/Bcl6b^tm2Dent (involves: 129/Sv * C57BL/6)	decreased neutrophil cell number	J:123621
Bcl6b^tm2Dent/Bcl6b^tm2Dent (involves: 129/Sv * C57BL/6)	increased monocyte cell number	J:123621
Bcl6b^tm2Dent/Bcl6b^tm2Dent Rag1^tm1Mom/Rag1^tm1Mom (involves: 129/Sv * 129S7/SvEvBrd * C57BL/6)	decreased lymphocyte cell number	J:123621
Bcl10^m1Btlr/Bcl10^m1Btlr (C57BL/6J-Bcl10^m1Btlr)	abnormal humoral immune response	J:265122
	decreased B-1 B cell number	J:265122
	decreased IgG level	J:265122
	increased CD4-positive, alpha-beta T cell number	J:265122
	increased IgE level	J:265122
	increased IgM level	J:265122
	increased single-positive T cell number	J:265122
	increased T cell number	J:265122
Bcl10^tm1Mak/Bcl10^tm1Mak (involves: 129P2/OlaHsd)	abnormal cytotoxic T cell physiology	J:67297
	abnormal dendritic cell physiology	J:111706
	abnormal immune cell physiology	J:67297
	abnormal response to infection	J:67297
	abnormal T cell activation	J:67297
	abnormal T cell differentiation	J:67297
	decreased activated T cell number	J:67297
	decreased B cell proliferation	J:109545, J:67297
	decreased double-positive T cell number	J:67297
	decreased IgG level	J:67297
	decreased IgM level	J:67297
	decreased immunoglobulin level	J:67297
	decreased T cell proliferation	J:109545, J:67297
	decreased thymocyte number	J:67297
	increased double-negative T cell number	J:67297
	increased susceptibility to infection	J:67297
Bcl10^tm1Mak/Bcl10^tm1Mak Cd19^tm1(cre)Cgn/Cd19⁺ Gt(ROSA)26Sor^{tm2(CARD11*L225LI)Jrld}/Gt(ROSA)26Sor⁺ (involves: 129P2/OlaHsd)	immune system phenotype	J:228288
Bcl10^tm1Swm/Bcl10^tm1Swm (involves: 129P2/OlaHsd)	abnormal B cell differentiation	J:85147
	abnormal humoral immune response	J:85147
	abnormal marginal zone B cell physiology	J:85147
	decreased B cell number	J:85147
	decreased B cell proliferation	J:85147
	decreased B-1 B cell number	J:85147
	decreased follicular B cell number	J:85147
	decreased marginal zone B cell number	J:85147
	decreased mature B cell number	J:85147
	increased susceptibility to bacterial infection	J:85147
Bcl10^tm1Swm/Bcl10^tm1Swm (involves: 129P2/OlaHsd * C57BL/6)	abnormal cytokine secretion	J:122394
	abnormal dendritic cell physiology	J:122394
Bcl11a^tm1Ngc/Bcl11a⁺ (involves: 129S1/Sv)	abnormal T cell differentiation	J:194616
	decreased DN2 thymocyte number	J:194616
	decreased lymphocyte cell number	J:207383
Bcl11a^tm1Ngc/Bcl11a^tm1Ngc (involves: 129S1/Sv * C57BL/6J)	abnormal dendritic cell differentiation	J:207383
	abnormal immunoglobulin heavy chain V(D)J recombination	J:83646
	absent B cells	J:207383, J:83646
	absent CD4-positive, alpha-beta T cells	J:83646
	absent lymphocyte	J:207383
	decreased plasmacytoid dendritic cell number	J:207383
	decreased T cell number	J:83646
	increased CD8-positive, alpha-beta T cell number	J:83646
	increased double-negative T cell number	J:83646
	increased gamma-delta T cell number	J:83646
	small thymus	J:83646
	thymus hypoplasia	J:83646
Bcl11a^tm1Pwt/Bcl11a^tm1Pwt Commd10^{Tg(Vav1-icre)A2Kio}/Commd10⁺ (involves: C57BL/6 * C57BL/10 * CBA/Ca)	decreased B cell number	J:207383
	decreased circulating interferon-alpha level	J:207383
	decreased plasmacytoid dendritic cell number	J:207383
Bcl11a^tm1Pwt/Bcl11a^tm1Pwt Gt(ROSA)26Sor^tm1(EYFP)Cos/Gt(ROSA)26Sor⁺ Tg(Mx1-cre)1Cgn/0 (involves: 129X1/SvJ * C57BL/6 * CBA)	abnormal dendritic cell differentiation	J:207383
	decreased B cell number	J:207383
	decreased dendritic cell number	J:207383
	decreased plasmacytoid dendritic cell number	J:207383
Bcl11a^tm1Pwt/Bcl11a^tm1Pwt Kdm1a^tm1.1Sho/Kdm1a^tm1.1Sho Tg(Mx1-cre)1Cgn/0 (involves: 129 * C57BL/6 * CBA)	decreased leukocyte cell number	J:196140
Bcl11a^tm1Pwt/Bcl11a^tm1Pwt Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA)	decreased leukocyte cell number	J:196140
Bcl11a^tm2.1Peli/Bcl11a^tm2.1Peli Gt(ROSA)26Sor^{tm2(cre/ERT2)Brn}/Gt(ROSA)26Sor⁺ (involves: 129P2/OlaHsd * 129S1/Sv)	abnormal immune system morphology	J:194616
	abnormal T cell differentiation	J:194616
	decreased B cell number	J:194616
	decreased DN2 thymocyte number	J:194616
	decreased immature B cell number	J:194616
	decreased pre-B cell number	J:194616
	decreased pro-B cell number	J:194616
	increased B cell apoptosis	J:194616
Bcl11a^tm2.1Peli/Bcl11a^tm2.1Peli Trp53^tm1Brn/Trp53^tm1Brn Gt(ROSA)26Sor^{tm2(cre/ERT2)Brn}/Gt(ROSA)26Sor⁺ (involves: 129P2/OlaHsd * 129S1/Sv)	immune system phenotype	J:194616
Bcl11b^tm1.2Leid/Bcl11b^tm1.2Leid (involves: C57BL/6 * SJL)	absent T cells	J:147182
Bcl11b^tm1.2Leid/Bcl11b^tm1.2Leid (involves: C57BL/6 * SJL)	thymus hypoplasia	J:147182
Bcl11b^tm1Avram/Bcl11b^tm1Avram Tcra^tm1Mom/Tcra^tm1Mom Tg(Cd4-cre)1Cwi/? (involves: 129 * C57BL/6 * DBA/2)	abnormal positive T cell selection	J:128515
	decreased double-positive T cell number	J:128515
	thymus hypoplasia	J:128515
Bcl11b^tm1Avram/Bcl11b^tm1Avram Tg(Cd4-cre)1Cwi/? (involves: 129 * C57BL/6 * DBA/2)	abnormal leukocyte morphology	J:128515
	abnormal positive T cell selection	J:128515
	abnormal thymocyte activation	J:128515
	decreased CD4-positive, alpha-beta T cell number	J:128515
	decreased CD8-positive, alpha-beta T cell number	J:128515
	decreased double-negative T cell number	J:128515
	decreased double-positive T cell number	J:128515
	enlarged mesenteric lymph nodes	J:128515
	increased B cell number	J:128515
	increased dendritic cell number	J:128515
	increased gamma-delta T cell number	J:128515
	increased NK cell number	J:128515
	increased spleen weight	J:128515
	spleen hyperplasia	J:128515
	thymus hypoplasia	J:128515
Bcl11b^tm1Avram/Bcl11b^tm1Avram Tg(Cd4-cre)1Cwi/? Tg(LCKprBCL2)36Sjk/? (involves: 129 * C57BL/6 * DBA/2)	abnormal positive T cell selection	J:128515
	decreased CD4-positive, alpha-beta T cell number	J:128515
	decreased CD8-positive, alpha-beta T cell number	J:128515
	decreased double-positive T cell number	J:128515
	thymus hypoplasia	J:128515
Bcl11b^tm1Jpk/Bcl11b^tm1Jpk (involves: BALB/c * C57BL/6 * CBA)	abnormal T cell differentiation	J:83651
	abnormal T cell morphology	J:83651
	abnormal T cell receptor beta chain V(D)J recombination	J:83651
	abnormal thymus cortex morphology	J:83651
	abnormal thymus medulla morphology	J:83651
	absent thymus corticomedullary boundary	J:83651
	decreased double-positive T cell number	J:83651
	increased CD8-positive, alpha-beta T cell number	J:83651
	increased double-negative T cell number	J:83651
	increased thymocyte apoptosis	J:83651
	thymus hypoplasia	J:83651
Bcl11b^tm1Peli/Bcl11b^tm1Peli Gt(ROSA)26Sor^{tm2(cre/ERT2)Brn}/Gt(ROSA)26Sor⁺ (involves: 129P2/OlaHsd * 129S5/SvEvBrd * C57BL/6J)	abnormal NK cell differentiation	J:161373
Bcl11b^tm2.1Jpk/Bcl11b⁺ Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * C57BL/6J * DBA/2)	immune system phenotype	J:210122
Bcl11b^tm2.1Jpk/Bcl11b⁺ Tg(Lck-cre)1Jtak/0 (involves: C57BL/6)	abnormal T cell number	J:210122
	decreased CD4-positive, alpha-beta T cell number	J:210122
	decreased CD8-positive, alpha-beta T cell number	J:210122
	decreased double-positive T cell number	J:210122
	decreased thymocyte number	J:210122
	increased double-negative T cell number	J:210122
Bclaf1^tm1Raz/Bclaf1⁺ (involves: 129P2/OlaHsd * C57BL/6)	decreased T cell proliferation	J:158087
Bclaf1^tm1Raz/Bclaf1^tm1Raz (involves: 129P2/OlaHsd * C57BL/6)	decreased CD8-positive, alpha-beta T cell number	J:158087
	decreased T cell proliferation	J:158087
	increased B cell number	J:158087
Bcmd2^CAST/EiJ/Bcmd2^CAST/EiJ (AW.CAST-Bcmd2)	increased mast cell number	J:75340
Bco2^tm1Dnp/Bco2^tm1Dnp (involves: 129S6/SvEvTac * C57BL/6)	enlarged spleen	J:166153
Bco2^tm1Dnp/Bco2^tm1Dnp (involves: 129S6/SvEvTac * C57BL/6)	increased spleen weight	J:166153
Bcor^tm1.1Vjba/Y Commd10^{Tg(Vav1-icre)A2Kio}/Commd10⁺ (involves: 129S1/Sv * C57BL/6 * CBA/Ca)	increased neutrophil cell number	J:231455
Bcr^{tm1(BCR/ABL)Tsr}/Bcr⁺ Runx1^tm3Dow/Runx1⁺ Tg(Vav1-cre)#Cgp/0 (involves: C57BL/6)	decreased lymphocyte cell number	J:203111
	increased monocyte cell number	J:203111
	increased neutrophil cell number	J:203111
Bcr^tm1Hkp/Bcr^tm1Hkp (involves: 129S2/SvPas)	abnormal neutrophil physiology	J:23804
	increased leukocyte cell number	J:23804
	increased neutrophil cell number	J:23804
	increased susceptibility to endotoxin shock	J:23804
	sepsis	J:23804
Bcs1l^tm1.1Levp/Bcs1l^tm1.1Levp (B6.129-Bcs1l^tm1.1Levp)	abnormal macrophage morphology	J:273501
	increased macrophage cell number	J:273501
	increased neutrophil cell number	J:273501
	liver inflammation	J:273501
Bdkrb1^tm1Bdr/Bdkrb1^tm1Bdr (involves: 129P2/OlaHsd)	abnormal acute inflammation	J:63271
Bdkrb1^tm1Bdr/Bdkrb1^tm1Bdr (involves: 129P2/OlaHsd)	decreased susceptibility to endotoxin shock	J:135789
Bdkrb1^tm2Bdr/Bdkrb1^tm2Bdr Bdkrb2^tm1Jfh/Bdkrb2^tm1Jfh (involves: 129S7/SvEvBrd * C57BL/6)	decreased susceptibility to endotoxin shock	J:135789
Bdp1^em1(IMPC)Tcp/Bdp1⁺ (C57BL/6N-Bdp1^em1(IMPC)Tcp/Cmmr)	abnormal spleen morphology	J:211773
	decreased neutrophil cell number	J:211773
	increased lymphocyte cell number	J:211773
Bean1^em1(IMPC)H/Bean1^em1(IMPC)H (C57BL/6N-Bean1^em1(IMPC)H/H)	decreased lymphocyte cell number	J:211773
	increased eosinophil cell number	J:211773
Becn1^tm1.1Bflu/Becn1^tm1.1Bflu Tg(Cd4-cre)1Cwi/0 (involves: 129S1/Sv * C57BL/6 * DBA/2)	abnormal CD4-positive, alpha-beta T cell physiology	J:203090
	decreased CD4-positive, alpha-beta T cell number	J:203090
	decreased CD8-positive, alpha-beta T cell number	J:203090
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:203090
	decreased T cell proliferation	J:203090
	increased T cell apoptosis	J:203090
Becn1^{tm1b(KOMP)Wtsi}/Becn1⁺ (C57BL/6N-Becn1^{tm1b(KOMP)Wtsi}/Ieg)	increased leukocyte cell number	J:211773
Becn1^tm1Blev/Becn1⁺ (involves: 129X1/SvJ * C57BL/6J)	abnormal immune system morphology	J:86953
	increased spleen germinal center number	J:86953
	increased spleen germinal center size	J:86953
Becn1^tm1Ebr/Becn1^tm1Ebr Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd)	abnormal circulating chemokine level	J:235399
	abnormal macrophage physiology	J:235399
	abnormal spleen morphology	J:235399
	decreased circulating interleukin-10 level	J:235399
	glomerulonephritis	J:235399
	increased anti-double stranded DNA antibody level	J:235399
	increased anti-nuclear antigen antibody level	J:235399
	increased autoantibody level	J:235399
	increased circulating interleukin-1 beta level	J:235399
	increased circulating interleukin-6 level	J:235399
	increased circulating interleukin-12b level	J:235399
	increased IgG level	J:235399
	increased lymphocyte cell number	J:235399
	increased monocyte cell number	J:235399
	increased neutrophil cell number	J:235399
	increased susceptibility to systemic lupus erythematosus	J:235399
Becn1^tm1Smoc/Becn1^tm1Smoc Foxp3^{tm4(YFP/icre)Ayr}/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal regulatory T cell physiology	J:306129
Becn1^tm1Smoc/Becn1^tm1Smoc Zfp91^tm1Smoc/Zfp91^tm1Smoc Foxp3^{tm4(YFP/icre)Ayr}/Y (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal regulatory T cell physiology	J:306129
Belr1^BALB/cJ/Belr1^BALB/cJ (involves: BALB/cJ * C57BL/6J)	decreased susceptibility to parasitic infection	J:133125
Belr1^BALB/cJ/Belr1^BALB/cJ (B6.C-H2^d/bByJ)	decreased susceptibility to parasitic infection	J:133125
Berr1^WLA/Pas/? (involves: C57BL/6JRj * WLA/Pas)	decreased susceptibility to parasitic infection	J:78027
Berr2^WLA/Pas/? (involves: C57BL/6JRj * WLA/Pas)	decreased susceptibility to parasitic infection	J:78027
Best3^tm1.1Zhoj/Best3^tm1.1Zhoj Tg(Tagln-cre)1Her/0 (involves: C57BL/6 * SJL)	aortitis	J:338981
Bex2^{tm1b(EUCOMM)Hmgu}/Bex2^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Bex2^{tm1b(EUCOMM)Hmgu}/Ieg)	increased leukocyte cell number	J:211773
Bex6^{tm1.1(KOMP)Vlcg}/Bex6^{tm1.1(KOMP)Vlcg} (B6N(Cg)-Bex6^{tm1.1(KOMP)Vlcg}/J)	increased leukocyte cell number	J:211773
Bgn^tm1Mfy/Y (involves: 129S4/SvJae * C57BL/6)	osteoarthritis	J:76203
Bgn^tm1Mfy/Y Fmod^tm1Aol/Fmod^tm1Aol (involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6)	osteoarthritis	J:76203
Bgn^tm1Mfy/Y Fmod^tm1Aol/Fmod^tm1Aol (involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)	accelerated temporomandibular joint osteoarthritis	J:112779, J:117908
Bgn^tm1Mfy/Bgn^tm1Mfy (involves: 129S4/SvJae)	osteoarthritis	J:222369
Bgn^tm1Mfy/Bgn^tm1Mfy Epyc^tm1Mhok/Epyc^tm1Mhok (involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6J)	osteoarthritis	J:222369
Bgn^tm1Mfy/Bgn^tm1Mfy Fmod^tm1Aol/Fmod^tm1Aol (involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)	accelerated temporomandibular joint osteoarthritis	J:117908
bhe/bhe (Not Specified)	chronic inflammation	J:85113
Bhlhe40^tm1Tan/Bhlhe40^tm1Tan (either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6))	abnormal CD4-positive T cell differentiation	J:72651
	abnormal CD4-positive, alpha-beta T cell physiology	J:72651
	abnormal immune system cell morphology	J:72651
	abnormal immune system physiology	J:72651
	abnormal lymph node germinal center morphology	J:72651
	abnormal susceptibility to autoimmune disorder	J:72651
	abnormal T cell activation	J:72651
	decreased double-positive T cell number	J:72651
	decreased interleukin-2 secretion	J:72651
	decreased T cell proliferation	J:72651
	increased anti-nuclear antigen antibody level	J:72651
	increased CD4-positive, alpha-beta T cell number	J:72651
	increased CD8-positive, alpha-beta T cell number	J:72651
	increased double-negative T cell number	J:72651
	increased IgE level	J:72651
	increased IgG1 level	J:72651
	increased spleen germinal center number	J:72651
	increased spleen white pulp amount	J:72651
	lymph node hyperplasia	J:72651
	spleen hyperplasia	J:72651
	thymus hyperplasia	J:72651
Bhlhe41^tm1.2Cdon/Bhlhe41^tm1.2Cdon (B6.129S6-Bhlhe41^tm1.2Cdon)	abnormal lymphocyte cell number	J:157740
	abnormal T-helper 2 cell differentiation	J:157740
	decreased eosinophil cell number	J:157740
	decreased interferon-gamma secretion	J:157740
	decreased interleukin-2 secretion	J:157740
	decreased interleukin-5 secretion	J:157740
	decreased interleukin-13 secretion	J:157740
	decreased macrophage cell number	J:157740
	decreased neutrophil cell number	J:157740
	decreased T cell proliferation	J:157740
	increased interleukin-4 secretion	J:157740
	increased interleukin-17 secretion	J:157740
Bhmt^{tm1b(EUCOMM)Hmgu}/Bhmt^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Bhmt^{tm1b(EUCOMM)Hmgu}/Bay)	increased spleen weight	J:211773
Bicdl1^{tm2b(EUCOMM)Wtsi}/Bicdl1^{tm2b(EUCOMM)Wtsi} (C57BL/6N-Bicdl1^{tm2b(EUCOMM)Wtsi}/Bay)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Bicdl2^em1(IMPC)Mbp/Bicdl2^em1(IMPC)Mbp (C57BL/6N-Bicdl2^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Bid^tm1Sjk/Bid^tm1Sjk (involves: 129X1/SvJ * C57BL/6)	decreased susceptibility to endotoxin shock	J:117693
Bin1^tm1Gcp/Bin1^tm1Gcp (involves: 129S6/SvEvTac * C57BL/6J)	immune system phenotype	J:83753
Bin1^tm1Gcp/Bin1^tm2Gcp Tg(Wap-cre)11738Mam/0 (involves: 129S6/SvEvTac * C57BL/6 * FVB/N * SJL)	endometrium inflammation	J:117330
Bin3^tm1Gcp/Bin3^tm1Gcp (involves: 129 * C57BL/6)	enlarged spleen	J:133313
	liver inflammation	J:133313
	lung inflammation	J:133313
Birc2^tm1Jda/Birc2^tm1Jda (B6.129P2-Birc2^tm1Jda)	decreased lymphocyte cell number	J:97656
Birc2^tm1Rbr/Birc2^tm1Rbr Birc3^tm1.1Rbr/Birc3^tm1.1Rbr (involves: C57BL/6 * NZB)	immune system phenotype	J:172843
Birc2^tm1Rbr/Birc2^tm1Rbr Birc3^tm1.1Rbr/Birc3^tm1.1Rbr Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129P2/OlaHsd * C57BL/6 * NZB)	decreased B cell apoptosis	J:172843
	decreased germinal center B cell number	J:172843
	decreased spleen germinal center size	J:172843
	enlarged lymph nodes	J:172843
	enlarged spleen	J:172843
	increased B cell number	J:172843
	increased follicular B cell number	J:172843
	increased marginal zone B cell number	J:172843
Birc2^tm1Rbr/Birc2^tm1Rbr Birc3^tm1.1Rbr/Birc3^tm1.1Rbr Cd19^tm1(cre)Cgn/Cd19⁺ Tnfrsf13c^tm1Mass/Tnfrsf13c^tm1Mass (involves: 129P2/OlaHsd * C57BL/6 * NZB)	immune system phenotype	J:172843
Birc2^tm1Rbr/Birc2^tm1Rbr Birc3^tm1Rbr/Birc3^tm1Rbr Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129P2/OlaHsd * C57BL/6 * NZB)	immune system phenotype	J:172843
Birc2^tm2.1Jda/Birc2^tm2.1Jda (B6.Cg-Birc2^tm2.1Jda)	immune system phenotype	J:199221
	increased interferon-gamma secretion	J:199221
	increased T cell proliferation	J:199221
Birc3^tm1Jda/Birc3^tm1Jda (B6.Cg-Birc3^tm1Jda)	abnormal gut-associated lymphoid tissue morphology	J:166899
	abnormal lymphocyte cell number	J:166899
	decreased B cell apoptosis	J:166899
	decreased follicular B cell number	J:166899
	decreased IgG1 level	J:166899
	decreased immature B cell number	J:166899
	enlarged mesenteric lymph nodes	J:166899
	increased B cell number	J:166899
	increased B cell proliferation	J:166899
	increased IgA level	J:166899
	increased IgG3 level	J:166899
	increased IgM level	J:166899
	increased marginal zone B cell number	J:166899
	increased T cell number	J:166899
	lymph node hyperplasia	J:166899
Birc3^tm1Jda/Birc3^tm1Jda (involves: 129 * C57BL/6)	increased interferon-gamma secretion	J:199221
Birc3^tm1Jda/Birc3^tm1Jda (involves: 129 * C57BL/6)	increased T cell proliferation	J:199221
Birc3^tm1Rgk/Birc3^tm1Rgk (B6.129X1-Birc3^tm1Rgk)	abnormal cytokine secretion	J:144012
	abnormal immune cell physiology	J:144012
	abnormal interleukin-1 beta secretion	J:144012
	abnormal interleukin-12 secretion	J:144012
	abnormal leukocyte cell number	J:144012
	abnormal macrophage physiology	J:144012
	abnormal T cell physiology	J:144012
	abnormal tumor necrosis factor secretion	J:144012
	decreased macrophage cell number	J:144012
	decreased susceptibility to endotoxin shock	J:144012
Birc5^tm1Mak/Birc5^tm1Mak Tg(Lck-cre)I57Jxm/0 (involves: 129P2/OlaHsd)	abnormal T cell morphology	J:90892
	abnormal thymus corticomedullary boundary morphology	J:90892
	decreased double-negative T cell number	J:90892
	decreased thymocyte number	J:90892
	increased T cell apoptosis	J:90892
	small thymus	J:90892
Birc5^tm1Wnt/Birc5^tm1Emc Tg(Cd4-cre)1Cwi/0 (involves: 129S/SvEv * C57BL/6 * DBA/2)	abnormal T cell differentiation	J:87435
Birc5^tm1Wnt/Birc5^tm1Emc Tg(Lck-cre)1Cwi/0 (involves: 129S/SvEv * C57BL/6 * DBA/2)	decreased double-positive T cell number	J:87435
	decreased T cell number	J:87435
	increased double-negative T cell number	J:87435
	small lymph nodes	J:87435
	thymus hypoplasia	J:87435
Birc6^tm1Nai/Birc6^tm1Nai (involves: 129S4/SvJae * C57BL/6J)	increased thymocyte apoptosis	J:96768
Bld/Bld⁺ (involves: BALB/cCi)	increased incidence of corneal inflammation	J:5076
Blk^m1Btlr/Blk^m1Btlr (C57BL/6J-Blk^m1Btlr)	increased IgE level	J:255004
Blk^m1Btlr/Blk^m1Btlr (C57BL/6J-Blk^m1Btlr)	increased interleukin-1 beta secretion	J:255004
Blk^tm1Tara/Blk^tm1Tara Fyn^tm1Sor/Fyn^tm1Sor Lyn^tm1Ard/Lyn^tm1Ard (either: B6.129-Lyn^tm1Ard Fyn^tm1Sor Blk^tm1Tara or (involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6))	abnormal B cell differentiation	J:115080
	abnormal pro-B cell differentiation	J:115080
	arrested B cell differentiation	J:115080
	decreased B cell number	J:115080
	decreased immature B cell number	J:115080
	decreased pre-B cell number	J:115080
Blm^tm3Brd/Blm^tm3Brd (involves: 129S7/SvEvBrd * C57BL/6)	decreased IgM level	J:66261
Blm^tm4Ches/Blm^tm4Ches Cd19^tm1(cre)Cgn/Cd19⁺ Nsmce2^tm2.1Ofc/Nsmce2^tm2.1Ofc (involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * SJL)	abnormal B cell morphology	J:227197
	abnormal B cell physiology	J:227197
	decreased B cell number	J:227197
	small spleen	J:227197
Blm^tm4Ches/Blm^tm4Ches Trp53bp1^tm1Jc/Trp53bp1^tm1Jc Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129P2/OlaHsd * 129S6/SvEvTac)	abnormal class switch recombination	J:194603
Blmh^tm1Geh/Blmh^tm1Geh (either: (involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J))	dermatitis	J:54585
Blnk^em1(IMPC)H/Blnk^em1(IMPC)H (C57BL/6N-Blnk^em1(IMPC)H/H)	decreased basophil cell number	J:211773
	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
	decreased spleen weight	J:211773
	increased eosinophil cell number	J:211773
	increased neutrophil cell number	J:211773
	small spleen	J:211773
Blnk^m1Btlr/Blnk^m1Btlr (C57BL/6J-Blnk^m1Btlr)	arrested B cell differentiation	J:159439
	decreased IgG level	J:159439
	decreased IgM level	J:159439
	decreased mature B cell number	J:159439
	increased CD4-positive, alpha-beta T cell number	J:159439
	increased CD8-positive, alpha-beta T cell number	J:159439
Blnk^m1Btlr/Blnk^m1Btlr (involves: C57BL/6J)	arrested B cell differentiation	J:185495
	decreased IgM level	J:185495
	immune system phenotype	J:185495
Blnk^tm1Achn/Blnk⁺ (involves: 129S4/SvJae * 129X1/SvJ * BALB/c * C3H * C57BL/6)	decreased B cell proliferation	J:82430
Blnk^tm1Achn/Blnk⁺ Btk^tm1Wk/Btk^tm1Wk Tg(IGH-Btk)1Witt/0 (involves: 129S4/SvJae * 129X1/SvJ * BALB/c * C3H * C57BL/6)	abnormal B cell physiology	J:82430
	decreased B cell proliferation	J:82430
Blnk^tm1Achn/Blnk^tm1Achn (involves: 129X1/SvJ)	abnormal B cell differentiation	J:58805
	abnormal mature B cell morphology	J:58805
	absent B-1b cells	J:58805
	arrested B cell differentiation	J:58805
	decreased B-1a cell number	J:58805
	decreased immunoglobulin level	J:58805
	decreased mature B cell number	J:58805
	decreased splenocyte number	J:58805
	increased pro-B cell number	J:58805
Blnk^tm1Dkit/Blnk^tm1Dkit (involves: C57BL/6)	abnormal B cell apoptosis	J:143854
	abnormal B cell differentiation	J:84040
	abnormal immature B cell morphology	J:94297
	abnormal plasma cell differentiation	J:143854
	abnormal pre-B cell morphology	J:84040
	arrested B cell differentiation	J:143854
	decreased follicular B cell number	J:143854
	decreased IgG3 level	J:143854
	decreased IgM level	J:143854
	decreased immature B cell number	J:84040
	decreased marginal zone B cell number	J:143854
	decreased mature B cell number	J:84040
	decreased transitional stage B cell number	J:143854
	increased anti-double stranded DNA antibody level	J:94297
	increased B cell apoptosis	J:143854
Blnk^tm1Dkit/Blnk^tm1Dkit Cd19^tm1(cre)Cgn/Cd19^tm1(cre)Cgn (involves: 129P2/OlaHsd * C57BL/6 * NZB)	abnormal pre-B cell morphology	J:84040
	absent immature B cells	J:84040
	absent mature B cells	J:84040
	arrested B cell differentiation	J:84040
	decreased pre-B cell number	J:84040
	enlarged lymph nodes	J:84040
	enlarged spleen	J:84040
Blnk^tm1Dkit/Blnk^tm1Dkit Igh-J^{tm1(3H9-VDJ)Mwg}/Igh-J⁺ (involves: C57BL/6 * NZB)	abnormal immature B cell morphology	J:94297
Blnk^tm1Dkit/Blnk^tm1Dkit Igh-J^{tm1(3H9-VDJ)Mwg}/Igh-J⁺ Igk-J^tm1Mwg/Igk-J⁺ (involves: C57BL/6 * NZB)	abnormal immature B cell morphology	J:94297
Blnk^tm1Dkit/Blnk^tm1Dkit Prkcd^tm1Kin/Prkcd^tm1Kin (involves: 129P2/OlaHsd * C57BL/6 * NZB)	abnormal B cell proliferation	J:143854
	abnormal immunoglobulin level	J:143854
	abnormal plasma cell differentiation	J:143854
	arrested B cell differentiation	J:143854
	decreased B-1 B cell number	J:143854
	decreased B-2 B cell number	J:143854
	decreased follicular B cell number	J:143854
	decreased marginal zone B cell number	J:143854
	increased B cell apoptosis	J:143854
	increased IgA level	J:143854
	increased IgG1 level	J:143854
	increased IgG2b level	J:143854
	increased IgG3 level	J:143854
	increased IgM level	J:143854
Blnk^tm1Kplm/Blnk^tm1Kplm (involves: 129P2/OlaHsd)	abnormal B cell activation	J:61130, J:131161
	abnormal B cell differentiation	J:61130, J:131161
	absent B-1a cells	J:61130
	decreased B cell number	J:61130, J:131161
	decreased B cell proliferation	J:61130
	decreased immature B cell number	J:61130
	decreased mature B cell number	J:61130
	decreased pre-B cell number	J:61130, J:120460
	increased B cell apoptosis	J:131161
	increased pro-B cell number	J:61130, J:131161
	spleen hypoplasia	J:131161
Blnk^tm1Kplm/Blnk^tm1Kplm Igh^tm4Cgn/Igh⁺ Igk^tm1Rsky/Igk⁺ (involves: 129P2/OlaHsd)	abnormal B cell differentiation	J:120460
	decreased B cell number	J:120460
	increased pre-B cell number	J:120460
	increased transitional stage B cell number	J:120460
Blnk^tm1Kplm/Blnk^tm1Kplm Plcg2^tm1.1Kuro/Plcg2⁺ (involves: 129P2/OlaHsd)	abnormal B cell activation	J:131161
	decreased B cell number	J:131161
	increased B cell apoptosis	J:131161
Blnk^tm1Kplm/Blnk^tm1Kplm Plcg2^tm1.1Kuro/Plcg2^tm1.1Kuro (involves: 129P2/OlaHsd)	decreased B cell number	J:131161
	increased B cell apoptosis	J:131161
	spleen hypoplasia	J:131161
Blnk^tm1Pjln/Blnk^tm1Pjln (involves: BALB/c)	abnormal pre-B cell morphology	J:58740
	arrested B cell differentiation	J:58740
	decreased IgG3 level	J:58740
	decreased IgM level	J:58740
	decreased mature B cell number	J:58740
	enlarged spleen	J:80332
	increased mature B cell number	J:157575
	increased pre-B cell number	J:58740, J:80332
Blnk^tm1Pjln/Blnk^tm1Pjln Btk^tm1Gsv/Y (involves: 129P2/OlaHsd * BALB/c * C57BL/6)	abnormal B cell differentiation	J:94768
	decreased IgG3 level	J:94768
	decreased IgM level	J:94768
	decreased immature B cell number	J:94768
	decreased immunoglobulin level	J:94768
	decreased mature B cell number	J:94768
Blnk^tm1Pjln/Blnk^tm1Pjln Btk^tm1Gsv/Y Tg(CD19-BTKK430R)XK24Rwhe/? (involves: 129P2/OlaHsd BALB/c * C57BL/6 * FVB)	abnormal B cell differentiation	J:94768
	decreased IgG3 level	J:94768
	decreased IgM level	J:94768
	decreased immunoglobulin level	J:94768
Blnk^tm1Pjln/Blnk^tm1Pjln Btk^tm1Wk/Btk^tm1Wk (involves: 129S4/SvJae * BALB/c * C57BL/6)	arrested B cell differentiation	J:70406
Bloc1s3^rp/Bloc1s3^rp (involves: C57BL/10ScSn * C57BL/Tb)	abnormal NK cell physiology	J:6801
Bloc1s4^em1(IMPC)Mbp/Bloc1s4^em1(IMPC)Mbp (C57BL/6NCrl-Bloc1s4^em1(IMPC)Mbp/MbpMmucd)	increased monocyte cell number	J:211773
Bloc1s5^mu-Btlr/Bloc1s5^mu-Btlr (C57BL/6J-Bloc1s5^mu-Btlr)	immune system phenotype	J:137494
Bloc1s6^em1(IMPC)Mbp/Bloc1s6^em1(IMPC)Mbp (C57BL/6N-Bloc1s6^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
Bloc1s6^pa/Bloc1s6^pa (B6.Cg-Bloc1s6^pa/J)	abnormal NK cell physiology	J:6801
Bloc1s6^pa/Bloc1s6^pa (B6.Cg-Bloc1s6^pa/J)	lung inflammation	J:4098
Bmal1^em1Bwu/Bmal1^em1Bwu (C57BL/6-Bmal1^em1Bwu)	abnormal macrophage physiology	J:340220
Bmal1^tm1Bra/Bmal1^tm1Bra (B6.129-Bmal1^tm1Bra)	decreased basophil cell number	J:191844
	decreased leukocyte cell number	J:110697
	decreased lymphocyte cell number	J:110697
	decreased spleen weight	J:110697
	impaired leukocyte tethering or rolling	J:191844
	increased circulating fibrinogen level	J:191844
	increased eosinophil cell number	J:191844
	increased incidence of corneal inflammation	J:110697
	increased leukocyte cell number	J:191844
	increased lymphocyte cell number	J:191844
	increased monocyte cell number	J:110697
	increased neutrophil cell number	J:110697, J:191844
Bmal1^tm1Bra/Bmal1^tm1Bra (involves: 129/Sv * C57BL/6)	abnormal B cell differentiation	J:118522
	abnormal T cell subpopulation ratio	J:118522
	decreased B cell number	J:135933, J:118522
	decreased follicular B cell number	J:118522
	decreased IgG1 level	J:118522
	decreased lymphocyte cell number	J:135933, J:118522
	decreased transitional stage B cell number	J:118522
	increased neutrophil cell number	J:135933
Bmf^tm1.1Ast/Bmf^tm1.1Ast (B6.Cg-Bmf^tm1.1Anst)	abnormal B cell morphology	J:133084
	abnormal immune system cell morphology	J:133084
	abnormal spleen morphology	J:133084
	decreased B cell apoptosis	J:133084
	decreased T cell apoptosis	J:133084
	enlarged spleen	J:133084
	increased follicular B cell number	J:133084
	increased immature B cell number	J:133084
	increased immunoglobulin level	J:133084
	increased mature B cell number	J:133084
	increased pre-B cell number	J:133084
	increased T cell derived lymphoma incidence	J:133084
	increased transitional stage B cell number	J:133084
	spleen hyperplasia	J:133084
Bmf^tm1Rjd/Bmf^tm1Rjd (B6.129S6-Bmf^tm1Rjd)	decreased T cell apoptosis	J:153652
	enlarged spleen	J:153652
	increased B cell number	J:153652
	increased CD8-positive, alpha-beta T cell number	J:153652
	increased splenocyte number	J:153652
Bmf^tm3.1Rjd/Bmf^tm3.1Rjd (B6.129S6-Bmf^tm3.1Rjd)	decreased CD4-positive, alpha-beta T cell number	J:153652
Bmgr2^C57BL/6J/? Prf1^tm1Sdz/Prf1^tm1Sdz (involves: 129S6/SvEvTac * C57BL/6J)	abnormal response to transplant	J:116666
Bmgr3^{129S6/SvEvTac}/Bmgr3^{129S6/SvEvTac} Prf1^tm1Sdz/Prf1^tm1Sdz (involves: 129S6/SvEvTac * C57BL/6J)	abnormal response to transplant	J:116666
Bmgr4^C57BL/6J/? Ebmgr1^{129S6/SvEvTac}/Ebmgr1^{129S6/SvEvTac} Prf1^tm1Sdz/Prf1^tm1Sdz (involves: 129S6/SvEvTac * C57BL/6J)	abnormal response to transplant	J:116666
Bmgr4^C57BL/6J/? Prf1^tm1Sdz/Prf1^tm1Sdz (involves: 129S6/SvEvTac * C57BL/6J)	abnormal response to transplant	J:116666
Bmi1^tm1Brn/Bmi1^tm1Brn (either: (involves: 129P2/OlaHsd) or (involves: 129P2/OlaHsd * FVB))	abnormal double-negative T cell morphology	J:17712
	abnormal spleen red pulp morphology	J:17712
	abnormal spleen white pulp morphology	J:17712
	abnormal thymus involution	J:17712
	decreased IgM level	J:17712
	decreased immature B cell number	J:17712
	decreased mature B cell number	J:17712
	decreased splenocyte proliferation	J:17712
	decreased thymocyte number	J:17712
	lung inflammation	J:17712
	small spleen	J:17712
	thymus cortex hypoplasia	J:17712
Bmi1^tm1Brn/Bmi1^tm1Brn (involves: 129P2/OlaHsd)	decreased double-positive T cell number	J:134271
Bmi1^tm1Brn/Bmi1^tm1Brn E2f6^tm1Lees/E2f6^tm1Lees (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)	decreased double-positive T cell number	J:134271
Bmi1^tm1Sgon/Bmi1^tm1Sgon Commd10^{Tg(Vav1-icre)A2Kio}/? (involves: 129S1/Sv * 129X1/SvJ * C57BL/10 * CBA/Ca)	abnormal immune system cell morphology	J:221849
	abnormal immune system organ morphology	J:221849
	abnormal spleen morphology	J:221849
	abnormal spleen periarteriolar lymphoid sheath morphology	J:221849
	abnormal spleen white pulp morphology	J:221849
	abnormal thymus morphology	J:221849
	absent spleen germinal center	J:221849
	decreased B cell number	J:221849
	decreased spleen red pulp amount	J:221849
	decreased spleen white pulp amount	J:221849
	decreased T cell number	J:221849
	small spleen	J:221849
	small thymus	J:221849
	thymus atrophy	J:221849
Bmi1^tm1Sgon/Bmi1^tm1Sgon Gt(ROSA)26Sor^{tm1(cre/ERT2)Tyj}/? (involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)	decreased lymphocyte cell number	J:221849
	decreased spleen weight	J:221849
	immune system phenotype	J:221849
Bmp1^tm1.1Dgr/Bmp1^tm1.1Dgr Tll1^tm2.1Dgr/Tll1^tm2.1Dgr Ndor1^{Tg(UBC-cre/ERT2)1Ejb}/0 (involves: 129S/SvEv * 129S6/SvEvTac * C57BL/6 * SJL)	increased osteoclast cell number	J:210366
Bmp2^tm1.1Mis/Bmp2^tm1.2Mis Tg(Col1a1-cre)1Bek/0 (involves: 129S4/SvJaeSor * 129S7/SvEvBrd * CD-1)	decreased osteoclast cell number	J:210409
Bmp2^tm1Cjt/Bmp2^tm1Cjt Bmp4^tm1Jfm/Bmp4^tm1Jfm Tg(Prrx1-cre)1Cjt/0 (involves: 129S4/SvJaeSor * C57BL/6 * SJL)	abnormal bone marrow development	J:118257
Bmp5^se-Ca/Bmp5⁺ (SEACGn.CB-Bmp5^se-Ca)	granulomatous inflammation	J:5086
Bmp5^se-Ca/Bmp5^se-Ca (CBA/Ca-Bmp5^se-Ca)	granulomatous inflammation	J:5086
Bmp5^se-Ca/Bmp5^se-Ca (SEACGn.CB-Bmp5^se-Ca)	granulomatous inflammation	J:5086
Bmp5^se/Bmp5^se (SEC/1Gn)	granulomatous inflammation	J:5086
Bmp5^se/Bmp5^se (SEAC/Gn)	granulomatous inflammation	J:5086
Bmp7^tm1.1Dgra/Bmp7^tm1.1Dgra Tg(Prrx1-cre)1Cjt/0 (involves: 129S6/SvEvTac * C57BL/6J * C57BL/6NTac * SJL/J)	joint inflammation	J:221175
	osteoarthritis	J:221175
Bmp7^{tm1a(EUCOMM)Hmgu}/Bmp7⁺ (C57BL/6N-Bmp7^{tm1a(EUCOMM)Hmgu}/H)	increased monocyte cell number	J:165965
Bmp7^tm1Rob/Bmp7⁺ Bmp8a^tm1Blh/Bmp8a^tm1Blh (involves: 129S/SvEv * 129S6/SvEvTac * Black Swiss * C57BL/6)	granulomatous inflammation	J:78867
Bmp8a^tm1Blh/Bmp8a⁺ Bmp8b^tm1Blh/Bmp8b⁺ (involves: 129/Sv * 129S6/SvEvTac * Black Swiss)	granulomatous inflammation	J:46927
Bmp8a^tm1Blh/Bmp8a^tm1Blh (involves: 129S6/SvEvTac * Black Swiss)	granulomatous inflammation	J:46927
Bmp10^b2b2711Clo/Bmp10^b2b2711Clo (C57BL/6J-Bmp10^b2b2711Clo)	thymus hypoplasia	J:175213
Bmpr1a^tm2.1Bhr/Bmpr1a^tm2.1Bhr Tg(CAG-cre/Esr1)5Amc/0 (involves: 129S7/SvEvBrd C57BL/6 * CBA)	stomach inflammation	J:163367
Bmpr1a^tm2.1Bhr/Bmpr1a^tm2.1Bhr Tg(Col1a1-cre/Esr1*)1Mis/0 (involves: 129S7/SvEvBrd)	abnormal osteoclast differentiation	J:143588
	abnormal osteoclast physiology	J:143588
	decreased osteoclast cell number	J:143588
Bmpr1a^tm2.1Bhr/Bmpr1a^tm2.2Bhr Tg(Gdf5-cre,-ALPP)1Kng/0 (involves: 129 * C57BL/6 * FVB/N-Tg(Gdf5-cre-ALPP)1Kng)	osteoarthritis	J:97780
Bmpr2^tm1Kmi/Bmpr2⁺ (involves: 129S4/SvJae * C57BL/6J)	abnormal leukocyte physiology	J:117167
Bmx^tm1Ali/Bmx^tm1Ali (involves: 129S1/Sv * 129X1/SvJ)	decreased susceptibility to induced arthritis	J:173099
Bnc1^em1(IMPC)H/Bnc1^em1(IMPC)H (C57BL/6NTac-Bnc1^em1(IMPC)H/H)	abnormal spleen morphology	J:211773
	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Bnip1^{tm2b(KOMP)Wtsi}/Bnip1⁺ (C57BL/6N-Bnip1^{tm2b(KOMP)Wtsi}/Nju)	increased eosinophil cell number	J:211773
Bnip3l^tm1.1Gwd/Bnip3l^tm1.1Gwd (involves: 129 * C57BL/6)	abnormal spleen morphology	J:141583
	abnormal thrombopoiesis	J:141583
	enlarged spleen	J:141583
	increased spleen red pulp amount	J:141583
Bnip3l^tm1Ney/Bnip3l^tm1Ney (Not Specified)	enlarged spleen	J:141545
Bnip3l^tm1Ney/Bnip3l^tm1Ney (Not Specified)	spleen hyperplasia	J:141545
Bnip5^{tm1.1(KOMP)Vlcg}/Bnip5^{tm1.1(KOMP)Vlcg} (C57BL/6N-Bnip5^{tm1.1(KOMP)Vlcg}/MbpMmucd)	abnormal spleen morphology	J:211773
	small spleen	J:211773
Boc^{tm1b(KOMP)Wtsi}/Boc^{tm1b(KOMP)Wtsi} (C57BL/6N-Boc^{tm1b(KOMP)Wtsi}/H)	increased basophil cell number	J:211773
Bod1^{tm1b(KOMP)Wtsi}/Bod1⁺ (C57BL/6N-Bod1^{tm1b(KOMP)Wtsi}/Nju)	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
Bod1l^em1Bltn/Bod1l^em1Bltn Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129P2/OlaHsd * C57BL/6J)	decreased IgG1 level	J:337726
	decreased IgG level	J:337726
Bod1l^em1Bltn/Bod1l^em1Bltn Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte}/Gt(ROSA)26Sor⁺ (involves: C57BL/6J * C57BL/6NTac)	abnormal class switch recombination	J:337726
	decreased IgG1 level	J:337726
Bok^tm1.1Ast/Bok^tm1.1Ast (involves: BALB/cJ * C57BL/6)	immune system phenotype	J:203179
	increased spleen weight	J:203179
	increased thymus weight	J:203179
Bok^{tm1b(EUCOMM)Hmgu}/Bok^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Bok^{tm1b(EUCOMM)Hmgu}/Tcp)	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
Bomb1^NSF/N/Bomb1^NSF/N (involves: NFS/N * SL/Kh)	increased pre-B cell number	J:55364
Bomb1^SL/Kh/Bomb1^SL/Kh (involves: NFS/N * SL/Kh)	increased pre-B cell number	J:55364
Bpgm^m1Pgrs/Bpgm^m1Pgrs (involves: C57BL/6 * C57BL/10J)	decreased susceptibility to parasitic infection induced morbidity/mortality	J:301620
	enlarged spleen	J:301620
	immune system phenotype	J:301620
Bpgm^m1Pgrs/Bpgm^m1Pgrs (involves: A/J)	decreased susceptibility to parasitic infection induced morbidity/mortality	J:301620
Bpi^tm1.1Buls/Bpi^tm1.1Buls (involves: BALB/cJ * C57BL/6J)	abnormal circulating interleukin level	J:346703
	abnormal immune cell physiology	J:346703
	abnormal interleukin secretion	J:346703
	decreased circulating interferon-gamma level	J:346703
	enlarged mesenteric lymph nodes	J:346703
	immune system phenotype	J:346703
	increased susceptibility to induced colitis	J:346703
	increased T cell number	J:346703
Bpifa1^m1Ingm/Bpifa1^m1Ingm (involves: C3HeB/FeJ)	increased interleukin-1 alpha secretion	J:195535
	increased interleukin-1 beta secretion	J:195535
	increased susceptibility to bacterial infection	J:195535
	increased susceptibility to otitis media	J:221346
	increased tumor necrosis factor secretion	J:195535
	lung inflammation	J:195535
Bpifa1^{tm1(KOMP)Vlcg}/Bpifa1^{tm1(KOMP)Vlcg} (involves: C57BL/6J * C57BL/6NTac)	increased susceptibility to bacterial infection	J:171589
Bpifa1^tm1.1Jpst/Bpifa1^tm1.1Jpst Scgb1a1^{tm1(cre/ERT)Blh}/Scgb1a1^{tm1(cre/ERT)Blh} (involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * SJL)	increased susceptibility to Orthomyxoviridae infection	J:265391
	increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:265391
Bpifa1^tm1.2Jpst/Bpifa1^tm1.2Jpst (involves: BALB/cJ * C57BL/6 * C57BL/6J * SJL)	increased susceptibility to Orthomyxoviridae infection	J:265391
	increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:265391
Bptf^em1Zfa/Bptf^em1Zfa Tg(Rorc-cre)1Litt/0 (involves: C57BL/6 * FVB)	increased susceptibility to bacterial infection	J:259392
	increased susceptibility to bacterial infection induced morbidity/mortality	J:259392
Bptf^tm1.1Cwu/Bptf^tm1.1Cwu Emx1^tm1(cre)Krj/Emx1⁺ (involves: 129S1/Sv * 129S2/SvPas * C57BL/6)	microgliosis	J:334252
Braf^tm1(ARAF)Urr/Braf^tm1(ARAF)Urr (involves: 129S1/Sv * C57BL/6 * CD-1)	decreased spleen weight	J:112971
	decreased thymus weight	J:112971
Braf^tm1Bbd/Braf⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	abnormal immune system physiology	J:170095
	abnormal thymus morphology	J:170095
	decreased thymocyte number	J:170095
	increased splenocyte apoptosis	J:170095
	increased thymocyte apoptosis	J:170095
	thymus atrophy	J:170095
Braf^tm1Bbd/Braf⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * CD-1)	abnormal immune system physiology	J:170095
	abnormal thymus morphology	J:170095
	decreased thymocyte number	J:170095
	increased splenocyte apoptosis	J:170095
	increased thymocyte apoptosis	J:170095
	thymus atrophy	J:170095
Braf^tm1Bbd/Braf⁺ (B6.129-Braf^tm1Bbd)	abnormal immune system physiology	J:170095
	abnormal thymus morphology	J:170095
	decreased thymocyte number	J:170095
	increased splenocyte apoptosis	J:170095
	increased thymocyte apoptosis	J:170095
	thymus atrophy	J:170095
Braf^tm1Cpri/Braf⁺ Tg(Mx1-cre)1Cgn/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA)	decreased leukocyte cell number	J:104375
	enlarged spleen	J:104375
Braf^tm1Mmcm/Braf^tm1Mmcm Cd207^{tm2.1(cre)Bjec}/Cd207⁺ (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)	increased dendritic cell number	J:211690
	liver inflammation	J:211690
	lung inflammation	J:211690
Braf^tm1Mmcm/Braf^tm1Mmcm Tg(Itgax-cre)1-1Reiz/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA)	cytokine storm	J:211690
	enlarged lymph nodes	J:211690
	granulomatous inflammation	J:211690
	hepatosplenomegaly	J:211690
	increased dendritic cell number	J:211690
	increased inflammatory response	J:211690
Braf^tm1Tumg/Braf⁺ Tg(CAG-cre)2Osb/0 (involves: C57BL * C57BL/6J * DBA)	abnormal lymph organ development	J:216228
Braf^tm1Wds/Braf^tm1Wds Raf1^tm2Bacc/Raf1^tm2Bacc H2az2^{Tg(Wnt1-cre)11Rth}/H2az2⁺ (involves: 129P2/OlaHsd * C57BL/6J * CBA/J)	small thymus	J:144862
Braf^tm2Cpri/Braf⁺ Tg(CMV-cre)1Cgn/0 (B6.Cg-Braf^tm2Cpri Tg(CMV-cre)1Cgn)	enlarged spleen	J:187371
	increased spleen weight	J:187371
	lymphoid hyperplasia	J:187371
Brap^em1(IMPC)Mbp/Brap⁺ (C57BL/6NCrl-Brap^em1(IMPC)Mbp/Mmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
Brca1^tm2.1Cxd/Brca1^tm2.1Cxd Shld1^em1Nus/Shld1^em1Nus (involves: 129S6/SvEvTac * C57BL/6NCrl)	abnormal class switch recombination	J:307190
Brca1^tm2.1Cxd/Brca1^tm2.1Cxd Trp53^tm1Brd/Trp53⁺ (involves: 129S6/SvEvTac * 129S7/SvEvBrd)	enlarged thymus	J:81541
	increased T cell derived lymphoma incidence	J:81541
Brca1^tm2.1Cxd/Brca1^tm2.1Cxd Trp53^tm1Brd/Trp53^tm1Brd (involves: 129S6/SvEvTac * 129S7/SvEvBrd)	increased T cell derived lymphoma incidence	J:81541
Brca1^tm2.1Cxd/Brca1^tm2.1Cxd Trp53bp1^tm1Jc/Trp53bp1^tm1Jc (involves: 129 * 129S6/SvEvTac)	abnormal class switch recombination	J:307190
Brca1^tm2Mak/Brca1^tm2Mak Cdkn1a^tm1Tyj/Cdkn1a^tm1Tyj Tg(Lck-cre)548Jxm/? (involves: 129P2/OlaHsd * C57BL/6 * CBA)	decreased thymocyte number	J:63282
	immune system phenotype	J:63282
Brca1^tm2Mak/Brca1^tm2Mak Chek2^tm1Mak/Chek2^tm1Mak Tg(Lck-cre)548Jxm/? (involves: 129P2/OlaHsd * C57BL/6 * CBA)	immune system phenotype	J:90512
	increased T cell derived lymphoma incidence	J:90512
Brca1^tm2Mak/Brca1^tm2Mak Tg(BCL2)36Wehi/? Tg(Lck-cre)548Jxm/? (involves: 129P2/OlaHsd * C57BL/6 * CBA)	immune system phenotype	J:63282
Brca1^tm2Mak/Brca1^tm2Mak Tg(Lck-cre)548Jxm/? (involves: 129P2/OlaHsd * C57BL/6 * CBA)	abnormal immune system organ morphology	J:63282
	abnormal T cell number	J:63282
	decreased double-positive T cell number	J:63282
	decreased single-positive T cell number	J:63282
	decreased T cell proliferation	J:63282
	decreased thymocyte number	J:63282
	increased double-negative T cell number	J:63282
Brca1^tm2Mak/Brca1^tm2Mak Tg(Lck-cre)548Jxm/? Tg(TcrLCMV)327Sdz/? (involves: 129P2/OlaHsd * C57BL/6 * CBA)	abnormal T cell number	J:63282
	decreased double-positive T cell number	J:63282
	decreased T cell proliferation	J:63282
	decreased thymocyte number	J:63282
	increased double-negative T cell number	J:63282
Brca1^tm2Mak/Brca1^tm2Mak Tg(Lck-cre)548Jxm/? Trp53^tm1Brd/Trp53^tm1Brd (involves: 129P2/OlaHsd * C57BL/6 * CBA)	immune system phenotype	J:63282
	increased T cell derived lymphoma incidence	J:90512
Brca1^tm5.1Cxd/Brca1^tm5.1Cxd (involves: 129S6/SvEvTac * FVB/N)	dermatitis	J:155810
	increased T cell derived lymphoma incidence	J:155810
Brca2^tm1Cam/Brca2^tm1Cam (involves: 129S/SvEv * MF1)	increased T cell derived lymphoma incidence	J:46812
Brca2^tm1Cam/Brca2^tm1Cam (involves: 129S/SvEv * MF1)	increased thymus weight	J:46812
Brca2^tm1Cbl/Brca2^tm1Cbl (either: (involves: 129S2/SvPas * C57BL/10) or (involves: 129S2/SvPas * C57BL/6 * DBA/2))	increased T cell derived lymphoma incidence	J:44386
Brca2^tm1Hst/Brca2^tm1Hst (involves: 129S7/SvEvBrd * C57BL/6)	sepsis	J:82434
Brca2^tm1Kamc/Brca2^tm1Kamc (involves: 129P2/OlaHsd * BALB/c)	spleen hypoplasia	J:144998
Brca2^tm1Mak/Brca2^tm2Mak Tg(Lck-cre)548Jxm/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA)	immune system phenotype	J:79697
	increased T cell apoptosis	J:79697
Brca2^tm1Mak/Brca2^tm2Mak Trp53^tm1Brd/Trp53^tm1Brd Tg(Lck-cre)548Jxm/0 (involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * CBA)	immune system phenotype	J:79697
	increased activated T cell number	J:79697
Brd2^{em1(IMPC)Wtsi}/Brd2⁺ (C57BL/6N-Brd2^{em1(IMPC)Wtsi}/WtsiIeg)	decreased CD8-positive, alpha-beta T cell number	J:211773
	increased CD4-positive, alpha-beta T cell number	J:211773
Brd2^{em1(IMPC)Wtsi}/Brd2^{em1(IMPC)Wtsi} (C57BL/6N-Brd2^{em1(IMPC)Wtsi}/WtsiIeg)	abnormal thymus topology	J:239583
	absent connection between subcutaneous lymph vessels and lymph sac	J:239583
	blood in lymph vessels	J:239583
	small thymus	J:239583
Brd2^{Gt(RRT234)Byg}/Brd2⁺ (B6.129P2-Brd2^{Gt(RRT234)Byg})	increased circulating interleukin-1 beta level	J:159964
Brd2^{Gt(RRT234)Byg}/Brd2⁺ (B6.129P2-Brd2^{Gt(RRT234)Byg})	increased circulating tumor necrosis factor level	J:159964
Brd9^em1(IMPC)Tcp/Brd9⁺ (C57BL/6N-Brd9^em1(IMPC)Tcp/Cmmr)	increased neutrophil cell number	J:211773
Brf1^tm1Arte/Brf1^tm1Arte Tg(Cyp1a1-cre)1Dwi/0 (involves: C57BL/6 * CBA)	liver inflammation	J:285667
Brix1^{tm1b(KOMP)Mbp}/Brix1⁺ (C57BL/6N-Brix1^{tm1b(KOMP)Mbp}/Mhzh)	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
Brpf1^{tm1a(EUCOMM)Wtsi}/Brpf1⁺ (Not Specified)	decreased T cell number	J:165965
Brpf1^{tm1a(EUCOMM)Wtsi}/Brpf1⁺ (Not Specified)	increased monocyte cell number	J:165965
Brwd1^em1(IMPC)Tcp/Brwd1^em1(IMPC)Tcp (C57BL/6N-Brwd1^em1(IMPC)Tcp/Cmmr)	abnormal spleen morphology	J:211773
Bscl2^tm1.1Lchan/Bscl2^tm1.1Lchan (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	enlarged spleen	J:183701
Bscl2^tm1.2Gliu/Bscl2^tm1.2Gliu (involves: 129 * 129S4/SvJaeSor * C57BL/6 * FVB/N)	enlarged spleen	J:173404
Bscl2^{tm1b(EUCOMM)Hmgu}/Bscl2^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Bscl2^{tm1b(EUCOMM)Hmgu}/Ics)	increased large unstained cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Bsg^tm1.1Znc/Bsg^tm1.1Znc Tg(Lck-cre)19Hhan/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA)	abnormal T cell activation	J:207886
	decreased double-positive T cell number	J:207886
	decreased single-positive T cell number	J:207886
	decreased thymocyte number	J:207886
	decreased thymus weight	J:207886
	immune system phenotype	J:207886
	increased T cell proliferation	J:207886
Bsg^tm1Tmu/Bsg^tm1Tmu (involves: 129S2/SvPas * C57BL/6J)	interstitial pneumonia	J:46376
Bsg^tm1Tmu/Bsg^tm1Tmu (involves: 129/Sv * 129S2/SvPas)	interstitial pneumonia	J:46376
Bsg^tm1Tmu/Bsg^tm1Tmu (involves: 129S2/SvPas)	decreased circulating complement protein level	J:287636
	glomerulonephritis	J:287636
	increased spleen weight	J:287636
	increased splenocyte number	J:287636
	increased susceptibility to systemic lupus erythematosus	J:287636
	increased T-helper 17 cell number	J:287636
Bsp/Bsp (C57BL/6By)	abnormal spleen morphology	J:6856
Bsp/Bsp⁺ (C57BL/6By)	abnormal spleen morphology	J:6856
Bst1^tm1Thir/Bst1^tm1Thir (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell physiology	J:111424
	abnormal humoral immune response	J:111424
	decreased B-1 B cell number	J:111424
	decreased IgA level	J:111424
	decreased IgG3 level	J:111424
	decreased immature B cell number	J:111424
	immune system phenotype	J:111424
	increased B cell number	J:111424
Bst2^tm1.1Bsz/Bst2^tm1.1Bsz (involves: C57BL/6)	enlarged lymph nodes	J:180252
	enlarged spleen	J:180252
	increased susceptibility to Retroviridae infection	J:180252
Btbd1^{tm1a(KOMP)Wtsi}/Btbd1^{tm1a(KOMP)Wtsi} (C57BL/6N-Btbd1^{tm1a(KOMP)Wtsi}/Wtsi)	increased CD8-positive, naive alpha-beta T cell number	J:211773
Btbd2^em1(IMPC)Mbp/Btbd2^em1(IMPC)Mbp (C57BL/6N-Btbd2^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
Btbd3^{tm1b(EUCOMM)Hmgu}/Btbd3^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Btbd3^{tm1b(EUCOMM)Hmgu}/Ccpcz)	increased CD8-positive, CD25-positive alpha-beta T cell number	J:211773
Btbd7^{em1(IMPC)Ccpcz}/Btbd7^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Btbd7^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Btbd8^em1Lych/Btbd8^em1Lych (involves: C57BL/6)	decreased macrophage cytokine production	J:349252
Btbd8^em1Lych/Btbd8^em1Lych (involves: C57BL/6)	decreased susceptibility to induced colitis	J:349252
Btbd16^{tm2b(EUCOMM)Hmgu}/Btbd16^{tm2b(EUCOMM)Hmgu} (C57BL/6N-Btbd16^{tm2b(EUCOMM)Hmgu}/Bay)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	increased spleen weight	J:211773
Btbd18^{em1(IMPC)Ccpcz}/Btbd18^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Btbd18^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Btc^em1(IMPC)Mbp/Btc^em1(IMPC)Mbp (C57BL/6N-Btc^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
	increased neutrophil cell number	J:211773
Btf3^em1(IMPC)Tcp/Btf3⁺ (C57BL/6NCrl-Btf3^em1(IMPC)Tcp/Tcp)	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
	enlarged lymph nodes	J:211773
Btg1^em1(IMPC)Mbp/Btg1^em1(IMPC)Mbp (C57BL/6NCrl-Btg1^em1(IMPC)Mbp/Mmucd)	decreased lymphocyte cell number	J:211773
	enlarged spleen	J:211773
	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
Btk^m1Anu/Btk^m1Anu (involves: BXSB/MpJ * C57BL/6JAnu * SB/Le)	decreased B cell number	J:104190
Btk^m1Anu/Btk^m1Anu X/Yaa (involves: BXSB/MpJ * C57BL/6JAnu * SB/Le)	decreased B cell number	J:104190
Btk^m2Anu/Btk^m2Anu (C57BL/6NCrl-Btk^m2Anu)	increased IgM level	J:104190
Btk^m2Anu/Btk^m2Anu (C57BL/6NCrl-Btk^m2Anu)	increased immature B cell number	J:104190
Btk^{tm1a(EUCOMM)Hmgu}/Y (C57BL/6N-Btk^{tm1a(EUCOMM)Hmgu}/Ics)	increased CD4-positive, alpha-beta T cell number	J:165965
Btk^tm1Gsv/Y (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell calcium ion homeostasis	J:94768
	abnormal B cell differentiation	J:35769
	abnormal humoral immune response	J:120989
	abnormal immune system physiology	J:35769
	absent B-1a cells	J:35769
	absent mature B cells	J:35769
	decreased B cell number	J:35769
	decreased IgG3 level	J:35769
	decreased IgM level	J:35769
	decreased immature B cell number	J:35769
	decreased immunoglobulin level	J:120989
Btk^tm1Gsv/Y Tg(CD19-BTKK430R)XK24Rwhe/? (involves: 129P2/OlaHsd C57BL/6 * FVB)	abnormal lymphocyte cell number	J:120989
	abnormal pre-B cell morphology	J:120989
	absent B-1a cells	J:120989
	decreased B cell apoptosis	J:120989
	decreased B cell number	J:120989
	decreased immunoglobulin level	J:120989
	immune system phenotype	J:94768
Btk^tm1Gsv/Btk⁺ (involves: 129P2/OlaHsd * C57BL/6)	absent B-1a cells	J:35769
	decreased B cell number	J:35769
	decreased mature B cell number	J:35769
Btk^tm1Witt/Btk^tm1Wk (involves: 129S4/SvJae * 129X1/SvJ)	immune system phenotype	J:104167
Btk^tm1Wk/Btk^tm1Wk (involves: 129S4/SvJae * C57BL/6)	abnormal B cell activation	J:28968
	abnormal B cell differentiation	J:28968
	abnormal lymph node germinal center morphology	J:82298
	decreased B cell proliferation	J:82298
	decreased IgG3 level	J:28968, J:82298
	decreased IgM level	J:28968, J:82298
	decreased mature B cell number	J:28968, J:82298
	decreased spleen germinal center number	J:82298
	decreased spleen germinal center size	J:82298
	increased pro-B cell number	J:28968
Btk^tm1Wk/Btk^tm1Wk Cd40^tm1Geha/Cd40^tm1Geha (involves: 129S4/SvJae * C57BL/6)	abnormal humoral immune response	J:82298
	absent lymph node germinal center	J:82298
	absent spleen germinal center	J:82298
	decreased B cell number	J:82298
	decreased B cell proliferation	J:82298
	decreased IgA level	J:82298
	decreased IgG2a level	J:82298
	decreased IgG2b level	J:82298
	decreased IgG3 level	J:82298
	decreased IgM level	J:82298
	decreased mature B cell number	J:82298
Btk^tm1Wk/Btk^tm1Wk Tec^tm1Welm/Tec^tm1Welm (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell differentiation	J:66080
	abnormal humoral immune response	J:66080
	abnormal spleen marginal zone morphology	J:66080
	abnormal spleen morphology	J:66080
	abnormal spleen white pulp morphology	J:66080
	decreased B cell number	J:66080
	decreased B cell proliferation	J:66080
	decreased IgG2a level	J:66080
	decreased IgG3 level	J:66080
	decreased IgM level	J:66080
	decreased immunoglobulin level	J:66080
	increased pre-B cell number	J:66080
Btk^tm1Wk/Btk^tm1Wk Tg(IGH-Btk)1Witt/0 (involves: 129S4/SvJae * 129X1/SvJ * BALB/c * C3H * C57BL/6)	decreased B cell proliferation	J:82430
Btk^vila/Btk^vila (C57BL/6JAnu-Btk^vila/AnuApb)	abnormal leukocyte morphology	J:104190
	decreased B cell number	J:104190
	decreased IgD level	J:104190
	increased IgE level	J:104190
	increased IgG level	J:104190
Btk^xid/Y (CBA/HN-Btk^xid)	decreased B cell number	J:81429
	decreased B cell proliferation	J:81429
	decreased splenocyte number	J:81429
Btk^xid/Y (involves: CBA/HN * DBA/2N)	decreased B cell number	J:81429
	decreased B cell proliferation	J:81429
	spleen hypoplasia	J:81429
Btk^xid/? (involves: BALB/c * CBA/N)	decreased B cell proliferation	J:108696
	decreased B-1 B cell number	J:108696
	decreased IgG3 level	J:108696
	decreased IgM level	J:108696
	decreased mature B cell number	J:108696
Btk^xid/Y Ikzf3^tm1Kge/Ikzf3^tm1Kge (involves: 129S4/SvJae * CBA/CaHN)	decreased follicular B cell number	J:69477
Btk^xid/? Ptpn6^me/Ptpn6^me (involves: C57BL/6J * CBA/N * NFS)	increased autoantibody level	J:30994
	increased IgM level	J:30994
	increased splenocyte proliferation	J:30994
Btk^xid/? Tg(IGH-Btk)1Witt/0 (involves: BALB/c * C3H * C57BL/6 * CBA/N)	decreased B cell proliferation	J:108696
	decreased B-1 B cell number	J:108696
	decreased IgG3 level	J:108696
	decreased IgM level	J:108696
Btk^xid/? Tg(IGH-Btk)1Witt/Tg(IGH-Btk)1Witt (involves: BALB/c * C3H * C57BL/6 * CBA/N)	decreased B cell proliferation	J:108696
	decreased B-1 B cell number	J:108696
	decreased IgG3 level	J:108696
	decreased IgM level	J:108696
Btk^xid/Btk^xid (CBA/CaHN-Btk^xid/J)	abnormal macrophage physiology	J:92639
	abnormal neutrophil physiology	J:92639
	decreased acute inflammation	J:92639
	decreased follicular B cell number	J:69477
	decreased neutrophil cell number	J:92639
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:92639
	impaired myelopoiesis	J:92639
	impaired neutrophil phagocytosis	J:92639
	increased susceptibility to bacterial infection induced morbidity/mortality	J:128518
	increased susceptibility to induced colitis	J:92639
Btk^xid/Btk^xid (involves: CBA/HN * DBA/2N)	abnormal B cell physiology	J:81429
	abnormal B cell proliferation	J:81429
	decreased B cell number	J:81429
	spleen hypoplasia	J:81429
Btk^xid/Btk^xid (CBA/HN-Btk^xid)	abnormal lymphopoiesis	J:7981
	abnormal pre-B cell morphology	J:7981
	autoimmune response	J:125114
	decreased B cell number	J:81429
	decreased B cell proliferation	J:81429
	decreased splenocyte number	J:81429
Btk^xid/Btk^xid (involves: C57BL/6 * CBA)	immune system phenotype	J:113083
Btk^xid/Btk^xid (B6.CBA-Btk^xid)	decreased transitional stage B cell number	J:145687
Btk^xid/Btk^xid Ikzf3^tm1Kge/Ikzf3^tm1Kge (involves: 129S4/SvJae * CBA/CaHN)	decreased follicular B cell number	J:69477
Btla^tm1Dgra/Btla^tm1Dgra (involves: C57BL/6)	abnormal peripheral T cell anergy	J:147751
Btla^tm1Dgra/Btla^tm1Dgra (involves: C57BL/6)	abnormal T cell activation	J:147751
Btla^tm1Dgra/Btla^tm1Dgra Tg(TcraTcrb)425Cbn/? (involves: C57BL/6)	abnormal peripheral T cell anergy	J:147751
Btla^tm1Dgra/Btla^tm1Dgra Tg(TcraTcrb)1100Mjb/? (involves: C57BL/6)	abnormal peripheral T cell anergy	J:147751
Btla^tm1Kay/Btla^tm1Kay (involves: 129S6/SvEvTac * C57BL/6J)	abnormal T cell activation	J:89864
Btla^tm1Kmm/Btla^tm1Kmm (involves: 129S/SvEv)	abnormal humoral immune response	J:84084
	increased B cell proliferation	J:84084
	increased IgG1 level	J:84084
	increased IgG2a level	J:84084
	increased IgG2b level	J:84084
	increased susceptibility to experimental autoimmune encephalomyelitis	J:84084
	increased T cell proliferation	J:84084
Btla^tm1Kmm/Btla^tm1Kmm (B6.129S-Btla^tm1Kmm)	abnormal T cell activation	J:119356
	decreased interferon-gamma secretion	J:119356
	decreased interleukin-2 secretion	J:119356
	decreased T cell proliferation	J:119356
	increased length of allograft survival	J:119356
	increased T cell proliferation	J:119356
Btla^tm1Kmm/Btla^tm1Kmm Pdcd1^tm1Hon/Pdcd1^tm1Hon (B6.129S-Pdcd1^tm1Hon Btla^tm1Kmm)	decreased length of allograft survival	J:119356
	increased T cell proliferation	J:119356
Btla^tm1Kmm/Btla^tm1Kmm Tg(DO11.10)10Dlo/? (involves: 129S/SvEv * BALB/c * C3H * C57BL/6)	increased T cell proliferation	J:84084
Btn2a2^tm1.2Wrth/Btn2a2^tm1.2Wrth (C57BL/6-Btn2a2^tm1.2Wrth)	abnormal T-helper 1 physiology	J:232636
	abnormal T-helper 2 physiology	J:232636
	increased anti-nuclear antigen antibody level	J:232636
	increased IgG1 level	J:232636
	increased IgG2c level	J:232636
	increased IgG level	J:232636
	increased response to antigen	J:232636
	increased susceptibility to experimental autoimmune encephalomyelitis	J:232636
Btnl1^em1Ahay/Btnl1^em1Ahay (Not Specified)	abnormal CD8 positive, alpha-beta intraepithelial T cell morphology	J:236526
Btnl1^em1Ahay/Btnl1^em1Ahay (Not Specified)	decreased gamma-delta intraepithelial T cell number	J:236526
Btnl1^em3Ahay/Btnl1^em3Ahay Btnl6^em2Ahay/Btnl6^em2Ahay Tg(Vil1-cre/ERT2)23Syr/0 (involves: BALB/c * C57BL/6J * DBA/2)	immune system phenotype	J:291989
Btnl1^em4Ahay/Btnl1^em4Ahay Tg(Vil1-cre/ERT2)23Syr/0 (involves: C57BL/6 * DBA/2)	immune system phenotype	J:291989
Btnl1^tm1(KOMP)Mbp/Btnl1^tm1(KOMP)Mbp (C57BL/6N-Btnl1^tm1(KOMP)Mbp)	abnormal CD8 positive, alpha-beta intraepithelial T cell morphology	J:236526
	decreased gamma-delta intraepithelial T cell number	J:236526
Btnl1^tm1(KOMP)Mbp/Btnl1^tm1(KOMP)Mbp Foxn1^nu/Foxn1^nu (involves: albino stock * C57BL/6N)	decreased gamma-delta intraepithelial T cell number	J:236526
Btnl1^tm1(KOMP)Mbp/Btnl1^tm1(KOMP)Mbp Gt(ROSA)26Sor^{tm1(rtTAM2)Jae}/0 Tg(tetO-Btnl1)#Ahay/0 (involves: 129S4/SvJae C57BL/6 * C57BL/6N)	decreased gamma-delta intraepithelial T cell number	J:236526
Btnl1^tm1(KOMP)Mbp/Btnl1^tm1(KOMP)Mbp Tg(tetO-Btnl1)#Ahay/0 Tg(Vil-rtTA2M2)1Rsmi/0 (involves: C57BL/6N FVB/N)	decreased gamma-delta intraepithelial T cell number	J:236526
Btnl2^em1Wche/Btnl2^em1Wche (C57BL/6-Btnl2^em1Wche)	abnormal cytokine level	J:321348
	abnormal gamma-delta T cell morphology	J:321348
	large intestinal inflammation	J:321348
Btnl4^em1(IMPC)Tcp/Btnl4^em1(IMPC)Tcp (C57BL/6N-Btnl4^em1(IMPC)Tcp/1Cmmr)	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Btnl4^tm1(KOMP)Mbp/Btnl4^tm1(KOMP)Mbp (C57BL/6N-Btnl4^tm1(KOMP)Mbp)	immune system phenotype	J:291989
Btnl6^em1.1Ahay/Btnl6^em1.1Ahay (Not Specified)	decreased CD4-positive, gamma-delta intraepithelial T cell number	J:291989
Btnl6^em1Ahay/Btnl6^em1Ahay Tg(Vil1-cre)20Syr/0 (involves: C57BL/6 * DBA/2)	decreased CD4-positive, gamma-delta intraepithelial T cell number	J:291989
Btrc^{tm1b(KOMP)Wtsi}/Btrc^{tm1b(KOMP)Wtsi} (C57BL/6N-Btrc^{tm1b(KOMP)Wtsi}/H)	increased monocyte cell number	J:211773
Btrc^tm1Kin/Btrc^tm1Kin (involves: C57BL/6)	abnormal lymphocyte morphology	J:84639
Btrc^tm1Paga/Btrc^tm1Paga Fbxw11^tm1Ybn/Fbxw11^tm1Ybn Tg(Vil1-cre/ERT2)23Syr/? (involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6 * DBA/2)	increased circulating interleukin-1 beta level	J:206654
	intestinal inflammation	J:206654
Bub1^tm1.1Tvd/Bub1^tm1.1Tvd (B6.129P2-Bub1^tm1.1Tvd)	increased leukocyte cell number	J:143035
Bub1b^{Gt(neo-btk)1Dai}/Bub1b⁺ (involves: 129S4/SvJae * C57BL/6)	enlarged spleen	J:88223
Bub1b^tm1.1Hsl/Bub1b⁺ (involves: 129 * C57BL/6)	enlarged spleen	J:201641
	increased B cell proliferation	J:201641
	increased spleen white pulp amount	J:201641
Bud13^{em1(IMPC)Ccpcz}/Bud13⁺ (C57BL/6NCrl-Bud13^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
Bxs6^BXSB/MpJ/Bxs6^BXSB/MpJ (involves: BXSB/MpJ * C57BL/10ScSnOlaHsd)	autoimmune response	J:145903
	glomerulonephritis	J:145903
	increased autoantibody level	J:145903
Bxs6^BXSB/MpJ/Bxs6^BXSB/MpJ (B10.BXSB-(D13Mit3-D13Mit78))	autoimmune response	J:145049
	increased anti-double stranded DNA antibody level	J:145049
	increased anti-single stranded DNA antibody level	J:145049
	increased autoantibody level	J:145049
Bxs6^BXSB/MpJ/Bxs6^BXSB/MpJ Gpab1^C57BL/6J/? (involves: BXSB/MpJ * C57BL/10ScSnOlaHsd)	autoimmune response	J:145903
	increased autoantibody level	J:145903
Bxs6^BXSB/MpJ/Bxs6^BXSB/MpJ X/Yaa (B10.BXSB-(D13Mit3-D13Mit78) Yaa)	autoimmune response	J:145049
	enlarged spleen	J:145049
	glomerulonephritis	J:145049
	increased anti-double stranded DNA antibody level	J:145049
	increased anti-single stranded DNA antibody level	J:145049
	increased autoantibody level	J:145049
C1galt1^ptl1/C1galt1^ptl1 (C57BL/6-C1galt1^ptl1)	abnormal thrombopoiesis	J:115272
	glomerulonephritis	J:115272
	kidney inflammation	J:115272
C1galt1^ptl1/C1galt1^ptl1 Rag1^tm1Bal/Rag1^tm1Bal (involves: 129S4/SvJae * C57BL/6)	kidney inflammation	J:115272
C1qa^tm1Mjw/C1qa^tm1Mjw (involves: 129P2/Ola * 129S/SvEv * C57BL/6)	glomerulonephritis	J:47315
	increased anti-histone antibody level	J:47315
	increased anti-nuclear antigen antibody level	J:47315
	increased susceptibility to bacterial infection	J:83712
C1qa^tm1Mjw/C1qa^tm1Mjw (involves: 129P2/Ola * 129S/SvEv)	immune system phenotype	J:47315
C1qa^tm1Mjw/C1qa^tm1Mjw Sle16^{129S6/SvEvTac}/Sle16^{129S6/SvEvTac} (involves: 129S/SvEv * 129X1/Sv * C57BL/6)	increased anti-chromatin antibody level	J:118645
	increased anti-double stranded DNA antibody level	J:118645
	increased anti-nuclear antigen antibody level	J:118645
	increased anti-single stranded DNA antibody level	J:118645
	increased susceptibility to systemic lupus erythematosus	J:118645
C1qa^tm1Mjw/C1qa^tm1Mjw Sle16^{129S6/SvEvTac}/Sle16^C57BL/6 (involves: 129S/SvEv * 129X1/Sv * C57BL/6)	increased anti-chromatin antibody level	J:118645
	increased anti-double stranded DNA antibody level	J:118645
	increased anti-nuclear antigen antibody level	J:118645
	increased anti-single stranded DNA antibody level	J:118645
	increased susceptibility to systemic lupus erythematosus	J:118645
C1qa^tm1Mjw/C1qa^tm1Mjw Sle18^C57BL/6/Sle18^C57BL/6 (involves: 129S/SvEv * 129X1/Sv * C57BL/6)	increased anti-nuclear antigen antibody level	J:118645
	increased susceptibility to systemic lupus erythematosus	J:118645
C1qa^tm1Mjw/C1qa^tm1Mjw Sle18^C57BL/6/Sle18^C57BL/6 (involves: 129P2/Ola * 129S/SvEv * C57BL/6)	increased anti-nuclear antigen antibody level	J:118645
	increased susceptibility to systemic lupus erythematosus	J:118645
C1qa^tm1Mjw/C1qa^tm1Mjw Sle19^C57BL/6/? (involves: 129S/SvEv * 129X1/Sv * C57BL/6)	increased anti-nuclear antigen antibody level	J:118645
	increased susceptibility to systemic lupus erythematosus	J:118645
C1qa^tm1Mjw/C1qa^tm1Mjw Sle19^C57BL/6/? (involves: 129P2/Ola * 129S/SvEv * C57BL/6)	increased anti-nuclear antigen antibody level	J:118645
	increased susceptibility to systemic lupus erythematosus	J:118645
C1qa^tm1Mjw/C1qa^tm1Mjw Sle21^129P2/Ola/? Sle18^C57BL/6/Sle18^C57BL/6 (involves: 129P2/Ola * 129S/SvEv * C57BL/6)	increased anti-nuclear antigen antibody level	J:118645
	increased susceptibility to systemic lupus erythematosus	J:118645
C1qa^tm1Mjw/C1qa^tm1Mjw Sle21^129P2/Ola/Sle21^129P2/Ola (involves: 129P2/Ola * 129S/SvEv * C57BL/6)	increased anti-chromatin antibody level	J:118645
	increased anti-double stranded DNA antibody level	J:118645
	increased anti-nuclear antigen antibody level	J:118645
	increased anti-single stranded DNA antibody level	J:118645
	increased susceptibility to systemic lupus erythematosus	J:118645
C1qa^tm1Mjw/C1qa^tm1Mjw Sle21^129P2/Ola/Sle21^C57BL/6 (involves: 129P2/Ola * 129S/SvEv * C57BL/6)	increased anti-chromatin antibody level	J:118645
	increased anti-double stranded DNA antibody level	J:118645
	increased anti-nuclear antigen antibody level	J:118645
	increased anti-single stranded DNA antibody level	J:118645
	increased susceptibility to systemic lupus erythematosus	J:118645
C1ql2^em1(IMPC)Mbp/C1ql2^em1(IMPC)Mbp (C57BL/6N-C1ql2^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
C1ql3^em1(IMPC)H/C1ql3^em1(IMPC)H (C57BL/6NTac-C1ql3^em1(IMPC)H/H)	decreased eosinophil cell number	J:211773
	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
	decreased monocyte cell number	J:211773
C1ql4^tm1Lex/C1ql4^tm1Lex (B6.129S5-C1ql4^tm1Lex)	decreased leukocyte cell number	J:344722
C1ql4^tm1Lex/C1ql4^tm1Lex (B6.129S5-C1ql4^tm1Lex)	decreased lymphocyte cell number	J:344722
C1qtnf1^em1(IMPC)Mbp/C1qtnf1^em1(IMPC)Mbp (C57BL/6N-C1qtnf1^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
C1qtnf3^tm1Yiw/C1qtnf3^tm1Yiw (involves: C57BL/6NSlc)	immune system phenotype	J:211893
	increased IgG level	J:211893
	increased susceptibility to induced arthritis	J:211893
	joint inflammation	J:211893
C1qtnf4^em1Smoc/C1qtnf4^em1Smoc (C57BL/6JSmoc-C1qtnf4^em1Smoc/Smoc)	abnormal macrophage differentiation	J:302282
	increased circulating interleukin-6 level	J:302282
	increased circulating interleukin-18 level	J:302282
	increased circulating tumor necrosis factor level	J:302282
	increased susceptibility to endotoxin shock	J:302282
	increased tumor necrosis factor secretion	J:302282
C1qtnf6^tm1Yiw/C1qtnf6^tm1Yiw (involves: 129P2/OlaHsd * C57BL/6J)	immune system phenotype	J:227217
	increased anti-nuclear antigen antibody level	J:227217
	increased autoantibody level	J:227217
C1qtnf6^tm1Yiw/C1qtnf6^tm1Yiw (B6.129P2-C1qtnf6^tm1Yiw)	abnormal complement pathway	J:227217
	abnormal complement protein level	J:227217
	immune system phenotype	J:227217
	increased B cell number	J:227217
	increased circulating complement protein level	J:227217
	increased IgG level	J:227217
	increased susceptibility to experimental autoimmune encephalomyelitis	J:227217
	increased susceptibility to induced arthritis	J:227217
	increased susceptibility to type III hypersensitivity reaction	J:227217
C1qtnf7^{tm1(KOMP)Vlcg}/C1qtnf7^{tm1(KOMP)Vlcg} (C57BL/6N-C1qtnf7^{tm1(KOMP)Vlcg})	increased macrophage cell number	J:244352
C2cd3^em1(IMPC)Tcp/C2cd3⁺ (C57BL/6N-C2cd3^em1(IMPC)Tcp/Tcp)	decreased lymphocyte cell number	J:211773
C2cd3^em1(IMPC)Tcp/C2cd3⁺ (C57BL/6N-C2cd3^em1(IMPC)Tcp/Tcp)	increased neutrophil cell number	J:211773
C3^tm1Crr/C3^tm1Crr (involves: 129S4/SvJae * C57BL/6)	abnormal cell-mediated immunity	J:30152
	abnormal humoral immune response	J:64282
	abnormal immune system morphology	J:44240
	abnormal immune system physiology	J:44240
	abnormal mast cell physiology	J:44240
	abnormal spleen germinal center morphology	J:64282
	abnormal tumor necrosis factor level	J:44240
	decreased circulating interleukin-6 level	J:166640, J:152533
	decreased circulating tumor necrosis factor level	J:152533
	decreased mast cell number	J:44240
	decreased neutrophil cell number	J:44240
	decreased osteoclast cell number	J:166640
	decreased spleen germinal center number	J:64282
	decreased spleen germinal center size	J:64282
	immune system phenotype	J:64282
	increased susceptibility to bacterial infection	J:44240, J:30152
	increased susceptibility to bacterial infection induced morbidity/mortality	J:205353
	liver inflammation	J:30152
C3^tm1Crr/C3^tm1Crr (B6.129S4-C3^tm1Crr)	abnormal inflammatory response	J:113463
	abnormal neutrophil morphology	J:113463
	brain inflammation	J:123658
	decreased susceptibility to autoimmune hemolytic anemia	J:145432
C3^tm1Crr/C3^tm1Crr (B6;129S4-C3^tm1Crr/J)	decreased susceptibility to Coronaviridae infection	J:286325
C3^tm1Crr/C3^tm1Crr (B6;129S4-C3^tm1Crr/J)	increased susceptibility to bacterial infection	J:136745
C3^tm1Crr/C3^tm1Crr (involves: 129S4/SvJae)	glomerulonephritis	J:44715
C3^tm1Crr/C3^tm1Crr C4b^tm1Crr/C4b^tm1Crr Fas^lpr/Fas^lpr (involves: 129S4/SvJae * C57BL/6 * MRL)	abnormal immune system physiology	J:127292
	enlarged cervical lymph nodes	J:127292
	enlarged spleen	J:127292
	increased anti-double stranded DNA antibody level	J:127292
	increased anti-nuclear antigen antibody level	J:127292
C3^tm1Crr/C3^tm1Crr Cd59a^tm1Bpm/Cd59a^tm1Bpm (B6.129-Cd59a^tm1Bpm C3^tm1Crr)	increased T cell proliferation	J:122201
C3^tm1Crr/C3^tm1Crr Fas^lpr/Fas^lpr (involves: 129S4/SvJae * C57BL/6 * MRL)	decreased susceptibility to autoimmune disorder	J:127292
	immune system phenotype	J:127292
C3^tm1Crr/C3^tm1Crr Fcer1g^tm1Rav/Fcer1g^tm1Rav Tg(Ins2-TFRC/OVA)296Wehi/0 (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)	decreased susceptibility to autoimmune diabetes	J:122114
C3^tm1Crr/C3^tm1Crr Tg(Ins2-TFRC/OVA)296Wehi/0 (involves: 129S4/SvJae * C57BL/6)	decreased susceptibility to autoimmune diabetes	J:122114
	increased interferon-gamma secretion	J:122114
	increased T cell proliferation	J:122114
	insulitis	J:122114
C3^tm1Crr/C3^tm1Crr Zbtb20^{Tg(PDGFB-APPSwInd)20Lms}/? (involves: 129S4/SvJae * C57BL/6)	increased microglial cell activation	J:135902
C3^tm1Hrc/C3^tm1Hrc (either: (involves: 129S2/SvPas * C57BL/6) or (involves: 129X1/SvJ * C57BL/6))	increased susceptibility to bacterial infection	J:56193
C3^tm1Hrc/C3^tm1Hrc (B6.129-C3^tm1Hrc)	impaired complement alternative pathway	J:177350
C3^tm1Hrc/C3^tm1Hrc Cr1l^tm1Hmo/Cr1l^tm1Hmo (involves: 129/Sv * 129X1/SvJ * C57BL/6)	abnormal complement pathway	J:76578
C3^tm1Hrc/C3^tm1Hrc Lama2^dy/Lama2^dy (either: (involves: 129S2/SvPas * 129P1/ReJ) or (involves: 129X1/SvJ * 129P1/ReJ))	decreased IgM level	J:102959
	increased IgG level	J:102959
	increased IgM level	J:102959
C3^tm1Hrc/C3^tm1Hrc Vsig4^tm1Gne/Vsig4^tm1Gne (involves: 129/Sv * C57BL/6N)	immune system phenotype	J:138691
C3^tm1Pkna/C3^tm1Pkna (D1.129P2-C3^tm1Pkna)	decreased susceptibility to induced arthritis	J:88872
C3ar1^tm1Cge/C3ar1^tm1Cge (involves: 129S4/SvJae * C57BL/6)	decreased circulating interleukin-6 level	J:166640
C3ar1^tm1Cge/C3ar1^tm1Cge (involves: 129S4/SvJae * C57BL/6)	decreased osteoclast cell number	J:166640
C3ar1^tm1Raw/C3ar1⁺ (involves: 129X1/SvJ * C57BL/6)	abnormal immune system physiology	J:68807
C3ar1^tm1Raw/C3ar1^tm1Raw (involves: 129X1/SvJ * C57BL/6)	increased circulating interleukin-1 beta level	J:68807
C3ar1^tm1Raw/C3ar1^tm1Raw (involves: 129X1/SvJ * C57BL/6)	increased susceptibility to endotoxin shock	J:68807
C3ar1^tm1Raw/C3ar1^tm1Raw (B6.129X1(B6)-C3ar1^tm1Raw)	abnormal adaptive immunity	J:80071
	abnormal eosinophil physiology	J:80071
	abnormal interleukin level	J:80071
	abnormal T-helper 2 cell differentiation	J:80071
	abnormal T-helper 2 physiology	J:80071
	decreased eosinophil cell number	J:80071
	decreased IgE level	J:80071
	decreased IgG1 level	J:80071
	decreased interleukin-4 secretion	J:80071
	decreased lymphocyte cell number	J:80071
	decreased neutrophil cell number	J:80071
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:93791
	impaired neutrophil recruitment	J:80071
	increased circulating interleukin-1 beta level	J:93791
	increased susceptibility to type I hypersensitivity reaction	J:80071
C3ar1^tm1Raw/C3ar1^tm1Raw Cpn1^tm1Raw/Cpn1^tm1Raw (B6.129-C3ar1^tm1Raw Cpn1^tm1Raw)	increased acute inflammation	J:148315
C4b^tm1Crr/C4b^tm1Crr (involves: 129S4/SvJae * C57BL/6)	abnormal humoral immune response	J:64282
	abnormal spleen germinal center morphology	J:64282
	decreased spleen germinal center number	J:64282
	decreased spleen germinal center size	J:64282
	decreased susceptibility to bacterial infection	J:30152
	immune system phenotype	J:64282, J:30152
	increased susceptibility to bacterial infection induced morbidity/mortality	J:30152
	liver inflammation	J:30152
C4b^tm1Crr/C4b^tm1Crr (involves: 129S4/SvJae * C57BL/6J)	abnormal immune system physiology	J:111811
	glomerulonephritis	J:111811
	increased anti-double stranded DNA antibody level	J:111811
	increased anti-nuclear antigen antibody level	J:111811
	increased anti-single stranded DNA antibody level	J:111811
	increased macrophage cell number	J:111811
	increased neutrophil cell number	J:111811
	increased spleen germinal center number	J:111811
	increased spleen weight	J:111811
C4b^tm1Crr/C4b^tm1Crr (involves: 129S4/SvJae)	decreased susceptibility to Coronaviridae infection	J:286325
C4b^tm1Crr/C4b^tm1Crr (involves: 129S4/SvJae)	glomerulonephritis	J:44715
C4b^tm1Crr/C4b^tm1Crr Fas^lpr/Fas^lpr (involves: 129S4/SvJae * C57BL/6 * MRL)	abnormal immune system physiology	J:127292
	enlarged cervical lymph nodes	J:127292
	enlarged spleen	J:127292
	increased anti-double stranded DNA antibody level	J:127292
	increased anti-nuclear antigen antibody level	J:127292
C4bp^tm1Raw/C4bp^tm1Raw (B6.129-C4bp^tm1Raw)	increased circulating interleukin-6 level	J:244020
C5ar1^tm1Cge/C5ar1^tm1Cge (involves: 129S4/SvJae)	abnormal humoral immune response	J:35529
	impaired neutrophil recruitment	J:69177
	increased susceptibility to bacterial infection	J:69177
C5ar1^tm1Cge/C5ar1^tm1Cge (involves: 129S4/SvJae * C57BL/6)	decreased circulating interleukin-6 level	J:166640
C5ar1^tm1Cge/C5ar1^tm1Cge (involves: 129S4/SvJae * C57BL/6)	decreased osteoclast cell number	J:166640
C5ar1^tm1Raw/C5ar1^tm1Raw (B6.Cg-C5ar1^tm1Raw)	immune system phenotype	J:139786
C5ar1^tm1Raw/C5ar1^tm1Raw (B6.Cg-C5ar1^tm1Raw)	increased spleen germinal center number	J:139786
C5ar1^tm1Song/C5ar1^tm1Song (involves: 129S6/SvEvTac * C57BL/6)	abnormal neutrophil physiology	J:184056
C5ar2^em1(IMPC)H/C5ar2^em1(IMPC)H (C57BL/6NTac-C5ar2^em1(IMPC)H/H)	decreased eosinophil cell number	J:211773
	increased neutrophil cell number	J:211773
C5ar2^tm1Cge/C5ar2^tm1Cge (B6.129S1-C5ar2^tm1Cge)	abnormal immune cell physiology	J:104092
C5ar2^tm1Cge/C5ar2^tm1Cge (B6.129S1-C5ar2^tm1Cge)	increased inflammatory response	J:104092
C8a^{tm1b(EUCOMM)Hmgu}/C8a^{tm1b(EUCOMM)Hmgu} (C57BL/6N-C8a^{tm1b(EUCOMM)Hmgu}/Tcp)	increased lymphocyte cell number	J:211773
C9^em1Sjlg/C9⁺ (C57BL/6-C9^em1Sjlg)	impaired complement classical pathway	J:301607
C9^em1Sjlg/C9^em1Sjlg (C57BL/6-C9^em1Sjlg)	decreased interleukin-1 beta secretion	J:301607
	decreased susceptibility to endotoxin shock	J:301607
	impaired complement classical pathway	J:301607
C9orf72^em1Eggn/C9orf72^em1Eggn (involves: C57BL/6)	enlarged cervical lymph nodes	J:240357
	enlarged spleen	J:240357
	increased anti-double stranded DNA antibody level	J:240357
C9orf72^em5Lutzy/C9orf72^em5Lutzy (C57BL/6-C9orf72^em5Lutzy)	abnormal macrophage physiology	J:101977
	abnormal microglial cell physiology	J:101977
	enlarged lymph nodes	J:101977
	enlarged spleen	J:101977
C9orf72^{tm1.1(KOMP)Mbp}/C9orf72^{tm1.1(KOMP)Mbp} (C57BL/6N-C9orf72^{tm1.1(KOMP)Mbp}/Ucd)	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	increased spleen weight	J:211773
C9orf72^tm1.1Eggn/C9orf72⁺ (involves: C57BL/6 * C57BL/6N)	abnormal circulating interleukin level	J:240357
	decreased circulating interleukin-2 level	J:240357
	dermatitis	J:240357
	increased autoantibody level	J:240357
	increased IgG level	J:240357
	increased IgM level	J:240357
C9orf72^tm1.1Eggn/C9orf72^tm1.1Eggn (involves: C57BL/6 * C57BL/6N)	abnormal circulating cytokine level	J:240357
	abnormal lymphocyte morphology	J:240357
	abnormal spleen morphology	J:240357
	brain inflammation	J:240357
	dermatitis	J:240357
	enlarged spleen	J:240357
	increased anti-double stranded DNA antibody level	J:240357
	increased autoantibody level	J:240357
	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:240357
	increased IgG level	J:240357
	increased IgM level	J:240357
	increased leukocyte cell number	J:240357
	increased neutrophil cell number	J:240357
	increased splenocyte number	J:240357
	increased susceptibility to autoimmune disorder	J:240357
	liver inflammation	J:240357
C9orf72^tm1Eggn/C9orf72⁺ (involves: C57BL/6 * C57BL/6N)	dermatitis	J:240357
C9orf72^tm1Eggn/C9orf72^tm1Eggn (involves: C57BL/6 * C57BL/6N)	abnormal circulating cytokine level	J:240357
	abnormal lymphocyte morphology	J:240357
	dermatitis	J:240357
	enlarged cervical lymph nodes	J:240357
	enlarged spleen	J:240357
	increased anti-double stranded DNA antibody level	J:240357
	increased leukocyte cell number	J:240357
	increased neutrophil cell number	J:240357
	increased susceptibility to autoimmune disorder	J:240357
C9orf72^tm1Lagi/C9orf72^tm1Lagi (involves: C57BL/6 * C57BL/6N)	abnormal celiac lymph node morphology	J:232242
	abnormal cervical lymph node morphology	J:232242
	abnormal lymph node cell ratio	J:232242
	decreased lymphocyte cell number	J:232242
	enlarged cervical lymph nodes	J:232242
	enlarged spleen	J:232242
	increased neutrophil cell number	J:232242
Cab39^em1(IMPC)Tcp/Cab39⁺ (C57BL/6NCrl-Cab39^em1(IMPC)Tcp/Cmmr)	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
	increased monocyte cell number	J:211773
Cabin1^{em1(IMPC)Ccpcz}/Cabin1⁺ (C57BL/6NCrl-Cabin1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Cabin1^tm1.1Che/Cabin1^tm1.1Che (involves: 129S4/SvJae * BALB/c)	abnormal cytokine secretion	J:72760
	abnormal humoral immune response	J:72760
	immune system phenotype	J:72760
	increased IgE level	J:72760
	increased IgG1 level	J:72760
	increased IgG2b level	J:72760
Cabp1^{tm1b(EUCOMM)Wtsi}/Cabp1^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Cabp1^{tm1b(EUCOMM)Wtsi}/H)	decreased lymphocyte cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
	increased spleen weight	J:211773
Cacna1a^tg-6J/Cacna1a^tg-6J (involves: BALB/cByJ * C57BL/6J)	abnormal spleen red pulp morphology	J:82238
	thymus atrophy	J:82238
Cacna1c^tm2Itl/Cacna1c⁺ (involves: 129S6/SvEvTac * C57BL/6NTac)	dermatitis	J:201506
Cacna1g^em1(IMPC)Mbp/Cacna1g^em1(IMPC)Mbp (C57BL/6N-Cacna1g^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
Cacna1i^{tm1b(KOMP)Wtsi}/Cacna1i^{tm1b(KOMP)Wtsi} (C57BL/6N-Cacna1i^{tm1b(KOMP)Wtsi}/Bay)	abnormal spleen morphology	J:211773
Cacna2d1^em1(IMPC)Mbp/Cacna2d1^em1(IMPC)Mbp (C57BL/6N-Cacna2d1^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	increased monocyte cell number	J:211773
	small spleen	J:211773
Cacna2d2^du-td/Cacna2d2^du-td (involves: DBA/2J)	abnormal thymus involution	J:12166
Cacna2d2^em1(IMPC)Mbp/Cacna2d2⁺ (C57BL/6N-Cacna2d2^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	increased spleen weight	J:211773
Cacna2d2^em1(IMPC)Mbp/Cacna2d2^em1(IMPC)Mbp (C57BL/6N-Cacna2d2^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	small spleen	J:211773
Cacna2d2^tm1Svi/Cacna2d2^tm1Svi (involves: 129S1/Sv * C57BL/6J)	rhinitis	J:92396
	thymus hypoplasia	J:92396
Cacna2d3^{Tn(pb-Act-RFP)1.1Zhu}/Cacna2d3^{Tn(pb-Act-RFP)1.1Zhu} (FVB/NJ-Cacna2d3^{Tn(pb-Act-RFP)1.1Zhu})	abnormal macrophage physiology	J:267961
	increased susceptibility to bacterial infection	J:267961
Cacnb3^tm1Acv/Cacnb3^tm1Acv (involves: 129S1/Sv * 129X1/SvJ)	abnormal CD4-positive, alpha-beta T cell physiology	J:115345
	abnormal interleukin secretion	J:115345
	decreased interferon-gamma secretion	J:115345
Cacnb4^lh/Cacnb4^lh (B6EiC3Sn a/A-Cacnb4^lh/J)	abnormal CD4-positive, alpha-beta T cell physiology	J:115345
	abnormal interleukin secretion	J:115345
	abnormal lymph node morphology	J:5281
	abnormal Peyer's patch germinal center morphology	J:5281
	abnormal thymus involution	J:5281
	absent thymus corticomedullary boundary	J:5281
	decreased double-positive T cell number	J:115345
	decreased interferon-gamma secretion	J:115345
	decreased interleukin-2 secretion	J:115345
	decreased lymphocyte cell number	J:5281
	decreased Peyer's patch number	J:5281
	enlarged lymph nodes	J:5281
	small Peyer's patches	J:5281
	small spleen	J:5281
	small thymus	J:5281
Cacnb4^lh/Cacnb4^lh (BALB/cGn-Cacnb4^lh)	abnormal thymus involution	J:12166
Cacnb4^lh/Cacnb4^lh (BALB/cGn-Cacnb4^lh)	increased length of allograft survival	J:5766
Cacnb4^lh/Cacnb4^lh (involves: BALB/cGn)	increased IgG1 level	J:5883
Cactin^{em1(IMPC)Ccpcz}/Cactin⁺ (C57BL/6NCrl-Cactin^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Cacybp^{GT(OST39970)Lex}/Cacybp^{GT(OST39970)Lex} (involves: 129S5/SvEvBrd)	abnormal spleen white pulp morphology	J:110899
	abnormal T cell morphology	J:110899
	decreased thymocyte number	J:110899
	small thymus medulla	J:110899
	spleen hypoplasia	J:110899
	thymus hypoplasia	J:110899
Cacybp^{tm1b(EUCOMM)Wtsi}/Cacybp⁺ (C57BL/6N-Cacybp^{tm1b(EUCOMM)Wtsi}/Tcp)	increased neutrophil cell number	J:211773
Cadm1^{Gt(Ayu21-W34)Imeg}/Cadm1^{Gt(Ayu21-W34)Imeg} (involves: C57BL/6 * CBA/JNCrlj)	abnormal T cell differentiation	J:178612
	abnormal T cell receptor V(D)J recombination	J:178612
	decreased CD4-positive, alpha-beta T cell number	J:178612
	decreased CD8-positive, alpha-beta T cell number	J:178612
	decreased interferon-gamma secretion	J:178612
	decreased interleukin-2 secretion	J:178612
	decreased interleukin-4 secretion	J:178612
	decreased T cell proliferation	J:178612
	increased double-positive T cell number	J:178612
Cadps2^{em1(IMPC)Rbrc}/Cadps2^{em1(IMPC)Rbrc} (C57BL/6NJcl-Cadps2^{em1(IMPC)Rbrc}/Rbrc)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
Calb1^{em1(IMPC)Ccpcz}/Calb1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Calb1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
	small spleen	J:211773
Calcr^tm1Dgal/Calcr⁺ Iapp^tm1Sgm/Iapp⁺ (involves: 129P2/OlaHsd)	increased osteoclast cell number	J:88964
Calcr^tm1Rda/Calcr^tm1Rda Tg(CMV-cre)1Cgn/0 (B6.Cg-Calcr^tm1Rda Tg(CMV-cre)1Cgn)	abnormal osteoclast physiology	J:150982
Calcrl^tm1Kmca/Calcrl^tm1Kmca (129S6/SvEvTac-Calcrl^tm1Kmca)	abnormal lymph organ development	J:130930
Calcrl^tm1Kmca/Calcrl^tm1Kmca (involves: 129S6/SvEvTac)	decreased uterine NK cell number	J:201446
Calu^em1(IMPC)Tcp/Calu⁺ (C57BL/6N-Calu^em1(IMPC)Tcp/Tcp)	small lymph nodes	J:211773
Camk1d^em1(IMPC)Mbp/Camk1d^em1(IMPC)Mbp (C57BL/6NCrl-Camk1d^em1(IMPC)Mbp/Mmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Camk2g^tm1.1Irt/Camk2g^tm1.1Irt (involves: C57BL/6 * C57BL/6J)	decreased macrophage apoptosis	J:154647
Camk2g^tm1.1Irt/Camk2g^tm1.1Irt (involves: C57BL/6J)	increased susceptibility to colitis induced morbidity/mortality	J:243363
Camk2g^tm1.1Irt/Camk2g^tm1.1Irt (involves: C57BL/6J)	increased susceptibility to induced colitis	J:243363
Camk4^{em1(IMPC)Ccpcz}/Camk4^{em1(IMPC)Ccpcz} (C57BL/6N-Camk4^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
	small spleen	J:211773
Camk4^tm1Tch/Camk4^tm1Tch (B6.129X1-Camk4^tm1Tch)	abnormal osteoclast differentiation	J:129599
Camk4^tm1Tch/Camk4^tm1Tch (B6.129X1-Camk4^tm1Tch)	decreased osteoclast cell number	J:129599
Caml^tm1Rjb/Caml^tm2Rjb Tg(Lck-cre)1Cwi/0 (involves: 129 * C57BL/6 * DBA/2)	decreased single-positive T cell number	J:100536
	decreased thymocyte number	J:100536
	increased T cell apoptosis	J:100536
Caml^tm1Rjb/Caml^tm2Rjb Tg(Lck-cre)1Cwi/0 Tg(TcraTcrb)1100Mjb/0 (involves: 129 * C57BL/6 * DBA/2)	abnormal negative T cell selection	J:100536
	abnormal positive T cell selection	J:100536
	decreased thymocyte number	J:100536
Camp^tm1.1Jimw/Camp^tm1.1Jimw (involves: C57BL/6)	decreased dendritic cell number	J:199611
Camp^tm1Rlg/Camp⁺ (involves: 129X1/SvJ * C57BL/6)	increased susceptibility to bacterial infection	J:72924
Camp^tm1Rlg/Camp^tm1Rlg (involves: 129X1/SvJ * C57BL/6)	increased incidence of corneal inflammation	J:199719
	increased neutrophil cell number	J:199719
	increased susceptibility to bacterial infection	J:72924
	increased susceptibility to fungal infection	J:199719
Camp^tm1Rlg/Camp^tm1Rlg (129X1(B6)-Camp^tm1Rlg/Kini)	increased susceptibility to bacterial infection	J:109553
Camp^tm1Rlg/Camp^tm1Rlg (129X1(B6)-Camp^tm1Rlg/Kini)	increased susceptibility to bacterial infection induced morbidity/mortality	J:109553
Camsap3^{tm1a(EUCOMM)Wtsi}/Camsap3^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Camsap3^{tm1a(EUCOMM)Wtsi}/Wtsi)	increased gamma-delta T cell number	J:211773
	increased leukocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Cand1^em1(IMPC)Mbp/Cand1⁺ (C57BL/6NCrl-Cand1^em1(IMPC)Mbp/Mmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Canx^{em1(IMPC)Ccpcz}/Canx⁺ (C57BL/6NCrl-Canx^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Canx^{em1(IMPC)Ccpcz}/Canx^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Canx^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Canx^{Gt(KST286)Byg}/Canx^{Gt(KST286)Byg} (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:164553
Cap2^{tm1a(EUCOMM)Wtsi}/Cap2^{tm1a(EUCOMM)Wtsi} (involves: C57BL/6J * C57BL/6N)	eye inflammation	J:234044
	increased susceptibility to infection	J:234044
Capg^tm1Djk/Capg^tm1Djk (involves: 129S4/SvJae)	abnormal macrophage physiology	J:86517
Capg^tm1Djk/Capg^tm1Djk (involves: 129S4/SvJae)	impaired macrophage phagocytosis	J:86517
Capg^tm1Djk/Capg^tm1Djk (involves: 129S4/SvJae * BALB/c * C57BL/6)	abnormal dendritic cell physiology	J:86277
	impaired macrophage phagocytosis	J:86277
	impaired neutrophil chemotaxis	J:86277
	increased susceptibility to bacterial infection	J:86277
Capg^tm1Djk/Capg^tm1Djk Gsn^tm1Djk/Gsn^tm1Djk (involves: 129S4/SvJae)	abnormal macrophage physiology	J:86517
	impaired macrophage phagocytosis	J:86517
Capn1^tm1Dgen/Capn1^tm1Dgen (involves: 129P2/OlaHsd * C57BL/6)	abnormal leukocyte adhesion	J:183585
Capn5^tm1Nde/Capn5^tm1Nde (involves: 129X1/SvJ * C57BL/6J)	immune system phenotype	J:87678
Capop^NOD/Capop^NOD (involves: C57BL/6 * NOD)	decreased T cell apoptosis	J:68151
Capza1^em1(IMPC)Tcp/Capza1^em1(IMPC)Tcp (C57BL/6NCrl-Capza1^em1(IMPC)Tcp/Tcp)	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
	increased monocyte cell number	J:211773
Capza2^{tm1b(KOMP)Wtsi}/Capza2^{tm1b(KOMP)Wtsi} (C57BL/6N-Capza2^{tm1b(KOMP)Wtsi}/Wtsi)	blood in lymph vessels	J:239583
Car2^{tm1(KOMP)Vlcg}/Car2^{tm1(KOMP)Vlcg} (involves: C57BL/6 * C57BL/6NTac)	increased susceptibility to bacterial infection	J:216402
	pyelonephritis	J:216402
Car6^{em1(IMPC)Ccpcz}/Car6^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Car6^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	decreased NK cell number	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
	increased eosinophil cell number	J:211773
Car6^tm1Pwp/Car6^tm1Pwp (B6.129S6-Car6^tm1Pwp)	abnormal Peyer's patch follicle morphology	J:172854
Car9^tm1Lex/Car9^tm1Lex (B6;129S5-Car9^tm1Lex/Mmucd)	increased mature B cell number	J:171883
Card6^tm1.1Aldu/Card6^tm1.1Aldu (B6.129P2-Card6^tm1.1Aldu)	immune system phenotype	J:132634
Card9^tm1Jrld/Card9^tm1Jrld (involves: 129P2/OlaHsd)	abnormal dendritic cell physiology	J:111706
Card9^tm1Jrld/Card9^tm1Jrld (involves: 129P2/OlaHsd)	increased susceptibility to fungal infection	J:111706
Card9^tm1Tks/Card9^tm1Tks (B6.129-Card9^tm1Tks)	abnormal chemokine secretion	J:141143
	abnormal cytokine secretion	J:122394
	abnormal dendritic cell physiology	J:122394
	abnormal macrophage physiology	J:141143, J:122394
	decreased interleukin-6 secretion	J:160680
	decreased interleukin-10 secretion	J:160680
	decreased interleukin-12b secretion	J:160680
	decreased interleukin-23 secretion	J:160680
	decreased tumor necrosis factor secretion	J:160680
	immune system phenotype	J:122394
	increased susceptibility to bacterial infection	J:122394
Card9^tm1Xlin/Card9^tm1Xlin (involves: 129/Sv * C57BL/6)	abnormal cytokine level	J:117799
	abnormal innate immunity	J:117799
	abnormal macrophage physiology	J:117799
	increased susceptibility to bacterial infection	J:117799
Card11^{em1(IMPC)Ccpcz}/Card11^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Card11^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	decreased effector memory CD8-positive, alpha-beta T cell number	J:211773
	decreased effector memory T-helper cell number	J:211773
	decreased spleen weight	J:211773
	enlarged thymus	J:211773
	increased CD4-positive, alpha-beta T cell number	J:211773
	increased CD8-positive, alpha-beta T cell number	J:211773
	increased CD8-positive, naive alpha-beta T cell number	J:211773
	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
	increased T cell number	J:211773
	increased T-helper cell number	J:211773
	small spleen	J:211773
Card11^em1Welu/Card11⁺ (involves: C57BL/6)	decreased marginal zone B cell number	J:292926
	decreased transitional stage T1 B cell number	J:292926
	decreased transitional stage T3 B cell number	J:292926
	impaired humoral immune response	J:292926
	increased transitional stage T2 B cell number	J:292926
Card11^em1Welu/Card11^em1Welu (involves: C57BL/6)	abnormal B cell differentiation	J:292926
	abnormal germinal center B cell morphology	J:292926
	abnormal plasma cell differentiation	J:292926
	decreased B cell proliferation	J:292926
	decreased B-1 B cell number	J:292926
	decreased B-1a cell number	J:292926
	decreased germinal center B cell number	J:292926
	decreased IgG level	J:292926
	decreased IgM level	J:292926
	decreased marginal zone B cell number	J:292926
	decreased pre-B cell number	J:292926
	decreased transitional stage T1 B cell number	J:292926
	decreased transitional stage T3 B cell number	J:292926
	impaired humoral immune response	J:292926
	increased follicular B cell number	J:292926
	increased transitional stage T2 B cell number	J:292926
Card11^em2Welu/Card11⁺ (involves: C57BL/6)	increased B-1 B cell number	J:292926
Card11^em2Welu/Card11⁺ (involves: C57BL/6)	increased marginal zone B cell number	J:292926
Card11^em2Welu/Card11^em2Welu (involves: C57BL/6)	abnormal plasma cell differentiation	J:292926
	decreased mature B cell number	J:292926
	enlarged spleen	J:292926
	increased B cell proliferation	J:292926
	increased B-1a cell number	J:292926
	increased B-1b cell number	J:292926
	increased germinal center B cell number	J:292926
	increased marginal zone B cell number	J:292926
	increased pre-B cell number	J:292926
	increased transitional stage T2 B cell number	J:292926
Card11^em3Welu/Card11^em3Welu (Not Specified)	decreased B-1 B cell number	J:292926
Card11^em3Welu/Card11^em3Welu (Not Specified)	decreased marginal zone B cell number	J:292926
Card11^m1Btlr/Card11^m1Btlr (C57BL/6J-Card11^m1Btlr)	abnormal CD4-positive, CD25-positive, alpha-beta regulatory T cell morphology	J:149767
	abnormal cytokine secretion	J:149767
	abnormal cytotoxic T cell physiology	J:139069
	abnormal double-negative T cell morphology	J:149767, J:139069
	abnormal NK cell physiology	J:139069
	abnormal T cell activation	J:139069
	decreased B cell proliferation	J:149767, J:139069
	decreased B-1 B cell number	J:149767, J:139069
	decreased gamma-delta T cell number	J:149767, J:139069
	decreased IgG1 level	J:149767, J:139069
	decreased IgG2a level	J:149767, J:139069
	decreased IgG2b level	J:149767, J:139069
	decreased IgG2c level	J:149767
	decreased IgG3 level	J:149767, J:139069
	decreased IgM level	J:149767, J:139069
	decreased immunoglobulin level	J:139069
	decreased interferon-gamma secretion	J:139069
	decreased interleukin-2 secretion	J:139069
	decreased mature B cell number	J:149767, J:139069
	decreased memory T cell number	J:149767, J:139069
	decreased NK cell number	J:149767, J:139069
	decreased NK T cell number	J:149767, J:139069
	decreased regulatory T cell number	J:149767
	decreased T cell proliferation	J:149767, J:139069
	dermatitis	J:149767, J:139069
	immune system phenotype	J:139069
Card11^M2Btlr/Card11^M2Btlr (involves: C57BL/6J)	decreased IgM level	J:198555
Card11^m3Btlr/Card11^m3Btlr (C57BL/6J-Card11^m3Btlr)	increased B-1a cell number	J:221487
Card11^M4Btlr/Card11⁺ (C57BL/6J-Card11^M4Btlr)	decreased B-1a cell number	J:254856
Card11^M4Btlr/Card11⁺ (C57BL/6J-Card11^M4Btlr)	increased B-1b cell number	J:254856
Card11^M4Btlr/Card11^M4Btlr (C57BL/6J-Card11^M4Btlr)	decreased B-1a cell number	J:254856
	decreased IgM level	J:254856
	impaired humoral immune response	J:254856
	increased B-1b cell number	J:254856
Card11^M5Btlr/Card11⁺ (C57BL/6J-Card11^M5Btlr)	decreased IgM level	J:254879
	impaired humoral immune response	J:254879
	increased B-1 B cell number	J:254879
	increased B-1a cell number	J:254879
Card11^M5Btlr/Card11^M5Btlr (C57BL/6J-Card11^M5Btlr)	decreased IgM level	J:254879
	impaired humoral immune response	J:254879
	increased B-1 B cell number	J:254879
	increased B-1a cell number	J:254879
Card11^M6Btlr/Card11^M6Btlr (C57BL/6J-Card11^M6Btlr)	increased alpha-beta T cell number	J:272116
Card11^M7Btlr/Card11^M7Btlr (C57BL/6J-Card11^M7Btlr)	abnormal T cell differentiation	J:274762
	decreased B cell number	J:274762
	decreased B-1 B cell number	J:274762
	decreased central memory CD4-positive, alpha-beta T cell number	J:274762
	decreased effector memory CD4-positive, alpha-beta T cell number	J:274762
	decreased effector memory CD8-positive, alpha-beta T cell number	J:274762
	increased CD4-positive, alpha-beta T cell number	J:274762
	increased CD8-positive, alpha-beta T cell number	J:274762
	increased T cell number	J:274762
Card11^m8Btlr/Card11^m8Btlr (C57BL/6J-Card11^m8Btlr)	abnormal B cell differentiation	J:274940
	decreased B cell number	J:274940
	decreased B-1a cell number	J:274940
	decreased effector memory CD8-positive, alpha-beta T cell number	J:274940
	decreased IgG level	J:274940
	decreased IgM level	J:274940
	decreased response to antigen	J:274940
	impaired humoral immune response	J:274940
	increased B-1b cell number	J:274940
	increased CD4-positive, alpha-beta T cell number	J:274940
	increased CD8-positive, alpha-beta T cell number	J:274940
	increased NK T cell number	J:274940
	increased T cell number	J:274940
Card11^tm1.1Litt/Card11^tm1.1Litt Gt(ROSA)26Sor^{tm1(cre/ERT2)Thl}/Gt(ROSA)26Sor⁺ Tg(TcraTcrb)425Cbn/? (involves: 129/Sv * 129P2/OlaHsd * BALB/c * C57BL/6)	abnormal T cell activation	J:180410
Card11^tm1.1Litt/Card11^tm1.1Litt Tnfrsf4^tm2(cre)Nik/Tnfrsf4⁺ (involves: 129P2/OlaHsd * 129X1/SvJ)	abnormal T cell activation	J:180410
	immune system phenotype	J:180410
	respiratory system inflammation	J:180410
Card11^tm1Litt/Card11^tm1Litt (involves: 129P2/OlaHsd)	abnormal B cell proliferation	J:89322
	abnormal double-negative T cell morphology	J:89322
	abnormal T cell activation	J:89322
	abnormal T cell differentiation	J:89322
	abnormal T cell proliferation	J:89322
	absent B-1a cells	J:89322
	decreased IgA level	J:89322
	decreased IgG1 level	J:89322
	decreased IgG2b level	J:89322
	decreased IgG3 level	J:89322
	decreased IgM level	J:89322
	decreased immunoglobulin level	J:89322
Card11^tm1Pngr/Card11^tm1Pngr (involves: 129P2/OlaHsd)	abnormal B cell differentiation	J:84036
	abnormal B cell physiology	J:84036
	abnormal interleukin-2 secretion	J:84036
	abnormal lymphocyte morphology	J:84036
	abnormal T cell activation	J:84036
	absent B-1a cells	J:84036
	decreased B cell proliferation	J:84036
	decreased IgA level	J:84036
	decreased IgE level	J:84036
	decreased IgG1 level	J:84036
	decreased IgG2a level	J:84036
	decreased IgG2b level	J:84036
	decreased IgG3 level	J:84036
	decreased IgG level	J:84036
	decreased IgM level	J:84036
	decreased immunoglobulin level	J:84036
	decreased NK cell number	J:84036
Card11^tm1Pngr/Card11^tm1Pngr (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:122394
Card11^tm1Vmd/Card11⁺ (involves: 129S6/SvEvTac * C57BL/6N)	decreased B cell proliferation	J:95800
Card11^tm1Vmd/Card11^tm1Vmd (involves: 129S6/SvEvTac * C57BL/6N)	abnormal B cell physiology	J:95800
	absent immature B cells	J:95800
	decreased B cell proliferation	J:95800
	decreased IgA level	J:95800
	decreased IgG1 level	J:95800
	decreased IgG2a level	J:95800
	decreased IgG2b level	J:95800
	decreased IgG3 level	J:95800
	decreased IgG level	J:95800
	decreased IgM level	J:95800
	decreased T cell proliferation	J:95800
Card11^tm1Xav/Card11^tm1Xav (involves: 129 * C57BL/6)	abnormal T cell activation	J:132226
	abnormal T-helper 2 cell differentiation	J:132226
	decreased circulating interleukin-4 level	J:132226
	decreased circulating interleukin-5 level	J:132226
	decreased IgE level	J:132226
	increased CD4-positive, alpha-beta T cell number	J:132226
	increased CD8-positive, alpha-beta T cell number	J:132226
	lung inflammation	J:132226
Card11^unm/Card11^unm (C57BL/6JSfdAnu-Card11^unm/Anu)	abnormal B cell differentiation	J:84042
	abnormal immune system physiology	J:84042
	abnormal T cell activation	J:84042
	decreased B-1 B cell number	J:84042
	decreased IgG3 level	J:84042
	decreased IgM level	J:84042
	decreased immunoglobulin level	J:84042
	dermatitis	J:84042
	erythroderma	J:84042
	increased IgE level	J:84042
	increased immunoglobulin level	J:84042
	increased inflammatory response	J:84042
	lymph node hyperplasia	J:84042
	spleen hyperplasia	J:84042
Card14^{em1(IMPC)Ccpcz}/Card14^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Card14^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Card14^em1Maak/Card14^em1Maak (C57BL/6JJmsSlc-Card14^em1Maak)	skin inflammation	J:360877
Card14^em1Tshu/Card14^em1Tshu (C57BL/6-Card14^em1Tshu)	decreased susceptibility to chemically induced skin inflammation	J:289239
Card14^em2Tshu/Card14⁺ (involves: C57BL/6)	abnormal gamma-delta T cell number	J:289239
	increased alpha-beta T cell number	J:289239
	skin inflammation	J:289239
Card14^em3Tshu/Card14⁺ (involves: C57BL/6)	skin inflammation	J:289239
Card14^em3Tshu/Card14⁺ Il17a^tm1Cdon/Il17a^tm1Cdon (involves: C57BL/6)	decreased inflammatory response	J:289239
Card14^em9Lutzy/Card14⁺ (C57BL/6J-Card14^em9Lutzy/J)	skin inflammation	J:262723
Card14^tm1Lex/Card14^tm1Lex (B6.129S-Card14^tm1Lex)	decreased susceptibility to chemically induced skin inflammation	J:253409
Card19^tm1Rwen/Card19^tm1Rwen (involves: 129P2/OlaHsd * C57BL/6)	decreased autoantibody level	J:336763
	immune system phenotype	J:336763
Card19^tm1Rwen/Card19^tm1Rwen Tg(IghelMD4)4Ccg/0 (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell activation	J:336763
Card19^tm1Rwen/Card19^tm1Rwen Tg(IghelMD4)4Ccg/0 Tg(ML5sHEL)5Ccg/0 (involves: 129P2/OlaHsd * C57BL/6 * C57BL/6JSfd)	decreased B cell number	J:336763
	decreased B cell proliferation	J:336763
	increased B cell apoptosis	J:336763
	increased B cell number	J:336763
Carm1^{tm1b(EUCOMM)Hmgu}/Carm1⁺ (C57BL/6N-Carm1^{tm1b(EUCOMM)Hmgu}/Nju)	decreased lymphocyte cell number	J:211773
Carm1^tm1Mtb/Carm1^tm1Mtb (involves: 129S6/SvEvTac)	arrested T cell differentiation	J:159958
Carm1^tm2.1Mtb/Carm1^tm2.1Mtb (involves: 129S4/SvJaeSor * 129S6/SvEvTac * Black Swiss)	arrested T cell differentiation	J:159958
	thymus hypoplasia	J:159958
carmelo/carmelo (involves: 129S1/SvImJ * C57BL/6J)	decreased susceptibility to parasitic infection induced morbidity/mortality	J:220661
Carmil2^bas/Carmil2^bas (involves: C3HeB/FeJ * C57BL/6)	decreased interferon-gamma secretion	J:205441
	decreased interleukin-2 secretion	J:205441
	decreased regulatory T cell number	J:205441
	decreased T cell proliferation	J:205441
	enlarged thymus	J:205441
	immune system phenotype	J:205441
Carmil2^bas/Carmil2^{tm1a(KOMP)Mbp} (involves: C3HeB/FeJ * C57BL/6 * C57BL/6N)	decreased interleukin-2 secretion	J:205441
	decreased regulatory T cell number	J:205441
	decreased T cell proliferation	J:205441
Carmil3^em1(IMPC)Mbp/Carmil3^em1(IMPC)Mbp (C57BL/6N-Carmil3^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
Cartpt^tm1Hmh/Cartpt^tm1Hmh (Not Specified)	abnormal osteoclast morphology	J:97566
Cartpt^tm1Hmh/Cartpt^tm1Hmh (Not Specified)	increased osteoclast cell number	J:97566
Casp1^tm1Flv/Casp1^tm1Flv Casp4^del/Casp4^del (involves: 129S2/SvPas * C57BL/6)	abnormal cytokine secretion	J:24258
	decreased circulating interferon-gamma level	J:115310
	decreased interferon-gamma secretion	J:115310
	decreased interleukin-1 alpha secretion	J:24258
	decreased interleukin-1 beta secretion	J:24258
	decreased interleukin-6 secretion	J:24258
	decreased interleukin-18 secretion	J:115310
	decreased susceptibility to endotoxin shock	J:43088
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:57101
	decreased thymocyte apoptosis	J:24258
	decreased tumor necrosis factor secretion	J:24258
	impaired neutrophil chemotaxis	J:124226
	increased susceptibility to bacterial infection	J:117251
Casp1^tm1Flv/Casp1^tm1Flv Casp4^del/Casp4^del (B6.129S2-Casp1^tm1Flv)	decreased interleukin-1 beta secretion	J:160545
	increased susceptibility to induced colitis	J:173245
Casp1^tm1Flv/Casp1^tm1Flv Casp4^del/Casp4^del Il1r1^tm1Imx/Il1r1^tm1Imx (involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6)	decreased susceptibility to endotoxin shock	J:43088
Casp1^tm1Flv/Casp1^tm1Flv Casp4^del/Casp4^del Slc11a1^r/Slc11a1^r (involves: 129S2/SvPas)	increased susceptibility to bacterial infection	J:124378
Casp1^tm1Flv/Casp1^tm1Flv Casp4^del/Casp4^del Slc11a1^s/Slc11a1^s (B6.129S2-Casp1^tm1Flv)	cecum inflammation	J:124378
	increased susceptibility to bacterial infection	J:124378
Casp1^tm1Sesh/Casp1⁺ Casp4^del/Casp4⁺ (involves: 129S2/SvPas * C57BL/6)	decreased interleukin-1 beta secretion	J:22964
Casp1^tm1Sesh/Casp1⁺ Casp4^del/Casp4⁺ (involves: 129S1/SvImJ * 129S2/SvPas * NOD)	abnormal macrophage physiology	J:99748
Casp1^tm1Sesh/Casp1^tm1Sesh Casp4^del/Casp4^del (involves: 129S2/SvPas * C57BL/6)	abnormal inflammatory response	J:80568
	abnormal macrophage physiology	J:22964
	abnormal neutrophil physiology	J:80568
	decreased circulating interleukin-1 alpha level	J:22964
	decreased circulating interleukin-1 beta level	J:22964
	decreased circulating interleukin-6 level	J:22964
	decreased circulating tumor necrosis factor level	J:22964
	decreased interleukin-1 alpha secretion	J:22964
	decreased interleukin-1 beta secretion	J:88212, J:22964
	decreased susceptibility to endotoxin shock	J:22964, J:40691
	decreased T cell apoptosis	J:40691
	immune system phenotype	J:40691
Casp1^tm1Sesh/Casp1^tm1Sesh Casp4^del/Casp4^del (NOD.129S2(B6)-Casp1^tm1Sesh Casp4^del/LtJ)	decreased interleukin-1 alpha secretion	J:87250
	decreased interleukin-1 beta secretion	J:87250
	decreased interleukin-18 secretion	J:87250
Casp1^tm1Sesh/Casp1^tm1Sesh Casp4^del/Casp4^del (C3N.129S2-Casp1^tm1Sesh Casp4^del)	abnormal response to infection	J:86761
Casp1^tm1Sesh/Casp1^tm1Sesh Casp4^del/Casp4^del (B10.Cg-Casp1^tm1Sesh Casp4^del H2^r H2-T18^b)	decreased inflammatory response	J:63488
	decreased susceptibility to bacterial infection	J:63488
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:63488
Casp1^tm1Sesh/Casp1^tm1Sesh Casp4^del/Casp4^del (involves: 129 * 129S2/SvPas * C57BL/6)	decreased interleukin-1 beta secretion	J:50775
Casp1^tm1Sesh/Casp1^tm1Sesh Casp4^del/Casp4^del (C3.129S2-Casp1^tm1Sesh Casp4^del)	abnormal macrophage physiology	J:136368
	decreased interleukin-1 beta secretion	J:136368
	increased susceptibility to bacterial infection	J:136368
	increased susceptibility to bacterial infection induced morbidity/mortality	J:136368
Casp1^tm1Sesh/Casp1^tm1Sesh Casp4^del/Casp4^del (B6.129S2(NOD)-Casp1^tm1Sesh Casp4^del)	decreased circulating interleukin-1 alpha level	J:193522
	decreased circulating interleukin-1 beta level	J:193522
	decreased circulating interleukin-18 level	J:193522
	decreased interleukin-1 alpha secretion	J:193522
	decreased interleukin-1 beta secretion	J:193522
	decreased interleukin-18 secretion	J:193522
	decreased macrophage apoptosis	J:193522
	decreased susceptibility to endotoxin shock	J:193522
Casp1^tm1Sesh/Casp1^tm1Sesh Casp4^del/Casp4^del Slc11a1^r/Slc11a1^s (involves: 129/Sv * 129S2/SvPas * C57BL/6)	increased susceptibility to bacterial infection	J:112400
Casp1^tm1Sesh/Casp1^tm1Sesh Casp4^del/Casp4^del Slc11a1^s/Slc11a1^s (B6.129S2-Casp1^tm1Sesh Casp4^del)	abnormal macrophage physiology	J:112400
	increased susceptibility to bacterial infection	J:112400
Casp1^tm1Sesh/Casp1^tm1Sesh Casp4^del/Casp4^del Tg(Casp4)#Gne/0 (involves: 129S2/SvPas * C57BL/6 * NOD/ShiLtJ)	decreased circulating interleukin-1 beta level	J:193522
	decreased circulating interleukin-18 level	J:193522
	decreased interleukin-1 alpha secretion	J:193522
	decreased interleukin-1 beta secretion	J:193522
	decreased interleukin-18 secretion	J:193522
	decreased macrophage apoptosis	J:193522
	decreased susceptibility to endotoxin shock	J:193522
Casp1^tm1Sesh/Casp1^tm1Sesh Nlrp1a^Neut1/Nlrp1a^Neut1 (involves: 129S2/SvPas * C57BL/6)	immune system phenotype	J:191055
	increased circulating interleukin-18 level	J:191055
Casp2^tm1Vaux/Casp2^tm1Vaux Casp9^tm1Flv/Casp9^tm1Flv (involves: 129S1/Sv * C57BL/6)	abnormal T cell physiology	J:91156
Casp2^tm1Yuan/Casp2^tm1Yuan (involves: 129S4/SvJae * C57BL/6J * DBA/2)	abnormal B cell apoptosis	J:47601
Casp3^tm1Flv/Casp3^tm1Flv (involves: 129S1/Sv * C57BL/6)	abnormal bone marrow development	J:94703
	abnormal osteoclast physiology	J:94703
	decreased thymocyte number	J:36821
	immune system phenotype	J:36821
Casp3^tm1Flv/Casp3^tm1Flv Casp7^tm1Flv/Casp7⁺ (B6.129S-Casp3^tm1Flv Casp7^tm1Flv)	decreased thymocyte apoptosis	J:105496
Casp3^tm1Flv/Casp3^tm1Flv Casp7^tm1Flv/Casp7^tm1Flv (B6.129S-Casp3^tm1Flv Casp7^tm1Flv)	decreased thymocyte apoptosis	J:105496
Casp3^tm1Flv/Casp3^tm1Flv Tg(Scgb1a1-rtTA,tetO-Ifng)14Eli/0 (involves: 129S1/Sv * C57BL/6 * CBA)	increased lymphocyte cell number	J:100854
	increased macrophage cell number	J:100854
	increased neutrophil cell number	J:100854
Casp3^tm1Mak/Casp3^tm1Mak (B6.129P2-Casp3^tm1Mak)	decreased inflammatory response	J:97650, J:179279
Casp3^tm1Mak/Casp3^tm1Mak Tg(TcrLCMV)327Sdz/0 (B6.Cg-Casp3^tm1Mak Tg(TcrLCMV)327Sdz)	abnormal CD8-positive, alpha beta T cell morphology	J:97650
Casp4^tm1.1Vmd/Casp4^tm1.1Vmd (involves: C57BL/6)	decreased circulating interleukin-1 alpha level	J:193522
	decreased circulating interleukin-1 beta level	J:193522
	decreased circulating interleukin-18 level	J:193522
	decreased interleukin-1 alpha secretion	J:193522
	decreased interleukin-1 beta secretion	J:193522
	decreased macrophage apoptosis	J:193522
	decreased susceptibility to endotoxin shock	J:193522
Casp4^tm1Yuan/Casp4^tm1Yuan (involves: 129S4/SvJae * C57BL/6J * DBA/2)	decreased circulating interleukin-1 alpha level	J:46167
	decreased circulating interleukin-1 beta level	J:46167
	decreased susceptibility to endotoxin shock	J:46167
Casp4^tm1Yuan/Casp4^tm1Yuan (B6.129S4(D2)-Casp4^tm1Yuan/J)	decreased interleukin-1 beta secretion	J:270123
Casp4^tm1Yuan/Casp4^tm1Yuan (B6.129S4(D2)-Casp4^tm1Yuan/J)	decreased interleukin-18 secretion	J:270123
Casp7^tm1.1Acau/Casp7^tm1.1Acau (B6.Cg-Casp7^tm1.1Acau)	immune system phenotype	J:179279
Casp7^tm1Flv/Casp7^tm1Flv (B6.129S6-Casp7^tm1Flv)	immune system phenotype	J:105496
Casp8^em1Hbz/Casp8^em1Hbz (involves: C57BL/6)	decreased CD8-positive, alpha-beta T cell number	J:342732
Casp8^em1Hbz/Casp8^em1Hbz (involves: C57BL/6)	enlarged spleen	J:342732
Casp8^em1Hbz/Casp8^em1Hbz Mlkl^em1Hbz/Mlkl^em1Hbz (involves: C57BL/6)	decreased B cell number	J:342732
	decreased leukocyte cell number	J:342732
	decreased lymphocyte cell number	J:342732
	decreased mature B cell number	J:342732
	decreased T cell number	J:342732
	enlarged spleen	J:342732
	increased CD11b-high dendritic cell number	J:342732
	increased granulocyte number	J:342732
	increased macrophage cell number	J:342732
Casp8^em1Hbz/Casp8^em1Hbz Ripk1^em1Hbz/Ripk1^em1Hbz Ripk3^tm1Xidw/Ripk3^tm1Xidw (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	decreased leukocyte cell number	J:342732
	decreased lymphocyte cell number	J:342732
	decreased mature B cell number	J:342732
	decreased T cell number	J:342732
Casp8^em1Hbz/Casp8^em1Hbz Ripk3^tm1Xidw/Ripk3^tm1Xidw (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	decreased B cell number	J:342732
	decreased leukocyte cell number	J:342732
	decreased lymphocyte cell number	J:342732
	decreased mature B cell number	J:342732
	decreased T cell number	J:342732
	enlarged spleen	J:342732
	increased CD11b-high dendritic cell number	J:342732
	increased granulocyte number	J:342732
	increased macrophage cell number	J:342732
Casp8^m1Btlr/Casp8^m1Btlr (C57BL/6J-Casp8^m1Btlr)	decreased CD4-positive, alpha-beta T cell number	J:255007
	decreased CD8-positive, naive alpha-beta T cell number	J:255007
	decreased T cell number	J:255007
	increased CD8-positive, alpha-beta T cell number	J:255007
	increased effector memory CD4-positive, alpha-beta T cell number	J:255007
Casp8^M2Btlr/Casp8^M2Btlr (C57BL/6J-Casp8^M2Btlr)	increased effector memory CD8-positive, alpha-beta T cell number	J:272851
Casp8^tm1.1Raz/Casp8^tm1.1Raz Otulin^em1Gvl/Otulin^em1Gvl Ripk3^tm1Vmd/Ripk3^tm1Vmd (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6J)	enlarged lymph nodes	J:312394
	immune system phenotype	J:312394
Casp8^tm1.1Raz/Casp8^tm1.1Raz Ripk3^tm1Vmd/Ripk3^tm1Vmd (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ)	abnormal macrophage physiology	J:170815
	decreased macrophage apoptosis	J:170815
	decreased thymocyte apoptosis	J:170814
	enlarged axillary lymph nodes	J:170815
	enlarged cervical lymph nodes	J:170815
	enlarged lymph nodes	J:170814
	enlarged spleen	J:170815, J:170814
	enlarged thymus	J:170814
	immune system phenotype	J:170815
	increased B cell number	J:170815
	increased inflammatory response	J:170815
	increased leukocyte cell number	J:170815
	increased spleen white pulp amount	J:170815
	increased T cell number	J:170815, J:170814
	large lymphoid organs	J:170814
	lymph node hyperplasia	J:170815
Casp8^tm1.1Vmd/Casp8^tm1.1Vmd Ripk3^tm2Vmd/Ripk3^tm2Vmd (involves: C57BL/6N)	enlarged lymph nodes	J:209137
	enlarged spleen	J:209137
	increased T cell number	J:209137
Casp8^tm1Clie/Casp8^tm1Clie Tg(Alb1-cre)7Gsc/0 (involves: 129P2/OlaHsd * C57BL/6 * FVB/N)	liver inflammation	J:218665
Casp8^tm1Hed/Casp8^tm1Hed Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129P2/OlaHsd)	abnormal adaptive immunity	J:116713
	abnormal immunoglobulin level	J:116713
	decreased B cell number	J:116713
	decreased B cell proliferation	J:116713
	decreased B-1 B cell number	J:116713
	decreased marginal zone B cell number	J:116713
	spleen hypoplasia	J:116713
Casp8^tm1Hed/Casp8^tm1Hed Tg(KRT14-cre)1Efu/0 (Not Specified)	abnormal T cell physiology	J:167299
	dermatitis	J:167299
	increased IgE level	J:167299
	increased IgG1 level	J:167299
	increased mast cell number	J:167299
Casp8^tm1Raz/Casp8^tm1Raz Tg(Lck-cre)548Jxm/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA)	abnormal CD8-positive, alpha-beta T cell physiology	J:82759
	abnormal lymphocyte morphology	J:107455
	abnormal T cell activation	J:107455
	abnormal T cell morphology	J:82759
	abnormal T cell physiology	J:107455
	abnormal T cell proliferation	J:107455
	abnormal T cell subpopulation ratio	J:107455, J:82759
	decreased CD4-positive, alpha-beta T cell number	J:82759
	decreased CD8-positive, alpha-beta T cell number	J:82759
	decreased leukocyte cell number	J:107455
	decreased T cell apoptosis	J:82759
	decreased T cell number	J:82759
	decreased T cell proliferation	J:82759
	enlarged lymph nodes	J:107455
	enlarged spleen	J:107455
	increased B cell number	J:107455
	increased lymphocyte cell number	J:107455
	increased T cell number	J:107455
	lymphoid hyperplasia	J:107455
Casp8^tm1Wll/Casp8^tm1.1Yuan Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129S1/Sv * 129X1/SvJ * MF1)	abnormal macrophage differentiation	J:92722
Casp9^tm1Flv/Casp9^tm1Flv (involves: 129S1/Sv * C57BL/6)	abnormal thymocyte apoptosis	J:49088
	decreased T cell apoptosis	J:91156
	immune system phenotype	J:49088
Casp9^tm1Mak/Casp9^tm1Mak (either: (involves: 129P2/OlaHsd * C57BL/6J) or (involves: 129P2/OlaHsd * CD-1))	abnormal splenocyte apoptosis	J:49087
	abnormal thymocyte apoptosis	J:49087
	immune system phenotype	J:49087
Casp12^tm1Dwni/Casp12^tm1Dwni (involves: 129S1/SvImJ * C57BL/6)	decreased susceptibility to bacterial infection	J:144912
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:144912
	increased circulating interleukin-18 level	J:144912
	increased interferon-gamma secretion	J:144912
	increased interleukin-1 beta secretion	J:144912
	increased susceptibility to endotoxin shock	J:144912
Casp14^{em1(IMPC)Ccpcz}/Casp14^{em1(IMPC)Ccpcz} (C57BL/6N-Casp14^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Casr^Nuf/Casr^Nuf (involves: 102/El * C3H/He)	tongue inflammation	J:92612
Casz1^{Gt(CJ0565)Wtsi}/Casz1^{Gt(CJ0565)Wtsi} (involves: 129P2/OlaHsd * C57BL/6)	abnormal lymphatic vessel morphology	J:242127
	enlarged lymphatic vessel	J:242127
Cav1^tm1Mls/Cav1^tm1Mls (involves: 129/Sv * C57BL/6 * SJL)	abnormal chemokine secretion	J:115914
	abnormal cytokine level	J:115914
	abnormal macrophage physiology	J:115914
	abnormal neutrophil physiology	J:139304
	abnormal osteoclast morphology	J:141361
	decreased susceptibility to endotoxin shock	J:139304
	impaired neutrophil recruitment	J:115914
	increased circulating CXCL10 level	J:115914
	increased circulating interferon-gamma level	J:115914
	increased circulating interleukin-6 level	J:115914
	increased circulating tumor necrosis factor level	J:115914
	increased susceptibility to bacterial infection	J:115914
	increased susceptibility to bacterial infection induced morbidity/mortality	J:115914
	lung inflammation	J:87282
Cav1^tm1Mls/Cav1^tm1Mls Cav3^tm1Mls/Cav3^tm1Mls (involves: 129/Sv * C57BL/6J * SJL)	heart inflammation	J:77372
Cbfa2t2^tm1Swh/Cbfa2t2^tm1Swh (either: B6.129S6-Cbfa2t2^tm1Swh or (involves: 129S6/SvEvTac * C57BL/6))	small intestinal inflammation	J:102172
Cbfa2t3^tm1.1Swh/Cbfa2t3^tm1.1Swh (involves: 129S6/SvEvTac * C57BL/6 * FVB/N)	abnormal myelopoiesis	J:140967
	decreased immature B cell number	J:140967
	enlarged spleen	J:140967
Cbfb^tm1Itan/Cbfb^tm1Itan Rr94^tm3.1Litt/Rr94^tm3.1Litt Tg(Cd4-cre)1Cwi/0 (involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * FVB/N)	abnormal double-positive T cell morphology	J:158962
	abnormal T cell subpopulation ratio	J:158962
	decreased CD4-positive, alpha-beta T cell number	J:158962
	decreased double-positive T cell number	J:158962
	increased CD8-positive, alpha-beta T cell number	J:158962
	increased double-positive T cell number	J:158962
Cbfb^tm1Itan/Cbfb^tm1Itan Tg(Cd4-cre)1Cwi/0 (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	abnormal CD8-positive, alpha beta T cell morphology	J:158962, J:125953
	abnormal CD8-positive, alpha-beta T cell number	J:125953
	abnormal T cell differentiation	J:125953
	abnormal T-helper 1 cell differentiation	J:125953
	decreased CD8-positive, alpha-beta T cell number	J:158962
	increased double-positive T cell number	J:158962
	increased IgA level	J:125953
	increased IgE level	J:125953
	increased IgG1 level	J:125953
	increased immunoglobulin level	J:125953
	lung inflammation	J:125953
Cbfb^tm1Itan/Cbfb^tm1Itan Tg(Lck-cre)1Cwi/0 (involves: 129P2/OlaHsd)	abnormal CD4-positive T cell differentiation	J:125953
	abnormal CD8-positive, alpha-beta T cell differentiation	J:125953
	abnormal double-positive T cell morphology	J:125953
	abnormal T-helper 1 cell differentiation	J:125953
	decreased thymocyte number	J:125953
Cbfb^tm1Itan/Cbfb^tm1Itan Zbtb7b^tm2Litt/Zbtb7b⁺ Tg(Lck-cre)1Cwi/0 (involves: 129P2/OlaHsd * C57BL/6)	abnormal T cell differentiation	J:141144
	decreased CD4-positive, alpha-beta T cell number	J:141144
Cbfb^tm1Itan/Cbfb^tm1Itan Zbtb7b^tm2Litt/Zbtb7b^tm1.2Litt Tg(Lck-cre)1Cwi/0 (involves: 129P2/OlaHsd * C57BL/6)	abnormal T cell differentiation	J:141144
	decreased CD4-positive, alpha-beta T cell number	J:141144
Cbfb^tm1Lhc/Cbfb^tm1Lhc Tg(Mx1-cre)1Cgn/0 (involves: 129S6/SvEvTac * C57BL/6 * CBA)	abnormal myelopoiesis	J:105040
	abnormal spleen morphology	J:105040
	enlarged spleen	J:105040
	increased leukocyte cell number	J:105040
Cbfb^tm1Spe/Cbfb^tm1Spe Tg(Tek-GFP/Cbfb)1Spe/0 (either: (involves: 129S4/SvJae * BALB/c * CD-1) or (involves: 129S4/SvJae * C57BL/6 * CD-1))	abnormal myelopoiesis	J:80670
	abnormal splenic cell ratio	J:80670
	increased CD4-positive, alpha-beta T cell number	J:80670
	small thymus	J:80670
	spleen hypoplasia	J:80670
Cbfb^tm1Spe/Cbfb^tm1Spe Tg(Tek-GFP/Cbfb)2Spe/0 (either: (involves: 129S4/SvJae * BALB/c * CD-1 * Swiss Webster) or (involves: 129S4/SvJae * C57BL/6 * CD-1 * Swiss Webster))	abnormal myelopoiesis	J:80670
	abnormal splenic cell ratio	J:80670
	increased CD4-positive, alpha-beta T cell number	J:80670
	small thymus	J:80670
	spleen hypoplasia	J:80670
Cbfb^tm1Spe/Cbfb^tm2.1Spe (involves: 129S4/SvJae)	abnormal splenic cell ratio	J:124224
	abnormal T cell differentiation	J:124224
	abnormal thymus cell ratio	J:124224
	abnormal thymus morphology	J:124224
	decreased double-positive T cell number	J:124224
	increased CD4-positive, alpha-beta T cell number	J:124224
	thymus hypoplasia	J:124224
Cbfb^tm1Tok/Cbfb^tm1Tok Tg(Gata1-Cbfb)1Tok/0 (involves: 129P2/OlaHsd * C57BL/6J)	absent T cells	J:80668
	decreased lymphocyte cell number	J:80668
	small spleen	J:80668
	small thymus	J:80668
Cbfb^tm2.1Spe/Cbfb^tm2.1Spe (involves: 129S4/SvJae)	abnormal splenic cell ratio	J:124224
	abnormal T cell differentiation	J:124224
	abnormal thymus cell ratio	J:124224
	abnormal thymus morphology	J:124224
	decreased double-positive T cell number	J:124224
	increased CD4-positive, alpha-beta T cell number	J:124224
	thymus hypoplasia	J:124224
Cbfb^tm2Itan/Cbfb^tm2Itan (Not Specified)	abnormal lymph organ development	J:168918
	abnormal peripheral lymph node morphology	J:168918
	absent Peyer's patches	J:168918
	decreased Peyer's patch number	J:168918
Cbfb^tm5Ppl/Cbfb⁺ (Not Specified)	abnormal mononuclear cell differentiation	J:193140
Cbfb^tm5Ppl/Cbfb⁺ (Not Specified)	myeloid hyperplasia	J:193140
Cbfb^tm6Ppl/Cbfb⁺ (involves: 129S/SvEv * C57BL/6)	decreased B cell number	J:252447
Cbl^tm1.1Hua/Cbl^tm1.1Hua Lat^tm1Les/Lat^tm1Les (involves: 129P2/OlaHsd)	abnormal thymus development	J:91369
	increased CD4-positive, alpha-beta T cell number	J:91369
	liver inflammation	J:91369
	lung inflammation	J:91369
	thymus hypoplasia	J:91369
Cbl^tm1.1Hua/Cbl^tm1.1Hua Lcp2^tm1Gak/Lcp2^tm1Gak (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ)	abnormal cytokine secretion	J:91369
	abnormal T cell differentiation	J:91369
	enlarged spleen	J:91369
	increased CD4-positive, alpha-beta T cell number	J:91369
	liver inflammation	J:91369
	lung inflammation	J:91369
Cbl^tm1.1Hua/Cbl^tm1.1Hua Lcp2^tm1Gak/Lcp2^tm1Gak Rag2^tm1Fwa/Rag2^tm1Fwa (involves: 129P2/OlaHsd * 129S/SvEv * 129S1/Sv * 129X1/SvJ)	abnormal T cell differentiation	J:91369
Cbl^tm1Ddlb/Cbl^tm1Ddlb (involves: 129S1/Sv * C57BL/6J)	abnormal lymph node cell ratio	J:76895
	abnormal spleen morphology	J:76895
	abnormal splenic cell ratio	J:76895
	abnormal thymus cell ratio	J:76895
	enlarged lymph nodes	J:76895
	enlarged spleen	J:76895
Cbl^tm1Ddlb/Cbl^tm1Ddlb (involves: 129S1/Sv)	abnormal T cell physiology	J:81965
	enlarged spleen	J:81965
	increased spleen red pulp amount	J:81965
	spleen hyperplasia	J:81965
Cbl^tm1Ddlb/Cbl^tm1Ddlb (involves: 129S1/Sv * C57BL/6)	enlarged spleen	J:103366
	increased spleen red pulp amount	J:103366
	spleen hyperplasia	J:103366
Cbl^tm1Ddlb/Cbl^tm2Wlan (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal double-negative T cell morphology	J:103366
	abnormal lymph node cell ratio	J:103366
	abnormal spleen morphology	J:103366
	abnormal splenic cell ratio	J:103366
	abnormal T cell activation	J:103366
	abnormal T cell differentiation	J:103366
	abnormal T cell physiology	J:103366
	abnormal thymus morphology	J:103366
	abnormal thymus size	J:103366
	decreased single-positive T cell number	J:103366
	enlarged spleen	J:103366
	increased spleen red pulp amount	J:103366
	spleen hyperplasia	J:103366
	thymus hypoplasia	J:103366
Cbl^tm1Soga/Cbl^tm1Soga (Not Specified)	enlarged spleen	J:151543
Cbl^tm1Soga/Cbl^tm1Soga Tg(Tec-BCR/ABL1)5Hhi/0 (involves: C57BL/6 * DBA/2)	enlarged lymph nodes	J:151543
Cbl^tm1Wlan/Cbl^tm1Wlan (involves: 129S1/Sv * C57BL/6)	abnormal T cell physiology	J:81965
	enlarged spleen	J:81965
	increased spleen red pulp amount	J:81965
	myeloid hyperplasia	J:81965
	spleen hyperplasia	J:81965
Cbl^tm2Hua/Cbl^tm2Hua Cblb^tm1Hua/Cblb^tm1Hua Tg(Lck-cre)I57Jxm/0 (involves: 129P2/OlaHsd * C57BL/6 * ICR)	abnormal immune system physiology	J:80427
	abnormal T cell morphology	J:80427
	dermatitis	J:80427
	enlarged spleen	J:80427
	increased T cell proliferation	J:80427
Cbl^tm2Wlan/Cbl^tm2Wlan (involves: 129X1/SvJ * C57BL/6)	abnormal spleen morphology	J:103366
	abnormal thymus morphology	J:103366
	abnormal thymus size	J:103366
	enlarged spleen	J:103366
	increased spleen red pulp amount	J:103366
	spleen hyperplasia	J:103366
	thymus hypoplasia	J:103366
Cblb^tm1Hua/Cblb^tm1Hua (Not Specified)	increased T cell proliferation	J:89761
Cblb^tm1Hua/Cblb^tm1Hua (B6.129P2-Cblb^tm1Hua)	increased interleukin-2 secretion	J:94685
	increased susceptibility to experimental autoimmune encephalomyelitis	J:94685
	increased T cell proliferation	J:94685
Cblb^tm1Hua/Cblb^tm1Hua Ubash3b^tm1Jni/Ubash3b^tm1Jni Ubash3a^tm1Jni/Ubash3a^tm1Jni (Not Specified)	increased susceptibility to experimental autoimmune encephalomyelitis	J:89761
	increased T cell proliferation	J:89761
Cblb^tm1Pngr/Cblb^tm1Pngr (involves: 129 * C57BL/6)	abnormal mast cell physiology	J:126361
	increased interleukin-6 secretion	J:126361
	increased tumor necrosis factor secretion	J:126361
Cblb^tm1Pngr/Cblb^tm1Pngr (B6.129P2-Cblb^tm1Pngr)	increased T cell proliferation	J:141390
Cblb^tm1Pngr/Cblb^tm1Pngr Itk^tm1Litt/Itk^tm1Litt (B6.129-Itk^tm1Litt Cblb^tm1Pngr)	abnormal T cell morphology	J:141390
	abnormal T-helper 2 cell differentiation	J:141390
	decreased interleukin-2 secretion	J:141390
	decreased T cell number	J:141390
	immune system phenotype	J:141390
Cblb^tm1Pngr/Cblb^tm1Pngr Vav1^tm1Tyb/Vav1^tm1Tyb Was^tm1Sbs/Was^tm1Sbs (involves: 129P2/OlaHsd * 129S2/SvPas * 129S6/SvEvTac)	abnormal T cell physiology	J:79550
Cblb^tm1Pngr/Cblb^tm1Pngr Was^tm1Sbs/Was^tm1Sbs (Not Specified)	abnormal T cell physiology	J:79550
Cblb^tm1Wlan/Cblb^tm1Wlan (involves: 129X1/SvJ * C57BL/6)	abnormal mast cell physiology	J:126361
	increased interleukin-6 secretion	J:126361
	increased tumor necrosis factor secretion	J:126361
Cblif^{tm1a(KOMP)Wtsi}/Cblif^{tm1a(KOMP)Wtsi} (C57BL/6N-Cblif^{tm1a(KOMP)Wtsi})	increased CD4-positive, alpha-beta T cell number	J:236022
	increased susceptibility to bacterial infection	J:236022
	increased susceptibility to bacterial infection induced morbidity/mortality	J:236022
	increased T cell number	J:236022
Cbs^tm1Unc/Cbs^tm1Unc (involves: 129P2/OlaHsd * C57BL/6J)	abnormal interleukin level	J:101303
	abnormal tumor necrosis factor level	J:101303
	absent uterine NK cells	J:190486
	decreased uterine NK cell number	J:190486
	liver inflammation	J:101303
Cbs^tm1Unc/Cbs^tm1Unc Tg(Mt1-CBSS466L)EB86Waku/0 (involves: 129P2/OlaHsd C3H * C57BL/6)	increased Ly6C high monocyte number	J:168131
	increased monocyte cell number	J:168131
Cbx1^{em1(IMPC)Ccpcz}/Cbx1⁺ (C57BL/6NCrl-Cbx1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	small spleen	J:211773
Cbx2^tm1Cim/Cbx2^tm1Cim (involves: 129P2/OlaHsd * BALB/c)	arrested T cell differentiation	J:38487
Cbx2^tm1Cim/Cbx2^tm1Cim (involves: 129P2/OlaHsd * BALB/c)	decreased splenocyte proliferation	J:38487
Cbx3^tm1Ics/Cbx3^tm1Ics (involves: 129S2/SvPas * C57BL/6)	immune system phenotype	J:186702
Cbx4^tm1.1Gxu/Cbx4^tm1.2Gxu Tg(Foxn1-cre)1Tbo/0 (involves: 129S2/SvPas * C57BL/6J)	abnormal lymphopoiesis	J:194053
	abnormal thymus development	J:194053
	abnormal thymus physiology	J:194053
	decreased double-positive T cell number	J:194053
	decreased T cell number	J:194053
	thymus atrophy	J:194053
	thymus hypoplasia	J:194053
Cbx4^tm1.2Gxu/Cbx4^tm1.2Gxu (involves: 129S2/SvPas * C57BL/6J)	abnormal thymus development	J:194053
	abnormal thymus physiology	J:194053
	thymus hypoplasia	J:194053
Cbx5^{em1(IMPC)Ccpcz}/Cbx5^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Cbx5^{em1(IMPC)Ccpcz}/Ccpcz)	increased monocyte cell number	J:211773
Cbx5^tm1.1Ics/Cbx5^tm1.1Ics (involves: 129S2/SvPas * C57BL/6)	abnormal T-helper 2 physiology	J:186702
	immune system phenotype	J:186702
Cbx6^{tm1a(EUCOMM)Wtsi}/Cbx6^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Cbx6^{tm1a(EUCOMM)Wtsi}/Wtsi)	blood in lymph vessels	J:239583
Cby1^tm1Ktkm/Cby1^tm1Ktkm (B6.129-Cby1^tm1Ktkm)	increased susceptibility to bacterial infection	J:147413
	increased susceptibility to otitis media	J:147413
	sinus inflammation	J:147413
Cc2d1a^{tm1a(KOMP)Wtsi}/Cc2d1a^{tm1a(KOMP)Wtsi} (involves: C57BL/6J * C57BL/6N)	decreased interferon-beta secretion	J:190401
	decreased interleukin-6 secretion	J:190401
Ccar2^Gt(XN876)Byg/Ccar2^Gt(XN876)Byg (involves: 129P2/OlaHsd * C57BL/6)	decreased tumor necrosis factor secretion	J:156677
Ccbe1^tm1Lex/Ccbe1^tm1Lex (involves: 129S5/SvEvBrd)	abnormal lymphangiogenesis	J:186594
Ccbe1^tm1Lex/Ccbe1^tm1Lex (involves: 129S5/SvEvBrd)	absent lymphatic vessels	J:186594
Ccbe1^tm1Mlkn/Ccbe1^tm1Mlkn (either: B6.129-Ccbe1^tm1Mlkn or (involves: 129 * C57BL/6))	abnormal macrophage physiology	J:196696
	absent lymphatic vessels	J:196696
	decreased macrophage cell number	J:196696
Ccdc18^{em1(IMPC)Ccpcz}/Ccdc18^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Ccdc18^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
Ccdc25^em1(IMPC)Mbp/Ccdc25⁺ (C57BL/6N-Ccdc25^em1(IMPC)Mbp/MbpMmucd)	small spleen	J:211773
Ccdc32^em1(IMPC)J/Ccdc32⁺ (C57BL/6NJ-Ccdc32^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
Ccdc39^b2b2025.1Clo/Ccdc39^b2b2025.1Clo (C57BL/6J-Ccdc39^b2b2025.1Clo)	absent spleen	J:175213
	spleen hypoplasia	J:175213
Ccdc40^em1(IMPC)J/Ccdc40^em1(IMPC)J (C57BL/6NJ-Ccdc40^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
Ccdc50^em2Gpt/Ccdc50^em2Gpt (C57BL/6J-Ccdc50^em2Gpt)	decreased susceptibility to Herpesvirales infection	J:345495
	decreased susceptibility to Herpesvirales infection induced morbidity/mortality	J:345495
	increased circulating interferon-beta level	J:345495
	increased interferon-beta secretion	J:345495
Ccdc86^tm1Hfuj/Ccdc86⁺ (involves: C57BL/6NTac)	abnormal T cell morphology	J:151722
Ccdc86^tm1Hfuj/Ccdc86⁺ (involves: C57BL/6NTac)	decreased T cell apoptosis	J:151722
Ccdc88b^em1(IMPC)Tcp/Ccdc88b^em1(IMPC)Tcp (C57BL/6NCrl-Ccdc88b^em1(IMPC)Tcp/Tcp)	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
	enlarged lymph nodes	J:211773
Ccdc88b^m1Pgrs/Ccdc88b^m1Pgrs (involves: C57BL/6J * C57BL/10J)	decreased CD8-positive, alpha-beta T cell number	J:230618
	decreased interferon-gamma secretion	J:230618
	decreased susceptibility to parasitic infection	J:230618
	decreased susceptibility to parasitic infection induced morbidity/mortality	J:230618
	decreased T cell proliferation	J:230618
	decreased tumor necrosis factor secretion	J:230618
	immune system phenotype	J:230618
Ccdc88b^m1Pgrs/Ccdc88b^m1Pgrs (involves: 129S1/SvImJ * C57BL/6J * C57BL/10J)	decreased susceptibility to parasitic infection induced morbidity/mortality	J:230618
Ccdc92^{tm1a(KOMP)Mbp}/Ccdc92^{tm1a(KOMP)Mbp} (C57BL/6N-Ccdc92^{tm1a(KOMP)Mbp})	decreased circulating interleukin-1 beta level	J:332421
	decreased circulating interleukin-18 level	J:332421
	decreased inflammatory response	J:332421
	decreased macrophage cell number	J:332421
Ccdc110^{em1(IMPC)Ccpcz}/Ccdc110^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Ccdc110^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Ccdc124^{tm1b(KOMP)Wtsi}/Ccdc124^{tm1b(KOMP)Wtsi} (C57BL/6N-Ccdc124^{tm1b(KOMP)Wtsi}/Nju)	small spleen	J:211773
Ccdc127^{tm1b(EUCOMM)Wtsi}/Ccdc127^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Ccdc127^{tm1b(EUCOMM)Wtsi}/Wtsi)	increased leukocyte cell number	J:211773
Ccdc154^ntl/Ccdc154^ntl (involves: 129S7/SvEvBrd * C57BL/6J)	enlarged spleen	J:226596
Ccdc166^em1(IMPC)J/Ccdc166^em1(IMPC)J (C57BL/6NJ-Ccdc166^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
Ccdc171^m1Anu/Ccdc171⁺ (C57BL/NCrlAnu-Ccdc171^m1Anu/Anu)	decreased IgD level	J:104190
	decreased mature B cell number	J:104190
	increased IgM level	J:104190
Ccdc171^m1Anu/Ccdc171^m1Anu (C57BL/NCrlAnu-Ccdc171^m1Anu/Anu)	decreased IgD level	J:104190
	decreased mature B cell number	J:104190
	increased IgM level	J:104190
Ccdc183^{em1(IMPC)Hmgu}/Ccdc183^{em1(IMPC)Hmgu} (C57BL/6NCrl-Ccdc183^{em1(IMPC)Hmgu}/Ieg)	increased neutrophil cell number	J:211773
Ccdc198^{em1(IMPC)Ccpcz}/Ccdc198^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Ccdc198^{em1(IMPC)Ccpcz}/Ph)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	decreased eosinophil cell number	J:337480
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Cchcr1^em1Aoka/Cchcr1⁺ (C57BL/6NJcl-Cchcr1^em1Aoka)	immune system phenotype	J:309941
Cchcr1^em1Aoka/Cchcr1^em1Aoka (C57BL/6NJcl-Cchcr1^em1Aoka)	immune system phenotype	J:309941
Cckbr^tm1Tom/Cckbr^tm1Tom (involves: 129S4/SvJae * C57BL/6J)	decreased susceptibility to endotoxin shock	J:143853
Ccl1^tm1Sman/Ccl1^tm1Sman (B6.129-Ccl1^tm1Sman)	abnormal inflammatory response	J:138942
Ccl1^tm1Sman/Ccl1^tm1Sman (B6.129-Ccl1^tm1Sman)	abnormal regulatory T cell physiology	J:138942
Ccl2^tm1.1Pame/Ccl2^tm1.1Pame Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:171379
Ccl2^tm1.1Pame/Ccl2^tm1.1Pame Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺ (involves: C57BL/6 * DBA)	immune system phenotype	J:171379
Ccl2^tm1.1Pame/Ccl2^tm1.1Pame Tg(Nes-cre)1Kln/0 (involves: C57BL/6 * SJL)	abnormal leukocyte migration	J:171379
	increased susceptibility to bacterial infection	J:171379
Ccl2^tm1.1Pame/Ccl2^tm1.1Pame Tg(Tek-cre)12Flv/0 (involves: C3H * C57BL/6)	abnormal leukocyte migration	J:171379
	increased susceptibility to bacterial infection	J:171379
Ccl2^tm1.1Tyos/Ccl2^tm1.1Tyos (involves: 129S1/Sv * C57BL/6)	abnormal chemokine level	J:151874
	abnormal chemokine secretion	J:151874
	abnormal neutrophil physiology	J:151874
	impaired macrophage chemotaxis	J:151874
Ccl2^tm1.1Tyos/Ccl2^tm1.1Tyos (involves: 129S1/Sv)	abnormal dendritic cell chemotaxis	J:199611
	abnormal dendritic cell physiology	J:199611
	decreased dendritic cell number	J:199611
Ccl2^tm1Lex/Ccl2^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6)	impaired macrophage chemotaxis	J:191510
Ccl2^tm1Rol/Ccl2⁺ Mpz^tm1Msch/Mpz⁺ (involves: 129S4/SvJae * 129S7/SvEvBrd)	abnormal macrophage derived foam cell morphology	J:133028
	decreased macrophage cell number	J:133028
Ccl2^tm1Rol/Ccl2⁺ Tg(PMP22)C61Clh/0 (involves: 129S4/SvJae * C57BL/6J * CBA/Ca)	increased macrophage cell number	J:158350
Ccl2^tm1Rol/Ccl2^tm1Rol (involves: 129S4/SvJae * 129X1/SvJ * C57BL/6)	abnormal monocyte morphology	J:45920
	decreased interferon-gamma secretion	J:45920
	decreased interleukin-4 secretion	J:45920
	decreased interleukin-5 secretion	J:45920
	decreased susceptibility to type IV hypersensitivity reaction	J:45920
	impaired macrophage chemotaxis	J:45920
Ccl2^tm1Rol/Ccl2^tm1Rol (involves: 129S4/SvJae * C57BL/6)	abnormal macrophage chemotaxis	J:116878
	abnormal T cell physiology	J:116878
	decreased interferon-gamma secretion	J:116878
	decreased interleukin-1 beta secretion	J:116878
	decreased interleukin-12b secretion	J:116878
	decreased susceptibility to induced colitis	J:116878
	impaired macrophage chemotaxis	J:108533
Ccl2^tm1Rol/Ccl2^tm1Rol (involves: 129S4/SvJae)	abnormal macrophage physiology	J:155025
	abnormal monocyte morphology	J:121281
	decreased inflammatory response	J:155025
	decreased lymphocyte cell number	J:147697
	decreased macrophage cell number	J:147697
	impaired macrophage chemotaxis	J:147697
	increased circulating interferon-gamma level	J:155025
	increased circulating interleukin-10 level	J:155025
	increased circulating tumor necrosis factor level	J:155025
	increased susceptibility to infection induced morbidity/mortality	J:155025
	increased susceptibility to parasitic infection	J:155025
Ccl2^tm1Rol/Ccl2^tm1Rol (B6.129S4-Ccl2^tm1Rol)	abnormal chemokine level	J:151874, J:118606
	abnormal chemokine secretion	J:151874
	abnormal cytokine secretion	J:68145
	abnormal macrophage chemotaxis	J:109290
	abnormal neutrophil physiology	J:151874
	decreased interferon-gamma secretion	J:68145
	decreased leukocyte cell number	J:68145
	decreased macrophage cell number	J:147328
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:68145
	impaired macrophage chemotaxis	J:151874, J:68145, J:118606
	increased CD4-positive, alpha-beta T cell number	J:68145
	increased IgG1 level	J:68145
	increased IgG level	J:147328
	increased interleukin-10 secretion	J:68145
	increased neutrophil cell number	J:118606
	increased osteoclast cell number	J:109290
Ccl2^tm1Rol/Ccl2^tm1Rol (SJL.129S4-Ccl2^tm1Rol)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:68145
Ccl2^tm1Rol/Ccl2^tm1Rol ((129S4/SvJae x C57BL/6)F1)	decreased macrophage cell number	J:119615
Ccl2^tm1Rol/Ccl2^tm1Rol (B6.129S4-Ccl2^tm1Rol/J)	abnormal microglial cell physiology	J:141739
Ccl2^tm1Rol/Ccl2^tm1Rol Cx3cr1^tm1Litt/Cx3cr1^tm1Litt (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6J)	abnormal macrophage physiology	J:200877
	abnormal microglial cell morphology	J:200877
	increased microglial cell activation	J:200877
Ccl2^tm1Rol/Ccl2^tm1Rol Mpz^tm1Msch/Mpz⁺ (involves: 129S4/SvJae * 129S7/SvEvBrd)	abnormal cytokine level	J:133028
	decreased macrophage cell number	J:133028
	increased macrophage cell number	J:133028
Ccl2^tm1Rol/Ccl2^tm1Rol Tg(Ccr2-EGFP)8Pame/0 (involves: 129S4/SvJae * C57BL/6J)	abnormal leukocyte migration	J:171379
Ccl2^tm1Rol/Ccl2^tm1Rol Tg(PMP22)C61Clh/0 (involves: 129S4/SvJae * C57BL/6J * CBA/Ca)	increased macrophage cell number	J:158350
Ccl2^tm1Tyos/Ccl2^tm1Tyos (involves: 129S1/Sv * C57BL/6)	abnormal chemokine level	J:151874
Ccl2^tm1Tyos/Ccl2^tm1Tyos (involves: 129S1/Sv * C57BL/6)	abnormal chemokine secretion	J:151874
Ccl3^tm1Unc/Ccl3^tm1Unc (involves: 129P2/OlaHsd)	abnormal susceptibility to Orthomyxoviridae infection	J:107677
	cecum inflammation	J:107677
	decreased susceptibility to bacterial infection	J:107677
	decreased susceptibility to Orthomyxoviridae infection	J:107677
	decreased susceptibility to Picornaviridae infection	J:28704
Ccl3^tm1Unc/Ccl3^tm1Unc (B6.129P2-Ccl3^tm1Unc/J)	decreased neutrophil cell number	J:94599
Ccl3^tm1Unc/Ccl3^tm1Unc (B6.129P2-Ccl3^tm1Unc/J)	decreased susceptibility to type III hypersensitivity reaction	J:94599
Ccl3^tm1Unc/Ccl3^tm1Unc (involves: 129P2/OlaHsd * C57BL/6)	decreased microglial cell activation	J:153059
Ccl3^tm1Unc/Ccl3^tm1Unc Hexb^tm1Rlp/Hexb^tm1Rlp (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)	abnormal tumor necrosis factor level	J:90687
	CNS inflammation	J:90687
Ccl4^em1Narl/Ccl4^em1Narl (C57BL/6JNarl-Ccl4^em1Narl)	decreased inflammatory response	J:346348
Ccl4^em1Narl/Ccl4^em1Narl (C57BL/6JNarl-Ccl4^em1Narl)	decreased susceptibility to autoimmune diabetes	J:346348
Ccl5^tm1Hso/Ccl5^tm1Hso (involves: 129P2/OlaHsd * C57BL/6)	decreased CD4-positive, alpha-beta T cell number	J:75842
	decreased interferon-gamma secretion	J:75842
	decreased interleukin-2 secretion	J:75842
	decreased susceptibility to type IV hypersensitivity reaction	J:75842
	decreased T cell proliferation	J:75842
Ccl7^tm1Ifc/Ccl7^tm1Ifc (involves: 129S4/SvJae)	abnormal monocyte morphology	J:121281
Ccl11^tm1Mer/Ccl11^tm1Mer (involves: 129S6/SvEvTac * NIH Black Swiss)	decreased eosinophil cell number	J:38945
	impaired eosinophil recruitment	J:38945
Ccl11^tm1Mer/Ccl11^tm1Mer (129S.129S6-Ccl11^tm1Mer)	decreased eosinophil cell number	J:102034
Ccl11^tm1Mer/Ccl11^tm1Mer Ccl24^tm1Mer/Ccl24^tm1Mer (129S.129S6(Cg)-Ccl24^tm1Mer Ccl11^tm1Mer)	abnormal immune system physiology	J:102034
	abnormal inflammatory response	J:102034
Ccl11^tm1Mer/Ccl11^tm1Mer Ccl24^tm1Mer/Ccl24^tm1Mer (involves: 129S6/SvEvTac)	decreased eosinophil cell number	J:115273
Ccl12^tm1.1Ifc/Ccl12^tm1.1Ifc (involves: 129S4/SvJae)	immune system phenotype	J:121281
Ccl12^tm1Ifc/Ccl12^tm1Ifc (involves: 129S4/SvJae)	immune system phenotype	J:121281
Ccl17^em1(IMPC)H/Ccl17^em1(IMPC)H (C57BL/6N-Ccl17^em1(IMPC)H/H)	increased spleen weight	J:211773
Ccl17^tm1.1Ifo/Ccl17^tm1.1Ifo (involves: 129P2/OlaHsd * C57BL/6)	decreased susceptibility to type IV hypersensitivity reaction	J:159098
	increased length of allograft survival	J:159098
Ccl17^{tm2.1(cre)Ifo}/Ccl17⁺ Hif1a^tm3Rsjo/Hif1a^tm3Rsjo (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal dendritic cell number	J:187773
	abnormal interleukin-1 beta secretion	J:187773
	abnormal leukocyte migration	J:187773
	abnormal tumor necrosis factor secretion	J:187773
	immune system phenotype	J:187773
Ccl19^tm1Cys/Ccl19^tm1Cys (B6.129X1-Ccl19^tm1Cys)	abnormal immune system morphology	J:126345
Ccl19^tm1Cys/Ccl19^tm1Cys (B6.129X1-Ccl19^tm1Cys)	decreased T cell number	J:126345
Ccl19^tm1Cys/Ccl19^tm1Cys (involves: 129X1/SvJ)	immune system phenotype	J:244640
Ccl21a^tm1Yout/Ccl21a^tm1Yout (involves: C57BL/6NCrlj * CBA/JNCrlj)	abnormal negative T cell selection	J:244640
	abnormal spleen morphology	J:244640
	decreased alpha-beta T cell number	J:244640
	decreased B cell number	J:244640
	decreased thymocyte number	J:244640
	immune system phenotype	J:244640
	lacrimal gland inflammation	J:244640
	small thymus medulla	J:244640
Ccl22^{tm1(KOMP)Vlcg}/Ccl22^{tm1(KOMP)Vlcg} (involves: C57BL/6NTac)	abnormal dendritic cell physiology	J:236051
Ccl24^tm1Mer/Ccl24^tm1Mer (129S.129S6-Ccl24^tm1Mer)	abnormal immune system physiology	J:98708, J:102034
Ccl24^tm1Mer/Ccl24^tm1Mer (involves: 129S6/SvEvTac * C57BL/6J)	abnormal immune system physiology	J:98708
Ccl25^em1(IMPC)H/Ccl25^em1(IMPC)H (C57BL/6N-Ccl25^em1(IMPC)H/H)	enlarged spleen	J:211773
	increased spleen weight	J:211773
Ccl25^tm1.1Mal/Ccl25^tm1.1Mal (B6.129S2-Ccl25^tm1.1Mal)	abnormal gamma-delta T cell number	J:136944
	abnormal mesenteric lymph node morphology	J:136944
	abnormal T cell subpopulation ratio	J:136944
	decreased gamma-delta intraepithelial T cell number	J:136944
Ccl25^tm1.1Mal/Ccl25^tm1.1Mal Tnf^tm2Gkl/Tnf⁺ (involves: 129S/SvEv * 129S2/SvPas * C57BL/6)	abnormal alpha-beta intraepithelial T cell morphology	J:136667
	abnormal T cell subpopulation ratio	J:136667
	decreased gamma-delta intraepithelial T cell number	J:136667
	intestinal inflammation	J:136667
Ccl27a^em1Nax/Ccl27a^em1Nax Ccl27al^em1Nax/Ccl27al^em1Nax Ccl27b^em1Nax/Ccl27b^em1Nax (involves: C57BL/6)	impaired leukocyte migration	J:330550
	increased interleukin-17 secretion	J:330550
	increased susceptibility to chemically induced skin inflammation	J:330550
Ccl27a^em1Nax/Ccl27a^em1Nax Ccl27al^em1Nax/Ccl27al^em1Nax Ccl27b^em1Nax/Ccl27b^em1Nax Ccr10^tm1.1Nax/Ccr10⁺ (involves: C57BL/6)	impaired leukocyte migration	J:330550
	increased interleukin-10 secretion	J:330550
	uterus inflammation	J:330550
Ccl27a^{tm1.1(KOMP)Vlcg}/Ccl27a^{tm1.1(KOMP)Vlcg} (C57BL/6N-Ccl27a^{tm1.1(KOMP)Vlcg}/MbpMmucd)	decreased regulatory T cell number	J:330550
	immune system phenotype	J:330550
Ccl27a^{tm1.1(KOMP)Vlcg}/Ccl27a^{tm1.1(KOMP)Vlcg} Ccr10^tm1.1Nax/Ccr10⁺ (B6.Cg-Ccl27a^{tm1.1(KOMP)Vlcg} Ccr10^tm1.1Nax)	immune system phenotype	J:330550
Ccl28^{em1(IMPC)Ccpcz}/Ccl28^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Ccl28^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Ccl28^tm1Takna/Ccl28^tm1Takna (C57BL/6J-Ccl28^tm1Takna)	abnormal immune system cell morphology	J:256896
	decreased IgA level	J:256896
	increased IgG level	J:256896
	increased susceptibility to induced colitis	J:256896
Ccm2^tm1Kwhi/Ccm2^tm1.1Kwhi Tg(Pdgfb-icre/ERT2,-EGFP)1Frut/? (involves: C57BL/6 * CBA)	CNS inflammation	J:173947
Ccm2^tm2.1Sbn/Ccm2^tm2.1Sbn Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA)	microgliosis	J:174085
Ccn3^em1(IMPC)Mbp/Ccn3^em1(IMPC)Mbp (C57BL/6N-Ccn3^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	small spleen	J:211773
Ccn3^tm1.1Ecan/Ccn3^tm1.1Ecan (B6.Cg-Ccn3^tm1.1Ecan)	abnormal osteoclast differentiation	J:158478
Ccn3^tm1.1Ecan/Ccn3^tm1.1Ecan (B6.Cg-Ccn3^tm1.1Ecan)	abnormal osteoclast physiology	J:158478
Ccna1^tm1Djw/Ccna1^tm1Djw Ccna2^tm1.1Pisc/Ccna2^tm1.1Pisc Tg(Mx1-cre)1Cgn/0 (involves: 129S7/SvEvBrd * C57BL/6 * CBA)	decreased leukocyte cell number	J:155178
Ccnb1ip1^em1(IMPC)Tcp/Ccnb1ip1^em1(IMPC)Tcp (C57BL/6NCrl-Ccnb1ip1^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Ccnb2^tm1Thnt/Ccnb2^tm1Thnt (involves: 129P2/OlaHsd * C57BL/6)	increased double-negative T cell number	J:47430
	small thymus	J:47430
Ccnc^tm1.1Pisc/Ccnc^tm1.1Pisc Tg(Lck-LMO1)11Sjk/0 Tg(Mx1-cre)1Cgn/0 (Not Specified)	increased T cell derived lymphoma incidence	J:217695
Ccnd1^tm1Dsn/Ccnd1^tm1Dsn Ccnd2^tm1Wbg/Ccnd2^tm1Wbg Ccnd3^tm1Pisc/Ccnd3^tm1Pisc (involves: 129P2/OlaHsd * 129S2/SvPas)	abnormal lymphopoiesis	J:92563
Ccnd1^tm1Dsn/Ccnd1^tm1Dsn Cdkn1b^tm1Mlf/Cdkn1b^tm1Mlf (involves: 129 * C57BL/6)	enlarged spleen	J:66707
	enlarged thymus	J:66707
	thymus hyperplasia	J:66707
Ccnd3^{tm1.1(Ccnd2)Iaai}/Ccnd3^{tm1.1(Ccnd2)Iaai} (involves: 129S6/SvEvTac)	decreased B cell proliferation	J:192031
	decreased double-positive T cell number	J:192031
	decreased pre-B cell number	J:192031
	decreased T cell proliferation	J:192031
	small thymus	J:192031
	thymus hypoplasia	J:192031
Ccnd3^tm1Pisc/Ccnd3^tm1Pisc (Not Specified)	decreased B cell proliferation	J:192031
	decreased double-positive T cell number	J:88120, J:192031
	decreased lymphocyte cell number	J:88120
	decreased pre-B cell number	J:192031
	decreased T cell proliferation	J:88120, J:192031
	increased double-negative T cell number	J:88120
	small thymus	J:192031
	thymus hypoplasia	J:88120, J:192031
Ccnd3^tm1Pisc/Ccnd3^tm1Pisc Cdkn1b^tm1Mlf/Cdkn1b^tm1Mlf (involves: 129S4/SvJaeSor)	decreased double-positive T cell number	J:192031
	decreased T cell proliferation	J:192031
	thymus hypoplasia	J:192031
Ccnd3^tm1Pisc/Ccnd3^tm1Pisc Cdkn1b^tm1Mlf/Cdkn1b^tm1Mlf Rb1^tm2Brn/Rb1^tm2Brn Tg(Mx1-cre)1Cgn/0 (involves: 129S4/SvJaeSor * C57BL/6 * CBA)	immune system phenotype	J:192031
Ccnd3^tm1Pisc/Ccnd3^tm1Pisc Rag2^tm1Fwa/Rag2^tm1Fwa (involves: 129S/SvEv)	increased T cell proliferation	J:88120
Ccnd3^tm1Pisc/Ccnd3^tm1Pisc Rb1^tm2Brn/Rb1^tm2Brn Tg(Mx1-cre)1Cgn/0 (involves: 129 * C57BL/6 * CBA)	decreased double-positive T cell number	J:192031
	decreased T cell proliferation	J:192031
	thymus hypoplasia	J:192031
Ccnd3^tm1Pisc/Ccnd3^tm1Pisc Tg(Lck)4220Rmp/0 (involves: C57BL/6J * DBA/2)	increased T cell derived lymphoma incidence	J:88120
Ccnd3^tm1Pisc/Ccnd3^tm1Pisc Trp53^tm1Tyj/Trp53^tm1Tyj (involves: 129S2/SvPas)	increased T cell derived lymphoma incidence	J:88120
Ccnd3^tm2.1Pisc/Ccnd3^tm2.1Pisc Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA)	decreased double-positive T cell number	J:192032
	decreased leukocyte cell number	J:192032
	small thymus	J:192032
Ccne1^tm1Clur/Ccne1^tm1Clur (involves: 129S4/SvJae)	abnormal myeloid leukocyte morphology	J:136692
	abnormal spleen red pulp morphology	J:136692
	enlarged spleen	J:136692
	immune system phenotype	J:136692
	spleen hyperplasia	J:136692
Ccne1^tm1Jro/Ccne1^tm1Jro (either: 129-Ccne1^tm1Jro or B6.129-Ccne1^tm1Jro)	increased spleen weight	J:99695
	increased splenocyte proliferation	J:99695
Ccne1^tm1Pisc/Ccne1^tm1Pisc Ccne2^tm1Pisc/Ccne2^tm1Pisc (involves: 129S2/SvPas)	abnormal thrombopoiesis	J:85224
Ccno^{tm1b(EUCOMM)Wtsi}/Ccno^{tm1b(EUCOMM)Wtsi} (involves: C57BL/6 * C57BL/6N * CBA)	immune system phenotype	J:220709
Ccnt1^em1(IMPC)J/Ccnt1⁺ (C57BL/6NJ-Ccnt1^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
Ccnt1^em1(IMPC)J/Ccnt1^em1(IMPC)J (C57BL/6NJ-Ccnt1^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
Ccnt1^{Gt(RRR115)Byg}/Ccnt1^{Gt(RRR115)Byg} (involves: 129P2/OlaHsd)	abnormal thymus physiology	J:130071
	autoimmune response	J:130071
	immune system phenotype	J:130071
	lacrimal gland inflammation	J:130071
	salivary gland inflammation	J:130071
Ccpg1^{tm1a(EUCOMM)Hmgu}/Ccpg1^{tm1a(EUCOMM)Hmgu} (C57BL/6N-Ccpg1^{tm1a(EUCOMM)Hmgu})	pancreas inflammation	J:256708
Ccr1^tm1Cge/Ccr1^tm1Cge (involves: 129S4/SvJae)	decreased tumor necrosis factor secretion	J:43569
	glomerulonephritis	J:115119
	immune system phenotype	J:115119
	impaired neutrophil recruitment	J:43569
	increased IgG2a level	J:115119
	increased interferon-gamma secretion	J:115119
	increased susceptibility to type IV hypersensitivity reaction	J:115119
	increased tumor necrosis factor secretion	J:115119
	lung inflammation	J:43569
Ccr1^tm1Cge/Ccr1^tm1Cge (involves: 129S4/SvJae * C57BL/6)	cecum inflammation	J:107677
	decreased susceptibility to bacterial infection	J:107677
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:63952
	immune system phenotype	J:63952
	increased length of allograft survival	J:59235
Ccr1^tm1Cge/Ccr1^tm1Cge (involves: 129S4/SvJae * BALB/c)	abnormal chemokine secretion	J:169909
	abnormal circulating chemokine level	J:169909
	abnormal macrophage physiology	J:169909
	decreased circulating interferon-gamma level	J:169909
	decreased interleukin-10 secretion	J:169909
	decreased susceptibility to bacterial infection	J:169909
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:169909
	decreased tumor necrosis factor secretion	J:169909
	increased interleukin-12 secretion	J:169909
	increased macrophage nitric oxide production	J:169909
	increased tumor necrosis factor secretion	J:169909
Ccr1^tm1Cge/Ccr1^tm1Cge (C.129S4-Ccr1^tm1Cge)	decreased CD4-positive, alpha-beta T cell number	J:95242
	decreased CD8-positive, alpha-beta T cell number	J:95242
	decreased interleukin-13 secretion	J:95242
	decreased susceptibility to Riboviria infection	J:95242
Ccr1^tm1Gao/Ccr1^tm1Gao (involves: 129S4/SvJae * C57BL/6)	abnormal neutrophil physiology	J:41324
	granulomatous inflammation	J:41324
	immune system phenotype	J:41324
	increased susceptibility to fungal infection	J:41324
	increased susceptibility to parasitic infection	J:41324
Ccr1^tm1Gao/Ccr1^tm1Gao (involves: C57BL/6)	decreased mast cell number	J:94599
Ccr1^tm1Gao/Ccr1^tm1Gao (involves: C57BL/6)	decreased susceptibility to type III hypersensitivity reaction	J:94599
Ccr1^tm1Gao/Ccr1^tm1Gao (B6.129S4-Ccr1^tm1Gao)	abnormal cellular extravasation	J:104744
	abnormal leukocyte adhesion	J:104744
	bronchiolitis	J:162707
	increased susceptibility to Coronaviridae infection	J:162707
	increased susceptibility to Coronaviridae infection induced morbidity/mortality	J:162707
Ccr1^tm1Gao/Ccr1^tm1Gao (involves: 129S4/SvJae)	abnormal Kupffer cell morphology	J:152548
Ccr1l1^em1Semp/Ccr1l1^em1Semp (C57BL/6NTac-Ccr1l1^em1Semp)	immune system phenotype	J:304824
Ccr1l1^em2Semp/Ccr1l1^em2Semp (C57BL/6NTac-Ccr1l1^em2Semp)	immune system phenotype	J:304824
Ccr2^em1(IMPC)H/Ccr2^em1(IMPC)H (C57BL/6N-Ccr2^em1(IMPC)H/H)	decreased lymphocyte cell number	J:211773
	decreased monocyte cell number	J:211773
	decreased neutrophil cell number	J:211773
	increased eosinophil cell number	J:211773
Ccr2^{tm1.1(CCR2)Rodb}/Ccr2^{tm1.1(CCR2)Rodb} (involves: C57BL/6)	abnormal macrophage morphology	J:203000
	immune system phenotype	J:203000
Ccr2^tm1.1Dnc/Ccr2^tm1.1Dnc (Not Specified)	abnormal dendritic cell chemotaxis	J:223508
	decreased CD11b-high dendritic cell number	J:223508
	increased CD11b-high dendritic cell number	J:223508
	increased dendritic cell number	J:223508
Ccr2^tm1.1Mpa/Ccr2^tm1.1Mpa (involves: BALB/cJ * C57BL/6)	decreased macrophage cell number	J:189044
Ccr2^tm1.1Mpa/Ccr2^tm1.1Mpa (involves: BALB/cJ * C57BL/6)	decreased monocyte cell number	J:189044
Ccr2^tm1Blck/Ccr2^tm1Blck (B6.129P2-Ccr2^tm1Blck)	abnormal cellular extravasation	J:104744
Ccr2^tm1Blck/Ccr2^tm1Blck (B6.129P2-Ccr2^tm1Blck)	abnormal leukocyte adhesion	J:104744
Ccr2^tm1Blck/Ccr2^tm1Blck Fas^lpr/Fas^lpr (MRL.Cg-Ccr2^tm1Blck Fas^lpr)	abnormal immune system organ morphology	J:113343
	abnormal interferon level	J:113343
	abnormal lymphocyte cell number	J:113343
	abnormal tumor necrosis factor level	J:113343
	enlarged lymph nodes	J:113343
	enlarged spleen	J:113343
	glomerulonephritis	J:113343
	kidney inflammation	J:113343
Ccr2^tm1Brv/Ccr2^tm1Brv (involves: 129S1/Sv * ICR)	abnormal spleen morphology	J:111517
	enlarged spleen	J:111517
	impaired macrophage chemotaxis	J:111517
	increased eosinophil cell number	J:111517
	increased susceptibility to bacterial infection	J:111517
	liver inflammation	J:111517
Ccr2^tm1Ifc/Ccr2⁺ (involves: 129S4/SvJae * C57BL/6)	impaired macrophage chemotaxis	J:121703
Ccr2^tm1Ifc/Ccr2^tm1Ifc (B6.129S4-Ccr2^tm1Ifc/J)	abnormal leukocyte migration	J:106738
	abnormal leukocyte physiology	J:122119
	abnormal microglial cell physiology	J:106738
	abnormal osteoclast cell number	J:149360
	abnormal osteoclast differentiation	J:149360
	abnormal osteoclast physiology	J:149360
	decreased acute inflammation	J:106738
	decreased interferon-gamma secretion	J:106738
	decreased osteoclast cell number	J:149360
	increased susceptibility to Coronaviridae infection	J:106738
	increased susceptibility to Coronaviridae infection induced morbidity/mortality	J:106738
Ccr2^tm1Ifc/Ccr2^tm1Ifc (involves: 129S4/SvJae)	abnormal monocyte morphology	J:121281
Ccr2^tm1Ifc/Ccr2^tm1Ifc (involves: 129S4/SvJae * C57BL/6)	abnormal immune serum protein physiology	J:118971
	abnormal Langerhans cell physiology	J:112594
	abnormal macrophage chemotaxis	J:44345
	abnormal microglial cell physiology	J:121703
	decreased inflammatory response	J:44345
	decreased interferon-gamma secretion	J:75838, J:44345
	decreased interleukin-2 secretion	J:44345
	decreased interleukin-6 secretion	J:75838
	decreased splenocyte proliferation	J:75838
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:75838
	decreased susceptibility to type I hypersensitivity reaction	J:118971
	decreased T cell proliferation	J:75838
	impaired macrophage chemotaxis	J:81363, J:44345, J:121703
	increased interferon-gamma secretion	J:61542
	increased tumor necrosis factor secretion	J:61542
Ccr2^tm1Ifc/Ccr2^tm1Ifc (B6.129S4-Ccr2^tm1Ifc)	decreased susceptibility to induced colitis	J:161138
	immune system phenotype	J:154558
	impaired leukocyte tethering or rolling	J:154558
Ccr2^tm1Ifc/Ccr2^tm1Ifc Tg(APPSWE)2576Kha/0 (involves: 129S4/SvJae * C57BL/6 * SJL)	abnormal microglial cell physiology	J:121703
Ccr2^tm1Mae/Ccr2^tm1Mae (involves: 129P2/OlaHsd * C57BL/6J)	abnormal cytokine secretion	J:110814
	decreased CD4-positive, alpha-beta T cell number	J:110814
	decreased inflammatory response	J:110814
	increased B cell number	J:110814
	increased CD8-positive, alpha-beta T cell number	J:110814
	increased susceptibility to induced colitis	J:110814
Ccr2^tm1Mae/Ccr2^tm1Mae (B6.129P2-Ccr2^tm1Mae)	bronchiolitis	J:162707
	decreased macrophage cell number	J:147328
	increased IgG level	J:147328
	increased susceptibility to Coronaviridae infection	J:162707
Ccr2^tm1Mae/Ccr2^tm1Mae (involves: 129P2/OlaHsd)	abnormal chemokine secretion	J:151874
	abnormal leukocyte migration	J:171379
	impaired macrophage chemotaxis	J:191510, J:151874
Ccr2^tm1Mae/Ccr2^tm1Mae (involves: 129P2/OlaHsd * BALB/c)	abnormal leukocyte physiology	J:162714
	decreased neutrophil cell number	J:162714
	impaired macrophage chemotaxis	J:162714
Ccr2^tm1Mpa/Ccr2^tm1Mpa Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6 * CBA)	decreased macrophage cell number	J:189044
Ccr2^tm2.1Ifc/Ccr2^tm2.1Ifc Cx3cr1^tm1Litt/Cx3cr1⁺ (involves: 129P2/OlaHsd * C57BL/6 * FVB/N)	abnormal leukocyte physiology	J:166664
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:166664
Ccr2^tm2.1Ifc/Ccr2^tm2.1Ifc Cx3cr1^tm1Litt/Cx3cr1^tm1Litt (involves: 129P2/OlaHsd * C57BL/6 * FVB/N)	abnormal leukocyte physiology	J:166664
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:166664
Ccr3^{em1(IMPC)Ccpcz}/Ccr3^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Ccr3^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Ccr3^tm1Cge/Ccr3^tm1Cge (involves: 129S4/SvJae * BALB/c)	abnormal eosinophil cell number	J:74509
	abnormal eosinophil physiology	J:74509, J:75347
	abnormal mast cell physiology	J:74509
	decreased circulating interleukin-4 level	J:115273
	decreased eosinophil cell number	J:115273, J:74509, J:75347
	decreased monocyte cell number	J:115273
	impaired eosinophil chemotaxis	J:74509
	impaired eosinophil recruitment	J:74509, J:75347
	increased eosinophil cell number	J:74509
	increased mast cell degranulation	J:74509
Ccr4^tm1Pwr/Ccr4^tm1Pwr (involves: 129P2/OlaHsd * C57BL/6)	abnormal chemokine secretion	J:70088
	abnormal cytokine secretion	J:120221
	abnormal splenocyte physiology	J:70088
	decreased eosinophil cell number	J:120221
	decreased IgE level	J:120221
	decreased interleukin-1 beta secretion	J:70088
	decreased interleukin-4 secretion	J:120221
	decreased interleukin-5 secretion	J:120221
	decreased interleukin-10 secretion	J:120221
	decreased interleukin-13 secretion	J:120221
	decreased lymphocyte cell number	J:70088
	decreased macrophage cell number	J:70088
	decreased susceptibility to endotoxin shock	J:70088
	decreased susceptibility to fungal infection	J:120221
	decreased tumor necrosis factor secretion	J:70088
	immune system phenotype	J:70088
	increased IgE level	J:120221
	increased IgG1 level	J:120221
	increased interferon-gamma secretion	J:120221
	increased interleukin-4 secretion	J:120221
	increased interleukin-5 secretion	J:120221
	increased interleukin-10 secretion	J:120221
	increased macrophage cell number	J:120221
	increased neutrophil cell number	J:120221
	increased tumor necrosis factor secretion	J:120221
Ccr4^tm1Pwr/Ccr4^tm1Pwr (B6.129P2-Ccr4^tm1Pwr)	increased CD8-positive, alpha-beta T cell number	J:95239
	increased length of allograft survival	J:95239
	increased NK T cell number	J:95239
Ccr5^tm1Blck/Ccr5^tm1Blck (B6.129P2-Ccr5^tm1Blck)	abnormal cellular extravasation	J:104744
	abnormal leukocyte adhesion	J:104744
	increased length of allograft survival	J:105072
Ccr5^tm1Brv/Ccr5^tm1Brv (either: (involves: 129S1/Sv * ICR) or (involves: 129S1/Sv * 129X1/SvJ * ICR))	abnormal cytokine secretion	J:46941
	decreased interleukin-1 beta secretion	J:46941
	decreased interleukin-6 secretion	J:46941
	decreased susceptibility to endotoxin shock	J:46941
	increased IgG1 level	J:46941
	increased interferon-gamma secretion	J:46941
	increased interleukin-4 secretion	J:46941
	increased susceptibility to bacterial infection	J:46941
	increased susceptibility to type IV hypersensitivity reaction	J:46941
Ccr5^tm1Kuz/Ccr5^tm1Kuz (involves: 129P2/OlaHsd * C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:110814
	abnormal CD8-positive, alpha beta T cell morphology	J:110814
	abnormal cytokine level	J:110814
	abnormal Kupffer cell morphology	J:152548
	abnormal NK T cell physiology	J:100869
	decreased microglial cell activation	J:153059
	decreased NK cell number	J:135308
	decreased susceptibility to induced colitis	J:110814
	decreased susceptibility to Retroviridae infection	J:132342
	impaired macrophage chemotaxis	J:153059, J:84243, J:64293
	increased NK T cell number	J:110814
	increased susceptibility to fungal infection	J:64293
Ccr5^tm1Kuz/Ccr5^tm1Kuz (B6.129P2-Ccr5^tm1Kuz)	bronchiolitis	J:162707
Ccr5^tm1Kuz/Ccr5^tm1Kuz (B6.129P2-Ccr5^tm1Kuz)	increased susceptibility to Coronaviridae infection	J:162707
Ccr5^tm1Kuz/Ccr5^tm1Kuz (involves: 129P2/OlaHsd)	decreased inflammatory response	J:227458
Ccr5^tm1Kuz/Ccr5^tm1Kuz Cxcr4^tm1Qma/Cxcr4^tm1Qma (involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6)	decreased susceptibility to Retroviridae infection	J:132342
Ccr5^tm1Sush/Ccr5^tm1Sush (B6.129P2-Ccr5^tm1Sush)	abnormal leukocyte physiology	J:94937
Ccr5^tm1Sush/Ccr5^tm1Sush (B6.129P2-Ccr5^tm1Sush)	decreased T cell proliferation	J:94937
Ccr6^tm1(EGFP)Irw/Ccr6^tm1(EGFP)Irw (involves: 129S6/SvEvTac * C57BL/6)	abnormal alpha-beta intraepithelial T cell morphology	J:85086
	abnormal B cell physiology	J:120122
	abnormal CD4-positive, alpha-beta intraepithelial T cell morphology	J:85086
	abnormal CD8 positive, alpha-beta intraepithelial T cell morphology	J:85086
	abnormal follicular dendritic cell physiology	J:113363
	abnormal gut-associated lymphoid tissue morphology	J:113363, J:120122
	abnormal Peyer's patch morphology	J:120122
	abnormal T cell physiology	J:85086
	decreased B cell number	J:120122
	decreased Peyer's patch number	J:120122
	impaired B cell migration	J:120122
	increased T cell proliferation	J:85086
Ccr6^tm1(EGFP)Irw/Ccr6^tm1(EGFP)Irw (B6.129S6-Ccr6^tm1(EGFP)Irw)	decreased interleukin-4 secretion	J:132012
	decreased interleukin-12 secretion	J:132012
	decreased susceptibility to bacterial infection	J:132012
	decreased tumor necrosis factor secretion	J:132012
	increased interferon-gamma secretion	J:132012
Ccr6^{tm1.1(KOMP)Vlcg}/Ccr6^{tm1.1(KOMP)Vlcg} (C57BL/6N-Ccr6^{tm1.1(KOMP)Vlcg}/Ucd)	abnormal spleen morphology	J:211773
Ccr6^tm1.1Jmf/Ccr6^tm1.1Jmf (B6.129-Ccr6^tm1.1Jmf)	abnormal CD4-positive, alpha-beta T cell physiology	J:152716
	abnormal dendritic cell physiology	J:152716
	abnormal interleukin secretion	J:152716
	decreased inflammatory response	J:152716
Ccr6^tm1Gma/Ccr6^tm1Gma (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:68191
	abnormal myeloid dendritic cell morphology	J:68191
	abnormal Peyer's patch follicle morphology	J:68191
	abnormal Peyer's patch morphology	J:68191
	decreased inflammatory response	J:68191
	decreased leukocyte cell number	J:68191
	increased leukocyte cell number	J:68191
Ccr6^tm1Gma/Ccr6^tm1Gma Tg(Rorc-EGFP)1Ebe/? (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal effector T cell morphology	J:137020
Ccr6^tm1Lira/Ccr6^tm1Lira (involves: 129)	abnormal follicular dendritic cell antigen presentation	J:113363
	abnormal Peyer's patch T cell area morphology	J:113363
	abnormal T cell physiology	J:123150
Ccr6^tm1Lira/Ccr6^tm1Lira (involves: 129 * C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:148286
	abnormal CD4-positive, alpha-beta T cell physiology	J:148286
	abnormal gut-associated lymphoid tissue morphology	J:76461
	abnormal intraepithelial T cell number	J:76461
	abnormal lymphocyte morphology	J:148286
	abnormal macrophage physiology	J:124358
	abnormal myeloid dendritic cell morphology	J:124358
	abnormal peritoneal macrophage morphology	J:124358
	abnormal Peyer's patch germinal center morphology	J:76461
	abnormal Peyer's patch morphology	J:76461
	decreased B cell number	J:148286
	decreased CD4-positive, alpha-beta T cell number	J:148286
	decreased CD8-positive, alpha-beta T cell number	J:148286
	decreased IgA level	J:76461
	decreased IgG3 level	J:76461
	decreased inflammatory response	J:124358
	decreased interleukin-10 secretion	J:124358
	decreased interleukin-12 secretion	J:124358
	decreased macrophage cytokine production	J:124358
	decreased macrophage nitric oxide production	J:124358
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:148286
	decreased tumor necrosis factor secretion	J:124358
	increased activated T cell number	J:76461
	increased B-1 B cell number	J:124358
	increased double-positive T cell number	J:76461
	increased IgM level	J:76461
	increased susceptibility to Riboviria infection	J:76461
	increased T cell number	J:76461
Ccr6^tm1Lira/Ccr6^tm1Lira (B6.129-Ccr6^tm1Lira)	decreased IgE level	J:71096
	decreased interleukin-5 secretion	J:71096
	decreased susceptibility to type I hypersensitivity reaction	J:71096
	impaired eosinophil recruitment	J:71096
Ccr7^m1Btlr/Ccr7⁺ (C57BL/6J-Ccr7^m1Btlr)	decreased macrophage cell number	J:221477
Ccr7^m1Btlr/Ccr7^m1Btlr (C57BL/6J-Ccr7^m1Btlr)	decreased macrophage cell number	J:221477
Ccr7^m1Btlr/Ccr7^m1Btlr (C57BL/6J-Ccr7^m1Btlr)	increased single-positive T cell number	J:221477
Ccr7^tm1Dgen/Ccr7^tm1Dgen (involves: 129P2/OlaHsd * C57BL/6)	chronic inflammation	J:101679
Ccr7^tm1Rfor/Ccr7^tm1Rfor (involves: 129P2/OlaHsd * BALB/c)	abnormal B cell activation	J:57976
	abnormal class switch recombination	J:57976
	abnormal dendritic cell physiology	J:57976
	abnormal humoral immune response	J:57976
	abnormal leukocyte migration	J:57976
	abnormal lymph node cortex morphology	J:57976
	abnormal lymph node germinal center morphology	J:57976
	abnormal lymph node T cell domain morphology	J:57976
	abnormal Peyer's patch T cell area morphology	J:57976
	abnormal spleen marginal sinus morphology	J:57976
	abnormal spleen periarteriolar lymphoid sheath morphology	J:57976
	abnormal spleen red pulp morphology	J:57976
	abnormal T cell physiology	J:57976
	decreased CD4-positive, alpha-beta T cell number	J:57976
	decreased dendritic cell number	J:57976
	decreased IgG3 level	J:57976
	decreased susceptibility to type IV hypersensitivity reaction	J:57976
	decreased T cell number	J:57976
	enlarged spleen	J:57976
	impaired B cell migration	J:57976
	increased CD4-positive, alpha-beta T cell number	J:57976
	increased IgE level	J:57976
	increased IgG1 level	J:57976
	increased IgG2a level	J:57976
	increased T cell number	J:57976
	small lymph nodes	J:57976
	small Peyer's patches	J:57976
Ccr7^tm1Rfor/Ccr7^tm1Rfor (involves: 129/Sv * 129P2/OlaHsd * C57BL/6)	abnormal dendritic cell physiology	J:134784
Ccr7^tm1Rfor/Ccr7^tm1Rfor (B6.129P2-Ccr7^tm1Rfor)	abnormal dendritic cell physiology	J:183989
	abnormal leukocyte migration	J:93960, J:110910
	abnormal thymus cortex morphology	J:93960
	immune system phenotype	J:93960
	increased inflammatory response	J:110910
	increased susceptibility to autoimmune disorder	J:110910
	lacrimal gland inflammation	J:110910
	parotid gland inflammation	J:110910
	salivary gland inflammation	J:110910
	small thymus medulla	J:93960
	submandibular gland inflammation	J:110910
Ccr7^tm1Rfor/Ccr7^tm1Rfor (B6.129P2(C)-Ccr7^tm1Rfor/J)	decreased susceptibility to bacterial infection	J:210086
Ccr7^tm1Rfor/Ccr7^tm1Rfor (involves: 129P2/OlaHsd)	abnormal dendritic cell chemotaxis	J:223508
	decreased CD11b-high dendritic cell number	J:223508
	decreased CD103-positive CD11b-low dendritic cell number	J:223508
Ccr7^tm1Rfor/Ccr7^tm1Rfor Tg(DO11.10)10Dlo/? (involves: 129P2/OlaHsd * BALB/c * C3H * C57BL/6)	abnormal leukocyte migration	J:123482
	abnormal regulatory T cell physiology	J:123482
Ccr8^tm1Lira/Ccr8^tm1Lira (involves: 129S/SvEv * C57BL/6)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:118417
Ccr9^tm1.1Mal/Ccr9^tm1.1Mal (involves: 129S2/SvPas * C57BL/6)	abnormal leukocyte cell number	J:72386
	abnormal T cell differentiation	J:72386
	decreased double-positive T cell number	J:72386
	decreased pro-B cell number	J:72386
	decreased T cell number	J:72386
	increased T cell number	J:72386
Ccr9^tm1.1Mal/Ccr9^tm1.1Mal (involves: 129S2/SvPas)	abnormal gamma-delta T cell number	J:136944
	abnormal mesenteric lymph node morphology	J:136944
	abnormal T cell subpopulation ratio	J:136944
	decreased gamma-delta intraepithelial T cell number	J:136944
Ccr9^tm1.1Mal/Ccr9^tm1.1Mal Tnf^tm2Gkl/Tnf⁺ (involves: 129S/SvEv * 129S2/SvPas * C57BL/6)	abnormal alpha-beta intraepithelial T cell morphology	J:136667
	abnormal T cell subpopulation ratio	J:136667
	decreased gamma-delta intraepithelial T cell number	J:136667
	intestinal inflammation	J:136667
Ccr9^tm1Ccb/Ccr9^tm1Ccb (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal T cell differentiation	J:94596
	decreased thymocyte number	J:94596
Ccr9^tm1Lov/Ccr9^tm1Lov (involves: 129)	abnormal gamma-delta intraepithelial T cell morphology	J:110846
	decreased CD8-positive, gamma-delta intraepithelial T cell number	J:110846
	decreased lymphocyte cell number	J:110846
	increased gamma-delta T cell number	J:110846
Ccr10^tm1.1Nax/Ccr10^tm1.1Nax (B6.129S4(Cg)-Ccr10^tm1.1Nax)	decreased gamma-delta intraepithelial T cell number	J:165323
Ccr10^tm1Cge/Ccr10^tm1Cge (C.129S4-Ccr10^tm1Cge)	abnormal leukocyte migration	J:140728
	abnormal plasma cell morphology	J:140728
	decreased IgA level	J:140728
Ccrl2^tm1Lex/Ccrl2^tm1Lex (involves: 129S/SvEvBrd * C57BL/6)	decreased susceptibility to type I hypersensitivity reaction	J:140110
Ccrl2^tm1Ssoz/Ccrl2^tm1Ssoz (B6.129-Ccrl2^tm1Ssoz)	abnormal dendritic cell chemotaxis	J:165873
	abnormal hypersensitivity reaction	J:165873
	abnormal T-helper 2 physiology	J:165873
	decreased interleukin-4 secretion	J:165873
	decreased interleukin-5 secretion	J:165873
	decreased interleukin-13 secretion	J:165873
	lymph node hypoplasia	J:165873
Cd1^tm1Gru/Cd1^tm1Gru (involves: 129S2/SvPas * BALB/c)	abnormal eosinophil cell number	J:84720
	absent NK T cells	J:47769
	decreased CD4-positive, alpha-beta T cell number	J:126220
	decreased interleukin-4 secretion	J:47769
	decreased susceptibility to infection induced morbidity/mortality	J:126220
	immune system phenotype	J:47769
	myocarditis	J:126220
Cd1d1^em1(IMPC)H/Cd1d1^em1(IMPC)H (C57BL/6NTac-Cd1d1^em1(IMPC)H/H)	increased basophil cell number	J:211773
Cd1d1^tm1.1Aben/Cd1d1^tm1.1Aben Lyz2^tm1(cre)Ifo/Lyz2⁺ (B6.Cg-Cd1d1^tm1.1Aben Lyz2^tm1(cre)Ifo)	decreased interferon-gamma secretion	J:183087
	decreased interleukin-4 secretion	J:183087
	immune system phenotype	J:183087
Cd1d1^tm1.1Aben/Cd1d1^tm1.1Aben Tg(Cd4-cre)1Cwi/0 (B6.Cg-Cd1d1^tm1.1Aben Tg(Cd4-cre)1Cwi)	decreased NK T cell number	J:183087
Cd1d1^tm1.1Aben/Cd1d1^tm1.1Aben Tg(Itgax-cre,-EGFP)4097Ach/0 (C57BL/6-Cd1d1^tm1.1Aben Tg(Itgax-cre,-EGFP)4097Ach)	decreased interferon-gamma secretion	J:183087
	decreased interleukin-4 secretion	J:183087
	immune system phenotype	J:183087
Cd1d1^tm1.1Boes/Cd1d1^tm1.1Boes (involves: C57BL/6)	abnormal dendritic cell antigen presentation	J:151699
	abnormal interleukin-4 secretion	J:151699
	abnormal NK T cell morphology	J:151699
	abnormal NK T cell physiology	J:151699
	decreased interleukin-2 secretion	J:151699
	decreased NK T cell number	J:151699
Cd1d1^tm1.1Boes/Cd1d1^tm1.1Boes Cd74^tm1Doi/Cd74^tm1Doi (involves: 129S2/SvPas * C57BL/6)	abnormal dendritic cell antigen presentation	J:151699
Cd1d1^tm1.2Aben/Cd1d1^tm1.2Aben (B6(C)-Cd1d1^tm1.2Aben/J)	abnormal CD4-positive T cell differentiation	J:177038
	abnormal T cell activation	J:177038
	increased susceptibility to bacterial infection	J:177038
	increased susceptibility to bacterial infection induced morbidity/mortality	J:177038
	lung inflammation	J:177038
Cd1d1^tm1Crw/Cd1d1^tm1Crw (involves: 129S4/SvJae * C57BL/6)	decreased NK T cell number	J:76976
Cd1d1^tm1Crw/Cd1d1^tm1Crw (B6.129S4-Cd1d1^tm1Crw)	decreased IgG level	J:99107
Cd1d1^tm1Crw/Cd1d1^tm1Crw (B6.129S4-Cd1d1^tm1Crw)	decreased susceptibility to induced arthritis	J:99107
Cd1d1^tm1Luc/Cd1d1^tm1Luc (B6.129S6-Cd1d1^tm1Luc)	autoimmune response	J:122245
Cd1d1^tm1Luc/Cd1d1^tm1Luc (B6.129S6-Cd1d1^tm1Luc)	decreased regulatory T cell number	J:122245
Cd1d1^tm1Luc/Cd1d1^tm1Luc (involves: 129S6/SvEvTac * C57BL/6)	arrested T cell differentiation	J:125679
	decreased acute inflammation	J:93915
	decreased interferon-gamma secretion	J:93915, J:39748
	decreased interleukin-4 secretion	J:39748
	decreased NK T cell number	J:39748
	decreased tumor necrosis factor secretion	J:93915
Cd1d1^tm1Luc/Cd1d1^tm1Luc (C.129S6-Cd1d1^tm1Luc)	decreased interleukin-4 secretion	J:121187
	glomerulonephritis	J:121187
	increased anti-double stranded DNA antibody level	J:121187
	increased anti-nuclear antigen antibody level	J:121187
	increased IgG3 level	J:121187
	kidney inflammation	J:121187
Cd1d1^tm1Luc/Cd1d1^tm1Luc Cx3cr1^tm1Litt/Cx3cr1^tm1Litt (B6.129-Cd1d1^tm1Luc Cx3cr1^tm1Litt)	decreased NK cell number	J:129712
	increased susceptibility to experimental autoimmune encephalomyelitis	J:129712
Cd1d1^tm2Aben/Del(3Cd1d2-Cd1d1)1Crw (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)	abnormal antigen presentation	J:174337
Cd1d1^tm2Aben/Cd1d1^tm2Aben (B6.129P2-Cd1d1^tm2Aben)	abnormal antigen presentation	J:174337
Cd1d1^tm2Aben/Cd1d1^tm2Aben (B6.129P2-Cd1d1^tm2Aben)	decreased NK T cell number	J:174337
Cd1d1^tm2Aben/Cd1d1^tm2Aben (involves: 129P2/OlaHsd * C57BL/6)	abnormal antigen presentation	J:174337
	decreased NK T cell number	J:174337
Cd2ap^em1Irgu/Cd2ap^em1Irgu (C57BL/6-Cd2ap^em1Irgu)	kidney inflammation	J:294238
Cd2ap^tm1Shaw/Cd2ap^tm1Shaw (involves: 129X1/SvJ)	decreased T cell proliferation	J:57971
	spleen atrophy	J:57971
	thymus atrophy	J:57971
Cd2bp2^tm1.1Tbh/Cd2bp2^tm1.1Tbh Tg(Mx1-cre)1Cgn/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * C57BL/6N * CBA/J)	impaired macrophage phagocytosis	J:283435
Cd3d^tm1Kap/Cd3d^tm1Kap (C57BL/6-Cd3d^tm1Kap)	arrested T cell differentiation	J:39925
	decreased CD4-positive, alpha-beta T cell number	J:39925
	decreased CD8-positive, alpha-beta T cell number	J:39925
Cd3e^m1Btlr/Cd3e^m1Btlr (C57BL/6J-Cd3e^m1Btlr)	abnormal thymus morphology	J:132486
	absent T cells	J:132486
	arrested T cell differentiation	J:132486
	increased T cell apoptosis	J:132486
	small thymus	J:132486
Cd3e^m1Btlr/Cd3e^m1Btlr (involves: C57BL/6J)	abnormal class switch recombination	J:185495
Cd3e^m2Btlr/Cd3e^m2Btlr (C57BL/6J-Cd3e^m2Btlr)	abnormal CD8-positive, alpha-beta T cell differentiation	J:274934
	abnormal T cell differentiation	J:274934
	decreased CD4-positive, alpha-beta T cell number	J:274934
	decreased CD8-positive, naive alpha-beta T cell number	J:274934
	increased CD8-positive, alpha-beta T cell number	J:274934
	increased central memory CD8 positive, alpha-beta T cell number	J:274934
Cd3e^tm1.1Geno/Cd3e^tm1.1Geno (involves: C57BL/6)	abnormal double-positive T cell morphology	J:192604
	abnormal T cell differentiation	J:192604
	abnormal T cell number	J:192604
	increased DN3 thymocyte number	J:192604
Cd3e^tm1.1Geno/Cd3e^tm1.1Geno Tg(TcraH-Y,TcrbH-Y)71Vbo/0 (involves: C57BL/6 * C57BL/6J * DBA/2J)	abnormal negative T cell selection	J:192604
	abnormal positive T cell selection	J:192604
	increased DN3 thymocyte number	J:192604
Cd3e^tm1.1Geno/Cd3e^tm1.1Geno Tg(TcrAND)53Hed/0 (involves: C57BL/6 * SJL)	abnormal CD4-positive T cell differentiation	J:192604
	abnormal positive T cell selection	J:192604
	increased DN3 thymocyte number	J:192604
Cd3e^tm1.1Geno/Cd3e^tm1.1Geno Tg(TcraTcrb)1100Mjb/0 (involves: C57BL/6)	abnormal positive T cell selection	J:192604
	abnormal T cell differentiation	J:192604
	abnormal thymus cell ratio	J:192604
	decreased double-positive T cell number	J:192604
	decreased T cell number	J:192604
	increased DN3 thymocyte number	J:192604
Cd3e^tm1.1Lov/Cd3e^tm1.1Lov (Not Specified)	abnormal T cell morphology	J:72144
	arrested T cell differentiation	J:72144
	decreased double-positive T cell number	J:72144
	increased double-negative T cell number	J:72144
Cd3e^tm1.1Lov/Cd3e^tm1.1Lov Trdc^tm1Mal/Trdc^tm1Mal (involves: C57BL/6)	abnormal double-negative T cell morphology	J:112658
Cd3e^tm1Cpt/Cd3e^tm1Cpt (involves: 129S4/SvJae * C57BL/6)	absent T cells	J:54756
	decreased double-positive T cell number	J:54756
	thymus hypoplasia	J:54756
Cd3e^tm1Cpt/Cd3e^tm1Cpt Tg(CD3E)26Cpt/0 (involves: 129S4/SvJae * C57BL/6 * CBA)	decreased double-positive T cell number	J:54756
	decreased T cell number	J:54756
	thymus hypoplasia	J:54756
Cd3e^tm1Lov/Cd3e^tm1Lov (involves: 129S1/Sv * 129X1/SvJ)	abnormal T cell morphology	J:72144
	arrested T cell differentiation	J:72144
	decreased double-positive T cell number	J:72144
	increased double-negative T cell number	J:72144
Cd3e^tm1Mal/Cd3e^tm1Mal (involves: C57BL/6)	absent CD4-positive, alpha-beta T cells	J:77098
	absent CD8-positive, alpha-beta T cells	J:77098
	arrested T cell differentiation	J:77098
Cd3e^tm1Mal/Cd3e^tm1Mal (C57BL/6-Cd3e^tm1Mal)	abnormal B cell morphology	J:81133
	abnormal double-negative T cell morphology	J:81133
	abnormal regulatory T cell physiology	J:125748
	absent T cells	J:131351
	arrested T cell differentiation	J:81133
Cd3e^tm1Mal/Cd3e^tm1Mal Lat^tm1.1Mal/Lat^tm1.1Mal (involves: 129S2/SvPas * C57BL/6)	absent CD4-positive, alpha-beta T cells	J:77098
	absent CD8-positive, alpha-beta T cells	J:77098
	arrested T cell differentiation	J:77098
	immune system phenotype	J:77098
Cd3e^tm1Mal/Cd3e^tm1Mal Nlrp1a^Neut1/Nlrp1a^Neut1 (involves: C57BL/6)	increased neutrophil cell number	J:191055
	increased susceptibility to infection induced morbidity/mortality	J:191055
	skin inflammation	J:191055
Cd3g^tm1.1Cage/Cd3g^tm1.1Cage (B6.129P2-Cd3g^tm1.1Cage)	abnormal response to infection	J:153813
	decreased CD8-positive, alpha-beta T cell number	J:153813
	decreased thymocyte number	J:153813
	increased T cell apoptosis	J:153813
	spleen hypoplasia	J:153813
Cd3g^tm1.1Cage/Cd3g^tm1.1Cage Tg(TcrLCMV)318Sdz/0 (involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * FVB/N)	abnormal response to infection	J:142387
	abnormal T cell physiology	J:142387
	immune system phenotype	J:142387
Cd3g^tm1Amk/Cd3g^tm1Amk (involves: 129P2/OlaHsd)	abnormal CD8-positive, alpha-beta T cell physiology	J:77504
	abnormal T cell activation	J:77504
	abnormal T cell differentiation	J:77504
	abnormal T cell physiology	J:77504
	abnormal T cell proliferation	J:77504
	decreased cytotoxic T cell cytolysis	J:77504
	decreased thymocyte number	J:114561
	lymph node hypoplasia	J:77504
	thymus hypoplasia	J:77504
Cd3g^tm1Amk/Cd3g^tm1Amk Tg(Igh-Pim1)1Brn/0 (involves: 129P2/OlaHsd * C57BL/6LiA * CBA)	decreased thymocyte number	J:114561
Cd3g^tm2Amk/Cd3g^tm2Amk (involves: 129P2/OlaHsd * FVB)	immune system phenotype	J:77504
Cd4^del/Cd4^del (C57BR/cdJ-Cd4^del)	abnormal immune system organ morphology	J:46692
	abnormal lymph node T cell domain morphology	J:46692
	abnormal spleen morphology	J:46692
	absent CD4-positive, alpha-beta T cells	J:46692
	decreased IgG level	J:46692
	decreased IgM level	J:46692
	decreased immunoglobulin level	J:46692
	increased CD8-positive, alpha-beta T cell number	J:46692
Cd4^em1Litt/Cd4^em1Litt (involves: C57BL/6J)	immune system phenotype	J:333574
Cd4^em1Litt/Cd4^em1Litt Rr386^em1Pdi/Rr386^em1Pdi (involves: C57BL/6J)	abnormal lymphocyte activation involved in immune response	J:333574
	decreased T helper 1 cell number	J:333574
	immune system phenotype	J:333574
Cd4^m1Btlr/Cd4^m1Btlr (C57BL/6J-Cd4^m1Btlr)	absent CD4-positive, alpha-beta T cells	J:212900
Cd4^m1Btlr/Cd4^m1Btlr (C57BL/6J-Cd4^m1Btlr)	impaired humoral immune response	J:212900
Cd4^maat/Cd4^maat (C57BL/6JAnu-Cd4^maat/Apb)	abnormal CD4-positive, alpha beta T cell morphology	J:104190
	abnormal double-positive T cell morphology	J:104190
	decreased CD4-positive, alpha-beta T cell number	J:104190
	increased CD8-positive, alpha-beta T cell number	J:104190
Cd4^sesh/Cd4^sesh (C57BL/6JAnu-Cd4^sesh/AnuApb)	abnormal CD4-positive, alpha beta T cell morphology	J:104190
	abnormal double-positive T cell morphology	J:104190
	decreased T cell number	J:104190
Cd4^thth/Cd4^thth (C57BL/6JSfdAnu-Cd4^thth)	absent CD4-positive, alpha-beta T cells	J:104190
Cd4^{tm1(cre/ERT2)Thbu}/Cd4⁺ Gfm1^{tm1c(EUCOMM)Wtsi}/Gfm1^{tm1c(EUCOMM)Wtsi} (involves: C57BL/6 * C57BL/6N * SJL)	abnormal T-helper 17 cell differentiation	J:302272
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:302272
	increased CD8-positive, alpha-beta T cell number	J:302272
	increased single-positive T cell number	J:302272
Cd4^{tm1(cre/ERT2)Thbu}/Cd4⁺ Tgfbr2^tm1Karl/Tgfbr2^tm1Karl (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	immune system phenotype	J:204579
	increased memory T cell number	J:204579
	increased regulatory T cell number	J:204579
Cd4^tm1Doi/Cd4^tm1Doi Lag3^tm1Doi/Lag3^tm1Doi (involves: 129 * C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:33272
	increased double-negative T cell number	J:33272
Cd4^tm1Doi/Cd4^tm1Litt Lag3^tm1Doi/Lag3⁺ (involves: 129 * C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:33272
	increased double-negative T cell number	J:33272
Cd4^tm1Jrp/Cd4^tm1Jrp (either: B6.129S2-Cd4^tm1Jrp or B10.Cg-Cd4^tm1Jrp)	abnormal T cell differentiation	J:45168
	decreased CD4-positive, alpha-beta T cell number	J:45168
	decreased double-positive T cell number	J:45168
	increased CD8-positive, alpha-beta T cell number	J:45168
Cd4^tm1Jrp/Cd4^tm1Jrp Tg(TcrAND)53Hed/0 (either: (involves: 129S2/SvPas * C57BL/6 * SJL) or (involves: 129S2/SvPas * C57BL/6 * C57BL/10 * SJL))	abnormal T cell number	J:45168
	thymus hyperplasia	J:45168
Cd4^tm1Knw/Cd4^tm1Knw (B6.129S-Cd4^tm1Knw/J)	decreased CD4-positive, alpha-beta T cell number	J:87828
	increased CD8-positive, alpha-beta T cell number	J:87828
	increased susceptibility to parasitic infection	J:87828
Cd4^tm1Knw/Cd4^tm1Knw (NOD.Cg-Cd4^tm1Knw)	decreased susceptibility to autoimmune diabetes	J:93553
Cd4^tm1Knw/Cd4^tm1Knw Tg(TcraAI4)1Dvs/0 Tg(TcrbAI4)1Dvs/0 (NOD.Cg-Cd4^tm1Knw Tg(TcraAI4)1Dvs Tg(TcrbAI4)1Dvs)	increased susceptibility to autoimmune diabetes	J:93553
Cd4^tm1Litt/Cd4^tm1Litt (involves: 129S2/SvPas)	abnormal CD4-positive, alpha-beta T cell physiology	J:50435
	absent CD4-positive, alpha-beta T cells	J:50435
	decreased CD4-positive, alpha-beta T cell number	J:158962
	decreased T cell proliferation	J:50435
	increased CD8-positive, alpha-beta T cell number	J:158962, J:50435
Cd4^tm1Litt/Cd4^tm1Litt Foxp3^sf Otc^spf/Y (involves: 129/Rl * 129S2/SvPas)	abnormal CD8-positive, alpha beta T cell morphology	J:20865
	abnormal cytokine secretion	J:20865
	abnormal immune system organ morphology	J:20865
	enlarged lymph nodes	J:20865
	increased IgG level	J:20865
	increased IgM level	J:20865
	increased interleukin-4 secretion	J:20865
	increased interleukin-6 secretion	J:20865
	increased tumor necrosis factor secretion	J:20865
Cd4^tm1Litt/Cd4^tm1Litt Tg(Cd4-CD4)2362Litt/0 (involves: 129S2/SvPas * C57BL/6 * SJL)	immune system phenotype	J:50435
Cd4^tm1Litt/Cd4^tm1Nik Tg(Lck-cre)3778Nik/0 (involves: 129S2/SvPas * 129X1/SvJ * C57BL/6 * DBA/2)	abnormal CD4-positive, alpha-beta T cell physiology	J:73479
	abnormal interleukin-4 secretion	J:73479
	abnormal T-helper 2 physiology	J:73479
	decreased T cell proliferation	J:73479
Cd4^tm1Litt/Cd4^tm1Nik Tg(Lck-cre)3785Nik/0 (involves: 129S2/SvPas * 129X1/SvJ * C57BL/6 * DBA/2)	abnormal CD4-positive, alpha-beta T cell physiology	J:73479
	decreased CD4-positive, alpha-beta T cell number	J:73479
	increased CD8-positive, alpha-beta T cell number	J:73479
	increased T cell apoptosis	J:73479
	increased T cell proliferation	J:73479
Cd4^tm1Litt/Cd4^tm1Nik Tg(Lck-icre)3779Nik/0 (involves: 129S2/SvPas * 129X1/SvJ * C57BL/6 * DBA/2)	abnormal CD4-positive, alpha-beta T cell physiology	J:73479
	decreased T cell proliferation	J:73479
Cd4^tm1Mak/Cd4^tm1Mak (involves: 129S2/SvPas * C57BL/6 * DBA/2)	abnormal CD4-positive, alpha-beta T cell physiology	J:68957
	increased CD8-positive, alpha-beta T cell number	J:68957
	increased susceptibility to Picornaviridae infection	J:92227
Cd4^tm1Mak/Cd4^tm1Mak (PL.129S2(B6)-Cd4^tm1Mak/Rdgz)	brain inflammation	J:92227
Cd4^tm1Mak/Cd4^tm1Mak (PL.129S2(B6)-Cd4^tm1Mak/Rdgz)	increased susceptibility to Picornaviridae infection	J:92227
Cd4^tm1Mak/Cd4^tm1Mak (SJL.129S2(B6)-Cd4^tm1Mak/Rdgz)	brain inflammation	J:92227
Cd4^tm1Mak/Cd4^tm1Mak (SJL.129S2(B6)-Cd4^tm1Mak/Rdgz)	increased susceptibility to Picornaviridae infection	J:92227
Cd4^tm1Mak/Cd4^tm1Mak (involves: 129S2/SvPas)	immune system phenotype	J:110749
Cd4^tm1Mak/Cd4^tm1Mak (B6.129S2-Cd4^tm1Mak/J)	absent plasma cells	J:133047
Cd4^tm1Mak/Cd4^tm1Mak (B6.129S2-Cd4^tm1Mak/J)	immune system phenotype	J:133047
Cd4^tm1Mak/Cd4^tm1Mak Cd8a^tm1Mak/Cd8a^tm1Mak (involves: 129S2/SvPas * C57BL/6 * DBA/2)	abnormal double-negative T cell morphology	J:12572
	abnormal gamma-delta T cell number	J:12572
	abnormal T cell differentiation	J:12572
	abnormal T cell number	J:12572
	decreased cytotoxic T cell cytolysis	J:12572
	decreased double-positive T cell number	J:12572
	increased length of allograft survival	J:12572
	small thymus medulla	J:12572
Cd4^tm1Mak/Cd4^tm1Mak Cd8a^tm1Mak/Cd8a^tm1Mak (involves: 129S2/SvPas)	increased susceptibility to viral infection	J:110749
Cd4^tm1Mak/Cd4^tm1Mak Igh-J^{tm2(3H9-VDJ)Mwg}/Igh-J⁺ (B6.Cg-Cd4^tm1Mak Igh-J^{tm2(3H9-VDJ)Mwg})	increased anti-double stranded DNA antibody level	J:142389
Cd4^tm1Mak/Cd4^tm1Mak Tnf^tm2Gkl/Tnf⁺ (involves: 129S/SvEv * 129S2/SvPas * C57BL/6J)	small intestinal inflammation	J:108572
Cd4^tm1Nik/Cd4^tm1Nik Tnfrsf4^tm2(cre)Nik/Tnfrsf4⁺ (involves: 129X1/SvJ)	abnormal regulatory T cell physiology	J:152472
Cd4ts1^BALB/c/? (involves: BALB/c * C3H * C57BL/6 * DBA/2)	abnormal CD4-positive, alpha beta T cell morphology	J:83220
Cd4ts2^DBA/2/? (involves: BALB/c * C3H * C57BL/6 * DBA/2)	abnormal CD4-positive, alpha beta T cell morphology	J:83220
Cd4ts3^BALB/c/? (involves: BALB/c * C3H * C57BL/6 * DBA/2)	abnormal CD4-positive, alpha beta T cell morphology	J:83220
Cd4ts4^C3H/? (involves: BALB/c * C3H * C57BL/6 * DBA/2)	abnormal CD4-positive, alpha beta T cell morphology	J:83220
Cd4ts5^BALB/c/? (involves: BALB/c * C3H * C57BL/6 * DBA/2)	abnormal CD4-positive, alpha beta T cell morphology	J:83220
Cd4ts5^C57BL/6/? (involves: BALB/c * C3H * C57BL/6 * DBA/2)	increased memory T cell number	J:83220
Cd4ts6^DBA/2/? (involves: BALB/c * C3H * C57BL/6 * DBA/2)	abnormal CD4-positive, alpha beta T cell morphology	J:83220
Cd4vts1^DBA/2/? (involves: BALB/c * C3H * C57BL/6 * DBA/2)	abnormal CD4-positive, alpha beta T cell morphology	J:83220
Cd5^{tm1.1(KOMP)Mbp}/Cd5^{tm1.1(KOMP)Mbp} (C57BL/6N-Cd5^{tm1.1(KOMP)Mbp}/Ucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	increased spleen weight	J:211773
Cd5^tm1.1Chra/Cd5^tm1.1Chra (involves: C57BL/6 * FVB/N)	abnormal T cell anergy	J:189919
	abnormal T cell physiology	J:189919
	decreased B cell number	J:189919
	decreased CD4-positive, alpha-beta T cell number	J:189919
	decreased double-positive T cell number	J:189919
	decreased follicular B cell number	J:189919
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:189919
	decreased T cell proliferation	J:189919
	decreased T-helper 17 cell number	J:189919
	increased double-negative T cell number	J:189919
	increased T cell proliferation	J:189919
Cd5^tm1.1Chra/Cd5^tm1.1Chra Tg(Tcra2D2,Tcrb2D2)1Kuch/0 (involves: C57BL/6 * FVB/N)	decreased interferon-gamma secretion	J:189919
	decreased interleukin-2 secretion	J:189919
	decreased T cell proliferation	J:189919
	decreased T helper 1 cell number	J:189919
	increased interferon-gamma secretion	J:189919
	increased interleukin-6 secretion	J:189919
	increased interleukin-17 secretion	J:189919
Cd5^tm1Cgn/Cd5^tm1Cgn (B6.129P2-Cd5^tm1Cgn)	abnormal T cell anergy	J:189919
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:189919
	increased regulatory T cell number	J:189919
	increased T cell proliferation	J:189919
Cd5l^tm1Nto/Cd5l^tm1Nto (involves: 129P2/OlaHsd * C57BL/6)	abnormal double-positive T cell morphology	J:52195
	decreased thymocyte number	J:52195
	immune system phenotype	J:52195
	increased susceptibility to bacterial infection	J:82352
Cd6^tm1Linf/Cd6^tm1Linf (D1.Cg-Cd6^tm1Linf)	abnormal B cell physiology	J:238478
	decreased B cell proliferation	J:238478
	decreased B-1 B cell number	J:238478
	decreased B-1a cell number	J:238478
	decreased IgM level	J:238478
	decreased interleukin-6 secretion	J:238478
	increased B-1a cell number	J:238478
	increased B-1b cell number	J:238478
Cd7^tm1Bfh/Cd7^tm1Bfh (involves: 129 * C57BL/6)	immune system phenotype	J:48758
	increased double-positive T cell number	J:48758
	increased thymocyte number	J:48758
Cd7^tm1Bfh/Cd7^tm1Bfh (B6.129-Cd7^tm1Bfh)	decreased cytotoxic T cell cytolysis	J:48758
	decreased interferon-gamma secretion	J:48758
	immune system phenotype	J:48758
	increased double-positive T cell number	J:48758
	increased thymocyte number	J:48758
Cd7^tm1Fabo/Cd7^tm1Fabo (involves: 129S4/SvJae * C57BL/6)	immune system phenotype	J:45026
Cd8a^m1Btlr/Cd8a^m1Btlr (C57BL/6J-Cd8a^m1Btlr)	abnormal CD4-positive T cell differentiation	J:221492
	abnormal CD8-positive, alpha-beta T cell differentiation	J:221492
	increased susceptibility to Herpesvirales infection	J:221492
Cd8a^m2Btlr/Cd8a^m2Btlr (C57BL/6J-Cd8a^m2Btlr)	abnormal CD8-positive, alpha-beta T cell physiology	J:236677
Cd8a^m2Btlr/Cd8a^m2Btlr (C57BL/6J-Cd8a^m2Btlr)	increased CD8-positive, alpha-beta memory T cell proliferation	J:236677
Cd8a^{tm1.1(cre)Koni}/Cd8a^{tm1.1(cre)Koni} (involves: C57BL/6J * C57BL/6NHsd * SJL)	decreased CD8-positive, alpha-beta T cell number	J:177182
Cd8a^tm1.1Kio/Cd8a^tm1.1Kio (involves: 129S4/SvJae * C57BL/10 * CBA/Ca)	abnormal CD4-positive T cell differentiation	J:76799
Cd8a^tm1.1Litt/Cd8a^tm1.1Litt (either: (involves: 129P2/OlaHsd * AKR) or (involves: 129P2/OlaHsd * C57BL/6))	abnormal CD8-positive, alpha beta T cell morphology	J:50624
Cd8a^tm1.1Welm/Cd8a^tm1.1Welm (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:113136
Cd8a^tm1Asin/Cd8a^tm1Asin (involves: 129S1/Sv * 129X1/SvJ * FVB/N)	abnormal double-positive T cell morphology	J:126026
Cd8a^tm1Asin/Cd8a^tm1Asin Cd8b1^tm1Litt/Cd8b1^tm1Litt H2-Ab1^b-tm1Gru/H2-Ab1^b-tm1Gru (involves: 129 * FVB/N)	decreased CD4-positive, alpha-beta T cell number	J:126026
	increased CD8-positive, alpha-beta T cell number	J:126026
Cd8a^tm1Asin/Cd8a^tm1Asin Rag2^tm1Fwa/Rag2^tm1Fwa Tg(TcraH-Y,TcrbH-Y)71Vbo/? (involves: 129S/SvEv * 129S1/Sv * 129X1/SvJ * C57BL/6J * DBA/2J)	abnormal CD8-positive, alpha beta T cell morphology	J:125259
Cd8a^tm1Asin/Cd8a^tm1Asin Tg(CD2-TcraF5,CD2-TcrbF5)1Kio/? (involves: 129S1/Sv * 129X1/SvJ * C57BL/10 * FVB/N)	abnormal positive T cell selection	J:126026
	decreased CD4-positive, alpha-beta T cell number	J:126026
	increased CD8-positive, alpha-beta T cell number	J:126026
Cd8a^tm1Asin/Cd8a^tm1Mak (involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * FVB/N)	abnormal positive T cell selection	J:126026
	abnormal T cell subpopulation ratio	J:126026
	increased CD8-positive, alpha-beta T cell number	J:126026
Cd8a^tm1Mak/Cd8a^tm1Mak (involves: 129S2/SvPas * C57BL/6 * DBA/2)	abnormal cytotoxic T cell physiology	J:68956
	absent CD8-positive, alpha-beta T cells	J:68956
	increased susceptibility to Picornaviridae infection	J:92227
Cd8a^tm1Mak/Cd8a^tm1Mak (PL.129S2(B6)-Cd8a^tm1Mak/Rdgz)	increased susceptibility to Picornaviridae infection	J:92227
Cd8a^tm1Mak/Cd8a^tm1Mak (SJL.129S2(B6)-Cd8a^tm1Mak/Rdgz)	increased susceptibility to Picornaviridae infection	J:92227
Cd8a^tm1Mak/Cd8a^tm1Mak (B6.129S2-Cd8a^tm1Mak)	abnormal response to transplant	J:91742
Cd8a^tm1Mak/Cd8a^tm1Mak (involves: 129S2/SvPas)	immune system phenotype	J:110749
Cd8a^tm1Mak/Cd8a^tm1Mak Il15^tm1Imx/Il15^tm1Imx X/Yaa (BXSB.Cg-Cd8a^tm1Mak Il15^tm1Imx/Dcr)	abnormal spleen B cell follicle morphology	J:179430
	increased anti-nuclear antigen antibody level	J:179430
	increased IgG1 level	J:179430
	increased IgG2a level	J:179430
	increased IgG2b level	J:179430
	increased monocyte cell number	J:179430
	increased splenocyte number	J:179430
	increased susceptibility to systemic lupus erythematosus	J:179430
Cd8a^tm1Mak/Cd8a^tm1Mak X/Yaa (BXSB.129S2(B6)-Cd8a^tm1Mak/4Dcr)	increased susceptibility to systemic lupus erythematosus	J:179430
Cd8a^tm1Mak/Cd8a^tm1Mak Zbtb7b^hd/Zbtb7b^hd (involves: B6.129S2-Cd8a^tm1Mak * B6.Cg-Thpok^hd)	absent CD4-positive, alpha-beta T cells	J:95867
Cd8b1^M1Btlr/Cd8b1⁺ (C57BL/6J-Cd8b1^M1Btlr)	decreased CD8-positive, naive alpha-beta T cell number	J:255009
Cd8b1^M1Btlr/Cd8b1⁺ (C57BL/6J-Cd8b1^M1Btlr)	increased CD4-positive, alpha-beta T cell number	J:255009
Cd8b1^M1Btlr/Cd8b1^M1Btlr (C57BL/6J-Cd8b1^M1Btlr)	decreased CD8-positive, naive alpha-beta T cell number	J:255009
	enhanced humoral immune response	J:255009
	increased CD4-positive, alpha-beta T cell number	J:255009
	increased IgG level	J:255009
Cd8b1^m2Btlr/Cd8b1^m2Btlr (C57BL/6J-Cd8b1^m2Btlr)	abnormal B cell differentiation	J:274761
	abnormal CD8-positive, alpha-beta T cell differentiation	J:274761
	decreased CD8-positive, alpha-beta T cell number	J:274761
	decreased CD8-positive, naive alpha-beta T cell number	J:274761
	decreased T cell number	J:274761
	increased CD4-positive, alpha-beta T cell number	J:274761
	increased central memory CD8 positive, alpha-beta T cell number	J:274761
	increased effector memory CD8-positive, alpha-beta T cell number	J:274761
Cd8b1^tm1Litt/Cd8b1⁺ Tg(Cd8b1)46Erob/0 (involves: 129S4/SvJae * C57BL/6 * CBA)	abnormal T cell subpopulation ratio	J:110916
	decreased T cell number	J:110916
	decreased thymocyte number	J:110916
Cd8b1^tm1Litt/Cd8b1⁺ Tg(TcraH-Y,TcrbH-Y)71Vbo/0 (involves: 129S4/SvJae * C57BL/6J * DBA/2)	decreased double-positive T cell number	J:112551
Cd8b1^tm1Litt/Cd8b1^tm1Litt (involves: 129S4/SvJae * C57BL/6J)	abnormal cytotoxic T cell physiology	J:112551
	abnormal T cell subpopulation ratio	J:110916
	decreased CD8-positive, alpha-beta T cell number	J:112551, J:110916
	decreased thymocyte number	J:110916
Cd8b1^tm1Litt/Cd8b1^tm1Litt Tg(TcraH-Y,TcrbH-Y)71Vbo/0 (involves: 129S4/SvJae * C57BL/6J * DBA/2)	abnormal lymph node cell ratio	J:112551
	abnormal negative T cell selection	J:112551
	abnormal positive T cell selection	J:112551
	decreased CD8-positive, alpha-beta T cell number	J:112551
	increased CD4-positive, alpha-beta T cell number	J:112551
Cd8b1^tm1Wpfl/Cd8b1^tm1Wpfl (involves: 129S2/SvPas)	abnormal CD8-positive, alpha beta T cell morphology	J:19928
	abnormal CD8-positive, alpha-beta T cell differentiation	J:19928
	abnormal T cell subpopulation ratio	J:19928
	decreased CD8-positive, alpha-beta T cell number	J:19928
	decreased thymocyte number	J:19928
	immune system phenotype	J:19928
Cd8mts1^DBA/2/? (involves: BALB/c * C3H * C57BL/6 * DBA/2)	increased memory T cell number	J:83220
Cd8mts2^BALB/c/? (involves: BALB/c * C3H * C57BL/6 * DBA/2)	increased memory T cell number	J:83220
Cd8mts3^C57BL/6/? (involves: BALB/c * C3H * C57BL/6 * DBA/2)	increased memory T cell number	J:83220
Cd8mts4^DBA/2/? (involves: BALB/c * C3H * C57BL/6 * DBA/2)	increased memory T cell number	J:83220
Cd8mts5^BALB/c/? (involves: BALB/c * C3H * C57BL/6 * DBA/2)	abnormal CD4-positive, alpha beta T cell morphology	J:83220
Cd8mts5^C57BL/6/? (involves: BALB/c * C3H * C57BL/6 * DBA/2)	increased memory T cell number	J:83220
Cd8mts6^C3H/? (involves: BALB/c * C3H * C57BL/6 * DBA/2)	increased CD8-positive, alpha-beta T cell number	J:83220
Cd8ts1^DBA/2/? (involves: BALB/c * C3H * C57BL/6 * DBA/2)	increased CD8-positive, alpha-beta T cell number	J:83220
Cd8ts2^C57BL/6/? (involves: BALB/c * C3H * C57BL/6 * DBA/2)	increased CD8-positive, alpha-beta T cell number	J:83220
Cd8ts3^C3H/? (involves: BALB/c * C3H * C57BL/6 * DBA/2)	increased CD8-positive, alpha-beta T cell number	J:83220
Cd8ts3^DBA/2/? (involves: BALB/c * C3H * C57BL/6 * DBA/2)	abnormal CD4-positive, alpha beta T cell morphology	J:83220
Cd14^hdl/Cd14^hdl (C57BL/6-Cd14^hdl)	abnormal interferon secretion	J:98908
	decreased susceptibility to endotoxin shock	J:98908
	decreased tumor necrosis factor secretion	J:98908
	increased susceptibility to Riboviria infection	J:98908
Cd14^tm1Frm/Cd14⁺ (involves: 129S4/SvJae * C57BL/6J)	abnormal cytokine secretion	J:65107
	decreased interleukin-6 secretion	J:65107
	decreased tumor necrosis factor secretion	J:65107
Cd14^tm1Frm/Cd14^tm1Frm (involves: 129S4/SvJae * C57BL/6J)	abnormal cytokine secretion	J:65107
	decreased interleukin-6 secretion	J:65107
	decreased tumor necrosis factor secretion	J:65107
Cd14^tm1Frm/Cd14^tm1Frm (involves: 129S4/SvJae)	abnormal interferon secretion	J:98908
	decreased susceptibility to endotoxin shock	J:98908
	increased susceptibility to Riboviria infection	J:98908
Cd14^tm1Frm/Cd14^tm1Frm (B6.129S4-Cd14^tm1Frm)	abnormal cytokine level	J:96680
	abnormal interleukin level	J:96680
	abnormal tumor necrosis factor level	J:96680
Cd14^tm1Smg/Cd14^tm1Smg (involves: 129S1/Sv * C57BL/6)	decreased circulating interleukin-6 level	J:32729
	decreased circulating tumor necrosis factor level	J:32729
	decreased interleukin-6 secretion	J:32729
	decreased susceptibility to bacterial infection	J:32729
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:32729
	decreased susceptibility to endotoxin shock	J:32729
	decreased tumor necrosis factor secretion	J:32729
Cd14^tm1Smg/Cd14^tm1Smg (C.129S1-CD14^tm1Smg)	abnormal macrophage physiology	J:116691
	abnormal neutrophil physiology	J:127072
	decreased susceptibility to bacterial infection	J:127072
	decreased tumor necrosis factor secretion	J:116691
Cd14^tm1Smg/Cd14^tm1Smg (B6.129S1-CD14^tm1Smg)	decreased susceptibility to bacterial infection	J:127072
Cd14^tm1Smg/Cd14^tm1Smg (involves: 129S1/Sv)	abnormal tumor necrosis factor level	J:103464
Cd14^tm1Smg/Cd14^tm1Smg Tlr4^Lps-d/Tlr4^Lps-d (C3.129S1-CD14^tm1Smg)	abnormal macrophage physiology	J:116691
	decreased tumor necrosis factor secretion	J:116691
Cd19^em2(IMPC)Ics/Cd19^em2(IMPC)Ics (C57BL/6N-Cd19^em2(IMPC)Ics/Ics)	decreased lymphocyte cell number	J:211773
	increased monocyte cell number	J:211773
Cd19^tm1(cre)Cgn/? Gt(ROSA)26Sor^{tm1(HBEGF)Awai}/Gt(ROSA)26Sor^{tm1(HBEGF)Awai} (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell morphology	J:131076
	abnormal lymph node cell ratio	J:131076
	abnormal lymphocyte cell number	J:131076
	abnormal lymphocyte morphology	J:131076
	abnormal splenic cell ratio	J:131076
	absent immature B cells	J:131076
	absent mature B cells	J:131076
Cd19^tm1(cre)Cgn/Cd19⁺ Cd1d1^tm1.1Aben/Cd1d1^tm1.1Aben (B6.Cg-Cd1d1^tm1.1Aben Cd19^tm1(cre)Cgn)	immune system phenotype	J:183087
Cd19^tm1(cre)Cgn/Cd19⁺ Ctnnbl1^tm1.1Crad/Ctnnbl1^tm1.1Crad (involves: 129P2/OlaHsd * C57BL/6 * SJL)	decreased B cell proliferation	J:232010
Cd19^tm1(cre)Cgn/Cd19⁺ Cxcr4^tm1Tng/Cxcr4^tm2Tng (involves: 129P2/OlaHsd * C57BL/6)	decreased plasma cell number	J:109147
Cd19^tm1(cre)Cgn/Cd19⁺ Derl2^tm1.1Hpl/Derl2^tm1.1Hpl (involves: 129P2/OlaHsd)	immune system phenotype	J:170650
Cd19^tm1(cre)Cgn/Cd19⁺ Ell2^tm1.1Cmil/Ell2^tm1.1Cmil (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)	decreased IgA level	J:234692
	decreased IgG1 level	J:234692
	decreased IgM level	J:234692
	decreased immunoglobulin level	J:234692
	decreased mature B cell number	J:234692
	decreased plasma cell number	J:234692
	decreased transitional stage T1 B cell number	J:234692
	decreased transitional stage T2 B cell number	J:234692
	decreased transitional stage T3 B cell number	J:234692
	impaired humoral immune response	J:234692
	increased follicular B cell number	J:234692
	increased immature B cell number	J:234692
	increased pre-B cell number	J:234692
	increased pro-B cell number	J:234692
Cd19^tm1(cre)Cgn/Cd19⁺ Ell2^tm2.1Cmil/Ell2^tm2.1Cmil (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)	decreased IgA level	J:234692
	decreased IgG1 level	J:234692
	decreased IgM level	J:234692
	decreased immunoglobulin level	J:234692
	decreased mature B cell number	J:234692
Cd19^tm1(cre)Cgn/Cd19⁺ Ep300^tm2Reck/Ep300⁺ (involves: 129/Sv * 129P2/OlaHsd * C57BL/6)	abnormal adaptive immunity	J:147840
	abnormal B cell differentiation	J:147840
	abnormal humoral immune response	J:147840
	abnormal spleen marginal zone macrophage morphology	J:147840
	abnormal transitional stage B cell morphology	J:147840
	arteritis	J:147840
	decreased B cell proliferation	J:147840
	decreased marginal zone B cell number	J:147840
	enlarged lymph nodes	J:147840
	enlarged spleen	J:147840
	glomerulonephritis	J:147840
	increased activated T cell number	J:147840
	increased anti-double stranded DNA antibody level	J:147840
	increased B cell apoptosis	J:147840
	increased B cell number	J:147840
	increased IgG2b level	J:147840
	increased immunoglobulin level	J:147840
	increased spleen weight	J:147840
	increased susceptibility to systemic lupus erythematosus	J:147840
	intermingled spleen red and white pulp	J:147840
	kidney inflammation	J:147840
Cd19^tm1(cre)Cgn/Cd19⁺ Ep300^tm2Reck/Ep300⁺ (involves: 129/Sv * 129P2/OlaHsd * FVB/N)	increased susceptibility to systemic lupus erythematosus	J:147840
Cd19^tm1(cre)Cgn/Cd19⁺ Fas^lpr/Fas^tm1Cgn (involves: 129P2/OlaHsd * C57BL/6 * MRL)	enlarged lymph nodes	J:114948
	enlarged spleen	J:114948
Cd19^tm1(cre)Cgn/Cd19⁺ Fas^lpr/Fas^tm1Cgn Tg(Cd4-cre)1Cwi/0 (involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * MRL)	enlarged lymph nodes	J:114948
	enlarged spleen	J:114948
	increased double-negative T cell number	J:114948
Cd19^tm1(cre)Cgn/Cd19⁺ Fas^tm1Ach/Fas^tm1Ach (involves: 129P2/OlaHsd * BALB/c)	enlarged spleen	J:123556
	increased anti-nuclear antigen antibody level	J:123556
	increased immunoglobulin level	J:123556
	increased lymphocyte cell number	J:123556
Cd19^tm1(cre)Cgn/Cd19⁺ Fas^tm1Cgn/Fas^tm1Cgn (B6.Cg-Cd19^tm1(cre)Cgn Fas^tm1Cgn)	increased anti-single stranded DNA antibody level	J:114948
Cd19^tm1(cre)Cgn/Cd19⁺ Gna12^tm1Citb/Gna12^tm1Citb Gna13^tm2.1Soff/Gna13^tm2.1Soff (involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6N)	abnormal B cell physiology	J:117663
	decreased marginal zone B cell number	J:117663
Cd19^tm1(cre)Cgn/Cd19⁺ Gt(ROSA)26Sor^{tm1(CTNNB1)Nerl}/Gt(ROSA)26Sor^{tm1(CTNNB1)Nerl} (involves: 129P2/OlaHsd * BALB/c)	immune system phenotype	J:112660
Cd19^tm1(cre)Cgn/Cd19⁺ Gt(ROSA)26Sor^tm1(DTA)Riet/Gt(ROSA)26Sor⁺ (involves: 129P2/OlaHsd)	decreased B cell number	J:92789
Cd19^tm1(cre)Cgn/Cd19⁺ Gt(ROSA)26Sor^{tm1(ITK/SYK)Jrld}/Gt(ROSA)26Sor⁺ (involves: 129P2/OlaHsd)	abnormal T cell activation	J:160931
	enlarged spleen	J:160931
	increased T cell derived lymphoma incidence	J:160931
	increased T cell proliferation	J:160931
Cd19^tm1(cre)Cgn/Cd19⁺ Gt(ROSA)26Sor^tm1Uzs/Gt(ROSA)26Sor⁺ (involves: 129P2/OlaHsd * BALB/c)	immune system phenotype	J:130768
Cd19^tm1(cre)Cgn/Cd19⁺ Gt(ROSA)26Sor^{tm2(CARD11*L225LI)Jrld}/Gt(ROSA)26Sor⁺ (involves: 129P2/OlaHsd)	abnormal B cell activation	J:228288
	abnormal plasmablast number	J:228288
	abnormal spleen morphology	J:228288
	enlarged lymph nodes	J:228288
	enlarged spleen	J:228288
	increased B cell number	J:228288
	increased B cell proliferation	J:228288
	increased plasma cell number	J:228288
	spleen hyperplasia	J:228288
Cd19^tm1(cre)Cgn/Cd19⁺ Gt(ROSA)26Sor^{tm2(CARD11*L225LI)Jrld}/Gt(ROSA)26Sor⁺ Malt1^tm1Mak/Malt1^tm1Mak (involves: 129P2/OlaHsd)	immune system phenotype	J:228288
Cd19^tm1(cre)Cgn/Cd19⁺ Gt(ROSA)26Sor^{tm2(Cd74/MOG)Awai}/Gt(ROSA)26Sor⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell physiology	J:140751
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:140751
Cd19^tm1(cre)Cgn/Cd19⁺ Gt(ROSA)26Sor^{tm2(Cd74/MOG)Awai}/Gt(ROSA)26Sor⁺ Il10^tm1Roer/Il10^tm1Roer (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell physiology	J:140751
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:140751
Cd19^tm1(cre)Cgn/Cd19⁺ Gt(ROSA)26Sor^{tm4(Ikbkb)Rsky}/Gt(ROSA)26Sor⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell physiology	J:113365
	abnormal splenic cell ratio	J:113365
	decreased B cell apoptosis	J:113365
	increased B cell number	J:113365
Cd19^tm1(cre)Cgn/Cd19⁺ Gt(ROSA)26Sor^{tm4(Ikbkb)Rsky}/Gt(ROSA)26Sor⁺ Tnfrsf13c^tm1Mass/Tnfrsf13c^tm1Mass (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:113365
Cd19^tm1(cre)Cgn/Cd19⁺ Gt(ROSA)26Sor^{tm5(Map3k14)Rsky}/Gt(ROSA)26Sor^{tm5(Map3k14)Rsky} (involves: 129P2/OlaHsd * C57BL/6)	enlarged lymph nodes	J:139293
	enlarged spleen	J:139293
	increased marginal zone B cell number	J:139293
	increased mature B cell number	J:139293
Cd19^tm1(cre)Cgn/Cd19⁺ Gt(ROSA)26Sor^{tm5(Map3k14)Rsky}/Gt(ROSA)26Sor^{tm5(Map3k14)Rsky} Tnfrsf13c^tm1Mass/Tnfrsf13c^tm1Mass (involves: 129P2/OlaHsd * C57BL/6)	decreased lymphocyte cell number	J:139293
	decreased mature B cell number	J:139293
Cd19^tm1(cre)Cgn/Cd19⁺ Gt(ROSA)26Sor^{tm6(Map3k14)Rsky}/Gt(ROSA)26Sor^{tm6(Map3k14)Rsky} (involves: 129P2/OlaHsd * C57BL/6)	abnormal Peyer's patch morphology	J:139293
	abnormal spleen B cell follicle morphology	J:139293
	decreased B-1 B cell number	J:139293
	enlarged lymph nodes	J:139293
	enlarged spleen	J:139293
	increased mature B cell number	J:139293
Cd19^tm1(cre)Cgn/Cd19⁺ Gt(ROSA)26Sor^{tm6(Map3k14)Rsky}/Gt(ROSA)26Sor^{tm6(Map3k14)Rsky} Tnfrsf13c^tm1Mass/Tnfrsf13c^tm1Mass (involves: 129P2/OlaHsd * C57BL/6)	increased lymphocyte cell number	J:139293
	increased mature B cell number	J:139293
Cd19^tm1(cre)Cgn/Cd19⁺ Ifnar1^tm1Uka/Ifnar1^tm1Uka (B6.129P2-Cd19^tm1(cre)Cgn Ifnar1^tm1Uka)	decreased IgG1 level	J:129128
	decreased IgG2a level	J:129128
	decreased IgG3 level	J:129128
	decreased IgM level	J:129128
Cd19^tm1(cre)Cgn/Cd19⁺ Igbp1^tm1Imku/Y (involves: 129P2/OlaHsd)	abnormal B cell physiology	J:74619
	abnormal somatic hypermutation frequency	J:74619
	abnormal spleen germinal center morphology	J:74619
	decreased B cell number	J:74619
	decreased B cell proliferation	J:74619
	decreased follicular B cell number	J:74619
	decreased immunoglobulin level	J:74619
	decreased pre-B cell number	J:74619
Cd19^tm1(cre)Cgn/Cd19⁺ Ikbkb^tm1Cgn/Ikbkb^tm1.1Cgn (involves: 129P2/OlaHsd * C57BL/6)	decreased B-1 B cell number	J:79132
	decreased follicular B cell number	J:79132
	decreased immature B cell number	J:79132
	decreased marginal zone B cell number	J:79132
	decreased mature B cell number	J:79132
	increased B cell proliferation	J:79132
Cd19^tm1(cre)Cgn/Cd19⁺ Ikbkb^tm2Cgn/Ikbkb^tm2.1Cgn (involves: 129P2/OlaHsd * C57BL/6)	decreased B-1 B cell number	J:79132
	decreased follicular B cell number	J:79132
	decreased marginal zone B cell number	J:79132
	decreased mature B cell number	J:79132
Cd19^tm1(cre)Cgn/Cd19⁺ Ikbkb^tm2Mka/Ikbkb^tm2Mka (involves: 129/Sv * 129P2/OlaHsd * C57BL/6)	abnormal B cell activation	J:82995
	decreased B cell number	J:82995
	decreased B cell proliferation	J:82995
	decreased B-1 B cell number	J:82995
	decreased IgG level	J:82995
	decreased IgM level	J:82995
	decreased marginal zone B cell number	J:82995
	increased B cell apoptosis	J:82995
Cd19^tm1(cre)Cgn/Cd19⁺ Ikbkg^tm1.1Mpa/Y (involves: 129P2/OlaHsd * C57BL/6)	decreased B-1 B cell number	J:79132
	decreased follicular B cell number	J:79132
	decreased immature B cell number	J:79132
	decreased marginal zone B cell number	J:79132
	decreased mature B cell number	J:79132
	increased B cell proliferation	J:79132
Cd19^tm1(cre)Cgn/Cd19⁺ Il10^tm1Roer/Il10^tm1Roer (involves: 129P2/OlaHsd)	abnormal CD8-positive, alpha-beta T cell physiology	J:151551
	abnormal myeloid leukocyte morphology	J:151551
	decreased circulating interleukin-10 level	J:151551
	increased B cell number	J:151551
	increased CD4-positive, alpha-beta T cell number	J:151551
	increased plasma cell number	J:151551
Cd19^tm1(cre)Cgn/Cd19⁺ Il10ra^tm1.1Jack/Il10ra^tm1.1Jack (involves: 129P2/OlaHsd * BALB/c * C57BL/6)	immune system phenotype	J:157787
Cd19^tm1(cre)Cgn/Cd19⁺ Inpp5d^tm1Rav/Inpp5d^tm1Rav Pten^tm1Hwu/Pten^tm1Hwu (involves: 129P2/OlaHsd * 129S4/SvJae)	abnormal B cell morphology	J:166155
	abnormal B cell physiology	J:166155
	abnormal myeloid leukocyte morphology	J:166155
	decreased B cell number	J:166155
	enlarged spleen	J:166155
	increased B cell number	J:166155
	increased B cell proliferation	J:166155
	increased spleen white pulp amount	J:166155
Cd19^tm1(cre)Cgn/Cd19⁺ Irf8^tm1.1Hm/Irf8^tm1.1Hm (involves: 129P2/OlaHsd * C57BL/6)	abnormal spleen marginal zone morphology	J:168923
	decreased follicular B cell number	J:168923
	immune system phenotype	J:168923
	increased B cell number	J:168923
	increased B-2 B cell number	J:168923
	increased follicular B cell number	J:168923
	increased marginal zone B cell number	J:168923
	increased transitional stage B cell number	J:168923
Cd19^tm1(cre)Cgn/Cd19⁺ Klhl6^tm2Sato/Klhl6^tm2Sato (either: (involves: 129P2/OlaHsd * 129T2/SvEms) or (involves: 129P2/OlaHsd * BALB/c) or (involves: 129P2/OlaHsd * CD-1))	abnormal B cell differentiation	J:101363
	abnormal lymph node germinal center morphology	J:101363
	decreased B cell number	J:101363
Cd19^tm1(cre)Cgn/Cd19⁺ Kmt2a^tm1.1Erns/Kmt2a^tm1.1Erns (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL)	immune system phenotype	J:147265
Cd19^tm1(cre)Cgn/Cd19⁺ Ltb^tm1Avt/Ltb^tm1Avt (involves: 129P2/OlaHsd * C57BL/6)	abnormal adaptive immunity	J:79129
	abnormal spleen B cell follicle morphology	J:79129
	abnormal spleen follicular dendritic cell network	J:79129
	decreased marginal zone B cell number	J:79129
	decreased spleen germinal center number	J:79129
	decreased spleen germinal center size	J:79129
	small Peyer's patches	J:79129
Cd19^tm1(cre)Cgn/Cd19⁺ Ltb^tm1Avt/Ltb^tm1Avt Tg(Lck-cre)1Jtak/? (involves: 129P2/OlaHsd * C57BL/6)	absent follicular dendritic cells	J:79129
Cd19^tm1(cre)Cgn/Cd19⁺ Ltbr^tm1Avt/Ltbr^tm1Avt (involves: 129P2/OlaHsd)	immune system phenotype	J:158663
Cd19^tm1(cre)Cgn/Cd19⁺ Ltbr^tm1Avt/Ltbr^tm1Avt Tg(Lck-cre)I57Jxm/0 (involves: 129P2/OlaHsd)	immune system phenotype	J:158663
Cd19^tm1(cre)Cgn/Cd19⁺ Map3k7^tm1Aki/Map3k7^tm1.1Aki (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell physiology	J:112597
	decreased B cell proliferation	J:112597
	decreased B-1 B cell number	J:112597
	decreased IgG1 level	J:112597
	decreased IgG3 level	J:112597
	decreased IgG level	J:112597
	decreased immunoglobulin level	J:112597
Cd19^tm1(cre)Cgn/Cd19⁺ Mcl1^tm2Sjk/Mcl1^tm3Sjk (involves: 129P2/OlaHsd * 129X1/SvJ)	abnormal B cell differentiation	J:86906
	absent early pro-B cells	J:86906
	absent late pro-B cells	J:86906
	absent pre-B cells	J:86906
	arrested B cell differentiation	J:86906
	decreased B cell number	J:86906
	increased B cell apoptosis	J:86906
Cd19^tm1(cre)Cgn/Cd19⁺ Mirc30^tm1.1Rdf/Mirc30^tm1.1Rdf (involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6)	increased B cell number	J:156946
	increased B-1a cell number	J:156946
	increased spleen white pulp amount	J:156946
Cd19^tm1(cre)Cgn/Cd19⁺ Myd88^em1.1Rsky/Myd88⁺ (involves: C57BL/6NTac)	abnormal splenic cell ratio	J:308792
	enlarged spleen	J:308792
	increased germinal center B cell number	J:308792
	increased IgM level	J:308792
	increased plasma cell number	J:308792
Cd19^tm1(cre)Cgn/Cd19⁺ Myd88^em1.1Rsky/Myd88^em1.1Rsky (involves: C57BL/6NTac)	increased B cell proliferation	J:308792
Cd19^tm1(cre)Cgn/Cd19⁺ Notch2^tm1.1Hhi/Notch2⁺ (involves: 129P2/OlaHsd * C57BL/6 * CBA)	decreased marginal zone B cell number	J:83476
Cd19^tm1(cre)Cgn/Cd19⁺ Notch2^tm2Hhi/Notch2^tm1.1Hhi (involves: 129P2/OlaHsd * C57BL/6 * CBA)	abnormal spleen marginal zone morphology	J:83476
	absent marginal zone B cells	J:83476
	decreased transitional stage B cell number	J:83476
Cd19^tm1(cre)Cgn/Cd19⁺ Pax5^tm1Mbu/Pax5^tm3Mbu (involves: 129P2/OlaHsd * 129S2/SvPas)	abnormal B cell differentiation	J:75504
	abnormal class switch recombination	J:75504
	decreased IgG1 level	J:75504
	decreased IgG3 level	J:75504
	decreased IgG level	J:75504
	decreased immature B cell number	J:75504
	decreased immunoglobulin level	J:75504
	decreased mature B cell number	J:75504
	decreased pre-B cell number	J:75504
Cd19^tm1(cre)Cgn/Cd19⁺ Pdia3^tm1Gjh/Pdia3^tm1Gjh (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell physiology	J:112606
Cd19^tm1(cre)Cgn/Cd19⁺ Prdm1^tm1Clme/Prdm1^tm1Clme (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ)	abnormal B cell differentiation	J:101890
	abnormal memory B cell number	J:101890
	abnormal plasma cell differentiation	J:101890
	abnormal plasma cell morphology	J:101890, J:114881
	decreased IgG level	J:101890
	decreased IgM level	J:101890
	decreased immunoglobulin level	J:101890
	decreased plasma cell number	J:101890
	increased spleen germinal center number	J:101890
	increased spleen germinal center size	J:101890
Cd19^tm1(cre)Cgn/Cd19⁺ Pten^tm1Hwu/Pten^tm1Hwu (involves: 129P2/OlaHsd * 129S4/SvJae)	abnormal B cell negative selection	J:155314
	abnormal B cell physiology	J:83213
	abnormal class switch recombination	J:114881
	abnormal plasma cell morphology	J:114881
	decreased IgG level	J:114881
	decreased spleen germinal center number	J:83213
	increased B cell apoptosis	J:83213
	increased B cell number	J:83213
	increased B cell proliferation	J:155314, J:83213
	increased B-1 B cell number	J:83213
	increased IgM level	J:114881
	increased marginal zone B cell number	J:83213
Cd19^tm1(cre)Cgn/Cd19⁺ Pten^tm1Hwu/Pten^tm1Hwu Tg(IghelMD4)4Ccg/0 Tg(ML5sHEL)5Ccg/0 (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)	abnormal peripheral B cell anergy	J:155314
Cd19^tm1(cre)Cgn/Cd19⁺ Ptpn6^tm1Rsky/Ptpn6^tm1Rsky (involves: 129P2/OlaHsd * C57BL/6)	abnormal humoral immune response	J:123568
	abnormal immune system physiology	J:123568
	abnormal leukocyte cell number	J:123568
	abnormal lymph organ size	J:123568
	decreased B cell proliferation	J:123568
	decreased follicular B cell number	J:123568
	decreased marginal zone B cell number	J:123568
	enlarged lymph nodes	J:123568
	enlarged spleen	J:123568
	increased B cell number	J:123568
	increased B-1a cell number	J:123568
	increased granulocyte number	J:123568
	increased macrophage cell number	J:123568
	increased plasma cell number	J:123568
	increased susceptibility to systemic lupus erythematosus	J:123568
	increased T cell number	J:123568
Cd19^tm1(cre)Cgn/Cd19⁺ Rac1^tm1Tyb/Rac1^tm1Tyb (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)	immune system phenotype	J:86765
Cd19^tm1(cre)Cgn/Cd19⁺ Rac1^tm1Tyb/Rac1^tm1Tyb Rac2^tm1Mddw/Rac2^tm1Mddw (involves: 129P2/OlaHsd * 129S/SvEv * 129S4/SvJae * C57BL/6)	arrested B cell differentiation	J:86765
	decreased B cell number	J:86765
	decreased B-1 B cell number	J:86765
	decreased follicular B cell number	J:86765
	decreased marginal zone B cell number	J:86765
	decreased transitional stage B cell number	J:86765
Cd19^tm1(cre)Cgn/Cd19⁺ Rapgef2^tm1.1Hous/Rapgef2^tm1.1Hous (involves: 129P2/OlaHsd * 129S1/Sv)	immune system phenotype	J:165879
Cd19^tm1(cre)Cgn/Cd19⁺ Rbpj^tm1Hon/Rbpj^tm1Hon (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell differentiation	J:76240
	decreased marginal zone B cell number	J:121523, J:76240
	increased follicular B cell number	J:121523, J:76240
	increased IgG3 level	J:76240
	increased susceptibility to bacterial infection	J:76240
	increased susceptibility to bacterial infection induced morbidity/mortality	J:76240
Cd19^tm1(cre)Cgn/Cd19⁺ Rbpj^tm1Hon/Rbpj^tm1Hon Spen^tm2.1Hon/Spen^tm2.1Hon (involves: 129P2/OlaHsd * C57BL/6 * CBA)	decreased marginal zone B cell number	J:121523
	increased follicular B cell number	J:121523
Cd19^tm1(cre)Cgn/Cd19⁺ Slc3a2^tm1.1Mgin/Slc3a2^tm1.1Mgin (involves: 129 * C57BL/6 * SJL)	abnormal B cell activation	J:148000
	abnormal B cell physiology	J:148000
	abnormal class switch recombination	J:148000
	abnormal plasma cell differentiation	J:148000
	decreased B cell proliferation	J:148000
	decreased germinal center B cell number	J:148000
	decreased IgG level	J:148000
	decreased IgM level	J:148000
	immune system phenotype	J:148000
Cd19^tm1(cre)Cgn/Cd19⁺ Slc3a2^tm1.1Mgin/Slc3a2^tm1Yai (involves: 129 * C57BL/6 * SJL)	decreased IgG3 level	J:148000
	decreased IgM level	J:148000
Cd19^tm1(cre)Cgn/Cd19⁺ Spen^tm2.1Hon/Spen^tm2.1Hon (involves: 129P2/OlaHsd * C57BL/6 * CBA)	decreased follicular B cell number	J:121523
	increased marginal zone B cell number	J:121523
Cd19^tm1(cre)Cgn/Cd19⁺ Srsf3^tm1Pjln/Srsf3^tm1Pjln (involves: 129P2/OlaHsd * BALB/c)	decreased B cell number	J:113645
Cd19^tm1(cre)Cgn/Cd19⁺ Tbl1xr1^{tm1c(EUCOMM)Hmgu}/Tbl1xr1^{tm1c(EUCOMM)Hmgu} Tg(Vav-BCL2)69Jad/0 (involves: 129P2/OlaHsd * C57BL/6J * C57BL/6N)	abnormal B cell differentiation	J:292118
	abnormal lymphocyte morphology	J:292118
	abnormal spleen morphology	J:292118
Cd19^tm1(cre)Cgn/Cd19⁺ Tcf3^tm1Mbu/Tcf3^tm1.2Mbu (involves: 129P2/OlaHsd * C57BL/6 * SJL)	decreased B cell number	J:137719
	decreased immature B cell number	J:137719
	decreased mature B cell number	J:137719
	decreased pre-B cell number	J:137719
	decreased pro-B cell number	J:137719
	decreased transitional stage B cell number	J:137719
Cd19^tm1(cre)Cgn/Cd19⁺ Tcf3^tm1Mbu/Tcf3^tm1.2Mbu Tg(Vav-BCL2)69Jad/0 (involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J * SJL)	decreased pre-B cell number	J:137719
Cd19^tm1(cre)Cgn/Cd19⁺ Tgfbr2^tm1Roes/Tgfbr2^tm1Roes (involves: 129P2/OlaHsd * BALB/c)	abnormal B cell physiology	J:90558
	abnormal B-1 B cell morphology	J:90558
	abnormal B-1 B cell number	J:90558
	absent plasma cells	J:90558
	decreased IgA level	J:90558
	enlarged Peyer's patches	J:90558
	increased IgG level	J:90558
	increased IgM level	J:90558
	increased leukocyte cell number	J:90558
Cd19^tm1(cre)Cgn/Cd19⁺ Tnf^tm2.1Gkl/Tnf^tm2.1Gkl (involves: 129P2/OlaHsd * 129S/SvEv * 129S6/SvEvTac * C57BL/6J)	immune system phenotype	J:108572
Cd19^tm1(cre)Cgn/Cd19⁺ Tnfaip3^tm1.1Awai/Tnfaip3^tm1.1Awai (involves: 129P2/OlaHsd)	decreased B-1a cell number	J:175422
	decreased B-1b cell number	J:175422
	decreased marginal zone B cell number	J:175422
	decreased mature B cell number	J:175422
	enlarged spleen	J:175422
	increased anti-nuclear antigen antibody level	J:175422
	increased B cell number	J:175422
	increased B cell proliferation	J:175422
	increased follicular B cell number	J:175422
	increased germinal center B cell number	J:175422
	increased IgA level	J:175422
	increased IgG2a level	J:175422
	increased IgM level	J:175422
	increased splenocyte number	J:175422
	increased T cell number	J:175422
Cd19^tm1(cre)Cgn/Cd19⁺ Tnfaip3^tm2Ama/Tnfaip3⁺ (involves: 129P2/OlaHsd * C57BL/6)	decreased B cell apoptosis	J:163917
	increased autoantibody level	J:163917
	increased germinal center B cell number	J:163917
	increased immunoglobulin level	J:163917
	increased plasma cell number	J:163917
	increased susceptibility to autoimmune disorder	J:163917
Cd19^tm1(cre)Cgn/Cd19⁺ Tnfrsf13c^tm1Mass/Tnfrsf13c^tm1Mass (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell differentiation	J:172843
Cd19^tm1(cre)Cgn/Cd19⁺ Tnfsf13b^tm1Msc/Tnfsf13b^tm1Msc Traf2^tm1Rbr/Traf2^tm1Rbr (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)	increased follicular B cell number	J:132877
	increased marginal zone B cell number	J:132877
Cd19^tm1(cre)Cgn/Cd19⁺ Traf2^tm1Rbr/Traf2^tm1Rbr (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell physiology	J:132877
	increased follicular B cell number	J:132877
	increased marginal zone B cell number	J:132877
	lymph node hyperplasia	J:132877
Cd19^tm1(cre)Cgn/Cd19⁺ Traf2^tm1Rbr/Traf2^tm1Rbr Traf3^tm1Rbr/Traf3^tm1Rbr (involves: 129P2/OlaHsd * C57BL/6 * SJL)	abnormal B cell physiology	J:132877
	increased marginal zone B cell number	J:132877
Cd19^tm1(cre)Cgn/Cd19⁺ Traf3^tm1Rbr/Traf3^tm1Rbr (involves: 129P2/OlaHsd * C57BL/6 * SJL)	abnormal B cell physiology	J:132877
	increased follicular B cell number	J:132877
	increased marginal zone B cell number	J:132877
	lymph node hyperplasia	J:132877
Cd19^tm1(cre)Cgn/Cd19⁺ Ube2n^tm1Aki/Ube2n^tm1Aki (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell physiology	J:112287
	abnormal humoral immune response	J:112287
	abnormal spleen marginal zone morphology	J:112287
	decreased B cell number	J:112287
	decreased B cell proliferation	J:112287
	decreased immunoglobulin level	J:112287
	decreased marginal zone B cell number	J:112287
	increased B cell apoptosis	J:112287
Cd19^tm1(cre)Cgn/Cd19⁺ Wac^em2Cya/Wac^em2Cya (B6.Cg-Cd19^tm1(cre)Cgn Wac^em2Cya)	abnormal plasma cell differentiation	J:345327
	decreased B cell proliferation	J:345327
	decreased IgG1 level	J:345327
	decreased IgG2b level	J:345327
	decreased IgG3 level	J:345327
	decreased IgM level	J:345327
	decreased plasma cell number	J:345327
	impaired humoral immune response	J:345327
Cd19^tm1(cre)Cgn/Cd19^tm1(cre)Cgn (involves: 129P2/OlaHsd)	abnormal B cell differentiation	J:27463
	abnormal B cell physiology	J:27463
	abnormal immunoglobulin level	J:27463
	absent spleen germinal center	J:83213, J:27463
	decreased B-1 B cell number	J:83213, J:27463
	decreased IgE level	J:27463
	decreased IgG1 level	J:27463
	decreased IgM level	J:27463
Cd19^tm1(cre)Cgn/Cd19^tm1(cre)Cgn Igh^tm1Mnz/Igh^tm1Mnz (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell physiology	J:75653
Cd19^tm1(cre)Cgn/Cd19^tm1(cre)Cgn Igh^tm2Mnz/Igh^tm2Mnz (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell physiology	J:75653
Cd19^tm1(cre)Cgn/Cd19^tm1(cre)Cgn Pten^tm1Hwu/Pten^tm1Hwu (involves: 129P2/OlaHsd * 129S4/SvJae)	immune system phenotype	J:83213
Cd19^tm1(cre)Cgn/Cd19^tm1(cre)Cgn Tg(IghelMD4)4Ccg/0 (involves: 129P2/OlaHsd * C57BL/6)	decreased B cell number	J:155314
	immune system phenotype	J:155314
Cd19^tm1(cre)Cgn/Cd19^tm1(cre)Cgn Tg(IghelMD4)4Ccg/0 Tg(ML5sHEL)5Ccg/0 (involves: 129P2/OlaHsd * C57BL/6)	decreased B cell number	J:155314
	immune system phenotype	J:155314
Cd19^{tm1(cre/ERT2)Rsky}/Cd19⁺ Myd88^em1.1Rsky/Myd88⁺ (involves: 129P2/OlaHsd * C57BL/6NTac)	increased IgM level	J:308792
	increased plasma cell number	J:308792
Cd19^tm1Tft/Cd19^tm1Tft (Not Specified)	abnormal B cell physiology	J:27236
	decreased B cell number	J:27236
	decreased B cell proliferation	J:27236
	decreased B-1 B cell number	J:27236
	decreased IgA level	J:27236
	decreased IgG1 level	J:27236
	decreased IgG2a level	J:27236
	decreased IgG2b level	J:27236
	decreased IgG3 level	J:27236
	decreased IgM level	J:27236
Cd19^tm1Tft/Cd19^tm1Tft (involves: 129/Sv * C57BL/6)	decreased neutrophil cell number	J:66111
Cd19^tm1Tft/Cd19^tm1Tft (involves: 129/Sv * C57BL/6)	decreased tumor necrosis factor secretion	J:66111
Cd19^tm1Tft/Cd19^tm1Tft (involves: 129 * C57BL/6)	abnormal humoral immune response	J:71174
	decreased B cell number	J:71174
	decreased B cell proliferation	J:71174
	decreased B-1 B cell number	J:71174
	decreased IgA level	J:71174
	decreased IgG1 level	J:71174
	decreased IgG2b level	J:71174
	decreased IgM level	J:71174
Cd19^tm1Tft/Cd19^tm1Tft (B6.Cg-Cd19^tm1Tft)	abnormal B cell physiology	J:136210
	decreased anti-double stranded DNA antibody level	J:136210
	decreased anti-nuclear antigen antibody level	J:136210
	decreased circulating interferon-gamma level	J:136210
	decreased circulating interleukin-4 level	J:136210
	decreased circulating interleukin-6 level	J:136210
	decreased circulating interleukin-10 level	J:136210
	decreased circulating tumor necrosis factor level	J:136210
	decreased IgA level	J:136210
	decreased IgG1 level	J:136210
	decreased IgG2a level	J:136210
	decreased IgG2b level	J:136210
	decreased IgG3 level	J:136210
	decreased IgM level	J:136210
	decreased interleukin-10 secretion	J:106487
	increased CD8-positive, alpha-beta T cell number	J:106487
	increased interferon-gamma secretion	J:106487
	increased susceptibility to experimental autoimmune encephalomyelitis	J:106487
Cd19^tm1Tft/Cd19^tm1Tft Lyn^tm1Sor/Lyn^tm1Sor (involves: 129S4/SvJaeSor * C57BL/6)	abnormal humoral immune response	J:71174
	decreased anti-double stranded DNA antibody level	J:71174
	decreased B cell number	J:71174
	decreased B cell proliferation	J:71174
	decreased B-1 B cell number	J:71174
	decreased mature B cell number	J:71174
	decreased susceptibility to systemic lupus erythematosus	J:71174
	enlarged spleen	J:71174
	immune system phenotype	J:71174
Cd22^m1Anu/Cd22^m1Anu (C57BL/6JAnu-Cd22^m1Anu/AnuApb)	arrested B cell differentiation	J:104190
Cd22^m1Anu/Cd22^m1Anu (C57BL/6JAnu-Cd22^m1Anu/AnuApb)	decreased B cell number	J:104190
Cd22^m1Btlr/Cd22^m1Btlr (C57BL/6J-Cd22^m1Btlr)	abnormal B cell differentiation	J:173079
Cd22^m1Btlr/Cd22^m1Btlr (C57BL/6J-Cd22^m1Btlr)	abnormal humoral immune response	J:173079
Cd22^m1Btlr/Cd22^m1Btlr (involves: C57BL/6J)	abnormal B cell differentiation	J:185495
	decreased IgM level	J:185495
	immune system phenotype	J:185495
Cd22^m2Btlr/Cd22^m2Btlr (C57BL/6J-Cd22^m2Btlr)	abnormal B cell differentiation	J:215821
Cd22^m2Btlr/Cd22^m2Btlr (C57BL/6J-Cd22^m2Btlr)	abnormal CD4-positive, alpha-beta T cell physiology	J:215821
Cd22^m3Btlr/Cd22^m3Btlr (C57BL/6J-Cd22^m3Btlr)	decreased B cell number	J:220066
Cd22^m3Btlr/Cd22^m3Btlr (C57BL/6J-Cd22^m3Btlr)	increased B-1a cell number	J:220066
Cd22^m4Btlr/Cd22^m4Btlr (C57BL/6J-Cd22^m4Btlr)	decreased B cell number	J:224660
	decreased B-2 B cell number	J:224660
	decreased memory B cell number	J:224660
	increased B-1a cell number	J:224660
Cd22^m5Btlr/Cd22^m5Btlr (C57BL/6J-Cd22^m5Btlr)	decreased B cell number	J:254827
	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:254827
	increased CD8-positive, alpha-beta memory T cell number	J:254827
Cd22^{tm1.1(CD22)Lnit}/Cd22^{tm1.1(CD22)Lnit} (involves: 129S4/SvJae)	abnormal B cell calcium ion homeostasis	J:189017
	abnormal B cell physiology	J:189017
	decreased B cell number	J:189017
	decreased marginal zone B cell number	J:189017
	decreased transitional stage T1 B cell number	J:189017
	decreased transitional stage T2 B cell number	J:189017
	immune system phenotype	J:189017
	impaired B cell migration	J:189017
Cd22^{tm1b(EUCOMM)Wtsi}/Cd22^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Cd22^{tm1b(EUCOMM)Wtsi}/Tcp)	increased monocyte cell number	J:211773
Cd22^tm1Eac/Cd22⁺ Lyn^tm1Ard/Lyn⁺ Ptpn6^me-v/Ptpn6⁺ Tg(IghelMD4)4Ccg/0 (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell negative selection	J:110531
	abnormal mature B cell morphology	J:110531
	increased IgM level	J:110531
Cd22^tm1Eac/Cd22⁺ Lyn^tm1Ard/Lyn⁺ Tg(IghelMD4)4Ccg/0 (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell negative selection	J:110531
	abnormal mature B cell morphology	J:110531
Cd22^tm1Eac/Cd22⁺ Ptpn6^me-v/Ptpn6⁺ Tg(IghelMD4)4Ccg/0 (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell negative selection	J:110531
	abnormal mature B cell morphology	J:110531
Cd22^tm1Eac/Cd22⁺ Tg(IghelMD4)4Ccg/0 (involves: 129P2/OlaHsd * C57BL/6)	abnormal mature B cell morphology	J:110531
Cd22^tm1Eac/Cd22^tm1Eac (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell activation	J:37451
	abnormal B cell proliferation	J:37451, J:132991
	abnormal mature B cell morphology	J:37451
	abnormal transitional stage B cell morphology	J:132991
	decreased IgG1 level	J:37451
	decreased IgG3 level	J:37451
	decreased IgM level	J:37451
	decreased marginal zone B cell number	J:132991
	decreased mature B cell number	J:37451, J:132991
	decreased memory B cell number	J:37451
	increased B cell apoptosis	J:132991
Cd22^tm1Lam/Cd22^tm1Lam (involves: 129 * C57BL/6)	abnormal B cell activation	J:125719
	decreased marginal zone B cell number	J:125719
	decreased mature B cell number	J:125719
Cd22^tm1Lam/Cd22^tm1Lam Igh^tm1.2Rsky/Igh⁺ (involves: 129 * BALB/c * C57BL/6)	abnormal class switch recombination	J:125719
Cd22^tm1Lam/Cd22^tm1Lam Igh^tm1.2Rsky/Igh^tm1.2Rsky (involves: 129 * BALB/c * C57BL/6)	abnormal B cell activation	J:125719
	decreased B-1a cell number	J:125719
Cd22^tm1Lnit/Cd22^tm1Lnit (involves: 129P2/OlaHsd * C57BL/6)	decreased marginal zone B cell number	J:198790
	immune system phenotype	J:198790
Cd22^tm1Msn/Cd22^tm1Msn (either: (involves: 129S/SvEv * BALB/c) or (involves: 129S/SvEv * C57BL/6J))	abnormal B cell activation	J:76974
	abnormal B cell calcium ion homeostasis	J:76974
	abnormal immune system physiology	J:76974
	abnormal immunoglobulin level	J:76974
	abnormal mature B cell morphology	J:76974
	increased anti-double stranded DNA antibody level	J:76974, J:76975
	increased B-1 B cell number	J:76974
	increased IgG2a level	J:76975
	increased IgG level	J:76975
	increased IgM level	J:76974
Cd22^tm1Tft/Cd22^tm1Tft (involves: 129P2/OlaHsd * C57BL/6)	decreased B cell number	J:92736
	decreased marginal zone B cell number	J:92736
	decreased mature B cell number	J:92736
	increased B cell proliferation	J:92736
Cd22^tm2Lnit/Cd22^tm2Lnit (involves: 129P2/OlaHsd * C57BL/6)	absent mature B cells	J:198790
	autoimmune response	J:198790
	decreased marginal zone B cell number	J:198790
	immune system phenotype	J:198790
Cd22^tm2Tft/Cd22^tm2Tft (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	decreased B cell number	J:92736
	decreased B cell proliferation	J:92736
	increased B cell proliferation	J:92736
Cd22^tm2Tft/Cd22^tm2Tft (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal peripheral B cell anergy	J:208364
	decreased B cell number	J:208364
	decreased B cell proliferation	J:208364
	increased activation-induced B cell apoptosis	J:208364
Cd22^tm2Tft/Cd22^tm2Tft Endou^tm1Tft/Endou^tm1Tft (involves: 129S/SvEv * 129S1/Sv * 129X1/SvJ * C57BL/6)	immune system phenotype	J:208364
Cd22^tm3Lnit/Cd22^tm3Lnit (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)	abnormal B cell physiology	J:198790
	abnormal immune system morphology	J:198790
	abnormal immune system physiology	J:198790
	absent mature B cells	J:198790
	autoimmune response	J:198790
	decreased B cell number	J:198790
	decreased marginal zone B cell number	J:198790
	decreased transitional stage B cell number	J:198790
	immune system phenotype	J:198790
	increased B cell apoptosis	J:198790
	increased IgG1 level	J:198790
Cd22^tm3Tft/Cd22^tm3Tft (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	decreased B cell number	J:92736
	decreased B cell proliferation	J:92736
	increased B cell proliferation	J:92736
Cd24a^tm1Pjln/Cd24a^tm1Pjln (C57BL/6-Cd24a^tm1Pjln)	abnormal B cell differentiation	J:76695
	dark spleen	J:76695
	decreased immature B cell number	J:76695
	decreased pre-B cell number	J:76695
	immune system phenotype	J:76695
	increased susceptibility to parasitic infection	J:76695
Cd27^{em1(IMPC)Ccpcz}/Cd27^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Cd27^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
Cd27^tm1Jbo/Cd27^tm1Jbo (either: B6.129P2-CD27^tm1Jbo or 129P2/OlaHsd-Tnfrsf7^tm1Jbo)	abnormal CD4-positive, alpha-beta T cell physiology	J:65516
	abnormal cytotoxic T cell physiology	J:65516
	abnormal T cell physiology	J:65516
Cd27^tm1Jbo/Cd27^tm1Jbo (B6.129P2-Cd27^tm1Jbo)	abnormal leukopoiesis	J:97606
	decreased regulatory T cell number	J:198200
	immune system phenotype	J:198200
	increased leukocyte cell number	J:97606
	increased T cell apoptosis	J:198200
Cd27^tm1Jbo/Cd27^tm1Jbo Tg(CD19-Tnfsf7)#Rvl/0 (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:88620
Cd28^tm1.1Huen/Cd28^tm1.1Huen Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte}/Gt(ROSA)26Sor⁺ (involves: C57BL/6 * C57BL/6NTac)	abnormal regulatory T cell physiology	J:191101
	decreased regulatory T cell number	J:191101
Cd28^{tm1a(EUCOMM)Hmgu}/Cd28^{tm1a(EUCOMM)Hmgu} (C57BL/6N-Cd28^{tm1a(EUCOMM)Hmgu}/H)	decreased T cell number	J:165965
	increased CD4-positive, alpha-beta T cell number	J:165965
	increased leukocyte cell number	J:165965
Cd28^tm1Jmg/Cd28^tm1Jmg (involves: 129S2/SvPas * 129X1/SvJ * C57BL/6)	abnormal cytokine secretion	J:124570
	abnormal germinal center B cell physiology	J:124570
	abnormal lymphopoiesis	J:124570
	decreased immunoglobulin level	J:124570
	decreased interleukin-2 secretion	J:124570
Cd28^tm1Jmg/Cd28^tm1Jmg (B6.129X1-Cd28^tm1Jmg)	decreased interleukin-2 secretion	J:149888
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:149888
	increased susceptibility to type I hypersensitivity reaction	J:149888
Cd28^tm1Jmg/Cd28^tm1Mak (involves: 129S2/SvPas * 129X1/SvJ * C57BL/6)	abnormal cytokine secretion	J:124570
	abnormal germinal center B cell physiology	J:124570
	abnormal lymphopoiesis	J:124570
	decreased immunoglobulin level	J:124570
	decreased interleukin-2 secretion	J:124570
	decreased T cell proliferation	J:149888, J:124570
Cd28^tm1Ltu/Cd28^tm1Ltu Foxp3^{tm4(YFP/icre)Ayr}/Foxp3⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	decreased regulatory T cell number	J:194503
	decreased T cell proliferation	J:194503
	enlarged lymph nodes	J:194503
	enlarged spleen	J:194503
	increased activated T cell number	J:194503
	increased B cell number	J:194503
	increased susceptibility to autoimmune disorder	J:194503
	increased susceptibility to experimental autoimmune encephalomyelitis	J:194503
	skin inflammation	J:194503
Cd28^tm1Mak/Cd28⁺ Cd5^tm1Cgn/Cd5^tm1Cgn (either: (involves: 129P2/OlaHsd * 129S2/SvPas * BALB/c * C57BL/6) or (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * DBA/1 * LP))	abnormal T cell clonal deletion	J:110925
Cd28^tm1Mak/Cd28^tm1Mak (involves: 129S2/SvPas * C57BL/6 * DBA/2)	abnormal CD4-positive, alpha-beta T cell physiology	J:14194
	abnormal class switch recombination	J:14194
	decreased IgG1 level	J:14194
	decreased IgG2b level	J:14194
	decreased immunoglobulin level	J:14194
	decreased interleukin-2 secretion	J:14194
	decreased T cell proliferation	J:14194
	increased IgG2a level	J:14194
Cd28^tm1Mak/Cd28^tm1Mak (NOD.129S2-Cd28^tm1Mak)	abnormal CD4-positive, alpha-beta T cell physiology	J:61905
	abnormal response to transplant	J:61905
	increased susceptibility to autoimmune diabetes	J:93421
	increased T cell proliferation	J:93421
Cd28^tm1Mak/Cd28^tm1Mak (involves: 129S2/SvPas)	abnormal class switch recombination	J:123989
	abnormal regulatory T cell physiology	J:191101
	decreased interferon-gamma secretion	J:205441
	decreased interleukin-2 secretion	J:205441, J:130882
	decreased regulatory T cell number	J:191101, J:205441
	decreased spleen germinal center number	J:123989
	decreased T cell proliferation	J:205441, J:130882, J:123989
	enlarged thymus	J:205441
Cd28^tm1Mak/Cd28^tm1Mak (involves: 129S2/SvPas * NOD)	abnormal T-helper 1 physiology	J:35353
	abnormal T-helper 2 physiology	J:35353
	decreased IgG2a level	J:35353
	decreased interleukin-2 secretion	J:35353
	decreased interleukin-4 secretion	J:35353
	decreased T cell proliferation	J:35353
	increased interferon-gamma secretion	J:35353
	increased susceptibility to autoimmune diabetes	J:35353
Cd28^tm1Mak/Cd28^tm1Mak (involves: 129S2/SvPas * C57BL/6)	abnormal NK cell physiology	J:95353
	decreased circulating interferon-gamma level	J:95353
	decreased circulating interleukin-4 level	J:95353
	decreased interleukin-2 secretion	J:149888
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:149888
	decreased T cell proliferation	J:149888
	increased susceptibility to type I hypersensitivity reaction	J:149888
	increased T cell apoptosis	J:149888
Cd28^tm1Mak/Cd28^tm1Mak (B6.129S2-Cd28^tm1Mak)	abnormal cytotoxic T cell physiology	J:76373
Cd28^tm1Mak/Cd28^tm1Mak (B6.129S2-Cd28^tm1Mak/J)	brain inflammation	J:57613
Cd28^tm1Mak/Cd28^tm1Mak (B6.129S2-Cd28^tm1Mak/J)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:57613
Cd28^tm1Mak/Cd28^tm1Mak Cd5^tm1Cgn/Cd5⁺ (either: (involves: 129P2/OlaHsd * 129S2/SvPas * BALB/c * C57BL/6) or (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * DBA/1 * LP))	abnormal T cell clonal deletion	J:110925
Cd28^tm1Mak/Cd28^tm1Mak Cd5^tm1Cgn/Cd5^tm1Cgn (either: (involves: 129P2/OlaHsd * 129S2/SvPas * BALB/c * C57BL/6) or (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * DBA/1 * LP))	abnormal T cell clonal deletion	J:110925
	increased CD4-positive, alpha-beta T cell number	J:110925
	increased CD8-positive, alpha-beta T cell number	J:110925
Cd28^tm1Mak/Cd28^tm1Mak Cd40lg^tm1Flv/Cd40lg^tm1Flv (NOD.Cg-Cd40lg^tm1Flv Cd28^tm1Mak)	decreased regulatory T cell number	J:93421
	increased susceptibility to autoimmune diabetes	J:93421
	insulitis	J:93421
Cd28^tm1Mak/Cd28^tm1Mak Ndfip1^{Gt(RRD002)Byg}/Ndfip1^{Gt(RRD002)Byg} (involves: 129P2/OlaHsd * 129S2/SvPas)	esophageal inflammation	J:205692
	increased eosinophil cell number	J:205692
	increased interleukin-2 secretion	J:205692
	increased interleukin-4 secretion	J:205692
Cd28^tm1Mak/Cd28^tm1Mak Rc3h1^san/Rc3h1⁺ (involves: 129S2/SvPas * C57BL/6 * C57BL/6JSfdAnu)	increased T cell derived lymphoma incidence	J:189087
Cd28^tm1Mak/Cd28^tm1Mak Stat6^tm1Gru/Stat6^tm1Gru (C.129S2(B6)-Cd28^tm1Mak Stat6^tm1Gru)	increased susceptibility to parasitic infection	J:90987
Cd28^tm1Mak/Cd28^tm1Mak Tg(Cd4-cre)1Cwi/? Traf6^tm2Ywc/Traf6^tm2Ywc (involves: 129S2/SvPas * C57BL/6 * DBA/2)	decreased interleukin-2 secretion	J:130882
	decreased T cell proliferation	J:130882
	increased activated T cell number	J:130882
	increased memory T cell number	J:130882
Cd28^tm1Mak/Cd28^tm1Mak Tg(H2-K-Cd86)7All/0 (involves: BALB/c * C57BL/6 * CBA)	abnormal T cell differentiation	J:112266
Cd28^tm1Mak/Cd28^tm1Mak Tg(TcrLCMV)327Sdz/0 (involves: 129S2/SvPas * C57BL/6 * DBA/2)	abnormal T cell anergy	J:123989
	decreased cytotoxic T cell cytolysis	J:123989
	decreased splenocyte proliferation	J:123989
	decreased T cell proliferation	J:123989
Cd28^tm1Mak/Cd28^tm1Mak Tnfsf9^tm1Thw/Tnfsf9^tm1Thw (involves: 129 * 129S2/SvPas * C57BL/6)	abnormal cytotoxic T cell physiology	J:76373
	increased length of allograft survival	J:76373
Cd28^tm1Mak/Cd28^tm1Mak Tnfsf14^tm1Kpf/Tnfsf14^tm1Kpf (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)	increased length of allograft survival	J:77250
Cd28^tm1Pjl/Cd28^tm1Pjl (involves: 129P2/OlaHsd * C57BL/6)	abnormal class switch recombination	J:83722
	abnormal cytotoxic T cell physiology	J:83722
	abnormal immunoglobulin level	J:83722
	decreased IgG1 level	J:83722
	decreased IgG2a level	J:83722
	decreased IgM level	J:83722
	decreased interleukin-12 secretion	J:83722
	decreased susceptibility to type IV hypersensitivity reaction	J:83722
	increased splenocyte proliferation	J:83722
Cd28^tm1Pjl/Cd28^tm1Pjl Tg(DO11.10)10Dlo/0 (involves: 129P2/OlaHsd * BALB/c * C3H * C57BL/6)	abnormal T cell activation	J:25536
	abnormal T cell proliferation	J:25536
	abnormal thymocyte activation	J:25536
	decreased interleukin-2 secretion	J:25536
Cd28^tm1Pjl/Cd28^tm1Pjl Tg(H2-K-Cd86)27All/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA)	decreased B cell number	J:112475
Cd28^tm1Pjl/Cd28^tm1Pjl Tnfrsf9^tm1Byk/Tnfrsf9^tm1Byk (either: B6.Cg-Cd28^tm1Pjl Tnfrsf9^tm1Byk or C.Cg-Cd28^tm1Pjl Tnfrsf9^tm1Byk)	abnormal class switch recombination	J:83722
	abnormal cytotoxic T cell physiology	J:83722
	decreased IgG1 level	J:83722
	decreased IgG2a level	J:83722
	decreased IgM level	J:83722
	decreased interleukin-12 secretion	J:83722
	decreased splenocyte proliferation	J:83722
	decreased susceptibility to type IV hypersensitivity reaction	J:83722
Cd28^tm1Shr/Cd28^tm1Shr (involves: 129S4/SvJae * BALB/c * C57BL/6)	decreased CD4-positive, alpha-beta T cell number	J:68642
	decreased interleukin-2 secretion	J:68642
	decreased T cell proliferation	J:68642
Cd28^tm1Shr/Cd28^tm1Shr Ctla4^tm1Shr/Ctla4⁺ (C.129S4-Cd28^tm1Shr Ctla4^tm1Shr)	abnormal CD8-positive, alpha beta T cell morphology	J:125259
	increased susceptibility to autoimmune disorder	J:125259
Cd28^tm1Shr/Cd28^tm1Shr Ctla4^tm1Shr/Ctla4^tm1Shr (C.129S4-Cd28^tm1Shr Ctla4^tm1Shr)	abnormal interferon level	J:68642
	abnormal interleukin secretion	J:68642
	decreased CD4-positive, alpha-beta T cell number	J:68642
	decreased T cell proliferation	J:68642
	increased length of allograft survival	J:68642
Cd33^tm1Avrk/Cd33^tm1Avrk (involves: 129X1/SvJ * C57BL/6)	decreased inflammatory response	J:83728
Cd34^tm1Lal/Cd34^tm1Lal (involves: 129S2/SvPas)	decreased splenocyte number	J:30621
Cd34^tm1Szk/Cd34^tm1Szk (involves: 129P2/OlaHsd * C57BL/6J)	decreased eosinophil cell number	J:32799
Cd34^tm1Szk/Cd34^tm1Szk (involves: 129P2/OlaHsd * C57BL/6J)	immune system phenotype	J:32799
Cd36^em1(IMPC)Mbp/Cd36^em1(IMPC)Mbp (C57BL/6N-Cd36^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Cd36^obl/Cd36^obl (C57BL/6-Cd36^obl)	abnormal cell-mediated immunity	J:96018
	abnormal macrophage physiology	J:96018
	endophthalmitis	J:96018
	increased susceptibility to bacterial infection	J:96018
Cd36^tm1Frm/Cd36^tm1Frm (involves: 129S4/SvJae)	abnormal microglial cell physiology	J:140907
Cd36^tm1Frm/Cd36^tm1Frm (involves: 129S4/SvJae * C57BL/6J)	abnormal chemokine level	J:80658
Cd36^tm1Frm/Cd36^tm1Frm (involves: 129S4/SvJae * C57BL/6J)	abnormal macrophage physiology	J:80658
Cd36^tm1Frm/Cd36^tm1Frm (B6.129S4-Cd36^tm1Frm)	abnormal response to infection	J:100140
	decreased interleukin-6 secretion	J:100140
	decreased interleukin-12 secretion	J:100140
	decreased tumor necrosis factor secretion	J:100140
	impaired macrophage phagocytosis	J:100140
	increased susceptibility to bacterial infection induced morbidity/mortality	J:100140
	sepsis	J:100140
Cd36^tm1Mfe/Cd36^tm1Mfe (B6.129S1-Cd36^tm1Mfe)	abnormal B cell morphology	J:130897
	abnormal plasma cell differentiation	J:130897
	decreased IgG1 level	J:130897
	decreased IgG2a level	J:130897
	decreased IgG2c level	J:130897
	decreased IgG level	J:130897
	decreased IgM level	J:130897
	decreased immunoglobulin level	J:130897
	increased transitional stage B cell number	J:130897
Cd36^tm1Mfe/Cd36^tm1Mfe (involves: 129S1/Sv)	abnormal macrophage chemotaxis	J:89664
Cd37^tm1Hor/Cd37^tm1Hor (involves: 129P2/OlaHsd * C57BL/6)	abnormal class switch recombination	J:63315
	abnormal humoral immune response	J:63315
	abnormal lymph node germinal center morphology	J:63315
	decreased IgG1 level	J:63315
	decreased spleen germinal center number	J:63315
	decreased spleen germinal center size	J:63315
	immune system phenotype	J:63315
Cd38^{em1(IMPC)Ccpcz}/Cd38^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Cd38^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	decreased CD4-positive NK T cell number	J:211773
	decreased CD4-positive, alpha-beta T cell number	J:211773
	decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	decreased effector memory T-helper cell number	J:211773
	decreased memory-marker CD4-positive NK T cell number	J:211773
	decreased NK T cell number	J:211773
	decreased T-helper cell number	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
	increased NK cell number	J:211773
Cd38^tm1Lnd/Cd38^tm1Lnd (involves: 129P2/OlaHsd * C57BL/6J)	abnormal humoral immune response	J:49170
Cd38^tm1Lnd/Cd38^tm1Lnd (NOD.129P2(B6)-Cd38^tm1Lnd/LtJ)	increased susceptibility to autoimmune diabetes	J:108097
	increased T cell apoptosis	J:108097
	insulitis	J:108097
Cd40^m1Btlr/Cd40^m1Btlr (C57BL/6J-Cd40^m1Btlr)	impaired humoral immune response	J:221482
Cd40^m2Btlr/Cd40^m2Btlr (C57BL/6J-Cd40^m2Btlr)	abnormal humoral immune response	J:254828
Cd40^m2Btlr/Cd40^m2Btlr (C57BL/6J-Cd40^m2Btlr)	decreased IgG level	J:254828
Cd40^tm1Arah/Cd40^tm1Arah (B6.129S1-Cd40^tm1Arah)	abnormal immunoglobulin level	J:120512
	abnormal response to transplant	J:120512
	absent spleen germinal center	J:120512
	decreased IgE level	J:120512
	decreased IgG1 level	J:120512
	decreased IgG2b level	J:120512
	decreased IgG level	J:120512
	decreased IgM level	J:120512
	increased IgG3 level	J:120512
	increased IgM level	J:120512
Cd40^tm1Geha/Cd40^tm1Geha (involves: 129S4/SvJae * C57BL/6)	abnormal lymph node germinal center morphology	J:82298
	decreased IgA level	J:82298
	decreased IgG1 level	J:82298
	decreased IgG2a level	J:82298
	decreased IgG2b level	J:82298
	decreased spleen germinal center number	J:82298
	decreased spleen germinal center size	J:82298
Cd40^tm1Kik/Cd40⁺ Mir146^tm1.1Lfl/Mir146^tm1.1Lfl Tg(Cr2-cre)3Cgn/0 (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:266124
	increased T follicular helper cell number	J:266124
Cd40^tm1Kik/Cd40^tm1Kik (B6.129P2-Cd40^tm1Kik/J)	abnormal dendritic cell physiology	J:86998
Cd40^tm1Kik/Cd40^tm1Kik (B6.129P2-Cd40^tm1Kik/J)	increased susceptibility to bacterial infection	J:86998
Cd40^tm1Kik/Cd40^tm1Kik (involves: 129P2/OlaHsd * C57BL/6)	abnormal humoral immune response	J:25007
	absent spleen germinal center	J:25007
	decreased IgA level	J:25007
	decreased IgE level	J:25007
	decreased IgG1 level	J:25007
	decreased IgG2a level	J:25007
	decreased IgG2b level	J:25007
	decreased IgG3 level	J:25007
	decreased immunoglobulin level	J:25007
	decreased neutrophil cell number	J:25007
	decreased susceptibility to type II hypersensitivity reaction	J:61673
	immune system phenotype	J:25007
Cd40^tm1Kik/Cd40^tm1Kik (involves: 129P2/OlaHsd)	absent germinal center B cells	J:190943
	decreased B cell number	J:190943
	immune system phenotype	J:173115
Cd40^tm1Kik/Cd40^tm1Kik Ltbr^tm1Mmat/Ltbr^tm1Mmat (involves: 129P2/OlaHsd * C57BL/6 * CBA)	abnormal thymus epithelium morphology	J:173115
	abnormal thymus medulla morphology	J:173115
	immune system phenotype	J:173115
Cd40^tm1Kik/Cd40^tm1Kik Tg(Tnfsf13b)1Fma/? (B6.Cg-Cd40^tm1Kik Tg(Tnfsf13b)1Fma)	abnormal B cell activation	J:113556
	abnormal class switch recombination	J:113556
	absent spleen germinal center	J:113556
	glomerulonephritis	J:113556
	increased anti-double stranded DNA antibody level	J:113556
	increased marginal zone B cell number	J:113556
Cd40^tm1Kik/Cd40^tm1Kik Tnfsf11^tm1Pngr/Tnfsf11^tm1Pngr (involves: 129P2/OlaHsd)	abnormal thymus epithelium morphology	J:173115
Cd40^tm1Kik/Cd40^tm1Kik Traf3ip2^tm1.1Lix/Traf3ip2^tm1.1Lix (involves: 129 * 129P2/OlaHsd * BALB/c)	abnormal B cell physiology	J:138560
	enlarged lymph nodes	J:93923
	enlarged spleen	J:93923
	immune system phenotype	J:138560
	increased follicular B cell number	J:138560
	increased marginal zone B cell number	J:138560
	increased transitional stage B cell number	J:138560
Cd40lg^m1Btlr/Y (involves: C57BL/6J)	abnormal class switch recombination	J:185495
	decreased IgG level	J:185495
	immune system phenotype	J:185495
Cd40lg^m1Btlr/Cd40lg^m1Btlr (C57BL/6J-Cd40lg^m1Btlr)	decreased IgG level	J:162147
Cd40lg^m1Btlr/Cd40lg^m1Btlr (C57BL/6J-Cd40lg^m1Btlr)	immune system phenotype	J:162147
Cd40lg^m1Btlr/Cd40lg^m1Btlr (involves: C57BL/6J)	abnormal class switch recombination	J:185495
	decreased IgG level	J:185495
	immune system phenotype	J:185495
Cd40lg^tm1Flv/Y Fas^lpr/Fas^lpr (involves: 129P2/OlaHsd * 129S2/SvPas * MRL)	decreased autoantibody level	J:38492
	decreased IgG level	J:38492
	decreased immunoglobulin level	J:38492
Cd40lg^tm1Flv/Y Fas^lpr/Fas^lpr Tcra^tm1Mjo/Tcra^tm1Mjo (involves: 129P2/OlaHsd * 129S2/SvPas * MRL)	decreased autoantibody level	J:38492
	increased anti-double stranded DNA antibody level	J:38492
Cd40lg^tm1Flv/Cd40lg^tm1Flv (involves: 129S2/SvPas * C57BL/6)	abnormal adaptive immunity	J:25010
	abnormal class switch recombination	J:25010
	abnormal immune system morphology	J:25010
	abnormal immune system physiology	J:25010
	abnormal osteoclast differentiation	J:120087
	abnormal T cell differentiation	J:25010
	abnormal T-helper 2 physiology	J:25010
	absent spleen germinal center	J:25010
	decreased double-positive T cell number	J:25010
	decreased IgA level	J:25010
	decreased IgD level	J:25010
	decreased IgE level	J:25010
	decreased IgG1 level	J:25010
	decreased IgG3 level	J:25010
	decreased immunoglobulin level	J:25010
	increased CD4-positive, alpha-beta T cell number	J:25010
Cd40lg^tm1Flv/Cd40lg^tm1Flv (NOD.129S2-Cd40lg^tm1Flv)	decreased regulatory T cell number	J:93421
Cd40lg^tm1Flv/Cd40lg^tm1Flv (NOD.129S2-Cd40lg^tm1Flv)	decreased susceptibility to autoimmune diabetes	J:93421
Cd40lg^tm1Flv/Cd40lg^tm1Flv Fas^lpr/Fas^lpr (involves: 129P2/OlaHsd * 129S2/SvPas * MRL)	decreased autoantibody level	J:38492
	decreased IgG level	J:38492
	decreased immunoglobulin level	J:38492
Cd40lg^tm1Flv/Cd40lg^tm1Flv Fas^lpr/Fas^lpr Tcra^tm1Mjo/Tcra^tm1Mjo (involves: 129P2/OlaHsd * 129S2/SvPas * MRL)	decreased autoantibody level	J:38492
	increased anti-double stranded DNA antibody level	J:38492
Cd40lg^tm1Imx/Y (involves: 129S2/SvPas * C57BL/6)	abnormal antigen presentation	J:21137
	abnormal class switch recombination	J:21137
	abnormal immune system organ morphology	J:21137
	abnormal immune system physiology	J:21137
	abnormal lymph node morphology	J:21137
	absent lymph node germinal center	J:21137
	absent spleen germinal center	J:21137
	decreased IgA level	J:21137
	decreased IgE level	J:21137
	decreased IgG1 level	J:21137
	decreased IgG2b level	J:21137
	decreased immunoglobulin level	J:21137
	immune system phenotype	J:21137
	lymph node hypoplasia	J:21137
Cd40lg^tm1Imx/Y (B6.129S2-Cd40lg^tm1Imx/J)	abnormal leukocyte adhesion	J:108988
Cd40lg^tm1Imx/Cd40lg^tm1Imx (involves: 129S2/SvPas * C57BL/6J * BALB/c)	abnormal T cell clonal deletion	J:110925
Cd40lg^tm1Imx/Cd40lg^tm1Imx (involves: 129S2/SvPas * C57BL/6)	increased susceptibility to prion infection	J:115487
	microgliosis	J:115487
Cd40lg^tm1Parl/Y Commd10^{Tg(Vav1-icre)A2Kio}/Commd10⁺ (involves: 129 * C57BL/6 * C57BL/10 * CBA/Ca)	decreased IgM level	J:213459
	increased IgG1 level	J:213459
Cd40lg^tm1Parl/Y Tg(Cd4-cre)1Cwi/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)	immune system phenotype	J:213459
Cd40lg^tm1Parl/Y Tg(Tek-cre)1Ywa/0 (involves: 129 * C57BL/6 * CD-1 * SJL)	decreased IgA level	J:213459
	decreased IgG1 level	J:213459
	decreased IgG2a level	J:213459
	decreased IgG3 level	J:213459
	decreased IgM level	J:213459
Cd40lg^tm1Parl/Cd40lg^tm1Parl Commd10^{Tg(Vav1-icre)A2Kio}/Commd10⁺ (involves: 129 * C57BL/6 * C57BL/10 * CBA/Ca)	decreased IgM level	J:213459
	increased IgG1 level	J:213459
Cd40lg^tm1Parl/Cd40lg^tm1Parl Tg(Cd4-cre)1Cwi/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)	immune system phenotype	J:213459
Cd40lg^tm1Parl/Cd40lg^tm1Parl Tg(Tek-cre)1Ywa/0 (involves: 129 * C57BL/6 * CD-1 * SJL)	decreased IgA level	J:213459
	decreased IgG1 level	J:213459
	decreased IgG2a level	J:213459
	decreased IgG3 level	J:213459
	decreased IgM level	J:213459
Cd44^M1Btlr/Cd44^M1Btlr (C57BL/6J-Cd44^M1Btlr)	decreased alpha-beta T cell number	J:267483
	decreased CD4-positive, alpha-beta T cell number	J:267483
	decreased CD8-positive, alpha-beta T cell number	J:267483
	decreased central memory CD4-positive, alpha-beta T cell number	J:267483
	decreased central memory CD8 positive, alpha-beta T cell number	J:267483
	decreased effector memory CD4-positive, alpha-beta T cell number	J:267483
Cd44^tm1.1Ugu/Cd44^tm1.1Ugu (involves: 129/Sv * C57BL/6)	abnormal T-helper 1 physiology	J:62867
	abnormal T-helper 2 physiology	J:62867
	immune system phenotype	J:62867
Cd44^tm1.1Ugu/Cd44^tm1.1Ugu (B6.129(Cg)-Cd44^tm1.1Ugu)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:199279
Cd44^tm1.1Ugu/Cd44^tm1.1Ugu (SJL.129(Cg)-Cd44^tm1.1Ugu)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:199279
Cd44^tm1.1Ugu/Cd44^tm1.1Ugu (SJL.129(Cg)-Cd44^tm1.1Ugu)	decreased T cell proliferation	J:199279
Cd44^tm1.1Ugu/Cd44^tm1.1Ugu Il10^tm1Cgn/Il10^tm1Cgn (involves: 129/Sv * C57BL/6)	abnormal immune system physiology	J:62867
Cd44^tm1Hbg/Cd44⁺ Tnf^tm2Gkl/Tnf⁺ (involves: 129S/SvEv * 129S1/Sv * 129X1/SvJ * C57BL/6)	ileum inflammation	J:145626
Cd44^tm1Hbg/Cd44^tm1Hbg (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:68069
	abnormal CD8-positive, alpha beta T cell morphology	J:68069
	abnormal leukocyte migration	J:68069
	abnormal neutrophil physiology	J:94850
Cd44^tm1Hbg/Cd44^tm1Hbg (involves: 129S1/Sv * 129X1/SvJ)	abnormal osteoclast differentiation	J:101563
	abnormal response to infection	J:86947
	increased acute inflammation	J:131974
Cd44^tm1Hbg/Cd44^tm1Hbg (B6.129-Cd44^tm1Hbg)	decreased mast cell histamine storage	J:146846
Cd44^tm1Hbg/Cd44^tm1Hbg (B6.129-Cd44^tm1Hbg)	decreased mast cell number	J:146846
Cd44^tm1Hbg/Cd44^tm1Hbg Tg(TNF)197Gkl/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)	abnormal osteoclast differentiation	J:97992
	abnormal osteoclast morphology	J:97992
	autoimmune arthritis	J:97992
	increased circulating interleukin-1 level	J:97992
	increased circulating interleukin-6 level	J:97992
	increased interleukin-1 secretion	J:97992
	increased interleukin-6 secretion	J:97992
	increased osteoclast cell number	J:97992
Cd44^tm1Hbg/Cd44^tm1Hbg Tnf^tm2Gkl/Tnf⁺ (involves: 129S/SvEv * 129S1/Sv * 129X1/SvJ * C57BL/6)	immune system phenotype	J:145626
Cd44^tm1Mak/Cd44⁺ (involves: 129P2/OlaHsd * C57BL/6J)	abnormal leukocyte migration	J:99032
Cd44^tm1Mak/Cd44^tm1Mak (involves: 129P2/OlaHsd * C57BL/6J)	abnormal leukocyte migration	J:99032
	immune system phenotype	J:72658
	increased susceptibility to parasitic infection	J:72658
Cd44^tm1Mak/Cd44^tm1Mak (B6.129P2-Cd44^tm1Mak)	abnormal circulating cytokine level	J:69351
	abnormal leukocyte migration	J:108245
	decreased activation-induced cell death of T cells	J:69351
	impaired macrophage phagocytosis	J:111216
	impaired natural killer cell mediated cytotoxicity	J:110889
	increased circulating interferon-gamma level	J:69351
	increased circulating interleukin-2 level	J:69351
	increased circulating tumor necrosis factor level	J:69351
	liver inflammation	J:69351
	lung inflammation	J:111216, J:108245
Cd44^tm1Mak/Cd44^tm1Mak (D1.129P2-Cd44^tm1Mak)	increased susceptibility to induced arthritis	J:95275
Cd44^tm1Mak/Cd44^tm1Mak (involves: 129P2/OlaHsd * C57BL/6)	abnormal chemokine secretion	J:155691
	abnormal circulating chemokine level	J:155691
	abnormal interleukin secretion	J:155691
	decreased acute inflammation	J:114341
	decreased circulating tumor necrosis factor level	J:155691
	increased interleukin-1 beta secretion	J:155691
	increased interleukin-6 secretion	J:155691
	increased interleukin-10 secretion	J:155691
	increased tumor necrosis factor secretion	J:155691
	peritoneal inflammation	J:155691
Cd44^tm1Mak/Cd44^tm1Mak Itgal^tm1Mak/Itgal^tm1Mak (B6.129P2-Cd44^tm1Mak Itgal^tm1Mak)	impaired natural killer cell mediated cytotoxicity	J:110889
Cd44^tm1Ugu/Cd44^tm1Ugu (involves: 129/Sv * C57BL/6)	abnormal T-helper 1 physiology	J:62867
	abnormal T-helper 2 physiology	J:62867
	immune system phenotype	J:62867
Cd44^tm2.1Ugu/Cd44^tm2.1Ugu (B6.129-Cd44^tm2.1Ugu)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:199279
Cd44^tm2.1Ugu/Cd44^tm2.1Ugu (B6.129-Cd44^tm2.1Ugu)	decreased T cell proliferation	J:199279
Cd44^tm2Kmz/Cd44^tm2Kmz (DBA/1LacJ-Cd44^tm2Kmz)	decreased susceptibility to induced arthritis	J:74268
Cd44^tm2Kmz/Cd44^tm2Kmz (involves: BALB/c * DBA/1)	abnormal CD4-positive, alpha-beta T cell physiology	J:114317
	abnormal leukocyte adhesion	J:114317
	decreased susceptibility to type IV hypersensitivity reaction	J:114317
	impaired leukocyte tethering or rolling	J:114317
	impaired neutrophil recruitment	J:114317
Cd44^tm2Kmz/Cd44^tm2Kmz Sell^tm2Hyn/Sell^tm2Hyn (involves: 129S2/SvPas * BALB/c * DBA/1)	abnormal CD4-positive, alpha-beta T cell physiology	J:114317
	abnormal leukocyte adhesion	J:114317
	decreased susceptibility to type IV hypersensitivity reaction	J:114317
	impaired leukocyte tethering or rolling	J:114317
	impaired neutrophil recruitment	J:114317
Cd47^tm1Fpl/Cd47⁺ (B6.129S7-Cd47^tm1Fpl)	increased susceptibility to bacterial infection induced morbidity/mortality	J:36489
Cd47^tm1Fpl/Cd47^tm1Fpl (involves: 129S7/SvEvBrd)	decreased T cell number	J:36489
Cd47^tm1Fpl/Cd47^tm1Fpl (involves: 129S7/SvEvBrd)	impaired neutrophil recruitment	J:148196
Cd47^tm1Fpl/Cd47^tm1Fpl (B6.129S7-Cd47^tm1Fpl)	abnormal neutrophil physiology	J:36489
	decreased osteoclast cell number	J:116609
	impaired granulocyte bactericidal activity	J:36489
	impaired neutrophil chemotaxis	J:36489
	impaired neutrophil phagocytosis	J:36489
	increased susceptibility to bacterial infection	J:36489
	increased susceptibility to bacterial infection induced morbidity/mortality	J:36489
Cd47^tm1Fpl/Cd47^tm1Fpl (C.129S7-Cd47^tm1Fpl)	decreased osteoclast cell number	J:116609
Cd47^tm1Fpl/Cd47^tm1Fpl (NOD.129S7-Cd47^tm1Fpl)	abnormal spleen morphology	J:76580
	abnormal splenic cell ratio	J:76580
	enlarged spleen	J:76580
Cd47^tm1Fpl/Cd47^tm1Fpl (involves: 129S7/SvEvBrd * C57BL/6)	abnormal cytokine level	J:134866
	abnormal osteoclast differentiation	J:147367
	abnormal tumor necrosis factor level	J:134866
	decreased leukocyte cell number	J:134866
	decreased neutrophil cell number	J:134866
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:134866
	increased susceptibility to bacterial infection	J:134866
Cd48^tm1Rsr/Cd48^tm1Rsr (B6.129S4-Cd48^tm1Rsr)	abnormal T cell activation	J:53718
	decreased T cell proliferation	J:53718
	increased CD4-positive, alpha-beta T cell number	J:53718
Cd52^{em1(IMPC)Ccpcz}/Cd52^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Cd52^{em1(IMPC)Ccpcz}/Ccpcz)	decreased NK T cell number	J:211773
Cd53^tm1.1Nmg/Cd53^tm1.1Nmg (involves: C57BL/6J)	abnormal B cell physiology	J:260065
Cd55^tm1Mme/Cd55^tm1Mme (involves: 129P2/OlaHsd * C57BL/6)	increased susceptibility to experimental autoimmune myasthenia gravis	J:80116
Cd55^tm1Song/Cd55^tm1Song (involves: 129S6/SvEvTac * C57BL/6)	abnormal complement pathway	J:52968
	immune system phenotype	J:52968
	impaired complement alternative pathway	J:52968
	impaired complement classical pathway	J:52968
Cd55^tm1Song/Cd55^tm1Song (involves: 129S6/SvEvTac)	abnormal complement pathway	J:76578
Cd55^tm1Song/Cd55^tm1Song (B6.129S6-Cd55^tm1Song)	increased susceptibility to experimental autoimmune myasthenia gravis	J:113567
Cd55^tm1Song/Cd55^tm1Song Cd59a^tm1Bpm/Cd59a^tm1Bpm (B6.129-Cd55^tm1Song Cd59a^tm1Bpm)	abnormal complement pathway	J:113567
	increased susceptibility to experimental autoimmune myasthenia gravis	J:113567
	myositis	J:113567
Cd59a^tm1Bpm/Cd59a^tm1Bpm (involves: 129 * C57BL/6)	increased susceptibility to experimental autoimmune encephalomyelitis	J:89014
Cd59a^tm1Bpm/Cd59a^tm1Bpm (involves: 129)	abnormal complement pathway	J:148367
	increased macrophage cell number	J:148367
	increased susceptibility to induced arthritis	J:146711
Cd59a^tm1Bpm/Cd59a^tm1Bpm (B6.129-Cd59a^tm1Bpm)	abnormal CD4-positive, alpha-beta T cell physiology	J:119703, J:123582
	abnormal complement pathway	J:92414
	abnormal humoral immune response	J:119703
	decreased B cell proliferation	J:119703
	decreased IgG level	J:119703
	decreased plasma cell number	J:119703
	decreased susceptibility to Poxviridae infection	J:122201
	increased CD4-positive, alpha-beta T cell number	J:123582
	increased double-positive T cell number	J:123582
	increased neutrophil cell number	J:123582
	increased susceptibility to experimental autoimmune myasthenia gravis	J:113567
	increased susceptibility to Orthomyxoviridae infection	J:123582
	increased T cell proliferation	J:122201
	lung inflammation	J:123582
	myositis	J:113567
Cd59a^tm1Bpm/Cd59a^tm1Bpm (involves: 129 * BALB/c)	increased susceptibility to Orthomyxoviridae infection	J:123582
Cd59a^tm1Song/Cd59a^tm1Song (involves: 129S6/SvEvTac)	abnormal complement pathway	J:76578
Cd59a^tm1Song/Cd59a^tm1Song Cd55^tm1Song/Cd55^tm1Song (involves: 129S6/SvEvTac * C57BL/6)	abnormal complement pathway	J:76578
Cd68^tm1Shnd/Cd68^tm1Shnd (either: B6.129-Cd68^tm1Shnd or (involves: 129S1/Sv * 129X1/SvJ))	abnormal dendritic cell antigen presentation	J:175275
Cd68^tm1Xfen/Cd68^tm1Xfen (C57BL/6J-Cd68^tm1Xfen)	abnormal osteoclast morphology	J:178120
Cd68^tm1Xfen/Cd68^tm1Xfen (C57BL/6J-Cd68^tm1Xfen)	abnormal osteoclast physiology	J:178120
Cd69^tm1Fsm/Cd69^tm1Fsm (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal B cell differentiation	J:61329
	abnormal humoral immune response	J:61329
	immune system phenotype	J:61329
	increased IgG2a level	J:61329
	increased IgM level	J:61329
	increased immature B cell number	J:61329
	increased pre-B cell number	J:61329
Cd69^tm1Naka/Cd69^tm1Naka (C.129P2-Cd69^tm1Naka)	decreased susceptibility to induced arthritis	J:84940
	impaired neutrophil chemotaxis	J:84940
	impaired neutrophil recruitment	J:84940
Cd69^tm1Naka/Cd69^tm1Naka (B6.129P2-Cd69^tm1Naka)	abnormal CD4-positive, alpha-beta T cell physiology	J:184704
	abnormal humoral immune response	J:184704
	abnormal memory T cell physiology	J:184704
	abnormal T cell physiology	J:184704
	decreased CD4-positive, alpha-beta T cell number	J:184704
	decreased interferon-gamma secretion	J:184704
	decreased tumor necrosis factor secretion	J:184704
Cd70^tm1(cre)Jbo/Cd70^tm1(cre)Jbo (B6.129P2-Cd70^tm1(cre)Jbo)	decreased regulatory T cell number	J:198200
	immune system phenotype	J:198200
Cd70^tm1.1Jda/Cd70^tm1.1Jda (B6.Cg-Cd70^tm1.1Jda)	abnormal CD8-positive, alpha-beta T cell physiology	J:193042
	abnormal immune system physiology	J:193042
	abnormal T cell physiology	J:193042
	decreased CD8-positive, alpha-beta T cell number	J:193042
	immune system phenotype	J:193042
	increased susceptibility to Riboviria infection	J:193042
Cd72^b/Cd72^b Fas^lpr/Fas^lpr (involves: C57BL/6 * C57BL/6JJmsSlc * MRL/Mp)	abnormal B cell number	J:204782
	abnormal T cell number	J:204782
	autoimmune response	J:204782
	decreased anti-double stranded DNA antibody level	J:204782
	decreased anti-nuclear antigen antibody level	J:204782
	decreased IgG level	J:204782
	decreased spleen weight	J:204782
	decreased susceptibility to autoimmune disorder	J:204782
Cd72^c/Cd72^c (involves: C57BL/6 * MRL)	immune system phenotype	J:204782
Cd72^c/Cd72^c (involves: C57BL/6 * MRL)	increased B cell proliferation	J:204782
Cd72^c/Cd72^c Fas^lpr/Fas^lpr (involves: C57BL/6 * C57BL/6JJmsSlc * MRL/Mp)	abnormal B cell number	J:204782
	abnormal T cell number	J:204782
	autoimmune response	J:204782
	enlarged lymph nodes	J:204782
	increased anti-chromatin antibody level	J:204782
	increased anti-double stranded DNA antibody level	J:204782
	increased anti-single stranded DNA antibody level	J:204782
	increased IgG level	J:204782
	increased spleen weight	J:204782
	increased susceptibility to systemic lupus erythematosus	J:204782
	liver inflammation	J:204782
	lung inflammation	J:204782
Cd72^tm1Jrp/Cd72^tm1Jrp (either: (involves: 129P2/OlaHsd) or (involves: 129P2/OlaHsd * C57BL/6))	abnormal B cell activation	J:76990
	abnormal B cell calcium ion homeostasis	J:76990
	abnormal B cell differentiation	J:76990
	decreased B cell number	J:76990
	decreased B-2 B cell number	J:76990
	decreased follicular B cell number	J:76990
	decreased mature B cell number	J:76990
	increased B cell proliferation	J:76990
	increased B-1 B cell number	J:76990
	increased B-1a cell number	J:76990
	increased IgM level	J:76990
	increased immature B cell number	J:76990
	increased marginal zone B cell number	J:76990
	increased pre-B cell number	J:76990
	increased pro-B cell number	J:76990
Cd72^tm1Jrp/Cd72^tm1Jrp Tg(BCL2)22Wehi/0 (either: (involves: 129P2/OlaHsd * C57BL/6JWehi * SJL/JWehi) or (involves: 129P2/OlaHsd * C57BL/6 * C57BL/6JWehi * SJL/JWehi))	abnormal B cell physiology	J:76990
	decreased mature B cell number	J:76990
	increased immature B cell number	J:76990
Cd72^tm1Tsub/Cd72^tm1Tsub (involves: C57BL/6J)	glomerulonephritis	J:204782
	immune system phenotype	J:204782
	increased anti-chromatin antibody level	J:204782
	increased anti-double stranded DNA antibody level	J:204782
	increased anti-single stranded DNA antibody level	J:204782
	increased B cell proliferation	J:204782
	increased spleen weight	J:204782
	lung inflammation	J:204782
Cd72^tm1Tsub/Cd72^tm1Tsub Fas^lpr/Fas^lpr (involves: C57BL/6J * C57BL/6JJmsSlc * MRL/Mp)	abnormal B cell number	J:204782
	abnormal T cell number	J:204782
	autoimmune response	J:204782
	enlarged lymph nodes	J:204782
	glomerulonephritis	J:204782
	increased anti-chromatin antibody level	J:204782
	increased anti-double stranded DNA antibody level	J:204782
	increased anti-single stranded DNA antibody level	J:204782
	increased spleen weight	J:204782
	liver inflammation	J:204782
	lung inflammation	J:204782
Cd74^em1(IMPC)H/Cd74^em1(IMPC)H (C57BL/6N-Cd74^em1(IMPC)H/H)	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
	increased eosinophil cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Cd74^tm1Doi/Cd74^tm1Doi (either: (involves: 129/Sv * B10.BR) or (involves: 129/Sv * C57BL/6))	abnormal antigen presentation	J:4119
	abnormal level of surface class II molecules	J:45185
	decreased CD4-positive, alpha-beta T cell number	J:4119, J:45185
	increased CD8-positive, alpha-beta T cell number	J:4119
Cd74^tm1Doi/Cd74^tm1Doi (involves: 129S2/SvPas)	abnormal dendritic cell antigen presentation	J:151699
Cd74^tm1Doi/Cd74^tm1Doi H2-DMa^tm1Doi/H2-DMa^tm1Doi (involves: 129S2/SvPas * C57BL/6)	abnormal professional antigen presenting cell physiology	J:42482
	decreased CD4-positive, alpha-beta T cell number	J:42482
	increased CD8-positive, alpha-beta T cell number	J:42482
Cd74^tm1Doi/Cd74^tm1Doi Tap1^tm1Arp/Tap1^tm1Arp (involves: 129S2/SvPas * C57BL/6)	abnormal T cell number	J:113083
Cd74^tm1Eae/Cd74^tm1Eae (involves: 129S2/SvPas)	abnormal level of surface class II molecules	J:65917
	decreased B cell proliferation	J:113050, J:132865
	decreased CD4-positive, alpha-beta T cell number	J:113050
	decreased IgM level	J:113050
Cd74^tm1Eae/Cd74^tm1Eae (B6.129S2-Cd74^tm1Eae)	abnormal lymph node cell ratio	J:112084
Cd74^tm1Eae/Cd74^tm1Eae (B6.129S2-Cd74^tm1Eae)	arrested B cell differentiation	J:112084
Cd74^tm1Liz/Cd74^tm1Liz (involves: 129S/SvEv * C57BL/6J)	abnormal antigen presentation	J:72243
	abnormal antigen presentation via MHC class II	J:65918
	abnormal level of surface class II molecules	J:65918
	decreased CD4-positive, alpha-beta T cell number	J:65918
	decreased interferon-gamma secretion	J:72243
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:72243
	decreased T cell proliferation	J:72243
	defective assembly of class II molecules	J:65918
Cd74^tm1Liz/Cd74^tm1Liz (B6.129S-Cd74^tm1Liz)	abnormal antigen presentation	J:125654
	abnormal antigen presentation via MHC class II	J:28966
	abnormal level of surface class II molecules	J:28966
	abnormal T-helper 1 physiology	J:125654
	decreased CD4-positive, alpha-beta T cell number	J:28966
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:125654
	decreased susceptibility to type IV hypersensitivity reaction	J:125654
	decreased T cell proliferation	J:28966
	defective assembly of class II molecules	J:28966
Cd74^tm1Liz/Cd74^tm1Liz (involves: 129S/SvEv * C57BL/6)	abnormal antigen presentation via MHC class II	J:111565
Cd74^tm1Liz/Cd74^tm1Liz (involves: 129S/SvEv * BALB/cAn)	abnormal antigen presentation via MHC class II	J:110927, J:113714
	abnormal B cell differentiation	J:110927
	abnormal dendritic cell antigen presentation	J:110927
	abnormal professional antigen presenting cell physiology	J:113714
	decreased CD4-positive, alpha-beta T cell number	J:110927, J:113714
	increased immature B cell number	J:110927
Cd74^tm1Liz/Cd74^tm1Liz (involves: 129S/SvEv * BALB/c * C57BL)	abnormal antigen presentation via MHC class II	J:110927
	abnormal B cell differentiation	J:110927
	abnormal dendritic cell antigen presentation	J:110927
	abnormal T cell proliferation	J:110927
	increased immature B cell number	J:110927
Cd74^tm1Liz/Cd74^tm1Liz (involves: 129S/SvEv * C57BL * C57BL/10 * C57BR)	abnormal antigen presentation via MHC class II	J:110927
	abnormal B cell differentiation	J:110927
	abnormal dendritic cell antigen presentation	J:110927
	abnormal T cell proliferation	J:110927
	increased immature B cell number	J:110927
Cd74^tm1Liz/Cd74^tm1Liz (involves: 129S/SvEv)	abnormal positive T cell selection	J:125548
Cd74^tm1Liz/Cd74^tm1Liz (B6.129S-Cd74^tm1Liz/J)	decreased B cell number	J:194664
Cd74^tm1Liz/Cd74^tm1Liz H2-DMa^tm1Liz/H2-DMa^tm1Liz (involves: 129S/SvEv * BALB/c)	decreased CD4-positive, alpha-beta T cell number	J:113714
Cd74^tm1Liz/Cd74^tm1Liz H2-DMa^tm1Luc/H2-DMa^tm1Luc Tg(CD74)AR194Ayr/? (involves: 129S/SvEv * 129S4/SvJae * C57BL/6J * DBA/2J)	abnormal antigen presentation via MHC class II	J:88717
	decreased CD4-positive, alpha-beta T cell number	J:88717
Cd74^tm1Liz/Cd74^tm1Liz H2-DMa^tm1Luc/H2-DMa^tm1Luc Tg(CD74)1Ayr/0 (involves: 129S/SvEv 129S4/SvJae * C57BL/6J * DBA/2J)	abnormal antigen presentation via MHC class II	J:88717
	decreased CD4-positive, alpha-beta T cell number	J:88717
Cd74^tm1Liz/Cd74^tm1Liz Sppl2a^tm1Basc/Sppl2a^tm1Basc (B6.129-Sppl2a^tm1Basc Cd74^tm1Liz)	decreased B cell number	J:194664
	decreased Peyer's patch number	J:194664
	immune system phenotype	J:194664
Cd74^tm1Liz/Cd74^tm1Liz Sppl2a^tm1Dgen/Sppl2a^tm1Dgen (involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6)	decreased follicular B cell number	J:194595
	immune system phenotype	J:194595
Cd74^tm2Liz/Cd74^tm1Liz (involves: 129S/SvEv * C57BL/6)	abnormal antigen presentation via MHC class II	J:28966
	immune system phenotype	J:28966
	increased T cell proliferation	J:28966
Cd74^tm2Liz/Cd74^tm2Liz (involves: 129S/SvEv * C57BL/6)	decreased interleukin-2 secretion	J:72243
Cd74^tm2Liz/Cd74^tm2Liz (involves: 129S/SvEv * C57BL/6)	increased susceptibility to experimental autoimmune encephalomyelitis	J:72243
Cd74^tm3Liz/Cd74^tm3Liz (involves: 129S/SvEv * C57BL/6)	abnormal antigen presentation via MHC class II	J:82880
	abnormal level of surface class II molecules	J:82880
	decreased interleukin-2 secretion	J:72243
	defective assembly of class II molecules	J:82880
	immune system phenotype	J:82880
	increased susceptibility to experimental autoimmune encephalomyelitis	J:72243
Cd79a^m1Anu/Cd79a^m1Anu (involves: C57BL/6JSfdAnu * C57BL/10Sg * C57BR/cd)	absent pre-B cells	J:104190
	decreased IgG level	J:104190
Cd79a^m1Anu/Cd79a^m1Anu (C57BL/6-Cd79a^m1Anu)	absent pre-B cells	J:171924
Cd79a^m1Anu/Cd79a^m1Anu Rasgrp1^m1Anu/Rasgrp1^m1Anu (involves: C57BL/6JSfdAnu * CBA/J)	immune system phenotype	J:207898
Cd79a^m1Btlr/Cd79a^m1Btlr (involves: C57BL/6J * C57BL/10J)	abnormal humoral immune response	J:174338
	decreased B cell number	J:174338
	decreased IgG level	J:174338
	decreased IgM level	J:174338
Cd79a^m1Btlr/Cd79a^m1Btlr (involves: C57BL/6J)	abnormal class switch recombination	J:185495
	decreased B cell number	J:185495
	decreased IgG level	J:185495
	decreased IgM level	J:185495
Cd79a^m2Btlr/Cd79a^m2Btlr (C57BL/6J-Cd79a^m2Btlr)	decreased B-1 B cell number	J:254836
	decreased IgM level	J:254836
	impaired humoral immune response	J:254836
Cd79a^tm1(cre)Reth/Cd79a⁺ Commd3^tm1.1Ksuz/Commd3^tm1.1Ksuz (involves: BALB/c * C57BL/6NSlc * SJL)	abnormal follicular B cell physiology	J:278399
	abnormal plasmablast number	J:278399
	abnormal spleen B cell follicle morphology	J:278399
	decreased follicular B cell number	J:278399
	decreased IgG1 level	J:278399
	decreased IgG2b level	J:278399
	decreased IgG2c level	J:278399
	decreased IgM level	J:278399
	decreased mature B cell number	J:278399
	decreased spleen germinal center number	J:278399
	immune system phenotype	J:278399
Cd79a^tm1(cre)Reth/Cd79a⁺ Commd8^tm1.1Ksuz/Commd8^tm1.1Ksuz (involves: BALB/c * C57BL/6NSlc * SJL)	abnormal follicular B cell physiology	J:278399
	abnormal plasmablast number	J:278399
	abnormal spleen B cell follicle morphology	J:278399
	decreased follicular B cell number	J:278399
	decreased IgG1 level	J:278399
	decreased IgG2b level	J:278399
	decreased IgG2c level	J:278399
	decreased IgG3 level	J:278399
	decreased IgM level	J:278399
	decreased mature B cell number	J:278399
	decreased spleen germinal center number	J:278399
	immune system phenotype	J:278399
Cd79a^tm1(cre)Reth/Cd79a⁺ Ctnnbl1^tm1.1Crad/Ctnnbl1^tm1.1Crad (involves: 129P2/OlaHsd * BALB/c * C57BL/6 * SJL)	abnormal B cell proliferation	J:232010
	abnormal class switch recombination	J:232010
	decreased B cell proliferation	J:232010
	immune system phenotype	J:232010
Cd79a^tm1(cre)Reth/Cd79a⁺ Dicer1^tm1Mmk/Dicer1^tm1Mmk Tg(BCL2)22Wehi/0 (involves: BALB/c * C57BL/6JWehi * SJL/JWehi)	decreased B cell number	J:135783
	decreased mature B cell number	J:135783
Cd79a^tm1(cre)Reth/Cd79a⁺ Dynll1^tm1.1Jhh/Dynll1^tm1.1Jhh (B6.Cg-Dynll1^tm1.1Jhh Cd79a^tm1(Cre)Reth)	abnormal B cell morphology	J:230105
	decreased immature B cell number	J:230105
	decreased mature B cell number	J:230105
	decreased pre-B cell number	J:230105
Cd79a^tm1(cre)Reth/Cd79a⁺ Dynll1^tm1.1Jhh/Dynll1^tm1.1Jhh Tg(IghMyc)22Bri/0 (B6.Cg-Dynll1^tm1.1Jhh Cd79a^tm1(Cre)Reth Tg(IghMyc)22Bri)	decreased immature B cell number	J:230105
Cd79a^tm1(cre)Reth/Cd79a⁺ Eif4a1^tm1.1Bea/Eif4a1^tm1.1Bea (involves: 129P2/OlaHsd * BALB/c * C57BL/6)	decreased B cell number	J:344730
	decreased pro-B cell number	J:344730
Cd79a^tm1(cre)Reth/Cd79a⁺ Eif4b^tm1.1Tnr/Eif4b^tm1.1Tnr Eif4h^{tm1c(EUCOMM)Wtsi}/Eif4h^{tm1c(EUCOMM)Wtsi} (involves: BALB/c * C57BL/6 * C57BL/6N)	decreased IgG1 level	J:344730
	decreased mature B cell number	J:344730
Cd79a^tm1(cre)Reth/Cd79a⁺ Huwe1^tm1.1Mak/Y (B6.Cg-Cd79a^tm1(cre)Reth Huwe1^tm1.1Mak)	abnormal B cell differentiation	J:181705
	abnormal class switch recombination	J:181705
	abnormal humoral immune response	J:181705
	absent B-1a cells	J:181705
	decreased B cell proliferation	J:181705
	decreased follicular B cell number	J:181705
	decreased IgA level	J:181705
	decreased IgG1 level	J:181705
	decreased IgG2a level	J:181705
	decreased IgG3 level	J:181705
	decreased IgM level	J:181705
	decreased marginal zone B cell number	J:181705
	decreased mature B cell number	J:181705
	decreased pre-B cell number	J:181705
	decreased transitional stage B cell number	J:181705
	increased B cell apoptosis	J:181705
	increased susceptibility to Riboviria infection	J:181705
Cd79a^tm1(cre)Reth/Cd79a⁺ Huwe1^tm1.1Mak/Y Trp53^tm1Brn/Trp53^tm1Brn (involves: 129P2/OlaHsd * C57BL/6 * SJL)	abnormal class switch recombination	J:181705
	absent B-1a cells	J:181705
	decreased IgG1 level	J:181705
	decreased IgM level	J:181705
	immune system phenotype	J:181705
Cd79a^tm1(cre)Reth/Cd79a⁺ Ikzf1^tm3.1Mbu/Ikzf1^tm3.1Mbu (involves: 129P2/OlaHsd * BALB/c * C57BL/6 * SJL)	abnormal B cell differentiation	J:209928
	abnormal B cell number	J:209928
	decreased pre-B cell number	J:209928
	increased pro-B cell number	J:209928
Cd79a^tm1(cre)Reth/Cd79a⁺ Inpp5d^tm1Rav/Inpp5d^tm1Rav (involves: 129 * BALB/c * C57BL/6)	increased anti-chromatin antibody level	J:178833
	increased anti-double stranded DNA antibody level	J:178833
	increased anti-nuclear antigen antibody level	J:178833
	increased anti-single stranded DNA antibody level	J:178833
	increased autoantibody level	J:178833
	increased IgG level	J:178833
	increased susceptibility to systemic lupus erythematosus	J:178833
Cd79a^tm1(cre)Reth/Cd79a⁺ Nfkbiz^tm1.1Muta/Nfkbiz^tm1.1Muta (involves: BALB/c * C57BL/6)	immune system phenotype	J:194832
Cd79a^tm1(cre)Reth/Cd79a⁺ Nr4a1^tm1Pcn/Nr4a1^tm1Pcn (involves: 129 * BALB/c)	increased B cell proliferation	J:306652
Cd79a^tm1(cre)Reth/Cd79a⁺ Nr4a1^tm1Pcn/Nr4a1^tm1Pcn Nr4a3^em1Juz/Nr4a3^em1Juz (involves: 129 * BALB/c * C57BL/6)	decreased B cell apoptosis	J:306652
	immune system phenotype	J:306652
	increased B cell proliferation	J:306652
Cd79a^tm1(cre)Reth/Cd79a⁺ Orai1^tm1Smua/Orai1^tm1Smua (involves: BALB/c * C57BL/6J)	abnormal B cell activation	J:345485
	abnormal B cell physiology	J:345485
	immune system phenotype	J:345485
Cd79a^tm1(cre)Reth/Cd79a⁺ Orai1^tm1Smua/Orai1^tm1Smua Orai3^em1.1Treb/Orai3^em1.1Treb (involves: BALB/c * C57BL/6J * C57BL/6N)	abnormal B cell activation	J:345485
	abnormal B cell physiology	J:345485
	decreased B cell proliferation	J:345485
	immune system phenotype	J:345485
Cd79a^tm1(cre)Reth/Cd79a⁺ Orai3^em1.1Treb/Orai3^em1.1Treb (involves: BALB/c * C57BL/6J * C57BL/6N)	abnormal B cell activation	J:345485
	immune system phenotype	J:345485
Cd79a^tm1(cre)Reth/Cd79a⁺ Phf5a^tm1.1Oux/Phf5a^tm1.1Oux (involves: BALB/c * C57BL/6J)	abnormal B cell physiology	J:345807
	abnormal B cell receptor editing	J:345807
	abnormal immunoglobulin heavy chain V(D)J recombination	J:345807
	decreased B cell number	J:345807
	decreased early pro-B cell number	J:345807
	decreased immature B cell number	J:345807
	decreased late pro-B cell number	J:345807
	decreased mature B cell number	J:345807
	decreased pre-B cell number	J:345807
	increased pre-pro B cell number	J:345807
	small spleen	J:345807
Cd79a^tm1(cre)Reth/Cd79a⁺ Phf5a^tm1.1Oux/Phf5a^tm1.1Oux Tg(IghelMD4)4Ccg/0 (involves: BALB/c * C57BL/6 * C57BL/6J)	abnormal B cell number	J:345807
Cd79a^tm1(cre)Reth/Cd79a⁺ Slc39a10^tm1.1Tfk/Slc39a10^tm1.1Tfk (involves: 129S1/Sv * 129X1/SvJ * BALB/c * C57BL/6J)	decreased B cell number	J:213935
	decreased IgA level	J:213935
	decreased IgE level	J:213935
	decreased IgG1 level	J:213935
	decreased IgG2b level	J:213935
	decreased IgG2c level	J:213935
	decreased IgG3 level	J:213935
	decreased IgM level	J:213935
	decreased immunoglobulin level	J:213935
	decreased pro-B cell number	J:213935
	spleen atrophy	J:213935
Cd79a^tm1(cre)Reth/Cd79a⁺ Was^tm1.1Ldn/Y (involves: BALB/c * C57BL/6)	abnormal B cell physiology	J:182528
	decreased B cell number	J:182528
	decreased follicular B cell number	J:182528
	decreased marginal zone B cell number	J:182528
	decreased mature B cell number	J:182528
	increased anti-chromatin antibody level	J:182528
	increased anti-double stranded DNA antibody level	J:182528
	increased anti-single stranded DNA antibody level	J:182528
	increased autoantibody level	J:182528
	increased germinal center B cell number	J:182528
	increased IgM level	J:182528
	increased plasma cell number	J:182528
Cd79a^tm1(cre)Reth/Cd79a⁺ Was^tm1.1Ldn/Was⁺ (involves: BALB/c * C57BL/6)	abnormal B cell number	J:182528
	abnormal B cell proliferation	J:182528
Cd79a^tm1(cre)Reth/Cd79a⁺ Was^tm1.1Ldn/Was^tm1.1Ldn (involves: BALB/c * C57BL/6)	abnormal B cell physiology	J:182528
	decreased B cell number	J:182528
	decreased follicular B cell number	J:182528
	decreased marginal zone B cell number	J:182528
	decreased mature B cell number	J:182528
	increased anti-chromatin antibody level	J:182528
	increased anti-double stranded DNA antibody level	J:182528
	increased anti-single stranded DNA antibody level	J:182528
	increased autoantibody level	J:182528
	increased germinal center B cell number	J:182528
	increased IgM level	J:182528
	increased plasma cell number	J:182528
Cd79a^tm1(cre)Reth/Cd79a^tm1(cre)Reth Mzb1^tm1.1Rug/Mzb1^tm1.1Rug (involves: 129S2/SvPas * BALB/c * C57BL/6 * SJL)	abnormal B cell number	J:211639
	decreased pre-B cell number	J:211639
	increased late pro-B cell number	J:211639
	increased pro-B cell number	J:211639
	small spleen	J:211639
Cd79a^{tm1.1(BAP31N-EGFP)Pld}/Cd79a^{tm1.1(BAP31N-EGFP)Pld} (Not Specified)	abnormal immune system cell morphology	J:75114
Cd79a^tm1.1Cgn/Cd79a⁺ Cd79b^tm1Gzmn/Cd79b^tm1Gzmn (involves: 129P2/OlaHsd)	decreased B cell number	J:179254
	decreased pre-B cell number	J:179254
	increased pro-B cell number	J:179254
Cd79a^tm1.1Cgn/Cd79a^tm1.1Cgn (involves: 129P2/OlaHsd)	decreased B-1a cell number	J:124400
Cd79a^tm1.1Cgn/Cd79a^tm1.1Cgn (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell activation	J:71100
	decreased B-1 B cell number	J:71100
	decreased IgG1 level	J:71100
	decreased marginal zone B cell number	J:71100
	decreased mature B cell number	J:71100
Cd79a^tm1.1Cgn/Cd79a^tm1.1Cgn Cd79b^tm1Gzmn/Cd79b⁺ (involves: 129P2/OlaHsd)	decreased B cell number	J:179254
	decreased pre-B cell number	J:179254
	increased pro-B cell number	J:179254
Cd79a^tm1.1Cgn/Cd79a^tm1.1Cgn Cd79b^tm1Gzmn/Cd79b^tm1Gzmn (involves: 129/Sv * 129P2/OlaHsd * C57BL/6)	abnormal B cell differentiation	J:124400
Cd79a^tm1.1Cgn/Cd79a^tm1.1Cgn Cd79b^tm1Gzmn/Cd79b^tm1Gzmn (involves: 129P2/OlaHsd)	abnormal B cell differentiation	J:179254
	absent pre-B cells	J:179254
	decreased B cell number	J:179254
	increased pro-B cell number	J:179254
Cd79a^tm1.1Cgn/Cd79a^tm1.1Cgn Cd79b^tm2.1Mnz/Cd79b^tm2.1Mnz (involves: 129/Sv * 129P2/OlaHsd * C57BL/6)	absent mature B cells	J:71100
	arrested B cell differentiation	J:71100
Cd79a^tm1.1Cgn/Cd79a^tm1.1Cgn Cd79b^tm3Mnz/Cd79b^tm3Mnz (involves: 129/Sv * 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:128768
Cd79a^tm1.1Rsky/Cd79a^tm1.1Rsky (involves: C57BL/6)	abnormal humoral immune response	J:179254
	decreased IgG2b level	J:179254
	decreased IgG2c level	J:179254
	decreased IgG3 level	J:179254
	decreased marginal zone B cell number	J:179254
	decreased mature B cell number	J:179254
	immune system phenotype	J:179254
	increased anti-single stranded DNA antibody level	J:179254
	increased IgG2b level	J:179254
	increased IgG2c level	J:179254
	increased immature B cell number	J:179254
	increased pre-B cell number	J:179254
	increased transitional stage B cell number	J:179254
	increased transitional stage T1 B cell number	J:179254
	increased transitional stage T2 B cell number	J:179254
	increased transitional stage T3 B cell number	J:179254
Cd79a^{tm2(cre/Esr1*)Reth}/Cd79a⁺ Rag1^tm1.1Sadu/Rag1^tm1.1Sadu (involves: BALB/c)	arrested B cell differentiation	J:155473
Cd79a^{tm2(cre/Esr1*)Reth}/Cd79a⁺ Rag1^tm1.1Sadu/Rag1^tm1.1Sadu (involves: BALB/c)	immune system phenotype	J:155473
Cd79a^tm2Cgn/Cd79a^tm2Cgn (involves: C57BL/6 * C.B-20)	decreased B cell number	J:80885
	decreased immunoglobulin level	J:80885
	decreased mature B cell number	J:80885
Cd79a^tm2Cgn/Cd79a^tm2Cgn (involves: C57BL/6)	decreased mature B cell number	J:71100, J:66840
	decreased pre-B cell number	J:71100, J:66840
	increased pro-B cell number	J:66840
Cd79a^tm2Cgn/Cd79a^tm2Cgn Cd79b^tm2.1Mnz/Cd79b^tm2.1Mnz (involves: 129/Sv * C57BL/6)	arrested B cell differentiation	J:66840
	decreased transitional stage B cell number	J:66840
Cd79a^tm2Pld/Cd79a^tm2Pld (BALB/c-Cd79a^tm2Pld)	abnormal B cell differentiation	J:87492
	abnormal T cell differentiation	J:87492
	absent mature B cells	J:87492
	decreased double-positive T cell number	J:87492
Cd79a^tm2Pld/Cd79a^tm2Pld Cd79b^tm1Mnz/Cd79b^tm1Mnz (involves: 129S1/Sv * BALB/c)	absent pre-B cells	J:87492
Cd79a^tm3Cgn/Cd79a^tm3Cgn Tg(Mx1-cre)1Cgn/? (involves: C57BL/6 * CBA)	abnormal metallophilic macrophage morphology	J:88620
	abnormal spleen marginal zone macrophage morphology	J:88620
	abnormal spleen red pulp morphology	J:88620
	decreased B cell number	J:88620
Cd79a^tm3Cgn/Cd79a^tm4.1Cgn (involves: C57BL/6 * CBA)	immune system phenotype	J:88620
Cd79a^tm4.1Cgn/Cd79a^tm4.1Cgn (involves: C57BL/6)	abnormal B cell differentiation	J:91091
Cd79a^tm4.1Cgn/Cd79a^tm4.1Cgn Igh^tm1.2Rsky/Igh⁺ (involves: BALB/c * C57BL/6)	abnormal pro-B cell differentiation	J:125719
Cd79a^tm4Cgn/Cd79a^tm4.1Cgn Tg(Cr2-cre)3Cgn/0 (involves: 129P2/OlaHsd * C57BL/6)	decreased B cell number	J:91091
	decreased IgD level	J:91091
	decreased IgM level	J:91091
Cd79a^tm4Cgn/Cd79a^tm4.1Cgn Tg(Mx1-cre)1Cgn/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA)	absent immature B cells	J:91091
	arrested B cell differentiation	J:91091
	decreased B cell number	J:91091
	decreased follicular B cell number	J:91091
	decreased marginal zone B cell number	J:91091
Cd79a^tm5.1Cgn/Cd79a⁺ Igh^tm1.2Rsky/Igh⁺ (involves: 129 * BALB/c * C57BL/6)	abnormal class switch recombination	J:125719
Cd79a^tm5.1Cgn/Cd79a^tm5.1Cgn (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell differentiation	J:91091
Cd79a^tm5.1Cgn/Cd79a^tm5.1Cgn (involves: 129 * C57BL/6)	abnormal B cell morphology	J:125719
	decreased B-1a cell number	J:125719
	decreased immature B cell number	J:125719
	decreased mature B cell number	J:125719
	decreased pre-B cell number	J:125719
	decreased T cell number	J:125719
	increased pro-B cell number	J:125719
Cd79a^tm5.1Cgn/Cd79a^tm5.1Cgn Igh^tm1.2Rsky/Igh⁺ (involves: 129 * BALB/c * C57BL/6)	abnormal class switch recombination	J:125719
Cd79a^tm5.1Cgn/Cd79a^tm5.1Cgn Igh^tm1.2Rsky/Igh^tm1.2Rsky (involves: 129 * BALB/c * C57BL/6)	abnormal B cell morphology	J:125719
	abnormal class switch recombination	J:125719
	decreased immature B cell number	J:125719
	decreased mature B cell number	J:125719
	decreased pre-B cell number	J:125719
	decreased T cell number	J:125719
	increased B-1b cell number	J:125719
	increased pro-B cell number	J:125719
Cd79a^tm5Cgn/Cd79a^tm5.1Cgn Tg(Cr2-cre)3Cgn/0 (involves: 129P2/OlaHsd * C57BL/6)	decreased B cell number	J:91091
Cd79a^tm5Cgn/Cd79a^tm5.1Cgn Tg(Mx1-cre)1Cgn/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA)	absent immature B cells	J:91091
	arrested B cell differentiation	J:91091
	decreased B cell number	J:91091
Cd79a^tm6Cgn/Cd79a^tm6Cgn (involves: C57BL/6)	abnormal B cell number	J:113407
	abnormal B cell physiology	J:113407
	abnormal humoral immune response	J:113407
	abnormal immunoglobulin level	J:113407
	decreased B cell proliferation	J:113407
	decreased B-1a cell number	J:113407
	decreased IgG2a level	J:113407
	decreased IgG3 level	J:113407
	decreased IgM level	J:113407
	immune system phenotype	J:113407
	increased transitional stage B cell number	J:113407
Cd79a^tm7Cgn/Cd79a^tm7Cgn (involves: C57BL/6)	abnormal immune system physiology	J:113407
Cd79b^m1Btlr/Cd79b^m1Btlr (C57BL/6J-Cd79b^m1Btlr)	decreased B cell number	J:267537
	decreased B-1 B cell number	J:267537
	decreased NK cell number	J:267537
	increased alpha-beta T cell number	J:267537
	increased CD4-positive, alpha-beta T cell number	J:267537
	increased CD8-positive, alpha-beta T cell number	J:267537
Cd79b^m1Ghost/Cd79b^m1Ghost (B10.Cg-Ptprc^a Cd79b^m1Ghost H2^a)	abnormal B cell differentiation	J:157450
	absent B cells	J:157450
	absent Peyer's patches	J:157450
	arrested B cell differentiation	J:157450
	decreased IgA level	J:157450
	decreased IgG level	J:157450
Cd79b^M2Btlr/Cd79b^M2Btlr (C57BL/6J-Cd79b^M2Btlr)	abnormal lymphocyte morphology	J:272863
	decreased B cell number	J:272863
	decreased B-1 B cell number	J:272863
Cd79b^tm1Gzmn/Cd79b^tm1Gzmn (involves: 129/Sv * C57BL/6)	abnormal immune system physiology	J:124400
	decreased B-1a cell number	J:124400
	decreased IgG1 level	J:124400
	increased IgD level	J:124400
	increased IgM level	J:124400
Cd79b^tm1Mnz/Cd79b^tm1Mnz (involves: 129S1/Sv)	abnormal pro-B cell differentiation	J:78601
	abnormal pro-B cell morphology	J:78601
	arrested B cell differentiation	J:78601
Cd79b^tm1Mnz/Cd79b^tm1Mnz Tg(BCL2)22Wehi/0 Tg(IghelMD4)4Ccg/0 Tg(Rag2-Igb)1Mnz/0 (involves: 129S1/Sv * C57BL/6 * C57BL/6JWehi * SJL/JWehi)	arrested B cell differentiation	J:78601
Cd79b^tm1Mnz/Cd79b^tm1Mnz Tg(BCL2)22Wehi/0 Tg(Rag2-Igb)1Mnz/0 (involves: 129S1/Sv * C57BL/6JWehi * SJL/JWehi)	arrested B cell differentiation	J:78601
Cd79b^tm1Mnz/Cd79b^tm1Mnz Tg(IghelMD4)4Ccg/0 Tg(Rag2-Igb)1Mnz/0 (involves: 129S1/Sv * C57BL/6)	abnormal immature B cell morphology	J:78601
	arrested B cell differentiation	J:78601
Cd79b^tm1Mnz/Cd79b^tm1Mnz Tg(Rag2-Igb)1Mnz/0 (involves: 129S1/Sv)	abnormal pre-B cell morphology	J:78601
	arrested B cell differentiation	J:78601
Cd79b^tm2.1Mnz/Cd79b^tm2.1Mnz (involves: 129 * C57BL/6)	decreased mature B cell number	J:71100
Cd79b^tm2.1Mnz/Cd79b^tm2.1Mnz (involves: 129/Sv * C57BL/6)	abnormal B cell activation	J:66840
	arrested B cell differentiation	J:66840
	decreased mature B cell number	J:66840
	decreased pre-B cell number	J:66840
	decreased transitional stage B cell number	J:66840
	increased pro-B cell number	J:66840
Cd79b^tm3Mnz/Cd79b^tm3Mnz (involves: 129/Sv * C57BL/6)	abnormal B cell physiology	J:128768
	abnormal immature B cell morphology	J:128768
	abnormal immune system physiology	J:128768
	decreased B cell number	J:128768
	decreased B cell proliferation	J:128768
	decreased B-1a cell number	J:128768
	decreased immature B cell number	J:128768
	decreased mature B cell number	J:128768
	increased marginal zone B cell number	J:128768
	increased pro-B cell number	J:128768
Cd80^tm1Lbgn/Cd80^tm1Lbgn (C3.Cg-Cd80^tm1Lbgn)	abnormal T cell physiology	J:110947
Cd80^tm1Shr/Cd80^tm1Shr (involves: 129S4/SvJae)	abnormal immunoglobulin level	J:39089
Cd80^tm1Shr/Cd80^tm1Shr (involves: 129S4/SvJae)	decreased B cell proliferation	J:74662
Cd80^tm1Shr/Cd80^tm1Shr Cd86^tm1Shr/Cd86^tm1Shr (B6.129S4-Cd80^tm1Shr Cd86^tm1Shr)	brain inflammation	J:57613
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:57613
	decreased T cell proliferation	J:57613
	increased interferon-gamma secretion	J:57613
	increased tumor necrosis factor secretion	J:57613
Cd80^tm1Shr/Cd80^tm1Shr Cd86^tm2Shr/Cd86^tm2Shr (involves: 129S4/SvJae)	abnormal lymph node B cell domain morphology	J:39089
	abnormal spleen morphology	J:39089
	abnormal T cell physiology	J:57090
	abnormal T cell proliferation	J:57090
	decreased IgG1 level	J:39089
	decreased IgG2a level	J:39089
	decreased IgG level	J:39089
	decreased regulatory T cell number	J:205441, J:113109
	increased IgG3 level	J:39089
	increased IgM level	J:39089
	increased susceptibility to autoimmune diabetes	J:113109
Cd80^tm1Shr/Cd80^tm1Shr Cd86^tm2Shr/Cd86^tm2Shr (involves: 129S4/SvJae * NOD)	abnormal CD4-positive, alpha-beta T cell physiology	J:61905
	abnormal cytokine secretion	J:61905
	increased susceptibility to autoimmune diabetes	J:61905
	insulitis	J:61905
Cd80^tm1Shr/Cd80^tm1Shr Cd86^tm2Shr/Cd86^tm2Shr (129.SJL-Cd86^tm2Shr)	decreased interleukin-2 secretion	J:78992
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:78992
	increased susceptibility to experimental autoimmune encephalomyelitis	J:78992
Cd80^tm1Shr/Cd80^tm1Shr Cd86^tm2Shr/Cd86^tm2Shr (involves: 129S4/SvJae * C57BL/6J * SJL)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:78992
Cd80^tm1Shr/Cd80^tm1Shr Cd86^tm2Shr/Cd86^tm2Shr (involves: 129S4/SvJae * BALB/c)	abnormal T cell number	J:112266
	decreased double-positive T cell number	J:112266
Cd80^tm1Shr/Cd80^tm1Shr Cd86^tm2Shr/Cd86^tm2Shr Ctla4^tm1Shr/Ctla4^tm1Shr (involves: 129S4/SvJae * BALB/c)	abnormal cytokine secretion	J:57090
	abnormal T cell physiology	J:57090
	increased T cell proliferation	J:57090
Cd80^tm1Shr/Cd80^tm1Shr Cd86^tm2Shr/Cd86^tm2Shr Tg(Ighm-Ctla4Ig/Cd80)1Jbs/0 (involves: 129S4/SvJae * FVB/N * NOD)	decreased regulatory T cell number	J:113109
	decreased susceptibility to autoimmune diabetes	J:113109
	insulitis	J:113109
Cd81^tm1Geha/Cd81^tm1Geha (involves: 129S4/SvJae * C57BL/6)	abnormal B cell morphology	J:43975
	decreased B-1 B cell number	J:43975
	decreased B-1a cell number	J:43975
	increased B cell proliferation	J:43975
	increased IgA level	J:43975
	increased IgG3 level	J:43975
	increased IgM level	J:43975
Cd81^tm1Lvy/Cd81^tm1Lvy (involves: 129S1/Sv * 129X1/SvJ)	abnormal B cell morphology	J:40394
	abnormal T-helper 2 physiology	J:40394
	decreased IgG1 level	J:40394
	decreased IgG level	J:40394
	decreased susceptibility to parasitic infection	J:126000
Cd81^tm1Lvy/Cd81^tm1Lvy (CByJ.129-Cd81^tm1Lvy)	abnormal T-helper 2 physiology	J:46171
Cd81^tm1Lvy/Cd81^tm1Lvy (CByJ.129-Cd81^tm1Lvy)	decreased susceptibility to type I hypersensitivity reaction	J:46171
Cd81^tm1Lvy/Cd81^tm1Lvy (either: (B6ByJ.129-Cd81^tm1Lvy x CByJ.129-Cd81^tm1Lvy)F1 or (CByJ.129-Cd81^tm1Lvy x B6ByJ.129-Cd81^tm1Lvy)F1)	abnormal microglial cell morphology	J:79426
Cd81^tm1Tmiy/Cd81^tm1Tmiy (involves: 129/Sv * C57BL/6)	abnormal B cell differentiation	J:41830
	abnormal immune system cell morphology	J:41830
	abnormal macrophage physiology	J:83795
	abnormal T cell proliferation	J:41830
	decreased B cell proliferation	J:41830
	decreased B-1 B cell number	J:41830
	increased B cell proliferation	J:41830
Cd81^tm1Tmiy/Cd81^tm1Tmiy Cd9^tm1Mek/Cd9^tm1Mek (involves: 129/Sv * C57BL/6)	abnormal macrophage physiology	J:83795
	increased osteoclast cell number	J:83795
Cd82^tm1Kjbr/Cd82^tm1Kjbr (Not Specified)	abnormal cellular extravasation	J:326451
	abnormal macrophage differentiation	J:326451
	abnormal neutrophil physiology	J:326451
	impaired leukocyte tethering or rolling	J:326451
	increased macrophage cell number	J:326451
	increased neutrophil cell number	J:326451
	increased susceptibility to bacterial infection	J:326451
Cd83^anu/Cd83^anu (involves: C57BL/6JAnu * CBA/CaJAnu)	abnormal B cell morphology	J:104190
	abnormal dendritic cell morphology	J:104190
	decreased CD4-positive, alpha-beta T cell number	J:104190
Cd83^lcd4/Cd83^lcd4 (involves: C57BL/6J)	abnormal CD4-positive T cell differentiation	J:92721
	abnormal CD4-positive, alpha-beta T cell physiology	J:92721
	decreased susceptibility to type IV hypersensitivity reaction	J:92721
	decreased T cell proliferation	J:92721
Cd83^tm1.1Lnjt/Cd83^tm1.1Lnjt (involves: C57BL/6 * C57BL/6N)	decreased CD4-positive, alpha-beta T cell number	J:236611
Cd83^tm1.1Lnjt/Cd83^tm1.1Lnjt H2-Ab1^b-tm2Hpl/H2-Ab1^b-tm2Hpl (involves: 129S4/SvJae * C57BL/6 * C57BL/6N)	immune system phenotype	J:236611
Cd83^tm1.1Lnjt/Cd83^tm1.1Lnjt Marchf1^tm1.1Sish/Marchf1^tm1.1Sish (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * C57BL/6N)	decreased CD4-positive, alpha-beta T cell number	J:236611
Cd83^tm1.1Lnjt/Cd83^tm1.1Lnjt Marchf8^tm1.1Lkle/Marchf8^tm1.1Lkle (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * C57BL/6N)	immune system phenotype	J:236611
Cd83^tm1Tft/Cd83^tm1Tft (involves: 129S4/SvJae * C57BL/6)	abnormal CD4-positive T cell differentiation	J:75700
	abnormal humoral immune response	J:75700
	arrested T cell differentiation	J:75700
	decreased CD4-positive, alpha-beta T cell number	J:75700
	decreased IgA level	J:75700
	decreased IgG1 level	J:75700
	decreased IgG2a level	J:75700
	decreased IgG2b level	J:75700
	decreased IgG3 level	J:75700
	decreased IgM level	J:75700
	decreased susceptibility to type IV hypersensitivity reaction	J:75700
Cd84^tm1Pls/Cd84^tm1Pls (C57BL/6J-Cd84^tm1Pls)	abnormal CD4-positive, alpha-beta T cell physiology	J:157915
	abnormal long lived plasma cell morphology	J:157915
	decreased CD4-positive, alpha-beta T cell number	J:157915
	decreased germinal center B cell number	J:157915
	decreased IgG level	J:157915
	decreased interleukin-21 secretion	J:157915
	decreased spleen germinal center size	J:157915
Cd84^tm1Pls/Cd84^tm1Pls Tg(TcraTcrb)425Cbn/? (B6.Cg-Cd84^tm1Pls Tg(TcraTcrb)425Cbn)	abnormal CD4-positive, alpha-beta T cell physiology	J:157915
Cd86^tm1Shr/Cd86^tm1Shr (NOD.129S4-Cd86^tm1Shr)	abnormal T cell proliferation	J:142046
	decreased regulatory T cell number	J:93421
	decreased susceptibility to autoimmune diabetes	J:71352
	decreased T cell proliferation	J:93421
	increased autoantibody level	J:142046
	increased interferon-gamma secretion	J:142046
	increased susceptibility to autoimmune diabetes	J:93421
Cd86^tm1Shr/Cd86^tm1Shr (involves: 129S4/SvJae)	abnormal humoral immune response	J:39089
	absent spleen germinal center	J:39089
	decreased IgG level	J:39089
Cd86^tm1Shr/Cd86^tm1Shr (B6.129S4-Cd86^tm1Shr)	decreased T cell proliferation	J:57613
Cd86^tm1Shr/Cd86^tm1Shr (B6.129S4-Cd86^tm1Shr)	increased interferon-gamma secretion	J:57613
Cd86^tm1Shr/Cd86^tm1Shr Marchf1^tm1.1Sish/Marchf1^tm1.1Sish (involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)	decreased interleukin-12 secretion	J:157516
	decreased tumor necrosis factor secretion	J:157516
Cd86^tm2Shr/Cd86^tm2Shr Icos^tm1Flv/Icos^tm1Flv (involves: 129S1/Sv * 129S4/SvJaeSor)	abnormal cytokine level	J:112600
Cd93^tm1Mbo/Cd93^tm1Mbo (either: 129/Sv or B6.129-Cd93^tm1Mbo or (involves: 129/Sv * C57BL/6))	impaired macrophage phagocytosis	J:88610
Cd96^{em1(IMPC)Wtsi}/Cd96^{em1(IMPC)Wtsi} (C57BL/6N-Cd96^{em1(IMPC)Wtsi}/WtsiOulu)	increased leukocyte cell number	J:211773
Cd96^tm1.1Mjs/Cd96^tm1.1Mjs (B6.129P2(Cg)-Cd96^tm1.1Mjs)	abnormal NK cell physiology	J:209990
	immune system phenotype	J:209990
	increased inflammatory response	J:209990
	increased susceptibility to endotoxin shock	J:209990
Cd99^{Gt(Ayu21-B6T44)Imeg}/Cd99^{Gt(Ayu21-B6T44)Imeg} (involves: C57BL/6)	immune system phenotype	J:207031
Cd99^{Gt(Ayu21-B6T44)Imeg}/Cd99^{Gt(Ayu21-B6T44)Imeg} (involves: C57BL/6 * C57BL/6NSlc)	abnormal splenocyte physiology	J:212222
Cd99l2^tm1.1Dvst/Cd99l2^tm1.1Dvst Tg(Tek-cre)1Ywa/0 (involves: 129S6/SvEvTac * BALB/c * C57BL/6)	abnormal cellular extravasation	J:193021
	decreased susceptibility to type IV hypersensitivity reaction	J:193021
Cd99l2^tm1.2Dvst/Cd99l2^tm1.2Dvst (involves: 129S6/SvEvTac * BALB/c * C57BL/6)	abnormal cellular extravasation	J:193021
Cd101^tm1.1Dil/Cd101^tm1.1Dil (involves: BALB/cJ * C57BL/6 * C57BL/6NTac)	decreased granulocyte number	J:175943
Cd109^tm1Mat/Cd109^tm1Mat (involves: 129S6/SvEvTac * C57BL/6J)	skin inflammation	J:188696
Cd151^tm1Lka/Cd151^tm1Lka (C57BL/6-Cd151^tm1Lka)	abnormal T cell proliferation	J:91605
Cd151^tm1Nki/Cd151^tm1Nki (involves: 129P2/OlaHsd * FVB/N)	tubulointerstitial nephritis	J:114988
Cd160^tm1Yxf/Cd160^tm1Yxf (C57BL/6-Cd160^tm1Yxf)	decreased interferon-gamma secretion	J:222131
Cd160^tm1Yxf/Cd160^tm1Yxf Rag1^tm1Mom/Rag1^tm1Mom (B6.Cg-Rag1^tm1Mom Cd160^tm1Yxf)	decreased interferon-gamma secretion	J:222131
Cd163^{tm1(KOMP)Vlcg}/Cd163^{tm1(KOMP)Vlcg} (involves: C57BL/6NTac)	abnormal circulating cytokine level	J:224919
	abnormal macrophage chemotaxis	J:224919
Cd163^{tm1(KOMP)Vlcg}/Cd163^{tm1(KOMP)Vlcg} (involves: C57BL/6NTac)	lung inflammation	J:233977
Cd177^{tm1(KOMP)Vlcg}/Cd177^{tm1(KOMP)Vlcg} (involves: C57BL/6NTac)	abnormal neutrophil physiology	J:225335
	decreased monocyte cell number	J:225335
	decreased neutrophil cell number	J:225335
	immune system phenotype	J:225335
Cd180^tm1Kmiy/Cd180^tm1Kmiy (involves: 129P2/OlaHsd * C57BL/6)	abnormal humoral immune response	J:63145
	decreased IgG2b level	J:137066
	decreased IgG3 level	J:137066
Cd180^tm1Kmiy/Cd180^tm1Kmiy (involves: 129P2/OlaHsd * C57BL/6 * NZB * NZW)	decreased IgG2a level	J:137066
	decreased IgG3 level	J:137066
Cd180^tm1Kmiy/Cd180^tm1Kmiy Fas^lpr/Fas^lpr (MRL.Cg-Cd180^tm1Kmiy Fas^lpr)	blood vessel inflammation	J:137066
	decreased B cell number	J:137066
	decreased CD8-positive, alpha-beta T cell number	J:137066
	decreased IgG2a level	J:137066
	decreased IgG3 level	J:137066
	enlarged lymph nodes	J:137066
	enlarged spleen	J:137066
	glomerulonephritis	J:137066
	increased anti-nuclear antigen antibody level	J:137066
	increased autoantibody level	J:137066
	increased double-negative T cell number	J:137066
Cd200^tm1Jods/Cd200^tm1Jods (C57BL/6-Cd200^tm1Jods)	abnormal cytokine level	J:95862
	abnormal immune system organ morphology	J:65982
	abnormal immune system physiology	J:65982
	abnormal lymph node morphology	J:65982
	abnormal macrophage physiology	J:65982
	abnormal microglial cell morphology	J:65982
	abnormal microglial cell physiology	J:65982
	enlarged lymph nodes	J:65982
	increased macrophage cell number	J:79906, J:65982
	increased spleen red pulp amount	J:65982
	increased susceptibility to experimental autoimmune encephalomyelitis	J:65982
	increased susceptibility to experimental autoimmune uveoretinitis	J:79906
	increased susceptibility to induced arthritis	J:65982
Cd200r1^tm1.1Rmgo/Cd200r1^tm1.1Rmgo (C57BL/6-Cd200r1^tm1.1Rmgo)	abnormal dendritic cell physiology	J:134313
	abnormal professional antigen presenting cell physiology	J:135069
	abnormal response to transplant	J:135069
	increased interleukin-12b secretion	J:135069
	increased tumor necrosis factor secretion	J:135069
Cd200r1^tm1.1Rmgo/Cd200r1^tm1.1Rmgo Tg(tetO/CMV-CD200)1Rmgo/Tg(tetO/CMV-CD200)1Rmgo (involves: C57BL/6)	abnormal dendritic cell physiology	J:134313
Cd200r1^tm1Eakj/Cd200r1^tm1Eakj (Not Specified)	abnormal macrophage physiology	J:326965
	decreased interferon-beta secretion	J:192198
	decreased interleukin-1 beta secretion	J:192198
	decreased interleukin-6 secretion	J:192198
	decreased susceptibility to Herpesvirales infection	J:192198
	decreased susceptibility to Herpesvirales infection induced morbidity/mortality	J:192198
Cd207^{tm1(Hbegf/EGFP)Bjec}/Cd207⁺ (involves: C57BL/6 * SJL)	absent Langerhans cell	J:137517
	decreased dendritic cell number	J:137452
	decreased susceptibility to type IV hypersensitivity reaction	J:137517
	increased susceptibility to Orthomyxoviridae infection	J:137452
Cd207^{tm1(Hbegf/EGFP)Bjec}/Cd207⁺ (involves: C57BL/6)	abnormal type IV hypersensitivity reaction	J:179630
Cd207^tm1.1Cfg/Cd207^tm1.1Cfg (involves: C57BL/6)	abnormal Peyer's patch morphology	J:217719
	decreased IgA level	J:217719
	decreased IgG1 level	J:217719
	decreased IgG2a level	J:217719
	decreased IgG3 level	J:217719
	decreased IgM level	J:217719
Cd207^tm1Mal/Cd207^tm1Mal (B6.129S2-Cd207^tm1Mal)	abnormal Langerhans cell morphology	J:95147
Cd207^{tm2.1(cre)Bjec}/Cd207⁺ (B6.Cg-CD207^{tm2.1(cre)Bjec})	immune system phenotype	J:179630
Cd207^{tm2.1(cre)Bjec}/Cd207⁺ Tgfbr1^tm1.1Karl/Tgfbr1^tm1.1Karl (involves: 129S4/SvJaeSor * C57BL/6)	abnormal type IV hypersensitivity reaction	J:179630
	decreased dendritic cell number	J:179630
Cd207^tm2.1Mal/Cd207^{tm3.1(HBEGF/EGFP)Mal} (involves: 129S2/SvPas)	abnormal Langerhans cell morphology	J:99114
	absent Langerhans cell	J:99114
	decreased Langerhans cell number	J:99114
Cd209a^tm1.1Cfg/Cd209a^tm1.1Cfg (involves: C57BL/6)	decreased IgG2b level	J:217719
	increased inflammatory response	J:217719
	increased lymphocyte cell number	J:217719
	increased mature B cell number	J:217719
	increased monocyte cell number	J:217719
	increased plasma cell number	J:217719
	increased spleen germinal center size	J:217719
	increased T cell proliferation	J:217719
Cd209a^tm1.1Cfg/Cd209a^tm1.1Cfg (B6.Cg-Cd209a^tm1.1Cfg/Mmucd)	immune system phenotype	J:194602
Cd209a^tm1Olne/Cd209a^tm1Olne (involves: C57BL/6 * C57BL/6J)	immune system phenotype	J:153503
Cd209b^tm1.1Cfg/Cd209b^tm1.1Cfg (involves: C57BL/6 * C57BL/6J)	immune system phenotype	J:153503
Cd209b^tm1.1Cfg/Cd209b^tm1.1Cfg (involves: C57BL/6)	decreased mature B cell number	J:217719
	impaired macrophage phagocytosis	J:288225
	increased eosinophil cell number	J:288225
	increased IgG2b level	J:217719
	increased IgG3 level	J:217719
	increased IgM level	J:217719
	increased macrophage cell number	J:217719
	increased susceptibility to bacterial infection	J:288225
	urinary bladder inflammation	J:288225
Cd209b^tm1Anjm/Cd209b^tm1Anjm (involves: 129P2/OlaHsd * C57BL/6)	abnormal macrophage physiology	J:94698
	impaired macrophage phagocytosis	J:94698
	increased susceptibility to bacterial infection	J:94698
	increased susceptibility to bacterial infection induced morbidity/mortality	J:94698
Cd209b^tm1Anjm/Cd209b^tm1Anjm (B6.129P2-Cd209b^tm1Anjm)	decreased interleukin-1 beta secretion	J:159646
	decreased interleukin-18 secretion	J:159646
	decreased susceptibility to endotoxin shock	J:159646
	decreased susceptibility to induced colitis	J:159646
	increased susceptibility to bacterial infection induced morbidity/mortality	J:94698
Cd209b^tm1Anjm/Cd209b^tm1Anjm (involves: 129P2/OlaHsd * BALB/c)	immune system phenotype	J:209808
Cd209b^tm1Anjm/Cd209b^tm1Anjm (C.129P2-Cd209b^tm1Anjm)	immune system phenotype	J:143766
Cd209c^{em1(IMPC)Ccpcz}/Cd209c^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Cd209c^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Cd209d^tm1.1Cfg/Cd209d^tm1.1Cfg (involves: C57BL/6 * C57BL/6J)	increased circulating tumor necrosis factor level	J:153503
	increased susceptibility to bacterial infection	J:153503
Cd209d^tm1.1Cfg/Cd209d^tm1.1Cfg (involves: C57BL/6)	increased B cell number	J:217719
Cd209d^tm1.1Cfg/Cd209d^tm1.1Cfg (involves: C57BL/6)	increased B cell proliferation	J:217719
Cd226^tm1.1Cln/Cd226^tm1.1Cln (B6.129P2-Cd226^tm1.1Cln)	decreased inflammatory response	J:209990
	decreased T cell proliferation	J:159749
	impaired natural killer cell mediated cytotoxicity	J:159749
Cd226^tm1.1Cln/Cd226^tm1.1Cln Tg(TcraTcrb)1100Mjb/0 (B6.Cg-Cd226^tm1.1Cln Tg(TcraTcrb)1100Mjb)	abnormal T cell activation	J:159749
	decreased cytotoxic T cell cytolysis	J:159749
	decreased interferon-gamma secretion	J:159749
	decreased T cell proliferation	J:159749
Cd226^tm1Shib/Cd226^tm1Shib (involves: BALB/c)	abnormal immune system physiology	J:165704
	decreased cytotoxic T cell cytolysis	J:165704
	impaired natural killer cell mediated cytotoxicity	J:165704
Cd244a^Chip/Cd244a⁺ (C57BL/6J-Cd244a^Chip)	abnormal NK cell physiology	J:196519
Cd244a^Chip/Cd244a⁺ (C57BL/6J-Cd244a^Chip)	impaired natural killer cell mediated cytotoxicity	J:196519
Cd244a^Chip/Cd244a^Chip (C57BL/6J-Cd244a^Chip)	abnormal NK cell physiology	J:196519
Cd244a^Chip/Cd244a^Chip (C57BL/6J-Cd244a^Chip)	impaired natural killer cell mediated cytotoxicity	J:196519
Cd244a^tm1Kmle/Cd244a^tm1Kmle (involves: C57BL/6)	impaired natural killer cell mediated cytotoxicity	J:166054
Cd244a^tm1Kmle/Cd244a^tm1Kmle (involves: C57BL/6)	increased natural killer cell mediated cytotoxicity	J:92740
Cd247^m1Btlr/Cd247^m1Btlr (C57BL/6J-Cd247^m1Btlr)	abnormal CD4-positive, alpha-beta T cell physiology	J:158794
Cd247^tm1Lov/Cd247^tm1Lov (involves: 129S4/SvJae)	abnormal single-positive T cell number	J:14170
	abnormal T-helper 1 cell morphology	J:14170
	abnormal T-helper 1 physiology	J:46914
	absent gamma-delta intraepithelial T cell	J:46914
	decreased CD4-positive, alpha-beta T cell number	J:14170
	decreased double-positive T cell number	J:14170
	decreased thymocyte number	J:14170
Cd247^tm1Lov/Cd247^tm1Lov Fcer1g^tm1Rav/Fcer1g^tm1Rav (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)	abnormal effector T cell morphology	J:46914
	abnormal T cell activation	J:46914
	abnormal T-helper 1 physiology	J:46914
	absent gamma-delta intraepithelial T cell	J:46914
	decreased thymocyte number	J:46914
	impaired natural killer cell mediated cytotoxicity	J:64764
Cd247^tm1Lov/Cd247^tm2.1Lov (involves: 129S4/SvJae)	immune system phenotype	J:192915
Cd247^tm1Mal/Cd247^tm1Mal (either: C57BL/6-Cd247^tm1Mal or (involves: BALB/c * C57BL/6))	abnormal intraepithelial T cell morphology	J:15272
	abnormal T cell differentiation	J:15272
	decreased CD4-positive, alpha-beta T cell number	J:15272
	decreased CD8-positive, alpha-beta T cell number	J:15272
	decreased double-positive T cell number	J:15272
	decreased single-positive T cell number	J:15272
	decreased thymocyte number	J:15272
	increased double-negative T cell number	J:15272
Cd247^tm1Mal/Cd247^tm1Mal (involves: C57BL/6)	abnormal double-negative T cell morphology	J:112990, J:110847
	abnormal T cell differentiation	J:112990
	abnormal T cell morphology	J:110847
	abnormal thymocyte activation	J:110847
	decreased double-positive T cell number	J:110847
Cd247^tm1Mal/Cd247^tm1Mal Lck^tm1Mak/Lck^tm1Mak (involves: 129S2/SvPas * C57BL/6)	abnormal double-negative T cell morphology	J:110847
	abnormal T cell differentiation	J:110847
	abnormal T cell morphology	J:110847
	abnormal thymocyte activation	J:110847
	decreased double-positive T cell number	J:110847
Cd247^tm1Mhu/Cd247^tm1Mhu (involves: 129S7/SvEvBrd * C57BL/6)	abnormal T cell differentiation	J:15579
	decreased CD4-positive, alpha-beta T cell number	J:15579
	decreased CD8-positive, alpha-beta T cell number	J:15579
	decreased double-positive T cell number	J:15579
	decreased splenocyte proliferation	J:15579
	decreased T cell proliferation	J:15579
	decreased thymocyte number	J:15579
	enlarged lymph nodes	J:15579
	enlarged spleen	J:15579
	enlarged thymus cortex	J:15579
	immune system phenotype	J:15579
	increased double-negative T cell number	J:15579
	small thymus	J:15579
	small thymus medulla	J:15579
	thymus hypoplasia	J:15579
Cd247^tm1Mhu/Cd247^tm1Mhu Fcer1g^tm1Rav/Fcer1g^tm1Rav (involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6)	decreased uterine NK cell number	J:100668
Cd247^tm1Tks/Cd247^tm1Tks (involves: 129P2/OlaHsd * C57BL/6)	abnormal alpha-beta intraepithelial T cell morphology	J:15271
	abnormal T cell proliferation	J:15271
	decreased CD4-positive, alpha-beta T cell number	J:15271
	decreased CD8-positive, alpha-beta T cell number	J:15271
	decreased double-positive T cell number	J:15271
	decreased single-positive T cell number	J:15271
	decreased thymocyte number	J:15271
	small thymus medulla	J:15271
Cd247^tm1Tks/Cd247^tm1Tks (B6.129P2-Cd247^tm1Tks)	abnormal NK cell morphology	J:66403
	abnormal NK cell physiology	J:66403
	decreased NK T cell number	J:28282
	increased interferon-gamma secretion	J:66403
	increased natural killer cell mediated cytotoxicity	J:66403
Cd247^tm2.1Lov/Cd247^tm2.1Lov (Not Specified)	abnormal gamma-delta T cell differentiation	J:192915
	abnormal NK T cell morphology	J:192915
	abnormal regulatory T cell physiology	J:192915
	abnormal T cell differentiation	J:192915
	abnormal T cell physiology	J:192915
	abnormal T-helper 1 cell differentiation	J:192915
	decreased CD4-positive, alpha-beta T cell number	J:192915
	decreased CD8-positive, alpha-beta T cell number	J:192915
	decreased thymocyte apoptosis	J:192915
	decreased thymocyte number	J:192915
	immune system phenotype	J:192915
	increased regulatory T cell number	J:192915
Cd247^tm2.1Lov/Cd247^tm2.1Lov (B6.Cg-Cd247^tm2.1Lov)	increased susceptibility to experimental autoimmune encephalomyelitis	J:192915
Cd247^tm2.1Lov/Cd247^tm2.1Lov Tg(TcraH-Y,TcrbH-Y)71Vbo/0 (involves: C57BL/6J * DBA/2J)	abnormal T cell differentiation	J:192915
Cd248^tm1Huso/Cd248^tm1Huso (involves: 129S/SvEv * C57BL/6)	immune system phenotype	J:107172
Cd274^tm1.1Lex/Cd274^tm1.1Lex (involves: 129S5/SvEvBrd)	abnormal cytokine secretion	J:126829
	decreased CD8-positive, alpha-beta T cell number	J:126829
	increased susceptibility to experimental autoimmune encephalomyelitis	J:126829
Cd274^tm1Igu/Cd274^tm1Igu Vsir^tm1Lex/Vsir^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6)	abnormal T cell activation	J:222944
Cd274^tm1Lpc/Cd274^tm1Lpc (B6.129S-Cd274^tm1Lpc)	abnormal CD8-positive, alpha-beta T cell physiology	J:89781
	decreased T cell apoptosis	J:89781
	increased activated T cell number	J:89781
	increased CD8-positive, alpha-beta T cell number	J:89781
	increased susceptibility to autoimmune disorder	J:89781
Cd274^tm1Lpc/Cd274^tm1Lpc (involves: 129S/SvEv)	abnormal chemokine secretion	J:158023
Cd274^tm1Lpc/Cd274^tm1Lpc (involves: 129S/SvEv)	increased tumor necrosis factor secretion	J:158023
Cd274^tm1Lpc/Cd274^tm1Lpc (involves: 129S/SvEv * C57BL/6)	abnormal dendritic cell physiology	J:152305
	abnormal T cell morphology	J:136330
	abnormal T-helper 1 cell differentiation	J:162539
	decreased susceptibility to Riboviria infection	J:136330
	decreased susceptibility to Riboviria infection induced morbidity/mortality	J:136330
	decreased T cell apoptosis	J:136330
	decreased T helper 1 cell number	J:162539
	increased CD8-positive, alpha-beta T cell number	J:152305
	increased IgG1 level	J:162539
	increased IgG2c level	J:162539
	increased susceptibility to bacterial infection	J:162539
	increased susceptibility to bacterial infection induced morbidity/mortality	J:162539
	increased susceptibility to experimental autoimmune encephalomyelitis	J:142815
	increased T cell number	J:142815
Cd274^tm1Lpc/Cd274^tm1Lpc (C.129S-Cd274^tm1Lpc)	abnormal regulatory T cell physiology	J:165841
	abnormal T follicular helper cell physiology	J:165841
	decreased germinal center B cell number	J:165841
	decreased IgG1 level	J:165841
	decreased IgG2a level	J:165841
	decreased interleukin-17 secretion	J:165841
	decreased plasma cell number	J:165841
	decreased T-helper 17 cell number	J:165841
	immune system phenotype	J:165841
	increased interferon-gamma secretion	J:165841
	increased interleukin-4 secretion	J:165841
	increased susceptibility to induced arthritis	J:165841
	increased T cell proliferation	J:165841
Cd274^tm1Shr/Cd274^tm1Shr (involves: C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:91480
Cd274^tm1Shr/Cd274^tm1Shr (involves: C57BL/6)	abnormal CD8-positive, alpha beta T cell morphology	J:91480
Cd274^tm1Shr/Cd274^tm1Shr (C.B6-Cd274^tm1Shr)	abnormal interleukin secretion	J:123785
	increased interferon-gamma secretion	J:123785
	increased susceptibility to autoimmune diabetes	J:123785
Cd274^tm1Shr/Cd274^tm1Shr Pdcd1lg2^tm3Shr/Pdcd1lg2^tm3Shr (C.B6-Cd274^tm1Shr Pdcd1lg2^tm3Shr)	abnormal dendritic cell physiology	J:123785
	decreased interleukin-4 secretion	J:123785
	increased interferon-gamma secretion	J:123785
	increased interleukin-2 secretion	J:123785
Cd274^tm1Shr/Cd274^tm1Shr Tg(TcraTcrb)1100Mjb/0 (involves: C57BL/6)	increased susceptibility to autoimmune diabetes	J:153040
Cd274^tm2Shr/Cd274^tm2Shr (involves: 129/Sv * 129S4/SvJae)	abnormal cytokine secretion	J:113851
Cd274^tm2Shr/Cd274^tm2Shr (involves: 129/Sv * 129S4/SvJae)	decreased susceptibility to parasitic infection	J:113851
Cd274^tm2Shr/Cd274^tm2Shr Pdcd1lg2^tm4Shr/Pdcd1lg2^tm4Shr (involves: 129S4/SvJae)	abnormal immune system physiology	J:160970
Cd276^tm1Lpc/Cd276^tm1Lpc (B6.129-Cd276^tm1Lpc)	abnormal T-helper 1 physiology	J:237700
	abnormal T-helper 2 physiology	J:237700
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:237700
	increased susceptibility to type I hypersensitivity reaction	J:237700
Cd276^tm1Lpc/Cd276^tm1Lpc (D1J.129-Cd276^tm1Lpc)	abnormal T-helper 1 physiology	J:237700
	abnormal T-helper 17 cell physiology	J:237700
	decreased susceptibility to induced arthritis	J:237700
Cd276^tm1Mak/Cd276^tm1Mak (involves: 129P2/OlaHsd * C57BL/6)	abnormal T-helper 1 physiology	J:84973
	immune system phenotype	J:84973
	increased anti-single stranded DNA antibody level	J:84973
	increased inflammatory response	J:84973
	increased susceptibility to experimental autoimmune encephalomyelitis	J:84973
	increased T cell proliferation	J:84973
Cd276^tm1Mak/Cd276^tm1Mak (C.129P2-Cd276^tm1Mak)	abnormal T-helper 1 physiology	J:84973
	increased inflammatory response	J:84973
	increased interferon-gamma secretion	J:84973
Cd276^tm1Wwh/Cd276^tm1Wwh (B6.Cg-B7h3^tm1Wwh)	abnormal cytokine secretion	J:95550
Cd276^tm1Wwh/Cd276^tm1Wwh (B6.Cg-B7h3^tm1Wwh)	abnormal response to transplant	J:95550
Cd300a^{tm1b(EUCOMM)Hmgu}/Cd300a^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Cd300a^{tm1b(EUCOMM)Hmgu}/Bay)	decreased eosinophil cell number	J:211773
Cd300a^tm1Shib/Cd300a^tm1Shib (B6JJcl.C-Cd300a^tm1Shib)	abnormal chemokine secretion	J:189144
	abnormal mast cell physiology	J:189144
	increased interleukin-10 secretion	J:189144
	increased interleukin-13 secretion	J:189144
	increased neutrophil cell number	J:189144
	increased tumor necrosis factor secretion	J:189144
Cd300c2^tm1Shib/Cd300c2^tm1Shib (B6.Cg-Cd300c2^tm1Shib)	increased B cell proliferation	J:177613
Cd300c^{em1(IMPC)Wtsi}/Cd300c^{em1(IMPC)Wtsi} (C57BL/6N-Cd300c^{em1(IMPC)Wtsi}/WtsiOulu)	increased leukocyte cell number	J:211773
Cd300lb^tm1Toki/Cd300lb^tm1Toki (B6.Cg-Cd300lb^tm1Toki)	immune system phenotype	J:163402
Cd300lf^tm1Gne/Cd300lf^tm1Gne (involves: C57BL/6N)	immune system phenotype	J:156819
	increased interleukin-1 alpha secretion	J:156819
	increased interleukin-1 beta secretion	J:156819
	increased interleukin-12 secretion	J:156819
	increased susceptibility to experimental autoimmune encephalomyelitis	J:156819
Cd300lf^tm1Toki/Cd300lf^tm1Toki (Not Specified)	abnormal interleukin secretion	J:190979
	abnormal mast cell physiology	J:190979
	immune system phenotype	J:190979
	increased interleukin-4 secretion	J:190979
	increased interleukin-5 secretion	J:190979
	increased interleukin-13 secretion	J:190979
	increased susceptibility to type I hypersensitivity reaction	J:190979
	respiratory system inflammation	J:190979
Cd302^tm1.1Dnjh/Cd302^tm1.1Dnjh (involves: C57BL/6)	abnormal CD8-positive, alpha-beta T cell physiology	J:301848
	abnormal dendritic cell physiology	J:301848
	decreased dendritic cell number	J:301848
	immune system phenotype	J:301848
Cd320^{Gt(CC0426)Wtsi}/Cd320^{Gt(CC0426)Wtsi} (involves: 129P2/OlaHsd * C57BL/6)	decreased leukocyte cell number	J:199961
Cdc7^{tm1.1(KOMP)Vlcg}/Cdc7⁺ (C57BL/6N-Cdc7^{tm1.1(KOMP)Vlcg}/Tcp)	decreased neutrophil cell number	J:211773
	increased lymphocyte cell number	J:211773
Cdc7^tm1Hmas/Cdc7^tm1Hmas Tg(EF1A-Cdc7)DKO28Hmas/0 (involves: 129S/Sv * C57BL/6)	immune system phenotype	J:85942
Cdc42^{tm1b(EUCOMM)Hmgu}/Cdc42⁺ (C57BL/6N-Cdc42^{tm1b(EUCOMM)Hmgu}/H)	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Cdc42ep5^{tm1(KOMP)Wtsi}/Cdc42ep5^{tm1(KOMP)Wtsi} (C57BL/6N-Cdc42ep5^{tm1(KOMP)Wtsi}/Nju)	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
Cdc73^tm1Btt/Cdc73^tm1Btt Tg(CAG-cre/Esr1)5Amc/0 (involves: 129S4/SvJae C57BL/6 * CBA)	small spleen	J:135255
Cdca7l^em1(IMPC)Mbp/Cdca7l^em1(IMPC)Mbp (C57BL/6NCrl-Cdca7l^em1(IMPC)Mbp/Mmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Cdcp2^em1(IMPC)Mbp/Cdcp2^em1(IMPC)Mbp (C57BL/6N-Cdcp2^em1(IMPC)Mbp/MbpMmucd)	small spleen	J:211773
Cdcs1^C3H/HeJBir/Cdcs1^C3H/HeJBir (involves: B6.129P2-Il10^tm1Cgn/Lt * C3Bir.129P2(B6)-Il10^tm1Cgn/Lt)	abnormal immune system physiology	J:72978
Cdcs1^C3H/HeJBir/Cdcs1^C57BL/6J (involves: C3H/HeJBir-Il10^tm1Cgn * C57BL/6J-Il10^tm1Cgn)	colitis	J:72978
Cdcs2^C3H/HeJBir/Cdcs2^C3H/HeJBir (involves: B6.129P2-Il10^tm1Cgn/Lt * C3Bir.129P2(B6)-Il10^tm1Cgn/Lt)	intestinal inflammation	J:72978
Cdcs2^C3H/HeJBir/Cdcs2^C57BL/6J (involves: B6.129P2-Il10^tm1Cgn/Lt * C3Bir.129P2(B6)-Il10^tm1Cgn/Lt)	intestinal inflammation	J:72978
Cdcs3^C3H/HeJBir/Cdcs3^C3H/HeJBir (involves: B6.129P2-Il10^tm1Cgn/Lt * C3Bir.129P2(B6)-Il10^tm1Cgn/Lt)	intestinal inflammation	J:72978
Cdcs4^C3H/HeJBir/Cdcs4^C57BL/6J (involves: C3H/HeJBir * C57BL/6J)	intestinal inflammation	J:72978
Cdcs4^C57BL/6J/Cdcs4^C57BL/6J (involves: C3H/HeJBir * C57BL/6J)	intestinal inflammation	J:72978
Cdcs5^C57BL/6J/Cdcs5^C57BL/6J (involves: C3H/HeJBir * C57BL/6J)	intestinal inflammation	J:72978
Cdcs6^C57BL/6J/? (involves: B6.129P2-Il10^tm1Cgn/Lt * C3Bir.129P2(B6)-Il10^tm1Cgn/Lt)	intestinal inflammation	J:72978
Cdcs7^C3H/HeJBir/Cdcs7^C3H/HeJBir (involves: C3H/HeJBir * C57BL/6J)	intestinal inflammation	J:78917
Cdcs8^C57BL/6J/Cdcs8^C57BL/6J (involves: C3H/HeJBir * C57BL/6J)	intestinal inflammation	J:78917
Cdcs9^C3H/HeJBir/Cdcs9^C3H/HeJBir (involves: C3H/HeJBir * C57BL/6J)	intestinal inflammation	J:78917
Cdcs9^C3H/HeJBir/Cdcs9^C57BL/6J (involves: C3H/HeJBir * C57BL/6J)	intestinal inflammation	J:78917
Cdcs10^C3H/HeJBir/Cdcs10^C3H/HeJBir (involves: C3H/HeJBir-Il10^tm1Cgn * C57BL/6J-Il10^tm1Cgn)	intestinal inflammation	J:78917
Cdcs10^C3H/HeJBir/Cdcs10^C57BL/6J (involves: C3H/HeJBir-Il10^tm1Cgn * C57BL/6J-Il10^tm1Cgn)	intestinal inflammation	J:72978
Cdh1^tm1Mlec/Cdh1^tm1Mlec (involves: 129S2/SvPas)	increased susceptibility to bacterial infection	J:142843
Cdh5^{tm3(Cdh5/Ctnna1)Dvst}/Cdh5^{tm3(Cdh5/Ctnna1)Dvst} (involves: 129 * C57BL/6)	abnormal cellular extravasation	J:177191
	abnormal leukocyte migration	J:177191
	abnormal lymphatic vessel endothelial cell morphology	J:213676
	immune system phenotype	J:213676
	increased leukocyte cell number	J:177191
	increased neutrophil cell number	J:177191
Cdh5^{tm3(Cdh5/Ctnna1)Dvst}/Cdh5^{tm3(Cdh5/Ctnna1)Dvst} (B6.Cg-Cdh5^{tm3(Cdh5/Ctnna1)Dvst})	abnormal lymphatic vessel endothelium morphology	J:213676
	abnormal lymphatic vessel morphology	J:213676
Cdh5^{tm4(Cdh5/Fkbp,Ptprb/Mtor)Dvst}/Cdh5^{tm4(Cdh5/Fkbp,Ptprb/Mtor)Dvst} (involves: C57BL/6)	abnormal cellular extravasation	J:178759
	impaired neutrophil recruitment	J:178759
Cdh5^tm5Dvst/Cdh5^tm5Dvst (B6.Cg-Cdh5^tm5Dvst)	abnormal cellular extravasation	J:209801
Cdh5^tm6Dvst/Cdh5^tm6Dvst (B6.Cg-Cdh5^tm6Dvst)	abnormal cellular extravasation	J:209801
Cdh10^{tm2b(KOMP)Wtsi}/Cdh10^{tm2b(KOMP)Wtsi} (C57BL/6N-Cdh10^{tm2b(KOMP)Wtsi}/Ucd)	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Cdh17^M1Btlr/Cdh17^M1Btlr (C57BL/6J-Cdh17^M1Btlr)	increased susceptibility to induced colitis	J:272090
Cdh17^tm1Ohn/Cdh17^tm1Ohn (involves: 129P2/OlaHsd * C57BL/6)	abnormal spleen marginal zone morphology	J:96738
	decreased B cell number	J:96738
	decreased B-1a cell number	J:96738
	decreased germinal center B cell number	J:96738
	decreased IgG level	J:96738
	decreased marginal zone B cell number	J:96738
	decreased mature B cell number	J:96738
	decreased spleen germinal center size	J:96738
	increased pre-B cell number	J:96738
	increased pro-B cell number	J:96738
Cdh23^{tm2b(EUCOMM)Wtsi}/Cdh23^{tm2b(EUCOMM)Wtsi} (C57BL/6N-Cdh23^{tm2b(EUCOMM)Wtsi}/Wtsi)	decreased leukocyte cell number	J:211773
Cdhr3^{em1(IMPC)Wtsi}/Cdhr3^{em1(IMPC)Wtsi} (C57BL/6NCrl-Cdhr3^{em1(IMPC)Wtsi}/Wtsi)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Cdk2^tm2Sgo/Cdk2^tm2Sgo Cdk4^tm2.1Bbd/Cdk4^tm2.1Bbd Polr2a^{tm1(cre/ERT2)Bbd}/? (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)	increased susceptibility to autoimmune diabetes	J:125217
Cdk4⁺/Cdk4⁺ Tg(Mt1-Hgf)#Lmb/0 (B6.Cg-Cdk4^tm1.1Bbd Tg(Mt1-Hgf)#Lmb)	abnormal axillary lymph node morphology	J:111992
	abnormal inguinal lymph node morphology	J:111992
Cdk4^tm1.1Bbd/Cdk4⁺ Tg(Mt1-Hgf)#Lmb/0 (B6.Cg-Cdk4^tm1.1Bbd Tg(Mt1-Hgf)#Lmb)	abnormal axillary lymph node morphology	J:111992
	abnormal inguinal lymph node morphology	J:111992
	enlarged axillary lymph nodes	J:111992
	enlarged inguinal lymph nodes	J:111992
Cdk4^tm1.1Bbd/Cdk4^tm1.1Bbd Tg(Mt1-Hgf)#Lmb/0 (B6.Cg-Cdk4^tm1.1Bbd Tg(Mt1-Hgf)#Lmb)	abnormal axillary lymph node morphology	J:111992
	abnormal inguinal lymph node morphology	J:111992
	enlarged axillary lymph nodes	J:111992
	enlarged inguinal lymph nodes	J:111992
Cdk4^tm1Kiyo/Cdk4⁺ Lin9^tm1Orc/Lin9⁺ (involves: 129S1/Sv)	decreased susceptibility to autoimmune diabetes	J:111333
Cdk5rap2^an/Cdk5rap2^an (Not Specified)	decreased leukocyte cell number	J:5439
Cdk5rap2^{Gt(RRO242)Byg}/Cdk5rap2⁺ (involves: 129P2/OlaHsd * C57BL/6J)	decreased leukocyte cell number	J:160533
Cdk5rap2^{Gt(RRO242)Byg}/Cdk5rap2^an (involves: 129P2/OlaHsd * C57BL/6J)	decreased leukocyte cell number	J:160533
Cdk5rap2^{tm1a(EUCOMM)Wtsi}/Cdk5rap2^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Cdk5rap2^{tm1a(EUCOMM)Wtsi}/Wtsi)	decreased leukocyte cell number	J:175295
Cdk6^tm1.1Phin/Cdk6^tm1.1Phin (involves: 129S4/SvJae * C57BL/6)	immune system phenotype	J:144975
Cdk6^tm1Bbd/Cdk6^tm1Bbd (involves: 129S1/Sv * 129X1/SvJ * CD-1)	abnormal spleen morphology	J:92529
	abnormal spleen red pulp morphology	J:92529
	abnormal thymus morphology	J:92529
	decreased leukocyte cell number	J:92529
	decreased T cell proliferation	J:92529
	increased single-positive T cell number	J:92529
	small spleen	J:92529
	spleen hypoplasia	J:92529
	thymus cortex atrophy	J:92529
	thymus hypoplasia	J:92529
Cdk6^tm1Phin/Cdk6⁺ Tg(Lck-Akt1*E40K)E-3Pnt/0 (involves: 129S4/SvJae)	increased T cell derived lymphoma incidence	J:144975
Cdk6^tm1Phin/Cdk6^tm1Phin (involves: 129S4/SvJae)	abnormal lymphopoiesis	J:144975
	abnormal T cell differentiation	J:144975
	abnormal thymocyte activation	J:144975
	decreased CD8-positive, alpha-beta T cell number	J:144975
	decreased double-negative T cell number	J:144975
	decreased double-positive T cell number	J:144975
	decreased thymocyte apoptosis	J:144975
	decreased thymocyte number	J:144975
	thymus atrophy	J:144975
	thymus hypoplasia	J:144975
Cdk6^tm1Phin/Cdk6^tm1Phin (involves: 129S4/SvJae * C57BL/6)	decreased DN1 thymic pro-T cell number	J:174697
	decreased DN2 thymocyte number	J:174697
	decreased double-positive T cell number	J:174697
	immune system phenotype	J:174697
	increased CD4-positive, alpha-beta T cell number	J:174697
	increased CD8-positive, alpha-beta T cell number	J:174697
	increased DN3 thymocyte number	J:174697
Cdk6^tm1Phin/Cdk6^tm1Phin Tg(Lck-Akt1*E40K)E-3Pnt/0 (involves: 129S4/SvJae)	abnormal T cell differentiation	J:144975
Cdk6^tm2.1Phin/Cdk6^tm2.1Phin (involves: 129 * C57BL/6 * FVB/N)	abnormal T cell differentiation	J:174697
	decreased DN1 thymic pro-T cell number	J:174697
	decreased DN2 thymocyte number	J:174697
	decreased DN4 thymocyte number	J:174697
	decreased double-positive T cell number	J:174697
	decreased thymocyte number	J:174697
	increased CD4-positive, alpha-beta T cell number	J:174697
	increased CD8-positive, alpha-beta T cell number	J:174697
	increased DN3 thymocyte number	J:174697
	increased double-negative T cell number	J:174697
	small thymus	J:174697
Cdk6^tm2.1Phin/Cdk6^tm2.1Phin Il2ra^tm1Dw/Il2ra^tm1Dw (involves: 129S4/SvJae * C57BL/6 * FVB/N)	increased CD4-positive, alpha-beta T cell number	J:174697
	increased CD8-positive, alpha-beta T cell number	J:174697
Cdk6^tm3.1Phin/Cdk6^tm3.1Phin (involves: 129 * C57BL/6 * FVB/N)	abnormal T cell differentiation	J:174697
	enlarged thymus	J:174697
	immune system phenotype	J:174697
	increased CD4-positive, alpha-beta T cell number	J:174697
	increased DN1 thymic pro-T cell number	J:174697
	increased T cell apoptosis	J:174697
	increased thymocyte number	J:174697
Cdk6^tm4.1Phin/Cdk6^tm4.1Phin (involves: 129 * C57BL/6 * FVB/N)	abnormal T cell differentiation	J:174697
	decreased DN1 thymic pro-T cell number	J:174697
	decreased DN2 thymocyte number	J:174697
	decreased DN4 thymocyte number	J:174697
	decreased double-positive T cell number	J:174697
	decreased thymocyte number	J:174697
	immune system phenotype	J:174697
	increased CD4-positive, alpha-beta T cell number	J:174697
	increased CD8-positive, alpha-beta T cell number	J:174697
	increased DN3 thymocyte number	J:174697
	small thymus	J:174697
Cdk10^tm1.2Kald/Cdk10^tm1.2Kald (involves: 129 * C57BL/6 * FVB/N)	abnormal spleen morphology	J:262333
Cdk12^em1(IMPC)Tcp/Cdk12⁺ (C57BL/6NCrl-Cdk12^em1(IMPC)Tcp/Tcp)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	increased spleen weight	J:211773
Cdkl2^{tm1b(EUCOMM)Hmgu}/Cdkl2^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Cdkl2^{tm1b(EUCOMM)Hmgu}/Bay)	abnormal spleen morphology	J:211773
Cdkn1a^{tm1.1(KOMP)Vlcg}/Cdkn1a^{tm1.1(KOMP)Vlcg} (C57BL/6N-Cdkn1a^{tm1.1(KOMP)Vlcg}/Ucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Cdkn1a^tm1Led/Cdkn1a^tm1Led (involves: 129S6/SvEvTac)	increased anti-double stranded DNA antibody level	J:76041
	increased anti-histone antibody level	J:76041
	increased anti-single stranded DNA antibody level	J:76041
	increased autoantibody level	J:76041
	increased T cell proliferation	J:76041
Cdkn1a^tm1Led/Cdkn1a^tm1Led Gadd45a^tm1Ajf/Gadd45a^tm1Ajf (either: (involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6) or (involves: 129S6/SvEvTac * 129X1/SvJ * C57BL/6))	abnormal lymphopoiesis	J:76041
	abnormal T cell activation	J:76041
	decreased basophil cell number	J:76041
	decreased eosinophil cell number	J:76041
	decreased leukocyte cell number	J:76041
	decreased lymphocyte cell number	J:76041
	glomerulonephritis	J:76041
	increased anti-double stranded DNA antibody level	J:76041
	increased anti-histone antibody level	J:76041
	increased anti-single stranded DNA antibody level	J:76041
	increased autoantibody level	J:76041
	increased IgG1 level	J:76041
	increased IgM level	J:76041
	increased inflammatory response	J:76041
	increased T cell proliferation	J:76041
Cdkn1a^tm1Led/Cdkn1a^tm1Led Zbtb17^tm1Cksn/Zbtb17^tm1Cksn Commd10^{Tg(Vav1-icre)A2Kio}/Commd10⁺ (B6.Cg-Zbtb17^tm1Cksn Cdkn1a^tm1Led Commd10^{Tg(Vav1-icre)A2Kio})	arrested T cell differentiation	J:170508
Cdkn1a^tm1Tyj/Cdkn1a^tm1Tyj (B6;129S2-Cdkn1a^tm1Tyj/J)	decreased monocyte cell number	J:108569
	decreased susceptibility to induced arthritis	J:108569
	impaired macrophage chemotaxis	J:108569
Cdkn1a^tm1Tyj/Cdkn1a^tm1Tyj (involves: 129S2/SvPas * C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:60292
	abnormal self tolerance	J:60292
	abnormal thymus physiology	J:70894
	enlarged cervical lymph nodes	J:60292
	enlarged lymph nodes	J:60292
	enlarged spleen	J:60292
	glomerulonephritis	J:60292, J:70894
	immune system phenotype	J:60292
	increased anti-double stranded DNA antibody level	J:60292
	increased anti-histone antibody level	J:60292
	increased anti-nuclear antigen antibody level	J:60292
	increased B cell number	J:60292
	increased IgG1 level	J:60292
	increased memory T cell number	J:60292
	increased spleen weight	J:60292
	increased T cell derived lymphoma incidence	J:70894
	increased T cell proliferation	J:60292
	lymph node hyperplasia	J:60292
	spleen hyperplasia	J:60292
Cdkn1a^tm1Tyj/Cdkn1a^tm1Tyj Tg(MMTV-vHaras)SH1Led/0 (involves: 129S2/SvPas * C57BL/6J * CD-1 * FVB/N)	enlarged spleen	J:66183
Cdkn1b^tm1Ako/Cdkn1b^tm1Ako (involves: 129S1/Sv * C57BL/6)	increased spleen weight	J:33401
	increased thymocyte number	J:33401
	increased thymus weight	J:33401
Cdkn1b^tm1Ako/Cdkn1b^tm1Ako Cdkn2c^tm1Yxi/Cdkn2c^tm1Yxi (involves: 129/Sv * 129S1/Sv * C57BL/6 * DBA/2)	enlarged spleen	J:50053
	enlarged thymus	J:50053
Cdkn1b^tm1Jro/Cdkn1b^tm1Jro (involves: 129S4/SvJaeSor * C57BL/6)	decreased T cell proliferation	J:71780
Cdkn1b^tm1Kin/Cdkn1b^tm1Kin (involves: 129P2/OlaHsd * C57BL/6)	enlarged spleen	J:33402
	enlarged thymus	J:33402
	increased T cell number	J:33402
	thymus hyperplasia	J:33402
Cdkn1b^tm1Kin/Cdkn1b^tm1Kin Skp2^tm1Kin/Skp2^tm1Kin (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:74265
Cdkn1b^tm1Mlf/Cdkn1b⁺ Crebbp^tm1Jvd/Crebbp^tm1Jvd Tg(MMTV-cre)4Mam/0 (involves: 129 * C57BL/6 * CBA * FVB)	increased T cell derived lymphoma incidence	J:88323
Cdkn1b^tm1Mlf/Cdkn1b^tm1Mlf (involves: 129S4/SvJaeSor * C57BL/6J)	abnormal spleen morphology	J:33400
	abnormal thymus morphology	J:33400
	enlarged spleen	J:33400
	enlarged thymus	J:33400
	increased T cell proliferation	J:33400
	spleen hyperplasia	J:33400
	thymus hyperplasia	J:33400
Cdkn1b^tm1Mlf/Cdkn1b^tm1Mlf (involves: 129S4/SvJaeSor)	enlarged spleen	J:107588
	enlarged thymus	J:107588
	spleen hypoplasia	J:107588
Cdkn1b^tm1Mlf/Cdkn1b^tm1Mlf Myc^tm1Atp/Myc⁺ (involves: 129P2/OlaHsd * 129S4/SvJaeSor * FVB/N)	decreased T cell proliferation	J:73369
Cdkn1b^tm1Mlf/Cdkn1b^tm1Mlf Tg(KRT5-CDK4)2303Mlrp/0 (involves: 129S4/SvJae * C57BL/6 * FVB * SENCAR * SSIN)	enlarged thymus	J:107588
	thymus hyperplasia	J:107588
Cdkn1b^tm1Mlf/Cdkn1b^tm1Mlf Trp53^tm1Brd/Trp53^tm1Brd (involves: C3H * C57BL/6J * NIH)	increased T cell derived lymphoma incidence	J:87536
Cdkn1b^tm1Mlf/Cdkn1b^tm1Mlf Trp53^tm1Brd/Trp53^tm1Brd (involves: 129S4/SvJaeSor * 129S7/SvEvBrd * C57BL/6J)	increased T cell derived lymphoma incidence	J:87536
Cdkn1b^tm2Kin/Cdkn1b^tm2Kin Rassf5^tm1Kina/Rassf5^tm1Kina (involves: C57BL/6 * CBA)	immune system phenotype	J:168749
Cdkn1b^tm3Jro/Cdkn1b^tm3Jro (involves: 129S4/SvJaeSor)	enlarged spleen	J:103819
Cdkn1b^tm3Jro/Cdkn1b^tm3Jro (involves: 129S4/SvJaeSor)	enlarged thymus	J:103819
Cdkn1c^tm1Kat/Cdkn1c^tm1Kat (involves: 129P2/OlaHsd * C57BL/6)	abnormal spleen white pulp morphology	J:61190
Cdkn2a^tm1Cjs/Cdkn2a^tm1Cjs (involves: 129X1/SvJ * C57BL/6)	increased T cell derived lymphoma incidence	J:44427
Cdkn2a^tm1Cjs/Cdkn2a^tm1Cjs Nop53^tm2.1Asuz/Nop53^tm2.1Asuz Tg(Lck-cre)#Jxm/0 (involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * CBA)	decreased thymocyte number	J:241062
Cdkn2a^tm1Rdp/Cdkn2a^tm1Rdp (involves: 129/Sv * C57BL/6 * SJL)	abnormal spleen morphology	J:53805
	abnormal spleen red pulp morphology	J:53805
	increased spleen white pulp amount	J:53805
Cdkn2a^tm1Rdp/Cdkn2a^tm1Rdp Rnf2^tm1Mvi/Rnf2^tm1Mvi Tg(Mx1-cre)1Cgn/0 (involves: 129 * C57BL/6 * C57BL/10 * CBA * SJL)	enlarged spleen	J:130397
Cdkn2a^tm1Rdp/Cdkn2a^tm1Rdp Tg(Tyr-NRASQ61K)1Bee/? (involves: 129/Sv C57BL/6 * DBA/2 * SJL)	enlarged lymph nodes	J:98545
Cdkn2a^tm2.1Rdp/Cdkn2a^tm2.1Rdp (involves: 129S6/SvEvTac * FVB/N)	increased CD4-positive, alpha-beta T cell number	J:71394
	increased CD8-positive, alpha-beta T cell number	J:71394
	increased double-positive T cell number	J:71394
	increased splenocyte proliferation	J:71394
	increased thymus weight	J:71394
	thymus hyperplasia	J:71394
Cdkn2b^tm1Bbd/Cdkn2b^tm1Bbd (involves: 129S1/Sv * C57BL/6)	abnormal lymph node germinal center morphology	J:63299
	abnormal lymph node secondary follicle morphology	J:63299
	abnormal lymphocyte morphology	J:63299
	abnormal spleen marginal zone morphology	J:63299
	abnormal spleen morphology	J:63299
	increased mature B cell number	J:63299
	lymph node hyperplasia	J:63299
	lymphoid hyperplasia	J:63299
	spleen hyperplasia	J:63299
Cdkn2b^tm1Bbd/Cdkn2b^tm1Bbd Cdkn2c^tm1Bbd/Cdkn2c^tm1Bbd (involves: 129S1/Sv * C57BL/6)	abnormal Langerhans cell morphology	J:63299
	abnormal lymphocyte morphology	J:63299
	enlarged spleen	J:63299
	lymph node hyperplasia	J:63299
	lymphoid hyperplasia	J:63299
Cdkn2b^tm1Bbd/Cdkn2b^tm1Bbd Pbx1^tm1Koss/Pbx1^tm1Koss Nkx2-5^tm2(cre)Rph/Nkx2-5⁺ (involves: 129P2/OlaHsd * 129S1/Sv)	abnormal spleen mesenchyme morphology	J:184521
	abnormal spleen morphology	J:184521
Cdkn2b^tm1Wff/Cdkn2b^tm1Wff Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6)	increased monocyte cell number	J:163498
	myeloid hyperplasia	J:163498
Cdkn2c^tm1Bbd/Cdkn2c^tm1Bbd (involves: 129S1/Sv * C57BL/6)	abnormal lymph node medulla morphology	J:63299
	enlarged lymph nodes	J:63299
	enlarged spleen	J:63299
	increased spleen white pulp amount	J:63299
	increased T cell derived lymphoma incidence	J:63299
	lymphoid hyperplasia	J:63299
Cdkn2c^tm1Yxi/Cdkn2c^tm1Yxi (involves: 129/Sv * C57BL/6 * DBA/2)	abnormal T cell physiology	J:50053
	abnormal thymus size	J:50053
	enlarged spleen	J:50053
	increased B cell number	J:50053
	increased T cell number	J:50053
	spleen hyperplasia	J:50053
	thymus hyperplasia	J:50053
Cds2^{Gt(OST184358)Lex}/Cds2⁺ (involves: 129S5/SvEvBrd * C57BL/6J)	decreased B cell number	J:103485
	increased T cell number	J:103485
Cdsn^tm1.1Ics/Cdsn^tm1.1Ics Tg(KRT14-cre/ERT2)1Ipc/0 (involves: 129S2/SvPas)	skin inflammation	J:153292
Ceacam1^Hv2-r/Ceacam1^Hv2-r (SJL/J)	decreased susceptibility to Coronaviridae infection	J:92495
Ceacam1^Hv2-r/Ceacam1^Hv2-r (SJL/J)	decreased susceptibility to viral infection	J:25438
Ceacam1^Hv2-s/Ceacam1^Hv2-s (Not Specified)	immune system phenotype	J:92495
Ceacam1^tm1.1Fta/Ceacam1^tm1.1Fta (C57BL/6(FVB)-Ceacam1^tm1.1Fta)	decreased susceptibility to Coronaviridae infection	J:198335
	decreased susceptibility to Coronaviridae infection induced morbidity/mortality	J:198335
Ceacam1^tm1Bcn/Ceacam1^tm1Bcn (either: (involves: 129S1/Sv * 129X1/SvJ * BALB/c) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6))	decreased susceptibility to Coronaviridae infection induced morbidity/mortality	J:70815
Ceacam1^tm1Rsb/Ceacam1^tm1Rsb Tg(Lck-cre)1Cwi/0 (involves: 129)	abnormal cytokine secretion	J:116136
	increased interferon-gamma secretion	J:116136
	increased interleukin-2 secretion	J:116136
	increased T cell proliferation	J:116136
Ceacam1^tm2Bcn/Ceacam1^tm2Bcn (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	decreased susceptibility to Coronaviridae infection	J:92376
Ceacam3^em1Btlr/Ceacam3^em1Btlr (C57BL/6J-Ceacam3^em1Btlr)	immune system phenotype	J:354285
Ceacam5^{em1(IMPC)Wtsi}/Ceacam5^{em1(IMPC)Wtsi} (C57BL/6N-Ceacam5^{em1(IMPC)Wtsi}/Wtsi)	increased leukocyte cell number	J:211773
Ceat1^CBA/J/Ceat1^NOD (involves: CBA/J * NOD-H2^k)	increased susceptibility to experimental autoimmune thyroiditis	J:77545
Ceat1^NOD/Ceat1^NOD (involves: CBA/J * NOD-H2^k)	increased susceptibility to experimental autoimmune thyroiditis	J:77545
Cebpa^{tm1.1(Cebpb)Ylee}/Cebpa^{tm1.1(Cebpb)Ylee} (involves: 129X1/SvJ * C57BL/6 * FVB/N)	immune system phenotype	J:77646
Cebpa^tm1Dgt/Cebpa^tm1Dgt Tg(Mx1-cre)1Cgn/0 (involves: 129S6/SvEvTac * C57BL/6 * CBA)	abnormal myelopoiesis	J:94682
	decreased granulocyte number	J:94682
	failure of myelopoiesis	J:94682
	sepsis	J:94682
Cebpa^tm1Gjd/Cebpa^tm1Gjd (B6.129S7-Cebpa^tm1Gjd)	failure of myelopoiesis	J:94682
Cebpa^tm1Nerl/Cebpa^tm1Nerl (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:72330
Cebpa^tm2Btp/Cebpa^tm2Btp (B6.129P2-Cebpa^tm2Btp)	abnormal myelopoiesis	J:187834
	decreased neutrophil cell number	J:187834
	enlarged spleen	J:187834
Cebpa^tm2Nerl/Cebpa^tm2Nerl (involves: 129P2/OlaHsd * C57BL/6)	abnormal granulocyte morphology	J:72330
	decreased granulocyte number	J:72330
	immune system phenotype	J:72330
Cebpa^tm3Nerl/Cebpa^tm3Nerl (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:72330
Cebpa^tm4Nerl/Cebpa^tm4Nerl (involves: 129P2/OlaHsd * C57BL/6)	abnormal granulocyte morphology	J:72330
	decreased granulocyte number	J:72330
	immune system phenotype	J:72330
Cebpa^tm8.1Nerl/Cebpa^tm8.1Nerl (involves: 129P2/OlaHsd * BALB/cJ * C57BL/6)	abnormal granulocyte morphology	J:136134
	abnormal leukocyte morphology	J:136134
	abnormal myeloid leukocyte morphology	J:136134
	decreased granulocyte number	J:136134
	decreased monocyte cell number	J:136134
	decreased neutrophil cell number	J:136134
	enlarged spleen	J:136134
	liver inflammation	J:136134
Cebpb^tm1.1Acle/Cebpb^tm1.1Acle (involves: 129P2/OlaHsd * BALB/c * C57BL/6)	abnormal osteoclast differentiation	J:150006
	abnormal osteoclast morphology	J:150006
	abnormal osteoclast physiology	J:150006
Cebpb^tm1.1Elgaz/Cebpb^tm1.1Elgaz Lyz2^{em1.1(cre)Elgaz}/Lyz2⁺ (BALB/cJ-Cebpb^tm1.1Elgaz Lyz2^em1.1Elgaz/Elgaz)	decreased circulating interleukin-10 level	J:247885
	decreased susceptibility to bacterial infection	J:247885
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:247885
	increased circulating interleukin-6 level	J:247885
	increased circulating tumor necrosis factor level	J:247885
Cebpb^tm1Aki/Cebpb^tm1Aki (involves: 129P2/OlaHsd * C57BL/6)	abnormal macrophage physiology	J:153025
	abnormal T-helper 1 physiology	J:153025
	decreased susceptibility to endotoxin shock	J:153025
	granulomatous inflammation	J:153025
	increased susceptibility to bacterial infection	J:153025
Cebpb^tm1Kish/Cebpb^tm1Kish (involves: 129P2/OlaHsd)	abnormal macrophage physiology	J:77003
	impaired macrophage phagocytosis	J:77003
	increased interleukin-12 secretion	J:126085
	increased susceptibility to bacterial infection	J:77003
Cebpb^tm1Pfj/Cebpb^tm1Pfj (involves: 129S1/Sv * C57BL/6)	abnormal osteoclast differentiation	J:150006
	abnormal osteoclast morphology	J:150006
	abnormal osteoclast physiology	J:150006
	abnormal tumor necrosis factor level	J:192313
Cebpb^tm1Vpo/Cebpb^tm1Vpo (involves: 129S/SvEv * MF1)	abnormal cell-mediated immunity	J:25215
	abnormal humoral immune response	J:25215
	abnormal innate immunity	J:25215
	abnormal lymph node B cell domain morphology	J:25215
	abnormal lymph node cortex morphology	J:25215
	abnormal lymph node medulla morphology	J:25215
	abnormal lymph node medullary cord morphology	J:25215
	abnormal lymph node secondary follicle morphology	J:25215
	abnormal lymph node T cell domain morphology	J:25215
	abnormal macrophage physiology	J:25215
	abnormal mucosa-associated lymphoid tissue morphology	J:25215
	abnormal plasma cell morphology	J:25215
	abnormal spleen red pulp morphology	J:25215
	abnormal spleen secondary B follicle morphology	J:25215
	abnormal spleen white pulp morphology	J:25215
	abnormal T-helper 1 physiology	J:25215
	abnormal T-helper 2 physiology	J:25215
	decreased circulating interleukin-12 level	J:25215
	decreased susceptibility to type IV hypersensitivity reaction	J:25215
	enlarged axillary lymph nodes	J:25215
	enlarged inguinal lymph nodes	J:25215
	enlarged lymph nodes	J:25215
	enlarged mesenteric lymph nodes	J:25215
	enlarged spleen	J:25215
	enlarged submandibular lymph nodes	J:25215
	glomerulonephritis	J:25215
	increased circulating interleukin-6 level	J:25215
	increased IgG level	J:25215
	increased susceptibility to fungal infection	J:25215
Cebpb^tm2.1Acle/Cebpb^tm2.1Acle (involves: 129P2/OlaHsd * BALB/cJ * C57BL/6)	abnormal osteoclast morphology	J:155795
	decreased osteoclast cell number	J:155795
	increased circulating interleukin-6 level	J:155795
Cebpb^tm3Nerl/Cebpb^tm3Nerl (either: B6.129P2-Cebpb^tm3Nerl or (involves: 129P2/OlaHsd * C57BL/6))	myositis	J:153686
Cebpd^tm1Pfj/Cebpd^tm1Pfj (involves: 129S1/Sv * C57BL/6)	abnormal cytokine level	J:192313
Cebpd^tm1Pfj/Cebpd^tm1Pfj (involves: 129S1/Sv * C57BL/6)	decreased inflammatory response	J:192313
Cebpe^tm1Kgx/Cebpe^tm1Kgx (involves: 129S6/SvEvTac * NIH Black Swiss)	abnormal eosinophil differentiation	J:76024
	abnormal granulocyte differentiation	J:76024
	abnormal myelopoiesis	J:76024
	abnormal neutrophil differentiation	J:76024
	abnormal neutrophil morphology	J:76024
	abnormal neutrophil physiology	J:76024
	colitis	J:76024
	conjunctivitis	J:76024
	decreased eosinophil cell number	J:76024
	decreased granulocyte number	J:76024
	enlarged lymph nodes	J:76024
	impaired myelopoiesis	J:76024
	increased inflammatory response	J:76024
	increased plasma cell number	J:76024
	increased susceptibility to bacterial infection	J:76024
	lung inflammation	J:76024
	osteomyelitis	J:76024
	peritoneal inflammation	J:76024
	rhinitis	J:76024
Cebpe^tm1Kgx/Cebpe^tm1Kgx (involves: 129S6/SvEvTac)	abnormal eosinophil differentiation	J:76024
	abnormal granulocyte differentiation	J:76024
	abnormal myelopoiesis	J:76024
	abnormal neutrophil differentiation	J:76024
	abnormal neutrophil morphology	J:76024
	abnormal neutrophil physiology	J:76024
	colitis	J:76024
	conjunctivitis	J:76024
	decreased eosinophil cell number	J:76024
	decreased granulocyte number	J:76024
	enlarged lymph nodes	J:76024
	impaired myelopoiesis	J:76024
	increased inflammatory response	J:76024
	increased plasma cell number	J:76024
	increased susceptibility to bacterial infection	J:76024
	lung inflammation	J:76024
	osteomyelitis	J:76024
	peritoneal inflammation	J:76024
	pleuritis	J:76024
	rhinitis	J:76024
Cebpg^tm1Aki/Cebpg^tm1Aki (involves: 129P2/OlaHsd)	abnormal NK cell physiology	J:58801
Cebpg^tm1Aki/Cebpg^tm1Aki (involves: 129P2/OlaHsd)	impaired natural killer cell mediated cytotoxicity	J:58801
Cecr2^{tm2b(EUCOMM)Hmgu}/Cecr2⁺ (C57BL/6N-Cecr2^{tm2b(EUCOMM)Hmgu}/Tcp)	enlarged lymph nodes	J:211773
Celf4^{tm1a(EUCOMM)Wtsi}/Celf4^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Celf4^{tm1a(EUCOMM)Wtsi}/Wtsi)	blood in lymph vessels	J:239583
Celsr1^ctb-2J/Celsr1^ctb-2J (STOCK Celsr1^ctb-2J/GrsrJ)	increased susceptibility to otitis media	J:229303
Celsr1^ctb/Celsr1^ctb (CByJ.Cg-Celsr1^ctb/GrsrJ)	increased susceptibility to otitis media	J:229303
Cemip2^tm1.1Cya/Cemip2^tm1.1Cya Tg(CAG-cre/Esr1)5Amc/0 (involves: C57BL/6 CBA)	abnormal lymph node morphology	J:317425
Cemip^tm1.1Okda/Cemip^tm1.1Okda (involves: C57BL/6NCrlj * CBA/JNCrlj)	decreased osteoclast cell number	J:241936
Cep68^em1(IMPC)J/Cep68^em1(IMPC)J (C57BL/6NJ-Cep68^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
Cep76^{tm1b(EUCOMM)Hmgu}/Cep76^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Cep76^{tm1b(EUCOMM)Hmgu}/Bay)	abnormal spleen morphology	J:211773
Cep85l^em1(IMPC)Mbp/Cep85l^em1(IMPC)Mbp (C57BL/6N-Cep85l^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
Cep290^b2b1454Clo/Cep290^b2b1454Clo (C57BL/6J-Cep290^b2b1454Clo)	accessory spleen	J:175213
	spleen hypoplasia	J:175213
Cep290^b2b1752Clo/Cep290^b2b1752Clo (C57BL/6J-Cep290^b2b1752Clo)	spleen hypoplasia	J:175213
Cer1^{em1(IMPC)Ccpcz}/Cer1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Cer1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Cerk^tm1Fbor/Cerk^tm1Fbor (involves: BALB/c)	decreased granulocyte number	J:131522
	decreased neutrophil cell number	J:131522
	immune system phenotype	J:131522
	increased leukocyte cell number	J:131522
	increased susceptibility to bacterial infection	J:131522
Cers1^{tm1b(EUCOMM)Hmgu}/Cers1⁺ (C57BL/6N-Cers1^{tm1b(EUCOMM)Hmgu}/H)	increased neutrophil cell number	J:211773
Cers3^tm1.1Rsnd/Cers3^tm1.1Rsnd (involves: 129P2/OlaHsd * C57BL/6)	increased susceptibility to fungal infection	J:179754
Cers6^tm1.1Arte/Cers6^tm1.1Arte (involves: BALB/cJ * C57BL/6N)	decreased inflammatory response	J:215519
Cers6^tm1.1Kwi/Cers6^tm1.1Kwi (involves: 129P2/OlaHsd * C57BL/6)	microgliosis	J:201327
Ces1c^{em1(IMPC)Ccpcz}/Ces1c^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Ces1c^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Ces2a^{tm1(KOMP)Vlcg}/Ces2a^{tm1(KOMP)Vlcg} (C57BL6/N-Ces2a^{tm1(KOMP)Vlcg})	liver inflammation	J:335459
Cfap20dc^em1(IMPC)J/Cfap20dc^em1(IMPC)J (C57BL/6NJ-Cfap20dc^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
Cfap47^{em1(IMPC)Hmgu}/Cfap47^{em1(IMPC)Hmgu} (C57BL/6NCrl-Cfap47^{em1(IMPC)Hmgu}/Ieg)	decreased spleen weight	J:211773
Cfap53^{em1(IMPC)Wtsi}/Cfap53^{em1(IMPC)Wtsi} (C57BL/6N-Cfap53^{em1(IMPC)Wtsi}/Wtsi)	abnormal thymus topology	J:239583
	blood in lymph vessels	J:239583
	small spleen	J:239583
Cfap161^{em1(IMPC)Ccpcz}/Cfap161^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Cfap161^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Cfb^tm1Hrc/Cfb⁺ Cfh^tm1Mbo/Cfh^tm1Mbo (involves: 129S/Sv * C57BL/6)	decreased circulating complement protein level	J:78193
Cfb^tm1Hrc/Cfb^tm1Hrc (involves: 129S/Sv * C57BL/6)	abnormal complement pathway	J:42679
Cfb^tm1Hrc/Cfb^tm1Hrc (involves: 129S/Sv * C57BL/6)	impaired complement alternative pathway	J:42679
Cfb^tm1Hrc/Cfb^tm1Hrc (involves: 129S/Sv)	decreased susceptibility to Coronaviridae infection	J:286325
Cfb^tm1Hrc/Cfb^tm1Hrc (involves: 129S/Sv)	impaired complement classical pathway	J:130108
Cfb^tm1Mbo/Cfb^tm1Mbo (involves: 129/Sv * C57BL/6)	increased susceptibility to bacterial infection	J:83712
Cfb^tm1Pkna/Cfb^tm1Pkna (D1.129P2-Cfb^tm1Pkna)	decreased susceptibility to induced arthritis	J:88872
Cfc1^b2b2736.1Clo/Cfc1^b2b2736.1Clo (C57BL/6J-Cfc1^b2b2736.1Clo)	accessory spleen	J:175213
	spleen hypoplasia	J:175213
Cfc1^tm1Cbm/Cfc1^tm1Cbm (Not Specified)	small spleen	J:58530
Cfc1^tm1Cbm/Cfc1^tm1Cbm (Not Specified)	spleen hypoplasia	J:58530
Cfc1^tm1Mms/Cfc1^tm1Mms (either: (involves: 129S6/SvEvTac * Black Swiss) or (involves: 129S6/SvEvTac * C57BL/6J))	absent spleen	J:58104
Cfd^tm1Yxu/Cfd^tm1Yxu (involves: 129P2/OlaHsd * C57BL/6J)	impaired complement alternative pathway	J:73125
Cfd^tm1Yxu/Cfd^tm1Yxu (B6.129P2-Cfd^tm1Yxu)	impaired complement alternative pathway	J:94855
Cfd^tm1Yxu/Cfd^tm1Yxu (B6.129P2-Cfd^tm1Yxu)	increased susceptibility to bacterial infection	J:94855
Cfh^tm1.1Song/Cfh^tm1.1Song (involves: C57BL/6)	decreased circulating complement protein level	J:240426
	decreased complement C5 level	J:240426
	decreased serum complement activity	J:240426
Cfh^tm1Mbo/Cfh⁺ (involves: 129/Sv * C57BL/6)	decreased circulating complement protein level	J:78193
Cfh^tm1Mbo/Cfh^tm1Mbo (involves: 129/Sv * C57BL/6)	decreased circulating complement protein level	J:78193
	glomerulonephritis	J:78193
	increased susceptibility to type III hypersensitivity reaction	J:78193
Cfh^tm1Mbo/Cfh^tm1Mbo (involves: 129)	abnormal complement protein level	J:125860
	decreased circulating complement protein level	J:125860, J:131403
	glomerulonephritis	J:131403
Cfh^tm1Mbo/Cfh^tm1Mbo Tg(CAG-Cfh)#Mcp/0 (involves: 129/Sv C57BL/6 * CBA)	abnormal circulating complement protein level	J:125860
	abnormal complement protein level	J:125860
Cfi^em1Jiwe/Cfi^em1Jiwe (involves: C57BL/6J)	abnormal complement protein level	J:308307
Cfi^em1Jiwe/Cfi^em1Jiwe (involves: C57BL/6J)	impaired complement alternative pathway	J:308307
Cfi^tm1Mcp/Cfi^tm1Mcp (involves: 129/Sv * C57BL/6)	decreased circulating complement protein level	J:131403
Cflar^tm1.1Pope/Cflar^tm1.2Pope Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd)	abnormal abdominal lymph node morphology	J:167430
	abnormal B cell number	J:167430
	abnormal CD4-positive, alpha-beta T cell number	J:167430
	abnormal CD8-positive, alpha-beta T cell number	J:167430
	abnormal lymphocyte cell number	J:167430
	abnormal myelopoiesis	J:167430
	abnormal spleen B cell follicle morphology	J:167430
	abnormal spleen marginal zone morphology	J:167430
	abnormal spleen morphology	J:167430
	abnormal spleen red pulp morphology	J:167430
	abnormal thymus corticomedullary boundary morphology	J:167430
	abnormal thymus morphology	J:167430
	decreased macrophage cell number	J:167430
	enlarged spleen	J:167430
	increased CD8-positive, alpha-beta T cell number	J:167430
	increased eosinophil cell number	J:167430
	increased granulocyte number	J:167430
	increased leukocyte cell number	J:167430
	increased monocyte cell number	J:167430
	increased neutrophil cell number	J:167430
Cflar^tm1Ywh/Cflar^tm1Ywh Tg(Lck-cre)548Jxm/0 (involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6 * CBA)	decreased single-positive T cell number	J:100558
	increased thymocyte apoptosis	J:100558
Cfmq1^129X1/SvJ/Cfmq1^C57BL/6J Cftr^tm1Unc/Cftr^tm1Unc (involves: 129X1/SvJ * C57BL/6J)	intestinal inflammation	J:101842
Cfmq2^129X1/SvJ/Cfmq2^129X1/SvJ Cftr^tm1Unc/Cftr^tm1Unc (involves: 129X1/SvJ * C57BL/6J)	intestinal inflammation	J:101842
Cfmq3^129X1/SvJ/Cfmq3^C57BL/6J Cftr^tm1Unc/Cftr^tm1Unc (involves: 129X1/SvJ * C57BL/6J)	intestinal inflammation	J:101842
Cfp^tm1Cmst/Cfp^tm1Cmst (B6.129P2-Cfp^tm1Cmst)	sepsis	J:131526
Cfp^tm1Song/Y (involves: 129 * C57BL/6)	abnormal complement pathway	J:130108
	impaired complement alternative pathway	J:130108
	impaired complement classical pathway	J:130108
Cfp^tm1Song/Cfp^tm1Song (involves: 129 * C57BL/6)	decreased susceptibility to induced arthritis	J:165497
Cfp^tm1Song/Cfp^tm1Song (involves: 129 * C57BL/6)	impaired complement alternative pathway	J:165497
Cfp^tm2.1Song/Cfp^tm2.1Song Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129 * 129P2/OlaHsd * C57BL/6 * SJL)	decreased susceptibility to induced arthritis	J:165497
	impaired complement alternative pathway	J:165497
Cfp^tm2.1Song/Cfp^tm2.1Song Tg(EIIa-cre)C5379Lmgd/0 (involves: 129 * C57BL/6 * FVB/N * SJL)	impaired complement alternative pathway	J:165497
Cftr^tm1Bay/Cftr^tm1Bay (involves: 129S7/SvEvBrd * C57BL/6J)	acute pancreas inflammation	J:15244
Cftr^tm1Cam/Cftr^tm1Cam (involves: 129S/SvEv)	increased susceptibility to infection	J:23850
Cftr^tm1Cam/Cftr^tm1Cam (involves: 129S/SvEv)	peritoneal inflammation	J:23850
Cftr^tm1Hgu/Cftr^tm1Hgu (involves: 129P2/OlaHsd)	increased susceptibility to bacterial infection	J:24119
Cftr^tm1Hgu/Cftr^tm1Hgu (involves: 129P2/OlaHsd)	lung inflammation	J:24119
Cftr^tm1Kth/Cftr^tm1Kth (involves: 129S7/SvEvBrd * C57BL/6J)	peritoneal inflammation	J:29074
Cftr^tm1Kth/Cftr^tm1Kth (B6.129S7-Cftr^tm1Kth)	increased susceptibility to bacterial infection induced morbidity/mortality	J:112450
Cftr^tm1Kth/Cftr^tm1Kth (B6.129S7-Cftr^tm1Kth)	lung inflammation	J:112450
Cftr^tm1Unc/Cftr^tm1Unc (B6.129P2-Cftr^tm1Unc/J)	increased susceptibility to bacterial infection induced morbidity/mortality	J:112450
Cftr^tm1Unc/Cftr^tm1Unc (B6.129P2-Cftr^tm1Unc/J)	lung inflammation	J:58571, J:112450
Cftr^tm1Unc/Cftr^tm1Unc (involves: 129P2/OlaHsd)	abnormal thymus involution	J:2079
	peritoneal inflammation	J:2079
	spleen hyperplasia	J:2079
Cftr^tm1Unc/Cftr^tm1Unc (B6.129P2-Cftr^tm1Unc)	lung inflammation	J:44904
Cftr^tm1Unc/Cftr^tm1Unc Tg(FABPCFTR)1Jaw/0 Tg(Scgb1a1-Scnn1b)6608Bouc/0 (involves: 129P2/OlaHsd * C3H * C57BL/6 * FVB/N)	respiratory system inflammation	J:191673
Cftr^tm2Cam/Cftr^tm2Cam (involves: 129S/SvEv)	peritoneal inflammation	J:27734
Cftr^tm2Mrc/Cftr^tm2Mrc (B6.129S6-Cftr^tm2Mrc)	abnormal alveolar macrophage morphology	J:112450
	decreased neutrophil cell number	J:112450
	increased susceptibility to bacterial infection induced morbidity/mortality	J:112450
	lung inflammation	J:112450
Cftr^tm3Hgu/Cftr^tm3Hgu (involves: 129P2/OlaHsd)	gallbladder inflammation	J:32766
Cftr^tm3Hgu/Cftr^tm3Hgu (involves: 129P2/OlaHsd)	peritoneal inflammation	J:32766
Cftr^tm3Mrc/Cftr^tm3Mrc (B6.129S6-Cftr^tm3Mrc)	increased susceptibility to bacterial infection induced morbidity/mortality	J:112450
Cftr^tm3Mrc/Cftr^tm3Mrc (B6.129S6-Cftr^tm3Mrc)	lung inflammation	J:112450
Cgas^{tm1a(EUCOMM)Hmgu}/Cgas^{tm1a(EUCOMM)Hmgu} (C57BL/6N-Cgas^{tm1a(EUCOMM)Hmgu})	abnormal dendritic cell physiology	J:201167
	abnormal immune cell physiology	J:201167
	abnormal macrophage physiology	J:201167
	abnormal plasmacytoid dendritic cell physiology	J:201167
	decreased circulating interferon-alpha level	J:201167
	decreased circulating interferon-beta level	J:201167
	increased susceptibility to Herpesvirales infection	J:201167
	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:201167
Cgas^{tm1a(EUCOMM)Hmgu}/Cgas^{tm1a(EUCOMM)Hmgu} (involves: C57BL/6N)	abnormal interferon secretion	J:234263
Cgas^{tm1a(EUCOMM)Hmgu}/Cgas^{tm1a(EUCOMM)Hmgu} Rnaseh2a^tm1Crh/Rnaseh2a^tm1Crh (involves: C57BL/6N)	immune system phenotype	J:232933
Cgas^{tm1a(EUCOMM)Hmgu}/Cgas^{tm1a(EUCOMM)Hmgu} Trex1^tm1Tld/Trex1^tm1Tld (involves: 129P2/OlaHsd * C57BL/6N)	increased susceptibility to Retroviridae infection	J:234263
Cgas^{tm1d(EUCOMM)Hmgu}/Cgas^{tm1d(EUCOMM)Hmgu} (involves: BALB/c * C57BL/6JJcl * C57BL/6N)	increased susceptibility to Flaviviridae infection	J:207826
	increased susceptibility to Flaviviridae infection induced morbidity/mortality	J:207826
	increased susceptibility to Herpesvirales infection	J:207826
	increased susceptibility to Poxviridae infection	J:207826
	increased susceptibility to Poxviridae infection induced morbidity/mortality	J:207826
Cgas^{tm1d(EUCOMM)Hmgu}/Cgas^{tm1d(EUCOMM)Hmgu} (involves: C57BL/6N)	immune system phenotype	J:265023
	increased susceptibility to Retroviridae infection	J:265023
Cgnz1^NZM2328/J/Cgnz1^NZM2328/J (involves: C57L/J * NZM2328/J)	increased susceptibility to systemic lupus erythematosus	J:71397
	kidney inflammation	J:71397
Cgref1^em1(IMPC)J/Cgref1^em1(IMPC)J (C57BL/6NJ-Cgref1^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
Cgrrf1^{tm1b(KOMP)Wtsi}/Cgrrf1^{tm1b(KOMP)Wtsi} (C57BL/6N-Cgrrf1^{tm1b(KOMP)Wtsi}/Wtsi)	increased CD5-positive gamma-delta T cell number	J:211773
	increased gamma-delta T cell number	J:211773
Ch25h^tm1Rus/Ch25h^tm1Rus (B6.129S6-Ch25h^tm1Rus)	increased IgA level	J:170807
	increased IgG2a level	J:170807
	increased IgG2b level	J:170807
	increased IgG3 level	J:170807
Chaf1b^{tm2c(EUCOMM)Hmgu}/Chaf1b⁺ Kras^tm4Tyj/Kras⁺ Tg(Mx1-cre)1Cgn/0 (involves: 129S4/SvJae * C57BL/6J * C57BL/6N * CBA/J)	increased leukocyte cell number	J:266848
Champ1^em1(IMPC)Mbp/Champ1⁺ (C57BL/6NCrl-Champ1^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	small spleen	J:211773
Char2a^C3H/HeJ/Char2a^C3H/HeJ (involves: C3H/HeJ * C57BL/6J)	increased susceptibility to parasitic infection	J:117548
Char2b^C3H/HeJ/Char2b^C3H/HeJ (involves: C3H/HeJ * C57BL/6J)	increased susceptibility to parasitic infection	J:117548
Char3^C3H/He/Char3^C57BL/6 (involves: C3H/He * C57BL/6)	decreased susceptibility to parasitic infection	J:72455
Char3^C57BL/6/Char3^C57BL/6 (involves: C3H/He * C57BL/6)	decreased susceptibility to parasitic infection	J:72455
Char4^C57BL/6J/Char4^C57BL/6J (involves: A/J * C57BL/6J)	decreased susceptibility to parasitic infection	J:71471
Char9^A/J/Char9^C57BL/6J (involves: A/J * C57BL/6J)	decreased susceptibility to parasitic infection	J:122131
Char9^C57BL/6J/Char9^C57BL/6J (involves: A/J * C57BL/6J)	decreased susceptibility to parasitic infection	J:122131
Char11^A/J/Char11^C57BL/6J (involves: A/J * C57BL/6J)	decreased susceptibility to parasitic infection	J:106220
Char11^C57BL/6J/Char11^C57BL/6J (involves: A/J * C57BL/6J)	decreased susceptibility to parasitic infection	J:106220
Chchd7^em3(IMPC)Tcp/Chchd7^em3(IMPC)Tcp (C57BL/6NCrl-Chchd7^em3(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Chchd10^em8Lutzy/Chchd10⁺ (C57BL/6NJ-Chchd10^em8Lutzy/J)	increased susceptibility to otitis media	J:272524
Chd2^{Gt(RRBO46)Byg}/Chd2⁺ (involves: 129P2/OlaHsd * C57BL/6)	arteritis	J:146176
	dark spleen	J:146743
	decreased lymphocyte cell number	J:146176
	enlarged lymph nodes	J:146743
	enlarged spleen	J:146743
	heart inflammation	J:146176
	increased CD4-positive, alpha-beta T cell number	J:146176
	increased spleen red pulp amount	J:146743
	increased T cell derived lymphoma incidence	J:146176
	interstitial pneumonia	J:146743
	liver inflammation	J:146743
	lymphoid hyperplasia	J:146176
	myocarditis	J:146743
Chd4^tm1.1Kge/Chd4^tm1.1Kge Tg(Lck-cre)1Cwi/0 (involves: C57BL/6 * SJL)	abnormal CD4-positive, alpha beta T cell morphology	J:109547
	abnormal T cell physiology	J:109547
	arrested T cell differentiation	J:109547
	decreased double-positive T cell number	J:109547
	increased CD8-positive, alpha-beta T cell number	J:109547
	lymph node hypoplasia	J:109547
	spleen hypoplasia	J:109547
Chd4^tm1.1Kge/Chd4^tm1.2Kge Tg(CAG-Bgeo/GFP)21Lbe/0 Tg(Lck-cre)1Cwi/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)	decreased T cell proliferation	J:109547
Chd4^tm1.1Kge/Chd4^tm1.2Kge Tg(Lck-cre)1Cwi/0 (involves: C57BL/6 * SJL)	thymus hypoplasia	J:109547
Chd4^tm1.2Kge/Chd4^tm1.2Kge Tg(Lck-cre)1Cwi/0 (involves: C57BL/6 * DBA/2 * SJL)	abnormal T cell differentiation	J:109547
	decreased double-positive T cell number	J:109547
	decreased T cell proliferation	J:109547
	increased CD8-positive, alpha-beta T cell number	J:109547
	increased double-negative T cell number	J:109547
	thymus hypoplasia	J:109547
Chd5^em1(IMPC)Mbp/Chd5^em1(IMPC)Mbp (C57BL/6NCrl-Chd5^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Chd7^Flo/Chd7⁺ (involves: C3HeB/FeJ)	keratoconjunctivitis sicca	J:104123
Chd7^{Gt(RRR136)Byg}/Chd7⁺ (involves: 129P2/OlaHsd * C57BL/6)	ectopic thymus	J:154590
	small thymus	J:154590
	thymus hypoplasia	J:154590
Chd7^Gt(XK403)Byg/Chd7⁺ Tbx1^tm1Bld/Tbx1⁺ (either: (involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6) or (involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * CD-1))	ectopic thymus	J:154590
Chd7^Looper/Chd7⁺ (BALB/c-Chd7^Looper)	blepharitis	J:252089
Chd7^Looper/Chd7⁺ (BALB/c-Chd7^Looper)	conjunctivitis	J:252089
Chd7^Ome/Chd7⁺ (involves: BALB/cByJ * C57BL/6J)	increased susceptibility to otitis media	J:187200
Chd7^{tm2a(EUCOMM)Wtsi}/Chd7⁺ (involves: 129S5/SvEvBrd * C57BL/6N)	decreased leukocyte cell number	J:330596
	decreased monocyte cell number	J:330596
	increased NK T cell number	J:330596
Chd7^Trooper/Chd7⁺ (BALB/c-Chd7^Trooper)	blepharitis	J:262283
Chd7^Trooper/Chd7⁺ (BALB/c-Chd7^Trooper)	conjunctivitis	J:262283
Chd7^Whi/Chd7⁺ (C3HeB/FeJ-Chd7^Whi)	decreased monocyte cell number	J:330596
Chd7^Whi/Chd7⁺ (C3HeB/FeJ-Chd7^Whi)	increased NK T cell number	J:330596
Chd7^Whi/Chd7⁺ (involves: C3HeB/FeJ)	keratoconjunctivitis sicca	J:104123
Chd8^em1(IMPC)Mbp/Chd8⁺ (C57BL/6N-Chd8^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	increased lymphocyte cell number	J:211773
Chd9^{tm1a(EUCOMM)Wtsi}/Chd9^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Chd9^{tm1a(EUCOMM)Wtsi}/Wtsi)	increased Langerhans cell number	J:211773
Chek2^tm1Mak/Chek2⁺ Rad50^tm2Jpt/Rad50^tm2Jpt (involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6)	abnormal pro-B cell morphology	J:103922
	decreased double-negative T cell number	J:103922
	decreased macrophage cell number	J:103922
Chfr^{tm1a(KOMP)Wtsi}/Chfr^{tm1a(KOMP)Wtsi} (C57BL/6NCrl-Chfr^{tm1a(KOMP)Wtsi}/Ccpcz)	abnormal spleen morphology	J:211773
Chi3l1^tm1Eli/Chi3l1^tm1Eli (B6.Cg-Chi3l1^tm1Eli)	abnormal dendritic cell physiology	J:148490
	abnormal macrophage morphology	J:148490
	abnormal plasmacytoid dendritic cell physiology	J:148490
	abnormal T-helper 2 physiology	J:148490
	decreased IgE level	J:148490
	decreased interleukin-4 secretion	J:148490
	decreased interleukin-13 secretion	J:148490
	decreased splenocyte proliferation	J:148490
	decreased T-helper 2 cell number	J:148490
	impaired eosinophil recruitment	J:148490
	impaired neutrophil recruitment	J:148490
	increased T cell apoptosis	J:148490
Chi3l1^tm1Eli/Chi3l1^tm1Eli Tg(Scgb1a1-rtTA,-tTS,tetO-CHI3L1)1Eli/0 (involves: 129 * C57BL/6)	immune system phenotype	J:148490
Chi3l1^tm1Eli/Chi3l1^tm1Eli Tg(Scgb1a1-rtTA,tetO-Il13)1Eli/0 (involves: C57BL/6 * CBA)	abnormal T-helper 2 cell number	J:148490
	abnormal T-helper 2 physiology	J:148490
Chia1^tm1.1Lof/Chia1^tm1.1Lof (C57BL/6-Chia1^tm1.1Lof)	decreased interleukin-13 secretion	J:257728
	immune system phenotype	J:257728
	increased lymphocyte cell number	J:257728
	increased neutrophil cell number	J:257728
Chic2^{tm1b(EUCOMM)Wtsi}/Chic2⁺ (C57BL/6N-Chic2^{tm1b(EUCOMM)Wtsi}/H)	enlarged spleen	J:211773
Chit1^tm1Eli/Chit1^tm1Eli (involves: C57BL/6)	decreased susceptibility to bacterial infection	J:189872
Chit1^tm1Eli/Chit1^tm1Eli Tg(Scgb1a1-Il13)2Eli/0 (involves: C57BL/6 * CBA)	decreased susceptibility to bacterial infection	J:189872
Chit1^tm1Eli/Chit1^tm1Eli Tg(Scgb1a1-rtTA,tetO-CHIT1)#Eli/0 (involves: C57BL/6)	decreased susceptibility to bacterial infection	J:189872
Chmp2b^em1(IMPC)Mbp/Chmp2b⁺ (C57BL/6NCrl-Chmp2b^em1(IMPC)Mbp/Mmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Chmp4c^{tm1b(EUCOMM)Wtsi}/Chmp4c^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Chmp4c^{tm1b(EUCOMM)Wtsi}/H)	decreased basophil cell number	J:211773
Chordc1^em1(IMPC)Mbp/Chordc1⁺ (C57BL/6N-Chordc1^em1(IMPC)Mbp/MbpMmucd)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Chordc1^tm1Mbra/Chordc1⁺ (involves: 129 * C57BL/6)	abnormal myelopoiesis	J:222040
	abnormal spleen morphology	J:222040
	enlarged spleen	J:222040
	increased leukocyte cell number	J:222040
Chrd^tm1Emdr/Chrd^tm1Emdr (either: B6SJL.129-Chrd^tm1Emdr or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * SJL/J))	athymia	J:83662
Chrd^tm1Emdr/Chrd^tm1Emdr (129S6.129-Chrd^tm1Emdr)	athymia	J:146769
Chrd^tm1Emdr/Chrd^tm1Emdr Tbx1^m1Jlk/Tbx1^m1Jlk (129/Sv-Tbx1^m1Jlk Chrd^tm1Emdr)	athymia	J:146769
Chrm1^tm1Jwe/Chrm1^tm1Jwe (involves: 129S6/SvEvTac * CF-1)	decreased cytotoxic T cell cytolysis	J:106393
Chrna3^tm1Bay/Chrna3^tm1Bay (involves: 129S7/SvEvBrd * C57BL/6)	increased susceptibility to bacterial infection	J:54994
	urinary bladder inflammation	J:54994
Chrna4^tm1Jpc/Chrna4^tm1Jpc (involves: C57BL/6)	decreased IgG level	J:103908
	decreased immunoglobulin level	J:103908
	immune system phenotype	J:103908
	increased IgG level	J:103908
Chrna5^em1(IMPC)H/Chrna5^em1(IMPC)H (C57BL/6N-Chrna5^em1(IMPC)H/H)	decreased lymphocyte cell number	J:211773
	increased basophil cell number	J:211773
	increased neutrophil cell number	J:211773
Chrna7^tm1Bay/Chrna7^tm1Bay (involves: 129S7/SvEvBrd * C57BL/6J)	decreased neutrophil cell number	J:140280
	increased lymphocyte cell number	J:140280
Chrna7^tm1Bay/Chrna7^tm1Bay (B6.Cg-Chrna7^tm1Bay)	abnormal interleukin level	J:89610
Chrna7^tm1Bay/Chrna7^tm1Bay (B6.Cg-Chrna7^tm1Bay)	abnormal tumor necrosis factor level	J:89610
Chrna7^tm1Bay/Chrna7^tm1Bay (involves: 129S7/SvEvBrd * C57BL/6)	decreased IgG level	J:103908
	decreased immunoglobulin level	J:103908
	immune system phenotype	J:103908
Chrnb2^tm1Jpc/Chrnb2^tm1Jpc (B6.129P2-Chrnb2^tm1Jpc)	decreased B cell number	J:112766
Chrnb2^tm1Jpc/Chrnb2^tm1Jpc (involves: 129P2/OlaHsd * C57BL/6J)	myeloid hyperplasia	J:140280
Chrnb2^tm1Jpc/Chrnb2^tm1Jpc (involves: 129P2/OlaHsd * C57BL/6)	abnormal immune system physiology	J:103908
	abnormal immunoglobulin level	J:103908
	decreased B cell number	J:103908
	decreased immunoglobulin level	J:103908
	immune system phenotype	J:103908
	increased B cell proliferation	J:103908
	increased IgG level	J:103908
Chrnb2^tm1Mdb/Chrnb2^tm1Mdb Chrnb4^tm1Mdb/Chrnb4^tm1Mdb (involves: 129S7/SvEvBrd * C57BL/6J)	increased susceptibility to bacterial infection	J:73590
	urinary bladder inflammation	J:73590
Chst1^{tm1(KOMP)Vlcg}/Chst1^{tm1(KOMP)Vlcg} (involves: C57BL/6NTac)	decreased B cell number	J:204813
	immune system phenotype	J:204813
	increased T cell number	J:204813
Chst1^{tm1(KOMP)Vlcg}/Chst1^{tm1(KOMP)Vlcg} Chst2^tm1Tmu/Chst2^tm1Tmu Chst4^tm1Sdr/Chst4^tm1Sdr (involves: 129S2/SvPas * C57BL/6NTac)	abnormal leukocyte migration	J:204813
Chst2^em1(IMPC)Mbp/Chst2^em1(IMPC)Mbp (C57BL/6N-Chst2^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Chst2^tm1Tmu/Chst2^tm1Tmu (involves: 129S2/SvPas * C57BL/6J)	abnormal leukocyte migration	J:92231
	abnormal leukocyte physiology	J:92231
Chst2^tm1Tmu/Chst2^tm1Tmu Chst4^tm1Sdr/Chst4^tm1Sdr (involves: 129S2/SvPas)	abnormal leukocyte migration	J:204813
Chst3^tm1Tmu/Chst3^tm1Tmu (involves: 129S2/SvPas * 129X1/SvJ)	decreased T cell number	J:73698
Chst3^tm1Tmu/Chst3^tm1Tmu (involves: 129S2/SvPas)	decreased neutrophil cell number	J:217719
	increased T cell proliferation	J:217719
	lymph node hypoplasia	J:217719
Chst4^tm1Mifu/Chst4^tm1Mifu (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal leukocyte migration	J:113195
	impaired leukocyte tethering or rolling	J:113195
Chst4^tm1Mifu/Chst4^tm1Mifu Gcnt1^tm1Jxm/Gcnt1^tm1Jxm (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal leukocyte migration	J:113195
	impaired leukocyte tethering or rolling	J:113195
Chst4^tm1Sdr/Chst4^tm1Sdr (involves: C57BL/6)	abnormal leukocyte adhesion	J:86759
	abnormal leukocyte migration	J:86759
	abnormal lymph node morphology	J:86759
	abnormal lymph node primary follicle morphology	J:86759
Chst10^{em1(IMPC)Hmgu}/Chst10^{em1(IMPC)Hmgu} (C57BL/6NCrl-Chst10^{em1(IMPC)Hmgu}/Ieg)	increased spleen weight	J:211773
Chst11^{tm1a(KOMP)Wtsi}/Chst11^{tm1a(KOMP)Wtsi} (C57BL/6N-Chst11^{tm1a(KOMP)Wtsi}/Wtsi)	abnormal thymus morphology	J:239583
	blood in lymph vessels	J:239583
Chst15^tm1Oh/Chst15^tm1Oh (involves: 129P2/OlaHsd * C57BL/6)	abnormal mast cell morphology	J:165927
Chsy1^em1(IMPC)Mbp/Chsy1^em1(IMPC)Mbp (C57BL/6NCrl-Chsy1^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Chsy1^skt/Chsy1^skt Pde6b⁺/Pde6b⁺ (mixed)	decreased macrophage cell number	J:286529
	decreased neutrophil cell number	J:286529
	kidney inflammation	J:286529
	microgliosis	J:286529
Chsy1^skt/Chsy1^tm1Lex (mixed)	microgliosis	J:286529
Chsy1^tm1Lex/Chsy1^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6J)	autoimmune arthritis	J:171883
	microgliosis	J:286529
Chtop^{tm1a(EUCOMM)Wtsi}/Chtop^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Chtop^{tm1a(EUCOMM)Wtsi}/Wtsi)	absent spleen	J:239583
	spleen hypoplasia	J:239583
Chuk^{em1(IMPC)Ccpcz}/Chuk⁺ (C57BL/6NCrl-Chuk^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged thymus	J:211773
Chuk^tm1Lex/Chuk^tm1Lex Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * 129S/SvEvBrd)	impaired macrophage chemotaxis	J:159873
	impaired neutrophil chemotaxis	J:159873
	impaired neutrophil recruitment	J:159873
Chuk^tm1Mka/Chuk^tm1Mka (B6.129-Chuk^tm1Mka)	abnormal B cell physiology	J:113556
Chuk^tm1Mpa/Chuk^tm1Mpa Ikbkb^tm2Cgn/Ikbkb^tm2Cgn Tg(Alb1-cre)7Gsc/0 (involves: C57BL/6 * FVB/N)	increased susceptibility to endotoxin shock	J:137861
Chuk^tm2Mka/Chuk^tm2Mka (B6.Cg-Chuk^tm2Mka)	abnormal B cell physiology	J:113556
Chuk^tm2Mka/Chuk^tm2Mka Tg(Tnfsf13b)1Fma/? (B6.Cg-Chuk^tm2Mka Tg(Tnfsf13b)1Fma)	abnormal B cell activation	J:113556
	absent spleen marginal zone	J:113556
	decreased marginal zone B cell number	J:113556
	increased anti-double stranded DNA antibody level	J:113556
	increased transitional stage B cell number	J:113556
Chuk^tm2Yhu/Chuk^tm2Yhu (involves: 129S1/Sv * 129X1/SvJ * FVB/N)	skin inflammation	J:197037
Chuk^tm2Yhu/Chuk^tm2Yhu Tg(Lor-CHUK)8Yhu/0 (involves: 129S1/Sv * 129X1/SvJ * FVB/N)	absent lymph nodes	J:197037
Chuk^tm2Yhu/Chuk^tm2Yhu Tg(Lor-CHUK)8Yhu/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)	increased CD4-positive, alpha-beta T cell number	J:197037
	increased CD8-positive, alpha-beta T cell number	J:197037
	increased macrophage cell number	J:197037
	increased neutrophil cell number	J:197037
	lung inflammation	J:197037
Churc1^{tm1b(EUCOMM)Wtsi}/Churc1^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Churc1^{tm1b(EUCOMM)Wtsi}/Wtsi)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
	increased effector memory T-helper cell number	J:211773
Cia2^DBA/1J/Cia2^DBA/1J (involves: DBA/1J * SWR/J)	abnormal immune system physiology	J:53356
Cia2^DBA/1J/Cia2^DBA/1J (involves: DBA/1J * FVB/N)	increased susceptibility to induced arthritis	J:116665
Cia2^DBA/1J/Cia2^SWR/J (involves: DBA/1J * SWR/J)	abnormal immune system physiology	J:53356
Cia5^C57BL/10/Cia5^C57BL/10 (involves: B10.RIII * RIIIS/J)	abnormal inflammatory response	J:50472
Cia5b^RIIIS/J/? (involves: C57BL/10 * RIIIS/J)	decreased susceptibility to induced arthritis	J:101767
Cia5b^RIIIS/J/Cia5b^RIIIS/J Cia32^B10.RIII/Cia32^RIIIS/J (involves: C57BL/10 * RIIIS/J)	decreased susceptibility to induced arthritis	J:101767
Cia5c^RIIIS/J/? (involves: C57BL/10 * RIIIS/J)	decreased susceptibility to induced arthritis	J:101767
Cia6^C57BL/10SnSg/Cia6^C57BL/10SnSg (involves: B10.Q * DBA/1)	abnormal inflammatory response	J:57012
Cia6^C57BL/10SnSg/Cia6^DBA/1J (involves: B10.Q * DBA/1)	abnormal inflammatory response	J:57012
Cia6^DBA/1J/Cia6^DBA/1J (involves: B10.Q * DBA/1)	decreased inflammatory response	J:57012
Cia7^DBA/1J/Cia7^C57BL/10SnSg (involves: B10.Q * DBA/1)	increased inflammatory response	J:57012
Cia7^DBA/1J/Cia7^DBA/1J (involves: B10.Q * DBA/1)	increased inflammatory response	J:57012
Cia7^DBA/1J/Cia7^DBA/1J (involves: B10.Q * DBA/1)	increased susceptibility to induced arthritis	J:122130
Cia8^DBA/1J/Cia8^DBA/1J (involves: B10.Q * DBA/1)	increased inflammatory response	J:57012
Cia9^C57BL/10SnSg/Cia9^NOD/ShiLtJ (involves: B10.D1-H2^q/SgJ * NOD.C3-H2^q/Rhd)	increased inflammatory response	J:69981
Cia9^NOD/ShiLtJ/Cia9^NOD/ShiLtJ (involves: B10.D1-H2^q/SgJ * NOD.C3-H2^q/Rhd)	abnormal immune system physiology	J:69981
Cia10^C57BL/10/Cia10^C57BL/10 (involves: C57BL/10 * RIIIS/J)	abnormal inflammatory response	J:50472
Cia10^C57BL/10/Cia10^C57BL/10 Cia5^C57BL/10/Cia5^C57BL/10 (involves: C57BL/10 * RIIIS/J)	abnormal inflammatory response	J:50472
Cia23^C57BL/10SnSg/Cia23^C57BL/10SnSg (involves: B10.D1-H2^q/SgJ * NOD.C3-H2^q/Rhd)	abnormal inflammatory response	J:69981
Cia23^C57BL/10SnSg/Cia23^NOD/ShiLtJ (involves: B10.D1-H2^q/SgJ * NOD.C3-H2^q/Rhd)	abnormal inflammatory response	J:69981
Cia23^C57BL/10SnSg/Cia23^NOD/ShiLtJ Cia9^C57BL/10SnSg/Cia9^C57BL/10SnSg (involves: B10.D1-H2^q/SgJ * NOD.C3-H2^q/Rhd)	decreased inflammatory response	J:69981
Cia26^RIIIS/J/Cia26^RIIIS/J Cia30^B10.RIII/? (involves: B10.RIII * RIIIS/J)	autoimmune arthritis	J:95848
Cia27^DBA/1J/? (involves: DBA/1J * FVB/N)	increased IgG level	J:116665, J:94347
Cia30^RIIIS/J/Cia30^RIIIS/J Cia5^B10.RIII/Cia5^B10.RIII (involves: B10.RIII * RIIIS/J)	decreased susceptibility to induced arthritis	J:95848
Cia31^B10.RIII/Cia31^RIIIS/J Cia5^B10.RIII/Cia5^B10.RIII (involves: B10.RIII * RIIIS/J)	autoimmune arthritis	J:95848
Cia31^B10.RIII/Cia31^RIIIS/J Cia5^RIIIS/J/Cia5^RIIIS/J (involves: C57BL/10 * RIIIS/J)	decreased susceptibility to induced arthritis	J:101767
Cia32^B10.RIII/Cia32^RIIIS/J Cia5^B10.RIII/Cia5^B10.RIII (involves: B10.RIII * RIIIS/J)	autoimmune arthritis	J:95848
Cia34^DBA/1J/Cia34^DBA/1J (involves: C57BL/10 * DBA/1J)	decreased autoantibody level	J:122130
Cia34^DBA/1J/Cia34^DBA/1J (involves: C57BL/10 * DBA/1J)	decreased susceptibility to induced arthritis	J:122130
Cia35^C57BL/10SnSg/Cia35^C57BL/10SnSg Cia42^DBA/1J/Cia42^DBA/1J (involves: B10.Q * DBA/1)	decreased susceptibility to induced arthritis	J:122130
Cia35^C57BL/10SnSg/Cia35^DBA/1J (involves: C57BL/10 * DBA/1J)	increased autoantibody level	J:122130
	increased susceptibility to induced arthritis	J:122130
Cia35^C57BL/10SnSg/Cia35^DBA/1J Cia42^DBA/1J/Cia42^DBA/1J (involves: B10.Q * DBA/1)	decreased susceptibility to induced arthritis	J:122130
Cia35^DBA/1J/Cia35^DBA/1J Cia42^DBA/1J/Cia42^DBA/1J (involves: B10.Q * DBA/1)	decreased susceptibility to induced arthritis	J:122130
Cia36^DBA/1J/Cia36^DBA/1J (involves: C57BL/10 * DBA/1J)	decreased autoantibody level	J:122130
Cia36^DBA/1J/Cia36^DBA/1J (involves: C57BL/10 * DBA/1J)	decreased susceptibility to induced arthritis	J:122130
Cia37^C57BL/10SnSg/Cia37^DBA/1J (involves: C57BL/10 * DBA/1J)	increased autoantibody level	J:122130
	increased susceptibility to induced arthritis	J:122130
Cia38^DBA/1J/Cia38^DBA/1J (involves: C57BL/10 * DBA/1J)	increased autoantibody level	J:122130
Cia38^DBA/1J/Cia38^DBA/1J (involves: C57BL/10 * DBA/1J)	increased susceptibility to induced arthritis	J:122130
Cia39^C57BL/10Sn/Cia39^C57BL/10Sn (involves: B10.Q/Lund-H2^q * B10.RIII/Lund-H2^r)	decreased susceptibility to induced arthritis	J:97801
Cia39^RIII/WySn/Cia39^RIII/WySn (involves: B10.Q/Lund-H2^q * B10.RIII/Lund-H2^r)	autoimmune arthritis	J:97801
Cia40^C57BL/10SnSg/Cia40^C57BL/10SnSg (involves: C57BL/10SnSg * DBA/1J * NFS/N)	increased susceptibility to induced arthritis	J:106522
Cia43^DBA/1J/Cia43^FVB/N (involves: DBA/1J * FVB/N)	increased susceptibility to induced arthritis	J:146242
Cia43^FVB/N/Cia43^FVB/N (involves: DBA/1J * FVB/N)	increased susceptibility to induced arthritis	J:146242
Ciaaq1^DBA/1J/Ciaaq1^DBA/1J (involves: DBA/1J * FVB/NJ)	increased autoantibody level	J:122919
Ciaaq1^DBA/1J/Ciaaq1^FVB/NJ (involves: DBA/1J * FVB/NJ)	increased autoantibody level	J:122919
Ciao2b^{em1(IMPC)Ccpcz}/Ciao2b⁺ (C57BL/6N-Ciao2b^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	increased neutrophil cell number	J:211773
	increased spleen weight	J:211773
Cib1^{tm1b(EUCOMM)Hmgu}/Cib1^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Cib1^{tm1b(EUCOMM)Hmgu}/Bay)	decreased neutrophil cell number	J:211773
Cib2^{tm1b(EUCOMM)Wtsi}/Cib2^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Cib2^{tm1b(EUCOMM)Wtsi}/H)	increased basophil cell number	J:211773
Cibar1^{tm1b(KOMP)Wtsi}/Cibar1^{tm1b(KOMP)Wtsi} (C57BL/6N-Cibar1^{tm1b(KOMP)Wtsi}/Wtsi)	decreased leukocyte cell number	J:274784, J:211773
Cideb^tm1Pli/Cideb^tm1Pli (Not Specified)	decreased spleen weight	J:126556
Cigs2^tm1.1Anse/Cigs2⁺ Il4^tm1(CD2)Mmrs/Il4⁺ (involves: 129 * BALB/cJ * C57BL/6)	decreased basophil cell number	J:181313
	decreased IgE level	J:181313
	decreased IgG1 level	J:181313
	decreased interleukin-4 secretion	J:181313
	immune system phenotype	J:181313
Cigs2^tm1.1Anse/Cigs2^tm1.1Anse (involves: BALB/cJ * C57BL/6)	abnormal class switch recombination	J:181313
	abnormal humoral immune response	J:181313
	abnormal susceptibility to infection	J:181313
	decreased IgE level	J:181313
	decreased IgG1 level	J:181313
	decreased interleukin-4 secretion	J:181313
	decreased interleukin-13 secretion	J:181313
	increased IgG2b level	J:181313
Cigs2^tm1.1Kubo/Cigs2^tm1.1Kubo (B6.Cg-Cigs2^tm1.1Kubo)	abnormal interleukin secretion	J:129048
	abnormal mast cell physiology	J:129048
	abnormal neutrophil physiology	J:129048
	decreased interleukin-4 secretion	J:167446, J:129048
	decreased interleukin-13 secretion	J:129048
Ciita^m1Btlr/Ciita^m1Btlr (C57BL/6J-Ciita^m1Btlr)	abnormal CD4-positive T cell differentiation	J:221483
	abnormal CD8-positive, alpha-beta T cell differentiation	J:221483
	impaired humoral immune response	J:221483
Ciita^tm1.1Dim/Ciita^tm1.1Dim (involves: 129S2/SvPas * C57BL/6 * SJL)	abnormal level of surface class II molecules	J:51885
	decreased CD4-positive, alpha-beta T cell number	J:51885
	decreased dendritic cell number	J:51885
Ciita^tm1Adm/Ciita⁺ (involves: 129S1/Sv * C57BL/6)	abnormal immune system physiology	J:117111
Ciita^tm1Adm/Ciita^tm1Adm (involves: 129S1/Sv * C57BL/6)	abnormal immune system physiology	J:117111
Ciita^tm1Ccum/Ciita^tm1Ccum (involves: 129S2/SvPas * C57BL/6J)	abnormal B cell physiology	J:96421
	abnormal CD4-positive, alpha-beta T cell physiology	J:31601
	abnormal cytokine secretion	J:64283
	abnormal dendritic cell physiology	J:96421
	abnormal level of surface class II molecules	J:31601, J:96421
	abnormal lymphocyte physiology	J:96421
	abnormal MHC II cell surface expression on macrophages	J:31601
	abnormal popliteal lymph node morphology	J:64283
	abnormal susceptibility to infection	J:64283
	abnormal T cell differentiation	J:64283
	abnormal T cell physiology	J:31601
	decreased CD4-positive, alpha-beta T cell number	J:31601
	decreased susceptibility to parasitic infection	J:64283
	decreased T cell proliferation	J:31601
	increased CD4-positive, alpha-beta T cell number	J:64283
	increased CD8-positive, alpha-beta T cell number	J:64283
	increased susceptibility to parasitic infection	J:64283
Ciita^tm1Ccum/Ciita^tm1Ccum (NOD.129S2(B6)-Ciita^tm1Ccum)	abnormal inflammatory response	J:106081
	abnormal level of surface class II molecules	J:106081
	abnormal T cell differentiation	J:106081
	decreased CD4-positive, alpha-beta T cell number	J:106081
	decreased susceptibility to autoimmune diabetes	J:107051
	increased CD8-positive, alpha-beta T cell number	J:106081
	insulitis	J:107051
	pancreas inflammation	J:106081
	periinsulitis	J:106081
Ciita^tm1Ccum/Ciita^tm1Ccum (involves: 129S2/SvPas * C57BL/6)	abnormal level of surface class II molecules	J:67941
Ciita^tm1Jpyt/Ciita^tm1Jpyt (involves: 129P2/OlaHsd * C57BL/6J)	abnormal T cell subpopulation ratio	J:57100
	decreased CD4-positive, alpha-beta T cell number	J:57100
	decreased IgG level	J:57100
	increased CD8-positive, alpha-beta T cell number	J:57100
	increased double-positive T cell number	J:57100
	increased IgM level	J:57100
Ciita^tm1Jpyt/Ciita^tm1Jpyt (B6.129P2-Ciita^tm1Jpyt)	abnormal T-helper 1 physiology	J:125654
Ciita^tm1Jpyt/Ciita^tm1Jpyt (B6.129P2-Ciita^tm1Jpyt)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:125654
Ciita^tm1Wrth/Ciita^tm1Wrth (B6.129P2-Ciita^tm1Wrth)	immune system phenotype	J:117111
Ciita^tm1Wrth/Ciita^tm1Wrth (involves: 129P2/OlaHsd * C57BL/6)	absent CD4-positive, alpha-beta T cells	J:233241
	increased osteoclast cell number	J:233241
Ciita^tm2Wrth/Ciita^tm2Wrth (involves: 129P2/OlaHsd * C57BL/6)	abnormal immunoglobulin level	J:92170
	decreased CD4-positive, alpha-beta T cell number	J:92170
Ciita^tm2Wrth/Ciita^tm2Wrth (B6.129P2-Ciita^tm2Wrth)	immune system phenotype	J:117111
Cilk1^{tm1b(KOMP)Mbp}/Cilk1^{tm1b(KOMP)Mbp} (C57BL/6N-Cilk1^{tm1b(KOMP)Mbp}/Ucd)	increased basophil cell number	J:211773
	increased neutrophil cell number	J:211773
Cimap1b^{em1(IMPC)Ccpcz}/Cimap1b^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Cimap1b^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Cimap2^Retro/Cimap2⁺ (involves: C57BL/6J)	increased CD8-positive, alpha-beta T cell number	J:223336
Cimap2^Retro/Cimap2⁺ (involves: C57BL/6J)	increased cytotoxic T cell cytolysis	J:223336
Cimap2^Retro/Cimap2^Retro (involves: C57BL/6J)	abnormal CD8-positive, alpha-beta cytotoxic T cell morphology	J:223336
	increased activated T cell number	J:223336
	increased CD8-positive, alpha-beta T cell number	J:223336
	increased central memory CD8 positive, alpha-beta T cell number	J:223336
	increased cytotoxic T cell cytolysis	J:223336
	increased interferon-gamma secretion	J:223336
	increased susceptibility to Riboviria infection induced morbidity/mortality	J:223336
	increased T cell proliferation	J:223336
Cimap2^{tm1a(KOMP)Wtsi}/Cimap2⁺ (involves: C57BL/6)	decreased CD8-positive, alpha-beta T cell number	J:223336
Cimap2^{tm1a(KOMP)Wtsi}/Cimap2⁺ (involves: C57BL/6)	decreased cytotoxic T cell cytolysis	J:223336
Cimip2b^{tm1(KOMP)Wtsi}/Cimip2b^{tm1(KOMP)Wtsi} (C57BL/6N-Cimip2b^{tm1(KOMP)Wtsi}/Nju)	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
Cinda1^BALB/c/? (involves: BALB/c * CcS-4/Dem)	increased T cell proliferation	J:40728
Cinda2^STS/A/? (involves: BALB/c * CcS-4/Dem)	increased T cell proliferation	J:40728
Cinda3^O20/A/Cinda3^O20/A (involves: O20/A * OcB-9/Dem)	decreased T cell proliferation	J:95917
Cinda3^OcB9/Dem/Cinda3^O20/A (involves: O20/A * OcB-9/Dem)	increased T cell proliferation	J:95917
Cinda4^OcB9/Dem/Cinda4^O20/A (involves: O20/A * OcB-9/Dem)	increased T cell proliferation	J:95917
Cinda4^OcB9/Dem/Cinda4^OcB9/Dem (involves: O20/A * OcB-9/Dem)	increased T cell proliferation	J:95917
Cinda5^OcB9/Dem/Cinda5^O20/A (involves: O20/A * OcB-9/Dem)	increased T cell proliferation	J:95917
Cinda5^OcB9/Dem/Cinda5^OcB9/Dem (involves: O20/A * OcB-9/Dem)	increased T cell proliferation	J:95917
Ciroz^b2b1167Clo/Ciroz^b2b1167Clo (C57BL/6J-Ciroz^b2b1167Clo)	spleen hypoplasia	J:175213
Cish^tm1.1Cdon/Cish^tm1.1Cdon Foxp3^{tm4(YFP/icre)Ayr}/Foxp3⁺ (involves: 129S/Sv * 129X1/SvJ * C57BL/6)	immune system phenotype	J:204829
Cish^tm1.1Cdon/Cish^tm1.1Cdon Tg(Cd4-cre)1Cwi/0 (involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6 * DBA/2)	abnormal T-helper 2 cell differentiation	J:204829
	increased eosinophil cell number	J:204829
	increased interleukin-4 secretion	J:204829
	increased interleukin-5 secretion	J:204829
	increased interleukin-10 secretion	J:204829
	increased interleukin-13 secretion	J:204829
	increased susceptibility to type I hypersensitivity reaction	J:204829
Cish^tm1.2Cdon/Cish^tm1.2Cdon (B6.129S6(Cg)-Cish^tm1.2Cdon)	abnormal CD4-positive T cell differentiation	J:204829
	abnormal immune system morphology	J:204829
	abnormal immune system physiology	J:204829
	abnormal T-helper 2 cell differentiation	J:204829
	immune system phenotype	J:204829
	increased eosinophil cell number	J:204829
	increased interleukin-4 secretion	J:204829
	increased interleukin-5 secretion	J:204829
	increased interleukin-9 secretion	J:204829
	increased interleukin-13 secretion	J:204829
	increased lymphocyte cell number	J:204829
	increased susceptibility to type I hypersensitivity reaction	J:204829
	increased T cell proliferation	J:204829
	lung inflammation	J:204829
	lymph node hyperplasia	J:204829
	spleen hyperplasia	J:204829
	thymus hyperplasia	J:204829
Cited2^tm1Bha/Cited2^tm1Bha (involves: 129P2/OlaHsd * C57BL/6J)	small spleen	J:92872
Cited2^tm1Bha/Cited2^tm1Bha (B6.129P2-Cited2^tm1Bha)	small spleen	J:92872
Ciz1^{Gt(IST13830B6)Tigm}/Ciz1^{Gt(IST13830B6)Tigm} (B6J.B6N-Ciz1^{Gt(IST13830B6)Tigm})	increased monocyte cell number	J:231433
	increased neutrophil cell number	J:231433
Ciz1^tm1.1Homy/Ciz1^tm1.1Homy (involves: 129P2/OlaHsd * C57BL/6 * DBA)	enlarged spleen	J:198470
	lymph node hyperplasia	J:198470
	thymus hyperplasia	J:198470
Ckb^{tm1.1(KOMP)Wtsi}/Ckb^{tm1.1(KOMP)Wtsi} (C57BL/6N-Ckb^{tm1.1(KOMP)Wtsi}/Ucd)	increased lymphocyte cell number	J:211773
Cks1b^tm1Sir/Cks1b^tm1Sir Tg(IghMyc)22Bri/? (involves: C57BL * C57BL/6 * SJL)	decreased B cell proliferation	J:121564
	decreased leukocyte cell number	J:121564
	decreased lymphocyte cell number	J:121564
	decreased spleen weight	J:121564
Clasp1^em1(IMPC)Mbp/Clasp1⁺ (C57BL/6NCrl-Clasp1^em1(IMPC)Mbp/Mmucd)	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Clca1^tm1.1Lex/Clca1^tm1.1Lex (involves: 129S/SvEvBrd)	abnormal chemokine level	J:125158
	increased inflammatory response	J:125158
	increased neutrophil cell number	J:125158
	lung inflammation	J:125158
Clca1^tm1Dgen/Clca1^tm1Dgen (involves: 129P2/OlaHsd * C57BL/6)	abnormal inflammatory response	J:112942
Clcf1^{tm1.1(KOMP)Vlcg}/Clcf1⁺ (C57BL/6N-Clcf1^{tm1.1(KOMP)Vlcg}/Ucd)	decreased leukocyte cell number	J:211773
Clcn1^em1(IMPC)Mbp/Clcn1^em1(IMPC)Mbp (C57BL/6NCrl-Clcn1^em1(IMPC)Mbp/MbpMmucd)	increased eosinophil cell number	J:211773
Clcn2^tm1Tjj/Clcn2^tm1Tjj (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal microglial cell physiology	J:122365
Clcn3^tm1Lamb/Clcn3^tm1Lamb (involves: 129S1/Sv * 129X1/SvJ)	abnormal neutrophil physiology	J:112692
	impaired neutrophil phagocytosis	J:112692
	sepsis	J:112692
Clcn3^tm1Tjj/Clcn3^tm1Tjj (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal microglial cell physiology	J:77635
Clcn7^tm1.1Lex/Clcn7^tm1.1Lex (involves: 129S5/SvEvBrd * C57BL/6J)	microgliosis	J:186049
Clcn7^tm1.1Mawa/Clcn7⁺ (involves: C57BL/6J * C57BL/6N * CD-1)	increased osteoclast cell number	J:254787
Clcn7^tm1.1Teti/Clcn7⁺ (involves: 129S2/SvPas * C57BL/6)	abnormal osteoclast physiology	J:203761
Clcn7^tm1.1Teti/Clcn7⁺ (involves: 129S2/SvPas * C57BL/6)	increased osteoclast cell number	J:203761
Clcn7^tm1Tjj/Clcn7^tm1Tjj (involves: 129P2/OlaHsd * C57BL/6)	abnormal osteoclast morphology	J:67273
	abnormal osteoclast physiology	J:67273
Clcn7^tm2Tjj/Clcn7^tm2Tjj (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal osteoclast morphology	J:67273, J:217031
	abnormal osteoclast physiology	J:67273
Clcn7^tm2Tjj/Clcn7^tm2Tjj (involves: 129S1/Sv * 129X1/SvJ)	microgliosis	J:155176
Clcn7^tm3.1Tjj/Clcn7^tm3.1Tjj Emx1^{tm1.1(cre)Ito}/Emx1⁺ (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * BALB/cJ * C57BL/6)	microgliosis	J:155176
Clcn7^tm4.1Tjj/Clcn7^tm4.1Tjj (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal osteoclast morphology	J:160702, J:217031
	abnormal osteoclast physiology	J:160702
Clcn7^tm5.1Tjj/Clcn7^tm5.1Tjj (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal osteoclast morphology	J:217031
Clcnka^m1Btlr/Clcnka^m1Btlr (C57BL/6J-Clcnka^m1Btlr)	increased susceptibility to induced colitis	J:271974
Clcnkb^em1(IMPC)Mbp/Clcnkb^em1(IMPC)Mbp (C57BL/6NCrl-Clcnkb^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	decreased lymphocyte cell number	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	increased basophil cell number	J:211773
	increased neutrophil cell number	J:211773
Cldn3^em1(IMPC)H/Cldn3^em1(IMPC)H (C57BL/6N-Cldn3^em1(IMPC)H/H)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Cldn9^em1(IMPC)H/Cldn9^em1(IMPC)H (C57BL/6NTac-Cldn9^em1(IMPC)H/H)	increased basophil cell number	J:211773
Cldn12^{tm1.1(KOMP)Vlcg}/Cldn12^{tm1.1(KOMP)Vlcg} (B6J.B6N-Cldn12^{tm1.1(KOMP)Vlcg})	immune system phenotype	J:279934
	increased leukocyte cell number	J:279934
	increased spleen weight	J:279934
Cldn18^tm1Lex/Cldn18^tm1Lex (involves: 129S5/SvEvBrd)	abnormal osteoclast differentiation	J:195931
Cldn18^tm1Lex/Cldn18^tm1Lex (involves: 129S5/SvEvBrd)	increased osteoclast cell number	J:195931
Clec1a^tm1Yiw/Clec1a^tm1Yiw (involves: C57BL/6J * C57BL/6NSlc)	abnormal dendritic cell antigen presentation	J:329240
	decreased CD8-positive, alpha-beta memory T cell proliferation	J:329240
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:329240
	immune system phenotype	J:329240
Clec1b^tm1.1Arte/Clec1b^tm1.1Arte Tg(Pf4-icre)Q3Rsko/0 (involves: C57BL/6)	abnormal lymphatic vessel endothelial cell morphology	J:181715
	abnormal lymphatic vessel morphology	J:181715
Clec1b^tm1.1Ksi/Clec1b^tm1.1Ksi (involves: C57BL/6)	abnormal lymphatic system physiology	J:165898
Clec1b^tm1.1Ksi/Clec1b^tm1.1Ksi (involves: C57BL/6)	abnormal lymphatic vessel morphology	J:165898
Clec1b^tm1.2Arte/Clec1b^tm1.2Arte (Not Specified)	abnormal lymphatic vessel morphology	J:181715
Clec1b^tm1.2Arte/Clec1b^tm1.2Arte (Not Specified)	decreased lymphatic vessel endothelial cell number	J:181715
Clec1b^tm1Ksi/Clec1b^tm1Ksi Tg(Pf4-icre)Q3Rsko/0 (involves: C57BL/6)	abnormal lymphatic vessel morphology	J:187533
Clec1b^tm1Lex/Clec1b^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6J)	abnormal mononuclear cell morphology	J:161922
Clec1b^tm1Mlkn/Clec1b^tm1Mlkn (involves: 129S4/SvJae * C57BL/6)	abnormal lymphatic vessel morphology	J:162815
Clec1b^tm2Mlkn/Clec1b^tm2Mlkn Tg(Pf4-icre)Q3Rsko/0 (involves: C57BL/6 * SJL)	lymph node hemorrhage	J:205423
Clec2d^tm1.1Mgil/Clec2d^tm1.1Mgil (C57BL/6-Clec2d^tm1.1Mgil)	abnormal osteoclast differentiation	J:143122
	increased osteoclast cell number	J:143122
Clec2d^tm1.1Mgil/Clec2d^tm1.1Mgil (involves: C57BL/6)	immune system phenotype	J:222057
Clec2h^tm1.1Apma/Clec2h^tm1.1Apma (B6(Cg)-Clec2h^tm1.1Apma)	kidney inflammation	J:322835
Clec2h^tm1.1Apma/Clec2h^tm1.1Apma Rag1^tm1Mom/Rag1^tm1Mom (B6.Cg-Rag1^tm1Mom Clec2h^tm1.1Apma)	kidney inflammation	J:322835
Clec4a2^tm1.1Cfg/Clec4a2^tm1.1Cfg (involves: C57BL/6)	enlarged lymph nodes	J:217719
	immune system phenotype	J:217719
	increased B cell proliferation	J:217719
	increased IgG2a level	J:217719
	increased IgG2b level	J:217719
	increased IgG3 level	J:217719
	increased inflammatory response	J:217719
Clec4a2^tm1Yiw/Clec4a2^tm1Yiw (involves: 129P2/OlaHsd * C57BL/6J)	abnormal circulating interleukin level	J:217720
	abnormal immune system morphology	J:217720
	abnormal immune system physiology	J:217720
	enthesitis	J:217720
	increased anti-nuclear antigen antibody level	J:217720
	increased autoantibody level	J:217720
	increased circulating interleukin-4 level	J:217720
	increased circulating interleukin-10 level	J:217720
	increased circulating interleukin-17 level	J:217720
	increased circulating interleukin-23 level	J:217720
	increased dendritic cell number	J:217720
	increased IgG1 level	J:217720
	increased IgG3 level	J:217720
	increased IgG level	J:217720
	increased inflammatory response	J:217720
	increased single-positive T cell number	J:217720
	increased susceptibility to induced arthritis	J:217720
	joint inflammation	J:217720
	salivary gland inflammation	J:217720
Clec4b1^em#Tsak/Clec4b1^em#Tsak (involves: C57BL/6N)	abnormal adaptive immunity	J:258645
	abnormal cytokine level	J:258645
	abnormal cytokine secretion	J:258645
	decreased interferon-gamma secretion	J:258645
	decreased interleukin-12 secretion	J:258645
	increased susceptibility to bacterial infection	J:258645
Clec4d^tm1.1Cfg/Clec4d^tm1.1Cfg (involves: C57BL/6)	decreased B cell proliferation	J:217719
	decreased T cell proliferation	J:217719
	immune system phenotype	J:203221
	increased B cell number	J:217719
	increased interferon-gamma secretion	J:203221
	increased interleukin-6 secretion	J:203221
	increased interleukin-10 secretion	J:203221
	increased interleukin-17 secretion	J:203221
	increased mature B cell number	J:217719
	increased susceptibility to bacterial infection	J:203221
	increased susceptibility to bacterial infection induced morbidity/mortality	J:203221
	increased tumor necrosis factor secretion	J:203221
	lung inflammation	J:203221
Clec4d^tm1.1Shoy/Clec4d^tm1.1Shoy (involves: 129P2/OlaHsd * C57BL/6)	abnormal antigen presentation	J:203159
	abnormal chemokine secretion	J:203159
	abnormal immune serum protein physiology	J:203159
	abnormal immune system physiology	J:203159
	abnormal interferon-gamma secretion	J:203159
	abnormal interleukin-17 secretion	J:203159
	abnormal response to infection	J:203159
	abnormal thymus morphology	J:203159
	decreased circulating interleukin-17 level	J:203159
	decreased dendritic cell number	J:203159
	decreased IgG level	J:203159
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:203159
	decreased susceptibility to type IV hypersensitivity reaction	J:203159
	decreased tumor necrosis factor secretion	J:203159
	granulomatous inflammation	J:203159
	lung inflammation	J:203159
Clec4e^tm1.1Cfg/Clec4e^tm1.1Cfg (B6.Cg-Clec4e^tm1.1Cfg)	abnormal macrophage physiology	J:136334
	decreased lymphocyte cell number	J:136334
	decreased monocyte cell number	J:136334
	decreased neutrophil cell number	J:136334
	decreased tumor necrosis factor secretion	J:136334
	increased susceptibility to fungal infection	J:136334
Clec4e^tm1Tks/Clec4e^tm1Tks (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal chemokine secretion	J:172959
	decreased interleukin-6 secretion	J:172959
	decreased interleukin-10 secretion	J:172959
	decreased neutrophil cell number	J:172959
	decreased susceptibility to fungal infection	J:172959
	decreased tumor necrosis factor secretion	J:172959
Clec4e^tm1Tks/Clec4e^tm1Tks (involves: 129S1/Sv * 129X1/SvJ)	abnormal chemokine secretion	J:203159
	abnormal immune serum protein physiology	J:203159
	abnormal interferon-gamma secretion	J:203159
	abnormal interleukin-17 secretion	J:203159
	abnormal response to infection	J:203159
	decreased circulating interleukin-17 level	J:203159
	decreased dendritic cell number	J:203159
	decreased IgG level	J:203159
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:203159
	decreased susceptibility to type IV hypersensitivity reaction	J:203159
	decreased tumor necrosis factor secretion	J:203159
Clec4f^tm1Ymed/Clec4f^tm1Ymed (B6.129S7-Clec4f^tm1Ymed)	abnormal macrophage cytokine production	J:203199
	decreased interferon-gamma secretion	J:203199
	immune system phenotype	J:203199
Clec4g^tm1.1Cfg/Clec4g^tm1.1Cfg (involves: C57BL/6)	increased lymphocyte cell number	J:217719
Clec4g^tm1.1Cfg/Clec4g^tm1.1Cfg (involves: C57BL/6)	increased monocyte cell number	J:217719
Clec4g^tm1.1Fhe/Clec4g^tm1.1Fhe (B6.129-Clec4g^tm1.1Fhe)	abnormal immune system cell morphology	J:200968
	abnormal immune system physiology	J:200968
	decreased susceptibility to Adenoviridae infection	J:194891
	immune system phenotype	J:200968
	increased activated T cell number	J:200968
	increased CD4-positive, alpha-beta T cell number	J:200968
	increased CD8-positive, alpha-beta T cell number	J:200968, J:194891
	liver inflammation	J:200968
Clec4n^tm1.2Mgne/Clec4n^tm1.2Mgne (involves: C57BL/6 * C57BL/6J)	abnormal chemokine secretion	J:209284
	abnormal interferon secretion	J:209284
	abnormal interleukin secretion	J:209284
	abnormal macrophage physiology	J:209284
	abnormal neutrophil physiology	J:209284
	abnormal susceptibility to fungal infection	J:209284
	abnormal tumor necrosis factor secretion	J:209284
	decreased interferon-gamma secretion	J:209284
	decreased interleukin-17 secretion	J:209284
	decreased tumor necrosis factor secretion	J:209284
	impaired macrophage phagocytosis	J:209284
	impaired neutrophil phagocytosis	J:209284
	increased interferon-gamma secretion	J:209284
	increased interleukin-1 alpha secretion	J:209284
	increased interleukin-1 beta secretion	J:209284
	increased interleukin-6 secretion	J:209284
	increased interleukin-17 secretion	J:209284
	increased susceptibility to fungal infection	J:209284
	increased tumor necrosis factor secretion	J:209284
Clec4n^tm1Yiw/Clec4n^tm1Yiw (B6.129P2-Clec4n^tm1Yiw)	abnormal CD4-positive T cell differentiation	J:160680
	decreased interferon-gamma secretion	J:160680
	decreased interleukin-6 secretion	J:160680
	decreased interleukin-10 secretion	J:160680
	decreased interleukin-12b secretion	J:160680
	decreased interleukin-17 secretion	J:160680
	decreased interleukin-23 secretion	J:160680
	decreased tumor necrosis factor secretion	J:160680
	increased susceptibility to infection induced morbidity/mortality	J:160680
Clec4n^tm1Yiw/Clec4n^tm1Yiw (involves: 129P2/OlaHsd)	increased susceptibility to fungal infection	J:209284
Clec5a^em1(IMPC)Mbp/Clec5a^em1(IMPC)Mbp (C57BL/6NCrl-Clec5a^em1(IMPC)Mbp/MbpMmucd)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Clec5a^tm1Cua/Clec5a^tm1Cua (involves: C57BL/6)	decreased susceptibility to induced arthritis	J:158811
Clec7a^tm1.1Bpip/Clec7a^tm1.1Bpip Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6J)	abnormal macrophage physiology	J:203908
	decreased tumor necrosis factor secretion	J:203908
	impaired macrophage phagocytosis	J:203908
	increased susceptibility to fungal infection	J:203908
Clec7a^tm1Gdb/Clec7a^tm1Gdb (involves: 129S6/SvEvTac * C57BL/6)	abnormal cytokine secretion	J:116669
	abnormal inflammatory response	J:116669
	abnormal macrophage physiology	J:116669
	abnormal neutrophil physiology	J:116669
	increased susceptibility to fungal infection	J:116669
Clec7a^tm1Gdb/Clec7a^tm1Gdb (B6.129S6-Clec7a^tm1Gdb)	abnormal circulating interleukin level	J:179011
	decreased circulating interleukin-17 level	J:179011
	increased susceptibility to fungal infection	J:179011
	lung inflammation	J:179011
Clec7a^tm1Yiw/Clec7a^tm1Yiw (C.129P2-Clec7a^tm1Yiw)	abnormal cytokine secretion	J:116670
	abnormal dendritic cell physiology	J:116670
	abnormal macrophage physiology	J:116670
	increased susceptibility to fungal infection	J:116670
Clec7a^tm1Yiw/Clec7a^tm1Yiw (involves: 129P2/OlaHsd * C57BL/6)	abnormal dendritic cell physiology	J:122394
	immune system phenotype	J:122394
Clec7a^tm1Yiw/Clec7a^tm1Yiw Myd88^tm1Aki/Myd88^tm1Aki (involves: 129P2/OlaHsd * BALB/cA * C57BL/6J)	abnormal cytokine secretion	J:116670
	abnormal dendritic cell physiology	J:116670
Clec9a^tm1.1Crs/Clec9a^tm1.1Crs (C57BL/6-Clec9a^tm1.1Crs)	abnormal dendritic cell antigen presentation	J:178441
Clec9a^tm1.1Kens/Clec9a^tm1.1Kens (involves: C57BL/6)	abnormal humoral immune response	J:181366
Clec9a^tm1Crs/Clec9a^tm1Crs (involves: 129S6/SvEvTac * C57BL/6)	abnormal dendritic cell antigen presentation	J:147472
Clec10a^m1/Clec10a^m1 (NC/Nga)	dermatitis	J:283174
	immune system phenotype	J:283174
	increased neutrophil cell number	J:283174
Clec10a^tm1Hed/Clec10a⁺ St3gal1^tm1Jxm/St3gal1^tm1Jxm (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	decreased CD8-positive, alpha-beta T cell number	J:78035
Clec10a^tm1Hed/Clec10a^tm1Hed (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	dermatitis	J:283174
	immune system phenotype	J:78035, J:283174
	increased neutrophil cell number	J:283174
Clec10a^tm1Hed/Clec10a^tm1Hed St3gal1^tm1Jxm/St3gal1^tm1Jxm (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	decreased CD8-positive, alpha-beta T cell number	J:78035
Clec12a^tm1Gdb/Clec12a^tm1Gdb (involves: C57BL/6)	increased susceptibility to bacterial infection	J:224869
Clec12a^tm1Gdb/Clec12a^tm1Gdb (involves: C57BL/6)	increased susceptibility to bacterial infection induced morbidity/mortality	J:224869
Clec12a^tm1Jrld/Clec12a^tm1Jrld (B6J.129-Clec12a^tm1Jrld)	abnormal chemokine secretion	J:210326
	abnormal neutrophil physiology	J:210326
	immune system phenotype	J:210326
	increased inflammatory response	J:210326
	increased tumor necrosis factor secretion	J:210326
Clic4^tm1.1Aidi/Clic4^tm1.1Aidi (involves: C57BL/6 * C57BL/6J)	abnormal chemokine secretion	J:175404
	decreased circulating interleukin-6 level	J:175404
	decreased circulating tumor necrosis factor level	J:175404
	decreased interleukin-6 secretion	J:175404
	decreased interleukin-12 secretion	J:175404
	decreased susceptibility to endotoxin shock	J:175404
	decreased tumor necrosis factor secretion	J:175404
	increased susceptibility to bacterial infection	J:175404
Clic4^tm1.1Yus/Clic4^tm1.1Yus (involves: 129S4/SvJae * C57BL/6J)	impaired macrophage phagocytosis	J:183611
Clic5^jbg/Clic5^jbg (involves: C3H/HeJ * C57BL/6)	decreased eosinophil cell number	J:160186
	decreased monocyte cell number	J:160186
	decreased neutrophil cell number	J:160186
Clip2^{em1(IMPC)Ccpcz}/Clip2^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Clip2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
Clk1^{tm1a(EUCOMM)Wtsi}/Clk1^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Clk1^{tm1a(EUCOMM)Wtsi}/Ics)	decreased granulocyte number	J:165965
Cln3^em1Dprc/Cln3^em1Dprc (C57BL/6-Cln3^em1Dprc)	increased microglial cell activation	J:294634
Cln3^tm1Nbm/Cln3^tm1Nbm (involves: 129S6/SvEvTac * C57BL/6J)	abnormal dendritic cell physiology	J:233445
	abnormal macrophage physiology	J:233445
	abnormal professional antigen presenting cell morphology	J:233445
	decreased macrophage cytokine production	J:233445
Cln8^em1(IMPC)Mbp/Cln8^em1(IMPC)Mbp (C57BL/6N-Cln8^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Clnk^{em1(IMPC)Ccpcz}/Clnk^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Clnk^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Clnk^tm1Rygo/Clnk^tm1Rygo (B6.129P2-Clnk^tm1Rygo)	abnormal interferon-gamma secretion	J:131738
	abnormal NK T cell physiology	J:131738
	decreased interleukin-4 secretion	J:131738
	immune system phenotype	J:131738
	increased natural killer cell mediated cytotoxicity	J:131738
Clnk^tm1Rygo/Clnk^tm1Rygo (involves: 129P2/OlaHsd * BALB/c)	immune system phenotype	J:131621
	increased interferon-gamma secretion	J:131621
	increased natural killer cell mediated cytotoxicity	J:131621
Clnk^tm1Rygo/Clnk^tm1Rygo Lcp2^tm1Geha/Lcp2^tm1Geha (involves: 129P2/OlaHsd * 129S4/SvJae * BALB/c)	decreased interferon-gamma secretion	J:131621
	impaired natural killer cell mediated cytotoxicity	J:131621
	increased NK cell number	J:131621
Clnk^tm1Vei/Clnk^tm1Vei (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal mast cell physiology	J:91590
	immune system phenotype	J:91590
	increased natural killer cell mediated cytotoxicity	J:91590
Clock^{em1(IMPC)Ccpcz}/Clock^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Clock^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	decreased CD8-positive, naive alpha-beta T cell number	J:211773
	decreased effector memory T-helper cell number	J:211773
	decreased spleen weight	J:211773
	enlarged thymus	J:211773
	increased CD4-positive, alpha-beta T cell number	J:211773
	increased eosinophil cell number	J:211773
	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
	increased T-helper cell number	J:211773
Clp1^tm1.1Pngr/Clp1^tm1.1Pngr (CBA.Cg-Clp1^tm1.1Pngr)	abnormal microglial cell morphology	J:209564
Clpp^{Gt(IST11134F10)Tigm}/Clpp^{Gt(IST11134F10)Tigm} (involves: C57BL/6N)	abnormal T cell activation	J:203140
	dermatitis	J:203140
Clpp^{Gt(IST13563G11)Tigm}/Clpp^{Gt(IST13563G11)Tigm} (involves: C57BL/6N)	abnormal T cell activation	J:203140
	dermatitis	J:203140
Clpp^{tm1a(EUCOMM)Wtsi}/Clpp^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Clpp^{tm1a(EUCOMM)Wtsi}/Wtsi)	decreased CD4-positive NK T cell number	J:211773
	decreased effector memory CD8-positive, alpha-beta T cell number	J:211773
	decreased gamma-delta T cell number	J:211773
	decreased memory-marker CD4-negative NK T cell number	J:211773
	decreased memory-marker CD4-positive NK T cell number	J:211773
	decreased NK T cell number	J:211773
	increased B cell number	J:211773
	increased KLRG1-positive NK cell number	J:211773
	increased leukocyte cell number	J:211773
	increased Ly6C high monocyte number	J:211773
	increased Ly6C low monocyte number	J:211773
	increased mature B cell number	J:211773
	increased monocyte cell number	J:211773
Clptm1^em1(IMPC)Tcp/Clptm1⁺ (C57BL/6N-Clptm1^em1(IMPC)Tcp/Cmmr)	enlarged lymph nodes	J:211773
	increased monocyte cell number	J:211773
Clptm1l^{tm1d(EUCOMM)Wtsi}/Clptm1l⁺ (involves: 129S4/SvJaeSor * BALB/cJ * C57BL/6N)	abnormal class switch recombination	J:265892
Clptm1l^{tm1d(EUCOMM)Wtsi}/Clptm1l^{tm1d(EUCOMM)Wtsi} (involves: 129S4/SvJaeSor * BALB/cJ * C57BL/6N)	immune system phenotype	J:265892
Clptm1l^{tm1d(EUCOMM)Wtsi}/Clptm1l^{tm1d(EUCOMM)Wtsi} Prdm1^tm1Nutt/Prdm1⁺ (involves: 129S4/SvJaeSor * BALB/cJ * C57BL/6 * C57BL/6N)	immune system phenotype	J:265892
Clptq1^NZB/BlNJ/Clptq1^NZB/BlNJ (B6.NZB-(D4Mit193-D4Mit33))	enlarged spleen	J:143646
	enlarged thymus	J:143646
	increased B-1a cell number	J:143646
	increased NK T cell number	J:143646
Clrn1^{tm1.1(KOMP)Vlcg}/Clrn1^{tm1.1(KOMP)Vlcg} (C57BL/6N-Clrn1^{tm1.1(KOMP)Vlcg}/Ucd)	abnormal spleen morphology	J:211773
cls/cls (involves: DBA/1Lac)	immune system phenotype	J:15088
Clspn^{tm1(KOMP)Vlcg}/Clspn⁺ (C57BL/6N-Clspn^{tm1(KOMP)Vlcg})	increased B cell number	J:332163
	lymphoid hyperplasia	J:332163
Clstn1^{tm1b(EUCOMM)Hmgu}/Clstn1^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Clstn1^{tm1b(EUCOMM)Hmgu}/H)	increased basophil cell number	J:211773
Clta^tm1.2Fmb/Clta^tm1.2Fmb (involves: C57BL/6)	abnormal class switch recombination	J:235591
Clta^tm1.2Fmb/Clta^tm1.2Fmb (involves: C57BL/6)	decreased germinal center B cell number	J:235591
Clu^tm1Jakh/Clu^tm1Jakh (involves: Black Swiss * FVB/N)	heart inflammation	J:65660
Clu^tm1Jakh/Clu^tm1Jakh (involves: Black Swiss * FVB/N)	myocarditis	J:65660
Cluh^{em1(IMPC)Ccpcz}/Cluh⁺ (C57BL/6N-Cluh^{em1(IMPC)Ccpcz}/Ccpcz)	increased Ly6C-positive mature NK cell number	J:211773
Cma1^tm1Mfg/Cma1^tm1Mfg (either: (involves: 129 * C57BL/6) or (involves: 129 * BALB/c))	abnormal mast cell physiology	J:98963
Cmah^tm1Avrk/Cmah^tm1Avrk Dmd^mdx/Dmd^mdx (involves: 129X1/SvJ * C57BL/10ScSn)	increased macrophage cell number	J:164594
	increased monocyte cell number	J:164594
Cmah^tm1Avrk/Cmah^tm1Avrk Dock2^m1Hsd/Dock2^m1Hsd (B6NHsd.Cg-Dock2^m1Hsd Cmah^tm1Avrk)	abnormal B cell activation	J:144035
	decreased follicular B cell number	J:144035
	decreased marginal zone B cell number	J:144035
Cmah^tm1Avrk/Cmah^tm1Avrk Dock2^m1Hsd/Dock2^m1Hsd Siae^tm1.2Avrk/Siae^tm1.2Avrk (B6NHsd.Cg-Siae^tm1.2Avrk Dock2^m1Hsd Cmah^tm1Avrk)	abnormal B cell activation	J:144035
	decreased follicular B cell number	J:144035
	decreased marginal zone B cell number	J:144035
Cmah^tm1Ykoz/Cmah^tm1Ykoz (B6.129P2-Cmah^tm1Ykoz)	abnormal B cell physiology	J:121365
	abnormal humoral immune response	J:121365
	abnormal interleukin secretion	J:121365
	abnormal T cell physiology	J:121365
	decreased interferon-gamma secretion	J:121365
	immune system phenotype	J:121365
	increased B cell proliferation	J:121365
	increased IgG1 level	J:121365
Cmas^tm1.1Bwei/Cmas^tm1.1Bwei Tg(NPHS2-cre)295Lbh/0 (involves: 129P2/OlaHsd * C57BL/6 * SJL)	tubular nephritis	J:286022
Cmcs^CBA/N/? (involves: CBA/N * DBA/2)	abnormal immune system physiology	J:94127
Cmcs^DBA/2/? (involves: CBA/N * DBA/2)	abnormal immune system physiology	J:94127
Cmip^{tm1a(EUCOMM)Wtsi}/Cmip^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Cmip^{tm1a(EUCOMM)Wtsi}/Wtsi)	abnormal lymphatic vessel morphology	J:239583
Cmklr1^tm1Dgen/Cmklr1^tm1Dgen (B6.Cg-Cmklr1^tm1Dgen)	abnormal alveolar macrophage morphology	J:157190
	abnormal dendritic cell physiology	J:157190
	abnormal immune system morphology	J:157190
	abnormal macrophage chemotaxis	J:157190
	abnormal professional antigen presenting cell physiology	J:157190
	increased neutrophil cell number	J:157190
	increased susceptibility to endotoxin shock	J:157190
	lung inflammation	J:157190
Cmklr1^tm1Drg/Cmklr1^tm1Drg (Not Specified)	impaired macrophage chemotaxis	J:133968
Cmklr1^tm1Drg/Cmklr1^tm1Drg (Not Specified)	impaired neutrophil recruitment	J:133968
Cms1^DBA/2J/? (involves: C57BL/6J * DBA/2J)	decreased susceptibility to fungal infection	J:55132
Cms2^DBA/2J/? (involves: C57BL/6J * DBA/2J)	decreased susceptibility to infection	J:55132
Cmtm4^{tm1d(EUCOMM)Wtsi}/Cmtm4^{tm1d(EUCOMM)Wtsi} (involves: C57BL/6J * C57BL/6N)	decreased CD8-positive, alpha-beta T cell number	J:333836
	decreased inflammatory response	J:333836
	decreased susceptibility to chemically induced skin inflammation	J:333836
	immune system phenotype	J:333836
	increased B cell number	J:333836
Cmtm5^{tm1c(KOMP)Wtsi}/Cmtm5^{tm1c(KOMP)Wtsi} Cnp^tm1(cre)Kan/Cnp⁺ (B6.Cg-Cnp^tm1(cre)Kan Cmtm5^{tm1c(KOMP)Wtsi})	microgliosis	J:327261
Cmtm7^{tm2a(EUCOMM)Hmgu}/Cmtm7⁺ Rag1^tm1Fwa/Rag1^tm1Fwa (chimera involves: C57BL/6 * C57BL/6N)	abnormal B cell physiology	J:207033
	abnormal B-1a B cell morphology	J:207033
	decreased B cell proliferation	J:207033
	decreased B-1a cell number	J:207033
	decreased IgG2b level	J:207033
	decreased IgM level	J:207033
	decreased plasma cell number	J:207033
Cmtr1^{tm1b(EUCOMM)Hmgu}/Cmtr1^{tm1b(EUCOMM)Hmgu} Emx1^tm1(cre)Krj/Emx1⁺ Tg(Thy1-YFP)HJrs/0 (involves: 129S2/SvPas * C57BL/6J * C57BL/6N * CBA)	abnormal susceptibility to Riboviria infection	J:300305
Cndp2^em1(IMPC)Mbp/Cndp2^em1(IMPC)Mbp (C57BL/6NCrl-Cndp2^em1(IMPC)Mbp/Mmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
Cnga3^{tm1.1(KOMP)Vlcg}/Cnga3⁺ (C57BL/6N-Cnga3^{tm1.1(KOMP)Vlcg}/Ucd)	enlarged spleen	J:211773
Cngb3^{em1(IMPC)Ccpcz}/Cngb3^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Cngb3^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Cnmd^tm1Ska/Cnmd^tm1Ska (involves: C57BL/6 * CBA)	abnormal osteoclast physiology	J:81137
Cnn2^tm1.1Jin/Cnn2^tm1.1Jin Cnn3^tm1.1Hjum/Cnn3^tm1.1Hjum Cd79a^tm1(cre)Reth/Cd79a⁺ (involves: 129S6/SvEvTac * 129X1/SvJ * BALB/c)	immune system phenotype	J:237712
Cnn2^tm1.2Jin/Cnn2^tm1.2Jin (B6.129X1-Cnn2^tm1.2Jin)	abnormal immune system cell morphology	J:141867
	abnormal macrophage chemotaxis	J:141867
	abnormal macrophage physiology	J:141867
	decreased granulocyte number	J:141867
	decreased monocyte cell number	J:141867
	decreased neutrophil cell number	J:141867
	immune system phenotype	J:141867
	increased macrophage cell number	J:141867
Cnn2^tm1Jin/Cnn2^tm1Jin (B6.129X1-Cnn2^tm1Jin)	decreased monocyte cell number	J:141867
	decreased neutrophil cell number	J:141867
	immune system phenotype	J:141867
Cnn3^tm1.1Hjum/Cnn3^tm1.1Hjum Cd79a^tm1(cre)Reth/Cd79a⁺ (involves: 129S6/SvEvTac * BALB/c)	immune system phenotype	J:237712
Cnot3^tm1.1Tya/Cnot3⁺ (B6.129P2(Cg)-Cnot3^tm1.1Tya)	abnormal osteoclast differentiation	J:206802
Cnot3^tm1.1Tya/Cnot3⁺ (B6.129P2(Cg)-Cnot3^tm1.1Tya)	increased osteoclast cell number	J:206802
Cnot4^{tm1b(EUCOMM)Wtsi}/Cnot4⁺ (C57BL/6N-Cnot4^{tm1b(EUCOMM)Wtsi}/Wtsi)	decreased KLRG1-positive NK cell number	J:211773
Cnppd1^{tm1.1(KOMP)Vlcg}/Cnppd1^{tm1.1(KOMP)Vlcg} (B6N(Cg)-Cnppd1^{tm1.1(KOMP)Vlcg}/J)	increased leukocyte cell number	J:211773
Cnpy2^{em1(IMPC)Wtsi}/Cnpy2⁺ (C57BL/6N-Cnpy2^{em1(IMPC)Wtsi}/Wtsi)	increased effector memory T-helper cell number	J:211773
Cnpy3^tm1Kmiy/Cnpy3^tm1Kmiy (involves: C57BL/6)	abnormal lymphocyte physiology	J:128513
	abnormal macrophage physiology	J:128513
	decreased interleukin-6 secretion	J:128513
	decreased tumor necrosis factor secretion	J:128513
Cnr2^tm1Zim/Cnr2^tm1Zim (involves: 129 * C57BL/6)	abnormal macrophage physiology	J:62417
Cnr2^tm1Zim/Cnr2^tm1Zim (involves: 129 * C57BL/6)	immune system phenotype	J:62417
Cntf^tm1Mpin/Cntf^tm1Mpin (involves: 129S2/SvPas)	abnormal microglial cell morphology	J:15313
Cntf^tm1Mpin/Cntf^tm1Mpin (B6.129S2-Cntf^tm1Mpin)	increased susceptibility to experimental autoimmune encephalomyelitis	J:126852
Cntn5^em1(IMPC)Mbp/Cntn5^em1(IMPC)Mbp (C57BL/6N-Cntn5^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
Coasy^em1(IMPC)H/Coasy⁺ (C57BL/6NTac-Coasy^em1(IMPC)H/H)	increased neutrophil cell number	J:211773
Cobl^{em1(IMPC)Ccpcz}/Cobl^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Cobl^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
	increased effector memory T-helper cell number	J:211773
Cobll1^{em1(IMPC)Ccpcz}/Cobll1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Cobll1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Cog5^{em1(IMPC)Ccpcz}/Cog5⁺ (C57BL/6NCrl-Cog5^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Cog6^{tm1a(EUCOMM)Wtsi}/Cog6^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Cog6^{tm1a(EUCOMM)Wtsi}/Wtsi)	decreased alpha-beta T cell number	J:211773
	decreased CD4-positive NK T cell number	J:211773
	decreased CD8-positive, alpha-beta T cell number	J:211773
	decreased CD8-positive, naive alpha-beta T cell number	J:211773
	decreased effector memory CD8-positive, alpha-beta T cell number	J:211773
	decreased Ly6C-positive immature NK cell number	J:211773
	decreased Ly6C-positive mature NK cell number	J:211773
	decreased marginal zone B cell number	J:211773
	decreased memory-marker CD4-negative NK T cell number	J:211773
	decreased memory-marker CD4-positive NK T cell number	J:211773
	decreased memory-marker gamma-delta T cell number	J:211773
	decreased memory-marker NK cell number	J:211773
	decreased NK cell number	J:211773
	decreased NK T cell number	J:211773
	decreased T cell number	J:211773
	decreased T-helper cell number	J:211773
	decreased transitional stage T2 B cell number	J:211773
	increased anti-nuclear antigen antibody level	J:211773
	increased B-2 B cell number	J:211773
	increased CD4-negative NK T cell number	J:211773
	increased CD4-positive, alpha-beta memory T cell number	J:211773
	increased CD4-positive, alpha-beta T cell number	J:211773
	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	increased CD5-positive gamma-delta T cell number	J:211773
	increased effector memory T-helper cell number	J:211773
	increased eosinophil cell number	J:211773
	increased follicular B cell number	J:211773
	increased gamma-delta T cell number	J:211773
	increased granulocyte number	J:211773
	increased KLRG1+ CD4 alpha-beta T cell number	J:211773
	increased KLRG1+ CD8 alpha-beta T cell number	J:211773
	increased KLRG1-positive CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	increased KLRG1-positive NK cell number	J:211773
	increased KLRG1-positive T-helper cell number	J:211773
	increased leukocyte cell number	J:211773
	increased Ly6C high monocyte number	J:211773
	increased memory CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	increased memory-marker gamma-delta T cell number	J:211773
	increased memory-marker NK cell number	J:211773
	increased monocyte cell number	J:211773
	increased plasma cell number	J:211773
Col1a1^Aga2/Col1a1⁺ (C3HeB/FeJ-Col1a1^Aga2)	lung inflammation	J:185988
Col1a1^M1Jrt/Col1a1⁺ (involves: C3H/HeJ * C57BL/6J * FVB/NJ)	osteoarthritis	J:216423
Col1a1^M1Jrt/Col1a1⁺ (involves: C57BL/6 * FVB/N)	autoimmune arthritis	J:228439
Col1a1^{tm1(CAG-Ezh2)Meln}/Col1a1⁺ Ighg1^tm1(cre)Cgn/Ighg1⁺ (involves: 129P2/OlaHsd 129S4/SvJae * C57BL/6)	immune system phenotype	J:199122
	increased germinal center B cell number	J:199122
	increased spleen germinal center number	J:199122
	increased spleen germinal center size	J:199122
Col1a1^{tm1(CAG-Mir22)Ppp}/Col1a1^{tm1(CAG-Mir22)Ppp} Tg(Mx1-cre)1Cgn/0 (Not Specified)	decreased leukocyte cell number	J:199366
	enlarged spleen	J:199366
	increased myeloid dendritic cell number	J:199366
	increased T cell derived lymphoma incidence	J:199366
Col1a1^{tm1(KRT18-ACE2)Irb}/Col1a1⁺ (involves: 129S4/SvJae * C57BL/6)	increased cytokine level	J:368665
	increased susceptibility to Coronaviridae infection	J:368665
	interstitial pneumonia	J:368665
Col1a1^{tm1(tetO-Cyp26b1)Mfra}/Col1a1⁺ Gt(ROSA)26Sor^{tm1(rtTAM2)Jae}/Gt(ROSA)26Sor⁺ (involves: 129S4/SvJae C57BL/6)	abnormal lymphatic vessel morphology	J:206581
Col1a1^{tm1(tetO-Fos)Wag}/Col1a1⁺ Tg(KRT5-rtTA)T2D6Sgkd/0 (involves: 129S4/SvJae * C57BL/6 * FVB/N)	immune system phenotype	J:201145
	increased CD4-positive, alpha-beta T cell number	J:201145
	increased granulocyte number	J:201145
	skin inflammation	J:201145
Col1a1^{tm1(tetO-GFP/RNAi:Rad21)Iaai}/Col1a1⁺ Gt(ROSA)26Sor^{tm1(rtTAM2)Jae}/Gt(ROSA)26Sor⁺ (involves: 129S4/SvJae C57BL/6)	decreased B cell number	J:229031
Col1a1^{tm1(tetO-Irf4)Sing}/Col1a1^{tm1(tetO-Irf4)Sing} Gt(ROSA)26Sor^{tm1(rtTAM2)Jae}/Gt(ROSA)26Sor⁺ Irf4^tm1Mak/Irf4⁺ (involves: 129P2/OlaHsd 129S4/SvJae * C57BL/6)	abnormal class switch recombination	J:203903
	abnormal plasma cell differentiation	J:203903
Col1a1^{tm1(tetO-Irf4)Sing}/Col1a1^{tm1(tetO-Irf4)Sing} Gt(ROSA)26Sor^{tm1(rtTAM2)Jae}/Gt(ROSA)26Sor⁺ Irf4^tm1Mak/Irf4^tm1Mak (involves: 129P2/OlaHsd 129S4/SvJae * C57BL/6)	abnormal class switch recombination	J:203903
	abnormal plasma cell differentiation	J:203903
Col1a1^{tm1(tetO-RNAi:Rps19)Karl}/Col1a1⁺ Gt(ROSA)26Sor^{tm1(rtTAM2)Jae}/Gt(ROSA)26Sor^{tm1(rtTAM2)Jae} (involves: 129S4/SvJae * C57BL/6)	decreased lymphocyte cell number	J:179085
Col1a1^{tm1(tetO-RNAi:Rps19)Karl}/Col1a1^{tm1(tetO-RNAi:Rps19)Karl} Gt(ROSA)26Sor^{tm1(rtTAM2)Jae}/Gt(ROSA)26Sor^{tm1(rtTAM2)Jae} (involves: 129S4/SvJae * C57BL/6)	decreased lymphocyte cell number	J:179085
	decreased neutrophil cell number	J:179085
Col1a1^{tm1(tetO-Stat1)Biat}/Col1a1^{tm1(tetO-Stat1)Biat} Gt(ROSA)26Sor^{tm1(rtTAM2)Jae}/Gt(ROSA)26Sor^{tm1(rtTAM2)Jae} Stat1^tm1Dlv/Stat1^tm1Dlv (involves: 129S/SvEv * 129S4/SvJae * C57BL/6)	abnormal susceptibility to infection induced morbidity/mortality	J:212694
Col1a1^{tm1(tetO-Tcfap2c)Hsc}/Col1a1⁺ Gt(ROSA)26Sor^{tm1(rtTAM2)Jae}/Gt(ROSA)26Sor⁺ (involves: 129S4/SvJae C57BL/6)	immune system phenotype	J:174049
Col1a1^{tm1(tetO-Yod1)Hpl}/Col1a1^{tm1(tetO-Yod1)Hpl} Gt(ROSA)26Sor^{tm1(rtTAM2)Jae}/Gt(ROSA)26Sor^{tm1(rtTAM2)Jae} (involves: 129S4/SvJae * C57BL/6)	abnormal CD8-positive, alpha-beta T cell physiology	J:194608
	abnormal professional antigen presenting cell physiology	J:194608
	immune system phenotype	J:194608
Col1a1^{tm1(tetO-Yod1)Hpl}/Col1a1^{tm1(tetO-Yod1)Hpl} Gt(ROSA)26Sor^{tm1(rtTAM2)Jae}/Gt(ROSA)26Sor^{tm1(rtTAM2)Jae} Tap1^tm1Arp/Tap1^tm1Arp (involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)	abnormal professional antigen presenting cell physiology	J:194608
Col1a1^tm1Jae/Col1a1^tm1Jae (involves: 129S4/SvJae * C57BL/6)	abnormal osteoclast physiology	J:53079
Col1a1^{tm2(tetO-Fosl2,-DsRed)Wag}/Col1a1⁺ Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0 (involves: 129S4/SvJae * C57BL/6 * CD-1)	abnormal osteoclast morphology	J:211215
Col1a1^{tm2(tetO-GFP/RNAi:Smc1a)Iaai}/Col1a1⁺ Gt(ROSA)26Sor^{tm1(rtTAM2)Jae}/Gt(ROSA)26Sor⁺ (involves: 129S4/SvJae C57BL/6)	decreased B cell number	J:229031
	enlarged spleen	J:229031
	increased neutrophil cell number	J:229031
	increased spleen red pulp amount	J:229031
	myeloid hyperplasia	J:229031
	myeloid metaplasia	J:229031
Col1a1^{tm2(tetO-GFP/RNAi:Smc1a)Iaai}/Col1a1^{tm3(tetO-GFP/RNAi:Stag2)Iaai} Gt(ROSA)26Sor^{tm1(rtTAM2)Jae}/Gt(ROSA)26Sor⁺ (involves: 129S4/SvJae C57BL/6)	abnormal spleen morphology	J:229031
	decreased B cell number	J:229031
	enlarged spleen	J:229031
	myeloid hyperplasia	J:229031
Col1a1^{tm2(tetO-IDH2R140Q)Ppp}/Col1a1^{tm2(tetO-IDH2R140Q)Ppp} Gt(ROSA)26Sor^{tm1(rtTAM2)Jae}/? (involves: 129S4/SvJae C57BL/6)	enlarged spleen	J:210097
Col1a1^{tm2(tetO-Pou5f1)Jae}/Col1a1⁺ Gt(ROSA)26Sor^{tm1(rtTAM2)Jae}/Gt(ROSA)26Sor⁺ (involves: 129S4/SvJae C57BL/6)	spleen atrophy	J:98920
	thymus atrophy	J:98920
Col1a1^{tm2(tetO-RNAi:Rps19)Karl}/Col1a1⁺ Gt(ROSA)26Sor^{tm1(rtTAM2)Jae}/Gt(ROSA)26Sor^{tm1(rtTAM2)Jae} (involves: 129S4/SvJae * C57BL/6)	decreased lymphocyte cell number	J:179085
Col1a1^{tm2(tetO-RNAi:Rps19)Karl}/Col1a1^{tm2(tetO-RNAi:Rps19)Karl} Gt(ROSA)26Sor^{tm1(rtTAM2)Jae}/Gt(ROSA)26Sor^{tm1(rtTAM2)Jae} (involves: 129S4/SvJae * C57BL/6)	decreased lymphocyte cell number	J:179085
	decreased neutrophil cell number	J:179085
Col1a1^{tm3(tetO-Fosl1,-DsRed)Wag}/Col1a1⁺ Gt(ROSA)26Sor^{tm1(rtTAM2)Jae}/Gt(ROSA)26Sor⁺ (involves: 129S4/SvJae C57BL/6)	enlarged spleen	J:213764
Col1a1^{tm3(tetO-Fosl1,-DsRed)Wag}/Col1a1⁺ Tg(Cebpb-tTA)5Bjd/0 (involves: 129S4/SvJae * C57BL/6 * NMRI)	decreased circulating interleukin-6 level	J:210545
	liver inflammation	J:210545
Col1a1^{tm3(tetO-GFP/RNAi:Apc)Slowe}/Col1a1⁺ Gt(ROSA)26Sor^{tm1(rtTAM2)Jae}/Gt(ROSA)26Sor⁺ (involves: 129S4/SvJae C57BL/6)	increased T cell derived lymphoma incidence	J:171191
Col1a1^{tm3(tetO-GFP/RNAi:Stag2)Iaai}/Col1a1⁺ Gt(ROSA)26Sor^{tm1(rtTAM2)Jae}/Gt(ROSA)26Sor⁺ (involves: 129S4/SvJae C57BL/6)	decreased B cell number	J:229031
Col1a1^{tm4(tetO-GFP/RNAi:Apc)Slowe}/Col1a1⁺ Gt(ROSA)26Sor^{tm1(rtTAM2)Jae}/Gt(ROSA)26Sor⁺ (involves: 129S4/SvJae C57BL/6)	increased T cell derived lymphoma incidence	J:171191
Col1a1^{tm6(tetO-MSI2)Jae}/Col1a1⁺ Gt(ROSA)26Sor^{tm1(rtTAM2)Jae}/Gt(ROSA)26Sor⁺ (involves: 129S4/SvJae C57BL/6)	abnormal leukocyte morphology	J:163322
	abnormal myelopoiesis	J:163322
	decreased lymphocyte cell number	J:163322
	decreased neutrophil cell number	J:163322
	enlarged spleen	J:163322
	increased leukocyte cell number	J:163322
	increased spleen weight	J:163322
	spleen hyperplasia	J:163322
Col1a2^{tm1b(EUCOMM)Wtsi}/Col1a2^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Col1a2^{tm1b(EUCOMM)Wtsi}/BayMmucd)	decreased lymphocyte cell number	J:211773
	enlarged spleen	J:211773
	increased large unstained cell number	J:211773
	increased leukocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Col2a1^{em1(IMPC)Ccpcz}/Col2a1⁺ (C57BL/6NCrl-Col2a1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	increased monocyte cell number	J:211773
Col2a1^tm1Prc/Col2a1⁺ Col9a1^tm1Jae/Col9a1^tm1Jae (involves: 129/Sv * 129S2/SvPas)	osteoarthritis	J:117910
Col2a1^tm1Prc/Col2a1^tm1Prc (involves: 129/Sv * C57BL/6)	immune system phenotype	J:30041
Col3a1^m1Btlr/Col3a1^m1Btlr (C57BL/6J-Col3a1^m1Btlr)	increased alpha-beta T cell number	J:271973
	increased CD4-positive, alpha-beta T cell number	J:271973
	increased CD8-positive, alpha-beta T cell number	J:271973
	increased susceptibility to induced colitis	J:271973
Col3a1^Tsk2/Col3a1⁺ (C3H101H-Col3a1^Tsk2/H)	adipose tissue inflammation	J:31216
Col3a1^Tsk2/Col3a1⁺ (C3H101H-Col3a1^Tsk2/H)	skin inflammation	J:31216
Col4a1^tm1.1Ics/Col4a1⁺ (involves: 129S2/SvPas * C57BL/6)	kidney inflammation	J:240798
Col4a1^tm1.1Ics/Col4a1^tm1.1Ics (involves: 129S2/SvPas * C57BL/6)	kidney inflammation	J:240798
Col4a2^{em1(IMPC)Wtsi}/Col4a2^{em1(IMPC)Wtsi} (C57BL/6N-Col4a2^{em1(IMPC)Wtsi}/WtsiOulu)	abnormal thymus topology	J:239583
	blood in lymph vessels	J:239583
	small thymus	J:239583
Col4a3^tm1.1Rkl/Col4a3⁺ (involves: C57BL/6)	glomerulonephritis	J:167404
Col4a3^{tm1b(EUCOMM)Wtsi}/Col4a3^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Col4a3^{tm1b(EUCOMM)Wtsi}/H)	decreased basophil cell number	J:211773
	decreased lymphocyte cell number	J:211773
	increased large unstained cell number	J:211773
	increased neutrophil cell number	J:211773
Col4a3^tm1Dec/Col4a3^tm1Dec (involves: 129X1/SvJ * C57BL/6)	glomerulonephritis	J:37963
Col4a3^tm1Dec/Col4a3^tm1Dec (129-Col4a3^tm1Dec/J)	glomerulonephritis	J:158731
Col4a3^tm1Dec/Col4a3^tm1Dec (B6.129X1-Col4a3^tm1Dec)	glomerulonephritis	J:167404
Col4a3^tm1Dec/Col4a3^tm1Dec Itga1^tm1Gdnr/Itga1^tm1Gdnr (involves: 129S4/SvJae * 129X1/SvJ * BALB/c)	tubular nephritis	J:71378
Col4a3^tm1Dec/Col4a3^tm1Dec Sostdc1^tm1Myan/Sostdc1^tm1Myan (involves: 129X1/SvJ)	glomerulonephritis	J:158731
Col4a3^tm1Jhm/Col4a3^tm1Jhm (involves: 129S1/Sv * 129X1/SvJ)	glomerulonephritis	J:37017
Col4a3^tm1Jhm/Col4a3^tm1Jhm Mmp9^tm1Tvu/Mmp9^tm1Tvu (involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ)	glomerulonephritis	J:63137
Col4a4^bwk/Col4a4^bwk (NON;NZO-Col4a4^bwk/J)	kidney inflammation	J:223185
Col4a4^bwk/Col4a4^bwk (NON;NZO-Col4a4^bwk/J)	tubulointerstitial nephritis	J:223185
Col4a4^bwk/Col4a4^bwk (D2.NON(NZO)-Col4a4^bwk/GrsrJ)	kidney inflammation	J:223185
Col4a4^bwk/Col4a4^bwk (129S1.NON(NZO)-Col4a4^bwk/PgnJ)	kidney inflammation	J:223185
Col4a4^m1H/Col4a4^m1H (involves: C3H/HeH * C57BL/6J)	increased leukocyte cell number	J:285510
Col4a5^{tm1b(EUCOMM)Wtsi}/Y (C57BL/6N-Col4a5^{tm1b(EUCOMM)Wtsi}/Cnrm)	increased leukocyte cell number	J:211773
Col4a5^{tm1b(EUCOMM)Wtsi}/Col4a5^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Col4a5^{tm1b(EUCOMM)Wtsi}/Cnrm)	increased large unstained cell number	J:211773
	increased neutrophil cell number	J:211773
	increased spleen weight	J:211773
Col4a5^tm1Yseg/Y (B6.Cg-Col4a5^tm1Yseg)	tubulointerstitial nephritis	J:102306
Col5a2^{em1(IMPC)Ccpcz}/Col5a2⁺ (C57BL/6NCrl-Col5a2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Col6a3^em1(IMPC)Tcp/Col6a3^em1(IMPC)Tcp (C57BL/6N-Col6a3^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Col7a1^em#Jtol/Col7a1^em#Jtol (involves: 129S4/SvJae * BALB/c * C57BL/Ka * NOD)	absent B cells	J:280214
	absent NK T cells	J:280214
	absent T cells	J:280214
Col9a1^tm1Jae/Col9a1^tm1Jae (either: (involves: 129S2/SvPas * BALB/c) or (involves: 129S2/SvPas * C57BL))	osteoarthritis	J:18628
Col9a1^tm1Jae/Col9a1^tm1Jae (involves: 129S2/SvPas)	osteoarthritis	J:117910
Col9a3^em1(IMPC)Tcp/Col9a3^em1(IMPC)Tcp (C57BL/6N-Col9a3^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Col10a1^tm1.1Rpbh/Col10a1^tm1.1Rpbh (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	decreased osteoclast cell number	J:154052
Col10a1^tm1Bhr/Col10a1^tm1Bhr (involves: 129S7/SvEvBrd * C57BL/6)	abnormal spleen morphology	J:62230
	absent lymph nodes	J:62230
	decreased B cell number	J:62230
	decreased double-positive T cell number	J:62230
	decreased spleen red pulp amount	J:62230
	decreased spleen weight	J:62230
	decreased thymocyte number	J:62230
	decreased thymus weight	J:62230
	increased CD4-positive, alpha-beta T cell number	J:62230
	increased double-negative T cell number	J:62230
	increased single-positive T cell number	J:62230
	small spleen	J:62230
	small thymus	J:62230
	spleen hypoplasia	J:62230
	thymus hypoplasia	J:62230
Col10a1^tm1Ksec/Col10a1^tm1Ksec (involves: 129S/SvEv * C57BL/6)	abnormal T-helper 2 cell differentiation	J:193886
	decreased dendritic cell number	J:193886
	decreased interleukin-2 secretion	J:193886
	decreased interleukin-4 secretion	J:193886
	decreased interleukin-10 secretion	J:193886
	decreased interleukin-17 secretion	J:193886
	increased B cell number	J:193886
	increased interleukin-4 secretion	J:193886
	increased T-helper cell number	J:193886
Col11a1^cho/Col11a1⁺ (involves: C57BL/6Fr)	osteoarthritis	J:106282
Col13a1^tm1Pih/Col13a1^tm1Pih (either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J))	myositis	J:71939
Col17a1^em1Dcr/Col17a1^em1Dcr Lamc2^jeb/Lamc2^jeb (B6.Cg-Lamc2^jeb Col17a1^em1Dcr/Dcr)	ear inflammation	J:352187
Col17a1^em2Dcr/Col17a1^em2Dcr Lamc2^jeb/Lamc2^jeb (C57BL/6J-Col17a1^em2Dcr/Dcr)	ear inflammation	J:352187
Col17a1^{tm1.1(COL17A1)Zliu}/Col17a1^{tm1.1(COL17A1)Zliu} (involves: 129P2/OlaHsd * C57BL/6J)	increased mast cell degranulation	J:261781
	increased neutrophil cell number	J:261781
Col17a1^tm1Shzu/Col17a1^tm1Shzu Tg(KRT14-COL17A1)1Shzu/0 (involves: 129S/SvEv * C57BL/6J * C57BL/6Ncr)	decreased autoantibody level	J:121695
Col17a1^tm1Tiin/Col17a1^tm1Tiin (involves: C57BL/6)	increased autoantibody level	J:220622
	increased basophil cell number	J:220622
	increased eosinophil cell number	J:220622
	increased IgE level	J:220622
	increased monocyte cell number	J:220622
	increased neutrophil cell number	J:220622
	skin inflammation	J:220622
Col26a1^em3(IMPC)Tcp/Col26a1^em3(IMPC)Tcp (C57BL/6NCrl-Col26a1^em3(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Col27a1^em1(IMPC)Mbp/Col27a1⁺ (C57BL/6N-Col27a1^em1(IMPC)Mbp/MbpMmucd)	enlarged spleen	J:211773
	small spleen	J:211773
Colec11^tm1Lex/Colec11^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6)	abnormal complement protein level	J:234934
Colec12^em1(IMPC)Mbp/Colec12^em1(IMPC)Mbp (C57BL/6N-Colec12^em1(IMPC)Mbp/MbpMmucd)	small spleen	J:211773
Colgalt2^tm1.1Hwei/Colgalt2^tm1.1Hwei (involves: C57BL/6J)	abnormal CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:310468
	abnormal regulatory T cell morphology	J:310468
	increased circulating interleukin-1 beta level	J:310468
	increased circulating interleukin-4 level	J:310468
	increased circulating interleukin-6 level	J:310468
	increased circulating interleukin-9 level	J:310468
	increased T cell apoptosis	J:310468
Commd8^tm1.1Ksuz/Commd8^tm1.1Ksuz Igh^tm1Mnz/Igh⁺ Cd79a^tm1(cre)Reth/Cd79a⁺ (involves: 129P2/OlaHsd * BALB/c * C57BL/6NSlc * SJL)	abnormal spleen B cell follicle morphology	J:278399
Commd9^{tm1b(KOMP)Wtsi}/Commd9⁺ (C57BL/6N-Commd9^{tm1b(KOMP)Wtsi}/H)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Commd10^{Tg(Vav1-icre)A2Kio}/0 Map3k7^tm1.1Arte/Map3k7^tm1.1Arte (involves: C57BL/10 * C57BL/6J * C57BL/6NTac * CBA/Ca)	decreased interleukin-6 secretion	J:332172
	decreased interleukin-10 secretion	J:332172
	decreased interleukin-12b secretion	J:332172
	decreased macrophage cell number	J:332172
	decreased tumor necrosis factor secretion	J:332172
	enlarged axillary lymph nodes	J:332172
	enlarged inguinal lymph nodes	J:332172
	enlarged spleen	J:332172
	increased B cell number	J:332172
	increased lymphocyte cell number	J:332172
	increased neutrophil cell number	J:332172
	increased splenocyte number	J:332172
Commd10^{Tg(Vav1-icre)A2Kio}/0 Nfil3^tm1.2Kubo/Nfil3^tm1.2Kubo (involves: 129 * C57BL/6 * C57BL/10 * CBA/Ca)	decreased dendritic cell number	J:334296
Commd10^{Tg(Vav1-icre)A2Kio}/? Tnfrsf14^tm1.1Kro/Tnfrsf14^tm1.1Kro (involves: C57BL/6NCrl * C57BL/10 * CBA * SJL)	decreased susceptibility to Herpesvirales infection	J:243038
Commd10^{Tg(Vav1-icre)A2Kio}/Commd10⁺ Zbtb11^tm1.1Lieg/Zbtb11^tm1.1Lieg (involves: C57BL/6J * C57BL/10 * CBA/Ca)	abnormal lymphopoiesis	J:343208
	abnormal myelopoiesis	J:343208
Comp^tm1Mbri/Comp^tm1Mbri (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	osteoarthritis	J:125086
Comt^tm1Kara/Comt^tm1Kara (involves: 129S4/SvJaeSor)	increased interferon-gamma secretion	J:137276
Comt^tm1Kara/Comt^tm1Kara (involves: 129S4/SvJaeSor)	increased uterine NK cell number	J:137276
Cop1^{Gt(XR0653)1.1Wtsi}/Cop1^{Gt(XR0653)1.1Wtsi} (involves: 129P2/OlaHsd * C57BL/6 * CBA)	increased T cell derived lymphoma incidence	J:178271
Copa^tm1.1Shum/Copa⁺ (B6(CBA)-Copa^tm1.1Shum)	abnormal B cell morphology	J:288425
	abnormal T cell activation	J:288425
	bronchiolitis	J:288425
	decreased double-positive T cell number	J:288425
	increased effector memory T-helper cell number	J:288425
	increased single-positive T cell number	J:288425
	lung inflammation	J:288425
Copg1^em1Geha/Copg1^em1Geha (involves: C57BL/6)	abnormal B cell physiology	J:345528
	abnormal IgG level	J:345528
	decreased circulating interferon-gamma level	J:345528
	immune system phenotype	J:345528
	increased susceptibility to bacterial infection induced morbidity/mortality	J:345528
	increased T cell apoptosis	J:345528
Cops5^tm1Rpar/Cops5^tm1Rpar Tg(Lck-cre)548Jxm/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA * SJL)	decreased double-positive T cell number	J:132114
	decreased single-positive T cell number	J:132114
	decreased thymocyte number	J:132114
	increased T cell apoptosis	J:132114
	thymus medulla hypoplasia	J:132114
Cops5^tm1Rpar/Cops5^tm1Rpar Tg(Lck-cre)548Jxm/0 Tg(TcraTcrb)425Cbn/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA * SJL)	decreased thymocyte number	J:132114
Cops5^tm1Rpar/Cops5^tm1Rpar Tg(Lck-cre)548Jxm/0 Trp53^tm1Tyj/Trp53^tm1Tyj (involves: 129 * C57BL/6 * CBA * SJL)	decreased thymocyte number	J:132114
Cops6^{Gt(RRI087)Byg}/Cops6⁺ (involves: 129P2/OlaHsd * C57BL/6J)	increased thymocyte apoptosis	J:172038
Cops7a^{tm1b(KOMP)Mbp}/Cops7a^{tm1b(KOMP)Mbp} (C57BL/6N-Cops7a^{tm1b(KOMP)Mbp}/Ucd)	increased monocyte cell number	J:211773
Cops8^{em1(IMPC)Ccpcz}/Cops8⁺ (C57BL/6NCrl-Cops8^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Cops8^tm1Nwe/Cops8^tm1.1Nwe Tg(Cd4-cre)1Cwi/? (involves: 129S1/Sv * C57BL/6 * DBA/2)	abnormal CD4-positive, alpha-beta T cell physiology	J:126339
	abnormal T cell activation	J:126339
	decreased interleukin-2 secretion	J:126339
	decreased T cell number	J:126339
	decreased T cell proliferation	J:126339
Coq6^em1Shcm/Coq6^em1Shcm (C57BL/6-Coq6^em1Shcm)	increased susceptibility to bacterial infection	J:360514
Coq6^em1Shcm/Coq6^em1Shcm (C57BL/6-Coq6^em1Shcm)	increased susceptibility to bacterial infection induced morbidity/mortality	J:360514
Cora1^BALB/c/Cora1^BALB/c (involves: BALB/c * STS/A)	abnormal cytokine secretion	J:52119
Cora1^STS/A/Cora1^STS/A (involves: BALB/c * STS/A)	abnormal cytokine secretion	J:52119
Coro1a^koy/Coro1a^koy (C57BL/6-Coro1a^koy)	abnormal T cell physiology	J:141431
	decreased CD4-positive, alpha-beta T cell number	J:141431
	decreased CD8-positive, alpha-beta T cell number	J:141431
	decreased thymocyte number	J:141431
Coro1a^{Lmb3-C57BL/6Scr}/Coro1a^{Lmb3-C57BL/6Scr} (MRL.Cg-Coro1a^C57BL/6Scr Fas^lpr)	decreased autoantibody level	J:125557
	decreased spleen weight	J:125557
	decreased susceptibility to systemic lupus erythematosus	J:125557
	glomerulonephritis	J:125557
	small lymph nodes	J:125557
Coro1a^{Lmb3-MRL/MpScr}/Coro1a^{Lmb3-MRL/MpScr} (involves: C57BL/6-Fas^lpr * MRL-Fas^lpr)	enlarged lymph nodes	J:45708
	enlarged spleen	J:45708
Coro1a^{Lmb3-MRL/MpScr}/Coro1a^{Lmb3-MRL/MpScr} (B6.MRL-Coro1a^MRL/MpScr Fas^lpr)	enlarged lymph nodes	J:125557
	increased spleen weight	J:125557
	increased susceptibility to systemic lupus erythematosus	J:125557
Coro1a^ptcd/Coro1a^ptcd (B6.CTS-Coro1a^ptcd)	abnormal effector T cell morphology	J:141431
	abnormal T cell activation	J:141431
	abnormal T cell physiology	J:141431
	decreased CD4-positive, alpha-beta T cell number	J:141431
	decreased CD8-positive, alpha-beta T cell number	J:141431
	increased T cell apoptosis	J:141431
	increased thymocyte number	J:141431
Coro1a^ptcd/Coro1a^tm1Achn (B6.Cg-Coro1a^ptcd Coro1a^tm1Achn)	abnormal effector T cell morphology	J:141431
	abnormal T cell activation	J:141431
	abnormal T cell physiology	J:141431
	decreased CD4-positive, alpha-beta T cell number	J:141431
	decreased CD8-positive, alpha-beta T cell number	J:141431
	increased thymocyte number	J:141431
Coro1a^tm1Achn/Coro1a^tm1Achn (involves: 129X1/SvJ * C57BL/6)	abnormal leukocyte migration	J:111593
	decreased CD4-positive, alpha-beta T cell number	J:111593
	decreased CD8-positive, alpha-beta T cell number	J:111593
	decreased memory T cell number	J:111593
	decreased T cell number	J:111593
Coro1a^tm1Achn/Coro1a^tm1Achn (B6.129X1-Coro1a^tm1Achn)	decreased thymocyte number	J:141431
Coro1a^tm1Achn/Coro1a^tm1Achn (B6.129X1-Coro1a^tm1Achn)	increased T cell apoptosis	J:141431
Coro1a^tm1Achn/Coro1a^tm1Achn (involves: 129X1/SvJ)	decreased interleukin-6 secretion	J:177785
	decreased tumor necrosis factor secretion	J:177785
	increased mast cell degranulation	J:177785
Coro1a^tm1Achn/Coro1a^tm1Achn Coro1b^tm1.1Nfoe/Coro1b^tm1.1Nfoe (involves: 129X1/SvJ * C57BL/6N)	decreased interleukin-6 secretion	J:177785
	decreased tumor necrosis factor secretion	J:177785
	increased mast cell degranulation	J:177785
	increased susceptibility to type I hypersensitivity reaction	J:177785
Coro1a^tm1Jpie/Coro1a^tm1Jpie (involves: 129 * C57BL/6)	abnormal T cell activation	J:133258
	abnormal thymocyte activation	J:133258
	decreased B cell number	J:133258
	decreased CD4-positive, alpha-beta T cell number	J:133258
	decreased CD8-positive, alpha-beta T cell number	J:133258
	decreased interleukin-2 secretion	J:133258
	decreased monocyte cell number	J:133258
	decreased susceptibility to bacterial infection	J:133404
	decreased T cell proliferation	J:133258
	impaired macrophage phagocytosis	J:133404
Coro1b^tm1.1Nfoe/Coro1b^tm1.1Nfoe (B6N.129X1-Coro1b^tm1.1Nfoe)	immune system phenotype	J:177785
Coro1c^{tm1a(KOMP)Wtsi}/Coro1c^{tm1a(KOMP)Wtsi} (C57BL/6N-Coro1c^{tm1a(KOMP)Wtsi}/Wtsi)	blood in lymph vessels	J:239583
Cotl1^{tm1b(EUCOMM)Hmgu}/Cotl1^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Cotl1^{tm1b(EUCOMM)Hmgu}/Ieg)	increased leukocyte cell number	J:211773
Cox4i2^tm1Hutt/Cox4i2⁺ (B6.129-Cox4i2^tm1Hutt)	lung inflammation	J:187640
Cox4i2^tm1Hutt/Cox4i2^tm1Hutt (B6.129-Cox4i2^tm1Hutt)	immune system phenotype	J:233986
Cox4i2^tm1Hutt/Cox4i2^tm1Hutt (B6.129-Cox4i2^tm1Hutt)	lung inflammation	J:187640
Cox6b1^em1(IMPC)Tcp/Cox6b1⁺ (C57BL/6NCrl-Cox6b1^em1(IMPC)Tcp/Tcp)	increased spleen weight	J:211773
Cox10^tm1Ctm/Cox10^tm1Ctm Slc6a3^{tm1.1(cre)Bkmn}/? (B6.Cg-Cox10^tm1Ctm Slc6a3^{tm1.1(cre)Bkmn})	abnormal chemokine secretion	J:231810
	increased interleukin-1 beta secretion	J:231810
	increased microglial cell activation	J:231810
	microgliosis	J:231810
Cox19^{tm1b(EUCOMM)Hmgu}/Cox19⁺ (C57BL/6N-Cox19^{tm1b(EUCOMM)Hmgu}/Tcp)	enlarged lymph nodes	J:211773
Cp^tm1Hrs/Cp^tm1Hrs (involves: 129X1/SvJ * Black Swiss)	increased spleen iron level	J:57730
Cp^tm1Hrs/Cp^tm1Hrs Heph^sla/Y (involves: 129X1/SvJ * C57BL/6)	eye inflammation	J:136925
Cp^tm1Yos/Cp^tm1Yos (involves: 129P2/OlaHsd * BALB/c)	abnormal Kupffer cell morphology	J:79916
Cpa1^tm1.1Satom/Cpa1^tm1.1Satom (involves: C57BL/6NCrl * FVB/N)	pancreas inflammation	J:300042
Cpa3^tm1Hrr/Cpa3^tm1Hrr (involves: 129P2/OlaHsd * C57BL/6)	abnormal mast cell morphology	J:99367
Cpa3^tm3(icre)Hrr/Cpa3⁺ (B6.129P2-Cpa3^tm3(icre)Hrr)	abnormal inflammatory response	J:178942
	absent mast cells	J:178942
	decreased basophil cell number	J:178942
	immune system phenotype	J:178942
Cpa3^tm3(icre)Hrr/Cpa3⁺ (involves: 129P2/OlaHsd * BALB/c * C57BL/6)	decreased susceptibility to type I hypersensitivity reaction	J:178942
Cpa3^tm3(icre)Hrr/Cpa3⁺ Fgfr1^tm1Upir/Fgfr1^tm1Upir Fgfr2^tm1Dor/Fgfr2^tm1Dor Tg(KRT5-cre)5132Jlj/0 (involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * C57BL/6J * DBA/2J)	absent mast cells	J:221184
	skin inflammation	J:221184
Cpa3^tm3(icre)Hrr/Cpa3⁺ Gt(ROSA)26Sor^tm1Hjf/? Notch1^tm1Agt/Notch1^tm1Agt (involves: 129 * C57BL/6)	abnormal dendritic cell differentiation	J:143731
	abnormal T cell receptor beta chain V(D)J recombination	J:143731
Cpa3^tm3(icre)Hrr/Cpa3⁺ Notch1^tm1Agt/Notch1^tm1Agt (involves: 129 * C57BL/6)	abnormal B cell differentiation	J:143731
	abnormal B cell morphology	J:143731
	abnormal T cell receptor beta chain V(D)J recombination	J:143731
	decreased double-negative T cell number	J:143731
	decreased double-positive T cell number	J:143731
	increased single-positive T cell number	J:143731
	thymus hypoplasia	J:143731
Cpap^{tm1a(EUCOMM)Wtsi}/Cpap^{tm1a(EUCOMM)Wtsi} (B6Brd;B6N-Tyr^c-Brd Cpap^{tm1a(EUCOMM)Wtsi}/Wtsi)	increased CD8-positive, alpha-beta T cell number	J:194085
	increased T cell number	J:194085
Cpb2^tm1Efp/Cpb2⁺ Plg^tm1Dco/Plg⁺ (involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6)	abnormal inflammatory response	J:80114
Cpb2^tm1Efp/Cpb2^tm1Efp Plg^tm1Dco/Plg⁺ (involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6)	abnormal inflammatory response	J:80114
Cpb2^tm1Mng/Cpb2^tm1Mng (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal chemokine level	J:107340
	abnormal tumor necrosis factor level	J:107340
Cpb2^tm1Nok/Cpb2^tm1Nok (involves: 129P2/OlaHsd * BALB/c)	impaired complement alternative pathway	J:93733
Cpb2^tm1Nok/Cpb2^tm1Nok (involves: 129P2/OlaHsd * BALB/c)	increased inflammatory response	J:93733
Cpe^{tm1b(EUCOMM)Hmgu}/Cpe^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Cpe^{tm1b(EUCOMM)Hmgu}/Ieg)	increased leukocyte cell number	J:211773
Cpgi5563^{tm1.1(NCC)Wcs}/Cpgi5563^{tm1.1(NCC)Wcs} (C57BL/6N-Cpgi5563^{tm1.1(NCC)Wcs}/Wtsi)	decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:277622
	decreased CD8-positive, alpha-beta T cell number	J:277622
	decreased effector memory CD4-positive, alpha-beta T cell number	J:277622
	decreased gamma-delta T cell number	J:277622
Cplane2^b2b2827Clo/Cplane2^b2b2827Clo (C57BL/6J-Cplane2^b2b2827Clo)	thymus hypoplasia	J:175213
Cpm^{em1(IMPC)Ccpcz}/Cpm^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Cpm^{em1(IMPC)Ccpcz}/Ccpcz)	decreased CD8-positive, alpha-beta T cell number	J:211773
	immune system phenotype	J:211773
	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
	increased effector memory T-helper cell number	J:211773
Cpn1^tm1Raw/Cpn1^tm1Raw (B6.129S1-Cpn1^tm1Raw)	abnormal complement pathway	J:148315
Cpn1^tm1Raw/Cpn1^tm1Raw (B6.129S1-Cpn1^tm1Raw)	increased acute inflammation	J:148315
Cpne5^{tm2b(EUCOMM)Hmgu}/Cpne5^{tm2b(EUCOMM)Hmgu} (C57BL/6N-Cpne5^{tm2b(EUCOMM)Hmgu}/Bay)	abnormal spleen morphology	J:211773
Cpox^Rbc16/Cpox⁺ (involves: C57BL/6)	enlarged spleen	J:244493
Cpox^Rbc16/Cpox⁺ (involves: C57BL/6)	increased spleen red pulp amount	J:244493
Cpq^em1(IMPC)Tcp/Cpq^em1(IMPC)Tcp (C57BL/6N-Cpq^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Cps1^em1(IMPC)H/Cps1⁺ (C57BL/6NTac-Cps1^em1(IMPC)H/H)	decreased neutrophil cell number	J:211773
Cps1^em1(IMPC)H/Cps1⁺ (C57BL/6NTac-Cps1^em1(IMPC)H/H)	increased lymphocyte cell number	J:211773
Cpsf6^em1Bcgen/Cpsf6⁺ (Not Specified)	decreased susceptibility to Riboviria infection	J:346988
Cpsf6^em1Bcgen/Cpsf6⁺ (Not Specified)	increased interferon-beta secretion	J:346988
Cpt1c^Gt(XL823)Byg/Cpt1c⁺ Nf1^tm1Tyj/Nf1⁺ Trp53^tm1Tyj/Trp53⁺ (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)	spleen hyperplasia	J:228258
Cpt2^{tm1b(KOMP)Wtsi}/Cpt2^{tm1b(KOMP)Wtsi} (C57BL/6N-Cpt2^{tm1b(KOMP)Wtsi}/Wtsi)	blood in lymph vessels	J:239583
Cpvl^em1(IMPC)Tcp/Cpvl^em1(IMPC)Tcp (C57BL/6NCrl-Cpvl^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Cpxm1^em1(IMPC)Tcp/Cpxm1^em1(IMPC)Tcp (C57BL/6N-Cpxm1^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
	increased monocyte cell number	J:211773
Cr1l^tm1.1Song/Cr1l^tm1.1Song Tg(Cd4-cre)1Cwi/0 (involves: 129S6/SvEvTac * C57BL/6 * DBA/2 * SJL)	decreased CD4-positive, alpha-beta T cell number	J:146538
	decreased CD8-positive, alpha-beta T cell number	J:146538
	decreased lymphocyte cell number	J:146538
	increased B cell number	J:146538
	lymph node hypoplasia	J:146538
Cr1l^tm1.1Song/Cr1l^tm1.1Song Tg(Lck-cre)548Jxm/0 (involves: 129S6/SvEvTac * C57BL/6 * DBA/2 * SJL)	decreased CD4-positive, alpha-beta T cell number	J:146538
	decreased CD8-positive, alpha-beta T cell number	J:146538
	decreased lymphocyte cell number	J:146538
	increased B cell number	J:146538
	lymph node hypoplasia	J:146538
Cr1l^tm1.1Song/Cr1l^tm1.1Song Vsig4^tm1Gne/Vsig4^tm1Gne Tg(Cd4-cre)1Cwi/0 (involves: 129S6/SvEvTac * C57BL/6N * DBA/2 * SJL)	decreased lymphocyte cell number	J:146538
Cr1l^tm1Hmo/Cr1l^tm1Hmo (involves: 129X1/SvJ)	increased inflammatory response	J:59432
Cr2^M1Btlr/Cr2^M1Btlr (C57BL/6J-Cr2^M1Btlr)	decreased IgG level	J:267527
Cr2^M1Btlr/Cr2^M1Btlr (C57BL/6J-Cr2^M1Btlr)	impaired humoral immune response	J:267527
Cr2^tm1.1Jhws/Cr2^tm1.1Jhws (B6.Cg-Cr2^tm1.1Jhws)	immune system phenotype	J:155241
Cr2^tm1.1Jhws/Cr2^tm1.1Jhws (Not Specified)	abnormal germinal center B cell physiology	J:205353
	decreased B-1a cell number	J:205353
	decreased IgG2b level	J:205353
	decreased IgG2c level	J:205353
	decreased IgG3 level	J:205353
	decreased IgM level	J:205353
	immune system phenotype	J:205353
	increased susceptibility to bacterial infection induced morbidity/mortality	J:205353
Cr2^tm1Crr/Cr2^tm1Crr (involves: 129S7/SvEvBrd * C57BL/6)	abnormal B-1 B cell morphology	J:31942
	abnormal humoral immune response	J:31942, J:69452
	abnormal immune system morphology	J:69452
	abnormal spleen germinal center morphology	J:31942
	decreased B cell number	J:31942
	decreased B-1a cell number	J:69452
	decreased IgG2a level	J:31942
	decreased IgG2b level	J:31942
	decreased IgG3 level	J:31942
	decreased IgG level	J:31942, J:69452
	decreased IgM level	J:69452
	decreased immunoglobulin level	J:69452
	decreased neutrophil cell number	J:66111
	decreased spleen germinal center number	J:31942, J:69452
	decreased spleen germinal center size	J:31942
	decreased tumor necrosis factor secretion	J:66111
	immune system phenotype	J:31942
Cr2^tm1Crr/Cr2^tm1Crr (involves: 129S7/SvEvBrd * C57BL/6J)	increased anti-double stranded DNA antibody level	J:111811
Cr2^tm1Crr/Cr2^tm1Crr (involves: 129S7/SvEvBrd)	decreased follicular B cell number	J:69477
Cr2^tm1Crr/Cr2^tm1Crr (involves: 129S7/SvEvBrd)	increased marginal zone B cell number	J:69477
Cr2^tm1Crr/Cr2^tm1Crr Ggta1^tm1Jbl/Ggta1^tm1Jbl (involves: 129S2/SvPas * 129S7/SvEvBrd)	abnormal humoral immune response	J:113488
Cr2^tm1Hmo/Cr2^tm1Hmo (involves: 129S7/SvEvBrd)	decreased IgG level	J:35112
Cr2^tm1Hmo/Cr2^tm1Hmo (involves: 129S7/SvEvBrd)	decreased IgM level	J:35112
Cr2^tm1Hmo/Cr2^tm1Hmo (B6.129S7-Cr2^tm1Hmo)	increased susceptibility to bacterial infection	J:94855
Cr2^tm1Hmo/Cr2^tm1Hmo (involves: 129S7/SvEvBrd * C57BL/6)	abnormal B cell activation	J:151991
	abnormal B cell physiology	J:151991
	abnormal class switch recombination	J:151991
	abnormal memory B cell differentiation	J:151991
Cr2^tm1Tft/Cr2^tm1Tft (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	abnormal adaptive immunity	J:95979
	decreased IgG1 level	J:95979
	decreased IgG2b level	J:95979
	decreased IgG3 level	J:95979
	decreased IgG level	J:95979
	decreased IgM level	J:95979
	decreased spleen germinal center number	J:95979
	increased susceptibility to bacterial infection	J:95979
Cr2^{tm2.1(HLA-A)Crr}/Cr2^{tm2.1(HLA-A)Crr} (involves: C57BL/6)	abnormal B cell physiology	J:151991
	abnormal class switch recombination	J:151991
	abnormal memory B cell differentiation	J:151991
Cr2^{tm2.1(HLA-A)Crr}/Cr2^{tm2.1(HLA-A)Crr} Tg(IghelMD4)4Ccg/? (involves: C57BL/6)	abnormal B cell activation	J:151991
Cr2^tm2.1Jhws/Cr2^tm2.1Jhws (B6.129-Cr2^tm2.1Jhws)	abnormal germinal center B cell physiology	J:205353
	decreased IgG3 level	J:205353
	decreased IgM level	J:205353
	immune system phenotype	J:205353
	increased IgM level	J:205353
Crabp1^{tm1b(EUCOMM)Wtsi}/Crabp1^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Crabp1^{tm1b(EUCOMM)Wtsi}/Tcp)	increased monocyte cell number	J:211773
Cracr2a^tm1.1Ygwa/Cracr2a^tm1.1Ygwa Tg(Cd4-cre)1Cwi/0 (B6.Cg-Cracr2a^tm1.1Ygwa Tg(Cd4-cre)1Cwi)	abnormal CD4-positive, alpha-beta T cell physiology	J:259523
	decreased interleukin-2 secretion	J:259523
Crat^em1(IMPC)Bay/Crat^em1(IMPC)Bay (C57BL/6N-Crat^em1(IMPC)Bay/Bay)	small lymph nodes	J:211773
Crb1^rd8+em1Boc/Crb1^rd8+em1Boc Jak3^m1J/Jak3^m1J (B6.Cg-Crb1^rd8+em1Boc Jak3^m1J/Boc)	small spleen	J:265859
	small thymus	J:265859
Crb1^rd8/Crb1^rd8 Jak3^m1J/Jak3^m1J (B6.Cg-Crb1^rd8 Jak3^m1J/BocJ)	decreased spleen weight	J:265859
	small spleen	J:265859
	small thymus	J:265859
Crbn^tm1.1Ble/Crbn^tm1.1Ble (involves: C57BL/6)	decreased B cell number	J:267091
	decreased granulocyte number	J:267091
	decreased leukocyte cell number	J:267091
	decreased T cell number	J:267091
Creb3l2^{em1(IMPC)Ccpcz}/Creb3l2⁺ (C57BL/6NCrl-Creb3l2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Creb3l3^tm1.1Sad/Creb3l3^tm1.1Sad (involves: 129 * C57BL/6 * FVB/N)	decreased acute inflammation	J:140018
	decreased circulating serum amyloid protein level	J:140018
Crebbp^{Gt(U-San)112Imeg}/Crebbp⁺ (involves: C57BL/6 * CBA)	abnormal tumor necrosis factor level	J:75361
Crebbp^tm1Dli/Crebbp⁺ (involves: 129S6/SvEvTac * C57BL/6)	abnormal granulocyte morphology	J:191503
	abnormal leukocyte morphology	J:191503
	absent pre-B cells	J:60630
	decreased B cell number	J:60630
	decreased lymphocyte cell number	J:191503
	enlarged spleen	J:191503, J:60630
	increased granulocyte number	J:191503
Crebbp^tm1Jvd/Crebbp^tm1Jvd Ep300^tm2Pkb/Ep300^tm2Pkb Tg(Lck-cre)548Jxm/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA)	abnormal T cell number	J:105505
	decreased double-positive T cell number	J:105505
	increased double-negative T cell number	J:105505
Crebbp^tm1Jvd/Crebbp^tm1Jvd Tg(Lck-cre)548Jxm/0 (involves: 129 * C57BL/6 * CBA)	decreased CD4-positive, alpha-beta T cell number	J:105505
	decreased T cell number	J:105505
	decreased thymocyte number	J:105505
	increased double-positive T cell number	J:105505
	increased T cell derived lymphoma incidence	J:105505
	small thymus	J:105505
Crebbp^tm1Jvd/Crebbp^tm1Jvd Tg(MMTV-cre)4Mam/0 (involves: 129 * C57BL/6 * FVB)	decreased double-positive T cell number	J:88323
	increased CD8-positive, alpha-beta T cell number	J:88323
	increased T cell derived lymphoma incidence	J:88323
Crebbp^tm1Pkb/Crebbp^tm1Pkb (involves: 129P2/OlaHsd * C57BL/6)	decreased thymocyte number	J:98329
Crh^tm1Maj/Crh^tm1Maj (involves: 129S2/SvPas * C57BL/6)	abnormal cell-mediated immunity	J:98419
	abnormal cytokine secretion	J:98419
	abnormal inflammatory response	J:98419
	abnormal professional antigen presenting cell physiology	J:98419
	decreased inflammatory response	J:90690, J:72196
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:98419
	decreased T cell proliferation	J:98419
	increased circulating interleukin-6 level	J:72196
	increased splenocyte number	J:98419
Crhr2^tm1Mpsp/Crhr2^tm1Mpsp (involves: 129X1/SvJ * C57BL/6J)	immune system phenotype	J:61510
cri/cri (involves: DBA/2J)	decreased leukocyte cell number	J:6327
cri/cri (involves: DBA/2J)	decreased neutrophil cell number	J:6327
Crim1^{em1(IMPC)Wtsi}/Crim1^{em1(IMPC)Wtsi} (C57BL/6N-Crim1^{em1(IMPC)Wtsi}/WtsiOrl)	absent connection between subcutaneous lymph vessels and lymph sac	J:239583
	blood in lymph vessels	J:239583
Crim1^{Gt(KST264)Byg}/Crim1^{Gt(KST264)Byg} (involves: 129P2/OlaHsd * C57BL/6 * CD-1)	kidney inflammation	J:172334
Crip3^tm1Mjb/Crip3^tm1Mjb (either: (involves: 129S/Sv) or (involves: 129S/Sv * C57BL/6))	decreased thymocyte number	J:72942
	small thymus	J:72942
	thymus hypoplasia	J:72942
Crispld2^tm1Lex/Crispld2^tm1Lex (B6;129S5-Crispld2^tm1Lex/Mmucd)	abnormal immune system morphology	J:171883
	abnormal immune system physiology	J:171883
Crkl^tm1Imo/Crkl^tm1Imo (involves: 129S4/SvJaeSor * C57BL/6J)	abnormal thymus development	J:67826
Crl1^A/WySnJ/Crl1^A/WySnJ (B10.A-H2^a/SgSnJ)	abnormal B cell physiology	J:5442
Crl1^AKR/J/Crl1^AKR/J (involves: AKR/J * DBA/2J)	abnormal B cell physiology	J:5442
Crl1^DBA/2J/Crl1^DBA/2J (involves: AKR/J * DBA/2J)	abnormal B cell physiology	J:5442
Crlf2^em1(IMPC)Mbp/Crlf2^em1(IMPC)Mbp (C57BL/6N-Crlf2^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Crlf2^tm1Jni/Crlf2^tm1Jni (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:89031
Crlf2^tm1Jni/Crlf2^tm1Jni (involves: 129P2/OlaHsd)	respiratory system inflammation	J:187770
Crlf2^tm1Wjl/Crlf2^tm1Wjl (involves: 129 * C57BL/6)	abnormal lymphopoiesis	J:108209
	decreased B cell number	J:108209
	decreased single-positive T cell number	J:108209
Crlf2^tm1Wjl/Crlf2^tm1Wjl (involves: BALB/c)	abnormal cytokine secretion	J:107431
	abnormal T cell proliferation	J:107431
	decreased immunoglobulin level	J:107431
	decreased splenocyte proliferation	J:107431
	lung inflammation	J:107431
Crlf2^tm1Wjl/Crlf2^tm1Wjl (Not Specified)	colitis	J:175844
Crocc2^{em1(IMPC)Ccpcz}/Crocc2^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Crocc2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Crocc^tm1Tili/Crocc^tm1Tili (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	lung inflammation	J:98885
Crot^em1Akw/Crot^em1Akw Ldlr^tm1Her/Ldlr^tm1Her (B6.Cg-Crot^em1Akw Ldlr^tm1Her)	blood vessel inflammation	J:331161
Crp^tm1Hjf/Crp⁺ (C57BL/6-Crp^tm1Hjf)	decreased circulating C-reactive protein level	J:170409
Crp^tm1Hjf/Crp^tm1Hjf (C57BL/6-Crp^tm1Hjf)	decreased circulating C-reactive protein level	J:170409
Crppa^em1(IMPC)H/Crppa⁺ (C57BL/6NTac-Crppa^em1(IMPC)H/H)	increased neutrophil cell number	J:211773
Crsl/Crsl⁺ (involves: C3HeB/FeJ)	keratoconjunctivitis sicca	J:104123
Crtam^tm1Achn/Crtam^tm1Achn (involves: 129 * C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:145314
	abnormal interleukin secretion	J:145314
	abnormal T cell activation	J:145314
	abnormal T-helper 1 physiology	J:145314
	decreased interferon-gamma secretion	J:145314
	decreased interleukin-17 secretion	J:145314
	increased CD4-positive, alpha-beta T cell number	J:145314
	increased CD8-positive, alpha-beta T cell number	J:145314
	increased susceptibility to bacterial infection	J:145314
	increased T cell proliferation	J:145314
Crtam^tm1Tks/Crtam^tm1Tks (B6.Cg-Crtam^tm1Tks)	abnormal response to infection	J:152770
Crtam^tm1Tks/Crtam^tm1Tks (B6.Cg-Crtam^tm1Tks)	immune system phenotype	J:152770
Crtc1^{tm1a(EUCOMM)Wtsi}/Crtc1⁺ (C57BL/6N-Crtc1^{tm1a(EUCOMM)Wtsi}/Ics)	increased IgG2b level	J:165965
Crx^{em1(IMPC)Ccpcz}/Crx^{em1(IMPC)Ccpcz} (C57BL/6N-Crx^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
	increased NK cell number	J:211773
	small thymus	J:211773
Cry1^em1(IMPC)H/Cry1^em1(IMPC)H (C57BL/6N-Cry1^em1(IMPC)H/H)	increased leukocyte cell number	J:211773
Cry1^tm1Jhjh/Cry1^tm1Jhjh Cry2^tm1Jhjh/Cry2^tm1Jhjh (involves: 129P2/OlaHsd * C57BL/6)	abnormal T cell activation	J:159504
	increased circulating interleukin-1 beta level	J:159504
	increased circulating interleukin-6 level	J:159504
	increased circulating tumor necrosis factor level	J:159504
	increased susceptibility to induced arthritis	J:159504
	increased tumor necrosis factor secretion	J:159504
Cry2^tm1Jhjh/Cry2^tm1Jhjh (involves: 129P2/OlaHsd * C57BL/6)	abnormal osteoclast physiology	J:163112
Csf1^op/Csf1^op (C57BL/6J-Csf1^op)	abnormal osteoclast morphology	J:5634
	abnormal spleen red pulp morphology	J:5634
	decreased macrophage cell number	J:110981
	decreased osteoclast cell number	J:5634
Csf1^op/Csf1^op (B6C3Fe a/a-Csf1^op/J)	abnormal Kupffer cell morphology	J:26978
	abnormal Langerhans cell morphology	J:112594
	abnormal Langerhans cell physiology	J:112594
	abnormal microglial cell morphology	J:49613
	abnormal osteoclast differentiation	J:19549, J:4732
	abnormal osteoclast morphology	J:26978
	abnormal perivascular macrophage morphology	J:49613
	abnormal spleen red pulp morphology	J:26978
	abnormal splenic cell ratio	J:104139
	abnormal splenocyte physiology	J:19549
	absent Langerhans cell	J:112594
	decreased leukocyte cell number	J:104139
	decreased macrophage cell number	J:26978, J:104139
	decreased monocyte cell number	J:104139
	decreased osteoclast cell number	J:73663
	thymus cortex hypoplasia	J:26978
	thymus medulla atrophy	J:26978
Csf1^op/Csf1^op (involves: C3HeB/FeJ * C57BL/6J)	abnormal osteoclast cell number	J:33189
	abnormal osteoclast differentiation	J:38039
	decreased osteoclast cell number	J:33189
Csf1^op/Csf1^op (B6;C3Fe a/a-Csf1^op/J)	abnormal microglial cell morphology	J:170081
	decreased macrophage cell number	J:30863, J:147697
	impaired macrophage chemotaxis	J:147697
Csf1^op/Csf1^op Csf2^tm1Ard/Csf2^tm1Ard (involves: 129P2/OlaHsd * C57BL/6)	decreased leukocyte cell number	J:19089
	increased neutrophil cell number	J:19089
	interstitial pneumonia	J:19089
	lung inflammation	J:19089
Csf1^op/Csf1^op Galc^twi/Galc^twi (involves: C3HeB/Fe * C57BL/6J * CE/J)	impaired macrophage chemotaxis	J:170081
Csf1^op/Csf1^op Mpz^tm1Msch/Mpz⁺ (involves: 129S7/SvEvBrd * C57BL/6)	immune system phenotype	J:67581
Csf1^op/Csf1^op Sh3bp2^tm1Bjro/Sh3bp2^tm1Bjro (involves: 129S4/SvJae * BALB/cJ * C57BL/6J)	abnormal lymph node cell ratio	J:117880
	increased circulating tumor necrosis factor level	J:117880
	liver inflammation	J:117880
Csf1^{tm1.1(CSF1)Flv}/Csf1^{tm1.1(CSF1)Flv} Csf2/Il3^{tm1.1(CSF2,IL3)Flv}/Csf2/Il3^{tm1.1(CSF2,IL3)Flv} Il2rg^tm1.1Flv/Il2rg^tm1.1Flv Rag2^tm1.1Flv/Rag2^tm1.1Flv Tg(SIRPA)1Flv/0 Thpo^{tm1.1(TPO)Flv}/Thpo^{tm1.1(TPO)Flv} (involves: 129S4/SvJae * BALB/cAnNTac)	abnormal response to transplant	J:207289
Csf1^{tm1.1(CSF1)Flv}/Csf1^{tm1.1(CSF1)Flv} Csf2/Il3^{tm1.1(CSF2,IL3)Flv}/Csf2/Il3^{tm1.1(CSF2,IL3)Flv} Il2rg^tm1.1Flv/Il2rg^tm1.1Flv Rag2^tm1.1Flv/Rag2^tm1.1Flv Thpo^{tm1.1(TPO)Flv}/Thpo^{tm1.1(TPO)Flv} (involves: 129S4/SvJae * BALB/cAnNTac)	abnormal response to transplant	J:207289
Csf1^{tm1.1(CSF1)Flv}/Csf1^{tm1.1(CSF1)Flv} Il2rg^tm1.1Flv/Il2rg^tm1.1Flv Csf2/Il3^{tm1.1(CSF2,IL3)Flv}/Csf2/Il3^{tm1.1(CSF2,IL3)Flv} Rag2^tm1.1Flv/Rag2^tm1.1Flv Tg(SIRPA)1Flv/0 Thpo^{tm1.1(TPO)Flv}/Thpo^{tm1.1(TPO)Flv} (involves: 129S4/SvJae * BALB/cAnNTac)	abnormal response to transplant	J:207289
Csf1^{tm1.1(CSF1)Flv}/Csf1^{tm1.1(CSF1)Flv} Il2rg^tm1.1Flv/Il2rg^tm1.1Flv Csf2/Il3^{tm1.1(CSF2,IL3)Flv}/Csf2/Il3^{tm1.1(CSF2,IL3)Flv} Rag2^tm1.1Flv/Rag2^tm1.1Flv Thpo^{tm1.1(TPO)Flv}/Thpo^{tm1.1(TPO)Flv} (involves: 129S4/SvJae * BALB/cAnNTac)	abnormal response to transplant	J:207289
Csf1^{tm1.1(CSF1)Flv}/Csf1^{tm1.1(CSF1)Flv} Il2rg^tm1.1Flv/Il2rg^tm1.1Flv Rag2^tm1.1Flv/Rag2^tm1.1Flv (involves: 129P2/OlaHsd * 129S/SvEv * 129S4/SvJae * BALB/cAnNTac)	abnormal immune system physiology	J:177073
	immune system phenotype	J:177073
Csf1^tm1.2Sabw/Csf1^tm1.2Sabw (involves: 129S4/SvJaeSor * C57BL/6)	abnormal Kupffer cell morphology	J:180199
	abnormal myeloid leukocyte morphology	J:180199
	decreased B cell number	J:180199
	decreased lymphocyte cell number	J:180199
	decreased macrophage cell number	J:180199
	decreased monocyte cell number	J:180199
	decreased osteoclast cell number	J:180199
	decreased spleen weight	J:180199
	increased granulocyte number	J:180199
	increased T cell number	J:180199
	small spleen	J:180199
Csf1r^tm1Ers/Csf1r⁺ (B6.129X1-Csf1r^tm1Ers)	microgliosis	J:219294
Csf1r^tm1Ers/Csf1r^tm1Ers (involves: 129X1/SvJ * C3Heb/FeJ * C57BL/6J)	abnormal circulating cytokine level	J:73663
	abnormal leukocyte cell number	J:73663
	abnormal osteoclast differentiation	J:73663
	abnormal spleen morphology	J:73663
	decreased Langerhans cell number	J:73663
	decreased lymphocyte cell number	J:73663
	decreased macrophage cell number	J:73663
	decreased monocyte cell number	J:73663
	increased granulocyte number	J:73663
	increased spleen weight	J:73663
Csf1r^tm1Ers/Csf1r^tm1Ers (FVB.129X1-Csf1r^tm1Ers)	abnormal Langerhans cell physiology	J:112594
	abnormal macrophage differentiation	J:112594
	abnormal osteoclast morphology	J:111489
	absent Langerhans cell	J:112594
Csf2/Il3^{tm1.1(CSF2,IL3)Flv}/Csf2/Il3^{tm1.1(CSF2,IL3)Flv} Il2rg^tm1.1Flv/Il2rg^tm1.1Flv Rag2^tm1.1Flv/Rag2^tm1.1Flv (involves: 129S4/SvJae * BALB/cAnNCr * BALB/cAnNTac)	abnormal response to transplant	J:168302
Csf2^tm1Ard/Csf2^tm1Ard (involves: 129P2/OlaHsd * C57BL/6)	abnormal alveolar macrophage morphology	J:18747
	abnormal leukocyte physiology	J:86386
	abnormal MHC II cell surface expression on macrophages	J:86386
	abnormal spleen size	J:67766
	impaired macrophage chemotaxis	J:86386
	increased susceptibility to bacterial infection	J:18747, J:53659
	increased susceptibility to fungal infection	J:18747
	increased susceptibility to parasitic infection	J:67766
	lung inflammation	J:18747
	lymphoid hyperplasia	J:18747
Csf2^tm1Dran/Csf2^tm1Dran Ifng^tm1Ts/Ifng^tm1Ts Il3^tm1Glli/Il3^tm1Glli (involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6)	increased eosinophil cell number	J:83086
	increased IgE level	J:83086
	increased IgG1 level	J:83086
	increased immunoglobulin level	J:83086
	increased inflammatory response	J:83086
Csf2^tm1Dran/Csf2^tm1Dran Il3^tm1Glli/Il3^tm1Glli (B6.129S2-Csf2^tm1Dran Il3^tm1Glli)	abnormal leukocyte physiology	J:83086
	decreased susceptibility to type IV hypersensitivity reaction	J:67404
	glomerulonephritis	J:83086
	increased anti-double stranded DNA antibody level	J:83086
	increased eosinophil cell number	J:67404
	lung inflammation	J:67404
Csf2^tm1Dran/Csf2^tm1Dran Il3^tm1Glli/Il3^tm1Glli (C.129S2-Csf2^tm1Dran Il3^tm1Glli)	decreased susceptibility to type IV hypersensitivity reaction	J:67404
	increased eosinophil cell number	J:67404
	lung inflammation	J:67404
Csf2^tm1Mlg/Csf2^tm1Mlg (involves: 129S2/SvPas)	abnormal alveolar macrophage morphology	J:17978
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:148120
	lymphoid hyperplasia	J:17978
Csf2ra^em1Szut/Csf2ra^em1Szut (C57BL/6-Csf2ra^em1Szut)	abnormal alveolar macrophage morphology	J:322934
	impaired macrophage phagocytosis	J:322934
	increased lymphocyte cell number	J:322934
	lung inflammation	J:322934
Csf2rb^tm1Cgb/Csf2rb^tm1Cgb (involves: 129S1/Sv * C57BL/6)	decreased eosinophil cell number	J:29737
Csf2rb^tm1Cgb/Csf2rb^tm1Cgb (involves: 129S1/Sv * C57BL/6)	lung inflammation	J:29737
Csf2rb^tm1Clsc/Csf2rb^tm1Clsc Csf2rb2^tm1Cgb/Csf2rb2^tm1Cgb (C.129S1-Csf2rb2^tm1Cgb Csf2rb^tm1Clsc)	abnormal dendritic cell physiology	J:130939
	abnormal interleukin secretion	J:130939
	abnormal plasmacytoid dendritic cell physiology	J:130939
	abnormal T cell activation	J:130939
	abnormal T cell physiology	J:130939
	decreased interleukin-4 secretion	J:130939
	decreased interleukin-5 secretion	J:130939
	decreased interleukin-13 secretion	J:130939
	decreased susceptibility to type I hypersensitivity reaction	J:130939
	decreased T cell proliferation	J:130939
	impaired eosinophil recruitment	J:130939
	increased IgG1 level	J:130939
	lymph node hyperplasia	J:130939
Csf2rb^tm1Mur/Csf2rb^tm1Mur (involves: 129P2/OlaHsd * C57BL/6)	abnormal eosinophil physiology	J:35829
	decreased eosinophil cell number	J:35829
	lung inflammation	J:35829
Csf2rb^tm1Mur/Csf2rb^tm1Mur (involves: 129P2/OlaHsd)	abnormal eosinophil physiology	J:24122
	decreased eosinophil cell number	J:24122
	increased susceptibility to infection	J:24122
	lung inflammation	J:24122
Csf2rb^tm1Mur/Csf2rb^tm1Mur Il3^tm1Tyb/Il3^tm1Tyb (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)	abnormal eosinophil physiology	J:35829
	decreased eosinophil cell number	J:35829
	lung inflammation	J:35829
Csf2rb^{tm2b(EUCOMM)Hmgu}/Csf2rb⁺ (C57BL/6N-Csf2rb^{tm2b(EUCOMM)Hmgu}/Orl)	increased eosinophil cell number	J:211773
Csf3^em1(IMPC)H/Csf3^em1(IMPC)H (C57BL/6NTac-Csf3^em1(IMPC)H/H)	decreased eosinophil cell number	J:211773
	decreased neutrophil cell number	J:211773
	increased lymphocyte cell number	J:211773
Csf3^tm1Ard/Csf3⁺ (involves: 129P2/OlaHsd * C57BL/6)	decreased neutrophil cell number	J:20400
Csf3^tm1Ard/Csf3^tm1Ard (involves: 129P2/OlaHsd * C57BL/6)	abnormal neutrophil physiology	J:20400
	decreased leukocyte cell number	J:20400
	decreased monocyte cell number	J:20400
	decreased neutrophil cell number	J:20400
	impaired myelopoiesis	J:20400
	increased susceptibility to bacterial infection	J:20400
Csf3^tm1Ard/Csf3^tm1Ard Junb^tm3Wag/Junb^tm3Wag Tg(KRT5-cre)1Tak/0 (involves: 129/Sv * 129P2/OlaHsd * C3H * C57BL/6)	increased susceptibility to systemic lupus erythematosus	J:155575
Csf3r^tm1Eur/Csf3r^tm1Eur (involves: 129P2/OlaHsd * C57BL/6 * FVB)	abnormal neutrophil differentiation	J:48503
	decreased neutrophil cell number	J:48503
Csf3r^tm1Link/Csf3r^tm1Link (involves: 129X1/SvJ * NIH Black Swiss)	abnormal monocyte morphology	J:37618
	decreased monocyte cell number	J:37618
	decreased neutrophil cell number	J:37618
Csf3r^tm1Link/Csf3r^tm1Link (involves: 129X1/SvJ)	impaired neutrophil chemotaxis	J:79825
Csf3r^tm1Link/Csf3r^tm1Link (B6.129X1-Csf3r^tm1Link)	impaired neutrophil chemotaxis	J:79567
Csf3r^tm2Eur/Csf3r^tm2Eur (involves: 129P2/OlaHsd * FVB)	decreased neutrophil cell number	J:185115
Csf3r^tm2Link/Csf3r⁺ Elane^tm1Link/Elane⁺ (involves: 129X1/SvJ * C57BL/6)	immune system phenotype	J:131496
Csf3r^tm2Link/Csf3r^tm2Link (B6.129X1-Csf3r^tm2Link)	abnormal neutrophil physiology	J:79567
Csf3r^tm3Link/Csf3r^tm3Link (B6.129X1-Csf3r^tm3Link)	immune system phenotype	J:79567
Csf3r^tm3Link/Csf3r^tm3Link (involves: 129X1/SvJ * C57BL/6)	decreased neutrophil cell number	J:67612
Csf3r^{tm4(Epor)Link}/Csf3r^{tm4(Epor)Link} (involves: 129X1/SvJ * C57BL/6)	decreased granulocyte number	J:79825
	decreased neutrophil cell number	J:79825
	impaired neutrophil chemotaxis	J:79825
Csf3r^{tm4(Epor)Link}/Csf3r^{tm4(Epor)Link} (B6.129X1-Csf3r^{tm4(Epor)Link})	decreased neutrophil cell number	J:79567
	impaired neutrophil chemotaxis	J:79567
Csgalnact1^tm1.1Migar/Csgalnact1^tm1.1Migar (involves: C57BL/6N * C57BL/6NCrlj * CBA/JNCrlj)	periodontium inflammation	J:269621
Csk^tm1Sor/Csk⁺ Ptprc^ltng/Ptprc^ltng (involves: 129S7/SvEvBrd * C57BL/6)	thymus hypoplasia	J:158876
Csk^tm1Sor/Csk⁺ Ptprc^ltng/Ptprc^tm1Mak (involves: 129S7/SvEvBrd * C57BL/6)	abnormal T cell differentiation	J:158876
	thymus hypoplasia	J:158876
Csk^tm1Tara/Csk^tm1Tara Tg(Mx1-cre)1Cgn/0 (involves: 129P2/OlaHsd * C57BL/6 * CB20 * CBA)	abnormal CD4-positive T cell differentiation	J:49654
	absent CD8-positive, alpha-beta T cells	J:49654
	enlarged thymus	J:49654
Csk^tm1Tara/Csk^tm2Tara Elane^tm1(cre)Roes/Elane⁺ (involves: 129P2/OlaHsd * CB20 * C57BL/6)	abnormal granulocyte physiology	J:89716
	abnormal myelopoiesis	J:89716
	increased acute inflammation	J:89716
	increased susceptibility to bacterial infection	J:89716
Csmd3^em1(IMPC)Mbp/Csmd3^em1(IMPC)Mbp (C57BL/6NCrl-Csmd3^em1(IMPC)Mbp/Mmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
Csnk1a1^{tm1c(KOMP)Wtsi}/Csnk1a1^{tm1c(KOMP)Wtsi} Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * C57BL/6N * CBA)	abnormal spleen red pulp morphology	J:216977
	bone marrow failure	J:216977
Csnk1g1^em1(IMPC)J/Csnk1g1^em1(IMPC)J (C57BL/6NJ-Csnk1g1^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
Csnk2a2^em1(IMPC)Mbp/Csnk2a2^em1(IMPC)Mbp (C57BL/6N-Csnk2a2^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Cspg4^tm1Wbst/Cspg4^tm1Wbst (involves: 129S1/Sv * 129X1/SvJ)	abnormal macrophage physiology	J:184220
Cspt^C57BL/6/Cspt^C57BL/6 (involves: C57BL/6 * NOD/ShLtDoi * SJL)	increased CD8-positive, alpha-beta T cell number	J:97046
Cspt^C57BL/6/Cspt^NOD/ShiLtDoi (involves: C57BL/6 * NOD/ShLtDoi * SJL)	increased CD8-positive, alpha-beta T cell number	J:97046
Csrnp1^tm1Jni/Csrnp1^tm1Jni (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:129366
Csrnp1^tm1Jni/Csrnp1^tm1Jni Csrnp2^tm1Jni/Csrnp2^tm1Jni (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:129366
Csrnp2^tm1Jni/Csrnp2^tm1Jni (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:129366
Csrnp3^tm1Jni/Csrnp3^tm1Jni (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:129366
Cst6^{em1(IMPC)Ccpcz}/Cst6⁺ (C57BL/6NCrl-Cst6^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	small spleen	J:211773
Cst7^tm1.2Arte/Cst7^tm1.2Arte (involves: C57BL/6)	abnormal eosinophil morphology	J:258944
	abnormal eosinophil physiology	J:258944
	abnormal hypersensitivity reaction	J:258944
	decreased eosinophil cell number	J:258944
	increased susceptibility to parasitic infection	J:258944
Cstb^{tm1b(EUCOMM)Wtsi}/Cstb^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Cstb^{tm1b(EUCOMM)Wtsi}/Orl)	decreased lymphocyte cell number	J:211773
	increased monocyte cell number	J:211773
Cstb^tm1Rm/Cstb^tm1Rm (either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6))	increased incidence of corneal inflammation	J:50587
	uveitis	J:50587
Ct55^em1Xdzg/Ct55^em1Xdzg (involves: C57BL/6)	decreased susceptibility to induced colitis	J:280149
Ctbs^tm1Tbec/Ctbs^tm1Tbec (involves: 129S2/SvPas * C57BL/6N)	abnormal Kupffer cell morphology	J:185162
Ctc1^tm1.1Schg/Ctc1^tm1.1Schg (involves: 129S7/SvEvBrd * C57BL/6)	decreased splenocyte proliferation	J:184809
	small spleen	J:184809
	small thymus	J:184809
Ctcf^tm2Gal/Ctcf⁺ Tg(Lck-cre)1Cwi/0 (involves: 129P2/OlaHsd * C57BL/6)	decreased CD4-positive, alpha-beta T cell number	J:143271
	decreased CD8-positive, alpha-beta T cell number	J:143271
	thymus hypoplasia	J:143271
Ctcf^tm2Gal/Ctcf^tm2Gal Rag2^tm1Fwa/Rag2^tm1Fwa Tg(Lck-cre)1Cwi/0 (involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6 * C57BL/10)	decreased double-positive T cell number	J:143271
Ctcf^tm2Gal/Ctcf^tm2Gal Tg(Lck-cre)1Cwi/0 (involves: 129P2/OlaHsd * C57BL/6)	abnormal T cell differentiation	J:143271
	abnormal T cell morphology	J:143271
	decreased CD4-positive, alpha-beta T cell number	J:143271
	decreased CD8-positive, alpha-beta T cell number	J:143271
	decreased double-positive T cell number	J:143271
	decreased single-positive T cell number	J:143271
	increased double-negative T cell number	J:143271
	increased single-positive T cell number	J:143271
	thymus hypoplasia	J:143271
Ctcf^tm2Gal/Ctcf^tm2Gal Tg(Lck-cre)1Cwi/0 Tg(TcraH-Y,TcrbH-Y)71Vbo/0 (involves: 129P2/OlaHsd * C57BL/6 * C57BL/10 * DBA/2J)	abnormal T cell differentiation	J:143271
	decreased CD4-positive, alpha-beta T cell number	J:143271
	decreased CD8-positive, alpha-beta T cell number	J:143271
	decreased double-positive T cell number	J:143271
Ctcf^tm2Gal/Ctcf^tm2Gal Tg(Lck-cre)1Cwi/0 Tg(TcraTcrb)425Cbn/0 (involves: 129P2/OlaHsd * C57BL/6)	abnormal T cell differentiation	J:143271
	decreased CD4-positive, alpha-beta T cell number	J:143271
	decreased double-positive T cell number	J:143271
	decreased T cell number	J:143271
	increased double-negative T cell number	J:143271
	increased single-positive T cell number	J:143271
Ctdspl2^{tm2b(KOMP)Wtsi}/Ctdspl2⁺ (C57BL/6N-Ctdspl2^{tm2b(KOMP)Wtsi}/Bay)	increased spleen weight	J:211773
ctl/ctl (A/WySnJ-ctl/GrsrJ)	autoimmune arthritis	J:91389
Ctl1^NZB/BlN/Ctl1^C57BL/10 (involves: C57BL/10 * NZB/BlN)	abnormal T cell physiology	J:6736
Ctla4^m1Btlr/Ctla4^m1Btlr (C57BL/6J-Ctla4^m1Btlr)	decreased CD8-positive, naive alpha-beta T cell number	J:265263
	increased effector memory CD4-positive, alpha-beta T cell number	J:265263
	increased effector memory CD8-positive, alpha-beta T cell number	J:265263
Ctla4^tm1All/Ctla4^tm1All (involves: 129S1/Sv * 129X1/SvJ)	abnormal thymus morphology	J:42481
	decreased double-positive T cell number	J:42481
	decreased T cell number	J:42481
	increased double-negative T cell number	J:42481
	lymph node hypoplasia	J:42481
Ctla4^tm1All/Ctla4^tm1All (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * NOD)	increased acute inflammation	J:109887
Ctla4^tm1All/Ctla4^tm1All Rag1^tm1Mom/Rag1^tm1Mom Tg(TcrAND)53Hed/0 (involves: 129S/Sv * 129X1/SvJ * C57BL/6 * SJL)	abnormal T cell activation	J:119845
	increased interleukin-4 secretion	J:119845
	increased T cell proliferation	J:119845
Ctla4^tm1All/Ctla4^tm1All Rag1^tm1Mom/Rag1^tm1Mom Tg(TcraTcrb)8Rest/0 (involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ * C57BL/6)	immune system phenotype	J:140448
Ctla4^tm1All/Ctla4^tm1All Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * NOD * SJL)	abnormal splenocyte physiology	J:109887
	enlarged spleen	J:109887
	increased acute inflammation	J:109887
	insulitis	J:109887
Ctla4^tm1All/Ctla4^tm1All Tg(TcrAND)53Hed/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)	abnormal lymphopoiesis	J:119845
	abnormal T cell activation	J:119845
	abnormal T cell subpopulation ratio	J:119845
	increased CD4-positive, alpha-beta T cell number	J:119845
	increased CD8-positive, alpha-beta T cell number	J:119845
Ctla4^tm1All/Ctla4^tm1All Tg(TcraTcrb)8Rest/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	decreased CD8-positive, alpha-beta T cell number	J:140448
	increased CD4-positive, alpha-beta T cell number	J:140448
	increased interferon-gamma secretion	J:140448
Ctla4^tm1Mak/Ctla4^tm1Mak (involves: 129P2/OlaHsd * BALB/c)	increased interferon-gamma secretion	J:140085
	increased interleukin-2 secretion	J:140085
	increased interleukin-4 secretion	J:140085
	increased interleukin-17 secretion	J:140085
Ctla4^tm1Saka/Ctla4^tm1Saka Foxp3^tm1(cre)Saka/Y (involves: BALB/c)	abnormal immunoglobulin level	J:140085
	abnormal regulatory T cell physiology	J:140085
	abnormal splenic cell ratio	J:140085
	increased autoantibody level	J:140085
	increased IgE level	J:140085
	increased IgG level	J:140085
	increased inflammatory response	J:140085
	increased interferon-gamma secretion	J:140085
	increased interleukin-2 secretion	J:140085
	increased interleukin-4 secretion	J:140085
	increased regulatory T cell number	J:140085
	lung inflammation	J:140085
	lymph node hyperplasia	J:140085
	myocarditis	J:140085
	salivary gland inflammation	J:140085
	spleen hyperplasia	J:140085
	stomach inflammation	J:140085
Ctla4^tm1Shr/Ctla4^tm1Shr (either: (involves: 129S4/SvJae * BALB/c) or (involves: 129S4/SvJae * C57BL/6))	abnormal cytokine secretion	J:30393
	abnormal lymph node cell ratio	J:30393
	abnormal splenic cell ratio	J:30393
	abnormal T cell differentiation	J:30393
	abnormal T cell morphology	J:30393
	decreased double-positive T cell number	J:30393
	enlarged lymph nodes	J:30393
	enlarged spleen	J:30393
	increased double-negative T cell number	J:30393
	increased T cell number	J:30393
	increased T cell proliferation	J:30393
	joint inflammation	J:30393
	lung inflammation	J:30393
	myocarditis	J:30393
	pancreas inflammation	J:30393
	salivary gland inflammation	J:30393
Ctla4^tm1Shr/Ctla4^tm1Shr (B6.129S4-Ctla4^tm1Shr)	abnormal regulatory T cell physiology	J:146644
	abnormal T cell physiology	J:146644
	autoimmune response	J:146644
Ctla4^tm1Shr/Ctla4^tm1Shr Rag2^tm1Fwa/Rag2^tm1Fwa Tg(DO11.10)10Dlo/0 (involves: 129S/Sv * BALB/c * C3H * C57BL/6)	abnormal cytokine secretion	J:110446
	abnormal T cell physiology	J:110446
	immune system phenotype	J:110446
Ctla4^tm1Shr/Ctla4^tm1Shr Tg(DO11.10)10Dlo/0 (involves: 129S4/SvJae * BALB/c * C3H * C57BL/6)	abnormal T cell physiology	J:57090
	enlarged lymph nodes	J:57090
	enlarged spleen	J:57090
	increased T cell proliferation	J:57090
Ctnnb1^{tm1(Nfkbia)Rsu}/Ctnnb1⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal cervical lymph node morphology	J:71744
	abnormal macrophage physiology	J:71744
	abnormal peripheral lymph node morphology	J:71744
	absent peripheral lymph nodes	J:71744
	absent Peyer's patches	J:71744
	absent popliteal lymph nodes	J:71744
	conjunctivitis	J:71744
	decreased Peyer's patch number	J:71744
	increased granulocyte number	J:71744
	increased inflammatory response	J:71744
	increased leukocyte cell number	J:71744
	increased susceptibility to otitis media	J:71744
	increased susceptibility to parasitic infection	J:71744
	keratoconjunctivitis sicca	J:71744
	small axillary lymph nodes	J:71744
	small brachial lymph nodes	J:71744
	small Peyer's patches	J:71744
Ctnnb1^tm1Mmt/Ctnnb1⁺ Ctsk^tm1(cre)Ska/Ctsk⁺ (involves: 129X1/SvJ * C57BL/6NCrlj * CBA/JNCrlj)	abnormal osteoclast differentiation	J:178340
Ctnnb1^tm1Mmt/Ctnnb1⁺ Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * 129X1/SvJ)	abnormal osteoclast differentiation	J:178340
Ctnnb1^tm1Mmt/Ctnnb1⁺ Pparg^{tm1.1(tTA)Jmgr}/Pparg⁺ Tg(tetO-cre)1Jaw/0 (involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6)	abnormal osteoclast differentiation	J:178340
	decreased osteoclast cell number	J:178340
	increased splenocyte number	J:178340
Ctnnb1^tm1Mmt/Ctnnb1⁺ Tg(Col1a1-cre)1Kry/0 (involves: 129X1/SvJ * FVB)	decreased osteoclast cell number	J:98430
Ctnnb1^tm1Mmt/Ctnnb1⁺ Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0 (involves: 129X1/SvJ * CD-1)	abnormal osteoclast differentiation	J:114494
Ctnnb1^{tm2(Nfkbia)Rsu}/Ctnnb1⁺ Tg(CMV-cre)1Cgn/0 (involves: 129P2/OlaHsd * BALB/cJ * C57BL/6)	abnormal lymph node morphology	J:71744
	abnormal macrophage physiology	J:71744
	abnormal Peyer's patch morphology	J:71744
	increased granulocyte number	J:71744
	increased inflammatory response	J:71744
	increased leukocyte cell number	J:71744
	increased susceptibility to otitis media	J:71744
	keratoconjunctivitis sicca	J:71744
Ctnnb1^tm2Kem/Ctnnb1⁺ Ctsk^tm1(cre)Ska/Ctsk⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6NCrlj * CBA/JNCrlj)	increased osteoclast cell number	J:178340
Ctnnb1^tm2Kem/Ctnnb1⁺ Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ)	increased osteoclast cell number	J:178340
Ctnnb1^tm2Kem/Ctnnb1⁺ Pparg^{tm1.1(tTA)Jmgr}/Pparg⁺ Tg(tetO-cre)1Jaw/0 (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal osteoclast physiology	J:178340
	increased osteoclast cell number	J:178340
Ctnnb1^tm2Kem/Ctnnb1⁺ Tg(Tek-cre)1Ywa/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)	increased osteoclast cell number	J:178340
Ctnnb1^tm2Kem/Ctnnb1^tm2Kem Ctsk^tm1(cre)Ska/Ctsk⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6NCrlj * CBA/JNCrlj)	increased osteoclast cell number	J:178340
Ctnnb1^tm2Kem/Ctnnb1^tm2Kem Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ)	increased osteoclast cell number	J:178340
Ctnnb1^tm2Kem/Ctnnb1^tm2Kem Pparg^{tm1.1(tTA)Jmgr}/Pparg⁺ Tg(tetO-cre)1Jaw/0 (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal osteoclast physiology	J:178340
	decreased osteoclast cell number	J:178340
Ctnnb1^tm2Kem/Ctnnb1^tm2Kem Pparg^{tm1.1(tTA)Jmgr}/Pparg⁺ Tg(tetO-cre)1Jaw/0 Tg(tetO-HIST1H2BJ/GFP)47Efu/0 (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1)	abnormal osteoclast differentiation	J:178340
Ctnnb1^tm2Kem/Ctnnb1^tm2Kem Tg(Col1a1-cre)1Kry/0 (involves: 129S1/Sv * 129X1/SvJ * FVB)	increased osteoclast cell number	J:98430
Ctnnb1^tm2Kem/Ctnnb1^tm2Kem Tg(KRT14-cre/ERT)20Efu/0 (involves: 129S1/Sv * 129X1/SvJ * CD-1)	cutaneous mastocytosis	J:204142
Ctnnb1^tm2Kem/Ctnnb1^tm2Kem Tg(Tek-cre)1Ywa/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)	decreased osteoclast cell number	J:178340
Ctnnb1^tm4Wbm/Ctnnb1^tm4Wbm Krt14^tm1(cre)Wbm/Krt14⁺ (involves: 129P2/OlaHsd)	decreased gamma-delta T cell number	J:202499
	increased neutrophil cell number	J:202499
Ctnnb1^tm4Wbm/Ctnnb1^tm4Wbm Tg(Pdx1-cre)6Tuv/0 (involves: 129P2/OlaHsd * FVB/N)	pancreas inflammation	J:119908
Ctps1^em1(IMPC)Tcp/Ctps1⁺ (C57BL/6N-Ctps1^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Ctps1^{tm1c(KOMP)Wtsi}/Ctps1^{tm1c(KOMP)Wtsi} Commd10^{Tg(Vav1-icre)A2Kio}/0 (B6.Cg-Ctps1^{tm1c(KOMP)Wtsi} Commd10^{Tg(Vav1-icre)A2Kio})	abnormal spleen morphology	J:348981
	decreased B cell number	J:348981
	decreased double-positive T cell number	J:348981
	decreased NK cell number	J:348981
	decreased T cell number	J:348981
	decreased T cell proliferation	J:348981
	increased CD4-positive, alpha-beta T cell number	J:348981
	increased CD8-positive, alpha-beta T cell number	J:348981
	small thymus	J:348981
	thymus hypoplasia	J:348981
Ctps1^{tm1c(KOMP)Wtsi}/Ctps1^{tm1c(KOMP)Wtsi} Ctps2^{tm1c(EUCOMM)Hmgu}/Ctps2⁺ Tg(Cd4-cre)1Cwi/0 (involves: 129S/Sv * C57BL/6 * DBA/2)	decreased T cell proliferation	J:348981
Ctps1^{tm1c(KOMP)Wtsi}/Ctps1^{tm1c(KOMP)Wtsi} Ctps2^{tm1c(EUCOMM)Hmgu}/Ctps2^{tm1c(EUCOMM)Hmgu} Tg(Cd4-cre)1Cwi/0 (involves: 129S/Sv * C57BL/6 * DBA/2)	decreased T cell number	J:348981
	decreased T cell proliferation	J:348981
Ctps1^{tm1c(KOMP)Wtsi}/Ctps1^{tm1c(KOMP)Wtsi} Gt(ROSA)26Sor^{tm1(cre/ERT2)Tyj}/Gt(ROSA)26Sor⁺ (B6.Cg-Ctps1^{tm1c(KOMP)Wtsi} Gt(ROSA)26Sor^{tm1(cre/ERT2)Tyj})	abnormal spleen morphology	J:348981
	abnormal thymus physiology	J:348981
	decreased germinal center B cell number	J:348981
	decreased IgM level	J:348981
	decreased lymphocyte cell number	J:348981
	decreased T cell proliferation	J:348981
	decreased T follicular helper cell number	J:348981
	impaired humoral immune response	J:348981
	increased CD8-positive, alpha-beta T cell number	J:348981
	small thymus	J:348981
	thymus hypoplasia	J:348981
Ctps1^{tm1c(KOMP)Wtsi}/Ctps1^{tm1c(KOMP)Wtsi} Tg(Cd4-cre)1Cwi/0 (involves: 129S/Sv * C57BL/6 * DBA/2)	decreased effector memory T-helper cell number	J:348981
	decreased T cell proliferation	J:348981
	increased CD8-positive, naive alpha-beta T cell number	J:348981
Ctps1^{tm1c(KOMP)Wtsi}/Ctps1^{tm1c(KOMP)Wtsi} Tg(Cd4-cre)1Cwi/0 Foxp3^sf/Y Rag1^tm1Mom/Rag1⁺ (mixed)	decreased inflammatory response	J:348981
	decreased regulatory T cell number	J:348981
	decreased T cell proliferation	J:348981
	enlarged spleen	J:348981
	thymus hypoplasia	J:348981
Ctps1^{tm1c(KOMP)Wtsi}/Ctps1^{tm1c(KOMP)Wtsi} Tg(Cd8a-cre)1Itan/0 (B6(129S4)-Ctps1^{tm1c(KOMP)Wtsi} Tg(Cd8a-cre)1Itan)	decreased T cell proliferation	J:348981
Ctrb1^em1Toth/Ctrb1^em1Toth (C57BL/6N-Ctrb1^em1Toth)	increased susceptibility to induced pancreatitis	J:294171, J:294035
Ctrc^m1/Ctrc^m1 (C57BL/6-Ctrc^m1)	increased susceptibility to induced pancreatitis	J:291240
Ctrq1^C3H/HeJ/Ctrq1^C3H/HeJ (involves: C3H/HeJ * C57BL/6J)	increased susceptibility to bacterial infection	J:106111
Ctrq2^C3H/HeJ/Ctrq2^C3H/HeJ (involves: C3H/HeJ * C57BL/6J)	decreased susceptibility to bacterial infection	J:106111
Ctrq2^C3H/HeJ/Ctrq2^C57BL/6J (involves: C3H/HeJ * C57BL/6J)	decreased susceptibility to bacterial infection	J:106111
Ctrq3^C3H/HeJ/Ctrq3^C3H/HeJ (involves: C3H/HeJ * C57BL/6J)	increased susceptibility to bacterial infection	J:106111
Ctrq3^C3H/HeJ/Ctrq3^C57BL/6J (involves: C3H/HeJ * C57BL/6J)	increased susceptibility to bacterial infection	J:106111
Ctsa^tm1Adz/Ctsa^tm1Adz (either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129P2/OlaHsd * FVB/NJ))	enlarged spleen	J:29674
Ctsa^{tm2b(EUCOMM)Hmgu}/Ctsa^{tm2b(EUCOMM)Hmgu} (C57BL/6N-Ctsa^{tm2b(EUCOMM)Hmgu}/H)	enlarged spleen	J:211773
	increased monocyte cell number	J:211773
	increased spleen weight	J:211773
Ctsb^tm1Jde/Ctsb⁺ (NOD.129P2-Ctsb^tm1Jde)	decreased susceptibility to autoimmune diabetes	J:153355
Ctsb^tm1Jde/Ctsb⁺ (NOD.129P2-Ctsb^tm1Jde)	insulitis	J:153355
Ctsb^tm1Jde/Ctsb^tm1Jde (either: (involves: 129P2/OlaHsd * 129/Sv) or (involves: 129P2/OlaHsd * C57BL/6))	immune system phenotype	J:47432
Ctsb^tm1Jde/Ctsb^tm1Jde (NOD.129P2-Ctsb^tm1Jde)	decreased susceptibility to autoimmune diabetes	J:153355
	insulitis	J:153355
	salivary gland inflammation	J:153355
Ctsb^tm1Jde/Ctsb^tm1Jde Serpina3g^tm1.1Arp/Serpina3g^tm1.1Arp (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:189782
Ctsc^tm1Ley/Ctsc^tm1Ley (either: 129X1/SvJ-Ctsc^tm1Ley or (involves: 129X1/SvJ * C57BL/6))	abnormal cytotoxic T cell physiology	J:77312
	abnormal T cell physiology	J:77312
Ctsc^tm1Ley/Ctsc^tm1Ley (B6.129X1-Ctsc^tm1Ley)	abnormal chemokine level	J:131520
	abnormal leukocyte migration	J:131520
	abnormal response to infection	J:131520
	decreased circulating interleukin-6 level	J:131520
	impaired neutrophil recruitment	J:131520
	increased circulating interleukin-6 level	J:88160
	sepsis	J:88160
Ctsc^tm1Ley/Ctsc^tm1Ley Il6^tm1Kopf/Il6^tm1Kopf (involves: 129S2/SvPas * 129X1/SvJ * C57BL/6)	immune system phenotype	J:88160
Ctsd^m1J/Ctsd^m1J (C3HeB/FeJ-Ctsd^m1J/GrsrJ)	thymus atrophy	J:229377
Ctsd^tm1.1Thre/Ctsd^tm1.1Thre Edil3^{Tg(Sox2-cre)1Amc}/Edil3⁺ (involves: C57BL/6 * C57BL/6N * CBA * SJL)	decreased double-positive T cell number	J:227618
	microgliosis	J:227618
	thymus atrophy	J:227618
Ctsd^tm1.1Thre/Ctsd^tm1.1Thre Tg(Nes-cre)1Kln/0 (involves: C57BL/6 * C57BL/6N * SJL)	abnormal thymus morphology	J:227618
	decreased double-positive T cell number	J:227618
	microgliosis	J:227618
Ctsd^tm1Cptr/Ctsd^tm1Cptr (either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129P2/OlaHsd))	abnormal antigen presentation	J:47432
	abnormal microglial cell morphology	J:71688
	abnormal spleen B cell follicle morphology	J:28201
	abnormal spleen white pulp morphology	J:28201
	decreased double-positive T cell number	J:28201
	decreased lymphocyte cell number	J:28201
	thymus hypoplasia	J:28201
Ctse^{C57BL/6JOlaHsd}/Ctse^{C57BL/6JOlaHsd} (involves: 129S2/SvPasHsd * C57BL/6JOlaHsd)	abnormal dendritic cell antigen presentation	J:128538
	abnormal dendritic cell physiology	J:128538
	abnormal immune system physiology	J:128538
Ctse^tm1Kjy/Ctse⁺ (involves: C57BL/6)	increased IgE level	J:108745
Ctse^tm1Kjy/Ctse^tm1Kjy (involves: C57BL/6)	dermatitis	J:108745
	increased circulating interleukin-1 beta level	J:108745
	increased circulating interleukin-18 level	J:108745
	increased double-positive T cell number	J:108745
	increased eosinophil cell number	J:108745
	increased IgE level	J:108745
	increased interleukin-4 secretion	J:108745
	increased interleukin-5 secretion	J:108745
Ctsg^tm1.1Roes/Ctsg^tm1.1Roes (involves: 129P2/OlaHsd)	decreased susceptibility to bacterial infection induced morbidity/mortality	J:77597
Ctsg^tm1.1Roes/Ctsg^tm1.1Roes (involves: 129P2/OlaHsd)	increased susceptibility to infection induced morbidity/mortality	J:77597
Ctsg^tm1.1Roes/Ctsg^tm1.1Roes Elane^tm1(cre)Roes/Elane^tm1(cre)Roes (involves: 129P2/OlaHsd)	decreased susceptibility to endotoxin shock	J:77597
	increased susceptibility to fungal infection	J:77597
Ctsg^tm1Ley/Ctsg^tm1Ley (either: (involves: 129X1/SvJ * C57BL/6) or (involves: 129X1/SvJ))	immune system phenotype	J:59006
Ctsg^tm1Ley/Ctsg^tm1Ley Elane^tm1Sds/Elane^tm1Sds (involves: 129X1/SvJ)	immune system phenotype	J:131496
Ctsg^tm1Ley/Ctsg^tm1Ley Elane^tm1Sds/Elane^tm1Sds (B6.129X1-Elane^tm1Sds Ctsg^tm1Ley)	immune system phenotype	J:131520
Ctsg^{tm2.1(PML/RARA)Ley}/Ctsg⁺ (involves: 129X1/SvJ * C57BL/6)	abnormal myelopoiesis	J:84230, J:86458
	enlarged spleen	J:84230
	increased leukocyte cell number	J:84230
Ctsg^{tm2.1(PML/RARA)Ley}/Ctsg⁺ (involves: 129 * 129X1/SvJ * C57BL/6)	abnormal spleen morphology	J:166479
	enlarged spleen	J:166479
	increased spleen weight	J:166479
Ctsg^{tm2.1(PML/RARA)Ley}/Ctsg⁺ Elane^tm1Sds/Elane^tm1Sds (involves: 129S/SvEv * 129X1/SvJ * C57BL/6)	abnormal myelopoiesis	J:86458
Ctsg^{tm3.1(PML/RARA)Ley}/Ctsg⁺ (involves: 129 * C57BL/6)	abnormal spleen morphology	J:166479
	enlarged spleen	J:166479
	increased spleen weight	J:166479
Ctsk^tm1(cre)Ska/Ctsk⁺ Esr1^tm1Mma/Esr1^tm1Mma (involves: 129S2/SvPas * C57BL/6 * SJL)	abnormal osteoclast physiology	J:127179
	increased osteoclast cell number	J:127179
Ctsk^tm1(cre)Ska/Ctsk⁺ Plekhm1^tm1.1Hzhao/Plekhm1^tm1.1Hzhao (involves: C57BL/6J * C57BL/6NCrlj * CBA/JNCrlj)	abnormal osteoclast morphology	J:236517
	abnormal osteoclast physiology	J:236517
Ctsk^tm1(cre)Ska/Ctsk⁺ Snx10^{tm1c(EUCOMM)Raba}/Snx10^{tm1c(EUCOMM)Raba} (involves: 129S4/SvJae * C57BL/6 * C57BL/6J * C57BL/6NCrlj * CBA/JNCrlj)	abnormal osteoclast physiology	J:224711
Ctsk^tm1.1Rbar/Ctsk^tm1.1Rbar Tg(Itgam-cre)AJva/0 (involves: C57BL/6)	increased osteoclast cell number	J:194492
Ctsk^tm1.1Rbar/Ctsk^tm1.1Rbar Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA)	abnormal osteoclast differentiation	J:194492
	abnormal osteoclast physiology	J:194492
	increased osteoclast cell number	J:194492
Ctsk^tm1Mbs/Ctsk^tm1Mbs (B6.129-Ctsk^tm1Mbs)	abnormal osteoclast physiology	J:128098
Ctsk^tm1Mbs/Ctsk^tm1Mbs (B6.129-Ctsk^tm1Mbs)	increased osteoclast cell number	J:128098
Ctsk^tm1Psa/Ctsk^tm1Psa (involves: 129X1/SvJ * C57BL/6J)	abnormal osteoclast physiology	J:50934
Ctsk^tm1Vuo/Ctsk^tm1Vuo (involves: 129S7/SvEvBrd * C57BL/6J)	abnormal osteoclast morphology	J:95525
	increased osteoclast cell number	J:95525
Ctsk^tm1Ypl/Ctsk^tm1Ypl (B6.129S4-Ctsk^tm1Ypl)	increased osteoclast cell number	J:117870
Ctsk^tm1Ypl/Ctsk^tm1Ypl (129S4/SvJae-Ctsk^tm1Ypl)	increased osteoclast cell number	J:117870
Ctsl^m1Btlr/Ctsl^m1Btlr (C57BL/6J-Ctsl^m1Btlr)	abnormal CD4-positive T cell differentiation	J:272869
	abnormal CD8-positive, alpha beta T cell morphology	J:272869
	abnormal CD8-positive, alpha-beta T cell differentiation	J:272869
	abnormal T cell differentiation	J:272869
	decreased alpha-beta T cell number	J:272869
	decreased CD4-positive, alpha-beta T cell number	J:272869
	increased alpha-beta T cell number	J:272869
	increased CD8-positive, alpha-beta T cell number	J:272869
	increased central memory CD4-positive, alpha-beta T cell number	J:272869
	increased central memory CD8 positive, alpha-beta T cell number	J:272869
	increased effector memory CD4-positive, alpha-beta T cell number	J:272869
Ctsl^nkt/Ctsl^nkt (either: (involves: 129S2/SvPas * BALB/c) or (involves: 129S2/SvPas * C57BL/6) or (involves: 129S2/SvPas * DBA/2))	abnormal immune system organ morphology	J:54856
	decreased CD4-positive, alpha-beta T cell number	J:54856
	dermatitis	J:54856
	increased inflammatory response	J:54856
	liver inflammation	J:54856
	lymph node hyperplasia	J:54856
	lymph node inflammation	J:54856
	thymus atrophy	J:54856
Ctsl^nkt/Ctsl^nkt (B6.Cg-Ctsl^nkt)	dermatitis	J:78460
Ctsl^nkt/Ctsl^nkt (B6.Cg-Ctsl^nkt)	enlarged lymph nodes	J:78460
Ctsl^nkt/Ctsl^nkt (C.Cg-Ctsl^nkt)	abnormal immune system organ morphology	J:78460
	abnormal leukocyte cell number	J:99009
	abnormal lymph node cortex morphology	J:99009
	abnormal lymph node morphology	J:99009
	abnormal thymus corticomedullary boundary morphology	J:99009
	abnormal thymus lobule morphology	J:99009
	abnormal thymus morphology	J:99009
	decreased CD4-positive, alpha-beta T cell number	J:99009
	dermatitis	J:78460
	dilated lymph node medullary sinus	J:99009
	enlarged lymph nodes	J:78460, J:99009
	enlarged thymus cortex	J:99009
	increased CD8-positive, alpha-beta T cell number	J:99009
Ctsl^tm1.2Thre/Ctsl^tm1.2Thre (involves: C57BL/6 * C57BL/6N)	decreased CD4-positive, alpha-beta T cell number	J:216506
Ctsl^tm1Alpk/Ctsl^tm1Alpk (involves: 129P2/OlaHsd * C57BL/6)	abnormal osteoclast physiology	J:99755
	decreased osteoclast cell number	J:99755
	dermatitis	J:99755
	folliculitis	J:99755
	granulomatous inflammation	J:99755
Ctsl^tm1Alpk/Ctsl^tm1Alpk (B6.129P2-Ctsl^tm1Alpk)	granulomatous inflammation	J:99755
Ctsl^tm1Cptr/Ctsl⁺ (NOD.129P2-Ctsl^tm1Cptr)	decreased susceptibility to autoimmune diabetes	J:153355
Ctsl^tm1Cptr/Ctsl⁺ (NOD.129P2-Ctsl^tm1Cptr)	insulitis	J:153355
Ctsl^tm1Cptr/Ctsl^tm1Cptr (involves: 129P2/OlaHsd * C57BL/6J)	increased regulatory T cell number	J:153355
Ctsl^tm1Cptr/Ctsl^tm1Cptr (NOD.129P2-Ctsl^tm1Cptr)	decreased CD4-positive, alpha-beta T cell number	J:153355
	decreased susceptibility to autoimmune diabetes	J:153355
	increased regulatory T cell number	J:153355
	salivary gland inflammation	J:153355
Ctsl^tm1Cptr/Ctsl^tm1Cptr (involves: 129P2/OlaHsd)	decreased CD4-positive, alpha-beta T cell number	J:216506
Ctsm^{tm1(KOMP)Wtsi}/Ctsm^{tm1(KOMP)Wtsi} (C57BL/6N-Ctsm^{tm1(KOMP)Wtsi}/Nju)	increased monocyte cell number	J:211773
Ctss^em1(IMPC)H/Ctss^em1(IMPC)H (C57BL/6NTac-Ctss^em1(IMPC)H/H)	decreased spleen weight	J:211773
Ctss^m1Btlr/Ctss^m1Btlr (C57BL/6J-Ctss^m1Btlr)	decreased IgG level	J:267491
Ctss^m1Btlr/Ctss^m1Btlr (C57BL/6J-Ctss^m1Btlr)	impaired humoral immune response	J:267491
Ctss^tm1Eae/Ctss⁺ (NOD.D1-Ctss^tm1Eae)	insulitis	J:153355
Ctss^tm1Eae/Ctss^tm1Eae (involves: C57BL/6 * DBA/1LacJ)	abnormal B lymphocyte antigen presentation	J:53399
Ctss^tm1Eae/Ctss^tm1Eae (involves: C57BL/6 * DBA/1LacJ)	decreased susceptibility to induced arthritis	J:53399
Ctss^tm1Eae/Ctss^tm1Eae (NOD.D1-Ctss^tm1Eae)	decreased susceptibility to autoimmune diabetes	J:153355
	insulitis	J:153355
	salivary gland inflammation	J:153355
Ctss^tm1Hap/Ctss^tm1Hap (B6.129S2-Ctss^tm1Hap)	abnormal B cell physiology	J:96401
	abnormal cytokine secretion	J:96401
	abnormal humoral immune response	J:96401
	abnormal interleukin secretion	J:96401
	abnormal professional antigen presenting cell physiology	J:96401
	abnormal T cell physiology	J:96401
	decreased IgG level	J:96401
	decreased IgM level	J:96401
	decreased susceptibility to experimental autoimmune myasthenia gravis	J:96401
Ctss^tm1Hap/Ctss^tm1Hap Ldlr^tm1Her/Ldlr^tm1Her (B6.129S-Ctss^tm1Hap Ldlr^tm1Her)	abnormal leukocyte migration	J:82520
Ctss^tm1Hap/Ctss^tm1Hap Tg(Scgb1a1-rtTA,tetO-Ifng)14Eli/0 (involves: 129S2/SvPas * C57BL/6 * CBA)	increased lymphocyte cell number	J:100854
	increased macrophage cell number	J:100854
	increased neutrophil cell number	J:100854
Ctsw^tm1Ctnp/Ctsw^tm1Ctnp (involves: 129X1/SvJ * C57BL/6)	immune system phenotype	J:91265
Cttn^tm1.2Dvst/Cttn^tm1.2Dvst (either: B6.Cg-Cttn^tm1.2Dvst or (involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * DBA/2 * SJL))	abnormal cellular extravasation	J:177602
	abnormal leukocyte adhesion	J:177602
	abnormal leukocyte migration	J:177602
	abnormal neutrophil physiology	J:177602
Cttnbp2^{tm1b(KOMP)Wtsi}/Cttnbp2^{tm1b(KOMP)Wtsi} (C57BL/6N-Cttnbp2^{tm1b(KOMP)Wtsi}/Wtsi)	decreased transitional stage T1 B cell number	J:211773
	increased memory CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	increased plasma cell number	J:211773
Ctu2^{tm1(KOMP)Wtsi}/Ctu2⁺ (C57BL/6N-Ctu2^{tm1(KOMP)Wtsi}/Nju)	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
Cuedc2^tm1Qxia/Cuedc2^tm1Qxia (involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NTac)	abnormal macrophage physiology	J:211782
	increased macrophage cytokine production	J:211782
	increased susceptibility to induced colitis	J:211782
Cul4a/Pcid2^tm2Ktc/Cul4a/Pcid2^tm2Ktc Tg(Mx1-cre)1Cgn/0 (involves: 129S/SvEv * C57BL/6 * CBA * FVB/N)	abnormal leukocyte morphology	J:138468
	abnormal spleen capsule morphology	J:138468
	abnormal spleen morphology	J:138468
	decreased lymphocyte cell number	J:138468
	decreased monocyte cell number	J:138468
	decreased neutrophil cell number	J:138468
	decreased spleen red pulp amount	J:138468
	decreased spleen weight	J:138468
	decreased spleen white pulp amount	J:138468
	small thymus	J:138468
	spleen hypoplasia	J:138468
Cul4a/Pcid2^tm2Ktc/Cul4a/Pcid2^tm2Ktc Tg(Mx1-cre)1Cgn/0 (involves: 129S/SvEv * C57BL/6 * CBA * FVB/N)	abnormal leukocyte morphology	J:138468
	abnormal spleen capsule morphology	J:138468
	abnormal spleen morphology	J:138468
	decreased lymphocyte cell number	J:138468
	decreased monocyte cell number	J:138468
	decreased neutrophil cell number	J:138468
	decreased spleen red pulp amount	J:138468
	decreased spleen weight	J:138468
	decreased spleen white pulp amount	J:138468
	small thymus	J:138468
	spleen hypoplasia	J:138468
Cul4a^{tm1b(EUCOMM)Hmgu}/Cul4a^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Cul4a^{tm1b(EUCOMM)Hmgu}/Ccpcz)	decreased spleen weight	J:211773
Cul5^{tm1.1(KOMP)Vlcg}/Cul5⁺ (involves: C57BL/6NTac)	decreased interleukin-1 alpha secretion	J:244502
	decreased interleukin-6 secretion	J:244502
	decreased tumor necrosis factor secretion	J:244502
Cul5^{tm1.1(KOMP)Vlcg}/Cul5⁺ (C57BL/6N-Cul5^{tm1.1(KOMP)Vlcg}/Ucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	increased spleen weight	J:211773
Cul9^{em1(IMPC)Ccpcz}/Cul9^{em1(IMPC)Ccpcz} (C57BL/6N-Cul9^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Cux1^tm1Rhsc/Cux1^tm1Rhsc (involves: 129S1/Sv * C57BL/6J)	abnormal myelopoiesis	J:100055
	abnormal T cell differentiation	J:100055
	abnormal tumor necrosis factor level	J:100055
	decreased B cell number	J:100055
	decreased double-positive T cell number	J:100055
	decreased thymocyte number	J:100055
	small thymus	J:100055
	thymus cortex hypoplasia	J:100055
	thymus hypoplasia	J:100055
Cux1^tm2Ejn/Cux1^tm2Ejn (involves: 129S4/SvJae * C57BL/6)	increased susceptibility to bacterial infection	J:74660
Cux1^tm2Ejn/Cux1^tm2Ejn (involves: 129S4/SvJae * C57BL/6)	rhinitis	J:74660
Cuzd1^tm1Ljm/Cuzd1^tm1Ljm (involves: 129S6/SvEvTac * Black Swiss)	increased susceptibility to induced pancreatitis	J:80980
Cwc22^em1(IMPC)Mbp/Cwc22⁺ (C57BL/6NCrl-Cwc22^em1(IMPC)Mbp/Mmucd)	abnormal spleen morphology	J:211773
Cwc27^tm1Lex/Cwc27^tm1Lex (B6;129S5-Cwc27^tm1Lex/Mmucd)	abnormal immune system physiology	J:171883
Cx3cl1^tm1.1Yono/Cx3cl1^tm1.1Yono (involves: C57BL/6J)	abnormal dendritic cell physiology	J:271242
Cx3cl1^tm1.1Yono/Cx3cl1^tm1.1Yono (involves: C57BL/6J)	decreased inflammatory response	J:271242
Cx3cl1^tm1Lira/Cx3cl1^tm1Lira (involves: 129S/SvEv * C57BL/6)	immune system phenotype	J:68831
Cx3cl1^tm1Lira/Cx3cl1^tm1Lira (involves: C57BL/6)	decreased monocyte cell number	J:145036
Cx3cl1^tm1Sgs/Cx3cl1^tm1Sgs Ldlr^tm1Her/Ldlr^tm1Her (involves: B6.129S4-Cx3cl1^tm1Sgs * B6.129S7-Ldlr^tm1Her/J)	impaired macrophage chemotaxis	J:95279
Cx3cr1^tm1Ifc/Cx3cr1^tm1Ifc (involves: 129S4/SvJae * C57BL/6)	abnormal NK cell physiology	J:82033
	abnormal response to transplant	J:82033
	immune system phenotype	J:82033
	impaired macrophage chemotaxis	J:82033
Cx3cr1^tm1Litt/Cx3cr1⁺ (B6.129P2-Cx3cr1^tm1Litt)	increased susceptibility to experimental autoimmune encephalomyelitis	J:129712
Cx3cr1^tm1Litt/Cx3cr1⁺ (B6.129P2-Cx3cr1^tm1Litt)	microgliosis	J:110266
Cx3cr1^tm1Litt/Cx3cr1⁺ Psen1^tm1Mpm/Psen1^tm1Mpm Tg(APPSwe,tauP301L)1Lfa/0 Tg(Thy1-YFP)HJrs/0 (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)	abnormal microglial cell morphology	J:159680
	abnormal microglial cell physiology	J:159680
Cx3cr1^tm1Litt/Cx3cr1^tm1Litt (involves: 129P2/OlaHsd * C57BL/6)	abnormal leukocyte physiology	J:162714
	decreased monocyte cell number	J:145036
	immune system phenotype	J:84544
	impaired macrophage chemotaxis	J:162714
Cx3cr1^tm1Litt/Cx3cr1^tm1Litt (C.129P2-Cx3cr1^tm1Litt)	immune system phenotype	J:84544
Cx3cr1^tm1Litt/Cx3cr1^tm1Litt (involves: 129P2/OlaHsd)	abnormal dendritic cell physiology	J:271242, J:95694
	decreased inflammatory response	J:271242
	increased dendritic cell number	J:210086
	increased susceptibility to bacterial infection induced morbidity/mortality	J:95694
Cx3cr1^tm1Litt/Cx3cr1^tm1Litt (B6.129P2-Cx3cr1^tm1Litt)	abnormal leukocyte physiology	J:124722
	abnormal microglial cell morphology	J:265696
	abnormal microglial cell physiology	J:110266, J:265696
	abnormal NK cell physiology	J:129712
	brain inflammation	J:129712
	decreased NK cell number	J:129712
	immune system phenotype	J:129712
	increased susceptibility to experimental autoimmune encephalomyelitis	J:129712
	microgliosis	J:110266
Cx3cr1^tm1Litt/Cx3cr1^tm1Litt H2-Ab1^b-tm1Hpl/H2-Ab1⁺ (involves: 129P2/OlaHsd * 129S4/SvJae)	abnormal response to infection	J:95694
Cx3cr1^tm1Zm/Cx3cr1^tm1Zm (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal splenocyte physiology	J:103047
Cx3cr1^{tm2.1(cre/ERT2)Litt}/Cx3cr1⁺ Vps35^{Gt(RRK261)Byg}/Vps35^{Gt(RRK261)Byg} (involves: 129P2/OlaHsd * C57BL/6)	decreased interleukin-1 beta secretion	J:292365
	decreased interleukin-6 secretion	J:292365
	decreased tumor necrosis factor secretion	J:292365
	increased interleukin-4 secretion	J:292365
	increased interleukin-10 secretion	J:292365
	increased macrophage cell number	J:292365
	microgliosis	J:292365
Cx3cr1^{tm3(Hbegf)Litt}/Cx3cr1^{tm3(Hbegf)Litt} Tg(Itgax-cre)1-1Reiz/? (involves: 129P2/OlaHsd * C57BL/6 * CBA)	decreased susceptibility to bacterial infection	J:210086
Cxadr^em1(IMPC)Mbp/Cxadr⁺ (C57BL/6N-Cxadr^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	small spleen	J:211773
Cxadr^tm1.1Ics/Cxadr^tm1.1Ics Tg(CAG-cre/Esr1)5Amc/0 (involves: 129S2/SvPas C57BL/6 * C57BL/6J * CBA)	enlarged thymus	J:174138
	increased thymocyte number	J:174138
Cxcl1^em1(IMPC)Mbp/Cxcl1^em1(IMPC)Mbp (C57BL/6N-Cxcl1^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
	increased monocyte cell number	J:211773
Cxcl5^tm1.1Mkch/Cxcl5^tm1.1Mkch (B6.129P2-Cxcl5^tm1.1Mkch)	decreased interferon-alpha secretion	J:208901
	decreased interleukin-1 alpha secretion	J:208901
	decreased interleukin-6 secretion	J:208901
	decreased neutrophil cell number	J:208901
	decreased susceptibility to bacterial infection	J:208901
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:208901
	decreased tumor necrosis factor secretion	J:208901
	immune system phenotype	J:208901
Cxcl5^tm1Gscw/Cxcl5^tm1Gscw (involves: 129)	abnormal circulating chemokine level	J:162629
	abnormal neutrophil physiology	J:162629
	decreased circulating interleukin-6 level	J:162629
	decreased susceptibility to bacterial infection	J:162629
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:162629
	decreased susceptibility to endotoxin shock	J:162629
	increased granulocyte number	J:162629
Cxcl5^tm1Gscw/Cxcl5^tm1Gscw Ackr1^tm1Scp/Ackr1^tm1Scp (involves: 129/Sv * 129P2/OlaHsd * C57BL/6)	abnormal circulating chemokine level	J:162629
Cxcl9^{tm1b(EUCOMM)Wtsi}/Cxcl9^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Cxcl9^{tm1b(EUCOMM)Wtsi}/H)	decreased neutrophil cell number	J:211773
	increased lymphocyte cell number	J:211773
Cxcl9^tm1Jmf/Cxcl9^tm1Jmf (either: B6.129S4-Cxcl9^tm1Jmf or (involves: 129S4/SvJae * C57BL/6))	decreased IgG level	J:121818
	decreased immunoglobulin level	J:121818
	immune system phenotype	J:121818
Cxcl9^tm1Jmf/Cxcl9^tm1Jmf (B6.129S4-Cxcl9^tm1Jmf)	abnormal cytokine secretion	J:120743
Cxcl9^tm1Jmf/Cxcl9^tm1Jmf (B6.129S4-Cxcl9^tm1Jmf)	decreased inflammatory response	J:120743
Cxcl10^tm1Adl/Cxcl10^tm1Adl (involves: 129S4/SvJae * 129X1/SvJ)	decreased IgG2a level	J:75584
	decreased interferon-gamma secretion	J:75584
	decreased splenocyte proliferation	J:75584
	decreased susceptibility to type IV hypersensitivity reaction	J:75584
Cxcl10^tm1Adl/Cxcl10^tm1Adl (involves: 129S4/SvJae * C57BL/6)	abnormal interferon level	J:75584
	abnormal T cell physiology	J:75584
	decreased CD8-positive, alpha-beta T cell number	J:75584
	increased susceptibility to Hepadnaviridae infection	J:75584
Cxcl10^tm1Adl/Cxcl10^tm1Adl (B6.129S4-Cxcl10^tm1Adl)	abnormal cytokine secretion	J:120743
	CNS inflammation	J:87076
	increased susceptibility to experimental autoimmune encephalomyelitis	J:87076
	increased susceptibility to Herpesvirales infection	J:120743
Cxcl11^em1Groj/Cxcl11^em1Groj (C57BL/6J-Cxcl11^em1Groj)	abnormal B cell morphology	J:345391
	immune system phenotype	J:345391
	increased CD8-positive, alpha-beta T cell number	J:345391
Cxcl12^tm1.1Sjm/Cxcl12^tm1.1Sjm Ndor1^{Tg(UBC-cre/ERT2)1Ejb}/? (involves: 129S/SvEv * C57BL/6)	decreased leukocyte cell number	J:194748
	decreased lymphocyte cell number	J:194748
Cxcl12^tm1.1Sjm/Cxcl12^tm1.1Sjm Tg(Prrx1-cre)1Cjt/? (involves: C57BL/6 * SJL/J)	abnormal B cell differentiation	J:194748
Cxcl12^tm1.1Ystz/Cxcl12^tm1.2Ystz Tg(CAG-cre/Esr1)5Amc/0 (involves: 129X1/SvJ C57BL/6 * CBA * FVB/N)	decreased pro-B cell number	J:168434
	increased neutrophil cell number	J:168434
Cxcl12^tm1Tng/Cxcl12^tm1.1Link Tg(BGLAP-cre)1Clem/0 (involves: 129P2/OlaHsd * C57BL/6J * C57BL/6NTac * FVB/N)	decreased B cell number	J:193594
Cxcl12^tm1Tng/Cxcl12^tm1.1Link Tg(Prrx1-cre)1Cjt/0 (involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL/J)	decreased B cell number	J:193594
	decreased pre-pro B cell number	J:193594
Cxcl12^tm1Tng/Cxcl12^tm1.1Link Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0 (involves: 129P2/OlaHsd * C57BL/6 * CD-1 * FVB/N)	decreased B cell number	J:193594
	decreased pre-pro B cell number	J:193594
Cxcl12^tm1Tng/Cxcl12^tm1Tng (involves: 129P2/OlaHsd)	decreased pre-B cell number	J:34750
	decreased pro-B cell number	J:34750
	impaired myelopoiesis	J:49070
Cxcl12^{tm3.1(HBEGF/EGFP)Tng}/Cxcl12⁺ (B6.Cg-Cxcl12^{tm3.1(HBEGF/EGFP)Tng})	decreased pro-B cell number	J:164657
	increased B cell apoptosis	J:164657
Cxcl13^em2(IMPC)H/Cxcl13^em2(IMPC)H (C57BL/6NTac-Cxcl13^em2(IMPC)H/H)	increased basophil cell number	J:211773
	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
Cxcl13^m1Btlr/Cxcl13^m1Btlr (C57BL/6J-Cxcl13^m1Btlr)	increased B-1 B cell number	J:221480
Cxcl13^tm1Cys/Cxcl13^tm1Cys (involves: 129X1/SvJ * C57BL/6)	abnormal B cell physiology	J:78282
	abnormal lymph node germinal center morphology	J:78282
	abnormal Peyer's patch morphology	J:78282
	abnormal spleen B cell follicle morphology	J:78282
	abnormal spleen marginal zone morphology	J:78282
	absent axillary lymph nodes	J:78282
	absent brachial lymph nodes	J:78282
	absent follicular dendritic cells	J:78282
	absent inguinal lymph nodes	J:78282
	decreased lymph node number	J:78282
	decreased Peyer's patch number	J:78282
	decreased spleen germinal center size	J:78282
	small Peyer's patches	J:78282
Cxcl13^tm1Cys/Cxcl13^tm1Cys (B6.129X1-Cxcl13^tm1Cys)	impaired B cell migration	J:118931
Cxcl13^tm1Mmi/Cxcl13^tm1Mmi (involves: C57BL/6)	abnormal B cell physiology	J:84804
	abnormal leukocyte adhesion	J:84804
	abnormal leukocyte migration	J:84804
Cxcl14^tm1Bmsr/Cxcl14^tm1Bmsr (involves: 129/Sv * C57BL/6)	immune system phenotype	J:118303
Cxcl14^tm1Tha/Cxcl14^tm1Tha (involves: C57BL/6 * CBA)	decreased macrophage cell number	J:126841
Cxcl15^tm1Lira/Cxcl15^tm1Lira (involves: 129 * C57BL/6J)	decreased neutrophil cell number	J:67605
	immune system phenotype	J:67605
	increased susceptibility to bacterial infection	J:67605
Cxcl16^tm1Syon/Cxcl16^tm1Syon (B6.129P2-Cxcl16^tm1Syon)	decreased circulating interferon-gamma level	J:155199
	decreased circulating interleukin-4 level	J:155199
	decreased interferon-gamma secretion	J:155199
	decreased interleukin-4 secretion	J:155199
	decreased NK T cell number	J:155199
	decreased susceptibility to bacterial infection	J:155199
Cxcr2^{tm1(IL8RB)Dktr}/Cxcr2^{tm1(IL8RB)Dktr} (involves: 129S2/SvPas * C57BL/6)	decreased spleen weight	J:113489
	immune system phenotype	J:113489
	increased granulocyte number	J:113489
	increased leukocyte cell number	J:113489
Cxcr2^{tm1a(EUCOMM)Wtsi}/Cxcr2^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Cxcr2^{tm1a(EUCOMM)Wtsi}/Wtsi)	decreased B cell number	J:211773
	decreased CD8-positive, alpha-beta T cell number	J:211773
	decreased immature B cell number	J:211773
	decreased mature B cell number	J:211773
	decreased pre-B cell number	J:211773
	decreased pre-pro B cell number	J:211773
	decreased T cell number	J:211773
	increased anti-nuclear antigen antibody level	J:211773
	increased CD4-positive, alpha-beta memory T cell number	J:211773
	increased CD8-positive, alpha-beta memory T cell number	J:211773
	increased CD103-positive CD11b-low dendritic cell number	J:211773
	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
	increased effector memory T-helper cell number	J:211773
	increased eosinophil cell number	J:211773
	increased gamma-delta T cell number	J:211773
	increased granulocyte number	J:211773
	increased KLRG1+ CD4 alpha-beta T cell number	J:211773
	increased KLRG1+ CD8 alpha-beta T cell number	J:211773
	increased leukocyte cell number	J:211773
	increased Ly6C high monocyte number	J:211773
	increased Ly6C low monocyte number	J:211773
	increased memory-marker CD4-positive NK T cell number	J:211773
	increased memory-marker gamma-delta T cell number	J:211773
	increased memory-marker NK cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Cxcr2^tm1Mwm/Cxcr2⁺ (C.129S2(B6)-Cxcr2^tm1Mwm/J)	impaired neutrophil recruitment	J:63935
Cxcr2^tm1Mwm/Cxcr2^tm1Mwm (involves: 129S2/SvPas * C57BL/6J)	abnormal granulocyte differentiation	J:19570
	abnormal myelopoiesis	J:19570
	abnormal spleen white pulp morphology	J:19570
	enlarged cervical lymph nodes	J:19570
	enlarged lymph nodes	J:19570
	enlarged spleen	J:19570
	impaired neutrophil chemotaxis	J:19570
	increased B cell number	J:19570
	increased circulating interleukin-6 level	J:19570
	increased neutrophil cell number	J:19570
	lymph node medullary cord hyperplasia	J:19570
	myeloid hyperplasia	J:19570
Cxcr2^tm1Mwm/Cxcr2^tm1Mwm (C.129S2(B6)-Cxcr2^tm1Mwm/J)	abnormal chemokine level	J:73947
	abnormal cytokine secretion	J:72824
	abnormal eosinophil physiology	J:73947
	abnormal interleukin level	J:73947, J:87365
	abnormal leukocyte physiology	J:94170
	abnormal neutrophil physiology	J:93946, J:73947
	abnormal NK T cell physiology	J:66399
	abnormal T cell physiology	J:73947
	abnormal T-helper 1 physiology	J:73947
	abnormal T-helper 2 physiology	J:73947
	decreased susceptibility to fungal infection	J:73947
	decreased susceptibility to induced arthritis	J:142880
	impaired neutrophil chemotaxis	J:65905, J:72824
	impaired neutrophil recruitment	J:65425, J:63935, J:93116
	increased IgE level	J:73947
	increased susceptibility to bacterial infection	J:65905
	increased susceptibility to Herpesvirales infection	J:87365
	increased susceptibility to parasitic infection	J:72824
Cxcr2^tm1Mwm/Cxcr2^tm1Mwm (involves: 129S2/SvPas * BALB/c)	abnormal myelopoiesis	J:113489
	abnormal neutrophil physiology	J:113489
	decreased thymus weight	J:113489
	increased granulocyte number	J:113489
	increased spleen weight	J:113489
Cxcr2^tm1Mwm/Cxcr2^tm1Mwm (involves: 129S2/SvPas)	decreased susceptibility to bacterial infection induced morbidity/mortality	J:208901
Cxcr2^tm1Rmra/Cxcr2^tm1Rmra Tg(Mx1-cre)1Cgn/0 (involves: 129S/SvEv * C57BL/6 * C57BL/6NTac * CBA)	abnormal neutrophil physiology	J:204482
Cxcr3^tm1Raks/Cxcr3^tm1Raks (B6.129P2-Cxcr3^tm1Raks)	kidney inflammation	J:152790
Cxcr3^tm1Wwh/Y (B6.Cg-Cxcr3^tm1Wwh)	abnormal cellular extravasation	J:107646
	abnormal interferon level	J:91359
	impaired macrophage chemotaxis	J:107646
	increased length of allograft survival	J:65916
	lung inflammation	J:91359
Cxcr3^tm1Wwh/Cxcr3^tm1Wwh (B6.Cg-Cxcr3^tm1Wwh)	abnormal cellular extravasation	J:96905, J:107646
	abnormal interferon level	J:91359
	decreased susceptibility to Riboviria infection	J:96905
	decreased susceptibility to Riboviria infection induced morbidity/mortality	J:96905
	impaired macrophage chemotaxis	J:107646
	increased length of allograft survival	J:65916
	lung inflammation	J:91359
Cxcr4^em1(IMPC)Mbp/Cxcr4⁺ (C57BL/6NCrl-Cxcr4^em1(IMPC)Mbp/MbpMmucd)	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
	increased monocyte cell number	J:211773
Cxcr4^tm1.1Bala/Cxcr4⁺ (B6.129S2-Cxcr4^tm1.1Bala)	abnormal CD4-positive, alpha-beta T cell number	J:186735
	abnormal immune system cell morphology	J:186735
	abnormal immune system morphology	J:186735
	abnormal immune system organ morphology	J:186735
	abnormal immune system physiology	J:186735
	abnormal lymph node B cell domain morphology	J:186735
	abnormal lymph node morphology	J:186735
	abnormal neutrophil morphology	J:186735
	abnormal NK cell physiology	J:178789
	abnormal spleen morphology	J:186735
	abnormal spleen white pulp morphology	J:186735
	abnormal thymus morphology	J:186735
	decreased B cell apoptosis	J:186735
	decreased B cell number	J:186735
	decreased immature B cell number	J:186735
	decreased leukocyte cell number	J:186735
	decreased NK cell number	J:178789
	decreased spleen weight	J:186735
	decreased T cell number	J:186735
	increased IgG level	J:186735
	increased IgM level	J:186735
	increased immunoglobulin level	J:186735
	increased mature B cell number	J:186735
	increased NK cell number	J:178789
Cxcr4^tm1Qma/Cxcr4^tm1Qma (involves: 129X1/SvJ)	decreased pro-B cell number	J:49070
Cxcr4^tm1Qma/Cxcr4^tm1Qma (involves: 129X1/SvJ)	impaired myelopoiesis	J:49070
Cxcr4^tm1Qma/Cxcr4^tm1Qma (involves: 129X1/SvJ * C57BL/6)	decreased susceptibility to Retroviridae infection	J:132342
Cxcr4^tm1Qma/Cxcr4^tm1Qma (involves: 129X1/SvJ * C57BL/6)	increased susceptibility to Retroviridae infection induced morbidity/mortality	J:132342
Cxcr4^tm1Tng/Cxcr4^tm1Tng (involves: 129P2/OlaHsd)	abnormal B cell differentiation	J:69256
Cxcr4^tm1Tng/Cxcr4^tm1Tng (involves: 129P2/OlaHsd)	failure of myelopoiesis	J:69256
Cxcr4^tm1Tng/Cxcr4^tm1Tng (B6.Cg-Cxcr4^tm1Tng)	abnormal T cell differentiation	J:82996
Cxcr4^tm1Tng/Cxcr4^tm1Tng (B6.Cg-Cxcr4^tm1Tng)	decreased double-positive T cell number	J:82996
Cxcr4^tm1Yiw/Cxcr4^tm1Yiw Tg(Lck-cre)1Jtak/0 (involves: 129P2/OlaHsd)	abnormal leukocyte migration	J:164872
	decreased susceptibility to induced arthritis	J:164872
	decreased thymocyte number	J:164872
Cxcr4^tm1Yzo/Cxcr4^tm1Yzo (Not Specified)	abnormal B cell differentiation	J:167314
	abnormal B cell physiology	J:167314
	abnormal leukopoiesis	J:69255
	abnormal lymphopoiesis	J:69255
	impaired myelopoiesis	J:69255
Cxcr4^tm2Yzo/Cxcr4^tm2Yzo Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129P2/OlaHsd)	abnormal B cell differentiation	J:94911
	abnormal Peyer's patch follicle morphology	J:94911
	decreased B-1 B cell number	J:94911
	decreased B-2 B cell number	J:94911
	decreased immunoglobulin level	J:94911
	decreased mature B cell number	J:94911
	decreased plasma cell number	J:94911
Cxcr4^tm2Yzo/Cxcr4^tm2Yzo Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6)	increased lymphocyte cell number	J:217569
	increased monocyte cell number	J:217569
	increased neutrophil cell number	J:217569
Cxcr4^tm2Yzo/Cxcr4^tm2Yzo Tg(Fabp4-cre)1Rev/0 (involves: 129P2/OlaHsd * C57BL/6)	abnormal macrophage cell number	J:217569
	decreased B cell number	J:217569
	decreased CD4-positive, alpha-beta T cell number	J:217569
	increased CD8-positive, alpha-beta T cell number	J:217569
Cxcr4^tm2Yzo/Cxcr4^tm3.1Yzo Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129P2/OlaHsd)	abnormal B cell differentiation	J:167314
Cxcr4^tm3.1Yzo/Cxcr4^tm3.1Yzo (Not Specified)	abnormal B cell physiology	J:167314
	decreased pro-B cell number	J:167314
	impaired myelopoiesis	J:167314
Cxcr5^tm1.1Namt/Cxcr5^tm1.1Namt Tg(Itgax-cre)1-1Reiz/0 (involves: C57BL/6 * C57BL/6J * CBA)	abnormal dendritic cell chemotaxis	J:241561
	decreased follicular dendritic cell number	J:241561
	decreased susceptibility to prion infection	J:241561
	immune system phenotype	J:241561
Cxcr5^tm1.1Namt/Cxcr5^tm1.1Namt Tg(Itgax-cre)1-1Reiz/0 Tg(Prnp)a20Cwe/0 (involves: C57BL/6 * C57BL/6J * CBA)	decreased susceptibility to prion infection	J:241561
Cxcr5^tm1Lipp/Cxcr5^tm1Lipp (involves: 129S2/SvPas * CD-1)	abnormal leukocyte migration	J:37126
	abnormal Peyer's patch morphology	J:37126
	abnormal spleen primary B follicle morphology	J:37126
	abnormal spleen secondary B follicle morphology	J:37126
	absent axillary lymph nodes	J:78282
	absent brachial lymph nodes	J:78282
	absent cervical lymph nodes	J:78282
	absent follicular dendritic cells	J:78282
	absent inguinal lymph nodes	J:78282, J:37126
	absent lymph nodes	J:78282
	absent Peyer's patches	J:37126
	absent spleen germinal center	J:37126
	increased B cell number	J:37126
Cxv1^F/St/Cxv1^F/St (involves: AKR/J * F/St)	abnormal immune cell physiology	J:7030
Cxv2^DBA/2J/? (involves: C57BL/6J * DBA/2J)	abnormal immune cell physiology	J:6143
Cyb5d1^{tm1.1(KOMP)Vlcg}/Cyb5d1^{tm1.1(KOMP)Vlcg} (B6N(Cg)-Cyb5d1^{tm1.1(KOMP)Vlcg}/J)	increased leukocyte cell number	J:211773
Cyb5r3^{tm1c(KOMP)Wtsi}/Cyb5r3^{tm1c(KOMP)Wtsi} Tg(Myh11-icre/ERT2)1Soff/0 (B6.Cg-Cyb5r3^{tm1c(KOMP)Wtsi} Tg(Myh11-icre/ERT2)1Soff)	decreased monocyte cell number	J:280543
Cyb561d2^{tm1b(EUCOMM)Wtsi}/Cyb561d2^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Cyb561d2^{tm1b(EUCOMM)Wtsi}/Bay)	abnormal spleen morphology	J:211773
Cyba^nmf333/Cyba^nmf333 (A.B6 Tyr⁺-Cyba^nmf333/J)	abnormal neutrophil physiology	J:132359
	increased inflammatory response	J:132359
	increased susceptibility to bacterial infection	J:132359
	lung inflammation	J:132359
	sepsis	J:132359
Cyba^{tm1a(EUCOMM)Wtsi}/Cyba^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Cyba^{tm1a(EUCOMM)Wtsi}/Wtsi)	increased leukocyte cell number	J:211773
Cyba^tm1Dgh/Cyba^tm1Dgh (B6.Cg-Cyba^tm1Dgh)	abnormal T cell activation	J:231269
Cyba^tm1Dgh/Cyba^tm1Dgh (B6.Cg-Cyba^tm1Dgh)	decreased inflammatory response	J:231269
Cybb^tm1.1Abk/Cybb^tm1.1Abk Lyz2^tm1(cre)Ifo/? (B6.Cg-Lyz2^tm1(cre)Ifo Cybb^tm1.1Abk)	abnormal macrophage chemotaxis	J:245699
	enlarged spleen	J:245699
Cybb^tm1Din/Y (involves: 129S/SvEv * C57BL/6)	abnormal immune system physiology	J:22868
	abnormal macrophage physiology	J:22868
	abnormal neutrophil physiology	J:22868
	increased inflammatory response	J:22868
	increased susceptibility to bacterial infection	J:22868
	increased susceptibility to infection	J:22868
Cybb^tm1Din/Cybb^tm1Din (involves: 129S/SvEv * C57BL/6)	immune system phenotype	J:64232
Cybb^tm1Din/Cybb^tm1Din (B6.129S-Cybb^tm1Din)	granulomatous inflammation	J:146231
	immune system phenotype	J:113463
	increased acute inflammation	J:110181
Cybb^tm1Din/Cybb^tm1Din (B6.129S-Cybb^tm1Din/J)	abnormal circulating chemokine level	J:235399
	abnormal macrophage physiology	J:235399
	decreased circulating interleukin-10 level	J:235399
	glomerulonephritis	J:235399
	increased anti-double stranded DNA antibody level	J:235399
	increased anti-nuclear antigen antibody level	J:235399
	increased autoantibody level	J:235399
	increased circulating interleukin-1 beta level	J:235399
	increased circulating interleukin-6 level	J:235399
	increased circulating interleukin-12b level	J:235399
	increased IgG level	J:235399
	increased lymphocyte cell number	J:235399
	increased monocyte cell number	J:235399
	increased neutrophil cell number	J:235399
	increased susceptibility to systemic lupus erythematosus	J:235399
Cybb^tm1Din/Cybb^tm1Din Nrros^tm1Lex/Nrros^tm1Lex (B6.129S-Nrros^tm1Lex Cybb^tm1Din)	immune system phenotype	J:209569
Cybb^{tm2b(KOMP)Wtsi}/Cybb^{tm2b(KOMP)Wtsi} (C57BL/6N-Cybb^{tm2b(KOMP)Wtsi}/H)	increased spleen weight	J:211773
Cycs^tm1Mak/Cycs^tm1Mak (involves: C57BL/6)	absent pre-B cells	J:98949
	decreased B cell number	J:98949
	decreased leukocyte cell number	J:98949
	decreased T cell number	J:98949
	increased spleen weight	J:98949
	spleen hyperplasia	J:98949
	thymus atrophy	J:98949
	thymus hypoplasia	J:98949
Cyld^tm1.1Awai/Cyld^tm1.1Awai (Not Specified)	abnormal B cell differentiation	J:126113
	abnormal B cell morphology	J:126113
	abnormal B cell physiology	J:126113
	abnormal class switch recombination	J:126113
	abnormal humoral immune response	J:126113
	abnormal Peyer's patch germinal center morphology	J:126113
	abnormal spleen marginal zone morphology	J:126113
	abnormal spleen morphology	J:126113
	decreased B-1 B cell number	J:126113
	decreased IgG3 level	J:126113
	decreased IgM level	J:126113
	decreased immature B cell number	J:126113
	enlarged lymph nodes	J:126113
	enlarged Peyer's patches	J:126113
	enlarged spleen	J:126113
	increased B cell number	J:126113
	increased follicular B cell number	J:126113
	increased IgA level	J:126113
	increased IgG1 level	J:126113
	increased IgG2a level	J:126113
	increased IgG2b level	J:126113
	increased marginal zone B cell number	J:126113
	increased pro-B cell number	J:126113
Cyld^tm1.1Mpa/Cyld^tm1.1Mpa Fadd^tm1Mpa/Fadd^tm1Mpa Tg(Vil1-cre)997Gum/0 (B6.Cg-Fadd^tm1Mpa Cyld^tm1.1Mpa Tg(Vil1-cre)997Gum)	cecum inflammation	J:175865
Cyld^tm1.1Mpa/Cyld^tm1.1Mpa Ikbkg^tm1.1Mpa/Y Tg(Vil1-cre)997Gum/0 (B6.Cg-Cyld^tm1.1Mpa Ikbkg^tm1.1Mpa Tg(Vil1-cre)997Gum)	colitis	J:175865
Cyld^tm1.1Mpa/Cyld^tm1.1Mpa Ikbkg^tm1.1Mpa/Ikbkg^tm1.1Mpa Tg(Vil1-cre)997Gum/0 (B6.Cg-Cyld^tm1.1Mpa Ikbkg^tm1.1Mpa Tg(Vil1-cre)997Gum)	colitis	J:175865
Cyld^tm1Awai/Cyld^tm1Awai Tg(CD19-cre/ERT2)1Cgn/? (Not Specified)	abnormal mature B cell morphology	J:126113
	decreased B-1 B cell number	J:126113
	decreased immature B cell number	J:126113
	enlarged lymph nodes	J:126113
	enlarged Peyer's patches	J:126113
	enlarged spleen	J:126113
	increased B cell number	J:126113
Cyld^tm1Jdgl/Cyld^tm1Jdgl (involves: 129 * C57BL/6J)	decreased susceptibility to bacterial infection	J:124327
Cyld^tm1Jdgl/Cyld^tm1Jdgl (involves: 129 * C57BL/6J)	decreased susceptibility to bacterial infection induced morbidity/mortality	J:124327
Cyld^tm1Lex/Cyld^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6)	abnormal inflammatory response	J:114972
	immune system phenotype	J:114972
	increased susceptibility to induced colitis	J:114972
	thymus hyperplasia	J:114972
Cyld^tm1Ref/Cyld^tm1Ref (Not Specified)	immune system phenotype	J:126113
Cyld^tm1Scs/Cyld^tm1Scs (involves: 129S1/Sv * 129X1/SvJ)	abnormal B cell differentiation	J:112392
	abnormal T cell number	J:112392
	decreased CD4-positive, alpha-beta T cell number	J:112392
	decreased CD8-positive, alpha-beta T cell number	J:112392
	increased double-positive T cell number	J:112392
Cyp1a1^tm1.1Dwn/Cyp1a1^tm1.1Dwn (B6.129P2-Cyp1a1^tm1.1Dwn)	decreased lymphocyte cell number	J:163973
	decreased spleen weight	J:163973
	decreased thymus weight	J:163973
	increased neutrophil cell number	J:163973
Cyp1a1^tm1.1Dwn/Cyp1a1^tm1.1Dwn (involves: 129P2/OlaHsd * C57BL/6)	decreased leukocyte cell number	J:122409
	small spleen	J:122409
	small thymus	J:122409
Cyp1a1^tm4.1Dwn/Cyp1a1^tm4.1Dwn (B6.129X1-Cyp1a1^tm4.1Dwn)	decreased lymphocyte cell number	J:163973
	decreased spleen weight	J:163973
	decreased thymus weight	J:163973
	increased neutrophil cell number	J:163973
Cyp1a^tm1Dwn/Cyp1a^tm1Dwn (B6.129-Cyp1a^tm1Dwn)	decreased leukocyte cell number	J:122409
	small spleen	J:122409
	small thymus	J:122409
Cyp2ab1^{tm1b(KOMP)Wtsi}/Cyp2ab1^{tm1b(KOMP)Wtsi} (C57BL/6N-Cyp2ab1^{tm1b(KOMP)Wtsi}/Bay)	abnormal spleen morphology	J:211773
Cyp2c70^em1Sjka/Cyp2c70^em1Sjka (C57BL/6-Cyp2c70^em1Sjka)	increased spleen weight	J:330641
Cyp2c70^em1Sjka/Cyp2c70^em1Sjka (C57BL/6-Cyp2c70^em1Sjka)	liver inflammation	J:330641
Cyp2c70^em1Utr/Cyp2c70^em1Utr (C57BL/6J-Cyp2c70^em1Utr)	liver inflammation	J:302190
Cyp2c^tm1104Arte/Cyp2c^tm1104Arte (B6NTac(Cg)-Cyp2c^tm1104Arte/Arte)	liver inflammation	J:241121
Cyp2c^{tm1897.1(Alb-CYP2C9)Arte}/Cyp2c^{tm1897.1(Alb-CYP2C9)Arte} (B6(Cg)-Cyp2c^{tm1897.1(Alb-CYP2C9)Arte}/Arte)	liver inflammation	J:241121
Cyp2d22^em1(IMPC)Tcp/Cyp2d22^em1(IMPC)Tcp (C57BL/6NCrl-Cyp2d22^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Cyp2f2^em1(IMPC)H/Cyp2f2^em1(IMPC)H (C57BL/6N-Cyp2f2^em1(IMPC)H/H)	enlarged spleen	J:211773
Cyp2g1^{tm1(rtTA)Lane}/Cyp2g1⁺ Tg(SFTPC-rtTA,tetO-Tnf)320-1Gwho/0 (involves: 129 * C57BL/6 * SJL)	increased macrophage cell number	J:157842
	rhinitis	J:157842
Cyp4v3^em1Xsu/Cyp4v3^em1Xsu (C57BL/6J-Cyp4v3^em1Xsu)	increased microglial cell activation	J:321817
Cyp7a1^{tm1b(EUCOMM)Wtsi}/Cyp7a1^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Cyp7a1^{tm1b(EUCOMM)Wtsi}/Ieg)	increased leukocyte cell number	J:211773
Cyp7b1^tm1Rus/Cyp7b1^tm1Rus (involves: 129S/SvEv * C57BL/6J)	decreased IgA level	J:170807
Cyp11a1^tm2Bcc/Cyp11a1^tm2Bcc (Not Specified)	decreased T cell apoptosis	J:133007
Cyp11b1^tm1Chjk/Cyp11b1^tm1Chjk (involves: 129P2/OlaHsd * C57BL/6J)	decreased thymus weight	J:147610
Cyp19a1^{tm1b(EUCOMM)Hmgu}/Cyp19a1^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Cyp19a1^{tm1b(EUCOMM)Hmgu}/H)	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Cyp19a1^tm1Esi/Cyp19a1^tm1Esi (involves: 129S6/SvEvTac * C57BL/6)	abnormal spleen germinal center morphology	J:92438
	enlarged mesenteric lymph nodes	J:92438
	enlarged spleen	J:92438
	increased autoantibody level	J:92438
	increased B cell number	J:92438
	increased granulocyte number	J:92438
	increased IgG level	J:92438
	increased leukocyte cell number	J:92438
	increased lymphocyte cell number	J:92438
	increased mature B cell number	J:92438
	kidney inflammation	J:92438
	salivary gland inflammation	J:92438
	spleen hyperplasia	J:92438
Cyp19a1^tm1Sih/Cyp19a1^tm1Sih (involves: 129S/SvEv)	increased anti-single stranded DNA antibody level	J:216958
	increased autoantibody level	J:216958
	increased dendritic cell number	J:216958
	increased macrophage cell number	J:216958
	increased susceptibility to autoimmune disorder	J:216958
	lacrimal gland inflammation	J:216958
	salivary gland inflammation	J:216958
Cyp19a1^tm1Toda/Cyp19a1^tm1Toda (involves: 129P2/OlaHsd * C57BL/6J)	increased osteoclast cell number	J:114305
Cyp21a1^em1(IMPC)Tcp/Cyp21a1⁺ (C57BL/6NCrl-Cyp21a1^em1(IMPC)Tcp/Tcp)	enlarged spleen	J:211773
Cyp26b1^tm1Hmd/Cyp26b1^tm1Hmd (involves: 129S1/Sv * 129X1/SvJ)	abnormal lymphatic vessel endothelial cell morphology	J:206581
Cyp26b1^tm1Hmd/Cyp26b1^tm1Hmd Tg(Prox1-EGFP)KY221Gsat/0 (involves: 129S1/Sv * 129X1/SvJ * FVB/NTac)	abnormal lymphatic vessel endothelial cell morphology	J:206581
	abnormal lymphatic vessel morphology	J:206581
Cyp27b1^{tm1b(EUCOMM)Hmgu}/Cyp27b1^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Cyp27b1^{tm1b(EUCOMM)Hmgu}/Tcp)	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
Cyp27b1^tm1Dgo/Cyp27b1^tm1Dgo (involves: 129S1/Sv * 129X1/SvJ * BALB/c)	decreased osteoclast cell number	J:70030
	decreased T cell number	J:70030
	enlarged lymph nodes	J:70030
Cyp51^tm1.1Bfro/Cyp51^tm1.1Bfro (involves: 129P2/OlaHsd * C57BL/6)	abnormal lymphatic vessel morphology	J:173366
	abnormal lymphatic vessel smooth muscle morphology	J:173366
Cypr1^STS/A/? (involves: BALB/c * STS/A)	abnormal cytokine secretion	J:52119
Cypr2^BALB/c/? (involves: BALB/c * STS/A)	abnormal cytokine secretion	J:52119
Cypr3^BALB/c/? (involves: BALB/c * STS/A)	abnormal cytokine secretion	J:52119
Cyren^em1Vokh/Cyren^em1Vokh (C57BL/6-Cyren^em1Vokh)	abnormal class switch recombination	J:306598
Cyren^{tm1.1(KOMP)Vlcg}/Cyren^{tm1.1(KOMP)Vlcg} (involves: C57BL/6NTac)	abnormal class switch recombination	J:265834
Cyrib^em1Erob/Cyrib^em1Erob (involves: C57BL/6J)	abnormal double-positive T cell morphology	J:361791
	abnormal intraepithelial T cell number	J:361791
	abnormal lymph node cell ratio	J:361791
	abnormal negative T cell selection	J:361791
	abnormal T cell clonal deletion	J:361791
	abnormal T cell differentiation	J:361791
	abnormal thymocyte activation	J:361791
	abnormal thymus cell ratio	J:361791
	decreased CD4-positive, alpha-beta T cell number	J:361791
	decreased CD8-positive, alpha-beta T cell number	J:361791
	decreased gamma-delta intraepithelial T cell number	J:361791
	decreased regulatory T cell number	J:361791
	decreased T cell number	J:361791
	decreased thymocyte number	J:361791
	increased T cell apoptosis	J:361791
	increased thymocyte apoptosis	J:361791
Cyrib^m1Ivdi/Cyrib^m1Ivdi (involves: 129S1/Sv * 129X1/SvJ * DBA/2J)	abnormal spleen morphology	J:282597
	abnormal spleen white pulp morphology	J:282597
	increased circulating interleukin-6 level	J:282597
	increased circulating interleukin-10 level	J:282597
	increased circulating tumor necrosis factor level	J:282597
	increased neutrophil cell number	J:282597
	increased susceptibility to bacterial infection induced morbidity/mortality	J:282597
Cyrib^{tm1c(KOMP)Wtsi}/Cyrib^{tm1d(KOMP)Wtsi} Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * 129S4/SvJaeSor * BcA17/Skmn * C57BL/6N)	abnormal circulating chemokine level	J:282597
	abnormal neutrophil physiology	J:282597
	increased circulating CXCL10 level	J:282597
	increased circulating interleukin-6 level	J:282597
	increased circulating interleukin-10 level	J:282597
	increased circulating tumor necrosis factor level	J:282597
	increased susceptibility to bacterial infection induced morbidity/mortality	J:282597
Cys1^cpk/Cys1^cpk (involves: C57BL/6J * CD-1)	spleen hypoplasia	J:33739
Cys1^cpk/Cys1^cpk (involves: C57BL/6J * CD-1)	thymus hypoplasia	J:33739
Cys1^cpk/Cys1^cpk (129.B6-Cys1^cpk)	liver inflammation	J:116210
Cysltr1^tm1Ykn/Cysltr1^tm1Ykn (involves: C57BL/6)	decreased susceptibility to type I hypersensitivity reaction	J:77087
Cysltr1^tm1Ykn/Cysltr1^tm1Ykn (involves: C57BL/6)	respiratory system inflammation	J:88647
Cysltr1^tm1Ykn/Cysltr1^tm1Ykn (C.B6-Cysltr1^tm1Ykn)	immune system phenotype	J:182213
Cysltr1^tm1Ykn/Cysltr1^tm1Ykn Cysltr2^tm1Ykn/Cysltr2^tm1Ykn (involves: BALB/c * C57BL/6)	abnormal immune system physiology	J:198383
Cysltr1^tm1Ykn/Cysltr1^tm1Ykn Cysltr2^tm1Ykn/Cysltr2^tm1Ykn Oxgr1^{tm1(KOMP)Vlcg}/Oxgr1^{tm1(KOMP)Vlcg} (involves: BALB/c * C57BL/6 * C57BL/6NTac)	abnormal immune system physiology	J:198383
Cysltr2^tm1Ykn/Cysltr2^tm1Ykn (C57BL/6-Cysltr2^tm1Ykn)	decreased susceptibility to type I hypersensitivity reaction	J:94488
Cysltr2^tm1Ykn/Cysltr2^tm1Ykn (C.B6-Cysltr2^tm1Ykn)	autoimmune response	J:182213
Cystm1^{tm1b(EUCOMM)Hmgu}/Cystm1^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Cystm1^{tm1b(EUCOMM)Hmgu}/Ieg)	increased leukocyte cell number	J:211773
Cyth2^{tm1d(EUCOMM)Wtsi}/Cyth2^{tm1d(EUCOMM)Wtsi} (involves: C57BL/6N)	decreased eosinophil cell number	J:307633
	decreased susceptibility to type I hypersensitivity reaction	J:307633
Cytip^tm1Tes/Cytip^tm1Tes (involves: 129S1/Sv * FVB/N)	abnormal CD8-positive, alpha-beta cytotoxic T cell morphology	J:110320
	abnormal cellular extravasation	J:110320
	abnormal leukocyte migration	J:110320
	decreased leukocyte cell number	J:110320
	decreased lymphocyte cell number	J:110320
	lymph node hypoplasia	J:110320
Cytip^tm1Wtw/Cytip^tm1Wtw (involves: 129S6/SvEvTac * C57BL/6)	abnormal response to transplant	J:112168
	immune system phenotype	J:112168
Cytl1^tm1Chun/Cytl1^tm1Chun (involves: 129S4/SvJae * C57BL/6)	increased susceptibility to induced arthritis	J:175377
D6Wsu163e^{tm1b(EUCOMM)Wtsi}/D6Wsu163e^{tm1b(EUCOMM)Wtsi} (C57BL/6N-D6Wsu163e^{tm1b(EUCOMM)Wtsi}/Wtsi)	decreased CD4-positive, alpha-beta T cell number	J:211773
	decreased memory-marker NK cell number	J:211773
	increased CD8-positive, alpha-beta T cell number	J:211773
	increased CD8-positive, naive alpha-beta T cell number	J:211773
D630045J12Rik^{tm1b(KOMP)Wtsi}/D630045J12Rik^{tm1b(KOMP)Wtsi} (C57BL/6N-D630045J12Rik^{tm1b(KOMP)Wtsi}/Tcp)	enlarged lymph nodes	J:211773
Daam2^{tm1b(KOMP)Wtsi}/Daam2^{tm1b(KOMP)Wtsi} (C57BL/6N-Daam2^{tm1b(KOMP)Wtsi}/Wtsi)	increased large unstained cell number	J:211773
Dab1^scm-4J/Dab1^scm-4J (CBA/J-Dab1^scm-4J/GrsrJ)	thymus atrophy	J:153275
Dach2^{em1(IMPC)Ccpcz}/Dach2^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Dach2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	increased eosinophil cell number	J:211773
	small lymph nodes	J:211773
	small spleen	J:211773
Dact2^{tm1b(EUCOMM)Wtsi}/Dact2^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Dact2^{tm1b(EUCOMM)Wtsi}/Bay)	abnormal spleen morphology	J:211773
Dad1^tm1Kni/Dad1⁺ (involves: 129S/SvEv)	decreased thymus weight	J:99897
Dagla^{tm1a(EUCOMM)Wtsi}/Dagla^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Dagla^{tm1a(EUCOMM)Wtsi}/Nju)	small spleen	J:211773
	small thymus	J:211773
Dapp1^{Gt(OST111213)Lex}/Dapp1^{Gt(OST111213)Lex} (B6.Cg-Dapp1^{Gt(OST111213)Lex})	abnormal humoral immune response	J:110009
	decreased B cell proliferation	J:110009
	decreased IgG3 level	J:110009
	increased susceptibility to bacterial infection	J:110009
Dapp1^tm1Mnz/Dapp1^tm1Mnz (B6.129P2-Dapp1^tm1Mnz)	abnormal B cell activation	J:86182
	decreased B cell proliferation	J:86182
	decreased B-1a cell number	J:86182
	decreased IgG3 level	J:86182
	decreased IgM level	J:86182
Daw1^b2b1116Clo/Daw1^b2b1116Clo (C57BL/6J-Daw1^b2b1116Clo)	spleen hypoplasia	J:175213
Daw1^b2b1584Clo/Daw1^b2b1584Clo (C57BL/6J-Daw1^b2b1584Clo)	absent spleen	J:175213
Dbacl^C57BL/6Jcl/Dbacl^C57BL/6Jcl (NOD.B6-(D4Mit193-D4Mit17))	increased susceptibility to autoimmune diabetes	J:144964
	insulitis	J:144964
Dbn1^{tm1a(KOMP)Wtsi}/Dbn1⁺ (C57BL/6N-Dbn1^{tm1a(KOMP)Wtsi}/Wtsi)	increased leukocyte cell number	J:211773
Dbn1^{tm1b(KOMP)Wtsi}/Dbn1⁺ (C57BL/6N-Dbn1^{tm1b(KOMP)Wtsi}/Wtsi)	increased CD8-positive, alpha-beta T cell number	J:211773
Dbnl^{Gt(betageo)11Byg}/Dbnl^{Gt(betageo)11Byg} (involves: 129P2/OlaHsd * C57BL/6)	abnormal T cell activation	J:119847
	abnormal T cell physiology	J:119847
	decreased IgG1 level	J:119847
	decreased IgM level	J:119847
	decreased immunoglobulin level	J:119847
	decreased interleukin-2 secretion	J:119847
	decreased T cell proliferation	J:119847
	immune system phenotype	J:119847
Dbnl^tm1Jwnd/Dbnl⁺ (involves: BALB/c)	increased spleen weight	J:109363
Dbnl^tm1Jwnd/Dbnl^tm1Jwnd (involves: BALB/c)	increased spleen weight	J:109363
Dbr1^{Gt(YTA280)Byg}/Dbr1⁺ (involves: 129P2/OlaHsd)	abnormal class switch recombination	J:223318
Dcaf5^{em1(IMPC)Ccpcz}/Dcaf5^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Dcaf5^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
	increased NK cell number	J:211773
	increased spleen weight	J:211773
	small spleen	J:211773
Dcaf8^{em1(IMPC)Ccpcz}/Dcaf8^{em1(IMPC)Ccpcz} (C57BL/6N-Dcaf8^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Dcaf12^{em1(IMPC)Ccpcz}/Dcaf12^{em1(IMPC)Ccpcz} (C57BL/6N-Dcaf12^{em1(IMPC)Ccpcz}/Ccpcz)	decreased CD8-positive, naive alpha-beta T cell number	J:211773
	increased effector memory T-helper cell number	J:211773
Dcaf15^{tm1a(EUCOMM)Hmgu}/Dcaf15^{tm1a(EUCOMM)Hmgu} (C57BL/6NCrl-Dcaf15^{tm1a(EUCOMM)Hmgu}/Ccpcz)	abnormal thymus morphology	J:211773
	decreased effector memory CD8-positive, alpha-beta T cell number	J:211773
	decreased effector memory T-helper cell number	J:211773
	decreased spleen weight	J:211773
	enlarged thymus	J:211773
	increased CD4-positive, alpha-beta T cell number	J:211773
	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	increased CD8-positive, alpha-beta T cell number	J:211773
	increased CD8-positive, naive alpha-beta T cell number	J:211773
	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
	increased NK cell number	J:211773
	increased T cell number	J:211773
	increased T-helper cell number	J:211773
Dcbld2^{tm1a(KOMP)Wtsi}/Dcbld2^{tm1a(KOMP)Wtsi} (C57BL/6N-Dcbld2^{tm1a(KOMP)Wtsi}/Wtsi)	increased anti-nuclear antigen antibody level	J:211773
Dcc^{Tg(H2-Kb-Jak2V617F)1Shmd}/Dcc⁺ (involves: C57BL/6 DBA/2)	abnormal neutrophil morphology	J:130189
	abnormal spleen morphology	J:130189
	decreased spleen white pulp amount	J:130189
	enlarged spleen	J:130189
	increased granulocyte number	J:130189
	increased leukocyte cell number	J:130189
	increased spleen red pulp amount	J:130189
	increased spleen weight	J:130189
	myeloid hyperplasia	J:130189
Dcc^{tm1b(NCOM)Mfgc}/Dcc⁺ (C57BL/6N-Dcc^{tm1b(NCOM)Mfgc}/Tcp)	increased neutrophil cell number	J:211773
Dck^m1Btlr/Dck⁺ (C57BL/6J-Dck^m1Btlr)	decreased B cell number	J:236696
Dck^m1Btlr/Dck^m1Btlr (C57BL/6J-Dck^m1Btlr)	decreased B cell number	J:236696
	decreased CD4-positive, alpha-beta T cell number	J:236696
	decreased IgG level	J:236696
	decreased response to antigen	J:236696
	increased CD8-positive, alpha-beta T cell number	J:236696
	increased IgE level	J:236696
	increased macrophage cell number	J:236696
Dck^memi/Dck^memi (C57BL/6J-Dck^memi)	abnormal myeloid leukocyte morphology	J:184080
	abnormal response to infection	J:184080
	abnormal T cell differentiation	J:184080
	decreased B cell number	J:184080
	decreased CD4-positive, alpha-beta T cell number	J:184080
	enlarged spleen	J:184080
	increased effector memory CD4-positive, alpha-beta T cell number	J:184080
	increased effector memory CD8-positive, alpha-beta T cell number	J:184080
	increased T cell apoptosis	J:184080
	increased T cell proliferation	J:184080
	small thymus	J:184080
	thymus hypoplasia	J:184080
Dck^tm1.1Radu/Dck^tm1.1Radu (involves: 129S4/SvJae * BALB/cJ * C57BL/6 * C57BL/6J)	abnormal double-negative T cell morphology	J:158373
	abnormal peripheral lymph node morphology	J:158373
	abnormal spleen morphology	J:158373
	abnormal T cell differentiation	J:158373
	abnormal thymus morphology	J:158373
	absent spleen white pulp	J:158373
	decreased B cell number	J:158373
	decreased double-positive T cell number	J:158373
	decreased pre-B cell number	J:158373
	decreased T cell number	J:158373
	increased double-negative T cell number	J:158373
	increased pro-B cell number	J:158373
	increased spleen weight	J:158373
	thymus hypoplasia	J:158373
Dclk1^{tm1a(EUCOMM)Wtsi}/Dclk1⁺ (C57BL/6N-Dclk1^{tm1a(EUCOMM)Wtsi}/Wtsi)	increased anti-nuclear antigen antibody level	J:211773
Dclk1^{tm1a(EUCOMM)Wtsi}/Dclk1^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Dclk1^{tm1a(EUCOMM)Wtsi}/Wtsi)	increased anti-nuclear antigen antibody level	J:211773
Dclre1a^tm1Rleg/Dclre1a^tm1Rleg (involves: 129S7/SvEvBrd)	immune system phenotype	J:102381
Dclre1a^tm1Rleg/Dclre1a^tm1Rleg (involves: 129S7/SvEvBrd)	increased susceptibility to bacterial infection	J:102381
Dclre1a^tm1Rleg/Dclre1a^tm1Rleg Trp53^tm1Tyj/Trp53^tm1Tyj (involves: 129S2/SvPas * 129S7/SvEvBrd)	increased T cell derived lymphoma incidence	J:102381
Dclre1c^m1Brck/Dclre1c^m1Brck (involves: C3H * C57BL/6)	absent B cells	J:207533
Dclre1c^m1Brck/Dclre1c^m1Brck (involves: C3H * C57BL/6)	absent T cells	J:207533
Dclre1c^m1Brck/Dclre1c^m1Brck (involves: C57BL/6)	absent B cells	J:207533
	absent CD4-positive, alpha-beta T cells	J:207533
	absent CD8-positive, alpha-beta T cells	J:207533
	decreased DN1 thymic pro-T cell number	J:207533
	decreased DN4 thymocyte number	J:207533
	decreased double-positive T cell number	J:207533
	decreased pre-B cell number	J:207533
	immune system phenotype	J:207533
Dclre1c^m1Btlr/Dclre1c^m1Btlr (C57BL/6J-Dclre1c^m1Btlr)	decreased B cell number	J:217790
	decreased IgM level	J:217790
	decreased response to antigen	J:217790
	decreased single-positive T cell number	J:217790
	decreased T cell number	J:217790
	impaired humoral immune response	J:217790
	increased macrophage cell number	J:217790
	increased neutrophil cell number	J:217790
	increased NK cell number	J:217790
Dclre1c^M2Btlr/Dclre1c^M2Btlr (C57BL/6J-Dclre1c^M2Btlr)	decreased CD4-positive, alpha-beta T cell number	J:265131
	decreased CD8-positive, naive alpha-beta T cell number	J:265131
	decreased single-positive T cell number	J:265131
	decreased T cell number	J:265131
	increased central memory CD8 positive, alpha-beta T cell number	J:265131
	increased effector memory CD4-positive, alpha-beta T cell number	J:265131
	increased effector memory CD8-positive, alpha-beta T cell number	J:265131
Dclre1c^m3Btlr/Dclre1c^m3Btlr (C57BL/6J-Dclre1c^m3Btlr)	decreased B cell number	J:265132
	decreased B-1 B cell number	J:265132
	decreased CD4-positive, alpha-beta T cell number	J:265132
	decreased CD8-positive, alpha-beta T cell number	J:265132
	decreased CD8-positive, naive alpha-beta T cell number	J:265132
	decreased NK T cell number	J:265132
	decreased single-positive T cell number	J:265132
	decreased T cell number	J:265132
	increased central memory CD4-positive, alpha-beta T cell number	J:265132
	increased effector memory CD4-positive, alpha-beta T cell number	J:265132
	increased effector memory CD8-positive, alpha-beta T cell number	J:265132
Dclre1c^tm1.1Fwa/Dclre1c^tm1.1Fwa (involves: 129S6/SvEvTac * C57BL/6)	arrested B cell differentiation	J:80995
	arrested T cell differentiation	J:80995
Dclre1c^tm1.1Jpdv/Dclre1c^tm1.1Jpdv (involves: 129P1/ReJ)	abnormal B cell differentiation	J:137743
	abnormal T cell receptor V(D)J recombination	J:194422
	arrested T cell differentiation	J:137712
Dclre1c^tm1Fwa/Dclre1c^tm1Fwa (involves: 129S6/SvEvTac * C57BL/6)	absent immature B cells	J:80995
	arrested B cell differentiation	J:80995
	arrested T cell differentiation	J:80995
	decreased thymocyte number	J:80995
Dclre1c^tm1Fwa/Dclre1c^tm1Fwa (involves: 129S6/SvEvTac)	abnormal T cell receptor beta chain V(D)J recombination	J:147864
	absent B cells	J:147864
	arrested B cell differentiation	J:147864
	decreased CD4-positive, alpha-beta T cell number	J:147864
	decreased CD8-positive, alpha-beta T cell number	J:147864
	decreased double-positive T cell number	J:147864
	decreased thymocyte number	J:147864
	spleen hypoplasia	J:147864
Dclre1c^tm1Jsek/Dclre1c^tm1Jsek (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal immunoglobulin heavy chain V(D)J recombination	J:147864
	abnormal T cell receptor beta chain V(D)J recombination	J:147864
	decreased B cell number	J:147864
	decreased CD4-positive, alpha-beta T cell number	J:147864
	decreased CD8-positive, alpha-beta T cell number	J:147864
	decreased double-positive T cell number	J:147864
	decreased pre-B cell number	J:147864
	decreased thymocyte number	J:147864
	increased pro-B cell number	J:147864
	spleen hypoplasia	J:147864
Dclre1c^tm2.1Jpdv/Dclre1c^tm2.2Jpdv Tg(Cr2-cre)3Cgn/0 (involves: 129S2/SvPas * C57BL/6)	abnormal class switch recombination	J:153841
	immune system phenotype	J:153841
Dclre1c^tm2.2Jpdv/Dclre1c^tm2.2Jpdv (B6.129S2-Dclre1c^tm2.2Jpdv)	abnormal mononuclear cell morphology	J:153841
	absent immature B cells	J:153841
	arrested B cell differentiation	J:153841
	arrested T cell differentiation	J:153841
	decreased CD4-positive, alpha-beta T cell number	J:153841
	decreased CD8-positive, alpha-beta T cell number	J:153841
	decreased double-positive T cell number	J:153841
	decreased mature B cell number	J:153841
	decreased splenocyte number	J:153841
	decreased thymocyte number	J:153841
Dclre1c^tm2Mcow/Dclre1c^tm2Mcow (involves: 129/Sv * C57BL/6)	abnormal leukocyte physiology	J:96535
	abnormal lymph node morphology	J:96535
	abnormal spleen B cell follicle morphology	J:96535
	absent thymus cortex	J:96535
	arrested B cell differentiation	J:96535
	arrested T cell differentiation	J:96535
	decreased B cell proliferation	J:96535
	decreased lymphocyte cell number	J:96535
	decreased T cell proliferation	J:96535
	decreased thymocyte number	J:96535
	decreased thymus weight	J:96535
	small lymph nodes	J:96535
	small spleen	J:96535
Dcn^tm1Ioz/Dcn⁺ (either: C.Cg-Dcn^tm1Ioz or C3.Cg-Dcn^tm1Ioz)	decreased susceptibility to bacterial infection	J:68640
Dcn^tm1Ioz/Dcn⁺ Trp53^tm1Brd/Trp53^tm1Brd (involves: 129/Sv * Black Swiss * C57BL/6)	increased T cell derived lymphoma incidence	J:53511
Dcn^tm1Ioz/Dcn^tm1Ioz (involves: 129S1/Sv * 129X1/SvJ * Black Swiss)	immune system phenotype	J:39212
	tubular nephritis	J:75298
Dcn^tm1Ioz/Dcn^tm1Ioz (either: C.Cg-Dcn^tm1Ioz or C3.Cg-Dcn^tm1Ioz)	decreased susceptibility to bacterial infection	J:68640
Dcn^tm1Ioz/Dcn^tm1Ioz (C.129(Cg)-Dcn^tm1Ioz)	abnormal humoral immune response	J:92428
Dcn^tm1Ioz/Dcn^tm1Ioz Trp53^tm1Brd/Trp53^tm1Brd (involves: 129/Sv * Black Swiss * C57BL/6)	enlarged thymus	J:53511
	increased T cell derived lymphoma incidence	J:53511
	thymus hyperplasia	J:53511
Dcstamp^tm1Suda/Dcstamp^tm1Suda (Not Specified)	abnormal macrophage physiology	J:100555
	abnormal osteoclast differentiation	J:100555
	abnormal osteoclast physiology	J:100555
Dctn1^tm2.1Cai/Dctn1^tm2.1Cai Tg(Thy1-cre)1Vln/? (involves: 129S4/SvJaeSor * 129X1/SvJ * C57BL/6 * FVB/N)	microgliosis	J:264431
Dcun1d1^{Gt(RRR261)Byg}/Dcun1d1^{Gt(RRR261)Byg} (involves: 129P2/OlaHsd)	lymphoid hypoplasia	J:262901
	spleen hypoplasia	J:262901
Ddb1^{em1(IMPC)Ccpcz}/Ddb1⁺ (C57BL/6N-Ddb1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Ddc^tm1.1Rhrs/Ddc^tm1.1Rhrs Tg(Ggt1-cre)M3Egn/0 (involves: 129 * C57BL/6 * SJL)	tubulointerstitial nephritis	J:175630
Ddc^tm1.1Rhrs/Ddc^tm1.1Rhrs Tg(Ggt1-cre)M3Egn/0 (129.Cg-Ddc^tm1.1Rhrs Tg(Ggt1-cre)M3Egn)	tubulointerstitial nephritis	J:175630
Ddit3^tm1Dron/Ddit3^tm1Dron (involves: 129S1/Sv * 129X1/SvJ * FVB/N)	decreased susceptibility to Retroviridae infection	J:112354
Ddit3^tm1Dron/Ddit3^tm1Dron (B6.129-Ddit3^tm1Dron)	abnormal macrophage activation involved in immune response	J:153833
Ddit3^tm1Dron/Ddit3^tm1Dron (B6.129-Ddit3^tm1Dron)	decreased macrophage apoptosis	J:153833
Ddit3^tm1Dron/Ddit3^tm1Dron Tg(Col2a1-rtTA,tetO-COMP)2Jath/0 (involves: 129X1/SvJ 129S1/Sv * C57BL/6)	decreased inflammatory response	J:233238
Ddit3^tm2.1Dron/Ddit3^tm2.1Dron (B6.129S(Cg)-Ddit3^tm2.1Dron/J)	abnormal T cell morphology	J:214136
	white adipose tissue inflammation	J:214136
Ddost^{tm1.1(KOMP)Vlcg}/Ddost⁺ (C57BL/6N-Ddost^{tm1.1(KOMP)Vlcg}/Ucd)	enlarged lymph nodes	J:211773
	small spleen	J:211773
Ddr1^tm1Wfv/Ddr1^tm1Wfv Ldlr^tm1Her/Ldlr^tm1Her (involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ)	decreased macrophage cell number	J:149015
Ddrgk1^{tm1c(EUCOMM)Hmgu}/Ddrgk1^{tm1c(EUCOMM)Hmgu} Gt(ROSA)26Sor^{tm1(cre/ERT2)Tyj}/Gt(ROSA)26Sor⁺ (involves: 129S4/SvJae * C3H * C57BL/6 * C57BL/6N)	decreased granulocyte number	J:231701
	decreased lymphocyte cell number	J:231701
	decreased monocyte cell number	J:231701
Ddx19b^em1Chaw/Ddx19b⁺ (C57BL/6-Ddx19b^em1Chaw)	increased interferon-alpha secretion	J:289833
Ddx19b^em1Chaw/Ddx19b⁺ (C57BL/6-Ddx19b^em1Chaw)	increased interferon-beta secretion	J:289833
Ddx23^{em1(IMPC)Wtsi}/Ddx23⁺ (C57BL/6N-Ddx23^{em1(IMPC)Wtsi}/Wtsi)	increased leukocyte cell number	J:211773
Ddx41^tm1.1Arte/Ddx41^tm1.1Arte Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6N)	immune system phenotype	J:265023
	increased susceptibility to Retroviridae infection	J:265023
Ddx41^tm1.1Arte/Ddx41^tm1.1Arte Tg(Itgax-cre)1-1Reiz/0 (involves: C57BL/6 * C57BL/6N * CBA)	immune system phenotype	J:265023
	increased susceptibility to Retroviridae infection	J:265023
Ddx46^em1(IMPC)Tcp/Ddx46⁺ (C57BL/6N-Ddx46^em1(IMPC)Tcp/Cmmr)	enlarged lymph nodes	J:211773
Ddx46^em1Caox/Ddx46⁺ (involves: C57BL/6J)	abnormal innate immunity	J:271836
	abnormal macrophage physiology	J:271836
	decreased susceptibility to Riboviria infection	J:271836
	increased circulating interferon-beta level	J:271836
	increased interferon-beta secretion	J:271836
	increased interleukin-1 beta secretion	J:271836
	increased interleukin-6 secretion	J:271836
	increased macrophage cytokine production	J:271836
	increased tumor necrosis factor secretion	J:271836
Ddx52^{tm1a(EUCOMM)Wtsi}/Ddx52⁺ (C57BL/6N-Ddx52^{tm1a(EUCOMM)Wtsi}/Ics)	decreased NK cell number	J:165965
Ddx60^{tm1b(EUCOMM)Wtsi}/Ddx60^{tm1b(EUCOMM)Wtsi} (involves: C57BL/6N)	decreased circulating interferon-beta level	J:228452
	increased circulating interferon-alpha level	J:228452
	increased susceptibility to Riboviria infection	J:228452
	increased susceptibility to Riboviria infection induced morbidity/mortality	J:228452
Ddx60^{tm1b(EUCOMM)Wtsi}/Ddx60^{tm1b(EUCOMM)Wtsi} Mavs^tm1Tsse/Mavs^tm1Tsse (involves: 129 * C57BL/6N)	increased susceptibility to Riboviria infection induced morbidity/mortality	J:228452
Dedd^tm1Tmiy/Dedd^tm1Tmiy (B6.Cg-Dedd^tm1Tmiy)	decreased spleen weight	J:119734
Def6^{Gt(OST307148)Lex}/Def6^{Gt(OST307148)Lex} (involves: 129S5/SvEvBrd * C57BL/6)	abnormal cytokine secretion	J:106469
	abnormal spleen germinal center morphology	J:106469
	decreased T cell apoptosis	J:106469
	enlarged lymph nodes	J:106469
	enlarged spleen	J:106469
	increased anti-nuclear antigen antibody level	J:106469
	increased IgG level	J:106469
	increased immature B cell number	J:106469
	increased immunoglobulin level	J:106469
	increased memory T cell number	J:106469
	increased T cell number	J:106469
Defb1^tm1Hgu/Defb1^tm1Hgu (involves: 129P2/OlaHsd * C57BL/6N)	immune system phenotype	J:76528
Defb1^tm1Jmw/Defb1⁺ (B6.129S5-Defb1^tm1Jmw)	increased susceptibility to bacterial infection	J:76529
Defb1^tm1Jmw/Defb1^tm1Jmw (B6.129S5-Defb1^tm1Jmw)	increased susceptibility to bacterial infection	J:76529
Defb3^tm1Lex/Defb3^tm1Lex (B6;129S5-Defb3^tm1Lex/Mmucd)	increased susceptibility to bacterial infection	J:168725
Defb3^tm1Xen/Defb3^tm1Xen (involves: C57BL/6)	increased incidence of corneal inflammation	J:199719
	increased neutrophil cell number	J:199719
	increased susceptibility to fungal infection	J:199719
Defb14^tm1Wme/Defb14^tm1Wme (B6.129P2-Defb14^tm1Wme)	immune system phenotype	J:180788
Del(1)1Brk/Del(1)1Brk (involves: 129S6/SvEvTac * C57BL/6J * CBA/J)	abnormal spleen morphology	J:100202
	abnormal spleen white pulp morphology	J:100202
	enlarged spleen	J:100202
	increased leukocyte cell number	J:100202
	increased spleen red pulp amount	J:100202
Del(1Aim2-Ifi205)1Stsn/+ Trex1^tm1Tld/Trex1^tm1Tld (involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6N)	heart inflammation	J:234263
	increased autoantibody level	J:234263
	increased inflammatory response	J:234263
	kidney inflammation	J:234263
	myositis	J:234263
	stomach inflammation	J:234263
Del(1Aim2-Ifi205)1Stsn/Del(1Aim2-Ifi205)1Stsn (B6(129S4)-Del(1Aim2-Ifi205)1Stsn)	abnormal interferon secretion	J:234263
	decreased interleukin-1 beta secretion	J:234263
	decreased macrophage apoptosis	J:234263
Del(1Aim2-Ifi205)1Stsn/Del(1Aim2-Ifi205)1Stsn (involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6N)	stomach inflammation	J:234263
Del(1Aim2-Ifi205)1Stsn/Del(1Aim2-Ifi205)1Stsn Trex1^tm1Tld/Trex1^tm1Tld (involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6N)	heart inflammation	J:234263
	increased autoantibody level	J:234263
	increased inflammatory response	J:234263
	kidney inflammation	J:234263
	myositis	J:234263
	stomach inflammation	J:234263
Del(2Duoxa2-Duoxa1)1Sref/Del(2Duoxa2-Duoxa1)1Sref (involves: 129S6/SvEvTac * C57BL/6J)	decreased spleen weight	J:205165
Del(3Bglap2-Bglap)2Kry/Del(3Bglap2-Bglap)2Kry (involves: 129S7/SvEvBrd * C57BL/6)	increased osteoclast cell number	J:34440
Del(3Cd1d2-Cd1d1)1Crw/Del(3Cd1d2-Cd1d1)1Crw (involves: 129S4/SvJae * C57BL/6)	abnormal antigen presentation	J:174337
	abnormal NK T cell physiology	J:112657
	decreased CD4-positive, alpha-beta T cell number	J:174337
	decreased interleukin-4 secretion	J:39749
	decreased NK T cell number	J:112657, J:174337, J:39749, J:76976
Del(3Cd1d2-Cd1d1)1Crw/Del(3Cd1d2-Cd1d1)1Crw Tcra^Ln1Ogu/Tcra⁺ (involves: 129/Sv * C57BL/6)	abnormal NK T cell morphology	J:152041
Del(3Cd1d2-Cd1d1)1Crw/Del(3Cd1d2-Cd1d1)1Crw Tg(TcraAV19AJ33)1Shima/0 (involves: 129S4/SvJae * C57BL/6)	abnormal NK T cell morphology	J:112657
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:112657
	increased interleukin-10 secretion	J:112657
Del(3Cd1d2-Cd1d1)1Sbp/Del(3Cd1d2-Cd1d1)1Sbp (either: B6NTac.129S6-Del(3Cd1d2-Cd1d1)1Sbp or (involves: 129S6/SvEvTac * C57BL/6NTac))	abnormal immune tolerance	J:58315
Del(3Cd1d2-Cd1d1)1Sbp/Del(3Cd1d2-Cd1d1)1Sbp (involves: 129S6/SvEvTac)	abnormal dendritic cell antigen presentation	J:151699
	decreased NK T cell number	J:151699
Del(3Gbp2-ps-Gbp5)1Ktak/Del(3Gbp2-ps-Gbp5)1Ktak (involves: C57BL/6)	immune system phenotype	J:187397
	increased susceptibility to parasitic infection	J:187397
	increased susceptibility to parasitic infection induced morbidity/mortality	J:187397
Del(4C4-C5)1Lap/+ (involves: 129S6/SvEvTac)	enlarged spleen	J:158126
Del(4C4-C5)1Lap/Del(4C4-C5)1Lap (involves: 129S6/SvEvTac)	enlarged spleen	J:158126
Del(4D4Mit190-D4Mit51)2Aam/+ (involves: 129S7/SvEvBrd)	spleen hyperplasia	J:121726
Del(6Ephb6-Trpv6)1Mhed/+ (involves: 129S/SvEv)	dermatitis	J:133151
Del(6Ephb6-Trpv6)1Mhed/Del(6Ephb6-Trpv6)1Mhed (involves: 129S/SvEv)	dermatitis	J:133151
Del(6Gimap5-Gimap3)1Yout/Del(6Gimap5-Gimap3)1Yout (involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj)	abnormal T cell physiology	J:209926
	decreased B cell number	J:209926
	decreased NK cell number	J:209926
	decreased T cell number	J:209926
Del(6Snca)1Slab/Del(6Snca)1Slab Tg(Th-SNCA)1Mgsp/0 (involves: C57BL/6J C57BL/6JOlaHsd * CBA/Ca)	abnormal microglial cell morphology	J:108310
	brain inflammation	J:108310
Del(7)Tyr^c-3H/Del(7)Tyr^c-3H (involves: 101/H * C3H/HeH)	abnormal thymus morphology	J:5063
Del(7Ifitm5-Ifitm6)1Masu/+ (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:137940
Del(7Mrgpra2a-Mrgpra2b)1Xzd/Del(7Mrgpra2a-Mrgpra2b)1Xzd (C57BL/6J-Del(7Mrgpra2a-Mrgpra2b)1Xzd)	abnormal neutrophil physiology	J:332494
	decreased interleukin-1 beta secretion	J:332494
	increased susceptibility to bacterial infection	J:332494
Del(7Pira1-Lilra6)1Fgla/Del(7Pira1-Lilra6)1Fgla (involves: C57BL/6)	decreased susceptibility to graft versus host disease	J:290663
Del(7Pira1-Lilra6)1Fgla/Del(7Pira1-Lilra6)1Fgla Il2rg^tm1Wjl/Il2rg^tm1Wjl Rag2^tm1Fwa/Rag2^tm1Fwa (involves: C57BL/6J * C57BL/6NTac)	abnormal response to transplant	J:290663
Del(8A4-B3)7H/+ (involves: 101/H * C3H/HeH)	abnormal lymphatic vessel morphology	J:123074
Del(8Ddx19a-Ddx19b)1Chaw/+ (C57BL/6-Del(8Ddx19a-Ddx19b)1Chaw)	decreased susceptibility to Picornaviridae infection	J:289833
	decreased susceptibility to Picornaviridae infection induced morbidity/mortality	J:289833
	increased interferon-alpha secretion	J:289833
	increased interferon-beta secretion	J:289833
Del(8Ddx19a-Ddx19b)2Chaw/+ (C57BL/6-Del(8Ddx19a-Ddx19b)2Chaw)	increased interferon-alpha secretion	J:289833
	increased interferon-beta secretion	J:289833
Del(8Defa1-Def)2Xzd/Del(8Defa1-Def)2Xzd Tg(KRT14-cre)1Amc/0 (involves: C57BL/6J * CBA)	increased susceptibility to bacterial infection	J:332494
Del(8Defb1-Defb13)1Jrdo/Del(8Defb1-Defb13)1Jrdo (involves: 129P2/OlaHsd * C57BL/6N)	immune system phenotype	J:204187
Del(9Apoa1-Apoa4)1Hmez/Del(9Apoa1-Apoa4)1Hmez (involves: 129P2/OlaHsd * C57BL/6)	increased macrophage derived foam cell number	J:109005
Del(9Casp1-Casp4)1Bhk/Del(9Casp1-Casp4)1Bhk (129-Del(9Casp1-Casp4)1Bhk)	abnormal macrophage physiology	J:189777
	decreased interleukin-1 alpha secretion	J:189777
	decreased interleukin-1 beta secretion	J:189777
Del(9Cd3g-Cd3d)1Cpt/Del(9Cd3g-Cd3d)1Cpt (involves: 129S4/SvJae * C57BL/6)	absent gamma-delta T cells	J:76991
	arrested T cell differentiation	J:76991
	decreased alpha-beta T cell number	J:76991
	thymus hypoplasia	J:76991
Del(9Hspb2-Cryab)1Wawr/Del(9Hspb2-Cryab)1Wawr (involves: 129S4/SvJae)	osteoarthritis	J:72926
Del(10Prmt2-Col6a1)1Yah/+ (involves: 129P2/OlaHsd * C57BL/6 * SJL)	abnormal cytokine level	J:167506
	abnormal macrophage physiology	J:167506
	lung inflammation	J:167506
	respiratory system inflammation	J:167506
Del(10Prtn3-Elane)1Deje/Del(10Prtn3-Elane)1Deje (involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ)	abnormal neutrophil physiology	J:137674
	immune system phenotype	J:137674
	impaired neutrophil recruitment	J:137674
Del(11Cxcl16-Zmynd15)1Ifc/Del(11Cxcl16-Zmynd15)1Ifc (B6.129S-Ldlr^tm1Her Del(11Cxcl16-Zmynd15)1Ifc)	abnormal macrophage physiology	J:123851
Del(11Hoxb3-Hoxb4)1Karl/Del(11Hoxb3-Hoxb4)1Karl (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	abnormal spleen morphology	J:83563
	decreased spleen weight	J:83563
	spleen hypoplasia	J:83563
Del(11Hoxb3-Hoxb4)1Karl/Del(11Hoxb3-Hoxb4)1Karl Hoxa9^tm1Mrc/Hoxa9^tm1Mrc (involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ * C57BL/6)	decreased spleen weight	J:126371
	spleen hypoplasia	J:126371
Del(11Jmjd6-Mettl23)1Ysfk/Del(11Jmjd6-Mettl23)1Ysfk (involves: C57BL/6)	abnormal thymus development	J:90288
	impaired macrophage chemotaxis	J:90288
	impaired macrophage phagocytosis	J:90288
	thymus hypoplasia	J:90288
Del(11Nlrp1a-Nlrp1c-ps)1Smas/Del(11Nlrp1a-Nlrp1c-ps)1Smas (Not Specified)	decreased neutrophil cell number	J:191055
	increased susceptibility to Riboviria infection	J:191055
Del(11Stat5a-Stat5b)1Mam/Del(11Stat5a-Stat5b)1Mam (involves: 129 * 129S6/SvEvTac * C57BL/6)	absent gamma-delta T cells	J:122463
	arrested B cell differentiation	J:122463
	decreased B cell number	J:122463
	decreased CD8-positive, alpha-beta T cell number	J:122463
	small lymph nodes	J:122463
	small spleen	J:122463
	small thymus	J:122463
Del(13Naip1-Naip5)1Vnce/Del(13Naip1-Naip5)1Vnce (involves: C57BL/6)	decreased inflammatory response	J:294930
Del(13Naip1-Naip5)1Vnce/Del(13Naip1-Naip5)1Vnce Nlrc4^em2Vnce/Nlrc4^em2Vnce (involves: C57BL/6)	decreased inflammatory response	J:294930
Del(13Naip1-Naip5)1Vnce/Del(13Naip1-Naip5)1Vnce Nlrp3^tm1Vmd/Nlrp3^tm1Vmd (involves: C57BL/6J * C57BL/6N)	decreased inflammatory response	J:294930
Del(14Ltb4r2-Ltb4r1)1Bodd/+ (involves: 129S4/SvJaeSor * C57BL/6)	decreased susceptibility to induced arthritis	J:131779
Del(14Ltb4r2-Ltb4r1)1Bodd/Del(14Ltb4r2-Ltb4r1)1Bodd (involves: 129S4/SvJaeSor * C57BL/6)	decreased pannus formation	J:163271
	decreased susceptibility to induced arthritis	J:131779
	immune system phenotype	J:131779
	impaired neutrophil chemotaxis	J:163271
Del(14Trim13-Dleu2)4Rdf/Del(14Trim13-Dleu2)4Rdf (involves: 129S1/Sv * 129S4/SvJaeSor * C57BL/6)	abnormal B cell proliferation	J:156946
	increased B cell number	J:156946
	increased B-1a cell number	J:156946
	increased spleen white pulp amount	J:156946
Del(14Trim13-Rnaseh2b)6Rdf/+ Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6)	abnormal lymphopoiesis	J:179879
	increased B cell number	J:179879
Del(15Rr357-Rr303293)2Jta/Del(15Rr357-Rr303293)2Jta (involves: C57BL/6)	immune system phenotype	J:257088
Del(15Rr316124-Rr313939)2Fsp/+ Myc^tm1Atp/Myc⁺ (involves: 129P2/OlaHsd * C57BL/6)	decreased B cell number	J:257739
	decreased granulocyte number	J:257739
Del(15Rr316124-Rr313939)2Fsp/+ Rr331^em1Fsp/Rr331⁺ (involves: C57BL/6)	decreased B cell number	J:257739
	increased pre-B cell number	J:257739
Del(15Rr316124-Rr313939)2Fsp/+ Rr307328^em1Fsp/Rr307328⁺ (involves: C57BL/6)	decreased B cell number	J:257739
	increased pre-B cell number	J:257739
Del(15Rr316124-Rr313939)2Fsp/Del(15Rr316124-Rr313939)2Fsp (Not Specified)	decreased B cell number	J:257739
	decreased granulocyte number	J:257739
Del(16Dgcr2-Hira)1Rak/+ (involves: 129/Sv * 129S6/SvEvTac * C57BL/6 * FVB/N * SJL)	immune system phenotype	J:67796
Del(16Es2el-Ufd1l)217Bld/+ (involves: 129S7/SvEvBrd * C57BL/6)	immune system phenotype	J:57757
Del(16Pi4ka-Hira)1Atai/+ (C57BL/6N-Del(16Pi4ka-Hira)1Atai)	thymus hypoplasia	J:285407
Del(17Btnl1-Btnl6)1Ahay/Del(17Btnl1-Btnl6)1Ahay (involves: BALB/c * C57BL/6J)	decreased CD4-positive, gamma-delta intraepithelial T cell number	J:291989
Del(17Trem1-Trem3)1Jkt/Del(17Trem1-Trem3)1Jkt (involves: 129P2/OlaHsd * BALB/cJ * C57BL/6)	abnormal chemokine level	J:194295
	abnormal circulating chemokine level	J:194295
	abnormal cytokine level	J:194295
	abnormal cytokine secretion	J:194295
	impaired neutrophil chemotaxis	J:194295
	increased circulating interleukin-1 alpha level	J:194295
	increased circulating interleukin-6 level	J:194295
	increased circulating interleukin-10 level	J:194295
	increased circulating tumor necrosis factor level	J:194295
	increased interleukin-1 alpha secretion	J:194295
	increased interleukin-1 beta secretion	J:194295
	increased interleukin-6 secretion	J:194295
	increased interleukin-10 secretion	J:194295
	increased interleukin-17 secretion	J:194295
	increased susceptibility to bacterial infection	J:194295
	increased susceptibility to bacterial infection induced morbidity/mortality	J:194295
Del(18Pcdhg)1Xzw/Del(18Pcdhg)1Xzw (Not Specified)	microgliosis	J:188341
Del(19Poll-Dcpd)1Nmt/Del(19Poll-Dcpd)1Nmt (involves: 129P2/OlaHsd)	sinus inflammation	J:75779
Dennd1b^tm1.1Achn/Dennd1b^tm1.1Achn Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	lymph node hyperplasia	J:229307
Dennd1b^tm1.2Achn/Dennd1b^tm1.2Achn (involves: C57BL/6)	abnormal interleukin secretion	J:229307
	abnormal T cell number	J:229307
	abnormal T-helper 2 physiology	J:229307
	immune system phenotype	J:229307
	lymph node hyperplasia	J:229307
Dennd5b^em1(IMPC)Tcp/Dennd5b^em1(IMPC)Tcp (C57BL/6N-Dennd5b^em1(IMPC)Tcp/Tcp)	abnormal spleen morphology	J:211773
	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
Dennd5b^m1Anu/Dennd5b^m1Anu (C57BL/6NCrl-Dennd5b^m1Anu/Anu)	immune system phenotype	J:104190
Dennd10^{em1(IMPC)Ccpcz}/Dennd10^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Dennd10^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Derm1^NC/Nga/Derm1^NC/Nga (involves: MSM/Ms * NC/Nga)	dermatitis	J:68698
Derms^BALB/cByJ/? (involves: BALB/cByJ * C3H/HeJ * C57BL/6J * DBA/2J)	dermatitis	J:80574
Derms^DBA/2J/? (involves: BALB/cByJ * C3H/HeJ * C57BL/6J * DBA/2J)	dermatitis	J:80574
Dexi^em1Kslr/Dexi^em1Kslr (NOD/ShiLtJ-Dexi^em1Kslr)	immune system phenotype	J:285312
Dffb^{em1(IMPC)Wtsi}/Dffb^{em1(IMPC)Wtsi} (C57BL/6N-Dffb^{em1(IMPC)Wtsi}/Wtsi)	increased anti-nuclear antigen antibody level	J:211773
Dffb^tm1Osa/Dffb^tm1Osa Dnase2a^tm1Osa/Dnase2a^tm1Osa (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal T cell differentiation	J:81474
	abnormal thymus morphology	J:81474
	decreased double-positive T cell number	J:81474
	increased double-negative T cell number	J:81474
	small thymus	J:81474
	thymus hypoplasia	J:81474
Dgcr2^{tm1b(EUCOMM)Wtsi}/Dgcr2^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Dgcr2^{tm1b(EUCOMM)Wtsi}/Bay)	abnormal spleen morphology	J:211773
Dgka^tm1Xpz/Dgka^tm1Xpz (involves: 129 * C57BL/6)	abnormal lymphocyte anergy	J:113564
	increased interleukin-2 secretion	J:113564
	increased T cell number	J:113564
Dgka^tm1Xpz/Dgka^tm1Xpz Dgkz^tm1Gak/Dgkz^tm1Gak (involves: 129 * 129X1/SvJ * C57BL/6)	abnormal T cell differentiation	J:113564
	abnormal thymocyte activation	J:113564
Dgkz^tm1Gak/Dgkz^tm1Gak (involves: 129X1/SvJ * C57BL/6)	abnormal cytokine level	J:293120
	abnormal cytokine secretion	J:293120
	abnormal inflammatory response	J:293120
	abnormal interferon level	J:85149
	abnormal macrophage physiology	J:293120
	abnormal T cell activation	J:85149
	abnormal T cell physiology	J:85149
	decreased CD4-positive, alpha-beta T cell number	J:85149
	decreased CD8-positive, alpha-beta T cell number	J:85149
	decreased interleukin-6 secretion	J:293120
	decreased susceptibility to induced arthritis	J:293120
	decreased susceptibility to Riboviria infection	J:85149
	increased B cell number	J:85149
	increased T cell proliferation	J:85149
Dgkz^tm1Gak/Dgkz^tm1Gak (B6.129X1-Dgkz^tm1Gak)	abnormal interleukin-2 secretion	J:113564
	abnormal lymphocyte anergy	J:113564
	increased T cell number	J:113564
Dh/Dh (Not Specified)	absent spleen	J:152370, J:112
Dh/Dh⁺ (Not Specified)	absent spleen	J:152370, J:112
	enlarged lymph nodes	J:30753
	increased granulocyte number	J:30753
	increased lymphocyte cell number	J:30753
Dh/Dh⁺ (B6.CBA-Dh)	abnormal T cell differentiation	J:5834
	absent spleen	J:5834
	decreased immunoglobulin level	J:5834
Dh/Dh⁺ Foxn1^nu/Foxn1^nu (involves: N:NIH(S))	abnormal Peyer's patch morphology	J:6062
	absent spleen	J:6062
	athymia	J:6062
	decreased leukocyte cell number	J:6062
	increased IgA level	J:6062
Dh/Dh⁺ H2^d/H2^d (NZB.Cg-Dh)	absent spleen	J:12036
	decreased B cell proliferation	J:12036
	decreased IgG1 level	J:12036
	decreased IgG level	J:12036
	decreased IgM level	J:12036
	decreased susceptibility to graft versus host disease	J:12036
	glomerulonephritis	J:12036
	increased anti-erythrocyte antigen antibody level	J:12036
	increased anti-nuclear antigen antibody level	J:12036
	increased anti-single stranded DNA antibody level	J:12036
	increased autoantibody level	J:12036
	increased T cell proliferation	J:12036
Dhcr7^em1(IMPC)Mbp/Dhcr7⁺ (C57BL/6N-Dhcr7^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Dhfr^orana/Dhfr⁺ (involves: C57BL/6JAnu)	enlarged spleen	J:236197
Dhps^{tm2c(EUCOMM)Wtsi}/Dhps^{tm2c(EUCOMM)Wtsi} Tg(CAG-cre/Esr1)5Amc/0 (involves: C57BL/6J C57BL/6N * CBA * SJL)	decreased spleen red pulp amount	J:236582
	spleen hypoplasia	J:236582
Dhrs4^tm1Lex/Dhrs4^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6J)	abnormal humoral immune response	J:171883
	decreased IgG2a level	J:171883
Dhrs7b^{Gt(OST255410)Lex}/Dhrs7b^{Gt(OST255410)Lex} (B6;129S5-Dhrs7b^{Gt(OST255410)Lex}/Mmucd)	thymus atrophy	J:171883
Dhx8^em1(IMPC)Mbp/Dhx8⁺ (C57BL/6NCrl-Dhx8^em1(IMPC)Mbp/Mmucd)	abnormal spleen morphology	J:211773
	enlarged thymus	J:211773
Dhx9^{Tn(pb-Act-RFP)1.071225026-HRAZhu}/Dhx9⁺ (involves: FVB/NJ)	immune system phenotype	J:207361
Dhx9^{Tn(pb-Act-RFP)1.071225026-HRAZhu}/Dhx9⁺ Igs12^tm1Zhu/Igs12^tm1Zhu Ptprc^a/Ptprc^b Tg(Lck-cre)#Zhu/0 (involves: 129S6/SvEvTac * C57BL/6 * FVB/NJ * SJL/J)	abnormal T cell differentiation	J:207361
Dhx15^{tm1c(EUCOMM)Wtsi}/Dhx15^{tm1c(EUCOMM)Wtsi} Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129P2/OlaHsd * C3H * C57BL/6N)	abnormal B cell differentiation	J:284624
	decreased B cell number	J:284624
	decreased B cell proliferation	J:284624
	decreased pre-B cell number	J:284624
	decreased spleen weight	J:284624
	spleen hypoplasia	J:284624
Dhx15^{tm1c(EUCOMM)Wtsi}/Dhx15^{tm1c(EUCOMM)Wtsi} Tg(Cd4-cre)1Cwi/0 (involves: C3H * C57BL/6N * DBA/2)	decreased CD4-positive, alpha-beta T cell number	J:284624
	decreased CD8-positive, alpha-beta T cell number	J:284624
Dhx35^{tm1b(EUCOMM)Wtsi}/Dhx35^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Dhx35^{tm1b(EUCOMM)Wtsi}/Wtsi)	absent connection between subcutaneous lymph vessels and lymph sac	J:239583
Dhx36^tm1.2Pmt/Dhx36^tm1.2Pmt Commd10^{Tg(Vav1-icre)A2Kio}/Commd10⁺ (involves: 129P2/Ola * 129S4/SvJaeSor * C57BL/6 * C57BL/10 * CBA/Ca)	enlarged spleen	J:185179
	intermingled spleen red and white pulp	J:185179
	thymus hypoplasia	J:185179
Dhx36^tm1.2Pmt/Dhx36^tm1.2Pmt Tg(Mx1-cre)1Cgn/0 (involves: 129P2/Ola * 129S4/SvJaeSor * C57BL/6 * CBA)	abnormal leukopoiesis	J:185179
Dhx40^{tm1b(KOMP)Wtsi}/Dhx40^{tm1b(KOMP)Wtsi} (C57BL/6N-Dhx40^{tm1b(KOMP)Wtsi}/Wtsi)	increased spleen weight	J:211773
Dhx58^tm1Aki/Dhx58^tm1Aki (involves: 129/Sv * C57BL/6)	decreased circulating interferon-beta level	J:156867
	decreased interferon-beta secretion	J:156867
	decreased interleukin-6 secretion	J:156867
	increased susceptibility to Picornaviridae infection	J:156867
	increased susceptibility to Picornaviridae infection induced morbidity/mortality	J:156867
Dhx58^tm1Gnb/Dhx58^tm1Gnb (involves: 129P2/OlaHsd * C57BL/6J)	abnormal interferon secretion	J:146113
	abnormal susceptibility to Riboviria infection	J:146113
	decreased interferon-alpha secretion	J:146113
	decreased interferon-beta secretion	J:146113
	decreased susceptibility to Riboviria infection	J:146113
	increased circulating interferon-gamma level	J:146113
	increased circulating interleukin-12 level	J:146113
	increased interferon-alpha secretion	J:146113
	increased interferon-beta secretion	J:146113
	increased susceptibility to Picornaviridae infection	J:146113
Dhx58^tm1Itl/Dhx58^tm1Itl (C57BL/6-Dhx58^tm1Itl)	decreased interferon-beta secretion	J:187386
	decreased interferon-gamma secretion	J:187386
	decreased tumor necrosis factor secretion	J:187386
	increased susceptibility to Flaviviridae infection	J:187386
	increased susceptibility to Flaviviridae infection induced morbidity/mortality	J:187386
	increased T cell apoptosis	J:187386
Dhx58^tm2.1Aki/Dhx58^tm2.1Aki (involves: 129/Sv * C57BL/6)	decreased interferon-beta secretion	J:156867
	decreased interleukin-6 secretion	J:156867
	increased susceptibility to Picornaviridae infection	J:156867
	increased susceptibility to Picornaviridae infection induced morbidity/mortality	J:156867
Diaph1^M1Btlr/Diaph1⁺ (C57BL/6J-Diaph1^M1Btlr)	abnormal CD4-positive, alpha-beta T cell number	J:254820
	abnormal CD8-positive, alpha-beta T cell number	J:254820
	decreased IgE level	J:254820
	increased central memory CD4-positive, alpha-beta T cell number	J:254820
	increased central memory CD8 positive, alpha-beta T cell number	J:254820
Diaph1^M1Btlr/Diaph1^M1Btlr (C57BL/6J-Diaph1^M1Btlr)	abnormal CD4-positive, alpha-beta T cell number	J:254820
	abnormal CD8-positive, alpha-beta T cell number	J:254820
	decreased effector memory CD8-positive, alpha-beta T cell number	J:254820
	decreased IgE level	J:254820
	increased central memory CD4-positive, alpha-beta T cell number	J:254820
	increased central memory CD8 positive, alpha-beta T cell number	J:254820
	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:254820
Diaph1^M2Btlr/Diaph1⁺ (C57BL/6J-Diaph1^M2Btlr)	decreased B-1 B cell number	J:254819
Diaph1^M2Btlr/Diaph1^M2Btlr (C57BL/6J-Diaph1^M2Btlr)	decreased B-1 B cell number	J:254819
Diaph1^M2Btlr/Diaph1^M2Btlr (C57BL/6J-Diaph1^M2Btlr)	decreased CD8-positive, alpha-beta memory T cell number	J:254819
Diaph1^m3Btlr/Diaph1^m3Btlr (C57BL/6J-Diaph1^m3Btlr)	decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:254818
	decreased CD8-positive, naive alpha-beta T cell number	J:254818
	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:254818
	increased CD8-positive, alpha-beta memory T cell number	J:254818
	increased central memory CD4-positive, alpha-beta T cell number	J:254818
	increased central memory CD8 positive, alpha-beta T cell number	J:254818
	increased effector memory CD4-positive, alpha-beta T cell number	J:254818
	increased effector memory CD8-positive, alpha-beta T cell number	J:254818
Diaph1^tm1.1Sna/Diaph1^tm1.1Sna (B6.Cg-Diaph1^tm1.1Sna)	abnormal humoral immune response	J:126090
	abnormal leukocyte migration	J:126090
	decreased CD4-positive, alpha-beta T cell number	J:126090
	decreased CD8-positive, alpha-beta T cell number	J:126090
	decreased T cell number	J:126090
	decreased T cell proliferation	J:126090
	increased single-positive T cell number	J:126090
Diaph1^tm1Asal/Diaph1^tm1Asal (involves: 129S1/Sv * C57BL/6)	abnormal lymph node morphology	J:124319
	abnormal spleen germinal center morphology	J:124319
	abnormal spleen morphology	J:124319
	absent spleen white pulp	J:124319
	decreased lymphocyte cell number	J:124319
	dermatitis	J:124319
	increased granulocyte number	J:124319
	increased leukocyte cell number	J:124319
	increased monocyte cell number	J:124319
	increased neutrophil cell number	J:124319
	increased spleen weight	J:124319
Diaph3^tm1.1Pji/Diaph3^tm1.1Pji Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6J * CBA/J)	enlarged spleen	J:293763
Dice1b^C57BL/10Sn/Dice1b^C57BL/10Sn (involves: B10.D2-H2^d/oSnJ * BALB/cAnN)	decreased susceptibility to parasitic infection	J:95337
Dicer1^{Gt(RRF266)Byg}/Dicer1^{Gt(RRF266)Byg} (involves: 129P2/OlaHsd * C57BL/6)	decreased susceptibility to Riboviria infection	J:123635
	increased susceptibility to Herpesvirales infection	J:123635
	increased susceptibility to Riboviria infection	J:123635
Dicer1^m1Btlr/Dicer1^m1Btlr (C57BL/6J-Dicer1^m1Btlr)	decreased CD4-positive, alpha-beta T cell number	J:265172
	decreased CD8-positive, alpha-beta T cell number	J:265172
	decreased CD8-positive, naive alpha-beta T cell number	J:265172
	decreased single-positive T cell number	J:265172
	decreased T cell number	J:265172
	increased B-1 B cell number	J:265172
	increased central memory CD8 positive, alpha-beta T cell number	J:265172
	increased effector memory CD4-positive, alpha-beta T cell number	J:265172
	increased effector memory CD8-positive, alpha-beta T cell number	J:265172
Dicer1^{tm1b(EUCOMM)Wtsi}/Dicer1⁺ (C57BL/6N-Dicer1^{tm1b(EUCOMM)Wtsi}/H)	absent spleen	J:211773
	decreased neutrophil cell number	J:211773
	decreased spleen weight	J:211773
Dicer1^tm1Bdh/Dicer1⁺ H2az2^{Tg(Wnt1-cre)11Rth}/H2az2⁺ (involves: 129 * C57BL/6 * CBA/J)	abnormal thymus development	J:166758
Dicer1^tm1Bdh/Dicer1^tm1Bdh Aicda^tm1(cre)Njen/Aicda⁺ (involves: 129 * C57BL/6)	abnormal germinal center B cell physiology	J:181782
	abnormal humoral immune response	J:181782
	absent memory B cells	J:181782
	absent plasma cells	J:181782
	decreased germinal center B cell number	J:181782
	decreased immunoglobulin level	J:181782
	immune system phenotype	J:181782
Dicer1^tm1Bdh/Dicer1^tm1Bdh Foxp3^{tm4(YFP/icre)Ayr}/Y (involves: 129S1/Sv * 129X1/SvJ)	blood vessel inflammation	J:138683
	enlarged lymph nodes	J:138683
	enlarged spleen	J:138683
	liver inflammation	J:138683
	lung inflammation	J:138683
Dicer1^tm1Bdh/Dicer1^tm1Bdh Foxp3^{tm4(YFP/icre)Ayr}/Foxp3^{tm4(YFP/icre)Ayr} (involves: 129S1/Sv * 129X1/SvJ)	blood vessel inflammation	J:138683
	enlarged lymph nodes	J:138683
	enlarged spleen	J:138683
	liver inflammation	J:138683
	lung inflammation	J:138683
Dicer1^tm1Bdh/Dicer1^tm1Bdh H2az2^{Tg(Wnt1-cre)11Rth}/H2az2⁺ (involves: 129 * C57BL/6 * CBA/J)	athymia	J:166758
Dicer1^tm1Bdh/Dicer1^tm1Bdh Tg(Cd4-cre)1Cwi/0 (involves: 129 * C57BL/6 * DBA/2)	decreased regulatory T cell number	J:138683
Dicer1^tm1Bdh/Dicer1^tm1Bdh Tg(Foxp3-EGFP/icre)1aJbs/0 (involves: 129 * NOD/ShiLt)	abnormal CD4-positive, alpha-beta T cell physiology	J:138808
	abnormal effector T cell morphology	J:138808
	abnormal lymph node cell ratio	J:138808
	abnormal regulatory T cell morphology	J:138808
	abnormal regulatory T cell physiology	J:138808
	abnormal splenic cell ratio	J:138808
	decreased regulatory T cell number	J:138808
	enlarged lymph nodes	J:138808
	enlarged spleen	J:138808
	liver inflammation	J:138808
	lung inflammation	J:138808
Dicer1^tm1Dli/Dicer1^tm1Dli Tg(Cd4-cre)1Cwi/? (involves: 129 * C57BL/6 * DBA/2)	abnormal cytotoxic T cell physiology	J:100546
	abnormal T-helper 1 physiology	J:100546
	abnormal T-helper 2 physiology	J:100546
	decreased T cell number	J:100546
	decreased T cell proliferation	J:100546
	immune system phenotype	J:100546
	increased T cell apoptosis	J:100546
Dicer1^tm1Mmk/Dicer1^tm1.1Mmk Cd79a^tm1(cre)Reth/Cd79a⁺ (involves: BALB/c)	abnormal immunoglobulin V(D)J recombination	J:135783
	decreased B cell number	J:135783
Dicer1^tm1Mmk/Dicer1^tm1Mmk Cd79a^tm1(cre)Reth/Cd79a⁺ (involves: BALB/c)	arrested B cell differentiation	J:135783
	decreased immature B cell number	J:135783
	decreased mature B cell number	J:135783
	decreased pre-B cell number	J:135783
	increased pro-B cell number	J:135783
Dicer1^tm1Mmk/Dicer1^tm1Mmk Tg(IghelMD4)4Ccg/0 Cd79a^tm1(cre)Reth/Cd79a⁺ (involves: BALB/c)	decreased B cell number	J:135783
	decreased mature B cell number	J:135783
Dicer1^tm1Mmk/Dicer1^tm1Mmk Tg(Lck-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	decreased T cell number	J:98192
	decreased thymocyte number	J:98192
	increased gamma-delta T cell number	J:98192
Dicer1^tm1Mmk/Dicer1^tm1Mmk Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0 (involves: 129 * C57BL/6 * CD-1)	abnormal granulocyte differentiation	J:158901
	abnormal myeloid leukocyte morphology	J:158901
	abnormal neutrophil morphology	J:158901
	decreased B cell number	J:158901
	decreased leukocyte cell number	J:158901
	enlarged spleen	J:158901
Dicer1^tm1Tara/Dicer1^tm1Tara Foxn1^tm3(cre)Nrm/Foxn1⁺ (involves: 129P2/OlaHsd * C57BL/6NHsd)	abnormal positive T cell selection	J:180783
	abnormal thymus cortex morphology	J:180783
	abnormal thymus epithelium morphology	J:180783
	abnormal thymus involution	J:180783
	abnormal thymus medulla morphology	J:180783
	abnormal thymus morphology	J:180783
	abnormal thymus physiology	J:180783
	decreased CD4-positive, alpha-beta T cell number	J:180783
	decreased CD8-positive, alpha-beta T cell number	J:180783
	increased susceptibility to induced arthritis	J:180783
Dido1^tm1Cmar/Dido1⁺ (involves: 129S1/Sv * 129X1/SvJ)	abnormal splenic cell ratio	J:101201
	abnormal splenocyte morphology	J:101201
	increased granulocyte number	J:101201
	increased monocyte cell number	J:101201
	increased spleen weight	J:101201
	spleen hyperplasia	J:101201
Dido1^tm1Cmar/Dido1^tm1Cmar (involves: 129S1/Sv * 129X1/SvJ)	abnormal splenic cell ratio	J:101201
	abnormal splenocyte morphology	J:101201
	immune system phenotype	J:101201
	increased granulocyte number	J:101201
	increased monocyte cell number	J:101201
	increased spleen weight	J:101201
	increased spleen white pulp amount	J:101201
	spleen hyperplasia	J:101201
Dido1^tm3Cmar/Dido1^tm3.1Cmar Ndor1^{Tg(UBC-cre/ERT2)1Ejb}/Ndor1⁺ (involves: 129S/SvEv * C57BL/6)	liver inflammation	J:328215
Dip2b^{tm1a(EUCOMM)Wtsi}/Dip2b⁺ (B6JTyr;B6N-Dip2b^{tm1a(EUCOMM)Wtsi}/Wtsi)	decreased leukocyte cell number	J:175295
Dip2c^em1(IMPC)Tcp/Dip2c⁺ (C57BL/6N-Dip2c^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
	increased monocyte cell number	J:211773
	small thymus	J:211773
Dipk2b^em1(IMPC)Mbp/Dipk2b^em1(IMPC)Mbp (C57BL/6N-Dipk2b^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
Dis3^tm1.1Uba/Dis3^tm1.1Uba Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte}/Gt(ROSA)26Sor⁺ (involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NTac)	abnormal B cell morphology	J:302856
	abnormal class switch recombination	J:302856
Dis3l^{em1(IMPC)Ccpcz}/Dis3l⁺ (C57BL/6NCrl-Dis3l^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	increased eosinophil cell number	J:211773
Disc1^em1(IMPC)Mbp/Disc1^em1(IMPC)Mbp (C57BL/6N-Disc1^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
Disp3^em1(IMPC)Mbp/Disp3^em1(IMPC)Mbp (C57BL/6N-Disp3^em1(IMPC)Mbp/Ucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Dkc1^tm1.1Pjma/Y (B6.129X1(FVB)-Dkc1^tm1.1Pjma)	decreased B cell number	J:217050
Dkc1^tm1.1Pjma/Y (B6.129X1(FVB)-Dkc1^tm1.1Pjma)	decreased T cell number	J:217050
Dkc1^tm1Ppp/Y (involves: 129S1/Sv)	abnormal spleen morphology	J:81054
	decreased B cell number	J:81054
	decreased leukocyte cell number	J:81054
	decreased lymphocyte cell number	J:81054
	decreased pre-B cell number	J:81054
	decreased spleen red pulp amount	J:81054
	decreased spleen white pulp amount	J:81054
	enlarged spleen	J:81054
	lung inflammation	J:81054
Dkc1^tm1Ppp/Dkc1⁺ (involves: 129S1/Sv)	abnormal immune system cell morphology	J:81054
Dkc1^tm1Ppp/Dkc1⁺ (involves: 129S1/Sv)	abnormal immune system organ morphology	J:81054
Dkk2^tm1Dwu/Dkk2^tm1Dwu (involves: 129)	abnormal osteoclast differentiation	J:100858
Dkk2^tm1Dwu/Dkk2^tm1Dwu (involves: 129)	increased osteoclast cell number	J:100858
Dkk3^tm1Cni/Dkk3^tm1Cni (involves: 129X1/SvJ * C57BL/6)	decreased NK cell number	J:106922
Dkk3^tm1Cni/Dkk3^tm1Cni (involves: 129X1/SvJ * C57BL/6)	increased IgM level	J:106922
Dlg1^tm1Rlh/Dlg1^tm1Rlh Tg(Cd4-cre)1Cwi/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)	abnormal CD4-positive, alpha-beta T cell physiology	J:191788
	abnormal cytokine secretion	J:191788
	abnormal T-helper 1 physiology	J:191788
	abnormal T-helper 2 physiology	J:191788
	decreased interferon-gamma secretion	J:191788
	decreased interleukin-2 secretion	J:191788
	decreased tumor necrosis factor secretion	J:191788
	increased interleukin-4 secretion	J:191788
	increased interleukin-5 secretion	J:191788
Dlgap2^{em1(IMPC)Mhzh}/Dlgap2^{em1(IMPC)Mhzh} (C57BL/6N-Dlgap2^{em1(IMPC)Mhzh}/Mhzh)	decreased lymphocyte cell number	J:211773
	increased eosinophil cell number	J:211773
	increased neutrophil cell number	J:211773
Dlk1^tm1.1Jvs/Dlk1⁺ Myf5^tm3(cre)Sor/Myf5⁺ (involves: 129P2/SvPas * 129S4/SvJaeSor * C57BL/6 * FVB/N)	increased inflammatory response	J:167124
Dlk1^tm1Srba/Dlk1^tm1Srba (involves: 129X1/SvJ * C57BL/6)	abnormal B cell number	J:145076
	abnormal spleen B cell follicle morphology	J:145076
	abnormal spleen marginal zone morphology	J:145076
	decreased immature B cell number	J:145076
	decreased mature B cell number	J:145076
	increased IgG1 level	J:145076
	increased IgG2a level	J:145076
	increased IgG2b level	J:145076
	increased IgG2c level	J:145076
	increased IgG3 level	J:145076
	increased IgM level	J:145076
	increased immature B cell number	J:145076
	increased immunoglobulin level	J:145076
	increased marginal zone B cell number	J:145076
	increased transitional stage B cell number	J:145076
Dll1^m1Mhda/Dll1⁺ (C3HeB/FeJ-Dll1^m1Mhda)	immune system phenotype	J:150183
Dll1^tm1Gos/Dll1⁺ (C3Fe.129-Dll1^tm1Gos)	decreased B-1 B cell number	J:150183
	decreased CD4-positive, alpha-beta T cell number	J:150183
	decreased CD8-positive, alpha-beta T cell number	J:150183
	decreased IgA level	J:150183
	decreased IgG1 level	J:150183
	decreased IgG2b level	J:150183
	decreased IgG3 level	J:150183
	increased B cell number	J:150183
	increased CD8-positive, alpha-beta T cell number	J:150183
Dll1^tm1Gos/Dll1⁺ (involves: 129S1/Sv * 129X1/SvJ)	decreased CD4-positive, alpha-beta T cell number	J:150183
Dll1^tm1Gos/Dll1⁺ (involves: 129S1/Sv * 129X1/SvJ)	increased B cell number	J:150183
Dll1^tm1Mjo/Dll1^tm1Mjo Tg(KRT5-cre)1Tak/? Tg(Mx1-cre)1Cgn/? (involves: 129 * C3H * C57BL/6 * CBA)	immune system phenotype	J:90630
Dll1^tm1Mjo/Dll1^tm1Mjo Tg(Mx1-cre)1Cgn/? (involves: 129 * C57BL/6 * CBA)	absent marginal zone B cells	J:90630
Dll1^tm3.1Gos/Dll1^tm3.1Gos (Not Specified)	immune system phenotype	J:213529
Dll4^tm1Frad/Dll4^tm1Frad Foxn1^tm3(cre)Nrm/Foxn1⁺ (B6.Cg-Dll4^tm1Frad Foxn1^tm3(cre)Nrm)	abnormal T cell differentiation	J:143472
	abnormal thymus cell ratio	J:143472
	decreased CD4-positive, alpha-beta T cell number	J:143472
	decreased CD8-positive, alpha-beta T cell number	J:143472
	decreased double-positive T cell number	J:143472
	decreased thymocyte number	J:143472
	increased immature B cell number	J:143472
Dll4^tm1Frad/Dll4^tm1Frad Tg(Mx1-cre)1Cgn/0 (B6.Cg-Dll4^tm1Frad Tg(Mx1-cre)1Cgn)	immune system phenotype	J:143472
Dll4^tm1Kaho/Dll4^tm1Kaho Tg(Foxn1-cre)8Ghr/0 (involves: C57BL/6 * DBA/2)	abnormal lymphopoiesis	J:143473
	absent CD4-positive, alpha-beta T cells	J:143473
	absent CD8-positive, alpha-beta T cells	J:143473
	decreased double-positive T cell number	J:143473
	thymus hypoplasia	J:143473
Dmbt1^tm1Janm/Dmbt1^tm1Janm (involves: 129P2/OlaHsd * C57BL/6)	increased susceptibility to induced colitis	J:130258
Dmd^em1Cmusr/Y (BALB/c-Dmd^em1Cmusr)	enlarged spleen	J:353371
Dmd^em1Eno/Y (involves: C57BL/6J)	myositis	J:253191
Dmd^em4Eno/Y (C57BL/6-Dmd^em4Eno)	myositis	J:285447
Dmd^em4Eno/Dmd^em4Eno (C57BL/6-Dmd^em4Eno)	myositis	J:285447
Dmd^mdx/Y (C57BL/10ScSn-Dmd^mdx/J)	increased interferon-gamma secretion	J:150572
	increased interleukin-2 secretion	J:150572
	increased interleukin-4 secretion	J:150572
	increased interleukin-6 secretion	J:150572
	increased interleukin-12 secretion	J:150572
	increased tumor necrosis factor secretion	J:150572
Dmd^mdx/Y (involves: C57BL/10ScSn)	diaphragmitis	J:140282
Dmd^mdx/Y (involves: C57BL/10ScSn)	myositis	J:140282
Dmd^mdx/Y Spp1^tm1Blh/Spp1^tm1Blh (involves: 129S6/SvEvTac * C57BL/6 * C57BL/10 * C57BL/10ScSn)	decreased granulocyte number	J:150572
	decreased neutrophil cell number	J:150572
	decreased T cell number	J:150572
	increased regulatory T cell number	J:150572
	increased T cell number	J:150572
Dmd^mdx/Y Terc^tm1Rdp/Terc^tm1Rdp (involves: 129/Sv * C57BL/6J * C57BL/10ScSn * SJL)	myositis	J:167294
Dmd^mdx/Y Tg(DMD)#Spc/0 (involves: 129P2/OlaHsd C57BL/10ScSn * DBA/2)	myositis	J:280218
Dmd^mdx/Y Utrn^tm1Jrs/Utrn⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/10ScSn)	diaphragmitis	J:140282
	myositis	J:140282
Dmd^mdx/Dmd^mdx (C57BL/10ScSn-Dmd^mdx/J)	increased interferon-gamma secretion	J:150572
	increased interleukin-2 secretion	J:150572
	increased interleukin-4 secretion	J:150572
	increased interleukin-6 secretion	J:150572
	increased interleukin-12 secretion	J:150572
	increased tumor necrosis factor secretion	J:150572
	myositis	J:226314
Dmd^mdx/Dmd^mdx (D2.B10-Dmd^mdx/J)	heart inflammation	J:226314
Dmd^mdx/Dmd^mdx (D2.B10-Dmd^mdx/J)	myositis	J:226314
Dmd^mdx/Dmd^mdx Dusp1^tm1Brv/Dusp1^tm1Brv (involves: 129S2/SvPas * C57BL/6 * C57BL/10ScSn)	myositis	J:162340
Dmd^mdx/Dmd^mdx Mmp9^tm1Tvu/Mmp9⁺ (B10.Cg-Mmp9^tm1Tvu Dmd^mdx)	decreased macrophage cell number	J:150030
Dmd^mdx/Dmd^mdx Mmp9^tm1Tvu/Mmp9^tm1Tvu (B10.Cg-Mmp9^tm1Tvu Dmd^mdx)	decreased macrophage cell number	J:150030
Dmd^mdx/Dmd^mdx Prkdc^scid/Prkdc^scid (involves: BALB/c * C57BL/10ScSn * C57BL/Ka)	absent CD4-positive, alpha-beta T cells	J:125527
	absent CD8-positive, alpha-beta T cells	J:125527
	decreased B cell number	J:125527
Dmd^mdx/Dmd^mdx Spp1^tm1Blh/Spp1^tm1Blh (involves: 129S6/SvEvTac * C57BL/6 * C57BL/10 * C57BL/10ScSn)	decreased granulocyte number	J:150572
	decreased neutrophil cell number	J:150572
	decreased T cell number	J:150572
	increased regulatory T cell number	J:150572
	increased T cell number	J:150572
Dmd^tm1.1Know/Dmd^tm1.1Know (involves: C3H)	decreased susceptibility to Picornaviridae infection	J:207775
Dmd^tm1.1Know/Dmd^tm1.1Know (involves: C3H)	myocarditis	J:207775
Dmd^tm1Kmf/Y (involves: C57BL/6)	myositis	J:233298
Dmp1^tm1Mis/Dmp1^tm1Mis (involves: 129S7/SvEvBrd * C57BL/6)	increased susceptibility to bacterial infection	J:241769
Dmp1^tm1Mis/Dmp1^tm1Mis (involves: 129S7/SvEvBrd * CD-1)	abnormal bone marrow development	J:184352
Dmp1^tm1Mis/Dmp1^tm1Mis (involves: 129S7/SvEvBrd * CD-1)	decreased osteoclast cell number	J:184352
Dmtf1^tm1Cjs/Dmtf1⁺ Kras^tm2Tyj/Kras⁺ (involves: 129S2/SvPas * C57BL/6)	increased T cell derived lymphoma incidence	J:126002
Dmtf1^tm1Cjs/Dmtf1⁺ Kras^tm3Tyj/Kras⁺ (involves: 129S4/SvJae * C57BL/6)	increased T cell derived lymphoma incidence	J:126002
Dmtf1^tm1Cjs/Dmtf1^tm1Cjs (involves: 129/Sv * C57BL/6)	abnormal T cell physiology	J:63444
Dmtf1^tm1Cjs/Dmtf1^tm1Cjs (involves: 129/Sv * C57BL/6)	decreased thymocyte number	J:63444
Dmtf1^tm1Cjs/Dmtf1^tm1Cjs Kras^tm2Tyj/Kras⁺ (involves: 129S2/SvPas * C57BL/6)	increased T cell derived lymphoma incidence	J:126002
Dmtf1^tm1Cjs/Dmtf1^tm1Cjs Kras^tm3Tyj/Kras⁺ (involves: 129S4/SvJae * C57BL/6)	increased T cell derived lymphoma incidence	J:126002
Dmxl2^{tm1a(EUCOMM)Wtsi}/Dmxl2^{tm1a(EUCOMM)Wtsi} (C57BL/6N-A^tm1Brd Dmxl2^{tm1a(EUCOMM)Wtsi}/WtsiH)	blood in lymph vessels	J:239583
Dnaaf4^b2b811.1Clo/Dnaaf4^b2b811.1Clo (C57BL/6J-Dnaaf4^b2b811.1Clo)	abnormal spleen morphology	J:205312
Dnaaf4^tm1.2Jjlo/Dnaaf4^tm1.2Jjlo (involves: 129S1/Sv * 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6J)	abnormal spleen morphology	J:205312
Dnaaf5^em1Slb/Dnaaf5^em1Slb (C57BL/6-Dnaaf5^em1Slb)	sinus inflammation	J:342770
Dnaaf5^em1Slb/Dnaaf5^em2Slb (C57BL/6-Dnaaf5^em1Slb Dnaaf5^em2Slb)	sinus inflammation	J:342770
Dnaaf9^{tm1b(EUCOMM)Hmgu}/Dnaaf9^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Dnaaf9^{tm1b(EUCOMM)Hmgu}/Tcp)	increased neutrophil cell number	J:211773
Dnah2^em1(IMPC)Tcp/Dnah2^em1(IMPC)Tcp (C57BL/6N-Dnah2^em1(IMPC)Tcp/Tcp)	abnormal lymph node morphology	J:211773
Dnah5^b2b2451Clo/Dnah5^b2b2451Clo (C57BL/6J-Dnah5^b2b2451Clo)	abnormal spleen morphology	J:175213
Dnah5^b2b2925Clo/Dnah5^b2b2925Clo (C57BL/6J-Dnah5^b2b2925Clo)	absent spleen	J:175213
Dnah5^hlb612/Dnah5^hlb612 (involves: C57BL/6J)	abnormal spleen morphology	J:130755
Dnah5^hlb612/Dnah5^hlb612 (involves: C57BL/6J)	absent spleen	J:130755
Dnah5^Tg1Htz/Dnah5^Tg1Htz (involves: C57BL/6 * CBA/J)	increased susceptibility to otitis media	J:76189
Dnah5^Tg1Htz/Dnah5^Tg1Htz (involves: C57BL/6 * CBA/J)	sinus inflammation	J:76189
Dnah11^b2b1289Clo/Dnah11^b2b1289Clo (C57BL/6J-Dnah11^b2b1289Clo)	accessory spleen	J:175213
Dnah11^b2b1727Clo/Dnah11^b2b1727Clo (C57BL/6J-Dnah11^b2b1727Clo)	spleen hypoplasia	J:175213
Dnah11^b2b1775Clo/Dnah11^b2b1775Clo (C57BL/6J-Dnah11^b2b1775Clo)	spleen hypoplasia	J:175213
Dnah11^iv/Dnah11^iv (SI/Col Tyrp1^b Dnah11^iv/J)	abnormal spleen morphology	J:4058
Dnai1^b2b1526Clo/Dnai1^b2b1526Clo (C57BL/6J-Dnai1^b2b1526Clo)	spleen hypoplasia	J:175213
Dnai1^tm1.1Leo/Dnai1^tm1.1Leo Gt(ROSA)26Sor^{tm1(cre/ERT)Nat}/Gt(ROSA)26Sor⁺ (involves: 129 * C57BL/6)	rhinosinusitis	J:155730
Dnai2^em1(IMPC)Tcp/Dnai2⁺ (C57BL/6NCrl-Dnai2^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Dnajc2^em1(IMPC)J/Dnajc2⁺ (C57BL/6NJ-Dnajc2^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
Dnajc3^m1Btlr/Dnajc3^m1Btlr (C57BL/6J-Dnajc3^m1Btlr)	increased CD4-positive, alpha-beta T cell number	J:265248
	increased CD8-positive, alpha-beta memory T cell number	J:265248
	increased single-positive T cell number	J:265248
	increased susceptibility to induced colitis	J:265248
	increased T cell number	J:265248
Dnajc11^spc/Dnajc11^spc (B6.Cg-Dnajc11^spc)	decreased B cell number	J:221543
	decreased double-positive T cell number	J:221543
	decreased leukocyte cell number	J:221543
	decreased thymus weight	J:221543
	enlarged thymus medulla	J:221543
	increased CD4-positive, alpha-beta T cell number	J:221543
	increased CD8-positive, alpha-beta T cell number	J:221543
	increased DN1 thymic pro-T cell number	J:221543
	increased double-negative T cell number	J:221543
	spleen hypoplasia	J:221543
	thymus cortex atrophy	J:221543
	thymus hypoplasia	J:221543
Dnajc15^{Gt(RRN226)Byg}/Dnajc15^{Gt(RRN226)Byg} (B6.129P2-Dnajc15^{Gt(RRN226)Byg})	abnormal CD8-positive, alpha beta T cell morphology	J:204025
	immune system phenotype	J:204025
Dnajc15^{tm1b(KOMP)Wtsi}/Dnajc15^{tm1b(KOMP)Wtsi} (C57BL/6N-Dnajc15^{tm1b(KOMP)Wtsi}/Bay)	abnormal spleen morphology	J:211773
Dnal1^{tm1.1(KOMP)Vlcg}/Dnal1⁺ (C57BL/6N-Dnal1^{tm1.1(KOMP)Vlcg}/Ucd)	decreased eosinophil cell number	J:211773
Dnase1^tm1Tmo/Dnase1⁺ (involves: 129P2/OlaHsd * C57BL/6)	enlarged spleen	J:62549
	glomerulonephritis	J:62549
	increased anti-nuclear antigen antibody level	J:62549
	kidney inflammation	J:62549
Dnase1^tm1Tmo/Dnase1^tm1Tmo (involves: 129P2/OlaHsd * C57BL/6)	enlarged spleen	J:62549
	glomerulonephritis	J:62549
	increased anti-nuclear antigen antibody level	J:62549
	increased susceptibility to systemic lupus erythematosus	J:62549
	kidney inflammation	J:62549
Dnase1^tm1Tmo/Dnase1^tm1Tmo (involves: 129P2/OlaHsd * CD-1)	decreased susceptibility to systemic lupus erythematosus	J:110060
Dnase1^tm2092.1Arte/Dnase1^tm2092.1Arte (involves: C57BL/6)	glomerulonephritis	J:277126
	increased anti-double stranded DNA antibody level	J:277126
	increased anti-histone antibody level	J:277126
	increased anti-nuclear antigen antibody level	J:277126
	increased autoantibody level	J:277126
	increased susceptibility to systemic lupus erythematosus	J:277126
Dnase1l2^em1(IMPC)Bay/Dnase1l2^em1(IMPC)Bay (C57BL/6N-Dnase1l2^em1(IMPC)Bay/Bay)	abnormal spleen morphology	J:211773
Dnase1l2^{tm1.1(KOMP)Wtsi}/Dnase1l2^{tm1.1(KOMP)Wtsi} (C57BL/6N-Dnase1l2^{tm1.1(KOMP)Wtsi}/Bay)	abnormal spleen morphology	J:211773
Dnase1l3^em1(IMPC)Mbp/Dnase1l3^em1(IMPC)Mbp (C57BL/6NCrl-Dnase1l3^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	increased spleen weight	J:211773
Dnase2a^tm1Osa/Dnase2a^tm1Osa (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal thymus morphology	J:81474
	small thymus	J:81474
	thymus hypoplasia	J:81474
Dnase2a^tm1Osa/Dnase2a^tm1Osa Ifnar1^tm1Agt/Ifnar1^tm1Agt (involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6)	abnormal cytokine level	J:114982
	abnormal macrophage morphology	J:114982
	abnormal spleen morphology	J:238323
	enlarged spleen	J:238323, J:114982
	increased anti-double stranded DNA antibody level	J:114982
	increased autoantibody level	J:238323
	increased circulating interleukin-10 level	J:238323
	increased circulating interleukin-18 level	J:114982
	increased circulating tumor necrosis factor level	J:238323, J:114982
	increased spleen red pulp amount	J:114982
	increased spleen weight	J:238323
	increased synovial pannus formation	J:238323, J:114982
	joint inflammation	J:238323, J:114982
	rheumatoid arthritis	J:238323, J:114982
Dnase2a^tm1Osa/Dnase2a^tm2Osa Tg(Mx1-cre)1Cgn/0 (involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6 * CBA)	abnormal cytokine level	J:114982
	abnormal macrophage morphology	J:114982
	increased circulating interleukin-18 level	J:114982
	increased circulating tumor necrosis factor level	J:114982
	increased synovial pannus formation	J:114982
	joint inflammation	J:114982
	rheumatoid arthritis	J:114982
Dnm2^tm2.1Ics/Dnm2⁺ (involves: C57BL/6J)	immune system phenotype	J:288372
Dnm2^tm2.1Ics/Dnm2⁺ (involves: C57BL/6J)	increased macrophage cell number	J:288372
Dnmbp^em1(IMPC)Mbp/Dnmbp^em1(IMPC)Mbp (C57BL/6N-Dnmbp^em1(IMPC)Mbp/Ucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Dnmt1^{tm1(tetO-BCL2)Sjk}/Dnmt1⁺ Tg(IghMyc)22Bri/0 Tg(MMTVtTA)1Mam/0 (involves: 129S4/SvJae * C57BL/6)	enlarged spleen	J:93549
Dnmt1^tm2Jae/Dnmt1^tm2Jae Cd79a^tm1(cre)Reth/Cd79a⁺ (involves: 129S4/SvJae * BALB/c * C57BL/6)	abnormal B cell differentiation	J:113645
	decreased pro-B cell number	J:113645
Dnmt3b^tm1Enl/Dnmt3b^tm6Enl (involves: 129S4/SvJae * C57BL/6)	decreased thymocyte number	J:106540
	increased thymocyte apoptosis	J:106540
	small thymus	J:106540
Dnmt3b^tm1Enl/Dnmt3b^tm7Enl (involves: 129S4/SvJae * C57BL/6)	decreased double-positive T cell number	J:106540
	decreased thymocyte number	J:106540
	increased double-negative T cell number	J:106540
	increased thymocyte apoptosis	J:106540
	small thymus	J:106540
Dnmt3b^tm6Enl/Dnmt3b^tm6Enl (involves: 129S4/SvJae * C57BL/6)	decreased thymocyte number	J:106540
	increased thymocyte apoptosis	J:106540
	small thymus	J:106540
Dnmt3b^tm6Enl/Dnmt3b^tm7Enl (involves: 129S4/SvJae * C57BL/6)	decreased thymocyte number	J:106540
	increased thymocyte apoptosis	J:106540
Dnmt3b^tm7Enl/Dnmt3b^tm7Enl (involves: 129S4/SvJae * C57BL/6)	decreased thymocyte number	J:106540
	increased thymocyte apoptosis	J:106540
	small thymus	J:106540
Dntt^tm1Fwa/Dntt^tm1Fwa (chimera involves: 129S/SvEv)	abnormal immune system morphology	J:75921
Dntt^tm1Gfn/Dntt^tm1Gfn Fas^lpr/Fas^lpr (involves: 129S2/SvPas * C57BL/6 * MRL/MpJ)	decreased autoantibody level	J:110248
Dntt^tm1Gfn/Dntt^tm1Gfn Polm^tm1Crey/Polm^tm1Crey (involves: 129P2/OlaHsd * 129S2/SvPas)	abnormal immunoglobulin light chain V-J recombination	J:113406
	immune system phenotype	J:113406
Dntt^tm1Tok/Dntt^tm1Tok (involves: 129P2/OlaHsd * C57BL/6)	abnormal lymphocyte cell number	J:61801
	abnormal T cell morphology	J:61801
	decreased gamma-delta T cell number	J:61801
Dnttip1^em1Shmc/Dnttip1^em1Shmc (C57BL/6J-Dnttip1^em1Shmc)	immune system phenotype	J:291786
Dock1^b2b3190Clo/Dock1^b2b3190Clo (C57BL/6J-Dock1^b2b3190Clo)	thymus hypoplasia	J:175213
Dock2^m1Anu/Dock2^m1Anu (C57BL/6JAnu-Dock2^m1Anu)	decreased B cell number	J:104190
Dock2^m1Anu/Dock2^m1Anu (C57BL/6JAnu-Dock2^m1Anu)	decreased T cell number	J:104190
Dock2^m1Btlr/Dock2^m1Btlr (involves: C57BL/6J)	abnormal B cell differentiation	J:173592
	abnormal class switch recombination	J:185495
	abnormal humoral immune response	J:173592
	decreased B cell number	J:185495
	decreased IgG level	J:185495
	decreased T cell number	J:185495
	immune system phenotype	J:185495
Dock2^m1Hsd/Dock2^m1Hsd Irf5^tm1Ttg/Irf5^tm1Ttg (B6NHsd.Cg-Irf5^tm1Ttg Dock2^m1Hsd)	abnormal B cell differentiation	J:182658
	abnormal response to infection	J:182658
	absent marginal zone B cells	J:182658
	decreased follicular B cell number	J:182658
	decreased interferon-alpha secretion	J:182658
	decreased plasmacytoid dendritic cell number	J:182658
	decreased splenocyte number	J:182658
	increased B cell number	J:182658
	increased immature B cell number	J:182658
	increased plasmacytoid dendritic cell number	J:182658
Dock2^m1Hsd/Dock2^m1Hsd Siae^tm1.2Avrk/Siae^tm1.2Avrk (B6NHsd.Cg-Siae^tm1.2Avrk Dock2^m1Hsd)	abnormal B cell activation	J:144035
	abnormal immunoglobulin level	J:144035
	decreased B-1a cell number	J:144035
	decreased follicular B cell number	J:144035
	decreased marginal zone B cell number	J:231437, J:144035
	decreased T cell number	J:144035
	glomerulonephritis	J:144035
	increased anti-double stranded DNA antibody level	J:144035
	increased anti-histone antibody level	J:144035
	increased anti-single stranded DNA antibody level	J:144035
	increased B cell proliferation	J:144035
	increased B-1b cell number	J:144035
	increased CD4-positive, alpha-beta memory T cell number	J:231437
	increased IgE level	J:144035
	increased IgG1 level	J:144035
	increased IgG2a level	J:144035
	increased IgG2b level	J:144035
	increased IgG3 level	J:144035
	increased IgM level	J:144035
	spleen hypoplasia	J:144035
Dock2^m2Anu/Dock2^m2Anu (C57BL/6JAnu-Dock2^m2Anu)	abnormal T cell morphology	J:104190
	decreased mature B cell number	J:104190
	decreased T cell number	J:104190
Dock2^m2Btlr/Dock2^m2Btlr (C57BL/6J-Dock2^m2Btlr)	abnormal humoral immune response	J:173670
	decreased B cell number	J:173670
	decreased CD4-positive, alpha-beta T cell number	J:173670
	decreased CD8-positive, alpha-beta T cell number	J:173670
Dock2^m2Btlr/Dock2^m2Btlr (involves: C57BL/6J)	abnormal B cell differentiation	J:185495
	abnormal class switch recombination	J:185495
	abnormal humoral immune response	J:185495
	decreased B cell number	J:185495
	decreased IgG level	J:185495
	decreased T cell number	J:185495
	immune system phenotype	J:185495
Dock2^m3Anu/Dock2^m3Anu (C57BL/6NCrl-Dock2^m3Anu/Anu)	abnormal CD4-positive, alpha beta T cell morphology	J:104190
	abnormal CD8-positive, alpha beta T cell morphology	J:104190
	decreased CD4-positive, alpha-beta T cell number	J:104190
Dock2^m3Btlr/Dock2^m3Btlr (C57BL/6J-Dock2^m3Btlr)	abnormal CD4-positive T cell differentiation	J:191187
	abnormal CD8-positive, alpha-beta T cell differentiation	J:191187
	abnormal humoral immune response	J:191187
	abnormal immune system physiology	J:191187
	decreased CD4-positive, alpha-beta T cell number	J:191187
	decreased CD8-positive, alpha-beta T cell number	J:191187
Dock2^m4Btlr/Dock2^m4Btlr (C57BL/6J-Dock2^m4Btlr)	abnormal B cell differentiation	J:221486
	abnormal CD4-positive T cell differentiation	J:221486
	abnormal CD8-positive, alpha-beta T cell differentiation	J:221486
Dock2^m5Btlr/Dock2⁺ (C57BL/6J-Dock2^m5Btlr)	abnormal CD4-positive T cell differentiation	J:225938
	abnormal CD8-positive, alpha-beta T cell differentiation	J:225938
	decreased CD4-positive, alpha-beta T cell number	J:225938
	decreased single-positive T cell number	J:225938
	increased CD8-positive, alpha-beta T cell number	J:225938
	increased single-positive T cell number	J:225938
Dock2^m5Btlr/Dock2^m5Btlr (C57BL/6J-Dock2^m5Btlr)	abnormal B cell differentiation	J:225938
	abnormal CD4-positive T cell differentiation	J:225938
	abnormal CD8-positive, alpha-beta T cell differentiation	J:225938
	decreased CD4-positive, alpha-beta T cell number	J:225938
	decreased single-positive T cell number	J:225938
	increased B cell number	J:225938
	increased CD8-positive, alpha-beta T cell number	J:225938
	increased single-positive T cell number	J:225938
Dock2^m6Btlr/Dock2^m6Btlr (C57BL/6J-Dock2^m6Btlr)	decreased IgE level	J:236689
Dock2^m6Btlr/Dock2^m6Btlr (C57BL/6J-Dock2^m6Btlr)	decreased response to antigen	J:236689
Dock2^m7Btlr/Dock2⁺ (C57BL/6J-Dock2^m7Btlr)	decreased B cell number	J:255181
	increased macrophage cell number	J:255181
	increased neutrophil cell number	J:255181
Dock2^m7Btlr/Dock2^m7Btlr (C57BL/6J-Dock2^m7Btlr)	decreased B cell number	J:255181
	increased IgE level	J:255181
	increased macrophage cell number	J:255181
	increased neutrophil cell number	J:255181
	increased NK cell number	J:255181
Dock2^m8Btlr/Dock2^m8Btlr (C57BL/6J-Dock2^m8Btlr)	decreased CD4-positive, alpha-beta T cell number	J:272402
Dock2^m8Btlr/Dock2^m8Btlr (C57BL/6J-Dock2^m8Btlr)	increased CD8-positive, alpha-beta T cell number	J:272402
Dock2^M9Btlr/Dock2^M9Btlr (C57BL/6J-Dock2^M9Btlr)	increased CD8-positive, alpha-beta T cell number	J:272403
Dock2^m10Btlr/Dock2^m10Btlr (C57BL/6J-Dock2^m10Btlr)	decreased B-1b cell number	J:272404
Dock2^m10Btlr/Dock2^m10Btlr (C57BL/6J-Dock2^m10Btlr)	increased NK cell number	J:272404
Dock2^m11Btlr/Dock2^m11Btlr (C57BL/6J-Dock2^m11Btlr)	abnormal B cell differentiation	J:272405
	abnormal CD4-positive T cell differentiation	J:272405
	abnormal CD8-positive, alpha-beta cytotoxic T cell morphology	J:272405
	decreased B cell number	J:272405
	decreased CD4-positive, alpha-beta T cell number	J:272405
	decreased CD8-positive, naive alpha-beta T cell number	J:272405
	decreased NK cell number	J:272405
	increased B-1 B cell number	J:272405
	increased CD8-positive, alpha-beta T cell number	J:272405
	increased central memory CD4-positive, alpha-beta T cell number	J:272405
	increased central memory CD8 positive, alpha-beta T cell number	J:272405
	increased effector memory CD4-positive, alpha-beta T cell number	J:272405
Dock2^M12Btlr/Dock2^M12Btlr (C57BL/6J-Dock2^M12Btlr)	decreased B-1a cell number	J:272406
Dock2^m13Btlr/Dock2^m13Btlr (C57BL/6J-Dock2^m13Btlr)	increased alpha-beta T cell number	J:272437
Dock2^m13Btlr/Dock2^m13Btlr (C57BL/6J-Dock2^m13Btlr)	increased CD8-positive, alpha-beta T cell number	J:272437
Dock2^M14Btlr/Dock2^M14Btlr (C57BL/6J-Dock2^M14Btlr)	abnormal lymphocyte morphology	J:272438
Dock2^M14Btlr/Dock2^M14Btlr (C57BL/6J-Dock2^M14Btlr)	increased CD8-positive, alpha-beta T cell number	J:272438
Dock2^m15Btlr/Dock2^m15Btlr (C57BL/6J-Dock2^m15Btlr)	decreased B cell number	J:274942
	decreased CD4-positive, alpha-beta T cell number	J:274942
	decreased CD8-positive, naive alpha-beta T cell number	J:274942
	decreased T cell number	J:274942
	increased B-1 B cell number	J:274942
	increased CD8-positive, alpha-beta T cell number	J:274942
	increased central memory CD8 positive, alpha-beta T cell number	J:274942
	increased NK cell number	J:274942
Dock2^M16Btlr/Dock2^M16Btlr (C57BL/6J-Dock2^M16Btlr)	abnormal CD8-positive, alpha-beta T cell number	J:274971
Dock2^{tm1b(EUCOMM)Wtsi}/Dock2^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Dock2^{tm1b(EUCOMM)Wtsi}/BayMmucd)	increased spleen weight	J:211773
Dock2^tm1Tsas/Dock2^tm1Tsas (involves: C57BL/6)	abnormal immune system morphology	J:71005
	abnormal leukocyte migration	J:71005
	abnormal Peyer's patch morphology	J:71005
	abnormal spleen morphology	J:71005
	abnormal spleen white pulp morphology	J:71005
	decreased marginal zone B cell number	J:71005
	lymph node hypoplasia	J:71005
	spleen hypoplasia	J:71005
Dock2^tm1Tsas/Dock2^tm1Tsas (B6.Cg-Dock2^tm1Tsas)	decreased lymphocyte cell number	J:130919
	decreased mature B cell number	J:130919
	decreased T cell number	J:130919
	impaired neutrophil chemotaxis	J:113266
Dock2^tm1Tsas/Dock2^tm1Tsas Tg(Tcra2B4)1Mmd/? Tg(Tcrb2B4)1Mmd/? (involves: C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:84581
	abnormal T cell physiology	J:84581
	decreased double-positive T cell number	J:84581
Dock3^tm1Dasc/Dock3^tm1Dasc (B6.Cg-Dock3^tm1Dasc)	abnormal microglial cell physiology	J:144341
Dock7^mnlt/Dock7^mnlt (C57BL/6J-Dock7^mnlt)	immune system phenotype	J:146458
Dock8^cpm/Dock8^cpm (C57BL/6JSfdAnu-Dock8^cpm)	abnormal humoral immune response	J:155516
	decreased marginal zone B cell number	J:155516
	decreased spleen germinal center size	J:155516
	decreased T cell number	J:155516
Dock8^cpm/Dock8^pri (C57BL/6J-Dock8^cpm/Dock8^pri)	decreased marginal zone B cell number	J:155516
Dock8^cpm/Dock8^pri (C57BL/6J-Dock8^cpm/Dock8^pri)	decreased T cell number	J:155516
Dock8^m1Anu/Dock8^m1Anu (C57BL/6NCrl-Dock8^m1Anu/Anu)	decreased activated T cell number	J:104190
	decreased IgM level	J:104190
	decreased T cell number	J:104190
Dock8^m1Btlr/Dock8^m1Btlr (C57BL/6J-Dock8^m1Btlr)	decreased IgG level	J:234247
Dock8^m1Btlr/Dock8^m1Btlr (C57BL/6J-Dock8^m1Btlr)	impaired humoral immune response	J:234247
Dock8^m2Anu/Dock8^m2Anu (C57BL/6NCrl-Dock8^m2Anu/Anu)	absent marginal zone B cells	J:104190
	decreased activated T cell number	J:104190
	decreased IgM level	J:104190
	decreased T cell number	J:104190
Dock8^M2Btlr/Dock8^M2Btlr (C57BL/6J-Dock8^M2Btlr)	decreased CD8-positive, alpha-beta T cell number	J:272530
Dock8^M3Btlr/Dock8^M3Btlr (C57BL/6J-Dock8^M3Btlr)	decreased IgG level	J:272531
Dock8^M3Btlr/Dock8^M3Btlr (C57BL/6J-Dock8^M3Btlr)	impaired humoral immune response	J:272531
Dock8^m4Btlr/Dock8^m4Btlr (C57BL/6J-Dock8^m4Btlr)	abnormal B cell differentiation	J:274856
	abnormal CD4-positive T cell differentiation	J:274856
	abnormal CD8-positive, alpha-beta T cell differentiation	J:274856
	abnormal T cell differentiation	J:274856
	decreased B-1 B cell number	J:274856
	decreased CD4-positive, alpha-beta T cell number	J:274856
	decreased CD8-positive, alpha-beta T cell number	J:274856
	decreased CD8-positive, naive alpha-beta T cell number	J:274856
	decreased T cell number	J:274856
	increased CD4-positive, alpha-beta T cell number	J:274856
	increased central memory CD4-positive, alpha-beta T cell number	J:274856
	increased central memory CD8 positive, alpha-beta T cell number	J:274856
	increased effector memory CD4-positive, alpha-beta T cell number	J:274856
	increased effector memory CD8-positive, alpha-beta T cell number	J:274856
Dock8^pri/Dock8^pri (C57BL/6JAnu-Dock8^pri)	abnormal humoral immune response	J:155516
	decreased B-1 B cell number	J:155516
	decreased germinal center B cell number	J:155516
	decreased marginal zone B cell number	J:155516
	decreased spleen germinal center size	J:155516
	decreased T cell number	J:155516
Dock8^pri/Dock8^pri (involves: C57BL/6JAnu)	abnormal cellular extravasation	J:238772
Dock8^pri/Dock8^pri (involves: C57BL/6JAnu)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:238772
Dock8^tm1Ysfk/Dock8^tm1Ysfk (B6.Cg-Dock8^tm1Ysfk)	abnormal dendritic cell physiology	J:185165
	decreased CD4-positive, alpha-beta T cell number	J:185165
	decreased CD8-positive, alpha-beta T cell number	J:185165
	decreased follicular dendritic cell number	J:185165
	decreased IgG level	J:185165
	decreased marginal zone B cell number	J:185165
	decreased T cell proliferation	J:185165
Dock8^tm1Ysfk/Dock8^tm1Ysfk Tg(TcrAND)53Hed/0 (involves: C57BL/6 * SJL)	dermatitis	J:305132
Dock9^tm1Thar/Dock9^tm1Thar (involves: C57BL/6)	immune system phenotype	J:300632
Dock10^{tm1a(EUCOMM)Hmgu}/Dock10^{tm1a(EUCOMM)Hmgu} (C57BL/6N-Dock10^{tm1a(EUCOMM)Hmgu}/Ieg)	abnormal B cell physiology	J:236911
	abnormal follicular B cell physiology	J:236911
	abnormal spleen marginal zone morphology	J:238172
	abnormal thymus cell ratio	J:238172
	arrested B cell differentiation	J:236911
	decreased B cell number	J:236911
	decreased follicular B cell number	J:236911
	decreased marginal zone B cell number	J:236911
	immune system phenotype	J:238172
	increased single-positive T cell number	J:236911
	increased T cell number	J:236911
Dock10^tm1Thar/Dock10^tm1Thar (involves: C57BL/6)	abnormal microglial cell chemotaxis	J:300632
	decreased B cell number	J:300632
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:300632
	impaired macrophage chemotaxis	J:300632
Dock11^tm1.1Mmar/Dock11^tm1.1Mmar (Not Specified)	abnormal metallophilic macrophage morphology	J:238172
	abnormal spleen marginal zone morphology	J:238172
	abnormal thymus cell ratio	J:238172
	decreased marginal zone B cell number	J:238172
	immune system phenotype	J:238172
Dock11^tm1Thar/Dock11^tm1Thar (involves: C57BL/6)	immune system phenotype	J:300632
Dock11^tm1Thar/Dock11^tm1Thar (involves: C57BL/6)	impaired macrophage chemotaxis	J:300632
Dohh^tm1.2Sbal/Dohh⁺ (B6.129(Cg)-Dohh^tm1.2Sbal)	abnormal spleen morphology	J:214321
Dok1^tm1Ppp/Dok1^tm1Ppp (129S1/Sv-Dok1^tm1Ppp)	abnormal T cell proliferation	J:95640
Dok1^tm1Ppp/Dok1^tm1Ppp Dok2^tm1Ppp/Dok2^tm1Ppp (129S1/Sv-Dok1^tm1Ppp Dok2^tm1Ppp)	abnormal leukocyte physiology	J:95334
	enlarged spleen	J:95334
	increased leukocyte cell number	J:95334
	increased monocyte cell number	J:95334
	increased neutrophil cell number	J:95334
Dok1^tm1Ppp/Dok1^tm1Ppp Dok2^tm1Ppp/Dok2^tm1Ppp Dok3^tm1Ppp/Dok3^tm1Ppp (129S1/Sv-Dok1^tm1Ppp Dok2^tm1Ppp Dok3^tm1Ppp)	increased leukocyte cell number	J:158011
Dok1^tm1Yyam/Dok1^tm1Yyam (involves: 129S4/SvJae * C57BL/6)	decreased IgM level	J:95641
Dok1^tm1Yyam/Dok1^tm1Yyam (involves: 129S4/SvJae * C57BL/6)	increased B cell proliferation	J:95641
Dok1^tm1Yyam/Dok1^tm1Yyam Dok2^tm1Yyam/Dok2^tm1Yyam (B6.129-Dok1^tm1Yyam Dok2^tm1Yyam)	abnormal leukocyte physiology	J:95335
	abnormal myelopoiesis	J:95335
	enlarged spleen	J:95335
	increased leukocyte cell number	J:95335
	increased monocyte cell number	J:95335
	increased neutrophil cell number	J:95335
Dok1^tm1Yyam/Dok1^tm1Yyam Dok2^tm1Yyam/Dok2^tm1Yyam (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)	abnormal macrophage physiology	J:163407
Dok1^tm1Yyam/Dok1^tm1Yyam Dok2^tm1Yyam/Dok2^tm1Yyam Dok3^tm1Brs/Dok3^tm1Brs (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)	abnormal macrophage physiology	J:163407
	increased macrophage cell number	J:163407
Dok1^tm1Yyam/Dok1^tm1Yyam Dok2^tm1Yyam/Dok2^tm1Yyam Tg(Tec-BCR/ABL1)5Hhi/0 (involves: C57BL/6)	enlarged lymph nodes	J:95335
	enlarged thymus	J:95335
Dok1^tm1Yyam/Dok1^tm1Yyam Tg(Tec-BCR/ABL1)5Hhi/0 (involves: C57BL/6)	enlarged lymph nodes	J:95335
	enlarged thymus	J:95335
Dok2^tm1Ppp/Dok2^tm1Ppp (129S1/Sv-Dok2^tm1Ppp)	abnormal granulocyte physiology	J:95334
Dok2^tm1Yyam/Dok2^tm1Yyam Tg(Tec-BCR/ABL1)5Hhi/0 (involves: C57BL/6)	enlarged lymph nodes	J:95335
	enlarged thymus	J:95335
Dok3^tm1Brs/Dok3^tm1Brs (involves: C57BL/6)	increased macrophage cell number	J:163407
Dok3^tm1Kplm/Dok3^tm1Kplm (involves: 129P2/OlaHsd)	abnormal B cell calcium ion homeostasis	J:280795
	abnormal B cell physiology	J:280795
	enhanced humoral immune response	J:280795
	increased B cell proliferation	J:280795
	increased IgG3 level	J:280795
	increased IgM level	J:280795
Dok7^{tm1.1(KOMP)Vlcg}/Dok7⁺ (C57BL/6N-Dok7^{tm1.1(KOMP)Vlcg}/Ucd)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Dop1b^{tm1a(EUCOMM)Wtsi}/Dop1b^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Dop1b^{tm1a(EUCOMM)Wtsi}/Wtsi)	increased leukocyte cell number	J:211773
Dot1l^tm1.1Saam/Dot1l^tm1.1Saam Tg(VAV1-cre)1Graf/0 (involves: 129S1/Sv * C57BL/6)	abnormal leukopoiesis	J:193161
	decreased lymphocyte cell number	J:193161
	decreased neutrophil cell number	J:193161
Dp(11Cops3-Rnf112)1Jrl/0 (involves: 129S7/SvEvBrd * C57BL/6)	decreased spleen weight	J:83302
Dp(16Cbr1-Fam3b)1Rhr/0 Gata1^tm8.2Sho/Y (involves: 129S1/Sv * 129S6/SvEvTac)	enlarged spleen	J:184564
	increased monocyte cell number	J:184564
Dp(17Nfkbil1-Or2h1)1Cogr/0 (involves: 129S6/SvEvTac * C57BL/6J)	immune system phenotype	J:190754
Dpcd/Poll^{Gt(OST280355)Lex}/Dpcd/Poll^{Gt(OST280355)Lex} (involves: 129S5/SvEvBrd * C57BL/6Brd)	increased susceptibility to otitis media	J:185566
Dph6^{tm1a(KOMP)Wtsi}/Dph6^{tm1a(KOMP)Wtsi} (C57BL/6N-Dph6^{tm1a(KOMP)Wtsi}/Wtsi)	decreased CD8-positive, alpha-beta T cell number	J:211773
	decreased CD8-positive, naive alpha-beta T cell number	J:211773
	decreased effector memory CD8-positive, alpha-beta T cell number	J:211773
	decreased Ly6C-positive mature NK cell number	J:211773
	decreased mature B cell number	J:211773
	decreased NK T cell number	J:211773
	decreased T-helper cell number	J:211773
	increased CD4-positive, alpha-beta memory T cell number	J:211773
	increased CD4-positive, alpha-beta T cell number	J:211773
	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	increased CD5-positive gamma-delta T cell number	J:211773
	increased CD11b-low dendritic cell number	J:211773
	increased dendritic cell number	J:211773
	increased effector memory T-helper cell number	J:211773
	increased gamma-delta T cell number	J:211773
	increased granulocyte number	J:211773
	increased KLRG1-positive CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	increased KLRG1-positive T-helper cell number	J:211773
	increased marginal zone B cell number	J:211773
	increased memory CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	increased memory-marker CD4-negative NK T cell number	J:211773
	increased memory-marker gamma-delta T cell number	J:211773
	increased monocyte cell number	J:211773
	increased plasma cell number	J:211773
	increased plasmacytoid dendritic cell number	J:211773
Dpp3^{tm1d(EUCOMM)Hmgu}/Dpp3^{tm1d(EUCOMM)Hmgu} (involves: BALB/c * C57BL/6 * C57BL/6J * C57BL/6N * SJL)	abnormal interferon-gamma secretion	J:294242
	increased interleukin-1 beta secretion	J:294242
	increased interleukin-6 secretion	J:294242
	increased interleukin-10 secretion	J:294242
	increased osteoclast cell number	J:294242
	increased tumor necrosis factor secretion	J:294242
Dpp4^em1Rba/Dpp4⁺ (C57BL/6J-Dpp4^em1Rba)	decreased susceptibility to Coronaviridae infection induced morbidity/mortality	J:279834
	increased susceptibility to Coronaviridae infection	J:279834
	lung inflammation	J:279834
Dpp4^em1Rba/Dpp4^em1Rba (C57BL/6J-Dpp4^em1Rba)	decreased lymphocyte cell number	J:279723
	increased monocyte cell number	J:279723
	increased neutrophil cell number	J:279723
	increased susceptibility to Coronaviridae infection	J:279723, J:279834
	increased susceptibility to Coronaviridae infection induced morbidity/mortality	J:279834
	lung inflammation	J:279834
Dpp4^em3Gpt/Dpp4^em3Gpt (C57BL/6JGpt-Dpp4^em3Gpt)	immune system phenotype	J:324112
Dpp4^{tm1(DPP4)Vlcg}/? (involves: 129S6/SvEvTac * C57BL/6NTac)	increased susceptibility to Coronaviridae infection	J:223728
	interstitial pneumonia	J:223728
	lung inflammation	J:223728
Dpp4^{tm1(DPP4)Vlcg}/? (involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NTac)	increased CD4-positive, alpha-beta T cell number	J:238079
	increased CD8-positive, alpha-beta T cell number	J:238079
	increased macrophage cell number	J:238079
	increased neutrophil cell number	J:238079
	increased susceptibility to Coronaviridae infection	J:238079
	lung inflammation	J:238079
	pleuritis	J:238079
Dpp4^{tm1.1(DPP4)Pbmj}/Dpp4^{tm1.1(DPP4)Pbmj} (involves: C57BL/6 * C57BL/6NTac)	increased susceptibility to Coronaviridae infection	J:242025
	increased susceptibility to Coronaviridae infection induced morbidity/mortality	J:242025
	lung inflammation	J:242025
Dpp4^{tm1b(EUCOMM)Wtsi}/Dpp4^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Dpp4^{tm1b(EUCOMM)Wtsi}/Ics)	decreased lymphocyte cell number	J:211773
Dpp9^{em1(IMPC)Ccpcz}/Dpp9⁺ (C57BL/6NCrl-Dpp9^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
Dppa1^{tm1b(KOMP)Wtsi}/Dppa1⁺ (C57BL/6N-Dppa1^{tm1b(KOMP)Wtsi}/Bay)	abnormal spleen morphology	J:211773
Dpy19l4^em1(IMPC)J/Dpy19l4^em1(IMPC)J (C57BL/6NJ-Dpy19l4^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
Drc1^b2b1654Clo/Drc1^b2b1654Clo (C57BL/6J-Drc1^b2b1654Clo)	absent spleen	J:175213
Drd1^tm1Jcd/Drd1^tm1Jcd Drd2^tm1Ebo/Drd2⁺ (involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)	small intestinal inflammation	J:91781
Drd1^tm2Jcd/Drd1⁺ Tg(Camk2a-cre)2Gsc/0 (involves: 129S4/SvJae * FVB/N)	abnormal microglial cell physiology	J:120070
Drd2^tm1Low/Drd2^tm1Low (B6.129S2-Drd2^tm1Low/J)	decreased spleen weight	J:106832
	increased interleukin-1 beta secretion	J:194407
	microgliosis	J:194407
Drd3^em1(IMPC)Mbp/Drd3^em1(IMPC)Mbp (C57BL/6N-Drd3^em1(IMPC)Mbp/MbpMmucd)	small spleen	J:211773
Drgx^em1(IMPC)Mbp/Drgx⁺ (C57BL/6N-Drgx^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Drosha^tm1Litt/Drosha^tm1.1Litt Foxp3^{tm4(YFP/icre)Ayr}/Y (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)	abnormal interferon-gamma secretion	J:138683
	abnormal interleukin-4 secretion	J:138683
	abnormal T cell activation	J:138683
	blood vessel inflammation	J:138683
	enlarged lymph nodes	J:138683
	enlarged spleen	J:138683
	increased CD8-positive, alpha-beta T cell number	J:138683
	increased leukocyte cell number	J:138683
	liver inflammation	J:138683
	lung inflammation	J:138683
Drosha^tm1Litt/Drosha^tm1.1Litt Foxp3^{tm4(YFP/icre)Ayr}/Foxp3^{tm4(YFP/icre)Ayr} (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)	abnormal interferon-gamma secretion	J:138683
	abnormal interleukin-4 secretion	J:138683
	abnormal regulatory T cell morphology	J:138683
	abnormal T cell activation	J:138683
	blood vessel inflammation	J:138683
	enlarged lymph nodes	J:138683
	enlarged spleen	J:138683
	increased CD8-positive, alpha-beta T cell number	J:138683
	increased leukocyte cell number	J:138683
	liver inflammation	J:138683
	lung inflammation	J:138683
Drosha^tm1Litt/Drosha^tm1.1Litt Gt(ROSA)26Sor^{tm1(cre/ERT)Nat}/Gt(ROSA)26Sor⁺ (involves: 129 * 129P2/OlaHsd * C57BL/6 * FVB/N)	abnormal interferon-gamma secretion	J:138683
Drosha^tm1Litt/Drosha^tm1.1Litt Tg(Cd4-cre)1Cwi/0 (involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * FVB/N)	abnormal immune system physiology	J:138683
	decreased CD8-positive, alpha-beta T cell number	J:138683
	decreased double-positive T cell number	J:138683
	decreased lymphocyte cell number	J:138683
	decreased regulatory T cell number	J:138683
	decreased thymocyte number	J:138683
	immune system phenotype	J:138683
	increased activated T cell number	J:138683
	increased gamma-delta T cell number	J:138683
	increased granulocyte number	J:138683
	intestinal inflammation	J:138683
	liver inflammation	J:138683
	lung inflammation	J:138683
Dsc1^tm1Dga/Dsc1^tm1Dga (involves: C57BL/6J)	dermatitis	J:73102
Dsc2^tm1.1Leu/Dsc2^tm1.1Leu Tg(Vil1-cre)20Syr/0 (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	immune system phenotype	J:302333
Dsg2^m1Btlr/Dsg2^m1Btlr (C57BL/6J-Dsg2^m1Btlr)	increased susceptibility to induced colitis	J:271975
Dsg2^m2Btlr/Dsg2^m2Btlr (C57BL/6J-Dsg2^m2Btlr)	increased susceptibility to induced colitis	J:271976
Dsg2^m3Btlr/Dsg2^m3Btlr (C57BL/6J-Dsg2^m3Btlr)	increased susceptibility to induced colitis	J:271977
Dsg2^{tm1d(EUCOMM)Wtsi}/Dsg2^{tm1d(EUCOMM)Wtsi} (involves: C57BL/6J * C57BL/6N)	heart inflammation	J:235770
Dsg2^tm3.1Leu/Dsg2^tm3.1Leu Tg(Vil1-cre)20Syr/0 (involves: 129S7/SvEvBrd * C57BL/6 * DBA/2)	increased susceptibility to colitis induced morbidity/mortality	J:302333
	increased susceptibility to induced colitis	J:302333
Dsg3^bal/Dsg3^bal (C57BL/6J-Dsg3^bal/J)	cutaneous mastocytosis	J:18223
Dsg3^bal/Dsg3^bal (C57BL/6J-Dsg3^bal/J)	increased IgE level	J:18223
Dsg3^sqk/Dsg3^sqk (C57BL/6-Dsg3^sqk)	conjunctivitis	J:219200
	decreased B cell number	J:219200
	decreased double-positive T cell number	J:219200
	decreased immature B cell number	J:219200
	decreased lymphocyte cell number	J:219200
	decreased pre-B cell number	J:219200
	decreased single-positive T cell number	J:219200
	decreased transitional stage B cell number	J:219200
	increased neutrophil cell number	J:219200
	increased susceptibility to infection	J:219200
Dsg3^tm1Stan/Dsg3^tm1Stan (involves: 129X1/SvJ * C57BL/6J)	conjunctivitis	J:40804
Dsg4^hage/Dsg4^hage Fas^lpr/Fas^lpr X/Yaa (EOD-Dsg4^hage)	abnormal effector T cell morphology	J:140028
Dsg4^hage/Dsg4^hage Fas^lpr/Fas^lpr X/Yaa (EOD-Dsg4^hage)	abnormal mast cell morphology	J:140028
Dsg4^lah-J/Dsg4^lah-J (involves: DBA/1LacJ)	abnormal peripheral lymph node morphology	J:83117
	dermatitis	J:83117
	increased IgE level	J:83117
Dsg4^lah/Dsg4^lah (LAH/Pas)	dermatitis	J:33849
Dsp^em1(IMPC)Mbp/Dsp⁺ (C57BL/6N-Dsp^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
Dsp^em1(IMPC)Mbp/Dsp⁺ (C57BL/6N-Dsp^em1(IMPC)Mbp/MbpMmucd)	enlarged lymph nodes	J:211773
Dspp^tm1Kul/Dspp^tm1Kul (B6;129-Dspp^tm1Kul/Mmnc)	periodontium inflammation	J:241990
Dssc1^C3H/HeJ/Dssc1^C57BL/6J (involves: C3H/HeJ * C57BL/6J)	colitis	J:52852
Dssc1^C57BL/6J/Dssc1^C57BL/6J (involves: C3H/HeJ * C57BL/6J)	colitis	J:52852
Dssc2^C3H/HeJ/Dssc2^C3H/HeJ (involves: C3H/HeJ * C57BL/6J)	colitis	J:52852
Dssc2^C3H/HeJ/Dssc2^C57BL/6J (involves: C3H/HeJ * C57BL/6J)	colitis	J:52852
Dst^Tg4/Dst^Tg4 (involves: C57BL/6 * CD-1)	conjunctivitis	J:209161
Dstn^corn1/Dstn^corn1 (A.BY-H2^bc H2-T18^f/SnJ)	abnormal lymphangiogenesis	J:98465
Dstn^corn1/Dstn^corn1 (A.BY-H2^bc H2-T18^f/SnJ)	immune system phenotype	J:98465
Dstn^corn1/Dstn^corn1 (A.BY-H2^bc H2-T18^f/SnJ-Dstn^corn1/J)	immune system phenotype	J:139239
Dtnbp1^sdy-Btlr/Dtnbp1^sdy-Btlr (C57BL/6J-Dtnbp1^sdy-Btlr)	impaired natural killer cell mediated cytotoxicity	J:133620
Dtnbp1^sdy-Btlr/Dtnbp1^sdy-Btlr (C57BL/6J-Dtnbp1^sdy-Btlr)	increased susceptibility to Herpesvirales infection	J:133620
Dtnbp1^{tm1b(EUCOMM)Hmgu}/Dtnbp1^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Dtnbp1^{tm1b(EUCOMM)Hmgu}/Tcp)	decreased lymphocyte cell number	J:211773
	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Dtx1^tm1.1Mzl/Dtx1^tm1.1Mzl Tg(Cd4-cre)1Cwi/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)	abnormal thymocyte activation	J:151605
	increased anti-double stranded DNA antibody level	J:151605
	increased anti-histone antibody level	J:151605
	increased autoantibody level	J:151605
	increased interleukin-2 secretion	J:151605
	increased T cell proliferation	J:151605
Dtx1^tm1.2Mzl/Dtx1^tm1.2Mzl (B6.129-Dtx1^tm1.2Mzl)	abnormal lymphocyte morphology	J:151605
	abnormal lymphocyte physiology	J:151605
	abnormal regulatory T cell physiology	J:151605
	abnormal T cell anergy	J:151605
	abnormal thymocyte activation	J:151605
	decreased marginal zone B cell number	J:151605
	decreased thymocyte apoptosis	J:151605
	glomerulonephritis	J:151605
	increased anti-double stranded DNA antibody level	J:151605
	increased anti-histone antibody level	J:151605
	increased B cell proliferation	J:151605
	increased interferon-gamma secretion	J:151605
	increased interleukin-2 secretion	J:151605
	increased interleukin-4 secretion	J:151605
	increased T cell proliferation	J:151605
	liver inflammation	J:151605
	lung inflammation	J:151605
	spleen hyperplasia	J:151605
Dtx1^tm1Mjb/Dtx1^tm1Mjb (either: B6.129S6-Dtx1^tm1Mjb or (involves: 129S6/SvEvTac * C57BL/6))	immune system phenotype	J:114658
Dtx1^tm1Mjb/Dtx1^tm1Mjb Dtx2^tm1Mjb/Dtx2^tm1Mjb (involves: 129S6/SvEvTac * C57BL/6)	immune system phenotype	J:114658
Dtx2^tm1Mjb/Dtx2^tm1Mjb (involves: 129S6/SvEvTac)	immune system phenotype	J:114658
Dtx4^{em1(IMPC)Ccpcz}/Dtx4⁺ (C57BL/6N-Dtx4^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Ducm1^129X1/SvJ/Ducm1^129X1/SvJ (involves: 129X1/SvJ * C57BL/6J)	abnormal professional antigen presenting cell physiology	J:86617
Ducm1^129X1/SvJ/Ducm1^C57BL/6J (involves: 129X1/SvJ * C57BL/6J)	abnormal professional antigen presenting cell physiology	J:86617
Duox2^em1(IMPC)Mbp/Duox2^em1(IMPC)Mbp (C57BL/6N-Duox2^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	decreased lymphocyte cell number	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	increased neutrophil cell number	J:211773
	small spleen	J:211773
Duoxa2^{tm1b(KOMP)Wtsi}/Duoxa2^{tm1b(KOMP)Wtsi} (C57BL/6N-Duoxa2^{tm1b(KOMP)Wtsi}/Wtsi)	decreased B cell number	J:211773
	decreased B-2 B cell number	J:211773
	decreased CD8-positive, alpha-beta T cell number	J:211773
	decreased CD11b-high dendritic cell number	J:211773
	decreased effector memory T-helper cell number	J:211773
	decreased follicular B cell number	J:211773
	decreased immature B cell number	J:211773
	decreased KLRG1-positive NK cell number	J:211773
	decreased leukocyte cell number	J:211773
	decreased Ly6C low monocyte number	J:211773
	decreased mature B cell number	J:211773
	decreased memory CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	decreased memory-marker gamma-delta T cell number	J:211773
	decreased NK cell number	J:211773
	decreased transitional stage T1 B cell number	J:211773
	increased alpha-beta T cell number	J:211773
	increased CD4-positive, alpha-beta T cell number	J:211773
	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	increased CD8-positive, alpha-beta T cell number	J:211773
	increased CD8-positive, naive alpha-beta T cell number	J:211773
	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
	increased neutrophil cell number	J:211773
	increased plasmacytoid dendritic cell number	J:211773
	increased T cell number	J:211773
	increased T-helper cell number	J:211773
Dusp1^tm1Brv/Dusp1^tm1Brv (involves: 129S2/SvPas)	abnormal cytokine secretion	J:118832
Dusp1^tm1Brv/Dusp1^tm1Brv (involves: 129S2/SvPas)	lung inflammation	J:118832
Dusp1^tm1Brv/Dusp1^tm1Brv (involves: 129S2/SvPas * C57BL/6)	increased circulating interleukin-6 level	J:118833
	increased circulating interleukin-10 level	J:118833
	increased circulating tumor necrosis factor level	J:118833
	increased interleukin-6 secretion	J:118833
	increased susceptibility to endotoxin shock	J:118833
	increased tumor necrosis factor secretion	J:118833
Dusp1^tm1Brv/Dusp1^tm1Brv (involves: 129S2/SvPas * various)	immune system phenotype	J:125919
	increased mast cell degranulation	J:125919
	increased susceptibility to type I hypersensitivity reaction	J:125919
Dusp1^tm1Brv/Dusp1^tm1Brv (C3.129S2-Dusp1^tm1Brv)	abnormal chemokine secretion	J:164929
	increased granulocyte number	J:164929
	increased interleukin-1 beta secretion	J:164929
	increased interleukin-6 secretion	J:164929
	increased susceptibility to bacterial infection	J:164929
	lung inflammation	J:164929
Dusp1^tm1Lex/Dusp1^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6)	abnormal chemokine level	J:126383
	abnormal innate immunity	J:126383
	abnormal interleukin level	J:126383
	increased circulating interferon-gamma level	J:126383
	increased circulating interleukin-6 level	J:126383
	increased circulating interleukin-10 level	J:126383
	increased circulating tumor necrosis factor level	J:126383
	increased susceptibility to endotoxin shock	J:126383
	increased susceptibility to induced arthritis	J:126383
Dusp2^tm1Cmac/Dusp2^tm1Cmac (B6.Cg-Dusp2^tm1Cmac)	abnormal cytokine secretion	J:112609
	abnormal macrophage activation involved in immune response	J:112609
	abnormal mast cell physiology	J:112609
	decreased susceptibility to induced arthritis	J:112609
Dusp4^Gt(XG164)Byg/Dusp4^Gt(XG164)Byg (B6.129P2-Dusp4^Gt(XG164)Byg)	immune system phenotype	J:180366
	increased CD4-positive, alpha-beta T cell number	J:180366
	increased interleukin-10 secretion	J:180366
	increased T cell proliferation	J:180366
Dusp4^tm1Jmol/Dusp4^tm1Jmol (involves: 129)	decreased B cell apoptosis	J:140567
Dusp4^tm1Plev/Dusp4^tm1Plev (involves: 129/Sv * C57BL/6)	abnormal macrophage physiology	J:170774
	decreased IgG2a level	J:170774
	decreased interferon-gamma secretion	J:170774
	decreased interleukin-10 secretion	J:170774
	increased IgG1 level	J:170774
	increased interleukin-4 secretion	J:170774
	increased interleukin-6 secretion	J:170774
	increased interleukin-12 secretion	J:170774
	increased interleukin-13 secretion	J:170774
	increased susceptibility to parasitic infection	J:170774
	increased tumor necrosis factor secretion	J:170774
Dusp5^tm1.1Achn/Dusp5^tm1.1Achn (involves: C57BL/6NCrl)	abnormal susceptibility to parasitic infection	J:218203
	immune system phenotype	J:218203
	increased T cell proliferation	J:218203
	increased thymocyte number	J:218203
Dusp5^tm1.1Achn/Dusp5^tm1.1Achn Rag2^tm1.1Cgn/Rag2^tm1.1Cgn (involves: C57BL/6NCrl)	abnormal eosinophil physiology	J:218203
	abnormal susceptibility to parasitic infection	J:218203
	increased eosinophil cell number	J:218203
Dusp5^{tm1a(KOMP)Wtsi}/Dusp5^{tm1a(KOMP)Wtsi} (C57BL/6-Dusp5^{tm1a(KOMP)Wtsi})	abnormal CD8-positive, alpha beta T cell morphology	J:240637
	abnormal T cell physiology	J:240637
	increased effector memory CD8-positive, alpha-beta T cell number	J:240637
	increased T cell apoptosis	J:240637
	increased T cell proliferation	J:240637
Dusp5^{tm1d(KOMP)Wtsi}/Dusp5^{tm1d(KOMP)Wtsi} (B6(Cg)-Dusp5^{tm1d(KOMP)Wtsi})	increased T cell apoptosis	J:240637
Dusp6^tm1Jmol/Dusp6^tm1Jmol (involves: 129 * C57BL/6)	increased spleen weight	J:142966
Dusp10^tm1Flv/Dusp10^tm1Flv (involves: 129S6/SvEvTac)	abnormal adaptive immunity	J:92104
	abnormal cytokine secretion	J:92104
	abnormal interleukin secretion	J:92104
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:92104
	decreased T cell proliferation	J:92104
	increased activated T cell number	J:92104
	increased interferon-gamma secretion	J:92104
	increased susceptibility to type I hypersensitivity reaction	J:92104
	increased tumor necrosis factor secretion	J:92104
Dusp11^{Gt(BB0198)Wtsi}/Dusp11^{Gt(BB0198)Wtsi} (B6.129P2-Dusp11^{Gt(BB0198)Wtsi})	abnormal macrophage activation involved in immune response	J:301503
	immune system phenotype	J:301503
	increased circulating interleukin-1 beta level	J:301503
	increased circulating interleukin-6 level	J:301503
	increased circulating tumor necrosis factor level	J:301503
	increased macrophage cytokine production	J:301503
	increased susceptibility to endotoxin shock	J:301503
Dusp12^em1(IMPC)Mbp/Dusp12⁺ (C57BL/6N-Dusp12^em1(IMPC)Mbp/Ucd)	increased basophil cell number	J:211773
Dusp14^{Gt(OST210117)Lex}/Dusp14^{Gt(OST210117)Lex} (B6.129S5-Dusp14^{Gt(OST210117)Lex})	abnormal cytokine secretion	J:209403
	abnormal humoral immune response	J:209403
	abnormal T cell activation	J:209403
	immune system phenotype	J:209403
	increased susceptibility to experimental autoimmune encephalomyelitis	J:209403
	increased T cell proliferation	J:209403
	increased T-helper 1 cell number	J:209403
	increased T-helper 17 cell number	J:209403
Dusp16^em1(IMPC)Tcp/Dusp16^em1(IMPC)Tcp (C57BL/6NCrl-Dusp16^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	increased spleen weight	J:211773
Dusp22^tm1Tht/Dusp22^tm1Tht (B6.129S7-Dusp22^tm1Tht)	abnormal B cell activation	J:213253
	abnormal cytokine level	J:213253
	abnormal T cell activation	J:213253
	decreased B cell proliferation	J:213253
	decreased IgG3 level	J:213253
	decreased IgM level	J:213253
	decreased immunoglobulin level	J:213253
	enlarged spleen	J:213253
	increased circulating interferon-gamma level	J:213253
	increased circulating interleukin-6 level	J:213253
	increased circulating interleukin-17 level	J:213253
	increased circulating tumor necrosis factor level	J:213253
	increased inflammatory response	J:213253
	increased interferon-gamma secretion	J:213253
	increased interleukin-2 secretion	J:213253
	increased interleukin-4 secretion	J:213253
	increased interleukin-17 secretion	J:213253
	increased spleen white pulp amount	J:213253
	increased susceptibility to autoimmune disorder	J:213253
	increased susceptibility to experimental autoimmune encephalomyelitis	J:213253
	increased T cell proliferation	J:213253
	kidney inflammation	J:213253
	liver inflammation	J:213253
	lung inflammation	J:213253
Dvl3^b2b2866Clo/Dvl3^b2b2866Clo (C57BL/6J-Dvl3^b2b2866Clo)	thymus hypoplasia	J:175213
Dync1li1^em1(IMPC)Tcp/Dync1li1⁺ (C57BL/6NCrl-Dync1li1^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Dyrk1a^tm1Jdc/Dyrk1a^tm1Jdc Tg(Mx1-cre)1Cgn/0 (involves: 129/Sv * C57BL/6J * C57BL/6NTac * CBA/J)	decreased B cell number	J:223138
	decreased double-positive T cell number	J:223138
	decreased immature B cell number	J:223138
	decreased mature B cell number	J:223138
	decreased pre-B cell number	J:223138
	decreased thymocyte number	J:223138
	increased T cell apoptosis	J:223138
Dyrk1b^{tm1b(EUCOMM)Wtsi}/Dyrk1b⁺ (C57BL/6N-Dyrk1b^{tm1b(EUCOMM)Wtsi}/Ics)	decreased large unstained cell number	J:211773
	decreased lymphocyte cell number	J:211773
Dyrk2^em1(IMPC)Ics/Dyrk2⁺ (C57BL/6N-Dyrk2^em1(IMPC)Ics/Ics)	decreased large unstained cell number	J:211773
Dysf^im/Dysf⁺ Large1^myd/Large1^myd (involves: C57BL/6 * SJL/J)	myositis	J:221523
Dysf^im/Dysf^im Fktn^tm1Ttd/Fktn^tm2(FCMD)Ttd (involves: 129S7/SvEvBrd * C57BL/6 * SJL/J)	myositis	J:221523
Dysf^im/Dysf^im Large1^myd/Large1^myd (involves: C57BL/6 * SJL/J)	myositis	J:221523
Dysf^tm1Kcam/Dysf^tm1Kcam (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	myositis	J:171870
Dytn^em1(IMPC)J/Dytn^em1(IMPC)J (C57BL/6NJ-Dytn^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
E2f1^{Tg(Wnt1-cre)2Sor}/E2f1⁺ Snrpb^em1Lajm/Snrpb⁺ (involves: C3H * C57BL/6 * C57BL/6J * CD1)	athymia	J:326544
E2f1^tm1Meg/E2f1^tm1Meg (either: (involves: 129/Sv * 129S4/SvJae) or (involves: 129/Sv * 129S4/SvJae * C57BL/6))	abnormal double-positive T cell morphology	J:33100
	enlarged thymus	J:33100
	increased CD4-positive, alpha-beta T cell number	J:33100
	increased CD8-positive, alpha-beta T cell number	J:33100
	increased T cell derived lymphoma incidence	J:33100
	increased thymocyte number	J:33100
	increased thymus weight	J:33100
E2f1^tm1Meg/E2f1^tm1Meg (NOD.Cg-E2f1^tm1Meg)	abnormal CD4-positive, alpha beta T cell morphology	J:93708
	abnormal CD8-positive, alpha beta T cell morphology	J:93708
	abnormal double-positive T cell morphology	J:93708
	decreased double-positive T cell number	J:93708
	decreased regulatory T cell number	J:93708
	enlarged thymus	J:93708
	increased interferon-gamma secretion	J:93708
	increased interleukin-4 secretion	J:93708
	increased susceptibility to autoimmune diabetes	J:93708
	increased T cell number	J:93708
	increased thymocyte number	J:93708
	insulitis	J:93708
	salivary gland inflammation	J:93708
E2f1^tm1Meg/E2f1^tm1Meg (involves: 129S4/SvJae * C57BL/6)	decreased T cell proliferation	J:76318
E2f2^tm1Zubi/E2f2^tm1Zubi (involves: 129S1/Sv * C57BL/6)	abnormal immune system morphology	J:76318
	abnormal immune system physiology	J:76318
	abnormal spleen white pulp morphology	J:76318
	abnormal T cell differentiation	J:76318
	abnormal T cell subpopulation ratio	J:76318
	enlarged spleen	J:76318
	glomerulonephritis	J:76318
	increased anti-double stranded DNA antibody level	J:76318
	increased inflammatory response	J:76318
	increased memory T cell number	J:76318
	increased spleen weight	J:76318
	increased susceptibility to autoimmune disorder	J:76318
	increased T cell proliferation	J:76318
	liver inflammation	J:76318
	lung inflammation	J:76318
E2f2^tm1Zubi/E2f2^tm1Zubi Tg(TcraH-Y,TcrbH-Y)71Vbo/? (involves: 129S1/Sv * C57BL/6 * C57BL/6J * DBA/2J)	abnormal immune system morphology	J:76318
	abnormal immune system physiology	J:76318
	enlarged spleen	J:76318
	increased CD8-positive, alpha-beta T cell number	J:76318
	increased inflammatory response	J:76318
	increased susceptibility to autoimmune disorder	J:76318
	increased T cell proliferation	J:76318
	thymus hypoplasia	J:76318
E2f3^tm1Lees/E2f3^tm1Lees (involves: 129S2/SvPas * C57BL/6)	lung inflammation	J:75765
E2f4^tm1Jrn/E2f4^tm1Jrn (involves: 129P2/OlaHsd * C57BL/6)	abnormal granulocyte morphology	J:64192
	decreased double-positive T cell number	J:64192
	decreased granulocyte number	J:64192
	decreased thymocyte number	J:64192
	increased double-negative T cell number	J:64192
	increased NK cell number	J:64192
	thymus hypoplasia	J:64192
E2f4^tm1Lees/E2f4^tm1Lees (involves: 129S2/SvPas * C57BL/6)	increased susceptibility to bacterial infection	J:64193
	increased susceptibility to otitis media	J:64193
	rhinitis	J:64193
E2f4^tm1Lees/E2f4^tm1Lees Rb1^tm1Tyj/Rb1⁺ (involves: 129S2/SvPas * C57BL/6)	increased susceptibility to infection	J:81082
E2f6^{em1(IMPC)Ccpcz}/E2f6^{em1(IMPC)Ccpcz} (C57BL/6NCrl-E2f6^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	small spleen	J:211773
	small thymus	J:211773
Eae1^A/J/Eae1^A/J (involves: A/J * C57BL/10SnJ)	increased susceptibility to experimental autoimmune encephalomyelitis	J:30574
Eae1^PL/J/Eae1^PL/J (involves: C57BL/10SnJ * PL/J)	increased susceptibility to experimental autoimmune encephalomyelitis	J:30574
Eae2^B10.RIII/Eae2^RIIIS/J (involves: B10.RIII * RIIIS/J)	autoimmune arthritis	J:95848
Eae2^RIIIS/J/Eae2^RIIIS/J (involves: B10.RIII * RIIIS/J)	decreased susceptibility to induced arthritis	J:95848
Eae2b^C57BL/10SnSg/Eae2b^C57BL/10SnSg (involves: B10.RIII * RIIIS/J)	CNS inflammation	J:96204
Eae4^ABH/? (involves: ABH * NOD)	increased susceptibility to experimental autoimmune encephalomyelitis	J:29171
Eae5^B10.S/DvTe/Eae5^SJL/J (involves: B10.S/DvTe * SJL/J)	increased susceptibility to experimental autoimmune encephalomyelitis	J:49054
Eae5^SJL/J/Eae5^SJL/J (involves: B10.S/DvTe * SJL/J)	increased susceptibility to experimental autoimmune encephalomyelitis	J:49054
Eae7^B10.S/DvTe/Eae7^B10.S/DvTe (involves: B10.S/DvTe * SJL/J)	brain inflammation	J:49054
	increased susceptibility to experimental autoimmune encephalomyelitis	J:49054
Eae7^B10.S/DvTe/Eae7^SJL/J (involves: B10.S/DvTe * SJL/J)	brain inflammation	J:49054
Eae7^B10.S/DvTe/Eae7^SJL/J (involves: B10.S/DvTe * SJL/J)	increased susceptibility to experimental autoimmune encephalomyelitis	J:49054
Eae7^SJL/J/Eae7^SJL/J (involves: B10.S/DvTe * SJL/J)	brain inflammation	J:49054
Eae7^SJL/J/Eae7^SJL/J (involves: B10.S/DvTe * SJL/J)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:49054
Eae9^B10.S/DvTe/Eae9^SJL/J (involves: B10.S/DvTe * SJL/J)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:49054
Eae10^SJL/J/Eae10^SJL/J (involves: B10.S/DvTe * SJL/J)	increased susceptibility to experimental autoimmune encephalomyelitis	J:49054
Eae11^SJL/J/? (involves: B10.S/DvTe * SJL/J)	increased susceptibility to experimental autoimmune encephalomyelitis	J:53193
Eae12^SJL/J/Eae12^SJL/J (involves: B10.S/DvTe * SJL/J)	increased susceptibility to experimental autoimmune encephalomyelitis	J:53193
Eae13^SJL/J/? (involves: B10.S/DvTe * SJL/J)	increased susceptibility to experimental autoimmune encephalomyelitis	J:53193
Eae14^C57BL/10/? (involves: B10.S/DvTe * SJL/J)	increased susceptibility to experimental autoimmune encephalomyelitis	J:69083
Eae16^SJL/J/? (involves: B10.S/DvTe * SJL/J)	increased inflammatory response	J:67840
Eae17^SJL/J/? (involves: B10.S/DvTe * SJL/J)	increased susceptibility to experimental autoimmune encephalomyelitis	J:69083
Eae18^NOD/Eae18^NOD (involves: ABH * NOD)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:29171
Eae21^SJL/J/? (involves: B10.S/DvTe * SJL/J)	increased inflammatory response	J:67840
Eae22^SJL/J/? (involves: B10.S/DvTe * SJL/J)	increased inflammatory response	J:67840
Eae23^SJL/J/? (involves: B10.S/DvTe * SJL/J)	increased inflammatory response	J:67840
Eae25^SJL/J/? (involves: B10.S/DvTe * SJL/J)	increased inflammatory response	J:69083
Eae26^B10.RIII/Eae26^B10.RIII (involves: B10.RIII * RIIIS/J)	increased susceptibility to experimental autoimmune encephalomyelitis	J:73850
Eae26^B10.RIII/Eae26^RIIIS/J (involves: B10.RIII * RIIIS/J)	increased susceptibility to experimental autoimmune encephalomyelitis	J:73850
Eae27^C57BL/10SnSg/Eae27^RIIIS/J (involves: B10.RIII * RIIIS/J)	CNS inflammation	J:96204
Eae27^RIIIS/J/Eae27^RIIIS/J (involves: B10.RIII * RIIIS/J)	CNS inflammation	J:96204
Eae33^C57BL/10SnSg/? (involves: B10.S * SJL/J)	increased susceptibility to experimental autoimmune encephalomyelitis	J:99793
Eae34^C57BL/10SnSg/? (involves: B10.S * SJL/J)	increased susceptibility to experimental autoimmune encephalomyelitis	J:99793
Eae35^C57BL/10SnSg/? (involves: B10.S * SJL/J)	increased susceptibility to experimental autoimmune encephalomyelitis	J:99793
Eae36^SJL/J/? (involves: B10.S * SJL/J)	increased susceptibility to autoimmune disorder	J:99793
Eae37^C57BL/10SnSg/? (involves: B10.S * SJL/J)	increased susceptibility to autoimmune disorder	J:99793
Eae38^C57BL/10SnSg/? (involves: B10.S * SJL/J)	increased susceptibility to autoimmune disorder	J:99793
Eae39^C57BL/10SnSg/Eae39^RIIIS/J (involves: B10.RIII * RIIIS/J)	CNS inflammation	J:96204
Eae39^RIIIS/J/Eae39^RIIIS/J (involves: B10.RIII * RIIIS/J)	CNS inflammation	J:96204
Eae41^C57BL/10SnSg/Eae41^C57BL/10SnSg (involves: B10.RIII * RIIIS/J)	CNS inflammation	J:96204
Eae42^C57BL/10SnSg/? (involves: B10.S * SJL/J)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:34892
Eae42^SJL/J/? (involves: B10.S * SJL/J)	increased susceptibility to experimental autoimmune encephalomyelitis	J:34892
Eae43^B10.S/DvTe/? (involves: B10.S/DvTe * SJL/J)	increased susceptibility to experimental autoimmune encephalomyelitis	J:53193
Eae43^B10.S/DvTe/Eae43^B10.S/DvTe (involves: B10.S/DvTe * SJL/J)	increased susceptibility to experimental autoimmune encephalomyelitis	J:49054
Eae44a^B10.S/DvTe/Eae44a^B10.S/DvTe (involves: B10.S/DvTe * SJL/J)	increased susceptibility to experimental autoimmune encephalomyelitis	J:56752
Eae44a^B10.S/DvTe/Eae44a^SJL/J (involves: B10.S/DvTe * SJL/J)	brain inflammation	J:49054
Eae44a^SJL/J/Eae44a^SJL/J (involves: B10.S/DvTe * SJL/J)	brain inflammation	J:49054
Eae44b^B10.S/DvTe/Eae44b^SJL/J (involves: B10.S/DvTe * SJL/J)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:56752
Eae44b^SJL/J/Eae44b^SJL/J (involves: B10.S/DvTe * SJL/J)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:56752
Eaf1^tm1.1Zhow/Eaf1^tm1.1Zhow Eaf2^tm1Zhow/Eaf2^tm1Zhow Tg(Pbsn-cre)4Prb/0 (involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J * DBA/2)	prostate gland inflammation	J:288972
Eaf1^tm1.1Zhow/Eaf1^tm1.1Zhow Tg(Pbsn-cre)4Prb/0 (B6(Cg)-Eaf1^tm1.1Zhow Tg(Pbsn-cre)4Prb)	prostate gland inflammation	J:288972
Eaf2^tm1Zhow/Eaf2^tm1Zhow (involves: 129P2/OlaHsd)	prostate gland inflammation	J:288972
Eamcd1^A/WySn/Eamcd1^A/WySn (B10.A-(D1Mit65-D1Mit334))	myocarditis	J:145043
Eamcd2^A/WySn/Eamcd2^A/WySn (involves: A.SW-H2^s/J * B10.S-H2^s/J)	myocarditis	J:96562
Ebag9^tm1Rehm/Ebag9^tm1Rehm (either: (involves: 129P2/OlaHsd * BALB/c) or (involves: 129P2/OlaHsd * C57BL/6))	abnormal CD8-positive, alpha beta T cell morphology	J:152534
	abnormal cytotoxic T cell physiology	J:152534
	abnormal memory T cell physiology	J:152534
	decreased susceptibility to bacterial infection	J:152534
Ebf1^em1(IMPC)Mbp/Ebf1⁺ (C57BL/6N-Ebf1^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
Ebf1^m1Btlr/Ebf1^m1Btlr (C57BL/6J-Ebf1^m1Btlr)	decreased B cell number	J:265157
	decreased IgD level	J:265157
	increased CD4-positive, alpha-beta T cell number	J:265157
	increased single-positive T cell number	J:265157
	increased T cell number	J:265157
Ebf1^m2Btlr/Ebf1^m2Btlr (C57BL/6J-Ebf1^m2Btlr)	abnormal humoral immune response	J:265158
	decreased B cell number	J:265158
	decreased B-1 B cell number	J:265158
	decreased B-2 B cell number	J:265158
	decreased IgD level	J:265158
	decreased IgM level	J:265158
	increased B-1a cell number	J:265158
	increased B-1b cell number	J:265158
	increased CD4-positive, alpha-beta T cell number	J:265158
	increased IgM level	J:265158
	increased single-positive T cell number	J:265158
	increased T cell number	J:265158
	increased tumor necrosis factor secretion	J:265158
Ebf1^M3Btlr/Ebf1^M3Btlr (C57BL/6J-Ebf1^M3Btlr)	decreased B-1 B cell number	J:265160
	increased CD4-positive, alpha-beta T cell number	J:265160
	increased single-positive T cell number	J:265160
	increased T cell number	J:265160
Ebf1^M4Btlr/Ebf1^M4Btlr (C57BL/6J-Ebf1^M4Btlr)	decreased B cell number	J:267560
	decreased NK cell number	J:267560
	increased alpha-beta T cell number	J:267560
	increased CD4-positive, alpha-beta T cell number	J:267560
	increased CD8-positive, alpha-beta T cell number	J:267560
Ebf1^M5Btlr/Ebf1^M5Btlr (C57BL/6J-Ebf1^M5Btlr)	abnormal lymphocyte morphology	J:272841
	decreased B cell number	J:272841
	decreased B-1 B cell number	J:272841
Ebf1^m6Btlr/Ebf1^m6Btlr (C57BL/6J-Ebf1^m6Btlr)	abnormal lymphocyte morphology	J:272842
	decreased B cell number	J:272842
	decreased B-1 B cell number	J:272842
	decreased effector memory CD4-positive, alpha-beta T cell number	J:272842
	decreased IgD level	J:272842
	increased alpha-beta T cell number	J:272842
	increased CD4-positive, alpha-beta T cell number	J:272842
	increased CD8-positive, alpha-beta T cell number	J:272842
Ebf1^Serv/Ebf1⁺ (C57BL/6JAnu-Ebf1^Serv)	decreased B cell number	J:104190
Ebf1^tm1.1Rug/Ebf1^tm1.1Rug Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129P2/OlaHsd * C57BL/6 * SJL)	decreased B-1 B cell number	J:182210
	decreased marginal zone B cell number	J:182210
Ebf1^tm1.1Rug/Ebf1^tm1.1Rug Cd79a^tm1(cre)Reth/Cd79a⁺ (involves: BALB/c * C57BL/6 * SJL)	arrested B cell differentiation	J:182210
Ebf1^tm1.1Rug/Ebf1^tm1.1Rug Ighg1^tm1(cre)Cgn/Ighg1⁺ (involves: 129P2/OlaHsd * C57BL/6 * SJL)	decreased germinal center B cell number	J:182210
Ebf1^tm1.1Rug/Ebf1^tm1.1Rug Polr2a^{tm1(cre/ERT2)Bbd}/Polr2a⁺ (involves: C57BL/6 * SJL)	abnormal germinal center B cell physiology	J:182210
	arrested B cell differentiation	J:182210
	decreased B cell proliferation	J:182210
	decreased germinal center B cell number	J:182210
	decreased IgG1 level	J:182210
	decreased IgG3 level	J:182210
	decreased immature B cell number	J:182210
	decreased marginal zone B cell number	J:182210
	decreased pre-B cell number	J:182210
	decreased spleen germinal center number	J:182210
	decreased transitional stage B cell number	J:182210
	immune system phenotype	J:182210
	increased B cell apoptosis	J:182210
	increased B cell number	J:182210
Ebf1^tm1.1Rug/Ebf1^tm1.1Rug Polr2a^{tm1(cre/ERT2)Bbd}/Polr2a⁺ Tg(BCL2)#Wehi/0 (involves: C57BL/6 * C57BL/6JWehi * SJL * SJL/JWehi)	decreased immature B cell number	J:182210
	decreased pre-B cell number	J:182210
Ebf1^tm1.1Rug/Ebf1^tm1.1Rug Tg(Cr2-cre)3Cgn/0 (involves: C57BL/6 * SJL)	decreased B-1 B cell number	J:182210
	decreased marginal zone B cell number	J:182210
Ebf1^tm1Rug/Ebf1^tm1Rug (involves: 129S2/SvPas)	abnormal B cell morphology	J:52607
	absent B-1 B cells	J:52607
	absent mature B cells	J:52607
	arrested B cell differentiation	J:52607
	decreased IgM level	J:52607
	decreased pro-B cell number	J:52607
Ebf1^tm1Rug/Ebf1^tm1Rug (involves: 129S2/SvPas * 129X1/SvJ * C57BL/6)	increased osteoclast cell number	J:147179
Ebf2^em1(IMPC)Mbp/Ebf2⁺ (C57BL/6N-Ebf2^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	small spleen	J:211773
Ebi3^Gt716Lex/Ebi3^Gt716Lex (involves: 129S5/SvEvBrd * C57BL/6)	abnormal CD4-positive, alpha-beta T cell number	J:286951
	abnormal T cell activation	J:286951
	brain inflammation	J:286951
	decreased interleukin-10 secretion	J:286951
	increased CD8-positive, alpha-beta T cell number	J:286951
	increased interferon-gamma secretion	J:286951
	increased macrophage cell number	J:286951
	increased susceptibility to Coronaviridae infection	J:286951
	increased susceptibility to Coronaviridae infection induced morbidity/mortality	J:286951
Ebi3^Gt716Lex/Ebi3^Gt716Lex Tg(DO11.10)10Dlo/0 (involves: 129S5/SvEvBrd * BALB/c * C3H * C57BL/6)	abnormal circulating interleukin level	J:134148
	abnormal T cell differentiation	J:134148
	decreased susceptibility to bacterial infection	J:134148
	increased circulating interleukin-17 level	J:134148
	increased interleukin-17 secretion	J:134148
Ebi3^tm1Nkma/Ebi3^tm1Nkma Fas^lpr/Fas^lpr (MRL.Cg-Ebi3^tm1Nkma Fas^lpr)	abnormal cytokine level	J:181669
	decreased circulating interferon-gamma level	J:181669
	increased circulating interleukin-4 level	J:181669
	increased IgE level	J:181669
	increased IgG1 level	J:181669
	increased IgG level	J:181669
	increased immunoglobulin level	J:181669
Ebi3^tm1Rsb/Ebi3^tm1Rsb (involves: 129X1/SvJ * C57BL/6)	abnormal immune system morphology	J:81014
	abnormal immune system physiology	J:81014
	abnormal T-helper 1 cell morphology	J:97822
	abnormal T-helper 2 cell morphology	J:97822
	decreased interleukin-4 secretion	J:81014
	decreased NK cell number	J:81014
	decreased susceptibility to induced colitis	J:81014
	decreased T-helper 2 cell number	J:81014
	increased interferon-gamma secretion	J:81014
	increased susceptibility to parasitic infection	J:97822
Ebna1bp2^em1(IMPC)Tcp/Ebna1bp2⁺ (C57BL/6N-Ebna1bp2^em1(IMPC)Tcp/Cmmr)	enlarged spleen	J:211773
Ece1^tm1Reh/Ece1^tm1Reh (involves: 129S6/SvEvTac * C57BL/6)	persistent cervical thymus	J:46640
Ecm1^{tm1b(EUCOMM)Hmgu}/Ecm1⁺ (C57BL/6N-Ecm1^{tm1b(EUCOMM)Hmgu}/H)	decreased neutrophil cell number	J:211773
Ecm1^tm1Bsun/Ecm1^tm1Bsun (involves: 129 * C57BL/6)	abnormal T-helper 2 physiology	J:168252
	decreased IgE level	J:168252
	decreased susceptibility to type I hypersensitivity reaction	J:168252
	immune system phenotype	J:168252
	increased susceptibility to autoimmune disorder	J:168252
Ecrg4^{tm1b(EUCOMM)Hmgu}/Ecrg4^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Ecrg4^{tm1b(EUCOMM)Hmgu}/Orl)	decreased large unstained cell number	J:211773
Ecscr^{tm1.1(KOMP)Vlcg}/Ecscr^{tm1.1(KOMP)Vlcg} (C57BL/6N-Ecscr^{tm1.1(KOMP)Vlcg}/Ucd)	abnormal thymus morphology	J:211773
	small thymus	J:211773
Eda^Ta-6J/Y (C57BL/6J A^w-J-Eda^Ta-6J/J)	blepharitis	J:99510
	conjunctivitis	J:99510
	corneal limbitis	J:99510
	eye inflammation	J:99510
	increased incidence of corneal inflammation	J:99510
Eda^Ta-6J/Y Tg(MMTVtTA)1Mam/0 Tg(tetO-Eda*A1)1Dsch/0 (involves: C57BL/6J)	immune system phenotype	J:99510
Edc3^em1(IMPC)Tcp/Edc3⁺ (C57BL/6NCrl-Edc3^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Edc3^em1(IMPC)Tcp/Edc3^em1(IMPC)Tcp (C57BL/6NCrl-Edc3^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Eddm3b^{tm1b(KOMP)Wtsi}/Eddm3b^{tm1b(KOMP)Wtsi} (C57BL/6N-Eddm3b^{tm1b(KOMP)Wtsi}/Nju)	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
Edil3^Tg(lacZ)1Tq/Edil3^Tg(lacZ)1Tq (Not Specified)	increased susceptibility to induced arthritis	J:254384
Edil3^tm1Tq/Edil3^tm1Tq (B6.129S6-Edil3^tm1Tq)	abnormal cellular extravasation	J:141063
	abnormal leukocyte adhesion	J:141063
	abnormal neutrophil physiology	J:141063
	enhanced leukocyte tethering or rolling	J:141063
Edil3^tm1Tq/Edil3^tm1Tq Itgal^tm1Bll/Itgal^tm1Bll (involves: 129 * C57BL/6)	abnormal cellular extravasation	J:141063
	abnormal neutrophil physiology	J:141063
Ednra^tm1Ywa/Ednra^tm1Ywa (129S/SvEv-Ednra^tm1Ywa)	ectopic thymus	J:46639
Ednra^tm1Ywa/Ednra^tm1Ywa (129S/SvEv-Ednra^tm1Ywa)	thymus hypoplasia	J:46639
Ednrb^tm1Nrd/Ednrb^tm1Nrd Gt(ROSA)26Sor^{tm14(CAG-tdTomato)Hze}/Gt(ROSA)26Sor⁺ H2az2^{Tg(Wnt1-cre)11Rth}/H2az2⁺ (involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * C57BL/6 * CBA/J)	abnormal mature B cell number	J:233811
	abnormal Peyer's patch morphology	J:233811
	abnormal spleen morphology	J:233811
	abnormal splenic cell ratio	J:233811
	decreased B cell number	J:233811
	decreased germinal center B cell number	J:233811
	decreased IgA level	J:233811
	decreased marginal zone B cell number	J:233811
	decreased spleen red pulp amount	J:233811
	decreased spleen weight	J:233811
	decreased spleen white pulp amount	J:233811
	large intestinal inflammation	J:233811
	small Peyer's patches	J:233811
	small spleen	J:233811
Ednrb^tm1Ywa/Ednrb⁺ (involves: 129S/SvEvBrd)	decreased acute inflammation	J:103977
Ednrb^tm1Ywa/Ednrb^tm1Ywa (involves: 129S5/SvEvBrd)	decreased acute inflammation	J:103977
Eef1a1^tm2Arge/Eef1a1⁺ Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA)	abnormal double-positive T cell morphology	J:197167
Eef1a2^wst/Eef1a2^wst (B6C3Fe a/a-Eef1a2^wst/J)	decreased plasma cell number	J:7903
	decreased spleen weight	J:6766
	decreased susceptibility to type IV hypersensitivity reaction	J:6766
	decreased thymus weight	J:6766
	lymphoid hypoplasia	J:6766
	small lymph nodes	J:6766
Eef1a2^wst/Eef1a2^wst (Not Specified)	thymus atrophy	J:50410
Eef1d^em1(IMPC)Mbp/Eef1d⁺ (C57BL/6NCrl-Eef1d^em1(IMPC)Mbp/MbpMmucd)	increased neutrophil cell number	J:211773
Eef1e1^{Gt(OST377244)Lex}/Eef1e1⁺ (involves: 129S5/SvEvBrd * C57BL/6)	decreased splenocyte apoptosis	J:96923
	increased splenocyte proliferation	J:96923
Efemp1^tm2Lmar/Efemp1^tm2Lmar (involves: 129X1/SvJ * C57BL/6)	abnormal spleen morphology	J:132043
	decreased spleen weight	J:132043
Efhd2^{tm1(KOMP)Vlcg}/Efhd2^{tm1(KOMP)Vlcg} (C57BL/6-Efhd2^{tm1(KOMP)Vlcg})	abnormal response to infection	J:228565
	immune system phenotype	J:228565
	increased germinal center B cell number	J:228565
	increased IgE level	J:228565
	increased IgG1 level	J:228565
	increased IgG2a level	J:228565
	increased IgM level	J:228565
	increased plasma cell number	J:228565
	increased spleen germinal center size	J:228565
Efnb1^tm1.1Jwu/Efnb1^tm1.1Jwu Efnb2^tm1.1Jwu/Efnb2^tm1.1Jwu Tg(Lck-cre)I540Jxm/0 (B6.Cg-Efnb2^tm1.1Jwu Efnb1^tm1.1Jwu Tg(Lck-cre)I540Jxm)	abnormal T cell differentiation	J:178148
	abnormal T-helper 1 cell differentiation	J:178148
	abnormal T-helper 17 cell differentiation	J:178148
	decreased CD4-positive, alpha-beta T cell number	J:178148
	decreased CD8-positive, alpha-beta T cell number	J:178148
	decreased DN4 thymocyte number	J:178148
	decreased double-positive T cell number	J:178148
	decreased spleen weight	J:178148
	decreased T cell number	J:178148
	decreased thymus weight	J:178148
	increased DN3 thymocyte number	J:178148
	increased double-negative T cell number	J:178148
	increased length of allograft survival	J:178148
	increased susceptibility to Riboviria infection	J:178148
	increased thymocyte apoptosis	J:178148
	small spleen	J:178148
	small thymus	J:178148
	spleen hypoplasia	J:178148
	thymus hypoplasia	J:178148
Efnb1^tm1.1Jwu/Efnb1^tm1.1Jwu Tg(Lck-cre)I540Jxm/0 (B6.Cg-Efnb1^tm1.1Jwu Tg(Lck-cre)I540Jxm)	immune system phenotype	J:178148
Efnb2^tm1.1Jwu/Efnb2^tm1.1Jwu Tg(Lck-cre)I540Jxm/0 (B6.Cg-Efnb2^tm1.1Jwu Tg(Lck-cre)I540Jxm)	immune system phenotype	J:178148
Efnb2^tm5.1Kln/Efnb2^tm5.1Kln (involves: C57BL/6)	abnormal afferent lymphatic vessel morphology	J:95885
	abnormal lymph circulation	J:95885
	abnormal lymphatic vessel morphology	J:95885
Efnb2^tm5.1Kln/Efnb2^tm5.1Kln (involves: CD-1)	abnormal lymphatic vessel morphology	J:95885
Efnb2^tm5.1Kln/Efnb2^tm5.1Kln Flt4^tm1Ali/Flt4⁺ (involves: C57BL/6)	abnormal afferent lymphatic vessel morphology	J:95885
	abnormal lymphatic vessel morphology	J:95885
Efnb2^tm6Kln/Efnb2^tm6Kln (involves: C57BL/6)	abnormal lymph circulation	J:95885
Efnb2^tm6Kln/Efnb2^tm6Kln (involves: C57BL/6)	abnormal lymphatic vessel morphology	J:95885
Efs^tm1Kale/Efs⁺ (either: (involves: 129X1/SvJ) or (involves: 129X1/SvJ * C57BL/6J))	increased IgA level	J:103757
	increased IgG level	J:103757
	increased inflammatory response	J:103757
	small intestinal inflammation	J:103757
Efs^tm1Kale/Efs^tm1Kale (either: (involves: 129X1/SvJ) or (involves: 129X1/SvJ * C57BL/6J))	abnormal interleukin secretion	J:103757
	abnormal T cell physiology	J:103757
	increased IgA level	J:103757
	increased IgG level	J:103757
	increased immunoglobulin level	J:103757
	increased inflammatory response	J:103757
	increased interferon-gamma secretion	J:103757
	kidney inflammation	J:103757
	liver inflammation	J:103757
	lung inflammation	J:103757
	small intestinal inflammation	J:103757
Eftud2^{tm1b(KOMP)Wtsi}/Eftud2⁺ (C57BL/6N-Eftud2^{tm1b(KOMP)Wtsi}/Ics)	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
Egfr^Mhdadsk5/Egfr⁺ (involves: 129S1/SvImJ * C3HeB/FeJ)	increased susceptibility to Coronaviridae infection	J:243599
Egfr^Mhdadsk5/Egfr⁺ (involves: 129S1/SvImJ * C3HeB/FeJ)	increased susceptibility to Coronaviridae infection induced morbidity/mortality	J:243599
Egfr^{tm1a(EUCOMM)Wtsi}/Egfr⁺ (C57BL/6N-Egfr^{tm1a(EUCOMM)Wtsi}/Wtsi)	decreased leukocyte cell number	J:175295
Egfr^tm1Dwt/Egfr^tm1Dwt Sox9^tm3(cre)Crm/Sox9⁺ (involves: 129S6/SvEvTac * 129S7/SvEvBrd)	dermatitis	J:229771
	increased IgE level	J:229771
	increased T-helper 1 cell number	J:229771
	increased T-helper 2 cell number	J:229771
	increased T-helper 17 cell number	J:229771
Egfr^tm1Msi/Egfr^tm1Msi Tg(Alb1-cre)7Gsc/? (involves: 129P2/OlaHsd * C57BL/6 * FVB/N)	increased circulating tumor necrosis factor level	J:125912
Egfr^tm1Msi/Egfr^tm1Msi Tg(Mx1-cre)1Cgn/? (involves: 129P2/OlaHsd * C57BL/6 * CBA)	increased circulating tumor necrosis factor level	J:125912
Egln1^tm1.1Brei/Egln1^tm1.1Brei Tg(CD68-icre)1Bwlx/0 (involves: C57BL/6)	abnormal lymphocyte cell number	J:194598
	abnormal spleen morphology	J:194598
	enlarged spleen	J:194598
	increased spleen weight	J:194598
Egln1^tm1.1Fsl/Egln1⁺ (C57BL/6-Egln1^tm1.1Fsl)	increased spleen weight	J:202737
Egln1^tm1Fong/Egln1^tm1Fong (involves: 129S6/SvEvTac * C57BL/6 * CD-1 * FVB/N * SJL)	abnormal lymph organ development	J:114669
Egln1^tm2.1Fsl/Egln1^tm2.1Fsl Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte}/Gt(ROSA)26Sor⁺ (B6.Cg-Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte} Egln1^tm2.1Fsl)	increased spleen weight	J:202737
Egln1^tm2.1Fsl/Egln1^tm2.1Fsl Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte}/Gt(ROSA)26Sor⁺ Hif1a^tm3Rsjo/Hif1a^tm3Rsjo (B6.Cg-Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte} Egln1^tm2.1Fsl Hif1a^tm3Rsjo)	increased spleen weight	J:202737
Egln1^tm2.1Fsl/Egln1^tm2.1Fsl Pax3^tm1(cre)Joe/Pax3⁺ (involves: 129 * C57BL/6)	increased spleen weight	J:202737
Egln1^tm2.2Fsl/Egln1⁺ (B6.Cg-Egln1^tm2.2Fsl)	increased spleen weight	J:202737
Egln1^tm2Fong/Egln1^tm2Fong Gt(ROSA)26Sor^{tm1(cre/ERT2)Alj}/Gt(ROSA)26Sor⁺ (involves: 129S6/SvEvTac * C57BL/6)	abnormal splenic cell ratio	J:132720
	enlarged spleen	J:132720
	increased leukocyte cell number	J:132720
Egln2^tm1Fong/Egln2^tm1Fong Egln3^tm1Fong/Egln3^tm1Fong (involves: 129S6/SvEvTac * C57BL/6)	abnormal splenic cell ratio	J:132720
	enlarged spleen	J:132720
Egr1^{tm1b(NCOM)Mfgc}/Egr1⁺ (C57BL/6N-Egr1^{tm1b(NCOM)Mfgc}/Tcp)	increased lymphocyte cell number	J:211773
Egr1^tm1Jmi/Egr1^tm1Jmi (B6.129-Egr1^tm1Jmi)	abnormal circulating tumor necrosis factor level	J:128421
	increased osteoclast cell number	J:51107
	liver inflammation	J:128421
Egr1^tm1Jmi/Egr1^tm1Jmi (involves: 129 * C57BL/6)	abnormal leukocyte cell number	J:123870
	abnormal leukocyte morphology	J:123870
	abnormal microglial cell physiology	J:135238
	abnormal neutrophil morphology	J:123870
	abnormal tumor necrosis factor level	J:105638
	decreased inflammatory response	J:152898
	immune system phenotype	J:105638
	increased lymphocyte cell number	J:123870
	increased spleen weight	J:123870
	increased T cell derived lymphoma incidence	J:123870
Egr1^tm1Jmi/Egr1^tm1Jmi Tg(Scgb1a1-rtTA,-tTS,tetO-TGFB1)1Eli/? (involves: 129 C57BL/6)	lung inflammation	J:92469
Ehbp1l1^{tm1a(EUCOMM)Wtsi}/Ehbp1l1^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Ehbp1l1^{tm1a(EUCOMM)Wtsi}/Wtsi)	blood in lymph vessels	J:239583
Ehmt1^{tm1b(EUCOMM)Hmgu}/Ehmt1⁺ (C57BL/6N-Ehmt1^{tm1b(EUCOMM)Hmgu}/Nju)	increased neutrophil cell number	J:211773
Ehmt2^tm1.1Cza/Ehmt2^tm1.1Cza Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2 * SJL)	decreased IgG1 level	J:160938
	decreased interleukin-4 secretion	J:160938
	increased IgG2a level	J:160938
	increased interferon-gamma secretion	J:160938
	increased susceptibility to parasitic infection	J:160938
Ehmt2^tm1.1Cza/Ehmt2^tm1.1Cza Tg(VAV1-cre)1Graf/0 (involves: C57BL/6 * SJL)	decreased interleukin-4 secretion	J:160938
	decreased interleukin-5 secretion	J:160938
	decreased interleukin-13 secretion	J:160938
	increased interferon-gamma secretion	J:160938
	increased interleukin-17 secretion	J:160938
	increased susceptibility to parasitic infection	J:160938
Eid2b^em1(IMPC)J/Eid2b⁺ (C57BL/6NJ-Eid2b^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
Eif1ad^{tm1b(EUCOMM)Hmgu}/Eif1ad⁺ (C57BL/6N-Eif1ad^{tm1b(EUCOMM)Hmgu}/Bay)	increased large unstained cell number	J:211773
Eif2a^em1(IMPC)Mbp/Eif2a^em1(IMPC)Mbp (C57BL/6N-Eif2a^em1(IMPC)Mbp/Ucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Eif2ak1^em1(IMPC)Bay/Eif2ak1^em1(IMPC)Bay (C57BL/6N-Eif2ak1^em1(IMPC)Bay/BayMmucd)	increased spleen weight	J:211773
Eif2ak2^em1(IMPC)Mbp/Eif2ak2^em1(IMPC)Mbp (C57BL/6N-Eif2ak2^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	small spleen	J:211773
Eif2ak2^em1Btlr/Eif2ak2^em1Btlr (C57BL/6J-Eif2ak2^em1Btlr)	immune system phenotype	J:354285
Eif2ak2^em1Btlr/Eif2ak2^em1Btlr Zfp574^em1Btlr/Zfp574^em1Btlr (C57BL/6J-Zfp574^em1Btlr Eif2ak2^em1Btlr)	abnormal B cell physiology	J:354285
	abnormal class switch recombination	J:354285
	abnormal humoral immune response	J:354285
	decreased lymphocyte cell number	J:354285
Eif2ak2^tm1Cwe/Eif2ak2^tm1Cwe (involves: 129S/SvEv * C57BL/6)	increased interleukin-4 secretion	J:66112
	increased susceptibility to Picornaviridae infection	J:30617
	increased susceptibility to type IV hypersensitivity reaction	J:66112
	increased T cell proliferation	J:66112
Eif2ak2^tm1Cwe/Eif2ak2^tm1Cwe (involves: 129)	immune system phenotype	J:114555
Eif2ak2^tm1Cwe/Eif2ak2^tm1Cwe Rnasel^tm1Slvm/Rnasel^tm1Slvm (involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6)	increased susceptibility to Picornaviridae infection	J:55974
Eif2ak2^tm1Jcbe/Eif2ak2^tm1Jcbe (involves: 129S4/SvJae * BALB/c)	immune system phenotype	J:53258
Eif2ak2^tm1Jcbe/Eif2ak2^tm1Jcbe (involves: 129S4/SvJae)	immune system phenotype	J:63671
	increased susceptibility to Orthomyxoviridae infection	J:63671
	increased susceptibility to Riboviria infection	J:167126, J:63671
Eif2ak3^tm1.1Drc/Eif2ak3^tm1.1Drc Tg(Ela1-cre)16Eps/0 (involves: 129S6/SvEvTac)	acute pancreas inflammation	J:129974
Eif2ak4^m1Btlr/Eif2ak4^m1Btlr (C57BL/6J-Eif2ak4^m1Btlr)	abnormal macrophage physiology	J:173669
	increased susceptibility to Adenoviridae infection	J:173669
	increased susceptibility to Herpesvirales infection	J:173669
Eif2ak4^tm1.2Dron/Eif2ak4^tm1.2Dron (involves: 129S6/SvEvTac * C57BL/6 * CBA)	abnormal cytokine secretion	J:120813
	abnormal dendritic cell physiology	J:120813
Eif2b5^tm1Itl/Eif2b5^tm1Itl (involves: 129S/SvEv)	abnormal microglial cell physiology	J:192103
Eif2d^em1(IMPC)Mbp/Eif2d^em1(IMPC)Mbp (C57BL/6N-Eif2d^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Eif2s2^em3(IMPC)Bay/Eif2s2⁺ (C57BL/6N-Eif2s2^em3(IMPC)Bay/Bay)	abnormal spleen morphology	J:211773
Eif4a1^tm1.1Bea/Eif4a1^tm1.1Bea Tg(Fcer2a-cre)5Mbu/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA)	decreased B cell proliferation	J:344730
	decreased germinal center B cell number	J:344730
	decreased IgG1 level	J:344730
Eif4b^tm1.1Smoc/Eif4b⁺ Tg(SFTPC-rtTA)5Jaw/0 Tg(tetO-cre)1Jaw/0 (involves: 129 * C57BL/6)	increased susceptibility to Riboviria infection	J:311140
Eif4b^tm1.1Smoc/Eif4b^tm1.1Smoc Ndor1^{Tg(UBC-cre/ERT2)1Ejb}/Ndor1⁺ (involves: 129 * C57BL/6)	decreased leukocyte cell number	J:311140
	decreased lymphocyte cell number	J:311140
	decreased NK cell number	J:311140
	increased macrophage cell number	J:311140
	increased neutrophil cell number	J:311140
	increased susceptibility to induced colitis	J:311140
	increased susceptibility to Orthomyxoviridae infection	J:311140
	increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:311140
	lung inflammation	J:311140
	small spleen	J:311140
	small thymus	J:311140
Eif4b^tm1.1Smoc/Eif4b^tm1.1Smoc Tg(SFTPC-rtTA)5Jaw/0 Tg(tetO-cre)1Jaw/0 (involves: 129 * C57BL/6)	increased susceptibility to Orthomyxoviridae infection	J:311140
Eif4g1^{em1(IMPC)Hmgu}/Eif4g1⁺ (C57BL/6NCrl-Eif4g1^{em1(IMPC)Hmgu}/Ieg)	decreased spleen weight	J:211773
Elac2^em1Afi/Elac2^em1Afi (C57BL/6N-Elac2^em1Afi)	prostate gland inflammation	J:336403
Elane^M1Btlr/Elane^M1Btlr (C57BL/6J-Elane^M1Btlr)	decreased tumor necrosis factor secretion	J:218967
Elane^tm1(cre)Roes/Elane^tm1(cre)Roes (involves: 129)	decreased susceptibility to bacterial infection induced morbidity/mortality	J:77597
Elane^tm1(cre)Roes/Elane^tm1(cre)Roes (involves: 129)	increased susceptibility to infection induced morbidity/mortality	J:77597
Elane^tm1(cre)Roes/Elane^tm1(cre)Roes (involves: 129S6/SvEvTac)	impaired neutrophil recruitment	J:137674
Elane^tm1Link/Elane^tm1Link (involves: 129X1/SvJ * C57BL/6)	immune system phenotype	J:131496
Elane^tm1Sds/Elane^tm1Sds (129X1/SvJ-Elane^tm1Sds)	abnormal neutrophil physiology	J:47420
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:47420
	increased susceptibility to bacterial infection	J:47420
	increased susceptibility to bacterial infection induced morbidity/mortality	J:47420
Elane^tm1Sds/Elane^tm1Sds (involves: 129X1/SvJ * C57BL/6)	abnormal inflammatory response	J:113463
Elapor1^{tm1b(EUCOMM)Hmgu}/Elapor1⁺ (C57BL/6N-Elapor1^{tm1b(EUCOMM)Hmgu}/Ics)	decreased lymphocyte cell number	J:211773
Elavl1^tm1.1Atas/Elavl1^tm1.1Atas Tnfrsf4^tm2(cre)Nik/Tnfrsf4⁺ (involves: 129X1/SvJ * C57BL/6)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:207013
	decreased T cell proliferation	J:207013
	decreased T-helper 17 cell number	J:207013
Elavl1^tm1.1Dkon/Elavl1^tm1.1Dkon Lyz2^tm1(cre)Ifo/Lyz2⁺ (B6.129P2-Elavl1^tm1.1Dkon Lyz2^tm1(cre)Ifo)	abnormal macrophage chemotaxis	J:184388
	immune system phenotype	J:184388
	increased circulating interleukin-1 beta level	J:184388
	increased circulating interleukin-6 level	J:184388
	increased circulating interleukin-12 level	J:184388
	increased circulating tumor necrosis factor level	J:184388
	increased macrophage cell number	J:184388
	increased monocyte cell number	J:184388
	increased susceptibility to endotoxin shock	J:184388
	increased susceptibility to induced colitis	J:184388
Elavl1^tm1.1Dkon/Elavl1^tm1.1Dkon Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6J)	immune system phenotype	J:184388
	increased circulating interleukin-1 beta level	J:184388
	increased circulating interleukin-6 level	J:184388
	increased circulating interleukin-12 level	J:184388
	increased circulating tumor necrosis factor level	J:184388
	increased susceptibility to endotoxin shock	J:184388
Elavl1^tm1.1Thla/Elavl1⁺ (involves: 129S1/Sv)	spleen hypoplasia	J:155109
Elavl1^tm1.1Thla/Elavl1⁺ (involves: 129S1/Sv)	thymus hypoplasia	J:155109
Elavl1^tm1Dkon/Elavl1^tm1Dkon Edil3^{Tg(Sox2-cre)1Amc}/Edil3⁺ (involves: 129P2/OlaHsd * C57BL/6 * CBA)	abnormal spleen development	J:149149
	absent spleen	J:149149
Elavl1^tm1Dkon/Elavl1^tm1Dkon Tg(Lck-cre)I57Jxm/0 (B6.Cg-Elavl1^tm1Dkon Tg(Lck-cre)I57Jxm)	abnormal positive T cell selection	J:148866
	abnormal T cell physiology	J:148866
	abnormal thymocyte activation	J:148866
	decreased CD4-positive, alpha-beta T cell number	J:148866
	decreased CD8-positive, alpha-beta T cell number	J:148866
	increased double-negative T cell number	J:148866
	increased double-positive T cell number	J:148866
	increased single-positive T cell number	J:148866
Elavl1^tm1Dkon/Elavl1^tm1Dkon Tg(Lck-cre)I57Jxm/0 Tg(TcraH-Y,TcrbH-Y)71Vbo/? (B6.Cg-Elavl1^tm1Dkon Tg(Lck-cre)I57Jxm Tg(TcraH-Y,TcrbH-Y)71Vbo)	abnormal negative T cell selection	J:148866
	increased thymocyte number	J:148866
Elavl1^tm1Lix/Elavl1^tm1Lix Tg(Scgb1a1-rtTA)2Jaw/0 Tg(tetO-cre)1Jaw/0 (involves: 129 * C57BL/6)	decreased inflammatory response	J:204952
	lung inflammation	J:204952
Elavl1^tm1Thla/Elavl1^tm1Thla Gt(ROSA)26Sor^{tm1(cre/ERT2)Alj}/Gt(ROSA)26Sor⁺ (involves: 129)	abnormal B cell physiology	J:155109
	abnormal myeloid leukocyte morphology	J:155109
	decreased B cell apoptosis	J:155109
	decreased double-positive T cell number	J:155109
	decreased granulocyte number	J:155109
	decreased leukocyte cell number	J:155109
	increased granulocyte number	J:155109
	increased T cell apoptosis	J:155109
	lymph node hypoplasia	J:155109
	spleen hypoplasia	J:155109
	thymus hypoplasia	J:155109
Elf1^tm1Jml/Elf1^tm1Jml (Not Specified)	abnormal B cell differentiation	J:100734
Elf1^tm1Jml/Elf1^tm1Jml (Not Specified)	abnormal B cell physiology	J:100734
Elf4^em1Hdu/Elf4^em1Hdu (C57BL/6-Elf4^em1Hdu)	abnormal CD4-positive T cell differentiation	J:328935
	abnormal interferon level	J:328935
	abnormal interleukin level	J:328935
	abnormal macrophage physiology	J:328935
	abnormal tumor necrosis factor level	J:328935
	increased susceptibility to viral infection	J:328935
Elf4^tm1Nim/Elf4^tm1Nim (B6.129S1-Elf4^tm1Nim)	abnormal inflammatory response	J:79568
	abnormal lymphocyte morphology	J:79568
	abnormal lymphocyte physiology	J:79568
	abnormal NK cell physiology	J:79568
	abnormal T cell differentiation	J:79568
	decreased cytotoxic T cell cytolysis	J:79568
	decreased NK cell number	J:79568
	decreased NK T cell number	J:79568
	impaired natural killer cell mediated cytotoxicity	J:79568
	increased B cell number	J:79568
	increased B cell proliferation	J:79568
	increased T cell proliferation	J:79568
	large lymphoid organs	J:79568
Elfn2^{tm1.1(KOMP)Vlcg}/Elfn2^{tm1.1(KOMP)Vlcg} (C57BL/6N-Elfn2^{tm1.1(KOMP)Vlcg}/Ucd)	increased eosinophil cell number	J:211773
Elk1^tm1Nor/Y (involves: 129P2/OlaHsd * C57BL/6N)	immune system phenotype	J:87597
Elk3^tm1Wlyk/Elk3^tm1Wlyk (either: (involves: 129/Sv) or (involves: 129/Sv * C57BL/6))	lymphangiectasis	J:71816
Elk4^{tm1a(EUCOMM)Wtsi}/Elk4^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Elk4^{tm1a(EUCOMM)Wtsi}/H)	decreased CD4-positive, alpha-beta T cell number	J:165965
	decreased CD8-positive, alpha-beta T cell number	J:165965
	decreased mature B cell number	J:165965
	decreased T cell number	J:165965
	increased B cell number	J:165965
	increased T cell number	J:165965
Elk4^tm1Rtr/Elk4^tm1Rtr (either: (involves: 129/Sv) or (involves: 129/Sv * C57BL/6))	abnormal positive T cell selection	J:88515
	abnormal T cell selection	J:88515
	decreased CD4-positive, alpha-beta T cell number	J:88515
	decreased CD8-positive, alpha-beta T cell number	J:88515
	decreased single-positive T cell number	J:88515
	decreased T cell number	J:88515
	decreased thymocyte number	J:88515
Elk4^tm1Rtr/Elk4^tm1Rtr Tg(TcraH-Y,TcrbH-Y)71Vbo/? (involves: 129/Sv * C57BL/6 * DBA/2J)	abnormal positive T cell selection	J:88515
	decreased CD8-positive, alpha-beta T cell number	J:88515
Elk4^tm1Rtr/Elk4^tm1Rtr Tg(TcraTcrb)425Cbn/? (involves: 129/Sv * C57BL/6)	abnormal positive T cell selection	J:88515
	abnormal splenic cell ratio	J:88515
	decreased CD4-positive, alpha-beta T cell number	J:88515
Elk4^tm1Rtr/Elk4^tm1Rtr Tg(TcrLCMV)327Sdz/? (involves: 129/Sv * C57BL/6 * DBA/2)	abnormal positive T cell selection	J:88515
	decreased CD8-positive, alpha-beta T cell number	J:88515
Elmo1^M1Btlr/Elmo1^M1Btlr (C57BL/6J-Elmo1^M1Btlr)	decreased B cell number	J:265231
	decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:265231
	decreased IgM level	J:265231
	impaired humoral immune response	J:265231
	increased B-1 B cell number	J:265231
	increased CD8-positive, alpha-beta memory T cell number	J:265231
Elmo1^m2Btlr/Elmo1^m2Btlr (C57BL/6J-Elmo1^m2Btlr)	decreased B cell number	J:265232
Elmo1^m3Btlr/Elmo1^m3Btlr (C57BL/6J-Elmo1^m3Btlr)	decreased central memory CD8 positive, alpha-beta T cell number	J:271894
	decreased NK cell number	J:271894
	increased CD8-positive, alpha-beta T cell number	J:271894
Elmo1^M4Btlr/Elmo1^M4Btlr (C57BL/6J-Elmo1^M4Btlr)	abnormal B cell morphology	J:271969
	abnormal T cell morphology	J:271969
	decreased CD4-positive, alpha-beta T cell number	J:271969
	increased B-1 B cell number	J:271969
	increased CD8-positive, alpha-beta T cell number	J:271969
Elmo1^{tm1a(EUCOMM)Wtsi}/Elmo1^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Elmo1^{tm1a(EUCOMM)Wtsi}/Wtsi)	increased leukocyte cell number	J:211773
Elmod1^{tm1a(EUCOMM)Hmgu}/Elmod1^{tm1a(EUCOMM)Hmgu} (C57BL/6N-Elmod1^{tm1a(EUCOMM)Hmgu}/H)	decreased B cell number	J:165965
	decreased leukocyte cell number	J:165965
Elmod1^{tm1b(EUCOMM)Hmgu}/Elmod1^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Elmod1^{tm1b(EUCOMM)Hmgu}/H)	decreased large unstained cell number	J:211773
	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
	decreased monocyte cell number	J:211773
	increased eosinophil cell number	J:211773
Elovl3^tm1Jaco/Elovl3^tm1Jaco (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	dermatitis	J:88477
Elp1^tm1.1Id/Elp1^tm1.2Id (involves: 129S1/Sv * C57BL/6 * C57BL/6J * CBA)	conjunctivitis	J:188923
Elp1^tm1.2Id/Elp1^tm1.2Id (involves: 129S1/Sv * C57BL/6 * C57BL/6J * CBA)	conjunctivitis	J:188923
Elsgp1^C57BL/6J/Elsgp1^NZB/BlNJ (involves: C57BL/6J * NZB/BlNJ)	abnormal immune serum protein physiology	J:63674
Elsgp1^NZB/BlNJ/Elsgp1^NZB/BlNJ (involves: C57BL/6J * NZB/BlNJ)	abnormal immune serum protein physiology	J:63674
Elsgp1^NZB/BlNJ/Elsgp1^NZB/BlNJ Elsgp2^NZB/BlNJ/Elsgp2^NZB/BlNJ (involves: C57BL/6J * NZB/BlNJ)	abnormal immune serum protein physiology	J:63674
Elsgp2^C57BL/6J/Elsgp2^NZB/BlNJ (involves: C57BL/6J * NZB/BlNJ)	abnormal immune serum protein physiology	J:63674
Elsgp2^NZB/BlNJ/Elsgp2^NZB/BlNJ (involves: C57BL/6J * NZB/BlNJ)	abnormal immune serum protein physiology	J:63674
Elsgp3^C57BL/6J/Elsgp3^NZB/BlNJ (involves: C57BL/6J * NZB/BlNJ)	abnormal immune serum protein physiology	J:63674
Elsgp3^NZB/BlNJ/Elsgp3^NZB/BlNJ (involves: C57BL/6J * NZB/BlNJ)	abnormal immune serum protein physiology	J:63674
Elsgp4^NZB/BlNJ/Elsgp4^NZB/BlNJ (involves: BALB/cByJ * NZB/BlNJ)	abnormal immune serum protein physiology	J:89134
Elsgp4^NZW/LacJ/? (involves: BALB/cByJ * NZW/LacJ)	abnormal immune serum protein physiology	J:89134
Emc4^{tm1(KOMP)Wtsi}/Emc4⁺ (C57BL/6N-Emc4^{tm1(KOMP)Wtsi}/Nju)	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
Emc8^{tm1b(EUCOMM)Hmgu}/Emc8⁺ (C57BL/6N-Emc8^{tm1b(EUCOMM)Hmgu}/H)	increased neutrophil cell number	J:211773
Eme1^{tm1.1(KOMP)Wtsi}/Eme1^{tm1.1(KOMP)Wtsi} (C57BL/6N-Eme1^{tm1.1(KOMP)Wtsi}/Bay)	abnormal spleen morphology	J:211773
Eml3^em1(IMPC)J/Eml3⁺ (C57BL/6NJ-Eml3^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
Emp2^tm1.1Tac/Emp2^tm1.1Tac Tg(Zp3-cre)93Knw/0 (involves: C57BL/6 * C57BL/6J * C57BL/6N)	increased leukocyte cell number	J:243365
	increased uterine NK cell number	J:243365
Emsy^{em1(IMPC)Ccpcz}/Emsy⁺ (C57BL/6NCrl-Emsy^{em1(IMPC)Ccpcz}/Ccpcz)	increased NK cell number	J:211773
Emv30^b/Emv30^b Prkdc^scid/Prkdc^scid (NOD.Cg-Emv30^b Prkdc^scid/Dvs)	increased T cell derived lymphoma incidence	J:29951
Emv72^a/Emv72^a (involves: BALB/cAnNCr * C57BL/6NCr)	abnormal cytotoxic T cell physiology	J:194735
Emv72^b/Emv72^b (CAnNCr.B6NCr-Emv72^b)	abnormal cytotoxic T cell physiology	J:194735
Emv72^b/Emv72^b (CAnNCr.B6NCr-Emv72^b)	abnormal T cell morphology	J:194735
Emv72^b/Emv72^b (involves: BALB/cAnNCr * C57BL/6NCr)	abnormal cytotoxic T cell physiology	J:194735
En1^tm1(Tnf)Fpit/En1^tm1(Tnf)Fpit (involves: C57BL/6)	increased monocyte cell number	J:170743
En1^tm1(Tnf)Fpit/En1^tm1(Tnf)Fpit (involves: C57BL/6)	microgliosis	J:170743
Endou^tm1Tft/Endou^tm1Tft (involves: 129S/SvEv * C57BL/6)	immune system phenotype	J:208364
Endou^tm1Tft/Endou^tm1Tft Tg(IghelMD4)4Ccg/0 Tg(ML5sHEL)5Ccg/0 (involves: 129S/SvEv * C57BL/6 * C57BL/6JSfd)	decreased activation-induced B cell apoptosis	J:208364
	immune system phenotype	J:208364
	increased autoantibody level	J:208364
Eng^em1(IMPC)Mbp/Eng⁺ (C57BL/6N-Eng^em1(IMPC)Mbp/MbpMmucd)	increased neutrophil cell number	J:211773
Enkur^tm1Hmf/Enkur^tm1Hmf (involves: 129 * C57BL/6J)	abnormal spleen morphology	J:253966
Enkur^tm1Hmf/Enkur^tm1Hmf (involves: 129 * C57BL/6J)	absent spleen	J:253966
Enpep^tm1Mdc/Enpep^tm1Mdc (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:47424
Enpp1^asj/Enpp1^asj (C57BL/6J-Enpp1^asj/GrsrJ)	increased susceptibility to otitis media	J:251638
	joint inflammation	J:174912
	osteoarthritis	J:174912
	osteomyelitis	J:174912
Enpp1^{em1(IMPC)Ccpcz}/Enpp1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Enpp1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	small thymus	J:211773
Enpp1^ttw/Enpp1^ttw (involves: ICR)	osteoarthritis	J:19124, J:37369
Enpp2^tm1Lex/Enpp2⁺ (involves: 129S/SvEvBrd * C57BL/6J)	abnormal chemokine level	J:103485
	decreased circulating interleukin-6 level	J:103485
	decreased circulating tumor necrosis factor level	J:103485
	decreased susceptibility to endotoxin shock	J:103485
Enpp3^tm1Ktak/Enpp3^tm1Ktak (either: (involves: 129S4/SvJae * C57BL/6) or (involves: 129S4/SvJae * BALB/c * C57BL/6))	abnormal basophil physiology	J:223825
	abnormal mast cell physiology	J:223825
	immune system phenotype	J:223825
	increased basophil cell number	J:223825
	increased IgE level	J:223825
	increased interleukin-4 secretion	J:223825
	increased mast cell number	J:223825
	increased susceptibility to type I hypersensitivity reaction	J:223825
	intestinal inflammation	J:223825
	lung inflammation	J:223825
Enpp3^tm1Ktak/Enpp3^tm1Ktak P2rx7^tm1Gab/P2rx7^tm1Gab (either: (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6) or (involves: 129P2/OlaHsd * 129S4/SvJae * BALB/c * C57BL/6))	immune system phenotype	J:223825
	increased basophil cell number	J:223825
	increased mast cell number	J:223825
Entpd1^{tm1a(EUCOMM)Wtsi}/Entpd1^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Entpd1^{tm1a(EUCOMM)Wtsi}/Ieg)	increased T cell number	J:165965
Entpd1^tm1Rdr/Entpd1^tm1Rdr (involves: 129S2/SvPas)	abnormal neutrophil physiology	J:129091
Entpd1^tm1Rdr/Entpd1^tm1Rdr (involves: 129S2/SvPas)	spleen fibrosis	J:57505
Entpd5^tm1Rre/Entpd5^tm1Rre (involves: 129S5/SvEvBrd * C57BL/6J)	abnormal Kupffer cell morphology	J:163795
	liver inflammation	J:163795
Entpd7^tm1Ktak/Entpd7^tm1Ktak (B6.Cg-Entpd7^tm1Ktak)	abnormal CD4-positive, alpha-beta T cell number	J:191188
	decreased susceptibility to bacterial infection	J:191188
	increased susceptibility to experimental autoimmune encephalomyelitis	J:191188
	increased T-helper 17 cell number	J:191188
Entpd8^tm1Ktak/Entpd8^tm1Ktak (C.Cg-Entpd8^tm1Ktak)	increased susceptibility to induced colitis	J:311564
Entpd8^tm1Ktak/Entpd8^tm1Ktak P2rx4^tm1Ando/P2rx4^tm1Ando (involves: 129S4/SvJae * BALB/c * C57BL/6)	abnormal susceptibility to induced colitis	J:311564
Eomes^tm1.1Bflu/Eomes^tm1.1Bflu Tbx21^tm1Glm/Tbx21^tm1Glm Tg(Cd4-cre)1Cwi/0 (involves: 129S6/SvEvTac * C57BL/6 * DBA/2 * SJL)	abnormal leukocyte migration	J:163822
	decreased CD4-positive, alpha-beta T cell number	J:163822
	decreased CD8-positive, alpha-beta T cell number	J:163822
	decreased interferon-gamma secretion	J:163822
	decreased memory T cell number	J:163822
	increased interleukin-4 secretion	J:163822
	increased interleukin-17 secretion	J:163822
Eomes^tm1.1Bflu/Eomes^tm1.1Bflu Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2 * SJL)	abnormal leukocyte migration	J:163822
	decreased memory T cell number	J:163822
Eomes^tm1.1Twa/? Il15^tm1Imx/Il15^tm1Imx (involves: C57BL/6 * C57BL/6N)	abnormal NK cell differentiation	J:210160
Eomes^tm1.1Twa/? Tbx21^tm1Glm/Tbx21^tm1Glm (involves: 129S6/SvEvTac * C57BL/6N)	abnormal NK cell differentiation	J:210160
Eomes^tm1.1Twa/? Tg(CD2-Tbx21)#Staka/? (involves: C57BL/6N)	abnormal NK cell differentiation	J:210160
Eomes^tm1.1Twa/? Tg(Itgax-TGFBR2)1Flv/? (involves: C3H * C57BL/6 * C57BL/6N)	abnormal NK cell differentiation	J:210160
Eomes^tm1Apr/Eomes⁺ (involves: C57BL/6)	decreased memory T cell number	J:112679
Eomes^tm1Apr/Eomes⁺ (involves: C57BL/6)	decreased NK cell number	J:112679
Eomes^tm1Apr/Eomes⁺ Tbx21^tm1Srnr/Tbx21^tm1Srnr (involves: C57BL/6)	decreased interferon-gamma secretion	J:112679
	decreased memory T cell number	J:112679
	decreased NK cell number	J:112679
	decreased NK T cell number	J:112679
Eomes^tm1Srnr/Eomes^tm1Srnr Tbx21^tm1Srnr/Tbx21^tm1Srnr Tg(Cd4-cre)1Cwi/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)	abnormal CD8-positive, alpha-beta T cell differentiation	J:137655
	abnormal immune system physiology	J:137655
	abnormal interleukin level	J:137655
	abnormal leukocyte physiology	J:137655
	abnormal T cell morphology	J:137655
	decreased CD8-positive, alpha-beta T cell number	J:137655
	decreased memory T cell number	J:137655
	increased neutrophil cell number	J:137655
	increased susceptibility to Riboviria infection	J:137655
Eomes^tm1Srnr/Eomes^tm1Srnr Tg(Cd4-cre)1Cwi/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)	decreased memory T cell number	J:137655
	immune system phenotype	J:137655
Ep300^Plt6/Ep300⁺ Mpl^tm1Wsa/Mpl^tm1Wsa (involves: 129S1/Sv * C57BL/6)	increased eosinophil cell number	J:140200
Ep300^Plt6/Ep300^Plt6 (involves: 129S1/Sv * C57BL/6)	decreased B cell number	J:140200
	decreased eosinophil cell number	J:140200
	decreased leukocyte cell number	J:140200
	decreased lymphocyte cell number	J:140200
Ep300^tm1Pkb/Ep300⁺ Myb^tm1Ssp/Myb⁺ (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)	decreased thymocyte number	J:98329
Ep300^tm1Pkb/Ep300^tm1Pkb (involves: 129P2/OlaHsd * C57BL/6)	decreased thymocyte number	J:98329
Ep300^tm2Pkb/Ep300^tm2Pkb Tg(Lck-cre)548Jxm/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA)	decreased single-positive T cell number	J:105505
	decreased thymocyte number	J:105505
	increased double-positive T cell number	J:105505
	small thymus	J:105505
Epas1^tm1.1Fsl/Epas1⁺ (involves: C57BL/6 * C57BL/6NTac)	increased leukocyte cell number	J:199595
	increased lymphocyte cell number	J:199595
	increased monocyte cell number	J:199595
Epas1^tm1.1Fsl/Epas1^tm1.1Fsl (involves: C57BL/6 * C57BL/6NTac)	increased leukocyte cell number	J:199595
	increased monocyte cell number	J:199595
	increased spleen weight	J:199595
Epas1^tm1Mcs/Epas1^tm1.1Mcs Ndor1^{Tg(UBC-cre/ERT2)1Ejb}/0 (involves: 129X1/SvJ * FVB/N)	enlarged spleen	J:119731
Epb41^tm1Cnby/Epb41^tm1Cnby (involves: 129S/SvEv * 129S1/Sv * 129X1/SvJ)	decreased spleen iron level	J:77852
	enlarged spleen	J:77852
	increased spleen red pulp amount	J:77852
Epb42^tm1Llp/Epb42^tm1Llp (involves: 129P2/OlaHsd * C57BL/6J)	increased spleen iron level	J:67412
	increased spleen weight	J:67412
Epc1^{tm1a(EUCOMM)Wtsi}/Epc1⁺ (Not Specified)	decreased leukocyte cell number	J:175295
Epcam^tm1.1Mcu/Epcam^tm1.1Mcu Tg(CD207-cre)1Dhka/0 (involves: 129 * C57BL/6 * C57BL/6J * SJL/J)	abnormal Langerhans cell morphology	J:182665
	abnormal Langerhans cell physiology	J:182665
	increased susceptibility to type IV hypersensitivity reaction	J:182665
Epcam^tm1.2Msiv/Epcam^tm1.2Msiv (involves: C57BL/6 * FVB/N * SJL)	small intestinal inflammation	J:210901
Epdr1^{tm1b(NCOM)Mfgc}/Epdr1^{tm1b(NCOM)Mfgc} (C57BL/6N-Epdr1^{tm1b(NCOM)Mfgc}/Tcp)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Epg5^em1(IMPC)H/Epg5^em1(IMPC)H (C57BL/6NTac-Epg5^em1(IMPC)H/H)	decreased lymphocyte cell number	J:211773
	increased basophil cell number	J:211773
	increased large unstained cell number	J:211773
	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
	increased spleen weight	J:211773
Epg5^tm1Ygz/Epg5^tm1Ygz (involves: 129S1/Sv * 129X1/SvJ * C57BL/6N)	microgliosis	J:196603
Epgn^tm1.1Msdr/Epgn^tm1.1Msdr (involves: 129P2/OlaHsd * C57BL/6N)	increased spleen weight	J:194427
Epha1^tm1Sld/Epha1^tm1Sld (involves: 129 * C57BL/6J)	endometrium inflammation	J:142722
Epha1^tm1Sld/Epha1^tm1Sld (involves: 129 * C57BL/6J)	vaginal inflammation	J:142722
Epha2^em1(IMPC)Mbp/Epha2^em1(IMPC)Mbp (C57BL/6N-Epha2^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
Epha3^em1(IMPC)Mbp/Epha3^em1(IMPC)Mbp (C57BL/6N-Epha3^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	small spleen	J:211773
Epha6^{tm1b(KOMP)Wtsi}/Epha6^{tm1b(KOMP)Wtsi} (C57BL/6N-Epha6^{tm1b(KOMP)Wtsi}/Tcp)	abnormal spleen morphology	J:211773
Ephb1^em1(IMPC)Mbp/Ephb1^em1(IMPC)Mbp (C57BL/6N-Ephb1^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	small spleen	J:211773
Ephb2^em1(IMPC)Mbp/Ephb2^em1(IMPC)Mbp (C57BL/6N-Ephb2^em1(IMPC)Mbp/MbpMmucd)	enlarged spleen	J:211773
	small spleen	J:211773
Ephb4^tm1.1Jwu/Ephb4^tm1.1Jwu Tg(KRT5-cre)1Tak/0 (involves: 129 * C3H * C57BL/6)	immune system phenotype	J:206160
Ephb6^tm1Jwu/Ephb6^tm1Jwu (involves: 129)	abnormal cytokine secretion	J:94701
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:94701
	decreased susceptibility to type IV hypersensitivity reaction	J:94701
	decreased T cell proliferation	J:94701
Ephb6^tm1Tom/Ephb6^tm1Tom (involves: 129S4/SvJae * C57BL/6J)	immune system phenotype	J:79747
Ephb6^tm2Tom/Ephb6^tm2Tom (involves: 129S4/SvJae * C57BL/6J)	immune system phenotype	J:79747
epi/? (involves: CBA/J)	decreased leukocyte cell number	J:27487
	decreased lymphocyte cell number	J:27487
	increased neutrophil cell number	J:27487
Epm2a^{Tg(TcraK,TcrbK)TG-BFlv}/Epm2a⁺ (involves: C57BL/6J * CBA/J)	increased CD8-positive, alpha-beta T cell number	J:107545
Epm2a^{Tg(TcraK,TcrbK)TG-BFlv}/Epm2a⁺ (involves: C57BL/6 * C57BL/10 * C57BR/cd * CBA/J)	increased T cell derived lymphoma incidence	J:112696
Epm2a^{Tg(TcraK,TcrbK)TG-BFlv}/Epm2a⁺ Tg(Ela1-TAg)18Bri/0 (involves: C57BL/6 * CBA/J * SJL)	pancreas inflammation	J:107545
Epo^{Tg(TAg/Epo)134.3LCPjr}/Epo^{Tg(TAg/Epo)134.3LCPjr} (involves: C57BL/6 * CBA)	increased spleen weight	J:79374
Epor^{tm1.2(EPOR)Jtp}/Epor^{tm1.2(EPOR)Jtp} (involves: 129P2/OlaHsd * C57BL/6)	decreased spleen weight	J:67205
Eppin^em1(IMPC)Mbp/Eppin^em1(IMPC)Mbp (C57BL/6N-Eppin^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Eps8l2^{tm1b(EUCOMM)Wtsi}/Eps8l2^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Eps8l2^{tm1b(EUCOMM)Wtsi}/H)	increased basophil cell number	J:211773
	increased large unstained cell number	J:211773
	increased monocyte cell number	J:211773
Eps15^{tm1a(KOMP)Wtsi}/Eps15^{tm1a(KOMP)Wtsi} (B6JTyr;B6N-Eps15^{tm1a(KOMP)Wtsi}/Wtsi)	decreased leukocyte cell number	J:165965
Eps15^{tm1a(KOMP)Wtsi}/Eps15^{tm1a(KOMP)Wtsi} (involves: C57BL/6 * C57BL/6N)	dermatitis	J:213427
Eps15^tm1Noff/Eps15^tm1Noff (B6.129-Eps15^tm1Noff)	abnormal spleen B cell follicle morphology	J:195689
	abnormal spleen marginal zone morphology	J:195689
	abnormal spleen white pulp morphology	J:195689
	decreased B cell number	J:195689
	decreased leukocyte cell number	J:195689
	decreased lymphocyte cell number	J:195689
	immune system phenotype	J:195689
	increased marginal zone B cell number	J:195689
Eps15^tm1Noff/Eps15^tm1Noff (involves: 129 * C57BL/6)	abnormal marginal zone B cell morphology	J:195689
	increased marginal zone B cell number	J:195689
	increased transitional stage T1 B cell number	J:195689
Epsti1^em1Mjnh/Epsti1^em1Mjnh (Not Specified)	abnormal macrophage differentiation	J:272013
Epsti1^em1Mjnh/Epsti1^em1Mjnh (Not Specified)	decreased macrophage cell number	J:272013
Epx^{tm1.1(cre)Jlee}/Epx⁺ Gt(ROSA)26Sor^tm1(DTA)Lky/Gt(ROSA)26Sor⁺ (involves: 129P2/OlaHsd * C57BL/6)	decreased eosinophil cell number	J:198489
Epx^{tm1.1(cre)Jlee}/Epx^{tm1.1(cre)Jlee} (B6.Cg-Epx^{tm1.1(cre)Jlee}/Jlee)	immune system phenotype	J:198489
Epx^{tm1b(EUCOMM)Wtsi}/Epx^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Epx^{tm1b(EUCOMM)Wtsi}/Orl)	increased monocyte cell number	J:211773
Epx^tm1Nal/Epx^tm1Nal (involves: 129P2/OlaHsd * 129X1/SvJ)	abnormal eosinophil morphology	J:70567
Epx^tm1Nal/Epx^tm1Nal (involves: 129P2/OlaHsd * 129X1/SvJ)	immune system phenotype	J:70567
Epyc^tm1Mhok/Epyc^tm1Mhok (involves: 129S7/SvEvBrd * C57BL/6J)	osteoarthritis	J:222369
Erap1^tm1.1Gnie/Erap1^tm1.1Gnie (involves: 129S6/SvEvTac * C57BL/6)	abnormal antigen presentation	J:143988
	abnormal cytotoxic T cell physiology	J:143988
	abnormal response to infection	J:143988
	decreased interferon-gamma secretion	J:143988
	decreased level of surface class I molecules	J:143988
	decreased T cell proliferation	J:143988
Erap1^tm1Dgen/Erap1^tm1Dgen (involves: 129P2/OlaHsd * C57BL/6)	enlarged spleen	J:101679
	thymus hyperplasia	J:101679
Erap1^tm1Iay/Erap1^tm1Iay (involves: C57BL/6)	abnormal cytotoxic T cell physiology	J:111047
Erap1^tm1Iay/Erap1^tm1Iay (involves: C57BL/6)	decreased level of surface class I molecules	J:111047
Erap1^tm1Luc/Erap1⁺ (involves: 129S6/SvEvTac)	abnormal antigen presentation	J:122479
Erap1^tm1Luc/Erap1⁺ (involves: 129S6/SvEvTac)	decreased level of surface class I molecules	J:122479
Erap1^tm1Luc/Erap1^tm1Luc (involves: 129S6/SvEvTac)	abnormal antigen presentation	J:122479
	abnormal CD8-positive, alpha-beta T cell physiology	J:122479
	abnormal lymphocyte physiology	J:122479
	decreased level of surface class I molecules	J:122479
	immune system phenotype	J:122479
	increased level of surface class I molecules	J:122479
Erap1^tm1Luc/Erap1^tm1Luc Rag2^tm1Fwa/Rag2^tm1Fwa Tg(TcrLCMV)327Sdz/Tg(TcrLCMV)327Sdz (involves: 129S/SvEv * 129S6/SvEvTac * C57BL/6 * C57BL/10SgSnAi * DBA/2)	immune system phenotype	J:122479
Erap1^tm1Nsha/Erap1^tm1Nsha (B6.129S6-Erap1^tm1Nsha)	abnormal antigen presentation via MHC class I	J:112389, J:116606
	abnormal CD8-positive, alpha-beta T cell physiology	J:112389, J:116606
	abnormal cytokine secretion	J:116606
	decreased level of surface class I molecules	J:112389
Erap1^tm1Nsha/Erap1^tm1Nsha Tap1^tm1Arp/Tap1^tm1Arp (B6.129-Erap1^tm1Nsha Tap1^tm1Arp)	abnormal antigen presentation via MHC class I	J:112389
Erap1^tm1Nsha/Erap1^tm1Nsha Tap1^tm1Arp/Tap1^tm1Arp (involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/10 * DBA/2)	abnormal antigen presentation via MHC class I	J:116606
Erars1^DBA/2J/? (involves: BXD2/TyJ * C57BL/6J * DBA/2J)	increased anti-nuclear antigen antibody level	J:96064
Erars1^DBA/2J/? (involves: BXD2/TyJ * C57BL/6J * DBA/2J)	increased immunoglobulin level	J:96064
Erars2^C57BL/6J/? (involves: BXD2/TyJ * C57BL/6J * DBA/2J)	abnormal humoral immune response	J:96064
Erars2^C57BL/6J/? (involves: BXD2/TyJ * C57BL/6J * DBA/2J)	increased immunoglobulin level	J:96064
Erbb3^tm1.1Dwt/Erbb3^tm2.1Dwt Tg(Vil1-cre)997Gum/0 (involves: 129S6/SvEvTac * C57BL/6 * SJL)	increased susceptibility to induced colitis	J:152703
Erbb4^tm1Grl/Erbb4^tm1Grl Tg(Myh6-ERBB4)HT2Gass/0 (involves: 129S1/Sv * 129X1/SvJ)	increased granulocyte number	J:132190
	lung inflammation	J:132190
Ercc1^tm1Jhjh/Ercc1^tm1Jhjh (involves: C57BL/6 * FVB/N)	abnormal class switch recombination	J:92471
	decreased B cell proliferation	J:92471
	spleen hypoplasia	J:92471
Ercc1^tm2Jhjh/Ercc1^tm2Jhjh (involves: 129P2/OlaHsd * C57BL/6)	abnormal spleen morphology	J:41161
Ercc2^{tm2(ERCC2)Jhjh}/Ercc2^{tm2(ERCC2)Jhjh} (involves: 129P2/OlaHsd * C57BL/6)	enlarged spleen	J:76608
Ercc2^{tm2(ERCC2)Jhjh}/Ercc2^{tm2(ERCC2)Jhjh} (involves: 129P2/OlaHsd)	immune system phenotype	J:47993
Ercc2^tm3Jhjh/Ercc2^tm3Jhjh (involves: 129 * C57BL/6J)	microgliosis	J:179808
Ercc5^tm1Shm/Ercc5^tm1Shm (involves: 129S2/SvPas * C57BL/6J)	decreased spleen weight	J:53756
Ercc6^tm1Gvh/Ercc6^tm1Gvh (involves: 129P2/OlaHsd * C57BL/6J)	microgliosis	J:179808
Ercc6^tm1Gvh/Ercc6^tm1Gvh Xpa^tm1Gvh/Xpa^tm1Hvs Tg(Camk2a-cre)1Szi/0 (involves: 129P2/OlaHsd * C57BL/6J * CBA)	microgliosis	J:179808
Ercc6^tm1Gvh/Ercc6^tm1Gvh Xpa^tm1Gvh/Xpa^tm1Hvs Tg(Pcp2-cre)2Mpin/0 (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6J)	microgliosis	J:179808
Ercc6l2^em1Mengf/Ercc6l2^em1Mengf (Not Specified)	abnormal class switch recombination	J:311900
	decreased IgA level	J:311900
	decreased IgG1 level	J:311900
	decreased IgG2b level	J:311900
	decreased IgG3 level	J:311900
	decreased IgG level	J:311900
	decreased T cell number	J:311900
	immune system phenotype	J:311900
Ercc6l2^em1Mengf/Ercc6l2^em1Mengf Nhej1^em1Mengf/Nhej1^em1Mengf (Not Specified)	abnormal T cell receptor V(D)J recombination	J:311900
Ercc6l2^em2Mengf/Ercc6l2^em2Mengf (Not Specified)	abnormal class switch recombination	J:311900
Ercc6l2^em2Mengf/Ercc6l2^em2Mengf (Not Specified)	immune system phenotype	J:311900
Ercc8^tm1Jhjh/Ercc8^tm1Jhjh (involves: 129P2/OlaHsd * C57BL/6J)	microgliosis	J:179808
Ereg^tm1Dwt/Ereg^tm1Dwt (129S6/SvEvTac-Ereg^tm1Dwt)	increased susceptibility to induced colitis	J:93327
Ereg^tm1Sawa/Ereg^tm1Sawa (involves: 129X1/SvJ * C57BL/6J)	dermatitis	J:92618
Erg^em1(IMPC)Bay/Erg⁺ (C57BL/6N-Erg^em1(IMPC)Bay/Bay)	abnormal spleen morphology	J:211773
Erg^em1(IMPC)Bay/Erg⁺ (C57BL/6N-Erg^em1(IMPC)Bay/Bay)	decreased leukocyte cell number	J:211773
Erg^mld2/Erg⁺ (involves: 129S1/Sv * C57BL/6)	decreased transitional stage B cell number	J:137835
Erg^mld2/Erg⁺ Mpl^tm1Wsa/Mpl^tm1Wsa (B6.Cg-Mpl^tm1Wsa Erg^mld2)	decreased leukocyte cell number	J:137835
Erg^tm1.1Iwamo/Erg^tm1.1Iwamo Tg(Gdf5-cre,-ALPP)1Kng/? (involves: 129S4/SvJaeSor * C57BL/6 * FVB/N)	increased susceptibility to induced arthritis	J:243715
	osteoarthritis	J:243715
Erlec1^em1(IMPC)Mbp/Erlec1^em1(IMPC)Mbp (C57BL/6N-Erlec1^em1(IMPC)Mbp/Ucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
Erlin1^em1(IMPC)Tcp/Erlin1^em1(IMPC)Tcp (C57BL/6N-Erlin1^em1(IMPC)Tcp/Tcp)	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
Ermp1^em1Gjom/Ermp1⁺ (Not Specified)	kidney inflammation	J:361886
Ern1^tm1Rjk/Ern1^tm1Rjk (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	abnormal pro-B cell morphology	J:106975
Ern1^tm2.1Tiw/Ern1^tm2.1Tiw Xbp1^tm2Glm/Xbp1^tm2Glm Tg(Vil1-cre)997Gum/0 (involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * SJL)	small intestinal inflammation	J:206084
Ern2^m1Btlr/Ern2^m1Btlr (C57BL/6J-Ern2^m1Btlr)	increased susceptibility to induced colitis	J:216045
Ern2^M2Btlr/Ern2^M2Btlr (C57BL/6J-Ern2^M2Btlr)	increased susceptibility to induced colitis	J:234237
Ern2^m3Btlr/Ern2^m3Btlr (C57BL/6J-Ern2^m3Btlr)	increased susceptibility to induced colitis	J:236686
Ern2^tm1Dron/Ern2^tm1Dron (either: 129S6/SvEvTac-Ern2^tm1Dron or B6.129S6-Ern2^tm1Dron)	increased susceptibility to induced colitis	J:67934
Ero1a^{Gt(XST171)Byg}/Ero1a^{Gt(XST171)Byg} (involves: 129P2/OlaHsd * C57BL/6J)	abnormal macrophage physiology	J:153833
	decreased macrophage apoptosis	J:153833
Errfi1^tm1Gvw/Errfi1^tm1Gvw (Not Specified)	accelerated temporomandibular joint osteoarthritis	J:100927
	enlarged thymus	J:100927
	osteoarthritis	J:100927
Errfi1^tm1Gvw/Errfi1^tm1Gvw Rag2^tm1Fwa/Rag2^tm1Fwa (involves: 129S/SvEv)	osteoarthritis	J:100927
Errfi1^tm3.1Gvw/Errfi1^tm3.1Gvw Tg(CMV-cre)1Cgn/0 (involves: 129 * 129S4/SvJaeSor * BALB/cJ)	osteoarthritis	J:206807
Errfi1^tm3.1Gvw/Errfi1^tm3.1Gvw Tg(Col2a1-cre)1Asz/0 (involves: 129S1/Sv * 129S4/SvJaeSor * C57BL/6 * CBA)	osteoarthritis	J:206807
Esam^tm1Dvst/Esam^tm1Dvst (B6.129-Esam1^tm1Dvst)	abnormal cellular extravasation	J:124397
Esam^tm1Dvst/Esam^tm1Dvst (B6.129-Esam1^tm1Dvst)	abnormal leukocyte migration	J:124397
Esm1^tm1.1Rha/Esm1^tm1.1Rha (involves: 129S6/SvEvTac * BALB/c * C57BL/6 * C57BL/6NTac)	abnormal cellular extravasation	J:246778
Esmr^DBA/2NCrj/Esmr^DBA/2NCrj (involves: C57BL/6NCrj * DBA/2NCrj)	decreased susceptibility to parasitic infection	J:74563
Espl1^Gt(XL058)Byg/Espl1⁺ Trp53^tm1Tyj/Trp53^tm1Tyj (B6.129-Trp53^tm1Tyj Espl1^Gt(XL058)Byg)	abnormal splenocyte morphology	J:174926
	increased splenocyte proliferation	J:174926
Espn^je/? f/f Hps6^ru/Hps6^ru (JE/LeJ)	abnormal mast cell degranulation	J:37255
Esr1^tm1.1Lja/Esr1^tm1.1Mma (involves: 129P2/OlaHsd * 129S2/SvPas * 129X1/SvJ * C57BL/6)	abnormal osteoclast physiology	J:128135
Esr1^tm1.1Mma/Esr1^tm1.1Mma (involves: 129S2/SvPas * C57BL/6)	abnormal immunoglobulin level	J:171276
	abnormal thymus physiology	J:171276
Esr1^tm1.1Ohl/Esr1^tm1.1Ohl (involves: 129S2/SvPas * C57BL/6)	abnormal immunoglobulin level	J:171276
	abnormal thymus physiology	J:171276
Esr1^tm1.1Scma/Esr1^tm1.1Scma Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6)	abnormal osteoclast physiology	J:156947
	increased osteoclast cell number	J:156947
Esr1^tm1Arnal/Esr1^tm1Arnal (involves: C57BL/6)	abnormal immunoglobulin level	J:171276
Esr1^tm1Arnal/Esr1^tm1Arnal (involves: C57BL/6)	increased osteoclast cell number	J:171276
Esr1^tm1Ksk/Esr1^tm1Ksk (involves: 129P2/OlaHsd * C57BL/6J)	abnormal B cell number	J:82423
	abnormal class switch recombination	J:82423
	abnormal immunoglobulin level	J:82423
	abnormal lymph node cell ratio	J:88156
	abnormal spleen physiology	J:88156
	decreased CD4-positive, alpha-beta T cell number	J:110416
	decreased CD8-positive, alpha-beta T cell number	J:110416
	glomerulonephritis	J:88156
	increased anti-double stranded DNA antibody level	J:88156
	increased double-positive T cell number	J:110416
	increased IgG3 level	J:88156
	increased plasma cell number	J:88156
	increased spleen germinal center number	J:88156
	thymus hypoplasia	J:110416
Esr1^tm1Ksk/Esr1^tm1Ksk (involves: 129P2/OlaHsd)	decreased immature B cell number	J:110923
	decreased mature B cell number	J:110923
	spermatic granuloma	J:60490
Esr1^tm1Ksk/Esr1^tm1Ksk (involves: 129P2/OlaHsd * C57BL/6N)	abnormal B cell differentiation	J:63462
	abnormal thymus physiology	J:111590
	decreased B cell number	J:63462
	decreased immature B cell number	J:63462
	decreased mature B cell number	J:63462
	decreased thymocyte number	J:111590
	decreased thymus weight	J:111590
Esr1^tm1Ksk/Esr1^tm1Ksk Esr2^tm1Unc/Esr2^tm1Unc (involves: 129P2/OlaHsd * C57BL/6J)	abnormal B cell number	J:82423
	abnormal class switch recombination	J:82423
	abnormal immunoglobulin level	J:82423
	decreased CD4-positive, alpha-beta T cell number	J:110416
	decreased CD8-positive, alpha-beta T cell number	J:110416
	decreased spleen weight	J:110416
	increased double-positive T cell number	J:110416
	thymus hypoplasia	J:110416
Esr1^tm1Ksk/Esr1^tm1Ksk Inha^tm1Bay/Inha^tm1Bay (involves: 129P2/OlaHsd * 129S6/SvEvTac * 129S7/SvEvBrd)	liver inflammation	J:84989
Esr2^tm1.2Pcn/Esr2^tm1.2Pcn (involves: 129S2/SvPas * C57BL/6 * SJL)	immune system phenotype	J:132171
Esr2^tm1Mma/Esr2^tm1Mma (involves: 129S2/SvPas)	increased neutrophil cell number	J:165719
Esr2^tm1Unc/Esr2^tm1Unc (involves: 129P2/OlaHsd * C57BL/6J)	abnormal B cell number	J:82423
	abnormal leukopoiesis	J:83617
	abnormal lymphopoiesis	J:83617
	enlarged lymph nodes	J:83617
	enlarged spleen	J:83617
	increased granulocyte number	J:83617
	increased leukocyte cell number	J:83617
	increased monocyte cell number	J:83617
	increased neutrophil cell number	J:83617
	increased pre-B cell number	J:83617
	increased pro-B cell number	J:83617
	spleen hyperplasia	J:83617
	spleen hypoplasia	J:110416
Esr2^tm1Unc/Esr2^tm1Unc (involves: 129P2/OlaHsd)	colitis	J:107308
Esr2^tm1Unc/Esr2^tm1Unc (involves: 129P2/OlaHsd)	urinary bladder inflammation	J:122274
Esrp2^em1(IMPC)Tcp/Esrp2^em1(IMPC)Tcp (C57BL/6NCrl-Esrp2^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Esrra^tm1Vgi/Esrra^tm1Vgi (involves: 129S1/Sv * 129X1/SvJ)	abnormal osteoclast differentiation	J:160910
	decreased osteoclast cell number	J:160910
	increased splenocyte number	J:160910
Ess2^tm1.1Nbioc/Ess2^tm1.1Nbioc Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6N * DBA/2)	abnormal CD4-positive, alpha-beta T cell physiology	J:339504
	decreased CD4-positive, alpha-beta T cell number	J:339504
	decreased CD8-positive, alpha-beta T cell number	J:339504
	decreased CD8-positive, naive alpha-beta T cell number	J:339504
	decreased memory T cell number	J:339504
	immune system phenotype	J:339504
	increased gamma-delta T cell number	J:339504
	increased NK T cell number	J:339504
Esyt2^{tm2b(KOMP)Wtsi}/Esyt2⁺ (C57BL/6N-Esyt2^{tm2b(KOMP)Wtsi}/Bay)	enlarged spleen	J:211773
Etfb^{em1(IMPC)Hmgu}/Etfb⁺ (C57BL/6NCrl-Etfb^{em1(IMPC)Hmgu}/Ieg)	increased spleen weight	J:211773
Etnk1^{tm1b(EUCOMM)Wtsi}/Etnk1^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Etnk1^{tm1b(EUCOMM)Wtsi}/Bay)	abnormal spleen morphology	J:211773
Ets1^m1Anu/Ets1^m1Anu (C57BL/6NCrl-Ets1^m1Anu/Anu)	immune system phenotype	J:104190
Ets1^tm1.1Dds/Ets1⁺ (129S6/SvEvTac-Ets1^tm1.1Dds)	abnormal thymus morphology	J:121460
	decreased memory T cell number	J:121460
	decreased thymocyte apoptosis	J:121460
	enlarged thymus	J:121460
	increased splenocyte apoptosis	J:121460
	increased thymus weight	J:121460
Ets1^tm1.1Dds/Ets1^tm1.1Dds (129S6/SvEvTac-Ets1^tm1.1Dds)	abnormal CD8-positive, alpha beta T cell morphology	J:121460
	abnormal lymphopoiesis	J:121460
	abnormal spleen morphology	J:121460
	abnormal spleen red pulp morphology	J:121460
	abnormal thymus cortex morphology	J:121460
	abnormal thymus morphology	J:121460
	abnormal thymus subcapsular epithelium morphology	J:121460
	decreased B cell number	J:121460
	decreased CD4-positive, alpha-beta T cell number	J:121460
	decreased leukocyte cell number	J:121460
	decreased memory T cell number	J:121460
	decreased spleen weight	J:121460
	decreased thymocyte apoptosis	J:121460
	enlarged thymus	J:121460
	increased double-positive T cell number	J:121460
	increased splenocyte apoptosis	J:121460
	increased thymus weight	J:121460
	small spleen	J:121460
Ets1^tm1Fwa/Ets1^tm1Fwa (B6.129S4-Ets1^tm1Fwa)	abnormal B cell differentiation	J:93845
	absent B-1a cells	J:93845
	decreased B cell number	J:93845
	decreased B cell proliferation	J:93845
	decreased mature B cell number	J:93845
	decreased pro-B cell number	J:93845
	immune system phenotype	J:93845
	increased B cell apoptosis	J:93845
	increased pro-B cell number	J:93845
Ets1^tm1Jml/Ets1^tm1Jml (involves: 129S/SvEv * C57BL/6)	abnormal CD8-positive, alpha-beta T cell differentiation	J:125056
	decreased CD4-positive, alpha-beta T cell number	J:125056
	decreased CD8-positive, alpha-beta T cell number	J:125056
	increased double-negative T cell number	J:125056
	thymus hypoplasia	J:125056
Ets1^tm1Jml/Ets1^tm1Jml Tg(TcraH-Y,TcrbH-Y)71Vbo/0 (involves: 129S/SvEv * C57BL/6 * C57BL/6J * DBA/2J)	decreased CD8-positive, alpha-beta T cell number	J:125056
	immune system phenotype	J:125056
	increased double-negative T cell number	J:125056
Ets1^tm2Jml/Ets1^tm2Jml (involves: 129X1/SvJ * C57BL/6)	abnormal CD8-positive, alpha beta T cell morphology	J:50627
	abnormal leukocyte physiology	J:50627
	abnormal NK cell physiology	J:50627
	abnormal T cell activation	J:50627
	decreased NK cell number	J:50627
	decreased T cell number	J:50627
	decreased T cell proliferation	J:50627
	decreased thymocyte number	J:50627
	impaired natural killer cell mediated cytotoxicity	J:50627
	increased plasma cell number	J:50627
Etv2^tm1Dlim/Etv2^tm2.1Dlim Tg(Mx1-cre)1Cgn/0 (involves: 129S4/SvJaeSor * C57BL/6 * CBA)	decreased leukocyte cell number	J:172687
	impaired myelopoiesis	J:172687
	spleen hypoplasia	J:172687
Etv6^{em1(IMPC)Rbrc}/Etv6⁺ (C57BL/6NJcl-Etv6^{em1(IMPC)Rbrc}/Rbrc)	increased large unstained cell number	J:211773
	increased spleen weight	J:211773
Etv6^em3Knic/Etv6⁺ (involves: C57BL/6J)	abnormal B cell number	J:342774
Etv6^{tm1(RUNX1)Haho}/Etv6⁺ Tg(CD2-icre)4Kio/0 (involves: 129S1/Sv * C57BL/6 * C57BL/10 * CBA/Ca)	immune system phenotype	J:151639
Etv6^{tm1(RUNX1)Haho}/Etv6⁺ Tg(Gata1-cre)1Sho/0 (involves: 129S1/Sv * C57BL/6 * CD-1 * Swiss Webster)	abnormal B cell differentiation	J:151639
	immune system phenotype	J:151639
Etv6^{tm1(RUNX1)Haho}/Etv6⁺ Tg(Mx1-cre)1Cgn/0 (involves: 129S1/Sv * C57BL/6 * CBA)	abnormal lymphopoiesis	J:151639
	decreased B cell number	J:151639
	decreased lymphocyte cell number	J:151639
	decreased neutrophil cell number	J:151639
	immune system phenotype	J:151639
	myeloid hyperplasia	J:151639
Etv6^{tm1(RUNX1)Haho}/Etv6⁺ Tg(VAV1-cre)1Graf/0 (involves: 129S1/Sv * C57BL/6)	arrested B cell differentiation	J:151639
	decreased B cell number	J:151639
	decreased pre-B cell number	J:151639
	decreased pro-B cell number	J:151639
Etv6^tm2Sho/Etv6^tm2Sho Tg(Mx1-cre)1Cgn/? (involves: 129S1/Sv * C57BL/6 * CBA)	decreased neutrophil cell number	J:93052
Evc2^em1(IMPC)Mbp/Evc2^em1(IMPC)Mbp (C57BL/6N-Evc2^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	small spleen	J:211773
Evl^tm1Lfr/Evl^tm1Lfr (involves: 129X1/SvJ * C57BL/6)	abnormal leukocyte migration	J:94077
Ewsr1^tm1(ERG)Thr/Ewsr1⁺ Rag1^tm1(cre)Thr/Rag1⁺ (involves: 129S/SvEv)	increased lymphocyte cell number	J:98679
	increased T cell derived lymphoma incidence	J:98679
Ewsr1^{tm1b(EUCOMM)Wtsi}/Ewsr1⁺ (C57BL/6N-Ewsr1^{tm1b(EUCOMM)Wtsi}/Tcp)	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
Ewsr1^tm1Sblee/Ewsr1^tm1Sblee (involves: 129S6/SvEvTac * Black Swiss)	decreased double-positive T cell number	J:122058
	decreased immature B cell number	J:122058
	decreased leukocyte cell number	J:122058
	decreased mature B cell number	J:122058
	decreased pre-B cell number	J:122058
	spleen hypoplasia	J:122058
	thymus hypoplasia	J:122058
exf/exf (involves: C3H/HeN(MTV^-))	conjunctivitis	J:5649
exf/exf (involves: C3H/HeN(MTV^-))	increased susceptibility to bacterial infection	J:5649
Exo1^tm2Wed/Exo1^tm2Wed (involves: 129 * C57BL/6)	abnormal class switch recombination	J:198719
Exo1^tm2Wed/Exo1^tm2Wed (involves: 129 * C57BL/6)	abnormal somatic hypermutation frequency	J:198719
Exo1^tm3.1Wed/Exo1^tm3.1Wed (involves: 129 * C57BL/6)	immune system phenotype	J:198719
Exoc6^hbd/Exoc6^hbd (AB.Cg-Exoc6^hbd)	decreased spleen iron level	J:8251
Exoc6^hbd/Exoc6^hbd (AB.Cg-Exoc6^hbd)	enlarged spleen	J:8251
Exph5^tm1Tiz/Exph5^tm1Tiz (B6NJcl.Cg-Exph5^tm1Tiz/Tiz)	abnormal interleukin secretion	J:313415
	abnormal T-helper 2 physiology	J:313415
	increased interleukin-5 secretion	J:313415
	increased interleukin-13 secretion	J:313415
	increased susceptibility to type I hypersensitivity reaction	J:313415
Extl1^em1Caox/Extl1^em1Caox Tg(Itgax-cre)1-1Reiz/0 (involves: C57BL/6 * CBA)	abnormal dendritic cell chemotaxis	J:333437
	abnormal dendritic cell migration	J:333437
	abnormal dendritic cell physiology	J:333437
	abnormal regulatory T cell morphology	J:333437
	chronic inflammation	J:333437
	decreased acute inflammation	J:333437
	decreased dendritic cell number	J:333437
	decreased T helper 1 cell number	J:333437
	enlarged lymph nodes	J:333437
	enlarged spleen	J:333437
	immune system phenotype	J:333437
	increased B cell number	J:333437
	increased circulating interleukin-6 level	J:333437
	increased circulating interleukin-17 level	J:333437
	increased circulating tumor necrosis factor level	J:333437
	increased IgG level	J:333437
	increased immunoglobulin level	J:333437
	increased interleukin-6 secretion	J:333437
	increased Ly6C high monocyte number	J:333437
	increased susceptibility to autoimmune disorder	J:333437
	increased susceptibility to bacterial infection induced morbidity/mortality	J:333437
	increased T cell number	J:333437
	increased T-helper 17 cell number	J:333437
Extl3^em1(IMPC)Mbp/Extl3⁺ (C57BL/6N-Extl3^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Eya1^tm1Rilm/Eya1^tm1Rilm (either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * BALB/c) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6))	athymia	J:79848, J:57313
Eya2^em1(IMPC)Mbp/Eya2^em1(IMPC)Mbp (C57BL/6N-Eya2^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	small spleen	J:211773
Eya2^tm2Px/Eya2^tm2Px (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	small thymus	J:311538
Eya4^tm1Jse/Eya4^tm1Jse (involves: 129S6/SvEvTac * CBA/J)	increased susceptibility to otitis media	J:131873
Ezh1^tm1Sgon/Ezh1^tm1Sgon Tg(VAV1-cre)1Graf/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal myeloid leukocyte morphology	J:193722
	absent spleen germinal center	J:193722
	decreased B cell number	J:193722
	decreased immature B cell number	J:193722
	decreased pro-B cell number	J:193722
	decreased spleen red pulp amount	J:193722
	decreased spleen white pulp amount	J:193722
	lymphoid hypoplasia	J:193722
	small spleen	J:193722
Ezh2^em1Jbn/Ezh2⁺ (C57BL/6J-Ezh2^em1Jbn)	increased spleen weight	J:267184
Ezh2^tm1.1Nesh/Ezh2⁺ Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129 * 129P2/OlaHsd * C57BL/6)	abnormal spleen morphology	J:239472
	abnormal spleen white pulp morphology	J:239472
	enlarged lymph nodes	J:239472
	enlarged spleen	J:239472
Ezh2^tm1.1Nesh/Ezh2^tm1.1Nesh Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129 * 129P2/OlaHsd * C57BL/6)	enlarged lymph nodes	J:239472
	enlarged spleen	J:239472
Ezh2^tm1Tara/Ezh2^tm1Tara Cd19^tm1(cre)Cgn/? (involves: 129P2/OlaHsd)	immune system phenotype	J:83216
Ezh2^tm1Tara/Ezh2^tm1Tara Igh^tm2Cgn/? Tg(Mx1-cre)1Cgn/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA)	immune system phenotype	J:83216
Ezh2^tm1Tara/Ezh2^tm1Tara Ighg1^tm1(cre)Cgn/Ighg1⁺ (involves: 129P2/OlaHsd)	decreased B cell proliferation	J:199122
	decreased germinal center B cell number	J:199122
	decreased IgG1 level	J:199122
	decreased IgG2b level	J:199122
	decreased IgG3 level	J:199122
	decreased spleen germinal center number	J:199122
	decreased spleen germinal center size	J:199122
	immune system phenotype	J:199122
Ezh2^tm1Tara/Ezh2^tm1Tara Tg(Mx1-cre)1Cgn/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA)	abnormal B cell differentiation	J:83216
	abnormal immunoglobulin V(D)J recombination	J:83216
	abnormal pro-B cell morphology	J:83216
	decreased immature B cell number	J:83216
	decreased pre-B cell number	J:83216
Ezh2^tm2Sho/Ezh2^tm2.1Sho Tg(Mx1-cre)1Cgn/0 (involves: 129S1/Sv * C57BL/6 * CBA)	decreased double-positive T cell number	J:182211
	decreased thymocyte number	J:182211
	enlarged lymph nodes	J:182211
	enlarged spleen	J:182211
	increased double-negative T cell number	J:182211
Ezh2^tm2Sho/Ezh2^tm2Sho Pgr^tm2(cre)Lyd/Pgr⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	decreased uterine NK cell number	J:290765
Ezh2^tm2Sho/Ezh2^tm2Sho Tg(Mx1-cre)1Cgn/0 (involves: 129S1/Sv * C57BL/6 * CBA)	decreased double-positive T cell number	J:182211
	decreased thymocyte number	J:182211
	enlarged lymph nodes	J:182211
	enlarged spleen	J:182211
	increased double-negative T cell number	J:182211
Ezr^tm2Aim/Ezr^tm2Aim Tg(Cd4-cre)1Cwi/0 (involves: 129S4/SvJae * C57BL/6 * DBA/2)	decreased interleukin-2 secretion	J:143487
F2^tm1Jld/F2^tm1Jld Tg(Mx1-cre)1Cgn/0 (B6.Cg-F2^tm1Jld Tg(Mx1-cre)1Cgn)	increased susceptibility to bacterial infection	J:144572
F2^tm2Jld/F2⁺ (B6.129P2-F2^tm2Jld)	decreased susceptibility to endotoxin shock	J:174629
F2^tm2Jld/F2⁺ (involves: 129P2/OlaHsd * C57BL/6 * DBA/2J)	decreased susceptibility to induced arthritis	J:174629
F2^tm2Jld/F2⁺ (involves: 129P2/OlaHsd * C57BL/6 * DBA/2J)	decreased synovial pannus formation	J:174629
F2r^tm1Ajc/F2r^tm1Ajc (involves: 129S4/SvJae * C57BL/6)	immune system phenotype	J:132733
F2r^tm1Ajc/F2r^tm1Ajc F2rl1^tm1Cgh/F2rl1^tm1Cgh (involves: 129S4/SvJae * C57BL/6)	increased susceptibility to endotoxin shock	J:132733
F2r^tm1Pago/F2r^tm1Pago (involves: 129P2/OlaHsd * C57BL/6)	decreased inflammatory response	J:124648
F2r^tm1Pago/F2r^tm1Pago (involves: 129P2/OlaHsd * C57BL/6)	decreased susceptibility to induced colitis	J:94420
F2r^tm1Pago/F2r^tm1Pago (B6.129P2-F2r^tm1Pago)	immune system phenotype	J:88245
F2r^tm1Pago/F2r^tm1Pago (involves: 129P2/OlaHsd)	abnormal cytokine level	J:133917
	abnormal lymph node morphology	J:133917
	decreased susceptibility to endotoxin shock	J:133917
	enlarged mesenteric lymph nodes	J:133917
F2rl1^tm1Bpd/F2rl1^tm1Bpd (involves: 129P2/OlaHsd * C57BL/6)	decreased inflammatory response	J:124648
	increased inflammatory response	J:96196
	increased susceptibility to induced pancreatitis	J:96196
F2rl1^tm1Bpd/F2rl1^tm1Bpd (B6.129P2-F2rl1^tm1Bpd)	decreased susceptibility to endotoxin shock	J:88245
F2rl1^tm1Bpd/F2rl1^tm1Bpd (B6.129P2-F2rl1^tm1Bpd)	immune system phenotype	J:88245
F2rl1^tm1Cgh/F2rl1^tm1Cgh (involves: 129S4/SvJae * C57BL/6)	glomerulonephritis	J:124303
	immune system phenotype	J:132733
	impaired leukocyte tethering or rolling	J:76626
F2rl1^tm1Cgh/F2rl1^tm1Cgh (B6.129S4-F2rl1^tm1Cgh)	decreased dendritic cell number	J:113591
F2rl1^tm1Jkaw/F2rl1^tm1Jkaw (involves: 129P2/OlaHsd * C57BL/6)	decreased susceptibility to type IV hypersensitivity reaction	J:106127
F2rl1^tm1Mslb/F2rl1^tm1Mslb (involves: 129X1/SvJ * C57BL/6)	decreased IgE level	J:79757
F2rl1^tm1Mslb/F2rl1^tm1Mslb (involves: 129X1/SvJ * C57BL/6)	decreased inflammatory response	J:79757
F2rl1^tm1Wrf/F2rl1^tm1Wrf (involves: 129P2/OlaHsd * C57BL/6)	decreased susceptibility to induced arthritis	J:81119
F2rl1^tm1Wrf/F2rl1^tm1Wrf (involves: 129P2/OlaHsd)	decreased circulating interleukin-18 level	J:102762
F2rl1^tm1Wrf/F2rl1^tm1Wrf (involves: 129P2/OlaHsd)	liver inflammation	J:102762
F2rl3^tm1Cgh/F2rl3^tm1Cgh (involves: 129S4/SvJae * C57BL/6)	immune system phenotype	J:132733
F3^tm1.1Dwr/F3^tm1.1Dwr (involves: 129S1/Sv * 129X1/SvJ * MF1 * Swiss)	abnormal cellular extravasation	J:91165
	abnormal leukocyte adhesion	J:91165
	decreased B cell number	J:91165
	decreased circulating interleukin-1 beta level	J:91165
	decreased circulating interleukin-6 level	J:91165
	decreased circulating tumor necrosis factor level	J:91165
	decreased leukocyte cell number	J:91165
	decreased neutrophil cell number	J:91165
	decreased susceptibility to endotoxin shock	J:91165
	impaired leukocyte tethering or rolling	J:91165
F3^tm1Dco/F3^tm1Dco Tg(F3)1Nmk/0 (B6.Cg-F3^tm1Dco Tg(F3)1Nmk)	abnormal interleukin level	J:88245
	decreased susceptibility to endotoxin shock	J:88245
F3^tm1Gjb/F3⁺ (involves: 129X1/SvJ * C57BL/6)	abnormal chemokine secretion	J:128891
	abnormal macrophage physiology	J:128891
	decreased interleukin-6 secretion	J:128891
	immune system phenotype	J:128891
F8^tm1.1Len/Y (B6.Cg-F8^tm1.1Len)	abnormal immune tolerance	J:266699
F8^tm1Kaz/Y (involves: 129S4/SvJae * C57BL/6)	abnormal immune tolerance	J:266699, J:178969
F8^tm1Kaz/Y Tg(Alb-F8R593C)T4Mcal/0 (involves: 129S4/SvJae C57BL/6 * FVB/N)	immune system phenotype	J:178969
F9^tm1Dws/Y (involves: 129P2/OlaHsd * C57BL/6)	enlarged spleen	J:44497
F11^tm1Gjb/F11^tm1Gjb Proc^tm1Fjc/Proc^tm1Fjc (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal lymph circulation	J:67398
	abnormal lymph node cortex morphology	J:67398
	abnormal lymph node morphology	J:67398
	abnormal neutrophil morphology	J:67398
	decreased leukocyte cell number	J:67398
	decreased neutrophil cell number	J:67398
	enlarged lymph nodes	J:67398
	lung inflammation	J:67398
	lymph node hemorrhage	J:67398
F11r^tm1.1Dej/F11r^tm1.1Dej (Not Specified)	abnormal dendritic cell physiology	J:92592
F11r^tm1.1Dej/F11r^tm1.1Dej (Not Specified)	increased susceptibility to type IV hypersensitivity reaction	J:92592
F11r^tm1Dej/F11r^tm1.1Dej Tg(Tek-cre)1Ywa/0 (Not Specified)	immune system phenotype	J:92592
Fa2h^em1(IMPC)Mbp/Fa2h^em1(IMPC)Mbp (C57BL/6NCrl-Fa2h^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Fabp1^{tm1b(EUCOMM)Hmgu}/Fabp1^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Fabp1^{tm1b(EUCOMM)Hmgu}/Cnrm)	decreased large unstained cell number	J:211773
	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
	decreased monocyte cell number	J:211773
Fabp2^{em1(IMPC)Hmgu}/Fabp2^{em1(IMPC)Hmgu} (C57BL/6N-Fabp2^{em1(IMPC)Hmgu}/Ieg)	enlarged lymph nodes	J:211773
Fabp5^tm1Kdo/Fabp5^tm1Kdo (involves: C57BL/6)	immune system phenotype	J:75715
Fadd^tm1Mpa/Fadd^tm1Mpa Ikbkg^tm1.1Mpa/Ikbkg^tm1.1Mpa Tg(Alb1-cre)7Gsc/0 (involves: C57BL/6 * FVB/N)	liver inflammation	J:118336
Fadd^tm1Mpa/Fadd^tm1Mpa Mlkl^tm1.1Wsa/Mlkl^tm1.1Wsa Otulin^{tm1c(EUCOMM)Hmgu}/Otulin^{tm1c(EUCOMM)Hmgu} Tg(KRT14-cre)1Cgn/0 (involves: C57BL/6 * C57BL/6N * DBA/2)	immune system phenotype	J:312394
Fadd^tm1Mpa/Fadd^tm1Mpa Mog^tm1(cre)Gkl/Mog⁺ (involves: C57BL/6 * SJL)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:167475
	immune system phenotype	J:167475
Fadd^tm1Mpa/Fadd^tm1Mpa Myd88^tm1Aki/Myd88^tm1Aki Tg(Vil1-cre)997Gum/0 (B6.Cg-Fadd^tm1Mpa Myd88^tm1Aki Tg(Vil1-cre)997Gum)	cecum inflammation	J:175865
Fadd^tm1Mpa/Fadd^tm1Mpa Tg(Vil1-cre)997Gum/0 (B6.Cg-Fadd^tm1Mpa Tg(Vil1-cre)997Gum)	cecum inflammation	J:175865
	colitis	J:175865
Fadd^tm1Mpa/Fadd^tm1Mpa Tnf^tm1Gkl/Tnf^tm1Gkl Tg(Vil1-cre)997Gum/0 (B6.Cg-Fadd^tm1Mpa Tnf^tm1Gkl Tg(Vil1-cre)997Gum)	cecum inflammation	J:175865
	colitis	J:175865
Fadd^tm1Wnt/Fadd^tm1Wnt Tg(Fadd)33Wnt/0 (involves: 129S4/SvJae * C57BL/6 * CBA)	immune system phenotype	J:69617
Fadd^tm1Wnt/Fadd^tm1Wnt Tg(Fadd)33Wnt/0 Tg(Lck-cre)I57Jxm/0 (involves: 129S4/SvJae * C57BL/6 * CBA * ICR)	abnormal T cell differentiation	J:69617
	decreased CD4-positive, alpha-beta T cell number	J:69617
	decreased CD8-positive, alpha-beta T cell number	J:69617
	decreased double-positive T cell number	J:69617
	increased B cell number	J:69617
	increased double-negative T cell number	J:69617
	thymus hypoplasia	J:69617
Fadd^tm1Wnt/Fadd^tm1Wnt Tg(Fadd)33Wnt/0 Tg(Lck-cre)I57Jxm/0 Tg(Tcra2C,Tcrb2C)1Dlo/0 (involves: 129S4/SvJae * C57BL/6 * C57L * CBA * ICR * SJL)	increased double-negative T cell number	J:69617
	thymus hypoplasia	J:69617
Fadd^tm1Wnt/Fadd^tm1Wnt Tg(Fadd/EGFP)#Jizh/? Tg(Cd4-cre)1Cwi/? (involves: 129S4/SvJae * C57BL/6 * DBA/2)	decreased activated T cell number	J:113207
	decreased single-positive T cell number	J:113207
	immune system phenotype	J:113207
	increased B cell number	J:113207
Fadd^tm1Wnt/Fadd^tm1Wnt Tg(Fadd/EGFP)#Jizh/? Tg(Lck-cre)1Cwi/? (involves: 129S4/SvJae)	decreased activated T cell number	J:113207
	decreased single-positive T cell number	J:113207
	immune system phenotype	J:113207
	increased B cell number	J:113207
Fadd^tm1Wnt/Fadd^tm1Wnt Tg(Fadd/EGFP)#Jizh/? Tg(Mx1-cre)1Cgn/? (involves: 129S4/SvJae * C57BL/6 * CBA)	spleen hypoplasia	J:168722
	thymus hypoplasia	J:168722
Fadd^tm2.1Wnt/Fadd^tm2.1Wnt Tg(Cd4-cre)1Cwi/? (B6.Cg-Tg(Cd4-cre)1Cwi Fadd^tm2.1Wnt)	abnormal T cell proliferation	J:162312
	abnormal T cell subpopulation ratio	J:162312
	abnormal thymocyte apoptosis	J:162312
	enlarged lymph nodes	J:162312
	enlarged spleen	J:162312
	increased B cell number	J:162312
	increased susceptibility to parasitic infection	J:162312
Fads1^{Gt(IST11525H2)Tigm}/Fads1⁺ (C57BL/6-Fads1^{Gt(IST11525H2)Tigm})	decreased interferon-gamma secretion	J:186265
	decreased tumor necrosis factor secretion	J:186265
Fads1^{Gt(IST11525H2)Tigm}/Fads1^{Gt(IST11525H2)Tigm} (C57BL/6-Fads1^{Gt(IST11525H2)Tigm})	abnormal mononuclear cell morphology	J:186265
	decreased interferon-gamma secretion	J:186265
	decreased regulatory T cell number	J:186265
	decreased tumor necrosis factor secretion	J:186265
Fads2^tm1Mtna/Fads2^tm1Mtna (involves: 129S6/SvEvTac * C57BL/6J)	abnormal spleen white pulp morphology	J:153293
	abnormal thymus cortex morphology	J:153293
	dermatitis	J:153293
	enlarged spleen	J:153293
	increased spleen red pulp amount	J:153293
	lymphoid hypoplasia	J:153293
	small thymus	J:153293
Fads2^tm1Wst/Fads2^tm1Wst (involves: 129P2/OlaHsd)	abnormal macrophage physiology	J:140341
Fah^em1(IMPC)Mbp/Fah⁺ (C57BL/6N-Fah^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
Fah^em1(IMPC)Mbp/Fah⁺ (C57BL/6N-Fah^em1(IMPC)Mbp/MbpMmucd)	enlarged spleen	J:211773
Fah^tm1Mgo/Fah^tm1Mgo (involves: 129S7/SvEvBrd * PT)	kidney inflammation	J:77295
Fah^tm1Mgo/Fah^tm1Mgo (involves: 129S7/SvEvBrd * C57BL)	liver inflammation	J:27735
Fah^tm1Mgo/Fah^tm1Mgo Hgd^aku/Hgd⁺ (involves: 129S7/SvEvBrd * NB)	kidney inflammation	J:77295
Faim2^{em1(IMPC)Ccpcz}/Faim2^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Faim2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	small spleen	J:211773
Faim^tm1Kplm/Faim^tm1Kplm (involves: 129P2/OlaHsd * C57BL/6)	increased B cell apoptosis	J:164184
	increased thymocyte apoptosis	J:164184
	liver inflammation	J:164184
Fam3a^em1Cya/Fam3a^em1Cya (involves: C57BL/6)	increased macrophage cell number	J:295206
	increased NK T cell number	J:295206
	increased T cell number	J:295206
Fam3d^em1Wko/Fam3d^em1Wko (C57BL/6-Fam3d^em1Wko)	abnormal cytokine level	J:300819
	abnormal neutrophil physiology	J:304594
	colitis	J:300819
	decreased Ly6C high monocyte number	J:304594
	decreased macrophage cell number	J:304594
	decreased neutrophil cell number	J:304594
	enlarged spleen	J:300819
	increased leukocyte cell number	J:300819
	increased neutrophil cell number	J:304594, J:300819
	increased susceptibility to colitis induced morbidity/mortality	J:300819
	increased susceptibility to induced colitis	J:300819
Fam13a^{tm1e(KOMP)Wtsi}/Fam13a^{tm1e(KOMP)Wtsi} (C57BL/6N-Fam13a^{tm1e(KOMP)Wtsi})	white adipose tissue inflammation	J:258290
Fam20c^tm1.1Cqi/Fam20c^tm1.1Cqi Tg(Col1a1-cre)2Bek/0 (involves: 129S6/SvEvTac * CD-1)	dental pulp inflammation	J:225679
	periodontium inflammation	J:225679
Fam53a^{em1(IMPC)Ccpcz}/Fam53a^{em1(IMPC)Ccpcz} (C57BL/6N-Fam53a^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Fam72a^{tm1.1(KOMP)Vlcg}/Fam72a^{tm1.1(KOMP)Vlcg} (C57BL/6NTac-Fam72a^{tm1.1(KOMP)Vlcg})	abnormal class switch recombination	J:326431
	abnormal somatic hypermutation frequency	J:326431
	increased B cell apoptosis	J:326431
	increased germinal center B cell number	J:326431
Fam72a^{tm1.1(KOMP)Vlcg}/Fam72a^{tm1.1(KOMP)Vlcg} Msh2^tm1Mak/Msh2^tm1Mak (C57BL/6NTac-Fam72a^{tm1.1(KOMP)Vlcg} Msh2^tm1Mak)	abnormal class switch recombination	J:326431
	abnormal somatic hypermutation frequency	J:326431
Fam76b^{Gt(IST14004H1)Tigm}/Fam76b^{Gt(IST14004H1)Tigm} (C57BL/6-Fam76b^{Gt(IST14004H1)Tigm})	abnormal macrophage physiology	J:358021
	abnormal spleen germinal center morphology	J:358021
	abnormal spleen white pulp morphology	J:358021
	abnormal splenic cell ratio	J:358021
	decreased B cell number	J:358021
	enlarged spleen	J:358021
	increased inflammatory response	J:358021
	increased interleukin-6 secretion	J:358021
	increased microglial cell activation	J:358021
	increased spleen weight	J:358021
	increased tumor necrosis factor secretion	J:358021
	microgliosis	J:358021
Fam81a^{em1(IMPC)Ccpcz}/Fam81a^{em1(IMPC)Ccpcz} (C57BL/6N-Fam81a^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Fam83d^{em1(IMPC)Ccpcz}/Fam83d^{em1(IMPC)Ccpcz} (C57BL/6N-Fam83d^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Fam83h^{em1(IMPC)Ccpcz}/Fam83h^{em1(IMPC)Ccpcz} (C57BL/6N-Fam83h^{em1(IMPC)Ccpcz}/Ccpcz)	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
Fam83h^{em2(IMPC)Ccpcz}/Fam83h⁺ (C57BL/6NCrl-Fam83h^{em2(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
Fam110b^{tm1a(EUCOMM)Wtsi}/Fam110b⁺ (C57BL/6N-Fam110b^{tm1a(EUCOMM)Wtsi}/Cnrm)	decreased mature B cell number	J:165965
	increased leukocyte cell number	J:165965
Fam120c^{em1(IMPC)Ccpcz}/Y (C57BL/6NCrl-Fam120c^{em1(IMPC)Ccpcz}/Ccpcz)	decreased NK cell number	J:211773
Fam120c^{em1(IMPC)Ccpcz}/Fam120c^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Fam120c^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Fam124a^{em1(IMPC)Ccpcz}/Fam124a^{em1(IMPC)Ccpcz} (C57BL/6N-Fam124a^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Fam151b^{tm1b(EUCOMM)Hmgu}/Fam151b^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Fam151b^{tm1b(EUCOMM)Hmgu}/H)	increased neutrophil cell number	J:211773
Fam161a^{Gt(462E7)Cmhd}/Fam161a^{Gt(462E7)Cmhd} (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	microgliosis	J:214319
Fam161b^{em1(IMPC)Ccpcz}/Fam161b^{em1(IMPC)Ccpcz} (C57BL/6N-Fam161b^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Fam163a^{tm2b(KOMP)Wtsi}/Fam163a^{tm2b(KOMP)Wtsi} (C57BL/6N-Fam163a^{tm2b(KOMP)Wtsi}/Wtsi)	increased leukocyte cell number	J:211773
Fam167a^{em1(IMPC)Ccpcz}/Fam167a^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Fam167a^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Fam185a^{em1(IMPC)Ccpcz}/Fam185a^{em1(IMPC)Ccpcz} (C57BL/6N-Fam185a^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Fam209^{tm1b(KOMP)Wtsi}/Fam209^{tm1b(KOMP)Wtsi} (C57BL/6N-Fam209^{tm1b(KOMP)Wtsi}/Bay)	abnormal spleen morphology	J:211773
Fam210a^{tm1b(EUCOMM)Wtsi}/Fam210a⁺ (involves: BALB/cJ * C57BL/6N)	increased osteoclast cell number	J:261817
Fam210a^{tm1c(EUCOMM)Wtsi}/Fam210a^{tm1c(EUCOMM)Wtsi} Tg(ACTA1-cre/Esr1)2Kesr/0 (involves: C3H C57BL/6N * SJL)	increased osteoclast cell number	J:261817
Fam210a^{tm1c(EUCOMM)Wtsi}/Fam210a^{tm1c(EUCOMM)Wtsi} Tg(CAG-cre/Esr1)5Amc/0 (involves: C57BL/6N CBA * SJL)	increased osteoclast cell number	J:261817
Fam210b^em1Cya/Fam210b^em1Cya (involves: C57BL/6N)	abnormal splenocyte physiology	J:351618
	enlarged spleen	J:351618
	glomerulonephritis	J:351618
	increased anti-double stranded DNA antibody level	J:351618
	increased anti-nuclear antigen antibody level	J:351618
	increased IgG level	J:351618
	increased splenocyte number	J:351618
Fam210b^{tm1b(KOMP)Mbp}/Fam210b^{tm1b(KOMP)Mbp} (C57BL/6N-Fam210b^{tm1b(KOMP)Mbp}/Ucd)	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Fam219a^{em1(IMPC)Ccpcz}/Fam219a^{em1(IMPC)Ccpcz} (C57BL/6N-Fam219a^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Fam221a^{em1(IMPC)Ccpcz}/Fam221a^{em1(IMPC)Ccpcz} (C57BL/6N-Fam221a^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
	increased CD8-positive, naive alpha-beta T cell number	J:211773
	increased neutrophil cell number	J:211773
Fam227b^{em1(IMPC)Ccpcz}/Fam227b^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Fam227b^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Fam229b^em1(IMPC)Mbp/Fam229b^em1(IMPC)Mbp (C57BL/6NCrl-Fam229b^em1(IMPC)Mbp/MbpMmucd)	increased basophil cell number	J:211773
Fam234b^{tm1a(EUCOMM)Wtsi}/Fam234b^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Fam234b^{tm1a(EUCOMM)Wtsi}/Cnrm)	decreased CD8-positive, alpha-beta T cell number	J:165965
Fan1^{tm1a(KOMP)Wtsi}/Fan1^{tm1a(KOMP)Wtsi} (129S1.B6-Fan1^{tm1a(KOMP)Wtsi})	tubulointerstitial nephritis	J:242198
Fancc^tm1Mab/Fancc^tm1Mab Sod1^tm1Cep/Sod1^tm1Cep (involves: 129S1/Sv * 129X1/SvJ)	abnormal lymphocyte morphology	J:71134
	decreased leukocyte cell number	J:71134
	decreased lymphocyte cell number	J:71134
	decreased neutrophil cell number	J:71134
Fancd2^em1Tzh/Fancd2^em1Tzh (C57BL/6-Fancd2^em1Tzh)	enlarged spleen	J:284566
Fancl^{tm1b(EUCOMM)Hmgu}/Fancl^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Fancl^{tm1b(EUCOMM)Hmgu}/Nju)	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
Farp2^tm1Akum/Farp2^tm1Akum (B6.Cg-Farp2^tm1Akum)	abnormal osteoclast physiology	J:166376
	decreased osteoclast cell number	J:166376
	increased osteoclast cell number	J:166376
Farsa^{tm2a(EUCOMM)Wtsi}/Farsa⁺ (C57BL/6N-Farsa^{tm2a(EUCOMM)Wtsi}/Wtsi)	decreased leukocyte cell number	J:211773
Fas^lpr-cg/Fas^lpr-cg (CBA/KlJms-Fas^lpr-cg/J)	abnormal hypersensitivity reaction	J:24805, J:81770
	abnormal lymph organ size	J:24805
	abnormal T cell differentiation	J:24805
	autoimmune response	J:24805, J:81770
	enlarged lymph nodes	J:24805, J:81770
	enlarged spleen	J:24805
	increased anti-nuclear antigen antibody level	J:24805
	increased autoantibody level	J:81770
	increased IgG level	J:24805, J:81770
	increased IgM level	J:24805, J:81770
	increased immunoglobulin level	J:24805
	increased spleen weight	J:81770
Fas^lpr/Fas⁺ Tg(TcraTcrb)1100Mjb/? (involves: C57BL/6 * MRL/Mp)	liver inflammation	J:72817
Fas^lpr/Fas^lpr (MRL/Mp-Fas^lpr)	abnormal B cell morphology	J:108760
	abnormal B cell receptor editing	J:131138
	abnormal cytotoxic T cell physiology	J:7488
	abnormal immune system organ morphology	J:28885
	abnormal immune system physiology	J:28885
	abnormal interleukin level	J:8267
	abnormal lymph node cell ratio	J:6257
	abnormal lymph node morphology	J:27634
	abnormal marginal zone B cell morphology	J:131138
	abnormal T cell morphology	J:108760, J:8267
	abnormal T cell physiology	J:8267
	abnormal T cell proliferation	J:8267
	abnormal T-helper 2 physiology	J:6257
	abnormal thymus medulla morphology	J:28885
	abnormal type III hypersensitivity reaction	J:28885
	blood vessel inflammation	J:28885
	decreased interleukin-2 secretion	J:6638, J:7488
	enlarged lymph nodes	J:27634, J:108760, J:13757, J:28885
	enlarged Peyer's patches	J:28885
	enlarged spleen	J:28885
	enlarged thymus	J:13757
	glomerulonephritis	J:27634, J:13757, J:28885
	increased anti-double stranded DNA antibody level	J:27634, J:131138, J:6257
	increased anti-erythrocyte antigen antibody level	J:27634
	increased anti-nuclear antigen antibody level	J:27634, J:28885
	increased anti-single stranded DNA antibody level	J:27634
	increased autoantibody level	J:28885
	increased IgA level	J:28885
	increased IgG1 level	J:13757, J:28885
	increased IgG2a level	J:13757, J:28885
	increased IgG2b level	J:28885
	increased IgG level	J:27634
	increased IgM level	J:28885
	increased immunoglobulin level	J:13757, J:28885, J:6257
	increased susceptibility to autoimmune disorder	J:108760
	increased synovial pannus formation	J:27634
	increased thymus weight	J:28885
	lacrimal gland inflammation	J:18512
	lymph node hemorrhage	J:27634
	lymph node hyperplasia	J:27634
	lymph node necrosis	J:27634
	salivary gland inflammation	J:18512
	submandibular gland inflammation	J:21965
	thymus atrophy	J:27634
	thymus cortex atrophy	J:13757, J:28885
	thyroid gland inflammation	J:28171
Fas^lpr/Fas^lpr (MRL/Mp-Agtpbp1^atms Fas^lpr)	enlarged lymph nodes	J:103944
	enlarged spleen	J:103944
	enlarged thymus	J:103944
Fas^lpr/Fas^lpr (NOD.MRL(B6)-Fas^lpr)	decreased susceptibility to autoimmune diabetes	J:64051
Fas^lpr/Fas^lpr (MRL/MpJ-Fas^lpr/J)	abnormal immunoglobulin level	J:122315
	CNS inflammation	J:14151
	conjunctivitis	J:123192
	decreased IgG level	J:122315
	decreased immature B cell number	J:122315
	decreased marginal zone B cell number	J:122315
	decreased mature B cell number	J:122315
	decreased spleen germinal center number	J:122315
	decreased transitional stage B cell number	J:122315
	enlarged lymph nodes	J:92084, J:7454
	glomerulonephritis	J:92084, J:122315, J:127199, J:7454
	increased anti-double stranded DNA antibody level	J:92084, J:122315, J:7454
	increased anti-nuclear antigen antibody level	J:111811, J:92084, J:14151, J:7454
	increased autoantibody level	J:92084, J:14151
	increased IgG level	J:92084
	increased immunoglobulin level	J:122315, J:7454
	increased neutrophil cell number	J:127199
	increased plasma cell number	J:122315
	increased susceptibility to systemic lupus erythematosus	J:92084
	lymph node hemorrhage	J:7454
	lymph node necrosis	J:7454
	salivary gland inflammation	J:92084
Fas^lpr/Fas^lpr (NOD.MRL-Fas^lpr)	decreased susceptibility to autoimmune diabetes	J:78679
Fas^lpr/Fas^lpr (involves: C3H * MRL/Mp)	autoimmune response	J:1060
	increased anti-nuclear antigen antibody level	J:34296
	increased spleen weight	J:34296
	increased susceptibility to systemic lupus erythematosus	J:34296
	increased susceptibility to type III hypersensitivity reaction	J:34296
Fas^lpr/Fas^lpr (B6.MRL-Fas^lpr/J)	abnormal NK cell physiology	J:115033
	abnormal splenic cell ratio	J:132217
	brain inflammation	J:120427
	CNS inflammation	J:120427
	decreased B cell apoptosis	J:135830
	enlarged lymph nodes	J:119584
	increased anti-double stranded DNA antibody level	J:132217
	increased anti-histone antibody level	J:132217
	increased anti-nuclear antigen antibody level	J:132217
	increased anti-single stranded DNA antibody level	J:132217
	increased autoantibody level	J:132217
	increased follicular B cell number	J:132217
	increased immature B cell number	J:132217
	increased marginal zone B cell number	J:132217
	increased splenocyte number	J:132217
	increased susceptibility to bacterial infection	J:136745
	increased susceptibility to Picornaviridae infection	J:120427
	increased transitional stage B cell number	J:132217
	lymph node hyperplasia	J:132217
Fas^lpr/Fas^lpr (MRL-Fas^lpr)	abnormal T-helper 2 physiology	J:6257
	enlarged lymph nodes	J:126261
	glomerulonephritis	J:126261
	increased anti-double stranded DNA antibody level	J:126261
	increased anti-nuclear antigen antibody level	J:126261
	increased IgG level	J:126261
	increased IgM level	J:126261
	increased immunoglobulin level	J:6257
	increased spleen weight	J:126261
Fas^lpr/Fas^lpr (MRL.Cg-Irf1^tm1Mak Fas^lpr)	glomerulonephritis	J:114771
Fas^lpr/Fas^lpr (MRL.Cg-Irf1^tm1Mak Fas^lpr)	increased anti-double stranded DNA antibody level	J:114771
Fas^lpr/Fas^lpr (C3.MRL-Fas^lpr/J)	abnormal B cell activation	J:7454
	abnormal T cell morphology	J:7454
	decreased eosinophil cell number	J:106288
	decreased interleukin-2 secretion	J:7454
	enlarged lymph nodes	J:7454
	glomerulonephritis	J:7454
	immune system phenotype	J:7454
	increased anti-double stranded DNA antibody level	J:7454
	increased anti-nuclear antigen antibody level	J:7454
	increased autoantibody level	J:7454
	increased immunoglobulin level	J:7454
	lymph node hemorrhage	J:7454
	lymph node hyperplasia	J:7454
	lymph node necrosis	J:7454
Fas^lpr/Fas^lpr (B6.MRL-Fas^lpr)	decreased interleukin-2 secretion	J:6638
	enlarged lymph nodes	J:6638, J:135036, J:7454
	enlarged spleen	J:135036
	glomerulonephritis	J:135036, J:7454
	increased anti-double stranded DNA antibody level	J:7454
	increased anti-nuclear antigen antibody level	J:6638, J:135036
	increased autoantibody level	J:135036, J:7454
	increased double-negative T cell number	J:135036
	increased immunoglobulin level	J:7454
	lymph node hemorrhage	J:7454
	lymph node necrosis	J:7454
Fas^lpr/Fas^lpr (AK.MRL-Fas^lpr)	enlarged lymph nodes	J:7454
	glomerulonephritis	J:7454
	increased anti-double stranded DNA antibody level	J:7454
	increased anti-nuclear antigen antibody level	J:7454
	increased autoantibody level	J:7454
	increased immunoglobulin level	J:7454
	lymph node hemorrhage	J:7454
	lymph node necrosis	J:7454
Fas^lpr/Fas^lpr (C3.MRL-Fas^lpr)	abnormal interleukin level	J:8267
	abnormal T cell morphology	J:8267
	abnormal T cell physiology	J:8267
	abnormal T cell proliferation	J:8267
	lacrimal gland inflammation	J:1028
	salivary gland inflammation	J:1028
Fas^lpr/Fas^lpr (MRL/MpJ-Fas^lpr)	abnormal leukocyte adhesion	J:126009
	abnormal leukocyte morphology	J:126009
	autoimmune response	J:125114
	blood vessel inflammation	J:137066
	decreased activated T cell number	J:137066
	decreased B cell number	J:137066
	decreased CD4-positive, alpha-beta T cell number	J:137066
	decreased CD8-positive, alpha-beta T cell number	J:137066
	enlarged lymph nodes	J:137066
	enlarged spleen	J:137066
	glomerulonephritis	J:125114, J:132514, J:137066
	impaired leukocyte tethering or rolling	J:126009
	increased anti-nuclear antigen antibody level	J:137066
	increased autoantibody level	J:137066
	increased double-negative T cell number	J:137066
	increased immunoglobulin level	J:125114
Fas^lpr/Fas^lpr (involves: MRL/Mp)	decreased macrophage apoptosis	J:154647
Fas^lpr/Fas^lpr (involves: MRL/Mp)	increased susceptibility to bacterial infection	J:50903
Fas^lpr/Fas^lpr (involves: C57BL/6 * MRL/Mp)	enlarged spleen	J:73396
	increased anti-double stranded DNA antibody level	J:73396
	increased anti-single stranded DNA antibody level	J:73396
	increased IgA level	J:73396
	increased IgG1 level	J:73396
	increased IgG2a level	J:73396
	increased IgG2b level	J:73396
	increased IgG3 level	J:73396
	increased IgM level	J:73396
	lymph node hyperplasia	J:73396
Fas^lpr/Fas^lpr (involves: 129P2/OlaHsd * MRL)	enlarged lymph nodes	J:26250
	glomerulonephritis	J:45448
	increased double-negative T cell number	J:26250
	increased gamma-delta T cell number	J:26250
	kidney inflammation	J:45448
Fas^lpr/Fas^lpr Fcer1g^tm1Tks/Fcer1g^tm1Tks (MRL.Cg-Fcer1g^tm1Tks Fas^lpr)	arteritis	J:106188
	decreased susceptibility to type III hypersensitivity reaction	J:106188
	glomerulonephritis	J:106188
	immune system phenotype	J:106188
	increased anti-double stranded DNA antibody level	J:106188
	increased double-negative T cell number	J:106188
	increased IgG level	J:106188
	increased spleen weight	J:106188
Fas^lpr/Fas^lpr Havcr1^tm1Kuch/Havcr1^tm1Kuch (B6.Cg-Havcr1^tm1Kuch Fas^lpr)	abnormal immunoglobulin level	J:186484
	enlarged lymph nodes	J:186484
	enlarged spleen	J:186484
	increased activated T cell number	J:186484
	increased anti-double stranded DNA antibody level	J:186484
	increased autoantibody level	J:186484
	increased B cell number	J:186484
	increased CD4-positive, alpha-beta T cell number	J:186484
	increased CD8-positive, alpha-beta T cell number	J:186484
	increased double-negative T cell number	J:186484
	increased IgG1 level	J:186484
	increased IgG2a level	J:186484
	increased IgG2b level	J:186484
	increased IgG3 level	J:186484
	increased susceptibility to systemic lupus erythematosus	J:186484
	increased T cell number	J:186484
Fas^lpr/Fas^lpr Hspa13^tm1.1Smoc/Hspa13^tm1.1Smoc Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129P2/OlaHsd * 129S * C57BL/6 * MRL/Mp)	decreased autoantibody level	J:303927
	decreased susceptibility to systemic lupus erythematosus	J:303927
Fas^lpr/Fas^lpr Ifnar1^tm1Agt/Ifnar1^tm1Agt (MRL.Cg-Ifnar1^tm1Agt Fas^lpr)	enlarged lymph nodes	J:92084
	glomerulonephritis	J:92084
	increased anti-nuclear antigen antibody level	J:92084
	increased autoantibody level	J:92084
	increased IgA level	J:92084
	increased IgG2b level	J:92084
	increased IgG3 level	J:92084
	increased IgG level	J:92084
	increased IgM level	J:92084
	increased susceptibility to systemic lupus erythematosus	J:92084
	salivary gland inflammation	J:92084
Fas^lpr/Fas^lpr Ifnar1^tm1Agt/Ifnar1^tm1Agt Ifngr1^tm1Agt/Ifngr1^tm1Agt (MRL.Cg-Ifngr1^tm1Agt Ifnar1^tm1Agt Fas^lpr)	decreased anti-nuclear antigen antibody level	J:92084
	decreased autoantibody level	J:92084
	decreased IgG level	J:92084
	decreased susceptibility to systemic lupus erythematosus	J:92084
	glomerulonephritis	J:92084
	increased IgG level	J:92084
	increased susceptibility to systemic lupus erythematosus	J:92084
	salivary gland inflammation	J:92084
	small lymph nodes	J:92084
Fas^lpr/Fas^lpr Ifng^tm1Ts/Ifng⁺ (MRL.Cg-Ifng^tm1Ts Fas^lpr)	abnormal macrophage chemotaxis	J:123834
	glomerulonephritis	J:123834
	increased autoantibody level	J:123834
Fas^lpr/Fas^lpr Ifng^tm1Ts/Ifng^tm1Ts (MRL.Cg-Ifng^tm1Ts Fas^lpr)	abnormal macrophage chemotaxis	J:123834
	immune system phenotype	J:123834
	kidney inflammation	J:123834
	lung inflammation	J:123834
Fas^lpr/Fas^lpr Ifng^tm1Ts/Ifng^tm1Ts (involves: 129S7/SvEvBrd * DBA/1 * MRL/Mp)	abnormal lymph node size	J:39600
	abnormal spleen size	J:39600
	decreased anti-double stranded DNA antibody level	J:39600
	decreased anti-nuclear antigen antibody level	J:39600
	decreased autoantibody level	J:39600
	decreased double-negative T cell number	J:39600
	decreased IgA level	J:39600
	decreased IgG2a level	J:39600
	decreased IgG2b level	J:39600
	decreased IgM level	J:39600
	decreased immunoglobulin level	J:39600
	decreased susceptibility to systemic lupus erythematosus	J:39600
	enlarged lymph nodes	J:39600
	enlarged spleen	J:39600
Fas^lpr/Fas^lpr Ifngr1^tm1Agt/Ifngr1^tm1Agt (MRL.Cg-Ifngr1^tm1Agt Fas^lpr)	decreased anti-nuclear antigen antibody level	J:92084
	decreased autoantibody level	J:92084
	decreased IgA level	J:92084
	decreased IgG2a level	J:92084
	decreased IgG2b level	J:92084
	decreased IgG3 level	J:92084
	decreased IgM level	J:92084
	decreased susceptibility to systemic lupus erythematosus	J:92084
	glomerulonephritis	J:92084
	increased IgG1 level	J:92084
	increased IgG level	J:92084
	small lymph nodes	J:92084
Fas^lpr/Fas^lpr Igh-J^{tm2(3H9-VDJ)Mwg}/Igh-J⁺ (MRL.Cg-Fas^lpr Igh-J^{tm2(3H9-VDJ)Mwg})	abnormal B cell receptor editing	J:131138
	abnormal marginal zone B cell morphology	J:131138
	increased anti-double stranded DNA antibody level	J:131138
Fas^lpr/Fas^lpr Ighm^tm1Cgn/Ighm^tm1Cgn (involves: 129S2/SvPas * C57BL/6 * MRL/Mp)	abnormal humoral immune response	J:119584
	abnormal immunoglobulin level	J:119584
	arrested B cell differentiation	J:119584
	decreased IgM level	J:119584
	decreased mature B cell number	J:119584
	enlarged lymph nodes	J:119584
	increased autoantibody level	J:119584
	increased T cell number	J:119584
Fas^lpr/Fas^lpr Il2ra^tm1Dw/Il2ra^tm1Dw Tg(CD2-Ccdc86)1Hfuj/? (B6.Cg-Il2ra^tm1Dw Fas^lpr Tg(CD2-Ccdc86)1Hfuj)	enlarged spleen	J:151722
Fas^lpr/Fas^lpr Il4^tm1Cgn/Il4^tm1Cgn (MRL.Cg-Il4^tm1Cgn Fas^lpr)	glomerulonephritis	J:132514
	lacrimal gland inflammation	J:132514
Fas^lpr/Fas^lpr Il4^tm1Cgn/Il4^tm1Cgn (involves: 129P2/OlaHsd * C57BL/6J * MRL/Mp)	abnormal lymph node size	J:39600
	abnormal spleen size	J:39600
	decreased anti-nuclear antigen antibody level	J:39600
	decreased IgA level	J:39600
	decreased IgE level	J:39600
	decreased IgG1 level	J:39600
	decreased IgG3 level	J:39600
	decreased immunoglobulin level	J:39600
	decreased susceptibility to systemic lupus erythematosus	J:39600
	enlarged spleen	J:39600
	increased spleen weight	J:39600
	spleen hyperplasia	J:39600
Fas^lpr/Fas^lpr Il27ra^tm1Mak/Il27ra^tm1Mak (MRL.Cg-Il27ra^tm1Mak Fas^lpr)	abnormal T-helper 2 physiology	J:122148
	decreased anti-double stranded DNA antibody level	J:122148
	decreased IgG2a level	J:122148
	decreased interferon-gamma secretion	J:122148
	decreased susceptibility to systemic lupus erythematosus	J:122148
	glomerulonephritis	J:122148
	immune system phenotype	J:122148
	increased circulating interleukin-4 level	J:122148
	increased circulating interleukin-5 level	J:122148
	increased IgE level	J:122148
	increased IgG1 level	J:122148
Fas^lpr/Fas^lpr Irf1^tm1Mak/Irf1⁺ (MRL.Cg-Irf1^tm1Mak Fas^lpr)	glomerulonephritis	J:114771
	immune system phenotype	J:114771
	increased anti-double stranded DNA antibody level	J:114771
	increased CD4-positive, alpha-beta T cell number	J:114771
Fas^lpr/Fas^lpr Irf1^tm1Mak/Irf1^tm1Mak (MRL.Cg-Irf1^tm1Mak Fas^lpr)	abnormal cytokine secretion	J:114771
	decreased anti-double stranded DNA antibody level	J:114771
	glomerulonephritis	J:114771
	immune system phenotype	J:114771
	increased CD4-positive, alpha-beta T cell number	J:114771
Fas^lpr/Fas^lpr Itfg2^{Gt(OST215121)Lex}/Itfg2^{Gt(OST215121)Lex} (involves: 129S5/SvEvBrd * C57BL/6J * MRL/Mp)	decreased B cell number	J:205951
	enlarged lymph nodes	J:205951
	enlarged spleen	J:205951
	increased anti-double stranded DNA antibody level	J:205951
	increased anti-nuclear antigen antibody level	J:205951
	increased double-negative T cell number	J:205951
	increased IgG2a level	J:205951
	increased IgM level	J:205951
	increased susceptibility to systemic lupus erythematosus	J:205951
Fas^lpr/Fas^lpr Kdelr1^m1Btlr/Kdelr1^m1Btlr (involves: C57BL/6J * MRL/Mp)	immune system phenotype	J:224970
Fas^lpr/Fas^lpr Nos2^tm1Mrl/Nos2^tm1Mrl (involves: 129S7/SvEvBrd * MRL)	abnormal immunoglobulin level	J:42666
	decreased IgG level	J:42666
	decreased IgM level	J:42666
	immune system phenotype	J:42666
Fas^lpr/Fas^lpr Pou2af1^tm1Pmt/Pou2af1^tm1Pmt (involves: 129P2/OlaHsd * C57BL/6 * MRL)	abnormal T cell number	J:125114
	autoimmune response	J:125114
	decreased immunoglobulin level	J:125114
	decreased plasma cell number	J:125114
	increased B cell number	J:125114
Fas^lpr/Fas^lpr Selp^tm1Bay/Selp^tm1Bay (MRL.Cg-Selp^tm1Bay Fas^lpr)	abnormal chemokine secretion	J:127199
	abnormal leukocyte adhesion	J:126009
	dermatitis	J:127199
	glomerulonephritis	J:127199
	impaired leukocyte tethering or rolling	J:126009
	increased neutrophil cell number	J:127199
Fas^lpr/Fas^lpr Selplg^tm1Fur/Selplg^tm1Fur (MRL.Cg-Selplg^tm1Fur Fas^lpr)	abnormal chemokine level	J:127199
	dermatitis	J:127199
	glomerulonephritis	J:127199
Fas^lpr/Fas^lpr Sh2d1a^rpl/Sh2d1a^rpl (MRL/Mp-Fas^lpr Sh2d1a^rpl)	abnormal immune system physiology	J:126261
	increased anti-nuclear antigen antibody level	J:126261
Fas^lpr/Fas^lpr Spp1^tm1Rit/Spp1^tm1Rit (involves: 129S7/SvEvBrd * C57BL/6 * MRL/Mp)	enlarged spleen	J:73396
	increased anti-double stranded DNA antibody level	J:73396
	increased anti-single stranded DNA antibody level	J:73396
	increased IgA level	J:73396
	increased IgG1 level	J:73396
	increased IgG2a level	J:73396
	increased IgG2b level	J:73396
	increased IgG3 level	J:73396
	increased IgM level	J:73396
	kidney inflammation	J:73396
	lymph node hyperplasia	J:73396
Fas^lpr/Fas^lpr Tcra^tm1Mjo/Tcra⁺ (MRL.Cg-Tcra^tm1Mjo Fas^lpr)	immune system phenotype	J:108590
Fas^lpr/Fas^lpr Tcra^tm1Mjo/Tcra^tm1Mjo (involves: 129P2/OlaHsd * MRL)	immune system phenotype	J:26250
	increased gamma-delta intraepithelial T cell number	J:26250
	increased gamma-delta T cell number	J:26250
	increased T cell number	J:26250
	kidney inflammation	J:45448
Fas^lpr/Fas^lpr Tcra^tm1Mjo/Tcra^tm1Mjo (involves: 129P2/OlaHsd * 129S2/SvPas * MRL)	decreased autoantibody level	J:38492
	decreased immunoglobulin level	J:38492
Fas^lpr/Fas^lpr Tg(CD2-Foxj1)#Stlp/0 (MRL.Cg-Fas^lpr Tg(CD2-Foxj1)#Stlp)	abnormal T cell physiology	J:122222
	decreased CD4-positive, alpha-beta T cell number	J:122222
	decreased susceptibility to systemic lupus erythematosus	J:122222
	enlarged lymph nodes	J:122222
	enlarged spleen	J:122222
	increased anti-nuclear antigen antibody level	J:122222
	increased double-negative T cell number	J:122222
	kidney inflammation	J:122222
	liver inflammation	J:122222
	lung inflammation	J:122222
	salivary gland inflammation	J:122222
Fas^lpr/Fas^lpr Tg(H2-K-Cd86)27All/0 (involves: C57BL/6 * CBA * MRL/MpJ)	decreased B cell number	J:112475
Fas^lpr/Fas^lpr Tg(Ins2-Fasl)24Ach/0 (NOD.Cg-Fas^lpr Tg(Ins2-Fasl)24Ach)	decreased susceptibility to autoimmune diabetes	J:81416
Fas^lpr/Fas^lpr Tg(INS-Il10)#Sar/0 (NOD.Cg-Fas^lpr Tg(INS-Il10)#Sar)	increased susceptibility to autoimmune diabetes	J:64051
	insulitis	J:64051
Fas^lpr/Fas^lpr Tlr7^tm1Flv/Y (involves: 129S1/Sv * C57BL/6 * MRL/Mp)	abnormal B cell activation	J:113557
	abnormal CD4-positive, alpha beta T cell morphology	J:113557
	abnormal lymph node size	J:113557
	abnormal plasmacytoid dendritic cell physiology	J:113557
	decreased autoantibody level	J:113557
	decreased double-negative T cell number	J:113557
	decreased IgG2a level	J:113557
	decreased IgG3 level	J:113557
	decreased spleen weight	J:113557
	decreased susceptibility to systemic lupus erythematosus	J:113557
	increased anti-chromatin antibody level	J:113557
	increased autoantibody level	J:113557
Fas^lpr/Fas^lpr Tlr9^tm1Aki/Tlr9^tm1Aki (B6.Cg-Tlr9^tm1Aki Fas^lpr)	autoimmune response	J:135036
	decreased IgM level	J:135036
	enlarged lymph nodes	J:135036
	enlarged spleen	J:135036
	glomerulonephritis	J:135036
	increased double-negative T cell number	J:135036
	increased IgG level	J:135036
Fas^lpr/Fas^lpr Tlr9^tm1Aki/Tlr9^tm1Aki (MRL.Cg-Tlr9^tm1Aki Fas^lpr)	abnormal B cell activation	J:113557
	abnormal plasmacytoid dendritic cell physiology	J:113557
	decreased autoantibody level	J:113557
	enlarged lymph nodes	J:113557
	enlarged spleen	J:113557
	glomerulonephritis	J:113557
	increased autoantibody level	J:113557
	increased CD4-positive, alpha-beta T cell number	J:113557
	increased circulating interferon-alpha level	J:113557
	increased double-negative T cell number	J:113557
	increased IgG2a level	J:113557
	increased IgG3 level	J:113557
	increased IgG level	J:113557
	increased susceptibility to systemic lupus erythematosus	J:113557
	kidney inflammation	J:113557
Fas^lpr/Fas^lpr Tnfrsf1a^tm1.1Gkl/Tnfrsf1a^tm1.1Gkl (involves: 129/Sv * C57BL/6)	liver inflammation	J:92470
Fas^lpr/Fas^lpr Tnfrsf9^tm1Byk/Tnfrsf9^tm1Byk (MRL.Cg-Tnfrsf9^tm1Byk Fas^lpr)	enlarged lymph nodes	J:127197
	enlarged spleen	J:127197
	increased anti-nuclear antigen antibody level	J:127197
	increased B-1 B cell number	J:127197
	increased B-2 B cell number	J:127197
	increased CD4-positive, alpha-beta T cell number	J:127197, J:126929
	increased double-negative T cell number	J:127197, J:126929
	increased immunoglobulin level	J:127197
	increased interleukin-4 secretion	J:126929
	increased spleen germinal center number	J:127197
	increased susceptibility to systemic lupus erythematosus	J:127197
	lacrimal gland inflammation	J:126929
Fas^lpr/Fas^lpr Tnfrsf13c^Bcmd1/Tnfrsf13c⁺ (MRL.Cg-Tnfrsf13c^Bcmd1 Fas^lpr)	decreased B cell number	J:122315
	decreased marginal zone B cell number	J:122315
Fas^lpr/Fas^tm1.1Cgn (involves: C57BL/6 * MRL)	abnormal immune system morphology	J:114948
	enlarged lymph nodes	J:114948
	enlarged spleen	J:114948
Fas^lpr/Fas^tm1Cgn Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2 * MRL)	enlarged lymph nodes	J:114948
	enlarged spleen	J:114948
	increased double-negative T cell number	J:114948
Fas^m1Btlr/Fas^m1Btlr (C57BL/6J-Fas^m1Btlr)	decreased CD4-positive, alpha-beta T cell number	J:216052
	decreased CD8-positive, alpha-beta T cell number	J:216052
	increased neutrophil cell number	J:216052
	increased NK cell number	J:216052
Fas^m2Btlr/Fas^m2Btlr (C57BL/6J-Fas^m2Btlr)	increased central memory CD4-positive, alpha-beta T cell number	J:271891
Fas^m2Btlr/Fas^m2Btlr (C57BL/6J-Fas^m2Btlr)	increased effector memory CD4-positive, alpha-beta T cell number	J:271891
Fas^theo/Fas^theo (either: (involves: C57BL/6JAnu * C57BL/10SnSg * C57BR/cd) or (involves: C57BL/6JAnu * C57BL/10SnSg * C57BR/cd * CBA/CaJAnu))	enlarged lymph nodes	J:104190
	increased anti-nuclear antigen antibody level	J:104190
Fas^tm1.1Cgn/Fas^tm1.1Cgn (involves: C57BL/6)	abnormal immune system morphology	J:114948
	enlarged lymph nodes	J:114948
	enlarged spleen	J:114948
Fas^tm1Ach/Fas^tm1Ach Tg(GZMB-cre)1Jcb/? (involves: C57BL/6 * FVB/N)	increased anti-nuclear antigen antibody level	J:123556
	increased double-positive T cell number	J:123556
Fas^tm1Ach/Fas^tm1Ach Tg(Itgax-cre,-EGFP)4097Ach/? (Not Specified)	abnormal spleen morphology	J:123556
	abnormal spleen periarteriolar lymphoid sheath morphology	J:123556
	enlarged spleen	J:123556
	increased anti-nuclear antigen antibody level	J:123556
	increased dendritic cell number	J:123556
	increased IgG level	J:123556
	increased IgM level	J:123556
	increased immunoglobulin level	J:123556
Fas^tm1Ach/Fas^tm1Ach Tg(Lck-cre)548Jxm/? (involves: C57BL/6 * CBA)	increased anti-nuclear antigen antibody level	J:123556
	increased double-positive T cell number	J:123556
Fas^tm1Cgn/Fas^tm1Cgn (C57BL/6-Fas^tm1Cgn)	immune system phenotype	J:114948
Fas^tm1Cgn/Fas^tm1Cgn Cd19^tm1(cre)Cgn/Cd19⁺ Tg(Cd4-cre)1Cwi/0 (B6.Cg-Tg(Cd4-cre)1Cwi Cd19^tm1(cre)Cgn Fas^tm1Cgn)	increased anti-single stranded DNA antibody level	J:114948
Fas^tm1Cgn/Fas^tm1Cgn Mog^tm1(cre)Gkl/Mog⁺ (involves: C57BL/6)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:114741
	immune system phenotype	J:114741
Fas^tm1Cgn/Fas^tm1Cgn Mog^tm1(cre)Gkl/Mog⁺ Tnfrsf1a^tm1Mak/Tnfrsf1a^tm1Mak (involves: 129S2/SvPas * C57BL/6)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:114741
	immune system phenotype	J:114741
Fas^tm1Cgn/Fas^tm1Cgn Tg(Cd4-cre)1Cwi/0 (B6.Cg-Tg(Cd4-cre)1Cwi Fas^tm1Cgn)	abnormal immune system cell morphology	J:114948
	abnormal immune system organ morphology	J:114948
	abnormal thymus involution	J:114948
	alveolitis	J:114948
	decreased B cell number	J:114948
	decreased T cell number	J:114948
	enlarged spleen	J:114948
	increased activated T cell number	J:114948
	increased anti-single stranded DNA antibody level	J:114948
	increased double-negative T cell number	J:114948
	increased inflammatory response	J:114948
	increased memory T cell number	J:114948
	increased T cell apoptosis	J:114948
	kidney inflammation	J:114948
	liver inflammation	J:114948
	lung inflammation	J:114948
	lymph node hypoplasia	J:114948
	spleen hypoplasia	J:114948
Fas^tm1Cgn/Fas^tm1Cgn Tg(Lck-cre)I57Jxm/0 (B6.Cg-Fas^tm1Cgn Tg(Lck-cre)I57Jxm)	lymph node hypoplasia	J:114948
Fas^tm1Cgn/Fas^tm1Cgn Tg(Mx1-cre)1Cgn/0 (B6.Cg-Fas^tm1Cgn Tg(Mx1-cre)1Cgn)	abnormal immune system morphology	J:114948
	enlarged lymph nodes	J:114948
	enlarged spleen	J:114948
Fas^tm1Cgn/Fas^tm1Cgn Tnfrsf1a^tm1Mak/Tnfrsf1a^tm1Mak (involves: 129S2/SvPas * C57BL/6)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:114741
Fas^tm1Dlo/Fas^tm1Dlo (involves: 129P2/OlaHsd * C57BL/6)	abnormal thymus involution	J:90750
	enlarged lymph nodes	J:31847
	enlarged spleen	J:31847
	increased immunoglobulin level	J:31847
Fas^tm1Osa/Fas^tm1Osa (involves: 129P2/OlaHsd * C57BL/6)	abnormal hypersensitivity reaction	J:64296, J:32125
	abnormal lymph organ size	J:64296
	abnormal T cell clonal deletion	J:32125
	enlarged lymph nodes	J:64296, J:32125
	enlarged spleen	J:64296, J:32125
	increased anti-double stranded DNA antibody level	J:32125
	increased anti-single stranded DNA antibody level	J:32125
	increased autoantibody level	J:32125
	increased B cell number	J:32125
	increased IgG1 level	J:32125
	increased IgG2a level	J:32125
	increased IgG2b level	J:32125
	increased IgG3 level	J:32125
	increased IgG level	J:32125
	increased leukocyte cell number	J:32125
	increased lymphocyte cell number	J:64296, J:32125
	increased susceptibility to parasitic infection	J:81397
	lymphoid hyperplasia	J:64296
Fas^tm1Osa/Fas^tm1Osa Gzma^tm1Simn/Gzma^tm1Simn Gzmb^tm1Ley/Gzmb^tm1Ley (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)	increased susceptibility to parasitic infection	J:81397
Fas^tm1Vbo/Fas^tm1Vbo Tg(Ins2-cre)25Mgn/0 Tg(Ins2-HA)165Bri/0 Tg(Tcra/Tcrb)1Vbo/0 (Not Specified)	increased susceptibility to autoimmune diabetes	J:85985
Fasl^del1Hong/Fasl^del1Hong (either: (involves: 129 * BALB/c * C57BL/6) or (involves: 129X1/SvJ * C3H/HeJ * C57BL/6))	abnormal thymus cell ratio	J:112563
	enlarged lymph nodes	J:112563
	enlarged spleen	J:112563
	enlarged thymus	J:112563
	increased IgG level	J:112563
	increased IgM level	J:112563
Fasl^gld/Fasl^gld (C3H/HeJ-Fasl^gld/J)	abnormal lymph node morphology	J:7306
	abnormal T cell differentiation	J:12002, J:8267
	decreased B cell number	J:29572
	decreased cytotoxic T cell cytolysis	J:17698
	enlarged lymph nodes	J:7306, J:29572
	enlarged spleen	J:7306, J:29572
	increased anti-double stranded DNA antibody level	J:7306
	increased anti-nuclear antigen antibody level	J:7306, J:29572
	increased autoantibody level	J:7306
	increased IgA level	J:7306, J:29572
	increased IgG1 level	J:7306
	increased IgG2a level	J:7306
	increased IgG2b level	J:7306
	increased IgG level	J:29572
	increased IgM level	J:7306, J:29572
	increased immunoglobulin level	J:7306, J:29572
	increased leukocyte cell number	J:7306
	increased lymphocyte cell number	J:7306, J:29572
	increased neutrophil cell number	J:7306
	increased T cell number	J:29572
	interstitial pneumonia	J:7306
Fasl^gld/Fasl^gld (B6Smn.C3-Fasl^gld/J)	abnormal NK cell physiology	J:115033
	abnormal osteoclast physiology	J:127179
	brain inflammation	J:120427
	CNS inflammation	J:120427
	decreased granulocyte number	J:136745
	eye inflammation	J:136745
	increased susceptibility to bacterial infection	J:136745
	increased susceptibility to Picornaviridae infection	J:120427
	liver inflammation	J:135830
Fasl^gld/Fasl^gld (C3H/HeJ-Fasl^gld)	abnormal interleukin level	J:8267
	abnormal T cell morphology	J:8267
	abnormal T cell physiology	J:8267
	abnormal T cell proliferation	J:8267
Fasl^gld/Fasl^gld (involves: C3H/HeJ * C57BL/6)	dermatitis	J:153501
	enlarged lymph nodes	J:153501
	enlarged spleen	J:153501
	immune system phenotype	J:153501
	increased anti-nuclear antigen antibody level	J:153501
	increased circulating tumor necrosis factor level	J:153501
	increased IgE level	J:153501
	increased IgG1 level	J:153501
	increased IgG2a level	J:153501
	increased IgG2b level	J:153501
	increased IgG level	J:153501
	increased susceptibility to systemic lupus erythematosus	J:153501
	increased T cell number	J:153501
Fasl^gld/Fasl^gld (involves: C3H/HeJ)	abnormal osteoclast physiology	J:156947
	enlarged lymph nodes	J:171440
	enlarged spleen	J:171440
	increased spleen weight	J:171440
Fasl^gld/Fasl^gld (B6.C3-Fasl^gld)	abnormal lymph node morphology	J:91058
	enlarged lymph nodes	J:91058
	enlarged spleen	J:91058
	impaired macrophage phagocytosis	J:91058
	increased anti-nuclear antigen antibody level	J:91058
	increased autoantibody level	J:91058
	increased spleen weight	J:91058
Fasl^gld/Fasl^gld Ighm^tm1Cgn/Ighm^tm1Cgn (involves: 129S2/SvPas * C3H/HeJ * C57BL/6)	immune system phenotype	J:119584
Fasl^m1Btlr/Fasl^m1Btlr (C57BL/6J-Fasl^m1Btlr)	abnormal humoral immune response	J:212067
Fasl^m2Btlr/Fasl^m2Btlr (C57BL/6J-Fasl^m2Btlr)	decreased IgG level	J:224659
Fasl^m2Btlr/Fasl^m2Btlr (C57BL/6J-Fasl^m2Btlr)	impaired humoral immune response	J:224659
Fasl^tm1.1Ast/Fasl^tm1.1Ast (involves: BALB/cJ * C57BL/6)	decreased cytotoxic T cell cytolysis	J:153501
	dermatitis	J:153501
	enlarged lymph nodes	J:153501
	enlarged spleen	J:153501
	glomerulonephritis	J:153501
	immune system phenotype	J:153501
	increased anti-double stranded DNA antibody level	J:153501
	increased anti-nuclear antigen antibody level	J:153501
	increased circulating tumor necrosis factor level	J:153501
	increased IgA level	J:153501
	increased IgE level	J:153501
	increased IgG1 level	J:153501
	increased IgG2a level	J:153501
	increased IgG2b level	J:153501
	increased IgG level	J:153501
	increased IgM level	J:153501
	increased immunoglobulin level	J:153501
	increased susceptibility to systemic lupus erythematosus	J:153501
Fasl^tm1.1Bksa/Fasl^tm1.1Bksa (involves: 129)	enlarged lymph nodes	J:171440
	enlarged spleen	J:171440
	increased spleen weight	J:171440
Fasl^tm1.1Cgm/Fasl^tm1.1Cgm (involves: 129S2/SvPas * C57BL/6 * C57BL/6N)	immune system phenotype	J:168406
	increased B cell proliferation	J:168406
	increased germinal center B cell number	J:168406
	increased IgM level	J:168406
	increased plasma cell number	J:168406
	increased T cell proliferation	J:168406
Fasl^tm1.1Lest/Fasl^tm1.1Lest (involves: 129 * C57BL/6)	abnormal double-negative T cell morphology	J:87990
	abnormal lymph node morphology	J:87990
	autoimmune response	J:87990
	enlarged lymph nodes	J:87990
	enlarged spleen	J:87990
	glomerulonephritis	J:87990
	increased IgG level	J:87990
	lymphoid hyperplasia	J:87990
Fasl^tm1.1Lest/Fasl^tm1.1Lest (B6.129-Fasl^tm1.1Lest)	glomerulonephritis	J:87990
Fasl^tm2.1Ast/Fasl^tm2.1Ast (involves: BALB/cJ * C57BL/6)	abnormal cytotoxic T cell physiology	J:153501
Fastk^tm1.1Andp/Fastk^tm1.1Andp (B6.129S6-Fastk^tm1.1Andp)	abnormal chemokine secretion	J:160443
	abnormal neutrophil physiology	J:160443
	decreased interleukin-6 secretion	J:160443
	decreased interleukin-23 secretion	J:160443
	decreased neutrophil cell number	J:160443
	decreased tumor necrosis factor secretion	J:160443
Fastkd2^{tm1b(EUCOMM)Wtsi}/Fastkd2^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Fastkd2^{tm1b(EUCOMM)Wtsi}/Bay)	decreased spleen weight	J:211773
Fat1^{Gt(KST249)Byg}/Fat1^{Gt(KST249)Byg} Tg(Myl1-lacZ)1Ibdml/0 (involves: 129P2/OlaHsd)	lymphangiectasis	J:199157
	myositis	J:199157
Fat1^tm1.2Fhel/Fat1^tm1.2Fhel Tg(Myl1-lacZ)1Ibdml/0 (involves: 129S6/SvEvTac * BALB/cJ * C57BL/6J * SJL)	myositis	J:199157
Fat3^{em1(IMPC)Ccpcz}/Fat3^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Fat3^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Fbf1^{tm1a(EUCOMM)Wtsi}/Fbf1^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Fbf1^{tm1a(EUCOMM)Wtsi}/Wtsi)	increased leukocyte cell number	J:211773
Fblim1^tm1.1Chen/Fblim1^tm1.1Chen (involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)	abnormal osteoclast differentiation	J:186501
	abnormal osteoclast physiology	J:186501
	increased osteoclast cell number	J:186501
Fbln1^{Gt(XST011)Byg}/Fbln1^{Gt(XST011)Byg} (involves: 129P2/OlaHsd * C57BL/6)	thymus hypoplasia	J:137690
Fbln1^tm1Tmpl/Fbln1^tm1Tmpl (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	thymus hypoplasia	J:137690
Fbn1^em1(IMPC)H/Fbn1⁺ (C57BL/6NTac-Fbn1^em1(IMPC)H/H)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
	increased spleen weight	J:211773
Fbn1^tm1Lper/Fbn1⁺ (involves: 129/Sv * CD-1)	lung inflammation	J:167276
Fbn1^tm2.1Hcd/Fbn1⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * FVB/N)	abnormal interleukin secretion	J:206074
	abnormal T-helper 1 cell morphology	J:206074
	increased anti-nuclear antigen antibody level	J:206074
	increased autoantibody level	J:206074
	increased B cell number	J:206074
	increased interleukin-9 secretion	J:206074
	increased interleukin-13 secretion	J:206074
	increased plasma cell number	J:206074
Fbn1^tm2Rmz/Fbn1^tm2Rmz (involves: 129S1/Sv * 129X1/SvJ)	aortitis	J:54081
Fbn1^tm2Rmz/Fbn1^tm2Rmz (involves: 129S1/Sv * 129X1/SvJ)	lung inflammation	J:91815
Fbn1^tm3.1Hcd/Fbn1⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * FVB/N)	abnormal interleukin secretion	J:206074
	abnormal T-helper 1 cell morphology	J:206074
	increased anti-nuclear antigen antibody level	J:206074
	increased autoantibody level	J:206074
	increased B cell number	J:206074
	increased interleukin-9 secretion	J:206074
	increased interleukin-13 secretion	J:206074
	increased plasma cell number	J:206074
Fbn1^Tsk/Fbn1⁺ (B6.Cg-Fbn1^Tsk)	abnormal uterine NK cell morphology	J:1377
	alveolitis	J:15018, J:30961, J:6566
	increased autoantibody level	J:21987, J:14166
	increased mast cell number	J:8047
	increased susceptibility to type IV hypersensitivity reaction	J:7185
	lung inflammation	J:30961, J:6566
Fbn1^Tsk/Fbn1⁺ Il4^tm1Nnt/Il4^tm1Nnt (involves: C57BL/6 * C57BL/10 * DBA/2)	decreased interleukin-4 secretion	J:57957
Fbn1^Tsk/Fbn1⁺ Il4ra^tm1Sz/Il4ra⁺ (involves: BALB/cJ * C57BL/6J * C57BL/10 * DBA/2)	increased autoantibody level	J:68448
Fbn1^Tsk/Fbn1⁺ Il4ra^tm1Sz/Il4ra^tm1Sz (involves: BALB/cJ * C57BL/6J * C57BL/10 * DBA/2)	immune system phenotype	J:68448
Fbn1^Tsk/Fbn1⁺ Kit^W/Kit^W-v (involves: C57BL/6 * C57BL/10 * DBA/2 * WB/ReJ)	absent mast cells	J:24076
Fbn1^Tsk/Fbn1⁺ Stat6^tm1Gru/Stat6^tm1Gru (involves: 129S2/SvPas * C57BL/10 * DBA/2)	decreased interleukin-4 secretion	J:57957
Fbn1^Tsk/Fbn1⁺ Tgfb1^tm1N/Tgfb1⁺ (involves: 129S/SvEv * C57BL/6J * C57BL/10 * DBA/2)	immune system phenotype	J:68448
Fbp2^{tm2b(EUCOMM)Hmgu}/Fbp2⁺ (C57BL/6N-Fbp2^{tm2b(EUCOMM)Hmgu}/Ieg)	increased leukocyte cell number	J:211773
Fbrsl1^em1(IMPC)Tcp/Fbrsl1^em1(IMPC)Tcp (C57BL/6N-Fbrsl1^em1(IMPC)Tcp/Tcp)	enlarged spleen	J:211773
	small thymus	J:211773
Fbxl3^{em1(IMPC)Ccpcz}/Fbxl3^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Fbxl3^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	decreased effector memory T-helper cell number	J:211773
	decreased spleen weight	J:211773
Fbxl4^tm1.2Lrsn/Fbxl4^tm1.2Lrsn (involves: C57BL/6N)	liver inflammation	J:303084
Fbxl5^{Gt(OST386421)Lex}/Fbxl5⁺ (involves: 129S5/SvEvBrd * C57BL/6)	increased spleen iron level	J:193752
Fbxl5^tm2.1Kei/Fbxl5^tm2.1Kei Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺ (involves: C57BL/6 * DBA)	liver inflammation	J:176655
Fbxl18^{tm1b(EUCOMM)Hmgu}/Fbxl18^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Fbxl18^{tm1b(EUCOMM)Hmgu}/Mhzh)	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
Fbxl19^{tm1b(EUCOMM)Wtsi}/Fbxl19⁺ (C57BL/6N-Fbxl19^{tm1b(EUCOMM)Wtsi}/Nju)	decreased lymphocyte cell number	J:211773
	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
	increased leukocyte cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Fbxo4^tm1.1Jadi/Fbxo4⁺ (Not Specified)	myeloid hyperplasia	J:178645
Fbxo4^tm1.1Jadi/Fbxo4^tm1.1Jadi (Not Specified)	myeloid hyperplasia	J:178645
Fbxo7^{tm1a(EUCOMM)Hmgu}/Fbxo7^{tm1a(EUCOMM)Hmgu} (involves: C57BL/6N)	increased pro-B cell number	J:183053
Fbxo7^{tm1a(EUCOMM)Wtsi}/Fbxo7^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Fbxo7^{tm1a(EUCOMM)Wtsi}/Wtsi)	decreased leukocyte cell number	J:211773
Fbxo7^{tm1a(EUCOMM)Wtsi}/Fbxo7^{tm1a(EUCOMM)Wtsi} (involves: C57BL/6N)	abnormal effector T cell number	J:272313
	abnormal T cell differentiation	J:272313
	decreased CD4-positive, alpha-beta T cell number	J:272313
	decreased CD8-positive, alpha-beta T cell number	J:272313
	decreased T cell number	J:272313
	enlarged spleen	J:272313
	increased activated T cell number	J:272313
	increased double-negative T cell number	J:272313
	increased effector memory CD4-positive, alpha-beta T cell number	J:272313
	increased effector memory CD8-positive, alpha-beta T cell number	J:272313
	increased memory T cell number	J:272313
	increased spleen weight	J:272313
	increased susceptibility to bacterial infection	J:272313
	increased susceptibility to bacterial infection induced morbidity/mortality	J:272313
	thymus atrophy	J:272313
	thymus hypoplasia	J:272313
Fbxo7^{tm1c(EUCOMM)Wtsi}/Fbxo7^{tm1c(EUCOMM)Wtsi} Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6J * C57BL/6N)	decreased CD8-positive, alpha-beta T cell number	J:272313
	decreased T cell number	J:272313
	immune system phenotype	J:272313
Fbxo9^{tm1b(EUCOMM)Hmgu}/Fbxo9^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Fbxo9^{tm1b(EUCOMM)Hmgu}/Tcp)	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
Fbxo10^{tm1b(KOMP)Wtsi}/Fbxo10^{tm1b(KOMP)Wtsi} (C57BL/6N-Fbxo10^{tm1b(KOMP)Wtsi}/Nju)	decreased neutrophil cell number	J:211773
Fbxo11^Jf/Fbxo11⁺ (involves: BALB/cAnNCrl * C3H/HeN)	abnormal cytokine secretion	J:85263
Fbxo11^Jf/Fbxo11⁺ (involves: BALB/cAnNCrl * C3H/HeN)	increased susceptibility to otitis media	J:85263
Fbxo11^Jf/Fbxo11⁺ (involves: BALB/cAnNCrl * C3H/HeN * C57BL/6J)	increased susceptibility to otitis media	J:114851
Fbxo11^Jf/Fbxo11⁺ (involves: BALB/cAnNCrl)	increased susceptibility to otitis media	J:250208
Fbxo11^Jf/Fbxo11^Mutt (involves: BALB/c * C3H/HeN)	increased susceptibility to otitis media	J:114851
Fbxo21^em1Smbk/Fbxo21^em1Smbk Commd10^{Tg(Vav1-icre)A2Kio}/Commd10⁺ (B6.Cg-Fbxo21^em1Smbk Commd10^{Tg(Vav1-icre)A2Kio})	decreased spleen weight	J:333469
	increased T cell number	J:333469
Fbxo25^{em1(IMPC)Ccpcz}/Fbxo25^{em1(IMPC)Ccpcz} (C57BL/6N-Fbxo25^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Fbxo28^{em1(IMPC)Mhzh}/Fbxo28⁺ (C57BL/6N-Fbxo28^{em1(IMPC)Mhzh}/Mhzh)	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
Fbxo36^{tm1b(KOMP)Wtsi}/Fbxo36^{tm1b(KOMP)Wtsi} (C57BL/6N-Fbxo36^{tm1b(KOMP)Wtsi}/Nju)	decreased monocyte cell number	J:211773
	increased basophil cell number	J:211773
	increased neutrophil cell number	J:211773
Fbxw2^{tm1b(EUCOMM)Hmgu}/Fbxw2^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Fbxw2^{tm1b(EUCOMM)Hmgu}/Nju)	increased basophil cell number	J:211773
Fbxw7^tm1Iaai/Fbxw7^tm1Iaai Tg(Lck-cre)1Cwi/0 (involves: 129/Sv * C57BL/6)	immune system phenotype	J:137138
	increased T cell derived lymphoma incidence	J:137138
Fbxw7^tm1Iaai/Fbxw7^tm1Iaai Tg(Mx1-cre)1Cgn/0 (involves: 129/Sv * C57BL/6 * CBA)	abnormal T cell differentiation	J:137138
	decreased double-negative T cell number	J:137138
	thymus hypoplasia	J:137138
Fbxw7^tm1Iaai/Fbxw7^tm1Iaai Tg(Mx1-cre)1Cgn/0 (involves: 129 * C57BL/6 * CBA)	abnormal T cell differentiation	J:200006
Fbxw7^tm1Kei/Fbxw7^tm1Kei Myc^tm2Fwa/Myc^tm2Fwa Tg(Cd4-cre)1Cwi/? (involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * DBA/2)	immune system phenotype	J:128523
Fbxw7^tm1Kei/Fbxw7^tm1Kei Rbpj^tm1Hon/Rbpj^tm1Hon Tg(Cd4-cre)1Cwi/? (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	increased double-positive T cell number	J:128523
Fbxw7^tm1Kei/Fbxw7^tm1Kei Tg(Cd4-cre)1Cwi/? (involves: 129P2/OlaHsd * C57BL/6)	increased double-positive T cell number	J:128523
Fbxw7^tm1Kei/Fbxw7^tm1Kei Tg(Lck-cre)1Cwi/? (involves: 129P2/OlaHsd * C57BL/6)	abnormal T cell activation	J:128523
	arrested T cell differentiation	J:128523
	decreased single-positive T cell number	J:128523
	enlarged thymus	J:128523
	increased double-positive T cell number	J:128523
	increased T cell apoptosis	J:128523
Fbxw7^tm1Kei/Fbxw7^tm1Kei Trp53^tm1Tyj/Trp53^tm1Tyj Tg(Lck-cre)1Cwi/? (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)	immune system phenotype	J:128523
	increased T cell derived lymphoma incidence	J:128523
Fbxw7^tm2Iaai/Fbxw7⁺ Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA)	immune system phenotype	J:200006
Fbxw8^{tm1b(EUCOMM)Hmgu}/Fbxw8⁺ (C57BL/6N-Fbxw8^{tm1b(EUCOMM)Hmgu}/Nju)	decreased lymphocyte cell number	J:211773
	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
	increased neutrophil cell number	J:211773
Fbxw9^{tm1a(EUCOMM)Wtsi}/Fbxw9⁺ (C57BL/6N-Fbxw9^{tm1a(EUCOMM)Wtsi}/Bay)	absent spleen	J:211773
Fbxw9^{tm1a(EUCOMM)Wtsi}/Fbxw9^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Fbxw9^{tm1a(EUCOMM)Wtsi}/Bay)	absent lymph nodes	J:211773
Fbxw9^{tm1b(EUCOMM)Wtsi}/Fbxw9^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Fbxw9^{tm1b(EUCOMM)Wtsi}/Bay)	abnormal spleen morphology	J:211773
Fbxw10^em1(IMPC)Tcp/Fbxw10^em1(IMPC)Tcp (C57BL/6N-Fbxw10^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Fbxw16^{em1(IMPC)Ccpcz}/Fbxw16⁺ (C57BL/6N-Fbxw16^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
	increased CD8-positive, naive alpha-beta T cell number	J:211773
	small thymus	J:211773
Fbxw18^{em1(IMPC)Ccpcz}/Fbxw18⁺ (C57BL/6N-Fbxw18^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
	small spleen	J:211773
Fbxw20^{em1(IMPC)Ccpcz}/Fbxw20^{em1(IMPC)Ccpcz} (C57BL/6N-Fbxw20^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Fbxw25^{em1(IMPC)Ccpcz}/Fbxw25^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Fbxw25^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Fbxw26^{tm1b(KOMP)Wtsi}/Fbxw26^{tm1b(KOMP)Wtsi} (C57BL/6N-Fbxw26^{tm1b(KOMP)Wtsi}/Wtsi)	decreased memory-marker NK cell number	J:211773
	increased KLRG1-positive NK cell number	J:211773
	increased NK cell number	J:211773
Fcamr^tm1Shib/Fcamr^tm1Shib (involves: 129P2/OlaHsd * C57BL/6)	abnormal follicular dendritic cell antigen presentation	J:150824
	abnormal marginal zone B cell physiology	J:150824
	abnormal memory B cell differentiation	J:150824
	abnormal somatic hypermutation frequency	J:150824
	abnormal spleen germinal center morphology	J:150824
	increased spleen germinal center number	J:150824
	increased spleen germinal center size	J:150824
Fcamr^tm2Shib/Fcamr^tm2Shib (BALB/c-Fcamr^tm2Shib)	abnormal follicular dendritic cell antigen presentation	J:150824
	abnormal marginal zone B cell physiology	J:150824
	increased spleen germinal center number	J:150824
	increased spleen germinal center size	J:150824
Fcer1a^tm1Ftl/Fcer1a^tm1Ftl (CBy.129S2-Fcer1a^tm1Ftl)	abnormal humoral immune response	J:120702
	abnormal mast cell physiology	J:120702
	decreased circulating interleukin-4 level	J:120702
	decreased eosinophil cell number	J:120702
Fcer1a^tm1Knt/Fcer1a^tm1Knt (either: (involves: 129 * C57BL/6) or (involves: 129 * C57BL/6 * DBA/2))	abnormal mast cell physiology	J:39250
	decreased susceptibility to type I hypersensitivity reaction	J:113572, J:39250
Fcer1a^tm1Knt/Fcer1a^tm1Knt (involves: 129 * BALB/c)	abnormal mast cell physiology	J:78659
Fcer1a^tm1Knt/Fcer1a^tm1Knt (involves: 129 * BALB/c)	increased susceptibility to type I hypersensitivity reaction	J:78659
Fcer1a^tm1Knt/Fcer1a^tm1Knt Fcer2a^tm1Max/Fcer2a^tm1Max (B6.Cg-Fcer1a^tm1Knt Fcer2a^tm1Max)	abnormal mast cell physiology	J:144620
Fcer1a^tm1Knt/Fcer1a^tm1Knt Fcer2a^tm1Max/Fcer2a^tm1Max Fcgr1^tm1Jsv/Fcgr1^tm1Jsv Fcgr2b^tm1Ttk/Fcgr2b^tm1Ttk Fcgr3^tm1Jsv/Fcgr3^tm1Jsv (B6.Cg-Fcgr2b^tm1Ttk Fcgr3^tm1Jsv Fcer1a^tm1Knt Fcgr1^tm1Jsv Fcer2a^tm1Max)	abnormal macrophage physiology	J:144620
	abnormal mast cell physiology	J:144620
	increased susceptibility to type I hypersensitivity reaction	J:144620
Fcer1a^tm1Knt/Fcer1a^tm1Knt Tg(FCER1A)1Bhk/? (B6.129-Fcer1a^tm1Knt Tg(FCER1A)1Bhk)	abnormal macrophage physiology	J:144620
	increased tumor necrosis factor secretion	J:144620
Fcer1a^tm1Knt/Fcer1a^tm1Knt Tg(SV40/HTLV-FCER1A)1Bhk/0 (either: (involves: 129 * C57BL/6) or (involves: 129 * C57BL/6 * DBA/2))	abnormal type I hypersensitivity reaction	J:113572
Fcer1g^tm1Rav/Fcer1g^tm1Rav (involves: 129P2/OlaHsd * C57BL/6)	abnormal dendritic cell antigen presentation	J:83995
	abnormal immune cell physiology	J:39248
	abnormal immunoglobulin level	J:78659
	abnormal mast cell physiology	J:39248
	abnormal NK cell physiology	J:39248
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:126520
	decreased susceptibility to type I hypersensitivity reaction	J:78659, J:39248
	immune system phenotype	J:28282
	impaired macrophage phagocytosis	J:39248
	increased IgE level	J:78659
Fcer1g^tm1Rav/Fcer1g^tm1Rav (B6.129P2-Fcer1g^tm1Rav)	decreased interleukin-1 beta secretion	J:160680
	decreased interleukin-6 secretion	J:160680
	decreased interleukin-10 secretion	J:160680
	decreased interleukin-12b secretion	J:160680
	decreased interleukin-23 secretion	J:160680
	decreased tumor necrosis factor secretion	J:160680
Fcer1g^tm1Rav/Fcer1g^tm1Rav (involves: 129P2/OlaHsd)	increased susceptibility to parasitic infection	J:163761
Fcer1g^tm1Rav/Fcer1g^tm1Rav Del(7Tyrobp-Hcst)1Ttk/Del(7Tyrobp-Hcst)1Ttk (involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6)	abnormal osteoclast physiology	J:147155
Fcer1g^tm1Rav/Fcer1g^tm1Rav Hexb^tm1Rlp/Hexb^tm1Rlp (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)	increased immunoglobulin level	J:87617
Fcer1g^tm1Rav/Fcer1g^tm1Rav Tg(Ins2-TFRC/OVA)296Wehi/0 (involves: 129P2/OlaHsd * C57BL/6)	decreased susceptibility to autoimmune diabetes	J:122114
	decreased T cell proliferation	J:122114
Fcer1g^tm1Rav/Fcer1g^tm1Rav Tyrobp^tm1.1Viv/Tyrobp^tm1.1Viv (involves: 129P2/OlaHsd * C57BL/6)	decreased interferon-gamma secretion	J:100668
	decreased uterine NK cell number	J:100668
Fcer1g^tm1Rav/Fcer1g^tm1Rav Tyrobp^tm1Lll/Tyrobp^tm1Lll (involves: 129P2/OlaHsd * C57BL/6)	abnormal osteoclast differentiation	J:89583
Fcer1g^tm1Rav/Fcer1g^tm1Rav Tyrobp^tm1Lll/Tyrobp^tm1Lll (involves: 129P2/OlaHsd)	abnormal osteoclast physiology	J:147155
Fcer1g^tm1Tks/Fcer1g^tm1Tks (involves: C57BL/6)	abnormal antigen presentation	J:112160
	abnormal CD4-positive, alpha-beta T cell physiology	J:112160
	abnormal chemokine secretion	J:141143
	abnormal cytokine level	J:258645
	abnormal macrophage physiology	J:141143
	abnormal NK cell physiology	J:111365
	abnormal NK T cell physiology	J:111365
	decreased IgG1 level	J:112160
	decreased IgG2a level	J:112160
	decreased IgG2b level	J:112160
	decreased IgG3 level	J:112160
	decreased IgG level	J:112160
	decreased inflammatory response	J:50023
	decreased interferon-gamma secretion	J:111365, J:112160
	decreased interleukin-2 secretion	J:112160
	decreased susceptibility to type IV hypersensitivity reaction	J:112160
	decreased T cell proliferation	J:112160
	impaired macrophage phagocytosis	J:50023
	impaired natural killer cell mediated cytotoxicity	J:111365
Fcer1g^tm1Tks/Fcer1g^tm1Tks (C57BL/6-Fcer1g^tm1Tks)	decreased susceptibility to autoimmune hemolytic anemia	J:145432
Fcer1g^tm1Tks/Fcer1g^tm1Tks (involves: C57BL/6J)	abnormal chemokine secretion	J:203159
	abnormal interferon-gamma secretion	J:203159
	abnormal interleukin-17 secretion	J:203159
	decreased dendritic cell number	J:203159
	decreased tumor necrosis factor secretion	J:203159
Fcer2a^Hie/Fcer2a^Hie (NZB)	increased IgE level	J:93999
Fcer2a^tm1Kik/Fcer2a^tm1Kik (involves: 129P2/OlaHsd * C57BL/6)	abnormal cytokine secretion	J:129296
	abnormal humoral immune response	J:19437
	abnormal immune system physiology	J:129296
	increased immunoglobulin level	J:129296
Fcer2a^tm1Max/Fcer2a^tm1Max (involves: C57BL/6)	abnormal macrophage chemotaxis	J:57738
	decreased IgG1 level	J:18952
	decreased IgG2b level	J:18952
	impaired eosinophil recruitment	J:57738
	increased IgE level	J:57738, J:18952, J:107857
	increased IgM level	J:18952
	increased susceptibility to type I hypersensitivity reaction	J:57738
Fcer2a^tm1Max/Fcer2a^tm1Max Ighg1^tm1.1Pyu/Ighg1⁺ (involves: 129 * BALB/cJ * C57BL/6 * C57BL/6J)	decreased IgG1 level	J:198154
	decreased IgG2c level	J:198154
	decreased IgG level	J:198154
	increased IgE level	J:198154
	increased IgG2a level	J:198154
	increased susceptibility to type I hypersensitivity reaction	J:198154
Fcer2a^tm1Max/Fcer2a^tm1Max Ighg1^tm1.1Pyu/Ighg1^tm1.1Pyu (involves: 129 * BALB/cJ * C57BL/6 * C57BL/6J)	abnormal immunoglobulin level	J:198154
	decreased IgG2c level	J:198154
	decreased IgG level	J:198154
	increased IgE level	J:198154
	increased IgG2a level	J:198154
	increased susceptibility to type I hypersensitivity reaction	J:198154
Fcer2a^tm1Putt/Fcer2a⁺ (involves: 129S/SvEv * C57BL/6)	increased IgE level	J:69547
Fcer2a^tm1Putt/Fcer2a^tm1Putt (involves: 129S/SvEv * C57BL/6)	abnormal B cell proliferation	J:69547
Fcgr1^tm1Hoga/Fcgr1^tm1Hoga (involves: 129S1/Sv * 129X1/SvJ)	abnormal cell-mediated immunity	J:86281
	abnormal macrophage antigen presentation	J:86281
	decreased inflammatory response	J:86281
	impaired macrophage phagocytosis	J:86281
	increased IgG level	J:86281
Fcgr1^tm1Jgjw/Fcgr1^tm1Jgjw (involves: 129 * C57BL/6)	abnormal dendritic cell antigen presentation	J:112436
Fcgr1^tm1Jgjw/Fcgr1^tm1Jgjw (involves: 129 * C57BL/6)	abnormal dendritic cell differentiation	J:112436
Fcgr1^tm1Jsv/Fcgr1^tm1Jsv (involves: 129P2/OlaHsd * BALB/c)	abnormal dendritic cell antigen presentation	J:83995
	abnormal macrophage physiology	J:83995
	abnormal type I hypersensitivity reaction	J:83995
	decreased susceptibility to autoimmune hemolytic anemia	J:83995
	decreased susceptibility to induced arthritis	J:83995
	increased susceptibility to bacterial infection	J:83995
Fcgr1^tm1Jsv/Fcgr1^tm1Jsv Fcgr2b^tm1Ttk/Fcgr2b^tm1Ttk Fcgr3^tm1Jsv/Fcgr3^tm1Jsv (involves: 129P2/OlaHsd * 129S4/SvJae * BALB/c * C57BL/6)	impaired macrophage phagocytosis	J:83995
Fcgr2b^tm1.2Jsv/Fcgr2b⁺ X/Yaa (involves: C57BL/6 * FVB/N * SB/Le)	enlarged spleen	J:179175
	increased anti-chromatin antibody level	J:179175
	increased anti-double stranded DNA antibody level	J:179175
	increased monocyte cell number	J:179175
	increased susceptibility to systemic lupus erythematosus	J:179175
Fcgr2b^tm1.2Jsv/Fcgr2b^tm1.2Jsv Sle16^C57BL/6/Sle16^C57BL/6 (involves: C57BL/6 * FVB/N)	abnormal adaptive immunity	J:179175
	immune system phenotype	J:179175
	increased immunoglobulin level	J:179175
	increased susceptibility to induced arthritis	J:179175
	kidney inflammation	J:179175
Fcgr2b^tm1Kgcs/Fcgr2b⁺ (involves: C57BL/6)	decreased B cell apoptosis	J:190890
	increased anti-chromatin antibody level	J:190890
	increased anti-double stranded DNA antibody level	J:190890
	increased germinal center B cell number	J:190890
	increased IgG1 level	J:190890
	increased IgG3 level	J:190890
	increased IgM level	J:190890
	increased susceptibility to induced arthritis	J:190890
Fcgr2b^tm1Ttk/Fcgr2b⁺ X/Yaa (involves: 129S4/SvJae * C57BL/6 * SB/Le)	increased monocyte cell number	J:129409
Fcgr2b^tm1Ttk/Fcgr2b^tm1.2Jsv Sle21^129P2/Ola/Sle21^C57BL/6 (involves: 129P2/Ola * 129S4/SvJae * C57BL/6 * FVB/N)	enlarged spleen	J:179175
	increased anti-chromatin antibody level	J:179175
	increased anti-double stranded DNA antibody level	J:179175
	increased anti-histone antibody level	J:179175
	increased anti-single stranded DNA antibody level	J:179175
	increased spleen weight	J:179175
	increased susceptibility to systemic lupus erythematosus	J:179175
Fcgr2b^tm1Ttk/Fcgr2b^tm1Ttk (involves: 129S4/SvJae)	abnormal mast cell physiology	J:31133
	increased IgA level	J:31133
	increased IgG1 level	J:31133
	increased IgG2a level	J:31133
	increased IgG2b level	J:31133
	increased IgG3 level	J:31133
	increased IgG level	J:31133
	increased IgM level	J:31133
	increased susceptibility to type I hypersensitivity reaction	J:31133
Fcgr2b^tm1Ttk/Fcgr2b^tm1Ttk (C.129S4-Fcgr2b^tm1Ttk)	decreased susceptibility to parasitic infection	J:120905
Fcgr2b^tm1Ttk/Fcgr2b^tm1Ttk (B6.129S4-Fcgr2b^tm1Ttk)	abnormal hypersensitivity reaction	J:64152
	enlarged lymph nodes	J:64152
	enlarged spleen	J:64152
	glomerulonephritis	J:64152
	increased immunoglobulin level	J:64152
	increased inflammatory response	J:64152
	kidney inflammation	J:64152
	liver inflammation	J:64152
	lung inflammation	J:64152
	pancreas inflammation	J:64152
	salivary gland inflammation	J:64152
Fcgr2b^tm1Ttk/Fcgr2b^tm1Ttk (Not Specified)	increased susceptibility to induced arthritis	J:106191
Fcgr2b^tm1Ttk/Fcgr2b^tm1Ttk Il17a^tm1Yiw/Il17a⁺ (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)	glomerulonephritis	J:191090
	increased plasma cell number	J:191090
	increased spleen germinal center number	J:191090
	kidney inflammation	J:191090
Fcgr2b^tm1Ttk/Fcgr2b^tm1Ttk Il17a^tm1Yiw/Il17a^tm1Yiw (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)	decreased susceptibility to systemic lupus erythematosus	J:191090
	increased anti-double stranded DNA antibody level	J:191090
	increased anti-nuclear antigen antibody level	J:191090
	increased double-negative T cell number	J:191090
	increased plasma cell number	J:191090
	increased spleen germinal center number	J:191090
Fcgr2b^tm1Ttk/Fcgr2b^tm1Ttk Pdcd1^tm1Hon/Pdcd1^tm1Hon (involves: 129S2/SvPas * 129S4/SvJae * BALB/c)	abnormal cytokine level	J:207275
	abnormal urine cytokine level	J:207275
	increased autoantibody level	J:207275
	urinary bladder inflammation	J:207275
Fcgr2b^tm1Ttk/Fcgr2b^tm1Ttk Sle21^129P2/Ola/Sle21^129P2/Ola (B6.129S4-Fcgr2b^tm1Ttk)	abnormal adaptive immunity	J:179175
	enlarged spleen	J:179175
	increased anti-chromatin antibody level	J:179175
	increased anti-double stranded DNA antibody level	J:179175
	increased anti-histone antibody level	J:179175
	increased anti-single stranded DNA antibody level	J:179175
	increased autoantibody level	J:179175
	increased IgG2a level	J:179175
	increased immunoglobulin level	J:179175
	increased spleen weight	J:179175
	increased susceptibility to induced arthritis	J:179175
	increased susceptibility to systemic lupus erythematosus	J:179175
	kidney inflammation	J:179175
Fcgr2b^tm1Ttk/Fcgr2b^tm1Ttk Tg(Ins2-TFRC/OVA)296Wehi/0 (involves: 129S4/SvJae * C57BL/6)	increased susceptibility to autoimmune diabetes	J:122114
Fcgr2b^tm1Ttk/Fcgr2b^tm1Ttk Tlr7^tm1Flv/Y X/Yaa (B6.Cg-Fcgr2b^tm1Ttk Tlr7^tm1Flv Yaa)	abnormal splenocyte physiology	J:127600
	autoimmune response	J:127600
	enlarged spleen	J:127600
	increased anti-nuclear antigen antibody level	J:127600
	increased susceptibility to systemic lupus erythematosus	J:127600
Fcgr2b^tm1Ttk/Fcgr2b^tm1Ttk Traf3ip2^tm1Sbn/Traf3ip2⁺ (involves: 129 * 129S4/SvJae * C57BL/6)	abnormal neutrophil morphology	J:191090
	abnormal T cell morphology	J:191090
	increased anti-double stranded DNA antibody level	J:191090
	increased anti-nuclear antigen antibody level	J:191090
	increased autoantibody level	J:191090
	increased double-negative T cell number	J:191090
	increased IgG level	J:191090
	increased memory T cell number	J:191090
	increased monocyte cell number	J:191090
	increased myeloid dendritic cell number	J:191090
	increased neutrophil cell number	J:191090
	increased plasma cell number	J:191090
	increased plasmacytoid dendritic cell number	J:191090
	increased single-positive T cell number	J:191090
	increased spleen germinal center number	J:191090
	increased susceptibility to systemic lupus erythematosus	J:191090
	kidney inflammation	J:191090
Fcgr2b^tm1Ttk/Fcgr2b^tm1Ttk Traf3ip2^tm1Sbn/Traf3ip2^tm1Sbn (involves: 129 * 129S4/SvJae * C57BL/6)	abnormal T cell morphology	J:191090
	decreased susceptibility to systemic lupus erythematosus	J:191090
	increased anti-double stranded DNA antibody level	J:191090
	increased anti-nuclear antigen antibody level	J:191090
	increased autoantibody level	J:191090
	increased double-negative T cell number	J:191090
	increased IgG level	J:191090
Fcgr2b^tm1Ttk/Fcgr2b^tm1Ttk Traf3ip2^tm2Sbn/Traf3ip2⁺ (involves: 129S4/SvJae * BALB/c * C57BL/6)	enlarged spleen	J:191090
	increased germinal center B cell number	J:191090
	increased plasma cell number	J:191090
	increased spleen weight	J:191090
	spleen hyperplasia	J:191090
Fcgr2b^tm1Ttk/Fcgr2b^tm1Ttk Traf3ip2^tm2Sbn/Traf3ip2^tm2Sbn Cd79a^tm1(cre)Reth/Cd79a⁺ (involves: 129S4/SvJae * BALB/c * C57BL/6)	glomerulonephritis	J:191090
	increased germinal center B cell number	J:191090
	increased plasma cell number	J:191090
Fcgr2b^tm1Ttk/Fcgr2b^tm1Ttk X/Yaa (B6.Cg-Fcgr2b^tm1Ttk Yaa)	autoimmune response	J:127600
	enlarged spleen	J:127600
	increased anti-nuclear antigen antibody level	J:127600
	increased susceptibility to systemic lupus erythematosus	J:127600
Fcgr3^tm1Jsv/Fcgr3^tm1Jsv (involves: 129P2/OlaHsd * C57BL/6)	abnormal dendritic cell antigen presentation	J:83995
	abnormal type I hypersensitivity reaction	J:83995
	decreased mast cell degranulation	J:35057
	decreased susceptibility to autoimmune hemolytic anemia	J:83995
	decreased susceptibility to type II hypersensitivity reaction	J:35057
	impaired macrophage phagocytosis	J:35057
	impaired natural killer cell mediated cytotoxicity	J:35057
Fcgr3^tm1Jsv/Fcgr3^tm1Jsv (B6.129P2-Fcgr3^tm1Jsv/J)	abnormal leukocyte cell number	J:78297
	abnormal neutrophil physiology	J:78297
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:126520
	decreased susceptibility to induced arthritis	J:106191
	impaired neutrophil recruitment	J:78297
	increased neutrophil cell number	J:78297
Fcgr3^tm1Jsv/Fcgr3^tm1Jsv Sle21^129P2/Ola/Sle21^129P2/Ola (B6.129P2-Fcgr3^tm1Jsv)	enlarged spleen	J:179175
	increased activated T cell number	J:179175
	increased anti-chromatin antibody level	J:179175
	increased anti-double stranded DNA antibody level	J:179175
	increased anti-histone antibody level	J:179175
	increased anti-single stranded DNA antibody level	J:179175
	increased B cell number	J:179175
	increased spleen weight	J:179175
Fcgr3^tm1Ttk/Fcgr3^tm1Ttk (involves: 129X1/SvJ)	decreased susceptibility to type I hypersensitivity reaction	J:107371
Fcgr4^tm1.1Rav/Fcgr4^tm1.1Rav (involves: C57BL/6)	decreased susceptibility to induced arthritis	J:167375
Fcgr4^tm1.1Rav/Fcgr4^tm1.1Rav (involves: C57BL/6)	immune system phenotype	J:167375
Fcgr4^tm1Rav/Fcgr4^tm1Rav Tg(Ctsk-cre)1Rda/0 (involves: C57BL/6)	autoimmune arthritis	J:197378
	decreased osteoclast cell number	J:197378
Fcgrt^tm1Dcr/Fcgrt^tm1Dcr (either: 129 or (involves: 129 * C57BL/6))	decreased IgG level	J:94189
Fcgrt^tm1Dcr/Fcgrt^tm1Dcr (B6.129X1-Fcgrt^tm1Dcr/DcrJ)	decreased IgG level	J:110885
Fcgrt^tm1Dcr/Fcgrt^tm1Dcr Tg(CAG-FCGRT)276Dcr/0 (involves: 129X1/SvJ * C57BL/6 * C57BL/6J)	immune system phenotype	J:110885
Fcgrt^tm1Esw/Fcgrt^tm1Esw Tg(Tek-cre)1Ywa/0 (B6.Cg-Tg(Tek-cre)1Ywa Fcgrt^tm1Esw)	abnormal humoral immune response	J:146640
	decreased IgG1 level	J:146640
Fcmr^tm1.2Khl/Fcmr^tm1.2Khl (involves: C57BL/6)	abnormal granulocyte physiology	J:194323
	decreased B cell number	J:174871
	immune system phenotype	J:174871
	increased T cell apoptosis	J:174871
Fcmr^tm1Mak/Fcmr^tm1Mak (B6.129S2-Fcmr^tm1Mak)	abnormal cytokine secretion	J:194323
	abnormal granulocyte physiology	J:194323
	decreased interleukin-6 secretion	J:194323
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:194323
	decreased tumor necrosis factor secretion	J:194323
	impaired granulocyte bactericidal activity	J:194323
	increased susceptibility to bacterial infection	J:194323
	increased susceptibility to bacterial infection induced morbidity/mortality	J:194323
Fcmr^tm1Ohno/Fcmr^tm1Ohno (B6.129-Fcmr^tm1Ohno)	abnormal B cell morphology	J:190117
	abnormal immunoglobulin level	J:190117
	abnormal response to infection	J:190117
	decreased IgG1 level	J:190117
	decreased IgM level	J:190117
	decreased marginal zone B cell number	J:190117
	increased anti-chromatin antibody level	J:190117
	increased anti-double stranded DNA antibody level	J:190117
	increased B-1 B cell number	J:190117
	increased IgG3 level	J:190117
	increased IgM level	J:190117
	increased T cell number	J:190117
Fcna^tm1Tefu/Fcna^tm1Tefu (involves: 129S4/SvJae)	immune system phenotype	J:177350
Fcna^tm1Tefu/Fcna^tm1Tefu (B6.129-Fcna^tm1Tefu)	impaired lectin complement pathway	J:190858
	increased susceptibility to bacterial infection	J:190858
	increased susceptibility to bacterial infection induced morbidity/mortality	J:190858
Fcna^tm1Tefu/Fcna^tm1Tefu Fcnb^tm1Tefu/Fcnb^tm1Tefu (B6.129-Fcna^tm1Tefu Fcnb^tm1Yend)	impaired lectin complement pathway	J:190858
	increased susceptibility to bacterial infection	J:190858
	increased susceptibility to bacterial infection induced morbidity/mortality	J:190858
Fcna^tm1Tefu/Fcna^tm1Tefu Mbl1^tm1Kata/Mbl1^tm1Kata Mbl2^tm1Kata/Mbl2^tm1Kata (involves: 129S4/SvJae)	immune system phenotype	J:177350
Fcnb^tm1Tefu/Fcnb^tm1Tefu (B6.129-Fcnb^tm1Yend)	increased susceptibility to bacterial infection	J:190858
Fcnb^tm1Tefu/Fcnb^tm1Tefu (B6.129-Fcnb^tm1Yend)	increased susceptibility to bacterial infection induced morbidity/mortality	J:190858
Fcrl2^tm1Lex/Fcrl2^tm1Lex (B6;129S5-Fcrl2^tm1Lex/Mmucd)	decreased CD8-positive, alpha-beta T cell number	J:171883
Fcrla^tm1.1Cln/Fcrla^tm1.1Cln (involves: 129P2/OlaHsd * C57BL/6)	abnormal humoral immune response	J:163261
	immune system phenotype	J:163261
	increased IgG1 level	J:163261
Fcrla^{tm1b(KOMP)Wtsi}/Fcrla^{tm1b(KOMP)Wtsi} (C57BL/6N-Fcrla^{tm1b(KOMP)Wtsi}/Ucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Fcrlb^tm1Pdb/Fcrlb^tm1Pdb (B6.129-Fcrlb^tm1Pdb)	increased anti-nuclear antigen antibody level	J:165408
Fcrlb^tm1Pdb/Fcrlb^tm1Pdb (B6.129-Fcrlb^tm1Pdb)	increased IgG1 level	J:165408
Fdx2^{em1(IMPC)Rbrc}/Fdx2^{em1(IMPC)Rbrc} (C57BL/6NJcl-Fdx2^{em1(IMPC)Rbrc}/Rbrc)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	increased large unstained cell number	J:211773
	increased spleen weight	J:211773
Fdxr^tm1Xch/Fdxr⁺ (B6.Cg-Fdxr^tm1Xch)	chronic liver inflammation	J:244082
Fdxr^tm1Xch/Fdxr⁺ (B6.Cg-Fdxr^tm1Xch)	increased T cell derived lymphoma incidence	J:244082
Fech^m1Pas/Fech^m1Pas (involves: 129/Sv * BALB/c)	increased spleen weight	J:2021
Fech^m1Pas/Fech^{tm1.1(FECH)Emi} (involves: 129 BALB/cJ * C57BL/6J)	decreased eosinophil cell number	J:239515
	enlarged spleen	J:239515
Fem1a^tm1Seno/Fem1a^tm1Seno (C57BL/6-Fem1a^tm1Seno)	increased susceptibility to colitis induced morbidity/mortality	J:228893
Fem1a^tm1Seno/Fem1a^tm1Seno (C57BL/6-Fem1a^tm1Seno)	increased susceptibility to induced colitis	J:228893
Fen1^tm1Bhsh/Fen1^tm1Bhsh (involves: 129S1/Sv)	pale spleen	J:121378
Fen1^tm1Rak/Fen1⁺ (involves: 129/Sv * C57BL/6 * SJL/J)	thymus atrophy	J:77962
Fen1^tm2.1Bhsh/Fen1^tm2.1Bhsh (involves: 129S1/Sv)	increased thymus tumor incidence	J:218627
Fen1^tm2Klng/Fen1^tm2Klng (involves: 129X1/SvJ * C57BL/6)	abnormal spleen B cell follicle morphology	J:138901
	abnormal spleen marginal zone morphology	J:138901
	enlarged spleen	J:138901
	immune system phenotype	J:138901
	increased spleen B cell follicle number	J:138901
	increased spleen B cell follicle size	J:138901
	lymphoid hyperplasia	J:138901
Fen1^tm3.1Bhsh/Fen1⁺ (Not Specified)	chronic inflammation	J:231218
	enlarged spleen	J:231218
	glomerulonephritis	J:231218
	increased anti-double stranded DNA antibody level	J:231218
	increased anti-nuclear antigen antibody level	J:231218
	increased plasma cell number	J:231218
	increased susceptibility to autoimmune disorder	J:231218
	interstitial pneumonia	J:231218
	lung inflammation	J:231218
	lymphoid hyperplasia	J:231218
Fen1^tm3.1Bhsh/Fen1^tm3.1Bhsh (Not Specified)	chronic inflammation	J:231218
	enlarged spleen	J:231218
	glomerulonephritis	J:231218
	increased anti-double stranded DNA antibody level	J:231218
	increased anti-nuclear antigen antibody level	J:231218
	increased plasma cell number	J:231218
	increased susceptibility to autoimmune disorder	J:231218
	interstitial pneumonia	J:231218
	lung inflammation	J:231218
	lymphoid hyperplasia	J:231218
Fer^em1(IMPC)Tcp/Fer⁺ (C57BL/6N-Fer^em1(IMPC)Tcp/Tcp)	abnormal spleen morphology	J:211773
Fer^em1(IMPC)Tcp/Fer⁺ (C57BL/6N-Fer^em1(IMPC)Tcp/Tcp)	increased spleen weight	J:211773
Fer^em1(IMPC)Tcp/Fer^em1(IMPC)Tcp (C57BL/6N-Fer^em1(IMPC)Tcp/Tcp)	enlarged spleen	J:211773
Fermt1^tm1Ref/Fermt1^tm1Ref (involves: 129S1/Sv * 129X1/SvJ)	ileum inflammation	J:142913
	large intestinal inflammation	J:142913
Fermt3^tm1.1Efp/Fermt3^tm1.1Efp (involves: C57BL/6)	increased leukocyte cell number	J:227094
Fermt3^tm2.1Ref/Fermt3^tm2.1Ref Tg(Cd4-cre)1Cwi/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)	abnormal effector T cell morphology	J:203436
	abnormal T cell physiology	J:203436
Fes^tm1Mcs/Fes^tm1Mcs (involves: 129X1/SvJ)	abnormal leukocyte cell number	J:64748
	abnormal macrophage physiology	J:64748
	conjunctivitis	J:64748
	decreased B cell number	J:64748
	increased granulocyte number	J:64748
	increased monocyte cell number	J:64748
	increased neutrophil cell number	J:64748
	increased susceptibility to bacterial infection	J:64748
	thymus hypoplasia	J:64748
Fes^tm2Pag/Fes^tm2Pag (involves: 129S1/Sv * 129X1/SvJ * CD-1)	abnormal myelopoiesis	J:98590
	decreased B cell number	J:98590
	increased pre-B cell number	J:98590
	increased pro-B cell number	J:98590
	increased susceptibility to endotoxin shock	J:98590
Fezf2^{em1(IMPC)Hmgu}/Fezf2^{em1(IMPC)Hmgu} (C57BL/6NCrl-Fezf2^{em1(IMPC)Hmgu}/Ieg)	increased leukocyte cell number	J:211773
Ffar2^tm1Dgen/Ffar2^tm1Dgen (involves: C57BL/6)	abnormal granulocyte physiology	J:153951
	abnormal neutrophil physiology	J:153951
	impaired neutrophil chemotaxis	J:153951
	impaired neutrophil phagocytosis	J:153951
	increased susceptibility to induced arthritis	J:153951
	increased susceptibility to induced colitis	J:153951
	increased T cell number	J:153951
	lung inflammation	J:153951
Ffar2^tm2Lex/Ffar2^tm2Lex (involves: 129S7/SvEvBrd * C57BL/6)	abnormal cytokine level	J:157383
	abnormal inflammatory response	J:157383
	abnormal neutrophil morphology	J:157383
	decreased circulating tumor necrosis factor level	J:157383
	decreased susceptibility to induced colitis	J:157383
	decreased tumor necrosis factor secretion	J:157383
	impaired neutrophil chemotaxis	J:157383
	increased circulating tumor necrosis factor level	J:157383
	large intestinal inflammation	J:157383
	sepsis	J:157383
Fga^tm1Jld/Fga^tm1Jld (involves: 129P2/OlaHsd * CF-1)	decreased circulating fibrinogen level	J:28436
Fga^tm1Jld/Fga^tm1Jld (B6.129P2-Fga^tm1Jld)	decreased circulating fibrinogen level	J:28436
Fga^tm1Jld/Fga^tm1Jld Plg^tm1Jld/Plg^tm1Jld (involves: 129P2/OlaHsd * Black Swiss * CF-1)	immune system phenotype	J:36591
Fgd1^em1(IMPC)Tcp/Fgd1⁺ (C57BL/6NCrl-Fgd1^em1(IMPC)Tcp/Tcp)	enlarged thymus	J:211773
Fgd3^{em1(IMPC)Ccpcz}/Fgd3^{em1(IMPC)Ccpcz} (C57BL/6N-Fgd3^{em1(IMPC)Ccpcz}/Ccpcz)	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
Fgd5^em1(IMPC)Mbp/Fgd5⁺ (C57BL/6NCrl-Fgd5^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Fgf3^{tm4b(EUCOMM)Hmgu}/Fgf3⁺ (C57BL/6N-Fgf3^{tm4b(EUCOMM)Hmgu}/Bay)	enlarged lymph nodes	J:211773
Fgf7^tm1Efu/Fgf7^tm1Efu (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal immune system physiology	J:129368
	abnormal response to transplant	J:129368
	immune system phenotype	J:129368
	spleen hypoplasia	J:129368
Fgf8^tm1.3Mrt/Fgf8^tm1.4Mrt Tg(Tbx1-cre)1Joe/0 (involves: 129P2/OlaHsd)	abnormal thymus morphology	J:88814
	small thymus	J:88814
Fgf8^tm1.4Mrt/Fgf8⁺ Tbx1^tm1Bld/Tbx1⁺ (involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * ICR)	thymus hypoplasia	J:78686
Fgf8^tm1Mrc/Fgf8^tm1Moon Hoxa3^tm1(cre)Moon/Hoxa3⁺ (involves: 129/Sv * C57BL/6)	ectopic thymus	J:87304
	thymus hypoplasia	J:87304
Fgf8^tm1Mrc/Fgf8^tm2Mrc Hoxa3^tm1(cre)Moon/Hoxa3⁺ (involves: 129/Sv * C57BL/6)	ectopic thymus	J:87304
	thymus hypoplasia	J:87304
Fgf10^{tm1b(EUCOMM)Wtsi}/Fgf10⁺ (C57BL/6N-Fgf10^{tm1b(EUCOMM)Wtsi}/H)	decreased leukocyte cell number	J:211773
Fgf10^tm1Ska/Fgf10^tm1Ska (involves: C57BL/6 * CBA)	small thymus	J:114183
Fgf14^{em1(IMPC)Ccpcz}/Fgf14^{em1(IMPC)Ccpcz} (C57BL/6N-Fgf14^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
Fgf20^{em1(IMPC)Ccpcz}/Fgf20^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Fgf20^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Fgf23^{em1(IMPC)Ccpcz}/Fgf23⁺ (C57BL/6NCrl-Fgf23^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
Fgf23^tm1Blan/Fgf23^tm1Blan (involves: 129/Sv * C57BL/6)	small spleen	J:121006
Fgf23^tm1Tyam/Fgf23^tm1Tyam (involves: C57BL/6 * CBA)	decreased lymphocyte cell number	J:88172
	spleen hypoplasia	J:88172
	thymus atrophy	J:88172
Fgfbp3^{tm1.1(KOMP)Wtsi}/Fgfbp3^{tm1.1(KOMP)Wtsi} (C57BL/6N-Fgfbp3^{tm1.1(KOMP)Wtsi}/Ucd)	increased neutrophil cell number	J:211773
Fgfr1^Hspy/Fgfr1⁺ (C3HeB/FeJ-Hspy)	increased susceptibility to otitis media	J:95895
Fgfr1^tm1Upir/Fgfr1^tm1Upir Fgfr2^tm1Dor/Fgfr2^tm1Dor Tg(KRT5-cre)5132Jlj/0 (involves: 129X1/SvJ * C57BL/6 * C57BL/6J * DBA/2J)	abnormal chemokine level	J:221184
	abnormal mast cell morphology	J:221184
	dermatitis	J:221184
	increased IgE level	J:158802
	increased IgG1 level	J:158802
	increased IgG2a level	J:158802
	increased mast cell number	J:221184
	skin inflammation	J:158802, J:221184
Fgfr2^tm1Dor/Fgfr2^tm1.1Dor Twist2^tm1(cre)Dor/Twist2⁺ (involves: 129X1/SvJ)	abnormal osteoclast differentiation	J:90391
Fgfr2^tm1Dsn/Fgfr2^tm1Dsn Tg(KRT5-cre)5132Jlj/0 (involves: 129P2/OlaHsd * C57BL/6J * DBA/2J)	adipose tissue inflammation	J:119723
	increased gamma-delta T cell number	J:119723
	skin inflammation	J:119723
Fgfr2^tm1Ewj/Fgfr2⁺ Tg(EIIa-cre)C5379Lmgd/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * FVB/N)	abnormal thymus morphology	J:101174
	bronchiolectasis	J:101174
	decreased osteoclast cell number	J:101174
Fgfr2^tm3Dsn/Fgfr2^tm3Dsn (involves: 129P2/OlaHsd * C57BL/6)	abnormal thymus development	J:67731
Fgfr3^{tm1.1(FGFR3*)Ytc}/Fgfr3⁺ (involves: 129)	decreased osteoclast cell number	J:287271
Fgfr3^{tm1.1(FGFR3)Ytc}/Fgfr3^{tm1.1(FGFR3)Ytc} (involves: 129)	decreased osteoclast cell number	J:287271
Fgfr3^tm1Led/Fgfr3^tm1Led (involves: 129S6/SvEvTac)	increased osteoclast cell number	J:32105
Fgfr3^tm2Llm/Fgfr3⁺ Tg(CMV-cre)1Ipc/? (involves: 129S2/SvPas * C57BL/6 * SJL)	increased osteoclast cell number	J:183772
Fgfr3^tm2Llm/Fgfr3⁺ Tg(Col2a1-cre)1Bhr/? (involves: 129S2/SvPas * C57BL/6 * SJL)	increased osteoclast cell number	J:183772
Fgfr3^tm3.1Cxd/Fgfr3^tm3.1Cxd (involves: 129S6/SvEvTac)	abnormal osteoclast physiology	J:69849
Fgfr4^M1Btlr/Fgfr4^M1Btlr (C57BL/6J-Fgfr4^M1Btlr)	decreased B-1a cell number	J:265097
Fgg^tm1Lord/Fgg⁺ (involves: 129P2/OlaHsd * C57BL/6)	decreased circulating fibrinogen level	J:129828
Fgg^tm1Lord/Fgg^tm1Lord (involves: 129P2/OlaHsd * C57BL/6)	decreased circulating fibrinogen level	J:129828
Fgg^tm1Lord/Fgg^tm1Lord (involves: 129P2/OlaHsd * C57BL/6)	increased leukocyte cell number	J:129828
Fgg^tm2Jld/Fgg^tm2Jld (involves: 129P2/OlaHsd * Black Swiss * C57BL/6)	abnormal neutrophil physiology	J:90908
	increased susceptibility to bacterial infection	J:90908
Fgl1^{tm1b(EUCOMM)Hmgu}/Fgl1^{tm1b(EUCOMM)Hmgu} (involves: BALB/cJ * C57BL/6N)	decreased B cell number	J:269578
	dermatitis	J:269578
	increased anti-double stranded DNA antibody level	J:269578
	increased central memory CD8 positive, alpha-beta T cell number	J:269578
Fgl2^tm1Pam/Fgl2⁺ (involves: 129X1/SvJ * C57BL/6)	decreased susceptibility to Coronaviridae infection	J:99453
Fgl2^tm1Pam/Fgl2^tm1Pam (involves: 129X1/SvJ * C57BL/6)	decreased susceptibility to Coronaviridae infection	J:99453
Fgl2^tm1Pam/Fgl2^tm1Pam (involves: 129X1/SvJ * C57BL/6)	decreased susceptibility to Coronaviridae infection induced morbidity/mortality	J:99453
Fgl2^tm1Pam/Fgl2^tm1Pam (B6.129X1-Fgl2^tm1Pam)	abnormal B cell physiology	J:130895
	abnormal dendritic cell physiology	J:130895
	abnormal Peyer's patch follicle morphology	J:130895
	abnormal regulatory T cell physiology	J:130895
	abnormal T cell physiology	J:130895
	decreased dendritic cell apoptosis	J:130895
	decreased Peyer's patch number	J:130895
	decreased susceptibility to Coronaviridae infection	J:99453
	decreased susceptibility to Coronaviridae infection induced morbidity/mortality	J:99453
	enlarged spleen	J:130895
	glomerulonephritis	J:130895
	increased dendritic cell number	J:130895
	increased IgA level	J:130895
	increased IgG level	J:130895
	increased IgM level	J:130895
	increased regulatory T cell number	J:130895
	increased T cell proliferation	J:130895
Fgl2^tm1Pam/Fgl2^tm1Pam (involves: 129X1/SvJ * C57BL/6J)	increased length of allograft survival	J:98997
Fgl2^tm1Stsm/Fgl2^tm1Stsm (C57BL/6-Fgl2^tm1Stsm)	immune system phenotype	J:88648
Fgr^Mhdaali18/Fgr⁺ (C3HeB/FeJ-Fgr^Mhdaali18)	dermatitis	J:112868
Fgr^Mhdaali18/Fgr⁺ (C3HeB/FeJ-Fgr^Mhdaali18)	increased inflammatory response	J:112868
Fgr^Mhdaali18/Fgr^Mhdaali18 (C3HeB/FeJ-Fgr^Mhdaali18)	autoimmune arthritis	J:112868
Fgr^Mhdaali18/Fgr^Mhdaali18 (C3HeB/FeJ-Fgr^Mhdaali18)	dermatitis	J:112868
Fgr^tm1Hev/Fgr^tm1Hev (involves: 129S7/SvEvBrd * C57BL/6)	abnormal interferon-gamma secretion	J:131738
Fgr^tm1Hev/Fgr^tm1Hev (B6.129S7-Fgr^tm1Hev)	abnormal inflammatory response	J:113463
Fgr^tm1Hev/Fgr^tm1Hev Hck^tm1Hev/Hck^tm1Hev (involves: 129S7/SvEvBrd * C57BL/6J)	abnormal macrophage morphology	J:59037
	abnormal macrophage physiology	J:59037
	impaired macrophage phagocytosis	J:16994
	increased susceptibility to bacterial infection	J:16994
Fgr^tm1Hev/Fgr^tm1Hev Hck^tm1Hev/Hck^tm1Hev Lyn^tm1Sor/Lyn^tm1Sor (B6.Cg-Hck^tm1Hev Fgr^tm1Hev Lyn^tm1Sor)	abnormal inflammatory response	J:113463
	abnormal neutrophil physiology	J:113463
Fhip1b^em1(IMPC)Tcp/Fhip1b^em1(IMPC)Tcp (C57BL/6NCrl-Fhip1b^em1(IMPC)Tcp/Tcp)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Fhip2b^{em1(IMPC)Ccpcz}/Fhip2b^{em1(IMPC)Ccpcz} (C57BL/6N-Fhip2b^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Fhip2b^em1Wwan/Fhip2b^em1Wwan (involves: C57BL/6)	abnormal cytokine level	J:302658, J:285283
	enlarged spleen	J:285283
	increased leukocyte cell number	J:285283
	increased susceptibility to induced colitis	J:285283
	liver inflammation	J:302658
Fhit^tm1Hbn/Fhit⁺ (involves: 129X1/SvJ * C57BL/6)	decreased granulocyte number	J:71303
Fhit^tm1Hbn/Fhit⁺ (involves: 129X1/SvJ * C57BL/6)	increased susceptibility to infection	J:71303
Fhit^tm1Hbn/Fhit^tm1Hbn (involves: 129X1/SvJ * C57BL/6)	decreased granulocyte number	J:71303
Fhit^tm1Hbn/Fhit^tm1Hbn (involves: 129X1/SvJ * C57BL/6)	increased susceptibility to infection	J:71303
Fibcd1^tm1Spte/Fibcd1^tm1Spte (B6.129S1-Fibcd1^tm1Spte)	abnormal interferon secretion	J:340107
	abnormal tumor necrosis factor level	J:340107
	decreased cytokine level	J:340107
	decreased lymphocyte cell number	J:340107
	decreased susceptibility to fungal infection	J:340107
	decreased susceptibility to infection induced morbidity/mortality	J:340107
	increased cytokine level	J:340107
Fig4^plt1/Fig4^plt1 (involves: 129P2/OlaHsd * C3H * C57BL/6 * CAST/Ei * SJL)	spleen hypoplasia	J:122737
Fign^fi/Fign^fi (mixed)	conjunctivitis	J:13035
Fign^fi/Fign^fi (mixed)	eye inflammation	J:13035
Fis1^tm1.1Itl/Fis1^tm1.1Itl Tg(Ckmm-cre)5Khn/0 (involves: C57BL/6NTac * FVB)	increased circulating interferon-beta level	J:290485
	increased circulating interleukin-6 level	J:290485
	increased circulating interleukin-12b level	J:290485
	increased circulating interleukin-13 level	J:290485
Fitm2^tm1.1Dls/Fitm2^tm1.1Dls Tg(Fabp4-cre)1Rev/? (involves: 129S6/SvEvTac * C57BL/6J)	increased circulating tumor necrosis factor level	J:212437
Fkbp4^em1(IMPC)Mbp/Fkbp4^em1(IMPC)Mbp (C57BL/6N-Fkbp4^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Fkbp5^{tm1b(KOMP)Wtsi}/Fkbp5^{tm1b(KOMP)Wtsi} (C57BL/6N-Fkbp5^{tm1b(KOMP)Wtsi}/MbpMmucd)	increased basophil cell number	J:211773
	increased neutrophil cell number	J:211773
Fkbp11^em1(IMPC)Mbp/Fkbp11^em1(IMPC)Mbp (C57BL/6N-Fkbp11^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	small spleen	J:211773
Fkbp11^{Gt(OST298786)Lex}/Fkbp11^{Gt(OST298786)Lex} (involves: 129S5/SvEvBrd * C57BL/6J)	increased immunoglobulin level	J:103485
	increased inflammatory response	J:103485
Fkrp^tm1Scbr/Fkrp^tm1Scbr Sox1^tm1(cre)Take/Sox1⁺ (involves: C57BL/6NCrlj * CBA/JNCrlj)	myositis	J:207119
Fkrp^tm1Scbr/Fkrp^tm1Scbr Sox1^tm1(cre)Take/Sox1⁺ Tg(CAG-LARGE)126Fmu/0 (involves: C57BL/6NCrlj * C57BL/10 * CBA/Ca * CBA/JNCrlj)	myositis	J:207119
Flcn^tm1Baba/Flcn^tm1.1Lss Tg(CAG-cre/Esr1)1Lbe/0 (involves: 129S1/Sv 129X1/SvJ)	arrested B cell differentiation	J:189078
	decreased B cell number	J:189078
Flg^ft/Flg^ft (involves: C57BL/6)	skin inflammation	J:151110
Flg^ft/Flg^ft (B6.Cg-Flg^ft)	immune system phenotype	J:202453, J:151110
	increased IgE level	J:202453, J:151110
	increased IgG1 level	J:151110
	increased IgG2a level	J:151110
	increased IgG level	J:151110
	increased interferon-gamma secretion	J:151110
	increased interleukin-4 secretion	J:151110
	increased interleukin-5 secretion	J:151110
	increased interleukin-10 secretion	J:151110
	increased interleukin-13 secretion	J:151110
	increased interleukin-17 secretion	J:151110
	increased splenocyte proliferation	J:151110
Flg^ft/Flg^ft (Not Specified)	dermatitis	J:198332
Flg^ft/Flg^ft (STOCK a/a Tmem79^ma Flg^ft/J)	abnormal cytokine level	J:204304
Flg^ft/Flg^ft (STOCK a/a Tmem79^ma Flg^ft/J)	dermatitis	J:204304
Flg^ft/Flg^ft Tmem79^ma/Tmem79^ma (involves: CBA/CaGr)	blepharitis	J:202453
	increased IgE level	J:202453
	skin inflammation	J:202453
Flg^tm1Amag/Flg^tm1Amag (involves: 129S6/SvEvTac * BALB/c * C57BL/6NTac)	abnormal humoral immune response	J:198332
	dermatitis	J:198332
	increased IgE level	J:198332
	increased IgG1 level	J:198332
	increased inflammatory response	J:229771
	increased susceptibility to type IV hypersensitivity reaction	J:198332
Flg^tm1Amag/Flg^tm1Amag Tg(CD207-Dta)312Dhka/0 (involves: 129S6/SvEvTac * BALB/c * C57BL/6NTac * FVB)	decreased inflammatory response	J:229771
Fli1^tm1.1Dkw/Fli1⁺ (B6.129S6-Fli1^tm1.1Dkw)	decreased B cell number	J:137876
Fli1^tm1.1Dkw/Fli1^tm1.1Dkw (B6.129S6-Fli1^tm1.1Dkw)	abnormal B cell differentiation	J:137876
	abnormal class switch recombination	J:137876
	abnormal humoral immune response	J:137876
	abnormal splenic cell ratio	J:137876
	decreased B cell number	J:137876
	decreased B cell proliferation	J:137876
	decreased follicular B cell number	J:137876
	decreased IgG1 level	J:137876
	decreased IgG3 level	J:137876
	increased marginal zone B cell number	J:137876
	increased transitional stage B cell number	J:137876
	spleen hyperplasia	J:137876
Fli1^tm1Ber/Fli1^tm1Ber (either: (involves: 129S1/Sv * 129X1/SvJ * C57BL/6) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1))	decreased thymocyte number	J:33052
Fli1^tm1Ber/Fli1^tm1Ber (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1)	enlarged spleen	J:33052
Fli1^tm1Morl/Fli1^tm1Morl Tg(Mx1-cre)1Cgn/0 (involves: 129/Sv * C57BL/6 * CBA)	abnormal leukocyte morphology	J:167426
	abnormal thrombopoiesis	J:167426
	decreased granulocyte number	J:167426
	increased monocyte cell number	J:167426
	increased NK cell number	J:167426
Flicr^em1Doi/Flicr^em1Doi (NOD/ShiLtDoi-Flicr^em1Doi)	decreased susceptibility to autoimmune diabetes	J:241346
Flicr^em1Doi/Flicr^em1Doi (NOD/ShiLtDoi-Flicr^em1Doi)	insulitis	J:241346
Flna^tm1.2Caw/Flna⁺ (involves: 129S4/SvJae * C57BL/6)	increased leukocyte cell number	J:118252
Flnb^{tm1b(KOMP)Wtsi}/Flnb⁺ (C57BL/6N-Flnb^{tm1b(KOMP)Wtsi}/H)	decreased neutrophil cell number	J:211773
Flot1^tm1.1Arte/Flot1^tm1.1Arte (involves: C57BL/6J)	abnormal leukocyte physiology	J:166672
	impaired neutrophil chemotaxis	J:166672
	impaired neutrophil recruitment	J:166672
Flt1^tm1.1Fong/Flt1^tm1.1Fong Gt(ROSA)26Sor^{tm1(cre/ERT2)Thl}/Gt(ROSA)26Sor⁺ (involves: 129S6/SvEvTac * C57BL/6NCr * CD-1)	increased macrophage cell number	J:202202
Flt1^tm1Msh/Flt1^tm1Msh (involves: 129S4/SvJae * C57BL/6J)	impaired macrophage chemotaxis	J:49507
Flt3^{em1(IMPC)Ccpcz}/Flt3^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Flt3^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	decreased effector memory T-helper cell number	J:211773
	decreased NK cell number	J:211773
Flt3^m1Btlr/Flt3^m1Btlr (C57BL/6J-Flt3^m1Btlr)	abnormal dendritic cell antigen presentation	J:159599
	abnormal dendritic cell physiology	J:159599
	abnormal macrophage physiology	J:105543
	abnormal NK cell physiology	J:159599
	decreased circulating interferon-alpha level	J:159599
	decreased circulating interferon-gamma level	J:159599
	decreased circulating interleukin-12 level	J:159599
	decreased dendritic cell number	J:159599
	decreased interferon-alpha secretion	J:159599
	decreased interferon-gamma secretion	J:159599
	decreased interleukin-12 secretion	J:159599
	decreased NK cell number	J:159599
	decreased plasmacytoid dendritic cell number	J:159599
	decreased splenocyte number	J:159599
	increased circulating interleukin-6 level	J:159599
	increased circulating tumor necrosis factor level	J:159599
	increased susceptibility to Herpesvirales infection	J:105543
	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:159599
	increased susceptibility to Riboviria infection	J:105543
	small lymph nodes	J:159599
Flt3^tm1.1Dosm/Flt3⁺ (B6.129(C)-Flt3^tm1.1Dosm)	abnormal spleen morphology	J:205200
	arrested B cell differentiation	J:205200
	enlarged spleen	J:205200
	increased spleen white pulp amount	J:205200
Flt3^tm1Dgg/Flt3⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal B cell differentiation	J:126003
	decreased B cell number	J:126003
	decreased mature B cell number	J:126003
	decreased T cell number	J:126003
	enlarged spleen	J:126003
	increased granulocyte number	J:126003
	increased leukocyte cell number	J:126003
	increased monocyte cell number	J:126003
	increased spleen red pulp amount	J:126003
	increased spleen white pulp amount	J:126003
Flt3^tm1Dgg/Flt3⁺ Kmt2a^tm1Clgr/Kmt2a⁺ (involves: 129S1/Sv * 129X1/SvJ * BALB/c * C57BL/6J)	enlarged spleen	J:189096
	increased leukocyte cell number	J:189096
Flt3^tm1Dgg/Flt3^tm1Dgg (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal B cell differentiation	J:126003
	decreased B cell number	J:126003
	decreased mature B cell number	J:126003
	decreased T cell number	J:126003
	enlarged spleen	J:126003
	increased granulocyte number	J:126003
	increased leukocyte cell number	J:126003
	increased monocyte cell number	J:126003
	increased spleen red pulp amount	J:126003
	increased spleen white pulp amount	J:126003
Flt3^tm1Dgg/Flt3^tm1Dgg Kmt2a^tm1Clgr/Kmt2a⁺ (involves: 129S1/Sv * 129X1/SvJ * BALB/c * C57BL/6J)	enlarged spleen	J:189096
	increased leukocyte cell number	J:189096
Flt3^tm1Dosm/Flt3⁺ Tg(Mx1-cre)1Cgn/0 (B6.Cg-Flt3^tm1Dosm Tg(Mx1-cre)1Cgn)	abnormal spleen white pulp morphology	J:133528
	arrested B cell differentiation	J:133528
	decreased B cell number	J:133528
	decreased leukocyte cell number	J:133528
	decreased lymphocyte cell number	J:133528
	decreased neutrophil cell number	J:133528
	decreased pre-B cell number	J:133528
	enlarged spleen	J:133528
	increased dendritic cell number	J:133528
	increased granulocyte number	J:133528
	increased leukocyte cell number	J:133528
	increased monocyte cell number	J:133528
	increased neutrophil cell number	J:133528
	increased pro-B cell number	J:133528
	intermingled spleen red and white pulp	J:133528
Flt3^tm1Irl/Flt3^tm1Irl (either: 129S/SvEv-Flt3^tm1Irl or (involves: 129S/SvEv * C57BL/6J))	abnormal B cell differentiation	J:27238, J:99149
	decreased pre-B cell number	J:27238
	decreased pro-B cell number	J:27238
Flt3^tm1Irl/Flt3^tm1Irl Kit^W/Kit^W-v (involves: 129S/SvEv * C57BL/6)	abnormal leukocyte morphology	J:27238
	abnormal myelopoiesis	J:27238
	abnormal T cell number	J:27238
	decreased B cell number	J:27238
	decreased double-negative T cell number	J:27238
	decreased double-positive T cell number	J:27238
	decreased lymphocyte cell number	J:27238
	decreased pre-B cell number	J:27238
	decreased pro-B cell number	J:27238
	thymus hypoplasia	J:27238
Flt3^tm2.1Dosm/Flt3⁺ (B6.129(C)-Flt3^tm2.1Dosm)	abnormal B cell morphology	J:205200
	abnormal myelopoiesis	J:205200
	abnormal spleen morphology	J:205200
	enlarged spleen	J:205200
	increased leukocyte cell number	J:205200
	increased pre-pro B cell number	J:205200
	increased pro-B cell number	J:205200
	increased spleen white pulp amount	J:205200
	intermingled spleen red and white pulp	J:205200
	myeloid hyperplasia	J:205200
Flt3l^tm1Imx/Flt3l^tm1Imx (C57BL/6-Flt3l^tm1Imx)	abnormal dendritic cell morphology	J:62536, J:89868
	abnormal immature B cell morphology	J:62536
	abnormal immune system cell morphology	J:62536
	abnormal immune system organ morphology	J:62536
	abnormal leukocyte morphology	J:62536
	decreased B cell number	J:79569
	decreased double-negative T cell number	J:79569
	decreased leukocyte cell number	J:62536
	decreased lymphocyte cell number	J:62536
	decreased myeloid dendritic cell number	J:62536, J:89868
	decreased NK cell number	J:62536
	decreased plasmacytoid dendritic cell number	J:62536, J:89868
	decreased pre-B cell number	J:79569
	decreased pro-B cell number	J:79569, J:62536
	impaired myelopoiesis	J:62536
	increased IgM level	J:62536
	increased length of allograft survival	J:89868
	increased neutrophil cell number	J:62536
	lymph node hypoplasia	J:62536
	spleen hypoplasia	J:62536
Flt3l^tm1Imx/Flt3l^tm1Imx (involves: C57BL/6)	abnormal dendritic cell antigen presentation	J:223508
	abnormal dendritic cell chemotaxis	J:223508
	abnormal memory T cell physiology	J:189122
	abnormal T-helper 1 physiology	J:189122
	decreased CD11b-high dendritic cell number	J:223508
	decreased CD103-positive CD11b-low dendritic cell number	J:223508
	decreased dendritic cell number	J:189122
	decreased macrophage cell number	J:189122
	decreased monocyte cell number	J:189122
	decreased NK cell number	J:189122
	decreased plasmacytoid dendritic cell number	J:189122
	increased neutrophil cell number	J:189122
	increased susceptibility to parasitic infection	J:189122
Flt4^Chy/Flt4⁺ (involves: C3H)	abnormal lymph circulation	J:72387
	abnormal lymphangiogenesis	J:177405
	abnormal lymphatic vessel morphology	J:72387
Flt4^Chy/Flt4^Chy (involves: C3H)	abnormal lymphangiogenesis	J:177405
Flt4^Chy/Flt4^Chy (involves: C3H)	absent lymphatic vessels	J:177405
Flt4^tm1.1Ichi/Flt4⁺ Kras^tm1Mok/Kras⁺ (involves: 129S/SvEv * C57BL/6)	lymphatic vessel hypoplasia	J:159024
Flt4^tm1.1Ichi/Flt4⁺ Kras^tm1Mok/Kras⁺ Tg(HRAS)2Jic/0 (involves: 129S/SvEv * BALB/c * C57BL/6 * DBA/2)	lymphatic vessel hypoplasia	J:159024
Flt4^tm1.2Yhe/Flt4^tm1.2Yhe (involves: 129/Sv * C57BL/6J * FVB/N)	abnormal lymphangiogenesis	J:177405
	absent lymphatic vessels	J:177405
Flt4^tm1Ali/Flt4⁺ Nrp2^tm1Ddg/Nrp2⁺ (involves: C57BL/6)	abnormal lymphangiogenesis	J:156869
Flt4^tm1Ali/Flt4⁺ Nrp2^tm1Ddg/Nrp2^tm1Ddg (involves: C57BL/6)	abnormal lymphangiogenesis	J:156869
Flt4^tm1Ali/Flt4⁺ Tmem204^tm1.1Ali/Tmem204^tm1.1Ali (involves: BALB/c * C57BL/6)	abnormal lymphatic vessel smooth muscle morphology	J:159519
	enlarged lymphatic vessel	J:159519
Flt4^tm1Ali/Flt4^tm2Ali (involves: 129S1/Sv * 129X1/SvJ * ICR)	absent lymphatic vessels	J:137909
Flt4^tm2Ali/Flt4⁺ (involves: 129S1/Sv * 129X1/SvJ * ICR)	abnormal lymph circulation	J:137909
Flt4^tm2Ali/Flt4⁺ (involves: 129S1/Sv * 129X1/SvJ * ICR)	abnormal lymphatic vessel morphology	J:137909
Flt4^tm2Ali/Flt4^tm2Ali (involves: 129S1/Sv * 129X1/SvJ * ICR)	absent lymphatic vessels	J:137909
Flvcr1^tm1.1Jlab/Flvcr1^tm1.1Jlab (involves: 129S4/SvJae * C57BL/6 * DBA/2)	abnormal spleen morphology	J:132057
	enlarged spleen	J:132057
Flvcr2^tm1.2Tda/Flvcr2^tm1.2Tda (involves: C57BL/6J)	brain inflammation	J:287134
Flvcr2^{tm1a(EUCOMM)Hmgu}/Flvcr2^{tm1a(EUCOMM)Hmgu} (C57BL/6N-Flvcr2^{tm1a(EUCOMM)Hmgu}/Wtsi)	blood in lymph vessels	J:239583
fm/fm (involves: CBA/H)	abnormal lymph node morphology	J:275
	abnormal Peyer's patch morphology	J:275
	abnormal spleen morphology	J:5417, J:275
	abnormal thymus morphology	J:275
Fmnl1^tm1.2Sdb/Fmnl1^tm1.2Sdb Lyz2^tm1(cre)Ifo/Lyz2^tm1(cre)Ifo (involves: C3H * C57BL/6 * FVB/N)	abnormal Kupffer cell morphology	J:250144
	abnormal macrophage morphology	J:250144
	abnormal macrophage physiology	J:250144
	decreased macrophage cell number	J:250144
	impaired macrophage chemotaxis	J:250144
Fmo1^em1Anz/Fmo1^em1Anz (involves: C57BL/6N)	increased cytokine level	J:312983
Fmo3^em1(IMPC)Mbp/Fmo3^em1(IMPC)Mbp (C57BL/6N-Fmo3^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Fmo5^em1(IMPC)Mbp/Fmo5^em1(IMPC)Mbp (C57BL/6N-Fmo5^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Fmod^tm1Aol/Fmod^tm1Aol (involves: 129S1/Sv * 129X1/SvJ * CD-1)	osteoarthritis	J:79115
Fmod^tm1Aol/Fmod^tm1Aol Lum^tm1Chak/Lum^tm1Chak (involves: 129S1/Sv * 129X1/SvJ * CD-1)	osteoarthritis	J:79115
Fn1^tm1Bwg/Fn1^tm1Bwg (involves: 129S4/SvJae * C57BL/6)	immune system phenotype	J:90917
Fndc3a^em1(IMPC)Tcp/Fndc3a^em1(IMPC)Tcp (C57BL/6N-Fndc3a^em1(IMPC)Tcp/Tcp)	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
Fndc4^tm1.1Mabo/Fndc4^tm1.1Mabo (involves: C57BL/6 * BALB/c)	increased susceptibility to induced colitis	J:236896
Fndc9^{tm1.1(KOMP)Vlcg}/Fndc9^{tm1.1(KOMP)Vlcg} (C57BL/6N-Fndc9^{tm1.1(KOMP)Vlcg}/Ucd)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Fnip1^{em1(IMPC)Ccpcz}/Fnip1⁺ (C57BL/6NCrl-Fnip1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	small thymus	J:211773
Fnip1^{em1(IMPC)Ccpcz}/Fnip1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Fnip1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	decreased CD4-positive NK T cell number	J:211773
	decreased effector memory CD8-positive, alpha-beta T cell number	J:211773
	decreased effector memory T-helper cell number	J:211773
	decreased lymphocyte cell number	J:211773
	decreased memory-marker CD4-positive NK T cell number	J:211773
	decreased spleen weight	J:211773
	enlarged thymus	J:211773
	increased CD4-positive, alpha-beta T cell number	J:211773
	increased CD8-positive, alpha-beta T cell number	J:211773
	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
	increased neutrophil cell number	J:211773
	increased T cell number	J:211773
	increased T-helper cell number	J:211773
	small spleen	J:211773
Fnip1^{Gt(RRM154)Byg}/Fnip1^{Gt(RRM154)Byg} (involves: 129P2/OlaHsd * C57BL/6J)	absent B cells	J:189078
	absent B-2 B cells	J:189078
	arrested B cell differentiation	J:189078
	decreased B cell number	J:189078
	decreased B-1 B cell number	J:189078
	decreased mature B cell number	J:189078
	decreased pre-B cell number	J:189078
	decreased transitional stage B cell number	J:189078
	increased B cell apoptosis	J:189078
	increased pro-B cell number	J:189078
	small spleen	J:189078
Fnip1^{Gt(RRM154)Byg}/Fnip1^{Gt(RRM154)Byg} Igh^tm2Cgn/Igh^tm2Cgn (involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL)	absent B cells	J:189078
	absent B-2 B cells	J:189078
	decreased B-1 B cell number	J:189078
Fnip1^{Gt(RRM154)Byg}/Fnip1^{Gt(RRM154)Byg} Tg(BCL2)22Wehi/0 (involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL)	increased B cell number	J:189078
Fnip1^{Gt(RRM154)Byg}/Fnip1^{Gt(RRM154)Byg} Tg(IghelMD4)4Ccg/0 (involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL)	absent B cells	J:189078
	absent B-2 B cells	J:189078
	decreased B-1 B cell number	J:189078
	increased immature B cell number	J:189078
Fnip1^LPAB.1/Fnip1^LPAB.1 (C57BL/6J-Fnip1^LPAB.1)	abnormal B cell physiology	J:187318
	absent B cells	J:187318
	arrested B cell differentiation	J:187318
	decreased B-1 B cell number	J:187318
	decreased IgE level	J:187318
	decreased IgG1 level	J:187318
	decreased IgG2a level	J:187318
	decreased IgG level	J:187318
	decreased IgM level	J:187318
	increased B cell apoptosis	J:187318
Fnip1^LPAB.1/Fnip1^LPAB.1 Tg(IghMyc)22Bri/0 (involves: C57BL * C57BL/6J * SJL)	increased B cell apoptosis	J:187318
Fnip1^m1Btlr/Fnip1^m1Btlr (C57BL/6J-Fnip1^m1Btlr)	abnormal splenocyte morphology	J:234285
	absent B cells	J:234285
	decreased IgM level	J:234285
	decreased marginal zone B cell number	J:234285
Fnip1^m2Btlr/Fnip1^m2Btlr (C57BL/6J-Fnip1^m2Btlr)	decreased B cell number	J:265134
	increased B-1 B cell number	J:265134
	increased CD4-positive, alpha-beta T cell number	J:265134
	increased single-positive T cell number	J:265134
	increased T cell number	J:265134
Fnip1^M3Btlr/Fnip1^M3Btlr (C57BL/6J-Fnip1^M3Btlr)	abnormal B cell differentiation	J:272802
Fnip1^tm1.2Baba/Fnip1^tm1.2Baba (involves: C57BL/6 * C57BL/6J * FVB/N * SJL)	absent B cells	J:189078
	absent B-2 B cells	J:189078
	arrested B cell differentiation	J:189078
	decreased B cell number	J:189078
	decreased B-1 B cell number	J:189078
	decreased mature B cell number	J:189078
	decreased pre-B cell number	J:189078
	decreased transitional stage B cell number	J:189078
	increased B cell apoptosis	J:189078
	increased pro-B cell number	J:189078
	small spleen	J:189078
Fnip1^tm1.2Baba/Fnip1^tm1.2Baba Igh^tm2Cgn/Igh^tm2Cgn (involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL)	absent B cells	J:189078
	absent B-2 B cells	J:189078
	decreased B-1 B cell number	J:189078
Fnip1^tm1.2Baba/Fnip1^tm1.2Baba Tg(BCL2)22Wehi/0 (involves: C57BL/6 * FVB/N * SJL)	increased B cell number	J:189078
Fnip1^tm1.2Baba/Fnip1^tm1.2Baba Tg(IghelMD4)4Ccg/0 (involves: C57BL/6 * C57BL/6J * FVB/N * SJL)	absent B cells	J:189078
	absent B-2 B cells	J:189078
	decreased B-1 B cell number	J:189078
	increased immature B cell number	J:189078
Fntb^tm1Bbd/Fntb^tm1.1Bbd Polr2a^{tm1(cre/ERT2)Bbd}/Polr2a^{tm1(cre/ERT2)Bbd} (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL)	small spleen	J:98944
Fntb^tm1Bbd/Fntb^tm1Bbd Polr2a^{tm1(cre/ERT2)Bbd}/Polr2a^{tm1(cre/ERT2)Bbd} (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL)	small spleen	J:98944
Focad^em1(IMPC)Bay/Focad⁺ (C57BL/6N-Focad^em1(IMPC)Bay/BayMmucd)	decreased spleen weight	J:211773
Fos^tm1Pa/Fos^tm1Pa (involves: 129X1/SvJ * C57BL/6J)	abnormal lymphopoiesis	J:3233
Fos^tm1Wag/Fos^tm1Wag (involves: 129S2/SvPas)	decreased osteoclast cell number	J:65766
Fos^tm1Wag/Fos^tm1Wag (involves: 129S2/SvPas * C57BL/6)	abnormal cytokine secretion	J:118693
	abnormal macrophage physiology	J:118693
	abnormal spleen morphology	J:3493
	abnormal spleen white pulp morphology	J:3493
	abnormal thymus size	J:3493
	decreased B cell number	J:3493
	decreased double-positive T cell number	J:3493
	decreased splenocyte number	J:3493
	decreased thymocyte number	J:3493
	increased macrophage apoptosis	J:118693
	increased macrophage cytokine production	J:118693
	increased susceptibility to bacterial infection	J:118693
	increased T cell number	J:3493
Fos^tm1Wag/Fos^{tm2(Fosl1)Wag} (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)	decreased osteoclast cell number	J:65766
Fos^tm3.1Wag/Fos^tm3.1Wag (involves: 129P2/OlaHsd * C57BL/6 * SJL)	decreased interleukin-10 secretion	J:175064
	increased susceptibility to endotoxin shock	J:175064
	increased tumor necrosis factor secretion	J:175064
Fos^tm4.1Wag/Fos^tm4.1Wag (involves: 129P2/OlaHsd * C57BL/6 * SJL)	decreased interleukin-10 secretion	J:175064
	increased interleukin-6 secretion	J:175064
	increased susceptibility to endotoxin shock	J:175064
	increased tumor necrosis factor secretion	J:175064
Fos^tm5.1Wag/Fos^tm5.1Wag (involves: 129P2/OlaHsd * C57BL/6 * SJL)	abnormal osteoclast differentiation	J:175064
	decreased interleukin-10 secretion	J:175064
	decreased osteoclast cell number	J:175064
	increased circulating tumor necrosis factor level	J:175064
	increased interleukin-6 secretion	J:175064
	increased susceptibility to endotoxin shock	J:175064
	increased tumor necrosis factor secretion	J:175064
Fos^tm6.1Wag/Fos^tm6.1Wag (involves: 129P2/OlaHsd * C57BL/6 * SJL)	abnormal osteoclast differentiation	J:175064
	increased circulating interleukin-6 level	J:175064
	increased circulating interleukin-10 level	J:175064
	increased circulating tumor necrosis factor level	J:175064
	increased susceptibility to endotoxin shock	J:175064
Fos^tm7Wag/Fos^tm7Wag Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6)	decreased interleukin-10 secretion	J:175064
	increased circulating interleukin-6 level	J:175064
	increased circulating interleukin-10 level	J:175064
	increased circulating tumor necrosis factor level	J:175064
	increased interleukin-6 secretion	J:175064
	increased susceptibility to endotoxin shock	J:175064
	increased tumor necrosis factor secretion	J:175064
Fos^tm7Wag/Fos^tm7Wag Tg(Cd4-cre)1Cwi/0 (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	decreased CD4-positive, alpha-beta T cell number	J:190150
Fosl2^tm2.1Wag/Fosl2^tm2.1Wag (involves: 129P2/OlaHsd * C57BL/6)	abnormal osteoclast differentiation	J:137646
	abnormal osteoclast morphology	J:137646
	abnormal osteoclast physiology	J:137646
	increased osteoclast cell number	J:137646
Fosl2^tm2Wag/Fosl2^tm2Wag Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal osteoclast differentiation	J:137646
Fosl2^tm2Wag/Fosl2^tm2Wag Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0 (involves: 129P2/OlaHsd * C57BL/6 * CD-1)	abnormal osteoclast morphology	J:211215
Foxa1^tm1(cre)Sew/Foxa1⁺ Mst1r^tm1Sew/Mst1r^tm1Sew (involves: 129P2/OlaHsd * CD-1 * NIH Black Swiss)	decreased susceptibility to bacterial infection	J:105979
Foxa2^tm1.1Khk/Foxa2⁺ (involves: 129P2/OlaHsd * C57BL/6 * CD-1)	respiratory system inflammation	J:284174
Foxa2^tm1Khk/Foxa2^tm1Khk Tg(Scgb1a1-rtTA)1Jaw/0 Tg(tetO-cre)1Jaw/0 (Not Specified)	immune system phenotype	J:88601
Foxa2^tm1Khk/Foxa2^tm1Khk Tg(SFTPC-rtTA)5Jaw/0 Tg(tetO-cre)1Jaw/0 (involves: 129 * 129P2/OlaHsd * C57BL/6)	increased macrophage cell number	J:88601
	increased neutrophil cell number	J:88601
Foxc2^tm1.1Miu/Foxc2^tm1.1Miu Tg(Tek-cre)1Ywa/0 (involves: C57BL/6 * C57BL/6J * SJL)	abnormal lymphatic vessel morphology	J:316530
Foxc2^tm1Miu/Foxc2⁺ (involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J)	abnormal lymph circulation	J:83436
	abnormal thoracic duct morphology	J:83436
	enlarged lymph nodes	J:83436
	increased lymph node number	J:83436
	lymphangiectasis	J:83436
	lymphatic vessel hyperplasia	J:83436
Foxf1^em1Vvk/Foxf1⁺ (involves: C57BL/6 * DBA/2)	lung inflammation	J:296328
Foxh1^b2b2662Clo/Foxh1^b2b2662Clo (C57BL/6J-Foxh1^b2b2662Clo)	absent spleen	J:175213
	thymus hypoplasia	J:175213
Foxh1^tm1Hmd/Foxh1^tm1.1Hmd Tg(Leftb-cre)1Hmd/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6Cr)	spleen hypoplasia	J:82311
Foxi3^em3Akg/Foxi3^tm1.2Akg (involves: 129X1/SvJ * C57BL/6)	athymia	J:336768
Foxj3^{tm1b(EUCOMM)Wtsi}/Foxj3⁺ (C57BL/6N-Foxj3^{tm1b(EUCOMM)Wtsi}/Bay)	increased leukocyte cell number	J:211773
Foxm1^tm1Rhc/Foxm1^tm1Rhc Tg(Tek-cre)1Ywa/0 (involves: 129X1/SvJ * C57BL/6 * SJL)	lung inflammation	J:167773
Foxn1^nu-2J/Foxn1^nu-2J (B6(SJL)-Foxn1^nu-2J/GrsrJ)	athymia	J:192383
Foxn1^nu-StL/Foxn1^nu-StL (involves: C57BL/6)	absent T cells	J:63313
Foxn1^nu-StL/Foxn1^nu-StL (involves: C57BL/6)	athymia	J:63313
Foxn1^nu-StL/Foxn1^tm1Tbo (involves: 129S1/Sv * C57BL/6)	abnormal thymus development	J:63313
Foxn1^nu-StL/Foxn1^tm1Tbo (involves: 129S1/Sv * C57BL/6)	athymia	J:63313
Foxn1^nu-str/Foxn1^nu-str (AKR/J-Foxn1^nu-str/J)	abnormal humoral immune response	J:30715
	abnormal immune system cell morphology	J:30715
	abnormal immune system morphology	J:24755
	abnormal immune system organ morphology	J:30715
	abnormal immune system physiology	J:30715
	abnormal Peyer's patch germinal center morphology	J:30715
	abnormal Peyer's patch morphology	J:30715
	athymia	J:24755
	decreased immunoglobulin level	J:30715
	decreased lymphocyte cell number	J:30715
	decreased T cell number	J:30715
	increased eosinophil cell number	J:30715
	increased granulocyte number	J:30715
	increased length of allograft survival	J:30715
	increased neutrophil cell number	J:30715
	lymph node hypoplasia	J:30715
	spleen hypoplasia	J:30715
Foxn1^nu-Y/Foxn1^nu-Y (101/HY-Foxn1^nu-Y)	abnormal thymus development	J:4060
	absent T cells	J:4060
	athymia	J:4060, J:29022
Foxn1^nu/Foxn1⁺ (C.Cg-Foxn1^nu)	small thymus	J:7330
Foxn1^nu/Foxn1⁺ (involves: BALB/c)	blepharitis	J:12543
	increased incidence of corneal inflammation	J:12543
	increased susceptibility to Herpesvirales infection	J:12543
Foxn1^nu/Foxn1⁺ (NFS.Cg-Foxn1^nu)	abnormal thymus morphology	J:7330
Foxn1^nu/Foxn1⁺ (NFS.Cg-Foxn1^nu)	small thymus	J:7330
Foxn1^nu/Foxn1⁺ (B6N.Cg-Foxn1^nu)	small thymus	J:7330
Foxn1^nu/Foxn1⁺ (C3N.Cg-Foxn1^nu)	small thymus	J:7330
Foxn1^nu/Foxn1^nu (involves: NMRI)	abnormal thymus development	J:6363
Foxn1^nu/Foxn1^nu (Not Specified)	abnormal lymph node T cell domain morphology	J:202296
	abnormal Peyer's patch germinal center morphology	J:202296
	abnormal spleen morphology	J:202296
	abnormal splenic cell ratio	J:202296
	abnormal thymus morphology	J:202297
	athymia	J:202296, J:5059
	decreased leukocyte cell number	J:5059
	small spleen	J:202296
Foxn1^nu/Foxn1^nu (B6NTac.Cg-Foxn1^nu/Tac)	decreased susceptibility to parasitic infection	J:64283
Foxn1^nu/Foxn1^nu (involves: BALB/c)	abnormal circulating cytokine level	J:50903
	blepharitis	J:12543
	decreased circulating interleukin-2 level	J:50903
	decreased circulating interleukin-6 level	J:50903
	decreased circulating tumor necrosis factor level	J:50903
	decreased interferon-gamma secretion	J:50903
	decreased susceptibility to bacterial infection	J:50903
	increased susceptibility to Herpesvirales infection	J:12543
	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:12543
Foxn1^nu/Foxn1^nu (involves: C57BL/10Sn * C57BR/cd)	abnormal thymus development	J:7898
Foxn1^nu/Foxn1^nu (involves: CD-1)	athymia	J:106251
Foxn1^nu/Foxn1^nu (involves: CBA)	abnormal lymph node morphology	J:202808
	abnormal spleen physiology	J:202299
	abnormal T cell activation	J:202299
	decreased leukocyte cell number	J:202299
	decreased lymphocyte cell number	J:202299
	decreased T cell number	J:202808
	increased length of allograft survival	J:202299
Foxn1^nu/Foxn1^nu Fv4^r/Fv4^r (involves: BALB/c)	decreased susceptibility to Retroviridae infection	J:5714, J:5684
Foxn1^nu/Foxn1^nu Map3k14^aly/Map3k14^aly (involves: BALB/cAJcl * C57BL/6J)	absent B cells	J:96579
	absent lymph nodes	J:96579
	absent Peyer's patches	J:96579
	athymia	J:96579
	decreased gamma-delta intraepithelial T cell number	J:96579
	decreased T cell number	J:96579
Foxn1^nu/Foxn1^nu Tg(Foxn1)E1Hon/0 (involves: CD-1)	athymia	J:33866
Foxn1^nu/Foxn1^nu Tgfb1^tm1Doe/Tgfb1^tm1Doe (involves: 129S2/SvPas * BALB/c * CF-1)	abnormal T cell physiology	J:99033
	decreased inflammatory response	J:99033
Foxn1^nu/Foxn1^tm1.1Dmsu Tg(CAG-cre/Esr1)5Amc/0 (involves: 129/Sv C57BL/6 * CBA * SJL)	abnormal thymus epithelium morphology	J:159773
	decreased thymocyte number	J:159773
	increased thymocyte apoptosis	J:159773
Foxn1^sepe/Foxn1^sepe (BALB/c-Foxn1^sepe)	athymia	J:227974
Foxn1^{tm1.1(KOMP)Vlcg}/Foxn1^{tm1.1(KOMP)Vlcg} (C57BL/6N-Foxn1^{tm1.1(KOMP)Vlcg}/Tcp)	abnormal thymus morphology	J:211773
	athymia	J:211773
Foxn1^tm1.1Cbln/Foxn1⁺ (involves: 129P2/OlaHsd * C57BL/6)	thymus hyperplasia	J:177992
Foxn1^tm1.1Cbln/Foxn1⁺ Tg(Zp3-cre)3Mrt/? (involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6 * FVB/N)	immune system phenotype	J:177992
Foxn1^tm1.1Cbln/Foxn1^tm1.1Cbln (involves: 129P2/OlaHsd * C57BL/6)	abnormal lymphocyte cell number	J:177992
	decreased single-positive T cell number	J:177992
	increased DN1 thymic pro-T cell number	J:177992
	increased double-positive T cell number	J:177992
	thymus hypoplasia	J:177992
Foxn1^tm1.1Cbln/Foxn1^tm1Tbo (involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6)	absent T cells	J:177992
	small thymus	J:177992
Foxn1^tm1.1Cbln/Foxn1^tm1Tbo Gt(ROSA)26Sor^{tm2(cre/ERT2)Brn}/Gt(ROSA)26Sor⁺ (involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6)	immune system phenotype	J:177992
Foxn1^tm1.1Dmsu/Foxn1^tm1.1Dmsu Tg(CAG-cre/Esr1)5Amc/0 (involves: 129/Sv C57BL/6 * CBA * SJL)	abnormal thymus morphology	J:159773
	decreased double-positive T cell number	J:159773
	decreased thymocyte number	J:159773
	small thymus	J:159773
	thymus atrophy	J:159773
Foxn1^tm1.1Dmsu/Foxn1^tm1.1Dmsu Tg(KRT5-cre/ERT2)2Ipc/0 (involves: 129/Sv * C57BL/6 * SJL)	abnormal thymus corticomedullary boundary morphology	J:159773
	abnormal thymus medulla morphology	J:159773
	decreased thymocyte number	J:159773
	small thymus	J:159773
	thymus atrophy	J:159773
Foxn1^tm1.1Dmsu/Foxn1^tm1.1Dmsu Tg(KRT18-cre/ERT2)1Rgo/0 (involves: 129/Sv * C57BL/6 * FVB/N * SJL)	immune system phenotype	J:159773
Foxn1^tm1Dmsu/Foxn1^tm1Dmsu (involves: 129/Sv * C57BL/6)	athymia	J:159773
Foxn1^tm1Nrm/Foxn1^tm1Nrm (involves: 129X1/SvJ * C57BL/6J)	abnormal CD4-positive, alpha beta T cell morphology	J:86255
	abnormal CD8-positive, alpha beta T cell morphology	J:86255
	abnormal T cell differentiation	J:86255
	abnormal thymus development	J:86255
	abnormal thymus epithelium morphology	J:86255
	absent thymus cortex	J:86255
	absent thymus medulla	J:86255
	decreased CD4-positive, alpha-beta T cell number	J:86255
	decreased double-negative T cell number	J:86255
	decreased double-positive T cell number	J:86255
	decreased T cell number	J:86255
	decreased thymocyte number	J:86255
	small thymus	J:86255
	thymus cyst	J:86255
Foxn1^tm1Tbo/Foxn1^tm1Tbo (involves: 129S1/Sv)	abnormal leukocyte cell number	J:33796
	abnormal thymus development	J:33796
	abnormal thymus epithelium morphology	J:177992
	abnormal thymus morphology	J:33796
	absent T cells	J:33796
	athymia	J:33796
	increased B cell number	J:33796
Foxn1^tm2Nrm/Foxn1^tm2Nrm (either: (involves: 129/Sv) or (involves: C57BL/6))	immune system phenotype	J:125817
Foxn1^tm2Tbo/Foxn1^tm2Tbo Tg(KRT14-cre/ERT2)1Ipc/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	increased T cell number	J:110046
Foxn1^tm3(cre)Nrm/Foxn1⁺ Gt(ROSA)26Sor^{tm1(Tbx1)Rche}/Gt(ROSA)26Sor⁺ (involves: C57BL/6 * C57BL/6NHsd)	abnormal thymus development	J:214094
	abnormal thymus epithelium morphology	J:214094
	decreased thymocyte number	J:214094
	thymus hypoplasia	J:214094
Foxn1^tm3(cre)Nrm/Foxn1⁺ Mir205hg^tm1Oers/Mir205hg^tm1Oers (B6(Cg)-Mir205hg^tm1Oers Foxn1^tm3(cre)Nrm)	decreased thymocyte number	J:278363
	decreased thymus weight	J:278363
	thymus hypoplasia	J:278363
Foxn1^tm3(cre)Nrm/Foxn1^tm3(cre)Nrm (either: (involves: 129/Sv) or (involves: C57BL/6))	immune system phenotype	J:125817
Foxn4^{em1(IMPC)Ccpcz}/Foxn4⁺ (C57BL/6NCrl-Foxn4^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
Foxo1^tm1.1Rdp/Foxo1⁺ Igh-J^tm1Cgn/Igh^tm4Cgn Tg(Cr2-cre)3Cgn/0 (involves: 129P2/OlaHsd * 129S1/Sv)	increased B cell number	J:157297
Foxo1^tm1.1Stlp/Foxo1^tm1.1Stlp Tg(Lck-cre)1Cwi/0 (involves: 129S4/SvJae)	abnormal single-positive T cell number	J:154205
	decreased CD8-positive, alpha-beta T cell number	J:154205
	decreased double-positive T cell number	J:154205
	decreased T cell number	J:154205
	decreased T cell proliferation	J:154205
	decreased thymocyte apoptosis	J:154205
	increased CD4-positive, alpha-beta T cell number	J:154205
	increased CD8-positive, alpha-beta T cell number	J:154205
	small lymphoid organs	J:154205
	small spleen	J:154205
Foxo1^tm1Flv/Foxo1^tm1Flv Foxp3^{tm4(YFP/icre)Ayr}/Foxp3⁺ (involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ)	abnormal inflammatory response	J:189962
	abnormal regulatory T cell physiology	J:189962
	enlarged lymph nodes	J:189962
	enlarged spleen	J:189962
	increased CD4-positive, alpha-beta T cell number	J:189962
	increased CD8-positive, alpha-beta T cell number	J:189962
	increased interferon-gamma secretion	J:189962
	increased regulatory T cell number	J:189962
	increased T cell number	J:189962
	increased T cell proliferation	J:189962
Foxo1^tm1Flv/Foxo1^tm1Flv Gt(ROSA)26Sor^{tm1(CAG-FOXO1,GFP)Moli}/Gt(ROSA)26Sor⁺ Foxp3^{tm4(YFP/icre)Ayr}/Foxp3⁺ (involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * C57BL/6)	immune system phenotype	J:189962
Foxo1^tm1Flv/Foxo1^tm1Flv Ifng^tm1Ts/Ifng^tm1Ts Foxp3^{tm4(YFP/icre)Ayr}/Foxp3⁺ (involves: 129S1/Sv * 129S6/SvEvTac * 129S7/SvEvBrd * 129X1/SvJ)	immune system phenotype	J:189962
	increased CD4-positive, alpha-beta T cell number	J:189962
	increased CD8-positive, alpha-beta T cell number	J:189962
Foxo1^tm1Flv/Foxo1^tm1Flv Ndor1^{Tg(UBC-cre/ERT2)1Ejb}/0 (involves: 129S/SvEv * 129S6/SvEvTac * C57BL/6)	increased interferon-gamma secretion	J:189962
Foxo1^tm1Flv/Foxo1^tm1Flv Rag1^tm1Mom/Rag1^tm1Mom Tg(CD2-Il7r)1Asin/? Tg(Cd4-cre)1Cwi/? Tg(TcraTcrb)425Cbn/? (involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * DBA/2)	decreased T cell number	J:147057
Foxo1^tm1Flv/Foxo1^tm1Flv Rag1^tm1Mom/Rag1^tm1Mom Tg(Cd4-cre)1Cwi/? Tg(TcraTcrb)425Cbn/? (involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * DBA/2)	decreased T cell number	J:147057
Foxo1^tm1Flv/Foxo1^tm1Flv Tg(Cd4-cre)1Cwi/? (involves: 129S6/SvEvTac * C57BL/6 * DBA/2)	abnormal CD4-positive, alpha-beta T cell physiology	J:147057
	abnormal CD8-positive, alpha-beta T cell physiology	J:147057
	abnormal T cell activation	J:147057
	abnormal T cell physiology	J:147057
	enlarged lymph nodes	J:147057
	increased anti-double stranded DNA antibody level	J:147057
	increased anti-nuclear antigen antibody level	J:147057
	increased single-positive T cell number	J:147057
	increased susceptibility to induced colitis	J:147057
	increased T cell proliferation	J:147057
Foxo1^tm1Rdp/Foxo1^tm1.1Rdp Igh-J^tm1Cgn/Igh^tm4Cgn Tg(Cr2-cre)3Cgn/0 (involves: 129P2/OlaHsd * 129S1/Sv)	absent marginal zone B cells	J:157297
	increased B cell number	J:157297
Foxo1^tm1Rdp/Foxo1^tm1Rdp Foxo3^tm1Rdp/Foxo3^tm1Rdp Foxo4^tm1Rdp/Foxo4^tm1Rdp Tg(Mx1-cre)1Cgn/0 (involves: 129S6/SvEvTac * C57BL/6 * CBA * FVB/N)	increased T cell derived lymphoma incidence	J:118179
Foxo1^tm2.1Dac/Foxo1^tm2.1Dac (B6.Cg-Foxo1^tm2.1Dac)	decreased circulating tumor necrosis factor level	J:179687
Foxo3^Gt(XAO26)Byg/Foxo3^Gt(XAO26)Byg (involves: 129P2/OlaHsd)	abnormal immune system organ morphology	J:93593
	abnormal T cell activation	J:93593
	abnormal T cell physiology	J:93593
	enlarged lymph nodes	J:93593
	enlarged spleen	J:93593
	increased inflammatory response	J:93593
	increased T cell proliferation	J:93593
	kidney inflammation	J:93593
	lung inflammation	J:93593
	lymphoid hyperplasia	J:93593
	salivary gland inflammation	J:93593
	spleen hyperplasia	J:93593
Foxo3^tm1.1Rdp/Foxo3^tm1.1Rdp (involves: 129S6/SvEvTac * FVB/N)	dermatitis	J:118179
Foxo3^tm1Nmt/Foxo3^tm1Nmt (B6.Cg-Foxo3^tm1Nmt)	abnormal NK cell morphology	J:123409
Foxo3^tm1Nmt/Foxo3^tm1Nmt (B6.Cg-Foxo3^tm1Nmt)	increased NK cell number	J:123409
Foxo6^{tm1(KOMP)Vlcg}/Foxo6^{tm1(KOMP)Vlcg} (B6J.B6NTac-Foxo6^{tm1(KOMP)Vlcg})	abnormal Kupffer cell morphology	J:236585
	impaired macrophage chemotaxis	J:236585
Foxp1^tm1.1Pwt/Foxp1^tm1.1Pwt Tg(Cd4-cre)1Cwi/0 (involves: 129 * C57BL/6 * DBA/2)	abnormal T cell activation	J:156832
	decreased CD4-positive, alpha-beta T cell number	J:156832
	decreased CD8-positive, alpha-beta T cell number	J:156832
	immune system phenotype	J:156832
	increased T cell apoptosis	J:156832
Foxp1^tm1Rao/Foxp1^tm1Rao (B6.129-Foxp1^tm1Rao)	abnormal B cell differentiation	J:112644
	abnormal B cell physiology	J:112644
	arrested B cell differentiation	J:112644
	decreased mature B cell number	J:112644
Foxp2^tm2.2Woen/Foxp2⁺ (involves: C57BL/6 * C57BL/6J)	increased CD4-positive, alpha-beta T cell number	J:150425
Foxp2^tm2.2Woen/Foxp2⁺ (involves: C57BL/6 * C57BL/6J)	increased CD8-positive, alpha-beta T cell number	J:150425
Foxp3^sf/Y (either: 129Rl.Cg-Foxp3^sf or (involves: 101/Rl * C3Hf/Rl * STOCK MR))	abnormal B cell physiology	J:11262
	abnormal lymph node B cell domain morphology	J:11262
	abnormal lymph node medullary cord morphology	J:11262
	abnormal lymph node morphology	J:11262
	abnormal lymph node T cell domain morphology	J:11262
	abnormal lymphocyte morphology	J:11262
	abnormal macrophage morphology	J:11262
	abnormal spleen morphology	J:11262
	abnormal spleen white pulp morphology	J:11262
	abnormal thymus cortex morphology	J:11262
	abnormal thymus morphology	J:11262
	absent spleen marginal zone	J:11262
	blepharitis	J:11262
	decreased spleen B cell follicle number	J:11262
	dermatitis	J:11262
	enlarged lymph nodes	J:11262
	increased IgG level	J:11262
	increased IgM level	J:11262
	increased inflammatory response	J:11262
	increased leukocyte cell number	J:11262
	increased spleen red pulp amount	J:11262
	increased spleen weight	J:11262
	liver inflammation	J:11262
	small thymus	J:11262
Foxp3^sf/Y (involves: 101/H * C3H/HeH * STOCK MR)	abnormal spleen morphology	J:10398
	conjunctivitis	J:10398
	increased leukocyte cell number	J:10398
	increased spleen red pulp amount	J:10398
	increased spleen weight	J:10398
	increased spleen white pulp amount	J:10398
	intermingled spleen red and white pulp	J:10398
Foxp3^sf/? (Not Specified)	liver inflammation	J:138808
Foxp3^sf/? (Not Specified)	lung inflammation	J:138808
Foxp3^sf/Y (B6.Cg-Foxp3^sf)	abnormal CD4-positive, alpha beta T cell morphology	J:82560
	abnormal CD4-positive, alpha-beta T cell physiology	J:82560
	decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:82560
Foxp3^sf/Y (B6.Cg-Foxp3^sf/J)	lung inflammation	J:125129
	salivary gland inflammation	J:125129
	skin inflammation	J:125129
Foxp3^sf Otc^spf/Y (involves: 129/Rl)	enlarged lymph nodes	J:20865
	enlarged spleen	J:20865
	increased CD4-positive, alpha-beta T cell number	J:20865
Foxp3^sf/Foxp3^sf Tg(Rorc-EGFP)1Ebe/? (involves: C57BL/6)	abnormal effector T cell morphology	J:137020
Foxp3^{tm1(CD2/CD52)Shori}/Foxp3^{tm1(CD2/CD52)Shori} (involves: C57BL/6)	decreased regulatory T cell number	J:171378
	increased susceptibility to type IV hypersensitivity reaction	J:171378
Foxp3^tm1(cre)Saka/Y (involves: BALB/c)	increased autoantibody level	J:140085
Foxp3^tm1(cre)Saka/Y (involves: BALB/c)	stomach inflammation	J:140085
Foxp3^tm1.1Ayr/Y (involves: 129S1/Sv * 129X1/SvJ)	abnormal CD4-positive, alpha beta T cell morphology	J:82560
	abnormal CD4-positive, CD25-positive, alpha-beta regulatory T cell morphology	J:82560
	enlarged lymph nodes	J:82560
	enlarged spleen	J:82560
	increased susceptibility to autoimmune disorder	J:82560
	skin inflammation	J:82560
Foxp3^tm1.1Ayr/Y (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	dermatitis	J:117743
	enlarged spleen	J:117743
	increased susceptibility to autoimmune disorder	J:117743
	liver inflammation	J:117743
	lung inflammation	J:117743
	lymph node inflammation	J:117743
Foxp3^tm1.1Ayr/Y Rag1^tm1Mom/Rag1^tm1Mom Tg(TcraTcrb)425Cbn/0 (Not Specified)	immune system phenotype	J:97029
Foxp3^tm1.1Ayr/Foxp3^tm1.1Ayr (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal T cell differentiation	J:125405
	decreased double-positive T cell number	J:125405
	dermatitis	J:117743
	enlarged spleen	J:117743
	increased susceptibility to autoimmune disorder	J:117743
	liver inflammation	J:117743
	lung inflammation	J:117743
	lymph node inflammation	J:117743
	thymus hypoplasia	J:125405
Foxp3^tm1.1Ayr/Foxp3^tm1.1Ayr Mir146^tm1.1Bal/Mir146^tm1.1Bal (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal lymphocyte physiology	J:167922
	blepharitis	J:167922
	conjunctivitis	J:167922
	decreased interferon-gamma secretion	J:167922
	dermatitis	J:167922
	increased regulatory T cell number	J:167922
Foxp3^tm1.1Mal/Foxp3^tm1.1Mal Lat^tm1.1Mal/Lat^tm1.1Mal (involves: 129S2/SvPas * C57BL/6)	abnormal regulatory T cell physiology	J:131351
	decreased regulatory T cell number	J:131351
	thymus hypoplasia	J:131351
Foxp3^tm1Ayr/Y Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	dermatitis	J:97029
	enlarged lymph nodes	J:97029
	enlarged spleen	J:97029
	increased susceptibility to autoimmune disorder	J:97029
Foxp3^tm1Ayr/Foxp3^tm1Ayr Foxn1^tm3(cre)Nrm/Foxn1⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	immune system phenotype	J:125405
Foxp3^tm1Ayr/Foxp3^tm1Ayr Tg(Cd4-cre)1Cwi/? (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)	abnormal T cell differentiation	J:125405
	decreased double-positive T cell number	J:125405
	thymus hypoplasia	J:125405
Foxp3^tm1Flv/Foxp3⁺ B9d2/Tgfb1^tm1Flv/Tgfb1^tm2Flv Tg(Cd4-cre)1Cwi/? (involves: 129S6/SvEvTac * C57BL/6 * DBA/2)	increased regulatory T cell number	J:123547
Foxp3^tm1Kuch/? Il6^tm1Kopf/Il6^tm1Kopf (involves: 129S2/SvPas * C57BL/6)	abnormal CD4-positive T cell differentiation	J:123352
	decreased circulating interleukin-6 level	J:123352
	decreased interleukin-17 secretion	J:123352
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:123352
	increased regulatory T cell number	J:123352
Foxp3^tm1Tch/Y (C.129X1-Foxp3^tm1Tch)	abnormal chemokine level	J:117165
	abnormal cytokine secretion	J:117165
	abnormal inflammatory response	J:117165
	abnormal lymphocyte physiology	J:117165
	absent regulatory T cells	J:117165
	dermatitis	J:117165
	enlarged spleen	J:117165
	increased activated T cell number	J:117165
	increased CD4-positive, alpha-beta T cell number	J:117165
	increased CD8-positive, alpha-beta T cell number	J:117165
	increased circulating interferon-gamma level	J:117165
	increased circulating interleukin-4 level	J:117165
	increased circulating interleukin-5 level	J:117165
	increased circulating interleukin-6 level	J:117165
	increased circulating interleukin-10 level	J:117165
	increased circulating tumor necrosis factor level	J:117165
	increased eosinophil cell number	J:117165
	increased IgE level	J:117165
	increased IgG1 level	J:117165
	increased leukocyte cell number	J:117165
	increased lymphocyte cell number	J:117165
	increased monocyte cell number	J:117165
	respiratory system inflammation	J:117165
Foxp3^tm1Tch/Y (B6.129X1-Foxp3^tm1Tch)	abnormal inflammatory response	J:117165
	dermatitis	J:117165
	increased eosinophil cell number	J:117165
	increased IgE level	J:117165
	increased leukocyte cell number	J:117165
	increased lymphocyte cell number	J:117165
	increased monocyte cell number	J:117165
	respiratory system inflammation	J:117165
Foxp3^tm1Tch/Y Stat6^tm1Gru/Stat6^tm1Gru (C.129-Stat6^tm1Gru Foxp3^tm1Tch)	abnormal cytokine secretion	J:117165
	immune system phenotype	J:117165
	increased circulating interferon-gamma level	J:117165
	increased eosinophil cell number	J:117165
Foxp3^{tm2.1(EGFP/cre)Shori}/Y (involves: 129 * C57BL/6)	decreased regulatory T cell number	J:234397
Foxp3^{tm2.1(EGFP/cre)Shori}/Y Pdcd1^tm1Hon/Pdcd1^tm1Hon (involves: 129 * 129S2/SvPas * C57BL/6)	enlarged lymph nodes	J:234397
	enlarged spleen	J:234397
	increased effector memory T-helper cell number	J:234397
	increased susceptibility to autoimmune disorder	J:234397
	lymph node hyperplasia	J:234397
	pancreas inflammation	J:234397
	spleen hyperplasia	J:234397
Foxp3^tm2Ayr/Y (involves: 129S1/Sv * 129X1/SvJ)	immune system phenotype	J:97029
Foxp3^tm2Ayr/? Zap70^rps/Zap70^rps (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:211510
	abnormal double-positive T cell morphology	J:211510
	abnormal regulatory T cell number	J:211510
	abnormal T cell differentiation	J:211510
	decreased CD4-positive, alpha-beta T cell number	J:211510
	decreased CD8-positive, alpha-beta T cell number	J:211510
	immune system phenotype	J:211510
Foxp3^tm2Ayr/Foxp3⁺ Rnf128^tm1Cdon/Rnf128^tm1Cdon (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal regulatory T cell physiology	J:160681
Foxp3^tm2Ayr/Foxp3^tm2Ayr (involves: 129S1/Sv * 129X1/SvJ)	immune system phenotype	J:97029
Foxp3^tm2Flv/Y (involves: C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:118631
	abnormal CD8-positive, alpha-beta T cell physiology	J:118631
	abnormal immune system physiology	J:118631
	blepharitis	J:118631
	enlarged lymph nodes	J:118631
	enlarged spleen	J:118631
	increased autoantibody level	J:118631
Foxp3^tm2Tch/Y (C.129X1-Foxp3^tm2Tch)	immune system phenotype	J:120713
Foxp3^tm2Tch/Foxp3⁺ (C.129X1-Foxp3^tm2Tch)	immune system phenotype	J:120713
Foxp3^{tm3(HBEGF/GFP)Ayr}/Foxp3⁺ Gpr174^tm1Cys/Gpr174⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:222307
Foxp3^{tm3(HBEGF/GFP)Ayr}/Foxp3^{tm3(HBEGF/GFP)Ayr} (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:117743
	abnormal dendritic cell physiology	J:117743
	conjunctivitis	J:117743
	decreased T cell number	J:117743
	dermatitis	J:117743
	enlarged spleen	J:117743
	increased dendritic cell number	J:117743
	increased susceptibility to autoimmune disorder	J:117743
	liver inflammation	J:117743
	lung inflammation	J:117743
	lymph node inflammation	J:117743
Foxp3^tm3Tch/Y (C.129X1-Foxp3^tm3Tch)	abnormal CD4-positive, alpha beta T cell morphology	J:120636
	abnormal CD4-positive, alpha-beta T cell physiology	J:120636
	abnormal cytokine secretion	J:120636
	abnormal immune system organ morphology	J:120636
	abnormal lymphocyte physiology	J:120636
	abnormal regulatory T cell physiology	J:120636
	abnormal T cell subpopulation ratio	J:120636
	colitis	J:120636
	enlarged lymph nodes	J:120636
	enlarged spleen	J:120636
	increased T cell proliferation	J:120636
	thymus hypoplasia	J:120636
Foxp3^tm3Tch/Foxp3⁺ (C.129X1-Foxp3^tm3Tch)	abnormal CD4-positive, alpha-beta T cell physiology	J:120636
	decreased T cell number	J:120636
	decreased thymocyte number	J:120636
	increased T cell apoptosis	J:120636
Foxp3^{tm4(YFP/icre)Ayr}/Y Zfp91^tm1Smoc/Zfp91^tm1Smoc (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal regulatory T cell physiology	J:306129
	decreased regulatory T cell number	J:306129
	increased CD8-positive, alpha-beta T cell number	J:306129
	increased susceptibility to autoimmune disorder	J:306129
	increased susceptibility to induced colitis	J:306129
Foxp3^{tm4(YFP/icre)Ayr}/Foxp3⁺ Nr4a2^tm1.1Pcn/Nr4a2^tm1.1Pcn (involves: 129S1/Sv * 129X1/SvJ)	abnormal regulatory T cell morphology	J:205658
	abnormal regulatory T cell physiology	J:205658
Foxp3^{tm4(YFP/icre)Ayr}/Foxp3^{tm4(YFP/icre)Ayr} Ikzf4^tm1Djr/Ikzf4^tm1Djr (involves: 129S1/Sv * 129X1/SvJ)	chronic inflammation	J:294549
	decreased regulatory T cell number	J:294549
	enlarged lymph nodes	J:294549
	enlarged spleen	J:294549
	glomerulonephritis	J:294549
	granulomatous inflammation	J:294549
	increased germinal center B cell number	J:294549
	increased immunoglobulin level	J:294549
	increased spleen B cell follicle number	J:294549
	increased spleen germinal center number	J:294549
	increased susceptibility to experimental autoimmune encephalomyelitis	J:294549
	increased T cell number	J:294549
	increased T follicular helper cell number	J:294549
	small intestinal inflammation	J:294549
Foxp3^tm5.2Ayr/Foxp3^tm5.2Ayr (involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ)	abnormal gut-associated lymphoid tissue morphology	J:156942
	abnormal intraepithelial T cell morphology	J:156942
	abnormal mesenteric lymph node morphology	J:156942
	abnormal Peyer's patch morphology	J:156942
	abnormal T cell differentiation	J:156942
	decreased regulatory T cell number	J:156942
	increased T cell number	J:156942
Foxp3^tm6.2Ayr/Foxp3^tm6.2Ayr (involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ)	decreased regulatory T cell number	J:156942
Foxp3^tm7.2Ayr/Foxp3⁺ (involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ)	decreased regulatory T cell number	J:156942
Foxp3^tm7.2Ayr/Foxp3^tm7.2Ayr (involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ)	abnormal regulatory T cell morphology	J:156942
	decreased regulatory T cell number	J:156942
Foxp3^tm8Ayr/Y (B6.129-Foxp3^tm8Ayr)	autoimmune response	J:157377
Foxp3^{tm9(EGFP/cre/ERT2)Ayr}/Foxp3⁺ Il1r2^tm1.1Epi/Il1r2^tm1.1Epi (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * C57BL/6NTac)	abnormal adaptive immunity	J:347877
	abnormal alpha-beta T cell number	J:347877
	increased CD4-positive, alpha-beta T cell number	J:347877
	increased IgG level	J:347877
	increased spleen germinal center size	J:347877
	increased T follicular helper cell number	J:347877
Foxq1^sa-e1/Foxq1^sa-e1 (involves: 101/Rl * C3H/Rl)	abnormal lymphocyte cell number	J:75422
Foxq1^sa/Foxq1^sa (involves: 101/Rl * C3H/Rl)	impaired natural killer cell mediated cytotoxicity	J:7649
Foxq1^sa/Foxq1^sa Lyst^bg/Lyst^bg (involves: 101/Rl * C3H/Rl * C57BL/6J * C57BL10/Rl)	enlarged lymph nodes	J:5311
	increased susceptibility to infection	J:5311
	interstitial pneumonia	J:15166, J:5311
Foxq1^sa/Foxq1^sa Lyst^bg/Lyst^bg (involves: 101/Rl * C3H/Rl * C57BL10/Rl)	enlarged spleen	J:5311
	interstitial pneumonia	J:5311
	lung inflammation	J:5311
Foxr1^em1(IMPC)Tcp/Foxr1⁺ (C57BL/6NCrl-Foxr1^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
	small spleen	J:211773
Foxr1^em1(IMPC)Tcp/Foxr1^em1(IMPC)Tcp (C57BL/6NCrl-Foxr1^em1(IMPC)Tcp/Tcp)	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
Foxred1^em1(IMPC)Bay/Foxred1⁺ (C57BL/6N-Foxred1^em1(IMPC)Bay/Bay)	increased spleen weight	J:211773
Fpr1^tm1Gao/Fpr1^tm1Gao (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal innate immunity	J:53354
	impaired neutrophil chemotaxis	J:53354
	increased susceptibility to bacterial infection	J:53354
	increased susceptibility to bacterial infection induced morbidity/mortality	J:53354
Fpr2^tm1.1Jimw/Fpr2^tm1.1Jimw Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * 129X1/SvJ)	decreased susceptibility to induced colitis	J:197568
Fpr2^tm1.2Jimw/Fpr2^tm1.2Jimw (B6.129X1-Fpr2^tm1.2Jimw)	abnormal cytokine secretion	J:160074
	abnormal dendritic cell physiology	J:160074
	abnormal innate immunity	J:160074
	decreased dendritic cell number	J:160074
	decreased IgE level	J:160074
	decreased IgG1 level	J:160074
	decreased IgG2b level	J:160074
	decreased immunoglobulin level	J:160074
	decreased inflammatory response	J:160074
	decreased interferon-gamma secretion	J:160074
	decreased interleukin-2 secretion	J:160074
	decreased interleukin-4 secretion	J:160074
	decreased interleukin-5 secretion	J:160074
	decreased interleukin-13 secretion	J:160074
	impaired macrophage chemotaxis	J:160074
	impaired neutrophil chemotaxis	J:160074
	small lymph nodes	J:160074
Fpr2^tm1.2Jimw/Fpr2^tm1.2Jimw (involves: 129X1/SvJ)	abnormal dendritic cell chemotaxis	J:199611
	abnormal dendritic cell physiology	J:199611
	colitis	J:197568
	decreased acute inflammation	J:197568
	decreased dendritic cell number	J:199611
Fpr2^tm1Rjf/Fpr2^tm1Rjf (involves: 129S/SvEv * C57BL/6)	abnormal neutrophil physiology	J:159658
	impaired macrophage chemotaxis	J:159658
	increased acute inflammation	J:159658
	increased susceptibility to induced arthritis	J:159658
fpw/fpw (involves: C3H/HeJ * C57BL/6J)	decreased circulating interferon-gamma level	J:151726
	decreased circulating interleukin-1 alpha level	J:151726
	decreased circulating interleukin-6 level	J:151726
	increased circulating interleukin-10 level	J:151726
	increased circulating tumor necrosis factor level	J:151726
Fras1^{em1(IMPC)Ccpcz}/Fras1⁺ (C57BL/6NCrl-Fras1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
Frmd3^em1(IMPC)J/Frmd3^em1(IMPC)J (C57BL/6NJ-Frmd3^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
Frmd8^em2Smoc/Frmd8^em2Smoc Tg(Vil1-cre)997Gum/0 (involves: C57BL/6J * SJL)	increased spleen weight	J:338904
	increased susceptibility to colitis induced morbidity/mortality	J:338904
	increased susceptibility to induced colitis	J:338904
Fryl^{Gt(Ayu21-T312)Imeg}/Fryl^{Gt(Ayu21-T312)Imeg} (B6J.Cg-Fryl^{Gt(Ayu21-T312)Imeg})	kidney inflammation	J:260667
Fscn1^{Gt(OST124903)Lex}/Fscn1^{Gt(OST124903)Lex} (B6.129S5-Fscn1^{Gt(OST124903)Lex})	abnormal dendritic cell chemotaxis	J:169408
	abnormal dendritic cell physiology	J:169408
	abnormal Langerhans cell physiology	J:169408
Fsd2^em1(IMPC)Mbp/Fsd2^em1(IMPC)Mbp (C57BL/6N-Fsd2^em1(IMPC)Mbp/Ucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Fshr^tm1Saco/Fshr^tm1Saco (involves: 129)	enlarged spleen	J:70933
Fshr^tm1Saco/Fshr^tm1Saco (involves: 129)	increased pre-B cell number	J:65577
Fstl1^{tm1b(EUCOMM)Hmgu}/Fstl1^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Fstl1^{tm1b(EUCOMM)Hmgu}/H)	decreased neutrophil cell number	J:211773
	increased lymphocyte cell number	J:211773
Fth1^tm1.1Lck/Fth1^tm1.1Lck Tg(Mx1-cre)1Cgn/0 (B6.Cg-Fth1^tm1.1Lck Tg(Mx1-cre)1Cgn)	decreased spleen iron level	J:166515
	liver inflammation	J:166515
Ftl1^tm1.1Ruvi/Ftl1^tm1.1Ruvi (involves: 129 * C57BL/6)	abnormal mononuclear phagocyte morphology	J:244236
Fto^tm1.2Pzg/Fto^tm1.2Pzg (involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6)	dermatitis	J:166984
Fto^tm1.3Pzg/Fto^tm1.3Pzg (involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6)	dermatitis	J:166984
Fts/Fts⁺ (involves: C57BL/6 * SJL)	thymus hyperplasia	J:20159
Fts/Fts⁺ (B6.Cg-Fts)	abnormal CD4-positive T cell differentiation	J:108193
	abnormal T cell morphology	J:108193
	abnormal T cell physiology	J:108193
	increased thymocyte number	J:108193
	thymus hyperplasia	J:108193
Fubp1^em1(IMPC)Mbp/Fubp1⁺ (C57BL/6N-Fubp1^em1(IMPC)Mbp/Ucd)	abnormal lymph node morphology	J:211773
Fubp1^em1(IMPC)Mbp/Fubp1⁺ (C57BL/6N-Fubp1^em1(IMPC)Mbp/Ucd)	enlarged lymph nodes	J:211773
Fubp1^tm1.1Dlev/Fubp1^tm1.1Dlev (involves: 129 * C57BL/6)	decreased B cell number	J:229985
	lymphoid hypoplasia	J:229985
	spleen hypoplasia	J:229985
	thymus hypoplasia	J:229985
Fundc2^tm1Qim/Fundc2^tm1Qim (involves: C57BL/6)	immune system phenotype	J:301633
Furin^tm1Jwmc/Furin^tm1Jwmc Tg(Cd4-cre)1Cwi/0 (involves: 129P2/OlaHsd * C57BL/6 * SJL)	abnormal regulatory T cell physiology	J:204761
Fus^{Gt(U3NeoSV1)HO14Ggh}/Fus^{Gt(U3NeoSV1)HO14Ggh} (B6.129S2-Fus^{Gt(U3NeoSV1)HO14Ggh})	abnormal immunoglobulin level	J:60213
	decreased B cell number	J:60213
	decreased lymphocyte cell number	J:60213
	lymphoid hypoplasia	J:60213
	small thymus	J:60213
Fut2^tm1Sdo/Fut2^tm1Sdo (B6.129X1-Fut2^tm1Sdo)	increased susceptibility to fungal infection	J:90993
Fut4^tm1Jbl/Fut4^tm1Jbl (B6.129S2-Fut4^tm1Jbl)	impaired leukocyte tethering or rolling	J:79397
	increased eosinophil cell number	J:79397
	increased granulocyte number	J:79397
	increased monocyte cell number	J:79397
	increased neutrophil cell number	J:79397
Fut4^tm1Jbl/Fut4^tm1Jbl Fut7^tm1Jbl/Fut7^tm1Jbl (B6.129S2-Fut7^tm1Jbl Fut4^tm1Jbl)	abnormal immune system organ morphology	J:79397
	abnormal leukocyte migration	J:79397
	abnormal leukocyte physiology	J:79397
	abnormal lymph node primary follicle morphology	J:79397
	abnormal neutrophil physiology	J:79397
	decreased susceptibility to bacterial infection	J:115682
	decreased susceptibility to type IV hypersensitivity reaction	J:79388
	impaired leukocyte tethering or rolling	J:79397
	increased leukocyte cell number	J:79397
	increased neutrophil cell number	J:79397
	lymph node hypoplasia	J:79388, J:79397
	small lymph nodes	J:79397
Fut7^tm1Brs/Fut7^tm1Brs (involves: 129 * C57BL/6)	immune system phenotype	J:64232
Fut7^tm1Jbl/Fut7^tm1Jbl (involves: 129S2/SvPas * C57BL/6J * DBA/2J)	abnormal granulocyte physiology	J:35023
	abnormal immune system physiology	J:35023
	abnormal leukocyte adhesion	J:35023
	abnormal leukocyte migration	J:35023
	abnormal leukocyte physiology	J:35023
	abnormal leukocyte tethering or rolling	J:35023
	abnormal lymph node primary follicle morphology	J:35023
	impaired neutrophil recruitment	J:35023
Fut7^tm1Jbl/Fut7^tm1Jbl (B6.129S2-Fut7^tm1Jbl)	decreased susceptibility to type IV hypersensitivity reaction	J:79388, J:74776
Fut7^tm1Jbl/Fut7^tm1Jbl (B6.129S2-Fut7^tm1Jbl)	impaired neutrophil recruitment	J:79397
Fut8^{em1(IMPC)Wtsi}/Fut8^{em1(IMPC)Wtsi} (C57BL/6N-Fut8^{em1(IMPC)Wtsi}/Wtsi)	blood in lymph vessels	J:239583
Fv4^r/Fv4⁺ (involves: AKR/J * BALB/c * FRG)	decreased susceptibility to Retroviridae infection	J:5714, J:5684
Fxn^tm1Mkn/Fxn^tm1Mkn Tg(FXN)YG8Pook/0 (involves: 129/Sv * C57BL/6 * CBA)	brain inflammation	J:216422
Fxn^tm1Mkn/Fxn^tm1Pand (involves: 129/Sv * C57BL/6)	brain inflammation	J:216422
Fxr1^tm1Dln/Fxr1^tm1Dln (involves: 129P2/OlaHsd * C57BL/6)	small spleen	J:91191
Fyb1^tm1Gak/Fyb1^tm1Gak (B6.129-Fyb1^tm1Gak)	immune system phenotype	J:112087
Fyb1^tm1Gak/Fyb1^tm1Gak (involves: 129S1/Sv * 129X1/SvJ)	abnormal leukocyte adhesion	J:111368
	abnormal T cell physiology	J:126545
	decreased interleukin-2 secretion	J:111368, J:126545
	decreased T cell proliferation	J:111368, J:126545
	decreased thymocyte number	J:111368
Fyn^tm1Rmp/Fyn^tm1Rmp (involves: 129S2/SvPas * C57BL/6)	abnormal T cell activation	J:70886
	abnormal thymocyte activation	J:70886
	decreased T cell proliferation	J:70886
Fyn^tm1Rmp/Fyn^tm1Rmp (involves: 129S2/SvPas)	decreased gamma-delta T cell number	J:37062
Fyn^tm1Rmp/Fyn^tm1Rmp (involves: 129S2/SvPas)	decreased T cell number	J:37062
Fyn^tm1Rmp/Fyn^tm1Rmp (B6.129S2-Fyn^tm1Rmp)	abnormal eosinophil physiology	J:114287
	abnormal interleukin-4 secretion	J:114287
	decreased IgE level	J:114287
	decreased interleukin-2 secretion	J:114287
	increased interleukin-5 secretion	J:114287
	increased susceptibility to type I hypersensitivity reaction	J:114287
Fyn^tm1Rmp/Fyn^tm1Rmp Lck^tm1Mak/Lck^tm1Mak (involves: 129S2/SvPas)	abnormal alpha-beta intraepithelial T cell morphology	J:112977
	abnormal NK T cell number	J:37940
	absent CD4-positive, alpha-beta T cells	J:37940
	absent CD8-positive, alpha-beta T cells	J:37940
	absent T cells	J:37062
	arrested T cell differentiation	J:37062, J:37940
	decreased double-positive T cell number	J:37940
	decreased gamma-delta intraepithelial T cell number	J:112977, J:37940
	thymus hypoplasia	J:37062, J:37940
Fyn^tm1Sor/Fyn^tm1Sor (either: 129S7/SvEvBrd-Fyn^tm1Sor or (involves: 129S7/SvEvBrd * C57BL/6J))	abnormal immune cell physiology	J:2242
	abnormal T cell clonal deletion	J:2242
	abnormal T cell physiology	J:2242
	abnormal thymocyte activation	J:2242
	decreased interleukin-2 secretion	J:2242
	decreased T cell proliferation	J:2242
	increased IgG2a level	J:2242
	increased IgM level	J:2242
Fyn^tm1Sor/Fyn^tm1Sor (B6.129S7-Fyn^tm1Sor)	abnormal CD4-positive, alpha-beta T cell physiology	J:93886
	abnormal NK cell physiology	J:187430
	abnormal T cell proliferation	J:93886
	decreased IgE level	J:93886
	decreased interferon-gamma secretion	J:187430
Fyn^tm1Sor/Fyn^tm1Sor (involves: 129S7/SvEvBrd)	abnormal chemokine level	J:80658
Fyn^tm1Sor/Fyn^tm1Sor (involves: 129S7/SvEvBrd)	abnormal macrophage physiology	J:80658
Fyn^tm1Sor/Fyn^tm1Sor Lck^tm1Litt/Lck^tm1.1Litt Tnfrsf4^tm2(cre)Nik/Tnfrsf4⁺ (involves: 129S7/SvEvBrd * 129X1/SvJ)	abnormal regulatory T cell physiology	J:152472
	decreased regulatory T cell number	J:152472
	decreased T cell proliferation	J:152472
	enlarged lymph nodes	J:152472
	increased regulatory T cell number	J:152472
	increased T cell number	J:152472
Fyn^tm1Sor/Fyn^tm1Sor Yes1^tm1Sor/Yes1^tm1Sor (involves: 129S7/SvEvBrd)	enlarged spleen	J:20346
	increased spleen white pulp amount	J:20346
	myeloid hyperplasia	J:20346
Fyn^tm1Yik/Fyn^tm1Yik (involves: C57BL/6 * CBA)	abnormal cytokine secretion	J:99347
	abnormal interleukin secretion	J:99347
	increased susceptibility to experimental autoimmune uveoretinitis	J:99347
	increased tumor necrosis factor secretion	J:99347
Fyn^tm1Yik/Fyn^tm1Yik Ptk2^tm1Lfr/Ptk2⁺ (involves: 129X1/SvJ * C57BL/6 * CBA)	abnormal T cell differentiation	J:110771
	decreased double-positive T cell number	J:110771
	decreased thymocyte number	J:110771
	thymus cortex atrophy	J:110771
Fzd1^em1(IMPC)Mbp/Fzd1^em1(IMPC)Mbp (C57BL/6N-Fzd1^em1(IMPC)Mbp/MbpMmucd)	increased eosinophil cell number	J:211773
	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
	increased monocyte cell number	J:211773
Fzd9^tm1Uta/Fzd9^tm1Uta (involves: 129S6/SvEvTac * 129X1/SvJ)	abnormal lymph node medullary cord morphology	J:98133
	abnormal lymph node morphology	J:98133
	abnormal spleen marginal zone morphology	J:98133
	abnormal spleen red pulp morphology	J:98133
	decreased B cell number	J:98133
	decreased pre-B cell number	J:98133
	decreased pro-B cell number	J:98133
	enlarged lymph nodes	J:98133
	enlarged spleen	J:98133
	increased eosinophil cell number	J:98133
	increased leukocyte cell number	J:98133
	increased monocyte cell number	J:98133
	increased neutrophil cell number	J:98133
	thymus atrophy	J:98133
G2e3^em1(IMPC)Tcp/G2e3^em1(IMPC)Tcp (C57BL/6NCrl-G2e3^em1(IMPC)Tcp/Tcp)	abnormal spleen morphology	J:211773
G6pc2^tm1.1Pesa/G6pc2^tm1.1Pesa (NOD.129S2-G6pc2^tm1.1Pesa)	abnormal CD8-positive, alpha beta T cell morphology	J:160286
	abnormal CD8-positive, alpha-beta T cell physiology	J:160286
	decreased interferon-gamma secretion	J:160286
	decreased T cell proliferation	J:160286
	immune system phenotype	J:160286
G6pc3^tm1Jyc/G6pc3^tm1Jyc (involves: 129S4/SvJae * C57BL/6)	abnormal neutrophil physiology	J:120741
	decreased neutrophil cell number	J:120741
	impaired granulocyte bactericidal activity	J:120741
	increased granulocyte number	J:120741
	increased susceptibility to bacterial infection	J:120741
G6pd2^em1(IMPC)Tcp/G6pd2^em1(IMPC)Tcp (C57BL/6NCrl-G6pd2^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Gab2^tm1Gsf/Gab2^tm1Gsf (involves: BALB/c)	abnormal response to infection	J:122213
Gab2^tm1Gsf/Gab2^tm1Gsf (involves: BALB/c)	decreased susceptibility to Retroviridae infection	J:122429
Gab2^tm1Hhg/Gab2^tm1Hhg (involves: 129S4/SvJae)	decreased mast cell degranulation	J:70424
	decreased mast cell number	J:70424
	decreased susceptibility to type I hypersensitivity reaction	J:70424
	immune system phenotype	J:70424
Gab2^tm1Pngr/Gab2^tm1Pngr (B6.Cg-Gab2^tm1Pngr)	abnormal osteoclast differentiation	J:97515
	abnormal osteoclast morphology	J:97515
	decreased osteoclast cell number	J:97515
Gab2^tm1Thir/Gab2^tm1Thir (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal mast cell differentiation	J:75092
	abnormal mast cell physiology	J:75092
	decreased mast cell number	J:75092
Gab2^tm2.1Thir/Gab2^tm2.1Thir (involves: 129T/SvJcl * C57BL/6Jcl)	immune system phenotype	J:178045
Gab2^tm3.1Thir/Gab2^tm3.1Thir (involves: 129T/SvJcl * C57BL/6Jcl)	decreased mast cell degranulation	J:178045
	decreased mast cell number	J:178045
	decreased susceptibility to type I hypersensitivity reaction	J:178045
	immune system phenotype	J:178045
Gab2^tm4.1Thir/Gab2^tm4.1Thir (involves: 129T/SvJcl * C57BL/6Jcl)	decreased mast cell degranulation	J:178045
	decreased mast cell number	J:178045
	decreased susceptibility to type I hypersensitivity reaction	J:178045
	immune system phenotype	J:178045
Gab3^em1Khoe/Gab3^em1Khoe (C57BL/6-Gab3^em1Khoe)	abnormal mature NK cell morphology	J:291290
	abnormal NK cell physiology	J:291290
	abnormal uterine NK cell morphology	J:291290
	decreased NK cell number	J:291290
	immune system phenotype	J:291290
Gab3^m1Khoe/Gab3^m1Khoe (C57BL/6-Gab3^m1Khoe)	abnormal mature NK cell morphology	J:291290
	abnormal NK cell physiology	J:291290
	abnormal uterine NK cell morphology	J:291290
	decreased NK cell number	J:291290
	immune system phenotype	J:291290
Gabarapl2^{tm1b(EUCOMM)Hmgu}/Gabarapl2⁺ (C57BL/6N-Gabarapl2^{tm1b(EUCOMM)Hmgu}/H)	decreased lymphocyte cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Gabpa^Gt(XH074)Byg/Gabpa^Gt(XH074)Byg (involves: 129P2/OlaHsd * C57BL/6)	decreased thymocyte number	J:92671
	small thymus	J:92671
Gabpb1^tm1Hhx/Gabpb1^tm1Hhx (involves: 129 * C57BL/6)	immune system phenotype	J:137300
Gabpb2^{Gt(RRJ488)Byg}/Gabpb2^{Gt(RRJ488)Byg} (involves: 129P2/OlaHsd)	increased B cell proliferation	J:141846
	increased IgG1 level	J:141846
	increased IgM level	J:141846
	increased spleen germinal center number	J:141846
Gabra5^{em1(IMPC)Ccpcz}/Gabra5^{em1(IMPC)Ccpcz} (C57BL/6N-Gabra5^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
	small spleen	J:211773
Gabrb3^tm2.1Geh/Gabrb3^tm2.1Geh Tg(Cd4-cre)1Cwi/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)	abnormal CD4-positive T cell differentiation	J:333883
	abnormal CD4-positive, CD25-positive, alpha-beta regulatory T cell morphology	J:333883
	abnormal T-helper 17 cell differentiation	J:333883
	immune system phenotype	J:333883
	increased susceptibility to experimental autoimmune encephalomyelitis	J:333883
Gabrg1^{em1(IMPC)Ccpcz}/Gabrg1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Gabrg1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	small spleen	J:211773
Gad2^tm1Miya/Gad2^tm1Miya (NOD.129P2-Gad2^tm1Miya)	pancreas inflammation	J:88785
Gadd45a^tm1Ajf/Gadd45a^tm1Ajf (either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129X1/SvJ * C57BL/6))	abnormal lymphopoiesis	J:76041
	decreased basophil cell number	J:76041
	decreased eosinophil cell number	J:76041
	decreased leukocyte cell number	J:76041
	decreased lymphocyte cell number	J:76041
	glomerulonephritis	J:76041
	increased anti-double stranded DNA antibody level	J:76041
	increased anti-histone antibody level	J:76041
	increased anti-single stranded DNA antibody level	J:76041
	increased autoantibody level	J:76041
	increased IgG1 level	J:76041
	increased IgM level	J:76041
	increased inflammatory response	J:76041
	increased T cell number	J:76041
	increased T cell proliferation	J:76041
	increased thymocyte number	J:57882
	increased thymus weight	J:57882
Gadd45b^tm1Flv/Gadd45b^tm1Flv (involves: 129S6/SvEvTac)	abnormal CD4-positive, alpha-beta T cell physiology	J:87396
	abnormal dendritic cell physiology	J:87396
	abnormal T-helper 1 cell differentiation	J:87396
	abnormal T-helper 1 physiology	J:87396
	abnormal T-helper 2 physiology	J:87396
	decreased interferon-gamma secretion	J:87396
	decreased interleukin-2 secretion	J:87396
	decreased interleukin-4 secretion	J:87396
	decreased interleukin-6 secretion	J:87396
	decreased interleukin-12 secretion	J:87396
Gadd45b^tm1Flv/Gadd45b^tm1Flv (B6.129S6-Gadd45b^tm1Flv)	abnormal T-helper 1 physiology	J:118837
	glomerulonephritis	J:118837
	increased interferon-gamma secretion	J:118837
	increased susceptibility to experimental autoimmune encephalomyelitis	J:118837
	increased T cell proliferation	J:118837
	spleen hyperplasia	J:118837
Gadd45b^tm1Flv/Gadd45b^tm1Flv Gadd45g^tm1Flv/Gadd45g^tm1Flv (involves: 129S1/Sv * 129S6/SvEvTac)	abnormal T-helper 1 cell differentiation	J:87396
Gadd45b^tm1Flv/Gadd45b^tm1Flv Gadd45g^tm1Flv/Gadd45g^tm1Flv (involves: 129S1/Sv * 129S6/SvEvTac * C57BL/6)	glomerulonephritis	J:118837
	increased anti-double stranded DNA antibody level	J:118837
	increased anti-histone antibody level	J:118837
	increased IgG1 level	J:118837
	increased IgM level	J:118837
	increased mature B cell number	J:118837
	increased memory T cell number	J:118837
	spleen hyperplasia	J:118837
Gadd45g^tm1Flv/Gadd45g^tm1Flv (involves: 129S1/Sv)	abnormal NK cell physiology	J:87396
	abnormal T-helper 1 cell differentiation	J:87396
	abnormal T-helper 1 physiology	J:69475
	abnormal type IV hypersensitivity reaction	J:69475
	decreased interferon-gamma secretion	J:87396, J:69475
Gadd45g^tm1Jni/Gadd45g^tm1Jni (involves: 129P2/OlaHsd)	immune system phenotype	J:68832
Gak^{em1(IMPC)Ccpcz}/Gak⁺ (C57BL/6NCrl-Gak^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Galc^tm1Wngr/Galc^tm1Wngr (involves: 129S2/SvPas)	abnormal immune system physiology	J:78691
Galc^twi-5J/Galc^twi-5J (BXD32/TyJ-Galc^twi-5J/J)	abnormal leukocyte morphology	J:199132
Galc^twi/Galc^twi (B6.CE-Galc^twi/J)	abnormal microglial cell morphology	J:108359
Galc^twi/Galc^twi (B6.CE-Galc^twi/J)	abnormal osteoclast physiology	J:165361
Galc^twi/Galc^twi (involves: C57BL/6J * CE/J)	abnormal macrophage morphology	J:6390
Galc^twi/Galc^twi (involves: CE/J)	CNS inflammation	J:78223
Galc^twi/Galc^twi Glb1^tm1Adz/Glb1⁺ (involves: 129P2/OlaHsd * C57BL/6J * CE/J)	immune system phenotype	J:63197
Galc^twi/Galc^twi Glb1^tm1Adz/Glb1^tm1Adz (involves: 129P2/OlaHsd * C57BL/6J * CE/J)	abnormal macrophage physiology	J:63197
	enlarged spleen	J:63197
Galc^twi/Galc^twi Il6⁺/? (involves: 129S2/SvPas * C57BL/6J * CE/J)	abnormal tumor necrosis factor level	J:56656
Galc^twi/Galc^twi Il6^tm1Kopf/Il6^tm1Kopf (involves: 129S2/SvPas * C57BL/6J * CE/J)	abnormal tumor necrosis factor level	J:56656
Galnt1^tm1.1Jxm/Galnt1^tm1.1Jxm (B6NHsd.Cg-Galnt1^tm1.1Jxm)	abnormal immune system physiology	J:128982
	decreased B cell number	J:128982
	decreased basophil cell number	J:128982
	decreased eosinophil cell number	J:128982
	decreased germinal center B cell number	J:128982
	decreased IgG level	J:128982
	decreased leukocyte cell number	J:128982
	decreased plasma cell number	J:128982
	decreased spleen germinal center number	J:128982
	decreased T cell number	J:128982
	impaired leukocyte tethering or rolling	J:128982
	increased lymphocyte cell number	J:128982
	lymph node hypoplasia	J:128982
Galnt3^{em1(IMPC)Ccpcz}/Galnt3^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Galnt3^{em1(IMPC)Ccpcz}/Ccpcz)	increased eosinophil cell number	J:211773
Galnt3^tm1.1Cfg/Galnt3^tm1.1Cfg (involves: C57BL/6)	decreased monocyte cell number	J:217719
Galnt13^em1(IMPC)Mbp/Galnt13^em1(IMPC)Mbp (C57BL/6N-Galnt13^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	small spleen	J:211773
Galnt18^{tm1b(KOMP)Wtsi}/Galnt18^{tm1b(KOMP)Wtsi} (C57BL/6N-Galnt18^{tm1b(KOMP)Wtsi}/Wtsi)	increased NK cell number	J:211773
Galr1^em1(IMPC)H/Galr1^em1(IMPC)H (C57BL/6N-Galr1^em1(IMPC)H/H)	decreased lymphocyte cell number	J:211773
	enlarged spleen	J:211773
	increased eosinophil cell number	J:211773
Galr2^{Gt(OST105469)Lex}/Galr2^{Gt(OST105469)Lex} (involves: 129S5/SvEvBrd * C57BL/6J)	decreased B cell number	J:103485
	increased T cell number	J:103485
Galt^{Gt(E285B04)Wrst}/Galt^{Gt(E285B04)Wrst} (involves: 129P2/OlaHsd * C57BL/6J)	brain inflammation	J:234753
	liver inflammation	J:234753
Gapt^tm1.1Wz/Gapt^tm1.1Wz (Not Specified)	immune system phenotype	J:138146
	increased B cell proliferation	J:138146
	increased IgG2b level	J:138146
	increased IgG3 level	J:138146
	increased IgM level	J:138146
	increased marginal zone B cell number	J:138146
Gapvd1^em1(IMPC)Mbp/Gapvd1⁺ (C57BL/6N-Gapvd1^em1(IMPC)Mbp/Ucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Garem1^em1(IMPC)Mbp/Garem1^em1(IMPC)Mbp (C57BL/6N-Garem1^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	small spleen	J:211773
Garin1a^{em1(IMPC)Ccpcz}/Garin1a^{em1(IMPC)Ccpcz} (C57BL/6N-Garin1a^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Garin1b^{em1(IMPC)Ccpcz}/Garin1b^{em1(IMPC)Ccpcz} (C57BL/6N-Garin1b^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Garin2^{em1(IMPC)Ccpcz}/Garin2^{em1(IMPC)Ccpcz} (C57BL/6N-Garin2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Gars1^em1(IMPC)Tcp/Gars1⁺ (C57BL/6NCrl-Gars1^em1(IMPC)Tcp/Tcp)	small spleen	J:211773
Gas2l2^{tm1a(KOMP)Wtsi}/Gas2l2^{tm1a(KOMP)Wtsi} (C57BL/6N-Gas2l2^{tm1a(KOMP)Wtsi}/Wtsi)	abnormal thymus topology	J:239583
Gas6^tm1Hiar/Gas6^tm1Hiar (B6.129P2-Gas6^tm1Hiar)	immune system phenotype	J:112430
Gasa1^BALB/cCrSlc/Gasa1^BALB/cCrSlc (involves: BALB/cCrSlc * C57BL/6)	stomach inflammation	J:54699
Gasa1^BALB/cCrSlc/Gasa1^C57BL/6 (involves: BALB/cCrSlc * C57BL/6)	stomach inflammation	J:54699
Gasa2^BALB/cCrSlc/Gasa2^BALB/cCrSlc (involves: BALB/cCrSlc * C57BL/6)	stomach inflammation	J:54699
Gasa2^BALB/cCrSlc/Gasa2^BALB/cCrSlc Gasa4^BALB/cCrSlc/Gasa4^C57BL/6 (involves: BALB/cCrSlc * C57BL/6)	stomach inflammation	J:75277
Gasa2^BALB/cCrSlc/Gasa2^C57BL/6 (involves: BALB/cCrSlc * C57BL/6)	stomach inflammation	J:54699
Gasa3^BALB/cCrSlc/Gasa3^C57BL/6 (involves: BALB/cCrSlc * C57BL/6)	stomach inflammation	J:75277
Gasa4^BALB/cCrSlc/Gasa4^C57BL/6 (involves: BALB/cCrSlc * C57BL/6)	stomach inflammation	J:75277
Gast^tm1Lcs/Gast^tm1Lcs (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	stomach inflammation	J:97527
Gata1^Plt13/Gata1⁺ (BALB/c-Gata1^Plt13)	abnormal myelopoiesis	J:113720
	abnormal thrombopoiesis	J:113720
	enlarged spleen	J:113720
	increased spleen weight	J:113720
Gata1^tm1Mym/Y Tg(Gata1)#Mym/0 (involves: 129P2/OlaHsd C57BL/6 * DBA/2J)	increased leukocyte cell number	J:158252
Gata1^tm1Mym/Y Tg(Gata1V205G)1Mym/0 (involves: C57BL/6 DBA/2)	abnormal mononuclear cell morphology	J:89054
	abnormal thrombopoiesis	J:89054
Gata1^tm1Mym/Gata1⁺ (involves: 129P2/OlaHsd)	decreased spleen red pulp amount	J:88685
	decreased spleen white pulp amount	J:88685
	enlarged spleen	J:88685
	pale spleen	J:88685
Gata1^tm1Mym/Gata1^tm1Mym Tg(Gata1)#Mym/0 (involves: 129P2/OlaHsd C57BL/6 * DBA/2J)	increased leukocyte cell number	J:158252
Gata1^tm1Sho/Y Tg(Gata1)#Mym/0 (involves: 129S4/SvJae C57BL/6 * DBA/2J)	increased leukocyte cell number	J:158252
Gata1^tm1Sho/Gata1⁺ (involves: 129S4/SvJae * C57BL/6)	decreased eosinophil cell number	J:88711
Gata1^tm1Sho/Gata1^tm1Sho Tg(Gata1)#Mym/0 (involves: 129S4/SvJae C57BL/6 * DBA/2J)	increased leukocyte cell number	J:158252
Gata1^tm2Sho/Y (involves: 129S4/SvJae * C57BL/6 * CD-1)	abnormal spleen morphology	J:78348
	abnormal spleen red pulp morphology	J:78540
	decreased lymphocyte cell number	J:78348
	enlarged spleen	J:78348, J:78540
	increased neutrophil cell number	J:78348
	increased splenocyte number	J:78540
Gata1^tm2Sho/Gata1^tm2Sho (involves: 129S4/SvJae * C57BL/6 * CD-1)	abnormal spleen morphology	J:78348
	abnormal spleen red pulp morphology	J:78540
	decreased lymphocyte cell number	J:78348
	enlarged spleen	J:78348, J:78540
	increased neutrophil cell number	J:78348
	increased splenocyte number	J:78540
Gata1^tm2Sho/Gata1^tm2Sho (involves: 129S4/SvJae)	increased osteoclast cell number	J:111270
Gata1^tm6Sho/Y (involves: 129S1/Sv)	decreased eosinophil cell number	J:88711
Gata1^tm6Sho/Y (involves: 129S1/Sv)	enlarged spleen	J:88711
Gata1^tm6Sho/Gata1^tm6Sho (involves: 129S1/Sv)	decreased eosinophil cell number	J:88711
Gata1^tm6Sho/Gata1^tm6Sho (involves: 129S1/Sv * BALB/c)	abnormal leukocyte cell number	J:115273
	decreased circulating interleukin-4 level	J:115273
	decreased circulating interleukin-13 level	J:115273
	decreased eosinophil cell number	J:115273
	decreased lymphocyte cell number	J:115273
	increased neutrophil cell number	J:115273
Gata1^tm6Sho/Gata1^tm6Sho (C.129S1-Gata1^tm6Sho)	autoimmune response	J:182213
Gata3^tm1.1Mbu/Gata3^tm1.1Mbu (involves: 129P2/OlaHsd * C57BL/6 * SJL)	abnormal humoral immune response	J:123631
	decreased interleukin-4 secretion	J:123631
	increased interferon-gamma secretion	J:123631
Gata3^tm1Iho/Gata3^tm1Iho Il13^{tm1(YFP/cre)Lky}/Il13⁺ (involves: 129S4/SvJae)	decreased eosinophil cell number	J:178986
	increased susceptibility to parasitic infection	J:178986
Gata3^tm1Iho/Gata3^tm1Iho Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	abnormal T cell differentiation	J:86996
	decreased CD4-positive, alpha-beta T cell number	J:86996
Gata3^tm1Iho/Gata3^tm1Iho Tg(Cd4-cre)1Cwi/0 Tg(DO11.10)10Dlo/0 (involves: BALB/c * C3H * C57BL/6 * DBA/2)	decreased CD4-positive, alpha-beta T cell number	J:86996
Gata3^tm1Iho/Gata3^tm1Iho Tg(DO11.10)10Dlo/0 Tg(Lck-cre)1Cwi/0 (involves: BALB/c * C3H * C57BL/6)	arrested T cell differentiation	J:86996
	decreased CD4-positive, alpha-beta T cell number	J:86996
	decreased CD8-positive, alpha-beta T cell number	J:86996
	decreased double-positive T cell number	J:86996
	small thymus	J:86996
Gata3^tm1Iho/Gata3^tm1Iho Tg(Lck-cre)1Cwi/0 (involves: BALB/c)	abnormal CD8-positive, alpha-beta T cell number	J:86996
	abnormal T cell subpopulation ratio	J:86996
	arrested T cell differentiation	J:86996
	decreased CD4-positive, alpha-beta T cell number	J:86996
	decreased double-positive T cell number	J:86996
	decreased thymocyte number	J:86996
	increased T cell apoptosis	J:86996
	small thymus	J:86996
Gata3^tm1Jeng/Gata3^tm1Jeng (involves: 129S7/SvEvBrd)	abnormal immune system organ morphology	J:62552
Gata3^tm1Jfz/Gata3^tm1Jfz Rag2^tm1Fwa/Rag2^tm1Fwa Tg(Cd4-cre)1Cwi/0 Tg(Tcra5CC7,Tcrb5CC7)IWep/0 (involves: 129S/SvEv * C57BL/6 * DBA/2)	abnormal T cell differentiation	J:141145
Gata3^tm1Jfz/Gata3^tm1Jfz Tg(Cd4-cre)1Cwi/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)	abnormal CD4-positive, alpha beta T cell morphology	J:93538
	abnormal T cell differentiation	J:141145
	decreased CD4-positive, alpha-beta T cell number	J:141145
	decreased interleukin-13 secretion	J:172134
Gata3^tm1Jfz/Gata3^tm1Jfz Tg(Tnfrsf4-cre)1Nik/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:93538
	decreased IgE level	J:93538
	decreased T-helper 2 cell number	J:93538
	increased susceptibility to parasitic infection	J:93538
	increased T-helper 1 cell number	J:93538
Gata3^tm1Jml/Gata3^tm1Jml (involves: 129S/SvEv * C57BL/6)	abnormal immune system cell morphology	J:37093
Gata3^tm2Jeng/Gata3^tm2Jeng (Not Specified)	abnormal double-positive T cell morphology	J:155686
	abnormal T cell differentiation	J:155686
	abnormal T cell number	J:155686
	decreased double-negative T cell number	J:155686
	decreased gamma-delta T cell number	J:155686
	decreased thymocyte number	J:155686
Gata3^tm3Gsv/Gata3^tm3Gsv Tg(KRT14-cre)8Brn/0 (involves: 129P2/OlaHsd * FVB/N)	decreased T cell number	J:117058
Gata5^tm1.2Nemr/Gata5^tm1.2Nemr (Not Specified)	kidney inflammation	J:227997
Gata5^tm1Eno/Gata5^tm1Eno (involves: 129S6/SvEvTac * C57BL/6)	urethritis	J:63036
	vaginal inflammation	J:63036
Gatad2b^{tm1b(EUCOMM)Hmgu}/Gatad2b⁺ (C57BL/6N-Gatad2b^{tm1b(EUCOMM)Hmgu}/Ics)	increased monocyte cell number	J:211773
Gatm^em1Btlr/Gatm^em1Btlr (C57BL/6J-Gatm^em1Btlr)	immune system phenotype	J:252049
Gatm^em1Btlr/Gatm^em1Btlr (C57BL/6J-Gatm^em1Btlr)	increased susceptibility to induced colitis	J:252049
Gatm^em1Btlr/Gatm^m1Btlr (C57BL/6J-Gatm^em1Btlr/Gatm^m1Btlr)	increased susceptibility to induced colitis	J:252049
Gatm^m1Btlr/Gatm⁺ (C57BL/6J-Gatm^m1Btlr)	increased susceptibility to induced colitis	J:252049
Gatm^m1Btlr/Gatm^m1Btlr (C57BL/6J-Gatm^m1Btlr)	increased susceptibility to induced colitis	J:252049
Gba1^tm1.1Pmis/Gba1^tm1.1Pmis Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA)	abnormal circulating chemokine level	J:167081
	abnormal circulating cytokine level	J:167081
	abnormal T cell differentiation	J:167081
	abnormal thymus morphology	J:167081
	decreased circulating interleukin-1 alpha level	J:167081
	decreased circulating interleukin-1 beta level	J:167081
	decreased circulating interleukin-6 level	J:167081
	decreased circulating tumor necrosis factor level	J:167081
	decreased double-positive T cell number	J:167081
	enlarged spleen	J:167081
	increased circulating interferon-gamma level	J:167081
	increased circulating interleukin-2 level	J:167081
	increased circulating interleukin-3 level	J:167081
	increased circulating interleukin-9 level	J:167081
	increased circulating interleukin-10 level	J:167081
	increased circulating interleukin-13 level	J:167081
	spleen hyperplasia	J:167081
Gba1^tm1.1Pmis/Gba1^tm1.2Pmis Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA)	abnormal circulating chemokine level	J:167081
	abnormal circulating cytokine level	J:167081
	abnormal T cell differentiation	J:167081
	abnormal thymus morphology	J:167081
	decreased circulating interleukin-1 alpha level	J:167081
	decreased circulating interleukin-1 beta level	J:167081
	decreased circulating interleukin-6 level	J:167081
	decreased circulating tumor necrosis factor level	J:167081
	decreased double-positive T cell number	J:167081
	enlarged spleen	J:167081
	increased circulating interferon-gamma level	J:167081
	increased circulating interleukin-2 level	J:167081
	increased circulating interleukin-3 level	J:167081
	increased circulating interleukin-9 level	J:167081
	increased circulating interleukin-10 level	J:167081
	increased circulating interleukin-13 level	J:167081
	spleen hyperplasia	J:167081
Gba1^tm1Clk/Gba1^tm1.1Clk Tg(Tek-cre)12Flv/0 (involves: 129S1/Sv * 129X1/SvJ * C3H * C57BL/6J)	abnormal macrophage morphology	J:117763
	abnormal spleen morphology	J:117763
	increased spleen weight	J:117763
Gba1^tm1Karl/Gba1^tm1.1Karl Tg(Mx1-cre)1Cgn/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)	abnormal immune system organ morphology	J:113751
	abnormal response to transplant	J:113751
	abnormal spleen morphology	J:113751
	enlarged spleen	J:113751
	intermingled spleen red and white pulp	J:113751
Gba1^tm1Karl/Gba1^tm1Karl Tg(Nes-cre)1Kln/? (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)	abnormal microglial cell morphology	J:127108
Gba1^tm1Nsb/Gba1^tm1Nsb (involves: 129S/SvEv * C57BL/6)	abnormal macrophage morphology	J:1100
Gba1^tm1Rlp/Gba1^tm1Rlp (involves: 129S4/SvJae * C57BL/6)	abnormal inflammatory response	J:76409
	abnormal Kupffer cell morphology	J:76409
	abnormal lymph node morphology	J:76409
	abnormal macrophage morphology	J:76409
	abnormal spleen physiology	J:76409
	decreased leukocyte cell number	J:76409
	increased IgG level	J:76409
	increased spleen weight	J:76409
	liver inflammation	J:76409
	lung inflammation	J:76409
	lymph node inflammation	J:76409
	skin inflammation	J:76409
Gba1^tm2Ggb/Gba1^tm1Nsb (involves: 129S/SvEv * 129S5/SvEvBrd * C57BL/6)	abnormal spleen morphology	J:86334
Gba1^tm2Ggb/Gba1^tm2Ggb (involves: 129S5/SvEvBrd * C57BL/6)	abnormal spleen morphology	J:86334
Gba1^tm2Karl/Gba1^tm2Karl Tg(KRT14-cre)8Brn/? (involves: 129S1/Sv * 129X1/SvJ * FVB/N)	abnormal macrophage morphology	J:127108
Gba1^tm3Ggb/Gba1^tm1Nsb (involves: 129S/SvEv * 129S5/SvEvBrd * C57BL/6)	abnormal spleen morphology	J:86334
Gba1^tm3Ggb/Gba1^tm3Ggb (involves: 129S5/SvEvBrd)	abnormal spleen morphology	J:86334
Gba1^tm4Ggb/Gba1^tm1Nsb (involves: 129S/SvEv * 129S5/SvEvBrd * C57BL/6)	abnormal spleen morphology	J:86334
Gba1^tm4Ggb/Gba1^tm4Ggb (involves: 129S5/SvEvBrd * C57BL/6)	abnormal spleen morphology	J:86334
Gbp2-ps^tm1.1Ktak/Gbp2-ps^tm1.1Ktak (involves: C57BL/6)	immune system phenotype	J:187397
Gbp2-ps^tm1.1Ktak/Gbp2-ps^tm1.1Ktak Gbp5^tm1Ktak/Gbp5^tm1Ktak (involves: C57BL/6)	immune system phenotype	J:187397
Gbp2^tm1.1Kpf/Gbp2^tm1.1Kpf (involves: 129P2/OlaHsd)	immune system phenotype	J:192526
	increased susceptibility to parasitic infection	J:192526
	increased susceptibility to parasitic infection induced morbidity/mortality	J:192526
Gbp2b^tm1Tigm/Gbp2b^tm1Tigm (B6.129S5-Gbp2b^tm1Tigm/Jdmm)	abnormal macrophage physiology	J:172364
	immune system phenotype	J:172364
	increased susceptibility to bacterial infection	J:172364
	increased susceptibility to bacterial infection induced morbidity/mortality	J:172364
Gbp5^tm1Tigm/Gbp5^tm1Tigm (B6.Cg-Gbp5^tm1Tigm)	decreased circulating interleukin-1 beta level	J:183942
	decreased circulating interleukin-18 level	J:183942
	decreased interleukin-1 beta secretion	J:183942
	decreased interleukin-18 secretion	J:183942
	impaired neutrophil recruitment	J:183942
	increased susceptibility to bacterial infection	J:183942
Gbp7^tm1Ddgd/Gbp7^tm1Ddgd (B6.129P2-Gbp7^tm1Ddgd)	increased susceptibility to bacterial infection	J:314959
Gbp7^tm1Ddgd/Gbp7^tm1Ddgd (B6.129P2-Gbp7^tm1Ddgd)	increased susceptibility to bacterial infection induced morbidity/mortality	J:314959
Gbx2^tm1.1Mrt/Gbx2^tm1.1Mrt Fgf8^tm1.4Mrt/Fgf8⁺ (B6.129-Gbx2^tm1.1Mrt Fgf8^tm1.4Mrt)	abnormal thymus development	J:100584
Gca^tm1Roes/Gca^tm1Roes (involves: 129P2/OlaHsd * 129S2/SvPas)	decreased susceptibility to endotoxin shock	J:81436
Gcc2^em1Cya/Gcc2^em1Cya (C57BL/6J-Gcc2^em1Cya)	increased autoantibody level	J:346915
Gcnt1^{em1(IMPC)Ccpcz}/Gcnt1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Gcnt1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	decreased lymphocyte cell number	J:211773
	enlarged lymph nodes	J:211773
	increased eosinophil cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Gcnt1^tm1Jxm/Gcnt1^tm1Jxm (involves: 129/Sv * C57BL/6)	abnormal acute inflammation	J:86387
	abnormal B cell differentiation	J:86387
	abnormal immune system cell morphology	J:86387
	abnormal immune system physiology	J:86387
	abnormal inflammatory response	J:86387
	increased leukocyte cell number	J:86387
	increased neutrophil cell number	J:86387
Gcnt1^tm1Jxm/Gcnt1^tm1Jxm (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal leukocyte migration	J:113195
	impaired leukocyte tethering or rolling	J:113195
Gcnt2^tm1Tmu/Gcnt2^tm1Tmu (involves: 129S2/SvPas * C57BL/6)	decreased B cell number	J:100533
Gcnt3^tm1.1Jxm/Gcnt3^tm1.1Jxm (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	decreased IgA level	J:149909
	decreased IgG1 level	J:149909
	decreased IgG2a level	J:149909
	decreased IgG2b level	J:149909
	increased susceptibility to induced colitis	J:149909
Gcnt4^tm1.1Jxm/Gcnt4^tm1.1Jxm (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	increased neutrophil cell number	J:149909
Gcsam^tm1.1Rsky/Gcsam^tm1.1Rsky (involves: BALB/cJ * C57BL/6)	decreased Peyer's patch number	J:125784
	immune system phenotype	J:125784
	small Peyer's patches	J:125784
Gcsfis^C57BL/6J/? (involves: C57BL/6J * DBA/2J)	enlarged spleen	J:61462
Gcsfis^C57BL/6J/Gcsfis^C57BL/6J (B6.SJL-Ptprc^a Pepc^b/BoyJ)	enlarged spleen	J:61462
Gcsh^em1(IMPC)H/Gcsh⁺ (C57BL/6N-Gcsh^em1(IMPC)H/H)	increased basophil cell number	J:211773
Gda^{tm1a(KOMP)Wtsi}/Gda^{tm1a(KOMP)Wtsi} (C57BL/6N-Gda^{tm1a(KOMP)Wtsi}/Wtsi)	decreased T-helper cell number	J:211773
	increased effector memory T-helper cell number	J:211773
Gdap1^{tm2b(KOMP)Wtsi}/Gdap1^{tm2b(KOMP)Wtsi} (C57BL/6N-Gdap1^{tm2b(KOMP)Wtsi}/Ucd)	abnormal thymus morphology	J:211773
	small thymus	J:211773
Gdf1^tm1Sjl/Gdf1^tm1Sjl (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal spleen morphology	J:60755
Gdf2^tm1Lex/Gdf2^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6)	abnormal lymphatic vessel morphology	J:222016
Gdf2^tm1Lex/Gdf2^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6)	lymphangiectasis	J:222016
Gdf5^em1(IMPC)H/Gdf5^em1(IMPC)H (C57BL/6NTac-Gdf5^em1(IMPC)H/H)	decreased lymphocyte cell number	J:211773
Gdf6^{em1(IMPC)Ccpcz}/Gdf6⁺ (C57BL/6NCrl-Gdf6^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Gdf11^tm1Sjl/Gdf11^tm1Sjl (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	abnormal spleen morphology	J:94455
Gdi2^{Gt(S1-11F1)Sor}/Gdi2⁺ (B6.129S4-Gdi2^{Gt(S1-11F1)Sor})	immune system phenotype	J:326029
Gdnf^tm1Lmgd/Gdnf⁺ (B6.129-Gdnf^tm1Lmgd)	tubulointerstitial nephritis	J:103081
Gdnf^tm1Rosl/Gdnf^tm1Rosl (involves: 129S2/SvPas)	abnormal spleen red pulp morphology	J:33808
Gdpd3^m1Anu/Gdpd3^m1Anu (C57BL/6NCrl-Gdpd3^m1Anu/Anu)	immune system phenotype	J:104190
Gdpd5^{tm1b(EUCOMM)Hmgu}/Gdpd5⁺ (C57BL/6N-Gdpd5^{tm1b(EUCOMM)Hmgu}/Bay)	abnormal spleen morphology	J:211773
Gfap^tm1Pkny/Gfap^tm1Pkny Ppt1^tm1Hof/Ppt1^tm1Hof Vim^tm1Cba/Vim^tm1Cba (involves: 129P2/OlaHsd * 129S2/SvPas * 129S6/SvEvTac * C57BL/6)	abnormal cytokine level	J:177265
	brain inflammation	J:177265
Gfap^tm1Pkny/Gfap^tm1Pkny Vim^tm1Cba/Vim^tm1Cba (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)	decreased inflammatory response	J:123278
Gfer^tm1.1Crg/Gfer^tm1.1Crg Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺ (involves: 129 * C57BL/6 * DBA)	liver inflammation	J:227242
Gfi1^Gen/Gfi1⁺ (C57BL/6J-Gfi1^Gen)	abnormal myelopoiesis	J:182679
	abnormal NK cell differentiation	J:182679
	abnormal NK cell physiology	J:182679
	absent neutrophils	J:182679
	decreased NK cell degranulation	J:182679
	immune system phenotype	J:182679
Gfi1^tm1.1Wep/Gfi1^tm1.1Wep (B6.129-Gfi1^tm1.1Wep)	arrested T cell differentiation	J:117105
	decreased B cell number	J:117105
	small thymus	J:117105
	thymus hypoplasia	J:117105
Gfi1^tm1Tmo/Gfi1^tm1Tmo (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal cytokine secretion	J:75143
	abnormal granulocyte differentiation	J:75143
	abnormal monocyte differentiation	J:75143
	abnormal myelopoiesis	J:75143
	abnormal T cell differentiation	J:75143
	decreased B cell number	J:75143
	decreased granulocyte number	J:75143
	decreased lymphocyte cell number	J:75143
	decreased neutrophil cell number	J:75143
	decreased T cell number	J:75143
	decreased thymocyte number	J:75143
	increased interleukin-1 beta secretion	J:75143
	increased interleukin-10 secretion	J:75143
	increased susceptibility to endotoxin shock	J:75143
	increased tumor necrosis factor secretion	J:75143
Gfi1^tm1Tmo/Gfi1^tm1Tmo (involves: 129S1/Sv * 129X1/SvJ)	decreased B cell number	J:192927
	decreased granulocyte number	J:192927
	decreased neutrophil cell number	J:192927
	decreased thymocyte number	J:192927
	increased monocyte cell number	J:192927
Gfi1^tm1Wep/Gfi1^tm1Wep (B6.129-Gfi1^tm1Wep)	abnormal T cell proliferation	J:117105
Gfi1^tm1Wep/Gfi1^tm1Wep Tg(Cd4-cre)1Cwi/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)	abnormal T cell proliferation	J:117105
	abnormal T cell subpopulation ratio	J:117105
	abnormal T-helper 2 physiology	J:117105
Gfi1^tm2Tmo/Gfi1^tm2Tmo (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal T cell differentiation	J:93337
	decreased neutrophil cell number	J:93337
	decreased thymocyte number	J:93337
Gfi1^{tm3(Gfib1)Tmo}/Gfi1^{tm3(Gfib1)Tmo} (involves: 129S1/Sv * 129X1/SvJ)	abnormal monocyte morphology	J:116870
	decreased granulocyte number	J:116870
Gfi1^tm4Tmo/Gfi1^tm4Tmo (involves: 129S1/Sv * 129X1/SvJ)	abnormal lymphopoiesis	J:116870
	abnormal monocyte morphology	J:116870
	abnormal neutrophil morphology	J:116870
	abnormal T cell differentiation	J:116870
	decreased double-negative T cell number	J:116870
	decreased lymphocyte cell number	J:116870
	decreased neutrophil cell number	J:116870
	decreased thymocyte number	J:116870
Gfi1^{tm5.1(GFI1)Tmo}/Gfi1⁺ Kras^tm4Tyj/Kras⁺ Tg(Mx1-cre)1Cgn/0 (involves: 129S1/Sv 129S4/SvJae * 129X1/SvJ * C57BL/6 * CBA)	myeloid hyperplasia	J:192927
Gfi1^{tm5.1(GFI1)Tmo}/Gfi1^{tm5.1(GFI1)Tmo} (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	increased monocyte cell number	J:192927
Gfi1^{tm5.1(GFI1)Tmo}/Gfi1^{tm5.1(GFI1)Tmo} Kras^tm4Tyj/Kras⁺ Tg(Mx1-cre)1Cgn/0 (involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * CBA)	myeloid hyperplasia	J:192927
Gfi1^{tm6.1(GFI1)Tmo}/Gfi1^{tm6.1(GFI1)Tmo} Kras^tm4Tyj/Kras⁺ Tg(Mx1-cre)1Cgn/0 (involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * CBA)	myeloid hyperplasia	J:192927
Gfi1b^{em1(IMPC)Ccpcz}/Gfi1b⁺ (C57BL/6NCrl-Gfi1b^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Gfi1b^{tm1b(EUCOMM)Hmgu}/Gfi1b⁺ (C57BL/6N-Gfi1b^{tm1b(EUCOMM)Hmgu}/H)	decreased neutrophil cell number	J:211773
	increased lymphocyte cell number	J:211773
Gfi1b^tm2Tmo/Gfi1b^tm2Tmo Tg(Mx1-cre)1Cgn/? (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)	increased splenocyte number	J:167416
Gfra1^tm1Rosl/Gfra1^tm1Rosl (either: (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J) or (involves: 129S1/Sv * 129X1/SvJ * CD-1))	decreased Peyer's patch number	J:120816
Gfus^tm1Jbl/Gfus^tm1Jbl (involves: 129S2/SvPas * C57BL/6J)	increased leukocyte cell number	J:82239
	increased neutrophil cell number	J:82239
	large intestinal inflammation	J:82239
Ggct^em1.2Smoc/Ggct^em1.2Smoc (involves: C57BL/6J)	enlarged spleen	J:322242
Ggct^em1.2Smoc/Ggct^em1.2Smoc (involves: C57BL/6J)	increased spleen red pulp amount	J:322242
Ggh^em1(IMPC)Tcp/Ggh^em1(IMPC)Tcp (C57BL/6N-Ggh^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
ggld/ggld (MRL/MpJ-Fas^lpr/J-ggld)	decreased IgG1 level	J:14258
Ggps1^{tm1b(EUCOMM)Wtsi}/Ggps1⁺ (C57BL/6N-Ggps1^{tm1b(EUCOMM)Wtsi}/Ieg)	increased leukocyte cell number	J:211773
Ggt1^dwg/Ggt1^dwg ((STOCK Pou1f1^dw x T(8;16)17H)F1)	decreased spleen red pulp amount	J:14281
Ggt1^dwg/Ggt1^dwg ((STOCK Pou1f1^dw x T(8;16)17H)F1)	increased osteoclast cell number	J:14281
Ggt5^tm1Mwl/Ggt5^tm1Mwl (involves: 129S7/SvEvBrd * C57BL/6J)	decreased acute inflammation	J:77691
Ggta1^tm1Jbl/Ggta1⁺ Igh^tm1Jiac/Igh⁺ Igk^tm1Jiac/Igk^tm1Jiac (involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)	decreased mature B cell number	J:133032
Ggta1^tm1Jbl/Ggta1⁺ Igh^tm1Jiac/Igh^tm1Jiac Igk^tm1Jiac/Igk⁺ (involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)	decreased mature B cell number	J:133032
Ggta1^tm1Jbl/Ggta1⁺ Igh^tm1Jiac/Igh^tm1Jiac Igk^tm1Jiac/Igk^tm1Jiac (involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)	abnormal B cell physiology	J:133032
	abnormal B cell selection	J:133032
	decreased mature B cell number	J:133032
Ggta1^tm1Jbl/Ggta1^tm1Jbl (involves: 129S2/SvPas)	abnormal humoral immune response	J:113488, J:90851
	abnormal immunoglobulin level	J:113488
	abnormal response to transplant	J:90851
	decreased IgG level	J:90851
	increased IgM level	J:90851
Gh^{tm1.1(KOMP)Vlcg}/Gh^{tm1.1(KOMP)Vlcg} (C57BL/6N-Gh^{tm1.1(KOMP)Vlcg}/Ucd)	abnormal spleen morphology	J:211773
	decreased spleen weight	J:211773
	small spleen	J:211773
Ghr^tm1Arge/Ghr^tm1Arge (involves: 129S/SvEv * C57BL/6J)	small spleen	J:66913
Ghr^{tm1c(KOMP)Wtsi}/Ghr^{tm1c(KOMP)Wtsi} Tg(Fabp4-cre)1Rev/0 (involves: C57BL/6N)	decreased spleen weight	J:206358
	increased circulating interleukin-6 level	J:206358
Ghr^tm1Jjk/Ghr^tm1Jjk (involves: 129P2/OlaHsd * BALB/c)	decreased spleen weight	J:60207
Ghr^tm1Jjk/Ghr^tm1Jjk (involves: 129P2/OlaHsd * BALB/c)	decreased susceptibility to autoimmune diabetes	J:59132
Ghr^tm2Mwat/Ghr^tm2Mwat (involves: 129X1/SvJ * C57BL)	small spleen	J:95149
Ghrh^tm1Salv/Ghrh^tm1Salv (involves: 129 * C57BL/6)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:177054
Ghrhr^lit/Ghrhr^lit (C57BL/6J-Ghrhr^lit)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:85381
Gigyf2^{tm1b(EUCOMM)Wtsi}/Gigyf2^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Gigyf2^{tm1b(EUCOMM)Wtsi}/Bay)	decreased eosinophil cell number	J:211773
	increased spleen weight	J:211773
Gimap1^m1Btlr/Gimap1^m1Btlr (C57BL/6J-Gimap1^m1Btlr)	decreased B cell number	J:267546
	decreased B-1 B cell number	J:267546
	decreased CD8-positive, alpha-beta T cell number	J:267546
	decreased IgD level	J:267546
	increased CD4-positive, alpha-beta T cell number	J:267546
	increased IgM level	J:267546
Gimap1^tm1.1Gwb/Gimap1^tm1.1Gwb Tg(CD2-icre)4Kio/0 (involves: 129 * C57BL/6 * C57BL/10 * CBA/Ca)	abnormal CD4-positive, alpha-beta T cell physiology	J:160782
	abnormal CD8-positive, alpha-beta T cell physiology	J:160782
	decreased B cell number	J:160782
	decreased B-1a cell number	J:160782
	decreased B-1b cell number	J:160782
	decreased B-2 B cell number	J:160782
	decreased CD4-positive, alpha-beta T cell number	J:160782
	decreased CD8-positive, alpha-beta T cell number	J:160782
	decreased follicular B cell number	J:160782
	decreased lymphocyte cell number	J:160782
	decreased marginal zone B cell number	J:160782
	decreased T cell number	J:160782
	decreased thymocyte number	J:160782
	decreased transitional stage T2 B cell number	J:160782
Gimap3^tm1.1Yout/Gimap3^tm1.1Yout (involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj)	decreased T cell number	J:209926
	decreased thymocyte number	J:209926
Gimap4^tm1Jcbs/Gimap4^tm1Jcbs (B6.129P2-Gimap4^tm1Jcbs)	abnormal T cell physiology	J:135744
Gimap5^m1Btlr/Gimap5^m1Btlr (involves: C57BL/6J)	abnormal B cell physiology	J:160090
	abnormal B cell proliferation	J:160090
	abnormal NK T cell physiology	J:160090
	abnormal response to transplant	J:160090
	abnormal spleen B cell follicle morphology	J:160090
	colitis	J:160090
	decreased B cell number	J:160090
	decreased B cell proliferation	J:160090
	decreased B-1 B cell number	J:160090
	decreased CD8-positive, alpha-beta T cell number	J:160090
	decreased circulating interferon-gamma level	J:160090
	decreased circulating interleukin-4 level	J:160090
	decreased IgG1 level	J:160090
	decreased IgG2a level	J:160090
	decreased IgG2b level	J:160090
	decreased IgG3 level	J:160090
	decreased IgG level	J:160090
	decreased IgM level	J:160090
	decreased interferon-gamma secretion	J:160090
	decreased interleukin-4 secretion	J:160090
	decreased lymphocyte cell number	J:160090
	decreased mature B cell number	J:160090
	decreased NK cell number	J:160090
	decreased NK T cell number	J:160090
	decreased spleen B cell follicle number	J:160090
	decreased spleen B cell follicle size	J:160090
	decreased tumor necrosis factor secretion	J:160090
	increased granulocyte number	J:160090
	increased neutrophil cell number	J:160090
	intestinal inflammation	J:160090
	thymus atrophy	J:160090
Gimap5^m1Btlr/Gimap5^m1Btlr Tg(TcraH-Y,TcrbH-Y)71Vbo/0 (involves: C57BL/6J * DBA/2J)	decreased CD8-positive, alpha-beta T cell number	J:160090
	decreased thymocyte number	J:160090
Gimap5^tm1Wlr/Gimap5^tm1Wlr (either: B6.129-Gimap5^tm1Wlr or C.129-Gimap5^tm1Wlr)	abnormal CD8-positive, alpha-beta T cell differentiation	J:143620
	abnormal leukocyte morphology	J:143620
	abnormal lymphocyte cell number	J:143620
	abnormal response to transplant	J:143620
	abnormal spleen morphology	J:143620
	decreased B cell number	J:143620
	decreased CD4-positive, alpha-beta T cell number	J:143620
	decreased CD8-positive, alpha-beta T cell number	J:143620
	decreased NK cell number	J:143620
	decreased NK T cell number	J:143620
	decreased T cell number	J:143620
	increased granulocyte number	J:143620
	small lymph nodes	J:143620
	spleen hypoplasia	J:143620
Gimap5^tm1Yout/Gimap5^tm1Yout (involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj)	decreased T cell number	J:209926
Gimap6^tm1.1Gwb/Gimap6^tm1.1Gwb Tg(CD2-icre)4Kio/0 (involves: C57BL/6 * C57BL/10 * CBA/Ca)	abnormal leukocyte morphology	J:262059
	abnormal T cell physiology	J:262059
	decreased B cell number	J:262059
	decreased T cell number	J:262059
	increased B cell number	J:262059
	increased T cell apoptosis	J:262059
Gimap6^{tm1a(KOMP)Wtsi}/Gimap6^{tm1a(KOMP)Wtsi} (C57BL/6N-Gimap6^{tm1a(KOMP)Wtsi}/Wtsi)	decreased CD4-negative NK T cell number	J:211773
	decreased memory-marker CD4-negative NK T cell number	J:211773
	increased memory-marker CD4-negative NK T cell number	J:211773
	increased monocyte cell number	J:211773
Gin1^em1(IMPC)Mbp/Gin1^em1(IMPC)Mbp (C57BL/6N-Gin1^em1(IMPC)Mbp/MbpMmucd)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Git2^Gt(XG510)Byg/Git2^Gt(XG510)Byg (B6.129P2-Git2^Gt(XG510)Byg)	decreased marginal zone B cell number	J:160613
Git2^Gt(XG510)Byg/Git2^Gt(XG510)Byg (C.129P2-Git2^Gt(XG510)Byg)	decreased marginal zone B cell number	J:160613
Git2^Gt(XG510)Byg/Git2^Gt(XG510)Byg Tg(DO11.10)10Dlo/0 (involves: 129P2/OlaHsd * BALB/c * C3H * C57BL/6)	decreased CD4-positive, alpha-beta T cell number	J:160613
Git2^Gt(XG510)Byg/Git2^Gt(XG510)Byg Tg(TcraH-Y,TcrbH-Y)71Vbo/0 (involves: 129 * C57BL/6J * DBA/2J)	abnormal CD4-positive, alpha-beta T cell physiology	J:160613
	abnormal CD8-positive, alpha-beta T cell physiology	J:160613
	abnormal positive T cell selection	J:160613
	decreased CD8-positive, alpha-beta T cell number	J:160613
Git2^Gt(XG510)Byg/Git2^Gt(XG510)Byg Tg(TcraTcrb)425Cbn/0 (involves: 129P2/OlaHsd * C57BL/6)	decreased CD4-positive, alpha-beta T cell number	J:160613
Git2^tm1Hsb/Git2^tm1Hsb (involves: C57BL/6 * CBA)	abnormal neutrophil differentiation	J:112663
	abnormal neutrophil physiology	J:112663
	enlarged spleen	J:112663
	impaired neutrophil chemotaxis	J:112663
	increased susceptibility to fungal infection	J:112663
	lung inflammation	J:112663
Gja1^{em1(IMPC)Ccpcz}/Gja1⁺ (C57BL/6NCrl-Gja1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
Gja1^M1Jrt/Gja1⁺ (involves: C3H/HeJ * C57BL/6J)	heart inflammation	J:101733
Gja1^tm1.1Kwi/Gja1⁺ (involves: 129P2/OlaHsd)	abnormal neutrophil physiology	J:129091
Gja1^tm1Kwi/Gja1⁺ Tg(KRT5-cre)5132Jlj/0 (involves: 129P2/OlaHsd * C57BL/6J * DBA/2J)	abnormal lymphatic vessel morphology	J:188626
	absent lymphatic vessels	J:188626
Gja1^tm1Kwi/Gja1^{tm5(cre/ERT)Kwi} (involves: 129P2/OlaHsd)	abnormal neutrophil physiology	J:129091
Gjb1^tm1Kwi/Y Gjc2^tm1(EGFP)Kwi/Gjc2^tm1(EGFP)Kwi (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)	microgliosis	J:219594
	optic nerve inflammation	J:219594
	spinal cord inflammation	J:219594
Gjb2^{tm3.1(Gjb1)Kwi}/Gjb2⁺ Tg(KRT5-cre)5132Jlj/0 (involves: 129P2/OlaHsd * C57BL/6 * DBA/2J * SJL)	abnormal lymphatic vessel morphology	J:188626
Gjb2^{tm3.2(Gjb1)Kwi}/Gjb2⁺ (involves: 129P2/OlaHsd * BALB/c * C57BL/6 * SJL)	abnormal lymphatic vessel morphology	J:188626
	absent lymphatic vessels	J:188626
Gjb4^{tm1.1(KOMP)Vlcg}/Gjb4^{tm1.1(KOMP)Vlcg} (C57BL/6N-Gjb4^{tm1.1(KOMP)Vlcg}/Ucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Gjb6^tm1Kwi/Gjb6^tm1Kwi (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:85065
Gjc2^tm1(EGFP)Kwi/Gjc2^tm1(EGFP)Kwi (involves: 129P2/OlaHsd * C57BL/6)	microgliosis	J:174197
Gjc2^tm1(EGFP)Kwi/Gjc2^tm1(EGFP)Kwi Gjb1^tm1Kwi/Gjb1^tm1Kwi (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)	microgliosis	J:219594
	optic nerve inflammation	J:219594
	spinal cord inflammation	J:219594
Gjc2^tm2.1Kwi/Gjc2⁺ (involves: C57BL/6 * SJL)	microgliosis	J:174197
Gjc2^tm2.1Kwi/Gjc2^tm2.1Kwi (involves: C57BL/6 * SJL)	microgliosis	J:174197
Gjd4^tm1.1Malt/Gjd4^tm1.1Malt (involves: 129S2/SvPas * C57BL/6 * SJL)	decreased macrophage cell number	J:172698
Gk5^m5Btlr/Gk5^m5Btlr (C57BL/6J-Gk5^m5Btlr)	increased alpha-beta T cell number	J:265118
	increased CD8-positive, alpha-beta memory T cell number	J:265118
	increased central memory CD8 positive, alpha-beta T cell number	J:265118
Gkn2^{tm1.1(KOMP)Vlcg}/Gkn2^{tm1.1(KOMP)Vlcg} (involves: C57BL/6NTac)	abnormal chemokine level	J:234656
	abnormal cytokine level	J:234656
	abnormal innate immunity	J:234656
	abnormal interleukin level	J:234656
	abnormal susceptibility to bacterial infection	J:234656
	abnormal T-helper 1 physiology	J:234656
	abnormal tumor necrosis factor level	J:234656
	increased susceptibility to bacterial infection	J:234656
	stomach inflammation	J:234656
Glb1^tm1Jmat/Glb1^tm1Jmat (involves: C57BL/6 * CBA * ICR)	abnormal lymphopoiesis	J:43534
	abnormal macrophage chemotaxis	J:102576
	small spleen	J:43534
Glb1l2^tm1Lex/Glb1l2^tm1Lex (B6;129S5-Glb1l2^tm1Lex/Mmucd)	decreased leukocyte cell number	J:171883
	decreased lymphocyte cell number	J:171883
	decreased NK cell number	J:171883
Glg1^{Gt(RST092)Byg}/Glg1⁺ (B6J.129P2-Glg1^{Gt(RST092)Byg})	abnormal cellular extravasation	J:226586
	abnormal leukocyte adhesion	J:226586
	enhanced leukocyte tethering or rolling	J:226586
Glis2^tm1Amj/Glis2^tm1Amj (involves: 129P2/OlaHsd * C57BL/6)	glomerulonephritis	J:134208
Glmp^{Gt(P084H04)Wrst}/Glmp^{Gt(P084H04)Wrst} (involves: 129S2/SvPas * C57BL/6)	abnormal Kupffer cell morphology	J:208774
	increased spleen weight	J:208774
	liver inflammation	J:208774
Glmp^tm1Lex/Glmp^tm1Lex (B6;129S5-Glmp^tm1Lex/Mmucd)	abnormal immune system physiology	J:171883
Glmp^tm1Lex/Glmp^tm1Lex (B6;129S5-Glmp^tm1Lex/Mmucd)	liver inflammation	J:171883
Glra1^nmf11/Glra1^nmf11 (C57BL/6J-Glra1^nmf11/J)	small spleen	J:78134
Glra1^nmf11/Glra1^nmf11 (C57BL/6J-Glra1^nmf11/J)	thymus atrophy	J:78134
Glra2^{tm1b(KOMP)Wtsi}/Y (C57BL/6N-Glra2^{tm1b(KOMP)Wtsi}/H)	decreased monocyte cell number	J:211773
	decreased neutrophil cell number	J:211773
	increased lymphocyte cell number	J:211773
Glrb^em1(IMPC)Tcp/Glrb⁺ (C57BL/6NCrl-Glrb^em1(IMPC)Tcp/Tcp)	increased neutrophil cell number	J:211773
Glrb^em1(IMPC)Tcp/Glrb⁺ (C57BL/6NCrl-Glrb^em1(IMPC)Tcp/Tcp)	increased spleen weight	J:211773
Gls2^em1(IMPC)Tcp/Gls2^em1(IMPC)Tcp (C57BL/6N-Gls2^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Glt8d2^tm1Lex/Glt8d2^tm1Lex (B6;129S5-Glt8d2^tm1Lex/Mmucd)	abnormal adaptive immunity	J:171883
	decreased IgG1 level	J:171883
	decreased IgG2a level	J:171883
Glyr1^em1(IMPC)Tcp/Glyr1^em1(IMPC)Tcp (C57BL/6N-Glyr1^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Gm614^tm1.1Cya/Gm614^tm1.1Cya Ighg1^tm1(cre)Cgn/Ighg1⁺ (involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N)	decreased susceptibility to systemic lupus erythematosus	J:307345
	immune system phenotype	J:307345
	increased B cell apoptosis	J:307345
Gm4922^em1(IMPC)Tcp/Gm4922^em1(IMPC)Tcp (C57BL/6NCrl-Gm4922^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Gm5148^{em1(IMPC)Ccpcz}/Gm5148⁺ (C57BL/6NCrl-Gm5148^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Gm5148^{em1(IMPC)Ccpcz}/Gm5148^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Gm5148^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
Gm5544^{tm1a(KOMP)Wtsi}/Gm5544⁺ (C57BL/6N-Gm5544^{tm1a(KOMP)Wtsi}/Wtsi)	decreased marginal zone B cell number	J:211773
Gm5544^{tm1a(KOMP)Wtsi}/Gm5544^{tm1a(KOMP)Wtsi} (C57BL/6N-Gm5544^{tm1a(KOMP)Wtsi}/Wtsi)	blood in lymph vessels	J:239583
Gm7694^em1(IMPC)J/Gm7694^em1(IMPC)J (C57BL/6NJ-Gm7694^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
Gm10800^em1(IMPC)Mbp/Gm10800^em1(IMPC)Mbp (C57BL/6N-Gm10800^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Gm10851^{em1(IMPC)Ccpcz}/Gm10851^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Gm10851^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged thymus	J:211773
Gm15551^{em1(IMPC)Ccpcz}/Gm15551^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Gm15551^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Gm16685^em1Osb/Gm16685^em1Osb (C57BL/6N-Gm16685^em1Osb)	decreased susceptibility to colitis induced morbidity/mortality	J:303079
Gm26330^em1Liuq/Gm26330^em1Liuq (C57BL/6-Gm26330^em1Liuq)	decreased NK cell number	J:341056
Gm36723^em1Flv/Gm36723^em1Flv (C57BL/6-Gm36723^em1Flv)	abnormal lymphopoiesis	J:258967
	abnormal NK cell physiology	J:258967
	decreased interferon-gamma secretion	J:258967
	decreased lymphocyte cell number	J:258967
	decreased mature NK cell number	J:258967
	decreased NK cell number	J:258967
	decreased susceptibility to bacterial infection	J:258967
	immune system phenotype	J:258967
	impaired natural killer cell mediated cytotoxicity	J:258967
	increased immature NK cell number	J:258967
Gm36723^em2Flv/Gm36723^em2Flv (C57BL/6-Gm36723^em2Flv)	immune system phenotype	J:258967
Gm36723^em3Flv/Gm36723^em3Flv (C57BL/6-Gm36723^em3Flv)	decreased mature NK cell number	J:258967
Gm40600^em1Cya/Gm40600^em1Cya (C57BL/6-Gm40600^em1Cya)	abnormal plasmablast number	J:311878
	decreased B cell number	J:311878
	decreased IgA level	J:311878
	decreased IgE level	J:311878
	decreased IgG1 level	J:311878
	decreased IgG2b level	J:311878
	decreased IgG2c level	J:311878
	decreased IgG3 level	J:311878
	decreased IgG level	J:311878
	decreased IgM level	J:311878
	decreased plasma cell number	J:311878
	immune system phenotype	J:311878
	increased B cell number	J:311878
	increased IgA level	J:311878
	increased IgE level	J:311878
	increased IgG1 level	J:311878
	increased IgG2b level	J:311878
	increased IgG2c level	J:311878
	increased IgG3 level	J:311878
	increased IgG level	J:311878
	increased IgM level	J:311878
	increased plasma cell number	J:311878
Gm41610^em1Scrp/Gm41610^em1Scrp (C57BL/6-Gm41610^em1Scrp)	decreased susceptibility to endotoxin shock	J:302605
	immune system phenotype	J:302605
	increased circulating interleukin-5 level	J:302605
	increased circulating interleukin-13 level	J:302605
Gmds^{tm1a(KOMP)Wtsi}/Gmds^{tm1a(KOMP)Wtsi} (C57BL/6N-Gmds^{tm1a(KOMP)Wtsi}/Wtsi)	decreased alpha-beta T cell number	J:211773
	decreased CD4-positive NK T cell number	J:211773
	decreased CD4-positive, alpha-beta T cell number	J:211773
	decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	decreased CD8-positive, alpha-beta T cell number	J:211773
	decreased CD8-positive, naive alpha-beta T cell number	J:211773
	decreased dendritic cell number	J:211773
	decreased effector memory CD8-positive, alpha-beta T cell number	J:211773
	decreased KLRG1+ CD8 alpha-beta T cell number	J:211773
	decreased KLRG1-positive NK cell number	J:211773
	decreased Ly6C-positive mature NK cell number	J:211773
	decreased macrophage cell number	J:211773
	decreased mature NK cell number	J:211773
	decreased memory CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	decreased memory-marker CD4-negative NK T cell number	J:211773
	decreased memory-marker CD4-positive NK T cell number	J:211773
	decreased NK cell number	J:211773
	decreased plasmacytoid dendritic cell number	J:211773
	decreased regulatory T cell number	J:211773
	decreased T-helper cell number	J:211773
	decreased transitional stage T2 B cell number	J:211773
	increased CD4-negative NK T cell number	J:211773
	increased CD4-positive, alpha-beta T cell number	J:211773
	increased CD8-positive, alpha-beta T cell number	J:211773
	increased gamma-delta T cell number	J:211773
	increased granulocyte number	J:211773
	increased immature NK cell number	J:211773
	increased leukocyte cell number	J:211773
	increased Ly6C-positive NK T cell number	J:211773
	increased memory CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	increased memory-marker NK cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
	increased NK T cell number	J:211773
Gmfg^tm1Jyw/Gmfg^tm1Jyw (B6.Cg-Gmfg^tm1Jyw)	abnormal marginal zone B cell physiology	J:345500
	decreased lymphocyte chemotaxis	J:345500
	impaired B cell migration	J:345500
	increased IgM level	J:345500
Gmnn^tm1.1Kio/Gmnn^tm1.2Kio Tg(CD2-icre)4Kio/0 (involves: 129S4/SvJae * C57BL/10 * CBA/Ca)	decreased CD4-positive, alpha-beta T cell number	J:159657
	decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:159657
	decreased CD8-positive, alpha-beta T cell number	J:159657
	decreased DN1 thymic pro-T cell number	J:159657
	decreased DN4 thymocyte number	J:159657
	decreased double-positive T cell number	J:159657
	decreased memory T cell number	J:159657
	decreased T cell proliferation	J:159657
	decreased thymocyte number	J:159657
Gmnn^tm1Tjm/Gmnn^tm1Tjm Tg(Mx1-cre)1Cgn/0 (involves: 129/Sv * C57BL/6 * C57BL/6J * CBA)	abnormal spleen red pulp morphology	J:171741
	decreased granulocyte number	J:171741
	decreased leukocyte cell number	J:171741
	decreased neutrophil cell number	J:171741
Gmppa^em1(IMPC)Tcp/Gmppa^em1(IMPC)Tcp (C57BL/6N-Gmppa^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Gmps^em1(IMPC)Tcp/Gmps⁺ (C57BL/6NCrl-Gmps^em1(IMPC)Tcp/Tcp)	increased leukocyte cell number	J:211773
Gmps^em1(IMPC)Tcp/Gmps⁺ (C57BL/6NCrl-Gmps^em1(IMPC)Tcp/Tcp)	increased lymphocyte cell number	J:211773
Gna11^tm1Soff/Gna11^tm1Soff (involves: 129S7/SvEvBrd)	decreased susceptibility to type I hypersensitivity reaction	J:146132
Gna11^tm1Soff/Gna11^tm1Soff Gnaq^tm2Soff/Gnaq^tm2Soff Tg(Tek-icre/ERT2)1Soff/? (involves: 129P2/OlaHsd * 129S7/SvEvBrd * FVB/N)	decreased susceptibility to type I hypersensitivity reaction	J:146132
	immune system phenotype	J:146132
Gna12^tm1.1Cgh/Gna12^tm1.1Cgh Gna13^tm2Cgh/Gna13^tm2Cgh Tg(Mx1-cre)1Cgn/0 (involves: 129S4/SvJae * C57BL/6 * CBA)	abnormal germinal center B cell morphology	J:174313
	decreased B cell apoptosis	J:174313
	increased germinal center B cell number	J:174313
Gna12^tm1Citb/Gna12^tm1Citb Gna13^tm2.1Soff/Gna13^tm2.1Soff Tg(Lck-cre)548Jxm/0 (involves: 129S1/Sv * C57BL/6 * CBA)	abnormal CD4-positive, alpha-beta T cell physiology	J:149560
	increased CD4-positive, alpha-beta T cell number	J:149560
	increased CD8-positive, alpha-beta T cell number	J:149560
	increased interleukin-2 secretion	J:149560
	increased susceptibility to autoimmune diabetes	J:149560
	increased susceptibility to type IV hypersensitivity reaction	J:149560
	increased T cell proliferation	J:149560
	lymph node hyperplasia	J:149560
	thymus hyperplasia	J:149560
Gnai1^{tm1b(EUCOMM)Wtsi}/Gnai1^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Gnai1^{tm1b(EUCOMM)Wtsi}/Bay)	abnormal spleen morphology	J:211773
Gnai1^tm1Drs/Gnai1^tm1Drs Gnai3^tm1Lbi/Gnai3^tm1Lbi (involves: 129S/SvEv)	decreased interleukin-10 secretion	J:104683
	increased tumor necrosis factor secretion	J:104683
Gnai2^tm1Lbi/Gnai2^tm1Lbi (involves: 129S7/SvEvBrd * C57BL/6J)	colitis	J:24434
Gnai2^tm1Lbi/Gnai2^tm1Lbi (involves: 129S7/SvEvBrd)	abnormal cytokine level	J:121471
	abnormal cytokine secretion	J:30507
	abnormal immune system morphology	J:30507
	abnormal immune system physiology	J:30507
	abnormal neutrophil physiology	J:121471
	colitis	J:24434
	increased circulating interferon-gamma level	J:121471
	increased circulating interleukin-4 level	J:121471
	increased circulating interleukin-5 level	J:121471
	increased granulocyte number	J:30507
	increased IgA level	J:30507
	increased IgG level	J:30507
	increased immunoglobulin level	J:30507
	increased inflammatory response	J:30507
	increased interferon-gamma secretion	J:30507
	increased interleukin-2 secretion	J:30507
	increased single-positive T cell number	J:30507
	increased susceptibility to parasitic infection	J:121471
	increased T cell number	J:30507
	increased T cell proliferation	J:30507
	increased tumor necrosis factor secretion	J:30507
	large intestinal inflammation	J:30507
	peritoneal inflammation	J:30507
Gnai2^tm1Lbi/Gnai2^tm1Lbi (either: 129 or (involves: 129S7/SvEvBrd * C57BL/6J))	abnormal cytokine secretion	J:24434
	increased granulocyte number	J:24434
	increased IgG level	J:24434
	increased IgM level	J:24434
	increased thymocyte number	J:24434
Gnai2^tm1Lbi/Gnai2^tm1Lbi (129-Gnai2^tm1Lbi)	abnormal cytokine secretion	J:91100
	immune system phenotype	J:91100
	increased interleukin-1 beta secretion	J:91100
	increased tumor necrosis factor secretion	J:91100
Gnai2^tm1Lbi/Gnai2^tm1Lbi (B6.129S7-Gnai2^tm1Lbi)	abnormal cellular extravasation	J:120069
	abnormal eosinophil physiology	J:120069
	abnormal leukocyte adhesion	J:120069
	abnormal leukocyte cell number	J:121161
	abnormal T cell physiology	J:121161
	decreased eosinophil cell number	J:120069
	increased eosinophil cell number	J:120069
	increased lymphocyte cell number	J:120069
	increased monocyte cell number	J:120069
	increased neutrophil cell number	J:120069
Gnai2^tm1Lbi/Gnai2^tm1Lbi (involves: 129S7/SvEvBrd * C57BL/6)	abnormal cytokine secretion	J:91100
	colitis	J:91100
	increased interleukin-1 beta secretion	J:91100
	increased tumor necrosis factor secretion	J:91100
Gnai2^tm2.1Lbi/Gnai2^tm2.1Lbi Tg(Cd4-cre)1Cwi/0 (involves: 129S/SvEv * C57BL/6 * C57BL/6NTac * DBA)	decreased T-helper 17 cell number	J:194587
	increased susceptibility to induced colitis	J:194587
Gnai3^tm1Lbi/Gnai3^tm1Lbi (involves: 129S/SvEv * C57BL/6)	immune system phenotype	J:120069
Gnai3^tm1Lbi/Gnai3^tm1Lbi (B6.129S-Gnai3^tm1Lbi)	abnormal T cell physiology	J:121161
Gnao1^{tm1b(EUCOMM)Hmgu}/Gnao1⁺ (C57BL/6N-Gnao1^{tm1b(EUCOMM)Hmgu}/H)	decreased eosinophil cell number	J:211773
Gnas^Oedsml/Gnas⁺ (involves: 101/H * C3H/HeH)	abnormal inflammatory response	J:65007
Gnas^tm1Lsw/Gnas⁺ (involves: 129S4/SvJae * CD-1)	thymus cortex atrophy	J:49340
Gnb1l^em1(IMPC)Tcp/Gnb1l⁺ (C57BL/6NCrl-Gnb1l^em1(IMPC)Tcp/Tcp)	increased neutrophil cell number	J:211773
Gnb1l^{Gt(OST35527)Lex}/Gnb1l⁺ (B6;129S5-Gnb1l^{Gt(OST35527)Lex}/Orl)	abnormal spleen B cell follicle morphology	J:82809
	glomerulonephritis	J:82809
Gnb2^em1(IMPC)J/Gnb2^em1(IMPC)J (C57BL/6NJ-Gnb2^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
Gnb4^em1(IMPC)H/Gnb4^em1(IMPC)H (C57BL/6NTac-Gnb4^em1(IMPC)H/H)	enlarged spleen	J:211773
Gne^tm1.1Masn/Gne^tm1.1Masn (involves: 129P2/OlaHsd * C57BL/6)	kidney inflammation	J:184315
Gngt2^em1(IMPC)Bay/Gngt2^em1(IMPC)Bay (C57BL/6N-Gngt2^em1(IMPC)Bay/BayMmucd)	increased spleen weight	J:211773
Gnl2^{em1(IMPC)Ccpcz}/Gnl2⁺ (C57BL/6NCrl-Gnl2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Gnmt^tm1Ymac/Gnmt^tm1Ymac (involves: 129 * C57BL/6)	decreased leukocyte cell number	J:147857
	decreased monocyte cell number	J:147857
	decreased neutrophil cell number	J:147857
Gnpda1^{tm1b(KOMP)Mbp}/Gnpda1⁺ (C57BL/6N-Gnpda1^{tm1b(KOMP)Mbp}/Tcp)	increased neutrophil cell number	J:211773
Gnptab^em1(IMPC)Mbp/Gnptab⁺ (C57BL/6N-Gnptab^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Gnptab^nym/Gnptab^nym (involves: BALB/cAnNHsd * C3H/HeNHsd)	brain inflammation	J:218156
Gnptab^tm1Dkji/Gnptab^tm1Dkji (involves: 129 * C57BL/6)	increased interleukin-6 secretion	J:231531
Gnptab^tm1Kkol/Gnptab^tm1Kkol (involves: 129 * C57BL/6)	abnormal osteoclast physiology	J:202751
Gnptab^tm1Kkol/Gnptab^tm1Kkol (involves: 129 * C57BL/6)	increased osteoclast cell number	J:202751
Gnrh1^hpg/Gnrh1^hpg (HPG/BmJ)	abnormal splenic cell ratio	J:19436
	increased B cell number	J:19436
	increased immature B cell number	J:19436
	increased mature B cell number	J:19436
Gns^{tm1e(EUCOMM)Hmgu}/Gns^{tm1e(EUCOMM)Hmgu} (C57BL/6N-A^tm1Brd Gns^{tm1e(EUCOMM)Hmgu})	microgliosis	J:242250
Golga2^{tm1(KOMP)Vlcg}/Golga2^{tm1(KOMP)Vlcg} (involves: C57BL/6NTac)	increased alveolar macrophage number	J:270564
Golm1^{Gt(KST273)Byg}/Golm1^{Gt(KST273)Byg} (involves: 129P2/OlaHsd * C57BL/6)	kidney inflammation	J:151282
	liver inflammation	J:151282
Golph3^em1(IMPC)Tcp/Golph3⁺ (C57BL/6NCrl-Golph3^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Golph3^em1(IMPC)Tcp/Golph3^em1(IMPC)Tcp (C57BL/6NCrl-Golph3^em1(IMPC)Tcp/Tcp)	abnormal spleen morphology	J:211773
	enlarged thymus	J:211773
Golt1b^{tm1b(EUCOMM)Wtsi}/Golt1b^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Golt1b^{tm1b(EUCOMM)Wtsi}/Ieg)	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Gon4l^justy/Gon4l^justy (C3HeB/FeJ-Gon4l^justy)	abnormal humoral immune response	J:163412
	absent B cells	J:163412
	arrested B cell differentiation	J:163412
	decreased B cell number	J:163412
	decreased immature B cell number	J:163412
	decreased immunoglobulin level	J:163412
	decreased pro-B cell number	J:163412
	decreased spleen white pulp amount	J:163412
	decreased T cell number	J:163412
	small spleen	J:163412
	spleen hypoplasia	J:163412
Got1^{tm1b(EUCOMM)Hmgu}/Got1⁺ (C57BL/6N-Got1^{tm1b(EUCOMM)Hmgu}/H)	decreased basophil cell number	J:211773
	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
Got2^em1(IMPC)Mbp/Got2⁺ (C57BL/6N-Got2^em1(IMPC)Mbp/MbpMmucd)	enlarged spleen	J:211773
	small spleen	J:211773
Gp2^em1(IMPC)Mbp/Gp2^em1(IMPC)Mbp (C57BL/6N-Gp2^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Gp6^tm1Beni/Gp6^tm1Beni Clec1b^tm1.1Arte/Clec1b^tm1.1Arte Tg(Pf4-icre)Q3Rsko/0 (involves: 129 * C57BL/6)	abnormal lymphatic vessel morphology	J:217963
Gp6^{tm2b(EUCOMM)Hmgu}/Gp6^{tm2b(EUCOMM)Hmgu} (C57BL/6N-Gp6^{tm2b(EUCOMM)Hmgu}/Orl)	increased lymphocyte cell number	J:211773
Gp9^{tm1.1(KOMP)Vlcg}/Gp9^{tm1.1(KOMP)Vlcg} (C57BL/6N-Gp9^{tm1.1(KOMP)Vlcg}/Ucd)	increased basophil cell number	J:211773
Gpa33^tm1Jkhh/Gpa33^tm1Jkhh (B6.129-Gpa33^tm1Jkhh)	abnormal immune tolerance	J:224768
	increased dendritic cell number	J:224768
	increased susceptibility to induced colitis	J:224768
	increased susceptibility to type IV hypersensitivity reaction	J:224768
Gpa33^tm1Jkhh/Gpa33^tm1Jkhh (involves: 129 * C57BL/6)	increased susceptibility to colitis induced morbidity/mortality	J:231808
Gpa33^tm1Jkhh/Gpa33^tm1Jkhh (involves: 129 * C57BL/6)	increased susceptibility to induced colitis	J:231808
Gpatch2^em1Boui/Gpatch2^em1Boui (C57BL/6-Gpatch2^em1Boui)	decreased B cell number	J:336774
Gpatch2^em1Boui/Gpatch2^em1Boui (C57BL/6-Gpatch2^em1Boui)	immune system phenotype	J:336774
Gpatch3^em1(IMPC)Mbp/Gpatch3^em1(IMPC)Mbp (C57BL/6N-Gpatch3^em1(IMPC)Mbp/MbpMmucd)	enlarged lymph nodes	J:211773
	small spleen	J:211773
Gpatch4^{em1(IMPC)Ccpcz}/Gpatch4^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Gpatch4^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	decreased CD8-positive, alpha-beta T cell number	J:211773
	immune system phenotype	J:211773
	small spleen	J:211773
Gpbar1^{tm1.1(KOMP)Vlcg}/Gpbar1^{tm1.1(KOMP)Vlcg} (C57BL/6N-Gpbar1^{tm1.1(KOMP)Vlcg}/Ucd)	abnormal lymph node morphology	J:211773
Gpc1^em1(IMPC)Mbp/Gpc1^em1(IMPC)Mbp (C57BL/6N-Gpc1^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
Gpc3^tm1Arge/Y (either: (involves: 129S/SvEv * 129S1/Sv) or (involves: 129S1/Sv * C57BL/6J))	decreased spleen weight	J:75054
	increased spleen B cell follicle size	J:75054
	small spleen	J:75054
Gpc3^tm1Fil/Y (B6.Cg-Gpc3^tm1Fil)	increased susceptibility to bacterial infection	J:73877
	lung inflammation	J:73877
	rhinitis	J:73877
Gpc3^tm1Fil/Gpc3^tm1Fil (B6.Cg-Gpc3^tm1Fil)	increased susceptibility to bacterial infection	J:73877
Gpc3^tm1Fil/Gpc3^tm1Fil (B6.Cg-Gpc3^tm1Fil)	lung inflammation	J:73877
Gpc3^tm1Snd/Y (involves: 129X1/SvJ * C57BL/6)	abnormal osteoclast differentiation	J:104555
Gpcpd1^em1(IMPC)Tcp/Gpcpd1⁺ (C57BL/6N-Gpcpd1^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Gpdc1^C3H/HeN/Gpdc1^C3H/HeN (involves: C3H/HeN-Gnai2^tm1Uru * C57BL/6J-Gna2^tm1Uru)	colitis	J:95140
Gpdc2^C3H/HeN/Gpdc2^C3H/HeN (involves: C3H/HeN-Gnai2^tm1Uru * C57BL/6J-Gna2^tm1Uru)	colitis	J:95140
Gpdc3^C3H/HeN/? (involves: C3H/HeN-Gnai2^tm1Uru * C57BL/6J-Gna2^tm1Uru)	colitis	J:95140
Gper1^tm1Dgen/Gper1^tm1Dgen (B6.129-Gper1^tm1Dgen)	decreased CD4-positive, alpha-beta T cell number	J:151816
	decreased CD8-positive, alpha-beta T cell number	J:151816
	decreased T cell number	J:151816
Gpi1^b-m1Neu/Gpi1^b-m1Neu (C3.Cg-Gpi1^b-m1Neu)	increased spleen weight	J:35956
Gpi1^b-m2Neu/Gpi1^b-m2Neu (C3.Cg-Gpi1^b-m2Neu)	increased spleen weight	J:35956
Gpld1^{tm1.1(KOMP)Vlcg}/Gpld1^{tm1.1(KOMP)Vlcg} (C57BL/6N-Gpld1^{tm1.1(KOMP)Vlcg}/Ucd)	increased spleen weight	J:211773
Gpm6b^tm1Kan Plp1^tm1Kan/Y (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	microgliosis	J:193310
Gpnmb^tm1Ari/Gpnmb^tm1Ari (C57BL/6-Gpnmb^tm1Ari)	abnormal dendritic cell physiology	J:215931
Gpr15^tm1.1Litt/Gpr15^tm1.1Litt (B6.129P2-Gpr15^tm1.1Litt)	abnormal regulatory T cell physiology	J:199126
	decreased CD4-positive, alpha-beta T cell number	J:199126
	decreased double-negative T cell number	J:199126
	decreased regulatory T cell number	J:199126
	immune system phenotype	J:199126
	increased CD8-positive, alpha-beta T cell number	J:199126
	increased susceptibility to bacterial infection	J:199126
	increased susceptibility to bacterial infection induced morbidity/mortality	J:199126
	increased susceptibility to induced colitis	J:199126
Gpr15^tm1.1Litt/Gpr15^tm1.1Litt (involves: 129P2/OlaHsd * C57BL/6)	decreased regulatory T cell number	J:199126
	increased interferon-gamma secretion	J:199126
	increased interleukin-17 secretion	J:199126
Gpr15^tm1.1Litt/Gpr15^tm1.1Litt Rag2^tm1Fwa/Rag2^tm1Fwa Tg(TcraTcrb)425Cbn/0 (involves: 129P2/OlaHsd * 129S/SvEv * BALB/c * C57BL/6)	abnormal immune system physiology	J:199126
Gpr15lg^tm1Lex/Gpr15lg^tm1Lex (B6;129S5-Gpr15lg^tm1Lex/Mmucd)	increased IgG2a level	J:171883
Gpr17^{tm1b(KOMP)Mbp}/Gpr17^{tm1b(KOMP)Mbp} (C57BL/6N-Gpr17^{tm1b(KOMP)Mbp}/Tcp)	increased neutrophil cell number	J:211773
Gpr18^tm1.1Cys/Gpr18^tm1.1Cys (involves: C57BL/6)	decreased CD8-positive, alpha-beta T cell number	J:219661
	decreased CD8-positive, gamma-delta intraepithelial T cell number	J:219661
	immune system phenotype	J:219661
Gpr18^tm1Lex/Gpr18^tm1Lex (involves: 129S/SvEv * C57BL/6)	increased susceptibility to bacterial infection	J:226433
Gpr21^tm1Dgen/Gpr21^tm1Dgen (B6.129P2-Gpr21^tm1Dgen)	abnormal circulating chemokine level	J:181127
Gpr21^tm1Dgen/Gpr21^tm1Dgen (B6.129P2-Gpr21^tm1Dgen)	decreased circulating serum amyloid protein level	J:181127
Gpr31b^tm1Ktak/Gpr31b^tm1Ktak (B6.Cg-Gpr31b^tm1Ktak)	abnormal dendritic cell physiology	J:271242
	decreased inflammatory response	J:271242
	increased susceptibility to bacterial infection	J:271242
Gpr34^tm1.1Shbg/Gpr34^tm1.1Shbg (B6.Cg-Gpr34^tm1.1Shbg)	abnormal chemokine secretion	J:168120
	abnormal cytokine secretion	J:168120
	abnormal leukocyte migration	J:168120
	increased interferon-gamma secretion	J:168120
	increased interleukin-2 secretion	J:168120
	increased interleukin-4 secretion	J:168120
	increased interleukin-5 secretion	J:168120
	increased interleukin-10 secretion	J:168120
	increased interleukin-12 secretion	J:168120
	increased susceptibility to fungal infection	J:168120
	increased susceptibility to type IV hypersensitivity reaction	J:168120
	increased tumor necrosis factor secretion	J:168120
Gpr35^em1Niess/Gpr35^em1Niess (C57BL/6N-Gpr35^em1Niess)	immune system phenotype	J:300275
Gpr35^em1Niess/Gpr35^em1Niess (C57BL/6N-Gpr35^em1Niess)	increased susceptibility to induced colitis	J:300275
Gpr35^em2Niess/Gpr35^em2Niess Cx3cr1^{tm2.1(cre/ERT2)Litt}/Cx3cr1⁺ (involves: 129P2/OlaHsd * C57BL/6N)	increased susceptibility to induced colitis	J:300275
Gpr35^{tm1(KOMP)Vlcg}/Gpr35^{tm1(KOMP)Vlcg} (C57BL/6N-Gpr35^{tm1(KOMP)Vlcg}/MbpMmucd)	abnormal chemokine level	J:306520
	abnormal interleukin level	J:306520
	decreased susceptibility to colitis induced morbidity/mortality	J:306520
	decreased susceptibility to induced colitis	J:306520
Gpr55^tm1.1Mijr/Gpr55^tm1.1Mijr (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal osteoclast differentiation	J:153225
	abnormal osteoclast morphology	J:153225
	abnormal osteoclast physiology	J:153225
	decreased osteoclast cell number	J:153225
	increased osteoclast cell number	J:153225
Gpr65^tm1Witt/Gpr65^tm1Witt (B6.Cg-Gpr65^tm1Witt)	abnormal immune cell physiology	J:96112
Gpr65^tm1Witt/Gpr65^tm1Witt (B6.Cg-Gpr65^tm1Witt)	abnormal leukocyte physiology	J:96112
Gpr65^tm1Witt/Gpr65^tm1Witt (C.Cg-Gpr65^tm1Witt)	abnormal leukocyte physiology	J:96112
Gpr65^{Tn(sb-lacZ,GFP)T1.88Jtak}/Gpr65^{Tn(sb-lacZ,GFP)T1.88Jtak} (B6.Cg-Gpr65^{Tn(sb-lacZ,GFP)T1.88Jtak})	abnormal interleukin-1 beta secretion	J:208788
	abnormal macrophage physiology	J:146233
	decreased tumor necrosis factor secretion	J:146233
Gpr68^em1(IMPC)Bay/Gpr68^em1(IMPC)Bay (C57BL/6N-Gpr68^em1(IMPC)Bay/Bay)	decreased leukocyte cell number	J:211773
Gpr68^tm1.1Yaxu/Gpr68^tm1.1Yaxu (B6.Cg-Gpr68^tm1.1Yaxu)	abnormal osteoclast differentiation	J:149315
	abnormal osteoclast physiology	J:149315
	immune system phenotype	J:149315
Gpr68^tm1.1Yaxu/Gpr68^tm1.1Yaxu (involves: 129S4/SvJae * C57BL/6 * FVB/N)	abnormal macrophage physiology	J:149315
	abnormal osteoclast differentiation	J:149315
	abnormal osteoclast physiology	J:149315
	decreased macrophage cell number	J:149315
	increased monocyte cell number	J:149315
Gpr68^tm1Aha/Gpr68^tm1Aha (B6.129-Gpr68^tm1Aha)	immune system phenotype	J:146233
Gpr68^tm1Yaxu/Gpr68^tm1Yaxu (involves: C57BL/6)	abnormal macrophage physiology	J:149315
	abnormal osteoclast differentiation	J:149315
	abnormal osteoclast physiology	J:149315
	decreased monocyte cell number	J:149315
Gpr83^{em1(IMPC)Ccpcz}/Gpr83^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Gpr83^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	decreased CD4-positive NK T cell number	J:211773
	decreased memory-marker CD4-positive NK T cell number	J:211773
	decreased NK T cell number	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Gpr83^tm1.1Fpow/Gpr83^tm1.1Fpow (C.129-Gpr83^tm1.1Fpow)	decreased CD4-positive, alpha-beta T cell number	J:144445
	immune system phenotype	J:144445
	spleen hyperplasia	J:144445
Gpr84^tm1Lex/Gpr84^tm1Lex (involves: 129S/SvEvBrd * C57BL/6)	abnormal T-helper 2 physiology	J:186985
	immune system phenotype	J:186985
	increased interleukin-4 secretion	J:186985
	increased interleukin-5 secretion	J:186985
	increased interleukin-13 secretion	J:186985
Gpr89^ex/Gpr89^ex (C57BL/6J-Gpr89^ex)	abnormal T cell morphology	J:287198
Gpr89^ex/Gpr89^ex (C57BL/6J-Gpr89^ex)	abnormal T cell number	J:287198
Gpr89^tm1.1Ymae/Gpr89^tm1.1Ymae Tg(KRT5-cre)1Tak/0 (involves: C3H * C57BL/6)	dermatitis	J:189574
Gpr101^em7036Tac/Y (C57BL/6NTac-Gpr101^em7036Tac)	abnormal microglial cell activation	J:347398
	abnormal microglial cell morphology	J:347398
	increased circulating tumor necrosis factor level	J:347398
	increased inflammatory response	J:347398
	increased monocyte cell number	J:347398
Gpr108^tm1.1Brs/Gpr108^tm1.1Brs (involves: 129S6/SvEvTac)	decreased susceptibility to bacterial infection induced morbidity/mortality	J:266821
	decreased tumor necrosis factor secretion	J:266821
	increased interleukin-6 secretion	J:266821
	increased susceptibility to endotoxin shock	J:266821
	increased tumor necrosis factor secretion	J:266821
Gpr132^tm1Witt/Gpr132^tm1Witt (B6.129X1-Gpr132^tm1Witt)	impaired macrophage chemotaxis	J:96613
Gpr132^tm1Witt/Gpr132^tm1Witt (involves: 129X1/SvJ * BALB/c)	abnormal immune system organ morphology	J:69473
	abnormal lymph node morphology	J:69473
	abnormal lymphocyte physiology	J:69473
	enlarged inguinal lymph nodes	J:69473
	enlarged spleen	J:69473
	increased anti-nuclear antigen antibody level	J:69473
	increased B cell proliferation	J:69473
	increased IgA level	J:69473
	increased IgG1 level	J:69473
	increased immunoglobulin level	J:69473
	increased inflammatory response	J:69473
	increased T cell proliferation	J:69473
	kidney inflammation	J:69473
	liver inflammation	J:69473
	lung inflammation	J:69473
Gpr132^tm1Witt/Gpr132^tm1Witt Ldlr^tm1Her/Ldlr^tm1Her (B6.129-Ldlr^tm1Her Gpr132^tm1Witt)	decreased macrophage apoptosis	J:100498
Gpr137b^{tm1b(KOMP)Wtsi}/Gpr137b^{tm1b(KOMP)Wtsi} (C57BL/6N-Gpr137b^{tm1b(KOMP)Wtsi}/H)	increased neutrophil cell number	J:211773
Gpr146^em1(IMPC)H/Gpr146^em1(IMPC)H (C57BL/6NTac-Gpr146^em1(IMPC)H/H)	increased spleen weight	J:211773
Gpr146^em1Bdu/Gpr146^em1Bdu (C57BL/6-Gpr146^em1Bdu)	immune system phenotype	J:247263
Gpr155^em1(IMPC)Mbp/Gpr155^em1(IMPC)Mbp (C57BL/6N-Gpr155^em1(IMPC)Mbp/Ucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
Gpr174^tm1Cys/Y (B6.129-Gpr174^tm1Cys)	abnormal regulatory T cell physiology	J:222307
	abnormal T-helper 1 cell differentiation	J:222307
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:222307
	immune system phenotype	J:222307
	increased single-positive T cell number	J:222307
	increased T cell proliferation	J:222307
Gpr174^tm1Cys/Gpr174⁺ (B6.129-Gpr174^tm1Cys)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:222307
Gpr182^{tm2b(KOMP)Wtsi}/Gpr182^{tm2b(KOMP)Wtsi} (C57BL/6N-Gpr182^{tm2b(KOMP)Wtsi}/Ucd)	increased spleen weight	J:211773
Gpr182^{tm2c(KOMP)Wtsi}/Gpr182^{tm2c(KOMP)Wtsi} Tg(Cdh5-cre/ERT2)1Rha/0 (B6.Cg-Gpr182^{tm2c(KOMP)Wtsi} Tg(Cdh5-cre/ERT2)1Rha)	abnormal circulating chemokine level	J:305796
	increased circulating CXCL10 level	J:305796
	increased monocyte cell number	J:305796
	increased neutrophil cell number	J:305796
Gpr183^tm1.1Cys/Gpr183^tm1.1Cys (B6.129P2-Gpr183^tm1.1Cys)	abnormal follicular B cell physiology	J:151077
Gpr183^tm1.2Rbr/Gpr183^tm1.2Rbr (involves: C57BL/6 * FVB/N * SJL)	abnormal B cell physiology	J:151883
	decreased plasma cell number	J:151883
Gpr183^tm1.2Rbr/Gpr183^tm1.2Rbr Igh^tm1Rbr/Igh^tm1Rbr Tg(IgkHyHEL10)1Rbr/0 (involves: C57BL/6 * FVB/N * SJL)	abnormal B cell physiology	J:151883
	abnormal B cell proliferation	J:151883
	decreased B cell number	J:151883
	decreased IgG1 level	J:151883
	decreased IgM level	J:151883
	decreased plasma cell number	J:151883
	impaired B cell migration	J:151883
Gpr183^tm1Lex/Gpr183^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6)	abnormal circulating interferon-beta level	J:211122
	decreased myeloid dendritic cell number	J:211122
	decreased plasmacytoid dendritic cell number	J:211122
	increased circulating interferon-alpha level	J:211122
	increased circulating interferon-gamma level	J:211122
Gprc5a^tm1Rlo/Gprc5a^tm1Rlo (involves: 129 * C57BL/6)	lung inflammation	J:127821
Gprc5c^tm1Yhir/Gprc5c^tm1Yhir (B6.Cg-Gprc5c^tm1Yhir)	increased basophil cell number	J:176063
Gprc6a^{tm1.1(KOMP)Vlcg}/Gprc6a^{tm1.1(KOMP)Vlcg} (C57BL/6N-Gprc6a^{tm1.1(KOMP)Vlcg}/Ucd)	increased thymus weight	J:211773
Gpsm3^{Gt(IST12408A1)Tigm}/Gpsm3^{Gt(IST12408A1)Tigm} (involves: C57BL/6N)	abnormal leukocyte migration	J:193270
	abnormal leukocyte physiology	J:193270
	decreased monocyte cell number	J:193270
	decreased susceptibility to induced arthritis	J:193270
Gpx1^tm1Kola/Gpx1^tm1Kola (involves: 129S2/SvPas * BALB/c * CF-1)	increased inflammatory response	J:79183
Gpx1^tm1Kola/Gpx1^tm1Kola (B6.129S2(CF1)-Gpx1^tm1Kola)	immune system phenotype	J:100436
Gpx1^tm1Ysh/Gpx1⁺ Gpx2^tm2Coh/Gpx2^tm2Coh (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	intestinal inflammation	J:71506
Gpx1^tm1Ysh/Gpx1^tm1Ysh Gpx2^tm2Coh/Gpx2⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	intestinal inflammation	J:71506
Gpx1^tm1Ysh/Gpx1^tm1Ysh Gpx2^tm2Coh/Gpx2^tm2Coh (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	colitis	J:71506
	intestinal inflammation	J:71506
	small intestinal inflammation	J:71506
Gpx7^tm1Whle/Gpx7^tm1Whle (involves: 129P2/OlaHsd * C57BL/6)	abnormal humoral immune response	J:193993
	enlarged spleen	J:193993
	glomerulonephritis	J:193993
	increased anti-nuclear antigen antibody level	J:193993
Gpx8^tm1Lex/Gpx8^tm1Lex (B6;129S5-Gpx8^tm1Lex/Mmucd)	dermatitis	J:171883
Gramd2a^em1(IMPC)Tcp/Gramd2a^em1(IMPC)Tcp (C57BL/6NCrl-Gramd2a^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Grap2^tm1Amch/Grap2^tm1Amch (involves: 129S1/Sv * 129X1/SvJ)	arrested T cell differentiation	J:76696
	decreased CD4-positive, alpha-beta T cell number	J:76696
	decreased CD8-positive, alpha-beta T cell number	J:76696
	decreased thymocyte number	J:76696
	increased double-negative T cell number	J:76696
Grap2^tm1Amch/Grap2^tm1Amch Lcp2^tm1.1Wz/Lcp2^tm1.1Wz (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal T cell differentiation	J:150304
	decreased CD4-positive, alpha-beta T cell number	J:150304
	decreased CD8-positive, alpha-beta T cell number	J:150304
	decreased double-positive T cell number	J:150304
	decreased single-positive T cell number	J:150304
Grap2^tm1Eac/Grap2^tm1Eac (involves: C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:92023
	abnormal double-negative T cell morphology	J:92023
	decreased T cell number	J:92023
	decreased thymocyte number	J:92023
	increased activated T cell number	J:92023
	increased memory T cell number	J:92023
Grap^tm1Gsf/Grap^tm1Gsf (B6.129-Grap^tm1Gsf)	increased CD4-positive, alpha-beta T cell number	J:76243
Grap^tm1Gsf/Grap^tm1Gsf (B6.129-Grap^tm1Gsf)	increased T cell proliferation	J:76243
Grass1^C57BL/6J/Grass1^C57BL/6J (involves: C57BL/6J * DBA/2J)	decreased susceptibility to bacterial infection	J:134374
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:134374
	sepsis	J:134374
Grass1^C57BL/6J/Grass1^DBA/2J (involves: C57BL/6J * DBA/2J)	increased susceptibility to bacterial infection	J:134374
Grass1^C57BL/6J/Grass1^DBA/2J (involves: C57BL/6J * DBA/2J)	sepsis	J:134374
Grass1^DBA/2J/Grass1^DBA/2J (involves: C57BL/6J * DBA/2J)	increased susceptibility to bacterial infection	J:134374
Grass1^DBA/2J/Grass1^DBA/2J (involves: C57BL/6J * DBA/2J)	sepsis	J:134374
Grb2^tm1.1Hua/Grb2^tm1.1Hua Tg(DO11.10)10Dlo/0 Tg(Lck-cre)1Jtak/0 (involves: 129 * BALB/c * C3H * C57BL/6)	abnormal T cell differentiation	J:161294
	decreased CD4-positive, alpha-beta T cell number	J:161294
Grb2^tm1.1Hua/Grb2^tm1.1Hua Tg(Lck-cre)1Jtak/0 (involves: 129 * C57BL/6)	abnormal T cell differentiation	J:161294
	decreased CD4-positive, alpha-beta T cell number	J:161294
	decreased CD8-positive, alpha-beta T cell number	J:161294
	decreased double-positive T cell number	J:161294
	decreased thymocyte number	J:161294
Grb2^tm1.1Hua/Grb2^tm1.1Hua Tg(Lck-cre)1Jtak/0 Tg(TcraH-Y,TcrbH-Y)71Vbo/0 (involves: 129 * C57BL/6 * C57BL/6J * DBA/2J)	abnormal T cell differentiation	J:161294
	decreased CD4-positive, alpha-beta T cell number	J:161294
	decreased CD8-positive, alpha-beta T cell number	J:161294
	increased CD8-positive, alpha-beta T cell number	J:161294
	increased double-positive T cell number	J:161294
Grb2^tm1Lnit/Grb2^tm1Lnit Cd79a^tm1(cre)Reth/Cd79a⁺ (involves: BALB/c * BALB/cJ)	abnormal B cell differentiation	J:171222
	abnormal B cell physiology	J:171222
	abnormal memory B cell physiology	J:171222
	decreased B cell number	J:171222
	decreased follicular B cell number	J:171222
	decreased IgG3 level	J:171222
	decreased IgG level	J:171222
	decreased mature B cell number	J:171222
	decreased spleen germinal center number	J:171222
	decreased spleen germinal center size	J:171222
	decreased transitional stage T1 B cell number	J:171222
	decreased transitional stage T2 B cell number	J:171222
	increased B cell apoptosis	J:171222
	increased B cell proliferation	J:171222
	increased IgM level	J:171222
	increased plasma cell number	J:171222
Grb2^tm1Paw/Grb2⁺ (involves: 129S1/Sv * 129X1/SvJ * BALB/c)	decreased susceptibility to Retroviridae infection	J:122429
Grb2^tm1Paw/Grb2⁺ Pten^tm2Mak/Pten^tm2Mak Tg(Lck-cre)548Jxm/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA)	increased T cell derived lymphoma incidence	J:93530
Grb14^tm1Daly/Grb14^tm1Daly (involves: 129X1/SvJ * C57BL/6)	decreased spleen weight	J:87892
Greb1^em1Rkom/Greb1^em1Rkom (C57BL/6NJ-Greb1^em1Rkom)	abnormal response to transplant	J:346713
Grem2^em1Stpg/Grem2^em1Stpg (involves: 129S7/SvEvBrd * C57BL/6 * C57BL/6J)	ovary inflammation	J:318711
Grem2^tm1Akh/Grem2^tm1Akh (involves: 129/Sv * C57BL/6)	abnormal chemokine level	J:250034
	increased inflammatory response	J:250034
	increased interleukin-10 secretion	J:250034
	increased leukocyte cell number	J:250034
Grem2^tm1Lex/Grem2^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6)	immune system phenotype	J:227246
Grhl3^{tm1a(EUCOMM)Wtsi}/Grhl3⁺ (C57BL/6N-Grhl3^{tm1a(EUCOMM)Wtsi}/Ics)	decreased IgE level	J:165965
Grhpr^{Gt(OST383093)Lex}/Grhpr^{Gt(OST383093)Lex} (involves: 129S5/SvEvBrd * C57BL/6)	urinary bladder inflammation	J:181969
Grik3^em1(IMPC)Mbp/Grik3^em1(IMPC)Mbp (C57BL/6N-Grik3^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
Grk2^tm1Gwd/Grk2^tm1Gwd Cd79a^tm1(cre)Reth/Cd79a⁺ (involves: 129 * BALB/c * C57BL/6)	abnormal B cell physiology	J:176118
	decreased B cell number	J:176118
	increased B cell number	J:176118
	increased CD4-positive, alpha-beta T cell number	J:176118
	increased CD8-positive, alpha-beta T cell number	J:176118
	increased follicular B cell number	J:176118
	increased marginal zone B cell number	J:176118
Grk2^tm1Gwd/Grk2^tm1Mca Tg(Cd4-cre)1Cwi/0 (involves: 129 * C57BL/6 * DBA/2)	abnormal T cell physiology	J:176118
	decreased CD4-positive, alpha-beta T cell number	J:176118
	decreased CD8-positive, alpha-beta T cell number	J:176118
	decreased T cell number	J:176118
	impaired leukocyte tethering or rolling	J:176118
	increased B cell number	J:176118
Grk6^tm1.1Mca/Grk6^tm1.1Mca (involves: 129S4/SvJae * C57BL/6J)	abnormal B cell physiology	J:76872
	abnormal T cell physiology	J:76872
Grk6^tm1.1Mca/Grk6^tm1.1Mca (B6.129S4-Grk6^tm1.1Mca)	abnormal T cell subpopulation ratio	J:225063
	decreased CD8-positive, alpha-beta T cell number	J:225063
	decreased CD8-positive, naive alpha-beta T cell number	J:225063
	enlarged spleen	J:225063
	glomerulonephritis	J:225063
	impaired macrophage phagocytosis	J:225063
	increased anti-double stranded DNA antibody level	J:225063
	increased IgG level	J:225063
	increased memory T cell number	J:225063
	increased spleen iron level	J:225063
	increased spleen weight	J:225063
	increased spleen white pulp amount	J:225063
	increased splenocyte number	J:225063
Grn^tm1.1Aidi/Grn^tm1.1Aidi (involves: C57BL/6 * C57BL/6J)	abnormal chemokine secretion	J:156824
	abnormal macrophage physiology	J:156824
	abnormal microglial cell physiology	J:156824
	increased interleukin-6 secretion	J:156824
	increased interleukin-12 secretion	J:156824
	increased susceptibility to bacterial infection	J:156824
	increased tumor necrosis factor secretion	J:156824
	microgliosis	J:156824
Grn^tm1.1Aidi/Grn^tm1.1Aidi (involves: C57BL/6J)	kidney inflammation	J:268827
Grn^tm1.1Far/Grn^tm1.1Far (involves: 129S4/SvJae * FVB/N)	abnormal macrophage physiology	J:170823
Grn^tm1.1Far/Grn^tm1.1Far (involves: 129S4/SvJae * C57BL/6J * FVB/N)	increased interleukin-1 beta secretion	J:188324
	increased interleukin-6 secretion	J:188324
	increased interleukin-10 secretion	J:188324
	increased tumor necrosis factor secretion	J:188324
	microgliosis	J:188324
Grn^tm1.1Geno/Grn^tm1.1Geno (involves: 129 * C57BL/6J)	microgliosis	J:188420
Grn^tm1Blrl/Grn^tm1Blrl (involves: C57BL/6J)	microgliosis	J:182051
Grn^tm1Far/Grn^tm1Far Tg(ITGAM-cre)2781Gkl/0 (involves: 129S4/SvJae * C57BL/6 * CBA * FVB/N)	microgliosis	J:188324
Grn^tm2.1Far/Grn^tm2.1Far (involves: 129S4/SvJae * C57BL/6)	abnormal macrophage physiology	J:259651
Grn^tm2.1Far/Grn^tm2.1Far (involves: 129S4/SvJae * C57BL/6)	microgliosis	J:259651
Grp^em1(IMPC)H/Grp^em1(IMPC)H (C57BL/6NTac-Grp^em1(IMPC)H/H)	decreased monocyte cell number	J:211773
Grsf1^{tm1b(EUCOMM)Wtsi}/Grsf1^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Grsf1^{tm1b(EUCOMM)Wtsi}/Wtsi)	decreased leukocyte cell number	J:211773
Gsdma3^Ae/Gsdma3⁺ (involves: C57BL/6J * CAST/Ei)	enlarged lymph nodes	J:180149
	enlarged spleen	J:180149
	enlarged thymus	J:180149
	skin inflammation	J:180149
Gsdma3^M2Btlr/Gsdma3^M2Btlr (involves: C57BL/6J)	dermatitis	J:209203
Gsdma3^{tm1(KOMP)Vlcg}/Gsdma3^{tm1(KOMP)Vlcg} (C57BL/6N-Gsdma3^{tm1(KOMP)Vlcg}/Nju)	increased lymphocyte cell number	J:211773
Gsdma^em1Cya/Gsdma^em1Cya (C57BL/6J-Gsdma^em1Cya)	increased susceptibility to bacterial infection	J:326434
Gsdma^em1Cya/Gsdma^em1Cya (C57BL/6J-Gsdma^em1Cya)	increased susceptibility to bacterial infection induced morbidity/mortality	J:326434
Gsdmc^em1(IMPC)Tcp/Gsdmc^em1(IMPC)Tcp (C57BL/6NCrl-Gsdmc^em1(IMPC)Tcp/TcpMmucd)	enlarged lymph nodes	J:211773
	increased monocyte cell number	J:211773
Gsdmd^em1Fcw/Gsdmd^em2Fcw (involves: C57BL/6)	abnormal macrophage apoptosis	J:226781
Gsdmd^em1Fcw/Gsdmd^em2Fcw (involves: C57BL/6)	decreased interleukin-1 beta secretion	J:226781
Gsdmd^em1Flv/Gsdmd^em1Flv (C57BL/6N-Gsdmd^em1Flv)	increased susceptibility to Riboviria infection induced morbidity/mortality	J:243487
Gsdmd^em3Fcw/Gsdmd^em3Fcw (involves: C57BL/6)	abnormal macrophage apoptosis	J:226781
Gsdmd^em3Fcw/Gsdmd^em3Fcw (involves: C57BL/6)	decreased interleukin-1 beta secretion	J:226781
Gsdmd^em4Fcw/Gsdmd^em4Fcw (C57BL/6N-Gsdmd^em4Fcw/J)	abnormal macrophage apoptosis	J:101977
Gsdmd^em4Fcw/Gsdmd^em4Fcw (C57BL/6N-Gsdmd^em4Fcw/J)	abnormal susceptibility to bacterial infection	J:101977
Gsdmd^m1Btlr/Gsdmd^m1Btlr (C57BL/6J-Gsdmd^m1Btlr)	decreased interleukin-1 beta secretion	J:267555
Gsk3a^tm1Dral/Gsk3a^tm1Dral Gsk3b^tm1Dral/Gsk3b^tm1Dral (involves: 129P2/OlaHsd)	increased circulating interleukin-6 level	J:200517
Gsn^tm1Djk/Gsn^tm1Djk (either: (involves: 129S4/SvJae * BALB/c) or (involves: 129S4/SvJae * C57BL/6))	abnormal immune system physiology	J:24346
	abnormal osteoclast differentiation	J:60625
	abnormal osteoclast physiology	J:60625
	decreased inflammatory response	J:24346
	impaired neutrophil chemotaxis	J:24346
	impaired neutrophil recruitment	J:24346
	increased leukocyte cell number	J:24346
	increased neutrophil cell number	J:24346
Gsta4^tm1Pzim/Gsta4⁺ (involves: 129S1/Sv * 129S6/SvEvTac)	increased susceptibility to bacterial infection	J:87983
Gsta4^tm1Pzim/Gsta4^tm1Pzim (involves: 129S1/Sv * 129S6/SvEvTac)	abnormal bone marrow development	J:87983
	increased susceptibility to bacterial infection	J:87983
Gstcd^{tm1b(EUCOMM)Wtsi}/Gstcd^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Gstcd^{tm1b(EUCOMM)Wtsi}/Bay)	enlarged spleen	J:211773
Gstcd^{tm1b(EUCOMM)Wtsi}/Gstcd^{tm1b(EUCOMM)Wtsi} (C57BL/6-Gstcd^{tm1b(EUCOMM)Wtsi})	increased tumor necrosis factor secretion	J:279480
Gstk1^tm1Pgb/Gstk1^tm1Pgb (BALB/c-Gstk1^tm1Pgb)	decreased spleen red pulp amount	J:177201
	decreased spleen weight	J:177201
	glomerulonephritis	J:177201
	urethritis	J:177201
	urinary bladder inflammation	J:177201
Gstm4^{tm2b(EUCOMM)Hmgu}/Gstm4^{tm2b(EUCOMM)Hmgu} (C57BL/6N-Gstm4^{tm2b(EUCOMM)Hmgu}/Bay)	abnormal spleen morphology	J:211773
Gstt2^em1Rmah/Gstt2^em1Rmah (Not Specified)	decreased interleukin-12 secretion	J:358834
	decreased tumor necrosis factor secretion	J:358834
	increased inflammatory response	J:358834
	increased interleukin-6 secretion	J:358834
	increased interleukin-10 secretion	J:358834
	increased interleukin-12 secretion	J:358834
	increased tumor necrosis factor secretion	J:358834
Gstz1^tm1Pgb/Gstz1^tm1Pgb (BALB/c-Gstz1^tm1Pgb/AnuApb)	chronic inflammation	J:91519
	decreased leukocyte cell number	J:91519
	decreased spleen weight	J:91519
	liver inflammation	J:91519
Gsx1^tm1Ssp/Gsx1^tm1Ssp (involves: 129P2/OlaHsd)	decreased leukocyte cell number	J:31764
	decreased lymphocyte cell number	J:31764
	decreased neutrophil cell number	J:31764
Gt(ROSA)26Sor^{em1(DPP4)Yowa}/Gt(ROSA)26Sor^{em1(DPP4)Yowa} (C57BL/6-Gt(ROSA)26Sor^{em1(DPP4)Yowa})	increased susceptibility to Coronaviridae infection	J:279060
Gt(ROSA)26Sor^{em1(Ube2s)Chaw}/? (involves: C57BL/6)	decreased interferon level	J:306461
Gt(ROSA)26Sor^{em1(Ube2s)Chaw}/? (involves: C57BL/6)	increased susceptibility to Picornaviridae infection induced morbidity/mortality	J:306461
Gt(ROSA)26Sor^{tm1(B4galt1)Clib}/Gt(ROSA)26Sor^{tm1(B4galt1)Clib} Tg(Nes-cre)Wme/? (involves: 129S6/SvEvTac * C57BL/6 * CBA)	decreased acute inflammation	J:209737
	decreased circulating interleukin-6 level	J:209737
	decreased susceptibility to induced colitis	J:209737
Gt(ROSA)26Sor^{tm1(CAG-Bcl3,-EGFP)Hoev}/Gt(ROSA)26Sor⁺ Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129P2/OlaHsd)	abnormal B cell differentiation	J:208980
	abnormal B-2 B cell morphology	J:208980
	abnormal class switch recombination	J:208980
	abnormal follicular B cell morphology	J:208980
	abnormal Peyer's patch germinal center morphology	J:208980
	abnormal transitional stage T3 B cell morphology	J:208980
	absent marginal zone B cells	J:208980
	decreased B cell apoptosis	J:208980
	decreased B cell proliferation	J:208980
	decreased B-1 B cell number	J:208980
	decreased B-1a cell number	J:208980
	decreased IgG1 level	J:208980
	decreased IgG2b level	J:208980
	decreased IgG3 level	J:208980
	decreased IgM level	J:208980
	decreased immature B cell number	J:208980
	decreased marginal zone B cell number	J:208980
	decreased transitional stage T1 B cell number	J:208980
	enlarged spleen	J:208980
	increased lymphocyte cell number	J:208980
Gt(ROSA)26Sor^{tm1(CAG-CAMK2GT287D,-EGFP)Whua}/Gt(ROSA)26Sor⁺ Tg(Vil1-cre)997Gum/0 (involves: 129 C57BL/6)	decreased susceptibility to induced colitis	J:243363
Gt(ROSA)26Sor^{tm1(CAG-Foxn1/ERT2,-GFP)Cbln}/Gt(ROSA)26Sor⁺ Foxn1^tm3(cre)Nrm/Foxn1⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal thymus involution	J:208852
	increased T cell number	J:208852
Gt(ROSA)26Sor^{tm1(CAG-FOXO1,GFP)Moli}/Gt(ROSA)26Sor⁺ Foxp3^{tm4(YFP/icre)Ayr}/Foxp3⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	immune system phenotype	J:189962
Gt(ROSA)26Sor^{tm1(CAG-NPM1)Geno}/Gt(ROSA)26Sor⁺ Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 CBA)	enlarged spleen	J:196690
	myeloid hyperplasia	J:196690
Gt(ROSA)26Sor^{tm1(CAG-NPM1)Geno}/Gt(ROSA)26Sor^{tm1(CAG-NPM1)Geno} Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA)	enlarged spleen	J:196690
Gt(ROSA)26Sor^{tm1(CAG-SETBP1G870S,-EGFP)Ase}/Gt(ROSA)26Sor⁺ Commd10^{Tg(Vav1-icre)A2Kio}/Commd10⁺ (involves: C57BL/6N C57BL/10 * CBA/Ca)	abnormal spleen morphology	J:363041
	decreased lymphocyte cell number	J:363041
	hepatosplenomegaly	J:363041
	increased leukocyte cell number	J:363041
	myeloid hyperplasia	J:363041
Gt(ROSA)26Sor^{tm1(CAG-SETBP1G870S,-EGFP)Ase}/Gt(ROSA)26Sor^{tm1(CAG-SETBP1G870S,-EGFP)Ase} Commd10^{Tg(Vav1-icre)A2Kio}/Commd10⁺ (involves: C57BL/6N * C57BL/10 * CBA/Ca)	abnormal myelopoiesis	J:363041
	decreased leukocyte cell number	J:363041
	increased neutrophil cell number	J:363041
Gt(ROSA)26Sor^{tm1(CAG-Slc39a14*L438R)Wvh}/Gt(ROSA)26Sor⁺ Tg(Runx2-icre)1Jtuc/0 (involves: FVB/N)	increased osteoclast cell number	J:261326
Gt(ROSA)26Sor^{tm1(CARD14)Ribt}/Gt(ROSA)26Sor⁺ Malt1^{tm1c(EUCOMM)Hmgu}/Malt1^{tm1c(EUCOMM)Hmgu} Tg(KRT14-cre/ERT)20Efu/0 (involves: 129S6/SvEvTac C57BL/6NCrl * CD-1)	increased dendritic cell number	J:292094
	increased neutrophil cell number	J:292094
	skin inflammation	J:292094
Gt(ROSA)26Sor^{tm1(CARD14)Ribt}/Gt(ROSA)26Sor⁺ Tg(KRT14-cre/ERT)20Efu/0 (involves: 129S6/SvEvTac C57BL/6NCrl * CD-1)	increased dendritic cell number	J:292094
	increased neutrophil cell number	J:292094
	skin inflammation	J:292094
Gt(ROSA)26Sor^{tm1(cre/ERT2)Thl}/Gt(ROSA)26Sor⁺ Mcl1^tm1Ywh/Mcl1^tm1Ywh (involves: 129/Sv * 129S6/SvEvTac * C57BL/6)	increased T cell apoptosis	J:137400
Gt(ROSA)26Sor^{tm1(cre/ERT2)Thl}/Gt(ROSA)26Sor^{tm1(Tcfe2a/Tal1)Xhsu} (involves: 129/Sv * C57BL/6)	abnormal lymphopoiesis	J:144569
	abnormal myelopoiesis	J:144569
Gt(ROSA)26Sor^{tm1(cre/ERT2)Tyj}/Gt(ROSA)26Sor⁺ Tacc3^tm1.1Tno/Tacc3⁺ Trp53^tm1Tyj/Trp53^tm1Tyj (involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)	increased T cell derived lymphoma incidence	J:179414
Gt(ROSA)26Sor^{tm1(cre/ERT2)Tyj}/Gt(ROSA)26Sor⁺ Tacc3^tm1.1Tno/Tacc3^tm1.2Tno Trp53^tm1Tyj/Trp53^tm1Tyj (involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)	increased T cell derived lymphoma incidence	J:179414
Gt(ROSA)26Sor^{tm1(cre/ERT2)Tyj}/Gt(ROSA)26Sor^tm1(Pyy)Paba (involves: 129S4/SvJae)	abnormal osteoclast morphology	J:189512
	increased osteoclast cell number	J:189512
Gt(ROSA)26Sor^{tm1(cre/ERT)Nat}/Gt(ROSA)26Sor⁺ Il1r2^tm1.1Epi/Il1r2^tm1.1Epi (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * C57BL/6NTac)	abnormal adaptive immunity	J:347877
	increased IgG level	J:347877
	increased spleen germinal center size	J:347877
	increased T follicular helper cell number	J:347877
Gt(ROSA)26Sor^{tm1(cre/ERT)Nat}/Gt(ROSA)26Sor⁺ Pten^tm1Hwu/Pten^tm1Hwu (involves: 129 * 129S4/SvJae * BALB/c * C57BL/6)	increased T cell derived lymphoma incidence	J:130367
Gt(ROSA)26Sor^{tm1(CTNNB1)Nerl}/Gt(ROSA)26Sor^{tm1(CTNNB1)Nerl} Tg(Mx1-cre)1Cgn/0 (involves: 129P2/OlaHsd * BALB/c * C57BL/6 * CBA)	arrested T cell differentiation	J:112660
	decreased double-negative T cell number	J:112660
	decreased granulocyte number	J:112660
	decreased leukocyte cell number	J:112660
	impaired myelopoiesis	J:112660
	thymus hypoplasia	J:112660
Gt(ROSA)26Sor^tm1(DTA)Jpmb/Gt(ROSA)26Sor⁺ Tg(Plp1-cre/ERT)3Pop/0 (involves: 129S/SvEv * C57BL/6 * DBA/2)	autoimmune response	J:234435
	CNS inflammation	J:234435
	increased activated T cell number	J:234435
	lymph node inflammation	J:234435
Gt(ROSA)26Sor^tm1(DTA)Jpmb/Gt(ROSA)26Sor⁺ Tg(Trpv1-cre)1Hoon/0 (involves: 129S1/Sv)	decreased inflammatory response	J:169256
Gt(ROSA)26Sor^tm1(DTA)Lky/? Il5^{tm1.1(icre)Lky}/Il5⁺ Rag1^tm1Mom/Rag1^tm1Mom (involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6)	abnormal immune system physiology	J:206097
Gt(ROSA)26Sor^tm1(DTA)Lky/Gt(ROSA)26Sor⁺ Il13^{tm1(YFP/cre)Lky}/Il13^{tm1(YFP/cre)Lky} (involves: 129P2/OlaHsd * 129S4/SvJae)	decreased eosinophil cell number	J:178986
	decreased IgG1 level	J:178986
	decreased interleukin-5 secretion	J:178986
	decreased interleukin-13 secretion	J:178986
	increased susceptibility to parasitic infection	J:178986
Gt(ROSA)26Sor^tm1(DTA)Lky/Gt(ROSA)26Sor^tm1(DTA)Lky Tg(Cd4-cre)1Cwi/0 (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	abnormal CD4-positive, alpha-beta T cell physiology	J:133382
	abnormal CD8-positive, alpha-beta T cell differentiation	J:133382
	abnormal lymph node T cell domain morphology	J:133382
	abnormal spleen morphology	J:133382
	abnormal T cell receptor V(D)J recombination	J:133382
	decreased CD4-positive, alpha-beta T cell number	J:133382
	decreased CD8-positive, alpha-beta T cell number	J:133382
	decreased double-positive T cell number	J:133382
	decreased lymphocyte cell number	J:133382
	decreased NK T cell number	J:133382
	decreased regulatory T cell number	J:133382
	immune system phenotype	J:133382
	increased susceptibility to parasitic infection	J:133382
Gt(ROSA)26Sor^tm1(DTA)Riet/Gt(ROSA)26Sor^tm1(DTA)Riet Tg(Rorc-cre)1Litt/? (involves: 129P2/OlaHsd)	abnormal effector T cell morphology	J:137020
Gt(ROSA)26Sor^tm1(DUX4)Sqh/Gt(ROSA)26Sor⁺ Tg(ACTA1-cre/Esr1)2Kesr/0 (involves: 129S6/SvEvTac C3H * C57BL/6)	abnormal acute inflammation	J:268959
Gt(ROSA)26Sor^{tm1(ETV6/SYK)Hjum}/Gt(ROSA)26Sor⁺ Cd79a^{tm3(cre/ERT2)Reth}/Cd79a⁺ (involves: 129S6/SvEvTac * BALB/c)	abnormal circulating chemokine level	J:208904
	abnormal cytokine level	J:208904
	abnormal plasma cell differentiation	J:208904
	enlarged lymph nodes	J:208904
	enlarged spleen	J:208904
	increased B cell apoptosis	J:208904
	increased B cell number	J:208904
	increased B cell proliferation	J:208904
	increased circulating interferon-gamma level	J:208904
	increased circulating interleukin-6 level	J:208904
	increased circulating interleukin-10 level	J:208904
	increased circulating tumor necrosis factor level	J:208904
	increased IgM level	J:208904
	increased interferon-gamma secretion	J:208904
	increased interleukin-10 secretion	J:208904
	increased tumor necrosis factor secretion	J:208904
Gt(ROSA)26Sor^{tm1(ETV6/SYK)Hjum}/Gt(ROSA)26Sor⁺ Cd79a^{tm3(cre/ERT2)Reth}/Cd79a⁺ Tg(BCL2)22Wehi/0 (involves: 129S6/SvEvTac * BALB/c * C57BL/6JWehi * SJL/JWehi)	abnormal B cell physiology	J:208904
	abnormal plasma cell differentiation	J:208904
	enlarged lymph nodes	J:208904
	enlarged spleen	J:208904
Gt(ROSA)26Sor^{tm1(EWSR1/FLI1)Sbk}/Gt(ROSA)26Sor⁺ Tg(Mx1-cre)1Cgn/? (involves: 129S1/Sv * C57BL/6 * CBA)	abnormal lymph node B cell domain morphology	J:129039
	abnormal myelopoiesis	J:129039
	enlarged spleen	J:129039
	increased leukocyte cell number	J:129039
	increased spleen red pulp amount	J:129039
Gt(ROSA)26Sor^tm1(EYFP)Cos/Gt(ROSA)26Sor⁺ Ighg1^tm1(cre)Cgn/Ighg1⁺ Prdm1^tm2Masu/Prdm1^tm2Masu (involves: 129P2/OlaHsd * 129X1/SvJ)	abnormal germinal center B cell physiology	J:167612
	abnormal plasma cell differentiation	J:167612
	decreased IgG1 level	J:167612
	enlarged lymph nodes	J:167612
	enlarged spleen	J:167612
	increased germinal center B cell number	J:167612
Gt(ROSA)26Sor^tm1(EYFP)Cos/Gt(ROSA)26Sor⁺ Il22^{tm1.1(icre)Stck}/Il22⁺ (involves: 129X1/SvJ * C57BL/6N)	abnormal susceptibility to bacterial infection	J:220074
Gt(ROSA)26Sor^tm1(EYFP)Cos/Gt(ROSA)26Sor⁺ Kras^tm4Tyj/Kras⁺ Tg(Pdx1-cre)89.1Dam/0 (involves: 129 * C57BL/6 * CBA)	increased susceptibility to induced pancreatitis	J:289183
Gt(ROSA)26Sor^tm1(EYFP)Cos/Gt(ROSA)26Sor⁺ Plcg1^tm1Gcrp/Plcg1^tm1Rwen Tg(Cd4-cre)1Cwi/0 (involves: 129X1/SvJ * C57BL/6 * DBA/2)	abnormal CD4-positive T cell differentiation	J:157757
	abnormal CD8-positive, alpha-beta T cell differentiation	J:157757
	abnormal regulatory T cell physiology	J:157757
	abnormal T cell activation	J:157757
	decreased CD4-positive, alpha-beta T cell number	J:157757
	decreased CD8-positive, alpha-beta T cell number	J:157757
	decreased interferon-gamma secretion	J:157757
	decreased interleukin-2 secretion	J:157757
	decreased single-positive T cell number	J:157757
	decreased T cell number	J:157757
	decreased T cell proliferation	J:157757
	dermatitis	J:157757
	increased double-positive T cell number	J:157757
	increased T cell apoptosis	J:157757
Gt(ROSA)26Sor^tm1(EYFP)Cos/Gt(ROSA)26Sor⁺ Cd19^tm1(cre)Cgn/Cd19⁺ Rev3l^tm1.1Diaz/Rev3l^tm1.1Diaz (involves: 129P2/OlaHsd * 129X1/SvJ * BALB/c * C57BL/6 * C57BL/6NTac)	abnormal class switch recombination	J:188723
	abnormal somatic hypermutation frequency	J:188723
	decreased B cell proliferation	J:188723
	immune system phenotype	J:188723
Gt(ROSA)26Sor^{tm1(GNAQ)Cvrk}/Gt(ROSA)26Sor⁺ Tg(Mitf-cre)7114Gsb/0 (C3FeJ.Cg-Gt(ROSA)26Sor^{tm1(GNAQ)Cvkr} Tg(Mitf-cre)7114Gsb/Cvrk)	enlarged lymph nodes	J:225597
Gt(ROSA)26Sor^{tm1(gp80)Eces}/Gt(ROSA)26Sor⁺ Cd19^tm1(cre)Cgn/Cd19⁺ (either: (involves: 129/Sv * 129P2/OlaHsd * C57BL/6) or (involves: 129/Sv * 129P2/OlaHsd * BALB/c * C57BL/6))	abnormal class switch recombination	J:172031
	absent spleen germinal center	J:172031
	decreased B cell apoptosis	J:172031
	decreased B cell number	J:172031
	decreased germinal center B cell number	J:172031
	decreased IgA level	J:172031
	decreased IgG1 level	J:172031
	decreased IgG2a level	J:172031
	decreased IgG3 level	J:172031
	decreased plasma cell number	J:172031
	enlarged spleen	J:172031
	increased B cell number	J:172031
	increased IgE level	J:172031
	increased macrophage cell number	J:172031
	increased marginal zone B cell number	J:172031
	increased spleen weight	J:172031
	increased T cell number	J:172031
Gt(ROSA)26Sor^{tm1(gp80)Eces}/Gt(ROSA)26Sor⁺ Ighg1^tm1(cre)Cgn/Ighg1⁺ (either: (involves: 129/Sv * 129P2/OlaHsd * C57BL/6) or (involves: 129/Sv * 129P2/OlaHsd * BALB/c * C57BL/6))	abnormal class switch recombination	J:172031
	absent spleen germinal center	J:172031
	decreased B cell number	J:172031
	decreased follicular B cell number	J:172031
	decreased germinal center B cell number	J:172031
	decreased IgA level	J:172031
	decreased IgG1 level	J:172031
	decreased IgG2a level	J:172031
	decreased IgG2b level	J:172031
	decreased IgG3 level	J:172031
	decreased plasma cell number	J:172031
	enlarged spleen	J:172031
	increased B cell number	J:172031
	increased IgE level	J:172031
	increased macrophage cell number	J:172031
	increased marginal zone B cell number	J:172031
	increased spleen weight	J:172031
Gt(ROSA)26Sor^{tm1(H1/tetO-RNAi:Pdpk1)Mrl}/Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte} Pten^tm1Hwu/Pten^tm1Hwu (involves: 129S4/SvJae * C57BL/6)	decreased B cell number	J:170965
	enlarged lymph nodes	J:170965
	enlarged spleen	J:170965
	increased memory B cell number	J:170965
	increased spleen weight	J:170965
Gt(ROSA)26Sor^tm1(HA)Libl/Gt(ROSA)26Sor^tm1(HA)Libl Mog^tm1(cre)Gkl/? (involves: 129/Sv * C57BL/6)	immune system phenotype	J:137838
Gt(ROSA)26Sor^tm1(HA)Libl/Gt(ROSA)26Sor^tm1(HA)Libl Mog^tm1(cre)Gkl/? Tg(TcraCl4,TcrbCl4)1Shrm/0 (involves: 129/Sv * BALB/c * C57BL/6)	brain inflammation	J:137838
	optic nerve inflammation	J:137838
	spinal cord inflammation	J:137838
Gt(ROSA)26Sor^{tm1(HBEGF)Awai}/Gt(ROSA)26Sor^{tm1(HBEGF)Awai} Mog^tm1(cre)Gkl/? (involves: C57BL/6)	abnormal immune system physiology	J:131076
Gt(ROSA)26Sor^{tm1(HBEGF)Awai}/Gt(ROSA)26Sor^{tm1(HBEGF)Awai} Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	abnormal lymphocyte cell number	J:131076
	decreased single-positive T cell number	J:131076
Gt(ROSA)26Sor^{tm1(ITK/SYK)Jrld}/Gt(ROSA)26Sor⁺ Tg(Cd4-cre)1Cwi/0 (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	abnormal spleen morphology	J:160931
	abnormal T cell activation	J:160931
	abnormal T cell differentiation	J:160931
	decreased double-positive T cell number	J:160931
	decreased single-positive T cell number	J:160931
	decreased T cell number	J:160931
	enlarged spleen	J:160931
	immune system phenotype	J:160931
	increased T cell derived lymphoma incidence	J:160931
	increased T cell proliferation	J:160931
Gt(ROSA)26Sor^{tm1(MAML1)Wsp}/Gt(ROSA)26Sor⁺ Tg(Cd4-cre)1Cwi/0 (B6.Cg-Tg(Cd4-cre)1Cwi Gt(ROSA)26Sor^{tm1(MAML1)Wsp})	abnormal immunoglobulin level	J:113262
	abnormal T-helper 1 physiology	J:113262
	abnormal T-helper 2 physiology	J:113262
	decreased susceptibility to parasitic infection	J:113262
	increased susceptibility to parasitic infection	J:113262
Gt(ROSA)26Sor^{tm1(MAML1)Wsp}/Gt(ROSA)26Sor⁺ Tg(KRT14-rtTA)F42Efu/0 Tg(tetO-cre)1Jaw/0 (involves: 129 * C57BL/6 * FVB)	conjunctivitis	J:194073
Gt(ROSA)26Sor^{tm1(Mirn155)Rsky}/Gt(ROSA)26Sor^{tm1(Mirn155)Rsky} (involves: BALB/c * C57BL/6)	abnormal humoral immune response	J:121084
	increased germinal center B cell number	J:121084
Gt(ROSA)26Sor^{tm1(Nfatc2)Rao}/Gt(ROSA)26Sor⁺ Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 DBA/2)	abnormal interferon level	J:148341
	abnormal T cell activation	J:148341
Gt(ROSA)26Sor^{tm1(Notch1)Dam}/Gt(ROSA)26Sor⁺ Hes1^tm1.1Frad/Hes1^tm1.1Frad Tg(Mx1-cre)1Cgn/0 (involves: 129S4/SvJaeSor * C57BL/6 * CBA)	decreased B cell number	J:167000
Gt(ROSA)26Sor^{tm1(Notch1)Dam}/Gt(ROSA)26Sor⁺ Tg(Mx1-cre)1Cgn/0 (involves: 129S4/SvJaeSor * C57BL/6 * CBA)	decreased B cell number	J:167000
	enlarged spleen	J:167000
	increased leukocyte cell number	J:167000
Gt(ROSA)26Sor^{tm1(NOTCH1/GFP)Xhsu}/Gt(ROSA)26Sor⁺ Tg(Lck-cre)548Jxm/0 (B6.Cg-Gt(ROSA)26Sor^{tm1(NOTCH1/GFP)Xhsu} Tg(Lck-cre)548Jxm)	increased T cell derived lymphoma incidence	J:185287
Gt(ROSA)26Sor^tm1(Ntn4)Dyl/Gt(ROSA)26Sor⁺ Tg(KRT14-cre)1Amc/0 (involves: 129/Sv * C57BL/6 * CBA)	abnormal lymphangiogenesis	J:162807
	abnormal lymphatic vessel morphology	J:162807
	lymphatic vessel hyperplasia	J:162807
Gt(ROSA)26Sor^{tm1(OVAL/fla,GFP)Vnce}/Gt(ROSA)26Sor⁺ Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6J)	abnormal circulating cytokine level	J:260047
	decreased B cell number	J:260047
	decreased lymphocyte cell number	J:260047
	enlarged lymph nodes	J:260047
	enlarged spleen	J:260047
	glomerulonephritis	J:260047
	increased inflammatory response	J:260047
	increased monocyte cell number	J:260047
	increased neutrophil cell number	J:260047
	increased T cell number	J:260047
	joint inflammation	J:260047
	small intestinal inflammation	J:260047
Gt(ROSA)26Sor^{tm1(OVAL/fla,GFP)Vnce}/Gt(ROSA)26Sor⁺ Lyz2^tm1(cre)Ifo/Lyz2⁺ Nlrc4^tm1Vmd/Nlrc4^tm1Vmd (involves: 129P2/OlaHsd * C57BL/6J * C57BL/6NCrl)	immune system phenotype	J:260047
Gt(ROSA)26Sor^{tm1(OVAL/fla,GFP)Vnce}/Gt(ROSA)26Sor⁺ Lyz2^tm1(cre)Ifo/Lyz2⁺ Pycard^tm1Vmd/Pycard^tm1Vmd (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6J)	immune system phenotype	J:260047
	increased circulating interferon-gamma level	J:260047
	increased circulating interleukin-6 level	J:260047
	increased circulating tumor necrosis factor level	J:260047
Gt(ROSA)26Sor^{tm1(OVAL/fla,GFP)Vnce}/Gt(ROSA)26Sor⁺ Tg(Itgax-cre)1-1Reiz/0 (involves: C3H * C57BL/6 * C57BL/6J)	increased monocyte cell number	J:260047
	increased neutrophil cell number	J:260047
Gt(ROSA)26Sor^{tm1(OVAL/fla,GFP)Vnce}/Gt(ROSA)26Sor⁺ Tg(S100A8-cre,-EGFP)1Ilw/0 (involves: C3H * C57BL/6 * C57BL/6J)	abnormal circulating cytokine level	J:260047
	increased circulating interleukin-18 level	J:260047
	increased monocyte cell number	J:260047
	increased neutrophil cell number	J:260047
Gt(ROSA)26Sor^{tm1(Pik3caH1047R)Egan}/Gt(ROSA)26Sor⁺ Tg(MMTV-cre)#Tfln/0 Trp53^tm1Brn/Trp53⁺ (involves: 129P2/OlaHsd 129S6/SvEvTac)	increased T cell derived lymphoma incidence	J:170898
Gt(ROSA)26Sor^{tm1(Pik3caH1047R)Egan}/Gt(ROSA)26Sor⁺ Trp53^tm1Brn/Trp53^tm1Brn Tg(MMTV-cre)#Tfln/0 (involves: 129P2/OlaHsd 129S6/SvEvTac)	increased T cell derived lymphoma incidence	J:170898
Gt(ROSA)26Sor^{tm1(Ptpn22)Draw}/Gt(ROSA)26Sor⁺ Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129P2/OlaHsd C57BL/6)	enlarged spleen	J:201448
	glomerulonephritis	J:201448
	increased anti-double stranded DNA antibody level	J:201448
	increased autoantibody level	J:201448
	increased B cell number	J:201448
	increased germinal center B cell number	J:201448
	spleen hyperplasia	J:201448
Gt(ROSA)26Sor^{tm1(RNAi:Bmpr2)Dliu}/Gt(ROSA)26Sor⁺ (involves: 129 * C57BL/6J)	abnormal spleen morphology	J:145514
	abnormal spleen white pulp morphology	J:145514
	enlarged spleen	J:145514
Gt(ROSA)26Sor^tm1(rtTA)Awu/Gt(ROSA)26Sor^tm1(rtTA)Awu Xist^tm1Awu/Y (involves: 129S4/SvJae)	abnormal B cell differentiation	J:112954
	abnormal myelopoiesis	J:112954
	abnormal T cell differentiation	J:112954
	abnormal thymus morphology	J:112954
	absent pre-B cells	J:112954
	decreased double-positive T cell number	J:112954
	decreased granulocyte number	J:112954
	decreased immature B cell number	J:112954
	decreased macrophage cell number	J:112954
	decreased pro-B cell number	J:112954
	decreased thymocyte number	J:112954
	small thymus	J:112954
	thymus hypoplasia	J:112954
Gt(ROSA)26Sor^tm1(rtTA)Awu/Gt(ROSA)26Sor^tm1(rtTA)Awu Xist^tm1Awu/Xist^tm1Awu (involves: 129S4/SvJae)	small thymus	J:112954
Gt(ROSA)26Sor^{tm1(rtTA,EGFP)Nagy}/Gt(ROSA)26Sor⁺ Tg(CAG-cre)1Nagy/0 Tg(tetO-Vegfa)90Ala/0 (involves: 129S1/Sv * 129X1/SvJ * FVB/N * ICR)	enlarged lymph nodes	J:99607
	thymus atrophy	J:99607
Gt(ROSA)26Sor^{tm1(rtTA,EGFP)Nagy}/Gt(ROSA)26Sor⁺ Tg(Col2a1-cre)1Bhr/0 Tg(tetO-Vegfa)90Ala/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N * SJL)	decreased osteoclast cell number	J:156474
	enlarged spleen	J:156474
Gt(ROSA)26Sor^{tm1(sb11)Njen}/Gt(ROSA)26Sor⁺ TgTn(sb-T2/Onc2)6057Njen/0 (involves: C3H * C57BL/6)	increased T cell derived lymphoma incidence	J:102234
Gt(ROSA)26Sor^{tm1(sb11)Njen}/Gt(ROSA)26Sor⁺ TgTn(sb-T2/Onc2)6070Njen/0 (involves: C3H * C57BL/6)	increased T cell derived lymphoma incidence	J:102234
Gt(ROSA)26Sor^{tm1(sb11)Njen}/Gt(ROSA)26Sor⁺ TgTn(sb-T2/Onc2)6113Njen/0 (involves: C3H * C57BL/6)	increased T cell derived lymphoma incidence	J:102234
Gt(ROSA)26Sor^{tm1(sb11)Njen}/Gt(ROSA)26Sor⁺ TgTn(sb-T2/Onc3)12740Njen/0 (involves: C3H * C57BL/6J)	increased T cell derived lymphoma incidence	J:153656
Gt(ROSA)26Sor^{tm1(Stat3A661CN663C)Sbkv}/Gt(ROSA)26Sor^{tm1(Stat3A661CN663C)Sbkv} (involves: C57BL/6)	abnormal T-helper 17 cell differentiation	J:205858
Gt(ROSA)26Sor^{tm1(Stat3A661CN663C)Sbkv}/Gt(ROSA)26Sor^{tm1(Stat3A661CN663C)Sbkv} Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	increased circulating interleukin-17 level	J:205858
	increased interleukin-17 secretion	J:205858
	increased regulatory T cell number	J:205858
	increased T-helper 1 cell number	J:205858
	increased T-helper 17 cell number	J:205858
	lung inflammation	J:205858
Gt(ROSA)26Sor^{tm1(Tbx1/GFP)Bem}/Gt(ROSA)26Sor⁺ Foxg1^tm1(cre)Skm/Foxg1⁺ (involves: 129P2/OlaHsd * C57BL/6 * SJL)	athymia	J:204435
Gt(ROSA)26Sor^{tm1(tTA,tetO-Mir21)Fjsl}/Gt(ROSA)26Sor⁺ Tg(Nes-cre)1Wmz/0 (involves: C57BL/6 * C57BL/6J * SJL/J)	abnormal spleen morphology	J:163919
	abnormal thymus corticomedullary boundary morphology	J:163919
	abnormal thymus morphology	J:163919
	decreased leukocyte cell number	J:163919
	enlarged lymph nodes	J:163919
	enlarged spleen	J:163919
	enlarged thymus	J:163919
	intermingled spleen red and white pulp	J:163919
Gt(ROSA)26Sor^{tm1(tTA,tetO-Mir155)Fjsl}/Gt(ROSA)26Sor⁺ Tg(Nes-cre)1Wmz/0 (involves: 129 * C57BL/6 * FVB/N * SJL/J)	abnormal immune system morphology	J:185598
	enlarged lymph nodes	J:185598
	enlarged spleen	J:185598
	increased spleen weight	J:185598
	increased spleen white pulp amount	J:185598
	thymus hyperplasia	J:185598
Gt(ROSA)26Sor^{tm1.1(Aco1)Mwh}/Gt(ROSA)26Sor^{tm1.1(Aco1)Mwh} (B6.129P2(129S1)-Gt(ROSA)26Sor^{tm1.1(Aco1*)Mwh})	increased spleen iron level	J:196374
Gt(ROSA)26Sor^{tm1.1(CAG-PSTPIP1)Dtg}/Gt(ROSA)26Sor⁺ (involves: BALB/cJ * C57BL/6)	immune system phenotype	J:196002
Gt(ROSA)26Sor^{tm1.1(CAG-Trp53,-EGFP)Medz}/Gt(ROSA)26Sor^{tm1.1(CAG-Trp53,-EGFP)Medz} (involves: C57BL/6)	decreased thymocyte apoptosis	J:158953
Gt(ROSA)26Sor^{tm1.1(DUX4)Plj}/Gt(ROSA)26Sor⁺ (B6(Cg)-Gt(ROSA)26Sor^{tm1.1(DUX4)Plj})	enlarged lymph nodes	J:256652
	enlarged popliteal lymph nodes	J:256652
Gt(ROSA)26Sor^{tm1.1(DUX4)Plj}/Gt(ROSA)26Sor⁺ Ndor1^{Tg(UBC-cre/ERT2)1Ejb}/0 (involves: 129S/SvEv C57BL/6)	enlarged lymph nodes	J:256652
	enlarged popliteal lymph nodes	J:256652
Gt(ROSA)26Sor^{tm1.1(DUX4)Plj}/Gt(ROSA)26Sor⁺ Tg(ACTA1-cre/Esr1)2Kesr/0 (involves: C3H * C57BL/6)	increased acute inflammation	J:256652
Gt(ROSA)26Sor^{tm1.1(DUX4)Plj}/Gt(ROSA)26Sor^{tm1.1(DUX4)Plj} (B6(Cg)-Gt(ROSA)26Sor^{tm1.1(DUX4*)Plj})	preputial gland inflammation	J:256652
Gt(ROSA)26Sor^{tm1.1(Loxl2)Acan}/Gt(ROSA)26Sor^{tm1.1(Loxl2)Acan} (Not Specified)	epididymis inflammation	J:220689
	increased inflammatory response	J:220689
Gt(ROSA)26Sor^{tm1.1(Ubc-BCL3)Sbn}/Gt(ROSA)26Sor⁺ Cd79a^tm1(cre)Reth/Cd79a⁺ (involves: BALB/c * C57BL/6)	decreased B cell proliferation	J:207111
	decreased follicular B cell number	J:207111
	decreased marginal zone B cell number	J:207111
	increased follicular B cell number	J:207111
Gt(ROSA)26Sor^{tm1.1(Wls/YFP)Mbtr}/Gt(ROSA)26Sor⁺ (involves: C57BL/6)	decreased neutrophil cell number	J:202499
Gt(ROSA)26Sor^{tm1.2(CAG-PLS3,-GFP)Bwir}/Gt(ROSA)26Sor⁺ (B6N.Cg-Gt(ROSA)26Sor^{tm1.1(CAG-PLS3,-GFP)Bwir})	decreased osteoclast cell number	J:267292
Gt(ROSA)26Sor^tm1Fia/Gt(ROSA)26Sor⁺ Nf1^tm1Fcr/Nf1^tm1Par Tg(Tek-cre)1Ywa/0 (involves: 129S/SvEv * 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)	abnormal spleen morphology	J:114455
Gt(ROSA)26Sor^tm1Jus/Gt(ROSA)26Sor⁺ Tg(Lck-icre)3779Nik/0 (involves: C57BL/6 * C57BL/6J * C57BL/6N * DBA/2)	immune system phenotype	J:202090
Gt(ROSA)26Sor^tm1Jus/Gt(ROSA)26Sor⁺ Tg(MMTV-cre)4Mam/0 (involves: C57BL/6J * C57BL/6N * FVB/N)	abnormal leukocyte morphology	J:202090
	abnormal thymus physiology	J:202090
	arrested B cell differentiation	J:202090
	decreased B cell number	J:202090
	decreased double-positive T cell number	J:202090
	decreased mature B cell number	J:202090
	decreased pre-B cell number	J:202090
	decreased pro-B cell number	J:202090
	enlarged lymph nodes	J:202090
	enlarged spleen	J:202090
	enlarged thymus	J:202090
	increased CD8-positive, alpha-beta T cell number	J:202090
	increased inflammatory response	J:202090
	increased large unstained cell number	J:202090
	increased leukocyte cell number	J:202090
	increased single-positive T cell number	J:202090
	intermingled spleen red and white pulp	J:202090
	intestinal inflammation	J:202090
	kidney inflammation	J:202090
	liver inflammation	J:202090
	meningitis	J:202090
	stomach inflammation	J:202090
Gt(ROSA)26Sor^tm1Jus/Gt(ROSA)26Sor⁺ Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * C57BL/6J * C57BL/6N * CBA)	abnormal leukocyte morphology	J:202090
	abnormal thymus physiology	J:202090
	arrested B cell differentiation	J:202090
	decreased B cell number	J:202090
	decreased double-positive T cell number	J:202090
	decreased mature B cell number	J:202090
	decreased pre-B cell number	J:202090
	decreased pro-B cell number	J:202090
	enlarged lymph nodes	J:202090
	enlarged spleen	J:202090
	enlarged thymus	J:202090
	increased CD8-positive, alpha-beta T cell number	J:202090
	increased inflammatory response	J:202090
	increased large unstained cell number	J:202090
	increased leukocyte cell number	J:202090
	increased single-positive T cell number	J:202090
	intermingled spleen red and white pulp	J:202090
	intestinal inflammation	J:202090
	kidney inflammation	J:202090
	liver inflammation	J:202090
	meningitis	J:202090
	stomach inflammation	J:202090
Gt(ROSA)26Sor^tm1Sor/Gt(ROSA)26Sor⁺ Id3^tm2.1Zhu/Id3^tm2.1Zhu Tg(Lck-cre)#Zhu/0 (involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6 * SJL)	decreased T cell number	J:172701
Gt(ROSA)26Sor^tm1Sor/Gt(ROSA)26Sor⁺ Nr2f2^tm2.1Tsa/Nr2f2^tm2.1Tsa Prox1^{tm3(cre/ERT2)Gco}/Prox1⁺ (involves: 129S1/Sv * 129S4/SvJaeSor * 129S7/SvEvBrd * C57BL/6)	abnormal lymphatic vessel morphology	J:158959
Gt(ROSA)26Sor^tm1Sor/Gt(ROSA)26Sor⁺ Tbx1^tm3.1Bld/Tbx1^tm6(cre)Bld (involves: 129S4/SvJaeSor * 129S7/SvEvBrd)	abnormal lymphatic vessel morphology	J:159824
Gt(ROSA)26Sor^{tm2(CAG-Notch2)Uzs}/Gt(ROSA)26Sor⁺ Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129P2/OlaHsd 129S6/SvEvTac * C57BL/6J)	abnormal B cell differentiation	J:179036
	abnormal marginal zone B cell physiology	J:179036
	abnormal spleen marginal zone morphology	J:179036
	decreased B cell number	J:179036
	decreased B-1a cell number	J:179036
	decreased B-2 B cell number	J:179036
	decreased follicular B cell number	J:179036
	decreased IgG1 level	J:179036
	decreased IgG3 level	J:179036
	decreased IgM level	J:179036
	decreased spleen B cell follicle size	J:179036
	decreased spleen germinal center number	J:179036
	decreased transitional stage T2 B cell number	J:179036
	increased B cell proliferation	J:179036
	increased marginal zone B cell number	J:179036
	increased spleen weight	J:179036
	increased T cell number	J:179036
	increased transitional stage T1 B cell number	J:179036
Gt(ROSA)26Sor^{tm2(CAG-Notch2)Uzs}/Gt(ROSA)26Sor⁺ Cd19^tm1(cre)Cgn/Cd19^tm1(cre)Cgn (involves: 129P2/OlaHsd 129S6/SvEvTac * C57BL/6J)	abnormal B cell differentiation	J:179036
	abnormal spleen marginal zone morphology	J:179036
	decreased follicular B cell number	J:179036
	decreased mature B cell number	J:179036
	decreased pre-B cell number	J:179036
	decreased transitional stage T2 B cell number	J:179036
	increased marginal zone B cell number	J:179036
	increased transitional stage T1 B cell number	J:179036
Gt(ROSA)26Sor^{tm2(CAG-Notch2)Uzs}/Gt(ROSA)26Sor⁺ Cd79a^tm1(cre)Reth/Cd79a⁺ (involves: 129S6/SvEvTac BALB/c * C57BL/6J)	arrested B cell differentiation	J:179036
	decreased B cell number	J:179036
	decreased splenocyte number	J:179036
	increased T cell number	J:179036
Gt(ROSA)26Sor^{tm2(CAG-Nr5a1)Fjd}/Gt(ROSA)26Sor⁺ Pgr^tm2(cre)Lyd/Pgr⁺ (involves: 129S1/Sv * 129X1/SvJ)	uterus inflammation	J:269597
Gt(ROSA)26Sor^{tm2(CAG-PSTPIP1)Dtg}/Gt(ROSA)26Sor⁺ Commd10^{Tg(Vav1-icre)A2Kio}/Commd10⁺ (involves: C57BL/6 C57BL/10 * CBA/Ca)	immune system phenotype	J:196002
Gt(ROSA)26Sor^{tm2(cre/ERT2)Brn}/0 Tg(Sftpc-Grem1)105Mmyl/0 (involves: 129P2/OlaHsd * C57BL/6N)	lung inflammation	J:82809
Gt(ROSA)26Sor^{tm2(H1/tetO-RNAi:Kdm1a)Arte}/Gt(ROSA)26Sor⁺ (involves: C57BL/6)	abnormal granulocyte differentiation	J:192055
	abnormal monocyte differentiation	J:192055
	enlarged spleen	J:192055
	increased leukocyte cell number	J:192055
Gt(ROSA)26Sor^{tm2(ITK/Syk)Hjum}/Gt(ROSA)26Sor⁺ Tg(Cd4-cre)1Cwi/0 (involves: 129S6/SvEvTac * C57BL/6 * DBA/2)	abnormal circulating cytokine level	J:207306
	abnormal cytokine secretion	J:207306
	abnormal immunoglobulin level	J:207306
	abnormal spleen morphology	J:207306
	enlarged spleen	J:207306
	immune system phenotype	J:207306
	increased activated T cell number	J:207306
	increased CD4-positive, alpha-beta T cell number	J:207306
	increased circulating interferon-gamma level	J:207306
	increased circulating interleukin-2 level	J:207306
	increased circulating interleukin-4 level	J:207306
	increased circulating interleukin-6 level	J:207306
	increased circulating interleukin-10 level	J:207306
	increased circulating tumor necrosis factor level	J:207306
	increased IgA level	J:207306
	increased IgG level	J:207306
	increased IgM level	J:207306
	increased inflammatory response	J:207306
	increased interferon-gamma secretion	J:207306
	increased interleukin-2 secretion	J:207306
	increased interleukin-4 secretion	J:207306
	increased interleukin-6 secretion	J:207306
	increased interleukin-10 secretion	J:207306
	increased mature B cell number	J:207306
	increased plasma cell number	J:207306
	increased tumor necrosis factor secretion	J:207306
Gt(ROSA)26Sor^{tm2(ITK/Syk)Hjum}/Gt(ROSA)26Sor⁺ Tg(Lck-cre)I57Jxm/0 (involves: 129S6/SvEvTac * ICR)	abnormal circulating cytokine level	J:207306
	abnormal cytokine secretion	J:207306
	abnormal immunoglobulin level	J:207306
	abnormal spleen morphology	J:207306
	enlarged spleen	J:207306
	immune system phenotype	J:207306
	increased activated T cell number	J:207306
	increased CD4-positive, alpha-beta T cell number	J:207306
	increased circulating interferon-gamma level	J:207306
	increased circulating interleukin-2 level	J:207306
	increased circulating interleukin-4 level	J:207306
	increased circulating interleukin-6 level	J:207306
	increased circulating interleukin-10 level	J:207306
	increased circulating tumor necrosis factor level	J:207306
	increased IgA level	J:207306
	increased IgG level	J:207306
	increased IgM level	J:207306
	increased inflammatory response	J:207306
	increased interferon-gamma secretion	J:207306
	increased interleukin-2 secretion	J:207306
	increased interleukin-4 secretion	J:207306
	increased interleukin-6 secretion	J:207306
	increased interleukin-10 secretion	J:207306
	increased mature B cell number	J:207306
	increased plasma cell number	J:207306
	increased tumor necrosis factor secretion	J:207306
Gt(ROSA)26Sor^{tm2(Lmp1/CD40)Uzs}/Gt(ROSA)26Sor⁺ Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129P2/OlaHsd * BALB/c * C57BL/6)	abnormal B cell activation	J:137122
	abnormal B cell physiology	J:137122
	abnormal class switch recombination	J:137122
	abnormal humoral immune response	J:137122
	abnormal T cell activation	J:137122
	enlarged inguinal lymph nodes	J:137122
	enlarged spleen	J:137122
	increased B cell number	J:137122
	increased B cell proliferation	J:137122
	increased follicular B cell number	J:137122
	increased marginal zone B cell number	J:137122
	increased spleen B cell follicle size	J:137122
	increased spleen weight	J:137122
	increased T cell number	J:137122
Gt(ROSA)26Sor^{tm2(Lmp1/CD40)Uzs}/Gt(ROSA)26Sor⁺ Tg(Cr2-cre)3Cgn/0 (involves: BALB/c * C57BL/6)	abnormal immune system morphology	J:137122
	abnormal immune system physiology	J:137122
Gt(ROSA)26Sor^{tm2(Mirn150)Rsky}/Gt(ROSA)26Sor⁺ (involves: C57BL/6 * SJL/J)	decreased mature B cell number	J:127234
Gt(ROSA)26Sor^{tm2(Mirn150)Rsky}/Gt(ROSA)26Sor^{tm2(Mirn150)Rsky} (involves: C57BL/6 * SJL/J)	decreased B-1 B cell number	J:127234
	decreased B-2 B cell number	J:127234
	decreased CD4-positive, alpha-beta T cell number	J:127234
	decreased CD8-positive, alpha-beta T cell number	J:127234
	increased B cell apoptosis	J:127234
Gt(ROSA)26Sor^{tm2(Nfatc2)Rao}/Gt(ROSA)26Sor⁺ Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 DBA/2)	abnormal interferon level	J:148341
	abnormal T cell activation	J:148341
Gt(ROSA)26Sor^{tm2(sb11)Njen}/Gt(ROSA)26Sor⁺ TgTn(sb-T2/Onc2)6070Njen/0 (involves: 129 * C57BL/6 * C57BL/6J)	increased susceptibility to infection	J:153656
Gt(ROSA)26Sor^{tm2.1(CAG-PSTPIP1)Dtg}/Gt(ROSA)26Sor⁺ (involves: BALB/cJ C57BL/6)	increased circulating interleukin-1 alpha level	J:196002
	increased circulating interleukin-1 beta level	J:196002
	increased circulating tumor necrosis factor level	J:196002
Gt(ROSA)26Sor^{tm2.1(Cd74/MOG)Awai}/Gt(ROSA)26Sor⁺ (involves: C57BL/6 * BALB/cJ)	abnormal humoral immune response	J:140751
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:140751
Gt(ROSA)26Sor^{tm2.1(Mirn150)Rsky}/Gt(ROSA)26Sor⁺ (involves: C57BL/6 * SJL/J)	decreased mature B cell number	J:127234
Gt(ROSA)26Sor^{tm2.1(Mirn150)Rsky}/Gt(ROSA)26Sor^{tm2.1(Mirn150)Rsky} (involves: C57BL/6 * SJL/J)	arrested B cell differentiation	J:127234
	arrested T cell differentiation	J:127234
	decreased B-1 B cell number	J:127234
	decreased B-2 B cell number	J:127234
	decreased lymphocyte cell number	J:127234
	increased B cell apoptosis	J:127234
Gt(ROSA)26Sor^{tm2.1(sb11)Njen}/Gt(ROSA)26Sor⁺ TgTn(sb-T2/Onc2)6070Njen/0 (involves: 129 * C57BL/6 * C57BL/6J)	increased T cell derived lymphoma incidence	J:153656
Gt(ROSA)26Sor^tm2Sho/Gt(ROSA)26Sor⁺ Lef1^tm1Hhx/Lef1^tm1Hhx Tg(GZMB-cre)1Jcb/0 (involves: 129S4/SvJaeSor * C57BL/6 * FVB/N)	abnormal memory T cell physiology	J:189838
	decreased CD8-positive, alpha-beta T cell number	J:189838
Gt(ROSA)26Sor^{tm3(CAG-EYFP)Hze}/Gt(ROSA)26Sor⁺ Stat5a^tm2Mam Stat5b^tm1Mam/Del(11Stat5a-Stat5b)1Mam Tg(Mx1-cre)1Cgn/0 (involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NCr * CBA)	abnormal CD4-positive T cell differentiation	J:204829
Gt(ROSA)26Sor^{tm3(CAG-Il17a)Awai}/Gt(ROSA)26Sor⁺ Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	abnormal immune system physiology	J:144710
	abnormal neutrophil physiology	J:144710
	increased circulating interleukin-17 level	J:144710
	increased granulocyte number	J:144710
	increased interleukin-17 secretion	J:144710
Gt(ROSA)26Sor^{tm3(CAG-MIR17-92,-EGFP)Rsky}/Gt(ROSA)26Sor⁺ Tg(CD2-icre)4Kio/0 (involves: C57BL/6 * C57BL/10 * CBA/Ca)	decreased marginal zone B cell number	J:133215
	increased B-1a cell number	J:133215
Gt(ROSA)26Sor^{tm3(CAG-MIR17-92,-EGFP)Rsky}/Gt(ROSA)26Sor^{tm3(CAG-MIR17-92,-EGFP)Rsky} Tg(CD2-icre)4Kio/0 (involves: C57BL/6 * C57BL/10 * CBA/Ca)	abnormal B cell activation	J:133215
	abnormal B cell morphology	J:133215
	abnormal CD4-positive, alpha beta T cell morphology	J:133215
	abnormal CD4-positive, alpha-beta T cell physiology	J:133215
	abnormal immune system morphology	J:133215
	abnormal immune system physiology	J:133215
	abnormal immunoglobulin level	J:133215
	abnormal spleen marginal zone morphology	J:133215
	abnormal T cell activation	J:133215
	abnormal T cell differentiation	J:133215
	decreased marginal zone B cell number	J:133215
	decreased spleen red pulp amount	J:133215
	enlarged lymph nodes	J:133215
	immune system phenotype	J:133215
	increased anti-double stranded DNA antibody level	J:133215
	increased anti-single stranded DNA antibody level	J:133215
	increased B cell number	J:133215
	increased B cell proliferation	J:133215
	increased B-1a cell number	J:133215
	increased CD4-positive, alpha-beta T cell number	J:133215
	increased CD8-positive, alpha-beta T cell number	J:133215
	increased germinal center B cell number	J:133215
	increased IgG2a level	J:133215
	increased IgG2b level	J:133215
	increased IgG3 level	J:133215
	increased IgM level	J:133215
	increased lymphocyte cell number	J:133215
	increased spleen weight	J:133215
	increased spleen white pulp amount	J:133215
	intermingled spleen red and white pulp	J:133215
	lymph node hyperplasia	J:133215
	spleen hyperplasia	J:133215
Gt(ROSA)26Sor^{tm3.1(CAG-Il17a)Awai}/Gt(ROSA)26Sor⁺ (involves: BALB/c * C57BL/6)	increased granulocyte number	J:144710
	increased interleukin-17 secretion	J:144710
	skin inflammation	J:144710
Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/Gt(ROSA)26Sor⁺ Hnrnpl^tm1.1Tmo/Hnrnpl^tm1.1Tmo Tg(Lck-cre)548Jxm/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)	abnormal T cell differentiation	J:188749
Gt(ROSA)26Sor^{tm4(CAG-hsb5)Nki}/Gt(ROSA)26Sor⁺ Tg(Mx1-cre)1Cgn/0 Tg(Tal1-tTA)19Dgt/0 Tg(tetO-BCR/ABL1)2Dgt/0 TgTn(pb-sb-GrOnc)#aGsva/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA/J * DBA/2 * FVB/N)	increased basophil cell number	J:227558
	increased granulocyte number	J:227558
	increased leukocyte cell number	J:227558
	increased spleen weight	J:227558
Gt(ROSA)26Sor^{tm4(H1/tetO-RNAi:Ezh2)Arte}/Gt(ROSA)26Sor⁺ (C57BL/6-Gt(ROSA)26Sor^{tm4(H1/tetO-RNAi:Ezh2)Arte})	small lymph nodes	J:202724
Gt(ROSA)26Sor^{tm4(HIF2A)Kael}/Gt(ROSA)26Sor^{tm4(HIF2A)Kael} Tg(Vil1-cre/ERT2)23Syr/0 (involves: 129S6/SvEvTac * C57BL/6 * DBA/2)	increased susceptibility to colitis induced morbidity/mortality	J:307422
Gt(ROSA)26Sor^{tm4(Ikbkb)Rsky}/Gt(ROSA)26Sor⁺ Ighg1^tm1(cre)Cgn/Ighg1⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal spleen morphology	J:167612
	decreased germinal center B cell number	J:167612
	enlarged spleen	J:167612
	increased B cell number	J:167612
	increased IgG1 level	J:167612
	increased IgM level	J:167612
	increased plasma cell number	J:167612
Gt(ROSA)26Sor^{tm4(Ikbkb)Rsky}/Gt(ROSA)26Sor⁺ Ighg1^tm1(cre)Cgn/Ighg1⁺ Prdm1^tm2Masu/Prdm1^tm2Masu (involves: 129P2/OlaHsd * C57BL/6)	abnormal germinal center B cell physiology	J:167612
	abnormal plasma cell differentiation	J:167612
	decreased IgG1 level	J:167612
	increased germinal center B cell number	J:167612
Gt(ROSA)26Sor^{tm4(Ikbkb)Rsky}/Gt(ROSA)26Sor^{tm4(Ikbkb)Rsky} Igh-J^tm1Cgn/Igh^tm4Cgn Tg(Cr2-cre)3Cgn/0 (involves: 129P2/OlaHsd * C57BL/6)	increased B cell number	J:157297
Gt(ROSA)26Sor^{tm4(Wnt7b)Flng}/Gt(ROSA)26Sor⁺ Tg(Col1a1-cre)1Ack/0 (involves: FVB/N)	decreased osteoclast cell number	J:208766
	enlarged spleen	J:208766
	increased spleen weight	J:208766
Gt(ROSA)26Sor^{tm4(Wnt7b)Flng}/Gt(ROSA)26Sor⁺ Tg(Runx2-rtTAM2)#Flng/0 Tg(tetO-cre)1Jaw/0 (involves: 129 C57BL/6)	decreased osteoclast cell number	J:208766
Gt(ROSA)26Sor^{tm5(H1/tetO-RNAi:Ezh2)Arte}/Gt(ROSA)26Sor⁺ (C57BL/6-Gt(ROSA)26Sor^{tm5(H1/tetO-RNAi:Ezh2)Arte})	small lymph nodes	J:202724
Gt(ROSA)26Sor^{tm7(Pik3ca,-EGFP)Rsky}/Gt(ROSA)26Sor⁺ Tg(CAG-cre/Esr1)5Amc/0 (B6.Cg-Gt(ROSA)26Sor^{tm7(Pik3ca,-EGFP)Rsky} Tg(CAG-cre/Esr1)5Amc)	abnormal spleen morphology	J:264410
	enlarged lymphatic vessel	J:264410
Gt(ROSA)26Sor^{tm7(Pik3ca,-EGFP)Rsky}/Gt(ROSA)26Sor^{tm13(CAG-MYC,-CD2)Rsky} Ighg1^tm1(cre)Cgn/Ighg1⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal class switch recombination	J:191824
	increased germinal center B cell number	J:191824
Gt(ROSA)26Sor^{tm8(Map2k1,-EGFP)Rsky}/Gt(ROSA)26Sor⁺ Tg(Cd4-cre)1Cwi/0 Traf3ip3^{tm1c(KOMP)Wtsi}/Traf3ip3^{tm1c(KOMP)Wtsi} (involves: C57BL/6 C57BL/6N * DBA/2)	immune system phenotype	J:226431
Gt(ROSA)26Sor^{tm8(Map2k1,-EGFP)Rsky}/Gt(ROSA)26Sor^{tm8(Map2k1,-EGFP)Rsky} Igh-J^tm1Cgn/Igh^tm4Cgn Tg(Cr2-cre)3Cgn/0 (involves: 129P2/OlaHsd * C57BL/6)	decreased mature B cell number	J:157297
Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte}/? Tnfaip3^tm1Homy/Tnfaip3^tm1Homy (involves: 129S6/SvEvTac * C57BL/6J * C57BL/6NTac)	abnormal circulating cytokine level	J:212681
	abnormal circulating interleukin level	J:212681
	increased circulating interferon-gamma level	J:212681
	increased circulating interleukin-1 beta level	J:212681
	increased circulating interleukin-6 level	J:212681
	increased circulating tumor necrosis factor level	J:212681
	pale spleen	J:212681
	thymus atrophy	J:212681
Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte}/Gt(ROSA)26Sor⁺ Map3k14^tm1.1Gne/Map3k14^tm1.1Gne (B6(Cg)-Map3k14^tm1.1Gne Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte})	abnormal immunoglobulin level	J:240453
	decreased B cell number	J:240453
	decreased B cell proliferation	J:240453
	decreased germinal center B cell number	J:240453
	decreased IgA level	J:240453
	decreased IgG1 level	J:240453
	decreased IgM level	J:240453
	decreased Peyer's patch number	J:240453
	immune system phenotype	J:240453
Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte}/Gt(ROSA)26Sor⁺ Pten^tm1Hwu/Pten^tm1Hwu (involves: 129S4/SvJae * C57BL/6)	enlarged lymph nodes	J:170965
	enlarged spleen	J:170965
	increased spleen weight	J:170965
Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte}/Gt(ROSA)26Sor⁺ Ripk3^tm1Arte/Ripk3^tm1Arte (involves: C57BL/6NTac)	abnormal lymphocyte morphology	J:209137
	intestinal inflammation	J:209137
	thymus atrophy	J:209137
Gt(ROSA)26Sor^{tm9(Rac1,-EGFP)Rsky}/Gt(ROSA)26Sor^{tm9(Rac1,-EGFP)Rsky} Igh-J^tm1Cgn/Igh^tm4Cgn Tg(Cr2-cre)3Cgn/0 (involves: 129P2/OlaHsd * C57BL/6)	decreased mature B cell number	J:157297
Gt(ROSA)26Sor^{tm10(Lmp1)Rsky}/Gt(ROSA)26Sor⁺ (involves: BALB/cJ)	abnormal B cell morphology	J:181546
	increased B cell proliferation	J:181546
Gt(ROSA)26Sor^{tm10(Lmp1)Rsky}/Gt(ROSA)26Sor⁺ Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129P2/OlaHsd * BALB/cJ)	abnormal B cell differentiation	J:181546
	abnormal CD8-positive, alpha-beta T cell physiology	J:181546
	abnormal immune system physiology	J:181546
	decreased B cell number	J:181546
	decreased mature B cell number	J:181546
	decreased pre-B cell number	J:181546
	enlarged spleen	J:181546
	increased B cell number	J:181546
	increased B cell proliferation	J:181546
	increased CD4-positive, alpha-beta T cell number	J:181546
	increased CD8-positive, alpha-beta T cell number	J:181546
	increased pro-B cell number	J:181546
Gt(ROSA)26Sor^{tm10(Lmp1)Rsky}/Gt(ROSA)26Sor⁺ Tcrb^tm1Mom/Tcrb⁺ Tcrd^tm1Mom/Tcrd^tm1Mom Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129P2/OlaHsd * 129S2/SvPas * BALB/cJ)	enlarged spleen	J:181546
	increased B cell number	J:181546
Gt(ROSA)26Sor^{tm10(Lmp1)Rsky}/Gt(ROSA)26Sor⁺ Tcrb^tm1Mom/Tcrb^tm1Mom Tcrd^tm1Mom/Tcrd^tm1Mom Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129P2/OlaHsd * 129S2/SvPas * BALB/cJ)	enlarged spleen	J:181546
	increased B cell number	J:181546
Gt(ROSA)26Sor^{tm11(Lmp1)Rsky}/Gt(ROSA)26Sor⁺ (involves: C57BL/6)	abnormal B cell morphology	J:181546
	increased B cell proliferation	J:181546
Gt(ROSA)26Sor^{tm11(Lmp1)Rsky}/Gt(ROSA)26Sor⁺ Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell differentiation	J:181546
	abnormal CD4-positive, alpha-beta T cell physiology	J:181546
	abnormal CD8-positive, alpha-beta T cell physiology	J:181546
	abnormal immune system physiology	J:181546
	decreased B cell number	J:181546
	decreased mature B cell number	J:181546
	decreased pre-B cell number	J:181546
	enlarged spleen	J:181546
	increased B cell number	J:181546
	increased B cell proliferation	J:181546
	increased CD4-positive, alpha-beta T cell number	J:181546
	increased CD8-positive, alpha-beta T cell number	J:181546
	increased interferon-gamma secretion	J:181546
	increased pro-B cell number	J:181546
	increased tumor necrosis factor secretion	J:181546
Gt(ROSA)26Sor^{tm11(Lmp1)Rsky}/Gt(ROSA)26Sor⁺ Cd19^{tm1(cre/ERT2)Rsky}/Cd19⁺ (involves: 129P2/OlaHsd * C57BL/6J)	abnormal T cell physiology	J:217520
	enlarged spleen	J:217520
	increased activated T cell number	J:217520
	increased B cell number	J:217520
	increased CD4-positive, alpha-beta T cell number	J:217520
	increased CD8-positive, alpha-beta T cell number	J:217520
Gt(ROSA)26Sor^{tm11(Lmp1)Rsky}/Gt(ROSA)26Sor⁺ Tcrb^tm1Mom/Tcrb⁺ Tcrd^tm1Mom/Tcrd^tm1Mom Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)	enlarged spleen	J:181546
	increased B cell number	J:181546
Gt(ROSA)26Sor^{tm11(Lmp1)Rsky}/Gt(ROSA)26Sor⁺ Tcrb^tm1Mom/Tcrb^tm1Mom Tcrd^tm1Mom/Tcrd^tm1Mom Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)	enlarged spleen	J:181546
	increased B cell number	J:181546
Gt(ROSA)26Sor^{tm12(CD2)Rsky}/Gt(ROSA)26Sor⁺ Myc^tm2Fwa/Myc^tm2Fwa Ighg1^tm1(cre)Cgn/Ighg1⁺ (involves: 129P2/OlaHsd 129S6/SvEvTac * C57BL/6)	decreased spleen germinal center size	J:188564
Gt(ROSA)26Sor^{tm13(CAG-MYC,-CD2)Rsky}/Gt(ROSA)26Sor⁺ Myc^tm2Fwa/Myc^tm2Fwa Ighg1^tm1(cre)Cgn/Ighg1⁺ (involves: 129P2/OlaHsd 129S6/SvEvTac * C57BL/6)	immune system phenotype	J:188564
Gt(ROSA)26Sor^{tm18(Zeb2)Jhai}/Gt(ROSA)26Sor⁺ Tg(Tek-cre)1Ywa/0 Trp53^tm1Brn/Trp53^tm1Brn (involves: 129P2/OlaHsd * C57BL/6 * CD-1 * SJL)	increased T cell derived lymphoma incidence	J:263520
Gt(ROSA)26Sor^{tm18(Zeb2)Jhai}/Gt(ROSA)26Sor^{tm18(Zeb2)Jhai} Tg(Tek-cre)1Ywa/0 (involves: C57BL/6 * CD-1 * SJL)	increased thymus tumor incidence	J:263520
Gt(ROSA)26Sor^{tm18(Zeb2)Jhai}/Gt(ROSA)26Sor^{tm18(Zeb2)Jhai} Tg(Tek-cre)1Ywa/0 Trp53^tm1Brn/Trp53^tm1Brn (involves: 129P2/OlaHsd * C57BL/6 * CD-1 * SJL)	increased T cell derived lymphoma incidence	J:263520
Gtf2a1l^em1(IMPC)J/Gtf2a1l^em1(IMPC)J (C57BL/6NJ-Gtf2a1l^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
Gtf2ird1^{em1(IMPC)Ccpcz}/Gtf2ird1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Gtf2ird1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
	small spleen	J:211773
Gtpbp2^{tm1b(KOMP)Mbp}/Gtpbp2⁺ (C57BL/6N-Gtpbp2^{tm1b(KOMP)Mbp}/Ucd)	enlarged lymph nodes	J:211773
Gtpbp2^{tm1b(KOMP)Mbp}/Gtpbp2^{tm1b(KOMP)Mbp} (C57BL/6N-Gtpbp2^{tm1b(KOMP)Mbp}/Ucd)	enlarged lymph nodes	J:211773
Gtsf1l^em1(IMPC)J/Gtsf1l^em1(IMPC)J (C57BL/6NJ-Gtsf1l^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
Guca2a^em1(IMPC)Mbp/Guca2a^em1(IMPC)Mbp (C57BL/6N-Guca2a^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
Gucy1b1^tm1.1Frb/Gucy1b1^tm1.1Frb (involves: 129 * C57BL/6 * FVB/N)	peritoneal inflammation	J:121321
Gucy2c^tm1Gar/Gucy2c^tm1Gar (either: (involves: 129S6/SvEvTac * Black Swiss) or (involves: 129S6/SvEvTac * C57BL/6J))	decreased susceptibility to bacterial infection	J:43046
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:43046
Gucy2c^tm1Gian/Gucy2c^tm1Gian (involves: 129P2/OlaHsd * Black Swiss)	decreased susceptibility to infection	J:43682
Guk1^em1(IMPC)J/Guk1⁺ (C57BL/6NJ-Guk1^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
Gulo^{em1(IMPC)Ccpcz}/Gulo^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Gulo^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Gulo^sfx/Gulo^sfx (BALB/cBy-Gulo^sfx/J)	abnormal osteoclast differentiation	J:66648
	small spleen	J:66648
	small thymus	J:66648
Gulp1^tm1.2Kimj/Gulp1^tm1.2Kimj (involves: 129S4/SvJae * C57BL/6 * SJL)	abnormal osteoclast differentiation	J:340688
	abnormal osteoclast morphology	J:340688
	abnormal osteoclast physiology	J:340688
	increased osteoclast cell number	J:340688
Gvhd1^C57BL/10J/Gvhd1^C57BL/10J (involves: B10.D2-H2^d * C57BL/10J)	increased susceptibility to graft versus host disease	J:52834
Gvhd1^C57BL/10J/Gvhd1^C57BL/10J Gvhd2^C57BL/10J/Gvhd2^C57BL/10J (involves: B10.D2-H2^d * C57BL/10J)	increased susceptibility to graft versus host disease	J:52834
Gvhd2^C57BL/10J/Gvhd2^C57BL/10J (involves: B10.D2-H2^d * DBA/2J)	increased susceptibility to graft versus host disease	J:52834
Gvhd4^DBA/2J/Gvhd4^DBA/2J (involves: C57BL/10 * DBA/2J)	increased anti-single stranded DNA antibody level	J:66655
Gvhd4^DBA/2J/Gvhd4^DBA/2J Gvhd5^DBA/2J/Gvhd5^DBA/2J (involves: C57BL/10 * DBA/2J)	increased anti-single stranded DNA antibody level	J:66655
Gvhd5^DBA/2J/Gvhd5^DBA/2J (involves: C57BL/10 * DBA/2J)	increased anti-single stranded DNA antibody level	J:66655
Gy/Y (involves: 101/H * C3H/HeH)	blepharitis	J:8335
Gzma^tm1Ley/Gzma^tm1Ley (involves: 129X1/SvJ * C57BL/6)	decreased cytotoxic T cell cytolysis	J:49361
Gzma^tm1Simn/Gzma^tm1Simn (B6.Cg-Gzma^tm1Simn)	immune system phenotype	J:92718, J:28773
Gzma^tm1Simn/Gzma^tm1Simn Gzmb^tm1Ley/Gzmb^tm1Ley (involves: 129S2/SvPas * C57BL/6)	abnormal leukocyte physiology	J:44204
	immune system phenotype	J:44204
Gzma^tm1Simn/Gzma^tm1Simn Gzmb^tm1Ley/Gzmb^tm1Ley (B6.Cg-Gzma^tm1Simn Gzmb^tm1Ley)	immune system phenotype	J:92718
	increased susceptibility to Flaviviridae infection	J:90852
	increased susceptibility to parasitic infection	J:81397
Gzma^tm1Simn/Gzma^tm1Simn Gzmb^tm1Ley/Gzmb^tm1Ley Prf1^tm1Sdz/Prf1^tm1Sdz (B6.Cg-Gzma^tm1Simn Gzmb^tm1Ley Prf1^tm1Sdz)	immune system phenotype	J:92718
	increased susceptibility to Flaviviridae infection	J:90852
	increased susceptibility to parasitic infection	J:81397
Gzmb^tm1Asmv/Gzmb^tm1Asmv (involves: C57BL/6)	immune system phenotype	J:203720
Gzmb^tm1Ley/Gzmb^tm1Ley (involves: 129S2/SvPas * C57BL/6J)	decreased cytotoxic T cell cytolysis	J:23560
Gzmb^tm1Ley/Gzmb^tm1Ley (B6.129S2-Gzmb^tm1Ley)	impaired natural killer cell mediated cytotoxicity	J:113213
Gzmb^tm1Ley/Gzmb^tm1Ley (involves: 129X1/SvJ)	abnormal NK cell physiology	J:126114
Gzmb^tm1Ley/Gzmb^tm1Ley (involves: 129X1/SvJ)	decreased T cell apoptosis	J:126114
Gzmb^tm1Ley/Gzmb^tm1Ley Serpinb9^tm1.1Pib/Serpinb9^tm1.1Pib (involves: 129S2/SvPas * BALB/cJ * C57BL/6J)	decreased cytotoxic T cell apoptosis	J:252016
Gzmb^tm1Ley/Gzmb^tm1Ley Serpinb9^tm1Arp/Serpinb9^tm1Arp (involves: 129S2/SvPas * C57BL/6)	abnormal CD8-positive, alpha-beta cytotoxic T cell morphology	J:113349
	abnormal cytotoxic T cell physiology	J:113349
Gzmb^tm2.1Ley/Gzmb^tm2.1Ley (129X1/SvJ-Gzmb^tm2.1Ley)	decreased cytotoxic T cell cytolysis	J:96538
Gzmb^tm2Ley/Gzmb^tm2Ley (129X1/SvJ-Gzmb^tm2Ley)	abnormal immune system physiology	J:96538
Gzmb^tm2Ley/Gzmb^tm2Ley (129X1/SvJ-Gzmb^tm2Ley)	decreased cytotoxic T cell cytolysis	J:96538
Gzmk^tm1.1Pib/Gzmk^tm1.1Pib (B6(Cg)-Gzmk^tm1.1Pib)	immune system phenotype	J:302067
Gzmm^tm1(cre)Mjs/Gzmm^tm1(cre)Mjs (C57BL/6-Gzmm^tm1(cre)Mjs)	increased susceptibility to Herpesvirales infection	J:113213
H1f0^tm1Ais/H1f0^tm1Ais H1f2^tm2Ais/H1f2^tm2Ais H1f4^tm2Ais/H1f4^tm2Ais (involves: 129/Sv * C57BL/6 * SJL)	small thymus	J:83954
H1f2^tm2Ais/H1f2^tm2Ais H1f3^tm2Ais/H1f3⁺ H1f4^tm2Ais/H1f4^tm2Ais (involves: 129/Sv * C57BL/6 * SJL)	small thymus	J:83954
H2-Aa^b-tm1Blt/H2-Aa^b-tm1Blt (C57BL/6-H2-Aa^b-tm1Blt)	abnormal MHC II cell surface expression on macrophages	J:67924
	abnormal splenocyte physiology	J:16372
	abnormal T cell morphology	J:16372
	decreased CD4-positive, alpha-beta T cell number	J:16372
	enlarged lymph nodes	J:16372
	enlarged thymus	J:16372
	increased CD8-positive, alpha-beta T cell number	J:16372
	thymus hyperplasia	J:16372
H2-Ab1^b-tm1.1Jssh/H2-Ab1^b-tm1.1Jssh (C57BL/6-H2-Ab1^b-tm1.1Jssh)	abnormal dendritic cell antigen presentation	J:201198
	abnormal T cell differentiation	J:201198
	decreased regulatory T cell number	J:201198
H2-Ab1^b-tm1.1Sish/H2-Ab1^b-tm1.1Sish (involves: 129S1/Sv * 129X1/SvJ)	abnormal dendritic cell physiology	J:157516
	decreased interleukin-12 secretion	J:157516
	decreased tumor necrosis factor secretion	J:157516
H2-Ab1^b-tm1Doi/H2-Ab1⁺ (involves: 129S2/SvPas * C57BL/6 * NOD/Lt)	insulitis	J:93557
H2-Ab1^b-tm1Doi/H2-Ab1^b-tm1Doi (involves: 129S2/SvPas * C57BL/6)	abnormal B cell physiology	J:65736
	abnormal CD4-positive, alpha beta T cell morphology	J:65736
	abnormal CD4-positive, alpha-beta T cell physiology	J:65736
	abnormal cytokine secretion	J:64283
	abnormal immune system cell morphology	J:65736
	abnormal immune system morphology	J:65736
	abnormal immune system organ morphology	J:65736
	abnormal immune system physiology	J:65736
	abnormal lymph node cell ratio	J:65736
	abnormal spleen B cell follicle morphology	J:65736
	abnormal spleen marginal zone morphology	J:65736
	abnormal spleen morphology	J:65736
	abnormal spleen periarteriolar lymphoid sheath morphology	J:65736
	abnormal T cell physiology	J:65736
	absent spleen germinal center	J:65736
	decreased CD4-positive, alpha-beta T cell number	J:51885, J:65736
	decreased IgG1 level	J:65736
	decreased susceptibility to parasitic infection	J:64283
	increased CD4-positive, alpha-beta T cell number	J:64283
	increased CD8-positive, alpha-beta T cell number	J:65736, J:64283
	increased susceptibility to parasitic infection	J:64283
H2-Ab1^b-tm1Doi/H2-Ab1^b-tm1Doi (involves: 129S2/SvPas * C57BL/6 * NOD/Lt)	insulitis	J:93557
H2-Ab1^b-tm1Gru/H2-Ab1^b-tm1Gru (involves: 129S2/SvPas * C57BL/6J)	abnormal humoral immune response	J:74418
	abnormal response to transplant	J:91742
	decreased CD4-positive, alpha-beta T cell number	J:74418
	decreased IgG level	J:74418
	increased CD8-positive, alpha-beta T cell number	J:74418
	increased IgM level	J:74418
H2-Ab1^b-tm1Gru/H2-Ab1^b-tm1Gru (NOD.129S2-H2-Ab1^b-tm1Gru)	immune system phenotype	J:86540
H2-Ab1^b-tm1Gru/H2-Ab1^b-tm1Gru (B6.129S2-H2-Ab1^b-tm1Gru)	abnormal B cell physiology	J:91341
	abnormal lymphocyte physiology	J:91341
	decreased CD4-positive, alpha-beta T cell number	J:91341
H2-Ab1^b-tm1Gru/H2-Ab1^b-tm1Gru (involves: 129S2/SvPas * C57BL/6)	abnormal level of surface class II molecules	J:67941
	decreased CD4-positive, alpha-beta T cell number	J:67941
	decreased IgG1 level	J:67941
	decreased IgM level	J:67941
	decreased single-positive T cell number	J:67941
H2-Ab1^b-tm1Gru/H2-Ab1^b-tm1Gru Ighm^tm1Cgn/Ighm^tm1Cgn Tg(CD2-CD4,HLA-DQA1,HLA-DQB1)1Ell/Tg(CD2-CD4,HLA-DQA1,HLA-DQB1)1Ell (NOD.Cg-Ighm^tm1Cgn H2-Ab1^b-tm1Gru Tg(CD2-CD4,HLA-DQA1,HLA-DQB1)1Ell)	heart inflammation	J:113267
H2-Ab1^b-tm1Gru/H2-Ab1^b-tm1Gru Rag1^tm1Mom/Rag1^tm1Mom Tg(CD2-CD4,HLA-DQA1,HLA-DQB1)1Ell/Tg(CD2-CD4,HLA-DQA1,HLA-DQB1)1Ell (NOD.Cg-Rag1^tm1Mom H2-Ab1^b-tm1Gru Tg(CD2-CD4,HLA-DQA1,HLA-DQB1)1Ell)	abnormal response to transplant	J:113267
	heart inflammation	J:113267
	increased autoantibody level	J:113267
	myocarditis	J:113267
H2-Ab1^b-tm1Gru/H2-Ab1^b-tm1Gru Rag1^tm1Mom/Rag1^tm1Mom Tg(HLA-DQA1,HLA-DQB1)73Myl/0 (NOD.Cg-Rag1^tm1Mom H2-Ab1^b-tm1Gru Tg(HLA-DQA1,HLA-DQB1)73Myl)	abnormal response to transplant	J:88055
	myocarditis	J:88055
H2-Ab1^b-tm1Gru/H2-Ab1^b-tm1Gru Runx1^tm1Toku/Runx1^tm1Toku Runx3^tm1Itan/Runx3^tm1Itan Tg(Cd4-cre)1Cwi/0 (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * DBA/2)	abnormal interferon secretion	J:131081
	increased CD4-positive, alpha-beta T cell number	J:131081
H2-Ab1^b-tm1Gru/H2-Ab1^b-tm1Gru Tespa1^tm1Smoc/Tespa1^tm1Smoc (involves: 129 * 129S2/SvPas * C57BL/6)	absent CD4-positive, alpha-beta T cells	J:186446
	decreased CD8-positive, alpha-beta T cell number	J:186446
H2-Ab1^b-tm1Gru/H2-Ab1^b-tm1Gru Tg(Ab1TL)1Gru/0 (B6.Cg-H2-Ab1^b-tm1Gru Tg(Ab1TL)1Gru)	abnormal CD4-positive T cell differentiation	J:91341
	abnormal macrophage antigen presentation	J:91341
	abnormal professional antigen presenting cell physiology	J:91341
H2-Ab1^b-tm1Gru/H2-Ab1^b-tm1Gru Tg(CD2-CD4,HLA-DQA1,HLA-DQB1)1Ell/Tg(CD2-CD4,HLA-DQA1,HLA-DQB1)1Ell (NOD.Cg-H2-Ab1^b-tm1Gru Tg(CD2-CD4,HLA-DQA1,HLA-DQB1)1Ell)	autoimmune response	J:87013, J:86540
	decreased susceptibility to autoimmune disorder	J:87013
	heart inflammation	J:87013, J:86540
	immune system phenotype	J:87013
	increased autoantibody level	J:113267
	lung inflammation	J:86540
	myositis	J:86540
	salivary gland inflammation	J:86540
H2-Ab1^b-tm1Gru/H2-Ab1^b-tm1Gru Tg(CD4,HLA-DQA1,HLA-DQB1)N8Ell/Tg(CD4,HLA-DQA1,HLA-DQB1)N8Ell (NOD.Cg-H2-Ab1^b-tm1Gru Tg(CD4,HLA-DQA1,HLA-DQB1)N8Ell)	immune system phenotype	J:113267
	increased autoantibody level	J:113509
	thyroid gland inflammation	J:113509
H2-Ab1^b-tm1Gru/H2-Ab1^b-tm1Gru Tg(HLA-DQA1,HLA-DQB1)1Dv/0 Tg(HLA-DRB1)31Dmz/0 Tg(Ins2-CD80)3B7Flv/0 (involves: 129S2/SvPas * C57BL/6 * C57BL/10SnJ * CBA * SJL)	abnormal CD4-positive, alpha beta T cell morphology	J:68641
	abnormal CD8-positive, alpha beta T cell morphology	J:68641
	decreased susceptibility to autoimmune diabetes	J:68641
	salivary gland inflammation	J:68641
H2-Ab1^b-tm1Gru/H2-Ab1^b-tm1Gru Tg(HLA-DQA1,HLA-DQB1)1Dv/0 Tg(Ins2-CD80)3B7Flv/0 (B6.Cg-H2-Ab1^b-tm1Gru Tg(HLA-DQA1,HLA-DQB1)1Dv Tg(Ins2-CD80)3B7Flv)	increased susceptibility to autoimmune diabetes	J:59245
	salivary gland inflammation	J:59245
H2-Ab1^b-tm1Gru/H2-Ab1^b-tm1Gru Tg(HLA-DQA1,HLA-DQB1)1Dv/0 Tg(Ins2-CD80)3B7Flv/0 (involves: 129S2/SvPas * C57BL/6 * C57BL/10SnJ * CBA)	decreased interleukin-6 secretion	J:68641
	increased interferon-gamma secretion	J:68641
	increased susceptibility to autoimmune diabetes	J:68641
H2-Ab1^b-tm1Gru/H2-Ab1^b-tm1Gru Tg(HLA-DQA1,HLA-DQB1)70Myl/0 (NOD.Cg-H2-Ab1^b-tm1Gru Tg(HLA-DQA1,HLA-DQB1)70Myl)	heart inflammation	J:88055
	increased autoantibody level	J:88055
	insulitis	J:88055
	myocarditis	J:88055
	salivary gland inflammation	J:88055
H2-Ab1^b-tm1Gru/H2-Ab1^b-tm1Gru Tg(HLA-DQA1,HLA-DQB1)73Myl/0 (NOD.Cg-H2-Ab1^b-tm1Gru Tg(HLA-DQA1,HLA-DQB1)73Myl)	heart inflammation	J:88055
	increased autoantibody level	J:88055
	insulitis	J:88055
	myocarditis	J:88055
	salivary gland inflammation	J:88055
H2-Ab1^b-tm1Gru/H2-Ab1^b-tm1Gru Tg(HLA-DRB1)31Dmz/0 Tg(Ins2-CD80)3B7Flv/0 (involves: 129S2/SvPas * C57BL/6 * CBA * SJL)	abnormal CD4-positive, alpha beta T cell morphology	J:68641
	abnormal CD8-positive, alpha beta T cell morphology	J:68641
	decreased susceptibility to autoimmune diabetes	J:68641
	salivary gland inflammation	J:68641
H2-Ab1^b-tm1Gru/H2-Ab1^b-tm1Gru Tg(Ins2-CD80)3B7Flv/0 (involves: 129S2/SvPas * C57BL/6 * CBA)	decreased susceptibility to autoimmune diabetes	J:68641
H2-Ab1^b-tm1Gru/H2-Ab1^b-tm1Gru Themis^tm1Lov/Themis^tm1Lov (involves: 129)	abnormal negative T cell selection	J:151075
H2-Ab1^b-tm1Koni/H2-Ab1^b-tm1.1Koni Tg(Tek-cre)12Flv/0 (involves: 129X1/SvJ * C3H * C57BL/6 * C57BL/6J)	abnormal CD4-positive, CD25-positive, alpha-beta regulatory T cell morphology	J:131774
	abnormal T cell activation	J:131774
	decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:131774
	decreased level of surface class II molecules	J:131774
	immune system phenotype	J:131774
	increased CD4-positive, alpha-beta T cell number	J:131774
H2-Ab1^b-tm1Wug/H2-Ab1^b-tm1Wug (involves: C57BL/6)	abnormal B cell physiology	J:204951
	abnormal dendritic cell physiology	J:204951
	absent CD4-positive, alpha-beta T cells	J:204951
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:204951
H2-Ab1^b-tm1Wug/H2-Ab1^b-tm1Wug Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129S2/SvPas * C57BL/6)	abnormal B cell physiology	J:204951
	abnormal dendritic cell physiology	J:204951
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:204951
	immune system phenotype	J:204951
H2-Ab1^bm12/H2-Ab1^bm12 (B6(C)-H2-Ab1^bm12/KhEgJ)	abnormal level of surface class II molecules	J:100194
	abnormal T cell physiology	J:100123
	decreased susceptibility to autoimmune disorder	J:100123
	decreased susceptibility to experimental autoimmune myasthenia gravis	J:100213
	decreased susceptibility to parasitic infection	J:48242
H2-Ab1^bm12/H2-Ab1^bm12 (NZB.B6(C)-H2-Ab1^bm12)	abnormal immunoglobulin level	J:104189
	abnormal level of surface class II molecules	J:104189
	autoimmune response	J:4554
	decreased CD8-positive, alpha-beta T cell number	J:4554
	increased anti-double stranded DNA antibody level	J:104189
	increased anti-erythrocyte antigen antibody level	J:4554
	increased anti-single stranded DNA antibody level	J:104189
	increased B cell number	J:104189
	increased CD4-positive, alpha-beta T cell number	J:4554
	increased double-negative T cell number	J:4554
H2-Ab1^g7-em1Dvs/H2-Ab1^g7-em1Dvs H2-D1^b-em5Dvs/H2-D1^b-em5Dvs H2-K1^d-em1Dvs/H2-K1^d-em1Dvs (NOD/ShiLtDvs-H2-K1^d-em1Dvs H2-Ab1^g7-em1Dvs H2-D1^em5Dvs/Dvs)	abnormal T cell subpopulation ratio	J:257229
	decreased alpha-beta T cell number	J:257229
	decreased CD4-positive, alpha-beta T cell number	J:257229
	decreased susceptibility to autoimmune diabetes	J:257229
H2-Ab1^g7-em1Ygch/H2-Ab1^g7-em1Ygch (NOD/ShiLtJ-H2-Ab1^g7-em1Ygch)	decreased CD4-positive, alpha-beta T cell number	J:101977
H2-D1^b-em1Dvs/H2-D1^b-em1Dvs (NOD/ShiLtDvs-H2-D1^b-em1Dvs/Dvs)	abnormal immune system physiology	J:257229
	decreased susceptibility to autoimmune diabetes	J:257229
H2-D1^b-em2Dvs/H2-D1^b-em2Dvs (NOD/ShiLtDvs-H2-D1^b-em2Dvs/Dvs)	abnormal immune system physiology	J:257229
	decreased susceptibility to autoimmune diabetes	J:257229
H2-D1^b-em3Dvs/H2-D1^b-em3Dvs (NOD/ShiLtDvs-H2-D1^b-em3Dvs/Dvs)	abnormal immune system physiology	J:257229
	decreased susceptibility to autoimmune diabetes	J:257229
H2-D1^b-em4Dvs/H2-D1^b-em4Dvs (NOD/ShiLtDvs-H2-D1^b-em4Dvs/Dvs)	abnormal immune system physiology	J:257229
	decreased susceptibility to autoimmune diabetes	J:257229
H2-D1^b-em5Dvs/H2-D1^b-em5Dvs H2-K1^d-em1Dvs/H2-K1^d-em1Dvs (NOD/ShiLtDvs-H2-K1^d-em1Dvs H2-D1^b-em5Dvs/Dvs)	abnormal T cell subpopulation ratio	J:257229
	decreased susceptibility to autoimmune diabetes	J:257229
H2-D1^b-em5Dvs/H2-D1^b-em5Dvs H2-K1^d-em1Dvs/H2-K1^d-em1Dvs Tg(HLA-A/H2-D/B2M)1Dvs/? (NOD/ShiLtDvs-H2-K1^d-em1Dvs H2-D1^b-em5Dvs Tg(HLA-A/H2-D/B2M)1Dvs/Dvs)	autoimmune response	J:257229
	increased susceptibility to autoimmune diabetes	J:257229
	insulitis	J:257229
H2-D1^b-em5Dvs/H2-D1^b-em5Dvs H2-K1^d-em1Dvs/H2-K1^d-em1Dvs Tg(HLA-B39/H2-D/B2m)2Dvs/? (NOD/ShiLtDvs-H2-K1^d-em1Dvs H2-D1^b-em5Dvs Tg(HLA-B39/H2-D/B2M)2Dvs/Dvs)	autoimmune response	J:257229
	increased susceptibility to autoimmune diabetes	J:257229
	insulitis	J:257229
H2-D1^b-tm1Bpe/H2-D1^b-tm1Bpe H2-K1^b-tm1Bpe/H2-K1^b-tm1Bpe (involves: 129P2/OlaHsd * C57BL/6)	absent CD8-positive, alpha-beta T cells	J:57703
	decreased CD8-positive, alpha-beta T cell number	J:54709
	decreased susceptibility to Riboviria infection induced morbidity/mortality	J:54709
	increased CD4-positive, alpha-beta T cell number	J:54709
H2-D1^b-tm1Bpe/H2-D1^b-tm1Bpe H2-K1^b-tm1Bpe/H2-K1^b-tm1Bpe (B6.129P-H2-D1^b-tm1Bpe H2-K1^b-tm1Bpe)	abnormal cytotoxic T cell physiology	J:118960
H2-D1^b-tm1Bpe/H2-D1^b-tm1Bpe H2-K1^b-tm1Bpe/H2-K1^b-tm1Bpe Klra1^tm1.1Wyok/Klra1^tm1.1Wyok Tg(H2-D^d)28Bee/0 (involves: 129P2/OlaHsd * BALB/cJ * C57BL/6NTac * DBA/2)	abnormal NK cell physiology	J:252851
H2-D1^b-tm1Bpe/H2-D1^b-tm1Bpe H2-K1^b-tm1Bpe/H2-K1^b-tm1Bpe X/Yaa (BXSB.129P2(B6)-H2-K1^b-tm1Bpe H2-D1^b-tm1Bpe/Dcr)	increased susceptibility to systemic lupus erythematosus	J:179430
H2-D1^bm14/H2-D1^bm14 (C57BL/6)	abnormal T cell activation	J:97717
H2-D1^bm14/H2-D1^bm14 (C57BL/6)	spinal cord inflammation	J:97717
H2-DMa^tm1Doi/H2-DMa^tm1Doi (involves: 129S2/SvPas * C57BL/6)	abnormal professional antigen presenting cell physiology	J:31624
	immune system phenotype	J:31624
H2-DMa^tm1Liz/H2-DMa^tm1Liz (involves: BALB/cJ)	abnormal antigen presentation via MHC class II	J:113714
	abnormal CD4-positive, alpha beta T cell morphology	J:113714
	abnormal professional antigen presenting cell physiology	J:111565, J:113714
	defective assembly of class II molecules	J:113714
H2-DMa^tm1Lkrl/H2-DMa^tm1Lkrl (involves: 129P2/OlaHsd)	abnormal antigen presentation	J:31786
	abnormal CD4-positive, alpha-beta T cell physiology	J:31786
	abnormal positive T cell selection	J:31786
	abnormal professional antigen presenting cell physiology	J:31786
	decreased CD4-positive, alpha-beta T cell number	J:31786
H2-DMa^tm1Luc/H2-DMa^tm1Luc (involves: 129S4/SvJae)	abnormal antigen presentation via MHC class II	J:31625
	abnormal CD4-positive, alpha-beta T cell physiology	J:31625
	abnormal level of surface class II molecules	J:45185
	abnormal positive T cell selection	J:125548
	decreased CD4-positive, alpha-beta T cell number	J:31625, J:45185
	decreased interferon-gamma secretion	J:45185
	increased susceptibility to bacterial infection	J:45185
H2-DMa^tm1Luc/H2-DMa^tm1Luc (involves: 129S4/SvJae * C57BL/6)	abnormal antigen presentation	J:72243
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:72243
H2-DMa^tm1Luc/H2-DMa^tm1Luc (B6.129S4-H2-Dma^tm1Luc)	abnormal antigen presentation	J:125654
	abnormal T-helper 1 physiology	J:125654
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:125654
	decreased susceptibility to type IV hypersensitivity reaction	J:125654
H2-DMa^tm1Luc/H2-DMa^tm1Luc Cd74^tm1Doi/Cd74^tm1Doi (involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)	abnormal level of surface class II molecules	J:45185
	increased susceptibility to parasitic infection	J:45185
H2-DMa^tm2Liz/H2-DMa^tm2Liz (involves: C57BL/6 * C57BL/10 * C57BR * CBA)	abnormal antigen presentation via MHC class II	J:111565
	abnormal professional antigen presenting cell physiology	J:111565
	decreased T cell proliferation	J:111565
H2-K1^b-tm1Bpe/H2-K1^b-tm1Bpe (involves: 129P2/OlaHsd * C57BL/6)	decreased CD8-positive, alpha-beta T cell number	J:54709
	increased CD4-positive, alpha-beta T cell number	J:54709
H2-K1^d-em4Dvs/H2-K1^d-em4Dvs (NOD/ShiLtDvs-H2-K1^d-em4Dvs/Dvs)	abnormal immune system physiology	J:257229
	decreased susceptibility to autoimmune diabetes	J:257229
H2-K1^d-em5Dvs/H2-K1^d-em5Dvs (NOD/ShiLtDvs-H2-K1^d-em5Dvs/Dvs)	abnormal immune system physiology	J:257229
	decreased susceptibility to autoimmune diabetes	J:257229
H2-K1^d-em7Dvs/H2-K1^d-em7Dvs (NOD/ShiLtDvs-H2-K1^d-em7Dvs/Dvs)	abnormal immune system physiology	J:257229
	decreased susceptibility to autoimmune diabetes	J:257229
H2-K^bm1/H2-K^bm1 Tg(TcraTcrb)1100Mjb/? (involves: C57BL/6)	abnormal positive T cell selection	J:92867
H2-K^bm5/H2-K^bm5 Tg(TcraTcrb)1100Mjb/? (involves: C57BL/6)	abnormal positive T cell selection	J:133645
H2-K^dm4/H2-K^dm4 (involves: BALB/cKh * C57BL/6Kh)	immune system phenotype	J:109272
H2-K^dm5/H2-K^dm5 (involves: BALB/cKh * C57BL/6Kh)	immune system phenotype	J:109272
H2-M3^tm1Crw/H2-M3^tm1Crw (B6.129-H2-M3^tm1Crw)	abnormal CD8-positive, alpha beta T cell morphology	J:118960
	abnormal cytotoxic T cell physiology	J:118960
	abnormal innate immunity	J:118960
	decreased activated T cell number	J:118960
	decreased interferon-gamma secretion	J:118960
	decreased macrophage nitric oxide production	J:118960
	impaired natural killer cell mediated cytotoxicity	J:118960
	increased susceptibility to bacterial infection	J:118960
H2-Oa^tm1Dma/H2-Oa^tm1Dma (involves: 129/Sv * C57BL/6)	abnormal antigen presentation via MHC class II	J:65235
H2-Oa^tm1Dma/H2-Oa^tm1Dma (involves: 129/Sv * C57BL/6)	increased CD4-positive, alpha-beta T cell number	J:65235
H2-Oa^tm1Lkar/H2-Oa^tm1Lkar (involves: 129P2/OlaHsd)	abnormal antigen presentation via MHC class II	J:85084
	immune system phenotype	J:85084
	increased IgG1 level	J:85084
H2-Ob^em1Tvg/H2-Ob^em1Tvg (C57BL/6J-H2-Ob^em1Tvg/Tvg)	decreased susceptibility to Retroviridae infection	J:254532
	defective assembly of class II molecules	J:254532
	immune system phenotype	J:254532
H2-Ob^vic1/H2-Ob^vic1 (I/LnJ)	decreased susceptibility to Retroviridae infection	J:163153
H2-Ob^vic1/H2-Ob^vic1 (I/LnJ)	decreased susceptibility to viral infection	J:81554, J:60602
H2-Ob^vic1/H2-Ob^vic1 (C3N.I-H2-Ob^vic1)	decreased susceptibility to Retroviridae infection	J:254532
H2-Ob^vic1/H2-Ob^vic1 (B6.I-H2-Ob^vic1)	decreased susceptibility to Retroviridae infection	J:254532
H2-Ob^vic1/H2-Ob^vic1 (C.I-H2-Ob^vic1)	decreased susceptibility to Retroviridae infection	J:254532
H2-Q10^{tm1.1(KOMP)Mbp}/H2-Q10^{tm1.1(KOMP)Mbp} (involves: C57BL/6 * C57BL/6N)	decreased gamma-delta T cell number	J:294888
	decreased immature NK cell number	J:294888
	decreased mature NK cell number	J:294888
	decreased NK cell number	J:294888
	increased NK cell number	J:294888
H2-T18^b/H2-T18^b H2-T3^tm1Luc/H2-T3^tm1Luc (C57BL/6-H2-T3^tm1Luc)	abnormal CD8 positive, alpha-beta intraepithelial T cell morphology	J:142515
	abnormal CD8-positive, gamma-delta intraepithelial T cell morphology	J:142515
	abnormal intraepithelial T cell morphology	J:142515
	increased interferon-gamma secretion	J:142515
H2-T18^b/H2-T18^b H2-T3^tm1Luc/H2-T3^tm1Luc Tcra^tm1Mom/Tcra^tm1Mom (B6.Cg-Tcra^tm1Mom H2-T3^tm1Luc)	abnormal intraepithelial T cell number	J:142515
	colitis	J:142515
	enlarged mesenteric lymph nodes	J:142515
	increased interleukin-4 secretion	J:142515
H2-T23^tm1Cant/H2-T23^tm1Cant (involves: 129S6/SvEvTac * C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:142087, J:123555
	abnormal memory T cell physiology	J:123555
	increased susceptibility to bacterial infection	J:89808
	increased susceptibility to experimental autoimmune encephalomyelitis	J:89808
	increased susceptibility to Herpesvirales infection	J:89808
H2-T23^tm2Cant/H2-T23^tm2Cant (involves: 129S6/SvEvTac)	abnormal CD4-positive, alpha-beta T cell physiology	J:123555
H2-T23^tm2Cant/H2-T23^tm2Cant (B6.129S6-H2-T23^tm2Cant)	abnormal CD4-positive, alpha-beta T cell physiology	J:142087
H2-T23^tm2Cant/H2-T23^tm2Cant (B6.129S6-H2-T23^tm2Cant)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:142087
H2-T23^tm2Cant/H2-T23^tm2Cant Tg(Tcra2D2,Tcrb2D2)1Kuch/? (involves: 129S6/SvEvTac)	abnormal CD4-positive, alpha-beta T cell physiology	J:142087
	increased susceptibility to experimental autoimmune encephalomyelitis	J:142087
H2-T23^tm3Cant/H2-T23^tm3Cant (B6.129S6-H2-T23^tm3Cant)	increased susceptibility to experimental autoimmune encephalomyelitis	J:142087
H2-T23^tm3Cant/H2-T23^tm3Cant Tg(Tcra2D2,Tcrb2D2)1Kuch/? (involves: 129S6/SvEvTac * C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:142087
H2-T23^tm3Cant/H2-T23^tm3Cant Tg(TcraTcrb)425Cbn/? (involves: 129S6/SvEvTac * C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:142087
H2-T24^{em1(IMPC)Wtsi}/H2-T24^{em1(IMPC)Wtsi} (C57BL/6N-H2-T24^{em1(IMPC)Wtsi}/Wtsi)	increased leukocyte cell number	J:211773
H2^b/H2^b (NOD.B10SnJ-H2^b)	decreased susceptibility to autoimmune diabetes	J:14178
H2^b/H2^b (NOD.B10SnJ-H2^b)	periinsulitis	J:14178
H2^b/H2^b Itk^tm1Ljb/Itk^tm1Ljb Tg(TcrAND)53Hed/? (involves: C3H/HeJ * C57BL/6 * C57BL/10)	abnormal positive T cell selection	J:123795
	decreased CD4-positive, alpha-beta T cell number	J:123795
H2^b/H2^b Nfkbid^tm1Clay/Nfkbid^tm1Clay Rag2^tm1Fwa/Rag2^tm1Fwa Tg(TcraN15,TcrbN15)L2Elre/? (involves: 129S/SvEv * 129S6/SvEvTac * C57BL/6)	abnormal thymocyte activation	J:132071
	decreased interleukin-2 secretion	J:132071
	decreased T cell proliferation	J:132071
H2^b/H2^b Ptcra^tm1Vbo/Ptcra^tm1Vbo (involves: 129P2/OlaHsd)	decreased double-positive T cell number	J:131357
	decreased thymocyte number	J:131357
	spleen hypoplasia	J:131357
H2^b/H2^b Ptcra^tm1Vbo/Ptcra^tm1Vbo Tcra^tm1Mom/Tcra/Tcrd^{tm1.1(Tcra)Rsky} Tg(Tcrb)93Vbo/? (involves: 129P2/OlaHsd * C57BL/6J * DBA/2J)	abnormal T cell differentiation	J:131357
	decreased thymocyte number	J:131357
H2^b/H2^b Ptcra^tm1Vbo/Ptcra^tm1Vbo Tg(TcraH-Y,TcrbH-Y)71Vbo/? (involves: 129P2/OlaHsd * C57BL/6J * DBA/2J)	abnormal T cell differentiation	J:131357
H2^b/H2^b Rag1^tm1Mom/Rag1^tm1Mom Tg(Tcra19,Tcrb19)#Stl/0 (involves: 129S7/SvEvBrd * C57BL/6)	immune system phenotype	J:19795
H2^b/H2^b Rag2^tm1Fwa/Rag2^tm1Fwa Tg(TcraN15,TcrbN15)L2Elre/? (involves: 129S/SvEv * C57BL/6)	abnormal cytotoxic T cell physiology	J:133112
	arrested T cell differentiation	J:133112
	decreased CD4-positive, alpha-beta T cell number	J:133112
	increased CD8-positive, alpha-beta T cell number	J:133112
	increased T cell proliferation	J:133112
H2^b/H2^b Tcra/Tcrd^{tm1.1(Tcra)Rsky}/Tcra/Tcrd^{tm1.1(Tcra)Rsky} Tg(Tcrb)93Vbo/? (involves: 129P2/OlaHsd * C57BL/6J * DBA/2J)	abnormal negative T cell selection	J:81564
	abnormal T cell differentiation	J:81564
H2^b/H2^b Tcra/Tcrd^{tm1.1(Tcra)Rsky}/Tcra/Tcrd^{tm1.1(Tcra)Rsky} Tg(Tcrb)93Vbo/? (involves: 129P2/OlaHsd * C57BL/6J * DBA/2J)	abnormal negative T cell selection	J:81564
	abnormal T cell differentiation	J:81564
H2^b/H2^b Tcra^tm1Mom/Tcra/Tcrd^{tm1.1(Tcra)Rsky} Tg(Tcrb)93Vbo/? (involves: 129P2/OlaHsd * C57BL/6J * DBA/2J)	abnormal double-negative T cell morphology	J:131357
	abnormal double-positive T cell morphology	J:81564
	abnormal negative T cell selection	J:81564
	abnormal T cell differentiation	J:81564
	decreased double-positive T cell number	J:131357
	decreased thymocyte number	J:131357
H2^b/H2^d ((C57BL/6 x DBA/2)F1)	abnormal cytokine secretion	J:106141
	abnormal T cell differentiation	J:106141
	decreased susceptibility to parasitic infection	J:106141
	increased autoantibody level	J:106141
H2^b/H2^d Tg(Ins2-E3)1Dvs/0 (involves: BALB/c * C57BL/6 * DBA/2J)	increased length of allograft survival	J:109763
H2^b/H2^d Tg(TcraTcrb)1100Mjb/? (involves: BALB/c * C57BL/6)	abnormal negative T cell selection	J:133645
	decreased CD8-positive, alpha-beta T cell number	J:133645
	small thymus	J:133645
H2^b/H2^d Themis^tm1Gasc/Themis^tm1Gasc (involves: 129S6/SvEvTac * C57BL/6 * C57BL/10 * DBA/2)	abnormal negative T cell selection	J:151074
H2^b/H2^g7 (NOD.B10SnJ-H2^b)	decreased susceptibility to autoimmune diabetes	J:14178
H2^b/H2^g7 Tg(TcraR28,TcrbR28)KRNDim/0 (involves: C57BL/6 * NOD * SJL)	mitral valve inflammation	J:275827
	rheumatoid arthritis	J:36815, J:275827
H2^b/H2^k Itk^tm1Ljb/Itk^tm1Ljb Tg(TcrAND)53Hed/? (involves: C3H/HeJ * C57BL/6 * C57BL/10)	abnormal positive T cell selection	J:123795
	decreased CD4-positive, alpha-beta T cell number	J:123795
H2^b/H2^k Tg(TcraTcrb)1100Mjb/? (involves: C57BL/6 * C57BL/10Sg * C57BR/c)	abnormal negative T cell selection	J:133645
	decreased CD8-positive, alpha-beta T cell number	J:133645
	small thymus	J:133645
H2^b/H2^s Tg(TcraTcrb)1100Mjb/? (involves: A/WySn * C57BL/6 * C57BL/10Sg * Swiss)	abnormal negative T cell selection	J:133645
	decreased CD8-positive, alpha-beta T cell number	J:133645
	small thymus	J:133645
H2^d/H2^d (DBA/2)	abnormal cytokine secretion	J:106141
	abnormal T cell differentiation	J:106141
	decreased susceptibility to parasitic infection	J:106141
	increased autoantibody level	J:106141
H2^d/H2^d Rag2^tm1Fwa/Rag2^tm1Fwa Tg(TcraN15,TcrbN15)L2Elre/? (involves: 129S/SvEv * C57BL/6)	arrested T cell differentiation	J:133112
	decreased CD4-positive, alpha-beta T cell number	J:133112
	decreased CD8-positive, alpha-beta T cell number	J:133112
H2^d/H2^d Tcra/Tcrd^{tm1.1(Tcra)Rsky}/Tcra/Tcrd^{tm1.1(Tcra)Rsky} Tg(Tcrb)93Vbo/0 (involves: 129P2/OlaHsd * C57BL/6J * DBA/2J)	abnormal T cell differentiation	J:131357
	decreased thymocyte number	J:131357
H2^d/H2^d Tg(TcraP1.5,TcrbP1.5)29Amsv/0 Trap1a^tm1.1Jvde/Y (involves: 129 * BALB/cJ * C57BL/10 * DBA/2)	abnormal T cell clonal deletion	J:180807
H2^d/H2^d Trap1a^tm1.1Jvde/Y (involves: 129 * BALB/cJ * C57BL/10 * DBA/2)	abnormal CD8-positive, alpha-beta T cell physiology	J:180807
	abnormal immune tolerance	J:180807
H2^dlAb1-Ea/H2^dlAb1-Ea (B6.129S2-H2^dlAb1-Ea/J)	increased susceptibility to bacterial infection	J:123934
H2^dlAb1-Ea/H2^dlAb1-Ea (involves: 129S2/SvPas * C57BL/6)	abnormal immunoglobulin level	J:57484
	abnormal T cell number	J:57484
	decreased CD4-positive, alpha-beta T cell number	J:57484
	decreased IgG1 level	J:57484
	decreased IgG2a level	J:57484
	immune system phenotype	J:157516
	increased CD8-positive, alpha-beta T cell number	J:57484
	increased IgM level	J:57484
H2^dlAb1-Ea/H2^dlAb1-Ea Marchf1^tm1.1Sish/Marchf1^tm1.1Sish (involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6)	immune system phenotype	J:157516
H2^dlAb1-Ea/H2^dlAb1-Ea Psmb11^{tm1(Psmb8)Khog}/Psmb11^{tm1(Psmb8)Khog} (involves: 129S2/SvPas * C57BL/6)	abnormal T cell differentiation	J:196156
	decreased CD8-positive, alpha-beta T cell number	J:196156
H2^dlAb1-Ea/H2^dlAb1-Ea Rag1^tm1Mom/Rag1^tm1Mom Tg(HLA-DRA,HLA-DRB50101)hiKito/0 Tg(TRATL3A6,TRBTL3A6)#Kito/0 (involves: 129S2/SvPas 129S7/SvEvBrd * C57BL/6)	brain inflammation	J:189816
H2^dlAb1-Ea/H2^dlAb1-Ea Rag1^tm1Mom/Rag1^tm1Mom Tg(HLA-DRA,HLA-DRB50101)loKito/0 Tg(TRATL3A6,TRBTL3A6)#Kito/0 (involves: 129S2/SvPas 129S7/SvEvBrd * C57BL/6)	brain inflammation	J:189816
H2^dlAb1-Ea/H2^dlAb1-Ea Rr381^em2Kap/Rr381^em2Kap (involves: 129S2/SvPas * C57BL/6)	absent CD4-positive, alpha-beta T cells	J:333471
H2^dlAb1-Ea/H2^dlAb1-Ea Rr381^em4Kap/Rr381^em4Kap (involves: 129S2/SvPas * C57BL/6)	absent CD8-positive, alpha-beta T cells	J:333471
H2^dlAb1-Ea/H2^dlAb1-Ea Rr381^em5Kap/Rr381^em5Kap (involves: 129S2/SvPas * C57BL/6)	absent CD8-positive, alpha-beta T cells	J:333471
H2^dlAb1-Ea/H2^dlAb1-Ea Tg(HLA-DRA,HLA-DRB50101)hiKito/0 Tg(TRATL3A6,TRBTL3A6)#Kito/0 (involves: 129S2/SvPas C57BL/6)	abnormal cytokine secretion	J:189816
	brain inflammation	J:189816
	CNS inflammation	J:189816
	increased CD4-positive, alpha-beta T cell number	J:189816
	increased inflammatory response	J:189816
	increased interferon-gamma secretion	J:189816
	increased interleukin-17 secretion	J:189816
	increased susceptibility to experimental autoimmune encephalomyelitis	J:189816
	increased T-helper 1 cell number	J:189816
	increased T-helper 17 cell number	J:189816
H2^dlAb1-Ea/H2^dlAb1-Ea Tg(HLA-DRA,HLA-DRB50101)loKito/0 Tg(TRATL3A6,TRBTL3A6)#Kito/0 (involves: 129S2/SvPas C57BL/6)	brain inflammation	J:189816
	increased susceptibility to experimental autoimmune encephalomyelitis	J:189816
H2^g7/H2^g7 Ins2^tm1Jja/Ins2^tm1Jja Rag1^tm1Mom/Rag1^tm1Mom Tg(TcraBDC12-4.1)10Jos/0 Tg(TcrbBDC12-4.1)82Gse/0 (involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6 * FVB * NOD)	increased susceptibility to autoimmune diabetes	J:111874
H2^g7/H2^g7 Rag1^tm1Mom/Rag1^tm1Mom Tg(TcraBDC12-4.1)10Jos/0 Tg(TcrbBDC12-4.1)82Gse/0 (involves: 129S7/SvEvBrd * C57BL/6 * FVB * NOD)	increased susceptibility to autoimmune diabetes	J:111874
	insulitis	J:111874
H2^g7/H2^g7 Tg(Ins2-Vtcn1)#Xxz/0 Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0 (involves: C57BL/6 * NOD * SJL)	decreased interferon-gamma secretion	J:177612
	decreased interleukin-17 secretion	J:177612
	decreased regulatory T cell number	J:177612
	decreased susceptibility to autoimmune diabetes	J:177612
H2^g7/H2^g7 Tg(TcraAI4)1Dvs/0 Tg(TcrbAI4)1Dvs/0 (B6.NOD-(D17Mit21-D17Mit10) Tg(TcraAI4)1Dvs Tg(TcrbAI4)1Dvs)	increased susceptibility to autoimmune diabetes	J:167508
H2^g7/H2^g7 Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0 (B6.Cg-H2^g7 Tg(TcraBDC2.5,TcrbBDC2.5)1Doi)	decreased susceptibility to autoimmune diabetes	J:86926
H2^g7/H2^g7 Tg(TcraBDC12-4.1)10Jos/0 Tg(TcrbBDC12-4.1)82Gse/0 (involves: 129S7/SvEvBrd * C57BL/6 * FVB * NOD)	decreased susceptibility to autoimmune diabetes	J:111874
	insulitis	J:111874
H2^g7/H2^q Rag1^tm1Mom/Rag1^tm1Mom Tg(TcraBDC12-4.1)10Jos/0 Tg(TcrbBDC12-4.1)82Gse/0 (involves: 129S7/SvEvBrd * C57BL/6 * FVB * NOD)	increased susceptibility to autoimmune diabetes	J:111874
H2^h2/H2^g7 (NOD.Cg-H2^h2)	decreased susceptibility to autoimmune diabetes	J:14178
H2^h2/H2^h2 (NOD.Cg-H2^h2)	decreased susceptibility to autoimmune diabetes	J:14178
	insulitis	J:14178
	periinsulitis	J:14178
H2^h4/H2^g7 (NOD.Cg-H2^h4)	decreased susceptibility to autoimmune diabetes	J:14178
H2^h4/H2^h4 (NOD.Cg-H2^h4)	abnormal cytokine secretion	J:54563
	decreased susceptibility to autoimmune diabetes	J:14178
	insulitis	J:14178
	periinsulitis	J:14178
	thyroid gland inflammation	J:54563
H2ⁱ⁵/H2^g7 (NOD.Cg-H2ⁱ⁵)	decreased susceptibility to autoimmune diabetes	J:14178
H2ⁱ⁵/H2ⁱ⁵ (NOD.Cg-H2ⁱ⁵)	decreased susceptibility to autoimmune diabetes	J:14178
H2ⁱ⁵/H2ⁱ⁵ (NOD.Cg-H2ⁱ⁵)	periinsulitis	J:14178
H2ⁱ⁷/H2^g7 (NOD.Cg-H2ⁱ⁷)	decreased susceptibility to autoimmune diabetes	J:14178
H2ⁱ⁷/H2^g7 ((NOD x NOD.Cg-H2ⁱ⁷)F1)	insulitis	J:14178
H2ⁱ⁷/H2ⁱ⁷ (NOD.Cg-H2ⁱ⁷)	decreased susceptibility to autoimmune diabetes	J:14178
H2ⁱ⁷/H2ⁱ⁷ (NOD.Cg-H2ⁱ⁷)	periinsulitis	J:14178
H2^k/H2^g7 (NOD.Cg-H2^k)	decreased susceptibility to autoimmune diabetes	J:14178
H2^k/H2^k (NOD.Cg-H2^k)	increased susceptibility to autoimmune diabetes	J:14178
H2^k/H2^k (NOD.Cg-H2^k)	periinsulitis	J:14178
H2^k/H2^k Tg(TcraTcrbAD10)1Hed/? (involves: C57BL/6 * SJL)	increased CD4-positive, alpha-beta T cell number	J:124701
H2^q/? Ncf1^m1J/Ncf1^m1J (B6.Cg-Ncf1^m1J H2^q)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:92437
	increased susceptibility to experimental autoimmune encephalomyelitis	J:92437
	increased susceptibility to induced arthritis	J:92437
	increased susceptibility to type IV hypersensitivity reaction	J:92437
	rheumatoid arthritis	J:92437
H2^q/H2^q Rag1^tm1Mom/Rag1^tm1Mom Tg(TcraBDC12-4.1)10Jos/0 Tg(TcrbBDC12-4.1)82Gse/0 (involves: 129S7/SvEvBrd * C57BL/6 * FVB * NOD)	decreased susceptibility to autoimmune diabetes	J:111874
H2^u/H2^u Rag1^tm1Mom/Rag1^tm1Mom Tg(Tcra19,Tcrb19)#Stl/0 (either: (involves: 129S7/SvEvBrd * C57BL/6 * PL/J) or (involves: 129S7/SvEvBrd * C57BL/6 * C57BL/10 * PL/J))	increased susceptibility to autoimmune disorder	J:19795
H2^u/H2^u Tg(Tcra19,Tcrb19)#Stl/0 (either: (involves: C57BL/6 * PL/J) or (involves: C57BL/6 * C57BL/10 * PL/J))	increased susceptibility to autoimmune disorder	J:19795
	increased susceptibility to experimental autoimmune encephalomyelitis	J:19795
H2^u/H2^u Tg(TCRA)B1Jg/0 (B10.PL-H2^u H2-T18^a/(73NS)Sn-Tg(TCRA)B1Jg/J)	abnormal thymus cell ratio	J:92992
	decreased CD4-positive, alpha-beta T cell number	J:92992
	decreased double-positive T cell number	J:92992
	decreased thymocyte number	J:92992
	increased double-negative T cell number	J:92992
	increased T cell derived lymphoma incidence	J:92992
H2^u/H2^u Tg(TCRA)B1Jg/? Tg(TCRB)C14Jg/? (involves: C57BL/6 * C57BL/10SnSg * DBA/2 * PL/J)	abnormal CD4-positive, alpha-beta T cell physiology	J:92991
	abnormal effector T cell morphology	J:92991
	decreased CD8-positive, alpha-beta T cell number	J:92991
	decreased double-positive T cell number	J:92991
	increased autoantibody level	J:92991
	increased CD4-positive, alpha-beta T cell number	J:92991
	increased susceptibility to experimental autoimmune encephalomyelitis	J:92991
H2^u/H2^u Tg(TCRA)B1Jg/0 Tg(TCRB)C14Jg/0 (B10.PL-H2^u H2-T18^a/(73NS)Sn-Tg(TCRA)B1Jg Tg(TCRB)C14Jg)	abnormal double-negative T cell morphology	J:92992
	abnormal double-positive T cell morphology	J:92992
	abnormal thymus cell ratio	J:92992
	absent gamma-delta T cells	J:92992
	decreased double-positive T cell number	J:92992
	increased CD4-positive, alpha-beta T cell number	J:92992
	increased double-negative T cell number	J:92992
	increased T cell derived lymphoma incidence	J:92992
H2^u/H2^u Tg(TCRB)C14Jg/0 (B10.PL-H2^u H2-T18^a/(73NS)Sn-Tg(TCRB)C14Jg/J)	abnormal double-negative T cell morphology	J:92992
	abnormal double-positive T cell morphology	J:92992
	absent gamma-delta T cells	J:92992
H2ax^tm1Fwa/H2ax⁺ Trp53^tm1Brd/Trp53^tm1Brd (involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6)	increased T cell derived lymphoma incidence	J:84879
H2ax^tm1Fwa/H2ax^tm1Fwa (involves: 129S6/SvEvTac)	abnormal class switch recombination	J:84879
	decreased lymphocyte cell number	J:84879
	increased T cell derived lymphoma incidence	J:84879
H2ax^tm1Fwa/H2ax^tm1Fwa Trp53^tm1Brd/Trp53^tm1Brd (involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6)	increased T cell derived lymphoma incidence	J:84879
H2ax^tm1Nus/H2ax^tm1Nus (Not Specified)	abnormal class switch recombination	J:194603, J:120658
	decreased B cell number	J:76360
	decreased IgG level	J:73342
	decreased T cell number	J:76360
H2ax^tm1Nus/H2ax^tm1Nus Igh^tm1Mnz/Igh^tm1Mnz (involves: 129P2/OlaHsd)	immune system phenotype	J:120658
H2ax^tm1Nus/H2ax^tm1Nus Igh^tm2Mnz/Igh^tm2Mnz (involves: 129P2/OlaHsd)	immune system phenotype	J:120658
H2bc4^em1(IMPC)Tcp/H2bc4^em1(IMPC)Tcp (C57BL/6N-H2bc4^em1(IMPC)Tcp/Tcp)	enlarged spleen	J:211773
H4c1^{em1(IMPC)Ccpcz}/H4c1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-H4c1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
H4c16^em1(IMPC)Mbp/H4c16^em1(IMPC)Mbp (C57BL/6N-H4c16^em1(IMPC)Mbp/MbpMmucd)	enlarged thymus	J:211773
H13^{tm1b(KOMP)Wtsi}/H13^{tm1b(KOMP)Wtsi} (C57BL/6N-H13^{tm1b(KOMP)Wtsi}/Wtsi)	abnormal thymus topology	J:239583
	blood in lymph vessels	J:239583
Habp2^tm1Lex/Habp2^tm1Lex (involves: 129S7/SvEvBrd * BALB/c * C57BL/6)	liver inflammation	J:207454
Hace1^tm1Pngr/Hace1^tm1Pngr (involves: 129P2/OlaHsd * C57BL/6)	increased T cell derived lymphoma incidence	J:125183
Hamp^tm1Svl/Hamp^tm1Svl (involves: 129S2/SvPas * C57BL/6)	decreased spleen iron level	J:119004
Hamp^tm1Svl/Hamp^tm1Svl (involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6)	increased susceptibility to bacterial infection induced morbidity/mortality	J:199427
Hand2^tm1Cse/Hand2⁺ H2az2^{Tg(Wnt1-cre)11Rth}/H2az2⁺ (involves: 129S1/Sv * C57BL/6J * CBA/J)	abnormal thymus development	J:155265
Hapln3^{em1(IMPC)Hmgu}/Hapln3^{em1(IMPC)Hmgu} (C57BL/6NCrl-Hapln3^{em1(IMPC)Hmgu}/Ieg)	increased eosinophil cell number	J:211773
Hapstr1^tm1.1Menm/Hapstr1^tm1.1Menm Tg(CAG-cre/Esr1)5Amc/0 (involves: C57BL/6 C57BL/6J * CBA)	large intestinal inflammation	J:348964
Has1^{tm1b(KOMP)Wtsi}/Has1^{tm1b(KOMP)Wtsi} (C57BL/6N-Has1^{tm1b(KOMP)Wtsi}/H)	decreased eosinophil cell number	J:211773
	increased basophil cell number	J:211773
Havcr1^tm1Kuch/Havcr1^tm1Kuch (B6.Cg-Havcr1^tm1Kuch)	abnormal B cell physiology	J:186484
	abnormal CD4-positive, alpha-beta T cell physiology	J:186484
	abnormal dendritic cell physiology	J:186484
	abnormal T cell differentiation	J:186484
	autoimmune response	J:186484
	enlarged spleen	J:186484
	increased activated T cell number	J:186484
	increased anti-double stranded DNA antibody level	J:186484
	increased CD4-positive, alpha-beta T cell number	J:186484
	increased CD8-positive, alpha-beta T cell number	J:186484
	increased double-negative T cell number	J:186484
	increased T cell number	J:186484
Havcr1^tm1Shw/Havcr1^tm1Shw (C.129P2-Havcr1^tm1Shw)	immune system phenotype	J:166400
Havcr1^tm1Vlcg/Havcr1^tm1Vlcg (B6.129-Havcr1^tm1Vlcg)	immune system phenotype	J:187793
	increased interleukin-5 secretion	J:187793
	increased interleukin-13 secretion	J:187793
Havcr1^tm1Vlcg/Havcr1^tm1Vlcg (C.129-Havcr1^tm1Vlcg)	abnormal cytokine secretion	J:187793
	immune system phenotype	J:187793
	increased interleukin-4 secretion	J:187793
	increased interleukin-5 secretion	J:187793
	increased interleukin-10 secretion	J:187793
	increased interleukin-13 secretion	J:187793
	increased interleukin-17 secretion	J:187793
	respiratory system inflammation	J:187793
Havcr2^{tm1b(KOMP)Wtsi}/Havcr2^{tm1b(KOMP)Wtsi} (C57BL/6N-Havcr2^{tm1b(KOMP)Wtsi}/Ucd)	increased spleen weight	J:211773
Havcr2^tm1Bmed/Havcr2^tm1Bmed (B6.Cg-Havcr2^tm1Bmed)	abnormal CD8-positive, alpha-beta T cell physiology	J:189839
	decreased activation-induced cell death of T cells	J:189839
	decreased interferon-gamma secretion	J:189839
	decreased susceptibility to Orthomyxoviridae infection	J:189839
	decreased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:189839
	decreased T cell proliferation	J:189839
Havcr2^tm1Tbs/Havcr2^tm1Tbs (C.Cg-Havcr2^tm1Tbs)	immune system phenotype	J:86260
Havcr2^tm1Vlcg/Havcr2^tm1Vlcg (B6.129-Havcr2^tm1Vlcg)	decreased interferon-gamma secretion	J:209885
Havcr2^tm1Vlcg/Havcr2^tm1Vlcg (B6.129-Havcr2^tm1Vlcg)	decreased T cell number	J:209885
Havcr2^tm1Vlcg/Havcr2^tm1Vlcg Tg(TcraTcrb)1100Mjb/? (B6.Cg-Havcr2^tm1Vlcg Tg(TcraTcrb)1100Mjb)	decreased interferon-gamma secretion	J:209885
	decreased T cell number	J:209885
Hax1^tm1.1Gach/Hax1^tm1.1Gach (involves: BALB/c)	abnormal B cell number	J:174159
	abnormal lymphocyte morphology	J:174159
	abnormal T cell number	J:174159
	decreased B cell number	J:174159
	decreased B-1a cell number	J:174159
	decreased CD4-positive, alpha-beta T cell number	J:174159
	decreased CD8-positive, alpha-beta T cell number	J:174159
	decreased double-positive T cell number	J:174159
	decreased IgG2a level	J:174159
	decreased immature B cell number	J:174159
	decreased marginal zone B cell number	J:174159
	decreased mature B cell number	J:174159
	decreased pre-B cell number	J:174159
	decreased pro-B cell number	J:174159
	decreased thymocyte number	J:174159
	decreased transitional stage T1 B cell number	J:174159
	decreased transitional stage T2 B cell number	J:174159
	increased follicular B cell number	J:174159
	spleen hypoplasia	J:174159
	thymus hypoplasia	J:174159
Hax1^tm1Jni/Hax1^tm1Jni (involves: 129P2/OlaHsd * C57BL/6)	decreased double-positive T cell number	J:132627
	decreased immature B cell number	J:132627
	decreased leukocyte cell number	J:132627
	decreased lymphocyte cell number	J:132627
	decreased neutrophil cell number	J:132627
	decreased single-positive T cell number	J:132627
	decreased T cell number	J:132627
Hba^b2(th)/Hba⁺ (either: (involves: 101 * SEC) or (involves: 101 * C57BL * SEC))	increased leukocyte cell number	J:123943
Hba^tm1(HBA)Tow/Hba^tm1(HBA)Tow Hbb^{tm2(HBG1,HBB)Tow}/Hbb^{tm2(HBG1,HBB)Tow} (Not Specified)	abnormal Kupffer cell morphology	J:134980
	abnormal spleen white pulp morphology	J:134980
	enlarged spleen	J:134980
	increased spleen red pulp amount	J:134980
	spleen vascular congestion	J:134980
Hba^tm1(HBA)Tow/Hba^tm1(HBA)Tow Hbb^{tm2(HBG1,HBB)Tow}/Hbb^{tm2(HBG1,HBB)Tow} Slc12a4^Rbc10/Slc12a4⁺ (involves: 129 * BALB/c * C57BL/6J)	enlarged spleen	J:227339
	liver inflammation	J:227339
Hba^tm1(HBA)Tow/Hba^tm1(HBA)Tow Hbb^{tm2(HBG1,HBD,HBB)Ryan}/Hbb^{tm2(HBG1,HBD,HBB)Ryan} (Not Specified)	intermingled spleen red and white pulp	J:148521
	spleen hyperplasia	J:148521
Hba^tm1(HBA)Tow/Hba^tm1(HBA)Tow Hbb^{tm2(HBG1,HBD,HBB*)Ryan}/Hbb^{tm3(HBG1,HBB)Tow} (Not Specified)	spleen hyperplasia	J:148521
Hba^tm1Paz/Hba^tm1Paz Hbb^tm1Tow/Hbb^tm1Tow Tg(HBA-HBBs)41Paz/? (involves: 129S2/SvPas * 129S7/SvEvBrd * Black Swiss * C57BL/6 * DBA/2* FVB/N)	increased spleen weight	J:44161
	spleen vascular congestion	J:44161
Hbb-b1^MommeD7/Hbb-b1⁺ (involves: FVB/N)	enlarged spleen	J:142335, J:190446
Hbb-b1^MommeD7/Hbb-b1⁺ (involves: FVB/N)	increased spleen red pulp amount	J:190446
Hbb-b1^Rbc13/Hbb-b1⁺ (involves: BALB/c * C57BL/6)	enlarged spleen	J:190446
Hbb-b1^Rbc13/Hbb-b1⁺ (involves: BALB/c * C57BL/6)	increased spleen red pulp amount	J:190446
Hbb-b1^tm1Shs/Hbb-b1^tm1Shs (involves: C57BL/6)	enlarged spleen	J:78271
Hbb-b1^tm1Shs/Hbb-b1^tm1Shs (involves: C57BL/6)	increased spleen iron level	J:78271
Hbb-b1^tm1Unc/Hbb-b1⁺ Hbb-b2^tm1Unc/Hbb-b2⁺ (involves: 129P2/OlaHsd * C57BL/6J)	abnormal spleen morphology	J:88672, J:30155
	decreased spleen white pulp amount	J:30155
	increased spleen weight	J:30155
	intermingled spleen red and white pulp	J:30155
Hbb-b1^tm1Unc/Hbb-b1⁺ Hbb-b2^tm1Unc/Hbb-b2⁺ (involves: 129P2/OlaHsd * C57BL/6N)	enlarged spleen	J:185154
	increased spleen iron level	J:185154
Hbb-b1^tm1Unc/Hbb-b1⁺ Hbb-b2^tm1Unc/Hbb-b2⁺ (B6;129-Hbb-b1^tm1Unc Hbb-b2^tm1Unc/J)	abnormal spleen morphology	J:211331
Hbb-b1^tm1Unc/Hbb-b1⁺ Hbb-b2^tm1Unc/Hbb-b2⁺ (involves: 129P2/OlaHsd)	enlarged spleen	J:97548
Hbb-b1^tm1Unc/Hbb-b1⁺ Hbb-b2^tm1Unc/Hbb-b2⁺ Tg(HBB)L2Pai/0 (involves: 129P2/OlaHsd C57BL/6)	enlarged spleen	J:97548
Hbb-b1^tm1Unc/Hbb-b1⁺ Hbb-b2^tm1Unc/Hbb-b2⁺ Tmprss6^tm1Otin/Tmprss6⁺ (involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N)	abnormal spleen iron level	J:185154
	abnormal spleen size	J:185154
Hbb-b1^tm1Unc/Hbb-b1⁺ Hbb-b2^tm1Unc/Hbb-b2⁺ Tmprss6^tm1Otin/Tmprss6^tm1Otin (involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N)	abnormal spleen size	J:185154
Hbb^d3th/Hbb⁺ Tg(LCR-HBA1,LCR-HBB)1Tow/0 (involves: C57BL/6 DBA/2J * SJL)	enlarged spleen	J:127701
Hbb^d3th/Hbb⁺ Tg(LCR-HBA2,LCR-HBB)1Cos/0 (involves: C57BL/6J CBA/J * DBA/2J)	enlarged spleen	J:94193
Hbb^d3th/Hbb^d3th Tg(HBB-AR-HBA2,-HBB)58Rub/0 Tg(LCR-HBA2,LCR-HBB)11Cos/0 (involves: FVB/N Swiss Webster)	abnormal spleen morphology	J:94190
	enlarged spleen	J:94190
	increased spleen red pulp amount	J:94190
	spleen fibrosis	J:94190
	spleen vascular congestion	J:94190
Hbb^d4/Hbb^d4 (involves: 101/H)	abnormal macrophage morphology	J:7972
	enlarged spleen	J:7972
	increased spleen red pulp amount	J:7972
Hbb^{tm1.1(HBG1,HBB*)Ryan}/Hbb⁺ (involves: C57BL/6J)	abnormal spleen morphology	J:147906
	enlarged spleen	J:147906
	increased spleen iron level	J:147906
	increased spleen red pulp amount	J:147906
	intermingled spleen red and white pulp	J:147906
Hbb^tm1Tow/Hbb⁺ (involves: 129S2/SvPas * C57BL/6)	enlarged spleen	J:29087
Hbb^tm1Tow/Hbb⁺ (involves: 129S2/SvPas * C57BL/6)	increased spleen weight	J:29087
Hbb^tm2Unc/Hbb⁺ (involves: 129P2/OlaHsd * C57BL/6J)	enlarged spleen	J:64295
Hbb^tm2Unc/Hbb⁺ (involves: 129P2/OlaHsd * C57BL/6J)	increased spleen iron level	J:64295
Hbnr1^CBA/Hbnr1^SWR (involves: CBA * SWR)	decreased susceptibility to parasitic infection	J:82261, J:85787
Hbnr1^SWR/Hbnr1^SWR (involves: CBA * SWR)	decreased susceptibility to parasitic infection	J:82261, J:110034, J:85787
Hbnr2^CBA/Hbnr2^SWR (involves: CBA * SWR)	granulomatous inflammation	J:85787
Hbnr2^SWR/? (involves: CBA * SWR)	decreased susceptibility to parasitic infection	J:82261
Hbnr2^SWR/Hbnr2^SWR (involves: CBA * SWR)	decreased IgE level	J:85787
	decreased susceptibility to parasitic infection	J:110034
	granulomatous inflammation	J:85787
Hbnr3^CBA/Hbnr3^SWR (involves: CBA * SWR)	decreased susceptibility to parasitic infection	J:85787
Hbnr3^CBA/Hbnr3^SWR (involves: CBA * SWR)	increased susceptibility to parasitic infection	J:82261
Hbnr3^SWR/Hbnr3^SWR (involves: CBA * SWR)	increased susceptibility to parasitic infection	J:82261, J:85787
Hbnr4^SWR/Hbnr4^SWR (involves: CBA * SWR)	abnormal immune serum protein physiology	J:85787
Hbnr5^CBA/Hbnr5^SWR (involves: CBA * SWR)	decreased susceptibility to parasitic infection	J:85787
Hbnr5^SWR/Hbnr5^SWR (involves: CBA * SWR)	decreased susceptibility to parasitic infection	J:85787
Hbnr6^SWR/Hbnr6^SWR (involves: CBA * SWR)	increased IgE level	J:85787
Hbnr7^CBA/Hbnr7^SWR (involves: CBA * SWR)	decreased IgG1 level	J:85787
Hbnr7^SWR/Hbnr7^SWR (involves: CBA * SWR)	decreased IgG2b level	J:85787
Hbnr8^CBA/Hbnr8^SWR (involves: CBA * SWR)	decreased susceptibility to parasitic infection	J:85787
Hbnr8^SWR/Hbnr8^SWR (involves: CBA * SWR)	decreased susceptibility to parasitic infection	J:85787
Hbs1l^{tm1a(KOMP)Wtsi}/Hbs1l^{tm1a(KOMP)Wtsi} (C57BL/6N-Hbs1l^{tm1a(KOMP)Wtsi}/Wtsi)	decreased effector memory CD8-positive, alpha-beta T cell number	J:211773
	decreased Langerhans cell number	J:211773
	decreased mature B cell number	J:211773
	decreased memory-marker CD4-negative NK T cell number	J:211773
	decreased monocyte cell number	J:211773
	decreased T-helper cell number	J:211773
	increased CD4-positive, alpha-beta memory T cell number	J:211773
	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	increased CD5-positive gamma-delta T cell number	J:211773
	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
	increased leukocyte cell number	J:211773
	increased memory CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	increased regulatory T cell number	J:211773
Hc⁰/Hc⁰ (involves: C57BL/10SnJ)	increased susceptibility to bacterial infection	J:44240
Hc⁰/Hc⁰ Tg(TcrbBL17)1Lmor/0 (involves: DBA/1J * SWR/J)	decreased susceptibility to induced arthritis	J:134111
Hc¹/? Tg(TcrbBL17)1Lmor/0 (involves: DBA/1J * SWR/J)	increased susceptibility to induced arthritis	J:134111
Hcar1^{em1(IMPC)Ccpcz}/Hcar1^{em1(IMPC)Ccpcz} (C57BL/6N-Hcar1^{em1(IMPC)Ccpcz}/Ccpcz)	decreased effector memory T-helper cell number	J:211773
Hcfc2^em1Btlr/Hcfc2^em1Btlr (C57BL/6J-Hcfc2^em1Btlr)	decreased tumor necrosis factor secretion	J:251008
Hcfc2^fkls/Hcfc2⁺ (involves: C57BL/6J)	decreased interferon-beta secretion	J:251008
Hcfc2^fkls/Hcfc2⁺ (involves: C57BL/6J)	decreased tumor necrosis factor secretion	J:251008
Hcfc2^fkls/Hcfc2^fkls (C57BL/6J-Hcfc2^fkls)	abnormal innate immunity	J:94077
Hcfc2^fkls/Hcfc2^fkls (involves: C57BL/6J)	decreased circulating interferon-alpha level	J:251008
	decreased circulating interferon-beta level	J:251008
	decreased interferon-beta secretion	J:251008
	decreased tumor necrosis factor secretion	J:251008
	increased susceptibility to Herpesvirales infection	J:251008
	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:251008
	increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:251008
Hcfc2^fkls/Hcfc2^min (involves: C57BL/6J)	decreased tumor necrosis factor secretion	J:251008
Hcfc2^fkls/Hcfc2^sca (involves: C57BL/6J)	decreased tumor necrosis factor secretion	J:251008
Hck^tm1Ern/Hck^tm1Ern (involves: 129S1/Sv * C57BL/6)	abnormal alveolar macrophage morphology	J:111432
	abnormal immune system physiology	J:111432
	abnormal macrophage physiology	J:111432
	increased circulating tumor necrosis factor level	J:111432
	increased eosinophil cell number	J:111432
	increased interleukin-5 secretion	J:111432
	lung inflammation	J:111432
Hck^tm1Hev/Hck^tm1Hev (involves: 129S7/SvEvBrd * C57BL/6J)	impaired macrophage phagocytosis	J:16994
Hck^tm1Hev/Hck^tm1Hev (B6.129S7-Hck^tm1Hev)	abnormal inflammatory response	J:113463
Hck^tm1Hev/Hck^tm1Hev (B6.129S7-Hck^tm1Hev)	abnormal neutrophil physiology	J:113463
Hck^tm1Hev/Hck^tm1Hev Src^tm1Sor/Src^tm1Sor (involves: 129S7/SvEvBrd * C57BL/6J)	abnormal immune system organ morphology	J:31647
	abnormal spleen germinal center morphology	J:31647
	abnormal spleen morphology	J:31647
	abnormal splenic cell ratio	J:31647
	decreased leukocyte cell number	J:31647
	increased macrophage cell number	J:31647
	lymph node hypoplasia	J:31647
	thymus hypoplasia	J:31647
Hcls1^{em1(IMPC)Ccpcz}/Hcls1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Hcls1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Hcls1^tm1Wtn/Hcls1^tm1Wtn (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell physiology	J:28146
	abnormal humoral immune response	J:28146
	decreased B cell number	J:28146
	decreased T cell proliferation	J:28146
Hcls1^tm1Wtn/Hcls1^tm1Wtn Tg(TcraH-Y,TcrbH-Y)71Vbo/0 (involves: 129P2/OlaHsd * C57BL/6J * DBA/2J)	abnormal negative T cell selection	J:28146
	decreased double-positive T cell number	J:28146
Hcls1^tm2Wtn/Hcls1^tm2Wtn (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell physiology	J:28146
	abnormal humoral immune response	J:28146
	decreased B cell number	J:28146
	decreased T cell proliferation	J:28146
Hcn2^m1Btlr/Hcn2^m1Btlr (C57BL/6J-Hcn2^m1Btlr)	decreased CD8-positive, alpha-beta T cell number	J:255187
Hcn2^m1Btlr/Hcn2^m1Btlr (C57BL/6J-Hcn2^m1Btlr)	increased CD4-positive, alpha-beta T cell number	J:255187
Hcrt^{tm1.1(KOMP)Vlcg}/Hcrt^{tm1.1(KOMP)Vlcg} (C57BL/6N-Hcrt^{tm1.1(KOMP)Vlcg}/Ucd)	increased lymphocyte cell number	J:211773
Hcst^tm1.1Cln/Hcst^tm1.1Cln (involves: 129P2/OlaHsd * BALB/cJ * C57BL/6)	decreased CD8-positive, alpha-beta T cell number	J:80426
	immune system phenotype	J:80426
	impaired natural killer cell mediated cytotoxicity	J:80426
Hcst^tm1.1Cln/Hcst^tm1.1Cln (involves: 129P2/OlaHsd * C57BL/6)	decreased interferon-gamma secretion	J:100668
	decreased uterine NK cell number	J:100668
Hcst^tm1.1Cln/Hcst^tm1.1Cln (B6.129P2-Hcst^tm1.1Cln)	abnormal osteoclast differentiation	J:147155
	abnormal osteoclast physiology	J:147155
	decreased osteoclast cell number	J:147155
Hcst^tm1.1Cln/Hcst^tm1.1Cln Tyrobp^tm1Lll/Tyrobp^tm1Lll (B6.Cg-Hcst^tm1.1Cln Tyrobp^tm1Lll)	abnormal NK T cell physiology	J:147867
	abnormal response to infection	J:147867
Hcst^tm1.1Dnax/Hcst^tm1.1Dnax (involves: C57BL/6)	abnormal NK T cell physiology	J:147867, J:148086
	abnormal response to infection	J:147867
	decreased interferon-gamma secretion	J:147867
	immune system phenotype	J:148086
	impaired natural killer cell mediated cytotoxicity	J:148086
	increased interferon-gamma secretion	J:148086
	increased interleukin-4 secretion	J:148086
	increased spleen weight	J:148086
	increased susceptibility to experimental autoimmune encephalomyelitis	J:148086
Hdac1^tm1.1Pmt/Hdac1^tm1.1Pmt Hdac2^tm1.1Pmt/Hdac2^tm1.1Pmt Cd79a^tm1(cre)Reth/Cd79a⁺ (involves: 129P2/OlaHsd * BALB/c * C57BL/6 * FVB/N)	abnormal spleen morphology	J:157903
	arrested B cell differentiation	J:157903
	decreased B cell number	J:157903
	decreased pre-B cell number	J:157903
	decreased pro-B cell number	J:157903
	increased B cell apoptosis	J:157903
Hdac1^tm1.1Pmt/Hdac1^tm1.1Pmt Hdac2^tm1.1Pmt/Hdac2^tm1.1Pmt Tg(Fcer2a-cre)5Mbu/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA * FVB/N)	decreased B cell proliferation	J:157903
	increased B cell apoptosis	J:157903
Hdac1^tm1.1Shmc/Hdac1⁺ Hdac2^tm1.1Shmc/Hdac2^tm1.1Shmc Tg(Lck-cre)1Cwi/0 (involves: 129S7/SvEvBrd)	immune system phenotype	J:194769
Hdac1^tm1.1Shmc/Hdac1^tm1.1Shmc Hdac2^tm1.1Shmc/Hdac2⁺ Tg(Lck-cre)1Cwi/0 (involves: 129S7/SvEvBrd)	arrested T cell differentiation	J:194769
	decreased CD4-positive, alpha-beta T cell number	J:194769
	decreased CD8-positive, alpha-beta T cell number	J:194769
	decreased double-positive T cell number	J:194769
	enlarged spleen	J:194769
	enlarged thymus	J:194769
	increased double-negative T cell number	J:194769
	increased double-positive T cell number	J:194769
	increased single-positive T cell number	J:194769
	thymus hypoplasia	J:194769
Hdac1^tm1.1Shmc/Hdac1^tm1.1Shmc Hdac2^tm1.1Shmc/Hdac2^tm1.1Shmc Tg(Lck-cre)1Cwi/0 (involves: 129S7/SvEvBrd)	abnormal thymus corticomedullary boundary morphology	J:194769
	arrested T cell differentiation	J:194769
	decreased double-positive T cell number	J:194769
	decreased thymocyte number	J:194769
	enlarged spleen	J:194769
	enlarged thymus	J:194769
	increased double-positive T cell number	J:194769
	increased single-positive T cell number	J:194769
	increased T cell derived lymphoma incidence	J:194769
	increased T cell proliferation	J:194769
	increased thymocyte apoptosis	J:194769
	increased thymocyte number	J:194769
Hdac1^tm1.1Shmc/Hdac1^tm1.1Shmc Tg(Lck-cre)1Cwi/0 (involves: 129S7/SvEvBrd)	immune system phenotype	J:194769
Hdac2^tm1.1Shmc/Hdac2^tm1.1Shmc Tg(Lck-cre)1Cwi/0 (involves: 129S7/SvEvBrd)	immune system phenotype	J:194769
Hdac4^{em1(IMPC)Ccpcz}/Hdac4⁺ (C57BL/6N-Hdac4^{em1(IMPC)Ccpcz}/Ccpcz)	increased NK cell number	J:211773
Hdac6^tm1.1Pmt/Y (involves: 129P2/OlaHsd * C57BL/6)	decreased IgG level	J:132629
	decreased IgM level	J:132629
	immune system phenotype	J:132629
Hdac6^tm1.1Pmt/Hdac6^tm1.1Pmt (involves: 129P2/OlaHsd * C57BL/6)	decreased IgG level	J:132629
	decreased IgM level	J:132629
	immune system phenotype	J:132629
Hdac6^tm1.1Pmt/Hdac6^tm1.1Pmt (involves: 129P2/OlaHsd)	decreased circulating interleukin-10 level	J:228570
Hdac6^tm1.1Pmt/Hdac6^tm1.1Pmt (involves: 129P2/OlaHsd)	decreased interleukin-10 secretion	J:228570
Hdac11^tm1.2Mrl/Hdac11^tm1.2Mrl (involves: C57BL/6NTac)	decreased interferon-gamma secretion	J:222335
Hdac11^tm1.2Mrl/Hdac11^tm1.2Mrl (involves: C57BL/6NTac)	increased interleukin-10 secretion	J:228570
Hdc^tm1Nagy/Hdc^tm1Nagy (involves: 129S1/Sv * 129X1/SvJ)	abnormal mast cell morphology	J:70702
	decreased mast cell histamine storage	J:70702
	decreased mast cell number	J:70702
	decreased mast cell protease storage	J:70702
Hddc2^em1(IMPC)H/Hddc2^em1(IMPC)H (C57BL/6NTac-Hddc2^em1(IMPC)H/H)	decreased lymphocyte cell number	J:211773
	increased basophil cell number	J:211773
	increased neutrophil cell number	J:211773
Hddc3^{tm1.1(KOMP)Vlcg}/Hddc3^{tm1.1(KOMP)Vlcg} (C57BL/6N-Hddc3^{tm1.1(KOMP)Vlcg}/Ucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Hectd1^{tm1b(EUCOMM)Hmgu}/Hectd1⁺ (C57BL/6N-Hectd1^{tm1b(EUCOMM)Hmgu}/Nju)	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
Hectd3^{tm1(NCOM)Cmhd}/Hectd3^{tm1(NCOM)Cmhd} (C57BL/6N-Hectd3^{tm1(NCOM)Cmhd}/Nju)	small spleen	J:211773
	small thymus	J:211773
Hectd3^tm1Lex/Hectd3^tm1Lex (FVB.129S5(B6)-Hectd3^tm1Lex)	decreased circulating interferon-beta level	J:266602
	decreased circulating interleukin-1 beta level	J:266602
	decreased circulating interleukin-6 level	J:266602
	decreased circulating tumor necrosis factor level	J:266602
	decreased susceptibility to bacterial infection	J:266602
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:266602
Heg1^tm1Mlkn/Heg1^tm1Mlkn (either: B6.129-Heg1^tm1Mlkn or (involves: 129 * C57BL/6))	abnormal lymph circulation	J:146528
	abnormal lymphatic vessel endothelium morphology	J:146528
	lymphangiectasis	J:146528
Helb^{tm1(KOMP)Vlcg}/Helb^{tm1(KOMP)Vlcg} (involves: C57BL/6NTac)	immune system phenotype	J:231089
Hells^{tm1a(EUCOMM)Wtsi}/Hells^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Hells^{tm1a(EUCOMM)Wtsi}/Ieg)	decreased granulocyte number	J:165965
	decreased IgG1 level	J:165965
Hells^tm1Kmu/Hells^tm1Kmu (involves: 129S1/Sv)	decreased B cell number	J:61948
	increased CD8-positive, alpha-beta T cell number	J:61948
	increased double-negative T cell number	J:61948
	small spleen	J:61948
	small thymus	J:61948
Hells^tm1Rarc/Hells^tm1Rarc (involves: 129X1/SvJ * C57BL/6J)	small thymus	J:107145
	thymus hypoplasia	J:107145
hem1/hem1 (Not Specified)	decreased leukocyte cell number	J:85113
hem2/hem2 (Not Specified)	decreased leukocyte cell number	J:85113
Heph^{em1(IMPC)Ccpcz}/Y (C57BL/6NCrl-Heph^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
Heph^{em1(IMPC)Ccpcz}/Heph^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Heph^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
Hephl1^cw-thd/Hephl1^cw-thd (SJL/J)	abnormal humoral immune response	J:15004
Hephl1^cw/Hephl1^cw (CWD/LeJ)	abnormal immune system morphology	J:24875
	abnormal lymph node morphology	J:24875
	abnormal spleen morphology	J:24875
	enlarged spleen	J:24875
	enlarged thymus	J:24875
Herc1^{em3(IMPC)Wtsi}/Herc1^{em3(IMPC)Wtsi} (C57BL/6N-Herc1^{em3(IMPC)Wtsi}/Wtsi)	increased eosinophil cell number	J:211773
	increased leukocyte cell number	J:211773
	increased Ly6C high monocyte number	J:211773
	increased Ly6C low monocyte number	J:211773
	increased monocyte cell number	J:211773
Herc4^{tm1b(KOMP)Wtsi}/Herc4^{tm1b(KOMP)Wtsi} (C57BL/6N-Herc4^{tm1b(KOMP)Wtsi}/Nju)	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
Herc6^{tm1b(EUCOMM)Hmgu}/Herc6^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Herc6^{tm1b(EUCOMM)Hmgu}/Nju)	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
Herc6^tm1Kshim/Herc6^tm1Kshim (either: B6.Cg-Herc6^tm1Kshim or (involves: C57BL/6NCrlj * CBA/JNCrlj))	immune system phenotype	J:330459
Hes1^tm1.1Frad/Hes1^tm1.1Frad Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	immune system phenotype	J:167000
Hes1^tm1.1Frad/Hes1^tm1.1Frad Tg(Lck-cre)1Cwi/0 (involves: C57BL/6)	immune system phenotype	J:167000
Hes1^tm1.1Frad/Hes1^tm1.1Frad Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA)	abnormal T cell differentiation	J:167000
	decreased DN1 thymic pro-T cell number	J:167000
	decreased DN2 thymocyte number	J:167000
	decreased DN3 thymocyte number	J:167000
	decreased DN4 thymocyte number	J:167000
	decreased double-positive T cell number	J:167000
	decreased gamma-delta T cell number	J:167000
	increased DN1 thymic pro-T cell number	J:167000
	increased immature B cell number	J:167000
	thymus hypoplasia	J:167000
Hexb^{tm1b(EUCOMM)Hmgu}/Hexb^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Hexb^{tm1b(EUCOMM)Hmgu}/H)	increased monocyte cell number	J:211773
Hexb^tm1Rlp/Hexb^tm1Rlp (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)	CNS inflammation	J:90687
	increased circulating interleukin-4 level	J:87617
	increased immunoglobulin level	J:87617
Hexb^tm1Rlp/Hexb^tm1Rlp Tg(Hexb-tTA2S,tetO-Hexb)#Tjsa/0 (involves: 129S4/SvJae * C57BL/6 * CBA)	microgliosis	J:190450
Hexb^tm1Rlp/Hexb^tm1Rlp Tg(SYN1-tTA2S,tetO-Hexb)#Tjsa/0 (involves: 129S4/SvJae * C57BL/6 * CBA)	microgliosis	J:190450
Hfe^tm1.1Wsr/Hfe^tm1.1Wsr (involves: 129P2/OlaHsd * C57BL/6)	decreased spleen iron level	J:132134
Hfe^tm1Gfn/Hfe^tm1Gfn (involves: 129P2/OlaHsd * C57BL/6)	increased osteoclast cell number	J:262906
Hfe^tm1Gfn/Hfe^tm1Gfn (involves: 129P2/OlaHsd * C57BL/6)	increased spleen iron level	J:68025
Hfe^tm1Wsr/Hfe^tm1Wsr Tg(Alb1-cre)7Gsc/? (involves: 129P2/OlaHsd * C57BL/6 * FVB/N)	decreased spleen iron level	J:132134
Hfe^tm2Nca/Hfe^tm2Nca (involves: 129S6/SvEvTac)	decreased spleen iron level	J:78536
Hfe^tm2Nca/Hfe^tm2Nca (involves: 129S6/SvEvTac * C57BL/6J)	decreased spleen iron level	J:78536
Hfgi1^C57BL/6Ola/? (involves: C57BL/6Ola * BALB/cOla)	abnormal lymphopoiesis	J:123483
Hfgi1^C57BL/6Ola/? (involves: C57BL/6Ola * BALB/cOla)	stomach inflammation	J:123483
Hfgi2^C57BL/6Ola/? (involves: C57BL/6Ola * BALB/cOla)	abnormal lymphopoiesis	J:123483
Hfgi2^C57BL/6Ola/? (involves: C57BL/6Ola * BALB/cOla)	stomach inflammation	J:123483
Hgsnat^em4(IMPC)Tcp/Hgsnat^em4(IMPC)Tcp (C57BL/6NCrl-Hgsnat^em4(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Hgsnat^{tm1a(EUCOMM)Wtsi}/Hgsnat^{tm1a(EUCOMM)Wtsi} (involves: C57BL/6N * C57BL/6NTac)	abnormal Kupffer cell morphology	J:235361
	enlarged spleen	J:235361
	increased spleen weight	J:235361
	microgliosis	J:235361
Hhat^{em1(IMPC)Ccpcz}/Hhat⁺ (C57BL/6NCrl-Hhat^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
	increased memory-marker CD4-positive NK T cell number	J:211773
Hhex^tm1Ngu/Hhex^tm1Ngu (involves: 129/Sv * C57BL/6)	abnormal monocyte differentiation	J:65105
Hhip^tm1Amc/Hhip^tm1Amc (involves: 129S1/Sv * 129X1/SvJ)	abnormal spleen morphology	J:85472
Hhip^tm1Amc/Hhip^tm1Amc (involves: 129S1/Sv * 129X1/SvJ)	small spleen	J:85472
Hic1^tm1Sbb/Hic1⁺ (involves: 129S4/SvJae * C57BL/6)	dermatitis	J:81448
Hif1a^tm1Kats/Hif1a^tm1Kats (involves: 129 * C57BL/6)	abnormal cytokine level	J:117857
	abnormal interleukin secretion	J:117857
	increased interferon-gamma secretion	J:117857
	increased tumor necrosis factor secretion	J:117857
Hif1a^tm3Rsjo/Hif1a^tm3Rsjo Gt(ROSA)26Sor^tm1Sor/Gt(ROSA)26Sor⁺ Hprt1^{tm1(Pck1-cre)Vhh}/Y (involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ)	kidney inflammation	J:130751
Hif1a^tm3Rsjo/Hif1a^tm3Rsjo Hprt1^{tm1(Pck1-cre)Vhh}/Y Vhl^tm1Jae/Vhl^tm1Jae (involves: 129 * BALB/c * C57BL/6)	kidney inflammation	J:106705
Hif1a^tm3Rsjo/Hif1a^tm3Rsjo Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ)	abnormal leukocyte physiology	J:117348
	abnormal macrophage physiology	J:107682
	decreased inflammatory response	J:107682
	decreased susceptibility to induced arthritis	J:107682
	decreased tumor necrosis factor secretion	J:107682
	impaired macrophage chemotaxis	J:107682
Hif1a^tm3Rsjo/Hif1a^tm3Rsjo Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6)	decreased interleukin-1 alpha secretion	J:148597
	decreased interleukin-1 beta secretion	J:148597
	decreased interleukin-6 secretion	J:148597
	decreased interleukin-12 secretion	J:148597
	decreased susceptibility to endotoxin shock	J:148597
	decreased tumor necrosis factor secretion	J:148597
Hif1a^tm3Rsjo/Hif1a^tm3Rsjo Ndor1^{Tg(UBC-cre/ERT2)1Ejb}/0 (involves: 129S1/Sv * 129X1/SvJ)	immune system phenotype	J:119731
Hif1a^tm3Rsjo/Hif1a^tm3Rsjo Tg(Fabp1-cre)1Jig/0 (involves: 129S1/Sv * 129X1/SvJ * BALB/c * FVB/N)	increased susceptibility to induced colitis	J:93476
Hif1a^tm3Rsjo/Hif1a^tm3Rsjo Tg(Itgax-cre)1-1Reiz/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)	abnormal dendritic cell number	J:187773
	abnormal leukocyte migration	J:187773
	immune system phenotype	J:187773
Hif1a^tm3Rsjo/Hif1a^tm3Rsjo Tg(Lck-cre)1Jtak/0 (involves: 129S1/Sv * 129X1/SvJ)	increased interferon-gamma secretion	J:117857
Hif1a^tm3Rsjo/Hif1a^tm3Rsjo Tg(Tal1-cre/ERT)42-056Jrg/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal B cell differentiation	J:192126
	abnormal T cell differentiation	J:192126
Hif1an^em1(IMPC)Mbp/Hif1an^em1(IMPC)Mbp (C57BL/6N-Hif1an^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	increased neutrophil cell number	J:211773
Hip1^tm4Tsr/Hip1⁺ Runx1^tm3Dow/Runx1⁺ Tg(Mx1-cre)1Cgn/0 (involves: 129X1/SvJ * C57BL/6 * CBA)	abnormal myelopoiesis	J:151974
	abnormal spleen B cell follicle morphology	J:151974
	abnormal spleen morphology	J:151974
	enlarged spleen	J:151974
	increased granulocyte number	J:151974
	increased leukocyte cell number	J:151974
	increased neutrophil cell number	J:151974
	increased spleen red pulp amount	J:151974
	increased spleen weight	J:151974
	spleen hyperplasia	J:151974
Hip1^tm4Tsr/Hip1⁺ Tg(Mx1-cre)1Cgn/0 (involves: 129X1/SvJ * C57BL/6 * CBA)	abnormal myelopoiesis	J:151974
	abnormal spleen morphology	J:151974
	enlarged spleen	J:151974
	increased spleen red pulp amount	J:151974
	increased T cell derived lymphoma incidence	J:151974
Hira^{tm1a(EUCOMM)Wtsi}/Hira⁺ (C57BL/6N-Hira^{tm1a(EUCOMM)Wtsi}/Wtsi)	decreased leukocyte cell number	J:175295
Hirip3^{tm1.1(KOMP)Mbp}/Hirip3^{tm1.1(KOMP)Mbp} (C57BL/6N-Hirip3^{tm1.1(KOMP)Mbp}/Ucd)	increased basophil cell number	J:211773
	increased neutrophil cell number	J:211773
Hivep2^tm1Sis/Hivep2⁺ (involves: BALB/cA * C57BL/6NCrlj * CBA/JNCrlj)	decreased CD8-positive, alpha-beta T cell number	J:72249
	decreased single-positive T cell number	J:72249
Hivep2^tm1Sis/Hivep2^tm1Sis (involves: BALB/cA * C57BL/6NCrlj * CBA/JNCrlj)	abnormal immune system cell morphology	J:72249
	abnormal thymus cortex morphology	J:72249
	abnormal thymus lobule morphology	J:72249
	abnormal thymus medulla morphology	J:72249
	decreased single-positive T cell number	J:72249
	enlarged thymus cortex	J:72249
Hivep2^tm1Sis/Hivep2^tm1Sis (C.Cg-Hivep2^tm1Sis)	abnormal T-helper 2 cell morphology	J:96024
Hivep2^tm1Sis/Hivep2^tm1Sis (either: (involves: BALB/cA * C57BL/6NCrlj * CBA/JNCrlj) or (involves: C57BL/6J * C57BL/6NCrlj * CBA/JNCrlj))	CNS inflammation	J:263351
Hivep2^tm1Sis/Hivep2^tm1Sis Tg(DO11.10)10Dlo/? (involves: BALB/cA * C3H * C57BL/6NCrlj * CBA/JNCrlj)	abnormal positive T cell selection	J:96024
	abnormal T-helper 2 cell morphology	J:96024
	decreased single-positive T cell number	J:72249
Hivep3^tm1Glm/Hivep3^tm1Glm (involves: 129 * C57BL/6)	decreased interleukin-2 secretion	J:100058
Hivep3^tm1Glm/Hivep3^tm1Glm (Not Specified)	abnormal osteoclast differentiation	J:184764
	abnormal osteoclast physiology	J:184764
	decreased osteoclast cell number	J:184764
Hivep3^tm1Lcw/Hivep3^tm1Lcw (chimera involves: 129S/SvEv * 129X1/SvJ)	decreased double-positive T cell number	J:79652
Hjv^tm1Arbr/Hjv^tm1Arbr (involves: 129S4/SvJae * 129X1/SvJ)	decreased spleen iron level	J:100173
Hjv^tm1Kpan/Hjv^tm1Kpan Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺ (involves: 129S6/SvEvTac * C57BL/6)	abnormal macrophage morphology	J:231428
	decreased spleen iron level	J:231428
Hjv^tm1Nca/Hjv^tm1Nca (involves: 129S4/SvJae * 129S6/SvEvTac)	decreased spleen iron level	J:100178
Hjv^tm1Nca/Hjv^tm1Nca (involves: 129P2/OlaHsd * 129S4/SvJae * 129S6/SvEvTac * C57BL/6)	abnormal macrophage morphology	J:160248
	decreased spleen iron level	J:160248
Hjv^tm1Nca/Hjv^tm1Nca Tmprss6^tm1Dgen/Tmprss6⁺ (involves: 129P2/OlaHsd * 129S4/SvJae * 129S6/SvEvTac * C57BL/6)	abnormal macrophage morphology	J:160248
	decreased spleen iron level	J:160248
Hjv^tm1Nca/Hjv^tm1Nca Tmprss6^tm1Dgen/Tmprss6^tm1Dgen (involves: 129P2/OlaHsd * 129S4/SvJae * 129S6/SvEvTac * C57BL/6)	abnormal macrophage morphology	J:160248
	decreased spleen iron level	J:160248
Hk1^dea/Hk1^dea (A/J-Hk1^dea/J)	abnormal spleen morphology	J:72146
	increased spleen red pulp amount	J:72146
	increased spleen weight	J:72146
Hk3^em1(IMPC)Tcp/Hk3^em1(IMPC)Tcp (C57BL/6N-Hk3^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Hlb18/? (C57BL/6J-Hlb18)	increased leukocyte cell number	J:82961
Hlb95/? (C57BL/6J-Hlb95)	increased leukocyte cell number	J:82961
Hlb141/? (C57BL/6J-Hlb141)	decreased leukocyte cell number	J:82961
Hlb141/? (C57BL/6J-Hlb141)	decreased neutrophil cell number	J:82961
hlb145/? (C57BL/6J-hlb145/J)	decreased leukocyte cell number	J:82961
hlb156/? (C57BL/6J-hlb156/J)	decreased neutrophil cell number	J:82961
hlb258/? (involves: 129S4/SvJae * C57BL/6J)	decreased circulating fibrinogen level	J:82961
hlb385/? (C57BL/6J-hlb385/J)	decreased leukocyte cell number	J:82961
Hltf^tm1.1Hdin/Hltf^tm1.1Hdin Shprh^{Gt(RRJ453)Byg}/Shprh^{Gt(RRJ453)Byg} (involves: 129 * C57BL/6 * SJL)	immune system phenotype	J:177630
Hltf^tm1.1Hdin/Hltf^tm1.1Hdin Shprh^tm1Jhjh/Shprh^tm1Jhjh (involves: 129 * C57BL/6 * SJL)	immune system phenotype	J:177630
Hmbox1^em1(IMPC)Tcp/Hmbox1^em1(IMPC)Tcp (C57BL/6N-Hmbox1^em1(IMPC)Tcp/Tcp)	decreased lymphocyte cell number	J:211773
	enlarged lymph nodes	J:211773
Hmga1^tm1Afus/Hmga1⁺ (involves: 129S7/SvEvBrd * C57BL/6)	enlarged spleen	J:106702
Hmga1^tm1Afus/Hmga1^tm1Afus (involves: 129S7/SvEvBrd * C57BL/6)	enlarged spleen	J:106702
	lymphoid hyperplasia	J:106702
	myeloid hyperplasia	J:106702
Hmgb1^tm1.1Dltg/Hmgb1^tm1.1Dltg Tg(Pdx1-cre)6Tuv/0 (involves: C57BL/6 * FVB/N)	increased circulating interleukin-6 level	J:225260
	increased circulating tumor necrosis factor level	J:225260
	increased susceptibility to induced pancreatitis	J:225260
Hmgb1^tm1.1Ttg/Hmgb1^tm1.1Ttg Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd)	abnormal macrophage physiology	J:205499
	decreased macrophage cell number	J:205499
	impaired macrophage phagocytosis	J:205499
	increased circulating interleukin-1 beta level	J:205499
	increased circulating interleukin-18 level	J:205499
	increased interleukin-1 beta secretion	J:205499
	increased interleukin-18 secretion	J:205499
	increased macrophage apoptosis	J:205499
	increased susceptibility to bacterial infection	J:205499
	increased susceptibility to endotoxin shock	J:205499
Hmgb1^tm1.1Ttg/Hmgb1^tm1.1Ttg Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺ (involves: 129P2/OlaHsd * C57BL/6 * DBA)	increased circulating interleukin-1 beta level	J:205499
	increased circulating interleukin-18 level	J:205499
Hmgb1^tm1.1Ttg/Hmgb1^tm1.1Ttg Tg(Itgax-cre)1-1Reiz/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA)	increased circulating interleukin-1 beta level	J:205499
	increased circulating interleukin-18 level	J:205499
Hmgb3^tm1Dmb/Y (involves: 129S6/SvEvTac * 129X1/SvJ)	abnormal leukopoiesis	J:96514
Hmgn5^tm1.2Mbus/Y (involves: 129S4/SvJae * C57BL/6J)	decreased granulocyte number	J:199604
	decreased IgE level	J:199604
	increased CD8-positive, alpha-beta T cell number	J:199604
	increased IgA level	J:199604
Hmgn5^tm1.2Mbus/Hmgn5^tm1.2Mbus (involves: 129S4/SvJae * C57BL/6J)	decreased granulocyte number	J:199604
	decreased IgE level	J:199604
	increased CD8-positive, alpha-beta T cell number	J:199604
	increased IgA level	J:199604
Hmgxb3^{tm1a(EUCOMM)Wtsi}/Hmgxb3^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Hmgxb3^{tm1a(EUCOMM)Wtsi}/Wtsi)	blood in lymph vessels	J:239583
Hmgxb4^tm1.2Zhji/Hmgxb4^tm1.2Zhji (B6(Cg)-Hmgxb4^tm1.2Zhji)	decreased macrophage nitric oxide production	J:302603
Hmgxb4^tm1.2Zhji/Hmgxb4^tm1.2Zhji (B6(Cg)-Hmgxb4^tm1.2Zhji)	decreased susceptibility to endotoxin shock	J:302603
Hmox1^tm1.1Gkl/Hmox1^tm1.1Gkl Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129 * 129P2/OlaHsd * BALB/cJ * C57BL/6)	decreased interferon-beta secretion	J:148498
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:148498
	decreased susceptibility to Paramyxoviridae infection	J:148498
	increased B cell number	J:148498
	increased CD4-positive, alpha-beta T cell number	J:148498
	increased CD8-positive, alpha-beta T cell number	J:148498
	increased circulating tumor necrosis factor level	J:148498
	increased granulocyte number	J:148498
	increased interferon-gamma secretion	J:148498
	increased macrophage cell number	J:148498
	increased splenocyte proliferation	J:148498
	increased susceptibility to experimental autoimmune encephalomyelitis	J:148498
Hmox1^tm1.1Hes/Hmox1^tm1.1Hes Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6J * C57BL/6N)	decreased inflammatory response	J:214639
	decreased interleukin-1 beta secretion	J:214639
	decreased interleukin-6 secretion	J:214639
	decreased tumor necrosis factor secretion	J:214639
Hmox1^tm1.2Gkl/Hmox1^tm1.2Gkl (involves: 129 * BALB/cJ * C57BL/6)	enlarged spleen	J:148498
	increased inflammatory response	J:148498
	liver inflammation	J:148498
Hmox1^tm1Mlee/Hmox1^tm1Mlee (involves: 129S2/SvPas * BALB/c)	increased susceptibility to parasitic infection	J:153083
	increased susceptibility to parasitic infection induced morbidity/mortality	J:153083
Hmox1^tm1Poss/Hmox1⁺ Slc48a1^em1Ih/Slc48a1^em1Ih (involves: 129 * 129S2/SvPas * C57BL/6J)	decreased macrophage cell number	J:282829
Hmox1^tm1Poss/Hmox1^tm1Poss (involves: 129S2/SvPas * C57BL/6)	abnormal leukocyte cell number	J:79254
	abnormal lymph node cell ratio	J:79254
	abnormal splenic cell ratio	J:79254
	chronic inflammation	J:79254
	enlarged lymph nodes	J:79254
	enlarged spleen	J:79254
	glomerulonephritis	J:79254
	liver inflammation	J:79254
	lung inflammation	J:79254
	spleen hyperplasia	J:79254
Hmox1^tm1Poss/Hmox1^tm1Poss (involves: 129 * 129S2/SvPas * C57BL/6J)	decreased macrophage cell number	J:282829
Hmox1^tm1Poss/Hmox1^tm1Poss Slc48a1^em1Ih/Slc48a1^em1Ih (involves: 129 * 129S2/SvPas * C57BL/6J)	decreased macrophage cell number	J:282829
Hmox1^tm1Poss/Hmox1^tm1Poss Spic^tm2Kmm/Spic^tm2Kmm (involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6 * FVB/N)	decreased macrophage cell number	J:210804
Hmox2^{tm1b(EUCOMM)Hmgu}/Hmox2^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Hmox2^{tm1b(EUCOMM)Hmgu}/H)	decreased monocyte cell number	J:211773
	increased spleen weight	J:211773
Hnf1b^tm1Mya/Hnf1b^tm3Mya Tg(Alb1-cre)7Gsc/0 (involves: 129S2/SvPas * C57BL/6 * FVB/N)	liver inflammation	J:75935
Hnf1b^tm2Ics/Hnf1b⁺ (involves: 129 * C57BL/6N)	chronic pancreas inflammation	J:306082
Hnrnpa2b1^tm1.1Caox/Hnrnpa2b1^tm1.1Caox Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd)	abnormal interferon level	J:283622
	decreased circulating interferon-beta level	J:283622
	decreased interferon-beta secretion	J:283622
	immune system phenotype	J:283622
	increased susceptibility to Herpesvirales infection	J:283622
	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:283622
Hnrnpd^{tm1b(KOMP)Wtsi}/Hnrnpd⁺ (C57BL/6N-Hnrnpd^{tm1b(KOMP)Wtsi}/Nju)	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
Hnrnpd^tm1Rjsc/Hnrnpd^tm1Rjsc (involves: 129S6/SvEvTac * C57BL/6J)	abnormal macrophage physiology	J:116112
	increased circulating tumor necrosis factor level	J:116112
	increased susceptibility to bacterial infection	J:116112
	increased susceptibility to endotoxin shock	J:116112
Hnrnph1^{tm1b(KOMP)Wtsi}/Hnrnph1⁺ (C57BL/6N-Hnrnph1^{tm1b(KOMP)Wtsi}/Nju)	decreased neutrophil cell number	J:211773
	increased lymphocyte cell number	J:211773
Hnrnpl^tm1.1Tmo/Hnrnpl^tm1.1Tmo Tg(Lck-cre)548Jxm/0 (B6.Cg-Hnrnpl^tm1.1Tmo Tg(Lck-cre)548Jxm)	abnormal T cell differentiation	J:188749
	decreased CD4-positive, alpha-beta T cell number	J:188749
	decreased CD8-positive, alpha-beta T cell number	J:188749
	decreased double-positive T cell number	J:188749
	decreased T cell number	J:188749
	increased double-negative T cell number	J:188749
	increased T cell proliferation	J:188749
	thymus hypoplasia	J:188749
Hnrnpll^thdr/Hnrnpll^thdr (C57BL/6JSfdAnu-Hnrnpll^thdr/Anu)	abnormal memory T cell morphology	J:142641
	abnormal memory T cell physiology	J:142641
	abnormal T cell differentiation	J:142641
	decreased CD4-positive, alpha-beta T cell number	J:142641
Hook1^em1(IMPC)Tcp/Hook1^em1(IMPC)Tcp (C57BL/6NCrl-Hook1^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
	small spleen	J:211773
Hook2^em1(IMPC)Tcp/Hook2^em1(IMPC)Tcp (C57BL/6N-Hook2^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Hook3^{tm1b(NCOM)Mfgc}/Hook3^{tm1b(NCOM)Mfgc} (C57BL/6N-Hook3^{tm1b(NCOM)Mfgc}/Tcp)	increased basophil cell number	J:211773
Hormad2^{em1(IMPC)Ccpcz}/Hormad2^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Hormad2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
	small spleen	J:211773
Hoxa1^tm3.1Mrc/Hoxa1^tm3.1Mrc (involves: 129S1/Sv * 129X1/SvJ)	thymus hypoplasia	J:178887
Hoxa1^tm3.1Mrc/Hoxa1^tm3.1Mrc Hoxb1^tm3Mrc/Hoxb1⁺ (involves: 129S1/Sv * 129X1/SvJ)	small thymus	J:41540
Hoxa1^tm3.1Mrc/Hoxa1^tm3.1Mrc Hoxb1^tm3Mrc/Hoxb1^tm3Mrc (involves: 129S1/Sv * 129X1/SvJ)	athymia	J:41540
Hoxa3^tm1Kth/Hoxa3^tm1Kth (involves: 129S1/Sv * 129X1/SvJ)	athymia	J:60296
Hoxa3^tm1Kth/Hoxa3^tm1Kth Hoxd3^{tm3(Hoxa3)Mrc}/Hoxd3⁺ (involves: 129S1/Sv * 129X1/SvJ)	athymia	J:60296
Hoxa3^tm1Kth/Hoxa3^{tm2(Hoxd3)Mrc} (involves: 129S1/Sv * 129X1/SvJ)	immune system phenotype	J:60296
Hoxa3^tm1Mrc/Hoxa3⁺ Hoxb3^tm1Mrc/Hoxb3^tm1Mrc (involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6J)	ectopic thymus	J:46523
Hoxa3^tm1Mrc/Hoxa3⁺ Hoxd3^tm1Mrc/Hoxd3^tm1Mrc (involves: 129S7/SvEvBrd * C57BL/6J)	ectopic thymus	J:46523
Hoxa3^tm1Mrc/Hoxa3^tm1Mrc (involves: 129S7/SvEvBrd)	athymia	J:17753, J:161296
Hoxa3^tm1Mrc/Hoxa3^tm1Mrc Hoxd3^tm1Mrc/Hoxd3^tm1Mrc (involves: 129S7/SvEvBrd * C57BL/6J)	athymia	J:19447
Hoxa3^tm1Mrc/Hoxa3^tm2Nrm (involves: 129S7/SvEvBrd * C3H * C57BL/6 * C57BL/6NHsd)	athymia	J:161296
Hoxa3^tm1Mrc/Hoxa3^tm3.1Nrm H2az2^{Tg(Wnt1-cre)11Rth}/H2az2⁺ (involves: 129S7/SvEvBrd * C57BL/6J * CBA/J)	ectopic thymus	J:161296
Hoxa3^tm1Nrm/Hoxa3^tm1Mrc (involves: 129S7/SvEvBrd * C3H * C57BL/6 * C57BL/6NHsd)	athymia	J:161296
Hoxa3^tm1Nrm/Hoxa3^tm1Nrm (involves: C3H * C57BL/6 * C57BL/6NHsd)	athymia	J:161296
Hoxa3^{tm2(Hoxd3)Mrc}/Hoxa3^{tm2(Hoxd3)Mrc} (involves: 129S1/Sv * 129X1/SvJ)	immune system phenotype	J:60296
Hoxa3^tm2Nrm/Hoxa3^tm2Nrm (involves: C3H * C57BL/6 * C57BL/6NHsd)	athymia	J:161296
Hoxa3^tm2Nrm/Hoxa3^tm3.1Nrm H2az2^{Tg(Wnt1-cre)11Rth}/H2az2⁺ (involves: C3H * C57BL/6 * CBA/J)	ectopic thymus	J:161296
Hoxa5^tm1Rob/Hoxa5^tm1Rob (involves: 129S/SvEv * C57BL/6 * MF1)	abnormal alveolar macrophage morphology	J:113378
	lung inflammation	J:113378
Hoxa7^tm1Mrc/Hoxa7^tm1Mrc Hoxb7^tm1Mrc/Hoxb7^tm1Mrc (involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ)	small thymus	J:50942
Hoxa9^tm1Mrc/Hoxa9^tm1Mrc (B6.129S7-Hoxa9^tm1Mrc)	decreased spleen weight	J:126371
Hoxa9^tm1Mrc/Hoxa9^tm1Mrc (B6.129S7-Hoxa9^tm1Mrc)	spleen hypoplasia	J:126371
Hoxa11os^em1Kaf/Hoxa11os^em1Kaf (C57BL/6-Hoxa11os^em1Kaf)	abnormal cytokine secretion	J:344661
	increased susceptibility to induced colitis	J:344661
	intestinal inflammation	J:344661
Hoxb4^tm1.1Karl/Hoxb4^tm1.1Karl (involves: 129 * C57BL/6J)	spleen hypoplasia	J:90976
Hoxb6^tm1Cka/Hoxb6^tm1Cka (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:133561
Hoxb8^tm1.1Mrc/Hoxb8^tm1.1Mrc (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)	abnormal microglial cell morphology	J:162102
Hoxb9^tm1Mrc/Hoxb9^tm1Mrc (involves: 129S7/SvEvBrd)	small thymus	J:37847
Hoxc4^tm2.1Mrc/Hoxc4^tm2.1Mrc (involves: 129S/SvEv * C57BL/6)	abnormal class switch recombination	J:148278
	abnormal somatic hypermutation frequency	J:148278
	decreased IgA level	J:148278
	decreased IgE level	J:148278
	decreased IgG1 level	J:148278
	decreased IgG2a level	J:148278
	decreased IgG2b level	J:148278
	decreased IgG3 level	J:148278
	decreased IgM level	J:148278
	immune system phenotype	J:148278
Hp^tm1Skl/Hp^tm1Skl Hpx^tm1Altr/Hpx^tm1Altr (involves: 129/Sv * 129P2/OlaHsd * C57BL/6J)	enlarged spleen	J:80539
	increased spleen red pulp amount	J:80539
	liver inflammation	J:80539
Hpgds^tm1Urad/Hpgds^tm1Urad (B6.129-Hpgds^tm1Urad)	abnormal cytokine secretion	J:107651
	abnormal lymph node morphology	J:107651
	increased acute inflammation	J:107651
	increased inflammatory response	J:107651
	increased susceptibility to type I hypersensitivity reaction	J:197334
Hpi1^C57BL/6J/? (involves: A/J * C57BL/6J)	abnormal inflammatory response	J:69153
Hpi1^C57BL/6J/Hpi1^C57BL/6J Hpi2^C57BL/6J/Hpi2^C57BL/6J (involves: A/J * C57BL/6J)	abnormal inflammatory response	J:69153
Hpi2^C57BL/6J/? (involves: A/J * C57BL/6J)	abnormal inflammatory response	J:69153
Hprt1^b-m3/Y Impdh1^tm1Bmi/Impdh1^tm1Bmi (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal lymphopoiesis	J:85443
	decreased cytotoxic T cell cytolysis	J:85443
	decreased interleukin-4 secretion	J:85443
	decreased splenocyte proliferation	J:85443
	decreased T cell proliferation	J:85443
Hprt1^b-m3/Y Impdh2^tm1Bmi/Impdh2⁺ (involves: 129P2/OlaHsd)	abnormal cytotoxic T cell physiology	J:86045
Hprt1^b-m3/Y Impdh2^tm1Bmi/Impdh2⁺ (involves: 129P2/OlaHsd)	abnormal lymphocyte cell number	J:86045
Hprt1^{tm1(CAG-Tgfbr1)Lba}/Y Tg(Cd4-cre)1Cwi/0 (involves: 129 C57BL/6 * DBA/2)	abnormal T cell activation	J:148747
Hprt1^{tm1(CAG-Tgfbr1)Lba}/Y Tgfbr2^tm1.2Hlm/Tgfbr2^tm1.2Hlm Tg(Cd4-cre)1Cwi/0 (involves: 129 129S6/SvEvTac * C57BL/6 * DBA/2)	immune system phenotype	J:148747
Hprt1^{tm1(CAG-Tgfbr1)Lba}/Hprt1^{tm1(CAG-Tgfbr1)Lba} Tg(Cd4-cre)1Cwi/0 (involves: 129 * C57BL/6 * DBA/2)	abnormal T cell activation	J:148747
Hprt1^{tm1(CAG-Tgfbr1)Lba}/Hprt1^{tm1(CAG-Tgfbr1)Lba} Tgfbr2^tm1.2Hlm/Tgfbr2^tm1.2Hlm Tg(Cd4-cre)1Cwi/0 (involves: 129 * 129S6/SvEvTac * C57BL/6 * DBA/2)	immune system phenotype	J:148747
Hprt1^{tm1(CUX1)Anep}/Hprt1⁺ (either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129P2/OlaHsd * C57BL/6 * FVB))	abnormal spleen white pulp morphology	J:113393
	abnormal splenic cell ratio	J:113393
	decreased B cell number	J:113393
	enlarged lymph nodes	J:113393
	enlarged spleen	J:113393
	increased leukocyte cell number	J:113393
	increased neutrophil cell number	J:113393
	myeloid hyperplasia	J:113393
	spleen hyperplasia	J:113393
Hprt1^{tm1(Pck1-cre)Vhh}/Y Vhl^tm1Jae/Vhl^tm1Jae (involves: 129P2/OlaHsd * 129S4/SvJae * BALB/c * C57BL/6)	kidney inflammation	J:106705
Hprt1^{tm2(CUX1)Anep}/Hprt1⁺ (either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129P2/OlaHsd * C57BL/6 * FVB))	immune system phenotype	J:113393
Hps1^ep/Hps1^ep (involves: C3HeB/FeJ * C57BL/6J)	abnormal macrophage physiology	J:7869
Hps1^ep/Hps1^ep (B6.C3Fe-Hps1^ep/J)	abnormal NK cell physiology	J:6801
Hps1^ep/Hps1^ep (B6.C3Fe-Hps1^ep/J)	alveolitis	J:110157
Hps3^coa-Btlr/Hps3^coa-Btlr (C57BL/6J-Hps3^coa-Btlr)	immune system phenotype	J:137495
Hps5^ru2-2Btlr/Hps5^ru2-2Btlr (C57BL/6J-Hps5^ru2-2Btlr)	immune system phenotype	J:135220
Hps5^ru2-Btlr/Hps5^ru2-Btlr (C57BL/6J-Hps5^ru2-Btlr)	increased susceptibility to bacterial infection	J:133272
Hps5^ru2-Btlr/Hps5^ru2-Btlr (C57BL/6J-Hps5^ru2-Btlr)	increased susceptibility to Herpesvirales infection	J:133272
Hps6^em1(IMPC)Tcp/Hps6^em1(IMPC)Tcp (C57BL/6N-Hps6^em1(IMPC)Tcp/Tcp)	small spleen	J:211773
	small thymus	J:211773
Hps6^ru-2J/Hps6^ru-2J (C57BL/10J-Hps6^ru-2J)	immune system phenotype	J:6485
Hps6^ru-Btlr/Hps6^ru-Btlr (C57BL/6J-Hps6^ru-Btlr)	immune system phenotype	J:137496
Hpse^tm1.2Mdh/Hpse^tm1.2Mdh (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal dendritic cell chemotaxis	J:209913
	abnormal Langerhans cell morphology	J:209913
	decreased acute inflammation	J:209913
	decreased leukocyte cell number	J:209913
	impaired eosinophil recruitment	J:209913
	increased eosinophil cell number	J:209913
Hr^em1(IMPC)H/Hr^em1(IMPC)H (C57BL/6NTac-Hr^em1(IMPC)H/H)	decreased lymphocyte cell number	J:211773
Hr^em1(IMPC)H/Hr^em1(IMPC)H (C57BL/6NTac-Hr^em1(IMPC)H/H)	increased neutrophil cell number	J:211773
Hr^hr/Hr^hr (HRS/J)	decreased T cell number	J:6087
	decreased T cell proliferation	J:6375
	increased macrophage cell number	J:150402
Hr^hr/Hr^hr Tg(CD2-Stat6V625AT626A)78Mhk/0 (involves: C3H * SKH1)	blepharitis	J:230018
	eye inflammation	J:230018
	increased corneal pannus formation	J:230018
	Meibomian gland inflammation	J:230018
	uveitis	J:230018
Hr^m1Btlr/Hr^m1Btlr (C57BL/6J-Hr^m1Btlr)	immune system phenotype	J:138686
Hr^m1Enu/Hr^m1Enu (BALB/cJ-Hr^m1Enu)	granulomatous inflammation	J:108173
Hr^rh-bmh/Hr^rh-bmh (involves: C57BL/6JRj * CBA/JRj)	immune system phenotype	J:89321
Hr^rh-R/Hr^rh-R (involves: 101 * C3H/Rl * C57BL/RlEl * C57BL/10Rl * SEC/El)	decreased thymus weight	J:156542
Hr^rh/Hr^rh (Not Specified)	eye inflammation	J:16021
Hr^rh/Hr^rh (RHJ/LeJ)	thymus atrophy	J:57947
Hr^rhsl/Hr^rhsl (involves: BALB/c)	thymus atrophy	J:98859
Hr^USP/Hr^USP (either: (involves: A/J * BALB/c) or (involves: BALB/c * C57BL/6) or (involves: BALB/c * DBA/2))	abnormal immunoglobulin level	J:21316
	abnormal lymph node secondary follicle morphology	J:21316
	abnormal thymus involution	J:21316
	decreased IgM level	J:21316
	enlarged inguinal lymph nodes	J:21316
	enlarged popliteal lymph nodes	J:21316
	glomerulonephritis	J:21316
	increased IgG level	J:21316
	increased susceptibility to autoimmune disorder	J:21316
	lymph node inflammation	J:21316
	lymph node medullary cord hyperplasia	J:21316
	thymus cortex atrophy	J:21316
Hrg^tm1Wja/Hrg^tm1Wja (involves: 129P2/OlaHsd * C57BL/6)	increased circulating fibrinogen level	J:134621
Hrg^tm1Wja/Hrg^tm1Wja (involves: 129P2/OlaHsd * C57BL/6)	increased monocyte cell number	J:134621
Hrh1^Bphs-r/Hrh1^Bphs-r (C3H/HeJ)	immune system phenotype	J:4933, J:77938
Hrh1^Bphs-r/Hrh1^Bphs-s ((C3H/HeJ x SJL/J)F1)	abnormal immune system physiology	J:77938
	abnormal response to infection	J:77938
	increased susceptibility to bacterial infection	J:77938
	increased susceptibility to bacterial infection induced morbidity/mortality	J:77938
Hrh1^Bphs-s/Hrh1^Bphs-s (C3.SJL-Hrh1^Bphs-s)	abnormal response to infection	J:77938
	increased susceptibility to bacterial infection	J:77938
	increased susceptibility to bacterial infection induced morbidity/mortality	J:77938
Hrh1^tm1Wtn/Hrh1^tm1Wtn (involves: 129P2/OlaHsd * C57BL/6)	decreased B cell proliferation	J:111704
	decreased IgG3 level	J:111704
	decreased IgM level	J:111704
	decreased interferon-gamma secretion	J:111704
	decreased interleukin-2 secretion	J:111704
	decreased T cell number	J:111704
	decreased T cell proliferation	J:111704
	increased interleukin-4 secretion	J:111704
Hrh1^tm1Wtn/Hrh1^tm1Wtn (B6.129P2-Hrh1^tm1Wtn)	decreased inflammatory response	J:110367
	decreased interferon-gamma secretion	J:110367
	decreased interleukin-5 secretion	J:110367
	decreased interleukin-13 secretion	J:110367
	increased IgG level	J:110367
	increased IgM level	J:110367
Hrh3^Eae8-r/? (B10.S-H2^s/SgMcdJ)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:34892
Hrh3^Eae8-r/Hrh3^Eae8-r (involves: B10.S/DvTe * SJL/J)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:49054
Hrh3^Eae8-s/? (involves: B10.S * SJL/J)	increased susceptibility to experimental autoimmune encephalomyelitis	J:49054
Hrh3^tm1Twl/Hrh3^tm1Twl (involves: 129P2/OlaHsd)	immune system phenotype	J:132140
Hrh3^tm1Twl/Hrh3^tm1Twl (B6.129X1-Hrh3^tm1Twl)	increased susceptibility to experimental autoimmune encephalomyelitis	J:122269
Hrh4^tm1Lex/Hrh4⁺ (involves: 129S/SvEv * C57BL/6)	abnormal mast cell physiology	J:132140
Hrh4^tm1Lex/Hrh4^tm1Lex (involves: 129S/SvEv * C57BL/6)	abnormal mast cell physiology	J:131785
Hrh4^tm1Lex/Hrh4^tm1Lex (involves: 129S/SvEv * BALB/c)	abnormal chemokine level	J:131785
	abnormal dendritic cell physiology	J:131785
	abnormal interleukin level	J:131785
	decreased IgE level	J:131785
	decreased IgG1 level	J:131785
	decreased inflammatory response	J:131785
Hrl^{129S6/SvEvTac}/Hrl^C57BL/6J (involves: 129S6/SvEvTac * C57BL/6J)	decreased susceptibility to Herpesvirales infection	J:86189
Hrl^C57BL/6J/Hrl^C57BL/6J (involves: 129S6/SvEvTac * C57BL/6J)	decreased susceptibility to Herpesvirales infection	J:86189
Hs1bp3^em1(IMPC)J/Hs1bp3^em1(IMPC)J (C57BL/6NJ-Hs1bp3^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
Hs3st3b1^em2(IMPC)Mbp/Hs3st3b1^em2(IMPC)Mbp (C57BL/6N-Hs3st3b1^em2(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Hsd17b3^tm1.2Mpo/Hsd17b3^tm1.2Mpo (involves: 129S6/SvEvTac * C57BL/6N * C57BL/6NCrl)	increased spleen weight	J:301756
Hsd17b4^em1(IMPC)Tcp/Hsd17b4^em1(IMPC)Tcp (C57BL/6NCrl-Hsd17b4^em1(IMPC)Tcp/Tcp)	abnormal spleen morphology	J:211773
Hsd17b4^tm1Baes/Hsd17b4^tm1Baes (involves: 129S1/Sv * 129X1/SvJ)	microgliosis	J:201698
Hsd17b4^tm2Baes/Hsd17b4^tm2Baes Tg(Nes-cre)1Kln/0 (involves: 129 * C57BL/6 * SJL)	microgliosis	J:201698
Hsd17b11^{Gt(OST237628)Lex}/Hsd17b11^{Gt(OST237628)Lex} (B6;129S5-Hsd17b11^{Gt(OST237628)Lex}/Mmucd)	increased IgG2a level	J:171883
	increased immature B cell number	J:171883
Hsd17b13^tm1Lex/Hsd17b13^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6N)	liver inflammation	J:273927
Hsd17b14^tm1Lex/Hsd17b14^tm1Lex (B6;129S5-Hsd17b14^tm1Lex/Mmucd)	increased IgG2a level	J:171883
Hsf1^tm1Ijb/Hsf1^tm1Ijb (either: (involves: 129S6/SvEvTac * 129X1/SvJ) or (involves: 129S6/SvEvTac * BALB/c) or (involves: 129S6/SvEvTac * C57BL/6J) or (involves: 129S6/SvEvTac * ICR))	increased susceptibility to bacterial infection	J:58383
	increased tumor necrosis factor secretion	J:58383
Hsf1^tm1Ijb/Hsf1^tm1Ijb Tg(TTR-V30M)15Imeg/0 (involves: 129S6/SvEvTac * BALB/c * C57BL/6)	increased interleukin-1 beta secretion	J:156658
	increased tumor necrosis factor secretion	J:156658
Hsf2bp^{tm1b(EUCOMM)Hmgu}/Hsf2bp^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Hsf2bp^{tm1b(EUCOMM)Hmgu}/Ieg)	enlarged lymph nodes	J:211773
Hsfy2^em1(IMPC)J/Hsfy2^em1(IMPC)J (C57BL/6NJ-Hsfy2^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
Hsh2d^tm1Viss/Hsh2d^tm1Viss (B6.129-Hsh2d^tm1Viss)	immune system phenotype	J:111408
	increased interleukin-2 secretion	J:111408
	increased T cell proliferation	J:111408
Hsh2d^tm1Viss/Hsh2d^tm1Viss (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:111408
	abnormal CD8-positive, alpha-beta T cell physiology	J:111408
	increased spleen weight	J:111408
Hsp90aa1^tm1.1Udon/Hsp90aa1^tm1.1Udon (involves: C57BL/6)	abnormal dendritic cell antigen presentation	J:177143
	abnormal dendritic cell physiology	J:177143
	decreased interferon-gamma secretion	J:177143
Hsp90b1^tm1Zhli/Hsp90b1^tm1.1Zhli Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * 129S/SvEv)	abnormal cytokine secretion	J:118427
	abnormal inflammatory response	J:118427
	abnormal macrophage physiology	J:118427
	increased susceptibility to bacterial infection	J:118427
Hspa1b^tm1Clib/Hspa1b^tm1Clib (involves: 129P2/OlaHsd * C57BL/6J)	increased interleukin-6 secretion	J:76801
Hspa9^{Gt(IST14901H6)Tigm}/Hspa9⁺ (involves: C57BL/6N)	decreased pre-B cell number	J:227164
Hspa12a^tm1.1Zdi/Hspa12a^tm1.1Zdi (involves: 129 * C57BL/6)	abnormal macrophage morphology	J:302786
Hspa12a^tm1.1Zdi/Hspa12a^tm1.1Zdi (involves: 129 * C57BL/6)	increased susceptibility to endotoxin shock	J:302787
Hspa13^tm1.1Smoc/Hspa13^tm1.1Smoc Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129P2/OlaHsd * 129S * C57BL/6)	abnormal class switch recombination	J:303927
	abnormal humoral immune response	J:303927
	abnormal plasmablast number	J:303927
	abnormal somatic hypermutation frequency	J:303927
	decreased autoantibody level	J:303927
	decreased IgA level	J:303927
	decreased IgE level	J:303927
	decreased IgG1 level	J:303927
	decreased IgG2b level	J:303927
	decreased IgG2c level	J:303927
	decreased IgG3 level	J:303927
	decreased IgG level	J:303927
	decreased IgM level	J:303927
	decreased plasma cell number	J:303927
Hspb1^tm1.1Jdn/Hspb1^tm1.1Jdn (B6.129S2(Cg)-Hspb1^tm1.1Jdn)	abnormal chemokine secretion	J:209117
	abnormal macrophage physiology	J:209117
	abnormal neutrophil physiology	J:209117
	increased inflammatory response	J:209117
	increased interleukin-6 secretion	J:209117
Hspb8^em1(IMPC)J/Hspb8^em1(IMPC)J (C57BL/6NJ-Hspb8^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
Hspb8^tm1.1Depr/Hspb8^tm1.1Depr (B.129-Hspb8^tm1.1Depr)	decreased circulating interleukin-6 level	J:186292
Hspbap1^{tm1b(EUCOMM)Hmgu}/Hspbap1^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Hspbap1^{tm1b(EUCOMM)Hmgu}/Bay)	increased spleen weight	J:211773
Hspg2^tm1Rdgr/Hspg2^tm1Rdgr (involves: 129S1/Sv * 129X1/SvJ)	abnormal osteoclast morphology	J:121855
	increased osteoclast cell number	J:121855
	osteoarthritis	J:121855
Htr2c^tm1Jul/Y (B6.129S-Htr2c^tm1Jul)	abnormal tumor necrosis factor level	J:50262
Htr3a^tm1Ckn/Htr3a^tm1Ckn (involves: 129S1/Sv * C57BL/6J * DBA/2)	decreased lymphocyte cell number	J:90942
	kidney inflammation	J:90942
	prostate gland inflammation	J:90942
	pyelonephritis	J:90942
	seminal vesiculitis	J:90942
	tubulointerstitial nephritis	J:90942
Htra2^mnd2/Htra2^mnd2 (involves: C3H/HeJ * C57BL/6J * CAST/Ei)	abnormal thymus morphology	J:12780
	spleen atrophy	J:12780
Htra2^mnd2/Htra2^mnd2 (B6.Cg-Htra2^mnd2)	abnormal interleukin level	J:76481
Htra2^mnd2/Htra2^mnd2 (B6.Cg-Htra2^mnd2)	abnormal tumor necrosis factor level	J:76481
Htra2^mnd2/Htra2^mnd2 (involves: C57BL/6J)	abnormal immune system morphology	J:132627
	decreased double-positive T cell number	J:132627
	decreased pre-B cell number	J:132627
	decreased pro-B cell number	J:132627
	decreased single-positive T cell number	J:132627
Htra2^tm1.1Hohj/Htra2^tm1.1Hohj Tg(Nes-cre)1Kln/0 (involves: C57BL/6J)	spleen atrophy	J:225666
	thymus atrophy	J:225666
Htra2^tm1.2Hohj/Htra2^tm1.2Hohj (involves: C57BL/6 * C57BL/6J)	decreased lymphocyte cell number	J:225666
	spleen atrophy	J:225666
	thymus atrophy	J:225666
Htra2^tm1Jdo/Htra2^tm1Jdo (involves: 129P/Ola * C57BL/6)	small spleen	J:94227
Htra2^tm1Jdo/Htra2^tm1Jdo (involves: 129P/Ola * C57BL/6)	small thymus	J:94227
Htt^tm2Detl/Htt⁺ (B6J.129P2-Htt^tm2Detl)	microgliosis	J:220868
hubb/hubb (involves: ICR)	increased spleen weight	J:8170
Hvcn1^{Gt(RRN293)Byg}/Hvcn1^{Gt(RRN293)Byg} (B6.129P2-Hvcn1^{Gt(RRN293)Byg})	abnormal macrophage physiology	J:148032
	abnormal neutrophil physiology	J:148032
hvlk/hvlk (C57BL/6J-hvlk)	increased susceptibility to Herpesvirales infection	J:105543
Hyal1^tm1Stn/Hyal1^tm1Stn (involves: 129X1/SvJ * C57BL/6J)	osteoarthritis	J:136860
Hyal2^tm1.1Bfla/Hyal2^tm1.1Bfla (involves: 129P2/OlaHsd * BALB/c * C57BL/6)	increased spleen iron level	J:146040
Hycc1^{em1(IMPC)Ccpcz}/Hycc1^{em1(IMPC)Ccpcz} (C57BL/6N-Hycc1^{em1(IMPC)Ccpcz}/Ccpcz)	enlarged thymus	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Hydin^hyrh/Hydin^hyrh (involves: C57BL/6J * C57BL/10J * RIII)	rhinitis	J:137815
	thymus atrophy	J:137815
Iapp^tm1Sgm/Iapp⁺ (involves: 129P2/OlaHsd)	increased osteoclast cell number	J:88964
Iapp^tm1Sgm/Iapp^tm1Sgm (involves: 129P2/OlaHsd)	increased osteoclast cell number	J:88964
Ibdq1^C57BL/6J/Ibdq1^SAMP1/YitFcs (involves: C57BL/6J * SAMP1/YitFc)	ileum inflammation	J:84661
Ibdq1^SAMP1/YitFcs/Ibdq1^SAMP1/YitFcs (involves: C57BL/6J * SAMP1/YitFc)	ileum inflammation	J:84661
Ibdq2^SAMP1/YitFcs/Ibdq2^SAMP1/YitFcs (involves: AKR/J * SAMP1/YitFcs)	small intestinal inflammation	J:105411
Ibsp^tm1Jeau/Ibsp^tm1Jeau (involves: 129S1/Sv * 129X1/SvJ * CD-1)	abnormal osteoclast morphology	J:228156, J:136223
	decreased osteoclast cell number	J:136223
	increased osteoclast cell number	J:228156
Ibtk^Gt(XF224)Byg/Ibtk^Gt(XF224)Byg (involves: 129P2/OlaHsd * C57BL/6)	abnormal splenocyte physiology	J:174707
	immune system phenotype	J:174707
Ica1^{tm1b(EUCOMM)Wtsi}/Ica1^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Ica1^{tm1b(EUCOMM)Wtsi}/Tcp)	abnormal spleen morphology	J:211773
	small spleen	J:211773
Ica1^tm1Mdos/Ica1^tm1Mdos (NOD.129-Ica1^tm1Mdos)	abnormal T cell physiology	J:83526
Ica1^tm1Mdos/Ica1^tm1Mdos (NOD.129-Ica1^tm1Mdos)	decreased susceptibility to autoimmune diabetes	J:83526
Icam1^tm1Alb/Icam1^tm1Alb (B6.Cg-Icam1^tm1Alb)	abnormal leukocyte adhesion	J:100242
	abnormal leukocyte tethering or rolling	J:100242
	increased leukocyte cell number	J:100242
	increased neutrophil cell number	J:100242
Icam1^tm1Bay/Icam1^tm1Bay (involves: 129S7/SvEvBrd * C57BL/6J)	abnormal cellular extravasation	J:14565
	abnormal immune system physiology	J:14565
	decreased susceptibility to type IV hypersensitivity reaction	J:14565
	increased neutrophil cell number	J:14565
Icam1^tm1Bay/Icam1^tm1Bay (B6.129S7-Icam1^tm1Bay)	abnormal cellular extravasation	J:48271
	abnormal leukocyte migration	J:24239
	abnormal leukocyte tethering or rolling	J:48271
	decreased susceptibility to endotoxin shock	J:123460
	increased eosinophil cell number	J:48271
	increased lymphocyte cell number	J:48271
	increased monocyte cell number	J:48271
	increased neutrophil cell number	J:48271, J:24239
Icam1^tm1Bay/Icam1^tm1Bay (either: B6.129S7-Icam1^tm1Bay or (involves: 129S7/SvEvBrd * C57BL/6))	abnormal leukocyte tethering or rolling	J:31374
	increased leukocyte cell number	J:31374
Icam1^tm1Bay/Icam1^tm1Bay (B6.129S7-Icam1^tm1Bay/J)	decreased susceptibility to parasitic infection induced morbidity/mortality	J:193592
Icam1^tm1Bay/Icam1^tm1Bay (B6.129S7-Icam1^tm1Bay/J)	immune system phenotype	J:193592
Icam1^tm1Bay/Icam1^tm1Bay (involves: 129S7/SvEvBrd * C57BL/6)	decreased susceptibility to induced colitis	J:111227
	impaired neutrophil recruitment	J:112286
	increased neutrophil cell number	J:112286
	large intestinal inflammation	J:111227
Icam1^tm1Bay/Icam1^tm1Bay Sele^tm2Alb/Sele^tm2Alb Selp^tm1Bay/Selp^tm1Bay (involves: 129S7/SvEvBrd * C57BL/6)	decreased acute inflammation	J:112286
	impaired neutrophil chemotaxis	J:112286
	increased neutrophil cell number	J:112286
Icam1^tm1Bay/Icam1^tm1Bay Sell^tm1Tft/Sell^tm1Tft (B6.129-Sell^tm1Tft Icam1^tm1Bay)	abnormal cellular extravasation	J:48271
	abnormal inflammatory response	J:124291
	abnormal leukocyte tethering or rolling	J:48271
	abnormal macrophage physiology	J:124291
	abnormal mast cell physiology	J:124291
	impaired macrophage chemotaxis	J:124291
	increased eosinophil cell number	J:48271
	increased lymphocyte cell number	J:48271
	increased monocyte cell number	J:48271
	increased neutrophil cell number	J:48271
Icam1^tm1Bay/Icam1^tm1Bay Selp^tm1Bay/Selp^tm1Bay (involves: 129S7/SvEvBrd * C57BL/6J)	abnormal leukocyte migration	J:24239
	increased neutrophil cell number	J:24239
Icam1^tm1Bay/Icam1^tm1Bay Selp^tm1Bay/Selp^tm1Bay (either: B6.129S7-Selp^tm1Bay Icam1^tm1Bay or (involves: 129S7/SvEvBrd * C57BL/6))	impaired leukocyte tethering or rolling	J:31374
Icam1^tm1Bay/Icam1^tm1Bay Selp^tm1Bay/Selp^tm1Bay (B6.129S7-Icam1^tm1Bay Selp^tm1Bay/J)	immune system phenotype	J:119906
Icam1^tm1Cws/Icam1^tm1Cws (involves: C57BL/6)	abnormal macrophage morphology	J:100353
Icam1^tm1Jcgr/Icam1^tm1Jcgr (involves: 129S4/SvJae * C57BL/6 * DBA/2)	abnormal interleukin level	J:18743
	abnormal T cell physiology	J:18743
	abnormal tumor necrosis factor level	J:18743
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:18743
	decreased susceptibility to type IV hypersensitivity reaction	J:18743
	increased lymphocyte cell number	J:18743
	increased neutrophil cell number	J:18743
Icam1^tm1Jcgr/Icam1^tm1Jcgr (B6.129S4-Icam1^tm1Jcgr)	immune system phenotype	J:113463
Icam1^tm1Jcgr/Icam1^tm1Jcgr Ldlr^tm1Her/Ldlr^tm1Her (involves: 129S4/SvJae * 129S7/SvEvBrd)	increased neutrophil cell number	J:69597
Icam1^tm1Jcgr/Icam1^tm1Jcgr Ldlr^tm1Her/Ldlr^tm1Her Vcam1^tm1Dmil/Vcam1^tm1Dmil (involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6)	increased leukocyte cell number	J:69597
	increased lymphocyte cell number	J:69597
	increased monocyte cell number	J:69597
	increased neutrophil cell number	J:69597
Icam1^tm1Jcgr/Icam1^tm1Jcgr Tg(INS-Il10)#Sar/0 (NOD.Cg-Icam1^tm1Jcgr Tg(INS-Il10)#Sar)	decreased susceptibility to autoimmune diabetes	J:66103
	periinsulitis	J:66103
Icam1^tm1Jcgr/Icam1^tm1Jcgr Vcam1^tm1Dmil/Vcam1^tm1Dmil (involves: 129S4/SvJae * C57BL/6)	impaired macrophage chemotaxis	J:227109
Icam2^tm1Jcgr/Icam2^tm1Jcgr (involves: 129S4/SvJae * C57BL/6)	abnormal eosinophil physiology	J:54748
Ichs^C57BL/6J/Ichs^C57BL/6J (involves: A/J * C57BL/6J * C57BL/6JOlaHsd)	abnormal type I hypersensitivity reaction	J:63737
Ichs^{C57BL/6JOlaHsd}/Ichs^{C57BL/6JOlaHsd} (involves: A/J * C57BL/6J * C57BL/6JOlaHsd)	abnormal type I hypersensitivity reaction	J:63737
Icos^tm1.1Wks/Icos^tm1.1Wks (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal B cell number	J:155586
	abnormal B cell physiology	J:155586
	abnormal B cell selection	J:155586
	abnormal class switch recombination	J:155586
	abnormal immune system physiology	J:155586
	abnormal Peyer's patch germinal center morphology	J:155586
	abnormal spleen morphology	J:155586
	decreased CD4-positive, alpha-beta T cell number	J:155586
	decreased IgA level	J:155586
	decreased IgG1 level	J:155586
	decreased IgG2b level	J:155586
	decreased IgG2c level	J:155586
	decreased interleukin-4 secretion	J:155586
	decreased interleukin-21 secretion	J:155586
	decreased spleen germinal center number	J:155586
	small Peyer's patches	J:155586
Icos^tm1Dgry/Icos^tm1Dgry (B6.129P2-Icos^tm1Dgry)	abnormal CD4-positive, alpha-beta T cell physiology	J:123477
	abnormal immune system physiology	J:123477
	abnormal interleukin secretion	J:123477
	abnormal leukocyte cell number	J:123477
	abnormal memory B cell number	J:123477
	abnormal response to infection	J:123477
	abnormal T cell physiology	J:123477
	decreased germinal center B cell number	J:123477
	decreased IgG level	J:123477
	decreased interleukin-4 secretion	J:123477
	decreased interleukin-5 secretion	J:123477
	decreased plasma cell number	J:123477
	increased plasma cell number	J:123477
Icos^tm1Flv/Icos⁺ (NOD.129S1-Icos^tm1Flv)	insulitis	J:131529
Icos^tm1Flv/Icos^tm1Flv (involves: 129/Sv * C57BL/6)	abnormal immunoglobulin level	J:87123
	abnormal interferon level	J:87123
	abnormal interleukin level	J:87123
	abnormal T-helper 2 physiology	J:87123
	decreased IgE level	J:87123
	decreased IgG1 level	J:87123
	immune system phenotype	J:87123
	increased susceptibility to experimental autoimmune encephalomyelitis	J:87123
	small lymph nodes	J:87123
Icos^tm1Flv/Icos^tm1Flv (NOD.129S1-Icos^tm1Flv)	decreased anti-insulin autoantibody level	J:131529
	decreased autoantibody level	J:131529
	decreased IgG level	J:131529
	decreased interferon-gamma secretion	J:131529
	decreased susceptibility to autoimmune diabetes	J:131529
	decreased T cell number	J:131529
	immune system phenotype	J:131529
	insulitis	J:131529
Icos^tm1Flv/Icos^tm1Flv (involves: 129S1/Sv)	abnormal cytokine secretion	J:112600
Icos^tm1Flv/Icos^tm1Flv Rc3h1^san/Rc3h1⁺ (involves: 129S1/Sv * C57BL/6 * C57BL/6JSfdAnu)	increased T cell derived lymphoma incidence	J:189087
Icos^tm1Flv/Icos^tm1Flv Tg(Cd4-Maf)6666Glm/0 (involves: 129S1/Sv * C57BL/6)	abnormal cytokine secretion	J:112600
Icos^tm1Flv/Icos^tm1Flv Tg(TcraTcrb)425Cbn/0 (involves: 129S1/Sv * C57BL/6)	abnormal cytokine secretion	J:112600
Icos^tm1Mak/Icos^tm1Mak (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell number	J:155586
	abnormal B cell physiology	J:66702
	abnormal class switch recombination	J:66702
	abnormal immune system physiology	J:66702
	abnormal Peyer's patch germinal center morphology	J:155586
	abnormal spleen morphology	J:66702
	abnormal T cell physiology	J:66702
	decreased CD4-positive, alpha-beta T cell number	J:155586
	decreased IgA level	J:155586
	decreased IgE level	J:66702
	decreased IgG1 level	J:66702, J:155586
	decreased IgG2b level	J:155586
	decreased IgG2c level	J:155586
	decreased interleukin-21 secretion	J:155586
	decreased spleen germinal center number	J:66702, J:155586
	decreased spleen germinal center size	J:66702
	decreased T cell proliferation	J:66702
	small Peyer's patches	J:155586
Icos^tm1Shr/Icos^tm1Shr (Not Specified)	abnormal CD4-positive, alpha-beta T cell physiology	J:87124
	abnormal immunoglobulin level	J:87124
	abnormal interleukin level	J:87124
	abnormal spleen germinal center morphology	J:87124
	abnormal T cell differentiation	J:87124
	decreased IgE level	J:87124
	decreased IgG1 level	J:87124
	decreased IgG2a level	J:87124
	decreased IgG level	J:87124
	increased IgG3 level	J:87124
Icos^tm1Tkan/Icos^tm1Tkan (involves: 129S7/SvEvBrd * C57BL/6)	abnormal NK cell physiology	J:95353
	abnormal Peyer's patch germinal center morphology	J:95728
	decreased circulating interferon-gamma level	J:95353
	decreased circulating interleukin-4 level	J:95353
	small Peyer's patches	J:95728
Icosl^tm1Cdon/Icosl^tm1Cdon (involves: 129S6/SvEvTac)	abnormal immunoglobulin level	J:86697
	abnormal interferon level	J:86697
	abnormal interleukin secretion	J:86697
	abnormal T cell differentiation	J:86697
	abnormal T-helper 2 physiology	J:86697
	decreased IgE level	J:86697
	decreased IgG1 level	J:86697
	decreased IgG2a level	J:86697
	decreased IgG level	J:86697
	decreased IgM level	J:86697
	small spleen	J:86697
Icosl^tm1Kplm/Icosl^tm1Kplm (involves: 129P2/OlaHsd)	abnormal humoral immune response	J:84893
	abnormal immune serum protein physiology	J:84893
	abnormal spleen germinal center morphology	J:84893
	decreased IgA level	J:84893
	decreased IgG2a level	J:84893
	decreased IgG2b level	J:84893
	decreased interleukin-4 secretion	J:84893
	decreased interleukin-10 secretion	J:84893
	increased interferon-gamma secretion	J:84893
Icosl^tm1Mak/Icosl^tm1Mak (involves: 129P2/OlaHsd * C57BL/6)	abnormal class switch recombination	J:84668
	abnormal immune system physiology	J:84668
	abnormal spleen morphology	J:84668
	abnormal T-helper 2 cell differentiation	J:84668
	decreased IgG1 level	J:84668
	decreased inflammatory response	J:84668
	decreased spleen germinal center number	J:84668
	decreased spleen germinal center size	J:84668
	immune system phenotype	J:84668
Id1^tm1Zhu/Id1⁺ Id3^tm1Zhu/Id3^tm1Zhu (involves: 129S1/Sv * 129S4/SvJaeSor)	increased susceptibility to otitis media	J:311050
Id1^tm1Zhu/Id1^tm1Zhu (involves: 129S1/Sv * C57BL/6)	abnormal myelopoiesis	J:155384
	abnormal osteoclast differentiation	J:155384
	decreased lymphocyte cell number	J:119519
	increased monocyte cell number	J:155384
	increased neutrophil cell number	J:155384
	increased osteoclast cell number	J:155384
	myeloid hyperplasia	J:155384
Id1^tm1Zhu/Id1^tm1Zhu Id3^tm1Zhu/Id3⁺ (involves: 129S1/Sv * 129S4/SvJaeSor)	increased susceptibility to otitis media	J:311050
Id1^tm1Zhu/Id1^tm1Zhu Tcf3^tm1Wein/Tcf3^tm1Wein (involves: 129S1/Sv * 129S4/SvJaeSor * C57BL/6)	abnormal thymus corticomedullary boundary morphology	J:44278
	absent B cells	J:44278
	arrested B cell differentiation	J:44278
	decreased lymphocyte cell number	J:44278
	increased T cell derived lymphoma incidence	J:44278
	intermingled spleen red and white pulp	J:44278
Id2^tm1Ago/Id2^tm1Ago (B6.129-Id2^tm1Ago)	absent lymph nodes	J:116119
	absent NK cells	J:116119
	decreased CD8-positive, alpha-beta T cell number	J:116119
Id2^tm1Ago/Id2^tm1Ago Tg(TcraTcrb)1100Mjb/0 (B6.Cg-Id2^tm1Ago Tg(TcraTcrb)1100Mjb)	abnormal T cell activation	J:116119
Id2^tm1Gtbz/Id2^tm1Gtbz Nfil3^tm1.1Brad/Nfil3^tm1.1Brad (involves: C57BL/6)	immune system phenotype	J:194760
Id2^tm1Mais/Id2^tm1Mais (involves: 129X1/SvJ * C57BL/6)	abnormal immune system physiology	J:146624
Id2^tm1Yyk/Id2^tm1Yyk (involves: 129S1/Sv * 129X1/SvJ)	abnormal oropharyngeal lymphoid tissue morphology	J:78101
	absent Peyer's patches	J:53267
	decreased lymph node number	J:53267
	decreased NK cell number	J:53267
Id2^tm1Yyk/Id2^tm1Yyk (involves: 129S1/Sv * 129X1/SvJ * NMRI)	abnormal oropharyngeal lymphoid tissue morphology	J:78101
	absent Peyer's patches	J:53267
	decreased lymph node number	J:53267
	decreased NK cell number	J:53267
Id2^tm1Yyk/Id2^tm1Yyk (either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * FVB/NJ))	absent lymph nodes	J:125739
	absent Peyer's patches	J:125739
	decreased NK T cell number	J:125739
Id2^tm1Yyk/Id2^tm1Yyk Rorc^tm2Litt/Rorc⁺ (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ)	abnormal gut-associated lymphoid tissue morphology	J:87395
	abnormal immune system cell morphology	J:87395
	abnormal lymph organ development	J:87395
Id2^tm1Yyk/Id2^tm1Yyk Tcf3^tm1Cmu/Tcf3⁺ (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ)	absent axillary lymph nodes	J:125739
	absent brachial lymph nodes	J:125739
	absent inguinal lymph nodes	J:125739
	decreased NK T cell number	J:125739
Id2^tm1Yyk/Id2^tm1Yyk Tcf3^tm1Cmu/Tcf3^tm1Cmu (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ)	decreased B cell number	J:125739
	decreased NK T cell number	J:125739
	immune system phenotype	J:125739
	small lymph nodes	J:125739
Id2^tm2.1Ago/Id2⁺ Id3^tm2.1Cmu/Id3⁺ (involves: C57BL/6)	immune system phenotype	J:179006
Id2^tm2.1Gtbz/Id2^tm2.1Gtbz Tg(Itgax-cre)1-1Reiz/0 (involves: C57BL/6 * CBA)	immune system phenotype	J:194760
Id3^em1(IMPC)Mbp/Id3^em1(IMPC)Mbp (C57BL/6N-Id3^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	increased spleen weight	J:211773
Id3^tm1Cmu/Id3^tm1Cmu (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	abnormal double-positive T cell morphology	J:59969
	abnormal T cell differentiation	J:59969
Id3^tm1Zhu/Id3^tm1Zhu (involves: 129/Sv * C57BL/6)	abnormal T cell physiology	J:56950
	decreased B cell proliferation	J:56950
	decreased immunoglobulin level	J:56950
	immune system phenotype	J:56950
Id3^tm1Zhu/Id3^tm1Zhu (involves: 129S4/SvJaeSor * C57BL/6)	abnormal T cell differentiation	J:144696
Id3^tm1Zhu/Id3^tm1Zhu (involves: 129S4/SvJaeSor)	immune system phenotype	J:93916
	increased autoantibody level	J:93916
	lacrimal gland inflammation	J:93916
	salivary gland inflammation	J:93916
Id3^tm2.1Cmu/Id3^tm2.1Cmu (Not Specified)	decreased thymocyte number	J:176462
	increased B cell number	J:176462
	increased gamma-delta T cell number	J:176462
	increased T follicular helper cell number	J:176462
Id3^tm2.1Cmu/Id3^tm2.1Cmu Tcf3^tm4Zhu/Tcf3^tm4Zhu Tg(Cd4-cre)1Cwi/0 (involves: 129S4/SvJaeSor * C57BL/6 * DBA/2)	decreased thymocyte number	J:176462
	immune system phenotype	J:176462
Id3^tm2.1Zhu/Id3^tm2.1Zhu Tg(Lck-cre)#Zhu/0 (involves: 129S6/SvEvTac * C57BL/6 * SJL * SJL/J)	abnormal T cell differentiation	J:172701
	decreased CD4-positive, alpha-beta T cell number	J:172701
	decreased CD8-positive, alpha-beta T cell number	J:172701
	decreased T cell number	J:172701
	increased CD4-positive, alpha-beta memory T cell number	J:172701
	increased CD8-positive, alpha-beta memory T cell number	J:172701
	increased gamma-delta T cell number	J:172701
	parotid gland inflammation	J:172701
	submandibular gland inflammation	J:172701
Idc/Idc⁺ (involves: 101 * C3H)	blepharitis	J:6686
Idd1^NOD/Uf/Idd1^NOD/Uf (involves: C57BL/6 * NOD/Uf)	periinsulitis	J:33172
Idd1^NOD/Uf/Idd1^NOD/Uf (B6.NOD-(D17Mit164-D17Mit152))	increased CD4-positive, alpha-beta T cell number	J:92304
Idd2^NOD/Smrf/Idd2^NOD/Smrf (involves: NON/Lt * NOD/Smrf)	increased CD4-positive, alpha-beta T cell number	J:30526
Idd3^A/J/Idd3^A/J (NOD.A-Idd3^A/J)	increased susceptibility to autoimmune diabetes	J:120349
Idd3^C57BL/6/Idd3^C57BL/6 (NOD.B6-Idd3^C57BL/6)	decreased susceptibility to autoimmune diabetes	J:120349
Idd3^C57BL/10SnJ/Idd3^C57BL/10SnJ Idd5.2^C57BL/10SnJ/Idd5.2^C57BL/10SnJ (involves: C57BL/10SnJ * NOD/MrkTac)	insulitis	J:143549
Idd3^C57BL/10SnJ/Idd3^C57BL/10SnJ Idd5^C57BL/10SnJ/Idd5^C57BL/10SnJ (involves: C57BL/10 * NOD/MrkTac)	pancreas inflammation	J:88667
Idd3^CAST/EiJ/Idd3^CAST/EiJ (NOD.CAST-Idd3^CAST/EiJ)	increased susceptibility to autoimmune diabetes	J:120349
Idd3^CZECHI/EiJ/Idd3^CZECHI/EiJ (NOD.CZECH-Idd3^CZECHI/EiJ)	decreased susceptibility to autoimmune diabetes	J:120349
Idd3^NOD/? (involves: C57BL/10 * NOD)	pancreas inflammation	J:17906
Idd3^SWR/J/Idd3^SWR/J (NOD.SWR-Idd3^SWR/J)	increased susceptibility to autoimmune diabetes	J:120349
Idd4.3^C57L/Idd4.3^C57L (involves: C57L/J * NOD)	abnormal cytokine secretion	J:118951
	abnormal macrophage physiology	J:118951
	increased susceptibility to autoimmune diabetes	J:118951
Idd4^C57BL/6/Idd4^C57BL/6 (involves: C57BL/6 * DBA/2)	increased T cell proliferation	J:25969
Idd4^C57BL/6/Idd4^C57BL/6 (involves: C57BL/6 * NOD)	increased T cell proliferation	J:25969
Idd4^C57BL/6J/? (involves: C57BL/6J * NOD)	pancreas inflammation	J:73763
Idd4^NOD/Jsd/? (involves: NOD/Jsd * NOR/LtJ)	pancreas inflammation	J:99002
Idd4^NOD/Jsd/Idd4^NOD/Jsd Idd9^NOD/Jsd/Idd9^NOD/Jsd (involves: NOD/Jsd * NOR/LtJ)	pancreas inflammation	J:99002
Idd4^NOD/Idd4^NOD (B6.NOD-Idd4)	abnormal cytokine secretion	J:85823
Idd4^NOD/Idd4^NOD (B6.NOD-Idd4)	decreased NK T cell number	J:85823
Idd4^NOR/LtJ/? (involves: NOD/Jsd * NOR/LtJ)	pancreas inflammation	J:99002
Idd5^NOD/Uf/Idd5^NOD/Uf (involves: C57BL/6 * NOD/Uf)	periinsulitis	J:33172
Idd6.1^C3H/HeJ/Idd6.1^C3H/HeJ (involves: C3H/HeJ * NOD)	decreased susceptibility to autoimmune diabetes	J:115021
Idd6.2^C3H/HeJ/Idd6.2^C3H/HeJ (involves: C3H/HeJ * NOD)	decreased susceptibility to autoimmune diabetes	J:115021
Idd6.2^C3H/HeJ/Idd6.2^C3H/HeJ (NOD.C3-Idd6.2^C3H/HeJ)	decreased NK cell number	J:137837
Idd6.2^NOD/Idd6.2^NOD (B6.NOD-(D6Mit259-D6Mit304))	abnormal T cell differentiation	J:120148
Idd6.3^C3H/HeJ/Idd6.3^C3H/HeJ (involves: C3H/HeJ * NOD)	decreased susceptibility to autoimmune diabetes	J:115021
Idd6^C3H/HeJ/Idd6^C3H/HeJ (NOD.C3-Idd6^C3H/HeJ)	decreased interferon-gamma secretion	J:137837
	decreased interleukin-4 secretion	J:137837
	decreased NK cell number	J:137837
Idd6^C57BL/6/Idd6^NOD (involves: C57BL/6 * NOD)	decreased T cell proliferation	J:72360
Idd6^NOD/Idd6^NOD (involves: C57BL/6 * NOD)	decreased T cell proliferation	J:72360
Idd6^NOD/Idd6^NOD (B6.NOD-Idd6)	abnormal NK cell physiology	J:85823
Idd7^NOD/ShiLt/Idd7^NOD/ShiLt (involves: C57BL/6 * NOD/ShiLt)	abnormal T cell clonal deletion	J:131557
Idd9.1^C57BL/10SnJ/Idd9.1^C57BL/10SnJ (NOD.B10-Idd9.1^C57BL/10SnJ)	increased NK T cell number	J:85823
Idd9^NOD/Jsd/? (involves: NOD/Jsd * NOR/LtJ)	pancreas inflammation	J:99002
Idd9^NOR/LtJ/? (involves: NOD/Jsd * NOR/LtJ)	pancreas inflammation	J:99002
Idd10^NOD/ShiLt/Idd10^NOD/ShiLt Idd3^NOD/Idd3^NOD (B6.NOD-Idd3^NOD Idd10^NOD/Lt)	abnormal cytokine secretion	J:85823
	abnormal NK T cell physiology	J:85823
Idd13^NOD/ShiLt/Idd13^NOD/ShiLt (B6.NOD-Idd13)	abnormal cytokine secretion	J:85823
Idd13^NOD/ShiLt/Idd13^NOD/ShiLt (B6.NOD-Idd13)	abnormal NK T cell physiology	J:85823
Idd16.1^ALR/LtJ/Idd16.1^ALR/LtJ (involves: ALR/LtJ * NOD/LtJ)	pancreas inflammation	J:98187
Idh1^tm1Mak/Idh1^tm1Mak Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal spleen morphology	J:186700
	decreased B cell number	J:186700
	decreased CD4-positive, alpha-beta T cell number	J:186700
	decreased CD8-positive, alpha-beta T cell number	J:186700
	enlarged spleen	J:186700
	increased CD4-positive, alpha-beta T cell number	J:186700
Idh1^tm2Mak/Idh1^tm2Mak Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal spleen morphology	J:186700
	decreased B cell number	J:186700
	decreased CD4-positive, alpha-beta T cell number	J:186700
	decreased CD8-positive, alpha-beta T cell number	J:186700
	enlarged spleen	J:186700
	increased CD4-positive, alpha-beta T cell number	J:186700
Idh2^tm1Jwpk/Idh2^tm1Jwpk (involves: 129S4/SvJae * C57BL/6)	increased osteoclast cell number	J:272241
Idh3g^em1(IMPC)Bay/Idh3g^em1(IMPC)Bay (C57BL/6N-Idh3g^em1(IMPC)Bay/Bay)	abnormal spleen morphology	J:211773
Ido1^tm1Alm/Ido1^tm1Alm (involves: 129X1/SvJ * C57BL/6 * CBA)	abnormal cytokine secretion	J:120813
	abnormal dendritic cell physiology	J:120813
Ido1^tm1Alm/Ido1^tm1Alm (involves: 129X1/SvJ * BALB/c)	abnormal cytokine level	J:170565
	decreased leukocyte cell number	J:170565
	epididymis inflammation	J:170565
Ido1^tm1Alm/Ido1^tm1Alm (involves: 129X1/SvJ * C57BL/6J * FVB/N)	decreased susceptibility to type IV hypersensitivity reaction	J:211949
	increased interferon-gamma secretion	J:211949
	increased interleukin-6 secretion	J:211949
	increased tumor necrosis factor secretion	J:211949
Ido1^tm1Alm/Ido1^tm1Alm (involves: 129X1/SvJ * C57BL/6J)	abnormal macrophage morphology	J:282516
Ido1^tm1Alm/Ido1^tm1Alm (involves: 129X1/SvJ * C57BL/6J)	abnormal macrophage physiology	J:282516
Ido2^em1Lamn/Ido2^em1Lamn (involves: BALB/c * C57BL/6J)	decreased susceptibility to type IV hypersensitivity reaction	J:342726
Ido2^em1Lamn/Ido2^em1Lamn Tg(TcraR28,TcrbR28)KRNDim/0 (involves: C57BL/6 * C57BL/6J * SJL)	autoimmune arthritis	J:342726
Ido2^em2Lamn/Ido2^em2Lamn (involves: BALB/c * C57BL/6J)	decreased susceptibility to type IV hypersensitivity reaction	J:342726
Ido2^em2Lamn/Ido2^em2Lamn Tg(TcraR28,TcrbR28)KRNDim/0 (involves: C57BL/6 * C57BL/6J * SJL)	autoimmune arthritis	J:342726
Ido2^tm1.2Gcp/Ido2^tm1.2Gcp (involves: C57BL/6J * FVB/N)	abnormal chemokine secretion	J:211949
	abnormal regulatory T cell physiology	J:211949
	decreased interferon-gamma secretion	J:211949
	decreased interleukin-6 secretion	J:211949
	decreased susceptibility to type IV hypersensitivity reaction	J:211949
	decreased tumor necrosis factor secretion	J:211949
Ids^tm1Muen/Y (Not Specified)	abnormal lymph node morphology	J:108761
Ids^tm1Muen/Y (involves: C57BL/6)	increased spleen weight	J:259752
Idua^tm1Efn/Idua^tm1Efn (involves: C57BL/6)	abnormal microglial cell morphology	J:81974
	abnormal microglial cell physiology	J:81974
	increased susceptibility to otitis media	J:123676
Ier3^tm1Mxw/Ier3^tm1Mxw (involves: 129 * C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:157504
	abnormal interleukin level	J:157504
	abnormal macrophage physiology	J:157504
	abnormal response to infection	J:157504
	abnormal tumor necrosis factor level	J:157504
	abnormal tumor necrosis factor secretion	J:157504
	decreased regulatory T cell number	J:157504
	impaired macrophage phagocytosis	J:157504
	increased granulocyte number	J:157504
	increased neutrophil cell number	J:157504
	increased susceptibility to parasitic infection	J:157504
Ier3^tm1Mxw/Ier3^tm1Mxw (involves: C57BL/6)	decreased susceptibility to induced colitis	J:194587
Ier3^tm1Mxw/Ier3^tm1Mxw (involves: C57BL/6)	increased T-helper 17 cell number	J:194587
Ier3^tm1Mxw/Ier3^tm1Mxw Rag1^tm1Mom/Rag1^tm1Mom (involves: 129S7/SvEvBrd * C57BL/6)	decreased susceptibility to induced colitis	J:194587
If1^l/If1^l (involves: BALB/c)	abnormal circulating interferon level	J:5113
If1^l/If1^l (involves: BALB/c)	abnormal response to infection	J:38004
If1^l/If1^l (B6.C-Ifi44l^H28-c If1^l/(HW81)aByJ)	abnormal response to infection	J:38004
Ifi27l2a^{tm1(KOMP)Vlcg}/Ifi27l2a^{tm1(KOMP)Vlcg} (involves: C57BL/6NTac)	immune system phenotype	J:221531
Ifi30^tm1Cres/Ifi30^tm1Cres (involves: 129S1/Sv * C57BL/6)	abnormal professional antigen presenting cell physiology	J:72708
Ifi35^em1Hhl/Ifi35^em1Hhl (C57BL/6-Ifi35^em1Hhl)	decreased circulating interleukin-6 level	J:298909
	decreased circulating tumor necrosis factor level	J:298909
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:298909
	decreased susceptibility to endotoxin shock	J:298909
Ifi44^{tm1b(KOMP)Wtsi}/Ifi44^{tm1b(KOMP)Wtsi} (C57BL/6N-Ifi44^{tm1b(KOMP)Wtsi}/Tcp)	enlarged lymph nodes	J:211773
	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
Ifi44^{tm1b(KOMP)Wtsi}/Ifi44^{tm1b(KOMP)Wtsi} (involves: C57BL/6N)	decreased CXCL10 secretion	J:297991
	decreased interleukin-1 beta secretion	J:297991
	increased CD8-positive, alpha-beta T cell number	J:297991
	increased susceptibility to Riboviria infection	J:297991
Ifi47^tm1Gat/Ifi47^tm1Gat (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	immune system phenotype	J:87535
	increased susceptibility to parasitic infection	J:87535
Ifi204^tm1.1Cjul/Ifi204^tm1.1Cjul (B6.129(Cg)-Ifi204^tm1.1Cjul)	decreased circulating interferon-beta level	J:270123
	decreased circulating interleukin-1 beta level	J:270123
	decreased circulating interleukin-6 level	J:270123
	decreased circulating tumor necrosis factor level	J:270123
	decreased interferon-beta secretion	J:270123
	decreased interleukin-6 secretion	J:270123
	decreased susceptibility to endotoxin shock	J:270123
	decreased tumor necrosis factor secretion	J:270123
Ifi204^{tm1b(KOMP)Wtsi}/Ifi204^{tm1b(KOMP)Wtsi} (involves: BALB/cJ * C57BL/6J * C57BL/6N)	immune system phenotype	J:354143
Ifi207^{em1(IMPC)Wtsi}/Ifi207⁺ (C57BL/6N-Ifi207^{em1(IMPC)Wtsi})	increased susceptibility to Retroviridae infection	J:354143
Ifi207^{em1(IMPC)Wtsi}/Ifi207^{em1(IMPC)Wtsi} (C57BL/6N-Ifi207^{em1(IMPC)Wtsi})	decreased interferon-beta secretion	J:354143
	immune system phenotype	J:354143
	increased susceptibility to Retroviridae infection	J:354143
Ifi208^em1(IMPC)Mbp/Ifi208^em1(IMPC)Mbp (C57BL/6N-Ifi208^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	small spleen	J:211773
Ifih1^Rgsc422/Ifih1⁺ (D2JJcl.B6JJcl-Ifih1^Rgsc422)	abnormal chemokine level	J:209917
	abnormal cytokine level	J:209917
	abnormal dendritic cell antigen presentation	J:209917
	abnormal leukocyte cell number	J:209917
	abnormal macrophage activation involved in immune response	J:209917
	abnormal T cell activation	J:209917
	autoimmune response	J:209917
	chronic liver inflammation	J:209917
	glomerulonephritis	J:209917
	increased anti-double stranded DNA antibody level	J:209917
	increased anti-nuclear antigen antibody level	J:209917
	increased dendritic cell number	J:209917
	increased granulocyte number	J:209917
	increased IgA level	J:209917
	increased IgG level	J:209917
	increased IgM level	J:209917
	increased immunoglobulin level	J:209917
	increased inflammatory response	J:209917
	increased macrophage cell number	J:209917
	increased plasma cell number	J:209917
	increased susceptibility to systemic lupus erythematosus	J:209917
	skin inflammation	J:209917
Ifih1^Rgsc422/Ifih1⁺ Ifnar1^tm1Agt/Ifnar1⁺ (involves: 129S2/SvPas * C57BL/6JJcl * DBA/2JJcl)	glomerulonephritis	J:209917
Ifih1^Rgsc422/Ifih1⁺ Mavs^tm1Aki/Mavs⁺ (involves: C57BL/6JJcl * DBA/2JJcl)	glomerulonephritis	J:209917
Ifih1^Rgsc422/Ifih1⁺ Mavs^tm1Aki/Mavs^tm1Aki (involves: C57BL/6JJcl * DBA/2JJcl)	immune system phenotype	J:209917
Ifih1^Rgsc422/Ifih1^Rgsc422 (D2JJcl.B6JJcl-Ifih1^Rgsc422)	glomerulonephritis	J:209917
Ifih1^Rgsc422/Ifih1^Rgsc422 (D2JJcl.B6JJcl-Ifih1^Rgsc422)	increased susceptibility to systemic lupus erythematosus	J:209917
Ifih1^tm1.1Cln/Ifih1^tm1.1Cln (involves: 129X1/SvJ * C57BL/6)	abnormal cytokine secretion	J:110201
	decreased interferon-alpha secretion	J:110201
	decreased interleukin-6 secretion	J:110201
	increased susceptibility to Picornaviridae infection	J:110201
Ifih1^tm1.1Cln/Ifih1^tm1.1Cln (involves: 129X1/SvJ)	decreased interferon-beta secretion	J:240099
Ifih1^tm1Aki/Ifih1^tm1Aki (involves: 129/Sv * C57BL/6)	abnormal dendritic cell physiology	J:137522
	abnormal interferon level	J:137522
	abnormal interleukin level	J:137522
	increased susceptibility to Picornaviridae infection	J:137522
Ifih1^tm1Aki/Ifih1^tm1Aki Ticam1^tm1Aki/Ticam1^tm1Aki (involves: 129P2/OlaHsd)	abnormal interferon level	J:137522
	abnormal interleukin level	J:137522
Ifit1^{tm1(KOMP)Vlcg}/Ifit1^{tm1(KOMP)Vlcg} (involves: C57BL/6NTac)	increased susceptibility to Riboviria infection	J:187549
	increased susceptibility to Riboviria infection induced morbidity/mortality	J:187549
Ifit1^{tm1(KOMP)Vlcg}/Ifit1^{tm1(KOMP)Vlcg} (involves: C57BL/6 * C57BL/6NTac)	abnormal interferon level	J:205203
	abnormal T cell physiology	J:205203
	brain inflammation	J:205203
	increased susceptibility to Coronaviridae infection	J:205203
	increased susceptibility to Coronaviridae infection induced morbidity/mortality	J:205203
Ifit2^tm1.1Ebsb/Ifit2^tm1.1Ebsb (B6NCrl.129P2(C)-Ifit2^tm1.1Ebsb)	decreased circulating interleukin-1 beta level	J:199862
	decreased circulating interleukin-6 level	J:199862
	decreased circulating interleukin-12b level	J:199862
	decreased circulating tumor necrosis factor level	J:199862
	decreased interleukin-6 secretion	J:199862
	decreased tumor necrosis factor secretion	J:199862
	increased susceptibility to bacterial infection induced morbidity/mortality	J:199862
Ifit2^tm1.1Ebsb/Ifit2^tm1.1Ebsb (B6.129P2(C)-Ifit2^tm1.1Ebsb)	enhanced humoral immune response	J:233986
	increased IgE level	J:233986
	increased IgG1 level	J:233986
	increased IgG3 level	J:233986
	increased IgM level	J:233986
Ifit2^tm1.1Gcs/Ifit2⁺ (involves: C57BL/6)	increased susceptibility to Riboviria infection induced morbidity/mortality	J:195382
Ifit2^tm1.1Gcs/Ifit2^tm1.1Gcs (involves: C57BL/6)	increased susceptibility to Riboviria infection	J:195382
Ifit2^tm1.1Gcs/Ifit2^tm1.1Gcs (involves: C57BL/6)	increased susceptibility to Riboviria infection induced morbidity/mortality	J:195382
Ifitm1^tm1.1Ieg/Ifitm1^tm1.1Ieg (B6.129P2-Ifitm1^tm1.1Ieg)	decreased granulocyte number	J:192287
	decreased T cell number	J:192287
	immune system phenotype	J:192287
	increased IgE level	J:192287
Ifitm3^tm1Masu/Ifitm3^tm1Masu (involves: 129P2/OlaHsd * C57BL/6)	increased susceptibility to Orthomyxoviridae infection	J:183865
	increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:183865
	increased susceptibility to Riboviria infection	J:209781
Ifitm5^em1Pmof/Ifitm5⁺ (involves: CD-1)	abnormal osteoclast morphology	J:255349
Ifna6^tm1Aki/Ifna6⁺ Myd88^tm1Aki/Myd88^tm1Aki (involves: 129P2/OlaHsd)	abnormal plasmacytoid dendritic cell morphology	J:124340
	decreased interferon-alpha secretion	J:124340
Ifnar1^m1Btlr/Ifnar1^m1Btlr (C57BL/6J-Ifnar1^m1Btlr)	abnormal macrophage physiology	J:142790
	decreased interferon-alpha secretion	J:142790
	decreased interferon-beta secretion	J:142790
	immune system phenotype	J:142790
	increased susceptibility to Adenoviridae infection	J:142790
	increased susceptibility to Herpesvirales infection	J:142790
	increased susceptibility to Orthomyxoviridae infection	J:142790
	increased susceptibility to Riboviria infection	J:142790
Ifnar1^m2Btlr/Ifnar1^m2Btlr (involves: C57BL/6J)	decreased interferon-beta secretion	J:198556
Ifnar1^tm1Agt/Ifnar1^tm1Agt (involves: 129S2/SvPas)	abnormal cytokine secretion	J:114555
	abnormal dendritic cell physiology	J:114555
	abnormal immunoglobulin level	J:101427
	abnormal inflammatory response	J:114555
	abnormal NK cell physiology	J:79552, J:139001
	immune system phenotype	J:286237
	impaired natural killer cell mediated cytotoxicity	J:79552
	increased susceptibility to Coronaviridae infection	J:144400
	increased susceptibility to Coronaviridae infection induced morbidity/mortality	J:144400
	increased susceptibility to Herpesvirales infection	J:197569, J:81243
	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:115139
	increased susceptibility to Paramyxoviridae infection	J:160878
	increased susceptibility to Paramyxoviridae infection induced morbidity/mortality	J:160878
	increased susceptibility to Picornaviridae infection	J:137522
	increased susceptibility to Poxviridae infection	J:101427
Ifnar1^tm1Agt/Ifnar1^tm1Agt (involves: 129S2/SvPas * C57BL/6)	abnormal susceptibility to infection	J:120938
	immune system phenotype	J:238323
Ifnar1^tm1Agt/Ifnar1^tm1Agt (B6.129S2-Ifnar1^tm1Agt)	abnormal osteoclast morphology	J:76097
	abnormal response to infection	J:116703
	decreased interferon-alpha secretion	J:125611
	decreased interferon-beta secretion	J:125611
	decreased interleukin-6 secretion	J:199862
	decreased tumor necrosis factor secretion	J:199862
	impaired natural killer cell mediated cytotoxicity	J:118750
	increased susceptibility to bacterial infection induced morbidity/mortality	J:199862
Ifnar1^tm1Agt/Ifnar1^tm1Agt (involves: 129S2/SvPas * BALB/c * C57BL/6 * SJL)	increased susceptibility to Orthomyxoviridae infection	J:119783
Ifnar1^tm1Agt/Ifnar1^tm1Agt (involves: 129S2/SvPas * 129S6/SvEvTac)	abnormal CD8-positive, alpha-beta T cell physiology	J:54482
	abnormal interferon-gamma secretion	J:54482
	increased circulating interleukin-12 level	J:54482
	increased susceptibility to Riboviria infection	J:54482
Ifnar1^tm1Agt/Ifnar1^tm1Agt (involves: 129S2/SvPas * BALB/c)	abnormal cytokine level	J:291874
	abnormal mononuclear phagocyte morphology	J:291874
	decreased Ly6C high monocyte number	J:291874
	decreased susceptibility to Coronaviridae infection	J:291874
	decreased T cell apoptosis	J:291874
	increased CD4-positive, alpha-beta T cell number	J:291874
	increased CD8-positive, alpha-beta T cell number	J:291874
	increased susceptibility to Coronaviridae infection induced morbidity/mortality	J:291874
	increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:291874
Ifnar1^tm1Agt/Ifnar1^tm1Agt Ifngr1^tm1Agt/Ifngr1^tm1Agt (involves: 129S2/SvPas * 129S7/SvEvBrd)	abnormal immunoglobulin level	J:101427
	immune system phenotype	J:286237
	increased susceptibility to Herpesvirales infection	J:81243
	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:115139
	increased susceptibility to Poxviridae infection	J:101427
	increased susceptibility to Togaviridae infection	J:81243
Ifnar1^tm1Agt/Ifnar1^tm1Agt Myd88^tm1Aki/Myd88⁺ (B6.129-Myd88^tm1Aki Ifnar1^tm1Agt)	increased susceptibility to parasitic infection	J:140485
Ifnar1^tm1Agt/Ifnar1^tm1Agt Myd88^tm1Aki/Myd88^tm1Aki (involves: 129P2/OlaHsd * 129S2/SvPas)	abnormal leukocyte migration	J:171379
Ifnar1^tm1Agt/Ifnar1^tm1Agt Myd88^tm1Aki/Myd88^tm1Aki (B6.129-Myd88^tm1Aki Ifnar1^tm1Agt)	increased susceptibility to parasitic infection	J:140485
	increased susceptibility to parasitic infection induced morbidity/mortality	J:140485
Ifnar1^tm1Agt/Ifnar1^tm1Agt Otulin^{tm1c(EUCOMM)Hmgu}/Otulin^{tm1c(EUCOMM)Hmgu} Tg(KRT14-cre)1Cgn/0 (involves: 129S2/SvPas * C57BL/6 * C57BL/6N * DBA/2)	dermatitis	J:312394
	immune system phenotype	J:312394
Ifnar1^tm1Agt/Ifnar1^tm1Agt Slamf1^tm1Oono/Slamf1^tm1Oono (B6.129-Slamf1^tm1Oono Ifnar1^tm1Agt)	abnormal lymphopoiesis	J:117810
	increased susceptibility to Paramyxoviridae infection	J:117810
Ifnar1^tm1Agt/Ifnar1^tm1Agt Sp140^em1Vnce/Sp140^em1Vnce (B6.Cg-Sp140^em1Vnce Ifnar1^tm1Agt)	immune system phenotype	J:313901
Ifnar1^tm1Agt/Ifnar1^tm1Agt Tg(CD46)373Zbz/Tg(CD46)373Zbz (involves: 129S2/SvPas * C3H/He * C57BL/6)	brain inflammation	J:160878
	increased susceptibility to Paramyxoviridae infection	J:160878
	increased susceptibility to Paramyxoviridae infection induced morbidity/mortality	J:160878
	lung inflammation	J:160878
	meningitis	J:160878
Ifnar1^tm1Agt/Ifnar1^tm1Agt Tg(Hmgcr-MX1)LStae/Tg(Hmgcr-MX1)LStae (involves: 129S2/SvPas * BALB/c * C57BL/6 * SJL)	decreased susceptibility to Orthomyxoviridae infection	J:119783
	decreased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:119783
Ifnar1^tm1Agt/Ifnar1^tm1Agt Ythdf3^em1Caox/Ythdf3^em1Caox (involves: C57BL/6J)	abnormal macrophage physiology	J:276397
Ifnar1^tm1Pjh/Ifnar1^tm1Pjh (involves: 129S2/SvPas * BALB/c)	abnormal macrophage physiology	J:36004
	increased leukocyte cell number	J:36004
	increased susceptibility to Picornaviridae infection	J:36004
	increased susceptibility to Picornaviridae infection induced morbidity/mortality	J:36004
	increased susceptibility to Togaviridae infection	J:36004
	increased susceptibility to Togaviridae infection induced morbidity/mortality	J:36004
Ifnar1^tm1Pjh/Ifnar1^tm1Pjh (B6.129S2-Ifnar1^tm1Pjh)	decreased NK cell number	J:125812
Ifnar1^tm1Pjh/Ifnar1^tm1Pjh (B6.129S2-Ifnar1^tm1Pjh)	impaired natural killer cell mediated cytotoxicity	J:125812
Ifnar2^m1Btlr/Ifnar2^m1Btlr (C57BL/6J-Ifnar2^m1Btlr)	abnormal macrophage physiology	J:147329
	decreased interferon-alpha secretion	J:147329
	decreased interferon-beta secretion	J:147329
	increased susceptibility to Adenoviridae infection	J:147329
	increased susceptibility to Herpesvirales infection	J:147329
	increased susceptibility to Orthomyxoviridae infection	J:147329
	increased susceptibility to Riboviria infection	J:147329
Ifnar2^tm1Pjh/Ifnar2^tm1Pjh (B6.Cg-Ifnar2^tm1Pjh)	decreased NK cell number	J:125812
Ifnar2^tm1Pjh/Ifnar2^tm1Pjh (B6.Cg-Ifnar2^tm1Pjh)	impaired natural killer cell mediated cytotoxicity	J:125812
Ifnar2^tm1Pjh/Ifnar2^tm1Pjh (involves: C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:132662
	abnormal cytotoxic T cell physiology	J:132662
	decreased IgG1 level	J:132662
	decreased IgG2a level	J:132662
	decreased IgG level	J:132662
	decreased interferon-gamma secretion	J:132662
Ifnar2^tm1Pjh/Ifnar2^tm1Pjh Il6st^tm1Ern/Il6st^tm1Ern (involves: 129S1/Sv)	increased circulating interleukin-6 level	J:168781
	increased susceptibility to endotoxin shock	J:168781
Ifnb1^tm1Acgp/Ifnb1^tm1Acgp (involves: 129P2/OlaHsd * C57BL/6)	decreased circulating interferon-beta level	J:61048
	increased susceptibility to Poxviridae infection	J:61048
Ifnb1^tm1Acgp/Ifnb1^tm1Acgp (involves: 129P2/OlaHsd)	abnormal spleen primary B follicle morphology	J:86527
	decreased macrophage cell number	J:86527
	decreased mature B cell number	J:86527
	decreased monocyte cell number	J:86527
	decreased neutrophil cell number	J:86527
	decreased pro-B cell number	J:86527
	decreased tumor necrosis factor secretion	J:86527
	increased T cell proliferation	J:86527
Ifnb1^tm1Acgp/Ifnb1^tm1Acgp (B6.129P2-Ifnb1^tm1Acgp)	abnormal macrophage physiology	J:136368
Ifnb1^tm1Acgp/Ifnb1^tm1Acgp (B6.129P2-Ifnb1^tm1Acgp)	decreased interleukin-1 beta secretion	J:136368
Ifnb1^tm1Tl/Ifnb1^tm1Tl (B10.129P2-Ifnb1^tm1Tl)	abnormal macrophage physiology	J:83021
	abnormal microglial cell physiology	J:83021
	CNS inflammation	J:83021
	increased interferon-gamma secretion	J:83021
	increased interleukin-4 secretion	J:83021
	increased susceptibility to experimental autoimmune encephalomyelitis	J:83021
	increased tumor necrosis factor secretion	J:83021
Ifnb1^tm1Tl/Ifnb1^tm1Tl (B6.129P2-Ifnb1^tm1Tl)	decreased circulating interferon-alpha level	J:172226
	decreased circulating interferon-beta level	J:172226
	decreased susceptibility to bacterial infection	J:172226
Ifnb1^tm1Ttg/Ifnb1^tm1Ttg (B6.Cg-Ifnb1^tm1Ttg)	abnormal osteoclast morphology	J:76097
Ifnb1^tm1Ttg/Ifnb1^tm1Ttg (involves: C57BL/6)	abnormal response to infection	J:116703
Ifnb1^tm2.1Lien/Ifnb1^tm2.1Lien Tg(Itgax-cre)1-1Reiz/0 Tyr^c-2J/Tyr^c-2J (involves: C57BL/6 * CBA)	immune system phenotype	J:172226
Ifnb1^tm2.1Lien/Ifnb1^tm2.1Lien Tyr^c-2J/Tyr^c-2J (involves: C57BL/6)	immune system phenotype	J:172226
Ifnb1^tm2.1Lien/Ifnb1^tm2.1Lien Tyr^c-2J/Tyr^c-2J Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6)	decreased circulating interferon-alpha level	J:172226
	decreased circulating interferon-beta level	J:172226
	decreased susceptibility to bacterial infection	J:172226
Ifne^tm1.2Pjh/Ifne^tm1.2Pjh (involves: C57BL/6)	decreased NK cell number	J:197569
	increased susceptibility to bacterial infection	J:197569
	increased susceptibility to Herpesvirales infection	J:197569
Ifng^tm1.1Hayg/Ifng^tm1.1Hayg (involves: 129S4/SvJae * C57BL/6J)	abnormal B cell differentiation	J:220784
	abnormal circulating cytokine level	J:220784
	abnormal cytokine level	J:220784
	abnormal lymph node morphology	J:220784
	abnormal T cell activation	J:220784
	decreased leukocyte cell number	J:220784
	decreased mature B cell number	J:220784
	decreased pre-B cell number	J:220784
	increased T cell number	J:220784
	spleen atrophy	J:220784
	thymus atrophy	J:220784
Ifng^tm1Lky/Ifng^tm1Lky (involves: 129S4/SvJae * C57BL/6)	immune system phenotype	J:189794
Ifng^tm1Ts/Ifng^tm1Ts (involves: 129S7/SvEvBrd * C57BL/6)	abnormal macrophage physiology	J:66802
	abnormal MHC II cell surface expression on macrophages	J:66802
	abnormal NK cell physiology	J:66802, J:115033
	abnormal type IV hypersensitivity reaction	J:55740
	decreased length of allograft survival	J:44346
	decreased susceptibility to parasitic infection	J:189794
	decreased susceptibility to parasitic infection induced morbidity/mortality	J:189794
	immune system phenotype	J:119206
	increased splenocyte proliferation	J:66802
	increased susceptibility to bacterial infection	J:66802
Ifng^tm1Ts/Ifng^tm1Ts (NOD.129S7-Ifng^tm1Ts)	abnormal susceptibility to autoimmune disorder	J:33427
Ifng^tm1Ts/Ifng^tm1Ts (NOD.129S7-Ifng^tm1Ts)	decreased susceptibility to autoimmune diabetes	J:95105
Ifng^tm1Ts/Ifng^tm1Ts (NOD.Cg-Ifng^tm1Ts Prkdc^scid)	decreased susceptibility to autoimmune diabetes	J:72818
Ifng^tm1Ts/Ifng^tm1Ts (NOD.129S7(B6)-Ifng^tm1Ts/DvsJ)	abnormal cytotoxic T cell physiology	J:72818
	abnormal diapedesis	J:72818
	decreased susceptibility to autoimmune diabetes	J:72818
Ifng^tm1Ts/Ifng^tm1Ts (involves: 129S7/SvEvBrd)	abnormal cytokine level	J:112600
	abnormal immunoglobulin level	J:29170
	abnormal response to infection	J:110721, J:29170
	decreased susceptibility to type IV hypersensitivity reaction	J:29170
	impaired natural killer cell mediated cytotoxicity	J:73948
	increased IgG1 level	J:110721
	increased interleukin-17 secretion	J:132905
	increased susceptibility to bacterial infection	J:110856
	increased susceptibility to bacterial infection induced morbidity/mortality	J:110856
	increased susceptibility to Herpesvirales infection	J:29170
	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:29170
Ifng^tm1Ts/Ifng^tm1Ts (B6.129S7-Ifng^tm1Ts/J)	abnormal circulating cytokine level	J:47459
	abnormal cytokine secretion	J:120556
	abnormal dendritic cell antigen presentation	J:134949
	abnormal dendritic cell chemotaxis	J:134949
	abnormal dendritic cell physiology	J:134949
	abnormal humoral immune response	J:45665
	abnormal immune tolerance	J:45665
	abnormal immunoglobulin level	J:45665
	abnormal Langerhans cell physiology	J:134949
	abnormal macrophage chemotaxis	J:136628
	abnormal spleen morphology	J:47459
	abnormal spleen red pulp morphology	J:47459
	abnormal spleen white pulp morphology	J:47459
	abnormal type IV hypersensitivity reaction	J:45665
	decreased interferon-gamma secretion	J:120556
	decreased interleukin-10 secretion	J:120556, J:134949
	decreased length of allograft survival	J:44346
	enlarged mesenteric lymph nodes	J:50832
	enlarged spleen	J:47459
	glomerulonephritis	J:118730
	immune system phenotype	J:114783
	increased circulating interleukin-6 level	J:47459
	increased granulocyte number	J:47459
	increased interleukin-4 secretion	J:120556
	increased interleukin-12 secretion	J:134949
	increased leukocyte cell number	J:47459
	increased monocyte cell number	J:47459
	increased NK T cell number	J:122801
	increased susceptibility to bacterial infection	J:47459
	increased susceptibility to bacterial infection induced morbidity/mortality	J:47459
	increased susceptibility to parasitic infection	J:50832
	increased susceptibility to parasitic infection induced morbidity/mortality	J:50832
	increased susceptibility to type IV hypersensitivity reaction	J:118730
	pale spleen	J:47459
	stomach inflammation	J:120556
Ifng^tm1Ts/Ifng^tm1Ts (B6.129S7-Ifng^tm1Ts)	abnormal B cell physiology	J:112084
	abnormal cytokine secretion	J:18801, J:110826
	abnormal immunoglobulin level	J:18801
	abnormal lymph node cell ratio	J:112084
	abnormal response to infection	J:18801, J:110826
	abnormal response to transplant	J:42090
	decreased IgG2a level	J:18801
	decreased IgG3 level	J:18801
	increased CD8-positive, alpha-beta T cell number	J:112048
	increased IgE level	J:18801
	increased IgG1 level	J:18801, J:112048
	increased interleukin-2 secretion	J:112048
	increased interleukin-5 secretion	J:112048
	increased interleukin-10 secretion	J:112048
	increased susceptibility to Coronaviridae infection	J:112048
	increased susceptibility to Coronaviridae infection induced morbidity/mortality	J:112048
	increased susceptibility to parasitic infection	J:18801
	increased susceptibility to parasitic infection induced morbidity/mortality	J:18801, J:110826
	increased T cell derived lymphoma incidence	J:77491
Ifng^tm1Ts/Ifng^tm1Ts (involves: 129S7/SvEvBrd * C57BL/6J)	increased susceptibility to bacterial infection	J:15723
Ifng^tm1Ts/Ifng^tm1Ts (involves: 129S7/SvEvBrd * C57BL/6J)	increased susceptibility to bacterial infection induced morbidity/mortality	J:15723
Ifng^tm1Ts/Ifng^tm1Ts (C.129S7-Ifng^tm1Ts)	abnormal cytokine secretion	J:110826
	abnormal humoral immune response	J:45665
	abnormal immune tolerance	J:45665
	abnormal immunoglobulin level	J:45665
	abnormal response to infection	J:110826
	increased interleukin-5 secretion	J:110826
	increased susceptibility to bacterial infection induced morbidity/mortality	J:83180
	increased susceptibility to experimental autoimmune encephalomyelitis	J:34161
	increased susceptibility to parasitic infection	J:110826
	increased susceptibility to parasitic infection induced morbidity/mortality	J:110826
Ifng^tm1Ts/Ifng^tm1Ts (involves: 129S7/SvEvBrd * NOD)	immune system phenotype	J:33427
Ifng^tm1Ts/Ifng^tm1Ts (involves: 129S7/SvEvBrd * BALB/c)	abnormal susceptibility to infection	J:39478
	decreased IgE level	J:114213
	decreased inflammatory response	J:114213
	immune system phenotype	J:39881
Ifng^tm1Ts/Ifng^tm1Ts (involves: 129S7/SvEvBrd * DBA/1 * MRL/Mp)	decreased anti-double stranded DNA antibody level	J:39600
	decreased anti-nuclear antigen antibody level	J:39600
	decreased autoantibody level	J:39600
	decreased IgA level	J:39600
	decreased IgG2a level	J:39600
	decreased IgG2b level	J:39600
	decreased IgG3 level	J:39600
	decreased IgM level	J:39600
	decreased immunoglobulin level	J:39600
	decreased susceptibility to autoimmune disorder	J:39600
Ifng^tm1Ts/Ifng^tm1Ts (C.129S7(B6)-Ifng^tm1Ts/J)	abnormal adaptive immunity	J:115144
	abnormal circulating cytokine level	J:47459
	abnormal cytokine secretion	J:115144
	abnormal cytotoxic T cell physiology	J:115144
	abnormal inflammatory response	J:115144
	abnormal macrophage physiology	J:115144
	abnormal NK cell physiology	J:115144
	abnormal spleen morphology	J:115144
	abnormal spleen red pulp morphology	J:47459
	abnormal spleen white pulp morphology	J:47459
	abnormal uterine NK cell morphology	J:56503
	abnormal uterine NK cell physiology	J:56503
	decreased susceptibility to parasitic infection	J:50832
	enlarged spleen	J:47459
	increased circulating interleukin-6 level	J:47459
	increased granulocyte number	J:47459
	increased leukocyte cell number	J:47459
	increased monocyte cell number	J:47459
	increased susceptibility to bacterial infection	J:47459
	increased susceptibility to bacterial infection induced morbidity/mortality	J:47459
	increased uterine NK cell number	J:56503
	pale spleen	J:47459
Ifng^tm1Ts/Ifng^tm1Ts (involves: 129S7/SvEvBrd * A/WySn * C57BL/10SnSg * Swiss)	decreased IgG2a level	J:119207
	decreased IgG level	J:119207
	decreased susceptibility to autoimmune disorder	J:119207
	increased IgG1 level	J:119207
Ifng^tm1Ts/Ifng^tm1Ts Ldlr^tm1Her/Ldlr^tm1Her (B6.129S7-Ldlr^tm1Her Ifng^tm1Ts)	increased T cell number	J:103072
Ifng^tm1Ts/Ifng^tm1Ts Nlrp1a^Neut1/Nlrp1a^Neut1 (involves: 129S7/SvEvBrd * C57BL/6)	brain inflammation	J:191055
	immune system phenotype	J:191055
Ifng^tm1Ts/Ifng^tm1Ts Pld4^tm1.2Nemz/Pld4^tm1.2Nemz (involves: 129 * 129S7/SvEvBrd * C57BL/6J * FVB/N)	decreased NK T cell number	J:281205
Ifng^tm1Ts/Ifng^tm1Ts Socs1^tm1Jni/Socs1^tm1Jni (involves: 129S7/SvEvBrd)	increased interleukin-17 secretion	J:132905
Ifng^tm1Ts/Ifng^tm1Ts Socs1^tm1Wehi/Socs1^tm1Wehi (involves: 129S1/Sv * 129S7/SvEvBrd * C57BL/6)	enlarged thymus medulla	J:57474
Ifng^tm1Ts/Ifng^tm1Ts Tg(SFTPC-Il18)AThos/0 (involves: 129S7/SvEvBrd * C57BL/6 * C57BL/6N * DBA/2)	lung inflammation	J:147547
Ifng^tm1Ts/Ifng^tm1Ts Tgfb1^tm1Doe/Tgfb1^tm1Doe (C.129-Ifng^tm1Ts Tgfb1^tm1Doe)	liver inflammation	J:69346
Ifng^tm1Ts/Ifng^tm1Ts Tgfbr2^tm1.2Hlm/Tgfbr2^tm1.2Hlm Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0 Tg(Cd4-cre)1Cwi/0 (involves: 129 * C57BL/6 * DBA/2 * NOD * SJL)	immune system phenotype	J:196160
Ifng^tm1Ts/Ifng^tm1Ts Tnf^tm2Gkl/Tnf⁺ (involves: 129S/SvEv * 129S7/SvEvBrd * C57BL/6J)	small intestinal inflammation	J:108572
Ifng^tm1Ts/Ifng^tm1Ts Tnfrsf1a^tm1Blt/Tnfrsf1a^tm1Blt Tnfrsf1b^tm1Mwm/Tnfrsf1b^tm1Mwm (involves: 129P2/OlaHsd * 129S2/SvPas * 129S7/SvEvBrd * C57BL/6)	abnormal lymph node cortex morphology	J:119206
	abnormal lymph node primary follicle morphology	J:119206
	abnormal lymph node secondary follicle morphology	J:119206
	absent lymph node germinal center	J:119206
	absent spleen germinal center	J:119206
	increased eosinophil cell number	J:119206
	increased leukocyte cell number	J:119206
	increased lymphocyte cell number	J:119206
	increased susceptibility to fungal infection	J:119206
	lung inflammation	J:119206
	small Peyer's patches	J:119206
Ifng^tm1Yiw/Ifng^tm1Yiw (involves: 129X1/SvJ * C57BL/6)	decreased inflammatory response	J:41632, J:88226
Ifng^tm1Yiw/Ifng^tm1Yiw (B6.129X1-Ifng^tm1Yiw)	abnormal circulating interferon level	J:91691
	increased susceptibility to Coronaviridae infection	J:91691, J:50405
	increased susceptibility to Coronaviridae infection induced morbidity/mortality	J:91691, J:50405
	liver inflammation	J:50405
	peritoneal inflammation	J:50405
Ifng^tm1Yiw/Ifng^tm1Yiw (C.129X1-Ifng^tm1Yiw)	abnormal circulating interferon level	J:91691
	increased susceptibility to Coronaviridae infection	J:91691
	increased susceptibility to Coronaviridae infection induced morbidity/mortality	J:91691
Ifngr1^m1Btlr/Ifngr1^m1Btlr (C57BL/6J-Ifngr1^m1Btlr)	decreased macrophage cell number	J:236694
	decreased tumor necrosis factor secretion	J:236694
	increased B cell number	J:236694
Ifngr1^tm1.1Rds/Ifngr1^tm1.1Rds Commd10^{Tg(Vav1-icre)A2Kio}/Commd10⁺ (B6NTac.Cg-Ifngr1^tm1.1Rds Commd10^{Tg(Vav1-icre)A2Kio})	increased susceptibility to bacterial infection	J:206257
	increased susceptibility to bacterial infection induced morbidity/mortality	J:206257
Ifngr1^tm1.1Rds/Ifngr1^tm1.1Rds Tg(Itgax-cre,-EGFP)4097Ach/0 (B6NTac.Cg-Ifngr1^tm1.1Rds Tg(Itgax-cre,-EGFP)4097Ach)	decreased interferon-gamma secretion	J:206257
	decreased interleukin-12b secretion	J:206257
	increased susceptibility to bacterial infection	J:206257
	increased susceptibility to bacterial infection induced morbidity/mortality	J:206257
Ifngr1^tm1.1Rost/Ifngr1^tm1.1Rost (involves: BALB/cJ * C57BL/6)	abnormal chemokine level	J:152785
	decreased circulating interferon-gamma level	J:152785
	decreased circulating interleukin-12 level	J:152785
	immune system phenotype	J:152785
Ifngr1^tm1.2Rds/Ifngr1^tm1.2Rds (C57BL/6NTac-Ifngr1^tm1.2Rds)	decreased interleukin-12b secretion	J:206257
	increased susceptibility to bacterial infection	J:206257
	increased susceptibility to bacterial infection induced morbidity/mortality	J:206257
Ifngr1^tm1Agt/Ifngr1^tm1Agt (involves: 129S7/SvEvBrd)	abnormal immunoglobulin level	J:38363, J:101427
	abnormal response to infection	J:115139
	abnormal uterine NK cell morphology	J:56503
	abnormal uterine NK cell physiology	J:56503
	aortitis	J:115139
	arteritis	J:115139
	decreased circulating tumor necrosis factor level	J:17878
	decreased IgG2a level	J:38363
	decreased susceptibility to endotoxin shock	J:17878
	increased circulating interferon-gamma level	J:314959
	increased circulating interleukin-1 beta level	J:314959
	increased circulating interleukin-6 level	J:174397
	increased interferon-gamma secretion	J:38363
	increased susceptibility to bacterial infection	J:314959, J:174397
	increased susceptibility to bacterial infection induced morbidity/mortality	J:314959, J:174397
	increased susceptibility to experimental autoimmune encephalomyelitis	J:38363
	increased susceptibility to Herpesvirales infection	J:81243
	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:115139
	increased susceptibility to parasitic infection	J:114203
	increased susceptibility to Poxviridae infection	J:101427
	increased tumor necrosis factor secretion	J:38363
	increased uterine NK cell number	J:56503
Ifngr1^tm1Agt/Ifngr1^tm1Agt (involves: 129S7/SvEvBrd * C57BL/6)	abnormal cytotoxic T cell physiology	J:63815
	decreased IgG2a level	J:63815
	decreased IgG3 level	J:63815
	decreased susceptibility to experimental autoimmune myasthenia gravis	J:53577
	increased interferon-gamma secretion	J:99347
	increased interleukin-6 secretion	J:99347
	increased splenocyte proliferation	J:99347
	increased susceptibility to bacterial infection	J:63815
	increased susceptibility to experimental autoimmune uveoretinitis	J:99347
	increased susceptibility to Riboviria infection	J:63815
	increased susceptibility to Riboviria infection induced morbidity/mortality	J:63815
Ifngr1^tm1Agt/Ifngr1^tm1Agt (B6.129S7-Ifngr1^tm1Agt/J)	abnormal circulating chemokine level	J:152785
	abnormal lymphopoiesis	J:138728
	abnormal osteoclast differentiation	J:233116
	decreased CD4-positive, alpha-beta T cell number	J:138728
	decreased CD8-positive, alpha-beta T cell number	J:138728
	decreased circulating interleukin-12 level	J:152785
	decreased lymphocyte cell number	J:138728
	decreased susceptibility to bacterial infection	J:147443
	increased interferon-gamma secretion	J:138728
	increased susceptibility to graft versus host disease	J:138728
	spleen hypoplasia	J:138728
Ifngr1^tm1Agt/Ifngr1^tm1Agt (involves: 129S7/SvEvBrd * DBA/1OlaHsd)	decreased IgG2a level	J:40634
	increased susceptibility to induced arthritis	J:40634
Ifngr1^tm1Agt/Ifngr1^tm1Agt (129-Ifngr1^tm1Agt/J)	immune system phenotype	J:286237
Ifngr1^tm1Agt/Ifngr1^tm1Agt Tg(GZMB-Tax)#Lera/0 (involves: 129S7/SvEvBrd * C57BL/6)	abnormal osteoclast differentiation	J:147601
	abnormal osteoclast physiology	J:147601
	increased osteoclast cell number	J:147601
Ifngr1^tm1Dmer/Ifngr1^tm1Dmer (B6.Cg-Ifngr1^tm1Dmer)	abnormal response to infection	J:202844
Ifngr1^tm1Dmer/Ifngr1^tm1Dmer Tg(Thy1-cre)1Vln/0 (B6.Cg-Ifngr1^tm1Dmer Tg(Thy1-cre)1Vln)	abnormal response to infection	J:202844
Ifngr2^tm1Pbro/Ifngr2^tm1Pbro (involves: 129S1/Sv)	abnormal class switch recombination	J:48016
	abnormal T-helper 1 cell differentiation	J:48016
	decreased susceptibility to type IV hypersensitivity reaction	J:48016
	increased susceptibility to bacterial infection	J:48016
Ifngr2^tm1Pbro/Ifngr2^tm1Pbro (NOD.129S1-Ifngr2^tm1Pbro)	abnormal cytotoxic T cell physiology	J:72818
	abnormal diapedesis	J:72818
	abnormal T-helper 2 physiology	J:65986
	decreased susceptibility to autoimmune diabetes	J:72818
Ifnk^{tm1.1(KOMP)Vlcg}/Ifnk^{tm1.1(KOMP)Vlcg} (C57BL/6NTac-Ifnk^{tm1.1(KOMP)Vlcg})	decreased susceptibility to chemically induced skin inflammation	J:322130
	enlarged spleen	J:322130
Ifnl3^em1Mtba/Ifnl3^em1Mtba (involves: C57BL/6)	abnormal circulating interferon level	J:287260
	increased susceptibility to Orthomyxoviridae infection	J:287260
	increased susceptibility to Riboviria infection	J:287260
	increased susceptibility to viral infection	J:287260
Ifnlr1^{tm1b(EUCOMM)Wtsi}/Ifnlr1^{tm1b(EUCOMM)Wtsi} (B6(Cg)-Ifnlr1^{tm1b(EUCOMM)Wtsi})	increased susceptibility to Orthomyxoviridae infection	J:287260
	increased susceptibility to Riboviria infection	J:287260
	increased susceptibility to viral infection	J:287260
Ifnlr1^tm1Palu/Ifnlr1^tm1Palu (B6.Cg-Ifnlr1^tm1Palu)	abnormal susceptibility to infection	J:131989
Ifnlr1^tm1Palu/Ifnlr1^tm1Palu (involves: BALB/c * C57BL/6)	immune system phenotype	J:286237
Ift70b^em1(IMPC)Bay/Ift70b^em1(IMPC)Bay (C57BL/6N-Ift70b^em1(IMPC)Bay/Bay)	abnormal spleen morphology	J:211773
Ift140^b2b1283Clo/Ift140^b2b1283Clo (C57BL/6J-Ift140^b2b1283Clo)	absent spleen	J:175213
Iftap^tm1Mnz/Iftap^tm1Mnz (Not Specified)	immune system phenotype	J:254587
Igbp1^tm1Cbt/Y Tg(Lck-cre)1Cwi/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)	decreased thymocyte number	J:93221
Igbp1^tm1Cbt/Igbp1⁺ Tg(Lck-cre)1Cwi/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)	decreased thymocyte number	J:93221
Igbp1^tm1Imku/Y Tg(Lck-cre)I57Jxm/? (involves: 129P2/OlaHsd * ICR)	abnormal thymus cortex morphology	J:84395
	abnormal thymus corticomedullary boundary morphology	J:84395
	decreased double-negative T cell number	J:84395
	decreased T cell number	J:84395
	decreased thymocyte number	J:84395
Igdcc4^em1Bcgen/Igdcc4^em1Bcgen (involves: C57BL/6J)	decreased susceptibility to Orthomyxoviridae infection	J:320015
Igdcc4^em1Bcgen/Igdcc4^em1Bcgen (involves: C57BL/6J)	decreased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:320015
Igf1^tm1.1Dlr/Igf1^tm1.1Dlr Tg(Ttr-IGF1)1Sykr/0 (FVB.Cg-Igf1^tm1.1Dlr Tg(Ttr-IGF1)1Sykr)	increased spleen weight	J:157350
Igf1r^tm1Jcbr/Igf1r^tm1Jcbr Ndor1^{Tg(UBC-cre/ERT2)1Ejb}/0 (B6.Cg-Ndor1^{Tg(UBC-cre/ERT2)1Ejb} Igf1r^tm1Jcbr)	decreased susceptibility to type I hypersensitivity reaction	J:241924
Igf1r^tm2Arge/Igf1r^tm2Arge Tg(BGLAP-cre)1Clem/0 (involves: 129 * FVB/N)	abnormal osteoclast physiology	J:80190
	decreased osteoclast cell number	J:80190
Igf1sl2^C3H/HeJ/Igf1sl2^C3H/HeJ (B6.C3H-Igf1sl2^C3H/HeJ)	increased osteoclast cell number	J:111677
Igf2^tm1Snha/Igf2⁺ (involves: 129S1/Sv * 129X1/SvJ * ICR)	abnormal osteoclast differentiation	J:167738
Igf2bp1^{Gt(OST33739)Lex}/Igf2bp1^{Gt(OST33739)Lex} (involves: 129S5/SvEvBrd * C57BL/6)	spleen hypoplasia	J:89882
Igfbp1^tm1Taub/Igfbp1^tm1Taub (involves: 129X1/SvJ * C57BL/6)	liver inflammation	J:81123
Igfbp2^tm1Jep/Igfbp2^tm1Jep (either: (involves: 129P1/ReJ * 129S/SvEv) or (involves: 129S/SvEv * C57BL/6))	small spleen	J:64338
Igh-7^tm1.1Lam/Igh-7^tm1.1Lam (involves: BALB/c)	decreased IgE level	J:146733
Igh-7^tm1.1Lam/Igh-7^tm1.1Lam (involves: BALB/c)	decreased mature B cell number	J:146733
Igh-7^tm1Gach/Igh-7^tm1Gach (BALB/c-Igh-7^tm1Gach)	abnormal B cell number	J:143266
	enhanced B cell migration	J:143266
	increased IgE level	J:143266
	increased memory B cell number	J:143266
	increased plasma cell number	J:143266
Igh-7^tm1Lam/Igh-7^tm1Lam (involves: BALB/c)	decreased IgE level	J:146733
Igh-7^tm1Lam/Igh-7^tm1Lam (involves: BALB/c)	decreased mature B cell number	J:146733
Igh-7^tm1Lcwu/Igh-7^tm1Lcwu (involves: C57BL/6)	decreased IgE level	J:161452
Igh-7^tm1Lcwu/Igh-7^tm1Lcwu (involves: C57BL/6)	decreased mature B cell number	J:161452
Igh-7^tm1Led/Igh-7^tm1Led (involves: 129S4/SvJae * Black Swiss)	immune system phenotype	J:19552
Igh-7^tm1Led/Igh-7^tm1Led (C.129S4-Igh-7^tm1Led)	impaired eosinophil recruitment	J:133373
Igh-7^tm1Led/Igh-7^tm1Led Lyn^tm1Ard/Lyn^tm1Ard (involves: 129P2/OlaHsd * 129S4/SvJae)	abnormal circulating complement protein level	J:161523
	decreased B cell number	J:161523
	increased anti-double stranded DNA antibody level	J:161523
	increased anti-nuclear antigen antibody level	J:161523
	increased basophil cell number	J:161523
	increased IgA level	J:161523
	increased IgM level	J:161523
Igh-8^tm1.1Aak/Igh-8^tm1.1Aak (involves: 129S2/SvPas * C57BL/6)	abnormal class switch recombination	J:171251
Igh-8^tm1Aak/Igh-8^tm1Aak (involves: 129S2/SvPas * C57BL/6)	abnormal class switch recombination	J:107063
Igh-8^tm1Schr/Igh-8^tm1Schr (involves: 129P2/OlaHsd * Black Swiss)	increased IgM level	J:49847
Igh-8^tm1Schr/Igh-8^tm1Schr (C.129P2(BKSW)-Igh-8^tm1Schr)	increased IgG level	J:75577
	increased IgM level	J:75577
	increased susceptibility to bacterial infection	J:75577
Igh-8^{tm2(Ighg1)Aak}/Igh-8^{tm2(Ighg1)Aak} (involves: 129S2/SvPas)	abnormal class switch recombination	J:130574
	decreased IgG3 level	J:130574
Igh-8^tm2.1Aak/Igh-8^tm2.1Aak (involves: 129S2/SvPas * C57BL/6)	immune system phenotype	J:171251
Igh-J^{tm1(3H9-VDJ)Mwg}/Igh-J^{tm1(3H9-VDJ)Mwg} (involves: 129P2/OlaHsd * BALB/c * C57BL/6)	abnormal B cell receptor editing	J:126940
Igh-J^tm1(CB20)Rhd/Igh-J⁺ (involves: C57BL/10 * DBA/1)	abnormal B cell differentiation	J:179456
	decreased pre-B cell number	J:179456
	increased immature B cell number	J:179456
	increased marginal zone B cell number	J:179456
	increased mature B cell number	J:179456
	increased susceptibility to induced arthritis	J:179456
Igh-J^tm1(CB20)Rhd/Igh-J^tm1(CB20)Rhd (involves: C57BL/10 * DBA/1)	abnormal B cell differentiation	J:179456
	decreased pre-B cell number	J:179456
	increased immature B cell number	J:179456
	increased marginal zone B cell number	J:179456
	increased mature B cell number	J:179456
	increased susceptibility to induced arthritis	J:179456
Igh-J^{tm1(Ighel)Cys}/Igh-J^{tm1(Ighel)Cys} Myd88^tm1Aki/Myd88^tm1Aki Igkj1^{tm1(IgkHyHEL10)Mnz}/0 (involves: 129P2/OlaHsd)	increased IgM level	J:115059
Igh-J^{tm1(VDJ-KL25)Zbz}/Igh-J⁺ (involves: C57BL/6 * C57BL/6J * BALB/cJ)	increased IgG level	J:86411
	increased IgM level	J:86411
Igh-J^{tm1(VDJ-VI10)Zbz}/Igh-J⁺ (involves: C57BL/6 * C57BL/6J * BALB/cJ)	abnormal immune serum protein physiology	J:86411
Igh-J^tm1.1Lave/Igh-J⁺ (Not Specified)	abnormal B cell differentiation	J:155798
	decreased B cell number	J:155798
	decreased immature B cell number	J:155798
	decreased mature B cell number	J:155798
	decreased spleen weight	J:155798
	decreased T cell number	J:155798
	decreased transitional stage B cell number	J:155798
	decreased transitional stage T1 B cell number	J:155798
	decreased transitional stage T2 B cell number	J:155798
	increased pre-B cell number	J:155798
	increased pro-B cell number	J:155798
Igh-J^tm1.1Lave/Igh-J^tm1.1Lave (Not Specified)	abnormal B cell differentiation	J:155798
	abnormal immunoglobulin level	J:179317
	arrested B cell differentiation	J:179317
	decreased B cell number	J:155798, J:179317
	decreased IgM level	J:155798
	decreased immature B cell number	J:155798
	decreased mature B cell number	J:155798
	decreased spleen weight	J:155798
	decreased T cell number	J:155798
	decreased transitional stage B cell number	J:155798
	decreased transitional stage T1 B cell number	J:155798
	decreased transitional stage T2 B cell number	J:155798
	increased IgG level	J:155798
	increased pre-B cell number	J:155798
	increased pro-B cell number	J:155798
Igh-J^tm1.1Lave/Igh-J^tm1.1Lave Igk-J^tm1.1Lave/Igk-J^tm1.1Lave (Not Specified)	abnormal B cell clonal deletion	J:179317
	abnormal B cell differentiation	J:205708
	abnormal B cell physiology	J:205708
	abnormal immunoglobulin level	J:179317
	arrested B cell differentiation	J:205708, J:179317
	decreased B cell number	J:205708, J:179317
	decreased immature B cell number	J:205708
	decreased mature B cell number	J:205708
Igh-J^tm1.1Lave/Igh-J^tm1.1Lave Igk-J^tm1.1Lave/Igk-J^tm1.1Lave Tg(BCL2)22Wehi/0 (involves: C57BL/6JWehi * SJL/JWehi)	abnormal B cell differentiation	J:179317
Igh-J^tm1Aigl/Igh-J⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal B cell morphology	J:111543
	decreased B cell number	J:111543
	decreased B-1 B cell number	J:111543
	increased susceptibility to experimental autoimmune encephalomyelitis	J:111543
Igh-J^tm1Aigl/Igh-J⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)	increased susceptibility to experimental autoimmune encephalomyelitis	J:111543
Igh-J^tm1Aigl/Igh-J⁺ Mog^tm1Dpd/Mog^tm1Dpd Tg(Tcra2D2,Tcrb2D2)1Kuch/0 (involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6)	CNS inflammation	J:151335
	increased susceptibility to experimental autoimmune encephalomyelitis	J:151335
Igh-J^tm1Aigl/Igh-J⁺ Tg(Tcra2D2,Tcrb2D2)1Kuch/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	CNS inflammation	J:151335
	increased susceptibility to experimental autoimmune encephalomyelitis	J:151335
Igh-J^tm1Aigl/Igh-J^tm1Aigl Tg(H2-K^b-Tcra,-Tcrb)1640Kurs/0 (involves: 129S1/Sv * 129X1/SvJ * FVB/N * SJL/J)	increased autoantibody level	J:149511
	increased susceptibility to experimental autoimmune encephalomyelitis	J:149511
Igh-J^tm1Cgn/Igh^tm4Cgn Tg(Cr2-cre)3Cgn/0 (Not Specified)	decreased B cell number	J:79299
	decreased follicular B cell number	J:79299
	decreased marginal zone B cell number	J:79299
Igh-J^tm1Cgn/Igh^tm4Cgn Tg(Cr2-cre)3Cgn/0 (involves: 129P2/OlaHsd)	decreased mature B cell number	J:157297
Igh-J^tm1Cgn/Igh^tm11.1Cgn (involves: 129P2/OlaHsd)	abnormal B cell differentiation	J:113434
Igh-J^tm1Cgn/Igh-J⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell differentiation	J:64285
Igh-J^tm1Cgn/Igh^tm1Leck (involves: 129P2/OlaHsd * C57BL/6)	abnormal immunoglobulin light chain V-J recombination	J:144033
Igh-J^tm1Cgn/Igh-J^tm1Cgn (involves: 129P2/OlaHsd * C57BL/6)	absent mature B cells	J:64285
	arrested B cell differentiation	J:64285
Igh-J^tm1Dhu/Igh^tm3Tim (involves: 129 * C57BL/6)	abnormal B cell differentiation	J:102308
Igh-J^tm1Dhu/Igh^tm3Tim (involves: 129 * C57BL/6)	decreased B cell number	J:102308
Igh-J^tm1Dhu/Igh^tm1Tim (involves: 129X1/SvJ * C57BL/6)	abnormal B cell differentiation	J:88410
	abnormal B cell morphology	J:87624
	abnormal immune system organ morphology	J:87624
	abnormal spleen marginal zone morphology	J:87624
	abnormal spleen morphology	J:87624
Igh-J^tm1Dhu/Igh^tm2Tim (involves: 129X1/SvJ * C57BL/6)	abnormal lymph node morphology	J:87624
	abnormal spleen morphology	J:87624
	decreased marginal zone B cell number	J:87624
Igh-J^tm1Dhu/Igh-J⁺ Il2^tm1Hor/Il2^tm1Hor (involves: 129/Sv * C57BL/6)	colitis	J:29999
	enlarged mesenteric lymph nodes	J:29999
Igh-J^tm1Dhu/Igh-J^{tm1(VDJ-17.2.25)Wabl} Igk^tm1Dhu/Igk^tm1Dhu (Not Specified)	abnormal B cell differentiation	J:33628
	abnormal immature B cell morphology	J:89757
Igh-J^tm1Dhu/Igh-J^tm1Dhu Il2^tm1Hor/Il2^tm1Hor (involves: 129/Sv * C57BL/6)	colitis	J:29999
	enlarged mesenteric lymph nodes	J:29999
Igh-J^tm1Dhu/Igh-J^tm1Dhu Wdr1^rede/Wdr1^rede (involves: 129S7/SvEvBrd * BALB/c * C57BL/6)	abnormal immune system physiology	J:134092
Igh-J^tm1Dim/Igh-J⁺ Igk-J^tm1Dim/Igk-J⁺ (involves: 129S4/SvJae * C57BL/6)	abnormal B cell differentiation	J:107241
	increased IgG level	J:107241
	increased IgM level	J:107241
Igh-J^tm1Jkbv/Igh-J^tm1Jkbv (involves: 129P2/OlaHsd * C57BL/6)	abnormal T cell number	J:113083
	absent B cells	J:70038
	decreased IgM level	J:70038
Igh-J^tm1Jkbv/Igh-J^tm1Jkbv (involves: 129P2/OlaHsd)	absent mature B cells	J:137738
	arrested B cell differentiation	J:137738
	increased late pro-B cell number	J:137738
Igh-J^tm1Jkbv/Igh-J^tm1Jkbv Igkc^tm1Jkbv/Igkc^tm1Jkbv (involves: 129P2/OlaHsd)	absent B cells	J:23827
	absent mature B cells	J:137738, J:70620
	arrested B cell differentiation	J:137738, J:23827
	increased late pro-B cell number	J:137738
Igh-J^tm1Jkbv/Igh-J^tm1Jkbv Igkc^tm1Jkbv/Igkc^tm1Jkbv Tg(IGH@yH1)2BJkbv/0 Tg(IGK@yK1)9.2CJkbv/0 (involves: 129P2/OlaHsd)	abnormal B cell morphology	J:23827
	abnormal immunoglobulin level	J:23827
	increased mature B cell number	J:23827
Igh-J^tm1Jkbv/Igh-J^tm1Jkbv Igkc^tm1Jkbv/Igkc^tm1Jkbv Tg(IGH@yH1)2BJkbv/0 Tg(IGK@yK1)9.2CJkbv/Tg(IGK@yK1)9.2CJkbv (involves: 129P2/OlaHsd)	abnormal B cell differentiation	J:137738
	decreased immature B cell number	J:137738
	decreased mature B cell number	J:137738
	decreased pre-B cell number	J:137738
	increased late pro-B cell number	J:137738
Igh-J^tm1Jkbv/Igh-J^tm1Jkbv Igkc^tm1Jkbv/Igkc^tm1Jkbv Tg(IGH@yH1)2BJkbv/Tg(IGH@yH1)2BJkbv Tg(IGK@yK1)9.2CJkbv/Tg(IGK@yK1)9.2CJkbv (involves: 129P2/OlaHsd)	abnormal B cell differentiation	J:137738
	abnormal immunoglobulin level	J:137738
	decreased immature B cell number	J:137738
	decreased mature B cell number	J:137738
	decreased pre-B cell number	J:137738
	increased late pro-B cell number	J:137738
Igh-J^tm1Jkbv/Igh-J^tm1Jkbv Igkc^tm1Jkbv/Igkc^tm1Jkbv Tg(IGH@yH1)2BJkbv/Tg(IGH@yH1)2BJkbv Tg(IGK@yK2)J23.1Jkbv/Tg(IGK@yK2)J23.1Jkbv (involves: 129P2/OlaHsd)	abnormal B cell differentiation	J:137738
	decreased immature B cell number	J:137738
	decreased mature B cell number	J:137738
	decreased pre-B cell number	J:137738
	increased late pro-B cell number	J:137738
Igh-J^tm1Jkbv/Igh-J^tm1Jkbv Igkc^tm1Jkbv/Igkc^tm1Jkbv Tg(IGH@yH2)J9.2Jkbv/0 Tg(IGK@yK2)J23.1Jkbv/0 (involves: 129P2/OlaHsd * C57BL/6J)	abnormal B cell morphology	J:70620
	abnormal immunoglobulin heavy chain V(D)J recombination	J:70620
	abnormal immunoglobulin level	J:70620
	abnormal immunoglobulin light chain V-J recombination	J:70620
	increased mature B cell number	J:70620
Igh-J^tm1Jkbv/Igh-J^tm1Jkbv Igkc^tm1Jkbv/Igkc^tm1Jkbv Tg(IGH@yH2)J9.2Jkbv/0 Tg(IGK@yK2)J23.1Jkbv/Tg(IGK@yK2)J23.1Jkbv (involves: 129P2/OlaHsd)	abnormal immunoglobulin level	J:137738
	decreased immature B cell number	J:137738
	decreased mature B cell number	J:137738
	immune system phenotype	J:137738
Igh-J^tm1Jkbv/Igh-J^tm1Jkbv Igkc^tm1Jkbv/Igkc^tm1Jkbv Tg(IGH@yH2BM)7Amgn/0 Tg(IGK@yK2)J23.1Jkbv/0 (involves: 129P2/OlaHsd)	abnormal immunoglobulin level	J:139792
	decreased B cell number	J:139792
Igh-J^tm1Jkbv/Igh-J^tm1Jkbv Igkc^tm1Jkbv/Igkc^tm1Jkbv Tg(IGH@yH2CM)2Amgn/0 Tg(IGK@yK2)J23.1Jkbv/0 (involves: 129P2/OlaHsd)	abnormal immunoglobulin level	J:139792
	decreased B cell number	J:139792
Igh-J^tm1Jkbv/Igh-J^tm1Jkbv Igkc^tm1Jkbv/Igkc^tm1Jkbv Tg(IGH@yHG1/2)1Amgn/0 Tg(IGK@yK2)J23.1Jkbv/0 (involves: 129P2/OlaHsd)	abnormal immunoglobulin level	J:139792
Igh-J^tm1Jkbv/Igh-J^tm1Jkbv Igkc^tm1Jkbv/Igkc^tm1Jkbv Tg(IGH@yHG4)1Amgn/0 Tg(IGK@yK2)J23.1Jkbv/0 (involves: 129P2/OlaHsd)	abnormal immunoglobulin level	J:139792
Igh-J^tm1Jkbv/Igh-J^tm1Jkbv Tg(IGH@*)SALed/0 (involves: 129P2/OlaHsd)	decreased mature B cell number	J:137738
	immune system phenotype	J:137738
Igh-J^tm1Jkbv/Igh-J^tm1Jkbv Tg(IGH@yH1)2BJkbv/0 (involves: 129P2/OlaHsd)	abnormal B cell differentiation	J:137738
	decreased mature B cell number	J:137738
	decreased pre-B cell number	J:137738
	increased late pro-B cell number	J:137738
Igh-J^tm1Jkbv/Igh-J^tm1Jkbv Tg(IGH@yH1)2BJkbv/0 Tg(IGK@yK1)9.2CJkbv/0 (involves: 129P2/OlaHsd)	abnormal B cell morphology	J:23827
	abnormal immunoglobulin level	J:23827
	increased late pro-B cell number	J:23827
	increased mature B cell number	J:23827
Igh-J^tm1Jkbv/Igh-J^tm1Jkbv Tg(IGH@yH1)2BJkbv/Tg(IGH@yH1)2BJkbv (involves: 129P2/OlaHsd)	abnormal B cell differentiation	J:137738
	abnormal immunoglobulin level	J:137738
	decreased immature B cell number	J:137738
	decreased mature B cell number	J:137738
	decreased pre-B cell number	J:137738
	increased late pro-B cell number	J:137738
Igh-J^tm1Jkbv/Igh-J^tm1Jkbv Tg(IGH@yH2)J9.2Jkbv/0 (involves: 129P2/OlaHsd)	abnormal immunoglobulin level	J:137738
	decreased mature B cell number	J:137738
	immune system phenotype	J:137738
Igh-J^tm1Khyk/Igh-J⁺ (CB17.129X1-Igh-J^tm1Khyk)	increased B-1 B cell number	J:109979
Igh-J^tm1Mcdl/Igh-J^tm1Mcdl Igk-J^tm1Mcdl/Igk-J^tm1Mcdl Rag1^tm1Mom/Rag1^tm1Mom Tg(DO11.10)10Dlo/? (involves: 129S/Sv * BALB/c * C3H * C57BL/6)	abnormal spleen germinal center morphology	J:100072
	abnormal T cell differentiation	J:100072
	increased IgE level	J:100072
	increased IgG level	J:100072
Igh-J^{tm2(3H9-VDJ)Mwg}/Igh-J⁺ (involves: 129P2/OlaHsd BALB/c * C57BL/6)	abnormal B cell receptor editing	J:126940
	increased anti-double stranded DNA antibody level	J:126940
Igh-J^{tm2(3H9-VDJ)Mwg}/Igh-J⁺ (involves: 129P2/OlaHsd BALB/c)	abnormal B cell receptor editing	J:131138
	abnormal marginal zone B cell morphology	J:131138
	increased anti-double stranded DNA antibody level	J:131138
Igh-J^{tm2(3H9-VDJ)Mwg}/Igh-J⁺ (B6.129P2-Igh-J^{tm2(3H9-VDJ)Mwg})	decreased B cell number	J:142389
	increased anti-double stranded DNA antibody level	J:142389
	increased marginal zone B cell number	J:142389
	spleen hypoplasia	J:142389
Igh-J^{tm2.1(4E10)Lave}/Igh-J^{tm2.1(4E10)Lave} (involves: C57BL/6)	arrested B cell differentiation	J:205708
	decreased B-1a cell number	J:205708
	decreased IgG1 level	J:205708
	decreased IgG2b level	J:205708
	decreased IgG3 level	J:205708
	decreased IgG level	J:205708
	decreased IgM level	J:205708
Igh-J^{tm2.1(4E10)Lave}/Igh-J^{tm2.1(4E10)Lave} Igk-J^{tm2.1(4E10)Lave}/Igk-J^{tm2.1(4E10)Lave} (involves: C57BL/6)	abnormal B cell differentiation	J:205708
	abnormal B cell physiology	J:205708
	arrested B cell differentiation	J:205708
	decreased immature B cell number	J:205708
	decreased mature B cell number	J:205708
Igh-J^{tm3(3H9-VDJ)Mwg}/Igh-J^{tm3(3H9-VDJ)Mwg} (involves: 129P2/OlaHsd * BALB/c * C57BL/6)	abnormal B cell receptor editing	J:126940
	increased anti-double stranded DNA antibody level	J:126940
Igh-J^{tm3.1(48d)Lave}/Igh-J^{tm3.1(48d)Lave} (involves: C57BL/6)	decreased B-1a cell number	J:205708
	decreased IgG1 level	J:205708
	decreased IgG2b level	J:205708
	decreased IgM level	J:205708
	immune system phenotype	J:205708
Igh-V7183^tm1Cgn/Igh-V7183^tm1Cgn (either: (involves: 129P2/OlaHsd) or (involves: 129P2/OlaHsd * C57BL/6))	immune system phenotype	J:112978
Igh-V^{tm1(Igh-Vx24)Hmb}/Igh-V^{tm1(Igh-Vx24)Hmb} (involves: 129/Sv * C57BL/6)	increased T cell derived lymphoma incidence	J:54380
Igh-V^tm1Jjk/Igh-V^tm1Jjk (involves: 129S4/SvJae * C57BL/6)	abnormal adaptive immunity	J:62284
Igh-V^tm1Jjk/Igh-V^tm1Jjk (involves: 129S4/SvJae * C57BL/6)	increased susceptibility to bacterial infection	J:62284
Igh^deltaD/Igh⁺ (involves: C57BL/6 * DBA/2)	abnormal B cell differentiation	J:95981
	decreased B cell number	J:95981
	decreased immunoglobulin level	J:95981
Igh^deltaD/Igh^deltaD (involves: C57BL/6 * DBA/2)	abnormal B cell differentiation	J:95981
	abnormal immunoglobulin level	J:95981
	abnormal spleen morphology	J:95981
	arrested B cell differentiation	J:95981
	decreased B cell number	J:95981
	decreased follicular B cell number	J:95981
	decreased IgG1 level	J:95981
	increased IgA level	J:95981
	increased marginal zone B cell number	J:95981
Igh^deltaD/Igh^tm11.1Cgn (involves: C57BL/6 * DBA/2)	abnormal B cell differentiation	J:113434
Igh^tm1(IGH)Vlcg/Igh^tm1(IGH)Vlcg Igk^tm1(IGK)Vlcg/Igk^tm1(IGK)Vlcg (involves: 129S6/SvEvTac * C57BL/6N)	immune system phenotype	J:208620
Igh^{tm1(Ighppc1-5)Cche}/Igh⁺ (B6.Cg-Igh^{tm1(Ighppc1-5)Cche})	immune system phenotype	J:138356
	increased autoantibody level	J:138356
Igh^tm1(Myc)Janz/Igh⁺ (involves: 129X1/SvJ * C57BL/6)	enlarged lymph nodes	J:96785
	enlarged spleen	J:96785
	increased B cell apoptosis	J:96785
	increased B cell proliferation	J:96785
	lymphoid hyperplasia	J:96785
Igh^tm1(Myc)Janz/Igh⁺ Mdm4^tm1.1Wahl/Mdm4^tm1.1Wahl (involves: 129S/Sv * C57BL/6)	enlarged lymph nodes	J:150341
	enlarged spleen	J:150341
	increased splenocyte proliferation	J:150341
Igh^tm1(PAX5)Mbu/Igh⁺ (B6.Cg-Igh^tm1(PAX5)Mbu)	abnormal lymph node morphology	J:118111
	abnormal spleen morphology	J:118111
	abnormal T cell differentiation	J:118111
	abnormal thymus morphology	J:118111
	decreased double-negative T cell number	J:118111
	decreased double-positive T cell number	J:118111
	enlarged lymph nodes	J:118111
	enlarged spleen	J:118111
	enlarged thymus	J:118111
	increased pro-B cell number	J:118111
	increased T cell derived lymphoma incidence	J:118111
	thymus hypoplasia	J:118111
Igh^tm1(PAX5)Mbu/Igh⁺ Pax5^tm1Mbu/Pax5^tm1Mbu (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * CBA)	abnormal B cell differentiation	J:118111
	decreased B cell number	J:118111
	immune system phenotype	J:118111
Igh^tm1(PAX5)Mbu/Igh^tm1(PAX5)Mbu (B6.Cg-Igh^tm1(PAX5)Mbu)	abnormal lymph node morphology	J:118111
	abnormal spleen morphology	J:118111
	abnormal T cell differentiation	J:118111
	abnormal thymus morphology	J:118111
	decreased double-negative T cell number	J:118111
	decreased double-positive T cell number	J:118111
	enlarged lymph nodes	J:118111
	enlarged spleen	J:118111
	enlarged thymus	J:118111
	increased pro-B cell number	J:118111
	increased T cell derived lymphoma incidence	J:118111
	thymus hypoplasia	J:118111
Igh^{tm1(VH558)Mss}/Igh⁺ (involves: FVB/N)	abnormal B cell differentiation	J:130421
Igh^{tm1(VH558)Mss}/Igh^{tm1(VH558)Mss} (involves: FVB/N)	abnormal B cell differentiation	J:130421
Igh^{tm1.1(b12)Nemz}/Igh^{tm1.1(b12)Nemz} (involves: C57BL/6N * FVB/N)	decreased IgM level	J:205766
	decreased immature B cell number	J:205766
	increased B cell number	J:205766
Igh^{tm1.1(b12)Nemz}/Igh^{tm1.1(b12)Nemz} Igk^{tm1.1(b12)Nemz}/Igk^{tm1.1(b12)Nemz} (involves: C57BL/6N * C57BL/6NTac * FVB/N)	decreased IgM level	J:205766
	decreased immature B cell number	J:205766
	immune system phenotype	J:205766
	increased B cell number	J:205766
Igh^{tm1.1(Igh564)Tik}/Igh^{tm1.1(Igh564)Tik} Igk^{tm1(Igk564)Tik}/Igk^{tm1(Igk564)Tik} (B6.129S4-Igk^{tm1(Igk564)Tik} Igh^{tm1(Igh564)Tik})	glomerulonephritis	J:113555
Igh^{tm1.1(Rr361-HBB)Aak}/Igh^{tm1.1(Rr361-HBB)Aak} (129.129S2(Cg)-Igh^{tm1.1(Rr361-HBB)Aak})	abnormal class switch recombination	J:333279
	decreased IgA level	J:333279
	decreased IgE level	J:333279
	decreased IgG1 level	J:333279
	decreased IgG2a level	J:333279
	decreased IgG2b level	J:333279
Igh^{tm1.1(Tag)Rwhe}/Igh⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell morphology	J:150315
	enlarged spleen	J:150315
	increased B cell number	J:150315
	lymph node hyperplasia	J:150315
Igh^tm1.1Hmj/Igh^tm1.1Hmj (involves: 129S6/SvEvTac * C57BL/6J * FVB/N)	abnormal B cell differentiation	J:140486
	abnormal immunoglobulin heavy chain V(D)J recombination	J:140486
	decreased mature B cell number	J:140486
	immune system phenotype	J:140486
	spleen hypoplasia	J:140486
Igh^tm1.1Hws/Igh^tm1.1Hws (BALB/cJ-Igh^tm1.1Hws)	decreased IgM level	J:119391
	decreased immature B cell number	J:119391
	decreased immunoglobulin level	J:119391
	decreased pre-B cell number	J:119391
	increased late pro-B cell number	J:119391
Igh^tm1.1Hws/Igh^tm1.1Hws (involves: BALB/c)	decreased immature B cell number	J:142069
	decreased late pro-B cell number	J:142069
	increased early pro-B cell number	J:142069
	increased IgG3 level	J:142069
	increased IgM level	J:142069
Igh^tm1.1Lnit/Igh⁺ (involves: BALB/c * C57BL/6)	abnormal B cell differentiation	J:119484
Igh^tm1.1Rsky/Igh^tm1.1Rsky (BALB/c-Igh^tm1.1Rsky)	abnormal class switch recombination	J:125719
Igh^tm1.1Rsky/Igh^tm1.1Rsky (BALB/c-Igh^tm1.1Rsky)	decreased IgM level	J:125719
Igh^tm1.1Twin/Igh⁺ (involves: 129 * 129S4/SvJae * C57BL/6)	decreased pre-B cell number	J:174233
Igh^tm1.1Twin/Igh⁺ (involves: 129 * 129S4/SvJae * C57BL/6)	increased pro-B cell number	J:174233
Igh^tm1.1Twin/Igh^tm1.1Twin (involves: 129 * 129S4/SvJae * C57BL/6)	abnormal B cell differentiation	J:174233
	abnormal B cell morphology	J:174233
	abnormal B cell number	J:174233
	abnormal marginal zone B cell morphology	J:174233
	abnormal marginal zone B cell physiology	J:174233
	absent plasma cells	J:174233
	decreased B cell number	J:174233
	decreased B-1a cell number	J:174233
	decreased follicular B cell number	J:174233
	decreased IgG3 level	J:174233
	decreased IgG level	J:174233
	decreased IgM level	J:174233
	decreased immature B cell number	J:174233
	decreased mature B cell number	J:174233
	decreased transitional stage T2 B cell number	J:174233
	immune system phenotype	J:174233
Igh^tm1.1Twin/Igh^tm1.1Twin Plcg2^Ali5/Plcg2⁺ (involves: 129 * 129S4/SvJae * C3HeB/FeJ * C57BL/6)	immune system phenotype	J:174233
	increased B-1a cell number	J:174233
Igh^tm1.1Twin/Igh^tm1.1Twin Siglecg^tm1Lnit/Siglecg^tm1Lnit (involves: 129 * 129S4/SvJae * BALB/c * C57BL/6)	immune system phenotype	J:174233
Igh^tm1.1Vmd/Igh⁺ (involves: C57BL/6)	abnormal class switch recombination	J:201147
Igh^tm1.1Vmd/Igh^tm1.1Vmd (involves: C57BL/6)	abnormal class switch recombination	J:201147
	decreased IgG1 level	J:201147
	decreased IgG3 level	J:201147
	immune system phenotype	J:201147
	increased IgE level	J:201147
Igh^tm1.2Rsky/Igh⁺ (BALB/c-Igh^tm1.2Rsky)	increased IgG1 level	J:125719
Igh^tm1.2Rsky/Igh⁺ Tnfrsf13c^tm1Mass/Tnfrsf13c^tm1Mass (involves: BALB/c * C57BL/6)	decreased mature B cell number	J:125719
Igh^tm1.2Rsky/Igh^tm1.2Rsky (BALB/c-Igh^tm1.2Rsky)	abnormal B cell activation	J:125719
	abnormal B cell morphology	J:125719
	abnormal B cell proliferation	J:125719
	abnormal mature B cell morphology	J:125719
	decreased B-1a cell number	J:125719
	decreased IgA level	J:125719
	decreased IgD level	J:125719
	decreased IgE level	J:125719
	decreased IgM level	J:125719
	decreased immunoglobulin level	J:125719
	decreased pre-B cell number	J:125719
	decreased transitional stage B cell number	J:125719
	increased marginal zone B cell number	J:125719
	increased pro-B cell number	J:125719
Igh^tm1.2Rsky/Igh^tm1.2Rsky Tg(CD19-cre/ERT2)1Cgn/? (involves: BALB/c)	abnormal B cell activation	J:125719
	abnormal class switch recombination	J:125719
Igh^tm1Aak/Igh^tm1Aak (Not Specified)	abnormal B cell differentiation	J:158402
	decreased B cell number	J:158402
	decreased pre-B cell number	J:158402
	increased pro-B cell number	J:158402
Igh^tm1Cgn/Igh⁺ (involves: 129P2/OlaHsd)	abnormal B cell differentiation	J:79556
Igh^tm1Cgn/Igh^tm2Cgn (involves: 129P2/OlaHsd * BALB/c * C57BL/Ka)	abnormal B cell differentiation	J:79556
Igh^tm1Cog/Igh^tm1Cog (involves: 129S2/SvPas * C57BL/6)	abnormal immunoglobulin heavy chain V(D)J recombination	J:80654
	absent B cells	J:80654
	arrested B cell differentiation	J:80654
	decreased IgA level	J:80654
	decreased IgE level	J:80654
	decreased IgG1 level	J:80654
	decreased IgG2a level	J:80654
	decreased IgG2b level	J:80654
	decreased IgG3 level	J:80654
	decreased IgM level	J:80654
	decreased immunoglobulin level	J:80654
Igh^tm1Cys/Igh⁺ Tg(Igk)5Cys/0 (B6.Cg-Igh^tm1Cys Tg(Igk)5Cys)	abnormal B cell physiology	J:118931
	immune system phenotype	J:118931
Igh^tm1Cys/Igh⁺ Tg(Igk)5Cys/0 Tg(UBC-GFP)30Scha/Tg(UBC-GFP)30Scha (involves: 129X1/SvJ * C57BL/6 * CBA)	immune system phenotype	J:118931
Igh^tm1Emo/Igh^tm1Emo (involves: 129S1/Sv * C57BL/6 * FVB/N)	immune system phenotype	J:108098
Igh^tm1Kplm/Igh⁺ (involves: A/WySnJ * BALB/c)	abnormal B-1 B cell morphology	J:115788
Igh^tm1Kplm/Igh⁺ (Not Specified)	abnormal B cell differentiation	J:115292
Igh^tm1Kplm/Igh⁺ (Not Specified)	increased B cell number	J:115292
Igh^tm1Kplm/Igh⁺ Tg(Igk-V4CH27)1-2Shc/0 (involves: C57BL/6 * SJL)	increased B cell number	J:115292
Igh^tm1Kplm/Igh^tm3Cgn (involves: C57BL/6)	abnormal B cell differentiation	J:115292
Igh^tm1Kplm/Igh^tm3Cgn (involves: C57BL/6)	abnormal B cell number	J:115292
Igh^tm1Kplm/Igh^tm4Cgn (involves: 129P2/OlaHsd)	abnormal B cell differentiation	J:115292
	abnormal B cell number	J:115292
	abnormal B-1 B cell morphology	J:115292
Igh^tm1Kplm/Igh^tm4Cgn Tg(Igk-V4CH27)1-2Shc/0 (involves: 129P2/OlaHsd * C57BL/6 * SJL)	increased B cell number	J:115292
Igh^tm1Ktom/Igh^tm1Ktom (involves: ICR)	abnormal B cell physiology	J:59894
	abnormal immunoglobulin level	J:178635
	absent mature B cells	J:178635
Igh^tm1Ktom/Igh^tm1Ktom Igk^tm1Ktom/Igk^tm1Ktom Tc(HSA14)SC20Ktom/0 Tc(HSA2)W23Ktom/0 (involves: C57BL/6NCrlj * CBA/JNCrlj * ICR)	abnormal B cell physiology	J:59894
Igh^tm1Ktom/Igh^tm1Ktom Tc(HSA2)W23Ktom/0 (involves: C57BL/6NCrlj * CBA/JNCrlj * ICR)	abnormal B cell physiology	J:59894
Igh^tm1Leck/Igh⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell morphology	J:144033
	abnormal B-1a B cell morphology	J:144033
	abnormal immature B cell morphology	J:144033
	abnormal immunoglobulin light chain V-J recombination	J:144033
	abnormal mature B cell morphology	J:144033
Igh^tm1Leck/Igh^tm1Leck (involves: 129P2/OlaHsd * C57BL/6)	decreased B cell number	J:144033
Igh^tm1Mnz/Igh^tm1Mnz (B6.129P2-Igh^tm1Mnz)	abnormal B cell physiology	J:75653
	increased B cell apoptosis	J:75653
	increased B cell proliferation	J:75653
	increased IgG level	J:75653
	increased IgM level	J:75653
Igh^tm1Mnz/Igh^tm1Mnz Dis3^tm1.1Uba/Dis3^tm1.1Uba Aicda^tm1(cre)Uba/Aicda⁺ (involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6)	abnormal somatic hypermutation frequency	J:302856
Igh^tm1Mnz/Igh^tm1Mnz Lyn^tm1Sor/Lyn^tm1Sor (involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6)	abnormal B cell physiology	J:75653
	increased B cell proliferation	J:75653
Igh^tm1Rbr/Igh⁺ (C57BL/6-Igh^tm1Rbr)	abnormal B cell morphology	J:132538
Igh^tm1Rbr/Igh⁺ Tg(IgkHyHEL10)1Rbr/0 (involves: C57BL/6)	abnormal B cell morphology	J:132538
	abnormal B-2 B cell morphology	J:132538
	increased IgA level	J:132538
	increased IgG1 level	J:132538
	increased IgG2a level	J:132538
	increased IgG2b level	J:132538
	increased IgG3 level	J:132538
	increased IgM level	J:132538
	increased immature B cell number	J:132538
	increased immunoglobulin level	J:132538
Igh^tm1Rbr/Igh⁺ Tg(IgkHyHEL10)1Rbr/0 Tg(ML5sHEL)5Ccg/0 (involves: C57BL/6 * C57BL/6JSfd)	abnormal B cell anergy	J:132538
	abnormal B cell morphology	J:132538
	decreased follicular B cell number	J:132538
	decreased marginal zone B cell number	J:132538
	increased immature B cell number	J:132538
Igh^tm2(IGH)Vlcg/Igh^tm2(IGH)Vlcg Igk^tm2(IGK)Vlcg/Igk^tm2(IGK)Vlcg (involves: 129S6/SvEvTac * C57BL/6N)	immune system phenotype	J:208620
Igh^{tm2.1(4E10)Nemz}/Igh^{tm2.1(4E10)Nemz} Igk^{tm2.1(4E10)Nemz}/Igk^{tm2.1(4E10)Nemz} (involves: C57BL/6 * C57BL/6N * C57BL/6NTac * FVB/N)	decreased B cell number	J:101977
	decreased IgG level	J:101977
	decreased IgM level	J:101977
Igh^{tm2.1(Tag)Rwhe}/Igh⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell morphology	J:150315
	enlarged spleen	J:150315
	increased B cell number	J:150315
	lymph node hyperplasia	J:150315
Igh^tm2.1Fwa/Igh^tm2.1Fwa (involves: 129S/SvEv * C57BL/6)	abnormal class switch recombination	J:161437
	abnormal somatic hypermutation frequency	J:161437
	decreased IgG1 level	J:161437
	decreased mature B cell number	J:161437
	immune system phenotype	J:161437
	increased IgE level	J:161437
Igh^tm2.1Hws/Igh^tm2.1Hws (involves: BALB/c * C57BL/6NCrl * DBA/2NCrl)	abnormal humoral immune response	J:124421
	decreased B cell number	J:124421
	decreased B-1a cell number	J:124421
	decreased B-1b cell number	J:124421
	decreased follicular B cell number	J:124421
	decreased IgG level	J:124421
	decreased IgM level	J:124421
	decreased pre-B cell number	J:124421
	decreased transitional stage B cell number	J:124421
	increased early pro-B cell number	J:124421
	increased marginal zone B cell number	J:124421
Igh^tm2.1Hws/Igh^tm2.1Hws (involves: BALB/c)	abnormal B cell differentiation	J:142069
	decreased B-1a cell number	J:142069
	decreased follicular B cell number	J:142069
	decreased IgM level	J:142069
	decreased immature B cell number	J:142069
	decreased late pro-B cell number	J:142069
	decreased mature B cell number	J:142069
	decreased transitional stage B cell number	J:142069
	increased anti-nuclear antigen antibody level	J:142069
	increased early pro-B cell number	J:142069
	increased marginal zone B cell number	J:142069
Igh^tm2Cgn/Igh⁺ (involves: 129P2/OlaHsd * BALB/c * C57BL/Ka)	abnormal B cell differentiation	J:79556
Igh^tm2Cgn/Igh⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal immunoglobulin light chain V-J recombination	J:144033
Igh^tm2Cgn/Igh⁺ Igk^tm1Rsky/Igk⁺ (either: (involves: 129P2/OlaHsd) or (involves: 129P2/OlaHsd * BALB/c))	abnormal B cell differentiation	J:111431
	absent pre-B cells	J:111431
Igh^tm2Cgn/Igh⁺ Igk^tm2Rsky/Igk⁺ (involves: 129P2/OlaHsd)	abnormal class switch recombination	J:150435
Igh^tm2Cgn/Igh⁺ Igk^tm2Rsky/Igk⁺ Prkdc^scid/Prkdc^scid (involves: 129P2/OlaHsd * BALB/c * C57BL/Ka)	abnormal class switch recombination	J:150435
Igh^tm2Cgn/Igh⁺ Rr158^tm1Cgn/Rr158^tm1Cgn Arhgef1^tm1.1Rmt/Arhgef1^tm1.1Rmt (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell migration	J:113295
Igh^tm2Cgn/Igh⁺ Xrcc6^tm1Fwa/Xrcc6^tm1Fwa (involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6)	abnormal B cell differentiation	J:44361
Igh^tm2Cgn/Igh^tm2Cgn Igk^tm1Rsky/Igk^tm1Rsky Lig4^tm1Fwa/Lig4^tm1Fwa Trp53^tm1Tyj/Trp53^tm1Tyj (involves: 129P2/OlaHsd * 129S2/SvPas * 129S6/SvEvTac)	abnormal class switch recombination	J:126758
Igh^tm2Cgn/Igh^tm2Cgn Igk^tm1Rsky/Igk^tm1Rsky Trp53^tm1Tyj/Trp53^tm1Tyj Xrcc4^tm1Fwa/Xrcc4^tm1Fwa (involves: 129P2/OlaHsd * 129S2/SvPas * 129S6/SvEvTac)	abnormal class switch recombination	J:126758
Igh^tm2Cgn/Igh^tm3Cgn (involves: 129P2/OlaHsd * BALB/c * C57BL/6 * C57BL/Ka)	abnormal B cell differentiation	J:79556
Igh^tm2Cgn/Igh^tm4.1Fwa (involves: 129P2/OlaHsd * 129S6/SvEvTac)	abnormal immunoglobulin V(D)J recombination	J:176649
Igh^tm2Emo/Igh^tm2Emo (involves: 129S1/Sv * C57BL/6 * FVB/N)	abnormal B cell differentiation	J:108098
	absent pre-B cells	J:108098
Igh^tm2Mnz/Igh^tm2Mnz (B6.129P2-Igh^tm2Mnz)	increased B cell proliferation	J:75653
	increased IgG level	J:75653
	increased IgM level	J:75653
Igh^tm2Mnz/Igh^tm2Mnz Lyn^tm1Sor/Lyn^tm1Sor (involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6)	abnormal B cell physiology	J:75653
	increased B cell proliferation	J:75653
Igh^tm2Rsky/Igh⁺ Igk^tm1Rsky/Igk⁺ (either: (involves: 129P2/OlaHsd) or (involves: 129P2/OlaHsd * BALB/c))	abnormal B cell differentiation	J:111431
Igh^tm2Rsky/Igh⁺ Igk^tm2Rsky/Igk⁺ (either: (involves: 129P2/OlaHsd) or (involves: 129P2/OlaHsd * BALB/c))	abnormal B cell differentiation	J:111431
Igh^{tm3.1(IGH)Vlcg}/Igh^{tm3.1(IGH)Vlcg} Igk^{tm3.1(IGK)Vlcg}/Igk^{tm3.1(IGK)Vlcg} (involves: 129S6/SvEvTac * C57BL/6N)	immune system phenotype	J:208620
Igh^tm3.1Tim/Igh⁺ (involves: 129 * C57BL/6)	abnormal B cell differentiation	J:102308
Igh^tm3.1Tim/Igh⁺ (involves: 129 * C57BL/6)	abnormal spleen B cell follicle morphology	J:102308
Igh^tm3Cgn/Igh⁺ (involves: C57BL/6)	abnormal B cell differentiation	J:79556, J:115292
Igh^tm3Cgn/Igh^tm3Cgn (involves: C57BL/6)	abnormal immune system physiology	J:76117
Igh^tm3Cgn/Igh^tm3Cgn (involves: C57BL/6)	decreased immature B cell number	J:76117
Igh^tm3Hws/Igh^tm3Hws (BALB/c-Igh^tm3Hws)	abnormal immunoglobulin heavy chain V(D)J recombination	J:142068
Igh^tm3Hws/Igh^tm3Hws (involves: BALB/c)	abnormal immunoglobulin level	J:142069
	decreased B cell number	J:142069
	decreased follicular B cell number	J:142069
	decreased IgG1 level	J:142069
	decreased IgG2a level	J:142069
	decreased IgG2b level	J:142069
	decreased IgM level	J:142069
	decreased immature B cell number	J:142069
	decreased late pro-B cell number	J:142069
	decreased mature B cell number	J:142069
	decreased transitional stage B cell number	J:142069
	increased IgM level	J:142069
	spleen hypoplasia	J:142069
Igh^tm3Mnz/Igh^tm4.1Mnz (involves: C57BL/6)	immune system phenotype	J:159173
Igh^tm3Tim/Igh⁺ (involves: 129 * C57BL/6)	abnormal B cell differentiation	J:102308
Igh^tm3Tim/Igh⁺ (involves: 129 * C57BL/6)	abnormal spleen B cell follicle morphology	J:102308
Igh^tm4.1Cog/Igh^tm4.1Cog (involves: 129P2/OlaHsd * C57BL/6 * FVB/N)	abnormal class switch recombination	J:184094
	decreased IgA level	J:184094
	immune system phenotype	J:184094
	increased IgM level	J:184094
Igh^tm4.1Fwa/Igh⁺ (involves: 129S6/SvEvTac)	abnormal B cell differentiation	J:176649
Igh^tm4.1Fwa/Igh⁺ (involves: 129S6/SvEvTac)	abnormal immunoglobulin V(D)J recombination	J:176649
Igh^tm4.1Fwa/Igh^tm4.1Fwa (involves: 129S6/SvEvTac)	abnormal B cell differentiation	J:176649
Igh^tm4.1Fwa/Igh^tm4.1Fwa (involves: 129S6/SvEvTac)	abnormal immunoglobulin V(D)J recombination	J:176649
Igh^tm4Cgn/Igh⁺ (involves: 129P2/OlaHsd)	abnormal B cell differentiation	J:115292
Igh^tm4Cog/Igh⁺ (involves: 129S2/SvPas * C57BL/6)	decreased IgM level	J:109988
Igh^tm4Cog/Igh⁺ (involves: 129S2/SvPas * C57BL/6)	increased IgA level	J:109988
Igh^tm4Cog/Igh^tm4Cog (involves: 129S2/SvPas * C57BL/6)	absent Peyer's patches	J:109988
	absent spleen germinal center	J:109988
	small spleen	J:109988
Igh^tm5.1Cgn/Igh^tm5.1Cgn (BALB/c-Igh^tm5.1Cgn)	abnormal B cell activation	J:88472
	abnormal B cell differentiation	J:88472
	abnormal gut-associated lymphoid tissue morphology	J:88472
	abnormal lymph node germinal center morphology	J:88472
	abnormal mature B cell morphology	J:88472
	abnormal Peyer's patch germinal center morphology	J:88472
	absent B-1 B cells	J:88472
	absent B-1a cells	J:88472
	absent B-1b cells	J:88472
	absent spleen germinal center	J:88472
	decreased B cell number	J:88472
	decreased immature B cell number	J:88472
	decreased marginal zone B cell number	J:88472
	increased pro-B cell number	J:88472
Igh^tm5.1Fwa/Igh⁺ (involves: 129S6/SvEvTac)	abnormal B cell differentiation	J:176649
	decreased pre-B cell number	J:176649
	immune system phenotype	J:176649
Igh^tm5.1Fwa/Igh^tm5.1Fwa (involves: 129S6/SvEvTac)	abnormal B cell differentiation	J:176649
	decreased pre-B cell number	J:176649
	immune system phenotype	J:176649
Igh^tm5Cgn/Igh^tm5Cgn (involves: BALB/c)	absent B cells	J:88472
Igh^tm5Cgn/Igh^tm5Cgn (involves: BALB/c)	arrested B cell differentiation	J:88472
Igh^tm5Cgn/Igh^tm5Cgn Tg(CD19-cre/ERT2)1Cgn/0 (C.Cg-Igh^tm5Cgn Tg(CD19-cre/ERT2)1Cgn)	abnormal B cell differentiation	J:88472
	abnormal mature B cell morphology	J:88472
	abnormal Peyer's patch germinal center morphology	J:88472
	absent follicular B cells	J:88472
	absent marginal zone B cells	J:88472
	increased B cell number	J:88472
	increased pro-B cell number	J:88472
Igh^tm6Fwa/Igh^tm6Fwa (Not Specified)	immune system phenotype	J:176649
Igh^{tm7(VHB1-8)Cgn}/Igh⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal somatic hypermutation frequency	J:48835
Igh^tm7.1Fwa/Igh^tm7.1Fwa (Not Specified)	immune system phenotype	J:176649
Igh^{tm8(VHB1-8)Cgn}/Igh⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal somatic hypermutation frequency	J:48835
Igh^{tm9(VHB1-8)Cgn}/Igh⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal somatic hypermutation frequency	J:48835
Igh^tm11.1Cgn/Igh^tm11.1Cgn (Not Specified)	abnormal B cell differentiation	J:113434
	decreased B cell number	J:113434
	decreased immature B cell number	J:113434
	decreased mature B cell number	J:113434
	increased pro-B cell number	J:113434
Igh^tm12Cgn/Igh^tm12Cgn (involves: 129P2/OlaHsd)	abnormal somatic hypermutation frequency	J:66031
Igha^tm1(Myc)Janz/Igha⁺ (involves: 129S1/Sv * C57BL/6)	increased B cell apoptosis	J:90901
	increased B cell proliferation	J:90901
	increased plasma cell number	J:90901
Igha^tm1(Myc)Janz/Igha⁺ Tg(Igk-V21-Bax)1967Bvn/0 (involves: 129S1/Sv * C57BL/6 * FVB/N)	abnormal B cell apoptosis	J:90901
	abnormal plasma cell morphology	J:90901
	enlarged spleen	J:90901
	increased IgG level	J:90901
	increased IgM level	J:90901
	increased plasma cell number	J:90901
Igha^tm1(Myc)Janz/Igha⁺ Tg(Tnfsf13b)1Fma/0 (involves: 129S1/Sv * C57BL/6 * DBA/2J)	enlarged spleen	J:166158
	increased B cell number	J:166158
	increased lymphocyte cell number	J:166158
	increased mature B cell number	J:166158
	increased spleen white pulp amount	J:166158
Igha^tm1Grh/Igha^tm1Grh (involves: 129S7/SvEvBrd * C57BL/6)	abnormal dendritic cell physiology	J:125472
	abnormal immunoglobulin level	J:125472
	abnormal memory T cell physiology	J:125472
	abnormal T cell activation	J:53217
	decreased IgA level	J:53217, J:125472
	decreased IgE level	J:53217
	decreased IgG3 level	J:53217
	decreased interferon-gamma secretion	J:53217
	decreased T cell proliferation	J:125472
	immune system phenotype	J:53218
	increased IgG1 level	J:53217, J:125472
	increased IgG2a level	J:53217
	increased IgG2b level	J:53217
	increased IgG level	J:53217
	increased IgM level	J:53217, J:125472
	increased interferon-gamma secretion	J:125472
	increased interleukin-4 secretion	J:53217
	increased susceptibility to Orthomyxoviridae infection	J:125472
Igha^tm1Grh/Igha^tm1Grh (involves: 129 * C57BL/6)	increased susceptibility to parasitic infection	J:140515, J:74568
Igha^tm1Grh/Igha^tm1Grh Tg(Tnfsf13b)1Fma/Tg(Tnfsf13b)1Fma (involves: 129S7/SvEvBrd * C57BL/6 * DBA/2)	immune system phenotype	J:178227
Igha^tm2Grh/Igha^tm2Grh (involves: 129S7/SvEvBrd * C57BL/6)	abnormal class switch recombination	J:72521
Ighd^dmit/Ighd^dmit (C57BL/6JAnu-Ighd^dmit/AnuApb)	abnormal immunoglobulin level	J:104190
Ighd^M1Btlr/Ighd⁺ (C57BL/6J-Ighd^M1Btlr)	decreased B cell number	J:255202
Ighd^M1Btlr/Ighd^M1Btlr (C57BL/6J-Ighd^M1Btlr)	decreased B cell number	J:255202
Ighd^M1Btlr/Ighd^M1Btlr (C57BL/6J-Ighd^M1Btlr)	decreased IgD level	J:255202
Ighd^m2Btlr/Ighd⁺ (C57BL/6J-Ighd^m2Btlr)	decreased B cell number	J:255203
Ighd^m2Btlr/Ighd^m2Btlr (C57BL/6J-Ighd^m2Btlr)	decreased B cell number	J:255203
Ighd^m2Btlr/Ighd^m2Btlr (C57BL/6J-Ighd^m2Btlr)	decreased IgD level	J:255203
Ighd^tm1Cgn/Ighd^tm1Cgn (involves: 129P2/OlaHsd * C57BL/6)	abnormal immune system physiology	J:64281
Ighd^tm1Cgn/Ighd^tm1Cgn (involves: 129P2/OlaHsd * C57BL/6)	decreased IgE level	J:64281
Ighd^tm1Lam/Ighd⁺ (involves: 129S2/SvPas * C57BL/6)	decreased B cell number	J:111020
Ighd^tm1Lam/Ighd^tm1Lam (involves: 129S2/SvPas * C57BL/6)	abnormal B cell physiology	J:111020
	abnormal leukopoiesis	J:111020
	decreased IgG2b level	J:111020
	increased IgA level	J:111020
Ighe^M1Btlr/Ighe^M1Btlr (C57BL/6J-Ighe^M1Btlr)	decreased IgE level	J:267480
Ighg1^em1Wliu/Ighg1^em1Wliu (C57BL/6-Ighg1^em1Wliu)	abnormal plasma cell differentiation	J:266937
	enhanced humoral immune response	J:266937
	increased anti-double stranded DNA antibody level	J:266937
	increased anti-nuclear antigen antibody level	J:266937
	increased autoantibody level	J:266937
	increased germinal center B cell number	J:266937
	increased IgG1 level	J:266937
	increased plasma cell number	J:266937
Ighg1^tm1(cre)Cgn/0 Mef2b^tm1.1Rdf/Mef2b⁺ (involves: 129P2/OlaHsd * C57BL/6)	decreased germinal center B cell number	J:265465
Ighg1^tm1(cre)Cgn/0 Mef2b^tm1.1Rdf/Mef2b^tm1.1Rdf (involves: 129P2/OlaHsd * C57BL/6)	abnormal mature B cell morphology	J:265465
	decreased germinal center B cell number	J:265465
Ighg1^tm1(cre)Cgn/0 Mef2b^tm1.1Rdf/Mef2b^tm1.1Rdf Mef2c^tm2Eno/Mef2c^tm2Eno (involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6)	decreased germinal center B cell number	J:265465
Ighg1^tm1(cre)Cgn/0 Mef2b^tm2Rdf/Mef2b⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal mature B cell morphology	J:265465
	increased germinal center B cell number	J:265465
Ighg1^tm1(cre)Cgn/0 Mef2b^tm2Rdf/Mef2b^tm1.1Rdf (involves: 129P2/OlaHsd * C57BL/6)	abnormal mature B cell morphology	J:265465
	increased germinal center B cell number	J:265465
Ighg1^tm1(cre)Cgn/0 Mef2c^tm2Eno/Mef2c^tm2Eno (involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6)	decreased germinal center B cell number	J:265465
Ighg1^tm1(cre)Cgn/Ighg1⁺ Irf4^tm1Rdf/Irf4^tm1.1Rdf (involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6)	abnormal class switch recombination	J:112643
	abnormal memory B cell morphology	J:112643
	absent plasma cells	J:112643
	decreased IgG1 level	J:112643
	immune system phenotype	J:112643
Ighg1^tm1(cre)Cgn/Ighg1⁺ Myd88^em1.1Rsky/Myd88⁺ (involves: 129P2/OlaHsd * C57BL/6NTac)	abnormal somatic hypermutation frequency	J:308792
	abnormal splenic cell ratio	J:308792
	increased germinal center B cell number	J:308792
	increased IgM level	J:308792
	increased plasma cell number	J:308792
Ighg1^tm1(cre)Cgn/Ighg1⁺ Tbl1xr1^tm1.1Meln/Tbl1xr1⁺ (involves: 129P2/OlaHsd * C57BL/6J)	abnormal B cell differentiation	J:292118
	abnormal spleen morphology	J:292118
Ighg1^tm1(cre)Cgn/Ighg1⁺ Tbl1xr1^{tm1c(EUCOMM)Hmgu}/Tbl1xr1^{tm1c(EUCOMM)Hmgu} (involves: 129P2/OlaHsd * C57BL/6J)	abnormal B cell differentiation	J:292118
	abnormal spleen morphology	J:292118
Ighg1^tm1.1Ksho/Ighg1⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell physiology	J:39568
Ighg1^tm1.1Ksho/Ighg1⁺ (involves: 129P2/OlaHsd * C57BL/6)	decreased IgG1 level	J:39568
Ighg1^tm1.1Ksho/Ighg1^tm1.1Ksho (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell physiology	J:39568
	decreased IgG1 level	J:39568
Ighg1^tm1.1Pyu/Ighg1⁺ (B6.C(Cg)-Ighg1^tm1.1Pyu)	decreased IgG1 level	J:198154
	decreased IgG2c level	J:198154
	immune system phenotype	J:198154
	increased IgE level	J:198154
	increased IgG2a level	J:198154
	increased susceptibility to type I hypersensitivity reaction	J:198154
Ighg1^tm1.1Pyu/Ighg1^tm1.1Pyu (B6.C(Cg)-Ighg1^tm1.1Pyu)	decreased IgG1 level	J:198154
	decreased IgG2c level	J:198154
	immune system phenotype	J:198154
	increased IgE level	J:198154
	increased IgG2a level	J:198154
	increased IgG2b level	J:198154
	increased susceptibility to type I hypersensitivity reaction	J:198154
Ighg1^tm1Ksho/Ighg1⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell physiology	J:39568
Ighg1^tm1Ksho/Ighg1⁺ (involves: 129P2/OlaHsd * C57BL/6)	decreased IgG1 level	J:39568
Ighg1^tm1Ksho/Ighg1^tm1Ksho (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell physiology	J:39568
	absent memory B cells	J:39568
	decreased IgG1 level	J:39568
Ighg1^tm2Cgn/Ighg1⁺ ((C57BL/6 x 129P2/OlaHsd)F1)	abnormal class switch recombination	J:146428
Ighg1^tm2Cgn/Ighg1⁺ ((C57BL/6 x 129P2/OlaHsd)F1)	decreased IgG1 level	J:146428
Ighg1^tm3Cgn/Ighg1⁺ (involves: 129P2/OlaHsd * BALB/c * C57BL/6)	abnormal class switch recombination	J:166887
	decreased IgG1 level	J:166887
Ighg1^tm4Cgn/Ighg1^tm4Cgn (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:166887
Ighg2c^em1Wliu/Ighg2c^em1Wliu (C57BL/6J-Ighg2c^em1Wliu)	abnormal dendritic cell physiology	J:322180
	abnormal macrophage activation involved in immune response	J:322180
	abnormal macrophage physiology	J:322180
	abnormal plasma cell differentiation	J:322180
	decreased susceptibility to induced colitis	J:322180
	increased CD8-positive, alpha-beta T cell number	J:322180
	increased CD103-positive CD11b-low dendritic cell number	J:322180
	increased effector memory CD8-positive, alpha-beta T cell number	J:322180
	increased germinal center B cell number	J:322180
	increased IgG2c level	J:322180
	increased memory B cell number	J:322180
Ighg2c^em2Wliu/Ighg2c^em2Wliu (C57BL/6J-Ighg2c^em2Wliu)	abnormal macrophage activation involved in immune response	J:322180
	abnormal plasma cell differentiation	J:322180
	decreased germinal center B cell number	J:322180
	decreased IgG2c level	J:322180
	decreased memory B cell number	J:322180
	impaired macrophage phagocytosis	J:322180
Ighm^tm1(Bcl6)Rdf/? (involves: 129/Sv * C57BL/6)	abnormal B cell proliferation	J:98937
	abnormal spleen B cell follicle morphology	J:98937
	abnormal spleen morphology	J:98937
	decreased immunoglobulin level	J:98937
	decreased plasma cell number	J:98937
	enlarged spleen	J:98937
	increased spleen germinal center number	J:98937
	increased spleen white pulp amount	J:98937
Ighm^{tm1.1(IGH-2)Cog}/Ighm^{tm1.1(IGH-2)Cog} (involves: 129P2/OlaHsd * C57BL/6 * FVB/N)	abnormal B cell differentiation	J:157575
	abnormal plasma cell differentiation	J:157575
	decreased B cell number	J:157575
	decreased B cell proliferation	J:157575
	decreased B-1 B cell number	J:157575
	decreased follicular B cell number	J:157575
	decreased IgA level	J:157575
	decreased IgG1 level	J:157575
	decreased IgG2a level	J:157575
	decreased IgG3 level	J:157575
	decreased IgG level	J:157575
	decreased IgM level	J:157575
	decreased marginal zone B cell number	J:157575
	decreased mature B cell number	J:157575
	decreased Peyer's patch number	J:157575
	decreased pre-B cell number	J:157575
	decreased transitional stage B cell number	J:157575
	immune system phenotype	J:157575
	increased B cell number	J:157575
	increased B cell proliferation	J:157575
	increased plasma cell number	J:157575
	increased pro-B cell number	J:157575
	small lymph nodes	J:157575
	small Peyer's patches	J:157575
Ighm^tm1.1Aak/Ighm^tm1.1Aak (involves: 129S2/SvPas * C57BL/6)	abnormal class switch recombination	J:171251
	decreased B cell number	J:171251
	decreased pre-B cell number	J:171251
	immune system phenotype	J:171251
	increased pro-B cell number	J:171251
Ighm^tm1Bhe/Ighm^tm1Bhe (C.Cg-Ighm^tm1Bhe)	abnormal complement pathway	J:177421
	abnormal immune serum protein physiology	J:177421
	impaired complement classical pathway	J:177421
Ighm^tm1Cgn/Igh^tm3Tim (involves: 129 * C57BL/6)	abnormal B cell differentiation	J:102308
Ighm^tm1Cgn/Igh^tm3Tim (involves: 129 * C57BL/6)	decreased B cell number	J:102308
Ighm^tm1Cgn/Ighm⁺ (NOD.129S2-Ighm^tm1Cgn)	increased susceptibility to autoimmune diabetes	J:37287
Ighm^tm1Cgn/Ighm⁺ (involves: 129S2/SvPas * C57BL/6)	arrested B cell differentiation	J:70398
Ighm^tm1Cgn/Ighm⁺ Tg(Igh-6/Igh-V125)2Jwt/0 Tg(Igk-C/Igk-V125)1Jwt/0 (NOD.Cg-Ighm^tm1Cgn Tg(Igh-6/Igh-V125)2Jwt Tg(Igk-C/Igk-V125)1Jwt)	increased susceptibility to autoimmune diabetes	J:91865
	insulitis	J:91865
Ighm^tm1Cgn/Ighm⁺ Tg(Igh-6/Igh-V281)3Jwt/0 (NOD.Cg-Ighm^tm1Cgn Tg(Igh-6/Igh-V281)3Jwt)	insulitis	J:91865
Ighm^tm1Cgn/Ighm⁺ Tgfb1^tm1Doe/Tgfb1^tm1Doe (involves: 129S2/SvPas * C57BL/6 * CF-1)	thymus hypoplasia	J:99033
Ighm^tm1Cgn/Ighm^tm1Cgn (involves: 129S2/SvPas * C57BL/6)	abnormal B cell differentiation	J:64298, J:70398
	abnormal lymphatic vessel morphology	J:119344
	abnormal response to infection	J:119344
	absent immature B cells	J:64298
	absent mature B cells	J:64298
	arrested B cell differentiation	J:64298
	decreased IgM level	J:64298
	immune system phenotype	J:113083
Ighm^tm1Cgn/Ighm^tm1Cgn (NODCaj.129S2-Ighm^tm1Cgn)	insulitis	J:93190
Ighm^tm1Cgn/Ighm^tm1Cgn (NOD.129S2-Ighm^tm1Cgn)	decreased susceptibility to autoimmune diabetes	J:37287
Ighm^tm1Cgn/Ighm^tm1Cgn (B6.129S2-Ighm^tm1Cgn/J)	abnormal cytokine secretion	J:118565
	abnormal humoral immune response	J:119584
	abnormal spleen morphology	J:73100
	arrested B cell differentiation	J:119584
	decreased CD4-positive, alpha-beta T cell number	J:73100, J:118565
	decreased CD8-positive, alpha-beta T cell number	J:73100
	decreased dendritic cell number	J:73100
	decreased IgE level	J:125656
	decreased IgG1 level	J:125656
	decreased IgG level	J:119584, J:125656
	decreased immunoglobulin level	J:119584
	decreased spleen weight	J:73100
	immune system phenotype	J:73100, J:118565
	increased susceptibility to parasitic infection	J:74568
Ighm^tm1Cgn/Ighm^tm1Cgn (involves: 129S2/SvPas)	abnormal antigen presentation	J:112160
	abnormal CD4-positive, alpha-beta T cell physiology	J:112160
	abnormal metallophilic macrophage morphology	J:88620
	abnormal spleen marginal sinus morphology	J:88620
	abnormal spleen marginal zone macrophage morphology	J:88620
	absent follicular dendritic cells	J:88620
	absent mature B cells	J:118453
	arrested B cell differentiation	J:118453
	decreased IgA level	J:157450
	decreased IgG level	J:157450
	decreased susceptibility to type IV hypersensitivity reaction	J:112160
	decreased T cell proliferation	J:112160
	increased osteoclast cell number	J:157619
	increased susceptibility to induced arthritis	J:157619
	increased susceptibility to parasitic infection	J:163761
Ighm^tm1Cgn/Ighm^tm1Cgn (B6.129S2-Ighm^tm1Cgn)	abnormal CD8 positive, alpha-beta intraepithelial T cell morphology	J:126867
Ighm^tm1Cgn/Ighm^tm1Cgn (NOD.129S2-Ighm^tm1Cgn/DvsJ)	abnormal T cell number	J:80859
	abnormal T cell proliferation	J:80859
	absent B cells	J:80859
	decreased spleen B cell follicle number	J:80859
	decreased susceptibility to autoimmune diabetes	J:80859
Ighm^tm1Cgn/Ighm^tm1Cgn Igkc^tm1Bgmn/Igkc^tm1Bgmn Igl^tm2.1Bgmn/Igl^tm2.1Bgmn (involves: 129)	decreased IgG level	J:130864
	decreased IgM level	J:130864
Ighm^tm1Cgn/Ighm^tm1Cgn Nlrp1a^Neut1/Nlrp1a^Neut1 (involves: 129S2/SvPas * C57BL/6)	immune system phenotype	J:191055
Ighm^tm1Cgn/Ighm^tm1Cgn Tg(Igh-6/Igh-V125)2Jwt/0 Tg(Igk-C/Igk-V125)1Jwt/0 (NOD.Cg-Ighm^tm1Cgn Tg(Igh-6/Igh-V125)2Jwt Tg(Igk-C/Igk-V125)1Jwt)	insulitis	J:91865
Ighm^tm1Cgn/Ighm^tm1Cgn Tg(Igh-6/Igh-V281)3Jwt/0 (NOD.Cg-Ighm^tm1Cgn Tg(Igh-6/Igh-V281)3Jwt)	insulitis	J:91865
Ighm^tm1Cgn/Ighm^tm1Cgn Tg(Igh-VB1-8/Igh-6m)1Mjsk/? (NODCaj.Cg-Ighm^tm1Cgn Tg(Igh-VB1-8/Igh-6m)1Mjsk/FswJ)	increased susceptibility to autoimmune diabetes	J:93190
Ighm^tm1Cgn/Ighm^tm1Cgn Tg(IghelMD4)4Ccg/Tg(IghelMD4)4Ccg (NOD.Cg-Ighm^tm1Cgn Tg(IghelMD4)4Ccg/DvsJ)	abnormal B lymphocyte antigen presentation	J:80859
	abnormal mature B cell morphology	J:80859
	abnormal T cell proliferation	J:80859
	decreased CD8-positive, alpha-beta T cell number	J:80859
	decreased susceptibility to autoimmune diabetes	J:80859
	insulitis	J:80859
Ighm^tm1Cgn/Ighm^tm1Cgn Tg(TcraR28,TcrbR28)KRNDim/0 (involves: 129S2/SvPas * C57BL/6 * NOD * SJL)	immune system phenotype	J:36815
Ighm^tm1Cgn/Ighm^tm1Cgn Tgfb1^tm1Doe/Tgfb1^tm1Doe (involves: 129S2/SvPas * C57BL/6 * CF-1)	abnormal inflammatory response	J:99033
	thymus hypoplasia	J:99033
Ighm^tm1Cgn/Ighm^tm1Cgn Tnf^tm2Gkl/Tnf⁺ (involves: 129S/SvEv * 129S2/SvPas * C57BL/6J)	small intestinal inflammation	J:108572
Ighm^tm1Cgn/Ighm^tm1Cgn Trex1^tm1Tld/Trex1^tm1Tld (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)	increased inflammatory response	J:181257
	kidney inflammation	J:181257
	myocarditis	J:181257
	tubular nephritis	J:181257
Ighm^tm1Cgn/Ighm^tm1Cgn X/Yaa (BXSB.129S2(B6)-Ighm^tm1Cgn/Dcr)	decreased susceptibility to systemic lupus erythematosus	J:206236
Ighm^tm1Che/Ighm^tm1Che (involves: 129S4/SvJae * C57BL/6)	abnormal B cell physiology	J:47425
	abnormal follicular dendritic cell antigen presentation	J:47425
	abnormal humoral immune response	J:47425
	abnormal immune system physiology	J:47425
	abnormal metallophilic macrophage morphology	J:125338
	abnormal spleen B cell follicle morphology	J:125338
	abnormal spleen germinal center morphology	J:47425
	abnormal spleen marginal zone morphology	J:125338
	abnormal spleen morphology	J:125338
	abnormal spleen periarteriolar lymphoid sheath morphology	J:125338
	abnormal spleen white pulp morphology	J:125338
	decreased IgG1 level	J:47425
	decreased IgG2b level	J:47425
	decreased IgM level	J:47425
	increased B-1 B cell number	J:47425
	increased IgA level	J:47425
	increased IgG2a level	J:47425
	increased IgG3 level	J:47425
Ighm^tm1Che/Ighm^tm1Che (involves: 129 * C57BL/6)	increased susceptibility to parasitic infection	J:74568
Ighm^tm1Fbb/Ighm^tm1Fbb (involves: BALB/cJ)	immune system phenotype	J:57600
Ighm^tm1Fbb/Ighm^tm1Fbb (involves: BALB/cJ)	increased susceptibility to Riboviria infection	J:57600
Ighm^tm1Msn/Ighm⁺ (involves: 129S/SvEv)	decreased IgM level	J:49405
Ighm^tm1Msn/Ighm^tm1Msn (involves: 129S/SvEv)	abnormal B-1a B cell morphology	J:49405
	abnormal immature B cell morphology	J:49405
	abnormal mature B cell morphology	J:49405
	decreased IgG1 level	J:49405
	decreased IgM level	J:49405
	increased IgG3 level	J:49405
Ighm^tm1Msn/Ighm^tm1Msn (involves: 129S/SvEv * C57BL/6)	increased anti-double stranded DNA antibody level	J:111817
	increased autoantibody level	J:111817
	kidney inflammation	J:111817
Ighm^tm1Msn/Ighm^tm1Msn (B6.129S-Ighm^tm1Msn)	abnormal B-1a B cell morphology	J:80656
	abnormal splenic cell ratio	J:80656
	decreased follicular B cell number	J:80656
	decreased IgM level	J:80656
	increased marginal zone B cell number	J:80656
Ighm^tm1Msn/Ighm^tm1Msn Tg(Igh-6)1Msn/? (B6.129S-Ighm^tm1Msn)	abnormal B-1a B cell morphology	J:80656
	abnormal splenic cell ratio	J:80656
	decreased follicular B cell number	J:80656
	decreased IgM level	J:80656
	increased marginal zone B cell number	J:80656
Ighm^tm1Sls/Ighm^tm1Sls (Not Specified)	abnormal class switch recombination	J:99465
	decreased IgG1 level	J:99465
	decreased IgG2b level	J:99465
	decreased IgG3 level	J:99465
	decreased IgG level	J:99465
	increased IgM level	J:99465
Ighm^tm2.1Bgmn/Ighm^tm2.1Bgmn (involves: 129/Sv * C57BL/6 * CBA)	abnormal immune system physiology	J:118453
	absent mature B cells	J:118453
	arrested B cell differentiation	J:118453
	decreased immunoglobulin level	J:118453
Ighm^tm3Bgmn/Ighm^tm3Bgmn (involves: 129)	abnormal B cell activation	J:131633
	decreased B cell proliferation	J:131633
	decreased IgM level	J:131633
	decreased immature B cell number	J:131633
	decreased mature B cell number	J:131633
	increased B-1 B cell number	J:131633
Ighm^tm3Bgmn/Ighm^tm3Bgmn Igkc^tm1Bgmn/Igkc^tm1Bgmn Igl^tm2.1Bgmn/Igl^tm2.1Bgmn (involves: 129P2/OlaHsd * 129/Sv)	abnormal B cell differentiation	J:130864
	decreased IgG level	J:130864
	decreased IgM level	J:130864
Ighm^tm4Bgmn/Ighm^tm4Bgmn (involves: 129)	abnormal B cell activation	J:131633
	decreased B cell proliferation	J:131633
	decreased IgM level	J:131633
	decreased immature B cell number	J:131633
	decreased mature B cell number	J:131633
	increased B-1 B cell number	J:131633
Igk-J^tm1.1Lave/Igk-J^tm1.1Lave (Not Specified)	immune system phenotype	J:179317
Igk-J^tm1Cog/Igk-J^tm1.1Cog (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell number	J:110100
	abnormal plasma cell morphology	J:110100
	decreased B cell number	J:110100
	decreased naive B cell number	J:110100
	immune system phenotype	J:110100
	increased plasma cell number	J:110100
	increased pre-B cell number	J:110100
Igk-J^tm1Cog/Igk-J^tm1Cog (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell physiology	J:110100
	decreased B cell number	J:110100
Igk-J^tm1Mwg/Igk^tm1Dhu (involves: 129S7/SvEvBrd * C57BL/6)	immune system phenotype	J:76116
Igk-J^tm2Mwg/Igk^tm1Dhu (involves: 129P2/OlaHsd * 129S7/SvEvBrd)	immune system phenotype	J:76116
Igk^{tm1.1(b12)Nemz}/Igk^{tm1.1(b12)Nemz} (involves: C57BL/6NTac * FVB/N)	immune system phenotype	J:205766
Igk^tm1Dhu/Igk^tm1Dhu Iglc1^tm1.1Ust/Iglc1⁺ (involves: 129S7/SvEvBrd * C57BL/6 * FVB/N)	decreased B cell number	J:68144
Igk^tm1Dhu/Igk^tm1Dhu Iglc1^tm1.1Ust/Iglc1^tm1.1Ust (involves: 129S7/SvEvBrd * C57BL/6 * FVB/N)	decreased B cell number	J:68144
Igk^tm1Dhu/Igk^tm1Dhu Iglc1^tm1Ust/Iglc1⁺ (involves: 129S7/SvEvBrd * C57BL/6)	abnormal B cell differentiation	J:68144
	increased B cell number	J:68144
Igk^tm1Dhu/Igk^tm1Dhu Iglc1^tm1Ust/Iglc1^tm1Ust (involves: 129S7/SvEvBrd * C57BL/6)	increased B cell number	J:68144
Igk^tm1Dhu/Igk^tm1Dhu Iglc1^tm2Ust/Iglc1^tm2Ust (involves: 129S7/SvEvBrd * C57BL/6J)	abnormal B cell differentiation	J:74717
	decreased B cell number	J:74717
	decreased immature B cell number	J:74717
	decreased marginal zone B cell number	J:74717
	decreased mature B cell number	J:74717
	decreased transitional stage T1 B cell number	J:74717
	decreased transitional stage T2 B cell number	J:74717
Igk^tm1Dhu/Igk^tm1Dhu Iglc1^tm2Ust/Iglc1^tm2Ust (involves: 129S7/SvEvBrd)	increased B-1a cell number	J:113218
Igk^tm1Dhu/Igk^tm1Dhu Tg(H2-Ea-HA)HACIIAjca/0 Tg(Tcra/Tcrb)1Vbo/0 (C.Cg-Igk^tm1Dhu Tg(H2-Ea-HA)HACIIAjca Tg(Tcra/Tcrb)1Vbo)	autoimmune arthritis	J:209872
Igk^tm1Dhu/Igk^tm1Dhu Tg(H2-Ea-HA)HACIIAjca/0 Tg(TcraS106-1,TcrbS106-1)TS1SWAjca/0 (C.Cg-Igk^tm1Dhu Tg(H2-Ea-HA)HACIIAjca Tg(TcraS106-1,TcrbS106-1)TS1SWAjca)	abnormal CD4-positive, alpha beta T cell morphology	J:209872
	abnormal lymph node morphology	J:209872
	abnormal spleen morphology	J:209872
	absent B cells	J:209872
	decreased susceptibility to autoimmune disorder	J:209872
	increased CD4-positive, alpha-beta T cell number	J:209872
Igk^tm1Rsky/Igk⁺ Igll1^tm1Cgn/Igll1^tm1Cgn (involves: 129P2/OlaHsd * 129S2/SvPas * BALB/c * C57BL/6)	abnormal B cell differentiation	J:35357
	decreased B cell number	J:35357
	decreased immature B cell number	J:35357
	decreased mature B cell number	J:35357
	decreased pre-B cell number	J:35357
Igk^tm2Ybgn/Igk^tm2Ybgn (Not Specified)	decreased pre-B cell number	J:123344
Igk^tm2Ybgn/Igk^tm2Ybgn (Not Specified)	increased immature B cell number	J:123344
Igkc^tm1(IGKC)Mnz/Igkc⁺ Igk-J^tm1(CD4*)Mss/Igk-J⁺ (involves: 129S4/SvJae)	abnormal immunoglobulin light chain V-J recombination	J:143876
Igkc^tm1(IGKC)Mnz/Igkc⁺ Rr158^tm1(Igh)Xu/Rr158⁺ (Not Specified)	abnormal immune system morphology	J:124407
	decreased B cell number	J:124407
Igkc^tm1(IGKC)Mnz/Rr166^tm4.1Wtg (involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6)	abnormal B cell physiology	J:193015
	abnormal immunoglobulin level	J:193015
Igkc^tm1Bgmn/Igkc^tm1Bgmn (involves: 129P2/OlaHsd)	abnormal B cell number	J:28868, J:118712
	abnormal humoral immune response	J:28868
	abnormal Peyer's patch germinal center morphology	J:28868
	abnormal Peyer's patch morphology	J:28868
Igkc^tm1Bgmn/Igkc^tm1Bgmn Igl^tm1.1Bgmn/Igl^tm1.1Bgmn (involves: 129P2/OlaHsd * BALB/c * C57BL/6 * CBA)	abnormal immature B cell morphology	J:118712
	absent B cells	J:118712
	absent B-1 B cells	J:118712
	absent B-2 B cells	J:118712
	decreased B cell number	J:118712
	spleen hypoplasia	J:118712
Igkc^tm1Bgmn/Igkc^tm1Bgmn Igl^tm1Bgmn/Igl^tm1Bgmn (involves: 129P2/OlaHsd * BALB/c * C57BL/6 * CBA)	abnormal immature B cell morphology	J:118712
	absent B-1 B cells	J:118712
	absent B-2 B cells	J:118712
	absent mature B cells	J:118712
	decreased B cell number	J:118712
	spleen hypoplasia	J:118712
Igkc^tm1Bgmn/Igkc^tm1Bgmn Igl^tm2.1Bgmn/Igl^tm2.1Bgmn (involves: 129P2/OlaHsd * BALB/c * C57BL/6 * CBA)	absent B cells	J:118712
	arrested B cell differentiation	J:118712
Igkc^tm1Bgmn/Igkc^tm1Bgmn Igl^tm2.1Bgmn/Igl^tm2.1Bgmn (involves: 129P2/OlaHsd)	abnormal B cell differentiation	J:130864
	abnormal immunoglobulin heavy chain V(D)J recombination	J:130864
	abnormal plasma cell morphology	J:130864
	decreased IgG level	J:130864
	decreased IgM level	J:130864
Igkc^tm1Bgmn/Igkc^tm1Bgmn Igl^tm2Bgmn/Igl^tm2Bgmn (involves: 129P2/OlaHsd * BALB/c * C57BL/6 * CBA)	absent B cells	J:118712
	arrested B cell differentiation	J:118712
Igkc^tm1Cgn/Igkc⁺ (involves: C57BL/6)	increased mature B cell number	J:64287
Igkc^tm1Cgn/Igkc^tm1Cgn (involves: C57BL/6)	abnormal B cell differentiation	J:64287
	decreased mature B cell number	J:64287
	increased immature B cell number	J:64287
	increased mature B cell number	J:64287
	spleen hypoplasia	J:64287
Igkc^tm1Jkbv/Igkc^tm1Jkbv (Not Specified)	abnormal B cell differentiation	J:137738
	abnormal immunoglobulin level	J:137738
	abnormal immunoglobulin light chain V-J recombination	J:137738
	decreased immature B cell number	J:137738
	decreased mature B cell number	J:137738
	increased pre-B cell number	J:137738
Igkc^tm1Jkbv/Igkc^tm1Jkbv Tg(IGK@yK1)9.2CJkbv/0 (involves: 129P2/OlaHsd)	abnormal immunoglobulin level	J:137738
	decreased immature B cell number	J:137738
	decreased mature B cell number	J:137738
	increased pre-B cell number	J:137738
Igkc^tm1Jkbv/Igkc^tm1Jkbv Tg(IGK@yK1)9.2CJkbv/Tg(IGK@yK1)9.2CJkbv (involves: 129P2/OlaHsd)	abnormal B cell differentiation	J:137738
	abnormal immunoglobulin level	J:137738
	decreased immature B cell number	J:137738
	decreased mature B cell number	J:137738
	increased pre-B cell number	J:137738
Igkc^tm1Jkbv/Igkc^tm1Jkbv Tg(IGK@yK2)J23.1Jkbv/0 (involves: 129P2/OlaHsd)	abnormal B cell morphology	J:137738
	abnormal immunoglobulin level	J:137738
	immune system phenotype	J:137738
Igkc^tm1Jkbv/Igkc^tm1Jkbv Tg(IGK@yK2)J23.1Jkbv/Tg(IGK@yK2)J23.1Jkbv (involves: 129P2/OlaHsd)	abnormal B cell morphology	J:137738
	immune system phenotype	J:137738
Igkc^tm2(IGKC)Cgn/Igkc^tm2(IGKC)Cgn (involves: 129P2/OlaHsd)	abnormal B cell differentiation	J:113008
	immune system phenotype	J:113008
Igkc^tm2(IGKC)Cgn/Igkc^tm2(IGKC)Cgn Ighg1^{tm1(IGHG1)Rsky}/Ighg1^{tm1(IGHG1)Rsky} (involves: 129P2/OlaHsd)	immune system phenotype	J:127217
Igkrs^tm1Nemz/Igkrs^tm1Nemz (B6.129-Igkrs^tm1Nemz)	abnormal immunoglobulin light chain V-J recombination	J:132125
	decreased immature B cell number	J:132125
	decreased mature B cell number	J:132125
Igkrs^tm1Nemz/Igkrs^tm1Nemz Tg(BCL2)22Wehi/? (involves: 129 * C57BL)	increased anti-double stranded DNA antibody level	J:132125
Igkrs^tm1Nemz/Igkrs^tm1Nemz Tg(UBC-scFv)2Nemz/? (involves: 129 * C57BL/6 * DBA/2)	abnormal B cell clonal deletion	J:132125
	decreased immature B cell number	J:132125
	decreased mature B cell number	J:132125
Igl^tm1Cgn/Igl^tm1Cgn (involves: C57BL/6)	immune system phenotype	J:83289
Iglc1^tm1Ust/Iglc1^tm1Ust (involves: 129S7/SvEvBrd * C57BL/6)	abnormal B cell number	J:68144
	increased lymphocyte cell number	J:68144
Iglc1^tm2Ust/Iglc1⁺ (involves: 129S7/SvEvBrd * C57BL/6J)	abnormal immunoglobulin light chain V-J recombination	J:74717
Iglc1^tm2Ust/Iglc1^tm2Ust (involves: 129S7/SvEvBrd)	decreased B cell number	J:113218
Iglc1^tm2Ust/Iglc1^tm2Ust Ptpn6^me-v/Ptpn6^me-v (involves: 129S7/SvEvBrd * C57BL/6J)	decreased B cell number	J:113218
Igll1^tm1Cgn/Igll1^tm1Cgn (involves: 129S2/SvPas * C57BL/6)	abnormal B cell morphology	J:64284
	abnormal B-1 B cell number	J:64284
	abnormal lymphopoiesis	J:64284
	abnormal pre-B cell morphology	J:64284
	decreased B cell number	J:64284, J:35357
	decreased IgG1 level	J:64284
	decreased IgG2b level	J:64284
	decreased IgG3 level	J:64284
	decreased IgG level	J:64284
	increased pro-B cell number	J:64284
	spleen hypoplasia	J:64284
Igll1^tm1Cgn/Igll1^tm1Cgn Tg(Igk-V4CH27)1-2Shc/0 (involves: 129S2/SvPas * BALB/c * C57BL/6 * SJL)	abnormal B cell differentiation	J:35357
	decreased pre-B cell number	J:35357
Igll1^tm1Shim/Igll1^tm1Shim Vpreb1a^tm1Shim/Vpreb1a^tm1Shim Vpreb1b^tm1Shim/Vpreb1b^tm1Shim (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell differentiation	J:76947
	decreased B cell number	J:76947
	decreased B-1a cell number	J:76947
	decreased immature B cell number	J:76947
	decreased mature B cell number	J:76947
	decreased pre-B cell number	J:76947
	immune system phenotype	J:76947
	increased late pro-B cell number	J:76947
Iglon5^em1(IMPC)Mbp/Iglon5^em1(IMPC)Mbp (C57BL/6NCrl-Iglon5^em1(IMPC)Mbp/Mmucd)	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Ignpq1^BALB/cAJcl/Ignpq1^HIGA/Nsc (involves: BALB/cAJcl * HIGA/Nsc)	increased IgA level	J:116904
Ignpq1^HIGA/Nsc/Ignpq1^HIGA/Nsc (involves: BALB/cAJcl * HIGA/Nsc)	increased IgA level	J:116904
Ignpq2^BALB/cAJcl/Ignpq2^HIGA/Nsc (involves: BALB/cAJcl * HIGA/Nsc)	increased IgA level	J:116904
Ignpq2^HIGA/Nsc/Ignpq2^HIGA/Nsc (involves: BALB/cAJcl * HIGA/Nsc)	increased IgA level	J:116904
Ignpq3^BALB/cAJcl/Ignpq3^HIGA/Nsc (involves: BALB/cAJcl * HIGA/Nsc)	glomerulonephritis	J:116904
Ignpq3^HIGA/Nsc/Ignpq3^HIGA/Nsc (involves: BALB/cAJcl * HIGA/Nsc)	glomerulonephritis	J:116904
Igs2^{em1(Alb-Golm1)Jdon}/Igs2⁺ (involves: C57BL/6N)	decreased CD8-positive, alpha-beta T cell number	J:306528
Igs2^{tm1(CAG-Ptgs2os)Scrp}/Igs2^{tm1(CAG-Ptgs2os)Scrp} (involves: C57BL/6)	abnormal circulating cytokine level	J:325487
	increased circulating interleukin-10 level	J:325487
Igs2^{tm1(CAG-Ptgs2os)Scrp}/Igs2^{tm1(CAG-Ptgs2os)Scrp} Ptgs2os^em1Scrp/Ptgs2os^em1Scrp (involves: C57BL/6)	immune system phenotype	J:325487
Igtp^em1Myam/Igtp^em1Myam Irgm1^em1Myam/Irgm1^em1Myam (C57BL/6-Irgm1^em1Myam Igtp^em1Myam)	increased susceptibility to parasitic infection	J:308470
Igtp^em1Myam/Igtp^em1Myam Irgm1^em1Myam/Irgm1^em1Myam Irgm2^em2Myam/Irgm2^em2Myam (C57BL/6-Irgm1^em1Myam Igtp^em1Myam Irgm2^em2Myam)	increased susceptibility to parasitic infection	J:308470
Igtp^tm1Gvw/Igtp^tm1Gvw (involves: 129S1/Sv * C57BL/6)	immune system phenotype	J:59891
	increased circulating interferon-gamma level	J:59891
	increased circulating interleukin-12b level	J:59891
	increased susceptibility to parasitic infection	J:99144, J:59891
Iigp1^tm1.1Jcho/Iigp1^tm1.1Jcho (involves: C57BL/6)	increased susceptibility to parasitic infection	J:135070
Iigp1c^{em1(IMPC)Hmgu}/Iigp1c^{em1(IMPC)Hmgu} (C57BL/6N-Iigp1c^{em1(IMPC)Hmgu}/Ieg)	abnormal lymph node morphology	J:211773
Ikbip^em1Bcgen/Ikbip^em1Bcgen Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd)	abnormal cytokine level	J:282971
	decreased macrophage cytokine production	J:282971
	increased circulating interleukin-6 level	J:282971
	increased circulating tumor necrosis factor level	J:282971
	increased susceptibility to bacterial infection induced morbidity/mortality	J:282971
	increased susceptibility to induced colitis	J:282971
	lung inflammation	J:282971
Ikbkb^em1Macc/Ikbkb⁺ (involves: C57BL/6NCrl)	abnormal effector T cell number	J:290616
	abnormal T cell activation	J:290616
	decreased B cell number	J:290616
	decreased CD4-positive, alpha-beta T cell number	J:290616
	decreased CD8-positive, alpha-beta T cell number	J:290616
	decreased memory B cell number	J:290616
	decreased T cell number	J:290616
	increased regulatory T cell number	J:290616
Ikbkb^em1Macc/Ikbkb^em1Macc (involves: C57BL/6NCrl)	abnormal effector T cell number	J:290616
	abnormal T cell activation	J:290616
	decreased B cell number	J:290616
	decreased CD4-positive, alpha-beta T cell number	J:290616
	decreased CD8-positive, alpha-beta T cell number	J:290616
	decreased memory B cell number	J:290616
	decreased T cell number	J:290616
	increased regulatory T cell number	J:290616
Ikbkb^em1Smoc/Ikbkb^em1Smoc (C57BL/6J-Ikbkb^em1Smoc)	decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:309163
Ikbkb^M1Btlr/Ikbkb⁺ (C57BL/6J-Ikbkb^M1Btlr)	abnormal B cell physiology	J:225271
	abnormal CD8-positive, alpha-beta T cell differentiation	J:225271
	abnormal response to infection	J:225271
	increased response to antigen	J:225271
Ikbkb^M1Btlr/Ikbkb^M1Btlr (C57BL/6J-Ikbkb^M1Btlr)	abnormal B cell physiology	J:225271
	abnormal CD8-positive, alpha-beta T cell differentiation	J:225271
	increased susceptibility to viral infection	J:225271
Ikbkb^M2Btlr/Ikbkb^M2Btlr (C57BL/6J-Ikbkb^M2Btlr)	decreased central memory CD4-positive, alpha-beta T cell number	J:274802
Ikbkb^tm1.1Cgn/Ikbkb^tm1.1Cgn (involves: C57BL/6)	decreased interleukin-6 secretion	J:79132, J:85810
Ikbkb^tm1Cgn/Ikbkb^tm1.1Cgn Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	decreased CD4-positive, alpha-beta T cell number	J:85810
	decreased CD8-positive, alpha-beta T cell number	J:85810
	decreased single-positive T cell number	J:85810
	decreased T cell number	J:85810
Ikbkb^tm1Cgn/Ikbkb^tm1Cgn Il20ra^tm1Rsab/Il20ra^tm1Rsab Tg(KRT14-cre)1Cgn/0 (involves: C57BL/6 * DBA/2)	skin inflammation	J:208995
Ikbkb^tm1Cgn/Ikbkb^tm1Cgn Il22^tm1Jcrd/Il22^tm1Jcrd Tg(KRT14-cre)1Cgn/0 (involves: C57BL/6 * DBA/2)	skin inflammation	J:208995
Ikbkb^tm1Cgn/Ikbkb^tm1Cgn Il22ra1^tm1Rsab/Il22ra1^tm1Rsab Tg(KRT14-cre)1Cgn/0 (involves: C57BL/6 * DBA/2)	skin inflammation	J:208995
Ikbkb^tm1Cgn/Ikbkb^tm1Cgn Tg(KRT14-cre)1Cgn/0 (involves: C57BL/6 * DBA/2)	skin inflammation	J:208995
Ikbkb^tm1Cgn/Ikbkb^tm1Cgn Tg(Lck-cre)I57Jxm/0 (involves: C57BL/6 * ICR)	decreased CD4-positive, alpha-beta T cell number	J:85810
	decreased CD8-positive, alpha-beta T cell number	J:85810
Ikbkb^tm1Cgn/Ikbkb^tm1Cgn Tnfrsf1a^tm2Gkl/Tnfrsf1a^tm2Gkl Tg(KRT14-cre)1Cgn/0 (involves: 129S/SvEv * C57BL/6 * DBA/2)	skin inflammation	J:208995
Ikbkb^tm1Lex/Ikbkb^tm1Lex Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * 129S/SvEvBrd)	impaired macrophage chemotaxis	J:159873
	impaired neutrophil chemotaxis	J:159873
	impaired neutrophil recruitment	J:159873
Ikbkb^tm2.1Cgn/Ikbkb^tm2.1Cgn (involves: C57BL/6)	decreased interleukin-6 secretion	J:79132
Ikbkb^tm2Cgn/Ikbkb^tm2.1Cgn Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	abnormal humoral immune response	J:85810
	decreased CD4-positive, alpha-beta T cell number	J:85810
	decreased CD8-positive, alpha-beta T cell number	J:85810
	decreased IgE level	J:85810
Ikbkb^tm2Cgn/Ikbkb^tm2Cgn Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	decreased CD4-positive, alpha-beta T cell number	J:85810
	decreased memory T cell number	J:85810
	decreased regulatory T cell number	J:85810
Ikbkb^tm2Mka/Ikbkb^tm2.1Mka Tg(Vil-cre)1Mka/0 (involves: 129/Sv * C57BL/6)	decreased acute inflammation	J:83313
	decreased circulating tumor necrosis factor level	J:83313
	impaired neutrophil recruitment	J:83313
Ikbkb^tm2Mka/Ikbkb^tm2Mka Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129/Sv * 129P2/OlaHsd)	increased macrophage apoptosis	J:80159
Ikbke^tm1Tman/Ikbke^tm1Tman (B6.Cg-Ikbke^tm1Tman)	increased susceptibility to Orthomyxoviridae infection	J:119791
Ikbke^tm1Tman/Ikbke^tm1Tman (B6.Cg-Ikbke^tm1Tman)	lung inflammation	J:119791
Ikbkg^m1Btlr/Y (C57BL/6J-Ikbkg^m1Btlr)	decreased regulatory T cell number	J:139558
	decreased tumor necrosis factor secretion	J:139558
	immune system phenotype	J:139558
Ikbkg^tm1.1Chtr/Y Tg(Alb1-cre)7Gsc/0 (involves: C57BL/6 * FVB/N * SJL)	abnormal NK cell physiology	J:151485
	abnormal NK T cell physiology	J:151485
	decreased NK cell number	J:151485
	decreased NK T cell number	J:151485
	increased interferon-gamma secretion	J:151485
	liver inflammation	J:151485
Ikbkg^tm1.1Chtr/Ikbkg^tm1.1Chtr Tg(Alb1-cre)7Gsc/0 (involves: C57BL/6 * FVB/N * SJL)	abnormal NK cell physiology	J:151485
	abnormal NK T cell physiology	J:151485
	decreased NK cell number	J:151485
	decreased NK T cell number	J:151485
	increased circulating tumor necrosis factor level	J:151485
	increased interferon-gamma secretion	J:151485
	liver inflammation	J:151485
Ikbkg^tm1.1Dwat/Y Tnfrsf1a^tm1Imx/Tnfrsf1a^tm1Imx (involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NTac)	immune system phenotype	J:202106
	liver inflammation	J:202106
Ikbkg^tm1.1Dwat/Ikbkg⁺ (B6.Cg-Ikbkg^tm1.1Dwat)	decreased B cell number	J:202106
Ikbkg^tm1.1Dwat/Ikbkg⁺ (B6.Cg-Ikbkg^tm1.1Dwat)	enlarged spleen	J:202106
Ikbkg^tm1.1Mpa/Y Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	decreased CD4-positive, alpha-beta T cell number	J:85810
	decreased CD8-positive, alpha-beta T cell number	J:85810
	decreased single-positive T cell number	J:85810
	decreased T cell number	J:85810
	increased T cell apoptosis	J:85810
Ikbkg^tm1.1Mpa/Y Tg(Vil1-cre)997Gum/0 (B6.Cg-Ikbkg^tm1.1Mpa Tg(Vil1-cre)997Gum)	colitis	J:175865
Ikbkg^tm1.1Mpa/Ikbkg^tm1.1Mpa Cd79a^tm1(cre)Reth/Cd79a⁺ (involves: BALB/c * C57BL/6)	abnormal B cell differentiation	J:113365
	decreased B cell number	J:113365
	decreased mature B cell number	J:113365
Ikbkg^tm1.1Mpa/Ikbkg^tm1.1Mpa Tg(Alb1-cre)7Gsc/0 (involves: C57BL/6 * FVB/N)	abnormal cytokine secretion	J:118336
	abnormal inflammatory response	J:118336
	increased susceptibility to endotoxin shock	J:137861
	liver inflammation	J:118336
Ikbkg^tm1.1Mpa/Ikbkg^tm1.1Mpa Tg(Vil1-cre)997Gum/0 (B6.Cg-Ikbkg^tm1.1Mpa Tg(Vil1-cre)997Gum)	colitis	J:175865
Ikbkg^tm1Dwb/Ikbkg^tm1Dwb (Not Specified)	abnormal chemokine secretion	J:136353
	abnormal humoral immune response	J:136353
	decreased interleukin-6 secretion	J:136353
	decreased interleukin-12b secretion	J:136353
	decreased susceptibility to endotoxin shock	J:136353
	decreased tumor necrosis factor secretion	J:136353
Ikbkg^tm1Mak/Y (involves: 129P2/OlaHsd * C57BL/6)	increased interleukin-6 secretion	J:61666
Ikbkg^tm1Mka/Ikbkg⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	erythroderma	J:63054
	small spleen	J:63054
	small thymus	J:63054
Ikbkg^tm1Mpa/Y (involves: C57BL/6)	decreased interleukin-6 secretion	J:63055
Ikbkg^tm1Mpa/Y (involves: C57BL/6)	decreased tumor necrosis factor secretion	J:63055
Ikbkg^tm1Mpa/Ikbkg⁺ (involves: C57BL/6)	skin inflammation	J:63055
Ikzf1^m1Btlr/Ikzf1^m1Btlr (C57BL/6J-Ikzf1^m1Btlr)	abnormal natural killer cell mediated cytotoxicity	J:265249
	decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:265249
	decreased CD8-positive, naive alpha-beta T cell number	J:265249
	enhanced humoral immune response	J:265249
	increased B-1 B cell number	J:265249
	increased CD4-positive, alpha-beta T cell number	J:265249
	increased CD8-positive, alpha-beta T cell number	J:265249
	increased central memory CD4-positive, alpha-beta T cell number	J:265249
	increased central memory CD8 positive, alpha-beta T cell number	J:265249
	increased effector memory CD4-positive, alpha-beta T cell number	J:265249
	increased IgG level	J:265249
	increased response to antigen	J:265249
	increased single-positive T cell number	J:265249
	increased T cell number	J:265249
Ikzf1^m2Btlr/Ikzf1^m2Btlr (C57BL/6J-Ikzf1^m2Btlr)	decreased B cell number	J:265250
	decreased CD4-positive, alpha-beta T cell number	J:265250
	decreased CD8-positive, naive alpha-beta T cell number	J:265250
	decreased single-positive T cell number	J:265250
	decreased T cell number	J:265250
	increased CD8-positive, alpha-beta T cell number	J:265250
	increased central memory CD4-positive, alpha-beta T cell number	J:265250
	increased central memory CD8 positive, alpha-beta T cell number	J:265250
	increased effector memory CD4-positive, alpha-beta T cell number	J:265250
	increased effector memory CD8-positive, alpha-beta T cell number	J:265250
	increased single-positive T cell number	J:265250
Ikzf1^m3Btlr/Ikzf1^m3Btlr (C57BL/6J-Ikzf1^m3Btlr)	decreased CD4-positive, alpha-beta T cell number	J:265251
	increased B-1 B cell number	J:265251
	increased CD8-positive, alpha-beta T cell number	J:265251
	increased single-positive T cell number	J:265251
	increased T cell number	J:265251
Ikzf1^plstc/Ikzf1⁺ (C57BL/6JSfdAnu-Ikzf1^plstc)	abnormal B cell differentiation	J:84569
	abnormal lymphopoiesis	J:84569
	abnormal T cell differentiation	J:84569
	decreased double-negative T cell number	J:84569
	decreased double-positive T cell number	J:84569
	decreased mature B cell number	J:84569
	decreased pre-B cell number	J:84569
	decreased thymocyte number	J:84569
	increased pro-B cell number	J:84569
	increased T cell derived lymphoma incidence	J:84569
	myeloid hyperplasia	J:84569
Ikzf1^plstc/Ikzf1^plstc (C57BL/6JSfdAnu-Ikzf1^plstc)	abnormal granulocyte differentiation	J:84569
	abnormal lymphopoiesis	J:84569
	abnormal macrophage differentiation	J:84569
	abnormal myelopoiesis	J:84569
	absent pro-B cells	J:84569
	absent T cells	J:84569
	arrested B cell differentiation	J:84569
	decreased granulocyte number	J:84569
	increased macrophage cell number	J:84569
	thymus hypoplasia	J:84569
Ikzf1^tm1(Pax5)Mbu/Ikzf1⁺ Tg(Lck-cre)1Cwi/0 (involves: 129P2/OlaHsd * C57BL/6)	increased T cell derived lymphoma incidence	J:118111
Ikzf1^tm1(Pax5)Mbu/Ikzf1^tm1(Pax5)Mbu (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell number	J:80815
	abnormal dendritic cell morphology	J:80815
	abnormal T cell differentiation	J:80815
Ikzf1^tm1(Pax5)Mbu/Ikzf1^tm1(Pax5)Mbu Tg(Mx1-cre)1Cgn/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA)	abnormal T cell differentiation	J:80815
	arrested T cell differentiation	J:80815
	increased B cell number	J:80815
	increased early pro-B cell number	J:80815
	thymus hypoplasia	J:80815
Ikzf1^{tm1.1(Pax5)Mbu}/Ikzf1⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell differentiation	J:80815
	decreased double-positive T cell number	J:118111
	enlarged lymph nodes	J:118111
	enlarged spleen	J:118111
	enlarged thymus	J:118111
	increased B cell number	J:80815
	increased pro-B cell number	J:80815
	increased T cell derived lymphoma incidence	J:118111
	thymus hypoplasia	J:118111
Ikzf1^{tm1.1(Pax5)Mbu}/Ikzf1⁺ Tcf3^tm1Mbu/Tcf3^tm1Mbu Commd10^{Tg(Vav1-icre)A2Kio}/Commd10⁺ (involves: 129P2/OlaHsd * C57BL/10 * CBA/Ca)	abnormal immunoglobulin heavy chain V(D)J recombination	J:137719
	immune system phenotype	J:137719
Ikzf1^tm1.1Smale/Ikzf1^tm1.1Smale (B6.Cg-Ikzf1^tm1.1Smale)	decreased B cell number	J:208211
	decreased B-1a cell number	J:208211
	decreased B-1b cell number	J:208211
	decreased DN1 thymic pro-T cell number	J:208211
	decreased immature B cell number	J:208211
	decreased mature B cell number	J:208211
	decreased pre-B cell number	J:208211
	immune system phenotype	J:208211
	thymus hypoplasia	J:208211
Ikzf1^tm1Kast/Ikzf1^tm1Kast (involves: 129S2/SvPas)	abnormal B cell activation	J:82813
	abnormal B cell differentiation	J:82813
	decreased B cell number	J:82813
	decreased B cell proliferation	J:82813
	decreased B-1a cell number	J:82813
	decreased B-1b cell number	J:82813
	decreased IgG3 level	J:82813
	decreased spleen germinal center number	J:82813
Ikzf1^tm1Kge/Ikzf1⁺ (involves: 129S4/SvJae * C57BL/6)	abnormal lymph node cortex morphology	J:29355
	abnormal lymph node medulla morphology	J:29355
	abnormal T cell differentiation	J:29355
	abnormal thymocyte activation	J:29355
	abnormal thymus lobule morphology	J:29355
	abnormal thymus medulla morphology	J:29355
	decreased spleen red pulp amount	J:29355
	enlarged cervical lymph nodes	J:29355
	enlarged mesenteric lymph nodes	J:29355
	enlarged thymus	J:29355
	increased spleen white pulp amount	J:29355
	increased T cell proliferation	J:29355
	lymph node hyperplasia	J:29355
	spleen hyperplasia	J:29355
	thymus cortex hypoplasia	J:29355
Ikzf1^tm1Kge/Ikzf1⁺ (involves: 129S4/SvJae * BALB/c)	abnormal lymph node cortex morphology	J:29355
	abnormal lymph node medulla morphology	J:29355
	abnormal T cell differentiation	J:29355
	abnormal thymocyte activation	J:29355
	abnormal thymus lobule morphology	J:29355
	abnormal thymus medulla morphology	J:29355
	decreased spleen red pulp amount	J:29355
	enlarged cervical lymph nodes	J:29355
	enlarged mesenteric lymph nodes	J:29355
	enlarged thymus	J:29355
	increased spleen white pulp amount	J:29355
	increased T cell proliferation	J:29355
	lymph node hyperplasia	J:29355
	spleen hyperplasia	J:29355
	thymus cortex hypoplasia	J:29355
Ikzf1^tm1Kge/Ikzf1^tm1Kge (involves: 129S4/SvJae * C57BL/6)	abnormal eosinophil morphology	J:20671
	abnormal immune system organ morphology	J:20671
	abnormal NK cell morphology	J:20671
	abnormal spleen morphology	J:20671
	abnormal thymus cortex morphology	J:20671
	abnormal thymus morphology	J:20671
	absent axillary lymph nodes	J:20671
	absent B cells	J:20671
	absent cervical lymph nodes	J:20671
	absent inguinal lymph nodes	J:20671
	absent mesenteric lymph nodes	J:20671
	absent Peyer's patches	J:20671
	absent pre-B cells	J:20671
	arrested T cell differentiation	J:20671
	decreased gamma-delta intraepithelial T cell number	J:20671
	enlarged spleen	J:20671
	increased basophil cell number	J:20671
	increased susceptibility to bacterial infection	J:20671
	intermingled spleen red and white pulp	J:20671
	lung inflammation	J:20671
	thymus hypoplasia	J:20671
Ikzf1^tm1Kge/Ikzf1^tm1Kge (involves: 129S4/SvJae * BALB/c)	abnormal eosinophil morphology	J:20671
	abnormal immune system organ morphology	J:20671
	abnormal NK cell morphology	J:20671
	abnormal spleen morphology	J:20671
	abnormal thymus cortex morphology	J:20671
	abnormal thymus morphology	J:20671
	absent axillary lymph nodes	J:20671
	absent B cells	J:20671
	absent cervical lymph nodes	J:20671
	absent inguinal lymph nodes	J:20671
	absent mesenteric lymph nodes	J:20671
	absent Peyer's patches	J:20671
	absent pre-B cells	J:20671
	arrested T cell differentiation	J:20671
	decreased gamma-delta intraepithelial T cell number	J:20671
	enlarged spleen	J:20671
	increased basophil cell number	J:20671
	increased susceptibility to bacterial infection	J:20671
	intermingled spleen red and white pulp	J:20671
	lung inflammation	J:20671
	thymus hypoplasia	J:20671
Ikzf1^tm2.1Smale/Ikzf1^tm2.1Smale (B6.Cg-Ikzf1^tm2.1Smale)	abnormal lymphopoiesis	J:208211
	abnormal peripheral lymph node morphology	J:208211
	abnormal T cell differentiation	J:208211
	absent inguinal lymph nodes	J:208211
	absent NK cells	J:208211
	absent Peyer's patches	J:208211
	decreased B cell number	J:208211
	decreased DN2 thymocyte number	J:208211
	decreased DN3 thymocyte number	J:208211
	decreased double-negative T cell number	J:208211
	decreased double-positive T cell number	J:208211
	decreased immature B cell number	J:208211
	decreased mature B cell number	J:208211
	decreased plasmacytoid dendritic cell number	J:208211
	decreased pre-pro B cell number	J:208211
	immune system phenotype	J:208211
	increased gamma-delta T cell number	J:208211
	increased pre-B cell number	J:208211
	thymus cortex hypoplasia	J:208211
	thymus hypoplasia	J:208211
Ikzf1^tm2Kge/Ikzf1^tm2Kge (involves: 129S4/SvJae)	abnormal dendritic cell number	J:37317
	abnormal splenic cell ratio	J:37317
	abnormal T cell differentiation	J:208211, J:37317
	abnormal thymus development	J:37317
	absent axillary lymph nodes	J:37317
	absent B cells	J:208211, J:37317
	absent B-1a cells	J:37317
	absent cervical lymph nodes	J:37317
	absent inguinal lymph nodes	J:37317
	absent mesenteric lymph nodes	J:37317
	absent NK cells	J:208211, J:37317
	absent Peyer's patches	J:37317
	absent pre-B cells	J:37317
	absent pro-B cells	J:37317
	decreased double-positive T cell number	J:37317
	decreased gamma-delta intraepithelial T cell number	J:37317
	decreased granulocyte number	J:37317
	decreased mature gamma-delta T cell number	J:37317
	decreased plasmacytoid dendritic cell number	J:208211
	decreased splenocyte number	J:37317
	increased T cell proliferation	J:37317
	thymus hypoplasia	J:37317
Ikzf1^tm3.1Mbu/Ikzf1^tm3.1Mbu Cd79a^tm1(cre)Reth/Cd79a⁺ Rag2^tm1Fwa/Rag2^tm1Fwa (involves: 129P2/OlaHsd * 129S/SvEv * BALB/c * C57BL/6 * SJL)	decreased pro-B cell number	J:209928
Ikzf1^tm3.1Mbu/Ikzf1^tm3.1Mbu Il7r^{tm1.1(icre)Hrr}/Il7r⁺ (involves: 129P2/OlaHsd * C57BL/6 * SJL)	increased T cell derived lymphoma incidence	J:209928
Ikzf1^tm3Kge/Ikzf1^tm3Kge Tg(CD2-icre)4Kio/? (involves: C57BL/10 * CBA/Ca)	abnormal B cell physiology	J:209927
	impaired B cell migration	J:209927
	increased T cell derived lymphoma incidence	J:209927
Ikzf1^tm3Kge/Ikzf1^tm3Kge Tg(CD19-cre/ERT2)1Cgn/? (Not Specified)	abnormal B cell apoptosis	J:209927
	absent pre-B cells	J:209927
	decreased pre-B cell number	J:209927
Ikzf2^tm1.1Etms/Ikzf2^tm1.1Etms Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	abnormal regulatory T cell physiology	J:160098
Ikzf3^{tm1(KOMP)Vlcg}/Ikzf3^{tm1(KOMP)Vlcg} (C57BL/6N-Ikzf3^{tm1(KOMP)Vlcg}/Rbrc)	decreased large unstained cell number	J:211773
	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Ikzf3^tm1Kge/Ikzf3^tm1Kge (involves: 129S4/SvJae * C57BL/6)	abnormal B cell differentiation	J:50626
	abnormal spleen marginal zone morphology	J:50626
	abnormal type III hypersensitivity reaction	J:81805
	autoimmune response	J:81805
	decreased B cell number	J:81805
	decreased IgG2b level	J:50626
	decreased IgG3 level	J:50626
	decreased IgM level	J:50626
	decreased naive B cell number	J:81805
	enlarged spleen	J:50626
	glomerulonephritis	J:81805
	increased anti-double stranded DNA antibody level	J:81805
	increased anti-histone antibody level	J:81805
	increased anti-nuclear antigen antibody level	J:81805
	increased anti-single stranded DNA antibody level	J:81805
	increased autoantibody level	J:81805, J:50626
	increased B cell proliferation	J:50626
	increased IgE level	J:50626
	increased IgG1 level	J:50626
	increased IgG2a level	J:50626
	increased pre-B cell number	J:50626
	increased spleen germinal center number	J:50626
	increased T cell proliferation	J:50626
Ikzf3^tm1Kge/Ikzf3^tm1Kge (involves: 129S4/SvJae)	decreased marginal zone B cell number	J:69477
Ikzf3^tm1Kge/Ikzf3^tm1Kge (involves: 129S4/SvJae)	increased follicular B cell number	J:69477
Ikzf4^tm1.1Etms/Ikzf4^tm1.1Etms (Not Specified)	chronic inflammation	J:294549
	decreased T cell proliferation	J:295208
	immune system phenotype	J:295208
	increased susceptibility to experimental autoimmune encephalomyelitis	J:295208
Ikzf4^tm1Djr/Ikzf4^tm1Djr Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	chronic inflammation	J:294549
Ikzf5^{tm1(KOMP)Wtsi}/Ikzf5^{tm1(KOMP)Wtsi} (C57BL/6N-Ikzf5^{tm1(KOMP)Wtsi}/Rbrc)	increased large unstained cell number	J:211773
Il1a^tm1Yiw/Il1a^tm1Yiw (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	decreased circulating interleukin-1 alpha level	J:47429
	decreased interleukin-1 beta secretion	J:47429
Il1a^tm1Yiw/Il1a^tm1Yiw Il1b^tm1Yiw/Il1b^tm1Yiw (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	decreased circulating interleukin-1 alpha level	J:47429
	decreased circulating interleukin-1 beta level	J:47429
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:165513
	decreased susceptibility to type IV hypersensitivity reaction	J:165513
Il1a^tm1Yiw/Il1a^tm1Yiw Il1b^tm1Yiw/Il1b^tm1Yiw (involves: 129S1/Sv * 129X1/SvJ * BALB/c)	impaired neutrophil recruitment	J:50775
Il1a^tm1Yiw/Il1a^tm1Yiw Il1b^tm1Yiw/Il1b^tm1Yiw Tg(KRT14-CASP1)1Miz/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	dermatitis	J:78602
Il1a^tm1Yiw/Il1a^tm1Yiw Nlrp1a^Neut1/Nlrp1a^Neut1 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal inflammatory response	J:191055
	increased neutrophil cell number	J:191055
Il1b^tm1Dch/Il1b^tm1Dch (involves: 129S2/SvPas)	decreased interleukin-1 beta secretion	J:33465
	decreased susceptibility to type IV hypersensitivity reaction	J:33465
	immune system phenotype	J:189777
	increased susceptibility to bacterial infection	J:112400
Il1b^tm1Lvp/Il1b^tm1Lvp (involves: 129S7/SvEvBrd * C57BL/6)	abnormal interleukin-6 secretion	J:27234
	abnormal lymphocyte physiology	J:67001
	decreased acute inflammation	J:27234
	decreased circulating interleukin-1 beta level	J:27234
	decreased inflammatory response	J:27234
	decreased interferon-gamma secretion	J:67001
	decreased interleukin-2 secretion	J:67001
	decreased interleukin-4 secretion	J:67001
	decreased susceptibility to experimental autoimmune myasthenia gravis	J:67001
Il1b^tm1Lvp/Il1b^tm1Lvp (involves: 129S7/SvEvBrd)	abnormal macrophage physiology	J:136368
	decreased interleukin-1 beta secretion	J:136368
	decreased susceptibility to Togaviridae infection	J:52841
	decreased susceptibility to Togaviridae infection induced morbidity/mortality	J:52841
	decreased susceptibility to viral infection	J:135243
	decreased tumor necrosis factor secretion	J:82394
	increased susceptibility to bacterial infection induced morbidity/mortality	J:136368
Il1b^tm1Lvp/Il1b^tm1Lvp (129S7/SvEvBrd-Il1b^tm1Lvp)	immune system phenotype	J:173245
Il1b^tm1Yiw/Il1b^tm1Yiw (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	decreased circulating interleukin-1 beta level	J:47429
Il1f10^tm1Gpa/Il1f10^tm1Gpa (C.129-Il1f10^tm1Gpa)	immune system phenotype	J:260118
Il1r1^{em1(IMPC)Ccpcz}/Il1r1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Il1r1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Il1r1^em1Qizh/Il1r1^em1Qizh (C57BL/6-Il1r1^em1Qizh)	increased circulating interleukin-6 level	J:338375
	increased circulating tumor necrosis factor level	J:338375
	increased susceptibility to induced arthritis	J:338375
Il1r1^tm1Imx/Il1r1^tm1Imx (involves: 129 * C57BL/6)	decreased circulating interleukin-6 level	J:43088
	increased susceptibility to bacterial infection	J:58851
	osteomyelitis	J:58851
Il1r1^tm1Imx/Il1r1^tm1Imx (involves: 129S7/SvEvBrd)	abnormal neutrophil physiology	J:113110
Il1r1^tm1Imx/Il1r1^tm1Imx (involves: 129S7/SvEvBrd * C57BL/6)	abnormal neutrophil physiology	J:112999
	decreased susceptibility to experimental autoimmune uveoretinitis	J:115094
Il1r1^tm1Imx/Il1r1^tm1Imx (B6.129S7-Il1r1^tm1Imx/J)	decreased circulating interleukin-6 level	J:125570
	decreased circulating interleukin-18 level	J:125570
	decreased interleukin-6 secretion	J:148779, J:125570
	decreased tumor necrosis factor secretion	J:125570
	increased circulating interleukin-1 beta level	J:125570
	increased circulating interleukin-18 level	J:125570
	increased susceptibility to bacterial infection	J:125570
	increased susceptibility to bacterial infection induced morbidity/mortality	J:125570
	increased susceptibility to induced arthritis	J:125570
	sepsis	J:125570
Il1r1^tm1Imx/Il1r1^tm1Imx (B6.129S7-Il1r1^tm1Imx)	immune system phenotype	J:173245
Il1r1^tm1Imx/Il1r1^tm1Imx Tnfrsf1a^tm1Imx/Tnfrsf1a^tm1Imx (involves: 129S7/SvEvBrd * C57BL/6)	abnormal chemokine level	J:126652
	decreased interleukin-6 secretion	J:115094
	decreased susceptibility to experimental autoimmune uveoretinitis	J:115094
	impaired neutrophil recruitment	J:126652
	increased susceptibility to bacterial infection	J:58851
	interstitial pneumonia	J:126652
	lung inflammation	J:126652
	osteomyelitis	J:58851
Il1r1^tm1Imx/Il1r1^tm1Imx Vsig4^tm1Gne/Vsig4^tm1Gne (B6.Cg-Il1r1^tm1Imx Vsig4^tm1Gne)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:281762
	decreased T helper 1 cell number	J:281762
	decreased T-helper 17 cell number	J:281762
	increased susceptibility to induced colitis	J:281762
Il1r1^tm1Quan/Il1r1^tm1Quan (involves: C57BL/6)	abnormal inflammatory response	J:219864
Il1r1^tm1Quan/Il1r1^tm1Quan (involves: C57BL/6)	abnormal microglial cell activation	J:219864
Il1r1^tm1Quan/Il1r1^tm1Quan Lyz2^tm1(cre)Ifo/Lyz2^tm1(cre)Ifo (involves: 129P2/OlaHsd * C57BL/6)	abnormal inflammatory response	J:219864
	abnormal microglial cell activation	J:219864
Il1r1^tm1Quan/Il1r1^tm1Quan Tg(Tek-cre)12Flv/0 (involves: C3H * C57BL/6)	abnormal inflammatory response	J:219864
	abnormal microglial cell activation	J:219864
Il1r1^tm1Roml/Il1r1^tm1Roml (involves: 129S1/Sv * C57BL/6)	decreased circulating interleukin-6 level	J:42373
	decreased circulating serum amyloid protein level	J:42373
	decreased interleukin-6 secretion	J:42373
	decreased susceptibility to type IV hypersensitivity reaction	J:42373
	increased susceptibility to bacterial infection	J:42373
Il1r1^tm1Roml/Il1r1^tm1Roml (NOD.Cg-Il1r1^tm1Roml)	decreased susceptibility to autoimmune diabetes	J:87251
Il1r1^tm1Roml/Il1r1^tm1Roml (C.Cg-Il1r1^tm1Roml)	decreased eosinophil cell number	J:82863
	decreased immunoglobulin level	J:82863
	decreased T cell number	J:82863
	decreased T cell proliferation	J:82863
Il1r1^tm1Roml/Il1r1^tm1Roml (involves: 129S1/Sv * BALB/c)	impaired neutrophil chemotaxis	J:124226
Il1r1^tm1Roml/Il1r1^tm1Roml (involves: 129S1/Sv)	decreased neutrophil cell number	J:193548
Il1r1^tm1Roml/Il1r1^tm1Roml (involves: 129S1/Sv)	decreased susceptibility to induced arthritis	J:120707
Il1r1^tm1Roml/Il1r1^tm1Roml Mefv^{tm5.1(MEFV)Chae}/Mefv^{tm5.1(MEFV)Chae} (involves: 129S1/Sv * 129S6/SvEvTac * C57BL/6)	immune system phenotype	J:172117
	increased interleukin-1 beta secretion	J:172117
Il1r1^tm1Roml/Il1r1^tm1Roml Nlrp1a^Neut1/Nlrp1a^Neut1 (involves: 129S1/Sv * C57BL/6)	abnormal leukocyte cell number	J:191055
	abnormal leukopoiesis	J:191055
	decreased eosinophil cell number	J:191055
	decreased lymphocyte cell number	J:191055
	decreased monocyte cell number	J:191055
	immune system phenotype	J:191055
	increased susceptibility to Riboviria infection	J:191055
Il1r1^tm1Roml/Il1r1^tm1Roml Nlrp3^tm1Hhf/Nlrp3⁺ Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129 * C57BL/6)	skin inflammation	J:150054
Il1r2^tm1.2Epi/Il1r2^tm1.2Epi (involves: BALB/cJ * C57BL/6J * C57BL/6NTac)	abnormal CD8-positive, alpha-beta T cell number	J:347877
	abnormal T cell physiology	J:347877
	increased CD4-positive, alpha-beta T cell number	J:347877
	increased circulating interleukin-1 alpha level	J:347877
	increased circulating interleukin-6 level	J:347877
	increased inflammatory response	J:347877
Il1r2^tm1Yiw/Il1r2^tm1Yiw (B6.129P2-Il1r2^tm1Yiw)	abnormal macrophage physiology	J:274653
	immune system phenotype	J:274653
	increased macrophage cytokine production	J:274653
	increased susceptibility to induced arthritis	J:274653
	increased synovial pannus formation	J:274653
Il1r2^tm1Yiw/Il1r2^tm1Yiw Il1rn^tm1Yiw/Il1rn^tm1Yiw (B6.129-Il1r2^tm1Yiw Il1rn^tm1Yiw)	increased circulating tumor necrosis factor level	J:274653
Il1rap^tm1Roml/Il1rap^tm1Roml (involves: 129S1/Sv)	decreased interleukin-6 secretion	J:68065
Il1rl1^tm1Anjm/Il1rl1^tm1Anjm (involves: 129P2/OlaHsd * C57BL/6)	abnormal eosinophil physiology	J:61108
	abnormal interleukin secretion	J:61108
	abnormal T-helper 2 physiology	J:61108
	decreased interleukin-4 secretion	J:61108
	decreased interleukin-5 secretion	J:61108
	granulomatous inflammation	J:61108
Il1rl1^tm1Anjm/Il1rl1^tm1Anjm (involves: 129P2/OlaHsd)	decreased eosinophil cell number	J:159464
Il1rl1^tm1Anjm/Il1rl1^tm1Anjm (involves: 129P2/OlaHsd)	decreased IgE level	J:159464
Il1rl1^tm1Anjm/Il1rl1^tm1Anjm (C.129P2-Il1rl1^tm1Anjm)	increased susceptibility to induced pancreatitis	J:184801
Il1rl1^tm1Brl/Il1rl1^tm1Brl (involves: 129S/SvEv * C57BL/6)	abnormal response to infection	J:63507
	decreased interleukin-5 secretion	J:63507
	increased eosinophil cell number	J:63507
Il1rl2^tm1Hblu/Il1rl2^tm1Hblu (involves: 129 * C57BL/6)	abnormal dendritic cell physiology	J:296074
Il1rl2^tm1Hblu/Il1rl2^tm1Hblu (involves: 129 * C57BL/6)	abnormal macrophage activation involved in immune response	J:296074
Il1rl2^tm1Hblu/Il1rl2^tm1Hblu (involves: 129)	abnormal lymph node morphology	J:193548
	decreased gamma-delta T cell number	J:193548
	decreased interleukin-9 secretion	J:256437
	decreased interleukin-17 secretion	J:193548
	decreased leukocyte cell number	J:193548
	decreased macrophage cell number	J:193548
	decreased neutrophil cell number	J:193548
	decreased susceptibility to induced colitis	J:256437
	increased regulatory T cell number	J:256437
Il1rn^tm1.1Cga/Il1rn^tm1.1Cga Lyz2^tm1(cre)Ifo/Lyz2⁺ (D1.Cg-Il1rn^tm1.1Cga Lyz2^tm1(cre)Ifo)	abnormal chemokine secretion	J:162760
	increased interferon-gamma secretion	J:162760
	increased interleukin-1 beta secretion	J:162760
	increased interleukin-6 secretion	J:162760
	increased interleukin-17 secretion	J:162760
	increased susceptibility to induced arthritis	J:162760
	increased T cell proliferation	J:162760
Il1rn^tm1Dih/Il1rn⁺ (involves: 129S/SvEv * C57BL/6J)	decreased susceptibility to bacterial infection	J:36387
Il1rn^tm1Dih/Il1rn⁺ (involves: 129S/SvEv * C57BL/6J)	increased susceptibility to endotoxin shock	J:36387
Il1rn^tm1Dih/Il1rn^tm1Dih (involves: 129S/SvEv * C57BL/6J)	decreased circulating interleukin-1 level	J:36387
	decreased susceptibility to bacterial infection	J:36387
	increased acute inflammation	J:61600, J:88605
	increased circulating interleukin-6 level	J:61600
	increased circulating serum amyloid protein level	J:61600
	increased susceptibility to endotoxin shock	J:36387
Il1rn^tm1Nick/Il1rn⁺ (involves: 129P2/OlaHsd * MF1)	aortitis	J:59410
Il1rn^tm1Nick/Il1rn^tm1Nick (involves: 129P2/OlaHsd * MF1)	aortitis	J:59410
Il1rn^tm1Nick/Il1rn^tm1Nick (involves: 129P2/OlaHsd * MF1)	chronic inflammation	J:59410
Il1rn^tm1Nick/Il1rn^tm1Nick (involves: 129P2/OlaHsd * MF1 * BALB/cAnNHsd)	aortitis	J:89034
	immune system phenotype	J:89034
	skin inflammation	J:89034
Il1rn^tm1Nick/Il1rn^tm1Nick (involves: BALB/cAnNHsd)	aortitis	J:89034
	rheumatoid arthritis	J:89034
	skin inflammation	J:89034
Il1rn^tm1Nick/Il1rn^tm1Nick (involves: C57BL/6)	immune system phenotype	J:89034
Il1rn^tm1Nick/Il1rn^tm1Nick (involves: BALB/cAnNHsd * C57BL/6)	aortitis	J:89034
	immune system phenotype	J:89034
	rheumatoid arthritis	J:89034
Il1rn^tm1Sush/Il1rn^tm1Sush (involves: 129P2/OlaHsd * C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:97684
	abnormal dendritic cell differentiation	J:97684
	abnormal dendritic cell number	J:97684
	abnormal immune system organ morphology	J:97684
	abnormal T-helper 1 cell morphology	J:97684
	abnormal T-helper 2 cell morphology	J:97684
	granulomatous inflammation	J:97684
Il1rn^tm1Yiw/Il1rn^tm1Yiw (C.129-Il1rn^tm1Yiw)	increased interleukin-17 secretion	J:143719
Il1rn^tm1Yiw/Il1rn^tm1Yiw (C.129-Il1rn^tm1Yiw)	rheumatoid arthritis	J:143719
Il1rn^tm1Yiw/Il1rn^tm1Yiw Il17a^tm1Yiw/Il17a⁺ (involves: 129P2/OlaHsd * BALB/cA * C57BL/6J)	decreased susceptibility to induced arthritis	J:83408
Il2^m1/Il2^m1 (MRL/MpJ)	abnormal T cell activation	J:75331
Il2^tm1.1Flv/Il2^tm1.1Flv (NOD/ShiLtJ-Il2^tm1.1Flv)	abnormal susceptibility to autoimmune disorder	J:150823
Il2^tm1.1Kasm/Il2^tm1.1Kasm Ndor1^{Tg(UBC-cre/ERT2)1Ejb}/? (involves: 129S/SvEv * C57BL/6)	decreased circulating interleukin-17 level	J:190168
	immune system phenotype	J:190168
Il2^tm1Hor/Il2⁺ (NOD.129P2(B6)-Il2^tm1Hor/DvsJ)	increased susceptibility to autoimmune diabetes	J:120349
Il2^tm1Hor/Il2^tm1Hor (involves: 129P2/OlaHsd * C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:39981, J:39989, J:15573
	abnormal CD8 positive, alpha-beta intraepithelial T cell morphology	J:39981, J:15223
	abnormal class switch recombination	J:15573
	abnormal cytotoxic T cell physiology	J:39981
	abnormal gamma-delta intraepithelial T cell morphology	J:15223
	abnormal level of surface class II molecules	J:15223
	abnormal lymphocyte cell number	J:15223
	abnormal lymphocyte morphology	J:37220
	abnormal lymphocyte physiology	J:15223
	abnormal susceptibility to Riboviria infection	J:26861
	abnormal T-helper 1 cell differentiation	J:37220
	abnormal thymocyte activation	J:37220, J:39989
	colitis	J:37220, J:29999, J:15223
	decreased cytotoxic T cell cytolysis	J:15573, J:26198, J:26861
	decreased double-negative T cell number	J:15223
	decreased double-positive T cell number	J:37220
	decreased splenocyte proliferation	J:79241
	decreased T cell proliferation	J:39989, J:26198
	enlarged lymph nodes	J:15223
	enlarged mesenteric lymph nodes	J:29999
	enlarged spleen	J:15223
	impaired natural killer cell mediated cytotoxicity	J:15573
	increased B cell proliferation	J:16662
	increased double-negative T cell number	J:37220
	increased IgA level	J:15223
	increased IgE level	J:16662
	increased IgG1 level	J:39989, J:15223, J:16662
	increased IgG2a level	J:16662
	increased IgG2b level	J:16662
	increased length of allograft survival	J:26198
	increased pre-B cell number	J:16662
	increased pro-B cell number	J:16662
	increased single-positive T cell number	J:37220
	increased T cell proliferation	J:15223, J:16662
	lymph node hyperplasia	J:16662
Il2^tm1Hor/Il2^tm1Hor (C.129P2-Il2^tm1Hor)	abnormal lymphocyte morphology	J:29799
	abnormal regulatory T cell physiology	J:112603
	abnormal spleen morphology	J:29799
	enlarged lymph nodes	J:29799
	heart inflammation	J:29799
	increased B cell proliferation	J:29799
	increased germinal center B cell number	J:29799
	increased IgG level	J:29799
	increased inflammatory response	J:29799
	increased plasma cell number	J:29799
	increased spleen red pulp amount	J:29799
	increased susceptibility to autoimmune hemolytic anemia	J:29799
	increased T cell proliferation	J:29799
	liver inflammation	J:29799
	lung inflammation	J:29799
	pancreas inflammation	J:29799
	spleen hyperplasia	J:29799
Il2^tm1Hor/Il2^tm1Hor (B6.129P2-Il2^tm1Hor)	immune system phenotype	J:125748
	increased activated T cell number	J:28924
	increased CD4-positive, alpha-beta T cell number	J:28924
	increased CD8-positive, alpha-beta T cell number	J:28924
	increased T cell number	J:125748
	increased T cell proliferation	J:28924
Il2^tm1Hor/Il2^tm1Hor (C3.129P2-Il2^tm1Hor)	increased CD4-positive, alpha-beta T cell number	J:28924
Il2^tm1Hor/Il2^tm1Hor (C3.129P2-Il2^tm1Hor)	increased CD8-positive, alpha-beta T cell number	J:28924
Il2^tm1Hor/Il2^tm1Hor (B6.129P2-Il2^tm1Hor/J)	abnormal circulating cytokine level	J:190168
	abnormal response to transplant	J:113547
	abnormal T cell activation	J:190168
	abnormal T cell proliferation	J:190168
	decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:131774
	decreased circulating interferon-gamma level	J:190168
	decreased circulating interleukin-4 level	J:190168
	decreased circulating interleukin-13 level	J:190168
	decreased regulatory T cell number	J:113547
	enlarged lymph nodes	J:113547
	increased CD4-positive, alpha-beta T cell number	J:131774
	increased splenocyte number	J:131774
	increased susceptibility to autoimmune disorder	J:113547
	lacrimal gland inflammation	J:125129
	large intestinal inflammation	J:125129
	salivary gland inflammation	J:125129
Il2^tm1Hor/Il2^tm1Hor (involves: 129P2/OlaHsd)	increased regulatory T cell number	J:208318
Il2^tm1Hor/Il2^tm1Hor (involves: 129P2/OlaHsd * C57BL/6J)	increased circulating interleukin-17 level	J:120176
Il2^tm1Hor/Il2^tm1Hor (involves: 129P2/OlaHsd * C57BL/6J)	increased T-helper 17 cell number	J:120176
Il2^tm1Hor/Il2^tm1Hor Il4^tm1Cgn/Il4^tm1Cgn (involves: 129P2/OlaHsd * C57BL/6)	abnormal susceptibility to Riboviria infection	J:26861
	decreased cytotoxic T cell cytolysis	J:26861
	decreased IgG level	J:16662, J:26861
	increased B cell proliferation	J:16662
	increased pre-B cell number	J:16662
	increased pro-B cell number	J:16662
	increased T cell proliferation	J:16662
Il2^tm1Hor/Il2^tm1Hor Rag2^tm1Fwa/Rag2⁺ (involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6)	colitis	J:29999
	enlarged mesenteric lymph nodes	J:29999
Il2^tm1Hor/Il2^tm1Hor Rag2^tm1Fwa/Rag2^tm1Fwa (involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6)	immune system phenotype	J:29999
Il2^tm1Hor/Il2^tm1Hor Rag2^tm1Fwa/Rag2^tm1Fwa Tg(Tcra5CC7,Tcrb5CC7)IWep/0 (involves: 129P2/OlaHsd * C57BL/10)	abnormal T cell number	J:120176
	increased T-helper 17 cell number	J:120176
Il2^tm1Hor/Il2^tm1Hor Tcrb^tm1Mom/Tcrb^tm1Mom (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:135589
Il2^tm1Hor/Il2^tm1Hor Tg(DO11.10)10Dlo/? (C.Cg-Il2^tm1Hor Tg(DO11.10)10Dlo)	abnormal regulatory T cell physiology	J:88349
	increased activated T cell number	J:88349
	increased T cell proliferation	J:88349
Il2^tm1Hor/Il2^tm1Hor Tg(Pgk1-HA)1.1Vbo/? Tg(Tcra/Tcrb)1Vbo/? (C.Cg-Il2^tm1Hor Tg(Pgk1-HA)1.1Vbo Tg(Tcra/Tcrb)1Vbo)	abnormal regulatory T cell physiology	J:112603
	decreased regulatory T cell number	J:112603
	increased regulatory T cell number	J:112603
Il2ra^M1J/Il2ra^M1J (involves: 129S4/SvJae * C57BL/6)	abnormal regulatory T cell physiology	J:268677
Il2ra^{tm1b(EUCOMM)Wtsi}/Il2ra^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Il2ra^{tm1b(EUCOMM)Wtsi}/Orl)	abnormal spleen morphology	J:211773
	decreased lymphocyte cell number	J:211773
	enlarged lymph nodes	J:211773
	increased large unstained cell number	J:211773
	increased neutrophil cell number	J:211773
Il2ra^tm1Dw/Il2ra^tm1Dw (involves: 129S4/SvJae * C57BL/6)	abnormal B cell physiology	J:64279
	abnormal lymph organ size	J:64279
	abnormal T cell morphology	J:64279
	abnormal T cell physiology	J:64279
	colitis	J:64279
	enlarged lymph nodes	J:64279
	enlarged spleen	J:64279
	increased IgA level	J:64279
	increased IgG1 level	J:64279
	increased IgG2a level	J:64279
	increased IgG2b level	J:64279
	increased IgG level	J:64279
	increased lymphocyte cell number	J:64279
	increased memory T cell number	J:64279
Il2ra^tm1Dw/Il2ra^tm1Dw (B6.129S4-Il2ra^tm1Dw)	abnormal regulatory T cell physiology	J:125748
	abnormal T cell activation	J:125748
	lymphoid hyperplasia	J:125748
Il2ra^tm1Dw/Il2ra^tm1Dw (B6.129S4-Il2ra^tm1Dw/J)	lacrimal gland inflammation	J:125129
	large intestinal inflammation	J:125129
	lung inflammation	J:125129
	salivary gland inflammation	J:125129
Il2ra^tm1Dw/Il2ra^tm1Dw Tg(CD2-Ccdc86)1Hfuj/? (B6.Cg-Il2ra^tm1Dw Tg(CD2-Ccdc86)1Hfuj)	immune system phenotype	J:151722
	increased activated T cell number	J:151722
Il2ra^tm1Dw/Il2ra^tm1Dw Tg(Pgk1-HA)1.1Vbo/? Tg(Tcra/Tcrb)1Vbo/? (C.Cg-Il2ra^tm1Dw Tg(Pgk1-HA)1.1Vbo Tg(Tcra/Tcrb)1Vbo)	abnormal regulatory T cell physiology	J:112603
	decreased regulatory T cell number	J:112603
	increased regulatory T cell number	J:112603
Il2rb^m1Btlr/Il2rb^m1Btlr (C57BL/6J-Il2rb^m1Btlr)	decreased B cell number	J:267694
	decreased CD4-positive, alpha-beta T cell number	J:267694
	decreased CD8-positive, naive alpha-beta T cell number	J:267694
	increased effector memory CD4-positive, alpha-beta T cell number	J:267694
	increased effector memory CD8-positive, alpha-beta T cell number	J:267694
Il2rb^m2Btlr/Il2rb^m2Btlr (C57BL/6J-Il2rb^m2Btlr)	increased IgE level	J:272832
Il2rb^M3Btlr/Il2rb^M3Btlr (C57BL/6J-Il2rb^M3Btlr)	abnormal CD8-positive, alpha-beta T cell differentiation	J:272833
	abnormal T cell morphology	J:272833
	decreased CD8-positive, alpha-beta T cell number	J:272833
	decreased central memory CD8 positive, alpha-beta T cell number	J:272833
	decreased NK cell number	J:272833
	decreased NK T cell number	J:272833
	increased CD4-positive, alpha-beta T cell number	J:272833
	increased IgM level	J:272833
Il2rb^tm1Mak/Il2rb^tm1Mak (either: (involves: 129P2/OlaHsd) or (involves: 129S2/SvPas))	abnormal B cell activation	J:25940
	abnormal mononuclear cell morphology	J:25940
	abnormal T cell activation	J:25940
	decreased B cell number	J:25940
	decreased double-positive T cell number	J:25940
	decreased memory T cell number	J:25940
	enlarged lymph nodes	J:25940
	enlarged spleen	J:25940
	increased activated T cell number	J:25940
	increased anti-nuclear antigen antibody level	J:25940
	increased CD4-positive, alpha-beta T cell number	J:25940
	increased CD8-positive, alpha-beta T cell number	J:25940
	increased granulocyte number	J:25940
	increased IgE level	J:25940
	increased IgG1 level	J:25940
	increased neutrophil cell number	J:25940
	increased plasma cell number	J:25940
	increased susceptibility to autoimmune hemolytic anemia	J:25940
	thymus hypoplasia	J:25940
Il2rb^tm1Mak/Il2rb^tm1Mak (B6.129-Il2rb^tm1Mak)	abnormal lymphocyte morphology	J:113547
	abnormal response to transplant	J:113547
	abnormal spleen periarteriolar lymphoid sheath morphology	J:113547
	abnormal T cell activation	J:113547
	decreased regulatory T cell number	J:113547
	decreased T cell proliferation	J:113547
	enlarged lymph nodes	J:113547
	enlarged spleen	J:113547
	increased anti-double stranded DNA antibody level	J:113547
	increased susceptibility to autoimmune hemolytic anemia	J:113547
Il2rb^tm1Mak/Il2rb^tm1Mak (C.129-Il2rb^tm1Mak)	abnormal immune system organ morphology	J:113547
	abnormal lymphocyte morphology	J:113547
	abnormal marginal zone B cell morphology	J:113547
	abnormal spleen periarteriolar lymphoid sheath morphology	J:113547
	abnormal T cell activation	J:113547
	abnormal T cell clonal deletion	J:113547
	decreased CD8-positive, alpha-beta T cell number	J:113547
	decreased T cell proliferation	J:113547
	enlarged lymph nodes	J:113547
	enlarged spleen	J:113547
	increased anti-double stranded DNA antibody level	J:113547
	increased susceptibility to autoimmune hemolytic anemia	J:113547
	liver inflammation	J:113547
Il2rb^tm1Mak/Il2rb^tm1Mak (D2.129-Il2rb^tm1Mak)	abnormal T cell clonal deletion	J:113547
Il2rb^tm1Mak/Il2rb^tm1Mak Lck^tm1Mak/Lck^tm1Mak (involves: 129)	absent uterine NK cells	J:134589
Il2rb^tm1Mak/Il2rb^tm1Mak Rag2^tm1Fwa/Rag2^tm1Fwa (involves: 129 * 129S/SvEv)	decreased NK cell number	J:142654
Il2rg^tm1.1Asin/Il2rg^tm1Wjl Tg(Cd4-cre)1Cwi/0 (involves: 129S4/SvJae * C57BL/6 * DBA/2)	decreased CD4-positive, alpha-beta T cell number	J:190889
	decreased CD8-positive, alpha-beta T cell number	J:190889
Il2rg^tm1.1Asin/Il2rg^tm1Wjl Tg(Cd8a-cre)B8Asin/0 (involves: 129S4/SvJae C57BL/6)	decreased CD4-positive, alpha-beta T cell number	J:190889
	decreased CD8-positive, alpha-beta T cell number	J:190889
	decreased NK T cell number	J:190889
	decreased regulatory T cell number	J:190889
Il2rg^tm1.1Asin/Il2rg^tm1Wjl Tg(Cd8a-cre)B8Asin/0 Tg(LCKprBCL2)36Sjk/0 (involves: 129S4/SvJae C57BL/6)	decreased NK T cell number	J:190889
Il2rg^tm1.1Flv/Y Rag2^tm1.1Flv/Rag2^tm1.1Flv (involves: 129S4/SvJae * BALB/cAnNTac)	abnormal response to transplant	J:168303
	increased susceptibility to bacterial infection	J:168303
Il2rg^tm1.1Flv/Il2rg^tm1.1Flv Csf2/Il3^{tm1.1(CSF2,IL3)Flv}/Csf2/Il3^{tm1.1(CSF2,IL3)Flv} Rag2^tm1.1Flv/Rag2^tm1.1Flv (involves: 129S4/SvJae * BALB/cAnNCr * BALB/cAnNTac)	abnormal response to transplant	J:168302
Il2rg^tm1.1Flv/Il2rg^tm1.1Flv Rag2^tm1.1Flv/Rag2^tm1.1Flv (involves: 129S4/SvJae * BALB/cAnNTac)	abnormal response to transplant	J:168303
	increased susceptibility to bacterial infection	J:168303
Il2rg^tm1.1Flv/Il2rg^tm1.1Flv Rag2^tm1.1Flv/Rag2^tm1.1Flv Thpo^{tm1.1(TPO)Flv}/Thpo^{tm1.1(TPO)Flv} (involves: 129S4/SvJae * BALB/cAnNTac)	abnormal response to transplant	J:168301
Il2rg^tm1Cgn/Y (involves: 129 * CB20)	abnormal alpha-beta intraepithelial T cell morphology	J:22521
	abnormal class switch recombination	J:22521
	abnormal gamma-delta T cell differentiation	J:111821
	abnormal leukocyte morphology	J:22521
	abnormal thymocyte activation	J:22521
	absent gamma-delta intraepithelial T cell	J:111821
	absent gamma-delta T cells	J:111821
	absent NK cells	J:22521
	absent Peyer's patches	J:22521
	absent spleen germinal center	J:22521
	decreased IgE level	J:22521
	decreased IgM level	J:22521
	decreased mature B cell number	J:22521
	decreased plasma cell number	J:22521
	decreased pre-B cell number	J:22521
	decreased spleen white pulp amount	J:22521
	decreased T cell number	J:22521
	decreased T cell proliferation	J:22521
	impaired natural killer cell mediated cytotoxicity	J:22521
	spleen hypoplasia	J:22521
	thymus hypoplasia	J:111821, J:22521
Il2rg^tm1Cgn/Y Rag2^tm1Fwa/Rag2^tm1Fwa (B6.129-Rag2^tm1Fwa Il2rg^tm1Cgn)	absent B cells	J:132257
	absent NK cells	J:132257
	absent T cells	J:132257
Il2rg^tm1Cgn/Il2rg^tm1Cgn (involves: 129 * CB20)	abnormal alpha-beta intraepithelial T cell morphology	J:22521
	abnormal class switch recombination	J:22521
	abnormal leukocyte morphology	J:22521
	abnormal thymocyte activation	J:22521
	absent NK cells	J:22521
	absent Peyer's patches	J:22521
	absent spleen germinal center	J:22521
	decreased IgE level	J:22521
	decreased IgM level	J:22521
	decreased mature B cell number	J:22521
	decreased plasma cell number	J:22521
	decreased pre-B cell number	J:22521
	decreased spleen white pulp amount	J:22521
	decreased T cell number	J:22521
	decreased T cell proliferation	J:22521
	impaired natural killer cell mediated cytotoxicity	J:22521
	spleen hypoplasia	J:22521
	thymus hypoplasia	J:22521
Il2rg^tm1Cgn/Il2rg^tm1Cgn Kit^tm1.1Bsm/Kit^tm1.1Bsm (involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6)	arrested T cell differentiation	J:90485
Il2rg^tm1Cgn/Il2rg^tm1Cgn Rag2^tm1Fwa/Rag2^tm1Fwa (involves: 129P2/OlaHsd * 129S/SvEv)	abnormal interleukin secretion	J:142654
	decreased NK cell number	J:142654
	increased susceptibility to bacterial infection	J:142654
Il2rg^tm1Krf/Il2rg^tm1Krf (either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129P2/OlaHsd * FVB/N))	decreased thymocyte number	J:114561
Il2rg^tm1Krf/Il2rg^tm1Krf Tg(BCL2/IGH)1Tjd/0 (either: (involves: 129P2/OlaHsd * C3H/He * C57BL/6) or (involves: 129P2/OlaHsd * C3H/He * C57BL/6 * FVB/N))	decreased thymocyte number	J:114561
Il2rg^tm1Krf/Il2rg^tm1Krf Tg(Igh-Pim1)1Brn/0 (either: (involves: 129P2/OlaHsd * C57BL/6 * CBA) or (involves: 129P2/OlaHsd * C57BL/6 * CBA * FVB/N))	decreased thymocyte number	J:114561
Il2rg^tm1Sug/Y (either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129S6/SvEvTac * C57BL/6))	abnormal immune serum protein physiology	J:31167
	abnormal immune system cell morphology	J:31167
	abnormal immune system organ morphology	J:31167
	abnormal immunoglobulin level	J:31167
	abnormal myelopoiesis	J:31167
	abnormal splenic cell ratio	J:31167
	absent NK cells	J:31167
	absent spleen white pulp	J:31167
	arrested B cell differentiation	J:31167
	decreased IgG3 level	J:31167
	decreased IgG level	J:31167
	decreased lymphocyte cell number	J:31167
	decreased T cell number	J:31167
	decreased thymocyte number	J:31167
	enlarged Peyer's patches	J:31167
	enlarged spleen	J:31167
	increased macrophage cell number	J:31167
	increased monocyte cell number	J:31167
	increased neutrophil cell number	J:31167
	small lymph nodes	J:31167
	small thymus	J:31167
	thymus cortex hypoplasia	J:31167
	thymus hypoplasia	J:31167
Il2rg^tm1Sug/Il2rg^tm1Sug (B6.129-Il2rg^tm1Sug)	absent uterine NK cells	J:116952
Il2rg^tm1Wjl/Y (involves: 129S4/SvJae * C57BL/6)	abnormal B cell number	J:108209
	abnormal basophil physiology	J:24117
	abnormal CD4-positive, alpha beta T cell morphology	J:108209
	abnormal cell-mediated immunity	J:108209
	abnormal gut-associated lymphoid tissue morphology	J:24117
	abnormal immune serum protein physiology	J:108209
	abnormal immune system organ morphology	J:108209
	abnormal lymphocyte morphology	J:108209
	abnormal mast cell physiology	J:24117
	abnormal mesenteric lymph node morphology	J:24117
	abnormal thymocyte activation	J:24117
	absent gamma-delta intraepithelial T cell	J:24117
	absent gamma-delta T cells	J:24117
	absent NK cells	J:24117
	cecum inflammation	J:24117
	decreased CD8-positive, alpha-beta T cell number	J:24117
	decreased double-negative T cell number	J:24117
	decreased double-positive T cell number	J:24117
	decreased immature B cell number	J:24117
	decreased immunoglobulin level	J:24117
	decreased interferon-gamma secretion	J:24117
	decreased interleukin-2 secretion	J:24117
	decreased interleukin-4 secretion	J:24117
	decreased single-positive T cell number	J:24117
	decreased T cell proliferation	J:24117
	impaired natural killer cell mediated cytotoxicity	J:24117
	small lymph nodes	J:24117
	small thymus	J:24117
	small thymus cortex	J:24117
	spleen hyperplasia	J:24117
	spleen hypoplasia	J:24117
	thymus hyperplasia	J:108209
Il2rg^tm1Wjl/Y Crlf2^tm1Wjl/Crlf2^tm1Wjl (involves: 129S4/SvJae * C57BL/6)	thymus hypoplasia	J:108209
Il2rg^tm1Wjl/Y Prkdc^scid/Prkdc^scid (NOD.Cg-Prkdc^scid Il2rg^tm1Wjl/Sz)	abnormal immune system organ morphology	J:109833
	abnormal response to transplant	J:109833, J:140388
	abnormal splenic cell ratio	J:109833
	abnormal thymus morphology	J:109833
	decreased CD4-positive, alpha-beta T cell number	J:109833
	decreased CD8-positive, alpha-beta T cell number	J:109833
	decreased immature B cell number	J:109833
	decreased immunoglobulin level	J:109833
	decreased leukocyte cell number	J:109833
	decreased mature B cell number	J:109833
	decreased NK cell number	J:109833
	decreased spleen B cell follicle number	J:109833
	lymph node hypoplasia	J:109833
	small lymph nodes	J:109833
Il2rg^tm1Wjl/Y Rag1^tm1Mom/Rag1^tm1Mom (NOD.Cg-Rag1^tm1Mom Il2rg^tm1Wjl/SzJ)	abnormal adaptive immunity	J:140388
	abnormal innate immunity	J:140388
	abnormal response to transplant	J:140388
	abnormal spleen morphology	J:140388
	abnormal thymus morphology	J:140388
	absent NK T cells	J:140388
	absent thymus cortex	J:140388
	absent thymus medulla	J:140388
	decreased macrophage cell number	J:140388
	decreased spleen B cell follicle number	J:140388
	thymus cyst	J:140388
Il2rg^tm1Wjl/Il2rg^tm1Wjl (B6.129S4-Il2rg^tm1Wjl/J)	abnormal dendritic cell physiology	J:123902
	abnormal splenic cell ratio	J:123902
	decreased myeloid dendritic cell number	J:123902
Il2rg^tm1Wjl/Il2rg^tm1Wjl Prkdc^scid/Prkdc^scid (NOD.Cg-Prkdc^scid Il2rg^tm1Wjl/Sz)	abnormal immune system organ morphology	J:109833
	abnormal response to transplant	J:109833
	abnormal splenic cell ratio	J:109833
	abnormal thymus morphology	J:109833
	decreased CD4-positive, alpha-beta T cell number	J:109833
	decreased CD8-positive, alpha-beta T cell number	J:109833
	decreased immature B cell number	J:109833
	decreased immunoglobulin level	J:109833
	decreased leukocyte cell number	J:109833
	decreased mature B cell number	J:109833
	decreased NK cell number	J:109833
	decreased spleen B cell follicle number	J:109833
	lymph node hypoplasia	J:109833
	small lymph nodes	J:109833
	thymus cyst	J:109833
Il2rg^tm1Wjl/Il2rg^tm1Wjl Rag2^tm1Fwa/Rag2^tm1Fwa (involves: 129S/SvEv * 129S4/SvJae)	abnormal interferon secretion	J:140483
	absent NK cells	J:140483
	absent T cells	J:140483
	increased susceptibility to bacterial infection	J:140483
	lung inflammation	J:140483
Il2rg^tm1Wjl/Il2rg^tm1Wjl Tg(CD2-Ccdc86)1Hfuj/? (B6.Cg-Il2rg^tm1Wjl Tg(CD2-Ccdc86)1Hfuj)	decreased CD4-positive, alpha-beta T cell number	J:151722
	decreased CD8-positive, alpha-beta T cell number	J:151722
	decreased regulatory T cell number	J:151722
	decreased splenocyte number	J:151722
	immune system phenotype	J:151722
Il2rg^tm2Cgn/Y Tg(Mx1-cre)1Cgn/? (involves: 129P2/OlaHsd * C57BL/6 * CBA)	decreased NK cell number	J:132257
Il3^tm1Glli/Il3^tm1Glli (either: (involves: 129S2/SvPas * BALB/c) or (involves: 129S2/SvPas * C57BL/6))	abnormal mast cell differentiation	J:80500
	decreased susceptibility to type IV hypersensitivity reaction	J:80640
	increased susceptibility to parasitic infection	J:80500
Il3^tm1Glli/Il3^tm1Glli Kit^W/Kit^W-v (involves: 129S2/SvPas * C57BL/6 * WB)	increased susceptibility to parasitic infection	J:80500
Il3ra^m1/Il3ra^m1 (A/J)	abnormal leukopoiesis	J:23971
Il4/Il13^tm3Anjm/Il4/Il13^tm3Anjm (involves: 129P2/OlaHsd * C57BL/6)	abnormal immune system physiology	J:89095
	abnormal splenocyte physiology	J:72587
	abnormal susceptibility to infection	J:113543
	abnormal T-helper 2 physiology	J:89095
	decreased IgE level	J:113543, J:72587
	decreased IgG1 level	J:72587
	decreased IgG level	J:89095
	decreased susceptibility to parasitic infection	J:72587
	granulomatous inflammation	J:113543
	increased eosinophil cell number	J:113543
	increased susceptibility to parasitic infection	J:113543, J:89095
	increased susceptibility to parasitic infection induced morbidity/mortality	J:60609
Il4/Il13^tm3Anjm/Il4/Il13^tm3Anjm (C.129P2/OlaHsd-Il4/Il13^tm3Anjm)	abnormal interleukin-4 secretion	J:91403
	decreased IgE level	J:91403
	decreased interferon-gamma secretion	J:91403
	decreased interleukin-5 secretion	J:91403
	decreased interleukin-13 secretion	J:91403
	decreased susceptibility to autoimmune disorder	J:91403
	increased IgG2a level	J:91403
Il4/Il13^tm3Anjm/Il4/Il13^tm3Anjm (involves: 129P2/OlaHsd * BALB/c)	abnormal splenocyte physiology	J:60609
	abnormal susceptibility to infection	J:60609, J:131994
	decreased IgG1 level	J:178986
	decreased inflammatory response	J:60609, J:165513
	ileum inflammation	J:60609
	increased susceptibility to parasitic infection	J:60609
	increased susceptibility to parasitic infection induced morbidity/mortality	J:60609
Il4/Il13^tm3Anjm/Il4/Il13^tm3Anjm (involves: 129P2/OlaHsd * C57BL/6)	abnormal immune system physiology	J:89095
	abnormal splenocyte physiology	J:72587
	abnormal susceptibility to infection	J:113543
	abnormal T-helper 2 physiology	J:89095
	decreased IgE level	J:113543, J:72587
	decreased IgG1 level	J:72587
	decreased IgG level	J:89095
	decreased susceptibility to parasitic infection	J:72587
	granulomatous inflammation	J:113543
	increased eosinophil cell number	J:113543
	increased susceptibility to parasitic infection	J:113543, J:89095
	increased susceptibility to parasitic infection induced morbidity/mortality	J:60609
Il4/Il13^tm3Anjm/Il4/Il13^tm3Anjm (C.129P2/OlaHsd-Il4/Il13^tm3Anjm)	abnormal interleukin-4 secretion	J:91403
	decreased IgE level	J:91403
	decreased interferon-gamma secretion	J:91403
	decreased interleukin-5 secretion	J:91403
	decreased interleukin-13 secretion	J:91403
	decreased susceptibility to autoimmune disorder	J:91403
	increased IgG2a level	J:91403
Il4/Il13^tm3Anjm/Il4/Il13^tm3Anjm (involves: 129P2/OlaHsd * BALB/c)	abnormal splenocyte physiology	J:60609
	abnormal susceptibility to infection	J:60609, J:131994
	decreased IgG1 level	J:178986
	decreased inflammatory response	J:60609, J:165513
	ileum inflammation	J:60609
	increased susceptibility to parasitic infection	J:60609
	increased susceptibility to parasitic infection induced morbidity/mortality	J:60609
Il4^tm1(CD2)Irvr/Il4⁺ (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:111440
Il4^tm1(CD2)Mmrs/Il4^tm1(CD2)Mmrs (involves: 129)	decreased basophil cell number	J:181313
	decreased IgE level	J:178986
	decreased IgG1 level	J:178986
	decreased interleukin-4 secretion	J:181313
Il4^tm1.1Wep/Il4⁺ (C.129P2-Il4^tm1.1Wep)	decreased IgE level	J:138827
Il4^tm1.1Wep/Il4⁺ Stat6^tm1Gru/Stat6^tm1Gru (C.129-Stat6^tm1Gru Il4^tm1.1Wep)	abnormal T-helper 2 cell differentiation	J:138827
	decreased IgE level	J:138827
	impaired eosinophil recruitment	J:138827
Il4^tm1.1Wep/Il4^tm1.1Wep (involves: 129P2/OlaHsd * C57BL/6)	decreased interleukin-4 secretion	J:67964
Il4^tm1.1Wep/Il4^tm1.1Wep (C.129P2-Il4^tm1.1Wep)	abnormal T-helper 2 cell differentiation	J:138827
	decreased IgE level	J:138827
	impaired eosinophil recruitment	J:138827
Il4^tm1.1Wep/Il4^tm1.1Wep Stat6^tm1Gru/Stat6^tm1Gru (C.129-Stat6^tm1Gru Il4^tm1.1Wep)	abnormal T-helper 2 cell differentiation	J:138827
	decreased IgE level	J:138827
	impaired eosinophil recruitment	J:138827
Il4^tm1Cgn/Il4^tm1Cgn (B6.Cg-Il4^tm1Cgn)	abnormal humoral immune response	J:89095
Il4^tm1Cgn/Il4^tm1Cgn (B6.Cg-Il4^tm1Cgn)	abnormal T-helper 2 physiology	J:89095
Il4^tm1Cgn/Il4^tm1Cgn (NOD.129P2-Il4^tm1Cgn)	decreased susceptibility to autoimmune disorder	J:95105
Il4^tm1Cgn/Il4^tm1Cgn (NOD.129P2-Il4^tm1Cgn)	increased susceptibility to autoimmune disorder	J:95105
Il4^tm1Cgn/Il4^tm1Cgn (NOD.Cg-H2^b Il4^tm1Cgn)	lacrimal gland inflammation	J:105803
Il4^tm1Cgn/Il4^tm1Cgn (NOD.Cg-H2^b Il4^tm1Cgn)	salivary gland inflammation	J:105803
Il4^tm1Cgn/Il4^tm1Cgn (involves: 129P2/OlaHsd * NOD)	abnormal cytokine secretion	J:85924
Il4^tm1Cgn/Il4^tm1Cgn (involves: 129P2/OlaHsd * NOD)	decreased IgG1 level	J:85924
Il4^tm1Cgn/Il4^tm1Cgn (either: NOD.129-Il4^tm1Cgn or (involves: 129 * NOD))	autoimmune response	J:85924
	insulitis	J:85924
Il4^tm1Cgn/Il4^tm1Cgn (involves: 129P2/OlaHsd * C57BL/6)	abnormal cytokine secretion	J:704
	decreased IgE level	J:704
	decreased IgG1 level	J:704
	granulomatous inflammation	J:113543
Il4^tm1Cgn/Il4^tm1Cgn (MRL.129P2-Il4^tm1Cgn)	lacrimal gland inflammation	J:132514
Il4^tm1Cgn/Il4^tm1Cgn (B6.129P2-Il4^tm1Cgn/J)	immune system phenotype	J:160119, J:44346
Il4^tm1Cgn/Il4^tm1Cgn (involves: 129P2/OlaHsd * C57BL/6J * MRL/Mp)	decreased IgE level	J:39600
	decreased IgG1 level	J:39600
Il4^tm1Cgn/Il4^tm1Cgn (involves: 129P2/OlaHsd * A/WySn * C57BL/10SnSg * Swiss)	decreased IgG1 level	J:119207
	increased IgG2a level	J:119207
Il4^tm1Cgn/Il4^tm1Cgn Ndfip1^{Gt(RRD002)Byg}/Ndfip1^{Gt(RRD002)Byg} (involves: 129P2/OlaHsd)	esophageal inflammation	J:205692
	increased CD4-positive, alpha-beta T cell number	J:205692
	increased eosinophil cell number	J:205692
	increased inflammatory response	J:205692
	increased interleukin-2 secretion	J:205692
	increased neutrophil cell number	J:205692
	increased T cell number	J:205692
	lung inflammation	J:205692
Il4^tm1Cgn/Il4^tm1Cgn Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0 (NOD.Cg-Il4^tm1Cgn Tg(TcraBDC2.5,TcrbBDC2.5)1Doi)	decreased susceptibility to autoimmune diabetes	J:85924
	insulitis	J:85924
Il4^tm1Kopf/Il4^tm1Kopf (involves: 129S2/SvPas * C57BL/6)	abnormal response to infection	J:14593
	decreased IgE level	J:14593
	decreased IgG1 level	J:14593
	decreased interleukin-3 secretion	J:14593
	decreased interleukin-4 secretion	J:14593
	decreased interleukin-5 secretion	J:14593
	decreased interleukin-10 secretion	J:14593
	increased IgG level	J:14593
Il4^tm1Kopf/Il4^tm1Kopf (involves: 129S2/SvPas)	decreased eosinophil cell number	J:113065
	decreased IgE level	J:113065
	decreased interleukin-5 secretion	J:113065
Il4^tm1Kopf/Il4^tm1Kopf Lyn^tm1Ard/Lyn^tm1Ard (involves: 129P2/OlaHsd * 129S2/SvPas)	abnormal circulating complement protein level	J:161523
	decreased B cell number	J:161523
	decreased IgE level	J:161523
	decreased IgG1 level	J:161523
	increased anti-double stranded DNA antibody level	J:161523
	increased anti-nuclear antigen antibody level	J:161523
	increased basophil cell number	J:161523
	increased IgA level	J:161523
	increased IgG2a level	J:161523
	increased IgG2b level	J:161523
	increased IgM level	J:161523
	increased mast cell number	J:161523
Il4^tm1Lky/Il4⁺ Lat^tm1.1Mal/Lat^tm1.1Mal (involves: 129S2/SvPas * C57BL/6)	abnormal T-helper 2 physiology	J:151840
Il4^tm1Lky/Il4^tm1Lky Itk^tm1Litt/Itk^tm1Litt (involves: 129S4/SvJae * BALB/c * C57BL/6J)	abnormal cytokine secretion	J:129883
	abnormal response to infection	J:129883
	abnormal T-helper 2 physiology	J:129883
	immune system phenotype	J:129883
Il4^tm1Nnt/Il4^tm1Nnt (C57BL/6-Il4^tm1Nnt/J)	abnormal microglial cell morphology	J:125605
	abnormal T-helper 2 physiology	J:37196
	CNS inflammation	J:125605
	decreased IgE level	J:37196
	decreased IgG1 level	J:37196
	decreased IgM level	J:37196
	decreased interleukin-4 secretion	J:37196
	decreased interleukin-5 secretion	J:37196
	decreased interleukin-10 secretion	J:120556, J:37196
	granulomatous inflammation	J:37196
	increased IgA level	J:37196
	increased interferon-gamma secretion	J:120556, J:37196
	stomach inflammation	J:120556
Il4^tm1Nnt/Il4^tm1Nnt (involves: C57BL/6)	abnormal interleukin-4 secretion	J:91403
Il4^tm1Nnt/Il4^tm1Nnt (involves: C57BL/6)	decreased susceptibility to autoimmune disorder	J:91403
Il4^tm1Rao/Il4^tm1Rao (involves: 129S6/SvEvTac * C57BL/6)	abnormal mast cell physiology	J:78089
	abnormal T-helper 2 physiology	J:78089
	decreased interleukin-4 secretion	J:78089
	decreased interleukin-13 secretion	J:78089
Il4^tm2.1Kubo/Il4^tm2.1Kubo (B6.Cg-Il4^tm2.1Kubo)	decreased IgE level	J:167446
	decreased IgG1 level	J:167446
	decreased interleukin-4 secretion	J:167446
	impaired eosinophil recruitment	J:167446
	increased IgG2c level	J:167446
	increased interleukin-5 secretion	J:167446
	increased interleukin-13 secretion	J:167446
Il4^tm2Nnt/Il4^tm2Nnt (BALB/c-Il4^tm2Nnt/J)	abnormal dendritic cell antigen presentation	J:141937
	abnormal dendritic cell differentiation	J:141937
	decreased IgE level	J:31486
	decreased IgG1 level	J:31486
	decreased interleukin-5 secretion	J:141937
	decreased interleukin-13 secretion	J:141937
	decreased susceptibility to autoimmune disorder	J:141937
	increased interferon-gamma secretion	J:141937
Il4^tm2Nnt/Il4^tm2Nnt (BALB/c-Il4^tm2Nnt)	abnormal splenocyte physiology	J:60609
	abnormal susceptibility to infection	J:60609
	ileum inflammation	J:60609
	increased susceptibility to parasitic infection	J:60609
	increased susceptibility to parasitic infection induced morbidity/mortality	J:60609
Il4^tm2Nnt/Il4^tm2Nnt Tgfb1^tm1Doe/Tgfb1^tm1Doe (C.Cg-Tgfb1^tm1Doe Il4^tm2Nnt)	liver inflammation	J:69346
Il4^tm3.1Kubo/Il4^tm3.1Kubo (B6.Cg-Il4^tm3.1Kubo)	decreased interleukin-4 secretion	J:167446
Il4ppq^NZB/Slc/Il4ppq^NZW/Slc (involves: NZB/Slc * NZW/Slc)	abnormal cytokine secretion	J:117863
Il4ra^M1Btlr/Il4ra^M1Btlr (C57BL/6J-Il4ra^M1Btlr)	decreased IgE level	J:267558
Il4ra^M2Btlr/Il4ra^M2Btlr (C57BL/6J-Il4ra^M2Btlr)	decreased IgE level	J:272804
Il4ra^tm1Fbb/Il4ra^tm1Fbb (involves: BALB/c)	abnormal susceptibility to infection	J:55526
Il4ra^tm1Fbb/Il4ra^tm1Fbb (involves: BALB/cJ)	abnormal circulating cytokine level	J:133518
	abnormal circulating interferon-gamma level	J:133518
	abnormal cytokine secretion	J:114751
	abnormal immune system physiology	J:114751
	abnormal macrophage physiology	J:114751
	decreased T-helper 2 cell number	J:172134
	granulomatous inflammation	J:114751
	impaired macrophage chemotaxis	J:114751
	increased circulating interleukin-4 level	J:133518
	increased susceptibility to infection	J:114751
	increased susceptibility to parasitic infection	J:114751
	liver inflammation	J:114751
Il4ra^tm1Fbb/Il4ra^tm2Fbb Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * BALB/c)	abnormal immune system physiology	J:114751
	abnormal macrophage physiology	J:114751
	decreased susceptibility to parasitic infection	J:114751
	granulomatous inflammation	J:114751
	increased susceptibility to parasitic infection	J:114751
	liver inflammation	J:114751
Il4ra^tm1Sz/Il4ra^tm1Sz (BALB/c-Il4ra^tm1Sz/J)	abnormal microglial cell morphology	J:125605
	abnormal susceptibility to infection	J:131994
	abnormal T-helper 2 physiology	J:43656
	decreased IgE level	J:43656
	decreased IgG1 level	J:43656
	decreased interleukin-4 secretion	J:43656
	decreased interleukin-5 secretion	J:43656
	decreased interleukin-10 secretion	J:43656
	increased IgG2a level	J:43656
Il4ra^tm1Sz/Il4ra^tm1Sz (BALB/c-Il4ra^tm1Sz)	increased IgG2a level	J:110429
Il4ra^tm1Sz/Il4ra^tm1Sz (BALB/c-Il4ra^tm1Sz)	increased susceptibility to parasitic infection	J:110429
Il4ra^tm1Sz/Il4ra^tm1Sz Il7r^tm1.1Asin/Il7r^tm1Imx Tg(Cd8a-cre)B8Asin/0 (involves: 129S7/SvEvBrd BALB/cJ * C57BL/6)	decreased CD8-positive, alpha-beta T cell number	J:190889
Il4ra^tm1Tch/Il4ra^tm1Tch (involves: 129X1/SvJ * BALB/c)	abnormal immune serum protein physiology	J:86215
	abnormal T-helper 2 cell morphology	J:86215
	decreased T cell proliferation	J:86215
	increased IgE level	J:86215
	increased IgG level	J:86215
	respiratory system inflammation	J:86215
Il4ra^tm2Tch/Il4ra^tm2Tch (C.129X1-Il4ra^tm2Tch)	abnormal T-helper 2 physiology	J:152376
	increased circulating interleukin-4 level	J:152376
	increased eosinophil cell number	J:152376
	increased IgE level	J:152376
	increased monocyte cell number	J:152376
	increased susceptibility to type I hypersensitivity reaction	J:152376
	respiratory system inflammation	J:152376
Il4ra^tm2Tch/Il4ra^tm2Tch Tg(Scgb1a1-rtTA,tetO-Il13)1Eli/? (B6.Cg-Il4ra^tm2Tch Tg(Scgb1a1-rtTA,tetO-IL13)1Eli)	increased eosinophil cell number	J:152376
	respiratory system inflammation	J:152376
Il4ra^tm3.1Tch/Il4ra^tm3.1Tch (C.129X1-Il4ra^tm3.1Tch)	abnormal macrophage activation involved in immune response	J:160806
	increased IgE level	J:160806
	increased interleukin-4 secretion	J:160806
	increased susceptibility to type I hypersensitivity reaction	J:160806
Il5^{tm1.1(icre)Lky}/Il5⁺ (C57BL/6-Il5^{tm1.1(icre)Lky})	decreased circulating interleukin-5 level	J:206097
Il5^tm1Anjm/Il5^tm1Anjm (involves: 129P2/OlaHsd * C57BL/6)	abnormal mast cell morphology	J:113543
	abnormal mast cell physiology	J:113543
	abnormal susceptibility to infection	J:113543
	decreased eosinophil cell number	J:113543
	decreased IgE level	J:113543
	granulomatous inflammation	J:113543
	increased susceptibility to parasitic infection	J:113543
Il5^tm1Anjm/Il5^tm1Anjm Il9^tm1Anjm/Il9^tm1Anjm (involves: 129P2/OlaHsd * C57BL/6)	abnormal humoral immune response	J:113543
	abnormal interleukin level	J:113543
	abnormal mast cell morphology	J:113543
	abnormal mast cell physiology	J:113543
	abnormal susceptibility to infection	J:113543
	decreased eosinophil cell number	J:113543
	decreased IgE level	J:113543
	granulomatous inflammation	J:113543
	increased susceptibility to parasitic infection	J:113543
Il5^tm1Kopf/Il5^tm1Kopf (C57BL/6-Il5^tm1Kopf/J)	increased eosinophil cell number	J:30867
Il5^tm1Kopf/Il5^tm1Kopf (C57BL/6-Il5^tm1Kopf)	granulomatous inflammation	J:107418
	increased interferon-gamma secretion	J:107418
	increased lymphocyte cell number	J:30641
	increased neutrophil cell number	J:30641
Il5^tm1Ktk/Il5⁺ (B6.129S4-Il5^tm1Ktk)	decreased interleukin-5 secretion	J:180790
Il5^tm1Ktk/Il5^tm1Ktk (B6.129S4-Il5^tm1Ktk)	abnormal B-1 B cell morphology	J:180790
Il5^tm1Ktk/Il5^tm1Ktk (B6.129S4-Il5^tm1Ktk)	decreased interleukin-5 secretion	J:180790
Il5^tm2Anjm/Il5^tm2Anjm Il9^tm1Anjm/Il9^tm1Anjm (involves: 129P2/OlaHsd * C57BL/6)	abnormal immunoglobulin level	J:113543
	abnormal interleukin level	J:113543
	abnormal susceptibility to infection	J:113543
	granulomatous inflammation	J:113543
	increased eosinophil cell number	J:113543
	increased susceptibility to parasitic infection	J:113543
Il5^tm3Anjm/Il5^tm3Anjm (involves: 129P2/OlaHsd * C57BL/6)	granulomatous inflammation	J:113543
Il5^tm3Anjm/Il5^tm3Anjm Il9^tm1Anjm/Il9^tm1Anjm (involves: 129P2/OlaHsd * C57BL/6)	granulomatous inflammation	J:113543
Il5ra^tm1Ktk/Il5ra^tm1Ktk (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell differentiation	J:33140
	abnormal eosinophil cell number	J:33140
	abnormal immune system physiology	J:33140
	abnormal lymphopoiesis	J:33140
	abnormal T cell differentiation	J:33140
	decreased CD4-positive, alpha-beta T cell number	J:33140
	decreased IgA level	J:33140
	decreased IgG3 level	J:33140
	decreased IgM level	J:33140
	decreased immunoglobulin level	J:33140
	increased susceptibility to parasitic infection	J:33140
Il5ra^tm1Ktk/Il5ra^tm1Ktk (B6.129P2-Il5ra^tm1Ktk)	abnormal B-1 B cell morphology	J:89849
	decreased B cell proliferation	J:89849
	decreased B-1 B cell number	J:89849
	decreased IgA level	J:89849
	decreased IgG1 level	J:89849
	decreased IgG3 level	J:89849
	decreased IgM level	J:89849
Il5ra^tm1Ktk/Il5ra^tm1Ktk Lyn^tm1Tya/Lyn^tm1Tya (involves: 129P2/OlaHsd * C57BL/6)	abnormal immune system organ morphology	J:91089
	abnormal spleen B cell corona morphology	J:91089
	abnormal spleen white pulp morphology	J:91089
	decreased B-1 B cell number	J:91089
	enlarged lymph nodes	J:91089
	enlarged spleen	J:91089
	glomerulonephritis	J:91089
	increased anti-double stranded DNA antibody level	J:91089
	increased IgA level	J:91089
	increased IgM level	J:91089
	increased immunoglobulin level	J:91089
Il6^tm1.1Jho/Il6^tm1.1Jho Tg(GFAP-cre)8Gtm/0 (involves: 129S4/SvJaeSor * 129X1/SvJ * C57BL/6 * CBA)	microgliosis	J:211914
Il6^tm1Kopf/Il6⁺ Prdm1^tm1Clme/Prdm1^tm1Clme Tg(Itgax-cre)1-1Reiz/0 (involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6 * CBA)	immune system phenotype	J:178876
Il6^tm1Kopf/Il6⁺ Tg(ED-L2-IL1RN/IL1B)#Tcw/? (B6.Cg-Il6^tm1Kopf Tg(ED-L2-IL1RN/IL1B)#Tcw)	esophageal inflammation	J:180282
Il6^tm1Kopf/Il6^tm1Kopf (involves: 129S2/SvPas * C57BL/6)	abnormal acute phase protein level	J:17360
	abnormal microglial cell morphology	J:79142
	abnormal T cell differentiation	J:17360
	decreased cytotoxic T cell cytolysis	J:17360
	decreased T cell number	J:17360
	increased susceptibility to bacterial infection	J:17360
	increased susceptibility to induced colitis	J:79073
	increased susceptibility to Poxviridae infection	J:17360
Il6^tm1Kopf/Il6^tm1Kopf (B6.129S2-Il6^tm1Kopf/J)	abnormal interleukin-6 secretion	J:109359
	decreased interferon-gamma secretion	J:123351
	decreased pro-B cell number	J:117320
	decreased susceptibility to induced arthritis	J:208213
	increased interleukin-4 secretion	J:123351
Il6^tm1Kopf/Il6^tm1Kopf (involves: 129S2/SvPas)	abnormal inflammatory response	J:160966
	abnormal T cell physiology	J:159479
	decreased interleukin-17 secretion	J:159479
	increased susceptibility to bacterial infection induced morbidity/mortality	J:161073
Il6^tm1Kopf/Il6^tm1Kopf Il6st^tm1Ern/Il6st^tm1Ern (involves: 129S1/Sv * 129S2/SvPas)	decreased susceptibility to endotoxin shock	J:168781
	immune system phenotype	J:139226
Il6^tm1Kopf/Il6^tm1Kopf Inpp5d^tm1Rkh/Inpp5d^tm1Rkh (involves: 129 * C57BL/6)	abnormal lymphopoiesis	J:117320
	abnormal myelopoiesis	J:117320
	decreased pro-B cell number	J:117320
Il6^tm1Kopf/Il6^tm1Kopf Junb^tm3Wag/Junb^tm3Wag Tg(KRT5-cre)1Tak/0 (involves: 129/Sv * 129P2/OlaHsd * 129S2/SvPas * C3H * C57BL/6)	immune system phenotype	J:155575
	skin inflammation	J:155575
Il6^tm1Kopf/Il6^tm1Kopf Tank^tm1Aki/Tank^tm1Aki (involves: 129/Sv * 129S2/SvPas * C57BL/6)	immune system phenotype	J:151757
Il6^tm1Kopf/Il6^tm1Kopf Tg(ED-L2-IL1RN/IL1B)#Tcw/? (B6.Cg-Il6^tm1Kopf Tg(ED-L2-IL1RN/IL1B)#Tcw)	esophageal inflammation	J:180282
Il6^tm1Kopf/Il6^tm1Kopf Tg(Rorc-EGFP)1Ebe/? (involves: 129S2/SvPas * C57BL/6)	abnormal effector T cell morphology	J:137020
Il6^tm1Mur/Il6^tm1Mur (involves: 129P2/OlaHsd * C57BL/6)	abnormal neutrophil physiology	J:25684
	immune system phenotype	J:25684
	increased susceptibility to bacterial infection	J:25684
Il6^tm1Mur/Il6^tm1Mur (involves: 129/Sv * C57BL/6)	abnormal interferon level	J:40579
	abnormal lymphocyte cell number	J:40579
	absent NK cells	J:40579
	brain inflammation	J:40579
	increased susceptibility to parasitic infection	J:40579
Il6^tm1Mur/Il6^tm1Mur (B6.129P2(B6)-Il6^tm1Mur)	abnormal inflammatory response	J:85581
	abnormal microglial cell morphology	J:85581
	abnormal microglial cell physiology	J:85581
	abnormal osteoclast differentiation	J:65093
	abnormal osteoclast physiology	J:65093
Il6^tm1Poli/Il6^tm1Poli (involves: 129S/SvEv * MF1)	abnormal macrophage physiology	J:79314
	abnormal neutrophil physiology	J:79314
	abnormal osteoclast physiology	J:17249
	abnormal T-helper 1 cell morphology	J:79314
	abnormal T-helper 1 physiology	J:79314
	abnormal T-helper 2 physiology	J:79314
	decreased circulating interleukin-12 level	J:79314
	decreased IgA level	J:79314
	decreased IgE level	J:79314
	immune system phenotype	J:17249
	increased circulating interleukin-10 level	J:79314
	increased IgG2a level	J:79314
	increased susceptibility to fungal infection	J:79314
Il6^tm1Poli/Il6^tm1Poli (involves: 129S/SvEv * C57BL/6)	decreased inflammatory response	J:68063
Il6^tm1Poli/Il6^tm1Poli (involves: 129S/SvEv * C57BL/6)	impaired neutrophil recruitment	J:68063
Il6^tm1Poli/Il6^tm1Poli (CAnNCrl.129S(Cg)-Il6^tm1Poli)	abnormal B cell proliferation	J:42869
	abnormal immune system physiology	J:96706
	decreased inflammatory response	J:42869
Il6ra^{tm1.1(IL6R)Csk}/Il6ra^{tm1.1(IL6R)Csk} (involves: 129S6/SvEvTac * C57BL/6)	abnormal circulating serum amyloid protein level	J:207264
Il6ra^{tm1.1(IL6R)Csk}/Il6ra^{tm1.1(IL6R)Csk} Tg(H2-L-IL6)40Csk/0 (involves: 129S6/SvEvTac * C57BL/6)	enlarged lymph nodes	J:207264
	enlarged spleen	J:207264
	increased plasma cell number	J:207264
	increased spleen weight	J:207264
	increased spleen white pulp amount	J:207264
Il6ra^tm1.1Drew/Il6ra^tm1.1Drew Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: C57BL/6 * C57BL/6N * SJL)	immune system phenotype	J:160966
Il6ra^tm1.1Drew/Il6ra^tm1.1Drew Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺ (involves: C57BL/6 * C57BL/6N * SJL)	decreased acute inflammation	J:160966
Il6ra^tm1.1Jcbr/Il6ra^tm1.1Jcbr Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6)	decreased circulating interleukin-1 beta level	J:188445
	decreased circulating tumor necrosis factor level	J:188445
	decreased susceptibility to parasitic infection	J:188445
Il6ra^tm1.1Jcbr/Il6ra^tm1.1Jcbr Tg(Alb1-cre)7Gsc/0 (involves: C57BL/6 * FVB/N)	decreased circulating interleukin-1 beta level	J:188445
	decreased circulating tumor necrosis factor level	J:188445
	decreased susceptibility to parasitic infection	J:188445
	increased circulating interleukin-6 level	J:166367
	increased circulating tumor necrosis factor level	J:166367
Il6ra^tm1.2Drew/Il6ra^tm1.2Drew (involves: C57BL/6 * C57BL/6N * FVB/N * SJL)	abnormal inflammatory response	J:160966
Il6ra^tm1.2Jcbr/Il6ra^tm1.2Jcbr (involves: C57BL/6)	decreased circulating interleukin-1 beta level	J:188445
	decreased circulating tumor necrosis factor level	J:188445
	decreased susceptibility to parasitic infection	J:188445
	decreased susceptibility to parasitic infection induced morbidity/mortality	J:188445
	liver inflammation	J:202764
Il6ra^tm1Saj/Il6ra^tm1Saj (involves: 129P2/OlaHsd * C57BL/6J)	abnormal CD4-positive, alpha-beta T cell physiology	J:159479
Il6st^tm1Ard/Il6st^tm1Ard (involves: 129S1/Sv * C57BL/6)	abnormal leukocyte cell number	J:110742
	abnormal thrombopoiesis	J:110742
	cecum inflammation	J:79555
	conjunctivitis	J:79555
	decreased IgA level	J:79555
	decreased IgG level	J:79555
	decreased immunoglobulin level	J:79555
	increased inflammatory response	J:79555
	increased susceptibility to induced colitis	J:79073
	increased susceptibility to parasitic infection	J:79555
Il6st^tm1Ern/Il6st^tm1Ern (involves: 129S1/Sv * C57BL/6)	abnormal inflammatory response	J:139226
	decreased susceptibility to induced colitis	J:79073
	enlarged spleen	J:79073
	increased osteoclast cell number	J:87612
	increased susceptibility to induced arthritis	J:142883
	stomach inflammation	J:87206
Il6st^tm1Ern/Il6st^tm1Ern (involves: 129S1/Sv)	increased circulating interleukin-6 level	J:168781
	increased interleukin-6 secretion	J:168781
	increased neutrophil cell number	J:168781
	increased susceptibility to endotoxin shock	J:168781
Il6st^tm1Ern/Il6st^tm1Ern Stat1^tm1Rds/Stat1^tm1Rds (involves: 129S1/Sv)	abnormal inflammatory response	J:139226
Il6st^tm1Ern/Il6st^tm1Ern Stat3^tm1Aki/Stat3⁺ (involves: 129P2/OlaHsd * 129S1/Sv)	decreased circulating interleukin-6 level	J:168781
	decreased susceptibility to endotoxin shock	J:168781
	immune system phenotype	J:100160, J:142883, J:139226
Il6st^tm1Ern/Il6st^tm1Ern Tg(RP11-H2112)5Trme/0 (involves: 129S1/Sv * C57BL/6J * DBA/2J)	abnormal spleen size	J:234656
Il6st^tm1Ern/Il6st^tm1Ern Tg(RP11-H2112)9Trme/0 (involves: 129S1/Sv * C57BL/6J * DBA/2J)	abnormal spleen size	J:234656
Il6st^tm1Ern/Il6st^tm1Ern Tirap^tm1.1Pjh/Tirap^tm1.1Pjh (involves: 129S1/Sv)	decreased circulating interleukin-6 level	J:168781
	decreased susceptibility to endotoxin shock	J:168781
Il6st^tm1Kish/Il6st^tm1Kish (involves: 129P2/OlaHsd * C57BL/6)	thymus hypoplasia	J:75419
Il6st^tm1Kish/Il6st^tm1Kish (involves: 129P2/OlaHsd * CD-1)	abnormal bone marrow development	J:88710
	abnormal osteoclast differentiation	J:88710
	abnormal osteoclast morphology	J:88710
	abnormal osteoclast physiology	J:88710
	increased osteoclast cell number	J:88710
Il6st^tm1Thir/Il6st^tm1Thir (Not Specified)	abnormal B cell physiology	J:59922
	abnormal dendritic cell antigen presentation	J:113335
	decreased interleukin-4 secretion	J:59922
	enlarged axillary lymph nodes	J:59922
	enlarged cervical lymph nodes	J:59922
	enlarged inguinal lymph nodes	J:59922
	enlarged mesenteric lymph nodes	J:59922
	increased B cell number	J:59922
	increased CD4-positive, alpha-beta T cell number	J:59922
	increased CD8-positive, alpha-beta T cell number	J:59922
	increased IgG2a level	J:59922
	increased IgG2b level	J:59922
	increased interferon-gamma secretion	J:59922
	lymph node hyperplasia	J:59922
	spleen hyperplasia	J:59922
Il6st^tm1Thir/Il6st^tm1Thir (involves: 129 * C57BL/6)	abnormal T cell activation	J:133059
	abnormal T cell clonal deletion	J:133059
	abnormal thymocyte activation	J:133059
	decreased double-positive T cell number	J:133059
	increased activated T cell number	J:133059
	increased anti-double stranded DNA antibody level	J:133059
	increased anti-nuclear antigen antibody level	J:133059
	increased anti-single stranded DNA antibody level	J:133059
	increased autoantibody level	J:133059
	increased double-negative T cell number	J:133059
	increased IgA level	J:133059
	increased IgG1 level	J:133059
	increased IgG2a level	J:133059
	increased IgG2b level	J:133059
	increased neutrophil cell number	J:133059
	increased single-positive T cell number	J:133059
	rheumatoid arthritis	J:133059
Il6st^tm1Thir/Il6st^tm1Thir Rag2^tm1Fwa/Rag2^tm1Fwa (involves: 129S/SvEv * C57BL/6)	immune system phenotype	J:133059
Il6st^tm1Thir/Il6st^tm1Thir Tg(TcraH-Y,TcrbH-Y)71Vbo/? (involves: 129 * C57BL/6 * DBA)	abnormal negative T cell selection	J:133059
Il6st^tm1Wme/Il6st^tm1Wme (involves: 129P2/OlaHsd * C57BL/6)	abnormal immunoglobulin level	J:67677
	abnormal T cell differentiation	J:67677
	abnormal thrombopoiesis	J:67677
	decreased thymocyte number	J:67677
	increased IgE level	J:67677
	increased IgG level	J:67677
	increased leukocyte cell number	J:67677
Il6st^tm2Thir/Il6st^tm2Thir (Not Specified)	abnormal dendritic cell antigen presentation	J:113335
	decreased B-1a cell number	J:59922
	decreased IgG1 level	J:59922
	decreased IgG2a level	J:59922
	decreased IgG2b level	J:59922
	decreased interferon-gamma secretion	J:59922
	increased IgM level	J:59922
Il6st^tm3Thir/Il6st^tm3Thir (Not Specified)	decreased IgA level	J:59922
	decreased IgG2a level	J:59922
	decreased IgG2b level	J:59922
Il7^hlb368/Il7^hlb368 (C57BL/6J-Il7^hlb368/J)	abnormal T cell subpopulation ratio	J:118450
	absent axillary lymph nodes	J:118450
	absent cervical lymph nodes	J:118450
	absent mesenteric lymph nodes	J:118450
	absent Peyer's patches	J:118450
	absent popliteal lymph nodes	J:118450
	decreased leukocyte cell number	J:82961, J:118450
	decreased T cell number	J:118450
	small inguinal lymph nodes	J:118450
	small spleen	J:118450
	small thymus	J:118450
	spleen hypoplasia	J:118450
	thymus hypoplasia	J:118450
Il7^m1Jyen/Il7^m1Jyen (involves: C3H * C57BL/6)	abnormal myeloid leukocyte morphology	J:136470
	decreased B cell number	J:136470
	decreased single-positive T cell number	J:136470
	lymph node hypoplasia	J:136470
	spleen hypoplasia	J:136470
	thymus hypoplasia	J:136470
Il7^tm1.1Mysl/Il7⁺ (B6.129P2(Cg)-Il7^tm1.1Mysl)	decreased T cell number	J:200544
Il7^tm1.1Mysl/Il7⁺ (B6.129P2(Cg)-Il7^tm1.1Mysl)	small lymph nodes	J:200544
Il7^tm1.1Mysl/Il7^tm1.1Mysl (B6.129P2(Cg)-Il7^tm1.1Mysl)	abnormal mesenteric lymph node morphology	J:200544
	arrested B cell differentiation	J:200544
	decreased T cell number	J:200544
	decreased thymocyte number	J:200544
	immune system phenotype	J:200544
	small lymph nodes	J:200544
	thymus hypoplasia	J:200544
Il7^tm1Dnax/Il7^tm1Dnax (involves: 129P2/OlaHsd * C57BL/6)	abnormal CD8-positive, alpha beta T cell morphology	J:125259
	absent lymph nodes	J:24165
	absent Peyer's patches	J:24165
	arrested B cell differentiation	J:24165
	decreased lymphocyte cell number	J:24165
	decreased spleen weight	J:24165
	decreased thymus weight	J:24165
	small spleen	J:24165
	small thymus	J:24165
	spleen hypoplasia	J:24165
	thymus hypoplasia	J:24165
Il7^tm1Dnax/Il7^tm1Dnax (involves: 129P2/OlaHsd)	decreased thymocyte number	J:64861
Il7^tm1Dnax/Il7^tm1Dnax Rag2^tm1Fwa/Rag2^tm1Fwa (involves: 129P2/OlaHsd * 129S/SvEv)	decreased NK cell number	J:132257
Il7^tm1Hms/Il7^tm1Hms (involves: 129S6/SvEvTac)	spleen hypoplasia	J:43971
Il7^tm1Hms/Il7^tm1Hms (involves: 129S6/SvEvTac)	thymus hypoplasia	J:43971
Il7^tm2.1Iku/Il7^tm2.1Iku Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺ (involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * DBA)	abnormal B cell differentiation	J:190615
	abnormal NK T cell physiology	J:190615
	decreased B cell number	J:190615
	decreased double-negative T cell number	J:190615
	decreased lymphocyte cell number	J:190615
	decreased NK T cell number	J:190615
	decreased T cell number	J:190615
	immune system phenotype	J:190615
Il7r^tm1.1Asin/Il7r^tm1Imx Tg(Cd4-cre)1Cwi/0 (involves: 129S7/SvEvBrd * C57BL/6 * DBA/2)	decreased CD8-positive, alpha-beta T cell number	J:190889
Il7r^tm1.1Asin/Il7r^tm1Imx Tg(Cd8a-cre)B8Asin/0 (involves: 129S7/SvEvBrd C57BL/6)	decreased CD8-positive, alpha-beta T cell number	J:190889
Il7r^tm1Abra/Il7r^tm1Abra (B6.129S4-Il7r^tm1Abra)	abnormal CD4-positive, alpha-beta T cell physiology	J:125360
	abnormal T cell differentiation	J:125360
	abnormal T cell proliferation	J:125360
	decreased B cell number	J:125360
	decreased CD4-positive, alpha-beta T cell number	J:125360
	decreased CD8-positive, alpha-beta T cell number	J:125360
	decreased memory T cell number	J:125360
	decreased thymocyte number	J:125360
	increased double-positive T cell number	J:125360
Il7r^tm1Iku/Il7r^tm1Iku (involves: 129P2/OlaHsd * C57BL/6J)	abnormal B cell differentiation	J:34658
	abnormal gamma-delta T cell differentiation	J:34658
	abnormal T cell subpopulation ratio	J:34658
	absent mature gamma-delta T cells	J:34658
	absent Peyer's patches	J:45633
	decreased B-1 B cell number	J:34658
	decreased double-positive T cell number	J:34658
	decreased immature B cell number	J:34658
	decreased leukocyte cell number	J:34658
	decreased lymphocyte cell number	J:34658
	decreased mature B cell number	J:34658
	decreased T cell number	J:34658
	immune system phenotype	J:34658
	increased double-negative T cell number	J:34658
	small thymus	J:34658
	spleen hypoplasia	J:34658
	thymus hypoplasia	J:34658
Il7r^tm1Imx/Il7r^tm1Imx (involves: 129P3/J * 129S7/SvEvBrd)	arrested B cell differentiation	J:21135
	arrested T cell differentiation	J:21135
	decreased B cell number	J:21135
	decreased T cell number	J:21135
	lymph node hypoplasia	J:21135
	spleen hypoplasia	J:21135
	thymus hypoplasia	J:21135
Il7r^tm1Imx/Il7r^tm1Imx (B6.129S7-Il7r^tm1Imx)	abnormal T cell differentiation	J:125360
	decreased double-positive T cell number	J:125360
	decreased thymocyte number	J:125360
Il7r^tm1Imx/Il7r^tm1Imx (involves: 129S7/SvEvBrd)	decreased thymocyte number	J:64861
Il7r^tm1Imx/Il7r^tm1Imx Tg(Lck-Il7r)1676Trma/? (involves: 129S7/SvEvBrd * C57BL/6 * SJL)	decreased T cell proliferation	J:66400
	decreased thymocyte number	J:66400
	increased thymocyte apoptosis	J:66400
Il7r^tm2Iku/Il7r^tm2Iku Tg(Cd4-cre)1Cwi/? (involves: 129S6/SvEvTac * C57BL/6 * DBA/2)	abnormal CD4-positive T cell differentiation	J:193283
	abnormal CD8-positive, alpha-beta T cell differentiation	J:193283
	abnormal T cell morphology	J:193283
	decreased NK T cell number	J:193283
	increased B cell number	J:193283
	increased gamma-delta T cell number	J:193283
	increased thymocyte number	J:193283
Il7r^tm2Iku/Il7r^tm2Iku Tg(Cd4-cre)1Cwi/? Tg(H2-K-BCL2)1Josd/? (involves: 129S6/SvEvTac * C57BL/6 * C3H * DBA/2)	immune system phenotype	J:193283
Il9^tm1Anjm/Il9^tm1Anjm (involves: 129P2/OlaHsd * C57BL/6)	abnormal mast cell morphology	J:82881
	abnormal response to infection	J:82881
	granulomatous inflammation	J:82881, J:113543
	increased susceptibility to parasitic infection	J:82881
Il9^tm1Anjm/Il9^tm1Anjm (involves: C57BL/6)	abnormal cytokine secretion	J:115764
Il9^tm1Anjm/Il9^tm1Anjm (involves: C57BL/6)	immune system phenotype	J:115764
Il9^tm1Flv/Il9^tm1Flv (BALB/c-Il9^tm1Flv)	increased susceptibility to parasitic infection	J:208730
Il9r^tm1Jcrd/Il9r^tm1Jcrd (involves: C57BL/6)	abnormal regulatory T cell physiology	J:151907
	immune system phenotype	J:115764
	increased susceptibility to experimental autoimmune encephalomyelitis	J:151907
	increased T-helper 1 cell number	J:151907
Il10^tm1.1Roer/Il10^tm1.1Roer (involves: 129P2/OlaHsd * C57BL/6)	abnormal cytokine secretion	J:94537
	abnormal hypersensitivity reaction	J:94537
	abnormal innate immunity	J:94537
	increased susceptibility to bacterial infection	J:94537
	intestinal inflammation	J:94537
Il10^tm1.1Roer/Il10^tm1.1Roer (involves: 129P2/OlaHsd)	abnormal myeloid leukocyte morphology	J:151551
	decreased circulating interleukin-10 level	J:151551
	increased B cell number	J:151551
	increased myeloid dendritic cell number	J:151551
	increased plasma cell number	J:151551
	increased susceptibility to endotoxin shock	J:151551
	increased T cell number	J:151551
	spleen hyperplasia	J:151551
Il10^tm1Cgn/Il10^tm1Cgn (involves: 129P2/OlaHsd * C57BL/6)	abnormal cytokine level	J:35020
	abnormal immune system physiology	J:35020
	abnormal interferon level	J:35020, J:107077, J:125760
	abnormal interleukin level	J:35020, J:107077, J:51636
	abnormal Langerhans cell physiology	J:51636
	abnormal leukocyte morphology	J:35020
	abnormal level of surface class II molecules	J:15222
	abnormal lymphocyte cell number	J:35020
	abnormal myelopoiesis	J:15222
	abnormal response to infection	J:15222
	abnormal tumor necrosis factor level	J:107077, J:51636
	abnormal type IV hypersensitivity reaction	J:35510
	cecum inflammation	J:35020
	chronic inflammation	J:15222
	colitis	J:68476
	decreased length of allograft survival	J:44346
	decreased spleen iron level	J:15222
	decreased spleen red pulp amount	J:15222
	decreased T cell proliferation	J:125760
	immune system phenotype	J:107077, J:15222
	increased CD4-positive, alpha-beta T cell number	J:35020
	increased granulocyte number	J:35020, J:15222
	increased IgE level	J:62283
	increased IgG1 level	J:62283
	increased IgG2a level	J:62283
	increased interferon-gamma secretion	J:15222
	increased susceptibility to parasitic infection	J:123927
	increased susceptibility to type IV hypersensitivity reaction	J:51636
	increased thymus weight	J:107077
	intestinal inflammation	J:35020, J:107077, J:15222
	large intestinal inflammation	J:35020
	small intestinal inflammation	J:35020
	thymus hyperplasia	J:107077
Il10^tm1Cgn/Il10^tm1Cgn (involves: 129P2/OlaHsd)	abnormal cytokine secretion	J:117122
	abnormal inflammatory response	J:117122
	increased circulating interleukin-12 level	J:118833
	increased circulating tumor necrosis factor level	J:118833
	increased susceptibility to endotoxin shock	J:117122, J:118833
	intestinal inflammation	J:113376
Il10^tm1Cgn/Il10^tm1Cgn (B6.129P2-Il10^tm1Cgn/J)	abnormal chemokine level	J:157787
	abnormal cytokine level	J:157787, J:139972
	abnormal regulatory T cell physiology	J:125748
	cecum inflammation	J:157787
	increased circulating interferon-gamma level	J:157787
	increased circulating interleukin-1 alpha level	J:157787
	increased circulating interleukin-1 beta level	J:157787, J:139972
	increased circulating interleukin-2 level	J:157787
	increased circulating interleukin-6 level	J:157787, J:139972
	increased circulating interleukin-12 level	J:157787
	increased circulating interleukin-17 level	J:157787
	increased circulating tumor necrosis factor level	J:157787
	increased susceptibility to induced colitis	J:157787
	increased susceptibility to parasitic infection	J:157787
	large intestinal inflammation	J:149347
Il10^tm1Cgn/Il10^tm1Cgn (involves: 129P2/OlaHsd * C57BL/6 * DBA/1)	colitis	J:84100
Il10^tm1Cgn/Il10^tm1Cgn (involves: 129P2/OlaHsd * 129S/SvEv)	colitis	J:59872
Il10^tm1Cgn/Il10^tm1Cgn (B10.129P2(B6)-Il10^tm1Cgn/J)	decreased length of allograft survival	J:44346
Il10^tm1Cgn/Il10^tm1Cgn (B6.129P2-Il10^tm1Cgn)	abnormal circulating interleukin-6 level	J:191723
Il10^tm1Cgn/Il10^tm1Cgn (B6.129P2-Il10^tm1Cgn)	abnormal circulating interleukin-12b level	J:191723
Il10^tm1Cgn/Il10^tm1Cgn Il4^tm1Cgn/Il4^tm1Cgn (involves: 129P2/OlaHsd * C57BL/6)	abnormal T-helper 1 cell differentiation	J:111712
	increased interferon-gamma secretion	J:111712
Il10^tm1Cgn/Il10^tm1Cgn Il12b^tm1Jm/Il12b^tm1Jm (involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6)	abnormal T-helper 2 cell differentiation	J:111712
	increased interleukin-13 secretion	J:111712
Il10^tm1Cgn/Il10^tm1Cgn Il27ra^tm1Mak/Il27ra^tm1Mak (involves: 129P2/OlaHsd * C57BL/6)	abnormal T-helper 1 physiology	J:136179
	abnormal T-helper 2 physiology	J:136179
	colitis	J:136179
	decreased interferon-gamma secretion	J:136179
	decreased susceptibility to induced colitis	J:136179
	increased interleukin-13 secretion	J:136179
Il10^tm1Cgn/Il10^tm1Cgn Nfil3^tm1Look/Nfil3^tm1Look (involves: 129P2/OlaHsd * 129X1/SvJ)	colitis	J:209365
	increased interleukin-12 secretion	J:209365
Il10^tm1Cgn/Il10^tm1Cgn Nfil3^tm1Pbro/Nfil3^tm1Pbro (involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6)	colitis	J:209365
	increased interleukin-12 secretion	J:209365
Il10^tm1Cgn/Il10^tm1Cgn Rps6ka4^tm1Jsca/Rps6ka4^tm1Jsca Rps6ka5^tm1Jsca/Rps6ka5^tm1Jsca (B6.Cg-Il10^tm1Cgn Rps6ka5^tm1Jsca Rps6ka4^tm1Jsca)	decreased interleukin-10 secretion	J:139576
	increased interleukin-6 secretion	J:139576
	increased interleukin-12a secretion	J:139576
	increased interleukin-12b secretion	J:139576
	increased tumor necrosis factor secretion	J:139576
Il10^tm1Cgn/Il10^tm1Cgn Tg(MUC1)79.24Gend/0 (B6.Cg-Il10^tm1Cgn Tg(MUC1)79.24Gend)	large intestinal inflammation	J:149347
Il10^tm1Cgn/Il10^tm1Cgn Tg(Vil1-cre)997Gum/? Tlr5^tm1.1Gewr/Tlr5^tm1.1Gewr (involves: 129P2/OlaHsd * C57BL/6J * C57BL/6NTac * SJL)	colitis	J:229155
Il10^tm1Cgn/Il10^tm1Cgn Tlr5^tm1.1Gewr/Tlr5^tm1.1Gewr (involves: 129P2/OlaHsd * C57BL/6J * C57BL/6NTac)	colitis	J:229155
Il10^tm1Cgn/Il10^tm1Cgn Vdr^tm1Mbd/Vdr^tm1Mbd (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:107077
	abnormal cytokine level	J:107077
	abnormal lymph node cell ratio	J:107077
	abnormal splenic cell ratio	J:107077
	abnormal thymus corticomedullary boundary morphology	J:107077
	abnormal thymus involution	J:107077
	absent spleen white pulp	J:107077
	colitis	J:107077
	decreased lymphocyte cell number	J:107077
	decreased T cell proliferation	J:107077
	enlarged mesenteric lymph nodes	J:107077
	enlarged spleen	J:107077
	increased macrophage cell number	J:107077
	increased neutrophil cell number	J:107077
	increased spleen red pulp amount	J:107077
	increased T cell apoptosis	J:107077
	intestinal inflammation	J:107077
	thymus hypoplasia	J:107077
Il10^tm1Keny/Il10⁺ Nfil3^tm1.1Kubo/Nfil3^tm1.1Kubo (involves: 129 * C57BL/6)	decreased interleukin-10 secretion	J:172134
Il10^tm1Mhry/Il10^tm1Mhry (involves: 129P2/OlaHsd * C57BL/6)	intestinal inflammation	J:117628
Il10^tm1Roer/Il10^tm1Roer Foxp3^{tm4(YFP/icre)Ayr}/Y (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal regulatory T cell physiology	J:134513
	abnormal type IV hypersensitivity reaction	J:134513
	colitis	J:134513
	decreased interleukin-10 secretion	J:134513
	lung inflammation	J:134513
Il10^tm1Roer/Il10^tm1Roer Tg(Cd4-cre)1Cwi/0 (involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * DBA/2)	abnormal cytokine secretion	J:94537
	abnormal hypersensitivity reaction	J:94537
	abnormal lymph node morphology	J:94537
	increased susceptibility to parasitic infection	J:94537
	intestinal inflammation	J:94537
	liver inflammation	J:94537
	peritoneal inflammation	J:94537
Il10^tm2Roer/Il10^tm2Roer Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal cytokine secretion	J:117122
	abnormal inflammatory response	J:117122
	increased susceptibility to endotoxin shock	J:117122
Il10^tm2Roer/Il10^tm2Roer Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	abnormal inflammatory response	J:117122
	increased susceptibility to endotoxin shock	J:117122
Il10ra^m1Jskg/Il10ra^m1Jskg (B6.Cg-Il10ra^m1Jskg)	colitis	J:146644
Il10ra^NZW/Il10ra⁺ ((NZB x NZW)F1)	increased anti-chromatin antibody level	J:102087
Il10ra^NZW/Il10ra⁺ ((NZB x NZW)F1)	increased IgG level	J:102087
Il10ra^tm1.1Jack/Il10ra^tm1.1Jack Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * BALB/c * C57BL/6)	abnormal chemokine level	J:157787
	abnormal cytokine level	J:157787
	increased circulating interferon-gamma level	J:157787
	increased circulating interleukin-1 alpha level	J:157787
	increased circulating interleukin-1 beta level	J:157787
	increased circulating interleukin-2 level	J:157787
	increased circulating interleukin-12 level	J:157787
	increased circulating interleukin-17 level	J:157787
	increased circulating tumor necrosis factor level	J:157787
	increased susceptibility to parasitic infection	J:157787
Il10ra^tm1.1Jack/Il10ra^tm1.1Jack Tg(Cd4-cre)1Cwi/0 (involves: 129P2/OlaHsd * BALB/c * C57BL/6 * DBA/2)	immune system phenotype	J:157787
Il10ra^tm1.1Tlg/Il10ra^tm1.1Tlg Tg(Cd4-cre)1Cwi/? (B6.Cg-Tg(Cd4-cre)1Cwi Il10ra^tm1.1Tlg)	abnormal lymphocyte cell number	J:189797
	abnormal regulatory T cell number	J:189797
	autoimmune response	J:189797
	decreased splenocyte proliferation	J:189797
	decreased T cell number	J:189797
	immune system phenotype	J:189797
Il10ra^tm1.2Jack/Il10ra^tm1.2Jack (involves: 129P2/OlaHsd * BALB/c * C57BL/6 * DBA/2)	abnormal chemokine level	J:157787
	abnormal cytokine level	J:157787
	cecum inflammation	J:157787
	increased circulating interferon-gamma level	J:157787
	increased circulating interleukin-1 alpha level	J:157787
	increased circulating interleukin-1 beta level	J:157787
	increased circulating interleukin-2 level	J:157787
	increased circulating interleukin-6 level	J:157787
	increased circulating interleukin-12 level	J:157787
	increased circulating interleukin-17 level	J:157787
	increased circulating tumor necrosis factor level	J:157787
	increased susceptibility to induced colitis	J:157787
	increased susceptibility to parasitic infection	J:157787
Il10ra^{tm1b(KOMP)Wtsi}/Il10ra^{tm1b(KOMP)Wtsi} (C57BL/6N-Il10ra^{tm1b(KOMP)Wtsi}/Orl)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Il10rb^tm1Agt/Il10rb^tm1Agt (involves: 129S2/SvPas * C57BL/6)	abnormal granulocyte differentiation	J:45917
	abnormal lymph node medullary cord morphology	J:45917
	abnormal mesenteric lymph node morphology	J:45917
	abnormal spleen morphology	J:45917
	colitis	J:134156
	increased interferon-gamma secretion	J:134156
	increased interleukin-17 secretion	J:134156
	increased leukocyte cell number	J:45917
	increased spleen weight	J:45917
	large intestinal inflammation	J:45917
	spleen hyperplasia	J:45917
Il10rb^tm1Agt/Il10rb^tm1Agt Tg(Cd4-TGFBR2)16Flv/? (involves: 129S2/SvPas * C3H * C57BL/6)	abnormal cytokine level	J:134156
	abnormal cytokine secretion	J:134156
	colitis	J:134156
	increased circulating interferon-gamma level	J:134156
	increased circulating interleukin-6 level	J:134156
	increased circulating tumor necrosis factor level	J:134156
	increased interferon-gamma secretion	J:134156
	increased interleukin-17 secretion	J:134156
	increased tumor necrosis factor secretion	J:134156
	liver inflammation	J:134156
	lung inflammation	J:134156
	proctitis	J:134156
Il11^tm2.1Moto/Il11^tm2.1Moto Tg(BGLAP-cre)1Clem/0 (involves: C57BL/6NCrlj * CBA/JNCrlj * FVB/NJ)	abnormal circulating interleukin level	J:345337
Il11ra1^tm1Gos/Il11ra1^tm1Gos (involves: 129S2/SvPas * C57BL/6J)	immune system phenotype	J:48920
Il11ra1^tm1Gos/Il11ra1^tm1Gos (involves: 129S2/SvPas * C57BL/6J * CD-1)	abnormal NK cell differentiation	J:93811
	abnormal uterine NK cell morphology	J:93811
Il11ra1^tm1Wehi/Il11ra1^tm1Wehi (involves: 129S1/Sv * C57BL/6)	immune system phenotype	J:42921, J:79073
Il11ra1^tm1Wehi/Il11ra1^tm1Wehi Il6^tm1Kopf/Il6^tm1Kopf (involves: 129/Sv * C57BL/6)	increased susceptibility to induced colitis	J:79073
Il12a^m1Btlr/Il12a^m1Btlr (C57BL/6J-Il12a^m1Btlr)	increased susceptibility to Herpesvirales infection	J:267667
Il12a^tm1Cab/Il12a^tm1Cab (involves: 129S4/SvJae * C57BL/6)	decreased circulating interferon-gamma level	J:54482
Il12a^tm1Cab/Il12a^tm1Cab (involves: 129S4/SvJae * C57BL/6)	decreased circulating interleukin-12 level	J:54482
Il12a^tm1Cab/Il12a^tm1Cab (B6.129S4-Il12a^tm1Cab)	abnormal NK cell physiology	J:79552
Il12a^tm1Cab/Il12a^tm1Cab (B6.129S4-Il12a^tm1Cab)	decreased circulating interferon-gamma level	J:79552
Il12a^tm1Cab/Il12a^tm1Cab Il23a^tm1.1Thak/Il23a^tm1.1Thak (B6.Cg-Il12a^tm1Cab Il23a^tm1.1Thak)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:143970
Il12a^tm1Jm/Il12a^tm1Jm (129S1/Sv-Il12a^tm1Jm)	abnormal CD4-positive, alpha-beta T cell physiology	J:34164
	decreased susceptibility to type IV hypersensitivity reaction	J:34164
	increased susceptibility to parasitic infection	J:34164
Il12a^tm1Jm/Il12a^tm1Jm (B6.129S1-Il12a^tm1Jm)	immune system phenotype	J:120806
Il12a^tm1Jm/Il12a^tm1Jm (C.129S1-Il12a^tm1Jm)	impaired natural killer cell mediated cytotoxicity	J:125611
Il12a^tm1Jm/Il12a^tm1Jm (involves: 129S1/Sv)	abnormal NK cell physiology	J:139001
Il12a^tm1Jm/Il12a^tm1Jm Il12b^tm1Jm/Il12b^tm1Jm (B6.129S1-Il12a^tm1Jm Il12b^tm1Jm)	impaired natural killer cell mediated cytotoxicity	J:125611
Il12a^tm1Jm/Il12a^tm1Jm Rag2^tm1Fwa/Rag2^tm1Fwa (involves: 129S/SvEv * 129S1/Sv * 129S6/SvEvTac)	abnormal interferon secretion	J:140483
	decreased susceptibility to bacterial infection	J:140483
	lung inflammation	J:140483
Il12b^tm1Jm/Il12b^tm1Jm (B6.129S1-Il12b^tm1Jm/J)	abnormal CD8-positive, alpha-beta T cell physiology	J:111568
	abnormal granulocyte physiology	J:111568
	abnormal lymphocyte physiology	J:120806
	abnormal macrophage physiology	J:111568
	abnormal NK cell physiology	J:120806
	decreased circulating interferon-gamma level	J:120806
	decreased interleukin-17 secretion	J:111568
	decreased susceptibility to type IV hypersensitivity reaction	J:120806
	increased susceptibility to bacterial infection	J:120806
Il12b^tm1Jm/Il12b^tm1Jm (129S1/Sv-Il12b^tm1Jm)	abnormal CD4-positive, alpha-beta T cell physiology	J:34164
	decreased susceptibility to type IV hypersensitivity reaction	J:34164
	increased susceptibility to parasitic infection	J:34164
Il12b^tm1Jm/Il12b^tm1Jm (involves: 129S1/SvImJ)	abnormal T-helper 1 physiology	J:46514
	decreased interferon-gamma secretion	J:46514
	impaired natural killer cell mediated cytotoxicity	J:46514
Il12b^tm1Jm/Il12b^tm1Jm (involves: 129S1/Sv)	increased susceptibility to bacterial infection induced morbidity/mortality	J:161073
Il12b^tm1Jm/Il12b^tm1Jm Il18^tm1Aki/Il18^tm1Aki (involves: 129P2/OlaHsd * 129S1/SvImJ)	abnormal T-helper 1 physiology	J:46514
	decreased interferon-gamma secretion	J:46514
	impaired natural killer cell mediated cytotoxicity	J:46514
Il12b^tm1Jm/Il12b^tm1Jm Rag2^tm1Fwa/Rag2^tm1Fwa (involves: 129S/SvEv * 129S1/Sv)	abnormal chemokine secretion	J:140483
	abnormal interferon secretion	J:140483
	increased susceptibility to bacterial infection	J:140483
	lung inflammation	J:140483
Il12b^tm1Jm/Il12b^tm1Jm Tnf^tm2Gkl/Tnf⁺ (involves: 129S/SvEv * 129S1/Sv * C57BL/6J)	small intestinal inflammation	J:108572
Il12rb1^tm1Jm/Il12rb1^tm1Jm (involves: 129S1/Sv * C57BL/6J)	abnormal lymphocyte physiology	J:42105
	decreased circulating interferon-gamma level	J:42105
	decreased interferon-gamma secretion	J:42105
Il12rb1^tm1Jm/Il12rb1^tm1Jm Tg(Rorc-EGFP)1Ebe/? (involves: 129S1/Sv * C57BL/6)	abnormal effector T cell morphology	J:137020
Il12rb2^Ifnm-d/Il12rb2^Ifnm-d Tlr4^lps-del/Tlr4^lps-del (C57BL/10ScCr)	abnormal dendritic cell physiology	J:91014
	abnormal granulocyte physiology	J:91014
	abnormal immune cell physiology	J:91014
	abnormal macrophage physiology	J:91014
	abnormal NK cell physiology	J:91014
	decreased interferon-gamma secretion	J:91014, J:70821
	increased interleukin-4 secretion	J:91014
	increased susceptibility to bacterial infection	J:91014, J:70821
Il12rb2^tm1Jm/Il12rb2^tm1Jm (either: (involves: 129S1/Sv * BALB/cByJ) or (involves: 129S1/Sv * C57BL/6J))	abnormal lymphocyte physiology	J:65891
	abnormal NK cell physiology	J:65891
Il12rb2^tm1Jm/Il12rb2^tm1Jm (B6;129S1-Il12rb2^tm1Jm/J)	abnormal B cell activation	J:106805
	abnormal T cell activation	J:106805
	glomerulonephritis	J:106805
	increased anti-nuclear antigen antibody level	J:106805
	increased circulating interleukin-12 level	J:120061
	increased interleukin-6 secretion	J:106805
	liver inflammation	J:106805
	lymphoid hyperplasia	J:106805
	parotid gland inflammation	J:106805
	salivary gland inflammation	J:106805
	submandibular gland inflammation	J:106805
Il13^{tm1(YFP/cre)Lky}/Il13⁺ Il4^tm1(CD2)Mmrs/Il4⁺ Gt(ROSA)26Sor^tm1(DTA)Lky/Gt(ROSA)26Sor⁺ (involves: 129P2/OlaHsd * 129S4/SvJae)	decreased eosinophil cell number	J:178986
	increased susceptibility to parasitic infection	J:178986
Il13^tm1.1Anjm/Il13^tm1.1Anjm (involves: 129P2/OlaHsd * C57BL/6)	abnormal T-helper 2 cell differentiation	J:67965
	decreased circulating interleukin-13 level	J:67965
	decreased IgE level	J:67965
	decreased interleukin-4 secretion	J:67965
	decreased interleukin-5 secretion	J:67965
	decreased interleukin-10 secretion	J:67965
	decreased T-helper 2 cell number	J:67965
	increased IgG2b level	J:67965
	increased IgM level	J:67965
	increased interferon-gamma secretion	J:67965
Il13^tm1.1Anjm/Il13^tm1.1Anjm (C.129P2-Il13^tm1.1Anjm)	abnormal dendritic cell antigen presentation	J:141937
	abnormal dendritic cell differentiation	J:141937
	decreased IgE level	J:91403
	decreased interleukin-5 secretion	J:141937
	decreased interleukin-13 secretion	J:141937, J:91403
	decreased susceptibility to autoimmune disorder	J:141937, J:91403
	increased IgG2a level	J:91403
	increased interferon-gamma secretion	J:141937
Il13^tm1.1Anjm/Il13^tm1.1Anjm Tg(DO11.10)10Dlo/0 (involves: 129P2/OlaHsd * BALB/c * C3H * C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:91403
	decreased interleukin-13 secretion	J:91403
Il13^tm1Anjm/Il13⁺ Il4^tm1.1Wep/Il4⁺ (involves: 129P2/OlaHsd * BALB/c * C57BL/6)	decreased interleukin-4 secretion	J:69099
Il13^tm1Anjm/Il13^tm1Anjm (involves: 129P2/OlaHsd * C57BL/6)	abnormal interleukin secretion	J:82881
	decreased eosinophil cell number	J:82881
	decreased interleukin-4 secretion	J:82881
	decreased interleukin-5 secretion	J:82881
	decreased interleukin-9 secretion	J:82881
	granulomatous inflammation	J:82881, J:113543
	increased susceptibility to parasitic infection	J:113543
Il13^tm1Anjm/Il13^tm1Anjm (C.129P2-Il13^tm1Anjm)	decreased interleukin-4 secretion	J:69099
Il13^tm1Anjm/Il13^tm1Anjm (C.129P2-Il13^tm1Anjm)	decreased interleukin-13 secretion	J:69099
Il13^tm1Anjm/Il13^tm1Anjm Il5^tm3Anjm/Il5^tm3Anjm (involves: 129P2/OlaHsd * C57BL/6)	granulomatous inflammation	J:113543
	increased susceptibility to parasitic infection	J:113543
Il13^tm2Anjm/Il13^tm2Anjm (involves: 129P2/OlaHsd * C57BL/6)	abnormal splenocyte physiology	J:72587
	abnormal T-helper 2 physiology	J:89095
	decreased susceptibility to parasitic infection induced morbidity/mortality	J:60609
	immune system phenotype	J:72587
	increased susceptibility to parasitic infection	J:89095
Il13^tm2Anjm/Il13^tm2Anjm (C.129P2(B6)-Il13^tm2Anjm)	abnormal response to transplant	J:110188
	abnormal type I hypersensitivity reaction	J:123772
	increased length of allograft survival	J:110188
	increased susceptibility to type I hypersensitivity reaction	J:123772
Il13^tm2Anjm/Il13^tm2Anjm (involves: 129)	abnormal T-helper 2 cell differentiation	J:67965
	decreased circulating interleukin-13 level	J:67965
	decreased IgE level	J:67965
	decreased interleukin-4 secretion	J:67965
	decreased interleukin-5 secretion	J:67965
	decreased interleukin-10 secretion	J:67965
	decreased T-helper 2 cell number	J:67965
	increased IgG2b level	J:67965
	increased IgM level	J:67965
	increased interferon-gamma secretion	J:67965
Il13^tm2Anjm/Il13^tm2Anjm (involves: 129P2/OlaHsd * BALB/c * C57BL/6)	abnormal chemokine level	J:131994
	abnormal macrophage physiology	J:176092
	abnormal susceptibility to infection	J:131994
	decreased susceptibility to bacterial infection	J:176092
	decreased susceptibility to parasitic infection	J:60609
	decreased susceptibility to parasitic infection induced morbidity/mortality	J:60609
	impaired eosinophil recruitment	J:126675
	impaired neutrophil recruitment	J:105813
Il13^tm2Anjm/Il13^tm2Anjm (B6.129P2-Il13^tm2Anjm)	abnormal antigen presentation	J:131969
	abnormal leukocyte physiology	J:131969
	decreased macrophage cell number	J:131969
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:131969
Il13^tm3.1Anjm/Il13⁺ Il1rl1^tm1Anjm/Il1rl1^tm1Anjm (involves: 129P2/OlaHsd * BALB/c)	decreased eosinophil cell number	J:159464
Il13^tm3.1Anjm/Il13⁺ Il17rb^tm1Anjm/Il17rb^tm1Anjm (involves: BALB/c * C57BL/6)	decreased eosinophil cell number	J:159464
Il13^tm3.1Anjm/Il13⁺ Il17rb^tm1Anjm/Il17rb^tm1Anjm Il1rl1^tm1Anjm/Il1rl1^tm1Anjm (involves: 129P2/OlaHsd * BALB/c)	decreased eosinophil cell number	J:159464
Il13ra1^tm1Twy/Y (C.Cg-Il13ra1^tm1Twy)	abnormal response to infection	J:130488
	abnormal T-helper 2 physiology	J:130488
	decreased IgE level	J:130488
	decreased susceptibility to parasitic infection	J:130488
	increased CD4-positive, alpha-beta T cell number	J:130488
	increased circulating interleukin-5 level	J:130488
	increased eosinophil cell number	J:130488
	increased IgA level	J:130488
	increased IgG1 level	J:130488
	increased IgG3 level	J:130488
	increased T-helper 2 cell number	J:130488
Il13ra1^tm1Zagh/Il13ra1^tm1Zagh (involves: BALB/c * C57BL/6)	abnormal thymus development	J:183111
	impaired myelopoiesis	J:183111
Il13ra2^tm1Gru/Il13ra2^tm1Gru (C.Cg-Il13ra2^tm1Gru)	abnormal macrophage physiology	J:82376
	decreased circulating interleukin-13 level	J:82376
	decreased interleukin-4 secretion	J:82376
	decreased susceptibility to endotoxin shock	J:82376
	increased IgA level	J:82376
	increased IgE level	J:82376
	increased IgG2a level	J:82376
	increased IgG2b level	J:82376
	increased interferon-gamma secretion	J:82376
	increased interleukin-10 secretion	J:82376
Il15^m1Hwata/Il15^m1Hwata (Not Specified)	abnormal interleukin secretion	J:184570
	abnormal NK T cell number	J:184570
	decreased interferon-gamma secretion	J:184570
	decreased NK cell number	J:184570
	decreased NK T cell number	J:184570
Il15^tm1.1Iku/Il15⁺ (B6.Cg-Il15^tm1.1Iku)	immune system phenotype	J:206571
Il15^tm1Imx/Il15⁺ Myc^tm1Atp/Myc⁺ (involves: 129P2/OlaHsd * C57BL/6)	decreased memory T cell number	J:132730
Il15^tm1Imx/Il15^tm1Imx (involves: C57BL/6)	abnormal CD8-positive, alpha-beta T cell physiology	J:95221
	abnormal cytokine secretion	J:97620
	abnormal immune system morphology	J:60915
	abnormal immune system physiology	J:60915
	abnormal lymphocyte morphology	J:60915
	abnormal susceptibility to infection	J:60915
	absent uterine NK cells	J:84009
	decreased CD8-positive, alpha-beta T cell number	J:113408, J:60915
	decreased CD8-positive, gamma-delta intraepithelial T cell number	J:155298
	decreased dendritic cell number	J:97620
	decreased IgG level	J:97620
	decreased IgM level	J:97620
	decreased immunoglobulin level	J:97620
	decreased interferon-gamma secretion	J:97620
	decreased interleukin-12 secretion	J:97620
	decreased memory T cell number	J:132730
	decreased NK cell number	J:132730, J:142654, J:60915
	decreased regulatory T cell number	J:208318
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:84009
	decreased susceptibility to type IV hypersensitivity reaction	J:87137
	impaired natural killer cell mediated cytotoxicity	J:97620
	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:97038
	increased susceptibility to parasitic infection	J:97620
	increased susceptibility to Poxviridae infection induced morbidity/mortality	J:60915
	small lymph nodes	J:60915
Il15^tm1Imx/Il15^tm1Imx (C57BL/6-Il15^tm1Imx)	abnormal dendritic cell physiology	J:123902
Il15^tm1Imx/Il15^tm1Imx (C57BL/6-Il15^tm1Imx/Tac)	abnormal CD8-positive, alpha-beta T cell differentiation	J:111786
	abnormal thymus cell ratio	J:111786
	decreased CD8-positive, alpha-beta T cell number	J:111786
Il15^tm1Imx/Il15^tm1Imx Il7r^tm1.1Asin/Il7r^tm1Imx Tg(Cd8a-cre)B8Asin/0 (involves: 129S7/SvEvBrd C57BL/6)	decreased CD8-positive, alpha-beta T cell number	J:190889
Il15^tm1Imx/Il15^tm1Imx Itk^tm1Litt/Itk^tm1Litt (involves: 129S4/SvJae * C57BL/6)	abnormal thymus cell ratio	J:111786
Il15^tm1Imx/Il15^tm1Imx Itk^tm1Ljb/Itk^tm1Ljb (involves: 129 * C57BL/6 * C57BL/10)	decreased CD8-positive, alpha-beta T cell number	J:113408
Il15^tm1Imx/Il15^tm1Imx Myc^tm1Atp/Myc⁺ (involves: 129P2/OlaHsd * C57BL/6)	decreased memory T cell number	J:132730
	decreased NK cell number	J:132730
Il15^tm1Imx/Il15^tm1Imx Rag2^tm1Fwa/Rag2^tm1Fwa (involves: 129S/SvEv * C57BL/6)	decreased NK cell number	J:132257
Il15^tm1Imx/Il15^tm1Imx X/Yaa (BXSB.B6-Il15^tm1Imx/Dcr)	increased susceptibility to systemic lupus erythematosus	J:179430
Il15ra^tm1.1Nsl/Il15ra^tm1.1Nsl (involves: 129X1/SvJ * C57BL/6)	abnormal T cell apoptosis	J:73738
	decreased CD8-positive, alpha-beta T cell number	J:73738
	decreased memory T cell number	J:73738
	decreased NK cell number	J:73738
	decreased NK T cell number	J:73738
	decreased single-positive T cell number	J:73738
	increased CD4-positive, alpha-beta T cell number	J:73738
	increased thymocyte apoptosis	J:73738
	lymph node hypoplasia	J:73738
Il15ra^tm1.1Nsl/Il15ra^tm1.1Nsl (B6.129X1-Il15ra^tm1.1Nsl)	abnormal T cell activation	J:92705
	abnormal T cell proliferation	J:92705
	increased interleukin-2 secretion	J:92705
	increased T cell proliferation	J:92705
Il15ra^tm1.1Nsl/Il15ra^tm1.1Nsl Tg(TcrAND)53Hed/? (involves: 129X1/SvJ * C57BL/6 * SJL)	increased T cell proliferation	J:92705
Il15ra^tm1Ama/Il15ra^tm1Ama (involves: 129X1/SvJ)	abnormal NK cell physiology	J:119213
	decreased CD8-positive, alpha-beta T cell number	J:142570
	decreased CD8-positive, gamma-delta intraepithelial T cell number	J:155298
	decreased memory T cell number	J:142570
	decreased NK cell number	J:119213, J:142570
	decreased NK T cell number	J:142570
	decreased T cell proliferation	J:142570
	impaired natural killer cell mediated cytotoxicity	J:142570
Il15ra^tm1Ama/Il15ra^tm2.1Ama Lyz2^tm1(cre)Ifo/0 Tg(Itgax-cre)1-1Reiz/0 (involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * CBA)	abnormal immune system physiology	J:155298
	decreased CD8-positive, alpha-beta T cell number	J:155298
	decreased memory T cell number	J:155298
	decreased NK cell number	J:155298
Il15ra^tm1Ama/Il15ra^tm2.1Ama Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6J)	abnormal immune system physiology	J:155298
	abnormal NK cell differentiation	J:155298
	abnormal NK cell physiology	J:155298
	decreased CD8-positive, alpha-beta T cell number	J:155298
	decreased memory T cell number	J:155298
	decreased NK cell number	J:155298
Il15ra^tm1Ama/Il15ra^tm2.1Ama Tg(Itgax-cre)1-1Reiz/0 (involves: 129X1/SvJ * C57BL/6J * CBA)	abnormal NK cell differentiation	J:155298
	abnormal NK cell physiology	J:155298
	abnormal T cell subpopulation ratio	J:155298
	decreased CD8-positive, alpha-beta T cell number	J:155298
	decreased memory T cell number	J:155298
	decreased NK cell number	J:155298
Il15ra^tm1Ama/Il15ra^tm2.1Ama Tg(Vil1-cre)997Gum/0 (involves: C57BL/6J * SJL)	decreased CD8-positive, gamma-delta intraepithelial T cell number	J:155298
Il15ra^tm1Wjl/Il15ra^tm1Wjl (involves: 129 * C57BL/6)	abnormal T cell physiology	J:142570
	decreased CD8-positive, alpha-beta T cell number	J:142570
	decreased memory T cell number	J:142570
	decreased NK cell number	J:142570
	decreased NK T cell number	J:142570
	decreased T cell proliferation	J:142570
Il16^tm1Korn/Il16^tm1Korn (either: B6.129X1-Il16^tm1Korn or C.129X1-Il16^tm1Korn)	abnormal T cell physiology	J:97739
Il17a/Il17f^tm1.1Impr/Il17a/Il17f^tm1.1Impr (involves: C57BL/6)	abnormal effector T cell morphology	J:187400
	absent gamma-delta T cells	J:187400
	decreased interleukin-17 secretion	J:187400
	immune system phenotype	J:187400, J:189794
	increased gamma-delta T cell number	J:187400
	increased T cell proliferation	J:187400
Il17a/Il17f^tm1.1Impr/Il17a/Il17f^tm1.1Impr (involves: C57BL/6)	abnormal effector T cell morphology	J:187400
	absent gamma-delta T cells	J:187400
	decreased interleukin-17 secretion	J:187400
	immune system phenotype	J:187400, J:189794
	increased gamma-delta T cell number	J:187400
	increased T cell proliferation	J:187400
Il17a^em1(IMPC)Mbp/Il17a^em1(IMPC)Mbp (C57BL/6N-Il17a^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Il17a^tm1Cdon/Il17a^tm1Cdon (involves: C57BL/6)	chronic inflammation	J:136279
	decreased CD4-positive, alpha-beta T cell number	J:136279
	decreased IgG1 level	J:136279
	decreased IgG2a level	J:136279
	decreased IgG2b level	J:136279
	decreased IgM level	J:136279
	decreased interleukin-17 secretion	J:136279
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:136279
	increased susceptibility to induced colitis	J:136279
Il17a^tm1Yiw/Il17a^tm1Yiw (involves: 129P2/OlaHsd * C57BL/6J)	decreased IgG level	J:79127
	decreased immunoglobulin level	J:79127
	decreased interferon-gamma secretion	J:79127
	decreased susceptibility to type IV hypersensitivity reaction	J:79127
Il17a^tm1Yiw/Il17a^tm1Yiw (involves: 129P2/OlaHsd * BALB/cA * C57BL/6J)	abnormal interleukin level	J:79127
	abnormal Langerhans cell physiology	J:79127
	decreased IgE level	J:79127
	decreased IgG1 level	J:79127
	decreased immunoglobulin level	J:79127
	decreased susceptibility to type IV hypersensitivity reaction	J:79127
Il17a^tm1Yiw/Il17a^tm1Yiw (involves: 129P2/OlaHsd * C57BL/6)	increased susceptibility to bacterial infection	J:143719
Il17a^tm1Yiw/Il17a^tm1Yiw (involves: 129P2/OlaHsd)	abnormal immune system physiology	J:144710
	decreased neutrophil cell number	J:193548
	increased gamma-delta T cell number	J:193548
Il17a^tm1Yiw/Il17a^tm1Yiw (B6.129P2-Il17a^tm1Yiw)	increased susceptibility to infection induced morbidity/mortality	J:160680
Il17a^tm1Yiw/Il17a^tm1Yiw Il1rn^tm1Yiw/Il1rn^tm1Yiw (involves: 129P2/OlaHsd * BALB/cA * C57BL/6J)	decreased susceptibility to induced arthritis	J:83408
Il17a^tm1Yiw/Il17a^tm1Yiw Il17f^tm1Yiw/Il17f^tm1Yiw (involves: 129P2/OlaHsd * C57BL/6)	increased susceptibility to bacterial infection	J:143719
Il17a^tm1Yiw/Il17a^tm1Yiw Il17f^tm1Yiw/Il17f^tm1Yiw Il1rn^tm1Yiw/Il1rn^tm1Yiw (involves: 129 * BALB/c)	rheumatoid arthritis	J:143719
Il17a^tm1Yiw/Il17a^tm1Yiw Il17f^tm2Yiw/Il17f^tm2Yiw (involves: 129P2/OlaHsd * BALB/c)	decreased IgG3 level	J:143719
	enlarged submandibular lymph nodes	J:143719
	increased IgG1 level	J:143719
	increased IgG2a level	J:143719
	increased IgG2b level	J:143719
	increased susceptibility to bacterial infection	J:143719
	nasal inflammation	J:143719
Il17a^tm1Yiw/Il17a^tm1Yiw Il17f^tm2Yiw/Il17f^tm2Yiw (B6.129P2-Il17a^tm1Yiw Il17f^tm2Yiw)	decreased IgG3 level	J:143719
	enlarged submandibular lymph nodes	J:143719
	increased IgG1 level	J:143719
	increased IgG2a level	J:143719
	increased IgG2b level	J:143719
	increased susceptibility to infection induced morbidity/mortality	J:160680
Il17a^tm1Yiw/Il17a^tm1Yiw Tg(CD2-Rorc)#Staka/0 (involves: 129P2/OlaHsd * C57BL/6)	increased susceptibility to autoimmune disorder	J:230700
Il17b^em1Cya/Il17b^em1Cya (C57BL/6-Il17b^em1Cya)	abnormal cytokine level	J:339366
	increased macrophage cytokine production	J:339366
	increased neutrophil cell number	J:339366
	increased susceptibility to induced colitis	J:339366
Il17b^{Gt(371C12)Cmhd}/Il17b^{Gt(371C12)Cmhd} (B6.129-Il17b^{Gt(371C12)Cmhd})	abnormal chemokine secretion	J:229778
	abnormal interleukin secretion	J:229778
	decreased interleukin-4 secretion	J:229778
	increased eosinophil cell number	J:229778
	increased interleukin-1 beta secretion	J:229778
	increased interleukin-5 secretion	J:229778
	increased interleukin-6 secretion	J:229778
	increased interleukin-13 secretion	J:229778
	increased susceptibility to bacterial infection	J:229778
	increased susceptibility to induced colitis	J:229778
	increased T-helper 2 cell number	J:229778
	increased tumor necrosis factor secretion	J:229778
Il17b^{Gt(371C12)Cmhd}/Il17b^{Gt(371C12)Cmhd} Il25^tm1.1Cdon/Il25^tm1.1Cdon (involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * C57BL/6)	immune system phenotype	J:229778
Il17c^tm1.1Cdon/Il17c^tm1.1Cdon (involves: 129S6/SvEvTac)	decreased CD4-positive, alpha-beta T cell number	J:177650
	decreased interferon-gamma secretion	J:177650
	decreased interleukin-17 secretion	J:177650
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:177650
Il17c^tm1Lex/Il17c^tm1Lex (B6.129S5-Il17c^tm1Lex)	immune system phenotype	J:178967
Il17f^tm1Awai/Il17f⁺ (involves: 129S6/SvEvTac * C57BL/6)	decreased interleukin-17 secretion	J:144710
Il17f^tm1Awai/Il17f^tm1Awai (involves: 129S6/SvEvTac * C57BL/6)	abnormal immune system physiology	J:144710
	decreased interleukin-17 secretion	J:144710
Il17f^tm1Cdon/Il17f^tm1Cdon (involves: C57BL/6)	chronic inflammation	J:136279
	decreased acute inflammation	J:136279
	decreased interleukin-17 secretion	J:136279
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:136279
	decreased susceptibility to induced colitis	J:136279
	increased IgG2a level	J:136279
Il17f^tm1Yiw/Il17f^tm1Yiw (involves: 129P2/OlaHsd * C57BL/6)	increased susceptibility to bacterial infection	J:143719
Il17f^tm1Yiw/Il17f^tm1Yiw Il1rn^tm1Yiw/Il1rn^tm1Yiw (involves: 129 * BALB/c)	rheumatoid arthritis	J:143719
Il17ra^tm1.2Kurs/Il17ra^tm1.2Kurs (involves: 129S4/SvJae * BALB/cJ * C57BL/6 * SJL)	abnormal interleukin secretion	J:196483
	increased CD4-positive, alpha-beta T cell number	J:196483
	increased gamma-delta T cell number	J:196483
	increased interleukin-6 secretion	J:196483
	increased interleukin-17 secretion	J:196483
	increased T-helper 17 cell number	J:196483
	skin inflammation	J:196483
Il17ra^tm1Koll/Il17ra^tm1Koll (involves: 129 * C57BL/6)	abnormal granulocyte differentiation	J:71097
	abnormal interleukin-5 secretion	J:139080
	abnormal interleukin-13 secretion	J:139080
	decreased inflammatory response	J:139080
	decreased neutrophil cell number	J:71097
	impaired neutrophil recruitment	J:71097
	increased susceptibility to infection	J:71097
Il17ra^tm1Koll/Il17ra^tm1Koll (involves: 129)	abnormal T-helper 2 cell differentiation	J:158594
	decreased interleukin-9 secretion	J:158594
	decreased interleukin-17 secretion	J:177650
	impaired neutrophil recruitment	J:136279
Il17rb^tm1Anjm/Il17rb^tm1Anjm (BALB/c-Il17rb^tm1Anjm)	decreased eosinophil cell number	J:159464
	decreased IgE level	J:159464
	increased susceptibility to parasitic infection	J:159464
Il17rb^tm1Anjm/Il17rb^tm1Anjm Il1rl1^tm1Anjm/Il1rl1^tm1Anjm (involves: 129P2/OlaHsd * BALB/c)	decreased eosinophil cell number	J:159464
	decreased IgE level	J:159464
	increased susceptibility to parasitic infection	J:159464
Il17rb^tm1Bud/Il17rb^tm1Bud (B6.129-Il17rb^tm1Bud)	decreased inflammatory response	J:139080
	decreased interleukin-5 secretion	J:139080
	decreased interleukin-13 secretion	J:139080
Il17rb^tm1Lex/Il17rb^tm1Lex (C.129-Il17rb^tm1Lex)	abnormal chemokine secretion	J:159874
	abnormal osteoclast differentiation	J:159874
	decreased interleukin-5 secretion	J:159874
	decreased interleukin-6 secretion	J:159874
Il17rb^tm1Tgi/Il17rb⁺ (Not Specified)	decreased susceptibility to induced colitis	J:229778
Il17rb^tm1Tgi/Il17rb^tm1Tgi (B6.Cg-Il17rb^tm1Tgi)	abnormal interleukin secretion	J:184570
	decreased interleukin-9 secretion	J:184570
	decreased interleukin-10 secretion	J:184570
	decreased interleukin-13 secretion	J:184570
	decreased interleukin-17 secretion	J:184570
	decreased NK T cell number	J:184570
Il17rb^tm1Tgi/Il17rb^tm1Tgi (C.Cg-Il17rb^tm1Tgi)	abnormal interleukin secretion	J:184570
	decreased interleukin-5 secretion	J:184570
	decreased interleukin-9 secretion	J:184570
	decreased interleukin-10 secretion	J:184570
	decreased interleukin-13 secretion	J:184570
	decreased interleukin-17 secretion	J:184570
Il17rb^tm1Tgi/Il17rb^tm1Tgi (Not Specified)	decreased susceptibility to induced colitis	J:229778
Il17rc^em1(IMPC)Mbp/Il17rc^em1(IMPC)Mbp (C57BL/6NCrl-Il17rc^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Il17rc^tm1Lex/Il17rc^tm1Lex (involves: C57BL/6)	abnormal chemokine level	J:159874
	decreased inflammatory response	J:159874
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:159874
	increased interleukin-17 secretion	J:159874
Il17re^tm1Lex/Il17re^tm1Lex (B6.129S5-Il17re^tm1Lex)	increased susceptibility to induced colitis	J:178967
Il17re^tm1Sdl/Il17re^tm1Sdl (involves: C57BL/6)	increased susceptibility to bacterial infection	J:178966
Il17re^tm1Sdl/Il17re^tm1Sdl (involves: C57BL/6)	increased susceptibility to bacterial infection induced morbidity/mortality	J:178966
Il18^tm1Aki/Il18^tm1Aki (involves: 129P2/OlaHsd)	abnormal macrophage physiology	J:112400
	abnormal T-helper 1 physiology	J:46514
	decreased circulating interferon-gamma level	J:46514
	decreased circulating interleukin-18 level	J:122588, J:46514
	decreased interferon-gamma secretion	J:46514
	impaired natural killer cell mediated cytotoxicity	J:46514
	increased susceptibility to bacterial infection	J:112400
Il18^tm1Aki/Il18^tm1Aki (involves: 129P2/OlaHsd * C57BL/6)	abnormal microglial cell morphology	J:122031
Il18^tm1Aki/Il18^tm1Aki (C.129P2-Il18^tm1Aki)	stomach inflammation	J:120594
Il18^tm1Aki/Il18^tm1Aki (B6.129P2-Il18^tm1Aki)	impaired neutrophil chemotaxis	J:125285
	increased susceptibility to bacterial infection	J:125285
	increased susceptibility to induced colitis	J:173245
Il18^tm1Aki/Il18^tm1Aki Il1b^tm1Dch/Il1b^tm1Dch (involves: 129P2/OlaHsd * 129S2/SvPas)	increased susceptibility to bacterial infection	J:112400
Il18^tm1Aki/Il18^tm1Aki Nlrp1a^Neut1/Nlrp1a^Neut1 (involves: 129P2/OlaHsd * C57BL/6)	abnormal inflammatory response	J:191055
	increased neutrophil cell number	J:191055
	myocarditis	J:191055
Il18^tm1Aki/Il18^tm1Aki Tg(KRT14-CASP1)1Miz/0 (involves: 129P2/OlaHsd * C57BL/6)	decreased IgE level	J:78602
	decreased IgG1 level	J:78602
	immune system phenotype	J:78602
Il18^tm1Khe/Il18^tm1Khe (involves: 129P2/OlaHsd)	abnormal T cell morphology	J:62263
	decreased circulating interferon-gamma level	J:62263
	decreased circulating interleukin-18 level	J:62263
	decreased susceptibility to endotoxin shock	J:62263
	increased circulating tumor necrosis factor level	J:62263
Il18^tm1Khe/Il18^tm1Khe (B6.129P2-Il18^tm1Khe)	abnormal cytokine level	J:138759
	decreased circulating interferon-gamma level	J:138759
	decreased circulating interleukin-6 level	J:138759
	decreased circulating interleukin-18 level	J:138759
	decreased interferon-gamma secretion	J:138759
	decreased susceptibility to bacterial infection	J:138759
	decreased tumor necrosis factor secretion	J:138759
	increased dendritic cell number	J:138759
	increased macrophage cell number	J:138759
	increased NK cell number	J:138759
Il18^tm1Liew/Il18^tm1Liew (involves: 129P2/OlaHsd * CD-1)	abnormal interferon level	J:86621
	abnormal interleukin level	J:86621
	abnormal tumor necrosis factor level	J:86621
	increased susceptibility to bacterial infection	J:86621
	increased susceptibility to parasitic infection	J:86621
	sepsis	J:86621
Il18bp^{tm1(KOMP)Vlcg}/Il18bp^{tm1(KOMP)Vlcg} (C57BL/6-Il18bp^{tm1(KOMP)Vlcg})	abnormal NK cell differentiation	J:255309
	decreased interferon-gamma secretion	J:255309
	decreased KLRG1-positive NK cell number	J:255309
	decreased mature NK cell number	J:255309
	decreased NK cell number	J:255309
	increased circulating interferon-gamma level	J:255309
	increased immature NK cell number	J:255309
Il18bp^{tm1.1(KOMP)Vlcg}/Il18bp^{tm1.1(KOMP)Vlcg} (involves: C57BL/6N)	abnormal circulating chemokine level	J:261967
	abnormal lymph node morphology	J:261967
	abnormal macrophage activation involved in immune response	J:261967
	abnormal phagocyte morphology	J:261967
	abnormal spleen morphology	J:261967
	enlarged spleen	J:261967
	immune system phenotype	J:261967
	increased B cell number	J:261967
	increased circulating interferon-gamma level	J:261967
	increased circulating interleukin-18 level	J:261967
	increased macrophage cell number	J:261967
	increased monocyte cell number	J:261967
Il18r1^tm1Aki/Il18r1^tm1Aki (either: (involves: 129P2/OlaHsd) or (involves: 129P2/OlaHsd * C57BL/6))	abnormal T-helper 1 physiology	J:70298
	decreased interferon-gamma secretion	J:70298
	impaired natural killer cell mediated cytotoxicity	J:70298
Il18rap^tm1Yeh/Il18rap^tm1Yeh (Not Specified)	abnormal cytokine secretion	J:98417
Il18rap^tm1Yeh/Il18rap^tm1Yeh (Not Specified)	abnormal leukocyte physiology	J:98417
Il19^tm2Vlcg/Il19^tm2Vlcg (B6.Cg-Il19^tm2Vlcg)	decreased interleukin-6 secretion	J:229575
	decreased interleukin-10 secretion	J:229575
	decreased interleukin-13 secretion	J:229575
	immune system phenotype	J:229575
	increased interferon-gamma secretion	J:229575
	increased interleukin-1 beta secretion	J:229575
	increased interleukin-6 secretion	J:229575
	increased interleukin-12 secretion	J:229575
	increased susceptibility to colitis induced morbidity/mortality	J:229575
	increased susceptibility to induced colitis	J:229575
	increased tumor necrosis factor secretion	J:229575
Il20^tm1Lex/Il20^tm1Lex (B6;129S5-Il20^tm1Lex/Mmucd)	abnormal type IV hypersensitivity reaction	J:171883
Il20ra^tm1.1Misc/Il20ra^tm1.1Misc (involves: C57BL/6)	abnormal osteoclast differentiation	J:177783
Il20rb^tm1Uwe/Il20rb^tm1Uwe (B6.129P2-Il20rb^tm1Uwe)	abnormal cytotoxic T cell physiology	J:143497
	abnormal T-helper 1 physiology	J:143497
	decreased interleukin-4 secretion	J:143497
	decreased interleukin-10 secretion	J:143497
	increased interferon-gamma secretion	J:143497
	increased interleukin-2 secretion	J:143497
	increased memory T cell number	J:143497
	increased T cell proliferation	J:143497
Il20rb^tm1Uwe/Il20rb^tm1Uwe (C.129P2-Il20rb^tm1Uwe)	increased susceptibility to type IV hypersensitivity reaction	J:143497
Il21^tm1Lex/Il21^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6J)	abnormal gamma-delta T cell morphology	J:123351
	abnormal interleukin level	J:123351
	abnormal T cell differentiation	J:123351
	decreased CD4-positive, alpha-beta T cell number	J:123351
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:123351
	increased susceptibility to experimental autoimmune encephalomyelitis	J:137377
Il21^tm1Lex/Il21^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:137867
	abnormal CD4-positive, alpha-beta T cell physiology	J:137867
	abnormal germinal center B cell physiology	J:137867
	abnormal spleen germinal center morphology	J:137867
	decreased germinal center B cell number	J:137867
	decreased IgG1 level	J:137867
	decreased spleen germinal center number	J:137867
Il21^tm1Llit/Il21^tm1Llit (involves: 129 * C57BL/6J)	abnormal class switch recombination	J:114783
Il21^tm1Llit/Il21^tm1Llit (involves: 129 * C57BL/6J)	increased IgE level	J:114783
Il21r^tm1Day/Il21r^tm1Day (involves: BALB/c * C57BL/6)	abnormal CD4-positive T cell differentiation	J:136955, J:123352
	abnormal dendritic cell physiology	J:144708
	abnormal Langerhans cell physiology	J:144708
	abnormal memory T cell physiology	J:76043
	abnormal NK cell physiology	J:76043
	abnormal plasmacytoid dendritic cell physiology	J:144708
	abnormal T cell activation	J:76043
	abnormal T cell physiology	J:76043
	abnormal thymocyte activation	J:76043
	decreased CD4-positive, alpha-beta T cell number	J:123352
	decreased cytotoxic T cell cytolysis	J:76043
	decreased IgE level	J:144708
	decreased IgG1 level	J:76043, J:144708
	decreased IgG2a level	J:144708
	decreased IgG2b level	J:76043
	decreased interferon-gamma secretion	J:144708
	decreased interleukin-4 secretion	J:144708
	decreased interleukin-13 secretion	J:144708
	decreased interleukin-17 secretion	J:123352
	decreased susceptibility to type IV hypersensitivity reaction	J:144708
	impaired natural killer cell mediated cytotoxicity	J:76043
	increased IgE level	J:76043
	increased interferon-gamma secretion	J:76043, J:123352
Il21r^tm1Day/Il21r^tm1Day (C57BL/6-Il21r^tm1Day)	abnormal susceptibility to infection	J:111712
	abnormal T-helper 2 physiology	J:111712
	decreased IgG1 level	J:111712
	decreased IgG2b level	J:111712
	decreased interleukin-4 secretion	J:111712
	decreased interleukin-13 secretion	J:111712
	decreased interleukin-21 secretion	J:111712
Il21r^tm1Kopf/Il21r^tm1Kopf (involves: 129/Sv * BALB/c)	abnormal immunoglobulin level	J:137508
	abnormal lymphocyte physiology	J:137508
	decreased IgA level	J:137508
	decreased IgG1 level	J:137508
	immune system phenotype	J:137377
	impaired eosinophil recruitment	J:137508
	increased IgE level	J:137508
Il21r^tm1Kopf/Il21r^tm1Kopf (B6.129-Il21r^tm1Kopf)	abnormal immune system morphology	J:137508
	abnormal immune system physiology	J:137508
	abnormal immunoglobulin level	J:137508
	abnormal leukocyte physiology	J:137508
	abnormal lymphocyte physiology	J:137508
	abnormal T-helper 1 physiology	J:137508
	abnormal T-helper 2 physiology	J:137508
	decreased basophil cell number	J:137508
	decreased eosinophil cell number	J:137508
	decreased granulocyte number	J:137508
	decreased IgA level	J:137508
	decreased IgG1 level	J:137508
	granulomatous inflammation	J:137508
	impaired eosinophil recruitment	J:137508
	increased IgE level	J:137508
	increased susceptibility to experimental autoimmune encephalomyelitis	J:137377
Il21r^tm1Wjl/Il21r^tm1Wjl (involves: 129 * C57BL/6)	abnormal CD8-positive, alpha-beta T cell physiology	J:95221
	abnormal immunoglobulin level	J:80474
	decreased cytotoxic T cell cytolysis	J:95221
	decreased IgG1 level	J:80474
	decreased IgG2a level	J:80474
	decreased IgG2b level	J:80474
	decreased IgG3 level	J:80474
	decreased interleukin-17 secretion	J:124293
	increased IgE level	J:80474
Il21r^tm1Wjl/Il21r^tm1Wjl (NOD.Cg-Il21r^tm1Wjl)	abnormal CD4-positive T cell differentiation	J:139075
	decreased interleukin-17 secretion	J:139075
	decreased susceptibility to autoimmune diabetes	J:139075
	decreased T cell proliferation	J:139075
Il21r^tm1Wjl/Il21r^tm1Wjl Il4^tm1Cgn/Il4^tm1Cgn (involves: 129 * C57BL/6)	abnormal immunoglobulin level	J:80474
	abnormal lymph node germinal center morphology	J:80474
	decreased IgA level	J:80474
	decreased IgG1 level	J:80474
	decreased IgG2a level	J:80474
	decreased IgG2b level	J:80474
	decreased IgG3 level	J:80474
	decreased IgM level	J:80474
Il21r^tm1Wjl/Il21r^tm1Wjl X/Yaa (BXSB.129(Cg)-Il21r^tm1Wjl/Dcr)	decreased susceptibility to systemic lupus erythematosus	J:144484
Il22^{tm1.1(icre)Stck}/Il22^{tm1.1(icre)Stck} (involves: 129X1/SvJ * C57BL/6N)	increased susceptibility to bacterial infection	J:220074
Il22^tm1.1Lex/Il22^tm1.1Lex (involves: 129S5/SvEvBrd * C57BL/6)	abnormal cytokine secretion	J:118261
	ear inflammation	J:118261
Il22^tm1.1Lex/Il22^tm1.1Lex (involves: 129S5/SvEvBrd)	abnormal circulating cytokine level	J:179011
	colitis	J:161073
	decreased circulating interleukin-1 alpha level	J:179011
	decreased circulating interleukin-12 level	J:179011
	decreased circulating interleukin-12b level	J:179011
	decreased circulating tumor necrosis factor level	J:179011
	increased circulating interleukin-17 level	J:179011
	increased susceptibility to bacterial infection induced morbidity/mortality	J:161073
	increased susceptibility to fungal infection	J:179011
	lung inflammation	J:179011
Il22^tm1Flv/Il22⁺ (B6.Cg-Il22^tm1Flv)	increased susceptibility to endotoxin shock	J:126103
Il22^tm1Flv/Il22^tm1Flv (B6.Cg-Il22^tm1Flv)	increased susceptibility to endotoxin shock	J:126103
Il22^tm1Flv/Il22^tm1Flv (B6.Cg-Il22^tm1Flv)	liver inflammation	J:126103
Il22^tm1Flv/Il22^tm1Flv (involves: 129/Sv * C57BL/6)	increased susceptibility to induced colitis	J:189217
Il22^tm1Jcrd/Il22^tm1Jcrd (B6.Cg-Il22^tm1Jcrd)	immune system phenotype	J:155038
Il22^tm1Jcrd/Il22^tm1Jcrd (Not Specified)	decreased neutrophil cell number	J:193548
Il22^tm1Jcrd/Il22^tm1Jcrd (Not Specified)	increased interleukin-17 secretion	J:193548
Il22ra2^tm2Vlcg/Il22ra2^tm2Vlcg (B6.Cg-Il22ra2^tm2Vlcg)	colitis	J:189217
Il23a^tm1.1Thak/Il23a^tm1.1Thak (C57BL/6-Il23a^tm1.1Thak)	decreased interferon-gamma secretion	J:143970
	decreased interleukin-17 secretion	J:143970
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:143970
	decreased T cell proliferation	J:143970
Il23a^tm1Dnax/Il23a^tm1Dnax (involves: 129 * C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:95542
	decreased interleukin-17 secretion	J:95542
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:95542
Il23a^tm1Dnax/Il23a^tm1Dnax (B6.Cg-Il23a^tm1Dnax)	abnormal CD8-positive, alpha-beta T cell physiology	J:111568
	abnormal granulocyte physiology	J:111568
	abnormal interleukin level	J:111568
	abnormal macrophage physiology	J:111568
Il23a^tm1Dnax/Il23a^tm1Dnax (Not Specified)	decreased gamma-delta T cell number	J:193548
	decreased interleukin-17 secretion	J:193548
	decreased leukocyte cell number	J:193548
	decreased neutrophil cell number	J:193548
	decreased T cell number	J:193548
Il23a^tm1Gdy/Il23a⁺ (B6.Cg-Il23a^tm1Gdy)	increased susceptibility to induced colitis	J:139557
Il23a^tm1Gdy/Il23a^tm1Gdy (B6.Cg-Il23a^tm1Gdy)	increased susceptibility to induced colitis	J:139557
Il23a^tm1Ngh/Il23a^tm1Ngh (involves: 129S/SvEv * C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:88235
	abnormal CD8-positive, alpha beta T cell morphology	J:88235
	abnormal memory T cell physiology	J:88235
	decreased IgA level	J:88235
	decreased IgG2a level	J:88235
	decreased immunoglobulin level	J:88235
Il23a^tm1Ngh/Il23a^tm1Ngh (involves: 129 * C57BL/6)	abnormal circulating interleukin level	J:216867
	abnormal memory T cell physiology	J:120806
	decreased activated T cell number	J:120806
	decreased susceptibility to induced colitis	J:216867
	granulomatous inflammation	J:120806
	increased circulating interleukin-17 level	J:216867
	increased susceptibility to bacterial infection	J:120806
Il23a^tm1Ngh/Il23a^tm1Ngh (involves: 129)	increased susceptibility to bacterial infection induced morbidity/mortality	J:161073
Il23r^tm1.1Kuch/Il23r^tm1.1Kuch (involves: C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:151907
Il23r^tm1.1Kuch/Il23r^tm1.1Kuch (involves: C57BL/6)	decreased interleukin-9 secretion	J:151907
Il23r^tm1.1Ngh/Il23r^tm1.1Ngh (involves: C57BL/6)	abnormal circulating interleukin level	J:216867
	decreased susceptibility to induced colitis	J:216867
	increased circulating interleukin-17 level	J:216867
Il23r^tm1.1Ngh/Il23r^tm1.1Ngh Rag2^tm1Fwa/Rag2^tm1Fwa (involves: 129S/SvEv * C57BL/6)	abnormal circulating interleukin level	J:216867
	decreased interleukin-17 secretion	J:216867
Il23r^tm1Dnax/Il23r^tm1Dnax (C57BL/6-Il23r^tm1Dnax)	immune system phenotype	J:111568
Il23r^tm1Kuch/Il23r^tm1Kuch (C57BL/6-Il23r^tm1Kuch)	abnormal CD4-positive T cell differentiation	J:148248
	abnormal CD4-positive, alpha-beta T cell physiology	J:148248
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:148248
Il25^tm1.1Cdon/Il25^tm1.1Cdon (involves: 129S6/SvEvTac)	abnormal chemokine secretion	J:229778
	abnormal interleukin secretion	J:229778
	decreased eosinophil cell number	J:229778
	decreased interleukin-1 beta secretion	J:229778
	decreased interleukin-4 secretion	J:229778, J:158594
	decreased interleukin-5 secretion	J:229778, J:158594
	decreased interleukin-9 secretion	J:158594
	decreased interleukin-13 secretion	J:229778, J:158594
	decreased susceptibility to bacterial infection	J:229778
	decreased susceptibility to induced colitis	J:229778
	decreased T-helper 2 cell number	J:229778
	decreased tumor necrosis factor secretion	J:229778
	increased susceptibility to type I hypersensitivity reaction	J:158594
	lung inflammation	J:158594
Il25^tm1Anjm/Il25^tm1Anjm (involves: 129P2/OlaHsd * C57BL/6)	abnormal interleukin secretion	J:123748
	abnormal mesenteric lymph node morphology	J:123748
	decreased eosinophil cell number	J:123748
	decreased interleukin-5 secretion	J:123748
	decreased interleukin-13 secretion	J:123748
	increased IgE level	J:123748
	increased susceptibility to parasitic infection	J:123748
Il25^tm1Cdon/Il25^tm1Cdon Tg(Vil1-cre)997Gum/0 (involves: 129S6/SvEvTac * C57BL/6J * C57BL/6N * SJL)	decreased susceptibility to induced colitis	J:229778
Il25^tm1Dart/Il25^tm1Dart (C57BL/6-Il25^tm1Dart)	abnormal interferon level	J:123808
	abnormal interleukin level	J:123808
	abnormal response to infection	J:123808
	decreased IgG2a level	J:123808
	increased susceptibility to parasitic infection	J:123808
	intestinal inflammation	J:123808
Il25^tm1Dart/Il25^tm1Dart (involves: C57BL/6)	abnormal interleukin level	J:125296
	increased susceptibility to experimental autoimmune encephalomyelitis	J:125296
	increased T cell number	J:125296
Il27^{tm1b(EUCOMM)Wtsi}/Il27^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Il27^{tm1b(EUCOMM)Wtsi}/Wtsi)	decreased CD4-positive, alpha-beta memory T cell number	J:211773
	increased KLRG1-positive CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
Il27^tm1Cua/Il27^tm1Cua (C57BL/6-Il27^tm1Cua)	abnormal CD4-positive T cell differentiation	J:147706
	increased susceptibility to experimental autoimmune encephalomyelitis	J:147706
	increased susceptibility to type IV hypersensitivity reaction	J:147706
Il27^tm1Lex/Il27^tm1Lex (involves: 129S/SvEvBrd)	increased circulating interleukin-12b level	J:187660
	increased interferon-gamma secretion	J:187660
	increased susceptibility to parasitic infection induced morbidity/mortality	J:187660
Il27ra^tm1Fjs/Il27ra^tm1Fjs (B6.Cg-Il27ra^tm1Fjs)	abnormal T-helper 1 physiology	J:94856
	decreased susceptibility to bacterial infection	J:94856
	increased lymphocyte cell number	J:94856
Il27ra^tm1Mak/Il27ra^tm1Mak (B6.129P2-Il27ra^tm1Mak)	abnormal T-helper 1 physiology	J:116610, J:89509
	decreased circulating interferon-gamma level	J:116610
	decreased interferon-gamma secretion	J:116610, J:89509
	decreased susceptibility to experimental autoimmune uveoretinitis	J:116610
	immune system phenotype	J:88618
	increased circulating interferon-gamma level	J:88618
	increased circulating interleukin-1 beta level	J:88618
	increased circulating interleukin-4 level	J:88618
	increased circulating interleukin-6 level	J:88618
	increased circulating interleukin-12 level	J:88618
	increased circulating tumor necrosis factor level	J:88618
	increased interferon-gamma secretion	J:88618
	increased interleukin-4 secretion	J:88618
	increased susceptibility to bacterial infection	J:89509
	increased susceptibility to parasitic infection	J:89509
	increased T cell proliferation	J:89509
Il27ra^tm1Mak/Il27ra^tm1Mak (involves: 129P2/OlaHsd * C57BL/6)	increased susceptibility to induced arthritis	J:151552
Il31^tm1.1Snak/Il31^tm1.1Snak (B6N(Cg)-Il31^tm1.1Snak)	immune system phenotype	J:263831
Il31ra^tm1Jagr/Il31ra^tm1Jagr (involves: 129S5/SvEvBrd)	immune system phenotype	J:91124
Il31ra^tm1Ngh/Il31ra^tm1Ngh (C57BL/6-Il31ra^tm1Ngh)	spleen hypoplasia	J:123111
Il31ra^tm1Ngh/Il31ra^tm1Ngh (involves: C57BL/6)	abnormal interleukin level	J:123198
	abnormal macrophage physiology	J:123198
	granulomatous inflammation	J:123198
	increased IgE level	J:123198
	increased susceptibility to parasitic infection	J:123198
	increased T cell proliferation	J:123198
Il33^{tm1(KOMP)Vlcg}/Il33^{tm1(KOMP)Vlcg} (C57BL/6-Il33^{tm1(KOMP)Vlcg})	impaired macrophage chemotaxis	J:232676
Il33^tm1Aki/Il33^tm1Aki (involves: 129X1/SvJ * C57BL/6)	abnormal T-helper 2 physiology	J:182160
	decreased eosinophil cell number	J:182160
	decreased IgE level	J:182160
	immune system phenotype	J:182160
	increased susceptibility to parasitic infection	J:182160
Il33^tm1Amgn/Il33^tm1Amgn (B6.129-Il33^tm1Amgn)	abnormal immune cell physiology	J:192531
	decreased lymphocyte cell number	J:192531
	increased susceptibility to parasitic infection	J:192531
Il33^tm1Snak/Il33^tm1Snak (involves: C57BL/6 * CBA)	decreased inflammatory response	J:165513
	decreased interleukin-1 alpha secretion	J:165513
	decreased interleukin-1 beta secretion	J:165513
	decreased interleukin-6 secretion	J:165513
	decreased susceptibility to endotoxin shock	J:165513
	immune system phenotype	J:165513
	increased susceptibility to induced colitis	J:165513
	lung inflammation	J:165513
Il33^{tm2.1(IL33)Arte}/Il33^{tm2.1(IL33)Arte} (involves: BALB/c * BALB/cJBomTac)	immune system phenotype	J:227003
Il34^{tm1b(EUCOMM)Wtsi}/Il34^{tm1b(EUCOMM)Wtsi} (involves: BALB/cJ * C57BL/6N)	abnormal microglial cell morphology	J:187643
	absent Langerhans cell	J:187643
	decreased dendritic cell number	J:187643
	decreased interferon-gamma secretion	J:187643
	decreased Langerhans cell number	J:187643
	decreased susceptibility to fungal infection	J:187643
	decreased susceptibility to type IV hypersensitivity reaction	J:187643
	immune system phenotype	J:187643
	increased susceptibility to Flaviviridae infection	J:187643
	increased susceptibility to Flaviviridae infection induced morbidity/mortality	J:187643
	lymph node hypoplasia	J:187643
Il36a^tm1Yiw/Il36a^tm1Yiw (B6.129P2-Il36a^tm1Yiw)	abnormal cytokine level	J:263315
Il36a^tm1Yiw/Il36a^tm1Yiw (B6.129P2-Il36a^tm1Yiw)	immune system phenotype	J:263315
Il36g^tm1Lex/Il36g^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6J)	abnormal interleukin level	J:264077
	abnormal macrophage morphology	J:264077
	abnormal tumor necrosis factor level	J:264077
	decreased alveolar macrophage number	J:264077
	increased CD11b-high dendritic cell number	J:264077
	increased macrophage apoptosis	J:264077
	increased susceptibility to Orthomyxoviridae infection	J:264077
	increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:264077
Il36g^tm1Lex/Il36g^tm1Lex (involves: 129S5/SvEvBrd)	decreased CD4-positive, alpha-beta T cell number	J:256437
	decreased interleukin-9 secretion	J:256437
	decreased susceptibility to induced colitis	J:256437
	impaired neutrophil recruitment	J:280917
	increased CD4-positive, alpha-beta T cell number	J:256437
	increased regulatory T cell number	J:256437
	increased susceptibility to Herpesvirales infection	J:280917
	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:280917
Il36g^tm1Lex/Il36g^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6)	abnormal cytokine level	J:296074
	abnormal macrophage activation involved in immune response	J:296074
	impaired macrophage phagocytosis	J:296074
	increased susceptibility to bacterial infection	J:296074
	increased susceptibility to bacterial infection induced morbidity/mortality	J:296074
Il36rn^tm1Hblu/Il36rn⁺ Tg(KRT14-Il1f6)1Hblu/? (involves: 129 * C57BL/6 * DBA/2)	skin inflammation	J:126327
Il36rn^tm1Hblu/Il36rn^tm1Hblu (C.129(B6)-Il36rn^tm1Hblu)	increased susceptibility to chemically induced skin inflammation	J:260118
Il36rn^tm1Hblu/Il36rn^tm1Hblu Tg(KRT14-Il1f6)1Hblu/? (involves: 129 * C57BL/6 * DBA/2)	skin inflammation	J:126327
Il36rn^tm1Kopf/Il36rn^tm1Kopf (B6.129S5-Il36rn^tm1Kopf)	dermatitis	J:193548
	increased leukocyte cell number	J:193548
	increased neutrophil cell number	J:193548
Ilf2^tm1Pnk/Ilf2⁺ (involves: C57BL/6)	immune system phenotype	J:161086
Ilf3^tm1.1Itl/Ilf3^tm1.1Itl (Not Specified)	increased susceptibility to Adenoviridae infection	J:167126
Ilf3^tm1Pnk/Ilf3⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	immune system phenotype	J:161086
Ilk^tm1Star/Ilk^tm1Star Tg(KRT14-cre)1Amc/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)	skin inflammation	J:172934
Ilk^tm1Star/Ilk^tm1Star Tg(NPHS2-cre)295Lbh/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)	tubulointerstitial nephritis	J:129286, J:129244
Ilk^tm1Star/Ilk^tm2Star Tg(Acp5-cre)1Star/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal osteoclast physiology	J:197593
	increased osteoclast cell number	J:197593
Im1^Bioz:BP1/? (involves: Bioz:BP1 * Bioz:MP1)	abnormal humoral immune response	J:46394
Im2^Bioz:BP1/? (involves: Bioz:BP1 * Bioz:MP1)	abnormal humoral immune response	J:37251
Im2^Bioz:BP1/Im2^Bioz:BP1 (involves: Bioz:BP1 * Bioz:MP1)	abnormal humoral immune response	J:65671
Im3^Bioz:BP1/? (involves: Bioz:BP1 * Bioz:MP1)	abnormal humoral immune response	J:46394
Im4^Bioz:BP1/? (involves: Bioz:BP1 * Bioz:MP1)	abnormal humoral immune response	J:37251
Im5^Bioz:BP1/? (involves: Bioz:BP1 * Bioz:MP1)	abnormal humoral immune response	J:37251
Im6^Bioz:BP1/? (involves: Bioz:BP1 * Bioz:MP1)	abnormal humoral immune response	J:37251
Im7^Bioz:BP1/? (involves: Bioz:BP1 * Bioz:MP1)	abnormal humoral immune response	J:37251
Imebt1^DU6/? (involves: DU6 * DUKs)	increased spleen weight	J:99475
Imh1^NZB/Imh1^NZB (involves: NZB * NZW)	increased IgM level	J:26266
Imh1^NZB/Imh1^NZB (involves: NZB * NZW)	increased susceptibility to systemic lupus erythematosus	J:26266
Imh1^NZB/Imh1^NZW (involves: NZB * NZW)	increased IgM level	J:26266
Imh1^NZB/Imh1^NZW (involves: NZB * NZW)	increased susceptibility to systemic lupus erythematosus	J:22353
Imm1^NZW/Imm1^NZB (involves: NZB * NZW)	abnormal immune system physiology	J:26266
Imm1^NZW/Imm1^NZW (involves: NZB * NZW)	abnormal immune system physiology	J:26266
Immp2l^{Tg(HLA-A/H2-D)2Enge}/? ((C57BL/6 x CBA)F1)	abnormal cytotoxic T cell physiology	J:31937
	abnormal negative T cell selection	J:31937
	abnormal positive T cell selection	J:31937
Impact^{em1(IMPC)Ccpcz}/Impact^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Impact^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
Impdh1^tm1Bmi/Impdh1^tm1Bmi (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal immune system cell morphology	J:85443
	decreased T cell proliferation	J:85443
Impdh1^tm1Bmi/Impdh1^tm1Bmi Impdh2^tm1Bmi/Impdh2⁺ (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal cytotoxic T cell physiology	J:85443
	abnormal immune system cell morphology	J:85443
	abnormal lymphopoiesis	J:85443
	decreased splenocyte proliferation	J:85443
	decreased T cell proliferation	J:85443
Impdh2^tm1Bmi/Impdh2⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal lymphocyte cell number	J:86045
Impg1^em1Visu/Impg1^em1Visu Impg2^em1Visu/Impg2^em1Visu (involves: C57BL/6J * DBA/2)	microgliosis	J:288311
Impg2^em1Visu/Impg2^em1Visu (involves: C57BL/6J * DBA/2)	microgliosis	J:288311
Imraq1^DBA/2J/? (involves: C57BL/6J * DBA/2J)	increased IgG level	J:100370
Imraq2^DBA/2J/? Imraq3^C57BL/6J/? (involves: C57BL/6J * DBA/2J)	increased IgG level	J:100370
Imrfq1^C57BL/6J/? Imrfq2^C57BL/6J/? (involves: C57BL/6J * DBA/2J)	increased IgG level	J:100370
In(2a;Itch)18H/In(2a;Itch)18H (involves: 101/H * C3H/HeH)	abnormal alveolar macrophage morphology	J:24934
	chronic inflammation	J:24934
	immune system phenotype	J:205692
	increased inflammatory response	J:45910
	increased spleen red pulp amount	J:24934
	interstitial pneumonia	J:24934
	lung inflammation	J:24934
	lymph node hyperplasia	J:24934
Inava^tm1.1Itl/Inava^tm1.1Itl (involves: 129S6/SvEvTac * C57BL/6NTac)	increased susceptibility to bacterial infection	J:257317
	increased susceptibility to induced colitis	J:257317
Inca1^tm1Cmt/Inca1^tm1Cmt (involves: 129 * C57BL/6N)	abnormal spleen B cell follicle morphology	J:175667
	abnormal spleen morphology	J:175667
	abnormal spleen white pulp morphology	J:175667
	increased IgA level	J:175667
Ing1^{Gt(OST206270)Lex}/Ing1^{Gt(OST206270)Lex} (involves: 129S5/SvEvBrd * C57BL/6)	decreased thymocyte number	J:118602
	increased thymocyte apoptosis	J:118602
Ing1^tm1Avg/Ing1^tm1Avg (involves: 129S1/Sv * C57BL/6)	enlarged spleen	J:105658
Ing2^tm1.1Ccha/Ing2^tm1.1Ccha (involves: 129 * C57BL/6J * FVB/N)	spleen hyperplasia	J:167311
Ing4^em1(IMPC)Tcp/Ing4^em1(IMPC)Tcp (C57BL/6NCrl-Ing4^em2(IMPC)Tcp/Tcp)	increased neutrophil cell number	J:211773
Ing4^Gt(XG370)Byg/Ing4^Gt(XG370)Byg (involves: 129P2/OlaHsd * C57BL/6)	abnormal chemokine level	J:161381
	increased circulating interleukin-6 level	J:161381
	increased interleukin-6 secretion	J:161381
Ing5^tm1.1Avo/Ing5^tm1.1Avo (B6.Cg-Ing5^tm1.1Avo)	spleen hypoplasia	J:345308
Inha^tm1Bay/Inha^tm1Bay (involves: 129S7/SvEvBrd * C57BL/6)	chronic liver inflammation	J:20450
Inhbb^tm1Jae/Inhbb^tm1Jae (either: (129S4/SvJae-Inhbb^tm1Jae) or (involves: 129S4/SvJae * BALB/c) or (involves: 129S4/SvJae * C57BL/6))	increased incidence of corneal inflammation	J:16995
Inmt^em1(IMPC)Mbp/Inmt^em1(IMPC)Mbp (C57BL/6N-Inmt^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
Ino80^tm1.1Schg/Ino80⁺ Trp53^tm1Tyj/Trp53^tm1Tyj (involves: 129S2/SvPas * C57BL/6J)	increased T cell derived lymphoma incidence	J:221224
Inpp1^{tm1a(KOMP)Wtsi}/Inpp1^{tm1a(KOMP)Wtsi} (involves: C57BL/6 * C57BL/6N)	decreased susceptibility to bacterial infection	J:213427
Inpp4b^tm1.1Jva/Inpp4b^tm1.1Jva (B6.129-Inpp4b^tm1.1Jva)	abnormal osteoclast differentiation	J:177648
	abnormal osteoclast morphology	J:177648
	increased osteoclast cell number	J:177648
Inpp5d^el20/Inpp5d^el20 (B6.129-Inpp5d^el20)	abnormal lymphocyte cell number	J:173266
	decreased lymphocyte cell number	J:173266
	decreased pre-B cell number	J:173266
	decreased thymocyte number	J:173266
	enlarged spleen	J:173266
	increased circulating interleukin-6 level	J:173266
	increased IgG2a level	J:173266
	increased IgM level	J:173266
	increased immunoglobulin level	J:173266
	increased macrophage cell number	J:173266
	small thymus	J:173266
Inpp5d^m1Anu/Inpp5d^m1Anu (C57BL/6JAnu-Inpp5d^m1Anu)	lung inflammation	J:104190
Inpp5d^m1Btlr/Inpp5d^m1Btlr (C57BL/6J-Inpp5d^m1Btlr)	abnormal B cell differentiation	J:140987
	abnormal eosinophil physiology	J:140987
	abnormal neutrophil physiology	J:140987
	decreased cytotoxic T cell cytolysis	J:140987
	enlarged spleen	J:140987
	enlarged thymus	J:140987
	impaired natural killer cell mediated cytotoxicity	J:140987
Inpp5d^m2Btlr/Inpp5d^m2Btlr (C57BL/6J-Inpp5d^m2Btlr)	decreased B cell number	J:216053
Inpp5d^M3Btlr/Inpp5d⁺ (C57BL/6J-Inpp5d^M3Btlr)	decreased NK cell number	J:254907
Inpp5d^m4Btlr/Inpp5d^m4Btlr (C57BL/6J-Inpp5d^m4Btlr)	increased interferon-beta secretion	J:272854
Inpp5d^m4Btlr/Inpp5d^m4Btlr (C57BL/6J-Inpp5d^m4Btlr)	increased tumor necrosis factor secretion	J:272854
Inpp5d^m5Btlr/Inpp5d^m5Btlr (C57BL/6J-Inpp5d^m5Btlr)	abnormal CD8-positive, alpha-beta T cell differentiation	J:272856
	abnormal lymphocyte morphology	J:272856
	abnormal T cell differentiation	J:272856
	decreased alpha-beta T cell number	J:272856
	decreased B cell number	J:272856
	decreased CD4-positive, alpha-beta T cell number	J:272856
	decreased CD8-positive, alpha-beta T cell number	J:272856
	decreased CD8-positive, naive alpha-beta T cell number	J:272856
	decreased NK cell number	J:272856
	increased B-1 B cell number	J:272856
	increased CD8-positive, alpha-beta T cell number	J:272856
	increased central memory CD8 positive, alpha-beta T cell number	J:272856
	increased effector memory CD4-positive, alpha-beta T cell number	J:272856
	increased effector memory CD8-positive, alpha-beta T cell number	J:272856
Inpp5d^tm1.1Wgk/Inpp5d^tm1.1Wgk (involves: 129S6/SvEvTac * C57BL/6J)	abnormal leukocyte physiology	J:94861
	abnormal mononuclear cell differentiation	J:94861
	abnormal NK cell morphology	J:95215
	decreased susceptibility to graft versus host disease	J:95215, J:94861
	increased dendritic cell number	J:94861
	increased monocyte cell number	J:94861
	increased NK cell number	J:95215
Inpp5d^tm1Dmt/Inpp5d^tm1Dmt (involves: 129P2/OlaHsd)	abnormal leukocyte physiology	J:77739
	decreased B cell number	J:77739
	enlarged lymph nodes	J:77739
	enlarged spleen	J:77739
	increased leukocyte cell number	J:77739
Inpp5d^tm1Dmt/Inpp5d^tm1Dmt (B6.129P2/OlaHsd-Inpp5d^tm1Dmt)	decreased lymphocyte cell number	J:173266
	decreased pre-B cell number	J:173266
	increased circulating interleukin-6 level	J:173266
Inpp5d^tm1Rav/Inpp5d^tm1.1Rav Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal spleen marginal zone macrophage morphology	J:119256
	absent marginal zone B cells	J:119256
	enlarged spleen	J:119256
Inpp5d^tm1Rav/Inpp5d^tm1Rav Cd79a^tm1(cre)Reth/Cd79a⁺ Tg(IghAb36-65)1Wys/0 (involves: 129 * BALB/c * C57BL/6 * FVB/N)	abnormal B cell anergy	J:178833
	abnormal B cell negative selection	J:178833
	decreased B cell number	J:178833
	increased autoantibody level	J:178833
	increased plasma cell number	J:178833
Inpp5d^tm1Rav/Inpp5d^tm1Rav Tg(Cd4-cre)1Cwi/? (involves: C57BL/6 * DBA/2)	abnormal cytotoxic T cell physiology	J:122796
	abnormal humoral immune response	J:122796
	abnormal interferon level	J:122796
	abnormal interleukin secretion	J:122796
	abnormal lymph node germinal center morphology	J:122796
	decreased susceptibility to parasitic infection	J:122796
Inpp5d^tm1Rkh/Inpp5d^tm1Rkh (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	abnormal granulocyte differentiation	J:48193
	abnormal lymphopoiesis	J:48193
	abnormal macrophage chemotaxis	J:48193
	abnormal monocyte differentiation	J:48193
	decreased lymphocyte cell number	J:48193
	increased monocyte cell number	J:48193
	increased neutrophil cell number	J:48193
	increased spleen weight	J:48193
	spleen hyperplasia	J:48193
Inpp5d^tm1Rkh/Inpp5d^tm1Rkh (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal interleukin level	J:173301
	abnormal myelopoiesis	J:117320
	decreased pro-B cell number	J:117320
	ileum inflammation	J:173301
	increased circulating interleukin-6 level	J:117320
	intestinal inflammation	J:173301
Inpp5d^tm1Rkh/Inpp5d^tm1Rkh (involves: 129S1/Sv * 129X1/SvJ)	abnormal CD4-positive, alpha-beta T cell physiology	J:110864
	abnormal CD8-positive, alpha-beta T cell physiology	J:110864
	abnormal cell-mediated immunity	J:110864
	abnormal macrophage chemotaxis	J:110864
	abnormal osteoclast differentiation	J:78771
	abnormal osteoclast morphology	J:78771
	abnormal osteoclast physiology	J:78771
	abnormal T cell physiology	J:110864
	enhanced B cell migration	J:110864
	increased circulating interleukin-6 level	J:78771
	increased mast cell degranulation	J:120426
	increased osteoclast cell number	J:78771
Inpp5d^tm1Rkh/Inpp5d^tm1Rkh Rag1^tm1(GFP)Imku/Rag1⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)	abnormal lymphopoiesis	J:117320
Inpp5d^tm1Wgk/Inpp5d^tm1.1Wgk Tg(Mx1-cre)1Cgn/0 (B6.Cg-Inpp5d^tm1Wgk/Inpp5d^tm1.1Wgk Tg(Mx1-cre)1Cgn)	abnormal leukocyte physiology	J:144110
	abnormal myeloid leukocyte morphology	J:144110
Inpp5d^tm1Wgk/Inpp5d^tm1Wgk Tg(Mx1-cre)1Cgn/0 (B6.Cg-Inpp5d^tm1Wgk Tg(Mx1-cre)1Cgn)	decreased susceptibility to graft versus host disease	J:144110
Inpp5k^em1(IMPC)H/Inpp5k⁺ (C57BL/6NTac-Inpp5k^em1(IMPC)H/H)	increased neutrophil cell number	J:211773
Ins1^tm1Jja/Ins1^tm1Jja (NOD.129S2-Ins1^tm1Jja)	decreased susceptibility to autoimmune diabetes	J:85309
Ins1^tm1Jja/Ins1^tm1Jja Ins2^tm1Jja/Ins2^tm1Jja Tg(Ins2Y16A)1Ell/0 (NOD.Cg-Ins1^tm1Jja Ins2^tm1Jja Tg(Ins2Y16A)1Ell)	decreased susceptibility to autoimmune diabetes	J:98583
	salivary gland inflammation	J:98583
Ins1^tm1Jja/Ins1^tm1Jja Ins2^tm1Jja/Ins2^tm1Jja Tg(Ins2Y16A)3Ell/0 (NOD.Cg-Ins1^tm1Jja Ins2^tm1Jja Tg(Ins2Y16A)3Ell)	decreased anti-insulin autoantibody level	J:98583
	decreased susceptibility to autoimmune diabetes	J:98583
	salivary gland inflammation	J:98583
Ins1^tm1Jja/Ins1^tm1Jja Ins2^tm1Mnt/Ins2^tm1Mnt Tg(Aire-cre)1Mnt/0 (involves: 129S2/SvPas * 129S4/SvJaeSor * C57BL/6 * FVB/N)	abnormal immune system physiology	J:152798
	abnormal interferon-gamma secretion	J:152798
	abnormal T cell physiology	J:152798
	increased anti-insulin autoantibody level	J:152798
	pancreas inflammation	J:152798
Ins1^tm1Jja/Ins1^tm1Jja Tg(Ins2Y16A)1Ell/0 (NOD.Cg-Ins1^tm1Jja Tg(Ins2Y16A)1Ell)	increased susceptibility to autoimmune diabetes	J:98583
Ins1^tm1Jja/Ins1^tm1Jja Tg(Ins2Y16A)3Ell/0 (NOD.Cg-Ins1^tm1Jja Tg(Ins2Y16A)3Ell)	autoimmune response	J:98583
Ins2^Akita/Ins2⁺ (C57BL/6-Ins2^Akita/J)	abnormal microglial cell morphology	J:99412
	abnormal response to transplant	J:76224
	increased leukocyte cell number	J:99412
Ins2^Akita/Ins2⁺ Prf1^tm1Sdz/Prf1^tm1Sdz Rag1^tm1Mom/Rag1^tm1Mom (NOD.Cg-Rag1^tm1Mom Ins2^Akita Prf1^tm1Sdz)	absent mature B cells	J:138005
	absent T cells	J:138005
	increased granulocyte number	J:138005
	increased macrophage cell number	J:138005
	increased monocyte cell number	J:138005
Ins2^C95S/Ins2⁺ (C3HeB/FeJ-Ins2^C95S)	increased susceptibility to autoimmune diabetes	J:122098
Ins2^C95S/Ins2^C95S (C3HeB/FeJ-Ins2^C95S)	increased susceptibility to autoimmune diabetes	J:122098
Ins2^tm1Jja/Ins2^tm1Jja (NOD.129S2-Ins2^tm1Jja)	increased anti-insulin autoantibody level	J:85309
Ins2^tm1Jja/Ins2^tm1Jja (NOD.129S2-Ins2^tm1Jja)	insulitis	J:85309
Ins2^tm1Jja/Ins2^tm1Jja Tg(Ins2Y16A)3Ell/0 (NOD.Cg-Ins2^tm1Jja Tg(Ins2Y16A)3Ell)	autoimmune response	J:98583
	increased anti-insulin autoantibody level	J:98583
Insr^m1Btlr/Insr^m1Btlr (C57BL/6J-Insr^m1Btlr)	increased susceptibility to induced colitis	J:267534
Insr^tm1Khn/Insr^tm1Khn Lepr^tm1.1Chua/Lepr^tm1.1Chua Tg(Pomc1-cre)16Lowl/0 (involves: 129 * 129S4/SvJae * 129S6/SvEvTac * C57BL/6J * FVB/N)	liver inflammation	J:192274
	ovary inflammation	J:192274
	white adipose tissue inflammation	J:192274
Insyn2b^em1(IMPC)J/Insyn2b^em1(IMPC)J (C57BL/6NJ-Insyn2b^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
Invs^inv/Invs^inv (FVB/N-Invs^inv)	abnormal spleen morphology	J:48533
Invs^inv/Invs^inv (FVB/N-Invs^inv)	spleen hypoplasia	J:48533
Ip6k2^tm1.1Snyd/Ip6k2^tm1.1Snyd (B6.129-Ip6k2^tm1.1Snyd)	abnormal B cell physiology	J:212482
Ipo7^em1(IMPC)Mbp/Ipo7⁺ (C57BL/6N-Ipo7^em1(IMPC)Mbp/Ucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Ipp^{tm1.1(KOMP)Vlcg}/Ipp^{tm1.1(KOMP)Vlcg} (C57BL/6N-Ipp^{tm1.1(KOMP)Vlcg}/J)	decreased leukocyte cell number	J:211773
Iqce^{tm1b(EUCOMM)Hmgu}/Iqce^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Iqce^{tm1b(EUCOMM)Hmgu}/Ics)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Iqcm^em1(IMPC)Tcp/Iqcm⁺ (C57BL/6NCrl-Iqcm^em1(IMPC)Tcp/Cmmr)	increased monocyte cell number	J:211773
Iqcm^em1(IMPC)Tcp/Iqcm^em1(IMPC)Tcp (C57BL/6NCrl-Iqcm^em1(IMPC)Tcp/Cmmr)	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	increased monocyte cell number	J:211773
Iqgap1^{tm1b(EUCOMM)Wtsi}/Iqgap1^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Iqgap1^{tm1b(EUCOMM)Wtsi}/Tcp)	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
Irag1^{em1(IMPC)Ccpcz}/Irag1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Irag1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	decreased lymphocyte cell number	J:211773
	enlarged spleen	J:211773
	increased eosinophil cell number	J:211773
	increased neutrophil cell number	J:211773
	increased spleen weight	J:211773
Irak1^tm1.1Pcoh/? (involves: 129P2/OlaHsd)	decreased interferon-alpha secretion	J:205798
Irak1^tm1.1Pcoh/? (involves: 129P2/OlaHsd)	immune system phenotype	J:205798
Irak1^tm1.1Pcoh/? Irak2^tm1.1Pcoh/? (involves: 129P2/OlaHsd * C57BL/6)	decreased interferon-alpha secretion	J:205798
Irak1^tm1Jth/Y (B6.Cg-Irak1^tm1Jth)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:82302
Irak1^tm1Jth/Y Irak2^tm1Aki/Irak2^tm1Aki (involves: 129/Sv * C57BL/6)	abnormal dendritic cell physiology	J:136290
	abnormal macrophage physiology	J:136290
	decreased susceptibility to endotoxin shock	J:136290
Irak1^tm1Jth/Y Tg(Myh6-Tnf)1Brgi/? (involves: 129/Sv * C57BL/6J * SJL)	myocarditis	J:84829
Irak1^tm1Jth/Irak1^tm1Jth (B6.Cg-Irak1^tm1Jth)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:82302
Irak1^tm1Jth/Irak1^tm1Jth Tg(Myh6-Tnf)1Brgi/? (involves: 129/Sv * C57BL/6J * SJL)	myocarditis	J:84829
Irak2^tm1.1Pcoh/? (involves: C57BL/6)	decreased interferon-alpha secretion	J:205798
Irak2^tm1Aki/Irak2^tm1Aki (involves: 129/Sv * C57BL/6)	abnormal macrophage physiology	J:136290
Irak2^tm1Aki/Irak2^tm1Aki (involves: 129/Sv * C57BL/6)	decreased susceptibility to endotoxin shock	J:136290
Irak2^tm1Jth/Irak2^tm1Jth (involves: 129 * C57BL/6)	abnormal chemokine level	J:149258
	decreased circulating interleukin-6 level	J:149258
	decreased circulating tumor necrosis factor level	J:149258
	decreased interleukin-6 secretion	J:149258
	decreased susceptibility to endotoxin shock	J:149258
	decreased tumor necrosis factor secretion	J:149258
Irak3^tm1Flv/Irak3^tm1Flv (involves: 129S1/Sv * C57BL/6)	abnormal immune system morphology	J:78189
	abnormal inflammatory response	J:78189
	abnormal innate immunity	J:78189
	abnormal osteoclast physiology	J:98035
	abnormal Peyer's patch morphology	J:78189
	enlarged Peyer's patches	J:78189
	increased interleukin-6 secretion	J:78189
	increased interleukin-12b secretion	J:78189
	increased neutrophil cell number	J:78189
	increased osteoclast cell number	J:98035
	increased susceptibility to endotoxin shock	J:78189
	increased tumor necrosis factor secretion	J:78189
Irak3^tm1Flv/Irak3^tm1Flv (NOD.129S1(B6)-Irak3^tm1Flv)	abnormal dendritic cell physiology	J:229884
	abnormal professional antigen presenting cell physiology	J:229884
	abnormal T cell activation	J:229884
	abnormal T cell differentiation	J:229884
	increased anti-insulin autoantibody level	J:229884
	increased effector memory T-helper cell number	J:229884
	increased susceptibility to autoimmune diabetes	J:229884
	insulitis	J:229884
Irak4^{em1(IMPC)Ccpcz}/Irak4^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Irak4^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Irak4^m1Btlr/Irak4^m1Btlr (C57BL/6J-Irak4^m1Btlr)	decreased tumor necrosis factor secretion	J:133271
Irak4^m1Btlr/Irak4^m1Btlr Ptpn6^m1Btlr/Ptpn6^m1Btlr (C57BL/6J-Ptpn6^m1Btlr Irak4^m1Btlr)	immune system phenotype	J:142845
Irak4^m1Btlr/Irak4^m1Btlr Ticam1^Lps2/Ticam1^Lps2 (involves: C57BL/6J)	decreased tumor necrosis factor secretion	J:187583
Irak4^tm1Aki/Irak4^tm1Aki (involves: 129X1/SvJ * C57BL/6)	abnormal cytokine secretion	J:125729
	decreased B cell proliferation	J:125729
	decreased interferon-alpha secretion	J:125729
	decreased interleukin-6 secretion	J:125729
	decreased interleukin-12b secretion	J:125729
	decreased susceptibility to endotoxin shock	J:125729
	decreased tumor necrosis factor secretion	J:125729
	immune system phenotype	J:125729
Irak4^tm1Gram/Irak4^tm1Gram (involves: BALB/c)	abnormal chemokine secretion	J:121912
Irak4^tm1Gram/Irak4^tm1Gram (involves: BALB/c)	abnormal cytokine secretion	J:121912
Irak4^tm1Lix/Irak4^tm1Lix (involves: C57BL/6)	abnormal chemokine secretion	J:125732
	decreased acute inflammation	J:125732
	decreased circulating interleukin-6 level	J:125732
	decreased circulating tumor necrosis factor level	J:125732
	decreased interferon-alpha secretion	J:125732
	decreased interferon-beta secretion	J:125732
	decreased interleukin-6 secretion	J:125732
	decreased susceptibility to endotoxin shock	J:125732
	decreased tumor necrosis factor secretion	J:125732
Irak4^tm1Yeh/Irak4^tm1Yeh (involves: 129P2/OlaHsd * C57BL/6J)	abnormal cytokine level	J:76098
	abnormal cytokine secretion	J:76098
	abnormal macrophage physiology	J:76098
	abnormal NK cell physiology	J:76098
	decreased B cell proliferation	J:76098
	decreased circulating interferon-gamma level	J:76098
	decreased circulating interleukin-1 level	J:76098
	decreased circulating interleukin-6 level	J:76098
	decreased circulating tumor necrosis factor level	J:76098
	decreased interleukin-6 secretion	J:76098
	decreased susceptibility to endotoxin shock	J:76098
	decreased tumor necrosis factor secretion	J:76098
	increased susceptibility to bacterial infection	J:76098
Irak4^tm2Aki/Irak4^tm2Aki (involves: 129X1/SvJ * C57BL/6)	abnormal cytokine secretion	J:125729
	decreased B cell proliferation	J:125729
	decreased interferon-alpha secretion	J:125729
	decreased interleukin-6 secretion	J:125729
	decreased interleukin-12b secretion	J:125729
	decreased susceptibility to endotoxin shock	J:125729
	decreased tumor necrosis factor secretion	J:125729
	immune system phenotype	J:125729
Irav1^C57BL/J/Irav1^DBA/2J (involves: C57BL/6J * DBA/2J)	abnormal cell-mediated immunity	J:122129
Irav1^C57BL/J/Irav1^DBA/2J (involves: C57BL/6J * DBA/2J)	abnormal cytokine secretion	J:122129
Irav1^DBA/2J/Irav1^DBA/2J (involves: C57BL/6J * DBA/2J)	abnormal cell-mediated immunity	J:122129
Irav1^DBA/2J/Irav1^DBA/2J (involves: C57BL/6J * DBA/2J)	abnormal cytokine secretion	J:122129
Ireb2^tm1.2Mwh/Ireb2^tm1.2Mwh (involves: 129P2/OlaHsd * BALB/c * C57BL/6 * SJL)	decreased spleen iron level	J:103414
Ireb2^tm1Mwh/Ireb2^tm1Mwh (involves: 129P2/OlaHsd * C57BL/6J)	decreased spleen iron level	J:105124
Ireb2^tm1Roua/Ireb2^tm1Roua (B6.Cg-Ireb2^tm1Roua)	decreased spleen iron level	J:176655
Irf1^M1Btlr/Irf1⁺ (C57BL/6J-Irf1^M1Btlr)	decreased CD8-positive, alpha-beta T cell number	J:162995
	decreased NK cell number	J:162995
	immune system phenotype	J:162995
	impaired natural killer cell mediated cytotoxicity	J:162995
	increased susceptibility to Herpesvirales infection	J:162995
Irf1^M1Btlr/Irf1^M1Btlr (C57BL/6J-Irf1^M1Btlr)	decreased CD8-positive, alpha-beta T cell number	J:162995
	decreased interferon-alpha secretion	J:162995
	decreased interferon-beta secretion	J:162995
	decreased NK cell number	J:162995
	immune system phenotype	J:162995
	impaired natural killer cell mediated cytotoxicity	J:162995
	increased susceptibility to Herpesvirales infection	J:162995
Irf1^m2Btlr/Irf1^m2Btlr (C57BL/6J-Irf1^m2Btlr)	decreased CD8-positive, alpha-beta T cell number	J:267675
	decreased NK cell number	J:267675
	increased B-1 B cell number	J:267675
	increased CD4-positive, alpha-beta T cell number	J:267675
Irf1^M3Btlr/Irf1^M3Btlr (C57BL/6J-Irf1^M3Btlr)	decreased CD8-positive, alpha-beta T cell number	J:267677
Irf1^M3Btlr/Irf1^M3Btlr (C57BL/6J-Irf1^M3Btlr)	increased CD4-positive, alpha-beta T cell number	J:267677
Irf1^tm1Cwe/Irf1^tm1Cwe (involves: 129/Sv * C57BL/6)	abnormal cytokine level	J:110672
	abnormal immune system morphology	J:21235
	abnormal immune system physiology	J:43086
	abnormal immunoglobulin level	J:101427
	abnormal macrophage physiology	J:43086
	abnormal splenocyte morphology	J:21235
	abnormal T cell morphology	J:21235, J:36025
	abnormal thymus cell ratio	J:36025
	decreased CD8-positive, alpha-beta T cell number	J:21235
	decreased circulating interleukin-2 level	J:110672
	decreased susceptibility to induced arthritis	J:43086
	increased circulating interferon-gamma level	J:110672
	increased circulating interleukin-3 level	J:110672
	increased circulating interleukin-4 level	J:110672
	increased circulating interleukin-5 level	J:110672
	increased circulating interleukin-6 level	J:110672
	increased susceptibility to Poxviridae infection	J:101427
	increased T-helper 2 cell number	J:110672
Irf1^tm1Cwe/Irf1^tm1Cwe (involves: 129)	abnormal circulating interleukin-4 level	J:84367
	abnormal circulating interleukin-10 level	J:84367
	abnormal cytokine level	J:84367
	abnormal T cell proliferation	J:84367
	decreased circulating interferon-gamma level	J:84367
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:84367
	increased circulating interleukin-5 level	J:84367
	increased circulating interleukin-6 level	J:84367
	increased circulating interleukin-13 level	J:84367
Irf1^tm1Mak/Irf1^tm1Mak (either: (involves: 129S2/SvPas * C57BL/6J) or (involves: 129S2/SvPas * C57BL/6J * DBA/2))	abnormal response to infection	J:64286
	abnormal T cell number	J:64286
	decreased CD8-positive, alpha-beta T cell number	J:64286
	immune system phenotype	J:64286
	increased CD4-positive, alpha-beta T cell number	J:64286
	increased double-positive T cell number	J:64286
Irf1^tm1Mak/Irf1^tm1Mak (B6.129S2-Irf1^tm1Mak/J)	abnormal lymphocyte physiology	J:91927
Irf1^tm1Mak/Irf1^tm1Mak (B6.129S2-Irf1^tm1Mak/J)	decreased interferon-gamma secretion	J:91927
Irf2^tm1Mak/Irf2^tm1Mak (either: (involves: 129S2/SvPas * C57BL/6J) or (involves: 129S2/SvPas * C57BL/6J * DBA/2))	abnormal immune system physiology	J:64286
	abnormal response to infection	J:64286
	decreased B cell proliferation	J:64286
	decreased IgG2a level	J:64286
	decreased mature B cell number	J:64286
	decreased T cell number	J:64286
	immune system phenotype	J:64286
Irf2^tm1Mak/Irf2^tm1Mak (involves: 129S2/SvPas * C57BL/6)	dermatitis	J:66034
	enlarged inguinal lymph nodes	J:66034
	increased memory T cell number	J:66034
	lymph node hyperplasia	J:66034
Irf3^em1(IMPC)Mbp/Irf3^em1(IMPC)Mbp (C57BL/6N-Irf3^em1(IMPC)Mbp/MbpMmucd)	enlarged lymph nodes	J:211773
Irf3^tm1Ttg/Irf3^tm1Ttg (involves: 129S/SvEv * C57BL/6J)	abnormal circulating interferon level	J:98127
Irf3^tm1Ttg/Irf3^tm1Ttg (involves: 129S/SvEv * C57BL/6J)	increased susceptibility to Picornaviridae infection	J:98127
Irf3^tm1Ttg/Irf3^tm1Ttg Irf7^tm1Ttg/Irf7^tm1Ttg (involves: 129P2/OlaHsd * 129S/SvEv)	decreased interferon-beta secretion	J:158969
	decreased interleukin-1 beta secretion	J:158969
	increased susceptibility to bacterial infection	J:158969
	increased susceptibility to Herpesvirales infection	J:158969
	increased susceptibility to Paramyxoviridae infection	J:158969
Irf3^tm1Ttg/Irf3^tm1Ttg Irf9^tm1Ttg/Irf9^tm1Ttg (involves: 129S/SvEv * C57BL/6J)	abnormal cytokine secretion	J:98127
Irf3^tm1Ttg/Irf3^tm1Ttg Sting1^em1Jmin/Sting1^em1Jmin (involves: 129S/SvEv * C57BL/6N)	decreased single-positive T cell number	J:251372
	lung inflammation	J:251372
Irf4^em1(IMPC)Mbp/Irf4^em1(IMPC)Mbp (C57BL/6N-Irf4^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	decreased lymphocyte cell number	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
	increased neutrophil cell number	J:211773
	increased spleen weight	J:211773
Irf4^m1Btlr/Irf4^m1Btlr (C57BL/6J-Irf4^m1Btlr)	abnormal B cell activation	J:160882
	decreased IgG level	J:160882
	decreased IgM level	J:160882
Irf4^m1Btlr/Irf4^m1Btlr (involves: C57BL/6J)	abnormal class switch recombination	J:185495
	decreased IgG level	J:185495
	decreased IgM level	J:185495
	immune system phenotype	J:185495
Irf4^M2Btlr/Irf4⁺ (C57BL/6J-Irf4^M2Btlr)	abnormal B cell activation	J:234245
	decreased IgG level	J:234245
	decreased IgM level	J:234245
Irf4^M2Btlr/Irf4^M2Btlr (C57BL/6J-Irf4^M2Btlr)	abnormal B cell activation	J:234245
	decreased IgG level	J:234245
	decreased IgM level	J:234245
Irf4^tm1.1Rdf/Irf4^tm1.1Rdf (involves: 129S1/Sv * 129S4/SvJae * C57BL/6)	abnormal B cell differentiation	J:112643
	abnormal B cell physiology	J:112643
	absent spleen germinal center	J:112643
	decreased B cell proliferation	J:112643
	decreased IgG1 level	J:112643
Irf4^tm1Mak/Irf4^tm1Mak (involves: 129P2/OlaHsd)	abnormal B cell differentiation	J:42683
	abnormal immune system cell morphology	J:42683
	abnormal immune system physiology	J:42683
	abnormal lymph node morphology	J:42683
	abnormal spleen morphology	J:42683
	absent lymph node germinal center	J:42683
	absent plasma cells	J:42683
	absent spleen germinal center	J:42683
	arrested B cell differentiation	J:42683
	decreased B cell proliferation	J:42683
	decreased dendritic cell number	J:91043
	decreased immunoglobulin level	J:42683
	decreased T cell proliferation	J:42683
	enlarged lymph nodes	J:42683
	enlarged spleen	J:42683
	immune system phenotype	J:169863
	increased lymphocyte cell number	J:42683
	increased susceptibility to Riboviria infection	J:42683
Irf4^tm1Mak/Irf4^tm1Mak (B6.129P2-Irf4^tm1Mak)	abnormal CD4-positive, alpha beta T cell morphology	J:78909
	abnormal T-helper 1 cell differentiation	J:78909
	increased susceptibility to bacterial infection	J:78909
Irf4^tm1Mak/Irf4^tm1Mak (involves: 129P2/OlaHsd * C57BL/6)	decreased plasmacytoid dendritic cell number	J:97716
Irf4^tm1Mak/Irf4^tm1Mak (involves: 129P2/OlaHsd * C57BL/6)	increased susceptibility to bacterial infection	J:81744
Irf4^tm1Rdf/Irf4^tm1.1Rdf (involves: 129S1/Sv * 129S4/SvJae * C57BL/6)	immune system phenotype	J:112643
Irf4^tm1Rdf/Irf4^tm1.1Rdf (involves: 129S1/Sv * 129S4/SvJae * C57BL/6)	abnormal B cell physiology	J:112643
Irf5^{tm1e(EUCOMM)Wtsi}/Irf5^{tm1e(EUCOMM)Wtsi} (C57BL/6N-Irf5^{tm1e(EUCOMM)Wtsi}/Wtsi)	decreased CD4-positive, alpha-beta memory T cell number	J:211773
	decreased leukocyte cell number	J:211773
Irf5^tm1Ttg/Irf5^tm1Ttg (involves: 129P2/OlaHsd * C57BL/6)	abnormal T-helper 1 physiology	J:97567
	decreased circulating interleukin-6 level	J:97567
	decreased circulating interleukin-12b level	J:97567
	decreased circulating tumor necrosis factor level	J:97567
	decreased susceptibility to bacterial infection	J:97567
	immune system phenotype	J:182658
Irf5^tm1Ttg/Irf5^tm1Ttg (B6.129P2-Irf5^tm1Ttg)	abnormal response to infection	J:182658
	decreased interferon-alpha secretion	J:182658
	decreased interleukin-6 secretion	J:182658
	decreased tumor necrosis factor secretion	J:182658
	immune system phenotype	J:182658
Irf7^m1Btlr/Irf7⁺ (C57BL/6J-Irf7^m1Btlr)	decreased interferon-alpha secretion	J:159358
Irf7^m1Btlr/Irf7⁺ (C57BL/6J-Irf7^m1Btlr)	decreased interferon-beta secretion	J:159358
Irf7^m1Btlr/Irf7^m1Btlr (C57BL/6J-Irf7^m1Btlr)	decreased interferon-alpha secretion	J:159358
Irf7^m1Btlr/Irf7^m1Btlr (C57BL/6J-Irf7^m1Btlr)	decreased interferon-beta secretion	J:159358
Irf7^M2Btlr/Irf7⁺ (C57BL/6J-Irf7^M2Btlr)	decreased circulating interferon-beta level	J:217798
Irf7^M2Btlr/Irf7^M2Btlr (C57BL/6J-Irf7^M2Btlr)	decreased circulating interferon-beta level	J:217798
Irf7^tm1Ttg/Irf7^tm1Ttg (involves: 129P2/OlaHsd)	abnormal interferon level	J:97662
	abnormal T cell physiology	J:97662
	increased susceptibility to Herpesvirales infection	J:97662
	increased susceptibility to Picornaviridae infection	J:97662
Irf7^tm1Ttg/Irf7^tm1Ttg (B6.129P2-Irf7^tm1Ttg)	increased susceptibility to Orthomyxoviridae infection	J:233979
Irf7^tm1Ttg/Irf7^tm1Ttg (B6.129P2-Irf7^tm1Ttg)	increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:233979
Irf8^M1Btlr/Irf8^M1Btlr (C57BL/6J-Irf8^M1Btlr)	abnormal interferon secretion	J:166600
	decreased macrophage cell number	J:166600
	decreased monocyte cell number	J:166600
	increased neutrophil cell number	J:166600
Irf8^m2Btlr/Irf8^m2Btlr (C57BL/6J-Irf8^m2Btlr)	decreased CD8-positive, alpha-beta T cell number	J:274937
Irf8^m2Btlr/Irf8^m2Btlr (C57BL/6J-Irf8^m2Btlr)	increased CD4-positive, alpha-beta T cell number	J:274937
Irf8^myls/Irf8⁺ (involves: BXH2/TyJ * C57BL/6)	increased B cell number	J:168923
	increased B-1b cell number	J:168923
	increased follicular B cell number	J:168923
	increased transitional stage B cell number	J:168923
Irf8^myls/Irf8^myls (involves: BALB/cJ * BXH2/TyJ-Irf8^myls)	abnormal myelopoiesis	J:97931
	enlarged spleen	J:97931
Irf8^myls/Irf8^myls Slc11a1^r/Slc11a1^r (BXH2/TyJ)	abnormal myelopoiesis	J:97931
	decreased interferon-gamma secretion	J:97931
	decreased interleukin-12 secretion	J:97931
	enlarged spleen	J:97931
	increased susceptibility to bacterial infection	J:97931
Irf8^myls/Irf8^myls Slc11a1^r/Slc11a1^r (involves: BXH2/TyJ * C57BL/6J)	increased susceptibility to bacterial infection	J:97931
Irf8^myls/Irf8^myls Slc11a1^r/Slc11a1^r (involves: BALB/cJ * BXH2/TyJ)	increased susceptibility to bacterial infection	J:97931
Irf8^myls/Irf8^myls Slc11a1^r/Slc11a1^r (involves: BXH2/TyJ * C3H/HeJ)	enlarged spleen	J:97931
	increased susceptibility to bacterial infection	J:97931
Irf8^myls/Irf8^myls Slc11a1^r/Slc11a1^s (involves: BXH2/TyJ * C57BL/6J)	increased susceptibility to bacterial infection	J:97931
Irf8^myls/Irf8^myls Slc11a1^r/Slc11a1^s (involves: BALB/cJ * BXH2/TyJ)	increased susceptibility to bacterial infection	J:97931
Irf8^myls/Irf8^myls Slc11a1^s/Slc11a1^s (involves: BALB/cJ * BXH2/TyJ)	increased susceptibility to bacterial infection	J:97931
Irf8^tm1Hor/Irf8^tm1Hor (either: (involves: 129P2/OlaHsd) or (involves: 129P2/OlaHsd * C57BL/6))	abnormal cytotoxic T cell physiology	J:36038
	abnormal plasma cell number	J:36038
	decreased B cell number	J:36038
	decreased interferon-gamma secretion	J:36038
	decreased lymphocyte cell number	J:36038
	decreased T cell number	J:36038
	enlarged lymph nodes	J:36038
	hepatosplenomegaly	J:36038
	increased B cell number	J:36038
	increased granulocyte number	J:36038
	increased immunoglobulin level	J:36038
	increased leukocyte cell number	J:36038
	increased lymphocyte cell number	J:36038
	increased macrophage cell number	J:36038
	increased mature B cell number	J:36038
	increased spleen red pulp amount	J:36038
	increased spleen weight	J:36038
	increased susceptibility to Riboviria infection	J:36038
	spleen hyperplasia	J:36038
Irf8^tm1Hor/Irf8^tm1Hor (B6.129P2-Irf8^tm1Hor)	decreased follicular B cell number	J:168923
	increased B-1b cell number	J:168923
	increased marginal zone B cell number	J:168923
Irf8^tm1Hor/Irf8^tm1Hor (involves: 129P2/OlaHsd * C57BL/6)	abnormal humoral immune response	J:181366
Irf8^tm1Hor/Irf8^tm1Hor Irf4^tm1Mak/Irf4^tm1Mak (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell differentiation	J:84577
	abnormal pre-B cell morphology	J:84577
	absent B cells	J:84577
	arrested B cell differentiation	J:84577
	decreased dendritic cell number	J:97716
	decreased IgM level	J:84577
	decreased lymphocyte cell number	J:84577
	decreased plasmacytoid dendritic cell number	J:97716
	decreased T cell number	J:84577
	increased pre-B cell number	J:84577
Irf9^M1Btlr/Irf9⁺ (C57BL/6J-Irf9^M1Btlr)	increased circulating interferon-beta level	J:236674
Irf9^M1Btlr/Irf9^M1Btlr (C57BL/6J-Irf9^M1Btlr)	increased circulating interferon-beta level	J:236674
Irf9^tm1Ttg/Irf9^tm1Ttg (B6.Cg-Irf9^tm1Ttg)	decreased interferon-alpha secretion	J:97662
Irf9^tm1Ttg/Irf9^tm1Ttg (either: (involves: C57BL/6 * CBA * ICR) or (involves: A/J * C57BL/6 * CBA))	increased susceptibility to viral infection	J:77456
Irgc^em1(IMPC)Tcp/Irgc^em1(IMPC)Tcp (C57BL/6N-Irgc^em1(IMPC)Tcp/Tcp)	increased monocyte cell number	J:211773
Irgm1^tm1Gat/Irgm1^tm1Gat (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	immune system phenotype	J:87535
	increased circulating interferon-gamma level	J:87535
	increased circulating interleukin-12 level	J:87535
	increased susceptibility to bacterial infection	J:87535
	increased susceptibility to parasitic infection	J:87535
Irgm2^em1Myam/Irgm2^em1Myam (C57BL/6-Irgm2^em1Myam)	increased susceptibility to parasitic infection	J:308470
Irgm2^em1Myam/Irgm2^em1Myam (C57BL/6-Irgm2^em1Myam)	increased susceptibility to parasitic infection induced morbidity/mortality	J:308470
Irs1^Sml/Irs1^Sml (C3.Cg-Irs1^Sml H2^b/GrsrJ)	increased osteoclast cell number	J:163661
Irs1^tm1Mfw/Irs1^tm1Mfw Irs2^tm2Mfw/Irs2^tm2Mfw Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA)	increased susceptibility to autoimmune diabetes	J:137845
Irs1^tm1Tka/Irs1^tm1Tka (involves: C57BL/6 * CBA)	abnormal osteoclast differentiation	J:61479
Irs1^tm1Tka/Irs1^tm1Tka (involves: C57BL/6 * CBA)	abnormal osteoclast physiology	J:61479
Irs1^tm2Tka/Irs1^tm2Tka Irs2^tm2Tka/Irs2^tm2Tka Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺ (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA)	increased susceptibility to autoimmune diabetes	J:137846
Is(14)1Rdf Is(14)2Rdf/Del(14Trim13-Dleu2)4Rdf Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6)	increased B cell number	J:156946
	increased B-1a cell number	J:156946
	increased spleen white pulp amount	J:156946
Is(14)1Rdf Is(14)5Rdf/Del(14Trim13-Rnaseh2b)6Rdf Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6)	abnormal lymphopoiesis	J:179879
	increased B cell number	J:179879
Is(14)1Rdf/Is(14)1Rdf Is(14)5Rdf/Is(14)5Rdf Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6)	abnormal lymphopoiesis	J:179879
	increased B cell number	J:179879
Isg15^tm1Kpk/Isg15^tm1Kpk (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:100028
Isg20^em1Cya/Isg20^em1Cya Tg(Cdh16-cre)91Igr/0 (involves: C57BL/6N * ICR)	kidney inflammation	J:343183
Isl1^Drsh/Isl1⁺ (C3HeB/FeJ-Isl1^Drsh)	increased susceptibility to otitis media	J:202214
Isl1^tm1(cre)Sev/Isl1⁺ Pax9^tm1Rbal/Pax9^tm1.1Hpt (involves: 129 * C57BL/6J)	ectopic thymus	J:311535
	thymus hypoplasia	J:311535
Ism1^{em1(IMPC)Ccpcz}/Ism1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Ism1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged thymus	J:211773
Isy1^em1(IMPC)J/Isy1⁺ (C57BL/6NJ-Isy1^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
Itch^tm1.1Alta/Itch^tm1.1Alta Foxp3^{tm4(YFP/icre)Ayr}/Foxp3⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal immunoglobulin level	J:204685
	abnormal interleukin secretion	J:204685
	abnormal lymph organ size	J:204685
	abnormal lymphopoiesis	J:204685
	abnormal regulatory T cell physiology	J:204685
	abnormal T-helper 2 cell differentiation	J:204685
	abnormal T-helper 2 physiology	J:204685
	decreased CD4-positive, alpha-beta T cell number	J:204685
	dermatitis	J:204685
	enlarged lymph nodes	J:204685
	enlarged spleen	J:204685
	immune system phenotype	J:204685
	increased CD4-positive, alpha-beta T cell number	J:204685
	increased CD8-positive, alpha-beta T cell number	J:204685
	increased eosinophil cell number	J:204685
	increased IgA level	J:204685
	increased IgE level	J:204685
	increased IgG1 level	J:204685
	increased inflammatory response	J:204685
	increased interleukin-4 secretion	J:204685
	increased interleukin-5 secretion	J:204685
	increased interleukin-10 secretion	J:204685
	increased interleukin-13 secretion	J:204685
	increased interleukin-17 secretion	J:204685
	increased leukocyte cell number	J:204685
	increased regulatory T cell apoptosis	J:204685
	increased regulatory T cell number	J:204685
	lung inflammation	J:204685
Itch^tm1.1Alta/Itch^tm1.1Alta Gt(ROSA)26Sor^tm1Hjf/Gt(ROSA)26Sor⁺ Foxp3^{tm4(YFP/icre)Ayr}/Foxp3⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	immune system phenotype	J:204685
	increased inflammatory response	J:204685
Itch^{tm1b(EUCOMM)Hmgu}/Itch^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Itch^{tm1b(EUCOMM)Hmgu}/H)	decreased lymphocyte cell number	J:211773
	enlarged spleen	J:211773
	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
	increased large unstained cell number	J:211773
	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
	increased spleen weight	J:211773
Itfg2^{Gt(OST215121)Lex}/Itfg2^{Gt(OST215121)Lex} (involves: 129S5/SvEvBrd * C57BL/6J)	abnormal B cell activation	J:205951
	abnormal humoral immune response	J:205951
	abnormal splenocyte physiology	J:205951
	decreased B cell number	J:205951
	decreased IgE level	J:205951
	decreased IgG1 level	J:205951
	decreased IgG2a level	J:205951
	decreased IgG2b level	J:205951
	decreased IgG3 level	J:205951
	decreased lymphocyte cell number	J:205951
	decreased spleen germinal center number	J:205951
	decreased T follicular helper cell number	J:205951
	immune system phenotype	J:205951
	increased B cell number	J:205951
	spleen hyperplasia	J:205951
Itga2b^tm1Tlr/Itga2b^tm1Tlr (either: (involves: 129S1/Sv * 129X1/SvJ * BALB/c) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6))	enlarged spleen	J:63961
Itga3^tm1Son/Itga3^tm1Son Krt14^tm1(cre)Wbm/Krt14⁺ (involves: 129P2/OlaHsd * FVB/N)	skin inflammation	J:145988
Itga3^tm1Son/Itga3^tm1Son Tg(KRT5-cre)5132Jlj/? (involves: 129P2/OlaHsd * C57BL/6 * DBA)	skin inflammation	J:145988
Itga4^tm1Mgin/Itga4^tm1Mgin (B6.129-Itga4^tm1Mgin)	abnormal B cell physiology	J:106471
	abnormal lymphocyte physiology	J:106471
	abnormal T cell physiology	J:106471
	decreased monocyte cell number	J:106471
	decreased Peyer's patch number	J:106471
	impaired macrophage chemotaxis	J:106471
Itga4^tm1Mshi/Itga4^tm1Mshi (C57BL/6-Itga4^tm1Mshi)	abnormal cellular extravasation	J:144092
	abnormal leukocyte adhesion	J:144092
	abnormal leukocyte migration	J:144092
	abnormal mononuclear cell morphology	J:144092
	decreased B cell number	J:144092
	decreased lymphocyte cell number	J:144092
	decreased T cell number	J:144092
	small Peyer's patches	J:144092
Itga4^tm1Tpa/Itga4^tm1Tpa Tg(Mx1-cre)1Cgn/? (involves: 129S4/SvJaeSor * C57BL/6 * CBA)	abnormal B cell differentiation	J:86861
	decreased CD4-positive, alpha-beta T cell number	J:86861
	increased leukocyte cell number	J:86861
Itga5^tm1Hyn/Itga5⁺ Nisch^edsn/Nisch⁺ (C3H.Cg-Nisch^edsn Itga5^tm1Hyn)	increased susceptibility to otitis media	J:244907
Itga5^tm1Hyn/Itga5⁺ Nisch^edsn/Nisch^edsn (C3H.Cg-Nisch^edsn Itga5^tm1Hyn)	increased susceptibility to otitis media	J:244907
Itga6^tm1Son/Itga6^tm1Son (involves: 129P2/OlaHsd * FVB)	abnormal lymph node morphology	J:50235
	abnormal T cell physiology	J:50235
	decreased T cell number	J:50235
Itga9^tm1Des/Itga9^tm1Des (involves: 129S4/SvJae * C57BL/6)	abnormal lymph circulation	J:63038
Itgad^tm1.1Zimm/Itgad^tm1.1Zimm (involves: 129S6/SvEvTac * C57BL/6)	abnormal immune system physiology	J:130908
	abnormal macrophage physiology	J:130908
	abnormal susceptibility to infection	J:130908
	decreased susceptibility to parasitic infection	J:130908
	increased circulating interleukin-12 level	J:130908
	increased spleen weight	J:130908
	increased susceptibility to bacterial infection	J:130908
Itgad^tm1Bll/Itgad^tm1Bll (B6.129S7-Itgad^tm1Bll)	abnormal lymphocyte cell number	J:90954
	abnormal T cell activation	J:90954
	abnormal T cell subpopulation ratio	J:90954
	decreased CD4-positive, alpha-beta T cell number	J:90954
	decreased T cell proliferation	J:90954
	increased CD8-positive, alpha-beta T cell number	J:90954
Itgae^{tm1b(EUCOMM)Wtsi}/Itgae^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Itgae^{tm1b(EUCOMM)Wtsi}/H)	decreased large unstained cell number	J:211773
	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
	decreased monocyte cell number	J:211773
	decreased neutrophil cell number	J:211773
Itgae^tm1Cmp/Itgae^tm1Cmp (involves: 129S2/SvPas * BALB/c)	decreased lymphocyte cell number	J:55333
Itgae^tm1Cmp/Itgae^tm1Cmp (involves: 129S2/SvPas * BALB/c)	decreased T cell number	J:55333
Itgal^em1(IMPC)H/Itgal^em1(IMPC)H (C57BL/6NTac-Itgal^em1(IMPC)H/H)	increased spleen weight	J:211773
Itgal^tm1.1Mshi/Itgal^tm1.1Mshi (involves: C57BL/6)	abnormal diapedesis	J:168533
	abnormal leukocyte adhesion	J:168533
	abnormal leukocyte migration	J:168533
	decreased lymphocyte cell number	J:168533
	enhanced leukocyte tethering or rolling	J:168533
	small lymph nodes	J:168533
Itgal^tm1Bll/Itgal⁺ (involves: 129S7/SvEvBrd)	abnormal CD4-positive, alpha-beta T cell physiology	J:267548
Itgal^tm1Bll/Itgal^tm1Bll (involves: 129S7/SvEvBrd * C57BL/6J)	abnormal cellular extravasation	J:83226
	abnormal leukocyte adhesion	J:83226
	abnormal leukocyte migration	J:83226
	increased eosinophil cell number	J:83226
	increased leukocyte cell number	J:83226
	increased monocyte cell number	J:83226
	increased neutrophil cell number	J:83226
Itgal^tm1Bll/Itgal^tm1Bll (B6.129S7-Itgal^tm1Bll)	abnormal leukocyte adhesion	J:100242
	abnormal leukocyte tethering or rolling	J:100242
	decreased T cell proliferation	J:90954
	impaired natural killer cell mediated cytotoxicity	J:90954
	increased leukocyte cell number	J:100242
	increased neutrophil cell number	J:100242
Itgal^tm1Bll/Itgal^tm1Bll (B6.129S7-Itgal^tm1Bll/J)	abnormal inflammatory response	J:113463
Itgal^tm1Bll/Itgal^tm1Bll (involves: 129S7/SvEvBrd)	abnormal CD4-positive, alpha-beta T cell physiology	J:267548
	abnormal cellular extravasation	J:141063
	abnormal leukocyte adhesion	J:141063
	abnormal neutrophil physiology	J:141063
Itgal^tm1Hlz/Itgal^tm1Hlz (involves: 129P2/OlaHsd)	abnormal cellular extravasation	J:99286
	abnormal humoral immune response	J:99286
	abnormal leukocyte adhesion	J:99286
	abnormal T cell activation	J:99286
	decreased cytotoxic T cell cytolysis	J:99286
	decreased lymphocyte cell number	J:99286
	decreased neutrophil cell number	J:99286
	spleen hyperplasia	J:99286
Itgal^tm1Hogg/Itgal^tm1Hogg (involves: 129P2/OlaHsd)	abnormal leukocyte adhesion	J:82587
	abnormal leukocyte migration	J:82587
	abnormal lymph node morphology	J:82587
	decreased B cell number	J:82587
	decreased CD4-positive, alpha-beta T cell number	J:82587
	decreased CD8-positive, alpha-beta T cell number	J:82587
	decreased lymphocyte cell number	J:82587
	enlarged spleen	J:82587
	increased CD4-positive, alpha-beta T cell number	J:82587
	increased CD8-positive, alpha-beta T cell number	J:82587
	small lymph nodes	J:82587
Itgal^tm1Mak/Itgal⁺ (B6.129P2-Itgal^tm1Mak)	decreased susceptibility to endotoxin shock	J:123460
Itgal^tm1Mak/Itgal^tm1Mak (B6.129P2-Itgal^tm1Mak)	decreased susceptibility to endotoxin shock	J:123460
	impaired natural killer cell mediated cytotoxicity	J:110889
	increased circulating interleukin-2 level	J:123460
	increased circulating interleukin-10 level	J:123460
	increased circulating tumor necrosis factor level	J:123460
Itgal^tm1Wpfl/Itgal^tm1Wpfl (involves: 129)	abnormal cytotoxic T cell physiology	J:37160
	abnormal leukocyte physiology	J:37160
	abnormal lymphocyte physiology	J:37160
	immune system phenotype	J:37160
	lymph node hyperplasia	J:37160
Itgam^m1Btlr/Itgam⁺ (C57BL/6J-Itgam^m1Btlr)	abnormal dendritic cell number	J:236681
	decreased macrophage cell number	J:236681
	decreased neutrophil cell number	J:236681
	increased plasmacytoid dendritic cell number	J:236681
Itgam^m1Btlr/Itgam^m1Btlr (C57BL/6J-Itgam^m1Btlr)	abnormal dendritic cell number	J:236681
	decreased macrophage cell number	J:236681
	decreased neutrophil cell number	J:236681
	increased plasmacytoid dendritic cell number	J:236681
Itgam^m2Btlr/Itgam^m2Btlr (C57BL/6J-Itgam^m2Btlr)	decreased CD11b-high dendritic cell number	J:272532
Itgam^m3Btlr/Itgam^m3Btlr (C57BL/6J-Itgam^m3Btlr)	decreased CD11b-high dendritic cell number	J:272533
Itgam^tm1Bll/Itgam^tm1Bll (B6.129S7-Itgam^tm1Bll)	abnormal leukocyte adhesion	J:100242
	abnormal lymphocyte cell number	J:90954
	abnormal T cell activation	J:90954
	abnormal T cell subpopulation ratio	J:90954
	decreased CD4-positive, alpha-beta T cell number	J:90954
	decreased T cell proliferation	J:90954
	increased CD8-positive, alpha-beta T cell number	J:90954
	increased leukocyte cell number	J:100242
	increased neutrophil cell number	J:100242
	increased susceptibility to bacterial infection	J:94855
Itgam^tm1Bll/Itgam^tm1Bll (involves: 129S7/SvEvBrd * C57BL/6J)	abnormal cellular extravasation	J:83226
	abnormal leukocyte adhesion	J:83226
	abnormal leukocyte migration	J:83226
	abnormal neutrophil physiology	J:39092
	decreased eosinophil cell number	J:83226
	impaired neutrophil phagocytosis	J:39092
Itgam^tm1Myd/Itgam^tm1Myd (involves: 129S4/SvJae * BALB/c * C57BL/6)	abnormal leukocyte adhesion	J:38052
	impaired neutrophil phagocytosis	J:38052
	increased eosinophil cell number	J:38052
	increased neutrophil cell number	J:38052
Itgam^tm1Myd/Itgam^tm1Myd (involves: 129S4/SvJae * C57BL/6)	decreased neutrophil cell number	J:103873
Itgam^tm1Myd/Itgam^tm1Myd (B6.129S4-Itgam^tm1Myd)	abnormal inflammatory response	J:113463
	abnormal neutrophil morphology	J:113463
	abnormal neutrophil physiology	J:113463
Itgam^tm1Myd/Itgam^tm1Myd (involves: 129S4/SvJae)	impaired leukocyte tethering or rolling	J:198197
Itgam^tm1Myd/Itgam^tm1Myd (involves: 129S4/SvJae)	impaired neutrophil phagocytosis	J:155479
Itgam^tm1Myd/Itgam^tm1Myd Syk^tm1Tyb/Syk^tm1.2Tara Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * 129S2/SvPas * 129S4/SvJae * C57BL/6)	impaired granulocyte bactericidal activity	J:155479
Itgam^tm1Rws/Itgam^tm1Rws (involves: 129P2/OlaHsd * C57BL/6J)	abnormal macrophage physiology	J:65847
Itgav^tm1Blb/Itgav^tm1Blb Itgb1^tm1Ref/Itgb1^tm1Ref Itgb2^tm2Bay/Itgb2^tm2Bay Itgb7^tm1Cgn/Itgb7^tm1Cgn Tg(Mx1-cre)1Cgn/0 (involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ * C57BL/6 * CBA)	abnormal cellular extravasation	J:134784
	abnormal dendritic cell physiology	J:134784
	immune system phenotype	J:134784
Itgav^tm2Hyn/Itgav^tm2.1Hyn Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * FVB)	colitis	J:125508
	impaired macrophage phagocytosis	J:125508
	increased autoantibody level	J:125508
Itgav^tm2Hyn/Itgav^tm2.1Hyn Tg(Nes-cre)1Kln/0 (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB * SJL)	increased susceptibility to bacterial infection induced morbidity/mortality	J:94376
Itgav^tm2Hyn/Itgav^tm2.1Hyn Tg(Tek-cre)1Ywa/? (involves: 129S2/SvPas * C57BL/6 * FVB * SJL)	abnormal dendritic cell differentiation	J:125508
	abnormal immune system morphology	J:125508
	abnormal immune system physiology	J:125508
	abnormal interferon level	J:125508
	abnormal interleukin level	J:125508
	abnormal leukocyte morphology	J:125508
	abnormal tumor necrosis factor level	J:125508
	colitis	J:125508
	decreased regulatory T cell number	J:125508
	enlarged mesenteric lymph nodes	J:125508
	enlarged Peyer's patches	J:125508
	impaired macrophage phagocytosis	J:125508
	increased autoantibody level	J:125508
	increased inflammatory response	J:125508
	increased regulatory T cell number	J:125508
	large intestinal inflammation	J:125508
Itgax^M1Btlr/Itgax⁺ (C57BL/6J-Itgax^M1Btlr)	decreased dendritic cell number	J:236684
Itgax^M1Btlr/Itgax⁺ (C57BL/6J-Itgax^M1Btlr)	increased plasmacytoid dendritic cell number	J:236684
Itgax^M1Btlr/Itgax^M1Btlr (C57BL/6J-Itgax^M1Btlr)	decreased dendritic cell number	J:236684
Itgax^M1Btlr/Itgax^M1Btlr (C57BL/6J-Itgax^M1Btlr)	increased plasmacytoid dendritic cell number	J:236684
Itgax^{tm1.1(HBEGF)Ktak}/Itgax⁺ (involves: 129S4/SvJae * C57BL/6)	abnormal response to infection	J:162397
Itgax^tm1Bll/Itgax^tm1Bll (B6.129S7-Itgax^tm1Bll)	decreased interferon-gamma secretion	J:122187
	decreased interleukin-17 secretion	J:122187
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:122187
	decreased tumor necrosis factor secretion	J:122187
	increased interleukin-2 secretion	J:122187
	increased interleukin-12 secretion	J:122187
	increased susceptibility to bacterial infection	J:94855
	increased T cell proliferation	J:122187
Itgb1^tm1Ref/Itgb1^tm1Ref Tg(KRT5-cre)5132Jlj/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * DBA/2J)	skin inflammation	J:65038
Itgb2^M1Btlr/Itgb2^M1Btlr (C57BL/6J-Itgb2^M1Btlr)	abnormal NK cell differentiation	J:139559
	decreased interferon-gamma secretion	J:139559
	immune system phenotype	J:139559
Itgb2^m2Btlr/Itgb2^m2Btlr (C57BL/6J-Itgb2^m2Btlr)	increased interferon-beta secretion	J:265125
Itgb2^m3Btlr/Itgb2^m3Btlr (C57BL/6J-Itgb2^m3Btlr)	abnormal cytotoxic T cell cytolysis	J:265126
	decreased B cell number	J:265126
	decreased CD4-positive, alpha-beta T cell number	J:265126
	decreased CD8-positive, alpha-beta T cell number	J:265126
	decreased dendritic cell number	J:265126
	decreased IgG level	J:265126
	decreased macrophage cell number	J:265126
	decreased neutrophil cell number	J:265126
	decreased single-positive T cell number	J:265126
	impaired humoral immune response	J:265126
	impaired natural killer cell mediated cytotoxicity	J:265126
	increased dendritic cell number	J:265126
	increased effector memory CD4-positive, alpha-beta T cell number	J:265126
	increased IgE level	J:265126
	increased NK T cell number	J:265126
Itgb2^M4Btlr/Itgb2^M4Btlr (C57BL/6J-Itgb2^M4Btlr)	abnormal T cell differentiation	J:272843
Itgb2^M4Btlr/Itgb2^M4Btlr (C57BL/6J-Itgb2^M4Btlr)	increased effector memory CD4-positive, alpha-beta T cell number	J:272843
Itgb2^m5Btlr/Itgb2^m5Btlr (C57BL/6J-Itgb2^m5Btlr)	increased B-1b cell number	J:272844
Itgb2^tm1.1Arte/Itgb2^tm1.1Arte (involves: C57BL/6NTac)	abnormal T cell physiology	J:202261
	decreased T cell proliferation	J:202261
	enlarged spleen	J:202261
	increased B cell number	J:202261
	increased dendritic cell number	J:202261
	increased neutrophil cell number	J:202261
	increased T cell number	J:202261
	lymph node hypoplasia	J:202261
Itgb2^tm1Bay/Itgb2^tm1Bay (involves: 129S7/SvEvBrd)	decreased inflammatory response	J:13599
	increased granulocyte number	J:13599
	increased leukocyte cell number	J:13599, J:32126
	increased lymphocyte cell number	J:13599
Itgb2^tm1Bay/Itgb2^tm1Bay (involves: 129S7/SvEvBrd * PL/J)	abnormal cytokine level	J:109598
	abnormal spleen morphology	J:32126
	abnormal T cell activation	J:109598
	dermatitis	J:109598, J:32126
	enlarged lymph nodes	J:32126
	increased basophil cell number	J:32126
	increased eosinophil cell number	J:32126
	increased interferon-gamma secretion	J:109598
	increased leukocyte cell number	J:32126
	increased lymphocyte cell number	J:32126
	increased monocyte cell number	J:32126
	increased neutrophil cell number	J:32126
	increased T cell number	J:109598
	increased T-helper 1 cell number	J:109598
	myeloid hyperplasia	J:32126
Itgb2^tm1Bay/Itgb2^tm1Bay (involves: 129S7/SvEvBrd * C57BL/6J)	abnormal spleen red pulp morphology	J:13599
	myeloid hyperplasia	J:13599
Itgb2^tm1Bay/Itgb2^tm1Bay (involves: 129S7/SvEvBrd * C57BL/6J * PL/J)	dermatitis	J:84126
Itgb2^tm1Bay/Itgb2^tm1Bay Psrs1^PL/J/Psrs1^PL/J (B6.Cg-(D10Mit126-D10Mit38) Itgb2^tm1Bay)	rheumatoid arthritis	J:134251
Itgb2^tm1Bay/Itgb2^tm1Bay Psrs1^PL/J/Psrs1^PL/J (B6.Cg-(D10Mit75-D10Mit271) Itgb2^tm1Bay)	rheumatoid arthritis	J:134251
Itgb2^tm1Bay/Itgb2^tm2Bay (PL.129S7-Itgb2^tm1Bay Itgb2^tm2Bay)	dermatitis	J:84126
Itgb2^tm1Bay/Itgb2^tm2Bay (involves: 129S7/SvEvBrd * C57BL/6J * PL/J)	dermatitis	J:84126
Itgb2^tm2Bay/Itgb2^tm2Bay (involves: 129S7/SvEvBrd * C57BL/6J)	abnormal immune system cell morphology	J:48542
	abnormal leukocyte physiology	J:48542
	abnormal lymph organ size	J:48542
	abnormal neutrophil morphology	J:48542
	abnormal neutrophil physiology	J:48542
	abnormal T cell proliferation	J:48542
	conjunctivitis	J:48542
	dermatitis	J:48542
	enlarged lymph nodes	J:48542
	enlarged spleen	J:48542
	increased circulating interleukin-3 level	J:48542
	increased circulating interleukin-6 level	J:48542
	increased IgA level	J:48542
	increased IgG level	J:48542
	increased IgM level	J:48542
	increased immunoglobulin level	J:48542
	increased inflammatory response	J:48542
	increased leukocyte cell number	J:48542
	increased lymphocyte cell number	J:48542
	increased monocyte cell number	J:48542
	increased neutrophil cell number	J:48542
	increased susceptibility to bacterial infection	J:48542
	myeloid hyperplasia	J:48542
Itgb2^tm2Bay/Itgb2^tm2Bay (involves: 129S7/SvEvBrd)	decreased T cell proliferation	J:90954
Itgb2^tm2Bay/Itgb2^tm2Bay (B6.129S7-Itgb2^tm2Bay)	abnormal leukocyte adhesion	J:83226
	abnormal leukocyte migration	J:83226
	decreased susceptibility to bacterial infection	J:94855
	increased eosinophil cell number	J:83226
	increased leukocyte cell number	J:83226
	increased lymphocyte cell number	J:83226
	increased monocyte cell number	J:83226
	increased neutrophil cell number	J:83226
Itgb2^tm2Bay/Itgb2^tm2Bay (involves: 129S7/SvEvBrd * C57BL/6)	decreased acute inflammation	J:112286
	impaired neutrophil recruitment	J:112286
	increased neutrophil cell number	J:112286
Itgb2^tm2Bay/Itgb2^tm2Bay (PL.129S7-Itgb2^tm2Bay)	decreased susceptibility to type IV hypersensitivity reaction	J:109598
Itgb2l^tm1Jhws/Itgb2l^tm1Jhws (involves: 129/Sv * C57BL/6)	immune system phenotype	J:118477
Itgb3^tm1Hyn/Itgb3^tm1.1Wlbcr Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)	abnormal osteoclast differentiation	J:224675
	abnormal osteoclast morphology	J:224675
	decreased osteoclast cell number	J:224675
Itgb3^tm1Hyn/Itgb3^tm1.1Wlbcr Tg(Pf4-icre)Q3Rsko/0 (involves: 129S2/SvPas * C57BL/6)	enlarged spleen	J:224675
Itgb3^tm1Hyn/Itgb3^tm1Hyn (involves: 129S2/SvPas * C57BL/6)	abnormal macrophage physiology	J:119666
	dermatitis	J:52262
	enlarged spleen	J:52262
	impaired macrophage chemotaxis	J:119666
	increased monocyte cell number	J:119666
	myositis	J:119666
Itgb3^tm1Hyn/Itgb3^tm1Hyn (involves: 129S2/SvPas)	abnormal osteoclast morphology	J:60672
	abnormal osteoclast physiology	J:60672
	decreased macrophage cell number	J:96049
	increased osteoclast cell number	J:60672
Itgb3^tm1Hyn/Itgb3^tm1Hyn (involves: 129S2/SvPas * BALB/c)	immune system phenotype	J:131241
Itgb3^tm1Hyn/Itgb3^tm1Hyn (involves: 129S2/SvPas * BALB/c)	increased IgG level	J:131241
Itgb4^tm1Son/Itgb4^tm1Son (129P2/OlaHsd-Itgb4^tm1Son)	immune system phenotype	J:33713
Itgb4^tm2Son/Itgb4^tm2Son Tg(KRT14-cre)8Brn/0 (involves: 129P2/OlaHsd * FVB/N)	ear inflammation	J:96543
Itgb5^{tm1a(EUCOMM)Wtsi}/Itgb5^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Itgb5^{tm1a(EUCOMM)Wtsi}/Ics)	increased leukocyte cell number	J:165965
Itgb6^{em1(IMPC)Ccpcz}/Itgb6^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Itgb6^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Itgb6^tm1Des/Itgb6^tm1Des (involves: 129S4/SvJae * C57BL/6J)	respiratory system inflammation	J:33139
Itgb6^tm1Des/Itgb6^tm1Des (involves: 129S4/SvJae)	abnormal immune system physiology	J:120085
	absent Langerhans cell	J:120085
	decreased Langerhans cell number	J:120085
Itgb6^tm1Des/Itgb6^tm1Des (involves: 129S4/SvJae * C57BL/6 * SJL)	respiratory system inflammation	J:51592
Itgb6^tm1Des/Itgb6^tm1Des Mmp12^tm1Sds/Mmp12^tm1Sds (involves: 129/Sv * 129T2/SvEms)	lung inflammation	J:89578
Itgb6^tm1Des/Itgb6^tm1Des Tg(SFTPC-ITGB6)1Des/? (involves: 129S4/SvJae * C57BL/6 * SJL)	respiratory system inflammation	J:51592
Itgb7^tm1Cgn/Itgb7^tm1Cgn (involves: C57BL/6)	abnormal gut-associated lymphoid tissue morphology	J:34306
	abnormal immune system morphology	J:34306
	abnormal immune system physiology	J:34306
	abnormal lymphocyte physiology	J:34306
	abnormal Peyer's patch follicle morphology	J:34306
	abnormal response to infection	J:62733
	abnormal uterine NK cell morphology	J:44813
	decreased B cell number	J:34306
	decreased CD4-positive, alpha-beta T cell number	J:34306
	decreased eosinophil cell number	J:62733
	decreased mast cell number	J:62733
	immune system phenotype	J:111227
	impaired leukocyte tethering or rolling	J:34306
	increased susceptibility to parasitic infection	J:90262
	increased uterine NK cell number	J:44813
	small Peyer's patches	J:34306
Itgb7^tm1Cgn/Itgb7^tm1Cgn (C57BL/6-Itgb7^tm1Cgn/J)	abnormal leukocyte migration	J:127413
Itgb7^tm1Cgn/Itgb7^tm1Cgn (C57BL/6-Itgb7^tm1Cgn/J)	colitis	J:127413
Itgb7^tm1Cgn/Itgb7^tm1Cgn Tnf^tm2Gkl/Tnf⁺ (involves: 129S/SvEv * C57BL/6)	abnormal inflammatory response	J:136667
	autoimmune arthritis	J:136667
Itgb7^tm1Mshi/Itgb7^tm1Mshi (involves: C57BL/6)	abnormal leukocyte adhesion	J:127413
	abnormal leukocyte migration	J:127413
	colitis	J:127413
	small Peyer's patches	J:127413
Itk^m1Btlr/Itk^m1Btlr (C57BL/6J-Itk^m1Btlr)	abnormal CD4-positive, alpha-beta T cell physiology	J:236673
	abnormal CD8-positive, alpha-beta T cell physiology	J:236673
	increased CD8-positive, alpha-beta memory T cell proliferation	J:236673
	increased IgE level	J:236673
Itk^m2Btlr/Itk^m2Btlr (C57BL/6J-Itk^m2Btlr)	decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:254826
	decreased CD8-positive, alpha-beta memory T cell number	J:254826
	decreased CD8-positive, naive alpha-beta T cell number	J:254826
	increased B cell number	J:254826
	increased central memory CD4-positive, alpha-beta T cell number	J:254826
	increased central memory CD8 positive, alpha-beta T cell number	J:254826
	increased effector memory CD4-positive, alpha-beta T cell number	J:254826
Itk^tm1Lex/Itk^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6J)	decreased CD4-positive, alpha-beta T cell number	J:103485
	decreased CD8-positive, alpha-beta T cell number	J:103485
	increased B cell number	J:103485
Itk^tm1Litt/Itk^tm1Litt (involves: 129S4/SvJae * C57BL/6J)	decreased B cell number	J:31230
	decreased CD4-positive, alpha-beta T cell number	J:31230
	decreased T cell number	J:31230
	decreased T cell proliferation	J:31230
	immune system phenotype	J:31230
Itk^tm1Litt/Itk^tm1Litt (involves: 129S4/SvJae)	decreased T cell proliferation	J:54449
Itk^tm1Litt/Itk^tm1Litt (involves: 129S4/SvJae)	increased susceptibility to parasitic infection	J:54449
Itk^tm1Litt/Itk^tm1Litt (involves: 129S4/SvJae * C57BL/6)	abnormal CD8-positive, alpha-beta T cell differentiation	J:111786
	abnormal thymus cell ratio	J:111786
	decreased CD8-positive, alpha-beta T cell number	J:111786
Itk^tm1Litt/Itk^tm1Litt (B6.129S4-Itk^tm1Litt)	abnormal positive T cell selection	J:141390
	abnormal T cell morphology	J:141390
	decreased interleukin-2 secretion	J:141390
	decreased T cell number	J:141390
	decreased T cell proliferation	J:141390
	increased double-negative T cell number	J:141390
Itk^tm1Litt/Itk^tm1Litt Tg(DO11.10)10Dlo/0 (involves: 129S4/SvJae * BALB/c * C3H * C57BL/6J)	abnormal T-helper 2 physiology	J:129883
Itk^tm1Litt/Itk^tm1Litt Tg(TcraH-Y,TcrbH-Y)71Vbo/0 (involves: 129S4/SvJae * C57BL/6 * DBA/2J)	abnormal positive T cell selection	J:31230
	decreased CD4-positive, alpha-beta T cell number	J:31230
	increased double-positive T cell number	J:31230
Itk^tm1Litt/Itk^tm1Litt Tg(TcrAND)53Hed/0 (involves: 129S4/SvJae * C57BL/6 * SJL)	abnormal lymphocyte morphology	J:31230
	decreased CD4-positive, alpha-beta T cell number	J:31230
	increased double-negative T cell number	J:31230
Itk^tm1Litt/Itk^tm1Litt Txk^tm1Pls/Txk^tm1Pls (involves: 129S4/SvJae * 129S6/SvEvTac)	decreased CD4-positive, alpha-beta T cell number	J:54449
	decreased single-positive T cell number	J:54449
	decreased T cell proliferation	J:54449
	increased susceptibility to parasitic infection	J:54449
Itk^tm1Litt/Itk^tm1Litt Vav1^tm2Bbd/Vav1^tm2Bbd (B6.129-Itk^tm1Litt Vav1^tm2Bbd)	abnormal CD4-positive T cell differentiation	J:141390
	abnormal CD8-positive, alpha-beta T cell differentiation	J:141390
	abnormal positive T cell selection	J:141390
	abnormal T cell morphology	J:141390
	abnormal T cell physiology	J:141390
	decreased CD4-positive, alpha-beta T cell number	J:141390
	decreased CD8-positive, alpha-beta T cell number	J:141390
	decreased double-positive T cell number	J:141390
	decreased T cell number	J:141390
	decreased thymocyte number	J:141390
	increased B cell number	J:141390
	increased T cell apoptosis	J:141390
Itk^tm1Ljb/Itk^tm1Ljb (B6.129-Itk^tm1Ljb)	abnormal NK T cell morphology	J:120689
Itk^tm1Ljb/Itk^tm1Ljb (B6.129-Itk^tm1Ljb)	decreased NK T cell number	J:120689
Itk^tm1Ljb/Itk^tm1Ljb (involves: 129 * C57BL/6)	abnormal T cell activation	J:48231
	decreased CD4-positive, alpha-beta T cell number	J:48231
	decreased interleukin-2 secretion	J:48231
Itk^tm1Ljb/Itk^tm1Ljb (B10.129-Itk^tm1Ljb)	abnormal CD8-positive, alpha-beta T cell differentiation	J:113408
	abnormal CD8-positive, alpha-beta T cell physiology	J:113408
	abnormal gamma-delta T cell morphology	J:148531
	decreased CD4-positive, alpha-beta T cell number	J:123795
	decreased interferon-gamma secretion	J:148531
	increased CD8-positive, alpha-beta T cell number	J:113408, J:123795
	increased germinal center B cell number	J:148531
	increased IgE level	J:148531
	increased interferon-gamma secretion	J:113408
	increased interleukin-4 secretion	J:148531
	increased interleukin-10 secretion	J:148531
	increased interleukin-13 secretion	J:148531
	increased mature gamma-delta T cell number	J:148531
	increased memory T cell number	J:113408
Itk^tm1Ljb/Itk^tm1Ljb Rag1^tm1Mom/Rag1^tm1Mom Tg(Tcra5CC7,Tcrb5CC7)IWep/? (involves: 129 * C57BL/10)	abnormal CD4-positive T cell differentiation	J:93606
	decreased interferon-gamma secretion	J:93606
	decreased interleukin-4 secretion	J:93606
	decreased interleukin-5 secretion	J:93606
	decreased interleukin-10 secretion	J:93606
Itk^tm1Ljb/Itk^tm1Ljb Tcrd^tm1Mom/Tcrd^tm1Mom (involves: 129 * C57BL/6 * C57BL/10)	immune system phenotype	J:148531
Itk^tm1Ljb/Itk^tm1Ljb Tg(Tcra2B4)1Mmd/? Tg(Tcrb2B4)1Mmd/? (involves: C3H/HeJ * C57BL/6 * C57BL/10)	decreased CD4-positive, alpha-beta T cell number	J:123795
Itk^tm1Ljb/Itk^tm1Ljb Tg(Tcra5CC7,Tcrb5CC7)IWep/? (involves: 129 * C57BL/10)	decreased CD4-positive, alpha-beta T cell number	J:123795
Itk^tm1Ljb/Itk^tm1Ljb Tg(TcraTcrb)1100Mjb/? (involves: 129 * C57BL/6 * C57BL/10)	immune system phenotype	J:113408
Itk^tm1Ljb/Itk^tm1Ljb Txk^tm1Pls/Txk^tm1Pls (B6.129-Txk^tm1Pls Itk^tm1Ljb)	abnormal CD8-positive, alpha-beta T cell physiology	J:113408
	increased CD8-positive, alpha-beta T cell number	J:113408
	increased interferon-gamma secretion	J:113408
	increased memory T cell number	J:113408
Itln1^em1Cya/Itln1^em1Cya (involves: C57BL/6)	abnormal cytokine level	J:282124
	abnormal osteoclast physiology	J:282124
	increased circulating interleukin-1 alpha level	J:282124
	increased circulating interleukin-6 level	J:282124
	increased circulating interleukin-10 level	J:282124
	increased circulating tumor necrosis factor level	J:282124
	increased osteoclast cell number	J:282124
Itm2c^em1Nutt/Itm2c^em1Nutt Prdm1^tm1Nutt/Prdm1⁺ (involves: C57BL/6 * C57BL/6J)	immune system phenotype	J:265892
Itpkb^T-less/Itpkb^T-less (C57BL/6-Itpkb^T-less)	abnormal T cell physiology	J:89286
Itpkb^T-less/Itpkb^T-less (C57BL/6-Itpkb^T-less)	arrested T cell differentiation	J:89286
Itpkb^tm1Ssch/Itpkb^tm1Ssch (involves: 129S1/Sv * 129X1/SvJ * CD-1)	abnormal thymocyte activation	J:86257
	abnormal thymus involution	J:86257
	absent CD4-positive, alpha-beta T cells	J:86257
	absent CD8-positive, alpha-beta T cells	J:86257
	absent T cells	J:86257
	absent thymus medulla	J:86257
	arrested T cell differentiation	J:86257
	decreased IgG1 level	J:86257
	decreased IgG2a level	J:86257
	decreased IgG2b level	J:86257
	decreased IgG level	J:86257
	increased double-positive T cell number	J:86257
	increased susceptibility to parasitic infection	J:86257
Itpkb^tm1Ssch/Itpkb^tm1Ssch Itpkc^tm1Ssch/Itpkc^tm1Ssch (involves: 129S1/Sv * 129X1/SvJ * CD-1)	abnormal thymocyte activation	J:86257
	absent CD4-positive, alpha-beta T cells	J:86257
	absent CD8-positive, alpha-beta T cells	J:86257
	arrested T cell differentiation	J:86257
Ity2^C57BL/6J/Ity2^MOLF/EiJ (involves: C57BL/6J * MOLF/Ei)	decreased susceptibility to bacterial infection	J:45962
Ity2^MOLF/EiJ/Ity2^MOLF/EiJ (involves: C57BL/6J * MOLF/Ei)	decreased susceptibility to bacterial infection	J:126552, J:45962
Ity2a^MOLF/EiJ/Ity2a^MOLF/EiJ (involves: C57BL/6J * MOLF/Ei)	decreased susceptibility to bacterial infection	J:126552
Ity2b^MOLF/EiJ/Ity2b^MOLF/EiJ (involves: C57BL/6J * MOLF/Ei)	decreased susceptibility to bacterial infection	J:126552
Ity3^C57BL/6J/Ity3^C57BL/6J (involves: C57BL/6J * MOLF/Ei)	decreased susceptibility to bacterial infection	J:45962
Ity3^C57BL/6J/Ity3^MOLF/EiJ (involves: C57BL/6J * MOLF/Ei)	decreased susceptibility to bacterial infection	J:45962
Ity3^MOLF/EiJ/Ity3^MOLF/EiJ (involves: C57BL/6J * MOLF/Ei)	increased susceptibility to bacterial infection	J:126552, J:45962
Ity3^MOLF/EiJ/Ity3^MOLF/EiJ (B6.MOLF-Slc11a1^r Ity3^MOLF/EiJ)	abnormal cytokine secretion	J:108692
Jade2^em1(IMPC)Tcp/Jade2^em1(IMPC)Tcp (C57BL/6N-Jade2^em1(IMPC)Tcp/Tcp)	small spleen	J:211773
Jag2^tm1Grid/Jag2^tm1Grid (involves: 129S1/Sv * C57BL/6J)	abnormal gamma-delta T cell differentiation	J:46930
	abnormal thymus medulla morphology	J:46930
	abnormal thymus morphology	J:46930
	decreased gamma-delta T cell number	J:46930
Jagn1^{tm1c(EUCOMM)Hmgu}/Jagn1^{tm1c(EUCOMM)Hmgu} Commd10^{Tg(Vav1-icre)A2Kio}/Commd10⁺ (involves: C57BL/6N * C57BL/10 * CBA/Ca)	abnormal neutrophil morphology	J:214828
	abnormal neutrophil physiology	J:214828
	impaired neutrophil chemotaxis	J:214828
	impaired neutrophil recruitment	J:214828
	increased susceptibility to fungal infection	J:214828
Jak1^M1Mhda/Jak1⁺ (C3HeB/FeJ-Jak1^M1Mhda)	abnormal plasma cell morphology	J:199153
	ear inflammation	J:199153
	enlarged spleen	J:199153
	increased anti-nuclear antigen antibody level	J:199153
	increased IgA level	J:199153
	increased IgG1 level	J:199153
	increased IgG2a level	J:199153
	increased IgM level	J:199153
	increased immunoglobulin level	J:199153
	increased plasma cell number	J:199153
	skin inflammation	J:199153
Jak1^tm1Rds/Jak1^tm1Rds (involves: 129)	abnormal B cell differentiation	J:47300
	abnormal lymphopoiesis	J:47300
	abnormal T cell differentiation	J:47300
	arrested B cell differentiation	J:47300
	decreased B cell number	J:47300
	decreased thymocyte number	J:47300
	increased double-negative T cell number	J:47300
	small thymus	J:47300
Jak2^{tm1(JAK2)Argr}/Jak2⁺ Dppa3^tm1(cre)Peli/Dppa3⁺ (involves: 129S5/SvEvBrd * 129S7/SvEvBrd * C57BL/6)	increased leukocyte cell number	J:233169
	increased spleen weight	J:233169
Jak2^{tm1(JAK2)Argr}/Jak2⁺ Tg(Mx1-cre)1Cgn/0 (involves: 129S7/SvEvBrd * C57BL/6 * CBA)	decreased leukocyte cell number	J:164539
	enlarged spleen	J:164539
	increased leukocyte cell number	J:164539
Jak2^tm1.1Ble/Jak2⁺ Commd10^{Tg(Vav1-icre)A2Kio}/Commd10⁺ (involves: 129 * C57BL/6 * C57BL/10 * CBA/Ca)	abnormal cytokine level	J:257910
	enlarged spleen	J:257910
	increased granulocyte number	J:257910
	increased leukocyte cell number	J:257910
	increased neutrophil cell number	J:257910
Jak2^tm1.1Jlvl/Jak2^tm1.1Jlvl (involves: 129S2/SvPas * C57BL/6)	abnormal spleen morphology	J:163497
	decreased spleen white pulp amount	J:163497
	enlarged spleen	J:163497
	increased granulocyte number	J:163497
	increased leukocyte cell number	J:163497
	increased lymphocyte cell number	J:163497
	increased monocyte cell number	J:163497
	increased spleen red pulp amount	J:163497
Jak2^tm1.2Ble/Jak2⁺ (involves: 129S6/SvEvTac * C57BL/6 * FVB/N)	abnormal spleen morphology	J:160883
	abnormal spleen red pulp morphology	J:160883
	enlarged spleen	J:160883
	increased leukocyte cell number	J:160883
Jak2^tm1.2Ble/Jak2⁺ Picalm^tm1.1Tmae/Picalm^tm1.1Tmae Commd10^{Tg(Vav1-icre)A2Kio}/Commd10⁺ (involves: 129S6/SvEvTac * C57BL/6 * C57BL/10 * CBA * SJL)	decreased CD4-positive, alpha-beta T cell number	J:220728
	decreased CD8-positive, alpha-beta T cell number	J:220728
Jak2^tm1Mohi/Jak2⁺ Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA)	abnormal spleen red pulp morphology	J:183821
	abnormal spleen white pulp morphology	J:183821
	decreased B cell number	J:183821
	enlarged spleen	J:183821
	increased leukocyte cell number	J:183821
	increased neutrophil cell number	J:183821
	increased spleen red pulp amount	J:183821
	increased spleen weight	J:183821
	myeloid hyperplasia	J:183821
	spleen fibrosis	J:183821
Jak2^tm1Mohi/Jak2^tm1Mohi Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA)	abnormal spleen red pulp morphology	J:183821
	abnormal spleen white pulp morphology	J:183821
	decreased B cell number	J:183821
	decreased spleen white pulp amount	J:183821
	enlarged spleen	J:183821
	increased leukocyte cell number	J:183821
	increased neutrophil cell number	J:183821
	increased spleen red pulp amount	J:183821
	increased spleen weight	J:183821
	myeloid hyperplasia	J:183821
	spleen fibrosis	J:183821
Jak2^tm2.1Jlvl/Jak2⁺ Tg(Vav1-cre)#Cgp/0 (involves: 129S2/SvPas * C57BL/6NTac)	abnormal myelopoiesis	J:202234
	decreased B cell number	J:202234
	enlarged spleen	J:202234
	increased granulocyte number	J:202234
	increased leukocyte cell number	J:202234
	increased spleen weight	J:202234
	myeloid hyperplasia	J:202234
	spleen fibrosis	J:202234
Jak2^tm2.2Jlvl/Jak2⁺ (involves: 129S2/SvPas * C57BL/6 * C57BL/6NTac * SJL)	enlarged spleen	J:202234
	increased leukocyte cell number	J:202234
Jak3^bfy/Jak3^bfy (C57BL/6JSfdAnu-Jak3^bfy/AnuApb)	abnormal lymphopoiesis	J:104190
	abnormal T cell subpopulation ratio	J:104190
	decreased B cell number	J:104190
	decreased lymphocyte cell number	J:104190
	decreased T cell number	J:104190
	decreased thymocyte number	J:104190
	small thymus	J:104190
Jak3^em1(IMPC)Mbp/Jak3⁺ (C57BL/6N-Jak3^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
Jak3^m1Btlr/Jak3^m1Btlr (C57BL/6J-Jak3^m1Btlr)	abnormal T cell subpopulation ratio	J:217795
	decreased IgG level	J:217795
	decreased NK cell number	J:217795
	decreased response to antigen	J:217795
	decreased single-positive T cell number	J:217795
	decreased T cell number	J:217795
	impaired humoral immune response	J:217795
	increased effector memory CD4-positive, alpha-beta T cell number	J:217795
	increased effector memory CD8-positive, alpha-beta T cell number	J:217795
	increased IgE level	J:217795
	increased neutrophil cell number	J:217795
	increased single-positive T cell number	J:217795
	increased susceptibility to Herpesvirales infection	J:217795
Jak3^m1J/Jak3^m1J (B6.Cg-Crb1⁺ Jak3^m1J/Boc)	decreased spleen weight	J:265859
	decreased thymus weight	J:265859
	small spleen	J:265859
	small thymus	J:265859
Jak3^M1Pgrs/Jak3⁺ (involves: C57BL/6J * C57BL/10J)	decreased susceptibility to parasitic infection induced morbidity/mortality	J:185217
Jak3^M1Pgrs/Jak3^M1Pgrs (involves: C57BL/6J * C57BL/10J)	absent B cells	J:185217
	decreased B cell number	J:185217
	decreased interferon-gamma secretion	J:185217
	decreased NK cell number	J:185217
	decreased susceptibility to parasitic infection induced morbidity/mortality	J:185217
	enlarged spleen	J:185217
	increased CD4-positive, alpha-beta T cell number	J:185217
	increased CD8-positive, alpha-beta T cell number	J:185217
	increased susceptibility to bacterial infection	J:185217
	increased susceptibility to bacterial infection induced morbidity/mortality	J:185217
	small thymus	J:185217
Jak3^M1Pgrs/Jak3^tm1Ljb (involves: 129S4/SvJae * C57BL/6J * C57BL/10J)	decreased susceptibility to parasitic infection induced morbidity/mortality	J:185217
Jak3^m2Btlr/Jak3^m2Btlr (C57BL/6J-Jak3^m2Btlr)	increased B cell number	J:217796
Jak3^m2Btlr/Jak3^m2Btlr (C57BL/6J-Jak3^m2Btlr)	increased memory B cell number	J:217796
Jak3^m3Btlr/Jak3^m3Btlr (C57BL/6J-Jak3^m3Btlr)	abnormal T cell subpopulation ratio	J:225935
	decreased B cell number	J:225935
	decreased B-1 B cell number	J:225935
	decreased IgG level	J:225935
	decreased immature B cell number	J:225935
	decreased mature B cell number	J:225935
	decreased memory B cell number	J:225935
	decreased NK cell number	J:225935
	decreased single-positive T cell number	J:225935
	decreased T cell number	J:225935
	impaired humoral immune response	J:225935
	increased effector memory CD8-positive, alpha-beta T cell number	J:225935
	increased macrophage cell number	J:225935
	increased myeloid dendritic cell number	J:225935
Jak3^m4Btlr/Jak3^m4Btlr (C57BL/6J-Jak3^m4Btlr)	increased CD4-positive, alpha-beta T cell number	J:272398
Jak3^M5Btlr/Jak3^M5Btlr (C57BL/6J-Jak3^M5Btlr)	decreased NK T cell number	J:272399
Jak3^m6Btlr/Jak3^m6Btlr (C57BL/6J-Jak3^m6Btlr)	decreased CD8-positive, alpha-beta T cell number	J:272400
	decreased IgG level	J:272400
	impaired humoral immune response	J:272400
	increased CD4-positive, alpha-beta T cell number	J:272400
Jak3^M7Btlr/Jak3^M7Btlr (C57BL/6J-Jak3^M7Btlr)	abnormal CD4-positive T cell differentiation	J:272401
Jak3^m8Btlr/Jak3^m8Btlr (C57BL/6J-Jak3^m8Btlr)	decreased B cell number	J:274939
	decreased B-1 B cell number	J:274939
	decreased B-2 B cell number	J:274939
	decreased CD4-positive, alpha-beta T cell number	J:274939
	decreased CD8-positive, alpha-beta T cell number	J:274939
	decreased CD8-positive, naive alpha-beta T cell number	J:274939
	decreased dendritic cell number	J:274939
	decreased IgG level	J:274939
	decreased IgM level	J:274939
	decreased response to antigen	J:274939
	decreased T cell number	J:274939
	impaired humoral immune response	J:274939
	increased B-1b cell number	J:274939
	increased effector memory CD4-positive, alpha-beta T cell number	J:274939
Jak3^tm1Flv/Jak3^tm1Flv (involves: 129S1/Sv)	abnormal T cell proliferation	J:95794
	arrested B cell differentiation	J:95794
	decreased CD8-positive, alpha-beta T cell number	J:95794
	enlarged spleen	J:95794
	increased CD4-positive, alpha-beta T cell number	J:95794
	small lymph nodes	J:95794
	thymus hypoplasia	J:95794
Jak3^tm1Jni/Jak3^tm1Jni Crlf2^tm1Jni/Crlf2^tm1Jni (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell differentiation	J:89031
	decreased B cell number	J:89031
Jak3^tm1Ljb/Jak3⁺ (involves: 129S4/SvJae)	abnormal leukocyte morphology	J:56629
	decreased lymphocyte cell number	J:56629
	increased leukocyte cell number	J:56629
	increased monocyte cell number	J:56629
	increased neutrophil cell number	J:56629
Jak3^tm1Ljb/Jak3^tm1Ljb (involves: 129S4/SvJae * C57BL/6)	abnormal B cell morphology	J:29722
	abnormal immune system physiology	J:29722
	abnormal leukocyte physiology	J:90510
	abnormal lymphocyte physiology	J:90510
	abnormal response to infection	J:29722
	abnormal splenic cell ratio	J:29722
	abnormal T cell activation	J:29722
	arrested B cell differentiation	J:29722
	decreased IgG level	J:29722
	decreased immature B cell number	J:29722
	decreased mature B cell number	J:29722
	decreased T cell proliferation	J:29722
	lymph node hypoplasia	J:29722
	small lymph nodes	J:29722
	small Peyer's patches	J:29722
	small thymus	J:29722
	spleen hypoplasia	J:29722
	thymus hypoplasia	J:29722
Jak3^tm1Ljb/Jak3^tm1Ljb (involves: 129S4/SvJae)	abnormal leukocyte morphology	J:56629
	abnormal myelopoiesis	J:56629
	abnormal spleen morphology	J:56629
	abnormal spleen white pulp morphology	J:56629
	abnormal T cell activation	J:128694, J:56629
	abnormal T cell differentiation	J:64861
	abnormal T cell physiology	J:128694
	abnormal thymus cell ratio	J:128694
	absent B cells	J:128694
	absent lymph nodes	J:128694
	chronic inflammation	J:56629
	decreased lymphocyte cell number	J:56629
	decreased T cell proliferation	J:128694
	decreased thymocyte number	J:64861
	enlarged spleen	J:56629
	increased leukocyte cell number	J:56629
	increased monocyte cell number	J:56629
	increased neutrophil cell number	J:56629
	thymus hypoplasia	J:128694
Jak3^tm1Ljb/Jak3^tm1Ljb (B6;129S4-Jak3^tm1Ljb/J)	abnormal dendritic cell differentiation	J:123902
	abnormal dendritic cell morphology	J:123902
	abnormal dendritic cell physiology	J:123902
	abnormal splenic cell ratio	J:123902
	decreased CD4-positive, alpha-beta T cell number	J:123902
	decreased CD8-positive, alpha-beta T cell number	J:123902
	decreased myeloid dendritic cell number	J:123902
Jak3^tm1Ljb/Jak3^tm1Ljb Rag1^tm1Mom/Rag1^tm1Mom (involves: 129S4/SvJae * 129S7/SvEvBrd)	abnormal splenic cell ratio	J:56629
	immune system phenotype	J:56629
Jak3^tm1Ljb/Jak3^tm1Ljb Tg(Lck-Jak3)1Ljb/0 (involves: 129S4/SvJae * C3H * C57BL/6 * C57BL/10)	absent B cells	J:128694
	absent lymph nodes	J:128694
	decreased T cell proliferation	J:128694
	immune system phenotype	J:128694
Jak3^tm1Ljb/Jak3^tm1Ljb Tg(Lck-Jak3)2Ljb/0 (involves: 129S4/SvJae * C3H * C57BL/6)	abnormal T cell activation	J:56629
	enlarged spleen	J:56629
	immune system phenotype	J:56629
	increased leukocyte cell number	J:56629
Jak3^tm1Ljb/Jak3^tm1Ljb Tg(Lck-Jak3)2Ljb/0 (involves: 129S4/SvJae * C3H * C57BL/6 * C57BL/10)	abnormal T cell activation	J:128694
	abnormal T cell physiology	J:128694
	absent B cells	J:128694
	absent lymph nodes	J:128694
	decreased T cell proliferation	J:128694
	immune system phenotype	J:128694
Jak3^tm1Tks/Jak3⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal leukocyte physiology	J:31231
Jak3^tm1Tks/Jak3^tm1Tks (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell differentiation	J:31231
	abnormal CD4-positive, alpha beta T cell morphology	J:31231
	abnormal lymphopoiesis	J:31231
	abnormal mesenteric lymph node morphology	J:31231
	abnormal spleen periarteriolar lymphoid sheath morphology	J:31231
	abnormal spleen white pulp morphology	J:31231
	abnormal T cell morphology	J:31231
	abnormal T cell number	J:31231
	abnormal T cell physiology	J:31231
	abnormal thymus cortex morphology	J:31231
	abnormal thymus corticomedullary boundary morphology	J:31231
	abnormal thymus medulla morphology	J:31231
	absent Hassall's corpuscle	J:31231
	absent lymph nodes	J:31231
	absent NK cells	J:31231
	decreased B cell number	J:31231
	decreased pre-B cell number	J:31231
	decreased thymocyte number	J:31231
	small spleen	J:31231
	small thymus medulla	J:31231
	spleen hypoplasia	J:31231
	thymus cortex hypoplasia	J:31231
	thymus hypoplasia	J:31231
Jak3^wil/Jak3^wil (C57BL/6JSfdAnu-Jak3^wil/Anu)	arrested B cell differentiation	J:104190
	decreased CD8-positive, alpha-beta T cell number	J:104190
	decreased leukocyte cell number	J:104190
	large intestinal inflammation	J:104190
Jak3^X887Y/Jak3^X887Y (Not Specified)	abnormal immune system organ morphology	J:112658
	abnormal lymph node morphology	J:112658
	abnormal lymphocyte morphology	J:112658
	abnormal spleen morphology	J:112658
	abnormal thymus morphology	J:112658
Jak3^X887Y/Jak3^X887Y Trdc^tm1Mal/Trdc^tm1Mal (involves: C57BL/6)	immune system phenotype	J:112658
Jakmip2^em1(IMPC)J/Jakmip2^em1(IMPC)J (C57BL/6NJ-Jakmip2^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
Jam3^tm1Lex/Jam3^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6)	decreased neutrophil cell number	J:145994
Jam3^tm1Lex/Jam3^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6)	increased granulocyte number	J:145994
Jam3^tm1Rha/Jam3^tm1Rha (involves: 129P2/OlaHsd * C57BL/6)	increased granulocyte number	J:121841
	increased susceptibility to bacterial infection	J:121841
	lung inflammation	J:121841
Jam3^tm1Rha/Jam3^tm1Rha Tg(Tek-Jam3)1Maal/? (involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J * CBA)	immune system phenotype	J:121841
Jarid2^jumonji/Jarid2^jumonji (C.129P2-Jarid2^jumonji)	abnormal splenic cell ratio	J:42772
	abnormal thymus cell ratio	J:42772
	spleen hypoplasia	J:42772
	thymus hypoplasia	J:42772
Jarid2^jumonji/Jarid2^jumonji (either: B6.129P2-Jarid2^jumonji or D2.129P2-Jarid2^jumonji)	spleen hypoplasia	J:42772
	thymus hypoplasia	J:42772
Jchain^Mat1/? Miju^C3HeB/FeJ/Miju^C57BL/6J (involves: C3HeB/FeJ * C57BL/6J)	increased IgA level	J:91062
Jchain^tm1Jse/Jchain^tm1Jse (involves: 129X1/SvJ)	abnormal B cell physiology	J:75843
Jchain^tm1Jse/Jchain^tm1Jse (involves: 129X1/SvJ)	increased IgA level	J:34042, J:75843
Jchain^tm1Jse/Jchain^tm1Jse (C.129X1-Jchain^tm1Jse)	decreased susceptibility to Herpesvirales infection	J:62298
	decreased susceptibility to Herpesvirales infection induced morbidity/mortality	J:62298
	increased susceptibility to parasitic infection	J:140515
Jchain^tm1Tl/Jchain^tm1Tl (involves: 129P2/OlaHsd * BALB/cJ * C57BL/6)	abnormal humoral immune response	J:71355
	decreased IgG level	J:71355
	decreased IgM level	J:71355
	increased IgA level	J:71355
Jchain^tm2(Myc)Tl/Jchain^tm2(Myc)Tl (involves: 129P2/OlaHsd * BALB/cJ * C57BL/6)	abnormal humoral immune response	J:71355
Jchain^tm3Tl/Jchain⁺ (involves: 129P2/OlaHsd)	abnormal B cell physiology	J:56158
	abnormal immune cell physiology	J:49168
	decreased IgM level	J:49168, J:56158
	decreased plasma cell number	J:49168
	impaired complement classical pathway	J:49168
	increased IgA level	J:56158
	increased susceptibility to bacterial infection	J:56158
Jchain^tm3Tl/Jchain^tm3Tl (involves: 129P2/OlaHsd)	abnormal B cell physiology	J:56158
	abnormal immune cell physiology	J:49168
	decreased IgG level	J:49168
	decreased IgM level	J:49168, J:56158
	decreased plasma cell number	J:49168, J:56158
	impaired complement classical pathway	J:49168
	increased IgA level	J:49168, J:56158
	increased susceptibility to bacterial infection	J:56158
Jdp2^tm1Aki/Jdp2^tm1Aki (Not Specified)	abnormal neutrophil physiology	J:191061
	abnormal osteoclast differentiation	J:191061
	abnormal osteoclast morphology	J:191061
	increased susceptibility to bacterial infection	J:191061
	increased susceptibility to fungal infection	J:191061
Jmjd4^{em1(IMPC)Wtsi}/Jmjd4^{em1(IMPC)Wtsi} (C57BL/6N-Jmjd4^{em1(IMPC)Wtsi}/Wtsi)	increased leukocyte cell number	J:211773
Jmjd6^tm1Gbf/Jmjd6^tm1Gbf (C57BL/6-Ptdsr^tm1Gbf)	abnormal macrophage activation involved in immune response	J:98905
	small thymus	J:102098
	thymus hypoplasia	J:102098
Jmjd8^em1Kaso/Jmjd8^em1Kaso (C57BL/6-Jmjd8^em1Kaso)	decreased circulating interleukin-1 beta level	J:319518
Jmjd8^em1Kaso/Jmjd8^em1Kaso (C57BL/6-Jmjd8^em1Kaso)	decreased inflammatory response	J:319518
Jph4^tm1Hta/Jph4^tm1Hta (involves: 129S4/SvJae * C57BL/6J)	abnormal interleukin level	J:230995
Jph4^tm1Hta/Jph4^tm1Hta (involves: 129S4/SvJae * C57BL/6J)	abnormal T cell activation	J:230995
Jun^em1(IMPC)Mbp/Jun⁺ (C57BL/6N-Jun^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
Jun^em1(IMPC)Mbp/Jun⁺ (C57BL/6N-Jun^em1(IMPC)Mbp/MbpMmucd)	enlarged lymph nodes	J:211773
Jun^tm1Rsjo/Jun^tm1Rsjo Tg(KRT14-cre)8Brn/0 (involves: 129S1/Sv * 129X1/SvJ * FVB/N)	increased incidence of corneal inflammation	J:84743
Jun^tm4Wag/Jun^tm4Wag Junb^tm3Wag/Junb^tm3Wag Tg(Krt1-5-cre/ERT)1Ipc/0 (involves: 129P2/OlaHsd * C57BL/6 * SJL)	autoimmune arthritis	J:116380
	increased inflammatory response	J:116380
	skin inflammation	J:116380
Jun^tm4Wag/Jun^tm4Wag Tg(Sftpc-cre)1Blh/0 (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	abnormal cytokine level	J:179883
	abnormal tumor necrosis factor level	J:179883
	lung inflammation	J:179883
Junb^{tm1b(EUCOMM)Hmgu}/Junb⁺ (C57BL/6N-Junb^{tm1b(EUCOMM)Hmgu}/Bay)	increased spleen weight	J:211773
Junb^tm3Wag/Junb^tm3Wag Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal osteoclast morphology	J:88126
Junb^tm3Wag/Junb^tm3Wag Meox2^tm1(cre)Sor/Meox2⁺ (involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6)	abnormal osteoclast differentiation	J:88126
	decreased osteoclast cell number	J:88126
Junb^tm3Wag/Junb^tm3Wag Tg(KRT5-cre)1Tak/0 (involves: 129/Sv * 129P2/OlaHsd * C3H * C57BL/6)	dermatitis	J:155575
	glomerulonephritis	J:155575
	increased anti-histone antibody level	J:155575
	increased circulating interleukin-6 level	J:155575
	increased IgE level	J:155575
	increased inflammatory response	J:155575
	increased interleukin-6 secretion	J:155575
	increased plasma cell number	J:155575
	increased susceptibility to systemic lupus erythematosus	J:155575
	tubulointerstitial nephritis	J:155575
Jund^tm1Mya/Jund^tm1Mya (either: 129S2/SvPas or (involves: 129S2/SvPas * C57BL/6))	abnormal T-helper 2 physiology	J:89085
	immune system phenotype	J:53906
	increased susceptibility to endotoxin shock	J:65879
	increased T cell proliferation	J:89085
	liver inflammation	J:65879
Jup^tm1.1Glr/Jup^tm1.1Glr A1cf^{Tg(Myh6-cre/Esr1)1Jmk}/A1cf⁺ (involves: 129S6/SvEvTac C57BL/6 * FVB/N * SJL)	abnormal interleukin level	J:170618
	heart inflammation	J:170618
Kash5^em1(IMPC)J/Kash5^em1(IMPC)J (C57BL/6NJ-Kash5^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
Kat5^tm1Jwl/Kat5⁺ Tg(IghMyc)22Bri/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL * C57BL/6 * SJL)	abnormal B cell physiology	J:125164
Kat6a^tm1.1Glac/Kat6a^tm1.1Glac (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell differentiation	J:148955
	decreased immature B cell number	J:148955
	decreased pre-B cell number	J:148955
	decreased pro-B cell number	J:148955
	decreased spleen weight	J:148955
	decreased thymus weight	J:148955
	spleen hypoplasia	J:148955
	thymus hypoplasia	J:148955
Kat6a^tm1Avo/Kat6a⁺ (involves: 129 * BALB/c * FVB/N)	small thymus	J:188772
Kat6a^tm1Avo/Kat6a^tm1Avo (involves: 129/Sv * BALB/c * FVB/N)	abnormal thymus development	J:108453
	absent spleen	J:108453
	athymia	J:188772
	decreased double-negative T cell number	J:108453
	small thymus	J:108453, J:188772
	thymus hypoplasia	J:108453
Kat6a^tm1Iki/Kat6a^tm1Iki (Not Specified)	abnormal myelopoiesis	J:108699
Kat6a^tm1Iki/Kat6a^tm1Iki (Not Specified)	decreased B cell number	J:108699
Kat6a^tm2.2Avo/Kat6a⁺ Tbx1^tm1Bld/Tbx1⁺ (involves: 129S7/SvEvBrd * C57BL/6)	small thymus	J:188772
Kat8^em1(IMPC)Mbp/Kat8⁺ (C57BL/6N-Kat8^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
Kat14^{tm1a(KOMP)Wtsi}/Kat14^{tm1a(KOMP)Wtsi} (involves: C57BL/6 * C57BL/6N)	decreased susceptibility to bacterial infection	J:213427
Katnal1^em1(IMPC)Tcp/Katnal1⁺ (C57BL/6NCrl-Katnal1^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Katnal1^em1(IMPC)Tcp/Katnal1^em1(IMPC)Tcp (C57BL/6NCrl-Katnal1^em1(IMPC)Tcp/Tcp)	abnormal spleen morphology	J:211773
Katnal2^em1(IMPC)Tcp/Katnal2^em1(IMPC)Tcp (C57BL/6N-Katnal2^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	increased monocyte cell number	J:211773
	small spleen	J:211773
Kbtbd3^{em1(IMPC)Ccpcz}/Kbtbd3^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Kbtbd3^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
	increased neutrophil cell number	J:211773
Kbtbd11^{em1(IMPC)Wtsi}/Kbtbd11^{em1(IMPC)Wtsi} (C57BL/6N-Kbtbd11^{em1(IMPC)Wtsi}/Wtsi)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Kcna1^mceph/Kcna1^mceph (BALB/cByJ-Kcna1^mceph/J)	ear inflammation	J:119491
Kcna1^mceph/Kcna1^mceph (BALB/cByJ-Kcna1^mceph/J)	eye inflammation	J:119491
Kcna1^tm1Tem/Kcna1^tm1Tem (involves: 129S7/SvEvBrd * BALB/cByJ * C3HeB/FeJ)	ear inflammation	J:119491
	eye inflammation	J:119491
Kcna5^tm1Hket/Kcna5^tm1Hket (involves: 129S6/SvEvTac * 129S7/SvEvBrd)	abnormal microglial cell morphology	J:116545
Kcna10^em3(IMPC)Mbp/Kcna10⁺ (C57BL/6N-Kcna10^em3(IMPC)Mbp/Ucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Kcnab2^em1(IMPC)Mbp/Kcnab2^em1(IMPC)Mbp (C57BL/6NCrl-Kcnab2^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
Kcne1^{tm1b(EUCOMM)Hmgu}/Kcne1^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Kcne1^{tm1b(EUCOMM)Hmgu}/Ics)	decreased lymphocyte cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Kcne2^{tm1a(EUCOMM)Wtsi}/Kcne2^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Kcne2^{tm1a(EUCOMM)Wtsi})	decreased spleen iron level	J:230226
	stomach inflammation	J:230226
Kcne3^tm1Gwab/Kcne3^tm1Gwab (involves: C57BL/6)	increased inflammatory response	J:210381
Kcnh8^em1(IMPC)Mbp/Kcnh8^em1(IMPC)Mbp (C57BL/6N-Kcnh8^em1(IMPC)Mbp/Ucd)	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Kcnip1^em1(IMPC)H/Kcnip1^em1(IMPC)H (C57BL/6N-Kcnip1^em1(IMPC)H/H)	increased eosinophil cell number	J:211773
Kcnj8^gnite/Kcnj8^gnite (involves: C57BL/6J)	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:126658, J:105543
Kcnj8^mydy/Kcnj8^mydy (involves: C57BL/6J)	increased susceptibility to endotoxin shock	J:126658
Kcnj8^mydy/Kcnj8^mydy (involves: C57BL/6J)	increased susceptibility to Herpesvirales infection	J:126658
Kcnj8^slmbr/Kcnj8^slmbr (involves: C57BL/6J)	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:126658, J:105543
Kcnj8^sltr/Kcnj8^sltr (involves: C57BL/6J)	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:126658, J:105543
Kcnj8^sltr/Kcnj8^sltr (involves: C57BL/6J)	increased susceptibility to Riboviria infection	J:105543
Kcnj8^sos/Kcnj8^sos (C57BL/6J-Kcnj8^sos)	increased susceptibility to endotoxin shock	J:149353
Kcnj9^{tm1b(EUCOMM)Hmgu}/Kcnj9^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Kcnj9^{tm1b(EUCOMM)Hmgu}/H)	increased basophil cell number	J:211773
	increased neutrophil cell number	J:211773
Kcnj10^{tm1b(KOMP)Wtsi}/Kcnj10⁺ (C57BL/6N-Kcnj10^{tm1b(KOMP)Wtsi}/H)	decreased basophil cell number	J:211773
Kcnk13^em1(IMPC)H/Kcnk13^em1(IMPC)H (involves: C57BL/6NTac)	abnormal microglial cell morphology	J:256020
Kcnk13^em1(IMPC)H/Kcnk13^em1(IMPC)H (involves: C57BL/6NTac)	abnormal microglial cell physiology	J:256020
Kcnk13^em1(IMPC)H/Kcnk13^em1(IMPC)H (C57BL/6N-Kcnk13^em1(IMPC)H/H)	increased basophil cell number	J:211773
	increased monocyte cell number	J:211773
Kcnmb4^em1(IMPC)Mbp/Kcnmb4^em1(IMPC)Mbp (C57BL/6N-Kcnmb4^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
Kcnn4^{em1(IMPC)Ccpcz}/Kcnn4^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Kcnn4^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
	increased spleen weight	J:211773
	small thymus	J:211773
Kcnn4^tm1Jemn/Kcnn4^tm1Jemn (involves: 129S1/Sv * C57BL/6J)	abnormal T cell physiology	J:94478
Kcnn4^tm1Rklr/Kcnn4^tm1Rklr (involves: 129S/SvEv * C57BL/6)	enlarged spleen	J:148910
	increased spleen iron level	J:148910
	increased spleen weight	J:148910
Kcnt1^em1(IMPC)Mbp/Kcnt1^em1(IMPC)Mbp (C57BL/6N-Kcnt1^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	small spleen	J:211773
Kcnt2^em1(IMPC)Mbp/Kcnt2^em1(IMPC)Mbp (C57BL/6N-Kcnt2^em1(IMPC)Mbp/MbpMmucd)	small spleen	J:211773
Kctd1^em1(IMPC)J/Kctd1^em1(IMPC)J (C57BL/6NJ-Kctd1^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
Kctd9^em1Beij/Kctd9^em1Beij (BALB/c-Kctd9^em1Beij)	abnormal immature NK cell morphology	J:281803
	abnormal NK cell differentiation	J:281803
	abnormal NK cell physiology	J:281803
	decreased mature NK cell number	J:281803
	decreased susceptibility to Coronaviridae infection	J:281803
	decreased susceptibility to Coronaviridae infection induced morbidity/mortality	J:281803
	impaired natural killer cell mediated cytotoxicity	J:281803
	increased immature NK cell number	J:281803
	increased NK cell number	J:281803
Kdelr1^em1Btlr/Kdelr1^em1Btlr (involves: C57BL/6J * C57BL/6JJcl)	decreased lymphocyte cell number	J:224970
Kdelr1^em1Btlr/Kdelr1^em1Btlr Tg(Gt(ROSA)26Sor-Kdelr1)#Btlr/0 (C57BL/6J-Kdelr1^em1Btlr Tg(Gt(ROSA)26Sor-Kdelr1)#Btlr)	abnormal lymphocyte morphology	J:224970
Kdelr1^m1Btlr/Kdelr1^m1Btlr (C57BL/6J-Kdelr1^m1Btlr)	abnormal lymphocyte morphology	J:224970
	abnormal response to infection	J:224970
	abnormal T cell differentiation	J:224970
	absent NK T cells	J:224970
	decreased B cell number	J:224970
	decreased CD4-positive, alpha-beta T cell number	J:224970, J:158794
	decreased CD8-positive, alpha-beta T cell number	J:224970, J:158794
	decreased follicular B cell number	J:224970
	decreased lymphocyte cell number	J:224970
	decreased transitional stage T1 B cell number	J:224970
	decreased transitional stage T2 B cell number	J:224970
	immune system phenotype	J:224970
	increased marginal zone B cell number	J:224970
	increased susceptibility to Riboviria infection	J:224970
	thymus hypoplasia	J:158794
Kdm1a^{tm1(NCOM)Mfgc}/Kdm1a⁺ (C57BL/6N-Kdm1a^{tm1(NCOM)Mfgc}/Nju)	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
	small spleen	J:211773
Kdm1a^tm1.1Sho/Kdm1a^tm1.1Sho Commd10^{Tg(Vav1-icre)A2Kio}/Commd10⁺ (involves: 129 * C57BL/6 * C57BL/10 * CBA/Ca)	decreased leukocyte cell number	J:201572
Kdm1a^tm1.1Sho/Kdm1a^tm1.1Sho Tg(Mx1-cre)1Cgn/? (involves: 129 * C57BL/6 * CBA/Ca)	decreased granulocyte number	J:201572
	decreased neutrophil cell number	J:201572
Kdm3a^em1(IMPC)Mbp/Kdm3a^em1(IMPC)Mbp (C57BL/6N-Kdm3a^em1(IMPC)Mbp/MbpMmucd)	enlarged spleen	J:211773
	small spleen	J:211773
Kdm4c^{tm1a(KOMP)Wtsi}/Kdm4c⁺ (C57BL/6N-Kdm4c^{tm1a(KOMP)Wtsi}/Wtsi)	increased B cell number	J:165965
Kdm5a^tm1.1Kael/Kdm5a^tm1.1Kael (involves: 129S6/SvEvTac * C57BL/6 * FVB/N * SJL)	increased neutrophil cell number	J:137185
Kdm6a^tm1.1Afst/Kdm6a^tm1.1Afst Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte}/Gt(ROSA)26Sor⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * C57BL/6NTac)	abnormal granulocyte morphology	J:196401
	decreased leukocyte cell number	J:196401
	enlarged spleen	J:196401
	increased B cell number	J:196401
	increased spleen weight	J:196401
Kdm6a^tm1Cdcn/Y Tg(CAG-cre/Esr1)5Amc/0 (involves: C57BL/6J CBA)	enlarged spleen	J:263565
	increased granulocyte number	J:263565
	increased monocyte cell number	J:263565
	increased neutrophil cell number	J:263565
Kdm6a^tm1Cdcn/Y Tg(CAG-cre/Esr1)5Amc/0 Trp53^tm1Tyj/Trp53^tm1Tyj (involves: 129S2/SvPas C57BL/6J * CBA * FVB/N)	enlarged spleen	J:263565
	increased monocyte cell number	J:263565
	increased neutrophil cell number	J:263565
Kdm6a^tm1Cdcn/Kdm6a^tm1Cdcn Tg(CAG-cre/Esr1)5Amc/0 (involves: C57BL/6J CBA)	enlarged spleen	J:263565
	increased granulocyte number	J:263565
	increased monocyte cell number	J:263565
	increased neutrophil cell number	J:263565
Kdm6b^tm1Aki/Kdm6b^tm1Aki (involves: 129X1/SvJ * C57BL/6)	abnormal response to infection	J:164690
Kdm6b^tm1Aki/Kdm6b^tm1Aki (involves: 129X1/SvJ * C57BL/6)	impaired eosinophil recruitment	J:164690
Kdm8^{tm1a(EUCOMM)Wtsi}/Kdm8⁺ (C57BL/6N-Kdm8^{tm1a(EUCOMM)Wtsi}/Ics)	increased B cell number	J:165965
Kdr^tm1.1Jamb/Kdr^tm1.1Jamb (involves: 129S1/Sv * 129X1/SvJ * ICR)	abnormal lymphangiogenesis	J:154336
	lymphatic vessel hyperplasia	J:154336
Kdr^tm1.1Jamb/Kdr^tm1.1Jamb Tg(KRT14-cre)1Efu/0 (involves: 129S1/Sv * 129X1/SvJ * ICR)	lymphatic vessel hyperplasia	J:154336
Kdr^tm1.1Jamb/Kdr^tm1.1Jamb Tg(Pax6-cre,GFP)1Pgr/0 (involves: 129S1/Sv * 129X1/SvJ * FVB/N * ICR)	abnormal lymphatic vessel morphology	J:154336
	lymphatic vessel hyperplasia	J:154336
Kdr^tm1Jrt/Kdr⁺ Tmem204^tm1.1Ali/Tmem204^tm1.1Ali (involves: 129S1/Sv * 129X1/SvJ * BALB/c * C57BL/6)	abnormal lymphatic vessel smooth muscle morphology	J:159519
	enlarged lymphatic vessel	J:159519
Kdr^tm1Ykub/Kdr^tm1Ykub (Not Specified)	enlarged lymphatic vessel	J:217533
Kdr^tm1Ykub/Kdr^tm1Ykub (Not Specified)	lymphatic vessel hyperplasia	J:217533
Kera^tm1Cyl/Kera^tm1Cyl (involves: 129S6/SvEvTac)	abnormal inflammatory response	J:128992
Kera^tm1Cyl/Kera^tm1Cyl (involves: 129S6/SvEvTac)	decreased neutrophil cell number	J:128992
Khdrbs1^tm1Rchd/Khdrbs1^tm1Rchd (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal bone marrow development	J:115775
Khsrp^tm1.1Cyc/Khsrp^tm1.1Cyc (B6.Cg-Khsrp^tm1.1Cyc)	decreased susceptibility to Herpesvirales infection	J:175084
	decreased susceptibility to Herpesvirales infection induced morbidity/mortality	J:175084
	increased interferon-beta secretion	J:175084
Kif1c^{Ltxs1-DBA/2NCr}/Kif1c^{Ltxs1-DBA/2NCr} (involves: BALB/cAnPt * DBA/2NCr)	decreased susceptibility to infection	J:103336
Kif1c^{Ltxs1-DBA/2NCr}/Kif1c^{Ltxs1-DBA/2NCr} Ltxs2^DBA/2NCr/Ltxs2^DBA/2NCr Ltxs3^DBA/2NCr/Ltxs3^DBA/2NCr (involves: BALB/cAnPt * DBA/2NCr)	decreased susceptibility to infection	J:103336
Kif1c^Ltxs1/Kif1c⁺ (involves: C3H/HeJ * C57BL/6J)	increased susceptibility to bacterial infection	J:49726
Kif1c^Ltxs1/Kif1c^Ltxs1 (involves: C3H/HeJ * C57BL/6J)	increased susceptibility to bacterial infection	J:49726
Kif1c^{Orch3-BALB/cByJ}/Kif1c^{Orch3-BALB/cByJ} (involves: BALB/cByJ * DBA/2)	testis inflammation	J:35331
Kif1c^{Orch3-BALB/cByJ}/Kif1c^Orch3-DBA/2J (involves: BALB/cByJ * DBA/2)	decreased inflammatory response	J:35331
Kif1c^Orch3-DBA/2J/Kif1c^Orch3-DBA/2J (involves: BALB/cByJ * DBA/2)	decreased inflammatory response	J:35331
Kif5c^tm1dIcs/Kif5c⁺ (C57BL/6N-Kif5c^tm1dIcs/Ics)	decreased lymphocyte cell number	J:211773
Kif5c^tm1dIcs/Kif5c⁺ (C57BL/6N-Kif5c^tm1dIcs/Ics)	increased eosinophil cell number	J:211773
Kif9^em1(IMPC)Mbp/Kif9^em1(IMPC)Mbp (C57BL/6N-Kif9^em1(IMPC)Mbp/MbpMmucd)	small spleen	J:211773
Kif13b^{tm1b(EUCOMM)Wtsi}/Kif13b^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Kif13b^{tm1b(EUCOMM)Wtsi}/Wtsi)	decreased leukocyte cell number	J:211773
Kif15^em1Lium/Kif15^em1Lium (C57BL/6-Kif15^em1Lium)	decreased spleen white pulp amount	J:336767
	increased CD8-positive, alpha-beta T cell number	J:336767
	increased spleen red pulp amount	J:336767
	increased spleen weight	J:336767
	intermingled spleen red and white pulp	J:336767
Kif16b^{em1(IMPC)Ccpcz}/Kif16b^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Kif16b^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Kif27^{Gt(OST441915)Lex}/Kif27^{Gt(OST441915)Lex} (involves: 129S5/SvEvBrd * C57BL/6J)	increased susceptibility to otitis media	J:185566
	maxillary sinus inflammation	J:185566
Kifbp^{tm1a(KOMP)Wtsi}/Kifbp^{tm1a(KOMP)Wtsi} (C57BL/6N-Kifbp^{tm1a(KOMP)Wtsi}/Wtsi)	blood in lymph vessels	J:239583
Kiss1r^{tm1.1(KOMP)Vlcg}/Kiss1r^{tm1.1(KOMP)Vlcg} (C57BL/6N-Kiss1r^{tm1.1(KOMP)Vlcg}/Ucd)	increased spleen weight	J:211773
	increased thymus weight	J:211773
Kiss1r^tm1.1Lex/Kiss1r⁺ (involves: 129S4/SvJae)	decreased eosinophil cell number	J:181650
Kiss1r^tm1.1Lex/Kiss1r⁺ (involves: 129S4/SvJae)	decreased lymphocyte cell number	J:181650
Kiss1r^tm1.1Lex/Kiss1r^tm1.1Lex (involves: 129S4/SvJae)	decreased basophil cell number	J:181650
	decreased lymphocyte cell number	J:181650
	decreased monocyte cell number	J:181650
	decreased neutrophil cell number	J:181650
	increased spleen weight	J:181650
	increased thymus weight	J:181650
Kiss1r^tm1Gstn/Kiss1r^tm1Gstn (involves: 129P2/OlaHsd)	increased thymus weight	J:102113
Kit^tm1.1Bsm/Kit^tm1.1Bsm (involves: 129S1/Sv * BALB/c * C57BL/6J * FVB/N)	abnormal mast cell physiology	J:61141
	decreased mast cell number	J:61141
Kit^tm1.1Bsm/Kit^tm1.1Bsm (B6.129S1-Kit^tm1.1Bsm)	immune system phenotype	J:90485
Kit^tm1Ber/Kit^tm1Ber (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	decreased mast cell number	J:89602
	immune system phenotype	J:89602
Kit^tm1Bpr/Kit^tm1Bpr (either: (involves: 129/Sv) or (involves: 129/Sv * C57BL/6))	decreased mast cell number	J:100778
Kit^tm1Bsm/Kit^tm1Bsm (involves: 129S1/Sv * C57BL/6J)	decreased mast cell number	J:61141
Kit^tm2Ber/Kit^tm2Ber (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	decreased mast cell number	J:89602
	immune system phenotype	J:89602
Kit^tm2Bsm/Kit⁺ (involves: 129X1/SvJ * C57BL/6J)	increased mast cell degranulation	J:83616
Kit^tm2Bsm/Kit⁺ (involves: 129X1/SvJ * C57BL/6J)	increased mast cell number	J:83616
Kit^tm3.1Bsm/Kit^tm3.1Bsm (involves: 129S1/Sv * C57BL/6)	abnormal B cell differentiation	J:90485
	abnormal mast cell physiology	J:90485
	abnormal T cell differentiation	J:90485
	decreased B cell number	J:90485
	decreased mast cell number	J:90485
	immune system phenotype	J:90485
Kit^tm3.1Bsm/Kit^tm3.1Bsm (B6.129S1-Kit^tm3.1Bsm)	spleen hypoplasia	J:146561
Kit^tm3Ber/Kit^tm3Ber (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	arrested B cell differentiation	J:89602
	decreased mast cell number	J:89602
	enlarged spleen	J:89602
	increased B cell number	J:89602
	spleen hyperplasia	J:89602
Kit^tm4.1Bsm/Kit⁺ (involves: 129S1/Sv * C57BL/6J * FVB/N)	enlarged spleen	J:188434
	increased mast cell number	J:188434
	spleen hyperplasia	J:188434
Kit^W-37J/Kit⁺ (involves: C57BL/6 * C57BL/6J)	decreased mast cell number	J:27513
Kit^W-37J/Kit^W (involves: C57BL/6 * C57BL/6J * WB)	abnormal mast cell physiology	J:27513
Kit^W-37J/Kit^W (involves: C57BL/6 * C57BL/6J * WB)	decreased mast cell number	J:27513
Kit^W-42J/Kit⁺ (involves: C57BL/6 * C57BL/6J * WB)	decreased mast cell number	J:27513
Kit^W-42J/Kit^W (involves: C57BL/6 * C57BL/6J * WB)	abnormal mast cell physiology	J:27513
Kit^W-42J/Kit^W (involves: C57BL/6 * C57BL/6J * WB)	decreased mast cell number	J:27513
Kit^W-Btlr/Kit^W-Btlr (C57BL/6J-Kit^W-Btlr)	decreased mast cell number	J:133270
Kit^W-f/Kit^W-f (involves: C3H/HePas)	decreased mast cell number	J:27513
Kit^W-Jic/Kit⁺ (involves: C57BL/6)	decreased mast cell number	J:27513
Kit^W-Jic/Kit^W (involves: C57BL/6 * WB)	abnormal mast cell physiology	J:27513
Kit^W-Jic/Kit^W (involves: C57BL/6 * WB)	decreased mast cell number	J:27513
Kit^W-n/Kit^W-n (Not Specified)	decreased mast cell number	J:12107
Kit^W-n/Kit^W (involves: WB)	abnormal mast cell physiology	J:27513
Kit^W-n/Kit^W (involves: WB)	decreased mast cell number	J:27513
Kit^W-sh/Kit^W-sh (involves: 101/H * C3H/HeH)	decreased mast cell degranulation	J:157470
	decreased mast cell number	J:145444
	increased susceptibility to parasitic infection	J:163761
Kit^W-sh/Kit^W-sh (involves: C57BL/6J)	decreased susceptibility to type I hypersensitivity reaction	J:197334
Kit^W-sh/Kit^W-sh (B6.Cg-Kit^W-sh/HNihrJaeBsmGlliJ)	decreased susceptibility to type I hypersensitivity reaction	J:275367
Kit^W-sh/Kit^W-sh Lyn^tm1Ard/Lyn^tm1Ard (involves: 101 * 129P2/OlaHsd * C3H/HeH)	abnormal circulating complement protein level	J:161523
	decreased B cell number	J:161523
	glomerulonephritis	J:161523
	increased anti-double stranded DNA antibody level	J:161523
	increased anti-nuclear antigen antibody level	J:161523
	increased basophil cell number	J:161523
	increased IgA level	J:161523
	increased IgE level	J:161523
	increased IgG2b level	J:161523
	increased IgM level	J:161523
Kit^W-v/Kit⁺ (involves: C57BL * C57BL/6)	decreased mast cell number	J:27513
Kit^W-vkd/Kit^W-vkd (involves: 129P2/OlaHsd * BALB/c * C57BL/6 * WB)	abnormal B cell differentiation	J:79128
	abnormal T cell differentiation	J:79128
	decreased B cell number	J:79128
	decreased thymocyte number	J:79128
Kit^W/Kit⁺ Tg(PGK1-KITLG*220)441Daw/0 (involves: C3H/HeJ)	decreased mast cell number	J:32600
Kit^W/Kit^W-v (involves: C57BL/6 * WB)	abnormal response to transplant	J:6084
Kit^W/Kit^W-v ((WB/ReJ x C57BL/6J-Kit^W-v/J)F1-Kit^W/Kit^W-v/J)	abnormal interferon level	J:131785
	abnormal interleukin level	J:131785
	decreased inflammatory response	J:131785
	immune system phenotype	J:125656
	impaired neutrophil recruitment	J:123463
	kidney inflammation	J:113500
Kit^W/Kit^W-v (involves: C57BL/6)	decreased basophil cell number	J:178942
	decreased mast cell number	J:178942
	immune system phenotype	J:178942
Kit^W/Kit^W-v ((WB Kit^W x B6.Cg-Kit^W-v)F1)	decreased susceptibility to induced arthritis	J:178942
Kit^W/Kit^W-v ((WB Kit^W x B6.Cg-Kit^W-v)F1)	decreased susceptibility to type I hypersensitivity reaction	J:197334
Kit^W/Kit^W Tg(PDGFB-EPO)321Zbz/? (involves: C3H * C57BL/6)	abnormal B cell differentiation	J:79128
	abnormal T cell differentiation	J:79128
	decreased B cell number	J:79128
	decreased thymocyte number	J:79128
Kit^Wads/Kit^Wads (C57BL/6J-Kit^Wads)	decreased mast cell number	J:96391
Kitl^Sl-con/Kitl^Sl-con (either: (involves: C3H/HeJ) or (involves: C3H/HeN))	increased mast cell number	J:23593
Kitl^Sl-d/Kitl⁺ (either: (involves: C57BL/6 * DBA/2J) or (involves: C3H * C57BL/6 * DBA/2J * WC))	decreased mast cell number	J:6084
Kitl^Sl/Kitl⁺ (either: (involves: C3H * WC) or (involves: C3H * C57BL/6 * DBA/2J * WC))	decreased mast cell number	J:6084
Kitl^Sl/Kitl⁺ Tg(PGK1-KITLG*220)441Daw/0 (involves: C3H)	decreased mast cell number	J:32600
Kitl^Sl/Kitl^Sl-d (involves: C57BL/6 * WC)	dermatitis	J:5758
	stomach inflammation	J:2777
	thymus atrophy	J:5758
Kitl^Sl/Kitl^Sl-d (involves: C3H * C57BL/6 * DBA/2J * WC)	abnormal response to transplant	J:6084
Kitl^Sl/Kitl^Sl-d (involves: C3H * C57BL/6 * DBA/2J * WC)	decreased mast cell number	J:6084
Kitl^Sl/Kitl^Sl-d ((WC/ReJ Kitl^Sl x B6.D2-Kitl^Sl-d/J)F1-Kitl^Sl/Kitl^Sl-d/J)	abnormal osteoclast morphology	J:111273
Kitl^tm1.1Sjm/Kitl^tm2.1Sjm Lepr^tm2(cre)Rck/Lepr⁺ (involves: 129S6/SvEvTac * C57BL/6 * C57BL/Ka * SJL)	enlarged spleen	J:180431
	spleen hyperplasia	J:180431
Kitl^tm1.1Sjm/Kitl^tm2.1Sjm Lepr^tm2(cre)Rck/Lepr⁺ Tg(Tek-cre)12Flv/0 (involves: 129S6/SvEvTac * C3H * C57BL/6 * C57BL/Ka * SJL)	spleen hyperplasia	J:180431
Kitl^tm1Pbes/Kitl^tm1Pbes (involves: 129S1/Sv * C57BL/6J)	decreased mast cell number	J:50150
Kitl^tm2.1Pbes/Kitl^tm2.1Pbes (involves: 129S1/Sv * C57BL/6J * FVB/N)	increased mast cell number	J:157170
Kitl^tm3.1Pbes/Kitl^tm3.1Pbes (involves: 129S1/Sv * C57BL/6J * FVB/N)	decreased double-negative T cell number	J:157170
	decreased double-positive T cell number	J:157170
	decreased mast cell number	J:157170
	decreased T cell number	J:157170
	decreased thymocyte number	J:157170
Kl^ecalc1/Kl^ecalc1 (involves: C3H/HeH * C57BL/6J)	lung inflammation	J:229255
Kl^kl/Kl^kl (either: C.Cg-Kl^kl or (involves: C3H/HeJ * C57BL/6J))	abnormal leukocyte cell number	J:44109
	decreased osteoclast cell number	J:44109
	thymus atrophy	J:44109
Kl^kl/Kl^kl (involves: C3H/HeJ * C57BL/6J)	decreased B cell number	J:80503
Kl^kl/Kl^kl (involves: C3H/HeJ * C57BL/6J)	decreased osteoclast cell number	J:80503
Kl^kl/Kl^kl (involves: C3H/J * C57BL/6J)	abnormal osteoclast morphology	J:56666
Kl^kl/Kl^kl Tnfrsf11b^tm1Khs/Tnfrsf11b⁺ (involves: 129P2/OlaHsd * C3H * C57BL/6)	decreased B cell number	J:80503
Kl^m1Anu/Kl^m1Anu (C57BL/6NCrl-Kl^m1Anu/Anu)	abnormal spleen morphology	J:104190
Kl^m1Anu/Kl^m1Anu (C57BL/6NCrl-Kl^m1Anu/Anu)	small spleen	J:104190
Klf1^Nan/Klf1⁺ (either: B6.Cg-Klf1^Nan or WB.Cg-Klf1^Nan)	increased spleen weight	J:162530
Klf1^Nan/Klf1⁺ (involves: 101/H * C3H/HeH * PT)	enlarged spleen	J:13933
Klf1^Nan/Klf1⁺ (involves: 101/H * C3H/HeH * PT)	increased spleen iron level	J:13933
Klf2^tm1Ling/Klf2^tm1Ling (involves: 129P2/OlaHsd * C57BL/6J)	immune system phenotype	J:51402
Klf2^tm1Mlkn/Klf2^tm1Mlkn Tg(VAV1-cre)1Graf/0 (Not Specified)	absent T cells	J:127228
Klf2^tm2Ling/Klf2^tm2Ling Lyz2^tm1(cre)Ifo/0 (involves: 129P2/OlaHsd * 129S6/SvEvTac)	decreased Ly6C low monocyte number	J:239509
Klf2^tm2Ling/Klf2^tm2Ling Tg(Cd4-cre)1Cwi/? (involves: 129S6/SvEvTac * C57BL/6 * DBA/2)	abnormal T cell differentiation	J:151604
	decreased T cell number	J:151604
	increased IgE level	J:151604
	increased IgG1 level	J:151604
	increased interleukin-4 secretion	J:151604
	increased single-positive T cell number	J:151604
Klf3^{Gt(CH0516)Wtsi}/Klf3^{Gt(CH0516)Wtsi} (involves: 129P2/OlaHsd * C57BL/6)	increased leukocyte cell number	J:206507
	increased spleen weight	J:206507
Klf3^{Gt(XS0187)Wtsi}/Klf3^{Gt(XS0187)Wtsi} (involves: 129P2/OlaHsd * C57BL/6)	increased leukocyte cell number	J:206507
	increased spleen weight	J:206507
Klf3^m1Cmhd/Klf3⁺ (involves: C3H/HeJ * C57BL/6J)	increased spleen weight	J:206507
Klf4^tm1Khk/Klf4^tm1Khk Lyz2^tm1(cre)Ifo/0 (involves: 129P2/OlaHsd * 129S6/SvEvTac)	decreased Ly6C low monocyte number	J:239509
Klf4^tm1Khk/Klf4^tm1Khk Tg(Pax6-cre,GFP)1Pgr/0 (involves: 129S6/SvEvTac * FVB/N)	blepharitis	J:117671
Klf5^Gt(XB751)Byg/Klf5⁺ (B6.129P2-Klf5^Gt(XB751)Byg)	abnormal response to infection	J:136125
Klf5^M1Btlr/Klf5^M1Btlr (C57BL/6J-Klf5^M1Btlr)	increased susceptibility to induced colitis	J:265229
Klf5^tm1Jaw/Klf5^tm1Jaw Tg(Pax6-cre,GFP)1Pgr/0 (involves: FVB)	lacrimal gland inflammation	J:175263
Klf13^tm1Coll/Klf13^tm1Coll (involves: 129S/SvEv)	decreased leukocyte cell number	J:136545
	decreased lymphocyte cell number	J:136545
	enlarged spleen	J:136545
	spleen hyperplasia	J:136545
Klf13^tm1Kren/Klf13^tm1Kren (B6.129-Klf13^tm1Kren)	abnormal immune system cell morphology	J:145839
	abnormal immune system organ morphology	J:145839
	abnormal spleen morphology	J:145839
	abnormal T cell number	J:145839
	decreased splenocyte apoptosis	J:145839
	decreased thymocyte apoptosis	J:145839
	decreased thymocyte number	J:145839
	increased double-positive T cell number	J:145839
	increased splenocyte number	J:145839
	increased thymocyte number	J:145839
	spleen hyperplasia	J:145839
	thymus hyperplasia	J:145839
Klf15^tm1Jain/Klf15^tm1Jain (involves: 129X1/SvJ)	blood vessel inflammation	J:203920
Klf15^tm1Jain/Klf15^tm1Jain (involves: 129X1/SvJ)	increased macrophage cell number	J:203920
Klf16^em1(IMPC)J/Klf16⁺ (C57BL/6NJ-Klf16^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
Klhdc2^{tm1b(EUCOMM)Hmgu}/Klhdc2⁺ (C57BL/6N-Klhdc2^{tm1b(EUCOMM)Hmgu}/H)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Klhdc7b^em1(IMPC)H/Klhdc7b^em1(IMPC)H (C57BL/6N-Klhdc7b^em1(IMPC)H/H)	decreased lymphocyte cell number	J:211773
	increased eosinophil cell number	J:211773
Klhdc10^tm1Hijo/Klhdc10^tm1Hijo (B6J.B6N-Klhdc10^tm1Hijo)	decreased circulating interleukin-6 level	J:251158
	decreased inflammatory response	J:251158
	decreased interleukin-6 secretion	J:251158
Klhl1^{em1(IMPC)Ccpcz}/Klhl1^{em1(IMPC)Ccpcz} (C57BL/6N-Klhl1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
	small spleen	J:211773
Klhl6^{em1(IMPC)Ccpcz}/Klhl6^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Klhl6^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	decreased effector memory T-helper cell number	J:211773
	decreased lymphocyte cell number	J:211773
	enlarged thymus	J:211773
	increased CD4-positive, alpha-beta T cell number	J:211773
	increased CD8-positive, alpha-beta T cell number	J:211773
	increased CD8-positive, naive alpha-beta T cell number	J:211773
	increased T cell number	J:211773
	increased T-helper cell number	J:211773
	small spleen	J:211773
Klhl6^m1Anu/Klhl6^m1Anu (C57BL/6JAnu-Klhl6^m1Anu)	decreased B cell number	J:104190
	decreased mature B cell number	J:104190
	increased immature B cell number	J:104190
Klhl6^m1Btlr/Klhl6^m1Btlr (C57BL/6J-Klhl6^m1Btlr)	decreased B cell number	J:265167
	decreased central memory CD4-positive, alpha-beta T cell number	J:265167
	increased B-1b cell number	J:265167
	increased CD4-positive, alpha-beta T cell number	J:265167
	increased single-positive T cell number	J:265167
	increased T cell number	J:265167
Klhl6^m2Btlr/Klhl6^m2Btlr (C57BL/6J-Klhl6^m2Btlr)	decreased CD8-positive, alpha-beta T cell number	J:265168
	increased CD4-positive, alpha-beta T cell number	J:265168
	increased single-positive T cell number	J:265168
	increased T cell number	J:265168
Klhl6^M3Btlr/Klhl6^M3Btlr (C57BL/6J-Klhl6^M3Btlr)	increased alpha-beta T cell number	J:267699
	increased B-1a cell number	J:267699
	increased CD4-positive, alpha-beta T cell number	J:267699
	increased CD8-positive, alpha-beta T cell number	J:267699
Klhl6^m4Btlr/Klhl6^m4Btlr (C57BL/6J-Klhl6^m4Btlr)	increased B-1 B cell number	J:272394
Klhl6^M5Btlr/Klhl6^M5Btlr (C57BL/6J-Klhl6^M5Btlr)	increased B-1 B cell number	J:272395
Klhl6^m6Btlr/Klhl6^m6Btlr (C57BL/6J-Klhl6^m6Btlr)	increased alpha-beta T cell number	J:272396
Klhl6^m6Btlr/Klhl6^m6Btlr (C57BL/6J-Klhl6^m6Btlr)	increased CD4-positive, alpha-beta T cell number	J:272396
Klhl6^M7Btlr/Klhl6^M7Btlr (C57BL/6J-Klhl6^M7Btlr)	abnormal B cell differentiation	J:272397
Klhl6^M8Btlr/Klhl6^M8Btlr (C57BL/6J-Klhl6^M8Btlr)	decreased B cell number	J:274963
	increased CD4-positive, alpha-beta T cell number	J:274963
	increased T cell number	J:274963
Klhl6^tm1Sato/Klhl6^tm1Sato (either: (involves: 129T2/SvEms) or (involves: BALB/c) or (involves: CD-1))	abnormal adaptive immunity	J:101363
	abnormal B cell differentiation	J:101363
	abnormal lymph node germinal center morphology	J:101363
	abnormal spleen morphology	J:101363
	decreased B cell number	J:101363
	decreased follicular B cell number	J:101363
	decreased spleen weight	J:101363
	spleen hypoplasia	J:101363
Klhl14^tm1.1Jyw/Klhl14⁺ (involves: C57BL/6)	decreased B-1a cell number	J:263511
	immune system phenotype	J:263511
	increased B-1b cell number	J:263511
Klhl22^em1Cya/Klhl22^em1Cya (C57BL/6N-Klhl22^em1Cya/Cya)	decreased interferon-gamma secretion	J:297538
Klhl22^em1Cya/Klhl22^em1Cya (C57BL/6N-Klhl22^em1Cya/Cya)	decreased tumor necrosis factor secretion	J:297538
Klhl29^{tm1b(EUCOMM)Hmgu}/Klhl29⁺ (C57BL/6N-Klhl29^{tm1b(EUCOMM)Hmgu}/Ics)	increased large unstained cell number	J:211773
Klk4^{tm1.1(KOMP)Vlcg}/Klk4^{tm1.1(KOMP)Vlcg} (C57BL/6N-Klk4^{tm1.1(KOMP)Vlcg}/Ucd)	increased basophil cell number	J:211773
	increased neutrophil cell number	J:211773
Klk5^em1Mer/Klk5^em1Mer (BALB/c-Klk5^em1Mer)	abnormal acute inflammation	J:344772
Klk6^tm1Gsot/Klk6⁺ (involves: C57BL/6)	decreased inflammatory response	J:270051
Klk6^tm1Gsot/Klk6⁺ (involves: C57BL/6)	decreased susceptibility to chemically induced skin inflammation	J:270051
Klk6^tm1Gsot/Klk6^tm1Gsot (involves: C57BL/6)	abnormal cytokine level	J:270051
	decreased inflammatory response	J:270051
	decreased susceptibility to chemically induced skin inflammation	J:270051
Klk6^tm1Gsot/Klk6^tm1Gsot Spink5^tm1Drh/Spink5^tm1Drh (involves: 129P2/OlaHsd * C57BL/6)	abnormal cytokine level	J:289877
	decreased inflammatory response	J:289877
Klk8^{em1(IMPC)Ccpcz}/Klk8^{em1(IMPC)Ccpcz} (C57BL/6N-Klk8^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	decreased lymphocyte cell number	J:211773
	enlarged spleen	J:211773
Klk10^{em1(IMPC)Ccpcz}/Klk10^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Klk10^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	decreased CD8-positive, naive alpha-beta T cell number	J:211773
	enlarged thymus	J:211773
	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
	increased effector memory T-helper cell number	J:211773
Klk11^{em1(IMPC)Ccpcz}/Klk11^{em1(IMPC)Ccpcz} (C57BL/6N-Klk11^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Klra1^tm1.1Wyok/Klra1^tm1.1Wyok (involves: BALB/cJ * C57BL/6NTac)	abnormal natural killer cell mediated cytotoxicity	J:252851
Klra5^tm1.1Cgbr/Klra5^tm1.1Cgbr (involves: C57BL/6 * SJL)	immune system phenotype	J:169142
Klra5^tm1.2Glec/Klra5^tm1.2Glec (involves: C57BL/6)	immune system phenotype	J:201231
Klra8^Cmv1-del/Klra8^Cmv1-r ((BXD8/TyJ x C57BL/6)F1)	decreased susceptibility to Herpesvirales infection	J:79093
Klra8^Cmv1-del/Klra8^Cmv1-s ((BXD8/TyJ x BALB/c)F1)	increased susceptibility to Herpesvirales infection	J:79093
Klra8^Cmv1-del/Klra8^Cmv1-s ((BXD8/TyJ x DBA/2)F1)	increased susceptibility to Herpesvirales infection	J:79093
Klra8^Cmv1-r/Klra8^Cmv1-r (C.B6-Klra8^Cmv1-r)	decreased IgG1 level	J:97203
	decreased IgG2a level	J:97203
	decreased IgG2b level	J:97203
	decreased IgG3 level	J:97203
	decreased IgG level	J:97203
	decreased interleukin-4 secretion	J:97203
	decreased susceptibility to Herpesvirales infection	J:22486, J:79093
	increased circulating interferon-gamma level	J:97203
	increased IgM level	J:97203
	increased susceptibility to infection induced morbidity/mortality	J:97203
	increased susceptibility to parasitic infection	J:97203
Klra15^tm1.1Apma/Klra15^tm1.1Apma (B6.129-Klra15^tm1.1Apma)	impaired natural killer cell mediated cytotoxicity	J:189106
Klra17^tm1.1Apma/Klra17^tm1.1Apma (involves: 129S1/Sv * 129X1/SvJ)	abnormal plasmacytoid dendritic cell physiology	J:152288
	abnormal response to infection	J:152288
	decreased circulating interferon-alpha level	J:152288
	decreased circulating interleukin-12 level	J:152288
	decreased interferon-alpha secretion	J:152288
	decreased interleukin-12 secretion	J:152288
	increased plasmacytoid dendritic cell number	J:152288
	increased susceptibility to Herpesvirales infection	J:152288
Klrb1^{tm1b(EUCOMM)Wtsi}/Klrb1^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Klrb1^{tm1b(EUCOMM)Wtsi}/Ieg)	decreased leukocyte cell number	J:211773
	increased follicular B cell number	J:211773
Klrb1b^tm1.1Apma/Klrb1b^tm1.1Apma (B6.Cg-Klrb1b^tm1.1Apma)	abnormal NK cell physiology	J:222057
Klrc1^tm1Mmka/Klrc1^tm1Mmka (B6.129-Klrc1^tm1Mmka)	decreased CD8-positive, alpha-beta T cell number	J:222503
	decreased tumor necrosis factor secretion	J:222503
	immune system phenotype	J:222503
	increased interferon-gamma secretion	J:222503
	increased interleukin-2 secretion	J:222503
	increased susceptibility to Adenoviridae infection	J:222503
	increased susceptibility to Orthomyxoviridae infection	J:222503
	increased tumor necrosis factor secretion	J:222503
	liver inflammation	J:222503
	lung inflammation	J:222503
Klrd1^tm1.1Lll/Klrd1^tm1.1Lll (B6.129X1-Klrd1^tm1.1Lll)	immune system phenotype	J:167730
Klre1^tm1Tgi/Klre1^tm1Tgi (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	impaired natural killer cell mediated cytotoxicity	J:92262
Klrg2^em1(IMPC)H/Klrg2^em1(IMPC)H (C57BL/6NTac-Klrg2^em1(IMPC)H/H)	enlarged spleen	J:211773
Klrk1^em1(IMPC)Mbp/Klrk1^em1(IMPC)Mbp (C57BL/6NCrl-Klrk1^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Klrk1^tm1.1Bpol/Klrk1^tm1.1Bpol (C57BL/6-Klrk1^tm1.1Bpol)	abnormal NK cell differentiation	J:151878
	abnormal NK cell physiology	J:151878
	decreased B cell number	J:151878
	decreased susceptibility to Herpesvirales infection	J:151878
	decreased susceptibility to Herpesvirales infection induced morbidity/mortality	J:151878
	decreased T cell number	J:151878
	impaired natural killer cell mediated cytotoxicity	J:151878
	increased interferon-gamma secretion	J:151878
	spleen hypoplasia	J:151878
Klrk1^tm1Dhr/Klrk1^tm1Dhr (involves: C57BL/6 * CD-1)	impaired natural killer cell mediated cytotoxicity	J:134509
Klrk1^tm1Dhr/Klrk1^tm1Dhr (B6.Cg-Klrk1^tm1Dhr/J)	increased natural killer cell mediated cytotoxicity	J:221188
Klrk1^tm2.1Bpol/Klrk1^tm2.1Bpol (Not Specified)	abnormal NK cell differentiation	J:215590
Klrk1^tm2.1Bpol/Klrk1^tm2.1Bpol (Not Specified)	decreased susceptibility to Herpesvirales infection	J:215590
Kmt2a^tm1(AFF1)Ksy/Kmt2a⁺ (involves: 129S1/Sv * C57BL/6 * FVB)	abnormal lymphocyte morphology	J:110241
	enlarged spleen	J:110241
	increased leukocyte cell number	J:110241
	increased monocyte cell number	J:110241
	increased neutrophil cell number	J:110241
	increased pro-B cell number	J:110241
	lymphoid hyperplasia	J:110241
	myeloid hyperplasia	J:110241
Kmt2a^{tm1(MLL1/ERT)Divo}/? (involves: 129S4/SvJae * C57BL/6)	enlarged spleen	J:189329
	myeloid hyperplasia	J:189329
Kmt2a^{tm1.1(Sh3gl1)Lcc}/Kmt2a⁺ Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6)	enlarged lymph nodes	J:205605
	enlarged spleen	J:205605
	myeloid hyperplasia	J:205605
Kmt2a^tm1.1Erns/Kmt2a^tm1.1Erns Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL)	immune system phenotype	J:147265
Kmt2a^tm1.1Erns/Kmt2a^tm1.1Erns Tg(Lck-cre)1Cwi/0 (involves: 129S2/SvPas * C57BL/6 * SJL)	immune system phenotype	J:147265
Kmt2a^tm1Brad/Kmt2a^tm1Brad Commd10^{Tg(Vav1-icre)A2Kio}/? (involves: 129S4/SvJae * C57BL/6 * C57BL/10 * CBA/Ca)	decreased pre-B cell number	J:149811
Kmt2a^tm1Clgr/Kmt2a⁺ (B6.129-Kmt2a^tm1Clgr)	abnormal myelopoiesis	J:115001
Kmt2a^tm1Sjk/Kmt2a⁺ (involves: 129S2/SvPas * C3H * C57BL/6)	decreased B cell number	J:29958
Kmt2a^tm1Thr/Kmt2a⁺ Mllt3^tm2Thr/Mllt3⁺ Tg(Lck-cre)1Thr/? (involves: 129S/SvEv)	abnormal spleen red pulp morphology	J:100794
	abnormal spleen white pulp morphology	J:100794
	enlarged spleen	J:100794
	increased T cell derived lymphoma incidence	J:100794
Kmt2a^{tm2(MLLT3)Thr}/Kmt2a⁺ (involves: 129P2/OlaHsd)	enlarged spleen	J:56340
Kmt2a^{tm2(MLLT3)Thr}/Kmt2a^{tm2(MLLT3)Thr} (involves: 129P2/OlaHsd * C57BL/6 * FVB)	increased leukocyte cell number	J:110241
	increased neutrophil cell number	J:110241
	increased pro-B cell number	J:110241
Kmt2a^tm2Sjk/Kmt2a⁺ Tg(Mx1-cre)1Cgn/0 (involves: 129X1/SvJ * C57BL/6 * CBA)	abnormal spleen morphology	J:95914
	enlarged spleen	J:95914
	increased leukocyte cell number	J:95914
	increased spleen red pulp amount	J:95914
	myeloid hyperplasia	J:95914
Kmt2d^tm1.1Kaig/Kmt2d⁺ Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129P2/OlaHsd * C57BL/6)	increased germinal center B cell number	J:228913
	increased spleen germinal center size	J:228913
Kmt2d^tm1.1Kaig/Kmt2d^tm1.1Kaig Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell differentiation	J:228913
	decreased B cell number	J:228913
	decreased follicular B cell number	J:228913
	decreased IgG1 level	J:228913
	decreased IgM level	J:228913
	decreased mature B cell number	J:228913
	immune system phenotype	J:228913
	increased B cell proliferation	J:228913
	increased germinal center B cell number	J:228913
	increased spleen germinal center number	J:228913
	increased spleen germinal center size	J:228913
Kmt2d^tm1.1Kaig/Kmt2d^tm1.1Kaig Ighg1^tm1(cre)Cgn/Ighg1⁺ (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:228913
Kmt2d^{tm1.2(IMPC)Wtsi}/Kmt2d⁺ (C57BL/6N-Kmt2d^{tm1.2(IMPC)Wtsi}/Wtsi)	decreased leukocyte cell number	J:211773
Kmt2e^tm1.1Hjf/Kmt2e⁺ (B6.129P2-Kmte^tm1.1Hjf)	decreased thymocyte number	J:145579
	spleen hypoplasia	J:145579
	thymus hypoplasia	J:145579
Kmt2e^tm1.1Hjf/Kmt2e^tm1.1Hjf (B6.129P2-Kmte^tm1.1Hjf)	abnormal lymphopoiesis	J:145579
	decreased B cell number	J:145579
	decreased double-negative T cell number	J:145579
	decreased double-positive T cell number	J:145579
	decreased leukocyte cell number	J:145579
	decreased macrophage cell number	J:145579
	decreased pre-B cell number	J:145579
	decreased pro-B cell number	J:145579
	decreased T cell number	J:145579
	decreased thymocyte number	J:145579
	immune system phenotype	J:145579
	small lymph nodes	J:145579
	small spleen	J:145579
	small thymus	J:145579
	spleen hypoplasia	J:145579
	thymus hypoplasia	J:145579
Kmt2e^tm1Apa/Kmt2e^tm1Apa (129S6/SvEvTac-Kmt2e^tm1Apa)	abnormal granulocyte differentiation	J:145445
	abnormal neutrophil differentiation	J:145445
	abnormal neutrophil physiology	J:145445
	blepharitis	J:145445
	increased susceptibility to bacterial infection	J:145445
Kmt2e^tm1Nik/Kmt2e^tm1Nik (B6.Cg-Kmte^tm1Nik)	decreased NK cell number	J:145449
	decreased NK T cell number	J:145449
	increased neutrophil cell number	J:145449
Kmt5b^tm1Jnw/Kmt5b^tm1Jnw Kmt5c^tm1.1Jnw/Kmt5c^tm1.1Jnw Commd10^{Tg(Vav1-icre)A2Kio}/Commd10⁺ (involves: 129/Sv * C57BL/6J * C57BL/10 * CBA/Ca)	abnormal class switch recombination	J:139510
	abnormal lymphopoiesis	J:139510
	decreased B cell number	J:139510
	decreased double-positive T cell number	J:139510
	immune system phenotype	J:139510
Knl1^{tm1c(EUCOMM)Hmgu}/Knl1^{tm1c(EUCOMM)Hmgu} Tg(GFAP-cre)25Mes/0 (involves: 129S4/SvJaeSor * C57BL/6N * FVB/N)	microgliosis	J:278483
Knop1^{tm1b(EUCOMM)Wtsi}/Knop1^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Knop1^{tm1b(EUCOMM)Wtsi}/Bay)	increased spleen weight	J:211773
Kpna2^em1(IMPC)Mbp/Kpna2⁺ (C57BL/6N-Kpna2^em1(IMPC)Mbp/Ucd)	abnormal spleen morphology	J:211773
Kpna4^tm1Bdr/Kpna4^tm1Bdr (B6.Cg-Kpna4^tm1Bdr)	increased susceptibility to Orthomyxoviridae infection	J:302003
Kprp^tm1Msug/Kprp⁺ (involves: C57BL/6)	increased IgE level	J:286659
Kprp^tm1Msug/Kprp⁺ (involves: C57BL/6)	increased susceptibility to chemically induced skin inflammation	J:286659
Kptn^{tm1a(EUCOMM)Wtsi}/Kptn^{tm1a(EUCOMM)Wtsi} (involves: C57BL/6N)	increased susceptibility to bacterial infection	J:200082
Kras^tm1.1Khai/Kras⁺ Tg(Mx1-cre)1Cgn/0 (involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * C57BL/6J * CBA/J)	enlarged spleen	J:276349
	increased leukocyte cell number	J:276349
Kras^tm1Mok/Kras⁺ Nras^tm1Mok/Nras⁺ (involves: 129S/SvEv * C57BL/6 * DBA/2)	abnormal lymphatic vessel morphology	J:159024
Kras^tm2Tyj/Kras⁺ (involves: 129S2/SvPas * C57BL/6)	increased T cell derived lymphoma incidence	J:68981
Kras^tm2Tyj/Kras⁺ (involves: 129S2/SvPas)	increased T cell derived lymphoma incidence	J:68981
Kras^tm2Tyj/Kras⁺ Trp53^tm1Tyj/Trp53⁺ (involves: 129S2/SvPas * C57BL/6)	increased T cell derived lymphoma incidence	J:68981
Kras^tm2Tyj/Kras⁺ Trp53^tm1Tyj/Trp53^tm1Tyj (involves: 129S2/SvPas * C57BL/6)	increased T cell derived lymphoma incidence	J:68981
Kras^tm3Tyj/Kras⁺ (involves: 129S4/SvJae * C57BL/6)	increased T cell derived lymphoma incidence	J:68981
Kras^tm3Tyj/Kras⁺ (involves: 129S4/SvJae)	increased T cell derived lymphoma incidence	J:68981
Kras^tm3Tyj/Kras⁺ Mir21a^tm1.1Eno/Mir21a^tm1.1Eno (involves: 129S/SvEv * 129S4/SvJae * C57BL/6)	increased T cell derived lymphoma incidence	J:164198
Kras^tm3Tyj/Kras^tm3Tyj (involves: 129S4/SvJae)	increased T cell derived lymphoma incidence	J:237900
Kras^tm4.1Bbd/Kras⁺ (involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6J * FVB/N)	enlarged spleen	J:223433
Kras^tm4.1Bbd/Kras^tm4.1Bbd (involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6J * FVB/N)	decreased CD8-positive, alpha-beta T cell number	J:223433
	enlarged spleen	J:223433
	increased basophil cell number	J:223433
	increased eosinophil cell number	J:223433
	increased leukocyte cell number	J:223433
	increased neutrophil cell number	J:223433
	spleen vascular congestion	J:223433
Kras^tm4Tyj/Kras⁺ (involves: 129S4/SvJae)	increased regulatory T cell number	J:154046
Kras^tm4Tyj/Kras⁺ Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/Gt(ROSA)26Sor⁺ Tg(Flt3-cre)#Ccb/0 (involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6)	decreased B cell number	J:247853
	decreased double-negative T cell number	J:247853
	decreased double-positive T cell number	J:247853
	decreased T cell number	J:247853
	hepatosplenomegaly	J:247853
	increased dendritic cell number	J:247853
	increased leukocyte cell number	J:247853
	increased monocyte cell number	J:247853
	thymus atrophy	J:247853
Kras^tm4Tyj/Kras⁺ Krt19^{tm1(cre/ERT)Ggu}/Krt19⁺ Pten^tm2Mak/Pten^tm2Mak (involves: 129P2/OlaHsd * 129S4/SvJae * 129S6/SvEvTac)	lung inflammation	J:254370
Kras^tm4Tyj/Kras⁺ Lrrc17^tm1Nik/Lrrc17⁺ Srpk2^tm1Nik/Srpk2⁺ Tg(Mx1-cre)1Cgn/0 (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * CBA)	increased leukocyte cell number	J:161558
Kras^tm4Tyj/Kras⁺ Pggt1b^tm1Mbrg/Pggt1b⁺ Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129/Sv * 129P2/OlaHsd * C57BL/6)	abnormal spleen morphology	J:122107
	decreased lymphocyte cell number	J:122107
	increased neutrophil cell number	J:122107
Kras^tm4Tyj/Kras⁺ Pten^tm1Hwu/Pten^tm1Hwu Scgb1a1^{tm1.1(cre)Fjd}/Scgb1a1⁺ (involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)	lung inflammation	J:131721
Kras^tm4Tyj/Kras⁺ Stk11^tm1.2Rdp/Stk11^tm1.2Rdp (involves: 129S4/SvJae * 129S6/SvEvTac)	increased macrophage cell number	J:197037
Kras^tm4Tyj/Kras⁺ Tg(MUC1)79.24Gend/0 (involves: 129S4/SvJae * C57BL/6)	decreased interferon-gamma secretion	J:154046
	increased IgG level	J:154046
	increased IgM level	J:154046
	increased regulatory T cell number	J:154046
Kras^tm4Tyj/Kras⁺ Tg(Mx1-cre)1Cgn/0 (involves: 129S4/SvJae * BALB/c * C57BL/6 * CBA)	abnormal myelopoiesis	J:88163
	enlarged spleen	J:88163
	increased granulocyte number	J:88163
	increased leukocyte cell number	J:88163
	increased lymphoblastic lymphoma incidence	J:88163
	increased spleen red pulp amount	J:88163
	lymphoid hyperplasia	J:88163
	myeloid hyperplasia	J:88163
Kras^tm4Tyj/Kras⁺ Tg(Mx1-cre)1Cgn/0 (involves: 129S4/SvJae * C57BL/6 * CBA)	abnormal myelopoiesis	J:87429
	enlarged spleen	J:87429, J:115071
	increased leukocyte cell number	J:87429
	increased monocyte cell number	J:87429
	increased splenocyte proliferation	J:87429
	myeloid hyperplasia	J:87429
Kras^tm4Tyj/Kras⁺ Tg(Mx1-cre)1Cgn/0 (involves: 129S4/SvJae * C57BL/6 * C57BL/6J * CBA/J)	enlarged spleen	J:276349
Kras^tm4Tyj/Kras⁺ Tg(Scgb1a1-cre)1Kkw/? (involves: 129 * C57BL/6 * FVB/N)	increased inflammatory response	J:107260
Kras^tm4Tyj/Kras⁺ Tgfbr2^tm1.2Hlm/Tgfbr2^tm1.2Hlm (B6.129-Kras^tm4Tyj Tgfbr2^tm1.2Hlm)	abnormal myeloid leukocyte morphology	J:177379
	increased B cell number	J:177379
	increased T cell number	J:177379
Kras^tm4Tyj/Kras⁺ Tgfbr2^tm1.2Hlm/Tgfbr2^tm1.2Hlm Ptf1a^{tm1.1(cre)Cvw}/Ptf1a⁺ (involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * DBA/2)	enlarged spleen	J:116129
Kras^tm4Tyj/Kras⁺ Trp53^tm2Tyj/Trp53⁺ (involves: 129S4/SvJae)	lung inflammation	J:191425
Kras^tm4Tyj/Kras⁺ Trp53^tm2Tyj/Trp53⁺ Tg(Pdx1-cre)6Tuv/0 (involves: 129S4/SvJae * C57BL/6 * FVB/N)	increased T cell derived lymphoma incidence	J:98936
Kras^tm4Tyj/Kras^tm4Tyj Trim33^tm1Los/Trim33^tm1Los Tg(Pdx1-cre)89.1Dam/0 (involves: 129S2/SvPas * 129S4/SvJae * C57BL/6 * DBA/2)	pancreas inflammation	J:151781
Kremen1^{em1(IMPC)Ccpcz}/Kremen1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Kremen1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	small spleen	J:211773
Krt1^{em1(IMPC)Ccpcz}/Krt1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Krt1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	decreased NK cell number	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	increased CD8-positive, naive alpha-beta T cell number	J:211773
	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
	increased effector memory T-helper cell number	J:211773
	increased spleen weight	J:211773
Krt1^tm1Tmm/Krt1^tm1Tmm (involves: 129 * C57BL/6)	abnormal circulating interleukin level	J:200244
	abnormal interleukin secretion	J:200244
	increased circulating interleukin-18 level	J:200244
Krt2^{tm1a(KOMP)Wtsi}/Krt2^{tm1a(KOMP)Wtsi} (involves: C57BL/6N)	skin inflammation	J:214772
Krt5^{tm1.1(KOMP)Vlcg}/Krt5⁺ (C57BL/6N-Krt5^{tm1.1(KOMP)Vlcg}/Tcp)	abnormal lymph node morphology	J:211773
Krt8^{tm1b(EUCOMM)Hmgu}/Krt8⁺ (C57BL/6N-Krt8^{tm1b(EUCOMM)Hmgu}/Ics)	increased neutrophil cell number	J:211773
Krt8^tm1Rgo/Krt8^tm1Rgo (involves: 129S2/SvPas * C57BL/6 * FVB/N)	chronic inflammation	J:86719, J:98058
	enlarged spleen	J:22116
Krt10^tm1Tmm/Krt10⁺ (either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129P2/OlaHsd * BALB/c * C57BL/6))	increased susceptibility to infection	J:31853
Krt18^tm1Tmm/Krt18⁺ (involves: 129P2/OlaHsd)	liver inflammation	J:309021
Krt18^tm1Tmm/Krt18^tm1Tmm (involves: 129P2/OlaHsd)	liver inflammation	J:309021
Krt27^{em1(IMPC)Ccpcz}/Krt27^{em1(IMPC)Ccpcz} (C57BL/6N-Krt27^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged thymus	J:211773
Krt28^{em1(IMPC)Ccpcz}/Krt28^{em1(IMPC)Ccpcz} (C57BL/6N-Krt28^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
Krt33a^{em1(IMPC)Ccpcz}/Krt33a^{em1(IMPC)Ccpcz} (C57BL/6N-Krt33a^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Krt33a^Plsh-3Btlr/Krt33a⁺ (C57BL/6J-Krt33a^Plsh-3Btlr)	immune system phenotype	J:145290
Krt33b^{em1(IMPC)Ccpcz}/Krt33b^{em1(IMPC)Ccpcz} (C57BL/6N-Krt33b^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
	increased eosinophil cell number	J:211773
Krt34^{em1(IMPC)Ccpcz}/Krt34^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Krt34^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Krt72^{em1(IMPC)Ccpcz}/Krt72^{em1(IMPC)Ccpcz} (C57BL/6N-Krt72^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Krt76^{tm1a(KOMP)Wtsi}/Krt76^{tm1a(KOMP)Wtsi} (involves: C57BL/6 * C57BL/6N)	skin inflammation	J:232539
Krtap7-1^{em1(IMPC)Ccpcz}/Krtap7-1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Krtap7-1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
	small spleen	J:211773
Krtap8-1^{em1(IMPC)Ccpcz}/Krtap8-1^{em1(IMPC)Ccpcz} (C57BL/6N-Krtap8-1^{em1(IMPC)Ccpcz}/Ccpcz)	decreased CD4-positive, alpha-beta T cell number	J:211773
	decreased NK T cell number	J:211773
	decreased T-helper cell number	J:211773
Krtap9-5^{em1(IMPC)Ccpcz}/Krtap9-5^{em1(IMPC)Ccpcz} (C57BL/6N-Krtap9-5^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Ksr1^tm1Shaw/Ksr1^tm1Shaw (Not Specified)	decreased susceptibility to induced arthritis	J:140520
Ksr1^tm1Shaw/Ksr1^tm1Shaw (Not Specified)	decreased T cell proliferation	J:75739
Ksr1^tm1Shaw/Ksr1^tm1Shaw Tg(DO11.10)10Dlo/0 (involves: BALB/c * C3H * C57BL/6)	abnormal CD4-positive T cell differentiation	J:75739
	decreased interleukin-2 secretion	J:75739
	decreased T cell proliferation	J:75739
Ky^em1(IMPC)J/Ky⁺ (C57BL/6NJ-Ky^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
L3mbtl1^tm1.1Haho/L3mbtl1^tm1.1Haho (involves: 129S4/SvJae * C57BL/6)	immune system phenotype	J:166180
Lacc1^em1Arkr/Lacc1^em1Arkr (C57BL/6NTac-Lacc1^em1Arkr)	abnormal macrophage physiology	J:244365
	decreased circulating interleukin-1 beta level	J:244365
	decreased susceptibility to endotoxin shock	J:244365
Lacc1^em2Arkr/Lacc1^em2Arkr (C57BL/6NTac-Lacc1^em2Arkr)	abnormal macrophage physiology	J:244365
	decreased circulating interleukin-1 beta level	J:244365
	decreased susceptibility to endotoxin shock	J:244365
Lacc1^em3Arkr/Lacc1^em3Arkr (C57BL/6NTac-Lacc1^em3Arkr)	abnormal macrophage physiology	J:244365
	increased circulating interleukin-1 beta level	J:244365
	increased susceptibility to endotoxin shock	J:244365
Lacc1^em4Arkr/Lacc1^em4Arkr (C57BL/6NTac-Lacc1^em4Arkr)	abnormal macrophage physiology	J:244365
	increased circulating interleukin-1 beta level	J:244365
	increased susceptibility to endotoxin shock	J:244365
Lacc1^{tm1a(KOMP)Wtsi}/Lacc1^{tm1a(KOMP)Wtsi} (involves: C57BL/6N * C57BL/6NTac)	abnormal macrophage morphology	J:244365
	abnormal macrophage physiology	J:244365
	decreased circulating tumor necrosis factor level	J:244365
	decreased interleukin-1 beta secretion	J:244365
	increased circulating interleukin-1 beta level	J:244365
	increased susceptibility to endotoxin shock	J:244365
Lag3^tm1Daav/Lag3⁺ Tg(Foxp3-EGFP/cre)1cJbs/0 (NOD.Cg-Lag3^tm1Daav Tg(Foxp3-EGFP/cre)1cJbs)	decreased susceptibility to autoimmune diabetes	J:260063
Lag3^tm1Daav/Lag3^tm1Daav Tg(Foxp3-EGFP/cre)1cJbs/0 (NOD.Cg-Lag3^tm1Daav Tg(Foxp3-EGFP/cre)1cJbs)	abnormal CD8-positive, alpha-beta T cell physiology	J:260063
	abnormal effector T cell number	J:260063
	abnormal interleukin level	J:260063
	abnormal tumor necrosis factor level	J:260063
	decreased susceptibility to autoimmune diabetes	J:260063
Lag3^tm1Doi/Lag3^tm1Doi (involves: 129S2/SvPas * C57BL/6)	abnormal NK cell physiology	J:32509
	abnormal T cell physiology	J:89653
	enlarged spleen	J:89653
	increased CD4-positive, alpha-beta T cell number	J:89653
	increased CD8-positive, alpha-beta T cell number	J:89653
	increased single-positive T cell number	J:89653
Lage3^em1(IMPC)Tcp/Lage3^em1(IMPC)Tcp (C57BL/6N-Lage3^em1(IMPC)Tcp/Tcp)	increased neutrophil cell number	J:211773
Lair1^tm1.1Jco/Lair1^tm1.1Jco (involves: C57BL/6)	decreased CD4-positive, alpha-beta T cell number	J:180203
	decreased CD8-positive, alpha-beta T cell number	J:180203
	decreased IgG1 level	J:180203
	decreased thymocyte number	J:180203
	increased activated T cell number	J:180203
	increased B cell number	J:180203
	increased CD4-positive, alpha-beta memory T cell number	J:180203
	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:180203
	increased CD8-positive, alpha-beta memory T cell number	J:180203
	increased dendritic cell number	J:180203
	increased eosinophil cell number	J:180203
	increased marginal zone B cell number	J:180203
Lair1^tm1Jco/Lair1^tm1Jco Tg(Cd4-cre)1Cwi/? (involves: C57BL/6 * DBA/2)	decreased IgG2a level	J:180203
	decreased IgG2b level	J:180203
Lama2^dy/Lama2^dy (involves: 129P1/ReJ)	increased IgG level	J:102959
Lama2^dy/Lama2^dy (involves: 129P1/ReJ)	increased IgM level	J:102959
Lama2^tm1Eeng/Lama2^tm1Eeng (involves: 129S1/Sv)	myositis	J:170192
Lama2^tm1Stk/Lama2^tm1Stk (involves: 129P2/OlaHsd * BALB/c)	abnormal thymus corticomedullary boundary morphology	J:61802
	abnormal thymus physiology	J:61802
	decreased double-positive T cell number	J:61802
	decreased T cell number	J:61802
	thymus cortex hypoplasia	J:61802
Lama3^tm1.1Grsb/Lama3^tm1.1Grsb (involves: C57BL/6)	abnormal chemokine level	J:235712
	abnormal tumor necrosis factor level	J:235712
	increased alveolar macrophage number	J:235712
	lung inflammation	J:235712
Lama3^tm1Arte/Lama3^tm1Arte Tg(KRT14-cre/ERT)20Efu/0 (involves: C57BL/6 * CD-1)	skin inflammation	J:240054
Lama4^{tm1.1(KOMP)Vlcg}/Lama4^{tm1.1(KOMP)Vlcg} (C57BL/6N-Lama4^{tm1.1(KOMP)Vlcg}/Ucd)	increased basophil cell number	J:211773
Lama5^b2b2966.1Clo/Lama5^b2b2966.1Clo (C57BL/6J-Lama5^b2b2966.1Clo)	thymus hypoplasia	J:175213
Lama5^tm1Lsor/Lama5^tm1Lsor Tg(Tek-cre)1Ywa/0 (involves: C57BL/6 * SJL)	abnormal marginal zone B cell physiology	J:198783
	decreased marginal zone B cell number	J:198783
	decreased transitional stage T2 B cell number	J:198783
	increased B cell number	J:198783
	increased IgM level	J:198783
	increased transitional stage T1 B cell number	J:198783
Lama5^tm2Jhm/Lama5^tm1Jhm Tg(NPHS2-cre)295Lbh/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA * SJL)	tubulointerstitial nephritis	J:185850
Lamb2^tm1Jrs/Lamb2^tm1Jrs (involves: 129S1/Sv * 129X1/SvJ)	glomerulonephritis	J:23783
Lamc2^jeb/Lamc2^jeb (129X1/SvJ-Lamc2^jeb)	ear inflammation	J:158873
Lamp1^em1(IMPC)Mbp/Lamp1^em1(IMPC)Mbp (C57BL/6N-Lamp1^em1(IMPC)Mbp/MbpMmucd)	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
	small spleen	J:211773
Lamp2^tm1Psa/Lamp2^tm1Psa (either: (involves: 129P2/OlaHsd * 129/Sv * C57BL/6J) or (involves: 129P2/OlaHsd * 129/Sv))	abnormal thymus morphology	J:64151
	intermingled spleen red and white pulp	J:64151
Lamp3^em1(IMPC)Tcp/Lamp3^em1(IMPC)Tcp (C57BL/6N-Lamp3^em1(IMPC)Tcp/Tcp)	abnormal lymph node morphology	J:211773
Lamp3^em1Damme/Lamp3^em1Damme (involves: C57BL/6N)	increased macrophage cell number	J:324174
Lancl1^tm1.1Pfw/Lancl1^tm1.1Pfw (involves: 129 * C57BL/6)	brain inflammation	J:214805
Lancl2^{tm2a(KOMP)Wtsi}/Lancl2^{tm2a(KOMP)Wtsi} (involves: C57BL/6N)	decreased macrophage cell number	J:250673
	decreased regulatory T cell number	J:250673
	decreased susceptibility to bacterial infection	J:250673
Lancl2^{tm2c(KOMP)Wtsi}/Lancl2^{tm2c(KOMP)Wtsi} Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: C57BL/6N)	decreased macrophage cell number	J:250673
	decreased regulatory T cell number	J:250673
	decreased susceptibility to bacterial infection	J:250673
Lao1^tm1Oka/Lao1^tm1Oka (involves: 129S2/SvPas * C57BL/6J)	abnormal interleukin level	J:260668
	increased susceptibility to bacterial infection	J:260668
	increased susceptibility to bacterial infection induced morbidity/mortality	J:260668
	mastitis	J:260668
Lap3^tm1Klr/Lap3^tm1Klr (involves: 129 * C57BL/6)	immune system phenotype	J:119392
Laptm5^tm1Jow/Laptm5^tm1Jow (C57BL/6-Laptm5^tm1Jow)	abnormal T cell activation	J:137841
	abnormal type IV hypersensitivity reaction	J:137841
	immune system phenotype	J:137841
	increased interleukin-2 secretion	J:137841
	increased T cell proliferation	J:137841
Laq1^MRL/Laq1^MRL (involves: C57BL/6 * MRL)	increased susceptibility to autoimmune disorder	J:45708
Lar^SAMP1/? (involves: C57BL/10 * SAMP1)	abnormal humoral immune response	J:1953
Large1^myd/Large1^myd (MYD/Le-Os +/+ Large^myd/J)	myositis	J:5670
Large1^myd/Large1^myd (B6C3Fe a/a-Large1^myd/J)	myositis	J:27793
Larp1^em1(IMPC)Mbp/Larp1⁺ (C57BL/6N-Larp1^em1(IMPC)Mbp/Ucd)	abnormal spleen morphology	J:211773
Larp1^em1(IMPC)Mbp/Larp1⁺ (C57BL/6N-Larp1^em1(IMPC)Mbp/Ucd)	enlarged spleen	J:211773
Lat2^tm1Mal/Lat2^tm1Mal (involves: 129S2/SvPas)	abnormal mast cell physiology	J:93950
Lat2^tm1Mal/Lat2^tm1Mal (B6.129S2-Lat2^tm1Mal)	increased anti-nuclear antigen antibody level	J:126321
Lat2^tm1Mal/Lat2^tm1Mal Lime1^tm1.1Mal/Lime1^tm1.1Mal (involves: 129 * C57BL/6)	increased anti-nuclear antigen antibody level	J:126321
Lat2^tm1Wz/Lat2^tm1Wz (involves: C57BL/6)	abnormal mast cell physiology	J:93951
Lat2^tm1Wz/Lat2^tm1Wz (B6.Cg-Lat2^tm1Wz)	abnormal CD8-positive, alpha-beta T cell physiology	J:116157
	abnormal cytokine secretion	J:116157
	abnormal T cell physiology	J:116157
	increased anti-double stranded DNA antibody level	J:116157
	increased autoantibody level	J:116157
	increased T cell proliferation	J:116157
	spleen hyperplasia	J:116157
Lat2^tm1Wz/Lat2^tm1Wz (Not Specified)	abnormal T cell physiology	J:181866
	decreased interleukin-12 secretion	J:181866
	increased circulating interleukin-6 level	J:181866
	increased circulating tumor necrosis factor level	J:181866
	increased interferon-gamma secretion	J:181866
	increased interleukin-10 secretion	J:181866
	increased mast cell degranulation	J:181866
	increased susceptibility to endotoxin shock	J:181866
Lat2^tm2Wz/Lat2^tm2Wz Tg(Lck-cre)548Jxm/0 (involves: C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:116157
	enlarged spleen	J:116157
	increased activated T cell number	J:116157
	increased anti-double stranded DNA antibody level	J:116157
Lat2^tm3.1Wz/Lat2^tm3.1Wz (B6.Cg-Lat2^tm3.1Wz)	abnormal T cell physiology	J:181866
	enlarged spleen	J:181866
	immune system phenotype	J:181866
	increased interferon-gamma secretion	J:181866
	increased mast cell degranulation	J:181866
	increased memory T cell number	J:181866
	increased susceptibility to endotoxin shock	J:181866
Lat^tm1.1Lov/Lat^tm1.1Lov (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:116157, J:77099
	abnormal CD8-positive, alpha beta T cell morphology	J:77099
	abnormal cytokine secretion	J:77099
	abnormal double-negative T cell morphology	J:77099
	abnormal immunoglobulin level	J:77099
	abnormal lymph organ size	J:77099
	abnormal T cell differentiation	J:77099
	abnormal T cell physiology	J:77099
	decreased double-positive T cell number	J:77099
	decreased T cell proliferation	J:77099
	decreased thymocyte number	J:77099
	enlarged lymph nodes	J:116157, J:77099
	enlarged spleen	J:116157, J:77099
	increased activated T cell number	J:77099
	increased anti-double stranded DNA antibody level	J:116157
	increased anti-nuclear antigen antibody level	J:77099
	increased autoantibody level	J:77099
	increased IgE level	J:77099
	increased IgG1 level	J:77099
	increased IgM level	J:77099
	increased T cell proliferation	J:77099
	small thymus	J:77099
	spleen hyperplasia	J:116157
Lat^tm1.1Lov/Lat^tm1.1Lov Lat2^tm1Wz/Lat2^tm1Wz (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:116157
	enlarged lymph nodes	J:116157
	enlarged spleen	J:116157
	increased anti-double stranded DNA antibody level	J:116157
	spleen hyperplasia	J:116157
Lat^tm1.1Mal/Lat^tm1.1Mal (involves: 129S2/SvPas)	abnormal B cell activation	J:77098
	abnormal gamma-delta T cell differentiation	J:77098
	abnormal immune serum protein physiology	J:77098
	abnormal immune system organ morphology	J:77098
	abnormal lymph node germinal center morphology	J:125722
	abnormal lymph node secondary follicle morphology	J:125722
	abnormal lymphocyte morphology	J:77098
	abnormal spleen periarteriolar lymphoid sheath morphology	J:125722
	abnormal T cell selection	J:77098
	abnormal T cell subpopulation ratio	J:77098
	abnormal T-helper 2 physiology	J:125722
	chronic inflammation	J:77098
	decreased double-positive T cell number	J:77098
	enlarged lymph nodes	J:77098
	enlarged spleen	J:77098
	glomerulonephritis	J:125722
	increased anti-chromatin antibody level	J:125722
	increased anti-erythrocyte antigen antibody level	J:125722
	increased anti-nuclear antigen antibody level	J:125722
	increased B cell number	J:77098
	increased CD4-positive, alpha-beta T cell number	J:125722, J:77098
	increased eosinophil cell number	J:77098
	increased IgE level	J:125722, J:77098
	increased IgG1 level	J:262891, J:125722, J:77098
	increased IgM level	J:125722
	increased inflammatory response	J:262891
	increased interferon-gamma secretion	J:77098
	increased interleukin-4 secretion	J:77098
	increased memory T cell number	J:77098
	increased plasma cell number	J:125722
	increased spleen germinal center number	J:125722
	increased spleen weight	J:262891
	increased susceptibility to autoimmune hemolytic anemia	J:125722
	increased T cell proliferation	J:77098
	increased T-helper 2 cell number	J:77098
	kidney inflammation	J:262891
	liver inflammation	J:125722
	lung inflammation	J:125722
	pancreas inflammation	J:262891
	phlebitis	J:262891
	salivary gland inflammation	J:262891
	spleen hyperplasia	J:77098
	thymus hypoplasia	J:77098
Lat^tm1.1Mal/Lat^tm1.1Mal (involves: 129S2/SvPas * C57BL/6)	abnormal T cell proliferation	J:131351
Lat^tm1.1Mal/Lat^tm1.1Mal (involves: 129S2/SvPas * C57BL/6)	abnormal T-helper 2 physiology	J:131351
Lat^tm1.1Mal/Lat^{tm6.1(HBEGF/EGFP)Mal} (involves: 129S2/SvPas * C57BL/6)	abnormal T-helper 2 physiology	J:151840
Lat^tm1Bpay/Lat^tm1Bpay (involves: 129S2/SvPas)	abnormal T cell differentiation	J:103904
	arrested T cell differentiation	J:103904
	decreased double-negative T cell number	J:103904
	decreased T cell number	J:103904
	decreased thymocyte number	J:103904
	immune system phenotype	J:103904
	small thymus	J:103904
Lat^tm1Les/Lat^tm1.1Wz (involves: C57BL/6)	abnormal effector T cell morphology	J:147946
Lat^tm1Les/Lat^tm1.1Wz Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	abnormal effector T cell morphology	J:147946
	abnormal T cell differentiation	J:147946
	abnormal T cell physiology	J:147946
	decreased CD4-positive, alpha-beta T cell number	J:147946
	decreased CD8-positive, alpha-beta T cell number	J:147946
	decreased regulatory T cell number	J:147946
	decreased thymocyte number	J:147946
	increased double-positive T cell number	J:147946
	increased gamma-delta T cell number	J:147946
	small thymus	J:147946
Lat^tm1Les/Lat^tm1.2Wz (involves: C57BL/6 * FVB/N)	absent T cells	J:147946
Lat^tm1Les/Lat^tm1.2Wz (involves: C57BL/6 * FVB/N)	arrested T cell differentiation	J:147946
Lat^tm1Les/Lat^tm1Les (Not Specified)	abnormal T cell morphology	J:54059
	arrested T cell differentiation	J:116964, J:54059
	decreased double-negative T cell number	J:54059
	decreased T cell number	J:54059
	decreased thymocyte number	J:54059
	small thymus	J:54059
Lat^tm1Les/Lat^tm1Les Lat2^tm1Wz/Lat2^tm1Wz (involves: C57BL/6)	abnormal mast cell physiology	J:93951
Lat^tm1Les/Lat^tm1Les Lcp2^{tm5(Lat/Lcp2)Gak}/Lcp2^{tm5(Lat/Lcp2)Gak} (involves: 129S1/Sv * 129X1/SvJ)	arrested T cell differentiation	J:147721
	decreased double-positive T cell number	J:147721
Lat^tm1Les/Lat^tm1Les Tg(CD2-LAT2)1Wz/0 (Not Specified)	abnormal B cell physiology	J:116964
	abnormal interferon secretion	J:116964
	abnormal interleukin secretion	J:116964
	abnormal leukocyte physiology	J:116964
	abnormal single-positive T cell number	J:116964
	abnormal spleen periarteriolar lymphoid sheath morphology	J:116964
	abnormal T cell differentiation	J:116964
	decreased double-positive T cell number	J:116964
	enlarged spleen	J:116964
	increased IgG1 level	J:116964
	increased IgM level	J:116964
	increased interleukin-4 secretion	J:116964
	increased interleukin-10 secretion	J:116964
	small thymus	J:116964
	spleen hyperplasia	J:116964
Lat^tm2.1Lov/Lat^tm2.1Lov (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)	abnormal T cell differentiation	J:77695
	decreased T cell number	J:77695
	small thymus	J:77695
Lat^tm2.1Mal/Lat^tm2.1Mal (involves: 129S2/SvPas)	abnormal B cell activation	J:94074
	abnormal B cell differentiation	J:94074
	abnormal gamma-delta T cell differentiation	J:94074
	abnormal immune system organ morphology	J:94074
	abnormal lymphocyte morphology	J:94074
	abnormal lymphopoiesis	J:94074
	abnormal mature gamma-delta T cell morphology	J:94074
	abnormal plasma cell morphology	J:94074
	abnormal spleen morphology	J:94074
	abnormal spleen periarteriolar lymphoid sheath morphology	J:94074
	abnormal spleen white pulp morphology	J:94074
	abnormal T cell activation	J:94074
	abnormal T-helper 2 cell morphology	J:94074
	abnormal thymocyte activation	J:94074
	absent CD4-positive, alpha-beta T cells	J:94074
	absent CD8-positive, alpha-beta T cells	J:94074
	arrested T cell differentiation	J:94074
	decreased double-positive T cell number	J:94074
	enlarged lymph nodes	J:94074
	enlarged spleen	J:94074
	increased B cell number	J:94074
	increased IgE level	J:94074
	increased IgG1 level	J:94074
	increased immunoglobulin level	J:94074
	increased interleukin-4 secretion	J:94074
	increased mature gamma-delta T cell number	J:94074
	thymus hypoplasia	J:94074
Lat^tm2.1Mal/Lat^tm2.1Mal Lat2^tm1Mal/Lat2^tm1Mal (involves: 129S2/SvPas)	abnormal mast cell physiology	J:93950
Lat^tm3.1Mal/Lat^tm3.1Mal (involves: 129S2/SvPas)	abnormal gamma-delta T cell differentiation	J:94074
	abnormal lymph node cell ratio	J:94074
	abnormal splenic cell ratio	J:94074
	abnormal thymocyte activation	J:94074
	abnormal thymus cell ratio	J:94074
	absent CD4-positive, alpha-beta T cells	J:94074
	absent CD8-positive, alpha-beta T cells	J:94074
	absent mature gamma-delta T cells	J:94074
	arrested T cell differentiation	J:94074
	decreased double-positive T cell number	J:94074
	decreased T cell number	J:94074
	increased T cell number	J:94074
Lat^tm4.1Mal/Lat^tm4.1Mal (involves: 129P2/OlaHsd)	abnormal gamma-delta T cell differentiation	J:94074
	abnormal lymph node cell ratio	J:94074
	abnormal lymphocyte morphology	J:94074
	abnormal splenic cell ratio	J:94074
	abnormal thymocyte activation	J:94074
	abnormal thymus cell ratio	J:94074
	absent CD4-positive, alpha-beta T cells	J:94074
	absent CD8-positive, alpha-beta T cells	J:94074
	absent mature gamma-delta T cells	J:94074
	arrested T cell differentiation	J:94074
	decreased double-positive T cell number	J:94074
	decreased T cell number	J:94074
Lat^tm4.1Mal/Lat^tm4.1Mal Tg(LckF505)3073Rmp/? (involves: 129P2/OlaHsd C57BL/6 * DBA/2)	abnormal T-helper 2 physiology	J:151840
	increased CD4-positive, alpha-beta T cell number	J:151840
	increased IgE level	J:151840
	increased IgG1 level	J:151840
	increased interleukin-4 secretion	J:151840
	spleen hyperplasia	J:151840
Lat^tm4.1Mal/Lat^tm4.1Mal Trdc^tm1Mal/Trdc^tm1Mal (involves: 129P2/OlaHsd * C57BL/6)	abnormal double-negative T cell morphology	J:112658
Lat^tm4.1Mal/Lat^{tm6.1(HBEGF/EGFP)Mal} (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)	abnormal T-helper 2 physiology	J:151840
Lat^tm5.1Mal/Lat^tm5.1Mal (involves: C57BL/6)	arrested T cell differentiation	J:152363
Lat^{tm6.1(HBEGF/EGFP)Mal}/? Rag2^tm1Fwa/Rag2^tm1Fwa Tg(TcraH-Y,TcrbH-Y)1Pas/? (involves: 129S/SvEv * 129S2/SvPas * C57BL/6)	abnormal T cell physiology	J:138401
Lat^{tm6.1(HBEGF/EGFP)Mal}/Lat^{tm6.1(HBEGF/EGFP)Mal} (involves: 129S2/SvPas * C57BL/6)	abnormal T cell activation	J:151840
	abnormal T-helper 2 physiology	J:151840
	decreased interferon-gamma secretion	J:151840
Lat^{tm8.1(CD2,-ECFP)Mal}/Lat^{tm8.1(CD2,-ECFP)Mal} (involves: 129S2/SvPas * C57BL/6)	abnormal lymphocyte morphology	J:152149
	abnormal T cell receptor delta chain V(D)J recombination	J:152149
	abnormal T cell receptor gamma chain V-J recombination	J:152149
	arrested T cell differentiation	J:152149
	increased double-negative T cell number	J:152149
Lat^tm9Mal/Lat^tm9Mal (involves: C57BL/6)	abnormal B cell number	J:205441
	abnormal immune system morphology	J:205441
	abnormal immune system physiology	J:205441
	abnormal lymphopoiesis	J:205441
	increased T-helper 2 cell number	J:205441
Lat^tm9Mal/Lat^tm9Mal Carmil2^bas/Carmil2^bas (involves: C3HeB/FeJ * C57BL/6)	immune system phenotype	J:205441
Lax1^tm1Wz/Lax1^tm1Wz (involves: C57BL/6)	abnormal B cell calcium ion homeostasis	J:98403
	abnormal B cell physiology	J:98403
	abnormal spleen germinal center morphology	J:98403
	abnormal splenic cell ratio	J:98403
	abnormal T cell activation	J:98403
	abnormal T cell physiology	J:98403
	increased IgE level	J:98403
	increased IgG1 level	J:98403
	increased IgG2a level	J:98403
Layn^em1Romd/Layn^em1Romd Tg(Cd8a-cre,-GFP)1Yzo/0 (involves: C57BL/6)	abnormal CD8-positive, alpha-beta T cell physiology	J:302853
	immune system phenotype	J:302853
Lbca1^C57BL/6Igc/Lbca1^C57BL/6Igc (involves: BALB/cIgc * C57BL/6Igc)	abnormal B cell activation	J:139348
	increased B cell proliferation	J:139348
Lbca2^BALB/cIgc/Lbca2^C57BL/6Igc (involves: BALB/cIgc * C57BL/6Igc)	abnormal B cell activation	J:139348
	increased B cell proliferation	J:139348
Lbca2^C57BL/6Igc/Lbca2^C57BL/6Igc (involves: BALB/cIgc * C57BL/6Igc)	abnormal B cell activation	J:139348
	increased B cell proliferation	J:139348
Lbp^{tm1b(EUCOMM)Hmgu}/Lbp^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Lbp^{tm1b(EUCOMM)Hmgu}/H)	decreased eosinophil cell number	J:211773
	increased spleen weight	J:211773
Lbp^tm1Buru/Lbp^tm1Buru (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal immune serum protein physiology	J:44878
	decreased tumor necrosis factor secretion	J:44878
Lbp^tm1Buru/Lbp^tm1Buru (involves: 129S1/Sv * 129X1/SvJ * BALB/c)	decreased susceptibility to type I hypersensitivity reaction	J:67090
Lbp^tm1Buru/Lbp^tm1Buru (B6.129-Lbp^tm1Buru)	abnormal acute inflammation	J:129411
	abnormal chemokine level	J:129411
	abnormal innate immunity	J:129411
	abnormal neutrophil physiology	J:129411
	abnormal tumor necrosis factor secretion	J:129411
Lbp^tm1Jack/Lbp^tm1Jack (involves: 129P2/OlaHsd * BALB/c)	increased susceptibility to bacterial infection	J:43514
Lbr^em1(IMPC)Tcp/Lbr^em1(IMPC)Tcp (C57BL/6N-Lbr^em1(IMPC)Tcp/Tcp)	decreased lymphocyte cell number	J:211773
	enlarged lymph nodes	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Lbr^Gt(XE569)Byg/Lbr^Gt(XE569)Byg (involves: 129P2/OlaHsd * C57BL/6Cr)	abnormal granulocyte differentiation	J:138854
	abnormal granulocyte morphology	J:138854
	abnormal lymphocyte morphology	J:138854
	abnormal neutrophil morphology	J:138854
	enlarged lymph nodes	J:138854
Lbr^ic-2J/Lbr^ic-2J (involves: A/J)	abnormal immune system cell morphology	J:80915
Lbr^ic-3J/Lbr^ic-3J (involves: A/J)	abnormal immune system cell morphology	J:80915
Lbr^ic-J/Lbr⁺ (C57BL/6J-Lbr^ic-J)	abnormal granulocyte morphology	J:80915
Lbr^ic-J/Lbr⁺ ((NZW/LacJ x C57BL/6J-Lbr^ic-J/J)F1)	abnormal neutrophil morphology	J:234168
	enlarged spleen	J:234168
	increased anti-chromatin antibody level	J:234168
	increased anti-nuclear antigen antibody level	J:234168
	increased autoantibody level	J:234168
	increased susceptibility to systemic lupus erythematosus	J:234168
Lbr^ic-J/Lbr⁺ Tm7sf2^tm1Fdp/Tm7sf2^tm1Fdp (involves: 129S4/SvJae * C57BL/6)	abnormal spleen morphology	J:143838
Lbr^ic-J/Lbr^ic-J (C57BL/6J-Lbr^ic-J)	abnormal eosinophil morphology	J:80915
	abnormal lymphocyte morphology	J:80915
	abnormal neutrophil morphology	J:80915
Lbr^ic-J/Lbr^ic-J (involves: 129S4/SvJae * C57BL/6)	abnormal neutrophil differentiation	J:143838
Lbr^ic-J/Lbr^ic-J (involves: 129S4/SvJae * C57BL/6)	abnormal spleen morphology	J:143838
Lbr^ic-J/Lbr^lym3 (C57BL/6-Lbr^ic-J/Lbr^lym3)	decreased leukocyte cell number	J:180355
Lbr^ic-J/Lbr^lym3 (C57BL/6-Lbr^ic-J/Lbr^lym3)	decreased lymphocyte cell number	J:180355
Lbr^lym3/Lbr⁺ (C57BL/6-Lbr^lym3)	abnormal neutrophil morphology	J:180355
Lbr^lym3/Lbr^lym3 (C57BL/6-Lbr^lym3)	abnormal B cell physiology	J:180355
	abnormal lymphocyte cell number	J:180355
	abnormal lymphocyte morphology	J:180355
	abnormal neutrophil morphology	J:180355
	abnormal T cell physiology	J:180355
	decreased B cell number	J:180355
	decreased CD4-positive, alpha-beta T cell number	J:180355
	decreased CD8-positive, alpha-beta T cell number	J:180355
	decreased leukocyte cell number	J:180355
	decreased lymphocyte cell number	J:180355
	decreased T cell number	J:180355
	decreased T cell proliferation	J:180355
	lymph node hypoplasia	J:180355
	spleen hypoplasia	J:180355
	thymus hypoplasia	J:180355
Lbw2^NZB/BlScr/Lbw2^NZB/BlScr (involves: NZB * NZW)	glomerulonephritis	J:45708
	increased anti-chromatin antibody level	J:98150
	increased autoantibody level	J:98150
	increased spleen weight	J:98150
Lbw2^NZB/BlScr/Lbw2^NZW/LacScr (involves: NZB * NZW)	glomerulonephritis	J:20991
	increased anti-chromatin antibody level	J:98150
	increased autoantibody level	J:98150
Lbw2^NZW/LacScr/Lbw2^NZW/LacScr (involves: NZB * NZW)	decreased autoantibody level	J:98150
	decreased IgG level	J:98150
	decreased IgM level	J:98150
Lbw4^NZW/LacScr/? (involves: C57BL/6J * NZM2410/Aeg)	decreased immunoglobulin level	J:52863
Lbw5^NZW/LacScr/Lbw5^NZB/BlScr (involves: NZB/BlScr * NZW/LacScr)	increased susceptibility to systemic lupus erythematosus	J:20991
Lbw5^NZW/LacScr/Lbw5^NZW/LacScr (involves: NZB/BlScr * NZW/LacScr)	increased susceptibility to systemic lupus erythematosus	J:20991
Lbw6^NZW/LacScr/Lbw6^NZW/LacScr (involves: NZB/BlScr * NZW/LacScr)	increased susceptibility to systemic lupus erythematosus	J:20991
Lbw7^NZB/BlScr/Lbw7^NZB/BlScr (involves: NZB/BlScr * NZW/LacScr)	increased susceptibility to systemic lupus erythematosus	J:20991
Lbw7^NZB/BlScr/Lbw7^NZW/LacScr (involves: NZB/BlScr * NZW/LacScr)	increased susceptibility to systemic lupus erythematosus	J:20991
Lbw8^NZB/BlScr/Lbw8^NZB/BlScr (involves: NZB/BlScr * NZW/LacScr)	increased susceptibility to autoimmune disorder	J:20991
Lbw8^NZB/BlScr/Lbw8^NZW/LacScr (involves: NZB/BlScr * NZW/LacScr)	increased susceptibility to autoimmune disorder	J:20991
Lck^m1Btlr/Lck^m1Btlr (C57BL/6J-Lck^m1Btlr)	abnormal CD4-positive T cell differentiation	J:144695
	abnormal CD8-positive, alpha-beta T cell differentiation	J:144695
	decreased CD4-positive, alpha-beta T cell number	J:144695
	decreased CD8-positive, alpha-beta T cell number	J:144695
	decreased cytotoxic T cell cytolysis	J:144695
	thymus atrophy	J:144695
	thymus hypoplasia	J:144695
Lck^m2Btlr/Lck^m2Btlr (C57BL/6J-Lck^m2Btlr)	decreased CD4-positive, alpha-beta T cell number	J:203759
	decreased CD8-positive, alpha-beta T cell number	J:203759
	decreased IgG level	J:203759
Lck^m3Btlr/Lck^m3Btlr (C57BL/6J-Lck^m3Btlr)	abnormal T cell subpopulation ratio	J:217863
	decreased single-positive T cell number	J:217863
	increased activated T cell number	J:217863
	increased single-positive T cell number	J:217863
Lck^tm1.1Litt/Lck^tm1.1Litt (Not Specified)	abnormal immunoglobulin level	J:152472
	abnormal lymphocyte morphology	J:152472
	abnormal thymus morphology	J:152472
Lck^tm1Dbs/Lck^tm1Dbs (involves: C3H * C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:114660
	abnormal CD8-positive, alpha beta T cell morphology	J:114660
	abnormal double-negative T cell morphology	J:114660
	abnormal T cell differentiation	J:114660
	decreased T cell number	J:114660
	decreased T cell proliferation	J:114660
	decreased thymocyte number	J:114660
Lck^tm1Dbs/Lck^tm1Dbs Tg(TcraH-Y,TcrbH-Y)71Vbo/0 (involves: C3H * C57BL/6 * DBA/2J)	abnormal positive T cell selection	J:114660
	abnormal T cell differentiation	J:114660
	arrested T cell differentiation	J:114660
Lck^tm1Dbs/Lck^tm1Dbs Tg(TcraTcrb)425Cbn/0 (involves: C3H * C57BL/6)	abnormal positive T cell selection	J:114660
	arrested T cell differentiation	J:114660
Lck^tm1Dbs/Lck^tm1Dbs Tg(TcraTcrb)1100Mjb/0 (involves: C3H * C57BL/6)	abnormal positive T cell selection	J:114660
	decreased T cell proliferation	J:114660
Lck^tm1Litt/Lck^tm1.1Litt Tnfrsf4^tm2(cre)Nik/Tnfrsf4⁺ (involves: 129X1/SvJ)	abnormal regulatory T cell physiology	J:152472
	decreased regulatory T cell number	J:152472
	decreased T cell proliferation	J:152472
	enlarged lymph nodes	J:152472
	increased regulatory T cell number	J:152472
	increased T cell number	J:152472
Lck^tm1Mak/Lck^tm1Mak (involves: 129S2/SvPas)	abnormal alpha-beta intraepithelial T cell morphology	J:112977
	abnormal double-negative T cell morphology	J:110847
	abnormal lymphocyte morphology	J:1119
	abnormal single-positive T cell number	J:37062
	abnormal T cell morphology	J:110847
	abnormal thymocyte activation	J:110847
	decreased CD4-positive, alpha-beta T cell number	J:37940
	decreased CD8-positive, alpha-beta T cell number	J:37940
	decreased double-positive T cell number	J:1119, J:110847
	decreased gamma-delta intraepithelial T cell number	J:112977, J:37940
	decreased gamma-delta T cell number	J:37062
	decreased IgG1 level	J:1119
	decreased T cell number	J:1119, J:37062
	decreased thymocyte number	J:1119
	increased IgG2a level	J:1119
	increased IgG3 level	J:1119
	increased IgM level	J:1119
	thymus atrophy	J:1119
	thymus hypoplasia	J:37062, J:37940
Lck^tm1Mak/Lck^tm1Mak (B6.129S2-Lck^tm1Mak)	abnormal intraepithelial T cell morphology	J:111646
	abnormal intraepithelial T cell number	J:111646
	abnormal T cell differentiation	J:111646
	decreased cytotoxic T cell cytolysis	J:111646
	decreased gamma-delta intraepithelial T cell number	J:111646
Lck^tm1Mak/Lck^tm1Mak Rag1^tm1Mom/Rag1⁺ Tg(Lck-FynY528F)5525Cjg/0 (involves: 129S2/SvPas 129S7/SvEvBrd * C57BL/6)	abnormal T cell differentiation	J:37062
	decreased T cell number	J:37062
Lcmt1^{em1(IMPC)Rbrc}/Lcmt1⁺ (C57BL/6NJcl-Lcmt1^{em1(IMPC)Rbrc}/Rbrc)	increased large unstained cell number	J:211773
	increased spleen weight	J:211773
Lcn2^tm1Aade/Lcn2^tm1Aade (involves: 129P2/OlaHsd * C57BL/6)	increased susceptibility to bacterial infection	J:95107
	sepsis	J:95107
Lcn2^tm1Aade/Lcn2^tm1Aade (B6.129P2-Lcn2^tm1Aade)	increased spleen weight	J:169355
Lcn2^tm1Mak/Lcn2^tm1Mak (involves: 129P2/OlaHsd * C57BL/6J)	increased susceptibility to bacterial infection	J:106079
Lcn2^tm1Mrgr/Lcn2^tm1Mrgr (129(B6)-Lcn2^tm1Mrgr)	abnormal mast cell physiology	J:173490
	abnormal myelopoiesis	J:173490
	decreased thymocyte apoptosis	J:173490
	increased B cell number	J:173490
	increased leukocyte cell number	J:173490
	increased lymphocyte cell number	J:173490
	increased macrophage cell number	J:173490
	increased monocyte cell number	J:173490
	increased neutrophil cell number	J:173490
	increased splenocyte number	J:173490
	myeloid hyperplasia	J:173490
	spleen hyperplasia	J:173490
	thymus hyperplasia	J:173490
Lcn2^tm1Mrgr/Lcn2^tm1Mrgr (B6.129-Lcn2^tm1Mrgr)	abnormal mast cell physiology	J:173490
Lcn2^tm1Mrgr/Lcn2^tm1Mrgr (involves: 129 * C57BL/6)	abnormal mast cell physiology	J:173490
Lcn10^{tm1.1(KOMP)Vlcg}/Lcn10^{tm1.1(KOMP)Vlcg} (C57BL/6N-Lcn10^{tm1.1(KOMP)Vlcg}/MbpMmucd)	increased susceptibility to endotoxin shock	J:359002
Lcp1^tm1Erjb/Lcp1^tm1Erjb (involves: 129X1/SvJ)	abnormal macrophage physiology	J:161042
	abnormal neutrophil physiology	J:161042
	decreased interleukin-1 secretion	J:161042
	immune system phenotype	J:161042
	increased susceptibility to bacterial infection	J:161042
Lcp2^m1Khoe/Lcp2^m1Khoe (C57BL/6J-Lcp2^m1Khoe)	abnormal NK cell physiology	J:196519
Lcp2^m1Khoe/Lcp2^m1Khoe (C57BL/6J-Lcp2^m1Khoe)	impaired natural killer cell mediated cytotoxicity	J:196519
Lcp2^tm1.1Wz/Lcp2^tm1.1Wz (B6.Cg-Lcp2^tm1.1Wz)	abnormal effector T cell morphology	J:150304
	abnormal T cell differentiation	J:150304
	abnormal T cell subpopulation ratio	J:150304
	decreased CD4-positive, alpha-beta T cell number	J:150304
	decreased CD8-positive, alpha-beta T cell number	J:150304
	decreased double-negative T cell number	J:150304
	decreased interleukin-2 secretion	J:150304
	decreased T cell number	J:150304
	decreased T cell proliferation	J:150304
	decreased thymocyte number	J:150304
	immune system phenotype	J:150304
	increased double-negative T cell number	J:150304
	lymph node hypoplasia	J:150304
	small thymus	J:150304
Lcp2^tm1.1Wz/Lcp2^tm1.1Wz Tg(TcraH-Y,TcrbH-Y)71Vbo/0 (involves: C57BL/6 * C57BL/6J * DBA/2J)	abnormal T cell differentiation	J:150304
Lcp2^tm1Gak/Lcp2^tm2Gak Tg(Pf4-icre)Q3Rsko/0 Gt(ROSA)26Sor^tm1(EYFP)Cos/Gt(ROSA)26Sor⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal lymphatic vessel morphology	J:162815
	abnormal Peyer's patch morphology	J:162815
Lcp2^tm1Gak/Lcp2^tm2Gak Tg(VAV1-cre)1Graf/0 Gt(ROSA)26Sor^tm1(EYFP)Cos/Gt(ROSA)26Sor⁺ (involves: 129S1/Sv * 129X1/SvJ)	abnormal lymphatic vessel morphology	J:162815
Lcp2^tm1Geha/Lcp2^tm1Geha (involves: 129S4/SvJae)	decreased interferon-gamma secretion	J:131621
	impaired natural killer cell mediated cytotoxicity	J:131621
	increased NK cell number	J:131621
Lcp2^tm2Gak/Lcp2^tm2Gak Tg(Cd4-cre)1Cwi/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)	decreased CD4-positive, alpha-beta T cell number	J:107467
	decreased T cell apoptosis	J:107467
	increased CD8-positive, alpha-beta T cell number	J:107467
	increased gamma-delta T cell number	J:107467
	thymus hypoplasia	J:107467
Lcp2^tm3Gak/Lcp2^tm3Gak (involves: 129S6/SvEvTac * C57BL/6)	abnormal double-negative T cell morphology	J:132995
	abnormal negative T cell selection	J:132995
	abnormal T cell activation	J:132995
	abnormal T cell subpopulation ratio	J:132995
	decreased NK T cell number	J:132995
Lcp2^tm3Gak/Lcp2^tm3Gak (involves: 129S6/SvEvTac * BALB/c * C57BL/6)	abnormal negative T cell selection	J:132995
Lcp2^tm3Gak/Lcp2^tm3Gak Tg(TcraH-Y,TcrbH-Y)71Vbo/? (involves: 129S6/SvEvTac * C57BL/6 * DBA/2J)	abnormal negative T cell selection	J:132995
	immune system phenotype	J:132995
	increased CD8-positive, alpha-beta T cell number	J:132995
	increased double-positive T cell number	J:132995
Lcp2^tm3Gak/Lcp2^tm3Gak Tg(TcrAND)53Hed/? (involves: 129S6/SvEvTac * C57BL/6 * SJL)	abnormal positive T cell selection	J:132995
	abnormal thymocyte activation	J:132995
Lcp2^tm3Gak/Lcp2^tm4Gak (involves: 129S6/SvEvTac * C57BL/6 * FVB/N)	immune system phenotype	J:132995
Lcp2^tm4Gak/Lcp2^tm4Gak (involves: 129S6/SvEvTac * C57BL/6 * FVB/N)	abnormal double-negative T cell morphology	J:132995
	abnormal negative T cell selection	J:132995
	abnormal T cell activation	J:132995
	abnormal T cell subpopulation ratio	J:132995
	decreased NK T cell number	J:132995
Lcp2^tm4Gak/Lcp2^tm4Gak (involves: 129S6/SvEvTac * BALB/c * C57BL/6)	abnormal negative T cell selection	J:132995
Lcp2^tm4Gak/Lcp2^tm4Gak Tg(TcraH-Y,TcrbH-Y)71Vbo/? (involves: 129S6/SvEvTac * C57BL/6 * DBA * FVB/N)	abnormal negative T cell selection	J:132995
	increased double-positive T cell number	J:132995
Lcp2^tm4Gak/Lcp2^tm4Gak Tg(TcrAND)53Hed/? (involves: 129S6/SvEvTac * C57BL/6 * SJL)	abnormal positive T cell selection	J:132995
	abnormal thymocyte activation	J:132995
Lcp2^{tm5(Lat/Lcp2)Gak}/Lcp2^{tm5(Lat/Lcp2)Gak} (involves: 129S1/Sv * 129X1/SvJ)	abnormal thymocyte activation	J:147721
	arrested T cell differentiation	J:147721
	decreased double-positive T cell number	J:147721
	decreased single-positive T cell number	J:147721
	thymus hypoplasia	J:147721
Lcp2^twm/Lcp2^twm (C57BL/6JSfdAnu-Lcp2^twm/Anu)	abnormal double-positive T cell morphology	J:104190
	abnormal negative T cell selection	J:104190
	abnormal positive T cell selection	J:104190
	abnormal T cell physiology	J:104190
	arrested T cell differentiation	J:104190
	autoimmune response	J:104190
	decreased T cell number	J:104190
	decreased thymocyte number	J:104190
	increased IgE level	J:104190
	increased IgG level	J:104190
Lctlp1^DBA/1J/Lctlp1^DBA/1J (involves: DBA/1J * FVB/NJ)	increased CD8-positive, alpha-beta T cell number	J:122919
Lctlp1^DBA/1J/Lctlp1^FVB/NJ (involves: DBA/1J * FVB/NJ)	increased CD8-positive, alpha-beta T cell number	J:122919
Lctlp1^FVB/NJ/Lctlp1^FVB/NJ (involves: DBA/1J * FVB/NJ)	increased susceptibility to induced arthritis	J:122919
Lctlp2^DBA/1J/Lctlp2^DBA/1J (involves: DBA/1J * FVB/NJ)	increased CD8-positive, alpha-beta T cell number	J:122919
Lctlp2^DBA/1J/Lctlp2^FVB/NJ (involves: DBA/1J * FVB/NJ)	increased CD8-positive, alpha-beta T cell number	J:122919
Lctlp2^FVB/NJ/Lctlp2^FVB/NJ (involves: DBA/1J * FVB/NJ)	increased susceptibility to induced arthritis	J:122919
Ldb3^{tm2b(EUCOMM)Hmgu}/Ldb3⁺ (C57BL/6N-Ldb3^{tm2b(EUCOMM)Hmgu}/Bay)	increased basophil cell number	J:211773
	increased large unstained cell number	J:211773
Ldha^a-m1Neu/Ldha^a-m1Neu (involves: 101/El * C3H/El)	abnormal leukocyte morphology	J:132674
	increased neutrophil cell number	J:132674
	increased spleen weight	J:132674
	spleen hyperplasia	J:132674
Ldlr^Hlb301/Ldlr⁺ (C57BL/6J-Ldlr^Hlb301/J)	increased macrophage derived foam cell number	J:82961
Ldlr^Hlb301/Ldlr^Hlb301 (C57BL/6J-Ldlr^Hlb301/J)	increased macrophage derived foam cell number	J:82961
Ldlr^tm1Her/Ldlr^tm1Her (involves: 129S7/SvEvBrd * C57BL/6)	abnormal microglial cell morphology	J:116493
Ldlr^tm1Her/Ldlr^tm1Her (involves: 129S7/SvEvBrd * C57BL/6)	liver inflammation	J:175559
Ldlr^tm1Her/Ldlr^tm1Her (B6.129S7-Ldlr^tm1Her)	abnormal microglial cell morphology	J:137264
	decreased circulating interleukin-10 level	J:130794
	increased circulating interleukin-1 beta level	J:137264
	increased circulating interleukin-6 level	J:137264
	increased circulating tumor necrosis factor level	J:137264
Ldlr^tm1Her/Ldlr^tm1Her Lrp1^tm2Her/Lrp1^tm2Her Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * 129S7/SvEvBrd)	impaired macrophage phagocytosis	J:137404
Ldlr^tm1Her/Ldlr^tm1Her Lrp1^tm2Her/Lrp1^tm2Her Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J)	abnormal microglial cell physiology	J:144185
Ldlr^tm1Her/Ldlr^tm1Her Mapkapk2^tm1Mgl/Mapkapk2^tm1Mgl (involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6)	abnormal macrophage derived foam cell morphology	J:142788
	decreased macrophage cell number	J:142788
Ldlr^tm1Her/Ldlr^tm1Her Olr1^tm1Meht/Olr1^tm1Meht (involves: 129S7/SvEvBrd * 129X1/SvJ * C57BL/6)	increased circulating interleukin-10 level	J:130794
Ldlr^tm1Her/Ldlr^tm1Her Pfn1^tm1Wit/Pfn1⁺ (B6.129S-Ldlr^tm1Her Pfn1^tm1Wit)	impaired macrophage chemotaxis	J:140294
Ldlr^tm1Her/Ldlr^tm1Her Soat1^tm1Far/Soat1^tm1Far (involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6J)	skin inflammation	J:61147
Ldlr^tm1Her/Ldlr^tm1Her Tbx21^tm1Glm/Tbx21^tm1Glm (involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6)	abnormal interleukin secretion	J:96110
	decreased IgG level	J:96110
	decreased interferon-gamma secretion	J:96110
	increased IgM level	J:96110
Ldlr^tm1Her/Ldlr^tm1Her Tcra-J^tm1Tgi/Tcra-J^tm1Tgi (B6.129-Ldlr^tm1Her Tcra-J^tm1Tgi)	decreased interferon-gamma secretion	J:140276
Ldlr^tm1Her/Ldlr^tm1Her Tg(H2-K-AKR1B1)1Tj/0 (involves: 129S7/SvEvBrd * C57BL/6 * DBA/2)	abnormal macrophage physiology	J:100916
Ldlr^tm1Her/Ldlr^tm1Her Tlr2^tm1Kir/Tlr2^tm1Kir (B6.129-Tlr2^tm1Kir Ldlr^tm1Her)	abnormal cellular extravasation	J:131783
	decreased tumor necrosis factor secretion	J:131783
Ldlr^tm1Her/Ldlr^tm1Her Vwf^tm1Wgr/Vwf^tm1Wgr (B6.129S-Vwf^tm1Wgr Ldlr^tm1Her)	impaired leukocyte tethering or rolling	J:106677
Ldlrad3^em1Diam/Ldlrad3^em1Diam (C57BL/6-Ldlrad3^em1Diam)	decreased susceptibility to Togaviridae infection	J:300132
Ldlrad3^em1Diam/Ldlrad3^em2Diam (C57BL/6-Ldlrad3^em1Diam Ldlrad3^em2Diam)	decreased susceptibility to Togaviridae infection	J:300132
Ldlrad3^em2Diam/Ldlrad3^em2Diam (C57BL/6-Ldlrad3^em2Diam)	decreased susceptibility to Togaviridae infection	J:300132
Ldlrad4^{tm1b(EUCOMM)Wtsi}/Ldlrad4^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Ldlrad4^{tm1b(EUCOMM)Wtsi}/Wtsi)	decreased monocyte cell number	J:211773
Lect2^tm1Ymg/Lect2^tm1Ymg (involves: 129P2/OlaHsd * C57BL/6J)	abnormal cytokine secretion	J:90961
	abnormal leukocyte physiology	J:90961
	increased T cell apoptosis	J:90961
	increased T cell number	J:90961
	liver inflammation	J:90961
Lef1^{tm1.1(KOMP)Vlcg}/Lef1⁺ (C57BL/6N-Lef1^{tm1.1(KOMP)Vlcg}/Ucd)	increased monocyte cell number	J:211773
Lef1^tm1Hhx/Lef1^tm1Hhx Tcf7^tm1Cle/Tcf7^tm1Cle Gt(ROSA)26Sor^tm2Sho/Gt(ROSA)26Sor⁺ Tg(GZMB-cre)1Jcb/0 (involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6 * FVB/N)	abnormal memory T cell physiology	J:189838
	decreased CD8-positive, alpha-beta T cell number	J:189838
	decreased tumor necrosis factor secretion	J:189838
Lef1^tm1Rug/Lef1^tm1Rug (involves: 129S2/SvPas * C57BL/6)	immune system phenotype	J:18378
Lefty2^tm2Hmd/Lefty2^tm2Hmd (involves: 129P2/OlaHsd * C57BL/6)	accessory spleen	J:70483
Lemd2^em1(IMPC)Bay/Lemd2⁺ (C57BL/6N-Lemd2^em1(IMPC)Bay/Bay)	abnormal spleen morphology	J:211773
Lep^m1Yst/Lep^m1Yst (C57BL/6J-Lep^m1Yst)	increased macrophage cell number	J:167736
Lep^ob/Lep^ob (involves: C57BL/6J)	abnormal osteoclast differentiation	J:60001
Lep^ob/Lep^ob (B6.Cg-Lep^ob/J)	decreased NK cell number	J:117826
Lep^ob/Lep^ob (B6.Cg-Lep^ob/J)	lung inflammation	J:115772
Lep^ob/Lep^ob (B6.Cg-Lep^ob/OlaHsd)	abnormal acute inflammation	J:124815
	abnormal chemokine secretion	J:124815
	increased interleukin-6 secretion	J:124815
	increased susceptibility to endotoxin shock	J:124815
	liver inflammation	J:124815
Lep^ob/Lep^ob (involves: STOCK Mlph^ln a Tgfa^wa1 Cdh23^v Ednrb^s)	abnormal microglial cell physiology	J:115569
	decreased circulating tumor necrosis factor level	J:115569
Lep^ob/Lep^ob (involves: C57BL/6)	decreased CD4-positive, alpha-beta T cell number	J:164339
	decreased splenocyte number	J:164339
	decreased T cell proliferation	J:164339
Lep^ob/Lep^ob (B6.Cg-Lep^ob/JRj)	liver inflammation	J:277927
Lep^ob/Lep^ob Serpine1^tm1Mlg/Serpine1^tm1Mlg (involves: 129S2/SvPas * C57BL/6)	abnormal tumor necrosis factor level	J:70695
Lep^{tm1b(EUCOMM)Hmgu}/Lep^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Lep^{tm1b(EUCOMM)Hmgu}/Bay)	decreased spleen weight	J:211773
Lepr^db-5J/Lepr^db-5J (NOD/ShiLt-Lepr^db-5J)	abnormal CD4-positive, alpha beta T cell morphology	J:118304
	abnormal CD8-positive, alpha beta T cell morphology	J:118304
	pancreas inflammation	J:118305
	periinsulitis	J:118305
Lepr^db-lb/Lepr^db-lb (C57BL/6NCrl-Lepr^db-lb/Crl)	white adipose tissue inflammation	J:171755
Lepr^db-Pas/Lepr^db-Pas (involves: DW/Pas)	enlarged spleen	J:174584
Lepr^db/Lepr^db (involves: C57BLKS/J)	increased susceptibility to autoimmune diabetes	J:7005
Lepr^db/Lepr^db (B6.Cg-Dock7^m +/+ Lepr^db/J)	abnormal chemokine level	J:115772
	abnormal interleukin level	J:115772
	abnormal leukocyte morphology	J:115772
	decreased leukocyte cell number	J:115772
	increased circulating interleukin-6 level	J:115772
	increased neutrophil cell number	J:115772
	lung inflammation	J:115772
Lepr^db/Lepr^db (BKS.Cg-Dock7^m +/+ Lepr^db/OlaHsd)	abnormal acute inflammation	J:124815
	abnormal chemokine secretion	J:124815
	increased interleukin-6 secretion	J:124815
	increased susceptibility to endotoxin shock	J:124815
	liver inflammation	J:124815
Lepr^db/Lepr^db (involves: C57BL/6)	abnormal osteoclast differentiation	J:60001
Lepr^db/Lepr^db (B6.BKS(D)-Lepr^db/JOrlRj)	liver inflammation	J:277927
Lepr^db/Lepr^db (BKS.Cg-Dock7^m +/+ Lepr^db)	kidney inflammation	J:346348
Lepr^m7Btlr/Lepr^m7Btlr (C57BL/6J-Lepr^m7Btlr)	decreased response to antigen	J:236685
Lepr^m7Btlr/Lepr^m7Btlr (C57BL/6J-Lepr^m7Btlr)	increased IgE level	J:236685
Lepr^m8Btlr/Lepr^m8Btlr (C57BL/6J-Lepr^m8Btlr)	decreased CD8-positive, naive alpha-beta T cell number	J:267679
	increased effector memory CD4-positive, alpha-beta T cell number	J:267679
	increased effector memory CD8-positive, alpha-beta T cell number	J:267679
Lepr^tm1.1Rll/Lepr⁺ (129P3/J-Lepr^tm1.1Rll)	increased susceptibility to parasitic infection	J:172012
Lepr^tm1.1Rll/Lepr^tm1.1Rll (129P3/J-Lepr^tm1.1Rll)	increased susceptibility to parasitic infection	J:172012
Lepr^{tm1b(EUCOMM)Wtsi}/Lepr^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Lepr^{tm1b(EUCOMM)Wtsi}/H)	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
	decreased spleen weight	J:211773
	increased eosinophil cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Lepr^tm4Mgmj/Lepr^tm4Mgmj (B6.Cg-Lepr^tm4Mgmj)	decreased CD4-positive, alpha-beta T cell number	J:164339
	decreased splenocyte number	J:164339
	decreased T cell proliferation	J:164339
Leprot^tm1.2Damj/Leprot^tm1.2Damj (involves: 129S2/SvPas * C57BL/6N * FVB/N)	decreased cytokine level	J:349250
	decreased inflammatory response	J:349250
Lgals1^tm1Rob/Lgals1^tm1Rob (involves: 129S/SvEv)	increased interferon-gamma secretion	J:123416
	increased interleukin-2 secretion	J:123416
	increased susceptibility to experimental autoimmune encephalomyelitis	J:123416
Lgals1^tm1Rob/Lgals1^tm1Rob (involves: 129S/SvEv * 129S1/SvImJ * DBA/2J)	abnormal cytokine secretion	J:130208
Lgals2^tm1.1Cfg/Lgals2^tm1.1Cfg (involves: C57BL/6)	abnormal immune system physiology	J:217719
	decreased neutrophil cell number	J:217719
	enhanced humoral immune response	J:217719
	increased CD4-positive, alpha-beta T cell number	J:217719
	increased CD8-positive, alpha-beta T cell number	J:217719
	increased IgG2b level	J:217719
	increased IgG3 level	J:217719
	increased leukocyte cell number	J:217719
	increased lymphocyte cell number	J:217719
	increased spleen red pulp amount	J:217719
	increased susceptibility to type IV hypersensitivity reaction	J:217719
	increased T cell number	J:217719
Lgals3^tm1Ftl/Lgals3^tm1Ftl (B6.129S2-Lgals3^tm1Ftl)	abnormal CD8-positive, alpha-beta cytotoxic T cell morphology	J:109126
	abnormal dendritic cell physiology	J:109126
	abnormal interferon secretion	J:109126
	abnormal response to infection	J:109126
	brain inflammation	J:109126
	decreased macrophage cell number	J:109126
	increased IgG level	J:109126
	increased interleukin-12b secretion	J:109126
	increased susceptibility to parasitic infection	J:109126
	lung inflammation	J:109126
	small intestinal inflammation	J:109126
Lgals3^tm1Ftl/Lgals3^tm1Ftl (involves: 129S2/SvPas * C57BL/6)	abnormal leukocyte physiology	J:60741
	abnormal macrophage physiology	J:60741
	abnormal monocyte morphology	J:60741
	decreased lymphocyte cell number	J:60741
	decreased macrophage cell number	J:313172, J:60741
	decreased monocyte cell number	J:60741
	increased eosinophil cell number	J:60741
	increased macrophage apoptosis	J:60741
	peritoneal inflammation	J:60741
Lgals3^tm1Ftl/Lgals3^tm1Ftl (involves: 129S2/SvPas * CD-1)	liver inflammation	J:221030
Lgals3^tm1Poi/Lgals3^tm1Poi (involves: 129/Sv * C57BL/6 * SJL)	abnormal macrophage physiology	J:131971
	impaired macrophage chemotaxis	J:131971
	impaired macrophage phagocytosis	J:131407
	impaired neutrophil recruitment	J:131407
	increased interleukin-6 secretion	J:131407
	increased susceptibility to bacterial infection	J:131407
	increased tumor necrosis factor secretion	J:131407
	lung inflammation	J:131407
	sepsis	J:131407
Lgals3^tm1Poi/Lgals3^tm1Poi (involves: 129/Sv * C57BL/6 * MF1 * SJL)	decreased granulocyte number	J:110422
Lgals3bp^tm1Megt/Lgals3bp^tm1Megt (involves: 129P2/OlaHsd * C57BL/Ka)	increased circulating interferon-gamma level	J:94936
	increased circulating interleukin-12 level	J:94936
	increased susceptibility to endotoxin shock	J:94936
	increased tumor necrosis factor secretion	J:94936
Lgals8^{tm1(KOMP)Vlcg}/Lgals8^{tm1(KOMP)Vlcg} (involves: C57BL/6NTac)	abnormal lymphangiogenesis	J:235778
	decreased susceptibility to Herpesvirales infection	J:235778
Lgals9^tm1.1Cfg/Lgals9^tm1.1Cfg (involves: C57BL/6)	abnormal lymph node germinal center morphology	J:217719
	abnormal Peyer's patch morphology	J:217719
	enhanced humoral immune response	J:217719
	increased B cell proliferation	J:217719
	increased lymphocyte cell number	J:217719
	increased neutrophil cell number	J:217719
	increased spleen germinal center size	J:217719
	lymph node hyperplasia	J:217719
	spleen hyperplasia	J:217719
	thymus hyperplasia	J:217719
Lgals9^tm1Glp/Lgals9^tm1Glp (B6.129S6-Lgals9^tm1Glp)	decreased regulatory T cell number	J:132889
	increased susceptibility to induced arthritis	J:132889
	increased T-helper 1 cell number	J:132889
Lgmn^tm1Cptr/Lgmn^tm1Cptr (B6.129S6-Lgmn^tm1Cptr)	abnormal adaptive immunity	J:155339
	decreased interleukin-6 secretion	J:155339
	decreased interleukin-12b secretion	J:155339
	decreased tumor necrosis factor secretion	J:155339
	enlarged spleen	J:172774
Lgmn^tm1Ihn/Lgmn^tm1Ihn (involves: 129P2/OlaHsd * C57BL/6)	abnormal macrophage physiology	J:143886
	abnormal NK cell physiology	J:143886
	dark spleen	J:143886
	immune system phenotype	J:143886
	increased circulating tumor necrosis factor level	J:143886
	increased lymphocyte cell number	J:143886
	increased spleen weight	J:143886
lgr/lgr (Not Specified)	eye inflammation	J:13879
Lgr4^{Gt(LST020)Byg}/Lgr4^{Gt(LST020)Byg} (involves: 129P2/OlaHsd * C57BL/6)	increased corneal pannus formation	J:134299
	increased incidence of corneal inflammation	J:134299
Lgr5^{em1(IMPC)Kmpc}/Lgr5⁺ (C57BL/6NTac-Lgr5^{em1(IMPC)Kmpc}/Kmpc)	increased CD8-positive, CD25-positive alpha-beta T cell number	J:211773
	increased CD11b-high dendritic cell number	J:211773
Lgr6^{em1(IMPC)Ccpcz}/Lgr6^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Lgr6^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
	increased lymphocyte cell number	J:211773
Lhcgr^{tm1(KOMP)Vlcg}/Lhcgr^{tm1(KOMP)Vlcg} (C57BL/6N-Lhcgr^{tm1(KOMP)Vlcg}/Nju)	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
	small spleen	J:211773
	small thymus	J:211773
Lhcgr^tm1Hht/Lhcgr^tm1Hht (involves: 129S7/SvEvBrd * C57BL/6J)	enlarged spleen	J:105533
	epididymis inflammation	J:105533
	prostate gland inflammation	J:105533
	reproductive system inflammation	J:105533
Lhx5^{em1(IMPC)Ccpcz}/Lhx5⁺ (C57BL/6N-Lhx5^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
	increased leukocyte cell number	J:211773
Lif^tm1Cgre/Lif^tm1Cgre (involves: MF1)	abnormal macrophage morphology	J:96965
	increased eosinophil cell number	J:96965
	increased uterine NK cell number	J:96965
Lif^tm1Phb/Lif⁺ (involves: 129S2/SvPas * C57BL/6 * DBA/2)	decreased T cell proliferation	J:77410
Lif^tm1Phb/Lif^tm1Phb (involves: 129S2/SvPas * C57BL/6 * DBA/2)	decreased T cell proliferation	J:77410
Lif^tm1Stw/Lif^tm1Stw (involves: 129S1/Sv * C57BL/6)	increased acute inflammation	J:119777
Lif^tm1Stw/Lif^tm1Stw (involves: 129S1/Sv * C57BL/6)	increased circulating interleukin-1 beta level	J:119777
Lif^tm1Stw/Lif^tm1Stw (involves: 129S1/Sv * BALB/c)	decreased interleukin-10 secretion	J:136940
	decreased leukocyte cell number	J:136940
	increased circulating interleukin-6 level	J:136940
	increased circulating serum amyloid protein level	J:136940
	increased circulating tumor necrosis factor level	J:136940
	increased susceptibility to bacterial infection induced morbidity/mortality	J:136940
	increased susceptibility to endotoxin shock	J:136940
Lif^tm1Stw/Lif^tm1Stw (involves: 129S1/Sv * MF1)	abnormal osteoclast differentiation	J:137646
	abnormal osteoclast morphology	J:137646
	abnormal osteoclast physiology	J:137646
	increased osteoclast cell number	J:137646
Lifr^tm1Imx/Lifr^tm1Imx (involves: 129P3/J * 129S7/SvEvBrd * C57BL/6)	increased osteoclast cell number	J:25253
Lig1^tm1Dwm/Lig1^tm1Dwm (involves: 129P2/OlaHsd)	enlarged spleen	J:75962
Lig1^tm3Dwm/Lig1^tm3Dwm (involves: 129P2/OlaHsd * C57BL/6)	abnormal spleen physiology	J:77902
	abnormal thymus physiology	J:77902
	enlarged spleen	J:77902
Lig4^{em1(IMPC)Ccpcz}/Lig4⁺ (C57BL/6NCrl-Lig4^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Lig4^m1Btlr/Lig4^m1Btlr (C57BL/6J-Lig4^m1Btlr)	decreased B cell number	J:267684
	decreased CD4-positive, alpha-beta T cell number	J:267684
	decreased CD8-positive, naive alpha-beta T cell number	J:267684
	decreased IgD level	J:267684
	decreased IgG level	J:267684
	impaired humoral immune response	J:267684
	increased CD8-positive, alpha-beta T cell number	J:267684
	increased central memory CD8 positive, alpha-beta T cell number	J:267684
	increased effector memory CD4-positive, alpha-beta T cell number	J:267684
	increased NK cell number	J:267684
Lig4^m2Btlr/Lig4^m2Btlr (C57BL/6J-Lig4^m2Btlr)	decreased CD4-positive, alpha-beta T cell number	J:267692
Lig4^m2Btlr/Lig4^m2Btlr (C57BL/6J-Lig4^m2Btlr)	increased effector memory CD4-positive, alpha-beta T cell number	J:267692
Lig4^tiny/Lig4^tiny (C57BL/6-Lig4^tiny)	absent CD8-positive, alpha-beta T cells	J:104190
	decreased B cell number	J:122725
	decreased lymphocyte cell number	J:122725
Lig4^tm1Fwa/Lig4^tm1Fwa (involves: 129S6/SvEvTac * C57BL/6)	abnormal B cell differentiation	J:50865
	abnormal lymphopoiesis	J:50865
	abnormal T cell differentiation	J:63078
	arrested B cell differentiation	J:63078
	arrested T cell differentiation	J:50865
	decreased thymocyte number	J:63078
	small thymus	J:50865
Lig4^tm1Fwa/Lig4^tm1Fwa Tg(Cr2-cre)3Cgn/0 Xrcc4^tm2Fwa/Xrcc4^tm2Fwa (involves: 129S6/SvEvTac)	abnormal class switch recombination	J:126758
Lig4^tm1Fwa/Lig4^tm1Fwa Trp53^tm1Brd/Trp53^tm1Brd (involves: 129S6/SvEvTac * 129S7/SvEvBrd)	decreased thymocyte number	J:63078
	increased B cell number	J:63078
Lig4^tm2.1Fwa/Lig4^tm2.1Fwa (involves: 129S6/SvEvTac)	abnormal B cell activation	J:157574
	abnormal B cell differentiation	J:157574
	abnormal immune system cell morphology	J:157574
	abnormal immune system morphology	J:157574
	abnormal immune system organ morphology	J:157574
	abnormal immune system physiology	J:157574
	abnormal lymphocyte cell number	J:157574
	abnormal regulatory T cell morphology	J:157574
	abnormal T cell activation	J:157574
	abnormal T cell differentiation	J:157574
	abnormal T cell receptor beta chain V(D)J recombination	J:157574
	abnormal T cell receptor V(D)J recombination	J:157574
	abnormal thymus morphology	J:157574
	decreased B cell number	J:157574
	decreased CD4-positive, alpha-beta T cell number	J:157574
	decreased CD8-positive, alpha-beta T cell number	J:157574
	decreased double-negative T cell number	J:157574
	decreased double-positive T cell number	J:157574
	decreased IgA level	J:157574
	decreased IgG2b level	J:157574
	decreased IgG3 level	J:157574
	decreased IgG level	J:157574
	decreased IgM level	J:157574
	decreased immunoglobulin level	J:157574
	decreased interferon-gamma secretion	J:157574
	decreased interleukin-13 secretion	J:157574
	decreased spleen weight	J:157574
	decreased splenocyte number	J:157574
	decreased T cell proliferation	J:157574
	decreased thymocyte number	J:157574
	decreased thymus weight	J:157574
	increased anti-chromatin antibody level	J:157574
	increased anti-double stranded DNA antibody level	J:157574
	increased T cell apoptosis	J:157574
	increased T cell derived lymphoma incidence	J:157574
	intestinal inflammation	J:157574
	liver inflammation	J:157574
	small spleen	J:157574
	small thymus	J:157574
Lig4^tm3.1Fwa/Lig4^tm3.1Fwa Tg(Cr2-cre)3Cgn/0 (Not Specified)	abnormal class switch recombination	J:157537
Lilrb4a^tm1Eol/Lilrb4a^tm1Eol (B6.129P2-Lilrb4a^tm1Eol)	abnormal cellular extravasation	J:129969
	abnormal cytokine level	J:129969
	abnormal immune system cell morphology	J:129969
	abnormal immune system physiology	J:129969
	abnormal interferon level	J:129969
	abnormal interleukin level	J:129969
	abnormal leukocyte physiology	J:129969
	decreased IgE level	J:129969
	increased inflammatory response	J:129969
	increased macrophage cell number	J:129969
	increased mast cell degranulation	J:129969
	increased plasma cell number	J:129969
Lilrb4a^tm1Hrk/Lilrb4a^tm1Hrk (involves: 129/Sv * BALB/c)	abnormal mast cell physiology	J:70491
	increased mast cell degranulation	J:70491
	increased susceptibility to type I hypersensitivity reaction	J:70491
Lilrb4a^tm1Ttk/Lilrb4a^tm1Ttk (B6.129X1-Lilrb4a^tm1Ttk)	abnormal dendritic cell antigen presentation	J:141234
Lilrb4a^tm1Ttk/Lilrb4a^tm1Ttk (B6.129X1-Lilrb4a^tm1Ttk)	increased susceptibility to graft versus host disease	J:141234
Limd1^em1(IMPC)H/Limd1^em1(IMPC)H (C57BL/6NTac-Limd1^em1(IMPC)H/H)	increased basophil cell number	J:211773
Limd1^tm1Gdl/Limd1^tm1Gdl (involves: 129X1/SvJ)	abnormal macrophage physiology	J:118130
	abnormal osteoclast cell number	J:118130
	abnormal osteoclast physiology	J:118130
Lime1^tm1.1Mal/Lime1^tm1.1Mal (involves: 129S2/SvPas * C57BL/6)	immune system phenotype	J:126321
Lime1^tm1.1Mal/Lime1^tm1.1Mal Rag2^tm1Fwa/Rag2^tm1Fwa Tg(TcraH-Y,TcrbH-Y)1Pas/? (B6.Cg-Rag2^tm1Fwa Lime1^tm1.1Mal Tg(TcraH-Y,TcrbH-Y)1Pas)	abnormal CD4-positive T cell differentiation	J:126321
	increased CD4-positive, alpha-beta T cell number	J:126321
Limk2^{Gt(OST80053)Lex}/Limk2^{Gt(OST80053)Lex} (involves: 129S5/SvEvBrd * C57BL/6)	increased incidence of corneal inflammation	J:192231
Limk2^whe/Limk2^whe (B6.Cg-Lep^ob Limk2^whe/GrsrJ)	increased incidence of corneal inflammation	J:127016
Lipa^{tm1c(EUCOMM)Hmgu}/Lipa^{tm1c(EUCOMM)Hmgu} Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1^{Tg(Alb-cre)21Mgn} (involves: C57BL/6J * C57BL/6N * C57BL/6NTac)	liver inflammation	J:270182
Lipa^tm1Hodu/Lipa^tm1Hodu (involves: 129P2/OlaHsd * CF-1)	abnormal alveolar macrophage morphology	J:101217
	abnormal Kupffer cell morphology	J:68812
	abnormal spleen morphology	J:49674, J:68812
	chronic inflammation	J:101217
	enlarged mesenteric lymph nodes	J:68812
	enlarged spleen	J:68812
	hepatosplenomegaly	J:68812
	increased spleen weight	J:49674, J:68812
	lung inflammation	J:101217
Lipt1^em1(IMPC)Bay/Lipt1⁺ (C57BL/6N-Lipt1^em1(IMPC)Bay/Bay)	abnormal spleen morphology	J:211773
Listr1^BALB/cByJ/? (involves: BALB/cByJ * C57BL/6ByJ)	decreased susceptibility to bacterial infection	J:68879
Listr1^BALB/cByJ/? Listr2^C57BL/6ByJ/? (involves: BALB/cByJ * C57BL/6ByJ)	decreased susceptibility to bacterial infection	J:68879
Listr2^C57BL/6ByJ/? (involves: BALB/cByJ * C57BL/6ByJ)	decreased susceptibility to bacterial infection	J:68879
Litaf^tm1.1Ics/Litaf^tm1.1Ics (Not Specified)	impaired macrophage chemotaxis	J:186411
Litaf^tm1.1Ics/Litaf^tm1.1Ics (Not Specified)	increased macrophage cell number	J:186411
Litaf^tm1Samr/Litaf^tm1Samr (involves: 129S4/SvJae)	abnormal cytokine secretion	J:113750
Litaf^tm1Samr/Litaf^tm1Samr (involves: 129S4/SvJae)	decreased susceptibility to endotoxin shock	J:113750
ll/ll X/Yaa (BXSB/MpJScr-ll)	abnormal monocyte morphology	J:10973
	decreased anti-nuclear antigen antibody level	J:10973
	decreased CD4-positive, alpha-beta T cell number	J:10973
	decreased IgG level	J:10973
	decreased susceptibility to autoimmune disorder	J:10973
	increased T cell derived lymphoma incidence	J:10973
Lmb1^C57BL/6Scr/Lmb1^C57BL/6Scr (involves: C57BL/6-Fas^lpr * MRL-Fas^lpr)	enlarged lymph nodes	J:45708
	enlarged spleen	J:45708
	increased anti-double stranded DNA antibody level	J:45708
Lmb1^C57BL/6Scr/Lmb1^C57BL/6Scr (MRL.Cg-Lmb1^C57BL/6Scr Fas^lpr)	increased CD8-positive, alpha-beta T cell number	J:125557
	increased double-negative T cell number	J:125557
	increased spleen weight	J:125557
Lmb1^C57BL/6Scr/Lmb1^MRL/MpScr (involves: C57BL/6-Fas^lpr * MRL-Fas^lpr)	enlarged lymph nodes	J:45708
	enlarged spleen	J:45708
	increased anti-double stranded DNA antibody level	J:45708
Lmb1^MRL/MpScr/Lmb1^MRL/MpScr (B6.MRL-Lmb1^MRL/MpScr Fas^lpr)	enlarged lymph nodes	J:125557
Lmb2^C57BL/6Scr/Lmb2^MRL/MpScr (involves: C57BL/6-Fas^lpr * MRL-Fas^lpr)	enlarged lymph nodes	J:45708
	enlarged spleen	J:45708
	increased anti-double stranded DNA antibody level	J:45708
Lmb2^MRL/MpScr/Lmb2^MRL/MpScr (involves: C57BL/6-Fas^lpr * MRL-Fas^lpr)	enlarged lymph nodes	J:45708
	enlarged spleen	J:45708
	increased anti-double stranded DNA antibody level	J:45708
Lmb2^MRL/MpScr/Lmb2^MRL/MpScr (B6.MRL-Lmb2^MRL/MpScr Fas^lpr)	decreased double-negative T cell number	J:125557
Lmb4^MRL/MpScr/Lmb4^MRL/MpScr (involves: C57BL/6-Fas^lpr * MRL-Fas^lpr)	enlarged lymph nodes	J:45708
	enlarged spleen	J:45708
Lmb4^MRL/MpScr/Lmb4^MRL/MpScr (B6.MRL-Lmb4^MRL/MpScr Fas^lpr)	enlarged lymph nodes	J:125557
Lmbr1l^em1Btlr/Lmbr1l^em1Btlr (C57BL/6J-Lmbr1l^em1Btlr)	abnormal alpha-beta T cell morphology	J:274568
	abnormal B cell differentiation	J:274568
	abnormal cytotoxic T cell physiology	J:274568
	abnormal lymphocyte morphology	J:274568
	decreased CD4-positive, alpha-beta T cell number	J:274568
	decreased IgD level	J:274568
	decreased IgG level	J:274568
	decreased IgM level	J:274568
	decreased leukocyte cell number	J:274568
	decreased lymphocyte cell number	J:274568
	decreased monocyte cell number	J:274568
	decreased T cell number	J:274568
	impaired humoral immune response	J:274568
	impaired natural killer cell mediated cytotoxicity	J:274568
	increased IgM level	J:274568
Lmbr1l^m1Btlr/Lmbr1l^m1Btlr (C57BL/6J-Lmbr1l^m1Btlr)	abnormal CD4-positive T cell differentiation	J:274568
	abnormal CD8-positive, alpha-beta T cell differentiation	J:274568
	abnormal cytotoxic T cell physiology	J:274568
	abnormal T cell differentiation	J:274568
	decreased CD4-positive, alpha-beta T cell number	J:274568
	decreased CD8-positive, alpha-beta T cell number	J:274568
	decreased CD8-positive, naive alpha-beta T cell number	J:274568
	decreased dendritic cell number	J:274568
	decreased IgE level	J:274568
	decreased IgG level	J:274568
	decreased IgM level	J:274568
	decreased NK cell number	J:274568
	decreased NK T cell number	J:274568
	decreased T cell number	J:274568
	impaired humoral immune response	J:274568
	impaired natural killer cell mediated cytotoxicity	J:274568
	increased B-1 B cell number	J:274568
	increased central memory CD8 positive, alpha-beta T cell number	J:274568
	increased effector memory CD4-positive, alpha-beta T cell number	J:274568
	increased macrophage cell number	J:274568
	increased neutrophil cell number	J:274568
Lmbr1l^m2Btlr/Lmbr1l^m2Btlr (C57BL/6J-Lmbr1l^m2Btlr)	increased central memory CD4-positive, alpha-beta T cell number	J:274857
Lmna^Dhe/Lmna⁺ (B6(D2)-Lmna^Dhe/TyGrsrJ)	abnormal peritoneal macrophage morphology	J:188496
Lmna^Dhe/Lmna⁺ (B6(D2)-Lmna^Dhe/TyGrsrJ)	increased susceptibility to otitis media	J:188496
Lmna^tm1.1Otin/Lmna^tm1.1Otin (involves: 129P2/OlaHsd * C57BL/6)	small spleen	J:177632
	small thymus	J:177632
Lmna^tm1.1Otin/Lmna^tm1.1Otin (involves: 129P2/OlaHsd * C57BL/6NTac)	keratoconjunctivitis sicca	J:261974
Lmna^tm1Stw/Lmna^tm1Stw (involves: 129S1/Sv)	small spleen	J:58702
Lmna^tm1Stw/Lmna^tm1Stw (involves: 129S1/Sv)	thymus atrophy	J:58702
Lmo2^tm2(cre)Thr/Lmo2⁺ (involves: 129P2/OlaHsd * C57BL/6)	decreased granulocyte number	J:155870
Lmo2^tm2(cre)Thr/Lmo2⁺ (involves: 129P2/OlaHsd * C57BL/6)	decreased monocyte cell number	J:155870
Lmo2^tm2(cre)Thr/Lmo2⁺ Kmt2a^tm1Thr/Kmt2a⁺ Mllt1^tm1Thr/Mllt1⁺ (involves: 129S/SvEv)	abnormal spleen red pulp morphology	J:100794
	abnormal spleen white pulp morphology	J:100794
	enlarged spleen	J:84518, J:100794
Lmo2^tm3Thr/Lmo2^tm4Thr Cd19^tm1(cre)Thr/Cd19⁺ (involves: 129S/SvEv)	immune system phenotype	J:86869
Lmo2^tm3Thr/Lmo2^tm4Thr Rag1^tm1(cre)Thr/Rag1⁺ (involves: 129S/SvEv)	immune system phenotype	J:86869
Lmo2^tm3Thr/Lmo2^tm4Thr Tg(Lck-cre)1Thr/0 (involves: 129S/SvEv)	immune system phenotype	J:86869
Lmo4^tm1Slp/Lmo4^tm1Slp Commd10^{Tg(Vav1-icre)A2Kio}/Commd10⁺ (involves: 129S1/Sv * C57BL/6 * C57BL/10 * CBA/Ca)	abnormal acute inflammation	J:282740
	abnormal gut-associated lymphoid tissue morphology	J:282740
	abnormal lymphocyte physiology	J:282740
	abnormal lymphopoiesis	J:282740
	decreased Peyer's patch number	J:282740
	increased susceptibility to bacterial infection	J:282740
Lmo4^tm1Slp/Lmo4^tm1Slp Yeats4^em1Zfa/Yeats4^em1Zfa Commd10^{Tg(Vav1-icre)A2Kio}/Commd10⁺ (involves: 129S1/Sv * C57BL/6 * C57BL/10 * CBA/Ca)	abnormal acute inflammation	J:282740
	abnormal lymphocyte physiology	J:282740
	abnormal lymphopoiesis	J:282740
	increased susceptibility to bacterial infection	J:282740
Lmod3^em1(IMPC)Mbp/Lmod3⁺ (C57BL/6N-Lmod3^em1(IMPC)Mbp/Ucd)	abnormal spleen morphology	J:211773
Lmod3^em1(IMPC)Mbp/Lmod3⁺ (C57BL/6N-Lmod3^em1(IMPC)Mbp/Ucd)	enlarged spleen	J:211773
Lmod3^em1(IMPC)Mbp/Lmod3^em1(IMPC)Mbp (C57BL/6N-Lmod3^em1(IMPC)Mbp/Ucd)	decreased lymphocyte cell number	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
	increased neutrophil cell number	J:211773
Lmr1^BALB/c/Lmr1^BALB/c (involves: BALB/c * C57BL/6J)	increased susceptibility to parasitic infection	J:40874
Lmr1^BALB/c/Lmr1^BALB/c Lmr30^C57BL/6/Lmr30^BALB/c (involves: BALB/c * C57BL/6)	increased susceptibility to parasitic infection	J:57691
Lmr1^BALB/c/Lmr1^BALB/c Lmr30^C57BL/6/Lmr30^C57BL/6 (involves: BALB/c * C57BL/6)	increased susceptibility to parasitic infection	J:57691
Lmr1^BALB/c/Lmr1^C57BL/6J (involves: BALB/c * C57BL/6J)	decreased susceptibility to parasitic infection	J:40874
Lmr1^C57BL/6J/Lmr1^C57BL/6J (involves: BALB/c * C57BL/6J)	decreased susceptibility to parasitic infection	J:40874
Lmr2^BALB/c/Lmr2^BALB/c (involves: BALB/c * C57BL/6J)	increased susceptibility to parasitic infection	J:40874
Lmr2^BALB/c/Lmr2^C57BL/6J (involves: BALB/c * C57BL/6J)	decreased susceptibility to parasitic infection	J:40874
Lmr2^C57BL/6J/Lmr2^C57BL/6J (involves: BALB/c * C57BL/6J)	decreased susceptibility to parasitic infection	J:40874
Lmr3^BALB/cHeA/? (involves: BALB/cHeA * STS/A)	abnormal tumor necrosis factor level	J:82715
	enlarged spleen	J:82715
	increased IgE level	J:82715
Lmr3^BALB/cHeA/Lmr3^BALB/cHeA (involves: BALB/cHeA * STS/A)	spleen hyperplasia	J:108764
Lmr3^BALB/cHeA/Lmr3^CcS5/Dem (involves: BALB/cHeA * STS/A)	spleen hyperplasia	J:108764
Lmr4^BALB/cHeA/? Lmr5^BALB/cHeA/? (involves: BALB/cHeA * STS/A)	abnormal tumor necrosis factor level	J:82715
Lmr5^BALB/cHeA/? (involves: BALB/cHeA * STS/A)	abnormal interleukin level	J:82715
	abnormal tumor necrosis factor level	J:82715
	increased IgE level	J:82715
Lmr5^CcS5/Dem/Lmr5^CcS5/Dem (involves: BALB/cHeA * STS/A)	increased circulating interleukin-12 level	J:108764
Lmr7^BALB/cHeA/? (involves: BALB/cHeA * STS/A)	decreased splenocyte proliferation	J:108764
Lmr7^CcS5/Dem/? (involves: BALB/cHeA * STS/A)	spleen hyperplasia	J:82715
Lmr8^BALB/cHeA/? (involves: BALB/cHeA * STS/A)	increased IgE level	J:82717
Lmr8^BALB/cHeA/Lmr8^BALB/cHeA (involves: BALB/cHeA * STS/A)	spleen hyperplasia	J:108764
Lmr8^BALB/cHeA/Lmr8^CcS20/Dem (involves: BALB/cHeA * STS/A)	spleen hyperplasia	J:108764
Lmr9^BALB/cHeA/? (involves: BALB/cHeA * STS/A)	increased IgE level	J:82717
Lmr9^BALB/cHeA/Lmr9^CcS20/Dem (involves: BALB/cHeA * STS/A)	increased circulating interleukin-6 level	J:108764
Lmr9^CcS20/Dem/? (involves: BALB/cHeA * STS/A)	decreased IgE level	J:82717
Lmr9^CcS20/Dem/Lmr9^CcS20/Dem (involves: BALB/cHeA * STS/A)	increased circulating interleukin-6 level	J:108764
Lmr10^BALB/cHeA/? (involves: BALB/cHeA * STS/A)	increased IgE level	J:82717
Lmr10^CcS20/Dem/? (involves: BALB/cHeA * STS/A)	decreased IgE level	J:82717
Lmr11^BALB/cHeA/Lmr11^BALB/cHeA Lmr8^CcS20/Dem/Lmr8^CcS20/Dem (involves: BALB/cHeA * STS/A)	decreased IgE level	J:82717
Lmr11^BALB/cHeA/Lmr11^CcS20/Dem (involves: BALB/cHeA * STS/A)	increased circulating interleukin-6 level	J:108764
Lmr11^CcS20/Dem/Lmr11^CcS20/Dem (involves: BALB/cHeA * STS/A)	increased circulating interleukin-6 level	J:108764
Lmr12^BALB/cHeA/? (involves: BALB/cHeA * STS/A)	decreased IgE level	J:82717
Lmr12^BALB/cHeA/Lmr12^BALB/cHeA Lmr14^BALB/cHeA/Lmr14^BALB/cHeA (involves: BALB/cHeA * STS/A)	increased circulating tumor necrosis factor level	J:108764
Lmr12^BALB/cHeA/Lmr12^CcS16/Dem (involves: BALB/cHeA * STS/A)	increased circulating interleukin-4 level	J:108764
Lmr12^CcS16/Dem/? (involves: BALB/cHeA * STS/A)	increased IgE level	J:82717
Lmr12^CcS16/Dem/Lmr12^CcS16/Dem (involves: BALB/cHeA * STS/A)	increased circulating interleukin-4 level	J:108764
Lmr12^CcS16/Dem/Lmr12^CcS16/Dem Lmr19^BALB/cHeA/Lmr19^BALB/cHeA (involves: BALB/cHeA * STS/A)	spleen hyperplasia	J:108764
Lmr13^BALB/cHeA/? (involves: BALB/cHeA * STS/A)	decreased IgE level	J:82717
Lmr13^CcS16/Dem/Lmr13^CcS16/Dem Lmr14^CcS16/Dem/Lmr14^CcS16/Dem (involves: BALB/cHeA * STS/A)	decreased circulating tumor necrosis factor level	J:108764
Lmr14^BALB/cHeA/? (involves: BALB/cHeA * STS/A)	spleen hyperplasia	J:108764
Lmr14^BALB/cHeA/Lmr14^BALB/cHeA Lmr5^BALB/cHeA/? (involves: BALB/cHeA * STS/A)	increased IgE level	J:82715
Lmr14^BALB/cHeA/Lmr14^BALB/cHeA Lmr5^BALB/cHeA/Lmr5^BALB/cHeA (involves: BALB/cHeA * STS/A)	increased IgE level	J:82717
Lmr14^BALB/cHeA/Lmr14^CcS16/Dem (involves: BALB/cHeA * STS/A)	increased circulating interferon-gamma level	J:108764
Lmr14^CcS16/Dem/? (involves: BALB/cHeA * STS/A)	enlarged spleen	J:82716
Lmr14^CcS16/Dem/Lmr14^CcS16/Dem (involves: BALB/cHeA * STS/A)	increased circulating interferon-gamma level	J:108764
Lmr14^CcS16/Dem/Lmr14^CcS16/Dem Lmr5^BALB/cHeA/? (involves: BALB/cHeA * STS/A)	increased IgE level	J:82715
Lmr14^CcS16/Dem/Lmr14^CcS16/Dem Lmr5^BALB/cHeA/Lmr5^BALB/cHeA (involves: BALB/cHeA * STS/A)	increased IgE level	J:82717
Lmr14^CcS16/Dem/Lmr14^CcS16/Dem Lmr5^CcS5/Dem/Lmr5^CcS5/Dem (involves: BALB/cHeA * STS/A)	increased circulating interleukin-12 level	J:108764
Lmr15^BALB/cHeA/Lmr15^CcS16/Dem (involves: BALB/cHeA * STS/A)	decreased circulating interferon-gamma level	J:108764
Lmr15^CcS16/Dem/Lmr15^CcS16/Dem (involves: BALB/cHeA * STS/A)	decreased circulating interferon-gamma level	J:108764
Lmr16^STS/A/Lmr16^STS/A Lmr18^BALB/cHeA/Lmr18^BALB/cHeA (involves: BALB/cHeA * STS/A)	spleen hyperplasia	J:108764
Lmr17^BALB/cHeA/Lmr17^CcS20/Dem (involves: BALB/cHeA * STS/A)	increased circulating tumor necrosis factor level	J:108764
Lmr17^CcS20/Dem/Lmr17^CcS20/Dem (involves: BALB/cHeA * STS/A)	increased circulating tumor necrosis factor level	J:108764
Lmr17^CcS20/Dem/Lmr17^CcS20/Dem Lmr3^BALB/cHeA/Lmr3^BALB/cHeA (involves: BALB/cHeA * STS/A)	increased circulating interferon-gamma level	J:108764
Lmr18^BALB/cHeA/Lmr18^BALB/cHeA (involves: BALB/cHeA * STS/A)	decreased splenocyte proliferation	J:108764
Lmr18^BALB/cHeA/Lmr18^CcS20/Dem (involves: BALB/cHeA * STS/A)	decreased splenocyte proliferation	J:108764
Lmrq1^BALB/cAnSim/Lmrq1^C57BL/10Sn (involves: BALB/cAnNSim * C57BL/10J)	decreased susceptibility to parasitic infection	J:40624
Lmrq2^BALB/cAnSim/Lmrq2^C57BL/10Sn (involves: BALB/cAnNSim * C57BL/10J)	decreased susceptibility to parasitic infection	J:40624
Lmrq3^BALB/cAnSim/Lmrq3^C57BL/10Sn (involves: BALB/cAnNSim * C57BL/10J)	decreased susceptibility to parasitic infection	J:40624
Lmrq4^BALB/cAnSim/Lmrq4^C57BL/10Sn (involves: BALB/cAnNSim * C57BL/10J)	decreased susceptibility to parasitic infection	J:40624
Lmrq4^C57BL/10Sn/Lmrq4^C57BL/10Sn (C.B10-(D11Mit2-D11Mit29))	decreased susceptibility to parasitic infection	J:40624
Lmrq5^BALB/cAnNSim/Lmrq5^C57BL/10Sn (involves: BALB/cAnNSim * C57BL/10J)	decreased susceptibility to parasitic infection	J:40624
Lmrq6^BALB/cAnSim/Lmrq6^C57BL/10Sn (involves: BALB/cAnNSim * C57BL/10J)	decreased susceptibility to parasitic infection	J:40624
Lncucc1^em1Bwu/Lncucc1^em1Bwu (C57BL/6-Lncucc1^em1Bwu)	abnormal susceptibility to colitis induced morbidity/mortality	J:340220
Lncucc1^em1Bwu/Lncucc1^em1Bwu (C57BL/6-Lncucc1^em1Bwu)	increased susceptibility to induced colitis	J:340220
Lnx1^tm1Lex/Lnx1^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6J)	increased B-1b cell number	J:171883
Loricrin^{tm1.1(KOMP)Vlcg}/Loricrin⁺ (C57BL/6N-Loricrin^{tm1.1(KOMP)Vlcg}/Ucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Loricrin^{tm1.1(KOMP)Vlcg}/Loricrin^{tm1.1(KOMP)Vlcg} (C57BL/6N-Loricrin^{tm1.1(KOMP)Vlcg}/Ucd)	increased spleen weight	J:211773
Loricrin^tm1Der/Loricrin^tm1Der (FVB.129S7-Loricrin^tm1Der)	erythroderma	J:65187
Lox^tm1.1Khki/Lox^tm1.1Khki (involves: C57BL/6)	increased lymphocyte cell number	J:264295
Loxl2^tm1.2Acan/Loxl2^tm1.2Acan (Not Specified)	decreased inflammatory response	J:220689
Lpar2^tm1Dgen/Lpar2^tm1Dgen (B6.Cg-Lpar2^tm1Dgen)	abnormal dendritic cell physiology	J:184061
	decreased interleukin-10 secretion	J:184061
	increased IgE level	J:184061
	increased interleukin-13 secretion	J:184061
	increased susceptibility to type I hypersensitivity reaction	J:184061
	increased tumor necrosis factor secretion	J:184061
	lung inflammation	J:184061
Lpar4^tm1Sati/Y (involves: C57BL/6)	abnormal cellular extravasation	J:253134
	immune system phenotype	J:253134
	lymphangiectasis	J:167262
Lpar4^tm1Sati/Lpar4⁺ (involves: C57BL/6)	abnormal cellular extravasation	J:253134
Lpar4^tm1Sati/Lpar4^tm1Sati (involves: C57BL/6)	abnormal cellular extravasation	J:253134
	immune system phenotype	J:253134
	lymphangiectasis	J:167262
Lpar6^tm1.1Sati/Lpar6^tm1.1Sati (involves: C57BL/6 * C57BL/6NJcl * CBA)	abnormal cellular extravasation	J:253134
	immune system phenotype	J:253134
Lpin2^{tm1b(KOMP)Wtsi}/Lpin2^{tm1b(KOMP)Wtsi} (C57BL/6N-Lpin2^{tm1b(KOMP)Wtsi}/Tcp)	enlarged lymph nodes	J:211773
Lpin2^tm1Reue/Lpin2^tm1Reue (involves: C57BL/6J)	immune system phenotype	J:189894
Lpin3^{tm1b(KOMP)Wtsi}/Lpin3^{tm1b(KOMP)Wtsi} (C57BL/6N-Lpin3^{tm1b(KOMP)Wtsi}/Ucd)	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Lpn1^NZB/Lpn1^NZB (involves: NZB * NZW)	kidney inflammation	J:6026
Lpn1^NZB/Lpn1^NZW (involves: NZB * NZW)	kidney inflammation	J:6026
Lpn2^NZB/Lpn2^NZW (involves: NZB * NZW)	kidney inflammation	J:6026
Lpn2^NZW/Lpn2^NZW (involves: NZB * NZW)	kidney inflammation	J:6026
Lpo^em1Zlu/Lpo^em1Zlu (involves: C57BL/6 * SJL)	aortitis	J:307289
	arteritis	J:307289
	blood vessel inflammation	J:307289
	cardiovalvulitis	J:307289
	gallbladder inflammation	J:307289
	glomerulonephritis	J:307289
	increased inflammatory response	J:307289
	intestinal inflammation	J:307289
	liver inflammation	J:307289
	lung inflammation	J:307289
	mastitis	J:307289
	myocarditis	J:307289
	myositis	J:307289
	pancreas inflammation	J:307289
	stomach inflammation	J:307289
Lppl1^C57BL/6J/? (involves: C57BL/6J * DBA/2J)	abnormal leukocyte physiology	J:90647
Lprm3^MRL/MpJ/Lprm3^MRL/MpJ (involves: C3H/HeJ-Fas^lpr * MRL/MpJ-Fas^lpr)	glomerulonephritis	J:44625
Lprm4^MRL/MpJ/Lprm4^MRL/MpJ (involves: C3H/HeJ-Fas^lpr * MRL/MpJ-Fas^lpr)	enlarged spleen	J:44625
Lprm5^MRL/MpJ/Lprm5^MRL/MpJ (involves: C3H/HeJ-Fas^lpr * MRL/MpJ-Fas^lpr)	abnormal humoral immune response	J:44625
Lptl1^DBA/2J/? (involves: C57BL/6J * DBA/2J)	abnormal tumor necrosis factor level	J:90647
Lptl1^DBA/2J/Lptl1^DBA/2J Lptl2^DBA/2J/Lptl2^DBA/2J (involves: C57BL/6J * DBA/2J)	abnormal tumor necrosis factor level	J:90647
Lptl2^DBA/2J/? (involves: C57BL/6J * DBA/2J)	abnormal tumor necrosis factor level	J:90647
Lpxn^{tm1b(EUCOMM)Hmgu}/Lpxn^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Lpxn^{tm1b(EUCOMM)Hmgu}/Wtsi)	abnormal plasma cell differentiation	J:305662
	decreased IgM level	J:305662
	immune system phenotype	J:305662
Lratd2^{em1(IMPC)Ccpcz}/Lratd2^{em1(IMPC)Ccpcz} (C57BL/6N-Lratd2^{em1(IMPC)Ccpcz}/Ccpcz)	decreased eosinophil cell number	J:211773
	increased B-2 B cell number	J:211773
Lrba^em1Btlr/Lrba^em1Btlr (C57BL/6J-Lrba^em1Btlr)	increased susceptibility to induced colitis	J:274652
Lrba^em2Btlr/Lrba^em2Btlr (C57BL/6J-Lrba^em2Btlr)	increased susceptibility to induced colitis	J:274652
Lrba^em3Btlr/Lrba^em3Btlr (C57BL/6J-Lrba^em3Btlr)	increased susceptibility to induced colitis	J:274652
Lrba^{Gt(OST69142)Lex}/Lrba^{Gt(OST69142)Lex} (involves: 129 * 129S5/SvEvBrd)	abnormal NK cell physiology	J:237187
	decreased susceptibility to graft versus host disease	J:237187
	impaired natural killer cell mediated cytotoxicity	J:237187
	increased length of allograft survival	J:237187
	increased regulatory T cell number	J:237187
Lrba^m1Btlr/Lrba^m1Btlr (C57BL/6J-Lrba^m1Btlr)	increased susceptibility to induced colitis	J:274652
Lrba^m2Btlr/Lrba^m2Btlr (C57BL/6J-Lrba^m2Btlr)	increased susceptibility to induced colitis	J:274652
Lrch1^em1Hwa/Lrch1^em1Hwa (Not Specified)	abnormal cellular extravasation	J:238772
	immune system phenotype	J:238772
	increased susceptibility to experimental autoimmune encephalomyelitis	J:238772
Lrdm1^MRL/MpJ/? (involves: CAST/Ei * MRL/MpJ-Fas^lpr/J)	kidney inflammation	J:3304
Lrdm2^MRL/MpJ/? (involves: CAST/Ei * MRL/MpJ-Fas^lpr/J)	kidney inflammation	J:3304
Lrfn2^{Tg(CD2-Myb/en)5Kmw}/Lrfn2⁺ (involves: C57BL/10 * CBA)	abnormal lymph node morphology	J:125805
	decreased T cell number	J:126456
	decreased T cell proliferation	J:126456
Lrfn2^{Tg(CD2-Myb/en)5Kmw}/Lrfn2⁺ Tg(H2-K-Myc)1Brn/? (involves: C57BL/10 * CBA * FVB/N)	abnormal lymph node morphology	J:125805
	enlarged lymph nodes	J:125805
	enlarged spleen	J:125805
	lymph node hemorrhage	J:125805
	lymph node necrosis	J:125805
	spleen hyperplasia	J:125805
Lrfn2^{Tg(CD2-Myb/en)5Kmw}/Lrfn2^{Tg(CD2-Myb/en)5Kmw} (involves: C57BL/10 * CBA)	abnormal thymus cortex morphology	J:126456
	abnormal thymus medulla morphology	J:126456
	decreased CD8-positive, alpha-beta T cell number	J:126456
	decreased double-negative T cell number	J:126456
	decreased T cell number	J:126456
	decreased T cell proliferation	J:126456
	small spleen	J:126456
	small thymus	J:126456
Lrfn2^tm1.1Jaru/Lrfn2^tm1.1Jaru (B6.129P2(Cg)-Lrfn2^tm1.1Jaru)	decreased granulocyte number	J:301285
	decreased leukocyte cell number	J:301285
	decreased lymphocyte cell number	J:301285
Lrig1^m1Anu/Lrig1^m1Anu (C57BL/NCrlAnu-Lrig1^m1Anu)	immune system phenotype	J:104190
Lrig1^{tm1a(EUCOMM)Wtsi}/Lrig1^{tm1a(EUCOMM)Wtsi} (involves: C57BL/6 * C57BL/6N)	increased susceptibility to bacterial infection	J:213427
Lrig2^tm1.1Hhed/Lrig2^tm1.1Hhed (involves: 129 * C57BL/6 * FVB/N)	increased inflammatory response	J:205929
Lrig3^{em1(IMPC)Ccpcz}/Lrig3^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Lrig3^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Lrp1^tm2Her/Lrp1^tm2Her Tg(Camk2a-cre)T29-1Stl/0 (involves: 129S7/SvEvBrd * BALB/c * C57BL)	brain inflammation	J:167724
Lrp2^b2b2671Clo/Lrp2^b2b2671Clo (C57BL/6J-Lrp2^b2b2671Clo)	thymus hypoplasia	J:175213
Lrp3^em1Cya/Lrp3^em1Cya (C57BL/6N-Lrp3^em1Cya/Cya)	increased susceptibility to induced arthritis	J:345338
Lrp3^em1Cya/Lrp3^em1Cya (C57BL/6N-Lrp3^em1Cya/Cya)	osteoarthritis	J:345338
Lrp5^tm1Grw/Lrp5^tm1Grw (involves: 129S1/Sv * 129X1/SvJ)	decreased osteoclast cell number	J:104382
Lrp6^tm1Arma/Lrp6^tm1Arma (C57BL/6-Lrp6^tm1Arma)	liver inflammation	J:225450
Lrp12^em1Gpt/Lrp12^em1Gpt Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * C57BL/6JGpt * DBA/2)	abnormal CD4-positive, alpha-beta T cell physiology	J:338432
	enhanced leukocyte migration	J:338432
	immune system phenotype	J:338432
	increased susceptibility to induced colitis	J:338432
	increased T cell number	J:338432
Lrrc3^{tm1b(EUCOMM)Hmgu}/Lrrc3^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Lrrc3^{tm1b(EUCOMM)Hmgu}/Ics)	decreased lymphocyte cell number	J:211773
Lrrc4c^tm1Lex/Lrrc4c^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6J)	increased circulating interleukin-6 level	J:171883
Lrrc8a^tm1.1Geha/Lrrc8a^tm1.1Geha (B6.129S1(Cg)-Lrrc8a^tm1.1Geha)	abnormal B cell differentiation	J:211308
	abnormal T cell differentiation	J:211308
	abnormal T cell physiology	J:211308
	abnormal T cell selection	J:211308
	abnormal thymus apoptosis	J:211308
	abnormal thymus medulla morphology	J:211308
	abnormal thymus morphology	J:211308
	abnormal thymus physiology	J:211308
	absent thymus corticomedullary boundary	J:211308
	decreased B cell number	J:211308
	decreased CD4-positive, alpha-beta T cell number	J:211308
	decreased CD8-positive, alpha-beta T cell number	J:211308
	decreased DN2 thymocyte number	J:211308
	decreased DN3 thymocyte number	J:211308
	decreased DN4 thymocyte number	J:211308
	decreased double-negative T cell number	J:211308
	decreased double-positive T cell number	J:211308
	decreased immature B cell number	J:211308
	decreased marginal zone B cell number	J:211308
	decreased pre-B cell number	J:211308
	decreased T cell number	J:211308
	decreased T cell proliferation	J:211308
	decreased thymocyte number	J:211308
	decreased transitional stage B cell number	J:211308
	increased IgG2a level	J:211308
	increased pro-B cell number	J:211308
	increased regulatory T cell number	J:211308
	increased thymocyte apoptosis	J:211308
	small spleen	J:211308
	small thymus	J:211308
	small thymus cortex	J:211308
	thymus hypoplasia	J:211308
Lrrc8b^em1Bcgen/Lrrc8b^em1Bcgen (C57BL/6N-Lrrc8b^em1Bcgen)	immune system phenotype	J:288504
Lrrc8c^em1(IMPC)Mbp/Lrrc8c^em1(IMPC)Mbp (C57BL/6N-Lrrc8c^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
Lrrc8d^em1Bcgen/Lrrc8d^em1Bcgen (C57BL/6N-Lrrc8d^em1Bcgen)	immune system phenotype	J:288504
Lrrc8e^em1Bcgen/Lrrc8e^em1Bcgen (C57BL/6N-Lrrc8e^em1Bcgen)	abnormal circulating cytokine level	J:288504
	decreased circulating interferon-beta level	J:288504
	decreased circulating tumor necrosis factor level	J:288504
	decreased interferon-beta secretion	J:288504
	increased susceptibility to viral infection	J:288504
	increased susceptibility to viral infection induced morbidity/mortality	J:288504
Lrrc17^{em1(IMPC)Ccpcz}/Lrrc17^{em1(IMPC)Ccpcz} (C57BL/6N-Lrrc17^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Lrrc17^tm1Nik/Lrrc17⁺ Nf1^tm1Par/Nf1^tm1Par Srpk2^tm1Nik/Srpk2⁺ Tg(Mx1-cre)1Cgn/0 (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)	increased leukocyte cell number	J:161558
Lrrc19^tm1Ryag/Lrrc19^tm1Ryag (involves: C57BL/6J * C57BL/6NTac)	decreased circulating interleukin-6 level	J:271376
	decreased circulating tumor necrosis factor level	J:271376
	increased susceptibility to bacterial infection	J:271376
Lrrc25^em1Cya/Lrrc25^em1Cya (C57BL/6J-Lrrc25^em1Cya/Cya)	abnormal tumor necrosis factor level	J:270157
Lrrc25^em1Cya/Lrrc25^em1Cya (C57BL/6J-Lrrc25^em1Cya/Cya)	heart inflammation	J:270157
Lrrc30^{em1(IMPC)Rbrc}/Lrrc30^{em1(IMPC)Rbrc} (C57BL/6NJcl-Lrrc30^{em1(IMPC)Rbrc}/Rbrc)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
Lrrc32^tm1.1Hfuj/Lrrc32^tm1.1Hfuj Tg(Cd4-cre)1Cwi/0 (involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NTac * DBA/2)	abnormal regulatory T cell physiology	J:204761
	immune system phenotype	J:204761
Lrrc55os^em1Caox/Lrrc55os^em1Caox (C57BL/6-Lrrc55os^em1Caox)	decreased circulating interferon-beta level	J:293325
	immune system phenotype	J:293325
	increased susceptibility to Riboviria infection	J:293325
	increased susceptibility to Riboviria infection induced morbidity/mortality	J:293325
Lrrc56^em1(IMPC)Tcp/Lrrc56^em1(IMPC)Tcp (C57BL/6N-Lrrc56^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Lrrk1^tm1.1Smo/Lrrk1^tm1.1Smo (involves: 129S/Sv)	abnormal osteoclast physiology	J:208677
Lrrk1^tm1.1Smo/Lrrk1^tm1.1Smo (involves: 129S/Sv)	increased osteoclast cell number	J:208677
Lrrk1^{tm1b(KOMP)Wtsi}/Lrrk1^{tm1b(KOMP)Wtsi} (C57BL/6N-Lrrk1^{tm1b(KOMP)Wtsi}/H)	decreased eosinophil cell number	J:211773
	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
	increased spleen weight	J:211773
Lrrk2^tm1.1Cai/Lrrk2⁺ Tg(Camk2a-tTA)1Mmay/0 Tg(tetO-SNCAA53T)E2Cai/0 (involves: 129X1/SvJ C57BL/6)	microgliosis	J:156512
Lrrk2^tm1.1Cai/Lrrk2^tm1.1Cai (involves: 129X1/SvJ * C57BL/6)	microgliosis	J:156512
Lrrk2^tm2.1Shn/Lrrk2^tm2.1Shn (involves: 129 * C57BL/6)	kidney inflammation	J:160542
Lrrtm1^em1(IMPC)Mbp/Lrrtm1^em1(IMPC)Mbp (C57BL/6N-Lrrtm1^em1(IMPC)Mbp/Ucd)	increased monocyte cell number	J:211773
Lrrtm2^em1(IMPC)Mbp/Lrrtm2^em1(IMPC)Mbp (C57BL/6N-Lrrtm2^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Lse/Lse⁺ (B6C3Fe a/a-Lse/J)	keratoconjunctivitis sicca	J:338204
Lsm3^em1Caox/Lsm3^em1Caox (involves: C57BL/6J)	decreased susceptibility to Orthomyxoviridae infection	J:262834
	decreased susceptibility to Riboviria infection	J:262834
	decreased susceptibility to Riboviria infection induced morbidity/mortality	J:262834
	increased circulating interferon-alpha level	J:262834
	increased circulating interferon-beta level	J:262834
	increased circulating interleukin-6 level	J:262834
Lsm8^em1(IMPC)Mbp/Lsm8⁺ (C57BL/6N-Lsm8^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
Lsm14a^{tm1b(KOMP)Wtsi}/Lsm14a⁺ (C57BL/6N-Lsm14a^{tm1b(KOMP)Wtsi}/Nju)	increased basophil cell number	J:211773
Lsp1^tm1Jejb/Lsp1^tm1Jejb (involves: 129S1/Sv * 129X1/SvJ)	abnormal cellular extravasation	J:96022
	abnormal immune system morphology	J:64219
	abnormal leukocyte physiology	J:68128
	abnormal lymphopoiesis	J:64219
	impaired neutrophil chemotaxis	J:68128
	increased macrophage cell number	J:64219
Lsr1^A/J/? (involves: A/J * C57BL/6J)	increased susceptibility to bacterial infection	J:7345
Lsr1^C57BL/6J/? (involves: A/J * C57BL/6J)	decreased susceptibility to bacterial infection	J:7345
Lss^{tm1b(KOMP)Wtsi}/Lss⁺ (C57BL/6N-Lss^{tm1b(KOMP)Wtsi}/Ieg)	increased leukocyte cell number	J:211773
Lst1^{tm1(KOMP)Vlcg}/Lst1^{tm1(KOMP)Vlcg} (C57BL/6N-Lst1^{tm1(KOMP)Vlcg})	immune system phenotype	J:235700
	increased susceptibility to Orthomyxoviridae infection	J:235700
	increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:235700
Lta4h^tm1Bhk/Lta4h^tm1Bhk (involves: 129P2/OlaHsd * 129S/SvEv)	decreased acute inflammation	J:58985
	decreased susceptibility to type I hypersensitivity reaction	J:58985
Lta/Tnf^tm1Eug/Lta/Tnf^tm1Eug (involves: 129)	abnormal humoral immune response	J:31129
	abnormal spleen marginal zone morphology	J:31129
	abnormal spleen morphology	J:31129
	absent lymph nodes	J:31129
	absent Peyer's patches	J:31129
	decreased IgA level	J:31129
	decreased T cell number	J:31129
	increased B cell number	J:31129
	increased leukocyte cell number	J:31129
	increased susceptibility to parasitic infection	J:31129
	increased susceptibility to Poxviridae infection	J:31129
	increased susceptibility to Riboviria infection	J:31129
Lta/Tnf^tm1Eug/Lta/Tnf^tm1Eug (involves: 129/Sv * C57BL/6)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:115225
Lta/Tnf^tm1Eug/Lta/Tnf^tm1Eug (involves: 129/Sv * C57BL/6)	decreased susceptibility to parasitic infection	J:37696
Lta/Tnf^tm1Eug/Lta/Tnf^tm1Eug (B6.129-Lta/Tnf^tm1Eug)	decreased circulating interferon-gamma level	J:115034
	decreased IgG1 level	J:115034
	decreased IgG2a level	J:115034
	decreased IgG3 level	J:115034
	decreased interferon-gamma secretion	J:115034
	decreased susceptibility to induced arthritis	J:115034
	impaired macrophage phagocytosis	J:115034
	increased IgM level	J:115034
	increased susceptibility to bacterial infection	J:115034
	increased susceptibility to bacterial infection induced morbidity/mortality	J:115034
Lta/Tnf^tm1Eug/Lta/Tnf^tm1Eug (involves: 129 * C57BL/6J)	increased spleen weight	J:112797
Lta/Tnf^tm1Eug/Lta/Tnf^tm1Eug (involves: 129)	abnormal humoral immune response	J:31129
	abnormal spleen marginal zone morphology	J:31129
	abnormal spleen morphology	J:31129
	absent lymph nodes	J:31129
	absent Peyer's patches	J:31129
	decreased IgA level	J:31129
	decreased T cell number	J:31129
	increased B cell number	J:31129
	increased leukocyte cell number	J:31129
	increased susceptibility to bacterial infection	J:31129
	increased susceptibility to Poxviridae infection	J:31129
	increased susceptibility to Riboviria infection	J:31129
Lta/Tnf^tm1Eug/Lta/Tnf^tm1Eug (involves: 129/Sv * C57BL/6)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:115225
Lta/Tnf^tm1Eug/Lta/Tnf^tm1Eug (involves: 129/Sv * C57BL/6)	decreased susceptibility to parasitic infection	J:37696
Lta/Tnf^tm1Eug/Lta/Tnf^tm1Eug (B6.129-Lta/Tnf^tm1Eug)	decreased circulating interferon-gamma level	J:115034
	decreased IgG1 level	J:115034
	decreased IgG2a level	J:115034
	decreased IgG3 level	J:115034
	decreased interferon-gamma secretion	J:115034
	decreased susceptibility to induced arthritis	J:115034
	impaired macrophage phagocytosis	J:115034
	increased IgM level	J:115034
	increased susceptibility to bacterial infection	J:115034
	increased susceptibility to bacterial infection induced morbidity/mortality	J:115034
Lta/Tnf^tm1Eug/Lta/Tnf^tm1Eug (involves: 129 * C57BL/6J)	increased spleen weight	J:112797
Lta/Tnf^tm1Fda/Lta/Tnf^tm1Fda (involves: 129S1/Sv * 129X1/SvJ)	decreased susceptibility to endotoxin shock	J:39519
	decreased tumor necrosis factor secretion	J:39519
	increased susceptibility to bacterial infection	J:39519
Lta/Tnf^tm1Fda/Lta⁺ (involves: 129S1/Sv * 129X1/SvJ)	decreased susceptibility to endotoxin shock	J:39519
	decreased tumor necrosis factor secretion	J:39519
	increased susceptibility to bacterial infection	J:39519
Lta/Tnf^tm1Fda/Lta/Tnf^tm1Fda (involves: 129S1/Sv * 129X1/SvJ)	decreased susceptibility to endotoxin shock	J:39519
	decreased tumor necrosis factor secretion	J:39519
	increased susceptibility to bacterial infection	J:39519
Lta/Tnf^tm1Fda/Tnf⁺ (involves: 129S1/Sv * 129X1/SvJ)	decreased susceptibility to endotoxin shock	J:39519
	decreased tumor necrosis factor secretion	J:39519
	increased susceptibility to bacterial infection	J:39519
Lta/Tnf^tm1Jods/Lta/Tnf^tm1Jods (C57BL/6J-Lta/Tnf^tm1Jods)	abnormal spleen morphology	J:43602
	abnormal spleen white pulp morphology	J:43602
	absent lymph nodes	J:43602
	absent Peyer's patches	J:43602
	decreased immunoglobulin level	J:43602
	enlarged spleen	J:43602
	increased leukocyte cell number	J:43602
Lta/Tnf^tm1Jods/Lta/Tnf^tm1Jods (C57BL/6-Lta/Tnf^tm1Jods)	abnormal spleen white pulp morphology	J:78229
Lta/Tnf^tm1Jods/Lta/Tnf^tm1Jods (C57BL/6-Lta/Tnf^tm1Jods)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:47428
Lta/Tnf^tm1Jods/Lta/Tnf^tm1Jods (involves: C57BL/6)	abnormal gamma-delta T cell morphology	J:169863
Lta/Tnf^tm1Jods/Lta/Tnf^tm1Jods (C57BL/6J-Lta/Tnf^tm1Jods)	abnormal spleen morphology	J:43602
	absent lymph nodes	J:43602
	absent Peyer's patches	J:43602
	decreased immunoglobulin level	J:43602
	enlarged spleen	J:43602
	increased leukocyte cell number	J:43602
Lta/Tnf^tm1Jods/Lta/Tnf^tm1Jods (C57BL/6-Lta/Tnf^tm1Jods)	abnormal spleen white pulp morphology	J:78229
Lta/Tnf^tm1Jods/Lta/Tnf^tm1Jods (C57BL/6-Lta/Tnf^tm1Jods)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:47428
Lta/Tnf^tm1Jods/Lta/Tnf^tm1Jods (involves: C57BL/6)	abnormal gamma-delta T cell morphology	J:169863
Lta^hlb382/Lta^hlb382 (C57BL/6J-Lta^hlb382/J)	abnormal immune system organ morphology	J:134498
	absent lymph nodes	J:134498
	absent marginal zone B cells	J:134498
	absent mesenteric lymph nodes	J:134498
	absent Peyer's patches	J:134498
	absent spleen germinal center	J:134498
	absent spleen marginal zone	J:134498
	decreased NK cell number	J:134498
	decreased transitional stage B cell number	J:134498
	increased B-1b cell number	J:134498
	increased leukocyte cell number	J:82961
	liver inflammation	J:134498
	lung inflammation	J:134498
Lta^{tm1.1(KOMP)Vlcg}/Lta^{tm1.1(KOMP)Vlcg} (C57BL/6N-Lta^{tm1.1(KOMP)Vlcg}/Ucd)	decreased monocyte cell number	J:211773
	increased eosinophil cell number	J:211773
	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Lta^tm1.1Sned/Lta^tm1.1Sned (B6.129-Lta^tm1.1Sned)	abnormal circulating tumor necrosis factor level	J:109621
	abnormal class switch recombination	J:109621
	abnormal humoral immune response	J:109621
	abnormal immune system morphology	J:109621
	abnormal lymphopoiesis	J:109621
	absent Peyer's patches	J:109621
	decreased spleen white pulp amount	J:109621
	enlarged spleen	J:109621
	increased susceptibility to bacterial infection induced morbidity/mortality	J:109621
Lta^tm1Dch/Lta^tm1Dch (B6.129S2-Lta^tm1Dch)	abnormal class switch recombination	J:80616
	abnormal cytokine secretion	J:95222
	abnormal immune serum protein physiology	J:80616
	abnormal mucosa-associated lymphoid tissue morphology	J:95222
	abnormal spleen morphology	J:80616
	absent Peyer's patches	J:80616
	absent spleen germinal center	J:80616
	absent spleen marginal zone	J:80616
	decreased IgG level	J:80616
	decreased spleen B cell follicle number	J:80616
	decreased spleen white pulp amount	J:80616
	increased IgM level	J:80616
	increased leukocyte cell number	J:80616
Lta^tm1Dch/Lta^tm1Dch (involves: 129S2/SvPas * C57BL/6)	abnormal class switch recombination	J:109621
	abnormal humoral immune response	J:39746
	abnormal leukocyte cell number	J:17976
	abnormal lymph node morphology	J:17976
	abnormal lymph node primary follicle morphology	J:109621
	abnormal spleen morphology	J:17976, J:39746
	abnormal spleen periarteriolar lymphoid sheath morphology	J:17976
	absent axillary lymph nodes	J:17976
	absent cervical lymph nodes	J:17976
	absent inguinal lymph nodes	J:17976
	absent mesenteric lymph nodes	J:17976, J:39746
	absent Peyer's patches	J:17976
	absent popliteal lymph nodes	J:17976
	absent spleen marginal zone	J:17976
	decreased interferon-gamma secretion	J:109621
	decreased spleen white pulp amount	J:109621
	decreased T cell number	J:17976
	decreased tumor necrosis factor secretion	J:109621
	increased B cell number	J:17976
	increased leukocyte cell number	J:17976
Lta^tm1Dch/Lta^tm1Dch (B6.129S2-Lta^tm1Dch/J)	abnormal lymph organ development	J:73100
Lta^tm1Dch/Lta^tm1Dch (involves: 129S2/SvPas)	abnormal lymphocyte morphology	J:173115
	abnormal thymus epithelium morphology	J:173115
	abnormal thymus medulla morphology	J:173115
	small thymus medulla	J:173115
Lta^tm1Dch/Lta^tm1Dch Rorc^tm2Litt/Rorc⁺ (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)	abnormal gut-associated lymphoid tissue morphology	J:91566
Lta^tm1Dch/Lta^tm1Dch Tg(Igk-Lta/Ltb)4Cys/0 (involves: 129S2/SvPas * C57BL/6J * DBA/2J)	abnormal lymph organ development	J:73100
	abnormal spleen morphology	J:73100
	immune system phenotype	J:73100
Lta^tm1Dch/Lta^tm1Dch Tnfsf14^tm1Lpc/Tnfsf14^tm1Lpc (involves: 129S2/SvPas * 129X1/SvJ)	abnormal lymphocyte morphology	J:173115
	abnormal thymus epithelium morphology	J:173115
	small thymus medulla	J:173115
Lta^tm1Jods/Lta^tm1Jods (C57BL/6-Lta^tm1Jods)	abnormal immune system organ morphology	J:47428
	abnormal spleen morphology	J:47428
	abnormal spleen white pulp morphology	J:78229
	absent peripheral lymph nodes	J:47428
	absent Peyer's patches	J:47428
	increased lymphocyte cell number	J:47428
Lta^tm1Jods/Lta^tm1Jods (involves: C57BL/6)	abnormal thymus epithelium morphology	J:125864
Lta^tm1Tab/Lta^tm1Tab (either: (involves: 129S2/SvPas * C57BL/6J) or (involves: 129S2/SvPas * CF-1))	abnormal humoral immune response	J:28061
	absent lymph nodes	J:28061
	absent Peyer's patches	J:28061
	absent spleen marginal zone	J:28061
	decreased IgA level	J:28061
	decreased spleen white pulp amount	J:28061
	increased IgM level	J:28061
	increased leukocyte cell number	J:28061
	increased spleen weight	J:28061
Lta^tm1Tab/Lta^tm1Tab (involves: 129S2/SvPas * C57BL/6)	decreased tumor necrosis factor secretion	J:109621
Lta^tm1Tab/Lta^tm1Tab (B6.129S2-Lta^tm1Tab)	decreased susceptibility to parasitic infection	J:121070
Ltb4r1^tm1Adl/Ltb4r1^tm1Adl (involves: 129S4/SvJae * C57BL/6)	abnormal leukocyte adhesion	J:63873
	abnormal leukocyte migration	J:63873
	abnormal macrophage physiology	J:63873
	abnormal neutrophil physiology	J:63873
	impaired eosinophil recruitment	J:63873
	impaired neutrophil chemotaxis	J:63873
Ltb4r1^tm1Bodd/Ltb4r1^tm1Bodd (involves: 129S4/SvJaeSor * C57BL/6)	decreased susceptibility to autoimmune disorder	J:108446
Ltb4r1^tm1Bodd/Ltb4r1^tm1Bodd (involves: 129S4/SvJaeSor)	decreased susceptibility to induced arthritis	J:131779
Ltb4r1^tm1Bodd/Ltb4r1^tm1Bodd (involves: 129S4/SvJaeSor)	decreased synovial pannus formation	J:131779
Ltb4r1^tm1Bodd/Ltb4r1^tm1Bodd (either: (involves: 129S4/SvJaeSor * BALB/c ) or (involves: 129S4/SvJaeSor * C57BL/6))	decreased susceptibility to induced arthritis	J:163271
	impaired neutrophil chemotaxis	J:163271
Ltb4r1^tm1Tksh/Ltb4r1^tm1Tksh (B6.Cg-Ltb4r1^tm1Tksh)	abnormal cytokine secretion	J:118995
	decreased eosinophil cell number	J:118995
	decreased IgE level	J:118995
	decreased susceptibility to type I hypersensitivity reaction	J:197334
	lung inflammation	J:118995
Ltb4r1^tm1Tksh/Ltb4r1^tm1Tksh (C.Cg-Ltb4r1^tm1Tksh)	abnormal mast cell physiology	J:133998
Ltb4r1^tm1Tksh/Ltb4r1^tm1Tksh (involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj)	abnormal granulocyte physiology	J:118995
Ltb4r2^tm1Bodd/Ltb4r2^tm1Bodd (involves: 129S4/SvJaeSor * C57BL/6)	decreased susceptibility to induced arthritis	J:163271
	immune system phenotype	J:163271
Ltb4r2^tm1Tksh/Ltb4r2^tm1Tksh (C.Cg-Ltb4r2^tm1Tksh)	abnormal mast cell physiology	J:133998
Ltb4r2^tm1Tksh/Ltb4r2^tm1Tksh (B6.Cg-Ltb4r2^tm1Tksh)	decreased susceptibility to type I hypersensitivity reaction	J:197334
Ltb/Tnf/Lta^tm1Dvk/Ltb/Tnf/Lta^tm1Dvk (involves: C57BL/6)	decreased spleen white pulp amount	J:109621
Ltb/Tnf/Lta^tm1Dvk/Ltb/Tnf/Lta^tm1Dvk (B6.Cg-Ltb/Tnf/Lta^tm1Dvk)	abnormal class switch recombination	J:80616
	abnormal spleen morphology	J:80616
	absent axillary lymph nodes	J:80616
	absent brachial lymph nodes	J:80616
	absent inguinal lymph nodes	J:80616
	absent lymph nodes	J:80616
	absent mesenteric lymph nodes	J:80616
	absent Peyer's patches	J:80616
	absent popliteal lymph nodes	J:80616
	absent spleen germinal center	J:80616
	absent spleen marginal zone	J:80616
	decreased IgG level	J:80616
	decreased spleen B cell follicle number	J:80616
	decreased spleen white pulp amount	J:80616
	increased leukocyte cell number	J:80616
	increased susceptibility to bacterial infection	J:80616
Ltb/Tnf/Lta^tm1Dvk/Ltb/Tnf/Lta^tm1Dvk (involves: C57BL/6)	decreased spleen white pulp amount	J:109621
Ltb/Tnf/Lta^tm1Dvk/Ltb/Tnf/Lta^tm1Dvk (B6.Cg-Ltb/Tnf/Lta^tm1Dvk)	abnormal class switch recombination	J:80616
	abnormal spleen morphology	J:80616
	absent axillary lymph nodes	J:80616
	absent brachial lymph nodes	J:80616
	absent inguinal lymph nodes	J:80616
	absent lymph nodes	J:80616
	absent mesenteric lymph nodes	J:80616
	absent Peyer's patches	J:80616
	absent popliteal lymph nodes	J:80616
	absent spleen germinal center	J:80616
	absent spleen marginal zone	J:80616
	decreased IgG level	J:80616
	decreased spleen B cell follicle number	J:80616
	decreased spleen white pulp amount	J:80616
	increased leukocyte cell number	J:80616
	increased susceptibility to bacterial infection	J:80616
Ltb/Tnf/Lta^tm1Dvk/Ltb/Tnf/Lta^tm1Dvk (involves: C57BL/6)	decreased spleen white pulp amount	J:109621
Ltb/Tnf/Lta^tm1Dvk/Ltb/Tnf/Lta^tm1Dvk (B6.Cg-Ltb/Tnf/Lta^tm1Dvk)	abnormal class switch recombination	J:80616
	abnormal spleen morphology	J:80616
	absent axillary lymph nodes	J:80616
	absent brachial lymph nodes	J:80616
	absent inguinal lymph nodes	J:80616
	absent lymph nodes	J:80616
	absent mesenteric lymph nodes	J:80616
	absent Peyer's patches	J:80616
	absent popliteal lymph nodes	J:80616
	absent spleen germinal center	J:80616
	absent spleen marginal zone	J:80616
	decreased IgG level	J:80616
	decreased spleen B cell follicle number	J:80616
	decreased spleen white pulp amount	J:80616
	increased leukocyte cell number	J:80616
	increased susceptibility to bacterial infection	J:80616
Ltb/Tnf^tm1.1Dvk/Ltb/Tnf^tm1.1Dvk (involves: 129P2/OlaHsd * BALB/cJ * C57BL/6)	abnormal mesenteric lymph node morphology	J:58981
	abnormal spleen morphology	J:58981
	absent axillary lymph nodes	J:58981
	absent brachial lymph nodes	J:58981
	absent cervical lymph nodes	J:58981
	absent follicular dendritic cells	J:58981
	absent germinal center B cells	J:58981
	absent inguinal lymph nodes	J:58981
	absent peripheral lymph nodes	J:58981
	absent Peyer's patches	J:58981
	absent popliteal lymph nodes	J:58981
	absent spleen marginal zone	J:58981
	intermingled spleen red and white pulp	J:58981
Ltb/Tnf^tm1.1Dvk/Ltb/Tnf^tm1.1Dvk (involves: 129P2/OlaHsd * BALB/cJ * C57BL/6)	abnormal mesenteric lymph node morphology	J:58981
	abnormal spleen morphology	J:58981
	absent axillary lymph nodes	J:58981
	absent brachial lymph nodes	J:58981
	absent cervical lymph nodes	J:58981
	absent follicular dendritic cells	J:58981
	absent germinal center B cells	J:58981
	absent inguinal lymph nodes	J:58981
	absent peripheral lymph nodes	J:58981
	absent Peyer's patches	J:58981
	absent popliteal lymph nodes	J:58981
	absent spleen marginal zone	J:58981
	intermingled spleen red and white pulp	J:58981
Ltb^tm1Flv/Ltb^tm1Flv (involves: 129S1/Sv * C57BL/6J)	abnormal humoral immune response	J:39746
	abnormal mesenteric lymph node morphology	J:39746
	abnormal spleen morphology	J:39746
	abnormal spleen red pulp morphology	J:39746
	abnormal spleen white pulp morphology	J:39746
	absent peripheral lymph nodes	J:39746
	absent Peyer's patches	J:39746
	decreased IgA level	J:39746
Ltb^tm1Kpf/Ltb^tm1Kpf (B6.129P2-Ltb^tm1Kpf)	abnormal class switch recombination	J:80616
	abnormal spleen morphology	J:80616
	absent spleen marginal zone	J:80616
	colitis	J:158663
	decreased IgG level	J:80616
	decreased spleen B cell follicle number	J:80616
	decreased spleen white pulp amount	J:80616
	increased IgM level	J:80616
	increased leukocyte cell number	J:80616
	increased susceptibility to bacterial infection	J:80616, J:158663
	increased susceptibility to bacterial infection induced morbidity/mortality	J:158663
Ltb^tm1Kpf/Ltb^tm1Kpf (involves: 129P2/OlaHsd * C57BL/6)	abnormal mesenteric lymph node morphology	J:58981, J:42508
	abnormal spleen follicular dendritic cell network	J:42508
	abnormal spleen germinal center morphology	J:42508
	abnormal spleen marginal zone morphology	J:42508
	abnormal spleen morphology	J:58981, J:42508
	abnormal spleen red pulp morphology	J:42508
	absent axillary lymph nodes	J:42508
	absent brachial lymph nodes	J:42508
	absent cervical lymph nodes	J:58981
	absent follicular dendritic cells	J:58981
	absent inguinal lymph nodes	J:42508
	absent Peyer's patches	J:42508
	absent popliteal lymph nodes	J:42508
	absent spleen marginal zone	J:58981
	decreased spleen white pulp amount	J:109621
	increased lymphocyte cell number	J:42508
Ltb^tm1Kpf/Ltb^tm1Kpf Tnfsf14^tm1Kpf/Tnfsf14^tm1Kpf (involves: 129P2/OlaHsd * C57BL/6)	abnormal mesenteric lymph node morphology	J:77250
	abnormal spleen morphology	J:77250
	absent axillary lymph nodes	J:77250
	absent brachial lymph nodes	J:77250
	absent inguinal lymph nodes	J:77250
	absent lymph nodes	J:77250
	absent Peyer's patches	J:77250
	absent popliteal lymph nodes	J:77250
Ltb^tm1Krn/Ltb^tm1Krn (C57BL/6-Ltb^tm1Krn)	abnormal humoral immune response	J:78229
	abnormal mesenteric lymph node morphology	J:78229
	abnormal spleen morphology	J:78229
	absent cervical lymph nodes	J:78229
	absent peripheral lymph nodes	J:78229
	absent Peyer's patches	J:78229
	decreased IgG1 level	J:78229
	decreased IgG2a level	J:78229
	increased IgM level	J:78229
	increased susceptibility to parasitic infection	J:78229
	spleen hyperplasia	J:78229
Ltbp1^{tm1a(EUCOMM)Wtsi}/Ltbp1⁺ (B6JTyr;B6N-Ltbp1^{tm1a(EUCOMM)Wtsi}/Wtsi)	increased leukocyte cell number	J:175295
Ltbp3^{em1(IMPC)Ccpcz}/Ltbp3⁺ (C57BL/6NCrl-Ltbp3^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
Ltbp3^tm1Bdvc/Ltbp3^tm1Bdvc (involves: 129S6/SvEvTac)	osteoarthritis	J:76213, J:79920
Ltbp4^em1(IMPC)Tcp/Ltbp4^em1(IMPC)Tcp (C57BL/6NCrl-Ltbp4^em1(IMPC)Tcp/Tcp)	decreased basophil cell number	J:211773
	enlarged spleen	J:211773
	increased monocyte cell number	J:211773
Ltbp4^{Gt(U3Cre)1Vmel}/Ltbp4^{Gt(U3Cre)1Vmel} (B6.129S2-Ltbp4^{Gt(U3Cre)1Vmel})	colitis	J:78819
	enlarged spleen	J:78819
	proctitis	J:78819
Ltbr^m1Btlr/Ltbr^m1Btlr (C57BL/6J-Ltbr^m1Btlr)	abnormal B cell physiology	J:212068
Ltbr^m1Btlr/Ltbr^m1Btlr (C57BL/6J-Ltbr^m1Btlr)	abnormal humoral immune response	J:212068
Ltbr^m2Btlr/Ltbr^m2Btlr (C57BL/6J-Ltbr^m2Btlr)	abnormal humoral immune response	J:254823
Ltbr^m2Btlr/Ltbr^m2Btlr (C57BL/6J-Ltbr^m2Btlr)	abnormal IgG level	J:254823
Ltbr^m3Btlr/Ltbr^m3Btlr (C57BL/6J-Ltbr^m3Btlr)	impaired natural killer cell mediated cytotoxicity	J:264642
Ltbr^m3Btlr/Ltbr^m3Btlr (C57BL/6J-Ltbr^m3Btlr)	increased NK T cell number	J:264642
Ltbr^m4Btlr/Ltbr^m4Btlr (C57BL/6J-Ltbr^m4Btlr)	decreased alpha-beta T cell number	J:264820
	decreased CD4-positive, alpha-beta T cell number	J:264820
	decreased CD8-positive, alpha-beta T cell number	J:264820
	decreased NK cell number	J:264820
	decreased single-positive T cell number	J:264820
	increased B cell number	J:264820
	increased B-1 B cell number	J:264820
Ltbr^tm1.1Thhe/Ltbr^tm1.1Thhe Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6 * SJL)	abnormal macrophage physiology	J:183109
Ltbr^tm1Avt/Ltbr^tm1Avt Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd)	increased susceptibility to bacterial infection	J:158663
Ltbr^tm1Avt/Ltbr^tm1Avt Tg(Lck-cre)I57Jxm/0 (Not Specified)	immune system phenotype	J:158663
Ltbr^tm1Avt/Ltbr^tm1Avt Tg(Rorc-cre)1Litt/0 (Not Specified)	abnormal chemokine level	J:158663
	decreased neutrophil cell number	J:158663
	increased susceptibility to bacterial infection	J:158663
	increased susceptibility to bacterial infection induced morbidity/mortality	J:158663
Ltbr^tm1Avt/Ltbr^tm1Avt Tg(Vil1-cre)997Gum/0 (involves: C57BL/6J * SJL)	decreased neutrophil cell number	J:158663
	increased susceptibility to bacterial infection	J:158663
Ltbr^tm1Kpf/Ltbr^tm1Kpf (involves: 129P2/OlaHsd)	abnormal gamma-delta T cell morphology	J:169863
	abnormal immune system morphology	J:48837
	abnormal immune system organ morphology	J:48837
	abnormal immune system physiology	J:48837
	abnormal spleen B cell follicle morphology	J:48837
	abnormal spleen morphology	J:48837
	abnormal spleen periarteriolar lymphoid sheath morphology	J:48837
	absent marginal zone B cells	J:48837
	absent peripheral lymph nodes	J:48837
	absent Peyer's patches	J:48837
	decreased IgE level	J:86810
	decreased interleukin-17 secretion	J:169863
	enlarged spleen	J:48837
	immune system phenotype	J:169863
	increased B cell number	J:48837
	increased lymphocyte cell number	J:48837
	increased T cell number	J:48837
Ltbr^tm1Kpf/Ltbr^tm1Kpf (involves: 129P2/OlaHsd * C57BL/6)	decreased spleen white pulp amount	J:109621
Ltbr^tm1Kpf/Ltbr^tm1Kpf (B6.129P2-Ltbr^tm1Kpf)	decreased neutrophil cell number	J:158663
Ltbr^tm1Kpf/Ltbr^tm1Kpf Tg(Lck-Tnfsf14)24Yxf/? (B6.Cg-Ltbr^tm1Kpf Tg(Lck-Tnfsf14)24Yxf)	immune system phenotype	J:128976
Ltbr^tm1Mmat/Ltbr^tm1Mmat (involves: C57BL/6 * CBA)	abnormal lymphocyte morphology	J:173115
	abnormal spleen morphology	J:173115
	abnormal thymus epithelium morphology	J:173115
	abnormal thymus medulla morphology	J:173115
	absent follicular dendritic cells	J:173115
	absent mesenteric lymph nodes	J:173115
	absent spleen germinal center	J:173115
	small thymus medulla	J:173115
Ltbr^tm1Mmat/Ltbr^tm1Mmat Tnfsf11^tm1Pngr/Tnfsf11^tm1Pngr (involves: 129P2/OlaHsd * C57BL/6 * CBA)	abnormal thymus epithelium morphology	J:173115
Ltc4s^tm1Blam/Ltc4s^tm1Blam (involves: 129S7/SvEvBrd * C57BL/6)	immune system phenotype	J:110309
	respiratory system inflammation	J:88647
Ltc4s^tm1Blam/Ltc4s^tm1Blam (involves: 129S7/SvEvBrd * BALB/c)	abnormal hypersensitivity reaction	J:87909
	abnormal type I hypersensitivity reaction	J:87909
Ltc4s^tm1Blam/Ltc4s^tm1Blam (C.129S7-Ltc4s^tm1Blam)	autoimmune response	J:182213
Ltc4s^tm1Blam/Ltc4s^tm1Blam (B6.129S7-Ltc4s^tm1Blam)	decreased susceptibility to type I hypersensitivity reaction	J:197334
Ltf^tm1Omc/Ltf^tm1Omc (either: 129S/SvEv or (involves: 129S/SvEv * C57BL/6))	decreased spleen iron level	J:81005
Ltn1^{tm1b(EUCOMM)Hmgu}/Ltn1^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Ltn1^{tm1b(EUCOMM)Hmgu}/Ccpcz)	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
Ltv1^em1(IMPC)J/Ltv1⁺ (C57BL/6NJ-Ltv1^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
Ltxs2^BALB/cAnPt/Ltxs2^DBA/2NCr (involves: BALB/cAnPt * DBA/2NCr)	decreased susceptibility to infection	J:103336
Ltxs2^DBA/2NCr/Ltxs2^DBA/2NCr (involves: BALB/cAnPt * DBA/2NCr)	decreased susceptibility to infection	J:103336
Ltxs3^BALB/cAnPt/Ltxs3^DBA/2NCr (involves: BALB/cAnPt * DBA/2NCr)	decreased susceptibility to infection	J:103336
Ltxs3^DBA/2NCr/Ltxs3^DBA/2NCr (involves: BALB/cAnPt * DBA/2NCr)	decreased susceptibility to infection	J:103336
Luc7l^em1(IMPC)Mbp/Luc7l^em1(IMPC)Mbp (C57BL/6N-Luc7l^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Lum^tm1Wwk/Lum^tm1Wwk (involves: 129P2/OlaHsd)	abnormal inflammatory response	J:128992
Lum^tm1Wwk/Lum^tm1Wwk (involves: 129P2/OlaHsd)	decreased neutrophil cell number	J:128992
Lxw1^BXSB/Scr/? (involves: BXSB/Scr * NZW/LacScr)	increased anti-chromatin antibody level	J:86924
Lxw2^NZW/LacScr/Lxw2^NZW/LacScr (involves: BXSB/Scr * NZW/LacScr)	glomerulonephritis	J:86924
Lxw3^NZW/LacScr/? (involves: BXSB/Scr * NZW/LacScr)	increased anti-chromatin antibody level	J:86924
Lxw5^BXSB/Scr/Lxw5^BXSB/Scr (involves: BXSB/Scr * NZW/LacScr)	enlarged spleen	J:86924
Lxw5^NZW/LacScr/Lxw5^BXSB/Scr (involves: BXSB/Scr * NZW/LacScr)	enlarged spleen	J:86924
Lxw6^NZW/LacScr/Lxw6^NZW/LacScr (involves: BXSB/Scr * NZW/LacScr)	enlarged spleen	J:86924
Ly6a^tm1Pmf/Ly6a^tm1Pmf (B6.129P2-Ly6a^tm1Pmf)	abnormal immunoglobulin level	J:42594
	abnormal myeloid leukocyte morphology	J:81387
	abnormal T cell proliferation	J:42594
	decreased granulocyte number	J:81387
	decreased monocyte cell number	J:81387
	increased lymphocyte cell number	J:81387
Ly6a^tm1Pmf/Ly6a^tm1Pmf (C.129P2-Ly6a^tm1Pmf)	abnormal osteoclast differentiation	J:83409
Ly6a^tm1Pmf/Ly6a^tm1Pmf (C.129P2-Ly6a^tm1Pmf)	decreased osteoclast cell number	J:83409
Ly6a^{tm2(RUNX1)Grau}/Ly6a⁺ (involves: 129X1/SvJ * C57BL/6J)	abnormal spleen B cell follicle morphology	J:93408
	enlarged spleen	J:93408
	increased leukocyte cell number	J:93408
	increased neutrophil cell number	J:93408
	myeloid hyperplasia	J:93408
Ly6e^{tm1c(EUCOMM)Hmgu}/Ly6e^{tm1c(EUCOMM)Hmgu} Commd10^{Tg(Vav1-icre)A2Kio}/Commd10⁺ (B6.Cg-Ly6e^{tm1c(EUCOMM)Hmgu} Commd10^{Tg(Vav1-icre)A2Kio})	abnormal mononuclear cell morphology	J:291868
	decreased B cell number	J:291868
	decreased CD4-positive, alpha-beta T cell number	J:291868
	decreased dendritic cell number	J:291868
	decreased inflammatory response	J:291868
	decreased macrophage cell number	J:291868
	decreased neutrophil cell number	J:291868
	decreased NK cell number	J:291868
	increased susceptibility to Coronaviridae infection	J:291868
	increased susceptibility to Coronaviridae infection induced morbidity/mortality	J:291868
Ly6g^{tm2621(cre)Arte}/Ly6g^{tm2621(cre)Arte} (involves: C57BL/6)	immune system phenotype	J:227159
Ly9^tm1Mckn/Ly9^tm1Mckn (involves: 129/Sv * C57BL/6)	abnormal cytokine secretion	J:105482
	abnormal T-helper 2 cell morphology	J:105482
	decreased T cell proliferation	J:105482
Ly75^tm1Mnz/Ly75^tm1Mnz (Not Specified)	abnormal CD8-positive, alpha beta T cell morphology	J:97290
Ly75^tm1Mnz/Ly75^tm1Mnz (Not Specified)	abnormal cytotoxic T cell physiology	J:97289
Ly86^{tm1a(KOMP)Wtsi}/Ly86⁺ (C57BL/6N-Ly86^{tm1a(KOMP)Wtsi}/MbpMmucd)	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
Ly86^{tm1a(KOMP)Wtsi}/Ly86^{tm1a(KOMP)Wtsi} (C57BL/6N-Ly86^{tm1a(KOMP)Wtsi}/MbpMmucd)	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
Ly86^tm1Kmiy/Ly86^tm1Kmiy (involves: 129P2/OlaHsd * C57BL/6)	decreased B cell proliferation	J:109720
	decreased IgG2b level	J:137066
	decreased IgG3 level	J:137066
	increased IgG level	J:109720
	increased IgM level	J:109720
Ly96^m1Btlr/Ly96^m1Btlr (C57BL/6J-Ly96^m1Btlr)	decreased interleukin-1 beta secretion	J:265259
	decreased macrophage apoptosis	J:265259
	decreased tumor necrosis factor secretion	J:265259
Ly96^tm1Kmiy/Ly96^tm1Kmiy (involves: 129P2/OlaHsd * C57BL/6)	abnormal immune cell physiology	J:92494
	abnormal macrophage physiology	J:92494
	decreased B cell proliferation	J:92494
	decreased interleukin-6 secretion	J:92494
	decreased susceptibility to endotoxin shock	J:92494
	decreased tumor necrosis factor secretion	J:92494
	impaired neutrophil recruitment	J:92479
	increased susceptibility to bacterial infection	J:92494
Lyar^{Gt(RRG292)Byg}/Lyar^{Gt(RRG292)Byg} Trp53^tm1Tyj/Trp53^tm1Tyj (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)	increased T cell derived lymphoma incidence	J:263530
Lyg1^{tm1(KOMP)Vlcg}/Lyg1^{tm1(KOMP)Vlcg} (involves: C57BL/6NTac)	decreased CD4-positive, alpha-beta T cell number	J:256594
	decreased CD8-positive, alpha-beta T cell number	J:256594
	decreased interferon-gamma secretion	J:256594
Lyl1^tm1Fsky/Lyl1^tm1Fsky (involves: 129P2/OlaHsd * C57BL/6)	abnormal T cell differentiation	J:116300
	arrested B cell differentiation	J:116300
	decreased B cell number	J:116300
	decreased pro-B cell number	J:116300
Lyn^m1Anu/Lyn^m1Anu (C57BL/6JAnu-Lyn^m1Anu)	decreased B cell number	J:195155
Lyn^M1Btlr/Lyn⁺ (C57BL/6J-Lyn^M1Btlr)	decreased B cell number	J:214511
Lyn^M1Btlr/Lyn⁺ (C57BL/6J-Lyn^M1Btlr)	increased neutrophil cell number	J:214511
Lyn^M1Btlr/Lyn^M1Btlr (C57BL/6J-Lyn^M1Btlr)	decreased B cell number	J:214511
Lyn^M1Btlr/Lyn^M1Btlr (C57BL/6J-Lyn^M1Btlr)	increased neutrophil cell number	J:214511
Lyn^m2Anu/Lyn^m2Anu (C57B/6JAnu-Lyn^m2Anu/AnuApb)	decreased mature B cell number	J:104190
Lyn^m2Anu/Lyn^m2Anu (C57B/6JAnu-Lyn^m2Anu/AnuApb)	increased immature B cell number	J:104190
Lyn^M2Btlr/Lyn⁺ (C57BL/6J-Lyn^M2Btlr)	decreased IgG level	J:217146
	decreased IgM level	J:217146
	impaired humoral immune response	J:217146
Lyn^M2Btlr/Lyn^M2Btlr (C57BL/6J-Lyn^M2Btlr)	decreased IgG level	J:217146
	decreased IgM level	J:217146
	impaired humoral immune response	J:217146
Lyn^M3Btlr/Lyn⁺ (C57BL/6J-Lyn^M3Btlr)	decreased T cell number	J:236679
	increased B-1 B cell number	J:236679
	increased dendritic cell number	J:236679
	increased macrophage cell number	J:236679
Lyn^M3Btlr/Lyn^M3Btlr (C57BL/6J-Lyn^M3Btlr)	decreased T cell number	J:236679
	increased B-1 B cell number	J:236679
	increased dendritic cell number	J:236679
	increased macrophage cell number	J:236679
Lyn^m4Btlr/Lyn^m4Btlr (C57BL/6J-Lyn^m4Btlr)	decreased IgG level	J:272816
Lyn^m4Btlr/Lyn^m4Btlr (C57BL/6J-Lyn^m4Btlr)	impaired humoral immune response	J:272816
Lyn^mld4/Lyn^mld4 (involves: C57BL/6)	abnormal B cell activation	J:144799
	abnormal B cell morphology	J:144799
	abnormal myelopoiesis	J:144799
	decreased follicular B cell number	J:144799
	decreased marginal zone B cell number	J:144799
	decreased transitional stage B cell number	J:144799
	glomerulonephritis	J:144799
	increased anti-double stranded DNA antibody level	J:144799
	increased IgE level	J:144799
	increased IgM level	J:144799
	increased macrophage cell number	J:144799
	increased neutrophil cell number	J:144799
	increased T cell number	J:144799
	peritoneal inflammation	J:144799
	spleen hypoplasia	J:144799
Lyn^mld4/Lyn^mld4 Mpl^tm1Wsa/Mpl^tm1Wsa (B6.129S1-Mpl^tm1Wsa)	decreased leukocyte cell number	J:144799
Lyn^tm1.1Calo/Lyn^tm1.1Calo Myd88^tm1Defr/Myd88^tm1Defr Tg(Itgax-cre)1-1Reiz/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA)	immune system phenotype	J:200745
Lyn^tm1.1Calo/Lyn^tm1.1Calo Tg(Itgax-cre)1-1Reiz/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA)	abnormal circulating chemokine level	J:200745
	abnormal circulating cytokine level	J:200745
	abnormal dendritic cell physiology	J:200745
	abnormal leukocyte physiology	J:200745
	abnormal T cell activation	J:200745
	enlarged lymph nodes	J:200745
	enlarged spleen	J:200745
	glomerulonephritis	J:200745
	increased activated T cell number	J:200745
	increased autoantibody level	J:200745
	increased circulating interferon-gamma level	J:200745
	increased circulating interleukin-1 beta level	J:200745
	increased circulating interleukin-6 level	J:200745
	increased circulating interleukin-12 level	J:200745
	increased circulating interleukin-17 level	J:200745
	increased circulating tumor necrosis factor level	J:200745
	increased dendritic cell number	J:200745
	increased granulocyte number	J:200745
	increased inflammatory response	J:200745
	increased leukocyte cell number	J:200745
	increased monocyte cell number	J:200745
	increased plasma cell number	J:200745
	increased T cell number	J:200745
	liver inflammation	J:200745
	lung inflammation	J:200745
	lymph node hyperplasia	J:200745
	myeloid hyperplasia	J:200745
	skin inflammation	J:200745
Lyn^tm1Ard/Lyn⁺ Ptpn6^me-v/Ptpn6⁺ Tg(IghelMD4)4Ccg/0 (involves: 129P2/OlaHsd * C57BL/6)	abnormal mature B cell morphology	J:110531
Lyn^tm1Ard/Lyn⁺ Tg(IghelMD4)4Ccg/0 (involves: 129P2/OlaHsd * C57BL/6)	abnormal mature B cell morphology	J:110531
Lyn^tm1Ard/Lyn^tm1Ard (involves: 129P2/OlaHsd)	abnormal circulating complement protein level	J:161523
	abnormal level of surface class II molecules	J:161523
	decreased spleen red pulp amount	J:72269
	decreased spleen white pulp amount	J:72269
	enlarged spleen	J:72269
	glomerulonephritis	J:161523
	increased anti-double stranded DNA antibody level	J:161523
	increased anti-nuclear antigen antibody level	J:161523
	increased basophil cell number	J:161523
	increased IgA level	J:161523
	increased IgE level	J:161523
	increased IgG2b level	J:161523
	increased IgM level	J:161523
	increased mast cell number	J:161523
	increased neutrophil cell number	J:72269
Lyn^tm1Ard/Lyn^tm1Ard (B6.129P2-Lyn^tm1Ard)	abnormal B cell activation	J:144799
	abnormal B cell morphology	J:144799
	abnormal myelopoiesis	J:144799
	decreased follicular B cell number	J:144799
	decreased marginal zone B cell number	J:144799
	decreased transitional stage B cell number	J:144799
	glomerulonephritis	J:144799
	increased anti-double stranded DNA antibody level	J:144799
	increased anti-nuclear antigen antibody level	J:144799
	increased T cell number	J:144799
	peritoneal inflammation	J:144799
	spleen hypoplasia	J:144799
Lyn^tm1Ard/Lyn^tm1Ard Tg(IghelMD4)4Ccg/0 (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell activation	J:110531
	abnormal B cell negative selection	J:110531
	abnormal mature B cell morphology	J:110531
	absent B-1 B cells	J:110531
	increased IgM level	J:110531
Lyn^{tm1b(EUCOMM)Hmgu}/Lyn^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Lyn^{tm1b(EUCOMM)Hmgu}/H)	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
	enlarged spleen	J:211773
	increased eosinophil cell number	J:211773
	increased large unstained cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
	increased spleen weight	J:211773
	small thymus	J:211773
Lyn^tm1Mhi/Lyn^tm1Mhi (involves: 129S1/Sv)	decreased spleen weight	J:72269
Lyn^tm1Mhi/Lyn^tm1Mhi (involves: 129S1/Sv)	increased neutrophil cell number	J:72269
Lyn^tm1Sor/Lyn^tm1Sor (involves: 129S4/SvJae)	decreased B cell number	J:42037
	decreased mature B cell number	J:42037
	enlarged lymph nodes	J:42037
	enlarged spleen	J:42037
	increased anti-double stranded DNA antibody level	J:42037
	increased B cell proliferation	J:42037
Lyn^tm1Sor/Lyn^tm1Sor (B6.129S4-Lyn^tm1Sor)	abnormal inflammatory response	J:113463
Lyn^tm1Sor/Lyn^tm1Sor (involves: 129S4/SvJaeSor)	abnormal chemokine level	J:80658
	abnormal circulating chemokine level	J:200745
	abnormal circulating cytokine level	J:200745
	abnormal dendritic cell physiology	J:200745
	abnormal macrophage physiology	J:80658
	abnormal microglial cell physiology	J:80658
	decreased B cell number	J:200745
	decreased follicular B cell number	J:146161
	decreased marginal zone B cell number	J:146161
	decreased mature B cell number	J:146161
	decreased transitional stage B cell number	J:146161
	glomerulonephritis	J:146161, J:200745
	increased anti-double stranded DNA antibody level	J:146161
	increased autoantibody level	J:200745
	increased B cell proliferation	J:146161
	increased circulating interferon-gamma level	J:200745
	increased circulating interleukin-6 level	J:200745
	increased circulating interleukin-12 level	J:200745
	increased circulating interleukin-17 level	J:200745
	increased IgA level	J:146161
	increased IgM level	J:146161
	increased plasma cell number	J:200745
	liver inflammation	J:146161
	myeloid hyperplasia	J:146161
	spleen hyperplasia	J:146161
Lyn^tm1Sor/Lyn^tm1Sor (involves: 129S4/SvJaeSor * C57BL/6)	decreased B cell number	J:71174
	decreased B-1 B cell number	J:71174
	decreased mature B cell number	J:71174
	enlarged spleen	J:71174
	glomerulonephritis	J:71174
	increased anti-double stranded DNA antibody level	J:71174
	increased B cell proliferation	J:71174
	increased IgA level	J:71174
	increased IgG1 level	J:71174
	increased IgG2b level	J:71174
	increased IgG level	J:71174
	increased IgM level	J:71174
	increased susceptibility to systemic lupus erythematosus	J:71174
Lyn^tm1Tya/Lyn^tm1Tya (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell physiology	J:29751
	abnormal class switch recombination	J:29751
	abnormal spleen morphology	J:29751
	decreased B cell number	J:29751
	decreased B cell proliferation	J:29751
	decreased lymphocyte cell number	J:29751
	enlarged lymph nodes	J:29751
	enlarged spleen	J:29751
	glomerulonephritis	J:29751
	increased anti-double stranded DNA antibody level	J:29751
	increased IgA level	J:29751
	increased IgM level	J:29751
	increased immunoglobulin level	J:29751
	increased spleen white pulp amount	J:29751
	small Peyer's patches	J:29751
Lyn^weeb/Lyn^weeb (C57BL/6-Lyn^weeb)	decreased follicular B cell number	J:146161
	decreased marginal zone B cell number	J:146161
	decreased mature B cell number	J:146161
	decreased transitional stage B cell number	J:146161
	disorganized spleen B cell follicle	J:146161
	glomerulonephritis	J:146161
	increased anti-double stranded DNA antibody level	J:146161
	increased B cell proliferation	J:146161
	increased IgM level	J:146161
	liver inflammation	J:146161
	spleen hyperplasia	J:146161
Lynf1^C57BL/10J/Lynf1^C57BL/10J Lynf3^C57BL/10J/Lynf3^C57BL/10J (involves: B10.O20 * O20/A)	abnormal acute inflammation	J:128728
Lynf2^C57BL/10J/Lynf2^C57BL/10J Lynf3^C57BL/10J/Lynf3^C57BL/10J (involves: B10.O20 * O20/A)	abnormal acute inflammation	J:128728
Lynf2^O20/A/Lynf2^O20/A (involves: B10.O20 * O20/A)	abnormal acute inflammation	J:128728
Lynf4^C57BL/10J/Lynf4^C57BL/10J (involves: B10.O20 * O20/A)	abnormal acute inflammation	J:128728
Lynf4^C57BL/10J/Lynf4^O20/A (involves: B10.O20 * O20/A)	abnormal acute inflammation	J:128728
Lypd8^tm2Ktak/Lypd8^tm2Ktak (B6.Cg-Lypd8^tm2Ktak)	increased susceptibility to colitis induced morbidity/mortality	J:232706
Lypd8^tm2Ktak/Lypd8^tm2Ktak (B6.Cg-Lypd8^tm2Ktak)	increased susceptibility to induced colitis	J:232706
Lyset^em1Janc/Lyset^em1Janc (C57BL/6J-Tmem251^em1Janc)	decreased susceptibility to viral infection	J:330704
Lyset^em1Janc/Lyset^em2Janc (C57BL/6J-Tmem251^em1Janc Tmem251^em2Janc)	decreased susceptibility to viral infection	J:330704
Lyset^em2Janc/Lyset^em2Janc (C57BL/6J-Tmem251^em2Janc)	decreased susceptibility to viral infection	J:330704
Lyst^bg-2Btlr/Lyst^bg-2Btlr (C57BL/6J-Lyst^bg-2Btlr)	abnormal NK cell physiology	J:133617
Lyst^bg-2Btlr/Lyst^bg-2Btlr (C57BL/6J-Lyst^bg-2Btlr)	increased susceptibility to Herpesvirales infection	J:133617
Lyst^bg-2J/Lyst^bg-2J (C3.Cg-Lyst^bg-2J/J)	abnormal susceptibility to infection	J:147940
Lyst^bg-2J/Lyst^bg-2J (C3.Cg-Lyst^bg-2J/J)	decreased susceptibility to fungal infection	J:147940
Lyst^bg-5Btlr/Lyst⁺ (C57BL/6J-Lyst^bg-5Btlr)	impaired macrophage phagocytosis	J:217864
Lyst^bg-5Btlr/Lyst^bg-5Btlr (C57BL/6J-Lyst^bg-5Btlr)	impaired macrophage phagocytosis	J:217864
Lyst^bg-6Btlr/Lyst^bg-6Btlr (C57BL/6J-Lyst^bg-6Btlr)	increased susceptibility to Herpesvirales infection	J:220065
Lyst^bg-Btlr/Lyst^bg-Btlr (C57BL/6J-Lyst^bg-Btlr)	abnormal NK cell physiology	J:133616
	increased susceptibility to bacterial infection	J:133616
	increased susceptibility to Herpesvirales infection	J:133616
Lyst^bg-grey/Lyst^bg-grey (C57BL/6-Lyst^bg-grey)	abnormal dermal mast cell morphology	J:106442
Lyst^bg-J/Lyst^bg-J (C57BL/6J-Lyst^bg-J/J)	abnormal granulocyte morphology	J:34814
	abnormal neutrophil morphology	J:34814
	decreased macrophage cell number	J:34814
	impaired natural killer cell mediated cytotoxicity	J:34814
Lyst^bg-J/Lyst^bg-J Prkdc^scid/Prkdc^scid (B6.Cg-Lyst^bg-J Prkdc^scid/Sz)	abnormal complement pathway	J:34814
	abnormal granulocyte morphology	J:34814
	abnormal level of surface class II molecules	J:34814
	abnormal lymph node morphology	J:34814
	abnormal neutrophil morphology	J:34814
	abnormal Peyer's patch morphology	J:34814
	abnormal spleen white pulp morphology	J:34814
	abnormal thymus morphology	J:34814
	decreased B cell number	J:34814
	decreased CD4-positive, alpha-beta T cell number	J:34814
	decreased CD8-positive, alpha-beta T cell number	J:34814
	decreased immunoglobulin level	J:34814
	decreased lymphocyte cell number	J:34814
	decreased pre-B cell number	J:34814
	decreased T cell number	J:34814
	impaired natural killer cell mediated cytotoxicity	J:34814
	increased eosinophil cell number	J:34814
	increased granulocyte number	J:34814
	increased macrophage cell number	J:34814
	increased monocyte cell number	J:34814
	increased neutrophil cell number	J:34814
	increased NK cell number	J:34814
	small Peyer's patches	J:34814
	small thymus	J:34814
	spleen hypoplasia	J:34814
	thymus cyst	J:34814
Lyst^bg-Lac/Lyst^bg-Lac (CBA/CaLac-Lyst^bg-Lac)	absent NK T cells	J:29745
Lyst^bg/Lyst^bg (B6.C3Rl-Lyst^bg)	abnormal eosinophil morphology	J:5078
	abnormal lymphocyte morphology	J:5078
	abnormal neutrophil morphology	J:5078
	alveolitis	J:110157
	decreased cytotoxic T cell cytolysis	J:6692
	impaired natural killer cell mediated cytotoxicity	J:6302, J:6213
Lyst^bg/Lyst^bg (B6.C3Rl-Lyst^bg/J)	abnormal NK cell physiology	J:6801
Lyst^bg/Lyst^bg (B6.C3Rl-Lyst^bg/J)	increased susceptibility to parasitic infection	J:6946
Lyst^bg/Lyst^bg Prkdc^scid/Prkdc^scid (Not Specified)	increased susceptibility to infection	J:4752
Lyve1^{tm1.1(EGFP/cre)Cys}/Lyve1⁺ Sphk1^tm2Cgh/Sphk1^tm2Cgh Sphk2^tm1.1Cgh/Sphk2^tm1.1Cgh (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)	abnormal leukocyte migration	J:156826
	abnormal lymph node morphology	J:156826
	abnormal lymphatic vessel morphology	J:156826
	abnormal lymphocyte cell number	J:156826
	abnormal Peyer's patch T cell area morphology	J:156826
	decreased B cell number	J:156826
	decreased splenocyte number	J:156826
	decreased T cell number	J:156826
	immune system phenotype	J:156826
Lyve1^tm1Dgjk/Lyve1^tm1Dgjk (involves: 129 * C57BL/6)	immune system phenotype	J:117678
Lyve1^tm1Lhua/Lyve1^tm1Lhua (B6.129S1-Lyve1^tm1Lhua)	abnormal lymph circulation	J:117713
Lyve1^tm1Lhua/Lyve1^tm1Lhua (B6.129S1-Lyve1^tm1Lhua)	lymphangiectasis	J:117713
Lyz2^tm1(cre)Ifo/0 Nup85^tm1.1Yter/Nup85^tm1.1Yter (involves: 129P2/OlaHsd * C57BL/6)	decreased macrophage cell number	J:292726
Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6)	enlarged spleen	J:172024
Lyz2^tm1(cre)Ifo/Lyz2⁺ Nfkbiz^tm1.1Muta/Nfkbiz^tm1.1Muta (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:194832
Lyz2^tm1(cre)Ifo/Lyz2⁺ Nsd3^tm1.1Caox/Nsd3^tm1.1Caox (involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J * SJL)	decreased macrophage cytokine production	J:251909
	increased susceptibility to Riboviria infection	J:251909
	increased susceptibility to Riboviria infection induced morbidity/mortality	J:251909
Lyz2^tm1(cre)Ifo/Lyz2⁺ Pdcd10^tm1Wami/Pdcd10^tm1Wami (involves: 129 * 129P2/OlaHsd * C57BL/6)	abnormal neutrophil morphology	J:256076
	abnormal neutrophil physiology	J:256076
Lyz2^tm1(cre)Ifo/Lyz2⁺ Pikfyve^{tm1b(EUCOMM)Hmgu}/Pikfyve^{tm1b(EUCOMM)Hmgu} (involves: 129P2/OlaHsd * C57BL/6N)	abnormal alveolar macrophage morphology	J:244776
	decreased alveolar macrophage number	J:244776
	decreased regulatory T cell number	J:244776
	immune system phenotype	J:244776
	increased eosinophil cell number	J:244776
	increased interleukin-4 secretion	J:244776
	increased interleukin-13 secretion	J:244776
	increased susceptibility to type I hypersensitivity reaction	J:244776
Lyz2^tm1(cre)Ifo/Lyz2⁺ Rnf217^tm1.1Fudi/Rnf217^tm1.1Fudi (involves: 129P2/OlaHsd)	decreased spleen iron level	J:315675
Lyz2^tm1(cre)Ifo/Lyz2⁺ Selenow^{tm1c(EUCOMM)Wtsi}/Selenow^{tm1c(EUCOMM)Wtsi} (B6.Cg-Selenow^{tm1c(EUCOMM)Wtsi} Lyz2^tm1(cre)Ifo)	abnormal osteoclast differentiation	J:317012
Lyz2^tm1(cre)Ifo/Lyz2⁺ St18^{tm1c(KOMP)Wtsi}/St18^{tm1c(KOMP)Wtsi} (involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N)	immune system phenotype	J:298828
	increased circulating interleukin-1 beta level	J:298828
	increased inflammatory response	J:298828
Lyz2^tm1(cre)Ifo/Lyz2^tm1(cre)Ifo Nrros^tm1Wouy/Nrros^tm1Wouy (involves: 129P2/OlaHsd)	abnormal cellular extravasation	J:209569
	increased susceptibility to experimental autoimmune encephalomyelitis	J:209569
Lyz2^{tm1(HBEGF)Mtka}/Lyz2⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal alveolar macrophage morphology	J:145285
Lyz2^tm1.1Graf/Lyz2^tm1.1Graf (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	increased inflammatory response	J:82642
Lztr1^em2Tumg/Lztr1⁺ (C57BL/6J-Lztr1^em2Tumg)	abnormal lymphatic vessel morphology	J:361054
Lztr1^em2Tumg/Lztr1⁺ (C57BL/6J-Lztr1^em2Tumg)	enlarged spleen	J:361054
Lztr1^em2Tumg/Lztr1^em2Tumg (C57BL/6J-Lztr1^em2Tumg)	abnormal lymphatic vessel morphology	J:361054
m1Hefl/m1Hefl (C3HeB/FeJ-m1Hefl)	decreased B cell number	J:137446
X/m1Nish (involves: BALB/c * C57BL/6N)	absent B cells	J:204833
	absent Peyer's patches	J:204833
	decreased NK cell number	J:204833
X/m1Nish (involves: C57BL/6N)	abnormal B cell differentiation	J:204833
	abnormal NK cell differentiation	J:204833
	absent B cells	J:204833
	absent B-1 B cells	J:204833
	absent B-2 B cells	J:204833
	absent Peyer's patches	J:204833
	decreased B cell number	J:204833
	decreased B-1 B cell number	J:204833
	decreased IgG level	J:204833
	decreased IgM level	J:204833
	decreased immature B cell number	J:204833
	decreased NK cell number	J:204833
	decreased T cell proliferation	J:204833
	immune system phenotype	J:204833
	small lymph nodes	J:204833
m1Nish/m1Nish⁺ (involves: BALB/c * C57BL/6N)	immune system phenotype	J:204833
m1Nish/m1Nish⁺ (involves: C57BL/6N)	immune system phenotype	J:204833
m2Hefl/m2Hefl (C3HeB/FeJ-m2Hefl)	absent B cells	J:137446
m2Hefl/m2Hefl (C3HeB/FeJ-m2Hefl)	absent T cells	J:137446
m3Hefl/m3Hefl (C3HeB/FeJ-m3Hefl)	decreased CD8-positive, alpha-beta T cell number	J:137446
m3Hefl/m3Hefl (C3HeB/FeJ-m3Hefl)	decreased NK cell number	J:137446
m4Hefl/m4Hefl (C3HeB/FeJ-m4Hefl)	decreased T cell number	J:137446
m5Hefl/m5Hefl (C3HeB/FeJ-m5Hefl)	decreased T cell number	J:137446
M6pr^em1(IMPC)Mbp/M6pr^em1(IMPC)Mbp (C57BL/6N-M6pr^em1(IMPC)Mbp/MbpMmucd)	small spleen	J:211773
M7321Wlst/M7321Wlst⁺ (involves: 129S1/SvImJ * C57BL/6J)	abnormal thrombopoiesis	J:189491
M7324Wlst/M7324Wlst⁺ (involves: 129S1/SvImJ * C57BL/6J)	abnormal thrombopoiesis	J:189491
M7325Wlst/M7325Wlst⁺ (involves: 129S1/SvImJ * C57BL/6J)	abnormal thrombopoiesis	J:189491
m12137Asr/m12137Asr⁺ (C57BL/6J-m12137Asr)	decreased osteoclast cell number	J:132290
Macroh2a1^tm1.1Oxbo/Macroh2a1^tm1.1Oxbo (B6.Cg-Macroh2a1^tm1.1Oxbo)	decreased B cell number	J:293382
	decreased neutrophil cell number	J:293382
	increased eosinophil cell number	J:293382
	increased lymphocyte cell number	J:293382
Macroh2a1^tm1Peh/Macroh2a1^tm1Peh Macroh2a2^tm1.1Peh/Macroh2a2^tm1.1Peh (129S6.Cg-Macroh2a2^tm1.1Peh Macroh2a1^tm1Peh)	blepharitis	J:220524
Macroh2a2^{em1(IMPC)Hmgu}/Macroh2a2^{em1(IMPC)Hmgu} (C57BL/6NCrl-Macroh2a2^{em1(IMPC)Hmgu}/Ieg)	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Mad2l1^tm1Sorg/Mad2l1⁺ (involves: 129S2/SvPas * C57BL/6)	increased spleen germinal center number	J:62829
Madcam1^tm1.2Nwag/Madcam1^tm1.2Nwag (B6.129P2-Madcam1^tm1.2Nwag)	abnormal B cell physiology	J:169739
	decreased B cell number	J:169739
	decreased IgA level	J:169739
	decreased plasma cell number	J:169739
	increased plasma cell number	J:169739
	small Peyer's patches	J:169739
Maea^Gt(XG702)Byg/Maea^Gt(XG702)Byg (involves: 129P2/OlaHsd * C57BL/6J)	decreased macrophage cell number	J:114865
Maf^em1(IMPC)Mbp/Maf⁺ (C57BL/6N-Maf^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	small spleen	J:211773
Maf^Ofl/Maf^Ofl (either: 102/ElH or C3H/HeH)	tubular nephritis	J:82475
Maf^tm1Glm/Maf^tm1Glm (involves: 129/Sv * BALB/c)	decreased interleukin-4 secretion	J:78382
Mafb^tm1Jeng/Mafb^tm1Jeng (involves: 129P2/OlaHsd * C57BL/6J)	immune system phenotype	J:111415
Mafg^tm1Jeng/Mafg^tm1Jeng Mafk^tm1Jeng/Mafk^tm1Jeng (involves: 129S1/Sv * 129X1/SvJ)	enlarged spleen	J:61142
Mag^{tm1.1(KOMP)Vlcg}/Mag^{tm1.1(KOMP)Vlcg} (C57BL/6N-Mag^{tm1.1(KOMP)Vlcg}/J)	decreased leukocyte cell number	J:211773
Mag^tm1Rod/Mag^tm1Rod (involves: 129S1/Sv * 129X1/SvJ)	increased B cell proliferation	J:217719
Maged1^tm1.1Urfm/Maged1^tm1.1Urfm (involves: 129P2/OlaHsd)	abnormal tumor necrosis factor level	J:157549
Magi2^tm1Key/Magi2^tm1Key (involves: 129S4/SvJae)	tubulointerstitial nephritis	J:213553
Magix^{em1(IMPC)Hmgu}/Y (C57BL/6NCrl-Magix^{em1(IMPC)Hmgu}/Ieg)	decreased leukocyte cell number	J:211773
Magt1^{Gt(IST13422E1)Tigm}/Y (involves: C57BL/6N)	abnormal B cell morphology	J:260923
	decreased plasma cell number	J:260923
	decreased T cell number	J:260923
	increased B cell number	J:260923
	increased B cell proliferation	J:260923
	increased marginal zone B cell number	J:260923
Malat1^tm1.2Dlsp/Malat1^tm1.2Dlsp (B6J.Cg-Malat1^tm1.2Dlsp)	brain inflammation	J:239375
Malt1^m1Btlr/Malt1⁺ (C57BL/6J-Malt1^m1Btlr)	impaired humoral immune response	J:221474
Malt1^m1Btlr/Malt1^m1Btlr (C57BL/6J-Malt1^m1Btlr)	impaired humoral immune response	J:221474
Malt1^m2Btlr/Malt1⁺ (C57BL/6J-Malt1^m2Btlr)	decreased IgM level	J:224671
Malt1^m2Btlr/Malt1⁺ (C57BL/6J-Malt1^m2Btlr)	impaired humoral immune response	J:224671
Malt1^m2Btlr/Malt1^m2Btlr (C57BL/6J-Malt1^m2Btlr)	decreased IgG level	J:224671
	decreased IgM level	J:224671
	impaired humoral immune response	J:224671
Malt1^m3Btlr/Malt1⁺ (C57BL/6J-Malt1^m3Btlr)	decreased IgM level	J:224672
Malt1^m3Btlr/Malt1⁺ (C57BL/6J-Malt1^m3Btlr)	impaired humoral immune response	J:224672
Malt1^m3Btlr/Malt1^m3Btlr (C57BL/6J-Malt1^m3Btlr)	decreased IgG level	J:224672
	decreased IgM level	J:224672
	impaired humoral immune response	J:224672
Malt1^tm1Mak/Malt1^tm1Mak (involves: 129P2/OlaHsd)	abnormal dendritic cell physiology	J:111706
	decreased IgG level	J:109545
	decreased IgM level	J:109545
	decreased T cell proliferation	J:109545
Malt1^tm1Vmd/Malt1^tm1Vmd (involves: C57BL/6N)	abnormal B cell differentiation	J:86770
	abnormal double-negative T cell morphology	J:86770
	abnormal immune system morphology	J:86770
	abnormal spleen marginal zone morphology	J:86770
	abnormal T cell differentiation	J:86770
	abnormal T cell proliferation	J:86770
	absent B-1a cells	J:86770
	decreased immunoglobulin level	J:86770
	decreased interleukin-2 secretion	J:86770
Maml1^tm1Mkit/Maml1^tm1Mkit (involves: 129P2/OlaHsd * C57BL/6)	decreased marginal zone B cell number	J:122286
	decreased thymocyte number	J:122286
	increased double-negative T cell number	J:122286
Mamld1^{tm1.1(NCOM)Mfgc}/Y (C57BL/6N-Mamld1^{tm1.1(NCOM)Mfgc}/Tcp)	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
Man2a1^tm1Jxm/Man2a1^tm1Jxm (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal immune serum protein physiology	J:74579
	abnormal immune system physiology	J:74579
	abnormal self tolerance	J:74579
	abnormal spleen morphology	J:74579
	enlarged spleen	J:41621
	glomerulonephritis	J:74579
	immune system phenotype	J:74579
	increased IgA level	J:74579
	increased IgG level	J:74579
	increased IgM level	J:74579
	increased memory T cell number	J:74579
	liver inflammation	J:74579
	lung inflammation	J:74579
Man2a1^tm1Jxm/Man2a1^tm1Jxm Rag1^tm1Mom/Rag1^tm1Mom (B6.129-Rag1^tm1Mom Man2a1^tm1Jxm)	kidney inflammation	J:124348
Man2b1^tm1Psa/Man2b1^tm1Psa (involves: 129 * C57BL/6J)	abnormal Kupffer cell morphology	J:56659
Man2b1^tm1Psa/Man2b1^tm1Psa (involves: 129 * C57BL/6J)	abnormal spleen red pulp morphology	J:56659
Man2b2^{tm1b(KOMP)Wtsi}/Man2b2^{tm1b(KOMP)Wtsi} (C57BL/6N-Man2b2^{tm1b(KOMP)Wtsi}/Tcp)	decreased lymphocyte cell number	J:211773
	enlarged lymph nodes	J:211773
	increased eosinophil cell number	J:211773
	increased neutrophil cell number	J:211773
Man2c1^tm1.1Tbec/Man2c1^tm1.1Tbec (B6N.129P2-Man2c1^tm1.1Tbec)	abnormal microglial cell activation	J:205550
Manba^tm1Khf/Manba^tm1Khf (B6.129-Manba^tm1Khf)	abnormal Kupffer cell morphology	J:105427
Map2k3^tm1Flv/Map2k3^tm1Flv (involves: 129S1/Sv)	abnormal CD4-positive, alpha-beta T cell physiology	J:85266
Map2k3^tm1Flv/Map2k3^tm1Flv (involves: 129S1/Sv)	decreased T cell apoptosis	J:85266
Map2k3^tm1Flv/Map2k3^tm1Flv (B6.129S1-Map2k3^tm1Flv)	increased susceptibility to bacterial infection	J:124327
Map2k6^tm1Flv/Map2k6^tm1Flv (involves: 129S1/Sv)	abnormal thymocyte apoptosis	J:85266
Map2k6^tm1Ina/Map2k6^tm1Ina Tg(TcraH-Y,TcrbH-Y)71Vbo/0 (involves: 129P2/OlaHsd * C57BL/6J * DBA/2J)	abnormal thymus cell ratio	J:100093
Map3k1^tm1Glj/Map3k1^tm1Glj (involves: 129S/SvEv)	heart inflammation	J:78068
Map3k1^tm1Glj/Map3k1^tm1Glj (involves: 129S/SvEv)	immune system phenotype	J:62909
Map3k2^tm1Bisu/Map3k2^tm1Bisu (Not Specified)	abnormal cytokine secretion	J:78072
	abnormal T cell activation	J:78072
	increased T cell proliferation	J:78072
Map3k3^tm1Bisu/Map3k3^tm2Bisu Tg(Lck-cre)548Jxm/0 (involves: C57BL/6 * CBA)	abnormal T cell physiology	J:145923
	abnormal T cell proliferation	J:145923
	decreased CD4-positive, alpha-beta T cell number	J:145923
	decreased CD8-positive, alpha-beta T cell number	J:145923
	spleen hypoplasia	J:145923
Map3k3^tm1Kuro/Map3k3^tm1Kuro Tg(Lck-cre)1Jtak/0 (involves: C57BL/6)	decreased CD4-positive, alpha-beta T cell number	J:147103
	decreased CD8-positive, alpha-beta T cell number	J:147103
	decreased double-positive T cell number	J:147103
	decreased interferon-gamma secretion	J:147103
	decreased interleukin-2 secretion	J:147103
	decreased single-positive T cell number	J:147103
	decreased T cell proliferation	J:147103
	decreased thymocyte number	J:147103
	increased double-negative T cell number	J:147103
Map3k4^tm1Flv/Map3k4^tm1Flv (involves: 129S6/SvEvTac * C57BL/6)	abnormal T-helper 1 physiology	J:90112
	decreased interferon-gamma secretion	J:90112
Map3k5^tm1Hijo/Map3k5^tm1Hijo (involves: 129S4/SvJae * C57BL/6J)	immune system phenotype	J:251158
Map3k7^tm1.1Gkl/Map3k7^tm1.1Gkl Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6)	decreased circulating interleukin-10 level	J:211916
	decreased interleukin-10 secretion	J:211916
	increased circulating interleukin-1 beta level	J:211916
	increased circulating tumor necrosis factor level	J:211916
	increased inflammatory response	J:211916
	increased interleukin-1 beta secretion	J:211916
	increased interleukin-6 secretion	J:211916
	increased interleukin-10 secretion	J:211916
	increased susceptibility to endotoxin shock	J:211916
	increased tumor necrosis factor secretion	J:211916
Map3k7^tm1Aki/Map3k7^tm1Aki Tg(Alb1-cre)7Gsc/0 (involves: 129P2/OlaHsd * FVB/N)	liver inflammation	J:160521
Map3k7^tm1Aki/Map3k7^tm1Aki Tg(Lck-cre)1Jtak/0 (involves: 129P2/OlaHsd)	abnormal spleen morphology	J:112837
	abnormal T cell activation	J:112837
	absent regulatory T cells	J:112837
	colitis	J:112837
	decreased CD4-positive, alpha-beta T cell number	J:112837
	decreased CD8-positive, alpha-beta T cell number	J:112837
	decreased single-positive T cell number	J:112837
	decreased T cell number	J:112837
	decreased T cell proliferation	J:112837
	enlarged lymph nodes	J:112837
	enlarged spleen	J:112837
	increased memory T cell number	J:112837
	spleen hyperplasia	J:112837
Map3k7^tm1Aki/Map3k7^tm1Aki Tg(Lck-cre)1Jtak/0 (involves: 129P2/OlaHsd * C57BL/6)	abnormal alpha-beta intraepithelial T cell morphology	J:238318
	abnormal CD4-positive, alpha-beta T cell physiology	J:238318
	abnormal cytokine level	J:238318
	abnormal intraepithelial T cell number	J:238318
	abnormal regulatory T cell number	J:238318
	abnormal regulatory T cell physiology	J:238318
	abnormal T cell morphology	J:238318
	colitis	J:238318
	decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:238318
	decreased NK T cell number	J:238318
	increased CD4-positive, alpha-beta T cell number	J:238318
	increased gamma-delta intraepithelial T cell number	J:238318
	increased interferon-gamma secretion	J:238318
	increased interleukin-17 secretion	J:238318
Map3k7^tm1Zjc/Map3k7^tm1Zjc Tg(Lck-cre)548Jxm/0 (involves: 129S7/SvEvBrd * C57BL/6 * CBA)	decreased CD4-positive, alpha-beta T cell number	J:111794
	decreased CD8-positive, alpha-beta T cell number	J:111794
	decreased T cell number	J:111794
	increased thymocyte apoptosis	J:111794
Map3k8^M1Btlr/Map3k8⁺ (C57BL/6J-Map3k8^M1Btlr)	abnormal tumor necrosis factor secretion	J:140986
Map3k8^M1Btlr/Map3k8⁺ (C57BL/6J-Map3k8^M1Btlr)	decreased tumor necrosis factor secretion	J:140986
Map3k8^M1Btlr/Map3k8^M1Btlr (C57BL/6J-Map3k8^M1Btlr)	abnormal response to infection	J:140986
	decreased interferon-alpha secretion	J:140986
	decreased interferon-beta secretion	J:140986
	decreased interleukin-1 beta secretion	J:140986
	decreased interleukin-6 secretion	J:140986
	decreased tumor necrosis factor secretion	J:140986
	impaired natural killer cell mediated cytotoxicity	J:140986
	increased interleukin-12b secretion	J:140986
Map3k8^m2Btlr/Map3k8^m2Btlr (C57BL/6J-Map3k8^m2Btlr)	abnormal response to infection	J:212899
Map3k8^m3Btlr/Map3k8⁺ (C57BL/6J-Map3k8^m3Btlr)	decreased macrophage cytokine production	J:224668
Map3k8^m3Btlr/Map3k8⁺ (C57BL/6J-Map3k8^m3Btlr)	decreased tumor necrosis factor secretion	J:224668
Map3k8^m3Btlr/Map3k8^m3Btlr (C57BL/6J-Map3k8^m3Btlr)	decreased macrophage cytokine production	J:224668
Map3k8^m3Btlr/Map3k8^m3Btlr (C57BL/6J-Map3k8^m3Btlr)	decreased tumor necrosis factor secretion	J:224668
Map3k8^M4Btlr/Map3k8⁺ (C57BL/6J-Map3k8^M4Btlr)	decreased tumor necrosis factor secretion	J:254880
Map3k8^M4Btlr/Map3k8^M4Btlr (C57BL/6J-Map3k8^M4Btlr)	decreased tumor necrosis factor secretion	J:254880
Map3k8^tm1.2Gkl/Map3k8^tm1.2Gkl (involves: 129 * C57BL/6J * FVB/N)	decreased tumor necrosis factor secretion	J:193546
Map3k8^tm1Pnt/Map3k8^tm1Pnt (involves: 129S1/Sv * C57BL/6J)	decreased susceptibility to endotoxin shock	J:66503
	decreased tumor necrosis factor secretion	J:66503
	immune system phenotype	J:66503
Map3k8^tm1Pnt/Map3k8^tm1Pnt (involves: 129S1/Sv)	immune system phenotype	J:142340, J:196528
Map3k8^tm1Pnt/Map3k8^tm1Pnt Nfkb1^tm1Sley/Nfkb1^tm1Sley (involves: 129S1/Sv * 129S4/SvJae)	decreased circulating interleukin-12b level	J:196528
	decreased interleukin-12b secretion	J:196528
	decreased tumor necrosis factor secretion	J:196528
Map3k8^tm1Pnt/Map3k8^tm1Pnt Tnf^tm2Gkl/Tnf⁺ (involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6J)	increased CD8-positive, alpha-beta T cell number	J:108572
	increased single-positive T cell number	J:108572
	small intestinal inflammation	J:108572
Map3k8^tm1Sley/Map3k8^tm1Sley Nfkb1^tm1Sley/Nfkb1^tm1Sley (involves: 129S4/SvJae)	decreased tumor necrosis factor secretion	J:196528
Map3k8^tm1Tmat/Map3k8^tm1Tmat (involves: 129S/SvEv * C57BL/6)	abnormal cytokine secretion	J:92844
	abnormal dendritic cell antigen presentation	J:92844
	decreased IgE level	J:92844
	decreased IgG1 level	J:92844
	increased IgG2a level	J:92844
	increased T cell proliferation	J:92844
Map3k9^em1(IMPC)Mbp/Map3k9^em1(IMPC)Mbp (C57BL/6N-Map3k9^em1(IMPC)Mbp/MbpMmucd)	increased neutrophil cell number	J:211773
Map3k10^tm1Dsd/Map3k10^tm1Dsd Map3k11^tm1Rjd/Map3k11^tm1Rjd (involves: 129 * 129S6/SvEvTac * C57BL/6J)	abnormal circulating chemokine level	J:177426
	abnormal circulating cytokine level	J:177426
	abnormal response to infection	J:177426
Map3k10^tm1Dsd/Map3k10^tm1Dsd Map3k11^tm2.1Rjd/Map3k11^tm2.1Rjd (involves: 129 * C57BL/6J)	abnormal circulating chemokine level	J:177426
	abnormal circulating cytokine level	J:177426
	abnormal response to infection	J:177426
Map3k14^aly/Map3k14⁺ Relb^{Tg(H2-K1/GH1)106Bri}/Relb⁺ (involves: C57BL/6 * C57BL/6J)	decreased circulating interferon-gamma level	J:120659
	decreased NK T cell number	J:120659
	decreased Peyer's patch number	J:120659
	small Peyer's patches	J:120659
Map3k14^aly/Map3k14^aly (involves: C57BL/6J)	abnormal CD4-positive, CD25-positive, alpha-beta regulatory T cell morphology	J:87993, J:128211
	abnormal dendritic cell antigen presentation	J:128211
	abnormal dendritic cell physiology	J:128211
	abnormal immune system morphology	J:147681
	abnormal immune system physiology	J:147681
	abnormal NK T cell morphology	J:120659
	abnormal T cell activation	J:38580
	abnormal thymus corticomedullary boundary morphology	J:87993
	abnormal thymus medulla morphology	J:87993
	absent Peyer's patches	J:120659
	bile duct inflammation	J:48224
	decreased circulating interferon-gamma level	J:120659
	decreased circulating interleukin-4 level	J:120659
	decreased dendritic cell number	J:128211
	decreased IgE level	J:135748
	decreased mast cell number	J:135748
	decreased NK T cell number	J:120659
	decreased regulatory T cell number	J:128211
	increased eosinophil cell number	J:135748
	increased inflammatory response	J:38580, J:48224
	increased susceptibility to parasitic infection	J:135748
	kidney inflammation	J:38580
	lacrimal gland inflammation	J:38580
	liver inflammation	J:48224
	lung inflammation	J:48224
	pancreas inflammation	J:48224
	small thymus	J:147681
	thymus cyst	J:147681
Map3k14^aly/Map3k14^aly (involves: AEJ/GnRk * C57BL/6J)	abnormal immune system morphology	J:54529
	abnormal lymphocyte morphology	J:16865
	abnormal lymphopoiesis	J:16865
	abnormal spleen primary B follicle morphology	J:54529
	absent follicular dendritic cells	J:54529
	absent lymph nodes	J:16865, J:54529
	absent Peyer's patches	J:16865, J:54529
	absent spleen marginal zone	J:54529
	absent thymus corticomedullary boundary	J:16865, J:54529
	decreased B cell number	J:54529
	decreased IgA level	J:16865, J:54529
	decreased IgG level	J:16865, J:54529
	decreased IgM level	J:16865, J:54529
	decreased spleen B cell follicle number	J:16865
	increased length of allograft survival	J:16865
Map3k14^aly/Map3k14^aly (C57BL/6J-Map3k14^aly)	absent lymph nodes	J:16865
Map3k14^aly/Map3k14^aly (C57BL/6J-Map3k14^aly)	increased susceptibility to infection	J:16865
Map3k14^m1Btlr/Map3k14^m1Btlr (C57BL/6J-Map3k14^m1Btlr)	abnormal B cell activation	J:152065
	absent lymph nodes	J:152065
	arrested B cell differentiation	J:152065
	decreased B cell number	J:152065
	decreased IgG level	J:152065
Map3k14^m1Btlr/Map3k14^m1Btlr (involves: C57BL/6J)	abnormal class switch recombination	J:185495
	arrested B cell differentiation	J:185495
	decreased IgG level	J:185495
Map3k14^tm1.1Gne/Map3k14^tm1.1Gne Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129P2/OlaHsd * C57BL/6 * C57BL/6NTac)	decreased B cell number	J:280549
Map3k14^tm1.1Gne/Map3k14^tm1.1Gne Otub1^{tm1c(EUCOMM)Hmgu}/Otub1^{tm1c(EUCOMM)Hmgu} Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N * C57BL/6NTac)	immune system phenotype	J:280549
Map3k14^tm1.2Gne/Map3k14^tm1.2Gne (B6(Cg)-Map3k14^tm1.2Gne)	abnormal B cell physiology	J:240453
	abnormal spleen marginal zone morphology	J:240453
	abnormal thymus cell ratio	J:240453
	absent inguinal lymph nodes	J:240453
	absent Peyer's patches	J:240453
	absent popliteal lymph nodes	J:240453
	decreased B cell number	J:240453
	decreased B-2 B cell number	J:240453
	decreased follicular B cell number	J:240453
	decreased germinal center B cell number	J:240453
	decreased IgA level	J:240453
	decreased marginal zone B cell number	J:240453
	decreased transitional stage T1 B cell number	J:240453
	decreased transitional stage T2 B cell number	J:240453
	small axillary lymph nodes	J:240453
	small brachial lymph nodes	J:240453
Map3k14^tm1Rds/Map3k14^tm1Rds (involves: 129/Sv * C57BL/6)	abnormal spleen morphology	J:68125
	abnormal thymus morphology	J:68125
	absent axillary lymph nodes	J:68125
	absent cervical lymph nodes	J:68125
	absent inguinal lymph nodes	J:68125
	absent lymph nodes	J:68125
	absent mesenteric lymph nodes	J:68125
	absent Peyer's patches	J:68125
	absent popliteal lymph nodes	J:68125
	decreased IgA level	J:68125
	decreased IgG2b level	J:68125
	decreased immunoglobulin level	J:68125
Map3k14^tm1Rds/Map3k14^tm1Rds (involves: 129)	abnormal class switch recombination	J:188560
Map4k1^m1Anu/Map4k1^m1Anu (C57BL/6NCrl-Map4k1^m1Anu/Anu)	immune system phenotype	J:104190
Map4k1^tm1Ssaw/Map4k1^tm1Ssaw (B6.Cg-Map4k1^tm1Ssaw)	abnormal dendritic cell antigen presentation	J:150295
	abnormal dendritic cell physiology	J:150295
	increased interleukin-1 beta secretion	J:150295
	increased interleukin-6 secretion	J:150295
	increased interleukin-12 secretion	J:150295
	increased tumor necrosis factor secretion	J:150295
Map4k1^tm1Tht/Map4k1^tm1Tht (B6.129S7-Map4k1^tm1Tht)	increased susceptibility to experimental autoimmune encephalomyelitis	J:116613
Map4k1^tm1Tht/Map4k1^tm1Tht (involves: 129S7/SvEvBrd)	abnormal cytokine secretion	J:116613
	abnormal humoral immune response	J:116613
	increased T cell proliferation	J:116613
Map4k3^{Gt(RRO270)Byg}/Map4k3^{Gt(RRO270)Byg} (involves: 129P2/OlaHsd)	abnormal interleukin secretion	J:177642
	abnormal T-helper 1 cell differentiation	J:177642
	abnormal T-helper 2 cell differentiation	J:177642
	abnormal T-helper 17 cell differentiation	J:177642
	decreased IgG1 level	J:177642
	decreased IgG2a level	J:177642
	decreased IgG2b level	J:177642
	decreased IgG3 level	J:177642
	decreased IgM level	J:177642
	decreased immunoglobulin level	J:177642
	decreased interferon-gamma secretion	J:177642
	decreased interleukin-2 secretion	J:177642
	decreased interleukin-4 secretion	J:177642
	decreased interleukin-17 secretion	J:177642
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:177642
	decreased T cell proliferation	J:177642
	immune system phenotype	J:177642
Map4k5^{Gt(OST218153)Lex}/Map4k5^{Gt(OST218153)Lex} (B6;129S5-Map4k5^{Gt(OST218153)Lex}/Ieg)	increased CD4-positive, alpha-beta T cell number	J:82809
	increased IgG1 level	J:82809
Map7^mshi/Map7^mshi (involves: BALB/cBy)	decreased length of allograft survival	J:37165
Mapk1^tm1.1Hed/Mapk1^tm1.1Hed Tg(Lck-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	abnormal T cell subpopulation ratio	J:113280
	decreased CD4-positive, alpha-beta T cell number	J:113280
	decreased CD8-positive, alpha-beta T cell number	J:113280
Mapk1^tm1Gela/Mapk1^tm1Gela H2az2^{Tg(Wnt1-cre)11Rth}/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * CBA/J)	abnormal thymus morphology	J:144862
Mapk1^tm1Gela/Mapk1^tm1Gela Mapk3^tm1Gela/Mapk3⁺ H2az2^{Tg(Wnt1-cre)11Rth}/H2az2⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * CBA/J)	abnormal thymus morphology	J:144862
Mapk1^tm1Gela/Mapk1^tm1Gela Mapk3^tm1Gela/Mapk3^tm1Gela H2az2^{Tg(Wnt1-cre)11Rth}/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * CBA/J)	athymia	J:144862
Mapk1^tm1Hed/Mapk1^tm1Hed Mapk3^tm1Gpg/Mapk3^tm1Gpg Tg(Cd4-cre)1Cwi/0 (involves: 129/Sv * C57BL/6 * DBA/2)	abnormal positive T cell selection	J:113280
Mapk1^tm1Hed/Mapk1^tm1Hed Mapk3^tm1Gpg/Mapk3^tm1Gpg Tg(Cd4-cre)1Cwi/0 Tg(TcrAND)53Hed/0 (involves: 129/Sv * C57BL/6 * DBA/2 * SJL)	abnormal positive T cell selection	J:113280
	abnormal T cell subpopulation ratio	J:113280
Mapk1^tm1Hed/Mapk1^tm1Hed Mapk3^tm1Gpg/Mapk3^tm1Gpg Tg(Lck-cre)1Cwi/0 (involves: 129/Sv * C57BL/6 * DBA/2)	abnormal T cell proliferation	J:113280
	decreased thymocyte number	J:113280
	increased double-positive T cell number	J:113280
	small thymus	J:113280
Mapk1^tm1Hed/Mapk1^tm1Hed Mapk3^tm1Gpg/Mapk3^tm1Gpg Tg(TcraTcrb)1100Mjb/0 (involves: 129/Sv * C57BL/6)	decreased thymocyte number	J:113280
Mapk1^tm1Hed/Mapk1^tm1Hed Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	abnormal positive T cell selection	J:113280
	decreased CD4-positive, alpha-beta T cell number	J:113280
	decreased CD8-positive, alpha-beta T cell number	J:113280
	increased double-positive T cell number	J:113280
Mapk1^tm1Hed/Mapk1^tm1Hed Tg(Lck-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	abnormal T cell subpopulation ratio	J:113280
	decreased double-positive T cell number	J:113280
	decreased T cell proliferation	J:113280
Mapk1^tm1Hed/Mapk1^tm1Hed Tg(Lck-cre)1Cwi/0 Tg(TcrAND)53Hed/0 (involves: C57BL/6 * DBA/2 * SJL)	abnormal positive T cell selection	J:113280
	abnormal T cell subpopulation ratio	J:113280
Mapk1^tm1Hed/Mapk1^tm1Hed Tg(TcrAND)53Hed/0 (involves: C57BL/6 * DBA/2 * SJL)	abnormal double-positive T cell morphology	J:113280
	abnormal positive T cell selection	J:113280
Mapk1^tm1Hed/Mapk1^tm1Hed Tg(TcraTcrb)1100Mjb/0 (involves: C57BL/6)	decreased thymocyte number	J:113280
Mapk1^tm2Moga/Mapk1^tm2Moga Mapk3^tm1Gpg/Mapk3^tm1Gpg Tg(Mx1-cre)1Cgn/? (involves: 129/Sv * 129P2/OlaHsd * C57BL/6 * CBA)	abnormal pro-B cell differentiation	J:134528
	abnormal pro-B cell morphology	J:134528
	decreased pre-B cell number	J:134528
Mapk3^m1Btlr/Mapk3^m1Btlr (C57BL/6J-Mapk3^m1Btlr)	decreased interleukin-1 beta secretion	J:221481
Mapk3^tm1Gela/Mapk3^tm1Gela (either: 129(Cg)-Mapk3^tm1Gela or B6.129-Mapk3^tm1Gela)	abnormal cytokine secretion	J:107504
	increased susceptibility to experimental autoimmune encephalomyelitis	J:107504
Mapk3^tm1Gpg/Mapk3^tm1Gpg (involves: 129)	decreased T cell number	J:58468
Mapk3^tm1Gpg/Mapk3^tm1Gpg (involves: 129)	decreased T cell proliferation	J:58468
Mapk8^tm1Flv/Mapk8^tm1Flv (involves: 129S1/Sv)	abnormal cytokine secretion	J:51510
	abnormal T-helper 1 cell differentiation	J:51510
	increased T cell proliferation	J:51510
Mapk8^tm1Rjd/Mapk8^tm1Rjd Mapk9^tm2.1Rjd/Mapk9^tm2.1Rjd Lyz2^tm1(cre)Ifo/Lyz2⁺ (B6J.Cg-Lyz2^tm1(cre)Ifo Mapk9^tm2.1Rjd Mapk8^tm1Rjd)	abnormal chemokine level	J:192551
	abnormal circulating chemokine level	J:192551
	abnormal circulating cytokine level	J:192551
	abnormal macrophage differentiation	J:192551
	abnormal macrophage physiology	J:192551
	decreased inflammatory response	J:192551
	decreased macrophage cell number	J:192551
	decreased macrophage cytokine production	J:192551
	impaired macrophage chemotaxis	J:192551
Mapk8^tm1Wag/Mapk8⁺ Mapk9^tm1Mka/Mapk9⁺ (involves: 129)	abnormal T cell activation	J:78190
	decreased T cell apoptosis	J:78190
	decreased T cell proliferation	J:78190
Mapk8^tm1Wag/Mapk8⁺ Mapk9^tm1Mka/Mapk9^tm1Mka (involves: 129)	abnormal T cell activation	J:78190
	decreased T cell apoptosis	J:78190
	decreased T cell proliferation	J:78190
Mapk8^tm1Wag/Mapk8^tm1Wag (involves: 129P2/OlaHsd)	abnormal T cell activation	J:78190
	decreased T cell apoptosis	J:78190
	decreased T cell proliferation	J:78190
Mapk8^tm1Wag/Mapk8^tm1Wag Mapk9^tm1Mka/Mapk9⁺ (involves: 129)	abnormal T cell activation	J:78190
	decreased T cell apoptosis	J:78190
	decreased T cell proliferation	J:78190
Mapk9^tm1Flv/Mapk9^tm1Flv (involves: 129S2/SvPas)	abnormal T-helper 1 cell differentiation	J:50628
Mapk9^tm1Flv/Mapk9^tm1Flv Tnf^tm2Gkl/Tnf⁺ (involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6J)	immune system phenotype	J:108572
	small intestinal inflammation	J:108572
Mapk9^tm1Mka/Mapk9^tm1Mka (either: (involves: 129S2/SvPas) or (involves: 129S1/Sv * 129X1/SvJ))	abnormal T cell activation	J:78129
	decreased T cell apoptosis	J:78129
	decreased T cell proliferation	J:78129
Mapk11^tm1Jda/Mapk11^tm1Jda (B6.Cg-Mapk11^tm1Jda)	immune system phenotype	J:165966
Mapk11^tm1Jda/Mapk11^tm1Jda Mapk14^tm1Jda/Mapk14^tm1Jda (involves: 129 * C57BL/6)	abnormal T-helper 1 cell differentiation	J:165966
	abnormal T-helper 2 cell differentiation	J:165966
	abnormal T-helper 17 cell differentiation	J:165966
	decreased interferon-gamma secretion	J:165966
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:165966
	decreased susceptibility to induced arthritis	J:165966
	decreased T cell proliferation	J:165966
	decreased tumor necrosis factor secretion	J:165966
	increased interleukin-10 secretion	J:165966
Mapk11^tm1Jsca/Mapk11^tm1Jsca (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:107771
Mapk11^tm1Jsca/Mapk11^tm1Jsca Tnf^tm2Gkl/Tnf⁺ (involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6)	autoimmune arthritis	J:107771
	ileum inflammation	J:107771
Mapk14^tm1Jda/Mapk14^tm1Jda (B6.Cg-Mapk14^tm1Jda)	abnormal T-helper 1 physiology	J:146088
	decreased interferon-alpha secretion	J:146088
	decreased interferon-gamma secretion	J:146088
	decreased T cell proliferation	J:146088
	increased double-negative T cell number	J:146088
Mapkapk2^tm1.2Gkl/Mapkapk2^tm1.2Gkl (involves: BALB/cJ * C57BL/6)	decreased circulating tumor necrosis factor level	J:262876
	decreased tumor necrosis factor secretion	J:262876
Mapkapk2^{tm1b(EUCOMM)Hmgu}/Mapkapk2^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Mapkapk2^{tm1b(EUCOMM)Hmgu}/H)	increased eosinophil cell number	J:211773
	increased large unstained cell number	J:211773
	increased leukocyte cell number	J:211773
Mapkapk2^tm1Mgl/Mapkapk2^tm1Mgl (involves: 129P2/OlaHsd * C57BL/6J)	abnormal cytokine level	J:59678
	abnormal macrophage derived foam cell morphology	J:142788
	decreased circulating tumor necrosis factor level	J:59678
	decreased susceptibility to endotoxin shock	J:59678
	increased spleen germinal center size	J:59678
Mapkapk2^tm1Mgl/Mapkapk2^tm1Mgl (involves: 129S * C57BL/6)	decreased interferon-gamma secretion	J:76161
	decreased tumor necrosis factor secretion	J:76161
	impaired macrophage phagocytosis	J:76161
	increased interleukin-1 beta secretion	J:76161
	increased susceptibility to bacterial infection	J:76161
	increased susceptibility to bacterial infection induced morbidity/mortality	J:76161
Mapkapk2^tm1Mgl/Mapkapk2^tm1Mgl (involves: 129P2/OlaHsd * 129S/SvEvBrd * C57BL/6)	abnormal cytokine secretion	J:117668
Mapkapk2^tm1Mgl/Mapkapk2^tm1Mgl Mapkapk3^tm1.1Lex/Mapkapk3^tm1.1Lex (involves: 129P2/OlaHsd * 129S/SvEvBrd * C57BL/6)	abnormal cytokine secretion	J:117668
Mapkapk2^tm1Mgl/Mapkapk2^tm1Mgl Tnf^tm2Gkl/Tnf⁺ (involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6J)	granulomatous inflammation	J:108572
	immune system phenotype	J:108572
	small intestinal inflammation	J:108572
Mapkapk3^{em1(IMPC)Ccpcz}/Mapkapk3^{em1(IMPC)Ccpcz} (C57BL/6N-Mapkapk3^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Mapkapk3^tm1.1Lex/Mapkapk3^tm1.1Lex (involves: 129S/SvEvBrd * C57BL/6)	immune system phenotype	J:117668
Mapkbp1^{tm1b(EUCOMM)Hmgu}/Mapkbp1^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Mapkbp1^{tm1b(EUCOMM)Hmgu}/H)	increased spleen weight	J:211773
Mapt^tm1(EGFP)Klt/Mapt^tm1(EGFP)Klt Tg(MAPT)8cPdav/? (involves: 129S4/SvJae * C57BL/6 * Swiss Webster)	abnormal spleen B cell follicle morphology	J:174270
	abnormal spleen B cell follicle shape	J:174270
	abnormal spleen red pulp morphology	J:174270
	increased spleen B cell follicle size	J:174270
Mapt^{tm2.1(FUS)Neas}/Mapt⁺ (B6J.129P2(129S)-Mapt^{tm2.1(FUS)Neas})	microgliosis	J:232167
Mapt^{tm3.1(FUS)Neas}/Mapt⁺ (B6J.129P2(129S)-Mapt^{tm3.1(FUS)Neas})	microgliosis	J:232167
Mar1^tm1Wtg/Mar1⁺ (involves: 129S6/SvEvTac * C57BL/6)	abnormal immune system physiology	J:68024
Mar1^tm1Wtg/Mar1⁺ (involves: 129S6/SvEvTac * C57BL/6)	abnormal somatic hypermutation frequency	J:68024
Mar1^tm1Wtg/Mar1^tm1Wtg (involves: 129S6/SvEvTac * C57BL/6)	abnormal somatic hypermutation frequency	J:68024
Marchf1^tm1.1Sish/Marchf1^tm1.1Sish (involves: 129S1/Sv * 129X1/SvJ)	abnormal B cell physiology	J:119918
	abnormal dendritic cell antigen presentation	J:201198, J:157516
	abnormal dendritic cell morphology	J:119918
	abnormal level of surface class II molecules	J:119918
	abnormal T cell differentiation	J:201198
	decreased interleukin-12 secretion	J:157516
	decreased regulatory T cell number	J:201198
	decreased tumor necrosis factor secretion	J:157516
	immune system phenotype	J:201198
Marchf2^em1Cnu/Marchf2^em1Cnu (C57BL/6-Marchf2^em1Cnu)	decreased susceptibility to bacterial infection	J:297482
	decreased susceptibility to viral infection	J:297482
	increased circulating interferon-beta level	J:297482
	increased circulating interleukin-6 level	J:297482
	increased circulating interleukin-12 level	J:297482
	increased circulating tumor necrosis factor level	J:297482
	increased interleukin-6 secretion	J:297482
	increased interleukin-12 secretion	J:297482
	increased susceptibility to bacterial infection induced morbidity/mortality	J:297482
	increased susceptibility to endotoxin shock	J:297482
Marchf3^em1Hbsh/Marchf3^em1Hbsh (involves: C57BL/6J)	abnormal circulating cytokine level	J:267641
Marchf3^em1Hbsh/Marchf3^em1Hbsh (involves: C57BL/6J)	increased susceptibility to infection induced morbidity/mortality	J:267641
Marchf3^{tm1b(EUCOMM)Hmgu}/Marchf3^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Marchf3^{tm1b(EUCOMM)Hmgu}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Marchf5^tm1.1Ygi/Marchf5^tm1.1Ygi Tg(Emx1-cre)#Ito/0 (involves: C57BL/6)	increased microglial cell activation	J:284572
Marchf5^{tm1a(EUCOMM)Wtsi}/Marchf5⁺ (C57BL/6-Marchf5^{tm1a(EUCOMM)Wtsi})	decreased susceptibility to Riboviria infection induced morbidity/mortality	J:225000
	increased circulating interferon-beta level	J:225000
	increased circulating interleukin-6 level	J:225000
Marchf6^{tm1b(EUCOMM)Hmgu}/Marchf6^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Marchf6^{tm1b(EUCOMM)Hmgu}/Ccpcz)	decreased CD4-positive, alpha-beta T cell number	J:211773
	decreased T-helper cell number	J:211773
Marchf7^{Gt(ROSABetageo)1Summ}/Marchf7⁺ (involves: BALB/c)	abnormal cytokine secretion	J:96167
	abnormal interleukin level	J:96167
	increased interleukin-10 secretion	J:96167
	increased T cell proliferation	J:96167
Marchf7^{Gt(ROSABetageo)1Summ}/Marchf7^{Gt(ROSABetageo)1Summ} (involves: BALB/c)	abnormal cytokine secretion	J:96167
	abnormal interleukin level	J:96167
	increased interleukin-10 secretion	J:96167
	increased T cell proliferation	J:96167
Marchf8^{em2(IMPC)Ccpcz}/Marchf8^{em2(IMPC)Ccpcz} (C57BL/6N-Marchf8^{em2(IMPC)Ccpcz}/Ccpcz)	decreased eosinophil cell number	J:211773
Marchf8^tm1.1Lkle/Marchf8^tm1.1Lkle (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	immune system phenotype	J:236611
Marchf9^{tm1a(EUCOMM)Wtsi}/Marchf9^{tm1a(EUCOMM)Wtsi} (Not Specified)	decreased B cell number	J:165965
Marcksl1^tm1Fsh/Marcksl1^tm1Fsh (involves: 129S4/SvJae)	abnormal macrophage physiology	J:115146
Marco^tm1Ktry/Marco^tm1Ktry (B6.129S6-Marco^tm1Ktry)	abnormal macrophage physiology	J:115081
	abnormal spleen marginal zone morphology	J:122271
	impaired macrophage phagocytosis	J:115081
	increased inflammatory response	J:115081
	increased susceptibility to bacterial infection	J:115081, J:122271
Marco^tm1Ktry/Marco^tm1Ktry Msr1^tm1Csk/Msr1^tm1Csk (B6.129-Marco^tm1Ktry Msr1^tm1Csk)	abnormal macrophage physiology	J:122271
	abnormal spleen marginal zone morphology	J:122271
	increased IgM level	J:122271
	increased susceptibility to bacterial infection	J:122271
Marco^tm1Spt/Marco^tm1Spt (C57BL/6-Marco^tm1Spt)	abnormal dendritic cell chemotaxis	J:204315
	abnormal dendritic cell physiology	J:204315
	increased interferon-gamma secretion	J:204315
Marif1^C57BL/10J/Marif1^C57BL/10J (involves: O20/A * NXT-10/Dem)	abnormal immune serum protein physiology	J:90251
	decreased interleukin-12 secretion	J:90251
	decreased tumor necrosis factor secretion	J:90251
Marif2^C57BL/10J/Marif2^C57BL/10J (involves: O20/A * NXT-10/Dem)	abnormal immune serum protein physiology	J:90251
	decreased interleukin-12 secretion	J:90251
	increased tumor necrosis factor secretion	J:90251
Marif3^C57BL/10J/Marif3^C57BL/10J (involves: O20/A * NXT-10/Dem)	increased interleukin-12 secretion	J:90251
Mark2^tm1Hpw/Mark2^tm1Hpw (involves: 129X1/SvJ * C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:68830
	abnormal humoral immune response	J:68830
	abnormal immune system physiology	J:68830
	abnormal spleen B cell follicle morphology	J:68830
	decreased B cell proliferation	J:68830
	decreased IgG3 level	J:68830
	decreased IgM level	J:68830
	enlarged lymph nodes	J:68830
	enlarged spleen	J:68830
	glomerulonephritis	J:68830
	increased B cell number	J:68830
	increased B cell proliferation	J:68830
	increased interferon-gamma secretion	J:68830
	increased interleukin-4 secretion	J:68830
	increased spleen weight	J:68830
	kidney inflammation	J:68830
	lung inflammation	J:68830
	lymph node hyperplasia	J:68830
	salivary gland inflammation	J:68830
	spleen hyperplasia	J:68830
Mark4^em1(IMPC)Mbp/Mark4^em1(IMPC)Mbp (C57BL/6N-Mark4^em1(IMPC)Mbp/Ucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Marveld2^tm1.1Sria/Marveld2^tm1.1Sria (involves: 129X1/SvJ * C57BL/6J)	increased spleen weight	J:201580
Marveld3^{em1(IMPC)Ccpcz}/Marveld3^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Marveld3^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Masp1^tm1Tefu/Masp1^tm1Tefu (B6.129S4-Masp1^tm1Tefu)	impaired complement alternative pathway	J:177350
Masp1^tm1Tefu/Masp1^tm1Tefu (B6.129S4-Masp1^tm1Tefu)	impaired lectin complement pathway	J:134537
Masp2^tm1Tefu/Masp2^tm1Tefu (involves: 129 * C57BL/6)	abnormal complement pathway	J:140667
Masp2^tm1Wjsc/Masp2^tm1Wjsc (B6.129P2-Masp2^tm1Wjsc)	impaired lectin complement pathway	J:172218
Mast4^m1Anu/Mast4^m1Anu (C57BL/6NCrl-Mast4^m1Anu/Anu)	immune system phenotype	J:104190
Mat1a^tm1Jmm/Mat1a^tm1Jmm (involves: 129/Sv * C57BL/6)	liver inflammation	J:69408
Matn1^tm1Ref/Matn1^tm1Ref Matn2^tm1Asz/Matn2^tm1Asz Matn3^tm1Asz/Matn3^tm1Asz Matn4^tm1.1Asz/Matn4^tm1.1Asz (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	decreased double-positive T cell number	J:237230
	increased granulocyte number	J:237230
Matn3^tm1Brd/Matn3^tm1Brd (involves: 129S7/SvEvBrd * C57BL/6)	osteoarthritis	J:112002
Matr3^em1Tcp/Matr3^em1Tcp (C57BL/6J-Matr3^em1Tcp)	increased microglial cell activation	J:298091
Mavs^tm1Aki/Mavs^tm1Aki (Not Specified)	abnormal cytokine secretion	J:124405
	abnormal response to infection	J:124405
	decreased circulating interleukin-6 level	J:124405
	decreased interferon-alpha secretion	J:124405
	decreased interferon-beta secretion	J:124405
	decreased interleukin-6 secretion	J:124405
	increased susceptibility to Picornaviridae infection	J:124405
Mavs^tm1Aki/Mavs^tm1Aki (involves: 129P2/OlaHsd * C57BL/6)	decreased CD8-positive, alpha-beta T cell number	J:130954
	decreased circulating interferon-alpha level	J:130954
	decreased circulating interferon-beta level	J:130954
	decreased circulating interferon-gamma level	J:130954
	decreased circulating interleukin-6 level	J:130954
	decreased IgG1 level	J:130954
	decreased IgG2a level	J:130954
	decreased IgG level	J:130954
	decreased interferon-beta secretion	J:130954
	decreased interleukin-12b secretion	J:130954
Mavs^tm1Aki/Mavs^tm1Aki (involves: C57BL/6)	immune system phenotype	J:132662
Mavs^tm1Aki/Mavs^tm1Aki (involves: 129S/SvEv * C57BL/6)	abnormal circulating interferon level	J:162888
	abnormal dendritic cell physiology	J:162888
	abnormal macrophage physiology	J:162888
	brain inflammation	J:162888
	CNS inflammation	J:162888
	decreased CD4-positive, alpha-beta T cell number	J:162888
	decreased CD8-positive, alpha-beta T cell number	J:162888
	decreased interferon-beta secretion	J:162888
	enlarged spleen	J:162888
	immune system phenotype	J:162888
	increased circulating interferon-gamma level	J:162888
	increased circulating interleukin-6 level	J:162888
	increased circulating tumor necrosis factor level	J:162888
	increased dendritic cell number	J:162888
	increased IgG2a level	J:162888
	increased IgG level	J:162888
	increased IgM level	J:162888
	increased susceptibility to Flaviviridae infection	J:162888
	increased susceptibility to Flaviviridae infection induced morbidity/mortality	J:162888
Mavs^tm1Aki/Mavs^tm1Aki Ifna6^tm1Aki/Ifna6⁺ (involves: 129P2/OlaHsd)	abnormal alveolar macrophage morphology	J:124340
	abnormal macrophage morphology	J:124340
	abnormal myeloid dendritic cell morphology	J:124340
	decreased interferon-alpha secretion	J:124340
Mavs^tm1Aki/Mavs^tm1Aki Ticam1^tm1Aki/Ticam1^tm1Aki (involves: 129P2/OlaHsd * C57BL/6)	decreased CD8-positive, alpha-beta T cell number	J:130954
	decreased circulating interferon-alpha level	J:130954
	decreased circulating interferon-beta level	J:130954
	decreased circulating interferon-gamma level	J:130954
	decreased circulating interleukin-6 level	J:130954
	decreased circulating interleukin-12b level	J:130954
	decreased cytotoxic T cell cytolysis	J:130954
	decreased IgG1 level	J:130954
	decreased IgG2a level	J:130954
	decreased IgG level	J:130954
	decreased interferon-beta secretion	J:130954
	decreased interleukin-12b secretion	J:130954
Mavs^tm1Camb/Mavs^tm1Camb (involves: 129S6/SvEvTac * C57BL/6)	abnormal B cell calcium ion homeostasis	J:180356
	decreased B cell proliferation	J:180356
	decreased interleukin-12 secretion	J:180356
	decreased tumor necrosis factor secretion	J:180356
Mavs^tm1Itl/Mavs^tm1Itl Trex1^tm1Tld/Trex1^tm1Tld (involves: 129P2/OlaHsd * C57BL/6)	increased inflammatory response	J:181257
	myocarditis	J:181257
	myositis	J:181257
	skin inflammation	J:181257
	stomach inflammation	J:181257
Mavs^tm1Tsc/Mavs^tm1Tsc (Not Specified)	decreased interferon-beta secretion	J:136289
Mavs^tm1Tsse/Mavs^tm1Tsse Tg(PVR)1Kkst/0 (involves: 129 * C57BL/6 * ICR)	abnormal interferon-alpha secretion	J:179625
	decreased susceptibility to Picornaviridae infection induced morbidity/mortality	J:179625
Mavs^tm1Zjc/Mavs⁺ (involves: 129/Sv * C57BL/6)	abnormal innate immunity	J:110905
Mavs^tm1Zjc/Mavs⁺ (involves: 129/Sv * C57BL/6)	increased susceptibility to Riboviria infection	J:110905
Mavs^tm1Zjc/Mavs^tm1Zjc (involves: 129/Sv * C57BL/6)	abnormal dendritic cell physiology	J:110905
	abnormal innate immunity	J:110905
	abnormal macrophage physiology	J:110905
	increased susceptibility to Riboviria infection	J:110905
Mavs^tm1Zjc/Mavs^tm1Zjc (B6.Cg-Mavs^tm1Zjc)	abnormal circulating interferon level	J:243916
Mavs^tm1Zjc/Mavs^tm1Zjc Rnaseh2a^tm1Crh/Rnaseh2a^tm1Crh (Not Specified)	abnormal innate immunity	J:232933
Mb21d2^em1(IMPC)Mbp/Mb21d2^em1(IMPC)Mbp (C57BL/6N-Mb21d2^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
Mbd2^tm1Bh/Mbd2^tm1Bh (NOD.129P2(B6)-Mbd2^tm1Bh)	abnormal CD4-positive, alpha-beta T cell physiology	J:323838
	abnormal CD8-positive, alpha-beta cytotoxic T cell morphology	J:323838
	abnormal effector T cell morphology	J:323838
	enlarged lymph nodes	J:323838
	enlarged spleen	J:323838
	increased T cell proliferation	J:323838
	increased T-helper 1 cell number	J:323838
	increased T-helper 2 cell number	J:323838
	insulitis	J:323838
	salivary gland inflammation	J:323838
Mbd3^tm2Bh/Mbd3^tm2Bh Tg(Vil1-cre)20Syr/0 (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	increased susceptibility to induced colitis	J:167984
Mbd5^{tm1b(EUCOMM)Wtsi}/Mbd5⁺ (C57BL/6N-Mbd5^{tm1b(EUCOMM)Wtsi}/Ics)	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
Mbip^em1(IMPC)J/Mbip⁺ (C57BL/6NJ-Mbip^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
Mbis1^NOD/ShiLt/Mbis1^NOD/ShiLt (involves: BALB/c * NOD/Lt)	increased susceptibility to bacterial infection	J:75276
Mbis2^BALB/c/Mbis2^BALB/c (involves: BALB/c * NOD/Lt)	increased susceptibility to bacterial infection	J:75276
Mbis2^BALB/c/Mbis2^NOD/ShiLt (involves: BALB/c * NOD/Lt)	increased susceptibility to bacterial infection	J:75276
Mbis3^BALB/c/? (involves: BALB/c * NOD/Lt)	increased susceptibility to bacterial infection	J:75276
Mbis4^NOD/ShiLt/Mbis4^NOD/ShiLt (involves: BALB/c * NOD/Lt)	increased susceptibility to bacterial infection	J:75276
Mbl1^tm1.1Mnz/Mbl1^tm1.1Mnz (B6.129-Mbl1^tm1.1Mnz)	immune system phenotype	J:84540
Mbl1^tm1Kata/Mbl1^tm1Kata (involves: 129S4/SvJae * C57BL/6J)	decreased circulating tumor necrosis factor level	J:90437
Mbl1^tm1Kata/Mbl1^tm1Kata Mbl2^tm1Kata/Mbl2^tm1Kata (involves: 129 * C57BL/6)	abnormal B cell number	J:97686
	abnormal circulating interleukin-6 level	J:98124
	abnormal circulating tumor necrosis factor level	J:98124
	decreased germinal center B cell number	J:97686
	decreased macrophage cell number	J:98124
	decreased monocyte cell number	J:98124
	impaired macrophage phagocytosis	J:97686, J:98124
	increased B-1 B cell number	J:97686
	increased susceptibility to bacterial infection	J:98124
Mbl1^tm1Kata/Mbl1^tm1Kata Mbl2^tm1Kata/Mbl2^tm1Kata (involves: 129 * C57BL/6J)	abnormal complement pathway	J:106351
	abnormal response to infection	J:106352
	increased susceptibility to bacterial infection	J:106353
Mbl1^tm1Rala/Mbl1^tm1Rala (involves: 129X1/SvJ * C57BL/6J)	abnormal immunoglobulin level	J:145279
	decreased IgG2b level	J:145279
	decreased IgM level	J:145279
	increased IgG1 level	J:145279
	increased IgG2a level	J:145279
	increased IgG3 level	J:145279
	increased susceptibility to parasitic infection	J:145279
Mboat2^em1(IMPC)Mbp/Mboat2^em1(IMPC)Mbp (C57BL/6N-Mboat2^em1(IMPC)Mbp/Ucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Mboat7^{tm1b(KOMP)Wtsi}/Mboat7⁺ (C57BL/6N-Mboat7^{tm1b(KOMP)Wtsi}/H)	increased lymphocyte cell number	J:211773
Mbp^shi/Mbp^shi (C3Fe.SWV-Mbp^shi/J)	decreased susceptibility to Picornaviridae infection	J:41447
Mbp^shi/Mbp^shi (C3Fe.SWV-Mbp^shi/J)	immune system phenotype	J:41447
Mbp^shi/Mbp^shi (involves: BALB/c * C3HeB/Fe * SWV)	increased interferon-gamma secretion	J:48412
	increased interleukin-2 secretion	J:48412
	increased interleukin-4 secretion	J:48412
	increased susceptibility to experimental autoimmune encephalomyelitis	J:48412
	increased T cell proliferation	J:48412
Mbtps1^wrt/Mbtps1^wrt (C57BL/6J-Mbtps1^wrt)	decreased cytotoxic T cell cytolysis	J:94077
	decreased susceptibility to bacterial infection	J:123123
	increased interleukin-1 beta secretion	J:146454
	increased interleukin-6 secretion	J:146454
	increased susceptibility to Herpesvirales infection	J:94077, J:123123
	increased susceptibility to induced colitis	J:146454
Mc2r^tm1Dchi/Mc2r^tm1Dchi (B6.129P2-Mc2r^tm1Dchi)	increased spleen weight	J:127445
Mc2r^tm1Dchi/Mc2r^tm1Dchi (B6.129P2-Mc2r^tm1Dchi)	increased thymus weight	J:127445
Mc3r^tm1Butl/Mc3r^tm1Butl (B6.Cg-Mc3r^tm1Butl)	increased inflammatory response	J:178147
Mc4r^tm1Dhu/Mc4r^tm1Dhu (involves: 129S4/SvJae * C57BL/6J)	decreased osteoclast cell number	J:97566
Mc4r^tm1Lowl/Mc4r^tm1Lowl (involves: 129S4/SvJae * C57BL/6J)	increased circulating interleukin-6 level	J:177386
	liver inflammation	J:177386
	white adipose tissue inflammation	J:177386
Mc4r^tm1Matsu/Mc4r^tm1Matsu (C57BL/6J-Mc4r^tm1Matsu)	liver inflammation	J:285412
Mcam^tm1Lex/Mcam^tm1Lex (involves: 129S/SvEvBrd)	abnormal cytokine level	J:193167
	abnormal response to infection	J:193167
	decreased macrophage cytokine production	J:193167
Mcat^tm1.1Ssmi/Mcat^tm1.1Ssmi Tg(CAG-cre/Esr1)5Amc/0 (involves: 129P2/OlaHsd C57BL/6 * C57BL/6J * CBA)	abnormal immune system organ morphology	J:192213
	abnormal myelopoiesis	J:192213
	decreased leukocyte cell number	J:192213
	decreased lymphocyte cell number	J:192213
	enlarged spleen	J:192213
Mcemp1^em1Jngj/Mcemp1^em1Jngj (C57BL/6-Mcemp1^em1Jngj)	abnormal mast cell differentiation	J:335318
Mcemp1^em1Jngj/Mcemp1^em1Jngj (C57BL/6-Mcemp1^em1Jngj)	abnormal type I hypersensitivity reaction	J:335318
Mcidas^em2(IMPC)Tcp/Mcidas^em2(IMPC)Tcp (C57BL/6NCrl-Mcidas^em2(IMPC)Tcp/Tcp)	abnormal spleen morphology	J:211773
	increased leukocyte cell number	J:211773
Mcl1^em1(IMPC)Mbp/Mcl1⁺ (C57BL/6N-Mcl1^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
	small spleen	J:211773
Mcl1^tm1Dmta/Mcl1⁺ Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte}/Gt(ROSA)26Sor⁺ (B6.Cg-Mcl1^tm1Dmta Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte})	decreased germinal center B cell number	J:166069
	decreased memory B cell number	J:166069
Mcl1^tm1Dmta/Mcl1⁺ Tg(Aicda-cre)9Mbu/0 (B6.Cg-Mcl1^tm1Dmta Tg(Aicda-cre)9Mbu)	decreased germinal center B cell number	J:166069
	decreased memory B cell number	J:166069
Mcl1^tm1Dmta/Mcl1^tm1Dmta Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte}/Gt(ROSA)26Sor⁺ (B6.Cg-Mcl1^tm1Dmta Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte})	abnormal B cell differentiation	J:166069
	absent germinal center B cells	J:166069
	absent memory B cells	J:166069
	decreased naive B cell number	J:166069
Mcl1^tm1Dmta/Mcl1^tm1Dmta Tg(Aicda-cre)9Mbu/0 (B6.Cg-Mcl1^tm1Dmta Tg(Aicda-cre)9Mbu)	absent germinal center B cells	J:166069
	absent memory B cells	J:166069
	decreased IgG1 level	J:166069
	immune system phenotype	J:166069
Mcl1^tm1Yen/Mcl1^tm1Yen (B6.129-Mcl1^tm1Yen)	abnormal CD8-positive, alpha-beta T cell physiology	J:146246
	abnormal double-positive T cell morphology	J:146246
	decreased CD8-positive, alpha-beta T cell number	J:146246
	decreased double-negative T cell number	J:146246
	decreased single-positive T cell number	J:146246
Mcl1^tm1Yen/Mcl1^tm1Yen Tg(TcraH-Y,TcrbH-Y)71Vbo/? (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)	abnormal double-positive T cell morphology	J:146246
	decreased CD8-positive, alpha-beta T cell number	J:146246
Mcl1^tm1Yen/Mcl1^tm1Yen Tg(TcraTcrb)425Cbn/? (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal double-positive T cell morphology	J:146246
	decreased CD4-positive, alpha-beta T cell number	J:146246
Mcl1^tm1Ywh/Mcl1^tm1Ywh Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * 129S4/SvJae * 129S6/SvEvTac * C57BL/6)	abnormal neutrophil physiology	J:137502
	decreased granulocyte number	J:137502
	decreased neutrophil cell number	J:137502
	immune system phenotype	J:137502
	impaired neutrophil recruitment	J:137502
	increased eosinophil cell number	J:137502
Mcl1^tm1Ywh/Mcl1^tm1Ywh Tg(Cd4-cre)1Cwi/0 (involves: 129S6/SvEvTac * C57BL/6 * DBA/2)	decreased CD4-positive, alpha-beta T cell number	J:137400
	decreased CD8-positive, alpha-beta T cell number	J:137400
	decreased T cell number	J:137400
	increased double-positive T cell number	J:137400
	increased T cell apoptosis	J:137400
Mcl1^tm1Ywh/Mcl1^tm1Ywh Tg(Lck-cre)548Jxm/0 (involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * CBA)	abnormal T cell differentiation	J:137400
	decreased CD4-positive, alpha-beta T cell number	J:137400
	decreased CD8-positive, alpha-beta T cell number	J:137400
	decreased double-negative T cell number	J:137400
	decreased double-positive T cell number	J:137400
	decreased T cell number	J:137400
	increased T cell apoptosis	J:137400
	thymus hypoplasia	J:137400
Mcl1^tm2Sjk/Mcl1^tm3Sjk Tg(Lck-cre)1Cwi/0 (involves: 129X1/SvJ * C57BL/6 * DBA/2)	arrested T cell differentiation	J:86906
	decreased double-negative T cell number	J:86906
	decreased double-positive T cell number	J:86906
	decreased T cell number	J:86906
	decreased thymocyte number	J:86906
	increased T cell apoptosis	J:86906
Mcl1^tm2Sjk/Mcl1^tm3Sjk Tg(Mx1-cre)1Cgn/0 (involves: 129X1/SvJ * C57BL/6 * CBA)	decreased B cell number	J:86906
	decreased T cell number	J:86906
Mcl1^tm3Sjk/Mcl1^tm3Sjk Tg(Cpa3-cre)3Glli/0 (involves: 129X1/Sv * C57BL/6)	decreased basophil cell number	J:179080
	decreased inflammatory response	J:179080
	decreased mast cell number	J:179080
	decreased susceptibility to type I hypersensitivity reaction	J:179080
Mclr^RF/J/Mclr^SWR/J (involves: RF/J * SWR/J)	increased T cell derived lymphoma incidence	J:9614
Mclr^SWR/J/Mclr^SWR/J (involves: RF/J * SWR/J)	increased T cell derived lymphoma incidence	J:9614
Mcm2^{Gt(AB0178)Wtsi}/Mcm2⁺ Mcm4^chaos3/Mcm4^chaos3 (involves: 129P2/OlaHsd * C3HeB/FeJ * C57BL/6J)	increased T cell derived lymphoma incidence	J:165667
Mcm2^{tm1(cre/ERT2)Scpr}/Mcm2^{tm1(cre/ERT2)Scpr} (involves: 129S6/SvEvTac)	enlarged spleen	J:141493
Mcm3ap^tm1Imku/Mcm3ap^tm1Imku Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129P2/OlaHsd * C57BL/6 * CBA)	abnormal germinal center B cell physiology	J:88276
	abnormal memory B cell number	J:88276
	abnormal spleen germinal center morphology	J:88276
	decreased B cell number	J:88276
	decreased B cell proliferation	J:88276
	decreased germinal center B cell number	J:88276
	decreased IgG level	J:88276
Mcm4^chaos3/Mcm4^chaos3 (involves: C57BL/6J)	increased T cell derived lymphoma incidence	J:165667
Mcm4^Sdla/Mcm4⁺ (involves: C57BL/6)	decreased DN1 thymic pro-T cell number	J:194117
	enlarged lymph nodes	J:194117
	enlarged spleen	J:194117
Mcoln1^tm1Sasl/Mcoln1^tm1Sasl (involves: 129S6/SvEvTac * C57BL/6)	abnormal macrophage physiology	J:189070
Mcoln2^{tm1e.1(KOMP)Wtsi}/Mcoln2^{tm1e.1(KOMP)Wtsi} (involves: C57BL/6J * C57BL/6N)	abnormal chemokine level	J:239875
	abnormal chemokine secretion	J:239875
	abnormal innate immunity	J:239875
	impaired macrophage chemotaxis	J:239875
	impaired neutrophil chemotaxis	J:239875
Mcph1^{Tg(HLA-A2.1)1Enge}/Mcph1⁺ (involves: C57BL/6)	abnormal immune tolerance	J:52612
Mcph1^{Tg(HLA-A2.1)1Enge}/Mcph1⁺ (NOD.B6-Mcph1^{Tg(HLA-A2.1)1Enge})	increased susceptibility to autoimmune diabetes	J:109851
Mcph1^{Tg(HLA-A2.1)1Enge}/Mcph1^{Tg(HLA-A2.1)1Enge} (NOD.B6-Mcph1^{Tg(HLA-A2.1)1Enge})	immune system phenotype	J:109851
	increased susceptibility to autoimmune diabetes	J:109851
Mcph1^tm1.2Kali/Mcph1^tm1.2Kali (involves: 129S7/SvEvBrd * C57BL/6J)	abnormal T cell physiology	J:156371
Mcph1^{tm1a(EUCOMM)Wtsi}/Mcph1^{tm1a(EUCOMM)Wtsi} (involves: C57BL/6 * C57BL/6N)	increased B cell number	J:213427
Mcpt1^tm1Hrpm/Mcpt1^tm1Hrpm (involves: 129P2/OlaHsd * MF1)	abnormal mast cell morphology	J:93795
	decreased circulating tumor necrosis factor level	J:93616
	increased susceptibility to parasitic infection	J:93616, J:93795
Mcpt4^tm1Mabr/Mcpt4^tm1Mabr (involves: 129X1/SvJ * C57BL/6J)	abnormal mast cell physiology	J:84839
Mcpt8^{tm1.1(HBEGF)Hkar}/Mcpt8^{tm1.1(HBEGF)Hkar} (B6.Cg-Mcpt8^{tm1.1(HBEGF)Hkar})	decreased basophil cell number	J:163761
	immune system phenotype	J:163761
	increased susceptibility to parasitic infection	J:163761
Mcr^C57BL/10J/Mcr^NC (involves: C57BL/10J * NC)	cutaneous mastocytosis	J:8804
Mcr^NC/Mcr^NC (involves: C57BL/10J * NC)	cutaneous mastocytosis	J:8804
Mcts1^em1(IMPC)Mbp/Y (C57BL/6N-Mcts1^em1(IMPC)Mbp/Ucd)	enlarged spleen	J:211773
Mdc1^{Gt(OST441263)Lex}/Mdc1^{Gt(OST441263)Lex} (involves: 129S5/SvEvBrd * C57BL/6)	abnormal class switch recombination	J:137341
	small spleen	J:137341
	small thymus	J:137341
Mdfic^em1Nlh/Mdfic^em2Nlh (C57BL/6J-Mdfic^em1Nlh/Mdfic^em2Nlh)	abnormal lymph circulation	J:326462
	abnormal lymphatic vessel morphology	J:326462
Mdga2^{Tg(Prnp-PFN1*G118V)838Kiaei}/Mdga2⁺ (involves: C57BL/6N)	microgliosis	J:241428
Mdk^tm1Tmu/Mdk^tm1Tmu (129S2-Mdk^tm1Tmu)	tubular nephritis	J:93637
Mdk^tm1Tmu/Mdk^tm1Tmu (B6.129S2-Mdk^tm1Tmu)	abnormal macrophage chemotaxis	J:102069
	decreased macrophage cell number	J:102069
	impaired neutrophil chemotaxis	J:102069
Mdm2^tm1.1Ypz/Mdm2^tm1.1Ypz Tg(IghMyc)22Bri/0 (B6.Cg-Mdm2^tm1.1Ypz Tg(IghMyc)22Bri)	enlarged lymph nodes	J:164200
	enlarged Peyer's patches	J:164200
	enlarged thymus	J:164200
	spleen hyperplasia	J:164200
Mdm2^tm1Bay/Mdm2^tm1Mep (involves: 129S7/SvEvBrd * C57BL/6)	abnormal B cell differentiation	J:81065
	decreased double-negative T cell number	J:81065
	decreased double-positive T cell number	J:81065
	decreased granulocyte number	J:81065
	decreased immature B cell number	J:81065
	decreased leukocyte cell number	J:81065
	decreased lymphocyte cell number	J:81065
	decreased neutrophil cell number	J:81065
	decreased spleen weight	J:81065
	decreased T cell number	J:81065
	decreased thymocyte number	J:81065
	decreased thymus weight	J:81065
	spleen hypoplasia	J:81065
	thymus hypoplasia	J:81065
Mdm2^tm1Glo/Mdm2⁺ Mdm4^tm1Glo/Mdm4⁺ (involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6)	decreased leukocyte cell number	J:123661
	spleen atrophy	J:123661
	spleen hypoplasia	J:123661
	thymus atrophy	J:123661
	thymus hypoplasia	J:123661
Mdm2^tm1Glo/Mdm2⁺ Trp53^tm2Wahl/Trp53^tm2Wahl (involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6)	decreased leukocyte cell number	J:174375
	small thymus	J:174375
	spleen atrophy	J:174375
Mdm2^tm1Mep/Mdm2^tm1.1Mep (involves: 129S7/SvEvBrd * C57BL/6 * FVB)	decreased spleen weight	J:81065
	decreased thymus weight	J:81065
Mdm2^tm2.1Snj/Mdm2^tm2.1Snj (involves: 129S4/SvJae * C57BL/6)	decreased thymocyte apoptosis	J:189297
	enlarged spleen	J:189297
	increased T cell derived lymphoma incidence	J:189297
Mdm2^tm3.1Snj/Mdm2^tm3.1Snj (involves: 129S4/SvJae * C57BL/6)	immune system phenotype	J:189297
Mdm4^m1Btlr/Mdm4^m1Btlr (C57BL/6J-Mdm4^m1Btlr)	decreased CD8-positive, alpha-beta T cell number	J:265262
	decreased single-positive T cell number	J:265262
	increased CD4-positive, alpha-beta T cell number	J:265262
	increased single-positive T cell number	J:265262
Mdm4^m2Btlr/Mdm4^m2Btlr (C57BL/6J-Mdm4^m2Btlr)	decreased CD8-positive, alpha-beta T cell number	J:272830
Mdm4^m2Btlr/Mdm4^m2Btlr (C57BL/6J-Mdm4^m2Btlr)	increased CD4-positive, alpha-beta T cell number	J:272830
Mdm4^tm1.1Wahl/Mdm4^tm1.1Wahl (involves: 129S/Sv * C57BL/6)	decreased thymocyte apoptosis	J:150341
Mdm4^tm1.1Wahl/Mdm4^tm1.1Wahl (involves: 129S/Sv * C57BL/6)	increased leukocyte cell number	J:150341
Me1^em1(IMPC)Tcp/Me1^em1(IMPC)Tcp (C57BL/6NCrl-Me1^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Mecom^Jbo/Mecom⁺ (C3N.C-Mecom^Jbo)	abnormal neutrophil differentiation	J:113445
	immune system phenotype	J:113445
	increased susceptibility to otitis media	J:113445
	respiratory system inflammation	J:113445
Mecom^Jbo/Mecom⁺ (involves: BALB/c)	increased susceptibility to otitis media	J:250208
Mecom^tm1Aspe/Mecom^tm1Aspe (involves: 129S6/SvEvTac * C57BL/6)	increased leukocyte cell number	J:178429
Mecom^tm2.2Aspe/Mecom^tm2.2Aspe (involves: 129 * C57BL/6J * FVB/N)	abnormal immune system organ morphology	J:213829
	decreased B cell number	J:213829
	decreased leukocyte cell number	J:213829
Mecp2^tm1.1Bird/Y Sqle^Sum3-Jus/Sqle⁺ (involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J)	dermatitis	J:198551
Mecp2^tm1.1Bird/Y Sum2^M1Jus/Sum2⁺ (involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J)	dermatitis	J:198551
	eye inflammation	J:198551
Mecp2^tm1.1Bird/Y Sum4^M1Jus/Sum4⁺ (involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J)	dermatitis	J:198551
	eye inflammation	J:198551
Mecp2^tm1.1Bird/Y Sum5^M1Jus/Sum5⁺ (involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J)	eye inflammation	J:198551
Med18^{tm1a(EUCOMM)Wtsi}/Med18⁺ (C57BL/6N-Med18^{tm1a(EUCOMM)Wtsi}/H)	decreased leukocyte cell number	J:165965
Med19^{tm1c(EUCOMM)Wtsi}/Med19^{tm1c(EUCOMM)Wtsi} Tg(Adipoq-icre/ERT2)1Soff/0 (involves: C57BL/6J * C57BL/6N)	white adipose tissue inflammation	J:298822
Med20^em1(IMPC)J/Med20⁺ (C57BL/6NJ-Med20^em1(IMPC)J/J)	decreased leukocyte cell number	J:211773
Med28^{tm1.1(KOMP)Vlcg}/Med28⁺ (C57BL/6N-Med28^{tm1.1(KOMP)Vlcg}/Ucd)	abnormal spleen morphology	J:211773
	small spleen	J:211773
Mef2b^tm2Rdf/Mef2b⁺ Tg(Cr2-cre)3Cgn/0 (involves: C57BL/6)	abnormal mature B cell morphology	J:265465
	enlarged lymph nodes	J:265465
	enlarged mesenteric lymph nodes	J:265465
	enlarged spleen	J:265465
	increased germinal center B cell number	J:265465
Mef2c^tm1Jjs/Mef2c^tm1Jjs Mir223^tm1Fcam/Mir223^tm1Fcam Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129 * C57BL/6)	abnormal neutrophil differentiation	J:140009
	abnormal neutrophil physiology	J:140009
	increased neutrophil cell number	J:140009
Mefv^tm1Bhk/Mefv^tm1Bhk (129S6/SvEvTac-Mefv^tm1Bhk)	immune system phenotype	J:192443
	increased interleukin-1 beta secretion	J:192443
	increased interleukin-18 secretion	J:192443
Mefv^tm1Chae/Mefv^tm1Chae (either: (involves: 129S6/SvEvTac) or (involves: 129S6/SvEvTac * C57BL/6))	decreased macrophage apoptosis	J:82763
	increased inflammatory response	J:82763
	increased susceptibility to endotoxin shock	J:82763
Mefv^{tm3.1(MEFV)Chae}/Mefv^{tm3.1(MEFV)Chae} (B6.129S6-Mefv^{tm3.1(MEFV)Chae})	autoimmune arthritis	J:172117
	dermatitis	J:172117
	increased inflammatory response	J:172117
	increased leukocyte cell number	J:172117
Mefv^{tm4.1(MEFV)Chae}/Mefv^{tm4.1(MEFV)Chae} (B6.129S6-Mefv^{tm4.1(MEFV)Chae})	autoimmune arthritis	J:172117
	dermatitis	J:172117
	increased inflammatory response	J:172117
	increased leukocyte cell number	J:172117
Mefv^{tm5.1(MEFV)Chae}/Mefv^{tm5.1(MEFV)Chae} (B6.129S6-Mefv^{tm5.1(MEFV)Chae})	abnormal cytokine secretion	J:172117
	abnormal spleen germinal center morphology	J:172117
	autoimmune arthritis	J:172117
	decreased B cell number	J:172117
	decreased interleukin-3 secretion	J:172117
	decreased lymphocyte cell number	J:172117
	decreased T cell number	J:172117
	dermatitis	J:172117
	enlarged lymph nodes	J:172117
	enlarged spleen	J:172117
	increased circulating interleukin-1 beta level	J:172117
	increased circulating interleukin-6 level	J:172117
	increased circulating tumor necrosis factor level	J:172117
	increased granulocyte number	J:172117
	increased inflammatory response	J:172117
	increased interferon-gamma secretion	J:172117
	increased interleukin-1 alpha secretion	J:172117
	increased interleukin-1 beta secretion	J:172117
	increased interleukin-2 secretion	J:172117
	increased interleukin-4 secretion	J:172117
	increased interleukin-5 secretion	J:172117
	increased interleukin-9 secretion	J:172117
	increased interleukin-10 secretion	J:172117
	increased interleukin-12 secretion	J:172117
	increased interleukin-12b secretion	J:172117
	increased interleukin-13 secretion	J:172117
	increased interleukin-17 secretion	J:172117
	increased leukocyte cell number	J:172117
	increased macrophage cell number	J:172117
	increased monocyte cell number	J:172117
	increased neutrophil cell number	J:172117
	joint inflammation	J:172117
	liver inflammation	J:172117
	skin inflammation	J:172117
Mefv^{tm5.1(MEFV)Chae}/Mefv^{tm5.1(MEFV)Chae} Nlrp3^tm1Tsc/Nlrp3^tm1Tsc (involves: 129S6/SvEvTac * C57BL/6)	increased inflammatory response	J:172117
	increased interleukin-1 beta secretion	J:172117
Mefv^{tm5.1(MEFV)Chae}/Mefv^{tm5.1(MEFV)Chae} Pycard^tm1Tno/Pycard^tm1Tno (involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6)	decreased interleukin-1 beta secretion	J:172117
	immune system phenotype	J:172117
Mefv^{tm5.1(MEFV)Chae}/Mefv^{tm5.1(MEFV)Chae} Rag1^tm1Mom/Rag1^tm1Mom (involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6)	abnormal cytokine secretion	J:172117
	increased circulating interleukin-1 beta level	J:172117
	increased circulating interleukin-6 level	J:172117
	increased circulating tumor necrosis factor level	J:172117
	increased inflammatory response	J:172117
	increased interferon-gamma secretion	J:172117
	increased interleukin-1 beta secretion	J:172117
	increased interleukin-2 secretion	J:172117
	increased interleukin-4 secretion	J:172117
	increased interleukin-5 secretion	J:172117
	increased interleukin-9 secretion	J:172117
	increased interleukin-10 secretion	J:172117
	increased interleukin-12 secretion	J:172117
	increased interleukin-13 secretion	J:172117
	increased interleukin-17 secretion	J:172117
Megf8^b2b1702.2Clo/Megf8^b2b1702.2Clo (C57BL/6J-Megf8^b2b1702.2Clo)	spleen hypoplasia	J:175213
	thymus hypoplasia	J:175213
Megf8^hlb611/Megf8^hlb611 (involves: C57BL/6J)	absent spleen	J:146805
Megf8^hlb611/Megf8^hlb611 (involves: C57BL/6J)	accessory spleen	J:146805
Megf8^hlb611/Megf8^hlb611 (involves: C57BL/6J * C3H/HeJ)	absent spleen	J:146957
Megf8^hlb611/Megf8^hlb611 (involves: C57BL/6J * C3H/HeJ)	accessory spleen	J:146957
Meis3^{tm1b(EUCOMM)Hmgu}/Meis3^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Meis3^{tm1b(EUCOMM)Hmgu}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Men1^tm1.2Zqw/Men1^tm1.2Zqw Pgr^tm2(cre)Lyd/Pgr⁺ (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6)	decreased uterine NK cell number	J:322043
Men1^tm1Ctre/Men1⁺ (either: (involves: 129S6/SvEvTac * FVB/N) or (involves: 129S6/SvEvTac * Black Swiss * FVB/N))	pancreas inflammation	J:67128
Meox2^tm1(cre)Sor/Meox2⁺ Procr^tm2Cte/Procr^tm2Cte (involves: 129S4/SvJaeSor * 129S7/SvEvBrd * Black Swiss * C57BL/6)	decreased circulating fibrinogen level	J:119529
	increased circulating C-reactive protein level	J:119529
Meox2^tm1(cre)Sor/Meox2⁺ Slc40a1^tm2Nca/Slc40a1^tm2Nca (involves: 129S4/SvJae * 129S6/SvEvTac)	increased spleen iron level	J:129846
Meox2^tm1(cre)Sor/Meox2⁺ Tg(CAG-lacZ,-FUSR521G,-EGFP)682Gyu/0 (involves: 129S4/SvJaeSor C57BL/6)	microgliosis	J:216672
Meox2^tm1(cre)Sor/Meox2⁺ Tg(CAG-lacZ,-FUS,-EGFP)629Gyu/0 (involves: 129S4/SvJaeSor * C57BL/6)	microgliosis	J:216672
Mep1a^tm1Bond/Mep1a^tm1Bond (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal chemokine level	J:145685
	abnormal circulating interleukin-1 beta level	J:145037
	abnormal cytokine level	J:145037, J:145685
	abnormal leukocyte physiology	J:145037
	abnormal tumor necrosis factor level	J:145037
	increased circulating interleukin-1 beta level	J:145685
	increased circulating interleukin-6 level	J:145685
	increased susceptibility to induced colitis	J:145685
	urinary bladder inflammation	J:145037
Mep1b^tm1Bond/Mep1b^tm1Bond (B6.129-Mep1b^tm1Bond)	immune system phenotype	J:145037
Mep1b^tm1Bond/Mep1b^tm1Bond (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	decreased inflammatory response	J:132021
Mepe^tm1Tbrw/Mepe^tm1Tbrw (involves: 129P2/OlaHsd * C57BL/6)	abnormal osteoclast morphology	J:81218
Mertk^nmf12/Mertk^nmf12 (involves: C57BL/6J)	abnormal tumor necrosis factor level	J:175587
Mertk^tm1Gkm/Mertk^tm1Gkm (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	increased circulating tumor necrosis factor level	J:53423
	increased susceptibility to endotoxin shock	J:53423
	increased tumor necrosis factor secretion	J:53423
Mertk^tm1Gkm/Mertk^tm1Gkm (NOD.129P2-Mertk^tm1Gkm)	abnormal mononuclear cell morphology	J:147153
	decreased susceptibility to autoimmune diabetes	J:147153
	decreased T cell number	J:147153
	increased T cell apoptosis	J:147153
	insulitis	J:147153
Mertk^tm1Gkm/Mertk^tm1Gkm (B6.129P2-Mertk^tm1Gkm)	decreased autoantibody level	J:136377
Mertk^tm1Gkm/Mertk^tm1Gkm (B6.129P2-Mertk^tm1Gkm)	decreased susceptibility to graft versus host disease	J:136377
Mertk^tm1Gkm/Mertk^tm1Gkm Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0 (NOD.Cg-Mertk^tm1Gkm Tg(TcraBDC2.5,TcrbBDC2.5)1Doi)	decreased double-positive T cell number	J:147153
	increased CD8-positive, alpha-beta T cell number	J:147153
	increased T cell apoptosis	J:147153
Mertk^tm1Grl/Mertk^tm1Grl (involves: 129P2/OlaHsd)	enlarged spleen	J:54681
Mesp1^tm2(cre)Ysa/Mesp1⁺ Tbx1^tm1Bld/Tbx1^tm3Bld (involves: 129S7/SvEvBrd * C57BL/6 * CBA)	athymia	J:112457
	thymus hypoplasia	J:112457
Mesp1^tm2(cre)Ysa/Mesp1⁺ Tbx1^tm1Bld/Tbx1^tm5Bld (involves: 129S7/SvEvBrd * C57BL/6 * CBA)	athymia	J:112457
Met^tm1Gvw/Met⁺ (involves: 129 * C57BL/6J)	glomerulonephritis	J:94722
Met^tm2Gvw/Met⁺ (involves: 129 * C57BL/6J)	glomerulonephritis	J:94722
Met^tm4Gvw/Met⁺ (involves: 129 * C57BL/6J)	glomerulonephritis	J:94722
Metap1^em1(IMPC)Tcp/Metap1⁺ (C57BL/6NCrl-Metap1^em1(IMPC)Tcp/Cmmr)	small spleen	J:211773
Metrn^em1(IMPC)Mbp/Metrn^em1(IMPC)Mbp (C57BL/6NCrl-Metrn^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	increased neutrophil cell number	J:211773
Metrnl^{tm1d(KOMP)Wtsi}/Metrnl^{tm1d(KOMP)Wtsi} (involves: C57BL/6J * C57BL/6N)	decreased IgG level	J:268270
	increased IgM level	J:268270
	increased susceptibility to endotoxin shock	J:268270
	kidney inflammation	J:268270
	liver inflammation	J:268270
	uterus inflammation	J:268270
Mettl4^em1Dfel/Mettl4^em1Dfel (involves: 129/Sv * C57BL/6N)	decreased leukocyte cell number	J:278437
Mettl4^em1Dfel/Mettl4^em1Dfel (involves: 129/Sv * C57BL/6N)	enlarged spleen	J:278437
Mettl5^{em1(IMPC)Hmgu}/Mettl5^{em1(IMPC)Hmgu} (C57BL/6N-Mettl5^{em1(IMPC)Hmgu}/Ieg)	increased spleen weight	J:211773
Mettl14^em1(IMPC)Tcp/Mettl14⁺ (C57BL/6NCrl-Mettl14^em1(IMPC)Tcp/Tcp)	abnormal spleen morphology	J:211773
	small spleen	J:211773
Mettl23^{em1(IMPC)Hmgu}/Mettl23^{em1(IMPC)Hmgu} (C57BL/6NCrl-Mettl23^{em1(IMPC)Hmgu}/Ieg)	enlarged spleen	J:211773
	increased spleen weight	J:211773
Mettl25^em1(IMPC)Bay/Mettl25^em1(IMPC)Bay (C57BL/6N-Mettl25^em1(IMPC)Bay/BayMmucd)	increased spleen weight	J:211773
Mex3b^tm1.1Mbld/Mex3b^tm1.1Mbld Plekha5^{Tg(AMH-cre)1Flor}/Plekha5⁺ (involves: C57BL/6 * SJL)	increased anti-sperm antibody level	J:213588
Mex3b^tm1.2Mbld/Mex3b^tm1.2Mbld (involves: C57BL/6 * CBA)	impaired macrophage phagocytosis	J:213588
Mex3c^tm1Aki/Mex3c^tm1Aki (involves: 129X1/SvJ * C57BL/6)	abnormal cytokine secretion	J:208870
	decreased interferon-beta secretion	J:208870
	decreased interleukin-6 secretion	J:208870
	decreased interleukin-12 secretion	J:208870
Mexis^tm1.1Pton/Mexis^tm1.1Pton (involves: C57BL/6)	increased macrophage derived foam cell number	J:264834
Mfap2^{tm1a(KOMP)Wtsi}/Mfap2^{tm1a(KOMP)Wtsi} (involves: C57BL/6J * C57BL/6N)	decreased B cell number	J:236092
	decreased leukocyte cell number	J:236092
	decreased neutrophil cell number	J:236092
	increased B cell number	J:236092
	increased macrophage cell number	J:236092
	increased monocyte cell number	J:236092
	increased myeloid dendritic cell number	J:236092
	increased splenocyte number	J:236092
Mfap2^tm1Mech/Mfap2^tm1Mech (involves: 129X1/SvJ)	decreased macrophage cell number	J:203960
Mfap2^tm1Mech/Mfap2^tm1Mech (involves: 129X1/SvJ)	decreased monocyte cell number	J:203960
Mfap2^tm1Mech/Mfap2^tm1Mech Mfap5^tm1Mech/Mfap5^tm1Mech (involves: 129X1/SvJ)	decreased monocyte cell number	J:203960
	decreased neutrophil cell number	J:203960
	immune system phenotype	J:203960
Mfap4^{tm1b(NCOM)Mfgc}/Mfap4^{tm1b(NCOM)Mfgc} (C57BL/6N-Mfap4^{tm1b(NCOM)Mfgc}/Tcp)	enlarged lymph nodes	J:211773
Mfap5^tm1Mech/Mfap5^tm1Mech (Not Specified)	decreased neutrophil cell number	J:203960
Mfap5^tm1Mech/Mfap5^tm1Mech (Not Specified)	immune system phenotype	J:203960
Mfge8^{Gt(KST227)Byg}/Mfge8^{Gt(KST227)Byg} (B6.129P2-Mfge8^{Gt(KST227)Byg})	enlarged spleen	J:98314
	impaired macrophage phagocytosis	J:98314
Mfge8^{Gt(KST227)Byg}/Mfge8^{Gt(KST227)Byg} (involves: 129P2/OlaHsd * C57BL/6)	enlarged spleen	J:107106
	impaired macrophage phagocytosis	J:107106
	mastitis	J:107106
Mfge8^tm1Mcu/Mfge8^tm1Mcu (involves: 129X1/SvJ * C57BL/6NCr)	enlarged spleen	J:123138
Mfge8^tm1Mcu/Mfge8^tm1Mcu Tg(RIP1-Tag)2Dh/? (involves: 129X1/SvJ * C57BL/6J * C57BL/6NCr * DBA/2J)	decreased Langerhans cell number	J:123138
Mfge8^tm1Osa/Mfge8^tm1Osa (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal spleen morphology	J:90633
	enlarged spleen	J:90633
	impaired macrophage phagocytosis	J:90633
	increased anti-double stranded DNA antibody level	J:225063
	increased spleen B cell follicle size	J:90633
	increased spleen weight	J:90633
	increased spleen white pulp amount	J:90633
	spleen hyperplasia	J:90633
Mfge8^tm1Osa/Mfge8^tm1Osa (B6.129-Mfge8^tm1Osa)	immune system phenotype	J:187181
Mfge8^tm1Osa/Mfge8^tm1Osa Timd4^tm1Osa/Timd4^tm1Osa (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	impaired macrophage phagocytosis	J:187181
	increased anti-double stranded DNA antibody level	J:187181
	increased anti-nuclear antigen antibody level	J:187181
Mfge8^tm1Shur/Mfge8^tm1Shur (B6.129-Mfge8^tm1Shur)	spermatic granuloma	J:145962
Mfn1^tm2Dcc/Mfn1^tm2Dcc Mfn2^tm3Dcc/Mfn2^tm3Dcc Tg(Cd4-cre)1Cwi/0 (involves: 129 * C57BL/6 * C57BL/6J * DBA/2)	abnormal CD4-positive, alpha-beta T cell physiology	J:339075
Mfng^{em1(IMPC)Ccpcz}/Mfng^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Mfng^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	decreased NK T cell number	J:211773
	enlarged thymus	J:211773
Mfng^tm1.1Cfg/Mfng^tm1.1Cfg (involves: C57BL/6)	decreased macrophage cell number	J:217719
	decreased mature B cell number	J:217719
	decreased neutrophil cell number	J:217719
	increased B cell number	J:217719
	increased B cell proliferation	J:217719
	increased lymphocyte cell number	J:217719
Mfng^tm1Cjg/Mfng^tm1Cjg (B6.Cg-Mfng^tm1Cjg)	abnormal marginal zone B cell morphology	J:146621
Mfsd1^em1(IMPC)Tcp/Mfsd1⁺ (C57BL/6N-Mfsd1^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Mfsd1^em1(IMPC)Tcp/Mfsd1^em1(IMPC)Tcp (C57BL/6N-Mfsd1^em1(IMPC)Tcp/Tcp)	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
	enlarged spleen	J:211773
	increased neutrophil cell number	J:211773
Mfsd1^{tm1a(KOMP)Wtsi}/Mfsd1^{tm1a(KOMP)Wtsi} (involves: C57BL/6N)	enlarged spleen	J:280713
Mfsd2a^tm1Dls/Mfsd2a^tm1Dls (B6.Cg-Mfsd2a^tm1Dls)	abnormal microglial cell activation	J:234197
Mfsd2b^{tm1a(KOMP)Wtsi}/Mfsd2b^{tm1a(KOMP)Wtsi} (C57BL/6-Mfsd2b^{tm1a(KOMP)Wtsi})	decreased B cell number	J:250123
	decreased leukocyte cell number	J:250123
	decreased T cell number	J:250123
	enlarged spleen	J:250123
	increased susceptibility to type I hypersensitivity reaction	J:250123
Mfsd6^tm1Ryosh/Mfsd6^tm1Ryosh (B6.129S2-Mfsd6^tm1Ryosh)	abnormal leukocyte physiology	J:260694
	immune system phenotype	J:260694
	increased length of allograft survival	J:260694
Mfsd8^{tm1a(EUCOMM)Hmgu}/Mfsd8^{tm1a(EUCOMM)Hmgu} (involves: C57BL/6N)	abnormal spleen morphology	J:211608
	CNS inflammation	J:211608
	microgliosis	J:211608
Mfsd10^{tm1.1(KOMP)Vlcg}/Mfsd10^{tm1.1(KOMP)Vlcg} (C57BL/6N-Mfsd10^{tm1.1(KOMP)Vlcg}/J)	decreased leukocyte cell number	J:211773
Mgat2^tm1.1Jxm/Mgat2^tm1.1Jxm (involves: 129S1/Sv * 129X1/SvJ * ICR)	abnormal B cell differentiation	J:80661
	decreased T cell number	J:80661
	enlarged lymph nodes	J:80661
	enlarged spleen	J:80661
	glomerulonephritis	J:80661
Mgat4b^tm1.1Jxm/Mgat4b^tm1.1Jxm (B6.129-Mgat4b^tm1.1Jxm)	decreased neutrophil cell number	J:212313
Mgat4b^tm1.1Jxm/Mgat4b^tm1.1Jxm (B6.129-Mgat4b^tm1.1Jxm)	increased leukocyte cell number	J:212313
Mgat4d^{tm1b(KOMP)Wtsi}/Mgat4d^{tm1b(KOMP)Wtsi} (C57BL/6N-Mgat4d^{tm1b(KOMP)Wtsi}/Bay)	abnormal spleen morphology	J:211773
Mgat5^tm1Jwd/Mgat5^tm1Jwd (involves: 129S1/Sv * 129X1/SvJ)	abnormal inflammatory response	J:60960
	abnormal leukocyte physiology	J:94864
	abnormal T cell physiology	J:60960
	decreased interleukin-2 secretion	J:94864
	decreased interleukin-4 secretion	J:94864
	increased interleukin-10 secretion	J:94864
	increased tumor necrosis factor secretion	J:94864
Mgat5b^tm1.1Cfg/Mgat5b^tm1.1Cfg (involves: 129S6/SvEvTac)	decreased pre-B cell number	J:217719
	enhanced humoral immune response	J:217719
	increased IgG2b level	J:217719
Mgat5b^tm1Nta/Mgat5b^tm1Nta (Not Specified)	brain inflammation	J:199165
Mgl2^{tm1.1(HBEGF/EGFP)Aiwsk}/Mgl2⁺ (involves: C57BL/6 * FVB/N)	abnormal immune system physiology	J:201044
	abnormal lymph node size	J:201044
	abnormal T-helper 2 cell morphology	J:201044
	decreased B cell number	J:201044
	decreased CD4-positive, alpha-beta T cell number	J:201044
	decreased CD8-positive, alpha-beta T cell number	J:201044
	decreased dendritic cell number	J:201044
	decreased interleukin-4 secretion	J:201044
	decreased Langerhans cell number	J:201044
	increased susceptibility to parasitic infection	J:201044
Mgmt^tm1Mse/Mgmt^tm1Mse (involves: 129S/SvEv)	increased T cell derived lymphoma incidence	J:47642
Mgmt^tm1Mse/Mgmt^tm1Mse Mlh1^tm1Mse/Mlh1^tm1Mse (involves: 129S/SvEv)	increased T cell derived lymphoma incidence	J:47642
Mgrn1^em1(IMPC)Tcp/Mgrn1⁺ (C57BL/6NCrl-Mgrn1^em1(IMPC)Tcp/Tcp)	decreased lymphocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
	increased spleen weight	J:211773
Mgrn1^em1(IMPC)Tcp/Mgrn1^em1(IMPC)Tcp (C57BL/6NCrl-Mgrn1^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Mgst2^em1(IMPC)Mbp/Mgst2^em1(IMPC)Mbp (C57BL/6N-Mgst2^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	small spleen	J:211773
Mical2^em1(IMPC)Tcp/Mical2^em1(IMPC)Tcp (C57BL/6NCrl-Mical2^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Mical3^em1(IMPC)J/Mical3^em1(IMPC)J (C57BL/6NJ-Mical3^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
Micu1^em#Fink/Micu1^em#Fink (C57BL/6N-Micu1^em#Fink)	decreased B cell number	J:238984
	decreased follicular B cell number	J:238984
	increased B cell apoptosis	J:238984
Micu1^em#Fink/Micu1^em#Fink Smdt1^em1Fink/Smdt1⁺ (involves: C57BL/6J * C57BL/6N * CBA)	decreased B cell number	J:238984
Micu1^tm1bNarl/Micu1⁺ (C57BL/6N-Micu1^tm1bNarl/Narl)	decreased monocyte cell number	J:211773
Mid2^{tm1b(KOMP)Wtsi}/Y (C57BL/6N-Mid2^{tm1b(KOMP)Wtsi}/Ucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Mideas^em1Shmc/Mideas^em1Shmc (C57BL/6J-Mideas^em1Shmc)	immune system phenotype	J:291786
Mif^tm1Dvd/Mif^tm1Dvd (involves: 129S4/SvJae * C57BL/6)	decreased circulating tumor necrosis factor level	J:52300
	decreased susceptibility to bacterial infection	J:52300
	decreased susceptibility to endotoxin shock	J:52300
	increased interleukin-4 secretion	J:52300
	increased susceptibility to parasitic infection	J:52300
Mif^tm1Mky/Mif^tm1Mky (C.129-Mif^tm1Mky)	abnormal cytokine secretion	J:106380
	abnormal inflammatory response	J:106380
	decreased eosinophil cell number	J:106380
Miga2^{tm1a(KOMP)Wtsi}/Miga2^{tm1a(KOMP)Wtsi} (C57BL/6N-Miga2^{tm1a(KOMP)Wtsi}/Mmucd)	abnormal CD4-positive, alpha beta T cell morphology	J:339075
Miga2^{tm1a(KOMP)Wtsi}/Miga2^{tm1a(KOMP)Wtsi} Pnp2^em1Smoc/Pnp2^em1Smoc (C57BL/6-Miga2^{tm1a(KOMP)Wtsi} Pnp2^em1Smoc)	abnormal CD4-positive, alpha-beta T cell physiology	J:339075
Miga2^{tm1c(KOMP)Wtsi}/Miga2^{tm1c(KOMP)Wtsi} Tg(Cd4-cre)1Cwi/0 (B6.Cg-Miga2^{tm1c(KOMP)Wtsi} Tg(Cd4-cre)1Cwi)	abnormal CD4-positive, alpha-beta T cell physiology	J:339075
	abnormal immune system morphology	J:339075
	immune system phenotype	J:339075
Miju^C3HeB/FeJ/Miju^C57BL/6J (involves: C3HeB/FeJ * C57BL/6J)	increased IgA level	J:91062
Milr1^tm1Shib/Milr1^tm1Shib (involves: C57BL/6N)	decreased mast cell degranulation	J:161854
Milr1^tm1Shib/Milr1^tm1Shib (involves: C57BL/6N)	increased susceptibility to type I hypersensitivity reaction	J:161854
Minar1^em1(IMPC)Tcp/Minar1^em1(IMPC)Tcp (C57BL/6NCrl-Minar1^em1(IMPC)Tcp/Tcp)	abnormal thymus morphology	J:211773
Mink1^em1(IMPC)Tcp/Mink1^em1(IMPC)Tcp (C57BL/6N-Mink1^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Mipep^tm1.1Yhig/Mipep^tm1.1Yhig Tg(Adipoq-cre)1Evdr/0 (involves: C57BL/6J * C57BL/6N * FVB/NJ)	decreased T cell number	J:365489
	increased cytokine level	J:365489
	increased granulocyte number	J:365489
	increased inflammatory response	J:365489
	increased macrophage cell number	J:365489
	increased monocyte cell number	J:365489
	increased spleen weight	J:365489
	white adipose tissue inflammation	J:365489
Mir10b^em1Rosay/Mir10b^em1Rosay (C57BL/6J-Mir10b^em1Rosay)	large intestinal inflammation	J:342486
Mir21a^tm1.1Mer/Mir21a^tm1.1Mer (involves: 129S1/Sv * C57BL/6 * FVB/N)	abnormal cytokine level	J:179235
	abnormal cytokine secretion	J:179235
	abnormal interferon level	J:179235
	abnormal interleukin level	J:179235
	decreased interleukin-4 secretion	J:179235
	increased interferon-gamma secretion	J:179235
	increased interleukin-12 secretion	J:179235
	increased susceptibility to type I hypersensitivity reaction	J:179235
Mir21a^tm1.1Mer/Mir21a^tm1.1Mer (B6.129S1-Mir21a^tm1.1Mer)	increased susceptibility to type IV hypersensitivity reaction	J:179235
Mir27a^em1Bge/Mir27a^em1Bge (C57BL/6-Mir27a^em1Bge)	abnormal macrophage physiology	J:267961
Mir27a^em1Bge/Mir27a^em1Bge (C57BL/6-Mir27a^em1Bge)	decreased susceptibility to bacterial infection	J:267961
Mir33^tm1.1Koho/Mir33^tm1.1Koho (involves: C57BL/6)	abnormal macrophage physiology	J:165420
Mir34a^tm1.1Pisc/Mir34a^tm1.1Pisc Mirc21^tm1.1Pisc/Mirc21^tm1.1Pisc Mirc34^tm1.1Pisc/Mirc34^tm1.1Pisc (involves: 129S4/SvJae * C57BL/6 * C57BL/6J)	increased susceptibility to bacterial infection induced morbidity/mortality	J:256929
	nasal inflammation	J:256929
Mir34a^tm1.2Arte/Mir34a^tm1.2Arte (involves: C57BL/6N)	abnormal immune system cell morphology	J:221990
Mir34a^tm1.2Arte/Mir34a^tm1.2Arte (involves: C57BL/6N)	increased B cell number	J:221990
Mir100^em1Nju/Mir100^em1Nju Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺ (involves: C57BL/6 * DBA)	liver inflammation	J:281439
Mir122^tm1.1Apts/Mir122^tm1.1Apts (involves: 129 * C57BL/6)	increased circulating interleukin-6 level	J:190066
	increased macrophage cell number	J:190066
	increased monocyte cell number	J:190066
	liver inflammation	J:190066
Mir122^tm1.1Kgh/Mir122^tm1.1Kgh (involves: 129S1/Sv * 129X1/SvJ)	increased circulating interleukin-6 level	J:190067
	liver inflammation	J:190067
Mir122^tm1.2Kgh/Mir122^tm1.2Kgh Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA)	increased circulating interleukin-6 level	J:190067
	increased interleukin-6 secretion	J:190067
	increased monocyte cell number	J:190067
	increased neutrophil cell number	J:190067
	increased tumor necrosis factor secretion	J:190067
	liver inflammation	J:190067
Mir125a^tm1Smoc/Mir125a^tm1Smoc (involves: C57BL/6)	abnormal regulatory T cell physiology	J:224880
	decreased regulatory T cell number	J:224880
	immune system phenotype	J:224880
	increased interferon-gamma secretion	J:224880
	increased interleukin-17 secretion	J:224880
	increased susceptibility to experimental autoimmune encephalomyelitis	J:224880
Mir126a^tm2.1Smoc/Mir126a^tm2.1Smoc Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6J * C57BL/6N * DBA/2)	decreased T-helper 2 cell number	J:355195
	dermatitis	J:355195
	enlarged spleen	J:355195
	increased T-helper 1 cell number	J:355195
	increased T-helper 17 cell number	J:355195
Mir139^em1Jwli/Mir139^em1Jwli (C57BL/6J-Mir139^em1Jwli)	abnormal cytokine level	J:248779
	increased susceptibility to colitis induced morbidity/mortality	J:280467, J:248779
	increased susceptibility to induced colitis	J:248779
Mir140^tm1.1Asah/Mir140^tm1.1Asah (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)	increased susceptibility to induced arthritis	J:160358
	osteoarthritis	J:160358
Mir142^tm1.1Sbel/Mir142^tm1.1Sbel (involves: C57BL/6N)	decreased eosinophil cell number	J:227228
	decreased leukocyte cell number	J:227228
	decreased lymphocyte cell number	J:227228
	decreased monocyte cell number	J:227228
Mir142^tm1Teyo/Mir142^tm1Teyo (involves: C57BL/6)	decreased mast cell degranulation	J:211850
Mir142hg^{Gt(IST11580H2)Tigm}/Mir142hg^{Gt(IST11580H2)Tigm} (involves: C57BL/6N)	abnormal dendritic cell differentiation	J:207516
	abnormal dendritic cell morphology	J:207516
	decreased dendritic cell number	J:207516
	enlarged spleen	J:207516
	immune system phenotype	J:207516
	increased dendritic cell number	J:207516
	increased neutrophil cell number	J:207516
Mir144/Mir451a^tm1.1Mjwe/Mir144/Mir451a^tm1.1Mjwe (Not Specified)	increased spleen weight	J:163250
	spleen hyperplasia	J:163250
Mir144/Mir451a^tm1.1Mjwe/Mir144/Mir451a^tm1.1Mjwe (Not Specified)	increased spleen weight	J:163250
	spleen hyperplasia	J:163250
Mir144/Mir451a^tm1.2Doca/Mir144/Mir451a^tm1.2Doca (involves: 129P2/OlaHsd * 129S4/SvJaeSor * BALB/cJ)	enlarged spleen	J:163418
Mir144/Mir451a^tm1.2Doca/Mir144/Mir451a^tm1.2Doca (involves: 129P2/OlaHsd * 129S4/SvJaeSor * BALB/cJ)	enlarged spleen	J:163418
Mir146^tm1.1Bal/Mir146^tm1.1Bal (involves: C57BL/6)	abnormal lymphopoiesis	J:167922
	abnormal regulatory T cell physiology	J:167922
	decreased interferon-gamma secretion	J:167922
	decreased leukocyte cell number	J:173230
	decreased lymphocyte cell number	J:173230
	decreased monocyte cell number	J:173230
	enlarged spleen	J:173230
	increased regulatory T cell number	J:167922
	increased spleen weight	J:173230
	increased T cell derived lymphoma incidence	J:173230
	myeloid hyperplasia	J:167922, J:173230
Mir146^tm1.1Bal/Mir146^tm1.1Bal (involves: C57BL/6 * FVB/N)	abnormal immune system physiology	J:173671
	abnormal immune tolerance	J:173671
	abnormal macrophage physiology	J:173671
	abnormal T cell activation	J:173671
	increased circulating interleukin-1 beta level	J:173671
	increased circulating interleukin-6 level	J:173671
	increased circulating interleukin-10 level	J:173671
	increased circulating tumor necrosis factor level	J:173671
	increased interleukin-1 beta secretion	J:173671
	increased interleukin-6 secretion	J:173671
	increased macrophage nitric oxide production	J:173671
	increased susceptibility to bacterial infection induced morbidity/mortality	J:173671
	increased susceptibility to endotoxin shock	J:173671
	increased tumor necrosis factor secretion	J:173671
	myeloid hyperplasia	J:173671
Mir146^tm1.1Bal/Mir146^tm1.1Bal Tifab^tm1.1Dsta/Tifab^tm1.1Dsta (involves: 129 * C57BL/6 * C57BL/6J)	decreased lymphocyte cell number	J:229024
	decreased neutrophil cell number	J:229024
Mir146^tm1.1Lfl/Mir146^tm1.1Lfl Ighg1^tm1(cre)Cgn/Ighg1⁺ (involves: 129P2/OlaHsd * C57BL/6)	increased germinal center B cell number	J:266124
	increased T follicular helper cell number	J:266124
Mir146^tm1.1Lfl/Mir146^tm1.1Lfl Mir146b^tm1.1Lfl/Mir146b^tm1.1Lfl Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	increased germinal center B cell number	J:266124
	increased IgG level	J:266124
	increased T follicular helper cell number	J:266124
Mir146^tm1.1Lfl/Mir146^tm1.1Lfl Tg(CD2-icre)4Kio/0 (involves: C57BL/6 * C57BL/10 * CBA/Ca)	increased germinal center B cell number	J:266124
	increased T follicular helper cell number	J:266124
Mir146^tm1.1Lfl/Mir146^tm1.1Lfl Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	immune system phenotype	J:266124
Mir146^tm1.1Lfl/Mir146^tm1.1Lfl Tg(Cr2-cre)3Cgn/0 (involves: C57BL/6)	increased anti-double stranded DNA antibody level	J:266124
	increased germinal center B cell number	J:266124
	increased IgG1 level	J:266124
	increased IgG level	J:266124
	increased plasma cell number	J:266124
	increased T follicular helper cell number	J:266124
Mir146^tm2.1Bal/Mir146^tm2.1Bal (involves: 129S1/Sv * C57BL/6 * FVB/N)	abnormal immune system physiology	J:173671
	abnormal immune tolerance	J:173671
	abnormal macrophage physiology	J:173671
	abnormal spleen B cell follicle morphology	J:173671
	abnormal T cell activation	J:173671
	decreased lymphocyte cell number	J:173671
	decreased monocyte cell number	J:173671
	enlarged lymph nodes	J:173671
	enlarged spleen	J:173671
	immune system phenotype	J:173671
	increased acute inflammation	J:173671
	increased anti-double stranded DNA antibody level	J:173671
	increased circulating interleukin-1 beta level	J:173671
	increased circulating interleukin-6 level	J:173671
	increased circulating interleukin-10 level	J:173671
	increased circulating tumor necrosis factor level	J:173671
	increased interleukin-1 beta secretion	J:173671
	increased interleukin-6 secretion	J:173671
	increased macrophage nitric oxide production	J:173671
	increased spleen germinal center number	J:173671
	increased spleen germinal center size	J:173671
	increased spleen weight	J:173671
	increased susceptibility to bacterial infection induced morbidity/mortality	J:173671
	increased susceptibility to endotoxin shock	J:173671
	increased tumor necrosis factor secretion	J:173671
	myeloid hyperplasia	J:173671
Mir146b^tm1.1Lfl/Mir146b^tm1.1Lfl Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	immune system phenotype	J:266124
Mir147^tm1.2Xyn/Mir147^tm1.2Xyn (involves: C57BL/6)	immune system phenotype	J:332925
Mir148a^tm2942.1Arte/Mir148a^tm2942.1Arte Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal plasmablast number	J:307366
	decreased IgA level	J:307366
	decreased IgG level	J:307366
	decreased IgM level	J:307366
	decreased plasma cell number	J:307366
	impaired humoral immune response	J:307366
	increased memory B cell number	J:307366
Mir148a^tm2942.1Arte/Mir148a^tm2942.1Arte Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte}/Gt(ROSA)26Sor⁺ (involves: C57BL/6 * C57BL/6NTac)	abnormal B cell physiology	J:307366
	abnormal plasmablast number	J:307366
	decreased plasma cell number	J:307366
	impaired humoral immune response	J:307366
	increased plasma cell number	J:307366
Mir148a^tm2942.2Arte/Mir148a^tm2942.2Arte (involves: C57BL/6 * FVB/N)	abnormal B cell physiology	J:307366
	decreased plasma cell number	J:307366
Mir149^em1Ydw/Mir149^em1Ydw (C57BL/6J-Mir149^em1Ydw)	increased susceptibility to endotoxin shock	J:294318
Mir150^tm1Rsky/Mir150^tm1Rsky (involves: C57BL/6)	decreased B-2 B cell number	J:127234
	increased B-1 B cell number	J:127234
	increased IgA level	J:127234
	increased IgG1 level	J:127234
	increased IgG2b level	J:127234
	increased IgM level	J:127234
Mir155^tm1.1Brd/Mir155^tm1.1Brd (B6.Cg-Mir155^tm1.1Brd Tyr^c-Brd)	abnormal CD4-positive, alpha beta T cell morphology	J:121095
	abnormal CD4-positive, alpha-beta T cell physiology	J:121095
	abnormal dendritic cell physiology	J:121095
	abnormal T-helper 1 cell morphology	J:121095
	decreased IgG1 level	J:121095
	immune system phenotype	J:121095
	increased susceptibility to bacterial infection	J:121095
	increased T-helper 2 cell number	J:121095
Mir155^tm1.1Brd/Mir155^tm1.1Brd (B6.129S7-Mir155^tm1.1Brd)	decreased regulatory T cell number	J:146268
Mir155^tm1.1Rsky/Mir155^tm1.1Rsky (involves: 129 * C57BL/6)	abnormal B cell physiology	J:121084
	abnormal cytokine secretion	J:121084
	abnormal germinal center B cell physiology	J:121084
	abnormal humoral immune response	J:121084
	abnormal T cell physiology	J:121084
	decreased germinal center B cell number	J:121084
Mir155^tm1.1Rsky/Mir155^tm1.1Rsky (B6.Cg-Mir155^tm1Rsky/J)	abnormal T cell physiology	J:226678
	abnormal T-helper 17 cell differentiation	J:226678
	decreased effector memory T-helper cell number	J:226678
	decreased interleukin-6 secretion	J:226678
	decreased regulatory T cell number	J:226678
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:226678
	decreased T-helper 17 cell number	J:226678
Mir155^tm1Brd/Mir155^tm1Brd (involves: 129S7/SvEvBrd * C57BL/6)	abnormal B cell physiology	J:121095
	abnormal class switch recombination	J:121095
	abnormal cytokine secretion	J:121095
	decreased IgM level	J:121095
	immune system phenotype	J:121095
	intestinal inflammation	J:121095
	lung inflammation	J:121095
Mir155^tm1Rsky/Mir155^tm1Rsky (involves: 129/Sv * C57BL/6)	abnormal cytokine secretion	J:121084
	abnormal gut-associated lymphoid tissue morphology	J:121084
	abnormal humoral immune response	J:121084
	abnormal immune system morphology	J:121084
	abnormal immune system physiology	J:121084
	abnormal Peyer's patch germinal center morphology	J:121084
	decreased interferon-gamma secretion	J:121084
	decreased interleukin-4 secretion	J:121084
	decreased spleen germinal center number	J:121084
	decreased spleen germinal center size	J:121084
	decreased tumor necrosis factor secretion	J:121084
	increased interleukin-10 secretion	J:121084
Mir155^tm1Rsky/Mir155^tm1Rsky (involves: 129 * C57BL/6)	abnormal class switch recombination	J:136224
Mir181d^tm1.1Oers/Mir181d^tm1.1Oers (involves: C57BL/6)	immune system phenotype	J:212571
Mir181d^tm1.1Oers/Mir181d^tm1.1Oers (involves: C57BL/6)	increased T cell number	J:212571
Mir204^tm1.2Dic/Mir204^tm1.2Dic Mir211^tm1.2Dic/Mir211^tm1.2Dic (involves: 129S4/SvJaeSor * BALB/cJ * C57BL/6)	increased susceptibility to induced arthritis	J:345335
	increased synovial pannus formation	J:345335
Mir205hg^tm1.1Oers/Mir205hg^tm1.1Oers (B6(Cg)-Mir205hg^tm1.1Oers)	small thymus	J:278363
Mir210^tm1.1Wtsi/Mir210^tm1.1Wtsi (involves: C57BL/6J * C57BL/6N)	decreased germinal center B cell number	J:205868
	immune system phenotype	J:205868
	increased anti-chromatin antibody level	J:205868
	increased anti-double stranded DNA antibody level	J:205868
	increased anti-nuclear antigen antibody level	J:205868
Mir216a^em1Uf/Mir216a^em1Uf (C57BL/6-Mir216a^em1Uf)	increased susceptibility to induced pancreatitis	J:278847
Mir216a^em2Uf/Mir216a^em2Uf (C57BL/6-Mir216a^em2Uf)	increased susceptibility to induced pancreatitis	J:278847
Mir216b^em1Uf/Mir216b^em1Uf (C57BL/6-Mir216b^em1Uf)	increased susceptibility to induced pancreatitis	J:278847
Mir217^em1Uf/Mir217^em1Uf (C57BL/6-Mir217^em1Uf)	increased susceptibility to induced pancreatitis	J:278847
Mir217^em2Uf/Mir217^em2Uf (C57BL/6-Mir217^em2Uf)	increased susceptibility to induced pancreatitis	J:278847
Mir223^tm1Fcam/Mir223^tm1Fcam (involves: 129S4/SvJae * C57BL/6)	abnormal granulocyte physiology	J:140009
	abnormal neutrophil differentiation	J:140009
	abnormal neutrophil physiology	J:140009
	increased acute inflammation	J:140009
	increased granulocyte number	J:140009
	increased neutrophil cell number	J:140009
	lung inflammation	J:140009
Mir301^tm1Yoli/Mir301^tm1Yoli (involves: C57BL/6J)	abnormal response to transplant	J:237900
Mir338^em1Zchn/Mir338^em1Zchn (C57BL/6-Mir338^em1Zchn)	decreased osteoclast cell number	J:285968
Mir378b^em#Yoo/Mir378b^em#Yoo (C57BL/6J-Mir378b^em#Yoo)	abnormal chemokine secretion	J:307588
	abnormal susceptibility to bacterial infection	J:307588
	decreased interferon-gamma secretion	J:307588
	decreased interleukin-12 secretion	J:307588
	decreased tumor necrosis factor secretion	J:307588
Mir425^em1Nju/Mir425⁺ (involves: C57BL/6)	increased tumor necrosis factor secretion	J:280159
Mir451a^tm1.2Doca/Mir451a^tm1.2Doca (involves: 129P2/OlaHsd * 129S4/SvJaeSor * BALB/cJ)	enlarged spleen	J:163418
Mir451a^tm1Eno/Mir451a^tm1Eno (involves: C57BL/6)	enlarged spleen	J:163251
Mir497^em1Hgyu/Mir497^em1Hgyu (C57BL/6-Mir497^em1Hgyu)	increased susceptibility to induced colitis	J:357958
Mir511^em1Clib/Mir511^em1Clib (C57BL/6J-Mir511^em1Clib)	abnormal macrophage physiology	J:345580
Mir511^em1Clib/Mir511^em1Clib (C57BL/6J-Mir511^em1Clib)	decreased susceptibility to induced colitis	J:345580
Mir592^em1Jzhan/Mir592^em1Jzhan (Not Specified)	abnormal microglial cell morphology	J:323615
Mirc1^tm1.1Aven/Mirc1^tm1.1Aven (involves: 129S4/SvJae * C57BL/6 * SJL/J)	decreased alpha-beta T cell number	J:223213
	decreased B cell number	J:223213
	decreased pre-B cell number	J:223213
	decreased pro-B cell number	J:223213
	increased B cell apoptosis	J:223213
	small spleen	J:223213
Mirc1^tm1.2Tyj/Mirc1^tm1.2Tyj (involves: 129S4/SvJae * C57BL/6 * FVB/N * SJL)	abnormal B cell differentiation	J:134861
	decreased pre-B cell number	J:134861
	increased B cell apoptosis	J:134861
Mirc1^tm1.3Tyj/Mirc1^tm1.3Tyj (involves: 129S4/SvJae * C57BL/6 * FVB/N)	abnormal B cell differentiation	J:134861
	decreased pre-B cell number	J:134861
	increased B cell apoptosis	J:134861
Mirc1^tm1Tyj/Mirc1^tm1Tyj Tg(Mx1-cre)1Cgn/0 (involves: 129S4/SvJae * C57BL/6 * CBA * SJL)	abnormal immunoglobulin heavy chain V(D)J recombination	J:134861
	decreased pre-B cell number	J:134861
	increased B cell apoptosis	J:134861
Mirc1^tm2.1Aven/Mirc1^tm2.1Aven (involves: 129S4/SvJae * C57BL/6 * SJL/J)	decreased B cell number	J:223213
Mirc1^tm2.1Aven/Mirc1^tm2.1Aven Tg(IghMyc)22Bri/? (involves: 129S4/SvJae * C57BL/6 * SJL/J)	abnormal pre-B cell morphology	J:223213
	increased B cell apoptosis	J:223213
Mirc1^tm3.1Aven/Mirc1^tm3.1Aven (involves: 129S4/SvJae * C57BL/6 * SJL/J)	decreased alpha-beta T cell number	J:223213
	decreased B cell number	J:223213
	decreased pre-B cell number	J:223213
	decreased pro-B cell number	J:223213
	increased B cell apoptosis	J:223213
	small spleen	J:223213
Mirc11^tm1Rdhl/Mirc11^tm1Rdhl (B6.129-Mirc11^tm1Rdhl)	abnormal B cell differentiation	J:243248
	immune system phenotype	J:243248
	impaired myelopoiesis	J:243248
	increased B cell number	J:243248
	increased follicular B cell number	J:243248
	increased immature B cell number	J:243248
	increased mature B cell number	J:243248
	increased plasma cell number	J:243248
	increased pre-pro B cell number	J:243248
	increased pro-B cell number	J:243248
	increased transitional stage T1 B cell number	J:243248
Mirc13^tm1.1Mtm/Mirc13^tm1.1Mtm (Not Specified)	abnormal macrophage activation involved in immune response	J:256444
Mirc14^tm1.1Ankr/Mirc14^tm1.1Ankr (involves: C57BL/6)	abnormal alpha-beta intraepithelial T cell morphology	J:196134
	abnormal NK T cell morphology	J:196134
	abnormal T cell differentiation	J:196134
	decreased double-positive T cell number	J:196134
	decreased interferon-gamma secretion	J:196134
	decreased interleukin-4 secretion	J:196134
	decreased interleukin-13 secretion	J:196134
	decreased NK T cell number	J:196134
	immune system phenotype	J:196134
	increased CD4-positive, alpha-beta T cell number	J:196134
Mirc14^tm1.1Czc/Mirc14^tm1.1Czc Gt(ROSA)26Sor^{tm1(cre/ERT2)Tyj}/Gt(ROSA)26Sor⁺ (either: (involves: 129P2/OlaHsd * 129S4/SvJae * 129S4/SvJaeSor) or (involves: 129P2/OlaHsd * 129S4/SvJae * 129S4/SvJaeSor * C57BL/6))	decreased double-positive T cell number	J:188125
	thymus hypoplasia	J:188125
Mirc14^tm1.1Flv/Mirc14^tm1.1Flv Pten^tm1Hwu/Pten^tm1Hwu Tg(Cd4-cre)1Cwi/0 (involves: 129S4/SvJae * C57BL/6 * C57BL/6N * DBA/2 * SJL)	immune system phenotype	J:203157
Mirc14^tm1.1Flv/Mirc14^tm1.1Flv Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * C57BL/6N * DBA/2 * SJL)	decreased NK T cell number	J:203157
Mirc14^tm1.2Czc/Mirc14^tm1.2Czc (either: (involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor) or (involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6))	decreased B cell number	J:188125
	decreased DN3 thymocyte number	J:188125
	decreased double-positive T cell number	J:188125
	decreased germinal center B cell number	J:188125
	decreased thymocyte number	J:188125
	increased CD4-positive, alpha-beta T cell number	J:188125
	increased marginal zone B cell number	J:188125
Mirc14^tm1.2Flv/Mirc14^tm1.2Flv (involves: C57BL/6 * C57BL/6N * FVB/N * SJL)	abnormal T cell differentiation	J:203157
	abnormal T cell physiology	J:203157
	abnormal T cell receptor V(D)J recombination	J:203157
	decreased B cell number	J:203157
	decreased CD4-positive, alpha-beta T cell number	J:203157
	decreased CD8-positive, alpha-beta T cell number	J:203157
	decreased DN1 thymic pro-T cell number	J:203157
	decreased double-positive T cell number	J:203157
	decreased NK T cell number	J:203157
	decreased T cell proliferation	J:203157
	decreased thymocyte apoptosis	J:203157
	decreased thymocyte number	J:203157
Mirc14^tm1.2Flv/Mirc14^tm1.2Flv Mirc15^tm1.2Flv/Mirc15^tm1.2Flv (involves: C57BL/6 * C57BL/6N * FVB/N * SJL)	decreased B cell number	J:203157
	decreased immature B cell number	J:203157
	decreased pre-B cell number	J:203157
	increased pro-B cell number	J:203157
Mirc14^tm1.2Flv/Mirc14^tm1.2Flv Tg(Cd4-TcraDN32D3)1Aben/0 (involves: C57BL/6 * C57BL/6N * FVB/N * SJL)	abnormal NK T cell physiology	J:203157
	decreased NK T cell number	J:203157
Mirc14^tm1.2Flv/Mirc14^tm1.2Flv Tg(LCKprBCL2L1)12Sjk/0 (involves: C57BL/6 * C57BL/6N * FVB/N * SJL)	decreased NK T cell number	J:203157
Mirc15^tm1.2Czc/Mirc15^tm1.2Czc (either: (involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor) or (involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6))	immune system phenotype	J:188125
Mirc16^tm1.2Czc/Mirc16^tm1.2Czc (either: (involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor) or (involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6))	immune system phenotype	J:188125
	increased CD8-positive, alpha-beta T cell number	J:188125
Mirc19^tm1.2Arte/Mirc19^tm1.2Arte (involves: C57BL/6N)	immune system phenotype	J:200865
Mirc27^em1Hhzg/Mirc27^em1Hhzg Tg(Vav1-cre)#Cgp/0 (involves: 129S4/SvJae * C57BL/6 * C57BL/6NRj)	immune system phenotype	J:320883
Mirc29^tm1.1Cwh/Mirc29^tm1.1Cwh (involves: 129X1/SvJ)	immune system phenotype	J:189763
Mirc30^em1Hhzg/Mirc30^em1Hhzg Tg(Vav1-cre)#Cgp/0 (involves: 129S4/SvJae * C57BL/6 * C57BL/6NRj)	abnormal NK cell morphology	J:320883
	increased B cell number	J:320883
	increased pre-B cell number	J:320883
	increased pro-B cell number	J:320883
	increased spleen weight	J:320883
Mirc30^tm1.2Rdf/Mirc30^tm1.2Rdf (involves: 129S1/Sv * 129S4/SvJaeSor * C57BL/6)	abnormal B cell proliferation	J:156946
	increased B cell number	J:156946
	increased B-1a cell number	J:156946
	increased spleen white pulp amount	J:156946
Mirc32^tm1.1Jtm/Mirc32^tm1.1Jtm Tg(Myh11-cre,-EGFP)2Mik/? (B6.Cg-Mirc32^tm1.1Jtm Tg(Myh11-cre,-EGFP)2Mik)	increased susceptibility to induced colitis	J:214382
Mirc32^tm1.1Jtm/Mirc32^tm1.1Jtm Twist2^tm1(cre)Dor/Twist2⁺ (B6.129(Cg)-Twist2^{tm1.1(cre)Dor} Mirc32^tm1.1Jtm)	increased susceptibility to induced colitis	J:214382
Mirc32^tm1.2Jtm/Mirc32^tm1.2Jtm (B6.129(Cg)-Mirc32^tm1.2Jtm)	increased susceptibility to induced colitis	J:214382
Mirc33^tm1.1Cwh/Mirc33^tm1.1Cwh (involves: 129X1/SvJ)	abnormal T cell morphology	J:189763
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:189763
	increased interferon-gamma secretion	J:189763
	increased interleukin-17 secretion	J:189763
	increased T-helper 1 cell number	J:189763
	lymph node hypoplasia	J:189763
	lymphoid hypoplasia	J:189763
	spleen hypoplasia	J:189763
	thymus hypoplasia	J:189763
Mirc33^tm1Bdes/Mirc33^tm1Bdes (Not Specified)	abnormal thymus involution	J:180783
Mirc40^tm1Jzb/Mirc40^tm1Jzb (Not Specified)	increased microglial cell activation	J:244554
Misp^em2Nsas/Misp^em2Nsas (FVB/NJcl-Misp^em2Nsas)	abnormal interleukin level	J:333842
Misp^em2Nsas/Misp^em2Nsas (FVB/NJcl-Misp^em2Nsas)	increased susceptibility to induced colitis	J:333842
Mitf^mi-di/Mitf^mi-di ((PT x C3H/HeH)F1)	abnormal spleen germinal center morphology	J:8196
	abnormal spleen morphology	J:8196
	abnormal spleen red pulp morphology	J:8196
	abnormal spleen white pulp morphology	J:8196
Mitf^mi-ew/Mitf^mi-ew Tfe3^tm1Est/Tfe3^tm1Est (either: (involves: 129/Sv * 129S1/Sv * C57BL/6Bn * NAW) or (involves: 129S1/Sv * C57BL/6Bn * C57BL/6J * NAW))	abnormal osteoclast morphology	J:89821
Mitf^Mi-Or/Mitf^Mi-Or (involves: 101/Rl * C3H/Rl)	abnormal osteoclast morphology	J:30149
	abnormal osteoclast physiology	J:30149
	decreased osteoclast cell number	J:30149
	increased osteoclast cell number	J:30149
Mitf^mi-tg/Mitf^mi-tg (B6.Cg-Mitf^mi-tg)	abnormal mast cell physiology	J:53161
Mitf^mi-vga9/Mitf^mi-vga9 Tfe3^tm1Est/Tfe3^tm1Est (either: (involves: 129/Sv * 129S1/Sv * C57BL/6 * CBA) or (involves: 129S1/Sv * C57BL/6 * C57BL/6J * CBA))	abnormal osteoclast morphology	J:89821
Mitf^mi-vit/Mitf^mi-vit (C57BL/6J-Mitf^mi-vit)	abnormal Langerhans cell physiology	J:102101
Mitf^Mi/Mitf^Mi (Not Specified)	abnormal osteoclast morphology	J:5046
	decreased mast cell number	J:6889
	increased osteoclast cell number	J:5046
Mitf^Mi/Mitf^Mi (B6.Cg-Mitf^Mi)	abnormal mast cell physiology	J:53161
Mitf^Mi/Mitf^Mi (involves: C57BL/6J)	abnormal osteoclast morphology	J:89821
Mitf^Mi/Mitf^Mi Tfe3^tm1Est/Tfe3^tm1Est (either: (involves: 129/Sv * 129S1/Sv * C57BL/6J) or (involves: 129S1/Sv * C57BL/6J))	abnormal osteoclast morphology	J:89821
Mitf^{Tg(Tff3-Tmem207)2Tamo}/Mitf⁺ (involves: C57BL/6)	kidney inflammation	J:244533
Mki67^em1(IMPC)Mbp/Mki67^em1(IMPC)Mbp (C57BL/6NCrl-Mki67^em1(IMPC)Mbp/MbpMmucd)	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
	increased neutrophil cell number	J:211773
Mki67^em1Dfis/Mki67^em1Dfis (involves: C57BL/6J)	immune system phenotype	J:304800
Mkrn2^{tm1b(KOMP)Wtsi}/Mkrn2^{tm1b(KOMP)Wtsi} (C57BL/6N-Mkrn2^{tm1b(KOMP)Wtsi}/Wtsi)	decreased dendritic epidermal T cell number	J:211773
Mks1^hlb614/Mks1^hlb614 (involves: C3H * C57BL/6)	absent spleen	J:167534
Mks1^hlb614/Mks1^hlb614 (involves: C3H * C57BL/6)	accessory spleen	J:167534
Mlf1^tm1Swm/Mlf1^tm1Swm (involves: 129 * C57BL/6)	decreased splenocyte apoptosis	J:266833
Mlf1^tm1Swm/Mlf1^tm1Swm (involves: 129 * C57BL/6)	increased B cell number	J:266833
Mlh1^m1Btlr/Mlh1^m1Btlr (C57BL/6J-Mlh1^m1Btlr)	abnormal humoral immune response	J:265206
Mlh1^m1Btlr/Mlh1^m1Btlr (C57BL/6J-Mlh1^m1Btlr)	increased IgM level	J:265206
Mlh1^m2Btlr/Mlh1^m2Btlr (C57BL/6J-Mlh1^m2Btlr)	abnormal humoral immune response	J:265207
	decreased IgE level	J:265207
	increased IgM level	J:265207
Mlh1^m3Btlr/Mlh1^m3Btlr (C57BL/6J-Mlh1^m3Btlr)	abnormal humoral immune response	J:265208
	decreased IgE level	J:265208
	increased IgM level	J:265208
Mlh1^{tm1b(EUCOMM)Hmgu}/Mlh1^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Mlh1^{tm1b(EUCOMM)Hmgu}/H)	increased spleen weight	J:211773
Mlh1^tm1Mse/Mlh1^tm1Mse (involves: 129S/SvEv)	increased T cell derived lymphoma incidence	J:47642
Mlh1^tm1Rak/Mlh1⁺ (involves: 129P2/OlaHsd * C57BL/6)	increased T cell derived lymphoma incidence	J:53451
Mlh1^tm1Rak/Mlh1^tm1Rak (involves: 129P2/OlaHsd * C57BL/6)	increased T cell derived lymphoma incidence	J:53451
Mlh1^tm1Rak/Mlh1^tm1Rak (involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J)	increased T cell derived lymphoma incidence	J:153684
Mlkl^{em1(IMPC)Ccpcz}/Mlkl^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Mlkl^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Mlkl^em1Jhan/Mlkl^em1Jhan (involves: C57BL/6)	abnormal macrophage physiology	J:204622
Mlkl^em1Jhan/Mlkl^em1Jhan (involves: C57BL/6)	immune system phenotype	J:204622
Mlkl^m1Btlr/Mlkl⁺ (C57BL/6J-Mlkl^m1Btlr)	decreased inflammatory response	J:225934
Mlkl^m1Btlr/Mlkl^m1Btlr (C57BL/6J-Mlkl^m1Btlr)	decreased inflammatory response	J:225934
Mlkl^m2Btlr/Mlkl⁺ (C57BL/6J-Mlkl^m2Btlr)	decreased inflammatory response	J:234252
Mlkl^m2Btlr/Mlkl^m2Btlr (C57BL/6J-Mlkl^m2Btlr)	decreased inflammatory response	J:234252
Mlkl^m3Btlr/Mlkl⁺ (C57BL/6J-Mlkl^m3Btlr)	decreased inflammatory response	J:234251
Mlkl^m3Btlr/Mlkl^m3Btlr (C57BL/6J-Mlkl^m3Btlr)	decreased inflammatory response	J:234251
Mlkl^tm1.1Wsa/Mlkl^tm1.1Wsa Otulin^{tm1c(EUCOMM)Hmgu}/Otulin^{tm1c(EUCOMM)Hmgu} Tg(KRT14-cre)1Cgn/0 (involves: C57BL/6 * C57BL/6N * DBA/2)	dermatitis	J:312394
Mllt6^em1(IMPC)Tcp/Mllt6^em1(IMPC)Tcp (C57BL/6NCrl-Mllt6^em1(IMPC)Tcp/Tcp)	decreased lymphocyte cell number	J:211773
	enlarged spleen	J:211773
	increased neutrophil cell number	J:211773
	increased spleen weight	J:211773
Mllt10^em1(IMPC)Mbp/Mllt10⁺ (C57BL/6N-Mllt10^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	decreased lymphocyte cell number	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	increased neutrophil cell number	J:211773
Mlph^ln-Btlr/Mlph^ln-Btlr (C57BL/6J-Mlph^ln-Btlr)	immune system phenotype	J:133625
Mlrrq^DBA/2/Mlrrq^DBA/2 (C.D2-Mtv7^DBA/2)	decreased susceptibility to parasitic infection	J:41574
Mmab^{em1(IMPC)Hmgu}/Mmab⁺ (C57BL/6NCrl-Mmab^{em1(IMPC)Hmgu}/Ieg)	abnormal spleen morphology	J:211773
Mmachc^{tm1.1(NCOM)Mfgc}/Mmachc⁺ (C57BL/6N-Mmachc^{tm1.1(NCOM)Mfgc}/Tcp)	enlarged lymph nodes	J:211773
Mmd^tm1Beij/Mmd^tm1Beij (Not Specified)	abnormal macrophage differentiation	J:304637
	decreased susceptibility to induced arthritis	J:304637
	increased macrophage apoptosis	J:304637
	small inguinal lymph nodes	J:304637
Mme^tm1Cge/Mme^tm1Cge (B6.129S4-Mme^tm1Cge)	dermatitis	J:66854
Mme^tm1Cge/Mme^tm1Cge (B6.129S4-Mme^tm1Cge)	increased susceptibility to type I hypersensitivity reaction	J:66854
Mmgt2^{tm1b(EUCOMM)Wtsi}/Mmgt2^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Mmgt2^{tm1b(EUCOMM)Wtsi}/Bay)	decreased lymphocyte cell number	J:211773
	increased basophil cell number	J:211773
Mmp1a^tm1Otin/Mmp1a^tm1Otin (involves: 129P2/OlaHsd * C57BL/6J)	abnormal interleukin secretion	J:198586
	decreased inflammatory response	J:198586
	increased interferon-gamma secretion	J:198586
	increased interleukin-1 alpha secretion	J:198586
	increased interleukin-2 secretion	J:198586
	increased interleukin-17 secretion	J:198586
Mmp2^em1(IMPC)Mbp/Mmp2^em1(IMPC)Mbp (C57BL/6N-Mmp2^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Mmp2^tm1Ito/Mmp2^tm1Ito (involves: 129P2/OlaHsd * C57BL/6J)	abnormal inflammatory response	J:46091
	brain inflammation	J:94099
	decreased inflammatory response	J:46091
	increased susceptibility to experimental autoimmune encephalomyelitis	J:94099
Mmp2^tm1Ito/Mmp2^tm1Ito (involves: 129P2/OlaHsd)	autoimmune arthritis	J:121780
Mmp2^tm1Ito/Mmp2^tm1Ito (involves: 129P2/OlaHsd)	decreased osteoclast cell number	J:121780
Mmp2^tm1Ito/Mmp2^tm1Ito Timp1^tm1Pds/Timp1^tm1Pds (either: (involves: 129S4/SvJae) or (involves: C57BL/6))	decreased susceptibility to bacterial infection	J:94836
Mmp2^tm1Ito/Mmp2^tm1Ito Timp3^tm1Osya/Timp3^tm1Osya (involves: 129P2/OlaHsd * C57BL/6)	aortitis	J:193744
Mmp3^tm1Mrl/Mmp3^tm1Mrl (either: (129S7/SvEvBrd X B10.RIII)N2 or ((involves: 129S7/SvEvBrd * C57BL/6) X B10.RIII)N2)	autoimmune arthritis	J:46038
	joint inflammation	J:46038
	osteoarthritis	J:46038
Mmp3^tm1Mrl/Mmp3^tm1Mrl (either: 129S7/SvEvBrd or (involves: 129S7/SvEvBrd * C57BL/6))	abnormal CD4-positive, alpha-beta T cell physiology	J:93706
	increased susceptibility to bacterial infection	J:93706
Mmp3^tm1Mrl/Mmp3^tm1Mrl (involves: 129S7/SvEvBrd * C57BL/10ScSn * RIII)	abnormal lymphocyte physiology	J:55723
	decreased susceptibility to type IV hypersensitivity reaction	J:55723
Mmp3^tm1Mrl/Mmp3^tm1Mrl (involves: 129S7/SvEvBrd)	immune system phenotype	J:124841
Mmp3^tm1Mrl/Mmp3^tm1Mrl Timp1^tm1Pds/Timp1^tm1Pds (involves: C57BL/6)	decreased susceptibility to bacterial infection	J:94836
Mmp7^tm1Lmm/Mmp7^tm1Lmm (involves: 129S1/Sv * 129X1/SvJ)	decreased susceptibility to bacterial infection	J:153651
Mmp7^tm1Lmm/Mmp7^tm1Lmm (involves: 129S1/Sv * 129X1/SvJ)	immune system phenotype	J:55723
Mmp7^tm1Lmm/Mmp7^tm1Lmm (B6.129-Mmp7^tm1Lmm)	increased interleukin-1 beta secretion	J:149388
Mmp7^tm1Lmm/Mmp7^tm1Lmm (B6.129-Mmp7^tm1Lmm)	increased susceptibility to induced colitis	J:149388
Mmp7^tm1Lmm/Mmp7^tm1Lmm (involves: 129S/SvEv * 129S1/Sv * 129X1/SvJ)	abnormal macrophage physiology	J:124841
	decreased tumor necrosis factor secretion	J:124841
	impaired macrophage chemotaxis	J:124841
Mmp7^tm1Lmm/Mmp7^tm1Lmm Timp1^tm1Pds/Timp1^tm1Pds (involves: 129S4/SvJae)	decreased susceptibility to bacterial infection	J:94836
Mmp8^tm1Otin/Mmp8^tm1Otin (involves: 129X1/SvJ * C57BL/6J)	abnormal inflammatory response	J:86393
	chronic inflammation	J:86393
	increased susceptibility to bacterial infection	J:97118
Mmp8^tm1Otin/Mmp8^tm1Otin (involves: 129X1/SvJ * C57BL/6)	immune system phenotype	J:113463
Mmp8^tm1Otin/Mmp8^tm1Otin (involves: 129X1/SvJ)	immune system phenotype	J:148442
Mmp8^tm1Otin/Mmp8^tm1Otin Mmp9^tm1Tvu/Mmp9^tm1Tvu (involves: 129S6/SvEvTac * 129X1/SvJ * C57BL/6)	immune system phenotype	J:113463
Mmp9^tm1Arnd/Mmp9^tm1Arnd (involves: 129P2/OlaHsd)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:58833
Mmp9^tm1Tvu/Mmp9^tm1Tvu (involves: 129S6/SvEvTac)	abnormal chemokine level	J:84293
	abnormal dendritic cell physiology	J:84293
	abnormal Langerhans cell physiology	J:76157
	decreased dendritic cell number	J:84293
	decreased IgE level	J:84293
	decreased inflammatory response	J:84293
	increased circulating interferon-beta level	J:148442
	increased circulating interferon-gamma level	J:148442
	increased susceptibility to Picornaviridae infection	J:148442
	increased susceptibility to Picornaviridae infection induced morbidity/mortality	J:148442
	myocarditis	J:148442
Mmp9^tm1Tvu/Mmp9^tm1Tvu (FVB.129S6-Mmp9^tm1Tvu)	abnormal neutrophil physiology	J:104644
	decreased susceptibility to induced colitis	J:104644
	immune system phenotype	J:104644
Mmp9^tm1Tvu/Mmp9^tm1Tvu (129S6/SvEvTac-Mmp9^tm1Tvu)	immune system phenotype	J:113463
Mmp9^tm1Tvu/Mmp9^tm1Tvu (involves: 129/Sv * 129S6/SvEvTac)	decreased circulating interleukin-10 level	J:55723
Mmp9^tm1Tvu/Mmp9^tm1Tvu (involves: 129/Sv * 129S6/SvEvTac)	increased susceptibility to type IV hypersensitivity reaction	J:55723
Mmp9^tm1Tvu/Mmp9^tm1Tvu (involves: 129S6/SvEvTac * CD-1)	impaired myelopoiesis	J:149957
Mmp9^tm1Tvu/Mmp9^tm1Tvu (involves: 129S6/SvEvTac * C57BL/6)	abnormal chemokine level	J:88065
	abnormal cytokine secretion	J:88065
	abnormal leukocyte morphology	J:88065
	abnormal response to infection	J:126519
	decreased interferon-gamma secretion	J:88065
	increased eosinophil cell number	J:88065
	increased IgE level	J:88065
	increased interferon-gamma secretion	J:88065
	increased interleukin-4 secretion	J:88065
	increased interleukin-5 secretion	J:88065
	increased interleukin-13 secretion	J:88065
	increased lymphocyte cell number	J:88065
	increased macrophage cell number	J:88065
	increased monocyte cell number	J:88065
	increased T cell proliferation	J:88065
	increased T-helper 2 cell number	J:88065
	lung inflammation	J:88065
Mmp9^tm1Tvu/Mmp9^tm1Tvu (FVB.129S6(Cg)-Mmp9^tm1Tvu/J)	decreased susceptibility to Flaviviridae infection	J:153406
Mmp9^tm1Tvu/Mmp9^tm1Tvu (FVB.129S6(Cg)-Mmp9^tm1Tvu/J)	decreased susceptibility to Flaviviridae infection induced morbidity/mortality	J:153406
Mmp9^tm1Tvu/Mmp9^tm1Tvu (C3N.129S6-Mmp9^tm1Tvu)	decreased susceptibility to bacterial infection	J:150311
	decreased susceptibility to induced arthritis	J:150311
	joint inflammation	J:150311
Mmp9^tm1Tvu/Mmp9^tm1Tvu Tg(SOD1G93A)1Gur/0 (involves: 129S6/SvEvTac C57BL/6 * CD-1 * SJL)	decreased tumor necrosis factor secretion	J:141587
Mmp9^tm1Tvu/Mmp9^tm1Tvu Timp1^tm1Pds/Timp1^tm1Pds (involves: 129S4/SvJae * 129S6/SvEvTac)	immune system phenotype	J:94836
Mmp10^tm1Jkmg/Mmp10^tm1Jkmg (B6.129X1-Mmp10^tm1Jkmg)	increased susceptibility to bacterial infection	J:153651
Mmp10^tm1Jkmg/Mmp10^tm1Jkmg (B6.129X1-Mmp10^tm1Jkmg)	lung inflammation	J:153651
Mmp11^{tm1b(EUCOMM)Hmgu}/Mmp11^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Mmp11^{tm1b(EUCOMM)Hmgu}/Ics)	increased monocyte cell number	J:211773
Mmp12^tm1Sds/Mmp12^tm1Sds (involves: 129X1/SvJ)	abnormal macrophage physiology	J:32902
Mmp12^tm1Sds/Mmp12^tm1Sds Timp1^tm1Pds/Timp1^tm1Pds (either: (involves: 129S4/SvJae) or (involves: C57BL/6))	decreased susceptibility to bacterial infection	J:94836
Mmp13^{em1(IMPC)Ccpcz}/Mmp13^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Mmp13^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Mmp14^tm1Hbh/Mmp14^tm1Hbh (involves: 129P2/OlaHsd * Black Swiss)	abnormal osteoclast physiology	J:57969, J:86538
	autoimmune arthritis	J:57969
Mmp14^tm1Ktry/Mmp14^tm1Ktry (involves: 129X1/SvJ)	abnormal dendritic cell physiology	J:138782
Mmp15^{tm1b(KOMP)Wtsi}/Mmp15^{tm1b(KOMP)Wtsi} (C57BL/6N-Mmp15^{tm1b(KOMP)Wtsi}/Bay)	absent lymph nodes	J:211773
	athymia	J:211773
	enlarged spleen	J:211773
Mmp19^tm1Rase/Mmp19^tm1Rase (B6.129P2-Mmp19^tm1Rase)	abnormal cytokine level	J:137128
	abnormal T cell activation	J:137128
	abnormal T cell differentiation	J:137128
	decreased CD4-positive, alpha-beta T cell number	J:137128
	decreased CD8-positive, alpha-beta T cell number	J:137128
	decreased inflammatory response	J:137128
	decreased susceptibility to type IV hypersensitivity reaction	J:137128
	decreased T cell proliferation	J:137128
	increased double-positive T cell number	J:137128
Mmp20^{em1(IMPC)Ccpcz}/Mmp20^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Mmp20^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
Mmp24^tm1Otin/Mmp24^tm1Otin (involves: 129P2/OlaHsd * C57BL/6J)	abnormal mast cell degranulation	J:153230
	increased mast cell degranulation	J:153230
Mmp25^em1(IMPC)J/Mmp25^em1(IMPC)J (C57BL/6NJ-Mmp25^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
Mmp25^{Gt(IST14198E10)Tigm}/Mmp25^{Gt(IST14198E10)Tigm} (involves: C57BL/6N)	abnormal circulating cytokine level	J:347009
	abnormal macrophage activation involved in immune response	J:347009
	abnormal neutrophil physiology	J:347009
	decreased circulating interleukin-1 alpha level	J:347009
	decreased susceptibility to endotoxin shock	J:347009
	increased IgG level	J:347009
Mmp28^tm1Mani/Mmp28^tm1Mani (B6.129X1-Mmp28^tm1Mani)	abnormal chemokine secretion	J:145912
	abnormal cytokine secretion	J:145912
	abnormal macrophage chemotaxis	J:145912
	decreased susceptibility to bacterial infection	J:145912
	impaired neutrophil recruitment	J:145912
	increased interleukin-6 secretion	J:145912
	increased tumor necrosis factor secretion	J:145912
Mmrn1^{tm1b(EUCOMM)Hmgu}/Mmrn1^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Mmrn1^{tm1b(EUCOMM)Hmgu}/Cnrm)	increased large unstained cell number	J:211773
Mmut^tm1Cpv/Mmut^tm1Cpv (involves: 129S/SvEv * C57BL/6 * FVB/N)	tubulointerstitial nephritis	J:147313
Mmut^tm1Cpv/Mmut^tm1Cpv Tg(Alb-Mut)#Cpv/0 (involves: C57BL/6)	tubulointerstitial nephritis	J:200689
Mnx1^tm1Jhk/Mnx1^tm1Jhk (involves: 129P2/OlaHsd)	immune system phenotype	J:57314
Mnx1^tm4(cre)Tmj/Mnx1⁺ Tardbp^tm1.1Ckjs/Tardbp^tm1.2Cjks (involves: 129S1/Sv * C57BL/6J)	increased microglial cell activation	J:190254
Mocos^em2(IMPC)Ics/Mocos^em2(IMPC)Ics (involves: C57BL/6N)	kidney inflammation	J:336718
Mocos^em2(IMPC)Ics/Mocos^em2(IMPC)Ics (involves: C57BL/6N)	tubulointerstitial nephritis	J:336718
Mog^tm1(cre)Gkl/Mog^tm1(cre)Gkl Tg(Tcra2D2,Tcrb2D2)1Kuch/0 (C57BL/6-Mog^tm1(cre)Gkl Tg(Tcra2D2,Tcrb2D2)1Kuch)	increased susceptibility to experimental autoimmune encephalomyelitis	J:151335
Mog^tm1Dpd/Mog^tm1Dpd (B6.129S2-Mog^tm1Dpd)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:85155
Mog^tm1Dpd/Mog^tm1Dpd (B6.129S2-Mog^tm1Dpd)	immune system phenotype	J:85155
Mog^tm1Dpd/Mog^tm1Dpd Rag2^tm1Cgn/Rag2^tm1Cgn Tg(Tcra2D2,Tcrb2D2)1Kuch/0 (involves: 129S2/SvPas * C57BL/6)	increased susceptibility to experimental autoimmune encephalomyelitis	J:151335
Mog^tm1Dpd/Mog^tm1Dpd Tg(H2-K^b-Tcra,-Tcrb)1640Kurs/0 (SJL.Cg-Mog^tm1Dpd Tg(H2-K^b-Tcra,-Tcrb)1640Kurs)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:149511
Mog^tm1Dpd/Mog^tm1Dpd Tg(Tcra2D2,Tcrb2D2)1Kuch/0 (involves: 129S2/SvPas * C57BL/6)	CNS inflammation	J:151335
	increased susceptibility to experimental autoimmune encephalomyelitis	J:151335
Mog^tm1Reid/Mog^tm1Reid (B6.129S1/Sv-Mog^tm1Reid)	increased susceptibility to experimental autoimmune encephalomyelitis	J:86663
Mog^tm1Reid/Mog^tm1Reid (129/Sv-Mog^tm1Reid)	abnormal cytokine secretion	J:86663
	abnormal T-helper 1 physiology	J:86663
	increased interleukin-2 secretion	J:86663
	increased interleukin-6 secretion	J:86663
	increased susceptibility to experimental autoimmune encephalomyelitis	J:86663
	increased T cell proliferation	J:86663
Mogs^{tm1(KOMP)Vlcg}/Mogs⁺ (C57BL/6N-Mogs^{tm1(KOMP)Vlcg}/Bay)	absent lymph nodes	J:211773
	enlarged thymus	J:211773
Mol1^BALB/cByJ/Mol1^BALB/cByJ (involves: BALB/cByJ * C57BL/6ByJ)	decreased B cell proliferation	J:58921
Mol2^DBA/2N/Mol2^DBA/2N (involves: BALB/cAnFcr * DBA/2N)	increased inflammatory response	J:58921
Morc2a^{em1(IMPC)Wtsi}/Morc2a^{em1(IMPC)Wtsi} (C57BL/6N-Morc2a^{em1(IMPC)Wtsi}/WtsiOulu)	abnormal thymus topology	J:239583
	absent connection between subcutaneous lymph vessels and lymph sac	J:239583
	athymia	J:239583
	blood in lymph vessels	J:239583
	small thymus	J:239583
Morc3^{tm1b(EUCOMM)Hmgu}/Morc3⁺ (C57BL/6N-Morc3^{tm1b(EUCOMM)Hmgu}/Ics)	decreased lymphocyte cell number	J:211773
	increased large unstained cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Morc4^em1(IMPC)Mbp/Y (C57BL/6N-Morc4^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
Morc4^em1(IMPC)Mbp/Y (C57BL/6N-Morc4^em1(IMPC)Mbp/MbpMmucd)	enlarged lymph nodes	J:211773
Morc4^em1(IMPC)Mbp/Morc4^em1(IMPC)Mbp (C57BL/6N-Morc4^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
Morf4l1^tm1Kto/Morf4l1^tm1Kto (involves: 129S7/SvEvBrd)	spleen vascular congestion	J:97640
Morrbid^em1Flv/Morrbid⁺ (C57BL/6N-Morrbid^em1Flv)	decreased eosinophil cell number	J:236609
	decreased Ly6C high monocyte number	J:236609
	decreased neutrophil cell number	J:236609
Morrbid^em1Flv/Morrbid^em1Flv (C57BL/6N-Morrbid^em1Flv)	abnormal eosinophil physiology	J:236609
	abnormal leukocyte physiology	J:236609
	abnormal myelopoiesis	J:236609
	abnormal neutrophil physiology	J:236609
	decreased eosinophil cell number	J:236609
	decreased Ly6C high monocyte number	J:236609
	decreased Ly6C low monocyte number	J:236609
	decreased neutrophil cell number	J:236609
	immune system phenotype	J:236609
	increased susceptibility to bacterial infection	J:236609
	increased susceptibility to bacterial infection induced morbidity/mortality	J:236609
mpc253H/mpc253H (involves: BALB/c * C3H/HeH * C57BL/6J)	colitis	J:234901
Mpdk2^C57BL/6J/Mpdk2^CAST/Ei (involves: C57BL/6J * CAST/Ei)	bile duct inflammation	J:99468
Mpdk2^CAST/Ei/Mpdk2^CAST/Ei (involves: C57BL/6J * CAST/Ei)	bile duct inflammation	J:99468
Mpdk7^C57BL/6J/Mpdk7^CAST/Ei (involves: C57BL/6J * CAST/Ei)	bile duct inflammation	J:99468
Mpdk7^CAST/Ei/Mpdk7^CAST/Ei (involves: C57BL/6J * CAST/Ei)	bile duct inflammation	J:99468
Mpdk8^C57BL/6J/Mpdk8^CAST/Ei (involves: C57BL/6J * CAST/Ei)	bile duct inflammation	J:99468
Mpdk8^CAST/Ei/Mpdk8^CAST/Ei (involves: C57BL/6J * CAST/Ei)	bile duct inflammation	J:99468
Mpeg1^tm1Pod/Mpeg1⁺ (involves: 129X1/SvJ * C57BL/6)	abnormal susceptibility to infection induced morbidity/mortality	J:269474
Mpeg1^tm1Pod/Mpeg1⁺ (129X1/SvJ-Mpeg1^tm1Pod)	abnormal susceptibility to infection induced morbidity/mortality	J:269474
Mpeg1^tm1Pod/Mpeg1^tm1Pod (involves: 129X1/SvJ * C57BL/6)	abnormal susceptibility to infection induced morbidity/mortality	J:269474
Mpeg1^tm1Pod/Mpeg1^tm1Pod (129X1/SvJ-Mpeg1^tm1Pod)	abnormal susceptibility to infection induced morbidity/mortality	J:269474
Mpg^tm1Lds/Mpg^tm1Lds (involves: 129P2/OlaHsd * C57BL/6)	autoimmune response	J:118148
Mpg^tm1Lds/Mpg^tm1Lds (involves: 129P2/OlaHsd * C57BL/6)	decreased susceptibility to autoimmune diabetes	J:118148
Mpg^tm1Lds/Mpg^tm1Lds (involves: 129P2/OlaHsd)	immune system phenotype	J:47993
Mpg^tm1Rhe/Mpg^tm1Rhe (involves: 129P2/OlaHsd * C57BL/6J)	increased CD4-positive, alpha-beta T cell number	J:70603
Mpig6b^{tm1.1(KOMP)Vlcg}/Mpig6b^{tm1.1(KOMP)Vlcg} (C57BL/6N-Mpig6b^{tm1.1(KOMP)Vlcg}/Ucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	increased spleen weight	J:211773
Mpig6b^tm1.1Arte/Mpig6b^tm1.1Arte (involves: C57BL/6NTac)	abnormal spleen red pulp morphology	J:201266
	enlarged spleen	J:201266
	spleen fibrosis	J:201266
Mpl^{em1(IMPC)Ccpcz}/Mpl⁺ (C57BL/6NCrl-Mpl^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Mpl^{em1(IMPC)Ccpcz}/Mpl^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Mpl^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Mpl^hlb219/Mpl^hlb219 (C57BL/6J-Mpl^hlb219/J)	abnormal circulating cytokine level	J:146577
	decreased leukocyte cell number	J:146577
	enlarged spleen	J:146577
Mpl^tm1Mwm/Mpl^tm1Mwm (B6;129S2)	immune system phenotype	J:83264
Mpl^tm1Wsa/Mpl^tm1Wsa (involves: 129S1/Sv * C57BL/6)	immune system phenotype	J:32131
Mpl^tm1Wsa/Mpl^tm1Wsa (involves: 129S1/Sv)	abnormal circulating chemokine level	J:162629
Mpl^tm1Wsa/Mpl^tm1Wsa Myb^Plt3/Myb⁺ (involves: 129S1/Sv * C57BL/6)	abnormal thrombopoiesis	J:89601
Mpl^tm1Wsa/Mpl^tm1Wsa Myb^Plt3/Myb^Plt3 (involves: 129S1/Sv * C57BL/6)	abnormal B cell differentiation	J:89601
	abnormal spleen morphology	J:89601
	abnormal thrombopoiesis	J:89601
	decreased spleen B cell follicle size	J:89601
	increased spleen red pulp amount	J:89601
Mpl^tm1Wsa/Mpl^tm1Wsa Myb^Plt4/Myb⁺ (involves: 129S1/Sv * C57BL/6)	abnormal thrombopoiesis	J:89601
Mpl^tm1Wsa/Mpl^tm1Wsa Myb^Plt4/Myb^Plt4 (involves: 129S1/Sv * C57BL/6)	abnormal spleen morphology	J:89601
	abnormal thrombopoiesis	J:89601
	decreased leukocyte cell number	J:89601
	decreased spleen B cell follicle size	J:89601
	increased spleen red pulp amount	J:89601
Mpl^tm1Wsa/Mpl^tm1Wsa Suz12^{Gt(Betageo)1Khe}/Suz12⁺ (involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6)	abnormal thrombopoiesis	J:136262
	increased leukocyte cell number	J:136262
	increased lymphocyte cell number	J:136262
Mpl^tm1Wsa/Mpl^tm1Wsa Suz12^Plt8/Suz12⁺ (B6.Cg-Mpl^tm1Wsa Suz12^Plt8)	abnormal thrombopoiesis	J:136262
	increased leukocyte cell number	J:136262
	increased lymphocyte cell number	J:136262
Mpl^tm2.1Wsa/Mpl^tm2.1Wsa Tg(Pf4-icre)Q3Rsko/0 (involves: C57BL/6)	enlarged spleen	J:208120
Mpnd^em1(IMPC)J/Mpnd^em1(IMPC)J (C57BL/6NJ-Mpnd^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
Mpo^tm1Lus/Mpo^tm1Lus (involves: 129X1/SvJ * C57BL/6J)	abnormal neutrophil physiology	J:67586
	decreased inflammatory response	J:102688
	increased monocyte cell number	J:67586
	increased susceptibility to experimental autoimmune encephalomyelitis	J:102965
	increased susceptibility to fungal infection	J:67586
	sepsis	J:126649
Mpo^tm1Lus/Mpo^tm1Lus (B6.129X1-Mpo^tm1Lus)	abnormal neutrophil physiology	J:112488
Mpo^tm1Mae/Mpo^tm1Mae (involves: 129P2/OlaHsd * C57BL/6)	abnormal neutrophil physiology	J:53993
Mpo^tm1Mae/Mpo^tm1Mae (involves: 129P2/OlaHsd * C57BL/6)	increased susceptibility to fungal infection	J:53993
Mpp1^{em1(IMPC)Ccpcz}/Mpp1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Mpp1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	decreased effector memory T-helper cell number	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	increased CD4-positive, alpha-beta T cell number	J:211773
	increased effector memory T-helper cell number	J:211773
	increased T-helper cell number	J:211773
Mpp1^tm1Ahc/Mpp1^tm1Ahc (B6.129-Mpp1^tm1Ahc)	abnormal neutrophil physiology	J:154749
Mpp1^tm1Ahc/Mpp1^tm1Ahc (B6.129-Mpp1^tm1Ahc)	impaired neutrophil chemotaxis	J:154749
Mpped2^em1(IMPC)J/Mpped2^em1(IMPC)J (C57BL/6NJ-Mpped2^em1(IMPC)J/J)	increased leukocyte cell number	J:211773
Mptx2^em1Yoxi/Mptx2^em1Yoxi (C57BL/6J-Mptx2^em1Yoxi)	increased susceptibility to bacterial infection	J:326562
Mpv17l2^{tm1.1(KOMP)Mbp}/Mpv17l2^{tm1.1(KOMP)Mbp} (C57BL/6N-Mpv17l2^{tm1.1(KOMP)Mbp}/Ucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Mpz^tm1Msch/Mpz⁺ (involves: 129S7/SvEvBrd * C57BL/6)	abnormal cytokine secretion	J:82432
	abnormal macrophage chemotaxis	J:67581
	abnormal T-helper 1 physiology	J:82432
	increased monocyte cell number	J:82432
Mpz^tm1Msch/Mpz⁺ (involves: 129S7/SvEvBrd)	increased macrophage cell number	J:133028
Mpz^tm1Msch/Mpz⁺ (B6.129S7-Mpz^tm1Msch)	autoimmune response	J:59319
Mpz^tm1Msch/Mpz⁺ Rag1^tm1Mom/Rag1^tm1Mom (B6.129S7-Mpz^tm1Msch Rag1^tm1Mom)	absent CD4-positive, alpha-beta T cells	J:59319
	absent CD8-positive, alpha-beta T cells	J:59319
Mpz^tm1Msch/Mpz⁺ Tcra^tm1Mjo/Tcra^tm1Mjo (involves: 129P2/OlaHsd * 129S7/SvEvBrd * BALB/c * C57BL/6)	decreased T cell number	J:59319
Mpzl2^tm1Lex/Mpzl2^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6J)	decreased B cell number	J:171883
	increased CD8-positive, alpha-beta T cell number	J:171883
Mpzl3^rc/Mpzl3^rc (C57BL/6J-Mpzl3^rc/J)	abnormal spleen morphology	J:93038
	dermatitis	J:93038
	liver inflammation	J:93038
Mpzl3^tm1(KOMP)Mbp/Mpzl3^tm1(KOMP)Mbp (C57BL/6-Tyr^c-Brd Mpzl3^tm1(KOMP)Mbp)	seborrheic dermatitis	J:210832
	skin inflammation	J:210832
Mr1^tm1Gfn/Mr1^tm1Gfn (involves: 129P2/OlaHsd * BALB/c * C57BL/6)	abnormal B cell physiology	J:113083
	abnormal T cell number	J:113083
Mr1^tm1Gfn/Mr1^tm1Gfn (B6.129P2-Mr1^tm1Gfn)	increased susceptibility to experimental autoimmune encephalomyelitis	J:112657
Mr1^tm1Gfn/Mr1^tm1Gfn (involves: 129P2/OlaHsd)	abnormal susceptibility to bacterial infection	J:276912
Mras^{Gt(OST108223)Lex}/Mras^{Gt(OST108223)Lex} (B6;129S5-Mras^{Gt(OST108223)Lex}/Ieg)	decreased B cell number	J:82809
Mrc1^tm1Mnz/Mrc1^tm1Mnz (involves: 129P2/OlaHsd)	abnormal macrophage physiology	J:124290
Mrc1^tm1Mnz/Mrc1^tm1Mnz (B6.129P2-Mrc1^tm1Mnz)	decreased susceptibility to parasitic infection	J:194065
	decreased susceptibility to parasitic infection induced morbidity/mortality	J:194065
	decreased T cell number	J:194065
	increased granulocyte number	J:194065
Mrc1^tm1Mnz/Mrc1^tm1Mnz Mrc2^tm1Cmi/Mrc2^tm1Cmi (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ)	abnormal macrophage physiology	J:124290
Mre11a^tm1.1Rchd/Mre11a^tm1.1Rchd (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal class switch recombination	J:184053
Mreg^{tm1b(EUCOMM)Hmgu}/Mreg^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Mreg^{tm1b(EUCOMM)Hmgu}/Kmpc)	abnormal lymph node morphology	J:211773
Mrfap1^tm1Kto/Mrfap1^tm1Kto (involves: 129S7/SvEvBrd * C57BL/6J)	immune system phenotype	J:92967
Mrgprb2^em1(IMPC)Tcp/Mrgprb2^em1(IMPC)Tcp (C57BL/6NCrl-Mrgprb2^em1(IMPC)Tcp/Tcp)	small spleen	J:211773
Mrgprb2^em1Xzd/Mrgprb2^em1Xzd (C57BL/6-Mrgprb2^em1Xzd)	decreased inflammatory response	J:219209
	decreased mast cell degranulation	J:219209
	immune system phenotype	J:219209
Mri1^em1(IMPC)Bay/Mri1^em1(IMPC)Bay (C57BL/6N-Mri1^em1(IMPC)Bay/BayMmucd)	increased spleen weight	J:211773
Mroh8^{em1(IMPC)Ccpcz}/Mroh8^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Mroh8^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Mrpl12^em1(IMPC)Tcp/Mrpl12⁺ (C57BL/6NCrl-Mrpl12^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Mrps22^{tm1.1(KOMP)Vlcg}/Mrps22⁺ (B6N(Cg)-Mrps22^{tm1.1(KOMP)Vlcg}/J)	increased leukocyte cell number	J:211773
Mrs2^em1Muma/Mrs2^em1Muma (B6.Cg-Mrs2^em1Muma)	decreased susceptibility to endotoxin shock	J:298361
Ms4a1^tm1Msn/Ms4a1^tm1Msn (involves: 129S/SvEv * C57BL/6)	immune system phenotype	J:48688
Ms4a1^tm1Tft/Ms4a1^tm1Tft (involves: 129 * C57BL/6)	abnormal B cell calcium ion homeostasis	J:88933
	abnormal B cell number	J:88933
	abnormal B cell physiology	J:88933
	decreased B-1 B cell number	J:88933
	immune system phenotype	J:88933
	increased transitional stage B cell number	J:88933
Ms4a2^tm1Chr/Ms4a2^tm1Chr (involves: 129S1/Sv * 129X1/SvJ)	abnormal mast cell physiology	J:53106
Ms4a2^tm1Chr/Ms4a2^tm1Chr (involves: 129S1/Sv * 129X1/SvJ)	decreased susceptibility to type I hypersensitivity reaction	J:53106
Ms4a2^tm1Knt/Ms4a2^tm1Knt (involves: 129 * BALB/c)	abnormal cytokine secretion	J:47138
	abnormal mast cell physiology	J:47138
	decreased susceptibility to type I hypersensitivity reaction	J:47138
Ms4a2^tm1Knt/Ms4a2^tm1Knt Tg(SV40/HTLV-FCER1A)1Bhk/0 (involves: 129 * BALB/c)	abnormal cytokine secretion	J:47138
	abnormal mast cell physiology	J:47138
	decreased susceptibility to type I hypersensitivity reaction	J:47138
Ms4a4a^em1Wwz/Ms4a4a^em1Wwz (C57BL/6NCrl-Ms4a4a^em1Wwz)	abnormal macrophage physiology	J:296429
	decreased eosinophil cell number	J:296429
	decreased interleukin-4 secretion	J:296429
	decreased interleukin-13 secretion	J:296429
	impaired eosinophil recruitment	J:296429
Ms4a6d^em1Cya/Ms4a6d^em1Cya (involves: C57BL/6)	decreased susceptibility to endotoxin shock	J:342776
Ms4a6d^em1Ywch/Ms4a6d^em1Ywch (C57BL/6-Ms4a6d^em1Ywch)	decreased susceptibility to endotoxin shock	J:342776
Ms4a6d^em2Ywch/Ms4a6d^em2Ywch (C57BL/6-Ms4a6d^em2Ywch)	decreased susceptibility to endotoxin shock	J:342776
Ms4a7^em1.1Jddl/Ms4a7^em1.1Jddl (B6.Cg-Ms4a7^em1.1Jddl)	abnormal macrophage physiology	J:347975
	decreased circulating tumor necrosis factor level	J:347975
	decreased cytokine level	J:347975
	decreased interleukin-1 beta secretion	J:347975
	decreased macrophage cell number	J:347975
Ms4a7^em1Jddl/Ms4a7^em1Jddl Lyz2^tm1(cre)Ifo/Lyz2⁺ (B6.Cg-Lyz2^tm1(cre)Ifo Ms4a7^em1Jddl)	decreased circulating tumor necrosis factor level	J:347975
	decreased cytokine level	J:347975
Ms4a8a^em1(IMPC)Tcp/Ms4a8a^em1(IMPC)Tcp (C57BL/6NCrl-Ms4a8a^em1(IMPC)Tcp/Cmmr)	increased monocyte cell number	J:211773
Ms4a12^em1(IMPC)Mbp/Ms4a12^em1(IMPC)Mbp (C57BL/6N-Ms4a12^em1(IMPC)Mbp/Ucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
Msantd3^em1(IMPC)J/Msantd3^em1(IMPC)J (C57BL/6NJ-Msantd3^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
Msh2^tm1Htr/Msh2^tm1Htr (either: (involves: 129P2/OlaHsd) or (involves: 129P2/OlaHsd * FVB))	increased T cell derived lymphoma incidence	J:27469
Msh2^tm1Htr/Msh2^tm1Htr (involves: 129P2/OlaHsd)	abnormal class switch recombination	J:80893
	abnormal inflammatory response	J:80893
	abnormal somatic hypermutation frequency	J:155454
	decreased IgG1 level	J:80893
	decreased IgG3 level	J:80893
	immune system phenotype	J:47993
	increased T cell derived lymphoma incidence	J:45433
Msh2^tm1Htr/Msh2^tm1Htr (involves: 129P2/OlaHsd * FVB)	increased T cell derived lymphoma incidence	J:45433
Msh2^tm1Htr/Msh2^tm1Htr Pcna^tm1Jcbs/Pcna^tm1Jcbs (involves: 129P2/OlaHsd)	abnormal somatic hypermutation frequency	J:155454
Msh2^tm1Mak/Msh2^tm1Mak (involves: 129P2/OlaHsd * C57BL/6J)	immune system phenotype	J:28397
Msh2^tm1Mak/Msh2^tm1Mak (C57BL/6NTac-Msh2^tm1Mak)	abnormal class switch recombination	J:326431
Msh2^tm1Mak/Msh2^tm1Mak (C57BL/6NTac-Msh2^tm1Mak)	abnormal somatic hypermutation frequency	J:326431
Msh2^tm1Rak/Msh2^tm1Rak (involves: 129P2/OlaHsd)	abnormal class switch recombination	J:56764
Msh2^tm1Rak/Msh2^tm1Rak (involves: 129P2/OlaHsd)	decreased mature B cell number	J:56764
Msh2^tm1Wed/Msh2^tm1Wed (involves: C57BL/6)	abnormal class switch recombination	J:86278
Msh2^tm1Wed/Msh2^tm1Wed (involves: C57BL/6)	decreased IgG level	J:86278
Msh2^tm1Whl/Msh2^tm1Whl (involves: 129P2/OlaHsd * C57BL/6J)	increased lymphoblastic lymphoma incidence	J:79016
Msh2^tm1Whl/Msh2^tm1Whl Rb1^tm1Brd/Rb1⁺ (involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J)	increased lymphoblastic lymphoma incidence	J:79016
Msh5^{tm1b(EUCOMM)Wtsi}/Msh5^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Msh5^{tm1b(EUCOMM)Wtsi}/Ieg)	increased leukocyte cell number	J:211773
Msh6^m1Btlr/Msh6^m1Btlr (C57BL/6J-Msh6^m1Btlr)	decreased IgE level	J:255208
Msi2^em1(IMPC)Mbp/Msi2^em1(IMPC)Mbp (C57BL/6N-Msi2^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
	decreased spleen weight	J:211773
	small spleen	J:211773
Msi2^{Gt(E035H03)Wrst}/Msi2^{Gt(E035H03)Wrst} (B6.129P2-Msi2^{Gt(E035H03)Wrst})	abnormal myeloid leukocyte morphology	J:174870
	decreased B cell number	J:174870
	decreased CD4-positive, alpha-beta T cell number	J:174870
	decreased CD8-positive, alpha-beta T cell number	J:174870
	decreased DN2 thymocyte number	J:174870
	decreased DN3 thymocyte number	J:174870
	decreased double-negative T cell number	J:174870
	decreased double-positive T cell number	J:174870
	decreased granulocyte number	J:174870
	decreased immature B cell number	J:174870
	decreased leukocyte cell number	J:174870
	decreased macrophage cell number	J:174870
	decreased mature B cell number	J:174870
	decreased pre-B cell number	J:174870
	small spleen	J:174870
	small thymus	J:174870
	spleen hypoplasia	J:174870
	thymus hypoplasia	J:174870
Msi2^tm1.1Cjl/Msi2^tm1.1Cjl Tg(Mx1-cre)1Cgn/0 (involves: 129S4/SvJae * C57BL/6 * CBA)	decreased spleen weight	J:208349
	immune system phenotype	J:208349
	spleen hypoplasia	J:208349
Mslnl^{tm1b(EUCOMM)Wtsi}/Mslnl^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Mslnl^{tm1b(EUCOMM)Wtsi}/BayMmucd)	decreased monocyte cell number	J:211773
Msmb^tm1Xuan/Msmb^tm1Xuan (either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * CD-1))	enlarged lymph nodes	J:96884
Msmp^em1Jzx/Msmp^em1Jzx (C57BL/6-Msmp^em1Jzx)	abnormal macrophage differentiation	J:311042
	decreased circulating interleukin-6 level	J:311042
	decreased circulating tumor necrosis factor level	J:311042
	liver inflammation	J:311042
Msn^{tm1b(EUCOMM)Hmgu}/Msn^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Msn^{tm1b(EUCOMM)Hmgu}/J)	decreased leukocyte cell number	J:211773
Msn^tm1Sts/Y (involves: 129S4/SvJae * C57BL/6)	decreased B cell number	J:189837
	decreased CD4-positive, alpha-beta T cell number	J:189837
	decreased eosinophil cell number	J:189837
	decreased lymphocyte cell number	J:189837
	decreased neutrophil cell number	J:189837
	impaired leukocyte migration	J:189837
Msr1^tm1Csk/Msr1^tm1Csk (involves: 129X1/SvJ * ICR)	increased interleukin-12 secretion	J:110433
	increased susceptibility to bacterial infection induced morbidity/mortality	J:39079
	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:39079
Msr1^tm1Csk/Msr1^tm1Csk (involves: 129S7/SvEvBrd * C57BL/6J)	abnormal macrophage physiology	J:91911
Msr1^tm1Csk/Msr1^tm1Csk (B6.129X1-Msr1^tm1Csk)	decreased interferon-beta secretion	J:251008
Msr1^tm1Csk/Msr1^tm1Csk Scarf1^tm1Ishi/Scarf1^tm1Ishi (involves: 129S7/SvEvBrd * 129X1/SvJ * C57BL/6J)	abnormal macrophage physiology	J:91911
Mst1^tm1Jab/Mst1^tm1Jab (involves: 129P2/OlaHsd * Black Swiss)	abnormal macrophage physiology	J:46185
	immune system phenotype	J:46185
	increased susceptibility to induced colitis	J:46185
Mst1r^Fv2-s/Mst1r^Fv2-s (B6.DDD-Mst1r^Fv2-s)	enlarged spleen	J:5120
Mst1r^Fv2-s/Mst1r^Fv2-s (B6.DDD-Mst1r^Fv2-s)	increased susceptibility to Retroviridae infection	J:5120
Mst1r^Fv2-s/Mst1r^Fv2-s (either: A/Crgl or C57BL/Crgl)	decreased susceptibility to Retroviridae infection	J:167666
Mst1r^Fv2-s/Mst1r^Fv2-s (either: BALB/cCrgl or DBA/2Crgl or Swiss)	enlarged spleen	J:167666
	increased susceptibility to Retroviridae infection	J:167666
Mst1r^Fv2-s/Mst1r^Fv2-s (C3H/Crgl)	increased susceptibility to Retroviridae infection	J:167666
Mst1r^tm1.1Sew/Mst1r^tm1.1Sew (involves: 129/Ola * CD-1 * NIH Black Swiss)	abnormal macrophage physiology	J:75503
	abnormal type IV hypersensitivity reaction	J:75503
	increased acute inflammation	J:75503
	increased susceptibility to endotoxin shock	J:75503
Mst1r^tm1Ber/Mst1r^tm1Ber (involves: 129S1/Sv * 129X1/SvJ * CD-1)	abnormal macrophage physiology	J:76451
	abnormal type IV hypersensitivity reaction	J:76451
	immune system phenotype	J:76451
	increased inflammatory response	J:76451
	increased susceptibility to bacterial infection	J:76451
Mst1r^tm1Sjd/Mst1r⁺ (either: (involves: 129 * C57BL/6) or (involves: 129 * CD-1) or (involves: 129 * NIH Black Swiss))	abnormal macrophage physiology	J:54903
	increased susceptibility to bacterial infection	J:54903
Mst1r^{tm2(Mst1r)Sew}/Mst1r^{tm2(Mst1r)Sew} (involves: 129P2/OlaHsd * Black Swiss * FVB/N)	decreased spleen weight	J:215969
	increased susceptibility to Retroviridae infection	J:215969
Mst1r^{tm2(Mst1r)Sew}/Mst1r^{tm2(Mst1r)Sew} (FVB.129P2(Cg)-Mst1r^{tm2(Mst1r*)Sew})	increased circulating interferon-gamma level	J:215969
	increased interferon-gamma secretion	J:215969
Mstn^{em1(IMPC)Hmgu}/Mstn^{em1(IMPC)Hmgu} (C57BL/6NCrl-Mstn^{em1(IMPC)Hmgu}/Ieg)	decreased spleen weight	J:211773
	enlarged spleen	J:211773
Mstn^lean/Mstn^lean (C57BL/6J-Mstn^lean)	abnormal circulating tumor necrosis factor level	J:146513
Mstn^lean/Mstn^lean (C57BL/6J-Mstn^lean)	decreased circulating tumor necrosis factor level	J:146513
Msto1^em1(IMPC)Tcp/Msto1⁺ (C57BL/6N-Msto1^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Msto1^em1(IMPC)Tcp/Msto1⁺ (C57BL/6N-Msto1^em1(IMPC)Tcp/Tcp)	small spleen	J:211773
Msx1^tm1Rilm/Msx1⁺ Pax9^tm1Rbal/Pax9^tm1Rbal (involves: 129 * CD-1)	ectopic thymus	J:311535
	thymus hypoplasia	J:311535
Msx2^tm1Rilm/Msx2^tm1Rilm (either: (involves: 129S4/SvJae) or (involves: 129S4/SvJae * BALB/c) or (involves: 129S4/SvJae * C57BL/6J))	decreased osteoclast cell number	J:61509
Mt1^tm1Bri/Mt1^tm1Bri Mt2^tm1Bri/Mt2^tm1Bri (involves: 129S7/SvEvBrd)	abnormal microglial cell morphology	J:103102, J:53929
	abnormal microglial cell physiology	J:53929
	increased interleukin-1 beta secretion	J:103102
	increased interleukin-6 secretion	J:103102
	increased macrophage cell number	J:53929
	increased susceptibility to experimental autoimmune encephalomyelitis	J:103102
	increased tumor necrosis factor secretion	J:103102
Mt1^tm1Bri/Mt1^tm1Bri Mt2^tm1Bri/Mt2^tm1Bri (129S7/SvEvBrd-Mt1^tm1Bri Mt2^tm1Bri/J)	abnormal humoral immune response	J:110643
	abnormal lymphocyte physiology	J:110643
	abnormal microglial cell morphology	J:89429
	decreased B cell number	J:110643
	decreased T cell number	J:110643
	enlarged spleen	J:110643
	increased CD4-positive, alpha-beta T cell number	J:110643
	increased CD8-positive, alpha-beta T cell number	J:110643
	increased IgG level	J:110643
	increased IgM level	J:110643
	increased lymphocyte cell number	J:110643
	increased neutrophil cell number	J:120196
	increased plasma cell number	J:110643
	increased spleen weight	J:110643
	increased thymocyte apoptosis	J:57169
	kidney inflammation	J:126620
	lung inflammation	J:120196
	spleen hyperplasia	J:110643
mt-Co1^m1Jiha (involves: C57BL/6J * M. m. domesticus)	heart inflammation	J:132659
mt-Nd2^m1 (ALR/Lt)	decreased susceptibility to autoimmune diabetes	J:117602, J:97969
Mta1^{em1(IMPC)Ccpcz}/Mta1⁺ (C57BL/6NCrl-Mta1^{em1(IMPC)Ccpcz}/Ccpcz)	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
Mta2^tm1.1Yzha/Mta2^tm1.1Yzha (involves: 129S4/SvJae * C57BL/6 * FVB/N)	dermatitis	J:137101
	glomerulonephritis	J:137101
	increased anti-double stranded DNA antibody level	J:137101
	increased autoantibody level	J:137101
	increased circulating interferon-gamma level	J:137101
	increased circulating interleukin-2 level	J:137101
	increased circulating interleukin-4 level	J:137101
	increased susceptibility to systemic lupus erythematosus	J:137101
	increased T cell proliferation	J:137101
	liver inflammation	J:137101
	panniculitis	J:137101
	skin inflammation	J:137101
Mta2^tm1Yzha/Mta2^tm1Yzha Tg(Lck-cre)#Zhu/0 (involves: 129S4/SvJae * C57BL/6 * SJL)	immune system phenotype	J:137101
	increased T cell proliferation	J:137101
Mtap^em1(IMPC)Mbp/Mtap⁺ (C57BL/6N-Mtap^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Mtap^{Gt(RRK081)Byg}/Mtap⁺ (129P2/OlaHsd-Mtap^{Gt(RRK081)Byg})	arteritis	J:123675
Mtarc1^em1(IMPC)H/Mtarc1^em1(IMPC)H (C57BL/6NTac-Mtarc1^em1(IMPC)H/H)	increased spleen weight	J:211773
Mtbcq2^NMRI8/Fbn/? (involves: DBA/2OlaHsd * NMRI8/Fbn)	increased spleen weight	J:122125
Mtch2^{tm1b(EUCOMM)Hmgu}/Mtch2⁺ (C57BL/6N-Mtch2^{tm1b(EUCOMM)Hmgu}/Cnrm)	increased monocyte cell number	J:211773
Mtdh^tm1.2Dsar/Mtdh^tm1.2Dsar (either: B6.129(FVB)-Mtdh^tm1.2Dsar or (129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N))	decreased interleukin-1 beta secretion	J:216688
	decreased interleukin-6 secretion	J:216688
	decreased macrophage proliferation	J:216688
Mtf1^Thyls-BALB/c/Mtf1^Thyls-BALB/c (involves: BALB/c * MSM)	increased T cell derived lymphoma incidence	J:71358
Mtf1^Thyls-BALB/c/Mtf1^Thyls-MSM (involves: BALB/c * MSM)	increased T cell derived lymphoma incidence	J:85264, J:71358
Mtf1^tm1Wsc/Mtf1^tm1Wsc Tg(Mx1-cre)1Cgn/0 Tg(UBC-Mtf1)1Wsc/0 (involves: 129/Sv * C57BL/6 * CBA)	decreased leukocyte cell number	J:91119
	decreased lymphocyte cell number	J:91119
Mtfmt^em1Heb/Mtfmt⁺ (C57BL/6-Mtfmt^em1Heb)	decreased circulating interleukin-1 beta level	J:334467
Mtfmt^em1Heb/Mtfmt⁺ (C57BL/6-Mtfmt^em1Heb)	decreased inflammatory response	J:334467
Mtgq4^NMRI8/Fbn/? (involves: DBA/2OlaHsd * NMRI8/Fbn)	increased spleen weight	J:122125
Mthfd1^tm1.1Rzn/Mthfd1⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6N)	decreased leukocyte cell number	J:199578
	decreased neutrophil cell number	J:199578
Mtmr4^{tm1a(EUCOMM)Wtsi}/Mtmr4⁺ (Not Specified)	decreased IgE level	J:165965
Mtmr11^em1(IMPC)Tcp/Mtmr11^em1(IMPC)Tcp (C57BL/6NCrl-Mtmr11^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Mtor^chino/Mtor^chino (involves: C57BL/6JAnu)	decreased CD4-positive, alpha-beta T cell number	J:207898
	decreased splenocyte number	J:207898
	immune system phenotype	J:207898
Mtor^chino/Mtor^chino Rasgrp1^m1Anu/Rasgrp1^m1Anu (involves: C57BL/6JAnu * C57BL/6JSfdAnu * CBA/J)	immune system phenotype	J:207898
Mtor^tm1.1Lgm/Mtor^tm1.1Lgm (involves: 129S1/Sv * C57BL/6)	immune system phenotype	J:168600
Mtor^tm1.2Koz/Mtor^tm1.2Koz Tg(Cd4-cre)1Cwi/0 (involves: 129S4/SvJae * C57BL/6 * DBA/2)	abnormal T cell differentiation	J:150108
	abnormal T cell subpopulation ratio	J:150108
	abnormal thymus cell ratio	J:150108
	decreased interferon-gamma secretion	J:150108
	decreased interleukin-2 secretion	J:150108
	decreased interleukin-17 secretion	J:150108
	decreased T cell proliferation	J:150108
	decreased tumor necrosis factor secretion	J:150108
	increased regulatory T cell number	J:150108
Mtor^tm1Lgm/Mtor^tm1Lgm (involves: 129S1/Sv * C57BL/6)	abnormal B cell physiology	J:168600
	abnormal humoral immune response	J:168600
	abnormal T cell morphology	J:168600
	abnormal T cell physiology	J:168600
	decreased B cell number	J:168600
	decreased B cell proliferation	J:168600
	decreased double-positive T cell number	J:168600
	decreased follicular B cell number	J:168600
	decreased IgG level	J:168600
	decreased IgM level	J:168600
	decreased marginal zone B cell number	J:168600
	decreased monocyte cell number	J:168600
	decreased neutrophil cell number	J:168600
	decreased plasma cell number	J:168600
	decreased splenocyte apoptosis	J:168600
	decreased splenocyte proliferation	J:168600
	decreased thymocyte number	J:168600
	decreased transitional stage T1 B cell number	J:168600
	impaired B cell migration	J:168600
	increased CD4-positive, alpha-beta T cell number	J:168600
	increased CD8-positive, alpha-beta T cell number	J:168600
	small spleen	J:168600
Mtss1^{Gt(CSC156)Byg}/Mtss1^{Gt(CSC156)Byg} (B6.129P2-Mtss1^{Gt(CSC156)Byg})	abnormal B cell differentiation	J:186118
	abnormal B cell number	J:186118
	abnormal B cell physiology	J:186118
	decreased immature B cell number	J:186118
	enlarged spleen	J:186118
	increased inflammatory response	J:186118
	increased leukocyte cell number	J:186118
	increased pre-B cell number	J:186118
Mtus1^{Gt(RRA048)Byg}/Mtus1^{Gt(RRA048)Byg} (involves: 129P2/OlaHsd * C57BL/6)	glomerulonephritis	J:212144
	increased leukocyte cell number	J:212144
	increased lymphocyte cell number	J:212144
	increased susceptibility to systemic lupus erythematosus	J:212144
	insulitis	J:212144
	lymphoid hyperplasia	J:212144
	salivary gland inflammation	J:212144
Mtv7^BALB/c/Mtv7^BALB/c (involves: B10.Q * BALB/c * DBA/2)	increased susceptibility to induced arthritis	J:27701
Mtv7^BALB/c/Mtv7^DBA/2 (involves: B10.Q * BALB/c * DBA/2)	decreased susceptibility to induced arthritis	J:27701
Mtv7^DBA/2/Mtv7^DBA/2 (C.D2-Mtv7^DBA/2)	decreased susceptibility to induced arthritis	J:27701
Mtv8^em1Tvg/Mtv8^em1Tvg (C57BL/6J-Mtv8^em1Tvg)	immune system phenotype	J:346992
Mtx2^em1(IMPC)J/Mtx2⁺ (C57BL/6NJ-Mtx2^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
Muc2^eey/Muc2^eey (C57BL/6-Muc2^eey)	ileum inflammation	J:194148
	increased interferon-gamma secretion	J:194148
	increased interleukin-1 beta secretion	J:194148
	increased leukocyte cell number	J:194148
	increased susceptibility to induced colitis	J:194148
	increased tumor necrosis factor secretion	J:194148
Muc2^keny/Muc2^keny (C57BL/6JAnu-Muc2^keny/AnuApb)	enlarged lymph nodes	J:104190
Muc2^M1Btlr/Muc2⁺ (C57BL/6J-Muc2^M1Btlr)	increased susceptibility to induced colitis	J:150326
Muc2^M1Btlr/Muc2^M1Btlr (C57BL/6J-Muc2^M1Btlr)	increased susceptibility to induced colitis	J:150326
Muc2^m2Btlr/? (C57BL/6J-Muc2^m2Btlr)	increased susceptibility to induced colitis	J:159359
Muc2^m3Btlr/Muc2^m3Btlr (C57BL/6J-Muc2^m3Btlr)	increased susceptibility to induced colitis	J:254906
Muc2^tm1Avel/Muc2^tm1Avel (involves: 129P2/OlaHsd * C57BL/6)	colitis	J:216831
	large intestinal inflammation	J:216831
Muc2^wnn/Muc2⁺ (C57BL/6-Muc2^wnn)	increased susceptibility to induced colitis	J:194148
Muc2^wnn/Muc2^wnn (C57BL/6-Muc2^wnn)	colitis	J:194148
	ileum inflammation	J:194148
	increased interferon-gamma secretion	J:194148
	increased interleukin-1 beta secretion	J:194148
	increased interleukin-13 secretion	J:194148
	increased leukocyte cell number	J:194148
	increased lymphocyte cell number	J:194148
	increased susceptibility to induced colitis	J:194148
	increased tumor necrosis factor secretion	J:194148
Muc4^PWK/PhJ/Muc4^PWK/PhJ (PWK/PhJ)	abnormal susceptibility to viral infection	J:287566
Muc4^tm1Skb/Muc4^tm1Skb (involves: 129 * C57BL/6J)	decreased susceptibility to colitis induced morbidity/mortality	J:234205
Muc4^tm1Skb/Muc4^tm1Skb (involves: 129 * C57BL/6J)	decreased susceptibility to induced colitis	J:234205
Muc4^tm1Unc/Muc4^tm1Unc (B6NTac.129(FVB)-Muc4^tm1Unc/Rand)	increased susceptibility to Coronaviridae infection	J:287566
	increased susceptibility to Coronaviridae infection induced morbidity/mortality	J:287566
	increased susceptibility to Togaviridae infection	J:287566
Muc5ac^tm1.1Evns/Muc5ac^tm1.1Evns (B6.129S1-Muc5ac^tm1.1Evns)	increased circulating interferon-gamma level	J:177306
	increased susceptibility to parasitic infection	J:177306
Muc5b^tm1.2Evns/Muc5b^tm1.2Evns (B6.129S1-Muc5b^tm1.2Evns)	abnormal professional antigen presenting cell physiology	J:207159
	decreased interleukin-23 secretion	J:207159
	impaired macrophage phagocytosis	J:207159
	increased macrophage apoptosis	J:207159
	increased susceptibility to bacterial infection	J:207159
	increased susceptibility to bacterial infection induced morbidity/mortality	J:207159
	increased susceptibility to otitis media	J:207159
	respiratory system inflammation	J:207159
	sepsis	J:207159
Muc13^tm1.1Mamg/Muc13^tm1.1Mamg (involves: 129 * C57BL/6)	increased susceptibility to colitis induced morbidity/mortality	J:313870
	increased susceptibility to induced colitis	J:313870
	large intestinal inflammation	J:313870
	small intestinal inflammation	J:313870
Muc19^sld/Muc19^sld (NFS/N-Muc19^sld)	increased susceptibility to autoimmune disorder	J:216958, J:20364
Mug1^tm1Vln/Mug1^tm1Vln (B.129P2-Mug1^tm1Vln)	abnormal cytokine level	J:57485
Mug1^tm1Vln/Mug1^tm1Vln (B.129P2-Mug1^tm1Vln)	liver inflammation	J:57485
Mug1^tm2Vln/Mug1^tm2Vln Pzp^tm1Vln/Pzp^tm1Vln (B.129P2-Pzp^tm1Vln Mug1^tm2Vln)	abnormal cytokine level	J:57485
	abnormal uterine NK cell morphology	J:117841
	liver inflammation	J:57485
Mus81^tm1Esse/Mus81⁺ (involves: 129P2/OlaHsd * C57BL/6J)	increased inflammatory response	J:222498
Mus81^tm1Esse/Mus81^tm1Esse (involves: 129P2/OlaHsd * C57BL/6J)	increased interleukin-1 beta secretion	J:222498
	lung inflammation	J:222498
Mus81^tm1Raz/Mus81^tm1Raz (involves: 129P2/OlaHsd)	immune system phenotype	J:91570
Mx1^r/Mx1^r (B6.A2G-Mx1^r)	abnormal susceptibility to infection	J:120938
Mx1^r/Mx1^r (B6.A2G-Mx1^r)	decreased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:23752
Mx1^r/Mx1^r (C.A2G-Mx1^r)	decreased susceptibility to Orthomyxoviridae infection	J:23752
Mx1^r/Mx1^r (C.A2G-Mx1^r)	decreased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:23752
Mx1^r/Mx1^r (A2G)	decreased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:23752
Mx1^s1/Mx1^s1 (BALB/c)	increased susceptibility to Orthomyxoviridae infection	J:23752
Mx1^s1/Mx1^s1 (C57BL/6)	abnormal peritoneal macrophage morphology	J:23752
	abnormal susceptibility to infection	J:120938
	increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:23752
Mx1^s1/Mx1^s1 Tg(Hmgcr-MX1)LStae/? (involves: C57BL/6 * SJL)	decreased susceptibility to Orthomyxoviridae infection	J:128067
	decreased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:128067
	decreased susceptibility to Riboviria infection	J:128067
	decreased susceptibility to Riboviria infection induced morbidity/mortality	J:128067
Mx1^s2/Mx1^s2 (CBA/J)	increased susceptibility to Orthomyxoviridae infection	J:23752
Mxd1^tm1Rne/Mxd1^tm1Rne (involves: 129S4/SvJaeSor * C57BL/6)	abnormal B cell physiology	J:45945
	abnormal myeloid leukocyte morphology	J:45945
	immune system phenotype	J:45945
	increased granulocyte number	J:45945
Mxd4^em1(IMPC)J/Mxd4^em1(IMPC)J (C57BL/6NJ-Mxd4^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
Mxi1^tm1Rdp/Mxi1^tm1Rdp (involves: 129/Sv * C57BL/6J * SJL)	abnormal lymphocyte morphology	J:48236
	enlarged spleen	J:48236
	increased spleen white pulp amount	J:48236
	increased T cell proliferation	J:48236
Mxra8^em1Diam/Mxra8⁺ (C57BL/6J-Mxra8^em1Diam)	decreased susceptibility to Togaviridae infection	J:280585
Mxra8^em1Diam/Mxra8^em1Diam (C57BL/6J-Mxra8^em1Diam)	abnormal cytokine level	J:280585
	decreased inflammatory response	J:280585
	decreased susceptibility to Togaviridae infection	J:280585
Mxra8^em2Diam/Mxra8^em2Diam (C57BL/6J-Mxra8^em2Diam)	decreased susceptibility to Togaviridae infection	J:280585
Myb^boo/Myb^boo (involves: C57BL/6)	abnormal B cell differentiation	J:167270
	abnormal leukocyte morphology	J:167270
	abnormal spleen morphology	J:167270
	decreased neutrophil cell number	J:167270
	decreased spleen white pulp amount	J:167270
	enlarged spleen	J:167270
	increased spleen red pulp amount	J:167270
Myb^M303V/Myb^M303V (involves: 129S1/SvlmJ * C57BL/6)	arrested B cell differentiation	J:96507
	arrested T cell differentiation	J:96507
	decreased B cell number	J:96507
	decreased eosinophil cell number	J:96507
	decreased single-positive T cell number	J:96507
	decreased thymocyte number	J:96507
Myb^tm1.1Cgn/Myb⁺ (involves: 129P2/OlaHsd * C57BL/6)	arrested B cell differentiation	J:127234
	decreased B-1 B cell number	J:127234
	decreased mature B cell number	J:127234
	decreased pre-B cell number	J:127234
Myb^tm1Cgn/Myb^tm1.1Cgn Tg(Lck-cre)548Jxm/0 (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	decreased CD4-positive, alpha-beta T cell number	J:91122
	decreased double-positive T cell number	J:91122
	thymus hypoplasia	J:91122
Myb^tm1Cgn/Myb^tm1Cgn Tg(Lck-cre)1Cwi/0 (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	arrested T cell differentiation	J:91122
	decreased CD4-positive, alpha-beta T cell number	J:91122
	decreased CD8-positive, alpha-beta T cell number	J:91122
	decreased double-negative T cell number	J:91122
	decreased double-positive T cell number	J:91122
	decreased gamma-delta T cell number	J:91122
	thymus hypoplasia	J:91122
Myb^tm1Cgn/Myb^tm1Cgn Tg(Lck-cre)548Jxm/0 (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	decreased CD4-positive, alpha-beta T cell number	J:91122
	decreased double-positive T cell number	J:91122
	thymus hypoplasia	J:91122
Myb^tm1Epr/Myb^tm1Epr Tg(Cd4-cre)1Cwi/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)	abnormal T cell differentiation	J:93481
	decreased CD4-positive, alpha-beta T cell number	J:93481
	decreased double-positive T cell number	J:93481
	increased CD8-positive, alpha-beta T cell number	J:93481
	thymus hypoplasia	J:93481
Myb^tm1Epr/Myb^tm1Epr Tg(Lck-cre)548Jxm/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)	abnormal double-negative T cell morphology	J:93481
	abnormal T cell differentiation	J:93481
	decreased double-positive T cell number	J:93481
	thymus hypoplasia	J:93481
Myb^tm1Jof/Myb^tm1Jof (involves: 129/Sv * C57BL/6)	abnormal B cell differentiation	J:85344
	abnormal double-negative T cell morphology	J:85344
	abnormal T cell differentiation	J:85344
	decreased thymocyte number	J:85344
Myb^tm1Jof/Myb^tm1Ssp (involves: 129/Sv * C57BL/6)	abnormal T cell differentiation	J:85344
Myb^tm1Jof/Myb^tm1Ssp (involves: 129/Sv * C57BL/6)	decreased thymocyte number	J:85344
Myb^tm2.2Epr/Myb^tm2.2Epr (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	immune system phenotype	J:160189
Mybl1^tm1Epr/Mybl1^tm1Epr (involves: 129 * C57BL/6)	abnormal humoral immune response	J:67604
	abnormal spleen B cell follicle morphology	J:67604
	abnormal spleen marginal zone morphology	J:67604
	decreased B cell number	J:67604
	decreased IgG1 level	J:67604
	decreased IgG2a level	J:67604
	decreased IgG3 level	J:67604
	decreased spleen germinal center number	J:67604
	increased spleen red pulp amount	J:67604
	small spleen	J:67604
	spleen hypoplasia	J:67604
Mybl2^tm1.1Epr/Mybl2^tm1.1Epr Tg(Mx1-cre)1Cgn/0 (involves: 129X1/SvJ * C57BL/6 * CBA * FVB/N)	abnormal myelopoiesis	J:206816
	decreased B cell number	J:206816
	decreased leukocyte cell number	J:206816
	decreased lymphocyte cell number	J:206816
	decreased neutrophil cell number	J:206816
	decreased splenocyte number	J:206816
	decreased T cell number	J:206816
Mybl2^tm1.1Jof/Mybl2⁺ Tg(Zp3-cre)3Mrt/0 (involves: 129S2/SvPas * C57BL/6 * FVB/N)	abnormal myelopoiesis	J:196804
	decreased leukocyte cell number	J:196804
	decreased neutrophil cell number	J:196804
	enlarged spleen	J:196804
	increased granulocyte number	J:196804
	increased leukocyte cell number	J:196804
	increased monocyte cell number	J:196804
	myeloid hyperplasia	J:196804
Mybphl^{tm1a(KOMP)Wtsi}/Mybphl^{tm1a(KOMP)Wtsi} (C57BL/6N-Mybphl^{tm1a(KOMP)Wtsi}/Wtsi)	blood in lymph vessels	J:239583
Mybphl^{tm1b(KOMP)Wtsi}/Mybphl^{tm1b(KOMP)Wtsi} (C57BL/6N-Mybphl^{tm1b(KOMP)Wtsi}/Wtsi)	abnormal thymus morphology	J:239583
	blood in lymph vessels	J:239583
Myc^{tm1.1(Nmyc1)Fwa}/Myc^{tm1.1(Nmyc1)Fwa} (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:62573
Myc^tm1.1Cksn/Myc^tm1.1Cksn (B6.129-Myc^tm1.1Cksn)	immune system phenotype	J:170508
Myc^tm1Atp/Myc⁺ (involves: 129P2/OlaHsd * FVB/N)	decreased T cell proliferation	J:73369
	lymph node hypoplasia	J:73369
	lymphoid hypoplasia	J:73369
	small lymphoid organs	J:73369
	spleen hypoplasia	J:73369
Myc^tm1Atp/Myc⁺ (B6.129P2-Myc^tm1Atp)	abnormal NK cell physiology	J:132730
	decreased memory T cell number	J:132730
	decreased T cell proliferation	J:132730
	immune system phenotype	J:132730
Myc^tm1Atp/Myc^tm2.1Atp (involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL)	decreased T cell proliferation	J:73369
	immune system phenotype	J:73369
	lymph node hypoplasia	J:73369
	spleen hypoplasia	J:73369
Myc^tm1Atp/Myc^tm2.1Atp Tg(Mx1-cre)1Cgn/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA * FVB/N * SJL)	immune system phenotype	J:73369
Myc^tm1Lbox/Myc⁺ (involves: 129S1/Sv * 129X1/SvJ * FVB/N)	enlarged lymph nodes	J:97900
	enlarged spleen	J:97900
	increased B cell number	J:97900
	increased spleen weight	J:97900
Myc^tm1Lbox/Myc^tm1Lbox (involves: 129S1/Sv * 129X1/SvJ * FVB/N)	decreased T cell number	J:97900
	enlarged lymph nodes	J:97900
	enlarged spleen	J:97900
	increased B cell apoptosis	J:97900
	increased B cell number	J:97900
	increased B cell proliferation	J:97900
	increased spleen weight	J:97900
Myc^tm2.1Atp/Myc⁺ (involves: 129P2/OlaHsd * C57BL/6 * SJL)	decreased T cell proliferation	J:73369
Myc^tm2.1Atp/Myc^tm2.1Atp Tg(Mx1-cre)1Cgn/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA * FVB/N * SJL)	immune system phenotype	J:73369
Myc^tm2Fwa/Myc^tm2Fwa Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129P2/OlaHsd * 129S6/SvEvTac)	decreased B cell proliferation	J:67222
Myc^tm3(Tcrb)Fwa/Myc⁺ (involves: 129)	abnormal T cell receptor beta chain V(D)J recombination	J:131995
Mycl^tm1.1Kmm/Mycl^tm1.1Kmm (B6.129S6(C)-Mycl^tm1.1Kmm)	abnormal dendritic cell physiology	J:206430
	decreased dendritic cell number	J:206430
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:206430
Myct1^em1(IMPC)Mbp/Myct1^em1(IMPC)Mbp (C57BL/6N-Myct1^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Myct1^em1Choi/Myct1^em1Choi (involves: C57BL/6)	abnormal macrophage cell number	J:303692
	decreased regulatory T cell number	J:303692
	increased CD8-positive, alpha-beta T cell number	J:303692
Myd88^lkd/Myd88^lkd (C57BL/6-Myd88^lkd)	abnormal adaptive immunity	J:110094
	abnormal cell-mediated immunity	J:110094
	abnormal innate immunity	J:110094
	abnormal macrophage physiology	J:110094
	immune system phenotype	J:110094
Myd88^m3Btlr/Myd88^m3Btlr (C57BL/6J-Myd88^m3Btlr)	immune system phenotype	J:156848
Myd88^M4Btlr/Myd88⁺ (C57BL/6J-Myd88^M4Btlr)	decreased tumor necrosis factor secretion	J:254917
Myd88^M4Btlr/Myd88^M4Btlr (C57BL/6J-Myd88^M4Btlr)	decreased tumor necrosis factor secretion	J:254917
Myd88^poc/Myd88⁺ (C57BL/6-Myd88^poc)	immune system phenotype	J:110094
Myd88^poc/Myd88^poc (C57BL/6-Myd88^poc)	abnormal immune system physiology	J:110094
	abnormal macrophage physiology	J:110094
	immune system phenotype	J:110094
	increased susceptibility to bacterial infection	J:110094
	increased susceptibility to Herpesvirales infection	J:110094
Myd88^poc/Myd88^poc Ptpn6^m1Btlr/Ptpn6^m1Btlr (C57BL/6J-Ptpn6^m1Btlr Myd88^poc)	immune system phenotype	J:142845
Myd88^tm1.1Defr/Myd88^tm1.1Defr (B6.129P2(SJL)-Myd88^tm1.1Defr)	abnormal CD4-positive, alpha-beta T cell physiology	J:224849
	abnormal macrophage physiology	J:224849
	abnormal microglial cell physiology	J:224849
	decreased effector memory CD4-positive, alpha-beta T cell number	J:224849
	decreased interferon-gamma secretion	J:224849
	decreased leukocyte cell number	J:224849
	decreased macrophage cell number	J:224849
	decreased monocyte cell number	J:224849
	decreased neutrophil cell number	J:224849
	increased susceptibility to Coronaviridae infection	J:224849
	increased susceptibility to Coronaviridae infection induced morbidity/mortality	J:224849
Myd88^tm1.1Medz/Myd88^tm1.1Medz Foxp3^{tm4(YFP/icre)Ayr}/Foxp3⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	immune system phenotype	J:209373
Myd88^tm1.1Medz/Myd88^tm1.1Medz Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	abnormal CD4-positive, alpha-beta T cell physiology	J:209373
	abnormal memory T cell physiology	J:209373
	abnormal T-helper 1 physiology	J:209373
	abnormal T-helper 17 cell physiology	J:209373
Myd88^tm1Aki/Myd88^tm1Aki (Not Specified)	abnormal cytokine secretion	J:89257, J:88906
	abnormal dendritic cell physiology	J:96773
	abnormal macrophage physiology	J:96773
	abnormal NK cell physiology	J:88906
	abnormal NK T cell physiology	J:88906
	abnormal T cell physiology	J:96773
	decreased B cell proliferation	J:96773
	increased susceptibility to Herpesvirales infection	J:88906
Myd88^tm1Aki/Myd88^tm1Aki (B6.129P2-Myd88^tm1Aki)	abnormal chemokine secretion	J:102879
	abnormal cytokine secretion	J:116670, J:162707
	abnormal dendritic cell differentiation	J:139001
	abnormal dendritic cell physiology	J:116670, J:118954
	abnormal immune system physiology	J:121070
	abnormal innate immunity	J:162707
	abnormal macrophage physiology	J:116670
	abnormal NK cell physiology	J:139001
	abnormal response to infection	J:121070
	abnormal T cell physiology	J:97662
	bronchiolitis	J:162707
	decreased inflammatory response	J:123946
	decreased interferon-alpha secretion	J:97662
	decreased interferon-gamma secretion	J:116763, J:118954
	decreased interleukin-6 secretion	J:118954, J:121070
	decreased interleukin-12 secretion	J:116670
	decreased interleukin-12b secretion	J:116763, J:118954
	decreased susceptibility to parasitic infection	J:116763
	decreased tumor necrosis factor secretion	J:116670, J:116763, J:121070
	increased dendritic cell number	J:116763
	increased susceptibility to Coronaviridae infection	J:162707
	increased susceptibility to Coronaviridae infection induced morbidity/mortality	J:162707
	increased susceptibility to Picornaviridae infection	J:97662
Myd88^tm1Aki/Myd88^tm1Aki (involves: 129P2/OlaHsd)	abnormal cytokine level	J:174941
	abnormal cytokine secretion	J:167340
	abnormal dendritic cell physiology	J:174941, J:137522
	abnormal interferon level	J:137522
	abnormal macrophage physiology	J:174941
	abnormal neutrophil physiology	J:145345
	abnormal tumor necrosis factor level	J:103464, J:124334
	decreased circulating tumor necrosis factor level	J:139030
	decreased interferon-alpha secretion	J:144400
	decreased interferon-gamma secretion	J:210086
	decreased interleukin-6 secretion	J:167340
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:105435
	increased IgA level	J:210086
	increased IgE level	J:115059
	increased IgG1 level	J:115059
	increased susceptibility to bacterial infection	J:210086
	increased susceptibility to induced colitis	J:167340
	increased susceptibility to Picornaviridae infection	J:137522
Myd88^tm1Aki/Myd88^tm1Aki (involves: 129P2/OlaHsd * C57BL/6)	abnormal chemokine secretion	J:141143
	abnormal cytokine secretion	J:117688
	abnormal dendritic cell physiology	J:122394
	abnormal macrophage physiology	J:141143, J:117688
	decreased IgG2b level	J:137066
	decreased IgG3 level	J:137066
	decreased IgG level	J:137066
	decreased interleukin-1 beta secretion	J:124226
	decreased interleukin-6 secretion	J:147023
	immune system phenotype	J:132662
Myd88^tm1Aki/Myd88^tm1Aki (C.129P2-Myd88^tm1Aki)	decreased susceptibility to induced arthritis	J:178054
Myd88^tm1Aki/Myd88^tm1Aki (B6.129-Myd88^tm1Aki)	abnormal susceptibility to bacterial infection	J:189854
	decreased interleukin-6 secretion	J:189854
	decreased tumor necrosis factor secretion	J:189854
Myd88^tm1Aki/Myd88^tm1Aki Sh3bp2^tm1.1Ics/Sh3bp2^tm1.1Ics (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:221901
Myd88^tm1Aki/Myd88^tm1Aki Tank^tm1Aki/Tank^tm1Aki (involves: 129/Sv * 129P2/OlaHsd * C57BL/6)	increased anti-double stranded DNA antibody level	J:151757
Myd88^tm1Aki/Myd88^tm1Aki Tg(IghelMD4)4Ccg/0 Tg(KLK4mHEL)6Ccg/0 (involves: 129P2/OlaHsd * C57BL/6)	decreased mature B cell number	J:115059
	increased B-1 B cell number	J:115059
Myd88^tm1Aki/Myd88^tm1Aki Ticam1^tm1Aki/Ticam1⁺ (B6.129P2-Myd88^tm1Aki Ticam1^tm1Aki)	decreased macrophage cytokine production	J:140485
	decreased macrophage nitric oxide production	J:140485
	increased susceptibility to parasitic infection	J:140485
	increased susceptibility to parasitic infection induced morbidity/mortality	J:140485
Myd88^tm1Aki/Myd88^tm1Aki Ticam1^tm1Aki/Ticam1^tm1Aki (involves: 129P2/OlaHsd)	abnormal dendritic cell physiology	J:174941
	abnormal macrophage physiology	J:174941
Myd88^tm1Aki/Myd88^tm1Aki Ticam1^tm1Aki/Ticam1^tm1Aki (B6.129P2-Myd88^tm1Aki Ticam1^tm1Aki)	decreased macrophage cytokine production	J:140485
	decreased macrophage nitric oxide production	J:140485
	increased susceptibility to parasitic infection	J:140485
	increased susceptibility to parasitic infection induced morbidity/mortality	J:140485
Myd88^tm1Aki/Myd88^tm1Aki Tnfaip3^tm1.1Gvl/Tnfaip3^tm1.1Gvl Tg(Vil1-cre)997Gum/0 (involves: 129P2/OlaHsd * C57BL/6 * SJL)	increased susceptibility to induced colitis	J:163410
Myd88^tm1Aki/Myd88^tm1Aki Tnip1^tm1.1Pcoh/Tnip1^tm1.1Pcoh (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:176826
Myd88^tm1Aki/Myd88^tm1Aki Tradd^tm1.1Mpa/Tradd^tm1.1Mpa (involves: 129P2/OlaHsd * BALB/cJ * C57BL/6)	decreased circulating tumor necrosis factor level	J:139030
Myd88^tm1Defr/Myd88^tm1Defr Commd10^{Tg(Vav1-icre)A2Kio}/Commd10⁺ (involves: 129P2/OlaHsd * C57BL/6 * SJL)	abnormal NK cell physiology	J:139001
Myd88^tm1Defr/Myd88^tm1Defr Tg(Itgax-cre)1-1Reiz/0 (B6.Cg-Myd88^tm1Defr Tg(Itgax-cre)1-1Reiz)	abnormal dendritic cell antigen presentation	J:139001
	abnormal dendritic cell differentiation	J:139001
	abnormal dendritic cell physiology	J:139001
	abnormal NK cell physiology	J:139001
	abnormal T-helper 1 cell differentiation	J:139001
	decreased circulating interleukin-6 level	J:139001
	decreased circulating interleukin-12b level	J:139001
	decreased IgG1 level	J:139001
	decreased IgG2b level	J:139001
	decreased IgG2c level	J:139001
Myd88^tm1Defr/Myd88^tm1Defr Tnip1^tm1.2Ama/Tnip1^tm1.2Ama Tg(Itgax-cre)1-1Reiz/0 (involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J * CBA)	immune system phenotype	J:205446
Myd88^tm1Hlz/Myd88^tm1Hlz (B6.129P2-Myd88^tm1Hlz)	abnormal chemokine level	J:188968
	decreased circulating interleukin-6 level	J:188968
	decreased circulating interleukin-10 level	J:188968
	decreased circulating interleukin-12b level	J:188968
	decreased interleukin-6 secretion	J:188968
	decreased interleukin-10 secretion	J:188968
	decreased neutrophil cell number	J:188968
	decreased tumor necrosis factor secretion	J:188968
Myd88^tm1Hlz/Myd88^tm1Hlz Lyz2^tm1(cre)Ifo/Lyz2⁺ (B6.129P2-Myd88^tm1Hlz Lyz2^tm1(cre)Ifo)	abnormal circulating chemokine level	J:188968
	decreased CXCL10 level	J:188968
	immune system phenotype	J:188968
	increased circulating tumor necrosis factor level	J:188968
Mydgf^tm1Kcw/Mydgf^tm1Kcw (BALB/c-Mydgf^tm1Kcw)	decreased inflammatory response	J:216795
Myh1^{tm1b(KOMP)Wtsi}/Myh1^{tm1b(KOMP)Wtsi} (C57BL/6N-Myh1^{tm1b(KOMP)Wtsi}/J)	decreased leukocyte cell number	J:211773
Myh4^arl/Myh4^arl (involves: C3H/HeH * C57BL/6J)	myositis	J:181892
Myh6^tm1Jse/Myh6⁺ Tg(Myh6-TNNI3G203S)1Chs/0 (involves: 129X1/SvJ C57BL/6)	liver inflammation	J:153302
	lung inflammation	J:153302
Myh9^tm1.1Dash/Myh9⁺ (involves: 129S2/SvPas * C57BL/6 * C57BL/6J * CBA)	abnormal thrombopoiesis	J:204923
Myh9^tm1.1Mjk/Myh9⁺ (B6.129-Myh9^tm1.1Mjk)	abnormal neutrophil morphology	J:175367
Myh9^tm1.1Mjk/Myh9⁺ (B6.129-Myh9^tm1.1Mjk)	increased incidence of corneal inflammation	J:175367
Myh9^tm1.1Mjk/Myh9^tm1.1Mjk (B6.129-Myh9^tm1.1Mjk)	abnormal neutrophil morphology	J:175367
Myh9^tm5Rsad/Myh9^tm5Rsad (involves: 129S6/SvEvTac * C57BL/6J)	abnormal leukocyte migration	J:164684
	abnormal T cell physiology	J:164684
Myh9^tm5Rsad/Myh9^tm5Rsad Tg(Lck-cre)#Nik/0 (involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * DBA/2)	abnormal CD8-positive, alpha-beta T cell physiology	J:164684
	abnormal leukocyte adhesion	J:164684
	abnormal leukocyte migration	J:164684
	abnormal lymph node cell ratio	J:164684
	abnormal T cell physiology	J:164684
	decreased CD8-positive, alpha-beta T cell number	J:164684
Myh9^{tm6.1(EGFP/MYH9)Rsad}/Myh9⁺ (involves: 129S4/SvJae BALB/cJ * C57BL/6)	abnormal neutrophil morphology	J:175367
Myh9^tm7.1Rsad/Myh9⁺ (involves: BALB/cJ)	abnormal neutrophil morphology	J:175367
Myh9^tm7.1Rsad/Myh9^tm7.1Rsad (involves: BALB/cJ)	abnormal neutrophil morphology	J:175367
Myh10^tm7Rsad/Myh10^tm7Rsad Tg(Myh6-cre)2182Mds/0 (involves: 129S6/SvEvTac * C57BL/6J * FVB/N)	heart inflammation	J:170148
Myh15^em1(IMPC)J/Myh15^em1(IMPC)J (C57BL/6NJ-Myh15^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
Myl3^{tm1a(EUCOMM)Hmgu}/Myl3^{tm1a(EUCOMM)Hmgu} Tg(Col2a1-cre)1Xya/0 (involves: C57BL/6J * C57BL/6N)	osteoarthritis	J:343166
Myl3^{tm1a(EUCOMM)Hmgu}/Myl3^{tm1a(EUCOMM)Hmgu} Tg(Col2a1-cre/ERT)KA3Smac/0 (involves: C57BL/6J * C57BL/6N * FVB/N)	increased susceptibility to induced arthritis	J:343166
Mylk^tm1Mzhu/Mylk^tm1Mzhu Tagln^{tm1(cre/ERT2)Feil}/? (involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * C57BL/6)	small intestinal inflammation	J:141907
Myo1d^em1Btlr/Myo1d^em1Btlr (C57BL/6J-Myo1d^em1Btlr)	increased susceptibility to colitis induced morbidity/mortality	J:267525
Myo1d^em1Btlr/Myo1d^em1Btlr (C57BL/6J-Myo1d^em1Btlr)	increased susceptibility to induced colitis	J:267525
Myo1d^m1Btlr/Myo1d^m1Btlr (C57BL/6J-Myo1d^m1Btlr)	increased susceptibility to induced colitis	J:267525
Myo1d^m1Btlr/Myo1d^m2Btlr (C57BL/6J-Myo1d^m1Btlr/Myo1d^m2Btlr)	increased susceptibility to induced colitis	J:267525
Myo1d^m2Btlr/Myo1d^m2Btlr (C57BL/6J-Myo1d^m2Btlr)	increased susceptibility to induced colitis	J:267525
Myo1d^m3Btlr/Myo1d^m3Btlr (C57BL/6J-Myo1d^m3Btlr)	increased susceptibility to induced colitis	J:267525
Myo1d^m4Btlr/Myo1d^m4Btlr (C57BL/6J-Myo1d^m4Btlr)	increased susceptibility to induced colitis	J:267525
Myo1f^tm1.1Flv/Myo1f^tm1.1Flv (involves: 129S6/SvEvTac)	impaired neutrophil chemotaxis	J:113020
Myo1g^tm1.2Mfk/Myo1g^tm1.2Mfk (Not Specified)	abnormal B cell physiology	J:209304
	decreased B cell number	J:209304
	decreased tumor necrosis factor secretion	J:209304
	immune system phenotype	J:209304
	impaired B cell migration	J:209304
	increased B cell number	J:209304
Myo1g^tm1.2Mfk/Myo1g^tm1.2Mfk (involves: C57BL/6 * FVB/N * SJL)	abnormal T cell physiology	J:212451
Myo1g^tm1.2Mfk/Myo1g^tm1.2Mfk Tg(TcraTcrb)1100Mjb/0 (involves: C57BL/6 * FVB/N * SJL)	abnormal T cell physiology	J:212451
Myo3b^{tm1b(EUCOMM)Hmgu}/Myo3b^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Myo3b^{tm1b(EUCOMM)Hmgu}/J)	decreased leukocyte cell number	J:211773
Myo5a^d-2Btlr/Myo5a^d-2Btlr (C57BL/6J-Myo5a^d-2Btlr)	immune system phenotype	J:133118
Myo5a^d-Btlr/Myo5a^d-Btlr (C57BL/6J-Myo5a^d-Btlr)	immune system phenotype	J:133117
Myo5a^d-l20J/Myo5a^d-l20J (involves: C57BL/6J)	immune system phenotype	J:111253
Myo6^em1(IMPC)Tcp/Myo6^em1(IMPC)Tcp (C57BL/6N-Myo6^em1(IMPC)Tcp/Tcp)	decreased leukocyte cell number	J:211773
Myo9a^{tm1b(EUCOMM)Wtsi}/Myo9a^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Myo9a^{tm1b(EUCOMM)Wtsi}/Wtsi)	blood in lymph vessels	J:239583
Myo9b^tm1.2Bah/Myo9b^tm1.2Bah (B6.Cg-Myo9b^tm1.2Bah)	abnormal macrophage physiology	J:162326
	decreased leukocyte cell number	J:162326
	impaired macrophage chemotaxis	J:162326
Myo18a^{tm1c(KOMP)Wtsi}/Myo18a^{tm1c(KOMP)Wtsi} Gt(ROSA)26Sor^tm1(EYFP)Cos/Gt(ROSA)26Sor⁺ Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6N)	immune system phenotype	J:277320
Myoz1^{tm1b(EUCOMM)Hmgu}/Myoz1^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Myoz1^{tm1b(EUCOMM)Hmgu}/Ieg)	increased marginal zone B cell number	J:211773
Mypn^em1(IMPC)J/Mypn^em1(IMPC)J (C57BL/6NJ-Mypn^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
mypy/mypy (C57BL/6J-mypy)	abnormal macrophage physiology	J:105543
	increased susceptibility to Herpesvirales infection	J:105543
	increased susceptibility to Riboviria infection	J:105543
Mysm1^{tm1a(KOMP)Wtsi}/Mysm1^{tm1a(KOMP)Wtsi} (Not Specified)	decreased B cell number	J:165965
	decreased leukocyte cell number	J:165965
	decreased mature B cell number	J:165965
	increased granulocyte number	J:165965
	increased IgG2b level	J:165965
	increased T cell number	J:165965
Mysm1^{tm1b(KOMP)Wtsi}/Mysm1^{tm1b(KOMP)Wtsi} Tg(MMTV-cre)4Mam/0 (involves: 129 * C57BL/6N * FVB/N)	abnormal T cell differentiation	J:179287
	arrested B cell differentiation	J:179287
	decreased B cell number	J:179287
	decreased immature B cell number	J:179287
	decreased pre-B cell number	J:179287
	decreased pro-B cell number	J:179287
Mzb1^tm1.2Rug/Mzb1^tm1.2Rug (involves: 129S2/SvPas * BALB/cJ * C57BL/6 * SJL)	decreased pre-B cell number	J:211639
	immune system phenotype	J:211639
	impaired humoral immune response	J:211639
	increased pro-B cell number	J:211639
Mzf1^tm1Ppp/Mzf1^tm1Ppp (involves: 129)	abnormal bone marrow development	J:70407
Mzf1^tm1Ppp/Mzf1^tm1Ppp (involves: 129)	abnormal myelopoiesis	J:70407
N4bp1^em1Vmd/N4bp1^em1Vmd (C57BL/6N-N4bp1^em1Vmd)	decreased interleukin-6 secretion	J:297419
N4bp1^em1Vmd/N4bp1^em1Vmd (C57BL/6N-N4bp1^em1Vmd)	immune system phenotype	J:297419
N4bp1^tm1.2Vmd/N4bp1^tm1.2Vmd (involves: C57BL/6)	abnormal macrophage physiology	J:297419
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:297419
	increased activated T cell number	J:297419
	increased circulating interleukin-6 level	J:297419
	increased circulating tumor necrosis factor level	J:297419
	increased germinal center B cell number	J:297419
	increased interleukin-6 secretion	J:297419
	increased Ly6C high monocyte number	J:297419
	increased tumor necrosis factor secretion	J:297419
	lung inflammation	J:297419
Naa10^em1(IMPC)Mbp/Y (C57BL/6NCrl-Naa10^em1(IMPC)Mbp/Mmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	small spleen	J:211773
Naa10^em1(IMPC)Mbp/Naa10^em1(IMPC)Mbp (C57BL/6NCrl-Naa10^em1(IMPC)Mbp/Mmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Naa16^em1(IMPC)J/Naa16^em1(IMPC)J (C57BL/6NJ-Naa16^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
Naa25^em1(IMPC)Tcp/Naa25⁺ (C57BL/6NCrl-Naa25^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
	enlarged thymus	J:211773
Naa35^em1(IMPC)J/Naa35⁺ (C57BL/6NJ-Naa35^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
Naa38^{em1(IMPC)Ccpcz}/Naa38⁺ (C57BL/6N-Naa38^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged thymus	J:211773
Naaa^{tm1a(KOMP)Wtsi}/Naaa^{tm1a(KOMP)Wtsi} (B6NTac;B6N-A^tm1Brd Naaa^{tm1a(KOMP)Wtsi}/WtsiH)	decreased susceptibility to type IV hypersensitivity reaction	J:258438
Nabp2^tm1.1Kkha/Nabp2^tm1.1Kkha Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:195140
Nabp2^tm1.1Kkha/Nabp2^tm1.1Kkha Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte}/Gt(ROSA)26Sor⁺ (involves: C57BL/6 * C57BL/6NTac)	increased T cell derived lymphoma incidence	J:195140
	increased thymocyte apoptosis	J:195140
Nabp2^tm1.1Nfel/Nabp2^tm1.2Nfel Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL)	immune system phenotype	J:190019
Nabp2^tm1Schg/Nabp2^tm1Schg (involves: 129S7/SvEvBrd * C57BL/6)	increased spleen red pulp amount	J:228558
nad/nad (C(D2)-nad)	abnormal bronchus-associated lymphoid tissue morphology	J:156089
Nadsyn1^{tm1b(KOMP)Wtsi}/Nadsyn1^{tm1b(KOMP)Wtsi} (C57BL/6N-Nadsyn1^{tm1b(KOMP)Wtsi}/Ucd)	enlarged spleen	J:211773
Nagk^{tm1b(EUCOMM)Hmgu}/Nagk^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Nagk^{tm1b(EUCOMM)Hmgu}/H)	increased neutrophil cell number	J:211773
Naglu^tm1Efn/Naglu^tm1Efn (either: (involves: 129S/SvEv * C57BL/6) or (involves: C57BL/6))	abnormal Kupffer cell morphology	J:58950
	abnormal macrophage morphology	J:58950
Naglu^tm1Efn/Naglu^tm1Efn (involves: 129S/SvEv * C57BL/6J)	increased susceptibility to otitis media	J:129390
Naip5^Lgn1-s/Naip5^Lgn1-s (A/J)	increased susceptibility to bacterial infection	J:20633
Naip5^m1Btlr/Naip5^m1Btlr (C57BL/6J-Naip5^m1Btlr)	decreased interleukin-1 beta secretion	J:234250
Naip5^m2Btlr/Naip5⁺ (C57BL/6J-Naip5^m2Btlr)	decreased interleukin-1 beta secretion	J:234248
Naip5^m2Btlr/Naip5^m2Btlr (C57BL/6J-Naip5^m2Btlr)	decreased interleukin-1 beta secretion	J:234248
Naip5^tm1Vnce/Naip5^tm1Vnce (C57BL/6-Naip5^tm1Vnce)	decreased interleukin-1 beta secretion	J:141008
Naipc^tm1.1Kmma/Naipc^tm1.1Kmma (involves: BALB/cJ * C57BL/6)	decreased interleukin-1 beta secretion	J:222114
	decreased susceptibility to induced colitis	J:222114
Naipc^tm1Kmma/Naipc^tm1Kmma Lyz2^tm1(cre)Ifo/Lyz2⁺ (B6.Cg-Lyz2^tm1(cre)Ifo Naipc^tm1Kmma)	decreased susceptibility to induced colitis	J:222114
Naipc^tm1Kmma/Naipc^tm1Kmma Tg(Vil1-cre)997Gum/0 (B6.Cg-Naipc^tm1Kmma Tg(Vil1-cre)997Gum)	decreased susceptibility to induced colitis	J:222114
Nalcn^em1(IMPC)Mbp/Nalcn⁺ (C57BL/6N-Nalcn^em1(IMPC)Mbp/Ucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	increased neutrophil cell number	J:211773
Nampt^{Gt(RRR084)Byg}/Nampt⁺ (involves: 129P2/OlaHsd * C57BL/6)	decreased interleukin-6 secretion	J:194883
	decreased neutrophil cell number	J:194883
Nampt^tm1Oleo/Nampt^tm1Oleo Tg(CD2-icre)4Kio/0 (involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/10 * CBA/Ca)	decreased B cell number	J:141448
	decreased double-negative T cell number	J:141448
	decreased T cell number	J:141448
	thymus hypoplasia	J:141448
Napa^{em1(IMPC)Ccpcz}/Napa⁺ (C57BL/6NCrl-Napa^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Nat8f2^{tm1.1(KOMP)Vlcg}/Nat8f2^{tm1.1(KOMP)Vlcg} (C57BL/6N-Nat8f2^{tm1.1(KOMP)Vlcg}/J)	enlarged lymph nodes	J:211773
Nav1^em1(IMPC)Mbp/Nav1^em1(IMPC)Mbp (C57BL/6N-Nav1^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Nav2^em1(IMPC)Tcp/Nav2^em1(IMPC)Tcp (C57BL/6NCrl-Nav2^em1(IMPC)Tcp/Tcp)	increased neutrophil cell number	J:211773
Naxe^{tm1b(EUCOMM)Hmgu}/Naxe^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Naxe^{tm1b(EUCOMM)Hmgu}/Bay)	increased spleen weight	J:211773
Nba4^NZB/Nba4^NZB (involves: NZB * SWR)	glomerulonephritis	J:96060
	increased anti-double stranded DNA antibody level	J:96060
	increased anti-histone antibody level	J:96263
	increased anti-single stranded DNA antibody level	J:96060
	increased IgG3 level	J:96263
Nba4^NZB/Nba4^SWR (involves: NZB * SWR)	increased anti-histone antibody level	J:96263
Nba4^NZB/Nba4^SWR (involves: NZB * SWR)	increased IgG3 level	J:96263
Nba5^NZB/Nba5^NZB (C57BL/6-Nba5 Yaa)	glomerulonephritis	J:95829
Nba5^NZB/Nba5^NZB (C57BL/6-Nba5 Yaa)	increased susceptibility to type III hypersensitivity reaction	J:95829
Nba8^NZB/Nba8^NZB (involves: NZB * SWR)	glomerulonephritis	J:73097
Nba10^NZB/? (involves: C57BL/6 * NZB * SB/Le)	glomerulonephritis	J:95829
	increased anti-chromatin antibody level	J:95829
	increased anti-double stranded DNA antibody level	J:95829
	increased susceptibility to type III hypersensitivity reaction	J:95829
Nba10^NZB/Nba10^NZB Tg(Tnfsf13b)1Fma/0 (involves: C57BL/6 * DBA/2J * NZB)	glomerulonephritis	J:134128
	increased anti-chromatin antibody level	J:134128
	increased anti-double stranded DNA antibody level	J:134128
	increased B cell number	J:134128
	increased IgG level	J:134128
	increased IgM level	J:134128
	increased marginal zone B cell number	J:134128
	increased susceptibility to systemic lupus erythematosus	J:134128
Nba10^NZB/Nba10^NZB Tlr7^tm1Aki/Y X/Yaa (B6.Cg-Nba10^NZB Tlr7^tm1Aki Yaa)	abnormal immune serum protein physiology	J:137656
	glomerulonephritis	J:137656
	increased anti-chromatin antibody level	J:137656
	increased monocyte cell number	J:137656
Nba10^NZB/Nba10^NZB X/Yaa (C57BL/6-Nba2 Yaa)	abnormal immune serum protein physiology	J:137656
	glomerulonephritis	J:95829, J:137656
	increased anti-chromatin antibody level	J:137656
	increased anti-nuclear antigen antibody level	J:95829
	increased autoantibody level	J:137656
	increased monocyte cell number	J:137656, J:129409
	increased susceptibility to autoimmune disorder	J:95829
	increased susceptibility to type III hypersensitivity reaction	J:95829
Nba11^NZB/Nba11^NZB (involves: NZB * SWR)	glomerulonephritis	J:96263
Nba11^NZB/Nba11^SWR (involves: NZB * SWR)	glomerulonephritis	J:96263
Nba12^NZB/Nba12^NZB (involves: NZB * SWR)	increased anti-double stranded DNA antibody level	J:96263
Nba12^NZB/Nba12^SWR (involves: NZB * SWR)	increased anti-double stranded DNA antibody level	J:96263
Nbeal2^gps/Nbeal2^gps (129S1/SvImJ-Nbeal2^gps)	decreased neutrophil cell number	J:236370
Nbeal2^{tm1a(EUCOMM)Wtsi}/Nbeal2^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Nbeal2^{tm1a(EUCOMM)Wtsi}/Wtsi)	enlarged spleen	J:220801
	increased inflammatory response	J:220801
	increased leukocyte cell number	J:211773
Nbeal2^tm1Lex/Nbeal2^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6J)	enlarged spleen	J:201413
Nbn^em7Jpt/Nbn^tm2Zqw Tg(VAV1-cre)1Graf/0 (involves: 129P2/OlaHsd)	abnormal T cell morphology	J:277750
	absent mature B cells	J:277750
	decreased B cell number	J:277750
	decreased leukocyte cell number	J:277750
	decreased T cell number	J:277750
	decreased thymocyte number	J:277750
	increased CD8-positive, alpha-beta T cell number	J:277750
	increased pro-B cell number	J:277750
	increased T cell derived lymphoma incidence	J:277750
Nbn^tm1Jpt/Nbn^tm1Jpt (involves: 129S7/SvEvBrd)	immune system phenotype	J:75956
Nbn^tm1Nus/Nbn^tm2Nus Tg(CD19-cre/ERT2)1Cgn/0 (Not Specified)	abnormal B cell physiology	J:96102
	decreased B cell proliferation	J:96102
	decreased IgG1 level	J:96102
	decreased IgG2a level	J:96102
	decreased IgG2b level	J:96102
	decreased IgG3 level	J:96102
	decreased IgG level	J:96102
Nbn^tm1Xu/Nbn^tm1Xu (Not Specified)	abnormal cell-mediated immunity	J:75272
	decreased CD4-positive, alpha-beta T cell number	J:75272
	decreased mature B cell number	J:75272
	decreased pre-B cell number	J:75272
	decreased T cell number	J:75272
	increased T cell derived lymphoma incidence	J:75272
	thymus hypoplasia	J:75272
Nbn^tm1Zqw/Nbn⁺ (involves: 129S2/SvPas * C57BL/6)	increased T cell derived lymphoma incidence	J:86563
Nbn^tm2Zqw/Nbn^tm2Zqw Tg(VAV1-cre)1Graf/0 (involves: 129P2/OlaHsd)	abnormal bone marrow development	J:251434
	decreased leukocyte cell number	J:251434
Nbr1^tm1.1Jmos/Nbr1^tm1.1Jmos Tnfrsf4^tm2(cre)Nik/Tnfrsf4⁺ (involves: 129X1/SvJ * C57BL/6J)	abnormal T-helper 1 cell differentiation	J:165438
	abnormal T-helper 2 cell differentiation	J:165438
	decreased inflammatory response	J:165438
	decreased interferon-gamma secretion	J:165438
	decreased interleukin-4 secretion	J:165438
	decreased interleukin-5 secretion	J:165438
	decreased interleukin-13 secretion	J:165438
Nbr1^tm1Whca/Nbr1^tm1Whca (B6.129P2-Nbr1^tm1Whca)	abnormal osteoclast physiology	J:162412
Nbwa1^NZB/? (involves: BALB/c * NZB * NZW)	increased anti-chromatin antibody level	J:88464
	increased anti-double stranded DNA antibody level	J:88464
	increased anti-single stranded DNA antibody level	J:88464
	increased susceptibility to systemic lupus erythematosus	J:88464
Nbwa2^NZB/? (involves: BALB/c * NZB * NZW)	glomerulonephritis	J:88464
	increased IgG level	J:88464
	increased IgM level	J:88464
	increased susceptibility to systemic lupus erythematosus	J:88464
Nbwa2^NZW/? (involves: BALB/c * NZB * NZW)	increased anti-double stranded DNA antibody level	J:88464
Nbwa2^NZW/? (involves: BALB/c * NZB * NZW)	increased susceptibility to systemic lupus erythematosus	J:88464
Ncam2^{tm1b(EUCOMM)Hmgu}/Ncam2^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Ncam2^{tm1b(EUCOMM)Hmgu}/Orl)	increased eosinophil cell number	J:211773
Ncapd2^em1Cya/Ncapd2⁺ (C57BL/6N-Ncapd2^em1Cya)	decreased susceptibility to induced colitis	J:310248
Ncaph2^nes/Ncaph2^nes (C57BL/6JSfdAnu-Ncaph2^nes/Anu)	abnormal double-negative T cell morphology	J:123300
	abnormal splenic cell ratio	J:123300
	abnormal T cell morphology	J:123300
	abnormal thymus cell ratio	J:123300
	abnormal thymus cortex morphology	J:123300
	abnormal thymus corticomedullary boundary morphology	J:123300
	decreased CD8-positive, alpha-beta T cell number	J:123300
	decreased double-negative T cell number	J:123300
	decreased double-positive T cell number	J:123300
	decreased T cell number	J:123300
	decreased thymocyte number	J:123300
	thymus hypoplasia	J:123300
Ncaph2^nes/Ncaph2^nes Tg(TcrHEL3A9)1Mmd/0 (C57BL/6-Ncaph2^nes Tg(TcrHEL3A9)1Mmd)	abnormal double-negative T cell morphology	J:123300
	abnormal thymus cell ratio	J:123300
	decreased double-positive T cell number	J:123300
Nceh1^tm1Ishi/Nceh1^tm1Ishi (B6.129S7-Nceh1^tm1Ishi)	abnormal macrophage physiology	J:152385
Ncf1^em1(IMPC)Mbp/Ncf1^em1(IMPC)Mbp (C57BL/6N-Ncf1^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Ncf1^em1Nansh/Ncf1^em1Nansh (involves: C57BL/6J)	immune system phenotype	J:329553
Ncf1^m1J/Ncf1^m1J (B6.Cg-Dock7^m +/+ Lepr^db/J)	abnormal macrophage physiology	J:83428
	decreased susceptibility to Orthomyxoviridae infection	J:145306
	impaired granulocyte bactericidal activity	J:83428
Ncf1^tm1Hbd/Ncf1^tm1Hbd (involves: 129)	abnormal neutrophil physiology	J:77597, J:74593
Ncf1^tm1Hbd/Ncf1^tm1Hbd (involves: 129)	granulomatous inflammation	J:74593
Ncf1^tm1Hbd/Ncf1^tm1Hbd (involves: C57BL/6)	immune system phenotype	J:118561
Ncf1^tm1Shl/Ncf1^tm1Shl (involves: 129S2/SvPas * C57BL/6J)	abnormal response to infection	J:28267
	increased acute inflammation	J:28267
	increased susceptibility to infection	J:28267
Ncf1^tm1Shl/Ncf1^tm1Shl (B6.129S2-Ncf1^tm1Shl)	abnormal inflammatory response	J:142617
Ncf1^tm1Shl/Ncf1^tm1Shl (B6.129S2-Ncf1^tm1Shl)	granulomatous inflammation	J:111142
Ncf2^{tm1a(EUCOMM)Wtsi}/Ncf2^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Ncf2^{tm1a(EUCOMM)Wtsi}/Wtsi)	decreased alpha-beta T cell number	J:211773
	decreased leukocyte cell number	J:211773
	decreased NK cell number	J:211773
	decreased NK T cell number	J:211773
	decreased regulatory T cell number	J:211773
	decreased T cell number	J:211773
	increased KLRG1-positive NK cell number	J:211773
Ncf2^{tm1b(EUCOMM)Wtsi}/Ncf2⁺ (NZM2328.B6(Cg)-Ncf2^{tm1b(EUCOMM)Wtsi})	abnormal spleen germinal center morphology	J:260777
	increased activated T cell number	J:260777
	increased anti-double stranded DNA antibody level	J:260777
	increased B cell number	J:260777
	increased CD4-positive, alpha-beta memory T cell number	J:260777
	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:260777
	increased CD8-positive, alpha-beta T cell number	J:260777
	increased follicular B cell number	J:260777
	increased germinal center B cell number	J:260777
	increased susceptibility to systemic lupus erythematosus	J:260777
	increased T cell number	J:260777
Ncf2^{tm1b(EUCOMM)Wtsi}/Ncf2^{tm1b(EUCOMM)Wtsi} (B6(Cg)-Ncf2^{tm1b(EUCOMM)Wtsi})	decreased CD8-positive, alpha-beta T cell number	J:260777
	increased susceptibility to fungal infection	J:260777
	lung inflammation	J:260777
Ncf2^{tm1b(EUCOMM)Wtsi}/Ncf2^{tm1b(EUCOMM)Wtsi} (NZM2328.B6(Cg)-Ncf2^{tm1b(EUCOMM)Wtsi})	abnormal spleen germinal center morphology	J:260777
	increased activated T cell number	J:260777
	increased anti-double stranded DNA antibody level	J:260777
	increased B cell number	J:260777
	increased follicular B cell number	J:260777
	increased germinal center B cell number	J:260777
	increased susceptibility to systemic lupus erythematosus	J:260777
	increased T cell number	J:260777
Ncf4^tm1Pth/Ncf4^tm2Pth (involves: 129P2/OlaHsd * C57BL/6)	abnormal neutrophil physiology	J:119217
	immune system phenotype	J:119217
	increased susceptibility to bacterial infection	J:119217
Ncf4^tm2Pth/Ncf4^tm2Pth (involves: 129P2/OlaHsd * C57BL/6)	abnormal neutrophil physiology	J:121820
Ncf4^tm2Pth/Ncf4^tm2Pth (involves: 129P2/OlaHsd * C57BL/6)	increased susceptibility to bacterial infection	J:121820
Nckap1l^m1Btlr/Nckap1l^m1Btlr (C57BL/6J-Nckap1l^m1Btlr)	decreased alpha-beta T cell number	J:272079
	decreased B cell number	J:272079
	decreased CD4-positive, alpha-beta T cell number	J:272079
	decreased CD8-positive, alpha-beta T cell number	J:272079
	decreased CD8-positive, naive alpha-beta T cell number	J:272079
	decreased central memory CD8 positive, alpha-beta T cell number	J:272079
	decreased NK cell number	J:272079
	increased alpha-beta T cell number	J:272079
	increased CD8-positive, alpha-beta T cell number	J:272079
	increased effector memory CD4-positive, alpha-beta T cell number	J:272079
	increased effector memory CD8-positive, alpha-beta T cell number	J:272079
Nckap1l^m1Iri/Nckap1l^m1Iri (involves: C57BL/6)	abnormal CD4-positive T cell differentiation	J:141377
	abnormal immune system organ morphology	J:141377
	abnormal lymphopoiesis	J:141377
	abnormal regulatory T cell number	J:141377
	abnormal thymus lobule morphology	J:141377
	decreased CD4-positive, alpha-beta T cell number	J:141377
	decreased CD8-positive, alpha-beta T cell number	J:141377
	decreased double-positive T cell number	J:141377
	decreased lymphocyte cell number	J:141377
	decreased mature B cell number	J:141377
	decreased mature gamma-delta T cell number	J:141377
	decreased T cell proliferation	J:141377
	heart inflammation	J:141377
	impaired macrophage phagocytosis	J:141377
	impaired neutrophil chemotaxis	J:141377
	impaired neutrophil phagocytosis	J:141377
	increased circulating interleukin-6 level	J:141377
	increased circulating interleukin-17 level	J:141377
	increased double-negative T cell number	J:141377
	increased interleukin-6 secretion	J:141377
	increased interleukin-17 secretion	J:141377
	increased leukocyte cell number	J:141377
	increased neutrophil cell number	J:141377
	increased tumor necrosis factor secretion	J:141377
	liver inflammation	J:141377
	lung inflammation	J:141377
	lymph node hypoplasia	J:141377
	spleen hyperplasia	J:141377
	thymus hypoplasia	J:141377
Ncoa1^tm1Bwo/Ncoa1^tm1Bwo (involves: 129 * C57BL/6J)	immune system phenotype	J:109522
Ncoa2^em1(IMPC)Mbp/Ncoa2⁺ (C57BL/6N-Ncoa2^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	increased neutrophil cell number	J:211773
Ncoa2^tm1.2Ipc/Ncoa2^tm1.2Ipc (involves: 129S2/SvPas * C57BL/6J)	immune system phenotype	J:109522
Ncoa3^tm1Jxu/Ncoa3^tm1Jxu (involves: 129S6/SvEvTac * C57BL/6J)	abnormal B cell morphology	J:109522
	abnormal lymphopoiesis	J:109522
	abnormal spleen red pulp morphology	J:109522
	decreased splenocyte apoptosis	J:109522
	enlarged spleen	J:109522
	increased B cell number	J:109522
	increased B cell proliferation	J:109522
	increased CD4-positive, alpha-beta T cell number	J:109522
	increased CD8-positive, alpha-beta T cell number	J:109522
	increased leukocyte cell number	J:109522
	increased lymphocyte cell number	J:109522
	increased spleen germinal center size	J:109522
	increased T cell proliferation	J:109522
Ncoa3^tm1Jxu/Ncoa3^tm1Jxu (involves: 129S6/SvEvTac * C57BL/6)	decreased interleukin-1 beta secretion	J:120086
	increased circulating interleukin-1 beta level	J:120086
	increased circulating interleukin-6 level	J:120086
	increased circulating tumor necrosis factor level	J:120086
	increased interleukin-6 secretion	J:120086
	increased susceptibility to bacterial infection induced morbidity/mortality	J:120086
	increased susceptibility to endotoxin shock	J:120086
	increased tumor necrosis factor secretion	J:120086
Ncoa5^{tm1.1(KOMP)Mbp}/Ncoa5⁺ (C57BL/6N-Ncoa5^{tm1.1(KOMP)Mbp}/Tcp)	increased eosinophil cell number	J:211773
Ncoa5^tm1Hxia/Ncoa5⁺ (involves: 129 * C57BL/6)	chronic liver inflammation	J:207622
Ncor1^tm1Rsd/Ncor1^tm1Rsd (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	arrested T cell differentiation	J:65417
	small thymus	J:65417
Ncor2^tm1Rev/Ncor2^tm1Rev (involves: 129/Sv * C57BL/6)	abnormal spleen morphology	J:202976
	enlarged spleen	J:202976
	increased osteoclast cell number	J:202976
Ncr1^m1J/Ncr1^m1J Pepc^b/Pepc^b Ptprc^a/Ptprc^a (B6.SJL-Ptprc^a Pepc^b/BoyJ)	abnormal interferon level	J:257226
	abnormal NK cell physiology	J:257226
	abnormal susceptibility to infection induced morbidity/mortality	J:257226
	decreased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:257226
	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:257226
Ncr1^noe/Ncr1^noe (involves: C57BL/6J)	abnormal NK cell physiology	J:179728
	decreased CD4-positive, alpha-beta T cell number	J:179728
	decreased CD8-positive, alpha-beta memory T cell number	J:179728
	decreased CD8-positive, alpha-beta T cell number	J:179728
	decreased susceptibility to Herpesvirales infection	J:179728
	decreased susceptibility to Herpesvirales infection induced morbidity/mortality	J:179728
	increased NK cell number	J:179728
	increased susceptibility to bacterial infection	J:179728
Ncr1^{tm1.1(icre)Viv}/Ncr1^{tm1.1(icre)Viv} (involves: C57BL/6)	abnormal NK cell physiology	J:179728
	decreased susceptibility to Herpesvirales infection induced morbidity/mortality	J:179728
	decreased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:179728
Ncr1^tm1Oman/Ncr1^tm1Oman (involves: 129S1/Sv * 129X1/SvJ)	decreased NK cell number	J:112394
	impaired natural killer cell mediated cytotoxicity	J:112394
	increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:112394
Ncr1^tm2.1Viv/Ncr1⁺ (involves: C57BL/6)	immune system phenotype	J:186000
Ncstn^tm1.1Akli/Ncstn^tm1.1Akli Tet2^tm1.1Iaai/Tet2^tm1.1Iaai Tg(VAV1-cre)1Graf/0 (involves: 129S/SvEv * C57BL/6)	enlarged spleen	J:196407
	increased leukocyte cell number	J:196407
	myeloid hyperplasia	J:196407
Ncstn^tm1.1Akli/Ncstn^tm1.1Akli Tg(Mx1-cre)1Cgn/0 (involves: 129 * C57BL/6 * CBA * SJL)	abnormal spleen morphology	J:172442
	enlarged spleen	J:172442
	increased leukocyte cell number	J:172442
	increased monocyte cell number	J:172442
	increased spleen red pulp amount	J:172442
Ncstn^tm1.1Akli/Ncstn^tm1.1Akli Tg(VAV1-cre)1Graf/0 (involves: 129 * C57BL/6 * SJL)	abnormal spleen morphology	J:172442
	enlarged spleen	J:172442
	increased leukocyte cell number	J:172442
	increased monocyte cell number	J:172442
	increased spleen red pulp amount	J:172442
Ncstn^tm1.1Akli/Ncstn^tm1.1Akli Tg(VAV1-cre)1Graf/0 (involves: 129)	abnormal splenocyte physiology	J:196407
	enlarged spleen	J:196407
Ndfip1^{Gt(RRD002)Byg}/Ndfip1^{Gt(RRD002)Byg} (involves: 129P2/OlaHsd * C57BL/6)	abnormal T cell physiology	J:116617
	abnormal T-helper 2 physiology	J:116617
	dermatitis	J:116617
	increased activated T cell number	J:116617
	increased inflammatory response	J:116617
	increased spleen weight	J:116617
	increased T cell proliferation	J:116617
	lung inflammation	J:116617
Ndfip1^{Gt(RRD002)Byg}/Ndfip1^{Gt(RRD002)Byg} (involves: 129P2/OlaHsd)	abnormal T cell physiology	J:205692
	increased activated T cell number	J:205692
	increased interleukin-2 secretion	J:205692
	increased T cell proliferation	J:205692
Ndfip1^{Gt(RRD002)Byg}/Ndfip1^{Gt(RRD002)Byg} Rag1^tm1Mom/Rag1^tm1Mom Tg(TcraTcrb)425Cbn/0 (involves: 129P2/OlaHsd * 129S7/SvEvBrd * BALB/c * C57BL/6)	immune system phenotype	J:205692
Ndfip1^kru/Ndfip1^kru (involves: C57BL/6JSfdAnu)	immune system phenotype	J:188722
Ndfip1^kru/Ndfip1^kru (involves: C57BL/6JSfdAnu)	increased T-helper 2 cell number	J:188722
Ndfip1^tm1.1Pmo/Ndfip1^tm1.1Pmo Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	esophageal inflammation	J:205692
	increased activated T cell number	J:205692
	increased eosinophil cell number	J:205692
	skin inflammation	J:205692
Ndor1^{Tg(UBC-cre/ERT2)1Ejb}/Ndor1⁺ Rnpc3^{tm1c(EUCOMM)Wtsi}/Rnpc3^{tm1c(EUCOMM)Wtsi} (involves: 129S/SvEv * C57BL/6 * C57BL/6N)	decreased leukocyte cell number	J:267519
	decreased lymphocyte cell number	J:267519
	decreased monocyte cell number	J:267519
	decreased thymus weight	J:267519
	esophageal inflammation	J:267519
	small intestinal inflammation	J:267519
	thymus atrophy	J:267519
	thymus cortex atrophy	J:267519
	thymus medulla atrophy	J:267519
Ndor1^{Tg(UBC-cre/ERT2)1Ejb}/Ndor1⁺ Rraga^tm2Dmsa/Rraga^tm2Dmsa (involves: 129S/SvEv * 129S4/SvJae * C57BL/6)	decreased B cell number	J:213516
	enlarged spleen	J:213516
	increased monocyte cell number	J:213516
	myeloid hyperplasia	J:213516
Ndrg2^tm1.1Hori/Ndrg2^tm1.1Hori (B6.129-Ndrg2^tm1.1Hori)	abnormal microglial cell chemotaxis	J:214686
	decreased inflammatory response	J:214686
	decreased interleukin-6 secretion	J:214686
Ndrg2^tm1Kmori/Ndrg2⁺ (involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj)	increased T cell derived lymphoma incidence	J:210264
Ndrg2^tm1Kmori/Ndrg2^tm1Kmori (involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj)	increased T cell derived lymphoma incidence	J:210264
Ndrg3^em1(IMPC)Mbp/Ndrg3⁺ (C57BL/6NCrl-Ndrg3^em1(IMPC)Mbp/Mmucd)	enlarged spleen	J:211773
Ndst1^b2b2230Clo/Ndst1^b2b2230Clo (C57BL/6J-Ndst1^b2b2230Clo)	thymus hypoplasia	J:175213
Ndst1^tm1Je/Ndst1^tm1Je Tg(Tek-cre)1Ywa/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)	abnormal leukocyte adhesion	J:100456
	abnormal leukocyte migration	J:100456
	decreased inflammatory response	J:100456
	impaired leukocyte tethering or rolling	J:100456
Ndst2^tm1Lkj/Ndst2^tm1Lkj (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal mast cell morphology	J:57121
	decreased mast cell degranulation	J:57121
	decreased mast cell histamine storage	J:57121
	decreased mast cell number	J:57121
	decreased mast cell protease storage	J:57121
Ndst2^tm1Rls/Ndst2^tm1Rls (Not Specified)	abnormal response to infection	J:57120
	decreased mast cell degranulation	J:57120
	decreased mast cell histamine storage	J:57120
	decreased mast cell protease storage	J:57120
Ndst2^tm1Rls/Ndst2^tm1Rls (B6.Cg-Ndst2^tm1Rls)	abnormal mast cell differentiation	J:142880
Ndst2^tm1Rls/Ndst2^tm1Rls (B6.Cg-Ndst2^tm1Rls)	decreased susceptibility to induced arthritis	J:142880
Ndst3^tm1.1Grob/Ndst3^tm1.1Grob (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)	decreased CD8-positive, alpha-beta T cell number	J:138557
	decreased lymphocyte cell number	J:138557
Ndufs4^tm1.1Rpa/Ndufs4^tm1.1Rpa (involves: 129S4/SvJaeSor)	microgliosis	J:161393
Ndufs4^tm1.1Rpa/Ndufs4^tm1.1Rpa (B6.129S4-Ndufs4^tm1.1Rpa)	microgliosis	J:190475
Ndufs4^tm1Rpa/Ndufs4^tm1Rpa (B6.129S4-Ndufs4^tm1Rpa)	microgliosis	J:190475
Ndufs4^tm1Rpa/Ndufs4^tm1Rpa Tg(Nes-cre)1Kln/0 (involves: 129S4/SvJaeSor * C57BL/6 * SJL)	microgliosis	J:161393
Ndufs4^tm1Rpa/Ndufs4^tm1Rpa Tg(Nes-cre)1Kln/0 (B6.Cg-Tg(Nes-cre)1Kln Ndufs4^tm1Rpa)	microgliosis	J:190475
Nectin4^em1Jaa/Nectin4^em1Jaa (involves: C57BL/6N)	decreased susceptibility to type I hypersensitivity reaction	J:336809
Nedd1^em1(IMPC)H/Nedd1⁺ (C57BL/6NTac-Nedd1^em1(IMPC)H/H)	increased eosinophil cell number	J:211773
Nedd4^Gt(XA209)Byg/Nedd4^Gt(XA209)Byg (involves: 129P2/OlaHsd)	abnormal T cell activation	J:143560
	decreased B cell number	J:143560
	decreased IgG1 level	J:143560
	decreased IgG2b level	J:143560
	decreased IgG3 level	J:143560
	decreased interleukin-2 secretion	J:143560
	decreased T cell proliferation	J:143560
	increased CD4-positive, alpha-beta T cell number	J:143560
	increased CD8-positive, alpha-beta T cell number	J:143560
	increased IgM level	J:143560
	increased T cell number	J:143560
Nedd4^Gt(XB398)Byg/Nedd4^Gt(XB398)Byg (involves: 129P2/OlaHsd)	decreased B cell number	J:143560
	decreased IgG1 level	J:143560
	decreased IgG2b level	J:143560
	decreased IgG3 level	J:143560
	decreased interleukin-2 secretion	J:143560
	decreased T cell proliferation	J:143560
	increased CD4-positive, alpha-beta T cell number	J:143560
	increased CD8-positive, alpha-beta T cell number	J:143560
	increased IgM level	J:143560
	increased T cell number	J:143560
Nedd4^{tm2b(EUCOMM)Hmgu}/Nedd4⁺ (C57BL/6N-Nedd4^{tm2b(EUCOMM)Hmgu}/H)	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
Nedd4l^tm1.1Hkb/Nedd4l^tm1.1Hkb Tg(SFTPC-rtTA)5Jaw/0 Tg(tetO-cre)1Jaw/0 (involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL)	lung inflammation	J:169296
Nedd4l^tm1Shkr/Nedd4l^tm1Shkr (involves: C57BL/6 * C57BL/6J)	increased neutrophil cell number	J:205657
	lung inflammation	J:205657
Nedd4l^tm1Shkr/Nedd4l^tm1Shkr (involves: 129 * C57BL/6 * C57BL/6J)	lung inflammation	J:205657
Nedd9^m1Btlr/Nedd9^m1Btlr (C57BL/6J-Nedd9^m1Btlr)	decreased B-1a cell number	J:267702
	decreased B-1b cell number	J:267702
	increased susceptibility to Herpesvirales infection	J:267702
Nedd9^tm1Miku/Nedd9^tm1Miku (B6.CBA-Nedd9^tm1Miku)	abnormal B cell number	J:116716
	abnormal follicular B cell physiology	J:116716
	abnormal leukocyte migration	J:116716
	abnormal T cell physiology	J:116716
	decreased lymphocyte cell number	J:116716
	decreased marginal zone B cell number	J:116716
	increased follicular B cell number	J:116716
	lymph node hypoplasia	J:116716
	spleen hypoplasia	J:116716
Neil1^tm1Rsld/Neil1^tm1Rsld (involves: 129S1/Sv * C57BL/6)	joint inflammation	J:106077
Neil2^tm1.1Tkhz/Neil2^tm1.1Tkhz (involves: 129S6/SvEvTac * C57BL/6J * C57BL/6NCrl)	increased neutrophil cell number	J:225791
	lung inflammation	J:225791
Neil3^tm1Bjor/Neil3^tm1Bjor (involves: 129 * C57BL/6)	decreased microglial cell activation	J:180177
Nek2^em1(IMPC)Tcp/Nek2^em1(IMPC)Tcp (C57BL/6NCrl-Nek2^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Nek7^M1Btlr/Nek7⁺ (C57BL/6J-Nek7^M1Btlr)	abnormal macrophage physiology	J:226677
	decreased inflammatory response	J:226677
	decreased interleukin-1 beta secretion	J:226677
	decreased interleukin-18 secretion	J:226677
	immune system phenotype	J:226677
Nek7^M1Btlr/Nek7^M1Btlr (C57BL/6J-Nek7^M1Btlr)	abnormal macrophage physiology	J:226677
	decreased inflammatory response	J:226677
	decreased interleukin-1 beta secretion	J:226677
	decreased interleukin-18 secretion	J:226677
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:226677
	immune system phenotype	J:226677
Nek8^m1Btlr/Nek8^m1Btlr (C57BL/6J-Nek8^m1Btlr)	decreased CD8-positive, alpha-beta T cell number	J:267544
	decreased effector memory CD4-positive, alpha-beta T cell number	J:267544
	decreased effector memory CD8-positive, alpha-beta T cell number	J:267544
	increased CD4-positive, alpha-beta T cell number	J:267544
	increased susceptibility to induced colitis	J:267544
Nek9^{tm1a(EUCOMM)Wtsi}/Nek9⁺ (C57BL/6N-Nek9^{tm1a(EUCOMM)Wtsi}/Wtsi)	increased leukocyte cell number	J:211773
Nelfa^em1(IMPC)Tcp/Nelfa⁺ (C57BL/6NCrl-Nelfa^em1(IMPC)Tcp/Tcp)	increased spleen weight	J:211773
Nell1^em1(IMPC)Mbp/Nell1^em1(IMPC)Mbp (C57BL/6N-Nell1^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
Nemp1^em1(IMPC)Mbp/Nemp1^em1(IMPC)Mbp (C57BL/6NCrl-Nemp1^em1(IMPC)Mbp/Mmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	increased spleen weight	J:211773
Nemp2^em1(IMPC)Tcp/Nemp2^em1(IMPC)Tcp (C57BL/6N-Nemp2^em1(IMPC)Tcp/Tcp)	abnormal spleen morphology	J:211773
Neu1^a/Neu1^a (SM/J)	abnormal Kupffer cell morphology	J:147881
Neu1^tm1Adz/Neu1^tm1Adz (either: (involves: 129S1/Sv * C57BL/6) or (involves: 129S1/Sv * NMRI))	abnormal Kupffer cell morphology	J:76937
	abnormal microglial cell morphology	J:76937
	enlarged spleen	J:76937
	spleen hyperplasia	J:76937
Neurl2^{tm1.1(KOMP)Vlcg}/Neurl2^{tm1.1(KOMP)Vlcg} (C57BL/6N-Neurl2^{tm1.1(KOMP)Vlcg}/J)	decreased leukocyte cell number	J:211773
Neurl3^em1Luda/Neurl3^em1Luda (B6N.Cg-Neurl3^em1Luda)	increased susceptibility to Riboviria infection	J:344721
Neurl3^em1Luda/Neurl3^em1Luda (B6N.Cg-Neurl3^em1Luda)	increased susceptibility to Riboviria infection induced morbidity/mortality	J:344721
Neurl4^em1(IMPC)Mbp/Neurl4^em1(IMPC)Mbp (C57BL/6NCrl-Neurl4^em1(IMPC)Mbp/Mmucd)	abnormal spleen morphology	J:211773
	decreased leukocyte cell number	J:211773
	enlarged spleen	J:211773
	small spleen	J:211773
Nexmif^em1(IMPC)Tcp/Y (C57BL/6N-Nexmif^em1(IMPC)Tcp/Tcp)	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
	increased monocyte cell number	J:211773
	small spleen	J:211773
Nexmif^em1(IMPC)Tcp/Nexmif⁺ (C57BL/6N-Nexmif^em1(IMPC)Tcp/Tcp)	increased neutrophil cell number	J:211773
Nf1^tm1.1Kest/Nf1^{tm1c(KOMP)Wtsi} Tg(Dhh-cre)1Mejr/0 (involves: 129S4/SvJaeSor * C57BL/6 * C57BL/6N * C57BL/6NTac * FVB/N)	dermatitis	J:234172
Nf1^{tm1c(KOMP)Wtsi}/Nf1^{tm1c(KOMP)Wtsi} Tg(Dhh-cre)1Mejr/0 (involves: 129S4/SvJaeSor * C57BL/6 * C57BL/6N * FVB/N)	dermatitis	J:234172
Nf1^tm1Fcr/Nf1⁺ Pten^tm1Hwu/Pten^tm1Hwu Tg(Mx1-cre)1Cgn/0 (B6.Cg-Tg(Mx1-cre)1Cgn Nf1^tm1Fcr Pten^tm1Hwu)	abnormal spleen morphology	J:232645
	decreased B cell number	J:232645
	decreased lymphocyte cell number	J:232645
	decreased T cell number	J:232645
	enlarged spleen	J:232645
	increased granulocyte number	J:232645
	increased leukocyte cell number	J:232645
	increased macrophage cell number	J:232645
	increased monocyte cell number	J:232645
	increased spleen weight	J:232645
Nf1^tm1Fcr/Nf1^tm1Fcr (either: (involves: 129S/SvEv) or (involves: 129S/SvEv * C57BL/6J))	abnormal lymphatic vessel morphology	J:18048
Nf1^tm1Fcr/Nf1^tm1Par Tg(Tek-cre)1Ywa/0 (involves: 129S/SvEv * 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)	abnormal spleen morphology	J:114455
	absent spleen germinal center	J:114455
	enlarged spleen	J:114455
	spleen fibrosis	J:114455
Nf1^tm1Par/Nf1^tm1Fcr Tg(GFAP-cre)#Gtm/0 (involves: 129S/SvEv * 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)	abnormal microglial cell morphology	J:165209
Nf1^tm1Par/Nf1^tm1Par Tg(Mx1-cre)1Cgn/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)	abnormal myeloid leukocyte morphology	J:90973
	abnormal myelopoiesis	J:90973
	abnormal spleen morphology	J:90973
	enlarged spleen	J:90973
	increased granulocyte number	J:90973
	increased leukocyte cell number	J:90973
	increased lymphocyte cell number	J:90973
	increased monocyte cell number	J:90973
	increased neutrophil cell number	J:90973
Nf1^tm1Par/Nf1^tm1Par Tg(Prrx1-cre)1Cjt/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * C57BL/6N * SJL/J)	increased osteoclast cell number	J:193350
Nf1^tm1Tyj/Nf1⁺ (involves: 129S2/SvPas)	abnormal mast cell physiology	J:142439
Nf1^tm1Tyj/Nf1⁺ (involves: 129S2/SvPas)	increased mast cell degranulation	J:142439
Nf1^tm1Tyj/Nf1⁺ Pak1^tm1Cher/Pak1^tm1Cher (involves: 129S2/SvPas * C57BL/6)	abnormal mast cell physiology	J:142439
Nf1^tm1Tyj/Nf1⁺ Trp53^tm1Tyj/Trp53⁺ (involves: 129S2/SvPas * C57BL/6)	spleen hyperplasia	J:228258
Nf2^tm1Gth/Nf2^tm2Gth Tg(Mpz-cre)2Brn/0 (involves: 129P2/OlaHsd * FVB/N)	increased susceptibility to otitis media	J:63264
Nf2^tm2Gth/Nf2^tm2Gth Tg(Mpz-cre)1Brn/0 (involves: 129P2/OlaHsd * FVB/N)	increased susceptibility to otitis media	J:63264
Nf2^tm2Gth/Nf2^tm2Gth Tg(Mpz-cre)2Brn/0 (involves: 129P2/OlaHsd * FVB/N)	increased susceptibility to otitis media	J:63264
Nf2^tm2Gth/Nf2^tm2Gth Trp53^tm1Brn/Trp53^tm1Brn (involves: 129P2/OlaHsd * 129S7/SvEvBrd)	increased T cell derived lymphoma incidence	J:132943
Nfam1^{em1(IMPC)Ccpcz}/Nfam1^{em1(IMPC)Ccpcz} (C57BL/6N-Nfam1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Nfat5^tm1.1Itl/Nfat5^tm1.1Itl Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6NTac * FVB/N)	abnormal lymphatic vessel morphology	J:201429
Nfat5^tm1.1Joar/Nfat5^tm1.1Joar Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2 * SJL)	abnormal T cell physiology	J:148271
Nfat5^tm1Rao/Nfat5^tm1Rao (B6.129-Nfat5^tm1Rao)	tubulointerstitial nephritis	J:88636
Nfat5^tm1Snh/Nfat5⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal immunoglobulin level	J:91482
	decreased IgG level	J:91482
	decreased T cell proliferation	J:91482
	spleen hypoplasia	J:91482
	thymus hypoplasia	J:91482
Nfatc1^tm1.1Fbs/Nfatc1^tm1.1Fbs (C57BL/6-Nfatc1^tm1.1Fbs)	decreased interferon-gamma secretion	J:305649
	decreased interleukin-17 secretion	J:305649
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:305649
	decreased susceptibility to graft versus host disease	J:305649
	immune system phenotype	J:305649
	increased interleukin-2 secretion	J:305649
	increased regulatory T cell number	J:305649
Nfatc1^tm1Glm/Nfatc1^tm2Glm (chimera involves: 129S2/SvPas)	abnormal B cell physiology	J:78376
	abnormal immune system physiology	J:78376
	abnormal immunoglobulin level	J:78376
	abnormal interferon-gamma secretion	J:78376
	abnormal interleukin-2 secretion	J:78376
	abnormal lymphocyte cell number	J:78376
	abnormal lymphocyte physiology	J:78376
	abnormal T cell physiology	J:78376
	abnormal T-helper 2 physiology	J:78376
	decreased double-positive T cell number	J:78376
	decreased IgE level	J:78376
	decreased IgG1 level	J:78376
	decreased IgG2b level	J:78376
	decreased IgG3 level	J:78376
	decreased immunoglobulin level	J:78376
	decreased interleukin-4 secretion	J:78376
	decreased lymphocyte cell number	J:78376
	increased double-negative T cell number	J:78376
	increased IgA level	J:78376
	increased IgG2a level	J:78376
	increased IgM level	J:78376
	increased immunoglobulin level	J:78376
Nfatc1^tm1Rao/Nfatc1^tm1Rao Cd79a^tm1(cre)Reth/Cd79a⁺ (involves: BALB/c)	abnormal B cell calcium ion homeostasis	J:177319
	abnormal class switch recombination	J:177319
	abnormal marginal zone B cell physiology	J:177319
	decreased B cell number	J:177319
	decreased B cell proliferation	J:177319
	decreased B-1a cell number	J:177319
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:177319
	increased B cell apoptosis	J:177319
Nfatc1^tm1Rao/Nfatc1^tm1Rao Nfatc2^tm1Rao/Nfatc2^tm1Rao Cd79a^tm1(cre)Reth/Cd79a⁺ (involves: BALB/c)	abnormal B cell physiology	J:177319
	decreased interleukin-2 secretion	J:177319
Nfatc1^tm1Rao/Nfatc1^tm1Rao Tg(Fcer2a-cre)5Mbu/0 (involves: C57BL/6 * CBA)	abnormal B cell physiology	J:177319
	abnormal class switch recombination	J:177319
	decreased B cell proliferation	J:177319
	decreased IgG2a level	J:177319
	decreased IgG3 level	J:177319
	decreased IgM level	J:177319
	decreased interleukin-2 secretion	J:177319
	increased IgM level	J:177319
	increased interleukin-10 secretion	J:177319
Nfatc1^tm3Glm/Nfatc1^tm3Glm Sh3bp2^tm1Bjro/Sh3bp2^tm1Bjro Tg(Mx1-cre)1Cgn/0 (involves: 129S4/SvJae * C57BL/6 * CBA)	abnormal osteoclast differentiation	J:144598
	decreased osteoclast cell number	J:144598
	liver inflammation	J:144598
	lung inflammation	J:144598
	lymph node inflammation	J:144598
	stomach inflammation	J:144598
Nfatc1^tm3Glm/Nfatc1^tm3Glm Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA)	abnormal osteoclast differentiation	J:144598
	decreased osteoclast cell number	J:144598
Nfatc2^m1Anu/Nfatc2^m1Anu (C57BL/6NCrl-Nfatc2^m1Anu/Anu)	immune system phenotype	J:104190
Nfatc2^tm1Glm/Nfatc2^tm1Glm Nfatc3^{tm1c(EUCOMM)Hmgu}/Nfatc3^{tm1c(EUCOMM)Hmgu} Tg(Itgax-cre)1-1Reiz/0 (involves: C57BL/6 * C57BL/6N * CBA)	decreased interleukin-2 secretion	J:346703
Nfatc2^tm1Glm/Nfatc2^tm1Glm Nfatc3^tm1Glm/Nfatc3^tm1Glm (involves: 129S2/SvPas)	abnormal lymph node morphology	J:51339
	abnormal lymphocyte cell number	J:51339
	blepharitis	J:51339
	decreased T cell number	J:51339
	enlarged spleen	J:51339
	increased B cell number	J:51339
	increased inflammatory response	J:51339
	increased T cell number	J:51339
	interstitial pneumonia	J:51339
Nfatc2^tm1Rao/Nfatc2^tm1Rao (B6.Cg-Nfatc2^tm1Rao)	abnormal mast cell physiology	J:78089
	decreased interleukin-4 secretion	J:78089
	decreased interleukin-13 secretion	J:78089
	decreased tumor necrosis factor secretion	J:78089
Nfatc2^tm1Rao/Nfatc2^tm1Rao Nfatc3^tm1Grc/Nfatc3^tm1Grc Tg(Lck-cre)I57Jxm/0 (involves: ICR)	abnormal double-negative T cell morphology	J:141917
	abnormal T cell differentiation	J:141917
	increased T cell apoptosis	J:141917
Nfatc2^tm1Srf/Nfatc2^tm1Srf (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell number	J:110686
	abnormal B cell physiology	J:110686
	abnormal lymph node B cell domain morphology	J:110686
	abnormal lymphocyte physiology	J:110686
	abnormal spleen germinal center morphology	J:110686
	abnormal T cell physiology	J:110686
	abnormal thymus involution	J:110686
	enlarged spleen	J:110686
	enlarged thymus	J:110686
	increased activated T cell number	J:110686
	thymus hyperplasia	J:110686
Nfatc2^tm1Srf/Nfatc2^tm1Srf (involves: 129P2/OlaHsd)	abnormal immune system organ morphology	J:45252
	abnormal immune system physiology	J:45252
	abnormal interleukin secretion	J:45252
	abnormal lymph node morphology	J:45252
	abnormal T cell physiology	J:45252
	enlarged lymph nodes	J:45252
	enlarged spleen	J:45252
	increased B cell number	J:45252
	increased lymphocyte cell number	J:45252
	increased T cell number	J:45252
	lymph node hyperplasia	J:45252
Nfatc2^tm1Srf/Nfatc2^tm1Srf (B6.Cg-Nfatc2^tm1Srf)	abnormal CD4-positive, alpha-beta T cell physiology	J:86279
	abnormal T-helper 1 physiology	J:86279
	abnormal T-helper 2 physiology	J:86279
	decreased interferon-gamma secretion	J:86279
	increased IgE level	J:86279
	increased IgG1 level	J:86279
	increased immunoglobulin level	J:86279
	increased interleukin-4 secretion	J:86279
	increased interleukin-5 secretion	J:86279
Nfatc2ip^em1(IMPC)Ics/Nfatc2ip^em1(IMPC)Ics (C57BL/6N-Nfatc2ip^em1(IMPC)Ics/Ics)	increased eosinophil cell number	J:211773
Nfatc2ip^tm1.1Glm/Nfatc2ip^tm1.1Glm (either: B6.129-Nfatc2ip^tm1.1Glm or C.129-Nfatc2ip^tm1.1Glm)	abnormal interleukin secretion	J:157559
	abnormal leukocyte morphology	J:157559
	abnormal T-helper 2 physiology	J:157559
	decreased circulating interleukin-4 level	J:157559
	decreased interferon-gamma secretion	J:157559
	decreased interleukin-3 secretion	J:157559
	decreased interleukin-4 secretion	J:157559
	decreased interleukin-5 secretion	J:157559
	decreased interleukin-13 secretion	J:157559
	decreased mast cell number	J:157559
	decreased T-helper 2 cell number	J:157559
	increased susceptibility to parasitic infection	J:157559
Nfatc3^tm1.1Grc/Nfatc3^tm1.1Grc (involves: C57BL/6)	immune system phenotype	J:141917
Nfatc3^tm1.1Grc/Nfatc3^tm1.1Grc (involves: C57BL/6)	lymph node hypoplasia	J:141917
Nfatc3^tm1Glm/Nfatc3^tm1Glm Tg(DO11.10)10Dlo/? (involves: 129S2/SvPas * BALB/c * C3H * C57BL/6)	decreased double-positive T cell number	J:50124
	increased double-negative T cell number	J:50124
	small thymus	J:50124
Nfatc3^tm1Grc/Nfatc3^tm1Grc Tg(Lck-cre)I57Jxm/0 (involves: ICR)	abnormal T cell differentiation	J:141917
	decreased CD4-positive, alpha-beta T cell number	J:141917
	decreased CD8-positive, alpha-beta T cell number	J:141917
	decreased thymocyte number	J:141917
	increased double-negative T cell number	J:141917
	increased T cell apoptosis	J:141917
	lymph node hypoplasia	J:141917
	thymus hypoplasia	J:141917
Nfe2^{em1(IMPC)Ccpcz}/Nfe2⁺ (C57BL/6NCrl-Nfe2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
Nfe2^tm1Sho/Nfe2⁺ (C.129S4-Nfe2^tm1Sho)	enlarged spleen	J:125982
Nfe2^tm1Sho/Nfe2⁺ (C.129S4-Nfe2^tm1Sho)	increased susceptibility to Retroviridae infection	J:125982
Nfe2^tm1Sho/Nfe2^tm1Sho (involves: 129/Sv * 129S4/SvJae)	increased osteoclast cell number	J:111270
Nfe2l1^tm1Jefc/Nfe2l1^tm1Ywk Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺ (involves: 129X1/SvJ * C57BL/6J)	liver inflammation	J:97188
Nfe2l2^{em1(IMPC)Ccpcz}/Nfe2l2^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Nfe2l2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged thymus	J:211773
Nfe2l2^tm1.1Sred/Nfe2l2^tm1.1Sred Tg(Scgb1a1-cre)1Grau/0 (involves: C57BL/6 * C57BL/6J)	decreased interleukin-1 beta secretion	J:191916
	decreased tumor necrosis factor secretion	J:191916
Nfe2l2^tm1Mym/Nfe2l2^tm1Mym (involves: 129P2/OlaHsd * ICR)	abnormal macrophage physiology	J:118068
	decreased CD4-positive, alpha-beta T cell number	J:104016
	decreased T cell number	J:104016
	enlarged lymph nodes	J:104016
	glomerulonephritis	J:104016
	increased anti-double stranded DNA antibody level	J:104016
	increased anti-nuclear antigen antibody level	J:104016
	increased IgG level	J:104016
	increased IgM level	J:104016
	increased spleen weight	J:104016
	lung inflammation	J:118068
Nfe2l2^tm1Mym/Nfe2l2^tm1Mym (involves: 129P2/OlaHsd * C57BL/6J)	increased susceptibility to induced colitis	J:116676
Nfe2l2^tm1Mym/Nfe2l2^tm1Mym (involves: 129P2/OlaHsd * CD-1)	increased acute inflammation	J:122813
Nfe2l2^tm1Mym/Nfe2l2^tm1Mym (involves: 129P2/OlaHsd * C57BL/6)	abnormal leukocyte adhesion	J:150597
	increased circulating interleukin-6 level	J:136120
	increased circulating tumor necrosis factor level	J:136120
	increased susceptibility to experimental autoimmune uveoretinitis	J:150597
	liver inflammation	J:136120
Nfe2l2^tm1Ywk/Nfe2l2^tm1Ywk (involves: 129X1/SvJ)	abnormal spleen physiology	J:91407
	abnormal splenocyte physiology	J:91407
	decreased circulating interleukin-1 beta level	J:100106
	enlarged spleen	J:91407
	increased circulating interleukin-1 beta level	J:100106
	increased macrophage cell number	J:100106
	increased spleen weight	J:91407
	increased splenocyte apoptosis	J:91407
Nfe2l2^tm1Ywk/Nfe2l2^tm1Ywk (B6.129X1-Nfe2l2^tm1Ywk/J)	abnormal neutrophil physiology	J:233699
Nfe2l2^tm1Ywk/Nfe2l2^tm1Ywk (B6.129X1-Nfe2l2^tm1Ywk/J)	increased cytokine level	J:367804
Nfe2l2^tm1Ywk/Nfe2l2^tm1Ywk (B6.129X1-Nfe2l2^tm1Ywk)	increased anti-double stranded DNA antibody level	J:165602
Nfic^{em1(IMPC)Ccpcz}/Nfic^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Nfic^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
Nfil3^{tm1.1(KOMP)Vlcg}/Nfil3^{tm1.1(KOMP)Vlcg} (C57BL/6N-Nfil3^{tm1.1(KOMP)Vlcg}/Ucd)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	increased spleen weight	J:211773
	small thymus	J:211773
Nfil3^tm1.1Brad/Nfil3⁺ (B6.Cg-Nfil3^tm1.1Brad)	decreased NK cell number	J:152774
Nfil3^tm1.1Brad/Nfil3^tm1.1Brad (B6.Cg-Nfil3^tm1.1Brad)	abnormal NK cell differentiation	J:152774
	decreased interferon-gamma secretion	J:152774
	decreased NK cell number	J:152774
	immune system phenotype	J:152774
	impaired natural killer cell mediated cytotoxicity	J:152774
	increased memory T cell number	J:152774
	increased NK T cell number	J:152774
Nfil3^tm1.1Kubo/Nfil3^tm1.1Kubo (B6.Cg-Nfil3^tm1.1Kubo)	abnormal interleukin secretion	J:184570
	decreased interleukin-9 secretion	J:184570
	decreased interleukin-10 secretion	J:172134, J:184570
	decreased interleukin-13 secretion	J:172134, J:184570
	decreased interleukin-17 secretion	J:184570
	increased susceptibility to experimental autoimmune encephalomyelitis	J:172134
	increased susceptibility to induced colitis	J:172134
Nfil3^tm1.2Kubo/Nfil3^tm1.2Kubo Tg(Itgax-cre)1-1Reiz/0 (involves: 129 * C57BL/6 * CBA)	immune system phenotype	J:334296
Nfil3^tm1Look/Nfil3^tm1Look (B6.129X1-Nfil3^tm1Look)	abnormal NK cell differentiation	J:155677
	decreased interferon-gamma secretion	J:155677
	decreased NK cell number	J:155677
	impaired natural killer cell mediated cytotoxicity	J:155677
Nfil3^tm1Look/Nfil3^tm1Look (involves: 129X1/SvJ)	immune system phenotype	J:209365
Nfil3^tm1Pbro/Nfil3^tm1Pbro (involves: 129S6/SvEvTac * C57BL/6)	abnormal class switch recombination	J:156521
	decreased IgE level	J:156521
	decreased IgG1 level	J:156521
	decreased interleukin-4 secretion	J:156521
	immune system phenotype	J:156521
Nfil3^tm1Pbro/Nfil3^tm1Pbro (B6.129S6-Nfil3^tm1Pbro)	abnormal circulating cytokine level	J:209365
	abnormal cytokine secretion	J:209365
	abnormal leukocyte morphology	J:209365
	abnormal plasma cell morphology	J:209365
	colitis	J:209365
	decreased NK cell number	J:209365
	increased circulating interferon-gamma level	J:209365
	increased circulating interleukin-10 level	J:209365
	increased circulating interleukin-12b level	J:209365
	increased circulating interleukin-17 level	J:209365
	increased circulating tumor necrosis factor level	J:209365
	increased interferon-gamma secretion	J:209365
	increased interleukin-10 secretion	J:209365
	increased interleukin-12b secretion	J:209365
	increased interleukin-17 secretion	J:209365
	increased macrophage cytokine production	J:209365
	increased T-helper 17 cell number	J:209365
	increased tumor necrosis factor secretion	J:209365
Nfil3^tm1Pbro/Nfil3^tm1Pbro Rag1^tm1Mom/Rag1^tm1Mom (involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6)	immune system phenotype	J:209365
Nfkb1^M1Btlr/Nfkb1⁺ (C57BL/6J-Nfkb1^M1Btlr)	decreased IgG level	J:216054
Nfkb1^M1Btlr/Nfkb1⁺ (C57BL/6J-Nfkb1^M1Btlr)	impaired humoral immune response	J:216054
Nfkb1^M1Btlr/Nfkb1^M1Btlr (C57BL/6J-Nfkb1^M1Btlr)	decreased IgG level	J:216054
Nfkb1^M1Btlr/Nfkb1^M1Btlr (C57BL/6J-Nfkb1^M1Btlr)	impaired humoral immune response	J:216054
Nfkb1^m2Btlr/Nfkb1⁺ (C57BL/6J-Nfkb1^m2Btlr)	abnormal humoral immune response	J:254822
	decreased central memory CD4-positive, alpha-beta T cell number	J:254822
	decreased effector memory CD4-positive, alpha-beta T cell number	J:254822
	decreased IgM level	J:254822
Nfkb1^m2Btlr/Nfkb1^m2Btlr (C57BL/6J-Nfkb1^m2Btlr)	abnormal humoral immune response	J:254822
	decreased CD8-positive, naive alpha-beta T cell number	J:254822
	decreased central memory CD4-positive, alpha-beta T cell number	J:254822
	decreased effector memory CD4-positive, alpha-beta T cell number	J:254822
	decreased IgE level	J:254822
	decreased IgG level	J:254822
	decreased IgM level	J:254822
	increased central memory CD8 positive, alpha-beta T cell number	J:254822
Nfkb1^M3Btlr/Nfkb1⁺ (C57BL/6J-Nfkb1^M3Btlr)	abnormal humoral immune response	J:254821
	decreased IgE level	J:254821
	decreased IgG level	J:254821
	increased central memory CD8 positive, alpha-beta T cell number	J:254821
Nfkb1^M3Btlr/Nfkb1^M3Btlr (C57BL/6J-Nfkb1^M3Btlr)	abnormal humoral immune response	J:254821
	decreased IgE level	J:254821
	decreased IgG level	J:254821
	increased central memory CD8 positive, alpha-beta T cell number	J:254821
	increased susceptibility to induced colitis	J:254821
Nfkb1^M4Btlr/Nfkb1^M4Btlr (C57BL/6J-Nfkb1^M4Btlr)	decreased B-1 B cell number	J:265169
Nfkb1^M5Btlr/Nfkb1^M5Btlr (C57BL/6J-Nfkb1^M5Btlr)	decreased B-1a cell number	J:272117
	decreased IgE level	J:272117
	decreased interleukin-1 beta secretion	J:272117
Nfkb1^M6Btlr/Nfkb1^M6Btlr (C57BL/6J-Nfkb1^M6Btlr)	decreased IgE level	J:272148
Nfkb1^{tm1a(KOMP)Wtsi}/Nfkb1^{tm1a(KOMP)Wtsi} (B6JTyr;B6N-Nfkb1^{tm1a(KOMP)Wtsi}/Wtsi)	increased leukocyte cell number	J:175295, J:165965
Nfkb1^{tm1a(KOMP)Wtsi}/Nfkb1^{tm1a(KOMP)Wtsi} (involves: C57BL/6 * C57BL/6N)	decreased IgA level	J:213427
	decreased IgG1 level	J:213427
	decreased NK cell number	J:213427
	decreased regulatory T cell number	J:213427
	increased leukocyte cell number	J:213427
	increased susceptibility to bacterial infection	J:213427
	lymphoid hyperplasia	J:213427
Nfkb1^tm1Bal/Nfkb1^tm1Bal (B6;129P-Nfkb1^tm1Bal/J)	abnormal CD4-positive, alpha-beta T cell physiology	J:118907
	abnormal cytokine secretion	J:79107
	abnormal dendritic cell physiology	J:118907
	abnormal macrophage physiology	J:118907
	abnormal professional antigen presenting cell physiology	J:118907
	decreased susceptibility to autoimmune diabetes	J:118907
	immune system phenotype	J:118907
Nfkb1^tm1Bal/Nfkb1^tm1Bal (involves: 129P2/OlaHsd * C57BL/6)	abnormal class switch recombination	J:30268
	abnormal humoral immune response	J:37184
	abnormal Peyer's patch follicle morphology	J:77049
	abnormal Peyer's patch germinal center morphology	J:77049
	abnormal Peyer's patch T cell area morphology	J:77049
	cecum inflammation	J:67107
	decreased B cell proliferation	J:37184, J:30268
	decreased IgA level	J:37184
	decreased IgE level	J:37184
	decreased IgG1 level	J:37184
	decreased IgM level	J:30268
	decreased immunoglobulin level	J:37184
	decreased interleukin-6 secretion	J:37184
	decreased myeloid dendritic cell number	J:77049
	decreased Peyer's patch number	J:77049
	decreased susceptibility to Picornaviridae infection induced morbidity/mortality	J:37184
	increased susceptibility to bacterial infection	J:37184, J:67107
	increased susceptibility to bacterial infection induced morbidity/mortality	J:37184
	large intestinal inflammation	J:67107
	peritoneal inflammation	J:67107
	small Peyer's patches	J:77049
Nfkb1^tm1Bal/Nfkb1^tm1Bal (involves: 129P2/OlaHsd)	decreased marginal zone B cell number	J:65246
Nfkb1^tm1Bal/Nfkb1^tm1Bal (involves: 129P2/OlaHsd)	immune system phenotype	J:113514
Nfkb1^tm1Bal/Nfkb1^tm1Bal (B6.Cg-Nfkb1^tm1Bal/J)	abnormal B cell physiology	J:113556
Nfkb1^tm1Bal/Nfkb1^tm1Bal Nfkb2^tm1Sbn/Nfkb2^tm1Sbn (involves: 129P2/OlaHsd * 129S4/SvJae)	abnormal immune system organ morphology	J:45119
	abnormal macrophage physiology	J:45119
	abnormal osteoclast differentiation	J:45119
	abnormal spleen morphology	J:45119
	abnormal thymus cortex morphology	J:45119
	abnormal thymus medulla morphology	J:45119
	absent lymph nodes	J:45119
	absent spleen white pulp	J:45119
	arrested B cell differentiation	J:45119
	decreased B cell number	J:45119
	decreased CD4-positive, alpha-beta T cell number	J:45119
	decreased CD8-positive, alpha-beta T cell number	J:45119
	decreased dendritic cell number	J:45119
	decreased double-positive T cell number	J:45119
	decreased mature B cell number	J:45119
	decreased osteoclast cell number	J:45119
	decreased single-positive T cell number	J:45119
	decreased T cell number	J:45119
	increased granulocyte number	J:45119
	increased macrophage cell number	J:45119
	thymus hypoplasia	J:45119
Nfkb1^tm1Bal/Nfkb1^tm1Bal Rel^tm1Grd/Rel^tm1Grd (involves: 129P2/OlaHsd * 129S1/Sv)	abnormal immune system physiology	J:113514
	decreased interleukin-12 secretion	J:113514
Nfkb1^tm1Bal/Nfkb1^tm1Bal Rela^tm1Bal/Rela⁺ (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)	cecum inflammation	J:67107
	increased susceptibility to bacterial infection	J:67107
	large intestinal inflammation	J:67107
	peritoneal inflammation	J:67107
Nfkb1^tm1Bal/Nfkb1^tm1Bal Rela^tm1Bal/Rela^tm1Bal (involves: 129P2/OlaHsd * 129S4/SvJae)	abnormal dendritic cell differentiation	J:113514
	decreased dendritic cell number	J:113514
Nfkb1^tm1Bal/Nfkb1^tm1Bal Tg(Tnfsf13b)1Fma/? (B6.Cg-Nfkb1^tm1Bal Tg(Tnfsf13b)1Fma)	abnormal B cell activation	J:113556
	abnormal class switch recombination	J:113556
	decreased marginal zone B cell number	J:113556
	immune system phenotype	J:113556
	increased transitional stage B cell number	J:113556
Nfkb1^tm1Brv/Nfkb1^tm1Brv (involves: 129S1/Sv)	abnormal cytokine secretion	J:46912
	abnormal humoral immune response	J:46912
	abnormal inflammatory response	J:46912
	abnormal lymph organ size	J:46912
	abnormal lymphocyte physiology	J:46912
	decreased IgG3 level	J:46912
	decreased interleukin-2 secretion	J:46912
	decreased interleukin-4 secretion	J:46912
	decreased single-positive T cell number	J:46912
	decreased T cell proliferation	J:46912
	decreased tumor necrosis factor secretion	J:46912
	enlarged lymph nodes	J:46912
	enlarged spleen	J:46912
	increased B cell proliferation	J:46912
	increased IgE level	J:46912
	increased IgG1 level	J:46912
	increased immunoglobulin level	J:46912
	increased susceptibility to bacterial infection	J:46912
	liver inflammation	J:46912
	lung inflammation	J:46912
	myeloid hyperplasia	J:46912
Nfkb1^tm1Brv/Nfkb1^tm1Brv (involves: 129S1/Sv * C57BL/6)	decreased osteoclast cell number	J:44112
Nfkb1^tm1Brv/Nfkb1^tm1Brv Nfkb2^tm1Brv/Nfkb2⁺ (involves: 129S1/Sv * C57BL/6)	abnormal osteoclast differentiation	J:44112
	decreased osteoclast cell number	J:44112
Nfkb1^tm1Brv/Nfkb1^tm1Brv Nfkb2^tm1Brv/Nfkb2^tm1Brv (involves: 129S1/Sv * C57BL/6)	abnormal cytokine secretion	J:44112
	abnormal osteoclast differentiation	J:44112
	decreased interleukin-6 secretion	J:44112
	decreased osteoclast cell number	J:44112
	increased macrophage cell number	J:44112
Nfkb1^tm1Sley/Nfkb1^tm1Sley (involves: 129S4/SvJae * 129S8/SvEv)	abnormal inguinal lymph node morphology	J:142340
	absent inguinal lymph nodes	J:142340
	decreased circulating interleukin-2 level	J:142340
	decreased memory T cell number	J:142340
	decreased regulatory T cell number	J:142340
	decreased T cell proliferation	J:142340
	small inguinal lymph nodes	J:142340
Nfkb1^tm1Sley/Nfkb1^tm1Sley (involves: 129S4/SvJae * 129S8/SvEv * C57BL/6)	decreased memory T cell number	J:142340
	decreased NK T cell number	J:142340
	decreased regulatory T cell number	J:142340
Nfkb1^tm1Sley/Nfkb1^tm1Sley (involves: 129S4/SvJae)	decreased tumor necrosis factor secretion	J:196528
Nfkb2^Lym1/Nfkb2⁺ (BALB/c-Nfkb2^Lym1)	abnormal lymph node morphology	J:154812
	abnormal mesenteric lymph node morphology	J:154812
	abnormal spleen white pulp morphology	J:154812
	absent axillary lymph nodes	J:154812
	absent brachial lymph nodes	J:154812
	absent cervical lymph nodes	J:154812
	absent inguinal lymph nodes	J:154812
	absent Peyer's patches	J:154812
	decreased lymph node number	J:154812
	increased lymphocyte cell number	J:154812
	liver inflammation	J:154812
	lung inflammation	J:154812
Nfkb2^Lym1/Nfkb2⁺ (involves: BALB/c)	abnormal B cell differentiation	J:188560
Nfkb2^Lym1/Nfkb2⁺ Otub1^{tm1c(EUCOMM)Hmgu}/Otub1^{tm1c(EUCOMM)Hmgu} Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129P2/OlaHsd * BALB/c * C57BL/6 * C57BL/6N)	immune system phenotype	J:280549
Nfkb2^Lym1/Nfkb2^Lym1 (involves: BALB/c)	abnormal class switch recombination	J:154812
	abnormal lymph node morphology	J:154812
	abnormal osteoclast differentiation	J:154812
	abnormal peripheral lymph node morphology	J:154812
	abnormal plasma cell differentiation	J:154812
	abnormal spleen follicular dendritic cell network	J:154812
	abnormal spleen periarteriolar lymphoid sheath morphology	J:154812
	abnormal spleen primary B follicle morphology	J:154812
	abnormal spleen white pulp morphology	J:154812
	abnormal T cell differentiation	J:154812
	abnormal thymus cell ratio	J:154812
	abnormal thymus physiology	J:154812
	abnormal thymus size	J:154812
	absent axillary lymph nodes	J:154812
	absent brachial lymph nodes	J:154812
	absent cervical lymph nodes	J:154812
	absent inguinal lymph nodes	J:154812
	absent mesenteric lymph nodes	J:154812
	absent Peyer's patches	J:154812
	autoimmune response	J:154812
	decreased B cell proliferation	J:154812
	decreased follicular B cell number	J:154812
	decreased IgA level	J:154812
	decreased IgG1 level	J:154812
	decreased IgG2b level	J:154812
	decreased IgM level	J:154812
	decreased immunoglobulin level	J:154812
	decreased lymph node number	J:154812
	decreased marginal zone B cell number	J:154812
	decreased mature B cell number	J:154812
	decreased transitional stage B cell number	J:154812
	enlarged spleen	J:154812
	increased CD4-positive, alpha-beta T cell number	J:154812
	increased CD8-positive, alpha-beta T cell number	J:154812
	increased double-negative T cell number	J:154812
	increased double-positive T cell number	J:154812
	increased spleen red pulp amount	J:154812
	increased spleen weight	J:154812
	increased transitional stage B cell number	J:154812
	liver inflammation	J:154812
	lung inflammation	J:154812
Nfkb2^m2Btlr/Nfkb2^m2Btlr (C57BL/6J-Nfkb2^m2Btlr)	increased B-1a cell number	J:221493
Nfkb2^m3Btlr/Nfkb2^m3Btlr (C57BL/6J-Nfkb2^m3Btlr)	abnormal B cell differentiation	J:274960
	abnormal CD4-positive T cell differentiation	J:274960
	abnormal CD8-positive, alpha-beta T cell differentiation	J:274960
	abnormal T cell differentiation	J:274960
	decreased B cell number	J:274960
	decreased CD4-positive, alpha-beta T cell number	J:274960
	decreased effector memory CD8-positive, alpha-beta T cell number	J:274960
	decreased NK cell number	J:274960
	increased B-1 B cell number	J:274960
	increased CD4-positive, alpha-beta T cell number	J:274960
	increased CD8-positive, alpha-beta T cell number	J:274960
	increased CD8-positive, naive alpha-beta T cell number	J:274960
	increased T cell number	J:274960
Nfkb2^M4Btlr/Nfkb2^M4Btlr (C57BL/6J-Nfkb2^M4Btlr)	increased CD4-positive, alpha-beta T cell number	J:274961
	increased CD8-positive, alpha-beta T cell number	J:274961
	increased T cell number	J:274961
Nfkb2^m5Btlr/Nfkb2^m5Btlr (C57BL/6J-Nfkb2^m5Btlr)	increased B-1 B cell number	J:274962
Nfkb2^tm1Brv/Nfkb2^tm1Brv (involves: 129S1/Sv * C57BL/6)	abnormal cytokine secretion	J:43469
	abnormal lymph node B cell domain morphology	J:43469
	abnormal lymph node cortex morphology	J:43469
	abnormal lymphocyte cell number	J:43469
	abnormal T cell number	J:43469
	abnormal T cell subpopulation ratio	J:43469
	abnormal thymus corticomedullary boundary morphology	J:43469
	decreased double-positive T cell number	J:43469
	decreased spleen weight	J:43469
	enlarged lymph nodes	J:43469
	increased B cell proliferation	J:43469
	increased granulocyte number	J:43469
	increased interleukin-2 secretion	J:43469
	increased interleukin-4 secretion	J:43469
	increased interleukin-10 secretion	J:43469
	increased T cell proliferation	J:43469
	increased tumor necrosis factor secretion	J:43469
	intermingled spleen red and white pulp	J:43469
	spleen atrophy	J:43469
	spleen hypoplasia	J:43469
	thymus atrophy	J:43469
Nfkb2^tm1Rsch/Nfkb2^tm1Rsch (involves: 129P2/OlaHsd)	abnormal myeloid dendritic cell morphology	J:77049
	abnormal Peyer's patch follicle morphology	J:77049
	abnormal Peyer's patch germinal center morphology	J:77049
	abnormal Peyer's patch morphology	J:77049
	abnormal Peyer's patch T cell area morphology	J:77049
	decreased B cell number	J:77049
	decreased dendritic cell number	J:77049
	decreased myeloid dendritic cell number	J:77049
	increased plasmacytoid dendritic cell number	J:77049
	small Peyer's patches	J:77049
Nfkb2^tm1Sbn/Nfkb2^tm1Sbn (involves: 129S4/SvJae * C57BL/6)	abnormal class switch recombination	J:45437
	abnormal immunoglobulin level	J:45437
	abnormal lymphocyte cell number	J:45437
	abnormal metallophilic macrophage morphology	J:45437
	abnormal spleen B cell follicle morphology	J:45437
	abnormal spleen marginal zone macrophage morphology	J:45437
	abnormal spleen marginal zone morphology	J:45437
	abnormal spleen white pulp morphology	J:45437
	absent spleen germinal center	J:45437
	decreased B cell number	J:45437
	decreased IgA level	J:45437
	decreased IgG1 level	J:45437
	decreased IgG2a level	J:45437
	decreased IgG2b level	J:45437
	increased IgM level	J:45437
	increased susceptibility to parasitic infection	J:45437
	increased T cell number	J:45437
Nfkb2^tm2Brv/Nfkb2^tm2Brv (involves: 129S1/Sv * C57BL/6)	abnormal lymph node morphology	J:76380
	abnormal metallophilic macrophage morphology	J:76380
	abnormal spleen morphology	J:76380
	absent lymph node germinal center	J:76380
	absent spleen germinal center	J:76380
	absent spleen marginal zone	J:76380
	decreased B cell number	J:76380
	decreased B cell proliferation	J:76380
	decreased IgA level	J:76380
	decreased IgG1 level	J:76380
	decreased IgG3 level	J:76380
	increased CD4-positive, alpha-beta T cell number	J:76380
	increased CD8-positive, alpha-beta T cell number	J:76380
	increased IgG2a level	J:76380
	increased IgM level	J:76380
	increased splenocyte apoptosis	J:76380
Nfkb2^tm2Brv/Nfkb2^tm2Brv (involves: 129S1/Sv)	abnormal gamma-delta T cell morphology	J:169863
Nfkb2^tm2Brv/Nfkb2^tm2Brv (involves: 129S1/Sv)	decreased gamma-delta T cell number	J:169863
Nfkb2^tm2Brv/Nfkb2^tm2Brv Tg(Tnfsf13b)1Fma/? (B6.Cg-Nfkb2^tm2Brv Tg(Tnfsf13b)1Fma)	abnormal B cell activation	J:113556
	absent spleen marginal zone	J:113556
	decreased marginal zone B cell number	J:113556
	immune system phenotype	J:113556
Nfkb2^tm2Brv/Nfkb2^tm2Brv Traf3^tm1Bal/Traf3^tm1Bal (involves: 129S1/Sv * 129S4/SvJae * C57BL/6)	immune system phenotype	J:124635
Nfkb2^xdr/Nfkb2^xdr (C57BL/6JSfdAnu-Nfkb2^xdr/Anu)	abnormal metallophilic macrophage morphology	J:79725
	abnormal peripheral lymph node morphology	J:79725
	abnormal spleen follicular dendritic cell network	J:79725
	abnormal spleen morphology	J:79725
	abnormal spleen secondary B follicle morphology	J:79725
	decreased B-2 B cell number	J:79725
	decreased follicular B cell number	J:79725
	decreased marginal zone B cell number	J:79725
	decreased mature B cell number	J:79725
	decreased transitional stage T2 B cell number	J:79725
	increased B-1 B cell number	J:79725
Nfkb2^xdr/Nfkb2^xdr (involves: C57BL/6JSfdAnu * C57BL/10Sg * C57BR/cd * NOD)	decreased B cell number	J:79725
Nfkbia^tm1.1Kbp/Nfkbia^tm1.1Kbp (involves: 129P2/OlaHsd * C57BL/6)	abnormal granulocyte morphology	J:97945
	increased granulocyte number	J:97945
Nfkbia^tm1.1Pjc/Nfkbia^tm1.1Pjc (involves: C57BL/6)	abnormal circulating cytokine level	J:163686
	abnormal T cell activation	J:163686
	abnormal T cell number	J:163686
	autoimmune response	J:163686
	chronic inflammation	J:163686
	decreased CD4-positive, alpha-beta T cell number	J:163686
	decreased CD8-positive, alpha-beta T cell number	J:163686
	increased activated T cell number	J:163686
	increased anti-insulin autoantibody level	J:163686
	increased anti-nuclear antigen antibody level	J:163686
	increased circulating interleukin-1 alpha level	J:163686
	increased circulating interleukin-17 level	J:163686
	increased circulating tumor necrosis factor level	J:163686
	increased double-positive T cell number	J:163686
	increased memory T cell number	J:163686
	increased susceptibility to bacterial infection induced morbidity/mortality	J:163686
	increased T cell apoptosis	J:163686
	increased T cell proliferation	J:163686
	increased thymocyte number	J:163686
Nfkbia^tm1.1Smiy/Nfkbia⁺ (B6.129-Nfkbia^tm1.1Smiy)	decreased B cell number	J:168977
	decreased follicular B cell number	J:168977
	decreased marginal zone B cell number	J:168977
	decreased transitional stage T2 B cell number	J:168977
	increased pro-B cell number	J:168977
	small Peyer's patches	J:168977
Nfkbia^tm1.1Smiy/Nfkbia^tm1.1Smiy (B6.129-Nfkbia^tm1.1Smiy)	abnormal B cell differentiation	J:168977
	abnormal marginal zone B cell morphology	J:168977
	decreased B cell number	J:168977
	decreased B cell proliferation	J:168977
	decreased B-2 B cell number	J:168977
	decreased CD4-positive, alpha-beta memory T cell number	J:168977
	decreased follicular B cell number	J:168977
	decreased IgA level	J:168977
	decreased IgG1 level	J:168977
	decreased IgG2b level	J:168977
	decreased marginal zone B cell number	J:168977
	decreased mature B cell number	J:168977
	decreased Peyer's patch number	J:168977
	decreased regulatory T cell number	J:168977
	decreased transitional stage T2 B cell number	J:168977
	increased activation-induced B cell apoptosis	J:168977
	increased immature B cell number	J:168977
	increased pre-B cell number	J:168977
	increased pro-B cell number	J:168977
	small Peyer's patches	J:168977
Nfkbia^tm1Bal/Nfkbia^tm1Bal (involves: 129S4/SvJae * C57BL/6J)	abnormal granulocyte differentiation	J:30058
	decreased double-positive T cell number	J:30058
	increased leukocyte cell number	J:30058
	spleen atrophy	J:30058
	thymus atrophy	J:30058
Nfkbia^tm1Bal/Nfkbia^tm1Bal Nfkbie^tm1Syme/Nfkbie^tm1Syme (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA/2)	abnormal B cell differentiation	J:88142
	abnormal T cell differentiation	J:88142
	decreased immature B cell number	J:88142
	decreased pre-B cell number	J:88142
	increased B cell apoptosis	J:88142
	increased T cell apoptosis	J:88142
Nfkbia^tm1Fey/Nfkbia^tm1Fey (involves: 129S6/SvEvTac * C57BL/6)	abnormal B cell differentiation	J:110817
	abnormal humoral immune response	J:110817
	absent spleen germinal center	J:110817
	decreased double-negative T cell number	J:110817
	decreased T cell proliferation	J:110817
	decreased thymocyte number	J:110817
	increased B cell proliferation	J:110817
	increased IgA level	J:110817
	increased IgE level	J:110817
	increased IgG level	J:110817
	increased single-positive T cell number	J:110817
	small spleen	J:110817
	thymus atrophy	J:110817
Nfkbia^tm1Stw/Nfkbia^tm1Stw (involves: 129S1/Sv)	abnormal macrophage physiology	J:32527
	abnormal myelopoiesis	J:32527
	abnormal tumor necrosis factor level	J:32527
	dermatitis	J:32527
	increased macrophage cell number	J:32527
	increased monocyte cell number	J:32527
Nfkbib^tm1.2Rsch/Nfkbib^tm1.2Rsch (B6.129P2-Nfkbib^tm1.2Rsch)	abnormal cytokine secretion	J:176877
	abnormal immune system morphology	J:176877
	abnormal immune system physiology	J:176877
	abnormal interleukin-1 beta secretion	J:176877
	abnormal interleukin-6 secretion	J:176877
	abnormal tumor necrosis factor secretion	J:176877
	decreased B cell number	J:176877
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:176877
	increased macrophage cell number	J:176877
	increased marginal zone B cell number	J:176877
	increased memory T cell number	J:176877
Nfkbib^tm1Bal/Nfkbib^tm1Bal (B6.129S1-Nfkbib^tm1Bal)	decreased circulating interleukin-1 beta level	J:163302
	decreased circulating interleukin-6 level	J:163302
	decreased circulating tumor necrosis factor level	J:163302
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:163302
	decreased susceptibility to endotoxin shock	J:163302
	decreased susceptibility to induced arthritis	J:163302
	decreased tumor necrosis factor secretion	J:163302
Nfkbid^m1Btlr/Nfkbid^m1Btlr (involves: C57BL/6J)	abnormal class switch recombination	J:185495
	absent marginal zone B cells	J:185495
	decreased B cell proliferation	J:185495
	decreased B-1 B cell number	J:185495
	decreased B-1a cell number	J:185495
	decreased IgG1 level	J:185495
	decreased IgG3 level	J:185495
	decreased IgG level	J:185495
	decreased IgM level	J:185495
	immune system phenotype	J:185495
	increased B cell apoptosis	J:185495
Nfkbid^{tm1a(EUCOMM)Wtsi}/Nfkbid⁺ (C57BL/6N-Nfkbid^{tm1a(EUCOMM)Wtsi}/Cnrm)	decreased B cell number	J:165965
Nfkbid^{tm1a(EUCOMM)Wtsi}/Nfkbid^{tm1a(EUCOMM)Wtsi} (involves: C57BL/6N)	abnormal class switch recombination	J:185495
	decreased IgG level	J:185495
	decreased IgM level	J:185495
Nfkbid^tm1Clay/Nfkbid^tm1Clay (involves: 129S6/SvEvTac * C57BL/6)	abnormal NK cell physiology	J:132071
	abnormal thymocyte activation	J:132071
	decreased interferon-gamma secretion	J:132071
	decreased interleukin-2 secretion	J:132071
	decreased T cell proliferation	J:132071
Nfkbid^tm1Ktak/Nfkbid^tm1Ktak (involves: 129P2/OlaHsd * C57BL/6)	increased interferon-gamma secretion	J:113334
	increased interleukin-6 secretion	J:113334
	increased interleukin-12 secretion	J:113334
	increased interleukin-12b secretion	J:113334
	increased susceptibility to endotoxin shock	J:113334
	increased susceptibility to induced colitis	J:113334
Nfkbie^tm1Syme/Nfkbie^tm1Syme (either: (involves: 129P2/OlaHsd * C57BL/6 * DBA/2) or (involves: 129P2/OlaHsd * C57BL/6))	abnormal double-negative T cell morphology	J:88538
	increased IgG1 level	J:88538
	increased IgM level	J:88538
Nfkbiz^tm1.1Muta/Nfkbiz^tm1.1Muta Tg(CAG-cre)13Miya/? (involves: C57BL/6)	dermatitis	J:194832
Nfkbiz^tm1.1Muta/Nfkbiz^tm1.1Muta Tg(KRT5-cre)1Tak/? (involves: C3H * C57BL/6)	dermatitis	J:194832
Nfkbiz^tm1.1Muta/Nfkbiz^tm1.1Muta Tg(Lck-cre)1Jtak/? (involves: C57BL/6)	immune system phenotype	J:194832
Nfkbiz^tm1Aki/Nfkbiz⁺ Stat6^tm1Aki/Stat6^tm1Aki (C.129P2-Stat6^tm1Aki Nfkbiz^tm1Aki)	skin inflammation	J:141704
Nfkbiz^tm1Aki/Nfkbiz^tm1Aki (involves: 129P2/OlaHsd)	abnormal cytokine secretion	J:91297
	abnormal immune system organ morphology	J:194832
	abnormal immune system physiology	J:194832
	abnormal leukocyte physiology	J:91297
	abnormal lymph node cell ratio	J:194832
	abnormal lymphocyte morphology	J:194832
	abnormal T-helper 1 cell morphology	J:194832
	abnormal tumor necrosis factor secretion	J:91297
	blepharitis	J:96363
	conjunctivitis	J:96363
	corneal limbitis	J:96363
	decreased interleukin-6 secretion	J:91297
	decreased interleukin-12 secretion	J:91297
	dermatitis	J:194832, J:91297
	enlarged lymph nodes	J:194832
	enlarged spleen	J:194832
	eye inflammation	J:96363
	increased immunoglobulin level	J:194832
	interstitial pneumonia	J:194832
	lacrimal gland inflammation	J:194832
	periocular dermatitis	J:194832
Nfkbiz^tm1Aki/Nfkbiz^tm1Aki (C.129P2-Nfkbiz^tm1Aki)	blepharitis	J:141704
	conjunctivitis	J:141704
	dermatitis	J:141704
	eye inflammation	J:141704
	increased IgE level	J:141704
	perioral dermatitis	J:141704
	skin inflammation	J:141704
Nfkbiz^tm1Aki/Nfkbiz^tm1Aki Rag2^tm1Fwa/Rag2^tm1Fwa (involves: 129P2/OlaHsd * 129S/SvEv)	immune system phenotype	J:194832
Nfkbiz^tm1Aki/Nfkbiz^tm1Aki Stat6^tm1Aki/Stat6^tm1Aki (C.129P2-Stat6^tm1Aki Nfkbiz^tm1Aki)	blepharitis	J:141704
	dermatitis	J:141704
	eye inflammation	J:141704
	skin inflammation	J:141704
Nfkbiz^tm1Aki/Nfkbiz^tm1Aki Tnf^tm1Sek/Tnf^tm1Sek (involves: 129P2/OlaHsd * C57BL/6NCrlj * CBA/JNCrlj)	conjunctivitis	J:194832
	dermatitis	J:194832
Nfkbiz^tm1Mamo/Nfkbiz^tm1Mamo (involves: 129S7/SvEvBrd)	dermatitis	J:95040
Nfkbiz^tm1Mamo/Nfkbiz^tm1Mamo (involves: 129S7/SvEvBrd)	increased IgE level	J:95040
Ngfr^tm1Jae/Ngfr^tm1Jae (B6.129S4-Ngfr^tm1Jae)	abnormal Kupffer cell morphology	J:120368
Ngfr^tm1Jae/Ngfr^tm1Jae (B6.129S4-Ngfr^tm1Jae)	increased susceptibility to experimental autoimmune encephalomyelitis	J:112769
Ngfr^tm1Jae/Ngfr^tm1Jae (involves: 129S4/SvJae)	abnormal tumor necrosis factor level	J:157549
Ngp^{tm1b(KOMP)Wtsi}/Ngp^{tm1b(KOMP)Wtsi} (C57BL/6N-Ngp^{tm1b(KOMP)Wtsi}/Bay)	increased spleen weight	J:211773
Nhej1^tm1.1Ics/Nhej1⁺ (involves: 129 * C57BL/6)	decreased thymocyte number	J:194422
Nhej1^tm1.1Ics/Nhej1^tm1.1Ics (involves: 129 * C57BL/6)	abnormal T cell receptor V(D)J recombination	J:194422
	decreased lymphocyte cell number	J:194422
	decreased NK T cell number	J:194422
	decreased thymocyte number	J:194422
	increased thymocyte apoptosis	J:194422
Nhej1^tm1.1Ics/Nhej1^tm1.1Ics Trp53^tm1Tyj/Trp53^tm1Tyj (involves: 129S2/SvPas * C57BL/6)	abnormal T cell receptor V(D)J recombination	J:194422
	decreased NK T cell number	J:194422
	decreased thymocyte apoptosis	J:194422
Nhej1^tm1Fwa/Nhej1^tm1Fwa (involves: 129)	abnormal class switch recombination	J:138774
	decreased IgG1 level	J:138774
	decreased IgG3 level	J:138774
	increased IgM level	J:138774
	spleen hypoplasia	J:138774
	thymus hypoplasia	J:138774
Nhej1^tm1Fwa/Nhej1^tm1Fwa Trp53^tm1Tyj/Trp53^tm1Tyj (involves: 129)	increased T cell derived lymphoma incidence	J:138774
Nhej1^tm1Fwa/Nhej1^tm1Fwa Xrcc5^tm1Nus/Xrcc5^tm1Nus (involves: 129S6/SvEvTac * C57BL/6)	athymia	J:236776
	small spleen	J:236776
Nherf1^em1(IMPC)H/Nherf1^em1(IMPC)H (C57BL/6NTac-Nherf1^em1(IMPC)H/H)	increased basophil cell number	J:211773
	increased leukocyte cell number	J:211773
Nhlh1^{tm1b(KOMP)Wtsi}/Nhlh1⁺ (C57BL/6N-Nhlh1^{tm1b(KOMP)Wtsi}/Tcp)	enlarged lymph nodes	J:211773
Nhlh2^{tm1b(KOMP)Mbp}/Nhlh2^{tm1b(KOMP)Mbp} (C57BL/6N-Nhlh2^{tm1b(KOMP)Mbp}/Tcp)	increased spleen weight	J:211773
Nhsl2^em1(IMPC)Tcp/Y (C57BL/6N-Nhsl2^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Nhsl2^em1(IMPC)Tcp/Y (C57BL/6N-Nhsl2^em1(IMPC)Tcp/Tcp)	enlarged spleen	J:211773
Nhsl2^em1(IMPC)Tcp/Nhsl2^em1(IMPC)Tcp (C57BL/6N-Nhsl2^em1(IMPC)Tcp/Tcp)	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
Niban1^{em1(IMPC)Ccpcz}/Niban1^{em1(IMPC)Ccpcz} (C57BL/6N-Niban1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
Niban3^em1(IMPC)Mbp/Niban3^em1(IMPC)Mbp (C57BL/6N-Niban3^em1(IMPC)Mbp/MbpMmucd)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Niban3^tm1Jyw/Niban3^tm1Jyw (B6.Cg-Niban3^tm1Jyw)	abnormal B cell calcium ion homeostasis	J:282961
	abnormal B cell differentiation	J:282961
	abnormal class switch recombination	J:282961
	abnormal transitional stage B cell morphology	J:282961
	decreased B-1a cell number	J:282961
	decreased IgA level	J:282961
	decreased IgG2c level	J:282961
	enhanced humoral immune response	J:282961
	increased B cell number	J:282961
	increased B cell proliferation	J:282961
	increased follicular B cell number	J:282961
	increased IgG1 level	J:282961
	increased IgG3 level	J:282961
	increased IgG level	J:282961
	increased IgM level	J:282961
	increased transitional stage T2 B cell number	J:282961
Nid2^{Gt(GST011)Byg}/Nid2^{Gt(GST011)Byg} (involves: 129P2/OlaHsd)	osteoarthritis	J:229684
Ninj1^tm1Gto/Ninj1⁺ (B6.129P2-Ninj1^tm1Gto)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:209516
Ninj1^tm1Gto/Ninj1^tm1Gto (B6.129P2-Ninj1^tm1Gto)	abnormal leukocyte adhesion	J:209516
	abnormal leukocyte physiology	J:209516
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:209516
	impaired macrophage chemotaxis	J:209516
Ninj2^em1Cqxu/Ninj2^em1Cqxu (C57BL/6-Ninj2^em1Cqxu)	white adipose tissue inflammation	J:332575
Nipal2^{em1(IMPC)Ccpcz}/Nipal2^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Nipal2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
Nipal3^tm1Pbfd/Nipal3^tm1Pbfd (either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J))	decreased IgM level	J:152829
	decreased NK cell number	J:152829
	increased IgA level	J:152829
	increased IgE level	J:152829
	increased IgG2a level	J:152829
	increased IgM level	J:152829
Nipbl^{Gt(RRS564)Byg}/Nipbl⁺ (involves: 129P2/OlaHsd * CD-1)	abnormal inflammatory response	J:154117
	eye inflammation	J:154117
Nipbl^{Gt(RRS564)Byg}/Nipbl⁺ (involves: 129P2/OlaHsd * C57BL/6J * CD-1)	abnormal chemokine level	J:297059
Nipsnap3a^{tm1b(KOMP)Wtsi}/Nipsnap3a^{tm1b(KOMP)Wtsi} (C57BL/6N-Nipsnap3a^{tm1b(KOMP)Wtsi}/Wtsi)	increased effector memory T-helper cell number	J:211773
Nipsnap3b^em1(IMPC)J/Nipsnap3b^em1(IMPC)J (C57BL/6NJ-Nipsnap3b^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
Nisch^edsn/Nisch^edsn (C3H.B6-Nisch^edsn)	increased susceptibility to otitis media	J:244907
Nisch^edsn/Nisch^V33A (involves: BALB/c * C3H/HeH * C57BL/6J)	increased susceptibility to otitis media	J:244907
Nisch^{tm1b(EUCOMM)Hmgu}/Nisch^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Nisch^{tm1b(EUCOMM)Hmgu}/H)	increased spleen weight	J:211773
Nisch^V33A/Nisch^V33A (involves: BALB/c * C57BL/6J)	increased susceptibility to otitis media	J:244907
Nkap^tm1.1Viss/Y Tg(Lck-cre)1Cwi/0 (involves: 129S1/Sv * 129X1/SvJ)	arrested T cell differentiation	J:165961
	decreased CD4-positive, alpha-beta T cell number	J:165961
	decreased CD8-positive, alpha-beta T cell number	J:165961
	decreased DN4 thymocyte number	J:165961
	decreased double-positive T cell number	J:165961
	decreased thymocyte number	J:165961
	increased DN3 thymocyte number	J:165961
	thymus hypoplasia	J:165961
Nkapd1^tm1.1Tak/Nkapd1^tm1.1Tak Commd10^{Tg(Vav1-icre)A2Kio}/Commd10⁺ (involves: C57BL/6J * C57BL/10 * CBA/Ca)	abnormal B cell differentiation	J:350073
Nkapd1^tm1.1Tak/Nkapd1^tm1.1Tak Gt(ROSA)26Sor^{tm1(cre/ERT2)Tyj}/Gt(ROSA)26Sor⁺ (involves: 129S4/SvJae * C57BL/6 * C57BL/6J)	decreased leukocyte cell number	J:350073
	decreased lymphocyte cell number	J:350073
	small intestinal inflammation	J:350073
Nkg7^{tm1.1(KOMP)Vlcg}/Nkg7^{tm1.1(KOMP)Vlcg} (C57BL/6N-Nkg7^{tm1.1(KOMP)Vlcg}/Ucd)	increased eosinophil cell number	J:211773
Nkg7^{tm1.1(KOMP)Vlcg}/Nkg7^{tm1.1(KOMP)Vlcg} (involves: C57BL/6NTac)	abnormal CD8-positive, alpha-beta cytotoxic T cell morphology	J:301637
	abnormal mononuclear cell morphology	J:301637
	decreased CD4-positive, alpha-beta T cell number	J:301637
	decreased circulating interferon-gamma level	J:301637
	decreased circulating tumor necrosis factor level	J:301637
	decreased susceptibility to parasitic infection induced morbidity/mortality	J:301637
	decreased T helper 1 cell number	J:301637
	increased susceptibility to parasitic infection induced morbidity/mortality	J:301637
Nktcn1^C57BL/6J/Nktcn1^C57BL/6J (involves: C57BL/6J * NOD.B6-(D6Mit105-D6Mit135))	increased NK T cell number	J:85376
Nktcn1^C57BL/6J/Nktcn1^C57BL/6J (NOD.B6-(D1Mit369-D1Mit155)(D6Mit105-D6Mit135))	abnormal T cell differentiation	J:137521
	increased NK T cell number	J:137521
Nktcn1^C57BL/6J/Nktcn1^NOD/ShiLt (involves: C57BL/6J * NOD.B6-(D6Mit105-D6Mit135))	increased NK T cell number	J:85376
Nktcn2^C57BL/6J/Nktcn2^C57BL/6J (involves: C57BL/6J * NOD.B6-(D6Mit105-D6Mit135))	increased NK T cell number	J:85376
Nktcn2^C57BL/6J/Nktcn2^NOD/ShiLt (involves: C57BL/6J * NOD.B6-(D6Mit105-D6Mit135))	increased NK T cell number	J:85376
Nkx2-3^tm1Hha/Nkx2-3^tm1Hha (involves: 129S4/SvJae * C57BL/6)	abnormal spleen primary B follicle morphology	J:54198
	abnormal splenic cell ratio	J:54198
	absent spleen	J:54198
	absent spleen marginal zone	J:54198
	decreased spleen white pulp amount	J:54198
	small spleen	J:54198
Nkx2-3^tm1Hha/Nkx2-3^tm1Hha (involves: 129S4/SvJae)	abnormal leukocyte migration	J:62129
	abnormal marginal zone B cell morphology	J:62129
	abnormal mesenteric lymph node morphology	J:62129
	abnormal metallophilic macrophage morphology	J:62129
	abnormal Peyer's patch follicle morphology	J:62129
	abnormal spleen marginal sinus morphology	J:62129
	abnormal spleen marginal zone macrophage morphology	J:62129
	abnormal spleen morphology	J:62129
	abnormal spleen periarteriolar lymphoid sheath morphology	J:62129
	absent marginal zone B cells	J:62129
	absent spleen marginal zone	J:62129
	decreased B cell number	J:62129
	decreased lymphocyte cell number	J:62129
	decreased Peyer's patch number	J:62129
	decreased spleen weight	J:62129
	decreased spleen white pulp amount	J:62129
	decreased T cell number	J:62129
	intermingled spleen red and white pulp	J:62129
	small Peyer's patches	J:62129
	small spleen	J:62129
Nkx2-3^tm1Rph/Nkx2-3^tm1Rph (involves: 129S1/Sv * C57BL/6)	abnormal gut-associated lymphoid tissue morphology	J:64018
	abnormal leukocyte migration	J:64018
	abnormal mesenteric lymph node morphology	J:64018
	abnormal metallophilic macrophage morphology	J:64018
	abnormal spleen B cell follicle morphology	J:64018
	abnormal spleen periarteriolar lymphoid sheath morphology	J:64018
	abnormal spleen red pulp morphology	J:64018
	absent spleen	J:64018
	absent spleen marginal zone	J:64018
	decreased CD4-positive, alpha-beta T cell number	J:64018
	decreased Peyer's patch number	J:64018
	decreased plasma cell number	J:64018
	increased leukocyte cell number	J:64018
	small Peyer's patches	J:64018
	small spleen	J:64018
	spleen atrophy	J:64018
Nkx2-5^tm1(cre)Rjs/Nkx2-5⁺ Tbx1^tm1Bld/Tbx1^tm3Bld (involves: 129S7/SvEvBrd * C57BL/6)	small thymus	J:91013
Nkx2-5^tm1Wehi/Nkx2-5⁺ (involves: 129P2/OlaHsd)	spleen hypoplasia	J:184521
Nkx2-5^tm2(cre)Rph/Nkx2-5⁺ Pbx1^tm1.1Koss/Pbx1^tm1.1Koss (involves: 129P2/OlaHsd * 129S1/Sv)	abnormal spleen morphology	J:184521
	spleen hypoplasia	J:184521
Nkx2-5^tm2(cre)Rph/Nkx2-5^tm4Rph (involves: 129S1/Sv)	spleen hypoplasia	J:184521
Nkx3-2^tm1.1Tlu/Nkx3-2^tm1.1Tlu (either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J))	absent spleen	J:55583
Nkx3-2^tm1Bobh/Nkx3-2^tm1Bobh (involves: 129P2/OlaHsd * C57BL/6)	absent spleen	J:57112
Nkx3-2^tm1Tlu/Nkx3-2^tm1Tlu (either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J))	absent spleen	J:55583
Nkx3-2^tm1Tno/Nkx3-2^tm1Tno (involves: 129S4/SvJae * C57BL/6J)	absent spleen	J:77612
Nle1^tm1Cba/Nle1^tm1.1Cota Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129P2/OlaHsd * 129S2/SvPas)	immune system phenotype	J:204063
Nle1^tm1Cba/Nle1^tm1.1Cota Gt(ROSA)26Sor^{tm2(cre/ERT2)Brn}/Gt(ROSA)26Sor⁺ (involves: 129P2/OlaHsd * 129S2/SvPas)	abnormal immune system organ morphology	J:204063
	decreased granulocyte number	J:204063
	decreased macrophage cell number	J:204063
	decreased NK cell number	J:204063
	decreased T cell number	J:204063
	spleen hypoplasia	J:204063
	thymus hypoplasia	J:204063
Nlgn3^{em1(IMPC)Rbrc}/Y (C57BL/6NJcl-Nlgn3^{em1(IMPC)Rbrc}/Rbrc)	increased eosinophil cell number	J:211773
Nlk^tm1Tbo/Nlk^tm1Tbo (129S1/Sv-Nlk^tm1Tbo)	abnormal bone marrow development	J:73353
	abnormal immune system organ morphology	J:73353
	decreased double-positive T cell number	J:73353
	decreased gamma-delta T cell number	J:73353
	decreased lymphocyte cell number	J:73353
	decreased NK cell number	J:73353
	decreased pro-B cell number	J:73353
	decreased thymocyte number	J:73353
	impaired myelopoiesis	J:73353
	small lymph nodes	J:73353
	spleen hypoplasia	J:73353
	thymus hypoplasia	J:73353
Nlrc3^tm1Bhk/Nlrc3^tm1Bhk (B6.129S6-Nlrc3^tm1Bhk)	increased circulating interleukin-6 level	J:187586
	increased circulating tumor necrosis factor level	J:187586
	increased monocyte cell number	J:187586
	increased susceptibility to endotoxin shock	J:187586
	increased tumor necrosis factor secretion	J:187586
Nlrc4^em1Vnce/Nlrc4^em1Vnce (C57BL/6-Nlrc4^em1Vnce)	decreased inflammatory response	J:294930
Nlrc4^em1Vnce/Nlrc4^em1Vnce (C57BL/6-Nlrc4^em1Vnce)	increased susceptibility to bacterial infection induced morbidity/mortality	J:294930
Nlrc4^em1Vnce/Nlrc4^em1Vnce Nlrp3^tm1Vmd/Nlrp3^tm1Vmd (involves: C57BL/6J * C57BL/6N)	decreased inflammatory response	J:294930
Nlrc4^em2Vnce/Nlrc4^em2Vnce (C57BL/6-Nlrc4^em2Vnce)	decreased inflammatory response	J:294930
Nlrc4^em2Vnce/Nlrc4^em2Vnce Nlrp3^tm1Vmd/Nlrp3^tm1Vmd (involves: C57BL/6J * C57BL/6N)	decreased inflammatory response	J:294930
Nlrc4^em3Vnce/Nlrc4^em3Vnce (C57BL/6-Nlrc4^em3Vnce)	immune system phenotype	J:294930
Nlrc4^m1Btlr/Nlrc4⁺ (C57BL/6J-Nlrc4^m1Btlr)	decreased interleukin-1 beta secretion	J:225933
Nlrc4^m1Btlr/Nlrc4^m1Btlr (C57BL/6J-Nlrc4^m1Btlr)	decreased interleukin-1 beta secretion	J:225933
Nlrc4^tm1Gln/Nlrc4^tm1Gln (involves: 129S5/SvEvBrd)	immune system phenotype	J:173245
Nlrc4^tm1Gln/Nlrc4^tm1Gln Slc11a1^s/Slc11a1^s (B6.129S5-Nlrc4^tm1Gln)	increased susceptibility to bacterial infection	J:124378
Nlrc4^tm1Gne/Nlrc4^tm1Gne (involves: C57BL/6N)	immune system phenotype	J:189256
Nlrc4^tm1Nnz/Nlrc4^tm1Nnz (involves: 129 * C57BL/6J)	abnormal macrophage physiology	J:112671, J:117251
Nlrc4^tm1Nnz/Nlrc4^tm1Nnz (involves: 129 * C57BL/6J)	increased susceptibility to bacterial infection	J:117251
Nlrc4^tm1Vmd/Nlrc4^tm1Vmd (C57BL/6N-Nlrc4^tm1Vmd)	decreased interleukin-1 beta secretion	J:91292
Nlrc4^tm1Vmd/Nlrc4^tm1Vmd (involves: C57BL/6N)	abnormal cytokine secretion	J:106976
Nlrc4^tm1Vmd/Nlrc4^tm1Vmd (involves: C57BL/6N)	abnormal response to infection	J:106976
Nlrc4^tm1Vmd/Nlrc4^tm1Vmd Nlrp3^tm1Vmd/Nlrp3^tm1Vmd (C57BL/6-Nlrp3^tm1Vmd Nlrc4^tm1Vmd)	decreased interleukin-1 beta secretion	J:160545
Nlrc5^tm1.1Ggaur/Nlrc5^tm1.1Ggaur (involves: BALB/cJ)	abnormal T cell physiology	J:184076
	decreased CD8-positive, alpha-beta T cell number	J:184076
	enlarged spleen	J:184076
	immune system phenotype	J:184076
Nlrc5^tm1Aki/Nlrc5^tm1Aki (Not Specified)	immune system phenotype	J:168788
Nlrc5^tm1Itl/Nlrc5^tm1Itl (C57BL/6-Nlrc5^tm1Itl)	decreased interferon-beta secretion	J:188857
	decreased interleukin-6 secretion	J:188857
	immune system phenotype	J:188857
Nlrp1a^m1Btlr/Nlrp1a^m1Btlr (C57BL/6J-Nlrp1a^m1Btlr)	decreased B cell number	J:265173
	decreased B-1 B cell number	J:265173
	decreased B-1b cell number	J:265173
	decreased B-2 B cell number	J:265173
	decreased CD8-positive, alpha-beta T cell number	J:265173
	decreased central memory CD8 positive, alpha-beta T cell number	J:265173
	decreased NK cell number	J:265173
	decreased single-positive T cell number	J:265173
	decreased T cell number	J:265173
	increased effector memory CD8-positive, alpha-beta T cell number	J:265173
	increased IgE level	J:265173
	increased macrophage apoptosis	J:265173
	increased tumor necrosis factor secretion	J:265173
Nlrp1a^m2Btlr/Nlrp1a^m2Btlr (C57BL/6J-Nlrp1a^m2Btlr)	decreased B cell number	J:265174
	decreased interleukin-1 beta secretion	J:265174
	decreased NK cell number	J:265174
	increased dendritic cell number	J:265174
	increased macrophage apoptosis	J:265174
	increased neutrophil cell number	J:265174
Nlrp1a^Neut1/Nlrp1a⁺ (C.B6-Nlrp1a^Neut1)	increased inflammatory response	J:191055
	liver inflammation	J:191055
	lung inflammation	J:191055
	meningitis	J:191055
	myocarditis	J:191055
	pancreas inflammation	J:191055
Nlrp1a^Neut1/Nlrp1a^Neut1 (C.B6-Nlrp1a^Neut1)	decreased lymphocyte cell number	J:191055
	decreased macrophage cell number	J:191055
	enlarged spleen	J:191055
	increased inflammatory response	J:191055
	increased macrophage cytokine production	J:191055
	increased neutrophil cell number	J:191055
	liver inflammation	J:191055
	lung inflammation	J:191055
	meningitis	J:191055
	myocarditis	J:191055
	pancreas inflammation	J:191055
Nlrp1a^Neut1/Nlrp1a^Neut1 Pycard^tm1Vmd/Pycard^tm1Vmd (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal inflammatory response	J:191055
	increased neutrophil cell number	J:191055
Nlrp1b^tm1Bhk/Nlrp1b^tm1Bhk (129S6/SvEvTac-Nlrp1b^tm1Bhk)	abnormal macrophage physiology	J:189777
	decreased interleukin-1 alpha secretion	J:189777
	decreased interleukin-1 beta secretion	J:189777
Nlrp2^tm1.2Itl/Nlrp2^tm1.2Itl (involves: C57BL/6)	immune system phenotype	J:237496
Nlrp3^m1Btlr/Nlrp3^m1Btlr (C57BL/6J-Nlrp3^m1Btlr)	decreased interleukin-1 beta secretion	J:159357
Nlrp3^m2Btlr/? (C57BL/6J-Nlrp3^m2Btlr)	abnormal interleukin-1 beta secretion	J:164865
Nlrp3^m3Btlr/? (C57BL/6J-Nlrp3^m3Btlr)	abnormal interleukin-1 beta secretion	J:164866
Nlrp3^m4Btlr/Nlrp3^m4Btlr (involves: C57BL/6J)	decreased interleukin-1 beta secretion	J:171739
Nlrp3^m5Btlr/Nlrp3⁺ (C57BL/6J-Nlrp3^m5Btlr)	decreased interleukin-1 beta secretion	J:192651
Nlrp3^m5Btlr/Nlrp3^m5Btlr (C57BL/6J-Nlrp3^m5Btlr)	decreased interleukin-1 beta secretion	J:192651
Nlrp3^M6Btlr/Nlrp3⁺ (C57BL/6J-Nlrp3^M6Btlr)	decreased interleukin-1 beta secretion	J:216047
Nlrp3^M6Btlr/Nlrp3^M6Btlr (C57BL/6J-Nlrp3^M6Btlr)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:226677
Nlrp3^M7Btlr/Nlrp3⁺ (C57BL/6J-Nlrp3^M7Btlr)	abnormal macrophage cytokine production	J:216048
Nlrp3^M7Btlr/Nlrp3⁺ (C57BL/6J-Nlrp3^M7Btlr)	decreased interleukin-1 beta secretion	J:216048
Nlrp3^M7Btlr/Nlrp3^M7Btlr (C57BL/6J-Nlrp3^M7Btlr)	abnormal macrophage cytokine production	J:216048
Nlrp3^M7Btlr/Nlrp3^M7Btlr (C57BL/6J-Nlrp3^M7Btlr)	decreased interleukin-1 beta secretion	J:216048
Nlrp3^M8Btlr/Nlrp3⁺ (C57BL/6J-Nlrp3^M8Btlr)	decreased interleukin-1 beta secretion	J:217294
Nlrp3^M8Btlr/Nlrp3^M8Btlr (C57BL/6J-Nlrp3^M8Btlr)	decreased interleukin-1 beta secretion	J:217294
Nlrp3^M9Btlr/Nlrp3⁺ (C57BL/6J-Nlrp3^M9Btlr)	decreased interleukin-1 beta secretion	J:220071
Nlrp3^M9Btlr/Nlrp3^M9Btlr (C57BL/6J-Nlrp3^M9Btlr)	decreased interleukin-1 beta secretion	J:220071
Nlrp3^M10Btlr/Nlrp3⁺ (C57BL/6J-Nlrp3^M10Btlr)	decreased interleukin-1 beta secretion	J:234254
Nlrp3^M10Btlr/Nlrp3^M10Btlr (C57BL/6J-Nlrp3^M10Btlr)	decreased interleukin-1 beta secretion	J:234254
Nlrp3^M11Btlr/Nlrp3^M11Btlr (C57BL/6J-Nlrp3^M11Btlr)	decreased interleukin-1 beta secretion	J:255211
Nlrp3^m12Btlr/Nlrp3^m12Btlr (C57BL/6J-Nlrp3^m12Btlr)	decreased interleukin-1 beta secretion	J:272150
Nlrp3^tm1Bhk/Nlrp3^tm1Bhk (involves: 129S6/SvEvTac)	decreased interleukin-1 beta secretion	J:189777
Nlrp3^tm1Bhk/Nlrp3^tm1Bhk (involves: 129S6/SvEvTac)	immune system phenotype	J:189777
Nlrp3^tm1Bhk/Nlrp3^tm1Bhk (B6.129S6-Nlrp3^tm1Bhk/J)	decreased interleukin-1 beta secretion	J:253629
Nlrp3^tm1Bhk/Nlrp3^tm1Bhk (B6.129S6-Nlrp3^tm1Bhk/J)	white adipose tissue inflammation	J:256504
Nlrp3^tm1Flv/Nlrp3^tm1Flv (involves: 129S5/SvEvBrd * C57BL/6)	abnormal macrophage physiology	J:113333
	decreased circulating interleukin-1 beta level	J:113333
	decreased circulating interleukin-18 level	J:113333
	decreased susceptibility to endotoxin shock	J:113333
	decreased susceptibility to type IV hypersensitivity reaction	J:113333
Nlrp3^tm1Flv/Nlrp3^tm1Flv (B6.129S5-Nlrp3^tm1Flv)	decreased interleukin-1 beta secretion	J:164725
Nlrp3^tm1Flv/Nlrp3^tm1Flv (involves: 129S5/SvEvBrd)	decreased susceptibility to induced colitis	J:173245
Nlrp3^tm1Flv/Nlrp3^tm1Flv Slc11a1^s/Slc11a1^s (B6.129S5-Nlrp3^tm1Flv)	increased susceptibility to bacterial infection	J:124378
Nlrp3^tm1Flv/Nlrp3^tm1Hhf Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129 * C57BL/6)	increased inflammatory response	J:150054
Nlrp3^tm1Hhf/Nlrp3⁺ Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129/Sv * 129P2/OlaHsd * C57BL/6)	abnormal circulating chemokine level	J:150054
	abnormal circulating cytokine level	J:150054
	increased circulating interleukin-1 beta level	J:150054
	increased circulating interleukin-6 level	J:150054
	increased circulating interleukin-18 level	J:150054
	increased circulating tumor necrosis factor level	J:150054
	increased inflammatory response	J:150054
	increased leukocyte cell number	J:150054
	increased neutrophil cell number	J:150054
Nlrp3^tm1Hhf/Nlrp3⁺ Rag1^tm1Mom/Rag1^tm1Mom Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129/Sv * 129P2/OlaHsd * C57BL/6)	absent B cells	J:150054
	absent T cells	J:150054
Nlrp3^tm1Hhf/Nlrp3⁺ Tg(CAG-cre/Esr1)5Amc/? (involves: 129/Sv C57BL/6 * CBA)	skin inflammation	J:150054
Nlrp3^tm1Hhf/Nlrp3⁺ Tg(CAG-cre/Esr1)5Amc/? (involves: 129/Sv C57BL/6 * CBA)	abnormal dendritic cell antigen presentation	J:150054
	abnormal dendritic cell physiology	J:150054
	abnormal macrophage physiology	J:150054
Nlrp3^tm1Hhf/Nlrp3⁺ Tg(Zp3-cre)3Mrt/? (involves: 129/Sv * FVB/N)	increased inflammatory response	J:150054
	increased leukocyte cell number	J:150054
	increased neutrophil cell number	J:150054
Nlrp3^tm1Tsc/Nlrp3^tm1Tsc (C57BL/6-Nlrp3^tm1Tsc)	decreased interleukin-1 beta secretion	J:124226
Nlrp3^tm1Tsc/Nlrp3^tm1Tsc (involves: C57BL/6)	decreased interleukin-1 beta secretion	J:172117
Nlrp3^tm1Vmd/Nlrp3^tm1Vmd (involves: C57BL/6N)	abnormal cytokine secretion	J:106976
	abnormal response to infection	J:106976
	decreased susceptibility to endotoxin shock	J:106976
Nlrp3^tm1Vmd/Nlrp3^tm1Vmd (B6.B6N-Nlrp3^tm1Vmd)	decreased circulating interleukin-1 beta level	J:193522
	decreased circulating interleukin-18 level	J:193522
	decreased interleukin-1 beta secretion	J:193522
	decreased susceptibility to endotoxin shock	J:193522
	immune system phenotype	J:294930
Nlrp3^tm1Wstr/Nlrp3⁺ (involves: C57BL/6)	abnormal CD4-positive, alpha-beta T cell number	J:150053
	abnormal dendritic cell physiology	J:150053
	abnormal lymph node morphology	J:150053
	abnormal macrophage physiology	J:150053
	abnormal spleen red pulp morphology	J:150053
	chronic inflammation	J:150053
	dermatitis	J:150053
	enlarged lymph nodes	J:150053
	enlarged spleen	J:150053
	increased activated T cell number	J:150053
	increased anti-double stranded DNA antibody level	J:150053
	increased interleukin-1 beta secretion	J:150053
	increased interleukin-17 secretion	J:150053
	increased interleukin-18 secretion	J:150053
	increased leukocyte cell number	J:150053
	increased susceptibility to type IV hypersensitivity reaction	J:150053
	increased T-helper 1 cell number	J:150053
Nlrp3^tm2Hhf/Nlrp3⁺ Tg(CAG-cre/Esr1)5Amc/? (involves: 129/Sv C57BL/6 * CBA)	skin inflammation	J:150054
Nlrp3^tm2Hhf/Nlrp3⁺ Tg(CAG-cre/Esr1)5Amc/? (involves: 129/Sv C57BL/6 * CBA)	abnormal dendritic cell physiology	J:150054
	abnormal macrophage physiology	J:150054
Nlrp3^tm2Hhf/Nlrp3^tm2Hhf Vsig4^tm1Gne/Vsig4^tm1Gne (B6.Cg-Nlrp3^tm2Hhf Vsig4^tm1Gne)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:281762
Nlrp3^tm3.1Hhf/Nlrp3⁺ (involves: 129)	abnormal circulating chemokine level	J:202147
	abnormal osteoclast differentiation	J:202147
	decreased circulating interleukin-5 level	J:202147
	decreased circulating interleukin-12b level	J:202147
	decreased lymphocyte cell number	J:202147
	immune system phenotype	J:202147
	increased circulating interleukin-1 beta level	J:202147
	increased circulating interleukin-3 level	J:202147
	increased circulating interleukin-4 level	J:202147
	increased circulating interleukin-6 level	J:202147
	increased circulating interleukin-9 level	J:202147
	increased circulating interleukin-13 level	J:202147
	increased circulating interleukin-18 level	J:202147
	increased circulating tumor necrosis factor level	J:202147
	increased granulocyte number	J:202147
	increased inflammatory response	J:202147
	increased interferon-gamma secretion	J:202147
	increased interleukin-1 beta secretion	J:202147
	increased lymphocyte cell number	J:202147
	increased monocyte cell number	J:202147
	increased neutrophil cell number	J:202147
	increased osteoclast cell number	J:202147
	joint inflammation	J:202147
	meningitis	J:202147
	osteomyelitis	J:202147
Nlrp6^tm1Flv/Nlrp6^tm1Flv (B6.Cg-Nlrp6^tm1Flv)	decreased circulating interleukin-18 level	J:173245
	decreased interleukin-18 secretion	J:173245
	enlarged Peyer's patches	J:173245
	increased B cell number	J:173245
	increased IgA level	J:173245
	increased IgG2c level	J:173245
	increased leukocyte cell number	J:173245
	increased susceptibility to induced colitis	J:173245
	increased susceptibility to Riboviria infection induced morbidity/mortality	J:243487
Nlrp6^tm1Macha/Nlrp6^tm1Macha (involves: 129S5/SvEvBrd * C57BL/6J)	increased susceptibility to induced colitis	J:173352
Nlrp9b^em1Flv/Nlrp9b^em1Flv (C57BL/6N-Nlrp9b^em1Flv)	increased susceptibility to Riboviria infection induced morbidity/mortality	J:243487
Nlrp9b^{tm1b(KOMP)Wtsi}/Nlrp9b^{tm1b(KOMP)Wtsi} (C57BL/6N-Nlrp9b^{tm1b(KOMP)Wtsi}/H)	enlarged spleen	J:211773
Nlrp10^tm1Seis/Nlrp10^tm1Seis (involves: C57BL/6)	immune system phenotype	J:173245
Nlrp10^tm1Seis/Nlrp10^tm1Seis (B6.Cg-Nlrp10^tm1Seis)	abnormal adaptive immunity	J:183989
	abnormal dendritic cell physiology	J:183989
	abnormal T-helper 2 physiology	J:183989
	decreased dendritic cell number	J:183989
	decreased IgG1 level	J:183989
	decreased interferon-gamma secretion	J:183989
	decreased interleukin-17 secretion	J:183989
	decreased susceptibility to endotoxin shock	J:183989
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:183989
Nlrp12^tm1Jpyt/Nlrp12^tm1Jpyt (B6.Cg-Nlrp12^tm1Jpyt)	abnormal leukocyte migration	J:164725
	decreased neutrophil cell number	J:164725
	decreased susceptibility to type IV hypersensitivity reaction	J:164725
	impaired neutrophil chemotaxis	J:164725
Nlrp12^tm1Jpyt/Nlrp12^tm1Jpyt (Not Specified)	immune system phenotype	J:173245
Nlrp12^tm1Tdk/Nlrp12^tm1Tdk (B6.Cg-Nlrp12^tm1Tdk)	abnormal chemokine level	J:178951
	abnormal cytokine level	J:178951
	enlarged spleen	J:178951
	increased inflammatory response	J:178951
	increased susceptibility to induced colitis	J:178951
Nlrx1^em1(IMPC)Mbp/Nlrx1^em1(IMPC)Mbp (C57BL/6N-Nlrx1^em1(IMPC)Mbp/MbpMmucd)	small spleen	J:211773
Nlrx1^tm1Jpyt/Nlrx1^tm1Jpyt (involves: C57BL/6 * C57BL/6J)	abnormal macrophage physiology	J:173995
	abnormal neutrophil physiology	J:173995
	increased circulating interleukin-6 level	J:173995
	increased interferon-beta secretion	J:173995
	increased interleukin-1 beta secretion	J:173995
	increased interleukin-6 secretion	J:173995
	increased susceptibility to endotoxin shock	J:173995
	increased susceptibility to Orthomyxoviridae infection	J:173995
Nme2^{Gt(69C10)Cmhd}/Nme2^{Gt(69C10)Cmhd} (B6.129-Nme2^{Gt(69C10)Cmhd})	abnormal CD4-positive, alpha-beta T cell physiology	J:167387
	abnormal T-helper 1 physiology	J:167387
	abnormal T-helper 2 physiology	J:167387
	decreased interferon-gamma secretion	J:167387
	decreased interleukin-2 secretion	J:167387
	decreased interleukin-13 secretion	J:167387
	decreased tumor necrosis factor secretion	J:167387
	immune system phenotype	J:167387
Nme5^tm1Lex/Nme5^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6J)	maxillary sinus inflammation	J:185566
	nasal inflammation	J:185566
nmf4/nmf4 (C57BL/6J-nmf4/J)	small spleen	J:78134
nmf4/nmf4 (C57BL/6J-nmf4/J)	thymus cortex atrophy	J:78134
nmf356/nmf356 (C57BL/6J-nmf356/J)	thymus atrophy	J:87349
nmf370/nmf370 (C57BL/6J-nmf370/J)	ear inflammation	J:87349
nmf391/nmf391 (C57BL/6J-nmf391/J)	ear inflammation	J:87349
Nmi^em1Hhl/Nmi^em1Hhl (C57BL/6-Nmi^em1Hhl)	decreased circulating interleukin-6 level	J:298909
	decreased circulating tumor necrosis factor level	J:298909
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:298909
	decreased susceptibility to endotoxin shock	J:298909
Nmnat2^em1(IMPC)Mbp/Nmnat2⁺ (C57BL/6N-Nmnat2^em1(IMPC)Mbp/Ucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
Nmnat3^Gt(3020)Tgen/Nmnat3^Gt(3020)Tgen (involves: C57BL/6NCrlj * CBA/JNCrlj)	enlarged spleen	J:214107
	increased spleen iron level	J:214107
	increased spleen red pulp amount	J:214107
	increased spleen weight	J:214107
Nmt1^tm1.1Poru/Nmt1^tm1.1Poru Nmt2^tm1.1Poru/Nmt2^tm1.1Poru Tg(Lck-cre)1Cwi/0 (involves: C57BL/6 * DBA/2 * SJL)	abnormal CD4-positive, alpha beta T cell morphology	J:226234
	abnormal CD8-positive, alpha beta T cell morphology	J:226234
	decreased circulating interferon-gamma level	J:226234
	decreased circulating interleukin-2 level	J:226234
	decreased circulating tumor necrosis factor level	J:226234
	decreased DN4 thymocyte number	J:226234
	decreased double-positive T cell number	J:226234
	decreased interferon-gamma secretion	J:226234
	decreased interleukin-2 secretion	J:226234
	decreased single-positive T cell number	J:226234
	decreased splenocyte proliferation	J:226234
	decreased susceptibility to endotoxin shock	J:226234
	decreased T cell number	J:226234
	decreased T cell proliferation	J:226234
	immune system phenotype	J:226234
	increased double-negative T cell number	J:226234
	increased gamma-delta T cell number	J:226234
	increased T cell apoptosis	J:226234
	small thymus medulla	J:226234
Nmt1^tm1.1Poru/Nmt1^tm1.1Poru Tg(Lck-cre)1Cwi/0 (involves: C57BL/6 * DBA/2 * SJL)	abnormal CD4-positive, alpha beta T cell morphology	J:226234
	abnormal CD8-positive, alpha beta T cell morphology	J:226234
	decreased double-positive T cell number	J:226234
	decreased single-positive T cell number	J:226234
	decreased T cell number	J:226234
Nmt2^tm1.1Poru/Nmt2^tm1.1Poru Tg(Lck-cre)1Cwi/0 (involves: C57BL/6 * DBA/2 * SJL)	decreased double-positive T cell number	J:226234
	decreased single-positive T cell number	J:226234
	decreased T cell number	J:226234
Nmu^tm1Sjab/Nmu^tm1Sjab (involves: 129P2/OlaHsd * C57BL/6)	decreased circulating interleukin-6 level	J:142907
Nnat^em1(IMPC)Mbp/Nnat^em1(IMPC)Mbp (C57BL/6NCrl-Nnat^em1(IMPC)Mbp/Mmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
Nnmt^em1(IMPC)Mbp/Nnmt^em1(IMPC)Mbp (C57BL/6NCrl-Nnmt^em1(IMPC)Mbp/Mmucd)	enlarged spleen	J:211773
Noa/Noa⁺ (NOA)	cutaneous mastocytosis	J:43274
Noa/Noa⁺ (NOA)	increased IgE level	J:43274
Noc2l^tm1.1Arte/Noc2l^tm1.1Arte Tg(CD2-icre)4Kio/0 (involves: C57BL/6 * C57BL/10 * CBA/Ca)	abnormal B cell morphology	J:216490
	abnormal T cell morphology	J:216490
	abnormal T cell proliferation	J:216490
	abnormal thymus cell ratio	J:216490
	abnormal thymus involution	J:216490
	abnormal thymus morphology	J:216490
	absent T cells	J:216490
	arrested T cell differentiation	J:216490
	decreased alpha-beta T cell number	J:216490
	decreased DN3 thymocyte number	J:216490
	decreased DN4 thymocyte number	J:216490
	decreased double-positive T cell number	J:216490
	decreased immature B cell number	J:216490
	decreased mature B cell number	J:216490
	decreased pre-B cell number	J:216490
	decreased pro-B cell number	J:216490
	decreased single-positive T cell number	J:216490
	increased thymocyte apoptosis	J:216490
	small thymus	J:216490
	spleen hypoplasia	J:216490
	thymus hypoplasia	J:216490
Noc2l^tm1.1Arte/Noc2l^tm1.1Arte Trp53^tm1Brn/Trp53^tm1Brn Tg(CD2-icre)4Kio/0 (involves: 129P2/OlaHsd * C57BL/6 * C57BL/10 * CBA/Ca)	decreased pre-B cell number	J:216490
Nod1^tm1Bert/Nod1^tm1Bert (involves: C57BL/6)	immune system phenotype	J:117688
Nod1^tm1Inoh/Nod1^tm1Inoh (involves: 129P2/OlaHsd * C57BL/6)	abnormal chemokine secretion	J:118808
	abnormal cytokine secretion	J:118808
	abnormal immune system physiology	J:118808
	abnormal macrophage physiology	J:132126, J:118808
	decreased interleukin-6 secretion	J:132126
	decreased tumor necrosis factor secretion	J:132126
Nod1^tm1Inoh/Nod1^tm1Inoh Nod2^tm1Flv/Nod2^tm1Flv (involves: 129 * 129P2/OlaHsd * C57BL/6)	abnormal macrophage physiology	J:132126
	decreased interleukin-6 secretion	J:132126
	decreased tumor necrosis factor secretion	J:132126
	increased susceptibility to bacterial infection	J:132126
Nod2^em1(IMPC)Mbp/Nod2^em1(IMPC)Mbp (C57BL/6N-Nod2^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
Nod2^tm1Daph/Nod2^tm1Daph (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal macrophage physiology	J:157879
Nod2^tm1Flv/Nod2^tm1Flv (involves: 129S1/Sv * C57BL/6)	abnormal macrophage physiology	J:132126, J:96035
	abnormal susceptibility to infection	J:96035
	decreased IgG level	J:96035
	decreased interleukin-6 secretion	J:132126
	decreased susceptibility to endotoxin shock	J:96035
	decreased tumor necrosis factor secretion	J:132126
Nod2^tm1Flv/Nod2^tm1Flv (involves: 129S1/Sv)	abnormal response to infection	J:147177
	abnormal T-helper 1 physiology	J:147177
	impaired macrophage phagocytosis	J:147177
	impaired neutrophil phagocytosis	J:147177
	increased circulating interferon-gamma level	J:147177
	increased circulating interleukin-2 level	J:147177
	increased circulating tumor necrosis factor level	J:147177
	increased leukocyte cell number	J:147177
	increased neutrophil cell number	J:147177
	increased susceptibility to bacterial infection induced morbidity/mortality	J:147177
Nod2^tm1Flv/Nod2^tm1Flv (C.129S1-Nod2^tm1Flv)	decreased susceptibility to induced arthritis	J:178054
Nod2^tm1Jhgt/Nod2^tm1Jhgt (B6.Cg-Nod2^tm1Jhgt)	abnormal cytokine level	J:124575
	abnormal immune system morphology	J:124575
	abnormal immune system physiology	J:124575
	abnormal interferon level	J:124575
	abnormal interleukin level	J:124575
	abnormal lymph node B cell domain morphology	J:124575
	abnormal Peyer's patch morphology	J:124575
	abnormal response to infection	J:124575
	abnormal tumor necrosis factor level	J:124575
	enlarged Peyer's patches	J:124575
	increased CD4-positive, alpha-beta T cell number	J:124575
	increased double-negative T cell number	J:124575
	increased Peyer's patch number	J:124575
	increased susceptibility to induced colitis	J:124575
Nod2^tm1Mka/Nod2^tm1Mka (involves: C57BL/6)	abnormal cytokine level	J:96128
	abnormal macrophage morphology	J:96128
	increased interleukin-1 beta secretion	J:96128
	increased susceptibility to induced colitis	J:96128
Nod2^tm1Pmu/Nod2^tm1Pmu (involves: BALB/c * C57BL/6)	abnormal macrophage physiology	J:86264
Nod2^tm1Pmu/Nod2^tm1Pmu (involves: BALB/c * C57BL/6)	decreased susceptibility to endotoxin shock	J:86264
Nod2^tm1Vmd/Nod2^tm1Vmd (B6.129-Nod2^tm1Vmd)	abnormal cytokine secretion	J:106976
Nodal^tm1.1Mku/Nodal^tm2Mku Tg(T-cre)1Lwd/0 (involves: 129S1/Sv * C3H * C57BL/6)	absent spleen	J:142430
	small spleen	J:142430
Nodal^tm1.2Rob/Nodal^tm3Rob (involves: 129S/SvEv * MF1)	small spleen	J:79098
Nodal^tm1Hmd/Nodal⁺ Tg(Rr443-Lefty1,-lacZ)36Hmd/0 (either: (involves: 129S1/Sv * 129X1/SvJ * C57BL/6N) or (involves: 129S1/Sv * 129T2/SvEms * 129X1/SvJ))	small spleen	J:82703
Nodal^tm1Hmd/Nodal^tm1Hmd (either: (involves: 129S1/Sv * 129X1/SvJ * C57BL/6N) or (involves: 129S1/Sv * 129T2/SvEms * 129X1/SvJ))	abnormal spleen morphology	J:82703
	spleen hypoplasia	J:82703
Nol3^em1(IMPC)Mbp/Nol3^em1(IMPC)Mbp (C57BL/6N-Nol3^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	small spleen	J:211773
Nop53^tm2.1Asuz/Nop53^tm2.1Asuz Tg(Lck-cre)#Jxm/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA)	decreased thymocyte number	J:241062
Nop53^tm2.1Asuz/Nop53^tm2.1Asuz Trp53^tm1Tyj/Trp53^tm1Tyj Tg(Lck-cre)#Jxm/0 (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * CBA)	decreased thymocyte number	J:241062
Nos1^tm1Plh/Nos1^tm1Plh (involves: 129S4/SvJae)	abnormal leukocyte adhesion	J:55936
	abnormal neutrophil physiology	J:55936
	enhanced leukocyte tethering or rolling	J:55936
Nos1^tm1Plh/Nos1^tm1Plh (B6;129S4-Nos1^tm1Plh/J)	abnormal osteoclast differentiation	J:105612
Nos1^tm1Plh/Nos1^tm1Plh (B6.129S4-Nos1^tm1Plh/J)	decreased inflammatory response	J:103018
Nos1^tm1Plh/Nos1^tm1Plh Nos2^tm1Mrl/Nos2^tm1Mrl Nos3^tm1Plh/Nos3^tm1Plh (involves: 129S4/SvJae * 129S7/SvEvBrd)	abnormal osteoclast physiology	J:150159
	increased osteoclast cell number	J:150159
Nos2^tm1Lau/Nos2^tm1Lau (involves: 129P2/OlaHsd * C57BL/6)	abnormal adaptive immunity	J:90903
	abnormal immune system morphology	J:90903
	enlarged inguinal lymph nodes	J:90903
	immune system phenotype	J:64036, J:29677
	increased single-positive T cell number	J:90903
	increased susceptibility to bacterial infection	J:100513
	increased T cell proliferation	J:90903
	skin inflammation	J:64036
Nos2^tm1Lau/Nos2^tm1Lau (B6.129P2-Nos2^tm1Lau)	abnormal osteoclast morphology	J:112399
Nos2^tm1Lau/Nos2^tm1Lau (B6.129P2-Nos2^tm1Lau)	decreased susceptibility to induced colitis	J:87601
Nos2^tm1Lau/Nos2^tm1Lau (B6.129P2-Nos2^tm1Lau/J)	abnormal inflammatory response	J:103018
Nos2^tm1Lau/Nos2^tm1Lau (B6.129P2-Nos2^tm1Lau/J)	decreased inflammatory response	J:103018
Nos2^tm1Lau/Nos2^tm1Lau (involves: 129P2/OlaHsd)	immune system phenotype	J:55936
Nos2^tm1Liew/Nos2^tm1Liew (involves: 129P2/Ola * MF1)	abnormal T-helper 1 physiology	J:25755
	decreased inflammatory response	J:25755
	decreased susceptibility to endotoxin shock	J:25755
	increased interferon-gamma secretion	J:25755
	increased susceptibility to parasitic infection	J:25755
	increased T cell proliferation	J:25755
Nos2^tm1Liew/Nos2^tm1Liew (involves: 129 * 129P2/OlaHsd)	immune system phenotype	J:118561
Nos2^tm1Mrl/Nos2^tm1Mrl (involves: 129S7/SvEvBrd)	abnormal eosinophil cell number	J:51635
	abnormal immune system physiology	J:51635
	abnormal macrophage physiology	J:120499
	decreased eosinophil cell number	J:51635
	decreased susceptibility to endotoxin shock	J:25511
	increased IgG2a level	J:51635
	increased inflammatory response	J:51635
	increased interferon-gamma secretion	J:51635
	increased susceptibility to bacterial infection	J:25511
Nos2^tm1Mrl/Nos2^tm1Mrl (involves: 129S7/SvEvBrd * C57BL/6)	increased length of allograft survival	J:54764
Nos2^tm1Mrl/Nos2^tm1Mrl (involves: 129S7/SvEvBrd * C57BL/6)	pancreas inflammation	J:65562
Nos2^tm1Mrl/Nos2^tm1Mrl (B6.129S7-Nos2^tm1Mrl)	abnormal osteoclast differentiation	J:98070
	abnormal osteoclast morphology	J:98070
	abnormal response to infection	J:98070
	decreased osteoclast cell number	J:98070
Nos2^tm1Mrl/Nos2^tm1Mrl (involves: 129S7/SvEvBrd * PL/J)	increased susceptibility to experimental autoimmune encephalomyelitis	J:46192
Nos3^em1(IMPC)Mbp/Nos3^em1(IMPC)Mbp (C57BL/6N-Nos3^em1(IMPC)Mbp/Ucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	decreased lymphocyte cell number	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
	increased neutrophil cell number	J:211773
Nos3^m1Btlr/Nos3^m1Btlr (C57BL/6J-Nos3^m1Btlr)	increased susceptibility to induced colitis	J:225268
Nos3^M2Btlr/Nos3^M2Btlr (C57BL/6J-Nos3^M2Btlr)	increased susceptibility to induced colitis	J:272392
Nos3^tm1Plh/Nos3^tm1Plh (involves: 129S4/SvJae)	abnormal leukocyte adhesion	J:55936
	abnormal neutrophil physiology	J:55936
	enhanced leukocyte tethering or rolling	J:55936
Nos3^tm1Plh/Nos3^tm1Plh (involves: 129S4/SvJae * C57BL/6)	increased susceptibility to bacterial infection	J:105005
Nos3^tm1Plh/Nos3^tm1Plh (involves: 129S4/SvJae * C57BL/6)	increased susceptibility to bacterial infection induced morbidity/mortality	J:105005
Nos3^tm1Unc/Nos3^tm1Unc (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:36559
Nos3^tm1Unc/Nos3^tm1Unc (B6.129P2-Nos3^tm1Unc/J)	abnormal osteoclast physiology	J:129477
	increased inflammatory response	J:103018
	kidney inflammation	J:148626
Notch1^tm1Agt/Notch1^tm1Agt Notch2^tm1Frad/Notch2^tm1Frad Tg(Mx1-cre)1Cgn/0 (involves: 129 * BALB/c * C57BL/6 * CBA)	abnormal T cell differentiation	J:125373
	arrested T cell differentiation	J:125373
Notch1^tm1Agt/Notch1^tm1Agt Notch2^tm3Grid/Notch2^tm3Grid Tg(TcrAND)53Hed/? (involves: 129/Sv * 129S1/Sv * C57BL/6 * SJL)	abnormal humoral immune response	J:123631
	abnormal response to infection	J:123631
	decreased interleukin-4 secretion	J:123631
Notch1^tm1Agt/Notch1^tm1Agt Tg(Mx1-cre)1Cgn/0 (involves: 129 * C57BL/6 * CBA)	abnormal B cell differentiation	J:125373
	abnormal T cell differentiation	J:125373, J:55400
	abnormal thymus cell ratio	J:55400, J:143472
	abnormal thymus morphology	J:55400
	decreased CD4-positive, alpha-beta T cell number	J:55400
	decreased CD8-positive, alpha-beta T cell number	J:55400
	decreased double-negative T cell number	J:55400
	decreased double-positive T cell number	J:55400
	decreased single-positive T cell number	J:55400
	decreased thymocyte number	J:55400
	increased immature B cell number	J:143472
	small thymus	J:55400
Notch1^tm1Con/Notch1⁺ (involves: 129S1/Sv * 129X1/SvJ * CD-1)	aortic valve inflammation	J:187551
Notch1^tm2Pst/Notch1^tm2Pst (B6.Cg-Notch1^tm2Pst)	abnormal T cell differentiation	J:131563
	decreased double-negative T cell number	J:131563
	decreased T cell number	J:131563
	decreased thymocyte number	J:131563
	increased T cell apoptosis	J:131563
Notch1^tm2Rko/Notch1^tm2Rko Notch2^tm1Rko/Notch2^tm1Rko Notch3^{Gt(PST033)Byg}/Notch3⁺ Tg(Mx1-cre)1Cgn/0 (involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * CBA)	abnormal spleen morphology	J:172442
	enlarged spleen	J:172442
	increased spleen red pulp amount	J:172442
Notch1^tm2Rko/Notch1^tm2Rko Notch2^tm1Rko/Notch2^tm1Rko Notch3^{Gt(PST033)Byg}/Notch3^{Gt(PST033)Byg} Tg(Mx1-cre)1Cgn/0 (involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * CBA)	abnormal spleen morphology	J:172442
	enlarged spleen	J:172442
	increased spleen red pulp amount	J:172442
Notch1^tm2Rko/Notch1^tm3(cre)Rko (involves: 129X1/SvJ * C57BL/6)	abnormal spleen morphology	J:171829
	chronic liver inflammation	J:171829
	enlarged spleen	J:171829
Notch2^{Gt(betageo)1Byg}/Notch2⁺ (B6.129P2-Notch2^{Gt(betageo)1Byg})	decreased marginal zone B cell number	J:146621
Notch2^tm1.1Ecan/Notch2⁺ (involves: 129 * 129S1/Sv * C57BL/6J)	abnormal osteoclast differentiation	J:230045
	abnormal osteoclast morphology	J:230045
	increased osteoclast cell number	J:230045
Notch2^tm1.1Hhi/Notch2^tm1.1Hhi Tg(Cd8a-cre)1Itan/0 (involves: C57BL/6 * CBA)	abnormal CD8-positive, alpha-beta T cell physiology	J:141009
	abnormal cytotoxic T cell physiology	J:141009
	increased susceptibility to parasitic infection	J:141009
Notch2^tm1.1Hhtg/Notch2⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	abnormal interleukin level	J:311038
	abnormal osteoclast differentiation	J:311038
	increased circulating interleukin-6 level	J:311038
	increased interleukin-6 secretion	J:311038
	increased osteoclast cell number	J:311038
Notch2^tm1Frad/Notch2^tm1Frad Tg(Mx1-cre)1Cgn/0 (involves: BALB/c * C57BL/6 * CBA)	abnormal B cell differentiation	J:125373
	absent marginal zone B cells	J:125373
Notch2^tm1Yha/Notch2⁺ (B6.129-Notch2^tm1Yha)	abnormal spleen marginal zone morphology	J:85379
	decreased B-1 B cell number	J:85379
	decreased marginal zone B cell number	J:85379
Notch2^tm2.1Ecan/Notch2^tm2.1Ecan Tg(BGLAP-cre)1Clem/0 (involves: C57BL/6J * FVB/NJ)	increased osteoclast cell number	J:246017
Notch2^tm2Hhi/Notch2^tm1.1Hhi Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA)	decreased marginal zone B cell number	J:83476
	immune system phenotype	J:83476
Notch3^em1Ecan/Notch3⁺ (C57BL/6J-Notch3^em1Ecan)	abnormal osteoclast differentiation	J:270682
Notch3^em1Ecan/Notch3⁺ (C57BL/6J-Notch3^em1Ecan)	increased osteoclast cell number	J:270682
Notch3^{tm1.1(KOMP)Vlcg}/Notch3^{tm1.1(KOMP)Vlcg} (C57BL/6N-Notch3^{tm1.1(KOMP)Vlcg}/Ucd)	increased neutrophil cell number	J:211773
	increased spleen weight	J:211773
Notch3^tm1Khan/Notch3^tm1Khan (involves: C57BL/6 * CBA)	decreased thymocyte number	J:98284
Notch3^tm1Khan/Notch3^tm1Khan (involves: C57BL/6 * CBA)	small thymus	J:98284
Notum^em1(IMPC)Tcp/Notum⁺ (C57BL/6NCrl-Notum^em1(IMPC)Tcp/Tcp)	small spleen	J:211773
Notum^{Gt(OST172035)Lex}/Notum^{Gt(OST172035)Lex} (involves: 129S5/SvEvBrd * C57BL/6)	chronic inflammation	J:274615
	increased leukocyte cell number	J:274615
	periodontium inflammation	J:266040
Nox1^tm1.1Anrt/Nox1^tm1.1Anrt Tg(Vil1-cre)997Gum/0 (involves: C57BL/6J * SJL)	colitis	J:194294
Nox1^tm1Cyn/Y (involves: 129S1/Sv * 129X1/SvJ)	abnormal cytokine secretion	J:218649
Nox4^em1(IMPC)Mbp/Nox4^em1(IMPC)Mbp (C57BL/6N-Nox4^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
Nox4^tm1Syb/Nox4^tm1Syb (involves: 129S4/SvJae)	decreased interleukin-1 beta secretion	J:298830
	decreased susceptibility to endotoxin shock	J:298830
	decreased tumor necrosis factor secretion	J:298830
Noxa1^{em1(IMPC)Ccpcz}/Noxa1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Noxa1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Npas2^em1(IMPC)Mbp/Npas2^em1(IMPC)Mbp (C57BL/6N-Npas2^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	decreased lymphocyte cell number	J:211773
	enlarged lymph nodes	J:211773
	increased neutrophil cell number	J:211773
Npas3^tm1Mesu/Npas3^tm1Mesu (B6.129S6-Npas3^tm1Mesu)	bronchiectasis	J:150793
Npat^{tm1b(EUCOMM)Wtsi}/Npat^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Npat^{tm1b(EUCOMM)Wtsi}/Wtsi)	blood in lymph vessels	J:239583
Npc1^m1N/Npc1^m1N (involves: BALB/c)	abnormal alveolar macrophage morphology	J:204311
Npc1^m1N/Npc1^m1N (involves: BALB/c)	enlarged spleen	J:76733
Npc1^m1N/Npc1^m1N (BALB/cNctr-Npc1^m1N/J)	enlarged spleen	J:179744
	microgliosis	J:209834
	nasal inflammation	J:209834
Npc1^m1N/Npc1^m1N (involves: BALB/c * C57BL/6 * CBA)	increased microglial cell activation	J:144240
Npc1^m1N/Npc1^m1N (B6.C-Npc1^m1N)	microgliosis	J:157113
Npc1^m1N/Npc1^m1N (BALB/c-Npc1^m1N)	abnormal macrophage morphology	J:221855
	abnormal microglial cell activation	J:221855
	increased macrophage derived foam cell number	J:221855
	increased microglial cell activation	J:221855
Npc1^m1N/Npc1^m1N (involves: BALB/c * C3H/HeJ * C57BL/6J)	microgliosis	J:188345
Npc1^m1N/Npc1^m1N Tg(PRNP-APPSweInd)8Dwst/0 (involves: BALB/c * C3H/HeJ * C57BL/6J)	microgliosis	J:188345
Npc1^m1N/Npc1^m1N Tlr4^tm1Aki/Tlr4^tm1Aki (involves: 129P2/OlaHsd * BALB/c)	abnormal cytokine secretion	J:118352
Npc1^m1N/Npc1^tm1.1Apl Tg(CAG-cre/Esr1)5Amc/0 (B6J.Cg-Npc1^m1N/Npc1^tm1.1Apl Tg(CAG-cre/Esr1)5Amc)	microgliosis	J:176888
Npc1^m1N/Npc1^tm1.1Apl Tg(Syn1-cre)671Jxm/0 (B6J.Cg-Npc1^m1N/Npc1^tm1.1Apl Tg(Syn1-cre)671Jxm)	microgliosis	J:176888
Npc1^m1N/Npc1^tm1.2Apl (B6.Cg-Npc1^m1N/Npc1^tm1.2Apl)	microgliosis	J:157113
Npc1^nmf164/Npc1^nmf164 (C57BL/6J-Npc1^nmf164/J)	enlarged spleen	J:179744
	increased macrophage derived foam cell number	J:179744
	increased microglial cell activation	J:179744
Npc1^spm/Npc1^spm (C57BLKS/J-Npc1^spm/J)	enlarged spleen	J:7245
Npc1^spm/Npc1^spm (C57BLKS/J-Npc1^spm/J)	increased macrophage derived foam cell number	J:7245
Npc1^tm1.1Apl/Npc1^tm1.2Apl Tg(Pcp2-cre)2Mpin/0 (B6.Cg-Npc1^tm1.1Apl/Npc1^tm1.2Apl Tg(Pcp2-cre)2Mpin)	microgliosis	J:157113
Npc1^tm1.1Dso/Npc1^tm1.1Dso (B6.129-Npc1^tm1.1Dso)	abnormal macrophage morphology	J:221855
	abnormal microglial cell activation	J:221855
	increased macrophage cell number	J:221855
	increased macrophage derived foam cell number	J:221855
	increased microglial cell activation	J:221855
	microgliosis	J:221855
Npc2^{Gt(LST105)Byg}/Npc2^{Gt(LST105)Byg} (B6.129P2-Npc2^{Gt(LST105)Byg})	abnormal immune system morphology	J:125609
	abnormal immune system physiology	J:125609
Npc2^tm1Plob/Npc2^tm1Plob (involves: 129S1/Sv * C57BL/6)	decreased NK cell number	J:125609
Npc2^tm1Plob/Npc2^tm1Plob (C.129S1-Npc2^tm1Plob)	abnormal NK cell physiology	J:125609
	abnormal T cell physiology	J:125609
	decreased NK cell number	J:125609
Npc2^tm1Plob/Npc2^tm1Plob (involves: 129S1/Sv * BALB/c)	abnormal alveolar macrophage morphology	J:204311
Npepps^tm1Klr/Npepps^tm1Klr (involves: 129 * C57BL/6)	immune system phenotype	J:131502
Npffr2^tm1.2Ics/Npffr2^tm1.2Ics (involves: C57BL/6N)	abnormal macrophage activation involved in immune response	J:245025
	decreased macrophage cell number	J:245025
	decreased macrophage proliferation	J:245025
Nphp3^pcy/Nphp3^pcy (KK-Nphp3^pcy)	kidney inflammation	J:8302
Nphp3^pcy/Nphp3^pcy (either: D2.KK-Nphp3^pcy or (involves: DBA/2Fg * DBA/2J * KK))	kidney inflammation	J:11399
Nphp3^pol/Nphp3^pol (C57BL/6JSfdAnu-Nphp3^pol/Anu)	kidney inflammation	J:104190
Npl^{Gt(OST15553)Lex}/Npl^{Gt(OST15553)Lex} (involves: 129S5/SvEvBrd * C57BL/6J)	immune system phenotype	J:103485
Npm1^tm1Gsva/Npm1⁺ Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA)	decreased B cell number	J:172071
	enlarged spleen	J:172071
	increased granulocyte number	J:172071
	increased leukocyte cell number	J:172071
	increased spleen weight	J:172071
Npm1^tm1Hft/Npm1⁺ (involves: 129)	abnormal granulocyte differentiation	J:194999
	abnormal spleen B cell follicle morphology	J:194999
	enlarged spleen	J:194999
	increased granulocyte number	J:194999
	increased leukocyte cell number	J:194999
	increased monocyte cell number	J:194999
	increased spleen weight	J:194999
	myeloid hyperplasia	J:194999
Npm1^tm1Ppp/Npm1⁺ (involves: 129S1/Sv * C57BL/6)	abnormal thrombopoiesis	J:101494
Npr1^tm1Gar/Npr1^tm1Gar (B6.129S7-Npr1^tm1Gar)	impaired neutrophil chemotaxis	J:70496
Npr2^cn/Npr2^cn (AKR/J)	small spleen	J:5109
Npr3^tm1Unc/Npr3^tm1Unc (involves: 129 * C57BL/6)	abnormal osteoclast morphology	J:56058
Nprl3^tm1.1Drhi/Nprl3^tm1.1Drhi (involves: 129P2/OlaHsd)	abnormal lymph organ development	J:183988
Npsr1^{tm1b(KOMP)Wtsi}/Npsr1^{tm1b(KOMP)Wtsi} (C57BL/6N-Npsr1^{tm1b(KOMP)Wtsi}/Rbrc)	increased eosinophil cell number	J:211773
Npsr1^tm1Bhk/Npsr1^tm1Bhk (either: (involves: 129S6/SvEvTac * BALB/c) or (involves: 129S6/SvEvTac * C57BL/6))	immune system phenotype	J:144688
Npsr1^tm1Bhk/Npsr1^tm1Bhk (129S/SvEv-Npsr1^tm1Bhk)	immune system phenotype	J:144688
Npy1r^tm1.1Wpg/Npy1r^tm1.1Wpg (involves: 129X1/SvJ * C57BL/6)	abnormal immune cell physiology	J:118850
	abnormal immune system organ morphology	J:118850
	abnormal immune system physiology	J:118850
	abnormal immunoglobulin level	J:118850
	abnormal inflammatory response	J:118850
	abnormal lymph node cell ratio	J:118850
	abnormal macrophage physiology	J:118850
	abnormal professional antigen presenting cell physiology	J:118850
	abnormal spleen morphology	J:118850
	abnormal splenic cell ratio	J:118850
	abnormal T cell activation	J:118850
	abnormal T cell number	J:118850
	abnormal T-helper 1 physiology	J:118850
	decreased B cell number	J:118850
	decreased CD8-positive, alpha-beta T cell number	J:118850
	decreased circulating interleukin-12 level	J:118850
	decreased circulating tumor necrosis factor level	J:118850
	decreased IgG2a level	J:118850
	decreased interferon-gamma secretion	J:118850
	decreased marginal zone B cell number	J:118850
	decreased mature B cell number	J:118850
	decreased susceptibility to type IV hypersensitivity reaction	J:118850
	decreased transitional stage B cell number	J:118850
	increased CD4-positive, alpha-beta T cell number	J:118850
	increased CD8-positive, alpha-beta T cell number	J:118850
	increased IgA level	J:118850
	increased IgG2b level	J:118850
	increased IgM level	J:118850
	increased immunoglobulin level	J:118850
	increased single-positive T cell number	J:118850
	small spleen	J:118850
Npy2r^em1(IMPC)H/Npy2r^em1(IMPC)H (C57BL/6N-Npy2r^em1(IMPC)H/H)	enlarged spleen	J:211773
	increased spleen weight	J:211773
Npy2r^tm1.1Hhz/Npy2r^tm1.1Hhz (involves: 129X1/SvJ * BALB/cJ * C57BL/6)	decreased osteoclast cell number	J:84570
Npy2r^tm1Hhz/Npy2r^tm1Hhz (involves: 129X1/SvJ * C57BL/6)	decreased osteoclast cell number	J:97455
Nqo2^tm1Akj/Nqo2^tm1Akj (Not Specified)	abnormal lymphopoiesis	J:80549
Nqo2^tm1Akj/Nqo2^tm1Akj (Not Specified)	increased granulocyte number	J:80549
Nr1d1^{tm1(KOMP)Vlcg}/Nr1d1^{tm1(KOMP)Vlcg} (C57BL/6N-Nr1d1^{tm1(KOMP)Vlcg}/Bay)	decreased NK cell number	J:211773
Nr1h2^tm1.1Gstr/Nr1h2^tm1.1Gstr (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	increased microglial cell activation	J:278794
Nr1h2^tm1.1Gstr/Nr1h2^tm1.1Gstr Nr1h3^tm1.1Gstr/Nr1h3^tm1.1Gstr (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	increased macrophage derived foam cell number	J:81790, J:234268
	lung inflammation	J:234268
Nr1h2^tm1Djm/Nr1h2^tm1Djm (involves: 129S6/SvEvTac * C57BL/6)	increased susceptibility to bacterial infection	J:81696
Nr1h2^tm1Djm/Nr1h2^tm1Djm Nr1h3^tm1Djm/Nr1h3^tm1Djm (involves: 129S6/SvEvTac * C57BL/6)	abnormal macrophage morphology	J:125452
	increased susceptibility to bacterial infection	J:81696
Nr1h3^tm1Djm/Nr1h3^tm1Djm (involves: 129S6/SvEvTac * C57BL/6)	increased inflammatory response	J:158168
	increased susceptibility to bacterial infection	J:81696
Nr1h3^tm1Wexi/Nr1h3^tm1Wexi (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	decreased susceptibility to endotoxin shock	J:155709
Nr1h4^tm1.1Mbj/Nr1h4^tm1.1Mbj (B6N.B6-Nr1h4^tm1.1Mbj)	increased spleen weight	J:200842
Nr1h4^tm1.1Mbj/Nr1h4^tm1.1Mbj (B6N.B6-Nr1h4^tm1.1Mbj)	liver inflammation	J:200842
Nr1h4^tm1Gonz/Nr1h4^tm1Gonz (involves: 129X1/SvJ * C57BL/6)	liver inflammation	J:118204
Nr2c2^tm1Amj/Nr2c2^tm1Amj (B6.129-Nr2c2^tm1Amj)	decreased inflammatory response	J:169333
Nr2f2^tm2.1Tsa/Nr2f2^tm2.1Tsa Rbpj^tm1Hon/Rbpj^tm1Hon Tg(Tek-cre)1Ywa/0 (involves: 129S1/Sv * 129S7/SvEvBrd * C57BL/6 * SJL)	decreased lymphatic vessel endothelial cell number	J:158959
Nr2f2^tm2.1Tsa/Nr2f2^tm2.1Tsa Tg(Tek-cre)1Ywa/0 (involves: 129S1/Sv * 129S7/SvEvBrd * C57BL/6 * SJL)	decreased lymphatic vessel endothelial cell number	J:158959
Nr3c1^tm1.1Jaci/Nr3c1^tm1.1Jaci Tg(Myh6-cre)2182Mds/0 (involves: C57BL/6 * FVB/N)	heart inflammation	J:201995
Nr3c1^tm1.1Jda/Nr3c1⁺ Tg(Lck-cre)548Jxm/0 (B6.Cg-Nr3c1^tm1.1Jda Tg(Lck-cre)548Jxm)	decreased thymocyte apoptosis	J:189951
Nr3c1^tm1.1Jda/Nr3c1^tm1.1Jda Rag2^tm1.1Cgn/Rag2^tm1.1Cgn Tg(Lck-cre)548Jxm/0 Tg(TcrAND)53Hed/0 (B6.Cg-Rag2^tm1.1Cgn Nr3c1^tm1.1Jda Tg(Lck-cre)548Jxm Tg(TcrAND)53Hed)	decreased double-positive T cell number	J:189951
Nr3c1^tm1.1Jda/Nr3c1^tm1.1Jda Tcra^tm1Mom/Tcra^tm1Mom Tg(Lck-cre)548Jxm/0 (B6.Cg-Tcra^tm1Mom Nr3c1^tm1.1Jda Tg(Lck-cre)548Jxm)	decreased double-positive T cell number	J:189951
Nr3c1^tm1.1Jda/Nr3c1^tm1.1Jda Tg(Lck-cre)548Jxm/0 (B6.Cg-Nr3c1^tm1.1Jda Tg(Lck-cre)548Jxm)	abnormal humoral immune response	J:189951
	decreased CD4-positive, alpha-beta T cell number	J:189951
	decreased CD8-positive, alpha-beta T cell number	J:189951
	decreased double-positive T cell number	J:189951
	decreased single-positive T cell number	J:189951
	decreased thymocyte apoptosis	J:189951
	thymus hypoplasia	J:189951
Nr3c1^tm1Dage/Nr3c1⁺ (involves: 129P1/ReJ * C57BL/6 * C57BL/6J * SJL)	decreased B cell number	J:147914
Nr3c1^tm1Dage/Nr3c1^tm1Dage (involves: 129P1/ReJ * C57BL/6 * C57BL/6J * SJL)	decreased B cell number	J:147914
	decreased CD4-positive, alpha-beta T cell number	J:147914
	decreased CD8-positive, alpha-beta T cell number	J:147914
	decreased macrophage cell number	J:147914
Nr3c1^tm1Ljm/Nr3c1^tm1Ljm (involves: 129S6/SvEvTac * C57BL/6)	abnormal thymocyte apoptosis	J:82174
Nr3c1^tm2.1Gsc/Nr3c1⁺ (B6.129P2-Nr3c1^tm2.1Gsc)	decreased T cell apoptosis	J:126427
Nr3c1^tm2.1Gsc/Nr3c1⁺ (B6.129P2-Nr3c1^tm2.1Gsc)	increased susceptibility to experimental autoimmune encephalomyelitis	J:137157
Nr3c1^tm2.1Ljm/Nr3c1^tm2.1Ljm Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * 129S6/SvEvTac)	abnormal interleukin-6 secretion	J:197150
	abnormal monocyte cell number	J:197150
	increased interleukin-1 beta secretion	J:197150
Nr3c1^tm2Gsc/Nr3c1^tm2Gsc Lyz2^tm1(cre)Ifo/Lyz2⁺ (B6.129P2-Lyz2^tm1(cre)Ifo Nr3c1^tm2Gsc)	immune system phenotype	J:137157
Nr3c1^tm2Gsc/Nr3c1^tm2Gsc Tg(Lck-cre)I57Jxm/0 (B6.Cg-Nr3c1^tm2Gsc Tg(Lck-cre)I57Jxm)	decreased T cell apoptosis	J:137157
	increased susceptibility to experimental autoimmune encephalomyelitis	J:137157
Nr3c1^tm2Ljm/Nr3c1^tm2Ljm Tg(Lck-cre)548Jxm/? (involves: 129S6/SvEvTac * C57BL/6 * CBA)	abnormal interferon level	J:97484
	abnormal interleukin level	J:97484
	abnormal tumor necrosis factor level	J:97484
	cecum inflammation	J:97484
	increased susceptibility to endotoxin shock	J:97484
Nr4a1^tm1Jmi/Nr4a1^tm1Jmi (involves: 129S2/SvPas)	decreased B cell apoptosis	J:306652
	immune system phenotype	J:77686
	increased B cell proliferation	J:306652
Nr4a1^tm1Jmi/Nr4a1^tm1Jmi (involves: 129S2/SvPas * C57BL/6)	decreased Ly6C low monocyte number	J:239509
Nr4a1^tm1Jmi/Nr4a1^tm1Jmi (involves: 129S2/SvPas * C57BL/6)	increased susceptibility to endotoxin shock	J:239509
Nr4a1^tm1Jmi/Nr4a1^tm1Jmi Nr4a3^tm1Omc/Nr4a3^tm1Omc (involves: 129S/SvEv * 129S2/SvPas * C57BL/6)	abnormal leukopoiesis	J:121903
	abnormal myelopoiesis	J:121903
	abnormal spleen morphology	J:121903
	abnormal thymus morphology	J:121903
	decreased lymphocyte cell number	J:121903
	enlarged lymph nodes	J:121903
	enlarged spleen	J:121903
	increased eosinophil cell number	J:121903
	increased granulocyte number	J:121903
	increased leukocyte cell number	J:121903
	increased neutrophil cell number	J:121903
Nr4a1^tm1Pcn/Nr4a1^tm1Pcn Foxp3^{tm4(YFP/icre)Ayr}/Foxp3⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	immune system phenotype	J:205658
Nr4a1^tm1Pcn/Nr4a1^tm1Pcn Tg(Cr2-cre)3Cgn/0 (involves: 129)	increased B cell proliferation	J:306652
Nr4a2^tm1.1Pcn/Nr4a2⁺ Foxp3^{tm4(YFP/icre)Ayr}/Foxp3⁺ (involves: 129S1/Sv * 129X1/SvJ)	abnormal regulatory T cell morphology	J:205658
Nr4a2^tm1.1Pcn/Nr4a2^tm1.1Pcn Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte}/Gt(ROSA)26Sor⁺ (involves: C57BL/6 * C57BL/6NTac)	abnormal regulatory T cell morphology	J:205658
	abnormal T-helper 1 cell differentiation	J:205658
	abnormal T-helper 17 cell differentiation	J:205658
Nr4a2^tm1.1Pcn/Nr4a2^tm1.1Pcn Tg(Lck-cre)1Jtak/0 (Not Specified)	abnormal regulatory T cell morphology	J:205658
	abnormal T-helper 1 cell differentiation	J:205658
	abnormal T-helper 17 cell differentiation	J:205658
	decreased regulatory T cell number	J:205658
	immune system phenotype	J:205658
	increased CD4-positive, alpha-beta T cell number	J:205658
	increased susceptibility to induced colitis	J:205658
	increased T-helper 1 cell number	J:205658
Nr5a2^tm1Auw/Nr5a2⁺ (involves: 129P2/OlaHsd)	increased susceptibility to induced colitis	J:123697
Nr5a2^tm1Sjns/Nr5a2^tm1Sjns Tg(Vil1-cre/ERT2)23Syr/? (involves: 129/Sv * C57BL/6 * DBA/2 * SJL)	increased susceptibility to induced colitis	J:123697
Nras^tm1.1Emfu/Nras^tm1.1Emfu (involves: 129S1/Sv * FVB/N)	abnormal granulocyte differentiation	J:189834
	abnormal leukocyte cell number	J:189834
	abnormal thymus morphology	J:189834
	decreased monocyte cell number	J:189834
	decreased spleen weight	J:189834
	increased granulocyte number	J:189834
	increased T cell number	J:189834
Nras^tm1Tyj/Nras^tm1Tyj Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA)	abnormal myelopoiesis	J:174880
	enlarged spleen	J:204263, J:174880
	increased leukocyte cell number	J:204263
	increased monocyte cell number	J:204263
	increased neutrophil cell number	J:204263
	myeloid hyperplasia	J:204263
Nrbp1^{tm3b(EUCOMM)Wtsi}/Nrbp1⁺ (C57BL/6N-Nrbp1^{tm3b(EUCOMM)Wtsi}/Wtsi)	decreased CD4-positive, alpha-beta T cell number	J:211773
	increased CD8-positive, alpha-beta T cell number	J:211773
Nrp1^tm1Ddg/Nrp1^tm1Ddg (involves: 129P2/OlaHsd)	abnormal dendritic cell physiology	J:161856
Nrp1^tm1Ddg/Nrp1^tm1Ddg (involves: 129P2/OlaHsd)	abnormal T cell physiology	J:161856
Nrp2^tm1.2Mom/Nrp2⁺ Sema3f^tm1.2Ddg/Sema3f⁺ (involves: 129P2/OlaHsd)	abnormal lymphatic vessel endothelial cell morphology	J:226501
Nrp2^tm1.2Mom/Nrp2^tm1.2Mom (involves: 129P2/OlaHsd)	abnormal lymphatic system physiology	J:226501
	abnormal lymphatic vessel endothelial cell morphology	J:226501
	abnormal lymphatic vessel morphology	J:226501
	lymphatic vessel hyperplasia	J:226501
Nrp2^tm1Ddg/Nrp2^tm1Ddg (involves: C57BL/6)	abnormal lymphangiogenesis	J:156869
Nrros^tm1Lex/Nrros^tm1Lex (B6.129S5-Nrros^tm1Lex)	decreased susceptibility to infection	J:209569
Nrros^tm1Lex/Nrros^tm1Lex (B6.129S5-Nrros^tm1Lex)	increased susceptibility to experimental autoimmune encephalomyelitis	J:209569
Nrsn2^{em1(IMPC)Kmpc}/Nrsn2^{em1(IMPC)Kmpc} (C57BL/6NTac-Nrsn2^{em1(IMPC)Kmpc}/Kmpc)	abnormal lymph node morphology	J:211773
Nrtn^tm1Jmi/Nrtn^tm1Jmi (involves: 129X1/SvJ * C57BL/6)	increased incidence of corneal inflammation	J:85753
Nrtn^tm1Jmi/Nrtn^tm1Jmi (involves: 129X1/SvJ * C57BL/6)	keratoconjunctivitis sicca	J:85753
Nrxn1^{tm1b(KOMP)Wtsi}/Nrxn1⁺ (C57BL/6N-Nrxn1^{tm1b(KOMP)Wtsi}/H)	increased neutrophil cell number	J:211773
Nrxn1^{tm1b(KOMP)Wtsi}/Nrxn1^{tm1b(KOMP)Wtsi} (C57BL/6N-Nrxn1^{tm1b(KOMP)Wtsi}/H)	decreased lymphocyte cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Nsd3^{tm1b(EUCOMM)Hmgu}/Nsd3^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Nsd3^{tm1b(EUCOMM)Hmgu}/H)	small spleen	J:211773
Nsg1^{tm1.1(KOMP)Vlcg}/Nsg1^{tm1.1(KOMP)Vlcg} (C57BL/6N-Nsg1^{tm1.1(KOMP)Vlcg}/Ucd)	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Nsl1^em1(IMPC)J/Nsl1⁺ (C57BL/6NJ-Nsl1^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
Nsmaf^tm1Mkr/Nsmaf^tm1Mkr (involves: 129P2/OlaHsd)	abnormal T cell physiology	J:54972
Nsmaf^tm1Mkr/Nsmaf^tm1Mkr (involves: 129P2/OlaHsd)	immune system phenotype	J:54972
Nsmaf^tm1Mkr/Nsmaf^tm1Mkr (B6.129P2-Nsmaf^tm1Mkr)	decreased susceptibility to endotoxin shock	J:89524
Nsmce1^{em1(IMPC)Wtsi}/Nsmce1⁺ (C57BL/6N-Nsmce1^{em1(IMPC)Wtsi}/Wtsi)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Nsmce2^tm2.1Ofc/Nsmce2^tm2.1Ofc Ndor1^{Tg(UBC-cre/ERT2)1Ejb}/0 (involves: 129S/SvEv * C57BL/6 * SJL)	abnormal thymus physiology	J:227197
Nsrp1^tm1.1Cdj/Nsrp1^tm1.1Cdj Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2 * SJL)	abnormal T cell number	J:306261
	decreased CD4-positive, alpha-beta T cell number	J:306261
	decreased CD8-positive, alpha-beta T cell number	J:306261
	immune system phenotype	J:306261
	increased memory T cell number	J:306261
	increased T cell apoptosis	J:306261
	increased T cell proliferation	J:306261
Nss1^NOD/ShiLtJ/Nss1^NOD/ShiLtJ (involves: C57BL/10 * NOD)	salivary gland inflammation	J:73932
Nsun2^{tm1a(EUCOMM)Wtsi}/Nsun2^{tm1a(EUCOMM)Wtsi} (B6JTyr;B6N-Nsun2^{tm1a(EUCOMM)Wtsi}/Wtsi)	abnormal thymus capsule morphology	J:239583
Nsun5^{tm2b(EUCOMM)Wtsi}/Nsun5^{tm2b(EUCOMM)Wtsi} (C57BL/6N-Nsun5^{tm2b(EUCOMM)Wtsi}/J)	decreased lymphocyte cell number	J:211773
	decreased spleen weight	J:211773
	increased neutrophil cell number	J:211773
Nsv1^C57BL/6J/? (involves: BALB/cBy * C57BL/6J)	increased susceptibility to viral infection	J:71216
Nt5c3^em1(IMPC)Tcp/Nt5c3^em1(IMPC)Tcp (C57BL/6NCrl-Nt5c3^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Nt5e^em1(IMPC)Mbp/Nt5e^em1(IMPC)Mbp (C57BL/6NCrl-Nt5e^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Ntan1^tm1Avar/Ntan1^tm1Avar (involves: 129)	abnormal T cell physiology	J:62140
	decreased splenocyte proliferation	J:62140
	increased acute inflammation	J:62140
Ntaq1^{tm1.1(KOMP)Vlcg}/Ntaq1^{tm1.1(KOMP)Vlcg} (C57BL/6N-Ntaq1^{tm1.1(KOMP)Vlcg}/J)	increased leukocyte cell number	J:211773
Ntn4^{tm1b(KOMP)Wtsi}/Ntn4^{tm1b(KOMP)Wtsi} (C57BL/6N-Ntn4^{tm1b(KOMP)Wtsi}/Wtsi)	abnormal spleen morphology	J:211773
Ntrk1^{tm1b(EUCOMM)Wtsi}/Ntrk1⁺ (C57BL/6N-Ntrk1^{tm1b(EUCOMM)Wtsi}/H)	increased basophil cell number	J:211773
Ntrk1^tm1Tes/Ntrk1^tm1Tes Tg(Tuba1-cre)1Tes/0 (involves: 129S1/Sv)	abnormal mast cell physiology	J:93578
	increased B-1 B cell number	J:93578
	increased IgG1 level	J:93578
	increased IgG2a level	J:93578
	increased IgM level	J:93578
	increased immunoglobulin level	J:93578
Nub1^{tm1b(EUCOMM)Hmgu}/Nub1^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Nub1^{tm1b(EUCOMM)Hmgu}/Ccpcz)	abnormal spleen morphology	J:211773
	decreased CD4-negative NK T cell number	J:211773
	decreased CD4-positive, alpha-beta T cell number	J:211773
	decreased CD5-positive Ly6C-positive T cell number	J:211773
	decreased CD8-positive, alpha-beta T cell number	J:211773
	decreased CD11b-high dendritic cell number	J:211773
	decreased Ly6C-positive NK T cell number	J:211773
	decreased memory-marker CD4-negative NK T cell number	J:211773
	decreased NK cell number	J:211773
	decreased NK T cell number	J:211773
	enlarged spleen	J:211773
	immune system phenotype	J:211773
	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
	increased effector memory T-helper cell number	J:211773
	increased Ly6C-positive NK T cell number	J:211773
Nucb1^em1(IMPC)Mbp/Nucb1^em1(IMPC)Mbp (C57BL/6NCrl-Nucb1^em1(IMPC)Mbp/Mmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Nucb2^tm1.2Vdix/Nucb2^tm1.2Vdix (involves: C57BL/6)	increased interleukin-1 beta secretion	J:270674
Nucb2^tm1.2Vdix/Nucb2^tm1.2Vdix (involves: C57BL/6)	increased tumor necrosis factor secretion	J:270674
Nucks1^{tm1b(EUCOMM)Hmgu}/Nucks1^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Nucks1^{tm1b(EUCOMM)Hmgu}/Ieg)	enlarged lymph nodes	J:211773
	increased leukocyte cell number	J:211773
Nudc^{tm1c(KOMP)Mbp}/Nudc^{tm1c(KOMP)Mbp} Tg(Rho-icre)1Ck/0 (involves: C57BL/6 * C57BL/6N * SJL)	increased microglial cell activation	J:346299
Nudcd3^{em1(IMPC)Wtsi}/Nudcd3^{em1(IMPC)Wtsi} (C57BL/6N-Nudcd3^{em1(IMPC)Wtsi}/Wtsi)	abnormal immunoglobulin light chain V-J recombination	J:351330
	abnormal T cell differentiation	J:351330
	abnormal T cell receptor V(D)J recombination	J:351330
	decreased NK T cell number	J:351330
	increased DN3 thymocyte number	J:351330
	increased double-negative T cell number	J:351330
	increased double-positive T cell number	J:351330
	increased IgE level	J:351330
	increased IgG2b level	J:351330
	increased IgM level	J:351330
	increased memory T cell number	J:351330
	increased pre-B cell number	J:351330
	thymus hypoplasia	J:351330
Nudt1^tm1Tts/Nudt1^tm1Tts Ogg1^tm1Yun/Ogg1^tm1Yun (involves: 129S/SvEv * C57BL/6JJcl)	microgliosis	J:193978
Nudt2^{tm1a(EUCOMM)Wtsi}/Nudt2^{tm1a(EUCOMM)Wtsi} (C57BL/6-Nudt2^{tm1a(EUCOMM)Wtsi})	immune system phenotype	J:315167
Nudt7^em1Ejj/Nudt7^em1Ejj (involves: C57BL/6N)	increased susceptibility to induced arthritis	J:266261
Nudt7^em1Ejj/Nudt7^em1Ejj (involves: C57BL/6N)	osteoarthritis	J:266261
Nudt15^em1Maska/Nudt15⁺ (C57BL/6-Nudt15^em1Maska)	decreased neutrophil cell number	J:285800
Nudt15^em1Maska/Nudt15^em1Maska (C57BL/6-Nudt15^em1Maska)	decreased neutrophil cell number	J:285800
Nudt21^tm1.1Ejwpj/Nudt21^tm1.1Ejwpj Tg(Col1a1-cre/ERT2)1Crm/0 (involves: C57BL/6J * CBA/J)	increased acute inflammation	J:283035
Nuggc^{em1(IMPC)Ccpcz}/Nuggc^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Nuggc^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Nuggc^tm1Diaz/Nuggc^tm1Diaz Edil3^{Tg(Sox2-cre)1Amc}/Edil3⁺ (involves: C57BL/6 * C57BL/6J * CBA)	abnormal somatic hypermutation frequency	J:190402
	immune system phenotype	J:190402
Nup35^m1Apb/Nup35^m1Apb (involves: C57BL/6N)	abnormal macrophage morphology	J:235141
Nup62cl^em1(IMPC)J/Y (C57BL/6NJ-Nup62cl^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
Nup85^tm1.1Yter/Nup85^tm1.1Yter Tg(CAG-cre/Esr1)5Amc/0 (involves: C57BL/6 CBA)	decreased Ly6C high monocyte number	J:292726
	decreased Ly6C low monocyte number	J:292726
	decreased macrophage cell number	J:292726
Nup98^tm1Bmaf/Nup98⁺ (involves: 129S6/SvEvTac * C57BL/6)	abnormal level of surface class I molecules	J:110907
	abnormal level of surface class II molecules	J:110907
	abnormal MHC II cell surface expression on macrophages	J:110907
	decreased B cell number	J:110907
	decreased CD4-positive, alpha-beta T cell number	J:110907
	decreased IgG1 level	J:110907
	decreased IgG level	J:110907
	decreased T cell proliferation	J:110907
	increased T cell proliferation	J:110907
Nup155^em1(IMPC)Mbp/Nup155⁺ (C57BL/6NCrl-Nup155^em1(IMPC)Mbp/Mmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Nup210^enuI476T/Nup210^enuI476T (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal alpha-beta T cell morphology	J:266693
	decreased CD4-positive, alpha-beta T cell number	J:266693
Nup210^enuI476T/Nup210^{tm1a(EUCOMM)Hmgu} (involves: 129S1/Sv * 129X1/SvJ * C57BL/6N)	decreased CD4-positive, alpha-beta T cell number	J:266693
Nup210^tm1.1Mdan/Nup210^tm1.1Mdan (B6.Cg-Nup210^tm1.1Mdan)	abnormal CD4-positive, alpha-beta T cell number	J:282451
	abnormal CD4-positive, alpha-beta T cell physiology	J:282451
	abnormal lymphocyte morphology	J:282451
	abnormal T cell activation	J:282451
	decreased CD4-positive, alpha-beta T cell number	J:282451
	decreased leukocyte cell number	J:282451
	increased effector memory T-helper cell number	J:282451
Nup210^{tm1b(EUCOMM)Hmgu}/Nup210^{tm1b(EUCOMM)Hmgu} (involves: C57BL/6N)	decreased alpha-beta T cell number	J:266693
	decreased CD4-positive, alpha-beta T cell number	J:266693
	decreased CD8-positive, alpha-beta T cell number	J:266693
	decreased T cell number	J:266693
	immune system phenotype	J:266693
	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:266693
	increased CD8-positive, alpha-beta T cell number	J:266693
	increased central memory CD8 positive, alpha-beta T cell number	J:266693
	increased T-helper 1 cell number	J:266693
Nup210^tm1Mdan/Nup210^tm1Mdan Tg(Cd4-cre/ERT2)11Gnri/0 (involves: 129X1/SvJ * C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:282451
Nus1^tm1Wcsa/Nus1^tm1Wcsa Tg(Cdh5-cre/ERT2)1Rha/0 (Not Specified)	abnormal jugular lymph sac morphology	J:230506
Nwa2^NZW/LacJ/Nwa2^NZW/LacJ (involves: BALB/cJ * NZW/LacJ)	increased anti-histone antibody level	J:35434
Nwa2^NZW/LacJ/Nwa2^NZW/LacJ (involves: BALB/cJ * NZW/LacJ)	increased anti-single stranded DNA antibody level	J:35434
Nwd1^em2.1Sisa/Nwd1^em2.1Sisa (involves: C57BL/6 * C57BL/6N * DBA/2)	abnormal Kupffer cell morphology	J:363603
	increased leukocyte cell number	J:363603
Nwd2^{em1(IMPC)Ccpcz}/Nwd2^{em1(IMPC)Ccpcz} (C57BL/6N-Nwd2^{em1(IMPC)Ccpcz}/Ccpcz)	decreased CD8-positive, naive alpha-beta T cell number	J:211773
Nxn^{tm1b(EUCOMM)Wtsi}/Nxn⁺ (C57BL/6N-Nxn^{tm1b(EUCOMM)Wtsi}/Ccpcz)	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
Nxnl1^tm1.2Tlev/Nxnl1^tm1.2Tlev (involves: BALB/c * BALB/cJ * C57BL/6)	microgliosis	J:186370
Nxnl2^{em1(IMPC)Ccpcz}/Nxnl2⁺ (C57BL/6NCrl-Nxnl2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Nxnl2^{em1(IMPC)Ccpcz}/Nxnl2^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Nxnl2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Oas1b^Flv-mr/Oas1b^Flv-mr (MOLD/RkJ)	decreased susceptibility to Flaviviridae infection	J:3674
Oas1b^Flv-r/Oas1b^Flv-r (multiple strains)	decreased susceptibility to Flaviviridae infection	J:15009
Oas1b^Flv-r/Oas1b^Flv-r (C3.PRI-Oas1b^Flv-r)	decreased susceptibility to Flaviviridae infection	J:175365
Oas1b^Flv-s/Oas1b^Flv-s (multiple strains)	increased susceptibility to Flaviviridae infection	J:15009
Oas1b^tm1.1Brin/Oas1b^tm1.1Brin (involves: 129X1/SvJ * C57BL/6J)	decreased susceptibility to Flaviviridae infection	J:175365
Oas1c^{em1(IMPC)Ccpcz}/Oas1c^{em1(IMPC)Ccpcz} (C57BL/6N-Oas1c^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
	small spleen	J:211773
Oasl1^tm1Yjk/Oasl1^tm1Yjk (B6.129P2-Oasl1^tm1Yjk)	abnormal circulating interferon level	J:194467
	decreased susceptibility to Picornaviridae infection	J:194467
	decreased susceptibility to Picornaviridae infection induced morbidity/mortality	J:194467
Obp2b^{em1(IMPC)Kmpc}/Obp2b^{em1(IMPC)Kmpc} (C57BL/6NTac-Obp2b^{em1(IMPC)Kmpc}/Kmpc)	abnormal lymph node morphology	J:211773
Oca2^p-3Btlr/Oca2^p-3Btlr (C57BL/6J-Oca2^p-3Btlr)	abnormal NK cell physiology	J:133623
Oca2^p-3Btlr/Oca2^p-3Btlr (C57BL/6J-Oca2^p-3Btlr)	increased susceptibility to bacterial infection	J:133623
Oca2^p-4Btlr/Oca2^p-4Btlr (C57BL/6J-Oca2^p-4Btlr)	immune system phenotype	J:133624
Oca2^p-4Btlr/Oca2^p-4Btlr (C57BL/6J-Oca2^p-4Btlr)	increased susceptibility to bacterial infection	J:133624
Oca2^p-8Btlr/Oca2^p-8Btlr (C57BL/6J-Oca2^p-8Btlr)	increased susceptibility to induced colitis	J:264643
Oca2^p-23DFiOD/Oca2^p-x (Not Specified)	increased spleen weight	J:66645
Oca2^p-30PUb/Oca2^p-x (Not Specified)	increased spleen weight	J:89922
Oca2^p-Btlr/Oca2^p-Btlr (C57BL/6J-Oca2^p-Btlr)	immune system phenotype	J:133621
Ociad1^em1(IMPC)J/Ociad1^em1(IMPC)J (C57BL/6NJ-Ociad1^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
Ociad1^tm1.1Msin/Ociad1^tm1.1Msin (involves: BALB/cJ * C57BL/6NCrlj * CBA/JNCrlj)	decreased B cell number	J:279239
	decreased T cell number	J:279239
	enlarged spleen	J:279239
	increased granulocyte number	J:279239
	increased macrophage cell number	J:279239
	increased monocyte cell number	J:279239
	increased neutrophil cell number	J:279239
	increased spleen germinal center size	J:279239
Ocln^{Gt(ROSA)39Tshi}/Ocln^{Gt(ROSA)39Tshi} (involves: DBA/2)	stomach inflammation	J:110222
Ocln^tm1Sts/Ocln^tm1Sts (involves: 129S4/SvJae * C57BL/6)	stomach inflammation	J:99467
Ocln^tm1Tshi/Ocln^tm1Tshi (involves: C57BL/6 * DBA/2)	stomach inflammation	J:110222
Ocln^tm2Sts/Ocln^tm2Sts (involves: 129S4/SvJae * C57BL/6)	stomach inflammation	J:99467
Ocstamp^{tm2a(KOMP)Wtsi}/Ocstamp^{tm2a(KOMP)Wtsi} (involves: C57BL/6J * C57BL/6N)	abnormal osteoclast morphology	J:233553
Odad2^b2b227.1Clo/Odad2^b2b227.1Clo (C57BL/6J-Odad2^b2b227.1Clo)	spleen hypoplasia	J:175213
Odad2^em1(IMPC)Mbp/Odad2^em1(IMPC)Mbp (C57BL/6N-Odad2^em1(IMPC)Mbp/MbpMmucd)	small spleen	J:211773
Odad3^b2b1885Clo/Odad3^b2b1885Clo (C57BL/6J-Odad3^b2b1885Clo)	spleen hypoplasia	J:175213
Odad3^{tm1b(EUCOMM)Hmgu}/Odad3^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Odad3^{tm1b(EUCOMM)Hmgu}/Cnrm)	abnormal spleen morphology	J:278798
	absent spleen	J:278798
	enlarged spleen	J:278798
Odaph^{em1(IMPC)Ccpcz}/Odaph^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Odaph^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Odf2^tm1.1Sats/Odf2^tm1.2Sats Tg(CAG-cre)13Miya/0 (involves: C57BL/6 * C57BL/6J)	immune system phenotype	J:181294
	increased susceptibility to otitis media	J:181294
	sinus inflammation	J:181294
oed/oed (STOCK pc-oed)	increased granulocyte number	J:5609
oed/oed (STOCK pc-oed)	increased leukocyte cell number	J:5609
Ogdh^{tm1e(KOMP)Wtsi}/Ogdh⁺ (C57BL/6N-Ogdh^{tm1e(KOMP)Wtsi}/Wtsi)	blood in lymph vessels	J:239583
Ogg1^tm1Yun/Ogg1^tm1Yun (involves: 129S/SvEv * C57BL/6JJcl)	microgliosis	J:193978
Ogn^{tm1b(KOMP)Wtsi}/Ogn^{tm1b(KOMP)Wtsi} (C57BL/6N-Ogn^{tm1b(KOMP)Wtsi}/J)	decreased leukocyte cell number	J:211773
Ogt^tm1Gwh/Y Tg(Lck-cre)548Jxm/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)	decreased CD4-positive, alpha-beta T cell number	J:93112
	decreased CD8-positive, alpha-beta T cell number	J:93112
	decreased double-positive T cell number	J:93112
	decreased T cell number	J:93112
	decreased thymocyte number	J:93112
	increased T cell apoptosis	J:93112
oh/oh (Not Specified)	increased macrophage cell number	J:5300
Olah^em1Kedk/Olah^em1Kedk (involves: C57BL/6)	abnormal macrophage morphology	J:353571
	abnormal macrophage physiology	J:353571
	decreased susceptibility to Orthomyxoviridae infection	J:353571
	decreased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:353571
	spleen hyperplasia	J:353571
Olfm4^tm1Gpro/Olfm4^tm1Gpro (involves: 129X1/SvJ * Black Swiss)	abnormal cytokine level	J:161279
	increased circulating interleukin-3 level	J:161279
	increased circulating interleukin-12 level	J:161279
	increased susceptibility to bacterial infection	J:161279
	stomach inflammation	J:161279
Olr1^tm1Meht/Olr1^tm1Meht (B6.129X1-Olr1^tm1Meht/Meht)	increased circulating interleukin-10 level	J:130794
Oma1^tm1Otin/Oma1^tm1Otin (involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NCr)	granulomatous inflammation	J:184716
Onecut1^tm1.1Mga/Onecut1^tm1.1Mga Tg(Pdx1-cre)89.1Dam/0 (involves: 129S6/SvEvTac * C57BL/6 * CBA * SJL)	pancreas inflammation	J:155058
Opn3^em1(IMPC)Mbp/Opn3^em1(IMPC)Mbp (C57BL/6NCrl-Opn3^em1(IMPC)Mbp/Mmucd)	decreased leukocyte cell number	J:211773
	increased basophil cell number	J:211773
Oprl1^em1(IMPC)Mbp/Oprl1^em1(IMPC)Mbp (C57BL/6N-Oprl1^em1(IMPC)Mbp/MbpMmucd)	enlarged spleen	J:211773
Oprm1^tm1Lyu/Oprm1⁺ (involves: Black Swiss)	increased splenocyte proliferation	J:39864
Oprm1^tm1Lyu/Oprm1^tm1Lyu (involves: Black Swiss)	increased splenocyte proliferation	J:39864
Optn^tm1.2Jda/Optn^tm1.2Jda (involves: 129S4/SvJae * C57BL/6J)	immune system phenotype	J:207113
Optn^tm1.2Jda/Optn^tm1.2Jda (B6.Cg-Optn^tm1.2Jda)	immune system phenotype	J:207113
Or1e1c^em1(IMPC)Mbp/Or1e1c^em1(IMPC)Mbp (C57BL/6NCrl-Or1e1c^em1(IMPC)Mbp/Mmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Or1e32^em1(IMPC)Mbp/Or1e32^em1(IMPC)Mbp (C57BL/6NCrl-Or1e32^em1(IMPC)Mbp/Mmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
Or9g4^em1(IMPC)Mbp/Or9g4^em1(IMPC)Mbp (C57BL/6N-Or9g4^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Orai1^Gt(XL922)Byg/Orai1⁺ (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	abnormal mast cell physiology	J:130479
	decreased interferon-gamma secretion	J:130479
Orai1^Gt(XL922)Byg/Orai1^Gt(XL922)Byg (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	abnormal mast cell physiology	J:130479
	decreased interferon-gamma secretion	J:130479
	decreased interleukin-2 secretion	J:130479
	decreased susceptibility to type I hypersensitivity reaction	J:130479
Orai1^tm1.1Hjm/Orai1^tm1.1Hjm Orai2^{tm1.1(KOMP)Vlcg}/Orai2^{tm1.1(KOMP)Vlcg} Tg(Cd4-cre)1Cwi/0 (B6.Cg-Tg(Cd4-cre)1Cwi Orai1^tm1.1Hjm Orai2^{tm1.1(KOMP)Vlcg})	abnormal CD4-positive helper T cell morphology	J:241365
	abnormal T cell physiology	J:241365
	decreased germinal center B cell number	J:241365
	decreased IgG level	J:241365
	decreased regulatory T cell number	J:241365
	decreased single-positive T cell number	J:241365
	immune system phenotype	J:241365
	lymph node hyperplasia	J:241365
	spleen hyperplasia	J:241365
Orai1^tm1.1Hjm/Orai1^tm1.1Hjm Tg(Cd4-cre)1Cwi/0 (B6.Cg-Orai1^tm1.1Hjm Tg(Cd4-cre)1Cwi)	abnormal T cell physiology	J:241365
Orai1^tm1Rao/Orai1⁺ (C57BL/6-Orai1^tm1Rao)	abnormal B cell activation	J:139730
Orai1^tm1Rao/Orai1⁺ (C57BL/6-Orai1^tm1Rao)	abnormal T cell activation	J:139730
Orai1^tm1Rao/Orai1^tm1Rao (involves: C57BL/6NTac * ICR)	abnormal B cell activation	J:139730
	abnormal cell-mediated immunity	J:139730
	abnormal cytokine secretion	J:139730
	abnormal mast cell physiology	J:139730
	abnormal T cell activation	J:139730
	abnormal thymocyte activation	J:139730
	blepharitis	J:139730
	decreased interferon-gamma secretion	J:139730
	decreased interleukin-2 secretion	J:139730
	decreased interleukin-4 secretion	J:139730
	decreased interleukin-10 secretion	J:139730
Orai2^{tm1.1(KOMP)Vlcg}/Orai2^{tm1.1(KOMP)Vlcg} (B6.Cg-Orai2^{tm1.1(KOMP)Vlcg})	abnormal macrophage physiology	J:241365
	abnormal T cell physiology	J:241365
Orai2^tm1.1Itl/Orai2^tm1.1Itl Tg(Cma1-cre)#Roer/0 (involves: 129S4/SvJaeSor * C57BL/6 * C57BL/6N)	increased susceptibility to type I hypersensitivity reaction	J:278536
Orai2^tm1.2Itl/Orai2^tm1.2Itl (involves: 129S4/SvJaeSor * BALB/cJ * C57BL/6 * C57BL/6N)	abnormal mast cell physiology	J:278536
	increased mast cell degranulation	J:278536
Orch4^BALB/cByJ/Orch4^BALB/cByJ (involves: BALB/cByJ * DBA/2)	testis inflammation	J:35331
Orch4^BALB/cByJ/Orch4^DBA/2J (involves: BALB/cByJ * DBA/2)	decreased inflammatory response	J:35331
Orch4^DBA/2J/Orch4^DBA/2J (involves: BALB/cByJ * DBA/2)	decreased inflammatory response	J:35331
Orch5^BALB/cByJ/Orch5^BALB/cByJ (involves: BALB/cByJ * DBA/2)	testis inflammation	J:35331
Orch5^BALB/cByJ/Orch5^DBA/2J (involves: BALB/cByJ * DBA/2)	decreased inflammatory response	J:35331
Orch5^DBA/2J/Orch5^DBA/2J (involves: BALB/cByJ * DBA/2)	decreased inflammatory response	J:35331
Orgwq1^M16i/? (involves: CAST/Ei * M16i)	increased spleen weight	J:78471
Orgwq2^M16i/? (involves: CAST/Ei * M16i)	increased spleen weight	J:78471
Orgwq6^M16i/? (involves: CAST/Ei * M16i)	increased spleen weight	J:78471
Orgwq7^M16i/? (involves: CAST/Ei * M16i)	increased spleen weight	J:78471
Orgwq8^M16i/? (involves: CAST/Ei * M16i)	increased spleen weight	J:78471
Orm2^em1Bcgen/Orm2^em1Bcgen (involves: C57BL/6J)	liver inflammation	J:333118
Orm2^{tm1(KOMP)Vlcg}/Orm2^{tm1(KOMP)Vlcg} (C57BL/6N-Orm2^{tm1(KOMP)Vlcg}/Mmucd)	kidney inflammation	J:292194
Ormdl1^em1Pdra/Ormdl1^em1Pdra (C57BL/6J-Ormdl1^em1Pdra)	immune system phenotype	J:349248
Ormdl1^em1Pdra/Ormdl1^em1Pdra Ormdl2^em1Pdra/Ormdl2^em1Pdra (C57BL/6-Ormdl1^em1Pdra Ormdl2^em1Pdra)	immune system phenotype	J:349248
Ormdl1^em1Pdra/Ormdl1^em1Pdra Ormdl3^em1Pdra/Ormdl3^em1Pdra (C57BL/6-Ormdl1^em1Pdra Ormdl3^em1Pdra)	abnormal mast cell physiology	J:349248
Ormdl2^em1Pdra/Ormdl2^em1Pdra (C57BL/6-Ormdl2^em1Pdra)	immune system phenotype	J:349248, J:328837
Ormdl2^em1Pdra/Ormdl2^em1Pdra Ormdl3^em1Pdra/Ormdl3^em1Pdra (C57BL/6-Ormdl2^em1Pdra Ormdl3^em1Pdra)	abnormal mast cell physiology	J:328837
	abnormal type I hypersensitivity reaction	J:328837
	increased interleukin-4 secretion	J:328837
	increased interleukin-6 secretion	J:328837
	increased mast cell degranulation	J:328837
	increased tumor necrosis factor secretion	J:328837
Ormdl3^em1Pdra/Ormdl3^em1Pdra (C57BL/6-Ormdl3^em1Pdra)	abnormal mast cell physiology	J:328837
	abnormal type I hypersensitivity reaction	J:328837
	increased mast cell degranulation	J:328837
Ormdl3^em1Quli/Ormdl3^em1Quli (Not Specified)	abnormal spleen morphology	J:251260
	abnormal splenic cell ratio	J:251260
	small spleen	J:251260
Os/Os⁺ (ROP/GnLeJ)	glomerulonephritis	J:28323
Osbp^em1(IMPC)Tcp/Osbp⁺ (C57BL/6NCrl-Osbp^em1(IMPC)Tcp/Cmmr)	enlarged lymph nodes	J:211773
Oscar^tm1Ywc/Oscar^tm1Ywc (involves: 129P2/OlaHsd)	abnormal osteoclast differentiation	J:178250
Oscar^tm1Ywc/Oscar^tm1Ywc Tyrobp^tm1Ttk/Tyrobp^tm1Ttk (involves: 129P2/OlaHsd * C57BL/6)	abnormal osteoclast differentiation	J:178250
	abnormal osteoclast morphology	J:178250
	abnormal osteoclast physiology	J:178250
	decreased osteoclast cell number	J:178250
Osmr^tm1Mtan/Osmr^tm1Mtan (B6.129S-Osmr^tm1Mtan)	increased circulating interleukin-10 level	J:214124
	increased circulating tumor necrosis factor level	J:214124
	increased inflammatory response	J:214124
	white adipose tissue inflammation	J:214124
Ostm1^gl/Ostm1^gl (GL/Le Edar^dl-J +/+ Ostm1^gl/J)	eye inflammation	J:13053
Otc^em1(IMPC)Tcp/Otc⁺ (C57BL/6NCrl-Otc^em1(IMPC)Tcp/Tcp)	enlarged thymus	J:211773
Otc^spf-ash/Y (involves: C57BL/6)	increased susceptibility to parasitic infection	J:23205
Otc^spf-ash/Y (B6EiC3Sn a/A-Otc^spf-ash/J)	increased susceptibility to endotoxin shock	J:108979
Otop1^{em1(IMPC)Ccpcz}/Otop1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Otop1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Otub1^{tm1c(EUCOMM)Hmgu}/Otub1^{tm1c(EUCOMM)Hmgu} Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N)	abnormal B cell activation	J:280549
	abnormal follicular B cell morphology	J:280549
	decreased B-1 B cell number	J:280549
	decreased immature B cell number	J:280549
	decreased T cell number	J:280549
	enlarged spleen	J:280549
	increased anti-double stranded DNA antibody level	J:280549
	increased anti-nuclear antigen antibody level	J:280549
	increased B cell number	J:280549
	increased B-2 B cell number	J:280549
	increased circulating interleukin-6 level	J:280549
	increased IgA level	J:280549
	increased IgG2a level	J:280549
	increased IgG2b level	J:280549
	increased IgM level	J:280549
	increased immunoglobulin level	J:280549
	increased marginal zone B cell number	J:280549
	increased mature B cell number	J:280549
	increased susceptibility to autoimmune disorder	J:280549
	increased susceptibility to systemic lupus erythematosus	J:280549
Otud1^em2Gpt/Otud1^em2Gpt (C57BL/6-Otud1^em2Gpt)	abnormal innate immunity	J:287309
	decreased susceptibility to Herpesvirales infection	J:287309
	decreased susceptibility to Riboviria infection	J:287309
	increased circulating interferon-beta level	J:287309
	increased susceptibility to endotoxin shock	J:287309
Otud3^em1Nju/Otud3^em1Nju (involves: C57BL/6N)	abnormal chemokine secretion	J:294274
	decreased susceptibility to Riboviria infection	J:294274
	decreased susceptibility to Riboviria infection induced morbidity/mortality	J:294274
	increased interferon-beta secretion	J:294274
Otud5^tm1Vmd/Otud5^tm1Vmd Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	abnormal T-helper 17 cell differentiation	J:219495
	decreased regulatory T cell number	J:219495
	decreased thymocyte number	J:219495
	immune system phenotype	J:219495
	increased circulating interleukin-17 level	J:219495
	increased interleukin-9 secretion	J:219495
	increased interleukin-17 secretion	J:219495
	increased interleukin-21 secretion	J:219495
	intestinal inflammation	J:219495
Otud5^tm1Vmd/Otud5^tm1Vmd Tg(Vav1-cre)#Cgp/0 (involves: C57BL/6)	abnormal T-helper 17 cell differentiation	J:219495
Otud6a^em1Smoc/Otud6a^em1Smoc (C57BL/6J-Otud6a^em1Smoc)	abnormal innate immunity	J:345141
	decreased susceptibility to Herpesvirales infection	J:345141
	decreased susceptibility to Riboviria infection	J:345141
Otud6a^{tm1(KOMP)Vlcg}/Otud6a^{tm1(KOMP)Vlcg} (C57BL/6N-Otud6a^{tm1(KOMP)Vlcg}/Nju)	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
Otud6b^{tm1b(EUCOMM)Wtsi}/Otud6b⁺ (C57BL/6N-Otud6b^{tm1b(EUCOMM)Wtsi}/Wtsi)	increased basophil cell number	J:211773
Otud7b^{tm1(NCOM)Cmhd}/Otud7b^{tm1(NCOM)Cmhd} (involves: C57BL/6N)	abnormal granulocyte physiology	J:209709
Otud7b^tm1Dgen/Otud7b^tm1Dgen (involves: 129 * C57BL/6)	decreased activation-induced B cell apoptosis	J:194553
	decreased susceptibility to bacterial infection	J:194553
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:194553
	increased B cell number	J:194553
	increased B cell proliferation	J:194553
	increased IgA level	J:194553
	lymphoid hyperplasia	J:194553
Otulin^em1(IMPC)Bay/Otulin⁺ (C57BL/6N-Otulin^em1(IMPC)Bay/Bay)	abnormal spleen morphology	J:211773
Otulin^em1Gvl/Otulin^{tm1c(EUCOMM)Hmgu} Tg(KRT14-cre)1Cgn/0 (involves: C57BL/6 * C57BL/6J * C57BL/6N * DBA/2)	dermatitis	J:312394
Otulin^{tm1c(EUCOMM)Hmgu}/Otulin^{tm1c(EUCOMM)Hmgu} Tg(KRT14-cre)1Cgn/0 (involves: C57BL/6 * C57BL/6N * DBA/2)	dermatitis	J:312394
Otulin^{tm1c(EUCOMM)Hmgu}/Otulin^{tm1c(EUCOMM)Hmgu} Tg(KRT14-cre)1Cgn/0 Tnfrsf1a^tm1Mak/Tnfrsf1a^tm1Mak (involves: 129S2/SvPas * C57BL/6 * C57BL/6N * DBA/2)	immune system phenotype	J:312394
Oxgr1^{tm1(KOMP)Vlcg}/Oxgr1^{tm1(KOMP)Vlcg} (involves: BALB/c * C57BL/6NTac)	abnormal immune system physiology	J:198383
Oxsr1^tm1.1Arte/Oxsr1⁺ (involves: 129S/SvEvBrd)	abnormal dendritic cell morphology	J:191351
Oxsr1^tm1.1Arte/Oxsr1⁺ (involves: 129S/SvEvBrd)	abnormal dendritic cell physiology	J:191351
P2rx2^tm1Ckn/P2rx2^tm1Ckn P2rx3^tm1Ckn/P2rx3^tm1Ckn (involves: 129P2/OlaHsd * C57BL/6)	lung inflammation	J:86890
P2rx4^tm1Ando/P2rx4^tm1Ando (involves: 129S4/SvJae * BALB/c * C57BL/6)	abnormal neutrophil physiology	J:311564
P2rx4^tm1Dgen/P2rx4^tm1Dgen (involves: 129P2/OlaHsd * C57BL/6)	abnormal macrophage physiology	J:145232
P2rx5^tm1Lex/P2rx5^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6J)	decreased CD8-positive, alpha-beta T cell number	J:82809
	increased NK cell number	J:82809
P2rx7^tm1Gab/P2rx7^tm1Gab (either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129P2/OlaHsd * C57BL/6 * DBA/2))	abnormal interleukin-6 secretion	J:66835
	decreased interleukin-1 beta secretion	J:66835
	increased osteoclast cell number	J:84145
P2rx7^tm1Gab/P2rx7^tm1Gab (B6.129P2-P2rx7^tm1Gab/J)	abnormal mast cell physiology	J:190651
P2rx7^tm1Ipch/P2rx7^tm1Ipch (B6.Cg-P2rx7^tm1Ipch)	abnormal inflammatory response	J:101945
P2rx7^tm1Ipch/P2rx7^tm1Ipch (involves: 129)	immune system phenotype	J:97422
P2rx7^tm1Ipch/P2rx7^tm1Ipch (involves: 129 * C57BL/6)	abnormal macrophage physiology	J:118561
P2rx7^tm1Lex/P2rx7^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6)	abnormal macrophage physiology	J:145020
P2ry6^tm1.1Brob/P2ry6^tm1.1Brob (involves: 129S1/Sv * 129X1/SvJ * CD-1)	abnormal macrophage physiology	J:169742
P2ry6^tm1Jabo/P2ry6^tm1Jabo Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte}/Gt(ROSA)26Sor⁺ (involves: 129 * C57BL/6 * C57BL/6NTac)	decreased IgE level	J:179177
	decreased T cell apoptosis	J:179177
	increased eosinophil cell number	J:179177
	increased interferon-gamma secretion	J:179177
	increased interleukin-4 secretion	J:179177
	increased interleukin-5 secretion	J:179177
	increased interleukin-13 secretion	J:179177
	increased neutrophil cell number	J:179177
	increased T cell proliferation	J:179177
	lung inflammation	J:179177
P2ry6^tm1Jabo/P2ry6^tm1Jabo Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte}/Gt(ROSA)26Sor⁺ (B6.Cg-Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte} P2ry6^tm1Jabo)	increased eosinophil cell number	J:179177
	increased interferon-gamma secretion	J:179177
	increased interleukin-4 secretion	J:179177
	increased interleukin-5 secretion	J:179177
	increased interleukin-13 secretion	J:179177
	increased neutrophil cell number	J:179177
	lung inflammation	J:179177
P2ry14^tm1.1Shbg/P2ry14^tm1.1Shbg (involves: 129S6/SvEvTac * C57BL/6)	increased spleen weight	J:223427
P4hb^tm1.1Geno/P4hb^tm1.2Geno Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd)	decreased neutrophil cell number	J:197556
	impaired neutrophil recruitment	J:197556
p23-ST1/p23-ST1 (C57BL/6J-p23-ST1)	microgliosis	J:158278
Paam1^MRL/MpJ/Paam1^MRL/MpJ (involves: C3H/HeJ * MRL/MpJ)	increased susceptibility to autoimmune disorder	J:76107
Paam2^MRL/MpJ/Paam2^MRL/MpJ (involves: C3H/HeJ * MRL/MpJ)	increased susceptibility to autoimmune disorder	J:76107
Pabir2^{em1(IMPC)Ccpcz}/Y (C57BL/6NCrl-Pabir2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
	small spleen	J:211773
Pabir2^{em1(IMPC)Ccpcz}/Pabir2^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Pabir2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Pacsin1^{Gt(OST287788)Lex}/Pacsin1^{Gt(OST287788)Lex} (B6.129S5-Pacsin1^{Gt(OST287788)Lex})	abnormal plasmacytoid dendritic cell physiology	J:187784
	decreased circulating interferon-alpha level	J:187784
	decreased interferon-alpha secretion	J:187784
	immune system phenotype	J:187784
Pacsin3^tm1.2Bqu/Pacsin3^tm1.2Bqu (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	myositis	J:255013
Padi2^tm1Lex/Padi2^tm1Lex (B6.129S5-Padi2^tm1Lex)	abnormal mast cell physiology	J:190651
Padi2^tm1Lex/Padi2^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6)	autoimmune response	J:190651
Padi4^em1(IMPC)Mbp/Padi4^em1(IMPC)Mbp (C57BL/6N-Padi4^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Padi4^tm1.1Kmow/Padi4^tm1.1Kmow (involves: BALB/cJ * C57BL/6)	abnormal neutrophil physiology	J:174934
	decreased susceptibility to Orthomyxoviridae infection	J:174934
Padi4^tm1.1Kmow/Padi4^tm1.1Kmow Tg(CMV-cre)1Cgn/0 (involves: BALB/cJ * C57BL/6)	immune system phenotype	J:190651
Padi4^tm1.1Ywan/Padi4^tm1.1Ywan (involves: 129S4/SvJae)	abnormal neutrophil physiology	J:165718
	impaired neutrophil phagocytosis	J:165718
	increased susceptibility to bacterial infection	J:165718
Pag1^tm1.1Tara/Pag1^tm1.1Tara (C57BL/6-Pag1^tm1.1Tara)	immune system phenotype	J:159011
Pag1^tm1Kplm/Pag1^tm1Kplm (involves: 129P2/OlaHsd * C57BL/6)	increased thymocyte number	J:101365
Pag1^tm1Tara/Pag1^tm1Tara Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	immune system phenotype	J:159011
Pah^em1(IMPC)Tcp/Pah⁺ (C57BL/6NCrl-Pah^em1(IMPC)Tcp/Tcp)	small spleen	J:211773
Paip1^em1(IMPC)Tcp/Paip1^em1(IMPC)Tcp (C57BL/6NCrl-Paip1^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Pak1^tm1Cher/Pak1^tm1Cher (B6.129S2-Pak1^tm1Cher)	abnormal mast cell physiology	J:142439
Pak1^tm1Cher/Pak1^tm1Cher (B6.129S2-Pak1^tm1Cher)	decreased mast cell degranulation	J:145444
Pak5^em1(IMPC)Mbp/Pak5^em1(IMPC)Mbp (C57BL/6N-Pak5^em1(IMPC)Mbp/Ucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
Palm^tm1.2Kili/Palm^tm1.2Kili Tg(Ins2-VEGFC)#Pepr/0 (involves: C57BL/6N)	abnormal lymphangiogenesis	J:237034
Palm^tm1.2Kili/Palm^tm1.2Kili Tg(RIP1-Tag)2Dh/0 Tg(Ins2-VEGFC)#Pepr/0 (involves: C57BL/6J * C57BL/6N * DBA/2J)	abnormal lymphangiogenesis	J:237034
Pals1^tm1Caw/Pals1^tm1Caw Tg(rx3-icre)1Mjam/0 (Not Specified)	microgliosis	J:184469
Pals2^{em1(IMPC)Rbrc}/Pals2^{em1(IMPC)Rbrc} (C57BL/6NJcl-Pals2^{em1(IMPC)Rbrc}/Rbrc)	abnormal spleen morphology	J:211773
Pamr1^{em1(IMPC)Ccpcz}/Pamr1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Pamr1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
Pan2^{tm1b(KOMP)Wtsi}/Pan2^{tm1b(KOMP)Wtsi} (C57BL/6N-Pan2^{tm1b(KOMP)Wtsi}/Mhzh)	increased eosinophil cell number	J:211773
Pan3^em1(IMPC)Tcp/Pan3⁺ (C57BL/6N-Pan3^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Pank1^tm1.1Suja/Pank1^tm1.1Suja Pank2^tm1.1Suja/Pank2^tm1.1Suja (involves: 129S/SvEv * C57BL/6J * FVB/N)	decreased spleen weight	J:189609
	small spleen	J:189609
Pank2^{em1(IMPC)Ccpcz}/Pank2^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Pank2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	immune system phenotype	J:211773
	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
Pank3^{tm1b(KOMP)Mbp}/Pank3^{tm1b(KOMP)Mbp} (C57BL/6N-Pank3^{tm1b(KOMP)Mbp}/Bay)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Panx1^tm1.2Vmd/Panx1^tm1.2Vmd (C57BL/6N-Panx1^tm1.2Vmd)	abnormal T cell physiology	J:173213
Panx1^tm1.2Vmd/Panx1^tm1.2Vmd (C57BL/6N-Panx1^tm1.2Vmd)	immune system phenotype	J:173213
Panx2^{tm1b(KOMP)Wtsi}/Panx2^{tm1b(KOMP)Wtsi} (C57BL/6N-Panx2^{tm1b(KOMP)Wtsi}/Ucd)	increased spleen weight	J:211773
Panx3^{tm1c(KOMP)Wtsi}/Panx3^{tm1c(KOMP)Wtsi} Tg(Col2a1-cre)1Star/0 (involves: C3H * C57BL/6 * C57BL/6J * C57BL/6N)	decreased susceptibility to induced arthritis	J:233542
Panx3^{tm1d(KOMP)Wtsi}/Panx3^{tm1d(KOMP)Wtsi} (involves: BALB/cJ * C3H * C57BL/6 * C57BL/6N)	decreased susceptibility to induced arthritis	J:233542
Pappa2^tm1Lex/Pappa2^tm1Lex (C57BL/6-Pappa2^tm1Lex)	increased spleen weight	J:174887
Papss2^bm/Papss2^bm (involves: C57BL/6J * LDJ/Le)	autoimmune arthritis	J:166514
Pard3^{tm1b(KOMP)Wtsi}/Pard3⁺ (C57BL/6N-Pard3^{tm1b(KOMP)Wtsi}/H)	decreased basophil cell number	J:211773
Parg^tm1Zqw/Parg^tm1Zqw (involves: 129P2/OlaHsd * C57BL/6)	increased circulating tumor necrosis factor level	J:92244
Parg^tm1Zqw/Parg^tm1Zqw (involves: 129P2/OlaHsd * C57BL/6)	increased susceptibility to endotoxin shock	J:92244
Parg^{tm2b(KOMP)Mbp}/Parg⁺ (C57BL/6N-Parg^{tm2b(KOMP)Mbp}/J)	decreased leukocyte cell number	J:211773
Parl^tm1.1Bdes/Parl^tm1.1Bdes (involves: 129P2/OlaHsd * C57BL/6J)	abnormal B cell morphology	J:116017
	decreased B cell number	J:116017
	decreased double-positive T cell number	J:116017
	decreased lymphocyte cell number	J:116017
	increased T cell apoptosis	J:116017
	spleen atrophy	J:116017
	thymus atrophy	J:116017
Parl^tm1.1Bdes/Parl^tm1.1Bdes (involves: 129P2/OlaHsd)	abnormal thymus apoptosis	J:269785
	microgliosis	J:269785
	spleen atrophy	J:269785
	thymus atrophy	J:269785
Parl^tm1Bdes/Parl^tm1Bdes Tg(Nes-cre)1Kln/0 (involves: 129P2/OlaHsd * C57BL/6 * SJL)	abnormal thymus apoptosis	J:269785
	spleen atrophy	J:269785
	thymus atrophy	J:269785
Parp1^{em1(IMPC)Ccpcz}/Parp1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Parp1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Parp1^{tm1b(EUCOMM)Hmgu}/Parp1^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Parp1^{tm1b(EUCOMM)Hmgu}/Ics)	decreased NK cell number	J:211773
	immune system phenotype	J:211773
	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
Parp1^tm1Jmdm/Parp1^tm1Jmdm (involves: 129S2/SvPas * C57BL/6)	abnormal inflammatory response	J:117701
	abnormal leukocyte migration	J:117701
Parp1^tm1Jmdm/Parp1^tm1Jmdm (involves: 129S2/SvPas)	immune system phenotype	J:47993
Parp1^tm1Zqw/Parp1^tm1Zqw (involves: 129/Sv * C57BL/6)	decreased inflammatory response	J:94497
Parp1^tm1Zqw/Parp1^tm1Zqw (129S-Parp1^tm1Zqw/J)	abnormal microglial cell physiology	J:96548
Parp1^tm1Zqw/Parp1^tm1Zqw (129S-Parp1^tm1Zqw/J)	decreased inflammatory response	J:95418
Parp1^tm1Zqw/Parp1^tm1Zqw (involves: 129S2/SvPas)	immune system phenotype	J:146533
Parp1^tm2Zqw/Parp1^tm2Zqw (either: (involves: 129P2/OlaHsd * 129/Sv) or (involves: 129P2/OlaHsd * C57BL/6))	abnormal inflammatory response	J:93479
	abnormal macrophage physiology	J:93479
	decreased circulating interleukin-1 beta level	J:93479
	decreased circulating tumor necrosis factor level	J:93479
	decreased inflammatory response	J:93479
	decreased susceptibility to endotoxin shock	J:93479
Parp9^tm1.2Arte/Parp9^tm1.2Arte (involves: C57BL/6N * FVB/N)	abnormal circulating interferon level	J:306337
	abnormal interferon secretion	J:306337
	abnormal response to infection	J:306337
Parp12^{tm1.1(KOMP)Vlcg}/Parp12^{tm1.1(KOMP)Vlcg} (C57BL/6N-Parp12^{tm1.1(KOMP)Vlcg}/Ucd)	increased basophil cell number	J:211773
	increased neutrophil cell number	J:211773
Parp14^{Gt(OST415485)Lex}/Parp14^{Gt(OST415485)Lex} (involves: 129S5/SvEvBrd * C57BL/6)	decreased B cell proliferation	J:146533
	decreased IgA level	J:146533
	decreased marginal zone B cell number	J:146533
	increased B cell apoptosis	J:146533
	increased B cell proliferation	J:146533
	increased follicular B cell number	J:146533
Parva^{em1(IMPC)Ccpcz}/Parva⁺ (C57BL/6NCrl-Parva^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Parvb^{tm1a(EUCOMM)Wtsi}/Parvb^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Parvb^{tm1a(EUCOMM)Wtsi}/Cnrm)	decreased mature B cell number	J:165965
	decreased NK cell number	J:165965
	decreased T cell number	J:165965
Patz1^tm1.1Welm/Patz1^tm1.1Welm (involves: 129P2/OlaHsd)	abnormal T cell subpopulation ratio	J:158947
	decreased splenocyte number	J:158947
	decreased thymocyte number	J:158947
Patz1^tm1.1Welm/Patz1^tm1.1Welm Tg(TcraTcrb)425Cbn/0 (involves: C57BL/6)	abnormal T cell subpopulation ratio	J:158947
	decreased CD8-positive, alpha-beta T cell number	J:158947
	increased CD4-positive, alpha-beta T cell number	J:158947
Patz1^tm1.1Welm/Patz1^tm1.1Welm Tg(TcraTcrb)1100Mjb/0 (involves: 129P2/OlaHsd * C57BL/6)	abnormal T cell subpopulation ratio	J:158947
	decreased CD8-positive, alpha-beta T cell number	J:158947
	increased CD4-positive, alpha-beta T cell number	J:158947
Patz1^tm1.2Welm/Patz1^tm1.2Welm Commd10^{Tg(Vav1-icre)A2Kio}/Commd10⁺ (B6.Cg-Patz1^tm1.2Welm Commd10^{Tg(Vav1-icre)A2Kio})	abnormal mast cell differentiation	J:209168
	decreased interleukin-6 secretion	J:209168
	immune system phenotype	J:209168
Patz1^tm1.2Welm/Patz1^tm1.2Welm Tg(Cma1-cre)#Roer/0 (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:209168
Pawr^tm1Jmos/Pawr^tm1Jmos (involves: 129/Sv * CD-1)	abnormal T-helper 2 physiology	J:85495
	enlarged spleen	J:85495
	increased B cell proliferation	J:85495
	increased lymphocyte cell number	J:85495
	increased T cell proliferation	J:85495
	spleen hyperplasia	J:85495
Pax1^un-i/Pax1⁺ (either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J))	decreased CD4-positive, alpha-beta T cell number	J:100951
	decreased CD8-positive, alpha-beta T cell number	J:100951
	decreased thymocyte number	J:100951
Pax1^un-i/Pax1^un-i (either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J))	decreased CD4-positive, alpha-beta T cell number	J:100951
	decreased CD8-positive, alpha-beta T cell number	J:100951
	decreased double-negative T cell number	J:100951
	decreased double-positive T cell number	J:100951
	decreased thymocyte number	J:100951
	increased double-negative T cell number	J:100951
Pax1^un/Pax1⁺ Tcf3^tm1Cmu/Tcf3^tm1Cmu (involves: 129P2/OlaHsd * C3H * C57BL/6)	abnormal T cell differentiation	J:103567
	abnormal T cell subpopulation ratio	J:103567
Pax3^Sp-1H/Pax3^Sp-1H (involves: 101/H * C3H/HeH * C57BL/6)	abnormal thymus morphology	J:88412
Pax3^{tm1(FOXO1A)Gcg}/Pax3⁺ (either: (involves: 129X1/SvJ * C57BL/6) or (involves: 129X1/SvJ * NMRI))	abnormal thymus lobule morphology	J:79365
	ectopic thymus	J:79365
Pax5^m1Btlr/Pax5^m1Btlr (C57BL/6J-Pax5^m1Btlr)	decreased B cell number	J:220072
	decreased IgA level	J:220072
	decreased IgG1 level	J:220072
	decreased IgG2a level	J:220072
	decreased IgG2b level	J:220072
	decreased IgG level	J:220072
	decreased IgM level	J:220072
	impaired humoral immune response	J:220072
	increased macrophage cell number	J:220072
	increased monocyte cell number	J:220072
	increased single-positive T cell number	J:220072
	increased T cell number	J:220072
Pax5^m2Btlr/Pax5⁺ (C57BL/6J-Pax5^m2Btlr)	decreased B-1b cell number	J:254824
Pax5^m2Btlr/Pax5^m2Btlr (C57BL/6J-Pax5^m2Btlr)	decreased B-1b cell number	J:254824
Pax5^m2Btlr/Pax5^m2Btlr (C57BL/6J-Pax5^m2Btlr)	increased B-1 B cell number	J:254824
Pax5^m3Btlr/Pax5⁺ (C57BL/6J-Pax5^m3Btlr)	decreased B cell number	J:254825
Pax5^m3Btlr/Pax5^m3Btlr (C57BL/6J-Pax5^m3Btlr)	abnormal humoral immune response	J:254825
	decreased B cell number	J:254825
	decreased B-1 B cell number	J:254825
	decreased IgG level	J:254825
	decreased IgM level	J:254825
	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:254825
	increased CD8-positive, alpha-beta memory T cell number	J:254825
Pax5^m4Btlr/Pax5^m4Btlr (C57BL/6J-Pax5^m4Btlr)	decreased IgD level	J:265140
Pax5^M5Btlr/Pax5^M5Btlr (C57BL/6J-Pax5^M5Btlr)	decreased IgD level	J:265141
Pax5^{tm1b(EUCOMM)Wtsi}/Pax5⁺ (C57BL/6N-Pax5^{tm1b(EUCOMM)Wtsi}/Ieg)	decreased leukocyte cell number	J:211773
	immune system phenotype	J:211773
	increased CD4-positive NK T cell number	J:211773
	increased memory-marker CD4-positive NK T cell number	J:211773
Pax5^tm1Mbu/Pax5^tm1Mbu (involves: 129S2/SvPas * C57BL/6)	abnormal B cell differentiation	J:38813
	abnormal lymphopoiesis	J:38813
	absent B-2 B cells	J:113076
	absent mature B cells	J:113076
	arrested B cell differentiation	J:113076
	decreased B cell number	J:113076
	decreased B-1 B cell number	J:113076
	decreased immature B cell number	J:113076
	decreased immunoglobulin level	J:113076
	increased T cell number	J:113076
Pax5^tm1Mbu/Pax5^tm1Mbu (involves: 129S2/SvPas)	abnormal B cell physiology	J:123629
	abnormal immunoglobulin heavy chain V(D)J recombination	J:139510
	arrested B cell differentiation	J:75504
	enhanced B cell migration	J:123629
Pax5^tm1Mbu/Pax5^tm1Mbu (either: 129 or (involves: 129S2/SvPas * C57BL/6J))	abnormal late pro-B cell	J:21935
	abnormal lymphopoiesis	J:21935
	absent late pro-B cells	J:21935
	arrested B cell differentiation	J:21935
Pax5^tm1Mbu/Pax5^tm3Mbu Tg(Mx1-cre)1Cgn/? (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * CBA)	decreased mature B cell number	J:75504
Pax5^tm3.1Mbu/Pax5^tm3.1Mbu (involves: 129P2/OlaHsd * C57BL/6)	arrested B cell differentiation	J:75504
Pax5^tm3Mbu/Pax5⁺ Tcf3^tm1(PBX1)Mlc/Tcf3⁺ Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal pro-B cell morphology	J:226241
	arrested B cell differentiation	J:226241
	decreased immature B cell number	J:226241
Pax5^tm4(CD2)Mbu/Pax5^tm4(CD2)Mbu (B6.129P2-Pax5^tm4(CD2*)Mbu)	immune system phenotype	J:144100
Pax5^tm5Mbu/Pax5^tm5Mbu (B6.129P2-Pax5^tm5Mbu)	immune system phenotype	J:144100
Pax5^tm6.1Mbu/Pax5^tm6.1Mbu (B6.129P2-Pax5^tm6.1Mbu)	immune system phenotype	J:173158
Pax6^Sey-4H/Pax6⁺ (involves: 101/H * C3H/HeCrj * C3H/HeH)	increased susceptibility to induced pancreatitis	J:124276
Pax6^Sey-Neu/Pax6⁺ (involves: 102 * C3H)	increased corneal pannus formation	J:83026
Pax7^{tm1.1(HBEGF,-EYFP)Mal}/Pax7⁺ (involves: C57BL/6)	myositis	J:180899
Pax9^tm1.1Hpt/Pax9^tm1.1Hpt Tg(Pgk1-cre)1Lni/? (involves: 129S2/SvPas * BALB/c * C57BL/6 * SJL)	abnormal thymus lobule morphology	J:125026
Pax9^tm1Rbal/Pax9^tm1Rbal (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	athymia	J:49857
Pax9^tm1Rbal/Pax9^tm1Rbal (involves: 129S1/Sv * 129X1/SvJ * CD-1)	ectopic thymus	J:311535
	thymus hypoplasia	J:311535
Paxx^em1(IMPC)Mbp/Paxx^em1(IMPC)Mbp (C57BL/6NCrl-Paxx^em1(IMPC)Mbp/Mmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
Paxx^em1Spj/Paxx^em1Spj (C57BL/6NTac-Paxx^em1Spj)	decreased B cell number	J:236776
	decreased CD4-positive, alpha-beta T cell number	J:236776
	decreased CD8-positive, alpha-beta T cell number	J:236776
	decreased follicular B cell number	J:236776
	decreased splenocyte number	J:236776
	decreased T cell number	J:236776
	decreased transitional stage B cell number	J:236776
	immune system phenotype	J:236776
	increased mature B cell number	J:236776
Paxx^em1Spj/Paxx^em1Spj Nhej1^tm1Fwa/Nhej1^tm1Fwa (involves: 129S6/SvEvTac * C57BL/6NTac)	abnormal thymus involution	J:236776
	absent lymphocyte	J:236776
	athymia	J:236776
	decreased spleen weight	J:236776
	decreased splenocyte number	J:236776
	small spleen	J:236776
Pbat1^BXSB/Slc/Pbat1^BXSB/Slc (involves: BXSB/Slc * NZW/Slc)	increased autoantibody level	J:49899
Pbat1^BXSB/Slc/Pbat1^NZW/Slc (involves: BXSB/Slc * NZW/Slc)	increased autoantibody level	J:49899
Pbat2^BXSB/Slc/Pbat2^BXSB/Slc (involves: BXSB/Slc * NZW/Slc)	increased autoantibody level	J:49899
Pbat2^BXSB/Slc/Pbat2^NZW/Slc (involves: BXSB/Slc * NZW/Slc)	increased autoantibody level	J:49899
Pbbcp1^C57BL/6J/? (involves: C57BL/6J * DBA/2J)	increased B cell number	J:74270
Pbk^tm1Zgdo/Pbk^tm1Zgdo (Not Specified)	decreased interleukin-6 secretion	J:176985
	increased interleukin-6 secretion	J:176985
	increased tumor necrosis factor secretion	J:176985
Pbrm1^tm1Zhwa/Pbrm1^tm1Zhwa Tg(Cd4-cre)1Cwi/? (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	abnormal T-helper 2 cell differentiation	J:236906
	decreased T cell proliferation	J:236906
	immune system phenotype	J:236906
	increased interleukin-4 secretion	J:236906
	increased interleukin-10 secretion	J:236906
Pbwg1.9^{M. m. castaneus}/? (involves: C57BL/6J * M. m. castaneus)	increased spleen weight	J:121981
Pbx1^em1Dunw/Pbx1^em1Dunw (C57BL/6J-Pbx1^em1Dunw)	ectopic thymus	J:320934
	spleen hypoplasia	J:320934
	thymus hypoplasia	J:320934
Pbx1^tm1.1Koss/Pbx1^tm1.1Koss Tg(WT1-cre)AG11Dbdr/0 (involves: 129P2/OlaHsd * C57BL/6)	spleen hypoplasia	J:184521
Pbx1^tm1.1Koss/Pbx1^tm1.2Koss Tmem163^{Tg(ACTB-cre)2Mrt}/0 (involves: 129P2/OlaHsd * FVB/N)	absent spleen	J:184521
Pbx1^tm1Koss/Pbx1^tm1Koss Nkx2-5^tm2(cre)Rph/Nkx2-5⁺ (involves: 129P2/OlaHsd * 129S1/Sv)	abnormal spleen mesenchyme morphology	J:184521
	abnormal spleen morphology	J:184521
	spleen hypoplasia	J:184521
Pbx1^tm1Koss/Pbx1^tm1Koss Pbx2^tm1Mlc/Pbx2⁺ Nkx2-5^tm2(cre)Rph/Nkx2-5⁺ (involves: 129P2/OlaHsd * 129S/Sv * 129S1/Sv)	abnormal spleen morphology	J:184521
	spleen hypoplasia	J:184521
Pbx1^tm1Mlc/Pbx1^tm1Mlc (involves: 129S6/SvEvTac * C57BL/6)	absent spleen	J:71996, J:70684
Pbx1^tm1Mlc/Pbx1^tm1Mlc (involves: 129S6/SvEvTac * C57BL/6)	ectopic thymus	J:71996
Pbx1^tm1Mlc/Pbx1^tm2.1Mlc (involves: 129S6/SvEvTac)	abnormal lymph node primary follicle morphology	J:132963
	decreased CD4-positive, alpha-beta T cell number	J:132963
	decreased CD8-positive, alpha-beta T cell number	J:132963
	decreased mature B cell number	J:132963
Pbx1^tm1Mlc/Pbx1^tm3.1Mlc Tg(Tek-cre)1Ywa/0 (involves: 129S6/SvEvTac * C57BL/6 * SJL)	abnormal spleen morphology	J:149799
	abnormal thymus morphology	J:149799
	decreased B cell number	J:149799
	decreased double-negative T cell number	J:149799
	decreased pre-B cell number	J:149799
	decreased pro-B cell number	J:149799
	decreased T cell number	J:149799
	small spleen	J:149799
	small thymus	J:149799
	spleen hypoplasia	J:149799
	thymus hypoplasia	J:149799
Pbx2^tm1Mlc/Pbx2^tm1Mlc (either: 129S/Sv or (involves: 129S/Sv * C57BL/6))	immune system phenotype	J:91079
Pbx4^em2Hncs/Pbx4^em2Hncs (involves: C57BL/6J * DBA * ICR)	decreased lymphocyte cell number	J:349843
Pbx4^em2Hncs/Pbx4^em2Hncs (involves: C57BL/6J * DBA * ICR)	increased neutrophil cell number	J:349843
Pbxip1^tm1Cya/Pbxip1^tm1Cya Tg(Col2a1-cre/ERT)KA3Smac/0 (involves: FVB/N)	osteoarthritis	J:270267
Pcare^tm1Kpal/Pcare^tm1Kpal (involves: C57BL/6J * C57BL/6NTac)	increased microglial cell activation	J:220866
Pcd4ts1^DBA/2/? (involves: BALB/c * C3H * C57BL/6 * DBA/2)	abnormal CD4-positive, alpha beta T cell morphology	J:83220
Pcd4ts2^BALB/c/? (involves: BALB/c * C3H * C57BL/6 * DBA/2)	abnormal CD4-positive, alpha beta T cell morphology	J:83220
Pcd4ts3^BALB/c/? (involves: BALB/c * C3H * C57BL/6 * DBA/2)	abnormal CD4-positive, alpha beta T cell morphology	J:83220
Pcd8ts1^C57BL/6/? (involves: BALB/c * C3H * C57BL/6 * DBA/2)	increased CD8-positive, alpha-beta T cell number	J:83220
Pcdh7^em1Ywc/Pcdh7^em1Ywc (Not Specified)	decreased osteoclast cell number	J:298915
Pcdha2^em1(IMPC)Tcp/Pcdha2^em1(IMPC)Tcp (C57BL/6N-Pcdha2^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Pcdhb13^em1(IMPC)Tcp/Pcdhb13^em1(IMPC)Tcp (C57BL/6N-Pcdhb13^em1(IMPC)Tcp/Tcp)	decreased basophil cell number	J:211773
	enlarged lymph nodes	J:211773
Pcdhg^em5Rwb/Pcdhg^em5Rwb (C57BL/6J-Pcdhg^em5Rwb/Rwb)	microgliosis	J:285314
Pcdhg^em41Rwb/Pcdhg^em41Rwb (C57BL/6J-Pcdhg^em41Rwb/Rwb)	microgliosis	J:285314
Pcdhg^tm1.1Tman/Pcdhg^tm1.1Tman (involves: 129S4/SvJae * C57BL/6)	microgliosis	J:188341
Pcgf2^{tm1b(KOMP)Mbp}/Pcgf2⁺ (C57BL/6N-Pcgf2^{tm1b(KOMP)Mbp}/Tcp)	abnormal spleen morphology	J:211773
	small spleen	J:211773
Pcgf2^tm1Hko/Pcgf2^tm1Hko (involves: BALB/c * C57BL/6)	abnormal T-helper 2 physiology	J:71268
	decreased lymphocyte cell number	J:71268
	decreased thymocyte number	J:71268
Pcgf3^{TgTn(sb-cHS4,Tyr)2349AOve}/Pcgf3^{TgTn(sb-cHS4,Tyr)2349AOve} (FVB/N-Pcgf3^{TgTn(sb-cHS4,Tyr)2349AOve})	absent spleen	J:175597
Pcid2^tm1Imku/Pcid2^tm1Imku Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129P2/OlaHsd * C57BL/6 * CBA)	abnormal spleen B cell follicle morphology	J:166080
	decreased follicular B cell number	J:166080
	decreased marginal zone B cell number	J:166080
	decreased mature B cell number	J:166080
Pck2^em1(IMPC)Tcp/Pck2^em1(IMPC)Tcp (C57BL/6N-Pck2^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Pclaf^tm1.1Lkd/Pclaf^tm1.1Lkd (involves: C57BL/6)	decreased leukocyte cell number	J:177782
	spleen hypoplasia	J:177782
	thymus hypoplasia	J:177782
Pclaf^{tm1a(EUCOMM)Wtsi}/Pclaf^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Pclaf^{tm1a(EUCOMM)Wtsi}/Wtsi)	decreased CD11b-high dendritic cell number	J:211773
	decreased dendritic cell number	J:211773
	decreased immature NK cell number	J:211773
	decreased plasmacytoid dendritic cell number	J:211773
	decreased regulatory T cell number	J:211773
	decreased T cell number	J:211773
	increased CD11b-low dendritic cell number	J:211773
	increased dendritic cell number	J:211773
	increased mature NK cell number	J:211773
	increased memory CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	increased pro-B cell number	J:211773
Pcm1^em1(IMPC)Tcp/Pcm1^em1(IMPC)Tcp (C57BL/6NCrl-Pcm1^em1(IMPC)Tcp/Tcp)	decreased spleen weight	J:211773
	small spleen	J:211773
Pcmt1^tm1Shs/Pcmt1^tm1Shs (involves: 129P2/OlaHsd * C57BL/6)	small spleen	J:46228
Pcna^tm1.1Mdsc/Pcna^tm1.1Mdsc Tg(Pcna*K164R)1Mdsc/0 (involves: FVB/N)	abnormal class switch recombination	J:141098
	abnormal somatic hypermutation frequency	J:141098
Pcna^tm1Jcbs/Pcna^tm1Jcbs (involves: 129P2/OlaHsd * C57BL/6)	abnormal somatic hypermutation frequency	J:125916
Pcna^tm1Jcbs/Pcna^tm1Jcbs (involves: 129P2/OlaHsd)	abnormal somatic hypermutation frequency	J:155454, J:177630
Pcna^tm1Jcbs/Pcna^tm1Jcbs Ung^tm1Tld/Ung^tm1Tld (involves: 129P2/OlaHsd)	abnormal somatic hypermutation frequency	J:155454
Pcolce2^tm1Ccb/Pcolce2^tm1Ccb Ppp1r16b^tm1Ccb/Ppp1r16b^tm1Ccb (involves: 129S1/Sv * 129X1/SvJ)	immune system phenotype	J:124347
Pcsk1^tm1Dfs/Pcsk1^tm1Dfs (involves: 129 * C57BL/6J)	abnormal peritoneal macrophage morphology	J:184882
	abnormal spleen marginal zone morphology	J:184882
	abnormal spleen white pulp morphology	J:184882
	abnormal T-helper 1 cell differentiation	J:184882
	decreased follicular dendritic cell number	J:184882
	decreased NK T cell number	J:184882
	decreased T cell number	J:184882
	enlarged spleen	J:184882
	increased circulating interferon-gamma level	J:184882
	increased circulating interleukin-1 beta level	J:184882
	increased circulating interleukin-6 level	J:184882
	increased circulating interleukin-10 level	J:184882
	increased circulating interleukin-12 level	J:184882
	increased circulating tumor necrosis factor level	J:184882
	increased interleukin-1 beta secretion	J:184882
	increased lymphocyte cell number	J:184882
	increased susceptibility to endotoxin shock	J:184882
	intermingled spleen red and white pulp	J:184882
Pcsk5^vcc/Pcsk5^vcc (involves: C57BL/6J)	abnormal thymus lobule morphology	J:136243
Pcsk5^vcc/Pcsk5^vcc (involves: C57BL/6J)	small thymus	J:136243
Pcsk9^{em1(IMPC)Ccpcz}/Pcsk9^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Pcsk9^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged thymus	J:211773
	increased CD4-positive, alpha-beta T cell number	J:211773
	increased T-helper cell number	J:211773
Pctp^tm1Bor/Pctp^tm1Bor (B6.129P2-Pctp^tm1Bor)	abnormal macrophage physiology	J:115284
Pctp^tm1Bor/Pctp^tm1Bor (B6.129P2-Pctp^tm1Bor)	increased macrophage apoptosis	J:115284
Pcyt1a^tm1Irt/Pcyt1a^tm1Irt Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129 * C57BL/6J)	abnormal immune cell physiology	J:65639
	abnormal macrophage physiology	J:65639
Pdap1^em1Rkuhn/Pdap1^em1Rkuhn Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N)	abnormal B cell physiology	J:298705
	abnormal class switch recombination	J:298705
	abnormal somatic hypermutation frequency	J:298705
	decreased germinal center B cell number	J:298705
	decreased mature B cell number	J:298705
	increased B cell apoptosis	J:298705
Pdcd1^tm1.1Liux/Pdcd1^tm1.1Liux (involves: C57BL/6)	decreased regulatory T cell number	J:190150
Pdcd1^tm1.1Liux/Pdcd1^tm1.1Liux (involves: C57BL/6)	increased T-helper 1 cell number	J:190150
Pdcd1^tm1.1Liux/Pdcd1^tm1.1Liux Tg(MMTV-PyVT)634Mul/0 (involves: C57BL/6 * FVB/N)	decreased interleukin-17 secretion	J:190150
	decreased regulatory T cell number	J:190150
	decreased T-helper 2 cell number	J:190150
	decreased T-helper 17 cell number	J:190150
	increased interferon-gamma secretion	J:190150
	increased interleukin-2 secretion	J:190150
	increased T-helper 1 cell number	J:190150
	increased tumor necrosis factor secretion	J:190150
Pdcd1^tm1.1Shr/Pdcd1^tm1.1Shr (involves: C57BL/6)	decreased B-1 B cell number	J:153040
Pdcd1^tm1.1Shr/Pdcd1^tm1.1Shr (involves: C57BL/6)	increased regulatory T cell number	J:153040
Pdcd1^tm1.1Shr/Pdcd1^tm1.1Shr Tg(TcraTcrb)1100Mjb/0 (involves: C57BL/6)	abnormal immune tolerance	J:153040
	decreased T cell proliferation	J:153040
	increased susceptibility to autoimmune diabetes	J:153040
	increased T cell proliferation	J:153040
	insulitis	J:153040
	pancreas inflammation	J:153040
Pdcd1^tm1Hon/Pdcd1^tm1Hon (involves: 129S2/SvPas * C57BL/6)	abnormal immunoglobulin level	J:50688
	abnormal leukopoiesis	J:50688
	abnormal myelopoiesis	J:50688
	enlarged spleen	J:50688
	increased B cell number	J:50688
	increased B cell proliferation	J:50688
	increased B-1 B cell number	J:50688
	increased IgA level	J:50688
	increased IgG2b level	J:50688
	increased IgG3 level	J:50688
	increased lymphocyte cell number	J:50688
Pdcd1^tm1Hon/Pdcd1^tm1Hon (B6.129S2-Pdcd1^tm1Hon)	abnormal response to transplant	J:119356
	autoimmune arthritis	J:78802
	glomerulonephritis	J:78802
Pdcd1^tm1Hon/Pdcd1^tm1Hon (C.129S2(B6)-Pdcd1^tm1Hon)	increased autoantibody level	J:66979
Pdcd1^tm1Hon/Pdcd1^tm1Hon (involves: 129S2/SvPas)	abnormal T cell activation	J:222944
	increased IgA level	J:222944
	increased IgM level	J:222944
	increased inflammatory response	J:222944
	increased interferon-gamma secretion	J:222944
Pdcd1^tm1Hon/Pdcd1^tm1Hon Tg(Tcra2D2,Tcrb2D2)1Kuch/0 (involves: 129S2/SvPas)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:140751
Pdcd1^tm1Hon/Pdcd1^tm1Hon Vsir^tm1Lex/Vsir^tm1Lex (involves: 129S2/SvPas * 129S5/SvEvBrd * C57BL/6)	abnormal T cell activation	J:222944
	immune system phenotype	J:222944
	increased IgA level	J:222944
	increased IgM level	J:222944
	increased inflammatory response	J:222944
	increased interferon-gamma secretion	J:222944
	increased interleukin-17 secretion	J:222944
	increased tumor necrosis factor secretion	J:222944
Pdcd1^tm1Hon/Pdcd1^tm1Hon Vsir^tm1Lex/Vsir^tm1Lex Tg(Tcra2D2,Tcrb2D2)1Kuch/0 (involves: 129S2/SvPas * 129S5/SvEvBrd * C57BL/6)	increased susceptibility to experimental autoimmune encephalomyelitis	J:222944
Pdcd1^tm1Llc/Pdcd1^tm1Llc (involves: 129S5/SvEvBrd)	abnormal cytokine secretion	J:126829
	decreased CD8-positive, alpha-beta T cell number	J:126829
	increased susceptibility to experimental autoimmune encephalomyelitis	J:126829
Pdcd1lg2^tm1.1Lex/Pdcd1lg2^tm1.1Lex (involves: 129S5/SvEvBrd)	decreased CD8-positive, alpha-beta T cell number	J:126829
Pdcd1lg2^tm1Dmp/Pdcd1lg2^tm1Dmp (involves: 129X1/SvJ * 129S1/Sv * C57BL/6)	abnormal dendritic cell antigen presentation	J:84457
Pdcd1lg2^tm1Dmp/Pdcd1lg2^tm1Dmp (C.129-Pdcd1lg2^tm1Dmp)	abnormal cytokine secretion	J:99212
	abnormal cytotoxic T cell physiology	J:99212
	decreased IgG2a level	J:99212
	decreased T cell proliferation	J:99212
Pdcd1lg2^tm1Shr/Pdcd1lg2^tm1Shr (involves: 129/Sv * 129S4/SvJae)	increased IgG2a level	J:113851
	increased IgM level	J:113851
	increased susceptibility to parasitic infection	J:113851
Pdcd1lg2^tm2Shr/Pdcd1lg2^tm2Shr (C.B6-Pdcd1lg2^tm2Shr)	abnormal dendritic cell physiology	J:123785
	increased interferon-gamma secretion	J:123785
	increased interleukin-2 secretion	J:123785
Pdcd1lg2^tm3Shr/Pdcd1lg2^tm3Shr (involves: C57BL/6 * NOD/MrkTac)	abnormal CD8-positive, alpha-beta T cell physiology	J:123785
	increased CD4-positive, alpha-beta T cell number	J:123785
	increased CD8-positive, alpha-beta T cell number	J:123785
	increased susceptibility to autoimmune diabetes	J:123785
	insulitis	J:123785
	lymph node hyperplasia	J:123785
Pdcd4^tm1Yhcn/Pdcd4^tm1Yhcn (B6.129S6-Pdcd4^tm1Yhcn)	abnormal cytokine secretion	J:120583
	decreased susceptibility to autoimmune diabetes	J:120583
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:120583
Pdcd6ip^{em1(IMPC)Hmgu}/Pdcd6ip^{em1(IMPC)Hmgu} (C57BL/6N-Pdcd6ip^{em1(IMPC)Hmgu}/Ieg)	enlarged lymph nodes	J:211773
Pdcd6ip^em1(IMPC)Mbp/Pdcd6ip^em1(IMPC)Mbp (C57BL/6NCrl-Pdcd6ip^em1(IMPC)Mbp/Mmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Pdcd10^tm1Kwhi/Pdcd10^tm1.1Kwhi Tg(Pdgfb-icre/ERT2,-EGFP)1Frut/? (involves: C57BL/6 * CBA)	CNS inflammation	J:173947
Pde2a^em1(IMPC)H/Pde2a⁺ (C57BL/6NTac-Pde2a^em1(IMPC)H/H)	increased neutrophil cell number	J:211773
Pde4a^tm1Mct/Pde4a^tm1Mct (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:106828
Pde4b^tm1Mct/Pde4b⁺ Pde4d^tm1Mct/Pde4d^tm1Mct (involves: 129P2/OlaHsd * C57BL/6)	impaired neutrophil recruitment	J:94853
Pde4b^tm1Mct/Pde4b^tm1Mct (involves: 129X1/SvJ * C57BL/6)	decreased tumor necrosis factor secretion	J:76862
Pde4b^tm1Mct/Pde4b^tm1Mct (involves: 129P2/OlaHsd * C57BL/6)	decreased tumor necrosis factor secretion	J:106828
	impaired neutrophil chemotaxis	J:94853
	impaired neutrophil recruitment	J:94853
Pde4b^tm1Mct/Pde4b^tm1Mct Pde4d^tm1Mct/Pde4d⁺ (involves: 129P2/OlaHsd * C57BL/6)	impaired neutrophil recruitment	J:94853
Pde4d^tm1Mct/Pde4d^tm1Mct (involves: 129P2/OlaHsd * C57BL/6)	abnormal tumor necrosis factor level	J:94853
	immune system phenotype	J:106828
	impaired neutrophil chemotaxis	J:94853
	impaired neutrophil recruitment	J:94853
Pde7a^{Gt(Betageo-puro)1Yang}/Pde7a^{Gt(Betageo-puro)1Yang} (involves: 129P2/OlaHsd * C57BL/6)	abnormal humoral immune response	J:86923
Pde7b^tm1Pfi/Pde7b^tm1Pfi (involves: 129 * C57BL/6)	immune system phenotype	J:322967
Pdgfb^tm1Cbet/Pdgfb^tm2Cbet Tg(Tie1-cre)9Ref/0 (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)	abnormal microglial cell morphology	J:89186
Pdgfc^{tm1b(EUCOMM)Hmgu}/Pdgfc⁺ (C57BL/6N-Pdgfc^{tm1b(EUCOMM)Hmgu}/Ieg)	enlarged spleen	J:211773
	increased CD4-negative, CD25-positive NK T cell number	J:211773
	increased granulocyte number	J:211773
	increased monocyte cell number	J:211773
Pdgfra^{em1(IMPC)Ccpcz}/Pdgfra⁺ (C57BL/6NCrl-Pdgfra^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal thymus morphology	J:211773
	decreased CD8-positive, naive alpha-beta T cell number	J:211773
	enlarged lymph nodes	J:211773
	enlarged thymus	J:211773
	increased CD4-positive NK T cell number	J:211773
	increased memory-marker CD4-positive NK T cell number	J:211773
	increased NK T cell number	J:211773
Pdgfra^tm8Sor/Pdgfra^tm8Sor H2az2^{Tg(Wnt1-cre)11Rth}/H2az2⁺ (Not Specified)	small thymus	J:81153
Pdgfra^tm8Sor/Pdgfra^tm8Sor Pdgfrb^tm1Mdt/Pdgfrb^tm1Mdt H2az2^{Tg(Wnt1-cre)11Rth}/H2az2⁺ (involves: C57BL/6 * CBA)	abnormal thymus development	J:122584
	thymus hypoplasia	J:122584
Pdgfra^tm12.1Sor/Pdgfra⁺ (involves: 129 * C57BL/6)	abnormal immune system organ morphology	J:146617
Pdgfrb^b2b2903Clo/Pdgfrb^b2b2903Clo (C57BL/6J-Pdgfrb^b2b2903Clo)	thymus hypoplasia	J:175213
Pdha2^em1(IMPC)Bay/Pdha2^em1(IMPC)Bay (C57BL/6N-Pdha2^em1(IMPC)Bay/Bay)	abnormal spleen morphology	J:211773
Pdia6^em1Btlr/Pdia6^m1Btlr (involves: C57BL/6J)	abnormal circulating cytokine level	J:288824
	abnormal T cell physiology	J:288824
	decreased B cell number	J:288824
	decreased double-negative T cell number	J:288824
	decreased double-positive T cell number	J:288824
	decreased follicular B cell number	J:288824
	decreased leukocyte cell number	J:288824
	decreased lymphocyte cell number	J:288824
	decreased monocyte cell number	J:288824
	decreased NK T cell number	J:288824
	decreased pre-B cell number	J:288824
	decreased transitional stage B cell number	J:288824
	increased marginal zone B cell number	J:288824
	increased marginal zone precursor B cell number	J:288824
	increased mature B cell number	J:288824
	spleen hypoplasia	J:288824
	thymus hypoplasia	J:288824
Pdia6^m1Btlr/Pdia6^m1Btlr (C57BL/6J-Pdia6^m1Btlr)	immune system phenotype	J:288824
Pdia6^{tm1b(EUCOMM)Hmgu}/Pdia6⁺ (C57BL/6N-Pdia6^{tm1b(EUCOMM)Hmgu}/Ieg)	decreased CD4-positive NK T cell number	J:211773
	enlarged lymph nodes	J:211773
Pdik1l^em1(IMPC)Mbp/Pdik1l^em1(IMPC)Mbp (C57BL/6NCrl-Pdik1l^em1(IMPC)Mbp/Mmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	increased spleen weight	J:211773
Pdk2^em1(IMPC)Mbp/Pdk2^em1(IMPC)Mbp (C57BL/6N-Pdk2^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Pdk4^tm1Tok/Pdk4^tm1Tok (B6.129P2-Pdk4^tm1Tok)	abnormal osteoclast cell number	J:179789
	abnormal osteoclast differentiation	J:179789
	abnormal osteoclast morphology	J:179789
Pdlim2^tm1Gru/Pdlim2^tm1Gru (Not Specified)	abnormal T-helper 1 physiology	J:99108
	increased interferon-gamma secretion	J:99108
	increased susceptibility to bacterial infection	J:99108
Pdlim7^em1(IMPC)Mbp/Pdlim7^em1(IMPC)Mbp (C57BL/6N-Pdlim7^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Pdlim7^{Gt(OST445990)Lex}/Pdlim7^{Gt(OST445990)Lex} (B6.129S5-Pdlim7^{Gt(OST445990)Lex})	increased lymphocyte cell number	J:209780
	increased monocyte cell number	J:209780
Pdpk1^tm1.1Mlw/Pdpk1^tm1.1Mlw Rag2^tm1Fwa/Rag2^tm1Fwa Tnfrsf4^tm2(cre)Nik/Tnfrsf4⁺ Gt(ROSA)26Sor^tm1(EYFP)Cos/Gt(ROSA)26Sor⁺ (involves: 129S/SvEv * 129X1/SvJ * C57BL/6)	dermatitis	J:226194
Pdpk1^tm1.1Mlw/Pdpk1^tm1.1Mlw Tnfrsf4^tm2(cre)Nik/Tnfrsf4⁺ Gt(ROSA)26Sor^tm1(EYFP)Cos/Gt(ROSA)26Sor⁺ (involves: 129X1/SvJ * C57BL/6)	abnormal regulatory T cell number	J:226194
	abnormal T cell physiology	J:226194
	dermatitis	J:226194
	enlarged lymph nodes	J:226194
	enlarged spleen	J:226194
Pdpk1^tm1Dral/Pdpk1^tm1Dral (B6.129P2-Pdpk1^tm1Dral)	small spleen	J:136089
Pdpk1^tm1Mlw/Pdpk1^tm1.1Daca Tg(Cd4-cre)1Cwi/0 (involves: 129P2/OlaHsd * BALB/c * C57BL/6 * DBA/2)	abnormal CD8-positive, alpha beta T cell morphology	J:165626
	decreased NK T cell number	J:165626
	decreased T cell number	J:165626
Pdpk1^tm1Mlw/Pdpk1^tm1Mlw Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	abnormal CD8-positive, alpha beta T cell morphology	J:165626
	abnormal NK T cell morphology	J:165626
	abnormal T cell differentiation	J:165626
	absent NK T cells	J:165626
	decreased NK T cell number	J:165626
	decreased T cell number	J:165626
	decreased T cell proliferation	J:165626
	immune system phenotype	J:165626
Pdpn^tm1(cre)Mlkn/Pdpn^tm1(cre)Mlkn (involves: 129S4/SvJae * C57BL/6)	abnormal lymphatic vessel morphology	J:162815
Pdpn^tm1Mcws/Pdpn⁺ (involves: 129S6/SvEvTac)	abnormal lymphatic vessel morphology	J:94978
Pdpn^tm1Mcws/Pdpn⁺ (involves: 129S6/SvEvTac)	lymphangiectasis	J:94978
Pdpn^tm1Mcws/Pdpn^tm1Mcws (involves: 129S6/SvEvTac)	abnormal lymph circulation	J:94978
	abnormal lymphatic vessel morphology	J:94978
	lymphangiectasis	J:94978
Pdpn^tm2.1Mlkn/Pdpn^tm2.1Mlkn Rag1^tm1Mom/Rag1^tm1Mom Tg(Pdgfrb-cre)9Rha/0 (involves: 129S7/SvEvBrd * C57BL/6)	absent lymphocyte	J:205423
Pdpn^tm2.1Mlkn/Pdpn^tm2.1Mlkn Tg(CAG-cre/Esr1)5Amc/0 (involves: C57BL/6 CBA)	abnormal lymph node morphology	J:205423
	absent peripheral lymph nodes	J:205423
Pdpn^tm2.1Mlkn/Pdpn^tm2.1Mlkn Tg(CAG-cre/Esr1)5Amc/0 (involves: 129 C57BL/6)	abnormal lymphangiogenesis	J:235778
Pdpn^tm2.1Mlkn/Pdpn^tm2.1Mlkn Tg(Pdgfrb-cre)9Rha/0 (involves: C57BL/6)	lymph node hemorrhage	J:205423
Pdpr^{tm1b(EUCOMM)Wtsi}/Pdpr^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Pdpr^{tm1b(EUCOMM)Wtsi}/Ics)	decreased large unstained cell number	J:211773
Pdss2^kd/Pdss2^kd (CBA/H-Pdss2^kd)	tubulointerstitial nephritis	J:197578
Pdss2^kd/Pdss2^kd (B6.CBACaH(CAST)-Pdss2^kd)	tubulointerstitial nephritis	J:101779
Pdss2^tm1Dalg/Pdss2^tm1Dalg Tg(NPHS2-cre)295Lbh/? (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	tubulointerstitial nephritis	J:136670
Pdx1^tm1Ted/Pdx1⁺ (involves: 129P2/OlaHsd)	pancreas inflammation	J:82969
Pdx1^tm1Ted/Pdx1^tm1Ted (involves: 129P2/OlaHsd)	immune system phenotype	J:20779
Pdxp^em1(IMPC)J/Pdxp^em1(IMPC)J (C57BL/6NJ-Pdxp^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
Pdzd8^{tm1b(EUCOMM)Wtsi}/Pdzd8⁺ (C57BL/6N-Pdzd8^{tm1b(EUCOMM)Wtsi}/Wtsi)	increased large unstained cell number	J:211773
Pdzk1^{tm2b(EUCOMM)Wtsi}/Pdzk1^{tm2b(EUCOMM)Wtsi} (C57BL/6N-Pdzk1^{tm2b(EUCOMM)Wtsi}/Wtsi)	abnormal lymphatic vessel morphology	J:239583
	absent connection between subcutaneous lymph vessels and lymph sac	J:239583
	blood in lymph vessels	J:239583
Pdzph1^{em1(IMPC)Ccpcz}/Pdzph1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Pdzph1^{em1(IMPC)Ccpcz}/Ccpcz)	increased basophil cell number	J:211773
Pebp1^em1(IMPC)Tcp/Pebp1^em1(IMPC)Tcp (C57BL/6NCrl-Pebp1^em1(IMPC)Tcp/Tcp)	decreased eosinophil cell number	J:211773
	enlarged lymph nodes	J:211773
	small spleen	J:211773
Pecam1^tm1Mak/Pecam1⁺ (D1.129P2-Pecam1^tm1Mak)	increased susceptibility to induced arthritis	J:106275
Pecam1^tm1Mak/Pecam1^tm1Mak (D1.129P2-Pecam1^tm1Mak)	abnormal leukocyte physiology	J:106275
	increased interferon-gamma secretion	J:106275
	increased susceptibility to induced arthritis	J:106275
	joint inflammation	J:106275
Pecam1^tm1Mak/Pecam1^tm1Mak (B6.129P2-Pecam1^tm1Mak)	abnormal cytokine secretion	J:95226
	liver inflammation	J:95226
	spleen vascular congestion	J:95226
Pecam1^tm1Mak/Pecam1^tm1Mak Pitgp^C57BL/6/Pitgp^C57BL/6 (involves: 129P2/OlaHsd * C57BL/6 * FVB/N)	peritoneal inflammation	J:144817
Peli1^tm1.1Arte/Peli1^tm1.1Arte (involves: C57BL/6N)	abnormal cytokine secretion	J:191578
	abnormal peripheral lymph node morphology	J:191578
	decreased interferon-alpha secretion	J:191578
	decreased interferon-beta secretion	J:191578
	decreased interleukin-6 secretion	J:191578
	decreased interleukin-10 secretion	J:191578
	decreased interleukin-12 secretion	J:191578
	decreased tumor necrosis factor secretion	J:191578
	enlarged lymph nodes	J:191578
	immune system phenotype	J:191578
	lymphoid hyperplasia	J:191578
Peli1^{tm1b(EUCOMM)Wtsi}/Peli1^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Peli1^{tm1b(EUCOMM)Wtsi}/Ucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	increased neutrophil cell number	J:211773
	increased spleen weight	J:211773
Peli1^tm1Tigm/Peli1^tm1Tigm (involves: 129/Sv * C57BL/6)	decreased B cell proliferation	J:152781
	decreased circulating interferon-beta level	J:152781
	decreased circulating interleukin-6 level	J:152781
	decreased circulating interleukin-12b level	J:152781
	decreased circulating tumor necrosis factor level	J:152781
	decreased interleukin-12 secretion	J:152781
	decreased susceptibility to endotoxin shock	J:152781
	increased B cell apoptosis	J:152781
Peli2^tm1.1Arte/Peli2^tm1.1Arte (involves: C57BL/6)	abnormal circulating cytokine level	J:265431
	abnormal cytokine secretion	J:265431
	decreased circulating interleukin-1 beta level	J:265431
	decreased interleukin-1 beta secretion	J:265431
	decreased interleukin-18 secretion	J:265431
	increased macrophage apoptosis	J:265431
Peli3^tm1.1Arte/Peli3^tm1.1Arte (involves: C57BL/6NTac)	abnormal dendritic cell physiology	J:188556
	abnormal macrophage cytokine production	J:188556
	decreased susceptibility to Picornaviridae infection	J:188556
	decreased susceptibility to Picornaviridae infection induced morbidity/mortality	J:188556
Penk-rs^tm1Pig/Penk-rs^tm1Pig (B6.129-Penk-rs^tm1Pig)	abnormal T-helper 2 physiology	J:62435
	decreased T-helper 2 cell number	J:62435
	lung inflammation	J:62435
Pepd^{tm1a(KOMP)Wtsi}/Pepd^{tm1a(KOMP)Wtsi} (C57BL/6N-Pepd^{tm1a(KOMP)Wtsi}/Ucd)	decreased immature B cell number	J:211773
	decreased Ly6C-positive NK T cell number	J:211773
	decreased transitional stage T1 B cell number	J:211773
	increased CD4-positive, alpha-beta T cell number	J:211773
	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
	increased effector memory T-helper cell number	J:211773
	increased leukocyte cell number	J:211773
	increased memory CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	increased memory-marker CD4-negative NK T cell number	J:211773
	increased memory-marker NK cell number	J:211773
Pepd^{tm1b(KOMP)Wtsi}/Pepd^{tm1b(KOMP)Wtsi} (C57BL/6N-Pepd^{tm1b(KOMP)Wtsi}/Ieg)	decreased B-1a cell number	J:211773
	decreased CD5-positive Ly6C-positive T cell number	J:211773
	decreased follicular B cell number	J:211773
	enlarged lymph nodes	J:211773
Perp^tm1Att/Perp^tm1Att (involves: 129S4/SvJae)	decreased thymocyte apoptosis	J:86549
Perp^tm2Att/Perp^tm2Att Tg(KRT14-cre/ERT2)1Ipc/0 (involves: 129S4/SvJae)	skin inflammation	J:167545
Pex1^tm1.1Hrw/Pex1^tm1.1Hrw (involves: C57BL/6NTac)	liver inflammation	J:278655
Pex1^tm1.1Hrw/Pex1^tm1.1Hrw (involves: C57BL/6NTac)	phlebitis	J:278655
Pex5^tm1Pec/Pex5^tm1Pec Cnp^tm1(cre)Kan/Cnp⁺ (involves: 129S1/Sv * 129X1/SvJ)	abnormal inflammatory response	J:123503
	microgliosis	J:123503
Pex7^tm1Nbra/Pex7^tm1Nbra (involves: 129S/SvEv * C57BL/6)	liver inflammation	J:158845
Pex7^tm1Rjaw/Pex7^tm1Rjaw (Swiss)	abnormal osteoclast morphology	J:92346
Pex26^{tm1.1(KOMP)Vlcg}/Pex26⁺ (C57BL/6N-Pex26^{tm1.1(KOMP)Vlcg}/Ucd)	enlarged spleen	J:211773
Pfas^Sofa-2J/Pfas⁺ (B6(Cg)-Pfas^Sofa-2J/GrsrJ)	abnormal transitional stage B cell morphology	J:223062
Pfdn1^{Gt(GTR1.3)1Rul}/Pfdn1^{Gt(GTR1.3)1Rul} (involves: 129)	abnormal B cell activation	J:137415
	abnormal B cell differentiation	J:137415
	abnormal B cell morphology	J:137415
	abnormal neutrophil morphology	J:137415
	abnormal spleen morphology	J:137415
	abnormal spleen red pulp morphology	J:137415
	abnormal spleen white pulp morphology	J:137415
	abnormal splenic cell ratio	J:137415
	abnormal T cell activation	J:137415
	abnormal thymus cell ratio	J:137415
	abnormal thymus morphology	J:137415
	decreased B-1 B cell number	J:137415
	decreased B-2 B cell number	J:137415
	decreased pre-B cell number	J:137415
	decreased thymus weight	J:137415
	sinus inflammation	J:137415
	small spleen	J:137415
	spleen hypoplasia	J:137415
	thymus hypoplasia	J:137415
Pfkfb2^{tm1b(KOMP)Wtsi}/Pfkfb2^{tm1b(KOMP)Wtsi} (C57BL/6N-Pfkfb2^{tm1b(KOMP)Wtsi}/Nju)	decreased neutrophil cell number	J:211773
	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
	increased lymphocyte cell number	J:211773
Pfkfb3^tm1.1Pec/Pfkfb3^tm1.1Pec Tg(Pdgfb-icre/ERT2,-EGFP)1Frut/0 (involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NCrl * CBA)	abnormal macrophage morphology	J:296552
	abnormal macrophage physiology	J:296552
Pfkm^tm1Fbos/Pfkm^tm1Fbos (involves: 129S6/SvEvTac * C57BL/6J)	enlarged spleen	J:152153
	increased spleen weight	J:152153
Pgam1^tm1.1Hiko/Pgam1^tm1.1Hiko Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	abnormal CD4-positive T cell differentiation	J:293746
	abnormal CD8-positive, alpha-beta T cell differentiation	J:293746
	abnormal effector T cell number	J:293746
	decreased acute inflammation	J:293746
	decreased CD4-positive, alpha-beta T cell number	J:293746
	decreased CD8-positive, alpha-beta T cell number	J:293746
	decreased interleukin-2 secretion	J:293746
	decreased NK T cell number	J:293746
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:293746
	decreased T-helper 2 cell number	J:293746
	decreased T-helper 17 cell number	J:293746
Pgam5^{tm1d(EUCOMM)Wtsi}/Pgam5^{tm1d(EUCOMM)Wtsi} (involves: C57BL/6N)	abnormal interleukin-1 beta secretion	J:240016
	abnormal macrophage activation involved in immune response	J:240016
	decreased interleukin-1 beta secretion	J:240016
Pgap3^tm1.1Ymra/Pgap3^tm1.1Ymra (involves: 129 * C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:181221
	abnormal T cell morphology	J:181221
	decreased T cell proliferation	J:181221
	immune system phenotype	J:181221
	increased susceptibility to experimental autoimmune encephalomyelitis	J:181221
	increased T cell proliferation	J:181221
Pgap3^tm1.1Ymra/Pgap3^tm1.1Ymra (B6.Cg-Pgap3^tm1.1Ymra)	abnormal T-helper 2 cell differentiation	J:203443
	decreased B cell proliferation	J:203443
	immune system phenotype	J:203443
	impaired macrophage phagocytosis	J:203443
	increased anti-double stranded DNA antibody level	J:203443
	increased anti-single stranded DNA antibody level	J:203443
	increased spleen germinal center number	J:203443
Pgap3^tm1Ymra/Pgap3^tm1Ymra Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129P2/OlaHsd)	immune system phenotype	J:203443
Pgap3^tm1Ymra/Pgap3^tm1Ymra Tg(Lck-cre)#Jxm/0 (involves: C57BL/6 * CBA)	immune system phenotype	J:203443
Pgap4^em1Osbir/Pgap4^em1Osbir (involves: C57BL/6NSlc)	increased Ly6C-positive immature NK cell number	J:333707
	increased susceptibility to infection induced morbidity/mortality	J:333707
	increased susceptibility to prion infection	J:333707
Pgbd1^em1(IMPC)Tcp/Pgbd1^em1(IMPC)Tcp (C57BL/6NCrl-Pgbd1^em1(IMPC)Tcp/Tcp)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
Pgc^{em1(IMPC)Ccpcz}/Pgc^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Pgc^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Pgcka1^{em1(IMPC)Ccpcz}/Pgcka1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Pgcka1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	small spleen	J:211773
Pgd^tm1.1Pse/Pgd^tm1.1Pse Foxp3^{tm4(YFP/icre)Ayr}/Foxp3⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	abnormal CD4-positive helper T cell morphology	J:313817
	abnormal regulatory T cell physiology	J:313817
	blepharitis	J:313817
	ear inflammation	J:313817
	enlarged lymph nodes	J:313817
	enlarged spleen	J:313817
	increased circulating interferon-gamma level	J:313817
	increased circulating interleukin-4 level	J:313817
	increased circulating interleukin-5 level	J:313817
	increased circulating interleukin-17 level	J:313817
	increased IgA level	J:313817
	increased IgD level	J:313817
	increased IgE level	J:313817
	increased IgG2a level	J:313817
	increased IgG3 level	J:313817
	increased IgM level	J:313817
	increased interferon-gamma secretion	J:313817
	increased susceptibility to type I hypersensitivity reaction	J:313817
	increased T cell number	J:313817
Pgd^tm1.1Pse/Pgd^tm1.1Pse Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	abnormal alpha-beta T cell morphology	J:306553
	abnormal CD8-positive, alpha beta T cell morphology	J:306553
	abnormal CD8-positive, alpha-beta T cell physiology	J:306553
	abnormal T cell differentiation	J:306553
	decreased CD4-positive, alpha-beta T cell number	J:306553
	decreased CD8-positive, alpha-beta T cell number	J:306553
Pgd^tm1.1Pse/Pgd^tm1.1Pse Tg(Cd4-cre)1Cwi/0 Tg(TcraTcrb)8Rest/0 (involves: C57BL/6 * DBA/2)	abnormal CD8-positive, alpha-beta T cell physiology	J:306553
Pgd^tm1.1Pse/Pgd^tm1.1Pse Tg(Cd4-cre)1Cwi/0 Tg(TcraTcrb)1100Mjb/0 (involves: C57BL/6 * DBA/2)	abnormal cytotoxic T cell physiology	J:306553
Pgf^{em1(IMPC)Ccpcz}/Pgf^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Pgf^{em1(IMPC)Ccpcz}/Ccpcz)	decreased NK cell number	J:211773
Pgf^tm1Pec/Pgf^tm1Pec (involves: 129)	decreased susceptibility to type IV hypersensitivity reaction	J:81388
Pgia1^BALB/cCrl/Pgia1^DBA/2Crl (involves: BALB/cCrl * DBA/2Crl)	increased autoantibody level	J:66460
	increased susceptibility to autoimmune disorder	J:66460
Pgia2^BALB/cCrl/? (involves: BALB/cCrl * DBA/2Crl)	increased autoantibody level	J:66460
Pgia3^DBA/2Crl/? (involves: BALB/cCrl * DBA/2Crl)	increased autoantibody level	J:66460
Pgia3^DBA/2Crl/? (involves: BALB/cCrl * DBA/2Crl)	increased inflammatory response	J:66460
Pgia4^BALB/cCrl/? (involves: BALB/cCrl * DBA/2Crl)	increased autoantibody level	J:66460
Pgia5^BALB/cCrl/? (involves: BALB/cCrl * DBA/2Crl)	increased inflammatory response	J:66460
Pgia6^BALB/cCrl/? (involves: BALB/cCrl * DBA/2Crl)	increased autoantibody level	J:66460
Pgia7^BALB/cCrl/? (involves: BALB/cCrl * DBA/2Crl)	increased autoantibody level	J:66460
Pgia8^DBA/2/Pgia8^DBA/2 (C.D2-(D15Mit12-D15Mit267))	decreased susceptibility to induced arthritis	J:137478
Pgia8^DBA/2/Pgia8^DBA/2 (involves: BALB/c * DBA/2)	decreased interleukin-6 secretion	J:137478
	decreased susceptibility to induced arthritis	J:137478
	increased tumor necrosis factor secretion	J:137478
Pgia8^DBA/2Crl/? (involves: BALB/cCrl * DBA/2Crl)	increased inflammatory response	J:66460
Pgia9^BALB/cCrl/? (involves: BALB/cCrl * DBA/2Crl)	increased inflammatory response	J:66460
Pgia9^DBA/2/Pgia9^DBA/2 (C.D2-(D15Mit267-D15Mit41))	decreased susceptibility to induced arthritis	J:137478
Pgia9^DBA/2/Pgia9^DBA/2 (involves: BALB/c * DBA/2)	decreased susceptibility to induced arthritis	J:137478
	increased interleukin-6 secretion	J:137478
	increased tumor necrosis factor secretion	J:137478
Pgia10^BALB/cCrl/? (involves: BALB/cCrl * DBA/2Crl)	increased autoantibody level	J:66460
Pgia10^BALB/cCrl/? (involves: BALB/cCrl * DBA/2Crl)	increased inflammatory response	J:66460
Pgia11^BALB/cCrl/? (involves: BALB/cCrl * DBA/2Crl)	increased autoantibody level	J:66460
Pgia12^BALB/cCrl/? (involves: BALB/cCrl * DBA/2Crl)	increased inflammatory response	J:66460
Pgia13^C3H/HeJCr/Pgia13^C3H/HeJCr (involves: C3H/HeJCr * C57BL/6)	increased susceptibility to induced arthritis	J:65424
Pgia14^C3H/HeJCr/Pgia14^C3H/HeJCr (involves: C3H/HeJCr * C57BL/6)	increased susceptibility to induced arthritis	J:65424
Pgia15^C3H/HeJCr/Pgia15^C3H/HeJCr (involves: C3H/HeJCr * C57BL/6)	increased susceptibility to induced arthritis	J:65424
Pgia16^C3H/HeJCr/Pgia16^C3H/HeJCr (involves: C3H/HeJCr * C57BL/6)	increased susceptibility to autoimmune disorder	J:65424
Pgia26^BALB/cCrl/? (involves: BALB/cCrl * DBA/2Crl)	increased inflammatory response	J:84150
Pgia26^DBA/2Crl/? (involves: BALB/cCrl * DBA/2Crl)	abnormal inflammatory response	J:84150
Pgia39^DBA/2Crl/? Pgia6^BALB/cCrl/Pgia6^DBA/2Crl (involves: BALB/cCrl * DBA/2Crl)	decreased inflammatory response	J:84150
Pgia39^DBA/2Crl/Pgia39^DBA/2Crl Pgia6^DBA/2Crl/Pgia6^DBA/2Crl (involves: BALB/cCrl * DBA/2Crl)	increased susceptibility to induced arthritis	J:84150
Pgia39^DBA/2Crl/Pgia39^DBA/2Crl Pgia26^BALB/cCrl/Pgia26^BALB/cCrl (involves: BALB/cCrl * DBA/2Crl)	increased susceptibility to induced arthritis	J:84150
Pgis1^DBA/2/Pgis1^DBA/2 (involves: BALB/c * DBA/2)	increased susceptibility to induced arthritis	J:107496
Pgis1^DBA/2/Pgis1^DBA/2 Pgis2^BALB/c/Pgis2^BALB/c (involves: BALB/c * DBA/2)	increased susceptibility to induced arthritis	J:107496
Pgis1^DBA/2/Pgis1^DBA/2 Pgis2^BALB/c/Pgis2^DBA/2 (involves: BALB/c * DBA/2)	increased susceptibility to induced arthritis	J:107496
Pgis2^BALB/c/Pgis2^BALB/c (involves: BALB/c * DBA/2)	increased susceptibility to induced arthritis	J:107496
Pgis2^BALB/c/Pgis2^DBA/2 (involves: BALB/c * DBA/2)	increased susceptibility to induced arthritis	J:107496
Pglyrp1^tm1.1Lky/Pglyrp1^tm1.1Lky (B6.129S4-Pglyrp1^tm1.1Lky)	abnormal neutrophil physiology	J:171412
	increased susceptibility to bacterial infection	J:171412
Pglyrp1^tm1Rdz/Pglyrp1^tm1Rdz (involves: 129S5/SvEvBrd)	abnormal neutrophil physiology	J:84680
	impaired granulocyte bactericidal activity	J:84680
	increased susceptibility to bacterial infection	J:84680
	increased susceptibility to bacterial infection induced morbidity/mortality	J:84680
Pglyrp1^tm1Rdz/Pglyrp1^tm1Rdz (C.129S-Pglyrp1^tm1Rdz)	increased susceptibility to induced arthritis	J:178054
Pglyrp1^tm1Rdz/Pglyrp1^tm1Rdz (involves: 129S5/SvEvBrd * BALB/c)	abnormal chemokine secretion	J:178053
	increased interleukin-6 secretion	J:178053
	increased susceptibility to induced colitis	J:178053
Pglyrp1^tm1Rdz/Pglyrp1^tm1Rdz Pglyrp2^tm1Rdz/Pglyrp2^tm1Rdz (C.129S-Pglyrp1^tm1Rdz Pglyrp2^tm1Rdz)	decreased susceptibility to induced arthritis	J:178054
Pglyrp2^tm1Lky/Pglyrp2^tm1Lky (involves: 129S4/SvJae * C57BL/6)	abnormal macrophage physiology	J:159600
	abnormal tumor necrosis factor level	J:159600
	decreased circulating interleukin-6 level	J:159600
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:159600
Pglyrp2^tm1Rdz/Pglyrp2^tm1Rdz (C.129S-Pglyrp2^tm1Rdz)	abnormal circulating chemokine level	J:178054
Pglyrp2^tm1Rdz/Pglyrp2^tm1Rdz (C.129S-Pglyrp2^tm1Rdz)	decreased susceptibility to induced arthritis	J:178054
Pglyrp2^tm1Rdz/Pglyrp2^tm1Rdz (involves: 129S/SvEv * BALB/c)	abnormal chemokine secretion	J:178053
	increased interleukin-6 secretion	J:178053
	increased susceptibility to induced colitis	J:178053
Pglyrp3^tm1Rdz/Pglyrp3^tm1Rdz (C.129S-Pglyrp3^tm1Rdz)	immune system phenotype	J:178054
Pglyrp3^tm1Rdz/Pglyrp3^tm1Rdz (involves: 129S6/SvEvTac * BALB/c)	abnormal chemokine secretion	J:178053
	increased interleukin-6 secretion	J:178053
	increased susceptibility to induced colitis	J:178053
Pglyrp4^{em1(IMPC)Ccpcz}/Pglyrp4^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Pglyrp4^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
	small thymus	J:211773
Pglyrp4^tm1Rdz/Pglyrp4^tm1Rdz (C.129S-Pglyrp4^tm1Rdz)	immune system phenotype	J:178054
Pglyrp4^tm1Rdz/Pglyrp4^tm1Rdz (involves: 129S6/SvEvTac * BALB/c)	abnormal chemokine secretion	J:178053
	increased interleukin-6 secretion	J:178053
	increased susceptibility to induced colitis	J:178053
Pgm3^{Gt(W037B08)Wrst}/Pgm3^mld1 (involves: 129S1/Sv * C57BL/6)	abnormal T cell differentiation	J:125094
	absent follicular B cells	J:125094
	decreased B cell number	J:125094
	decreased leukocyte cell number	J:125094
	decreased T cell number	J:125094
	glomerulonephritis	J:125094
	increased pro-B cell number	J:125094
	increased spleen red pulp amount	J:125094
Pgm3^mld1/Pgm3^mld1 (C57BL/6-Pgm3^mld1)	abnormal thrombopoiesis	J:125094
	absent follicular B cells	J:125094
	decreased B cell number	J:125094
	decreased leukocyte cell number	J:125094
	increased pro-B cell number	J:125094
	increased spleen red pulp amount	J:125094
	increased spleen weight	J:125094
Pgr^tm1Bwo/Pgr^tm1Bwo (either: (involves: 129S7/SvEvBrd) or (involves: 129S7/SvEvBrd * C57BL/6))	uterus inflammation	J:28980
Pgr^tm1Bwo/Pgr^tm1Bwo (involves: 129S7/SvEvBrd)	abnormal osteoclast morphology	J:145383
Pgr^tm1Lyd/Pgr^tm1Lyd (involves: 129S7/SvEvBrd)	abnormal cytokine secretion	J:130208
Pgr^tm2(cre)Lyd/Pgr⁺ Cripto^tm2.2Mms/Cripto^tm2.2Mms (involves: 129/Sv * C57BL/6N * CD-1)	endometrium inflammation	J:324146
Pgrmc1^em1Ejho/Pgrmc1^em1Ejho (involves: C57BL/6N)	liver inflammation	J:268130
Pgrmc2^tm1.1Jjp/Pgrmc2^tm1.1Jjp Pgr^tm2(cre)Lyd/Pgr⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	decreased uterine NK cell number	J:247103
Phactr1^em1(IMPC)Mbp/Phactr1^em1(IMPC)Mbp (C57BL/6NCrl-Phactr1^em1(IMPC)Mbp/Mmucd)	abnormal spleen morphology	J:211773
	decreased leukocyte cell number	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Phb1^em1(IMPC)H/Phb1⁺ (C57BL/6NTac-Phb1^em1(IMPC)H/H)	increased large unstained cell number	J:211773
Phc1^tm1Os/Phc1^tm1Os (involves: 129S2/SvPas * C57BL/6)	abnormal B cell differentiation	J:75707
	decreased spleen weight	J:43764
	decreased thymus weight	J:43764
Phc2^tm1Hko/Phc2^tm1Hko (B6.129-Phc2^tm1Hko)	immune system phenotype	J:100027
Phex^Hyp-Duk/Y (involves: BALB/cAnBomUrd)	ear inflammation	J:132678
Phex^Hyp-Duk/Y (involves: BALB/cAnBomUrd)	increased susceptibility to otitis media	J:132678
Phex^Hyp/? (involves: C57BL/6J)	enthesitis	J:192371
Phex^Mhdabap024/Y (C3HeB/FeJ-Phex^Mhdabap024)	decreased circulating C-reactive protein level	J:264682
Phex^Ska1/Phex^Ska1 (C57BL/6-Phex^Ska1)	abnormal osteoclast physiology	J:79953
Phf6^em1Wencc/Y Tg(Vav1-cre)#Cgp/0 (Not Specified)	abnormal effector T cell number	J:278804
	abnormal splenic cell ratio	J:278804
	abnormal thymus cell ratio	J:278804
	decreased CD4-positive, alpha-beta T cell number	J:278804
	decreased CD8-positive, alpha-beta T cell number	J:278804
	decreased double-negative T cell number	J:278804
	decreased lymphocyte cell number	J:278804
	enlarged spleen	J:278804
	immune system phenotype	J:278804
	increased B cell number	J:278804
	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:278804
	increased pro-B cell number	J:278804
Phf6^em1Wencc/Phf6^em1Wencc Tg(Vav1-cre)#Cgp/0 (Not Specified)	abnormal effector T cell number	J:278804
	abnormal splenic cell ratio	J:278804
	abnormal thymus cell ratio	J:278804
	decreased CD4-positive, alpha-beta T cell number	J:278804
	decreased CD8-positive, alpha-beta T cell number	J:278804
	decreased double-negative T cell number	J:278804
	decreased lymphocyte cell number	J:278804
	enlarged spleen	J:278804
	immune system phenotype	J:278804
	increased B cell number	J:278804
	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:278804
	increased leukocyte cell number	J:278804
	increased pro-B cell number	J:278804
Phf6^tm1.1Avo/Y Tg(Tek-cre)1Ywa/0 (involves: C57BL/6 * SJL)	abnormal T cell differentiation	J:276228
	decreased DN2 thymocyte number	J:276228
	increased circulating interferon-alpha level	J:276228
	increased plasmacytoid dendritic cell number	J:276228
Phf8^tm1dIcs/Phf8^tm1dIcs (C57BL/6N-Phf8^tm1dIcs/Ics)	decreased lymphocyte cell number	J:211773
Phf8^tm1dIcs/Phf8^tm1dIcs (C57BL/6N-Phf8^tm1dIcs/Ics)	increased neutrophil cell number	J:211773
Phf11d^m1H/Phf11d^m1H (C3H.CAnNCrl(C3)-Phf11d^m1H)	abnormal inflammatory response	J:217094
Phf19^tm1.1Ldc/Phf19^tm1.1Ldc (Not Specified)	enlarged spleen	J:313068
Phf20^Gt(XN131)Byg/Phf20^Gt(XN131)Byg (involves: 129P2/OlaHsd)	abnormal T cell differentiation	J:228714
	decreased double-positive T cell number	J:228714
	decreased thymocyte number	J:228714
	increased double-negative T cell number	J:228714
	intermingled spleen red and white pulp	J:228714
	small spleen	J:228714
	small thymus	J:228714
	thymus hypoplasia	J:228714
Phf20l1^em1(IMPC)Tcp/Phf20l1^em1(IMPC)Tcp (C57BL/6N-Phf20l1^em1(IMPC)Tcp/Tcp)	decreased lymphocyte cell number	J:211773
	enlarged lymph nodes	J:211773
	increased spleen weight	J:211773
Phip^{em1(IMPC)Wtsi}/Phip⁺ (C57BL/6N-Phip^{em1(IMPC)Wtsi}/Wtsi)	increased leukocyte cell number	J:211773
Phka1^em1(IMPC)Tcp/Y (C57BL/6N-Phka1^em1(IMPC)Tcp/Tcp)	small spleen	J:211773
Phlda1^tm1Ywc/Phlda1^tm1Ywc (involves: 129S1/Sv * C57BL/6J)	immune system phenotype	J:72947
Phldb2^em1(IMPC)H/Phldb2^em1(IMPC)H (C57BL/6NTac-Phldb2^em1(IMPC)H/H)	increased basophil cell number	J:211773
Phlpp1^tm1.1Saco/Phlpp1^tm1.1Saco (involves: 129 * C57BL/6)	immune system phenotype	J:231241
Phlpp1^tm1.1Saco/Phlpp1^tm1.1Saco Phlpp2^{tm1d(EUCOMM)Hmgu}/Phlpp2^{tm1d(EUCOMM)Hmgu} (involves: 129 * C57BL/6N)	decreased susceptibility to induced colitis	J:231241
Phlpp2^{tm1d(EUCOMM)Hmgu}/Phlpp2^{tm1d(EUCOMM)Hmgu} (involves: C57BL/6N)	immune system phenotype	J:231241
Phrf1^em1(IMPC)Tcp/Phrf1^em1(IMPC)Tcp (C57BL/6N-Phrf1^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
	small spleen	J:211773
Phyh^{tm1b(EUCOMM)Wtsi}/Phyh^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Phyh^{tm1b(EUCOMM)Wtsi}/Tcp)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Phyh^tm1Safe/Phyh^tm1Safe (involves: 129P2/OlaHsd * 129X1/SvJ * Black Swiss * FVB/N)	liver inflammation	J:142512
Pi4ka^m1Btlr/Pi4ka^m1Btlr (C57BL/6J-Pi4ka^m1Btlr)	decreased macrophage apoptosis	J:265261
	decreased tumor necrosis factor secretion	J:265261
	increased interleukin-1 beta secretion	J:265261
Pi4ka^m2Btlr/Pi4ka^m2Btlr (C57BL/6J-Pi4ka^m2Btlr)	increased alpha-beta T cell number	J:272852
	increased CD4-positive, alpha-beta T cell number	J:272852
	increased central memory CD4-positive, alpha-beta T cell number	J:272852
Pi4ka^{tm1b(EUCOMM)Wtsi}/Pi4ka⁺ (C57BL/6N-Pi4ka^{tm1b(EUCOMM)Wtsi}/Tcp)	increased monocyte cell number	J:211773
Pi4ka^tm2.1Arte/Pi4ka⁺ Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte}/Gt(ROSA)26Sor⁺ (involves: C57BL/6NTac)	abnormal spleen morphology	J:188779
Pi16^{Gt(OST292194)Lex}/Pi16^{Gt(OST292194)Lex} (involves: 129S5/SvEvBrd * C57BL/6J)	abnormal lymph node B cell domain morphology	J:94077
	abnormal spleen germinal center morphology	J:94077
	increased regulatory T cell number	J:94077
Pi16^tm1.2Engl/Pi16^tm1.2Engl (involves: 129S1/Sv * 129X1/SvJ * C57BL/6N * SJL)	abnormal immune system physiology	J:244259
Pias1^tm1Kes/Pias1^tm1Kes (involves: 129S/Sv * C57BL/6)	decreased susceptibility to Riboviria infection induced morbidity/mortality	J:92167
	increased susceptibility to bacterial infection induced morbidity/mortality	J:92167
	increased susceptibility to endotoxin shock	J:92167
Pias4^tm1Rug/Pias4^tm1Rug (involves: 129S2/SvPas * C57BL/6)	abnormal myelopoiesis	J:94291
Picalm^tm1.1Tmae/Picalm^tm1.1Tmae Commd10^{Tg(Vav1-icre)A2Kio}/Commd10⁺ (involves: 129S6/SvEvTac * C57BL/6 * C57BL/10 * CBA * SJL)	decreased CD4-positive, alpha-beta T cell number	J:220728
	decreased CD8-positive, alpha-beta T cell number	J:220728
Picalm^tm1.1Tmae/Picalm^tm1.1Tmae Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA * SJL)	decreased CD4-positive, alpha-beta T cell number	J:220728
	decreased CD8-positive, alpha-beta T cell number	J:220728
	enlarged spleen	J:220728
Picalm^tm1Towa/Picalm^tm1Towa (involves: C57BL/6J * C57BL/6NCrlj * CBA/JNCrlj)	abnormal B cell differentiation	J:185312
	decreased spleen B cell follicle number	J:185312
	enlarged spleen	J:185312
Pierce1^{Gt(OST3440)Lex}/Pierce1^{Gt(OST3440)Lex} (either: (involves: 129S5/SvEvBrd * C57BL/6J) or (involves: 129S5/SvEvBrd * C57BL/6J * FVB/N))	abnormal spleen morphology	J:252050
Pierce1^{tm2b(EUCOMM)Wtsi}/Pierce1^{tm2b(EUCOMM)Wtsi} (C57BL/6N-Pierce1^{tm2b(EUCOMM)Wtsi}/Wtsi)	blood in lymph vessels	J:239583
Piezo1^em1Dbee/Piezo1^em1Dbee (C57BL/6-Piezo1^em1Dbee)	increased spleen weight	J:368272
Piezo1^tm2.1Apat/Piezo1^tm2.1Apat Commd10^{Tg(Vav1-icre)A2Kio}/Commd10⁺ (involves: C57BL/6 * C57BL/10 * CBA)	abnormal splenic cell ratio	J:229436
	dark spleen	J:229436
Piga^tm1Tak/Piga^tm1Tak Tg(FES-cre)31Bsl/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA/Ca)	abnormal T cell activation	J:162065
	abnormal T cell morphology	J:162065
	abnormal T cell physiology	J:162065
	decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:162065
Pigr^tm1Fejo/Pigr^tm1Fejo (involves: 129P2/OlaHsd * C57BL/6)	abnormal immunoglobulin level	J:57987
	abnormal immunoglobulin transcytosis	J:57987
	decreased IgA level	J:57987
	increased IgA level	J:57987
	increased IgG level	J:57987
Pigr^tm1Fejo/Pigr^tm1Fejo (involves: 129 * C57BL/6)	increased IgA level	J:140515
Pigr^tm1Fejo/Pigr^tm1Fejo (involves: 129 * C57BL/6)	increased susceptibility to parasitic infection	J:140515
Pigr^tm1Ohw/Pigr^tm1Ohw (involves: 129X1/SvJ * C57BL/6J)	decreased IgA level	J:58454
	increased IgA level	J:58454
	increased IgE level	J:58454
	increased IgG level	J:58454
Pigr^tm1Ohw/Pigr^tm1Ohw (B6.129X1-Pigr^tm1Ohw)	abnormal CD8 positive, alpha-beta intraepithelial T cell morphology	J:97824
	abnormal intraepithelial T cell number	J:97824
	abnormal lymphocyte physiology	J:97824
	decreased IgA level	J:108538
	decreased interferon-gamma secretion	J:108538
	decreased tumor necrosis factor secretion	J:108538
	increased IgA level	J:108538, J:97824
	increased susceptibility to bacterial infection	J:108538
Pigr^tm1Ohw/Pigr^tm1Ohw Tcrb^tm1Mom/Tcrb^tm1Mom Tcrd^tm1Mom/Tcrd^tm1Mom (involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6J)	decreased lymphocyte cell number	J:97824
	immune system phenotype	J:97824
	increased IgA level	J:97824
Pigr^tm1Rast/Pigr^tm1Rast (C57BL/6-Pigr^tm1Rast)	abnormal immune system cell morphology	J:81984
	abnormal immunoglobulin level	J:81984
	abnormal immunoglobulin transcytosis	J:81984
	decreased IgA level	J:81984
	increased IgA level	J:81984
	increased IgG level	J:81984
Pigv^b2b2859Clo/Pigv^b2b2859Clo (C57BL/6J-Pigv^b2b2859Clo)	thymus hypoplasia	J:175213
Pik3ap1^m1Btlr/Pik3ap1^m1Btlr (involves: C57BL/6J)	arrested B cell differentiation	J:185495
	decreased IgM level	J:185495
	immune system phenotype	J:185495
Pik3ap1^m2Btlr/Pik3ap1^m2Btlr (C57BL/6J-Pik3ap1^m2Btlr)	decreased B-1a cell number	J:255271
	impaired humoral immune response	J:255271
	increased B-1b cell number	J:255271
	increased IgM level	J:255271
Pik3ap1^M3Btlr/Pik3ap1^M3Btlr (C57BL/6J-Pik3ap1^M3Btlr)	decreased B-1 B cell number	J:272019
Pik3ap1^{tm1b(KOMP)Wtsi}/Pik3ap1^{tm1b(KOMP)Wtsi} (C57BL/6N-Pik3ap1^{tm1b(KOMP)Wtsi}/Orl)	decreased lymphocyte cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Pik3ap1^tm1Kuro/Pik3ap1^tm1Kuro (involves: 129P2/OlaHsd)	abnormal B cell differentiation	J:75075
	absent B-1a cells	J:84669
	decreased B cell number	J:84669
	decreased B cell proliferation	J:84669
	decreased follicular B cell number	J:84669
	decreased IgG2b level	J:75075
	decreased IgG3 level	J:75075
	decreased IgM level	J:75075
	decreased immunoglobulin level	J:75075
	decreased pre-B cell number	J:75075
	spleen hypoplasia	J:75075
Pik3c2a^{Gt(OST288105)Lex}/Pik3c2a^{Gt(OST288105)Lex} (involves: 129S5/SvEvBrd * C57BL/6J)	enlarged spleen	J:169710
	glomerulonephritis	J:169710
	immune system phenotype	J:169710
	increased anti-double stranded DNA antibody level	J:169710
	increased B cell number	J:169710
	increased CD4-positive, alpha-beta T cell number	J:169710
	increased CD8-positive, alpha-beta T cell number	J:169710
	increased granulocyte number	J:169710
	increased IgA level	J:169710
	increased IgG level	J:169710
	increased IgM level	J:169710
	increased leukocyte cell number	J:169710
	increased monocyte cell number	J:169710
	increased neutrophil cell number	J:169710
Pik3c2a^{tm1b(EUCOMM)Hmgu}/Pik3c2a⁺ (C57BL/6N-Pik3c2a^{tm1b(EUCOMM)Hmgu}/Tcp)	decreased lymphocyte cell number	J:211773
	enlarged lymph nodes	J:211773
	increased neutrophil cell number	J:211773
Pik3c2a^tm1Bvan/Pik3c2a⁺ (involves: C57BL/6)	abnormal thrombopoiesis	J:226344
Pik3c3^tm1.1Flv/Pik3c3^tm1.1Flv Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * C57BL/6N * DBA/2)	abnormal T cell number	J:184753
	decreased CD4-positive, alpha-beta T cell number	J:184753
	decreased CD8-positive, alpha-beta T cell number	J:184753
Pik3c3^tm1.1Flv/Pik3c3^tm1.1Flv Tg(Cd8a-cre)1Itan/0 (involves: C57BL/6 * C57BL/6N)	abnormal CD4-positive, alpha beta T cell morphology	J:184753
	abnormal CD8-positive, alpha beta T cell morphology	J:184753
	decreased CD4-positive, alpha-beta T cell number	J:184753
	decreased CD8-positive, alpha-beta T cell number	J:184753
	decreased lymphocyte cell number	J:184753
	immune system phenotype	J:184753
	increased T cell apoptosis	J:184753
Pik3ca^tm1Jdo/Pik3ca^tm1Jdo (B6.129S7(Cg)-Pik3ca^tm1Jdo)	abnormal lymphangiogenesis	J:122866
Pik3ca^tm1Jdo/Pik3ca^tm1Jdo (B6.129S7(Cg)-Pik3ca^tm1Jdo)	abnormal lymphatic vessel morphology	J:122866
Pik3cd^em1.1Pls/Pik3cd⁺ (Not Specified)	abnormal B cell differentiation	J:282486
	abnormal class switch recombination	J:282486
	abnormal follicular B cell physiology	J:282486
	abnormal gut-associated lymphoid tissue morphology	J:282486
	abnormal IgG1 level	J:282486
	abnormal immune tolerance	J:282486
	abnormal innate immunity	J:282486
	abnormal lymph node germinal center morphology	J:282486
	abnormal mesenteric lymph node morphology	J:282486
	abnormal Peyer's patch germinal center morphology	J:282486
	abnormal Peyer's patch morphology	J:282486
	abnormal plasmablast number	J:282486
	decreased B cell apoptosis	J:282486
	decreased CD4-positive, alpha-beta T cell number	J:282486
	decreased follicular B cell number	J:282486
	decreased leukocyte cell number	J:282486
	decreased naive B cell number	J:282486
	enlarged lymph nodes	J:282486
	enlarged spleen	J:282486
	impaired humoral immune response	J:282486
	increased activated T cell number	J:282486
	increased anti-double stranded DNA antibody level	J:282486
	increased anti-nuclear antigen antibody level	J:282486
	increased B cell proliferation	J:282486
	increased B-1a cell number	J:282486
	increased germinal center B cell number	J:282486
	increased IgA level	J:282486
	increased IgG level	J:282486
	increased IgM level	J:282486
	increased lymphocyte activation involved in immune response	J:282486
	increased lymphocyte cell number	J:282486
	increased marginal zone B cell number	J:282486
	increased plasma cell number	J:282486
	increased response to antigen	J:282486
	increased T follicular helper cell number	J:282486
	increased transitional stage B cell number	J:282486
	increased transitional stage T1 B cell number	J:282486
	lymph node hyperplasia	J:282486
	lymphoid hyperplasia	J:282486
	spleen hyperplasia	J:282486
Pik3cd^{Gt(OST451938)Lex}/Pik3cd^{Gt(OST451938)Lex} (involves: 129S5/SvEvBrd * C57BL/6J)	decreased IgG1 level	J:103485
	increased leukocyte cell number	J:103485
	increased lymphocyte cell number	J:103485
Pik3cd^m1Btlr/Pik3cd^m1Btlr (C57BL/6J-Pik3cd^m1Btlr)	abnormal humoral immune response	J:213049
Pik3cd^m2Btlr/Pik3cd⁺ (C57BL/6J-Pik3cd^m2Btlr)	decreased B-1 B cell number	J:236693
	decreased IgG level	J:236693
	decreased IgM level	J:236693
	decreased response to antigen	J:236693
Pik3cd^m2Btlr/Pik3cd^m2Btlr (C57BL/6J-Pik3cd^m2Btlr)	decreased B-1 B cell number	J:236693
	decreased B-1a cell number	J:236693
	decreased IgG level	J:236693
	decreased IgM level	J:236693
	decreased response to antigen	J:236693
	increased circulating interferon-alpha level	J:236693
	increased IgE level	J:236693
	increased response to antigen	J:236693
	increased susceptibility to Herpesvirales infection	J:236693
Pik3cd^tm1.1Bvan/Pik3cd^tm1.1Bvan (involves: 129P2/OlaHsd * BALB/c)	abnormal B cell differentiation	J:78412
	abnormal Peyer's patch germinal center morphology	J:78412
	absent spleen germinal center	J:78412
	decreased B-1 B cell number	J:78412
	decreased IgA level	J:78412
	decreased IgM level	J:78412
	decreased immunoglobulin level	J:78412
	increased neutrophil cell number	J:78412
	intestinal inflammation	J:78412
	spleen hypoplasia	J:78412
Pik3cd^tm1Jni/Pik3cd^tm1Jni (involves: 129P2/OlaHsd)	abnormal B cell calcium ion homeostasis	J:80614
	abnormal humoral immune response	J:80614
	absent B-1 B cells	J:80614
	absent spleen germinal center	J:80614
	decreased B cell number	J:80614
	decreased B cell proliferation	J:80614
	decreased immunoglobulin level	J:80614
	decreased mature B cell number	J:80614
	small lymph nodes	J:80614
	small spleen	J:80614
Pik3cd^tm1Jni/Pik3cd^tm1Jni (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:124330
Pik3cd^tm1Jni/Pik3cd^tm1Jni Pik3cg^tm1Pngr/Pik3cg^tm1Pngr (involves: 129P2/OlaHsd * C57BL/6)	abnormal NK cell differentiation	J:124330
	decreased cytotoxic T cell cytolysis	J:124330
	decreased interferon-gamma secretion	J:124330
	decreased NK cell number	J:124330
	decreased T cell number	J:124330
	spleen hypoplasia	J:124330
Pik3cd^tm1Tnr/Pik3cd^tm1Tnr (involves: 129S4/SvJae)	abnormal B cell physiology	J:113491
	abnormal humoral immune response	J:79133
	decreased B cell number	J:79133
	decreased B cell proliferation	J:113491, J:79133
	decreased B-1 B cell number	J:79133
	decreased B-2 B cell number	J:79133
	decreased IgG1 level	J:79133
	decreased IgG2a level	J:79133
	decreased IgG2b level	J:79133
	decreased IgG3 level	J:79133
	decreased IgM level	J:79133
	decreased marginal zone B cell number	J:79133
Pik3cd^tm1Tnr/Pik3cd^tm1Tnr (B6.129S4-Pik3cd^tm1Tnr)	decreased inflammatory response	J:134324
Pik3cd^tm1Tnr/Pik3cd^tm1Tnr (B6.129S4-Pik3cd^tm1Tnr)	decreased susceptibility to induced arthritis	J:134324
Pik3cd^tm1Tnr/Pik3cd^tm1Tnr Pik3cg^tm1Pngr/Pik3cg^tm1Pngr (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)	abnormal T cell differentiation	J:125791
	abnormal T cell physiology	J:125791
	abnormal thymus lobule morphology	J:125791
	decreased CD4-positive, alpha-beta T cell number	J:125791
	decreased CD8-positive, alpha-beta T cell number	J:125791
	decreased double-positive T cell number	J:125791
	decreased lymphocyte cell number	J:125791
	decreased T cell number	J:125791
	small thymus	J:125791
	thymus hypoplasia	J:125791
Pik3cd^tm1Tnr/Pik3cd^tm1Tnr Pik3cg^tm1Pngr/Pik3cg^tm1Pngr (B6.129-Pik3cd^tm1Tnr Pik3cg^tm1Pngr)	decreased inflammatory response	J:134324
	decreased susceptibility to induced arthritis	J:134324
	impaired neutrophil chemotaxis	J:134324
	impaired neutrophil recruitment	J:134324
Pik3cd^tm1Tnr/Pik3cd^tm1Tnr Pten^tm2.1Ppp/Pten^tm2.1Ppp Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJae * C57BL/6)	abnormal class switch recombination	J:130950
	immune system phenotype	J:130950
	increased marginal zone B cell number	J:130950
Pik3cd^tm1Tnr/Pik3cd^tm1Tnr Tg(BCL2)36Wehi/0 (involves: 129S4/SvJae * C57BL/6JWehi * SJL/JWehi)	decreased follicular B cell number	J:130950
Pik3cd^tm2.1Tnr/Pik3cd^tm2.1Tnr Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:164283
	increased IgE level	J:164283
Pik3cd^tm2.1Tnr/Pik3cd^tm2.1Tnr Tg(Cd4-cre)1Cwi/0 (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	abnormal adaptive immunity	J:164283
	abnormal humoral immune response	J:164283
	decreased CD4-positive, alpha-beta T cell number	J:164283
	decreased CD8-positive, alpha-beta T cell number	J:164283
	decreased germinal center B cell number	J:164283
	decreased IgG1 level	J:164283
	decreased spleen germinal center number	J:164283
	decreased spleen germinal center size	J:164283
	decreased T cell number	J:164283
	decreased T follicular helper cell number	J:164283
Pik3cd^tm2.1Tnr/Pik3cd^tm2.1Tnr Tnfrsf4^tm2(cre)Nik/Tnfrsf4⁺ (involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6)	abnormal humoral immune response	J:164283
	decreased germinal center B cell number	J:164283
	decreased IgG1 level	J:164283
	decreased spleen germinal center number	J:164283
	decreased T follicular helper cell number	J:164283
Pik3cg^tm1Dwu/Pik3cg^tm1Dwu (Not Specified)	decreased immunoglobulin level	J:60348
Pik3cg^tm1Dwu/Pik3cg^tm1Dwu (Not Specified)	impaired neutrophil chemotaxis	J:60348
Pik3cg^tm1Dwu/Pik3cg^tm1Dwu (B6.Cg-Pik3cg^tm1Dwu)	abnormal CD8-positive, alpha-beta T cell physiology	J:131923
	abnormal response to infection	J:131923
	decreased CD8-positive, alpha-beta T cell number	J:131923
	immune system phenotype	J:131923
	increased susceptibility to Poxviridae infection	J:131923
Pik3cg^tm1Dwu/Pik3cg^tm1Dwu Tg(TcraTcrb)1100Mjb/0 (involves: C57BL/6)	abnormal CD8-positive, alpha-beta T cell physiology	J:131923
	abnormal response to infection	J:131923
	immune system phenotype	J:131923
Pik3cg^tm1Ehi/Pik3cg^tm1Ehi (Not Specified)	impaired macrophage chemotaxis	J:91945
Pik3cg^tm1Ehi/Pik3cg^tm1Ehi (Not Specified)	impaired neutrophil recruitment	J:91945
Pik3cg^tm1Lste/Pik3cg^tm1Lste (involves: 129P2/OlaHsd * C57BL/6)	abnormal neutrophil physiology	J:147259
	impaired neutrophil chemotaxis	J:147259
	impaired neutrophil recruitment	J:147259
Pik3cg^tm1Lste/Pik3cg^tm1Lste (involves: 129P2/OlaHsd)	impaired neutrophil chemotaxis	J:238900
Pik3cg^tm1Pngr/Pik3cg^tm1Pngr (involves: 129P2/OlaHsd * C57BL/6)	abnormal immune cell physiology	J:60347
	abnormal neutrophil physiology	J:60347
	abnormal NK cell differentiation	J:124330
	abnormal T cell activation	J:60347
	abnormal T cell differentiation	J:60347
	abnormal T cell physiology	J:60347
	abnormal T-helper 2 physiology	J:60347
	decreased CD4-positive, alpha-beta T cell number	J:60347
	decreased cytotoxic T cell cytolysis	J:124330
	decreased interferon-gamma secretion	J:60347, J:124330
	decreased interleukin-2 secretion	J:60347
	decreased T cell proliferation	J:60347
	decreased thymocyte number	J:60347
	impaired neutrophil chemotaxis	J:60347
	impaired neutrophil recruitment	J:60347
	increased eosinophil cell number	J:60347
	increased monocyte cell number	J:60347
	increased neutrophil cell number	J:60347
	thymus hypoplasia	J:60347
Pik3cg^tm1Pngr/Pik3cg^tm1Pngr (B6.129P2-Pik3cg^tm1Pngr)	decreased inflammatory response	J:134324
	decreased susceptibility to induced arthritis	J:134324
	impaired neutrophil chemotaxis	J:134324
Pik3cg^tm1Wym/Pik3cg^tm1Wym (either: 129/Sv-Pik3cg^tm1Wym or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6))	abnormal leukocyte physiology	J:60349
	abnormal neutrophil physiology	J:60349
	impaired macrophage chemotaxis	J:60349
	impaired neutrophil chemotaxis	J:60349
	impaired neutrophil recruitment	J:60349
	increased neutrophil cell number	J:60349
	increased susceptibility to bacterial infection	J:60349
Pik3cg^tm1Wym/Pik3cg^tm1Wym (involves: 129S1/Sv * 129X1/SvJ)	abnormal neutrophil physiology	J:147259
	impaired neutrophil chemotaxis	J:238900
	impaired neutrophil recruitment	J:147259
Pik3cg^tm2Ehi/Pik3cg^tm2Ehi (Not Specified)	abnormal inflammatory response	J:124856
	abnormal macrophage physiology	J:124856
	decreased macrophage cell number	J:124856
	decreased neutrophil cell number	J:124856
	impaired macrophage chemotaxis	J:124856
	impaired neutrophil chemotaxis	J:124856
	increased interleukin-1 beta secretion	J:124856
	increased interleukin-6 secretion	J:124856
	increased leukocyte cell number	J:124856
	increased tumor necrosis factor secretion	J:124856
Pik3ip1^m1Anu/Pik3ip1^m1Anu (C57BL/6NCrl-Pik3ip1^m1Anu/Anu)	immune system phenotype	J:104190
Pik3r1^m1Btlr/Pik3r1^m1Btlr (C57BL/6J-Pik3r1^m1Btlr)	decreased B cell number	J:254890
	decreased B-1a cell number	J:254890
	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:254890
	increased CD8-positive, alpha-beta memory T cell number	J:254890
Pik3r1^M2Btlr/Pik3r1⁺ (C57BL/6J-Pik3r1^M2Btlr)	decreased B-1 B cell number	J:254892
	decreased B-1a cell number	J:254892
	decreased B-1b cell number	J:254892
	decreased B-2 B cell number	J:254892
	decreased NK T cell number	J:254892
	increased B-1b cell number	J:254892
Pik3r1^m3Btlr/Pik3r1^m3Btlr (C57BL/6J-Pik3r1^m3Btlr)	increased B-1b cell number	J:272853
Pik3r1^tm1Dfr/Pik3r1^tm1Dfr (involves: 129S6/SvEvTac * C57BL/6)	arrested B cell differentiation	J:52229
	decreased B cell proliferation	J:52229
	decreased mature B cell number	J:52229
Pik3r1^tm1Dfr/Pik3r1^tm1Dfr (involves: 129S6/SvEvTac)	abnormal B cell differentiation	J:104166
	decreased immature B cell number	J:104166
	decreased mature B cell number	J:104166
	decreased pre-B cell number	J:104166
	increased pro-B cell number	J:104166
Pik3r1^tm1Dfr/Pik3r1^tm1Dfr Plcg2^tm1Jni/Plcg2^tm1Jni (involves: 129P2/OlaHsd * 129S6/SvEvTac)	abnormal B cell differentiation	J:104166
	arrested B cell differentiation	J:104166
	decreased immature B cell number	J:104166
	decreased mature B cell number	J:104166
	decreased pre-B cell number	J:104166
	immune system phenotype	J:104166
	increased B cell apoptosis	J:104166
Pik3r1^tm1Tka/Pik3r1^tm1Tka (involves: C57BL/6 * CBA)	abnormal B cell physiology	J:113491
	abnormal humoral immune response	J:52228
	decreased B cell number	J:52228
	decreased B cell proliferation	J:113491, J:52228
	decreased mature B cell number	J:52228
	decreased pre-B cell number	J:52228
	decreased pro-B cell number	J:52228
	increased susceptibility to bacterial infection	J:52228
Pik3r1^tm2Dfr/Pik3r1^tm2Dfr (either: C.129S6-Pik3r1^tm2Dfr or (involves: 129S6/SvEvTac * BALB/c * C57BL/6))	abnormal B cell differentiation	J:94077
Pik3r4^tm1.1Mpnd/Pik3r4^tm1.1Mpnd Tg(ACTA1-cre)79Jme/0 (involves: 129S2/SvPas * C57BL/6J * C57BL/6N * SJL)	myositis	J:198770
Pik3r5^tm1Lste/Pik3r5^tm1Lste (involves: 129P2/OlaHsd * C57BL/6)	impaired neutrophil chemotaxis	J:147259
	impaired neutrophil recruitment	J:147259
Pik3r5^tm1Lste/Pik3r5^tm1Lste (involves: 129P2/OlaHsd)	impaired neutrophil chemotaxis	J:238900
Pik3r5^tm1Lste/Pik3r5^tm1Lste (involves: 129P2/OlaHsd)	increased neutrophil cell number	J:238900
Pik3r6^tm1.1Lste/Pik3r6^tm1.1Lste (Not Specified)	abnormal neutrophil physiology	J:238900
	decreased granulocyte number	J:238900
	decreased lymphocyte cell number	J:238900
	immune system phenotype	J:238900
	increased neutrophil cell number	J:238900
Pikfyve^{Gt(AT0926)Wtsi}/Pikfyve^{Gt(AT0926)Wtsi} (involves: 129P2/OlaHsd * C57BL/6)	abnormal spleen morphology	J:190368
	abnormal thymus morphology	J:190368
	spleen hypoplasia	J:190368
	thymus hypoplasia	J:190368
Pikfyve^tm2.1Tssk/Pikfyve^tm2.1Tssk Tg(Vil1-cre)20Syr/0 (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	intestinal inflammation	J:193689
Pilra^tm1Osb/Pilra^tm1Osb (B6.129-Pilra^tm1Osb)	abnormal leukocyte adhesion	J:191085
	abnormal neutrophil physiology	J:191085
	increased neutrophil cell number	J:191085
	increased susceptibility to bacterial infection induced morbidity/mortality	J:191085
	increased susceptibility to endotoxin shock	J:191085
Pilrb1^tm1Pgh/Pilrb1^tm1Pgh (involves: C57BL/6)	abnormal chemokine level	J:157763
	abnormal cytokine level	J:157763
	abnormal cytokine secretion	J:157763
	decreased circulating interleukin-1 beta level	J:157763
	decreased circulating interleukin-6 level	J:157763
	decreased circulating tumor necrosis factor level	J:157763
	decreased interleukin-1 beta secretion	J:157763
	decreased susceptibility to bacterial infection	J:157763
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:157763
	decreased tumor necrosis factor secretion	J:157763
	increased circulating interferon-gamma level	J:157763
	increased circulating interleukin-12 level	J:157763
	increased interferon-gamma secretion	J:157763
	increased interleukin-10 secretion	J:157763
	increased interleukin-12 secretion	J:157763
Pim1^tm1Pwl/Pim1^tm1Pwl (involves: 129P2/OlaHsd * BALB/c)	abnormal mast cell physiology	J:15259, J:14715
Pim1^tm1Pwl/Pim1^tm1Pwl Pim2^tm1Brn/Pim2^tm1Brn Pim3^tm1Brn/Pim3^tm1Brn (involves: 129P/Ola * FVB/N)	decreased B cell number	J:91592
	decreased B cell proliferation	J:91592
	decreased pre-B cell number	J:91592
	decreased pro-B cell number	J:91592
	decreased T cell proliferation	J:91592
	increased early pro-B cell number	J:91592
Pim2^tm1.1Lex/Pim2^tm1.1Lex (involves: 129S/SvEvBrd * C57BL/6)	decreased interleukin-6 secretion	J:166403
Pim2^tm1Brn/Pim2^tm1Brn (involves: 129P/Ola * FVB/N)	decreased T cell proliferation	J:91592
Pink1^tm1Hbu/Pink1^tm1Hbu (involves: 129S7/SvEvBrd * C57BL/6)	increased interleukin-1 beta secretion	J:169471
	increased interleukin-10 secretion	J:169471
	increased interleukin-12 secretion	J:169471
Pip4k2c^{tm1b(KOMP)Wtsi}/Pip4k2c^{tm1b(KOMP)Wtsi} (involves: C57BL/6J * C57BL/6N)	abnormal circulating chemokine level	J:234283
	abnormal T cell activation	J:234283
	chronic inflammation	J:234283
	chronic liver inflammation	J:234283
	decreased regulatory T cell number	J:234283
	increased CD4-positive, alpha-beta T cell number	J:234283
	increased CD8-positive, alpha-beta T cell number	J:234283
	increased circulating interferon-gamma level	J:234283
	increased circulating interleukin-2 level	J:234283
	increased circulating interleukin-4 level	J:234283
	increased circulating interleukin-10 level	J:234283
	increased circulating interleukin-12 level	J:234283
	increased circulating interleukin-12b level	J:234283
	increased IgG3 level	J:234283
	increased inflammatory response	J:234283
	increased interferon-gamma secretion	J:234283
	increased interleukin-17 secretion	J:234283
	increased T cell proliferation	J:234283
	increased T-helper cell number	J:234283
	intestinal inflammation	J:234283
	kidney inflammation	J:234283
	lung inflammation	J:234283
	salivary gland inflammation	J:234283
Pip4p1^{em1(IMPC)Ccpcz}/Pip4p1^{em1(IMPC)Ccpcz} (C57BL/6N-Pip4p1^{em1(IMPC)Ccpcz}/Ccpcz)	increased CD4-negative, CD25-positive NK T cell number	J:211773
Pip5k1b^tm1Tssk/Pip5k1b^tm1Tssk (involves: 129P2/OlaHsd * C57BL/6)	abnormal mast cell physiology	J:97991
	increased susceptibility to type I hypersensitivity reaction	J:97991
Pip5k1c^tm1.2Ref/Pip5k1c^tm1.2Ref Tg(TcraTcrb)425Cbn/0 (involves: BALB/c * C57BL/6)	abnormal T cell physiology	J:164732
	decreased B cell number	J:164732
	decreased dendritic cell number	J:164732
	increased interferon-gamma secretion	J:164732
	increased interleukin-2 secretion	J:164732
	increased T cell proliferation	J:164732
Pip^tm1Myal/Pip^tm1Myal (involves: 129S/SvEv * C57BL/6)	abnormal thymus corticomedullary boundary morphology	J:202016
	arteritis	J:202016
	colitis	J:202016
	enlarged submandibular lymph nodes	J:202016
	enlarged thymus	J:202016
	enlarged thymus medulla	J:202016
Pirb^em1Fgla/Pirb^em1Fgla (C57BL/6-Pirb^em1Fgla)	decreased length of allograft survival	J:290663
Pirb^tm1Ttk/Pirb^tm1Ttk (involves: 129X1/SvJ)	abnormal B cell activation	J:76770
	abnormal dendritic cell differentiation	J:76770
	abnormal immune system cell morphology	J:76770
	abnormal leukocyte physiology	J:76770
	abnormal T cell physiology	J:76770
	abnormal T-helper 2 physiology	J:76770
	increased B cell proliferation	J:76770
	increased B-1 B cell number	J:76770
Pitm1^C57BL/FaDk/Pitm1^C57BL/FaDk (involves: C57BL/FaDk * RIII/FaDk)	decreased susceptibility to prion infection	J:70033
Pitm1^C57BL/FaDk/Pitm1^RIII/FaDk (involves: C57BL/FaDk * RIII/FaDk)	decreased susceptibility to prion infection	J:70033
Pitm2^C57BL/FaDk/Pitm2^C57BL/FaDk (involves: C57BL/FaDk * RIII/FaDk)	decreased susceptibility to prion infection	J:70033
Pitm2^C57BL/FaDk/Pitm2^RIII/FaDk (involves: C57BL/FaDk * RIII/FaDk)	decreased susceptibility to prion infection	J:70033
Pitm3^C57BL/FaDk/Pitm3^C57BL/FaDk (involves: C57BL/FaDk * RIII/FaDk)	decreased susceptibility to prion infection	J:70033
Pitm3^C57BL/FaDk/Pitm3^RIII/FaDk (involves: C57BL/FaDk * RIII/FaDk)	decreased susceptibility to prion infection	J:70033
Pitm4^C57BL/FaDk/Pitm4^C57BL/FaDk (involves: C57BL/FaDk * RIII/FaDk)	decreased susceptibility to prion infection	J:70033
Pitm4^C57BL/FaDk/Pitm4^RIII/FaDk (involves: C57BL/FaDk * RIII/FaDk)	decreased susceptibility to prion infection	J:70033
Pitpnm1^{tm1a(EUCOMM)Wtsi}/Pitpnm1^{tm1a(EUCOMM)Wtsi} (involves: C57BL/6N)	decreased leukocyte cell number	J:207051
Pitx2^tm1Hmd/Pitx2^tm1Hmd (involves: C3H * C57BL/6 * C57BL/6J)	small spleen	J:128475
Pitx2^tm1Jfm/Pitx2^tm1Jfm (involves: 129S4/SvJaeSor)	spleen hypoplasia	J:57674
Pitx2^tm1Rsd/Pitx2^tm1Rsd (involves: 129S1/Sv * 129X1/SvJ)	abnormal spleen morphology	J:57673
Pitx2^tm3.1Jfm/Pitx2^tm3.1Jfm (involves: 129S4/SvJaeSor)	small spleen	J:92872
Pitx3^eyl/Pitx3^eyl (involves: C3H/He * C57BL/6)	abnormal immunoglobulin level	J:156878
	decreased IgG3 level	J:156878
	decreased IgM level	J:156878
	decreased leukocyte cell number	J:156878
	increased CD4-positive, alpha-beta T cell number	J:156878
	increased CD8-positive, alpha-beta T cell number	J:156878
	increased granulocyte number	J:156878
Pitx3^tm1.1Cai/Pitx3⁺ Tg(tetO-SNCAA53T)E2Cai/0 (involves: 129 C57BL/6J * FVB/N)	microgliosis	J:185958
Pja2^tm1.2Afel/Pja2^tm1.2Afel (involves: 129S6/SvEvTac * C57BL/6J)	kidney inflammation	J:345592
Pja2^{tm1b(EUCOMM)Wtsi}/Pja2⁺ (C57BL/6N-Pja2^{tm1b(EUCOMM)Wtsi}/Bay)	abnormal spleen morphology	J:211773
Pja2^{tm1b(EUCOMM)Wtsi}/Pja2^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Pja2^{tm1b(EUCOMM)Wtsi}/Bay)	abnormal spleen morphology	J:211773
Pkd1^{tm1b(EUCOMM)Hmgu}/Pkd1⁺ (C57BL/6N-Pkd1^{tm1b(EUCOMM)Hmgu}/Bay)	increased neutrophil cell number	J:211773
Pkd1^tm1Djmp/Pkd1^tm1Djmp (involves: 129P2/OlaHsd * C57BL/6)	kidney inflammation	J:94582
Pkd1^tm1Jzh/Pkd1⁺ (either: (involves: 129S4/SvJae * C57BL/6) or (involves: 129S4/SvJae * BALB/c))	bile duct inflammation	J:52573
	kidney inflammation	J:52573
Pkd2^tm1Dwo/Pkd2^tm1Dwo (either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6))	absent spleen	J:77401
Pkhd1^tm1.1Ggg/Pkhd1^tm1.1Ggg (involves: 129S/SvEv * 129S4/SvJae * C57BL/6)	bile duct inflammation	J:125113
Pkhd1^tm1Som/Pkhd1^tm1Som (involves: 129S/SvEv * C57BL/6)	enlarged spleen	J:131370
Pkhd1l1^em1(IMPC)H/Pkhd1l1^em1(IMPC)H (C57BL/6N-Pkhd1l1^em1(IMPC)H/H)	decreased lymphocyte cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Pklr^char4/Pklr^char4 (involves: A/J * C57BL/6)	decreased susceptibility to parasitic infection	J:141722, J:86735
	decreased susceptibility to parasitic infection induced morbidity/mortality	J:141722
	enlarged spleen	J:86735
Pklr^slc/Pklr^slc (CBA/NSlc-Pklr^slc)	decreased susceptibility to parasitic infection	J:141722
	decreased susceptibility to parasitic infection induced morbidity/mortality	J:141722
	enlarged spleen	J:30035
	increased susceptibility to bacterial infection induced morbidity/mortality	J:128518
Pkn1^{tm1b(KOMP)Wtsi}/Pkn1^{tm1b(KOMP)Wtsi} (C57BL/6N-Pkn1^{tm1b(KOMP)Wtsi}/H)	decreased large unstained cell number	J:211773
	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
	decreased neutrophil cell number	J:211773
Pkn1^tm1Kik/Pkn1^tm1Kik (B6.129P2-Pkn1^tm1Kik)	abnormal germinal center B cell physiology	J:193187
	abnormal somatic hypermutation frequency	J:193187
	decreased activation-induced B cell apoptosis	J:193187
	glomerulonephritis	J:193187
	immune system phenotype	J:193187
	increased anti-double stranded DNA antibody level	J:193187
	increased B cell proliferation	J:193187
	increased germinal center B cell number	J:193187
	increased IgG1 level	J:193187
	increased IgG2a level	J:193187
	increased IgG2b level	J:193187
	increased IgM level	J:193187
	increased spleen germinal center size	J:193187
	increased splenocyte number	J:193187
Pkn3^tm1.1Mrl/Pkn3⁺ Pten^tm1Hwu/Pten^tm1Hwu Tg(Mx1-cre)1Cgn/0 (involves: 129S4/SvJae * C57BL/6 * CBA/J)	enlarged spleen	J:216983
	enlarged thymus	J:216983
Pkn3^tm1.1Mrl/Pkn3^tm1.1Mrl Pten^tm1Hwu/Pten^tm1Hwu Tg(Mx1-cre)1Cgn/0 (involves: 129S4/SvJae * C57BL/6 * CBA/J)	enlarged spleen	J:216983
	enlarged thymus	J:216983
Pknox1^{Gt(OST71835)Lex}/Pknox1^{Gt(OST71835)Lex} (involves: 129S5/SvEvBrd * C57BL/6)	decreased single-positive T cell number	J:103769
	increased double-negative T cell number	J:103769
	increased T cell apoptosis	J:103769
	thymus hypoplasia	J:103769
Pknox1^tm1Ngc/Pknox1⁺ Tg(IghMyc)22Bri/0 (involves: C57BL * SJL)	decreased B cell apoptosis	J:192251
	increased B cell proliferation	J:192251
Pknox1^tm2.1Fbla/Pknox1^tm2.1Fbla Gt(ROSA)26Sor^{tm2(cre/ERT2)Brn}/Gt(ROSA)26Sor⁺ (involves: 129P2/OlaHsd)	decreased pre-B cell number	J:192251
	increased pro-B cell number	J:192251
Pknox2^{em1(IMPC)Ccpcz}/Pknox2^{em1(IMPC)Ccpcz} (C57BL/6N-Pknox2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	small spleen	J:211773
Pkp3^tm1.1Fvr/Pkp3^tm1.1Fvr (involves: 129P2/OlaHsd * C57BL/6 * CBA * SJL)	dermatitis	J:136451
	enlarged lymph nodes	J:136451
Pla1a^em1(IMPC)J/Pla1a^em1(IMPC)J (C57BL/6NJ-Pla1a^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
Pla1a^em1Appsc/Pla1a^em1Appsc (C57BL/6J-Pla1a^em1Appsc)	abnormal interleukin level	J:333902
	decreased susceptibility to chemically induced skin inflammation	J:333902
	decreased susceptibility to induced arthritis	J:333902
	increased lymphocyte cell number	J:333902
Pla2g2d^{tm1.1(KOMP)Vlcg}/Pla2g2d^{tm1.1(KOMP)Vlcg} (C57BL/6N-Pla2g2d^{tm1.1(KOMP)Vlcg}/J)	decreased leukocyte cell number	J:211773
Pla2g2d^tm1.1Mhg/Pla2g2d^tm1.1Mhg (B6.Cg-Pla2g2d^tm1.1Mhg)	immune system phenotype	J:197334
Pla2g2d^tm1.1Mhg/Pla2g2d^tm1.1Mhg (B6NCrSlc.Cg-Pla2g2d^tm1.1Mhg)	abnormal cytotoxic T cell physiology	J:229035
	abnormal dendritic cell migration	J:229035
	abnormal dendritic cell physiology	J:201008
	abnormal effector T cell morphology	J:201008
	decreased interleukin-6 secretion	J:201008
	decreased susceptibility to Coronaviridae infection	J:229035
	decreased susceptibility to Coronaviridae infection induced morbidity/mortality	J:229035
	decreased tumor necrosis factor secretion	J:201008
	immune system phenotype	J:201008
	increased CD4-positive, alpha-beta T cell number	J:229035, J:201008
	increased CD8-positive, alpha-beta T cell number	J:229035
	increased dendritic cell number	J:201008
	increased interferon-gamma secretion	J:229035
	increased susceptibility to type IV hypersensitivity reaction	J:201008
Pla2g2e^tm1Mhg/Pla2g2e^tm1Mhg (B6.Cg-Pla2g2e^tm1Mhg)	immune system phenotype	J:197334
Pla2g2f^tm1Mhg/Pla2g2f^tm1Mhg (B6.Cg-Pla2g2f^tm1Mhg)	immune system phenotype	J:197334
Pla2g3^tm1Murm/Pla2g3^tm1Murm (involves: 129S/SvEv * C57BL/6)	abnormal mast cell differentiation	J:197334
	abnormal mast cell morphology	J:197334
	decreased mast cell degranulation	J:197334
	decreased susceptibility to type I hypersensitivity reaction	J:197334
	ear inflammation	J:197334
Pla2g4a^tm1Jvb/Pla2g4a^tm1Jvb (involves: 129S4/SvJae)	abnormal mast cell differentiation	J:54619
Pla2g4a^tm1Jvb/Pla2g4a^tm1Jvb (involves: 129S4/SvJae)	increased mast cell degranulation	J:54619
Pla2g4a^tm1Jvb/Pla2g4a^tm1Jvb (involves: 129S4/SvJae * BALB/c)	immune system phenotype	J:110309
Pla2g4a^tm1Tksh/Pla2g4a^tm1Tksh (involves: 129P2/OlaHsd * C57BL/6J)	increased susceptibility to type I hypersensitivity reaction	J:39254
Pla2g4a^tm1Tksh/Pla2g4a^tm1Tksh (NOD.129P2(B6)-Pla2g4a^tm1Tksh)	abnormal macrophage physiology	J:99775
	insulitis	J:99775
Pla2g4a^tm1Tksh/Pla2g4a^tm1Tksh (B6.129P2-Pla2g4a^tm1Tksh)	abnormal cytokine level	J:107430
	decreased interferon-gamma secretion	J:107430
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:107430
	decreased tumor necrosis factor secretion	J:107430
	immune system phenotype	J:197334
Pla2g4e^em1Murm/Pla2g4e^em1Murm (C57BL/6NSlc-Pla2g4e^em1Murm)	increased susceptibility to chemically induced skin inflammation	J:333700
Pla2g5^{em1(IMPC)Ccpcz}/Pla2g5^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Pla2g5^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
	increased eosinophil cell number	J:211773
Pla2g5^tm1Jarm/Pla2g5^tm1Jarm (involves: 129 * C57BL/6J)	abnormal macrophage physiology	J:89490
Pla2g5^tm1Jarm/Pla2g5^tm1Jarm (involves: 129 * C57BL/6J)	decreased acute inflammation	J:89490
Pla2g5^tm1Jarm/Pla2g5^tm1Jarm (involves: 129 * BALB/c)	impaired macrophage phagocytosis	J:110309
Pla2g5^tm1Jarm/Pla2g5^tm1Jarm (C.129-Pla2g5^tm1Jarm)	impaired macrophage phagocytosis	J:110309
Pla2g5^tm1Jarm/Pla2g5^tm1Jarm (involves: 129 * C57BL/6)	impaired macrophage phagocytosis	J:110309
Pla2g5^tm1Jarm/Pla2g5^tm1Jarm (B6.129-Pla2g5^tm1Jarm)	immune system phenotype	J:197334
Pla2g5^tm1Jarm/Pla2g5^tm1Jarm (B6.129-Pla2g5^tm1Jarm)	impaired macrophage phagocytosis	J:110309
Pla2g6^m1Sein/Pla2g6^m1Sein (C57BL/6JJcl-Pla2g6^m1Sein)	decreased double-positive T cell number	J:155328
Pla2g7^tm1.1Mcap/Pla2g7^tm1.1Mcap (B6.Cg-Pla2g7^tm1.1Mcap)	decreased susceptibility to bacterial infection induced morbidity/mortality	J:228564
Pla2g7^tm1.1Mcap/Pla2g7^tm1.1Mcap (B6.Cg-Pla2g7^tm1.1Mcap)	increased susceptibility to bacterial infection	J:228564
Pla2g10^Gt712Lex/Pla2g10^Gt712Lex (involves: 129S5/SvEvBrd * C57BL/6J)	abnormal interleukin level	J:125607
	decreased CD4-positive, alpha-beta T cell number	J:125607
	decreased CD8-positive, alpha-beta T cell number	J:125607
	decreased eosinophil cell number	J:125607
	decreased IgE level	J:125607
	decreased inflammatory response	J:125607
	decreased T cell number	J:125607
Pla2g10^tm1Kiku/Pla2g10^tm1Kiku (B6.129P2-Pla2g10^tm1Kiku)	abnormal neutrophil physiology	J:155082
	decreased neutrophil cell number	J:155082
	immune system phenotype	J:197334
	impaired neutrophil chemotaxis	J:155082
Pla2g15^tm1.1Jash/Pla2g15^tm1.1Jash (involves: 129S1/Sv * C57BL/6)	abnormal macrophage morphology	J:111561
	abnormal macrophage physiology	J:111561
	abnormal spleen morphology	J:111561
	increased macrophage cell number	J:111561
	increased macrophage derived foam cell number	J:111561
	increased spleen weight	J:111561
Pla2r1^tm1Itoh/Pla2r1^tm1Itoh (involves: 129P2/OlaHsd * C57BL/6)	decreased susceptibility to endotoxin shock	J:44868
Plaat3^em1(IMPC)Tcp/Plaat3^em1(IMPC)Tcp (C57BL/6NCrl-Plaat3^em1(IMPC)Tcp/Tcp)	abnormal spleen morphology	J:211773
Plaat3^em1Ueda/Plaat3^em1Ueda (C57BL/6NCrSlc-Plaat3^em1Ueda)	white adipose tissue inflammation	J:343807
Plaat5^em1(IMPC)Tcp/Plaat5^em1(IMPC)Tcp (C57BL/6N-Plaat5^em1(IMPC)Tcp/Tcp)	increased eosinophil cell number	J:211773
Plac8^tm1Bhk/Plac8^tm1Bhk (involves: 129S6/SvEvTac * C57BL/6)	abnormal neutrophil physiology	J:145277
Plac8^tm1Bhk/Plac8^tm1Bhk (129S/SvEv-Plac8^tm1Bhk)	abnormal neutrophil physiology	J:145277
	increased leukocyte cell number	J:145277
	increased neutrophil cell number	J:145277
	increased susceptibility to bacterial infection	J:145277
Plac9^{tm1b(EUCOMM)Hmgu}/Plac9^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Plac9^{tm1b(EUCOMM)Hmgu}/H)	decreased neutrophil cell number	J:211773
Plag1^{em1(IMPC)Hmgu}/Plag1^{em1(IMPC)Hmgu} (C57BL/6N-Plag1^{em1(IMPC)Hmgu}/Ieg)	decreased CD8-positive, naive alpha-beta T cell number	J:211773
Plat^tm1Mlg/Plat^tm1Mlg (involves: 129S2/SvPas * C57BL/6)	abnormal acute phase protein level	J:63134, J:82604
	immune system phenotype	J:17427
	increased macrophage cell number	J:63134
Plat^tm1Mlg/Plat^tm1Mlg (B6.Cg-Plat^tm1Mlg)	abnormal acute phase protein level	J:75303
	abnormal cytokine level	J:75303
	autoimmune arthritis	J:75303
	chronic joint inflammation	J:75303
Plat^tm1Mlg/Plat^tm1Mlg (involves: 129S2/SvPas)	abnormal microglial cell physiology	J:144185
Plat^tm1Mlg/Plat^tm1Mlg (B6.129S2-Plat^tm1Mlg/J)	abnormal susceptibility to Coronaviridae infection	J:288556
Plat^tm1Mlg/Plat^tm1Mlg (B6.129S2-Plat^tm1Mlg/J)	increased susceptibility to Coronaviridae infection induced morbidity/mortality	J:288556
Plau^tm1.1Bug/Plau^tm1.1Bug (involves: C57BL/6)	chronic inflammation	J:164542
	liver inflammation	J:164542
	trachea inflammation	J:164542
Plau^{tm1b(EUCOMM)Wtsi}/Plau^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Plau^{tm1b(EUCOMM)Wtsi}/H)	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Plau^tm1Mlg/Plau^tm1Mlg (involves: 129S2/SvPas * C57BL/6)	abnormal acute phase protein level	J:63134, J:82604
	abnormal cell-mediated immunity	J:87817, J:95638
	abnormal macrophage physiology	J:17427
	abnormal neutrophil physiology	J:75573, J:91980
	impaired granulocyte bactericidal activity	J:91980
	impaired macrophage chemotaxis	J:63134
	impaired neutrophil phagocytosis	J:91980
	increased lymphocyte cell number	J:63134
	increased susceptibility to fungal infection	J:95637
	increased susceptibility to parasitic infection	J:87817
Plau^tm1Mlg/Plau^tm1Mlg (B6.Cg-Plau^tm1Mlg)	abnormal acute phase protein level	J:68083
	abnormal cytokine level	J:75303
	decreased inflammatory response	J:68083
	decreased susceptibility to induced arthritis	J:75303
	decreased T cell proliferation	J:75303
	impaired macrophage chemotaxis	J:68083
Plau^tm1Mlg/Plau^tm1Mlg (B6.129S2-Plau^tm1Mlg)	chronic inflammation	J:164542
	increased inflammatory response	J:164542
	liver inflammation	J:164542
	trachea inflammation	J:164542
Plaur^tm1Jld/Plaur^tm1Jld (involves: 129P2/OlaHsd * Black Swiss)	abnormal macrophage physiology	J:26874
Plaur^tm1Jld/Plaur^tm1Jld (B6.129P2-Plaur^tm1Jld)	chronic inflammation	J:164542
	increased inflammatory response	J:164542
	liver inflammation	J:164542
	trachea inflammation	J:164542
Plaur^tm1Jld/Plaur^tm1Jld Tg(MSR1-Plau)1Ddi/0 (B6.Cg-Plaur^tm1Jld Tg(MSR1-Plau)1Ddi)	heart inflammation	J:113474
Plaur^tm1Mlg/Plaur^tm1Mlg (involves: 129S2/SvPas * C57BL/6)	abnormal cytokine level	J:75573
	abnormal macrophage physiology	J:31253
	abnormal neutrophil physiology	J:75573, J:91980
	impaired neutrophil phagocytosis	J:91980
	increased susceptibility to bacterial infection	J:75573
Plcb1^em1(IMPC)Mbp/Plcb1⁺ (C57BL/6N-Plcb1^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Plcb2^{tm1b(KOMP)Wtsi}/Plcb2^{tm1b(KOMP)Wtsi} (C57BL/6N-Plcb2^{tm1b(KOMP)Wtsi}/Ucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Plcb2^tm1Dwu/Plcb2^tm1Dwu (involves: 129)	abnormal leukocyte physiology	J:41948
	decreased susceptibility to bacterial infection	J:41948
	decreased susceptibility to infection	J:41948
	decreased susceptibility to viral infection	J:41948
Plcb2^tm1Dwu/Plcb2^tm1Dwu Plcb3^tm1Dwu/Plcb3^tm1Dwu (involves: 129S1/Sv)	abnormal neutrophil physiology	J:60348
	increased immunoglobulin level	J:60348
Plcd1^tm1.1Kfu/Plcd1^tm1.1Kfu Tg(KRT14-cre)1Amc/0 (involves: C57BL/6 * C57BL/6JJcl * CBA)	decreased B cell number	J:205633
	enlarged inguinal lymph nodes	J:205633
	increased circulating interleukin-17 level	J:205633
	increased granulocyte number	J:205633
	increased interleukin-17 secretion	J:205633
	increased NK T cell number	J:205633
	increased susceptibility to type IV hypersensitivity reaction	J:205633
Plcd1^tm1Tta/Plcd1^tm1Tta (involves: 129P2/OlaHsd)	abnormal granulocyte differentiation	J:205633
	decreased B cell number	J:205633
	enlarged axillary lymph nodes	J:205633
	enlarged inguinal lymph nodes	J:205633
	enlarged lymph nodes	J:205633
	enlarged spleen	J:205633
	increased circulating interleukin-17 level	J:205633
	increased granulocyte number	J:205633
	increased interleukin-17 secretion	J:205633
	increased leukocyte cell number	J:205633
Plce1^em1(IMPC)Mbp/Plce1^em1(IMPC)Mbp (C57BL/6N-Plce1^em1(IMPC)Mbp/MbpMmucd)	decreased lymphocyte cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Plcg1^tm1Gcrp/Plcg1^tm1Rwen Tg(Cd4-cre)1Cwi/0 (either: B6.Cg-Plcg1^tm1Gcrp/Plcg1^tm1Rwen Tg(Cd4-cre)1Cwi or (involves: 129X1/SvJ * C57BL/6 * DBA/2))	abnormal T cell activation	J:157757
	decreased regulatory T cell number	J:157757
	decreased T cell number	J:157757
	dermatitis	J:157757
	ear inflammation	J:157757
	increased anti-double stranded DNA antibody level	J:157757
	increased CD4-positive, alpha-beta T cell number	J:157757
	increased T cell proliferation	J:157757
	skin inflammation	J:157757
Plcg1^tm1Gcrp/Plcg1^tm1Rwen Tg(Cd4-cre)1Cwi/0 Tg(TcraH-Y,TcrbH-Y)71Vbo/0 (involves: 129X1/SvJ * C57BL/6 * DBA/2)	decreased CD8-positive, alpha-beta T cell number	J:157757
	decreased double-negative T cell number	J:157757
	increased CD8-positive, alpha-beta T cell number	J:157757
	increased double-positive T cell number	J:157757
	thymus hyperplasia	J:157757
Plcg2^al/Plcg2^al (involves: 129 * C57BL/6)	abnormal lymphatic vessel morphology	J:143529
Plcg2^Ali5/Plcg2⁺ (C3HeB/FeJ-Plcg2^Ali5)	abnormal B cell physiology	J:97930
	chronic inflammation	J:97930
	decreased B-2 B cell number	J:97930
	dermatitis	J:97930
	osteoarthritis	J:97930
Plcg2^Ali5/Plcg2⁺ (involves: C57BL/6J * C3HeB/FeJ-Plcg2^Ali5)	abnormal B cell physiology	J:97930
	glomerulonephritis	J:97930
	immune system phenotype	J:97930
Plcg2^Ali5/Plcg2⁺ Rag1^tm1Mom/Rag1^tm1Mom (involves: 129S7/SvEvBrd * C3HeB/FeJ * C3HeB/FeJ-Plcg2^Ali5)	chronic inflammation	J:97930
	dermatitis	J:97930
	osteoarthritis	J:97930
Plcg2^Ali5/Plcg2^Ali5 (involves: C57BL/6J * C3HeB/FeJ-Plcg2^Ali5)	abnormal B cell physiology	J:97930
	chronic inflammation	J:97930
	decreased mature B cell number	J:97930
	decreased transitional stage B cell number	J:97930
	glomerulonephritis	J:97930
Plcg2^Ali14/Plcg2⁺ (C3HeB/FeJ-Plcg2^Ali14)	abnormal inflammatory response	J:166106
Plcg2^em1Msasn/Plcg2^em1Msasn (B6.Cg-Plcg2^em1Msasn/J)	impaired macrophage phagocytosis	J:308279
Plcg2^m1Btlr/Plcg2^m1Btlr (C57BL/6J-Plcg2^m1Btlr)	decreased IgM level	J:165702
Plcg2^m1Btlr/Plcg2^m1Btlr (involves: C57BL/6J)	abnormal B cell differentiation	J:185495
	decreased IgM level	J:185495
	immune system phenotype	J:185495
Plcg2^M2Btlr/Plcg2⁺ (C57BL/6J-Plcg2^M2Btlr)	decreased tumor necrosis factor secretion	J:218966
Plcg2^M2Btlr/Plcg2^M2Btlr (C57BL/6J-Plcg2^M2Btlr)	decreased tumor necrosis factor secretion	J:218966
Plcg2^M3Btlr/Plcg2^M3Btlr (C57BL/6J-Plcg2^M3Btlr)	abnormal humoral immune response	J:265101
	decreased B-1a cell number	J:265101
	decreased IgM level	J:265101
Plcg2^m4Btlr/Plcg2^m4Btlr (C57BL/6J-Plcg2^m4Btlr)	decreased CD8-positive, naive alpha-beta T cell number	J:272862
Plcg2^m4Btlr/Plcg2^m4Btlr (C57BL/6J-Plcg2^m4Btlr)	increased effector memory CD8-positive, alpha-beta T cell number	J:272862
Plcg2^tm1.1Kuro/Plcg2^tm1.1Kuro (B6.Cg-Plcg2^tm1.1Kuro)	decreased interferon-gamma secretion	J:131621
Plcg2^tm1.1Kuro/Plcg2^tm1.1Kuro (B6.Cg-Plcg2^tm1.1Kuro)	impaired natural killer cell mediated cytotoxicity	J:131621
Plcg2^tm1.1Kuro/Plcg2^tm1.1Kuro (Not Specified)	abnormal B cell differentiation	J:131161
	abnormal NK cell physiology	J:187430
	increased pro-B cell number	J:131161
	spleen hyperplasia	J:131161
Plcg2^tm1Ichi/Plcg2^tm1Ichi (involves: 129 * C57BL/6)	abnormal lymphatic vessel morphology	J:143529
Plcg2^tm1Jni/Plcg2^tm1Jni (involves: 129P2/OlaHsd)	abnormal B cell calcium ion homeostasis	J:80614
	abnormal dendritic cell chemotaxis	J:157619
	abnormal dendritic cell morphology	J:157619
	abnormal dendritic cell physiology	J:157619
	arrested B cell differentiation	J:86373
	decreased B cell proliferation	J:80614
	decreased follicular B cell number	J:86373
	decreased mature B cell number	J:104166
	decreased susceptibility to induced arthritis	J:157619
	increased B cell apoptosis	J:86373
	increased pro-B cell number	J:104166
	increased transitional stage T2 B cell number	J:86373
Plcg2^tm1Jni/Plcg2^tm1Jni (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell differentiation	J:117023
	abnormal B cell physiology	J:117023
	abnormal osteoclast differentiation	J:114607
	decreased interferon-gamma secretion	J:100716
	decreased osteoclast cell number	J:114607
	impaired natural killer cell mediated cytotoxicity	J:100716
	increased B cell proliferation	J:117023
	increased pre-B cell number	J:117023
	increased susceptibility to Herpesvirales infection	J:100716
Plcg2^tm1Jni/Plcg2^tm1Jni Tg(IghMyc)22Bri/0 (involves: 129P2/OlaHsd * C57BL * C57BL/6 * SJL)	enlarged lymph nodes	J:117023
Plcg2^tm1Kuro/Plcg2^tm1Kuro Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA)	abnormal humoral immune response	J:63744
	decreased B cell proliferation	J:63744
	decreased mature B cell number	J:63744
	decreased pre-B cell number	J:63744
	immune system phenotype	J:63744
	increased B-1a cell number	J:63744
	increased immature B cell number	J:63744
	increased pro-B cell number	J:63744
Plcl2^tm1Tta/Plcl2^tm1Tta (involves: 129P2/OlaHsd)	abnormal adaptive immunity	J:85960
	abnormal B cell calcium ion homeostasis	J:85960
	decreased B-1a cell number	J:85960
	decreased mature B cell number	J:85960
	increased anti-nuclear antigen antibody level	J:85960
	increased B cell proliferation	J:85960
	increased IgM level	J:85960
Pld2^tm1.1Mjow/Pld2^tm1.1Mjow (Not Specified)	abnormal neutrophil physiology	J:183062
Pld3^em1Nemz/Pld3^em1Nemz (C57BL/6J-Pld3^em1Nemz)	immune system phenotype	J:281205
Pld3^em1Nemz/Pld3^em1Nemz (C57BL/6J-Pld3^em1Nemz)	increased interleukin-6 secretion	J:281205
Pld3^em1Nemz/Pld3^em1Nemz Pld4^tm1.2Nemz/Pld4^tm1.2Nemz (B6.Cg-Pld3^em1Nemz Pld4^tm1.1Nemz)	abnormal circulating chemokine level	J:281205
	hemophagocytosis	J:281205
	increased circulating CXCL10 level	J:281205
	increased circulating interferon-gamma level	J:281205
	increased circulating tumor necrosis factor level	J:281205
	liver inflammation	J:281205
Pld4^em1(IMPC)Mbp/Pld4^em1(IMPC)Mbp (C57BL/6N-Pld4^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
	increased monocyte cell number	J:211773
	increased spleen weight	J:211773
Pld4^thss/Pld4^thss (BALB/cJ-Pld4^thss/GrsrJ)	abnormal alpha-beta T cell morphology	J:278304
	abnormal immunoglobulin level	J:278304
	enlarged lymph nodes	J:278304
	enlarged spleen	J:278304
	increased anti-nuclear antigen antibody level	J:278304
	increased IgA level	J:278304
	increased IgE level	J:278304
	increased IgG2b level	J:278304
	increased IgG3 level	J:278304
	increased IgG level	J:278304
	increased IgM level	J:278304
	increased macrophage cell number	J:278304
	increased marginal zone B cell number	J:278304
	increased plasma cell number	J:278304
	increased plasmacytoid dendritic cell number	J:278304
	increased spleen germinal center number	J:278304
	lymph node hyperplasia	J:278304
	spleen hyperplasia	J:278304
Pld4^tm1.1Nemz/Pld4^tm1.1Nemz Tg(Itgax-cre)1-1Reiz/0 (involves: 129 * C57BL/6 * C57BL/6J * CBA)	abnormal peritoneal macrophage morphology	J:281205
Pld4^tm1.2Nemz/Pld4^tm1.2Nemz (B6.129(Cg)-Pld4^tm1.1Nemz)	abnormal leukocyte cell number	J:281205
	abnormal peritoneal macrophage morphology	J:281205
	decreased B-1 B cell number	J:281205
	decreased NK T cell number	J:281205
	enlarged spleen	J:281205
	immune system phenotype	J:281205
	increased circulating CXCL10 level	J:281205
	increased circulating interferon-gamma level	J:281205
	increased marginal zone B cell number	J:281205
	increased monocyte cell number	J:281205
Pld4^tm1.2Nemz/Pld4^tm1.2Nemz Rag1^tm1Mom/Rag1^tm1Mom (involves: 129 * 129S7/SvEvBrd * C57BL/6J * FVB/N)	abnormal peritoneal macrophage morphology	J:281205
	decreased NK T cell number	J:281205
Pld4^tm1.2Nemz/Pld4^tm1.2Nemz Tlr9^M7Btlr/Tlr9^M7Btlr (involves: 129 * C57BL/6J * FVB/N)	immune system phenotype	J:281205
Plec^tm3Gwi/Plec^tm3Gwi (involves: 129P2/OlaHsd)	abnormal T cell physiology	J:104701
Plec^tm3Gwi/Plec^tm3Gwi (involves: 129P2/OlaHsd)	impaired macrophage chemotaxis	J:104701
Plek2^tm1Pji/Plek2^tm1Pji (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal granulocyte differentiation	J:257910
	enlarged spleen	J:257910
Plek2^tm1Pji/Plek2^tm1Pji Jak2^tm1.1Ble/Jak2⁺ Commd10^{Tg(Vav1-icre)A2Kio}/Commd10⁺ (involves: 129 * C57BL/6 * C57BL/10 * CBA/Ca)	abnormal granulocyte differentiation	J:257910
	immune system phenotype	J:257910
Plekha5^em1(IMPC)Tcp/Plekha5^em1(IMPC)Tcp (C57BL/6NCrl-Plekha5^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
	increased spleen weight	J:211773
Plekha7^tm1.1Janc/Plekha7^tm1.1Janc (involves: C57BL/6)	decreased susceptibility to bacterial infection	J:227858
Plekha7^tm1.1Janc/Plekha7^tm1.1Janc (involves: C57BL/6)	decreased susceptibility to bacterial infection induced morbidity/mortality	J:227858
Plekhf1^tm1.1Caox/Plekhf1^tm1.1Caox Lyz2^tm1(cre)Ifo/Lyz2⁺ (B6.Cg-Plekhf1^tm1.1Caox Lyz2^tm1(cre)Ifo)	abnormal cytokine secretion	J:277440
	abnormal macrophage physiology	J:277440
	decreased circulating interferon-beta level	J:277440
	decreased circulating interleukin-6 level	J:277440
	decreased circulating tumor necrosis factor level	J:277440
	increased susceptibility to bacterial infection	J:277440
	increased susceptibility to bacterial infection induced morbidity/mortality	J:277440
Plekhg2^em1(IMPC)J/Plekhg2^em1(IMPC)J (C57BL/6NJ-Plekhg2^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
Plekhm1^tm1.2Hzhao/Plekhm1^tm1.2Hzhao (involves: 129S1/Sv * C57BL/6J)	abnormal osteoclast morphology	J:236517
	abnormal osteoclast physiology	J:236517
Plekhm2^{tm1a(EUCOMM)Wtsi}/Plekhm2^{tm1a(EUCOMM)Wtsi} (B6JTyr;B6N-Plekhm2^{tm1a(EUCOMM)Wtsi}/Wtsi)	increased leukocyte cell number	J:165965
Plekhm2^{tm1a(EUCOMM)Wtsi}/Plekhm2^{tm1a(EUCOMM)Wtsi} (involves: C57BL/6J * C57BL/6N)	decreased susceptibility to bacterial infection	J:233985
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:233985
	increased leukocyte cell number	J:233985
Plekho2^em1Lzhn/Plekho2^em1Lzhn (C57BL/6-Plekho2^em1Lzhn)	decreased macrophage cell number	J:270531
	immune system phenotype	J:270531
	increased macrophage apoptosis	J:270531
Plet1^tm1Cupe/Plet1^tm1Cupe (Not Specified)	abnormal dendritic cell migration	J:271548
	abnormal dendritic cell number	J:271548
	increased dendritic cell number	J:271548
Plg^tm1.1Fjc/Plg^tm1.1Fjc (involves: C57BL/6 * C57BL/6JJcl)	enlarged lymph nodes	J:210802
Plg^tm1.1Fjc/Plg^tm1.1Fjc (involves: C57BL/6 * C57BL/6JJcl)	increased circulating fibrinogen level	J:210802
Plg^tm1Dco/Plg⁺ (involves: 129S2/SvPas * 129X1/SvJ * C57BL/6)	abnormal inflammatory response	J:80114
Plg^tm1Dco/Plg^tm1Dco (involves: 129S2/SvPas * C57BL/6)	abnormal acute phase protein level	J:82604
Plg^tm1Dco/Plg^tm1Dco (involves: 129S2/SvPas * 129X1/SvJ * C57BL/6)	abnormal inflammatory response	J:80114
Plg^tm1Dco/Plg^tm1Dco (involves: 129S2/SvPas)	enlarged lymph nodes	J:210802
Plg^tm1Dco/Plg^tm1Dco (involves: 129S2/SvPas)	increased circulating fibrinogen level	J:210802
Plg^tm1Jld/Plg^tm1Jld (involves: 129P2/OlaHsd * NIH Black Swiss)	proctitis	J:39419
Plg^tm1Jld/Plg^tm1Jld (B6.129P2-Plg^tm1Jld)	conjunctivitis	J:46096
Plg^tm1Jld/Plg^tm1Jld (B6.129P2-Plg^tm1Jld)	eye inflammation	J:46096
Plg^tm1Jld/Plg^tm1Jld (involves: 129P2/OlaHsd * Black Swiss)	colitis	J:36591
Plg^tm1Jld/Plg^tm1Jld (B6.129P2-Plg^tm1Jld/J)	abnormal microglial cell physiology	J:141739
Plgr1^BALB/cJ/Plgr1^BALB/cJ (involves: BALB/cJ * C57BL/6J)	decreased susceptibility to bacterial infection	J:138895
Plgr1^BALB/cJ/Plgr1^BALB/cJ (B6.C-Plgr1^BALB/cJ)	decreased susceptibility to bacterial infection	J:138895
Plgr1^BALB/cJ/Plgr1^C57BL/6J (involves: BALB/cJ * C57BL/6J)	decreased susceptibility to bacterial infection	J:138895
Plgr1^BALB/cJ/Plgr1^C57BL/6J (B6.C-Plgr1^BALB/cJ)	decreased susceptibility to bacterial infection	J:138895
Plgrkt^tm1Lmls/Plgrkt⁺ (B6.Cg-Plgrkt^tm1Lmls)	dermatitis	J:282437
Plgrkt^tm1Lmls/Plgrkt^tm1Lmls (B6.Cg-Plgrkt^tm1Lmls)	abnormal macrophage physiology	J:282437
	dermatitis	J:282437
	impaired leukocyte migration	J:282437
	impaired macrophage chemotaxis	J:282437
Plin2^tm1.1Asg/Plin2^tm1.1Asg (B6.129S2(Cg)-Plin2^tm1.1Asg)	decreased inflammatory response	J:196302
Plp1^jp-rsh/Plp1⁺ (either: STOCK Rb(1.3)1Bnr or (involves: BALB/c * DBA/2 * STOCK Rb(1.3)1Bnr))	abnormal microglial cell morphology	J:604
Plp1^jp-rsh/Plp1^jp-rsh (involves: 101/H * C3H)	decreased susceptibility to Picornaviridae infection	J:41447
Plp1^{tm1c(EUCOMM)Wtsi}/Y Cnp^tm1(cre)Kan/Cnp⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6N)	increased T cell number	J:245100
	microgliosis	J:245100
Plp1^tm1Kan/Y (involves: 129S1/Sv * 129X1/SvJ)	abnormal microglial cell morphology	J:48031
Plp1^tm1Kan/Y (involves: 129S1/Sv * 129X1/SvJ)	microgliosis	J:245100
Plp1^tm1Kan/Y (B6.129-Plp1^tm1Kan)	microgliosis	J:201143
Plp1^tm1Kan/Y Cnp^tm1(cre)Kan/Cnp⁺ (involves: 129S1/Sv * 129X1/SvJ)	increased T cell number	J:245100
	microgliosis	J:245100
Plp1^tm1Kan/Y Tspan2^tm1Hbw/Tspan2^tm1Hbw (B6.Cg-Tspan2^tm1Hbw Plp1^tm1Kan)	brain inflammation	J:201143
	microgliosis	J:201143
Plpp5^tm1(KOMP)Mbp/Plpp5^tm1(KOMP)Mbp Prdm1^tm1Nutt/Prdm1⁺ (involves: C57BL/6 * C57BL/6N)	immune system phenotype	J:265892
Plppr5^{em1(IMPC)Ccpcz}/Plppr5^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Plppr5^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged thymus	J:211773
Pls1^tm1Fri/Pls1^tm1Fri (B6.129-Pls1^tm1Fri)	increased susceptibility to colitis induced morbidity/mortality	J:216723
Pls1^tm1Fri/Pls1^tm1Fri (B6.129-Pls1^tm1Fri)	increased susceptibility to induced colitis	J:216723
Plscr1^tm1Lex/Plscr1^tm1Lex (129S/SvEvBrd-Plscr1^tm1Lex)	abnormal granulocyte differentiation	J:76790
	abnormal myelopoiesis	J:76790
	abnormal neutrophil differentiation	J:76790
	decreased granulocyte number	J:76790
	decreased neutrophil cell number	J:76790
Plscr1^tm1Lex/Plscr1^tm1Lex Plscr3^tm1Sims/Plscr3^tm1Sims (involves: 129S7/SvEvBrd * C57BL/6J)	abnormal myelopoiesis	J:92404
plt/plt (involves: DDD/1)	abnormal immune system organ morphology	J:47819
	abnormal immune system physiology	J:47819
	abnormal leukocyte cell number	J:47819
	abnormal leukocyte migration	J:47819, J:47460
	abnormal lymph node T cell domain morphology	J:47819, J:47460
	abnormal peripheral lymph node morphology	J:47819
	abnormal spleen red pulp morphology	J:47460
	abnormal spleen white pulp morphology	J:47460
	decreased single-positive T cell number	J:15290
	decreased T cell number	J:47819
	increased memory T cell number	J:47460
	increased T cell number	J:47819
	lymph node hypoplasia	J:15290, J:47460
	small Peyer's patches	J:47460
plt/plt (C.DDD-plt)	abnormal T cell activation	J:119345
	decreased single-positive T cell number	J:119345
	increased length of allograft survival	J:119345
plt/plt (B6.DDD-plt)	abnormal leukocyte migration	J:93960
	abnormal thymus cortex morphology	J:93960
	immune system phenotype	J:93960
	small thymus medulla	J:93960
plt/plt (either: B6.DDD-plt or C.DDD-plt)	abnormal leukocyte migration	J:110910
	increased inflammatory response	J:110910
	increased susceptibility to autoimmune disorder	J:110910
	lacrimal gland inflammation	J:110910
	parotid gland inflammation	J:110910
	salivary gland inflammation	J:110910
	submandibular gland inflammation	J:110910
Plvap^{tm1e(EUCOMM)Hmgu}/Plvap^{tm1e(EUCOMM)Hmgu} Tg(TIE2GFP)287Sato/0 (involves: C57BL/6N * FVB/N)	small spleen	J:203907
Plxna1^tm1Kik/Plxna1^tm1Kik (either: B6.Cg-Plxna1^tm1Kik or C.Cg-Plxna1^tm1Kik)	abnormal CD4-positive, alpha-beta T cell physiology	J:110786
	abnormal dendritic cell physiology	J:110786
Plxna1^tm1Kik/Plxna1^tm1Kik (Not Specified)	abnormal dendritic cell physiology	J:161856
Plxna1^tm1Kik/Plxna1^tm1Kik Tg(TcraTcrb)425Cbn/? (involves: BALB/c * C57BL/6)	decreased T cell proliferation	J:161856
Plxna1^tm1Tmj/Plxna1^tm1Tmj (involves: 129S/SvEv)	abnormal lymphatic vessel endothelial cell morphology	J:226501
Plxna1^tm1Tmj/Plxna1^tm1Tmj (involves: 129S/SvEv)	abnormal lymphatic vessel morphology	J:226501
Plxna2^tm1Hfu/Plxna2^tm1Hfu (involves: C57BL/6NCrlj * CBA/JNCrlj)	abnormal lymphatic vessel morphology	J:226501
Plxna4^em1(IMPC)Mbp/Plxna4^em1(IMPC)Mbp (C57BL/6NCrl-Plxna4^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	small spleen	J:211773
Plxnc1^em1(IMPC)Mbp/Plxnc1^em1(IMPC)Mbp (C57BL/6N-Plxnc1^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	small spleen	J:211773
Plxnd1^b2b1863Clo/Plxnd1^b2b1863Clo (C57BL/6J-Plxnd1^b2b1863Clo)	thymus hypoplasia	J:175213
Plxnd1^b2b3150Clo/Plxnd1^b2b3150Clo (C57BL/6J-Plxnd1^b2b3150Clo)	thymus hypoplasia	J:175213
Plyid^HIGA/Nsc/Plyid^HIGA/Nsc (involves: BALB/cA * HIGA/Nsc)	abnormal humoral immune response	J:91769
	increased IgA level	J:91769
Pmaip1^tm1Ast/Pmaip1^tm1Ast (C57BL/6-Pmaip1^tm1Ast)	abnormal NK cell morphology	J:123409
Pmaip1^tm1Ast/Pmaip1^tm1Ast (involves: C57BL/6)	immune system phenotype	J:132819
Pmepa1^em1Akt/Pmepa1^em1Akt (C57BL/6N-Pmepa1^em1Akt)	abnormal osteoclast differentiation	J:329578
	abnormal osteoclast physiology	J:329578
	decreased osteoclast cell number	J:329578
Pml^{tm1(PML/RARA)Ley}/Pml⁺ Tg(CAG-cre/Esr1)5Amc/0 (involves: BALB/cJ C57BL/6 * CBA)	enlarged spleen	J:172024
Pml^tm1.1Ews/Pml^tm1.1Ews (involves: 129 * 129P2/OlaHsd)	increased T cell derived lymphoma incidence	J:262172
Pml^tm1.1Ews/Pml^tm1.1Ews Tg(PML-RARA)556Kog/0 (FVB.Cg-Pml^tm1.1Ews Tg(PML-RARA)556Kog)	enlarged spleen	J:262172
	increased leukocyte cell number	J:262172
Pml^tm1Ppp/Pml⁺ Trp53^tm3.1Glo/Trp53⁺ (B6.129S7(Cg)-Pml^tm1Ppp Trp53^tm3.1Glo)	hepatosplenomegaly	J:317504
	increased T cell derived lymphoma incidence	J:317504
Pml^tm1Ppp/Pml^tm1Ppp (involves: 129S7/SvEvBrd)	abnormal immune system cell morphology	J:46381
	abnormal myelopoiesis	J:46381
	decreased granulocyte number	J:46381
	decreased leukocyte cell number	J:46381
	increased susceptibility to bacterial infection	J:46381
Pml^tm1Ppp/Pml^tm1Ppp Trp53^tm3.1Glo/Trp53⁺ (B6.129S7(Cg)-Pml^tm1Ppp Trp53^tm3.1Glo)	hepatosplenomegaly	J:317504
	increased T cell derived lymphoma incidence	J:317504
Pmm2^{tm1b(EUCOMM)Hmgu}/Pmm2⁺ (C57BL/6N-Pmm2^{tm1b(EUCOMM)Hmgu}/Tcp)	enlarged lymph nodes	J:211773
Pms2^tm1.1Wed/Pms2^tm1.1Wed (involves: 129S6/SvEvTac * C57BL/6NCr)	abnormal class switch recombination	J:162378
	increased T cell derived lymphoma incidence	J:162378
Pms2^tm1Lisk/Pms2^tm1Lisk (involves: 129S2/SvPas)	abnormal class switch recombination	J:162378
Pnliprp2^tm1Gru/Pnliprp2^tm1Gru (involves: 129S2/SvPas * BALB/c)	decreased cytotoxic T cell cytolysis	J:51627
Pnma8b^em1(IMPC)Tcp/Pnma8b^em1(IMPC)Tcp (C57BL/6NCrl-Pnma8b^em1(IMPC)Tcp/Cmmr)	decreased neutrophil cell number	J:211773
	increased lymphocyte cell number	J:211773
Pno1^tm1Jwu/Pno1⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	immune system phenotype	J:191966
Pnp2^em1Smoc/Pnp2^em1Smoc (C57BL/6J-Pnp2^em1Smoc)	immune system phenotype	J:339075
Pnp^bata/Pnp^bata (C57BL/6JSfdAnu-Pnp^bata)	decreased B cell proliferation	J:104190
	decreased marginal zone B cell number	J:104190
	increased T follicular helper cell number	J:104190
Pnp^e/Pnp^e (C57BL/6J-Pnp^e)	abnormal leukocyte physiology	J:39328
Pnp^e/Pnp^e (C57BL/6J-Pnp^e)	thymus hypoplasia	J:39328
Pnp^f/Pnp^f (involves: C3H/HeHa * C57BL/6J)	increased double-negative T cell number	J:522
Pnp^f/Pnp^f (C57BL/6J-Pnp^f)	abnormal leukocyte cell number	J:39328
	abnormal leukocyte physiology	J:39328
	decreased CD8-positive, alpha-beta T cell number	J:39328
	decreased double-positive T cell number	J:39328
	thymus hypoplasia	J:39328
Pnp^g/Pnp^g (involves: C57BL/6 * DBA/2J)	abnormal leukocyte cell number	J:39328
	abnormal leukocyte physiology	J:39328
	decreased CD8-positive, alpha-beta T cell number	J:39328
	decreased double-positive T cell number	J:39328
	increased double-negative T cell number	J:39328
	thymus hypoplasia	J:39328
Pnp^M1Btlr/Pnp^M1Btlr (C57BL/6J-Pnp^M1Btlr)	impaired humoral immune response	J:265147
Pnp^M1Btlr/Pnp^M1Btlr (C57BL/6J-Pnp^M1Btlr)	increased IgM level	J:265147
Pnp^m2Btlr/Pnp^m2Btlr (C57BL/6J-Pnp^m2Btlr)	decreased B-1a cell number	J:265150
	decreased B-2 B cell number	J:265150
	decreased CD4-positive, alpha-beta T cell number	J:265150
	decreased CD8-positive, naive alpha-beta T cell number	J:265150
	decreased T cell number	J:265150
	increased B-1b cell number	J:265150
	increased CD8-positive, alpha-beta memory T cell number	J:265150
	increased central memory CD4-positive, alpha-beta T cell number	J:265150
	increased central memory CD8 positive, alpha-beta T cell number	J:265150
	increased effector memory CD4-positive, alpha-beta T cell number	J:265150
	increased effector memory CD8-positive, alpha-beta T cell number	J:265150
Pnp^tm1Cmr/Pnp^tm1Cmr (involves: 129)	abnormal myelopoiesis	J:62870
	decreased CD4-positive, alpha-beta T cell number	J:62870
	decreased CD8-positive, alpha-beta T cell number	J:62870
	decreased cytotoxic T cell cytolysis	J:62870
	decreased double-positive T cell number	J:62870
	decreased single-positive T cell number	J:62870
	increased double-negative T cell number	J:62870
	increased pre-B cell number	J:62870
	increased thymocyte apoptosis	J:62870
Pnpla5^em1(IMPC)Mbp/Pnpla5^em1(IMPC)Mbp (C57BL/6N-Pnpla5^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Podxl2^{tm1.1(KOMP)Vlcg}/Podxl2^{tm1.1(KOMP)Vlcg} (C57BL/6N-Podxl2^{tm1.1(KOMP)Vlcg}/Ucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	increased neutrophil cell number	J:211773
Pofut1^tm2Pst/Pofut1^tm1Pst Shh^{tm2(cre/ERT2)Cjt}/Shh⁺ (involves: 129/Sv * 129S6/SvEvTac * C57BL/6J * SJL)	lung inflammation	J:150051
Polb^tm1.1Jbsw/Polb⁺ (involves: 129/Sv * C57BL/6)	dermatitis	J:206872
	enlarged cervical lymph nodes	J:206872
	glomerulonephritis	J:206872
	increased anti-nuclear antigen antibody level	J:206872
	increased IgG level	J:206872
	lymph node inflammation	J:206872
	salivary gland inflammation	J:206872
Polb^tm1.1Jbsw/Polb^tm1.1Jbsw (involves: 129/Sv * C57BL/6)	abnormal immunoglobulin heavy chain V(D)J recombination	J:206872
	abnormal somatic hypermutation frequency	J:206872
	abnormal spleen germinal center morphology	J:206872
	dermatitis	J:206872
	enlarged cervical lymph nodes	J:206872
	glomerulonephritis	J:206872
	increased anti-nuclear antigen antibody level	J:206872
	increased germinal center B cell number	J:206872
	increased IgG level	J:206872
	increased spleen germinal center number	J:206872
	increased splenocyte apoptosis	J:183837, J:206872
	increased susceptibility to systemic lupus erythematosus	J:206872
	increased T-helper 2 cell number	J:206872
	lymph node inflammation	J:206872
	salivary gland inflammation	J:206872
Polb^{tm1a(KOMP)Wtsi}/Polb^{tm1a(KOMP)Wtsi} (C57BL/6N-Polb^{tm1a(KOMP)Wtsi}/Wtsi)	abnormal lymphatic vessel topology	J:239583
Polb^tm1Rsky/Polb^tm1Rsky Tg(Lck-cre)I57Jxm/0 (involves: 129P2/OlaHsd * ICR)	immune system phenotype	J:67942
Pold1^tm1.1Bdp/Pold1^tm1.1Bdp (B6.129-Pold1^tm1.1Bdp)	increased T cell derived lymphoma incidence	J:153684
Pold1^tm1.1Bdp/Pold1^tm1.1Bdp Pole^tm1.1Bdp/Pole^tm1.1Bdp (B6.129-Pole^tm1.1Bdp Pold1^tm1.1Bdp)	increased T cell derived lymphoma incidence	J:153684
Pold1^tm1.1Uchi/Pold1^tm1.1Uchi (C57BL/6-Pold1^tm1.1Uchi)	enlarged thymus	J:144992
Pold1^tm1Bdp/Pold1^tm1Bdp (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	increased T cell derived lymphoma incidence	J:100685
Pold1^tm1Uchi/Pold1^tm1.1Uchi (C57BL/6-Pold1^tm1Uchi/Pold1^tm1.1Uchi)	enlarged thymus	J:144992
Pold4^em1(IMPC)J/Pold4^em1(IMPC)J (C57BL/6NJ-Pold4^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
Pole2^em1(IMPC)Mbp/Pole2⁺ (C57BL/6NCrl-Pole2^em1(IMPC)Mbp/Mmucd)	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Pole3^em1Tbo/Pole3^em1Tbo (FVB-Pole3^em1Tbo)	decreased B cell number	J:298827
	decreased lymphocyte cell number	J:298827
	decreased splenocyte number	J:298827
	decreased thymocyte number	J:298827
Pole3^em2Tbo/Pole3^em2Tbo (FVB-Pole3^em2Tbo)	decreased B cell number	J:298827
	decreased lymphocyte cell number	J:298827
	decreased splenocyte number	J:298827
	decreased thymocyte number	J:298827
Pole3^em3Tbo/Pole3^em3Tbo (FVB-Pole3^em3Tbo)	abnormal thymus apoptosis	J:298827
	decreased B cell number	J:298827
	decreased DN4 thymocyte number	J:298827
	decreased double-positive T cell number	J:298827
	decreased gamma-delta T cell number	J:298827
	decreased immature B cell number	J:298827
	decreased lymphocyte cell number	J:298827
	decreased pre-B cell number	J:298827
	decreased splenocyte number	J:298827
	decreased thymocyte number	J:298827
	increased DN3 thymocyte number	J:298827
	increased thymocyte apoptosis	J:298827
	small spleen	J:298827
	small thymus	J:298827
Pole3^em4Tbo/Pole3^em4Tbo (FVB-Pole3^em4Tbo)	abnormal thymus apoptosis	J:298827
	decreased B cell number	J:298827
	decreased DN4 thymocyte number	J:298827
	decreased immature B cell number	J:298827
	decreased lymphocyte cell number	J:298827
	decreased pre-B cell number	J:298827
	decreased splenocyte number	J:298827
	decreased thymocyte number	J:298827
	increased DN3 thymocyte number	J:298827
	increased thymocyte apoptosis	J:298827
Pole3^{tm1(KOMP)Vlcg}/Pole3^{tm1(KOMP)Vlcg} (involves: C57BL/6NTac * FVB)	decreased DN4 thymocyte number	J:298827
	increased DN3 thymocyte number	J:298827
Pole4^{tm1(KOMP)Vlcg}/Pole4^{tm1(KOMP)Vlcg} (involves: 129S1/Sv * 129X1/SvJ * C57BL/6NTac * FVB/N)	abnormal B cell differentiation	J:261973
	abnormal mesenteric lymph node morphology	J:261973
	abnormal spleen B cell follicle morphology	J:261973
	abnormal T cell differentiation	J:261973
	abnormal thymus morphology	J:261973
	absent thymus cortex	J:261973
	arrested B cell differentiation	J:261973
	athymia	J:261973
	decreased B cell number	J:261973
	decreased leukocyte cell number	J:261973
	decreased lymphocyte cell number	J:261973
	decreased single-positive T cell number	J:261973
	decreased spleen weight	J:261973
	increased double-negative T cell number	J:261973
	increased granulocyte number	J:261973
	increased monocyte cell number	J:261973
	increased T cell derived lymphoma incidence	J:261973
	small spleen	J:261973
Pole4^{tm1(KOMP)Vlcg}/Pole4^{tm1(KOMP)Vlcg} Trp53^tm1Brd/Trp53⁺ (involves: C57BL/6J * C57BL/6NTac)	decreased leukocyte cell number	J:261973
	decreased lymphocyte cell number	J:261973
	increased granulocyte number	J:261973
	increased monocyte cell number	J:261973
	increased T cell derived lymphoma incidence	J:261973
Pole4^{tm1(KOMP)Vlcg}/Pole4^{tm1(KOMP)Vlcg} Trp53^tm1Brd/Trp53^tm1Brd (involves: C57BL/6J * C57BL/6NTac)	immune system phenotype	J:261973
Pole^tm1.1Bdp/Pole^tm1.1Bdp (B6.129-Pole^tm1.1Bdp)	enlarged spleen	J:153684
Polg^tm1.1Suom/Polg^tm1.1Suom (involves: C57BL/6JOlaHsd)	brain inflammation	J:365276
	decreased circulating interferon-beta level	J:365276
	decreased circulating interferon-gamma level	J:365276
	increased circulating interleukin-6 level	J:365276
	increased susceptibility to Flaviviridae infection	J:365276
	liver inflammation	J:365276
Polg^tm1Prol/Polg^tm1Prol (involves: 129S7/SvEvBrd * C57BL/6J * ICR)	abnormal thymus involution	J:99764
Polg^tm1Prol/Polg^tm1Prol (B6J.129S7-Polg^tm1Prol)	abnormal lymphopoiesis	J:154187
	decreased double-positive T cell number	J:154187
	decreased immature B cell number	J:154187
	decreased lymphocyte cell number	J:154187
	decreased mature B cell number	J:154187
	decreased pre-B cell number	J:154187
	decreased pro-B cell number	J:154187
	decreased thymocyte number	J:154187
Polh^tm1Crey/Polh^tm1Crey (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell physiology	J:98037
Polh^tm1Crey/Polh^tm1Crey Poli^d/Poli^d (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell physiology	J:98037
Polh^tm1Fmh/Polh^tm1Fmh (involves: C57BL/6)	abnormal B cell physiology	J:99721
Poli^d/Poli^d Polk^tm1Hohm/Polk^tm1Hohm (involves: 129X1/SvJ * C57BL/6 * CBA)	immune system phenotype	J:105111
Polk^tm1.1Rsky/Polk^tm1.1Rsky (involves: 129P2/OlaHsd * BALB/cJ * C57BL/6)	immune system phenotype	J:80212
Polk^tm1Hohm/Polk^tm1Hohm (involves: 129X1/SvJ * C57BL/6 * CBA)	immune system phenotype	J:105111
Polk^tm1Hohm/Polk^tm1Hohm (involves: C57BL/6 * CBA)	immune system phenotype	J:83202
Poll^tm1Crey/Poll^tm1Crey (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:75927
Poll^tm1Crey/Poll^tm1Crey (involves: 129P2/OlaHsd)	abnormal immunoglobulin heavy chain V(D)J recombination	J:113406
Poll^tm1Crey/Poll^tm1Crey (involves: 129P2/OlaHsd)	immune system phenotype	J:113406
Poll^tm1Crey/Poll^tm1Crey Polm^tm1Crey/Polm^tm1Crey (involves: 129P2/OlaHsd)	abnormal B cell differentiation	J:113406
	abnormal immunoglobulin heavy chain V(D)J recombination	J:113406
	abnormal immunoglobulin light chain V-J recombination	J:113406
	decreased B cell number	J:113406
Polm^m1Btlr/Polm^m1Btlr (C57BL/6J-Polm^m1Btlr)	decreased B cell number	J:272866
Polm^m2Btlr/Polm^m2Btlr (C57BL/6J-Polm^m2Btlr)	abnormal lymphocyte morphology	J:272867
Polm^m2Btlr/Polm^m2Btlr (C57BL/6J-Polm^m2Btlr)	decreased B cell number	J:272867
Polm^tm1Abnd/Polm^tm1Abnd (involves: 129/Sv * BALB/c)	abnormal B cell number	J:97782
Polm^tm1Crey/Polm^tm1Crey (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell proliferation	J:85190
	abnormal Peyer's patch morphology	J:85190
	decreased B cell number	J:75927, J:85190
	immune system phenotype	J:75927
	lymphoid hypoplasia	J:85190
Polm^tm1Crey/Polm^tm1Crey (involves: 129P2/OlaHsd)	abnormal immunoglobulin light chain V-J recombination	J:113406
Polq^em1(IMPC)Mbp/Polq^em1(IMPC)Mbp (C57BL/6N-Polq^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	small spleen	J:211773
Polq^tm1Jcs/Polq^tm1Jcs (involves: 129S4/SvJae * C57BL/6J)	abnormal somatic hypermutation frequency	J:103365
Polq^tm1Jow/Polq^tm1Jow (involves: 129S1/Sv * 129X1/SvJ * C57BL/6N)	abnormal B cell physiology	J:101409
	abnormal somatic hypermutation frequency	J:101409
	decreased IgG1 level	J:101409
	decreased IgG level	J:101409
	decreased IgM level	J:101409
	decreased immunoglobulin level	J:101409
Polq^tm2Jow/Polq^tm2Jow (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal somatic hypermutation frequency	J:115989
Polr1b^em1(IMPC)Tcp/Polr1b⁺ (C57BL/6NCrl-Polr1b^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
	enlarged thymus	J:211773
Polr2a^{tm1(cre/ERT2)Bbd}/Polr2a⁺ Rnf2^tm1Mvi/Rnf2^tm1Mvi (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * C57BL/10 * SJL)	decreased B cell number	J:130397
Polr3a^em2(IMPC)Tcp/Polr3a⁺ (C57BL/6NCrl-Polr3a^em2(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Polr3a^tm1Iwil/Polr3a^tm1Iwil Tg(CAG-cre/Esr1*)5Amc/0 (Not Specified)	increased microglial cell activation	J:364909
Polrmt^em1(IMPC)Mbp/Polrmt⁺ (C57BL/6N-Polrmt^em1(IMPC)Mbp/Ucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
Pomc^{em1(IMPC)Rbrc}/Pomc⁺ (C57BL/6NJcl-Pomc^{em1(IMPC)Rbrc}/Rbrc)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Pomc^tm1Low/Pomc^tm1Low (involves: 129S2/SvPas * C57BL/6)	increased circulating interleukin-6 level	J:102955
	increased interleukin-6 secretion	J:102955
	increased splenocyte proliferation	J:102955
	increased tumor necrosis factor secretion	J:102955
Pomk^{em1(IMPC)Hmgu}/Pomk⁺ (C57BL/6NCrl-Pomk^{em1(IMPC)Hmgu}/Ieg)	increased spleen weight	J:211773
Pomt1^{Gt(OST194127)Lex}/Pomt1⁺ (involves: 129S5/SvEvBrd * C57BL/6J)	decreased IgG level	J:103485
	increased neutrophil cell number	J:103485
Pon2^Gt(XE661)Byg/Pon2^Gt(XE661)Byg (B6.129P2-Pon2^Gt(XE661)Byg)	abnormal macrophage chemotaxis	J:116935
	abnormal macrophage physiology	J:116935
	increased susceptibility to bacterial infection	J:116935
Pon3^tm1Dmsh/Pon3^tm1Dmsh (B6J.129X1-Pon3^tm1Dmsh)	liver inflammation	J:234615
Postn^tm1Sjc/Postn^tm1Sjc (involves: C57BL/6)	periodontium inflammation	J:103753
Postn^tm1Sjc/Postn^tm1Sjc (B6.Cg-Postn^tm1Sjc)	increased osteoclast cell number	J:200192
Pot1b^tm1.1Schg/Pot1b^tm1.1Schg Terc^tm1Rdp/Terc⁺ (involves: 129/Sv * 129S6/SvEvTac * C57BL/6 * SJL)	abnormal granulocyte morphology	J:144553
	decreased granulocyte number	J:144553
	decreased leukocyte cell number	J:144553
Pot1b^tm1.1Schg/Pot1b^tm1.1Schg Terc^tm1Rdp/Terc^tm1Rdp (involves: 129/Sv * 129S6/SvEvTac * C57BL/6 * SJL)	abnormal granulocyte morphology	J:144553
Pou1f1^dw/Pou1f1^dw (DW/J Pou1f1^dw)	decreased B cell number	J:110683
Pou2af1^{tm1b(KOMP)Wtsi}/Pou2af1^{tm1b(KOMP)Wtsi} (C57BL/6N-Pou2af1^{tm1b(KOMP)Wtsi}/Ucd)	decreased lymphocyte cell number	J:211773
	decreased spleen weight	J:211773
	increased neutrophil cell number	J:211773
Pou2af1^tm1Pjln/Pou2af1^tm1Pjln (C57BL/6-Pou2af1^tm1Pjln)	absent spleen germinal center	J:37085
	decreased B cell number	J:37085
	decreased IgA level	J:37085
	decreased IgG1 level	J:37085
	decreased IgG2a level	J:37085
	decreased IgG2b level	J:37085
	decreased IgG3 level	J:37085
	spleen hypoplasia	J:37085
Pou2af1^tm1Pjln/Pou2af1^tm1Pjln (involves: C57BL/6)	abnormal B cell differentiation	J:67362
	abnormal T-helper 1 physiology	J:123039
	abnormal T-helper 2 physiology	J:123039
	decreased B cell number	J:123039, J:67362
	decreased immature B cell number	J:67362
	decreased interferon-gamma secretion	J:123039
	decreased interleukin-2 secretion	J:123039
	decreased mature B cell number	J:67362
	decreased T cell number	J:123039
	increased B cell apoptosis	J:67362
	increased interleukin-4 secretion	J:123039
	increased interleukin-13 secretion	J:123039
	increased susceptibility to parasitic infection	J:123039
Pou2af1^tm1Pjln/Pou2af1^tm1Pjln Tg(tetO-Pou2af1)1Pjln/0 Tg(tTA)1Pjln/0 (involves: C57BL/6)	decreased B cell number	J:67362
	decreased immunoglobulin level	J:67362
	decreased mature B cell number	J:67362
	immune system phenotype	J:67362
Pou2af1^tm1Pmt/Pou2af1^tm1Pmt (involves: 129P2/OlaHsd * C57BL/6)	decreased immunoglobulin level	J:125114
Pou2af1^tm1Pmt/Pou2af1^tm1Pmt Ikzf3^tm1Kge/Ikzf3^tm1Kge (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)	absent spleen germinal center	J:81805
	arrested B cell differentiation	J:81805
	decreased IgA level	J:81805
	decreased IgD level	J:81805
	decreased IgE level	J:81805
	decreased IgG level	J:81805
	decreased IgM level	J:81805
	decreased immunoglobulin level	J:81805
Pou2af1^tm1Rgr/Pou2af1^tm1Rgr (either: (involves: 129P2/OlaHsd) or (involves: 129S1/Sv))	abnormal B cell differentiation	J:114816, J:35785
	abnormal Peyer's patch germinal center morphology	J:35785
	abnormal pre-B cell morphology	J:114816
	absent lymph node germinal center	J:35785
	absent spleen germinal center	J:35785
	arrested B cell differentiation	J:114816
	decreased B cell number	J:114816
	decreased B cell proliferation	J:35785
	decreased IgA level	J:35785
	decreased IgE level	J:35785
	decreased IgG1 level	J:35785
	decreased IgG2a level	J:35785
	decreased IgG2b level	J:35785
	decreased IgG3 level	J:35785
	decreased IgG level	J:35785
	decreased immunoglobulin level	J:35785
	increased B cell proliferation	J:114816
	increased IgM level	J:35785
Pou2af3^{tm1b(NCOM)Mfgc}/Pou2af3^{tm1b(NCOM)Mfgc} (C57BL/6N-Pou2af3^{tm1b(NCOM)Mfgc}/Tcp)	decreased lymphocyte cell number	J:211773
	increased leukocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Pou2f2^tm1Bal/Pou2f2⁺ (involves: 129S2/SvPas)	decreased IgG1 level	J:4555
	decreased IgM level	J:4555
	decreased mature B cell number	J:4555
Pou2f2^tm1Bal/Pou2f2^tm1Bal (involves: 129S2/SvPas * C57BL/6)	arrested B cell differentiation	J:88240
	decreased B cell number	J:88240
	decreased immunoglobulin level	J:88240
Pou2f2^tm1Bal/Pou2f2^tm1Bal (involves: 129S2/SvPas)	decreased IgG1 level	J:4555
	decreased IgM level	J:4555
	decreased mature B cell number	J:4555
Pou2f2^tm1Lmc/Pou2f2^tm1Lmc (involves: C57BL/6)	arrested B cell differentiation	J:88240
	decreased B cell number	J:88240
	decreased B-1 B cell number	J:88240
	decreased immunoglobulin level	J:88240
Ppara^tm1Gonz/Ppara^tm1Gonz (involves: 129S4/SvJae)	heart inflammation	J:63801
Ppara^tm1Gonz/Ppara^tm1Gonz (involves: 129S4/SvJae)	increased susceptibility to type IV hypersensitivity reaction	J:258438
Ppard^tm1Dsvg/Ppard^tm1Dsvg (involves: 129S2/SvPas * C57BL/6)	increased osteoclast cell number	J:219677
Ppard^tm1Jps/Ppard^tm1Jps (involves: 129/Sv * C57BL/6N)	skin inflammation	J:63040
Pparg^tm1.1Gonz/Pparg^tm1.1Gonz Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6)	abnormal macrophage activation involved in immune response	J:168799
	abnormal peritoneal macrophage morphology	J:168799
	glomerulonephritis	J:168799
	impaired macrophage phagocytosis	J:168799
	increased anti-double stranded DNA antibody level	J:168799
	increased anti-nuclear antigen antibody level	J:168799
	increased anti-single stranded DNA antibody level	J:168799
	increased autoantibody level	J:168799
	increased IgG level	J:168799
	increased IgM level	J:168799
Pparg^tm1.1Gonz/Pparg^tm1.1Gonz Tg(Mx1-cre)1Cgn/? (involves: 129X1/SvJ * C57BL/6 * CBA * FVB/N)	abnormal macrophage physiology	J:75777
Pparg^tm1Tka/Pparg⁺ (involves: C57BL/6 * CBA)	abnormal bone marrow development	J:89250
Pparg^tm1Tka/Pparg⁺ (involves: C57BL/6 * CBA)	leukostasis	J:116269
Pparg^tm1Tka/Pparg⁺ (involves: C57BL/6 * CBA * ICR)	abnormal B cell physiology	J:58222
	abnormal humoral immune response	J:58222
	immune system phenotype	J:58222
	increased B cell proliferation	J:58222
	increased IgG level	J:58222
	increased IgM level	J:58222
	increased interferon-gamma secretion	J:58222
	increased interleukin-2 secretion	J:58222
	increased susceptibility to induced arthritis	J:58222
Pparg^tm1Wwah/Pparg⁺ (Not Specified)	immune system phenotype	J:71272
Pparg^tm2Rev/Pparg^tm2Rev Tg(Cd4-cre)1Cwi/? (involves: 129S4/SvJae * C57BL/6 * DBA/2)	abnormal T-helper 17 cell differentiation	J:153358
	increased susceptibility to experimental autoimmune encephalomyelitis	J:153358
Pparg^tm2Rev/Pparg^tm2Rev Tg(Krt1-15-cre/PGR)22Cot/? (involves: 129S4/SvJae C57BL/6 * SJL)	skin inflammation	J:150977
Pparg^tm2Rev/Pparg^tm2Rev Tg(Tek-cre)1Ywa/? (involves: 129S4/SvJae * C57BL/6 * SJL)	abnormal osteoclast differentiation	J:160910
	abnormal osteoclast morphology	J:130475
	abnormal spleen morphology	J:130475
	abnormal splenocyte morphology	J:130475
	decreased osteoclast cell number	J:130475
	enlarged spleen	J:130475
	increased splenocyte number	J:130475
	skin inflammation	J:123403
Pparg^tm2Rev/Pparg^tm2Rev Tg(Tek-cre)12Flv/? (B6.Cg-Pparg^tm2Rev Tg(Tek-cre)12Flv)	enlarged spleen	J:154216
Ppargc1a^tm1Aztc/Ppargc1a⁺ (C57BL/6-Ppargc1a^tm1Aztc)	increased thymus weight	J:82809
Ppargc1a^tm1Brsp/Ppargc1a⁺ (involves: 129 * FVB/N)	immune system phenotype	J:127403
Ppargc1a^tm1Brsp/Ppargc1a⁺ (involves: 129S4/SvJae * C57BL/6)	increased inflammatory response	J:264271
Ppargc1a^tm1Brsp/Ppargc1a^tm1Brsp (involves: 129 * FVB/N)	increased interleukin-6 secretion	J:127403
Ppargc1a^tm1Brsp/Ppargc1a^tm2Brsp Tg(Myog-cre)1Eno/0 (involves: 129 * C57BL/6 * FVB/N)	increased circulating interleukin-6 level	J:127403
Ppargc1a^tm2Brsp/Ppargc1a⁺ Tg(Myog-cre)1Eno/0 (involves: 129 * C57BL/6)	increased circulating interleukin-6 level	J:127403
Ppargc1b^tm1.2Rev/Ppargc1b^tm1.2Rev Tg(Tek-cre)1Ywa/0 (involves: 129/Sv * C57BL/6 * C57BL/6J * SJL)	abnormal osteoclast differentiation	J:160910
Ppbp^{tm1(KOMP)Vlcg}/Ppbp^{tm1(KOMP)Vlcg} (involves: C57BL/6NTac)	abnormal leukocyte migration	J:198197
	abnormal leukocyte physiology	J:198197
	immune system phenotype	J:198197
Ppbp^{tm1.1(KOMP)Vlcg}/Ppbp^{tm1.1(KOMP)Vlcg} (C57BL/6N-Ppbp^{tm1.1(KOMP)Vlcg}/Ucd)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
	increased spleen weight	J:211773
Ppfibp2^em1(IMPC)Tcp/Ppfibp2^em1(IMPC)Tcp (C57BL/6NCrl-Ppfibp2^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Ppia^em1(IMPC)Mbp/Ppia^em1(IMPC)Mbp (C57BL/6NCrl-Ppia^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	increased spleen weight	J:211773
Ppia^tm1Lubn/Ppia^tm1Lubn (129S6.129P2-Ppia^tm1Lubn)	abnormal CD4-positive, alpha-beta T cell physiology	J:93591
	blepharitis	J:93591
	heart inflammation	J:93591
	increased circulating interleukin-4 level	J:93591
	increased IgE level	J:93591
	increased IgG1 level	J:93591
	increased immunoglobulin level	J:93591
	increased inflammatory response	J:93591
	increased interleukin-2 secretion	J:93591
	increased interleukin-4 secretion	J:93591
	increased susceptibility to type I hypersensitivity reaction	J:93591
	increased T cell number	J:93591
	liver inflammation	J:93591
	pancreas inflammation	J:93591
	spleen hyperplasia	J:93591
Ppic^em1Igc/Ppic^em1Igc (C57BL/6-Ppic^em1Igc)	decreased NK cell number	J:321155
	increased transitional stage T1 B cell number	J:321155
	increased transitional stage T2 B cell number	J:321155
Ppil1^em1(IMPC)Mbp/Ppil1⁺ (C57BL/6N-Ppil1^em1(IMPC)Mbp/MbpMmucd)	small spleen	J:211773
Ppl^{tm1b(KOMP)Wtsi}/Ppl^{tm1b(KOMP)Wtsi} (C57BL/6N-Ppl^{tm1b(KOMP)Wtsi}/Tcp)	enlarged lymph nodes	J:211773
Ppm1a^tm1.2Lavi/Ppm1a^tm1.2Lavi (B.129(Cg)-Ppm1a^tm1.2Lavi)	increased acute inflammation	J:216372
Ppm1d^tm1Lad/Ppm1d^tm1Lad (involves: 129S7/SvEvBrd * C57BL/6)	chronic inflammation	J:74284
	decreased B cell proliferation	J:74284
	decreased CD8-positive, alpha-beta T cell number	J:74284
	decreased T cell proliferation	J:74284
	enlarged spleen	J:74284
	increased CD4-positive, alpha-beta T cell number	J:74284
	increased susceptibility to Orthomyxoviridae infection	J:74284
	lymphoid hyperplasia	J:74284
	myeloid hyperplasia	J:74284
	small thymus	J:74284
	spleen hyperplasia	J:74284
Ppm1m^{tm2b(EUCOMM)Hmgu}/Ppm1m^{tm2b(EUCOMM)Hmgu} (C57BL/6N-Ppm1m^{tm2b(EUCOMM)Hmgu}/Bay)	decreased large unstained cell number	J:211773
Ppm1n^em1(IMPC)Mbp/Ppm1n^em1(IMPC)Mbp (C57BL/6N-Ppm1n^em1(IMPC)Mbp/MbpMmucd)	increased neutrophil cell number	J:211773
Ppp1r8^tm1.1Itl/Ppp1r8^tm1Ave Tg(Alb1-cre)7Gsc/0 (involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * C57BL/6NTac * FVB/N)	liver inflammation	J:238108
Ppp1r12a^tm1Mzhu/Ppp1r12a^tm1Mzhu Tg(Acta2-cre)#Xya/0 (involves: 129S6/SvEvTac * C57BL/6 * CBA)	small intestinal inflammation	J:207752
Ppp1r13b^tm1Suda/Ppp1r13b^tm1Suda (involves: 129S1/Sv * 129X1/SvJ * ICR)	abnormal lymph circulation	J:135686
	abnormal lymphatic vessel morphology	J:135686
Ppp1r13b^tm1Suda/Ppp1r13b^tm1Suda Trp53^tm1Sia/Trp53^tm1Sia (involves: various)	abnormal lymphatic vessel morphology	J:135686
Ppp1r13l^wa3-J/Ppp1r13l^wa3-J (BALB/cJ-Ppp1r13l^wa3-J/J)	heart inflammation	J:264272
Ppp1r14c^tm1Uhl/Ppp1r14c^tm1Uhl (B6;129S6-Ppp1r14c^tm1Uhl/J)	increased susceptibility to Coronaviridae infection	J:288523
Ppp1r15a^tm1.1Ajf/Ppp1r15a^tm1.1Ajf (involves: 129 * C57BL/6)	abnormal splenic cell ratio	J:106905
	increased spleen weight	J:106905
Ppp1r17^em1(IMPC)H/Ppp1r17^em1(IMPC)H (C57BL/6NTac-Ppp1r17^em1(IMPC)H/H)	increased neutrophil cell number	J:211773
Ppp1r18^em1Mgin/Ppp1r18^em1Mgin (B6J.B6N-Ppp1r18^em1Mgin)	abnormal T cell physiology	J:331428
	decreased B cell number	J:331428
	decreased T cell number	J:331428
	immune system phenotype	J:331428
	impaired leukocyte migration	J:331428
	increased leukocyte cell number	J:331428
	increased neutrophil cell number	J:331428
	small spleen	J:331428
	spleen hypoplasia	J:331428
Ppp1r18^em2Mgin/Ppp1r18^em2Mgin (B6J.B6NHsd-Ppp1r18^em2Mgin)	immune system phenotype	J:331428
Ppp1r18^em3Mgin/Ppp1r18^em3Mgin (B6J.B6N-Ppp1r18^em3Mgin)	abnormal T cell physiology	J:331428
	decreased B cell number	J:331428
	decreased T cell number	J:331428
	immune system phenotype	J:331428
	impaired leukocyte migration	J:331428
	increased leukocyte cell number	J:331428
	increased neutrophil cell number	J:331428
	small spleen	J:331428
	spleen hypoplasia	J:331428
Ppp2r1b^{tm1b(EUCOMM)Wtsi}/Ppp2r1b^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Ppp2r1b^{tm1b(EUCOMM)Wtsi}/Nju)	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
Ppp2r2b^{tm1b(KOMP)Wtsi}/Ppp2r2b^{tm1b(KOMP)Wtsi} (C57BL/6N-Ppp2r2b^{tm1b(KOMP)Wtsi}/Tcp)	increased leukocyte cell number	J:211773
	increased monocyte cell number	J:211773
Ppp2r2d^em1(IMPC)Mbp/Ppp2r2d^em1(IMPC)Mbp (C57BL/6N-Ppp2r2d^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
Ppp2r2d^em1Gct/Ppp2r2d^em1Gct Tg(Lck-icre)3779Nik/0 (involves: C57BL/6 * DBA/2)	abnormal regulatory T cell physiology	J:308373
	increased interleukin-2 secretion	J:308373
Ppp2r3c^tm1Imku/Ppp2r3c^tm1Imku Tg(CD19-cre/ERT2)1Cgn/? (involves: C57BL/6)	abnormal B cell activation	J:100706
	abnormal humoral immune response	J:100706
	decreased B cell number	J:100706
	decreased B cell proliferation	J:100706
	decreased B-1a cell number	J:100706
	decreased follicular B cell number	J:100706
	decreased immature B cell number	J:100706
	decreased mature B cell number	J:100706
	decreased pre-B cell number	J:100706
	decreased spleen germinal center size	J:100706
	decreased transitional stage B cell number	J:100706
	increased pro-B cell number	J:100706
	increased T cell number	J:100706
	increased transitional stage B cell number	J:100706
	small spleen	J:100706
Ppp2r5a^em1(IMPC)Mbp/Ppp2r5a^em1(IMPC)Mbp (C57BL/6N-Ppp2r5a^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
Ppp2r5a^{Gt(IST13127C10)Tigm}/Ppp2r5a^{Gt(IST13127C10)Tigm} (C57BL/6N-Ppp2r5a^{Gt(IST13127C10)Tigm})	enlarged mesenteric lymph nodes	J:254808
	enlarged spleen	J:254808
Ppp2r5c^em1(IMPC)Mbp/Ppp2r5c^em1(IMPC)Mbp (C57BL/6N-Ppp2r5c^em1(IMPC)Mbp/Ucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Ppp3ca^tm1Jse/Ppp3ca^tm1Jse (either: (involves: 129S4/SvJae * Black Swiss) or (involves: 129S4/SvJae * C57BL/6))	decreased interferon-gamma secretion	J:71750
	decreased interleukin-2 secretion	J:71750
	decreased interleukin-4 secretion	J:71750
	decreased T cell proliferation	J:71750
Ppp3cb^{em1(IMPC)Ccpcz}/Ppp3cb^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Ppp3cb^{em1(IMPC)Ccpcz}/Ccpcz)	decreased CD4-positive NK T cell number	J:211773
	decreased CD4-positive, alpha-beta T cell number	J:211773
	decreased CD8-positive, alpha-beta T cell number	J:211773
	decreased memory-marker CD4-positive NK T cell number	J:211773
	decreased NK T cell number	J:211773
	decreased T-helper cell number	J:211773
	immune system phenotype	J:211773
	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
	increased effector memory T-helper cell number	J:211773
Ppp3cb^M1Btlr/Ppp3cb⁺ (C57BL/6J-Ppp3cb^M1Btlr)	abnormal CD4-positive, alpha-beta T cell physiology	J:236670
	abnormal CD8-positive, alpha-beta T cell physiology	J:236670
	abnormal NK cell physiology	J:236670
	increased CD8-positive, alpha-beta memory T cell proliferation	J:236670
Ppp3cb^M1Btlr/Ppp3cb^M1Btlr (C57BL/6J-Ppp3cb^M1Btlr)	abnormal CD4-positive, alpha-beta T cell physiology	J:236670
	abnormal CD8-positive, alpha-beta T cell physiology	J:236670
	abnormal NK cell physiology	J:236670
	increased CD8-positive, alpha-beta memory T cell proliferation	J:236670
Ppp3cb^m2Btlr/Ppp3cb⁺ (C57BL/6J-Ppp3cb^m2Btlr)	abnormal CD4-positive, alpha-beta T cell physiology	J:236671
	abnormal CD8-positive, alpha-beta T cell physiology	J:236671
	increased CD8-positive, alpha-beta memory T cell proliferation	J:236671
Ppp3cb^m2Btlr/Ppp3cb^m2Btlr (C57BL/6J-Ppp3cb^m2Btlr)	abnormal CD4-positive, alpha-beta T cell physiology	J:236671
	abnormal CD8-positive, alpha-beta T cell physiology	J:236671
	abnormal NK cell physiology	J:236671
	decreased response to antigen	J:236671
	increased CD8-positive, alpha-beta memory T cell proliferation	J:236671
Ppp3cb^M3Btlr/Ppp3cb⁺ (C57BL/6J-Ppp3cb^M3Btlr)	decreased CD8-positive, alpha-beta memory T cell number	J:254889
Ppp3cb^M3Btlr/Ppp3cb⁺ (C57BL/6J-Ppp3cb^M3Btlr)	increased central memory CD4-positive, alpha-beta T cell number	J:254889
Ppp3cb^M3Btlr/Ppp3cb^M3Btlr (C57BL/6J-Ppp3cb^M3Btlr)	decreased CD8-positive, alpha-beta memory T cell number	J:254889
	decreased CD8-positive, naive alpha-beta T cell number	J:254889
	increased central memory CD4-positive, alpha-beta T cell number	J:254889
	increased central memory CD8 positive, alpha-beta T cell number	J:254889
Ppp3cb^M4Btlr/Ppp3cb⁺ (C57BL/6J-Ppp3cb^M4Btlr)	decreased CD8-positive, alpha-beta memory T cell number	J:254905
Ppp3cb^M4Btlr/Ppp3cb⁺ (C57BL/6J-Ppp3cb^M4Btlr)	increased central memory CD8 positive, alpha-beta T cell number	J:254905
Ppp3cb^M4Btlr/Ppp3cb^M4Btlr (C57BL/6J-Ppp3cb^M4Btlr)	decreased CD8-positive, alpha-beta memory T cell number	J:254905
Ppp3cb^M4Btlr/Ppp3cb^M4Btlr (C57BL/6J-Ppp3cb^M4Btlr)	increased central memory CD8 positive, alpha-beta T cell number	J:254905
Ppp3cb^m5Btlr/Ppp3cb^m5Btlr (C57BL/6J-Ppp3cb^m5Btlr)	abnormal T cell morphology	J:272839
Ppp3cb^m5Btlr/Ppp3cb^m5Btlr (C57BL/6J-Ppp3cb^m5Btlr)	decreased CD8-positive, alpha-beta T cell number	J:272839
Ppp3cb^M6Btlr/Ppp3cb^M6Btlr (C57BL/6J-Ppp3cb^M6Btlr)	abnormal lymphocyte morphology	J:272840
	decreased alpha-beta T cell number	J:272840
	decreased CD4-positive, alpha-beta T cell number	J:272840
	decreased CD8-positive, alpha-beta T cell number	J:272840
Ppp3cb^tm1Jmk/Ppp3cb^tm1Jmk (involves: 129S6/SvEvTac * C57BL/6)	abnormal T cell differentiation	J:77729
	decreased single-positive T cell number	J:77729
	decreased T cell number	J:77729
	decreased T cell proliferation	J:77729
	decreased thymus weight	J:75775
	thymus hypoplasia	J:77729
Ppp3cb^tm1Jmk/Ppp3cb^tm1Jmk (involves: 129S6/SvEvTac)	abnormal cytokine secretion	J:109586
Ppp3cb^tm1Jmk/Ppp3cb^tm1Jmk (involves: 129S6/SvEvTac)	decreased T cell proliferation	J:109586
Ppp3r1^tm2Grc/Ppp3r1^tm2.1Grc Tg(Lck-cre)1Cwi/0 (involves: 129S6/SvEvTac * C57BL/6 * DBA/2)	abnormal lymph node cell ratio	J:89771
	abnormal positive T cell selection	J:89771
	abnormal splenic cell ratio	J:89771
Ppp3r1^tm2Grc/Ppp3r1^tm2Grc Tg(Lck-cre)1Cwi/0 (involves: 129S6/SvEvTac * C57BL/6 * DBA/2)	decreased thymocyte number	J:89771
	thymus hypoplasia	J:89771
Ppp4c^tm1Tht/Ppp4c^tm1Tht Tg(Lck-cre)548Jxm/0 (involves: C57BL/6 * CBA)	abnormal positive T cell selection	J:117684
	abnormal T cell activation	J:117684
	abnormal T cell differentiation	J:117684
	decreased CD4-positive, alpha-beta T cell number	J:117684
	decreased CD8-positive, alpha-beta T cell number	J:117684
	decreased double-positive T cell number	J:117684
	decreased single-positive T cell number	J:117684
	increased double-negative T cell number	J:117684
Ppp4c^tm1Tht/Ppp4c^tm1Tht Tg(Lck-cre)548Jxm/0 Tg(TcraTcrb)425Cbn/0 (involves: BALB/c * C57BL/6 * CBA)	abnormal positive T cell selection	J:117684
	decreased double-positive T cell number	J:117684
	decreased single-positive T cell number	J:117684
Ppp4r3b^{tm1b(EUCOMM)Hmgu}/Ppp4r3b^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Ppp4r3b^{tm1b(EUCOMM)Hmgu}/Ieg)	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Ppp5c^tm1.2Rhon/Ppp5c^tm1.2Rhon (B6.129X1-Ppp5c^tm1.2Rhon)	enlarged spleen	J:178164
Ppp5c^{tm1a(EUCOMM)Wtsi}/Ppp5c^{tm1a(EUCOMM)Wtsi} (involves: C57BL/6 * C57BL/6N)	increased CD4-positive, alpha-beta T cell number	J:213427
	increased CD8-positive, alpha-beta T cell number	J:213427
	increased T cell number	J:213427
	lymphoid hyperplasia	J:213427
Ppp6c^tm1Shma/Ppp6c^tm1Shma Tg(KRT14-cre/ERT)20Efu/0 (involves: C57BL/6 * CBA * CD-1)	increased susceptibility to chemically induced skin inflammation	J:231809
Ppt1^tm1.1Dprc/Ppt1^tm1.1Dprc (involves: 129S6/SvEvTac * BALB/cJ * C57BL/6)	abnormal microglial cell activation	J:213552
Ppt1^tm1Aj/Ppt1^tm1Aj (involves: 129S4/SvJae * C57BL/6)	abnormal spleen morphology	J:95522
Ppt1^tm1Aj/Ppt1^tm1Aj (involves: 129S4/SvJae * C57BL/6)	brain inflammation	J:95522
Ppt1^tm1Hof/Ppt1^tm1Hof (involves: 129S6/SvEvTac * C57BL/6J)	microgliosis	J:280337
Ppt1^tm1Hof/Ppt1^tm1Hof (involves: 129P2/OlaHsd * 129S2/SvPas * 129S6/SvEvTac * C57BL/6)	abnormal cytokine level	J:177265
	brain inflammation	J:177265
Ppt2^tm1Hof/Ppt2^tm1Hof (involves: 129S6/SvEvTac * C57BL/6J)	abnormal spleen morphology	J:86202
	decreased spleen B cell follicle number	J:86202
	enlarged spleen	J:86202
	increased macrophage cell number	J:86202
	increased spleen weight	J:86202
Pram1^tm1Gak/Pram1^tm1Gak (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal neutrophil physiology	J:95253
Pramel1^em1(IMPC)Tcp/Pramel1^em1(IMPC)Tcp (C57BL/6NCrl-Pramel1^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Pramel12^em1(IMPC)Mbp/Pramel12^em1(IMPC)Mbp (C57BL/6N-Pramel12^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Prap1^tm1Lex/Prap1^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6J)	abnormal humoral immune response	J:171883
	increased immunoglobulin level	J:171883
Prap1^tm1Lex/Prap1^tm1Lex (B6.129S5-Prap1^tm1Lex)	increased circulating interleukin-2 level	J:304152
	increased circulating interleukin-4 level	J:304152
	increased circulating interleukin-12 level	J:304152
	increased inflammatory response	J:304152
	increased interleukin-12b secretion	J:304152
Prcd^tm1Vya/Prcd^tm1Vya (B6.Cg-Prcd^tm1Vya)	increased microglial cell activation	J:276708
Prdm1^tm1.1Liz/Prdm1^tm1.1Liz (involves: 129S/SvEv)	abnormal splenocyte physiology	J:163979
Prdm1^tm1.1Liz/Prdm1^tm1.1Liz (involves: 129S/SvEv)	absent plasma cells	J:196531
Prdm1^tm1Clme/Prdm1^tm1Clme Tg(Itgax-cre)1-1Reiz/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)	abnormal CD4-positive, alpha-beta T cell physiology	J:178876
	abnormal germinal center B cell physiology	J:178876
	abnormal immune system physiology	J:178876
	abnormal T follicular helper cell differentiation	J:178876
	increased anti-double stranded DNA antibody level	J:178876
	increased anti-nuclear antigen antibody level	J:178876
	increased autoantibody level	J:178876
	increased germinal center B cell number	J:178876
	increased IgG level	J:178876
	increased immunoglobulin level	J:178876
	increased interleukin-6 secretion	J:178876
	increased spleen germinal center number	J:178876
	increased splenocyte number	J:178876
	increased T follicular helper cell number	J:178876
	kidney inflammation	J:178876
Prdm1^tm2.1Liz/Prdm1^tm2.1Liz (involves: 129S/SvEv)	immune system phenotype	J:153979
Prdm1^tm2.1Nutt/Prdm1^tm2.1Nutt Tg(Lck-cre)1Cwi/? (involves: C57BL/6)	increased susceptibility to Orthomyxoviridae infection	J:151858
Prdm1^tm3.1Liz/Prdm1^tm3.1Liz (involves: 129S/SvEv)	immune system phenotype	J:196531
Prdm4^{tm1b(EUCOMM)Hmgu}/Prdm4^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Prdm4^{tm1b(EUCOMM)Hmgu}/H)	absent spleen	J:211773
Prdm8^{em1(IMPC)Wtsi}/Prdm8⁺ (C57BL/6N-Prdm8^{em1(IMPC)Wtsi}/Wtsi)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
	small spleen	J:211773
Prdm8^{em1(IMPC)Wtsi}/Prdm8^{em1(IMPC)Wtsi} (C57BL/6N-Prdm8^{em1(IMPC)Wtsi}/Wtsi)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Prdm11^tm1.1Ahl/Prdm11^tm1.1Ahl (B6.129(C)-Prdm11^tm1.1Ahl)	abnormal humoral immune response	J:233986
	decreased CD4-positive, alpha-beta T cell number	J:233986
	decreased neutrophil cell number	J:233986
	increased B cell number	J:233986
	increased interferon-gamma secretion	J:233986
	increased interleukin-2 secretion	J:233986
Prdm13^em1(IMPC)Tcp/Prdm13^em1(IMPC)Tcp (C57BL/6NCrl-Prdm13^em1(IMPC)Tcp/Tcp)	abnormal spleen morphology	J:211773
	increased spleen weight	J:211773
Prdm14^{tm1a(EUCOMM)Wtsi}/Prdm14^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Prdm14^{tm1a(EUCOMM)Wtsi}/Bay)	increased effector memory T-helper cell number	J:211773
Prdm16^{Gt(OST67423)Lex}/Prdm16⁺ (involves: 129S5/SvEvBrd * C57BL/6J)	increased leukocyte cell number	J:103485
Prdm16^tm1.1Brsp/Prdm16^tm1.1Brsp Tg(Adipoq-cre)1Evdr/0 (involves: 129/Sv * C57BL/6 * FVB/N)	increased macrophage cell number	J:208683
Prdt1^CAST/EiJH/Prdt1^CAST/EiJH (involves: CAST/Ei * NZW/OlaHsd)	decreased susceptibility to prion infection	J:80787
Prdt1^NZW/OlaHsd/Prdt1^NZW/OlaHsd (involves: CAST/Ei * NZW/OlaHsd)	increased susceptibility to prion infection	J:80787
Prdt3^CAST/EiJH/Prdt3^CAST/EiJH (involves: CAST/Ei * NZW/OlaHsd)	decreased susceptibility to prion infection	J:80787
Prdt3^NZW/OlaHsd/Prdt3^NZW/OlaHsd (involves: CAST/Ei * NZW/OlaHsd)	increased susceptibility to prion infection	J:80787
Prdx1^flro/Prdx1^flro (C57BL/10JAnu-Prdx1^flro/AnuApb)	abnormal lymphocyte morphology	J:104190
Prdx1^tm1Rave/Prdx1^tm1Rave (involves: 129S6/SvEvTac * C57BL/6)	abnormal NK T cell number	J:84677
	abnormal spleen morphology	J:84677
	enlarged spleen	J:84677
	impaired natural killer cell mediated cytotoxicity	J:84677
	increased spleen weight	J:84677
	increased T cell derived lymphoma incidence	J:84677
Prdx2^tm1Yu/Prdx2^tm1Yu (involves: 129S4/SvJae)	enlarged spleen	J:84271
	increased spleen red pulp amount	J:84271
	increased spleen weight	J:84271
Prdx3^{Gt(Betageo-puro)711Lex}/Prdx3^{Gt(Betageo-puro)711Lex} (involves: 129S5/SvEvBrd * C57BL/6)	lung inflammation	J:118595
Prdx5^{tm1.1(KOMP)Vlcg}/Prdx5^{tm1.1(KOMP)Vlcg} (involves: C57BL/6J * C57BL/6NTac)	immune system phenotype	J:271141
	increased circulating interleukin-12b level	J:271141
	increased circulating tumor necrosis factor level	J:271141
	increased interleukin-6 secretion	J:271141
	increased interleukin-12b secretion	J:271141
	increased tumor necrosis factor secretion	J:271141
Prep^{Gt(RRM213)Byg}/Prep⁺ (B6.129P2-Prep^{Gt(RRM213)Byg})	increased spleen weight	J:151643
Prex1^tm1Dwu/Prex1^tm1Dwu (Not Specified)	impaired neutrophil chemotaxis	J:102213
Prex1^tm1Hcew/Prex1^tm1Hcew (involves: 129P2/OlaHsd * C57BL/6)	impaired neutrophil chemotaxis	J:102214
	impaired neutrophil recruitment	J:102214
	increased neutrophil cell number	J:102214
Prf1^m1Btlr/Prf1^m1Btlr (C57BL/6J-Prf1^m1Btlr)	increased susceptibility to Herpesvirales infection	J:216044
Prf1^m1Btlr/Prf1^m1Btlr (C57BL/6J-Prf1^m1Btlr)	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:216044
Prf1^tm1Clrk/Prf1^tm1Clrk (involves: 129S7/SvEvBrd * C57BL/6)	decreased cytotoxic T cell cytolysis	J:21531
	immune system phenotype	J:21531
	increased susceptibility to Riboviria infection	J:21531
Prf1^tm1Clrk/Prf1^tm1Clrk (C.129S7(B6)-Prf1^tm1Clrk)	abnormal cytokine secretion	J:71576
	immune system phenotype	J:71576
	increased activated T cell number	J:71576
	increased interferon-gamma secretion	J:71576
	increased susceptibility to Riboviria infection	J:71576
	increased tumor necrosis factor secretion	J:71576
Prf1^tm1Clrk/Prf1^tm1Clrk (involves: 129S7/SvEvBrd * BALB/c * NOD)	decreased susceptibility to autoimmune diabetes	J:64051
Prf1^tm1Clrk/Prf1^tm1Clrk Tg(INS-Il10)#Sar/0 (involves: 129S7/SvEvBrd * BALB/c * NOD)	decreased susceptibility to autoimmune diabetes	J:64051
Prf1^tm1Sdz/Prf1⁺ (NOD.B6-Prf1^tm1Sdz)	decreased susceptibility to autoimmune diabetes	J:43468
	insulitis	J:43468
	periinsulitis	J:43468
Prf1^tm1Sdz/Prf1⁺ (A.B6-Prf1^tm1Sdz)	impaired natural killer cell mediated cytotoxicity	J:211842
Prf1^tm1Sdz/Prf1^tm1Sdz (C57BL/6-Prf1^tm1Sdz)	abnormal inflammatory response	J:17986
	abnormal leukocyte physiology	J:17986
	abnormal NK cell physiology	J:113213
	decreased cytotoxic T cell cytolysis	J:17986
	impaired natural killer cell mediated cytotoxicity	J:17986
	increased interleukin-10 secretion	J:123934
	increased susceptibility to bacterial infection	J:123934
	increased susceptibility to infection	J:17986
	increased susceptibility to parasitic infection	J:81397
	increased susceptibility to Riboviria infection	J:17986
Prf1^tm1Sdz/Prf1^tm1Sdz (NOD.B6-Prf1^tm1Sdz)	decreased susceptibility to autoimmune diabetes	J:43468
	insulitis	J:43468
	periinsulitis	J:43468
Prf1^tm1Sdz/Prf1^tm1Sdz (C57BL/6-Prf1^tm1Sdz/J)	abnormal circulating cytokine level	J:92260
	abnormal cytotoxic T cell physiology	J:193137
	abnormal lymph node morphology	J:92260
	abnormal lymphocyte physiology	J:120427
	abnormal macrophage activation involved in immune response	J:92260
	abnormal spleen white pulp morphology	J:92260
	abnormal T cell activation	J:92260
	brain inflammation	J:92260, J:120427
	CNS inflammation	J:120427
	decreased circulating fibrinogen level	J:92260
	decreased cytotoxic T cell cytolysis	J:193137
	decreased interferon-gamma secretion	J:92260
	decreased leukocyte cell number	J:193137
	decreased neutrophil cell number	J:193137
	decreased NK cell degranulation	J:193137
	immune system phenotype	J:120427
	increased circulating interferon-alpha level	J:92260
	increased circulating interferon-gamma level	J:92260, J:193137
	increased circulating interleukin-1 beta level	J:193137
	increased circulating interleukin-6 level	J:92260, J:193137
	increased circulating interleukin-10 level	J:92260
	increased circulating interleukin-18 level	J:92260
	increased circulating tumor necrosis factor level	J:92260, J:193137
	increased spleen red pulp amount	J:92260
	increased susceptibility to Picornaviridae infection	J:120427
	increased susceptibility to Riboviria infection	J:92260, J:193137
	increased susceptibility to Riboviria infection induced morbidity/mortality	J:92260
	increased susceptibility to viral infection induced morbidity/mortality	J:193137
	liver inflammation	J:92260
	lymph node inflammation	J:92260
	lymph node necrosis	J:92260
Prf1^tm1Sdz/Prf1^tm1Sdz (involves: BALB/c * C57BL/6)	impaired natural killer cell mediated cytotoxicity	J:73948
Prf1^tm1Sdz/Prf1^tm1Sdz (C.B6-Prf1^tm1Sdz)	increased T cell derived lymphoma incidence	J:77491
Prf1^tm1Sdz/Prf1^tm1Sdz (A.B6-Prf1^tm1Sdz)	impaired natural killer cell mediated cytotoxicity	J:211842
Prf1^tm1Sdz/Prf1^tm1Sdz Rag1^tm1Mom/Rag1^tm1Mom (NOD.Cg-Rag1^tm1Mom Prf1^tm1Sdz/SzJ)	abnormal response to transplant	J:91764
Prf1^tm1Sdz/Prf1^tm1Sdz X/Yaa (BXSB.B6-Prf1^tm1Sdz/Dcr)	autoimmune response	J:179430
Prf1^tm1Tsc/Prf1⁺ (involves: 129S2/SvPas)	decreased cytotoxic T cell cytolysis	J:21731
Prf1^tm1Tsc/Prf1⁺ (involves: 129S2/SvPas)	impaired natural killer cell mediated cytotoxicity	J:21731
Prf1^tm1Tsc/Prf1^tm1Tsc (involves: 129S2/SvPas)	decreased cytotoxic T cell cytolysis	J:21731
	decreased susceptibility to bacterial infection	J:50903
	impaired natural killer cell mediated cytotoxicity	J:21731
Prf1^tm1Tsc/Prf1^tm1Tsc (129X1.129S2-Prf1^tm1Tsc)	abnormal NK cell physiology	J:126114
Prf1^tm1Tsc/Prf1^tm1Tsc (129X1.129S2-Prf1^tm1Tsc)	decreased T cell apoptosis	J:126114
Prg2^tm1Nal/Prg2^tm1Nal (involves: 129P2/OlaHsd * 129X1/SvJ)	abnormal eosinophil morphology	J:65655
	abnormal inflammatory response	J:65655
	respiratory system inflammation	J:65655
Primpol^em1Nki/Primpol^em1Nki (C57BL/6-Primpol^em1Nki)	abnormal somatic hypermutation frequency	J:242620
Primpol^em1Nki/Primpol^em1Nki (C57BL/6-Primpol^em1Nki)	immune system phenotype	J:242620
Prkaa1^tm1Sbj/Prkaa1^tm1Sbj (involves: 129)	increased spleen weight	J:147215
Prkaa2^{tm1b(EUCOMM)Hmgu}/Prkaa2^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Prkaa2^{tm1b(EUCOMM)Hmgu}/H)	enlarged spleen	J:211773
Prkab1^em1(IMPC)Bay/Prkab1^em1(IMPC)Bay (C57BL/6N-Prkab1^em1(IMPC)Bay/Bay)	increased spleen weight	J:211773
Prkab1^{tm1b(KOMP)Wtsi}/Prkab1⁺ (C57BL/6N-Prkab1^{tm1b(KOMP)Wtsi}/Ccpcz)	decreased Ly6C-positive mature NK cell number	J:211773
	decreased lymphocyte cell number	J:211773
Prkab1^{tm1b(KOMP)Wtsi}/Prkab1^{tm1b(KOMP)Wtsi} (C57BL/6N-Prkab1^{tm1b(KOMP)Wtsi}/Wtsi)	increased memory-marker CD4-negative NK T cell number	J:211773
	increased memory-marker gamma-delta T cell number	J:211773
Prkab1^{tm1b(KOMP)Wtsi}/Prkab1^{tm1b(KOMP)Wtsi} (C57BL/6N-Prkab1^{tm1b(KOMP)Wtsi}/Ucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	increased spleen weight	J:211773
Prkab1^{tm1b(KOMP)Wtsi}/Prkab1^{tm1b(KOMP)Wtsi} (C57BL/6N-Prkab1^{tm1b(KOMP)Wtsi}/H)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
	increased spleen weight	J:211773
Prkab1^{tm1b(KOMP)Wtsi}/Prkab1^{tm1b(KOMP)Wtsi} (C57BL/6N-Prkab1^{tm1b(KOMP)Wtsi}/Bay)	increased spleen weight	J:211773
Prkab1^{tm1b(KOMP)Wtsi}/Prkab1^{tm1b(KOMP)Wtsi} (involves: C57BL/6N)	enlarged spleen	J:236972
	increased spleen iron level	J:236972
	increased spleen red pulp amount	J:236972
	increased spleen weight	J:236972
Prkab1^{tm1b(KOMP)Wtsi}/Prkab1^{tm1b(KOMP)Wtsi} (C57BL/6N-Prkab1^{tm1b(KOMP)Wtsi}/Ccpcz)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	increased spleen weight	J:211773
Prkab1^tm1Eihl/Prkab1^tm1Eihl (involves: C57BL/6)	decreased circulating interleukin-6 level	J:158295
Prkab2^{tm1b(EUCOMM)Hmgu}/Prkab2⁺ (C57BL/6N-Prkab2^{tm1b(EUCOMM)Hmgu}/H)	increased eosinophil cell number	J:211773
Prkag1^tm1.2Mfor/Prkag1^tm1.2Mfor (involves: 129S2/SvPas * C57BL/6 * C57BL/6NTac * FVB/N)	abnormal Kupffer cell morphology	J:167779
	enlarged spleen	J:167779
	increased spleen iron level	J:167779
	increased spleen red pulp amount	J:167779
Prkag2^tm1.1Geno/Prkag2^tm1.1Geno (B6J.129S(Cg)-Prkag2^tm1.1Geno)	abnormal inflammatory response	J:235379
	white adipose tissue inflammation	J:235379
Prkag2^tm3.1Mrl/? (C57BL/6-Prkag2^tm3.1Mrl/Tac)	kidney inflammation	J:237375
Prkar1a^tm2Gsm/Prkar1a^tm2Gsm Tg(Cr2-cre)3Cgn/0 (involves: 129X1/SvJ * C57BL/6)	abnormal class switch recombination	J:147785
Prkar1b^tm1Gsm/Prkar1b^tm1Gsm (Not Specified)	decreased inflammatory response	J:43080
Prkcb^M1Btlr/Prkcb⁺ (C57BL/6J-Prkcb^M1Btlr)	decreased IgM level	J:164864
Prkcb^M1Btlr/Prkcb^M1Btlr (C57BL/6J-Prkcb^M1Btlr)	decreased IgM level	J:164864
Prkcb^M1Btlr/Prkcb^M1Btlr (involves: C57BL/6J)	decreased IgM level	J:185495
Prkcb^M1Btlr/Prkcb^M1Btlr (involves: C57BL/6J)	immune system phenotype	J:185495
Prkcb^M2Btlr/Prkcb⁺ (C57BL/6J-Prkcb^M2Btlr)	decreased IgM level	J:217791
	decreased response to antigen	J:217791
	impaired humoral immune response	J:217791
Prkcb^M2Btlr/Prkcb^M2Btlr (C57BL/6J-Prkcb^M2Btlr)	decreased IgM level	J:217791
	decreased response to antigen	J:217791
	impaired humoral immune response	J:217791
Prkcb^M3Btlr/Prkcb⁺ (C57BL/6J-Prkcb^M3Btlr)	decreased IgM level	J:217793
	decreased response to antigen	J:217793
	impaired humoral immune response	J:217793
Prkcb^M3Btlr/Prkcb^M3Btlr (C57BL/6J-Prkcb^M3Btlr)	decreased IgM level	J:217793
	decreased response to antigen	J:217793
	impaired humoral immune response	J:217793
Prkcb^M4Btlr/Prkcb^M4Btlr (C57BL/6J-Prkcb^M4Btlr)	decreased B-1 B cell number	J:274860
	increased CD4-positive, alpha-beta T cell number	J:274860
	increased CD8-positive, alpha-beta T cell number	J:274860
	increased T cell number	J:274860
Prkcb^M5Btlr/Prkcb^M5Btlr (C57BL/6J-Prkcb^M5Btlr)	decreased IgM level	J:274861
Prkcb^M5Btlr/Prkcb^M5Btlr (C57BL/6J-Prkcb^M5Btlr)	impaired humoral immune response	J:274861
Prkcb^M6Btlr/Prkcb^M6Btlr (C57BL/6J-Prkcb^M6Btlr)	decreased B-1 B cell number	J:274862
Prkcb^tilc/Prkcb⁺ (involves: C57BL/6JSfdAnu)	abnormal humoral immune response	J:221236
	decreased IgG3 level	J:221236
	decreased IgM level	J:221236
Prkcb^tilc/Prkcb^tilc (C57BL/6JSfdAnu-Prkcb^tilc/AnuApb)	decreased IgM level	J:104190
Prkcb^tilc/Prkcb^tilc (involves: C57BL/6JSfdAnu)	abnormal humoral immune response	J:221236
	decreased B cell proliferation	J:221236
	decreased B-1a cell number	J:221236
	decreased IgG3 level	J:221236
	decreased IgM level	J:221236
	immune system phenotype	J:221236
Prkcb^tm1Tara/Prkcb⁺ (involves: 129)	abnormal humoral immune response	J:34818
	decreased IgG3 level	J:34818
	decreased IgM level	J:34818
Prkcb^tm1Tara/Prkcb^tm1Tara (involves: 129)	abnormal humoral immune response	J:34818
	decreased B cell number	J:34818
	decreased B cell proliferation	J:34818
	decreased B-1 B cell number	J:34818
	decreased B-1a cell number	J:34818
	decreased IgG3 level	J:34818
	decreased IgM level	J:34818
	immune system phenotype	J:34818
Prkcd^M1Btlr/Prkcd^M1Btlr (C57BL/6J-Prkcd^M1Btlr)	increased susceptibility to induced colitis	J:265145
Prkcd^m2Btlr/Prkcd^m2Btlr (C57BL/6J-Prkcd^m2Btlr)	enhanced humoral immune response	J:265146
	increased IgM level	J:265146
	increased NK cell number	J:265146
	increased susceptibility to induced colitis	J:265146
Prkcd^tm1.1Chou/Prkcd^tm1.1Chou (involves: C57BL/6 * C57BL/6NTac)	abnormal neutrophil physiology	J:217880
Prkcd^tm1Kin/Prkcd^tm1Kin (involves: 129P2/OlaHsd * C57BL/6)	abnormal immunoglobulin level	J:143854
	abnormal lymph node germinal center morphology	J:76135
	abnormal Peyer's patch germinal center morphology	J:76135
	abnormal plasma cell differentiation	J:143854
	enlarged lymph nodes	J:76135
	enlarged spleen	J:76135
	glomerulonephritis	J:76135
	increased acute inflammation	J:76135
	increased anti-chromatin antibody level	J:76135
	increased B cell number	J:76135
	increased B cell proliferation	J:76135, J:143854
	increased follicular B cell number	J:143854
	increased IgA level	J:76135, J:143854
	increased IgG1 level	J:76135, J:143854
	increased IgM level	J:143854
	increased interleukin-6 secretion	J:76135
	increased marginal zone B cell number	J:143854
	increased spleen germinal center number	J:76135
	increased transitional stage B cell number	J:143854
Prkcd^tm1Msg/Prkcd^tm1Msg (involves: 129X1/SvJ * C57BL/6J)	abnormal neutrophil physiology	J:91377
Prkcd^tm1Msg/Prkcd^tm1Msg (involves: 129X1/SvJ * C57BL/6J)	decreased neutrophil cell number	J:91377
Prkcd^tm1Qxu/Prkcd^tm1Qxu (involves: 129P2/OlaHsd)	abnormal response to transplant	J:78680
Prkcd^tm1Qxu/Prkcd^tm1Qxu (involves: 129P2/OlaHsd * C57BL/6)	enlarged lymph nodes	J:76134
	enlarged spleen	J:76134
	immune system phenotype	J:76134
	increased anti-nuclear antigen antibody level	J:76134
	increased B cell apoptosis	J:76134
	increased B cell number	J:76134
	increased IgA level	J:76134
	increased IgG1 level	J:76134
	increased IgM level	J:76134
Prkcd^tm1Qxu/Prkcd^tm1Qxu Tg(IghelMD4)4Ccg/0 Tg(KLK4mHEL)6Ccg/0 (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:76134
Prkcd^tm1Qxu/Prkcd^tm1Qxu Tg(IghelMD4)4Ccg/0 Tg(ML5sHEL)5Ccg/0 (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell physiology	J:76134
	abnormal B cell proliferation	J:76134
	abnormal self tolerance	J:76134
	abnormal spleen primary B follicle morphology	J:76134
	autoimmune response	J:76134
	decreased B cell number	J:76134
	immune system phenotype	J:76134
	increased spleen germinal center number	J:76134
Prkce^m1Btlr/Prkce^m1Btlr (C57BL/6J-Prkce^m1Btlr)	decreased dendritic cell number	J:267703
Prkce^m1Btlr/Prkce^m1Btlr (C57BL/6J-Prkce^m1Btlr)	decreased NK cell number	J:267703
Prkce^tm1Bai/Prkce^tm1Bai (Not Specified)	immune system phenotype	J:94663
Prkce^tm1Bsca/Prkce^tm1Bsca (involves: 129P2/OlaHsd * C57BL/6)	decreased circulating interleukin-1 beta level	J:103337
	decreased circulating tumor necrosis factor level	J:103337
	decreased macrophage apoptosis	J:103337
	decreased macrophage nitric oxide production	J:103337
	decreased T cell proliferation	J:103337
	increased susceptibility to bacterial infection	J:103337
Prkce^tm1Ltg/Prkce^tm1Ltg (involves: 129P2/OlaHsd * FVB/N)	decreased tumor necrosis factor secretion	J:86056
Prkcg^tm1Stl/Prkcg^tm1Stl (Not Specified)	decreased inflammatory response	J:25061
Prkch^tm1.2Gasc/Prkch^tm1.2Gasc (involves: C57BL/6 * FVB/N * SJL)	abnormal brachial lymph node morphology	J:186080
	abnormal cervical lymph node morphology	J:186080
	abnormal effector T cell morphology	J:186080
	abnormal lymph node morphology	J:186080
	decreased B cell number	J:186080
	decreased CD4-positive, alpha-beta T cell number	J:186080
	decreased CD8-positive, alpha-beta T cell number	J:186080
	decreased DN1 thymic pro-T cell number	J:186080
	decreased DN4 thymocyte number	J:186080
	decreased double-positive T cell number	J:186080
	decreased lymphocyte cell number	J:186080
	decreased T cell number	J:186080
	decreased T cell proliferation	J:186080
	enlarged axillary lymph nodes	J:186080
	enlarged cervical lymph nodes	J:186080
	enlarged inguinal lymph nodes	J:186080
	enlarged lymph nodes	J:186080
	increased B cell number	J:186080
	increased CD4-positive, alpha-beta T cell number	J:186080
	increased CD8-positive, alpha-beta T cell number	J:186080
	increased memory T cell number	J:186080
	increased T cell number	J:186080
	thymus hypoplasia	J:186080
Prkch^tm1.2Gasc/Prkch^tm1.2Gasc Prkcq^tm1Litt/Prkcq^tm1Litt (involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL)	abnormal positive T cell selection	J:186080
	decreased CD4-positive, alpha-beta T cell number	J:186080
	decreased CD8-positive, alpha-beta T cell number	J:186080
	decreased DN1 thymic pro-T cell number	J:186080
	decreased DN4 thymocyte number	J:186080
	decreased double-negative T cell number	J:186080
	decreased double-positive T cell number	J:186080
	decreased T cell proliferation	J:186080
	immune system phenotype	J:186080
Prkci^tm1Rfar/Prkci⁺ Tg(Ckmm-cre)5Khn/? (involves: 129P2/OlaHsd * C57BL/6 * FVB)	increased susceptibility to autoimmune diabetes	J:123964
Prkcq^m1Btlr/Prkcq^m1Btlr (C57BL/6J-Prkcq^m1Btlr)	decreased IgG level	J:255214
Prkcq^m1Btlr/Prkcq^m1Btlr (C57BL/6J-Prkcq^m1Btlr)	impaired humoral immune response	J:255214
Prkcq^m2Btlr/Prkcq^m2Btlr (C57BL/6J-Prkcq^m2Btlr)	decreased IgG level	J:255216
Prkcq^m2Btlr/Prkcq^m2Btlr (C57BL/6J-Prkcq^m2Btlr)	impaired humoral immune response	J:255216
Prkcq^tm1.1Bai/Prkcq^tm1.1Bai (involves: 129P2/OlaHsd * C57BL/6J)	abnormal T cell physiology	J:83733
	decreased interleukin-2 secretion	J:83733
	decreased T cell proliferation	J:83733
Prkcq^tm1Litt/Prkcq^tm1Litt (involves: 129P2/OlaHsd)	abnormal T cell activation	J:83922
	decreased interleukin-2 secretion	J:83922
	decreased T cell proliferation	J:83922, J:123989
	immune system phenotype	J:123989
Prkcq^tm1Litt/Prkcq^tm1Litt (B6.129P2-Prkcq^tm1Litt)	abnormal CD4-positive, alpha-beta T cell physiology	J:94285
	abnormal T-helper 1 cell differentiation	J:94285
	abnormal T-helper 2 physiology	J:94285
	decreased interferon-gamma secretion	J:129421, J:94285
	decreased interleukin-2 secretion	J:129421, J:94285
	decreased interleukin-4 secretion	J:129421, J:94285
	decreased interleukin-5 secretion	J:94285
	decreased interleukin-13 secretion	J:94285
	decreased interleukin-17 secretion	J:129421
	decreased splenocyte proliferation	J:129421
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:129421
	decreased T cell proliferation	J:94285
	immune system phenotype	J:94285
Prkcq^tm1Litt/Prkcq^tm1Litt (involves: 129P2/OlaHsd * C57BL/6)	abnormal effector T cell morphology	J:186080
	abnormal positive T cell selection	J:186080
	decreased CD4-positive, alpha-beta T cell number	J:186080
	decreased CD8-positive, alpha-beta T cell number	J:186080
	decreased DN1 thymic pro-T cell number	J:186080
	decreased NK T cell number	J:141128
	decreased T cell proliferation	J:186080
	immune system phenotype	J:141128
	increased T cell apoptosis	J:141128
Prkcq^tm1Litt/Prkcq^tm1Litt (either: (involves: 129/Sv * 129P2/OlaHsd) or (involves: 129P2/OlaHsd * C57BL/6))	abnormal response to infection	J:141930
	decreased T cell apoptosis	J:141930
	decreased T cell proliferation	J:141930
Prkcq^tm1Litt/Prkcq^tm1Litt Tcra^tm1Mom/Tcra^tm1Mom (involves: 129P2/OlaHsd * 129S2/SvPas)	decreased interleukin-4 secretion	J:135589
	decreased T cell proliferation	J:135589
	immune system phenotype	J:135589
Prkcq^tm1Litt/Prkcq^tm1Litt Tg(DO11.10)10Dlo/0 (involves: 129 * BALB/c * C3H * C57BL/6)	decreased T cell apoptosis	J:141930
Prkcq^tm1Litt/Prkcq^tm1Litt Tg(Lck-Notch3)#Issc/0 (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	enlarged spleen	J:96010
	increased spleen weight	J:96010
Prkcq^tm1Litt/Prkcq^tm1Litt Tg(LCKprBCL2L1)12Sjk/0 (involves: 129P2/OlaHsd * C57BL/6)	decreased NK T cell number	J:141128
	immune system phenotype	J:141128
Prkcq^tm1Litt/Prkcq^tm1Litt Tg(TcrLCMV)327Sdz/0 (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	abnormal T cell anergy	J:123989
	decreased cytotoxic T cell cytolysis	J:123989
	decreased splenocyte proliferation	J:123989
	decreased T cell proliferation	J:123989
Prkcz^tm1Jmos/Prkcz^tm1Jmos (involves: 129P2/OlaHsd * 129/Sv)	abnormal Peyer's patch follicle morphology	J:72720
	abnormal Peyer's patch morphology	J:72720
	abnormal spleen marginal zone morphology	J:72720
	decreased B cell number	J:72720
	decreased spleen B cell follicle size	J:72720
	immune system phenotype	J:72720
	small Peyer's patches	J:72720
Prkd1^{em2(IMPC)Wtsi}/Prkd1⁺ (C57BL/6N-Prkd1^{em2(IMPC)Wtsi}/Wtsi)	increased leukocyte cell number	J:211773
Prkd2^{Gt(RRJ380)Byg}/Prkd2^{Gt(RRJ380)Byg} (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:166867
Prkd2^tm1.1Daca/Prkd2^tm1.1Daca (involves: C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:166867
	abnormal CD8-positive, alpha-beta T cell physiology	J:166867
	decreased IgG1 level	J:166867
	decreased IgM level	J:166867
	decreased interferon-gamma secretion	J:166867
	decreased interleukin-2 secretion	J:166867
	immune system phenotype	J:166867
Prkd2^tm1.1Shoy/Prkd2^tm1.1Shoy Prkd3^tm1.1Shoy/Prkd3^tm1.1Shoy Tg(BCL2)25Wehi/0 Tg(Lck-cre)1Jtak/0 (involves: 129 * C57BL/6 * C57BL/6JWehi * SJL/JWehi)	decreased thymocyte number	J:236298
Prkd2^tm1.1Shoy/Prkd2^tm1.1Shoy Prkd3^tm1.1Shoy/Prkd3^tm1.1Shoy Tg(Lck-cre)1Jtak/0 (involves: 129 * C57BL/6)	decreased thymocyte number	J:236298
	small thymus medulla	J:236298
Prkd2^tm1.1Shoy/Prkd2^tm1.1Shoy Prkd3^tm1.1Shoy/Prkd3^tm1.1Shoy Tg(Lck-cre)1Jtak/0 Tg(TcraH-Y,TcrbH-Y)71Vbo/0 (involves: 129 * C57BL/6 * C57BL/6J * DBA/2J)	decreased thymocyte number	J:236298
	increased double-positive T cell number	J:236298
Prkd2^tm1.1Shoy/Prkd2^tm1.1Shoy Prkd3^tm1.1Shoy/Prkd3^tm1.1Shoy Tg(Lck-cre)1Jtak/0 Tg(TcraTcrb)425Cbn/0 (involves: 129 * BALB/c * C57BL/6)	decreased thymocyte number	J:236298
Prkd2^tm1.1Shoy/Prkd2^tm1.1Shoy Prkd3^tm1.1Shoy/Prkd3^tm1.1Shoy Tg(Lck-cre)1Jtak/0 Tg(TcraTcrb)1100Mjb/0 (involves: 129 * C57BL/6)	decreased thymocyte number	J:236298
Prkd2^tm1.1Shoy/Prkd2^tm1.1Shoy Tg(Lck-cre)1Jtak/0 (involves: 129 * C57BL/6)	immune system phenotype	J:236298
Prkdc^berty/Prkdc^berty (C57BL/6JAnu-Prkdc^berty)	absent B cells	J:104190
Prkdc^berty/Prkdc^berty (C57BL/6JAnu-Prkdc^berty)	absent T cells	J:104190
Prkdc^em2(IMPC)Ics/Prkdc^em2(IMPC)Ics (C57BL/6N-Prkdc^em2(IMPC)Ics/Ics)	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
	increased eosinophil cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Prkdc^hanky/Prkdc^hanky (either: C57BL/6JAnu or (involves: C57BL/6JAnu * CBA/CaJ))	cecum inflammation	J:104190
	colitis	J:104190
	decreased lymphocyte cell number	J:104190
	enlarged mesenteric lymph nodes	J:104190
	increased plasma cell number	J:104190
	interstitial pneumonia	J:104190
	liver inflammation	J:104190
	lymph node hyperplasia	J:104190
	myeloid hyperplasia	J:104190
Prkdc^m1Anu/Prkdc^m1Anu (C57BL/6JAnu-Prkdc^m1Anu)	abnormal lymphocyte morphology	J:104190
Prkdc^m1Btlr/Prkdc^m1Btlr (C57BL/6J-Prkdc^m1Btlr)	abnormal immune system physiology	J:178522
Prkdc^m1Btlr/Prkdc^m1Btlr (involves: C57BL/6J)	abnormal class switch recombination	J:185495
	decreased B cell number	J:185495
	decreased IgG level	J:185495
	decreased IgM level	J:185495
Prkdc^m2Btlr/Prkdc^m2Btlr (C57BL/6J-Prkdc^m2Btlr)	abnormal B cell physiology	J:204502
	decreased B cell number	J:204502
	decreased CD4-positive, alpha-beta T cell number	J:204502
	decreased CD8-positive, alpha-beta T cell number	J:204502
	decreased IgG level	J:204502
	decreased IgM level	J:204502
Prkdc^m3Btlr/Prkdc^m3Btlr (C57BL/6J-Prkdc^m3Btlr)	decreased IgG level	J:224665
Prkdc^m3Btlr/Prkdc^m3Btlr (C57BL/6J-Prkdc^m3Btlr)	impaired humoral immune response	J:224665
Prkdc^m4Btlr/Prkdc^m4Btlr (C57BL/6J-Prkdc^m4Btlr)	decreased B cell number	J:255217
	increased B-1b cell number	J:255217
	increased neutrophil cell number	J:255217
Prkdc^m5Btlr/Prkdc^m5Btlr (C57BL/6J-Prkdc^m5Btlr)	increased alpha-beta T cell number	J:255220
Prkdc^m5Btlr/Prkdc^m5Btlr (C57BL/6J-Prkdc^m5Btlr)	increased CD4-positive, alpha-beta T cell number	J:255220
Prkdc^m6Btlr/Prkdc^m6Btlr (C57BL/6J-Prkdc^m6Btlr)	decreased CD8-positive, naive alpha-beta T cell number	J:255221
	increased alpha-beta T cell number	J:255221
	increased CD4-positive, alpha-beta T cell number	J:255221
	increased CD8-positive, alpha-beta T cell number	J:255221
Prkdc^m7Btlr/Prkdc^m7Btlr (C57BL/6J-Prkdc^m7Btlr)	abnormal humoral immune response	J:255223
	decreased IgG level	J:255223
	increased effector memory CD4-positive, alpha-beta T cell number	J:255223
Prkdc^M8Btlr/Prkdc⁺ (C57BL/6J-Prkdc^M8Btlr)	decreased CD8-positive, alpha-beta T cell number	J:255224
Prkdc^M8Btlr/Prkdc^M8Btlr (C57BL/6J-Prkdc^M8Btlr)	decreased CD8-positive, alpha-beta T cell number	J:255224
	increased CD4-positive, alpha-beta T cell number	J:255224
	increased plasmacytoid dendritic cell number	J:255224
Prkdc^M9Btlr/Prkdc⁺ (C57BL/6J-Prkdc^M9Btlr)	decreased B-1a cell number	J:255268
	decreased effector memory CD4-positive, alpha-beta T cell number	J:255268
	increased B cell number	J:255268
	increased B-1b cell number	J:255268
Prkdc^M9Btlr/Prkdc^M9Btlr (C57BL/6J-Prkdc^M9Btlr)	decreased B-1a cell number	J:255268
	decreased effector memory CD4-positive, alpha-beta T cell number	J:255268
	increased B cell number	J:255268
	increased B-1b cell number	J:255268
Prkdc^M10Btlr/Prkdc⁺ (C57BL/6J-Prkdc^M10Btlr)	decreased CD8-positive, alpha-beta T cell number	J:255269
Prkdc^M10Btlr/Prkdc^M10Btlr (C57BL/6J-Prkdc^M10Btlr)	decreased CD8-positive, alpha-beta T cell number	J:255269
Prkdc^M11Btlr/Prkdc⁺ (C57BL/6J-Prkdc^M11Btlr)	enhanced humoral immune response	J:255270
Prkdc^M11Btlr/Prkdc⁺ (C57BL/6J-Prkdc^M11Btlr)	increased IgM level	J:255270
Prkdc^M11Btlr/Prkdc^M11Btlr (C57BL/6J-Prkdc^M11Btlr)	enhanced humoral immune response	J:255270
Prkdc^M11Btlr/Prkdc^M11Btlr (C57BL/6J-Prkdc^M11Btlr)	increased IgM level	J:255270
Prkdc^m12Btlr/Prkdc^m12Btlr (C57BL/6J-Prkdc^m12Btlr)	decreased B cell number	J:264708
	decreased B-1 B cell number	J:264708
	decreased CD4-positive, alpha-beta T cell number	J:264708
	decreased CD8-positive, alpha-beta T cell number	J:264708
	decreased CD8-positive, naive alpha-beta T cell number	J:264708
	decreased NK T cell number	J:264708
	decreased single-positive T cell number	J:264708
	decreased T cell number	J:264708
	increased central memory CD4-positive, alpha-beta T cell number	J:264708
	increased central memory CD8 positive, alpha-beta T cell number	J:264708
	increased effector memory CD4-positive, alpha-beta T cell number	J:264708
	increased NK cell number	J:264708
Prkdc^m13Btlr/Prkdc^m13Btlr (C57BL/6J-Prkdc^m13Btlr)	increased effector memory CD4-positive, alpha-beta T cell number	J:272441
Prkdc^m14Btlr/Prkdc^m14Btlr (C57BL/6J-Prkdc^m14Btlr)	abnormal CD4-positive T cell differentiation	J:272442
Prkdc^M15Btlr/Prkdc^M15Btlr (C57BL/6J-Prkdc^M15Btlr)	decreased B-1 B cell number	J:272445
Prkdc^M16Btlr/Prkdc^M16Btlr (C57BL/6J-Prkdc^M16Btlr)	abnormal CD8-positive, alpha-beta T cell differentiation	J:272520
Prkdc^m17Btlr/Prkdc^m17Btlr (C57BL/6J-Prkdc^m17Btlr)	increased plasmacytoid dendritic cell number	J:272521
Prkdc^m18Btlr/Prkdc^m18Btlr (C57BL/6J-Prkdc^m18Btlr)	abnormal B cell differentiation	J:274730
	abnormal CD4-positive T cell differentiation	J:274730
	abnormal CD8-positive, alpha-beta T cell differentiation	J:274730
	abnormal T cell differentiation	J:274730
	decreased alpha-beta T cell number	J:274730
	decreased B cell number	J:274730
	decreased B-1 B cell number	J:274730
	decreased CD4-positive, alpha-beta T cell number	J:274730
	decreased CD8-positive, alpha-beta T cell number	J:274730
	decreased CD8-positive, naive alpha-beta T cell number	J:274730
	increased CD4-positive, alpha-beta T cell number	J:274730
	increased CD8-positive, alpha-beta T cell number	J:274730
	increased central memory CD4-positive, alpha-beta T cell number	J:274730
	increased central memory CD8 positive, alpha-beta T cell number	J:274730
	increased effector memory CD4-positive, alpha-beta T cell number	J:274730
	increased effector memory CD8-positive, alpha-beta T cell number	J:274730
	increased T cell number	J:274730
Prkdc^m19Btlr/Prkdc^m19Btlr (C57BL/6J-Prkdc^m19Btlr)	abnormal B cell differentiation	J:274763
	abnormal CD4-positive T cell differentiation	J:274763
	abnormal CD8-positive, alpha-beta T cell differentiation	J:274763
	abnormal T cell differentiation	J:274763
	decreased B cell number	J:274763
	decreased B-1 B cell number	J:274763
	decreased CD4-positive, alpha-beta T cell number	J:274763
	decreased CD8-positive, alpha-beta T cell number	J:274763
	decreased CD8-positive, naive alpha-beta T cell number	J:274763
	decreased T cell number	J:274763
	increased central memory CD4-positive, alpha-beta T cell number	J:274763
	increased central memory CD8 positive, alpha-beta T cell number	J:274763
	increased effector memory CD4-positive, alpha-beta T cell number	J:274763
	increased effector memory CD8-positive, alpha-beta T cell number	J:274763
	increased NK cell number	J:274763
Prkdc^scid/Prkdc^scid (C.BKa-Prkdc^scid)	abnormal humoral immune response	J:6958
	abnormal response to transplant	J:22026
	abnormal spleen white pulp morphology	J:6958
	abnormal thymus morphology	J:6958
	absent B cells	J:6958
	absent Peyer's patches	J:6958
	absent pre-B cells	J:6958
	absent thymus cortex	J:6958
	decreased B cell proliferation	J:6958
	decreased IgG level	J:6958
	decreased immunoglobulin level	J:6958, J:22026
	decreased leukocyte cell number	J:6958
	decreased T cell proliferation	J:6958
	immune system phenotype	J:22026
	increased length of allograft survival	J:6958, J:22026
	increased T cell derived lymphoma incidence	J:6958
	lymph node hypoplasia	J:6958
	lymphoid hypoplasia	J:6958
	salivary gland inflammation	J:21965
	small lymphoid organs	J:6958
	small thymus	J:6958
	thymus cyst	J:6958
Prkdc^scid/Prkdc^scid (NOD.Cg-Prkdc^scid)	abnormal lymph node morphology	J:109833, J:22026
	abnormal response to transplant	J:109833, J:22026
	abnormal spleen white pulp morphology	J:109833, J:22026
	abnormal thymus corticomedullary boundary morphology	J:22026
	abnormal thymus lobule morphology	J:22026
	decreased B cell number	J:22026
	decreased CD4-positive, alpha-beta T cell number	J:109833, J:22026
	decreased CD8-positive, alpha-beta T cell number	J:109833, J:22026
	decreased immunoglobulin level	J:22026
	decreased level of surface class I molecules	J:22026
	decreased lymphocyte cell number	J:22026
	decreased mature B cell number	J:109833
	decreased NK cell number	J:22026
	decreased pre-B cell number	J:22026
	decreased T cell number	J:22026
	impaired complement classical pathway	J:22026
	impaired natural killer cell mediated cytotoxicity	J:22026
	increased granulocyte number	J:22026
	increased length of allograft survival	J:22026
	increased macrophage cell number	J:22026
	increased T cell derived lymphoma incidence	J:109833, J:22026
	spleen hypoplasia	J:109833, J:22026
	thymus cyst	J:22026
Prkdc^scid/Prkdc^scid (B6.Cg-Prkdc^scid/Sz)	abnormal complement pathway	J:34814, J:22026
	abnormal level of surface class II molecules	J:34814
	abnormal lymph node B cell domain morphology	J:34814
	abnormal NK cell physiology	J:34814
	abnormal Peyer's patch morphology	J:34814
	abnormal spleen white pulp morphology	J:34814
	abnormal thymus morphology	J:34814
	decreased B cell number	J:34814
	decreased CD4-positive, alpha-beta T cell number	J:34814
	decreased CD8-positive, alpha-beta T cell number	J:34814
	decreased immunoglobulin level	J:34814
	decreased lymphocyte cell number	J:34814
	decreased pre-B cell number	J:34814
	decreased T cell number	J:34814
	increased eosinophil cell number	J:34814
	increased granulocyte number	J:34814
	increased macrophage cell number	J:34814
	increased monocyte cell number	J:34814
	increased neutrophil cell number	J:34814
	increased NK cell number	J:34814
	small Peyer's patches	J:34814
	small thymus	J:34814
	spleen hypoplasia	J:34814
	stomach inflammation	J:120556
	thymus cyst	J:34814
Prkdc^scid/Prkdc^scid (NOD.Cg-Prkdc^scid/J)	abnormal response to transplant	J:91764
Prkdc^scid/Prkdc^scid (involves: BALB/c * C57BL/6 * C57BL/Ka)	abnormal NK cell physiology	J:115033
Prkdc^scid/Prkdc^scid Mcph1^{Tg(HLA-A2.1)1Enge}/Mcph1⁺ (NOD.Cg-Mcph1^{Tg(HLA-A2.1)1Enge} Prkdc^scid/Dvs)	abnormal splenocyte morphology	J:91764
Prkdc^scid/Prkdc^scid Rasa3^scat/Rasa3^scat (involves: BALB/c * BALB/cBy * C57BL)	abnormal immune system morphology	J:186485
Prkdc^scid/Prkdc^scid Sst1^C57BL/6J/Sst1^C57BL/6J (involves: C3HeB/FeJ * C57BL/6J)	decreased susceptibility to bacterial infection	J:93705
Prkdc^scid/Prkdc^scid Tg(B2M)55Hpl/0 Mcph1^{Tg(HLA-A2.1)1Enge}/Mcph1⁺ (NOD.Cg-Mcph1^{Tg(HLA-A2.1)1Enge} Prkdc^scid Tg(B2M)55Hpl/Sz)	abnormal response to transplant	J:91764
Prkdc^scid/Prkdc^scid Tg(CSF2)2Ygy/0 Tg(IL3)1Ygy/0 (CB17.Cg-Prkdc^scid Tg(CSF2)2Ygy Tg(IL3)1Ygy)	abnormal response to transplant	J:94302
Prkdc^scid/Prkdc^scid Tg(CSF2)2Ygy/0 Tg(IL3)1Ygy/0 Tg(KITLG)3Ygy/0 (CB17.Cg-Prkdc^scid Tg(CSF2)2Ygy Tg(IL3)1Ygy Tg(KITLG)3Ygy)	abnormal response to transplant	J:106416, J:94302
Prkdc^scid/Prkdc^scid Tg(CSF2)2Ygy/0 Tg(IL3)1Ygy/0 Tg(KITLG)3Ygy/0 (NOD.Cg-Prkdc^scid Tg(CSF2)2Ygy Tg(IL3)1Ygy Tg(KITLG)3Ygy)	abnormal response to transplant	J:107052
	decreased susceptibility to graft versus host disease	J:107052
Prkdc^scid/Prkdc^scid Tg(HLA-DRA0101,HLA-DRB10101)1Dmz/Tg(HLA-DRA0101,HLA-DRB10101)1Dmz (NOD.Cg-Tg(HLA-DRA0101,HLA-DRB10101)1Dmz Prkdc^scid/Gck)	abnormal professional antigen presenting cell morphology	J:126700
	absent T cells	J:126700
Prkdc^scid/Prkdc^scid Tg(Ins2-Fasl)24Ach/0 (NOD.Cg-Prkdc^scid Tg(Ins2-Fasl)24Ach)	decreased susceptibility to autoimmune diabetes	J:81416
	increased susceptibility to autoimmune diabetes	J:81416
Prkdc^scid/Prkdc^scid Tg(INS-Il10)#Sar/0 (NOD.Cg-Prkdc^scid Tg(INS-Il10)#Sar)	increased susceptibility to autoimmune diabetes	J:66103
Prkdc^scid/Prkdc^scid Tg(TcraAI4)1Dvs/0 Tg(TcrbAI4)1Dvs/0 (NOD.Cg-Prkdc^scid Tg(TcraAI4)1Dvs Tg(TcrbAI4)1Dvs)	abnormal CD4-positive, alpha beta T cell morphology	J:93553
	increased susceptibility to autoimmune diabetes	J:93553
Prkdc^scid/Prkdc^scid Tg(Tcrb)93Vbo/0 (involves: Balb/c * C57BL/Ka * C57BL/Lia * CBA/BrA)	abnormal CD4-positive, alpha beta T cell morphology	J:111476
	abnormal CD8-positive, alpha beta T cell morphology	J:111476
	abnormal double-positive T cell morphology	J:111476
	abnormal single-positive T cell number	J:111476
	abnormal T cell differentiation	J:111476
Prkdc^scid/Prkdc^scid Tg(TcrLCMV)327Sdz/? (NOD.Cg-Emv30^b Prkdc^scid Tg(TcrLCMV)327Sdz/DvsJ)	immune system phenotype	J:71050
Prkdc^scid/Prkdc^scid Tgfb1^tm1Doe/Tgfb1^tm1Doe (involves: 129 * C3H * CF-1)	decreased spleen weight	J:129629
Prkdc^{Tg(INS-PDE2)5-1Lmb}/? (involves: FVB/N)	abnormal thymus morphology	J:108405
Prkdc^tm1.1Bpcc/Prkdc^tm1.1Bpcc (involves: 129 * C57BL/6)	abnormal immunoglobulin V(D)J recombination	J:171351
	arrested B cell differentiation	J:171351
	decreased CD4-positive, alpha-beta T cell number	J:171351
	decreased CD8-positive, alpha-beta T cell number	J:171351
	decreased double-negative T cell number	J:171351
	decreased double-positive T cell number	J:171351
	decreased gamma-delta T cell number	J:171351
	decreased granulocyte number	J:171351
	decreased leukocyte cell number	J:171351
	decreased lymphocyte cell number	J:171351
	decreased macrophage cell number	J:171351
	decreased mature B cell number	J:171351
	decreased T cell number	J:171351
	small lymphoid organs	J:171351
Prkdc^tm1Fwa/Prkdc^tm1Fwa (involves: 129S6/SvEvTac * C57BL/6)	abnormal T cell receptor beta chain V(D)J recombination	J:50221
	abnormal T cell receptor V(D)J recombination	J:50221
	absent pre-B cells	J:50221
	arrested B cell differentiation	J:50221
	arrested T cell differentiation	J:50221
	decreased double-positive T cell number	J:50221
	decreased thymocyte number	J:50221
Prkdc^tm1Fwa/Prkdc^tm1Fwa (involves: 129S6/SvEvTac)	decreased splenocyte number	J:306598
Prkdc^tm1Gcl/Prkdc^tm1Gcl (involves: 129S1/Sv * C57BL/6)	abnormal immunoglobulin heavy chain V(D)J recombination	J:53765
	abnormal lymph node morphology	J:53765
	abnormal spleen morphology	J:53765
	abnormal T cell receptor beta chain V(D)J recombination	J:53765
	abnormal T cell receptor delta chain V(D)J recombination	J:53765
	absent mature B cells	J:53765
	absent Peyer's patches	J:53765
	absent thymus corticomedullary boundary	J:53765
	arrested B cell differentiation	J:53765
	increased T cell derived lymphoma incidence	J:53765
	small lymph nodes	J:53765
	small Peyer's patches	J:53765
	small spleen	J:53765
	small thymus	J:53765
	thymus hypoplasia	J:53765
Prkdc^tm1Gcl/Prkdc^tm1Gcl (involves: 129S1/Sv)	decreased thymocyte apoptosis	J:126920
Prkdc^tm1Get/Prkdc^tm1Get (involves: 129S4/SvJae * Black Swiss)	abnormal B cell differentiation	J:50222
	abnormal immunoglobulin heavy chain V(D)J recombination	J:50222
	abnormal immunoglobulin light chain V-J recombination	J:50222
	abnormal T cell differentiation	J:50222
	abnormal T cell number	J:50222
	abnormal T cell receptor alpha chain V-J recombination	J:50222
	abnormal T cell receptor beta chain V(D)J recombination	J:50222
	abnormal T cell receptor delta chain V(D)J recombination	J:50222
	abnormal thymus corticomedullary boundary morphology	J:50222
	arrested B cell differentiation	J:50222
	arrested T cell differentiation	J:50222
	decreased IgM level	J:50222
	decreased single-positive T cell number	J:50222
	decreased spleen white pulp amount	J:50222
	increased double-negative T cell number	J:50222
	increased double-positive T cell number	J:50222
	increased NK cell number	J:50222
	small lymph nodes	J:50222
	spleen hypoplasia	J:50222
	thymus hypoplasia	J:50222
Prkg1^{tm1b(KOMP)Wtsi}/Prkg1^{tm1b(KOMP)Wtsi} (C57BL/6N-Prkg1^{tm1b(KOMP)Wtsi}/H)	enlarged spleen	J:211773
Prkg1^tm2.1Naw/Prkg1^tm2.1Naw (involves: 129S1/Sv * 129X1/SvJ)	enlarged spleen	J:134639
Prl7d1^em1(IMPC)Tcp/Prl7d1^em1(IMPC)Tcp (C57BL/6NCrl-Prl7d1^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Prl7d1^em1Liga/Prl7d1^em1Liga (involves: C57BL/6)	increased uterine NK cell number	J:288761
Prl^tm1Hmn/Prl^tm1Hmn (involves: 129S2/SvPas)	immune system phenotype	J:45243
Prmt3^{tm1a(EUCOMM)Wtsi}/Prmt3^{tm1a(EUCOMM)Wtsi} (involves: C57BL/6 * C57BL/6N)	increased CD4-positive, alpha-beta T cell number	J:213427
	increased CD8-positive, alpha-beta T cell number	J:213427
	increased incidence of corneal inflammation	J:213427
	increased T cell number	J:213427
Prmt7^{tm1a(EUCOMM)Wtsi}/Prmt7^{tm1a(EUCOMM)Wtsi} (B6JTyr;B6N-Prmt7^{tm1a(EUCOMM)Wtsi}/Wtsi)	abnormal thymus topology	J:239583
	blood in lymph vessels	J:239583
Prmt9^em1Cya/Prmt9^em1Cya Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6N)	decreased susceptibility to viral infection	J:328263
	increased circulating interferon-beta level	J:328263
	increased interferon-beta secretion	J:328263
Prnp/Prnd^tm1Aag/Prnp/Prnd^tm1Aag (Not Specified)	immune system phenotype	J:89232
Prnp/Prnd^tm1Aag/Prnp/Prnd^tm1Aag (Not Specified)	immune system phenotype	J:89232
Prnp^a/Prnp^a (NZW)	increased susceptibility to prion infection	J:8918
Prnp^b/Prnp^b (I/LnJ)	decreased susceptibility to prion infection	J:8918
Prnp^c/Prnp^c (MAI/Pas)	decreased susceptibility to prion infection	J:90099
Prnp^{em2.1(PrnpD178N)Jwat}/Prnp^{em2.1(PrnpD178N)Jwat} (involves: 129S4/SvJae * C57BL/6)	dermatitis	J:361333
Prnp^{em3.1(PrnpE200K)Jwat}/Prnp^{em3.1(PrnpE200K)Jwat} (involves: 129S4/SvJae * C57BL/6)	dermatitis	J:361333
Prnp^{tm1(PRNP)Tkit}/Prnp^{tm1(PRNP)Tkit} (Not Specified)	decreased susceptibility to prion infection	J:86603
Prnp^{tm1(PRNP)Tkit}/Prnp^{tm1(PRNP)Tkit} (Not Specified)	increased susceptibility to prion infection	J:86603
Prnp^tm1Cwe/Prnp^tm1Cwe Tg(Lck-Prnp)33Cwe/0 (involves: 129S7/SvEvBrd * C57BL/6)	increased CD8-positive, alpha-beta T cell number	J:129512
	increased gamma-delta T cell number	J:129512
	thymus hypoplasia	J:129512
Prnp^tm1Cwe/Prnp^tm1Cwe Tg(Nefh-cre)22Jcol/? Tg(Prnp)37Jcol/? (involves: 129/Sv * 129S7/SvEvBrd * C57BL/6 * FVB)	decreased susceptibility to prion infection	J:126424
Prnp^tm1Cwe/Prnp^tm1Cwe Tg(Nefh-cre)22Jcol/? Tg(Prnp)46Jcol/? (involves: 129/Sv * 129S7/SvEvBrd * C57BL/6 * FVB)	decreased susceptibility to prion infection	J:74652
Prnp^tm1Cwe/Prnp^tm1Cwe Tg(PRNP)35Jcol/Tg(PRNP)35Jcol (involves: 129 * 129S7/SvEvBrd * C57BL/6 * FVB/N)	increased susceptibility to prion infection	J:131494
Prnp^tm1Cwe/Prnp^tm1Cwe Tg(Prnp)37Jcol/? (involves: 129/Sv * 129S7/SvEvBrd * C57BL/6 * FVB)	increased susceptibility to prion infection	J:74652, J:126424
Prnp^tm1Cwe/Prnp^tm1Cwe Tg(PRNP)45Jcol/Tg(PRNP)45Jcol (involves: 129 * 129S7/SvEvBrd * C57BL/6 * FVB/N)	increased susceptibility to prion infection	J:131494
Prnp^tm1Cwe/Prnp^tm1Cwe Tg(Prnp)46Jcol/? (involves: 129/Sv * 129S7/SvEvBrd * C57BL/6 * FVB)	immune system phenotype	J:74652
Prnp^tm1Cwe/Prnp^tm1Cwe Tg(Prnp)4053Sbp/0 (involves: 129S7/SvEvBrd * FVB/N)	increased susceptibility to prion infection	J:136434
Prnp^tm1Cwe/Prnp^tm1Cwe Tg(PRNP)23454Sbp/0 (involves: 129S7/SvEvBrd * FVB/N)	increased susceptibility to prion infection	J:236012
Prnp^tm1Cwe/Prnp^tm1Cwe Tg(Prnp)a19Cwe/0 (Not Specified)	increased susceptibility to prion infection	J:32214
Prnp^tm1Cwe/Prnp^tm1Cwe Tg(Prnp)a20Cwe/0 (Not Specified)	increased susceptibility to prion infection	J:32214
Prnp^tm1Cwe/Prnp^tm1Cwe Tg(Prnp)a20Cwe/0 (involves: 129S7/SvEvBrd * C57BL/6)	abnormal B cell morphology	J:129512
	abnormal T cell differentiation	J:129512
	decreased CD4-positive, alpha-beta T cell number	J:129512
	decreased CD8-positive, alpha-beta T cell number	J:129512
	decreased DN2 thymocyte number	J:129512
	decreased DN4 thymocyte number	J:129512
	decreased double-positive T cell number	J:129512
	decreased thymocyte number	J:129512
	increased DN3 thymocyte number	J:129512
	increased double-negative T cell number	J:129512
	increased gamma-delta T cell number	J:129512
	thymus atrophy	J:129512
Prnp^tm1Cwe/Prnp^tm1Cwe Tg(Prnp)c35Cwe/0 (Not Specified)	increased susceptibility to prion infection	J:32214
Prnp^tm1Cwe/Prnp^tm1Cwe Tg(PrnpS170NN174T)1020Aag/0 (involves: 129S7/SvEvBrd * C57BL/6)	decreased susceptibility to prion infection	J:143528
	microgliosis	J:143528
Prnp^tm1Edin/Prnp^tm1Edin (129P2/OlaHsd-Prnp^tm1Edin/EdinH)	abnormal susceptibility to prion infection	J:58820
Prnp^tm1Lnq/Prnp^tm1Lnq (involves: 129P2/OlaHsd * C57BL/6N)	decreased susceptibility to prion infection	J:154937
Prnp^tm1Miy/Prnp^tm1Miy (involves: 129S4/SvJae * C57BL/6)	decreased susceptibility to prion infection	J:69186
Prnp^tm1Rcm/Prnp^tm1Rcm (129P2/OlaHsd-Prnp^tm1Rcm)	abnormal susceptibility to prion infection	J:45908
Prnp^tm1Tuzi/Prnp⁺ (involves: 129P2/OlaHsd)	decreased susceptibility to prion infection	J:92302
Prnp^tm1Tuzi/Prnp⁺ Tg(CMV-cre)1Cgn/? (involves: 129P2/OlaHsd * BALB/cJ)	immune system phenotype	J:92302
Prnp^tm1Tuzi/Prnp^tm2Edin (involves: 129P2/OlaHsd)	decreased susceptibility to prion infection	J:92302
Prnp^tm1Tuzi/Prnp^tm2Edin Tg(CMV-cre)1Cgn/? (involves: 129P2/OlaHsd * BALB/cJ)	decreased susceptibility to prion infection	J:92302
Prnp^{tm2(PRNP129M)Tkit}/Prnp^{tm2(PRNP129M)Tkit} (Not Specified)	decreased susceptibility to prion infection	J:126777, J:105882
	increased susceptibility to prion infection	J:126777, J:105882
Prnp^{tm2(PRNP129M)Tkit}/Prnp^{tm2(PRNP129M)Tkit} Tg(Prnp-PRNP*129M)1Tkit/? (Not Specified)	decreased susceptibility to prion infection	J:126777
	increased susceptibility to prion infection	J:126777
Prnp^{tm2(PRNP129M)Tkit}/Prnp^{tm3(PRNP129V)Tkit} (Not Specified)	decreased susceptibility to prion infection	J:105882
Prnp^tm2Lnq/Prnp^tm2Lnq (involves: 129P2/OlaHsd * C57BL/6N)	immune system phenotype	J:154937
Prnp^tm2Tuzi/Prnp⁺ (involves: 129P2/OlaHsd)	immune system phenotype	J:92302
Prnp^tm2Tuzi/Prnp⁺ Tg(CMV-cre)1Cgn/? (involves: 129P2/OlaHsd * BALB/cJ)	decreased susceptibility to prion infection	J:92302
Prnp^tm2Tuzi/Prnp^tm2Edin (involves: 129P2/OlaHsd)	decreased susceptibility to prion infection	J:92302
Prnp^tm2Tuzi/Prnp^tm2Edin Tg(CMV-cre)1Cgn/? (involves: 129P2/OlaHsd * BALB/cJ)	decreased susceptibility to prion infection	J:92302
Prnp^{tm3(PRNP129V)Tkit}/Prnp^{tm3(PRNP129V)Tkit} (Not Specified)	abnormal spleen morphology	J:126777
	decreased susceptibility to prion infection	J:126777, J:105882
	increased susceptibility to prion infection	J:126777
Prnp^{tm3(PRNP129V)Tkit}/Prnp^{tm3(PRNP129V)Tkit} Tg(Prnp-PRNP*129V)139Tkit/? (Not Specified)	abnormal susceptibility to infection	J:126777
	decreased susceptibility to prion infection	J:105882
Prnp^{tm3(PRNP129V)Tkit}/Prnp^{tm3(PRNP129V)Tkit} Tg(Prnp-PRNP*129V)144Tkit/? (Not Specified)	decreased susceptibility to prion infection	J:105882
Prnp^{tm4(PRNP)Tkit}/Prnp^{tm4(PRNP)Tkit} (Not Specified)	increased susceptibility to prion infection	J:105882
Prnp^{tm4(PRNP)Tkit}/Prnp^{tm4(PRNP)Tkit} Tg(Prnp-PRNP)32Tkit/? (Not Specified)	increased susceptibility to prion infection	J:105882
Prnp^{tm5(PRNP)TKit}/Prnp^{tm5(PRNP)TKit} (Not Specified)	immune system phenotype	J:126777
Prnp^{tm5(PRNP)TKit}/Prnp^{tm5(PRNP)TKit} Tg(Prnp-PRNP*)1Tkit/? (Not Specified)	decreased susceptibility to prion infection	J:126777
	increased susceptibility to prion infection	J:126777
Prnr1^RIII/FaDk/Prnr1^RIII/FaDk (involves: C57BL/FaDk * RIII/FaDk)	decreased susceptibility to prion infection	J:89558
Prnr2^C57BL/FaDk/Prnr2^C57BL/FaDk (involves: C57BL/FaDk * RIII/FaDk)	decreased susceptibility to prion infection	J:89558
Prnr2^C57BL/FaDk/Prnr2^RIII/FaDk (involves: C57BL/FaDk * RIII/FaDk)	decreased susceptibility to prion infection	J:89558
Proc^tm1Fjc/Proc^tm1Fjc (involves: 129S1/Sv * 129X1/SvJ * Swiss)	abnormal innate immunity	J:50527
	liver inflammation	J:50527
Procr^tm1.1Pcl/Procr^tm1.1Pcl (involves: 129S2/SvPas * C57BL/6)	bone marrow failure	J:225914
	enlarged spleen	J:225914
	increased circulating interleukin-6 level	J:225914
	increased spleen red pulp amount	J:225914
	increased spleen weight	J:225914
	increased splenocyte number	J:225914
	increased susceptibility to endotoxin shock	J:225914
Proser2^{em1(IMPC)Ccpcz}/Proser2^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Proser2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Prox1^tm1Gco/Prox1⁺ (involves: 129S1/Sv * 129X1/SvJ * NMRI)	abnormal lymph circulation	J:102652, J:57646
	abnormal lymphatic vessel morphology	J:102652
	increased inflammatory response	J:102652
	increased macrophage cell number	J:102652
Prox1^tm1Gco/Prox1⁺ (involves: 129S1/Sv * 129X1/SvJ)	abnormal lymph circulation	J:57646
Prox1^tm1Gco/Prox1^tm1Gco (involves: 129S1/Sv * 129X1/SvJ * NMRI)	abnormal lymph organ development	J:57646
Prox1^tm1Gco/Prox1^tm2Gco Tg(Tek-cre)1Ywa/? (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)	absent lymphatic vessels	J:125507
Prox1^tm1Gco/Prox1^{tm5(GFP/cre)Gco} (involves: 129S1/Sv * 129X1/SvJ * NMRI)	decreased lymphatic vessel endothelial cell number	J:158959
Prox1^tm2Gco/Prox1⁺ Tg(Tek-cre)1Ywa/0 (involves: 129S1/Sv * C57BL/6 * NMRI * SJL)	abnormal lymph circulation	J:102652
	abnormal lymphatic vessel morphology	J:102652
Prox1^tm4.1Gco/Prox1^tm4.1Gco (involves: 129S1/Sv * C57BL/10 * CBA/Ca)	decreased lymphatic vessel endothelial cell number	J:158959
Prpf3^{tm1b(KOMP)Wtsi}/Prpf3⁺ (C57BL/6N-Prpf3^{tm1b(KOMP)Wtsi}/Bay)	increased neutrophil cell number	J:211773
Prph2^em1Sal/Prph2⁺ (C57BL/6J-Prph2^em1Sal)	eye inflammation	J:342243
Prph2^em1Sal/Prph2^em1Sal (C57BL/6J-Prph2^em1Sal)	eye inflammation	J:342243
Prph2^em1Sal/Prph2^em1Sal (C57BL/6J-Prph2^em1Sal)	increased microglial cell activation	J:342243
Prph2^Rd2/Prph2^Rd2 (O20/A-Prph2^Rd2)	abnormal macrophage morphology	J:6432
Prps1^{tm1b(EUCOMM)Wtsi}/Prps1⁺ (C57BL/6N-Prps1^{tm1b(EUCOMM)Wtsi}/Ics)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Prps2^{tm1a(KOMP)Wtsi}/Y (involves: C57BL/6N)	abnormal B cell physiology	J:214383
Prps2^{tm1a(KOMP)Wtsi}/Y Tg(IghMyc)22Bri/0 (involves: C57BL/6N * SJL)	abnormal B cell physiology	J:214383
	increased B cell apoptosis	J:214383
Prr7^{tm1(KOMP)Vlcg}/Prr7^{tm1(KOMP)Vlcg} (involves: C57BL/6NTac)	decreased CD4-positive, alpha-beta T cell number	J:237776
	immune system phenotype	J:237776
Prr27^{tm1b(KOMP)Wtsi}/Prr27^{tm1b(KOMP)Wtsi} (C57BL/6N-Prr27^{tm1b(KOMP)Wtsi}/Bay)	increased leukocyte cell number	J:211773
Prr30^em1(IMPC)J/Prr30^em1(IMPC)J (C57BL/6NJ-Prr30^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
Prrg4^em1(IMPC)Mbp/Prrg4^em1(IMPC)Mbp (C57BL/6NCrl-Prrg4^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Prss3b^tm1.1Satom/Prss3b⁺ (B6(FVB)-Prss3b^tm1.1Satom)	acute pancreas inflammation	J:267764
Prss3b^tm1.1Satom/Prss3b⁺ (B6(FVB)-Prss3b^tm1.1Satom)	chronic pancreas inflammation	J:267764
Prss8^tm1.1Hum/Prss8^tm1.2Hum Tg(KRT14-cre)1Ipc/0 (involves: 129/Sv * C57BL/6 * FVB/N * SJL)	thymus medulla hypoplasia	J:100139
Prss12^{em1(IMPC)Ccpcz}/Prss12^{em1(IMPC)Ccpcz} (C57BL/6N-Prss12^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Prss16^tm1.1Mal/Prss16⁺ Rag2^tm1Fwa/Rag2^tm1Fwa Tg(TcraH-Y,TcrbH-Y)1Pas/? (involves: 129S/SvEv * 129S2/SvPas * C57BL/6)	abnormal positive T cell selection	J:148034
	decreased CD4-positive, alpha-beta T cell number	J:148034
	decreased single-positive T cell number	J:148034
	lymph node hypoplasia	J:148034
Prss16^tm1.1Mal/Prss16^tm1.1Mal (involves: 129S2/SvPas * C57BL/6)	abnormal professional antigen presenting cell morphology	J:148034
	abnormal thymus cortex morphology	J:148034
Prss16^tm1.1Mal/Prss16^tm1.1Mal Rag2^tm1Fwa/Rag2^tm1Fwa Tg(TcraH-Y,TcrbH-Y)1Pas/? (involves: 129S/SvEv * 129S2/SvPas * C57BL/6)	abnormal positive T cell selection	J:148034
	decreased CD4-positive, alpha-beta T cell number	J:148034
	decreased double-positive T cell number	J:148034
	decreased single-positive T cell number	J:148034
	lymph node hypoplasia	J:148034
	spleen hypoplasia	J:148034
	thymus hypoplasia	J:148034
Prss16^tm1Cbo/Prss16^tm1Cbo (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	immune system phenotype	J:94751
Prss21^{em1(IMPC)Ccpcz}/Prss21⁺ (C57BL/6N-Prss21^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Prss27^{tm1.1(NCOM)Mfgc}/Prss27^{tm1.1(NCOM)Mfgc} (C57BL/6N-Prss27^{tm1.1(NCOM)Mfgc}/Tcp)	decreased monocyte cell number	J:211773
Prss33^{em1(IMPC)Ccpcz}/Prss33^{em1(IMPC)Ccpcz} (C57BL/6N-Prss33^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
	small spleen	J:211773
Prss34^tm1.1Hkar/Prss34^tm1.1Hkar (involves: C57BL/6)	decreased inflammatory response	J:238924
Prss34^tm1.1Hkar/Prss34^tm1.1Hkar (involves: C57BL/6)	immune system phenotype	J:238924
Prss35^{em1(IMPC)Ccpcz}/Prss35^{em1(IMPC)Ccpcz} (C57BL/6N-Prss35^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Prss47^{em1(IMPC)Ccpcz}/Prss47^{em1(IMPC)Ccpcz} (C57BL/6N-Prss47^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged thymus	J:211773
Prss48^{em1(IMPC)Ccpcz}/Prss48^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Prss48^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Prss50^{tm1a(EUCOMM)Hmgu}/Prss50^{tm1a(EUCOMM)Hmgu} (C57BL/6N-Prss50^{tm1a(EUCOMM)Hmgu}/H)	decreased CD8-positive, alpha-beta T cell number	J:165965
	decreased T cell number	J:165965
Prss53^{em3(IMPC)Wtsi}/Prss53^{em3(IMPC)Wtsi} (C57BL/6N-Prss53^{em3(IMPC)Wtsi}/Wtsi)	decreased leukocyte cell number	J:211773
Prss54^{em1(IMPC)Ccpcz}/Prss54^{em1(IMPC)Ccpcz} (C57BL/6N-Prss54^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	decreased CD4-positive NK T cell number	J:211773
	decreased memory-marker CD4-positive NK T cell number	J:211773
	decreased NK T cell number	J:211773
	enlarged thymus	J:211773
Prss55^{em1(IMPC)Ccpcz}/Prss55^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Prss55^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Prss56^em1(IMPC)J/Prss56^em1(IMPC)J (C57BL/6NJ-Prss56^em1(IMPC)J/J)	decreased leukocyte cell number	J:211773
Prss57^{em1(IMPC)Ccpcz}/Prss57^{em1(IMPC)Ccpcz} (C57BL/6N-Prss57^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	decreased NK T cell number	J:211773
	enlarged thymus	J:211773
Prss57^tm1.1Gne/Prss57^tm1.1Gne (C57BL/6N-Prss57^tm1.1Gne)	abnormal mast cell morphology	J:301479
	abnormal mast cell physiology	J:301479
	decreased mast cell histamine storage	J:301479
Prss57^tm1Lex/Prss57^tm1Lex (involves: 129S5/SvEvBrd)	abnormal mast cell physiology	J:301479
Prtn3^tm1.1Hrlu/Prtn3^tm1.1Hrlu (involves: C57BL/6)	abnormal neutrophil physiology	J:217636
Prtn3^tm1.1Hrlu/Prtn3^tm1.1Hrlu (involves: C57BL/6)	increased neutrophil cell number	J:217636
Prxl2a^{tm1(KOMP)Vlcg}/Prxl2a^{tm1(KOMP)Vlcg} (C57BL/6N-Prxl2a^{tm1(KOMP)Vlcg})	white adipose tissue inflammation	J:234040
Psap^tm1Ggb/Psap^tm1Ggb (involves: 129S/SvEv * C57BL/6J)	abnormal microglial cell physiology	J:121761
Psap^tm1Ggb/Psap^tm1Ggb (involves: 129S/SvEv * C57BL/6J)	dark spleen	J:121761
Psap^tm1Juma/Psap^tm1Juma (FVB.129S-Psap^tm1Juma)	abnormal microglial cell physiology	J:121761
Psap^tm1Suz/Psap^tm1Suz (involves: 129P2/OlaHsd)	abnormal macrophage morphology	J:113052
Psap^tm1Suz/Psap^tm1Suz (involves: 129P2/OlaHsd)	decreased spleen weight	J:106511
Psap^tm2Ggb/Psap^tm2Ggb (involves: 129S/SvEv * C57BL/6J)	CNS inflammation	J:137650
	kidney inflammation	J:137650
	microgliosis	J:198242
Psap^tm2Suz/Psap^tm2Suz (involves: 129S/SvEv * C57BL/6J)	abnormal macrophage morphology	J:78223
	CNS inflammation	J:78223
	microgliosis	J:198242
Psap^tm4.1Ggb/Psap^tm4.1Ggb (involves: 129S/SvEv * C57BL/6J)	microgliosis	J:198242
Psca^{tm1b(EUCOMM)Hmgu}/Psca^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Psca^{tm1b(EUCOMM)Hmgu}/Bay)	abnormal spleen morphology	J:211773
Pscr1^DBA/2/Pscr1^DBA/2 (involves: BALB/c * DBA/2)	decreased susceptibility to bacterial infection	J:8914
Pscr1^DBA/2/Pscr1^DBA/2 Pscr2^DBA/2/Pscr2^DBA/2 Pscr3^DBA/2/Pscr3^DBA/2 (involves: C57BL/6 * DBA/2)	decreased susceptibility to bacterial infection	J:8914
Pscr2^DBA/2/Pscr2^DBA/2 (involves: BALB/c * DBA/2)	decreased susceptibility to bacterial infection	J:8914
Pscr3^DBA/2/Pscr3^DBA/2 (involves: BALB/c * DBA/2)	decreased susceptibility to bacterial infection	J:8914
Psd^em1(IMPC)Mbp/Psd^em1(IMPC)Mbp (C57BL/6NCrl-Psd^em1(IMPC)Mbp/Mmucd)	abnormal spleen morphology	J:211773
	small spleen	J:211773
Psen1^tm1.1Ruvi/Psen1^tm1.1Ruvi Tg(APP)8.9Btla/0 (involves: 129S2/SvPas * C57BL/6J)	microgliosis	J:187475
Psen1^tm1Bdes/Psen1⁺ Psen2^tm1Bdes/Psen2^tm1Bdes (involves: 129P2/OlaHsd)	abnormal T cell subpopulation ratio	J:91235
	arteritis	J:91235
	autoimmune response	J:91235
	chronic inflammation	J:91235
	dermatitis	J:91235
	enlarged lymph nodes	J:91235
	enlarged spleen	J:91235
	glomerulonephritis	J:91235
	increased anti-single stranded DNA antibody level	J:91235
	increased immunoglobulin level	J:91235
	increased incidence of corneal inflammation	J:91235
	increased inflammatory response	J:91235
	increased leukocyte cell number	J:91235
	increased susceptibility to autoimmune disorder	J:91235
	kidney inflammation	J:91235
	skin inflammation	J:91235
Psen1^tm2Shn/Psen1^tm4.1Shn Psen2^tm1Haa/Psen2^tm1Haa Tg(Camk2a-cre)1Shn/0 (involves: 129 * 129S4/SvJae * C57BL/6 * C57BL/6J * CBA)	microgliosis	J:219929
Psen2^{em1(IMPC)Ccpcz}/Psen2^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Psen2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Psip1^{Gt(betageo)1Hgs}/Psip1^{Gt(betageo)1Hgs} (B6.129P2-Psip1^{Gt(betageo)1Hgs})	blepharitis	J:112975
	spleen atrophy	J:112975
Psip1^{Gt(betageo)1Hgs}/Psip1^{Gt(betageo)1Hgs} (either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129P2/OlaHsd * MF1))	blepharitis	J:112975
	spleen atrophy	J:112975
Psma8^em1(IMPC)Tcp/Psma8^em1(IMPC)Tcp (C57BL/6N-Psma8^em1(IMPC)Tcp/Tcp)	increased monocyte cell number	J:211773
	small thymus	J:211773
Psmb8^tm1Hjf/Psmb8^tm1Hjf (either: 129P2/OlaHsd or (involves: 129P2/OlaHsd * C57BL/6))	decreased level of surface class I molecules	J:20012
	defective intracellular transport of class I molecules	J:20012
Psmb8^tm1Hjf/Psmb8^tm1Hjf (involves: 129P2/OlaHsd)	abnormal dendritic cell antigen presentation	J:180765
Psmb8^tm1Hjf/Psmb8^tm1Hjf (involves: 129P2/OlaHsd)	decreased level of surface class I molecules	J:180765
Psmb8^tm1Hjf/Psmb8^tm1Hjf Tg(TcraTcrb)1100Mjb/? (involves: 129P2/OlaHsd * C57BL/6)	decreased CD8-positive, alpha-beta T cell number	J:107657
Psmb9^tm1Stl/Psmb9^tm1Stl (involves: 129P2/OlaHsd * C57BL/6)	abnormal CD8-positive, alpha-beta cytotoxic T cell morphology	J:21549
	abnormal immune system physiology	J:21549
	decreased CD8-positive, alpha-beta T cell number	J:21549
	increased susceptibility to Orthomyxoviridae infection	J:21549
Psmb10^tm1Mgro/Psmb10^tm1Mgro (involves: 129S2/SvPas * C57BL/6)	abnormal CD8-positive, alpha-beta cytotoxic T cell morphology	J:125058
	abnormal cytotoxic T cell physiology	J:125058
	decreased CD8-positive, alpha-beta T cell number	J:125058
	decreased T cell proliferation	J:125058
Psmb10^tm1Mgro/Psmb10^tm1Mgro Psmb9/Psmb8^tm1Klr/Psmb9/Psmb8^tm1Klr (B6.129-Psmb10^tm1Mgro Psmb9/Psmb8^tm1Klr)	abnormal antigen presentation via MHC class I	J:180765
	abnormal B lymphocyte antigen presentation	J:180765
	abnormal dendritic cell antigen presentation	J:180765
	decreased CD8-positive, alpha-beta T cell number	J:180765
	decreased level of surface class I molecules	J:180765
Psmb10^tm1Mgro/Psmb10^tm1Mgro Psmb9/Psmb8^tm1Klr/Psmb9/Psmb8^tm1Klr (B6.129-Psmb10^tm1Mgro Psmb9/Psmb8^tm1Klr)	abnormal antigen presentation via MHC class I	J:180765
	abnormal B lymphocyte antigen presentation	J:180765
	abnormal dendritic cell antigen presentation	J:180765
	decreased CD8-positive, alpha-beta T cell number	J:180765
	decreased level of surface class I molecules	J:180765
Psmb10^tm1Mgro/Psmb10^Tub6 (involves: 129S2/SvPas * C3HeB/FeJ)	decreased NK cell number	J:261081
	decreased T cell number	J:261081
	increased granulocyte number	J:261081
Psmb10^Tub6/Psmb10⁺ (C3HeB/FeJ-Psmb10^Tub6)	abnormal T cell activation	J:261081
	decreased CD4-positive, alpha-beta T cell number	J:261081
	decreased CD8-positive, alpha-beta T cell number	J:261081
	decreased interferon-gamma secretion	J:261081
	decreased T cell number	J:261081
	increased susceptibility to bacterial infection induced morbidity/mortality	J:261081
Psmb10^Tub6/Psmb10^Tub6 (C3HeB/FeJ-Psmb10^Tub6)	absent lymph nodes	J:261081
	absent spleen white pulp	J:261081
	athymia	J:261081
	decreased B cell number	J:261081
	decreased immunoglobulin level	J:261081
	decreased leukocyte cell number	J:261081
	decreased NK cell number	J:261081
	decreased spleen red pulp amount	J:261081
	decreased T cell number	J:261081
	increased circulating interleukin-1 level	J:261081
	increased circulating interleukin-6 level	J:261081
	increased circulating tumor necrosis factor level	J:261081
	increased granulocyte number	J:261081
	increased inflammatory response	J:261081
	skin inflammation	J:261081
Psmb10^Tub6/Psmb10^Tub6 (B6.C3Fe-Psmb10^Tub6)	increased granulocyte number	J:261081
Psmb10^Tub6/Psmb10^Tub6 (C.C3Fe-Psmb10^Tub6)	increased granulocyte number	J:261081
Psmb11^{em1(IMPC)Ccpcz}/Psmb11^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Psmb11^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	decreased CD8-positive, alpha-beta T cell number	J:211773
	decreased effector memory T-helper cell number	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
	increased CD4-positive NK T cell number	J:211773
	increased CD4-positive, alpha-beta T cell number	J:211773
	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
	increased effector memory T-helper cell number	J:211773
	increased memory-marker CD4-positive NK T cell number	J:211773
	increased NK T cell number	J:211773
	increased T-helper cell number	J:211773
Psmb11^{tm1(Psmb8)Khog}/Psmb11⁺ (involves: C57BL/6)	decreased CD8-positive, alpha-beta T cell number	J:196156
Psmb11^{tm1(Psmb8)Khog}/Psmb11^{tm1(Psmb8)Khog} (involves: C57BL/6)	abnormal CD8-positive, alpha beta T cell morphology	J:196156
	abnormal self tolerance	J:196156
	abnormal T cell differentiation	J:196156
	abnormal T cell receptor V(D)J recombination	J:196156
	decreased CD8-positive, alpha-beta T cell number	J:196156
	decreased memory T cell number	J:196156
	increased T cell proliferation	J:196156
Psmb11^{tm1(Psmb8)Khog}/Psmb11^{tm1(Psmb8)Khog} Psmb8^tm1Hjf/Psmb8^tm1Hjf (involves: 129P2/OlaHsd * C57BL/6)	decreased CD8-positive, alpha-beta T cell number	J:196156
Psmb11^{tm1.1(Psmb8)Khog}/Psmb11^{tm1.1(Psmb8)Khog} Psmb8^tm1Hjf/Psmb8^tm1Hjf (involves: 129P2/OlaHsd * C57BL/6 * C57BL/6NTac)	abnormal T cell receptor V(D)J recombination	J:196156
	decreased CD8-positive, alpha-beta T cell number	J:196156
Psmb11^tm1Smta/Psmb11^tm1Smta (involves: C57BL/6 * CBA)	decreased CD8-positive, alpha-beta T cell number	J:121869
Psmc4^tm1.1Ryot/Psmc4^tm1.2Ryot Tg(SLC18A3-cre)KMisa/0 (involves: C57BL/6 * C57BL/6N)	microgliosis	J:193770
Psme2^tm1Yya/Psme2^tm1Yya (involves: 129P2/OlaHsd)	abnormal CD8-positive, alpha-beta T cell physiology	J:58875
	decreased cytotoxic T cell cytolysis	J:58875
	defective assembly of class I molecules	J:58875
Psme3^tm1Jjm/Psme3^tm1Jjm (B6.129X1-Psme3^tm1Jjm)	decreased double-positive T cell number	J:88626
Psme3^tm1Jjm/Psme3^tm1Jjm (B6.129X1-Psme3^tm1Jjm)	increased susceptibility to fungal infection	J:88626
Psme4^b2b1508Clo/Psme4^b2b1508Clo (C57BL/6J-Psme4^b2b1508Clo)	thymus hypoplasia	J:175213
Psmf1^{tm1c(EUCOMM)Hmgu}/Psmf1^{tm1c(EUCOMM)Hmgu} Tg(Pcp2-cre)GN135Gsat/0 (involves: C57BL/6J * C57BL/6N * FVB/N)	microgliosis	J:282431
Pspc1^em1(IMPC)Mbp/Pspc1^em1(IMPC)Mbp (C57BL/6N-Pspc1^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	small spleen	J:211773
Psph^{tm1a(EUCOMM)Hmgu}/Psph^{tm1a(EUCOMM)Hmgu} (C57BL/6N-Psph^{tm1a(EUCOMM)Hmgu}/Wtsi)	abnormal thymus morphology	J:239583
	abnormal thymus topology	J:239583
	absent connection between subcutaneous lymph vessels and lymph sac	J:239583
	athymia	J:239583
	blood in lymph vessels	J:239583
	spleen hypoplasia	J:239583
Pstpip1^{em1(IMPC)Ccpcz}/Pstpip1^{em1(IMPC)Ccpcz} (C57BL/6N-Pstpip1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
	increased CD4-positive, alpha-beta T cell number	J:211773
	increased spleen weight	J:211773
	increased T-helper cell number	J:211773
Pstpip1^tm1.1Dtg/Pstpip1^tm1.1Dtg (involves: BALB/cJ * C57BL/6)	immune system phenotype	J:196002
Pstpip1^tm1Spg/Pstpip1^tm1Spg (involves: 129S/SvEv * C57BL/6)	abnormal immune system cell morphology	J:101977
	abnormal T cell physiology	J:101977
Pstpip2^cmo/Pstpip2^cmo (C.D2-Qa2)	chronic inflammation	J:1534
Pstpip2^cmo/Pstpip2^cmo (C.Cg-Pstpip2^cmo/J)	abnormal lymph node morphology	J:104476
	ear inflammation	J:104476
	enlarged spleen	J:104476
	osteomyelitis	J:104476, J:105410
Pstpip2^em1(IMPC)Tcp/Pstpip2^em1(IMPC)Tcp (C57BL/6NCrl-Pstpip2^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Pstpip2^Lupo/Pstpip2^Lupo (either: (involves: C3HeB/FeJ) or (involves: C3HeB/FeJ * C57BL/6J))	abnormal cytokine secretion	J:125785
	increased autoantibody level	J:125785
	increased IgE level	J:125785
	increased IgG1 level	J:125785
	increased IgG2a level	J:125785
	increased IgG level	J:125785
	skin inflammation	J:125785
Pstpip2^Lupo/Pstpip2^Lupo Rag1^tm1Mom/Rag1^tm1Mom (involves: 129S7/SvEvBrd * C3HeB/FeJ * C57BL/6J)	skin inflammation	J:125785
Pstpip2^m1Bcs/Pstpip2^m1Bcs (involves: C57BL/6)	abnormal inflammatory response	J:196534
	abnormal microglial cell morphology	J:196534
	autoimmune response	J:196534
	ear inflammation	J:196534
	skin inflammation	J:196534
pta/pta (C57BL/6J-pta)	thymus hypoplasia	J:94456
Ptafr^tm1Tksh/Ptafr^tm1Tksh (involves: 129P2/OlaHsd * C57BL/6)	decreased inflammatory response	J:87866
	increased susceptibility to parasitic infection	J:87866
	increased susceptibility to type I hypersensitivity reaction	J:88505
Ptafr^tm1Tksh/Ptafr^tm1Tksh (C57BL/6-Ptafr^tm1Tksh)	decreased susceptibility to bacterial infection	J:88589
Ptch1^tm1Bjw/Ptch1^tm1Bjw Tg(KRT14-cre)8Brn/0 (involves: 129T2/SvEms * FVB/N)	thymus hypoplasia	J:231264
Ptch1^tm1Hahn/Ptch1^tm1Hahn Gt(ROSA)26Sor^{tm2(cre/ERT2)Brn}/Gt(ROSA)26Sor⁺ (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal double-negative T cell morphology	J:127207
	abnormal thymus lobule morphology	J:127207
	decreased B cell number	J:127207
	decreased double-positive T cell number	J:127207
	decreased immature B cell number	J:127207
	decreased lymphocyte cell number	J:127207
	decreased pre-B cell number	J:127207
	decreased transitional stage B cell number	J:127207
	increased B cell number	J:127207
	increased double-negative T cell number	J:127207
	increased mature B cell number	J:127207
	increased neutrophil cell number	J:127207
	increased single-positive T cell number	J:127207
	thymus hypoplasia	J:127207
Ptch2^tm1Dgen/Ptch2^tm1Dgen (involves: 129P2/OlaHsd * C57BL/6)	enlarged spleen	J:101679
	increased neutrophil cell number	J:101679
Ptch2^{tm3b(EUCOMM)Hmgu}/Ptch2^{tm3b(EUCOMM)Hmgu} (C57BL/6N-Ptch2^{tm3b(EUCOMM)Hmgu}/Bay)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Ptchd1^{tm1b(KOMP)IcsOrl}/Y (C57BL/6N-Ptchd1^{tm1b(KOMP)IcsOrl}/Ics)	abnormal spleen morphology	J:211773
Ptcra^tm1(icre)Hjf/Ptcra^tm1(icre)Hjf (B6.129P2-Ptcra^tm1(icre)Hjf)	decreased DN4 thymocyte number	J:197923
	decreased double-positive T cell number	J:197923
	decreased thymocyte number	J:197923
Ptcra^tm1.1Shoy/Ptcra^tm1.1Shoy (involves: C57BL/6)	decreased double-positive T cell number	J:166147
	decreased T cell number	J:166147
	decreased thymocyte number	J:166147
	increased DN3 thymocyte number	J:166147
	increased gamma-delta T cell number	J:166147
	increased T cell number	J:166147
Ptcra^tm1Bjf/Ptcra⁺ (involves: 129X1/SvJ)	abnormal T cell differentiation	J:94338
	decreased double-negative T cell number	J:94338
	decreased single-positive T cell number	J:94338
Ptcra^tm1Vbo/Ptcra^tm1Vbo (involves: 129P2/OlaHsd * C57BL/6)	arrested T cell differentiation	J:91542
	increased double-negative T cell number	J:91542
Ptcra^tm1Vbo/Ptcra^tm1Vbo (involves: 129P2/OlaHsd)	abnormal double-positive T cell morphology	J:123569
	decreased DN4 thymocyte number	J:123569
	increased DN3 thymocyte number	J:123569
	thymus hypoplasia	J:123569
Ptdss1^{tm1b(EUCOMM)Hmgu}/Ptdss1^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Ptdss1^{tm1b(EUCOMM)Hmgu}/Ics)	decreased large unstained cell number	J:211773
Pten^tm1.1Gle/Pten⁺ (involves: 129S6/SvEvTac * Black Swiss * FVB/N)	increased T cell derived lymphoma incidence	J:158751
Pten^tm1.1Hwu/Pten⁺ (involves: 129S4/SvJae * BALB/c)	lymphoid hyperplasia	J:110567
Pten^tm1.2Mwst/Pten⁺ (involves: 129S6/SvEvTac * Black Swiss * FVB/N)	increased T cell derived lymphoma incidence	J:158751
Pten^tm1Engc/Pten^tm1Engc (involves: CD-1)	abnormal microglial cell physiology	J:210487
Pten^tm1Hwu/Pten^tm1Hwu Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * 129S4/SvJae)	abnormal alveolar macrophage morphology	J:148947
	abnormal cytokine level	J:148947
	abnormal macrophage chemotaxis	J:148947
	abnormal neutrophil physiology	J:148947, J:114699, J:145331
	decreased susceptibility to bacterial infection	J:148947
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:148947
	impaired neutrophil recruitment	J:148947
	increased susceptibility to bacterial infection	J:148947
	increased susceptibility to bacterial infection induced morbidity/mortality	J:148947
	lung inflammation	J:148947
Pten^tm1Hwu/Pten^tm1Hwu Rps6kb1^tm1Gtho/Rps6kb1^tm1Gtho Tg(Mx1-cre)1Cgn/0 (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * CBA)	enlarged spleen	J:169097
	enlarged thymus	J:169097
Pten^tm1Hwu/Pten^tm1Hwu Tg(CAG-EGFP,-PAX8/PPARG)1Rkoe/0 Tg(TPO-cre)1Shk/0 (involves: 129S4/SvJae * FVB/NCr * FVB/NJ)	abnormal thymus physiology	J:177181
Pten^tm1Hwu/Pten^tm1Hwu Tg(CD2-icre)4Kio/0 (involves: 129S4/SvJae * C57BL/6 * C57BL/10 * CBA/Ca)	enlarged thymus	J:216983
Pten^tm1Hwu/Pten^tm1Hwu Tg(Cdh5-cre)7Mlia/0 (involves: 129S4/SvJae * BALB/c * C57BL/6 * FVB/N)	enlarged lymph nodes	J:135172
	enlarged spleen	J:135172
	enlarged thymus	J:135172
	increased leukocyte cell number	J:135172
	increased neutrophil cell number	J:135172
Pten^tm1Hwu/Pten^tm1Hwu Tg(GZMB-cre)1Jcb/0 (involves: 129S4/SvJae * FVB/N)	abnormal CD8-positive, alpha-beta T cell physiology	J:164425
	decreased interleukin-2 secretion	J:164425
Pten^tm1Hwu/Pten^tm1Hwu Tg(Mx1-cre)1Cgn/0 (involves: 129S4/SvJae * C57BL/6 * CBA)	enlarged spleen	J:169097
	enlarged thymus	J:169097
Pten^tm1Hwu/Pten^tm1Hwu Tg(Mx1-cre)1Cgn/0 (BKS.Cg-Ptprc^b Thy1^a Tg(Mx1-cre)1Cgn Pten^tm1Hwu)	enlarged thymus	J:109085
	spleen hyperplasia	J:109085
Pten^tm1Hwu/Pten^tm1Hwu Tg(Mx1-cre)1Cgn/0 (B6.Cg-Tg(Mx1-cre)1Cgn Pten^tm1Hwu)	decreased B cell number	J:232645
	decreased lymphocyte cell number	J:232645
	decreased T cell number	J:232645
	enlarged spleen	J:232645
	increased granulocyte number	J:232645
	increased macrophage cell number	J:232645
	increased monocyte cell number	J:232645
	increased spleen weight	J:232645
Pten^tm1Hwu/Pten^tm1Hwu Tg(Pbsn-cre)4Prb/0 (involves: 129S4/SvJae * BALB/c * C57BL/6 * DBA/2)	prostate gland inflammation	J:93902
	pyelonephritis	J:124208
Pten^tm1Mak/Pten⁺ (involves: 129P2/OlaHsd * C57BL/6J)	enlarged Peyer's patches	J:63478
Pten^tm1Mak/Pten⁺ (involves: 129P2/OlaHsd * C57BL/6J)	increased T cell derived lymphoma incidence	J:50437
Pten^tm1Rps/Pten⁺ (involves: 129S1/Sv * C57BL/6J)	abnormal lymph node B cell domain morphology	J:53065
	enlarged spleen	J:53065
	enlarged thymus	J:53065
	lymph node hyperplasia	J:53065
Pten^tm2.1Gle/Pten⁺ (involves: 129S6/SvEvTac * Black Swiss * FVB/N)	increased T cell derived lymphoma incidence	J:158751
Pten^tm2.1Ppp/Pten^tm2.1Ppp Tnfrsf4^tm2(cre)Nik/Tnfrsf4⁺ (involves: 129S1/Sv * 129X1/SvJ)	increased germinal center B cell number	J:164283
	increased IgG1 level	J:164283
	increased T follicular helper cell number	J:164283
Pten^tm2Mak/Pten^tm2Mak Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺ (involves: 129P2/OlaHsd * C57BL/6 * DBA)	liver inflammation	J:138099
Ptf1a^tm1Pkwe/Ptf1a^tm1Pkwe (involves: 129P2/OlaHsd * C57BL/6)	abnormal spleen morphology	J:51571
Ptgdr2^tm1Byl/Ptgdr2^tm1Byl (involves: C57BL/6J)	abnormal cytokine secretion	J:107519
Ptgdr2^tm1Byl/Ptgdr2^tm1Byl (involves: C57BL/6J)	increased eosinophil cell number	J:107519
Ptgdr2^tm1Tasa/Ptgdr2^tm1Tasa (involves: 129/Sv * BALB/c)	impaired eosinophil recruitment	J:130892
Ptgdr2^tm1Tasa/Ptgdr2^tm1Tasa (C.129-Ptgdr2^tm1Tasa)	abnormal chemokine level	J:131146
	abnormal inflammatory response	J:131146
	decreased IgE level	J:131146
	decreased inflammatory response	J:131146
	decreased susceptibility to type IV hypersensitivity reaction	J:131146
Ptgdr2^tm1Tasa/Ptgdr2^tm1Tasa (B6.129-Ptgdr2^tm1Tasa)	increased susceptibility to type I hypersensitivity reaction	J:197334
Ptgdr^tm1Sna/Ptgdr^tm1Sna (involves: 129P2/OlaHsd * C57BL/6)	abnormal macrophage activation involved in immune response	J:243958
	brain inflammation	J:243958
	decreased microglial cell activation	J:243958
	increased CD4-positive, alpha-beta T cell number	J:243958
	increased interleukin-1 beta secretion	J:243958
	increased regulatory T cell number	J:243958
	increased susceptibility to Coronaviridae infection	J:243958
	increased susceptibility to Coronaviridae infection induced morbidity/mortality	J:243958
	respiratory system inflammation	J:61023
Ptgdr^tm1Sna/Ptgdr^tm1Sna (B6.129P2-Ptgdr^tm1Sna/Sna)	abnormal dermal mast cell morphology	J:197334
	abnormal mast cell physiology	J:197334
	decreased mast cell degranulation	J:197334
	decreased mast cell histamine storage	J:197334
	decreased susceptibility to type I hypersensitivity reaction	J:197334
Ptgds^tm1Mfg/Ptgds^tm1Mfg (involves: C57BL/6)	immune system phenotype	J:98963
Ptgds^tm1Ohy/Ptgds^tm1Ohy (B6.129P2-Ptgds^tm1Ohy)	abnormal dermal mast cell morphology	J:197334
	decreased mast cell degranulation	J:197334
	decreased mast cell histamine storage	J:197334
	decreased susceptibility to type I hypersensitivity reaction	J:197334
	immune system phenotype	J:197334
Ptger1^tm1Jdm/Ptger1^tm1Jdm (DBA/1LacJ-Ptger1^tm1Jdm)	immune system phenotype	J:72198, J:78964
Ptger1^tm1Sna/Ptger1^tm1Sna (B6CrSlc.129P2-Ptger1^tm1Sna/Sna)	abnormal CD8-positive, alpha-beta T cell differentiation	J:128435
	abnormal cervical lymph node morphology	J:128435
	abnormal interferon-gamma secretion	J:128435
	abnormal lymph node morphology	J:128435
	abnormal response to infection	J:82750
	abnormal T-helper 1 cell differentiation	J:128435
	decreased susceptibility to type IV hypersensitivity reaction	J:128435
	immune system phenotype	J:128435, J:197334
Ptger2^tm1.1Kand/Ptger2^tm1.1Kand Tg(ITGAM-cre)2781Gkl/0 (involves: C57BL/6 * CBA)	abnormal microglial cell physiology	J:202677
	decreased susceptibility to endotoxin shock	J:202677
Ptger2^tm1Brey/Ptger2^tm1Brey (involves: 129S6/SvEvTac * C57BL/6)	abnormal response to infection	J:120725
Ptger2^tm1Brey/Ptger2^tm1Brey (C.129S6-Ptger2^tm1Brey)	abnormal microglial cell physiology	J:97062
Ptger2^tm1Brey/Ptger2^tm1Brey (involves: 129S6/SvEvTac * BALB/c)	abnormal response to infection	J:164638
Ptger2^tm1Rsz/Ptger2^tm1Rsz (involves: 129S6/SvEvTac * C57BL/6)	abnormal osteoclast differentiation	J:77408
Ptger2^tm1Sna/Ptger2^tm1Sna (B6.129P2-Ptger2^tm1Sna/Sna)	immune system phenotype	J:197334
Ptger2^tm2Bhk/Ptger2^tm2Bhk (involves: 129P2/OlaHsd * 129S/SvEv)	immune system phenotype	J:78964
Ptger3^tm1Cof/Ptger3^tm1Cof (involves: 129P2/OlaHsd * 129S/SvEv)	immune system phenotype	J:78964
Ptger3^tm1Sna/Ptger3^tm1Sna (B6.129P2-Ptger3^tm1Sna/Sna)	abnormal response to infection	J:82750
Ptger3^tm1Sna/Ptger3^tm1Sna (B6.129P2-Ptger3^tm1Sna/Sna)	increased susceptibility to type I hypersensitivity reaction	J:197334
Ptger4^tm1.1Matb/Ptger4^tm1.1Matb Tg(Myh6-cre)2182Mds/0 (involves: 129S6/SvEvTac * FVB/N)	heart inflammation	J:158439
Ptger4^tm1Bhk/Ptger4^tm1Bhk (involves: 129P2/OlaHsd * 129S/SvEv)	lymphangiectasis	J:44108
Ptger4^tm1Bhk/Ptger4^tm1Bhk (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	abnormal circulating interleukin-6 level	J:78964
	abnormal circulating serum amyloid protein level	J:78964
	abnormal cytokine level	J:78964
	abnormal macrophage physiology	J:78964
	decreased susceptibility to induced arthritis	J:78964
	immune system phenotype	J:78964
	rheumatoid arthritis	J:78964
Ptger4^tm1Sna/Ptger4^tm1Sna (involves: 129P2/OlaHsd * C57BL/6)	abnormal Langerhans cell physiology	J:83725
	abnormal osteoclast differentiation	J:63070
	abnormal osteoclast physiology	J:63070
	abnormal T cell activation	J:83725
	decreased interferon-gamma secretion	J:83725
	decreased susceptibility to type IV hypersensitivity reaction	J:83725
	decreased T cell proliferation	J:83725
	immune system phenotype	J:83725, J:197334
Ptges2^tm1Kymm/Ptges2^tm1Kymm (B6.Cg-Ptges2^tm1Kymm)	increased susceptibility to type I hypersensitivity reaction	J:197334
Ptges^tm1.1Gaf/Ptges^tm1.1Gaf Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129 * C57BL/6)	abnormal leukocyte physiology	J:210141
	increased leukocyte cell number	J:210141
Ptges^tm1Aki/Ptges^tm1Aki (involves: 129X1/SvJ * C57BL/6)	abnormal inflammatory response	J:91821
	chronic inflammation	J:91821
	impaired macrophage chemotaxis	J:91821
Ptges^tm1Aki/Ptges^tm1Aki (B6.129P2-Ptges^tm1Aki)	increased susceptibility to type I hypersensitivity reaction	J:197334
Ptges^tm1Lpa/Ptges^tm1Lpa (DBA/1LacJ-Ptges^tm1Lpa)	decreased inflammatory response	J:89960, J:90980
Ptgfr^tm1Sna/Ptgfr^tm1Sna (B6.129P2-Ptgfr^tm1Sna)	immune system phenotype	J:197334
Ptgfrn^{em1(IMPC)Hmgu}/Ptgfrn^{em1(IMPC)Hmgu} (C57BL/6NCrl-Ptgfrn^{em1(IMPC)Hmgu}/Ieg)	increased neutrophil cell number	J:211773
Ptgir^tm1Sna/Ptgir^tm1Sna (involves: 129P2/OlaHsd * C57BL/6)	decreased acute inflammation	J:42275
Ptgir^tm1Sna/Ptgir^tm1Sna (B6.129P2-Ptgir^tm1Sna/Sna)	immune system phenotype	J:197334
Ptgis^em1(IMPC)Mbp/Ptgis^em1(IMPC)Mbp (C57BL/6N-Ptgis^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged thymus	J:211773
Ptgs1^tm1Fun/Ptgs1^tm1Fun (involves: 129S6/SvEvTac * C57BL/6)	decreased inflammatory response	J:97351
Ptgs1^tm1Unc/Ptgs1^tm1Unc (involves: 129P2/OlaHsd * C57BL/6)	decreased inflammatory response	J:29511
	enlarged spleen	J:60668
	increased susceptibility to endotoxin shock	J:75611
	increased susceptibility to induced colitis	J:158426, J:60668
Ptgs1^tm1Unc/Ptgs1^tm1Unc (B6.129P2-Ptgs1^tm1Unc)	decreased susceptibility to induced arthritis	J:110716
Ptgs2^tm1.1Fun/Ptgs2^tm1.1Fun (involves: 129S6/SvEvTac)	kidney inflammation	J:148699
Ptgs2^tm1.1Wls/Ptgs2^tm1.1Wls (B6.129-Ptgs2^tm1.1Wls)	increased susceptibility to endotoxin shock	J:156331
Ptgs2^tm1Jed/Ptgs2^tm1Jed (involves: 129S7/SvEvBrd)	immune system phenotype	J:29974
Ptgs2^tm1Jed/Ptgs2^tm1Jed (involves: 129S7/SvEvBrd)	pyelonephritis	J:29974
Ptgs2^tm1Jed/Ptgs2^tm1Jed (involves: 129S7/SvEvBrd * C57BL/6)	peritoneal inflammation	J:118171
Ptgs2^tm1Jed/Ptgs2^tm1Jed (involves: 129S7/SvEvBrd * CD-1)	abnormal response to infection	J:120725
Ptgs2^tm1Unc/Ptgs2⁺ (involves: 129/Sv * 129P2/OlaHsd * C57BL/6)	abnormal osteoclast differentiation	J:124756
Ptgs2^tm1Unc/Ptgs2^tm1Unc (involves: 129P2/OlaHsd * C57BL/6J)	abnormal macrophage physiology	J:29510
	abnormal mesenteric lymph node morphology	J:29510
	immune system phenotype	J:29510
	peritoneal inflammation	J:29510
	spleen hyperplasia	J:29510
	tubulointerstitial nephritis	J:29510
Ptgs2^tm1Unc/Ptgs2^tm1Unc (involves: 129/Sv * 129P2/OlaHsd * C57BL/6)	abnormal osteoclast differentiation	J:124756
Ptgs2^tm1Unc/Ptgs2^tm1Unc (involves: 129P2/OlaHsd * C57BL/6)	decreased susceptibility to endotoxin shock	J:75611
	enlarged spleen	J:60668
	increased leukocyte cell number	J:60668
	increased susceptibility to induced colitis	J:158426, J:60668
	increased tumor necrosis factor secretion	J:108054
	peritoneal inflammation	J:60668
Ptgs2^tm1Unc/Ptgs2^tm1Unc (B6.129P2-Ptgs2^tm1Unc)	abnormal class switch recombination	J:140698
	abnormal memory B cell differentiation	J:140698
	abnormal response to infection	J:140698
	decreased IgG1 level	J:140698
	decreased IgG2a level	J:140698
	decreased IgG3 level	J:140698
	decreased susceptibility to induced arthritis	J:110716
	increased IgM level	J:140698
Ptgs2^tm1Unc/Ptgs2^tm2.1Hahe (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)	increased susceptibility to induced colitis	J:158426
Ptgs2^{tm2(Ptgs1)Fun}/Ptgs2^{tm2(Ptgs1)Fun} (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal macrophage physiology	J:118171
Ptgs2^{tm2.1(Ptgs1)Fun}/Ptgs2^{tm2.1(Ptgs1)Fun} (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB)	abnormal macrophage physiology	J:118171
	kidney inflammation	J:118171
	peritoneal inflammation	J:118171
Ptgs2os^tm1Scrp/Ptgs2os^tm1Scrp (Not Specified)	abnormal chemokine level	J:325487
	decreased CCL3 level	J:325487
	decreased circulating CCL3 level	J:325487
	decreased circulating interleukin-6 level	J:325487
	decreased neutrophil cell number	J:325487
	increased interferon-beta secretion	J:325487
Pth1r^{tm1a(EUCOMM)Hmgu}/Pth1r^{tm1a(EUCOMM)Hmgu} (C57BL/6N-Pth1r^{tm1a(EUCOMM)Hmgu}/Wtsi)	abnormal thymus morphology	J:239583
	blood in lymph vessels	J:239583
	enlarged lymphatic vessel	J:239583
Pth^tm1Dgo/Pth^tm1Dgo (involves: 129S2/SvPas * C57BL/6J)	abnormal osteoclast morphology	J:76407
Pth^tm1Dgo/Pth^tm1Dgo (involves: 129S2/SvPas * C57BL/6J)	decreased osteoclast cell number	J:76407
Pth^tm1Dgo/Pth^tm1Dgo Pthlh^tm1Hmk/Pthlh^tm1Hmk (involves: 129S2/SvPas * C57BL/6J)	abnormal osteoclast morphology	J:76407
	decreased osteoclast cell number	J:76407
Pthlh^tm1Ack/Pthlh^tm1Ack Tg(Col1a1-cre)1Ack/0 (involves: 129S1/Sv * 129X1/SvJ * FVB/N)	abnormal osteoclast morphology	J:100918
	decreased osteoclast cell number	J:100918
Pthlh^tm1Ack/Pthlh^tm1Hmk Tg(LGB-cre)74Acl/0 (involves: 129 * C57BL/6 * CBA)	abnormal osteoclast morphology	J:86536
Pthlh^tm1Hmk/Pthlh⁺ (involves: 129S2/SvPas)	abnormal osteoclast morphology	J:100918
Pthlh^tm1Hmk/Pthlh^tm1Hmk (involves: 129S2/SvPas * C57BL/6J)	abnormal osteoclast morphology	J:76407
	decreased osteoclast cell number	J:76407
Pthlh^tm1Hmk/Pthlh^tm1Hmk Pth1r^tm1Hmk/Pth1r^tm2Hmk Tg(Col2a1-PTHLH)1Ecw/0 (involves: 129S2/SvPas * 129S4/SvJae * C57BL/6 * SJL)	abnormal bone marrow development	J:99641
Pthlh^tm2Ack/Pthlh^tm2Ack (involves: 129S2/SvPas * C57BL/6)	decreased osteoclast cell number	J:142669
Ptk2b^tm1Schl/Ptk2b^tm1Schl (involves: 129S1/Sv * 129X1/SvJ)	abnormal macrophage physiology	J:99741
	decreased acute inflammation	J:99741
	impaired macrophage chemotaxis	J:99741
Ptn^tm1Tmu/Ptn^tm1Tmu (B6.Cg-Ptn^tm1Tmu)	decreased macrophage cell number	J:102069
	impaired macrophage chemotaxis	J:102069
	impaired neutrophil recruitment	J:102069
Ptp4a1^em2(IMPC)Tcp/Ptp4a1^em2(IMPC)Tcp (C57BL/6NCrl-Ptp4a1^em2(IMPC)Tcp/Tcp)	small spleen	J:211773
Ptp4a2^em1(IMPC)Tcp/Ptp4a2^em1(IMPC)Tcp (C57BL/6N-Ptp4a2^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Ptp4a2^{Gt(AQ0673)Wtsi}/Ptp4a2^{Gt(AQ0673)Wtsi} (involves: 129P2/OlaHsd * C57BL/6)	decreased spleen weight	J:190411
Ptp4a3^em1(IMPC)Mbp/Ptp4a3^em1(IMPC)Mbp (C57BL/6N-Ptp4a3^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	small spleen	J:211773
Ptpmt1^tm2.1Ckq/Ptpmt1^tm2.1Ckq Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * SJL)	immune system phenotype	J:194929
Ptpmt1^tm2.1Ckq/Ptpmt1^tm2.1Ckq Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * SJL)	immune system phenotype	J:194929
Ptpmt1^tm2.1Ckq/Ptpmt1^tm2.1Ckq Tg(Lck-cre)1Cwi/0 (involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * SJL)	immune system phenotype	J:194929
Ptpmt1^tm2.1Ckq/Ptpmt1^tm2.1Ckq Tg(VAV1-cre)1Graf/0 (involves: 129S6/SvEvTac * C57BL/6J * SJL)	small spleen	J:194929
	small thymus	J:194929
Ptpn2^tm1.1Kry/Ptpn2^tm1.1Kry Tg(Col1a1-cre)1Kry/0 (involves: 129 * C57BL/6J * FVB)	abnormal osteoclast differentiation	J:183709
	abnormal osteoclast physiology	J:183709
Ptpn2^tm1Mtr/Ptpn2^tm1Mtr (involves: 129S4/SvJae * BALB/c)	abnormal B cell number	J:42595
	abnormal inflammatory response	J:90541
	abnormal spleen morphology	J:42595
	abnormal thymus involution	J:42595
	decreased B cell number	J:42595
	decreased double-positive T cell number	J:42595
	enlarged lymph nodes	J:42595
	enlarged spleen	J:42595
	increased B cell number	J:42595
	increased inflammatory response	J:90541
	increased interferon-gamma secretion	J:90541
	increased interleukin-12 secretion	J:90541
	increased macrophage cell number	J:42595
	increased mature B cell number	J:42595
	increased pre-B cell number	J:42595
	increased spleen red pulp amount	J:42595
	increased tumor necrosis factor secretion	J:90541
	lymph node hyperplasia	J:42595
	spleen hyperplasia	J:42595
Ptpn2^tm1Mtr/Ptpn2^tm1Mtr (C.129S4-Ptpn2^tm1Mtr)	abnormal lymph node morphology	J:186843
	abnormal negative T cell selection	J:186843
	abnormal positive T cell selection	J:186843
	abnormal T cell differentiation	J:186843
	abnormal T cell subpopulation ratio	J:186843
	decreased B cell number	J:186843
	decreased B-1 B cell number	J:186843
	decreased CD4-positive, alpha-beta T cell number	J:186843
	decreased double-positive T cell number	J:186843
	decreased follicular B cell number	J:186843
	decreased immature B cell number	J:186843
	decreased marginal zone B cell number	J:186843
	decreased mature B cell number	J:186843
	decreased single-positive T cell number	J:186843
	decreased T cell number	J:186843
	decreased thymocyte number	J:186843
	enlarged spleen	J:186843
	increased splenocyte number	J:186843
	thymus atrophy	J:186843
Ptpn2^tm1Mtr/Ptpn2^tm1Mtr (B6.129S4(C)-Ptpn2^tm1Mtr)	abnormal lymph node morphology	J:186843
	decreased B cell number	J:186843
	decreased B-1 B cell number	J:186843
	decreased CD4-positive, alpha-beta T cell number	J:186843
	decreased double-positive T cell number	J:186843
	decreased follicular B cell number	J:186843
	decreased immature B cell number	J:186843
	decreased marginal zone B cell number	J:186843
	decreased mature B cell number	J:186843
	decreased single-positive T cell number	J:186843
	decreased T cell number	J:186843
	decreased thymocyte number	J:186843
	thymus atrophy	J:186843
Ptpn2^tm2.1Ttig/Ptpn2^tm2.1Ttig (B6.Cg-Ptpn2^tm2.1Ttig)	abnormal negative T cell selection	J:186843
	abnormal positive T cell selection	J:186843
	abnormal T cell differentiation	J:186843
	abnormal T cell subpopulation ratio	J:186843
	decreased B cell number	J:186843
	decreased B-1 B cell number	J:186843
	decreased CD4-positive, alpha-beta T cell number	J:186843
	decreased double-positive T cell number	J:186843
	decreased follicular B cell number	J:186843
	decreased immature B cell number	J:186843
	decreased marginal zone B cell number	J:186843
	decreased mature B cell number	J:186843
	decreased single-positive T cell number	J:186843
	decreased thymocyte number	J:186843
	enlarged lymph nodes	J:186843
	thymus atrophy	J:186843
Ptpn3^tm1Pdk/Ptpn3^tm1Pdk Ptpn4^{Gt(OST146128)Lex}/Ptpn4^{Gt(OST146128)Lex} (involves: 129S5/SvEvBrd * C57BL/6)	immune system phenotype	J:144351
Ptpn4^{Gt(OST146128)Lex}/Ptpn4^{Gt(OST146128)Lex} (involves: 129S5/SvEvBrd * C57BL/6)	immune system phenotype	J:144351
Ptpn4^tm1.1Oers/Ptpn4^tm1.1Oers (B6.129S6-Ptpn4^tm1.1Oers)	immune system phenotype	J:138871
Ptpn6^em1.1Shoy/Ptpn6^em1.1Shoy (involves: C57BL/6)	decreased thymocyte number	J:236298
Ptpn6^m1Amgn/Ptpn6^m1Amgn (involves: C3H/HeSnJ * C57BL/6J * Swiss)	increased circulating interleukin-17 level	J:168664
Ptpn6^m1Anu/Ptpn6^m1Anu (C57BL/6JAnu-Ptpn6^m1Anu)	decreased IgM level	J:225105
Ptpn6^m1Btlr/Ptpn6^m1Btlr (C57BL/6J-Ptpn6^m1Btlr/Mmucd)	abnormal myeloid leukocyte morphology	J:142845
	decreased mature B cell number	J:142845
	decreased susceptibility to bacterial infection	J:142845
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:142845
	enlarged spleen	J:94077, J:142845
	increased anti-chromatin antibody level	J:142845
	increased IgM level	J:142845
	increased inflammatory response	J:94077
	increased neutrophil cell number	J:142845
	lung inflammation	J:142845
	salivary gland inflammation	J:142845
Ptpn6^m3Btlr/Ptpn6⁺ (C57BL/6J-Ptpn6^m3Btlr)	abnormal CD8-positive, alpha beta T cell morphology	J:234259
	decreased B cell number	J:234259
	decreased B-2 B cell number	J:234259
	decreased immature B cell number	J:234259
	decreased mature B cell number	J:234259
	increased B-1 B cell number	J:234259
	increased B-1a cell number	J:234259
	increased dendritic cell number	J:234259
	increased macrophage cell number	J:234259
Ptpn6^m3Btlr/Ptpn6^m3Btlr (C57BL/6J-Ptpn6^m3Btlr)	abnormal CD8-positive, alpha beta T cell morphology	J:234259
	decreased B cell number	J:234259
	decreased B-2 B cell number	J:234259
	decreased immature B cell number	J:234259
	decreased mature B cell number	J:234259
	increased B-1 B cell number	J:234259
	increased B-1b cell number	J:234259
	increased dendritic cell number	J:234259
	increased macrophage cell number	J:234259
Ptpn6^m4Btlr/Ptpn6^m4Btlr (C57BL/6J-Ptpn6^m4Btlr)	decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:264807
	decreased CD8-positive, naive alpha-beta T cell number	J:264807
	increased B-1 B cell number	J:264807
	increased CD8-positive, alpha-beta memory T cell number	J:264807
	increased central memory CD8 positive, alpha-beta T cell number	J:264807
	increased effector memory CD4-positive, alpha-beta T cell number	J:264807
	increased effector memory CD8-positive, alpha-beta T cell number	J:264807
Ptpn6^M5Btlr/Ptpn6^M5Btlr (C57BL/6J-Ptpn6^M5Btlr)	decreased B cell number	J:265075
	decreased B-1 B cell number	J:265075
	decreased CD8-positive, naive alpha-beta T cell number	J:265075
	decreased IgD level	J:265075
	decreased IgM level	J:265075
	increased central memory CD8 positive, alpha-beta T cell number	J:265075
Ptpn6^m6Btlr/Ptpn6^m6Btlr (C57BL/6J-Ptpn6^m6Btlr)	abnormal CD8-positive, alpha-beta T cell differentiation	J:272439
Ptpn6^m6Btlr/Ptpn6^m6Btlr (C57BL/6J-Ptpn6^m6Btlr)	abnormal T cell differentiation	J:272439
Ptpn6^m7Btlr/Ptpn6^m7Btlr (C57BL/6J-Ptpn6^m7Btlr)	abnormal T cell differentiation	J:272440
Ptpn6^me-B2/Ptpn6^me-B2 (involves: BALB/c)	abnormal circulating chemokine level	J:169850
	increased circulating interferon-gamma level	J:169850
	increased circulating interleukin-1 beta level	J:169850
	increased circulating interleukin-6 level	J:169850
	increased circulating interleukin-10 level	J:169850
	increased circulating serum amyloid protein level	J:169850
	increased IgG level	J:169850
	increased IgM level	J:169850
	increased neutrophil cell number	J:169850
	interstitial pneumonia	J:169850
	skin inflammation	J:169850
	small thymus	J:169850
Ptpn6^me-v/Ptpn6⁺ Tg(IghelMD4)4Ccg/0 (involves: 129P2/OlaHsd * C57BL/6)	abnormal mature B cell morphology	J:110531
Ptpn6^me-v/Ptpn6^me-v (C57BL/6J-Ptpn6^me-v)	abnormal immunoglobulin level	J:7665
	abnormal inflammatory response	J:20845
	abnormal plasma cell morphology	J:14936
	abnormal T cell physiology	J:1661
	abnormal thymus development	J:16613
	chronic inflammation	J:20845
	decreased B cell number	J:113218
	decreased mature B cell number	J:7905
	increased plasma cell number	J:7905
	interstitial pneumonia	J:7531
	rheumatoid arthritis	J:20845
Ptpn6^me/Ptpn6^me (C57BL/6J-Ptpn6^me/J)	abnormal granulocyte morphology	J:5579
	abnormal humoral immune response	J:5579
	abnormal immune system cell morphology	J:5579
	abnormal leukocyte cell number	J:5579
	abnormal Peyer's patch morphology	J:5579
	abnormal thymus morphology	J:5579
	autoimmune response	J:5579
	enlarged spleen	J:5579
	increased granulocyte number	J:5579
	increased IgA level	J:5579
	increased IgG level	J:5579
	increased IgM level	J:5579
	increased immunoglobulin level	J:5579
	increased leukocyte cell number	J:5579
	increased monocyte cell number	J:5579
	small thymus	J:5579
Ptpn6^me/Ptpn6^me (involves: C3H/HeN * C57BL/6J * NFS)	increased autoantibody level	J:30994
	increased IgM level	J:30994
	increased splenocyte proliferation	J:30994
Ptpn6^me/Ptpn6^me (involves: C3HeB/FeJ * C57BL/6)	abnormal microglial cell morphology	J:72655
Ptpn6^me/Ptpn6^me (C3FeLe.B6 a/a-Ptpn6^me/J)	increased microglial cell activation	J:88807
Ptpn6^me/Ptpn6^me (either: (involves: C3H * C57BL/6J) or (involves: C57BL/6J * C57BL/6N))	lung inflammation	J:5999
	thymus atrophy	J:5999
Ptpn9^tm1Dny/Ptpn9^tm1Dny (B6.129-Ptpn9^tm1Dny)	abnormal T cell differentiation	J:118880
Ptpn9^tm1Dny/Ptpn9^tm1Dny (B6.129-Ptpn9^tm1Dny)	decreased T cell proliferation	J:118880
Ptpn11^tm1.1Ics/Ptpn11⁺ (involves: 129S2/SvPas * C57BL/6 * FVB/N)	enlarged spleen	J:216593
Ptpn11^tm1Bgn/Ptpn11⁺ (involves: 129S4/SvJae * C57BL/6J)	enlarged spleen	J:91609
	increased leukocyte cell number	J:91609
	increased lymphocyte cell number	J:91609
	increased neutrophil cell number	J:91609
	myeloid hyperplasia	J:91609
Ptpn11^tm1Ckq/Ptpn11⁺ Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J)	myeloid hyperplasia	J:177285
Ptpn11^tm1Ckq/Ptpn11⁺ Tg(Lck-cre)1Cwi/0 (involves: 129S6/SvEvTac * C57BL/6J)	immune system phenotype	J:177285
	increased lymphoblastic lymphoma incidence	J:177285
Ptpn11^tm1Ckq/Ptpn11⁺ Tg(Mx1-cre)1Cgn/0 (involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * CBA)	arrested B cell differentiation	J:177285
	enlarged spleen	J:177285
	increased leukocyte cell number	J:177285
	increased lymphoblastic lymphoma incidence	J:177285
	increased neutrophil cell number	J:177285
	increased spleen weight	J:177285
	myeloid hyperplasia	J:177285
Ptpn11^tm1Gsf/Ptpn11^tm1Gsf Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA)	increased acute inflammation	J:172422
	increased circulating interleukin-6 level	J:172422
	liver inflammation	J:172422
Ptpn11^tm1Gsf/Ptpn11^tm1Gsf Stat3^tm1Vpo/Stat3^tm1Vpo Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺ (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA)	liver inflammation	J:172422
Ptpn11^tm6Bgn/Ptpn11⁺ Tg(CAG-cre/Esr1)5Amc/0 (involves: 129S6/SvEvTac C57BL/6 * CBA)	abnormal leukopoiesis	J:148430
Ptpn11^tm6Bgn/Ptpn11⁺ Tg(Mx1-cre)1Cgn/0 (involves: 129S6/SvEvTac * C57BL/6 * CBA)	abnormal leukopoiesis	J:148430
	abnormal splenic cell ratio	J:148430
	enlarged spleen	J:148430
	increased granulocyte number	J:148430
	increased leukocyte cell number	J:148430
	increased monocyte cell number	J:148430
	intermingled spleen red and white pulp	J:148430
Ptpn12^tm1Vei/Ptpn12^tm1Vei Tg(Cd4-cre)1Cwi/0 (B6.Cg-Tg(Cd4-cre)1Cwi Ptpn12^tm1Vei)	abnormal cytokine secretion	J:163910
	abnormal T cell physiology	J:163910
	decreased T cell proliferation	J:163910
Ptpn12^tm1Vei/Ptpn12^tm1Vei Tg(Lck-cre)1Cwi/0 (B6.Cg-Ptpn12^tm1Vei Tg(Lck-cre)1Cwi)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:163910
Ptpn13^tm1Gru/Ptpn13^tm1Gru (involves: C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:118426
	abnormal cytokine secretion	J:118426
	decreased susceptibility to bacterial infection	J:118426
Ptpn13^tm1Wjh/Ptpn13^tm1Wjh (involves: 129P2/OlaHsd * C57BL/6)	increased T-helper 2 cell number	J:144351
Ptpn13^tm1Wjh/Ptpn13^tm1Wjh Ptpn3^tm1Pdk/Ptpn3^tm1Pdk Ptpn4^{Gt(OST146128)Lex}/Ptpn4^{Gt(OST146128)Lex} (involves: 129P2/OlaHsd * 129S5/SvEvBrd * C57BL/6)	immune system phenotype	J:144351
Ptpn14^{Gt(RRR484)Byg}/Ptpn14^{Gt(RRR484)Byg} (involves: 129P2/OlaHsd)	lymphatic vessel hyperplasia	J:169186
Ptpn18^em1(IMPC)J/Ptpn18^em1(IMPC)J (C57BL/6NJ-Ptpn18^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
Ptpn22^tm1.1Draw/Ptpn22⁺ (involves: 129 * C57BL/6)	abnormal B cell differentiation	J:201448
	abnormal B cell morphology	J:201448
	abnormal B cell number	J:201448
	abnormal B cell physiology	J:201448
	abnormal T cell morphology	J:201448
	abnormal T cell number	J:201448
	abnormal T cell physiology	J:201448
	abnormal thymus morphology	J:201448
	autoimmune response	J:201448
	decreased B cell apoptosis	J:201448
	decreased follicular B cell number	J:201448
	decreased mature B cell number	J:201448
	enlarged spleen	J:201448
	increased anti-double stranded DNA antibody level	J:201448
	increased B cell number	J:201448
	increased B cell proliferation	J:201448
	increased CD4-positive, alpha-beta memory T cell number	J:201448
	increased double-positive T cell number	J:201448
	increased germinal center B cell number	J:201448
	increased IgG1 level	J:201448
	increased interleukin-2 secretion	J:201448
	increased regulatory T cell number	J:201448
	increased spleen germinal center size	J:201448
	increased T cell proliferation	J:201448
	increased transitional stage T1 B cell number	J:201448
	spleen hyperplasia	J:201448
	thymus hyperplasia	J:201448
Ptpn22^tm1.1Draw/Ptpn22^tm1.1Draw (involves: 129 * C57BL/6)	abnormal B cell activation	J:201448
	abnormal B cell differentiation	J:201448
	abnormal B cell morphology	J:201448
	abnormal B cell physiology	J:201448
	abnormal T cell differentiation	J:201448
	abnormal T cell morphology	J:201448
	abnormal T cell physiology	J:201448
	abnormal thymus morphology	J:201448
	autoimmune response	J:201448
	decreased B cell apoptosis	J:201448
	decreased follicular B cell number	J:201448
	decreased mature B cell number	J:201448
	enlarged spleen	J:201448
	glomerulonephritis	J:201448
	immune system phenotype	J:201448
	increased anti-double stranded DNA antibody level	J:201448
	increased anti-insulin autoantibody level	J:201448
	increased B cell number	J:201448
	increased B cell proliferation	J:201448
	increased double-positive T cell number	J:201448
	increased effector memory CD4-positive, alpha-beta T cell number	J:201448
	increased effector memory CD8-positive, alpha-beta T cell number	J:201448
	increased germinal center B cell number	J:201448
	increased IgE level	J:201448
	increased IgG1 level	J:201448
	increased IgG3 level	J:201448
	increased IgM level	J:201448
	increased inflammatory response	J:201448
	increased interleukin-2 secretion	J:201448
	increased regulatory T cell number	J:201448
	increased spleen germinal center size	J:201448
	increased T cell proliferation	J:201448
	increased transitional stage T1 B cell number	J:201448
	spleen hyperplasia	J:201448
	thymus hyperplasia	J:201448
Ptpn22^tm1.1Kas/Ptpn22^tm1.1Kas (involves: C57BL/6)	abnormal dendritic cell physiology	J:176519
	enlarged spleen	J:176519
	enlarged thymus	J:176519
	immune system phenotype	J:176519
	increased B cell proliferation	J:176519
	increased CD4-positive, alpha-beta T cell number	J:176519
	increased CD8-positive, alpha-beta T cell number	J:176519
	increased dendritic cell number	J:176519
	increased IgG2a level	J:176519
	increased IgG3 level	J:176519
	increased IgM level	J:176519
	increased interleukin-12 secretion	J:176519
	increased spleen germinal center number	J:176519
	increased spleen germinal center size	J:176519
	increased T cell number	J:176519
	increased T cell proliferation	J:176519
Ptpn22^tm1.1Kas/Ptpn22^tm1.1Kas Tg(TcraH-Y,TcrbH-Y)71Vbo/0 (involves: C57BL/6 * C57BL/6J * DBA/2J)	immune system phenotype	J:176519
Ptpn22^tm1.1Kas/Ptpn22^tm1.1Kas Tg(TcraTcrb)425Cbn/0 (involves: BALB/c * C57BL/6)	increased CD4-positive, alpha-beta T cell number	J:176519
	increased T cell proliferation	J:176519
Ptpn22^tm1Achn/Ptpn22^tm1Achn (involves: C57BL/6)	abnormal Peyer's patch germinal center morphology	J:90029
	abnormal T cell physiology	J:90029
	enlarged lymph nodes	J:90029
	enlarged spleen	J:90029
	increased B cell number	J:90029
	increased follicular B cell number	J:90029
	increased IgE level	J:90029
	increased IgG1 level	J:90029
	increased IgG2a level	J:90029
	increased spleen germinal center number	J:90029
Ptpn22^tm2Achn/Ptpn22^tm2Achn (involves: C57BL/6)	abnormal Peyer's patch germinal center morphology	J:90029
	abnormal T cell physiology	J:90029
	enlarged lymph nodes	J:90029
	enlarged spleen	J:90029
	increased B cell number	J:90029
	increased follicular B cell number	J:90029
	increased IgE level	J:90029
	increased IgG1 level	J:90029
	increased IgG2a level	J:90029
	increased spleen germinal center number	J:90029
Ptpn22^tm2Achn/Ptpn22^tm2Achn (B6.Cg-Ptpn22^tm2Achn)	abnormal double-positive T cell morphology	J:147129
	abnormal T cell activation	J:147129
	abnormal T cell subpopulation ratio	J:147129
	abnormal thymocyte activation	J:147129
	enlarged lymph nodes	J:147129
	increased memory T cell number	J:147129
Ptpn22^tm2Achn/Ptpn22^tm2Achn Ptprc^tm1Weis/Ptprc^tm1Weis (B6.Cg-Ptprc^tm1Weis Ptpn22^tm2Achn)	abnormal B cell activation	J:147129
	abnormal double-positive T cell morphology	J:147129
	abnormal follicular B cell physiology	J:147129
	abnormal lymphocyte cell number	J:147129
	abnormal T cell activation	J:147129
	abnormal T cell subpopulation ratio	J:147129
	abnormal thymocyte activation	J:147129
	decreased follicular B cell number	J:147129
	enlarged lymph nodes	J:147129
	glomerulonephritis	J:147129
	increased autoantibody level	J:147129
	increased memory T cell number	J:147129
	increased plasma cell number	J:147129
	increased transitional stage B cell number	J:147129
	liver inflammation	J:147129
	lung inflammation	J:147129
Ptprc^loc/Ptprc^loc (C57BL/6JSfdAnu-Ptprc^loc/AnuApb)	abnormal B cell number	J:104190
	abnormal double-positive T cell morphology	J:104190
	abnormal memory T cell number	J:104190
	abnormal T cell morphology	J:104190
	abnormal T cell selection	J:104190
	abnormal thymocyte activation	J:104190
	arrested T cell differentiation	J:104190
	decreased CD4-positive, alpha-beta T cell number	J:104190
	decreased CD8-positive, alpha-beta T cell number	J:104190
	decreased double-positive T cell number	J:104190
	decreased T cell number	J:104190
Ptprc^ltng/Ptprc^ltng (C57BL/6-Ptprc^ltng)	abnormal T cell differentiation	J:158876
	decreased CD4-positive, alpha-beta T cell number	J:158876
	decreased double-positive T cell number	J:158876
	thymus hypoplasia	J:158876
Ptprc^ltng/Ptprc^tm1Mak (involves: 129/Sv * C57BL/6)	abnormal T cell differentiation	J:158876
	decreased CD4-positive, alpha-beta T cell number	J:158876
	decreased double-positive T cell number	J:158876
	thymus hypoplasia	J:158876
Ptprc^ltng/Ptprc^tm1Mak Tg(TcraTcrb)425Cbn/0 (involves: 129/Sv * BALB/c * C57BL/6)	decreased CD4-positive, alpha-beta T cell number	J:158876
	thymus hypoplasia	J:158876
Ptprc^m1Btlr/Ptprc^m1Btlr (involves: C57BL/6J)	absent T cells	J:152064
Ptprc^m1Smv/Ptprc^m1Smv (involves: C57BL/6J * C57BL/10J)	abnormal CD4-positive T cell differentiation	J:214487
	abnormal CD8-positive, alpha-beta T cell differentiation	J:214487
	abnormal immune system cell morphology	J:214487
	abnormal immune system physiology	J:214487
	CNS inflammation	J:214487
	decreased DN4 thymocyte number	J:214487
	increased DN3 thymocyte number	J:214487
	increased double-negative T cell number	J:214487
	increased susceptibility to Herpesvirales infection	J:214487
Ptprc^m2Btlr/Ptprc^m2Btlr (C57BL/6J-Ptprc^m2Btlr)	abnormal humoral immune response	J:216796
	decreased B-1a cell number	J:216796
	decreased B-2 B cell number	J:216796
	decreased CD4-positive, alpha-beta memory T cell number	J:216796
	decreased CD8-positive, alpha-beta memory T cell number	J:216796
	decreased mature B cell number	J:216796
	decreased memory B cell number	J:216796
	decreased memory T cell number	J:216796
	decreased single-positive T cell number	J:216796
	increased B-1 B cell number	J:216796
	increased B-1b cell number	J:216796
	increased dendritic cell number	J:216796
	increased neutrophil cell number	J:216796
	increased single-positive T cell number	J:216796
Ptprc^m3Btlr/Ptprc^m3Btlr (C57BL/6J-Ptprc^m3Btlr)	decreased B cell number	J:254899
	decreased B-1a cell number	J:254899
	decreased B-2 B cell number	J:254899
	decreased CD8-positive, alpha-beta T cell number	J:254899
	increased B-1b cell number	J:254899
Ptprc^m4Btlr/Ptprc^m4Btlr (C57BL/6J-Ptprc^m4Btlr)	decreased B cell number	J:264808
	decreased CD4-positive, alpha-beta T cell number	J:264808
	decreased CD8-positive, alpha-beta T cell number	J:264808
	decreased CD8-positive, naive alpha-beta T cell number	J:264808
	decreased single-positive T cell number	J:264808
	decreased T cell number	J:264808
	increased B-1 B cell number	J:264808
	increased central memory CD4-positive, alpha-beta T cell number	J:264808
	increased central memory CD8 positive, alpha-beta T cell number	J:264808
	increased effector memory CD4-positive, alpha-beta T cell number	J:264808
	increased effector memory CD8-positive, alpha-beta T cell number	J:264808
Ptprc^M5Btlr/Ptprc^M5Btlr (C57BL/6J-Ptprc^M5Btlr)	increased alpha-beta T cell number	J:265143
Ptprc^M6Btlr/Ptprc^M6Btlr (C57BL/6J-Ptprc^M6Btlr)	decreased B-1a cell number	J:265186
	decreased B-1b cell number	J:265186
	decreased CD8-positive, naive alpha-beta T cell number	J:265186
	increased B-1 B cell number	J:265186
Ptprc^m7Btlr/Ptprc^m7Btlr (C57BL/6J-Ptprc^m7Btlr)	decreased alpha-beta T cell number	J:267486
	decreased B cell number	J:267486
	decreased CD4-positive, alpha-beta T cell number	J:267486
	decreased CD8-positive, alpha-beta T cell number	J:267486
	decreased CD8-positive, naive alpha-beta T cell number	J:267486
	decreased NK T cell number	J:267486
	increased B-1 B cell number	J:267486
	increased central memory CD4-positive, alpha-beta T cell number	J:267486
	increased central memory CD8 positive, alpha-beta T cell number	J:267486
	increased effector memory CD4-positive, alpha-beta T cell number	J:267486
	increased effector memory CD8-positive, alpha-beta T cell number	J:267486
Ptprc^M8Btlr/Ptprc^M8Btlr (C57BL/6J-Ptprc^M8Btlr)	increased B-1 B cell number	J:267487
Ptprc^M8Btlr/Ptprc^M8Btlr (C57BL/6J-Ptprc^M8Btlr)	increased central memory CD8 positive, alpha-beta T cell number	J:267487
Ptprc^M9Btlr/Ptprc^M9Btlr (C57BL/6J-Ptprc^M9Btlr)	abnormal B cell differentiation	J:272745
	abnormal CD8-positive, alpha beta T cell morphology	J:272745
	abnormal lymphocyte morphology	J:272745
	decreased B cell number	J:272745
	decreased NK cell number	J:272745
	increased CD8-positive, alpha-beta T cell number	J:272745
	increased effector memory CD4-positive, alpha-beta T cell number	J:272745
Ptprc^M10Btlr/Ptprc^M10Btlr (C57BL/6J-Ptprc^M10Btlr)	decreased B-1b cell number	J:272777
Ptprc^M10Btlr/Ptprc^M10Btlr (C57BL/6J-Ptprc^M10Btlr)	decreased IgE level	J:272777
Ptprc^M11Btlr/Ptprc^M11Btlr (C57BL/6J-Ptprc^M11Btlr)	abnormal B cell differentiation	J:274863
	abnormal CD8-positive, alpha-beta T cell differentiation	J:274863
	increased B-1 B cell number	J:274863
Ptprc^m12Btlr/Ptprc^m12Btlr (C57BL/6J-Ptprc^m12Btlr)	decreased B cell number	J:274972
	decreased CD4-positive, alpha-beta T cell number	J:274972
	decreased CD8-positive, alpha-beta T cell number	J:274972
	decreased CD8-positive, naive alpha-beta T cell number	J:274972
	decreased central memory CD8 positive, alpha-beta T cell number	J:274972
	decreased effector memory CD4-positive, alpha-beta T cell number	J:274972
	decreased T cell number	J:274972
	increased B-1 B cell number	J:274972
Ptprc^nim/Ptprc^nim (C57BL/6JAnu-Ptprc^nim)	decreased B cell number	J:225105
	decreased leukocyte cell number	J:225105
	decreased T cell number	J:225105
Ptprc^rain/Ptprc^rain (C57BL/6JAnu-Ptprc^rain/AnuApb)	abnormal leukocyte morphology	J:104190
Ptprc^strm/Ptprc^strm (C57BL/6JAnu-Ptprc^strm/AnuApb)	decreased B cell number	J:104190
Ptprc^strm/Ptprc^strm (C57BL/6JAnu-Ptprc^strm/AnuApb)	decreased T cell number	J:104190
Ptprc^tm1Holm/Ptprc^tm1Holm (involves: 129/Sv * C57BL/6)	abnormal B cell number	J:33466
	abnormal lymphopoiesis	J:33466
	abnormal T cell differentiation	J:33466
	decreased CD4-positive, alpha-beta T cell number	J:33466
	decreased CD8-positive, alpha-beta T cell number	J:33466
	decreased double-positive T cell number	J:33466
	decreased T cell number	J:33466
	decreased thymocyte number	J:33466
	increased double-negative T cell number	J:33466
	spleen hyperplasia	J:33466
Ptprc^tm1Holm/Ptprc^tm1Holm Tg(LckF505)2964Rmp/? (involves: 129/Sv C57BL/6 * DBA/2)	increased T cell derived lymphoma incidence	J:64671
	thymus hyperplasia	J:64671
Ptprc^tm1Holm/Ptprc^tm1Holm Tg(LckF505)3073Rmp/? (involves: 129/Sv C57BL/6 * DBA/2)	increased T cell derived lymphoma incidence	J:64671
	thymus hyperplasia	J:64671
Ptprc^tm1Mak/Ptprc^tm1Mak (involves: 129/Sv * C57BL/6)	abnormal response to infection	J:13163
	abnormal T cell subpopulation ratio	J:13163
	arrested T cell differentiation	J:158876
	decreased B cell proliferation	J:13163
	decreased CD4-positive, alpha-beta T cell number	J:13163
	decreased CD8-positive, alpha-beta T cell number	J:13163
	decreased cytotoxic T cell cytolysis	J:13163
	decreased T cell number	J:13163
	decreased T cell proliferation	J:13163
	decreased thymocyte number	J:13163
	increased double-negative T cell number	J:13163
Ptprc^tm1Mak/Ptprc^tm1Mak (involves: 129)	abnormal osteoclast morphology	J:141275
	abnormal osteoclast physiology	J:141275
	decreased mast cell degranulation	J:110782
	decreased susceptibility to type I hypersensitivity reaction	J:110782
Ptprc^tm1Mak/Ptprc^tm1Mak (B6.Cg-Ptprc^tm1Mak)	abnormal CD4-positive, alpha-beta intraepithelial T cell morphology	J:111646
	abnormal intraepithelial T cell morphology	J:111646
	abnormal intraepithelial T cell number	J:111646
	abnormal NK cell physiology	J:109462
	abnormal T cell differentiation	J:111646
	decreased cytotoxic T cell cytolysis	J:111646
	decreased gamma-delta intraepithelial T cell number	J:111646
	increased T cell apoptosis	J:111646
Ptprc^tm1Mak/Ptprc^tm1Mak Ptprj^tm1.2Weis/Ptprj^tm1.2Weis (involves: 129/Sv * 129P2/OlaHsd * BALB/cJ * C57BL/6)	abnormal B cell calcium ion homeostasis	J:131736
	abnormal cytokine secretion	J:131736
	abnormal follicular B cell morphology	J:131736
	abnormal myelopoiesis	J:131736
	decreased B cell number	J:131736
	impaired macrophage phagocytosis	J:131736
Ptprc^tm1Mak/Ptprc^tm1Mak Ptprj^tm1.2Weis/Ptprj^tm1.2Weis (B6.Cg-Ptprc^tm1Mak Ptprj^tm1.2Weis)	abnormal B cell differentiation	J:131736
	abnormal follicular B cell morphology	J:131736
	abnormal myelopoiesis	J:131736
	abnormal spleen morphology	J:131736
	abnormal transitional stage B cell morphology	J:131736
	decreased B cell number	J:131736
	decreased immature B cell number	J:131736
	decreased mature B cell number	J:131736
	liver inflammation	J:131736
	lung inflammation	J:131736
Ptprc^tm1Mak/Ptprc^tm1Mak Tg(TcraTcrb)425Cbn/0 (involves: 129/Sv * BALB/c * C57BL/6)	decreased CD4-positive, alpha-beta T cell number	J:158876
Ptprc^tm1Tyb/Ptprc^tm1Tyb (C.129S2-Ptprc^tm1Tyb)	abnormal positive T cell selection	J:57681
	abnormal T cell differentiation	J:57681
	abnormal T cell physiology	J:57681
	decreased CD4-positive, alpha-beta T cell number	J:57681
	decreased CD8-positive, alpha-beta T cell number	J:57681
	decreased double-positive T cell number	J:57681
	enlarged spleen	J:57681
	immune system phenotype	J:57681
	increased double-negative T cell number	J:57681
	thymus hypoplasia	J:57681
Ptprc^tm1Tyb/Ptprc^tm1Tyb (B6.129S2-Ptprc^tm1Tyb)	abnormal chemokine secretion	J:98190
	abnormal cytokine secretion	J:98190
	abnormal NK cell physiology	J:98190
	increased NK cell number	J:98190
Ptprc^tm1Weis/Ptprc⁺ (involves: 129X1/SvJ * C57BL/6)	increased anti-double stranded DNA antibody level	J:66501
	increased IgG2a level	J:66501
	increased susceptibility to autoimmune disorder	J:66501
Ptprc^tm1Weis/Ptprc^tm1Weis (involves: 129X1/SvJ * C57BL/6)	abnormal B cell activation	J:66501
	abnormal granulocyte differentiation	J:66501
	abnormal immune system organ morphology	J:66501
	abnormal leukocyte cell number	J:66501
	abnormal T cell activation	J:66501
	enlarged lymph nodes	J:66501
	enlarged spleen	J:66501
	glomerulonephritis	J:66501
	increased anti-double stranded DNA antibody level	J:66501
	increased B cell number	J:66501
	increased IgA level	J:66501
	increased IgG2a level	J:66501
	increased plasmacytoid dendritic cell number	J:66501
	increased spleen red pulp amount	J:66501
	increased spleen white pulp amount	J:66501
	increased susceptibility to autoimmune disorder	J:66501
	increased T cell number	J:66501
	lymph node hyperplasia	J:66501
Ptprc^tm1Weis/Ptprc^tm1Weis (B6.129X1-Ptprc^tm1Weis)	abnormal B cell activation	J:147129
	abnormal double-positive T cell morphology	J:147129
	abnormal follicular B cell physiology	J:147129
	abnormal T cell activation	J:147129
	abnormal T cell subpopulation ratio	J:147129
	abnormal thymocyte activation	J:147129
	decreased follicular B cell number	J:147129
	enlarged lymph nodes	J:147129
	immune system phenotype	J:109462
	increased memory T cell number	J:147129
	increased plasma cell number	J:147129
	increased transitional stage B cell number	J:147129
	liver inflammation	J:147129
	lung inflammation	J:147129
Ptprcap^tm1Svn/Ptprcap^tm1Svn (involves: C57BL/6)	enlarged lymph nodes	J:58712
Ptprcap^tm1Svn/Ptprcap^tm1Svn (involves: C57BL/6)	lymphoid hyperplasia	J:58712
Ptprcap^tm1Tho/Ptprcap^tm1Tho (involves: 129X1/SvJ)	immune system phenotype	J:58711
Ptprcap^tm1Tkda/Ptprcap^tm1Tkda (involves: 129X1/SvJ)	abnormal cytotoxic T cell physiology	J:48387
	decreased B cell proliferation	J:48387
	decreased T cell proliferation	J:48387
	immune system phenotype	J:48387
Ptprd^{tm2a(KOMP)Wtsi}/Ptprd^{tm2a(KOMP)Wtsi} (C57BL/6N-Ptprd^{tm2a(KOMP)Wtsi}/Wtsi)	increased leukocyte cell number	J:211773
Ptpre^tm1Ael/Ptpre^tm1Ael (involves: 129S6/SvEvTac * C57BL/6)	abnormal osteoclast differentiation	J:90031
	abnormal osteoclast physiology	J:90031
Ptprf^tm1Wjh/Ptprf^tm1Wjh (involves: 129P2/OlaHsd)	immune system phenotype	J:119456
Ptprj^tm1.2Weis/Ptprj^tm1.2Weis (involves: 129P2/OlaHsd * BALB/cJ * C57BL/6)	abnormal B cell differentiation	J:131736
	abnormal splenic cell ratio	J:131736
	increased B-2 B cell number	J:131736
	increased marginal zone B cell number	J:131736
Ptprn^tm1Aln/Ptprn^tm1Aln (NOD.129S4-Ptprn^tm1Aln)	increased susceptibility to autoimmune diabetes	J:107161
Ptprn^tm1Aln/Ptprn^tm1Aln (NOD.129S4-Ptprn^tm1Aln)	insulitis	J:107161
Ptprz1^{em1(IMPC)Ccpcz}/Ptprz1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Ptprz1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Ptprz1^tm1Mno/Ptprz1^tm1Mno (B6.129-Ptprz1^tm1Mno)	decreased susceptibility to bacterial infection	J:85826
Ptprz1^tm1Schl/Ptprz1^tm1Schl (involves: 129 * Swiss Webster)	increased susceptibility to experimental autoimmune encephalomyelitis	J:79860
Ptrh2^tm1.1Eruo/Ptrh2^tm1.1Eruo (C57BL/6-Ptrh2^tm1.1Eruo)	decreased neutrophil cell number	J:131853
Pts^{tm1b(EUCOMM)Wtsi}/Pts⁺ (C57BL/6N-Pts^{tm1b(EUCOMM)Wtsi}/H)	increased large unstained cell number	J:211773
Pttg1^{tm1b(EUCOMM)Wtsi}/Pttg1^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Pttg1^{tm1b(EUCOMM)Wtsi}/Tcp)	small spleen	J:211773
Pttg1^tm1Sme/Pttg1^tm1Sme (involves: 129S4/SvJae * C57BL/6)	abnormal immune system organ morphology	J:72267
	decreased IgG level	J:72267
	decreased IgM level	J:72267
	decreased immunoglobulin level	J:72267
	decreased spleen weight	J:72267
	increased T cell number	J:72267
	thymus hyperplasia	J:72267
Ptx3^tm1Mant/Ptx3^tm1Mant (either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6))	abnormal dendritic cell physiology	J:85080
	abnormal macrophage physiology	J:85080
	abnormal professional antigen presenting cell physiology	J:85080
	abnormal T-helper 1 physiology	J:85080
	impaired macrophage phagocytosis	J:85080
	increased susceptibility to bacterial infection	J:85080
	increased susceptibility to fungal infection	J:85080
	lung inflammation	J:85080
Ptx3^tm1Zuk/Ptx3^tm1Zuk (involves: 129S7/SvEvBrd * C57BL/6J)	increased susceptibility to Coronaviridae infection	J:188421
Puf60^tm1.1Kmtsu/Puf60⁺ Trp53^tm1Sia/Trp53^tm1Sia (involves: C57BL/6NCrlj * C57BL/6NCrSlc * CBA/JNCrlj)	increased leukocyte cell number	J:233347
	increased spleen weight	J:233347
	increased T cell derived lymphoma incidence	J:233347
	increased thymus weight	J:233347
Pura^tm1Kkh/Pura^tm1Kkh (involves: 129)	abnormal spleen morphology	J:85759
	abnormal thymus morphology	J:85759
	decreased spleen weight	J:85759
	small spleen	J:85759
Pvr^tm1Gbn/Pvr^tm1Gbn (either: (involves: 129S2/SvPas) or (involves: 129S2/SvPas * BALB/c))	abnormal response to infection	J:123540
	decreased IgA level	J:123540
	decreased IgG1 level	J:123540
	decreased IgG2a level	J:123540
	decreased IgG2b level	J:123540
	decreased IgG level	J:123540
Pvrig^em1(IMPC)Mbp/Pvrig^em1(IMPC)Mbp (C57BL/6N-Pvrig^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
Pvrig^tm1.2Sgng/Pvrig^tm1.2Sgng (B6(Cg)-Pvrig^tm1.1Sgng)	abnormal CD8-positive, alpha-beta T cell physiology	J:324171
Pvrig^tm1.2Sgng/Pvrig^tm1.2Sgng (B6(Cg)-Pvrig^tm1.1Sgng)	abnormal T cell physiology	J:324171
Pwwp3a^em1(IMPC)Tcp/Pwwp3a^em1(IMPC)Tcp (C57BL/6NCrl-Pwwp3a^em1(IMPC)Tcp/Tcp)	small thymus	J:211773
Pxdn^mhdakta048/Pxdn^mhdakta048 (involves: C3HeB/FeJ * C57BL/6J)	eye inflammation	J:213336
Pycard^tm1Ayaz/Pycard^tm1Ayaz Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6J)	decreased interleukin-1 alpha secretion	J:191239
	decreased interleukin-1 beta secretion	J:191239
	decreased interleukin-6 secretion	J:191239
	decreased tumor necrosis factor secretion	J:191239
Pycard^tm1Flv/Pycard^tm1Flv (involves: 129S5/SvEvBrd * C57BL/6)	abnormal macrophage physiology	J:113333
	decreased circulating interleukin-1 beta level	J:113333
	decreased circulating interleukin-18 level	J:113333, J:158969
	decreased interleukin-1 alpha secretion	J:113333
	decreased interleukin-1 beta secretion	J:113333
	decreased NK cell number	J:158969
	decreased susceptibility to endotoxin shock	J:113333
	decreased susceptibility to type IV hypersensitivity reaction	J:113333
	increased susceptibility to Herpesvirales infection	J:158969
Pycard^tm1Flv/Pycard^tm1Flv (B6.129S5-Pycard^tm1Flv)	enlarged Peyer's patches	J:173245
	increased IgA level	J:173245
	increased IgG2c level	J:173245
	increased susceptibility to induced colitis	J:173245
Pycard^tm1Flv/Pycard^tm1Flv Slc11a1^s/Slc11a1^s (B6.129S5-Pycard^tm1Flv)	increased susceptibility to bacterial infection	J:124378
Pycard^tm1Nnz/Pycard^tm1Nnz (involves: 129 * C57BL/6)	decreased interleukin-1 beta secretion	J:129871
Pycard^tm1Nnz/Pycard^tm1Nnz (involves: 129 * C57BL/6)	decreased interleukin-18 secretion	J:129871
Pycard^tm1Tno/Pycard^tm1Tno (involves: 129S4/SvJae * C57BL/6)	decreased interferon-gamma secretion	J:100807
	decreased interleukin-1 beta secretion	J:100807
	decreased interleukin-18 secretion	J:100807
	decreased susceptibility to endotoxin shock	J:100807
Pycard^tm1Vmd/Pycard^tm1Vmd (involves: 129S1/Sv * 129X1/SvJ * C57BL/6N)	decreased inflammatory response	J:91292
	decreased interleukin-1 alpha secretion	J:91292
	decreased interleukin-1 beta secretion	J:91292
	decreased interleukin-18 secretion	J:91292
Pycard^tm1Vmd/Pycard^tm1Vmd (involves: 129S1/Sv * 129X1/SvJ)	abnormal response to infection	J:106976
	decreased interleukin-1 beta secretion	J:124226, J:106976
	decreased interleukin-18 secretion	J:106976
Pycard^tm1Vmd/Pycard^tm1Vmd (B6.129-Pycard^tm1Vmd)	abnormal macrophage physiology	J:160545
	decreased circulating interleukin-1 beta level	J:193522
	decreased circulating interleukin-18 level	J:193522
	decreased interleukin-1 beta secretion	J:193522, J:160545
	decreased susceptibility to endotoxin shock	J:193522
	increased interferon-beta secretion	J:160545
	increased tumor necrosis factor secretion	J:160545
Pycr2^m1J/Pycr2^m1J (involves: C3H/HeJ * C57BL/6J)	decreased basophil cell number	J:308336
	decreased leukocyte cell number	J:308336
	decreased lymphocyte cell number	J:308336
Pycr2^{tm1a(EUCOMM)Wtsi}/Pycr2^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Pycr2^{tm1a(EUCOMM)Wtsi}/Wtsi)	decreased Ly6C low monocyte number	J:211773
	decreased monocyte cell number	J:211773
Pygl^{tm1a(KOMP)Wtsi}/Pygl^{tm1a(KOMP)Wtsi} (C57BL/6N-Pygl^{tm1a(KOMP)Wtsi})	liver inflammation	J:284765
Pymr^129X1/SvJMs/Pymr^NC/JicJcl (involves: 129X1/SvJMs * NC/JicJcl)	decreased susceptibility to parasitic infection	J:92924
Pymr^NC/JicJcl/Pymr^NC/JicJcl (involves: 129X1/SvJMs * NC/JicJcl)	increased susceptibility to parasitic infection	J:92924
Pzp^tm1Vln/Pzp^tm1Vln (involves: 129P2/OlaHsd * C57BL)	increased susceptibility to induced pancreatitis	J:28328
Pzp^tm1Vln/Pzp^tm1Vln (involves: 129P2/OlaHsd * C57BL)	pancreas inflammation	J:28328
Pzp^tm1Vln/Pzp^tm1Vln (B.129P2-Pzp^tm1Vln)	abnormal cytokine level	J:57485
Pzp^tm1Vln/Pzp^tm1Vln (B.129P2-Pzp^tm1Vln)	liver inflammation	J:57485
Pzp^tm1Vln/Pzp^tm1Vln (B6.129P2-Pzp^tm1Vln)	abnormal cytokine secretion	J:113532
Qpct^tm1.1Gne/Qpct^tm1.1Gne (C57BL/6N-Qpct^tm1.1Gne)	immune system phenotype	J:324112
Qpct^tm1.1Gne/Qpct^tm1.1Gne Qpctl^tm1.1Gne/Qpctl^tm1.1Gne (C57BL/6N-Qpctl^tm1.1Gne Qpct^tm1.1Gne)	decreased monocyte cell number	J:324112
Qpctl^tm1.1Gne/Qpctl^tm1.1Gne (C57BL/6N-Qpctl^tm1.1Gne)	decreased monocyte cell number	J:324112
Qpctl^tm1.1Gne/Qpctl^tm1.1Gne (C57BL/6N-Qpctl^tm1.1Gne)	increased monocyte cell number	J:324112
Qprt^{Gt(OST337946)Lex}/Qprt^{Gt(OST337946)Lex} (involves: 129S5/SvEvBrd * C57BL/6J)	abnormal cytokine level	J:282516
	abnormal macrophage morphology	J:282516
	abnormal macrophage physiology	J:282516
Qrich1^b2b2404Clo/Qrich1^b2b2404Clo (C57BL/6J-Qrich1^b2b2404Clo)	thymus hypoplasia	J:175213
Qsox1^b2b2673Clo/Qsox1^b2b2673Clo (C57BL/6J-Qsox1^b2b2673Clo)	spleen hypoplasia	J:175213
Rab2a^em2(IMPC)Tcp/Rab2a⁺ (C57BL/6NCrl-Rab2a^em2(IMPC)Tcp/Tcp)	increased spleen weight	J:211773
Rab6b^{Gt(OST68543)Lex}/Rab6b^{Gt(OST68543)Lex} (involves: 129S5/SvEvBrd * C57BL/6J)	immune system phenotype	J:103485
Rab7^tm1.1Ale/Rab7^tm1.1Ale Tg(Cd4-cre)1Cwi/? (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)	abnormal T cell morphology	J:211733
	abnormal T cell physiology	J:211733
	abnormal T cell subpopulation ratio	J:211733
	decreased CD4-positive, alpha-beta T cell number	J:211733
	decreased CD8-positive, alpha-beta T cell number	J:211733
	decreased T cell number	J:211733
	decreased T cell proliferation	J:211733
Rab7b^tm1Ciphe/Rab7b^tm1Ciphe Tg(Itgax-cre)1-1Reiz/0 (involves: C57BL/6N * CBA)	abnormal dendritic cell migration	J:321707
Rab11a^tm1.1Ngao/Rab11a^tm1.1Ngao Tg(Vil1-cre)997Gum/0 (involves: 129S4/SvJae * C57BL/6J * SJL)	abnormal cytokine secretion	J:215917
	increased cytokine level	J:278932
	increased interleukin-1 beta secretion	J:215917
	increased interleukin-6 secretion	J:215917
	intestinal inflammation	J:215917
Rab11a^tm1.1Ngao/Rab11a^tm1.1Ngao Tg(Vil1-cre/ERT2)23Syr/0 (involves: 129S4/SvJae * C57BL/6 * DBA/2)	increased interleukin-6 secretion	J:215917
Rab11fip2^em1(IMPC)Mbp/Rab11fip2^em1(IMPC)Mbp (C57BL/6NCrl-Rab11fip2^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
Rab13^tm1.1Ktg/Rab13^tm1.1Ktg (involves: C57BL/6)	abnormal leukocyte adhesion	J:259093
	abnormal T cell physiology	J:259093
	decreased lymphocyte cell number	J:259093
	decreased lymphocyte chemotaxis	J:259093
	immune system phenotype	J:259093
	impaired leukocyte migration	J:259093
	lymphoid hypoplasia	J:259093
	small inguinal lymph nodes	J:259093
	small spleen	J:259093
Rab19^{tm1b(EUCOMM)Hmgu}/Rab19^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Rab19^{tm1b(EUCOMM)Hmgu}/Ics)	decreased large unstained cell number	J:211773
	increased eosinophil cell number	J:211773
Rab20^{tm1a(EUCOMM)Hmgu}/Rab20^{tm1a(EUCOMM)Hmgu} (involves: C57BL/6N)	abnormal macrophage physiology	J:243883
Rab26^em1Guwa/Rab26^em1Guwa (Not Specified)	increased susceptibility to endotoxin shock	J:306921
Rab27a^ash/Rab27a^ash (involves: C3H/HeDiSn)	abnormal NK cell degranulation	J:111253
	decreased cytotoxic T cell cytolysis	J:111253, J:67600
	immune system phenotype	J:111253
	impaired natural killer cell mediated cytotoxicity	J:111253
Rab27a^ash/Rab27a^ash (B6.C3Sn-Rab27a^ash)	abnormal cytotoxic T cell physiology	J:193137
	decreased cytotoxic T cell cytolysis	J:193137
	decreased leukocyte cell number	J:193137
	decreased neutrophil cell number	J:193137
	decreased NK cell degranulation	J:193137
	increased circulating interferon-gamma level	J:193137
	increased circulating interleukin-1 beta level	J:193137
	increased circulating interleukin-6 level	J:193137
	increased circulating tumor necrosis factor level	J:193137
	increased susceptibility to Riboviria infection	J:193137
Rab27a^cct/Rab27a^cct (C57BL/6-Rab27a^cct)	abnormal neutrophil physiology	J:114299
Rab27a^cct/Rab27a^cct (C57BL/6-Rab27a^cct)	immune system phenotype	J:114299
Rab32^{tm1c(KOMP)Wtsi}/Rab32^{tm1c(KOMP)Wtsi} Tg(Itgax-cre)1-1Reiz/0 (involves: 129S4/SvJaeSor * C57BL/6 * C57BL/6N * CBA)	abnormal cytokine secretion	J:267497
	increased neutrophil cell number	J:267497
	increased susceptibility to bacterial infection	J:231298, J:267497
	increased susceptibility to colitis induced morbidity/mortality	J:267497
	increased susceptibility to induced colitis	J:267497
Rab33b^em1Rmr/Rab33b⁺ (involves: C57BL/6)	abnormal osteoclast differentiation	J:338833
	abnormal osteoclast morphology	J:338833
	increased osteoclast cell number	J:338833
Rab33b^em1Rmr/Rab33b^em1Rmr (involves: C57BL/6)	abnormal osteoclast morphology	J:338833
Rab33b^em1Rmr/Rab33b^em1Rmr (involves: C57BL/6)	increased osteoclast cell number	J:338833
Rab39b^em1(IMPC)Tcp/Y (C57BL/6NCrl-Rab39b^em1(IMPC)Tcp/Tcp)	decreased spleen weight	J:211773
Rab43^tm1.2Kmm/Rab43^tm1.2Kmm (B6.129S(C)-Rab43^tm1.2Kmm)	abnormal dendritic cell antigen presentation	J:101977
Rab44^em1Rbrc/Rab44^em1Rbrc (Not Specified)	abnormal mast cell physiology	J:304506
Rab44^em1Rbrc/Rab44^em1Rbrc (Not Specified)	increased susceptibility to type I hypersensitivity reaction	J:304506
Rabgap1^{tm1b(EUCOMM)Hmgu}/Rabgap1^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Rabgap1^{tm1b(EUCOMM)Hmgu}/Ieg)	decreased effector memory T-helper cell number	J:211773
	enlarged spleen	J:211773
	increased CD8-positive, naive alpha-beta T cell number	J:211773
	small spleen	J:211773
Rabgef1^tm1Glli/Rabgef1^tm1Glli (either: (involves: 129P2/OlaHsd * 129S/SvEv) or (involves: 129P2/OlaHsd * C57BL/6))	abnormal inflammatory response	J:91790
	abnormal mast cell morphology	J:91790
	chronic inflammation	J:91790
	cutaneous mastocytosis	J:91790
	increased IgE level	J:91790
	increased interleukin-6 secretion	J:91790
	increased tumor necrosis factor secretion	J:91790
Rabgef1^tm2Glli/Rabgef1^tm2Glli (WBB6F1)	increased interleukin-6 secretion	J:91790
Rabgef1^tm2Glli/Rabgef1^tm2Glli (WBB6F1)	increased tumor necrosis factor secretion	J:91790
Rabggta^gm/Rabggta⁺ (C57BL/6J-Rabggta^gm)	decreased cytotoxic T cell cytolysis	J:67600
Rabggta^gm/Rabggta^gm (C57BL/6J-Rabggta^gm)	decreased cytotoxic T cell cytolysis	J:67600
Rabggta^{tm1.1(KOMP)Vlcg}/Rabggta⁺ (C57BL/6N-Rabggta^{tm1.1(KOMP)Vlcg}/Nju)	decreased neutrophil cell number	J:211773
Rabl3^xm/Rabl3^em1Btlr (C57BL/6J-Rabl3^xm Rabl3^em1Btlr)	decreased leukocyte cell number	J:287198
	decreased lymphocyte cell number	J:287198
	spleen hypoplasia	J:287198
	thymus hypoplasia	J:287198
Rabl3^xm/Rabl3^xm (C57BL/6J-Rabl3^xm)	abnormal T cell morphology	J:287198
Rabl3^xm/Rabl3^xm (C57BL/6J-Rabl3^xm)	abnormal T cell number	J:287198
Rac1^em1(IMPC)Mbp/Rac1⁺ (C57BL/6N-Rac1^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Rac1^tm1Djk/Rac1^tm1.1Djk Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)	decreased acute inflammation	J:83457
	decreased leukocyte cell number	J:83457
	decreased neutrophil cell number	J:83457
	impaired neutrophil chemotaxis	J:83457
	impaired neutrophil recruitment	J:83457
Rac2^em1Shl/Rac2⁺ (involves: C57BL/6)	abnormal neutrophil morphology	J:276213
	decreased alpha-beta T cell number	J:276213
	decreased CD4-positive, alpha-beta T cell number	J:276213
	decreased CD8-positive, alpha-beta T cell number	J:276213
	decreased leukocyte cell number	J:276213
	decreased lymphocyte cell number	J:276213
	decreased T cell number	J:276213
	increased neutrophil cell number	J:276213
Rac2^m1Btlr/Rac2⁺ (C57BL/6J-Rac2^m1Btlr)	decreased IgM level	J:221478
Rac2^m1Btlr/Rac2⁺ (C57BL/6J-Rac2^m1Btlr)	impaired humoral immune response	J:221478
Rac2^m1Btlr/Rac2^m1Btlr (C57BL/6J-Rac2^m1Btlr)	decreased IgM level	J:221478
Rac2^m1Btlr/Rac2^m1Btlr (C57BL/6J-Rac2^m1Btlr)	impaired humoral immune response	J:221478
Rac2^M2Btlr/Rac2⁺ (C57BL/6J-Rac2^M2Btlr)	decreased B-1 B cell number	J:231801
	decreased B-1a cell number	J:231801
	increased B-1b cell number	J:231801
Rac2^M2Btlr/Rac2^M2Btlr (C57BL/6J-Rac2^M2Btlr)	decreased B-1 B cell number	J:231801
	decreased B-1a cell number	J:231801
	increased B-1b cell number	J:231801
Rac2^m3Btlr/Rac2⁺ (C57BL/6J-Rac2^m3Btlr)	decreased B-1a cell number	J:236680
Rac2^m3Btlr/Rac2⁺ (C57BL/6J-Rac2^m3Btlr)	increased B-1 B cell number	J:236680
Rac2^m3Btlr/Rac2^m3Btlr (C57BL/6J-Rac2^m3Btlr)	decreased B cell number	J:236680
	decreased B-1a cell number	J:236680
	decreased IgM level	J:236680
	decreased response to antigen	J:236680
	increased B-1b cell number	J:236680
	increased neutrophil cell number	J:236680
Rac2^M4Btlr/Rac2⁺ (C57BL/6J-Rac2^M4Btlr)	abnormal cytotoxic T cell physiology	J:255273
	decreased alpha-beta T cell number	J:255273
	decreased CD4-positive, alpha-beta T cell number	J:255273
	decreased CD8-positive, alpha-beta T cell number	J:255273
	decreased CD8-positive, naive alpha-beta T cell number	J:255273
	decreased IgG level	J:255273
	decreased IgM level	J:255273
	impaired humoral immune response	J:255273
	impaired natural killer cell mediated cytotoxicity	J:255273
	increased alpha-beta T cell number	J:255273
	increased CD8-positive, alpha-beta T cell number	J:255273
	increased central memory CD8 positive, alpha-beta T cell number	J:255273
	increased effector memory CD4-positive, alpha-beta T cell number	J:255273
	increased effector memory CD8-positive, alpha-beta T cell number	J:255273
	increased IgM level	J:255273
Rac2^M4Btlr/Rac2^M4Btlr (C57BL/6J-Rac2^M4Btlr)	abnormal cytotoxic T cell physiology	J:255273
	decreased alpha-beta T cell number	J:255273
	decreased CD4-positive, alpha-beta T cell number	J:255273
	decreased CD8-positive, alpha-beta T cell number	J:255273
	decreased CD8-positive, naive alpha-beta T cell number	J:255273
	decreased IgE level	J:255273
	decreased IgG level	J:255273
	decreased IgM level	J:255273
	impaired humoral immune response	J:255273
	impaired natural killer cell mediated cytotoxicity	J:255273
	increased alpha-beta T cell number	J:255273
	increased CD8-positive, alpha-beta T cell number	J:255273
	increased central memory CD4-positive, alpha-beta T cell number	J:255273
	increased central memory CD8 positive, alpha-beta T cell number	J:255273
	increased effector memory CD4-positive, alpha-beta T cell number	J:255273
	increased effector memory CD8-positive, alpha-beta T cell number	J:255273
Rac2^M5Btlr/Rac2⁺ (C57BL/6J-Rac2^M5Btlr)	increased CD8-positive, alpha-beta T cell number	J:255283
Rac2^M5Btlr/Rac2^M5Btlr (C57BL/6J-Rac2^M5Btlr)	decreased B-1a cell number	J:255283
	increased B-1b cell number	J:255283
	increased CD8-positive, alpha-beta T cell number	J:255283
Rac2^tm1Mddw/Rac2^tm1Mddw (involves: 129S/SvEv * C57BL/6)	abnormal granulocyte differentiation	J:53362
	abnormal neutrophil physiology	J:53362
	decreased leukocyte cell number	J:53362
	decreased neutrophil cell number	J:53362
	decreased T cell proliferation	J:119437
	impaired neutrophil chemotaxis	J:53362
	increased leukocyte cell number	J:53362
	increased neutrophil cell number	J:53362
	increased susceptibility to bacterial infection	J:53362
Rac2^tm1Mddw/Rac2^tm1Mddw (involves: 129S/SvEv)	abnormal neutrophil physiology	J:131305
Rac2^tm1Mddw/Rac2^tm1Mddw (B6.129S-Rac2^tm1Mddw)	abnormal neutrophil physiology	J:83457
Rac2^tm1Mddw/Rac2^tm1Mddw Tg(TcrAND)53Hed/0 (involves: 129S/SvEv * C57BL/6 * SJL)	abnormal T cell activation	J:119437
	decreased circulating interleukin-2 level	J:119437
	decreased T cell proliferation	J:119437
Racgap1^tm1Mahi/Racgap1^tm1Mahi Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA)	abnormal B cell differentiation	J:137760
	abnormal myelopoiesis	J:137760
	decreased pro-B cell number	J:137760
	decreased transitional stage B cell number	J:137760
Rad1^tm1.1Jcbs/Rad1^tm1.1Jcbs (involves: 129P2/OlaHsd * 129S4/SvJaeSor)	immune system phenotype	J:169551
Rad21^tm1.1Mmk/Rad21^tm1.1Mmk Tg(Cd4-cre)1Cwi/0 (involves: 129 * C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:175827
	abnormal CD4-positive, alpha-beta T cell physiology	J:175827
	abnormal T cell differentiation	J:175827
	decreased CD4-positive, alpha-beta T cell number	J:175827
	decreased CD8-positive, alpha-beta T cell number	J:175827
	decreased double-positive T cell number	J:175827
Rad23b^tm1Gvh/Rad23b^tm1Gvh (involves: 129P2/OlaHsd * C57BL/6)	blepharitis	J:74288
	conjunctivitis	J:74288
Rad50^tm1Flv/Rad50^tm1Flv (involves: 129S6/SvEvTac * C57BL/6)	abnormal T-helper 2 physiology	J:94870
	decreased interleukin-4 secretion	J:94870
	decreased interleukin-5 secretion	J:94870
	decreased interleukin-13 secretion	J:94870
Rad50^tm2.1Flv/Rad50^tm2.1Flv (B6.129S6-Rad50^tm2.1Flv)	decreased interleukin-4 secretion	J:196154
	decreased interleukin-5 secretion	J:196154
	decreased interleukin-13 secretion	J:196154
Rad50^tm2.1Flv/Rad50^tm2.2Flv Tg(Cd4-cre)1Cwi/0 (involves: 129S6/SvEvTac * C57BL/6 * DBA/2)	abnormal CD4-positive, alpha beta T cell morphology	J:165055
	abnormal T-helper 1 physiology	J:165055
	abnormal T-helper 2 physiology	J:165055
	decreased IgE level	J:165055
	decreased inflammatory response	J:165055
	decreased interferon-gamma secretion	J:165055
	decreased interleukin-4 secretion	J:165055
	decreased interleukin-5 secretion	J:165055
	decreased interleukin-13 secretion	J:165055
	immune system phenotype	J:165055
Rad50^tm2Jpt/Rad50^tm2Jpt (either: (involves: 129S6/SvEvTac * 129S7/SvEvBrd) or (involves: 129S7/SvEvBrd * C57BL/6))	abnormal immune system cell morphology	J:78820
	abnormal immune system organ morphology	J:78820
	abnormal spleen morphology	J:78820
	abnormal thymus morphology	J:78820
	decreased B cell number	J:78820
	decreased immature B cell number	J:78820
	decreased pre-B cell number	J:78820
	decreased T cell number	J:78820
	increased late pro-B cell number	J:78820
	increased macrophage cell number	J:78820
	increased T cell derived lymphoma incidence	J:78820
	spleen hyperplasia	J:78820
Rad50^tm2Jpt/Rad50^tm2Jpt (involves: 129S7/SvEvBrd * C57BL/6)	decreased double-negative T cell number	J:103922
	decreased macrophage cell number	J:103922
	decreased pro-B cell number	J:103922
Rad50^tm2Jpt/Rad50^tm2Jpt Smc1a^tm1Mbk/Smc1a^tm1Mbk (involves: 129S1/Sv * 129S7/SvEvBrd * C57BL/6)	abnormal pro-B cell morphology	J:103922
	decreased double-negative T cell number	J:103922
	decreased macrophage cell number	J:103922
Rad50^tm2Jpt/Rad50^tm2Jpt Trp53^tm1Tyj/Trp53^tm1Tyj (involves: 129S2/SvPas * 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6)	immune system phenotype	J:78820
	increased T cell derived lymphoma incidence	J:78820
Rad50^tm3.1Flv/Rad50^tm3.1Flv (B6.129S6-Rad50^tm3.1Flv)	decreased interleukin-4 secretion	J:196154
	decreased interleukin-5 secretion	J:196154
	decreased interleukin-13 secretion	J:196154
Rad50^tm4.1Flv/Rad50^tm4.1Flv (B6.129S6-Rad50^tm4.1Flv)	decreased interleukin-5 secretion	J:196154
	decreased interleukin-13 secretion	J:196154
	increased interleukin-4 secretion	J:196154
	increased interleukin-5 secretion	J:196154
	increased interleukin-13 secretion	J:196154
Rad52^tm1Aps/Rad52^tm1Aps (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:50357
Rad54l^tm1Jhjh/Rad54l^tm1Jhjh (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:39642
Rad54l^tm1Jhjh/Rad54l^tm1Jhjh (involves: 129P2/OlaHsd)	immune system phenotype	J:47993
Radil^em1(IMPC)Tcp/Radil^em1(IMPC)Tcp (C57BL/6NCrl-Radil^em1(IMPC)Tcp/Tcp)	abnormal spleen morphology	J:211773
Raet1d^em1Dhr/Raet1d^em1Dhr Raet1e^em1Dhr/Raet1e^em1Dhr (involves: C57BL/6)	increased natural killer cell mediated cytotoxicity	J:221188
Raf1^tm1.1Bgn/Raf1⁺ (involves: 129S6/SvEvTac * C57BL/6NCr)	enlarged spleen	J:172034
	increased leukocyte cell number	J:172034
	increased monocyte cell number	J:172034
	increased neutrophil cell number	J:172034
Rag1/Rag2^tm1Mnz/Rag1/Rag2^tm1Mnz (involves: 129P2/OlaHsd * C57BL/6)	abnormal double-negative T cell morphology	J:90487
	abnormal double-positive T cell morphology	J:90487
	abnormal T cell morphology	J:90487
	decreased T cell number	J:90487
Rag1/Rag2^tm1Mnz/Rag1/Rag2^tm1Mnz (involves: 129P2/OlaHsd * C57BL/6)	abnormal double-negative T cell morphology	J:90487
	abnormal double-positive T cell morphology	J:90487
	abnormal T cell morphology	J:90487
	decreased T cell number	J:90487
Rag1^coln/Rag1^coln (C57BL/6JAnu-Rag1^coln/AnuApb)	absent B cells	J:104190
Rag1^coln/Rag1^coln (C57BL/6JAnu-Rag1^coln/AnuApb)	absent T cells	J:104190
Rag1^em2Mvw/Rag1^em2Mvw (A/J-Rag1^em2Mvw/MvwJ)	absent B cells	J:332675
	absent T cells	J:332675
	arrested B cell differentiation	J:332675
	arrested T cell differentiation	J:332675
Rag1^em3Mvw/Rag1^em3Mvw (129S1/SvImJ-Rag1^em3Mvw/MvwJ)	absent B cells	J:332675
	absent T cells	J:332675
	arrested B cell differentiation	J:332675
	arrested T cell differentiation	J:332675
Rag1^m1Anu/Rag1^m1Anu (C57BL/6NCrl-Rag1^m1Anu/Anu)	decreased lymphocyte cell number	J:104190
Rag1^m1Btlr/Rag1^m1Btlr (C57BL/6J-Rag1^m1Btlr)	absent late pro-B cells	J:150635
	decreased CD4-positive, alpha-beta T cell number	J:150635
	decreased CD8-positive, alpha-beta T cell number	J:150635
Rag1^m2Btlr/Rag1^m2Btlr (involves: C57BL/6J)	abnormal class switch recombination	J:185495
	decreased B cell number	J:185495
	decreased IgG level	J:185495
	decreased IgM level	J:185495
	decreased T cell number	J:185495
Rag1^m3Btlr/Rag1^m3Btlr (C57BL/6J-Rag1^m3Btlr)	increased central memory CD8 positive, alpha-beta T cell number	J:272858
Rag1^m4Btlr/Rag1^m4Btlr (C57BL/6J-Rag1^m4Btlr)	abnormal CD8-positive, alpha-beta T cell differentiation	J:272094
	abnormal T cell differentiation	J:272094
	decreased B cell number	J:272094
	decreased CD8-positive, naive alpha-beta T cell number	J:272094
	increased alpha-beta T cell number	J:272094
	increased CD8-positive, alpha-beta T cell number	J:272094
	increased central memory CD8 positive, alpha-beta T cell number	J:272094
Rag1^tm1(cre)Thr/? Shcbp1^{tm1c(EUCOMM)Wtsi}/Shcbp1^{tm1c(EUCOMM)Wtsi} (involves: C57BL/6N)	immune system phenotype	J:212898
Rag1^tm1(cre)Thr/Rag1^tm1(cre)Thr (Not Specified)	abnormal lymphopoiesis	J:86869
Rag1^tm1(cre)Thr/Rag1^tm1(cre)Thr (Not Specified)	absent lymphocyte	J:86869
Rag1^tm1(GFP)Imku/? Zfp335^blt/Zfp335^blt (involves: C57BL/6 * CBA)	abnormal CD4-positive T cell differentiation	J:214793
Rag1^tm1(GFP)Imku/Rag1^tm1(GFP)Imku (involves: C57BL/6 * CBA)	abnormal immunoglobulin V(D)J recombination	J:79416
Rag1^tm1.1Sadu/Rag1^tm1.1Sadu (involves: BALB/c)	arrested B cell differentiation	J:155473
Rag1^tm1.1Sadu/Rag1^tm1.1Sadu Trdc^tm1Mal/Trdc^tm1Mal Gt(ROSA)26Sor^{tm2(cre/ERT2)Brn}/Gt(ROSA)26Sor⁺ (involves: 129P2/OlaHsd * BALB/c * C57BL/6)	absent gamma-delta T cells	J:187400
	decreased gamma-delta T cell number	J:187400
	increased gamma-delta T cell number	J:187400
	small thymus	J:187400
Rag1^tm1Bal/Rag1^tm1Bal Tg(TcraTcrb)1100Mjb/? (involves: 129S4/SvJae * C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:133645
	decreased CD4-positive, alpha-beta T cell number	J:133645
	increased CD8-positive, alpha-beta T cell number	J:133645
Rag1^tm1Bal/Rag1^tm1Bal Tnfrsf1a^tm1.1Gkl/Tnfrsf1a^tm1.1Gkl (involves: 129/Sv * C57BL/6)	liver inflammation	J:92470
Rag1^tm1Bal/Rag1^tm1Bal Vav1^tm2Tyb/Vav1^tm2Tyb (involves: 129S4/SvJae * 129S8/SvEv)	arrested T cell differentiation	J:113270
Rag1^tm1Bal/Rag1^tm1Bal Vav1^tm2Tyb/Vav1^tm2Tyb Tg(TcrAND)53Hed/0 (involves: 129S4/SvJae * 129S8/SvEv * C57BL/6 * SJL)	decreased CD4-positive, alpha-beta T cell number	J:113270
Rag1^tm1Fwa/Rag1^tm1Fwa (involves: 129)	abnormal B cell differentiation	J:86464
	abnormal T cell differentiation	J:86464
	decreased B cell number	J:86464
	increased double-negative T cell number	J:86464
	thymus hypoplasia	J:86464
Rag1^tm1Jsek/Rag1⁺ (involves: 129S6/SvEvTac)	abnormal B cell differentiation	J:146912
	abnormal immunoglobulin heavy chain V(D)J recombination	J:146912
	abnormal T cell differentiation	J:146912
	abnormal T cell receptor beta chain V(D)J recombination	J:146912
	decreased double-positive T cell number	J:146912
Rag1^tm1Jsek/Rag1^tm1Jsek (involves: 129S6/SvEvTac)	abnormal immunoglobulin heavy chain V(D)J recombination	J:146912
	abnormal immunoglobulin level	J:146912
	abnormal lymphopoiesis	J:146912
	abnormal T cell receptor beta chain V(D)J recombination	J:146912
	abnormal T cell receptor V(D)J recombination	J:146912
	absent immature B cells	J:146912
	absent mature B cells	J:146912
	arrested B cell differentiation	J:146912
	arrested T cell differentiation	J:146912
	decreased CD4-positive, alpha-beta T cell number	J:146912
	decreased CD8-positive, alpha-beta T cell number	J:146912
	decreased double-positive T cell number	J:146912
	decreased gamma-delta T cell number	J:146912
	increased double-negative T cell number	J:146912
	increased pro-B cell number	J:146912
	thymus hypoplasia	J:146912
Rag1^tm1Jsek/Rag1^tm1Jsek Trp53^tm1Tyj/Trp53^tm1Tyj (involves: 129S2/SvPas * 129S6/SvEvTac)	increased T cell derived lymphoma incidence	J:146912
Rag1^tm1Mom/Rag1⁺ Tg(LPV-TAg1135)11Tvd/0 (involves: 129/Sv * C57BL/6 * DBA/2)	increased T cell derived lymphoma incidence	J:47667
Rag1^tm1Mom/Rag1⁺ Tg(LPV-TAg1135)11Tvd/0 Tg(TcrLCMV)327Sdz/0 (involves: 129S7/SvEvBrd * C57BL/6 * DBA/2)	increased T cell derived lymphoma incidence	J:47667
Rag1^tm1Mom/Rag1^tm1Mom (involves: 129S7/SvEvBrd * CD-1)	abnormal B cell differentiation	J:1934
	abnormal immunoglobulin V(D)J recombination	J:1934
	abnormal inguinal lymph node morphology	J:1934
	abnormal T cell differentiation	J:1934
	abnormal T cell morphology	J:1934
	abnormal T cell receptor V(D)J recombination	J:1934
	absent mature B cells	J:1934
	decreased IgM level	J:1934
	spleen hypoplasia	J:1934
	thymus hypoplasia	J:1934
Rag1^tm1Mom/Rag1^tm1Mom (B6.129S7-Rag1^tm1Mom)	decreased IgM level	J:78613
	decreased immunoglobulin level	J:111828
	dermatitis	J:111828
	ear inflammation	J:111828
	increased eosinophil cell number	J:111828
Rag1^tm1Mom/Rag1^tm1Mom (involves: 129S7/SvEvBrd * C57BL/6 * FVB * NOD)	decreased lymphocyte cell number	J:111874
	small thymus	J:111874
Rag1^tm1Mom/Rag1^tm1Mom (NOD.129S7(B6)-Rag1^tm1Mom)	abnormal level of surface class II molecules	J:109843
	decreased CD4-positive, alpha-beta T cell number	J:109843
	decreased CD8-positive, alpha-beta T cell number	J:109843
	decreased immunoglobulin level	J:109843
	decreased mature B cell number	J:109843
	impaired natural killer cell mediated cytotoxicity	J:109843
	increased granulocyte number	J:109843
	increased immature B cell number	J:109843
	increased macrophage cell number	J:109843
	increased NK cell number	J:109843
	spleen hypoplasia	J:109843
Rag1^tm1Mom/Rag1^tm1Mom (involves: 129S7/SvEvBrd * C57BL/6)	abnormal lymphatic vessel morphology	J:119344
	abnormal response to infection	J:119344
	autoimmune response	J:138466
	decreased neutrophil cell number	J:119344
	decreased susceptibility to induced colitis	J:194587
Rag1^tm1Mom/Rag1^tm1Mom (involves: 129S7/SvEvBrd)	abnormal double-negative T cell morphology	J:112990
	abnormal thymus epithelium morphology	J:125864
	decreased inflammatory response	J:94420
Rag1^tm1Mom/Rag1^tm1Mom Prf1^tm1Sdz/Prf1^tm1Sdz (NOD.Cg-Rag1^tm1Mom Prf1^tm1Sdz/Sz)	abnormal level of surface class II molecules	J:109843
	abnormal lymph node cortex morphology	J:109843
	abnormal response to transplant	J:109843
	abnormal spleen white pulp morphology	J:109843
	abnormal thymus cortex morphology	J:109843
	decreased CD4-positive, alpha-beta T cell number	J:109843
	decreased CD8-positive, alpha-beta T cell number	J:109843
	decreased immunoglobulin level	J:109843
	decreased mature B cell number	J:109843
	impaired natural killer cell mediated cytotoxicity	J:109843
	increased granulocyte number	J:109843
	increased immature B cell number	J:109843
	increased macrophage cell number	J:109843
	increased NK cell number	J:109843
	increased T cell derived lymphoma incidence	J:109843
	spleen hypoplasia	J:109843
	thymus hypoplasia	J:109843
Rag1^tm1Mom/Rag1^tm1Mom Rasa3^scat/Rasa3^scat (involves: 129S7/SvEvBrd * BALB/cBy)	abnormal immune system morphology	J:186485
Rag1^tm1Mom/Rag1^tm1Mom Sh3bp2^tm1Bjro/Sh3bp2^tm1Bjro (involves: 129S4/SvJae * 129S7/SvEvBrd * BALB/cJ * C57BL/6J)	abnormal osteoclast differentiation	J:117880
	increased circulating tumor necrosis factor level	J:117880
	increased inflammatory response	J:117880
Rag1^tm1Mom/Rag1^tm1Mom Slc46a2^tm1Moki/Slc46a2⁺ Tg(TcraB12,TcrbB12)1Rest/0 (involves: 129 * C57BL/6)	arrested T cell differentiation	J:140121
	decreased double-positive T cell number	J:140121
	increased T cell apoptosis	J:140121
	thymus hypoplasia	J:140121
Rag1^tm1Mom/Rag1^tm1Mom Tg(CAG-Lyn)#Paau/0 (involves: 129S7/SvEvBrd C57BL/6)	decreased inflammatory response	J:151886
Rag1^tm1Mom/Rag1^tm1Mom Tg(Lck-Akt1E40K)E-3Pnt/0 (involves: 129S7/SvEvBrd C3H/He * C57BL/6)	increased double-positive T cell number	J:135903
	increased thymocyte number	J:135903
Rag1^tm1Mom/Rag1^tm1Mom Tg(LPV-TAg1135)11Tvd/0 (involves: 129/Sv * C57BL/6 * DBA/2)	abnormal T cell receptor V(D)J recombination	J:47667
	increased T cell derived lymphoma incidence	J:47667
Rag1^tm1Mom/Rag1^tm1Mom Tg(LPV-TAg1135)11Tvd/0 Tg(TcrLCMV)327Sdz/0 (involves: 129S7/SvEvBrd * C57BL/6 * DBA/2)	increased T cell derived lymphoma incidence	J:47667
Rag1^tm1Mom/Rag1^tm1Mom Tg(Tcra,Tcrb)HRCAll/0 (B6.Cg-Rag1^tm1Mom Tg(Tcra,Tcrb)HRCAll)	abnormal T cell differentiation	J:131347
	abnormal T cell subpopulation ratio	J:131347
	absent CD4-positive, alpha-beta T cells	J:131347
	increased CD8-positive, alpha-beta T cell number	J:131347
Rag1^tm1Mom/Rag1^tm1Mom Tg(TcraAI4)1Dvs/0 Tg(TcrbAI4)1Dvs/0 (NOD.Cg-Rag1^tm1Mom Tg(TcraAI4)1Dvs Tg(TcrbAI4)1Dvs/Dvs)	increased susceptibility to autoimmune diabetes	J:94192
Rag1^tm1Mom/Rag1^tm1Mom Tg(TcraBDC12-4.1)10Jos/0 Tg(TcrbBDC12-4.1)82Gse/0 (involves: 129S7/SvEvBrd * C57BL/6 * FVB * NOD)	decreased CD4-positive, alpha-beta T cell number	J:111874
	decreased lymphocyte cell number	J:111874
	decreased thymus weight	J:111874
	increased double-positive T cell number	J:111874
	increased susceptibility to autoimmune diabetes	J:111874
Rag1^tm1Mom/Rag1^tm1Mom Tnf^tm2Gkl/Tnf⁺ (involves: 129S/SvEv * 129S7/SvEvBrd * C57BL/6)	rheumatoid arthritis	J:54056
	small intestinal inflammation	J:54056
Rag1^tm1Mom/Rag1^tm1Mom Tnfrsf25^tm1Mjo/Tnfrsf25^tm1Mjo (involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6)	abnormal T cell differentiation	J:84536
Rag1^tm1Mom/Rag1^tm1Mom Tnfsf14^tm1Kpf/Tnfsf14^tm1Kpf (involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6)	decreased osteoclast cell number	J:294030
Rag1^tm1Mom/Rag1^tm1Mom Trp53^tm1Brd/Trp53^tm1Brd (involves: 129S7/SvEvBrd * C57BL)	increased T cell derived lymphoma incidence	J:141515
Rag1^tm1Mom/Rag1^tm1Mom Trp53^tm1Brd/Trp53^tm1Brd Xrcc5^tm1Dbr/Xrcc5^tm1Dbr (involves: 129S7/SvEvBrd * C57BL)	increased T cell derived lymphoma incidence	J:141515
Rag1^tm1Mom/Rag1^tm1Mom Tyrobp^tm1.1Viv/Tyrobp^tm1.1Viv (involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * C57BL/10)	abnormal osteoclast physiology	J:129304
Rag1^tm1Mom/Rag1^tm1Mom Vtcn1^tm1Lpc/Vtcn1^tm1Lpc (involves: 129S/SvEvBrd * 129S7/SvEvBrd * C57BL/6)	abnormal neutrophil differentiation	J:145712
	decreased susceptibility to bacterial infection	J:145712
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:145712
	increased neutrophil cell number	J:145712
	increased spleen weight	J:145712
Rag2^m1Btlr/Rag2^m1Btlr (C57BL/6J-Rag2^m1Btlr)	abnormal humoral immune response	J:203045
	decreased B cell number	J:203045
	decreased CD4-positive, alpha-beta T cell number	J:203045
	decreased IgG level	J:203045
	decreased IgM level	J:203045
Rag2^tm1.1Cgn/Rag2^tm1.1Cgn (C57BL/6-Rag2^tm1.1Cgn)	arrested B cell differentiation	J:72214
Rag2^tm1.1Cgn/Rag2^tm1.1Cgn (C57BL/6-Rag2^tm1.1Cgn)	arrested T cell differentiation	J:72214
Rag2^tm1.1Cgn/Rag2^tm1.1Cgn Tg(HLA-DR2)#Lfug/0 Tg(TCROb.1A12)#Lfug/0 (involves: C57BL/6 * DBA/2)	autoimmune response	J:134764
	CNS inflammation	J:134764
Rag2^tm1.1Cgn/Rag2^tm1.1Cgn Trex1^tm1Tld/Trex1^tm1Tld (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:181257
Rag2^tm1.1Desi/Rag2^tm1.1Desi (involves: 129X1/SvJ * C57BL/6)	abnormal immunoglobulin V(D)J recombination	J:168974
Rag2^tm1.1Desi/Rag2^tm1.1Desi Trp53^tm1Tyj/Trp53^tm1Tyj (involves: 129S2/SvPas * 129X1/SvJ * C57BL/6)	increased T cell derived lymphoma incidence	J:168974
Rag2^tm1.1Mss/Rag2^tm1.1Mss (involves: 129S6/SvEvTac)	abnormal lymphopoiesis	J:171970
	abnormal pre-B cell morphology	J:171970
	decreased pre-B cell number	J:171970
	increased DN3 thymocyte number	J:171970
Rag2^tm1.1Mss/Rag2^tm1.1Mss Trp53^tm1Tyj/Trp53^tm1Tyj (involves: 129S2/SvPas * 129S6/SvEvTac)	increased T cell derived lymphoma incidence	J:170462
Rag2^tm1Avla/Rag2^tm1Avla (involves: 129/Sv * C57BL/6)	abnormal B cell physiology	J:122108
	abnormal immune system cell morphology	J:122108
	abnormal immune system organ morphology	J:122108
	abnormal lymph node morphology	J:122108
	abnormal lymphocyte physiology	J:122108
	abnormal spleen morphology	J:122108
	abnormal thymus morphology	J:122108
	absent Hassall's corpuscle	J:122108
	absent Peyer's patches	J:122108
	arrested B cell differentiation	J:122108
	arrested T cell differentiation	J:122108
	colitis	J:122108
	decreased double-positive T cell number	J:122108
	decreased IgA level	J:122108
	decreased IgG level	J:122108
	decreased lymphocyte cell number	J:122108
	decreased NK T cell number	J:122108
	decreased spleen white pulp amount	J:122108
	decreased T cell proliferation	J:122108
	erythroderma	J:122108
	small cervical lymph nodes	J:122108
	small inguinal lymph nodes	J:122108
	small lymph nodes	J:122108
	small spleen	J:122108
Rag2^tm1Cgn/Rag2^tm1.1Cgn Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA)	abnormal B cell activation	J:72214
	absent immature B cells	J:72214
	absent pre-B cells	J:72214
	arrested B cell differentiation	J:72214
	arrested T cell differentiation	J:72214
	decreased follicular B cell number	J:72214
	decreased marginal zone B cell number	J:72214
	decreased mature B cell number	J:72214
	increased plasma cell number	J:72214
Rag2^tm1Cgn/Rag2^tm1Cgn Xrcc4^tm1Fwa/Xrcc4^tm2Fwa Tg(Cr2-cre)3Cgn/? (involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6)	abnormal class switch recombination	J:150339
Rag2^tm1Fwa/Rag2⁺ Tg(LPV-TAg1135)11Tvd/0 (involves: 129S/SvEv * C57BL/6 * DBA/2)	increased T cell derived lymphoma incidence	J:47667
Rag2^tm1Fwa/Rag2⁺ Trp53^tm1Tyj/Trp53^tm1Tyj (involves: 129S/SvEv * 129S2/SvPas * C57BL/6J)	increased T cell derived lymphoma incidence	J:47667
Rag2^tm1Fwa/Rag2^tm1Fwa (involves: 129S/SvEv * MF1)	abnormal effector T cell morphology	J:1935
	abnormal immunoglobulin V(D)J recombination	J:1935
	abnormal spleen morphology	J:1935
	abnormal T cell receptor V(D)J recombination	J:1935
	absent mature B cells	J:1935
	arrested B cell differentiation	J:1935
	arrested T cell differentiation	J:1935
	decreased CD4-positive, alpha-beta T cell number	J:1935
	decreased CD8-positive, alpha-beta T cell number	J:1935
	decreased double-positive T cell number	J:1935
	decreased IgM level	J:1935
	increased granulocyte number	J:1935
	increased macrophage cell number	J:1935
	increased natural killer cell mediated cytotoxicity	J:1935
	increased susceptibility to infection	J:1935
	lymph node hypoplasia	J:1935
	spleen hypoplasia	J:1935
	thymus hypoplasia	J:1935
Rag2^tm1Fwa/Rag2^tm1Fwa (involves: 129S/SvEv)	abnormal chemokine secretion	J:140483
	abnormal interferon secretion	J:140483
	abnormal macrophage physiology	J:140483
	abnormal response to transplant	J:116136
	abnormal T-helper 1 physiology	J:116136
	colitis	J:116136
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:140483
	decreased thymocyte number	J:114561
	increased susceptibility to bacterial infection	J:140483
	lung inflammation	J:140483
Rag2^tm1Fwa/Rag2^tm1Fwa (involves: 129S/SvEv * C57BL/6)	abnormal B cell morphology	J:81133
	arrested T cell differentiation	J:91542
	decreased double-negative T cell number	J:81133, J:91542
	decreased susceptibility to parasitic infection	J:64283
	decreased susceptibility to type IV hypersensitivity reaction	J:165513
	increased double-negative T cell number	J:91542
Rag2^tm1Fwa/Rag2^tm1Fwa Cd47^tm1Fpl/Cd47^tm1Fpl Il2rg^tm1Cgn/Y (involves: 129P2/OlaHsd * 129S/SvEv * 129S7/SvEvBrd * C57BL/6)	absent peripheral lymph nodes	J:203904
	decreased CD4-positive, alpha-beta T cell number	J:203904
	decreased lymphocyte cell number	J:203904
	decreased susceptibility to graft versus host disease	J:203904
	increased activated T cell number	J:203904
	increased CD8-positive, alpha-beta T cell number	J:203904
	increased susceptibility to Retroviridae infection	J:203904
Rag2^tm1Fwa/Rag2^tm1Fwa Rr299391^tm1.1Fwa/Rr299391^tm1.1Fwa (involves: 129P2/OlaHsd * 129S/SvEv)	abnormal T cell receptor delta chain V(D)J recombination	J:149413
Rag2^tm1Fwa/Rag2^tm1Fwa Sos1^tm1.1Les/Sos1^tm1.1Les Tg(Lck-cre)1Cwi/0 (involves: 129S/SvEv * C57BL/6)	abnormal T cell differentiation	J:174536
	decreased T cell proliferation	J:174536
Rag2^tm1Fwa/Rag2^tm1Fwa Tbata^tm1Faf/Tbata^tm1Faf (involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6)	abnormal T cell differentiation	J:166065
	increased thymocyte number	J:166065
Rag2^tm1Fwa/Rag2^tm1Fwa Tbx21^tm1Glm/Tbx21^tm1Glm (involves: 129S/SvEv * 129S6/SvEvTac)	colitis	J:141481
	increased tumor necrosis factor secretion	J:141481
	large intestinal inflammation	J:141481
Rag2^tm1Fwa/Rag2^tm1Fwa Tcra^Ln3Jae/Tcra⁺ Tcrb^Ln3Jae/Tcrb⁺ (involves: 129S/SvEv * 129S4/SvJae * C57BL/6)	abnormal double-negative T cell morphology	J:143006
	absent gamma-delta T cells	J:143006
	decreased CD4-positive, alpha-beta T cell number	J:143006
	increased CD8-positive, alpha-beta T cell number	J:143006
Rag2^tm1Fwa/Rag2^tm1Fwa Tcrb^Ln3Jae/Tcrb⁺ (involves: 129S/SvEv * 129S4/SvJae * C57BL/6)	abnormal double-negative T cell morphology	J:143006
	absent gamma-delta T cells	J:143006
	decreased CD4-positive, alpha-beta T cell number	J:143006
	increased double-positive T cell number	J:143006
Rag2^tm1Fwa/Rag2^tm1Fwa Tg(Cd4-NPM/ALK)N1Ingh/0 (involves: 129S/SvEv * C57BL/6 * Swiss Webster)	increased DN3 thymocyte number	J:235890
	increased T cell derived lymphoma incidence	J:235890
	increased thymus tumor incidence	J:235890
Rag2^tm1Fwa/Rag2^tm1Fwa Tg(DO11.10)10Dlo/0 (involves: 129S/SvEv * BALB/c * C3H * C57BL/6)	immune system phenotype	J:110446
Rag2^tm1Fwa/Rag2^tm1Fwa Tg(EmuSR-tTa)83Bop/0 Tg(tetO-Nfatct1)1Grc/0 (involves: 129S/SvEv C57BL/6J * CBA/J * FVB/N)	abnormal double-positive T cell morphology	J:141917
Rag2^tm1Fwa/Rag2^tm1Fwa Tg(Igh-Pim1)1Brn/0 (involves: 129S/SvEv * C57BL/6LiA * CBA)	decreased thymocyte number	J:114561
Rag2^tm1Fwa/Rag2^tm1Fwa Tg(Lck-Akt1)M-1Pnt/0 (involves: 129S/SvEv C3H/He * C57BL/6)	absent CD4-positive, alpha-beta T cells	J:135903
	absent CD8-positive, alpha-beta T cells	J:135903
	increased double-positive T cell number	J:135903
Rag2^tm1Fwa/Rag2^tm1Fwa Tg(LPV-TAg1135)11Tvd/0 (involves: 129S/SvEv * C57BL/6 * DBA/2)	increased T cell derived lymphoma incidence	J:47667
Rag2^tm1Fwa/Rag2^tm1Fwa Tg(Tcra5CC7,Tcrb5CC7)IWep/? Themis^5AT161/Themis^5AT161 (involves: 129S/SvEv * C57BL/6)	arrested T cell differentiation	J:151076
	increased double-positive T cell number	J:151076
Rag2^tm1Fwa/Rag2^tm1Fwa Tg(Tcra51-11.5,Tcrb51-11.5)AR206Ayr/0 (involves: 129S/SvEv * C57BL/6 * C57BL/6NTac * DBA/2)	abnormal CD4-positive T cell differentiation	J:125548
	abnormal positive T cell selection	J:125548
	decreased CD4-positive, alpha-beta T cell number	J:125548
	increased double-positive T cell number	J:125548
	thymus hyperplasia	J:125548
Rag2^tm1Fwa/Rag2^tm1Fwa Tg(TcraCN.B1,TcrbCN.B1)SM1Jen/0 (involves: 129S/SvEv * C57BL/6)	increased susceptibility to bacterial infection induced morbidity/mortality	J:162539
Rag2^tm1Fwa/Rag2^tm1Fwa Tg(TcraH-Y,TcrbH-Y)71Vbo/? (involves: 129S/SvEv * C57BL/6J * DBA/2J)	abnormal CD8-positive, alpha beta T cell morphology	J:125259
	abnormal CD8-positive, alpha-beta T cell physiology	J:125259
	abnormal cytotoxic T cell physiology	J:66565
Rag2^tm1Fwa/Rag2^tm1Fwa Tg(TcraH-Y,TcrbH-Y)71Vbo/? Themis^5AT161/Themis^5AT161 (involves: 129S/SvEv * C57BL/6 * DBA/2)	decreased single-positive T cell number	J:151076
Rag2^tm1Fwa/Rag2^tm1Fwa Tg(TcrHEL3A9)1Mmd/0 (involves: 129S/SvEv * C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:78309
	abnormal double-positive T cell morphology	J:78309
	abnormal T cell activation	J:78309
	abnormal T cell proliferation	J:78309
	abnormal thymus cell ratio	J:78309
	decreased CD4-positive, alpha-beta T cell number	J:78309
Rag2^tm1Fwa/Rag2^tm1Fwa Tg(TcrHEL3A9)1Mmd/0 Tg(TLK2mHEL)2Ccg/0 (involves: 129S/SvEv * C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:78309
	abnormal CD4-positive, alpha-beta T cell physiology	J:78309
	abnormal T cell activation	J:78309
	abnormal T cell proliferation	J:78309
	decreased CD4-positive, alpha-beta T cell number	J:78309
	decreased double-positive T cell number	J:78309
	thyroid gland inflammation	J:78309
Rag2^tm1Fwa/Rag2^tm1Fwa Trp53^tm1Tyj/Trp53^tm1Tyj (involves: 129S/SvEv * 129S2/SvPas * C57BL/6J)	increased T cell derived lymphoma incidence	J:47667
Rag2^tm1Fwa/Rag2^tm1Fwa Wdr1^rede/Wdr1^rede (involves: 129S/SvEv * C57BL/6)	abnormal immune system physiology	J:134092
Rag2^tm1Fwa/Rag2^tm1Mao (involves: 129S/SvEv * C57BL/6)	abnormal B cell number	J:81837
	abnormal gamma-delta T cell differentiation	J:81837
	arrested B cell differentiation	J:81837
	arrested T cell differentiation	J:81837
	decreased double-negative T cell number	J:81837
	decreased immature B cell number	J:81837
	decreased mature B cell number	J:81837
	decreased pre-B cell number	J:81837
	increased immature B cell number	J:81837
	thymus hypoplasia	J:81837
Rag2^tm1Libo/Rag2^tm1Libo (involves: 129S6/SvEvTac * C57BL/6 * FVB/N)	abnormal B cell differentiation	J:84563
	abnormal B cell physiology	J:84563
	decreased B cell number	J:84563
	decreased monocyte cell number	J:84563
	decreased pre-B cell number	J:84563
Rag2^tm1Mao/Rag2^tm1Mao (involves: 129S6/SvEvTac * C57BL/6)	abnormal immune system cell morphology	J:81837
Rag2^tm1Mao/Rag2^tm1Mao (involves: 129 * C57BL/6)	abnormal B cell number	J:81837
	abnormal gamma-delta T cell differentiation	J:81837
	arrested B cell differentiation	J:81837
	arrested T cell differentiation	J:81837
	decreased double-negative T cell number	J:81837
	decreased immature B cell number	J:81837
	decreased mature B cell number	J:81837
	decreased pre-B cell number	J:81837
	increased immature B cell number	J:81837
	thymus hypoplasia	J:81837
Rag2^tm1Tgi/Rag2^tm1Tgi (involves: 129S1/Sv * 129X1/SvJ)	abnormal Peyer's patch morphology	J:113641
	arrested B cell differentiation	J:113641
	arrested T cell differentiation	J:113641
	decreased B cell number	J:113641
	decreased double-positive T cell number	J:113641
	decreased thymocyte number	J:113641
Rag2^tm2.1Desi/Rag2^tm2.1Desi Trp53^tm1Tyj/Trp53^tm1Tyj (involves: 129S2/SvPas * 129X1/SvJ * C57BL/6)	increased T cell derived lymphoma incidence	J:168974
Rala^{tm1a(EUCOMM)Wtsi}/Rala^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Rala^{tm1a(EUCOMM)Wtsi}/Wtsi)	blood in lymph vessels	J:239583
Ralb^{tm1a(EUCOMM)Wtsi}/Ralb^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Ralb^{tm1a(EUCOMM)Wtsi}/Wtsi)	increased leukocyte cell number	J:211773
Ramp1^tm1.1Tsuj/Ramp1^tm1.1Tsuj (C.129S2-Ramp1^tm1.1Tsuj)	abnormal chemokine secretion	J:125974
	abnormal cytokine secretion	J:125974
	increased circulating interferon-gamma level	J:125974
	increased circulating interleukin-6 level	J:125974
	increased circulating tumor necrosis factor level	J:125974
Ramp1^{tm1b(EUCOMM)Wtsi}/Ramp1^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Ramp1^{tm1b(EUCOMM)Wtsi}/H)	increased basophil cell number	J:211773
Ramp2^tm1Kmca/Ramp2^tm1Kmca (involves: 129S6/SvEvTac * C57BL/6)	abnormal lymph organ development	J:130930
	abnormal lymphatic vessel morphology	J:130930
Ranbp17^em1(IMPC)Tcp/Ranbp17^em1(IMPC)Tcp (C57BL/6N-Ranbp17^em1(IMPC)Tcp/Tcp)	enlarged spleen	J:211773
Rap1a^tm1Laaq/Rap1a^tm1Laaq (either: B6.Cg-Rap1a^tm1Laaq or (involves: C57BL/6))	abnormal leukocyte migration	J:140471
	abnormal macrophage physiology	J:140471
	abnormal neutrophil physiology	J:140471
	immune system phenotype	J:140471
Rap1a^tm1Tze/Rap1a^tm1Tze (involves: 129P2/OlaHsd * C57BL/6)	abnormal leukocyte adhesion	J:144145
	decreased interleukin-2 secretion	J:144145
	decreased T cell proliferation	J:144145
Rap1gap2^m1Anu/Rap1gap2^m1Anu (C57BL/6NCrl-Rap1gap2^m1Anu/Anu)	immune system phenotype	J:104190
Rap1gap^em1(IMPC)H/Rap1gap^em1(IMPC)H (C57BL/6NTac-Rap1gap^em1(IMPC)H/H)	decreased lymphocyte cell number	J:211773
	increased eosinophil cell number	J:211773
	increased neutrophil cell number	J:211773
	increased spleen weight	J:211773
Rap1gds1^tm1Ytk/Rap1gds1^tm1Ytk (involves: 129X1/SvJ * C57BL/6 * DBA)	abnormal thymus morphology	J:62244
	decreased thymocyte number	J:62244
	increased thymocyte apoptosis	J:62244
	small thymus	J:62244
Rapgef2^tm1.1Hous/Rapgef2^tm1.1Hous Tg(Cd4-cre)1Cwi/0 (involves: 129S1/Sv * C57BL/6 * CBA)	immune system phenotype	J:165879
Rapgef2^tm1.1Hous/Rapgef2^tm1.1Hous Tg(Cdh5-cre)7Mlia/0 (involves: 129S1/Sv * FVB/N)	immune system phenotype	J:165879
Rapgef2^tm1.1Hous/Rapgef2^tm1.1Hous Tg(Mx1-cre)1Cgn/0 (involves: 129S1/Sv * C57BL/6 * CBA)	immune system phenotype	J:165879
Rapgef2^tm1.1Hous/Rapgef2^tm1.1Hous Tg(VAV1-cre)1Graf/0 (involves: 129S1/Sv)	immune system phenotype	J:165879
Rapgef3^tm1Skc/Rapgef3^tm1Skc (Not Specified)	insulitis	J:201171
Rapgef6^tm1.1Tkat/Rapgef6^tm1.1Tkat (involves: 129P2/OlaHsd * C57BL/6)	enlarged spleen	J:126164
Rapgef6^tm1.1Tkat/Rapgef6^tm1.1Tkat (involves: 129P2/OlaHsd)	enlarged spleen	J:218581
Raph1^tm1.2Fbg/Raph1^tm1.2Fbg (involves: 129S4/SvJae * C57BL/6)	abnormal cytokine level	J:238262
	increased inflammatory response	J:238262
	increased susceptibility to bacterial infection	J:238262
	large intestinal inflammation	J:238262
Rara^tm1.1Ybe/Rara^tm1.1Ybe (involves: C57BL/6N)	abnormal lymphopoiesis	J:207485
Rara^tm1Ipc/Rara^tm1Ipc Rarb^tm1Ipc/Rarb^tm1Ipc (involves: 129S2/SvPas)	persistent cervical thymus	J:21034
Rara^tm1Ipc/Rara^tm1Ipc Rarb^tm1Mma/Rarb^tm1Mma (involves: 129S2/SvPas * C57BL/6)	abnormal thymus morphology	J:43344
	persistent cervical thymus	J:43344
Rara^tm1Ipc/Rara^tm1Ipc Rarg^tm1Ipc/Rarg^tm1Ipc (involves: 129S2/SvPas)	persistent cervical thymus	J:21034
Rara^tm1Ipc/Rara^tm1Ipc Rarg^tm2Ipc/Rarg^tm2Ipc (involves: 129S2/SvPas)	ectopic thymus	J:42773
Rarres1^tm1.2Mhl/Rarres1^tm1.2Mhl (involves: 129S1/SvImJ * C57BL/6 * FVB/N * NIH Black Swiss)	abnormal B cell activation	J:324270
	abnormal B cell differentiation	J:324270
	abnormal B cell physiology	J:324270
	abnormal plasma cell differentiation	J:324270
	decreased B cell apoptosis	J:324270
	decreased spleen germinal center number	J:324270
	increased B cell proliferation	J:324270
Rarres2^tm1Yktk/Rarres2^tm1Yktk (B6.Cg-Rarres2^tm1Yktk)	decreased macrophage cell number	J:206120
Rasa1^tm1Wid/Rasa1^tm1Wid (involves: 129S/SvEv * 129S6/SvEvTac * C57BL/6N)	increased susceptibility to induced colitis	J:189241
Rasa3^hlb381/Rasa3^hlb381 (C57BL/6J-Rasa3^hlb381/J)	decreased leukocyte cell number	J:301035, J:221899
	enlarged spleen	J:221899
	increased spleen weight	J:301035
Rasa3^scat/Rasa3^scat (involves: BALB/cBy)	abnormal spleen morphology	J:186485
	decreased B cell number	J:186485
	decreased CD4-positive, alpha-beta T cell number	J:186485
	decreased CD8-positive, alpha-beta T cell number	J:186485
	decreased leukocyte cell number	J:186485
	decreased T cell number	J:186485
	enlarged spleen	J:186485
	increased spleen red pulp amount	J:186485
	pale spleen	J:186485
Rasa3^scat/Rasa3^scat (involves: BALB/cBy * BALB/cByJ)	decreased leukocyte cell number	J:301035
Rasa3^scat/Rasa3^scat (involves: BALB/cBy * BALB/cByJ)	increased spleen weight	J:301035
Rasa3^tm1.1Llp/Rasa3^tm1.1Llp Tg(Mx1-cre)1Cgn/? (involves: 129S1/SvImJ * C57BL/6J * CBA/J)	bone marrow failure	J:301035
	decreased leukocyte cell number	J:301035
	increased spleen weight	J:301035
Rasa4^tm1Ywh/Rasa4^tm1Ywh (B6.129S6-Rasa4^tm1Ywh)	impaired macrophage phagocytosis	J:100455
Rasa4^tm1Ywh/Rasa4^tm1Ywh (B6.129S6-Rasa4^tm1Ywh)	increased susceptibility to bacterial infection	J:100455
Rasal3^tm1.1Fuj/Rasal3^tm1.1Fuj (involves: C57BL/6N * C57BL/6NCrlj * CBA/JNCrlj)	decreased circulating interferon-gamma level	J:229641
	decreased circulating interleukin-4 level	J:229641
	decreased interferon-gamma secretion	J:229641
	decreased interleukin-4 secretion	J:229641
	decreased NK T cell number	J:229641
	increased granulocyte number	J:229641
Rasal3^{tm1b(EUCOMM)Hmgu}/Rasal3^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Rasal3^{tm1b(EUCOMM)Hmgu}/Orl)	decreased lymphocyte cell number	J:211773
	increased eosinophil cell number	J:211773
Rasgef1b^tm1.1Sila/Rasgef1b^tm1.2Sila Tg(CMV-cre)1Cgn/0 (involves: BALB/cJ * C57BL/6)	abnormal microglial cell morphology	J:344440
	abnormal tumor necrosis factor level	J:344440
Rasgrf2^tm1Esn/Rasgrf2^tm1Esn (involves: 129S1/Sv * C57BL/10 * C57BR/cd)	decreased interleukin-2 secretion	J:128985
	decreased tumor necrosis factor secretion	J:128985
Rasgrf2^tm1Esn/Rasgrf2^tm1Esn Vav1^tm1Tyb/Vav1^tm1Tyb (involves: 129S1/Sv * 129S2/SvPas * C57BL/10 * C57BR/cd)	abnormal T cell physiology	J:128985
	decreased interleukin-2 secretion	J:128985
	decreased T cell proliferation	J:128985
	decreased tumor necrosis factor secretion	J:128985
Rasgrp1^lag/Rasgrp1^lag (involves: 129 * C57BL/6)	abnormal lymph node morphology	J:85189
	abnormal positive T cell selection	J:85189
	abnormal T cell physiology	J:85189
	decreased T cell proliferation	J:85189
	enlarged lymph nodes	J:85189
	enlarged spleen	J:85189
	glomerulonephritis	J:85189
	increased B cell number	J:85189
	increased IgG level	J:85189
	increased susceptibility to systemic lupus erythematosus	J:85189
	increased T cell number	J:85189
Rasgrp1^m1Anu/Rasgrp1⁺ (involves: C57BL/6JSfdAnu * CBA/J)	increased anti-nuclear antigen antibody level	J:207898
Rasgrp1^m1Anu/Rasgrp1^m1Anu (C57BL/6JSfdAnu-Rasgrp1^m1Anu)	abnormal T cell differentiation	J:104190
Rasgrp1^m1Anu/Rasgrp1^m1Anu (C57BL/6JSfdAnu-Rasgrp1^m1Anu)	autoimmune response	J:104190
Rasgrp1^m1Anu/Rasgrp1^m1Anu (involves: C57BL/6JSfdAnu * CBA/J)	abnormal CD4-positive, alpha beta T cell morphology	J:207898
	immune system phenotype	J:207898
	increased anti-nuclear antigen antibody level	J:207898
	increased effector memory CD4-positive, alpha-beta T cell number	J:207898
Rasgrp1^m1Btlr/Rasgrp1^m1Btlr (C57BL/6J-Rasgrp1^m1Btlr)	abnormal humoral immune response	J:265163
	decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:265163
	decreased CD8-positive, naive alpha-beta T cell number	J:265163
	decreased IgM level	J:265163
	increased CD8-positive, alpha-beta memory T cell number	J:265163
	increased effector memory CD4-positive, alpha-beta T cell number	J:265163
	increased IgA level	J:265163
	increased IgE level	J:265163
	increased IgM level	J:265163
	increased NK cell number	J:265163
Rasgrp1^m2Anu/Rasgrp1^m2Anu (C57BL/6NCrl-Rasgrp1^m2Anu/Anu)	immune system phenotype	J:104190
Rasgrp1^m2Btlr/Rasgrp1^m2Btlr (C57BL/6J-Rasgrp1^m2Btlr)	decreased CD4-positive, alpha-beta T cell number	J:265163
	decreased CD8-positive, alpha-beta T cell number	J:265163
	decreased CD8-positive, naive alpha-beta T cell number	J:265163
	decreased single-positive T cell number	J:265163
	decreased T cell number	J:265163
	increased central memory CD4-positive, alpha-beta T cell number	J:265163
	increased central memory CD8 positive, alpha-beta T cell number	J:265163
	increased effector memory CD4-positive, alpha-beta T cell number	J:265163
	increased effector memory CD8-positive, alpha-beta T cell number	J:265163
	increased NK cell number	J:265163
Rasgrp1^m3Btlr/Rasgrp1^m3Btlr (C57BL/6J-Rasgrp1^m3Btlr)	decreased CD4-positive, alpha-beta T cell number	J:265255
	decreased CD8-positive, alpha-beta T cell number	J:265255
	decreased CD8-positive, naive alpha-beta T cell number	J:265255
	decreased single-positive T cell number	J:265255
	decreased T cell number	J:265255
	increased B cell number	J:265255
	increased B-1b cell number	J:265255
	increased central memory CD8 positive, alpha-beta T cell number	J:265255
	increased effector memory CD4-positive, alpha-beta T cell number	J:265255
	increased effector memory CD8-positive, alpha-beta T cell number	J:265255
	increased IgM level	J:265255
	increased neutrophil cell number	J:265255
	increased NK cell number	J:265255
Rasgrp1^M4Btlr/Rasgrp1^M4Btlr (C57BL/6J-Rasgrp1^M4Btlr)	abnormal T cell morphology	J:267490
Rasgrp1^m5Btlr/Rasgrp1^m5Btlr (C57BL/6J-Rasgrp1^m5Btlr)	increased NK cell number	J:272846
Rasgrp1^tm1.1Wz/Rasgrp1^tm1.1Wz (B6.Cg-Rasgrp1^tm1.1Wz)	abnormal CD4-positive T cell differentiation	J:225109
	abnormal CD8-positive, alpha-beta T cell differentiation	J:225109
	abnormal immune system cell morphology	J:225109
	abnormal immune system organ morphology	J:225109
	abnormal immune system physiology	J:225109
	abnormal immunoglobulin level	J:225109
	abnormal T cell differentiation	J:225109
	decreased single-positive T cell number	J:225109
	decreased T cell proliferation	J:225109
	enlarged spleen	J:225109
	immune system phenotype	J:225109
	increased autoantibody level	J:225109
	increased CD4-positive, alpha-beta memory T cell number	J:225109
	increased IgE level	J:225109
	increased IgG1 level	J:225109
	increased single-positive T cell number	J:225109
	increased spleen weight	J:225109
Rasgrp1^tm1.1Wz/Rasgrp1^tm1.1Wz Tg(TcraH-Y,TcrbH-Y)71Vbo/? (involves: C57BL/6J * DBA/2J)	decreased single-positive T cell number	J:225109
	increased double-positive T cell number	J:225109
Rasgrp1^tm1.1Wz/Rasgrp1^tm1.1Wz Tg(TcraTcrb)425Cbn/? (involves: C57BL/6 * BALB/c)	abnormal CD4-positive T cell differentiation	J:225109
Rasgrp1^tm1Jstn/Rasgrp1^tm1Jstn (involves: 129P3/J * C57BL/6J)	abnormal humoral immune response	J:108677
	decreased B cell number	J:108677
	decreased thymocyte number	J:108677
	enlarged spleen	J:108677
	increased immunoglobulin level	J:108677
	increased plasma cell number	J:108677
Rasgrp1^tm1Jstn/Rasgrp1^tm1Jstn (involves: 129P3/J)	abnormal CD4-positive, alpha beta T cell morphology	J:207898
	abnormal double-positive T cell morphology	J:207898
	decreased CD4-positive, alpha-beta T cell number	J:207898
	decreased CD8-positive, alpha-beta T cell number	J:207898
Rasgrp1^tm1Jstn/Rasgrp1^tm1Jstn Rasgrp3^tm1Jstn/Rasgrp3^tm1Jstn (involves: 129P3/J * C57BL/6J)	abnormal humoral immune response	J:108677
	decreased B cell number	J:108677
	decreased plasma cell number	J:108677
Rasgrp2^tm1Amg/Rasgrp2^tm1Amg (Not Specified)	abnormal neutrophil physiology	J:122618
Rasgrp2^tm1Amg/Rasgrp2^tm1Amg (Not Specified)	impaired neutrophil recruitment	J:122618
Rasgrp3^{em1(IMPC)Wtsi}/Rasgrp3^{em1(IMPC)Wtsi} (C57BL/6N-Rasgrp3^{em1(IMPC)Wtsi}/Wtsi)	increased CD8-positive, naive alpha-beta T cell number	J:211773
	increased effector memory T-helper cell number	J:211773
Rasgrp3^tm1Jstn/Rasgrp3^tm1Jstn (involves: 129P3/J * C57BL/6J)	abnormal humoral immune response	J:108677
	decreased B cell number	J:108677
	decreased IgG1 level	J:108677
	decreased IgG2a level	J:108677
	decreased IgG level	J:108677
Rasgrp4^tm1(cre)Rls/Rasgrp4^tm1(cre)Rls (C57BL/6-Rasgrp4^tm1(cre)Rls)	decreased susceptibility to induced arthritis	J:186519
	decreased susceptibility to induced colitis	J:186519
Rasgrp4^{tm1a(KOMP)Lste}/Rasgrp4^{tm1a(KOMP)Lste} (involves: C57BL/6)	abnormal neutrophil physiology	J:186412
	impaired neutrophil chemotaxis	J:186412
Rasgrp4^{tm1d(KOMP)Lste}/Rasgrp4^{tm1d(KOMP)Lste} (involves: 129S4/SvJaeSor * BALB/cJ * C57BL/6)	abnormal neutrophil physiology	J:186412
	impaired neutrophil chemotaxis	J:186412
Rassf1^tm1.2Brd/Rassf1^tm1.2Brd (involves: 129S7/SvEvBrd * C57BL/6)	immune system phenotype	J:101369
Rassf2^tm1Dlim/Rassf2^tm1Dlim (B6.Cg-Rassf2^tm1Dlim)	abnormal myeloid leukocyte morphology	J:181952
	abnormal osteoclast differentiation	J:181952
	abnormal spleen red pulp morphology	J:181952
	abnormal thymus epithelium morphology	J:181952
	decreased B cell number	J:181952
	decreased CD4-positive, alpha-beta T cell number	J:181952
	decreased CD8-positive, alpha-beta T cell number	J:181952
	decreased leukocyte cell number	J:181952
	decreased osteoclast cell number	J:181952
	decreased spleen weight	J:181952
	decreased T cell number	J:181952
	decreased thymus weight	J:181952
	spleen hypoplasia	J:181952
	thymus hypoplasia	J:181952
Rassf5^tm1Kina/Rassf5⁺ (involves: C57BL/6 * CBA * ICR)	lymphoid hypoplasia	J:92670
Rassf5^tm1Kina/Rassf5^tm1Kina (involves: C57BL/6 * CBA * ICR)	abnormal B cell differentiation	J:92670
	abnormal dendritic cell physiology	J:92670
	abnormal leukocyte migration	J:92670
	abnormal lymph node cell ratio	J:92670
	abnormal lymph node cortex morphology	J:92670
	abnormal spleen red pulp morphology	J:92670
	abnormal thymus cell ratio	J:92670
	abnormal thymus corticomedullary boundary morphology	J:92670
	abnormal thymus medulla morphology	J:92670
	decreased thymocyte number	J:92670
	spleen hypoplasia	J:92670
Rassf5^tm1Kina/Rassf5^tm1Kina (B6.Cg-Rassf5^tm1Kina)	abnormal lymphocyte physiology	J:168749
	enlarged lymph nodes	J:168749
	enlarged spleen	J:168749
	glomerulonephritis	J:168749
	increased anti-double stranded DNA antibody level	J:168749
	increased B cell number	J:168749
	increased B cell proliferation	J:168749
	increased IgG level	J:168749
	increased memory T cell number	J:168749
	increased plasma cell number	J:168749
	increased T cell number	J:168749
	increased T cell proliferation	J:168749
Raver1^{em1(IMPC)Hmgu}/Raver1^{em1(IMPC)Hmgu} (C57BL/6NCrl-Raver1^{em1(IMPC)Hmgu}/Ieg)	increased spleen weight	J:211773
Rb1^tm1Dwg/Rb1^tm1Dwg (involves: 129/Sv * C57BL/6)	abnormal macrophage morphology	J:105548
Rb1^tm1Mlh/Rb1^tm1Mlh (either: 129P2/OlaHsd-Rb1^tm1Mlh or (involves: 129P2/OlaHsd * BALB/c) or (involves: 129P2/OlaHsd * FVB/N))	abnormal myelopoiesis	J:2498
Rb1^tm1Tyj/Rb1^tm1Tyj (involves: 129S2/SvPas)	abnormal macrophage differentiation	J:105548
Rb1^tm2Mlh/Rb1^tm2Mlh (either: 129P2/OlaHsd-Rb1^tm2Mlh or (involves: 129P2/OlaHsd * BALB/c) or (involves: 129P2/OlaHsd * FVB/N))	abnormal myelopoiesis	J:2498
Rb1cc1^tm1.1Guan/Rb1cc1^tm1.1Guan Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd)	immune system phenotype	J:235399
Rb1cc1^tm1.1Guan/Rb1cc1^tm1.1Guan Tg(BEST1-cre)1Jdun/0 (involves: 129P2/OlaHsd * C57BL/6)	microgliosis	J:282249
Rb1cc1^tm1.1Guan/Rb1cc1^tm1.1Guan Tg(Tek-cre)12Flv/0 (B6.Cg-Rb1cc1^tm1.1Guan Tg(Tek-cre)12Flv)	abnormal myelopoiesis	J:167258
	increased neutrophil cell number	J:167258
Rbbp4^em1(IMPC)Mbp/Rbbp4⁺ (C57BL/6NCrl-Rbbp4^em1(IMPC)Mbp/Mmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Rbbp8^tm1Whl/Rbbp8^tm1.1Thl Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129P2/OlaHsd * 129S4/SvJaeSor)	immune system phenotype	J:194603
Rbl1^tm1Mru/Rbl1^tm1Mru (involves: 129S4/SvJae * BALB/cJ)	abnormal inflammatory response	J:51060
Rbl1^tm1Mru/Rbl1^tm1Mru (involves: 129S4/SvJae * BALB/cJ)	abnormal spleen red pulp morphology	J:51060
Rbm3^tm1Ttg/Rbm3^tm1Ttg (involves: 129P2/OlaHsd)	immune system phenotype	J:174947
Rbm4^{tm1a(EUCOMM)Hmgu}/Rbm4⁺ (C57BL/6N-Rbm4^{tm1a(EUCOMM)Hmgu}/Cnrm)	decreased IgG2b level	J:165965
Rbm7^em1Aki/Rbm7^em1Aki (B6.Cg-Rbm7^em1Aki)	decreased monocyte cell number	J:288329
Rbm10^em1(IMPC)Mbp/Y (C57BL/6NCrl-Rbm10^em1(IMPC)Mbp/MbpMmucd)	enlarged lymph nodes	J:211773
Rbm10^em1(IMPC)Mbp/Rbm10⁺ (C57BL/6NCrl-Rbm10^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Rbm15^tm1Dgg/Rbm15^tm1.1Dgg Tg(Mx1-cre)1Cgn/0 (involves: 129/Sv * C57BL/6 * CBA * FVB/N)	abnormal B cell differentiation	J:120321
	decreased B cell number	J:120321
	decreased pre-B cell number	J:120321
	increased spleen red pulp amount	J:120321
Rbm15^tm1Swm/Rbm15^tm1Swm Tg(Mx1-cre)1Cgn/0 (involves: 129X1/SvJ * C57BL/6 * CBA)	decreased leukocyte cell number	J:152262
	decreased lymphocyte cell number	J:152262
	decreased neutrophil cell number	J:152262
	increased spleen red pulp amount	J:152262
Rbm20^em1(IMPC)Mbp/Rbm20^em1(IMPC)Mbp (C57BL/6N-Rbm20^em1(IMPC)Mbp/MbpMmucd)	small spleen	J:211773
Rbm22^em1(IMPC)Mbp/Rbm22⁺ (C57BL/6NCrl-Rbm22^em1(IMPC)Mbp/Mmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
Rbm38^tm1.1Xch/Rbm38^tm1.1Xch (involves: C57BL/6 * FVB/N)	enlarged spleen	J:216929
Rbm38^tm1.1Xch/Rbm38^tm1.1Xch (involves: C57BL/6 * FVB/N)	increased spleen white pulp amount	J:216929
Rbm38^tm1.1Xch/Rbm38^tm1.1Xch Trp53^tm1Tyj/Trp53⁺ (involves: 129S2/SvPas * C57BL/6 * FVB/N)	abnormal spleen B cell follicle morphology	J:216929
Rbm43^em1Brsp/Rbm43^em1Brsp Tg(Adipoq-cre)1Evdr/0 (B6.Cg-Rbm43^em1Brsp Tg(Adipoq-cre)1Evdr)	abnormal innate immunity	J:363192
	decreased inflammatory response	J:363192
Rbp1^tm1Ipc/Rbp1^tm1Ipc (involves: 129S2/SvPas)	increased granulocyte number	J:67762
Rbp1^tm1Ipc/Rbp1^tm1Ipc (involves: 129S2/SvPas)	increased neutrophil cell number	J:67762
Rbpj^tm1Hon/Rbpj^tm1Hon (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:76240
Rbpj^tm1Hon/Rbpj^tm1Hon Tg(Cd4-cre)1Cwi/? (involves: 129P2/OlaHsd * C57BL/6 * DBA)	abnormal T-helper 2 cell differentiation	J:90018
Rbpj^tm1Hon/Rbpj^tm1Hon Tg(Itgax-cre)1-1Reiz/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA)	abnormal cytokine secretion	J:125869
	decreased dendritic cell number	J:125869
Rbpj^tm1Hon/Rbpj^tm1Hon Tg(Lck-cre)19Hhan/0 (involves: 129P2/OlaHsd * C57BL/6 * DBA)	abnormal CD4-positive helper T cell morphology	J:168475
	abnormal immune system physiology	J:168475
	abnormal regulatory T cell physiology	J:168475
	immune system phenotype	J:168475
	increased macrophage cell number	J:168475
	increased single-positive T cell number	J:168475
	increased splenocyte number	J:168475
	increased T cell number	J:168475
	increased T cell proliferation	J:168475
Rbpj^tm1Hon/Rbpj^tm1Hon Tg(Mx1-cre)1Cgn/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA)	abnormal B cell differentiation	J:99747
	abnormal lymphopoiesis	J:99747
	arrested T cell differentiation	J:125869, J:99747
	decreased dendritic cell number	J:125869
	decreased double-positive T cell number	J:99747
	decreased follicular dendritic cell number	J:125869
	decreased marginal zone B cell number	J:76240, J:99747
	decreased single-positive T cell number	J:99747
	decreased thymocyte number	J:99747
	increased B cell number	J:125869, J:99747
	increased double-negative T cell number	J:99747
	increased follicular B cell number	J:99747
	increased macrophage cell number	J:125869
	increased monocyte cell number	J:125869
	increased plasmacytoid dendritic cell number	J:125869
	small thymus	J:99747
Rbpj^tm1Kyo/Rbpj⁺ (involves: 129S2/SvPas * CD-1)	aortic valve inflammation	J:187551
Rbpj^tm1Kyo/Rbpj^tm1Kyo (involves: 129S2/SvPas)	abnormal humoral immune response	J:123631
	abnormal response to infection	J:123631
	decreased interleukin-4 secretion	J:123631
Rc3h1^{Gt(CC0753)Wtsi}/Rc3h1^{Gt(CC0753)Wtsi} (B6.129P2-Rc3h1^{Gt(CC0753)Wtsi})	chronic liver inflammation	J:199407
	ileum inflammation	J:199407
	intestinal inflammation	J:199407
Rc3h1^san/Rc3h1⁺ (involves: C57BL/6JSfdAnu)	abnormal lymph node germinal center morphology	J:189087
	abnormal lymph node morphology	J:189087
	abnormal T follicular helper cell physiology	J:189087
	enlarged lymph nodes	J:189087
	increased IgG level	J:189087
	increased spleen weight	J:189087
	increased T cell derived lymphoma incidence	J:189087
	increased T follicular helper cell number	J:189087
Rc3h1^san/Rc3h1^san (either: C57BL/6JSfdAnu-Rc3h1^san/Anu or (involves: C57BL/6JSfdAnu * CBA/Ca))	abnormal T cell differentiation	J:98938
	enlarged lymph nodes	J:98938
	glomerulonephritis	J:98938
	increased anti-double stranded DNA antibody level	J:98938
	increased anti-nuclear antigen antibody level	J:98938
	liver inflammation	J:98938
Rc3h1^san/Rc3h1^san (involves: C57BL/6JSfdAnu)	abnormal effector T cell morphology	J:199407
	abnormal intraepithelial T cell number	J:199407
	cecum inflammation	J:199407
	chronic liver inflammation	J:199407
	colitis	J:199407
	enlarged spleen	J:199407
	granulomatous inflammation	J:199407
	ileum inflammation	J:199407
	increased activated T cell number	J:199407
	increased CD4-positive, alpha-beta T cell number	J:199407
	increased circulating tumor necrosis factor level	J:196137
	increased T cell proliferation	J:199407
	lymphoid hyperplasia	J:199407
	small intestinal inflammation	J:199407
Rc3h1^san/Rc3h1^san Rc3h2^tm1.2Cgv/Rc3h2^tm1.2Cgv (involves: C57BL/6 * C57BL/6JSfdAnu)	increased circulating tumor necrosis factor level	J:196137
	increased inflammatory response	J:196137
	increased susceptibility to bacterial infection	J:196137
	increased T follicular helper cell number	J:196137
	kidney inflammation	J:196137
Rc3h1^tm1.1Mass/Rc3h1^tm1.1Mass Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129P2/OlaHsd * C57BL/6 * NZB * SJL)	abnormal effector T cell morphology	J:177784
	enlarged spleen	J:177784
	increased B cell number	J:177784
	increased eosinophil cell number	J:177784
	increased regulatory T cell number	J:177784
	increased spleen weight	J:177784
Rc3h1^tm1.1Mass/Rc3h1^tm1.1Mass Commd10^{Tg(Vav1-icre)A2Kio}/Commd10⁺ (involves: C57BL/6 * C57BL/10 * CBA/Ca * NZB * SJL)	abnormal B cell differentiation	J:177784
	abnormal effector T cell morphology	J:177784
	abnormal germinal center B cell physiology	J:177784
	abnormal spleen B cell follicle morphology	J:177784
	decreased B cell number	J:177784
	decreased IgA level	J:177784
	decreased IgG1 level	J:177784
	decreased IgG3 level	J:177784
	decreased immature B cell number	J:177784
	enlarged spleen	J:177784
	immune system phenotype	J:177784
	increased eosinophil cell number	J:177784
	increased IgG2b level	J:177784
	increased macrophage cell number	J:177784
	increased regulatory T cell number	J:177784
	increased spleen weight	J:177784
	increased splenocyte number	J:177784
	spleen hyperplasia	J:177784
Rc3h1^tm1.1Mass/Rc3h1^tm1.1Mass Rc3h2^{tm1c(KOMP)Wtsi}/Rc3h2^{tm1c(KOMP)Wtsi} Tg(Cd4-cre)1Cwi/? (involves: C57BL/6N * DBA/2)	abnormal B cell number	J:196136
	abnormal immune system cell morphology	J:196136
	abnormal immune system organ morphology	J:196136
	abnormal immune system physiology	J:196136
	abnormal spleen B cell follicle morphology	J:196136
	abnormal spleen morphology	J:196136
	abnormal spleen periarteriolar lymphoid sheath morphology	J:196136
	decreased CD4-positive, alpha-beta T cell number	J:196136
	decreased CD8-positive, alpha-beta T cell number	J:196136
	decreased T cell number	J:196136
	enlarged lymph nodes	J:196136
	enlarged spleen	J:196136
	increased germinal center B cell number	J:196136
	increased T cell proliferation	J:196136
	increased T follicular helper cell number	J:196136
Rc3h1^tm1.1Mass/Rc3h1^tm1.1Mass Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2 * NZB * SJL)	immune system phenotype	J:177784
	increased CD8-positive, alpha-beta T cell number	J:177784
	increased eosinophil cell number	J:177784
	increased macrophage cell number	J:177784
Rc3h1^tm1.2Cgv/Rc3h1^san (involves: C57BL/6 * C57BL/6JSfdAnu)	increased CD4-positive, alpha-beta T cell number	J:196137
	increased T follicular helper cell number	J:196137
Rc3h1^tm1.2Mass/Rc3h1^tm1.2Mass (involves: C57BL/6 * CBA * NZB * SJL)	abnormal thymus development	J:177784
Rc3h1^tm1.2Mass/Rc3h1^tm1.2Mass (involves: C57BL/6 * CBA * CD-1 * NZB * SJL)	abnormal effector T cell morphology	J:177784
	enlarged spleen	J:177784
	immune system phenotype	J:177784
	increased spleen weight	J:177784
Rc3h2^tm1.2Cgv/Rc3h2^tm1.2Cgv (involves: C57BL/6)	immune system phenotype	J:196137
	increased macrophage cytokine production	J:196137
	increased tumor necrosis factor secretion	J:196137
Rc3h2^{tm1a(KOMP)Wtsi}/Rc3h2^{tm1a(KOMP)Wtsi} (involves: C57BL/6N * NMRI)	immune system phenotype	J:196136
Rc3h2^{tm1c(KOMP)Wtsi}/Rc3h2^{tm1c(KOMP)Wtsi} Tg(Cd4-cre)1Cwi/? (involves: C57BL/6N * DBA/2)	immune system phenotype	J:196136
Rcan1^tm1Fmc/Rcan1^tm1Fmc (involves: 129S4/SvJae)	abnormal T cell apoptosis	J:85148
	abnormal T-helper 1 physiology	J:85148
	decreased IgG2a level	J:85148
	decreased interferon-gamma secretion	J:85148
	decreased T cell proliferation	J:85148
	increased susceptibility to endotoxin shock	J:152536
Rcan1^tm1Jmol/Rcan1^tm1Jmol Rcan2^tm1Jmol/Rcan2^tm1Jmol (involves: 129 * C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:109586
	abnormal cytokine secretion	J:109586
	decreased T cell proliferation	J:109586
Rcan1^tm1Jmol/Rcan1^tm1Jmol Rcan2^tm1Jmol/Rcan2^tm1Jmol Ppp3cb^tm1Jmk/Ppp3cb^tm1Jmk (involves: 129S6/SvEvTac * C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:109586
	abnormal CD4-positive, alpha-beta T cell physiology	J:109586
	abnormal CD8-positive, alpha beta T cell morphology	J:109586
	abnormal cytokine secretion	J:109586
	decreased T cell proliferation	J:109586
Rcbtb2^tm1.1Xyw/Rcbtb2⁺ (involves: C57BL/6 * CBA)	enlarged mesenteric lymph nodes	J:282928
Rcbtb2^tm1.1Xyw/Rcbtb2⁺ (involves: C57BL/6 * CBA)	enlarged spleen	J:282928
Rcbtb2^tm1.1Xyw/Rcbtb2^tm1.1Xyw (involves: C57BL/6 * CBA)	abnormal splenocyte physiology	J:282928
	enlarged mesenteric lymph nodes	J:282928
	enlarged spleen	J:282928
Rcc1l^{tm1a(EUCOMM)Hmgu}/Rcc1l⁺ (Not Specified)	decreased IgG1 level	J:165965
Rdh7^{tm1c(KOMP)Wtsi}/Rdh7^{tm1c(KOMP)Wtsi} Tg(RARE-Hspa1b/lacZ)12Jrt/0 Tg(Vil1-cre)997Gum/0 (involves: C57BL/6J * C57BL/6N * CD-1 * SJL)	decreased lymphocyte cell number	J:279231
	decreased susceptibility to bacterial infection	J:279231
	immune system phenotype	J:279231
Rdns/Rdns⁺ (C57BL/6J-Rdns/GrsrJ)	increased susceptibility to otitis media	J:223062
Rdur^em1Jiche/Rdur^em1Jiche (Not Specified)	increased circulating interleukin-1 level	J:340209
	increased circulating interleukin-6 level	J:340209
	increased susceptibility to viral infection	J:340209
	increased susceptibility to viral infection induced morbidity/mortality	J:340209
Recql4^tm1Abe/Recql4^tm1Abe (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal thymus corticomedullary boundary morphology	J:85574
	decreased spleen white pulp amount	J:85574
	small thymus	J:85574
Reep3^em1(IMPC)Tcp/Reep3^em1(IMPC)Tcp (C57BL/6NCrl-Reep3^em1(IMPC)Tcp/Cmmr)	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
Reg3g^tm1.1Lvh/Reg3g^tm1.1Lvh (B6.129-Reg3g^tm1.1Lvh)	immune system phenotype	J:177506
	increased IgA level	J:177506
	increased T-helper 1 cell number	J:177506
Reg3g^{tm1a(KOMP)Wtsi}/Reg3g^{tm1a(KOMP)Wtsi} (C57BL/6-Reg3g^{tm1a(KOMP)Wtsi})	increased susceptibility to Orthomyxoviridae infection	J:233979
Rel^M1Btlr/Rel⁺ (C57BL/6J-Rel^M1Btlr)	decreased IgE level	J:236682
	decreased IgG level	J:236682
	decreased IgM level	J:236682
	decreased response to antigen	J:236682
	increased CD4-positive, alpha-beta T cell number	J:236682
	increased T cell number	J:236682
Rel^M1Btlr/Rel^M1Btlr (C57BL/6J-Rel^M1Btlr)	decreased B-1 B cell number	J:236682
	decreased CD4-positive, alpha-beta T cell number	J:236682
	decreased CD8-positive, alpha-beta T cell number	J:236682
	decreased IgE level	J:236682
	decreased IgG level	J:236682
	decreased IgM level	J:236682
	decreased response to antigen	J:236682
	increased CD4-positive, alpha-beta T cell number	J:236682
	increased CD8-positive, alpha-beta T cell number	J:236682
	increased effector memory CD4-positive, alpha-beta T cell number	J:236682
	increased T cell number	J:236682
Rel^M2Btlr/Rel^M2Btlr (C57BL/6J-Rel^M2Btlr)	abnormal CD4-positive T cell differentiation	J:272778
	abnormal T cell differentiation	J:272778
	decreased alpha-beta T cell number	J:272778
	decreased B-1 B cell number	J:272778
	decreased CD4-positive, alpha-beta T cell number	J:272778
	decreased central memory CD4-positive, alpha-beta T cell number	J:272778
	decreased effector memory CD4-positive, alpha-beta T cell number	J:272778
Rel^m3Btlr/Rel^m3Btlr (C57BL/6J-Rel^m3Btlr)	decreased IgM level	J:272801
Rel^m3Btlr/Rel^m3Btlr (C57BL/6J-Rel^m3Btlr)	impaired humoral immune response	J:272801
Rel^{tm1b(EUCOMM)Wtsi}/Rel^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Rel^{tm1b(EUCOMM)Wtsi}/H)	decreased monocyte cell number	J:211773
Rel^tm1Brv/Rel^tm1Brv (involves: 129S1/Sv)	abnormal leukocyte physiology	J:46911
	abnormal macrophage morphology	J:46911
	abnormal macrophage physiology	J:46911
	abnormal spleen morphology	J:46911
	abnormal splenic cell ratio	J:46911
	abnormal T cell physiology	J:46911
	decreased IgG1 level	J:46911
	decreased IgG2b level	J:46911
	decreased IgG3 level	J:46911
	decreased IgG level	J:46911
	decreased spleen germinal center number	J:46911
	dermatitis	J:46911
	enlarged lymph nodes	J:46911
	enlarged spleen	J:46911
	impaired macrophage chemotaxis	J:46911
	increased IgA level	J:46911
	increased IgG2a level	J:46911
	increased IgM level	J:46911
	increased spleen B cell follicle size	J:46911
	increased susceptibility to bacterial infection	J:46911
Rel^tm1Grd/Rel⁺ (involves: 129S1/Sv * C57BL/6)	abnormal humoral immune response	J:28435
Rel^tm1Grd/Rel⁺ (involves: 129S1/Sv * C57BL/6)	decreased B cell proliferation	J:28435
Rel^tm1Grd/Rel^tm1Grd (involves: 129S1/Sv * C57BL/6)	abnormal cytokine secretion	J:37541, J:28435
	abnormal humoral immune response	J:28435
	abnormal macrophage physiology	J:37541
	decreased B cell proliferation	J:28435
	decreased IgG1 level	J:28435
	decreased IgG2a level	J:28435
	decreased IgG2b level	J:28435
	decreased IgG3 level	J:28435
	decreased IgM level	J:28435
	decreased susceptibility to parasitic infection	J:37541
	decreased T cell proliferation	J:28435
Rel^tm1Grd/Rel^tm1Grd (involves: 129S1/Sv)	immune system phenotype	J:113514
Rel^tm1Grd/Rel^tm1Grd Rela^tm1Bal/Rela^tm1Bal (B6.129S-Rel^tm1Grd Rela^tm1Bal)	abnormal monocyte differentiation	J:111325
	increased granulocyte number	J:111325
Rel^tm1Hcl/Rel⁺ (involves: 129S4/SvJae * C57BL/6)	decreased T cell proliferation	J:53513
Rel^tm1Hcl/Rel^tm1Hcl (involves: 129S4/SvJae * C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:79107, J:118907
	abnormal cytokine secretion	J:53513, J:79107
	abnormal dendritic cell physiology	J:118907
	abnormal macrophage physiology	J:118907
	abnormal memory B cell number	J:75621
	abnormal professional antigen presenting cell physiology	J:118907
	abnormal T-helper 1 cell differentiation	J:79107
	decreased B cell proliferation	J:75621
	decreased cytotoxic T cell cytolysis	J:53513
	decreased IgE level	J:58987
	decreased susceptibility to autoimmune diabetes	J:118907
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:79107
	decreased T cell proliferation	J:53513, J:79107
	immune system phenotype	J:53513, J:118907, J:58987
	increased eosinophil cell number	J:58987
Rela^tm1Asba/Rela^tm1Asba Tg(Vil1-cre)997Gum/0 (involves: 129 * C57BL/6J * SJL)	increased susceptibility to induced colitis	J:131977
Rela^tm1Bal/Rela^tm1Bal (involves: 129S4/SvJae)	decreased marginal zone B cell number	J:65246
Rela^tm1Bal/Rela^tm1Bal (involves: 129S4/SvJae)	immune system phenotype	J:113514
Rela^tm1Bal/Rela^tm1Bal Tnfrsf1a^tm1Imx/Tnfrsf1a^tm1Imx (involves: 129S4/SvJae * C57BL/6)	abnormal spleen germinal center morphology	J:60742
	abnormal thymus morphology	J:60742
	decreased spleen white pulp amount	J:60742
	heart inflammation	J:60742
	liver inflammation	J:60742
	lung inflammation	J:60742
Rela^tm1Mpa/Rela^tm1Mpa Tg(Alb1-cre)7Gsc/0 (involves: FVB/N)	increased susceptibility to endotoxin shock	J:137861
Rela^tm1Rsch/Rela^tm1Rsch Ptf1a^tm1(cre)Hnak/? (involves: C57BL/6)	abnormal interleukin level	J:122194
	abnormal tumor necrosis factor level	J:122194
	lung inflammation	J:122194
	pancreas inflammation	J:122194
Rela^tm1Rsch/Rela^tm1Rsch Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	abnormal gamma-delta T cell morphology	J:169863
Rela^tm1Rsch/Rela^tm1Rsch Tg(Lck-cre)I57Jxm/0 (involves: ICR)	abnormal gamma-delta T cell morphology	J:169863
	decreased interleukin-17 secretion	J:169863
	immune system phenotype	J:169863
	increased susceptibility to bacterial infection	J:169863
Rela^tm1Yuo/Rela^tm1Yuo (involves: 129S/SvEv)	abnormal lymphocyte physiology	J:63099
	decreased B cell proliferation	J:63099
	decreased double-positive T cell number	J:63099
	decreased IgA level	J:63099
	decreased IgG1 level	J:63099
	decreased T cell proliferation	J:63099
Rela^tm2.1Gho/Rela^tm2.1Gho (involves: 129S6/SvEvTac * C57BL/6)	abnormal spleen morphology	J:163663
	increased inflammatory response	J:163663
	increased neutrophil cell number	J:163663
	interstitial pneumonia	J:163663
	liver inflammation	J:163663
	lung inflammation	J:163663
	myositis	J:163663
Rela^tm2.1Gho/Rela^tm2.1Gho Tnfrsf1a^tm1Mak/Tnfrsf1a^tm1Mak (involves: 129S2/SvPas * 129S6/SvEvTac)	increased incidence of corneal inflammation	J:163663
	liver inflammation	J:163663
Relb^shep/Relb^shep (A;C-Relb^shep/GrsrJ)	liver inflammation	J:171971
Relb^{Tg(H2-K1/GH1)106Bri}/Relb⁺ (involves: C57BL/6)	decreased NK T cell number	J:120659
	decreased Peyer's patch number	J:120659
	small Peyer's patches	J:120659
Relb^{Tg(H2-K1/GH1)106Bri}/Relb^{Tg(H2-K1/GH1)106Bri} (C57BL/6-Relb^{Tg(H2-K1/GH1)106Bri})	abnormal antigen presentation	J:23081
	abnormal lymph node morphology	J:76450
	abnormal Peyer's patch morphology	J:76450
	absent thymus medulla	J:23081, J:76450
	decreased B cell number	J:76450
	decreased pre-B cell number	J:76450
	decreased T cell number	J:76450
	decreased T cell proliferation	J:76450
	enlarged spleen	J:76450
	glomerulonephritis	J:76450
	increased granulocyte number	J:23081, J:76450
	increased inflammatory response	J:23081, J:76450
	increased macrophage cell number	J:23081, J:76450
	liver inflammation	J:76450
	lung inflammation	J:76450
	skin inflammation	J:76450
Relb^{Tg(H2-K1/GH1)106Bri}/Relb^{Tg(H2-K1/GH1)106Bri} (involves: C57BL/6)	absent lymph nodes	J:120659
	absent Peyer's patches	J:120659
	decreased circulating interleukin-4 level	J:120659
	decreased NK T cell number	J:120659
	increased inflammatory response	J:120659
Relb^tm1.1Fwei/Relb^tm1.1Fwei Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	immune system phenotype	J:169863
Relb^tm1.1Fwei/Relb^tm1.1Fwei Tg(Lck-cre)I57Jxm/0 (involves: ICR)	abnormal gamma-delta T cell morphology	J:169863
	decreased interleukin-17 secretion	J:169863
	immune system phenotype	J:169863
	increased susceptibility to bacterial infection	J:169863
Relb^tm1Brv/Relb^tm1Brv (involves: 129S2/SvPas * C57BL/6)	abnormal cell-mediated immunity	J:22675
	abnormal cytokine level	J:40630
	abnormal cytotoxic T cell physiology	J:40630
	abnormal humoral immune response	J:40630
	abnormal immune system organ morphology	J:22675
	abnormal immune system physiology	J:22675, J:40630
	abnormal immunoglobulin level	J:40630
	abnormal interferon level	J:40630
	abnormal interleukin level	J:40630
	abnormal lymph node morphology	J:22675
	abnormal macrophage physiology	J:40630
	abnormal mesenteric lymph node morphology	J:22675
	abnormal tumor necrosis factor level	J:40630
	decreased B cell proliferation	J:40630
	decreased dendritic cell number	J:22675
	decreased spleen white pulp amount	J:22675
	decreased susceptibility to type IV hypersensitivity reaction	J:22675
	decreased T cell number	J:22675
	epididymis inflammation	J:22675
	impaired neutrophil phagocytosis	J:40630
	increased IgE level	J:40630
	increased IgM level	J:40630
	increased spleen red pulp amount	J:22675
	increased spleen weight	J:22675
	increased susceptibility to bacterial infection	J:40630
	increased susceptibility to Riboviria infection	J:40630
	intestinal inflammation	J:22675
	liver inflammation	J:22675
	lung inflammation	J:22675
	myeloid hyperplasia	J:22675
	myositis	J:22675
	ovary inflammation	J:22675
	salivary gland inflammation	J:22675
	stomach inflammation	J:22675
	thymus atrophy	J:22675
	thymus hypoplasia	J:22675
Relb^tm1Brv/Relb^tm1Brv (either: (involves: 129S2/SvPas) or (involves: C57BL/6) or (involves: 129S2/SvPas * C57BL/6))	dermatitis	J:63950
	increased eosinophil cell number	J:63950
	lung inflammation	J:63950
Relb^tm1Brv/Relb^tm1Brv (involves: 129S2/SvPas)	abnormal gamma-delta T cell morphology	J:169863
	decreased dendritic cell number	J:85808
	spleen hyperplasia	J:85808
Reln^em1(IMPC)Mbp/Reln⁺ (C57BL/6N-Reln^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
Relt^tm1Hlee/Relt^tm1Hlee (Not Specified)	abnormal T cell morphology	J:266480
	immune system phenotype	J:266480
	increased T cell proliferation	J:266480
Ren1^tm1Tkh/Ren1^tm1Tkh (C57BL/6-Ren1^tm1Tkh)	kidney inflammation	J:110082
Ret^tm2.1Cos/Ret^tm2.1Cos (involves: 129S1/Sv)	immune system phenotype	J:195828
Ret^tm6.1Vpa/Ret^tm6.2Vpa Tg(CD2-icre)4Kio/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/10 * CBA/Ca)	immune system phenotype	J:195828
Retn^tm1Laz/Retn^tm1Laz Tg(CD68-RETN)#Laz/? (involves: 129S6/SvEvTac * C57BL/6)	white adipose tissue inflammation	J:171262
Retnla^tm1Mer/Retnla^tm1Mer (C57BL/6-Retnla^tm1Mer)	abnormal chemokine secretion	J:144784
	decreased interleukin-5 secretion	J:144784
	decreased interleukin-6 secretion	J:144927
	decreased susceptibility to induced colitis	J:144784, J:144927
	impaired eosinophil recruitment	J:144784
	increased interleukin-10 secretion	J:144927
Retnla^tm1Mer/Retnla^tm1Mer (C.B6-Retnla^tm1Mer)	decreased susceptibility to induced colitis	J:144784, J:144927
Retnla^tm1Mer/Retnla^tm1Mer (involves: C57BL/6)	abnormal macrophage physiology	J:147863
	abnormal T-helper 2 physiology	J:147863
	increased IgE level	J:147863
	increased IgG1 level	J:147863
	increased interleukin-4 secretion	J:147863
	increased interleukin-5 secretion	J:147863
	increased interleukin-13 secretion	J:147863
Retnlb^tm1Gdw/Retnlb^tm1Gdw (involves: 129S/SvEv * C57BL/6)	decreased inflammatory response	J:114507
Retnlb^tm1Gdw/Retnlb^tm1Gdw (involves: 129S/SvEv * C57BL/6)	decreased susceptibility to induced colitis	J:114507
Retnlb^tm1Lex/Retnlb^tm1Lex (FVB.129S5-Retnlb^tm1Lex)	abnormal CD4-positive, alpha-beta T cell physiology	J:235058
	decreased circulating interleukin-6 level	J:235058
	increased circulating interleukin-13 level	J:235058
	increased neutrophil cell number	J:235058
	liver inflammation	J:235058
	white adipose tissue inflammation	J:235058
Retnlb^tm1Mer/Retnlb^tm1Mer (involves: 129S1/Sv * C57BL/6)	decreased susceptibility to induced colitis	J:141524
Retnlb^tm1Mer/Retnlb^tm1Mer (involves: 129S1/Sv * C57BL/6)	increased susceptibility to induced colitis	J:141524
Retnlb^tm1Mer/Retnlb^tm1Mer (involves: 129S1/Sv)	decreased IgG2a level	J:141446
	decreased interferon-gamma secretion	J:141446
	decreased susceptibility to parasitic infection	J:141446
	decreased tumor necrosis factor secretion	J:141446
	increased IgG1 level	J:141446
Retreg2^{em2(IMPC)Ccpcz}/Retreg2^{em2(IMPC)Ccpcz} (C57BL/6N-Retreg2^{em2(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
Rev1^tm1.1Jow/Rev1^tm1.1Jow (involves: C57BL/6)	abnormal somatic hypermutation frequency	J:151700
Rev1^tm1.1Jow/Rev1^tm1.1Jow (involves: C57BL/6)	immune system phenotype	J:151700
Rev1^tm1Ndew/Rev1^tm1Ndew (involves: 129P2/OlaHsd * C57BL/6)	abnormal somatic hypermutation frequency	J:119176
	immune system phenotype	J:119176
	lymphoid hypoplasia	J:119176
Rev3l^tm1.1Kunk/Rev3l^tm1.1Kunk (involves: C57BL/6)	abnormal somatic hypermutation frequency	J:188723
Rev3l^tm1.1Kunk/Rev3l^tm1.1Kunk (involves: C57BL/6)	immune system phenotype	J:188723
Rev3l^tm1Rsky/Rev3l^tm1.1Rsky Tg(Cr2-cre)3Cgn/? (involves: C57BL/6)	abnormal class switch recombination	J:146453
	abnormal somatic hypermutation frequency	J:146453
	decreased B cell proliferation	J:146453
	decreased germinal center B cell number	J:146453
	decreased IgG1 level	J:146453
Rev3l^tm1Rwd/Rev3l^tm2.1Rwd Trp53^tm1Brd/Trp53^tm1Brd Tg(MMTV-cre)1Mam/0 (involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * FVB/N)	increased T cell derived lymphoma incidence	J:158922
Rexo2^{tm1b(EUCOMM)Wtsi}/Rexo2⁺ (C57BL/6N-Rexo2^{tm1b(EUCOMM)Wtsi}/H)	decreased neutrophil cell number	J:211773
	increased lymphocyte cell number	J:211773
Rffl^{em1(IMPC)Ccpcz}/Rffl^{em1(IMPC)Ccpcz} (C57BL/6N-Rffl^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Rfk^em1(IMPC)Mbp/Rfk⁺ (C57BL/6NCrl-Rfk^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	small spleen	J:211773
Rfk^tm1.1Jcbr/Rfk^tm1.1Jcbr Tg(Mx1-cre)1Cgn/? (involves: C57BL/6 * CBA)	decreased macrophage nitric oxide production	J:151999
Rft1^{tm1b(KOMP)Wtsi}/Rft1⁺ (C57BL/6N-Rft1^{tm1b(KOMP)Wtsi}/Bay)	decreased lymphocyte cell number	J:211773
	increased basophil cell number	J:211773
	increased monocyte cell number	J:211773
Rftn1^tm1Ayos/Rftn1^tm1Ayos (B6.Cg-Rftn1^tm1Ayos)	abnormal CD4-positive T cell differentiation	J:150299
	decreased IgG2a level	J:150299
	decreased interferon-gamma secretion	J:150299
	decreased interleukin-4 secretion	J:150299
	decreased interleukin-17 secretion	J:150299
	decreased splenocyte number	J:150299
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:150299
Rfx5^tm1.1Ifo/Rfx5^tm1.1Ifo (involves: 129 * C57BL/6)	abnormal B lymphocyte antigen presentation	J:67941
	abnormal dendritic cell morphology	J:67941
	abnormal Kupffer cell morphology	J:67941
	abnormal level of surface class II molecules	J:67941
	abnormal MHC II cell surface expression on macrophages	J:67941
	abnormal thymus cortex morphology	J:67941
	decreased CD4-positive, alpha-beta T cell number	J:67941
	decreased IgG1 level	J:67941
	decreased IgM level	J:67941
	decreased single-positive T cell number	J:67941
Rfx5^tm1Ifo/Rfx5^tm1.1Ifo Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129 * C57BL/6 * C.B-20)	abnormal MHC II cell surface expression on macrophages	J:67924
Rfx5^tm1Ifo/Rfx5^tm1Ifo (involves: 129P2/OlaHsd * C57BL/6J)	immune system phenotype	J:282535
Rfx7^tm1.1Ggaur/Rfx7^tm1.1Ggaur Commd10^{Tg(Vav1-icre)A2Kio}/Commd10⁺ (involves: C57BL/6 * C57BL/10 * CBA/Ca)	abnormal NK cell morphology	J:282535
	decreased NK cell number	J:282535
	small spleen	J:282535
Rfx7^tm1.1Ggaur/Rfx7^tm1.1Ggaur Ncr1^{tm1.1(icre)Viv}/Ncr1⁺ (involves: C57BL/6)	abnormal NK cell physiology	J:282535
	decreased NK cell number	J:282535
	increased susceptibility to viral infection	J:282535
Rfx7^tm1.1Ggaur/Rfx7^tm1.1Ggaur Rptor^tm1.1Dmsa/Rptor⁺ Commd10^{Tg(Vav1-icre)A2Kio}/Commd10⁺ (involves: 129S/SvEv * C57BL/10 * CBA/Ca)	abnormal NK cell morphology	J:282535
	decreased NK cell number	J:282535
	small spleen	J:282535
Rgcc^tm1Hrus/Rgcc^tm1Hrus (involves: 129S6/SvEvTac * C57BL/6)	increased interleukin-2 secretion	J:279555
	increased T cell proliferation	J:279555
Rgl1^em1(IMPC)Mbp/Rgl1⁺ (C57BL/6N-Rgl1^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	increased neutrophil cell number	J:211773
Rgs1^tm1Jhk/Rgs1^tm1Jhk (B6.129P2-Rgs1^tm1Jhk)	abnormal B cell calcium ion homeostasis	J:90780
	abnormal dendritic cell physiology	J:89680
	abnormal spleen germinal center morphology	J:90780
	decreased plasma cell number	J:90780
	enhanced B cell migration	J:90780
	increased immunoglobulin level	J:90780
	increased marginal zone B cell number	J:90780
	small Peyer's patches	J:90780
Rgs2^em1(IMPC)H/Rgs2^em1(IMPC)H (C57BL/6NTac-Rgs2^em1(IMPC)H/H)	enlarged spleen	J:211773
Rgs2^tm1Pngr/Rgs2^tm1Pngr (involves: C57BL/6J)	abnormal T cell proliferation	J:77273
Rgs3^tm1Ndul/Rgs3^tm1Ndul (B6.129-Rgs3^tm1Ndul)	abnormal lymph node morphology	J:210195
	immune system phenotype	J:210195
	increased B cell number	J:210195
	increased CD4-positive, alpha-beta T cell number	J:210195
	increased CD8-positive, alpha-beta T cell number	J:210195
	increased susceptibility to type I hypersensitivity reaction	J:210195
	lung inflammation	J:210195
Rgs4^em1(IMPC)H/Rgs4^em1(IMPC)H (C57BL/6N-Rgs4^em1(IMPC)H/H)	decreased lymphocyte cell number	J:211773
	increased eosinophil cell number	J:211773
	increased spleen weight	J:211773
Rgs4^tm1Sdlk/Rgs4^tm1Sdlk Tg(Myh11-icre/ERT2)1Soff/? (involves: FVB/N)	abnormal macrophage chemotaxis	J:215588
Rgs5^tm1Jhk/Rgs5^tm1Jhk (involves: 129S/SvEv * C57BL/6)	decreased lymphocyte cell number	J:133897
Rgs9^{em1(IMPC)Ccpcz}/Rgs9^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Rgs9^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
Rgs10^tm1Ypl/Rgs10^tm1Ypl (involves: 129S4/SvJae * C57BL/6J)	abnormal osteoclast differentiation	J:123167
	decreased osteoclast cell number	J:123167
Rgs12^tm1.1Syy/Rgs12^tm1.1Syy Tg(Mx1-cre)1Cgn/0 (involves: 129 * C57BL/6 * CBA)	decreased osteoclast cell number	J:194057
Rgs13^tm1.1Jhk/Rgs13^tm1.1Jhk (involves: C57BL/6)	abnormal B cell differentiation	J:199530
	abnormal humoral immune response	J:199530
	abnormal spleen morphology	J:199530
	decreased B cell number	J:199530
	immune system phenotype	J:199530
	increased B cell number	J:199530
	increased germinal center B cell number	J:199530
	increased IgA level	J:199530
	increased IgG1 level	J:199530
	increased IgG2b level	J:199530
	increased IgG2c level	J:199530
	increased IgG3 level	J:199530
	increased IgM level	J:199530
	increased spleen germinal center number	J:199530
	increased spleen germinal center size	J:199530
Rgs13^tm1Drue/Rgs13^tm1Drue (B6.129S-Rgs13^tm1Drue)	abnormal mast cell physiology	J:130209
Rgs13^tm1Drue/Rgs13^tm1Drue (B6.129S-Rgs13^tm1Drue)	increased susceptibility to type I hypersensitivity reaction	J:130209
Rgs14^tm1Lex/Rgs14^tm1Lex (involves: 129S5/SvEvBrd)	immune system phenotype	J:103485
Rgs16^tm1.1Drue/Rgs16^tm1.1Drue (involves: C57BL/6)	abnormal T-helper 1 physiology	J:188966
	abnormal T-helper 2 physiology	J:188966
	granulomatous inflammation	J:188966
	increased interleukin-5 secretion	J:188966
	increased interleukin-10 secretion	J:188966
	increased interleukin-13 secretion	J:188966
	increased susceptibility to parasitic infection	J:188966
Rgsc14/Rgsc14⁺ (involves: C57BL/6JJcl * DBA/2JJcl)	increased leukocyte cell number	J:133634
Rgsc14/Rgsc14⁺ (involves: C57BL/6JJcl * DBA/2JJcl)	increased lymphocyte cell number	J:133634
Rgsc15/Rgsc15⁺ (involves: C57BL/6JJcl * DBA/2JJcl)	increased leukocyte cell number	J:133634
Rgsc15/Rgsc15⁺ (involves: C57BL/6JJcl * DBA/2JJcl)	increased lymphocyte cell number	J:133634
Rgsc17/Rgsc17⁺ (involves: C57BL/6JJcl * DBA/2JJcl)	decreased leukocyte cell number	J:133634
Rgsc17/Rgsc17⁺ (involves: C57BL/6JJcl * DBA/2JJcl)	decreased lymphocyte cell number	J:133634
Rgsc142/Rgsc142⁺ (involves: C57BL/6JJcl * DBA/2JJcl)	increased T cell derived lymphoma incidence	J:133634
Rgsc844/Rgsc844⁺ (involves: C57BL/6JJcl * DBA/2JJcl)	abnormal neutrophil physiology	J:133634
Rgsc1045/Rgsc1045⁺ (involves: C57BL/6JJcl * DBA/2JJcl)	abnormal neutrophil physiology	J:133634
Rgsc1354/Rgsc1354⁺ (involves: C3H * C57BL/6JJcl)	abnormal neutrophil physiology	J:133634
Rgsc1547/Rgsc1547⁺ (involves: C3H * C57BL/6JJcl)	increased susceptibility to otitis media	J:133634
Rhag^{em1(IMPC)Ccpcz}/Rhag^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Rhag^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged thymus	J:211773
Rhbdd1^tm1.1Mfm/Rhbdd1^tm1.1Mfm (involves: 129S/SvEv * C57BL/6J)	increased interleukin-6 secretion	J:346394
	increased susceptibility to endotoxin shock	J:346394
	increased tumor necrosis factor secretion	J:346394
Rhbdd3^tm1Caox/Rhbdd3^tm1Caox (B6.129S6-Rhbdd3^tm1Caox)	abnormal dendritic cell physiology	J:197348
	immune system phenotype	J:197348
	increased circulating interferon-gamma level	J:197348
	increased circulating interleukin-6 level	J:197348
	increased interferon-gamma secretion	J:197348
	increased interleukin-6 secretion	J:197348
	increased natural killer cell mediated cytotoxicity	J:197348
	increased NK cell number	J:197348
	liver inflammation	J:197348
Rhbdf1^tm1.1Mfm/Rhbdf1^tm1.1Mfm (involves: 129S/SvEv * 129S6/SvEvTac * C57BL/6J)	small spleen	J:203951
	small thymus	J:203951
Rhbdf2^cub/Rhbdf2^cub (B6.Cg-Rhbdf2^cub)	white adipose tissue inflammation	J:82006
Rhbdf2^m1Btlr/Rhbdf2^m1Btlr (C57BL/6J-Rhbdf2^m1Btlr)	decreased tumor necrosis factor secretion	J:187583
Rhbdf2^m1Btlr/Rhbdf2^{tm1a(KOMP)Wtsi} (involves: C57BL/6J * C57BL/6N)	decreased tumor necrosis factor secretion	J:187583
Rhbdf2^M2Btlr/Rhbdf2⁺ (C57BL/6J-Rhbdf2^M2Btlr)	abnormal immune system physiology	J:213194
Rhbdf2^M3Btlr/Rhbdf2⁺ (C57BL/6J-Rhbdf2^M3Btlr)	abnormal immune system physiology	J:220064
Rhbdf2^M3Btlr/Rhbdf2^M3Btlr (C57BL/6J-Rhbdf2^M3Btlr)	abnormal immune system physiology	J:220064
Rhbdf2^tm1.1Mfm/Rhbdf2^tm1.1Mfm (B6.129S-Rhbdf2^tm1.1Mfm)	decreased circulating tumor necrosis factor level	J:179654
Rhbdf2^tm1.1Mfm/Rhbdf2^tm1.1Mfm (B6.129S-Rhbdf2^tm1.1Mfm)	decreased tumor necrosis factor secretion	J:179654
Rhbdf2^{tm1a(KOMP)Wtsi}/Rhbdf2^{tm1a(KOMP)Wtsi} (involves: C57BL/6N)	decreased tumor necrosis factor secretion	J:187583
Rhbdf2^tm1Mak/Rhbdf2^tm1Mak (B6.129P2-Rhbdf2^tm1Mak)	abnormal B cell physiology	J:179653
	abnormal immune serum protein physiology	J:179653
	decreased circulating tumor necrosis factor level	J:179653
	decreased susceptibility to infection induced morbidity/mortality	J:179653
	decreased tumor necrosis factor secretion	J:179653
	increased susceptibility to bacterial infection	J:179653
	increased susceptibility to bacterial infection induced morbidity/mortality	J:179653
Rhbdf2^tm1Mak/Rhbdf2^tm1Mak (involves: 129P2/OlaHsd * C57BL/6)	abnormal leukocyte physiology	J:221411
	abnormal microglial cell physiology	J:221411
	decreased tumor necrosis factor secretion	J:221411
Rheb^tm1Pfw/Rheb^tm1Pfw Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	immune system phenotype	J:150108
Rho^tm2.1Kpal/Rho^tm2.1Kpal (involves: 129S6/SvEvTac * C57BL/6J * C57BL/6NTac)	microgliosis	J:194158
Rhoa^tm1.1Tpal/Rhoa⁺ Tg(Cd4-cre/ERT2)11Gnri/0 (involves: C57BL/6)	increased regulatory T cell number	J:257764
	increased T cell proliferation	J:257764
	increased T follicular helper cell number	J:257764
Rhobtb1^{em2(IMPC)Ccpcz}/Rhobtb1^{em2(IMPC)Ccpcz} (C57BL/6N-Rhobtb1^{em2(IMPC)Ccpcz}/Ccpcz)	increased Ly6C-positive NK T cell number	J:211773
Rhobtb3^{tm1a(KOMP)Wtsi}/Rhobtb3^{tm1a(KOMP)Wtsi} (involves: C57BL/6N)	decreased spleen weight	J:226884
Rhoc^tm1Mak/Rhoc^tm1Mak (involves: 129P2/OlaHsd)	immune system phenotype	J:100482
Rhof^tm1.2Dash/Rhof^tm1.2Dash (involves: 129)	abnormal spleen marginal zone morphology	J:303076
	decreased marginal zone B cell number	J:303076
	immune system phenotype	J:303076
Rhog^tm1Tnr/Rhog^tm1Tnr (involves: 129)	abnormal CD4-positive, alpha-beta T cell physiology	J:87580
	abnormal leukocyte physiology	J:87580
	abnormal T-helper 2 physiology	J:87580
	increased B cell proliferation	J:87580
	increased immunoglobulin level	J:87580
Rhoh^{tm1b(EUCOMM)Hmgu}/Rhoh^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Rhoh^{tm1b(EUCOMM)Hmgu}/Bay)	decreased leukocyte cell number	J:211773
Rhoh^tm1Brak/Rhoh^tm1Brak (involves: 129/Sv * C57BL/6)	abnormal double-negative T cell morphology	J:143161
	abnormal immune system organ morphology	J:143161
	abnormal lymphocyte cell number	J:143161
	abnormal splenic cell ratio	J:143161
	abnormal T cell proliferation	J:143161
	decreased CD4-positive, alpha-beta T cell number	J:143161
	decreased CD8-positive, alpha-beta T cell number	J:143161
	decreased double-positive T cell number	J:143161
	decreased single-positive T cell number	J:143161
	decreased T cell apoptosis	J:143161
	decreased T cell number	J:143161
	decreased T cell proliferation	J:143161
	increased double-negative T cell number	J:143161
	increased gamma-delta T cell number	J:143161
	increased NK cell number	J:143161
	increased NK T cell number	J:143161
	increased T cell number	J:143161
	increased T cell proliferation	J:143161
	spleen hypoplasia	J:143161
	thymus hypoplasia	J:143161
Rhoh^tm1Brak/Rhoh^tm1Brak Itgb2^tm2Bay/Itgb2^tm2Bay (involves: 129/Sv * C57BL/6)	decreased CD4-positive, alpha-beta T cell number	J:143161
	decreased CD8-positive, alpha-beta T cell number	J:143161
	decreased double-positive T cell number	J:143161
	decreased single-positive T cell number	J:143161
	increased double-negative T cell number	J:143161
Rhoh^tm1Brak/Rhoh^tm1Brak Tg(TcraTcrb)425Cbn/? (involves: 129/Sv * C57BL/6)	decreased CD4-positive, alpha-beta T cell number	J:143161
	immune system phenotype	J:143161
Rhoh^tm1Daw/Rhoh^tm1Daw (involves: 129 * C57BL/6)	arrested T cell differentiation	J:113565
	decreased double-positive T cell number	J:113565
	decreased T cell number	J:113565
	thymus hypoplasia	J:113565
Rhoh^tm1Hasu/Rhoh^tm1Hasu (B6.Cg-Rhoh^tm1Hasu)	abnormal mast cell physiology	J:143491
	decreased mast cell degranulation	J:143491
	decreased susceptibility to type I hypersensitivity reaction	J:143491
	immune system phenotype	J:143491
Rhs1^C57BL/6/Rhs1^C57BL/6 (involves: BALB/c * C57BL/6)	decreased susceptibility to Herpesvirales infection	J:69352
Ric1^{tm1a(EUCOMM)Hmgu}/Ric1^{tm1a(EUCOMM)Hmgu} (C57BL/6N-Ric1^{tm1a(EUCOMM)Hmgu}/H)	decreased B cell number	J:165965
	decreased leukocyte cell number	J:165965
	decreased mature B cell number	J:165965
Ric8b^{tm1b(EUCOMM)Hmgu}/Ric8b⁺ (C57BL/6N-Ric8b^{tm1b(EUCOMM)Hmgu}/Cnrm)	increased basophil cell number	J:211773
	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
Rictor^tm1.1Klg/Rictor^tm1.1Klg Tg(Mx1-cre)1Cgn/0 (B6.Cg-Rictor^tm1.1Klg Tg(Mx1-cre)1Cgn)	abnormal double-negative T cell morphology	J:189736
	decreased DN1 thymic pro-T cell number	J:189736
	decreased DN2 thymocyte number	J:189736
	decreased DN3 thymocyte number	J:189736
	decreased DN4 thymocyte number	J:189736
	decreased double-positive T cell number	J:189736
	decreased single-positive T cell number	J:189736
	decreased T cell proliferation	J:189736
	decreased thymus weight	J:189736
	immune system phenotype	J:189736
	increased double-negative T cell number	J:189736
	thymus hypoplasia	J:189736
Rictor^tm1.1Mnh/Rictor^tm1.1Mnh Tg(Fabp4-cre)1Rev/0 (B6.Cg-Rictor^tm1.1Mnh Tg(Fabp4-cre)1Rev)	increased spleen weight	J:150064
Rif1^{Gt(XT0278)Wtsi}/Rif1^{Gt(XT0278)Wtsi} (involves: 129P2/OlaHsd * CD-1 * MF1)	abnormal class switch recombination	J:195061
	decreased IgA level	J:195061
	decreased IgG1 level	J:195061
	decreased IgG2b level	J:195061
	decreased IgG3 level	J:195061
	decreased IgG level	J:195061
	immune system phenotype	J:195061
	increased susceptibility to bacterial infection	J:195061
Rigi^tm1Aki/Rigi^tm1Aki (involves: 129/Sv * C57BL/6)	abnormal dendritic cell physiology	J:137522
Rigi^tm1Aki/Rigi^tm1Aki (involves: 129/Sv * C57BL/6 * ICR)	abnormal interferon level	J:137522
Rigi^tm1Aki/Rigi^tm1Aki (involves: 129/Sv * C57BL/6 * ICR)	increased susceptibility to Flaviviridae infection induced morbidity/mortality	J:137522
Rigi^tm1Zgwg/Rigi^tm1Zgwg (involves: 129S1/Sv)	abnormal B cell differentiation	J:139016
	abnormal granulocyte morphology	J:139016
	abnormal granulocyte physiology	J:139016
	colitis	J:139868
	decreased Peyer's patch number	J:139868
	decreased T cell number	J:139868
	enlarged spleen	J:139016
	immune system phenotype	J:139016
	increased activated T cell number	J:139868
	increased granulocyte number	J:139016
	increased memory T cell number	J:139868
	increased susceptibility to induced colitis	J:139868
	small Peyer's patches	J:139868
Rin3^{tm1.1(KOMP)Vlcg}/Rin3^{tm1.1(KOMP)Vlcg} (involves: 129P2/OlaHsd * C57BL/6N)	abnormal osteoclast morphology	J:358899
Rinl^tm1.1Boun/Rinl^tm1.1Boun (B6.Cg-Rinl^tm1.1Boun)	abnormal susceptibility to Riboviria infection	J:346452
	enlarged spleen	J:346452
	immune system phenotype	J:346452
	increased B cell number	J:346452
	increased CD4-positive, alpha-beta T cell number	J:346452
	increased germinal center B cell number	J:346452
	increased splenocyte number	J:346452
	increased T follicular helper cell number	J:346452
Rinl^tm1.1Boun/Rinl^tm1.1Boun Tg(TcraTcrb)425Cbn/0 (involves: C57BL/6)	abnormal T follicular helper cell differentiation	J:346452
	increased CD4-positive, alpha-beta T cell number	J:346452
	increased T follicular helper cell number	J:346452
Riok2^{tm1c(KOMP)Wtsi}/Riok2⁺ Commd10^{Tg(Vav1-icre)A2Kio}/Commd10⁺ (involves: C57BL/6N * C57BL/10 * CBA/Ca)	abnormal CD4-positive, alpha beta T cell morphology	J:305794
	abnormal CD4-positive, alpha-beta T cell physiology	J:305794
	abnormal circulating interleukin level	J:305794
	abnormal immune system morphology	J:305794
	abnormal interleukin secretion	J:305794
	decreased neutrophil cell number	J:305794
	increased monocyte cell number	J:305794
	increased NK T cell number	J:305794
Riox1^tm1Qch/Riox1^tm1Qch Tg(Prrx1-cre)1Cjt/0 (involves: 129S6/SvEvTac * C57BL/6J * C57BL/6NCrl * SJL/J)	decreased osteoclast cell number	J:224562
Riox2^tm1Mtsun/Riox2^tm1Mtsun (B6CrSlc.Cg-Riox2^tm1Mtsun)	abnormal circulating interferon-gamma level	J:201871
	abnormal circulating interleukin-4 level	J:201871
	abnormal immunoglobulin level	J:201871
	decreased eosinophil cell number	J:201871
	decreased inflammatory response	J:201871
	decreased macrophage cell number	J:201871
	decreased neutrophil cell number	J:201871
Ripk1^tm1.1Vmd/Ripk1^tm1.1Vmd (involves: C57BL/6N)	increased thymocyte apoptosis	J:209137
Ripk1^tm1Led/Ripk1^tm1Led (involves: 129S6/SvEvTac)	abnormal immune system organ morphology	J:46522
	abnormal leukocyte cell number	J:46522
	abnormal lymph node morphology	J:46522
	abnormal thymus morphology	J:46522
	decreased thymocyte number	J:46522
	increased spleen red pulp amount	J:46522
	lymph node inflammation	J:46522
	lymph node necrosis	J:46522
Ripk2^tm1Cfl/Ripk2^tm1Cfl (involves: 129S5/SvEvBrd)	abnormal macrophage physiology	J:107130
Ripk2^tm1Flv/Ripk2^tm1Flv (involves: 129S1/Sv)	abnormal cytokine secretion	J:75400
	abnormal T-helper 1 physiology	J:75400
	decreased interleukin-6 secretion	J:75400
	decreased T cell proliferation	J:75400
	decreased tumor necrosis factor secretion	J:75400
Ripk2^tm1Flv/Ripk2^tm1Flv (involves: 129S1/Sv * C57BL/6)	abnormal macrophage physiology	J:132126
	decreased interleukin-6 secretion	J:132126
	decreased tumor necrosis factor secretion	J:132126
Ripk2^tm1Flv/Ripk2^tm1Flv Tnip1^tm1.1Pcoh/Tnip1^tm1.1Pcoh (involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6)	enlarged lymph nodes	J:176826
	enlarged spleen	J:176826
Ripk2^tm1Ghc/Ripk2^tm1Ghc (involves: 129S4/SvJae * C57BL/6)	decreased IgG2a level	J:75401
	decreased interferon-gamma secretion	J:75401
	decreased T cell proliferation	J:75401
	increased susceptibility to infection	J:75401
Ripk2^tm2Cfl/Ripk2^tm2Cfl (involves: 129S5/SvEvBrd)	immune system phenotype	J:107130
Ripk3^tm1Vmd/Ripk3^tm1Vmd (involves: 129S1/Sv * 129X1/SvJ * C57BL/6N)	immune system phenotype	J:87683
Ripk3^tm1Vmd/Ripk3^tm1Vmd (B6.129-Ripk3^tm1Vmd)	decreased inflammatory response	J:179279
Ripk4^tm1Pmh/Ripk4^tm1Pmh (involves: 129 * C57BL/6)	immune system phenotype	J:78593
Ripply3^tm1Sjt/Ripply3^tm1Sjt (involves: 129S1/Sv * C57BL/6)	abnormal thymus development	J:167713
	ectopic thymus	J:167713
	small thymus	J:167713
Rit1^tm1.1Tumg/Rit1⁺ (B6.Cg-Rit1^tm1.1Tumg)	enlarged spleen	J:277548
Rlim^{em1(IMPC)Rbrc}/Rlim⁺ (C57BL/6NJcl-Rlim^{em1(IMPC)Rbrc}/Rbrc)	abnormal lymph node morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged thymus	J:211773
Rmcf^r/Rmcf^r (DBA/1J)	decreased susceptibility to Retroviridae infection	J:7108
Rmcf^r/Rmcf^r (DBA/2J)	decreased susceptibility to Retroviridae infection	J:7108
Rmcf^r/Rmcf^r (CBA/N)	decreased susceptibility to Retroviridae infection	J:7108
Rmcf^s/Rmcf^s (CBA/J)	increased susceptibility to Retroviridae infection	J:7108
Rmcf^s/Rmcf^s (C57L/J)	increased susceptibility to Retroviridae infection	J:7108
Rmcf^s/Rmcf^s (C57BR/cdJ)	increased susceptibility to Retroviridae infection	J:7108
Rmp1^DBA/2J/Rmp1^DBA/2J (involves: C57BL/6J * DBA/2J)	increased susceptibility to Poxviridae infection	J:28150
Rmp2^DBA/2J/Rmp2^DBA/2J (involves: C57BL/6J * DBA/2J)	increased susceptibility to Poxviridae infection	J:11032
Rmp3^DBA/2J/Rmp3^DBA/2J (involves: C57BL/6J * DBA/2J)	increased susceptibility to Poxviridae infection	J:11032
Rmp4^C57BL/6NCr/Rmp4^C57BL/6NCr (involves: C57BL/6NCr * DBA/2NCr)	decreased susceptibility to Poxviridae infection	J:29241
Rmp5^C57BL/6NCr/Rmp5^C57BL/6NCr (involves: C57BL/6NCr * DBA/2NCr)	decreased susceptibility to Poxviridae infection	J:3240
Rmp6^C57BL/6NCr/Rmp6^C57BL/6NCr (involves: C57BL/6NCr * DBA/2NCr)	decreased susceptibility to Poxviridae infection	J:3240
Rmrp^{em1(IMPC)Ccpcz}/Rmrp⁺ (C57BL/6NCrl-Rmrp^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
Rnase4^em1Zpxu/Rnase4^em1Zpxu (Not Specified)	increased susceptibility to induced colitis	J:354138
Rnase4^em2Zpxu/Rnase4^em2Zpxu Tg(Vil1-cre)DNju/0 (involves: C57BL/6 * C57BL/6J)	increased susceptibility to induced colitis	J:354138
Rnase6^em1(IMPC)Tcp/Rnase6^em1(IMPC)Tcp (C57BL/6N-Rnase6^em1(IMPC)Tcp/Tcp)	increased monocyte cell number	J:211773
Rnase11^em1(IMPC)Mbp/Rnase11^em1(IMPC)Mbp (C57BL/6N-Rnase11^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	increased lymphocyte cell number	J:211773
	small spleen	J:211773
Rnase12^em1(IMPC)Mbp/Rnase12^em1(IMPC)Mbp (C57BL/6N-Rnase12^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
Rnaseh2a^em1(IMPC)Tcp/Rnaseh2a⁺ (C57BL/6NCrl-Rnaseh2a^em1(IMPC)Tcp/Tcp)	increased monocyte cell number	J:211773
	increased spleen weight	J:211773
Rnaseh2a^tm1Crh/Rnaseh2a^tm1Crh (Not Specified)	abnormal innate immunity	J:232933
Rnaseh2a^tm1Crh/Rnaseh2a^tm1Crh (Not Specified)	decreased susceptibility to Riboviria infection	J:232933
Rnaseh2a^tm1Crh/Rnaseh2a^tm1Crh Sting1^tm1Gnb/Sting1^tm1Gnb (involves: 129P2/OlaHsd)	immune system phenotype	J:232933
Rnaseh2b^em1Anu/Rnaseh2b⁺ Tlr7^em2Anu/Tlr7⁺ (C57BL/6NCrl-Rnaseh2b^em1Anu Tlr7^em2Anu)	abnormal immune system morphology	J:324448
	abnormal mature B cell morphology	J:324448
	increased autoantibody level	J:324448
	increased CD4-positive, alpha-beta T cell number	J:324448
	increased germinal center B cell number	J:324448
	increased plasma cell number	J:324448
	increased T follicular helper cell number	J:324448
Rnaseh2b^{tm1a(EUCOMM)Wtsi}/Rnaseh2b^{tm1a(EUCOMM)Wtsi} (involves: C57BL/6N)	thymus hypoplasia	J:186986
Rnaseh2b^{tm1c(EUCOMM)Wtsi}/Rnaseh2b^{tm1c(EUCOMM)Wtsi} Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N * SJL)	decreased B cell proliferation	J:186986
	immune system phenotype	J:186986
Rnasel^tm1Slvm/Rnasel^tm1Slvm (involves: 129P2/OlaHsd)	abnormal thymus morphology	J:44292
	decreased T cell apoptosis	J:44292
	enlarged thymus	J:44292
	increased susceptibility to Picornaviridae infection	J:44292
	thymus hyperplasia	J:44292
Rnaset2b^{tm1b(EUCOMM)Hmgu}/Rnaset2b^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Rnaset2b^{tm1b(EUCOMM)Hmgu}/H)	enlarged spleen	J:211773
Rnd2^em1(IMPC)Mbp/Rnd2^em1(IMPC)Mbp (C57BL/6NCrl-Rnd2^em1(IMPC)Mbp/Mmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Rnd3^{tm1b(EUCOMM)Hmgu}/Rnd3⁺ (C57BL/6N-Rnd3^{tm1b(EUCOMM)Hmgu}/H)	increased large unstained cell number	J:211773
Rnf2^tm1Mvi/Rnf2^tm1Mvi Tg(Mx1-cre)1Cgn/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * C57BL/10 * CBA)	abnormal B cell differentiation	J:130397
	decreased B cell number	J:130397
	decreased monocyte cell number	J:130397
Rnf5^{tm1.1(KOMP)Vlcg}/Rnf5⁺ (C57BL/6N-Rnf5^{tm1.1(KOMP)Vlcg}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Rnf5^{tm1.1(KOMP)Vlcg}/Rnf5^{tm1.1(KOMP)Vlcg} (C57BL/6N-Rnf5^{tm1.1(KOMP)Vlcg}/Ccpcz)	abnormal spleen morphology	J:211773
Rnf8^{Gt(AS0574)Wtsi}/Rnf8⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal class switch recombination	J:161240
Rnf8^{Gt(AS0574)Wtsi}/Rnf8^{Gt(AS0574)Wtsi} (involves: 129P2/OlaHsd * C57BL/6)	abnormal class switch recombination	J:161240
	decreased B cell number	J:161240
	decreased CD4-positive, alpha-beta T cell number	J:161240
	decreased CD8-positive, alpha-beta T cell number	J:161240
	decreased double-negative T cell number	J:161240
	decreased double-positive T cell number	J:161240
	decreased IgG1 level	J:161240
	decreased IgG2b level	J:161240
	decreased IgG3 level	J:161240
	decreased immature B cell number	J:161240
	decreased pre-B cell number	J:161240
	decreased pro-B cell number	J:161240
	decreased splenocyte number	J:161240
	decreased T cell number	J:161240
	decreased thymocyte number	J:161240
	increased T cell derived lymphoma incidence	J:161240
	increased thymocyte apoptosis	J:161240
Rnf8^{Gt(RRR260)Byg}/Rnf8^{Gt(RRR260)Byg} (involves: 129P2/OlaHsd * C57BL/6)	abnormal class switch recombination	J:161240
	decreased B cell number	J:161240
	decreased CD4-positive, alpha-beta T cell number	J:161240
	decreased CD8-positive, alpha-beta T cell number	J:161240
	decreased double-negative T cell number	J:161240
	decreased double-positive T cell number	J:161240
	decreased IgG1 level	J:161240
	decreased IgG2b level	J:161240
	decreased IgG3 level	J:161240
	decreased immature B cell number	J:161240
	decreased pre-B cell number	J:161240
	decreased pro-B cell number	J:161240
	decreased splenocyte number	J:161240
	decreased T cell number	J:161240
	decreased thymocyte number	J:161240
	increased T cell derived lymphoma incidence	J:161240
	increased thymocyte apoptosis	J:161240
Rnf10^{tm1b(KOMP)Wtsi}/Rnf10^{tm1b(KOMP)Wtsi} (C57BL/6N-Rnf10^{tm1b(KOMP)Wtsi}/Ics)	decreased lymphocyte cell number	J:211773
	increased monocyte cell number	J:211773
Rnf10^{tm1b(KOMP)Wtsi}/Rnf10^{tm1b(KOMP)Wtsi} (C57BL/6N-Rnf10^{tm1b(KOMP)Wtsi}/H)	increased large unstained cell number	J:211773
Rnf10^{tm1b(KOMP)Wtsi}/Rnf10^{tm1b(KOMP)Wtsi} (C57BL/6N-Rnf10^{tm1b(KOMP)Wtsi}/Bay)	abnormal spleen morphology	J:211773
Rnf19b^{em1(IMPC)Ccpcz}/Rnf19b⁺ (C57BL/6N-Rnf19b^{em1(IMPC)Ccpcz}/Ccpcz)	increased eosinophil cell number	J:211773
Rnf19b^tm1Jkorn/Rnf19b^tm1Jkorn (B6.129S-Rnf19b^tm1Jkorn)	decreased interferon-gamma secretion	J:157393
Rnf19b^tm1Jkorn/Rnf19b^tm1Jkorn (B6.129S-Rnf19b^tm1Jkorn)	impaired natural killer cell mediated cytotoxicity	J:157393
Rnf20^{Gt(RRJ249)Byg}/Rnf20⁺ (involves: 129P2/OlaHsd)	abnormal leukocyte physiology	J:268221
	abnormal T cell physiology	J:268221
	enlarged spleen	J:268221
	increased interferon-gamma secretion	J:268221
	increased spleen weight	J:268221
	increased susceptibility to induced colitis	J:268221
	increased tumor necrosis factor secretion	J:268221
Rnf31^tm1.1Kiwa/Rnf31^tm1.1Kiwa Cd79a^tm1(cre)Reth/Cd79a⁺ (involves: BALB/c * C57BL/6NCrlj * CBA/JNCrlj)	abnormal B-1 B cell morphology	J:201885
	abnormal humoral immune response	J:201885
	decreased B-1a cell number	J:201885
	decreased B-1b cell number	J:201885
	decreased IgA level	J:201885
	decreased IgG1 level	J:201885
	decreased IgG2a level	J:201885
	decreased IgG2b level	J:201885
	decreased IgG3 level	J:201885
	decreased IgM level	J:201885
	immune system phenotype	J:201885
Rnf34^{tm1a(EUCOMM)Hmgu}/Rnf34^{tm1a(EUCOMM)Hmgu} (C57BL/6NCrl-Rnf34^{tm1a(EUCOMM)Hmgu}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged thymus	J:211773
Rnf39^em1Zwei/Rnf39^em1Zwei (involves: C57BL/6)	decreased susceptibility to Riboviria infection	J:357975
	decreased susceptibility to Riboviria infection induced morbidity/mortality	J:357975
	increased interferon-beta secretion	J:357975
	increased interleukin-6 secretion	J:357975
Rnf40^tm1.1Sajo/Rnf40^tm1.1Sajo Tg(Car1-cre)5Flt/0 (involves: 129S2/SvPas * C57BL/6J)	decreased susceptibility to induced colitis	J:311838
Rnf43^em1(IMPC)Tcp/Rnf43^em1(IMPC)Tcp (C57BL/6NCrl-Rnf43^em1(IMPC)Tcp/Tcp)	enlarged spleen	J:211773
Rnf43^em1Mage/Rnf43^em1Mage (Not Specified)	immune system phenotype	J:276360
Rnf43^em2Mage/Rnf43^em2Mage (Not Specified)	immune system phenotype	J:276360
	increased interferon-gamma secretion	J:285428
	stomach inflammation	J:285428
Rnf115^em1(IMPC)H/Rnf115^em1(IMPC)H (C57BL/6N-Rnf115^em1(IMPC)H/H)	increased spleen weight	J:211773
Rnf115^em1Gpt/Rnf115^em1Gpt (C57BL/6JGpt-Rnf115^em1Gpt/Gpt)	decreased susceptibility to viral infection	J:297834
	decreased susceptibility to viral infection induced morbidity/mortality	J:297834
	increased circulating interferon-beta level	J:297834
	increased interferon-beta secretion	J:297834
	increased susceptibility to viral infection induced morbidity/mortality	J:297834
Rnf122^em1Caox/Rnf122^em1Caox (involves: C57BL/6J)	decreased susceptibility to Riboviria infection induced morbidity/mortality	J:344769
	immune system phenotype	J:344769
	increased circulating interferon-alpha level	J:344769
	increased circulating interferon-beta level	J:344769
	increased circulating interleukin-6 level	J:344769
	increased interferon-alpha secretion	J:344769
	increased interferon-beta secretion	J:344769
	increased interleukin-6 secretion	J:344769
	increased tumor necrosis factor secretion	J:344769
Rnf123^em1Nmea/Rnf123^em1Nmea (NC/Jic-Rnf123^em1Nmea)	decreased susceptibility to parasitic infection	J:327312
Rnf123^em1Nmea/Rnf123^em1Nmea (NC/Jic-Rnf123^em1Nmea)	decreased susceptibility to parasitic infection induced morbidity/mortality	J:327312
Rnf123^em2Nmea/Rnf123^em2Nmea (NC/Jic-Rnf123^em2Nmea)	decreased susceptibility to parasitic infection	J:327312
Rnf123^em2Nmea/Rnf123^em2Nmea (NC/Jic-Rnf123^em2Nmea)	decreased susceptibility to parasitic infection induced morbidity/mortality	J:327312
Rnf128^{tm1.1(KOMP)Vlcg}/Y (C57BL/6N-Rnf128^{tm1.1(KOMP)Vlcg}/Ccpcz)	increased effector memory T-helper cell number	J:211773
Rnf128^tm1.1Flv/Y (involves: 129S6/SvEvTac * C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:153216
	abnormal peripheral T cell anergy	J:153216
	increased circulating interleukin-2 level	J:153216
	increased interferon-gamma secretion	J:153216
	increased T cell proliferation	J:153216
Rnf128^tm1.1Flv/Y Tg(TcraTcrb)425Cbn/0 (involves: 129S6/SvEvTac * BALB/c * C57BL/6)	abnormal peripheral T cell anergy	J:153216
	decreased T cell proliferation	J:153216
	increased circulating interleukin-2 level	J:153216
Rnf128^tm1.1Flv/Rnf128^tm1.1Flv (involves: 129S6/SvEvTac * C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:153216
	abnormal peripheral T cell anergy	J:153216
	increased circulating interleukin-2 level	J:153216
	increased interferon-gamma secretion	J:153216
	increased T cell proliferation	J:153216
Rnf128^tm1.1Flv/Rnf128^tm1.1Flv Tg(TcraTcrb)425Cbn/0 (involves: 129S6/SvEvTac * BALB/c * C57BL/6)	abnormal peripheral T cell anergy	J:153216
	decreased T cell proliferation	J:153216
	increased circulating interleukin-2 level	J:153216
Rnf128^tm1.2Cmse/Rnf128^tm1.2Cmse (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal macrophage physiology	J:245025
Rnf128^tm1Cdon/Rnf128⁺ (involves: 129 * C57BL/6)	increased susceptibility to experimental autoimmune encephalomyelitis	J:160681
Rnf128^tm1Cdon/Rnf128^tm1Cdon (involves: C57BL/6)	increased anti-double stranded DNA antibody level	J:160681
	increased interferon-gamma secretion	J:160681
	increased interleukin-2 secretion	J:160681
	increased interleukin-17 secretion	J:160681
	increased T cell proliferation	J:160681
Rnf128^tm1Cdon/Rnf128^tm1Cdon (involves: 129 * C57BL/6)	abnormal immune tolerance	J:160681
	abnormal interleukin secretion	J:160681
	abnormal regulatory T cell physiology	J:160681
	CNS inflammation	J:160681
	decreased interleukin-4 secretion	J:160681
	decreased interleukin-5 secretion	J:160681
	decreased interleukin-13 secretion	J:160681
	enlarged mesenteric lymph nodes	J:160681
	enlarged spleen	J:160681
	increased anti-double stranded DNA antibody level	J:160681
	increased IgG1 level	J:160681
	increased IgM level	J:160681
	increased interferon-gamma secretion	J:160681
	increased interleukin-2 secretion	J:160681
	increased interleukin-4 secretion	J:160681
	increased interleukin-17 secretion	J:160681
	increased interleukin-21 secretion	J:160681
	increased splenocyte proliferation	J:160681
	increased susceptibility to experimental autoimmune encephalomyelitis	J:160681
	lung inflammation	J:160681
Rnf128^tm1Cdon/Rnf128^tm1Cdon Tg(TcraTcrb)425Cbn/0 (involves: 129 * BALB/c * C57BL/6)	abnormal immune tolerance	J:160681
	increased interferon-gamma secretion	J:160681
	increased interleukin-2 secretion	J:160681
	increased splenocyte proliferation	J:160681
Rnf135^em1(IMPC)Tcp/Rnf135^em1(IMPC)Tcp (C57BL/6NCrl-Rnf135^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Rnf139^{tm1(KOMP)Wtsi}/Rnf139^{tm1(KOMP)Wtsi} (involves: C57BL/6J * C57BL/6N)	liver inflammation	J:231404
Rnf144a^em1Smoc/Rnf144a^em1Smoc (C57BL/6JSmoc-Rnf144a^em1Smoc/Smoc)	abnormal innate immunity	J:347002
	increased susceptibility to Herpesvirales infection	J:347002
	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:347002
Rnf144b^em1Cya/Rnf144b^em1Cya (C57BL/6J-Rnf144b^em1Cya/Cya)	decreased susceptibility to Picornaviridae infection	J:357974
	decreased susceptibility to Picornaviridae infection induced morbidity/mortality	J:357974
	decreased susceptibility to Riboviria infection	J:357974
Rnf146^tm1.1Rtpl/Rnf146^tm1.1Rtpl Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6J)	abnormal osteoclast differentiation	J:243612
	increased circulating tumor necrosis factor level	J:243612
	increased osteoclast cell number	J:243612
Rnf148^{em1(IMPC)Ccpcz}/Rnf148^{em1(IMPC)Ccpcz} (C57BL/6N-Rnf148^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Rnf149^em1Staa/Rnf149^em1Staa (involves: BALB/c * C57BL/6)	increased leukocyte cell number	J:335358
	increased lymphocyte cell number	J:335358
	increased monocyte cell number	J:335358
	increased neutrophil cell number	J:335358
Rnf168^{Gt(156B6)Cmhd}/Rnf168^{Gt(156B6)Cmhd} (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal class switch recombination	J:198260
	abnormal T cell receptor delta chain V(D)J recombination	J:198260
	decreased gamma-delta T cell number	J:198260
	decreased IgG1 level	J:198260
	decreased IgG2a level	J:198260
	decreased IgG3 level	J:198260
	decreased IgG level	J:198260
	immune system phenotype	J:198260
	increased DN3 thymocyte number	J:198260
	increased double-negative T cell number	J:198260
Rnf168^{Gt(405F11)Cmhd}/Rnf168^{Gt(405F11)Cmhd} (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal class switch recombination	J:198260
	abnormal T cell receptor delta chain V(D)J recombination	J:198260
	decreased gamma-delta T cell number	J:198260
	decreased IgG1 level	J:198260
	decreased IgG2a level	J:198260
	decreased IgG3 level	J:198260
	decreased IgG level	J:198260
	immune system phenotype	J:198260
	increased DN3 thymocyte number	J:198260
	increased double-negative T cell number	J:198260
Rnf168^{tm2b(EUCOMM)Hmgu}/Rnf168^{tm2b(EUCOMM)Hmgu} (C57BL/6N-Rnf168^{tm2b(EUCOMM)Hmgu}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
	increased eosinophil cell number	J:211773
Rnf169^{tm1a(EUCOMM)Hmgu}/Rnf169^{tm1a(EUCOMM)Hmgu} (B6NTac;B6N-Rnf169^{tm1a(EUCOMM)Hmgu}/H)	increased monocyte cell number	J:165965
Rnf186^em1Ktak/Rnf186^em1Ktak (involves: C57BL/6 * DBA/2)	increased susceptibility to colitis induced morbidity/mortality	J:258197
Rnf186^em1Ktak/Rnf186^em1Ktak (involves: C57BL/6 * DBA/2)	increased susceptibility to induced colitis	J:258197
Rnf186^tm1Ktak/Rnf186^tm1Ktak (involves: 129S4/SvJae * C57BL/6)	increased susceptibility to colitis induced morbidity/mortality	J:258197
	increased susceptibility to induced colitis	J:258197
Rnf208^{em1(IMPC)Ccpcz}/Rnf208^{em1(IMPC)Ccpcz} (C57BL/6N-Rnf208^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged thymus	J:211773
	increased eosinophil cell number	J:211773
Rnf216^{tm1b(EUCOMM)Wtsi}/Rnf216^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Rnf216^{tm1b(EUCOMM)Wtsi}/Tcp)	decreased lymphocyte cell number	J:211773
	increased monocyte cell number	J:211773
Rnf223^{em1(IMPC)Ccpcz}/Rnf223^{em1(IMPC)Ccpcz} (C57BL/6N-Rnf223^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Rnft2^{tm1b(EUCOMM)Hmgu}/Rnft2^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Rnft2^{tm1b(EUCOMM)Hmgu}/Bay)	abnormal spleen morphology	J:211773
Rnpepl1^em1(IMPC)Mbp/Rnpepl1^em1(IMPC)Mbp (C57BL/6N-Rnpepl1^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
Ro60^tm1Woln/Ro60⁺ (involves: 129S1/Sv * C57BL/6)	increased anti-nuclear antigen antibody level	J:84627
Ro60^tm1Woln/Ro60⁺ (involves: 129S1/Sv * C57BL/6)	increased IgG2a level	J:84627
Ro60^tm1Woln/Ro60^tm1Woln (involves: 129S1/Sv * C57BL/6)	glomerulonephritis	J:84627
	increased anti-chromatin antibody level	J:84627
	increased anti-double stranded DNA antibody level	J:84627
	increased anti-histone antibody level	J:84627
	increased anti-nuclear antigen antibody level	J:84627
	increased anti-single stranded DNA antibody level	J:84627
	increased IgG2a level	J:84627
	increased IgM level	J:84627
Rock1^tm1Liao/Rock1⁺ (C57BL/6-Rock1^tm1Liao)	abnormal leukocyte adhesion	J:135152
	abnormal leukocyte migration	J:135152
	impaired macrophage chemotaxis	J:135152
	impaired neutrophil recruitment	J:135152
Rock1^tm1Sna/Rock1^tm1Sna (B6N.129X1-Rock1^tm1Sna)	blepharitis	J:98250
Rock2^tm1.1Itl/Rock2⁺ Tg(Tagln-cre)1Her/0 (B6.Cg-Rock2^tm1.1Itl Tg(Tagln-cre)1Her)	abnormal cytokine secretion	J:222206
Ror1^{em1(IMPC)Ccpcz}/Ror1⁺ (C57BL/6NCrl-Ror1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Rora^sg/Rora^sg (involves: C57BL/6)	abnormal immune system organ morphology	J:2228
	abnormal immune system physiology	J:2228
	abnormal macrophage physiology	J:28095
	immune system phenotype	J:52105
	increased IgE level	J:135863
	increased interleukin-1 secretion	J:28095
	lung inflammation	J:135863
	spleen atrophy	J:2228
	thymus atrophy	J:2228
Rorc^m1Btlr/Rorc^m1Btlr (C57BL/6J-Rorc^m1Btlr)	decreased CD4-positive, alpha-beta T cell number	J:203039
Rorc^m1Btlr/Rorc^m1Btlr (C57BL/6J-Rorc^m1Btlr)	decreased CD8-positive, alpha-beta T cell number	J:203039
Rorc^m2Btlr/Rorc^m2Btlr (C57BL/6J-Rorc^m2Btlr)	decreased IgM level	J:217792
	decreased response to antigen	J:217792
	impaired humoral immune response	J:217792
Rorc^m3Btlr/Rorc^m3Btlr (C57BL/6J-Rorc^m3Btlr)	abnormal CD4-positive, alpha beta T cell morphology	J:234257
	decreased B-2 B cell number	J:234257
	decreased CD4-positive, alpha-beta T cell number	J:234257
	decreased CD8-positive, naive alpha-beta T cell number	J:234257
	decreased IgG level	J:234257
	decreased IgM level	J:234257
	decreased response to antigen	J:234257
	impaired humoral immune response	J:234257
	increased B-1a cell number	J:234257
	increased B-1b cell number	J:234257
	increased CD8-positive, alpha-beta T cell number	J:234257
	increased effector memory CD4-positive, alpha-beta T cell number	J:234257
	increased effector memory CD8-positive, alpha-beta T cell number	J:234257
Rorc^tm1.1Zsun/Rorc^tm1.1Zsun (B6(129S4)-Rorc^tm1.1Zsun)	abnormal T-helper 17 cell differentiation	J:248565
	absent Peyer's patches	J:248565
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:248565
	small inguinal lymph nodes	J:248565
Rorc^tm1Amj/Rorc^tm1Amj (either: (involves: 129/Sv * C57BL/6) or (involves: 129/Sv * C57BL/6 * DBA/2))	abnormal interleukin level	J:123351
	abnormal lymph organ development	J:64381
	abnormal splenic cell ratio	J:64381
	abnormal T cell physiology	J:64381
	absent lymph nodes	J:64381
	absent Peyer's patches	J:64381
	decreased CD4-positive, alpha-beta T cell number	J:64381
	decreased CD8-positive, alpha-beta T cell number	J:64381
	decreased double-positive T cell number	J:64381
	decreased T cell number	J:64381
	decreased thymus weight	J:64381
	enlarged spleen	J:64381
	increased double-negative T cell number	J:64381
	increased T cell apoptosis	J:64381
	thymus hypoplasia	J:64381
Rorc^tm1Litt/Rorc^tm1Litt (involves: 129P2/OlaHsd)	abnormal CD8-positive, alpha-beta T cell differentiation	J:248565
	abnormal T cell differentiation	J:128344, J:248565
	abnormal T cell morphology	J:248565
	abnormal T-helper 17 cell differentiation	J:248565
	absent lymph nodes	J:248565
	colitis	J:158663
	decreased CD4-positive, alpha-beta T cell number	J:248565
	decreased double-positive T cell number	J:248565
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:248565
	decreased thymocyte number	J:248565
	increased susceptibility to bacterial infection	J:158663
	increased susceptibility to bacterial infection induced morbidity/mortality	J:158663
	increased thymocyte apoptosis	J:248565
Rorc^tm1Litt/Rorc^tm1Litt Tcra-J^tm3.1Krg/Tcra-J^tm3.1Krg (involves: 129P2/OlaHsd * 129S6/SvEvTac)	abnormal T cell differentiation	J:128344
Rorc^tm2Litt/Rorc^tm2Litt (involves: 129P2/OlaHsd)	abnormal CD4-positive, alpha-beta intraepithelial T cell morphology	J:91566
	abnormal CD8 positive, alpha-beta intraepithelial T cell morphology	J:91566
	abnormal gut-associated lymphoid tissue morphology	J:87395, J:91566
	abnormal lymph organ development	J:87395
	absent lymph nodes	J:87395
	absent Peyer's patches	J:87395
	decreased double-negative T cell number	J:91566
	decreased double-positive T cell number	J:87395
	decreased NK cell number	J:142654
	increased thymocyte apoptosis	J:87395
Rosq1^DBA/1J/Rosq1^DBA/1J (involves: DBA/1J * FVB/NJ)	abnormal neutrophil physiology	J:122919
Rosq1^DBA/1J/Rosq1^FVB/NJ (involves: DBA/1J * FVB/NJ)	abnormal neutrophil physiology	J:122919
Rpa1^tm1Wed/Rpa1⁺ (involves: 129/Sv * C57BL/6J * SJL)	increased lymphocyte cell number	J:99303
Rpap3^em1(IMPC)Mbp/Rpap3⁺ (C57BL/6N-Rpap3^em1(IMPC)Mbp/Ucd)	abnormal thymus morphology	J:211773
Rpap3^em1(IMPC)Mbp/Rpap3⁺ (C57BL/6N-Rpap3^em1(IMPC)Mbp/Ucd)	enlarged thymus	J:211773
Rpap3^{tm1c(KOMP)Wtsi}/Rpap3^{tm1c(KOMP)Wtsi} Tg(Vil1-cre/ERT2)23Syr/0 (involves: C57BL/6N * DBA/2)	small intestinal inflammation	J:314346
Rpe65^{tm1a(EUCOMM)Hmgu}/Rpe65^{tm1a(EUCOMM)Hmgu} (C57BL/6N-Rpe65^{tm1a(EUCOMM)Hmgu}/H)	decreased leukocyte cell number	J:165965
	increased leukocyte cell number	J:165965
Rpe^em1(IMPC)Mbp/Rpe⁺ (C57BL/6NCrl-Rpe^em1(IMPC)Mbp/Mmucd)	abnormal spleen morphology	J:211773
Rpe^em1(IMPC)Mbp/Rpe⁺ (C57BL/6NCrl-Rpe^em1(IMPC)Mbp/Mmucd)	enlarged spleen	J:211773
Rpgrip1l^{tm1a(EUCOMM)Wtsi}/Rpgrip1l^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Rpgrip1l^{tm1a(EUCOMM)Wtsi}/Wtsi)	absent connection between subcutaneous lymph vessels and lymph sac	J:239583
	absent spleen	J:239583
	spleen hypoplasia	J:239583
Rpl12^em1(IMPC)Mbp/Rpl12⁺ (C57BL/6NCrl-Rpl12^em1(IMPC)Mbp/Mmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Rpl13a^tm1.1Jesc/Rpl13a^tm1.1Jesc (NOD.129S5(Cg)-Rpl13a^tm1.1Jesc)	decreased susceptibility to autoimmune diabetes	J:237822
Rpl13a^tm1.1Mazu/Rpl13a^tm1.1Mazu Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: C57BL/6)	abnormal cytokine level	J:194920
	abnormal macrophage chemotaxis	J:194920
	increased circulating tumor necrosis factor level	J:194920
Rpl22^{Gt(GST000137)Lex}/Rpl22^{Gt(GST000137)Lex} (involves: 129S5/SvEvBrd)	abnormal T cell differentiation	J:123569
	abnormal T cell number	J:123569
	arrested T cell differentiation	J:123569
	decreased CD4-positive, alpha-beta T cell number	J:123569
	decreased CD8-positive, alpha-beta T cell number	J:123569
	decreased double-negative T cell number	J:123569
	decreased T cell number	J:123569
	glomerulonephritis	J:123569
	increased T cell apoptosis	J:123569
	thymus hypoplasia	J:123569
Rpl22^{Gt(YHB332)Byg}/Rpl22^{Gt(YHB332)Byg} (involves: 129P2/OlaHsd * C57BL/6)	abnormal thymus development	J:201164
	decreased B cell number	J:201164
	decreased T cell number	J:201164
Rpl27a^Sfa/Rpl27a⁺ (C57BL/6J-Rpl27a^Sfa)	decreased leukocyte cell number	J:174216
	small spleen	J:174216
	small thymus	J:174216
Rpl38^Ts/Rpl38⁺ (TSJ/Le)	increased susceptibility to otitis media	J:168509
Rplp1^tm1.1Melt/Rplp1^tm1.2Melt (Not Specified)	small thymus	J:218949
Rprd1b^tm1Tshu/Rprd1b^tm1Tshu Tg(Vil1-cre)20Syr/0 (involves: C57BL/6 * DBA/2)	increased susceptibility to colitis induced morbidity/mortality	J:300857
Rps6ka3^tm1.1Kry/Rps6ka3⁺ (involves: 129X1/SvJ)	immune system phenotype	J:89403
Rps6ka3^tm1.1Kry/Rps6ka3^tm1.1Kry (involves: 129X1/SvJ)	immune system phenotype	J:89403
Rps6ka4^tm1Jsca/Rps6ka4^tm1Jsca Rps6ka5^tm1Jsca/Rps6ka5^tm1Jsca (Not Specified)	decreased T cell proliferation	J:124301
	spleen hypoplasia	J:124301
Rps6ka4^tm1Jsca/Rps6ka4^tm1Jsca Rps6ka5^tm1Jsca/Rps6ka5^tm1Jsca (B6.Cg-Rps6ka5^tm1Jsca Rps6ka4^tm1Jsca)	abnormal cytokine level	J:139576
	abnormal cytokine secretion	J:139576
	decreased circulating interleukin-10 level	J:139576
	decreased interleukin-10 secretion	J:139576
	increased circulating interleukin-6 level	J:139576
	increased circulating interleukin-12a level	J:139576
	increased circulating interleukin-12b level	J:139576
	increased circulating tumor necrosis factor level	J:139576
	increased interleukin-6 secretion	J:139576
	increased interleukin-12a secretion	J:139576
	increased interleukin-12b secretion	J:139576
	increased susceptibility to endotoxin shock	J:139576
	increased tumor necrosis factor secretion	J:139576
	skin inflammation	J:139576
Rps9^tm1.1Geno/Rps9^tm1.1Geno (involves: C57BL/6)	decreased leukocyte cell number	J:329922
Rps9^tm1.1Geno/Rps9^tm1.1Geno (involves: C57BL/6)	increased monocyte cell number	J:329922
Rps12^em1.1Nbakr/Rps12⁺ (involves: C57BL/6J * FVB/N)	decreased leukocyte cell number	J:338970
Rps12^em1.1Nbakr/Rps12⁺ (involves: C57BL/6J * FVB/N)	decreased spleen weight	J:338970
Rps14^tm1.1Ble/Rps14⁺ Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6J * C57BL/6NTac * CBA/J)	enlarged spleen	J:233322
Rps14^tm1.1Ble/Rps14⁺ Tg(Mx1-cre)1Cgn/0 Trp53^tm2.1Tyj/Trp53⁺ (involves: 129S4/SvJae * C57BL/6J * C57BL/6NTac * CBA/J)	immune system phenotype	J:233322
Rps19bp1^{tm1.1(KOMP)Wtsi}/Rps19bp1⁺ (C57BL/6N-Rps19bp1^{tm1.1(KOMP)Wtsi}/Bay)	abnormal spleen morphology	J:211773
Rps27l^{Gt(IST11658B7)Tigm}/Rps27l^{Gt(IST11658B7)Tigm} (C57BL/6-Rps27l^{Gt(IST11658B7)Tigm})	decreased spleen weight	J:223276
	decreased thymus weight	J:223276
	increased thymocyte apoptosis	J:223276
	thymus cortex hypoplasia	J:223276
Rps27l^{Gt(IST11658B7)Tigm}/Rps27l^{Gt(IST11658B7)Tigm} (involves: 129 * C57BL/6N)	spleen hypoplasia	J:223276
	thymus hypoplasia	J:223276
Rps27l^{Gt(IST11658B7)Tigm}/Rps27l^{Gt(IST11658B7)Tigm} Trp53^tm1Tyj/Trp53⁺ (involves: 129S2/SvPas * C57BL/6N)	enlarged lymph nodes	J:223276
	enlarged spleen	J:223276
	increased T cell derived lymphoma incidence	J:223276
Rptor^tm1Ahir/Rptor^tm1Ahir Tg(Itgax-cre)1-1Reiz/0 (B6.Cg-Rptor^tm1Ahir Tg(Itgax-cre)1-1Reiz)	increased dendritic cell number	J:188676
	increased susceptibility to induced colitis	J:188676
Rpusd2^{tm1b(KOMP)Wtsi}/Rpusd2^{tm1b(KOMP)Wtsi} (C57BL/6N-Rpusd2^{tm1b(KOMP)Wtsi}/Bay)	increased spleen weight	J:211773
Rr7^tm1.1Kio/Rr7^tm1.1Kio (involves: 129S4/SvJae * C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:179326, J:164573
Rr7^tm1.1Kio/Rr7^tm1.1Kio (involves: 129S4/SvJae * C57BL/6)	immune system phenotype	J:164573
Rr7^tm2.1Kio/Rr7^tm2.1Kio (involves: 129S4/SvJae * C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:164573
Rr7^tm2.1Kio/Rr7^tm2.1Kio (involves: 129S4/SvJae * C57BL/6)	immune system phenotype	J:164573
Rr7^tm3.1Kio/Rr7⁺ (B6.129S4-Rr7^tm3.1Kio)	abnormal CD4-positive, alpha beta T cell morphology	J:179326
Rr7^tm3.1Kio/Rr7⁺ Commd10^{Tg(Vav1-icre)A2Kio}/Commd10⁺ (involves: 129S4/SvJae * C57BL/6 * C57BL/10 * CBA/Ca)	immune system phenotype	J:179326
Rr7^tm3.1Kio/Rr7⁺ Tg(CD2-icre)4Kio/0 (involves: 129S4/SvJae * C57BL/6 * C57BL/10 * CBA/Ca)	immune system phenotype	J:179326
Rr7^tm3.1Kio/Rr7⁺ Tg(Lck-cre)#Nik/0 (involves: 129S4/SvJae * C57BL/6 * DBA/2)	abnormal CD4-positive, alpha beta T cell morphology	J:179326
Rr7^tm4.1Kio/Rr7^tm4.1Kio (involves: 129S4/SvJae * C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:179326
Rr7^tm5.1Kio/Rr7^tm5.1Kio (involves: 129S4/SvJae * C57BL/6)	immune system phenotype	J:179326
Rr9^tm1.1Kubo/Rr9^tm1.1Kubo (C57BL/6-Rr9^tm1.1Kubo)	decreased interleukin-13 secretion	J:167446
Rr9^tm1.1Kubo/Rr9^tm1.1Kubo (C57BL/6-Rr9^tm1.1Kubo)	immune system phenotype	J:167446
Rr10^tm1.1Kubo/Rr10^tm1.1Kubo (B6.Cg-Rr10^tm1.1Kubo)	immune system phenotype	J:167446
Rr17^tm1.1Cdon/Rr17^tm1.1Cdon (involves: 129S6/SvEvTac * C57BL/6)	decreased interleukin-17 secretion	J:181186
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:181186
	immune system phenotype	J:181186
	increased interleukin-17 secretion	J:181186
Rr32^tm1.1Weav/Rr32^tm1.1Weav (involves: C57BL/6)	decreased interferon-gamma secretion	J:208819
Rr32^tm1.1Weav/Rr32^tm1.1Weav (involves: C57BL/6)	immune system phenotype	J:208819
Rr38^tm1.2Aafo/Rr38⁺ (involves: 129S4/SvJaeSor * BALB/cJ * C57BL/6)	decreased thymocyte number	J:227747
	immune system phenotype	J:227747
Rr38^tm1.2Aafo/Rr38^tm1.2Aafo (involves: 129S4/SvJaeSor * BALB/cJ * C57BL/6)	abnormal thymus physiology	J:227747
	decreased CD4-positive, alpha-beta T cell number	J:227747
	decreased CD8-positive, alpha-beta T cell number	J:227747
	decreased double-positive T cell number	J:227747
	decreased single-positive T cell number	J:227747
	decreased thymocyte number	J:227747
	decreased thymus weight	J:227747
	immune system phenotype	J:227747
	increased DN3 thymocyte number	J:227747
	small thymus	J:227747
	thymus hypoplasia	J:227747
Rr39^em1Ched/Rr39^em1Ched (C57BL/6-Rr39^em1Ched)	decreased Ly6C low monocyte number	J:239509
Rr39^em1Ched/Rr39^em1Ched (C57BL/6-Rr39^em1Ched)	immune system phenotype	J:239509
Rr79^em2Rtew/Rr79^em2Rtew (C57BL/6J-Rr79^em2Rtew/J)	abnormal T cell activation	J:332957
	abnormal T cell physiology	J:332957
	abnormal T cell subpopulation ratio	J:332957
Rr79^em2Rtew/Rr79^em2Rtew Tg(TcraTcrb)1100Mjb/? (involves: C57BL/6J)	abnormal T cell activation	J:332957
Rr94^tm3.1Litt/Rr94⁺ Rr112^tm4.1Litt/Rr112⁺ (involves: 129P2/OlaHsd * 129S4/SvJaeSor * FVB/N)	immune system phenotype	J:158962
Rr94^tm3.1Litt/Rr94⁺ Tg(Cd4-cre)1Cwi/0 Rr112^tm4.1Litt/Rr112⁺ (involves: 129P2/OlaHsd * 129S4/SvJaeSor * FVB/N)	abnormal T cell differentiation	J:158962
	abnormal T cell subpopulation ratio	J:158962
	decreased CD4-positive, alpha-beta T cell number	J:158962
	increased CD8-positive, alpha-beta T cell number	J:158962
Rr94^tm3.1Litt/Rr94^tm3.1Litt (involves: 129P2/OlaHsd * FVB/N)	immune system phenotype	J:158962
Rr94^tm3.1Litt/Rr94^tm3.1Litt Tg(Cd4-cre)1Cwi/0 (involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * FVB/N)	abnormal T cell differentiation	J:158962
	abnormal T cell subpopulation ratio	J:158962
	decreased CD4-positive, alpha-beta T cell number	J:158962
	decreased double-positive T cell number	J:158962
	increased CD8-positive, alpha-beta T cell number	J:158962
Rr94^tm3.2Litt/Rr94⁺ Rr112^tm4.1Litt/Rr112⁺ (involves: 129P2/OlaHsd * 129S4/SvJaeSor * FVB/N)	abnormal T cell differentiation	J:158962
	abnormal T cell subpopulation ratio	J:158962
	decreased CD4-positive, alpha-beta T cell number	J:158962
	increased CD8-positive, alpha-beta T cell number	J:158962
Rr94^tm3.2Litt/Rr94^tm3.2Litt (involves: 129P2/OlaHsd * FVB/N)	abnormal CD4-positive, alpha beta T cell morphology	J:158962
	abnormal double-positive T cell morphology	J:158962
	abnormal T cell differentiation	J:158962
	abnormal T cell subpopulation ratio	J:158962
	decreased CD4-positive, alpha-beta T cell number	J:158962
	decreased double-positive T cell number	J:158962
	immune system phenotype	J:158962
	increased CD8-positive, alpha-beta T cell number	J:158962
Rr94^tm3.2Litt/Rr94^tm3.2Litt H2-Ab1^b-tm1Gru/H2-Ab1^b-tm1Gru (involves: 129P2/OlaHsd * 129S2/SvPas * FVB/N)	abnormal T cell subpopulation ratio	J:158962
	decreased CD4-positive, alpha-beta T cell number	J:158962
	immune system phenotype	J:158962
	increased CD8-positive, alpha-beta T cell number	J:158962
Rr95^em1Pdi/Rr95^em1Pdi (Not Specified)	immune system phenotype	J:333574
Rr96^tm1.1Tich/Rr96⁺ Gt(ROSA)26Sor^{tm1(cre/ERT2)Thl}/Gt(ROSA)26Sor^{tm1(rtTAM2)Jae} (involves: 129 129S4/SvJae * C57BL/6)	abnormal T cell differentiation	J:191711
Rr96^tm1.1Tich/Rr96⁺ Gt(ROSA)26Sor^{tm1(rtTAM2)Jae}/Gt(ROSA)26Sor⁺ (involves: 129 129S4/SvJae * C57BL/6)	abnormal CD4-positive T cell differentiation	J:191711
Rr96^tm1.1Tich/Rr96^tm1.1Tich Gt(ROSA)26Sor^{tm1(rtTAM2)Jae}/Gt(ROSA)26Sor^{tm1(rtTAM2)Jae} (involves: 129 * 129S4/SvJae * C57BL/6)	abnormal T cell differentiation	J:191711
Rr96^tm1.1Tich/Rr96^tm1.1Tich Tg(ACTB-tTS)1Mllo/? (involves: 129 * C57BL/6)	decreased double-positive T cell number	J:191711
Rr96^tm1.1Yzo/Rr96^tm1.1Yzo (involves: 129P2/OlaHsd)	abnormal T cell differentiation	J:130559
	increased CD4-positive, alpha-beta T cell number	J:130559
	increased double-positive T cell number	J:130559
Rr96^tm1.1Yzo/Rr96^tm1.1Yzo H2-Ab1^b-tm1Gru/H2-Ab1^b-tm1Gru (involves: 129P2/OlaHsd * 129S2/SvPas)	abnormal T cell differentiation	J:130559
Rr96^tm1Yzo/Rr96^tm1Yzo Tg(Cd4-cre)1Cwi/? (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	abnormal T cell differentiation	J:130559
	increased double-positive T cell number	J:130559
Rr96^tm1Yzo/Rr96^tm1Yzo Tg(Cd8a-cre,-GFP)1Yzo/? (involves: 129P2/OlaHsd)	increased double-positive T cell number	J:130559
Rr96^tm2Litt/Rr96⁺ Zbtb7b^tm1.1Tani/Zbtb7b^tm1.1Tani (involves: 129 * 129P2/OlaHsd * C57BL/6)	increased double-negative T cell number	J:141142
Rr96^tm2Litt/Rr96⁺ Zbtb7b^tm1Itan/Zbtb7b^tm1.1Tani (involves: 129 * 129P2/OlaHsd * C57BL/6)	abnormal double-negative T cell morphology	J:141142
	decreased CD8-positive, alpha-beta T cell number	J:141142
Rr96^tm2Litt/Rr96^tm2Litt (involves: 129P2/OlaHsd)	abnormal CD8-positive, alpha beta T cell morphology	J:80690
Rr96^tm2Litt/Rr96^tm2Litt Tfap4^tm1.1Litt/Tfap4^tm1.1Litt (involves: 129P2/OlaHsd * C57BL/6 * FVB/N)	abnormal T cell differentiation	J:176461
Rr97^tm3Welm/Rr97^tm3Welm (involves: 129 * C57BL/6)	abnormal CD4-positive T cell differentiation	J:126027
	abnormal CD8-positive, alpha-beta T cell differentiation	J:126027
	abnormal dendritic cell morphology	J:126027
	abnormal double-positive T cell morphology	J:126027
	abnormal gamma-delta intraepithelial T cell morphology	J:126027
	abnormal T cell differentiation	J:126027
Rr98^tm1Welm/Rr98^tm1Welm (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:113136
Rr99^tm1Litt/Rr99^tm1Litt (either: (involves: 129P2/OlaHsd * AKR) or (involves: 129P2/OlaHsd * C57BL/6))	abnormal CD8-positive, alpha beta T cell morphology	J:50624
Rr100^tm2.1Welm/Rr100⁺ (involves: 129P2/OlaHsd * AKR.1 * C57BL/6)	abnormal T cell differentiation	J:113136
Rr100^tm2.1Welm/Rr100^tm2.1Welm (involves: 129P2/OlaHsd * C57BL/6)	abnormal T cell differentiation	J:113136
	abnormal T cell subpopulation ratio	J:113136
	decreased CD8-positive, alpha-beta T cell number	J:113136
	decreased double-positive T cell number	J:113136
	increased CD4-positive, alpha-beta T cell number	J:113136
Rr100^tm2.1Welm/Rr100^tm2.1Welm (involves: 129P2/OlaHsd)	abnormal T cell differentiation	J:158947
	decreased CD8-positive, alpha-beta T cell number	J:158947
	decreased double-positive T cell number	J:158947
	immune system phenotype	J:158947
	increased CD4-positive, alpha-beta T cell number	J:158947
Rr100^tm2.1Welm/Rr100^tm2.1Welm Patz1^tm1.1Welm/Patz1^tm1.1Welm (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:158947
Rr100^tm2.1Welm/Rr100^tm2.1Welm Tcra^tm1Mom/Tcra^tm1Mom (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)	abnormal T cell morphology	J:113136
Rr101^tm2Kio/Rr101^tm2Kio (involves: 129S2/SvPas * C57BL/6 * DBA/2)	immune system phenotype	J:110530
Rr104^tm1.2Mym/Rr104^tm1.2Mym Tg(Epo)458Mym/0 (involves: C57BL/6 DBA/2)	abnormal spleen morphology	J:231255
Rr123^tm1.1Vbo/Rr123^tm1.1Vbo (involves: 129S4/SvJae * C57BL/6 * FVB/N)	abnormal regulatory T cell morphology	J:191815
	immune system phenotype	J:191815
	increased regulatory T cell number	J:191815
Rr148^tm1.1Fwa/Rr148^tm1.1Fwa (involves: 129S6/SvEvTac)	abnormal B cell differentiation	J:101400
	arrested B cell differentiation	J:101400
	decreased immature B cell number	J:101400
	immune system phenotype	J:101400
	small spleen	J:101400
	spleen hypoplasia	J:101400
Rr148^tm1.1Fwa/Rr148^tm1.1Fwa Rag2^tm1Fwa/Rag2^tm1Fwa (involves: 129S/SvEv * 129S6/SvEvTac)	abnormal B cell differentiation	J:101400
Rr148^tm1Anbo/Rr148^tm1Anbo (involves: 129/Sv * C57BL/6 * FVB/N)	abnormal immunoglobulin heavy chain V(D)J recombination	J:136307
	decreased immature B cell number	J:136307
	decreased mature B cell number	J:136307
	decreased pre-B cell number	J:136307
Rr148^tm1Fwa/Rr148^tm1Fwa (129S6/SvEvTac-Rr148^tm1Fwa)	abnormal immature B cell morphology	J:101400
	absent B cells	J:101400
	absent Peyer's patches	J:101400
	arrested B cell differentiation	J:101400
	immune system phenotype	J:101400
	small spleen	J:101400
	spleen hypoplasia	J:101400
Rr148^tm1Fwa/Rr148^tm1Fwa Rag2^tm1Fwa/Rag2^tm1Fwa (involves: 129S/SvEv * 129S6/SvEvTac)	abnormal B cell differentiation	J:101400
Rr148^tm2Anbo/Rr148^tm2Anbo (involves: 129/Sv * C57BL/6 * FVB/N)	abnormal immunoglobulin heavy chain V(D)J recombination	J:136307
	decreased immature B cell number	J:136307
	decreased mature B cell number	J:136307
	decreased pre-B cell number	J:136307
Rr152^tm2Cog/Rr152⁺ (involves: 129S2/SvPas * C57BL/6)	decreased IgG1 level	J:90548
	decreased IgG2b level	J:90548
	decreased IgG3 level	J:90548
	decreased IgG level	J:90548
Rr152^tm2Cog/Rr152^tm2Cog (involves: 129S2/SvPas * C57BL/6)	decreased IgG1 level	J:90548
	decreased IgG2a level	J:90548
	decreased IgG2b level	J:90548
	decreased IgG3 level	J:90548
	decreased IgG level	J:90548
	increased pre-B cell number	J:90548
Rr152^tm3.1Cog/Rr152^tm3.1Cog (involves: 129P2/OlaHsd * C57BL/6 * FVB/N)	abnormal class switch recombination	J:71300
	decreased IgA level	J:71300
	decreased IgE level	J:71300
	decreased IgG2a level	J:71300
	decreased IgG2b level	J:71300
	decreased IgG3 level	J:71300
	decreased IgG level	J:71300
	decreased immunoglobulin level	J:71300
	immune system phenotype	J:71300
Rr152^tm3Cog/Rr152^tm3Cog (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell morphology	J:71300
	abnormal class switch recombination	J:71300
	decreased IgA level	J:71300
	decreased IgE level	J:71300
	decreased IgG1 level	J:71300
	decreased IgG2a level	J:71300
	decreased IgG2b level	J:71300
	decreased IgG3 level	J:71300
	decreased IgG level	J:71300
	decreased IgM level	J:71300
	decreased immunoglobulin level	J:71300
	immune system phenotype	J:71300
Rr152^tm5.1Cog/Rr152^tm5.1Cog (involves: 129P2/OlaHsd * C57BL/6)	abnormal class switch recombination	J:164513
	abnormal somatic hypermutation frequency	J:164513, J:333348
	decreased IgA level	J:164513
	decreased IgE level	J:164513
	decreased IgG2b level	J:164513
	decreased IgG3 level	J:164513
	decreased IgM level	J:164513
Rr155^tm1.1Erpi/Rr155^tm1.1Erpi (involves: 129P2/OlaHsd * C57BL/6 * FVB/N)	abnormal immunoglobulin level	J:160101
	decreased IgG1 level	J:160101
	decreased IgG2a level	J:160101
	immune system phenotype	J:160101
Rr156^tm6.1Cog/Rr156^tm6.1Cog (involves: 129P2/OlaHsd * C57BL/6)	decreased B cell number	J:165617
	decreased IgM level	J:165617
	immune system phenotype	J:165617
Rr156^tm6Cog/Rr156^tm6Cog (involves: 129P2/OlaHsd * C57BL/6)	decreased B cell number	J:165617
	decreased IgM level	J:165617
	immune system phenotype	J:165617
Rr158^tm1(Igh)Xu/Rr158^tm1(Igh)Xu (Not Specified)	abnormal immune system morphology	J:124407
	decreased B cell number	J:124407
	decreased immature B cell number	J:124407
	increased pre-B cell number	J:124407
Rr158^tm1Cgn/Rr158^tm1Cgn (either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129S2/SvPas * C57BL/6))	abnormal B cell differentiation	J:12574, J:64287
	decreased mature B cell number	J:64287
	increased mature B cell number	J:64287
	spleen hypoplasia	J:64287
Rr158^tm2Cgn/Rr158^tm2Cgn (either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129S2/SvPas * C57BL/6))	abnormal B cell differentiation	J:12574
Rr158^tm2Xu/Rr158^tm2Xu (Not Specified)	decreased B cell number	J:124407
Rr159^tm1.1Fwa/Rr159⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell differentiation	J:113715
Rr159^tm1.1Fwa/Rr159^tm1.1Fwa (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell differentiation	J:113715
	decreased B cell number	J:113715
Rr159^tm1Fwa/Rr159⁺ (involves: 129P2/OlaHsd * C57BL/6)	increased B cell number	J:113715
Rr159^tm1Fwa/Rr159^tm1Fwa (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell differentiation	J:113715
	decreased B cell number	J:113715
Rr160^tm1Wtg/Rr160^tm1Wtg (involves: 129S6/SvEvTac * C57BL/6)	abnormal immunoglobulin level	J:134885
	abnormal mature B cell morphology	J:134885
	abnormal somatic hypermutation frequency	J:134885
	decreased follicular B cell number	J:134885
	increased transitional stage B cell number	J:134885
Rr161^tm2.2Wtg/Rr161^tm2.2Wtg (involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6)	abnormal B cell differentiation	J:167472
	abnormal immunoglobulin V(D)J recombination	J:167472
	decreased B cell number	J:167472
	decreased pro-B cell number	J:167472
	increased pre-B cell number	J:167472
Rr162^tm3.1Wtg/Rr162^tm3.1Wtg (involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6)	abnormal immunoglobulin V(D)J recombination	J:172855
	immune system phenotype	J:172855
Rr163^tm1Lfdn/Rr163⁺ (either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129P2/OlaHsd * CB20))	abnormal immune system physiology	J:31727
	immune system phenotype	J:31727
Rr163^tm1Lfdn/Rr163^tm1Lfdn (either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129P2/OlaHsd * CB20))	abnormal immune system physiology	J:31727
	immune system phenotype	J:31727
Rr166^tm4.1Wtg/Rr166^tm4.1Wtg (involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6)	abnormal B cell differentiation	J:193015
	abnormal B cell physiology	J:193015
	abnormal immunoglobulin level	J:193015
	abnormal immunoglobulin light chain V-J recombination	J:193015
	abnormal pre-B cell morphology	J:193015
Rr169^tm2Rao/Rr169⁺ (involves: 129S6/SvEvTac * C57BL/6J)	abnormal T-helper 1 cell differentiation	J:94039
Rr169^tm2Rao/Rr169^tm2Rao (involves: 129S6/SvEvTac * C57BL/6J)	abnormal T-helper 1 cell differentiation	J:94039
	increased susceptibility to parasitic infection	J:94039
Rr170^tm1.1Iku/Rr170^tm1.1Iku (B6.Cg-Rr170^tm1.1Iku)	decreased T cell number	J:333539
	decreased T cell proliferation	J:333539
	immune system phenotype	J:333539
	increased T cell apoptosis	J:333539
Rr172^em1Kmm/Rr172^em1Kmm Rr253^em6Kmm/Rr253^em6Kmm (C57BL/6J-Rr253^em6Kmm Rr172^em1Kmm)	decreased dendritic cell number	J:334296
	decreased monocyte cell number	J:334296
	immune system phenotype	J:334296
	increased dendritic cell number	J:334296
Rr253^em1Kmm/Rr253^em1Kmm (C57BL/6-Rr253^em1Kmm)	abnormal class switch recombination	J:316113
	abnormal effector T cell number	J:316113
	abnormal peritoneal macrophage morphology	J:316113
	abnormal spleen B cell follicle morphology	J:316113
	decreased B cell number	J:316113
	decreased mature NK cell number	J:316113
	decreased monocyte cell number	J:316113
	decreased plasmacytoid dendritic cell number	J:316113
	decreased spleen B cell follicle number	J:316113
	decreased spleen B cell follicle size	J:316113
	increased dendritic cell number	J:316113
	increased lymphocyte cell number	J:316113
	increased neutrophil cell number	J:316113
	increased NK cell number	J:316113
	increased susceptibility to viral infection induced morbidity/mortality	J:316113
	increased T cell number	J:316113
	spleen hypoplasia	J:316113
Rr253^em3Kmm/Rr253^em3Kmm (C57BL/6J-Rr253^em3Kmm)	decreased dendritic cell number	J:334296
Rr253^em4Kmm/Rr253^em4Kmm (C57BL/6J-Rr253^em4Kmm)	immune system phenotype	J:334296
Rr253^em5Kmm/Rr253^em5Kmm (C57BL/6J-Rr253^em5Kmm)	decreased dendritic cell number	J:334296
Rr253^em5Kmm/Rr253^em5Kmm (C57BL/6J-Rr253^em5Kmm)	increased dendritic cell number	J:334296
Rr253^em6Kmm/Rr253^em6Kmm (C57BL/6J-Rr253^em6Kmm)	abnormal T-helper 2 physiology	J:334296
	decreased dendritic cell number	J:334296
	decreased monocyte cell number	J:334296
	decreased plasmacytoid dendritic cell number	J:334296
	immune system phenotype	J:334296
	increased dendritic cell number	J:334296
	increased susceptibility to parasitic infection induced morbidity/mortality	J:334296
Rr270^em1Mgn/Rr270^em1Mgn (involves: CD-1)	abnormal embryonic lymph sac morphology	J:328045
Rr308^tm1.1Fwa/Rr308^tm1.1Fwa (involves: 129P2/OlaHsd)	abnormal T cell differentiation	J:82616, J:82395
Rr308^tm1.1Fwa/Rr308^tm1.1Fwa (involves: 129P2/OlaHsd)	abnormal T cell receptor alpha chain V-J recombination	J:82616
Rr308^tm1Fwa/Rr308^tm1Fwa (involves: 129P2/OlaHsd)	abnormal T cell differentiation	J:82616
Rr308^tm1Fwa/Rr308^tm1Fwa (involves: 129P2/OlaHsd)	abnormal T cell receptor alpha chain V-J recombination	J:82616
Rr308^tm2Fwa/Rr308^tm2Fwa (Not Specified)	abnormal T cell differentiation	J:82395
Rr338^em1Jeng/Rr338^em1Jeng (Not Specified)	abnormal T cell differentiation	J:232438
	abnormal T cell number	J:232438
	decreased CD4-positive, alpha-beta T cell number	J:232438
Rr347^em1Prdns/Rr347^em1Prdns (CBA/Ca-Rr347^em1Prdns)	absent Langerhans cell	J:281171
	decreased macrophage cell number	J:281171
	decreased microglial cell number	J:281171
	immune system phenotype	J:281171
	increased Ly6C low monocyte number	J:281171
Rr364^tm1.1Aak/Rr364^tm1.1Aak (129.129S2(Cg)-Rr364^tm1.1Aak)	abnormal class switch recombination	J:242276
	decreased IgG3 level	J:242276
	increased IgG2a level	J:242276
	increased IgG2b level	J:242276
Rr381^em1Kap/Rr381^em1Kap (involves: C57BL/6)	absent CD8-positive, alpha-beta T cells	J:333471
Rr381^em4Kap/Rr381^em4Kap (involves: C57BL/6)	absent CD8-positive, alpha-beta T cells	J:333471
Rr381^em5Kap/Rr381^em5Kap (involves: C57BL/6)	absent CD8-positive, alpha-beta T cells	J:333471
Rr381^tm1.1Tani/Rr381⁺ (Not Specified)	decreased CD8-positive, alpha-beta T cell number	J:131081
Rr383^tm1Caob/Rr383^tm1Caob (B6.Cg-Rr383^tm1Caob)	decreased osteoclast cell number	J:131132
Rr386^em1Pdi/Rr386^em1Pdi (involves: C57BL/6J)	immune system phenotype	J:333574
Rr394^em1Bhao/Rr394^em1Bhao (Not Specified)	abnormal T cell receptor alpha chain V-J recombination	J:333961
	decreased thymocyte number	J:333961
	increased DN3 thymocyte number	J:333961
Rr395^em1Bhao/Rr395^em1Bhao (Not Specified)	decreased double-positive T cell number	J:333961
	decreased thymocyte number	J:333961
	increased DN4 thymocyte number	J:333961
	increased thymocyte apoptosis	J:333961
Rr149356^tm1.1Pf/Rr149356^tm1.1Pf (either: 129P2/OlaHsd-Rr149356^tm1.1Pf or (involves: 129P2/OlaHsd * BALB/c))	abnormal T cell differentiation	J:34311
	abnormal thymus cortex morphology	J:34311
	abnormal thymus medulla morphology	J:34311
	abnormal thymus morphology	J:34311
	arrested T cell differentiation	J:34311
	decreased double-positive T cell number	J:34311
	decreased single-positive T cell number	J:34311
	decreased T cell number	J:34311
	decreased thymocyte number	J:34311
	increased double-negative T cell number	J:34311
	increased gamma-delta T cell number	J:34311
	lymph node hypoplasia	J:34311
Rr149356^tm1Abnd/Rr149356^tm1Abnd (involves: 129S1/Sv * 129X1/SvJ)	abnormal T cell differentiation	J:137580
	abnormal thymus morphology	J:137580
	arrested T cell differentiation	J:137580
	decreased double-positive T cell number	J:137580
	decreased single-positive T cell number	J:137580
	decreased T cell number	J:137580
	increased double-negative T cell number	J:137580
	increased gamma-delta T cell number	J:137580
	thymus hypoplasia	J:137580
Rr149356^tm1Che/Rr149356^tm1Che (involves: 129S4/SvJae * C57BL/6)	abnormal double-negative T cell morphology	J:106246, J:107306
	abnormal double-positive T cell morphology	J:106246, J:107306
Rr149356^tm1Che/Rr149356^tm1Che Tcrd^tm1Mom/Tcrd^tm1Mom Trp53^tm1Tyj/Trp53^tm1Tyj (involves: 129P2/OlaHsd * 129S2/SvPas * 129S4/SvJae * C57BL/6)	abnormal double-negative T cell morphology	J:106246
	increased T cell derived lymphoma incidence	J:106246
Rr149356^tm1Che/Rr149356^tm1Che Trp53^tm1Tyj/Trp53^tm1Tyj (involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)	abnormal double-negative T cell morphology	J:106246
	abnormal double-positive T cell morphology	J:106246
	increased T cell derived lymphoma incidence	J:106246
Rr250409^tm1Lky/Rr250409⁺ (involves: 129X1/SvJ * BALB/c * C57BL/6 * FVB)	decreased interleukin-4 secretion	J:125684
Rr250409^tm1Lky/Rr250409^tm1Lky (involves: 129X1/SvJ * BALB/c * C57BL/6 * FVB)	abnormal response to infection	J:125684
	decreased IgE level	J:125684
	decreased interleukin-4 secretion	J:125684
	decreased interleukin-5 secretion	J:125684
	decreased interleukin-13 secretion	J:125684
	decreased susceptibility to parasitic infection	J:125684
Rr250409^tm1Lky/Rr250409^tm1Lky (involves: 129X1/SvJ * BALB/c)	decreased interleukin-4 secretion	J:167446
Rr275254^tm2.1Dhr/Rr275254^tm2.1Dhr (involves: 129S4/SvJae * C57BL/6)	abnormal gamma-delta T cell differentiation	J:75624
	abnormal T cell receptor gamma chain V-J recombination	J:75624
Rr275254^tm2Dhr/Rr275254^tm2Dhr (involves: 129S4/SvJae)	abnormal gamma-delta T cell differentiation	J:75624
Rr275254^tm2Dhr/Rr275254^tm2Dhr (involves: 129S4/SvJae)	abnormal T cell receptor gamma chain V-J recombination	J:75624
Rr282726^tm1Dhr/Rr282726^tm1Dhr (involves: 129S4/SvJae * C57BL/6)	abnormal gamma-delta T cell differentiation	J:75624
	abnormal T cell receptor gamma chain V-J recombination	J:75624
Rr282729^tm1.1Iku/Rr282729^tm1.1Iku (C57BL/6J-Rr316^tm1.1Iku)	abnormal T cell receptor gamma chain V-J recombination	J:288442
	decreased gamma-delta T cell number	J:288442
Rr299391^tm1.1Fwa/Rr299391⁺ (involves: 129P2/OlaHsd * FVB/N)	decreased T cell number	J:55401
	decreased thymocyte number	J:55401
Rr299391^tm1.1Fwa/Rr299391^tm1.1Fwa (involves: 129P2/OlaHsd * FVB/N)	decreased T cell number	J:55401
	decreased thymocyte number	J:55401
Rragc^em1Efe/Rragc⁺ (Not Specified)	abnormal B cell activation	J:320567
	abnormal B cell physiology	J:320567
	abnormal class switch recombination	J:320567
	decreased B cell proliferation	J:320567
	decreased germinal center B cell number	J:320567
	decreased IgG1 level	J:320567
	decreased IgM level	J:320567
	decreased plasma cell number	J:320567
	decreased spleen germinal center size	J:320567
	impaired humoral immune response	J:320567
Rragc^em1Efe/Rragc⁺ Tg(Vav-BCL2)69Jad/0 (Not Specified)	decreased germinal center B cell number	J:320567
	decreased spleen germinal center size	J:320567
	decreased susceptibility to autoimmune disorder	J:320567
Rras2^{em1(IMPC)Ccpcz}/Rras2^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Rras2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
	increased NK cell number	J:211773
Rras2^{Gt(OST361011)Lex}/Rras2⁺ (involves: 129S5/SvEvBrd)	decreased B cell number	J:151653
	decreased follicular B cell number	J:151653
	decreased marginal zone B cell number	J:151653
	decreased memory T cell number	J:151653
	decreased spleen B cell follicle size	J:151653
	decreased spleen weight	J:151653
	decreased T cell number	J:151653
	spleen hypoplasia	J:151653
Rras2^{Gt(OST361011)Lex}/Rras2^{Gt(OST361011)Lex} (involves: 129S5/SvEvBrd)	abnormal B cell activation	J:151653
	abnormal B cell physiology	J:151653
	abnormal CD4-positive, alpha-beta T cell physiology	J:151653
	abnormal CD8-positive, alpha-beta T cell physiology	J:151653
	abnormal lymph node germinal center morphology	J:151653
	decreased B cell number	J:151653
	decreased B cell proliferation	J:151653
	decreased follicular B cell number	J:151653
	decreased marginal zone B cell number	J:151653
	decreased memory T cell number	J:151653
	decreased spleen B cell follicle size	J:151653
	decreased spleen weight	J:151653
	decreased T cell number	J:151653
	spleen hypoplasia	J:151653
Rras2^{Gt(OST361011)Lex}/Rras2^{Gt(OST361011)Lex} (B6.129S5-Rras2^{Gt(OST361011)Lex})	decreased B cell number	J:151653
	decreased memory T cell number	J:151653
	decreased T cell number	J:151653
Rras^{Gt(OST24882)Lex}/Rras^{Gt(OST24882)Lex} (B6;129S5-Rras^{Gt(OST24882)Lex}/Ieg)	decreased B cell number	J:82809
	increased CD4-positive, alpha-beta T cell number	J:82809
	increased CD8-positive, alpha-beta T cell number	J:82809
Rras^tm1Itl/Rras^tm1Itl (either: (involves: 129S6/SvEvTac) or (involves: 129S6/SvEvTac * C57BL/6))	immune system phenotype	J:181730
Rras^tm1Itl/Rras^tm1Itl (involves: 129S6/SvEvTac * C57BL/6)	abnormal dendritic cell morphology	J:181730
Rras^tm1Itl/Rras^tm1Itl (involves: 129S6/SvEvTac * C57BL/6)	abnormal dendritic cell physiology	J:181730
Rreb1^{tm1b(EUCOMM)Wtsi}/Rreb1⁺ (C57BL/6N-Rreb1^{tm1b(EUCOMM)Wtsi}/Wtsi)	increased leukocyte cell number	J:211773
Rrm2b^{Gt(OST85254)Lex}/Rrm2b^{Gt(OST85254)Lex} (involves: 129S5/SvEvBrd * C57BL/6J)	spleen atrophy	J:186071
	thymus atrophy	J:186071
Rrm2b^tm1Ynak/Rrm2b^tm1Ynak (involves: 129 * C57BL/6J)	abnormal mesenteric lymph node morphology	J:84841
	decreased spleen white pulp amount	J:84841
	thymus cortex hypoplasia	J:84841
Rsad1^{tm1.1(KOMP)Vlcg}/Rsad1⁺ (C57BL/6N-Rsad1^{tm1.1(KOMP)Vlcg}/Ucd)	enlarged lymph nodes	J:211773
	small thymus	J:211773
Rsad1^{tm1.1(KOMP)Vlcg}/Rsad1^{tm1.1(KOMP)Vlcg} (C57BL/6N-Rsad1^{tm1.1(KOMP)Vlcg}/Ucd)	enlarged lymph nodes	J:211773
Rsad2^tm1Aki/Rsad2^tm1Aki (involves: 129/Sv * C57BL/6)	decreased circulating interferon-alpha level	J:169840
	decreased interferon-alpha secretion	J:169840
	decreased interferon-beta secretion	J:169840
Rsad2^tm1Kchc/Rsad2^tm1Kchc (B6.129-Rsad2^tm1Kchc)	abnormal T-helper 2 cell differentiation	J:148305
	decreased IgG1 level	J:148305
	decreased interleukin-4 secretion	J:148305
	decreased interleukin-5 secretion	J:148305
	decreased interleukin-13 secretion	J:148305
	increased interferon-gamma secretion	J:148305
rsm1/rsm1 (either: P/J or P/N)	abnormal cell-mediated immunity	J:8396
Rsph9^em1Jwji/Rsph9^em1Jwji (B6.Cg-Rsph9^em1Jwji)	increased microglial cell activation	J:294184
	microgliosis	J:294184
	sinus inflammation	J:294184
Rspo1^{tm2b(KOMP)Wtsi}/Rspo1^{tm2b(KOMP)Wtsi} (C57BL/6N-Rspo1^{tm2b(KOMP)Wtsi}/Ics)	increased lymphocyte cell number	J:211773
Rtcb^{tm1c(KOMP)Wtsi}/Rtcb^{tm1c(KOMP)Wtsi} Tg(Fcer2a-cre)5Mbu/0 (involves: C57BL/6 * CBA * SJL)	abnormal B cell number	J:216740
	abnormal B cell physiology	J:216740
	abnormal plasma cell morphology	J:216740
	decreased IgM level	J:216740
Rthyd1^NOD/MrkTac/? (involves: B10.Br/SgSnJ * NOD-H2^k)	abnormal T cell clonal deletion	J:94684
Rthyd2^B10.Br/SgSnJ/? (involves: B10.Br/SgSnJ * NOD-H2^k)	abnormal T cell clonal deletion	J:94684
Rthyd3^B10.Br/SgSnJ/? (involves: B10.Br/SgSnJ * NOD-H2^k)	abnormal T cell clonal deletion	J:94684
Rthyd5^NOD/MrkTac/? (involves: B10.Br/SgSnJ * NOD-H2^k)	abnormal T cell clonal deletion	J:94684
Rtl5^em1Tmki/Rtl5^em1Tmki Rtl6^tm2.1Tmki/Rtl6^tm2.1Tmki (involves: C57BL/6NCrlj * C57BL/6NSlc * CBA/JNCrlj)	abnormal inflammatory response	J:329352
	decreased susceptibility to endotoxin shock	J:329352
Rtl5^tm1.1Tmki/Rtl5^tm1.1Tmki (involves: C57BL/6NCrlj * CBA/JNCrlj)	immune system phenotype	J:329352
Rtl5^tm1.1Tmki/Rtl5^tm1.1Tmki Rtl6^tm1.1Tmki/Rtl6^tm1.1Tmki (involves: C57BL/6NCrlj * C57BL/6NSlc * CBA/JNCrlj)	abnormal inflammatory response	J:329352
Rtl9^em2Tmki/Rtl9^em2Tmki (C57BL/6N-Rtl9^em2Tmki)	abnormal innate immunity	J:343808
Rtp4^em#Xzs/Rtp4^em#Xzs (involves: C57BL/6)	decreased susceptibility to parasitic infection	J:293929
	decreased susceptibility to parasitic infection induced morbidity/mortality	J:293929
	decreased susceptibility to viral infection	J:293929
Rtraf^{tm1b(EUCOMM)Hmgu}/Rtraf⁺ (C57BL/6N-Rtraf^{tm1b(EUCOMM)Hmgu}/H)	increased eosinophil cell number	J:211773
Rttn^em1(IMPC)Tcp/Rttn⁺ (C57BL/6NCrl-Rttn^em1(IMPC)Tcp/Tcp)	abnormal spleen morphology	J:211773
Rubcn^em1Dgre/Rubcn^em1Dgre (C57BL/6-Rubcn^em1Dgre)	abnormal macrophage physiology	J:261225
Rubcn^em1Dgre/Rubcn^em1Dgre (C57BL/6-Rubcn^em1Dgre)	immune system phenotype	J:261225
Rubcn^em1Dgre/Rubcn^em1Dgre (involves: C57BL/6 * C57BL/6N)	abnormal circulating chemokine level	J:235399
	abnormal macrophage physiology	J:235399
	abnormal spleen morphology	J:235399
	decreased circulating interleukin-10 level	J:235399
	glomerulonephritis	J:235399
	increased anti-double stranded DNA antibody level	J:235399
	increased anti-nuclear antigen antibody level	J:235399
	increased autoantibody level	J:235399
	increased CD8-positive, alpha-beta T cell number	J:235399
	increased circulating interleukin-1 beta level	J:235399
	increased circulating interleukin-6 level	J:235399
	increased circulating interleukin-12b level	J:235399
	increased IgG level	J:235399
	increased lymphocyte cell number	J:235399
	increased monocyte cell number	J:235399
	increased neutrophil cell number	J:235399
	increased susceptibility to systemic lupus erythematosus	J:235399
Rubcn^em1Dgre/Rubcn^em1Dgre Tg(CAG-EGFP/Map1lc3b)53Nmz/0 (involves: C57BL/6 * C57BL/6J * C57BL/6N * C57BL/6NCrlj * DBA/2)	abnormal macrophage morphology	J:261225
	abnormal macrophage physiology	J:261225
Rubcn^em1Dgre/Rubcn^em1Dgre Tg(CAG-EGFP/Map1lc3b)53Nmz/0 (involves: C57BL/6 * C57BL/6N * DBA/2)	abnormal circulating chemokine level	J:235399
	abnormal macrophage physiology	J:235399
	decreased circulating interleukin-10 level	J:235399
	increased circulating interleukin-1 beta level	J:235399
	increased circulating interleukin-6 level	J:235399
Runx1^{tm1(RUNX1)Gcg}/Runx1^{tm1(RUNX1)Gcg} Tg(Mx1-cre)1Cgn/0 (involves: 129S1/Sv * C57BL/6 * CBA)	abnormal granulocyte differentiation	J:106800
	abnormal myelopoiesis	J:106801
	abnormal T cell differentiation	J:106800
	decreased CD4-positive, alpha-beta T cell number	J:106800
	decreased double-positive T cell number	J:106800
	increased CD8-positive, alpha-beta T cell number	J:106800
	increased T cell derived lymphoma incidence	J:106800
Runx1^{tm1(RUNX1/EVI1)Kmit}/Runx1⁺ (involves: C57BL/6 * CBA)	abnormal myelopoiesis	J:118892
Runx1^tm1Itan/Runx1^tm1Itan (involves: 129P2/OlaHsd)	immune system phenotype	J:132661
Runx1^tm1Soga/Runx1^tm1.1Soga Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA)	abnormal B cell differentiation	J:88511
	abnormal T cell differentiation	J:88511
Runx1^tm1Soga/Runx1^tm1Soga Stag2^tm1.1Soga/Y Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6J * C57BL/6N * CBA/J)	decreased leukocyte cell number	J:289000
Runx1^tm1Spe/Runx1⁺ (either: (involves: 129S4/SvJae * BALB/c * C57BL/6 * CBA/Ca) or (involves: 129S4/SvJae * C57BL/6 * CBA/Ca))	increased T cell derived lymphoma incidence	J:80829
Runx1^tm1Spe/Runx1⁺ (either: (involves: 129S4/SvJae * BALB/c) or (involves: 129S4/SvJae * C57BL/6))	decreased CD4-positive, alpha-beta T cell number	J:120100
Runx1^tm1Spe/Runx1^tm1Spe (either: (involves: 129S4/SvJae * BALB/c) or (involves: 129S4/SvJae * C57BL/6))	impaired myelopoiesis	J:35115
Runx1^tm1Tani/Runx1^tm1Tani Runx3^tm1Itan/Runx3^tm1Itan Tg(Cd4-cre)1Cwi/? (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	decreased CD8-positive, alpha-beta T cell number	J:125959
Runx1^tm1Tani/Runx1^tm1Tani Tg(Cd4-cre)1Cwi/? (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	abnormal CD4-positive T cell differentiation	J:125959
	abnormal CD8-positive, alpha-beta T cell differentiation	J:125959
	abnormal double-positive T cell morphology	J:125959
	decreased CD4-positive, alpha-beta T cell number	J:125959
Runx1^tm1Tani/Runx1^tm1Tani Tg(Lck-cre)1Cwi/? (involves: 129P2/OlaHsd)	arrested T cell differentiation	J:125959
	decreased double-positive T cell number	J:125959
	decreased thymocyte number	J:125959
	increased double-negative T cell number	J:125959
Runx1^tm1Toku/Runx1⁺ Runx3^tm1Itan/Runx3^tm1Itan Tg(Cd4-cre)1Cwi/0 (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	decreased CD8-positive, alpha-beta T cell number	J:131081
Runx1^tm1Toku/Runx1^tm1Toku (involves: 129P2/OlaHsd * C57BL/6)	abnormal T cell subpopulation ratio	J:87697
	increased CD4-positive, alpha-beta T cell number	J:87697
	small thymus	J:87697
	thymus hypoplasia	J:87697
Runx1^tm1Toku/Runx1^tm1Toku Runx3^tm1Itan/Runx3⁺ Tg(Cd4-cre)1Cwi/0 (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	decreased CD4-positive, alpha-beta T cell number	J:131081
	decreased CD8-positive, alpha-beta T cell number	J:131081
Runx1^tm1Toku/Runx1^tm1Toku Runx3^tm1Itan/Runx3^tm1Itan Tg(Cd4-cre)1Cwi/0 (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	decreased CD4-positive, alpha-beta T cell number	J:131081
	decreased CD8-positive, alpha-beta T cell number	J:131081
Runx1^tm1Toku/Runx1^tm1Toku Tg(Cd4-cre)1Cwi/0 (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	decreased CD8-positive, alpha-beta T cell number	J:131081
Runx1^tm1Yg/Runx1^tm1Yg (either: (involves: 129/Sv * 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * ICR) or (involves: 129S1/Sv * 129X1/SvJ * MF1))	abnormal leukopoiesis	J:125830
	abnormal T cell differentiation	J:125830
	abnormal thymus corticomedullary boundary morphology	J:125830
	abnormal thymus lobule morphology	J:125830
	decreased single-positive T cell number	J:125830
	decreased thymocyte number	J:125830
	increased double-positive T cell number	J:125830
	increased thymocyte apoptosis	J:125830
	small thymus	J:125830
	thymus cyst	J:125830
	thymus hypoplasia	J:125830
Runx1^tm1Yg/Runx1^tm1Yg Tg(Lck-cre)1Jtak/? (either: (involves: 129/Sv * 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * ICR) or (involves: 129S1/Sv * 129X1/SvJ * MF1))	decreased T cell number	J:125830
Runx1^{tm2(Runx1)Toku}/Runx1^{tm2(Runx1)Toku} (involves: 129P2/OlaHsd * C57BL/6)	abnormal T cell subpopulation ratio	J:87697
Runx1^tm2.1Gss/Runx1^tm2.1Gss (involves: 129S4/SvJae * C57BL/6)	abnormal leukocyte morphology	J:214025
	abnormal spleen white pulp morphology	J:214025
	decreased CD8-positive, alpha-beta T cell number	J:214025
	decreased immature B cell number	J:214025
	decreased pre-pro B cell number	J:214025
	enlarged spleen	J:214025
	increased granulocyte number	J:214025
	increased macrophage cell number	J:214025
	increased mature B cell number	J:214025
	increased monocyte cell number	J:214025
	increased pro-B cell number	J:214025
	myeloid hyperplasia	J:214025
Runx1^tm2Buch/Runx1^tm2Buch Tg(Mx1-cre)1Cgn/? (involves: 129P2/OlaHsd * C57BL/6 * CBA)	abnormal immune system organ morphology	J:105709
	abnormal leukocyte morphology	J:105709
	abnormal lymph node size	J:105709
	abnormal thymus lobule morphology	J:105709
	decreased CD4-positive, alpha-beta T cell number	J:105709
	decreased CD8-positive, alpha-beta T cell number	J:105709
	decreased double-positive T cell number	J:105709
	decreased lymphocyte cell number	J:105709
	decreased mature B cell number	J:105709
	decreased spleen white pulp amount	J:105709
	decreased T cell number	J:105709
	decreased thymus weight	J:105709
	impaired myelopoiesis	J:105709
	increased mast cell number	J:105709
	increased monocyte cell number	J:105709
	increased neutrophil cell number	J:105709
	increased spleen red pulp amount	J:105709
	increased spleen weight	J:105709
	increased T cell derived lymphoma incidence	J:105709
	small Peyer's patches	J:105709
Runx1^tm2Itan/Runx1^tm2Itan (involves: 129P2/OlaHsd)	immune system phenotype	J:132661
Runx1^{tm3(Runx3)Toku}/Runx1^{tm3(Runx3)Toku} (involves: 129P2/OlaHsd)	abnormal thymus medulla morphology	J:98965
	decreased leukocyte cell number	J:98965
	decreased lymphocyte cell number	J:98965
	decreased thymocyte number	J:98965
	small spleen	J:98965
	small thymus	J:98965
	thymus hypoplasia	J:98965
Runx1^tm3Dow/Runx1⁺ Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA)	increased T cell derived lymphoma incidence	J:77129
Runx1^tm3Itan/Runx1^tm3Itan (involves: 129P2/OlaHsd * C57BL/6)	decreased leukocyte cell number	J:160791
Runx1^tm3Itan/Runx1^tm3Itan (involves: 129P2/OlaHsd)	abnormal axillary lymph node morphology	J:168918
	abnormal inguinal lymph node morphology	J:168918
	abnormal lymph organ development	J:168918
	abnormal Peyer's patch morphology	J:168918
	decreased CD4-positive, alpha-beta T cell number	J:168918
	decreased Peyer's patch number	J:168918
	decreased thymocyte number	J:168918
	small Peyer's patches	J:168918
Runx1^tm3Spe/Runx1^tm3Spe Spi1^tm2.1Dgt/Spi1^tm2.1Dgt Tg(Mx1-cre)1Cgn/0 (involves: 129S4/SvJae * C57BL/6 * CBA)	decreased B cell number	J:131217
	decreased thymus weight	J:131217
	increased granulocyte number	J:131217
	increased spleen weight	J:131217
Runx1^tm3Spe/Runx1^tm3Spe Tg(Mx1-cre)1Cgn/0 (involves: 129S4/SvJae * C57BL/6 * CBA)	arrested T cell differentiation	J:131217
	decreased B cell number	J:151639
	decreased double-negative T cell number	J:131217
	decreased thymus weight	J:131217
	increased double-negative T cell number	J:131217
	increased spleen weight	J:131217
Runx1^tm3Spe/Runx1^tm3Spe Tg(VAV1-cre)1Graf/0 (involves: 129S4/SvJae)	decreased B cell number	J:145700
	decreased double-positive T cell number	J:145700
	decreased lymphocyte cell number	J:145700
	decreased thymocyte number	J:145700
	increased granulocyte number	J:145700
	increased monocyte cell number	J:145700
Runx1^{tm4(Runx2)Toku}/Runx1^{tm4(Runx2)Toku} (involves: 129P2/OlaHsd)	decreased leukocyte cell number	J:98965
Runx1^tm4Spe/Runx1⁺ (involves: 129/Sv * C57BL/6)	decreased CD4-positive, alpha-beta T cell number	J:120100
Runx1^tm4Spe/Runx1^tm4Spe (involves: 129/Sv * C57BL/6)	decreased leukocyte cell number	J:120100
	decreased lymphocyte cell number	J:120100
	increased monocyte cell number	J:120100
Runx1^tm5Spe/Runx1⁺ (involves: 129/Sv * C57BL/6)	decreased CD4-positive, alpha-beta T cell number	J:120100
Runx1^tm6Spe/Runx1⁺ (involves: 129/Sv * C57BL/6)	decreased CD4-positive, alpha-beta T cell number	J:120100
Runx1^tm7Spe/Runx1⁺ (involves: 129/Sv * C57BL/6)	decreased CD4-positive, alpha-beta T cell number	J:120100
Runx1^tm8Spe/Runx1⁺ (involves: 129/Sv * C57BL/6)	decreased CD4-positive, alpha-beta T cell number	J:120100
Runx1^tm8Spe/Runx1^tm8Spe (involves: 129/Sv * C57BL/6)	lung inflammation	J:120100
Runx2^tm1Kish/Runx2⁺ (involves: 129P2/OlaHsd * C57BL/6)	enlarged thymus	J:162258
Runx2^tm1Kish/Runx2^tm1Kish (involves: 129P2/OlaHsd * C57BL/6)	abnormal osteoclast differentiation	J:59821, J:40783
	abnormal splenic cell ratio	J:53069
	decreased B cell number	J:53069
	decreased thymocyte number	J:40783
	enlarged spleen	J:53069
	increased granulocyte number	J:53069
Runx3^tm1Itan/Runx3^tm1Itan Tg(Cd4-cre)1Cwi/0 (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	abnormal CD8-positive, alpha beta T cell morphology	J:125953
	abnormal CD8-positive, alpha-beta T cell differentiation	J:125953
	decreased CD8-positive, alpha-beta T cell number	J:131081
	increased IgA level	J:125953
	lung inflammation	J:125953
Runx3^tm1Litt/Runx3^tm1Litt (involves: 129P2/OlaHsd)	abnormal CD8-positive, alpha-beta T cell differentiation	J:141144
Runx3^tm1Litt/Runx3^tm1Litt (involves: 129P2/OlaHsd)	abnormal double-positive T cell morphology	J:141144
Runx3^tm1Yg/Runx3^tm1Yg (either: (involves: 129S1/Sv * 129X1/SvJ * ICR) or (involves: 129S1/Sv * 129X1/SvJ * MF1))	abnormal cytokine level	J:93240
	abnormal dendritic cell differentiation	J:88424
	abnormal dendritic cell morphology	J:88424
	abnormal dendritic cell physiology	J:88424, J:100348
	abnormal inflammatory response	J:93240
	abnormal interferon level	J:93240
	abnormal interleukin level	J:93240
	abnormal mesenteric lymph node morphology	J:93240
	abnormal tumor necrosis factor level	J:93240
	absent Langerhans cell	J:88424
	colitis	J:93240
	increased dendritic cell number	J:88424, J:100348
	increased IgE level	J:100348
	intestinal inflammation	J:93240
	lung inflammation	J:88424
	small intestinal inflammation	J:93240
	stomach inflammation	J:93240
Runx3^tm1Yg/Runx3^tm1Yg (involves: 129S1/Sv * 129X1/SvJ)	abnormal CD8-positive, alpha beta T cell morphology	J:109584
Runx3^tm2Yg/Runx3^tm2Yg (involves: 129S1/Sv * 129X1/SvJ * BALB/c * C57BL/6 * ICR)	abnormal CD8-positive, alpha beta T cell morphology	J:109584
	abnormal dendritic cell differentiation	J:109584
Runx3^tm3.1Yg/Runx3^tm3.1Yg (Not Specified)	abnormal immune system physiology	J:224898
	absent Langerhans cell	J:224898
	intestinal inflammation	J:224898
Ruvbl1^tm1.1Oxbk/Ruvbl1^tm1.1Oxbk Tg(Mx1-cre)1Cgn/0 (involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J * CBA/J * SJL)	bone marrow failure	J:220926
Ruvbl2^M1Btlr/Ruvbl2⁺ (involves: C57BL/6J)	abnormal class switch recombination	J:185495
	decreased CD4-positive, alpha-beta T cell number	J:185495
	decreased CD8-positive, alpha-beta T cell number	J:185495
	decreased double-positive T cell number	J:185495
	decreased IgG1 level	J:185495
	decreased IgG level	J:185495
	decreased IgM level	J:185495
	decreased T cell number	J:185495
	immune system phenotype	J:185495
	increased thymocyte number	J:185495
Rwdd1^{tm1b(KOMP)Wtsi}/Rwdd1^{tm1b(KOMP)Wtsi} (C57BL/6N-Rwdd1^{tm1b(KOMP)Wtsi}/Wtsi)	decreased CD8-positive, alpha-beta T cell number	J:211773
	decreased Ly6C-positive mature NK cell number	J:211773
	decreased regulatory T cell number	J:211773
	increased CD4-positive, alpha-beta T cell number	J:211773
	increased memory-marker gamma-delta T cell number	J:211773
Rwdd2a^em1(IMPC)J/Rwdd2a^em1(IMPC)J (C57BL/6NJ-Rwdd2a^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
Rxfp2^{tm1a(EUCOMM)Wtsi}/Rxfp2^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Rxfp2^{tm1a(EUCOMM)Wtsi}/Ieg)	decreased IgE level	J:165965
	increased monocyte cell number	J:165965
Rxfp4^{tm1.1(KOMP)Vlcg}/Rxfp4^{tm1.1(KOMP)Vlcg} (C57BL/6N-Rxfp4^{tm1.1(KOMP)Vlcg}/J)	decreased leukocyte cell number	J:211773
Rxra^pke/Rxra^pke (C57BL/6J-Rxra^pke)	abnormal dendritic cell physiology	J:103186
	abnormal regulatory T cell physiology	J:103186
	abnormal T-helper 2 cell morphology	J:103186
Rxra^tm1Ipc/Rxra^tm4Ipc Rxrb^tm1Mma/Rxrb^tm1Pcn Tg(KRT14-cre/ERT2)1Ipc/0 (involves: 129S2/SvPas)	increased immunoglobulin level	J:102470
Rxra^tm1Krc/Rxra^tm1Krc Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)	abnormal macrophage activation involved in immune response	J:168799
	abnormal peritoneal macrophage morphology	J:168799
	glomerulonephritis	J:168799
	impaired macrophage phagocytosis	J:168799
	increased anti-double stranded DNA antibody level	J:168799
	increased anti-nuclear antigen antibody level	J:168799
	increased anti-single stranded DNA antibody level	J:168799
	increased autoantibody level	J:168799
	increased IgG level	J:168799
	increased IgM level	J:168799
Rxra^tm2Ipc/Rxra^tm4Ipc Tg(KRT14-cre)1Ipc/0 (involves: 129S2/SvPas * C57BL/6 * SJL)	abnormal Langerhans cell morphology	J:67149
	skin inflammation	J:67149
Rxra^tm4Ipc/Rxra^tm4Ipc Rxrb^tm1Pcn/Rxrb^tm1Pcn Tg(KRT14-cre/ERT2)1Ipc/0 (involves: 129S2/SvPas)	dermatitis	J:102470
	ear inflammation	J:102470
	enlarged cervical lymph nodes	J:102470
	enlarged spleen	J:102470
	increased leukocyte cell number	J:102470
	lymph node hyperplasia	J:102470
Ryk^em1(IMPC)Mbp/Ryk⁺ (C57BL/6NCrl-Ryk^em1(IMPC)Mbp/MbpMmucd)	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
	increased monocyte cell number	J:211773
Ryr1^{tm1b(EUCOMM)Hmgu}/Ryr1⁺ (C57BL/6N-Ryr1^{tm1b(EUCOMM)Hmgu}/H)	increased spleen weight	J:211773
Ryr2^{tm1(CAG-KRASG12V,-lacZ)Nobs}/Ryr2^{tm1(CAG-KRASG12V,-lacZ)Nobs} Trp53^tm1Sia/Trp53^tm1Sia (involves: 129X1/SvJ * C57BL/6 * CBA)	myositis	J:117828
Ryr2^tm1.1Hnis/Ryr2^tm1.1Hnis (involves: C57BL/6)	abnormal mesenteric lymph node morphology	J:228787
	abnormal spleen white pulp morphology	J:228787
	enlarged mesenteric lymph nodes	J:228787
	immune system phenotype	J:228787
	increased spleen weight	J:228787
	increased thymus weight	J:228787
	large lymphoid organs	J:228787
	thymus cortex hyperplasia	J:228787
S1pr1^tm1.1Cys/S1pr1^tm1.1Cys (involves: 129P2/OlaHsd * C3H * C57BL/6)	abnormal B cell physiology	J:176118
	decreased B cell number	J:176118
	immune system phenotype	J:176118
S1pr1^tm1.1Thla/S1pr1^tm1.1Thla (B6.Cg-S1pr1^tm1.1Thla)	abnormal leukocyte migration	J:163389
	abnormal lymphocyte physiology	J:163389
	increased CD4-positive, alpha-beta T cell number	J:163389
	increased CD8-positive, alpha-beta T cell number	J:163389
S1pr1^tm1Cys/S1pr1^tm1Cys (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell physiology	J:176118
	decreased B cell number	J:176118
	immune system phenotype	J:176118
S1pr1^tm1Jch/S1pr1^tm1Jch Tg(GFAP-cre)25Mes/? (involves: C57BL/6J * FVB/N)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:168824
S1pr1^tm1Jch/S1pr1^tm1Jch Tg(Nes-cre)1Kln/0 (involves: C57BL/6J * SJL)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:168824
S1pr1^tm1Jch/S1pr1^tm1Jch Tg(Syn1-cre)671Jxm/? (involves: C57BL/6J * CBA)	immune system phenotype	J:168824
S1pr1^tm1Rlp/S1pr1^tm1Rlp (involves: 129S6/SvEvTac)	abnormal NK cell differentiation	J:154069
S1pr1^tm1Rlp/S1pr1^tm1Rlp (involves: 129S6/SvEvTac)	decreased NK cell number	J:154069
S1pr1^{tm3.1(tTA,-Arrb2)Rlp}/S1pr1⁺ Tg(tetO-HIST1H2BJ/GFP)47Efu/0 (involves: 129S6/SvEvTac * C57BL/6 * CD-1 * FVB/N)	immune system phenotype	J:212772
S1pr2^tm1Ajml/S1pr2^tm1Ajml (involves: 129S5/SvEvBrd * C57BL/6)	abnormal spleen marginal zone morphology	J:154439
	increased germinal center B cell number	J:154439
	increased spleen germinal center number	J:154439
	increased spleen germinal center size	J:154439
	increased T cell number	J:154439
S1pr2^tm1Rlp/S1pr2^tm1Rlp (involves: 129S6/SvEvTac * C57BL/6)	abnormal spleen germinal center morphology	J:174313
	decreased B cell apoptosis	J:174313
	increased B cell number	J:174313
	increased B cell proliferation	J:174313
	increased germinal center B cell number	J:174313
	increased T cell number	J:174313
S1pr3^tm1Jch/S1pr3^tm1Jch (involves: 129S1/Sv * 129X1/SvJ)	abnormal cytokine level	J:133917
	decreased susceptibility to endotoxin shock	J:133917
	enlarged mesenteric lymph nodes	J:133917
S1pr3^tm1Rlp/S1pr3^tm1Rlp (involves: 129S6/SvEvTac * C57BL/6)	abnormal B cell physiology	J:91161
S1pr4^tm1Lipp/S1pr4^tm1Lipp (involves: 129X1/SvJ * C57BL/6J)	abnormal thrombopoiesis	J:179199
S1pr5^tm1Club/S1pr5^tm1Club (B6.129P2-S1pr5^tm1Club)	abnormal NK cell morphology	J:178789
	abnormal NK cell physiology	J:178789
	decreased NK cell number	J:178789
S1pr5^tm1Jch/S1pr5^tm1Jch (involves: 129P2/OlaHsd * C57BL/6)	abnormal NK cell differentiation	J:154069
S100a3^em1(IMPC)Mbp/S100a3^em1(IMPC)Mbp (C57BL/6NCrl-S100a3^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
S100a4^tm1.1Abres/S100a4^tm1.1Abres (B6.Cg-S100a4^tm1.1Abres)	abnormal eosinophil physiology	J:182865
	impaired macrophage chemotaxis	J:182865
S100a9^tm1Hogg/S100a9^tm1Hogg (involves: 129P2/OlaHsd * C57BL/6)	abnormal neutrophil morphology	J:82513
	abnormal neutrophil physiology	J:82513
	immune system phenotype	J:82513
S100a9^tm1Nck/S100a9^tm1Nck (B6.129P2-S100a9^tm1Nck)	decreased circulating tumor necrosis factor level	J:125179
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:125179
	decreased susceptibility to endotoxin shock	J:125179
	decreased susceptibility to fungal infection	J:209808
S100a9^tm1Nck/S100a9^tm1Nck (involves: 129P2/OlaHsd * C57BL/6)	abnormal cellular extravasation	J:81642
Saa3^{tm1(KOMP)Vlcg}/Saa3^{tm1(KOMP)Vlcg} (involves: C57BL/6NTac)	decreased circulating serum amyloid protein level	J:220630
Sac3d1^tm1Hnaka/Sac3d1⁺ (involves: 129P2/OlaHsd)	abnormal mast cell physiology	J:144601
Sac3d1^tm1Hnaka/Sac3d1^tm1Hnaka (involves: 129P2/OlaHsd)	abnormal B cell physiology	J:144601
	abnormal mast cell physiology	J:144601
	increased T cell proliferation	J:144601
	spleen hyperplasia	J:144601
	thymus hyperplasia	J:144601
Sacs^em1(IMPC)Tcp/Sacs^em1(IMPC)Tcp (C57BL/6NCrl-Sacs^em1(IMPC)Tcp/Tcp)	abnormal spleen morphology	J:211773
Sall3^{tm1.1(KOMP)Mbp}/Sall3⁺ (C57BL/6NCrl-Sall3^{tm1.1(KOMP)Mbp}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged thymus	J:211773
Sall4^tm1Brd/Sall4⁺ (involves: 129S7/SvEvBrd * C57BL/6J)	ear inflammation	J:117866
Sall4^tm1Brd/Sall4⁺ (involves: 129S7/SvEvBrd * C57BL/6J)	increased susceptibility to otitis media	J:117866
Samd3^{tm1.1(HBEGF)Wfkr}/Samd3⁺ (C57BL/6J-Samd3^{tm1.1(HBEGF)Wfkr})	abnormal NK cell differentiation	J:322359
	decreased memory T cell number	J:322359
	decreased NK cell number	J:322359
Samd3^{tm1.1(HBEGF)Wfkr}/Samd3^{tm1.1(HBEGF)Wfkr} (C57BL/6J-Samd3^{tm1.1(HBEGF)Wfkr})	decreased CD8-positive, alpha-beta memory T cell number	J:322359
	immune system phenotype	J:322359
Samd8^tm1Jia/Samd8^tm1Jia (involves: 129S6/SvEvTac * C57BL/6J)	immune system phenotype	J:220024
Samd9l^tm1Homy/Samd9l⁺ (involves: 129P2/OlaHsd)	abnormal myelopoiesis	J:202604
	abnormal neutrophil morphology	J:202604
	decreased neutrophil cell number	J:202604
	enlarged spleen	J:202604
	increased leukocyte cell number	J:202604
	increased susceptibility to Retroviridae infection	J:202604
Samd9l^tm1Homy/Samd9l^tm1Homy (involves: 129P2/OlaHsd)	abnormal myelopoiesis	J:202604
	abnormal neutrophil morphology	J:202604
	decreased neutrophil cell number	J:202604
	enlarged spleen	J:202604
	increased leukocyte cell number	J:202604
	increased susceptibility to Retroviridae infection	J:202604
Samhd1^tm1.2Crs/Samhd1^tm1.2Crs (involves: C57BL/6N * C57BL/6NTac)	increased susceptibility to Retroviridae infection	J:201909
Samhd1^{tm1d(EUCOMM)Wtsi}/Samhd1^{tm1d(EUCOMM)Wtsi} (involves: C57BL/6N)	abnormal response to infection	J:202757
	immune system phenotype	J:202757
Samhd1^tm2.2Crs/Samhd1^tm2.2Crs (involves: 129S6/SvEvTac * C57BL/6J)	increased susceptibility to Retroviridae infection	J:201909
Samsn1^tm1Xyw/Samsn1^tm1Xyw (B6.129P2-Samsn1^tm1Xyw)	abnormal dendritic cell physiology	J:158032
	abnormal T-helper 1 physiology	J:158032
	abnormal T-helper 2 physiology	J:158032
	increased B cell proliferation	J:158032
	increased B-1a cell number	J:158032
	increased circulating interferon-gamma level	J:158032
	increased IgG3 level	J:158032
	increased IgM level	J:158032
	increased interleukin-4 secretion	J:158032
	increased interleukin-12 secretion	J:158032
	increased T cell proliferation	J:158032
Sap130^{tm1a(KOMP)Mbp}/Sap130⁺ (C57BL/6N-Sap130^{tm1a(KOMP)Mbp}/Wtsi)	decreased leukocyte cell number	J:211773
Sarm1^tm1.1Diam/Sarm1^tm1.1Diam (involves: 129X1/SvJ * C57BL/6)	abnormal circulating tumor necrosis factor level	J:200140
	decreased microglial cell activation	J:200140
	immune system phenotype	J:200140, J:196200
	increased susceptibility to Flaviviridae infection	J:200140
	increased susceptibility to Flaviviridae infection induced morbidity/mortality	J:200140
Sarm1^tm1Aidi/Sarm1^tm1Aidi (involves: 129X1/SvJ * C57BL/6J)	immune system phenotype	J:126083
Sash3^tm1Hlz/Sash3^tm1Hlz (B6.129P2-Sash3^tm1Hlz)	abnormal B cell morphology	J:102171
	abnormal B cell physiology	J:102171
	abnormal CD4-positive T cell differentiation	J:102171
	abnormal CD8-positive, alpha-beta T cell differentiation	J:102171
	abnormal humoral immune response	J:102171
	abnormal immune system organ morphology	J:102171
	abnormal inflammatory response	J:102171
	abnormal marginal zone B cell physiology	J:102171
	abnormal T cell morphology	J:102171
	decreased double-positive T cell number	J:102171
	decreased IgG1 level	J:102171
	decreased IgG2a level	J:102171
	decreased IgG level	J:102171
	decreased IgM level	J:102171
	decreased interferon-gamma secretion	J:102171
	decreased interleukin-2 secretion	J:102171
	decreased interleukin-4 secretion	J:102171
	decreased interleukin-10 secretion	J:102171
	decreased marginal zone B cell number	J:102171
	decreased Peyer's patch number	J:102171
	decreased T cell proliferation	J:102171
	decreased tumor necrosis factor secretion	J:102171
	increased length of allograft survival	J:102171
	lymphoid hypoplasia	J:102171
Satb1^m1Anu/Satb1⁺ (C57L/6JAnu-Satb1^m1Anu)	abnormal CD4-positive, alpha beta T cell morphology	J:104190
Satb1^m1Anu/Satb1⁺ (C57L/6JAnu-Satb1^m1Anu)	abnormal CD8-positive, alpha beta T cell morphology	J:104190
Satb1^m1Anu/Satb1^m1Anu (C57L/6JAnu-Satb1^m1Anu)	abnormal CD4-positive, alpha beta T cell morphology	J:104190
Satb1^m1Anu/Satb1^m1Anu (C57L/6JAnu-Satb1^m1Anu)	abnormal CD8-positive, alpha beta T cell morphology	J:104190
Satb1^tm1Kos/Satb1^tm1Kos (involves: 129P2/OlaHsd * C57BL/6)	abnormal T cell differentiation	J:61085
	abnormal T cell proliferation	J:61085
	arrested T cell differentiation	J:61085
	decreased thymocyte number	J:61085
	small lymph nodes	J:61085
	small spleen	J:61085
	small thymus	J:61085
Satb1^tm2Kos/Satb1^tm2Kos Commd10^{Tg(Vav1-icre)A2Kio}/Commd10⁺ (involves: C57BL/6 * C57BL/10 * CBA/Ca)	absent regulatory T cells	J:252606
	increased anti-nuclear antigen antibody level	J:252606
	increased autoantibody level	J:252606
	increased susceptibility to autoimmune disorder	J:252606
	kidney inflammation	J:252606
	pancreas inflammation	J:252606
	salivary gland inflammation	J:252606
Satb2^{tm1b(KOMP)Wtsi}/Satb2⁺ (C57BL/6N-Satb2^{tm1b(KOMP)Wtsi}/Ucd)	enlarged lymph nodes	J:211773
Saxo1^{tm1b(EUCOMM)Hmgu}/Saxo1^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Saxo1^{tm1b(EUCOMM)Hmgu}/Ics)	decreased lymphocyte cell number	J:211773
	increased eosinophil cell number	J:211773
Saysd1^em1(IMPC)J/Saysd1^em1(IMPC)J (C57BL/6NJ-Saysd1^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
Sbds^tm1Dats/Sbds^tm1Dats Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0 (involves: C57BL/6 * CD-1)	abnormal myeloid leukocyte morphology	J:158901
	abnormal neutrophil morphology	J:158901
	decreased B cell number	J:158901
	decreased leukocyte cell number	J:158901
	decreased lymphocyte cell number	J:158901
Sbf1^em1(IMPC)Mbp/Sbf1^em1(IMPC)Mbp (C57BL/6N-Sbf1^em1(IMPC)Mbp/MbpMmucd)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Sbk1^{tm1b(EUCOMM)Wtsi}/Sbk1⁺ (C57BL/6N-Sbk1^{tm1b(EUCOMM)Wtsi}/Bay)	decreased leukocyte cell number	J:211773
Sbno1^{tm1b(EUCOMM)Hmgu}/Sbno1⁺ (C57BL/6N-Sbno1^{tm1b(EUCOMM)Hmgu}/H)	increased leukocyte cell number	J:211773
Sbno2^tm1.1Aki/Sbno2^tm1.1Aki (involves: 129 * C57BL/6)	abnormal osteoclast morphology	J:202853
	abnormal osteoclast physiology	J:202853
	immune system phenotype	J:202853
Sbsn^em1Ham/Sbsn^em1Ham (C57BL/6N-Sbsn^em1Ham)	decreased interleukin-4 secretion	J:296400
	decreased susceptibility to type IV hypersensitivity reaction	J:296400
	immune system phenotype	J:296400
	increased susceptibility to type IV hypersensitivity reaction	J:296400
Sbw1^NZB/BlScr/Sbw1^NZB/BlScr (involves: NZB/BlScr * NZW/LacScr)	enlarged spleen	J:20991
Sbw2^NZB/BlScr/Sbw2^NZB/BlScr (involves: NZB * NZW)	enlarged spleen	J:20991
Sbw2^NZB/BlScr/Sbw2^NZW/LacScr (involves: NZB * NZW)	enlarged spleen	J:20991
Scai^{tm1b(EUCOMM)Hmgu}/Scai^{tm1b(EUCOMM)Hmgu} (involves: C57BL/6N * FVB/N)	immune system phenotype	J:240463
Scara5^tm1Ktry/Scara5^tm1Ktry (B6N.129X1-Scara5^tm1Ktry)	adipose tissue inflammation	J:195536
	increased anti-nuclear antigen antibody level	J:195536
	interstitial pneumonia	J:195536
	liver inflammation	J:195536
	lung inflammation	J:195536
	skin inflammation	J:195536
	urinary bladder inflammation	J:195536
Scarb1^tm1.1Thh/Scarb1^tm1.1Thh (B6.129X1-Scarb1^tm1.1Thh)	increased circulating interleukin-6 level	J:114663
Scarb1^{tm1b(EUCOMM)Wtsi}/Scarb1^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Scarb1^{tm1b(EUCOMM)Wtsi}/Bay)	enlarged spleen	J:211773
	increased spleen weight	J:211773
Scarb1^tm1Thh/Scarb1^tm1Thh Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺ (B6.Cg-Scarb1^tm1Thh Speer6-ps1^{Tg(Alb-cre)21Mgn})	increased circulating interleukin-6 level	J:114663
Scarb2^em2(IMPC)Tcp/Scarb2^em2(IMPC)Tcp (C57BL/6NCrl-Scarb2^em2(IMPC)Tcp/Tcp)	decreased monocyte cell number	J:211773
	enlarged lymph nodes	J:211773
	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Scarb2^tm1Psa/Scarb2^tm1Psa (involves: 129P2/OlaHsd * C57BL/6N)	microgliosis	J:216676
Scarf1^tm1Tkms/Scarf1^tm1Tkms (involves: C57BL/6)	abnormal B cell physiology	J:208237
	abnormal dendritic cell physiology	J:208237
	abnormal spleen morphology	J:208237
	enlarged spleen	J:208237
	glomerulonephritis	J:208237
	immune system phenotype	J:208237
	impaired macrophage phagocytosis	J:208237
	increased anti-histone antibody level	J:208237
	increased anti-nuclear antigen antibody level	J:208237
	increased anti-single stranded DNA antibody level	J:208237
	increased B cell number	J:208237
	increased CD4-positive, alpha-beta T cell number	J:208237
	increased IgG level	J:208237
	increased lymphocyte cell number	J:208237
	increased spleen germinal center size	J:208237
	increased susceptibility to systemic lupus erythematosus	J:208237
	increased T follicular helper cell number	J:208237
	skin inflammation	J:208237
Scd1^ab-2J/Scd1^ab-2J (DBA/1LacJ-Scd1^ab-2J/J)	granulomatous inflammation	J:62699
Scd1^flk/Scd1^flk (C57BL/6J-Scd1^flk)	increased susceptibility to bacterial infection	J:100424
Scd2^swty/Scd2^swty (C57BL/6JSfdAnu-Scd2^swty/Anu)	blepharitis	J:104190
Scel^{em1(IMPC)Ccpcz}/Scel^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Scel^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Scg5^em1(IMPC)Mbp/Scg5^em1(IMPC)Mbp (C57BL/6NCrl-Scg5^em1(IMPC)Mbp/MbpMmucd)	increased monocyte cell number	J:211773
Scg5^tm1Led/Scg5^tm1Led (either: 129S6/SvEvTac or (involves: 129S6/SvEvTac * FVB) or (involves: 129S6/SvEvTac * C57BL/6))	spleen atrophy	J:53349
Scgb1a1^tm1Abm/Scgb1a1⁺ (involves: 129S1/Sv * 129X1/SvJ)	abnormal complement protein level	J:57504
Scgb1a1^tm1Abm/Scgb1a1⁺ (involves: 129S1/Sv * 129X1/SvJ)	increased IgA level	J:57504
Scgb1a1^tm1Abm/Scgb1a1^tm1Abm (involves: 129S1/Sv * 129X1/SvJ)	abnormal complement protein level	J:57504
	increased IgA level	J:57504
Scgn^em1Ezb/Scgn^em1Ezb (C57BL/6-Scgn^em1Ezb)	increased susceptibility to colitis induced morbidity/mortality	J:285572
Scgn^em2Ezb/Scgn^em2Ezb (C57BL/6-Scgn^em2Ezb)	increased susceptibility to colitis induced morbidity/mortality	J:285572
Scin^tm1Glog/Scin^tm1Glog Tg(Acp5-cre)4Rda/0 (either: (involves: 129 * C57BL/6) or (involves: 129 * C57BL/6 * CBA))	abnormal osteoclast differentiation	J:223220
	abnormal osteoclast morphology	J:223220
	abnormal osteoclast physiology	J:223220
Scl2^C57BL/6J/Scl2^C57BL/6J (involves: C57BL/6J * DBA/2J)	increased susceptibility to parasitic infection	J:12046
Scmh1^tm1Yota/Scmh1^tm1Yota (involves: 129X1/SvJ * C57BL/6)	decreased B cell number	J:194424
	decreased T cell number	J:194424
	myeloid hyperplasia	J:194424
Scml4^em1(IMPC)J/Scml4^em1(IMPC)J (C57BL/6NJ-Scml4^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
Scn3b^{tm1a(KOMP)Wtsi}/Scn3b^{tm1a(KOMP)Wtsi} (C57BL/6N-Scn3b^{tm1a(KOMP)Wtsi}/Wtsi)	myositis	J:232539
Scn8a^em1(IMPC)Bay/Scn8a⁺ (C57BL/6N-Scn8a^em1(IMPC)Bay/BayMmucd)	increased spleen weight	J:211773
Scn9a^tm1Dgen/Scn9a^tm1Dgen (either: (involves: 129P2/OlaHsd * BALB/c * C57BL/6) or (involves: 129P2/OlaHsd * C57BL/6 * CD-1))	dermatitis	J:223425
Sco1^{tm1c(KOMP)Wtsi}/Sco1^{tm1c(KOMP)Wtsi} Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺ (involves: C57BL/6 * C57BL/6N * DBA)	decreased leukocyte cell number	J:222036
	decreased spleen white pulp amount	J:222036
	increased spleen iron level	J:222036
	spleen atrophy	J:222036
Scp2^tm1Kier/Scp2^tm1Kier (involves: 129P2/OlaHsd * C57BL/6NCr)	liver inflammation	J:124895
Scr/Scr (involves: 101/H * C3H/HeH)	small thymus	J:3458
Sctr^tm1Bkcc/Sctr^tm1Bkcc (B6.129S7-Sctr^tm1Bkcc)	abnormal cytokine secretion	J:121376
	increased macrophage cell number	J:121376
	kidney inflammation	J:121376
Scyl1^tm1.1Spel/Scyl1^tm1.1Spel (involves: 129S6/SvEvTac * C57BL/6J)	microgliosis	J:192445
Scyl1^tm1Spel/Scyl1^tm1Spel Tg(Nes-cre)1Kln/0 (involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * SJL)	microgliosis	J:192445
Scyl2^tm1.1Spel/Scyl2^tm1.1Spel Tg(Nes-cre)1Kln/0 (involves: 129S6/SvEvTac * C57BL/6 * SJL)	microgliosis	J:225808
Scyl3^tm1.1Spel/Scyl3^tm1.1Spel (involves: 129S6/SvEvTac * C57BL/6J)	immune system phenotype	J:262629
Sdc1^tm1Cma/Sdc1^tm1Cma (either: (involves: 129S4/SvJae * BALB/c) or (involves: 129S4/SvJae * C57BL/6))	decreased susceptibility to bacterial infection	J:69845
Sdc1^tm1Cma/Sdc1^tm1Cma (either: C.Cg-Sdc1^tm1Cma or B6.Cg-Sdc1^tm1Cma)	increased inflammatory response	J:80682
Sdc1^tm1Cma/Sdc1^tm1Cma (B6.Cg-Sdc1^tm1Cma)	decreased susceptibility to bacterial infection	J:104294
Sdc1^tm1Cma/Sdc1^tm1Cma (B6.Cg-Sdc1^tm1Cma)	decreased susceptibility to bacterial infection induced morbidity/mortality	J:104294
Sdc1^tm1Cma/Sdc1^tm1Cma (involves: 129S4/SvJae)	decreased IgG1 level	J:107378
	decreased interleukin-10 secretion	J:107378
	decreased interleukin-13 secretion	J:107378
	increased susceptibility to parasitic infection	J:107378
Sdc4^{tm2b(KOMP)Wtsi}/Sdc4^{tm2b(KOMP)Wtsi} (C57BL/6N-Sdc4^{tm2b(KOMP)Wtsi}/H)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Sdhb^{tm1b(EUCOMM)Hmgu}/Sdhb⁺ (C57BL/6N-Sdhb^{tm1b(EUCOMM)Hmgu}/Ieg)	decreased neutrophil cell number	J:211773
seb/seb (Him:OF1)	dermatitis	J:64455
	lymph node hyperplasia	J:20987
	lymph node inflammation	J:20987
	skin inflammation	J:8983
Sec1^em1Cya/Sec1^em1Cya (C57BL/6-Sec1^em1Cya)	decreased susceptibility to bacterial infection induced morbidity/mortality	J:325740
Sec22b^{tm1c(EUCOMM)Wtsi}/Sec22b^{tm1c(EUCOMM)Wtsi} Tg(Itgax-cre)1-1Reiz/0 (involves: C57BL/6 * C57BL/6N * CBA * SJL)	immune system phenotype	J:255769
Sec23b^{Gt(AD0407)Wtsi}/Sec23b^{Gt(AD0407)Wtsi} (B6J.129P2-Sec23b^{Gt(AD0407)Wtsi})	pancreas inflammation	J:186391
Sec24b^em1(IMPC)Tcp/Sec24b⁺ (C57BL/6NCrl-Sec24b^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Sec63^{tm1b(EUCOMM)Hmgu}/Sec63⁺ (C57BL/6N-Sec63^{tm1b(EUCOMM)Hmgu}/Bay)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Secia1^DBA/1J/? (involves: DBA/1J * FVB/NJ)	increased susceptibility to induced arthritis	J:123131
Secia2^DBA/1J/? (involves: DBA/1J * FVB/NJ)	increased susceptibility to induced arthritis	J:123131
Secia3^FVB/NJ/? (involves: DBA/1J * FVB/NJ)	increased susceptibility to induced arthritis	J:123131
Secia4^DBA/1J/? (involves: DBA/1J * FVB/NJ)	increased susceptibility to induced arthritis	J:123131
Secia5^DBA/1J/? (involves: DBA/1J * FVB/NJ)	increased susceptibility to induced arthritis	J:123131
Secia6^DBA/1J/? (involves: DBA/1J * FVB/NJ)	increased susceptibility to induced arthritis	J:123131
Secia7^FVB/NJ/? (involves: DBA/1J * FVB/NJ)	increased susceptibility to induced arthritis	J:123131
Secia8^FVB/NJ/? (involves: DBA/1J * FVB/NJ)	increased susceptibility to induced arthritis	J:123131
Secisbp2^{tm1a(EUCOMM)Wtsi}/Secisbp2⁺ (Not Specified)	increased NK cell number	J:165965
Secisbp2^{tm1c(EUCOMM)Wtsi}/Secisbp2^{tm1c(EUCOMM)Wtsi} (C57BL/6N-Secisbp2^{tm1a(EUCOMM)Wtsi}/H)	increased leukocyte cell number	J:211773
Sectm1a^em1Gcfa/Sectm1a^em1Gcfa (C57BL/6-Sectm1a^em1Gcfa)	abnormal interleukin level	J:317204
	abnormal macrophage physiology	J:317204
	abnormal tumor necrosis factor level	J:317204
	heart inflammation	J:317204
	increased circulating interleukin-1 beta level	J:317204
	increased circulating interleukin-6 level	J:317204
	increased circulating tumor necrosis factor level	J:317204
	increased susceptibility to endotoxin shock	J:317204
Sele^tm1Alb/Sele^tm1Alb (involves: 129S7/SvEvBrd * C57BL/6J)	abnormal spleen morphology	J:101979
	eye inflammation	J:101979
	increased susceptibility to bacterial infection	J:101979
Sele^tm1Alb/Sele^tm1Alb (involves: 129S7/SvEvBrd * C57BL/6)	increased neutrophil cell number	J:112286
Sele^tm1Dmil/Sele^tm1Dmil (involves: 129S4/SvJae * C57BL/6J)	abnormal leukocyte adhesion	J:113169
Sele^tm1Hyn/Sele^tm1Hyn Sell^tm1Hyn/Sell^tm1Hyn Selp^tm1Hyn/Selp^tm1Hyn (involves: 129S2/SvPas * C57BL/6)	impaired eosinophil recruitment	J:57973
	impaired leukocyte tethering or rolling	J:57973
	impaired neutrophil recruitment	J:57973
	increased eosinophil cell number	J:57973
	increased leukocyte cell number	J:57973
	increased monocyte cell number	J:57973
	increased neutrophil cell number	J:57973
Sele^tm1Hyn/Sele^tm1Hyn Selp^tm1Hyn/Selp^tm1Hyn (involves: 129S2/SvPas)	abnormal cytokine level	J:31626
	abnormal granulocyte differentiation	J:31626
	abnormal myelopoiesis	J:31626
	impaired leukocyte tethering or rolling	J:31626
	impaired neutrophil recruitment	J:31626
	increased circulating interleukin-3 level	J:31626
	increased eosinophil cell number	J:31626
	increased leukocyte cell number	J:31626
	increased lymphocyte cell number	J:31626
	increased monocyte cell number	J:31626
	increased neutrophil cell number	J:31626
	increased spleen red pulp amount	J:31626
	increased spleen weight	J:31626
	increased susceptibility to bacterial infection	J:31626
	spleen hyperplasia	J:31626
Sele^tm1Hyn/Sele^tm1Hyn Selp^tm1Hyn/Selp^tm1Hyn (involves: 129S2/SvPas * C57BL/6)	impaired eosinophil recruitment	J:57973
	impaired leukocyte tethering or rolling	J:57973
	impaired neutrophil recruitment	J:57973
	increased eosinophil cell number	J:57973
	increased leukocyte cell number	J:57973
	increased monocyte cell number	J:57973
	increased neutrophil cell number	J:57973
Sele^tm1Roml/Sele^tm1Roml (involves: 129S1/Sv * C57BL/6)	abnormal T cell physiology	J:113536
Sele^tm1Roml/Sele^tm1Roml (involves: 129S1/Sv)	abnormal T cell physiology	J:113536
Sele^tm2Alb/Sele^tm2Alb Sell^tm2Alb/Sell^tm2Alb Selp^tm1Bay/Selp^tm1Bay (involves: 129S7/SvEvBrd * C57BL/6)	abnormal cellular extravasation	J:70682
	abnormal cervical lymph node morphology	J:70682
	abnormal spleen B cell follicle morphology	J:70682
	abnormal spleen B cell follicle shape	J:106550
	abnormal spleen morphology	J:70682
	decreased spleen B cell follicle number	J:106550
	enlarged lymph nodes	J:70682
	immune system phenotype	J:70682
	impaired leukocyte tethering or rolling	J:70682
	increased eosinophil cell number	J:70682
	increased leukocyte cell number	J:70682
	increased monocyte cell number	J:70682
	increased neutrophil cell number	J:106550, J:70682
	lung inflammation	J:70682
Sele^tm2Alb/Sele^tm2Alb Selp^tm1Bay/Selp^tm1Bay (involves: 129S7/SvEvBrd * C57BL/6J)	abnormal leukocyte cell number	J:101979
	eye inflammation	J:101979
	increased neutrophil cell number	J:101979
	increased susceptibility to bacterial infection	J:101979
Sele^tm2Alb/Sele^tm2Alb Selp^tm1Bay/Selp^tm1Bay (involves: 129S7/SvEvBrd * C57BL/6)	abnormal cytokine secretion	J:70682
	abnormal lymph node germinal center morphology	J:70682
	abnormal lymph node secondary follicle morphology	J:70682
	abnormal neutrophil physiology	J:112286
	abnormal spleen B cell follicle morphology	J:70682
	decreased acute inflammation	J:112286
	decreased spleen B cell follicle number	J:70682
	enlarged lymph nodes	J:70682
	impaired leukocyte tethering or rolling	J:70682
	increased eosinophil cell number	J:70682
	increased leukocyte cell number	J:70682
	increased monocyte cell number	J:70682
	increased neutrophil cell number	J:70682, J:112286
Sele^tm2Hyn/Sele^tm2Hyn (involves: 129S2/SvPas * C57BL/6)	enhanced leukocyte tethering or rolling	J:57973
Sele^tm2Hyn/Sele^tm2Hyn (involves: 129S2/SvPas * C57BL/6)	impaired neutrophil recruitment	J:57973
Sele^tm2Hyn/Sele^tm2Hyn (B6.129S2-Sele^tm2Hyn)	abnormal type IV hypersensitivity reaction	J:121083
	decreased mast cell number	J:121083
	increased mast cell number	J:121083
Selenbp1^tm1Hyama/Selenbp1^tm1Hyama (C57BL/6-Selenbp1^tm1Hyama)	decreased spleen weight	J:202420
	increased thymus weight	J:202420
Selenok^tm1.2Itl/Selenok^tm1.2Itl (involves: BALB/cJ * C57BL/6)	abnormal circulating chemokine level	J:169169
	abnormal macrophage physiology	J:169169
	abnormal neutrophil physiology	J:169169
	abnormal T cell physiology	J:169169
	decreased interleukin-6 secretion	J:169169
	decreased T cell proliferation	J:169169
	decreased tumor necrosis factor secretion	J:169169
	impaired neutrophil chemotaxis	J:169169
	increased susceptibility to Flaviviridae infection	J:169169
	increased susceptibility to Flaviviridae infection induced morbidity/mortality	J:169169
Selenop^tm1Rfb/Selenop^tm1Rfb (B6.129-Selenop^tm1Rfb)	increased susceptibility to parasitic infection	J:134536
Selenow^em#Hwl/Selenow^em#Hwl (C57BL/6-Selenow^em#Hwl)	abnormal osteoclast differentiation	J:317012
Selenow^em#Hwl/Selenow^em#Hwl (C57BL/6-Selenow^em#Hwl)	decreased osteoclast cell number	J:317012
Sell^m1Btlr/Sell^m1Btlr (C57BL/6J-Sell^m1Btlr)	decreased single-positive T cell number	J:217794
Sell^m2Btlr/Sell^m2Btlr (C57BL/6J-Sell^m2Btlr)	decreased response to antigen	J:231806
Sell^m2Btlr/Sell^m2Btlr (C57BL/6J-Sell^m2Btlr)	decreased single-positive T cell number	J:231806
Sell^tm1.1Rpmc/Sell^tm1.1Rpmc (involves: 129S1/Sv * C57BL/6J * FVB/N)	abnormal granulocyte physiology	J:249558
	abnormal neutrophil physiology	J:249558
	immune system phenotype	J:249558
	increased inflammatory response	J:249558
Sell^tm1Alb/Sell^tm1Alb (involves: 129S7/SvEvBrd * C57BL/6)	intermingled spleen red and white pulp	J:70682
Sell^{tm1b(EUCOMM)Hmgu}/Sell^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Sell^{tm1b(EUCOMM)Hmgu}/H)	increased spleen weight	J:211773
Sell^tm1Flv/Sell⁺ (involves: C57BL/6 * NOD)	decreased susceptibility to autoimmune diabetes	J:88947
Sell^tm1Flv/Sell⁺ (involves: C57BL/6 * NOD)	pancreas inflammation	J:88947
Sell^tm1Flv/Sell⁺ (NOD.Cg-Sell^tm1Flv)	immune system phenotype	J:88974
Sell^tm1Flv/Sell^tm1Flv (involves: 129S2/SvPas * C57BL/6)	abnormal type IV hypersensitivity reaction	J:89253
Sell^tm1Flv/Sell^tm1Flv (involves: 129S2/SvPas * C57BL/6)	decreased activated T cell number	J:89253
Sell^tm1Flv/Sell^tm1Flv (involves: C57BL/6 * NOD)	decreased susceptibility to autoimmune disorder	J:88947
Sell^tm1Flv/Sell^tm1Flv (involves: C57BL/6 * NOD)	pancreas inflammation	J:88947
Sell^tm1Flv/Sell^tm1Flv (NOD.Cg-Sell^tm1Flv)	immune system phenotype	J:88974
Sell^tm1Pest/Sell⁺ (involves: 129S4/SvJae * C57BL/6)	abnormal hypersensitivity reaction	J:112550
Sell^tm1Pest/Sell⁺ (involves: 129S4/SvJae * C57BL/6)	impaired leukocyte tethering or rolling	J:112550
Sell^tm1Pest/Sell^tm1Pest (involves: 129S4/SvJae)	abnormal hypersensitivity reaction	J:111233
	abnormal leukocyte adhesion	J:111233
	impaired leukocyte tethering or rolling	J:111233
	increased T cell proliferation	J:111233
Sell^tm1Pest/Sell^tm1Pest (involves: 129S4/SvJae * C57BL/6)	abnormal cell-mediated immunity	J:112550
	abnormal dendritic cell physiology	J:112550
	abnormal hypersensitivity reaction	J:112550
	abnormal leukocyte migration	J:112550
	abnormal splenic cell ratio	J:112550
	decreased T cell proliferation	J:112550
	enlarged spleen	J:112550
	immune system phenotype	J:112550
	impaired leukocyte tethering or rolling	J:112550
	lymph node hypoplasia	J:112550
	small popliteal lymph nodes	J:112550
Sell^tm1Tft/Sell^tm1Tft (involves: 129P2/OlaHsd * C57BL/6)	abnormal cellular extravasation	J:25005
	abnormal leukocyte migration	J:25005
	enlarged spleen	J:25005
	impaired leukocyte tethering or rolling	J:25005
Sell^tm1Tft/Sell^tm1Tft (B6.129-Sell^tm1Tft)	abnormal cellular extravasation	J:66107
Sell^tm1Tft/Sell^tm1Tft (B6.129-Sell^tm1Tft)	abnormal leukocyte migration	J:66107
Sell^tm1Tft/Sell^tm1Tft (B6.129P2-Sell^tm1Tft)	abnormal cellular extravasation	J:48271
	abnormal regulatory T cell number	J:141931
	abnormal regulatory T cell physiology	J:141931
	impaired leukocyte tethering or rolling	J:48271
	increased monocyte cell number	J:48271, J:142184
	lymph node hypoplasia	J:141931, J:142184
	spleen hyperplasia	J:141931
Sell^tm2.1Tft/Sell^tm2.1Tft (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal neutrophil physiology	J:142184
	spleen hyperplasia	J:142184
Sell^tm2Hyn/Sell^tm2Hyn (involves: 129S2/SvPas * C57BL/6)	decreased monocyte cell number	J:57973
	immune system phenotype	J:106550
	impaired leukocyte tethering or rolling	J:57973
	impaired neutrophil recruitment	J:57973
Sell^tm2Hyn/Sell^tm2Hyn (involves: 129S2/SvPas * BALB/c)	impaired leukocyte tethering or rolling	J:114317
Sell^tm2Tft/Sell^tm2.1Tft (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal leukocyte migration	J:142184
	abnormal neutrophil physiology	J:142184
	abnormal regulatory T cell number	J:141931
	abnormal regulatory T cell physiology	J:141931
	impaired leukocyte tethering or rolling	J:142184
Sell^tm2Tft/Sell^tm2Tft (involves: 129S1/Sv * 129X1/SvJ)	lymph node hypoplasia	J:142184
Sell^tm2Tft/Sell^tm2Tft (involves: 129S1/Sv * 129X1/SvJ)	spleen hyperplasia	J:142184
Sell^tm3Hyn/Sell^tm3Hyn Selp^tm1Hyn/Selp^tm1Hyn (involves: 129S2/SvPas * C57BL/6)	impaired eosinophil recruitment	J:57973
	impaired leukocyte tethering or rolling	J:57973
	impaired neutrophil recruitment	J:57973
	increased eosinophil cell number	J:57973
	increased leukocyte cell number	J:57973
	increased neutrophil cell number	J:57973
Sell^tm4Hyn/Sell^tm4Hyn Selp^tm1Hyn/Selp^tm1Hyn (involves: 129S2/SvPas * C57BL/6)	impaired leukocyte tethering or rolling	J:57973
	impaired neutrophil recruitment	J:57973
	increased eosinophil cell number	J:57973
Selp^tm1.1Rpmc/Selp^tm1.1Rpmc (B6.129S1-Selp^tm1.1Rpmc)	impaired leukocyte tethering or rolling	J:230041
Selp^tm1Bay/Selp^tm1Bay (involves: 129S7/SvEvBrd * C57BL/6J)	abnormal leukocyte migration	J:24239
	abnormal spleen morphology	J:101979
	eye inflammation	J:101979
	increased leukocyte cell number	J:101979
	increased neutrophil cell number	J:101979, J:24239
	increased susceptibility to bacterial infection	J:101979
Selp^tm1Bay/Selp^tm1Bay (D1.129S7(B6J)-Selp^tm1Bay)	abnormal cytokine secretion	J:57086
	increased IgG level	J:57086
	increased susceptibility to induced arthritis	J:57086
Selp^tm1Bay/Selp^tm1Bay (B6.129S7-Selp^tm1Bay/J)	abnormal T cell physiology	J:113536
Selp^tm1Bay/Selp^tm1Bay (either: B6.129S7-Selp^tm1Bay or (involves: 129S7/SvEvBrd * C57BL/6))	abnormal leukocyte tethering or rolling	J:31374
	increased leukocyte cell number	J:31374
Selp^tm1Bay/Selp^tm1Bay (involves: 129S7/SvEvBrd * C57BL/6)	increased neutrophil cell number	J:112286
Selp^tm1Bay/Selp^tm1Bay (B6.129S7-Selp^tm1Bay)	decreased mast cell number	J:121083
Selp^tm1Bay/Selp^tm1Bay (B6.129S7-Selp^tm1Bay)	decreased susceptibility to type IV hypersensitivity reaction	J:121083
Selp^tm1Hyn/Selp^tm1Hyn (involves: 129S2/SvPas * C57BL/6J)	impaired leukocyte tethering or rolling	J:77329
	impaired neutrophil recruitment	J:77329
	increased neutrophil cell number	J:77329
Selp^tm1Hyn/Selp^tm1Hyn (involves: 129S2/SvPas)	impaired leukocyte tethering or rolling	J:29814
	impaired macrophage chemotaxis	J:29814
	increased neutrophil cell number	J:29814
Selp^tm1Hyn/Selp^tm1Hyn (involves: 129S2/SvPas * C57BL/6)	impaired eosinophil recruitment	J:57973
	impaired leukocyte tethering or rolling	J:57973
	impaired neutrophil recruitment	J:57973
	increased eosinophil cell number	J:57973
	increased neutrophil cell number	J:57973
Selp^tm2Hyn/Selp^tm2Hyn (involves: 129S2/SvPas * C57BL/6J)	impaired leukocyte tethering or rolling	J:51068
Selp^tm2Hyn/Selp^tm2Hyn (involves: 129S2/SvPas * C57BL/6J)	impaired neutrophil recruitment	J:51068
Selplg^tm1Fur/Selplg^tm1Fur (involves: 129/Sv * C57BL/6J * SJL)	impaired leukocyte tethering or rolling	J:75412
	impaired neutrophil chemotaxis	J:75412
	increased eosinophil cell number	J:75412
	increased neutrophil cell number	J:75412
Selplg^tm1Rpmc/Selplg^tm1Rpmc (involves: 129S1/Sv * C57BL/6J)	abnormal leukocyte adhesion	J:75829
	impaired leukocyte tethering or rolling	J:75829, J:138731
	increased eosinophil cell number	J:75829
	increased leukocyte cell number	J:75829
	increased lymphocyte cell number	J:75829
	increased neutrophil cell number	J:75829
Selplg^tm1Rpmc/Selplg^tm1Rpmc (involves: 129S1/Sv)	abnormal chemokine secretion	J:115682
Selplg^tm1Rpmc/Selplg^tm1Rpmc (involves: 129S1/Sv)	immune system phenotype	J:115682
Selplg^tm2Rpmc/Selplg^tm2Rpmc (B6.Cg-Selplg^tm2Rpmc)	impaired leukocyte tethering or rolling	J:138731
Sema3a^tm1.1Tyag/Sema3a^tm1.1Tyag (involves: C57BL/6 * CBA)	abnormal dendritic cell physiology	J:161856
Sema3a^tm1.1Tyag/Sema3a^tm1.1Tyag (involves: C57BL/6 * CBA)	abnormal T cell physiology	J:161856
Sema3f^tm1.2Ddg/Sema3f^tm1.2Ddg (Not Specified)	abnormal lymphatic system physiology	J:226501
	abnormal lymphatic vessel endothelial cell morphology	J:226501
	abnormal lymphatic vessel morphology	J:226501
Sema3f^tm1.2Ddg/Sema3f^tm1.2Ddg Sema3g^{tm1(KOMP)Vlcg}/Sema3g^{tm1(KOMP)Vlcg} (involves: C57BL/6NTac)	abnormal lymphatic vessel endothelial cell morphology	J:226501
	abnormal lymphatic vessel morphology	J:226501
	lymphatic vessel hyperplasia	J:226501
Sema3g^{tm1(KOMP)Vlcg}/Sema3g^{tm1(KOMP)Vlcg} (involves: C57BL/6NTac)	abnormal lymphatic vessel morphology	J:226501
Sema4a^tm1Kik/Sema4a^tm1Kik (either: B6.Cg-Sema4a^tm1Kik or C.Cg-Sema4a^tm1Kik)	abnormal CD4-positive, alpha-beta T cell physiology	J:97027
	abnormal cytokine secretion	J:97027
	abnormal dendritic cell antigen presentation	J:97027
	abnormal T-helper 1 cell differentiation	J:97027
	decreased susceptibility to type IV hypersensitivity reaction	J:97027
Sema4b^tm1Akum/Sema4b^tm1Akum (either: B6.Cg-Sema4b^tm1Akum or C.Cg-Sema4b^tm1Akum)	abnormal immune system physiology	J:169386
	increased IgE level	J:169386
	increased IgG1 level	J:169386
Sema4d^{tm1b(EUCOMM)Wtsi}/Sema4d^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Sema4d^{tm1b(EUCOMM)Wtsi}/H)	enlarged spleen	J:211773
Sema4d^tm1Kik/Sema4d^tm1Kik (involves: 129P2/OlaHsd * C57BL/6)	abnormal B-1 B cell morphology	J:66033
	abnormal immunoglobulin level	J:66033
	decreased B cell proliferation	J:66033
	decreased B-1a cell number	J:66033
	decreased CD4-positive, alpha-beta T cell number	J:66033
	decreased spleen germinal center size	J:66033
	decreased T cell number	J:66033
	increased B cell number	J:66033
Sema4f^em1(IMPC)J/Sema4f^em1(IMPC)J (C57BL/6NJ-Sema4f^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
Sema5b^{tm1a(EUCOMM)Wtsi}/Sema5b^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Sema5b^{tm1a(EUCOMM)Wtsi}/Cnrm)	decreased T cell number	J:165965
Sema6c^tm1Matl/Sema6c^tm1Matl (Not Specified)	immune system phenotype	J:161856
Sema6d^tm1Kik/Sema6d^tm1Kik (Not Specified)	immune system phenotype	J:161856
Senp1^tm1.1Wami/Senp1^tm1.1Wami (involves: 129 * C57BL/6)	abnormal granulocyte differentiation	J:163428
Senp1^tm1.1Wami/Senp1^tm1.1Wami (involves: 129 * C57BL/6)	abnormal monocyte differentiation	J:163428
Senp1^tm1Wami/Senp1^tm1Wami Tg(Fabp4-cre)#Abel/0 (B6.Cg-Senp1^tm1Wami Tg(Fabp4-cre)#Abel)	abnormal chemokine level	J:228009
	abnormal circulating cytokine level	J:228009
	abnormal cytokine level	J:228009
	increased anti-insulin autoantibody level	J:228009
	increased circulating C-reactive protein level	J:228009
	increased circulating interleukin-1 beta level	J:228009
	increased circulating interleukin-6 level	J:228009
	increased circulating tumor necrosis factor level	J:228009
	increased susceptibility to autoimmune diabetes	J:228009
	myocarditis	J:228009
	pancreas inflammation	J:228009
Septin2^em1(IMPC)Tcp/Septin2⁺ (C57BL/6NCrl-Septin2^em1(IMPC)Tcp/Tcp)	increased monocyte cell number	J:211773
Septin5^{tm1b(EUCOMM)Hmgu}/Septin5⁺ (C57BL/6N-Septin5^{tm1b(EUCOMM)Hmgu}/Rbrc)	small spleen	J:211773
Septin7^tm1Mgl/Septin7^tm1Mgl Tg(CD2-icre)4Kio/0 (involves: 129P2/OlaHsd * C3H * C57BL/6 * C57BL/10 * CBA/Ca)	immune system phenotype	J:223786
Septin9^tm2.1Emfu/Septin9^tm2.1Emfu Tg(Lck-cre)548Jxm/0 (involves: C57BL/6 * CBA)	abnormal T cell differentiation	J:205027
	decreased CD4-positive, alpha-beta memory T cell number	J:205027
	decreased CD4-positive, alpha-beta T cell number	J:205027
	decreased CD8-positive, alpha-beta memory T cell number	J:205027
	decreased CD8-positive, alpha-beta T cell number	J:205027
	decreased DN4 thymocyte number	J:205027
	decreased regulatory T cell number	J:205027
	decreased single-positive T cell number	J:205027
	decreased T cell number	J:205027
	decreased T cell proliferation	J:205027
	increased CD8-positive, alpha-beta memory T cell number	J:205027
	increased DN3 thymocyte number	J:205027
	increased double-negative T cell number	J:205027
Septin9^tm2.1Emfu/Septin9^tm2.1Emfu Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA)	decreased CD8-positive, alpha-beta T cell number	J:205027
Serac1^em1(IMPC)Tcp/Serac1^em1(IMPC)Tcp (C57BL/6NCrl-Serac1^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Serf1^{tm1a(EUCOMM)Hmgu}/Serf1^{tm1a(EUCOMM)Hmgu} (C57BL/6N-Serf1^{tm1a(EUCOMM)Hmgu}/H)	decreased CD8-positive, alpha-beta T cell number	J:165965
	decreased T cell number	J:165965
Serinc5^em1Spst/Serinc5^em1Spst (C57BL/6-Serinc5^em1Spst)	immune system phenotype	J:291232
Serpina1^em#Chmu/Serpina1^em#Chmu (involves: C57BL/6J)	increased susceptibility to endotoxin shock	J:259615
Serpina1^em#Chmu/Serpina1^em#Chmu (involves: C57BL/6J)	respiratory system inflammation	J:259615
Serpina3c^em1Smoc/Serpina3c^em1Smoc (C57BL/6-Serpina3c^em1Smoc)	white adipose tissue inflammation	J:343846
Serpina3g^tm1.1Arp/Serpina3g^tm1.1Arp (involves: C57BL/6)	abnormal memory T cell morphology	J:189782
	abnormal response to infection	J:189782
	decreased CD8-positive, alpha-beta memory T cell number	J:189782
	decreased T cell proliferation	J:189782
Serpina3g^tm1.1Arp/Serpina3g^tm1.1Arp Tg(TcrLCMV)#Sdz/0 (involves: C57BL/6 * DBA/2)	decreased T cell proliferation	J:189782
Serpina3i^em1(IMPC)J/Serpina3i^em1(IMPC)J (C57BL/6NJ-Serpina3i^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
Serpina6^tm1Tew/Serpina6^tm1Tew (involves: 129/SvEmcTer * C57BL/6N)	abnormal circulating cytokine level	J:112974
	abnormal cytokine level	J:112974
	increased susceptibility to endotoxin shock	J:112974
Serpinb1a^tm1.1Cben/Serpinb1a^tm1.1Cben (129S6/SvEvTac-Serpinb1a^tm1.1Cben)	abnormal chemokine secretion	J:125918
	abnormal circulating cytokine level	J:125918
	abnormal neutrophil physiology	J:125918
	decreased neutrophil cell number	J:125918
	impaired neutrophil chemotaxis	J:125918
	increased interleukin-1 beta secretion	J:125918
	increased susceptibility to bacterial infection	J:125918
	increased susceptibility to bacterial infection induced morbidity/mortality	J:125918
	increased tumor necrosis factor secretion	J:125918
	lung inflammation	J:125918
	sepsis	J:125918
Serpinb2^tm1Dgi/Serpinb2^tm1Dgi (involves: 129S2/SvPas * C57BL/6J * DBA/2J)	abnormal leukocyte cell number	J:52283
	decreased lymphocyte cell number	J:52283
	decreased monocyte cell number	J:52283
	decreased neutrophil cell number	J:52283
	immune system phenotype	J:52283
Serpinb2^tm2Dgi/Serpinb2^tm2Dgi (involves: 129S2/SvPas * C57BL/6J * DBA/2J)	abnormal leukocyte cell number	J:52283
	decreased lymphocyte cell number	J:52283
	decreased monocyte cell number	J:52283
	decreased neutrophil cell number	J:52283
	immune system phenotype	J:52283
Serpinb3a^tm1Gsil/Serpinb3a^tm1Gsil (C.129-Serpinb3a^tm1Gsil)	decreased susceptibility to type I hypersensitivity reaction	J:189949
Serpinb9^{em1(IMPC)Ccpcz}/Serpinb9^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Serpinb9^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	decreased effector memory T-helper cell number	J:211773
Serpinb9^tm1.1Pib/Serpinb9^tm1.1Pib (involves: BALB/cJ * C57BL/6J)	abnormal dendritic cell antigen presentation	J:252016
	abnormal immune system morphology	J:252016
	abnormal immune system physiology	J:252016
	decreased cytotoxic T cell apoptosis	J:252016
	immune system phenotype	J:252016
Serpinb9^tm1Arp/Serpinb9^tm1Arp (involves: C57BL/6)	abnormal CD8-positive, alpha-beta cytotoxic T cell morphology	J:113349
	abnormal cytotoxic T cell physiology	J:113349
	decreased cytotoxic T cell cytolysis	J:113349
	increased susceptibility to Riboviria infection	J:113349
Serpinb9^tm1Arp/Serpinb9^tm1Arp Tg(TcrLCMV)327Sdz/0 (involves: C57BL/6)	abnormal response to transplant	J:113349
Serpinb10^em1(IMPC)Mbp/Serpinb10^em1(IMPC)Mbp (C57BL/6NCrl-Serpinb10^em1(IMPC)Mbp/Mmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	increased spleen weight	J:211773
Serpinc1^tm1Dwr/Serpinc1^tm1Dwr (involves: 129S1/Sv * 129X1/SvJ)	enlarged spleen	J:115658
	liver inflammation	J:115658
Serpine1^em1(IMPC)Tcp/Serpine1^em1(IMPC)Tcp (C57BL/6N-Serpine1^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Serpine1^tm1.1Vlp/Serpine1^tm1.1Vlp (involves: 129 * C57BL/6)	decreased susceptibility to endotoxin shock	J:229191
Serpine1^tm1Mlg/Serpine1^tm1Mlg (involves: 129S2/SvPas * C57BL/6)	abnormal acute inflammation	J:133227
	abnormal interleukin level	J:133227
	decreased circulating interleukin-6 level	J:133227
	glomerulonephritis	J:85989
	immune system phenotype	J:133227
	increased acute inflammation	J:133227
	increased granulocyte number	J:133227
	respiratory system inflammation	J:66093
Serpine1^tm1Mlg/Serpine1^tm1Mlg (B6.129S2-Serpine1^tm1Mlg/J)	heart inflammation	J:101486
	increased susceptibility to bacterial infection	J:124327
	increased susceptibility to Coronaviridae infection	J:288556
	increased susceptibility to Coronaviridae infection induced morbidity/mortality	J:288556
Serpine1^tm1Mlg/Serpine1^tm1Mlg (involves: 129S2/SvPas)	decreased susceptibility to endotoxin shock	J:229191
Serpine2^tm1Dmn/Serpine2^tm1Dmn (B6.129P2-Serpine2^tm1Dmn)	abnormal acute phase protein level	J:121263
Serpinf1^{tm1e.1(KOMP)Wtsi}/Serpinf1^{tm1e.1(KOMP)Wtsi} (C57BL/6N-Serpinf1^{tm1e.1(KOMP)Wtsi}/Bay)	abnormal spleen morphology	J:211773
Serpini2^pq/Serpini2^pq (involves: C57BL/6J)	abnormal B cell differentiation	J:115744
	abnormal pre-B cell morphology	J:115744
	abnormal pro-B cell morphology	J:115744
	decreased B cell number	J:115744
	decreased immature B cell number	J:115744
	decreased lymphocyte cell number	J:115744
	decreased pre-B cell number	J:115744
	decreased pro-B cell number	J:115744
	decreased T cell number	J:115744
	decreased thymocyte number	J:115744
	small spleen	J:115744
	small thymus	J:115744
	spleen hypoplasia	J:115744
	thymus hypoplasia	J:115744
Sertad2^{Gt(OST98734)Lex}/Sertad2^{Gt(OST98734)Lex} (B6.129S5-Sertad2^{Gt(OST98734)Lex})	abnormal macrophage physiology	J:194928
Sertad3^em1Bcgen/Sertad3^em1Bcgen (involves: C57BL/6N)	increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:300469
Ses1a^C57BL/6J/Ses1a^C57BL/6J (involves: 129 * C57BL/6J)	decreased susceptibility to bacterial infection	J:81412
Ses1a^C57BL/6J/Ses1a^C57BL/6J (involves: 129S6/SvEvTac * C57BL/6J)	decreased susceptibility to bacterial infection	J:100367
Ses1a^C57BL/6J/Ses1a^C57BL/6J (129.B6-Ses1a^C57BL/6J)	decreased susceptibility to bacterial infection	J:100367
Ses1a^C57BL/6J/Ses1a^C57BL/6J Ses4^C57BL/6J/Ses4^C57BL/6J (involves: 129S6/SvEvTac * C57BL/6J)	decreased susceptibility to bacterial infection	J:100367
Ses1a^C57BL/6J/Ses1a^C57BL/6J Ses5^C57BL/6J/Ses5^C57BL/6J (involves: 129S6/SvEvTac * C57BL/6J)	decreased susceptibility to bacterial infection	J:100367
Ses1a^C57BL/6J/Ses1a^C57BL/6J Ses6^C57BL/6J/Ses6^C57BL/6J (involves: 129S6/SvEvTac * C57BL/6J)	decreased susceptibility to bacterial infection	J:100367
Ses1b^C57BL/6J/Ses1b^C57BL/6J (involves: 129S6/SvEvTac * C57BL/6J)	decreased susceptibility to bacterial infection	J:100367
Ses1b^C57BL/6J/Ses1b^C57BL/6J (129.B6-Ses1b^C57BL/6J)	decreased susceptibility to bacterial infection	J:100367
Ses2^C57BL/6J/Ses2^C57BL/6J (involves: 129 * C57BL/6J)	decreased susceptibility to bacterial infection	J:81412
Ses3^C57BL/6J/Ses3^C57BL/6J (involves: 129 * C57BL/6J)	decreased susceptibility to bacterial infection	J:81412
Ses7^{129S6/SvEvTac}/Ses7^C57BL/6J Ses8^C57BL/6J/Ses8^C57BL/6J (involves: 129S6/SvEvTac * C57BL/6J)	decreased susceptibility to bacterial infection	J:100367
Ses7^C57BL/6J/Ses7^C57BL/6J Ses8^C57BL/6J/Ses8^C57BL/6J (involves: 129S6/SvEvTac * C57BL/6J)	decreased susceptibility to bacterial infection	J:100367
Ses9^C57BL/6J/Ses9^C57BL/6J Ses10^C57BL/6J/Ses10^C57BL/6J (involves: 129S6/SvEvTac * C57BL/6J)	decreased susceptibility to bacterial infection	J:100367
Sesn1^{tm1a(EUCOMM)Wtsi}/Sesn1^{tm1a(EUCOMM)Wtsi} (involves: C57BL/6N)	abnormal class switch recombination	J:240602
	abnormal effector T cell number	J:240602
	decreased B cell number	J:240602
	enlarged spleen	J:240602
	increased immunoglobulin level	J:240602
	increased interferon-gamma secretion	J:240602
	increased interleukin-2 secretion	J:240602
	increased NK T cell number	J:240602
	increased single-positive T cell number	J:240602
	increased splenocyte number	J:240602
	increased T cell proliferation	J:240602
Setd1a^{tm1a(EUCOMM)Wtsi}/Setd1a⁺ (C57BL/6N-Setd1a^{tm1a(EUCOMM)Wtsi}/Wtsi)	decreased leukocyte cell number	J:175295
Setd2^{tm1c(NCOM)Mfgc}/Setd2^{tm1c(NCOM)Mfgc} Tg(Lck-cre)#Zhu/0 (involves: C57BL/6 * SJL/J)	increased gamma-delta T cell number	J:243973
Setd3^{tm1.1(NCOM)Mfgc}/Setd3^{tm1.1(NCOM)Mfgc} (C57BL/6N-Setd3^{tm1.1(NCOM)Mfgc}/Tcp)	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
Setd3^{tm1.1(NCOM)Mfgc}/Setd3^{tm1.1(NCOM)Mfgc} (involves: C57BL/6NCrl)	decreased susceptibility to Riboviria infection	J:293475
Setd4^{tm1b(KOMP)Wtsi}/Setd4^{tm1b(KOMP)Wtsi} (involves: C57BL/6N)	decreased macrophage cytokine production	J:304151
Setd5^{tm1a(EUCOMM)Wtsi}/Setd5⁺ (C57BL/6N-Setd5^{tm1a(EUCOMM)Wtsi}/Wtsi)	abnormal thymus morphology	J:239583
	blood in lymph vessels	J:239583
	enlarged lymphatic vessel	J:239583
	increased monocyte cell number	J:211773
	increased regulatory T cell number	J:211773
	small thymus	J:239583
Setd7^tm1Frga/Setd7⁺ (involves: 129 * C57BL/6)	abnormal spleen physiology	J:136558
Setd7^tm1Frga/Setd7^tm1Frga (involves: 129 * C57BL/6)	abnormal spleen physiology	J:136558
Setdb2^tm1Desr/Setdb2^tm1Desr (B6.Cg-Setdb2^tm1Desr)	abnormal response to infection	J:222611
	increased neutrophil cell number	J:222611
	increased susceptibility to bacterial infection	J:222611
Setx^{tm1b(EUCOMM)Wtsi}/Setx^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Setx^{tm1b(EUCOMM)Wtsi}/Ics)	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
	increased eosinophil cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
	increased NK cell number	J:211773
sevr/sevr (C3H/HeJ-sevr/GrsrJ)	thymus atrophy	J:109437
Sf3b1^tm1.1Mdf/Sf3b1⁺ Tet2^tm1.1Iaai/Tet2^tm1.1Iaai Tg(Mx1-cre)1Cgn/? (involves: 129S/SvEv * 129S4/SvJae * C57BL/6 * CBA/J)	abnormal myelopoiesis	J:234976
	decreased B cell number	J:234976
	enlarged spleen	J:234976
	increased granulocyte number	J:234976
Sf3b1^tm1.1Mdf/Sf3b1⁺ Tg(Mx1-cre)1Cgn/? (involves: 129S4/SvJae * C57BL/6 * CBA/J)	abnormal myelopoiesis	J:234976
Sf3b1^tm1Hko/Sf3b1⁺ (Not Specified)	increased spleen red pulp amount	J:324276
Sfmbt2^em1(IMPC)Mbp/Sfmbt2⁺ (C57BL/6NCrl-Sfmbt2^em1(IMPC)Mbp/Mmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
Sfn^tm1Mak/Sfn^tm1Mak (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell differentiation	J:168328
	abnormal spleen B cell follicle morphology	J:168328
	abnormal spleen morphology	J:168328
	absent spleen marginal zone	J:168328
	decreased B cell number	J:168328
	decreased B-1a cell number	J:168328
	decreased follicular B cell number	J:168328
	decreased IgG level	J:168328
	decreased IgM level	J:168328
	decreased marginal zone B cell number	J:168328
	immune system phenotype	J:168328
	increased B cell apoptosis	J:168328
	increased B cell proliferation	J:168328
	increased susceptibility to Riboviria infection	J:168328
	increased susceptibility to Riboviria infection induced morbidity/mortality	J:168328
Sfrp1^tm1Bsk/Sfrp1^tm1Bsk (involves: 129S5/SvEvBrd * C57BL/6)	decreased leukocyte cell number	J:89547
	decreased lymphocyte cell number	J:89547
	decreased neutrophil cell number	J:89547
Sfrp4^tm1.1Blan/Sfrp4^tm1.1Blan (Not Specified)	increased osteoclast cell number	J:234467
Sfrp4^tm1.1Lex/Sfrp4^tm1.1Lex (Not Specified)	increased osteoclast cell number	J:234467
Sftpa1^tm1Haw/Sftpa1^tm1Haw (involves: 129/Sv * C57BL/6 * CD-1)	abnormal cytokine level	J:86024
	abnormal inflammatory response	J:85432
	abnormal interferon level	J:86024
	abnormal interleukin level	J:86024
	increased susceptibility to Orthomyxoviridae infection	J:86024
Sftpa1^tm1Kor/Sftpa1^tm1Kor (involves: 129P2/OlaHsd * NIH Black Swiss)	immune system phenotype	J:35250
	increased susceptibility to bacterial infection	J:120552, J:110382
	lung inflammation	J:110382
Sftpa1^tm1Kor/Sftpa1^tm1Kor (involves: 129P2/OlaHsd)	immune system phenotype	J:130958
Sftpa1^tm1Kor/Sftpa1^tm1Kor (involves: 129P2/OlaHsd)	lung inflammation	J:107841
Sftpa1^tm1Kor/Sftpa1^tm1Kor (involves: 129P2/OlaHsd * Black Swiss * C3H/HeN)	increased susceptibility to bacterial infection	J:130297
Sftpa1^tm2Haw/Sftpa1^tm2Haw Sftpd^tm2Haw/Sftpd^tm2Haw (involves: C57BL/6J * CD-1)	abnormal alveolar macrophage morphology	J:86022
	increased monocyte cell number	J:86022
Sftpc^tm1Swg/Sftpc^tm1Swg (either: 129 or (involves: 129 * Black Swiss))	conjunctivitis	J:82925
Sftpd^tm1Haw/Sftpd^tm1Haw (involves: C57BL/6J * CD-1)	abnormal alveolar macrophage morphology	J:98220, J:50147
Sftpd^tm1Haw/Sftpd^tm1Haw (involves: C57BL/6J * CD-1)	abnormal macrophage physiology	J:98220
Sftpd^tm1Jhf/Sftpd^tm1Jhf (involves: 129P2/OlaHsd * Black Swiss)	abnormal alveolar macrophage morphology	J:50436
	abnormal chemokine level	J:72681
	abnormal cytokine level	J:72681, J:62282
	abnormal macrophage morphology	J:62282, J:50436
	abnormal macrophage physiology	J:62282
	abnormal neutrophil physiology	J:72681
	increased macrophage cell number	J:62282, J:50436
	increased neutrophil cell number	J:72681
	increased susceptibility to Orthomyxoviridae infection	J:72681
	lung inflammation	J:62282, J:50436
Sfxn4^{tm1b(KOMP)Wtsi}/Sfxn4^{tm1b(KOMP)Wtsi} (C57BL/6N-Sfxn4^{tm1b(KOMP)Wtsi}/J)	decreased leukocyte cell number	J:211773
Sgca^tm1Kcam/Sgca^tm1Kcam (involves: 129S1/Sv * 129X1/SvJ)	heart inflammation	J:177563
Sgca^tm1Kcam/Sgca^tm1Kcam Sgce^tm1Vinni/Sgce^tm1Vinni (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6J)	heart inflammation	J:177563
Sgcb^tm1Oza/Sgcb^tm1Oza (involves: 129S4/SvJae * C57BL/6J)	myositis	J:57590
Sgce^em1(IMPC)H/Sgce^em1(IMPC)H (C57BL/6N-Sgce^em1(IMPC)H/H)	increased eosinophil cell number	J:211773
Sgk3^fz-ica/Sgk3^fz-ica (Swiss albino)	abnormal inflammatory response	J:107373
sgl/sgl (involves: C3H * C57BL/6J)	abnormal lymph node morphology	J:56826
sgl/sgl (involves: C3H * C57BL/6J)	conjunctivitis	J:56826
Sgms1^tm1Jia/Sgms1^tm1Jia (involves: C57BL/6)	abnormal cytokine level	J:201497
	abnormal cytokine secretion	J:201497
	decreased circulating interleukin-6 level	J:201497
	decreased circulating tumor necrosis factor level	J:201497
	decreased interleukin-6 secretion	J:201497
	decreased tumor necrosis factor secretion	J:201497
Sgms2^tm1Jia/Sgms2^tm1Jia (involves: 129 * C57BL/6)	abnormal macrophage morphology	J:162226
Sgms2^tm1Jia/Sgms2^tm1Jia (involves: 129 * C57BL/6)	abnormal macrophage physiology	J:162192, J:162226
Sgp5^NZB/? (involves: C57BL/6 * NZB * SB/Le)	abnormal immune serum protein physiology	J:95829
	glomerulonephritis	J:95829
	increased susceptibility to type III hypersensitivity reaction	J:95829
Sgp5^NZB/Sgp5^NZB (C57BL/6-Nba2 Yaa)	abnormal immune serum protein physiology	J:95829
Sgpl1^{Gt(OST58278)Lex}/Sgpl1^{Gt(OST58278)Lex} (involves: 129S5/SvEvBrd * C57BL/6J)	abnormal lymph node morphology	J:145159
	abnormal lymphopoiesis	J:145159
	abnormal osteoclast morphology	J:145159
	abnormal spleen periarteriolar lymphoid sheath morphology	J:145159
	decreased B cell number	J:145159
	decreased double-positive T cell number	J:145159
	decreased lymphocyte cell number	J:145159
	decreased neutrophil cell number	J:145159
	decreased pre-B cell number	J:145159
	decreased T cell number	J:145159
	increased CD4-positive, alpha-beta T cell number	J:145159
	increased CD8-positive, alpha-beta T cell number	J:145159
	increased granulocyte number	J:145159
	increased monocyte cell number	J:145159
	increased osteoclast cell number	J:145159
	lymph node hypoplasia	J:145159
	lymphoid hypoplasia	J:145159
	spleen hypoplasia	J:145159
	thymus cortex hypoplasia	J:145159
	thymus hypoplasia	J:145159
	thymus medulla hyperplasia	J:145159
Sgpl1^{Gt(OST58278)Lex}/Sgpl1^{tm1(SGPL1)Lex} (involves: 129S5/SvEvBrd * C57BL/6J)	abnormal immune system organ morphology	J:145159
	abnormal osteoclast morphology	J:145159
	decreased T cell number	J:145159
	thymus cortex hypoplasia	J:145159
	thymus medulla hyperplasia	J:145159
Sgpl1^{Gt(ROSA)78Sor}/Sgpl1^{Gt(ROSA)78Sor} (involves: 129S4/SvJaeSor)	kidney inflammation	J:117491
Sgpl1^{Gt(ROSA)78Sor}/Sgpl1^{Gt(ROSA)78Sor} (involves: 129S4/SvJaeSor * C57BL/6)	abnormal immune system physiology	J:187619
	abnormal leukocyte migration	J:187619
	abnormal T cell physiology	J:187619
	decreased lymphocyte cell number	J:187619
Sgpl1^{tm1(SGPL1)Lex}/Sgpl1^{tm1(SGPL1)Lex} (involves: 129S4/SvJae * 129S5/SvEvBrd * C57BL/6J)	abnormal immune system organ morphology	J:145159
	abnormal lymph node morphology	J:145159
	abnormal thymus lobule morphology	J:145159
	decreased B cell number	J:145159
	decreased CD4-positive, alpha-beta T cell number	J:145159
	decreased CD8-positive, alpha-beta T cell number	J:145159
	decreased lymphocyte cell number	J:145159
	decreased T cell number	J:145159
	increased single-positive T cell number	J:145159
Sgpl1^tm1.2Npa/Sgpl1^tm1.2Npa (involves: BALB/cJ * C57BL/6)	spleen hypoplasia	J:199525
Sgsh^mps3a/Sgsh^mps3a (involves: 129X1/SvJ * CD-1 * C57BL/6 * SJL)	enlarged spleen	J:72142
Sgsm1^{tm1b(EUCOMM)Wtsi}/Sgsm1^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Sgsm1^{tm1b(EUCOMM)Wtsi}/Wtsi)	decreased CD4-positive, alpha-beta T cell number	J:211773
	increased CD8-positive, alpha-beta T cell number	J:211773
Sh2b1^tm1Ayos/Sh2b1^tm1Ayos (involves: C57BL/6)	immune system phenotype	J:78931
Sh2b2^tm1Yeb/Sh2b2^tm1Yeb (involves: C57BL/6)	abnormal B cell differentiation	J:88527
	increased B-1 B cell number	J:88527
	increased IgG3 level	J:88527
Sh2b3^tm1Paw/Sh2b3^tm1Paw (either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6))	abnormal granulocyte differentiation	J:77248
	abnormal leukocyte cell number	J:77248
	abnormal monocyte differentiation	J:77248
	enlarged lymph nodes	J:77248
	enlarged spleen	J:77248
	increased B cell number	J:77248
	spleen fibrosis	J:77248
Sh2b3^tm1Paw/Sh2b3^tm1Paw (B6.129-Sh2b3^tm1Paw)	spleen hyperplasia	J:107464
Sh2b3^tm1Paw/Sh2b3^tm1Paw (involves: 129S1/Sv * 129X1/SvJ)	decreased B cell number	J:161643
	enlarged spleen	J:161643
	increased granulocyte number	J:161643
	increased leukocyte cell number	J:161643
	increased lymphocyte cell number	J:161643
	increased monocyte cell number	J:161643
	increased neutrophil cell number	J:161643
	myeloid hyperplasia	J:161643
Sh2d1a^tm1.1Knic/Y Gt(ROSA)26Sor^tm1(EYFP)Cos/Gt(ROSA)26Sor⁺ Ndor1^{Tg(UBC-cre/ERT2)1Ejb}/0 (involves: 129S/SvEv * 129X1/SvJ * C57BL/6)	abnormal NK T cell physiology	J:196692
	decreased circulating interleukin-4 level	J:196692
	decreased interferon-gamma secretion	J:196692
	immune system phenotype	J:196692
Sh2d1a^tm1.1Knic/Sh2d1a^tm1.1Knic Gt(ROSA)26Sor^tm1(EYFP)Cos/Gt(ROSA)26Sor⁺ Ndor1^{Tg(UBC-cre/ERT2)1Ejb}/0 (involves: 129S/SvEv * 129X1/SvJ * C57BL/6)	abnormal NK T cell physiology	J:196692
	decreased circulating interleukin-4 level	J:196692
	decreased interferon-gamma secretion	J:196692
	immune system phenotype	J:196692
Sh2d1a^tm1Cpt/Y (involves: 129S4/SvJae * C57BL/6)	abnormal cytokine secretion	J:97756
	abnormal germinal center B cell physiology	J:189126
	abnormal humoral immune response	J:189126
	abnormal immunoglobulin level	J:189126
	abnormal NK T cell physiology	J:189126
	decreased NK T cell number	J:189126
	increased susceptibility to Riboviria infection	J:97756
	increased T cell proliferation	J:97756
Sh2d1a^tm1Cpt/Y (involves: 129S4/SvJae * BALB/c)	abnormal cytokine secretion	J:97756
	abnormal germinal center B cell morphology	J:189126
	decreased germinal center B cell number	J:189126
	decreased IgE level	J:97756
	decreased IgG level	J:189126
	decreased NK T cell number	J:189126
	decreased susceptibility to parasitic infection	J:97756
	immune system phenotype	J:189126
Sh2d1a^tm1Cpt/Y Tcra-J^tm1Tgi/Tcra-J^tm1Tgi (involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * BALB/c)	decreased germinal center B cell number	J:189126
	decreased IgG level	J:189126
Sh2d1a^tm1Cpt/Sh2d1a⁺ (involves: 129S4/SvJae * C57BL/6)	abnormal cytokine secretion	J:97756
Sh2d1a^tm1Cpt/Sh2d1a⁺ (involves: 129S4/SvJae * C57BL/6)	increased T cell proliferation	J:97756
Sh2d1a^tm1Cpt/Sh2d1a^tm1Cpt (B6.129S4-Sh2d1a^tm1Cpt)	abnormal humoral immune response	J:97388
	absent NK T cells	J:97690
	decreased IgG1 level	J:97388
	decreased IgM level	J:97388
	decreased NK T cell number	J:97690
	decreased transitional stage B cell number	J:97690
	increased B cell number	J:97388
	increased IgG2a level	J:97388
Sh2d1a^tm1Cpt/Sh2d1a^tm1Cpt (C.129S4-Sh2d1a^tm1Cpt)	decreased IgG level	J:97388
	decreased IgM level	J:97388
	decreased spleen germinal center number	J:97388
Sh2d1a^tm1Cpt/Sh2d1a^tm1Cpt (involves: 129S4/SvJae * C57BL/6)	abnormal cytokine secretion	J:97756
	abnormal germinal center B cell physiology	J:189126
	abnormal humoral immune response	J:189126
	abnormal immunoglobulin level	J:189126
	abnormal NK T cell physiology	J:189126
	decreased NK T cell number	J:189126
	increased susceptibility to Riboviria infection	J:97756
	increased T cell proliferation	J:97756
Sh2d1a^tm1Cpt/Sh2d1a^tm1Cpt (involves: 129S4/SvJae * BALB/c)	abnormal cytokine secretion	J:97756
	abnormal germinal center B cell morphology	J:189126
	decreased germinal center B cell number	J:189126
	decreased IgE level	J:97756
	decreased IgG level	J:189126
	decreased NK T cell number	J:189126
	decreased susceptibility to parasitic infection	J:97756
	immune system phenotype	J:189126
Sh2d1a^tm1Cpt/Sh2d1a^tm1Cpt (involves: 129S4/SvJae)	impaired natural killer cell mediated cytotoxicity	J:166054
Sh2d1a^tm1Cpt/Sh2d1a^tm1Cpt Sh2d1b1/Sh2d1b2^tm1.1Cpt/Sh2d1b1/Sh2d1b2^tm1.1Cpt (involves: 129S4/SvJae * BALB/cJ)	impaired natural killer cell mediated cytotoxicity	J:166054
Sh2d1a^tm1Cpt/Sh2d1a^tm1Cpt Sh2d1b1/Sh2d1b2^tm1.1Cpt/Sh2d1b1/Sh2d1b2^tm1.1Cpt (involves: 129S4/SvJae * BALB/cJ)	impaired natural killer cell mediated cytotoxicity	J:166054
Sh2d1a^tm1Cpt/Sh2d1a^tm1Cpt Tcra-J^tm1Tgi/Tcra-J^tm1Tgi (involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * BALB/c)	decreased germinal center B cell number	J:189126
	decreased IgG level	J:189126
Sh2d1a^tm1Lyin/Y (involves: 129S2/SvPas * C57BL/6)	abnormal immune system physiology	J:97346
	chronic inflammation	J:97346
	decreased IgE level	J:97346
	decreased IgG level	J:97346
	decreased immunoglobulin level	J:97346
	increased CD8-positive, alpha-beta T cell number	J:97346
Sh2d1a^tm1Lyin/Sh2d1a^tm1Lyin (involves: 129S2/SvPas * C57BL/6)	abnormal immune system physiology	J:97346
	chronic inflammation	J:97346
	decreased IgE level	J:97346
	decreased IgG level	J:97346
	decreased immunoglobulin level	J:97346
	increased CD8-positive, alpha-beta T cell number	J:97346
Sh2d1a^tm1Lyin/Sh2d1a^tm1Lyin (involves: 129S1/Sv * 129X1/SvJ)	impaired natural killer cell mediated cytotoxicity	J:110195
Sh2d1a^tm1Pls/Y (involves: 129S6/SvEvTac)	abnormal CD4-positive, alpha-beta T cell physiology	J:157915
	abnormal cytotoxic T cell physiology	J:187431
	abnormal long lived plasma cell morphology	J:157915
	abnormal NK T cell morphology	J:196692
	decreased CD4-positive, alpha-beta T cell number	J:157915
	decreased IgG level	J:157915
	decreased interleukin-21 secretion	J:157915
Sh2d1a^tm1Pls/Sh2d1a^tm1Pls (either: 129S6/SvEvTac or (involves: 129S6/SvEvTac * C57BL/6))	abnormal lymphocyte cell number	J:70032
	abnormal T-helper 1 cell morphology	J:70032
	abnormal T-helper 2 cell morphology	J:70032
	decreased IgE level	J:70032
	increased susceptibility to infection	J:70032
	increased susceptibility to parasitic infection	J:70032
	increased susceptibility to Riboviria infection	J:70032
	increased T cell proliferation	J:70032
Sh2d1a^tm1Pls/Sh2d1a^tm1Pls (involves: BALB/c)	decreased susceptibility to parasitic infection	J:90484
Sh2d1a^tm1Pls/Sh2d1a^tm1Pls (involves: 129S6/SvEvTac * C57BL/6)	immune system phenotype	J:92740
Sh2d1a^tm1Pls/Sh2d1a^tm1Pls (B6.129S6-Sh2d1a^tm1Pls)	abnormal CD4-positive, alpha-beta T cell physiology	J:93886
	abnormal NK cell physiology	J:187430
	decreased IgE level	J:93886
	decreased interferon-gamma secretion	J:187430
Sh2d1a^tm1Pls/Sh2d1a^tm1Pls (involves: 129S6/SvEvTac)	abnormal CD4-positive, alpha-beta T cell physiology	J:157915
	abnormal cytotoxic T cell physiology	J:187431
	abnormal long lived plasma cell morphology	J:157915
	abnormal NK T cell morphology	J:196692
	decreased CD4-positive, alpha-beta T cell number	J:157915
	decreased IgG level	J:157915
	decreased interleukin-21 secretion	J:157915
Sh2d1a^tm1Pls/Sh2d1a^tm1Pls Sh2d1b1^tm3Vei/Sh2d1b1^tm3Vei (involves: 129S6/SvEvTac * C57BL/6)	abnormal NK cell physiology	J:187430
Sh2d1a^tm1Pls/Sh2d1a^tm1Pls Slamf6^tm1Lex/Slamf6^tm1Lex (B6.129S-Slamf6^tm1Lex Sh2d1a^tm1Pls)	immune system phenotype	J:187429
Sh2d1a^tm1Pls/Sh2d1a^tm1Pls Slamf6^tm1Pls/Slamf6^tm1Pls Tg(TcraTcrb)1100Mjb/0 (involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J)	immune system phenotype	J:187431
Sh2d1a^tm1Pls/Sh2d1a^tm1Pls Tg(DO11.10)10Dlo/Tg(DO11.10)10Dlo (involves: BALB/c * C3H * C57BL/6)	abnormal cytokine secretion	J:90484
Sh2d1a^tm1Pls/Sh2d1a^tm1Pls Tg(TcraTcrb)425Cbn/? (involves: 129S6/SvEvTac * C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:157915
Sh2d1a^tm1Pls/Sh2d1a^tm1Pls Tg(TcraTcrb)1100Mjb/0 (involves: 129S6/SvEvTac * C57BL/6)	abnormal cytotoxic T cell physiology	J:187431
	decreased cytotoxic T cell cytolysis	J:187431
	decreased interferon-gamma secretion	J:187431
Sh2d1a^tm1Vei/Sh2d1a^tm1Vei (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:93886
	abnormal memory T cell physiology	J:93886
	decreased IgE level	J:93886
Sh2d1a^tm1Vei/Sh2d1a^tm1Vei (B6.129-Sh2d1a^tm1Vei)	abnormal NK cell physiology	J:187430
Sh2d1a^tm1Vei/Sh2d1a^tm1Vei (B6.129-Sh2d1a^tm1Vei)	decreased interferon-gamma secretion	J:187430
Sh2d1a^tm1Vei/Sh2d1a^tm1Vei Sh2d1b1^tm3Vei/Sh2d1b1^tm3Vei (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal NK cell physiology	J:187430
Sh2d1a^tm2.1Cpt/Y Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte}/Gt(ROSA)26Sor⁺ (involves: C57BL/6 * C57BL/6NTac)	abnormal germinal center B cell physiology	J:189126
	abnormal humoral immune response	J:189126
	decreased IgG level	J:189126
	decreased IgM level	J:189126
	immune system phenotype	J:189126
Sh2d1a^tm2.1Cpt/Sh2d1a^tm2.1Cpt Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte}/Gt(ROSA)26Sor⁺ (involves: C57BL/6 * C57BL/6NTac)	abnormal germinal center B cell physiology	J:189126
	abnormal humoral immune response	J:189126
	decreased IgG level	J:189126
	decreased IgM level	J:189126
	immune system phenotype	J:189126
Sh2d1a^tm2.1Vei/Sh2d1a^tm2.1Vei (involves: C57BL/6)	decreased germinal center B cell number	J:131618
	decreased IgE level	J:131618
	decreased IgG1 level	J:131618
	decreased IgG2a level	J:131618
	decreased IgG2b level	J:131618
	decreased IgG3 level	J:131618
	decreased IgM level	J:131618
	decreased NK T cell number	J:131618
Sh2d1a^tm2Vei/Sh2d1a^tm2Vei Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:131618
Sh2d1a^tm2Vei/Sh2d1a^tm2Vei Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	decreased germinal center B cell number	J:131618
	decreased IgE level	J:131618
	decreased IgG1 level	J:131618
	decreased IgG2a level	J:131618
	decreased IgG2b level	J:131618
	decreased IgG3 level	J:131618
	decreased IgM level	J:131618
	decreased NK T cell number	J:131618
Sh2d1a^tm2Vei/Sh2d1a^tm2Vei Tg(Lck-cre)1Cwi/0 (involves: C57BL/6)	decreased germinal center B cell number	J:131618
	decreased IgE level	J:131618
	decreased IgG1 level	J:131618
	decreased IgG2a level	J:131618
	decreased IgG2b level	J:131618
	decreased IgG3 level	J:131618
	decreased IgM level	J:131618
	decreased NK T cell number	J:131618
Sh2d1b1/Sh2d1b2^tm1.1Cpt/Sh2d1b1/Sh2d1b2^tm1.1Cpt (involves: BALB/cJ)	decreased interferon-gamma secretion	J:166054
	impaired natural killer cell mediated cytotoxicity	J:166054
Sh2d1b1/Sh2d1b2^tm1.1Cpt/Sh2d1b1/Sh2d1b2^tm1.1Cpt (involves: BALB/cJ)	decreased interferon-gamma secretion	J:166054
	impaired natural killer cell mediated cytotoxicity	J:166054
Sh2d1b1^tm1.1Cpt/Sh2d1b1^tm1.1Cpt (involves: BALB/cJ * C57BL/6)	impaired natural killer cell mediated cytotoxicity	J:166054
Sh2d1b1^tm1Vei/Sh2d1b1^tm1Vei (involves: 129S1/Sv * 129X1/SvJ)	increased interferon-gamma secretion	J:110195
	increased natural killer cell mediated cytotoxicity	J:110195
Sh2d1b1^tm2Vei/Sh2d1b1^tm2Vei Sh2d1b2^tm1Vei/Sh2d1b2^tm1Vei (involves: 129S1/Sv * 129X1/SvJ)	impaired natural killer cell mediated cytotoxicity	J:145969
Sh2d1b1^tm3Vei/Sh2d1b1^tm3Vei (involves: C57BL/6)	abnormal NK cell physiology	J:187430
Sh2d1b2^tm1.1Cpt/Sh2d1b2^tm1.1Cpt (involves: BALB/cJ * C57BL/6)	impaired natural killer cell mediated cytotoxicity	J:166054
Sh2d1b2^tm1Vei/Sh2d1b2^tm1Vei (involves: 129S1/Sv * 129X1/SvJ)	impaired natural killer cell mediated cytotoxicity	J:145969
	increased natural killer cell mediated cytotoxicity	J:110195
Sh2d2a^tm1Jbs/Sh2d2a^tm1Jbs (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	decreased interferon-gamma secretion	J:64938
	decreased interleukin-2 secretion	J:64938
	decreased T cell proliferation	J:64938
	immune system phenotype	J:64938
	increased interleukin-4 secretion	J:64938
Sh2d3c^tm1Lex/Sh2d3c^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6)	abnormal B cell physiology	J:161448
	abnormal humoral immune response	J:161448
	abnormal leukocyte migration	J:161448
	abnormal marginal zone B cell physiology	J:161448
	decreased IgG1 level	J:161448
	decreased IgG2b level	J:161448
	decreased IgG3 level	J:161448
	decreased IgM level	J:161448
	decreased interleukin-6 secretion	J:161448
	decreased marginal zone B cell number	J:161448
Sh3bp2^tm1.1Ics/Sh3bp2⁺ (involves: 129S2/SvPas * C57BL/6)	abnormal circulating cytokine level	J:221901
	abnormal macrophage physiology	J:221901
	increased susceptibility to bacterial infection	J:221901
	increased tumor necrosis factor secretion	J:221901
Sh3bp2^tm1.1Ics/Sh3bp2^tm1.1Ics (involves: 129S2/SvPas * C57BL/6)	abnormal circulating cytokine level	J:221901
	enlarged lymph nodes	J:221901
	increased circulating interleukin-6 level	J:221901
	increased circulating interleukin-12 level	J:221901
	increased circulating tumor necrosis factor level	J:221901
	increased inflammatory response	J:221901
	increased monocyte cell number	J:221901
	increased tumor necrosis factor secretion	J:221901
Sh3bp2^tm1Bjro/Sh3bp2⁺ (involves: 129S4/SvJae * BALB/cJ * C57BL/6J)	abnormal osteoclast differentiation	J:117880
	abnormal osteoclast physiology	J:117880
	immune system phenotype	J:117880
	increased osteoclast cell number	J:117880
Sh3bp2^tm1Bjro/Sh3bp2^tm1Bjro (involves: 129S4/SvJae * BALB/cJ * C57BL/6J)	abnormal B cell number	J:117880
	abnormal immune system organ morphology	J:117880
	abnormal macrophage physiology	J:117880
	abnormal osteoclast differentiation	J:117880
	abnormal osteoclast physiology	J:117880
	blepharitis	J:117880
	dermatitis	J:117880
	enlarged lymph nodes	J:117880
	increased circulating tumor necrosis factor level	J:117880
	increased inflammatory response	J:117880
	increased osteoclast cell number	J:117880
	increased spleen red pulp amount	J:117880
	joint inflammation	J:117880
	liver inflammation	J:117880
	lung inflammation	J:117880
	myositis	J:117880
	osteomyelitis	J:117880
	spinal cord inflammation	J:117880
	stomach inflammation	J:117880
Sh3bp2^tm1Bjro/Sh3bp2^tm1Bjro Tnf^tm1Gkl/Tnf^tm1Gkl (involves: 129S/SvEv * 129S4/SvJae * BALB/cJ * C57BL/6J)	abnormal osteoclast differentiation	J:117880
	immune system phenotype	J:117880
Sh3bp2^tm1Geha/Sh3bp2^tm1Geha (Not Specified)	abnormal B cell number	J:110319
	abnormal B cell physiology	J:110319
	decreased B cell proliferation	J:110319
	immune system phenotype	J:110319
	increased pre-B cell number	J:110319
Sh3bp2^tm1Rtpl/Sh3bp2^tm1Rtpl (B6.129P2-Sh3bp2^tm1Rtpl)	abnormal B cell number	J:121380
	abnormal marginal zone B cell physiology	J:121380
	abnormal spleen marginal zone morphology	J:121380
	decreased B cell proliferation	J:121380
	decreased B-1 B cell number	J:121380
	decreased IgA level	J:121380
	decreased IgG1 level	J:121380
	decreased IgG3 level	J:121380
	decreased IgM level	J:121380
	decreased immunoglobulin level	J:121380
	decreased pro-B cell number	J:121380
	decreased transitional stage B cell number	J:121380
	increased B cell apoptosis	J:121380
	increased marginal zone B cell number	J:121380
Sh3bp2^tm1Rtpl/Sh3bp2^tm1Rtpl (involves: 129P2/OlaHsd * C57BL/6)	abnormal circulating cytokine level	J:221901
	abnormal interleukin-6 secretion	J:221901
	abnormal macrophage physiology	J:221901
	decreased tumor necrosis factor secretion	J:221901
	impaired macrophage phagocytosis	J:221901
Sh3glb2^{Gt(OST224737)Lex}/Sh3glb2^{Gt(OST224737)Lex} (B6.129S5-Sh3glb2^{Gt(OST224737)Lex})	abnormal response to infection	J:246421
Sh3kbp1^tm1Kuro/Sh3kbp1^tm1Kuro Cd79a^tm1(cre)Reth/Cd79a⁺ (involves: BALB/c * C57BL/6 * NZB)	abnormal B cell physiology	J:176805
	abnormal humoral immune response	J:176805
	abnormal lymphocyte cell number	J:176805
	decreased B cell number	J:176805
	decreased B-1a cell number	J:176805
	decreased follicular B cell number	J:176805
	decreased immature B cell number	J:176805
	decreased transitional stage T2 B cell number	J:176805
	decreased transitional stage T3 B cell number	J:176805
	immune system phenotype	J:176805
Sh3kbp1^tm1Kuro/Sh3kbp1^tm1Kuro Cd79a^tm1(cre)Reth/Cd79a⁺ Gt(ROSA)26Sor^{tm4(Ikbkb)Rsky}/? (involves: BALB/c * C57BL/6 * NZB)	decreased B-1a cell number	J:176805
	immune system phenotype	J:176805
Sh3pxd2a^{tm1b(EUCOMM)Wtsi}/Sh3pxd2a^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Sh3pxd2a^{tm1b(EUCOMM)Wtsi}/Wtsi)	abnormal lymphatic vessel morphology	J:239583
	abnormal thymus topology	J:239583
	absent connection between subcutaneous lymph vessels and lymph sac	J:239583
	blood in lymph vessels	J:239583
Sh3pxd2b^nee/Sh3pxd2b^nee (B10.Cg-H2^h4 Sh3pxd2b^nee/GrsrJ)	eye inflammation	J:262132
	hypopyon	J:262132
	increased susceptibility to otitis media	J:153369
Sh3tc1^{tm1b(EUCOMM)Hmgu}/Sh3tc1^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Sh3tc1^{tm1b(EUCOMM)Hmgu}/Orl)	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Sh3yl1^em1(IMPC)Mbp/Sh3yl1^em1(IMPC)Mbp (C57BL/6NCrl-Sh3yl1^em1(IMPC)Mbp/MbpMmucd)	increased monocyte cell number	J:211773
Sh3yl1^tm1Syb/Sh3yl1^tm1Syb (involves: C57BL/6N)	decreased interleukin-1 beta secretion	J:298830
	decreased susceptibility to endotoxin shock	J:298830
	decreased tumor necrosis factor secretion	J:298830
Sharpin^cpdm-Dem/Sharpin^cpdm-Dem (CBy.OcB3-Sharpin^cpdm-Dem)	abnormal immune system organ morphology	J:121810
	dermatitis	J:121810
	skin inflammation	J:121810
Sharpin^cpdm/Sharpin^cpdm (C57BL/KaLawRij-Sharpin^cpdm)	abnormal humoral immune response	J:53575
	abnormal immune system organ morphology	J:14539
	abnormal lymph node morphology	J:14539
	abnormal mesenteric lymph node morphology	J:53575
	abnormal peripheral lymph node morphology	J:53575
	abnormal spleen morphology	J:53575
	abnormal spleen white pulp morphology	J:31745, J:53575
	absent Peyer's patches	J:53575
	absent spleen B cell follicles	J:53575
	absent spleen germinal center	J:53575
	absent spleen marginal zone	J:53575
	cutaneous mastocytosis	J:31745, J:14539
	decreased B cell number	J:53575
	decreased CD4-positive, alpha-beta T cell number	J:53575
	decreased IgA level	J:53575
	decreased IgE level	J:31745, J:53575
	decreased IgG level	J:53575
	decreased immunoglobulin level	J:53575
	decreased T cell number	J:53575
	dermatitis	J:14539
	enlarged spleen	J:14539, J:53575
	esophageal inflammation	J:31745
	folliculitis	J:31745
	increased eosinophil cell number	J:31745, J:14539
	increased IgM level	J:53575
	joint inflammation	J:14539
	large lymphoid organs	J:31745
	lung inflammation	J:31745
	lymph node inflammation	J:31745
	stomach inflammation	J:31745
Sharpin^cpdm/Sharpin^cpdm (involves: C57BL/KaLawRij * FVB/NJ)	absent Peyer's patches	J:121810
	absent spleen B cell follicles	J:121810
	absent spleen germinal center	J:121810
	skin inflammation	J:121810
Shc1^tm1Ravi/Shc1^tm1Ravi Tg(Lck-cre)1Cwi/? (involves: 129 * C57BL/6)	abnormal double-negative T cell morphology	J:78180
	decreased double-positive T cell number	J:78180
	decreased single-positive T cell number	J:78180
	thymus hypoplasia	J:78180
Shcbp1^{tm1c(EUCOMM)Wtsi}/Shcbp1^{tm1c(EUCOMM)Wtsi} Tg(Lck-cre)1Cwi/? (involves: C57BL/6 * DBA/2)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:212898
	immune system phenotype	J:212898
Shcbp1^{tm1d(EUCOMM)Wtsi}/Shcbp1^{tm1d(EUCOMM)Wtsi} (involves: C57BL/6N * FVB/N)	decreased B cell number	J:212898
	decreased CD4-positive, alpha-beta T cell number	J:212898
	decreased macrophage cell number	J:212898
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:212898
	decreased T cell number	J:212898
	immune system phenotype	J:212898
Shisa6^em1(IMPC)Tcp/Shisa6^em1(IMPC)Tcp (C57BL/6N-Shisa6^em1(IMPC)Tcp/Tcp)	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Shisal1^{em1(IMPC)Ccpcz}/Shisal1^{em1(IMPC)Ccpcz} (C57BL/6N-Shisal1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Shld1^em1(IMPC)Mbp/Shld1^em1(IMPC)Mbp (C57BL/6NCrl-Shld1^em1(IMPC)Mbp/Mmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Shld1^em1Nus/Shld1^em1Nus (involves: C57BL/6NCrl)	abnormal class switch recombination	J:307190
Shmt2^em1(IMPC)Bay/Shmt2⁺ (C57BL/6N-Shmt2^em1(IMPC)Bay/Bay)	increased spleen weight	J:211773
sho/sho (Not Specified)	small thymus	J:255
Shprh^em1(IMPC)Tcp/Shprh^em1(IMPC)Tcp (C57BL/6NCrl-Shprh^em1(IMPC)Tcp/Tcp)	enlarged thymus	J:211773
Siae^tm1.2Avrk/Siae^tm1.2Avrk (B6J.129(Cg)-Siae^tm1.2Avrk)	immune system phenotype	J:231437
Siae^{tm1a(EUCOMM)Wtsi}/Siae^{tm1a(EUCOMM)Wtsi} (involves: C57BL/6N * C57BL/6NTac)	immune system phenotype	J:231437
Sials^MRL/MpJ/Sials^MRL/MpJ (involves: C3H/HeJ * MRL/MpJ)	salivary gland inflammation	J:66636
Sidt1^{tm1.1(KOMP)Vlcg}/Sidt1^{tm1.1(KOMP)Vlcg} (C57BL/6N-Sidt1^{tm1.1(KOMP)Vlcg}/Ucd)	abnormal lymph node morphology	J:211773
Sidt2^tm1.1Hzha/Sidt2^tm1.1Hzha (involves: 129S6/SvEvTac * C57BL/6J)	liver inflammation	J:236042
Sigirr^tm1Lix/Sigirr^tm1Lix (involves: 129S6/SvEvTac * BALB/c)	abnormal chemokine secretion	J:85151
	abnormal splenocyte proliferation	J:85151
	increased inflammatory response	J:85151
	increased susceptibility to endotoxin shock	J:85151
Sigirr^tm1Mant/Sigirr^tm1Mant (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	abnormal chemokine secretion	J:88907
	abnormal dendritic cell physiology	J:88907
	abnormal interleukin secretion	J:88907
	immune system phenotype	J:88907
	increased interleukin-6 secretion	J:88907
	increased susceptibility to induced colitis	J:88907
Siglec1^{tm1(HBEGF)Mtka}/Siglec1^{tm1(HBEGF)Mtka} 1700016L21Rik^{Tg(Itgax-HBEGF/EGFP)57Lan}/? (involves: 129S1/Sv * 129X1/SvJ * FVB/N)	abnormal dendritic cell physiology	J:123958
	abnormal immune system physiology	J:123958
	abnormal immune tolerance	J:123958
	abnormal macrophage physiology	J:123958
	abnormal metallophilic macrophage morphology	J:123958
	abnormal spleen marginal zone macrophage morphology	J:123958
Siglec1^tm1Croc/Siglec1^tm1Croc (B6.129-Siglec1^tm1Croc)	abnormal B cell number	J:105546
	abnormal T cell subpopulation ratio	J:105546
	decreased circulating interleukin-6 level	J:189854
	decreased circulating tumor necrosis factor level	J:189854
	decreased follicular B cell number	J:105546
	decreased IgM level	J:105546
	decreased interleukin-6 secretion	J:189854
	decreased interleukin-10 secretion	J:189854
	decreased interleukin-12 secretion	J:189854
	decreased tumor necrosis factor secretion	J:189854
	impaired macrophage phagocytosis	J:189854
	increased CD8-positive, alpha-beta T cell number	J:105546
	increased marginal zone B cell number	J:105546
	increased susceptibility to bacterial infection	J:189854
Siglec1^tm2.1Croc/Siglec1^tm2.1Croc (B6.129P2(C)-Siglec1^tm2.1Croc)	decreased circulating interleukin-6 level	J:189854
	decreased circulating tumor necrosis factor level	J:189854
	decreased susceptibility to bacterial infection	J:189854
	impaired macrophage phagocytosis	J:189854
Siglec15^tm1Yohi/Siglec15^tm1Yohi (B6.129S6-Siglec15^tm1Yohi)	abnormal osteoclast differentiation	J:193852
Siglece^{tm1.1(SIGLEC16)Avrk}/Siglece^{tm1.1(SIGLEC16)Avrk} (involves: C57BL/6)	abnormal cytokine level	J:264224
	decreased susceptibility to bacterial infection	J:264224
	increased circulating interleukin-6 level	J:264224
	increased circulating interleukin-12 level	J:264224
Siglece^tm1Arte/Siglece^tm1Arte (involves: C57BL/6)	abnormal macrophage physiology	J:195429
Siglece^tm1Arte/Siglece^tm1Arte (involves: C57BL/6)	abnormal neutrophil physiology	J:195429
Siglece^tm1Croc/Siglece^tm1Croc (B6.129P2-Siglece^tm1Croc)	abnormal macrophage physiology	J:195429
Siglece^tm1Croc/Siglece^tm1Croc (B6.129P2-Siglece^tm1Croc)	abnormal neutrophil physiology	J:195429
Siglecf^tm1.2Avrk/Siglecf^tm1.2Avrk (B6.129(FVB)-Siglecf^tm1.2Avrk)	abnormal eosinophil differentiation	J:204811
	abnormal eosinophil physiology	J:204811
	immune system phenotype	J:204811
	increased eosinophil cell number	J:204811
	lung inflammation	J:204811
Siglecg^M1Btlr/Siglecg^M1Btlr (C57BL/6J-Siglecg^M1Btlr)	increased B-1 B cell number	J:265179
Siglecg^m2Btlr/Siglecg^m2Btlr (C57BL/6J-Siglecg^m2Btlr)	decreased CD8-positive, alpha-beta memory T cell number	J:265183
	increased B-1 B cell number	J:265183
	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:265183
Siglecg^M3Btlr/Siglecg^M3Btlr (C57BL/6J-Siglecg^M3Btlr)	decreased B-2 B cell number	J:265185
	decreased IgM level	J:265185
	increased B-1 B cell number	J:265185
	increased B-1a cell number	J:265185
Siglecg^M4Btlr/Siglecg^M4Btlr (C57BL/6J-Siglecg^M4Btlr)	increased B-1 B cell number	J:272021
Siglecg^M5Btlr/Siglecg^M5Btlr (C57BL/6J-Siglecg^M5Btlr)	increased B-1a cell number	J:272022
Siglecg^tm1Lnit/Siglecg^tm1Lnit (involves: BALB/c)	abnormal plasma cell differentiation	J:123353
	autoimmune response	J:123353
	decreased IgG2a level	J:123353
	increased B-1 B cell number	J:123353
	increased B-1a cell number	J:123353
	increased B-1b cell number	J:123353
	increased IgM level	J:123353
Siglecg^tm1Yliu/Siglecg^tm1Yliu (C57BL/6-Siglecg^tm1Yliu)	increased B-1a cell number	J:130017
	increased IgM level	J:130017
	increased pre-B cell number	J:130017
Siglech^tm1.1Cfg/Siglech^tm1.1Cfg (involves: C57BL/6)	immune system phenotype	J:214874
Siglech^tm1.1Cfg/Siglech^tm1.1Cfg (involves: C57BL/6)	increased T cell proliferation	J:217719
Siglech^tm1.1Cln/Siglech⁺ Tg(CLEC4C-HBEGF)956Cln/0 (involves: C57BL/6)	decreased plasmacytoid dendritic cell number	J:166504
Siglech^tm1.1Ksat/Siglech^tm1.1Ksat (B6.Cg-Siglech^tm1.1Ksat)	abnormal circulating cytokine level	J:179283
	abnormal dendritic cell antigen presentation	J:179283
	abnormal plasmacytoid dendritic cell physiology	J:179283
	abnormal regulatory T cell morphology	J:179283
	decreased circulating interferon-alpha level	J:179283
	decreased circulating interleukin-12b level	J:179283
	decreased plasmacytoid dendritic cell number	J:179283
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:179283
	decreased susceptibility to infection induced morbidity/mortality	J:179283
	decreased T-helper 17 cell number	J:179283
	increased circulating interferon-alpha level	J:179283
	increased circulating interleukin-12b level	J:179283
	increased T-helper 17 cell number	J:179283
Sik2^tm1Lex/Sik2^tm1Lex (involves: 129S/SvEvBrd)	increased inflammatory response	J:229999
Sik3^{tm1a(EUCOMM)Hmgu}/Sik3^{tm1a(EUCOMM)Hmgu} (C57BL/6N-Sik3^{tm1a(EUCOMM)Hmgu}/Wtsi)	decreased alpha-beta T cell number	J:211773
	decreased CD4-positive NK T cell number	J:211773
	decreased CD4-positive, alpha-beta T cell number	J:211773
	decreased CD5-positive gamma-delta T cell number	J:211773
	decreased early germinal center B cell number	J:211773
	decreased effector memory T-helper cell number	J:211773
	decreased gamma-delta T cell number	J:211773
	decreased germinal center B cell number	J:211773
	decreased KLRG1-positive NK cell number	J:211773
	decreased KLRG1-positive T-helper cell number	J:211773
	decreased Ly6C-positive mature NK cell number	J:211773
	decreased memory-marker CD4-negative NK T cell number	J:211773
	decreased memory-marker CD4-positive NK T cell number	J:211773
	decreased NK cell number	J:211773
	decreased NK T cell number	J:211773
	decreased regulatory T cell number	J:211773
	decreased T cell number	J:211773
	decreased T-helper cell number	J:211773
	increased CD4-negative NK T cell number	J:211773
	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	increased CD8-positive, alpha-beta T cell number	J:211773
	increased CD8-positive, naive alpha-beta T cell number	J:211773
	increased effector memory T-helper cell number	J:211773
	increased eosinophil cell number	J:211773
	increased follicular B cell number	J:211773
	increased granulocyte number	J:211773
	increased KLRG1+ CD8 alpha-beta T cell number	J:211773
	increased KLRG1-positive CD4-negative NK T cell number	J:211773
	increased KLRG1-positive CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	increased KLRG1-positive T-helper cell number	J:211773
	increased Ly6C-positive NK T cell number	J:211773
	increased memory-marker gamma-delta T cell number	J:211773
	increased memory-marker NK cell number	J:211773
	increased NK cell number	J:211773
	increased plasmacytoid dendritic cell number	J:211773
Sike1^em1Cya/Sike1^em1Cya (C57BL/6N-Sike1^em1Cya/Cya)	abnormal tumor necrosis factor level	J:367804
	increased cytokine level	J:367804
	increased interferon level	J:367804
	increased interleukin level	J:367804
Sin3b^tm1.2Rdp/Sin3b^tm1.2Rdp (involves: 129 * C57BL/6 * FVB/N * SJL)	abnormal granulocyte differentiation	J:154855
	decreased granulocyte number	J:154855
Sinhcaf^tm1.2Hmd/Sinhcaf^tm1.2Hmd (involves: 129 * C57BL/6)	spleen hypoplasia	J:313620
Sipa1^tm1Nm/Sipa1⁺ (involves: 129P2/OlaHsd * C57BL/6)	enlarged spleen	J:97239
Sipa1^tm1Nm/Sipa1⁺ (involves: 129P2/OlaHsd * C57BL/6)	increased leukocyte cell number	J:97239
Sipa1^tm1Nm/Sipa1^tm1Nm (involves: 129P2/OlaHsd * C57BL/6)	enlarged spleen	J:97239
	increased granulocyte number	J:97239
	increased leukocyte cell number	J:97239
	spleen hyperplasia	J:97239
Sirpa^{tm1b(EUCOMM)Hmgu}/Sirpa^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Sirpa^{tm1b(EUCOMM)Hmgu}/Bay)	enlarged spleen	J:211773
	increased spleen weight	J:211773
Sirpa^tm1Nog/Sirpa^tm1Nog (involves: 129P2/OlaHsd * C57BL/6)	abnormal Langerhans cell physiology	J:88694
	abnormal macrophage physiology	J:79592
	decreased T cell number	J:79592
Sirt1^{tm1b(EUCOMM)Wtsi}/Sirt1⁺ (C57BL/6N-Sirt1^{tm1b(EUCOMM)Wtsi}/H)	increased basophil cell number	J:211773
Sirt1^tm1Fwa/Sirt1^tm1Fwa (involves: 129/Sv * 129S6/SvEvTac)	immune system phenotype	J:85542
Sirt1^tm1Mcby/Sirt1^tm1Mcby (involves: 129)	decreased CD8-positive, alpha-beta T cell number	J:81010
	interstitial pneumonia	J:81010
	lung inflammation	J:81010
Sirt1^tm1Mcby/Sirt1^tm1Mcby (involves: 129S1/Sv * 129X1/SvJ * CD-1)	decreased CD8-positive, alpha-beta T cell number	J:81010
	glomerulonephritis	J:160869
	increased anti-nuclear antigen antibody level	J:160869
	increased immunoglobulin level	J:160869
	interstitial pneumonia	J:81010
	lung inflammation	J:81010
Sirt1^tm1Mcby/Sirt1^tm1Mcby (involves: 129S1/Sv * 129X1/SvJ)	increased autoantibody level	J:241633
Sirt1^tm2.1Mcby/Sirt1^tm2.1Mcby (involves: 129S1/Sv * 129X1/SvJ * CD-1)	enlarged spleen	J:180628
Sirt3^tm1.1Fwa/Sirt3^tm1.1Fwa (involves: 129S6/SvEvTac)	abnormal cytokine level	J:178653
	increased circulating interferon-gamma level	J:178653
	increased circulating interleukin-6 level	J:178653
	increased circulating interleukin-10 level	J:178653
	increased circulating interleukin-12 level	J:178653
	increased circulating tumor necrosis factor level	J:178653
	liver inflammation	J:178653
Sirt6^tm1Fwa/Sirt6^tm1Fwa (involves: 129S6/SvEvTac * 129X1/SvJ)	abnormal B cell differentiation	J:112817
	abnormal lymphopoiesis	J:112817
	colitis	J:112817
	decreased double-positive T cell number	J:112817
	decreased leukocyte cell number	J:112817
	spleen hypoplasia	J:112817
Sirt6^tm2.1Cxd/Sirt6^tm2.1Cxd (involves: 129S6/SvEvTac * NIH Black Swiss)	abnormal spleen physiology	J:167023
Sirt6^tm2.2Cxd/Sirt6^tm2.2Cxd (involves: 129S6/SvEvTac * FVB/N * NIH Black Swiss)	abnormal spleen physiology	J:167023
Sirt7^tm1Evbo/Sirt7^tm1Evbo (involves: 129/Sv * C57BL/6)	abnormal cytokine level	J:147652
	increased granulocyte number	J:147652
	increased interleukin-4 secretion	J:147652
	increased interleukin-12 secretion	J:147652
	increased interleukin-13 secretion	J:147652
Sirt7^tm1Fwa/Sirt7^tm1Fwa (involves: 129S1/Sv)	increased macrophage cell number	J:205529
Sirt7^tm1Fwa/Sirt7^tm1Fwa (involves: 129S1/Sv)	liver inflammation	J:205529
Sit1^tm1Lsmn/Sit1^tm1Lsmn (B6.Cg-Sit1^tm1Lsmn)	abnormal cytokine secretion	J:100408
	abnormal lymphocyte cell number	J:100408
	abnormal T cell differentiation	J:100408
	abnormal T-helper 1 cell differentiation	J:100408
	decreased CD4-positive, alpha-beta T cell number	J:100408
	decreased CD8-positive, alpha-beta T cell number	J:100408
	increased double-positive T cell number	J:100408
	increased interferon-gamma secretion	J:100408
	increased interleukin-2 secretion	J:100408
	increased mature gamma-delta T cell number	J:100408
	increased susceptibility to experimental autoimmune encephalomyelitis	J:100408
	increased T cell proliferation	J:100408
	increased tumor necrosis factor secretion	J:100408
	lymph node hypoplasia	J:100408
	thymus hyperplasia	J:100408
Sit1^tm1Lsmn/Sit1^tm1Lsmn Tg(TcraH-Y,TcrbH-Y)71Vbo/? (involves: C57BL/6 * C57BL/6J * DBA/2J)	abnormal CD8-positive, alpha beta T cell morphology	J:100408
	abnormal positive T cell selection	J:100408
	abnormal T cell differentiation	J:100408
Sit1^tm1Lsmn/Sit1^tm1Lsmn Tg(TcrLCMV)327Sdz/0 (involves: C57BL/6)	abnormal positive T cell selection	J:100408
	abnormal T cell selection	J:100408
	thymus hypoplasia	J:100408
Six1^em1(IMPC)Mbp/Six1⁺ (C57BL/6N-Six1^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	decreased leukocyte cell number	J:211773
	enlarged spleen	J:211773
	small spleen	J:211773
Six1^tm1Kwk/Six1^tm1Kwk (involves: 129P2/OlaHsd * C57BL/6)	athymia	J:104488
Six1^tm1Mair/Six1^tm1Mair (involves: 129S2/SvPas)	athymia	J:84417
Ska1^{em1(IMPC)Ccpcz}/Ska1⁺ (C57BL/6NCrl-Ska1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
Skap1^Gt713Lex/Skap1^Gt713Lex (B6.129S5-Skap1^Gt713Lex)	abnormal CD4-positive, alpha-beta T cell physiology	J:126545
	abnormal immune system physiology	J:126545
	abnormal T cell physiology	J:126545
	decreased interferon-gamma secretion	J:126545
	decreased interleukin-2 secretion	J:126545
	decreased T cell proliferation	J:126545
	immune system phenotype	J:126545
Skap2^{Gt(VICTR20)21Lex}/Skap2^{Gt(VICTR20)21Lex} (B6.129S5-Skap2^{Gt(VICTR20)21Lex})	abnormal B cell activation	J:101373
	abnormal dendritic cell antigen presentation	J:151350
	abnormal dendritic cell physiology	J:151350
	decreased B cell proliferation	J:101373
	decreased IgG2a level	J:101373
	decreased IgM level	J:101373
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:101373
Skic8^em1(IMPC)Tcp/Skic8⁺ (C57BL/6NCrl-Skic8^em1(IMPC)Tcp/Tcp)	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	increased monocyte cell number	J:211773
Skida1^{tm1.1(KOMP)Wtsi}/Skida1⁺ (C57BL/6N-Skida1^{tm1.1(KOMP)Wtsi}/Ucd)	enlarged lymph nodes	J:211773
	enlarged thymus	J:211773
Skida1^{tm1.1(KOMP)Wtsi}/Skida1^{tm1.1(KOMP)Wtsi} (C57BL/6N-Skida1^{tm1.1(KOMP)Wtsi}/Ucd)	enlarged thymus	J:211773
	small spleen	J:211773
Skil^tm1Sis/Skil⁺ (involves: C57BL/6 * CBA)	increased T cell derived lymphoma incidence	J:62174
Skil^tm1Spw/Skil^tm1Spw (either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6))	abnormal immune system cell morphology	J:84554
	abnormal immune system organ morphology	J:84554
	decreased T cell proliferation	J:84554
	enlarged spleen	J:84554
Skil^tm2Spw/Skil^tm2Spw (either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6))	decreased T cell proliferation	J:84554
	immune system phenotype	J:84554
Skint1^m1Tac/Skint1^m1Tac (FVB/NTac)	abnormal T cell differentiation	J:139711
Skint1^m1Tac/Skint1^m1Tac (FVB/NTac)	abnormal T cell morphology	J:139711
Skint2^em2Htaka/Skint2^em2Htaka (C57BL/6-Skint2^em2Htaka)	decreased dendritic epidermal T cell number	J:291989
skp/skp (CXB5/ByJ-skp/GrsrJ)	thymus atrophy	J:153578
Skp2^tm1Kin/Skp2^tm1Kin (involves: 129P2/OlaHsd)	abnormal immunoglobulin V(D)J recombination	J:168974
Sla2^{em1(IMPC)Ccpcz}/Sla2^{em1(IMPC)Ccpcz} (C57BL/6N-Sla2^{em1(IMPC)Ccpcz}/Ccpcz)	decreased NK cell number	J:211773
Sla2^tm1Amch/Sla2^tm1Amch (involves: 129)	immune system phenotype	J:169170
Sla^tm1Weis/Sla^tm1Weis (involves: 129 * C57BL/6)	abnormal double-positive T cell morphology	J:71804
Sla^tm1Weis/Sla^tm1Weis Sla2^tm1Amch/Sla2^tm1Amch (involves: 129)	abnormal dendritic cell differentiation	J:169170
	abnormal dendritic cell physiology	J:169170
	decreased interleukin-12 secretion	J:169170
	decreased tumor necrosis factor secretion	J:169170
Sla^tm1Weis/Sla^tm1Weis Tg(DO11.10)10Dlo/0 (involves: 129 * BALB/c * C3H * C57BL/6)	abnormal positive T cell selection	J:71804
	abnormal T cell differentiation	J:71804
Sla^tm1Weis/Sla^tm1Weis Zap70^tm1Weis/Zap70^tm1Weis (involves: 129 * 129X1/SvJ * C57BL/6)	abnormal T cell differentiation	J:71804
	decreased CD4-positive, alpha-beta T cell number	J:71804
Slamf1^tm1Cpt/Slamf1^tm1Cpt (B6.129S4-Slamf1^tm1Cpt)	abnormal cytokine secretion	J:90484
	abnormal macrophage physiology	J:90484
	increased susceptibility to parasitic infection	J:90484
Slamf1^tm1Cpt/Slamf1^tm1Cpt (C.129S4-Slamf1^tm1Cpt)	abnormal cytokine secretion	J:90484
Slamf1^tm1Cpt/Slamf1^tm1Cpt (C.129S4-Slamf1^tm1Cpt)	abnormal macrophage physiology	J:90484
Slamf1^tm1Cpt/Slamf1^tm1Cpt Tg(DO11.10)10Dlo/Tg(DO11.10)10Dlo (involves: BALB/c * C3H * C57BL/6)	abnormal cytokine secretion	J:90484
Slamf1^tm1Oono/Slamf1^tm1Oono (B6.129-Slamf1^tm1Oono)	increased susceptibility to Paramyxoviridae infection	J:117810
Slamf1^tm1Vei/Slamf1^tm1Vei (involves: 129 * C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:133047, J:93886
Slamf1^tm1Vei/Slamf1^tm1Vei (involves: 129 * C57BL/6)	immune system phenotype	J:133047
Slamf6^tm1Dhow/Slamf6^tm1Dhow (involves: 129/Sv * C57BL/6)	abnormal neutrophil physiology	J:98995
	abnormal T-helper 2 physiology	J:98995
	decreased interleukin-4 secretion	J:98995
	decreased susceptibility to parasitic infection	J:98995
	impaired granulocyte bactericidal activity	J:98995
	increased circulating interleukin-12b level	J:98995
	increased circulating interleukin-16 level	J:98995
	increased circulating tumor necrosis factor level	J:98995
	increased susceptibility to bacterial infection	J:98995
	increased susceptibility to bacterial infection induced morbidity/mortality	J:98995
Slamf6^tm1Lex/Slamf6^tm1Lex (B6.129S5-Slamf6^tm1Lex)	immune system phenotype	J:187429
Slamf6^tm1Pls/Slamf6^tm1Pls Tg(TcraTcrb)1100Mjb/0 (involves: C57BL/6 * C57BL/6J)	immune system phenotype	J:187431
Slamf7^tm1Vei/Slamf7^tm1Vei (involves: 129S1/Sv * 129X1/SvJ)	impaired natural killer cell mediated cytotoxicity	J:145969
Slamf8^tm1Mill/Slamf8^tm1Mill (involves: BALB/c)	abnormal macrophage physiology	J:188963
Slamf8^tm1Mill/Slamf8^tm1Mill (involves: BALB/c)	increased susceptibility to bacterial infection	J:188963
Slamf9^em1Isha/Slamf9^em1Isha (involves: C57BL/6)	abnormal plasmacytoid dendritic cell physiology	J:279164
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:279164
	increased plasmacytoid dendritic cell number	J:279164
Slc1a5^tm1Tac/Slc1a5^tm1Tac (involves: 129S/SvEv * C57BL/6)	abnormal T cell physiology	J:254980
	abnormal T-helper 1 cell differentiation	J:254980
	abnormal T-helper 2 cell differentiation	J:254980
	abnormal T-helper 17 cell differentiation	J:254980
	decreased B cell number	J:254980
	decreased CD4-positive, alpha-beta memory T cell number	J:254980
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:254980
	decreased T helper 1 cell number	J:254980
	decreased T-helper 17 cell number	J:254980
	immune system phenotype	J:254980
	increased CD4-positive, alpha-beta T cell number	J:254980
Slc2a4^tm1Mch/Slc2a4⁺ (involves: 129/Sv * C57BL/6J * CD-1 * SJL)	heart inflammation	J:43650
Slc2a5^{tm1b(EUCOMM)Wtsi}/Slc2a5^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Slc2a5^{tm1b(EUCOMM)Wtsi}/Ieg)	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Slc2a6^em1Kusu/Slc2a6^em1Kusu (involves: C57BL/6JCrlj)	abnormal macrophage physiology	J:270487
	increased circulating tumor necrosis factor level	J:270487
	increased susceptibility to endotoxin shock	J:270487
Slc2a9^tm1.2Thor/Slc2a9^tm1.2Thor (involves: C57BL/6 * C57BL/6N)	kidney inflammation	J:153089
	tubulointerstitial nephritis	J:153089
Slc2a10^G128E/Slc2a10^G128E (C3HeB/FeJ-Slc2a10^G128E)	abnormal spleen morphology	J:161835
Slc3a1^pbl/Slc3a1^pbl (C3HeB/FeJ-Slc3a1^pbl)	tubulointerstitial nephritis	J:85461
Slc3a1^pbl/Slc3a1^pbl (involves: C3HeB/FeJ * MRL/MpJ)	kidney inflammation	J:85461
Slc3a1^{tm1.1(KOMP)Vlcg}/Slc3a1^{tm1.1(KOMP)Vlcg} (C57BL/6N-Slc3a1^{tm1.1(KOMP)Vlcg}/Ucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	increased eosinophil cell number	J:211773
	increased spleen weight	J:211773
Slc3a2^tm1.1Merl/Slc3a2⁺ Tg(Vil1-cre)997Gum/0 (B6.Cg-Slc3a2^tm1.1Merl Tg(Vil1-cre)997Gum)	decreased susceptibility to induced colitis	J:173946
Slc3a2^tm1.1Yait/Slc3a2^tm1.1Yait Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6NCrSlc)	abnormal macrophage antigen presentation	J:188365
	abnormal macrophage differentiation	J:188365
	abnormal macrophage morphology	J:188365
	abnormal macrophage physiology	J:188365
	impaired macrophage phagocytosis	J:188365
Slc4a1^tm1Ahc/Slc4a1^tm1Ahc (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	abnormal immune system organ morphology	J:35637
	enlarged spleen	J:35637
Slc4a1^tm1Dmb/Slc4a1^tm1Dmb (involves: 129S6/SvEvTac)	abnormal splenic cell ratio	J:145243
Slc4a1^tm1Llp/Slc4a1^tm1Llp (involves: 129S4/SvJae * C57BL/6J)	enlarged spleen	J:35487
Slc4a1^tm1Phsl/Slc4a1^tm1Phsl (involves: 129 * 129S6/SvEvTac * Black Swiss)	enlarged spleen	J:152245
Slc4a2^tm1Ges/Slc4a2^tm1Ges (involves: 129S6/SvEvTac)	abnormal osteoclast morphology	J:193823
Slc4a2^tm1Ges/Slc4a2^tm1Ges (involves: 129S6/SvEvTac)	abnormal osteoclast physiology	J:193823
Slc4a2^tm2Ges/Slc4a2^tm2Ges Ctsk^tm1(cre)Ska/Ctsk⁺ (involves: C57BL/6NCrlj * CBA/JNCrlj)	abnormal osteoclast morphology	J:193823
	abnormal osteoclast physiology	J:193823
Slc4a2^tm2Ges/Slc4a2^tm2Ges Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA)	abnormal osteoclast morphology	J:193823
	abnormal osteoclast physiology	J:193823
Slc4a4^tm1.1Slin/Slc4a4^tm1.1Slin (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	enlarged spleen	J:186877
	increased spleen weight	J:186877
Slc4a4^tm1Ges/Slc4a4^tm1Ges (involves: 129S6/SvEvTac * Black Swiss)	decreased lymphocyte cell number	J:120867
	disorganized spleen B cell follicle	J:120867
	enlarged spleen	J:120867
	increased spleen red pulp amount	J:120867
	increased spleen white pulp amount	J:120867
Slc4a10^{tm1b(KOMP)Wtsi}/Slc4a10^{tm1b(KOMP)Wtsi} (C57BL/6N-Slc4a10^{tm1b(KOMP)Wtsi}/H)	small spleen	J:211773
Slc5a2^m2Btlr/Slc5a2^m2Btlr (C57BL/6J-Slc5a2^m2Btlr)	increased susceptibility to induced colitis	J:265117
Slc5a2^m2Btlr/Slc5a2^m2Btlr (C57BL/6J-Slc5a2^m2Btlr)	increased tumor necrosis factor secretion	J:265117
Slc5a2^tm1Lex/Slc5a2^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6J)	decreased susceptibility to autoimmune diabetes	J:195941
Slc5a6^tm1.1Said/Slc5a6^tm1.1Said Tg(Vil1-cre)997Gum/? (involves: C57BL/6)	immune system phenotype	J:194700
Slc5a6^tm1.1Said/Slc5a6^tm1.1Said Tg(Vil1-cre/ERT2)23Syr/0 (involves: C57BL/6 * DBA/2)	cecum inflammation	J:307482
	small intestinal inflammation	J:307482
Slc5a7^{tm1a(KOMP)Wtsi}/Slc5a7^{tm1a(KOMP)Wtsi} (C57BL/6N-Slc5a7^{tm1a(KOMP)Wtsi}/Wtsi)	blood in lymph vessels	J:239583
Slc6a6^em1(IMPC)Mbp/Slc6a6^em1(IMPC)Mbp (C57BL/6N-Slc6a6^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
	increased monocyte cell number	J:211773
Slc6a8^tm1.2Lbar/Y (involves: 129 * 129S1/Sv * C57BL/6J * C57BL/6N)	microgliosis	J:238578
Slc6a14^tm1Gana/Slc6a14^tm1Gana (Not Specified)	abnormal circulating chemokine level	J:226105
	abnormal circulating cytokine level	J:226105
	decreased circulating interleukin-1 alpha level	J:226105
	decreased circulating interleukin-4 level	J:226105
Slc6a14^tm1Gana/Slc6a14^tm1Gana Tg(MMTV-PyVT)634Mul/0 (Not Specified)	abnormal immunoglobulin level	J:226105
Slc7a2^tm1Clm/Slc7a2^tm1Clm (involves: 129S7/SvEvBrd * C57BL/6)	abnormal immune system physiology	J:69414
Slc7a5^em1(IMPC)H/Slc7a5⁺ (C57BL/6NTac-Slc7a5^em1(IMPC)H/H)	increased basophil cell number	J:211773
Slc7a7^em1Lbu/Slc7a7^em1Lbu (involves: 129/SvEv * C57BL/6)	abnormal spleen germinal center morphology	J:293773
	decreased lymphocyte cell number	J:293773
	decreased spleen weight	J:293773
	increased neutrophil cell number	J:293773
	increased spleen red pulp amount	J:293773
Slc7a7^{Gt(OST41878)Lex}/Slc7a7^{Gt(OST41878)Lex} (B6.129S-Slc7a7^{Gt(OST41878)Lex})	increased spleen weight	J:125847
Slc7a9^tm1Nune/Slc7a9^tm1Nune (involves: 129P2/OlaHsd * C57BL/6J)	tubulointerstitial nephritis	J:85462
Slc7a11^m1Mtka/Slc7a11^m1Mtka (C57BL/6-Slc7a11^m1Mtka)	abnormal dendritic cell physiology	J:159323
	abnormal macrophage physiology	J:159323
	immune system phenotype	J:159323
Slc9a2^tm1Ges/Slc9a2^tm1Ges (involves: 129X1/SvJ * Black Swiss)	stomach inflammation	J:65754
Slc9a4^tm1Ges/Slc9a4^tm1Ges (involves: 129S6/SvEvTac * Black Swiss)	stomach inflammation	J:98566
Slc9a6^tm1Dgen/Y (B6.129P2-Slc9a6^tm1Dgen/J)	microgliosis	J:262453
Slc9a8^m1Btlr/Slc9a8^m1Btlr (C57BL/6J-Slc9a8^m1Btlr)	increased susceptibility to induced colitis	J:267481
Slc9b1^em1(IMPC)Mbp/Slc9b1^em1(IMPC)Mbp (C57BL/6N-Slc9b1^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Slc11a1^em1(IMPC)Mbp/Slc11a1^em1(IMPC)Mbp (C57BL/6N-Slc11a1^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	decreased lymphocyte cell number	J:211773
	enlarged spleen	J:211773
	increased neutrophil cell number	J:211773
Slc11a1^r/Slc11a1^r (C3H/HeJ-Slc11a1^r)	decreased susceptibility to bacterial infection	J:35004
Slc11a1^r/Slc11a1^r (129/Sv)	decreased susceptibility to bacterial infection	J:81412
Slc11a1^r/Slc11a1^s ((129/Sv x BALB/c)F1)	decreased susceptibility to bacterial infection	J:28278
Slc11a1^s/Slc11a1^r ((129/Sv x C57BL/6J)F1)	abnormal susceptibility to bacterial infection	J:81412
Slc11a1^s/Slc11a1^s (C57BL/6J)	increased susceptibility to bacterial infection	J:81412
Slc11a1^s/Slc11a1^s (BALB/c)	increased susceptibility to bacterial infection	J:28278
Slc11a1^tm1Mcg/Slc11a1^s (involves: 129S4/SvJae * BALB/c)	increased susceptibility to bacterial infection	J:28278
Slc11a1^tm1Mcg/Slc11a1^tm1Mcg (involves: 129S4/SvJae * BALB/c)	increased susceptibility to bacterial infection	J:28278
Slc11a2^mk/Slc11a2^mk (MK/ReJ)	increased spleen weight	J:5167
Slc11a2^mk/Slc11a2^mk (SEC.Cg-Slc11a2^mk)	increased spleen weight	J:5167
Slc11a2^tm2Nca/Slc11a2^tm2Nca Tg(Vil1-cre)20Syr/? (involves: 129S6.129S4-Slc11a2^tm2Nca * C57BL/6 * DBA/2)	abnormal spleen morphology	J:98088
	decreased spleen iron level	J:98088
	enlarged spleen	J:98088
	increased spleen red pulp amount	J:98088
Slc12a1^urehr3/Slc12a1^urehr3 (involves: C3HeB/FeJ)	pyelitis	J:159994
Slc12a1^urehr3/Slc12a1^urehr3 (involves: C3HeB/FeJ)	pyelonephritis	J:159994
Slc12a2^em1Dlp/Slc12a2⁺ (involves: C57BL/6J * DBA/2J)	increased susceptibility to bacterial infection	J:285398
Slc12a2^em1Dlp/Slc12a2^em1Dlp (involves: C57BL/6J * DBA/2J)	increased lymphocyte cell number	J:285398
	increased susceptibility to bacterial infection	J:285398
	large intestinal inflammation	J:285398
Slc12a5^em1(IMPC)Mbp/Slc12a5⁺ (C57BL/6N-Slc12a5^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	small spleen	J:211773
Slc13a3^{tm1b(KOMP)Wtsi}/Slc13a3^{tm1b(KOMP)Wtsi} (C57BL/6N-Slc13a3^{tm1b(KOMP)Wtsi}/Ucd)	decreased lymphocyte cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Slc13a5^{tm1b(EUCOMM)Hmgu}/Slc13a5^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Slc13a5^{tm1b(EUCOMM)Hmgu}/Ieg)	increased leukocyte cell number	J:211773
Slc14a1^tm1Ask/Slc14a1^tm1Ask (involves: C57BL/6J * CD-1)	decreased spleen weight	J:125840
Slc15a1^{em1(IMPC)Ccpcz}/Slc15a1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Slc15a1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Slc15a3^{tm1a(KOMP)Wtsi}/Slc15a3^{tm1a(KOMP)Wtsi} (C57BL/6N-Slc15a3^{tm1a(KOMP)Wtsi})	abnormal myeloid dendritic cell morphology	J:210445
Slc15a3^{tm1b(KOMP)Wtsi}/Slc15a3^{tm1b(KOMP)Wtsi} (C57BL/6N-Slc15a3^{tm1b(KOMP)Wtsi}/H)	increased monocyte cell number	J:211773
Slc15a4^m1Btlr/Slc15a4^m1Btlr (C57BL/6J-Slc15a4^m1Btlr)	abnormal interferon secretion	J:166600
	decreased interleukin-6 secretion	J:166600
	decreased interleukin-12 secretion	J:166600
	decreased tumor necrosis factor secretion	J:166600
Slc15a4^tm1Tkyo/Slc15a4^tm1Tkyo (involves: C57BL/6)	abnormal circulating cytokine level	J:270965
	abnormal cytokine secretion	J:270965
	decreased circulating interleukin-1 beta level	J:270965
	decreased circulating interleukin-6 level	J:270965
	decreased interferon-beta secretion	J:270965
	decreased interleukin-1 beta secretion	J:270965
	decreased interleukin-6 secretion	J:270965
	decreased interleukin-12 secretion	J:270965
	decreased interleukin-12b secretion	J:270965
	decreased interleukin-15 secretion	J:270965
	decreased interleukin-18 secretion	J:270965
	decreased susceptibility to induced colitis	J:270965
	decreased tumor necrosis factor secretion	J:270965
Slc17a1^em1(IMPC)J/Slc17a1^em1(IMPC)J (C57BL/6NJ-Slc17a1^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
Slc17a8^em1(IMPC)Mbp/Slc17a8^em1(IMPC)Mbp (C57BL/6N-Slc17a8^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
Slc19a1^tm1Gold/Slc19a1^tm1Gold (involves: 129/Sv * C57BL/6 * SJL)	abnormal lymphopoiesis	J:68666
	decreased lymphocyte cell number	J:68666
	small spleen	J:68666
	small thymus	J:68666
Slc19a2^tm1Gelb/Slc19a2^tm1Gelb (involves: 129X1/SvJ)	abnormal myelopoiesis	J:79974
Slc19a3^tm1Said/Slc19a3^tm1Said (involves: C57BL/6)	chronic liver inflammation	J:170952
Slc19a3^tm1Said/Slc19a3^tm1Said (involves: C57BL/6)	kidney inflammation	J:170952
Slc20a1^tm1.1Lbek/Slc20a1^tm1.1Lbek Tg(Mx1-cre)1Cgn/0 (involves: 129S2/SvPas * C57BL/6 * C57BL/6J * CBA)	enlarged spleen	J:194198
	increased leukocyte cell number	J:194198
	intermingled spleen red and white pulp	J:194198
	spleen hyperplasia	J:194198
Slc20a1^tm1Lbek/Slc20a1^tm1Lbek (involves: 129S2/SvPas * C57BL/6J)	abnormal spleen morphology	J:194198
	enlarged spleen	J:194198
	increased spleen weight	J:157997
Slc20a2^{tm1a(EUCOMM)Wtsi}/Slc20a2^{tm1a(EUCOMM)Wtsi} (C57BL/6NTac-Slc20a2^{tm1a(EUCOMM)Wtsi}/Ieg)	microgliosis	J:223197
Slc22a4^tm1Atsu/Slc22a4^tm1Atsu (involves: C57BL/6J)	intestinal inflammation	J:207006
Slc22a6^tm1Dgen/Slc22a6^tm1Dgen (involves: 129P2/OlaHsd * C57BL/6)	increased thymus weight	J:101679
Slc22a7^em1(IMPC)Tcp/Slc22a7^em1(IMPC)Tcp (C57BL/6NCrl-Slc22a7^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Slc22a29^em1(IMPC)Mbp/Slc22a29^em1(IMPC)Mbp (C57BL/6N-Slc22a29^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Slc23a4^{tm1a(KOMP)Wtsi}/Slc23a4^{tm1a(KOMP)Wtsi} (C57BL/6N-2010107G12Rik^{tm1a(KOMP)Wtsi}/Wtsi)	decreased leukocyte cell number	J:175295
Slc24a3^em#Ebje/Slc24a3^em#Ebje (C57BL/6J-Slc24a3^em#Ebje)	increased susceptibility to induced colitis	J:308448
Slc24a4^{tm1b(KOMP)Wtsi}/Slc24a4⁺ (C57BL/6N-Slc24a4^{tm1b(KOMP)Wtsi}/H)	enlarged thymus	J:211773
Slc25a17^Gt(XB686)Byg/Slc25a17^Gt(XB686)Byg (involves: 129P2/OlaHsd * C57BL/6 * Swiss Webster)	abnormal Kupffer cell morphology	J:291257
	liver inflammation	J:291257
Slc25a37^tm1.1Kapl/Slc25a37^tm1.2Kapl Speer6-ps1^{Tg(Alb-cre)21Mgn}/? (involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6J * C57BL/6NCr * DBA)	enlarged spleen	J:173284
Slc25a37^tm1.1Kapl/Slc25a37^tm1.2Kapl Tg(Mx1-cre)1Cgn/? (involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6J * C57BL/6NCr * CBA)	abnormal B cell morphology	J:173284
	abnormal lymphocyte morphology	J:173284
	abnormal spleen morphology	J:173284
	abnormal T cell morphology	J:173284
	enlarged spleen	J:173284
Slc25a42^em1(IMPC)J/Slc25a42⁺ (C57BL/6NJ-Slc25a42^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
Slc25a46^atc/Slc25a46^atc (B6.Cg-Slc25a46^atc)	decreased spleen weight	J:242350
	decreased thymus weight	J:242350
	microgliosis	J:242350
	spleen hypoplasia	J:242350
	thymus hypoplasia	J:242350
Slc26a1^tm1Mark/Slc26a1^tm1Mark (involves: 129X1/SvJ * CD-1)	kidney inflammation	J:158567
Slc26a4^m2Btlr/Slc26a4^m2Btlr (C57BL/6J-Slc26a4^m2Btlr)	increased susceptibility to induced colitis	J:236690
Slc28a3^em1(IMPC)H/Slc28a3^em1(IMPC)H (C57BL/6N-Slc28a3^em1(IMPC)H/H)	increased large unstained cell number	J:211773
	increased monocyte cell number	J:211773
Slc29a1^tm2Msg/Slc29a1^tm2Msg Epor^{tm1.1(EGFP/icre)Uk}/Epor⁺ (involves: 129X1/SvJ * BALB/cJ)	decreased interleukin-6 secretion	J:244602
Slc29a2^{Gt(OST207791)Lex}/Slc29a2^{Gt(OST207791)Lex} (involves: 129S5/SvEvBrd)	decreased interleukin-6 secretion	J:203572
Slc29a3^em1(IMPC)Mbp/Slc29a3^em1(IMPC)Mbp (C57BL/6NCrl-Slc29a3^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	increased spleen weight	J:211773
	small thymus	J:211773
Slc29a3^{em1(IMPC)Wtsi}/Slc29a3^{em1(IMPC)Wtsi} (C57BL/6N-Slc29a3^{em1(IMPC)Wtsi}/Wtsi)	increased leukocyte cell number	J:211773
Slc29a3^tm1Lex/Slc29a3^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6)	abnormal macrophage morphology	J:179286
	abnormal macrophage physiology	J:179286
	enlarged lymph nodes	J:179286
	enlarged spleen	J:179286
	immune system phenotype	J:179286
	increased macrophage apoptosis	J:179286
	increased macrophage cell number	J:179286
	increased susceptibility to bacterial infection	J:179286
	increased susceptibility to bacterial infection induced morbidity/mortality	J:179286
	myeloid hyperplasia	J:179286
Slc30a2^tm1Kgna/Slc30a2^tm1Kgna (involves: 129 * C57BL/6)	abnormal macrophage physiology	J:264481
Slc30a4^em1(IMPC)Tcp/Slc30a4^em1(IMPC)Tcp (C57BL/6NCrl-Slc30a4^em1(IMPC)Tcp/Tcp)	small thymus	J:211773
Slc30a4^lm/Slc30a4^lm (C57BL/6J-Slc30a4^lm)	dermatitis	J:5911, J:7690
Slc31a1^tm2Djt/Slc31a1^tm2Djt Tg(Vil1-cre)997Gum/0 (involves: 129 * C57BL/6 * FVB/N * SJL)	decreased spleen weight	J:129741
Slc33a1^tm1.1Lpu/Slc33a1⁺ (involves: 129S7/SvEvBrd * C57BL/6)	abnormal circulating cytokine level	J:211266
	abnormal cytokine secretion	J:211266
	abnormal T cell activation	J:211266
	brain inflammation	J:211266
	conjunctivitis	J:211266
	decreased B cell number	J:211266
	dermatitis	J:211266
	immune system phenotype	J:211266
	increased B cell number	J:211266
	increased circulating interleukin-17 level	J:211266
	increased circulating interleukin-18 level	J:211266
	increased inflammatory response	J:211266
	increased interferon-gamma secretion	J:211266
	increased interleukin-4 secretion	J:211266
	increased interleukin-17 secretion	J:211266
	increased neutrophil cell number	J:211266
	increased susceptibility to infection	J:211266
	microgliosis	J:211266
	preputial gland inflammation	J:211266
	prostate gland inflammation	J:211266
	salivary gland inflammation	J:211266
	stomach inflammation	J:211266
	urinary bladder inflammation	J:211266
Slc35c1^tm1Cknr/Slc35c1^tm1Cknr (involves: 129/Sv * 129P2/OlaHsd * C57BL/6)	abnormal leukocyte adhesion	J:121151
	abnormal lymph node primary follicle morphology	J:121151
	impaired leukocyte tethering or rolling	J:121151
	increased eosinophil cell number	J:121151
	increased leukocyte cell number	J:121151
	increased lymphocyte cell number	J:121151
	increased monocyte cell number	J:121151
	increased neutrophil cell number	J:121151
	lymph node hypoplasia	J:121151
Slc37a2^em1(IMPC)Mbp/Slc37a2^em1(IMPC)Mbp (C57BL/6NCrl-Slc37a2^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
Slc37a2^tm1Dgen/Slc37a2^tm1Dgen (involves: 129P2/OlaHsd * C57BL/6J)	abnormal macrophage physiology	J:311521
	increased interleukin-1 beta secretion	J:311521
	increased interleukin-6 secretion	J:311521
	increased susceptibility to endotoxin shock	J:311521
	increased tumor necrosis factor secretion	J:311521
Slc37a4^tm1Jyc/Slc37a4^tm1Jyc (involves: 129S4/SvJae * C57BL/6)	abnormal chemokine secretion	J:86005
	abnormal inflammatory response	J:86005
	abnormal myelopoiesis	J:86005
	abnormal neutrophil physiology	J:86005
	abnormal spleen morphology	J:86005
	absent spleen white pulp	J:86005
	decreased inflammatory response	J:86005
	decreased lymphocyte cell number	J:86005
	decreased neutrophil cell number	J:86005
	impaired neutrophil chemotaxis	J:86005
	small spleen	J:86005
Slc38a2^{tm1a(KOMP)Wtsi}/Slc38a2⁺ (C57BL/6N-Slc38a2^{tm1a(KOMP)Wtsi}/Wtsi)	increased leukocyte cell number	J:211773
Slc38a7^{em1(IMPC)Ccpcz}/Slc38a7^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Slc38a7^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Slc38a8^em1Cya/Slc38a8^em1Cya (C57BL/6J-Slc38a8^em1Cya)	decreased susceptibility to viral infection	J:336781
Slc38a8^em1Cya/Slc38a8^em1Cya (C57BL/6J-Slc38a8^em1Cya)	decreased susceptibility to viral infection induced morbidity/mortality	J:336781
Slc39a3^tm1Gka/Slc39a3^tm1Gka (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal CD8-positive, alpha-beta cytotoxic T cell morphology	J:99161
	decreased double-positive T cell number	J:99161
	increased CD4-positive, alpha-beta T cell number	J:99161
Slc39a5^tm1.1Gka/Slc39a5^tm1.1Gka (involves: 129P2/OlaHsd * C57BL/6 * FVB/N)	increased susceptibility to induced pancreatitis	J:209760
Slc39a5^tm1Gka/Slc39a5^tm1Gka Tg(Cela1-cre/ERT)1Lgdn/0 (involves: 129P2/OlaHsd * C57BL/6)	increased susceptibility to induced pancreatitis	J:209760
Slc39a10^tm1.1Tfk/Slc39a10^tm1.1Tfk Tg(Foxn1-cre)8Ghr/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)	increased thymocyte apoptosis	J:254216
	thymus hypoplasia	J:254216
Slc40a1^ffe/Slc40a1⁺ (either: (involves: 129X1/SvJ * C57BL/6J) or (involves: C3H/HeJ * C57BL/6J))	abnormal macrophage physiology	J:118592
Slc40a1^Pcm/Slc40a1⁺ (A.Cg-Slc40a1^Pcm)	abnormal spleen development	J:98335
	abnormal spleen physiology	J:98335
	decreased spleen iron level	J:98335
	increased splenocyte apoptosis	J:98335
	small spleen	J:98335
Slc40a1^Pcm/Slc40a1^Pcm (A.Cg-Slc40a1^Pcm)	abnormal spleen development	J:98335
	decreased spleen iron level	J:98335
	increased splenocyte apoptosis	J:98335
	small spleen	J:98335
Slc40a1^tm1.1Mmfe/Slc40a1⁺ (involves: 129P2/OlaHsd * C57BL/6)	decreased spleen iron level	J:215585
Slc40a1^tm1.1Mmfe/Slc40a1^tm1.1Mmfe (involves: 129P2/OlaHsd * C57BL/6)	decreased spleen iron level	J:215585
Slc40a1^tm1Nca/Slc40a1⁺ (involves: 129S4/SvJae * 129S6/SvEvTac)	increased spleen iron level	J:129846
Slc40a1^tm2Nca/Slc40a1^tm2Nca Tg(Vil1-cre/ERT2)23Syr/0 (involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * DBA/2)	decreased spleen iron level	J:129846
Slc43a2^{Gt(258C1)Cmhd}/Slc43a2^{Gt(258C1)Cmhd} (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1)	liver inflammation	J:237439
Slc44a4^tm1.2Said/Slc44a4^tm1.2Said (involves: BALB/cJ * C57BL/6J * C57BL/6N)	increased susceptibility to induced colitis	J:351314
Slc46a2^tm1Moki/Slc46a2^tm1Moki (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	thymus hypoplasia	J:140121
Slc48a1^em1Ih/Slc48a1^em1Ih (involves: 129 * C57BL/6J)	abnormal macrophage morphology	J:282829
	abnormal macrophage physiology	J:282829
	dark spleen	J:282829
	decreased macrophage cell number	J:282829
	enlarged spleen	J:282829
	increased spleen iron level	J:282829
Slc51b^em1(IMPC)Mbp/Slc51b^em1(IMPC)Mbp (C57BL/6NCrl-Slc51b^em1(IMPC)Mbp/Mmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Slc52a2^{tm1.1(KOMP)Vlcg}/Slc52a2⁺ (C57BL/6N-Slc52a2^{tm1.1(KOMP)Vlcg}/Ucd)	enlarged lymph nodes	J:211773
Slco1a5^tm1Lex/Slco1a5^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6J)	abnormal CD8-positive, alpha beta T cell morphology	J:103485
	increased B cell number	J:103485
Slco4c1^{em1(IMPC)Ccpcz}/Slco4c1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Slco4c1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
Sle1^NZM2410/Aeg/Sle1^NZM2410/Aeg Sle3^NZM2410/Aeg/Sle3^NZM2410/Aeg (B6;NZM-Sle1^NZM2410/Aeg Sle2^NZM2410/Aeg Sle3^NZM2410/Aeg/LmoJ)	abnormal marginal zone B cell physiology	J:138314
	increased marginal zone B cell number	J:138314
Sle1^NZW/Sle1^NZW Sles1^NZW/Sles1^NZW (involves: C57BL/6 * NZW)	abnormal T cell physiology	J:100678
	decreased susceptibility to systemic lupus erythematosus	J:100678
Sle1^NZW/Sle1^NZW Tg(Tnfsf13b)1Fma/0 (involves: C57BL/6 * DBA/2J * NZW)	glomerulonephritis	J:134128
	increased B cell number	J:134128
	increased IgG level	J:134128
	increased IgM level	J:134128
	increased marginal zone B cell number	J:134128
	increased susceptibility to systemic lupus erythematosus	J:134128
Sle1a^C57BL/6J/Sle1a^NZM2410/J (involves: C57BL/6J * NZM2410/J)	increased anti-chromatin antibody level	J:67544
Sle1a^NZM2410/J/Sle1a^NZM2410/J (involves: C57BL/6J * NZM2410/J)	increased anti-chromatin antibody level	J:67544
Sle1b^C57BL/6J/Sle1b^NZM2410/J (involves: C57BL/6J * NZM2410/J)	increased anti-chromatin antibody level	J:67544
Sle1b^NZM2410/J/Sle1b^NZM2410/J (involves: C57BL/6J * NZM2410/J)	increased anti-chromatin antibody level	J:67544
Sle1c^C57BL/6J/Sle1c^NZM2410/J (involves: C57BL/6J * NZM2410/J)	increased anti-chromatin antibody level	J:67544
Sle1c^NZB/Sle1c^NZM2410/J (involves: C57BL/6J * NZB * NZM2410/J)	glomerulonephritis	J:145133
	increased autoantibody level	J:145133
Sle1c^NZM2410/J/Sle1c^NZM2410/J (involves: C57BL/6J * NZM2410/J)	increased anti-chromatin antibody level	J:67544
Sle2^NZM2410/Aeg/Sle2^NZM2410/Aeg (involves: C57BL/6J * NZM2410/Aeg)	glomerulonephritis	J:25006
Sle3^NZM2410/Aeg/? (involves: C57BL/6J * NZM2410/Aeg)	glomerulonephritis	J:52863
	increased IgG level	J:52863
	increased IgM level	J:52863
Sle6^NZW/Sle6^NZW (involves: C57BL/6 * NZW)	increased susceptibility to systemic lupus erythematosus	J:57246
Sle7^BXSB/J/Sle7^BXSB/J (involves: BXSB/J * C57BL/10Ola)	glomerulonephritis	J:60445
Sle8^BXSB/J/Sle8^BXSB/J (involves: BXSB/J * C57BL/10Ola)	glomerulonephritis	J:60445
Sle9^BXSB/J/Sle9^BXSB/J (involves: BXSB/J * C57BL/10Ola)	increased anti-nuclear antigen antibody level	J:60445
Sle10^BXSB/J/Sle10^BXSB/J (involves: BXSB/J * C57BL/10Ola)	enlarged lymph nodes	J:60445
Sle11^BXSB/J/Sle11^BXSB/J (involves: BXSB/J * C57BL/10Ola)	increased IgG3 level	J:60445
Sle12^C57BL/6J/Sle12^C57BL/6J (involves: C57BL/6J * NZM2410/Aeg)	glomerulonephritis	J:52863
Sle12^C57BL/6J/Sle12^NZM2410/Aeg (involves: C57BL/6J * NZM2410/Aeg)	glomerulonephritis	J:52863
Sle12^NZM2410/Aeg/Sle12^NZM2410/Aeg (involves: C57BL/6J * NZM2410/Aeg)	glomerulonephritis	J:52863
Sle16^{129S6/SvEvTac}/? (involves: 129X1/Sv * C57BL/6)	abnormal immune serum protein physiology	J:93297
Sle16^{129S6/SvEvTac}/Sle16^{129S6/SvEvTac} (B6.129-Sle16^{129S6/SvEvTac})	increased autoantibody level	J:122132
	increased susceptibility to systemic lupus erythematosus	J:122132
Sle17^{129S6/SvEvTac}/? (involves: 129S6/SvEvTac * C57BL/6)	abnormal immune serum protein physiology	J:93297
Sle18^C57BL/6/? (involves: 129X1/Sv * C57BL/6)	abnormal immune serum protein physiology	J:93297
Sles1^C57BL/6/Sles1^C57BL/6 (involves: C57BL/6 * NZW)	increased susceptibility to systemic lupus erythematosus	J:57246
Sles1^C57BL/6/Sles1^NZW (involves: C57BL/6 * NZW)	abnormal immune system physiology	J:57246
Sles1^NZW/Sles1^NZW (involves: C57BL/6 * NZW)	decreased susceptibility to systemic lupus erythematosus	J:57246
Sles2^C57BL/6/Sles2^C57BL/6 (involves: C57BL/6 * NZW)	increased susceptibility to systemic lupus erythematosus	J:57246
Sles2^C57BL/6/Sles2^NZW (involves: C57BL/6 * NZW)	increased susceptibility to systemic lupus erythematosus	J:57246
Sles2^NZW/Sles2^NZW (involves: C57BL/6 * NZW)	decreased susceptibility to systemic lupus erythematosus	J:57246
Sles3^C57BL/6/Sles3^C57BL/6 (involves: C57BL/6 * NZW)	increased susceptibility to systemic lupus erythematosus	J:57246
Sles3^C57BL/6/Sles3^NZW (involves: C57BL/6 * NZW)	increased susceptibility to systemic lupus erythematosus	J:57246
Sles3^NZW/Sles3^NZW (involves: C57BL/6 * NZW)	decreased susceptibility to systemic lupus erythematosus	J:57246
Sles4^C57BL/6/Sles4^C57BL/6 (involves: C57BL/6 * NZW)	increased susceptibility to systemic lupus erythematosus	J:57246
Sles4^C57BL/6/Sles4^NZW (involves: C57BL/6 * NZW)	increased susceptibility to systemic lupus erythematosus	J:57246
Sles4^NZW/Sles4^NZW (involves: C57BL/6 * NZW)	decreased susceptibility to systemic lupus erythematosus	J:57246
Slfn1^tm1Aki/Slfn1^tm1Aki (Not Specified)	immune system phenotype	J:158985, J:258797
Slfn2^m1Btlr/Slfn2^m1Btlr (C57BL/6J-Slfn2^m1Btlr)	abnormal leukocyte physiology	J:158985
	abnormal T cell activation	J:158985
	abnormal T cell proliferation	J:158985
	decreased CD4-positive, alpha-beta T cell number	J:158985
	decreased CD8-positive, alpha-beta T cell number	J:158985
	decreased monocyte cell number	J:158985
	decreased T cell proliferation	J:158985
	increased neutrophil cell number	J:158985
	increased susceptibility to bacterial infection	J:158985
	increased susceptibility to bacterial infection induced morbidity/mortality	J:158985
	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:158985
	increased susceptibility to Riboviria infection	J:158985
	increased T cell apoptosis	J:158985
Slfn2^m2Btlr/Slfn2^m2Btlr (C57BL/6J-Slfn2^m2Btlr)	decreased IgG level	J:234262
	decreased response to antigen	J:234262
	impaired humoral immune response	J:234262
Slfn3^tm1Aki/Slfn3^tm1Aki (Not Specified)	immune system phenotype	J:158985, J:258797
Slfn4^{tm1c(EUCOMM)Wtsi}/Slfn4^{tm1c(EUCOMM)Wtsi} Gli1^{tm3(cre/ERT2)Alj}/Gli1⁺ (involves: 129S6/SvEvTac * Black Swiss * C57BL/6 * Swiss Webster)	abnormal CD8-positive, alpha-beta cytotoxic T cell morphology	J:337060
	abnormal interleukin level	J:337060
	abnormal tumor necrosis factor level	J:337060
	decreased susceptibility to bacterial infection	J:337060
Slfn5^tm1Aki/Slfn5^tm1Aki (Not Specified)	immune system phenotype	J:258797
Slfn8^tm1Aki/Slfn8^tm1Aki (involves: 129X1/SvJ * C57BL/6)	decreased interferon-gamma secretion	J:258797
	decreased interleukin-1 beta secretion	J:258797
	decreased interleukin-6 secretion	J:258797
	decreased interleukin-17 secretion	J:258797
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:258797
	immune system phenotype	J:258797
Slfn9^em1Liudp/Slfn9^em1Liudp (C57BL/6-Slfn9^em1Liudp)	abnormal innate immunity	J:351319
Slfn9^em1Liudp/Slfn9^em1Liudp (C57BL/6-Slfn9^em1Liudp)	abnormal macrophage activation involved in immune response	J:351319
Slfn14^em1Nvm/Slfn14⁺ (C57BL/6J-Slfn14^em1Nvm)	enlarged spleen	J:325381
Slfn14^em1Nvm/Slfn14⁺ (C57BL/6J-Slfn14^em1Nvm)	increased spleen weight	J:325381
Slitrk5^em1(IMPC)Mbp/Slitrk5^em1(IMPC)Mbp (C57BL/6N-Slitrk5^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
Slpd1^NZB/BlNJ/Slpd1^NZB/BlNJ (involves: DBA/2J * NZB/BlNJ)	increased B cell proliferation	J:124364
Slpi^tm1Ktak/Slpi^tm1Ktak (B6.129P2-Slpi^tm1Ktak)	increased susceptibility to bacterial infection	J:132933
Slpi^tm1Nkw/Slpi^tm1Nkw (involves: 129P2/OlaHsd * C57BL/6)	abnormal macrophage physiology	J:82214
	increased B cell proliferation	J:82214
	increased interleukin-6 secretion	J:82214
	increased susceptibility to endotoxin shock	J:82214
Slu7^{tm1a(KOMP)Wtsi}/Slu7⁺ (C57BL/6N-Slu7^{tm1a(KOMP)Wtsi}/Wtsi)	decreased leukocyte cell number	J:211773
Slurp2^tm1Lex/Slurp2^tm1Lex (involves: 129P2/OlaHsd * 129S5/SvEvBrd * C57BL/6)	immune system phenotype	J:231067
Slx4^{tm1a(EUCOMM)Wtsi}/Slx4^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Slx4^{tm1a(EUCOMM)Wtsi})	abnormal lymphopoiesis	J:168567
	decreased leukocyte cell number	J:168567
Smad2^tm3Rob/Smad2^tm3Rob Smad3^tm1Xfw/Smad3^tm1Xfw (involves: 129/Sv * 129S/SvEv * C57BL/6 * ICR)	osteoarthritis	J:95374
Smad3^em1(IMPC)H/Smad3⁺ (C57BL/6NTac-Smad3^em1(IMPC)H/H)	decreased lymphocyte cell number	J:211773
Smad3^tm1Cxd/Smad3^tm1Cxd (either: (involves: 129S6/SvEvTac * C57BL/6) or (involves: 129S6/SvEvTac * NIH Black Swiss))	abnormal immune system morphology	J:53510
	abnormal T cell activation	J:53510
	abnormal T cell physiology	J:53510
	abnormal thymus involution	J:53510
	colitis	J:53510
	enlarged lymph nodes	J:53510
	enlarged mesenteric lymph nodes	J:53510
	impaired neutrophil chemotaxis	J:53510
	increased inflammatory response	J:53510
	increased leukocyte cell number	J:53510
	increased monocyte cell number	J:53510
	increased neutrophil cell number	J:53510
	pancreas inflammation	J:53510
	small intestinal inflammation	J:53510
	small spleen	J:53510
	spleen hypoplasia	J:53510
	stomach inflammation	J:53510
	thymus hypoplasia	J:53510
Smad3^tm1Cxd/Smad3^tm1Cxd (B6.129S6-Smad3^tm1Cxd)	tubulointerstitial nephritis	J:102084
Smad3^tm1Cxd/Smad3^tm1Cxd (involves: 129S6/SvEvTac)	abnormal leukocyte physiology	J:59673
	decreased B cell apoptosis	J:140567
	osteoarthritis	J:68792
Smad3^tm1Cxd/Smad3^tm1Cxd (involves: 129S6/SvEvTac * C57BL/6)	abnormal CD4-positive T cell differentiation	J:136955
Smad3^tm1Par/Smad3^tm1Par (129-Smad3^tm1Par/J)	abnormal circulating interleukin-6 level	J:175290
	abnormal cytokine secretion	J:175290
	decreased interleukin-6 secretion	J:175290
	increased inflammatory response	J:106572
Smad3^tm1Xfw/Smad3^tm1Xfw (involves: 129/Sv * C57BL/6)	abnormal B cell proliferation	J:53948
	abnormal cytokine secretion	J:53948
	abnormal T cell proliferation	J:53948
	immune system phenotype	J:53948
Smad4^tm1.1Gsu/Smad4^tm1.1Gsu Ptf1a^{tm1.1(cre)Cvw}/Ptf1a⁺ Tg(MtTGFA)Lmb/0 (involves: 129S1/Sv * 129X1/SvJ * CD-1)	chronic pancreas inflammation	J:229184
Smad4^tm2.1Cxd/Smad4^tm2.1Cxd Tg(Foxn1-cre)8Ghr/0 (B6.Cg-Smad4^tm2.1Cxd Tg(Foxn1-cre)8Ghr)	abnormal thymus physiology	J:138837
	small thymus	J:138837
Smad4^tm2.1Cxd/Smad4^tm2.1Cxd Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0 (involves: 129S6/SvEvTac * C57BL/6J * CD-1)	decreased osteoclast cell number	J:211171
Smad7^{Gt(YHC053)Byg}/Smad7^{Gt(YHC053)Byg} (involves: 129P2/OlaHsd * C57BL/6J)	abnormal thymus morphology	J:212881
	thymus hypoplasia	J:212881
Smad7^tm1.1Ink/Smad7^tm1.1Ink Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	abnormal T-helper 1 cell differentiation	J:184670
	decreased activated T cell number	J:184670
	decreased interferon-gamma secretion	J:184670
	decreased interleukin-9 secretion	J:184670
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:184670
	decreased T cell proliferation	J:184670
	immune system phenotype	J:184670
Smad7^tm1Rheu/Smad7^tm1Rheu (involves: 129S1/Sv * 129X1/SvJ * CD-1)	abnormal class switch recombination	J:120714
	decreased B cell proliferation	J:120714
	increased B cell apoptosis	J:120714
Smad9^tm3Jfm/Smad9^tm3Jfm (involves: 129S4/SvJaeSor)	lung inflammation	J:150213
Smap1^tm1.1Sata/Smap1^tm1.1Sata (B6.Cg-Smap1^tm1.1Sata)	abnormal myelopoiesis	J:196385
	abnormal neutrophil morphology	J:196385
	enlarged spleen	J:196385
	increased neutrophil cell number	J:196385
Smarca4^tm1.2Pcn/Smarca4^tm1.2Pcn Tg(Lck-cre)1Cwi/0 (Not Specified)	abnormal T cell morphology	J:144072
	decreased double-negative T cell number	J:144072
Smarca4^tm1.2Pcn/Smarca4^tm1.2Pcn Tg(Lck-cre)1Cwi/0 Tg(LCKprBCL2L1)12Sjk/0 (Not Specified)	abnormal T cell morphology	J:144072
	decreased double-positive T cell number	J:144072
	increased double-negative T cell number	J:144072
	increased thymocyte number	J:144072
Smarca4^tm1.2Pcn/Smarca4^tm1Mag Tg(Lck-cre)1Cwi/? (involves: 129S/Sv * C57BL/6 * DBA/2)	abnormal T cell differentiation	J:85191
	absent CD8-positive, alpha-beta T cells	J:85191
	arrested T cell differentiation	J:85191
	decreased CD4-positive, alpha-beta T cell number	J:85191
	decreased double-negative T cell number	J:85191
	decreased double-positive T cell number	J:85191
	thymus hypoplasia	J:85191
Smarca4^tm1.2Pcn/Smarca4^tm1Mag Tg(Lck-cre)1Cwi/? Tg(LCKprBCL2)36Sjk/? (involves: 129S/Sv * C57BL/6 * DBA/2)	arrested T cell differentiation	J:85191
Smarca4^tm1.2Pcn/Smarca4^tm1Tich Tg(Lck-cre)1Cwi/0 (involves: 129)	abnormal T cell morphology	J:144072
	decreased double-negative T cell number	J:144072
	decreased thymocyte number	J:144072
Smarca4^tm1.2Pcn/Smarca4^tm1Tich Tg(Lck-cre)1Cwi/0 Tg(LCKprBCL2L1)12Sjk/0 (involves: 129)	abnormal T cell morphology	J:144072
	decreased double-positive T cell number	J:144072
	increased double-negative T cell number	J:144072
	increased thymocyte number	J:144072
Smarca4^tm1Tich/Smarca4⁺ (involves: 129)	immune system phenotype	J:144072
Smarca4^tm1Tich/Smarca4⁺ Tg(Lck-cre)1Cwi/0 (involves: 129)	decreased double-negative T cell number	J:144072
	decreased double-positive T cell number	J:144072
	decreased single-positive T cell number	J:144072
	decreased thymocyte number	J:144072
Smarcad1^tm1Gos/Smarcad1^tm1Gos (129S2/SvPas-Smarcad1^tm1Gos)	immune system phenotype	J:56661
Smarcal1^tm1.1Cfbo/Smarcal1^tm1.1Cfbo (either: B6.129-Smarcal1^tm1.1Cfbo or (involves: 129 * C57BL/6))	decreased B cell number	J:183899
Smarcb1^{tm1b(EUCOMM)Hmgu}/Smarcb1⁺ (C57BL/6N-Smarcb1^{tm1b(EUCOMM)Hmgu}/Bay)	decreased leukocyte cell number	J:211773
Smarcb1^tm1Sho/Smarcb1^tm3Sho Tg(Mx1-cre)1Cgn/? (involves: 129S1/Sv * 129S6/SvEvTac * C57BL/6 * CBA)	abnormal lymph node morphology	J:80224
	abnormal spleen morphology	J:80224
	enlarged lymph nodes	J:80224
	enlarged spleen	J:80224
	increased eosinophil cell number	J:80224
	increased T cell derived lymphoma incidence	J:80224
Smarcc1^tm2.1Rhs/Smarcc1^tm2.1Rhs Tg(Mx1-cre)1Cgn/0 (involves: BALB/c * C57BL/6 * CBA)	abnormal immature B cell morphology	J:184060
	abnormal immunoglobulin heavy chain V(D)J recombination	J:184060
	abnormal pre-B cell morphology	J:184060
	abnormal pro-B cell morphology	J:184060
	arrested B cell differentiation	J:184060
	decreased B cell number	J:184060
	decreased B cell proliferation	J:184060
	decreased early pro-B cell number	J:184060
	decreased follicular B cell number	J:184060
	decreased late pro-B cell number	J:184060
	decreased pro-B cell number	J:184060
	increased B cell apoptosis	J:184060
Smarce1^tm1Tich/Smarce1^tm2.1Tich Gt(ROSA)26Sor^{tm3(CAG-flpo/ERT2)Alj}/Gt(ROSA)26Sor⁺ Tg(Cd4-cre)1Cwi/0 (involves: 129S6/SvEvTac * C57BL/6 * DBA/2)	immune system phenotype	J:194195
Smc3^{tm1a(EUCOMM)Wtsi}/Smc3⁺ (involves: C57BL/6N)	increased T cell number	J:200082
Smc5^{tm1b(KOMP)Wtsi}/Smc5⁺ (C57BL/6N-Smc5^{tm1b(KOMP)Wtsi}/Ics)	decreased lymphocyte cell number	J:211773
	increased eosinophil cell number	J:211773
	increased neutrophil cell number	J:211773
Smc6^tm1.1Arln/Smc6^tm1.1Arln (involves: 129P2/OlaHsd * C57BL/6 * FVB)	decreased IgG2b level	J:220422
	increased leukocyte cell number	J:220422
Smcr8^em1Btlr/Smcr8^em1Btlr (C57BL/6J-Smcr8^em1Btlr)	enlarged lymph nodes	J:268243
	enlarged spleen	J:268243
	increased CD4-positive, alpha-beta T cell number	J:268243
	increased CD8-positive, alpha-beta T cell number	J:268243
	increased circulating interleukin-12b level	J:268243
	increased interleukin-6 secretion	J:268243
	increased susceptibility to induced colitis	J:268243
	increased tumor necrosis factor secretion	J:268243
Smcr8^em1Btlr/Smcr8^em1Btlr Tlr3^tm1Flv/Tlr3^tm1Flv Tlr7^tm1Aki/Tlr7^tm1Aki Tlr9^tm1Aki/Tlr9^tm1Aki (involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6J)	immune system phenotype	J:268243
Smcr8^em2Btlr/Smcr8^em2Btlr (C57BL/6J-Smcr8^em2Btlr)	enlarged lymph nodes	J:268243
	enlarged spleen	J:268243
	increased CD4-positive, alpha-beta T cell number	J:268243
	increased CD8-positive, alpha-beta T cell number	J:268243
	increased circulating interleukin-12b level	J:268243
	increased interleukin-6 secretion	J:268243
	increased susceptibility to induced colitis	J:268243
	increased tumor necrosis factor secretion	J:268243
Smcr8^m1Btlr/Smcr8⁺ (C57BL/6J-Smcr8^m1Btlr)	increased susceptibility to induced colitis	J:268243
Smcr8^m1Btlr/Smcr8^m1Btlr (C57BL/6J-Smcr8^m1Btlr)	increased susceptibility to induced colitis	J:268243
Smcr8^m1Btlr/Smcr8^m1Btlr (C57BL/6J-Smcr8^m1Btlr)	increased tumor necrosis factor secretion	J:268243
Smcr8^m2Btlr/Smcr8^m2Btlr (C57BL/6J-Smcr8^m2Btlr)	increased susceptibility to induced colitis	J:268243
Smcr8^m2Btlr/Smcr8^m2Btlr (C57BL/6J-Smcr8^m2Btlr)	increased tumor necrosis factor secretion	J:268243
Smcr8^m3Btlr/Smcr8^m3Btlr (C57BL/6J-Smcr8^m3Btlr)	increased susceptibility to induced colitis	J:268243
Smcr8^m3Btlr/Smcr8^m3Btlr (C57BL/6J-Smcr8^m3Btlr)	increased tumor necrosis factor secretion	J:268243
Smg1^{Gt(AG0297)Wtsi}/Smg1⁺ (involves: 129P2/OlaHsd * C57BL/6)	chronic inflammation	J:193626
	decreased circulating interleukin-1 beta level	J:193626
	enlarged spleen	J:193626
	increased circulating interleukin-6 level	J:193626
Smg6^em1(IMPC)Mbp/Smg6⁺ (C57BL/6NCrl-Smg6^em1(IMPC)Mbp/Mmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Smg9^{tm1b(EUCOMM)Wtsi}/Smg9^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Smg9^{tm1b(EUCOMM)Wtsi}/Wtsi)	absent connection between subcutaneous lymph vessels and lymph sac	J:239583
	blood in lymph vessels	J:239583
Smim3^tm1Anjm/Smim3⁺ Cd74^tm1Anjm/Cd74⁺ Lmo2^tm2(cre)Thr/Lmo2⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal mast cell morphology	J:155870
	decreased granulocyte number	J:155870
	decreased monocyte cell number	J:155870
Smim20^em1(IMPC)J/Smim20⁺ (C57BL/6NJ-Smim20^em1(IMPC)J/Mmjax)	immune system phenotype	J:350521
Smim20^em1(IMPC)J/Smim20^em1(IMPC)J (C57BL/6NJ-Smim20^em1(IMPC)J/Mmjax)	immune system phenotype	J:350521
Smim23^em1(IMPC)Mbp/Smim23^em1(IMPC)Mbp (C57BL/6N-Smim23^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
Smoc1^{tm1b(EUCOMM)Wtsi}/Smoc1⁺ (C57BL/6N-Smoc1^{tm1b(EUCOMM)Wtsi}/H)	decreased lymphocyte cell number	J:211773
	increased basophil cell number	J:211773
	increased large unstained cell number	J:211773
	increased neutrophil cell number	J:211773
Smoc1^{tm1b(EUCOMM)Wtsi}/Smoc1^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Smoc1^{tm1b(EUCOMM)Wtsi}/H)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Smpd1^tm1Esc/Smpd1⁺ (involves: 129S1/Sv * C57BL/6J)	abnormal immune system cell morphology	J:70489
Smpd1^tm1Esc/Smpd1^tm1Esc (involves: 129S1/Sv * C57BL/6J)	abnormal granulocyte physiology	J:81982
	immune system phenotype	J:44401
	increased macrophage derived foam cell number	J:81982
	increased susceptibility to bacterial infection	J:81982
Smpd1^tm1Wst/Smpd1^tm1Wst (involves: 129P2/OlaHsd * C57BL/6)	enlarged spleen	J:26748
	hepatosplenomegaly	J:26748
	increased macrophage derived foam cell number	J:26748
Smpdl3b^{tm1a(EUCOMM)Wtsi}/Smpdl3b^{tm1a(EUCOMM)Wtsi} (C57BL/6-Smpdl3b^{tm1a(EUCOMM)Wtsi})	abnormal chemokine secretion	J:224870
	abnormal circulating chemokine level	J:224870
	abnormal macrophage morphology	J:224870
	increased circulating interleukin-6 level	J:224870
	increased circulating interleukin-12b level	J:224870
	increased circulating tumor necrosis factor level	J:224870
	increased neutrophil cell number	J:224870
	increased susceptibility to endotoxin shock	J:224870
Sms^{tm1a(EUCOMM)Wtsi}/Y (involves: C57BL/6 * C57BL/6N)	increased NK cell number	J:213427
Sms^{tm1a(EUCOMM)Wtsi}/Y (involves: C57BL/6 * C57BL/6N)	increased NK T cell number	J:213427
Smtn^tm1Gve/Smtn^tm1Gve (involves: 129/Sv * C57BL/6)	intestinal inflammation	J:104648
Smtn^tm1Gve/Smtn^tm1Gve (involves: 129/Sv * C57BL/6)	sepsis	J:104648
Smurf2^{Gt(RRA098)Byg}/Smurf2^{Gt(RRA098)Byg} (involves: 129P2/OlaHsd * C57BL/6)	enlarged spleen	J:189320
Smyd5^{tm1a(EUCOMM)Wtsi}/Smyd5^{tm1a(EUCOMM)Wtsi} Tg(Vil1-cre)997Gum/0 (B6.Cg-Smyd5^{tm1a(EUCOMM)Wtsi} Tg(Vil1-cre)997Gum)	decreased susceptibility to induced colitis	J:339411
Snai2^tm1Look/Snai2^tm1Look (involves: 129X1/SvJ * C57BL/6)	blepharitis	J:80652
Snai2^tm1Look/Snai2^tm1Look (involves: 129X1/SvJ * C57BL/6)	immune system phenotype	J:80652
Snai2^tm2Grid/Snai2⁺ Snai3^tm1.2Jhws/Snai3^tm1.2Jhws (involves: 129/Sv * 129S1/Sv * C57BL/6)	abnormal thymus cortex morphology	J:204710
	abnormal thymus medulla morphology	J:204710
	decreased B cell number	J:204710
	disorganized spleen B cell follicle	J:204710
Snai2^tm2Grid/Snai2^tm2Grid (involves: 129S1/Sv)	abnormal T cell differentiation	J:78323
	blepharitis	J:48521
	conjunctivitis	J:48521
	decreased leukocyte cell number	J:78323
	small thymus	J:78323
Snai2^tm2Grid/Snai2^tm2Grid Snai3^tm1.2Jhws/Snai3⁺ (involves: 129/Sv * 129S1/Sv * C57BL/6)	abnormal thymus cortex morphology	J:204710
	abnormal thymus medulla morphology	J:204710
	decreased B cell number	J:204710
	disorganized spleen B cell follicle	J:204710
	increased macrophage cell number	J:204710
	increased neutrophil cell number	J:204710
Snai2^tm2Grid/Snai2^tm2Grid Snai3^tm1.2Jhws/Snai3^tm1.2Jhws (involves: 129/Sv * 129S1/Sv * C57BL/6)	abnormal thymus cortex morphology	J:204710
	abnormal thymus involution	J:204710
	abnormal thymus medulla morphology	J:204710
	decreased B cell number	J:204710
	decreased double-positive T cell number	J:204710
	disorganized spleen B cell follicle	J:204710
	increased macrophage cell number	J:204710
	increased neutrophil cell number	J:204710
	increased single-positive T cell number	J:204710
	small spleen	J:204710
	small thymus	J:204710
	thymus fibrosis	J:204710
Snai3^tm1.1Jhws/Snai3^tm1.1Jhws Tg(Lck-cre)548Jxm/0 (involves: 129/Sv * C57BL/6 * CBA)	immune system phenotype	J:204710
Snca^em1(IMPC)H/Snca^em1(IMPC)H (C57BL/6NTac-Snca^em1(IMPC)H/H)	increased spleen weight	J:211773
Snca^tm1Rosl/Snca^tm1Rosl (involves: 129X1/SvJ)	decreased susceptibility to bacterial infection	J:138194
Snca^tm1Rosl/Snca^tm1Rosl Tg(Prnp-SNCA)7Vle/Tg(Prnp-SNCA)7Vle (involves: 129X1/SvJ * C3H * C57BL/6)	abnormal response to infection	J:138194
Snca^tm1Rosl/Snca^tm1Rosl Tg(Prnp-SNCAA53T)83Vle/Tg(Prnp-SNCAA53T)83Vle (involves: 129X1/SvJ * C3H * C57BL/6)	increased susceptibility to bacterial infection	J:138194
Snd1^em1(IMPC)Tcp/Snd1⁺ (C57BL/6NCrl-Snd1^em1(IMPC)Tcp/Tcp)	decreased lymphocyte cell number	J:211773
	decreased spleen weight	J:211773
	increased neutrophil cell number	J:211773
	small thymus	J:211773
Snd1^tm1.2Elws/Snd1^tm1.2Elws (involves: C57BL/6)	immune system phenotype	J:324590
Snhg15^tm1Nju/Snhg15^tm1Nju (involves: C57BL/6J)	immune system phenotype	J:291983
Snord50a/Snord50b^tm1.1Soen/Snord50a/Snord50b^tm1.1Soen (B6.129P2-Snord50a/Snord50b^tm1.1Soen)	enlarged lymph nodes	J:206419
	enlarged spleen	J:206419
Snord50a/Snord50b^tm1.1Soen/Snord50a/Snord50b^tm1.1Soen (B6.129P2-Snord50a/Snord50b^tm1.1Soen)	enlarged lymph nodes	J:206419
	enlarged spleen	J:206419
Snrk^tm1.1Hxu/Snrk^tm1.1Hxu Tg(Adipoq-cre)1Evdr/0 (B6.Cg-Snrk^tm1.1Hxu Tg(Adipoq-cre)1Evdr)	abnormal circulating chemokine level	J:257980
	brown adipose tissue inflammation	J:257980
	increased circulating interleukin-6 level	J:257980
	increased circulating tumor necrosis factor level	J:257980
	white adipose tissue inflammation	J:257980
Snrnp40^em1Btlr/Snrnp40^swp (C57BL/6J-Snrnp40^em1Btlr/Snrnp40^swp)	abnormal CD4-positive, alpha-beta T cell physiology	J:282417
	abnormal CD8-positive, alpha-beta T cell physiology	J:282417
	abnormal thymus development	J:282417
	decreased B cell number	J:282417
	decreased CD4-positive, alpha-beta T cell number	J:282417
	decreased CD8-positive, alpha-beta T cell number	J:282417
	decreased DN1 thymic pro-T cell number	J:282417
	decreased DN4 thymocyte number	J:282417
	decreased lymphocyte cell number	J:282417
	decreased monocyte cell number	J:282417
	decreased NK cell number	J:282417
	decreased T cell number	J:282417
	decreased T cell proliferation	J:282417
	immune system phenotype	J:282417
	impaired natural killer cell mediated cytotoxicity	J:282417
	increased central memory CD8 positive, alpha-beta T cell number	J:282417
	increased circulating interferon-beta level	J:282417
	increased circulating interferon-gamma level	J:282417
	increased circulating interleukin-6 level	J:282417
	increased circulating interleukin-12 level	J:282417
	increased circulating interleukin-17 level	J:282417
	increased circulating tumor necrosis factor level	J:282417
	increased effector memory CD8-positive, alpha-beta T cell number	J:282417
	increased susceptibility to viral infection	J:282417
	increased susceptibility to viral infection induced morbidity/mortality	J:282417
	small thymus	J:282417
	thymus hypoplasia	J:282417
Snx8^tm1Hbsh/Snx8^tm1Hbsh (Not Specified)	abnormal chemokine secretion	J:254306
	abnormal circulating chemokine level	J:254306
	abnormal dendritic cell physiology	J:254306
	abnormal macrophage physiology	J:254306
	decreased circulating CXCL10 level	J:254306
	decreased circulating tumor necrosis factor level	J:254306
	decreased CXCL10 secretion	J:254306
	decreased macrophage cytokine production	J:254306
	immune system phenotype	J:254306
	increased susceptibility to bacterial infection	J:254306
	increased susceptibility to bacterial infection induced morbidity/mortality	J:254306
Snx8^{tm2a(EUCOMM)Hmgu}/Snx8^{tm2a(EUCOMM)Hmgu} (C57BL/6N-Snx8^{tm2a(EUCOMM)Hmgu}/Wtsi)	increased leukocyte cell number	J:211773
Snx10^em1Ael/Snx10^em1Ael (involves: 129 * C57BL/6J * C57BL/6JOlaHsd)	abnormal osteoclast morphology	J:289051
	abnormal osteoclast physiology	J:289051
	decreased osteoclast cell number	J:289051
	osteomyelitis	J:289051
Snx10^em2Ael/Snx10^em2Ael (involves: 129 * C57BL/6J * C57BL/6JOlaHsd)	abnormal osteoclast morphology	J:289051
	abnormal osteoclast physiology	J:289051
	decreased osteoclast cell number	J:289051
	osteomyelitis	J:289051
Snx10^{tm1a(EUCOMM)Raba}/Snx10^{tm1a(EUCOMM)Raba} (involves: 129S4/SvJae * C57BL/6 * C57BL/6J)	abnormal osteoclast physiology	J:224711
Snx13^{tm1b(EUCOMM)Hmgu}/Snx13⁺ (C57BL/6N-Snx13^{tm1b(EUCOMM)Hmgu}/Ieg)	increased leukocyte cell number	J:211773
Snx15^{tm1.1(KOMP)Vlcg}/Snx15^{tm1.1(KOMP)Vlcg} (C57BL/6N-Snx15^{tm1.1(KOMP)Vlcg}/J)	decreased leukocyte cell number	J:211773
Snx20^tm1Lex/Snx20^tm1Lex Tg(Prm-cre)58Og/0 (involves: 129S/SvEvBrd * 129S4/SvJae)	immune system phenotype	J:131282
Snx27^tm1Lslo/Snx27^tm1Lslo (involves: 129P2/OlaHsd)	small spleen	J:171001
Soat1^ald/Soat1^ald (AKR/O)	thymus hyperplasia	J:12157
Soat1^m1Anu/Soat1^m1Anu (C57BL/6NCrl-Soat1^m1Anu/Anu)	immune system phenotype	J:104190
Soat1^tm1Far/Soat1^tm1Far (involves: 129S4/SvJae * C57BL/6)	abnormal macrophage morphology	J:37049
Socs1^tm1.1Ayr/Socs1^tm1.1Ayr (involves: C57BL/6)	abnormal T cell physiology	J:226678
	decreased effector memory T-helper cell number	J:226678
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:226678
Socs1^tm1Ayos/Socs1^tm1Ayos Foxp3^{tm4(YFP/icre)Ayr}/Foxp3⁺ (involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)	blepharitis	J:167922
	conjunctivitis	J:167922
	dermatitis	J:167922
	increased regulatory T cell number	J:167922
Socs1^tm1Ayos/Socs1^tm1Ayos Tg(Lck-cre)1Jtak/0 (involves: 129S4/SvJae * C57BL/6)	abnormal CD4-positive T cell differentiation	J:132905
	abnormal CD4-positive, alpha-beta T cell physiology	J:132905
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:132905
Socs1^tm1Ayos/Socs1^tm1Ayos Tg(Tek-cre)1Ywa/0 (involves: 129S4/SvJae * C57BL/6 * SJL)	decreased CD4-positive, alpha-beta T cell number	J:132905
	increased CD8-positive, alpha-beta T cell number	J:132905
Socs1^tm1Jni/Socs1⁺ (Not Specified)	abnormal cytokine level	J:91651
Socs1^tm1Jni/Socs1⁺ (Not Specified)	abnormal interleukin level	J:91651
Socs1^tm1Jni/Socs1^tm1Jni (Not Specified)	abnormal cytokine secretion	J:57475
	abnormal T cell differentiation	J:57475
	decreased B cell number	J:57475
	decreased thymocyte number	J:57475
Socs1^tm1Kish/Socs1^tm1Kish (involves: 129P2/OlaHsd * C57BL/6J)	abnormal spleen morphology	J:51685
	abnormal spleen white pulp morphology	J:51685
	absent thymus corticomedullary boundary	J:51685
	decreased lymphocyte cell number	J:51685
Socs1^tm1Kish/Socs1^tm1Kish (B6.129P2-Socs1^tm1Kish)	abnormal lymphocyte physiology	J:69472
	increased activated T cell number	J:69472
	increased NK T cell number	J:69472
	liver inflammation	J:69472
	thymus atrophy	J:69472
Socs1^tm1Kish/Socs1^tm1Kish Stat1^tm1Rds/Stat1^tm1Rds (involves: 129/Sv * 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:69472
	increased activated T cell number	J:69472
	liver inflammation	J:69472
	thymus atrophy	J:69472
Socs1^tm1Kish/Socs1^tm1Kish Stat6^tm1Aki/Stat6^tm1Aki (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:69472
	increased activated T cell number	J:69472
	liver inflammation	J:69472
	thymus atrophy	J:69472
Socs1^tm1Wehi/Socs1^tm1Wehi (involves: 129S1/Sv * C57BL/6)	abnormal follicular B cell morphology	J:51281
	abnormal inflammatory response	J:57474
	abnormal lymph node B cell domain morphology	J:51281
	abnormal macrophage physiology	J:57474
	abnormal mature B cell morphology	J:51281
	abnormal Peyer's patch morphology	J:51281
	abnormal spleen white pulp morphology	J:57474
	decreased B cell number	J:51281
	decreased eosinophil cell number	J:51281
	decreased leukocyte cell number	J:57474
	decreased lymphocyte cell number	J:51281
	decreased pre-B cell number	J:51281
	decreased susceptibility to Togaviridae infection induced morbidity/mortality	J:57474
	heart inflammation	J:51281
	increased inflammatory response	J:72528
	increased spleen red pulp amount	J:51281
	liver inflammation	J:51281
	pancreas inflammation	J:51281
	small thymus	J:51281
	thymus cortex atrophy	J:57474, J:51281
Socs1^tm1Wehi/Socs1^tm3Wehi Tg(Lck-cre)I57Jxm/0 (involves: 129P2/OlaHsd * C57BL/6 * ICR)	abnormal CD4-positive, alpha beta T cell morphology	J:83009
	abnormal CD8-positive, alpha beta T cell morphology	J:83009
	abnormal T cell activation	J:83009
	abnormal T cell differentiation	J:83009
	abnormal T cell subpopulation ratio	J:83009
	decreased B cell number	J:83009
	enlarged lymph nodes	J:83009
	enlarged thymus medulla	J:83009
	increased CD4-positive, alpha-beta T cell number	J:83009
	increased CD8-positive, alpha-beta T cell number	J:83009
	lymph node hyperplasia	J:83009
	thymus hyperplasia	J:83009
Socs1^tm2Wehi/Socs1^tm2Wehi (C57BL/6-Socs1^tm2Wehi)	absent spleen germinal center	J:72528
	glomerulonephritis	J:72528
	increased incidence of corneal inflammation	J:72528
	increased inflammatory response	J:72528
	intestinal inflammation	J:72528
	liver inflammation	J:72528
	myocarditis	J:72528
	myositis	J:72528
	pancreas inflammation	J:72528
	salivary gland inflammation	J:72528
	skin inflammation	J:72528
	thymus atrophy	J:72528
Socs1^tm3.1Wehi/Socs1^tm3.1Wehi (C57BL/6-Socs1^tm3.1Wehi)	abnormal inflammatory response	J:83009
Socs1^tm3.1Wehi/Socs1^tm3.1Wehi (C57BL/6-Socs1^tm3.1Wehi)	increased circulating interferon-gamma level	J:83009
Socs2^tm1Wehi/Socs2^tm1Wehi (involves: C57BL/6 * C57BL/6J)	abnormal circulating cytokine level	J:186227
	abnormal macrophage physiology	J:186227
	increased circulating interferon-gamma level	J:186227
	increased circulating interleukin-1 beta level	J:186227
	increased interferon-gamma secretion	J:186227
	increased interleukin-1 beta secretion	J:186227
	increased tumor necrosis factor secretion	J:186227
	liver inflammation	J:186227
Socs3^tm1Ayos/Socs3^tm1Ayos Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129 * C57BL/6)	decreased susceptibility to endotoxin shock	J:92040
Socs3^tm1Jni/Socs3⁺ (involves: 129P2/OlaHsd)	increased interleukin-2 secretion	J:128797
Socs3^tm1Robb/Socs3^tm1Robb (involves: C57BL/6)	enlarged spleen	J:145513
	increased neutrophil cell number	J:145513
	increased susceptibility to induced arthritis	J:145513
Socs3^tm1Wsa/Socs3^tm2Wsa Lyz2^tm1(cre)Ifo/? (involves: 129P2/OlaHsd * C57BL/6)	abnormal macrophage physiology	J:83645
Socs3^tm1Wsa/Socs3^tm2Wsa Tg(Vav1-cre)1Awr/0 (involves: C57BL/6)	abnormal granulocyte differentiation	J:89785
	abnormal myelopoiesis	J:89785
	enlarged spleen	J:89785
	increased inflammatory response	J:89785
	increased neutrophil cell number	J:89785
	liver inflammation	J:89785
	lung inflammation	J:89785
	peritoneal inflammation	J:89785
Socs4^m1Nch/Socs4^m1Nch (C.C3Fe-Socs4^m1Nch)	abnormal chemokine secretion	J:241977
	abnormal T cell activation	J:241977
	decreased T cell number	J:241977
	immune system phenotype	J:241977
	increased interferon-gamma secretion	J:241977
	increased interleukin-1 secretion	J:241977
	increased interleukin-4 secretion	J:241977
	increased interleukin-5 secretion	J:241977
	increased interleukin-6 secretion	J:241977
	increased interleukin-12b secretion	J:241977
	increased interleukin-13 secretion	J:241977
	increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:241977
	increased T cell number	J:241977
Socs4^m1Nch/Socs4^m1Nch (C3H/He-Socs4^m1Nch)	immune system phenotype	J:241977
Socs4^m1Nch/Socs4^m1Nch (C3H/He-Socs4^m1Nch)	increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:241977
Socs4^m1Nch/Socs4^m1Nch (C6.C3Fe-Socs4^m1Nch)	immune system phenotype	J:241977
Socs4^m1Nch/Socs4^m1Nch (C6.C3Fe-Socs4^m1Nch)	increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:241977
Socs6^tm1Dlk/Socs6^tm1Dlk (involves: C57BL/6)	immune system phenotype	J:77039
Sod1^m1H/Sod1^m1H (involves: C3H/HeH * C57BL/6J)	liver inflammation	J:219360
Sod1^m1H/Sod1^m1H (involves: C3H/HeH * C57BL/6J)	microgliosis	J:219360
Sod1^tm1Leb/Sod1^tm1Leb (involves: 129S7/SvEvBrd * C57BL/6)	blepharitis	J:219024
	increased circulating interleukin-6 level	J:219024
	increased circulating tumor necrosis factor level	J:219024
	increased interleukin-6 secretion	J:219024
	increased tumor necrosis factor secretion	J:219024
	Meibomian gland inflammation	J:219024
Sod2^tm1Leb/Sod2^tm1Leb (B6.129S7-Sod2^tm1Leb/J)	impaired myelopoiesis	J:36148
Sod3^tm1Mrkl/Sod3^tm1Mrkl (D1.129P2-Sod3^tm1Mrkl)	autoimmune arthritis	J:106273
	increased susceptibility to induced arthritis	J:106273
	increased synovial pannus formation	J:106273
	increased tumor necrosis factor secretion	J:106273
Sod3^tm1Svp/Sod3^tm1Svp (involves: 129S6/SvEvTac * C57BL/6NTac)	decreased susceptibility to endotoxin shock	J:285340
Son^em1.1Bcgen/Son⁺ (B6(Cg)-Son^em1.1Bcgen)	abnormal B cell differentiation	J:347709
	abnormal naive B cell morphology	J:347709
	abnormal transitional stage B cell morphology	J:347709
	decreased follicular B cell number	J:347709
	decreased IgA level	J:347709
	decreased IgM level	J:347709
	decreased leukocyte cell number	J:347709
	decreased lymphocyte cell number	J:347709
	decreased monocyte cell number	J:347709
	decreased neutrophil cell number	J:347709
	decreased transitional stage T2 B cell number	J:347709
	increased marginal zone B cell number	J:347709
	increased pre-B cell number	J:347709
	increased transitional stage T1 B cell number	J:347709
Sorbs1^tm1Krc/Sorbs1^tm1Krc (B6.129-Sorbs1^tm1Krc)	decreased leukocyte cell number	J:121762
	decreased lymphocyte cell number	J:121762
	decreased monocyte cell number	J:121762
Sord^{em1(IMPC)Ccpcz}/Sord^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Sord^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
Sort1^tm1Camo/Sort1^tm1Camo (B6.129X1-Sort1^tm1Camo)	abnormal tumor necrosis factor level	J:157549
Sos1^tm1.1Les/Sos1^tm1.1Les Tg(Lck-cre)1Cwi/0 (involves: 129 * C57BL/6)	decreased CD4-positive, alpha-beta T cell number	J:174536
	decreased CD8-positive, alpha-beta T cell number	J:174536
	decreased DN4 thymocyte number	J:174536
	decreased double-negative T cell number	J:174536
	decreased double-positive T cell number	J:174536
	decreased gamma-delta T cell number	J:174536
	decreased T cell proliferation	J:174536
	decreased thymocyte number	J:174536
Sos1^tm1.2Rak/Sos1⁺ (involves: 129S/Sv * C57BL/6 * FVB/N * SJL)	enlarged spleen	J:171873
	increased leukocyte cell number	J:171873
	increased neutrophil cell number	J:171873
	increased spleen red pulp amount	J:171873
Sostdc1^tm1Snd/Sostdc1^tm1Snd (involves: C57BL/6)	decreased osteoclast cell number	J:216098
Sox2^tm3(TK)Hoch/Sox2⁺ (involves: 129S4/SvJae * C57BL/6)	stomach inflammation	J:177655
Sox2^tm3(TK)Hoch/Sox2⁺ (involves: 129S4/SvJae * C57BL/6)	tongue inflammation	J:177655
Sox4^Igt4/Del(13)36H (involves: 101/H * C3H/HeH * C57BL/6)	thymus hypoplasia	J:141688
Sox4^tm1Cle/Sox4^tm1Cle (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell differentiation	J:32741
	absent pre-B cells	J:32741
	decreased pro-B cell number	J:32741
Sox4^tm2Cle/Sox4^tm2Cle (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell differentiation	J:32741
	absent pre-B cells	J:32741
	decreased pro-B cell number	J:32741
Sox9^{em1(cre/ERT2)Smoc}/Sox9⁺ Tnfsf18^em1Pwan/Tnfsf18^em1Pwan (involves: C57BL/6J)	abnormal T cell activation	J:346395
	decreased CD8-positive, alpha-beta T cell number	J:346395
	decreased inflammatory response	J:346395
Sox11^tm1.2Vlf/Sox11⁺ Sox4^tm1.1Vlf/Sox4⁺ (involves: 129 * C57BL/6 * FVB/N)	small spleen	J:175338
Sox11^tm1.2Vlf/Sox11⁺ Sox12^tm1.1Vlf/Sox12^tm1.1Vlf Sox4^tm1.1Vlf/Sox4⁺ (involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6)	small spleen	J:175338
Sox11^tm1.2Vlf/Sox11^tm1.2Vlf (involves: 129 * C57BL/6)	absent spleen	J:175338
Sox11^tm1Weg/Sox11^tm1Weg (involves: 129S1/Sv * 129X1/SvJ)	absent spleen	J:92251
Sox13^tm1Jskg/Sox13⁺ (involves: C57BL/6)	decreased gamma-delta T cell number	J:117301
Sox13^tm1Jskg/Sox13^tm1Jskg (involves: C57BL/6)	decreased gamma-delta T cell number	J:117301
Sox13^tm1Jskg/Sox13^tm1Jskg (involves: C57BL/6)	increased T cell proliferation	J:117301
Sox14^{em1(IMPC)Ccpcz}/Sox14⁺ (C57BL/6N-Sox14^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Sox14^{em1(IMPC)Ccpcz}/Sox14^{em1(IMPC)Ccpcz} (C57BL/6N-Sox14^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged thymus	J:211773
Sox17^tm1Sjm/Sox17^tm2Sjm Tg(Mx1-cre)1Cgn/0 (involves: 129/Sv * C3H * C57BL/6 * C57BL/Ka * CBA)	decreased leukocyte cell number	J:123050
	spleen hypoplasia	J:123050
	thymus hypoplasia	J:123050
Sox17^tm1Ysk/Sox17⁺ (involves: 129S1/Sv * C57BL/6)	liver inflammation	J:194071
Sox17^tm1Ysk/Sox17⁺ (B6.129S1-Sox17^tm1Ysk)	gallbladder inflammation	J:241569
Sox17^tm1Ysk/Sox17⁺ (B6.129S1-Sox17^tm1Ysk)	liver inflammation	J:194071
Sox17^tm2Sjm/Sox17⁺ Tg(Pdx1-cre)6Tuv/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)	liver inflammation	J:241569
Sox18^Ra-Op/Sox18^Ra-Op (B6D2-Sox18^Ra-Op/J)	abnormal lymphatic vessel morphology	J:143564
Sox18^tm1Koop/Sox18^tm1Koop (B6.129-Sox18^tm1Koop)	abnormal lymphatic vessel morphology	J:143564
Sox21^em1(IMPC)Mbp/Sox21^em1(IMPC)Mbp (C57BL/6NCrl-Sox21^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	decreased lymphocyte cell number	J:211773
	enlarged lymph nodes	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Sp3^tm1Sus/Sp3^tm1Sus (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell differentiation	J:84837
	decreased CD4-positive, alpha-beta T cell number	J:84837
	small thymus	J:84837
Sp4^tm1Sus/Sp4^tm1Sus (involves: 129P2/OlaHsd * C57BL/6)	spleen hypoplasia	J:77894
Sp4^tm1Sus/Sp4^tm1Sus (involves: 129P2/OlaHsd * C57BL/6)	thymus hypoplasia	J:77894
Sp7^{em1(IMPC)Ccpcz}/Sp7⁺ (C57BL/6NCrl-Sp7^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
Sp110^em1Vnce/Sp110^em1Vnce (C57BL/6J-Sp110^em1Vnce)	immune system phenotype	J:313901
Sp140^em1Vnce/Sp140^em1Vnce (C57BL/6J-Sp140^em1Vnce)	increased susceptibility to bacterial infection	J:313901
Sp140^em1Vnce/Sp140^em1Vnce (C57BL/6J-Sp140^em1Vnce)	increased susceptibility to bacterial infection induced morbidity/mortality	J:313901
Spag11a^em1(IMPC)Mbp/Spag11a^em1(IMPC)Mbp (C57BL/6NCrl-Spag11a^em1(IMPC)Mbp/Mmucd)	increased monocyte cell number	J:211773
Spag11a^em2Mgef/Spag11a⁺ (C57BL/6NJNcbs-Spag11a^em2Mgef)	epididymis inflammation	J:363226
Spag11a^em2Mgef/Spag11a^em2Mgef (C57BL/6NJNcbs-Spag11a^em2Mgef)	spermatic granuloma	J:363226
Sparc^tm1Hwe/Sparc^tm1Hwe (involves: 129S/SvEv * C57BL/6J)	abnormal osteoclast morphology	J:61480
	decreased osteoclast cell number	J:61480
	eye inflammation	J:52120
	vitreous body inflammation	J:52120
Spata2^{tm1(KOMP)Vlcg}/Spata2^{tm1(KOMP)Vlcg} (C57BL/6-Spata2^{tm1(KOMP)Vlcg})	increased inflammatory response	J:244164
Spata2^{tm1.1(KOMP)Vlcg}/Spata2^{tm1.1(KOMP)Vlcg} (C57BL/6N-Spata2^{tm1.1(KOMP)Vlcg}/Ucd)	decreased lymphocyte cell number	J:211773
	increased eosinophil cell number	J:211773
Spata24^{tm1b(EUCOMM)Wtsi}/Spata24^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Spata24^{tm1b(EUCOMM)Wtsi}/BayMmucd)	decreased neutrophil cell number	J:211773
Spata31f3^{em1(IMPC)Ccpcz}/Spata31f3^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Spata31f3^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged thymus	J:211773
	increased CD8-positive, alpha-beta T cell number	J:211773
	increased CD8-positive, naive alpha-beta T cell number	J:211773
spcy/spcy (C57BL/6J-spcy)	abnormal innate immunity	J:94077
Spdef^tm1Shiv/Spdef^tm1Shiv (involves: 129S4/SvJae)	small intestinal inflammation	J:166876
Spdef^tm1Shiv/Spdef^tm1Shiv (involves: 129S4/SvJae)	stomach inflammation	J:166876
Spdye4b^{tm3b(EUCOMM)Wtsi}/Spdye4b^{tm3b(EUCOMM)Wtsi} (C57BL/6N-Spdye4b^{tm3b(EUCOMM)Wtsi}/Bay)	abnormal spleen morphology	J:211773
Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺ Trmu^tm1Tomik/Trmu^tm1Tomik (involves: C57BL/6 * DBA)	abnormal inflammatory response	J:235644
Spef2^bgh/Spef2^bgh (involves: 129S6/SvEvTac * C57BL/6J * C57BL/10J)	sinus inflammation	J:176695
Speg^{tm1b(KOMP)Wtsi}/Speg⁺ (C57BL/6N-Speg^{tm1b(KOMP)Wtsi}/Nju)	increased basophil cell number	J:211773
Spen^tm1Hon/Spen^tm1Hon (involves: 129P2/OlaHsd * C57BL/6J)	abnormal B cell differentiation	J:82332
Spg11^em1(IMPC)J/Spg11^em1(IMPC)J (C57BL/6NJ-Spg11^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
Sphk1^tm1.1Cgh/Sphk1^tm2Cgh Sphk2^tm1.1Cgh/Sphk2^tm1.1Cgh Tg(Mx1-cre)1Cgn/0 (involves: 129S4/SvJae * C57BL/6 * CBA)	abnormal immune serum protein physiology	J:120783
	abnormal NK cell differentiation	J:154069
	abnormal T cell differentiation	J:120783
	abnormal thymus cell ratio	J:120783
	decreased B cell number	J:120783
	decreased NK cell number	J:154069
	decreased T cell number	J:120783
	increased NK cell number	J:154069
Sphk1^tm1Npa/Sphk1^tm1Npa (BALB/c-Sphk1^tm1Npa)	increased B cell number	J:129314
Sphk1^tm1Rlp/Sphk1^tm1Rlp (involves: 129S6/SvEvTac)	abnormal cytokine level	J:133917
	decreased susceptibility to endotoxin shock	J:133917
	enlarged mesenteric lymph nodes	J:133917
Sphk2^{Gt(NPX039)Byg}/Sphk2^{Gt(NPX039)Byg} (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:102911
Sphk2^tm1.1Stlp/Sphk2^tm1.1Stlp (involves: BALB/c)	abnormal CD4-positive, alpha-beta T cell physiology	J:153014
Sphk2^tm1Npa/Sphk2^tm1Npa (BALB/c-Sphk2^tm1Npa)	abnormal B cell migration	J:129314
Sphk2^tm1Npa/Sphk2^tm1Npa (BALB/c-Sphk2^tm1Npa)	increased B cell number	J:129314
Spi1^tm1.1Dgt/Spi1^tm1.1Dgt (involves: 129S1/Sv * 129X1/SvJ)	abnormal spleen morphology	J:90331
	decreased B cell number	J:90331
	enlarged spleen	J:90331
	increased T cell derived lymphoma incidence	J:90331
	spleen hyperplasia	J:90331
Spi1^tm1.2Nutt/Spi1^tm1.2Nutt Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA)	abnormal granulocyte differentiation	J:98188
	abnormal spleen morphology	J:98188
	decreased B cell number	J:98188
	increased granulocyte number	J:98188
Spi1^tm1.3Dgt/Spi1^tm1.3Dgt (involves: 129S1/Sv * 129X1/SvJ * BALB/c * C57BL/6)	abnormal double-negative T cell morphology	J:106040
	abnormal T cell subpopulation ratio	J:106040
	arrested B cell differentiation	J:106040
	decreased B-1a cell number	J:106040
	decreased granulocyte number	J:106040
	decreased mature B cell number	J:106040
	decreased pre-B cell number	J:106040
	decreased pro-B cell number	J:106040
	decreased T cell number	J:106040
	decreased thymocyte number	J:106040
	increased B-1 B cell number	J:106040
	increased B-1b cell number	J:106040
	increased IgM level	J:106040
	increased lymphocyte cell number	J:106040
	increased T cell derived lymphoma incidence	J:106040
	increased T cell number	J:106040
	small thymus	J:106040
Spi1^tm1.3Dgt/Spi1^tm1.3Dgt (involves: 129 * BALB/c * C57BL/6)	abnormal spleen morphology	J:90331
	decreased B cell number	J:90331
	enlarged spleen	J:90331
	increased neutrophil cell number	J:90331
	increased spleen weight	J:90331
	increased T cell derived lymphoma incidence	J:90331
	spleen hyperplasia	J:90331
Spi1^tm1Kast/Spi1^tm1Kast (B6.129S2-Spi1^tm1Kast)	absent B cells	J:90543
Spi1^tm1Kast/Spi1^tm1Kast (B6.129S2-Spi1^tm1Kast)	failure of myelopoiesis	J:90543
Spi1^tm1Ram/Spi1^tm1Ram (involves: 129S2/SvPas)	decreased macrophage cell number	J:101493
Spi1^tm1Ram/Spi1^tm1Ram (involves: 129S2/SvPas * C57BL/6)	abnormal B cell number	J:36473
	abnormal macrophage differentiation	J:36473
	abnormal microglial cell morphology	J:116087
	abnormal neutrophil differentiation	J:36473
	abnormal T cell differentiation	J:36473
	abnormal T cell number	J:36473
	absent mature B cells	J:36473
	decreased CD4-positive, alpha-beta T cell number	J:36473
	decreased CD8-positive, alpha-beta T cell number	J:36473
	decreased double-positive T cell number	J:36473
	decreased macrophage cell number	J:36473
	decreased neutrophil cell number	J:36473
	decreased spleen red pulp amount	J:36473
	decreased thymocyte number	J:36473
	sepsis	J:36473
Spi1^tm1Rpd/Spi1^tm1Rpd (involves: 129/Sv * C57BL/6 * Black Swiss)	abnormal myelopoiesis	J:123079
	arrested B cell differentiation	J:123079
	enlarged spleen	J:123079
	impaired myelopoiesis	J:123079
Spi1^tm1Sing/Spi1⁺ Spib^tm1Mcs/Spib⁺ (involves: 129S/SvEv * 129X1/SvJ)	abnormal spleen germinal center morphology	J:88257
	decreased B cell proliferation	J:88257
Spi1^tm1Sing/Spi1⁺ Spib^tm1Mcs/Spib^tm1Mcs (involves: 129S/SvEv * 129X1/SvJ)	abnormal B cell differentiation	J:88257
	abnormal immature B cell morphology	J:88257
	absent spleen germinal center	J:88257
	decreased B cell number	J:88257
	decreased B cell proliferation	J:88257
	immune system phenotype	J:88257
	increased B cell apoptosis	J:88257
Spi1^tm1Sing/Spi1^tm1Sing (involves: 129S/SvEv)	abnormal B cell differentiation	J:20348
	abnormal granulocyte morphology	J:20348
	abnormal leukopoiesis	J:20348
	abnormal monocyte morphology	J:20348
	abnormal T cell differentiation	J:20348
Spi1^tm3Dgt/Spi1^tm3Dgt (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	decreased B cell number	J:131217
	decreased double-negative T cell number	J:131217
	increased double-negative T cell number	J:131217
	increased granulocyte number	J:131217
Spib^tm1Ksho/Spib^tm1Ksho (involves: C57BL/6J)	abnormal Peyer's patch morphology	J:187649
Spib^tm1Ksho/Spib^tm1Ksho (involves: C57BL/6J)	increased susceptibility to bacterial infection	J:187649
Spib^tm1Mcs/Spib^tm1Mcs (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal immature B cell morphology	J:88257
	decreased B cell proliferation	J:88257
Spib^tm1Mcs/Spib^tm1Mcs (involves: 129S1/Sv * 129X1/SvJ)	abnormal humoral immune response	J:45245
	abnormal spleen B cell follicle morphology	J:45245
	abnormal spleen germinal center morphology	J:45245
	abnormal spleen white pulp morphology	J:45245
	decreased B cell proliferation	J:45245
	decreased IgG1 level	J:45245
	decreased IgG2a level	J:45245
	decreased IgG2b level	J:45245
	increased B cell apoptosis	J:45245
	increased IgM level	J:45245
Spic^tm1.1Kmm/Spic^tm1.1Kmm (involves: 129S6/SvEvTac * C57BL/6)	abnormal macrophage morphology	J:143900
	impaired macrophage phagocytosis	J:143900
	increased spleen iron level	J:143900
	increased spleen weight	J:143900
Spic^tm1Kmm/Spic^tm1Kmm (involves: 129S6/SvEvTac * C57BL/6)	abnormal macrophage morphology	J:143900
	impaired macrophage phagocytosis	J:143900
	increased spleen iron level	J:143900
	increased spleen weight	J:143900
Spin4^em1Jbn/Y (involves: C57BL/6J)	increased spleen weight	J:347154
Spin4^em2Jbn/Y (involves: C57BL/6J)	increased spleen weight	J:347154
Spink1^tm1Kymm/Spink1^tm1Kymm (involves: C57BL/6NCrlj * CBA/JNCrlj)	small spleen	J:104647
Spink2^{tm1.1(KOMP)Vlcg}/Spink2^{tm1.1(KOMP)Vlcg} (C57BL/6N-Spink2^{tm1.1(KOMP)Vlcg}/Ucd)	increased basophil cell number	J:211773
Spink5^m1Btlr/Spink5^m1Btlr (involves: C57BL/6J)	increased neutrophil cell number	J:183755
Spink5^tm2.1Hov/Spink5^tm2.1Hov Tg(KRT5-cre/ERT2)2Ipc/0 (involves: C57BL/6 * C57BL/6JRj * SJL)	abnormal lymph node B cell domain morphology	J:357366
	abnormal lymph node germinal center morphology	J:357366
	abnormal spleen marginal zone morphology	J:357366
	abnormal spleen morphology	J:357366
	abnormal thymus morphology	J:357366
	arrested T cell differentiation	J:357366
	decreased double-positive T cell number	J:357366
	decreased spleen B cell follicle number	J:357366
	enlarged lymph nodes	J:357366
	enlarged spleen	J:357366
	increased chemokine level	J:357366
	increased IgE level	J:357366
	increased neutrophil cell number	J:357366
	increased spleen white pulp amount	J:357366
	lymph node hyperplasia	J:357366
	myeloid hyperplasia	J:357366
	skin inflammation	J:357366
	small thymus	J:357366
	spleen hypoplasia	J:357366
	thymus atrophy	J:357366
	thymus cortex hypoplasia	J:357366
	thymus hypoplasia	J:357366
Spink6^{em1(IMPC)Ccpcz}/Spink6^{em1(IMPC)Ccpcz} (C57BL/6N-Spink6^{em1(IMPC)Ccpcz}/Ccpcz)	decreased Ly6C-positive immature NK cell number	J:211773
	decreased macrophage cell number	J:211773
	increased Ly6C-positive mature NK cell number	J:211773
	increased monocyte cell number	J:211773
Spink7^em1Cya/Spink7^em1Cya (C57BL/6N-Spink7^em1Cya/Cya)	increased interleukin-1 beta secretion	J:310883
	increased interleukin-6 secretion	J:310883
	increased susceptibility to induced colitis	J:310883
Spink13^{em1(IMPC)Ccpcz}/Spink13^{em1(IMPC)Ccpcz} (C57BL/6N-Spink13^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Spink14^{tm1e(KOMP)Wtsi}/Spink14^{tm1e(KOMP)Wtsi} (C57BL/6N-Spink14^{tm1e(KOMP)Wtsi}/Wtsi)	decreased immature NK cell number	J:211773
	decreased macrophage cell number	J:211773
	decreased mature NK cell number	J:211773
	decreased NK cell number	J:211773
	increased anti-nuclear antigen antibody level	J:211773
	increased memory-marker NK cell number	J:211773
Spint1^tm2.1Hk/Spint1^tm2.1Hk Tg(Vil1-cre)997Gum/0 (involves: C57BL/6 * C57BL/6J * SJL)	increased susceptibility to induced colitis	J:179937
Spir1^BALB/cOlaHsd/Spir1^BALB/cOlaHsd (involves: BALB/cOlaHsd * CBA/CaOlaHsd)	decreased susceptibility to bacterial infection	J:84089
Spir1^BALB/cOlaHsd/Spir1^CBA/CaOlaHsd (involves: BALB/cOlaHsd * CBA/CaOlaHsd)	decreased susceptibility to bacterial infection	J:84089
Spir1^CBA/CaOlaHsd/Spir1^CBA/CaOlaHsd (involves: BALB/cOlaHsd * CBA/CaOlaHsd)	increased susceptibility to bacterial infection	J:84089
Splq1^L6/Splq1^L6 (involves: L6 * M16i)	decreased spleen weight	J:87793
Splq1^L6/Splq1^M16i (involves: L6 * M16i)	decreased spleen weight	J:87793
Splq2^L6/Splq2^L6 (involves: L6 * M16i)	decreased spleen weight	J:87793
Splq2^L6/Splq2^M16i (involves: L6 * M16i)	decreased spleen weight	J:87793
Splq3^L6/Splq3^L6 (involves: L6 * M16i)	decreased spleen weight	J:87793
Splq4^L6/Splq4^L6 (involves: L6 * M16i)	decreased spleen weight	J:87793
Splq4^L6/Splq4^M16i (involves: L6 * M16i)	decreased spleen weight	J:87793
Splq5^L6/Splq5^L6 (involves: L6 * M16i)	decreased spleen weight	J:87793
Splq5^L6/Splq5^M16i (involves: L6 * M16i)	decreased spleen weight	J:87793
Splq6^L6/Splq6^L6 (involves: L6 * M16i)	decreased spleen weight	J:87793
Splq6^L6/Splq6^M16i (involves: L6 * M16i)	decreased spleen weight	J:87793
Splq7^L6/Splq7^L6 (involves: L6 * M16i)	decreased spleen weight	J:87793
Splq8^L6/Splq8^L6 (involves: L6 * M16i)	decreased spleen weight	J:87793
Splq8^L6/Splq8^M16i (involves: L6 * M16i)	decreased spleen weight	J:87793
Splq9^L6/Splq9^L6 (involves: L6 * M16i)	decreased spleen weight	J:87793
Splwt1^LG/J/? (involves: LG/J * SM/J)	increased spleen weight	J:94605
Spm1^C57BL/6/? (involves: C57BL/6 * NZB)	abnormal immune system organ morphology	J:59427
Spmip2^{tm1b(EUCOMM)Hmgu}/Spmip2^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Spmip2^{tm1b(EUCOMM)Hmgu}/Bay)	abnormal spleen morphology	J:211773
Spn^tm1Bam/Spn^tm1Bam (involves: 129S4/SvJae * C57BL/6)	abnormal T cell physiology	J:29272
Spn^tm1Bam/Spn^tm1Bam (involves: 129S4/SvJae * C57BL/6)	increased T cell proliferation	J:29272, J:88252
Spn^tm1Bam/Spn^tm1Bam (B6;129S4-Spn^tm1Bam/J)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:86932
Spn^tm1Bam/Spn^tm1Bam (B6;129S4-Spn^tm1Bam/J)	immune system phenotype	J:66401
Spns2^tm1.1Nmoc/Spns2^tm1.1Nmoc Tg(Tek-cre)1Ywa/0 (involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj * SJL)	abnormal B cell physiology	J:184558
	abnormal effector T cell morphology	J:184558
	abnormal T cell physiology	J:184558
	decreased CD4-positive, alpha-beta T cell number	J:184558
	decreased CD8-positive, alpha-beta T cell number	J:184558
	decreased mature B cell number	J:184558
	increased CD4-positive, alpha-beta T cell number	J:184558
	increased CD8-positive, alpha-beta T cell number	J:184558
Spns2^tm1.2Nmoc/Spns2^tm1.2Nmoc (involves: C57BL/6NCrlj * CBA/JNCrlj)	abnormal B cell physiology	J:184558
	abnormal T cell physiology	J:184558
	decreased B-1 B cell number	J:184558
	decreased CD4-positive, alpha-beta T cell number	J:184558
	decreased CD8-positive, alpha-beta T cell number	J:184558
	decreased follicular B cell number	J:184558
	decreased immature B cell number	J:184558
	decreased leukocyte cell number	J:184558
	decreased mature B cell number	J:184558
	decreased transitional stage T1 B cell number	J:184558
	increased CD4-positive, alpha-beta T cell number	J:184558
	increased CD8-positive, alpha-beta T cell number	J:184558
	increased single-positive T cell number	J:184558
Spns2^{tm1a(KOMP)Wtsi}/Spns2^{tm1a(KOMP)Wtsi} (B6JTyr;B6N-Spns2^{tm1a(KOMP)Wtsi}/Wtsi)	decreased leukocyte cell number	J:165965
Spns2^{tm1a(KOMP)Wtsi}/Spns2^{tm1a(KOMP)Wtsi} (involves: C57BL/6 * C57BL/6N)	abnormal humoral immune response	J:188933
	decreased B cell number	J:188933, J:213427
	decreased B-1 B cell number	J:188933
	decreased CD4-positive, alpha-beta T cell number	J:188933, J:213427
	decreased CD8-positive, alpha-beta T cell number	J:188933, J:213427
	decreased follicular B cell number	J:188933
	decreased IgG1 level	J:188933
	decreased IgG level	J:188933
	decreased leukocyte cell number	J:188933, J:213427
	decreased mature B cell number	J:213427
	decreased T cell number	J:213427
	immune system phenotype	J:188933
	increased CD4-positive, alpha-beta T cell number	J:188933
	increased CD8-positive, alpha-beta T cell number	J:188933
	increased granulocyte number	J:213427
	increased incidence of corneal inflammation	J:213427
	increased monocyte cell number	J:213427
	increased NK cell number	J:213427
	increased NK T cell number	J:213427
	increased susceptibility to bacterial infection	J:213427
Spns2^{tm1b(KOMP)Wtsi}/Spns2^{tm1b(KOMP)Wtsi} (involves: 129S7/SvEvBrd * C57BL/6 * C57BL/6N)	decreased B cell number	J:188933
	decreased CD4-positive, alpha-beta T cell number	J:188933
	decreased CD8-positive, alpha-beta T cell number	J:188933
	increased CD4-positive, alpha-beta T cell number	J:188933
	increased CD8-positive, alpha-beta T cell number	J:188933
Spns2^{tm1b(KOMP)Wtsi}/Spns2^{tm1b(KOMP)Wtsi} (B6Brd;B6Dnk;B6N-Tyr^c-Brd Spns2^{tm1b(KOMP)Wtsi}/WtsiH)	decreased leukocyte cell number	J:211773
Spns2^{tm1c(KOMP)Wtsi}/Spns2^{tm1c(KOMP)Wtsi} (involves: 129S4/SvJaeSor * C57BL/6 * C57BL/6N)	immune system phenotype	J:188933
Spns2^tm1Tni/Spns2^tm1Tni (B6.Cg-Spns2^tm1Tni)	abnormal leukocyte cell number	J:225108
	abnormal mature B cell number	J:225108
	abnormal thymus morphology	J:225108
	decreased leukocyte cell number	J:225108
	decreased lymphocyte cell number	J:225108
	decreased monocyte cell number	J:225108
	decreased single-positive T cell number	J:225108
	decreased thymocyte number	J:225108
Spns3^em1(IMPC)Tcp/Spns3^em1(IMPC)Tcp (C57BL/6NCrl-Spns3^em1(IMPC)Tcp/Tcp)	increased eosinophil cell number	J:211773
Spnw1^DBA/2/Spnw1^DBA/2 Spnw4^DU6i/Spnw4^DU6i (involves: DBA/2 * DU6i)	increased spleen weight	J:101006
Spo11^tm1Mjn/Spo11^tm1Mjn (involves: 129X1/SvJ * C57BL/6)	immune system phenotype	J:74754
Spo11^{tm2b(KOMP)Wtsi}/Spo11^{tm2b(KOMP)Wtsi} (C57BL/6N-Spo11^{tm2b(KOMP)Wtsi}/Bay)	abnormal spleen morphology	J:211773
	increased spleen weight	J:211773
Spon2^tm1Mjb/Spon2^tm1Mjb (involves: 129S6/SvEvTac * C57BL/6)	abnormal interleukin level	J:87393
	abnormal susceptibility to infection	J:87393
	abnormal tumor necrosis factor level	J:87393
Spop^{tm1b(KOMP)Wtsi}/Spop⁺ (C57BL/6N-Spop^{tm1b(KOMP)Wtsi}/Tcp)	enlarged lymph nodes	J:211773
	small thymus	J:211773
Spp1^Ric-r/Spp1⁺ (AKR/J)	decreased susceptibility to bacterial infection	J:5949
Spp1^Ric-r/Spp1⁺ (A/J)	decreased susceptibility to bacterial infection	J:5949
Spp1^Ric-r/Spp1⁺ (BALB/cJ)	decreased susceptibility to bacterial infection	J:5949
Spp1^Ric-r/Spp1⁺ (C57BL/6J)	decreased susceptibility to bacterial infection	J:5949
Spp1^Ric-r/Spp1⁺ (C57L/J)	decreased susceptibility to bacterial infection	J:5949
Spp1^Ric-r/Spp1⁺ (SWR/J)	decreased susceptibility to bacterial infection	J:5949
Spp1^Ric-r/Spp1⁺ (C3H/Rv)	decreased susceptibility to bacterial infection induced morbidity/mortality	J:7240
Spp1^Ric-r/Spp1⁺ (C3H/Rv)	increased macrophage cell number	J:7240
Spp1^Ric-s/Spp1⁺ (A/HeJ)	increased susceptibility to bacterial infection	J:5949
Spp1^Ric-s/Spp1⁺ (C3H/HeJ)	increased susceptibility to bacterial infection	J:5949
Spp1^Ric-s/Spp1⁺ (C3H/HeN)	increased susceptibility to bacterial infection	J:5949
Spp1^Ric-s/Spp1⁺ (C3H/St)	increased susceptibility to bacterial infection	J:5949
Spp1^Ric-s/Spp1⁺ (CBA/J)	increased susceptibility to bacterial infection	J:5949
Spp1^Ric-s/Spp1⁺ (DBA/1J)	increased susceptibility to bacterial infection	J:5949
Spp1^Ric-s/Spp1⁺ (DBA/2J)	increased susceptibility to bacterial infection	J:5949
Spp1^Ric-s/Spp1⁺ (SJL/J)	increased susceptibility to bacterial infection	J:5949
Spp1^tm1.1Dhd/Spp1^tm1.1Dhd (involves: 129P2/OlaHsd * C57BL/6)	abnormal macrophage morphology	J:237104
	abnormal osteoclast physiology	J:237104
	decreased osteoclast cell number	J:237104
Spp1^tm1Blh/Spp1⁺ (BKSW.129S6-Spp1^tm1Blh)	abnormal immune system physiology	J:113585
Spp1^tm1Blh/Spp1⁺ (involves: 129S6/SvEvTac * Black Swiss)	abnormal leukocyte migration	J:86531
Spp1^tm1Blh/Spp1^tm1Blh (involves: 129S6/SvEvTac * Black Swiss)	abnormal chemokine level	J:127389
	abnormal leukocyte migration	J:86531
	abnormal leukocyte physiology	J:86531
	abnormal macrophage chemotaxis	J:140014
	abnormal macrophage physiology	J:127389
	abnormal response to infection	J:103013
	abnormal susceptibility to infection	J:140014
	decreased circulating interleukin-6 level	J:127389
	decreased leukocyte cell number	J:86531
	decreased macrophage cell number	J:127389
	granulomatous inflammation	J:140014
	increased lymphocyte cell number	J:103050
Spp1^tm1Blh/Spp1^tm1Blh (B6.129S6-Spp1^tm1Blh)	abnormal microglial cell morphology	J:118432
	decreased susceptibility to experimental autoimmune uveoretinitis	J:116272
	granulomatous inflammation	J:116272
Spp1^tm1Blh/Spp1^tm1Blh (involves: 129S6/SvEvTac * C57BL/6)	abnormal immune system physiology	J:119298
Spp1^tm1Blh/Spp1^tm1Blh (involves: 129S6/SvEvTac * C57BL/6)	decreased dendritic cell number	J:119298
Spp1^tm1Blh/Spp1^tm1Blh (BKSW.129S6-Spp1^tm1Blh)	abnormal immune system physiology	J:113585
Spp1^tm1Blh/Spp1^tm1Blh (BKSW.129S6-Spp1^tm1Blh)	impaired macrophage chemotaxis	J:113585
Spp1^tm1Rit/Spp1^tm1Rit (involves: 129S7/SvEvBrd * C57BL/6)	abnormal inflammatory response	J:60284
	abnormal osteoclast physiology	J:68872, J:56353
	abnormal response to infection	J:60284
	decreased interferon-gamma secretion	J:60284
	decreased interleukin-12 secretion	J:60284
	decreased osteoclast cell number	J:115395
	decreased susceptibility to Herpesvirales infection	J:60284
	decreased susceptibility to type IV hypersensitivity reaction	J:60284
	increased interleukin-4 secretion	J:60284
	increased interleukin-10 secretion	J:60284
	increased osteoclast cell number	J:56353, J:56535
Spp1^tm1Rit/Spp1^tm1Rit (B6.129S7-Spp1^tm1Rit)	decreased acute inflammation	J:93915
	decreased interferon-gamma secretion	J:93915
	decreased tumor necrosis factor secretion	J:93915
Sppl2a^chompB/Sppl2a^chompB (involves: C57BL/6)	abnormal class switch recombination	J:194595
	abnormal humoral immune response	J:194595
	decreased activation-induced B cell apoptosis	J:194595
	decreased B cell proliferation	J:194595
	decreased follicular B cell number	J:194595
	decreased IgG1 level	J:194595
	decreased IgG2b level	J:194595
	decreased IgG3 level	J:194595
	decreased IgM level	J:194595
	decreased marginal zone B cell number	J:194595
	decreased mature B cell number	J:194595
	decreased myeloid dendritic cell number	J:194595
	decreased plasmacytoid dendritic cell number	J:194595
	decreased transitional stage T2 B cell number	J:194595
	immune system phenotype	J:194595
Sppl2a^m1Anu/Sppl2a^m1Anu (involves: C57BL/6JAnu)	abnormal immunoglobulin level	J:194663
	abnormal mature B cell morphology	J:194663
	abnormal transitional stage B cell morphology	J:194663
	decreased IgG1 level	J:194663
	decreased IgM level	J:194663
	decreased marginal zone B cell number	J:194663
	decreased transitional stage T2 B cell number	J:194663
	decreased transitional stage T3 B cell number	J:194663
Sppl2a^m1Anu/Sppl2a^m1Anu Tg(Vav-BCL2)69Jad/? (involves: C57BL/6JAnu)	abnormal T cell number	J:194663
	decreased CD4-positive, alpha-beta T cell number	J:194663
	decreased double-negative T cell number	J:194663
	increased mature B cell number	J:194663
	increased plasmacytoid dendritic cell number	J:194663
Sppl2a^m1Btlr/Sppl2a^m1Btlr (C57BL/6J-Sppl2a^m1Btlr)	decreased IgG level	J:236687
Sppl2a^m1Btlr/Sppl2a^m1Btlr (C57BL/6J-Sppl2a^m1Btlr)	decreased response to antigen	J:236687
Sppl2a^m2Btlr/Sppl2a^m2Btlr (C57BL/6J-Sppl2a^m2Btlr)	decreased IgG level	J:236688
	decreased IgM level	J:236688
	decreased response to antigen	J:236688
Sppl2a^tm1Basc/Sppl2a^tm1Basc (involves: 129S1/Sv * 129X1/SvJ * C57BL/6NCrl)	abnormal B cell calcium ion homeostasis	J:194664
	abnormal B cell physiology	J:194664
	arrested B cell differentiation	J:194664
	decreased B cell number	J:194664
	decreased B-1 B cell number	J:194664
	decreased B-2 B cell number	J:194664
	decreased follicular B cell number	J:194664
	decreased IgA level	J:194664
	decreased IgG1 level	J:194664
	decreased IgG2a level	J:194664
	decreased IgG2b level	J:194664
	decreased IgG3 level	J:194664
	decreased IgM level	J:194664
	decreased marginal zone B cell number	J:194664
	decreased mature B cell number	J:194664
	decreased Peyer's patch number	J:194664
	decreased T cell number	J:194664
	decreased transitional stage T2 B cell number	J:194664
	small Peyer's patches	J:194664
	small spleen	J:194664
Sppl2a^tm1Basc/Sppl2a^tm1Basc Sppl2b^{Gt(Ayu21-T160)Imeg}/Sppl2b^{Gt(Ayu21-T160)Imeg} (B6N.Cg-Sppl2a^tm1Basc Sppl2b^{Gt(Ayu21-T160)Imeg})	abnormal mature B cell morphology	J:213519
	decreased B cell number	J:213519
	decreased immunoglobulin level	J:213519
Sppl2a^tm1Dgen/Sppl2a^tm1Dgen (B6.129P2-Sppl2a^tm1Dgen)	decreased B cell number	J:194595
	decreased B-1 B cell number	J:194595
	decreased follicular B cell number	J:194595
	decreased IgA level	J:194595
	decreased IgG1 level	J:194595
	decreased IgG2b level	J:194595
	decreased IgG3 level	J:194595
	decreased IgM level	J:194595
	decreased myeloid dendritic cell number	J:194595
	decreased transitional stage T2 B cell number	J:194595
Sppl2b^{Gt(Ayu21-T160)Imeg}/Sppl2b^{Gt(Ayu21-T160)Imeg} (B6N.Cg-Sppl2b^{Gt(Ayu21-T160)Imeg})	immune system phenotype	J:213519
Sppl3^tm1Itl/Sppl3^em1Pomz Ncr1^{tm1.1(icre)Viv}/Ncr1⁺ (involves: 129S/SvEv * C57BL/6 * C57BL/6J)	abnormal NK cell differentiation	J:280182
	decreased mature NK cell number	J:280182
	decreased NK cell number	J:280182
	increased immature NK cell number	J:280182
Sppl3^tm1Itl/Sppl3^tm1Itl Commd10^{Tg(Vav1-icre)A2Kio}/Commd10⁺ (involves: 129S/SvEv * C57BL/6 * C57BL/10 * CBA/Ca)	abnormal NK cell differentiation	J:280182
	decreased mature NK cell number	J:280182
	decreased NK cell number	J:280182
	immune system phenotype	J:280182
	impaired natural killer cell mediated cytotoxicity	J:280182
	increased immature NK cell number	J:280182
Sppl3^tm1Itl/Sppl3^tm1Itl Ncr1^{tm1.1(icre)Viv}/Ncr1⁺ (involves: 129S/SvEv * C57BL/6)	abnormal NK cell differentiation	J:280182
	abnormal NK cell physiology	J:280182
	decreased mature NK cell number	J:280182
	decreased NK cell number	J:280182
	impaired natural killer cell mediated cytotoxicity	J:280182
	increased immature NK cell number	J:280182
Spr^em1(IMPC)H/Spr⁺ (C57BL/6N-Spr^em1(IMPC)H/H)	increased neutrophil cell number	J:211773
Spred1^{em1(IMPC)Ccpcz}/Spred1^{em1(IMPC)Ccpcz} (C57BL/6N-Spred1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	decreased lymphocyte cell number	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
	increased CD4-positive NK T cell number	J:211773
	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
	increased effector memory T-helper cell number	J:211773
	increased memory-marker CD4-positive NK T cell number	J:211773
	increased neutrophil cell number	J:211773
	increased NK T cell number	J:211773
	increased spleen weight	J:211773
Spred1^tm1.1Ayos/Spred1^tm1.1Ayos (involves: 129 * C57BL/6 * SJL)	increased mast cell degranulation	J:186742
	increased mast cell number	J:186742
Spred1^tm1Hiin/Spred1^tm1Hiin (involves: C57BL/6)	abnormal cytokine secretion	J:95263
	abnormal eosinophil physiology	J:95263
	increased eosinophil cell number	J:95263
Spred2^em1(IMPC)Mbp/Spred2^em1(IMPC)Mbp (C57BL/6N-Spred2^em1(IMPC)Mbp/MbpMmucd)	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Spred3^em1(IMPC)Tcp/Spred3⁺ (C57BL/6NCrl-Spred3^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Sprol1^STS/A/? (involves: B10.O20/Dem * O20/A)	increased lymphocyte cell number	J:56029
Spryd4^{em1(IMPC)Ccpcz}/Spryd4^{em1(IMPC)Ccpcz} (C57BL/6N-Spryd4^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Spta1^ihj/Spta1^ihj (involves: HRS/J * LAH)	abnormal spleen morphology	J:105409
Spta1^ihj/Spta1^ihj (involves: HRS/J * LAH)	enlarged spleen	J:105409
Spta1^sph-2Bc/Spta1^sph-2Bc (involves: SELH)	dark spleen	J:7048
	enlarged spleen	J:7048
	increased leukocyte cell number	J:7048
Spta1^sph-3J/Spta1^sph-3J (NOD.Cg-H2^b Spta1^sph-3J)	decreased spleen iron level	J:157766
	enlarged spleen	J:157766
	increased spleen weight	J:157766
Spta1^sph-4J/Spta1^sph-4J (C57BL/6J-Spta1^sph-4J/Llp)	enlarged spleen	J:157766
Spta1^sph-4J/Spta1^sph-4J (C57BL/6J-Spta1^sph-4J/Llp)	increased spleen weight	J:157766
Spta1^sph-Dem/Spta1^sph-Dem (CcS3/Dem-Spta1^sph-Dem)	enlarged spleen	J:66966
Spta1^sph-ha/Spta1^sph-ha (involves: DBA/1J)	enlarged spleen	J:30699, J:14946
Spta1^sph-ha/Spta1^sph-ha (either: (B6.D1-Spta1^sph-ha x WB.D1-Spta1^sph-ha)F1 or (WB.D1-Spta1^sph-ha x B6.D1-Spta1^sph-ha)F1)	abnormal lymph node cell ratio	J:1967
	abnormal spleen morphology	J:6695
	abnormal splenic cell ratio	J:1967
	alveolitis	J:12830
	enlarged spleen	J:6695
	increased B cell number	J:1967
	increased B cell proliferation	J:1967
	increased CD4-positive, alpha-beta T cell number	J:1967
	increased CD8-positive, alpha-beta T cell number	J:1967
	increased IgA level	J:12830
	increased IgG level	J:12830
	increased leukocyte cell number	J:12830
	increased lymphocyte cell number	J:12830, J:1967
	increased monocyte cell number	J:12830
	increased neutrophil cell number	J:12830
	increased susceptibility to bacterial infection	J:12830
	increased T cell number	J:1967
	increased T cell proliferation	J:1967
	interstitial pneumonia	J:12830
	lymph node hyperplasia	J:12830, J:1967
Spta1^sph-ha/Spta1^sph-ha ((WB.D1-Spta1^sph-ha/Brk x B6.D1-Spta1^sph-ha/Brk)F1)	enlarged spleen	J:162532
Spta1^sph/Spta1^sph (either: (B6.C3-Spta1^sph x WB.C3-Spta1^sph)F1 or (WB.C3-Spta1^sph x B6.C3-Spta1^sph)F1)	abnormal spleen morphology	J:6695
	decreased susceptibility to parasitic infection	J:111131
	enlarged spleen	J:6695
Spta1^sph/Spta1^sph ((WB.C3-Spta1^sph x B6.C3-Spta1^sph)F1)	enlarged spleen	J:162532, J:44313
	glomerulonephritis	J:44313
	tubular nephritis	J:44313
Sptb^ja/Sptb^ja (129/Sv-Sptb^ja)	enlarged spleen	J:305
Sptb^ja/Sptb^ja ((WB.129-Sptb^ja/J x B6.129-Sptb^ja/J)F1)	enlarged spleen	J:162532, J:44313
	glomerulonephritis	J:44313
	increased spleen red pulp amount	J:44313
	tubular nephritis	J:44313
Sptb^m1Jus/Sptb^m1Jus (involves: 129S6/SvEvTac * C57BL/6)	enlarged spleen	J:159750
Sptbn4^qv/Sptbn4^qv (either: (involves: BALB/c) or (involves: C57BL/10))	eye inflammation	J:167
Sptlc2^tm1Yhir/Sptlc2^tm1Yhir Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte}/Gt(ROSA)26Sor⁺ (involves: C57BL/6 * C57BL/6NTac)	abnormal spleen morphology	J:202954
	abnormal thymus morphology	J:202954
	decreased lymphocyte cell number	J:202954
	decreased spleen weight	J:202954
	decreased thymus weight	J:202954
	increased neutrophil cell number	J:202954
Sptlc2^tm1Yhir/Sptlc2^tm1Yhir Tg(KRT5-cre)1Tak/0 (involves: C3H * C57BL/6)	abnormal dendritic epidermal T cell morphology	J:202388
	abnormal Langerhans cell morphology	J:202388
	abnormal Langerhans cell physiology	J:202388
	increased dendritic cell number	J:202388
	increased gamma-delta T cell number	J:202388
	increased T-helper 17 cell number	J:202388
	skin inflammation	J:202388
Spw1^SWR/J/Spw1^SWR/J Tg(CTSG-PML/RARA)135Ley/0 (involves: C3H/HeJ * C57BL/6J * SWR/J)	decreased spleen weight	J:139159
Spw2^SWR/J/? Tg(CTSG-PML/RARA)135Ley/0 (involves: C3H/HeJ * C57BL/6J * SWR/J)	decreased spleen weight	J:139159
Spw3^SWR/J/Spw3^SWR/J Tg(CTSG-PML/RARA)135Ley/0 (involves: C3H/HeJ * C57BL/6J * SWR/J)	increased spleen weight	J:139159
Spw4^SWR/J/Spw4^SWR/J Tg(CTSG-PML/RARA)135Ley/0 (involves: C3H/HeJ * C57BL/6J * SWR/J)	decreased spleen weight	J:139159
Spw5^SWR/J/Spw5^SWR/J Tg(CTSG-PML/RARA)135Ley/0 (involves: C3H/HeJ * C57BL/6J * SWR/J)	decreased spleen weight	J:139159
	increased spleen weight	J:139159
Spz1^em1(IMPC)Mbp/Spz1^em1(IMPC)Mbp (C57BL/6N-Spz1^em1(IMPC)Mbp/MbpMmucd)	increased neutrophil cell number	J:211773
Sqstm1^tm1.1Sral/Sqstm1⁺ (involves: 129/Sv * 129P2/OlaHsd * C57BL/6)	abnormal osteoclast differentiation	J:173755
	increased osteoclast cell number	J:173755
Sqstm1^tm1.1Sral/Sqstm1^tm1.1Sral (involves: 129/Sv * 129P2/OlaHsd * C57BL/6)	abnormal osteoclast differentiation	J:173755
	abnormal osteoclast morphology	J:173755
	increased osteoclast cell number	J:173755
Sqstm1^tm1Jjw/Sqstm1^tm1Jjw (involves: 129 * C57BL/6)	abnormal osteoclast differentiation	J:141179
Sqstm1^tm1Jjw/Sqstm1^tm1Jjw (involves: 129 * C57BL/6)	abnormal osteoclast physiology	J:141179
Sqstm1^tm1Jmos/Sqstm1^tm1Jmos (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal osteoclast differentiation	J:90010
	decreased interleukin-6 secretion	J:90010
	decreased osteoclast cell number	J:90010
Sqstm1^tm1Keta/Sqstm1^tm1Keta (involves: 129 * C57BL/6N)	abnormal osteoclast differentiation	J:264183
Sqstm1^tm1Keta/Sqstm1^tm1Keta (involves: 129 * C57BL/6N)	abnormal osteoclast physiology	J:264183
Sra1^{tm1a(EUCOMM)Hmgu}/Sra1^{tm1a(EUCOMM)Hmgu} (involves: C57BL/6J * C57BL/6N)	decreased circulating tumor necrosis factor level	J:214131
Src^tm1Sor/Src^tm1Sor (either: 129S7/SvEvBrd-Src^tm1Sor or (involves: 129S7/SvEvBrd * C57BL/6J))	increased inflammatory response	J:67040
	periodontium inflammation	J:67040
Srcr/Srcr⁺ (BALB/c-Srcr/Cui)	abnormal innate immunity	J:83618
Srd5a2^em1(IMPC)Mbp/Srd5a2^em1(IMPC)Mbp (C57BL/6N-Srd5a2^em1(IMPC)Mbp/MbpMmucd)	small spleen	J:211773
Srf^tm1Rmn/Srf^tm1Rmn H2az2^{Tg(Wnt1-cre)11Rth}/H2az2⁺ (involves: 129S6/SvEvTac * C57BL/6J * CBA/J)	athymia	J:144862
Srf^tm2Nor/Srf^tm2Nor Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129P2/OlaHsd)	abnormal mature B cell morphology	J:124767
	absent marginal zone B cells	J:124767
	decreased B cell number	J:124767
	decreased B-1 B cell number	J:124767
Srf^tm2Nor/Srf^tm2Nor Tg(Cd4-cre)1Cwi/? (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	decreased CD4-positive, alpha-beta T cell number	J:124767
	decreased CD8-positive, alpha-beta T cell number	J:124767
	decreased T cell number	J:124767
	decreased thymocyte number	J:124767
Srfbp1^em1(IMPC)J/Srfbp1⁺ (C57BL/6NJ-Srfbp1^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
Srgn^tm1Mabr/Srgn^tm1Mabr (involves: 129X1/SvJ)	abnormal mast cell morphology	J:93338
Srgn^tm1Mabr/Srgn^tm1Mabr (involves: 129X1/SvJ)	decreased mast cell number	J:93338
Sros1^em1Caox/Sros1^em1Caox (involves: C57BL/6J)	abnormal circulating chemokine level	J:306407
	decreased susceptibility to bacterial infection	J:306407
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:306407
	increased circulating CXCL10 level	J:306407
Srp14^em1(IMPC)Mbp/Srp14⁺ (C57BL/6NCrl-Srp14^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Srpk3^{tm1b(KOMP)Wtsi}/Y (C57BL/6N-Srpk3^{tm1b(KOMP)Wtsi}/Ucd)	increased monocyte cell number	J:211773
Srpx^tm1Hzi/Srpx^tm1Hzi (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal lymphocyte morphology	J:119999
	enlarged spleen	J:119999
	increased T cell derived lymphoma incidence	J:119999
Srr^Rgsc34/Srr⁺ (involves: C57BL/6JJcl * DBA/2JJcl)	abnormal neutrophil physiology	J:133634
Srrt^tm1.1Thsn/Srrt^tm1.2Thsn Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA)	abnormal thymus physiology	J:152729
	increased splenocyte apoptosis	J:152729
Srsf2^tm1.1Oaw/Srsf2⁺ Tg(Mx1-cre)1Cgn/? (B6.Cg-Tg(Mx1-cre)1Cgn Srsf2^tm1.1Oaw)	abnormal myelopoiesis	J:221404
	abnormal neutrophil morphology	J:221404
	decreased B cell number	J:221404
	failure of myelopoiesis	J:221404
Srsf2^tm1Xdfu/Srsf2⁺ Tg(Lck-cre)I57Jxm/? (involves: 129S4/SvJae * 129X1/SvJ * ICR)	decreased thymocyte number	J:88668
	decreased thymus weight	J:88668
Srsf2^tm1Xdfu/Srsf2^tm1Xdfu Tg(Lck-cre)I57Jxm/? (involves: 129S4/SvJae * 129X1/SvJ * ICR)	abnormal spleen white pulp morphology	J:88668
	abnormal T cell differentiation	J:88668
	absent thymus corticomedullary boundary	J:88668
	decreased double-positive T cell number	J:88668
	decreased T cell number	J:88668
	decreased thymocyte number	J:88668
	increased double-negative T cell number	J:88668
	small thymus	J:88668
Srsf2^tm1Xdfu/Srsf2^tm1Xdfu Tg(Mx1-cre)1Cgn/? (involves: 129S4/SvJae * C57BL/6J * CBA/J)	bone marrow failure	J:221404
Srsf3^tm1Pjln/Srsf3^tm1Pjln Cd79a^tm1(cre)Reth/Cd79a⁺ (involves: 129P2/OlaHsd * BALB/c)	decreased B cell number	J:113645
	decreased pre-B cell number	J:113645
	decreased pro-B cell number	J:113645
Srsf3^tm1Pjln/Srsf3^tm1Pjln Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺ (involves: BALB/c * C57BL/6 * DBA)	abnormal thymus development	J:205756
Srsf5^em1Nju/Srsf5^em1Nju (C57BL/6JGpt-Srsf5^em1Nju)	small spleen	J:311867
Srxn1^tm1Mtol/Srxn1^tm1Mtol (either: B6.129S2-Srxn1^tm1Mtol or (involves: 129S2/SvPasCrl * C57BL/6))	increased susceptibility to endotoxin shock	J:199277
Ss18l1^em1Zqi/Ss18l1⁺ (involves: C57BL/6)	increased microglial cell activation	J:278840
Ss18l1^em1Zqi/Ss18l1^em1Zqi (involves: C57BL/6)	increased microglial cell activation	J:278840
Ss18l1^em2Zqi/Ss18l1^em2Zqi (involves: C57BL/6)	increased microglial cell activation	J:278840
Ssb^tm1Rjma/Ssb^tm2.1Rjma Cd79a^tm1(cre)Reth/Cd79a⁺ (involves: 129S/SvEv * BALB/c)	arrested B cell differentiation	J:207687
	decreased B cell number	J:207687
	decreased IgG level	J:207687
	decreased IgM level	J:207687
	decreased spleen weight	J:207687
	immune system phenotype	J:207687
	small spleen	J:207687
Ssbp2^tm1Lana/Ssbp2^tm1Lana (involves: 129S/SvEv * C57BL/6)	arteritis	J:162035
	decreased lymphocyte cell number	J:162035
	increased pre-B cell number	J:162035
Ssbp2^tm1Lana/Ssbp2^tm1Lana Trp53^tm1Tyj/Trp53^tm1Tyj (involves: 129S/SvEv * 129S2/SvPas * BALB/c * C57BL/6)	increased T cell derived lymphoma incidence	J:162035
	thymus hypoplasia	J:162035
Ssh2^em1(IMPC)J/Ssh2^em1(IMPC)J (C57BL/6NJ-Ssh2^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
Ssial1^NOD/Ssial1^NOD (involves: C57BL/6J * NOD)	periinsulitis	J:11442
Ssial1^NOD/Ssial1^NOD (involves: C57BL/6J * NOD)	salivary gland inflammation	J:75908
Ssial2^NOD/? (involves: C57BL/6J * NOD)	salivary gland inflammation	J:75908
Ssial3^NOD/Ssial3^NOD (involves: C57BL/6J * NOD)	salivary gland inflammation	J:75908
Ssial4^C57BL/6/Ssial4^NOD (involves: C57BL/6J * NOD)	salivary gland inflammation	J:75908
Ssial4^NOD/Ssial4^NOD (involves: C57BL/6J * NOD)	salivary gland inflammation	J:75908
Sspn^{tm1b(EUCOMM)Hmgu}/Sspn^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Sspn^{tm1b(EUCOMM)Hmgu}/Ieg)	increased leukocyte cell number	J:211773
Ssr2^{tm1b(EUCOMM)Wtsi}/Ssr2^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Ssr2^{tm1b(EUCOMM)Wtsi}/Wtsi)	abnormal thymus morphology	J:239583
Sst1^C3HeB/FeJ/Sst1^C3HeB/FeJ (involves: C3HeB/FeJ * C57BL/6J)	increased susceptibility to bacterial infection	J:63410
Sst1^C3HeB/FeJ/Sst1^C3HeB/FeJ (B6.C3-Sst1^C3HeB/FejKrmn/Mmnc)	increased susceptibility to bacterial infection	J:313901
	increased susceptibility to bacterial infection induced morbidity/mortality	J:313901
Sst1^C3HeB/FeJ/Sst1^C57BL/6J (involves: C3HeB/FeJ * C57BL/6J)	decreased susceptibility to bacterial infection	J:63410
Sst1^C57BL/6J/Sst1^C57BL/6J (involves: C3HeB/FeJ * C57BL/6J)	decreased susceptibility to bacterial infection	J:63410, J:93705
Sst^tm1Low/Sst^tm1Low (B6.129P2-Sst^tm1Low)	immune system phenotype	J:126384
Sstr2^em1(IMPC)Mbp/Sstr2^em1(IMPC)Mbp (C57BL/6N-Sstr2^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	small spleen	J:211773
Sstr4^tm1Szo/Sstr4^tm1Szo (B6.129P2-Sstr4^tm1Szo)	abnormal granulocyte morphology	J:152015
	abnormal neutrophil physiology	J:152015
	increased interferon-gamma secretion	J:152015
	increased interleukin-1 beta secretion	J:152015
	increased susceptibility to type IV hypersensitivity reaction	J:152015
	increased tumor necrosis factor secretion	J:152015
Ssu2^{em1(IMPC)Ccpcz}/Ssu2^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Ssu2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Ssu72^tm1Cwl/Ssu72^tm1Cwl Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺ (B6.Cg-Ssu72^tm1Cwl Speer6-ps1^{Tg(Alb-cre)21Mgn})	liver inflammation	J:309624
St3gal2^tm1Jxm/St3gal2^tm1Jxm (Not Specified)	decreased T cell proliferation	J:217719
	increased spleen germinal center size	J:217719
	increased T cell number	J:217719
St3gal4^tm1.1Jxm/St3gal4^tm1.1Jxm (B6.129-St3gal4^tm1.1Jxm)	abnormal leukocyte tethering or rolling	J:117085
St3gal4^tm1.1Jxm/St3gal4^tm1.1Jxm (B6.129-St3gal4^tm1.1Jxm)	abnormal response to infection	J:136946
St3gal4^tm1.1Jxm/St3gal4^tm1.1Jxm (involves: 129S1/Sv * 129X1/SvJ)	abnormal leukocyte migration	J:189086
	decreased lymphocyte cell number	J:189086
	immune system phenotype	J:189086
St3gal4^tm1.1Jxm/St3gal4^tm1.1Jxm St3gal6^tm1.1Jxm/St3gal6^tm1.1Jxm (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal leukocyte migration	J:189086
	decreased lymphocyte cell number	J:189086
	impaired leukocyte tethering or rolling	J:189086
	impaired neutrophil recruitment	J:189086
	increased leukocyte cell number	J:189086
	increased neutrophil cell number	J:189086
St3gal6^tm1.1Jxm/St3gal6^tm1.1Jxm (B6.Cg-St3gal6^tm1.1Jxm)	immune system phenotype	J:189086
	impaired leukocyte tethering or rolling	J:189086
	impaired neutrophil recruitment	J:189086
St6gal1^tm1Jlau/St6gal1^tm1Jlau (129S4/SvJae-St6gal1^tm1Jlau)	abnormal neutrophil physiology	J:140702
	increased susceptibility to bacterial infection	J:140702
St6gal1^tm1Jlau/St6gal1^tm1Jlau (B6.129S4-St6gal1^tm1Jlau)	abnormal myelopoiesis	J:140547
	abnormal neutrophil physiology	J:140547
	increased neutrophil cell number	J:140547
	peritoneal inflammation	J:140547
St6gal1^tm1Jxm/St6gal1^tm1Jxm (involves: 129S1/Sv * 129X1/SvJ)	abnormal dendritic cell physiology	J:132991
	decreased marginal zone B cell number	J:132991
	decreased transitional stage B cell number	J:132991
	increased neutrophil cell number	J:140547
	peritoneal inflammation	J:140547
St6galnac1^em1Len/St6galnac1^em1Len (Not Specified)	increased susceptibility to colitis induced morbidity/mortality	J:324883
St6galnac2^tm1.1Cfg/St6galnac2^tm1.1Cfg (involves: 129S1/Sv * 129X1/SvJ)	decreased IgA level	J:217719
	increased B cell proliferation	J:217719
	increased pre-B cell number	J:217719
	increased spleen germinal center size	J:217719
St6galnac3^em1Staka/St6galnac3^em1Staka St6galnac4^em1Staka/St6galnac4^em1Staka (C57BL/6J-St6galnac3^em1Staka St6galnac4^em1Staka)	lymph node hemorrhage	J:340690
St8sia1^tm1Kfk/St8sia1^tm1Kfk (Not Specified)	decreased CD8-positive, alpha-beta T cell number	J:73818
	immune system phenotype	J:73818
	increased T cell proliferation	J:73818
St8sia6^em1(IMPC)Mbp/St8sia6^em1(IMPC)Mbp (C57BL/6N-St8sia6^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
St13^em1Gwzh/St13^em1Gwzh Tg(PRSS1/lacZ)#Gwzh/0 (Not Specified)	increased susceptibility to induced pancreatitis	J:345508
St14^tm1Bug/St14^tm1Bug (involves: 129P2/OlaHsd * Black Swiss)	decreased double-positive T cell number	J:87125
	increased thymocyte apoptosis	J:87125
St14^tm2Bug/St14^tm3Bug Tg(MMTV-cre)4Mam/0 (involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J * FVB/NJ * N:Black Swiss)	abnormal chemokine secretion	J:213072
	abnormal cytokine secretion	J:213072
	decreased CD4-positive, alpha-beta T cell number	J:213072
	decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:213072
	decreased CD8-positive, alpha-beta T cell number	J:213072
	decreased regulatory T cell number	J:213072
	increased anti-nuclear antigen antibody level	J:213072
	increased autoantibody level	J:213072
	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:213072
	increased effector memory CD4-positive, alpha-beta T cell number	J:213072
	increased effector memory CD8-positive, alpha-beta T cell number	J:213072
	lacrimal gland inflammation	J:213072
	submandibular gland inflammation	J:213072
St14^tm2Bug/St14^tm3Bug Tg(Vil1-cre)997Gum/0 (involves: 129P2/OlaHsd * 129S6/SvEvTac * Black Swiss * C57BL/6 * SJL)	colitis	J:153070
St14^tm3Bug/St14^tm3Bug (involves: 129S6/SvEvTac)	immune system phenotype	J:213072
Stag1^em1(IMPC)Mbp/Stag1⁺ (C57BL/6N-Stag1^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	small spleen	J:211773
Stag2^tm1.1Soga/Y Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6J * C57BL/6N * CBA/J)	decreased B cell number	J:289000
	decreased leukocyte cell number	J:289000
	enlarged spleen	J:289000
	increased granulocyte number	J:289000
	increased monocyte cell number	J:289000
Stam^tm2Sug/Stam^tm2Sug Stam2^tm1Sug/Stam2^tm1Sug Tg(Lck-cre)I57Jxm/0 (involves: 129S4/SvJae * C57BL/6 * ICR)	decreased T cell number	J:80617
	decreased T cell proliferation	J:80617
Stambp^tm1Sug/Stambp^tm1Sug (involves: 129S4/SvJae * C57BL/6)	immune system phenotype	J:72940
Stard7^{tm1a(EUCOMM)Wtsi}/Stard7⁺ (involves: C57BL/6N)	dermatitis	J:242746
	immune system phenotype	J:242746
	increased CD11b-high dendritic cell number	J:242746
	increased susceptibility to type I hypersensitivity reaction	J:242746
	lung inflammation	J:242746
Stard13^{tm1a(KOMP)Wtsi}/Stard13^{tm1a(KOMP)Wtsi} (involves: C57BL/6 * C57BL/6N)	increased susceptibility to bacterial infection	J:213427
	lymphoid hyperplasia	J:213427
Stat1^fae/Stat1^fae (C57BL/6JSfdAnu-Stat1^fae/Anu)	abnormal T cell activation	J:105311
	abnormal T-helper 2 physiology	J:105311
	increased IgG level	J:105311
Stat1^m1Anu/Stat1^m1Anu (C57BL/6JSfdAnu-Stat1^m1Anu)	abnormal response to infection	J:104190
Stat1^m1Btlr/Stat1^m1Btlr (C57BL/6J-Stat1^m1Btlr)	abnormal macrophage physiology	J:105543
	increased susceptibility to Herpesvirales infection	J:105543
	increased susceptibility to Riboviria infection	J:105543
Stat1^m2Btlr/Stat1^m2Btlr (C57BL/6J-Stat1^m2Btlr)	decreased interferon-gamma secretion	J:134096
	decreased NK cell degranulation	J:134096
	impaired natural killer cell mediated cytotoxicity	J:134096
	increased susceptibility to Herpesvirales infection	J:134096
Stat1^m3Btlr/Stat1^m3Btlr (C57BL/6J-Stat1^m3Btlr)	impaired natural killer cell mediated cytotoxicity	J:254835
Stat1^m4Btlr/Stat1^m4Btlr (C57BL/6J-Stat1^m4Btlr)	abnormal CD8-positive, naive alpha-beta T cell number	J:264800
	decreased B cell number	J:264800
	decreased B-1 B cell number	J:264800
	decreased CD8-positive, alpha-beta T cell number	J:264800
	decreased NK cell number	J:264800
	decreased single-positive T cell number	J:264800
	increased CD4-positive, alpha-beta T cell number	J:264800
	increased effector memory CD8-positive, alpha-beta T cell number	J:264800
	increased NK T cell number	J:264800
Stat1^m5Btlr/Stat1^m5Btlr (C57BL/6J-Stat1^m5Btlr)	abnormal CD4-positive T cell differentiation	J:274938
	abnormal CD8-positive, alpha-beta T cell differentiation	J:274938
	abnormal T cell differentiation	J:274938
	decreased CD8-positive, naive alpha-beta T cell number	J:274938
	decreased cytotoxic T cell cytolysis	J:274938
	increased CD4-positive, alpha-beta T cell number	J:274938
	increased effector memory CD4-positive, alpha-beta T cell number	J:274938
	increased effector memory CD8-positive, alpha-beta T cell number	J:274938
	increased T cell number	J:274938
Stat1^tm1Dlv/Stat1^tm1Dlv (either: (involves: 129S/SvEv * C57BL/6) or (involves: 129S/SvEv * C57BL/6 * CD-1))	abnormal leukocyte physiology	J:31325
	increased susceptibility to Coronaviridae infection	J:31325
	increased susceptibility to Riboviria infection	J:31325
Stat1^tm1Dlv/Stat1^tm1Dlv (B6.129-Stat1^tm1Dlv)	increased susceptibility to Herpesvirales infection	J:81243
Stat1^tm1Dlv/Stat1^tm1Dlv (B6.129-Stat1^tm1Dlv)	increased susceptibility to Togaviridae infection	J:81243
Stat1^tm1Dlv/Stat1^tm1Dlv (involves: 129S/SvEv)	abnormal MHC II cell surface expression on macrophages	J:130622
	decreased level of surface class I molecules	J:130622
	decreased susceptibility to endotoxin shock	J:130622
	immune system phenotype	J:99728
	increased circulating interferon-gamma level	J:130622
	increased susceptibility to bacterial infection	J:130622
	increased susceptibility to Riboviria infection	J:130622
Stat1^tm1Dlv/Stat1^tm1Dlv (B6.129S-Stat1^tm1Dlv)	abnormal NK cell physiology	J:79552
	impaired natural killer cell mediated cytotoxicity	J:79552
	increased circulating interferon-gamma level	J:79552
	increased circulating interleukin-12b level	J:79552
Stat1^tm1Dlv/Stat1^tm1Dlv Tg(ANPEP)270Mmul/Tg(ANPEP)270Mmul (involves: 129S/SvEv * ICR)	increased susceptibility to Coronaviridae infection	J:99728
Stat1^tm1Dlv/Stat1^tm1Dlv Tg(ANPEP)861Mmul/Tg(ANPEP)861Mmul (involves: 129S/SvEv * ICR)	increased susceptibility to Coronaviridae infection	J:99728
Stat1^tm1Rds/Stat1^tm1Rds (either: (involves: 129/Sv) or (involves: 129/Sv * C57BL/6))	increased susceptibility to bacterial infection	J:31326
	increased susceptibility to Riboviria infection	J:31326
Stat1^tm1Rds/Stat1^tm1Rds (involves: 129)	increased susceptibility to Herpesvirales infection	J:81243
	increased susceptibility to Riboviria infection	J:66564
	increased susceptibility to Togaviridae infection	J:81243
Stat1^tm1Rds/Stat1^tm1Rds (129S6/SvEv-Stat1^tm1Rds/Tac)	abnormal macrophage physiology	J:136368
	abnormal osteoclast differentiation	J:131353
	bronchiolitis	J:286237
	decreased circulating interferon-gamma level	J:122801
	decreased interleukin-1 beta secretion	J:136368
	increased NK T cell number	J:122801
	increased susceptibility to Coronaviridae infection	J:286237
	increased susceptibility to Coronaviridae infection induced morbidity/mortality	J:286237
	lung inflammation	J:286237
	peritoneal inflammation	J:286237
	pleuritis	J:286237
Stat1^tm1Rds/Stat1^tm1Rds (B6.129-Stat1^tm1Rds)	increased osteoclast cell number	J:84894
Stat1^tm1Rds/Stat1^tm1Rds Stat2^tm1Shnd/Stat2^tm1Shnd (involves: 129/Sv * 129S1/Sv * 129X1/SvJ)	increased susceptibility to Riboviria infection	J:66564
Stat1^tm1Rds/Stat1^tm1Rds Stat3^tm2Aki/Stat3^tm2Aki Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129/Sv * 129P2/OlaHsd * C57BL/6)	colitis	J:83280
	increased CD4-positive, alpha-beta T cell number	J:83280
	increased interferon-gamma secretion	J:83280
	increased interleukin-6 secretion	J:83280
	increased tumor necrosis factor secretion	J:83280
Stat1^tm1Tdec/Stat1^tm1Tdec (involves: 129P2/OlaHsd * BALB/c)	abnormal macrophage physiology	J:130622
	abnormal MHC II cell surface expression on macrophages	J:130622
	decreased susceptibility to endotoxin shock	J:130622
	increased susceptibility to bacterial infection	J:130622
	increased susceptibility to Riboviria infection	J:130622
Stat1^tm1Uvin/Stat1^tm1Uvin (involves: 129 * C57BL/6)	increased macrophage nitric oxide production	J:174863
Stat1^tm2.1Uvin/Stat1^tm2.1Uvin (B6.129P2-Stat1^tm2.1Uvin)	decreased susceptibility to endotoxin shock	J:209388
	immune system phenotype	J:209388
	increased susceptibility to bacterial infection	J:209388
	increased susceptibility to bacterial infection induced morbidity/mortality	J:209388
Stat1^{tm2b(EUCOMM)Wtsi}/Stat1^{tm2b(EUCOMM)Wtsi} (C57BL/6N-Stat1^{tm2b(EUCOMM)Wtsi}/Orl)	decreased lymphocyte cell number	J:211773
	enlarged lymph nodes	J:211773
	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
	increased large unstained cell number	J:211773
	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Stat2^m1Btlr/Stat2^m1Btlr (C57BL/6J-Stat2^m1Btlr)	decreased CD8-positive, alpha-beta T cell number	J:265265
	decreased central memory CD8 positive, alpha-beta T cell number	J:265265
	decreased single-positive T cell number	J:265265
Stat2^p117/Stat2^p117 (C57BL/6J-Stat2^P117)	abnormal level of surface class II molecules	J:164049
	decreased dendritic cell number	J:164049
	decreased level of surface class I molecules	J:164049
	decreased plasmacytoid dendritic cell number	J:164049
	increased susceptibility to Picornaviridae infection induced morbidity/mortality	J:164049
Stat2^{tm1.1(STAT2)Diam}/Stat2^{tm1.1(STAT2)Diam} (C57BL/6-Stat2^{tm1.1(STAT2)Diam})	increased susceptibility to Flaviviridae infection	J:261503
	increased susceptibility to Flaviviridae infection induced morbidity/mortality	J:261503
Stat2^tm1Jdf/Stat2^tm1Jdf Tg(DO11.10)10Dlo/0 (C.Cg-Stat2^tm1Jdf Tg(DO11.10)10Dlo)	immune system phenotype	J:95855
Stat2^tm1Shnd/Stat2^tm1Shnd (involves: 129S1/Sv * 129X1/SvJ)	abnormal T cell differentiation	J:66564
	increased susceptibility to Riboviria infection	J:66564
Stat3^tm1Aki/Stat3^tm1Aki Tg(Tek-cre)12Flv/0 (involves: 129P2/OlaHsd * C3H * C57BL/6)	abnormal interleukin level	J:123351
Stat3^tm1Desi/Stat3^tm1Desi (involves: 129X1/SvJ * C57BL/6)	increased susceptibility to endotoxin shock	J:77307
Stat3^tm1Dlv/Stat3^tm1Dlv Tg(Cd4-cre)1Cwi/? (involves: 129 * C57BL/6 * DBA/2)	abnormal CD4-positive T cell differentiation	J:124293
	abnormal gut-associated lymphoid tissue morphology	J:124293
	decreased interleukin-17 secretion	J:124293
	increased interferon-gamma secretion	J:124293
Stat3^tm1Dlv/Stat3^tm1Dlv Tg(Csf1r-icre)1Jwp/0 (involves: 129P2/OlaHsd * C57BL/6 * FVB)	abnormal acute inflammation	J:156593
	abnormal inflammatory response	J:156593
	colitis	J:156593
	increased granulocyte number	J:156593
	increased macrophage cell number	J:156593
	increased T cell number	J:156593
Stat3^tm1Dlv/Stat3^tm1Dlv Tg(MMTV-cre)4Mam/0 (involves: 129P2/OlaHsd * C57BL/6J * FVB)	decreased T-helper 17 cell number	J:120176
Stat3^tm1Dnl/Stat3^tm1Dlv (involves: C57BL/6)	decreased thymocyte number	J:87599
Stat3^tm1Dnl/Stat3^tm1Dlv (involves: C57BL/6)	increased thymocyte apoptosis	J:87599
Stat3^tm1Flv/Stat3^tm1Flv Tg(Tek-cre)1Xyfu/0 (involves: C57BL/6)	abnormal cytokine secretion	J:86655
	increased susceptibility to endotoxin shock	J:86655
Stat3^tm1Flv/Stat3^tm1Flv Tg(Tek-cre)12Flv/0 (involves: 129 * C3H * C57BL/6)	abnormal inflammatory response	J:81973
	abnormal innate immunity	J:81973
	abnormal T-helper 1 physiology	J:81973
	cecum inflammation	J:81973
	colitis	J:81973
	granulomatous inflammation	J:81973
	ileum inflammation	J:81973
	increased circulating interferon-gamma level	J:81973
	increased circulating tumor necrosis factor level	J:81973
	increased leukocyte cell number	J:81973
	intestinal inflammation	J:81973
	liver inflammation	J:81973
Stat3^tm1Vpo/Stat3^tm1Vpo Tg(Mx1-cre)1Cgn/0 (involves: 129P2/OlaHsd * BALB/cAn * C57BL/6 * CBA)	abnormal macrophage physiology	J:89194
	increased interleukin-6 secretion	J:89194
	increased tumor necrosis factor secretion	J:89194
Stat3^tm1Vpo/Stat3^tm2Vpo Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA * BALB/cAn)	abnormal macrophage physiology	J:89194
	increased interleukin-6 secretion	J:89194
	increased tumor necrosis factor secretion	J:89194
Stat3^tm1Xyfu/Stat3⁺ Tg(Myh6-cre)2182Mds/0 (involves: 129S1/Sv * FVB/N)	increased susceptibility to endotoxin shock	J:86400
	increased tumor necrosis factor secretion	J:86400
Stat3^tm1Xyfu/Stat3^tm1.1Xyfu Tg(Myh6-cre)2182Mds/0 (involves: 129S1/Sv * FVB/N)	increased susceptibility to endotoxin shock	J:86400
	increased tumor necrosis factor secretion	J:86400
Stat3^tm1Xyfu/Stat3^tm1.1Xyfu Tg(Ttr-cre)10-3Xyfu/? (involves: 129S1/Sv * C57BL/6)	increased monocyte cell number	J:128719
	increased neutrophil cell number	J:128719
Stat3^tm2Aki/Stat3^tm2Aki (involves: 129P2/OlaHsd * BALB/c * C57BL/6)	abnormal response to infection	J:122213
Stat3^tm2Aki/Stat3^tm2Aki Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6)	colitis	J:83280
	increased CD4-positive, alpha-beta T cell number	J:83280
	increased dendritic cell number	J:83280
	increased interferon-gamma secretion	J:83280
	increased interleukin-12 secretion	J:83280
	increased macrophage cell number	J:83280
Stat3^tm2Aki/Stat3^tm2Aki Tg(KRT5-cre)1Tak/0 (involves: 129P2/OlaHsd * C3H * C57BL/6)	conjunctivitis	J:194832
	dermatitis	J:194832
	lacrimal gland inflammation	J:194832
Stat3^tm2Aki/Stat3^tm2Aki Tg(Lck-cre)1Jtak/0 (involves: 129P2/OlaHsd)	decreased T cell proliferation	J:50443
	increased T cell apoptosis	J:50443
Stat3^tm2Aki/Stat3^tm2Aki Tg(SFTPC-rtTA)5Jaw/0 Tg(tetO-cre)1Jaw/0 (involves: 129 * 129P2/OlaHsd * C57BL/6)	abnormal cytokine level	J:87622
	lung inflammation	J:87622
Stat3^tm2Aki/Stat3^tm2Aki Tlr4^tm1Aki/Tlr4^tm1Aki Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6)	colitis	J:83280
	decreased interferon-gamma secretion	J:83280
	decreased susceptibility to endotoxin shock	J:83280
Stat3^tm2Aki/Stat3^tm2Aki Tnf^tm1Sek/Tnf^tm1Sek Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6 * CBA)	colitis	J:83280
	increased interferon-gamma secretion	J:83280
	increased interleukin-6 secretion	J:83280
	increased interleukin-12b secretion	J:83280
Stat3^tm3Vpo/Stat3^tm3Vpo (involves: C57BL/6 * CBA * BALB/cAn)	abnormal macrophage physiology	J:89194
Stat4^ity14/Stat4^ity14 (involves: 129S1/Sv * 129X1/SvJ)	decreased circulating interferon-gamma level	J:207092
	decreased interferon-gamma secretion	J:207092
	increased circulating interleukin-12 level	J:207092
	increased susceptibility to bacterial infection	J:207092
	increased susceptibility to bacterial infection induced morbidity/mortality	J:207092
Stat4^ity14/Stat4^tm1Gru (involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ)	increased susceptibility to bacterial infection induced morbidity/mortality	J:207092
Stat4^tm1Gru/Stat4^tm1Gru (involves: 129S2/SvPas * BALB/c)	abnormal lymphocyte physiology	J:34059
	abnormal NK cell physiology	J:34059
	abnormal T cell proliferation	J:34059
	abnormal T-helper 1 physiology	J:34059
	abnormal T-helper 2 physiology	J:34059
	decreased circulating interferon-gamma level	J:163843
	decreased interferon-gamma secretion	J:34059
	increased susceptibility to bacterial infection	J:163843
	increased susceptibility to bacterial infection induced morbidity/mortality	J:163843
Stat4^tm1Gru/Stat4^tm1Gru (NOD.129S2-Stat4^tm1Gru)	abnormal inflammatory response	J:90600
	decreased circulating interferon-gamma level	J:90600
	decreased circulating interleukin-2 level	J:90600
	decreased susceptibility to autoimmune diabetes	J:90600
Stat4^tm1Gru/Stat4^tm1Gru (C.129S2-Stat4^tm1Gru)	abnormal CD4-positive T cell differentiation	J:143729
	decreased circulating interferon-gamma level	J:90600
	decreased circulating interleukin-2 level	J:90600
Stat4^tm1Gru/Stat4^tm1Gru (involves: 129S2/SvPas)	abnormal cytokine secretion	J:112600
Stat4^tm1Gru/Stat4^tm1Gru Tg(Ins2-GP)34-20Olds/0 (involves: 129S2/SvPas * BALB/c * C57BL/6)	abnormal susceptibility to autoimmune disorder	J:107047
Stat4^tm1Gru/Stat4^tm1Gru Tg(Ins2-NP)25-3Olds/0 (involves: 129S2/SvPas * BALB/c * C57BL/6)	abnormal cytotoxic T cell physiology	J:107047
	decreased interferon-gamma secretion	J:107047
	decreased susceptibility to autoimmune diabetes	J:107047
	insulitis	J:107047
Stat4^tm1Jni/Stat4^tm1Jni (involves: 129P2/OlaHsd * C57BL/6)	abnormal NK cell physiology	J:79552
	decreased circulating interferon-gamma level	J:79552
	decreased susceptibility to autoimmune diabetes	J:96338
	increased interleukin-4 secretion	J:96338
Stat4^tm1Jni/Stat4^tm1Jni Stat6^tm1Jni/Stat6^tm1Jni (involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6)	decreased interleukin-4 secretion	J:96338
	increased interferon-gamma secretion	J:96338
	increased susceptibility to autoimmune diabetes	J:96338
Stat5a^tm1.1Wjl/Stat5a^tm1.1Wjl Stat5b^tm2.1Wjl/Stat5b^tm2.1Wjl (involves: 129S6/SvEvTac * C57BL/6J * FVB/N)	abnormal leukocyte morphology	J:187325
	abnormal regulatory T cell physiology	J:187325
	abnormal T cell subpopulation ratio	J:187325
	decreased CD8-positive, alpha-beta T cell number	J:187325
	decreased NK cell number	J:187325
	decreased T cell proliferation	J:187325
	increased T cell apoptosis	J:187325
Stat5a^tm1Jni/Stat5a^tm1Jni Stat5b^tm2Jni/Stat5b^tm2Jni (either: (involves: 129P2/OlaHsd) or (involves: 129X1/SvJ))	abnormal myelopoiesis	J:77412
	decreased leukocyte cell number	J:77412
	decreased T cell number	J:77412
	increased neutrophil cell number	J:77412
Stat5a^tm1Jni/Stat5a^tm1Jni Stat5b^tm2Jni/Stat5b^tm2Jni (involves: 129 * C57BL/6)	abnormal mast cell differentiation	J:84889
	abnormal mast cell physiology	J:84889
	absent mast cells	J:84889
	decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:122463
Stat5a^tm1Mam/Stat5a^tm1Mam (C.129S6-Stat5a^tm1Mam)	abnormal mast cell differentiation	J:101855
	abnormal mast cell morphology	J:101855
	decreased mast cell number	J:101855
Stat5a^tm1Mam/Stat5a^tm1Mam (involves: 129S6/SvEvTac * C57BL/6)	decreased NK cell number	J:112035
	decreased splenocyte number	J:112035
	impaired natural killer cell mediated cytotoxicity	J:112035
Stat5a^tm2Mam/Stat5a^tm2Mam Stat5b^tm1Mam/Stat5b⁺ (involves: 129S6/SvEvTac)	abnormal lymphopoiesis	J:258967
Stat5a^tm2Mam/Stat5a^tm2Mam Stat5b^tm1Mam/Stat5b^tm1Mam Tg(Cd4-cre)1Cwi/0 (involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * DBA/2)	increased circulating interleukin-17 level	J:120176
	increased interleukin-17 secretion	J:120176
Stat5a^tm2Mam/Stat5a^tm2Mam Stat5b^tm1Mam/Stat5b^tm1Mam Tg(Lck-cre)I57Jxm/0 (involves: 129 * 129S6/SvEvTac * C57BL/6 * ICR)	abnormal acute inflammation	J:122463
	abnormal T cell subpopulation ratio	J:122463
	decreased CD8-positive, alpha-beta T cell number	J:122463
	enlarged spleen	J:122463
Stat5a^tm2Mam/Stat5a^tm2Mam Stat5b^tm1Mam/Stat5b^tm1Mam Tg(Mx1-cre)1Cgn/0 (involves: 129S6/SvEvTac * C57BL/6 * CBA)	abnormal leukopoiesis	J:155489
	abnormal neutrophil differentiation	J:155489
	abnormal neutrophil physiology	J:155489
	decreased leukocyte cell number	J:155489
	decreased lymphocyte cell number	J:155489
	decreased monocyte cell number	J:155489
	decreased neutrophil cell number	J:155489
Stat5b^tm1Hwd/Stat5b^tm1Hwd (involves: C57BL/6)	abnormal double-negative T cell morphology	J:112035
	abnormal lymphocyte cell number	J:112035
	abnormal lymphocyte morphology	J:112035
	decreased CD8-positive, alpha-beta T cell number	J:112035
	decreased NK cell number	J:112035
	decreased splenocyte number	J:112035
	decreased T cell proliferation	J:112035
	decreased thymocyte number	J:112035
	impaired natural killer cell mediated cytotoxicity	J:112035
Stat5b^tm1Mam/Stat5b^tm1Mam Tg(Cd4-cre)1Cwi/0 (involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * DBA/2)	increased circulating interleukin-17 level	J:120176
	increased interleukin-17 secretion	J:120176
Stat5b^tm1Mam/Stat5b^tm1Mam Tg(Lck-cre)I57Jxm/0 (involves: 129 * 129S6/SvEvTac * C57BL/6 * ICR)	abnormal acute inflammation	J:122463
	abnormal T cell subpopulation ratio	J:122463
	decreased CD8-positive, alpha-beta T cell number	J:122463
	enlarged spleen	J:122463
Stat5b^tm1Mam/Stat5b^tm1Mam Tg(Mx1-cre)1Cgn/0 (involves: 129S6/SvEvTac * C57BL/6 * CBA)	abnormal leukopoiesis	J:155489
	abnormal neutrophil differentiation	J:155489
	abnormal neutrophil physiology	J:155489
	decreased leukocyte cell number	J:155489
	decreased lymphocyte cell number	J:155489
	decreased monocyte cell number	J:155489
	decreased neutrophil cell number	J:155489
Stat6^tm1Aki/Stat6^tm1Aki (involves: 129P2/OlaHsd)	abnormal T-helper 2 physiology	J:32561
	decreased B cell proliferation	J:32561
	decreased IgE level	J:32561
	decreased IgG1 level	J:32561
	decreased T cell proliferation	J:32561
	decreased T-helper 2 cell number	J:172134
	increased IgA level	J:32561
	increased IgG level	J:32561
Stat6^tm1Aki/Stat6^tm1Aki (C.129P2-Stat6^tm1Aki Nfkbiz^tm1Aki)	skin inflammation	J:141704
Stat6^tm1Aki/Stat6^tm1Aki Tg(KRT14-CASP1)1Miz/0 (involves: 129P2/OlaHsd * C57BL/6)	decreased IgE level	J:78602
	decreased IgG1 level	J:78602
	dermatitis	J:78602
	increased circulating interleukin-18 level	J:78602
Stat6^tm1Gru/Stat6⁺ Tg(Scgb1a1-Il13)2Eli/? (involves: 129S2/SvPas * C57BL/6 * CBA)	respiratory system inflammation	J:132385
Stat6^tm1Gru/Stat6^tm1Gru (C.129S2-Stat6^tm1Gru/J)	abnormal CD4-positive T cell differentiation	J:204829
	abnormal CD8-positive, alpha beta T cell morphology	J:125259
	abnormal humoral immune response	J:107370
	decreased IgA level	J:107370
	decreased IgG3 level	J:107370
	decreased IgM level	J:107370
	decreased interleukin-4 secretion	J:107370
	decreased susceptibility to Herpesvirales infection	J:107370
	increased interferon-gamma secretion	J:107370
	increased interleukin-2 secretion	J:107370
Stat6^tm1Gru/Stat6^tm1Gru (129S2/SvPas-Stat6^tm1Gru)	abnormal interleukin secretion	J:31932
	abnormal T-helper 2 cell differentiation	J:31932
	decreased IgE level	J:31932
	decreased interleukin-4 secretion	J:31932
	decreased interleukin-5 secretion	J:31932
	decreased T cell proliferation	J:31932
Stat6^tm1Gru/Stat6^tm1Gru (involves: 129S2/SvPas)	abnormal cytokine secretion	J:112600
Stat6^tm1Gru/Stat6^tm1Gru (involves: 129S2/SvPas * BALB/c)	abnormal acute inflammation	J:85386
	abnormal granulocyte physiology	J:85386
	abnormal macrophage physiology	J:85386
	immune system phenotype	J:85386
	impaired eosinophil chemotaxis	J:85386
	impaired neutrophil chemotaxis	J:85386
	increased circulating tumor necrosis factor level	J:85386
Stat6^tm1Gru/Stat6^tm1Gru (C.129S2-Stat6^tm1Gru)	abnormal circulating interleukin level	J:66222
	abnormal circulating interleukin-4 level	J:66222
	abnormal circulating interleukin-5 level	J:66222
	abnormal cytotoxic T cell physiology	J:65894
	abnormal immune serum protein physiology	J:66222
	abnormal immunoglobulin level	J:66222
	abnormal leukocyte migration	J:74497
	abnormal leukocyte physiology	J:74497
	decreased IgE level	J:74497, J:66222
	decreased IgG1 level	J:66222
	impaired eosinophil recruitment	J:66222
	increased IgG2a level	J:66222
Stat6^tm1Jni/Stat6^tm1Jni (involves: 129S/SvEv)	abnormal B cell physiology	J:32607
	abnormal B cell proliferation	J:32607
	abnormal class switch recombination	J:32607
	abnormal level of surface class II molecules	J:32607
	abnormal T-helper 1 cell differentiation	J:32607
	abnormal T-helper 2 cell differentiation	J:32607
	increased B cell apoptosis	J:146533
Stat6^tm1Jni/Stat6^tm1Jni (involves: 129S/SvEv * C57BL/6)	abnormal mast cell morphology	J:110429
	abnormal T-helper 1 cell differentiation	J:51096
	decreased IgE level	J:51096
	decreased IgG1 level	J:51096
	decreased interleukin-4 secretion	J:96338
	decreased susceptibility to autoimmune diabetes	J:96338
	increased IgE level	J:110429
	increased IgG1 level	J:110429
	increased IgG2a level	J:51096
	increased interferon-gamma secretion	J:51096, J:96338
	increased interleukin-12 secretion	J:51096
	increased susceptibility to parasitic infection	J:110429
Stau2^em1(IMPC)Mbp/Stau2^em1(IMPC)Mbp (C57BL/6N-Stau2^em1(IMPC)Mbp/MbpMmucd)	increased monocyte cell number	J:211773
Steap3^fred/Steap3^fred (C57BL/6-Steap3^fred)	enlarged spleen	J:145194
Steap3^tm1.1Atel/Steap3^tm1.1Atel (involves: C57BL/6)	abnormal spleen morphology	J:154356
	abnormal spleen red pulp morphology	J:154356
	decreased splenocyte apoptosis	J:154356
	increased spleen weight	J:154356
	increased spleen white pulp amount	J:154356
Steap4^tm1Dgen/Steap4^tm1Dgen (involves: 129P2/OlaHsd)	increased macrophage cell number	J:187736
Stia1^NOD/ShiLtDoi/? (involves: C57BL/6J * NOD/LtDoi)	increased inflammatory response	J:70882
Stia2^C57BL/6J/Stia2^C57BL/6J (involves: C57BL/6J * NOD/LtDoi)	increased inflammatory response	J:70882
Stia2^C57BL/6J/Stia2^NOD/ShiLtDoi (involves: C57BL/6J * NOD/LtDoi)	increased inflammatory response	J:70882
Stim1^em1(IMPC)Mbp/Stim1⁺ (C57BL/6N-Stim1^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Stim1^Sax/Stim1⁺ (involves: C3HeB/FeJ * C57BL/6)	abnormal thrombopoiesis	J:127381
	enlarged spleen	J:127381
	immune system phenotype	J:127381
	increased spleen red pulp amount	J:127381
Stim1^tm1.1Kuro/Stim1⁺ (C57BL/6-Stim1^tm1.1Kuro)	decreased susceptibility to type I hypersensitivity reaction	J:130477
Stim1^tm1.1Kuro/Stim1^tm1.1Kuro (C57BL/6-Stim1^tm1.1Kuro)	abnormal cytokine secretion	J:130477
	abnormal interleukin secretion	J:130477
	decreased interleukin-6 secretion	J:130477
	decreased interleukin-13 secretion	J:130477
	decreased mast cell degranulation	J:130477
	decreased tumor necrosis factor secretion	J:130477
Stim1^tm1.1Pg/Stim1⁺ (involves: C57BL/6)	decreased Ly6C low monocyte number	J:285187
	decreased NK cell number	J:285187
	enlarged spleen	J:285187
	increased Ly6C high monocyte number	J:285187
Stim1^tm1Kuro/Stim1^tm1Kuro Cd79a^tm1(cre)Reth/Cd79a⁺ (involves: BALB/c * C57BL/6)	abnormal B cell calcium ion homeostasis	J:172608
	decreased B cell proliferation	J:172608
	decreased interleukin-10 secretion	J:172608
Stim1^tm1Kuro/Stim1^tm1Kuro Stim2^tm1.1Kuro/Stim2^tm1.1Kuro Cd79a^tm1(cre)Reth/Cd79a⁺ (involves: BALB/c * C57BL/6)	abnormal B cell calcium ion homeostasis	J:172608
	abnormal B cell physiology	J:172608
	decreased B cell proliferation	J:172608
	decreased interleukin-10 secretion	J:172608
	immune system phenotype	J:172608
	increased CD4-positive, alpha-beta T cell number	J:172608
	increased CD8-positive, alpha-beta T cell number	J:172608
	increased interferon-gamma secretion	J:172608
	increased interleukin-10 secretion	J:172608
	increased interleukin-17 secretion	J:172608
	increased regulatory T cell number	J:172608
	increased susceptibility to experimental autoimmune encephalomyelitis	J:172608
Stim1^tm1Rao/Stim1^tm1Rao Stim2^tm1Rao/Stim2^tm1Rao Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2 * SJL)	abnormal B cell differentiation	J:133262
	abnormal CD4-positive, alpha-beta T cell physiology	J:133262
	abnormal granulocyte morphology	J:133262
	abnormal immune system morphology	J:133262
	abnormal immune system physiology	J:133262
	abnormal lymph organ size	J:133262
	abnormal T cell differentiation	J:133262
	blepharitis	J:133262
	decreased interferon-gamma secretion	J:133262
	decreased interleukin-2 secretion	J:133262
	decreased regulatory T cell number	J:133262
	decreased T cell proliferation	J:133262
	dermatitis	J:133262
	enlarged lymph nodes	J:133262
	enlarged spleen	J:133262
	increased germinal center B cell number	J:133262
	increased IgG1 level	J:133262
	increased lymphocyte cell number	J:133262
	increased spleen germinal center number	J:133262
Stim1^tm1Rao/Stim1^tm1Rao Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2 * SJL)	abnormal CD4-positive, alpha-beta T cell physiology	J:133262
	decreased interleukin-2 secretion	J:133262
	increased lymphocyte cell number	J:133262
Stim1^tm3Ics/Stim1⁺ (involves: C57BL/6N)	decreased lymphocyte cell number	J:277842
	decreased NK T cell number	J:277842
	decreased regulatory T cell number	J:277842
	increased monocyte cell number	J:277842
	increased neutrophil cell number	J:277842
	increased spleen weight	J:277842
	myositis	J:277842
Stim2^tm1.1Kuro/Stim2^tm1.1Kuro Cd79a^tm1(cre)Reth/Cd79a⁺ (involves: BALB/c * C57BL/6)	abnormal B cell calcium ion homeostasis	J:172608
	immune system phenotype	J:172608
Stim2^tm1Rao/Stim2^tm1Rao Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2 * SJL)	abnormal CD4-positive, alpha-beta T cell physiology	J:133262
	abnormal T-helper 1 physiology	J:133262
	abnormal T-helper 2 physiology	J:133262
	decreased interferon-gamma secretion	J:133262
	decreased interleukin-2 secretion	J:133262
	decreased interleukin-4 secretion	J:133262
Sting1^em1Jmin/Sting1⁺ (involves: C57BL/6N)	abnormal cytokine level	J:251372
	abnormal spleen morphology	J:251372
	decreased single-positive T cell number	J:251372
	enlarged spleen	J:251372
	increased circulating interleukin-10 level	J:251372
	increased circulating interleukin-13 level	J:251372
	increased circulating tumor necrosis factor level	J:251372
	increased IgM level	J:251372
	lung inflammation	J:251372
Sting1^gt/Sting1^gt (C57BL/6-Sting1^gt)	abnormal dendritic cell physiology	J:201167
	abnormal humoral immune response	J:201167
	abnormal immune cell physiology	J:201167
	abnormal macrophage physiology	J:201167
	abnormal plasmacytoid dendritic cell physiology	J:201167
	abnormal response to infection	J:168746
	decreased circulating interferon-alpha level	J:201167
	decreased circulating interferon-beta level	J:201167, J:168746
	increased susceptibility to Herpesvirales infection	J:201167
	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:201167
Sting1^gt/Sting1^gt (involves: C57BL/6)	immune system phenotype	J:265023
Sting1^gt/Sting1^gt (involves: C57BL/6)	increased susceptibility to Retroviridae infection	J:265023
Sting1^gt/Sting1^gt (C57BL/6J-Sting1^gt/J)	abnormal interferon-beta secretion	J:354143
	abnormal level of surface class I molecules	J:363611
	abnormal MHC II cell surface expression on macrophages	J:363611
	abnormal response to infection	J:354143
	increased susceptibility to Retroviridae infection	J:354143
Sting1^tm1Camb/Sting1^tm1Camb (involves: C57BL/6N)	decreased circulating interferon-beta level	J:179270
	decreased circulating interleukin-6 level	J:179270
	immune system phenotype	J:179270
Sting1^tm1Gnb/Sting1^tm1Gnb (involves: 129P2/OlaHsd * C57BL/6)	abnormal innate immunity	J:141011
	abnormal susceptibility to Herpesvirales infection	J:141011
	increased susceptibility to Riboviria infection	J:141011
Sting1^tm1Gnb/Sting1^tm1Gnb (involves: 129P2/OlaHsd)	abnormal response to infection	J:168746
Sting1^tm1Gnb/Sting1^tm1Gnb Trex1^tm1Tld/Trex1^tm1Tld (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:181257
Stip1^tm1.2Mamp/Stip1^tm1.2Mamp (involves: C57BL/6)	increased acute inflammation	J:201097
Stk3^tm1.1Jav/Stk3^tm1.1Jav (involves: 129 * C57BL/6)	immune system phenotype	J:153945
Stk3^tm1.1Jav/Stk3^tm1.1Jav Stk4^tm1Kina/Stk4^tm1Kina Tg(Nkx2-1-cre)2Sand/? (involves: 129 * C57BL/6)	lung inflammation	J:197340
Stk3^tm1.1Yy/Stk3^tm1Yy Stk4^tm1.1Yy/Stk4^tm1.1Yy Tg(CAG-cre/Esr1)5Amc/0 (involves: C57BL/6 CBA)	enlarged spleen	J:156541
Stk4^{Gt(AJ0315)Wtsi}/Stk4^{Gt(AJ0315)Wtsi} (B6.129P2-Stk4^{Gt(AJ0315)Wtsi})	abnormal memory T cell number	J:142674
	abnormal T cell differentiation	J:142674
	decreased CD4-positive, alpha-beta T cell number	J:142674
	decreased CD8-positive, alpha-beta T cell number	J:142674
	decreased spleen white pulp amount	J:142674
	increased interferon-gamma secretion	J:142674
	increased interleukin-2 secretion	J:142674
	increased interleukin-4 secretion	J:142674
	increased T cell apoptosis	J:142674
	increased T cell proliferation	J:142674
Stk4^m1Btlr/Stk4^m1Btlr (C57BL/6J-Stk4^m1Btlr)	abnormal humoral immune response	J:265233
	decreased B cell number	J:265233
	decreased CD4-positive, alpha-beta T cell number	J:265233
	decreased CD8-positive, alpha-beta T cell number	J:265233
	decreased IgD level	J:265233
	decreased single-positive T cell number	J:265233
	decreased T cell number	J:265233
	increased IgE level	J:265233
	increased IgM level	J:265233
	increased macrophage cell number	J:265233
	increased neutrophil cell number	J:265233
	increased NK cell number	J:265233
Stk4^m2Btlr/Stk4^m2Btlr (C57BL/6J-Stk4^m2Btlr)	decreased B-1 B cell number	J:265237
	decreased B-2 B cell number	J:265237
	decreased CD4-positive, alpha-beta T cell number	J:265237
	decreased CD8-positive, alpha-beta T cell number	J:265237
	decreased CD8-positive, naive alpha-beta T cell number	J:265237
	decreased IgD level	J:265237
	decreased single-positive T cell number	J:265237
	decreased T cell number	J:265237
	increased B-1b cell number	J:265237
	increased central memory CD4-positive, alpha-beta T cell number	J:265237
	increased central memory CD8 positive, alpha-beta T cell number	J:265237
	increased dendritic cell number	J:265237
	increased effector memory CD4-positive, alpha-beta T cell number	J:265237
	increased effector memory CD8-positive, alpha-beta T cell number	J:265237
	increased IgE level	J:265237
	increased macrophage cell number	J:265237
	increased neutrophil cell number	J:265237
	increased NK cell number	J:265237
Stk4^m3Btlr/Stk4^m3Btlr (C57BL/6J-Stk4^m3Btlr)	decreased CD4-positive, alpha-beta T cell number	J:265245
	decreased CD8-positive, alpha-beta T cell number	J:265245
	decreased single-positive T cell number	J:265245
	decreased T cell number	J:265245
Stk4^m4Btlr/Stk4^m4Btlr (C57BL/6J-Stk4^m4Btlr)	decreased CD11b-high dendritic cell number	J:272536
	decreased IgD level	J:272536
	decreased IgG level	J:272536
	impaired humoral immune response	J:272536
	increased B-1b cell number	J:272536
	increased dendritic cell number	J:272536
Stk4^m5Btlr/Stk4^m5Btlr (C57BL/6J-Stk4^m5Btlr)	abnormal CD4-positive T cell differentiation	J:272743
	abnormal T cell differentiation	J:272743
	decreased CD4-positive, alpha-beta T cell number	J:272743
	increased central memory CD4-positive, alpha-beta T cell number	J:272743
Stk4^tm1.1Kina/Stk4^tm1.1Kina (involves: C57BL/6)	abnormal B cell physiology	J:148791
	abnormal dendritic cell physiology	J:148791
	abnormal immune system organ morphology	J:148791
	abnormal leukocyte adhesion	J:148791
	abnormal leukocyte migration	J:148791
	abnormal marginal zone B cell morphology	J:148791
	abnormal Peyer's patch germinal center morphology	J:148791
	abnormal Peyer's patch T cell area morphology	J:148791
	abnormal spleen B cell follicle morphology	J:148791
	abnormal T cell physiology	J:148791
	decreased B cell number	J:148791
	decreased lymphocyte cell number	J:148791
	decreased marginal zone B cell number	J:148791
	decreased myeloid dendritic cell number	J:148791
	decreased spleen B cell follicle size	J:148791
	decreased T cell number	J:148791
	increased single-positive T cell number	J:148791
	increased T cell proliferation	J:148791
	thymus hyperplasia	J:148791
Stk4^tm1.1Wtao/Stk4^tm1.2Wtao Tg(Lck-cre)#Zhu/0 (involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6 * SJL/J)	decreased CD4-positive, alpha-beta T cell number	J:152323
	decreased CD8-positive, alpha-beta T cell number	J:152323
	decreased T cell number	J:152323
	increased single-positive T cell number	J:152323
	increased thymocyte number	J:152323
Stk4^tm1.2Wtao/Stk4^tm1.2Wtao (involves: 129S4/SvJaeSor * 129S6/SvEvTac)	abnormal CD4-positive, alpha-beta T cell physiology	J:152323
	abnormal CD8-positive, alpha-beta T cell physiology	J:152323
	abnormal T cell physiology	J:152323
	decreased B cell number	J:152323
	decreased CD4-positive, alpha-beta T cell number	J:152323
	decreased CD8-positive, alpha-beta T cell number	J:152323
	decreased lymphocyte cell number	J:152323
	increased single-positive T cell number	J:152323
	increased thymocyte number	J:152323
Stk4^tm1Dlim/Stk4^tm1Dlim (Not Specified)	abnormal T cell physiology	J:155001
Stk4^tm1Dlim/Stk4^tm1Dlim (Not Specified)	decreased T cell number	J:155001
Stk10^{em1(IMPC)Ccpcz}/Stk10^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Stk10^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	decreased lymphocyte cell number	J:211773
	increased eosinophil cell number	J:211773
	increased monocyte cell number	J:211773
Stk10^tm1Hkar/Stk10^tm1Hkar (involves: 129S1/Sv)	abnormal T cell physiology	J:60738
Stk11^tm1.1Mlfr/Stk11⁺ (involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6J)	enlarged spleen	J:104347
Stk11^tm1.1Rdp/Stk11^tm1.1Rdp Tg(Pdx1-cre)89.1Dam/0 (involves: 129S6/SvEvTac * C57BL/6 * CBA * FVB/N * ICR)	pancreas inflammation	J:134078
Stk11^tm1.1Rdp/Stk11^tm1.1Rdp Tg(Sprr2f-cre)1Dcas/0 (involves: 129S6/SvEvTac * FVB/N)	peritoneal inflammation	J:158190
	sepsis	J:158190
Stk11^tm1.1Sjm/Stk11^tm1.1Sjm Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA * SJL)	decreased leukocyte cell number	J:165090
	thymus hypoplasia	J:165090
Stk11^tm1Keis/Stk11^tm1Keis Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd)	increased circulating interleukin-10 level	J:191723
Stk17b^tm1Hed/Stk17b^tm1Hed (involves: 129X1/SvJ * C57BL/6)	increased T cell proliferation	J:94685
Stk17b^tm1Hed/Stk17b^tm1Hed (B6.129X1-Stk17b^tm1Hed)	abnormal cytokine secretion	J:94685
	decreased double-positive T cell number	J:94685
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:94685
	increased CD4-positive, alpha-beta T cell number	J:94685
	increased interferon-gamma secretion	J:94685
	increased interleukin-2 secretion	J:94685
	increased memory T cell number	J:94685
	increased T cell proliferation	J:94685
	increased tumor necrosis factor secretion	J:94685
Stk24^{Gt(AM0826)Wtsi}/Stk24^{Gt(AM0826)Wtsi} (B6.129P2-Stk24^{Gt(AM0826)Wtsi})	abnormal neutrophil morphology	J:256076
	abnormal neutrophil physiology	J:256076
	immune system phenotype	J:256076
Stk26^{tm1b(EUCOMM)Hmgu}/Y (C57BL/6N-Stk26^{tm1b(EUCOMM)Hmgu}/Ccpcz)	increased NK T cell number	J:211773
Stk26^{tm1b(EUCOMM)Hmgu}/Stk26^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Stk26^{tm1b(EUCOMM)Hmgu}/Ccpcz)	decreased monocyte cell number	J:211773
Stk36^tm1Fjs/Stk36^tm1Fjs (involves: 129S1/Sv * C57BL/6)	rhinitis	J:116391
	spleen atrophy	J:116391
	thymus atrophy	J:116391
Stk36^tm1Lex/Stk36^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6J)	increased susceptibility to otitis media	J:185566
Stk38^{tm1b(KOMP)Wtsi}/Stk38⁺ (C57BL/6N-Stk38^{tm1b(KOMP)Wtsi}/J)	increased leukocyte cell number	J:211773
Stk38^tm1Hem/Stk38⁺ (involves: 129P2/Ola * C57BL/6)	increased T cell derived lymphoma incidence	J:185408
Stk38^tm1Hem/Stk38^tm1Hem (involves: 129P2/Ola * C57BL/6)	abnormal T cell physiology	J:185408
	decreased thymocyte apoptosis	J:185408
	increased T cell derived lymphoma incidence	J:185408
Stk38^tm1Xen/Stk38^tm1Xen (involves: 129S5/SvEvBrd * C57BL/6)	immune system phenotype	J:224932
	increased circulating interleukin-6 level	J:224932
	increased circulating tumor necrosis factor level	J:224932
	increased interleukin-6 secretion	J:224932
	increased susceptibility to bacterial infection	J:224932
	increased susceptibility to bacterial infection induced morbidity/mortality	J:224932
	increased tumor necrosis factor secretion	J:224932
Stoml1^em1(IMPC)Tcp/Stoml1^em1(IMPC)Tcp (C57BL/6N-Stoml1^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Stoml2^tm1Jmad/Stoml2^tm1Jmad Tg(Cd4-cre)1Cwi/0 (B6.Cg-Tg(Cd4-cre)1Cwi Stoml2^tm1Jmad)	immune system phenotype	J:187226
Stra6^tm1Jwu/Stra6^tm1Jwu (B6.129-Stra6^tm1Jwu)	immune system phenotype	J:211118
Stra6l^{tm1b(KOMP)Wtsi}/Stra6l^{tm1b(KOMP)Wtsi} (C57BL/6N-Stra6l^{tm1b(KOMP)Wtsi}/Ucd)	decreased lymphocyte cell number	J:211773
	increased basophil cell number	J:211773
	increased neutrophil cell number	J:211773
Stub1^tm1Cpat/Stub1^tm1Cpat (involves: 129S/SvEv * C57BL/6)	increased thymocyte apoptosis	J:86213
	thymus atrophy	J:86213
	thymus hypoplasia	J:86213
Stx2^tm1Dcru/Stx2^tm1Dcru (involves: 129X1/SvJ * C57BL/6J)	decreased susceptibility to induced colitis	J:110376
Stx3^{Gt(EUCE320f12)1.1Hmgu}/Stx3^{Gt(EUCE320f12)1.1Hmgu} (B6.129P2(129S4)-Stx3^{Gt(EUCE320f12)1.1Hmgu})	immune system phenotype	J:275367
Stx3^{Gt(EUCE320f12)1.1Hmgu}/Stx3^{Gt(EUCE320f12)1.1Hmgu} Tg(Cma1-cre)ARoer/0 (B6.Cg-Stx3^{Gt(EUCE320f12)1.1Hmgu} Tg(Cma1-cre)ARoer)	abnormal mast cell degranulation	J:275367
	decreased mast cell degranulation	J:275367
	immune system phenotype	J:275367
Stx3^{Gt(EUCE320f12)1.2Hmgu}/Stx3⁺ (B6.129P2(Cg)-Stx3^{Gt(EUCE320f12)1.2Hmgu})	abnormal mast cell degranulation	J:275367
	immune system phenotype	J:275367
Stx4a^tm1.1Radac/Stx4a^tm1.1Radac (involves: 129S4/SvJaeSor * C57BL/6J)	immune system phenotype	J:275367
Stx4a^tm1.1Radac/Stx4a^tm1.1Radac Tg(Cma1-cre)ARoer/0 (involves: 129S4/SvJaeSor * C57BL/6 * C57BL/6J)	immune system phenotype	J:275367
Stx4a^tm1.2Radac/Stx4a⁺ (involves: 129S4/SvJaeSor * BALB/cJ * C57BL/6J)	immune system phenotype	J:275367
Stx7^{em1(IMPC)Rbrc}/Stx7^{em1(IMPC)Rbrc} (C57BL/6NJcl-Stx7^{em1(IMPC)Rbrc}/Rbrc)	abnormal thymus morphology	J:211773
	decreased large unstained cell number	J:211773
	small thymus	J:211773
Stx11^em1(IMPC)Mbp/Stx11^em1(IMPC)Mbp (C57BL/6N-Stx11^em1(IMPC)Mbp/MbpMmucd)	increased lymphocyte cell number	J:211773
Stx11^tm1.2Ics/Stx11^tm1.2Ics (involves: C57BL/6NTac)	abnormal cytotoxic T cell physiology	J:193137
	decreased cytotoxic T cell cytolysis	J:193137
	decreased leukocyte cell number	J:193137
	decreased neutrophil cell number	J:193137
	decreased NK cell degranulation	J:193137
	increased circulating interferon-gamma level	J:193137
	increased circulating interleukin-1 beta level	J:193137
	increased circulating interleukin-6 level	J:193137
	increased circulating tumor necrosis factor level	J:193137
	increased susceptibility to Riboviria infection	J:193137
Stx11^tm1Bupa/Stx11^tm1Bupa (B6.129-Stx11^tm1Bupa)	abnormal cell-mediated immunity	J:191103
	abnormal cytokine secretion	J:191103
	abnormal lymphocyte physiology	J:191103
	abnormal neutrophil physiology	J:191103
	impaired natural killer cell mediated cytotoxicity	J:191103
	increased interferon-gamma secretion	J:191103
	increased tumor necrosis factor secretion	J:191103
Stxbp2^tm1Bdic/Stxbp2⁺ (involves: 129S * C57BL/6)	decreased mast cell degranulation	J:188931
Stxbp2^tm1Bdic/Stxbp2⁺ (involves: 129S * C57BL/6)	decreased susceptibility to type I hypersensitivity reaction	J:188931
sty/sty (Not Specified)	small thymus	J:3675
Styk1^tm1Twa/Styk1^tm1Twa (C57BL/6N-Styk1^tm1Twa)	immune system phenotype	J:277150
Styk1^tm1Twa/Styk1^tm1Twa (B6J.B6N-Styk1^tm1Twa)	immune system phenotype	J:277150
Styxl2^em1(IMPC)Mbp/Styxl2^em1(IMPC)Mbp (C57BL/6N-Styxl2^em1(IMPC)Mbp/Ucd)	abnormal lymph node morphology	J:211773
Sucnr1^tm1Dgen/Sucnr1^tm1Dgen (B6.129P2-Sucnr1^tm1Dgen)	abnormal dendritic cell physiology	J:143337
	abnormal interleukin-2 secretion	J:143337
	abnormal Langerhans cell physiology	J:143337
	abnormal T cell activation	J:143337
	decreased T cell proliferation	J:143337
	increased length of allograft survival	J:143337
Suco^{Gt(KST050)Byg}/Suco^{Gt(KST050)Byg} (involves: 129P2/OlaHsd * C57BL/6 * CD-1)	abnormal osteoclast physiology	J:159823
	decreased osteoclast cell number	J:159823
Sufu^{tm1b(KOMP)Wtsi}/Sufu⁺ (C57BL/6N-Sufu^{tm1b(KOMP)Wtsi}/Ucd)	enlarged lymph nodes	J:211773
Sugct^tm1.2Kald/Sugct^tm1.2Kald (B6.Cg-Sugct^tm1.2Kald)	increased macrophage cell number	J:293423
	kidney inflammation	J:293423
	white adipose tissue inflammation	J:293423
Sugp1^em1(IMPC)Mbp/Sugp1⁺ (C57BL/6NCrl-Sugp1^em1(IMPC)Mbp/Mmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Sulf1^{Gt(OST352220)Lex}/Sulf1^{Gt(OST352220)Lex} (involves: 129S5/SvEvBrd * C57BL/6N)	decreased susceptibility to bacterial infection	J:171883
Sulf2^{em1(IMPC)Ccpcz}/Sulf2^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Sulf2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Sult1a1^{em1(IMPC)Ccpcz}/Sult1a1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Sult1a1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Sumf1^{Gt(RST760)Byg}/Sumf1^{Gt(RST760)Byg} (involves: 129P2/OlaHsd * C57BL/6)	abnormal macrophage morphology	J:120146
	abnormal microglial cell morphology	J:120146
	CNS inflammation	J:120146
	increased macrophage cell number	J:120146
Sun1^{tm1b(EUCOMM)Wtsi}/Sun1^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Sun1^{tm1b(EUCOMM)Wtsi}/Orl)	decreased lymphocyte cell number	J:211773
	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Sun2^{tm1b(EUCOMM)Hmgu}/Sun2^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Sun2^{tm1b(EUCOMM)Hmgu}/Bay)	increased large unstained cell number	J:211773
Sun5^em1(IMPC)Mbp/Sun5^em1(IMPC)Mbp (C57BL/6N-Sun5^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Supv3l1^tm2.1Jkl/Supv3l1^tm2.2Jkl Tg(CAG-cre/Esr1)5Amc/0 (involves: 129P2/OlaHsd 129S4/SvJaeSor * C57BL/6 * FVB/N)	abnormal T cell differentiation	J:144991
	decreased CD4-positive, alpha-beta T cell number	J:144991
	decreased CD8-positive, alpha-beta T cell number	J:144991
	decreased double-negative T cell number	J:144991
	decreased double-positive T cell number	J:144991
	increased macrophage derived foam cell number	J:144991
	lung inflammation	J:144991
	thymus atrophy	J:144991
	thymus hypoplasia	J:144991
Supv3l1^tm2Jkl/Supv3l1^tm2Jkl Tg(CAG-cre/Esr1)5Amc/0 (involves: 129P2/OlaHsd C57BL/6)	abnormal T cell differentiation	J:144991
	decreased CD4-positive, alpha-beta T cell number	J:144991
	decreased CD8-positive, alpha-beta T cell number	J:144991
	decreased double-negative T cell number	J:144991
	decreased double-positive T cell number	J:144991
	increased macrophage derived foam cell number	J:144991
	lung inflammation	J:144991
	thymus atrophy	J:144991
	thymus hypoplasia	J:144991
Supv3l1^tm2Jkl/Supv3l1^tm2Jkl Tg(Mx1-cre)1Cgn/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA)	increased macrophage derived foam cell number	J:144991
	increased plasma cell number	J:144991
	interstitial pneumonia	J:144991
Susd4^tm1Lex/Susd4^tm1Lex (B6.129S5-Susd4^tm1Lex)	abnormal complement protein level	J:306852
	abnormal microglial cell morphology	J:306852
	increased microglial cell activation	J:306852
Susd6^{tm1b(KOMP)Wtsi}/Susd6^{tm1b(KOMP)Wtsi} (C57BL/6N-Susd6^{tm1b(KOMP)Wtsi}/Bay)	decreased monocyte cell number	J:211773
	decreased neutrophil cell number	J:211773
	enlarged spleen	J:211773
	increased lymphocyte cell number	J:211773
Suv39h1^tm1Jnw/Suv39h1^tm1Jnw (involves: 129)	abnormal T-helper 2 physiology	J:186702
Suv39h1^tm1Jnw/Suv39h1^tm1Jnw (involves: 129)	decreased susceptibility to type I hypersensitivity reaction	J:186702
Suz12^Plt8/Suz12⁺ (involves: 129 * C57BL/6)	increased leukocyte cell number	J:136262
Suz12^Plt8/Suz12⁺ (involves: 129 * C57BL/6)	increased lymphocyte cell number	J:136262
Svep1^{tm1a(EUCOMM)Hmgu}/Svep1^{tm1a(EUCOMM)Hmgu} (involves: C57BL/6N)	abnormal lymphangiogenesis	J:244466
	abnormal lymphatic vessel morphology	J:244466
Swap70^tm1Jess/Swap70^tm1Jess (involves: 129T2/SvEms * 129X1/SvJ)	abnormal class switch recombination	J:71160
	decreased IgE level	J:71160
	increased autoantibody level	J:71160
Swq6^C57BL/6J/Swq6^CAST/EiJ (involves: C57BL/6J * CAST/EiJ)	increased spleen weight	J:117545
Swq6^CAST/EiJ/Swq6^CAST/EiJ (involves: C57BL/6J * CAST/EiJ)	increased spleen weight	J:117545
Swqnd1^NMRI8/Fbn/? (involves: DBA/2OlaHsd * NMRI8/Fbn)	decreased spleen weight	J:122125
Swqnd2^NMRI8/Fbn/? (involves: DBA/2OlaHsd * NMRI8/Fbn)	decreased spleen weight	J:122125
Swrl1^NZB/Swrl1^NZB (involves: NZB * SWR)	abnormal type II hypersensitivity reaction	J:73097
Swrl1^NZB/Swrl1^SWR (involves: NZB * SWR)	abnormal type II hypersensitivity reaction	J:73097
Swrl1^SWR/Swrl1^SWR (involves: NZB * SWR)	increased IgG3 level	J:96263
Swrl2^NZB/Swrl2^SWR (involves: NZB * SWR)	glomerulonephritis	J:73097
Swrl2^SWR/Swrl2^SWR (involves: NZB * SWR)	glomerulonephritis	J:73097
Swrl2^SWR/Swrl2^SWR (involves: NZB * SWR)	increased anti-single stranded DNA antibody level	J:96060
Swrl3^NZB/Swrl3^SWR (involves: NZB * SWR)	increased anti-double stranded DNA antibody level	J:96060
	increased anti-histone antibody level	J:96060
	increased anti-nuclear antigen antibody level	J:73097
Swrl3^SWR/Swrl3^SWR (involves: NZB * SWR)	increased anti-double stranded DNA antibody level	J:96060
	increased anti-histone antibody level	J:96060
	increased anti-nuclear antigen antibody level	J:73097
Swt1^em1(IMPC)J/Swt1^em1(IMPC)J (C57BL/6NJ-Swt1^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
Sycn^tm1Rja/Sycn^tm1Rja (involves: 129P2/OlaHsd)	increased susceptibility to induced pancreatitis	J:74654
Syk^m1Btlr/Syk^m1Btlr (involves: C57BL/6J)	decreased B cell number	J:199281
	increased neutrophil cell number	J:199281
	increased tumor necrosis factor secretion	J:199281
Syk^M2Btlr/Syk⁺ (C57BL/6J-Syk^M2Btlr)	abnormal NK cell differentiation	J:231803
Syk^M2Btlr/Syk⁺ (C57BL/6J-Syk^M2Btlr)	decreased inflammatory response	J:231803
Syk^M2Btlr/Syk^M2Btlr (C57BL/6J-Syk^M2Btlr)	abnormal NK cell differentiation	J:231803
Syk^M2Btlr/Syk^M2Btlr (C57BL/6J-Syk^M2Btlr)	decreased inflammatory response	J:231803
Syk^{tm1.1(cre)Fkfr}/Syk^{tm1.1(cre)Fkfr} Gt(ROSA)26Sor^tm1(EYFP)Cos/Gt(ROSA)26Sor^tm1(EYFP)Cos (involves: 129S1/Sv * 129X1/SvJ)	abnormal lymphangiogenesis	J:159112
	decreased leukocyte cell number	J:159112
	increased leukocyte cell number	J:159112
Syk^tm1.1Nns/Syk^tm1.1Nns Commd10^{Tg(Vav1-icre)A2Kio}/Commd10⁺ (involves: C57BL/10 * CBA/Ca)	abnormal lymphatic vessel morphology	J:181715
Syk^tm1.1Nns/Syk^tm1.1Nns Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd)	immune system phenotype	J:181715
Syk^tm1.1Nns/Syk^tm1.1Nns Tg(CD2-icre)4Kio/0 (involves: C57BL/10 * CBA/Ca)	immune system phenotype	J:181715
Syk^tm1.1Nns/Syk^tm1.1Nns Tg(Pf4-icre)Q3Rsko/0 (involves: C57BL/6)	abnormal lymphatic vessel endothelial cell morphology	J:181715
	abnormal lymphatic vessel morphology	J:181715
Syk^tm1.1Nns/Syk^tm1.1Nns Tg(Tie1-cre)9Ref/0 Commd10^{Tg(Vav1-icre)A2Kio}/Commd10⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/10 * CBA/Ca)	abnormal lymphatic vessel morphology	J:181715
Syk^tm1.1Tara/Syk^tm1.1Tara (involves: 129P2/OlaHsd * C57BL/6)	arrested B cell differentiation	J:115080
	increased B cell proliferation	J:114816
Syk^tm1.2Tara/Syk^tm1.2Tara Tg(Cr2-cre)3Cgn/0 (involves: 129P2/OlaHsd)	abnormal B cell morphology	J:208904
Syk^tm1.2Tara/Syk^tm1.2Tara Tg(Itgax-cre)1-1Reiz/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA)	immune system phenotype	J:181715
Syk^tm1Kuro/Syk^tm1Kuro Zap70^tm1Dlo/Zap70^tm1Dlo Cd79a^tm1(cre)Reth/? (involves: 129P2/OlaHsd * BALB/c * C57BL/6)	abnormal pro-B cell differentiation	J:134528
Syk^tm1Paw/Syk^tm1Paw (involves: 129S1/Sv * 129X1/SvJ)	abnormal B cell differentiation	J:29797
	abnormal lymphangiogenesis	J:159112
	abnormal lymphatic vessel endothelium morphology	J:159112
	abnormal lymphatic vessel morphology	J:159112
	absent pre-B cells	J:29797
	decreased late pro-B cell number	J:29797
	enlarged lymphatic vessel	J:159112
	lymphatic vessel hyperplasia	J:159112
Syk^tm1Tyb/Syk^tm1.2Tara Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)	abnormal neutrophil physiology	J:155479
	impaired granulocyte bactericidal activity	J:155479
Syk^tm1Tyb/Syk^tm1.2Tara Tg(S100A8-cre,-EGFP)1Ilw/0 (involves: 129P2/OlaHsd * 129S2/SvPas * C3H * C57BL/6)	impaired granulocyte bactericidal activity	J:155479
Syk^tm1Tyb/Syk^tm1Tyb (involves: 129S2/SvPas * C57BL/6 * DBA/2)	abnormal T cell number	J:29796
	arrested B cell differentiation	J:29796
Syk^tm1Tyb/Syk^tm1Tyb (involves: 129S2/SvPas * C57BL/6)	abnormal osteoclast differentiation	J:89583
Syk^tm1Tyb/Syk^tm1Tyb (involves: 129S2/SvPas)	abnormal dendritic cell antigen presentation	J:147472
	abnormal neutrophil physiology	J:155479
	decreased tumor necrosis factor secretion	J:155479
	impaired granulocyte bactericidal activity	J:155479
	impaired neutrophil phagocytosis	J:155479
Syk^tm1Tyb/Syk^tm1Tyb (involves: 129S2/SvPas * C57BL/6J)	abnormal lymphatic vessel morphology	J:181715
Syk^tm1Tyb/Syk^tm1Tyb (involves: 129S2/SvPas * C57BL/6J)	decreased lymphatic vessel endothelial cell number	J:181715
Syk^{tm2.1(ZAP70)Fkfr}/Syk^{tm2.1(ZAP70)Fkfr} (B6.129-Syk^{tm2.1(ZAP70)Fkfr})	abnormal B cell physiology	J:188422
	abnormal neutrophil physiology	J:188422
	arrested B cell differentiation	J:188422
	decreased B cell number	J:188422
	decreased DN1 thymic pro-T cell number	J:188422
	decreased IgG1 level	J:188422
	decreased IgG2a level	J:188422
	decreased IgG2b level	J:188422
	decreased marginal zone B cell number	J:188422
	decreased mature B cell number	J:188422
	decreased transitional stage B cell number	J:188422
	decreased transitional stage T1 B cell number	J:188422
	decreased transitional stage T2 B cell number	J:188422
	glomerulonephritis	J:188422
	immune system phenotype	J:188422
	increased anti-insulin autoantibody level	J:188422
	increased B cell apoptosis	J:188422
	increased CD4-positive, alpha-beta memory T cell number	J:188422
	increased CD4-positive, alpha-beta T cell number	J:188422
	increased CD8-positive, alpha-beta memory T cell number	J:188422
	increased CD8-positive, alpha-beta T cell number	J:188422
	increased DN3 thymocyte number	J:188422
	increased IgM level	J:188422
Syne1^tm1.1Mcn/Syne1^tm1.1Mcn (involves: 129S4/SvJae * 129S6/SvEvTac * C57BL)	conjunctivitis	J:144757
Syngr1^{em1(IMPC)Ccpcz}/Syngr1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Syngr1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Syngr3^em1Pave/Syngr3⁺ Tg(Prnp-MAPTP301S)PS19Vle/0 (involves: C3H C57BL/6)	microgliosis	J:303506
Synj1^{tm1b(EUCOMM)Wtsi}/Synj1⁺ (C57BL/6N-Synj1^{tm1b(EUCOMM)Wtsi}/H)	decreased monocyte cell number	J:211773
	decreased neutrophil cell number	J:211773
	increased lymphocyte cell number	J:211773
Synpo2^{tm1b(EUCOMM)Wtsi}/Synpo2⁺ (C57BL/6N-Synpo2^{tm1b(EUCOMM)Wtsi}/Ics)	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Syt7^tm1Nan/Syt7^tm1Nan (involves: 129S1/Sv * C57BL/6)	increased anti-nuclear antigen antibody level	J:85201
	increased inflammatory response	J:85201
	increased susceptibility to autoimmune disorder	J:85201
	myositis	J:85201
Sytl1^{tm1a(KOMP)Wtsi}/Sytl1^{tm1a(KOMP)Wtsi} (involves: C57BL/6 * C57BL/6N)	decreased CD4-positive, alpha-beta T cell number	J:213427
	decreased IgG2b level	J:213427
	decreased mature B cell number	J:213427
	decreased T cell number	J:213427
	epididymis inflammation	J:213427
	increased regulatory T cell number	J:213427
	meningitis	J:213427
Syvn1^tm1Tn/Syvn1⁺ (D1.Cg-Syvn1^tm1Tn)	decreased susceptibility to induced arthritis	J:86009
t^AE5/t^AE5 (Not Specified)	abnormal spleen morphology	J:83862
	abnormal thymus cortex morphology	J:83862
	abnormal thymus morphology	J:83862
	decreased spleen white pulp amount	J:83862
	increased mast cell number	J:83862
	increased susceptibility to infection	J:83862
	thymus cortex hypoplasia	J:83862
Tab2^tm2.1Aki/Tab2^tm2.1Aki Tab3^tm1Aki/Tab3^tm1Aki Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell physiology	J:195289
	abnormal immune serum protein physiology	J:195289
	decreased B cell proliferation	J:195289
	decreased B-1a cell number	J:195289
	decreased circulating interleukin-6 level	J:195289
	decreased IgD level	J:195289
	decreased IgE level	J:195289
	decreased IgG level	J:195289
	decreased immunoglobulin level	J:195289
	decreased mature B cell number	J:195289
	decreased plasma cell number	J:195289
	increased B cell apoptosis	J:195289
Tab2^tm2.1Aki/Tab2^tm2.1Aki Tab3^tm1Aki/Tab3^tm1Aki Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:195289
Tac4^tm1Albe/Tac4^tm1Albe (B6.129P2-Tac4^tm1Albe)	increased pro-B cell number	J:166471
Tacc3^tm1Jni/Tacc3^tm1Jni (involves: 129P2/OlaHsd * C57BL/6)	decreased thymocyte number	J:74762
	small thymus	J:74762
Tacr1^tm1Nge/Tacr1^tm1Nge (involves: 129S4/SvJae)	abnormal humoral immune response	J:35529
Tacr1^tm1Nge/Tacr1^tm1Nge (involves: 129S4/SvJae * C57BL)	abnormal mast cell physiology	J:84660
Tacr1^tm1Sph/Tacr1^tm1Sph (involves: 129P2/OlaHsd * C57BL/6)	decreased inflammatory response	J:46629
	joint inflammation	J:103700
Taf4^tm1Idvd/Taf4^tm1Idvd Tg(KRT14-cre/ERT2)1Ipc/0 (involves: C57BL/6 * SJL)	chronic inflammation	J:124111
Taf7^tm1.1Dss/Taf7^tm1.2Dss Tg(Cd8a*-cre)B8Asin/0 (involves: C57BL/6)	abnormal T cell differentiation	J:185745
	decreased CD4-positive, alpha-beta T cell number	J:185745
	decreased CD8-positive, alpha-beta T cell number	J:185745
	decreased double-positive T cell number	J:185745
	decreased single-positive T cell number	J:185745
	decreased T cell number	J:185745
	decreased T cell proliferation	J:185745
	decreased thymocyte number	J:185745
Taf7^tm1.1Dss/Taf7^tm1.2Dss Tg(Lck-cre)1Cwi/0 (involves: C57BL/6)	abnormal T cell differentiation	J:185745
	abnormal thymus physiology	J:185745
	decreased CD4-positive, alpha-beta T cell number	J:185745
	decreased CD8-positive, alpha-beta T cell number	J:185745
	decreased double-positive T cell number	J:185745
	decreased thymocyte number	J:185745
	increased double-negative T cell number	J:185745
	small thymus	J:185745
Taf15^em1(IMPC)Mbp/Taf15^em1(IMPC)Mbp (C57BL/6NCrl-Taf15^em1(IMPC)Mbp/MbpMmucd)	increased lymphocyte cell number	J:211773
Tagap1^em1(IMPC)Tcp/Tagap1⁺ (C57BL/6N-Tagap1^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Tagln2^em1(IMPC)Tcp/Tagln2^em1(IMPC)Tcp (C57BL/6N-Tagln2^em1(IMPC)Tcp/Tcp)	decreased lymphocyte cell number	J:211773
	enlarged spleen	J:211773
	increased neutrophil cell number	J:211773
Tagln2^tm1Cdj/Tagln2^tm1Cdj (involves: 129S4/SvJae * C57BL/6)	abnormal cytotoxic T cell physiology	J:256656
	abnormal T cell physiology	J:256656
	immune system phenotype	J:256656
Tagln2^tm1Cdj/Tagln2^tm1Cdj Tg(TcraTcrb)425Cbn/0 (involves: 129S4/SvJae * C57BL/6)	abnormal T cell activation	J:256656
Tagln2^tm1Cdj/Tagln2^tm1Cdj Tg(TcraTcrb)1100Mjb/0 (involves: 129S4/SvJae * C57BL/6)	abnormal T cell activation	J:256656
Tal1^Hpt/Tal1⁺ (HPT/Le)	decreased leukocyte cell number	J:1780
Tal1^tm1Por/Tal1^tm1Por (involves: 129P2/OlaHsd)	increased spleen weight	J:139179
Tal1^tm3Wehi/Tal1^tm2Wehi Tg(Mx1-cre)1Cgn/0 (involves: 129S1/Sv * C57BL/6 * CBA)	abnormal splenic cell ratio	J:81826
Tank^tm1Aki/Tank^tm1Aki (involves: 129/Sv * C57BL/6)	abnormal dendritic cell physiology	J:151757
	abnormal macrophage physiology	J:151757
	abnormal plasmacytoid dendritic cell physiology	J:151757
	glomerulonephritis	J:151757
	increased anti-double stranded DNA antibody level	J:151757
	increased anti-nuclear antigen antibody level	J:151757
	increased B cell proliferation	J:151757
	increased IgA level	J:151757
	increased IgG1 level	J:151757
	increased IgG2a level	J:151757
	increased IgG2b level	J:151757
	increased IgM level	J:151757
	increased interferon-alpha secretion	J:151757
	increased interleukin-6 secretion	J:151757
	increased mature B cell number	J:151757
	increased plasma cell number	J:151757
	increased tumor necrosis factor secretion	J:151757
	liver inflammation	J:151757
	lung inflammation	J:151757
	lymph node hyperplasia	J:151757
	spleen hyperplasia	J:151757
Taok1^em1(IMPC)Tcp/Taok1⁺ (C57BL/6NCrl-Taok1^em1(IMPC)Tcp/Tcp)	increased monocyte cell number	J:211773
Tap1^m1Btlr/Tap1^m1Btlr (C57BL/6J-Tap1^m1Btlr)	decreased CD8-positive, alpha-beta memory T cell number	J:254888
Tap1^m1Btlr/Tap1^m1Btlr (C57BL/6J-Tap1^m1Btlr)	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:254888
Tap1^m2Btlr/Tap1^m2Btlr (C57BL/6J-Tap1^m2Btlr)	decreased CD8-positive, alpha-beta T cell number	J:236697
Tap1^m2Btlr/Tap1^m2Btlr (C57BL/6J-Tap1^m2Btlr)	increased susceptibility to Herpesvirales infection	J:236697
Tap1^rose/Tap1^rose (C57BL/6JAnu-Tap1^rose/AnuApb)	decreased CD8-positive, alpha-beta T cell number	J:166104
Tap1^tm1Arp/Tap1^tm1Arp (involves: 129S2/SvPas * C57BL/6)	abnormal antigen presentation	J:122479
	abnormal dendritic cell antigen presentation	J:112436
	abnormal lymphocyte physiology	J:122479
	absent CD8-positive, alpha-beta T cells	J:3524
	decreased double-negative T cell number	J:3524
	decreased level of surface class I molecules	J:3524
	defective intracellular transport of class I molecules	J:3524
Tap1^tm1Arp/Tap1^tm1Arp (involves: 129S2/SvPas)	abnormal antigen presentation via MHC class I	J:64349
	abnormal dendritic cell antigen presentation	J:64349
	decreased CD8-positive, alpha-beta T cell number	J:64177, J:64349
	decreased cytotoxic T cell cytolysis	J:64349
	decreased level of surface class I molecules	J:64177, J:64349
	defective assembly of class I molecules	J:64177
	defective intracellular transport of class I molecules	J:64177
Tap1^tm1Arp/Tap1^tm1Arp (B6.129S2-Tap1^tm1Arp/J)	decreased CD8-positive, alpha-beta T cell number	J:123934
	decreased susceptibility to bacterial infection	J:123934
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:123934
	increased T-helper 1 cell number	J:123934
Tap1^tm1Arp/Tap1^tm1Arp X/Yaa (BXSB.129S2(B6)-Tap1^tm1Arp/Dcr)	increased susceptibility to systemic lupus erythematosus	J:179430
Tap1^tm1Hpl/Tap1^tm1Hpl (either: (involves: 129S2/SvPas * 129/Ola) or (involves: 129S2/SvPas * FVB))	immune system phenotype	J:60782
Tap2^jas/Tap2^jas (C57BL/6JSfdAnu-Tap2^jas/AnuApb)	absent CD8-positive, alpha-beta T cells	J:104190
Tap2^jas/Tap2^jas (C57BL/6JSfdAnu-Tap2^jas/AnuApb)	decreased CD8-positive, alpha-beta T cell number	J:166104
Tap2^m1Btlr/Tap2^m1Btlr (C57BL/6J-Tap2^m1Btlr)	abnormal cytotoxic T cell physiology	J:159355
	abnormal NK cell physiology	J:159355
	absent CD8-positive, alpha-beta T cells	J:159355
	decreased level of surface class I molecules	J:159355
	defective assembly of class I molecules	J:159355
Tap2^m2Btlr/Tap2^m2Btlr (C57BL/6J-Tap2^m2Btlr)	decreased CD8-positive, alpha-beta T cell number	J:217145
Tap2^m2Btlr/Tap2^m2Btlr (C57BL/6J-Tap2^m2Btlr)	increased CD4-positive, alpha-beta T cell number	J:217145
Tap2^m3Btlr/Tap2^m3Btlr (C57BL/6J-Tap2^m3Btlr)	decreased CD8-positive, alpha-beta T cell number	J:254929
	decreased CD8-positive, naive alpha-beta T cell number	J:254929
	decreased effector memory CD4-positive, alpha-beta T cell number	J:254929
	decreased NK T cell number	J:254929
	increased CD4-positive, alpha-beta T cell number	J:254929
	increased central memory CD8 positive, alpha-beta T cell number	J:254929
Tap2^M4Btlr/Tap2^M4Btlr (C57BL/6J-Tap2^M4Btlr)	increased CD4-positive, alpha-beta T cell number	J:272847
Tapbp^tm1Gjh/Tapbp^tm1Gjh (involves: 129S2/SvPas)	abnormal antigen presentation via MHC class I	J:64349
	abnormal dendritic cell antigen presentation	J:64349
	abnormal NK cell physiology	J:64349
	decreased cytotoxic T cell cytolysis	J:64349
	decreased level of surface class I molecules	J:64349
	decreased T cell number	J:64349
Tapbp^tm1Luc/Tapbp^tm1Luc (involves: 129S6/SvEvTac * C57BL/6)	abnormal lymphocyte physiology	J:122479
Tapbp^tm1Luc/Tapbp^tm1Luc (involves: 129S6/SvEvTac)	abnormal antigen presentation via MHC class I	J:64177
	abnormal cytotoxic T cell physiology	J:64177
	decreased CD8-positive, alpha-beta T cell number	J:64177
	decreased level of surface class I molecules	J:64177
	defective assembly of class I molecules	J:64177
Tapbp^tm1Luc/Tapbp^tm1Luc Tg(TcraTcrb)1100Mjb/? (involves: 129S6/SvEvTac * C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:64177
	abnormal CD8-positive, alpha beta T cell morphology	J:64177
	abnormal negative T cell selection	J:64177
	abnormal positive T cell selection	J:64177
	immune system phenotype	J:64177
Tapbp^tm1Luc/Tapbp^tm1Luc Tg(TcraTcrb)1100Mjb/? (involves: 129S6/SvEvTac)	immune system phenotype	J:64177
Tapr^BALB/c/? (involves: BALB/c * DBA/2)	abnormal inflammatory response	J:72894
Tardbp^tm1.1Neas/Tardbp^tm1.1Neas (B6(C3)-Tardbp^tm1.1Neas)	microgliosis	J:283769
Tardbp^tm2.1Neas/Tardbp^tm2.1Neas (B6(C3)-Tardbp^tm2.1Neas)	microgliosis	J:283769
Tarm1^tm1Yiw/Tarm1^tm1Yiw (involves: C57BL/6 * C57BL/6NSlc)	abnormal dendritic cell antigen presentation	J:301164
	abnormal dendritic cell differentiation	J:301164
	abnormal interleukin-6 secretion	J:301164
	abnormal lymphocyte physiology	J:301164
	abnormal tumor necrosis factor secretion	J:301164
	decreased B cell number	J:301164
	decreased CD4-positive, alpha-beta T cell number	J:301164
	decreased dendritic cell number	J:301164
	decreased IgG2a level	J:301164
	decreased IgG2b level	J:301164
	decreased IgG3 level	J:301164
	decreased interferon-gamma secretion	J:301164
	decreased interleukin-17 secretion	J:301164
	decreased susceptibility to induced arthritis	J:301164
	decreased synovial pannus formation	J:301164
	decreased T cell proliferation	J:301164
	decreased tumor necrosis factor secretion	J:301164
	immune system phenotype	J:301164
Tars3^em1(IMPC)J/Tars3^em1(IMPC)J (C57BL/6NJ-Tars3^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
Tas2r131^em1(IMPC)Bay/Tas2r131^em1(IMPC)Bay (C57BL/6N-Tas2r131^em1(IMPC)Bay/Bay)	abnormal spleen morphology	J:211773
Tas2r139^em1(IMPC)Mbp/Tas2r139^em1(IMPC)Mbp (C57BL/6NCrl-Tas2r139^em1(IMPC)Mbp/Mmucd)	abnormal spleen morphology	J:211773
	small spleen	J:211773
Tasl^em1Bcgen/Tasl^em1Bcgen (BALB/cJ-Tasl^em1Bcgen)	abnormal immune cell physiology	J:363059
	decreased interferon level	J:363059
	decreased susceptibility to systemic lupus erythematosus	J:363059
Tasp1^tm1Jjdh/Tasp1^tm1Jjdh Tg(Mx1-cre)1Cgn/? (involves: 129X1/SvJ * C57BL/6 * CBA)	decreased double-positive T cell number	J:112159
	decreased thymocyte number	J:112159
	decreased thymus weight	J:112159
Tax1bp1^tm1Ktj/Tax1bp1^tm1Ktj (B6.129P2-Tax1bp1^tm1Ktj)	abnormal hypersensitivity reaction	J:131849
	abnormal leukocyte physiology	J:131849
	abnormal macrophage chemotaxis	J:131849
	abnormal neutrophil physiology	J:131849
	abnormal T cell physiology	J:131849
	cardiovalvulitis	J:131849
	increased interleukin-1 beta secretion	J:131849
	increased interleukin-2 secretion	J:131849
	increased tumor necrosis factor secretion	J:131849
	skin inflammation	J:131849
tb/tb (Not Specified)	abnormal thymus involution	J:12166
Tbata^tm1Faf/Tbata^tm1Faf (involves: 129P2/OlaHsd * C57BL/6)	abnormal thymus epithelium morphology	J:166065
	enlarged thymus	J:166065
	immune system phenotype	J:166065
	increased double-negative T cell number	J:166065
	increased thymocyte number	J:166065
	thymus hyperplasia	J:166065
Tbc1d4^tm1.1Arte/Tbc1d4^tm1.1Arte (involves: C57BL/6)	decreased spleen weight	J:169477
Tbc1d4^{tm1b(EUCOMM)Hmgu}/Tbc1d4^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Tbc1d4^{tm1b(EUCOMM)Hmgu}/J)	decreased leukocyte cell number	J:211773
Tbc1d7^em1(IMPC)Bay/Tbc1d7⁺ (C57BL/6N-Tbc1d7^em1(IMPC)Bay/Bay)	abnormal lymph node morphology	J:211773
	enlarged spleen	J:211773
Tbc1d8b^em1(IMPC)Bay/Y (C57BL/6N-Tbc1d8b^em1(IMPC)Bay/BayMmucd)	decreased spleen weight	J:211773
Tbc1d10c^tm1.1Psou/Tbc1d10c^tm1.2Psou Cd79a^tm1(cre)Reth/Cd79a⁺ (involves: 129S2/SvPas * BALB/c * C57BL/6J)	abnormal B cell physiology	J:211913
	increased anti-double stranded DNA antibody level	J:211913
	increased IgG level	J:211913
	increased IgM level	J:211913
	increased susceptibility to systemic lupus erythematosus	J:211913
Tbc1d10c^tm1.1Psou/Tbc1d10c^tm1.2Psou Tg(Lck-cre)#Nik/0 (involves: 129S2/SvPas * C57BL/6 * C57BL/6J * DBA/2)	immune system phenotype	J:211913
Tbc1d10c^tm1.2Psou/Tbc1d10c^tm1.2Psou (involves: 129S2/SvPas * C57BL/6J)	abnormal B cell physiology	J:211913
	abnormal response to infection	J:211913
	abnormal T cell activation	J:211913
	immune system phenotype	J:211913
	increased anti-double stranded DNA antibody level	J:211913
	increased IgG level	J:211913
	increased susceptibility to systemic lupus erythematosus	J:211913
	increased T cell proliferation	J:211913
Tbc1d23^{Gt(BA0556)Wtsi}/Tbc1d23^{Gt(BA0556)Wtsi} (B6.129P2-Tbc1d23^{Gt(BA0556)Wtsi})	abnormal tumor necrosis factor level	J:181861
	increased circulating interleukin-6 level	J:181861
	increased circulating tumor necrosis factor level	J:181861
	increased inflammatory response	J:181861
Tbc1d32^b2b2284Clo/Tbc1d32^b2b2284Clo (C57BL/6J-Tbc1d32^b2b2284Clo)	spleen hypoplasia	J:175213
Tbk1^M1Btlr/Tbk1⁺ (involves: C57BL/6J)	abnormal interferon secretion	J:188770
Tbk1^M1Btlr/Tbk1⁺ (involves: C57BL/6J)	abnormal macrophage physiology	J:188770
Tbk1^tm1.1Lex/Tbk1⁺ (involves: 129S4/SvJae * 129S5/SvEvBrd)	abnormal inflammatory response	J:166476
	decreased basophil cell number	J:166476
	decreased eosinophil cell number	J:166476
Tbk1^tm1.1Lex/Tbk1^tm1.1Lex (involves: 129S4/SvJae * 129S5/SvEvBrd)	abnormal cytokine level	J:166476
	abnormal cytokine secretion	J:166476
	abnormal inflammatory response	J:166476
	decreased interferon-beta secretion	J:166476
	decreased NK T cell number	J:166476
	increased circulating interleukin-1 beta level	J:166476
	increased circulating interleukin-6 level	J:166476
	increased circulating interleukin-10 level	J:166476
	increased circulating tumor necrosis factor level	J:166476
	increased IgA level	J:166476
	increased interleukin-6 secretion	J:166476
	increased monocyte cell number	J:166476
	increased NK T cell number	J:166476
	increased spleen weight	J:166476
	increased susceptibility to bacterial infection induced morbidity/mortality	J:166476
	increased susceptibility to endotoxin shock	J:166476
	increased tumor necrosis factor secretion	J:166476
	lymphoid hyperplasia	J:166476
	skin inflammation	J:166476
Tbk1^tm1Aki/Tbk1^tm1Aki Tnf^tm1Sek/Tnf^tm1Sek (involves: 129P2/OlaHsd * C57BL/6 * CBA)	abnormal cytotoxic T cell physiology	J:132662
	decreased cytotoxic T cell cytolysis	J:132662
	decreased IgG1 level	J:132662
	decreased IgG2a level	J:132662
	decreased IgG level	J:132662
	decreased interferon-gamma secretion	J:132662
Tbk1^tm1Arte/Tbk1^tm1Arte Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129/SvEv * 129P2/OlaHsd * C57BL/6)	abnormal B cell physiology	J:188560
	abnormal class switch recombination	J:188560
	increased anti-double stranded DNA antibody level	J:188560
	increased anti-nuclear antigen antibody level	J:188560
	increased IgA level	J:188560
	increased IgM level	J:188560
	increased mature B cell number	J:188560
Tbk1^tm1Arte/Tbk1^tm1Arte Map3k14^tm1Rds/Map3k14^tm1Rds Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129/SvEv * 129P2/OlaHsd * C57BL/6)	abnormal B cell differentiation	J:188560
	abnormal immunoglobulin level	J:188560
Tbkbp1^tm1Aki/Tbkbp1^tm1Aki (Not Specified)	immune system phenotype	J:204786
Tbkbp1^{tm1b(EUCOMM)Wtsi}/Tbkbp1^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Tbkbp1^{tm1b(EUCOMM)Wtsi}/H)	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
Tbp^tm1.1Ees/Tbp^tm1.1Ees (B6.129X1(Cg)-Tbp^tm1.1Ees)	hemophagocytosis	J:77714
Tbrg1^{tm1a(KOMP)Wtsi}/Tbrg1^{tm1a(KOMP)Wtsi} (C57BL/6N-Tbrg1^{tm1a(KOMP)Wtsi})	enlarged spleen	J:225146
	increased marginal zone B cell number	J:225146
	increased spleen white pulp amount	J:225146
Tbrs1^C57BL/6J/Tbrs1^C57BL/6J (involves: C57BL/6J * DBA/2J)	decreased susceptibility to bacterial infection	J:67658
Tbrs2^C57BL/6J/Tbrs2^C57BL/6J (involves: C57BL/6J * DBA/2J)	decreased susceptibility to bacterial infection	J:67658
Tbrs2^C57BL/6J/Tbrs2^DBA/2J (involves: C57BL/6J * DBA/2J)	decreased susceptibility to bacterial infection	J:67658
Tbrs3^C57BL/6J/Tbrs3^C57BL/6J (involves: C57BL/6J * DBA/2J)	decreased susceptibility to bacterial infection	J:67658
Tbrs3^C57BL/6J/Tbrs3^C57BL/6J Tbrs4^C57BL/6J/Tbrs4^C57BL/6J (involves: C57BL/6J * DBA/2J)	decreased susceptibility to bacterial infection	J:83619
Tbrs3^C57BL/6J/Tbrs3^DBA/2J (involves: C57BL/6J * DBA/2J)	decreased susceptibility to bacterial infection	J:67658
Tbrs4^C57BL/6J/Tbrs4^C57BL/6J (involves: C57BL/6J * DBA/2J)	decreased susceptibility to bacterial infection	J:83619
Tbs1^I/StSnEgYCit/Tbs1^A/SnYCit (involves: A/SnYCit * I/StSnEgYCit)	decreased susceptibility to bacterial infection	J:80972
Tbs2^I/StSnEgYCit/Tbs2^A/SnYCit (involves: A/SnYCit * I/StSnEgYCit)	decreased susceptibility to bacterial infection	J:80972
Tbx1^m1H/Tbx1^m1H (involves: C3H/HeH * C57BL/6J)	small thymus	J:169366
Tbx1^m1Jlk/Tbx1^m1Jlk (129/Sv-Tbx1^m1Jlk)	athymia	J:146769
Tbx1^m1Jlk/Tbx1^tm1Bld (involves: 129)	athymia	J:146769
Tbx1^tm1.1Dsr/Tbx1^tm1.1Dsr (either: 129/Sv or (involves: 129/Sv * C57BL/6))	athymia	J:93588
Tbx1^tm1Bem/Tbx1⁺ (FVB.Cg-Tbx1^tm1Bem)	increased susceptibility to otitis media	J:91664
Tbx1^tm1Bem/Tbx1^tm1Bem (FVB.Cg-Tbx1^tm1Bem)	athymia	J:91664
Tbx1^tm1Bem/Tbx1^tm1Bem (FVB.Cg-Tbx1^tm1Bem)	thymus hypoplasia	J:91664
Tbx1^tm1Bld/Tbx1^tm1Bld (involves: 129S7/SvEvBrd)	abnormal lymphangiogenesis	J:159824
	abnormal lymphatic vessel morphology	J:159824
	athymia	J:146769
	lymphangiectasis	J:159824
Tbx1^tm1Bld/Tbx1^tm2.1Bem Tfap2a^tm1(cre)Moon/Tfap2a⁺ (either: (involves: 129/Sv * C57BL/6 * SJL) or (involves: 129/Sv * C57BL/6J * CBA * SJL))	athymia	J:154590
	thymus hypoplasia	J:154590
Tbx1^tm1Bld/Tbx1^tm3Bld Tg(CAG-cre/Esr1)5Amc/0 (involves: 129S7/SvEvBrd C57BL/6 * CBA)	abnormal lymphangiogenesis	J:159824
	abnormal lymphatic vessel morphology	J:159824
Tbx1^tm1Bld/Tbx1^tm3Bld Tg(Tek-cre)1Ywa/0 (involves: 129S7/SvEvBrd * C57BL/6 * SJL)	abnormal lymphangiogenesis	J:159824
	abnormal lymphatic vessel morphology	J:159824
Tbx1^tm1Bld/Tbx1^tm5Bld (involves: 129S7/SvEvBrd * C57BL/6)	athymia	J:112457
Tbx1^tm1Dsr/Tbx1^tm1Dsr (either: 129/Sv or (involves: 129/Sv * C57BL/6))	athymia	J:93588
Tbx1^tm1Pa/Tbx1^tm1Pa (either: (involves: 129) or (involves: 129 * C57BL/6) or (involves: 129 * C57BL/6 * Swiss Webster))	abnormal thymus development	J:70730
	athymia	J:70730
Tbx1^tm2.1Bem/Tbx1^tm2.2Bem Foxg1^tm1(cre)Skm/Foxg1⁺ (involves: 129 * C57BL/6J * SJL * Swiss Webster)	athymia	J:105980
Tbx3^em1(IMPC)Mbp/Tbx3⁺ (C57BL/6NCrl-Tbx3^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
Tbx20^em1(IMPC)Mbp/Tbx20⁺ (C57BL/6N-Tbx20^em1(IMPC)Mbp/MbpMmucd)	increased neutrophil cell number	J:211773
Tbx21^duane/Tbx21^duane (C57BL/6-Tbx21^duane)	abnormal NK cell differentiation	J:154069
	absent NK T cells	J:154069
	decreased NK cell number	J:154069
	increased NK cell number	J:154069
Tbx21^m1Btlr/Tbx21^m1Btlr (C57BL/6J-Tbx21^m1Btlr)	increased CD8-positive, alpha-beta T cell number	J:267478
	increased effector memory CD8-positive, alpha-beta T cell number	J:267478
	increased IgM level	J:267478
Tbx21^{tm1.1(flpe/ERT2)Gmld}/Tbx21^{tm1.1(flpe/ERT2)Gmld} (involves: 129S2/SvPas * C57BL/6)	decreased interferon-gamma secretion	J:207104
Tbx21^tm1Glm/Tbx21⁺ (involves: 129S6/SvEvTac * C57BL/6)	abnormal cytokine level	J:73833
	abnormal interleukin level	J:73832
	abnormal NK cell physiology	J:73833
	abnormal tumor necrosis factor level	J:73832
	decreased T helper 1 cell number	J:73833
Tbx21^tm1Glm/Tbx21^tm1Glm (involves: 129S6/SvEvTac * C57BL/6)	abnormal CD8-positive, alpha-beta cytotoxic T cell morphology	J:73833
	abnormal cytokine level	J:73832
	abnormal immunoglobulin level	J:73833
	abnormal interleukin level	J:73832
	abnormal NK cell physiology	J:73833
	abnormal T-helper 1 cell differentiation	J:73833
	abnormal tumor necrosis factor level	J:73832
	decreased interferon-gamma secretion	J:73833
	decreased T helper 1 cell number	J:73833
	impaired natural killer cell mediated cytotoxicity	J:73833
	increased natural killer cell mediated cytotoxicity	J:73833
	increased susceptibility to parasitic infection	J:73833
	increased T-helper 2 cell number	J:73833
	respiratory system inflammation	J:73832
Tbx21^tm1Glm/Tbx21^tm1Glm (C.129S6-Tbx21^tm1Glm/J)	abnormal CD4-positive, alpha-beta T cell physiology	J:111932
	abnormal cytokine secretion	J:111932
	CNS inflammation	J:111932
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:111932
Tbx21^tm1Glm/Tbx21^tm1Glm (B6.129S6-Tbx21^tm1Glm)	abnormal CD4-positive T cell differentiation	J:143729
Tbx21^tm1Glm/Tbx21^tm1Glm (involves: 129S6/SvEvTac)	abnormal cytokine level	J:112600
	abnormal leukocyte migration	J:163822
	decreased CD4-positive, alpha-beta T cell number	J:163822
	decreased memory T cell number	J:163822
	increased interleukin-17 secretion	J:163822
	increased susceptibility to induced colitis	J:141481
Tbx21^tm1Srnr/Tbx21⁺ (involves: C57BL/6)	absent NK T cells	J:112679
Tbx21^tm1Srnr/Tbx21⁺ (involves: C57BL/6)	decreased NK cell number	J:112679
Tbx21^tm1Srnr/Tbx21^tm1Srnr (involves: C57BL/6)	abnormal T-helper 1 cell morphology	J:112679
Tbx21^tm1Srnr/Tbx21^tm1Srnr (involves: C57BL/6)	decreased NK T cell number	J:112679
Tbx21^tm2Srnr/Tbx21⁺ Tg(Cd4-cre)1Cwi/0 (involves: 129 * C57BL/6 * DBA/2)	decreased CD8-positive, alpha-beta T cell number	J:174315
	increased susceptibility to Riboviria infection	J:174315
Tbx21^tm2Srnr/Tbx21^tm2Srnr Tg(Cd4-cre)1Cwi/0 (involves: 129 * C57BL/6 * DBA/2)	decreased CD8-positive, alpha-beta T cell number	J:174315
	immune system phenotype	J:137655
	increased interleukin-2 secretion	J:174315
	increased interleukin-17 secretion	J:174315
	increased susceptibility to Riboviria infection	J:174315
	increased tumor necrosis factor secretion	J:174315
Tbxa2r^tm1Cof/Tbxa2r^tm1Cof (either: (involves: 129P2/OlaHsd * C57BL/6 * DBA/2) or (involves: 129P2/OlaHsd * 129S/SvEv))	immune system phenotype	J:52125
Tbxa2r^tm1Sna/Tbxa2r^tm1Sna (either: (involves: 129/Ola * BALB/c) or (involves: 129/Ola * C57BL/6))	abnormal cervical lymph node morphology	J:84085
	abnormal immune serum protein physiology	J:84085
	abnormal immune system organ morphology	J:84085
	abnormal immune system physiology	J:84085
	abnormal lymph node morphology	J:84085
	abnormal type I hypersensitivity reaction	J:84085
	enlarged lymph nodes	J:84085
	enlarged spleen	J:84085
Tbxa2r^tm1Sna/Tbxa2r^tm1Sna (B6.Cg-Tbxa2r^tm1Sna)	increased susceptibility to type I hypersensitivity reaction	J:197334
Tbxas1^tm1Swl/Tbxas1^tm1Swl (involves: 129P2/OlaHsd * BALB/c * C57BL/6J)	decreased inflammatory response	J:90922
Tcaf2^{em1(IMPC)Ccpcz}/Tcaf2^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Tcaf2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Tcaim^{tm1b(EUCOMM)Wtsi}/Tcaim^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Tcaim^{tm1b(EUCOMM)Wtsi}/H)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Tcdel1^C57BL/6/Tcdel1^NOD/ShiLtDoi (involves: C57BL/6 * NOD/ShLtDoi * SJL)	decreased double-negative T cell number	J:97046
	increased double-positive T cell number	J:97046
Tcdel1^NOD/ShiLtDoi/Tcdel1^NOD/ShiLtDoi (involves: C57BL/6 * NOD/ShLtDoi * SJL)	decreased double-negative T cell number	J:97046
	increased double-positive T cell number	J:97046
Tcdel2^C57BL/6/Tcdel2^NOD/ShiLtDoi (involves: C57BL/6 * NOD/ShLtDoi * SJL)	decreased double-negative T cell number	J:97046
	increased double-positive T cell number	J:97046
Tcdel2^NOD/ShiLtDoi/Tcdel2^NOD/ShiLtDoi (involves: C57BL/6 * NOD/ShLtDoi * SJL)	decreased double-negative T cell number	J:97046
	increased double-positive T cell number	J:97046
Tcea2^em1(IMPC)J/Tcea2^em1(IMPC)J (C57BL/6NJ-Tcea2^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
Tceal3^em1(IMPC)Tcp/Y (C57BL/6NCrl-Tceal3^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Tcf3^tm1(PBX1)Mlc/Tcf3⁺ Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell physiology	J:226241
	abnormal pro-B cell differentiation	J:226241
	abnormal pro-B cell morphology	J:226241
	arrested B cell differentiation	J:226241
	decreased B cell number	J:226241
	decreased immature B cell number	J:226241
	enlarged lymph nodes	J:226241
	enlarged spleen	J:226241
	increased leukocyte cell number	J:226241
Tcf3^tm1(PBX1)Mlc/Tcf3⁺ Cd79a^tm1(cre)Reth/Cd79a⁺ (involves: BALB/c * C57BL/6)	arrested B cell differentiation	J:226241
	decreased B cell number	J:226241
	decreased immature B cell number	J:226241
	enlarged lymph nodes	J:226241
	enlarged spleen	J:226241
	increased leukocyte cell number	J:226241
Tcf3^tm1(PBX1)Mlc/Tcf3⁺ Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * C57BL/6J * CBA/J)	arrested B cell differentiation	J:226241
	decreased B cell number	J:226241
	decreased immature B cell number	J:226241
	enlarged lymph nodes	J:226241
	enlarged spleen	J:226241
	increased leukocyte cell number	J:226241
Tcf3^{tm1(TCF3/HLF)Homy}/Tcf3⁺ Tg(Mx1-cre)1Cgn/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA)	abnormal B cell differentiation	J:160392
	increased B cell number	J:160392
Tcf3^tm1.1Mbu/Tcf3⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell differentiation	J:137719
Tcf3^tm1Cmu/Tcf3⁺ (either: 129P2/OlaHsd-Tcf3^tm1Cmu or (involves: 129P2/OlaHsd * FVB/N))	decreased B cell number	J:67011
Tcf3^tm1Cmu/Tcf3^tm1Cmu (either: 129P2/OlaHsd-Tcf3^tm1Cmu or (involves: 129P2/OlaHsd * FVB/N))	abnormal immunoglobulin heavy chain V(D)J recombination	J:67011
	abnormal immunoglobulin V(D)J recombination	J:67011
	abnormal T cell subpopulation ratio	J:67011
	decreased B cell number	J:67011
	decreased lymphocyte cell number	J:67011
Tcf3^tm1Mbu/Tcf3^tm1.2Mbu Tg(Aicda-cre)9Mbu/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA * SJL)	abnormal germinal center B cell morphology	J:137719
	decreased B cell number	J:137719
	decreased germinal center B cell number	J:137719
	immune system phenotype	J:137719
Tcf3^tm1Mbu/Tcf3^tm1.2Mbu Tg(Fcer2a-cre)5Mbu/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA * SJL)	abnormal germinal center B cell morphology	J:137719
	decreased B cell number	J:137719
	decreased germinal center B cell number	J:137719
	immune system phenotype	J:137719
	increased marginal zone B cell number	J:137719
Tcf3^tm1Mbu/Tcf3^tm1Mbu Commd10^{Tg(Vav1-icre)A2Kio}/Commd10⁺ (involves: 129P2/OlaHsd * C57BL/10 * CBA/Ca)	decreased pro-B cell number	J:137719
Tcf3^tm1Mbu/Tcf3^tm1Mbu Tg(Ikzf1-Tcfe2a,-GFP)1Mbu/0 Commd10^{Tg(Vav1-icre)A2Kio}/Commd10⁺ (involves: 129P2/OlaHsd * C57BL * CBA)	immune system phenotype	J:137719
Tcf3^tm1Wein/Tcf3⁺ (either: (involves: 129/Sv * 129S4/SvJaeSor) or (involves: 129S4/SvJaeSor * C57BL/6J))	decreased B cell number	J:22134
Tcf3^tm1Wein/Tcf3⁺ (involves: 129S4/SvJaeSor)	abnormal B cell number	J:91042
Tcf3^tm1Wein/Tcf3⁺ (involves: 129S4/SvJaeSor)	decreased pre-B cell number	J:91042
Tcf3^tm1Wein/Tcf3^tm1Wein (either: (involves: 129 * 129S4/SvJaeSor) or (involves: 129S4/SvJaeSor * C57BL/6J))	abnormal B cell number	J:22134
	abnormal lymphocyte cell number	J:22134
	spleen atrophy	J:22134
Tcf3^tm1Wein/Tcf3^tm1Wein (involves: 129S4/SvJaeSor * C57BL/6)	enlarged thymus	J:44278
	increased T cell derived lymphoma incidence	J:44278
Tcf3^tm1Wein/Tcf3^tm3Zhu (involves: 129/Sv * 129S4/SvJaeSor * C57BL/6)	decreased pro-B cell number	J:47671
Tcf3^tm1Xhsu/Tcf3^tm1Xhsu (B6.129X1-Tcf3^tm1Xhsu)	immune system phenotype	J:132669
Tcf3^tm1Xhsu/Tcf3^tm1Xhsu (B6.129X1-Tcf3^tm1Xhsu)	increased B cell number	J:132669
Tcf3^tm1Xhsu/Tcf3^tm1Xhsu Tg(Lck-Stat5b)1Mafa/0 (involves: 129X1/SvJ C57BL/6 * FVB/N)	increased B cell proliferation	J:132669
Tcf3^tm1Zhu/Tcf3^tm1Zhu (involves: 129)	decreased B cell number	J:47671
Tcf3^tm1Zhu/Tcf3^tm1Zhu (involves: 129 * C57BL/6J)	decreased double-positive T cell number	J:136143
	increased double-negative T cell number	J:136143
	increased single-positive T cell number	J:136143
	thymus hypoplasia	J:136143
Tcf3^tm1Zhu/Tcf3^tm2Zhu (involves: 129 * C57BL/6)	decreased B cell number	J:47671
Tcf3^tm2Cmu/Tcf3^tm2Cmu (involves: 129P2/OlaHsd)	abnormal lymphopoiesis	J:118827
	absent pre-B cells	J:118827
	absent pro-B cells	J:118827
	decreased dendritic cell number	J:118827
	decreased NK cell number	J:118827
Tcf3^tm2Wein/Tcf3^tm2Wein (Not Specified)	abnormal immune system morphology	J:47671
Tcf3^tm2Wein/Tcf3^tm2Wein (Not Specified)	increased T cell derived lymphoma incidence	J:47671
Tcf3^tm2Zhu/Tcf3^tm2Zhu (involves: 129 * C57BL/6)	decreased pre-B cell number	J:47671
Tcf3^tm2Zhu/Tcf3^tm2Zhu (involves: 129 * C57BL/6)	decreased pro-B cell number	J:47671
Tcf3^tm3.1Cmu/Tcf3^tm3.1Cmu (involves: 129S/SvEv * FVB/N)	abnormal B cell differentiation	J:153423
	abnormal immunoglobulin light chain V-J recombination	J:153423
	decreased pre-B cell number	J:153423
Tcf3^tm3Zhu/Tcf3^tm3Zhu (involves: 129/Sv * C57BL/6)	decreased B cell number	J:47671
Tcf3^tm3Zhu/Tcf3^tm3Zhu (involves: 129/Sv * C57BL/6)	immune system phenotype	J:47671
Tcf3^tm4.1Cmu/Tcf3^tm4.1Cmu (involves: 129S/SvEv * FVB/N)	abnormal immunoglobulin light chain V-J recombination	J:153423
	absent B cells	J:153423
	arrested B cell differentiation	J:153423
	decreased pro-B cell number	J:153423
Tcf3^tm4Zhu/Tcf3^tm4Zhu Tg(Lck-cre)#Zhu/0 (involves: 129S4/SvJae * C57BL/6 * SJL)	immune system phenotype	J:75746
Tcf3^tm4Zhu/Tcf3^tm4Zhu Tg(Lck-cre)#Zhu/0 Tg(TcrAND)53Hed/0 (involves: 129S4/SvJae * C57BL/6 * SJL)	immune system phenotype	J:75746
Tcf3^tm5.1Cmu/Tcf3^tm5.1Cmu (involves: 129S/SvEv * C57BL/6)	immune system phenotype	J:183781
Tcf3^{tm6(Esr1)Zhu}/Tcf3^{tm6(Esr1)Zhu} (involves: 129/Sv * C57BL/6)	abnormal immunoglobulin heavy chain V(D)J recombination	J:154788
	arrested B cell differentiation	J:154788
Tcf4^tm1.1Hmb/Tcf4⁺ (involves: 129P2/OlaHsd * C57BL/6J)	increased double-negative T cell number	J:136143
Tcf4^tm1.1Hmb/Tcf4^tm1.1Hmb (involves: 129P2/OlaHsd * C57BL/6J)	abnormal T cell differentiation	J:136143
	abnormal T cell physiology	J:136143
	immune system phenotype	J:136143
	increased double-negative T cell number	J:136143
Tcf4^tm1Hmb/Tcf4^tm1Zhu Tg(Kit-cre)143Hmb/? (involves: 129P2/OlaHsd * C57BL/6 * CBA)	abnormal B cell differentiation	J:65236
	decreased double-positive T cell number	J:65236
	decreased thymocyte number	J:65236
	spleen hypoplasia	J:65236
Tcf4^tm1Zhu/Tcf4⁺ Tcf3^tm1Wein/Tcf3⁺ (involves: 129P2/OlaHsd)	decreased pro-B cell number	J:43324
Tcf4^tm1Zhu/Tcf4^tm1Zhu (involves: 129P2/OlaHsd * C57BL/6)	decreased pro-B cell number	J:43324
Tcf7^{tm1a(EUCOMM)Wtsi}/Tcf7^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Tcf7^{tm1a(EUCOMM)Wtsi}/Ics)	decreased CD4-positive, alpha-beta T cell number	J:165965
	decreased T cell number	J:165965
	increased B cell number	J:165965
Tcf7^tm1Cle/Tcf7^tm1Cle (involves: 129P2/OlaHsd)	abnormal memory T cell physiology	J:189838
	abnormal T cell differentiation	J:23255
	decreased CD8-positive, alpha-beta T cell number	J:189838
	decreased double-positive T cell number	J:23255
	decreased single-positive T cell number	J:23255
	decreased T cell number	J:23255
	increased osteoclast cell number	J:98430
	thymus cortex hypoplasia	J:23255
	thymus hypoplasia	J:23255
Tcf7^tm2Cle/Tcf7^tm2Cle (involves: 129P2/OlaHsd)	decreased double-positive T cell number	J:23255
	decreased single-positive T cell number	J:23255
	thymus hypoplasia	J:23255
Tcf7l2^m1Btlr/Tcf7l2^m1Btlr (C57BL/6J-Tcf7l2^m1Btlr)	increased susceptibility to induced colitis	J:267536
Tcf12^m1Btlr/Tcf12^m1Btlr (C57BL/6J-Tcf12^M1Btlr)	increased CD8-positive, alpha-beta T cell number	J:267564
Tcf12^M2Btlr/Tcf12^M2Btlr (C57BL/6J-Tcf12^M2Btlr)	decreased CD4-positive, alpha-beta T cell number	J:267666
	increased CD8-positive, alpha-beta T cell number	J:267666
	increased effector memory CD4-positive, alpha-beta T cell number	J:267666
Tcf12^M3Btlr/Tcf12^M3Btlr (C57BL/6J-Tcf12^M3Btlr)	decreased B cell number	J:271971
	decreased CD4-positive, alpha-beta T cell number	J:271971
	increased CD8-positive, alpha-beta T cell number	J:271971
Tcf12^m4Btlr/Tcf12^m4Btlr (C57BL/6J-Tcf12^m4Btlr)	abnormal B cell morphology	J:271972
	abnormal T cell morphology	J:271972
	decreased CD4-positive, alpha-beta T cell number	J:271972
	increased CD8-positive, alpha-beta T cell number	J:271972
Tcf12^tm1Zhu/Tcf12⁺ Tcf3^tm1Wein/Tcf3⁺ (involves: 129S4/SvJaeSor)	decreased pro-B cell number	J:43324
Tcf12^tm1Zhu/Tcf12⁺ Tcf3^tm4Zhu/Tcf3^tm4Zhu Tg(Lck-cre)#Zhu/0 (involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6 * SJL)	abnormal T cell differentiation	J:75746
	increased double-negative T cell number	J:75746
	increased single-positive T cell number	J:75746
Tcf12^tm1Zhu/Tcf12⁺ Tcf4^tm1Zhu/Tcf4⁺ (involves: 129P2/OlaHsd * 129S7/SvEvBrd)	decreased pro-B cell number	J:43324
Tcf12^tm1Zhu/Tcf12^tm1Zhu (involves: 129/Sv * C57BL/6)	decreased pro-B cell number	J:43324
Tcf12^tm1Zhu/Tcf12^tm1Zhu (involves: 129S7/SvEvBrd)	arrested T cell differentiation	J:120411
Tcf12^tm1Zhu/Tcf12^tm1Zhu (involves: 129S7/SvEvBrd)	decreased thymocyte number	J:120411
Tcf12^tm1Zhu/Tcf12^tm1Zhu (involves: 129S7/SvEvBrd * C57BL/6J)	decreased double-positive T cell number	J:136143
	increased CD8-positive, alpha-beta T cell number	J:136143
	increased double-negative T cell number	J:136143
	thymus hypoplasia	J:136143
Tcf12^tm1Zhu/Tcf12^tm2Zhu (involves: 129S7/SvEvBrd)	arrested T cell differentiation	J:120411
Tcf12^tm2Zhu/Tcf12^tm2Zhu (Not Specified)	abnormal B cell differentiation	J:120411
	abnormal response to transplant	J:120411
	abnormal T cell differentiation	J:120411
	absent T cells	J:120411
	arrested T cell differentiation	J:120411
	decreased double-positive T cell number	J:120411
	decreased immature B cell number	J:120411
	decreased pre-B cell number	J:120411
	decreased pro-B cell number	J:120411
	decreased thymocyte number	J:120411
	increased double-negative T cell number	J:120411
	thymus hypoplasia	J:120411
Tcf12^tm2Zhu/Tcf12^tm2Zhu Tg(TcrAND)53Hed/0 (involves: C57BL/6 * SJL)	abnormal CD4-positive, alpha beta T cell morphology	J:120411
	abnormal T cell subpopulation ratio	J:120411
	arrested T cell differentiation	J:120411
	increased T cell number	J:120411
Tcf12^tm3Zhu/Tcf12^tm3Zhu Tcf3^tm4Zhu/Tcf3^tm4Zhu Tg(Cd4-cre)1Cwi/0 (involves: 129S4/SvJae * C57BL/6 * DBA/2)	abnormal CD8-positive, alpha beta T cell morphology	J:129171
	abnormal T cell differentiation	J:129171
	decreased CD4-positive, alpha-beta T cell number	J:129171
	increased CD8-positive, alpha-beta T cell number	J:129171
Tcf12^tm3Zhu/Tcf12^tm3Zhu Tcf3^tm4Zhu/Tcf3^tm4Zhu Tg(Lck-cre)#Zhu/0 (involves: 129S4/SvJae * C57BL/6 * SJL/J)	decreased double-positive T cell number	J:129570
	decreased T cell number	J:129570
	increased double-negative T cell number	J:129570
	increased T cell proliferation	J:129570
	thymus hypoplasia	J:129570
Tcf12^tm3Zhu/Tcf12^tm3Zhu Tg(Lck-cre)#Zhu/0 (involves: C57BL/6 * SJL/J)	decreased thymocyte number	J:129570
	increased CD8-positive, alpha-beta T cell number	J:129570
Tcf21^em1(IMPC)Mbp/Tcf21⁺ (C57BL/6NCrl-Tcf21^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	small spleen	J:211773
Tcf21^tm1Eno/Tcf21^tm1Eno (involves: 129 * Black Swiss)	abnormal spleen development	J:64068
Tcf21^tm1Eno/Tcf21^tm1Eno (involves: 129 * Black Swiss)	absent spleen	J:64068
Tcf21^tm2Eno/Tcf21^tm2Eno (involves: 129 * Black Swiss)	abnormal spleen development	J:64068
Tcf21^tm2Eno/Tcf21^tm2Eno (involves: 129 * Black Swiss)	absent spleen	J:64068
Tcim^tm1Icle/Tcim^tm1Icle (B6.129-Tcim^tm1Icle)	abnormal mononuclear cell morphology	J:217318
	increased eosinophil cell number	J:217318
	increased leukocyte cell number	J:217318
	increased lymphocyte cell number	J:217318
	increased monocyte cell number	J:217318
	increased neutrophil cell number	J:217318
	lymphoid hyperplasia	J:217318
	myeloid hyperplasia	J:217318
Tcirg1^M1Jeau/Tcirg1⁺ (either: (involves: C3H/HeJ * C57BL/6) or (involves: C3H/HeJ * C57BL/6 * FVB/N))	abnormal osteoclast morphology	J:196503
	abnormal osteoclast physiology	J:196503
	increased osteoclast cell number	J:196503
Tcirg1^oc/Tcirg1^oc (B6C3Fe a/a-Tcirg1^oc/J)	abnormal osteoclast morphology	J:7870
Tcirg1^tm1.2Ywd/Tcirg1^tm1.2Ywd (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N * SJL)	abnormal macrophage physiology	J:150327
Tcirg1^tm1Utku/Tcirg1^tm1Utku (involves: 129X1/SvJ * C57BL/6)	abnormal immune serum protein physiology	J:92730
	abnormal immune system physiology	J:92730
	abnormal mesenteric lymph node morphology	J:92730
	abnormal peripheral lymph node morphology	J:92730
	abnormal Peyer's patch morphology	J:92730
	abnormal spleen B cell corona morphology	J:92730
	abnormal spleen morphology	J:92730
	abnormal spleen periarteriolar lymphoid sheath morphology	J:92730
	abnormal spleen red pulp morphology	J:92730
	abnormal spleen white pulp morphology	J:92730
	decreased B cell number	J:92730
	decreased lymphocyte cell number	J:92730
	decreased spleen B cell follicle size	J:92730
	decreased T cell number	J:92730
	increased granulocyte number	J:92730
	increased IgG1 level	J:92730
	increased IgG2a level	J:92730
	increased IgM level	J:92730
	increased immunoglobulin level	J:92730
	increased spleen germinal center number	J:92730
	thymus atrophy	J:92730
Tcirg1^tm1Ypl/Tcirg1^tm1Ypl (involves: 129S4/SvJae * C57BL/6J)	abnormal osteoclast physiology	J:58795
Tcpm1^BALB/c/Tcpm1^BALB/c (involves: BALB/c * C57BL/10)	abnormal effector T cell morphology	J:36255
Tcpm1^BALB/c/Tcpm1^C57BL/10Sn (involves: BALB/c * C57BL/10)	abnormal effector T cell morphology	J:36255
Tcra-J^tm1Jpdv/Tcra-J^tm1Jpdv (involves: 129P2/OlaHsd)	abnormal T cell differentiation	J:77518
Tcra-J^tm1Kgwa/Tcra-J^tm1Kgwa Tg(Tcrb2B4)1Mmd/0 (involves: 129P2/OlaHsd * C3H/HeJ * C57BL/6J)	abnormal T cell differentiation	J:50143
	increased double-positive T cell number	J:50143
Tcra-J^tm1Slek/Tcra-J^tm1Slek (involves: 129P2/OlaHsd)	abnormal T cell differentiation	J:101398
	decreased double-positive T cell number	J:101398
	decreased single-positive T cell number	J:101398
	increased double-negative T cell number	J:101398
	increased thymocyte number	J:101398
Tcra-J^tm1Tgi/Tcra-J^tm1Tgi (B6.129-Tcra-J^tm1Tgi)	decreased activated T cell number	J:99107
	decreased B cell number	J:99107
	decreased circulating interleukin-5 level	J:121037
	decreased IgE level	J:121037
	decreased IgG level	J:99107
	decreased susceptibility to induced arthritis	J:99107
	increased incidence of corneal inflammation	J:132503
	liver inflammation	J:135830
	lung inflammation	J:121037
Tcra-J^tm1Tgi/Tcra-J^tm1Tgi (involves: 129S1/Sv * 129X1/SvJ)	decreased circulating interferon-gamma level	J:155199
	decreased interferon-gamma secretion	J:155199
	decreased susceptibility to bacterial infection	J:155199
Tcra-J^tm1Tgi/Tcra-J^tm1Tgi (involves: 129S1/Sv * 129X1/SvJ * BALB/c)	abnormal eosinophil cell number	J:84720
	abnormal immune serum protein physiology	J:84720
	abnormal interleukin secretion	J:84720
	decreased IgE level	J:84720
	decreased interleukin-4 secretion	J:84720
	decreased interleukin-13 secretion	J:84720
	liver inflammation	J:105977
Tcra-J^tm1Tgi/Tcra-J^tm1Tgi (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	decreased NK T cell number	J:89695
	lung inflammation	J:89695
Tcra-J^tm1Tgi/Tcra-J^tm1Tgi (C.129-Tcra-J^tm1Tgi)	abnormal interleukin secretion	J:184570
	decreased interleukin-5 secretion	J:184570
	decreased interleukin-9 secretion	J:184570
	decreased interleukin-10 secretion	J:184570
	decreased interleukin-13 secretion	J:184570
	decreased interleukin-17 secretion	J:184570
Tcra-J^tm2.3Krg/Tcra-J^tm2.3Krg (involves: 129S/SvEv * C57BL/6)	abnormal T cell receptor alpha chain V-J recombination	J:147326
Tcra-J^tm3.1Krg/Tcra-J^tm3.1Krg (involves: 129S6/SvEvTac)	abnormal T cell differentiation	J:128344
Tcra-J^tm4.1Krg/Tcra-J^tm4.1Krg (involves: 129S6/SvEvTac)	abnormal T cell receptor alpha chain V-J recombination	J:147326
Tcra-J^tm5Krg/Tcra-J^tm5Krg (involves: 129S6/SvEvTac)	abnormal T cell receptor alpha chain V-J recombination	J:147326
Tcra^Ln1Ogu/Tcra⁺ (involves: 129/Sv * C57BL/6)	abnormal cytokine secretion	J:152041
	abnormal NK T cell morphology	J:152041
	abnormal T cell subpopulation ratio	J:152041
	decreased IgG2a level	J:152041
	decreased splenocyte number	J:152041
	decreased thymocyte number	J:152041
	increased IgG1 level	J:152041
	increased interferon-gamma secretion	J:152041
	increased interleukin-2 secretion	J:152041
	increased interleukin-4 secretion	J:152041
	increased interleukin-10 secretion	J:152041
	increased NK T cell number	J:152041
Tcra^Ln1Ogu/Tcra⁺ Tcrb^Ln1Ogu/Tcrb⁺ (involves: 129/Sv * C57BL/6)	abnormal T cell morphology	J:152069
Tcra^Ln2Ogu/Tcra⁺ Tcrb^Ln2Ogu/Tcrb⁺ (involves: 129/Sv * C57BL/6)	abnormal T cell morphology	J:152069
Tcra^Ln3Jae/Tcra⁺ (B6.Cg-Tcra^Ln3Jae)	abnormal double-negative T cell morphology	J:143006
	decreased CD4-positive, alpha-beta T cell number	J:143006
	decreased double-positive T cell number	J:143006
	increased CD8-positive, alpha-beta T cell number	J:143006
	thymus hypoplasia	J:143006
Tcra^Ln3Jae/Tcra⁺ Tcrb^Ln3Jae/Tcrb⁺ (B6.Cg-Tcrb^Ln3Jae Tcra^Ln3Jae)	abnormal double-negative T cell morphology	J:143006
	abnormal T cell differentiation	J:143006
	absent gamma-delta T cells	J:143006
	decreased CD4-positive, alpha-beta T cell number	J:143006
	decreased double-positive T cell number	J:143006
	increased CD8-positive, alpha-beta T cell number	J:143006
	thymus hypoplasia	J:143006
Tcra^tm1Cgn/Tcra^tm1Cgn Tg(Mx1-cre)1Cgn/0 (involves: 129S7/SvEvBrd * C57BL/6 * CBA)	abnormal CD4-positive, alpha beta T cell morphology	J:79298
	abnormal CD8-positive, alpha beta T cell morphology	J:79298
	abnormal memory T cell morphology	J:79298
	abnormal T cell morphology	J:79298
Tcra^tm1Cgn/Tcra^tm1Cgn Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA)	immune system phenotype	J:201417
Tcra^tm1Cgn/Tcra^tm1Mass Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA)	abnormal T cell physiology	J:201417
	increased T cell number	J:201417
Tcra^tm1Mass/Tcra⁺ Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	abnormal NK T cell morphology	J:201417
	decreased NK cell number	J:201417
	increased NK T cell number	J:201417
Tcra^tm1Mass/Tcra⁺ Tg(Nes-cre)Wme/0 (involves: C57BL/6 * CBA)	abnormal positive T cell selection	J:201417
	decreased NK T cell number	J:201417
	decreased thymocyte number	J:201417
	increased double-negative T cell number	J:201417
Tcra^tm1Mass/Tcra^tm1Mass (involves: C57BL/6)	arrested T cell differentiation	J:201417
Tcra^tm1Mjo/Tcra⁺ (NOD.129P2-Tcra^tm1Mjo)	abnormal T cell physiology	J:108590
Tcra^tm1Mjo/Tcra⁺ (NOD.129P2-Tcra^tm1Mjo)	decreased susceptibility to autoimmune diabetes	J:108590
Tcra^tm1Mjo/Tcra⁺ (SJL.129P2-Tcra^tm1Mjo)	immune system phenotype	J:108590
Tcra^tm1Mjo/Tcra^tm1Mjo (involves: 129P2/OlaHsd * BALB/c)	abnormal immune system organ morphology	J:1292
	abnormal splenic cell ratio	J:1292
	abnormal T cell morphology	J:1292
	abnormal thymus cortex morphology	J:1292
	absent thymus medulla	J:1292
	enlarged thymus cortex	J:1292
	increased activated T cell number	J:111129
	increased anti-double stranded DNA antibody level	J:111129
	increased anti-nuclear antigen antibody level	J:111129
	increased autoantibody level	J:111129
	increased B cell number	J:111129
	increased IgE level	J:111129
	increased IgG1 level	J:111129
	increased immunoglobulin level	J:111129
	small Peyer's patches	J:1292
Tcra^tm1Mjo/Tcra^tm1Mjo (NOD.129P2-Tcra^tm1Mjo)	increased activated T cell number	J:52940
Tcra^tm1Mjo/Tcra^tm1Mjo (involves: 129P2/OlaHsd)	colitis	J:37699
	decreased T cell proliferation	J:110898
	enlarged mesenteric lymph nodes	J:110898
	enlarged spleen	J:110898
	increased activated T cell number	J:110898
	increased gamma-delta T cell number	J:110898
	increased T cell number	J:110898
	spleen hyperplasia	J:110898
Tcra^tm1Mjo/Tcra^tm1Mjo X/Yaa (BXSB.129P2(Cg)-Tcra^tm1Mjo/Theo)	immune system phenotype	J:120153
Tcra^tm1Mom/Tcra/Tcrd^{tm1.1(Tcra)Rsky} H2^b/H2^b Tg(Tcrb)93Vbo/? (involves: 129P2/OlaHsd * C57BL/6J * DBA/2J)	abnormal double-negative T cell morphology	J:131357
	abnormal double-positive T cell morphology	J:81564
	abnormal negative T cell selection	J:81564
	abnormal T cell differentiation	J:81564
	decreased double-positive T cell number	J:131357
	decreased thymocyte number	J:131357
Tcra^tm1Mom/Tcra/Tcrd^{tm1.1(Tcra)Rsky} H2^d/H2^d Ptcra^tm1Vbo/Ptcra^tm1Vbo Tg(Tcrb)93Vbo/? (involves: 129P2/OlaHsd * C57BL/6J * DBA/2J)	abnormal T cell differentiation	J:131357
	decreased thymocyte number	J:131357
Tcra^tm1Mom/Tcra^tm1Mom (involves: 129S2/SvPas)	absent T cells	J:88620
Tcra^tm1Mom/Tcra^tm1Mom (B6.129S2-Tcra^tm1Mom)	abnormal response to transplant	J:91742
	colitis	J:135597
	increased mature gamma-delta T cell number	J:135597
	increased susceptibility to bacterial infection	J:106241
Tcra^tm1Mom/Tcra^tm1Mom (involves: 129S2/SvPas * C57BL/6)	abnormal response to infection	J:119344
	arrested T cell differentiation	J:3206
	colitis	J:15221
	decreased CD4-positive, alpha-beta T cell number	J:3206
	decreased CD8-positive, alpha-beta T cell number	J:3206
	decreased IgG level	J:119344
	increased gamma-delta intraepithelial T cell number	J:15221
Tcra^tm1Mom/Tcra^tm1Mom Tcra-J^tm1Kgwa/Tcra-J^tm1Kgwa (involves: 129P2/OlaHsd * 129S2/SvPas * C3H/HeJ * C57BL/6J)	increased double-negative T cell number	J:50143
Tcra^tm1Mom/Tcra^tm1Mom Tcrb^tm1Mom/Tcrb^tm1Mom (involves: 129 * BALB/c * C57BL/6)	arrested T cell differentiation	J:3206
	decreased double-positive T cell number	J:3206
	thymus hypoplasia	J:3206
Tcra^tm1Mom/Tcra^tm1Mom Tcrg^tm1.1Hish/Tcrg^tm1.1Hish (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)	absent gamma-delta T cells	J:135597
	colitis	J:135597
	impaired macrophage chemotaxis	J:135597
	impaired neutrophil recruitment	J:135597
Tcra^tm1Mom/Tcra^tm1Mom Tg(CD19-Tnfsf7)#Rvl/0 (involves: 129P2/OlaHsd * C57BL/6)	absent T cells	J:88620
Tcra^tm1Mom/Tcra^tm1Mom Tg(Lck-Akt1E40K)E-3Pnt/0 (involves: 129S2/SvPas C3H/He * C57BL/6)	arrested T cell differentiation	J:135903
Tcra^tm1Mom/Tcra^tm1Mom Tg(TcraAV19AJ33)1Shima/? (involves: 129S2/SvPas * C57BL/6)	abnormal NK T cell morphology	J:140924
	abnormal NK T cell physiology	J:140924
Tcra^tm1Mom/Tcra^tm1Mom Trex1^tm1Tld/Trex1^tm1Tld (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)	colitis	J:181257
	immune system phenotype	J:181257
	increased inflammatory response	J:181257
	myositis	J:181257
	skin inflammation	J:181257
Tcra^tm1Slek/Tcra^tm1Slek (Not Specified)	immune system phenotype	J:101719
Tcrb^Ln3Jae/Tcrb⁺ (B6.Cg-Tcrb^Ln3Jae)	abnormal double-negative T cell morphology	J:143006
Tcrb^Ln3Jae/Tcrb⁺ (B6.Cg-Tcrb^Ln3Jae)	absent gamma-delta T cells	J:143006
Tcrb^tm1(Tcrb)Chb/Tcrb^tm1(Tcrb)Chb (Not Specified)	abnormal double-negative T cell morphology	J:147947
	abnormal T cell morphology	J:147947
	decreased CD8-positive, alpha-beta T cell number	J:147947
	increased single-positive T cell number	J:147947
Tcrb^tm1(Tcrb)Chb/Tcrb^tm1Slek (Not Specified)	abnormal double-negative T cell morphology	J:147947
	abnormal T cell morphology	J:147947
	abnormal T cell receptor beta chain V(D)J recombination	J:147947
	decreased CD8-positive, alpha-beta T cell number	J:147947
	increased single-positive T cell number	J:147947
Tcrb^tm1(Tcrb)Fwa/Tcrb^tm1(Tcrb)Fwa (involves: 129)	abnormal T cell receptor beta chain V(D)J recombination	J:131995
Tcrb^tm1Mom/Tcrb⁺ Tg(SOD1G93A)1Gur/0 (B6.Cg-Tcrb^tm1Mom Tg(SOD1G93A)1Gur/J)	abnormal microglial cell physiology	J:143173
Tcrb^tm1Mom/Tcrb^tm1Mom (involves: 129P2/OlaHsd * BALB/c)	arrested T cell differentiation	J:3206
	colitis	J:15221
	decreased CD4-positive, alpha-beta T cell number	J:3206
	decreased CD8-positive, alpha-beta T cell number	J:3206
	decreased double-positive T cell number	J:3206
	thymus hypoplasia	J:3206
Tcrb^tm1Mom/Tcrb^tm1Mom Tcrd^tm1Mom/Tcrd^tm1Mom (FVB.129P2-Tcrb^tm1Mom Tcrd^tm1Mom)	immune system phenotype	J:75915
Tcrb^tm1Mom/Tcrb^tm1Mom Tcrd^tm1Mom/Tcrd^tm1Mom (involves: 129P2/OlaHsd * C57BL/6)	abnormal response to infection	J:119344
	decreased IgG level	J:119344
	immune system phenotype	J:126867
Tcrb^tm1Mom/Tcrb^tm1Mom Tcrd^tm1Mom/Tcrd^tm1Mom (B6.129P2-Tcrb^tm1Mom Tcrd^tm1Mom/J)	abnormal transitional stage B cell morphology	J:187766
	decreased autoantibody level	J:187766
	decreased IgE level	J:125656
	decreased IgG1 level	J:125656
	decreased IgG level	J:125656, J:187766
	decreased plasma cell number	J:187766
	decreased T cell number	J:187766
	increased B cell number	J:187766
	increased follicular B cell number	J:187766
	increased IgM level	J:187766
	increased immature B cell number	J:187766
	increased marginal zone B cell number	J:187766
	increased mature B cell number	J:187766
	increased transitional stage T2 B cell number	J:187766
	increased transitional stage T3 B cell number	J:187766
Tcrb^tm1Mom/Tcrb^tm1Mom Tcrd^tm1Mom/Tcrd^tm1Mom (involves: 129 * BALB/c * C57BL/6)	absent CD4-positive, alpha-beta T cells	J:3206
	absent CD8-positive, alpha-beta T cells	J:3206
	arrested T cell differentiation	J:3206
	colitis	J:15221
	decreased double-positive T cell number	J:3206
	thymus hypoplasia	J:3206
Tcrb^tm1Mom/Tcrb^tm1Mom Tcrd^tm1Mom/Tcrd^tm1Mom (involves: 129P2/OlaHsd)	decreased IgA level	J:97824
	decreased lymphocyte cell number	J:97824
	immune system phenotype	J:97824
	increased T cell number	J:97824
Tcrb^tm1Mom/Tcrb^tm1Mom Tcrd^tm1Mom/Tcrd^tm1Mom Igh-J^{tm2(3H9-VDJ)Mwg}/Igh-J⁺ (B6.129P2-Tcrb^tm1Mom Igh-J^{tm2(3H9-VDJ)Mwg} Tcrd^tm1Mom)	increased anti-double stranded DNA antibody level	J:142389
	increased marginal zone B cell number	J:142389
	spleen hypoplasia	J:142389
Tcrb^tm1Mom/Tcrb^tm1Mom Tcrd^tm1Mom/Tcrd^tm1Mom Traf3ip2^tm1.1Lix/Traf3ip2^tm1.1Lix (B6.129-Tcrb^tm1Mom Traf3ip2^tm1.1Lix Tcrd^tm1Mom)	abnormal transitional stage B cell morphology	J:187766
	decreased IgG level	J:187766
	decreased T cell number	J:187766
	immune system phenotype	J:187766
	increased anti-chromatin antibody level	J:187766
	increased anti-double stranded DNA antibody level	J:187766
	increased anti-histone antibody level	J:187766
	increased autoantibody level	J:187766
	increased IgM level	J:187766
	increased immature B cell number	J:187766
	increased marginal zone B cell number	J:187766
Tcrb^tm1Mom/Tcrb^tm1Mom Tg(H2-K-Cd86)7All/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA)	abnormal B cell differentiation	J:112475
	abnormal B cell morphology	J:112475
	decreased B cell number	J:112475
Tcrb^tm1Mom/Tcrb^tm1Mom Tg(KRT5-rtTA)1Glk/0 Tg(tetO/CMV-Tslp)#Sfz/0 (involves: 129P2/OlaHsd * C3H * C57BL/6 * FVB/N)	decreased IgE level	J:100506
	skin inflammation	J:100506
Tcrb^tm1Slek/Tcrb^tm1Slek (Not Specified)	immune system phenotype	J:119552
Tcrb^tm1Slek/Tcrb^tm5Slek (Not Specified)	abnormal T cell receptor beta chain V(D)J recombination	J:143738
Tcrb^tm1Slek/Tcrb^tm6Slek (Not Specified)	abnormal T cell receptor beta chain V(D)J recombination	J:143738
Tcrb^tm2(Tcrb)Fwa/Tcrb^tm3Slek (involves: 129)	abnormal T cell receptor beta chain V(D)J recombination	J:132446
Tcrb^tm2Slek/Tcrb^tm2Slek (Not Specified)	arrested T cell differentiation	J:119552
Tcrb^tm2Slek/Tcrb^tm2Slek (Not Specified)	decreased T cell number	J:119552
Tcrb^tm2Slek/Tcrb^tm2Slek Trbv13-2^tm1(CD2)Zhu/Trbv13-2^tm1(CD2)Zhu (involves: 129 * C57BL/6)	abnormal T cell differentiation	J:121608
Tcrb^tm3.1Che/Tcrb^tm3.1Che (involves: 129S4/SvJae)	immune system phenotype	J:120387
Tcrb^tm3Che/Tcrb^tm3Che (involves: 129S4/SvJae)	immune system phenotype	J:120387
Tcrb^tm3Slek/Tcrb^tm3Slek (Not Specified)	arrested T cell differentiation	J:119552
Tcrb^tm3Slek/Tcrb^tm3Slek (Not Specified)	decreased T cell number	J:119552
Tcrb^tm4Slek/Tcrb^tm4Slek (Not Specified)	immune system phenotype	J:119552
Tcrb^tm5Slek/Tcrb^tm5Slek (Not Specified)	abnormal T cell receptor beta chain V(D)J recombination	J:143738
Tcrb^tm6Slek/Tcrb^tm6Slek (Not Specified)	abnormal T cell receptor beta chain V(D)J recombination	J:143738
Tcrb^tm7Slek/Tcrb^tm7Slek (Not Specified)	abnormal T cell receptor beta chain V(D)J recombination	J:143738
Tcrb^tm8.1Slek/Tcrb^tm8.1Slek (Not Specified)	immune system phenotype	J:176070
Tcrb^tm9.1Slek/Tcrb^tm9.1Slek (Not Specified)	immune system phenotype	J:176070
Tcrd-V1^tm1Kjk/Tcrd-V1^tm1Kjk (involves: 129P2/OlaHsd * C57BL/6)	abnormal gamma-delta T cell differentiation	J:64863
	abnormal mature gamma-delta T cell morphology	J:64863
	abnormal T cell receptor delta chain V(D)J recombination	J:64863
	decreased gamma-delta intraepithelial T cell number	J:64863
Tcrd-V1^tm1Kjk/Tcrd-V1^tm1Kjk (B6.129P2-Tcrd-V1^tm1Kjk)	abnormal T cell receptor delta chain V(D)J recombination	J:128525
Tcrd-V1^tm1Kjk/Tcrd-V1^tm1Kjk (B6.129P2-Tcrd-V1^tm1Kjk)	decreased gamma-delta intraepithelial T cell number	J:128525
Tcrd^tm1Mom/Tcrd^tm1Mom (FVB.129P2-Tcrd^tm1Mom)	dermatitis	J:75915
Tcrd^tm1Mom/Tcrd^tm1Mom (FVB.129P2-Tcrd^tm1Mom)	increased susceptibility to type IV hypersensitivity reaction	J:75915
Tcrd^tm1Mom/Tcrd^tm1Mom (NOD.129P2-Tcrd^tm1Mom)	dermatitis	J:75915
Tcrd^tm1Mom/Tcrd^tm1Mom (B6.129P2-Tcrd^tm1Mom)	immune system phenotype	J:75915
Tcrd^tm1Mom/Tcrd^tm1Mom (either: (involves: 129P2/OlaHsd * BALB/cJ) or (involves: 129P2/OlaHsd * C57BL/6))	abnormal gamma-delta T cell differentiation	J:3865
	absent gamma-delta T cells	J:3865
Tcrd^tm1Mom/Tcrd^tm1Mom Tcrg^tm2.1Dhr/Tcrg^tm2.1Dhr (involves: 129 * C57BL/6)	abnormal T cell receptor gamma chain V-J recombination	J:75624
Tcrd^tm1Mom/Tcrd^tm1Mom Tnf^tm2Gkl/Tnf⁺ (involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6J)	small intestinal inflammation	J:108572
Tcrg^tm1.1Dhr/Tcrg^tm1.1Dhr (involves: 129)	abnormal T cell receptor gamma chain V-J recombination	J:133974
Tcrg^tm1.1Hish/Tcrg^tm1.1Hish (involves: 129P2/OlaHsd * C57BL/6)	absent gamma-delta T cells	J:135597
Tcrg^tm1Dhr/Tcrg^tm1Dhr (involves: 129)	abnormal T cell receptor gamma chain V-J recombination	J:133974
Tcrg^tm1Iku/Tcrg^tm1Iku (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:39791
Tcrg^tm1Scar/Tcrg^tm1Scar (B6.Cg-Tcrg^tm1Scar)	abnormal immune system organ morphology	J:105477
	enlarged spleen	J:105477
	enlarged thymus	J:105477
	impaired granulocyte bactericidal activity	J:105477
	increased macrophage cell number	J:105477
	increased T cell number	J:105477
	spleen hyperplasia	J:105477
	thymus hyperplasia	J:105477
Tcrg^tm2.1Dhr/Tcrg^tm2.1Dhr (involves: 129S4/SvJae * C57BL/6)	abnormal gamma-delta T cell differentiation	J:75624
	abnormal T cell receptor gamma chain V-J recombination	J:75624
Tdp1^em1(IMPC)Tcp/Tdp1^em1(IMPC)Tcp (C57BL/6NCrl-Tdp1^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Tdp2^tm1.1Huy/Tdp2^tm1.1Huy (involves: 129P2/OlaHsd * CD-1)	abnormal immature B cell morphology	J:195301
	abnormal immune system organ morphology	J:195301
	abnormal lymphopoiesis	J:195301
	decreased double-positive T cell number	J:195301
	spleen atrophy	J:195301
	thymus atrophy	J:195301
Tdrd3^{Gt(RRK474)Byg}/Tdrd3^{Gt(RRK474)Byg} (involves: 129P2/OlaHsd)	abnormal B cell differentiation	J:210647
	abnormal B cell physiology	J:210647
Tdrd7^nmf166/Tdrd7^nmf166 (involves: C3H * C57BL/6J)	uveitis	J:169836
Tec^tm1Welm/Tec^tm1Welm (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:66080
Tecpr1^tm1Chsa/Tecpr1^tm1Chsa (involves: 129S4/SvJae)	abnormal susceptibility to infection	J:198333
Tedc1^em1(IMPC)Tcp/Tedc1⁺ (C57BL/6NCrl-Tedc1^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Teddm1a^em1(IMPC)Tcp/Teddm1a^em1(IMPC)Tcp (C57BL/6N-Teddm1a^em1(IMPC)Tcp/Tcp)	decreased leukocyte cell number	J:211773
Tekt1^{em1(IMPC)Ccpcz}/Tekt1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Tekt1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
	small lymph nodes	J:211773
Ten1^{em1(IMPC)Hmgu}/Ten1^{em1(IMPC)Hmgu} (involves: C57BL/6NCrl)	abnormal cytokine secretion	J:365069
	abnormal thymus medulla morphology	J:365069
	bone marrow failure	J:365069
	increased inflammatory response	J:365069
	thymus atrophy	J:365069
	thymus cortex hypoplasia	J:365069
Tenm4^em1(IMPC)Tcp/Tenm4^em1(IMPC)Tcp (C57BL/6NCrl-Tenm4^em1(IMPC)Tcp/Tcp)	decreased spleen weight	J:211773
Tent2^{em1(IMPC)Ccpcz}/Tent2⁺ (C57BL/6NCrl-Tent2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Tent2^{em1(IMPC)Ccpcz}/Tent2^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Tent2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
Tent5a^{em1(IMPC)Ccpcz}/Tent5a^{em1(IMPC)Ccpcz} (C57BL/6N-Tent5a^{em1(IMPC)Ccpcz}/Ccpcz)	decreased Ly6C-positive mature NK cell number	J:211773
	decreased lymphocyte cell number	J:211773
	increased granulocyte number	J:211773
	increased leukocyte cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Tent5c^em1Adki/Tent5c^em1Adki (involves: C57BL/6JTar * CBA/WTar)	decreased B cell proliferation	J:252302
Tent5c^{tm1b(KOMP)Wtsi}/Tent5c^{tm1b(KOMP)Wtsi} (C57BL/6N-Tent5c^{tm1b(KOMP)Wtsi}/Wtsi)	absent connection between subcutaneous lymph vessels and lymph sac	J:239583
	blood in lymph vessels	J:239583
Terb1^{tm1b(KOMP)Mbp}/Terb1⁺ (C57BL/6N-Terb1^{tm1b(KOMP)Mbp}/Ucd)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Terc^tm1Rdp/Terc^tm1Rdp (involves: 129/Sv * C57BL/6J * SJL)	decreased B cell proliferation	J:60223
	decreased spleen B cell follicle number	J:60223
	decreased spleen germinal center number	J:60223
	decreased T cell proliferation	J:60223
	increased B cell apoptosis	J:60223
Terf1^tm1.1Blas/Terf1^tm1.1Blas Tg(KRT5-cre)1Tak/0 (involves: 129 * C3H * C57BL/6 * SJL)	skin inflammation	J:152077
Terf2ip^Gt(XD108)Byg/Terf2ip⁺ (involves: 129P2/OlaHsd * C57BL/6)	decreased susceptibility to bacterial infection induced morbidity/mortality	J:163158
	decreased susceptibility to endotoxin shock	J:163158
Tert^tm2.1Rdp/Tert^tm2.1Rdp (involves: C57BL/6)	decreased spleen weight	J:167227
Tert^tm2.1Rdp/Tert^tm2.1Rdp (involves: C57BL/6)	spleen atrophy	J:167227
Tespa1^tm1Smoc/Tespa1^tm1Smoc (B6.129-Tespa1^tmSmoc)	abnormal T cell differentiation	J:186446
	abnormal thymus morphology	J:186446
	decreased CD4-positive, alpha-beta T cell number	J:186446
	decreased CD8-positive, alpha-beta T cell number	J:186446
	decreased interferon-gamma secretion	J:186446
	decreased interleukin-2 secretion	J:186446
	decreased regulatory T cell number	J:186446
	decreased T cell number	J:186446
	decreased T cell proliferation	J:186446
	increased memory T cell number	J:186446
	increased T cell proliferation	J:186446
	small thymus medulla	J:186446
Tespa1^tm1Smoc/Tespa1^tm1Smoc Tg(TcraH-Y,TcrbH-Y)71Vbo/0 (involves: 129 * C57BL/6 * DBA/2J)	decreased CD8-positive, alpha-beta T cell number	J:186446
Tespa1^tm1Smoc/Tespa1^tm1Smoc Tg(TcraTcrb)425Cbn/0 (B6.Cg-Tespa1^tm1Smoc Tg(TcraTcrb)425Cbn)	abnormal T cell differentiation	J:186446
	decreased CD4-positive, alpha-beta T cell number	J:186446
	decreased CD8-positive, alpha-beta T cell number	J:186446
Tespa1^tm1Smoc/Tespa1^tm1Smoc Tg(TcraTcrb)1100Mjb/0 (B6.Cg-Tespa1^tm1Smoc Tg(TcraTcrb)1100Mjb)	abnormal T cell differentiation	J:186446
	decreased CD4-positive, alpha-beta T cell number	J:186446
	decreased CD8-positive, alpha-beta T cell number	J:186446
Tet1^tm1.1Gxu/Tet1^tm1.1Gxu (involves: 129 * 129P2/OlaHsd * C57BL/6J)	decreased spleen iron level	J:315675
Tet1^tm1.1Jae/Tet1^tm1.1Jae (involves: 129S4/SvJae * C57BL/6)	decreased neutrophil cell number	J:175858
Tet1^tm1.2Jae/Tet1^tm1.2Jae Tet2^tm1.1Iaai/Tet2⁺ Tet3^tm1.1Yzhg/Tet3^tm1.1Yzhg Tg(Rorc-cre)1Litt/0 (involves: 129 * 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB)	decreased effector memory T-helper cell number	J:333574
	immune system phenotype	J:333574
Tet1^tm1.2Jae/Tet1^tm1.2Jae Tet2^tm1.1Iaai/Tet2^tm1.1Iaai Tet3^tm1.1Yzhg/Tet3^tm1.1Yzhg Tg(Rorc-cre)1Litt/0 (involves: 129 * 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB)	enlarged lymph nodes	J:333574
	enlarged spleen	J:333574
	increased susceptibility to autoimmune disorder	J:333574
Tet2^{Gt(AN0709)Wtsi}/Tet2⁺ (B6.129P2-Tet2^{Gt(AN0709)Wtsi})	abnormal monocyte differentiation	J:174052
	abnormal spleen morphology	J:174052
	enlarged spleen	J:174052
	increased B cell number	J:174052
	increased leukocyte cell number	J:174052
	increased monocyte cell number	J:174052
	liver inflammation	J:174052
Tet2^{Gt(AN0709)Wtsi}/Tet2^{Gt(AN0709)Wtsi} (B6.129P2-Tet2^{Gt(AN0709)Wtsi})	abnormal monocyte differentiation	J:174052
	abnormal spleen morphology	J:174052
	decreased pre-B cell number	J:174052
	decreased pro-B cell number	J:174052
	enlarged spleen	J:174052
	increased B cell number	J:174052
	increased DN1 thymic pro-T cell number	J:174052
	increased double-negative T cell number	J:174052
	increased leukocyte cell number	J:174052
	increased monocyte cell number	J:174052
	liver inflammation	J:174052
Tet2^tm1.1Iaai/Tet2⁺ Tg(VAV1-cre)1Graf/0 (involves: 129S/SvEv * C57BL/6)	increased leukocyte cell number	J:174053
	increased monocyte cell number	J:174053
Tet2^tm1.1Iaai/Tet2^tm1.1Iaai Tg(Mx1-cre)1Cgn/0 (involves: 129S/SvEv * C57BL/6 * CBA)	abnormal myelopoiesis	J:234976
	decreased B cell number	J:234976
	enlarged spleen	J:234976
	increased granulocyte number	J:234976
Tet2^tm1.1Iaai/Tet2^tm1.1Iaai Tg(VAV1-cre)1Graf/0 (involves: 129S/SvEv * C57BL/6)	abnormal myeloid leukocyte morphology	J:174053
	enlarged spleen	J:174053
	increased leukocyte cell number	J:174053
	increased monocyte cell number	J:174053
	increased spleen weight	J:174053
	myeloid hyperplasia	J:174053
Tet2^tm1.1Mjxu/Tet2⁺ (involves: 129 * C57BL/6)	enlarged spleen	J:178415
	increased leukocyte cell number	J:178415
	increased monocyte cell number	J:178415
	myeloid hyperplasia	J:178415
Tet2^tm1.1Mjxu/Tet2^tm1.1Mjxu (involves: 129 * C57BL/6)	enlarged spleen	J:178415
	increased leukocyte cell number	J:178415
	increased monocyte cell number	J:178415
	increased neutrophil cell number	J:178415
	myeloid hyperplasia	J:178415
Tet2^tm1.2Rao/Tet2^tm1.2Rao (involves: C57BL/6NTac)	abnormal myelopoiesis	J:175222
Tet2^tm1.2Rao/Tet2^tm1.2Rao (involves: C57BL/6NTac)	increased splenocyte number	J:175222
Tet2^tm1Ics/Tet2^tm1Ics Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA)	abnormal spleen morphology	J:174052
	decreased pre-B cell number	J:174052
	decreased pro-B cell number	J:174052
	enlarged spleen	J:174052
	increased B cell number	J:174052
	increased DN1 thymic pro-T cell number	J:174052
	increased double-negative T cell number	J:174052
	increased leukocyte cell number	J:174052
	increased monocyte cell number	J:174052
	increased spleen red pulp amount	J:174052
Tex2^{tm1.1(KOMP)Vlcg}/Tex2⁺ (C57BL/6N-Tex2^{tm1.1(KOMP)Vlcg}/J)	decreased leukocyte cell number	J:211773
Tex29^{tm1.1(KOMP)Vlcg}/Tex29^{tm1.1(KOMP)Vlcg} (C57BL/6N-Tex29^{tm1.1(KOMP)Vlcg}/J)	decreased leukocyte cell number	J:211773
Tex261^{tm1b(EUCOMM)Wtsi}/Tex261^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Tex261^{tm1b(EUCOMM)Wtsi}/Wtsi)	increased leukocyte cell number	J:211773
Tfap4^tm1.1Litt/Tfap4^tm1.1Litt (involves: 129P2/OlaHsd * C57BL/6 * FVB/N)	abnormal T cell differentiation	J:176461
	immune system phenotype	J:176461
Tfeb^em1Xinli/Tfeb^em1Xinli (involves: C57BL/6J)	increased susceptibility to bacterial infection induced morbidity/mortality	J:342735
Tff2^tm1Blin/Tff2^tm1Blin (involves: 129S7/SvEvBrd * C57BL/6)	abnormal adaptive immunity	J:105277
	abnormal innate immunity	J:105277
Tff3^tm1Dkpy/Tff3^tm1Dkpy (involves: 129S4/SvJae)	increased susceptibility to induced colitis	J:35882
Tfpi2^tm1Dgen/Tfpi2^tm1Dgen (involves: 129P2/OlaHsd * C57BL/6J)	immune system phenotype	J:301794
	increased circulating interleukin-6 level	J:301794
	increased circulating interleukin-10 level	J:301794
	increased interleukin-10 secretion	J:301794
	increased susceptibility to bacterial infection	J:301794
	increased susceptibility to bacterial infection induced morbidity/mortality	J:301794
Tfpi^tm1Gjb/Tfpi^tm1Gjb (involves: 129)	abnormal acute phase protein level	J:51137
Tfr2^tm1.1Anro/Tfr2^tm1.1Anro (129.Cg-Tfr2^tm1.1Anro)	increased spleen iron level	J:160785
Tfr2^tm1.1Nsub/Tfr2^tm1.1Nsub (involves: 129T2/SvEms * C57BL/6)	decreased spleen iron level	J:114330
Tfr2^tm1.1Nsub/Tfr2^tm1.1Nsub (involves: 129T2/SvEms)	increased spleen iron level	J:160785
Tfr2^tm1Slu/Tfr2^tm1Slu (involves: 129X1/SvJ * C57BL/6J)	decreased spleen iron level	J:78360
Tfrc^tm1Nca/Tfrc⁺ (either: (involves: 129S4/SvJae * 129S6/SvEvTac) or (involves: 129S4/SvJae * C57BL/6))	decreased spleen iron level	J:54107
Tg(Ace2-ACE2)1Cqin/0 (involves: ICR)	alveolitis	J:141460
	increased susceptibility to Coronaviridae infection	J:141460, J:287631, J:288244
	interstitial pneumonia	J:141460, J:287631
	lymph node hemorrhage	J:141460
	lymph node necrosis	J:287631
	pyelitis	J:141460
	submandibular gland inflammation	J:141460
Tg(Acp5-Adam8)#Rood/0 (involves: BALB/c * C57BL/6)	abnormal osteoclast differentiation	J:172936
	abnormal osteoclast morphology	J:172936
	increased osteoclast cell number	J:172936
Tg(Acp5-Selenow)#Djeo/0 (involves: FVB/N)	abnormal osteoclast differentiation	J:317012
Tg(Acp5-Selenow)#Djeo/0 (involves: FVB/N)	increased osteoclast cell number	J:317012
Tg(ACTA1-Il15)10941Lsq/0 (involves: C3H * C57BL/6)	abnormal interleukin level	J:145611
Tg(ACTA1-Il15)11650Lsq/0 (involves: C3H C57BL/6)	abnormal interleukin level	J:145611
Tg(ACTA1-Il15)11650Lsq/0 (involves: C3H C57BL/6)	increased circulating interleukin-15 level	J:145611
Tg(Acta2-cre/ERT2)#Pcn/0 Tgfbr2^tm1Karl/Tgfbr2^tm1Karl Tg(H2-K-Fosl2,-EGFP)13Wag/0 (B6.Cg-Tgfbr2^tm1Karl Tg(Acta2-cre/ERT2)#Pcn Tg(H2-K-Fosl2,-EGFP)13Wag)	lung inflammation	J:238723
Tg(Acta2-RAC1G12V)33Pjgc/Tg(Acta2-RAC1G12V)33Pjgc (involves: C57BL/6 * FVB/N)	abnormal chemokine secretion	J:150015
	increased interleukin-6 secretion	J:150015
	increased tumor necrosis factor secretion	J:150015
Tg(ACTB-eGFP,-RAMP1)#Afru/0 Tg(Nes-cre)1Kln/0 (involves: C57BL/6J * SJL/J)	increased inflammatory response	J:120077
Tg(ACTB-Eif4e)#Ppp/0 Tg(IghMyc)22Bri/0 (involves: C57BL * SJL)	decreased B cell apoptosis	J:89878
Tg(ACTB-Fpr2)#Jimw/0 (involves: FVB)	abnormal dendritic cell physiology	J:160074
Tg(ACTB-Fpr2)#Jimw/0 (involves: FVB)	respiratory system inflammation	J:160074
Tg(ACTB-Mgat3)2Nta/0 (involves: C57BL/6 * DBA/2)	decreased leukocyte cell number	J:80227
	decreased lymphocyte cell number	J:80227
	decreased neutrophil cell number	J:80227
	decreased spleen B cell follicle number	J:80227
	spleen atrophy	J:80227
Tg(ACTB-TNFRSF6B)754Jwu/? (B6.Cg-Tg(Actb-TNFRSF6B)754Jwu)	abnormal CD4-positive, alpha beta T cell morphology	J:148162
	abnormal type IV hypersensitivity reaction	J:148162
	decreased leukocyte cell number	J:148162
	enlarged lymph nodes	J:148162
	enlarged spleen	J:148162
	increased anti-double stranded DNA antibody level	J:148162
	increased autoantibody level	J:148162
	increased B-1a cell number	J:148162
	increased IgE level	J:148162
	increased IgG1 level	J:148162
	increased IgG2b level	J:148162
	increased interleukin-4 secretion	J:148162
Tg(Actb-Tnfsf4)1Nish/0 (B6.D2-Tg(Actb-Tnfsf4)1Nish)	abnormal cytokine secretion	J:80214
	increased susceptibility to type IV hypersensitivity reaction	J:80214
	increased T cell proliferation	J:80214
Tg(Adipoq-Apol6)#Hsul/0 (C57BL/6J-Tg(Adipoq-Apol6)#Hsul)	white adipose tissue inflammation	J:344362
Tg(Adipoq-cre)1Evdr/0 Tg(CAG-Jmjd8)#Kaso/0 (involves: C57BL/6 * FVB/NJ)	white adipose tissue inflammation	J:319518
Tg(AGER)#Eca/0 (C57BL/6J-Tg(AGER)#Eca)	lung inflammation	J:205092
Tg(AGT)2-5Afu/0 (involves: C57BL/6)	heart inflammation	J:194606
Tg(Alb1-GP33/H2-K^b)1Hpi/0 (B6.Cg-Tg(Alb1-GP33/H2-K^b)1Hpi)	abnormal cytotoxic T cell physiology	J:162605
Tg(Alb1-GP33/H2-K^b)1Hpi/0 (B6.Cg-Tg(Alb1-GP33/H2-K^b)1Hpi)	decreased cytotoxic T cell cytolysis	J:162605
Tg(Alb1-GP33/H2-K^b)1Hpi/0 Tg(Alb1-HBV)66Bri/0 (involves: C57BL/6 * C57BL/10 * DBA/2)	liver inflammation	J:162605
Tg(Alb1-GP33/H2-K^b)1Hpi/0 Tg(Alb1-HBV)66Bri/0 Tg(TcrLCMV)318Sdz/0 (involves: C57BL/6 * C57BL/10 * DBA/2)	liver inflammation	J:162605
Tg(Alb1-GP33/H2-K^b)1Hpi/0 Tg(TcrLCMV)318Sdz/0 (involves: C57BL/6 * DBA/2)	decreased CD8-positive, alpha-beta T cell number	J:162605
Tg(Alb1-Myc)#Sst/0 Tg(MtTGFA)Lmb/0 (involves: C57BL/6 * CBA * CD-1)	decreased NK cell number	J:176432
	increased NK T cell number	J:176432
Tg(Alb1-Ren)1Unc/0 (involves: 129S6/SvEvTac * C57BL/6)	kidney inflammation	J:89252
Tg(Alb1-Ren)2Unc/0 (involves: 129S6/SvEvTac * C57BL/6)	kidney inflammation	J:89252
Tg(Alb1HBV)44Bri/0 (C57BL/6J-Tg(Alb1HBV)44Bri/J)	liver inflammation	J:223921
Tg(Alb-PDGFC)#Jcam/0 (involves: C57BL/6)	chronic liver inflammation	J:211984
	enlarged spleen	J:211984
	increased circulating interleukin-6 level	J:211984
Tg(Alb-PLG)1Dgi/0 (involves: C57BL/6 * C57BL/6J * SJL)	increased susceptibility to bacterial infection	J:120780
Tg(Alb-SND1)3aDsar/0 (involves: C57BL/6 * CBA)	chronic liver inflammation	J:242582
Tg(Alb-TAg)#Arnd/0 ((C3Fe.Cg-Tg(Alb-TAg)#Arnd x C57BL/6N)F1)	abnormal immune system physiology	J:171880
Tg(Amy1TAg)501Knw/0 (involves: C57BL/6)	abnormal CD8-positive, alpha-beta T cell physiology	J:84288
Tg(ANPEP)270Mmul/Tg(ANPEP)270Mmul (involves: ICR)	immune system phenotype	J:99728
Tg(ANPEP)861Mmul/Tg(ANPEP)861Mmul (involves: ICR)	immune system phenotype	J:99728
Tg(ANX6)2Agh/0 (FVB/N-Tg(ANX6)2Agh)	myocarditis	J:92579
Tg(ANX6)2Agh/0 (FVB/N-Tg(ANX6)2Agh)	thymus cortex hypoplasia	J:92579
Tg(aP2-SREBF1c)9884Reh/0 (involves: C57BL/6J * SJL)	abnormal abdominal lymph node morphology	J:50770
	decreased interleukin-6 secretion	J:249664
	decreased tumor necrosis factor secretion	J:249664
	enlarged spleen	J:50770
	liver inflammation	J:249664
Tg(APCS-Ifng)5Imeg/0 (involves: C57BL/6 * DBA/2)	abnormal cytokine level	J:135124
	chronic liver inflammation	J:135124
	increased circulating interleukin-12 level	J:135124
	liver inflammation	J:16979
	myocarditis	J:135124
	pancreas inflammation	J:135124
Tg(APCS-Tnfsf11)#aKhs/0 (C57BL/6J-Tg(APCS-Tnfsf11)#aKhs)	abnormal osteoclast morphology	J:264357
	enlarged thymus medulla	J:264357
	increased osteoclast cell number	J:264357
Tg(APOA1)1Rub/Tg(APOA1)1Rub (C57BL/6-Tg(APOA1)1Rub/J)	abnormal circulating interleukin-17 level	J:190966
Tg(APOA1)1Rub/Tg(APOA1)1Rub (C57BL/6-Tg(APOA1)1Rub/J)	abnormal spleen weight	J:190966
Tg(APOC1)1Lmh/Tg(APOC1)1Lmh (C57BL/6-Tg(APOC1)1Lmh)	dermatitis	J:65036
	enlarged spleen	J:65036
	folliculitis	J:65036
Tg(APOC1)1Lmh/Tg(APOC1)1Lmh (involves: C57BL/6)	dermatitis	J:135501
	increased IgE level	J:135501
	increased mast cell degranulation	J:135501
	skin inflammation	J:135501
Tg(APOE-DGAT1)1Far/0 (involves: C57BL/6NHsd)	liver inflammation	J:124005
Tg(APOE-DGAT2)1Far/0 (involves: C57BL/6NHsd)	liver inflammation	J:124005
Tg(APOE-FGF23R176Q)#Ack/0 (involves: C57BL/6J CBA)	decreased osteoclast cell number	J:93981
Tg(APOE-FGF23R176Q)#Ack/0 (involves: C57BL/6J CBA)	enthesitis	J:192371
Tg(APP695)3Dbo/0 Tg(PSEN1dE9)S9Dbo/0 (Not Specified)	abnormal microglial cell morphology	J:139070
Tg(APPSWE)2576Kha/0 (involves: C57BL/6 * SJL)	microgliosis	J:159623
Tg(APPswe,PSEN1dE9)85Dbo/0 (D2.Cg-Tg(APPswe,PSEN1dE9)85Dbo)	microgliosis	J:227541
Tg(APPSwFlLon,PSEN1M146LL286V)6799Vas/0 (involves: C57BL/6 * SJL)	brain inflammation	J:112949
Tg(APPSwFlLon,PSEN1M146LL286V)6799Vas/? (involves: C57BL/6 * SJL)	increased microglial cell activation	J:208030
Tg(ARR2/Pbsn-FGF8)3Prb/0 (involves: C57BL/6 * DBA/2)	increased inflammatory response	J:78918
Tg(ARR2/Pbsn-FGF8)3Prb/0 (involves: C57BL/6 * DBA/2)	prostate gland inflammation	J:78918
Tg(B2M)55Hpl/? Tg(CD8aCD8b)57Scr/? Tg(HLA-B)22Hpl/? (involves: C57BL/6 * C57BL/LiA * CBA)	abnormal cytotoxic T cell physiology	J:127813
Tg(B2M,HLA-B27:05)56-3Trg/0 (involves: C57BL/6 SJL/J)	immune system phenotype	J:74451
Tg(B19-RNAi:Il3)241Ckn/? (involves: BALB/cJ * C57BL/6J * FVB/N)	abnormal B cell differentiation	J:107618
	decreased interleukin-3 secretion	J:107618
	enlarged lymph nodes	J:107618
	enlarged spleen	J:107618
	increased pre-B cell number	J:107618
Tg(BCL2)22Wehi/0 (involves: C57BL/6JWehi * SJL/JWehi)	abnormal B cell differentiation	J:93111
	abnormal B cell physiology	J:93111
	increased B cell number	J:93111
	increased susceptibility to autoimmune disorder	J:93111
Tg(BCL2)22Wehi/0 (involves: C57BL/6J * C57BL/6JWehi)	increased B cell number	J:88565
Tg(BCL2)22Wehi/0 Tg(IghMyc)22Bri/0 (involves: C57BL/6 * C57BL/6JWehi * SJL/J * SJL/JWehi)	abnormal B cell morphology	J:69571
	abnormal pre-B cell morphology	J:69571
	enlarged lymph nodes	J:69571
	enlarged spleen	J:69571
	enlarged thymus	J:69571
	increased B cell number	J:69571
	increased leukocyte cell number	J:69571
	increased pre-B cell number	J:69571
Tg(BCL2)25Wehi/0 (involves: C57BL/6JWehi * SJL/JWehi)	abnormal B cell differentiation	J:131912
	abnormal plasma cell differentiation	J:131912
	abnormal T cell physiology	J:93111
	increased T cell number	J:93111
Tg(BCL2)36Wehi/0 (involves: C57BL/6JWehi * SJL/JWehi)	abnormal B cell physiology	J:93111
	abnormal T cell physiology	J:93111
	increased B cell number	J:93111
	increased immunoglobulin level	J:93111
	increased susceptibility to autoimmune disorder	J:93111
	increased T cell derived lymphoma incidence	J:93111
	increased T cell number	J:93111
Tg(BCL2)36Wehi/? (B6.Cg-Tg(BCL2)36Wehi/J)	abnormal B cell proliferation	J:90963
Tg(BCL2)36Wehi/? (B6.Cg-Tg(BCL2)36Wehi/J)	decreased B cell apoptosis	J:90963
Tg(BCL2/IGH)1Tjd/? (involves: C3H/He * C57BL/6)	abnormal B cell physiology	J:81147
	abnormal lymph node morphology	J:81147
	abnormal mononuclear cell differentiation	J:81147
	enlarged lymph nodes	J:81147
	enlarged spleen	J:81147
	increased B cell number	J:81147
	increased spleen white pulp amount	J:81147
	spleen hyperplasia	J:81147
Tg(BCL2/IGH)#Jcre/0 Tg(H2-K/Igh-Traf2)#Ywc/0 (involves: BALB/c C57BL/6 * CBA/J * FVB/N * SJL/J * SWR/J)	abnormal spleen marginal zone morphology	J:94116
	decreased B cell apoptosis	J:94116
	enlarged lymph nodes	J:94116
	enlarged spleen	J:94116
	increased B cell number	J:94116
	increased B-1a cell number	J:94116
	increased B-1b cell number	J:94116
	increased marginal zone B cell number	J:94116
	increased spleen weight	J:94116
Tg(BCL2/IGH)M23Tjd/? (involves: C3H/He * C57BL/6)	abnormal B cell physiology	J:81147
	abnormal lymph node morphology	J:81147
	abnormal mononuclear cell differentiation	J:81147
	enlarged lymph nodes	J:81147
	enlarged spleen	J:81147
	increased B cell number	J:81147
	increased spleen white pulp amount	J:81147
	spleen hyperplasia	J:81147
Tg(BLG-STAT5A)15Itb/0 (involves: FVB/N)	increased inflammatory response	J:80588
Tg(C9orf72)500Lpwr/0 (FVB/NJ-Tg(C9orf72)500Lpwr)	microgliosis	J:239579
Tg(CAG-ACE2)AC63Ctkt/0 (either: (involves: BALB/c * C3H/HeJ * C57BL/6J) or (involves: C3H/HeJ * C57BL/6 * C57BL/6J))	increased susceptibility to Coronaviridae infection	J:117824
Tg(CAG-ACE2)AC70Ctkt/0 (either: (involves: BALB/c * C3H/HeJ * C57BL/6J) or (involves: C3H/HeJ * C57BL/6 * C57BL/6J))	abnormal cytokine level	J:117824
	increased susceptibility to Coronaviridae infection	J:117824
	increased susceptibility to Coronaviridae infection induced morbidity/mortality	J:117824
	interstitial pneumonia	J:117824
Tg(CAG-APP)0304Shoj/0 (involves: C3H * C57BL/6N)	abnormal circulating serum amyloid protein level	J:100977
Tg(CAG-Bgeo,-Hras1,-EGFP)#Ichi/0 Tg(Flt4-cre)44Ichi/0 (involves: 129P2/OlaHsd * C57BL/6J)	lymphatic vessel hyperplasia	J:159024
Tg(CAG-Bgeo,-Hras1,-EGFP)#Ichi/0 Tg(Tek-cre)12Flv/0 (involves: 129P2/OlaHsd * C3H * C57BL/6)	lymphatic vessel hyperplasia	J:159024
Tg(CAG-Btc)2Ewo/0 (FVB/N-Tg(CAG-Btc)2Ewo)	increased spleen weight	J:103364
Tg(CAG-Btc)4Ewo/0 (FVB/N-Tg(CAG-Btc)4Ewo)	increased spleen weight	J:103364
Tg(CAG-C1qtnf6)#Yiw/0 (involves: C57BL/6JJcl)	abnormal complement protein level	J:227217
	decreased IgG level	J:227217
	decreased susceptibility to induced arthritis	J:227217
	impaired complement alternative pathway	J:227217
Tg(CAG-cat,-Il18)#Thos/0 Tg(SFTPC-rtTA)5Jaw/0 Tg(tetO-cre)1Jaw/0 (involves: 129 * C57BL/6)	increased interferon-gamma secretion	J:147547
	interstitial pneumonia	J:147547
Tg(CAG-cre/Esr1)5Amc/0 Tgfbr2^tm1.2Hlm/Tgfbr2^tm1.2Hlm (involves: 129S6/SvEvTac C57BL/6 * CBA)	microgliosis	J:221181
Tg(CAG-DPP4)4Yuzh/0 (C57BL/6-Tg(CAG-DPP4)4Yuzh)	abnormal circulating cytokine level	J:286175
	abnormal spleen morphology	J:286175
	brain inflammation	J:286175
	increased circulating interferon-gamma level	J:286175
	increased circulating interleukin-17 level	J:286175
	increased susceptibility to Coronaviridae infection	J:286175
	increased susceptibility to Coronaviridae infection induced morbidity/mortality	J:286175
	kidney inflammation	J:286175
	liver inflammation	J:286175
	lung inflammation	J:286175
Tg(CAG-DPP4)52Ctkt/0 (involves: C3H/HeJ * C57BL/6J)	abnormal mononuclear cell morphology	J:227925
	brain inflammation	J:227925
	increased inflammatory response	J:227925
	increased microglial cell activation	J:227925
	increased susceptibility to Coronaviridae infection	J:227925, J:258199
	increased susceptibility to Coronaviridae infection induced morbidity/mortality	J:227925, J:258199
	interstitial pneumonia	J:258199
	lung inflammation	J:227925
Tg(CAG-dsRed2/RNAi:Tardbp)6Zxu/0 (involves: C57BL/6 * C57BL/6J * FVB/NJ * SJL)	microgliosis	J:207750
Tg(CAG-Has2)99Nita/0 Tg(MMTV-cre)4Mam/0 Tg(MMTVneu)202Mul/0 (FVB.Cg-Tg(CAG-Has2)99Nita Tg(MMTV-cre)4Mam Tg(MMTVneu)202Mul)	abnormal lymphatic vessel morphology	J:130531
	impaired macrophage chemotaxis	J:164205
	increased macrophage cell number	J:164205
Tg(CAG-Has2)99Nita/0 Tg(MMTVneu)202Mul/0 (FVB.Cg-Tg(CAG-Has2)99Nita Tg(MMTVneu)202Mul)	abnormal lymphatic vessel morphology	J:130531
Tg(CAG-LacZ,-ACVR1,-EGFP)35-1Mis/0 (involves: C57BL/6 DBA/2)	myositis	J:142253
Tg(CAG-Lyn)#Paau/0 (B6.Cg-Tg(CAG-Lyn)#Paau)	skin inflammation	J:151886
Tg(CAG-Ncoa6)71Hwl/0 (involves: FVB)	lung inflammation	J:80609
	spleen atrophy	J:80609
	thymus atrophy	J:80609
Tg(CAG-Ncoa6)87Hwl/0 (involves: FVB)	lung inflammation	J:80609
	spleen atrophy	J:80609
	thymus atrophy	J:80609
Tg(CAG-Ncoa6)104Hwl/0 (involves: FVB)	spleen atrophy	J:80609
Tg(CAG-Ncoa6)104Hwl/0 (involves: FVB)	thymus atrophy	J:80609
Tg(CAG-NRIP1)51Row/0 (involves: FVB/N)	lung inflammation	J:175885
Tg(CAG-OVAL)916Jen/? (C57BL/6-Tg(CAG-OVAL)916Jen)	abnormal dendritic cell antigen presentation	J:91742
Tg(CAG-OVAL)916Jen/? (C57BL/6-Tg(CAG-OVAL)916Jen)	decreased length of allograft survival	J:91742
Tg(CAG-p35)1Miur/0 (involves: C57BL/6)	autoimmune response	J:126593
Tg(CAG-p35)1Miur/0 Tg(Mbp-cre)29Miur/0 (involves: C57BL/6)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:126593
Tg(CAG-Pgam2)#Hiko/0 (involves: C57BL/6)	increased susceptibility to chemically induced skin inflammation	J:306793
Tg(CAG-PGDS)1Groy/0 (involves: FVB/N)	abnormal cytokine secretion	J:107651
	abnormal lymph node morphology	J:107651
	decreased inflammatory response	J:107651
Tg(CAG-PLA2G3)#aMurm/0 (Not Specified)	increased mast cell degranulation	J:197334
Tg(CAG-PLA2G3)#aMurm/0 (Not Specified)	increased susceptibility to type I hypersensitivity reaction	J:197334
Tg(CAG-Ptafr)1Tksh/0 (B6;D2-Tg(CAG-Ptafr)1Tksh/TkshRbrc)	increased mast cell number	J:38639
Tg(CAG-Ptafr)1Tksh/0 (B6;D2-Tg(CAG-Ptafr)1Tksh/TkshRbrc)	increased susceptibility to endotoxin shock	J:38639
Tg(CAG-Romo1)#Xiwa/0 (involves: C57BL/6J)	decreased monocyte cell number	J:367536
Tg(CAG-Romo1)#Xiwa/0 (involves: C57BL/6J)	decreased neutrophil cell number	J:367536
Tg(CAG-SPTLC1C133W)8EAmcc/0 (involves: C3H C57BL/6)	microgliosis	J:155748
Tg(CAG-SYVN1)1Tn/? (D1.Cg-Tg(CAG-SYVN1)1Tn)	rheumatoid arthritis	J:86009
Tg(Camk2a-cre)2Gsc/0 Tg(H2-L^d)LoxNibl/0 (involves: C57BL/6 * FVB/N)	immune system phenotype	J:284394
Tg(Camk2a-tTA)1Mmay/0 Tg(tetO-APPSwInd)107Dbo/0 (involves: C3H/HeJ * C57BL/6 * CBA)	CNS inflammation	J:109829
Tg(Camk2a-tTA)1Mmay/0 Tg(tetO-APPSwInd)Dbo/0 (involves: C3H/HeJ * C57BL/6J)	microgliosis	J:236737
Tg(Camk2a-tTA)1Mmay/0 Tg(tetO-LRRK2)C77Cai/0 Tg(tetO-SNCA*A53T)E2Cai/0 (involves: C57BL/6)	microgliosis	J:156512
Tg(Camk2a-tTA)1Mmay/0 Tg(tetO-LRRK2)C7874Cai/0 Tg(tetO-SNCA*A53T)E2Cai/0 (involves: C57BL/6)	microgliosis	J:156512
Tg(Camk2a-tTA)1Mmay/0 Tg(tetO-LRRK2G2019S)E3Cai/0 Tg(tetO-SNCAA53T)E2Cai/0 (involves: C57BL/6)	microgliosis	J:156512
Tg(Camk2a-tTA)1Mmay/0 Tg(tetO-Mtor)#Atai/0 (involves: C57BL/6 DBA/2 * ICR)	microgliosis	J:211789
Tg(Camk2a-tTA)1Mmay/0 Tg(tetO-SNCA*A53T)E2Cai/0 (involves: C57BL/6)	microgliosis	J:156512
Tg(Camk2a-tTA)1Mmay/0 Tg(tetO-TARDBP)12Vle/0 (involves: C3H/HeJ * C57BL/6J)	microgliosis	J:170756
Tg(CD2-Ccdc86)1Hfuj/? (B6.FVB-Tg(CD2-Ccdc86)1Hfuj)	abnormal T cell morphology	J:151722
Tg(CD2-Ccdc86)1Hfuj/? (B6.FVB-Tg(CD2-Ccdc86)1Hfuj)	increased T cell apoptosis	J:151722
Tg(CD2-CD4,HLA-DQA1,HLA-DQB1)1Ell/Tg(CD2-CD4,HLA-DQA1,HLA-DQB1)1Ell (NOD/MrkTac-Tg(CD2-CD4,HLA-DQA1,HLA-DQB1)1Ell)	immune system phenotype	J:86540
Tg(CD2-Ceacam1*4L)1Rsb/0 (involves: C57BL/6)	abnormal T cell physiology	J:116136
	decreased interleukin-2 secretion	J:116136
	decreased T cell number	J:116136
	decreased T cell proliferation	J:116136
Tg(CD2-Ceacam14L)1Rsb/0 Tg(TcraTcrb)425Cbn/0 (involves: BALB/c C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:116136
Tg(CD2-Foxj1)#Stlp/0 (C57BL/6-Tg(CD2-Foxj1)#Stlp)	abnormal T cell physiology	J:122222
	decreased CD4-positive, alpha-beta T cell number	J:122222
	decreased CD8-positive, alpha-beta T cell number	J:122222
	immune system phenotype	J:122222
	increased single-positive T cell number	J:122222
	lymphoid hypoplasia	J:122222
Tg(CD2-Ifngr2)1Pbro/? (B6.Cg-Tg(CD2-Ifngr2)1Pbro)	abnormal T-helper 1 cell differentiation	J:134448
	abnormal T-helper 1 physiology	J:134448
	decreased susceptibility to type IV hypersensitivity reaction	J:134448
	immune system phenotype	J:134448
	increased susceptibility to parasitic infection	J:134448
Tg(CD2-Ifngr2)2Pbro/? (B6.Cg-Tg(CD2-Ifngr2)2Pbro)	abnormal T-helper 1 cell differentiation	J:134448
	abnormal T-helper 1 physiology	J:134448
	immune system phenotype	J:134448
	increased susceptibility to parasitic infection	J:134448
Tg(CD2-Ifngr2)2Pbro/? (NOD.Cg-Tg(CD2-Ifngr2)2Pbro)	abnormal splenic cell ratio	J:81981
	abnormal T-helper 1 physiology	J:81981
	decreased interferon-gamma secretion	J:81981
	decreased interleukin-4 secretion	J:81981
	decreased tumor necrosis factor secretion	J:81981
	immune system phenotype	J:81981
	insulitis	J:81981
	myositis	J:81981
	ovary inflammation	J:81981
Tg(CD2-LAT2)1Wz/0 (Not Specified)	abnormal CD8-positive, alpha-beta T cell physiology	J:116157
Tg(CD2-Lmo2)#Thr/0 (involves: C57BL/6 * CBA)	enlarged spleen	J:102058
Tg(CD2-Lmo2)#Thr/0 (involves: C57BL/6 * CBA)	enlarged thymus	J:102058
Tg(CD2-Lrch1)#Liux/0 (involves: C57BL/6)	abnormal cellular extravasation	J:238772
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:238772
	immune system phenotype	J:238772
Tg(CD2-Mir181d)38Oers/0 (involves: C57BL/6)	decreased CD8-positive, alpha-beta T cell number	J:212571
	decreased double-positive T cell number	J:212571
	decreased T cell number	J:212571
	immune system phenotype	J:212571
	thymus atrophy	J:212571
Tg(CD2-Mir181d)38Oers/0 Tg(TcraTcrb)425Cbn/0 (involves: C3H * C57BL/6)	decreased T cell number	J:212571
Tg(CD2-Myb/en)2Kmw/? (involves: C57BL/10 * CBA)	abnormal single-positive T cell number	J:126456
	decreased T cell number	J:126456
	decreased T cell proliferation	J:126456
	increased double-negative T cell number	J:126456
Tg(CD2-Myb/en)2Kmw/Tg(CD2-Myb/en)2Kmw (involves: C57BL/10 * CBA)	decreased double-positive T cell number	J:126456
	decreased T cell number	J:126456
	decreased T cell proliferation	J:126456
	increased double-negative T cell number	J:126456
	small spleen	J:126456
	small thymus	J:126456
Tg(CD2-Nfat5)1Snh/0 (involves: BALB/c * C57BL/6)	abnormal cytotoxic T cell physiology	J:80066
	abnormal T cell differentiation	J:80066
	abnormal T cell physiology	J:80066
	decreased CD4-positive, alpha-beta T cell number	J:80066
	decreased CD8-positive, alpha-beta T cell number	J:80066
	decreased splenocyte proliferation	J:80066
	decreased T cell number	J:80066
	decreased T cell proliferation	J:80066
	spleen hypoplasia	J:80066
	thymus hypoplasia	J:80066
Tg(CD2-Ppp2ca)#Gct/0 (involves: C57BL/6J)	abnormal T cell subpopulation ratio	J:184067
	enlarged lymph nodes	J:184067
	enlarged spleen	J:184067
	glomerulonephritis	J:184067
	increased germinal center B cell number	J:184067
	increased interleukin-17 secretion	J:184067
	increased neutrophil cell number	J:184067
Tg(CD2-Rorc)#Staka/0 (involves: C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:236222
	abnormal susceptibility to Picornaviridae infection	J:236222
	abnormal T-helper 17 cell physiology	J:236222
	decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:230700
	decreased CD8-positive, alpha-beta T cell number	J:236222
	decreased IgG2c level	J:236222
	decreased IgG3 level	J:236222
	decreased IgG level	J:236222
	decreased interferon-gamma secretion	J:236222
	decreased interleukin-10 secretion	J:236222
	increased anti-nuclear antigen antibody level	J:230700
	increased autoantibody level	J:230700
	increased effector memory CD4-positive, alpha-beta T cell number	J:230700
	increased interferon-gamma secretion	J:236222
	increased interleukin-17 secretion	J:236222
	increased susceptibility to autoimmune disorder	J:230700
	lacrimal gland inflammation	J:230700
	lung inflammation	J:230700
	salivary gland inflammation	J:230700
Tg(CD2-S1PR1)1Ejg/? (involves: C57BL/6 * DBA/2)	abnormal humoral immune response	J:96558
	abnormal lymphocyte chemotaxis	J:96558
	decreased activated T cell number	J:96558
	decreased susceptibility to type IV hypersensitivity reaction	J:96558
	decreased T cell proliferation	J:96558
	impaired leukocyte migration	J:96558
	increased activated T cell number	J:96558
	increased IgE level	J:96558
	increased T cell number	J:96558
Tg(CD2-Sh2d1a)#Vei/0 (involves: 129S1/Sv * 129X1/SvJ)	increased natural killer cell mediated cytotoxicity	J:110195
Tg(CD2-Sh2d1b1)#Vei/0 (B6.Cg-Tg(CD2-Sh2d1b1)#Vei)	decreased interferon-gamma secretion	J:110195
Tg(CD2-Sh2d1b1)#Vei/0 (B6.Cg-Tg(CD2-Sh2d1b1)#Vei)	impaired natural killer cell mediated cytotoxicity	J:110195
Tg(CD2-Sh2d1b2)#Vei/0 (B6.Cg-Tg(CD2-Sh2d1b2)#Vei)	impaired natural killer cell mediated cytotoxicity	J:110195
Tg(Cd2-Smad7)#Chbe/0 (involves: C57BL/6)	abnormal T-helper 1 cell differentiation	J:184670
	decreased interleukin-9 secretion	J:184670
	decreased interleukin-10 secretion	J:184670
	decreased interleukin-17 secretion	J:184670
	increased interferon-gamma secretion	J:184670
	increased susceptibility to experimental autoimmune encephalomyelitis	J:184670
Tg(CD2-Stat6V625AT626A)78Mhk/0 (involves: C3H * C57BL/6)	dermatitis	J:160119
Tg(CD2-TcraF5,CD2-TcrbF5)1Kio/0 (involves: C57BL/10)	abnormal positive T cell selection	J:113713
Tg(CD2-TcraF5,CD2-TcrbF5)1Kio/0 (involves: C57BL/10)	increased CD8-positive, alpha-beta T cell number	J:113713
Tg(CD2-TcraF5,CD2-TcrbF5)1Kio/0 (involves: C57BL/10 * CBA/Ca)	decreased CD8-positive, alpha-beta T cell number	J:113713
Tg(CD2-TcraF5,CD2-TcrbF5)1Kio/0 (involves: BALB/c * C57BL/10)	decreased CD8-positive, alpha-beta T cell number	J:113713
Tg(CD2-TcraF5,CD2-TcrbF5)1Kio/? (involves: 129S1/Sv * 129X1/SvJ * C57BL/10 * FVB/N)	abnormal positive T cell selection	J:126026
	decreased CD4-positive, alpha-beta T cell number	J:126026
	increased CD8-positive, alpha-beta T cell number	J:126026
Tg(CD2-TcraF5,CD2-TcrbF5)1Kio/0 Tg(Cd4-BCL2G101AD102AD103A)AWnt/0 (involves: C57BL/6 C57BL/10)	abnormal T cell clonal deletion	J:217939
	decreased thymocyte apoptosis	J:217939
	enlarged lymph nodes	J:217939
	increased T cell number	J:217939
Tg(CD2-TcraF5,CD2-TcrbF5)1Kio/0 Tg(LCKprBCL2)36Sjk/0 (involves: C57BL/6 * C57BL/10)	abnormal T cell clonal deletion	J:217939
	decreased thymocyte apoptosis	J:217939
Tg(CD2-Tgfbr2)1Grs/0 (C57BL/6-Tg(CD2-Tgfbr2)1Grs/Nci)	enlarged lymph nodes	J:97523
	enlarged spleen	J:97523
	increased T cell proliferation	J:97523
Tg(CD2-Tgfbr2)1Grs/? (C57BL/6-Tg(CD2-Tgfbr2)1Grs/Nci)	abnormal CD8-positive, alpha beta T cell morphology	J:93665
	increased T cell derived lymphoma incidence	J:93665
	increased T cell proliferation	J:93665
Tg(CD2-Zbtb7b)C8Rbo/? (involves: C57BL/6)	absent CD8-positive, alpha-beta T cells	J:97610
Tg(CD2-Zbtb7b)C8Rbo/? (involves: C57BL/6)	increased CD4-positive, alpha-beta T cell number	J:97610
Tg(CD2-Zbtb7b)C8Rbo/? Tg(TcraH-Y,TcrbH-Y)71Vbo/? (involves: C57BL/6 * DBA/2J)	abnormal T cell differentiation	J:97610
Tg(CD2-Zbtb7b)C8Rbo/? Tg(TcrLCMV)327Sdz/? (involves: C57BL/6 * DBA/2J)	abnormal T cell differentiation	J:97610
Tg(CD2-Zbtb7b)C8Rbo/? Themis^tm1Lov/Themis^tm1Lov (involves: 129)	abnormal T cell differentiation	J:151075
Tg(Cd3d-Il5)NJ.1638Nal/? (involves: C57BL/6J * CBA/J)	abnormal eosinophil differentiation	J:123440
	abnormal spleen morphology	J:123440
	abnormal T cell number	J:123440
	enlarged lymph nodes	J:123440
	increased eosinophil cell number	J:123440
	increased leukocyte cell number	J:123440
	increased mature B cell number	J:123440
	increased monocyte cell number	J:123440
	increased neutrophil cell number	J:123440
	increased spleen weight	J:123440
	peritoneal inflammation	J:123440
Tg(CD3E)26Cpt/Tg(CD3E)26Cpt (involves: C57BL/6J * CBA/J)	abnormal thymus corticomedullary boundary morphology	J:81711
	absent NK cells	J:81711
	arrested T cell differentiation	J:81711
	decreased double-positive T cell number	J:54756
	decreased T cell number	J:54756
	decreased thymocyte number	J:81711
	decreased uterine NK cell number	J:134589
	thymus hypoplasia	J:54756
Tg(Cd4-BCL2G101AD102A*D103A)AWnt/0 (involves: C57BL/6)	abnormal CD4-positive, alpha-beta T cell number	J:217939
	abnormal mesenteric lymph node morphology	J:217939
	abnormal splenic cell ratio	J:217939
	abnormal T cell clonal deletion	J:217939
	abnormal T cell proliferation	J:217939
	abnormal T cell subpopulation ratio	J:217939
	decreased double-positive T cell number	J:217939
	decreased thymocyte apoptosis	J:217939
	enlarged lymph nodes	J:217939
	enlarged spleen	J:217939
	glomerulonephritis	J:217939
	increased activated T cell number	J:217939
	increased anti-nuclear antigen antibody level	J:217939
	increased autoantibody level	J:217939
	increased B cell number	J:217939
	increased central memory CD8 positive, alpha-beta T cell number	J:217939
	increased interferon-gamma secretion	J:217939
	increased regulatory T cell number	J:217939
	increased single-positive T cell number	J:217939
	increased susceptibility to autoimmune disorder	J:217939
	increased T cell number	J:217939
	kidney inflammation	J:217939
	liver inflammation	J:217939
	lung inflammation	J:217939
	lymphoid hyperplasia	J:217939
	skin inflammation	J:217939
Tg(Cd4-BCL2G101AD102AD103A)AWnt/0 (involves: C57BL/6 CBA/J)	abnormal T cell clonal deletion	J:217939
	decreased thymocyte apoptosis	J:217939
Tg(Cd4-BCL2G101AD102AD103A)AWnt/0 Tg(Nr4a1-EGFP/cre)820Khog/0 (involves: C57BL/6 C57BL/6J)	abnormal T cell clonal deletion	J:217939
	decreased thymocyte apoptosis	J:217939
Tg(Cd4-BCL2G101AD102AD103A)AWnt/0 Tg(TcraH-Y,TcrbH-Y)71Vbo/0 (involves: C57BL/6 C57BL/6J * DBA/2J)	abnormal T cell clonal deletion	J:217939
	decreased thymocyte apoptosis	J:217939
Tg(Cd4-CD4)2362Litt/0 (involves: C57BL/6 * SJL)	immune system phenotype	J:50435
Tg(Cd4-CD4)2362Litt/0 Tg(HLA-DR2)#Lfug/0 Tg(TCROb.1A12)#Lfug/0 (involves: C57BL/6 * DBA/2 * SJL)	CNS inflammation	J:134764
	increased susceptibility to experimental autoimmune encephalomyelitis	J:134764
Tg(CD4-CIITA)357Ccum/? (involves: C57BL/6 * C57BL/6J * SJL)	increased osteoclast cell number	J:233241
Tg(Cd4-cre)1Cwi/? Tg(TcraTcrb)425Cbn/? Traf6^tm2Ywc/Traf6^tm2Ywc (involves: C57BL/6 * DBA/2)	abnormal lymphocyte anergy	J:130882
	increased interleukin-2 secretion	J:130882
Tg(Cd4-cre)1Cwi/0 Trmt6^em1Hbgl/Trmt6^em1Hbgl (involves: C57BL/6 * DBA/2J)	decreased CD4-positive, alpha-beta T cell number	J:336736
	decreased T cell proliferation	J:336736
Tg(Cd4-cre)1Cwi/0 Trmt61a^em1Hbgl/Trmt61a^em1Hbgl (involves: C57BL/6 * DBA/2J)	abnormal CD4-positive T cell differentiation	J:336736
	abnormal T cell activation	J:336736
	colitis	J:336736
	decreased CD4-positive, alpha-beta T cell number	J:336736
	decreased CD8-positive, alpha-beta T cell number	J:336736
	decreased T cell proliferation	J:336736
	increased CD4-positive, alpha-beta T cell number	J:336736
	increased CD8-positive, alpha-beta T cell number	J:336736
Tg(Cd4-DsRed)4Lt/0 (NOD/ShiLt-Tg(Cd4-DsRed)4Lt)	decreased susceptibility to autoimmune diabetes	J:127785
Tg(Cd4-Dtx1)1Mzl/? (involves: C57BL/6)	abnormal T cell activation	J:151605
	abnormal thymocyte activation	J:151605
	decreased interleukin-2 secretion	J:151605
	decreased T cell proliferation	J:151605
Tg(CD4-HIV)F21380Pjo/0 (involves: C3H * C57BL/6)	interstitial pneumonia	J:78756
	lymph node atrophy	J:78756
	spleen atrophy	J:78756
	thymus atrophy	J:78756
	tubular nephritis	J:78756
Tg(CD4-HIV)F21388Pjo/0 (involves: C3H * C57BL/6)	interstitial pneumonia	J:78756
	lymph node atrophy	J:78756
	spleen atrophy	J:78756
	thymus atrophy	J:78756
	tubular nephritis	J:78756
Tg(CD4-HIV)F21407Pjo/0 (involves: C3H * C57BL/6)	interstitial pneumonia	J:78756
	lymph node atrophy	J:78756
	spleen atrophy	J:78756
	thymus atrophy	J:78756
	tubular nephritis	J:78756
Tg(CD4-HIV)F26605Pjo/0 (involves: C3H * C57BL/6)	interstitial pneumonia	J:78756
	lymph node atrophy	J:78756
	spleen atrophy	J:78756
	thymus atrophy	J:78756
	tubular nephritis	J:78756
Tg(CD4-HIV)F26622Pjo/0 (involves: C3H * C57BL/6)	interstitial pneumonia	J:78756
	lymph node atrophy	J:78756
	spleen atrophy	J:78756
	thymus atrophy	J:78756
	tubular nephritis	J:78756
Tg(CD4-HIV)F26990Pjo/0 (involves: C3H * C57BL/6)	interstitial pneumonia	J:78756
	lymph node atrophy	J:78756
	spleen atrophy	J:78756
	thymus atrophy	J:78756
	tubular nephritis	J:78756
Tg(CD4-HIV)F27011Pjo/0 (involves: C3H * C57BL/6)	interstitial pneumonia	J:78756
	lymph node atrophy	J:78756
	spleen atrophy	J:78756
	thymus atrophy	J:78756
	tubular nephritis	J:78756
Tg(CD4-HIV)F27367Pjo/0 (involves: C3H * C57BL/6)	interstitial pneumonia	J:78756
	lymph node atrophy	J:78756
	spleen atrophy	J:78756
	thymus atrophy	J:78756
	tubular nephritis	J:78756
Tg(Cd4-Il17rb)#Cdon/? (involves: C57BL/6)	abnormal T cell differentiation	J:158594
	decreased interferon-gamma secretion	J:158594
	increased eosinophil cell number	J:158594
	increased interleukin-5 secretion	J:158594
	increased interleukin-9 secretion	J:158594
	increased interleukin-13 secretion	J:158594
	increased susceptibility to type I hypersensitivity reaction	J:158594
	lung inflammation	J:158594
Tg(CD4-Il17re)#Cdon/0 (involves: C57BL/6)	abnormal interleukin secretion	J:177650
	decreased interleukin-17 secretion	J:177650
	increased susceptibility to experimental autoimmune encephalomyelitis	J:177650
Tg(Cd4-NPM/ALK)N1Ingh/0 (either: (involves: BALB/c * Swiss Webster) or (involves: C57BL/6 * Swiss Webster))	increased immunoglobulin level	J:82127
	increased lymphoblastic lymphoma incidence	J:82127
Tg(Cd4-NPM/ALK)N1Ingh/0 (involves: C57BL/6 * Swiss Webster)	abnormal T cell differentiation	J:235890
	abnormal T cell morphology	J:235890
	increased DN3 thymocyte number	J:235890
	increased thymus tumor incidence	J:235890
Tg(Cd4-NPM/ALK)N1Ingh/0 Tg(TcraTcrb)1100Mjb/0 (involves: C57BL/6 * Swiss Webster)	abnormal double-negative T cell morphology	J:235890
	abnormal thymus morphology	J:235890
	increased T cell derived lymphoma incidence	J:235890
Tg(Cd4-TGFBR2)16Flv/? (involves: C3H * C57BL/6 * C57BL/10 * C57BR/cd)	abnormal T cell activation	J:97554
	abnormal T cell proliferation	J:97554
	abnormal thymus involution	J:97554
	colitis	J:97554
	decreased B cell number	J:97554
	glomerulonephritis	J:97554
	increased anti-nuclear antigen antibody level	J:97554
	increased IgA level	J:97554
	increased IgG1 level	J:97554
	increased IgG2a level	J:97554
	increased immunoglobulin level	J:97554
	increased inflammatory response	J:97554
	increased memory T cell number	J:97554
	liver inflammation	J:97554
	lung inflammation	J:97554
	lymph node hyperplasia	J:97554
	pancreas inflammation	J:97554
	spleen hyperplasia	J:97554
Tg(Cd4-TGFBR2)16Flv/? (involves: C3H * C57BL/6)	abnormal CD8-positive, alpha-beta regulatory T cell morphology	J:134473
	abnormal T cell proliferation	J:134473
	colitis	J:134156
	increased interferon-gamma secretion	J:134156
	increased tumor necrosis factor secretion	J:134156
Tg(Cd4-Zbtb16)1797Aben/? (C57BL/6-Tg(Cd4-Zbtb16)1797Aben)	decreased CD4-positive, alpha-beta T cell number	J:139690
	increased CD4-positive, alpha-beta memory T cell number	J:139690
	increased T-helper 2 cell number	J:139690
Tg(Cd8aCd8b)3Erob/0 (involves: C57BL/6 * DBA/2)	abnormal CD8-positive, alpha-beta T cell differentiation	J:93004
	abnormal double-positive T cell morphology	J:93004
	decreased CD4-positive, alpha-beta T cell number	J:93004
	decreased double-negative T cell number	J:93004
	increased CD8-positive, alpha-beta T cell number	J:93004
Tg(Cd8aCd8b)3Erob/0 Tg(TcraH-Y,TcrbH-Y)71Vbo/0 (involves: C57BL/6 * DBA/2)	abnormal CD4-positive, alpha beta T cell morphology	J:93004
	abnormal CD8-positive, alpha-beta T cell differentiation	J:93004
	increased CD8-positive, alpha-beta T cell number	J:93004
Tg(CD8aCD8b)57Scr/? (B6;SJL-Tg(CD8aCD8b)57Scr/J)	abnormal cytotoxic T cell physiology	J:92994
Tg(CD8aCD8b)57Scr/? (B6;SJL-Tg(CD8aCD8b)57Scr/J)	abnormal effector T cell morphology	J:92994
Tg(Cd8b1)46Erob/0 (involves: 129S4/SvJae * C57BL/6 * CBA)	abnormal T cell subpopulation ratio	J:110916
	decreased T cell number	J:110916
	decreased thymocyte number	J:110916
Tg(CD19)1Tft/0 (involves: C57BL/6 * C57BL/6J * SJL)	decreased B cell number	J:27236
Tg(CD19)1Tft/0 (involves: C57BL/6 * C57BL/6J * SJL)	increased B cell proliferation	J:27236
Tg(CD19)1Tft/Tg(CD19)1Tft (involves: C57BL/6 * C57BL/6J * SJL)	decreased B cell number	J:27236
	decreased IgG1 level	J:27236
	decreased IgG3 level	J:27236
	decreased immature B cell number	J:27236
	increased B cell proliferation	J:27236
	increased IgG2a level	J:27236
	increased IgG2b level	J:27236
	increased IgM level	J:27236
Tg(CD19-Tnfsf7)#Rvl/0 (involves: C57BL/6)	abnormal metallophilic macrophage morphology	J:88620
	abnormal spleen marginal zone macrophage morphology	J:88620
	abnormal spleen marginal zone morphology	J:88620
	decreased B cell number	J:88620
	decreased mature B cell number	J:88620
	decreased transitional stage B cell number	J:88620
Tg(CD46)2Gsv/0 (involves: C57BL/6 * FVB/N)	abnormal cell-mediated immunity	J:109895
	abnormal chemokine level	J:109895
	abnormal cytokine secretion	J:109895
	abnormal humoral immune response	J:109895
	abnormal response to transplant	J:113644
	decreased cytotoxic T cell cytolysis	J:109895
	increased susceptibility to Paramyxoviridae infection	J:109895
Tg(CD46)373Zbz/Tg(CD46)373Zbz (involves: C3H/He * C57BL/6)	immune system phenotype	J:160878
Tg(Cd68-BCL2)526Medz/0 (involves: 129 * C57BL/6)	abnormal immune cell physiology	J:82809
Tg(Cd68-BCL2)526Medz/0 (involves: 129 * C57BL/6)	increased inflammatory response	J:82809
Tg(Cd68-BCL2)533Medz/0 (involves: 129 * C57BL/6)	abnormal immune system cell morphology	J:82809
Tg(Cd68-BCL2)535Medz/0 (involves: 129 * C57BL/6)	abnormal dendritic cell physiology	J:211458
	decreased dendritic cell apoptosis	J:211458
	enlarged lymph nodes	J:82809
	enlarged spleen	J:82809
	increased inflammatory response	J:82809
Tg(Cd68-Fem1a)1Seno/0 (C57BL/6-Tg(Cd68-Fem1a)1Seno)	abnormal susceptibility to induced colitis	J:228893
Tg(Cd74-Nlrc4*)1Kyas/0 (involves: C57BL/6N)	abnormal spleen morphology	J:219652
	autoimmune arthritis	J:219652
	dermatitis	J:219652
	enlarged spleen	J:219652
	increased circulating interleukin-1 beta level	J:219652
	increased circulating interleukin-17 level	J:219652
	increased inflammatory response	J:219652
	increased interleukin-1 beta secretion	J:219652
	increased neutrophil cell number	J:219652
	increased splenocyte number	J:219652
	increased T cell number	J:219652
	joint inflammation	J:219652
	skin inflammation	J:219652
Tg(Cd79b-TCL1A)BKTeit/0 (involves: C3H * C57BL/6)	abnormal lymph node morphology	J:79703
	abnormal spleen morphology	J:79703
	abnormal thymus morphology	J:79703
	decreased B cell apoptosis	J:79703
	decreased T cell apoptosis	J:79703
	enlarged lymph nodes	J:79703
	enlarged spleen	J:79703
	increased B cell proliferation	J:79703
	increased lymphocyte cell number	J:79703
	increased T cell proliferation	J:79703
Tg(Cd152Ig)1Jbs/0 (involves: C3H * NOD)	increased susceptibility to autoimmune diabetes	J:35353
Tg(CD207-Dta)312Dhka/? (FVB-Tg(CD207-Dta)312Dhka)	absent Langerhans cell	J:113309
Tg(CD207-Dta)312Dhka/? (FVB-Tg(CD207-Dta)312Dhka)	increased susceptibility to type IV hypersensitivity reaction	J:113309
Tg(Cebpb-tTA)5Bjd/0 Tg(tetO-MYC,-OVAL)#Gtgm/0 (B6J.Cg-Tg(Cebpb-tTA)5Bjd Tg(tetO-MYC,-OVAL)#Gtgm)	abnormal immune tolerance	J:186226
Tg(Cga-LHB/CGB)94Jhn/? (involves: C57BL/6 * SJL)	pyelonephritis	J:55157
Tg(Cga-LHB/CGB)94Jhn/? (involves: C57BL/6 * SJL)	tubulointerstitial nephritis	J:55157
Tg(Chst4-cre)1Hkwa/0 (involves: C3H/HeN * C57BL/6)	immune system phenotype	J:147714
Tg(Ckm-APPSw)A2Lfa/0 (involves: C57BL/6 * SJL)	myositis	J:76338
Tg(Ckm-APPSw)A6Lfa/0 (involves: C57BL/6 * SJL)	myositis	J:76338
Tg(CKMM-tTA)A3Rhvh/0 Tg(tetO-H2-K1)#Papl/0 (B6.Cg-Tg(CKMM-tTA)A3Rhvh Tg(tetO-H2-K1)#Papl)	abnormal cytokine level	J:205907
	increased anti-nuclear antigen antibody level	J:205907
	increased autoantibody level	J:205907
	myositis	J:205907
Tg(CLEC4C-HBEGF)956Cln/0 (C57BL/6-Tg(CLEC4C-HBEGF)956Cln)	abnormal chemokine secretion	J:166504
	abnormal cytotoxic T cell physiology	J:166504
	abnormal NK cell physiology	J:166504
	abnormal NK T cell physiology	J:166504
	decreased CD8-positive, alpha-beta T cell number	J:166504
	decreased interferon-alpha secretion	J:166504
	decreased plasmacytoid dendritic cell number	J:166504
	decreased splenocyte number	J:166504
	impaired natural killer cell mediated cytotoxicity	J:166504
	increased interferon-gamma secretion	J:166504
	increased interleukin-12 secretion	J:166504
	increased susceptibility to Herpesvirales infection	J:166504
	small spleen	J:166504
Tg(Cma1-cre)ARoer/0 Tg(Kit*D814V)1Roer/0 (involves: C57BL/6)	colitis	J:169611
	increased mast cell number	J:169611
Tg(Cma1-cre)ARoer/0 Tg(Kit*D814V)3Roer/0 (involves: C57BL/6)	increased mast cell number	J:169611
Tg(CMV-cre)1Cgn/0 Tg(KitD814V)1Roer/0 (involves: BALB/cJ C57BL/6)	increased mast cell number	J:169611
	large intestinal inflammation	J:169611
Tg(CMV-cre)1Cgn/0 Tg(KitD814V)3Roer/0 (involves: BALB/cJ C57BL/6)	increased mast cell number	J:169611
Tg(CMV-cre)1Cgn/0 Trp53^tm4Att/Trp53⁺ (involves: 129S4/SvJae * BALB/cJ * C57BL/6J)	small thymus	J:217080
Tg(CMV-IghvaD11)CCat/0 Tg(CMV-IgkvaD11)BCat/0 (involves: C57BL/6 * SJL)	abnormal splenic cell ratio	J:79946
	increased splenocyte apoptosis	J:79946
Tg(CMV-IghvaD11)DCat/0 Tg(CMV-IgkvaD11)ACat/0 (involves: C57BL/6 * SJL)	abnormal splenic cell ratio	J:79946
	increased splenocyte apoptosis	J:79946
Tg(CMV-SALL4_iB)#Chai/? (Not Specified)	abnormal leukocyte morphology	J:115037
	abnormal myelopoiesis	J:115037
	abnormal neutrophil morphology	J:115037
	decreased leukocyte cell number	J:115037
	decreased neutrophil cell number	J:115037
	myeloid hyperplasia	J:115037
Tg(CMV-tTA)3Bjd/0 Tg(tetO-Prkar1ax2as)1Stra/0 (involves: C57BL/6 NMRI * SJL)	abnormal lymph node morphology	J:94953
	pancreas inflammation	J:94953
Tg(Cnp-EGFR)10Nrat/0 (involves: C57BL/6 * SJL)	increased mast cell number	J:95933
Tg(Cnp-Gpr17)1Qrlu/0 (Not Specified)	microgliosis	J:154602
Tg(Col1a1-cre)1Kry/0 Vdr^tm2Ska/Vdr^tm2Ska (involves: C57BL/6J * C57BL/6NCrlj * CBA/JNCrlj * FVB/N)	abnormal osteoclast differentiation	J:196471
	decreased osteoclast cell number	J:196471
Tg(Col1a1-Dkk1)1Hmk/? (B6.FVB-Tg(Col1a1-Dkk1)1Hmk)	abnormal osteoclast physiology	J:158620
	abnormal response to transplant	J:238121
	increased osteoclast cell number	J:158620
Tg(Col1a1-FGF2,-Sapphire)203Mmh/Tg(Col1a1-FGF2,-Sapphire)203Mmh (involves: FVB/N)	increased osteoclast cell number	J:159949
	osteoarthritis	J:240777
Tg(Col1a1-Runx2)#Pmt/0 (involves: BALB/c * C57BL/6)	increased osteoclast cell number	J:167992
Tg(Col1a1-TK*)#Rowe/0 (involves: CD-1)	decreased osteoclast cell number	J:112520, J:217781
Tg(Col1a1-TK*)#Rowe/0 (involves: CD-1)	increased spleen weight	J:112520
Tg(Col1a1-tTA)139Niss/0 Tg(tetO-HTR4D100A)7Niss/0 (FVB/N-Tg(Col1a1-tTA)139Niss Tg(tetO-HTR4D100A)7Niss)	increased osteoclast cell number	J:131617
Tg(Col2a1-cre/ERT2)1Dic/0 Tgfbr1^tm1.1Karl/Tgfbr1^tm1.1Karl (involves: 129 * C57BL/6)	osteoarthritis	J:271724
Tg(Col2a1-Fgfr3/GH)BDor/0 (FVB/N-Tg(Col2a1-Fgfr3/GH)BDor)	abnormal osteoclast differentiation	J:50292
Tg(Col2a1-Mir140)#Asah/0 (C57BL/6-Tg(Col2a1-Mir140)#Asah)	decreased susceptibility to induced arthritis	J:160358
Tg(Col2a1-rtTA,tetO-COMP)2Jath/0 (C57BL/6-Tg(Col2a1-rtTA,tetO-COMP)2Jath)	increased inflammatory response	J:233238
Tg(Col10a1-Tg*L2263P)1Rpbh/0 (Not Specified)	decreased osteoclast cell number	J:154052
Tg(Col10a1-TgL2263P)1Rpbh/Tg(Col10a1-TgL2263P)1Rpbh (Not Specified)	decreased osteoclast cell number	J:154052
Tg(Comp-tTA)#Yeli/0 Tg(tetO-DDR2)#Yeli/0 (Not Specified)	osteoarthritis	J:176308
Tg(Cr2-cre)3Cgn/? Xrcc4^tm1Fwa/Xrcc4^tm2Fwa (involves: 129P2/OlaHsd * 129S6/SvEvTac)	abnormal class switch recombination	J:150339
Tg(Crh)227.1Pbl/0 (involves: C57BL/6 * SJL)	decreased spleen weight	J:92996
Tg(Crh)227.1Pbl/0 (involves: C57BL/6 * SJL)	decreased thymus weight	J:92996
Tg(Csf1r-Tnfsf15,-EGFP)#Targ/0 (involves: C57BL/6)	increased interferon-gamma secretion	J:169462
Tg(Csf1r-Tnfsf15,-EGFP)#Targ/0 (involves: C57BL/6)	small intestinal inflammation	J:169462
Tg(CSF2)2Ygy/0 Tg(IL3)1Ygy/0 Tg(KITLG)3Ygy/0 (C.Cg-Tg(CSF2)2Ygy Tg(IL3)1Ygy Tg(KITLG)3Ygy)	abnormal response to transplant	J:107052
	decreased susceptibility to graft versus host disease	J:107052
Tg(CSTG-NPM1/RARA)#Sjch/0 (involves: C57BL/6)	enlarged spleen	J:55196
Tg(CSTG-NPM1/RARA)#Sjch/0 (involves: C57BL/6)	increased spleen red pulp amount	J:55196
Tg(CTSG-NUMA1/RARA)#Skr/0 (involves: C57BL/6)	abnormal spleen morphology	J:88103
	abnormal spleen red pulp morphology	J:88103
	enlarged spleen	J:88103
	increased granulocyte number	J:88103
	increased leukocyte cell number	J:88103
	increased neutrophil cell number	J:88103
	increased spleen germinal center size	J:88103
	increased spleen white pulp amount	J:88103
Tg(CTSG-PML/RARA)135Ley/? (Not Specified)	abnormal leukocyte cell number	J:77881
	abnormal spleen red pulp morphology	J:77881
	enlarged spleen	J:77881
	spleen hyperplasia	J:77881
Tg(CTSG-PML/RARA)135Ley/? (involves: C3H * C57BL/6)	abnormal spleen red pulp morphology	J:59080
	enlarged spleen	J:59080
	immune system phenotype	J:59080
	increased leukocyte cell number	J:59080
Tg(CTSG-PML/RARA)135Ley/0 Tg(CTSG-RARA/PML)#Ley/0 (involves: C3H * C57BL/6)	abnormal spleen red pulp morphology	J:59080
	enlarged spleen	J:59080
	immune system phenotype	J:59080
	increased leukocyte cell number	J:59080
Tg(CTSG-PML/RARA)135Ley/0 Wbcc1^SWR/J/? (involves: C3H/HeJ * C57BL/6J * SWR/J)	decreased leukocyte cell number	J:139159
Tg(CTSG-PML/RARA)135Ley/0 Wbcc2^SWR/J/? (involves: C3H/HeJ * C57BL/6J * SWR/J)	increased leukocyte cell number	J:139159
Tg(CTSG-PML/RARA)135Ley/0 Wbcc3^SWR/J/? (involves: C3H/HeJ * C57BL/6J * SWR/J)	increased leukocyte cell number	J:139159
Tg(CTSG-PML/RARA)6179Ppp/0 (Not Specified)	abnormal myelopoiesis	J:40373
	increased granulocyte number	J:40373
	increased leukocyte cell number	J:40373
Tg(CTSG-PML/RARA)#Ppp/0 (Not Specified)	abnormal myelopoiesis	J:78201, J:40373
	increased granulocyte number	J:40373
	increased leukocyte cell number	J:40373
Tg(CTSG-RARA/ZBTB16)#Ppp/0 (Not Specified)	abnormal myelopoiesis	J:65878
	enlarged spleen	J:65878
	myeloid hyperplasia	J:65878
Tg(CTSG-RARA/ZBTB16)#Ppp/0 Tg(CTSG-ZBTB16/RARA)#Ppp/0 (Not Specified)	abnormal myelopoiesis	J:65878
	increased leukocyte cell number	J:65878
Tg(CTSG-ZBTB16/RARA)#Ppp/0 (Not Specified)	abnormal myelopoiesis	J:78201
Tg(CTSG-ZBTB16/RARA)#Ppp/0 (Not Specified)	increased leukocyte cell number	J:65878, J:78201
Tg(CTSG-ZBTB16/RARA)#Sjch/0 (involves: C57BL/6)	abnormal myelopoiesis	J:55196
	abnormal spleen morphology	J:55196
	abnormal spleen red pulp morphology	J:55196
	enlarged spleen	J:55196
	increased leukocyte cell number	J:55196
	myeloid hyperplasia	J:55196
Tg(CYP1A1-PPARD)#Jfoe/0 (involves: C57BL/6J * CBA)	increased T cell proliferation	J:158907
Tg(CYP1A1-PPARD)#Jfoe/0 (involves: C57BL/6J * CBA)	skin inflammation	J:158907
Tg(Dct-Grm1)ESzc/0 (involves: C57BL/6J)	enlarged inguinal lymph nodes	J:83183
Tg(Dct-Grm1)ESzc/0 (involves: C57BL/6J)	enlarged submandibular lymph nodes	J:83183
Tg(DMD-APP)7Neve/0 (involves: C57BL/6 SJL)	abnormal microglial cell morphology	J:100978
Tg(DMD-APP)18Neve/0 (involves: C57BL/6 SJL)	abnormal microglial cell morphology	J:100978
Tg(DO11.10)10Dlo/? (involves: BALB/c * C3H * C57BL/6)	abnormal thymus physiology	J:70572
	decreased CD4-positive, alpha-beta T cell number	J:70572
	decreased double-positive T cell number	J:70572
Tg(DO11.10)10Dlo/0 Crlf2^tm1Wjl/Crlf2^tm1Wjl (involves: 129 * BALB/c * C3H * C57BL/6)	decreased inflammatory response	J:107431
Tg(DO11.10)10Dlo/? Tox^tm1.1Kay/Tox^tm1.1Kay (involves: 129S/Sv * BALB/c * C3H * C57BL/6)	arrested T cell differentiation	J:131287
	decreased T cell number	J:131287
Tg(DPP4)2Nnag/0 (B6.Cg-Tg(DPP4)2Nnag)	abnormal cytokine level	J:286321
	increased susceptibility to Coronaviridae infection	J:286321
	lung inflammation	J:286321
Tg(DPP4)2Nnag/0 Tmprss2^{tm1(KOMP)Vlcg}/Tmprss2^{tm1(KOMP)Vlcg} (involves: C57BL/6NCr * C57BL/6NTac * DBA)	abnormal cytokine secretion	J:283077
	decreased susceptibility to Coronaviridae infection	J:283077
Tg(DUX4)1Maar/? (involves: C57BL/6J CBA/J)	increased incidence of corneal inflammation	J:195481
Tg(ED-L2-IL1RN/IL1B)#Tcw/? (B6.Cg-Tg(ED-L2-IL1RN/IL1B)#Tcw)	abnormal interleukin level	J:180282
	enlarged spleen	J:180282
	esophageal inflammation	J:180282
	increased circulating interleukin-6 level	J:180282
	increased inflammatory response	J:180282
Tg(EEF1A1-SHC1)1Ravi/? Tg(Lck-cre)1Cwi/? (involves: 129 C57BL/6)	abnormal double-negative T cell morphology	J:78180
	decreased double-positive T cell number	J:78180
	decreased single-positive T cell number	J:78180
	thymus hypoplasia	J:78180
Tg(EIF1AX-Il31ra)1Jagr/0 (involves: C3H * C57BL/6)	abnormal immune system physiology	J:91124
	abnormal leukopoiesis	J:91124
	conjunctivitis	J:91124
	cutaneous mastocytosis	J:91124
	decreased T cell number	J:91124
	dermatitis	J:91124
	enlarged lymph nodes	J:91124
	increased activated T cell number	J:91124
	increased B cell number	J:91124
	increased memory T cell number	J:91124
Tg(Ela1-TAg)18Bri/0 (involves: C57BL/6 * SJL)	pancreas inflammation	J:107545
Tg(Ela1-TAg)79Mjt/0 Tg(MUC1)79.24Gend/0 (involves: C57BL/6 DBA/2)	immune system phenotype	J:64570
Tg(Ela2a-Prss1,-GFP)1Dbs/0 (C57BL/6-Tg(Ela2a-Prss1,-GFP)1Dbs)	chronic pancreas inflammation	J:144663
	increased susceptibility to induced pancreatitis	J:144663
Tg(Ela-KRASG12D)9Eps/0 (involves: C57BL/6 FVB)	increased regulatory T cell number	J:231759
Tg(Ela-KRASG12D)9Eps/0 (involves: C57BL/6 FVB)	pancreas inflammation	J:231759
Tg(Ela-KRASG12D)9Eps/0 Tg(Mt1-TGFBR2)AM3Epb/0 (involves: C57BL/6 * FVB)	increased regulatory T cell number	J:231759
	pancreas inflammation	J:231759
Tg(Ela-KRASG12D)9Eps/0 Tgfbr1^tm1Bopa/Tgfbr1⁺ (involves: 129S1/SvImJ C57BL/6 * FVB)	increased CD8-positive, alpha-beta T cell number	J:231759
Tg(Emu-FGFR3)A5Wmk/0 (FVB/N-Tg(Emu-FGFR3)A5Wmk)	lymphoid hyperplasia	J:160845
Tg(Emu-FGFR3)D3Wmk/0 (FVB/N-Tg(Emu-FGFR3)D3Wmk)	lymphoid hyperplasia	J:160845
Tg(Emu-Pim1)64aBrn/0 (involves: C57BL/6LiA * CBA)	enlarged lymph nodes	J:79624
	enlarged spleen	J:79624
	enlarged thymus	J:79624
	increased T cell derived lymphoma incidence	J:79624
Tg(Emu-TXLNA)1Amjr/0 (B6.Cg-Tg(Emu-TXLNA)1Amjr)	abnormal B cell physiology	J:117018
	enhanced humoral immune response	J:145185
	enlarged spleen	J:117018
	increased autoantibody level	J:117018
	increased B cell number	J:117018
	increased B-1 B cell number	J:117018
	increased B-2 B cell number	J:117018
	increased circulating interferon-alpha level	J:117018
	increased germinal center B cell number	J:117018
	increased IgA level	J:117018
	increased IgG2a level	J:117018
	increased IgM level	J:117018
	increased immunoglobulin level	J:117018
	increased marginal zone B cell number	J:117018
	increased plasma cell number	J:117018
	increased susceptibility to autoimmune disorder	J:117018, J:145185
	interstitial pneumonia	J:145185
	kidney inflammation	J:117018
	lacrimal gland inflammation	J:145185
	lymphoid hyperplasia	J:117018
	parotid gland inflammation	J:145185
	salivary gland inflammation	J:117018, J:145185
	submandibular gland inflammation	J:145185
Tg(Emu-Zfp521)1Homy/0 (Not Specified)	abnormal B cell differentiation	J:160392
Tg(Emu-Zfp521)1Homy/0 (Not Specified)	increased B cell number	J:160392
Tg(EmuSR-HDAC9)1468Kpet/0 (involves: C57BL/6 * CBA)	abnormal lymphocyte physiology	J:237420
	abnormal spleen marginal zone morphology	J:237420
	enlarged spleen	J:237420
	increased B cell number	J:237420
	increased B cell proliferation	J:237420
Tg(EmuSR-tTa)83Bop/0 Tg(IghMyc)22Bri/0 Tg(tetO-RNAi:Trp53)ASlowe/0 (involves: C57BL * C57BL/6 * FVB/N * SJL)	enlarged spleen	J:123006
Tg(EmuSR-tTa)83Bop/Tg(EmuSR-tTa)83Bop Tg(tetO-NPM1/ALK,-luc)2Gde/0 (involves: FVB/N)	enlarged lymph nodes	J:160236
	enlarged spleen	J:160236
Tg(EmuSR-tTa)83Bop/Tg(EmuSR-tTa)83Bop Tg(tetO-TPM3/ALK,-luc)2Gde/0 (involves: FVB/N)	enlarged lymph nodes	J:160236
	enlarged spleen	J:160236
Tg(Eno2-Hgf)1Tnak/0 Tg(SOD1G93A)^dl1Gur/0 (involves: C57BL/6 C57BL/6J * SJL/J)	microgliosis	J:128738
Tg(Eno2-Hmox1)2Main/Tg(Eno2-Hmox1)2Main (involves: C57BL/6J)	enlarged spleen	J:120240
Tg(EPO33)72Ptc/0 (involves: C57BL/6J * SJL/J)	enlarged spleen	J:92650
Tg(F2RL1)1Mslb/0 (involves: FVB/NCrl)	increased inflammatory response	J:79757
Tg(F2RL1)1Mslb/0 (involves: FVB/NCrl)	respiratory system inflammation	J:79757
Tg(Fabp1-cre)1Jig/0 Vhl^tm1Jae/Vhl^tm1Jae (involves: 129S4/SvJae * BALB/c * FVB/N)	decreased susceptibility to induced colitis	J:93476
Tg(Fabp2-Arg1)1Wla/Tg(Fabp2-Arg1)1Wla (involves: FVB)	abnormal B cell differentiation	J:80204
	abnormal Peyer's patch morphology	J:80204, J:80556
	decreased B cell number	J:80204
	decreased IgM level	J:80204
	decreased Peyer's patch number	J:80556
	decreased pre-B cell number	J:80204
	decreased spleen B cell follicle number	J:80204
	decreased spleen weight	J:80556
	decreased transitional stage B cell number	J:80204
	small Peyer's patches	J:80556
	small spleen	J:80204
Tg(Fabp4-Angptl2)5Yo/0 (involves: C57BL/6)	abnormal macrophage chemotaxis	J:152387
	chronic inflammation	J:152387
	white adipose tissue inflammation	J:152387
Tg(Fabp4-Apol6)#Hsul/0 (C57BL/6J-Tg(Fabp4-Apol6)#Hsul)	white adipose tissue inflammation	J:344362
Tg(Fabp4-Phb*Y114F)#Smis/0 (Not Specified)	abnormal circulating chemokine level	J:227976
	abnormal circulating cytokine level	J:227976
	abnormal lymph node morphology	J:227976
	abnormal spleen morphology	J:227976
	enlarged lymph nodes	J:227976
	enlarged spleen	J:227976
	increased lymphocyte cell number	J:227976
Tg(FCGR2A)11Mkz/0 Tg(PF4)#Zcy/0 (involves: C57BL/6 * SJL)	increased acute inflammation	J:72220
Tg(FCGR2A)11Mkz/Tg(FCGR2A)11Mkz (involves: C57BL/6 * SJL)	abnormal macrophage physiology	J:136516
	autoimmune arthritis	J:136516
	glomerulonephritis	J:136516
	increased anti-histone antibody level	J:136516
	increased IgG2a level	J:136516
	increased susceptibility to induced arthritis	J:136516
	increased synovial pannus formation	J:136516
	increased tumor necrosis factor secretion	J:136516
	interstitial pneumonia	J:136516
Tg(Fga,Fgb,Fgg)1Unc/? (C57BL/6-Tg(Fga,Fgb,Fgg)1Unc)	increased circulating fibrinogen level	J:118353
Tg(Fli1)1Ber/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1)	increased thymocyte number	J:33052
Tg(FOXJ1-ACE2)1Rba/0 (involves: C3H * C57BL/6)	decreased lymphocyte cell number	J:288386
	increased susceptibility to Coronaviridae infection	J:287092, J:288386
	increased susceptibility to Coronaviridae infection induced morbidity/mortality	J:287092, J:288386
	interstitial pneumonia	J:288386
Tg(Foxp3-HBEGF/EGFP)23.2Spar/0 (involves: C57BL/6NCrl)	decreased regulatory T cell number	J:125295
	enlarged lymph nodes	J:125295
	enlarged spleen	J:125295
	immune system phenotype	J:125295
	increased inflammatory response	J:125295
	increased spleen red pulp amount	J:125295
	increased spleen white pulp amount	J:125295
	increased susceptibility to type IV hypersensitivity reaction	J:125295
	insulitis	J:125295
	lung inflammation	J:125295
	lymph node hyperplasia	J:125295
	skin inflammation	J:125295
Tg(Gfap-gp120)2Lms/0 (involves: C57BL/6 * SJL)	abnormal microglial cell morphology	J:146427
Tg(Gfap-gp120)2Lms/0 (involves: C57BL/6 * SJL)	microgliosis	J:146427
Tg(Gfap-gp120)10Lms/0 (involves: C57BL/6 * SJL)	microgliosis	J:146427
Tg(Gfap-Ifna1)12Ilc/0 (involves: BALB/c * C57BL/6J)	CNS inflammation	J:68811
	decreased susceptibility to Riboviria infection	J:68811
	decreased susceptibility to Riboviria infection induced morbidity/mortality	J:68811
	meningoencephalitis	J:68811
Tg(Gfap-Ifna1)39Ilc/0 (involves: BALB/c * C57BL/6J)	CNS inflammation	J:68811
Tg(Gfap-Ifna1)39Ilc/0 (involves: BALB/c * C57BL/6J)	meningoencephalitis	J:68811
Tg(Gfap-Il6)G16Lms/0 Tg(Gfap-lacZ)1Lms/0 (involves: C57BL/6J * SJL)	immune system phenotype	J:125549
Tg(Gfap-Il6)G369Lms/0 (involves: C57BL/6J * SJL)	immune system phenotype	J:125549
Tg(Gfap-rtTA,tetO-MAOB,-lacZ)1Jkan/0 (involves: C57BL/6)	abnormal microglial cell activation	J:132679
Tg(Gfap-rtTA,tetO-MAOB,-lacZ)1Jkan/0 (involves: C57BL/6)	abnormal microglial cell morphology	J:132679
Tg(Gfap-TGFB1)64Lms/0 (involves: BALB/c * SJL)	immune system phenotype	J:27781
Tg(Gfap-TGFB1)64Lms/Tg(Gfap-TGFB1)64Lms (involves: BALB/c * SJL)	immune system phenotype	J:27781
Tg(Gfap-TK)7.1Mvs/0 (involves: C57BL/10 * CBA * CFLP)	abnormal inflammatory response	J:104241
	brain inflammation	J:113202
	increased neutrophil cell number	J:104241
	small intestinal inflammation	J:104241
Tg(Gfap-TNF)K21Gkl/0 (involves: C57BL/6 CBA)	CNS inflammation	J:106592
Tg(GFAP-tTA)78Pop/0 Tg(tetO-Ifng)184Pop/0 (B6.Cg-Tg(GFAP-tTA)78Pop Tg(tetO-Ifng)184Pop)	abnormal interferon-gamma secretion	J:109838
	CNS inflammation	J:109838
Tg(GNB1L,TBX1,GP1BB,SEPT5)23Bem/0 (either: FVB-Tg(GNB1L,TBX1,GP1BB,SEPT5)23Bem or (involves: C57BL/6 * FVB))	abnormal thymus development	J:67796
	abnormal thymus lobule morphology	J:67796
	decreased thymocyte number	J:67796
	thymus hypoplasia	J:67796
Tg(H2-Aa)26Dim/? Tg(H2-Ab1)62Dim/? (B6.Cg-Tg(H2-Aa)26Dim Tg(H2-Ab1)62Dim)	abnormal antigen presentation via MHC class II	J:110897
	abnormal level of surface class II molecules	J:110897
	immune system phenotype	J:110897
	increased immunoglobulin level	J:110897
Tg(H2-Aa)26Dim/? Tg(H2-Ab1)62Dim/? (SJL.Cg-Tg(H2-Aa)26Dim Tg(H2-Ab1)62Dim)	abnormal level of surface class II molecules	J:110897
	immune system phenotype	J:110897
Tg(H2-D-Il15)3304Clgr/? (FVB/N-Tg(H2-D-Il15)3304Clgr)	abnormal inflammatory response	J:67478
	abnormal lymphocyte physiology	J:67478
	abnormal T cell morphology	J:67478
	abnormal T cell subpopulation ratio	J:67478
	dermatitis	J:67478
	enlarged lymph nodes	J:67478
	enlarged spleen	J:67478
	increased lymphocyte cell number	J:67478
	increased memory T cell number	J:67478
	increased NK cell number	J:67478
	increased spleen white pulp amount	J:67478
Tg(H2-D^b)2Bujf/0 (FVB/NPas-Tg(H2-D^b)2Bujf)	decreased susceptibility to Picornaviridae infection	J:18556
Tg(H2-Ea)16Dim/? (involves: C57BL/6 * SJL)	increased immunoglobulin level	J:111128
Tg(H2-Ea-G6pc2)69Tkay/? (NOD-Tg(H2-Ea-G6pc2)69Tkay)	abnormal CD4-positive, alpha-beta T cell physiology	J:117352
	abnormal CD8-positive, alpha beta T cell morphology	J:117352
	abnormal immune tolerance	J:117352
	decreased T cell proliferation	J:117352
	increased anti-insulin autoantibody level	J:117352
	increased susceptibility to autoimmune diabetes	J:117352
	insulitis	J:117352
Tg(H2-Ea-HA)HACIIAjca/0 Tg(Tcra/Tcrb)1Vbo/0 (C.Cg-Tg(H2-Ea-HA)HACIIAjca Tg(Tcra/Tcrb)1Vbo)	abnormal CD4-positive, alpha beta T cell morphology	J:209872
	abnormal circulating cytokine level	J:209872
	autoimmune arthritis	J:209872
	heart inflammation	J:209872
	increased circulating interleukin-6 level	J:209872
	increased IgG level	J:209872
	joint inflammation	J:209872
	kidney inflammation	J:209872
Tg(H2-Ea-HA)HACIIAjca/0 Tg(TcraS106-1,TcrbS106-1)TS1SWAjca/0 (C.Cg-Tg(H2-Ea-HA)HACIIAjca Tg(TcraS106-1,TcrbS106-1)TS1SWAjca)	abnormal CD4-positive, alpha beta T cell morphology	J:209872
	abnormal CD4-positive, alpha-beta T cell physiology	J:209872
	abnormal circulating cytokine level	J:209872
	autoimmune arthritis	J:209872
	decreased circulating interleukin-6 level	J:209872
	enlarged lymph nodes	J:209872
	immune system phenotype	J:209872
	increased circulating interleukin-17 level	J:209872
	increased IgG level	J:209872
	joint inflammation	J:209872
Tg(H2-Ea-Il7)10Rhdr/0 (involves: C57BL/6)	abnormal B cell morphology	J:81133
Tg(H2-Ea-Il7)10Rhdr/0 (involves: C57BL/6)	abnormal double-negative T cell morphology	J:81133
Tg(H2-Ea-Il7)10Rhdr/0 (involves: C57BL/6 * DBA/2)	increased pre-B cell number	J:171924
Tg(H2-Ea-Il7)10Rhdr/0 (involves: C57BL/6 * DBA/2)	increased pro-B cell number	J:171924
Tg(H2-Ea-Ins2)1Wehi/0 (NOD/ShiLtJWehi-Tg(H2-Ea-Ins2)1Wehi)	abnormal T cell proliferation	J:100232
	immune system phenotype	J:100232
	salivary gland inflammation	J:100232
Tg(H2-Ea-Ins2)1Wehi/Tg(H2-Ea-Ins2)1Wehi (NOD/ShiLtJWehi-Tg(H2-Ea-Ins2)1Wehi)	abnormal CD8-positive, alpha beta T cell morphology	J:117352
	decreased anti-insulin autoantibody level	J:117352
	decreased T cell proliferation	J:117352
	immune system phenotype	J:117352
Tg(H2-Ea-LACK)1Ngkh/0 (C.Cg-Tg(H2-Ea-LACK)1Ngkh)	abnormal immune system physiology	J:181384
	abnormal T-helper 1 physiology	J:181384
	abnormal T-helper 2 physiology	J:181384
	decreased susceptibility to parasitic infection	J:181384
	decreased susceptibility to parasitic infection induced morbidity/mortality	J:181384
	decreased T-helper 2 cell number	J:181384
	increased T-helper 1 cell number	J:181384
Tg(H2-Ea-Tnfsf9)16Lpc/0 (involves: C57BL/6)	abnormal B cell physiology	J:132372
	abnormal lymph node B cell domain morphology	J:132372
	decreased B cell number	J:132372
	decreased IgG level	J:132372
	decreased spleen B cell follicle number	J:132372
	enlarged spleen	J:132372
	increased granulocyte number	J:132372
	increased lymphocyte cell number	J:132372
	increased macrophage cell number	J:132372
	increased memory T cell number	J:145439
	increased NK cell number	J:132372
	spleen hyperplasia	J:132372
Tg(H2-Ea^d)5Lt/0 (NOD/ShiLt-Tg(H2-Ea^d)5Lt)	autoimmune response	J:36435
	decreased interferon-gamma secretion	J:36435
	decreased susceptibility to autoimmune diabetes	J:36435
	increased interleukin-4 secretion	J:36435
	periinsulitis	J:36435
Tg(H2-Ea^d)12Lt/0 (NOD/ShiLt-Tg(H2-Ea^d)12Lt)	autoimmune response	J:36435
	decreased interferon-gamma secretion	J:36435
	decreased susceptibility to autoimmune diabetes	J:36435
	increased interleukin-4 secretion	J:36435
	insulitis	J:36435
Tg(H2-K1-HLA-A)28Mpla/0 (B10.Cg-Tg(H2-K1-HLA-A)28Mpla)	choroid inflammation	J:67871
Tg(H2-K1-HLA-A)28Mpla/0 (B10.Cg-Tg(H2-K1-HLA-A)28Mpla)	eye inflammation	J:67871
Tg(H2-K-BCL2)1Josd/0 (involves: C57BL/6 * C57BL/Ka * C3H)	abnormal lymph organ size	J:80894
	enlarged lymph nodes	J:80894
	enlarged spleen	J:80894
	enlarged thymus	J:80894
	increased leukocyte cell number	J:80894
Tg(H2-K-Cd86)7All/0 (involves: C57BL/6J * CBA)	abnormal B cell differentiation	J:112475
	decreased B cell number	J:112475
	increased CD4-positive, alpha-beta T cell number	J:112475
	increased CD8-positive, alpha-beta T cell number	J:112475
Tg(H2-K-Cd86)7All/0 (B6.Cg-Tg(H2-K-Cd86)7All)	abnormal inflammatory response	J:112266
	decreased B cell number	J:112266
	decreased CD4-positive, alpha-beta T cell number	J:112266
	increased CD8-positive, alpha-beta T cell number	J:112266
	increased T cell number	J:112266
	lymph node hyperplasia	J:112266
	lymphoid hyperplasia	J:112266
Tg(H2-K-Cd86)7All/0 (involves: BALB/c * C57BL/6 * CBA)	increased splenocyte number	J:112266
	lymph node hyperplasia	J:112266
	spleen hyperplasia	J:112266
Tg(H2-K-Cd86)27All/0 (involves: C57BL/6J * CBA)	abnormal B cell differentiation	J:112475
Tg(H2-K-Cd86)27All/0 (involves: C57BL/6J * CBA)	decreased B cell number	J:112475
Tg(H2-K-Cd86)31All/0 (involves: C57BL/6J * CBA)	increased CD4-positive, alpha-beta T cell number	J:112475
Tg(H2-K-Cd86)31All/0 (involves: C57BL/6J * CBA)	increased CD8-positive, alpha-beta T cell number	J:112475
Tg(H2-K-DUSP5)21Wjl/0 (involves: C57BL/6J * CBA)	abnormal T cell number	J:138077
	decreased single-positive T cell number	J:138077
	decreased T cell proliferation	J:138077
	dermatitis	J:138077
	increased CD4-positive, alpha-beta T cell number	J:138077
	increased CD8-positive, alpha-beta T cell number	J:138077
	increased double-positive T cell number	J:138077
	increased plasma cell number	J:138077
	increased single-positive T cell number	J:138077
	skin inflammation	J:138077
Tg(H2-K-Fosl1)1Wag/0 (involves: C57BL/6 * CBA)	enlarged spleen	J:64494
Tg(H2-K-Fosl2,-EGFP)13Wag/0 (either: 129.Cg-Tg(H2-K-Fosl2,-EGFP)13Wag or B6.Cg-Tg(H2-K-Fosl2,-EGFP)13Wag)	thymus fibrosis	J:139032
Tg(H2-K-Fosl2,-EGFP)13Wag/0 (B6.Cg-Tg(H2-K-Fosl2,-EGFP)13Wag)	lung inflammation	J:238723
Tg(H2-K-HLA-G,B2M)1Alm/0 (CBA/Ca-Tg(H2-K-HLA-G,B2M)1Alm/CmwJ)	abnormal cytotoxic T cell physiology	J:140016
	increased T cell proliferation	J:140016
Tg(H2-K-Hmga1)#Lmsr/0 (involves: C57BL/6 * SJL)	increased leukocyte cell number	J:90252
Tg(H2-K-IL6)2Srj/0 (B6.Cg-Tg(H2-K-IL6)2Srj)	abnormal granulocyte morphology	J:185153
	abnormal lymph node germinal center morphology	J:185153
	abnormal lymph node morphology	J:185153
	abnormal spleen germinal center morphology	J:185153
	abnormal spleen red pulp morphology	J:185153
	enlarged lymph nodes	J:185153
	enlarged spleen	J:185153
	increased IgG level	J:185153
	increased plasma cell number	J:185153
Tg(H2-K-MC159/EGFP)13Fkmc/0 (involves: C57BL/6)	abnormal lymphopoiesis	J:138050
	decreased B cell apoptosis	J:138050
	decreased T cell apoptosis	J:138050
	enlarged spleen	J:138050
	immune system phenotype	J:138050
	increased B cell proliferation	J:138050
	increased follicular B cell number	J:138050
Tg(H2-K-MC159/EGFP)13Fkmc/Tg(H2-K-MC159/EGFP)13Fkmc (involves: C57BL/6)	increased anti-double stranded DNA antibody level	J:138050
	increased double-negative T cell number	J:138050
	increased IgG2b level	J:138050
	increased T cell number	J:138050
Tg(H2-K-TcrbP14)128Mak/? (involves: C57BL/6 * C57L * DBA/2)	abnormal CD8-positive, alpha-beta T cell differentiation	J:111265
	abnormal T cell clonal deletion	J:111265
	abnormal T cell differentiation	J:111265
	increased CD8-positive, alpha-beta T cell number	J:111265
Tg(H2-K^b-IL21)5Wjl/0 (involves: 129)	abnormal B cell differentiation	J:93740
	abnormal class switch recombination	J:93740
	decreased follicular B cell number	J:93740
	decreased marginal zone B cell number	J:93740
	decreased mature B cell number	J:93740
	decreased transitional stage T2 B cell number	J:93740
	increased B cell apoptosis	J:93740
	increased IgG1 level	J:93740
	increased IgM level	J:93740
	increased immature B cell number	J:93740
	increased transitional stage T1 B cell number	J:93740
Tg(H2-K^b-Jak2V617F)2Shmd/0 (involves: C57BL/6 DBA/2)	abnormal spleen morphology	J:130189
	enlarged spleen	J:130189
	increased leukocyte cell number	J:130189
	increased neutrophil cell number	J:130189
	increased spleen red pulp amount	J:130189
	increased spleen weight	J:130189
	myeloid hyperplasia	J:130189
	spleen fibrosis	J:130189
Tg(H2-K^b-Tcra,-Tcrb)1640Kurs/0 (SJL.FVB-Tg(H2-K^b-Tcra,-Tcrb)1640Kurs)	abnormal cytokine level	J:149511
	brain inflammation	J:149511
	CNS inflammation	J:149511
	increased autoantibody level	J:149511
	increased susceptibility to experimental autoimmune encephalomyelitis	J:149511
	increased T-helper 1 cell number	J:149511
	increased T-helper 17 cell number	J:149511
Tg(H2-L-IL6)1Kish/Tg(H2-L-IL6)1Kish (C57BL/6-Tg(H2-L-IL6)1Kish)	abnormal myelopoiesis	J:128016
	enlarged lymph nodes	J:128016, J:138762
	enlarged spleen	J:128016, J:138762
	glomerulonephritis	J:128016, J:138762
	increased IgG1 level	J:128016
	increased monocyte cell number	J:128016
	increased neutrophil cell number	J:128016
	increased plasma cell number	J:128016, J:138762
Tg(H2-L-IL6)40Csk/0 (involves: C57BL/6)	enlarged lymph nodes	J:207264
	enlarged spleen	J:207264
	increased spleen weight	J:207264
Tg(H2-L-IL6)46Kish/Tg(H2-L-IL6)46Kish (C57BL/6-Tg(H2-L-IL6)46Kish)	enlarged axillary lymph nodes	J:40405
	enlarged mesenteric lymph nodes	J:40405
	glomerulonephritis	J:40405
	increased immunoglobulin level	J:40405
	increased plasma cell number	J:40405
Tg(H2-L-IL6)46Kish/Tg(H2-L-IL6)46Kish (involves: BALB/c * C57BL/6)	abnormal immune system organ morphology	J:40405
	abnormal lymph node morphology	J:40405
	enlarged mesenteric lymph nodes	J:40405
	increased IgA level	J:40405
	increased immunoglobulin level	J:40405
Tg(H2-L-IL6)46Kish/Tg(H2-L-IL6)46Kish (C.B6-Tg(H2-L-IL6)46Kish)	abnormal spleen trabecular artery morphology	J:177820
	abnormal spleen trabecular vein morphology	J:177820
	enlarged spleen	J:177820
	increased IgG1 level	J:74377
	increased IgG2b level	J:74377
	increased IgG level	J:74377
Tg(H2-L^d)LoxNibl/0 (C57BL/6-Tg(H2-L^d)LoxNibl)	decreased susceptibility to parasitic infection induced morbidity/mortality	J:284394
Tg(H2-L^d)LoxNibl/0 (C57BL/6-Tg(H2-L^d)LoxNibl)	increased response to antigen	J:284394
Tg(H2KePCC)2403Stoe/? (involves: C57BL/6 * SJL)	abnormal immune tolerance	J:92997
Tg(H2KePCC)2403Stoe/? Tg(TcraTcrbAD10)1Hed/? (involves: C57BL/6 * SJL)	abnormal immune tolerance	J:92997
	abnormal T cell anergy	J:92997
	decreased CD4-positive, alpha-beta T cell number	J:92997
Tg(H2KmPCC)2939Stoe/? (involves: C57BL/6 * SJL)	abnormal immune tolerance	J:92997
Tg(H2KmPCC)2939Stoe/0 Tg(Tcra2B4)1Mmd/0 Tg(Tcrb2B4)1Mmd/0 (involves: C3H/HeJ * C57BL/6 * SJL)	abnormal T cell differentiation	J:50143
	decreased T cell proliferation	J:50143
	decreased thymocyte number	J:50143
Tg(H2KmPCC)2939Stoe/? Tg(TcrAND)53Hed/? (involves: C57BL/6 * SJL)	abnormal immune tolerance	J:92997
	abnormal T cell anergy	J:92997
	decreased CD4-positive, alpha-beta T cell number	J:92997
Tg(H2KmPCC)2939Stoe/? Tg(TcraTcrbAD10)1Hed/? (involves: C57BL/6 * SJL)	abnormal immune tolerance	J:92997
	abnormal T cell anergy	J:92997
	decreased CD4-positive, alpha-beta T cell number	J:92997
Tg(HBB-Myc)#Cos/0 (involves: C57BL/6J * CBA/J)	abnormal immune system organ morphology	J:276641
Tg(HBB-Myc)#Cos/0 (involves: C57BL/6J * CBA/J)	kidney inflammation	J:276641
Tg(HBV)10Imeg/0 (involves: C57BL/6)	abnormal cytokine secretion	J:95283
Tg(HBV)10Imeg/0 (involves: C57BL/6)	abnormal dendritic cell physiology	J:95283
Tg(HBVX,-Myc)#Skp/Tg(HBVX,-Myc)#Skp (Not Specified)	increased macrophage cell number	J:81098
Tg(HCRT-tTA)1Ahky/0 Tg(tetO-DTA)1Gfi/0 (B6.Cg-Tg(HCRT-tTA)1Ahky Tg(tetO-DTA)1Gfi)	increased microglial cell activation	J:211045
Tg(HIV)26Aln/0 (involves: FVB/N)	kidney inflammation	J:90297
	myositis	J:90297
	uveitis	J:136652
Tg(HLA-A2/H2-K)1Scr/? (involves: C57BL/6)	abnormal cytotoxic T cell physiology	J:127813
Tg(HLA-A/H2-D/B2M)1Dvs/0 (NOD/ShiLtDvs-Tg(HLA-A/H2-D/B2M)1Dvs)	increased susceptibility to autoimmune diabetes	J:121685
Tg(HLA-B27)1Trg/0 (involves: C57BL/6 * SJL/J)	immune system phenotype	J:74451
Tg(HLA-B27)30-4Trg/? (involves: C57BL/6J * NOD)	decreased susceptibility to autoimmune diabetes	J:109851
Tg(HLA-DQA1,HLA-DQB1)1Dv/0 Tg(Ins2-CD80)3B7Flv/0 (B6.Cg-Tg(HLA-DQA1,HLA-DQB1)1Dv Tg(Ins2-CD80)3B7Flv)	decreased susceptibility to autoimmune diabetes	J:59245
Tg(HLA-DR2)#Lfug/0 Tg(TCROb.1A12)#Lfug/0 (involves: C57BL/6 * DBA/2)	CNS inflammation	J:134764
	increased susceptibility to experimental autoimmune encephalomyelitis	J:134764
Tg(HLA-DRA0101,HLA-DRB10101)1Dmz/Tg(HLA-DRA0101,HLA-DRB10101)1Dmz (involves: C57BL/6 * C57BL/10Sn * SJL/J)	abnormal T cell physiology	J:108635
	increased autoantibody level	J:108635
	increased susceptibility to induced arthritis	J:108635
Tg(Hmgcr-MX1)LStae/Tg(Hmgcr-MX1)LStae (involves: 129S2/SvPas * BALB/c * C57BL/6 * SJL)	decreased susceptibility to Orthomyxoviridae infection	J:119783
	decreased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:119783
Tg(HTT*)NXwy/0 (involves: FVB/NJ)	CNS inflammation	J:219890
Tg(ICAM1)4Grom/? (involves: BALB/cAnNTac)	increased susceptibility to Picornaviridae infection	J:92607
Tg(Igh3H9)41Mwg/? (involves: C57BL/6 * SJL)	abnormal B cell differentiation	J:119625
	decreased IgD level	J:119625
	increased anti-single stranded DNA antibody level	J:119625
Tg(Igh*-Mir125b-1)5Toki/0 (Not Specified)	enlarged spleen	J:178816
Tg(Igh*-Mir125b-1)116Toki/0 (Not Specified)	decreased B cell apoptosis	J:178816
	enlarged spleen	J:178816
	increased B cell number	J:178816
	increased T cell derived lymphoma incidence	J:178816
Tg(Igh-3/Igh-6VD93)1241Ust/? (C57BL/6-Tg(Igh-3/Igh-6VD93)1241Ust)	abnormal B cell morphology	J:135209
	decreased pre-B cell number	J:135209
Tg(Igh-3VD93)343Ust/? (involves: C57BL/6 * SJL)	abnormal B cell morphology	J:135209
Tg(Igh-3VD93)343Ust/? (involves: C57BL/6 * SJL)	decreased pre-B cell number	J:135209
Tg(Igh-6-Cd80)1Gjf/0 (involves: FVB)	abnormal CD4-positive, alpha-beta T cell physiology	J:44271
	abnormal humoral immune response	J:112474
	abnormal T cell activation	J:44271
	decreased B cell number	J:44271
	decreased immunoglobulin level	J:112474
Tg(Igh-6-Cd80)1Gjf/0 (B6.Cg-Tg(Igh-6-Cd80)1Gjf)	abnormal T cell number	J:112266
Tg(Igh-6-Cd80)1Gjf/0 (NOD.FVB-Tg(Igh-6-Cd80)1Gjf/JbsJ)	abnormal B cell activation	J:131077
	abnormal CD8-positive, alpha-beta T cell physiology	J:131077
	abnormal level of surface class II molecules	J:131077
	decreased B cell number	J:131077
	decreased B-2 B cell number	J:131077
	decreased follicular B cell number	J:131077
	decreased IgG1 level	J:131077
	decreased IgG2b level	J:131077
	decreased IgG3 level	J:131077
	decreased IgM level	J:131077
	decreased immature B cell number	J:131077
	decreased immunoglobulin level	J:131077
	decreased mature B cell number	J:131077
	decreased susceptibility to autoimmune diabetes	J:131077
	insulitis	J:131077
Tg(Igh-6-Cd86)1Akab/0 (involves: FVB)	abnormal CD4-positive, alpha-beta T cell physiology	J:44271
Tg(Igh-6-Cd86)1Akab/0 (involves: FVB)	decreased B cell number	J:44271
Tg(Igh-6/Igh-V125)2Jwt/0 Tg(Igk-C/Igk-V125)1Jwt/0 (NOD.B6-Tg(Igh-6/Igh-V125)2Jwt Tg(Igk-C/Igk-V125)1Jwt)	abnormal B cell number	J:91865
	increased susceptibility to autoimmune diabetes	J:91865
	insulitis	J:91865
Tg(Igh-6/Igh-V281)3Jwt/0 (NOD.B6-Tg(Igh-6/Igh-V281)3Jwt)	decreased susceptibility to autoimmune diabetes	J:91865
Tg(Igh-6/Igh-V281)3Jwt/0 (NOD.B6-Tg(Igh-6/Igh-V281)3Jwt)	insulitis	J:91865
Tg(Igh-Abl1)40Sco/0 (involves: C57BL/6JWehi * SJL/JWehi)	abnormal peripheral lymph node morphology	J:78204
	enlarged mesenteric lymph nodes	J:78204
	enlarged spleen	J:78204
Tg(Igh-Abl1)40Sco/0 Tg(IghMyc)22Bri/0 (involves: C57BL/6 * C57BL/6JWehi * SJL/J * SJL/JWehi)	enlarged mesenteric lymph nodes	J:78204
Tg(Igh-HMGA2)#Cro/0 (FVB/N-Tg(Igh-HMGA2)#Cro)	abnormal splenic cell ratio	J:233225
	decreased B cell number	J:233225
	decreased IgG1 level	J:233225
	decreased IgG2a level	J:233225
	decreased IgG2b level	J:233225
	decreased IgG3 level	J:233225
	decreased response to antigen	J:233225
	decreased T cell number	J:233225
	enlarged lymph nodes	J:233225
	enlarged spleen	J:233225
	increased circulating interleukin-6 level	J:233225
	increased circulating tumor necrosis factor level	J:233225
	increased T cell number	J:233225
Tg(Igh-HOX11)11Idd/0 (CD-1)	abnormal immunoglobulin V(D)J recombination	J:52782
	increased leukocyte cell number	J:52782
	myeloid hyperplasia	J:52782
	spleen hyperplasia	J:52782
Tg(Igh-Lmp2a)ERlon/0 (involves: C57BL/6 * SJL)	abnormal B cell proliferation	J:129571
Tg(Igh-Lmp2a)ERlon/0 (involves: C57BL/6 * SJL)	decreased B cell number	J:129571
Tg(Igh-Maf)68Staka/0 (C57BL/6-Tg(Igh-Maf)68Staka)	abnormal spleen morphology	J:168074
	enlarged spleen	J:168074
	increased IgG level	J:168074
	increased IgM level	J:168074
	increased immunoglobulin level	J:168074
	increased plasma cell number	J:168074
Tg(Igh-Maf)524Staka/0 (involves: C57BL/6 * C57BL/6J * DBA/2)	abnormal spleen morphology	J:168074
	enlarged spleen	J:168074
	increased IgG level	J:168074
	increased IgM level	J:168074
	increased immunoglobulin level	J:168074
	increased plasma cell number	J:168074
Tg(Igh-Mir29a,-Mir29b-1,-hrGFP)#Cro/0 (FVB/N-Tg(Igh-Mir29a,-Mir29b-1,-hrGFP)#Cro)	abnormal B cell physiology	J:162077
	abnormal lymphopoiesis	J:162077
	abnormal spleen morphology	J:162077
	decreased IgG1 level	J:162077
	decreased IgG2a level	J:162077
	decreased IgG2b level	J:162077
	enlarged spleen	J:162077
	increased B cell proliferation	J:162077
	increased B-1a cell number	J:162077
	spleen hyperplasia	J:162077
Tg(Igh-Mir29a,-Mir29b-1,-hrGFP)#Cro/0 Tg(Igh-V186.2-TCL1A)3Cro/0 (involves: C3H * C57BL/6 * FVB/N)	increased B-1a cell number	J:162077
	spleen hyperplasia	J:162077
Tg(Igh-Mir155)8Cro/0 (involves: FVB/N)	abnormal lymphopoiesis	J:109591
	abnormal spleen B cell follicle morphology	J:109591
	decreased leukocyte cell number	J:109591
	decreased spleen white pulp amount	J:109591
	enlarged spleen	J:109591
	increased B cell number	J:109591
	increased B cell proliferation	J:109591
	increased lymphoblastic lymphoma incidence	J:109591
	increased pre-B cell number	J:109591
	increased spleen white pulp amount	J:109591
	intermingled spleen red and white pulp	J:109591
Tg(Igh-Mir155)10Cro/0 (involves: FVB/N)	enlarged spleen	J:109591
Tg(Igh-Mir210)#aKgcs/Tg(Igh-Mir210)#aKgcs (B6.Cg-Tg(Igh-Mir210)#aKgcs)	abnormal class switch recombination	J:205868
	abnormal spleen marginal zone morphology	J:205868
	decreased IgA level	J:205868
	decreased IgG1 level	J:205868
	decreased IgG2a level	J:205868
	decreased IgG2b level	J:205868
	decreased IgG3 level	J:205868
	decreased marginal zone B cell number	J:205868
	decreased mature B cell number	J:205868
	decreased pre-B cell number	J:205868
	decreased pro-B cell number	J:205868
	immune system phenotype	J:205868
	increased B-1a cell number	J:205868
Tg(Igh-Nfil3)#Kubo/0 (B6.Cg-Tg(Igh-Nfil3)#Kubo)	increased interleukin-3 secretion	J:172134
	increased interleukin-10 secretion	J:172134
	increased interleukin-13 secretion	J:172134
Tg(Igh-Pim1)1Brn/0 (involves: C57BL/6LiA * CBA)	enlarged lymph nodes	J:79624
	enlarged spleen	J:79624
	enlarged thymus	J:79624
	increased T cell derived lymphoma incidence	J:79624
Tg(Igh-ROR1)1Kip/0 (C57BL/6-Tg(Igh-ROR1)1Kip)	enlarged spleen	J:206368
	increased lymphocyte cell number	J:206368
	increased mature B cell number	J:206368
Tg(Igh-ROR1)1Kip/0 Tg(Igh-V186.2-TCL1A)3Cro/0 (B6.Cg-Tg(Igh-ROR1)1Kip Tg(Igh-V186.2-TCL1A)3Cro)	enlarged spleen	J:206368
	increased lymphocyte cell number	J:206368
	increased mature B cell number	J:206368
Tg(Igh-TCL1A)1Ypek/0 (FVB/N-Tg(Igh-TCL1A)1Ypek)	abnormal circulating chemokine level	J:160184
	abnormal humoral immune response	J:160184
	abnormal lymphocyte physiology	J:160184
	decreased IgG1 level	J:160184
	decreased IgG2a level	J:160184
	decreased IgG2b level	J:160184
	decreased IgG3 level	J:160184
	decreased IgM level	J:160184
	enlarged spleen	J:160184
	increased circulating tumor necrosis factor level	J:160184
Tg(Igh-V186.2-TCL1A)3Cro/0 (involves: C3H * C57BL/6)	abnormal B cell morphology	J:76574
	increased marginal zone B cell number	J:76574
	peritoneal inflammation	J:76574
	spleen hyperplasia	J:76574
Tg(Igh-V-CD40lg)#Tsub/0 (C57BL/6-Tg(Igh-V-CD40lg)#Tsub)	glomerulonephritis	J:128824
	increased anti-double stranded DNA antibody level	J:128824
	increased anti-histone antibody level	J:128824
	increased anti-single stranded DNA antibody level	J:128824
Tg(Igh-V-CD40lg)#Tsub/0 (involves: C57BL/6)	abnormal bronchus-associated lymphoid tissue morphology	J:89855
	colitis	J:89855
	enlarged lymph nodes	J:89855
	enlarged spleen	J:89855
	glomerulonephritis	J:89855
	increased autoantibody level	J:89855
	increased IgG level	J:89855
	increased IgM level	J:89855
	increased interferon-gamma secretion	J:89855
	increased splenocyte number	J:89855
	increased splenocyte proliferation	J:89855
Tg(IGH@)SALed/0 (involves: C57BL/6 CD-1)	abnormal mature B cell morphology	J:131938
Tg(IGH@yH1)2BJkbv/0 (involves: 129P2/OlaHsd)	abnormal B cell morphology	J:23827
	abnormal immunoglobulin heavy chain V(D)J recombination	J:23827
	abnormal immunoglobulin level	J:23827
Tg(IGH@yH1)2BJkbv/0 Tg(IGK@yK1)9.2CJkbv/0 (involves: 129P2/OlaHsd)	abnormal B cell morphology	J:23827
	abnormal immunoglobulin level	J:23827
Tg(IghelMD4)4Ccg/0 (involves: C3H/HeJ * C57BL/6)	decreased pre-B cell number	J:115059
Tg(IghelMD4)4Ccg/0 (involves: C3H/HeJ * C57BL/6)	decreased pro-B cell number	J:115059
Tg(IghelMD4)4Ccg/0 (involves: C57BL/6)	abnormal B cell activation	J:73608
	decreased pre-B cell number	J:115059
	decreased pro-B cell number	J:115059
Tg(IghelMD4)4Ccg/0 (C57BL/6-Tg(IghelMD4)4Ccg)	abnormal B cell morphology	J:78308, J:109923, J:132538
	abnormal B-2 B cell morphology	J:132538
	abnormal germinal center B cell morphology	J:109923
	abnormal immature B cell morphology	J:109923
	abnormal mature B cell morphology	J:89156, J:109923
	abnormal plasma cell morphology	J:109923
	abnormal pro-B cell morphology	J:109923
	increased IgG2b level	J:132538
	increased IgM level	J:78308, J:132538
	increased immature B cell number	J:78308, J:132538
Tg(IghelMD4)4Ccg/0 Tg(KLK4mHEL)6Ccg/0 (NOD.B6-Tg(IghelMD4)4Ccg Tg(KLK4mHEL)6Ccg/Dvs)	decreased B cell number	J:89156
Tg(IghelMD4)4Ccg/0 Tg(KLK4mHEL)6Ccg/0 (C57BL/6-Tg(IghelMD4)4Ccg Tg(KLK4mHEL)6Ccg)	decreased B cell number	J:89156
Tg(IghelMD4)4Ccg/? Tg(KLK4mHEL)6Ccg/? (involves: C57BL/6)	arrested B cell differentiation	J:78307
	decreased mature B cell number	J:78307
	increased immature B cell number	J:78307
Tg(IghelMD4)4Ccg/0 Tg(ML5sHEL)5Ccg/0 (NOD.B6-Tg(IghelMD4)4Ccg Tg(ML5sHEL)5Ccg/Dvs)	abnormal B cell anergy	J:89156
	abnormal B cell clonal deletion	J:89156
	abnormal B cell morphology	J:89156
	decreased IgM level	J:89156
Tg(IghelMD4)4Ccg/0 Tg(ML5sHEL)5Ccg/0 (C57BL/6-Tg(IghelMD4)4Ccg Tg(ML5sHEL)5Ccg)	abnormal B cell anergy	J:89156, J:78308
	abnormal central B cell anergy	J:109923
	abnormal germinal center B cell morphology	J:109923
	abnormal immature B cell morphology	J:109923
	abnormal mature B cell morphology	J:109923
	abnormal plasma cell morphology	J:109923
	abnormal pro-B cell morphology	J:109923
	abnormal spleen B cell follicle morphology	J:109923
	decreased B cell number	J:89156
	decreased IgM level	J:89156, J:78308
Tg(IghelMD4)4Ccg/0 Tg(ML5sHEL)5Ccg/0 (involves: C57BL/6)	abnormal B cell anergy	J:73608, J:132538
	abnormal B cell physiology	J:76134
	abnormal spleen primary B follicle morphology	J:76134
	decreased B cell number	J:76134
	decreased marginal zone B cell number	J:132538
Tg(IghelMD4)4Ccg/Tg(IghelMD4)4Ccg (NOD.B6-Tg(IghelMD4)4Ccg/DvsJ)	abnormal mature B cell morphology	J:80859, J:89156
	abnormal T cell proliferation	J:80859
	decreased CD8-positive, alpha-beta T cell number	J:80859
	increased susceptibility to autoimmune diabetes	J:80859
Tg(IghelMD4)4Ccg/Tg(IghelMD4)4Ccg (involves: C57BL/6)	decreased pre-B cell number	J:171924
Tg(IghelMD4)4Ccg/Tg(IghelMD4)4Ccg (involves: C57BL/6)	decreased pro-B cell number	J:171924
Tg(IghH280)48Dvs/? (NOD/ShiLtDvs-Tg(IghH280)48Dvs/J)	increased susceptibility to autoimmune diabetes	J:274578
Tg(IghH280)48Dvs/? (NOD/ShiLtDvs-Tg(IghH280)48Dvs/J)	insulitis	J:274578
Tg(IghH280)48Dvs/? Tg(IgkH280)934Dvs/? (NOD/ShiLtDvs-Tg(IghH280)48Dvs Tg(IgkH280)934Dvs/Dvs)	increased susceptibility to autoimmune diabetes	J:274578
Tg(Ighm-Ctla4Ig/Cd80)1Jbs/0 (involves: FVB/N)	abnormal B cell physiology	J:113109
Tg(Ighm-Ctla4Ig/Cd80)1Jbs/0 (involves: FVB/N)	immune system phenotype	J:113109
Tg(Ighm-Ctla4Ig/Cd80)1Jbs/0 (NOD.FVB-Tg(Ighm-Ctla4Ig/Cd80)1Jbs)	decreased susceptibility to autoimmune diabetes	J:113109
	immune system phenotype	J:113109
Tg(IghMyc)22Bri/? (involves: C57BL * C57BL/6 * SJL)	enlarged spleen	J:121564
Tg(IghMyc)22Bri/? (involves: C57BL * C57BL/6 * SJL)	increased lymphocyte cell number	J:121564
Tg(IghMyc)22Bri/0 (involves: C57BL/6 * SJL)	abnormal lymphopoiesis	J:78177
	enlarged lymph nodes	J:78177
	enlarged spleen	J:78177
	enlarged thymus	J:78177
	increased leukocyte cell number	J:186117
	increased pre-B cell number	J:223213
Tg(IghMyc)22Bri/0 (B6.Cg-Tg(IghMyc)22Bri/J)	enlarged lymph nodes	J:354285, J:164200
Tg(IghMyc)22Bri/0 (B6.Cg-Tg(IghMyc)22Bri/J)	spleen hyperplasia	J:164200
Tg(IghMyc)22Bri/0 (involves: C57BL/6N * SJL)	increased B cell apoptosis	J:214383
Tg(IghMyc)22Bri/0 Tg(Igk-V21-Bax)1967Bvn/0 (involves: C57BL/6 * FVB/N)	enlarged spleen	J:89049
	increased transitional stage B cell number	J:89049
Tg(IghMyc)22Bri/0 Xiap^tm1Hs/Xiap^tm1Hs (B6.Cg-Xiap^tm1Hs Tg(IghMyc)22Bri)	decreased B cell proliferation	J:138979
	decreased leukocyte cell number	J:138979
	increased B cell apoptosis	J:138979
Tg(IghMyc)186Brn/0 Rpl24^Bst/Rpl24⁺ (involves: C57BL/LiA * C57BLKS * CBA/BrA)	immune system phenotype	J:142390
Tg(Igk-Lta/Ltb)4Cys/0 (involves: C57BL/6J * DBA/2J)	abnormal B cell morphology	J:73100
Tg(Igk-Lta/Ltb)10Cys/0 (involves: C57BL/6J * DBA/2J)	abnormal B cell morphology	J:73100
Tg(Igk-V21-Bax)1967Bvn/0 (involves: FVB/N)	abnormal plasma cell morphology	J:89049
	increased IgA level	J:89049
	increased IgE level	J:89049
	increased IgG1 level	J:89049
	increased IgG2a level	J:89049
	increased IgG level	J:89049, J:90901
	increased IgM level	J:89049
	increased immunoglobulin level	J:89049
	increased transitional stage B cell number	J:89049
Tg(IGK@yK1)9.2CJkbv/0 (involves: 129P2/OlaHsd)	abnormal B cell morphology	J:23827
	abnormal immunoglobulin level	J:23827
	abnormal immunoglobulin light chain V-J recombination	J:23827
Tg(IgkH280)934Dvs/? (NOD/ShiLtDvs-Tg(IgkH280)934Dvs/J)	increased susceptibility to autoimmune diabetes	J:274578
Tg(IgkH280)934Dvs/? (NOD/ShiLtDvs-Tg(IgkH280)934Dvs/J)	insulitis	J:274578
Tg(Igkv3-5-MYC)24Plbe/0 (C57BL/6J-Tg(Igkv3-5-MYC)DLoxP4Plbe/PlbeMmmh)	abnormal humoral immune response	J:131912
	abnormal immunoglobulin level	J:131912
	abnormal plasma cell differentiation	J:131912
	increased IgG1 level	J:131912
	increased IgG3 level	J:131912
	increased plasma cell number	J:131912
Tg(Igl-2MOPC315)1275Ust/? (C57BL/6-Tg(Igl-2MOPC315)1275Ust)	abnormal B cell morphology	J:134666
	decreased IgM level	J:134666
	decreased immature B cell number	J:134666
Tg(IGL-MYC)3Hm/0 (C57BL/6N-Tg(IGL-MYC)3Hm/Nci)	enlarged lymph nodes	J:65245
Tg(Il1rn)1Dih/0 (involves: C57BL/6 * CBA)	decreased circulating interleukin-6 level	J:88605
	decreased circulating serum amyloid protein level	J:61600
	decreased inflammatory response	J:88605
	decreased susceptibility to endotoxin shock	J:36387
	decreased susceptibility to Herpesvirales infection	J:88605
	increased susceptibility to bacterial infection	J:36387
Tg(Il1rn)1Dih/Tg(Il1rn)1Dih (involves: C57BL/6 * CBA)	decreased susceptibility to endotoxin shock	J:36387
	increased circulating interleukin-1 level	J:36387
	increased susceptibility to bacterial infection	J:36387
Tg(IL2-Il10)1Kro/0 (involves: C3H * C57BL/6)	abnormal cytokine secretion	J:41588
	decreased susceptibility to parasitic infection	J:41588
	increased susceptibility to bacterial infection	J:80569
Tg(IL3,CSF2)C42Pnc/0 (involves: C57BL/6 * CBA)	immune system phenotype	J:219403
Tg(ILK3mHEL)3Ccg/0 Tg(TcrHEL3A9)1Mmd/0 (involves: C57BL/6JSfd * C57BL/10Sg * C57BR/cd)	abnormal CD4-positive, alpha beta T cell morphology	J:78309
	abnormal CD4-positive, alpha-beta T cell physiology	J:78309
	abnormal T cell activation	J:78309
	abnormal T cell proliferation	J:78309
	decreased CD4-positive, alpha-beta T cell number	J:78309
	insulitis	J:78309
Tg(Ins1-Cat,Tyr)25Pne/0 (NOD.FVB-Tg(Ins1-Cat,Tyr)25Pne)	increased susceptibility to autoimmune diabetes	J:108415
Tg(Ins1-Cd80)378Psoh/0 Tg(Ins2-GP)#Psoh/0 Tg(TcrLCMV)327Sdz/0 (involves: C57BL/6 * DBA/2 * FVB/N)	insulitis	J:209714
	periinsulitis	J:209714
Tg(Ins1-EGFP/GH1)14Hara/0 (NOD/ShiLtJ-Tg(Ins1-EGFP/GH1)14Hara)	increased susceptibility to autoimmune diabetes	J:127015
Tg(Ins1-EGFP/GH1)14Hara/Tg(Ins1-EGFP/GH1)14Hara (NOD/ShiLtJ-Tg(Ins1-EGFP/GH1)14Hara)	decreased susceptibility to autoimmune disorder	J:127015
	insulitis	J:127015
Tg(Ins2Y16A)1Ell/0 (NOD-Tg(Ins2Y16A)1Ell)	increased susceptibility to autoimmune diabetes	J:98583
Tg(Ins2Y16A)3Ell/0 (NOD-Tg(Ins2Y16A)3Ell)	increased susceptibility to autoimmune diabetes	J:98583
Tg(Ins2-Ccl19)2Cys/0 (involves: C57BL/6 * DBA/2)	abnormal lymph organ development	J:77238
Tg(Ins2-Ccl21b)2Cys/0 (involves: C57BL/6 * DBA/2)	abnormal lymph organ development	J:77238
Tg(Ins2-CD80)3B7Flv/? (involves: C57BL/6 * CBA/Ca * NOD/Caj)	increased susceptibility to autoimmune diabetes	J:26618
	insulitis	J:26618
Tg(Ins2-CD80)3B7Flv/0 Tg(Ins2-H2-Ea^d,Ins2-H2-Eb1^b)187-7Bri/0 (involves: C57BL/6 * CBA/Ca * SJL)	increased susceptibility to autoimmune diabetes	J:93555
	insulitis	J:93555
Tg(Ins2-CD80)3B7Flv/0 Tg(Ins2-Tnf)17Flv/0 (involves: C57BL/6 * CBA/Ca)	abnormal cytokine secretion	J:93555
	increased susceptibility to autoimmune diabetes	J:93555
Tg(Ins2-CD86)12B70Flv/0 (involves: C57BL/6 * CBA/Ca)	abnormal cytokine secretion	J:93555
	decreased susceptibility to autoimmune diabetes	J:93555
	periinsulitis	J:93555
Tg(Ins2-CD86)12B70Flv/0 Tg(Ins2-H2-Ea^d,Ins2-H2-Eb1^b)187-7Bri/0 (involves: C57BL/6 * CBA/Ca * SJL)	abnormal cytokine secretion	J:93555
	increased susceptibility to autoimmune diabetes	J:93555
	insulitis	J:93555
Tg(Ins2-CD86)12B70Flv/0 Tg(Ins2-Tnf)17Flv/0 (involves: C57BL/6 * CBA/Ca)	abnormal cytokine secretion	J:93555
	increased susceptibility to autoimmune diabetes	J:93555
Tg(Ins2-Cd274)2Mdos/? (NOD/ShiLt-Tg(Ins2-Cd274)2Mdos)	increased susceptibility to autoimmune diabetes	J:118934
Tg(Ins2-cre)5Lt/0 (NOD/ShiLt-Tg(Ins2-cre)5Lt)	increased susceptibility to autoimmune diabetes	J:127015
Tg(Ins2-cre)5Lt/Tg(Ins2-cre)5Lt (NOD/ShiLt-Tg(Ins2-cre)5Lt)	decreased susceptibility to autoimmune disorder	J:127015
Tg(Ins2-cre)5Lt/Tg(Ins2-cre)5Lt (NOD/ShiLt-Tg(Ins2-cre)5Lt)	insulitis	J:127015
Tg(Ins2-crmA)27Ngkh/? (NOD-Tg(Ins2-CrmA)27Ngkh)	increased susceptibility to autoimmune diabetes	J:132052
Tg(Ins2-Cxcl13)1Cys/0 (involves: C57BL/6 * DBA/2)	abnormal lymph organ development	J:110548
Tg(Ins2-E3)1Dvs/? (NOD.Cg-Tg(Ins2-E3)1Dvs)	decreased susceptibility to autoimmune diabetes	J:68996
Tg(Ins2-E3309)5Dvs/? (NOD/ShiLtDvs-Tg(Ins2-E3309)5Dvs/Dvs)	decreased susceptibility to autoimmune diabetes	J:83195
Tg(Ins2-E3704)2Dvs/? (NOD/ShiLtDvs-Tg(Ins2-E3704)2Dvs)	decreased susceptibility to autoimmune diabetes	J:83195
Tg(Ins2-E3734)3Dvs/0 (NOD/ShiLtDvs-Tg(Ins2-E3734)3Dvs/DvsJ)	decreased susceptibility to autoimmune diabetes	J:106340
Tg(Ins2-E3734)4Dvs/? (NOD/ShiLtDvs-Tg(Ins2-E3734)4Dvs/DvsJ)	decreased susceptibility to autoimmune diabetes	J:106340
Tg(Ins2-FasI246N)1Ach/0 (NOD-Tg(Ins2-FasI246N)1Ach)	decreased susceptibility to autoimmune diabetes	J:81416
Tg(Ins2-FasI246N)1Ach/0 Tg(Ins2-Fasl)24Ach/0 (NOD-Tg(Ins2-FasI246N)1Ach Tg(Ins2-Fasl)24Ach)	decreased susceptibility to autoimmune diabetes	J:81416
Tg(Ins2-Fasl)24Ach/0 (NOD-Tg(Ins2-Fasl)24Ach/J)	increased susceptibility to autoimmune diabetes	J:78679, J:81416
Tg(Ins2-GAD2)1Lt/0 (NOD/ShiLt-Tg(Ins2-GAD2)1Lt)	insulitis	J:100251
Tg(Ins2-GAD2)2Lt/0 (NOD/ShiLt-Tg(Ins2-GAD2)2Lt)	abnormal cytokine secretion	J:100251
	decreased susceptibility to autoimmune diabetes	J:100251
	insulitis	J:100251
Tg(Ins2-GP)34-20Olds/0 (involves: BALB/c * C57BL/6)	abnormal lymphocyte physiology	J:81287
	abnormal T cell physiology	J:81287
	increased susceptibility to autoimmune diabetes	J:81287
Tg(Ins2-GP)#Psoh/0 (involves: C57BL/6)	insulitis	J:81285
Tg(Ins2-GP)#Psoh/0 Tg(TcrLCMV)327Sdz/0 (involves: C57BL/6 * DBA/2)	abnormal B cell selection	J:81285
Tg(Ins2-H2-Ea^d,Ins2-H2-Eb1^b)187-7Bri/0 (involves: C57BL/6 * SJL)	decreased susceptibility to autoimmune diabetes	J:93555
Tg(Ins2-HA)165Bri/0 (B10.Cg- H2^d Tg(Ins2-HA)165Bri/ShrmJ)	abnormal CD4-positive, alpha-beta T cell physiology	J:86430
	decreased T cell proliferation	J:86430
	immune system phenotype	J:86430
Tg(Ins2-HA)165Bri/0 Tg(TcraCl4,TcrbCl4)1Shrm/0 (involves: BALB/c * C57BL/6 * C57BL/10 * DBA/2)	insulitis	J:99756
Tg(Ins2-HA)165Bri/? Tg(TcraCl4,TcrbCl4)1Shrm/? (involves: BALB/c * C57BL/6 * C57BL/10)	insulitis	J:99756
Tg(Ins2-Iapp)6Soel/Tg(Ins2-Iapp)6Soel (involves: FVB/N)	decreased susceptibility to autoimmune diabetes	J:130022
Tg(Ins2-IAPP)RHFSoel/Tg(Ins2-IAPP)RHFSoel (involves: FVB/N)	increased susceptibility to autoimmune diabetes	J:130022
Tg(Ins2-Lta)#Flv/0 (involves: NOD)	insulitis	J:91820
	kidney inflammation	J:91820
	periinsulitis	J:91820
Tg(Ins2-Lta)#Flv/0 (involves: C57BL/6)	insulitis	J:91820
	kidney inflammation	J:91820
	periinsulitis	J:91820
Tg(Ins2-Lta)#Flv/0 (involves: C57BL/6 * CBA)	insulitis	J:127705
Tg(Ins2-Lta)#Flv/0 (involves: C57BL/6 * CBA)	periinsulitis	J:127705
Tg(Ins2-NP)25-3Olds/0 (involves: BALB/c * C57BL/6)	decreased susceptibility to autoimmune diabetes	J:81287
Tg(Ins2-NP)25-3Olds/0 (involves: BALB/c * C57BL/6)	increased susceptibility to autoimmune diabetes	J:81287
Tg(Ins2-OVA)59Wehi/? (involves: BALB/c * C57BL/6)	abnormal T cell activation	J:99560
Tg(Ins2-OVA)59Wehi/? (involves: BALB/c * C57BL/6)	increased susceptibility to autoimmune diabetes	J:99560
Tg(Ins2-OVA)307Wehi/? (involves: BALB/c * C57BL/6)	increased susceptibility to autoimmune diabetes	J:99560
Tg(Ins2-OVA)307Wehi/0 Tg(TcraTcrb)1100Mjb/0 (involves: C57BL/6 * C57BL/6JWehi)	autoimmune response	J:99451
Tg(Ins2-TFRC/OVA)296Wehi/0 (involves: C57BL/6)	abnormal CD8-positive, alpha beta T cell morphology	J:98589
	abnormal leukocyte migration	J:98589
	decreased interferon-gamma secretion	J:122114
	increased susceptibility to autoimmune diabetes	J:122114
Tg(Ins2-TFRC/OVA)296Wehi/0 1700016L21Rik^{Tg(Itgax-HBEGF/EGFP)57Lan}/0 (involves: C57BL/6 * FVB)	decreased T cell proliferation	J:122114
Tg(Ins2-TFRC/OVA)296Wehi/0 Tg(TcraTcrb)425Cbn/0 (involves: 129P2/OlaHsd * C57BL/6)	decreased CD4-positive, alpha-beta T cell number	J:135154
	increased double-positive T cell number	J:135154
Tg(Ins2-Tnf)17Flv/0 (involves: C57BL/6 * CBA * NOD)	immune system phenotype	J:91820
Tg(Ins2-Tnf)17Flv/0 (involves: C57BL/6 * CBA * NOD)	insulitis	J:91820
Tg(Ins2-Tnf)17Flv/0 (involves: C57BL/6 * CBA)	insulitis	J:91820
Tg(Ins2-Tnf)17Flv/0 (involves: C57BL/6)	decreased CD8-positive, alpha-beta T cell number	J:93555
Tg(Ins2-Tnf)17Flv/0 (involves: C57BL/6)	increased CD4-positive, alpha-beta T cell number	J:93555
Tg(INS-Il10)#Sar/0 (involves: BALB/c)	pancreas inflammation	J:107927
Tg(INS-Il10)#Sar/0 (involves: BALB/c)	periinsulitis	J:107927
Tg(INS-Il10)#Sar/0 Tnfrsf1a^tm1Mak/Tnfrsf1a^tm1Mak (involves: 129S2/SvPas * C57BL/6J * NOD)	increased susceptibility to autoimmune diabetes	J:64051
Tg(INS-Il10)#Sar/0 Tnfrsf1b^tm1Mwm/Tnfrsf1b^tm1Mwm (involves: 129S2/SvPas * C57BL/6J * NOD)	increased susceptibility to autoimmune diabetes	J:64051
Tg(INS-MT2A,Tyr)1Pne/0 (FVB-Tg(INS-MT2A,Tyr)1Pne)	abnormal response to transplant	J:95089
Tg(ITGA2)1067Fmw/0 Tg(ITGB1)0840Fmw/0 (involves: C57BL/10 * CBA)	dermatitis	J:30249
	eye inflammation	J:30249
Tg(ITGA2)1067Fmw/0 Tg(ITGB1)0869Fmw/0 (involves: C57BL/10 * CBA)	dermatitis	J:30249
	eye inflammation	J:30249
Tg(ITGA2)1067Fmw/0 Tg(ITGB1)0870Fmw/0 (involves: C57BL/10 * CBA)	dermatitis	J:30249
	eye inflammation	J:30249
Tg(ITGA2)1070Fmw/0 Tg(ITGB1)0840Fmw/0 (involves: C57BL/10 * CBA)	dermatitis	J:30249
	eye inflammation	J:30249
Tg(ITGA2)1070Fmw/0 Tg(ITGB1)0869Fmw/0 (involves: C57BL/10 * CBA)	dermatitis	J:30249
	eye inflammation	J:30249
Tg(ITGA2)1070Fmw/0 Tg(ITGB1)0870Fmw/0 (involves: C57BL/10 * CBA)	dermatitis	J:30249
	eye inflammation	J:30249
Tg(ITGA2)1075Fmw/0 Tg(ITGB1)0840Fmw/0 (involves: C57BL/10 * CBA)	dermatitis	J:30249
	eye inflammation	J:30249
Tg(ITGA2)1075Fmw/0 Tg(ITGB1)0869Fmw/0 (involves: C57BL/10 * CBA)	dermatitis	J:30249
	eye inflammation	J:30249
Tg(ITGA2)1075Fmw/0 Tg(ITGB1)0870Fmw/0 (involves: C57BL/10 * CBA)	dermatitis	J:30249
	eye inflammation	J:30249
Tg(ITGA5)0794Fmw/0 Tg(ITGB1)0840Fmw/0 (involves: C57BL/10 * CBA)	dermatitis	J:30249
	eye inflammation	J:30249
Tg(ITGA5)0794Fmw/0 Tg(ITGB1)0869Fmw/0 (involves: C57BL/10 * CBA)	dermatitis	J:30249
	eye inflammation	J:30249
Tg(ITGA5)0794Fmw/0 Tg(ITGB1)0870Fmw/0 (involves: C57BL/10 * CBA)	dermatitis	J:30249
	eye inflammation	J:30249
Tg(ITGA5)0844Fmw/0 Tg(ITGB1)0840Fmw/0 (involves: C57BL/10 * CBA)	dermatitis	J:30249
	eye inflammation	J:30249
Tg(ITGA5)0844Fmw/0 Tg(ITGB1)0869Fmw/0 (involves: C57BL/10 * CBA)	dermatitis	J:30249
	eye inflammation	J:30249
Tg(ITGA5)0844Fmw/0 Tg(ITGB1)0870Fmw/0 (involves: C57BL/10 * CBA)	dermatitis	J:30249
	eye inflammation	J:30249
Tg(ITGA5)0858Fmw/0 Tg(ITGB1)0840Fmw/0 (involves: C57BL/10 * CBA)	dermatitis	J:30249
	eye inflammation	J:30249
Tg(ITGA5)0858Fmw/0 Tg(ITGB1)0869Fmw/0 (involves: C57BL/10 * CBA)	dermatitis	J:30249
	eye inflammation	J:30249
Tg(ITGA5)0858Fmw/0 Tg(ITGB1)0870Fmw/0 (involves: C57BL/10 * CBA)	dermatitis	J:30249
	eye inflammation	J:30249
Tg(ITGAL-Hhex)2Hro/0 (C3HeB/FeJ-Tg(ITGAL-Hhex)2Hro)	abnormal double-negative T cell morphology	J:80777
	abnormal thymus corticomedullary boundary morphology	J:80777
	decreased double-positive T cell number	J:80777
	decreased leukocyte cell number	J:80777
	decreased lymphocyte cell number	J:80777
	decreased T cell number	J:80777
	increased CD8-positive, alpha-beta T cell number	J:80777
	thymus hypoplasia	J:80777
Tg(ITGAL-Ptprc^a)FRasch/Tg(ITGAL-Ptprc^a)FRasch (involves: BALB/c * C57BL/6)	abnormal T cell differentiation	J:158876
Tg(Itgam-FCAR)83Rcmo/0 (involves: C57BL/6 * NOD)	glomerulonephritis	J:120534
Tg(Itgam-FCAR)83Rcmo/0 (involves: C57BL/6 * NOD)	increased IgA level	J:120534
Tg(ITGAM-HBEGF/EGFP)34Lan/0 (involves: FVB/N)	abnormal macrophage morphology	J:95141
	decreased macrophage cell number	J:95141
	increased neutrophil cell number	J:95141
Tg(ITGAM-HBEGF/EGFP)34Lan/0 (NOD.FVB-Tg(ITGAM-HBEGF/EGFP)34Lan/Jdk)	decreased macrophage cell number	J:137009
	immune system phenotype	J:137009
Tg(Itgax-EGFP,-cre,-HBEGF,-luc)2Gjh/0 (C57BL/6-Tg(Itgax-EGFP,-cre,-HBEGF,-luc)2Gjh)	abnormal susceptibility to infection	J:194800
	immune system phenotype	J:194800
	increased monocyte cell number	J:194800
	increased neutrophil cell number	J:194800
Tg(Itgax-HBEGF/OVA/EGFP)1Garbi/0 (C57BL/6-Tg(Itgax-HBEGF/OVA/EGFP)1Garbi)	abnormal susceptibility to infection	J:194800
	decreased dendritic cell number	J:194800
	increased neutrophil cell number	J:194800
Tg(Itgax-TGFBR2)1Flv/0 (C.Cg-Tg(Itgax-TGFBR2)1Flv)	abnormal immune system physiology	J:98953
	abnormal interferon level	J:98953
	abnormal NK cell differentiation	J:98953
	decreased susceptibility to parasitic infection	J:98953
	immune system phenotype	J:98953
	increased NK cell number	J:98953
Tg(ITGB1)0840Fmw/0 (involves: C57BL/10 * CBA)	dermatitis	J:30249
Tg(ITGB1)0840Fmw/0 (involves: C57BL/10 * CBA)	eye inflammation	J:30249
Tg(ITGB1)0869Fmw/0 (involves: C57BL/10 * CBA)	dermatitis	J:30249
Tg(ITGB1)0869Fmw/0 (involves: C57BL/10 * CBA)	eye inflammation	J:30249
Tg(ITGB1)0870Fmw/0 (involves: C57BL/10 * CBA)	dermatitis	J:30249
Tg(ITGB1)0870Fmw/0 (involves: C57BL/10 * CBA)	eye inflammation	J:30249
Tg(IVL-KLK5)#Hov/0 (involves: C57BL/6 * CBA)	abnormal circulating cytokine level	J:210758
	abnormal inguinal lymph node morphology	J:210758
	enlarged lymph nodes	J:210758
	enlarged spleen	J:210758
	erythroderma	J:210758
	increased activated T cell number	J:210758
	increased IgE level	J:210758
	lymph node inflammation	J:210758
	skin inflammation	J:210758
Tg(JAK2V617F)FF1Rsko/0 Commd10^{Tg(Vav1-icre)A2Kio}/Commd10⁺ (involves: C57BL/6 C57BL/10 * CBA/Ca)	abnormal myelopoiesis	J:134364
	abnormal spleen morphology	J:134364
	decreased B cell number	J:134364
	decreased T cell number	J:134364
	enlarged spleen	J:134364
	increased neutrophil cell number	J:134364
	spleen fibrosis	J:134364
Tg(JAK2V617F)FF1Rsko/0 Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 CBA)	abnormal myelopoiesis	J:134364
	abnormal spleen morphology	J:134364
	decreased B cell number	J:134364
	decreased T cell number	J:134364
	enlarged spleen	J:134364
	increased neutrophil cell number	J:134364
	spleen fibrosis	J:134364
Tg(JAK2V617F)FF1Rsko/0 Tg(Tek-cre)1Arnd/0 (involves: C57BL/6 CBA * DBA/2)	decreased T cell number	J:206659
	enlarged spleen	J:206659
	increased neutrophil cell number	J:206659
Tg(K18-ACE2)2Prlmn/0 (involves: C57BL/6J * SJL/J)	increased susceptibility to Coronaviridae infection	J:283648
Tg(K18-ACE2)2Prlmn/0 (involves: C57BL/6J * SJL/J)	increased susceptibility to Coronaviridae infection induced morbidity/mortality	J:283648
Tg(K18-ACE2)2Prlmn/0 (B6.Cg-Tg(K18-ACE2)2Prlmn/J)	abnormal chemokine level	J:302313
	abnormal circulating chemokine level	J:294084
	abnormal circulating cytokine level	J:302313
	abnormal cytokine level	J:294084, J:302313
	abnormal interferon level	J:300960, J:302313
	abnormal interleukin level	J:300960, J:302313
	abnormal tumor necrosis factor level	J:300960, J:302313
	blood vessel inflammation	J:300960
	brain inflammation	J:294084
	bronchiolitis	J:302313
	conjunctivitis	J:294084
	cytokine storm	J:300960
	enhanced humoral immune response	J:302313
	increased circulating CXCL10 level	J:302313
	increased circulating interferon-gamma level	J:302313
	increased circulating interleukin-6 level	J:294084
	increased circulating interleukin-10 level	J:294084, J:302313
	increased circulating tumor necrosis factor level	J:294084
	increased CXCL10 level	J:300960
	increased IgG level	J:302313
	increased IgM level	J:302313
	increased leukocyte cell number	J:294084
	increased lymphocyte cell number	J:302313
	increased macrophage cell number	J:294084, J:302313
	increased neutrophil cell number	J:294084, J:300960, J:302313
	increased susceptibility to Coronaviridae infection	J:294084, J:300960, J:302313, J:368665, J:296067
	increased susceptibility to Coronaviridae infection induced morbidity/mortality	J:294084, J:300960, J:368665
	increased susceptibility to Orthomyxoviridae infection	J:296067
	increased susceptibility to viral infection	J:296067
	increased susceptibility to viral infection induced morbidity/mortality	J:296067
	increased T cell number	J:300960
	interstitial pneumonia	J:300960, J:302313
	liver inflammation	J:300960
	lung inflammation	J:294084, J:302313
	meningitis	J:294084, J:302313
	meningoencephalitis	J:300960, J:296067
	microgliosis	J:294084
	rhinitis	J:300960
Tg(KitD814V)1Roer/0 Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 CBA)	abnormal mast cell morphology	J:169611
	colitis	J:169611
	enlarged spleen	J:169611
	increased mast cell number	J:169611
	large intestinal inflammation	J:169611
	small intestinal inflammation	J:169611
Tg(KitD814V)2Roer/0 Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 CBA)	abnormal mast cell morphology	J:169611
	colitis	J:169611
	increased mast cell number	J:169611
	large intestinal inflammation	J:169611
	small intestinal inflammation	J:169611
Tg(KitD814V)3Roer/0 Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 CBA)	abnormal mast cell morphology	J:169611
	colitis	J:169611
	enlarged spleen	J:169611
	increased mast cell number	J:169611
	large intestinal inflammation	J:169611
Tg(KLK4mHEL)6Ccg/0 Tg(TcrHEL3A9)1Mmd/0 (involves: C57BL/6 * C57BL/10 * C57BR/cd)	decreased CD4-positive, alpha-beta T cell number	J:78309
	decreased double-positive T cell number	J:78309
Tg(KRT5-IKBKB)1Armz/0 (involves: C57BL/6 * DBA/2)	increased interleukin-1 alpha secretion	J:160072
	increased interleukin-6 secretion	J:160072
	increased tumor necrosis factor secretion	J:160072
Tg(KRT5-IKBKB)2Armz/0 (involves: C57BL/6 * DBA/2)	abnormal cytokine level	J:160072
	abnormal immune serum protein physiology	J:160072
	abnormal melanophage morphology	J:160072
	dermatitis	J:160072
	increased circulating interferon-gamma level	J:160072
	increased circulating interleukin-1 alpha level	J:160072
	increased circulating interleukin-2 level	J:160072
	increased circulating interleukin-4 level	J:160072
	increased circulating interleukin-5 level	J:160072
	increased circulating interleukin-6 level	J:160072
	increased circulating interleukin-10 level	J:160072
	increased circulating tumor necrosis factor level	J:160072
	increased interleukin-1 alpha secretion	J:160072
	increased interleukin-6 secretion	J:160072
	increased tumor necrosis factor secretion	J:160072
Tg(KRT5-Nfkbia)3Rto/0 Tg(Krt5-Tnfr1)#Rsab/0 Tnfrsf1a^tm1Mak/Tnfrsf1a^tm1Mak (involves: 129S2/SvPas C57BL/6 * CBA)	skin inflammation	J:208995
Tg(KRT5-rtTA)1Glk/0 Tg(tetO-Tfrc/EGFP/Ova)#Sfz/0 (involves: FVB/N)	immune system phenotype	J:199558
Tg(KRT5-rtTA)1Glk/0 Tg(tetO-Tfrc/EGFP/Ova)#Sfz/0 Tg(tetO/CMV-Tslp)#Sfz/0 (involves: C3H * C57BL/6 * FVB/N)	increased T cell proliferation	J:199558
	respiratory system inflammation	J:199558
	skin inflammation	J:199558
Tg(KRT5-rtTA)1Glk/0 Tg(tetO-TGFB1C223SC225S)1Glk/0 (involves: FVB/N)	dermatitis	J:70670
	skin inflammation	J:70670
Tg(KRT5-rtTA)1Glk/0 Tg(tetO/CMV-Tslp)#Sfz/0 (involves: C3H * C57BL/6 * FVB/N)	abnormal cytokine level	J:100506
	abnormal lymph node morphology	J:100506
	conjunctivitis	J:100506
	decreased IgG2a level	J:100506
	dermatitis	J:100506
	enlarged lymph nodes	J:100506
	enlarged spleen	J:100506
	increased CD4-positive, alpha-beta T cell number	J:100506
	increased IgE level	J:100506
	increased IgG1 level	J:100506
Tg(KRT5-rtTA)1Glk/0 Tg(tetO/CMV-Tslp)#Sfz/0 (C.Cg-Tg(KRT5-rtTA)1Glk Tg(tetO/CMV-Tslp)#Sfz)	abnormal B cell activation	J:182756
	increased autoantibody level	J:182756
	increased B cell proliferation	J:182756
	increased circulating interleukin-4 level	J:182756
	increased susceptibility to autoimmune hemolytic anemia	J:182756
Tg(KRT5-rtTA)#Glk/0 Tg(tetO-cre)1Jaw/0 Wls^tm1.1Lan/Wls^tm1.1Lan (involves: 129S6/SvEvTac * C57BL/6 * FVB/N)	cutaneous mastocytosis	J:204142
Tg(KRT5-rtTA)#Glk/0 Tg(tetO-S100a7a)#Yus/0 (involves: FVB/N)	abnormal chemokine secretion	J:168000
	increased interleukin-1 alpha secretion	J:168000
	increased tumor necrosis factor secretion	J:168000
Tg(KRT5-TGFB1)F2020Xjw/0 (involves: C57BL/6 * DBA/2 * ICR)	abnormal Langerhans cell morphology	J:90118
	abnormal Langerhans cell physiology	J:90118
	cutaneous mastocytosis	J:90118
	decreased Langerhans cell number	J:90118
	skin inflammation	J:90118
Tg(KRT5-tTA)1216Glk/0 Tg(tetO-Il13)1Tazh/0 (B6.Cg-Tg(KRT5-tTA)1216Glk Tg(tetO-Il13)1Tazh)	cutaneous mastocytosis	J:150232
	dermatitis	J:150232
	increased IgE level	J:150232
	increased IgG1 level	J:150232
	increased interleukin-4 secretion	J:150232
	increased interleukin-13 secretion	J:150232
Tg(KRT5-tTA)1216Glk/0 Tg(tetO-LMNA*G608G,-EGFP)VF1-07Maer/0 (involves: FVB/N)	periodontium inflammation	J:145312
	skin inflammation	J:145312
Tg(KRT5-tTA)1216Glk/0 Tg(tetO-Tek)1Dmt/0 (involves: CD-1 * FVB/N)	abnormal interleukin secretion	J:147438
	increased interferon-gamma secretion	J:147438
	increased interleukin-12 secretion	J:147438
	increased interleukin-17 secretion	J:147438
	increased interleukin-23 secretion	J:147438
	skin inflammation	J:147438
Tg(KRT5-tTA)1216Glk/0 Tg(tetO-TGFB1C223SC225S)1Glk/0 (involves: FVB/N)	dermatitis	J:70670
	skin inflammation	J:70670
Tg(Krt14-Angptl2)1Yo/0 (C.Cg-Tg(Krt14-Angptl2)1Yo)	skin inflammation	J:152387, J:181261
Tg(KRT14-CASP1)1Miz/0 (involves: C57BL/6)	abnormal T cell physiology	J:78602
	decreased T cell number	J:78602
	dermatitis	J:78602, J:79706
	increased circulating interleukin-18 level	J:78602, J:79706
	increased IgE level	J:78602
	increased IgG1 level	J:78602
	increased neutrophil cell number	J:78602
	increased susceptibility to bacterial infection	J:79706
	increased susceptibility to bacterial infection induced morbidity/mortality	J:79706
Tg(KRT14-cre)1Amc/0 Trpv3^tm1.1Clph/Trpv3^tm1.1Clph (involves: 129S4/SvJae * 129S4/SvJaeSor * C57BL/6 * C57BL/6J * CBA * Swiss Webster)	erythroderma	J:164741
Tg(KRT14-FIGF)2Ali/0 (involves: FVB/N)	lymphatic vessel hyperplasia	J:137909, J:68138
Tg(KRT14-FLT4/IGHG1)#Ali/0 (either: (involves: FVB/N) or (involves: BALB/c * DBA))	abnormal lymphatic vessel morphology	J:201429
	abnormal mononuclear phagocyte morphology	J:201429
Tg(Krt14-Ifnk)#Cya/0 (C57BL/6N-Tg(Krt14-Ifnk)#Cya)	enlarged spleen	J:322130
Tg(Krt14-Ifnk)#Cya/0 (C57BL/6N-Tg(Krt14-Ifnk)#Cya)	increased susceptibility to chemically induced skin inflammation	J:322130
Tg(KRT14-Il1f6)1Hblu/? (involves: C57BL/6 * DBA/2)	abnormal chemokine level	J:126327
Tg(KRT14-Il1f6)1Hblu/? (involves: C57BL/6 * DBA/2)	skin inflammation	J:126327
Tg(KRT14-Il4)#Lsch/0 (involves: BALB/cBy * C57BL/6)	blepharitis	J:126285
	conjunctivitis	J:126285
	decreased IgG2a level	J:126285
	dermatitis	J:126285
	increased IgE level	J:126285
	increased IgG1 level	J:126285
	increased mast cell degranulation	J:126285
	increased susceptibility to bacterial infection	J:126285
	skin inflammation	J:126285
Tg(KRT14-Il7)1Tsk/0 (FVB/N-Tg(KRT14-Il7)1Tsk)	blepharitis	J:42565
Tg(KRT14-Il7)1Tsk/0 (FVB/N-Tg(KRT14-Il7)1Tsk)	skin inflammation	J:42565
Tg(KRT14-Il7)1Tsk/Tg(KRT14-Il7)1Tsk (FVB/N-Tg(KRT14-Il7)1Tsk)	skin inflammation	J:42565
Tg(KRT14-Il18)#Knak/0 (C57BL/6-Tg(KRT14-Il18)#Knak)	abnormal T cell physiology	J:78602
	decreased T cell number	J:78602
	dermatitis	J:78602
	increased circulating interleukin-18 level	J:78602
	increased IgE level	J:78602
	increased IgG1 level	J:78602
	increased neutrophil cell number	J:78602
Tg(Krt14-Rac1*G12V)#Mrnk/0 (involves: CBA/CaJ)	abnormal circulating interleukin level	J:237134
	joint inflammation	J:237134
	skin inflammation	J:237134
Tg(KRT14-Tslp)1Pcn/0 (involves: C57BL/6 * SJL)	abnormal lymphocyte physiology	J:102470
	enlarged spleen	J:102470
	increased immunoglobulin level	J:102470
	lymph node hyperplasia	J:102470
Tg(KRT14-Vegfa)3Dtm/0 (FVB/N-Tg(KRT14-Vegfa)3Dtm)	abnormal leukocyte adhesion	J:104245
	abnormal lymphatic vessel morphology	J:111924
	enhanced leukocyte tethering or rolling	J:104245
	enlarged lymph nodes	J:92643
	enlarged lymphatic vessel	J:92643
	increased macrophage cell number	J:111924
	increased mast cell number	J:104245
Tg(KRT14-VEGFC*)1Ali/0 (involves: FVB/N)	lymphatic vessel hyperplasia	J:68138
Tg(KRT14-Vegfd)1Ali/0 Vegfc^tm1Ali/Vegfc⁺ (involves: 129S1/Sv * 129X1/SvJ * FVB)	abnormal lymphatic vessel morphology	J:137909
Tg(KRT14-VP16/NR1I2)13Sdub/? (involves: C57BL/6)	abnormal CD4-positive, alpha-beta T cell number	J:258435
	abnormal CD8-positive, alpha beta T cell morphology	J:258435
	abnormal dendritic cell migration	J:258435
	abnormal innate immunity	J:258435
	decreased interleukin-1 beta secretion	J:258435
	dermatitis	J:258435
	enhanced humoral immune response	J:258435
	enlarged lymph nodes	J:258435
	increased dendritic cell number	J:258435
	increased effector memory T-helper cell number	J:258435
	increased gamma-delta T cell number	J:258435
	increased IgE level	J:258435
	increased IgG1 level	J:258435
	increased leukocyte cell number	J:258435
	skin inflammation	J:258435
Tg(KRT18*R89C)22Rgo/0 (involves: FVB/N)	chronic liver inflammation	J:241700
Tg(KRT18*R89C)30Rgo/0 (involves: FVB/N)	chronic liver inflammation	J:241700
Tg(KRT18*R89C)50Rgo/0 (involves: FVB/N)	chronic liver inflammation	J:241700
Tg(KRT18-DPP4)3Pbmj/0 (involves: C57BL/6J * SJL/J)	abnormal cytokine secretion	J:285467
	abnormal mononuclear cell morphology	J:286231
	brain inflammation	J:285467
	increased lymphocyte cell number	J:286231
	increased susceptibility to Coronaviridae infection	J:286231, J:285467
	increased susceptibility to Coronaviridae infection induced morbidity/mortality	J:286231, J:285467
	interstitial pneumonia	J:286231
	lung inflammation	J:286231, J:285467
Tg(LANA,vFLIP,vCYC)801Dtmr/? (involves: C57BL/6)	abnormal B cell activation	J:196403
	abnormal B cell differentiation	J:196403
	abnormal germinal center B cell physiology	J:196403
	abnormal marginal zone B cell morphology	J:196403
	abnormal marginal zone B cell physiology	J:196403
	abnormal spleen morphology	J:196403
	enlarged spleen	J:196403
	increased B cell proliferation	J:196403
	increased germinal center B cell number	J:196403
	increased IgG1 level	J:196403
	increased IgG3 level	J:196403
	increased marginal zone B cell number	J:196403
	increased mature B cell number	J:196403
	increased plasma cell number	J:196403
Tg(Lck)4220Rmp/0 (involves: C57BL/6J * DBA/2)	increased T cell derived lymphoma incidence	J:88120
Tg(Lck-Akt1)M-1Pnt/0 (involves: C3H/He C57BL/6)	decreased thymocyte number	J:73487
	enlarged spleen	J:73487
	increased double-negative T cell number	J:135903
	increased single-positive T cell number	J:135903
	increased T cell derived lymphoma incidence	J:73487
Tg(Lck-Akt1E40K)E-3Pnt/0 (involves: C3H/He C57BL/6)	decreased thymocyte number	J:73487
	enlarged spleen	J:73487
	increased T cell derived lymphoma incidence	J:73487
Tg(Lck-Akt1*E40K)E-3Pnt/0 (Not Specified)	abnormal T cell differentiation	J:144975
Tg(Lck-Akt1*E40K)E-3Pnt/0 (Not Specified)	increased T cell derived lymphoma incidence	J:144975
Tg(Lck-Akt2*)#Test/0 (Not Specified)	increased T cell derived lymphoma incidence	J:153923
Tg(Lck-Bcl2l1)1Cant/? (B6.Cg-Tg(Lck-Bcl2l1)1Cant)	increased interleukin-2 secretion	J:77507
	increased memory T cell number	J:77507
	increased T cell proliferation	J:77507
Tg(Lck-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	decreased thymocyte number	J:226234
Tg(Lck-cre)548Jxm/? Tgfb1^tm2.1Doe/Tgfb1^tm2.1Doe (involves: 129S6/SvEvTac * Black Swiss * C57BL/6 * CBA)	abnormal immune system organ morphology	J:150024
	abnormal T cell activation	J:150024
	abnormal T cell subpopulation ratio	J:150024
	decreased spleen weight	J:150024
	decreased thymus weight	J:150024
	increased inflammatory response	J:150024
	increased interferon-gamma secretion	J:150024
	increased interleukin-2 secretion	J:150024
	lung inflammation	J:150024
	salivary gland inflammation	J:150024
	spleen hypoplasia	J:150024
	thymus hypoplasia	J:150024
Tg(Lck-cre)548Jxm/? Upf2^tm1Btp/Upf2^tm1Btp (involves: 129P2/OlaHsd * C57BL/6 * CBA)	abnormal T cell receptor beta chain V(D)J recombination	J:134765
	decreased CD4-positive, alpha-beta T cell number	J:134765
	decreased CD8-positive, alpha-beta T cell number	J:134765
	decreased double-positive T cell number	J:134765
	thymus hypoplasia	J:134765
Tg(Lck-cre)I57Jxm/? Traf2^tm1Rbr/Traf2^tm1Rbr (involves: C57BL/6 * ICR)	absent follicular B cells	J:132877
	absent marginal zone B cells	J:132877
	decreased mature B cell number	J:132877
Tg(Lck-cre)I57Jxm/? Traf3^tm1Rbr/Traf3^tm1Rbr (involves: C57BL/6 * ICR * SJL)	abnormal T cell physiology	J:132877
	decreased CD4-positive, alpha-beta T cell number	J:132877
	decreased CD8-positive, alpha-beta T cell number	J:132877
Tg(Lck-CrmA)1Hed/0 (involves: BALB/c * C57BL/6J)	decreased T cell apoptosis	J:100451
Tg(Lck-CrmA)1Hed/0 (involves: BALB/c * C57BL/6J)	immune system phenotype	J:100451
Tg(Lck-CrmA)1Hed/? (involves: BALB/c * C57BL/6J)	decreased thymocyte apoptosis	J:100451
Tg(Lck-CrmA)1Hed/0 Tg(TcraH-Y,TcrbH-Y)71Vbo/0 (BALB/c * C57BL/6)	immune system phenotype	J:100451
Tg(Lck-CrmA)1Hed/Tg(Lck-CrmA)1Hed (involves: BALB/c * C57BL/6J)	immune system phenotype	J:100451
Tg(Lck-Cxadr)1Jdgr/0 (FVB-Tg(Lck-Cxadr)1Jdgr)	abnormal T cell physiology	J:109884
	decreased T cell apoptosis	J:109884
	decreased T cell proliferation	J:109884
Tg(Lck-FADD)1Hed/0 (involves: BALB/c * C57BL/6)	abnormal T cell proliferation	J:100451
	arrested T cell differentiation	J:100451
	decreased T cell number	J:100451
	decreased thymocyte number	J:100451
Tg(Lck-FADD)1Hed/? (involves: BALB/c * C57BL/6)	abnormal T cell physiology	J:100451
	decreased thymocyte apoptosis	J:100451
	immune system phenotype	J:100451
Tg(Lck-FADD)1Hed/0 Tg(TcraH-Y,TcrbH-Y)71Vbo/0 (involves: BALB/c * C57BL/6J * C57L/J * DBA/2J)	immune system phenotype	J:100451
Tg(Lck-FADD)1Hed/Tg(Lck-FADD)1Hed (involves: BALB/c * C57BL/6)	abnormal T cell differentiation	J:100451
	decreased T cell number	J:100451
	decreased thymocyte number	J:100451
	immune system phenotype	J:100451
Tg(Lck-Hhex)1Hro/0 (C3HeB/FeJ-Tg(Lck-Hhex)1Hro)	abnormal double-negative T cell morphology	J:80777
	decreased double-positive T cell number	J:80777
	decreased leukocyte cell number	J:80777
	decreased lymphocyte cell number	J:80777
	decreased T cell number	J:80777
	increased CD8-positive, alpha-beta T cell number	J:80777
	thymus hyperplasia	J:80777
Tg(Lck-Id1)28Xhsu/0 (Not Specified)	increased T cell derived lymphoma incidence	J:58607
Tg(Lck-Il31)1Jagr/0 (involves: C3H * C57BL/6)	abnormal immune system physiology	J:91124
	abnormal leukopoiesis	J:91124
	conjunctivitis	J:91124
	cutaneous mastocytosis	J:91124
	decreased T cell number	J:91124
	dermatitis	J:91124
	enlarged lymph nodes	J:91124
	increased activated T cell number	J:91124
	increased B cell number	J:91124
	increased memory T cell number	J:91124
Tg(Lck-LMO1)11Sjk/0 Tg(STIL-TAL1)A5.3Alpa/0 (involves: C3H * C3H/HeRos * C57BL/6 * C57BL/10Ros)	abnormal inflammatory response	J:40868
	enlarged lymph nodes	J:40868
	enlarged spleen	J:40868
	enlarged thymus	J:40868
	increased leukocyte cell number	J:40868
	increased T cell derived lymphoma incidence	J:40868
Tg(Lck-Map3k8)3456Ngc/? (involves: C3H/HeJ * C57BL/6J)	increased T cell derived lymphoma incidence	J:39450
Tg(LCK-NFKBIA)5Dwb/0 (involves: C57BL/6 * DBA/2)	abnormal CD8-positive, alpha-beta T cell differentiation	J:93003
	decreased CD4-positive, alpha-beta T cell number	J:93003
	decreased CD8-positive, alpha-beta T cell number	J:93003
	decreased interleukin-2 secretion	J:93003
	decreased T cell proliferation	J:93003
	increased T cell apoptosis	J:93003
Tg(LCK-NFKBIA)5Dwb/? (involves: BALB/c * C57BL/6 * DBA/2)	abnormal T-helper 1 physiology	J:145531
	decreased interferon-gamma secretion	J:145531
	decreased susceptibility to type I hypersensitivity reaction	J:145531
	decreased susceptibility to type IV hypersensitivity reaction	J:145531
Tg(LCK-NFKBIA)5Dwb/? Tg(Tcra,Tcrb)1Mcd/? (involves: BALB/c * C57BL/6 * DBA/2)	decreased interferon-gamma secretion	J:145531
Tg(Lck-Notch3)#Issc/0 (involves: C57BL/6 * DBA/2)	abnormal T cell differentiation	J:63300
	enlarged lymph nodes	J:63300
	enlarged spleen	J:63300
	increased double-negative T cell number	J:63300
	increased lymphoblastic lymphoma incidence	J:63300
	increased T cell derived lymphoma incidence	J:96010
	increased thymocyte number	J:63300
	thymus hyperplasia	J:63300
Tg(Lck-Socs3)1Kubo/0 (Not Specified)	abnormal CD4-positive T cell differentiation	J:132905
	decreased interleukin-2 secretion	J:128797
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:132905
	decreased T cell number	J:128797
	decreased T cell proliferation	J:128797
	decreased thymocyte number	J:128797
Tg(Lck-Sox13)#Jskg/0 (involves: C57BL/6)	decreased double-positive T cell number	J:117301
	decreased T cell proliferation	J:117301
	decreased thymocyte number	J:117301
	increased thymocyte apoptosis	J:117301
Tg(Lck-Stat5b*)1Mafa/0 (Not Specified)	decreased mature B cell number	J:132669
Tg(Lck-Stat5b*)1Mafa/0 (Not Specified)	increased B cell proliferation	J:132669
Tg(Lck-Stk17b)26.1Wals/? (B6.Cg-Tg(Lck-Stk17b)26.1Wals)	decreased CD4-positive, alpha-beta T cell number	J:149973
	decreased CD8-positive, alpha-beta T cell number	J:149973
	decreased single-positive T cell number	J:149973
	decreased thymocyte number	J:149973
	enlarged spleen	J:149973
	increased anti-nuclear antigen antibody level	J:149973
	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:149973
	increased double-positive T cell number	J:149973
	increased interleukin-2 secretion	J:149973
	increased spleen weight	J:149973
	increased susceptibility to experimental autoimmune encephalomyelitis	J:149973
	increased T cell proliferation	J:149973
	spleen hyperplasia	J:149973
Tg(Lck-Stk17b)26.1Wals/? Tg(TcraH-Y,TcrbH-Y)71Vbo/? (involves: C57BL/6 * C57BL/10)	abnormal T cell differentiation	J:149973
	decreased CD8-positive, alpha-beta T cell number	J:149973
	decreased thymocyte number	J:149973
	increased CD8-positive, alpha-beta T cell number	J:149973
Tg(Lck-Tal1)4709Led/0 (FVB/N-Tg(Lck-Tal1)4709Led)	abnormal thymus morphology	J:36076
	enlarged spleen	J:36076
	increased lymphoblastic lymphoma incidence	J:36076
Tg(Lck-Tax)53Hall/0 (involves: C57BL/6)	enlarged lymph nodes	J:129531
	enlarged spleen	J:129531
	hepatosplenomegaly	J:129531
	increased susceptibility to fungal infection	J:129531
	increased T cell derived lymphoma incidence	J:129531
Tg(Lck-Tnfsf4)1Nish/0 (B6.Cg-Tg(Lck-Tnfsf4)1Nish)	abnormal CD4-positive, alpha-beta T cell physiology	J:194882
	abnormal cytokine secretion	J:80214
	abnormal T cell subpopulation ratio	J:194882
	increased CD4-positive, alpha-beta T cell number	J:194882
	increased interleukin-13 secretion	J:194882
	increased regulatory T cell number	J:194882
	increased susceptibility to type IV hypersensitivity reaction	J:80214
	increased T cell proliferation	J:80214
	lung inflammation	J:194882
Tg(Lck-Tnfsf4)1Nish/0 (C.Cg-Tg(Lck-Tnfsf4)1Nish)	abnormal CD4-positive, alpha-beta T cell physiology	J:194882
	increased CD4-positive, alpha-beta T cell number	J:194882
	increased interleukin-13 secretion	J:194882
	increased regulatory T cell number	J:194882
Tg(Lck-TNFSF13)3919Mhah/0 (B6.Cg-Tg(Lck-TNFSF13)3919Mhah)	abnormal immune system organ morphology	J:94628
	abnormal mesenteric lymph node morphology	J:94628
	abnormal spleen morphology	J:94628
	decreased B cell apoptosis	J:94628
	enlarged mesenteric lymph nodes	J:94628
	enlarged Peyer's patches	J:94628
	increased B cell number	J:94628
	increased B-1 B cell number	J:94628
	increased CD4-positive, alpha-beta T cell number	J:94628
	increased CD8-positive, alpha-beta T cell number	J:94628
	increased IgA level	J:94628
	intermingled spleen red and white pulp	J:94628
	spleen hyperplasia	J:94628
Tg(Lck-Tnfsf14)24Yxf/? (C57BL/6-Tg(Lck-Tnfsf14)24Yxf)	abnormal complement protein level	J:128976
	abnormal inflammatory response	J:128976
	abnormal lymph node cell ratio	J:129951
	abnormal T cell physiology	J:120962, J:129951
	colitis	J:129951
	glomerulonephritis	J:129951
	increased anti-double stranded DNA antibody level	J:129951
	increased anti-nuclear antigen antibody level	J:128976
	increased autoantibody level	J:129951
	increased IgA level	J:128976
	increased IgG level	J:128976
	increased spleen weight	J:129951
	increased T cell proliferation	J:129951
	intestinal inflammation	J:128976
	liver inflammation	J:129951
	lung inflammation	J:129951
	lymph node hyperplasia	J:129951
	myositis	J:129951
	small intestinal inflammation	J:120962
	spleen hyperplasia	J:129951
Tg(Lck-Tnfsf15,-EGFP)#Targ/0 (involves: C57BL/6)	increased CD4-positive, alpha-beta memory T cell number	J:169462
	increased CD8-positive, alpha-beta memory T cell number	J:169462
	increased interferon-gamma secretion	J:169462
	increased interleukin-17 secretion	J:169462
	small intestinal inflammation	J:169462
Tg(Lck-Tslp)1Chea/0 (B6.Cg-Tg(Lck-Tslp)1Chea)	enlarged lymph nodes	J:72982
	enlarged spleen	J:72982
	glomerulonephritis	J:72982
	increased anti-nuclear antigen antibody level	J:72982
	increased immunoglobulin level	J:72982
	increased spleen weight	J:72982
	liver inflammation	J:72982
	lung inflammation	J:72982
Tg(Lck-VIPR2)1Ejg/0 (C57BL/6-Tg(Lck-VIPR2)1Ejg)	decreased interferon-gamma secretion	J:127974
	decreased susceptibility to type IV hypersensitivity reaction	J:127974
	increased eosinophil cell number	J:127974
	increased IgE level	J:127974
	increased IgG1 level	J:127974
	increased interleukin-4 secretion	J:127974
	increased interleukin-5 secretion	J:127974
	increased susceptibility to type I hypersensitivity reaction	J:127974
Tg(Lck/Emu-Rftn1)1Ayos/? (involves: C57BL/6)	increased IgG1 level	J:150299
	increased IgG2a level	J:150299
	increased IgG3 level	J:150299
	increased IgM level	J:150299
	increased interferon-gamma secretion	J:150299
	increased interleukin-4 secretion	J:150299
	increased interleukin-17 secretion	J:150299
	increased susceptibility to experimental autoimmune encephalomyelitis	J:150299
	increased T cell proliferation	J:150299
Tg(LckIl4)1315Dbl/0 (involves: C57BL/6J * DBA/2J)	abnormal osteoclast physiology	J:107359
	abnormal T cell activation	J:92453
	abnormal T cell differentiation	J:92453
	abnormal T cell number	J:92453
	abnormal thymocyte activation	J:92453
	abnormal thymus cell ratio	J:92453
	abnormal thymus morphology	J:92453
	absent CD8-positive, alpha-beta T cells	J:92453
	decreased CD4-positive, alpha-beta T cell number	J:92453
	decreased double-positive T cell number	J:92453
	increased CD4-positive, alpha-beta T cell number	J:92453
	increased CD8-positive, alpha-beta T cell number	J:92453
	increased double-negative T cell number	J:92453
	increased IgG2a level	J:92453
	increased interleukin-4 secretion	J:92453
	increased susceptibility to parasitic infection	J:92453
	thymus cortex hypoplasia	J:92453
	thymus hypoplasia	J:92453
Tg(LckNotch1)9Erob/? (involves: C57BL/6 * CBA/J)	abnormal CD8-positive, alpha-beta T cell differentiation	J:93005
	abnormal thymus cell ratio	J:93005
	decreased CD4-positive, alpha-beta T cell number	J:93005
	increased CD8-positive, alpha-beta T cell number	J:93005
	increased T cell derived lymphoma incidence	J:93005
Tg(LCKprBCL2)36Sjk/? (involves: C3H * C57BL/6)	abnormal T cell number	J:28635
	abnormal T cell subpopulation ratio	J:11548
	abnormal thymus cell ratio	J:11548
	decreased T cell apoptosis	J:11548
	increased CD8-positive, alpha-beta T cell number	J:11548
	increased T cell derived lymphoma incidence	J:28635
	increased T cell number	J:11548
Tg(LCKprBCL2)36Sjk/0 (B6.Cg-Tg(LCKprBCL2)36Sjk)	abnormal CD4-positive, alpha-beta T cell number	J:217939
	abnormal T cell subpopulation ratio	J:217939
	increased regulatory T cell number	J:217939
Tg(LCKprBCL2)36Sjk/0 (involves: C57BL/6 * CBA/J)	abnormal T cell clonal deletion	J:217939
Tg(LCKprBCL2)36Sjk/0 (involves: C57BL/6 * CBA/J)	decreased thymocyte apoptosis	J:217939
Tg(LCKprBCL2)36Sjk/0 Tg(Nr4a1-EGFP/cre)820Khog/0 (involves: C57BL/6 * C57BL/6J)	abnormal T cell clonal deletion	J:217939
	decreased thymocyte apoptosis	J:217939
Tg(LCKprBCL2)36Sjk/0 Tg(TcraH-Y,TcrbH-Y)71Vbo/0 (involves: C57BL/6 * C57BL/6J * DBA/2J)	abnormal T cell clonal deletion	J:217939
	decreased thymocyte apoptosis	J:217939
Tg(LCR-HBA2,LCR-HBB)1Cos/0 (involves: C57BL/6J CBA/J)	enlarged spleen	J:94193
Tg(Ly6a-BCR/ABL1)IS1AIsg/0 (involves: C57BL/6J * CBA)	abnormal lymph node morphology	J:144382
	abnormal spleen morphology	J:144382
	increased leukocyte cell number	J:144382
	increased neutrophil cell number	J:144382
	increased spleen red pulp amount	J:144382
	increased spleen weight	J:144382
Tg(Ly6a-BCR/ABL1)IS1BIsg/0 (involves: C57BL/6J * CBA)	abnormal lymph node morphology	J:144382
	abnormal spleen morphology	J:144382
	increased leukocyte cell number	J:144382
	increased neutrophil cell number	J:144382
	increased spleen red pulp amount	J:144382
	increased spleen weight	J:144382
Tg(Ly6a-GCSAM)102AIsg/0 (involves: C57BL/6J * CBA)	abnormal spleen morphology	J:221238
	decreased B-1 B cell number	J:221238
	enlarged Peyer's patches	J:221238
	enlarged spleen	J:221238
	increased B cell proliferation	J:221238
	increased B-1 B cell number	J:221238
	increased IgG level	J:221238
	increased inflammatory response	J:221238
	increased spleen white pulp amount	J:221238
	lymphoid hyperplasia	J:221238
Tg(Ly6a-SET/NUP214)2969Gcg/0 (involves: FVB/NJ)	abnormal B cell differentiation	J:142938
	decreased leukocyte cell number	J:142938
	decreased lymphocyte cell number	J:142938
	decreased pre-B cell number	J:142938
	decreased pro-B cell number	J:142938
	increased B cell apoptosis	J:142938
Tg(Ly6a-TK,-BCR/ABL1)IS9AIsg/0 (involves: C57BL/6J * CBA)	increased leukocyte cell number	J:144382
Tg(Ly6a-TK,-BCR/ABL1)IS9AIsg/0 (involves: C57BL/6J * CBA)	increased neutrophil cell number	J:144382
Tg(Ly6e-MALT1)#Isg/0 (involves: C57BL/6 * CBA)	increased mature B cell number	J:185590
	increased pre-B cell number	J:185590
	increased pro-B cell number	J:185590
Tg(LYZ-rtTA2SM2,tetO-ELAVL1)632Dkon/0 (B6.Cg-Tg(LYZ-rtTA2SM2,tetO-ELAVL1)632Dkon)	decreased susceptibility to induced colitis	J:184388
Tg(Mbp-Pad2)28Fgm/0 (involves: CD-1)	abnormal tumor necrosis factor level	J:142650
Tg(Mbp-SNCA)1Ema/0 (involves: C57BL/6 * DBA/2)	brain inflammation	J:207162
Tg(MCL1)8Caig/0 (involves: C57BL/6 * SJL)	abnormal immature B cell morphology	J:50604
	abnormal leukocyte physiology	J:50604
	abnormal macrophage apoptosis	J:95913
	abnormal mast cell differentiation	J:50604
	abnormal monocyte differentiation	J:50604
	decreased B cell apoptosis	J:50604
	decreased splenocyte apoptosis	J:50604
	decreased T cell apoptosis	J:50604
	increased spleen white pulp amount	J:50604
	increased susceptibility to bacterial infection	J:95913
	increased T cell derived lymphoma incidence	J:69755
	increased thymocyte number	J:50604
	spleen hyperplasia	J:50604
Tg(Mcpt8-cre)1Voeh/0 (involves: C57BL/6)	decreased basophil cell number	J:164432
	decreased inflammatory response	J:164432
	immune system phenotype	J:164432
Tg(Mir125a)#Smoc/0 (involves: C57BL/6)	decreased interferon-gamma secretion	J:224880
Tg(Mir125a)#Smoc/0 (involves: C57BL/6)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:224880
Tg(ML5sHEL)5Ccg/0 (C57BL/6-Tg(ML5sHEL)5Ccg)	abnormal B cell anergy	J:78308
Tg(ML5sHEL)5Ccg/0 (involves: C57BL/6JSfd * CBA)	abnormal B cell anergy	J:78308
Tg(ML5sHEL)5Ccg/0 (involves: C57BL/6JSfd * CBA)	abnormal T cell anergy	J:78308
Tg(ML5sHEL)5Ccg/0 Tg(TcrHEL3A9)1Mmd/0 (involves: C57BL/6 * C57BL/10 * C57BR/cd)	abnormal CD4-positive, alpha beta T cell morphology	J:78309
	abnormal CD4-positive, alpha-beta T cell physiology	J:78309
	abnormal T cell activation	J:78309
	abnormal T cell proliferation	J:78309
	decreased CD4-positive, alpha-beta T cell number	J:78309
	decreased double-positive T cell number	J:78309
Tg(ML5sHEL)5Ccg/0 Tg(TcrHEL3A9)1Mmd/0 Tg(TLK2mHEL)2Ccg/0 (involves: C57BL/6JSfd * C57BL/10 * C57BR/cd)	abnormal CD4-positive, alpha beta T cell morphology	J:78309
	abnormal CD4-positive, alpha-beta T cell physiology	J:78309
	abnormal T cell activation	J:78309
	abnormal T cell proliferation	J:78309
	decreased CD4-positive, alpha-beta T cell number	J:78309
	decreased double-positive T cell number	J:78309
	thyroid gland inflammation	J:78309
Tg(MMTV-ENPP2)#Gbm/0 (FVB/N-Tg(MMTV-ENPP2)#Gbm)	mastitis	J:149661
Tg(MMTV-Erbb2)9Pjo/0 (involves: BALB/c * C3H * C57BL/6)	enlarged spleen	J:72129
Tg(MMTV-Erbb2)9Pjo/0 (involves: BALB/c * C3H * C57BL/6)	increased spleen red pulp amount	J:72129
Tg(MMTV-Erbb2)10Pjo/0 (involves: BALB/c * C3H * C57BL/6)	enlarged spleen	J:72129
Tg(MMTV-Erbb2)10Pjo/0 (involves: BALB/c * C3H * C57BL/6)	increased spleen red pulp amount	J:72129
Tg(MMTV-Erbb2)12Pjo/0 (involves: BALB/c * C3H * C57BL/6)	enlarged spleen	J:72129
Tg(MMTV-Erbb2)12Pjo/0 (involves: BALB/c * C3H * C57BL/6)	increased spleen red pulp amount	J:72129
Tg(MMTV-Erbb2)17Pjo/0 (involves: BALB/c * C3H * C57BL/6)	enlarged spleen	J:72129
Tg(MMTV-Erbb2)17Pjo/0 (involves: BALB/c * C3H * C57BL/6)	increased spleen red pulp amount	J:72129
Tg(MMTV-LPAR1)2Gbm/Tg(MMTV-LPAR1)2Gbm (FVB/N-Tg(MMTV-LPAR1)2Gbm)	mastitis	J:149661
Tg(MMTV-LPAR1)7Gbm/Tg(MMTV-LPAR1)7Gbm (FVB/N-Tg(MMTV-LPAR1)7Gbm)	mastitis	J:149661
Tg(MMTV-LPAR1)#Gbm/Tg(MMTV-LPAR1)#Gbm (FVB/N-Tg(MMTV-LPAR1)#Gbm)	mastitis	J:149661
Tg(MMTV-LPAR2)3Gbm/Tg(MMTV-LPAR2)3Gbm (FVB/N-Tg(MMTV-LPAR2)3Gbm)	mastitis	J:149661
Tg(MMTV-LPAR2)6Gbm/Tg(MMTV-LPAR2)6Gbm (FVB/N-Tg(MMTV-LPAR2)6Gbm)	mastitis	J:149661
Tg(MMTV-LPAR2)#Gbm/Tg(MMTV-LPAR2)#Gbm (FVB/N-Tg(MMTV-LPAR2)#Gbm)	mastitis	J:149661
Tg(MMTV-LPAR3)3Gbm/Tg(MMTV-LPAR3)3Gbm (FVB/N-Tg(MMTV-LPAR3)3Gbm)	mastitis	J:149661
Tg(MMTV-LPAR3)#Gbm/Tg(MMTV-LPAR3)#Gbm (FVB/N-Tg(MMTV-LPAR3)#Gbm)	mastitis	J:149661
Tg(MMTV-PyVT)#Mul/0 (B6.FVB-Tg(MMTV-PyVT)#Mul)	abnormal circulating cytokine level	J:147923
	abnormal lymph node cell ratio	J:147923
	abnormal lymph node morphology	J:147923
	abnormal splenic cell ratio	J:147923
	abnormal T cell physiology	J:147923
	decreased B cell proliferation	J:147923
	decreased splenocyte proliferation	J:147923
	decreased T cell proliferation	J:147923
	enlarged spleen	J:147923
	increased circulating tumor necrosis factor level	J:147923
	increased regulatory T cell number	J:147923
	increased splenocyte number	J:147923
Tg(MMTV-Scgb1a1)#Abm/0 (involves: C57BL/6 * SJL)	increased IgA level	J:57504
Tg(Mpz-RAF1/ESR1)A668Ayld/0 (involves: C57BL/6J * CBA/J)	increased inflammatory response	J:182703
	increased macrophage cell number	J:182703
	increased mast cell number	J:182703
	increased neutrophil cell number	J:182703
	increased T cell number	J:182703
Tg(Msmb-TAg)183-2Xuan/0 (involves: C57BL/6 * CBA)	enlarged lymph nodes	J:80313
Tg(Msr1-MMP9)#Apar/0 (B6.Cg-Tg(Msr1-MMP9)#Apar)	abnormal macrophage physiology	J:136830
	decreased inflammatory response	J:129959
	immune system phenotype	J:136830
Tg(MSR1-Plau)1Ddi/0 (involves: C57BL/6 * SJL)	heart inflammation	J:101486
Tg(Mt1-Crry)26Quig/? (involves: CD-1)	abnormal inflammatory response	J:117777
Tg(Mt1-IL6)28Gci/0 (involves: C57BL/6 * DBA/2)	abnormal spleen morphology	J:18424
	enlarged lymph nodes	J:18424
	enlarged spleen	J:177825, J:18424
	increased circulating interleukin-6 level	J:177825
	increased circulating serum amyloid protein level	J:177825
	increased granulocyte number	J:177825
	increased IgG1 level	J:18424
	increased IgG level	J:177825, J:18424
	increased leukocyte cell number	J:18424
	increased neutrophil cell number	J:18424
	increased plasma cell number	J:177825, J:18424
	increased plasmacytoid dendritic cell number	J:177825
Tg(Mt1-TGFBR2*)AM3Epb/0 (involves: FVB/N)	pancreas inflammation	J:76993
Tg(MT2A-TGFBR2)4Rser/0 (involves: C57BL/6 * DBA)	osteoarthritis	J:44579
Tg(MtTGFA)42Lmb/Tg(MtTGFA)42Lmb (involves: CD-1)	immune system phenotype	J:28452
Tg(MUC1)79.24Gend/0 (involves: C57BL/6)	abnormal humoral immune response	J:128899
	increased IgG level	J:154046
	increased IgM level	J:154046
Tg(Mup3-Plau)350-2Eps/? (C57BL/6-Tg(Mup3-Plau)350-2Eps)	increased interleukin-1 beta secretion	J:233146
	increased tumor necrosis factor secretion	J:233146
	liver inflammation	J:233146
Tg(Mx1-cre)1Cgn/0 Tg(Tal1-tTA)19Dgt/0 Tg(tetO-BCR/ABL1)2Dgt/0 TgTn(pb-sb-GrOnc)#aGsva/0 (involves: C57BL/6 * CBA/J * DBA/2 * FVB/N)	increased granulocyte number	J:227558
	increased leukocyte cell number	J:227558
Tg(Mx1-cre)1Cgn/0 Thoc5^tm1Tate/Thoc5^tm1Tate (involves: C57BL/6 * CBA)	abnormal lymphopoiesis	J:169944
	decreased leukocyte cell number	J:169944
	decreased spleen weight	J:169944
Tg(Mx1-cre)1Cgn/0 Tnfrsf13c^tm2.1Mass/Tnfrsf13c^tm2.1Mass (involves: C57BL/6 * CBA)	increased immature B cell number	J:170519
	increased pre-B cell number	J:170519
	increased pro-B cell number	J:170519
Tg(Mx1-cre)1Cgn/0 Traf2^tm1Rbr/Traf2^tm1Rbr (involves: C57BL/6 * CBA)	abnormal spleen marginal zone morphology	J:93890
	abnormal spleen morphology	J:93890
	enlarged lymph nodes	J:93890
	enlarged spleen	J:93890
	increased B cell number	J:93890
	increased marginal zone B cell number	J:93890
Tg(Mx1-cre)1Cgn/0 U2af1^tm1.1Hev/U2af1⁺ (involves: 129S6/SvEvTac * BALB/c * C57BL/6 * C57BL/6J * CBA/J)	decreased leukocyte cell number	J:267082
Tg(Mx1-cre)1Cgn/0 U2af1^tm1Mohi/U2af1^tm1Mohi (involves: C57BL/6J * CBA/J)	bone marrow failure	J:308564
	decreased leukocyte cell number	J:308564
	decreased neutrophil cell number	J:308564
Tg(Mx1-cre)1Cgn/0 Zmiz1^{tm1c(EUCOMM)Hmgu}/Zmiz1^{tm1c(EUCOMM)Hmgu} (involves: C57BL/6 * C57BL/6J * C57BL/6N * CBA/J)	decreased B cell number	J:234445
	decreased NK cell number	J:234445
	decreased T cell number	J:234445
	thymus hypoplasia	J:234445
Tg(Mx1-cre)1Cgn/0 Znrf1^tm1Lchs/Znrf1^tm1Lchs (involves: C57BL/6)	decreased susceptibility to endotoxin shock	J:250572
Tg(Myh6*/tetO-Capn1)L3Gwd/0 (involves: FVB/N)	heart inflammation	J:133797
Tg(Myh6-BAG3P209L)#Mswi/0 (involves: C57BL/6 DBA/2)	heart inflammation	J:234278
Tg(Myh6-Grem2)1Akh/0 (involves: C57BL/6)	decreased inflammatory response	J:250034
Tg(Myh6-Grem2)1Akh/0 (involves: C57BL/6)	decreased interleukin-10 secretion	J:250034
Tg(Myh6-IGF1)34Pia/0 (FVB/N-Tg(Myh6-IGF1)34Pia)	increased spleen weight	J:35215
Tg(Myh6-JUP)1Dpju/0 (FVB/N-Tg(Myh6-JUP)1Dpju)	heart inflammation	J:235770
Tg(Myh6-Tnf)1Brgi/? (involves: C57BL/6J * SJL)	myocarditis	J:84829, J:100006
Tg(Myh6-Tnf)2Brgi/? (involves: C57BL/6J * SJL)	myocarditis	J:84829, J:100006
Tg(Myh6-Tnnt2*R92Q)2Lnwd/0 (involves: C57BL/6)	heart inflammation	J:56911
Tg(Myh6-Tnnt2*R92Q)3Lnwd/0 (involves: C57BL/6)	heart inflammation	J:56911
Tg(Myh6-tTA)6Smbf/0 Tg(tetO-EDN1,-lacZ)9Mhus/0 (involves: C57BL/6 * CBA)	heart inflammation	J:131245
Tg(Myh6-tTA)6Smbf/0 Tg(tetO-HDAC5)1Eno/0 (involves: C3H C57BL/6 * CBA)	myocarditis	J:81967
Tg(Myh6-tTA)6Smbf/0 Tg(tetO-NOS2,-lacZ)240iMhus/0 (involves: C57BL/6 * CBA)	heart inflammation	J:132082
Tg(Myh6-tTA)6Smbf/0 Tg(tetO-Spp1)5Gad/0 (involves: C57BL/6 * CBA)	heart inflammation	J:194810
	myocarditis	J:194810
Tg(Myl1-SOD1G93A)#Amu/0 (FVB/NJ-Tg(Myl1-SOD1G93A)#Amu)	increased microglial cell activation	J:143747
Tg(Nlrp1b)1Die/0 (involves: 129S1/SvImJ * C57BL/6 * SJL)	abnormal macrophage physiology	J:99748
Tg(Nr4a1-EGFP/cre)820Khog/0 (C57BL/6-Tg(Nr4a1-EGFP/cre)820Khog)	immune system phenotype	J:172415
Tg(OMP-SV40T)13Bse/0 (involves: C57BL/6 * SJL)	abnormal immune tolerance	J:54269
Tg(Pcp2-TBP*)69Hmhl/0 (involves: FVB/N)	brain inflammation	J:174239
Tg(PF4-tTA/VP16)42Kra/0 Tg(tetO-Aurkb,lacZ)41Kra/0 (FVB/NJ-Tg(tetO-Aurkb,lacZ)41Kra Tg(PF4-tTA/VP16)42Kra)	abnormal thrombopoiesis	J:104239
Tg(PF4MER)6Kra/? (FVB/N-Tg(PF4MER)6Kra)	enlarged spleen	J:35507
Tg(Pgk1-HA)1.1Vbo/? Tg(Tcra/Tcrb)1Vbo/? (involves: 129 * BALB/c * C57BL/6J * DBA/2J)	decreased CD4-positive, alpha-beta T cell number	J:125750
	increased double-positive T cell number	J:125750
	increased regulatory T cell number	J:125750
Tg(Pgk1-HA)1.1Vbo/? Tg(Tcra/Tcrb)1Vbo/? (C.Cg-Tg(Pgk1-HA)1.1Vbo Tg(Tcra/Tcrb)1Vbo)	abnormal regulatory T cell physiology	J:112603
	increased regulatory T cell number	J:112603
Tg(PGK1-KITLG220)441Daw/Tg(PGK1-KITLG220)441Daw (C3H/HeJ-Tg(PGK1-KITLG*220)441Daw)	abnormal thymus morphology	J:32600
Tg(Pim1-Il9)5Jcrd/0 (involves: BALB/c * FVB/N)	increased susceptibility to type I hypersensitivity reaction	J:100568
Tg(Pim1-Il9)5Jcrd/0 (involves: FVB/N)	increased interleukin-5 secretion	J:115764
	increased susceptibility to type I hypersensitivity reaction	J:100568
	increased T cell derived lymphoma incidence	J:17848
Tg(Pklr-HRASG12V)21Ak/0 (involves: C57BL/6 DBA/2)	abnormal thymus morphology	J:44803
Tg(Pklr-HRASG12V)21Ak/0 (involves: C57BL/6 DBA/2)	enlarged thymus	J:44803
Tg(Pklr-Myc)73Ak/0 (B6.Cg-Tg(Pklr-Myc)73Ak)	decreased NK T cell number	J:184496
Tg(PLA2G2A)703Dsg/? (involves: C57BL/6 * C57BL/6J * SJL)	immune system phenotype	J:113573
Tg(PLP1*)4Rsj/0 (involves: CD-1)	CNS inflammation	J:161344
Tg(Plp1-Eif2ak3)18Pop/0 (C57BL/6J-Tg(Plp1-Eif2ak3)18Pop)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:238042
Tg(Plp1-LMNB1)1108Qsp/0 (involves: FVB/N)	microgliosis	J:226169
Tg(Plp1-SNCA)1Haa/0 (involves: C57BL/6 * DBA/2)	microgliosis	J:96778
Tg(PML-RARA)556Kog/? (involves: FVB/N)	abnormal neutrophil differentiation	J:39327
Tg(PML-RARA)556Kog/0 (FVB/N-Tg(PML-RARA)556Kog)	enlarged spleen	J:262172
Tg(PML-RARA)556Kog/0 (FVB/N-Tg(PML-RARA)556Kog)	increased leukocyte cell number	J:262172
Tg(PMP22)C61Clh/0 (B6.Cg-Tg(PMP22)C61Clh)	increased macrophage cell number	J:158350
Tg(Prdx6)153Pgn/0 (C57BL/6-Tg(Prdx6)153Pgn/Pgn)	abnormal macrophage physiology	J:86528
Tg(PRG1)18Wlad/0 (involves: C57BL/6J * CBA/J)	decreased susceptibility to Picornaviridae infection	J:127826
	increased susceptibility to Picornaviridae infection	J:92990
	increased susceptibility to Picornaviridae infection induced morbidity/mortality	J:92990
Tg(PRG3)9Wlad/0 (involves: C57BL/6J * CBA/J)	increased susceptibility to Picornaviridae infection	J:92990, J:127826
Tg(Prnp)4053Sbp/0 (involves: FVB/N)	increased susceptibility to prion infection	J:136434
Tg(Prnp)a20Cwe/0 (Not Specified)	increased susceptibility to prion infection	J:130657, J:143528
Tg(Prnp-APP)1Hmor/0 (B6.Cg-Tg(Prnp-APP)1Hmor)	microgliosis	J:159623
Tg(Prnp-ATXN792Q)6529Als/Y (involves: C3H/HeJ C57BL/6J)	colitis	J:135615
Tg(Prnp-FUS)WT3Cshw/0 (involves: C57BL/6 * Crl:CD-1(ICR))	microgliosis	J:189360
Tg(Prnp-FUS)WT3Cshw/Tg(Prnp-FUS)WT3Cshw (involves: C57BL/6 * Crl:CD-1(ICR))	microgliosis	J:189360
Tg(Prnp-Immt/SOD1G93A)7Gmnf/Tg(Prnp-Immt/SOD1G93A)7Gmnf (involves: C57BL/6 * CBA * SJL)	dermatitis	J:177846
Tg(Prnp-ITM2B)1Ruvi/Tg(Prnp-ITM2B)1Ruvi Tg(Prnp-MAPTP301L)#Ruvi/Tg(Prnp-MAPTP301L)#Ruvi (involves: C3HeB/FeJ * C57BL/6)	increased inflammatory response	J:197198
Tg(Prnp-ITM2B)7Jckr/0 (C57BL/6-Tg(Prnp-ITM2B)7Jckr)	microgliosis	J:159279
Tg(Prnp-MAPTP301L)JNPL3Hlmc/? (involves: C57BL/6 DBA/2)	eye inflammation	J:63887
Tg(Prnp-MAPTR406W)21807Dwst/? (FVB/N-Tg(Prnp-MAPTR406W)21807Dwst)	microgliosis	J:95971
Tg(Prnp-PFN1C71G)22Zxu/0 Tg(Thy1-PFN1C71G)67Zxu/Tg(Thy1-PFN1*C71G)67Zxu (involves: FVB/N)	microgliosis	J:235427
Tg(Prnp-TARDBP)96Dwc/0 Tg(Prnp-TARDBPQ331K)31Dwc/0 (involves: C3H C57BL/6)	microgliosis	J:239141
Tg(Prnp-TARDBPQ331K)31Dwc/? (involves: C3H C57BL/6)	microgliosis	J:239141
Tg(Prox1-EGFP)KY221Gsat/0 (involves: FVB/NTac)	abnormal lymphangiogenesis	J:235778
Tg(Prox1-EGFP)KY221Gsat/0 (involves: FVB/NTac)	abnormal lymphatic vessel endothelial cell morphology	J:235778
Tg(PRSS1/lacZ)#Gwzh/0 (Not Specified)	increased susceptibility to induced pancreatitis	J:345508
Tg(Psp-Rbbp4)1Yoha/0 (involves: C57BL/6)	abnormal antigen presentation	J:141378
	abnormal T cell activation	J:141378
	increased autoantibody level	J:141378
	increased interferon-gamma secretion	J:141378
	increased interleukin-2 secretion	J:141378
	increased interleukin-18 secretion	J:141378
	increased marginal zone B cell number	J:141378
	increased susceptibility to autoimmune disorder	J:141378
	lacrimal gland inflammation	J:141378
	salivary gland inflammation	J:141378
Tg(PTH-CCND1)PC2Anar/0 (FVB/N-Tg(PTH-CCND1)PC2Anar)	increased osteoclast cell number	J:69423
Tg(PVR)1Kkst/0 (involves: ICR)	increased susceptibility to Picornaviridae infection	J:153943
Tg(RIP1-Tag)5Dh/? (C3HeB/FeJ-Tg(RIP1-Tag)5Dh)	pancreas inflammation	J:80168
Tg(Rr158-H2-Ea^d)1Flv/0 Tg(Tcra1H3.1,Tcrb1H3.1)1Vire/0 (involves: C57BL/6 * SJL)	decreased double-positive T cell number	J:124574
	thymus hypoplasia	J:124574
Tg(rv-CYCLIN)29Dlh/0 (involves: C57BL/6 * SJL)	lymphoid hyperplasia	J:62478
Tg(rv-CYCLIN)29Dlh/0 (involves: C57BL/6 * SJL)	spleen hyperplasia	J:62478
Tg(Scgb1a1-IL6)9Flv/0 (involves: C57BL/6 * CBA)	lung inflammation	J:128762, J:156430
Tg(Scgb1a1-Il13)2Eli/? (involves: C57BL/6 * CBA)	abnormal leukocyte physiology	J:53612
Tg(Scgb1a1-Il13)2Eli/? (involves: C57BL/6 * CBA)	respiratory system inflammation	J:53612
Tg(Scgb1a1-Il17a)3Cdon/0 (C57BL/6-Tg(Scgb1a1-Il17a)3Cdon)	abnormal chemokine level	J:112600
Tg(Scgb1a1-Il17a)3Cdon/0 (C57BL/6-Tg(Scgb1a1-Il17a)3Cdon)	lung inflammation	J:112600
Tg(Scgb1a1-Il17f,GFP)1Cdon/? (C57BL/6-Tg(Scgb1a1-Il17f,GFP)1Cdon)	lung inflammation	J:136279
Tg(Scgb1a1-Muc5b,-AcGFP)#Evns/0 (involves: C57BL/6J * C57BL/6N)	decreased susceptibility to bacterial infection	J:207159
Tg(Scgb1a1-PLUNC)#Chuh/0 (involves: FVB/N)	decreased susceptibility to bacterial infection	J:171589
Tg(Scgb1a1-rtTA)1Jaw/0 Tg(tetO-Aimp1)29872Mcla/0 (involves: 129 * C57BL/6)	increased macrophage cell number	J:173904
Tg(Scgb1a1-rtTA)1Jaw/0 Tg(tetO-EGFRT790ML858R)19Kkw/0 (involves: 129 * C57BL/6 * FVB/N)	interstitial pneumonia	J:122849
Tg(Scgb1a1-rtTA)1Jaw/0 Tg(tetO-IL1B)KBry/0 (involves: 129 * C57BL/6)	abnormal chemokine level	J:107601, J:130523
	lung inflammation	J:107601, J:130523
Tg(Scgb1a1-rtTA,-tTS,tetO-CHI3L1)1Eli/0 (Not Specified)	abnormal macrophage morphology	J:148490
	decreased T cell apoptosis	J:148490
	increased T-helper 2 cell number	J:148490
Tg(Scgb1a1-rtTA,-tTS,tetO-TGFB1*)1Eli/0 (involves: C57BL/6)	lung inflammation	J:92469
Tg(Scgb1a1-rtTA,tetO-Ifng)14Eli/0 (involves: C57BL/6 * CBA)	increased lymphocyte cell number	J:100854
	increased macrophage cell number	J:100854
	increased neutrophil cell number	J:100854
Tg(Scgb1a1-rtTA,tetO-Il13)1Eli/0 (involves: C57BL/6 * CBA)	abnormal T-helper 2 physiology	J:148490
Tg(Scgb1a1-rtTA,tetO-Il13)1Eli/0 (involves: C57BL/6 * CBA)	increased T-helper 2 cell number	J:148490
Tg(Scgb1a1-Scnn1b)6608Bouc/0 (involves: C3H * C57BL/6)	bronchitis	J:91139
Tg(Scgb1a1-Scnn1b)6608Bouc/0 (B6.Cg-Tg(Scgb1a1-Scnn1b)6608Bouc)	respiratory system inflammation	J:191673
Tg(Scgb1a1-Scnn1b)6608Bouc/0 (C.Cg-Tg(Scgb1a1-Scnn1b)6608Bouc)	respiratory system inflammation	J:191673
Tg(SERPINA1E342K)#Slcw/0 (involves: C57BL/6 ICR)	liver inflammation	J:149132
Tg(SERPINA1-HBVX)1655Jtsb/0 (involves: C3H * C57BL/6 * ICR)	liver inflammation	J:90305
Tg(SERPINA1-IGHG1/Il1rl1)423Zbz/? (involves: C3H * C57BL/6)	abnormal eosinophil physiology	J:63507
	abnormal response to infection	J:63507
	decreased interleukin-5 secretion	J:63507
	increased eosinophil cell number	J:63507
X/Tg(SERPINC1-SV40)BPbr (involves: C57BL/6 * DBA/2)	increased macrophage cell number	J:84204
Tg(SFTPC-DPP4)3Pbmj/0 (involves: C57BL/6J * SJL/J)	abnormal susceptibility to Coronaviridae infection	J:285467
Tg(SFTPC-Il18)AThos/0 (B6N.Cg-Tg(SFTPC-Il18)AThos)	abnormal spleen morphology	J:147547
	enlarged spleen	J:147547
	increased interferon-gamma secretion	J:147547
	increased interleukin-13 secretion	J:147547
	lung inflammation	J:147547
Tg(SFTPC-rtTA)2Jaw/0 Tg(tetO-CTGF)#Swu/0 (involves: 129 * C57BL/6 * C57BL/6J)	lung inflammation	J:171151
Tg(SFTPC-rtTA,tetO-Tnf)320-1Gwho/0 (involves: C57BL/6 * SJL)	abnormal B cell morphology	J:97297
	abnormal bronchus-associated lymphoid tissue morphology	J:97297
	abnormal CD4-positive, alpha beta T cell morphology	J:97297
	abnormal dendritic cell morphology	J:97297
	abnormal T cell morphology	J:97297
	increased CD8-positive, alpha-beta T cell number	J:97297
	increased lymphocyte cell number	J:97297
	increased neutrophil cell number	J:97297
	lung inflammation	J:97297
Tg(SFTPC-Tnf)2Pva/0 (involves: C57BL/6 * DBA/2)	alveolitis	J:28120
Tg(SFTPC-Tnf)2Pva/0 (involves: C57BL/6 * DBA/2)	interstitial pneumonia	J:28120
Tg(Sirt1)ASrn/? (involves: C57BL/6 * CBA)	increased susceptibility to endotoxin shock	J:137868
Tg(SOD1G93A)1Gur/0 (B6.Cg-Tg(SOD1G93A)1Gur/J)	abnormal spleen morphology	J:138237
	abnormal T cell physiology	J:138237
	decreased spleen weight	J:138237
	decreased splenocyte number	J:138237
Tg(SOD1G93A)1Gur/0 (B6SJL-Tg(SOD1G93A)1Gur/J)	abnormal lymphocyte morphology	J:129215
	abnormal microglial cell morphology	J:165019, J:143173
	abnormal spleen morphology	J:138237
	abnormal splenic cell ratio	J:138237
	abnormal splenocyte morphology	J:138237
	CNS inflammation	J:110437
	decreased eosinophil cell number	J:129215
	decreased leukocyte cell number	J:129215
	decreased lymphocyte cell number	J:129215
	decreased monocyte cell number	J:129215
	decreased spleen weight	J:138237
	increased basophil cell number	J:129215
	microgliosis	J:146652, J:165019, J:110437, J:143173
	small spleen	J:138237
Tg(SOD1G93A)^dl1Gur/0 (involves: C57BL/6 C57BL/6J * SJL/J)	microgliosis	J:128738
Tg(SOD1H46R)LAra/0 (involves: C57BL/6 DBA/2)	microgliosis	J:221350
Tg(SOD1H46RC111S)PAra/0 (involves: C57BL/6 * DBA/2)	microgliosis	J:221350
Tg(SOD1H46RC111S)PAra/Tg(SOD1H46RC111S)PAra (involves: C57BL/6 * DBA/2)	microgliosis	J:221350
Tg(SOD1H46RC111S)QAra/0 (involves: C57BL/6 * DBA/2)	microgliosis	J:221350
Tg(SOD1L126Z)45Dbo/0 (involves: C3H/HeJ C57BL/6J)	microgliosis	J:219482
Tg(Stat3*)9199Alau/0 (involves: C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:210877
	abnormal T-helper 17 cell differentiation	J:210877
	decreased IgG1 level	J:210877
	decreased IgG3 level	J:210877
	increased IgE level	J:210877
	increased inflammatory response	J:210877
	increased neutrophil cell number	J:210877
	increased susceptibility to bacterial infection	J:210877
	increased susceptibility to bacterial infection induced morbidity/mortality	J:210877
	increased susceptibility to endotoxin shock	J:210877
	intestinal inflammation	J:210877
Tg(SV40-Ahr)1Poe/0 (involves: C57BL/6 * CBA)	absent B-1a cells	J:82428
	decreased B-1 B cell number	J:82428
	decreased thymus weight	J:77977
	increased B-2 B cell number	J:82428
	increased mature B cell number	J:82428
	increased pre-B cell number	J:82428
	increased pro-B cell number	J:82428
Tg(SV40-Igh-64C8)H3Hon/0 Tg(SV40-Igk4C8)L1Hon/0 (involves: C57BL/6)	abnormal B cell clonal deletion	J:139864
	abnormal B cell number	J:139864
	increased anti-erythrocyte antigen antibody level	J:139864
Tg(SV40-KLK7)1010Teg/0 (involves: C57BL/6J * CBA)	dermatitis	J:75714
Tg(SV40-NRAS*G12D)1Sco/? (Not Specified)	increased T cell derived lymphoma incidence	J:125150
Tg(SV40/HTLV-FCER1A)1Bhk/0 (involves: 129)	immune system phenotype	J:47138
Tg(SV)419Bri/Tg(SV)419Bri (C57BL/6J-Tg(SV)419Bri)	increased T cell derived lymphoma incidence	J:147031
Tg(SV)427Bri/0 (C57BL/6J-Tg(SV)427Bri)	enlarged thymus	J:79096
Tg(TARDBP)#Jpj/0 (involves: C3H * C57BL/6)	microgliosis	J:195184
Tg(TARDBPA315T)#Jpj/0 (involves: C3H C57BL/6)	microgliosis	J:195184
Tg(TARDBPG348C)#Jpj/0 (involves: C3H C57BL/6)	abnormal cytokine level	J:195184
Tg(TARDBPG348C)#Jpj/0 (involves: C3H C57BL/6)	microgliosis	J:195184
Tg(TCF3/HLF)1Mlc/0 (involves: FVB/N)	abnormal CD4-positive, alpha beta T cell morphology	J:55022
	abnormal thymus involution	J:55022
	arrested T cell differentiation	J:55022
	decreased CD4-positive, alpha-beta T cell number	J:55022
	decreased CD8-positive, alpha-beta T cell number	J:55022
	decreased double-positive T cell number	J:55022
	decreased T cell number	J:55022
	decreased thymocyte number	J:55022
	increased T cell derived lymphoma incidence	J:55022
	thymus hypoplasia	J:55022
Tg(Tcra2B4)1Mmd/? (involves: C3H/HeJ * C57BL/6)	abnormal thymus cell ratio	J:92992
	decreased CD4-positive, alpha-beta T cell number	J:92992
	decreased double-positive T cell number	J:92992
	decreased thymocyte number	J:92992
	increased double-negative T cell number	J:92992
Tg(Tcra2C,Tcrb2C)1Dlo/? (involves: C57BL/6 * SJL)	abnormal CD8-positive, alpha beta T cell morphology	J:125259
Tg(Tcra2C,Tcrb2C)1Dlo/? (involves: C57L * DBA/2 * SJL)	abnormal memory T cell physiology	J:95380
	decreased lymphocyte cell number	J:95380
	decreased thymocyte number	J:95380
	increased CD4-positive, alpha-beta T cell number	J:95380
	seborrheic dermatitis	J:95380
Tg(Tcra2D2,Tcrb2D2)1Kuch/0 (involves: C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:83278
	abnormal cytokine secretion	J:83278
	blepharitis	J:83278
	CNS inflammation	J:83278
	increased susceptibility to autoimmune disorder	J:83278
	increased susceptibility to experimental autoimmune encephalomyelitis	J:83278
Tg(Tcra2D2,Tcrb2D2)1Kuch/? (involves: C57BL/6 * CD-1)	decreased interleukin-17 secretion	J:125296
Tg(Tcra2D2,Tcrb2D2)1Kuch/0 (involves: 129P2/OlaHsd * C57BL/6)	abnormal T-helper 1 cell number	J:189919
	decreased interferon-gamma secretion	J:189919
	decreased interleukin-2 secretion	J:189919
	decreased interleukin-10 secretion	J:189919
	decreased T cell proliferation	J:189919
	decreased T-helper 2 cell number	J:189919
	decreased T-helper 17 cell number	J:189919
	increased interferon-gamma secretion	J:189919
	increased interleukin-6 secretion	J:189919
	increased interleukin-17 secretion	J:189919
	increased T cell apoptosis	J:189919
	increased T cell proliferation	J:189919
Tg(Tcra5CC7,Tcrb5CC7)IWep/0 (involves: C57BL/6)	abnormal T cell activation	J:73608
Tg(Tcra51-11.5,Tcrb51-11.5)AR206Ayr/0 (involves: C57BL/6 * DBA/2)	abnormal positive T cell selection	J:125548
Tg(Tcra,Tcrb)3Ayr/0 (involves: C57BL/6 * DBA/2)	abnormal lymphocyte anergy	J:80775
	abnormal positive T cell selection	J:125548
	decreased T cell proliferation	J:80775
Tg(Tcra,Tcrb)24Efro/0 (D1.Cg-Tg(Tcra,Tcrb)24Efro)	abnormal cytokine secretion	J:104243
	abnormal T cell differentiation	J:104243
	autoimmune response	J:104243
	decreased T cell proliferation	J:104243
	increased autoantibody level	J:104243
	increased memory T cell number	J:104243
	increased susceptibility to autoimmune disorder	J:104243
	increased T cell proliferation	J:104243
Tg(Tcra,Tcrb)HRCAll/0 (B6.Cg-Tg(Tcra,Tcrb)HRCAll)	abnormal T cell subpopulation ratio	J:131347
	decreased CD4-positive, alpha-beta T cell number	J:131347
	decreased cytotoxic T cell cytolysis	J:131347
	decreased interferon-gamma secretion	J:131347
	increased CD8-positive, alpha-beta T cell number	J:131347
Tg(Tcra,Tcrb)HRVAll/0 (B6.Cg-Tg(Tcra,Tcrb)HRVAll)	abnormal T cell subpopulation ratio	J:131347
	decreased CD4-positive, alpha-beta T cell number	J:131347
	increased CD8-positive, alpha-beta T cell number	J:131347
Tg(TcraAI4)1Dvs/0 (NOD-Tg(TcraAI4)1Dvs)	abnormal CD4-positive, alpha beta T cell morphology	J:93553
Tg(TcraAI4)1Dvs/0 (NOD-Tg(TcraAI4)1Dvs)	increased susceptibility to autoimmune diabetes	J:93553
Tg(TcraAI4)1Dvs/0 Tg(TcrbAI4)1Dvs/0 (NOD-Tg(TcraAI4)1Dvs Tg(TcrbAI4)1Dvs)	abnormal CD4-positive, alpha beta T cell morphology	J:93553
	abnormal CD8-positive, alpha beta T cell morphology	J:94192
	abnormal cytotoxic T cell physiology	J:94192
	increased susceptibility to autoimmune diabetes	J:94192
Tg(TcraAV19AJ33)1Shima/? (involves: 129S4/SvJae * C57BL/6)	abnormal NK T cell morphology	J:112657
	abnormal NK T cell physiology	J:112657
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:112657
Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0 (NOD.Cg-Tg(TcraBDC2.5,TcrbBDC2.5)1Doi)	decreased susceptibility to autoimmune diabetes	J:87251
	increased activated T cell number	J:52940
	insulitis	J:52940
Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0 (involves: C57BL/6 * NOD * SJL)	decreased dendritic cell number	J:137009
	immune system phenotype	J:135214
	insulitis	J:137009
Tg(TcraCl1,TcrbCl1)1Shrm/0 (B10.Cg-Thy1^a H2^d Tg(TcraCl1,TcrbCl1)1Shrm)	abnormal T cell subpopulation ratio	J:97745
Tg(TcraCl4,TcrbCl4)1Shrm/? (B10.Cg-H2^d Tg(TcraCl4,TcrbCl4)1Shrm)	abnormal CD8-positive, alpha-beta T cell differentiation	J:99756
	abnormal T cell subpopulation ratio	J:99756
Tg(TcraDN32D3)#Alhn/0 (involves: NOD)	decreased NK cell number	J:201417
	decreased thymocyte number	J:201417
	increased double-negative T cell number	J:201417
Tg(TcraH-Y,TcrbH-Y)71Vbo/? (involves: C57BL/6J * C57L/J * DBA/2J)	abnormal double-negative T cell morphology	J:79738
	abnormal T cell differentiation	J:79738, J:90776
	decreased thymocyte number	J:79738
	thymus hypoplasia	J:79738
Tg(TcraH-Y,TcrbH-Y)71Vbo/? (involves: C57BL/6 * DBA/2J)	abnormal cytotoxic T cell physiology	J:66565
Tg(TcraH-Y,TcrbH-Y)71Vbo/? (involves: C57BL/6 * DBA/2J)	abnormal T cell differentiation	J:97610
Tg(TcraH-Y,TcrbH-Y)71Vbo/? Themis^tm1Gasc/Themis^tm1Gasc (involves: 129S6/SvEvTac * C57BL/6 * DBA/2)	abnormal negative T cell selection	J:151074
	abnormal positive T cell selection	J:151074
Tg(TcraH-Y,TcrbH-Y)71Vbo/? Themis^tm1Lov/Themis^tm1Lov (involves: 129 * C57BL/6 * DBA/2)	abnormal negative T cell selection	J:151075
	abnormal positive T cell selection	J:151075
	decreased single-positive T cell number	J:151075
	increased double-positive T cell number	J:151075
Tg(TcraH-Y,TcrbH-Y)71Vbo/0 Tnfrsf25^tm1Mjo/Tnfrsf25^tm1Mjo (involves: 129P2/OlaHsd * C57BL/6J * DBA/2J)	abnormal negative T cell selection	J:84536
	abnormal thymus morphology	J:84536
	increased thymocyte number	J:84536
Tg(TcrAND)53Hed/? (involves: A/WySnSg * C57BL/6 * C57BL/10SnSg * SJL)	abnormal positive T cell selection	J:85777
	abnormal T cell differentiation	J:85777
	abnormal T cell proliferation	J:85777
	abnormal T cell subpopulation ratio	J:85777
	abnormal thymocyte activation	J:85777
	decreased CD8-positive, alpha-beta T cell number	J:85777
	decreased double-positive T cell number	J:85777
	increased CD4-positive, alpha-beta T cell number	J:85777
Tg(TcrAND)53Hed/? (involves: C57BL/6 * SJL)	abnormal lymph node cell ratio	J:124701
Tg(TcrAND)53Hed/? (involves: C57BL/6 * SJL)	increased CD4-positive, alpha-beta T cell number	J:124701
Tg(TcrAND)53Hed/? Themis^tm1Gasc/Themis^tm1Gasc (involves: 129S6/SvEvTac * C57BL/6 * SJL)	abnormal positive T cell selection	J:151074
	decreased CD4-positive, alpha-beta T cell number	J:151074
	decreased CD8-positive, alpha-beta T cell number	J:151074
	increased double-positive T cell number	J:151074
Tg(TcrAND)53Hed/? Themis^tm1Lov/Themis^tm1Lov (involves: 129 * C57BL/6 * SJL)	abnormal positive T cell selection	J:151075
	decreased single-positive T cell number	J:151075
	increased double-positive T cell number	J:151075
Tg(TcrAND)53Hed/? Zbtb7b^tm1.1Rbo/Zbtb7b^tm1.1Rbo (involves: C57BL/6 * SJL)	abnormal T cell differentiation	J:141145
Tg(TcraR28,TcrbR28)KRNDim/0 (involves: C57BL/6 * NOD * SJL)	abnormal lymphocyte cell number	J:36815
	abnormal macrophage chemotaxis	J:36815
	abnormal T cell activation	J:36815
	abnormal T cell anergy	J:36815
	abnormal T cell clonal deletion	J:36815
	abnormal T cell proliferation	J:36815
	chronic joint inflammation	J:36815
	decreased CD4-positive, alpha-beta T cell number	J:36815
	decreased CD8-positive, alpha-beta T cell number	J:36815
	enlarged spleen	J:36815
	glomerulonephritis	J:36815
	impaired neutrophil recruitment	J:36815
	increased B cell number	J:36815
	increased IgG1 level	J:36815
	kidney inflammation	J:36815
	rheumatoid arthritis	J:36815
Tg(TcraTcrb)8Rest/? (C57BL/6-Tg(TcraTcrb)8Rest)	abnormal CD8-positive, alpha-beta cytotoxic T cell morphology	J:85058
	abnormal cytotoxic T cell physiology	J:85058
	increased interferon-gamma secretion	J:85058
Tg(TcraTcrb)425Cbn/0 (involves: BALB/c * C57BL/6)	abnormal positive T cell selection	J:125548
Tg(TcraTcrb)425Cbn/? (involves: BALB/c * C57BL/6)	abnormal positive T cell selection	J:87876
Tg(TcraTcrb)425Cbn/? (involves: BALB/c * C57BL/6)	increased CD4-positive, alpha-beta T cell number	J:87876
Tg(TcraTcrb)425Cbn/0 (involves: C57BL/6)	abnormal cytokine level	J:112600
Tg(TcraTcrb)425Cbn/0 Trim30a^tm1Yjk/Trim30a^tm1Yjk (involves: 129P2/OlaHsd * BALB/c * C57BL/6)	increased T cell proliferation	J:215171
Tg(TcraTcrb)425Cbn/0 Trip10^tm1.1Geha/Trip10^tm1.1Geha (B6.Cg-Trip10^tm1.1Geha Tg(TcraTcrb)425Cbn)	abnormal effector T cell morphology	J:164363
	decreased CD4-positive, alpha-beta T cell number	J:164363
	immune system phenotype	J:164363
Tg(TcraTcrb)1100Mjb/? (involves: C57BL/6)	abnormal CD8-positive, alpha beta T cell morphology	J:92867
	abnormal cytotoxic T cell physiology	J:92867, J:133645
	abnormal positive T cell selection	J:92867, J:133645
	abnormal T cell clonal deletion	J:92867
	abnormal T cell subpopulation ratio	J:92867, J:133645
	decreased CD4-positive, alpha-beta T cell number	J:133645
	increased CD8-positive, alpha-beta T cell number	J:92867, J:133645
	increased T cell proliferation	J:92867
Tg(TcraTcrb)1100Mjb/? (involves: C57BL/6 * MRL/Mp)	liver inflammation	J:72817
Tg(TcraTcrb)1100Mjb/? Themis^tm1Gasc/Themis^tm1Gasc (involves: 129S6/SvEvTac * C57BL/6)	abnormal positive T cell selection	J:151074
	decreased CD8-positive, alpha-beta T cell number	J:151074
	increased double-positive T cell number	J:151074
Tg(TcraTcrbNY4.1)1Pesa/0 (NOD.Cg-Tg(TcraTcrbNY4.1)1Pesa)	increased susceptibility to autoimmune diabetes	J:108768
Tg(TcraTcrbNY4.1)1Pesa/0 (NOD.Cg-Tg(TcraTcrbNY4.1)1Pesa)	insulitis	J:108768
Tg(TcraTcrbNY8.3)1Pesa/? (involves: C57BL/6 * NOD * SJL)	pancreas inflammation	J:44202
Tg(TcraY1,TcrbY1)416Tev/0 (involves: C57BL/6J * DBA/2J)	abnormal immune tolerance	J:84288
Tg(Tcrb)93Vbo/0 (involves: C57BL/LiA * CBA/BrA)	abnormal T cell morphology	J:93247
Tg(Tcrb)93Vbo/0 (involves: C57BL/LiA * CBA/BrA)	abnormal T cell receptor beta chain V(D)J recombination	J:93247
Tg(Tcrb)93Vbo/0 (involves: C57BL/6 * C57BL/LiA * CBA/BrA)	abnormal CD8-positive, alpha-beta T cell differentiation	J:66565
	abnormal cytotoxic T cell physiology	J:66565
	abnormal T cell clonal deletion	J:66565
Tg(Tcrb)HRBAll/0 (B6.Cg-Tg(Tcrb)HRBAll)	immune system phenotype	J:131347
Tg(Tcrb-TCF3/PBX1)19Gusa/0 (involves: C3H * C57BL/6 * C57BL/6J)	decreased thymocyte number	J:95693
Tg(Tcrb-TCF3/PBX1)23Gusa/0 (involves: C3H * C57BL/6 * C57BL/6J)	decreased thymocyte number	J:95693
Tg(TcrbAI4)1Dvs/0 (NOD-Tg(TcrbAI4)1Dvs)	abnormal CD4-positive, alpha beta T cell morphology	J:93553
Tg(TcrbBL17)1Lmor/0 (involves: DBA/1J * SWR/J)	increased susceptibility to induced arthritis	J:134111
Tg(TcrbBL17)1Lmor/Tg(TcrbBL17)1Lmor (involves: DBA/1J * SWR/J)	increased susceptibility to induced arthritis	J:134111
Tg(TcrHEL3A9)1Mmd/0 (involves: C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:73608
	abnormal interleukin secretion	J:73608
	abnormal T cell activation	J:73608
	increased T cell proliferation	J:73608
Tg(TcrHEL3A9)1Mmd/0 (involves: C57BL/6 * C57BL/10 * C57BR/cd)	abnormal CD4-positive, alpha beta T cell morphology	J:78309
	abnormal double-positive T cell morphology	J:78309
	abnormal T cell activation	J:78309
	abnormal T cell proliferation	J:78309
	abnormal thymus cell ratio	J:78309
	decreased CD4-positive, alpha-beta T cell number	J:78309
Tg(TcrHEL3A9)1Mmd/0 Tg(TLK2mHEL)2Ccg/0 (involves: C57BL/6 * C57BL/10 * C57BR/cd)	abnormal CD4-positive, alpha beta T cell morphology	J:78309
	abnormal CD4-positive, alpha-beta T cell physiology	J:78309
	abnormal T cell activation	J:78309
	abnormal T cell proliferation	J:78309
	decreased CD4-positive, alpha-beta T cell number	J:78309
	decreased double-positive T cell number	J:78309
	thyroid gland inflammation	J:78309
Tg(TcrLCMV)1Aox/? (C57BL/6-Tg(TcrLCMV)1Aox)	abnormal cytotoxic T cell physiology	J:92228
	decreased CD8-positive, alpha-beta T cell number	J:92228
	decreased double-positive T cell number	J:92228
	increased CD4-positive, alpha-beta T cell number	J:92228
	increased double-negative T cell number	J:92228
	increased IgG level	J:92228
Tg(TcrLCMV)2Aox/? (C57BL/6-Tg(TcrLCMV)2Aox)	abnormal cytotoxic T cell physiology	J:92228
	decreased CD8-positive, alpha-beta T cell number	J:92228
	decreased double-positive T cell number	J:92228
	increased CD4-positive, alpha-beta T cell number	J:92228
	increased double-negative T cell number	J:92228
Tg(TcrLCMV)327Sdz/0 (involves: C57BL/6 * DBA/2)	decreased CD8-positive, alpha-beta T cell number	J:77696
	decreased cytotoxic T cell cytolysis	J:77696
	decreased double-positive T cell number	J:77696
	decreased T cell proliferation	J:77696
	thymus hypoplasia	J:77696
Tg(TcrLCMV)327Sdz/? (involves: C57BL/6 * DBA/2J)	abnormal T cell differentiation	J:97610
Tg(TcrLCMV)327Sdz/? (involves: C57BL/6 * DBA/2J)	decreased CD4-positive, alpha-beta T cell number	J:97610
Tg(TcrLCMV)327Sdz/Tg(TcrLCMV)327Sdz (NOD.Cg-Tg(TcrLCMV)327Sdz/Dvs)	autoimmune response	J:71050
Tg(Tek-cre)1Ywa/0 Thbd^tm2Rdr/Thbd^tm2Wlr (involves: 129S2/SvPas * C57BL/6 * SJL)	abnormal acute phase protein level	J:71269
	increased circulating interleukin-6 level	J:71269
	increased spleen weight	J:71269
Tg(Tek-cre)1Ywa/0 Trp53^tm1Brn/Trp53^tm1Brn (involves: 129P2/OlaHsd * C57BL/6 * CD-1 * SJL)	increased T cell derived lymphoma incidence	J:263520
Tg(Tek-Jam3)1Maal/? (B6.Cg-Tg(Tek-Jam3)1Maal)	abnormal cellular extravasation	J:99020
	abnormal leukocyte adhesion	J:99020
	abnormal leukocyte physiology	J:99020
	impaired neutrophil chemotaxis	J:99020
	lung inflammation	J:99020
	peritoneal inflammation	J:99020
Tg(Tek-Procr)1Cte/0 (B6.FVB-Tg(Tek-Procr)1Cte)	abnormal acute phase protein level	J:119637
	abnormal immune system physiology	J:119637
	abnormal inflammatory response	J:119637
Tg(Tek-Tnf)5382Mcla/0 (B6.Cg-Tg(Tek-Tnf)5382Mcla)	chronic inflammation	J:71622
	chronic liver inflammation	J:71622
	decreased inflammatory response	J:71622
	kidney inflammation	J:71622
	lung inflammation	J:71622
Tg(Tek-tTA)1Dmt/0 Tg(tetO-Tek)1Dmt/0 (involves: CD-1)	abnormal spleen red pulp morphology	J:137745
	abnormal spleen white pulp morphology	J:137745
	enlarged spleen	J:137745
	increased eosinophil cell number	J:137745
	increased T cell number	J:137745
	skin inflammation	J:96718, J:137745
Tg(tetO-BCR/ABL1)2Dgt/0 Tg(MMTVtTA)1Mam/0 (involves: C57BL/6 * FVB/N * SJL)	enlarged lymph nodes	J:72377
	enlarged spleen	J:72377
	increased leukocyte cell number	J:72377
Tg(tetO-BCR/ABL1)2Dgt/0 Tg(Tal1-tTA)19Dgt/0 (involves: C57BL/6 * DBA/2 * FVB/N)	abnormal lymph node morphology	J:96511
	abnormal lymphopoiesis	J:96511
	abnormal spleen red pulp morphology	J:96511
	abnormal splenic cell ratio	J:96511
	enlarged spleen	J:96511
	increased leukocyte cell number	J:96511
	increased neutrophil cell number	J:96511
Tg(tetO-BCR/ABL1)27Dgt/0 Tg(MMTVtTA)1Mam/0 (involves: C57BL/6 * FVB/N * SJL)	enlarged lymph nodes	J:72377
	enlarged spleen	J:72377
	increased leukocyte cell number	J:72377
Tg(tetO-MAP2K1)#Ahsa/? Tg(CD2-rtTA)CRza/? (involves: C57BL/6 * C57BL/10 * CBA * SJL)	immune system phenotype	J:174339
	increased anti-double stranded DNA antibody level	J:174339
Tg(tetO/CMV-CD200)1Rmgo/Tg(tetO/CMV-CD200)1Rmgo (involves: C57BL/6)	abnormal dendritic cell physiology	J:134313
Tg(TetOp-Polb/tTA)2Sbl/0 (B6.Cg-Tg(TetOp-Polb/tTA)2Sbl)	glomerulonephritis	J:152481
Tg(TG-SV40)#Cled/0 (involves: C57BL/6J * DBA/2J)	spleen hypoplasia	J:209788
Tg(TG-SV40)#Cled/0 (involves: C57BL/6J * DBA/2J)	thymus hypoplasia	J:209788
Tg(TG-TSHR)51.9Smcl/? (involves: BALB/c * C57BL/6)	immune system phenotype	J:118100
Tg(Tgfa)1Efu/0 (Not Specified)	ear inflammation	J:65045
Tg(Th-SNCA)5Eric/Tg(Th-SNCA)5Eric (involves: C57BL/6)	abnormal microglial cell physiology	J:140907
Tg(THY1-APP)2Somm/0 (involves: C57BL/6J * DBA/2)	brain inflammation	J:44603
Tg(Thy1-APP)3Somm/0 (involves: C57BL/6J * DBA/2)	brain inflammation	J:44603
Tg(Thy1-APP)3Somm/0 (involves: C57BL/6J * DBA/2)	microgliosis	J:134832
Tg(Thy1-AppR609DK612E)2Vln/0 (involves: C57BL * CBA/J)	abnormal microglial cell morphology	J:32213
Tg(Thy1-AppR609DK612E)4Vln/0 (involves: FVB)	abnormal microglial cell morphology	J:32213
Tg(Thy1-AppR609DK612E)6Vln/0 (involves: FVB)	abnormal microglial cell morphology	J:32213
Tg(Thy1-APPDutch)#Jckr/0 (involves: C57BL/6J)	microgliosis	J:92796
Tg(Thy1-APPSw)10Jiri/0 (involves: C3H * C57BL/6)	microgliosis	J:128647
Tg(Thy1-APPSw)10Jiri/0 Tg(Thy1-PSEN1M146V)#Jiri/0 (B6.Cg-Tg(Thy1-APPSw)10Jiri Tg(Thy1-PSEN1M146V)#Jiri)	microgliosis	J:156577
Tg(Thy1-APPSwDutIowa)BWevn/0 (involves: C57BL/6)	abnormal microglial cell physiology	J:124911
Tg(Thy1-APPSweLon)41Ema/0 (involves: C57BL/6 * DBA/2)	microgliosis	J:162842
Tg(Thy1-cmyc)6Kio/0 (Not Specified)	increased T cell derived lymphoma incidence	J:129440
Tg(Thy1-cmyc)6LKio/0 (Not Specified)	increased T cell derived lymphoma incidence	J:129440
Tg(Thy1-Fcer2a)2431Putt/? (involves: BALB/c * C57BL/6)	abnormal immune system physiology	J:129296
	decreased IgE level	J:20421
	decreased IgG1 level	J:20421
	increased eosinophil cell number	J:20421
Tg(Thy1-Fcer2a)2733Putt/? (involves: BALB/c * C57BL/6)	immune system phenotype	J:20421
Tg(Thy1-FUS)1Dit/0 (B6.Cg-Tg(Thy1-FUS)1Dit)	microgliosis	J:287782
Tg(Thy1-FUS)1Dit/0 Tg(Thy1-TARDBP)4Singh/0 (involves: C57BL/6J DBA/2J * SJL/J)	microgliosis	J:287782
Tg(Thy1-FUS)19Vlb/0 (B6.Cg-Tg(Thy1-FUS)19Vlb)	microgliosis	J:203550
Tg(Thy1-MAPT)1Avil/Tg(Thy1-MAPT)1Avil (involves: C57BL/6 * CBA)	microgliosis	J:201700
Tg(Thy1-MAPTP301S)2541Godt/Tg(Thy1-MAPTP301S)2541Godt (involves: C57BL/6J * CBA/Ca)	eye inflammation	J:108870
Tg(Thy1-PSEN1M146V,-APPSwe)10Arte/Tg(Thy1-PSEN1M146V,-APPSwe)10Arte (involves: C57BL/6 * CBA)	microgliosis	J:155410
Tg(Thy1-Snca)1S13Putt/? (involves: C57BL/6)	microgliosis	J:177661
Tg(Thy1-SNCA)61Ema/0 (involves: C57BL/6 * DBA/2)	abnormal microglial cell activation	J:238066
Tg(Thy1-SNCA)61Ema/0 (involves: C57BL/6 * DBA/2)	abnormal microglial cell morphology	J:238066
Tg(Thy1-Sncg)HvP36Putt/? (C57BL/6-Tg(Thy1-Sncg)HvP36Putt)	microgliosis	J:185793
Tg(Thy1-TARDBP)4Singh/0 (involves: C57BL/6J * SJL/J)	microgliosis	J:157550
Tg(Thy1-TARDBP)4Singh/Tg(Thy1-TARDBP)4Singh (involves: C57BL/6J * SJL/J)	microgliosis	J:157550
Tg(Thy1-TARDBP)6Singh/Tg(Thy1-TARDBP)6Singh (involves: C57BL/6 * C57BL/6J * SJL)	microgliosis	J:157550
Tg(Thy1-UBQLN2P497S)3Mont/? (involves: C3H C57BL/6 * C57BL/6J)	increased microglial cell activation	J:239510
Tg(Thy1-UBQLN2P506T)6Mont/? (involves: C3H C57BL/6 * C57BL/6J)	decreased microglial cell activation	J:239510
Tg(Thy1/THY1)T6Gsv/0 (involves: C57BL/10 * CBA)	abnormal mononuclear cell morphology	J:294621
	increased macrophage derived foam cell number	J:294621
	increased neutrophil cell number	J:294621
Tg(Thy1/THY1)T12Gsv/0 (involves: C57BL/10 * CBA)	increased IgG level	J:133943
Tg(Thy1/THY1)T12Gsv/0 (involves: C57BL/10 * CBA)	increased IgM level	J:133943
Tg(Tk1-DPP4)27Ysj/0 (involves: C57BL/6 * FVB/N)	abnormal chemokine level	J:290259
	abnormal innate immunity	J:290259
	abnormal interleukin level	J:290259
	abnormal macrophage activation involved in immune response	J:290259
	abnormal tumor necrosis factor level	J:290259
	increased susceptibility to Coronaviridae infection	J:290259
	increased susceptibility to Coronaviridae infection induced morbidity/mortality	J:290259
	lung inflammation	J:290259
Tg(Tlr7)1Boll/0 (involves: C57BL/6)	abnormal circulating chemokine level	J:127600
	abnormal dendritic cell morphology	J:127600
	abnormal spleen morphology	J:127600
	autoimmune response	J:127600
	decreased spleen white pulp amount	J:127600
	enlarged spleen	J:127600
	glomerulonephritis	J:127600
	increased anti-nuclear antigen antibody level	J:127600
	increased circulating interleukin-6 level	J:127600
	increased circulating tumor necrosis factor level	J:127600
	liver inflammation	J:127600
X/Tg(Tlr7)6Boll (involves: C57BL/6)	abnormal B cell activation	J:127600
	abnormal B cell morphology	J:127600
	abnormal dendritic cell morphology	J:127600
	abnormal T cell activation	J:127600
	autoimmune response	J:127600
	decreased marginal zone B cell number	J:127600
	enlarged spleen	J:127600
	glomerulonephritis	J:127600
	increased anti-nuclear antigen antibody level	J:127600
	increased mature B cell number	J:127600
	increased splenocyte proliferation	J:127600
	liver inflammation	J:127600
	lung inflammation	J:127600
Tg(TNF)197Gkl/0 (involves: C57BL/6 * CBA)	abnormal osteoclast differentiation	J:97992
	autoimmune arthritis	J:97992, J:92576
	increased osteoclast cell number	J:97992
Tg(TNF)197Gkl/0 Tnfrsf1a^tm1.1Gkl/Tnfrsf1a^tm1.1Gkl (involves: 129 * C57BL/6 * CBA)	autoimmune arthritis	J:92470
	increased synovial pannus formation	J:92470
Tg(TNF)3647Gkl/0 (involves: C57BL/6 * CBA)	autoimmune arthritis	J:190204
Tg(Tnf)6074Gkl/0 (involves: C57BL/6 * CBA)	abnormal microglial cell morphology	J:106592
Tg(Tnf)6074Gkl/0 (involves: C57BL/6 * CBA)	brain inflammation	J:106592
Tg(Tnf)6074Gkl/0 Tnfrsf1b^tm1Mwm/Tnfrsf1b^tm1Mwm (involves: 129S2/SvPas * C57BL/6 * CBA)	CNS inflammation	J:106592
Tg(TNFSF11)5516Edou/0 Tnfsf11^tles/Tnfsf11^tles (involves: 129S6/SvEvTac * C57BL/6J * CBA/J)	absent lymph nodes	J:233240
Tg(TNFSF11)5519Edou/0 (involves: C57BL/6J * CBA/J)	increased osteoclast cell number	J:233240
Tg(Tnfsf13b)1Fma/0 (involves: C57BL/6 * DBA/2J)	abnormal B cell morphology	J:58798
	abnormal B cell physiology	J:58798
	abnormal spleen follicular dendritic cell network	J:58798
	abnormal spleen morphology	J:58798
	abnormal spleen periarteriolar lymphoid sheath morphology	J:58798
	abnormal T cell number	J:58798
	abnormal T cell physiology	J:58798
	abnormal T cell subpopulation ratio	J:58798
	enlarged lymph nodes	J:58798
	enlarged Peyer's patches	J:58798
	enlarged spleen	J:58798
	increased anti-double stranded DNA antibody level	J:58798
	increased anti-single stranded DNA antibody level	J:58798
	increased autoantibody level	J:58798
	increased B cell number	J:58798
	increased IgG level	J:58798
	increased IgM level	J:58798
	increased immunoglobulin level	J:58798
	increased lymphocyte cell number	J:58798
	increased marginal zone B cell number	J:58798
	increased mature B cell number	J:58798
	increased plasma cell number	J:58798
	increased spleen B cell follicle size	J:58798
	increased spleen germinal center size	J:58798
	increased T cell number	J:58798
Tg(Tnfsf13b)1Fma/0 (B6.Cg-Tg(Tnfsf13b)1Fma)	abnormal B cell differentiation	J:73711
	abnormal B-1 B cell morphology	J:114782
	abnormal spleen germinal center morphology	J:114782
	abnormal spleen marginal zone morphology	J:114782
	increased autoantibody level	J:114782
	increased B cell number	J:114782
	increased B-1a cell number	J:114782
	increased B-1b cell number	J:114782
	increased IgA level	J:114782
	increased plasma cell number	J:114782
	kidney inflammation	J:73711
	salivary gland inflammation	J:73711
Tg(Tnfsf13b)1Fma/0 (involves: C57BL/6J * DBA/2J)	abnormal B cell differentiation	J:115788
Tg(Tnfsf13b)1Fma/0 (involves: C57BL/6J * DBA/2J)	abnormal B-1 B cell morphology	J:115788
Tg(Tnfsf13b)1Fma/? (B6.Cg-Tg(Tnfsf13b)1Fma)	abnormal B cell activation	J:113556
	abnormal marginal zone B cell physiology	J:113556
	abnormal spleen marginal zone morphology	J:113556
	glomerulonephritis	J:113556
	increased anti-double stranded DNA antibody level	J:113556
	increased B cell number	J:113556
	increased marginal zone B cell number	J:113556
	increased transitional stage B cell number	J:113556
Tg(Tnfsf13b)1Fma/? Tnfrsf13b^tm1Rjb/Tnfrsf13b^tm1Rjb (B6.Cg-Tnfrsf13b^tm1Rjb Tg(Tnfsf13b)1Fma)	abnormal class switch recombination	J:113556
Tg(Tnfsf13b)1Fma/? Tnfrsf13c^tm1Mass/Tnfrsf13c^tm1Mass (B6.Cg-Tnfrsf13c^tm1Mass Tg(Tnfsf13b)1Fma)	abnormal class switch recombination	J:113556
Tg(Tnfsf13b)1Fma/0 Tnfsf14^tm1Kpf/Tnfsf14^tm1Kpf (involves: 129P2/OlaHsd * C57BL/6 * DBA/2J)	abnormal spleen germinal center morphology	J:114782
	abnormal spleen marginal zone morphology	J:114782
	increased B cell number	J:114782
	increased IgA level	J:114782
	increased plasma cell number	J:114782
Tg(Tnfsf13b)1Fma/Tg(Tnfsf13b)1Fma (involves: C57BL/6 * DBA/2)	abnormal immunoglobulin level	J:178227
	increased B cell number	J:178227
	increased IgA level	J:178227
	increased IgM level	J:178227
	increased immunoglobulin level	J:178227
	increased marginal zone B cell number	J:178227
	increased transitional stage T2 B cell number	J:178227
	kidney inflammation	J:178227
Tg(Tox)1Kay/? Tox^tm1.1Kay/Tox^tm1.1Kay (involves: 129S6/SvEvTac * C57BL/6)	abnormal T cell number	J:131287
Tg(Trp53)1Srn/0 (involves: C57BL/6 * CBA)	increased thymocyte apoptosis	J:80311
Tg(Trp53)1Srn/0 Trp53^tm1Tyj/Trp53^tm1Tyj (involves: 129S2/SvPas * C57BL/6 * CBA)	decreased thymocyte apoptosis	J:80311
Tg(Trp53)bSrn/0 (involves: C57BL/6 * CBA)	increased thymocyte apoptosis	J:80311
Tg(Trp53A135V)L3Ber/0 (involves: C57BL/6 * CD-1)	decreased spleen weight	J:73757
Tg(Ttr-IGF1)1Sykr/0 (FVB/N-Tg(Ttr-IGF1)1Sykr)	increased spleen weight	J:157350
Tg(Tyr-NRASQ61K)1Bee/? (involves: BALB/c C57BL/6J * DBA/2)	skin inflammation	J:98545
Tg(Tyr-NRASQ61K)1Bee/? (involves: C57BL/6J DBA/2)	skin inflammation	J:98545
Tg(UBC-scFv)2Nemz/0 (involves: C57BL/6 * DBA/2)	abnormal B cell differentiation	J:96759
	abnormal B cell morphology	J:96759
	abnormal B cell receptor editing	J:96759
	abnormal B-1 B cell morphology	J:96759
	abnormal immune tolerance	J:96759
	abnormal immunoglobulin level	J:96759
	abnormal mature B cell morphology	J:96759
	decreased mature B cell number	J:96759
	decreased splenocyte number	J:96759
	spleen hypoplasia	J:96759
Tg(Umod*C147W)958Lura/0 (involves: FVB)	kidney inflammation	J:161532
Tg(Vav1-Asxl1Y588X)#Fcy/0 (C57BL/6-Tg(Vav1-Asxl1Y588X)#Fcy)	abnormal neutrophil morphology	J:257690
	abnormal spleen morphology	J:257690
	decreased leukocyte cell number	J:257690
	decreased lymphocyte cell number	J:257690
	enlarged spleen	J:257690
	hepatosplenomegaly	J:257690
	increased leukocyte cell number	J:257690
	increased monocyte cell number	J:257690
	increased neutrophil cell number	J:257690
Tg(VAV1-cre)1Graf/? Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/? Trip11^tm1.1Psmi/Trip11^tm1.2Psmi (involves: 129/Sv * C57BL/6)	immune system phenotype	J:253969
Tg(Vav1-ERG)#Jpim/0 (involves: C57BL/6)	abnormal thymus morphology	J:174808
	enlarged spleen	J:174808
	enlarged thymus	J:174808
Tg(Vav1-JAK2V617F)AZjz/0 (involves: C57BL/6 DBA/2)	enlarged spleen	J:135993
	increased granulocyte number	J:135993
	increased leukocyte cell number	J:135993
	increased spleen weight	J:135993
	spleen fibrosis	J:135993
Tg(Vav1-Lin28b)C3Apla/0 (involves: C57BL/6)	abnormal cytokine level	J:189197
	abnormal inflammatory response	J:189197
	abnormal T cell differentiation	J:189197
	abnormal thymus cell ratio	J:189197
	abnormal thymus cortex morphology	J:189197
	abnormal thymus corticomedullary boundary morphology	J:189197
	decreased CD4-positive, alpha-beta T cell number	J:189197
	decreased CD8-positive, alpha-beta T cell number	J:189197
	decreased double-positive T cell number	J:189197
	decreased leukocyte cell number	J:189197
	decreased lymphocyte cell number	J:189197
	decreased thymocyte number	J:189197
	enlarged lymph nodes	J:189197
	enlarged spleen	J:189197
	enlarged thymus medulla	J:189197
	increased CD8-positive, alpha-beta T cell number	J:189197
	increased effector memory CD4-positive, alpha-beta T cell number	J:189197
	increased effector memory CD8-positive, alpha-beta T cell number	J:189197
	increased eosinophil cell number	J:189197
	increased IgG level	J:189197
	increased neutrophil cell number	J:189197
	increased T cell derived lymphoma incidence	J:189197
	increased T cell proliferation	J:189197
Tg(Vav1-NUP98/HOXD13)C1Apla/0 (FVB/N-Tg(Vav1-NUP98/HOXD13)C1Apla)	abnormal neutrophil morphology	J:107446
	decreased leukocyte cell number	J:107446
Tg(Vav1-NUP98/HOXD13)G2Apla/0 (C57BL/6-Tg(Vav1-NUP98/HOXD13)G2Apla)	abnormal neutrophil morphology	J:107446
	decreased leukocyte cell number	J:107446
	decreased lymphocyte cell number	J:107446
	decreased neutrophil cell number	J:107446
Tg(Vav1-STAT5BN642H)726Biat/0 (C57BL/6NCrl-Tg(Vav1-STAT5BN642H)726Biat)	abnormal effector T cell number	J:257519
	abnormal lymph node morphology	J:257519
	abnormal spleen morphology	J:257519
	enlarged spleen	J:257519
	increased CD4-positive, alpha-beta T cell number	J:257519
	increased CD8-positive, alpha-beta T cell number	J:257519
	increased leukocyte cell number	J:257519
	increased T cell proliferation	J:257519
Tg(Vav-BCL2)69Jad/0 (involves: C57BL/6J)	abnormal class switch recombination	J:88565
	abnormal lymphocyte cell number	J:88565
	abnormal somatic hypermutation frequency	J:88565
	abnormal spleen germinal center morphology	J:88565
	enlarged lymph nodes	J:88565
	enlarged spleen	J:88565
	glomerulonephritis	J:88565
	increased B cell number	J:88565
	increased CD4-positive, alpha-beta T cell number	J:88565
	increased CD8-positive, alpha-beta T cell number	J:88565
	increased spleen germinal center number	J:88565
	increased spleen germinal center size	J:88565
	increased T cell derived lymphoma incidence	J:88565
	increased T cell number	J:88565
Tg(Vil1-cre)997Gum/? Tlr4^lps-del/Tlr4^lps-del Tlr5^tm1.1Gewr/Tlr5^tm1.1Gewr (involves: C57BL/6J * C57BL/6NTac * C57BL/10ScN * SJL)	large intestinal inflammation	J:229155
Tg(Vil1-cre)997Gum/? Tlr5^tm1.1Gewr/Tlr5^tm1.1Gewr (involves: C57BL/6J * C57BL/6NTac * SJL/J)	enlarged spleen	J:229155
	increased interleukin-1 beta secretion	J:229155
	increased susceptibility to colitis induced morbidity/mortality	J:229155
	large intestinal inflammation	J:229155
Tg(Vil1-cre)997Gum/0 Tnfrsf11a^tm1.1Irw/Tnfrsf11a^tm1.1Irw (involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NTac * SJL)	abnormal Peyer's patch epithelium morphology	J:219915, J:226603
	abnormal Peyer's patch follicle morphology	J:226603
	abnormal Peyer's patch germinal center morphology	J:226603
	abnormal Peyer's patch morphology	J:226603
	abnormal Peyer's patch T cell area morphology	J:226603
	decreased IgA level	J:226603
	decreased plasma cell number	J:226603
Tg(Vil-SLC3A2)HEMerl/0 (involves: FVB/N)	colitis	J:173946
	increased circulating tumor necrosis factor level	J:173946
	increased susceptibility to induced colitis	J:173946
Tg(VIM-Tag)3Pau/0 (involves: C57BL/6 * SJL/J)	enlarged thymus	J:91542
	increased double-negative T cell number	J:91542
	thymus hyperplasia	J:91542
Tg(VIM-Tag)3Pau/0 (either: (involves: C57BL/6 * CBA * SJL/J) or (involves: C57BL/6 * SJL/J))	glomerulonephritis	J:92226
Tg(Wnt1)1Hev/0 Zfp451^em1Ssli/Zfp451^em1Ssli (involves: C57BL/6 * SJL)	abnormal macrophage morphology	J:338905
	decreased chemokine level	J:338905
Tg^m3Btlr/Tg^m3Btlr (C57BL/6J-Tg^m3Btlr)	decreased B cell number	J:265197
	decreased IgE level	J:265197
	increased susceptibility to induced colitis	J:265197
Tg^m4Btlr/Tg^m4Btlr (C57BL/6J-Tg^m4Btlr)	decreased B cell number	J:272522
	decreased B-2 B cell number	J:272522
	increased alpha-beta T cell number	J:272522
	increased B-1a cell number	J:272522
	increased CD4-positive, alpha-beta T cell number	J:272522
	increased CD8-positive, alpha-beta T cell number	J:272522
	increased central memory CD4-positive, alpha-beta T cell number	J:272522
	increased IgE level	J:272522
	increased macrophage cell number	J:272522
Tg^M5Btlr/Tg^M5Btlr (C57BL/6J-Tg^M5Btlr)	increased central memory CD4-positive, alpha-beta T cell number	J:272523
Tg^m6Btlr/Tg^m6Btlr (C57BL/6J-Tg^m6Btlr)	increased alpha-beta T cell number	J:272525
tga/tga (C57BL/6J-tga)	thymus hypoplasia	J:94456
Tgfa^tm1Ard/Tgfa^tm1Ard (involves: 129P2/OlaHsd * C57BL/6)	increased incidence of corneal inflammation	J:4606
Tgfa^tm1Unc/Tgfa^tm1Unc (involves: 129P2/OlaHsd * C57BL/6J)	immune system phenotype	J:4605
Tgfa^wa1/Tgfa^wa1 (Not Specified)	conjunctivitis	J:13115
Tgfa^wa1/Tgfa^wa1 (Not Specified)	keratoconjunctivitis	J:13115
Tgfb1^{tm1(Tgfb3)Kul}/Tgfb1^{tm1(Tgfb3)Kul} (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal T cell morphology	J:204892
	immune system phenotype	J:204892
	increased monocyte cell number	J:204892
	increased regulatory T cell number	J:204892
Tgfb1^tm1Doe/Tgfb1^tm1Doe (involves: 129S2/SvPas * CF-1)	abnormal inflammatory response	J:2892
	abnormal Peyer's patch germinal center morphology	J:2892
	brain inflammation	J:2892
	conjunctivitis	J:2892
	decreased Peyer's patch number	J:2892
	diaphragmitis	J:2892
	enlarged lymph nodes	J:2892
	eye inflammation	J:2892
	heart inflammation	J:2892
	increased leukocyte cell number	J:2892
	lacrimal gland inflammation	J:2892
	liver inflammation	J:2892
	lung inflammation	J:2892
	myositis	J:2892
	pancreas inflammation	J:2892
	salivary gland inflammation	J:2892
	skin inflammation	J:2892
	small spleen	J:2892
	stomach inflammation	J:2892
Tgfb1^tm1Doe/Tgfb1^tm1Doe (involves: 129S2/SvPas * BALB/c * CF-1)	heart inflammation	J:69346
	increased interferon-gamma secretion	J:69346
	liver inflammation	J:69346
	lung inflammation	J:69346
Tgfb1^tm1Doe/Tgfb1^tm1Doe (C.129S2-Tgfb1^tm1Doe)	decreased CD4-positive, alpha-beta T cell number	J:69346
	heart inflammation	J:69346
	increased CD4-positive, alpha-beta T cell number	J:69346
	increased interferon-gamma secretion	J:69346
	increased T-helper 1 cell number	J:69346
	liver inflammation	J:69346
Tgfb1^tm1Doe/Tgfb1^tm2.1Doe Tg(Lck-cre)548Jxm/? (involves: 129S2/SvPas * 129S6/SvEvTac * Black Swiss * BALB/c * C57BL/6 * CBA)	lung inflammation	J:150024
	salivary gland inflammation	J:150024
Tgfb1^tm1Jmu/Tgfb1^tm1Jmu (involves: 129S6/SvEvTac * C57BL/6)	abnormal immune system physiology	J:120085
	absent Langerhans cell	J:120085
	heart inflammation	J:120085
	liver inflammation	J:120085
	lung inflammation	J:120085
	pancreas inflammation	J:120085
	stomach inflammation	J:120085
Tgfb1^tm1Jmu/Tgfb1^tm1Jmu (involves: 129S6/SvEvTac * C57BL/6 * Swiss Webster)	abnormal immune system physiology	J:120085
	absent Langerhans cell	J:120085
Tgfb1^tm1N/Tgfb1^tm1N (involves: 129S/SvEv)	abnormal immune system physiology	J:120085
	absent Langerhans cell	J:120085
	atrial endocarditis	J:50848
	increased inflammatory response	J:50848
	interstitial pneumonia	J:50848
	lymph node inflammation	J:50848
	myocarditis	J:50848
	pancreas inflammation	J:50848
	pericarditis	J:50848
	phlebitis	J:50848
	salivary gland inflammation	J:50848
Tgfb1^tm1Rif/Tgfb1^tm1Rif (Not Specified)	abnormal immune system physiology	J:141786
Tgfb1^tm1Rif/Tgfb1^tm1Rif (either: (involves: 129) or (involves: 129S/SvEv * C57BL/6))	absent Langerhans cell	J:142353
	cecum inflammation	J:142353
	heart inflammation	J:142353
	increased inflammatory response	J:142353
	large intestinal inflammation	J:142353
	lung inflammation	J:142353
	proctitis	J:142353
	small intestinal inflammation	J:142353
	stomach inflammation	J:142353
Tgfb1^tm2Flv/B9d2/Tgfb1^tm1Flv Tg(CD207-cre)1Dhka/? (involves: 129S6/SvEvTac * C57BL/6J * SJL/J)	decreased Langerhans cell number	J:126147
Tgfb1^tm3.1Flv/Tgfb1^tm3.1Flv Tg(Cd4-cre)1Cwi/0 (involves: 129 * C57BL/6 * DBA/2 * NOD)	increased regulatory T cell number	J:196160
	increased T-helper 1 cell number	J:196160
Tgfb1^tm3.1Flv/Tgfb1^tm3.1Flv Tg(Cd4-cre)1Cwi/0 Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0 (involves: 129 * C57BL/6 * DBA/2 * NOD * SJL)	increased regulatory T cell number	J:196160
	increased susceptibility to autoimmune diabetes	J:196160
	increased T-helper 1 cell number	J:196160
Tgfb2^tm1Doe/Tgfb2^tm1Doe (involves: 129P2/OlaHsd * Black Swiss)	abnormal macrophage physiology	J:73681
Tgfb3^{tm1.1(KOMP)Vlcg}/Tgfb3⁺ (C57BL/6N-Tgfb3^{tm1.1(KOMP)Vlcg}/Tcp)	enlarged lymph nodes	J:211773
Tgfbi^tm1Zhao/Tgfbi^tm1Zhao (involves: 129 * C57BL/6J)	enlarged spleen	J:143036
Tgfbi^tm1Zhao/Tgfbi^tm1Zhao (involves: 129 * C57BL/6J)	increased B cell number	J:143036
Tgfbr2^tm1.2Hlm/Tgfbr2^tm1.2Hlm Tg(Cd4-cre)1Cwi/0 (involves: 129S6/SvEvTac * C57BL/6 * DBA/2)	abnormal T cell activation	J:148747
	autoimmune response	J:148747
	liver inflammation	J:148747
Tgfbr2^tm1.2Hlm/Tgfbr2^tm1.2Hlm Tg(Cd4-cre)1Cwi/0 (involves: 129 * C57BL/6 * DBA/2 * NOD)	increased inflammatory response	J:196160
Tgfbr2^tm1.2Hlm/Tgfbr2^tm1.2Hlm Tg(Cd4-cre)1Cwi/0 Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0 (involves: 129 * C57BL/6 * DBA/2 * NOD * SJL)	abnormal abdominal lymph node morphology	J:196160
	abnormal immune serum protein physiology	J:196160
	abnormal immune system morphology	J:196160
	abnormal immune system organ morphology	J:196160
	abnormal immune system physiology	J:196160
	abnormal interleukin secretion	J:196160
	abnormal spleen morphology	J:196160
	decreased interleukin-9 secretion	J:196160
	decreased interleukin-17 secretion	J:196160
	decreased regulatory T cell number	J:196160
	immune system phenotype	J:196160
	increased interferon-gamma secretion	J:196160
	increased interleukin-2 secretion	J:196160
	increased interleukin-21 secretion	J:196160
	increased regulatory T cell number	J:196160
	increased susceptibility to autoimmune diabetes	J:196160
	pancreas inflammation	J:196160
Tgfbr2^tm1.2Hlm/Tgfbr2^tm1.2Hlm Tg(CD207-cre)1Dhka/? (involves: 129S6/SvEvTac * C57BL/6J * SJL/J)	decreased Langerhans cell number	J:126147
Tgfbr2^tm1.2Hlm/Tgfbr2^tm1.2Hlm Tg(Foxp3-EGFP/cre)1cJbs/0 Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0 (involves: 129S6/SvEvTac * C57BL/6 * NOD * SJL)	immune system phenotype	J:196160
	increased regulatory T cell number	J:196160
Tgfbr2^tm1.2Hlm/Tgfbr2^tm1.2Hlm Tnfrsf4^tm2(cre)Nik/Tnfrsf4⁺ Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0 (involves: 129 * C57BL/6 * NOD * SJL)	immune system phenotype	J:196160
	increased susceptibility to autoimmune diabetes	J:196160
Tgfbr2^tm1Karl/Tgfbr2^tm1Karl H2az2^{Tg(Wnt1-cre)11Rth}/H2az2⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)	small thymus	J:96359
Tgfbr2^tm1Karl/Tgfbr2^tm1Karl Tg(Mx1-cre)1Cgn/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)	eye inflammation	J:77844
	increased inflammatory response	J:77844
	liver inflammation	J:77844
	pancreas inflammation	J:77844
	small thymus	J:77844
	stomach inflammation	J:77844
Tgfbr3^tm1Stv/Tgfbr3^tm1Stv (involves: 129/Sv * C57BL/6)	abnormal spleen morphology	J:83727
Tgfbr3^tm1Stv/Tgfbr3^tm1Stv (involves: 129/Sv * C57BL/6)	decreased spleen white pulp amount	J:83727
Tgif1^tm1.1Caw/Tgif1^tm1.1Caw (B6.129S-Tgif1^tm1.1Caw)	abnormal cytokine level	J:198238
Tgif1^tm1.1Caw/Tgif1^tm1.1Caw (B6.129S-Tgif1^tm1.1Caw)	increased susceptibility to otitis media	J:198238
Tgm2^tm1.1Rmgr/Tgm2^tm1.1Rmgr (involves: 129S1/SvImJ * C57BL/6)	abnormal T cell physiology	J:95130
Tgm2^tm1Gml/Tgm2^tm1Gml (involves: C57BL/6)	decreased susceptibility to endotoxin shock	J:131975
	immune system phenotype	J:131975
	increased macrophage cell number	J:131975
Tgm2^tm1Gml/Tgm2^tm1Gml (involves: C57BL/6 * DBA/1LacJ)	abnormal thymus morphology	J:132254
Tgm2^tm1Gml/Tgm2^tm1Gml (involves: C57BL/6 * DBA/1LacJ)	impaired macrophage phagocytosis	J:132254
Tgm6^em1Bge/Tgm6^em1Bge (C57BL/6N-Tgm6^em1Bge)	increased susceptibility to bacterial infection	J:268324
TgTn(pb-CAG-Gm614)#Cya/0 (involves: C57BL/6)	decreased B cell apoptosis	J:307345
	immune system phenotype	J:307345
	increased susceptibility to systemic lupus erythematosus	J:307345
TgTn(pb-CAG-Gm40600)#Rew/0 (C57BL/6-TgTn(pb-CAG-Gm40600)#Rew)	abnormal plasmablast number	J:311878
	decreased B cell number	J:311878
	decreased IgA level	J:311878
	decreased IgE level	J:311878
	decreased IgG1 level	J:311878
	decreased IgG2b level	J:311878
	decreased IgG2c level	J:311878
	decreased IgG3 level	J:311878
	decreased IgG level	J:311878
	decreased IgM level	J:311878
	decreased plasma cell number	J:311878
	increased B cell number	J:311878
	increased IgA level	J:311878
	increased IgE level	J:311878
	increased IgG1 level	J:311878
	increased IgG2b level	J:311878
	increased IgG2c level	J:311878
	increased IgG3 level	J:311878
	increased IgG level	J:311878
	increased IgM level	J:311878
	increased plasma cell number	J:311878
Thap4^em1Nvl/Thap4^em1Nvl (C57BL/6JJcl-Thap4^em1Nvl)	increased thymus weight	J:350810
Thbd^tm1.1Hlwu/Thbd^tm1.1Hlwu Lyz2^tm1(cre)Ifo/Lyz2⁺ (B6.129-Thbd^tm1.1Hlwu Lyz2^tm1(cre)Ifo)	decreased circulating interleukin-6 level	J:188879
	decreased circulating tumor necrosis factor level	J:188879
	decreased susceptibility to bacterial infection	J:188879
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:188879
	decreased tumor necrosis factor secretion	J:188879
Thbd^tm1Wlr/Thbd^tm1Wlr (B6.129S2-Thbd^tm1Wlr)	abnormal spleen morphology	J:111502
	decreased circulating tumor necrosis factor level	J:111502
	increased circulating interleukin-1 beta level	J:111502
	increased circulating interleukin-6 level	J:111502
	increased susceptibility to endotoxin shock	J:111502
Thbd^tm1Wlr/Thbd^tm2Rdr (involves: 129S2/SvPas * C57BL/6)	abnormal spleen morphology	J:111502, J:47676
Thbd^tm2.1Emc/Thbd^tm2.1Emc (involves: 129/Sv * BALB/c * C57BL/6)	abnormal leukocyte adhesion	J:118000
	abnormal leukocyte physiology	J:118000
	increased circulating interleukin-1 beta level	J:118000
	increased circulating tumor necrosis factor level	J:118000
	increased susceptibility to endotoxin shock	J:118000
Thbd^tm2Emc/Thbd^tm2Emc (either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6))	abnormal leukocyte physiology	J:118000
Thbs1^tm1Hyn/Thbs1^tm1Hyn (either: (involves: 129S2/SvPas * 129/Sv) or (involves: 129S2/SvPas * C57BL/6))	increased eosinophil cell number	J:46182
	increased leukocyte cell number	J:46182
	increased lymphocyte cell number	J:46182
	increased monocyte cell number	J:46182
	increased neutrophil cell number	J:46182
	lung inflammation	J:46182, J:48446
	pancreas inflammation	J:48446
Thbs1^tm1Hyn/Thbs1^tm1Hyn (involves: 129S2/SvPas * C57BL/6)	decreased interferon-gamma secretion	J:153126
	decreased regulatory T cell number	J:153126
	increased anti-single stranded DNA antibody level	J:153126
	increased CD4-positive, alpha-beta T cell number	J:153126
	increased interleukin-17 secretion	J:153126
	lacrimal gland inflammation	J:153126
Thbs1^tm1Hyn/Thbs1^tm1Hyn Thbs2^tm1Bst/Thbs2^tm1Bst (involves: 129T2/SvEms * 129X1/SvJ)	impaired macrophage chemotaxis	J:78876
	lung inflammation	J:78876
Thbs2^em1(IMPC)Mbp/Thbs2^em1(IMPC)Mbp (C57BL/6NCrl-Thbs2^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Thbs4^tm1Dgen/Thbs4^tm1Dgen (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:301049
	increased macrophage cell number	J:301049
Thbs4^tm1Olsa/Thbs4^tm1Olsa (C57BL/6J-Thbs4^tm1Olsa)	decreased macrophage cell number	J:301049
Thcr^BALB/cJ/? (involves: BALB/cJ * C57BL/10J * DBA/2J)	decreased interferon-gamma secretion	J:86188
Thcr^BALB/cJ/? (involves: BALB/cJ * C57BL/10J * DBA/2J)	increased interleukin-4 secretion	J:86188
Thcr^C57BL/10Sn/? (involves: BALB/cJ * C57BL/10J * DBA/2J)	decreased interleukin-4 secretion	J:86188
Thcr^C57BL/10Sn/? (involves: BALB/cJ * C57BL/10J * DBA/2J)	increased interferon-gamma secretion	J:86188
Themis2^{tm1d(KOMP)Wtsi}/Themis2^{tm1d(KOMP)Wtsi} (involves: 129S4/SvJae * C57BL/6 * C57BL/6N * SJL)	immune system phenotype	J:232061
Themis^5AT161/Themis^5AT161 (involves: C57BL/6)	decreased CD4-positive, alpha-beta T cell number	J:151076
	decreased CD8-positive, alpha-beta T cell number	J:151076
	decreased regulatory T cell number	J:151076
	decreased single-positive T cell number	J:151076
Themis^m1Btlr/Themis^m1Btlr (C57BL/6J-Themis^m1Btlr)	abnormal lymphocyte morphology	J:211400
	decreased B-1a cell number	J:211400
	decreased CD4-positive, alpha-beta T cell number	J:211400
	decreased CD8-positive, alpha-beta T cell number	J:211400
	immune system phenotype	J:211400
	impaired humoral immune response	J:211400
Themis^m2Btlr/Themis^m2Btlr (C57BL/6J-Themis^m2Btlr)	decreased CD4-positive, alpha-beta T cell number	J:236691
	decreased T cell number	J:236691
	increased CD8-positive, alpha-beta T cell number	J:236691
	increased effector memory CD4-positive, alpha-beta T cell number	J:236691
Themis^m3Btlr/Themis^m3Btlr (C57BL/6J-Themis^m3Btlr)	abnormal CD8-positive, alpha-beta cytotoxic T cell morphology	J:254834
	decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:254834
	decreased CD8-positive, alpha-beta memory T cell number	J:254834
	decreased CD8-positive, naive alpha-beta T cell number	J:254834
	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:254834
	increased CD8-positive, alpha-beta memory T cell number	J:254834
	increased central memory CD4-positive, alpha-beta T cell number	J:254834
	increased central memory CD8 positive, alpha-beta T cell number	J:254834
	increased effector memory CD4-positive, alpha-beta T cell number	J:254834
Themis^M4Btlr/Themis^M4Btlr (C57BL/6J-Themis^M4Btlr)	decreased CD4-positive, alpha-beta T cell number	J:272849
Themis^m5Btlr/Themis^m5Btlr (C57BL/6J-Themis^m5Btlr)	abnormal CD4-positive T cell differentiation	J:274716
	abnormal CD8-positive, alpha-beta T cell differentiation	J:274716
	abnormal T cell differentiation	J:274716
	decreased alpha-beta T cell number	J:274716
	decreased CD4-positive, alpha-beta T cell number	J:274716
	decreased CD8-positive, alpha-beta T cell number	J:274716
	decreased CD8-positive, naive alpha-beta T cell number	J:274716
	increased CD8-positive, alpha-beta memory T cell number	J:274716
	increased central memory CD4-positive, alpha-beta T cell number	J:274716
	increased central memory CD8 positive, alpha-beta T cell number	J:274716
	increased effector memory CD4-positive, alpha-beta T cell number	J:274716
	increased effector memory CD8-positive, alpha-beta T cell number	J:274716
	increased NK T cell number	J:274716
Themis^Spotr/Themis⁺ (C57BL/6-Themis^Spotr)	decreased CD4-positive, alpha-beta T cell number	J:152601
Themis^Spotr/Themis⁺ (C57BL/6-Themis^Spotr)	decreased CD8-positive, alpha-beta T cell number	J:152601
Themis^Spotr/Themis^Spotr (C57BL/6-Themis^Spotr)	abnormal T cell differentiation	J:152601
	decreased CD4-positive, alpha-beta T cell number	J:152601
	decreased CD8-positive, alpha-beta T cell number	J:152601
	small thymus medulla	J:152601
Themis^tm1.1Hko/Themis⁺ (Not Specified)	decreased CD4-positive, alpha-beta T cell number	J:152601
Themis^tm1.1Hko/Themis⁺ (Not Specified)	decreased CD8-positive, alpha-beta T cell number	J:152601
Themis^tm1.1Hko/Themis^tm1.1Hko (Not Specified)	decreased CD4-positive, alpha-beta T cell number	J:152601
	decreased CD8-positive, alpha-beta T cell number	J:152601
	decreased single-positive T cell number	J:152601
Themis^tm1Gasc/Themis^tm1Gasc (B6.129S-Themis^tm1Gasc)	abnormal memory T cell morphology	J:151074
	abnormal positive T cell selection	J:151074
	abnormal regulatory T cell morphology	J:151074
	abnormal thymus medulla morphology	J:151074
	decreased CD4-positive, alpha-beta T cell number	J:151074
	decreased CD8-positive, alpha-beta T cell number	J:151074
	decreased T cell proliferation	J:151074
	decreased thymocyte number	J:151074
	increased double-positive T cell number	J:151074
Themis^tm1Hasu/Themis⁺ (involves: C57BL/6 * CBA)	decreased CD4-positive, alpha-beta T cell number	J:153235
Themis^tm1Hasu/Themis⁺ (involves: C57BL/6 * CBA)	decreased CD8-positive, alpha-beta T cell number	J:153235
Themis^tm1Hasu/Themis^tm1Hasu (involves: C57BL/6 * CBA)	abnormal T cell differentiation	J:153235
	decreased CD4-positive, alpha-beta T cell number	J:153235
	decreased CD8-positive, alpha-beta T cell number	J:153235
	decreased splenocyte number	J:153235
	decreased thymocyte number	J:153235
	increased memory T cell number	J:153235
	increased T cell proliferation	J:153235
Themis^tm1Lov/Themis^tm1Lov (involves: 129)	abnormal negative T cell selection	J:151075
	abnormal T cell differentiation	J:151075
	decreased CD4-positive, alpha-beta T cell number	J:151075
	decreased CD8-positive, alpha-beta T cell number	J:151075
	decreased regulatory T cell number	J:151075
	decreased single-positive T cell number	J:151075
	increased memory T cell number	J:151075
Thim^{Tg(Myh6-TGFB1)1Ljf}/Thim⁺ (involves: C3HeB/FeJ)	increased T cell derived lymphoma incidence	J:59903
thnh/thnh (NOD.Cg-H2^b thnh/J)	folliculitis	J:142872
Thnsl2^em1(IMPC)Tcp/Thnsl2^em1(IMPC)Tcp (C57BL/6NCrl-Thnsl2^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Thoc1^{em1(IMPC)Ccpcz}/Thoc1⁺ (C57BL/6NCrl-Thoc1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Thoc6^em5(IMPC)Tcp/Thoc6⁺ (C57BL/6NCrl-Thoc6^em5(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Thop1^em1(IMPC)Mbp/Thop1^em1(IMPC)Mbp (C57BL/6NCrl-Thop1^em1(IMPC)Mbp/MbpMmucd)	decreased leukocyte cell number	J:211773
Thop1^{Gt(CSG163)Byg}/Thop1^{Gt(CSG163)Byg} (B6.129P2-Thop1^{Gt(CSG163)Byg})	decreased lymphocyte cell number	J:290567
	decreased susceptibility to infection	J:290567
	decreased susceptibility to infection induced morbidity/mortality	J:290567
	increased granulocyte number	J:290567
	increased monocyte cell number	J:290567
	increased susceptibility to experimental autoimmune encephalomyelitis	J:290567
Thpo^tm1Mwm/Thpo^tm1Mwm (involves: 129S2/SvPas * C57BL/6)	immune system phenotype	J:83262
Thra^tm1Ffla/Thra⁺ Tg(Sycp1-cre)4Min/? (involves: 129/Sv * C57BL/6 * DBA/2)	decreased spleen weight	J:125353
Thra^tm1Syc/Thra⁺ (involves: 129S6/SvEvTac * C57BL/6J * NIH Black Swiss)	abnormal osteoclast physiology	J:217018
	decreased osteoclast cell number	J:217018
Thra^tm2Jas/Thra^tm2Jas (involves: 129)	abnormal osteoclast physiology	J:120899
Thra^tm2Jas/Thra^tm2Jas (involves: 129)	decreased osteoclast cell number	J:120899
Thra^tm2Ven/Thra^tm2Ven (involves: 129P2/OlaHsd * BALB/c)	abnormal osteoclast physiology	J:72959
Thrb^tm1Olc/Thrb^tm1Olc (involves: 129)	abnormal osteoclast physiology	J:120899
Thrb^tm1Olc/Thrb^tm1Olc (involves: 129)	increased osteoclast cell number	J:120899
Thtpa^em1(IMPC)Tcp/Thtpa^em1(IMPC)Tcp (C57BL/6NCrl-Thtpa^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Thyct1^C57BL/6J/Thyct1^C57BL/6J Thyct2^C57BL/6J/Thyct2^C57BL/6J (involves: C57BL/6J * DBA/2J)	thymus hyperplasia	J:85261
Thyct1^DBA/2J/Thyct1^DBA/2J Thyct2^DBA/2J/Thyct2^DBA/2J (involves: C57BL/6J * DBA/2J)	thymus hypoplasia	J:85261
Thyls2^MSM/Thyls2^MSM (involves: BALB/c * MSM)	increased T cell derived lymphoma incidence	J:87704
Thypr1^DBA/2J/? (involves: C57BL/6J * DBA/2J)	increased T cell proliferation	J:76931
Thypr2^DBA/2J/? (involves: C57BL/6J * DBA/2J)	increased T cell proliferation	J:76931
Tia1^tm1Andp/Tia1^tm1Andp (C.129S2-Tia1^tm1Andp)	abnormal macrophage physiology	J:88770
	immune system phenotype	J:88770
	increased susceptibility to endotoxin shock	J:88770
Tia1^tm1Andp/Tia1^tm1Andp (B6.Cg-Tia1^tm1Andp)	autoimmune arthritis	J:88443
Tia1^tm1Andp/Tia1^tm1Andp Zfp36^tm1Pjb/Zfp36^tm1Pjb (B6.Cg-Tia1^tm1Andp Zfp36^tm1Pjb)	abnormal macrophage physiology	J:88443
	autoimmune arthritis	J:88443
	increased neutrophil cell number	J:88443
	increased synovial pannus formation	J:88443
Ticam1^Lps2/Ticam1^Lps2 (involves: C57BL/6)	abnormal cytokine secretion	J:110201
	abnormal macrophage physiology	J:84896
	decreased circulating tumor necrosis factor level	J:86521
	decreased macrophage apoptosis	J:84896, J:92674
	decreased macrophage cytokine production	J:84896
	decreased macrophage nitric oxide production	J:84896
	decreased susceptibility to bacterial infection	J:86521, J:92674
	decreased susceptibility to endotoxin shock	J:84896
	decreased tumor necrosis factor secretion	J:84896
	increased susceptibility to Herpesvirales infection	J:84896
Ticam1^Lps2/Ticam1^Lps2 (C57BL/6J-Ticam1^Lps2)	abnormal circulating tumor necrosis factor level	J:138963
	abnormal cytokine secretion	J:167340
	decreased interleukin-6 secretion	J:167340
	decreased susceptibility to induced colitis	J:167340
	immune system phenotype	J:131353
Ticam1^Lps2/Ticam1^Lps2 (C57BL/6J-Ticam1^Lps2/J)	abnormal chemokine level	J:288471
	decreased CD8-positive, alpha-beta T cell number	J:288471
	decreased Ly6C low monocyte number	J:288471
	increased interferon-beta secretion	J:288471
	increased Ly6C high monocyte number	J:288471
	increased macrophage cell number	J:288471
	increased neutrophil cell number	J:288471
	increased plasmacytoid dendritic cell number	J:288471
	increased susceptibility to Coronaviridae infection	J:288471
	increased susceptibility to Coronaviridae infection induced morbidity/mortality	J:288471
Ticam1^Lps2/Ticam1^Lps2 Myd88^tm1Aki/Myd88^tm1Aki (involves: 129P2/OlaHsd * C57BL/6)	abnormal macrophage physiology	J:84896
	decreased tumor necrosis factor secretion	J:84896
Ticam1^M2Btlr/Ticam1⁺ (C57BL/6J-Ticam1^M2Btlr)	abnormal cytokine secretion	J:234240
	abnormal macrophage physiology	J:234240
	decreased macrophage cytokine production	J:234240
	decreased tumor necrosis factor secretion	J:234240
Ticam1^M2Btlr/Ticam1^M2Btlr (C57BL/6J-Ticam1^M2Btlr)	abnormal cytokine secretion	J:234240
	abnormal macrophage physiology	J:234240
	decreased macrophage cytokine production	J:234240
	decreased tumor necrosis factor secretion	J:234240
Ticam1^M3Btlr/Ticam1⁺ (C57BL/6J-Ticam1^M3Btlr)	decreased tumor necrosis factor secretion	J:255300
Ticam1^M3Btlr/Ticam1^M3Btlr (C57BL/6J-Ticam1^M3Btlr)	decreased tumor necrosis factor secretion	J:255300
Ticam1^tm1Aki/Ticam1^tm1Aki (involves: 129P2/OlaHsd)	abnormal B cell activation	J:174941
	abnormal B cell physiology	J:84679
	abnormal cytokine level	J:174941
	abnormal cytokine secretion	J:84679
	abnormal dendritic cell physiology	J:174941
	abnormal interleukin level	J:137522
	abnormal macrophage physiology	J:174941, J:84679
	abnormal microglial cell physiology	J:185198
	abnormal NK cell physiology	J:174941
	abnormal NK T cell physiology	J:174941
	decreased circulating interleukin-6 level	J:145306
	decreased splenocyte proliferation	J:84679
	decreased susceptibility to endotoxin shock	J:84679
	decreased susceptibility to Orthomyxoviridae infection	J:145306
	impaired macrophage phagocytosis	J:185198
Ticam1^tm1Aki/Ticam1^tm1Aki (involves: 129P2/OlaHsd * C57BL/6)	abnormal cytokine level	J:169158
	abnormal susceptibility to Poxviridae infection	J:162716
	decreased CD8-positive, alpha-beta T cell number	J:130954
	decreased circulating interferon-gamma level	J:130954
	decreased circulating interleukin-6 level	J:130954
	decreased circulating interleukin-12b level	J:130954
	decreased IgG2a level	J:130954
	decreased IgG level	J:130954
	decreased interferon-beta secretion	J:130954
	decreased interleukin-12b secretion	J:130954
	decreased susceptibility to type I hypersensitivity reaction	J:161445
	immune system phenotype	J:132662
	increased susceptibility to Picornaviridae infection	J:169158
	increased susceptibility to Picornaviridae infection induced morbidity/mortality	J:169158
	myocarditis	J:169158
Ticam1^tm1Aki/Ticam1^tm1Aki (B6.129P2-Ticam1^tm1Aki)	abnormal cytokine level	J:144301
	abnormal response to infection	J:144301
	decreased circulating tumor necrosis factor level	J:144301
	decreased macrophage cytokine production	J:144301
	impaired neutrophil recruitment	J:144301
	increased susceptibility to bacterial infection	J:144301
Ticam1^tm1Tsse/Ticam1^tm1Tsse (B6.129-Ticam1^tm1Tsse)	impaired natural killer cell mediated cytotoxicity	J:118750
Ticam1^tm1Tsse/Ticam1^tm1Tsse Tg(PVR)1Kkst/0 (involves: 129 * C57BL/6 * ICR)	abnormal interferon-alpha secretion	J:179625
	increased susceptibility to Picornaviridae infection	J:179625
	increased susceptibility to Picornaviridae infection induced morbidity/mortality	J:179625
Ticam2^M1Btlr/Ticam2⁺ (C57BL/6J-Ticam2^M1Btlr)	decreased tumor necrosis factor secretion	J:215010
Ticam2^M1Btlr/Ticam2^M1Btlr (C57BL/6J-Ticam2^M1Btlr)	decreased tumor necrosis factor secretion	J:215010
Ticam2^M2Btlr/Ticam2⁺ (C57BL/6J-Ticam2^M2Btlr)	decreased interleukin-1 beta secretion	J:254908
Ticam2^M2Btlr/Ticam2^M2Btlr (C57BL/6J-Ticam2^M2Btlr)	decreased interleukin-1 beta secretion	J:254908
Ticam2^M3Btlr/Ticam2⁺ (C57BL/6J-Ticam2^M3Btlr)	decreased tumor necrosis factor secretion	J:254912
Ticam2^M3Btlr/Ticam2^M3Btlr (C57BL/6J-Ticam2^M3Btlr)	decreased tumor necrosis factor secretion	J:254912
Ticam2^tm1Aki/Ticam2^tm1Aki (involves: C57BL/6)	abnormal immune system physiology	J:86256
	decreased interleukin-6 secretion	J:86256
	increased susceptibility to Coronaviridae infection	J:270045
Ticam2^tm1Btlr/Ticam2^tm1Btlr (C57BL/6J-Ticam2^tm1Btlr)	abnormal interferon secretion	J:133619
Ticam2^tm1Btlr/Ticam2^tm1Btlr (C57BL/6J-Ticam2^tm1Btlr)	decreased tumor necrosis factor secretion	J:133619
Tie1^tm1.1Scba/Tie1^tm1.1Scba (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)	abnormal lymphangiogenesis	J:158668
	abnormal lymphatic vessel morphology	J:158668
	lymphatic vessel hyperplasia	J:158668
Tie1^tm1Geno/Tie1^tm1Geno (involves: ICR)	abnormal lymphangiogenesis	J:159507
Tie1^tm1Jpa/Tie1^tm1Jpa (involves: 129S1/Sv * 129X1/SvJ * ICR)	abnormal lymphangiogenesis	J:159507
Tie1^tm1Scba/Tie1^tm1Scba (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal lymph circulation	J:158668
	abnormal lymphangiogenesis	J:158668
	abnormal lymphatic vessel morphology	J:158668
	lymphatic vessel hyperplasia	J:158668
Tifab^em1(IMPC)J/Tifab^em1(IMPC)J (C57BL/6NJ-Tifab^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
Tifab^tm1.1Dsta/Tifab⁺ (involves: 129 * C57BL/6 * C57BL/6J)	enlarged spleen	J:229024
Tifab^tm1.1Dsta/Tifab^tm1.1Dsta (involves: 129 * C57BL/6 * C57BL/6J)	abnormal neutrophil morphology	J:229024
	decreased leukocyte cell number	J:229024
	decreased lymphocyte cell number	J:229024
	decreased monocyte cell number	J:229024
	decreased neutrophil cell number	J:229024
	enlarged spleen	J:229024
Tigar^{Gt(EUCE0047g05)Hmgu}/Tigar^{Gt(EUCE0047g05)Hmgu} (involves: 129P2/OlaHsd)	increased susceptibility to induced colitis	J:198650
Tigar^tm1.1Khv/Tigar^tm1.1Khv Tg(CMV-cre)1Cgn/0 (involves: 129P2/OlaHsd * BALB/cJ * C57BL/6 * SJL)	increased susceptibility to induced colitis	J:198650
Tigit^tm1Sdl/Tigit^tm1Sdl (involves: C57BL/6)	abnormal professional antigen presenting cell physiology	J:168902
	decreased interleukin-10 secretion	J:168902
	immune system phenotype	J:209990
	increased susceptibility to experimental autoimmune encephalomyelitis	J:168902
	increased T cell proliferation	J:168902
Tigit^tm1Sdl/Tigit^tm1Sdl Tg(Tcra2D2,Tcrb2D2)1Kuch/0 (involves: C57BL/6)	decreased interleukin-10 secretion	J:168902
	increased susceptibility to experimental autoimmune encephalomyelitis	J:168902
Timd2^{tm1(GAL4)Pdre}/Timd2^{tm1(GAL4)Pdre} (C.129S4-Timd2^{tm1(GAL4)Pdre})	abnormal inflammatory response	J:125054
	abnormal interleukin secretion	J:125054
	increased eosinophil cell number	J:125054
	increased interferon-gamma secretion	J:125054
	increased lymphocyte cell number	J:125054
	increased tumor necrosis factor secretion	J:125054
Timd4^tm1Kuch/Timd4^tm1Kuch (C57BL/6-Timd4^tm1Kuch)	abnormal B cell physiology	J:160747
	abnormal macrophage physiology	J:160747
	increased anti-double stranded DNA antibody level	J:160747
	increased IgA level	J:160747
	increased IgG2a level	J:160747
	increased IgG2b level	J:160747
	increased interferon-gamma secretion	J:160747
	increased interleukin-17 secretion	J:160747
	increased splenocyte proliferation	J:160747
Timd4^tm1Kuch/Timd4^tm1Kuch (involves: C57BL/6)	abnormal circulating chemokine level	J:235399
	decreased circulating interleukin-10 level	J:235399
	increased anti-double stranded DNA antibody level	J:235399
	increased circulating interleukin-1 beta level	J:235399
	increased circulating interleukin-6 level	J:235399
	increased circulating interleukin-12b level	J:235399
	increased susceptibility to systemic lupus erythematosus	J:235399
Timd4^tm1Osa/Timd4^tm1Osa (involves: C57BL/6)	immune system phenotype	J:187181
Timd4^tm1Osa/Timd4^tm1Osa (involves: C57BL/6)	impaired macrophage phagocytosis	J:187181
Timd4^tm1Wouy/Timd4^tm1Wouy (involves: 129)	abnormal macrophage physiology	J:160304
	decreased tumor necrosis factor secretion	J:160304
	impaired macrophage phagocytosis	J:160304
	increased IgG2a level	J:160304
	increased leukocyte cell number	J:160304
	increased lymphocyte cell number	J:160304
	increased tumor necrosis factor secretion	J:160304
Timd6^{tm1b(KOMP)Wtsi}/Timd6⁺ (C57BL/6N-Timd6^{tm1b(KOMP)Wtsi}/H)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
	increased spleen weight	J:211773
Timm13^em1(IMPC)Tcp/Timm13⁺ (C57BL/6NCrl-Timm13^em1(IMPC)Tcp/Tcp)	abnormal spleen morphology	J:211773
	enlarged thymus	J:211773
Timmdc1^{Gt(OST407011)Lex}/Timmdc1⁺ (B6;129S5-Timmdc1^{Gt(OST407011)Lex}/Mmucd)	increased CD4-positive, alpha-beta T cell number	J:171883
Timp1^tm1Pds/Timp1^tm1Pds (involves: 129S4/SvJae)	decreased susceptibility to bacterial infection	J:94836
Timp1^tm1Pds/Timp1^tm1Pds (involves: C57BL/6)	decreased susceptibility to bacterial infection	J:94836
Timp1^tm1Pds/Timp1^tm1Pds (involves: 129S4/SvJae * C57BL/6)	increased neutrophil cell number	J:112941
Timp1^tm1Pds/Timp1^tm1Pds (involves: 129S4/SvJae * C57BL/6)	lung inflammation	J:112941
Timp2^{em1(IMPC)Hmgu}/Timp2^{em1(IMPC)Hmgu} (C57BL/6N-Timp2^{em1(IMPC)Hmgu}/Ieg)	increased follicular B cell number	J:211773
Timp2^tm1Pds/Timp2^tm1Pds (involves: 129S4/SvJae * C57BL/6)	increased neutrophil cell number	J:112941
Timp3^tm1Osya/Timp3^tm1Osya (B6.129P2-Timp3^tm1Osya)	aortitis	J:193744
Timp3^tm1Rkho/Timp3^tm1Rkho (B6.129-Timp3^tm1Rkho)	increased tumor necrosis factor secretion	J:92948
Timp3^tm1Rkho/Timp3^tm1Rkho (B6.129-Timp3^tm1Rkho)	liver inflammation	J:92948
Timp3^tm1Rkho/Timp3^tm1Rkho Tnf^tm1Gkl/Tnf^tm1Gkl (involves: 129 * 129S/SvEv * C57BL/6)	increased neutrophil cell number	J:112033
Timp4^em1(IMPC)Mbp/Timp4^em1(IMPC)Mbp (C57BL/6N-Timp4^em1(IMPC)Mbp/MbpMmucd)	small spleen	J:211773
Tincr^{em1(IMPC)Ccpcz}/Tincr^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Tincr^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Tinf2^tm2.2Tdl/Tinf2⁺ (involves: BALB/cJ * C57BL/6)	dermatitis	J:207367
	lymphoid hyperplasia	J:207367
	myeloid hyperplasia	J:207367
Tiparp^{Gt(ROSA)79Sor}/Tiparp^{Gt(ROSA)79Sor} (involves: 129S4/SvJaeSor)	kidney inflammation	J:117491
Tiparp^{Gt(ROSA)79Sor}/Tiparp^{Gt(ROSA)79Sor} (involves: 129S4/SvJaeSor * C57BL/6 * C57BL/6J)	abnormal thymus involution	J:250417
Tiparp^{tm1b(EUCOMM)Wtsi}/Tiparp^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Tiparp^{tm1b(EUCOMM)Wtsi}/Tcp)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Tir2^BALB/cOlaHsd/Tir2^{C57BL/6JOlaHsd} (involves: BALB/cOlaHsd * C57BL/6JOlaHsd)	abnormal immune serum protein physiology	J:40771
Tir2^{C57BL/6JOlaHsd}/Tir2^{C57BL/6JOlaHsd} (involves: A/JOlaHsd * C57BL/6JOlaHsd)	decreased susceptibility to parasitic infection	J:40771
Tir2^{C57BL/6JOlaHsd}/Tir2^{C57BL/6JOlaHsd} (involves: BALB/cOlaHsd * C57BL/6JOlaHsd)	decreased susceptibility to parasitic infection	J:40771
Tir2^{C57BL/6JOlaHsd}/Tir2^{C57BL/6JOlaHsd} (A.B6-Tir2)	decreased susceptibility to parasitic infection	J:97672
Tir2^{C57BL/6JOlaHsd}/Tir2^{C57BL/6JOlaHsd} (A.B6-(D5Mit200-D5Mit10))	decreased susceptibility to parasitic infection	J:135428
Tir3^BALB/cOlaHsd/Tir3^{C57BL/6JOlaHsd} (involves: BALB/cOlaHsd * C57BL/6JOlaHsd)	decreased susceptibility to parasitic infection	J:40771
Tir3^{C57BL/6JOlaHsd}/Tir3^{C57BL/6JOlaHsd} (involves: BALB/cOlaHsd * C57BL/6JOlaHsd)	decreased susceptibility to parasitic infection	J:40771
Tir3^{C57BL/6JOlaHsd}/Tir3^{C57BL/6JOlaHsd} (A.B6-Tir3)	decreased susceptibility to parasitic infection	J:97672
Tir3^{C57BL/6JOlaHsd}/Tir3^{C57BL/6JOlaHsd} (A.B6-(D1Mit60-D1Mit217))	decreased susceptibility to parasitic infection	J:135428
Tir4^{C57BL/6JOlaHsd}/? (involves: BALB/cOlaHsd * C57BL/6JOlaHsd)	decreased susceptibility to parasitic infection	J:40771
Tir4^{C57BL/6JOlaHsd}/Tir4^{C57BL/6JOlaHsd} (involves: A/JOlaHsd * C57BL/6JOlaHsd)	decreased susceptibility to parasitic infection	J:40771
Tir4^{C57BL/6JOlaHsd}/Tir4^{C57BL/6JOlaHsd} (involves: BALB/cOlaHsd * C57BL/6JOlaHsd)	decreased susceptibility to parasitic infection	J:40771
Tir4^{C57BL/6JOlaHsd}/Tir4^{C57BL/6JOlaHsd} (A.B6-Tir1)	decreased susceptibility to parasitic infection	J:97672
Tir4^{C57BL/6JOlaHsd}/Tir4^{C57BL/6JOlaHsd} (A.B6-(D17Mit29-D17Mit11))	decreased susceptibility to parasitic infection	J:135428
Tir9^C57BL/6/Tir9^C57BL/6 (involves: C57BL/6 * DBA/2)	increased susceptibility to parasitic infection	J:84716
Tir10^C57BL/6/Tir10^C57BL/6 (involves: C57BL/6 * DBA/2)	increased susceptibility to parasitic infection	J:84716
Tirap^m1Btlr/Tirap^m1Btlr (C57BL/6J-Tirap^m1Btlr)	abnormal interferon secretion	J:133618
Tirap^m1Btlr/Tirap^m1Btlr (C57BL/6J-Tirap^m1Btlr)	decreased tumor necrosis factor secretion	J:133618
Tirap^tm1Aki/Tirap^tm1Aki (involves: 129P2/OlaHsd * C57BL/6)	abnormal cytokine secretion	J:111205
	abnormal level of surface class II molecules	J:111205
	decreased IgG3 level	J:137066
Tirap^tm1Aki/Tirap^tm1Aki (B6.129P2-Tirap^tm1Aki)	abnormal dendritic cell physiology	J:118954
	decreased interleukin-6 secretion	J:118954
	decreased interleukin-12b secretion	J:118954
Tirap^tm1Medz/Tirap^tm1Medz (involves: 129S1/Sv * C57BL/6)	abnormal dendritic cell physiology	J:96773
	abnormal macrophage physiology	J:96773
	decreased B cell proliferation	J:96773
Tirap^tm1Medz/Tirap^tm1Medz (involves: 129S1/Sv)	abnormal macrophage physiology	J:96018
Tirap^tm1Medz/Tirap^tm1Medz (involves: 129S1/Sv)	increased susceptibility to bacterial infection	J:96018
Tk1^tm1Vnd/Tk1^tm1Vnd (involves: 129P2/OlaHsd * C57BL/6)	arteritis	J:101669
	liver inflammation	J:101669
	lung inflammation	J:101669
	lymph node atrophy	J:101669
	small spleen	J:101669
	spleen hypoplasia	J:101669
	thyroid gland inflammation	J:101669
Tkfc^{em1(IMPC)Ccpcz}/Tkfc^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Tkfc^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Tktl1^tm1Arte/Tktl1^tm1Arte (C57BL/6-Tktl1^tm1Arte)	increased susceptibility to induced colitis	J:171154
Tlag2^AKR/J/Tlag2^C57L/J (involves: AKR/J * C57L/J)	increased T cell derived lymphoma incidence	J:74369
Tlag2^AKR/J/Tlag2^C57L/J Tlag1^AKR/J/Tlag1^AKR/J (involves: AKR/J * C57L/J)	increased T cell derived lymphoma incidence	J:74369
Tle3^em1(IMPC)Mbp/Tle3^em1(IMPC)Mbp (C57BL/6N-Tle3^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	small spleen	J:211773
Tle4^em1(IMPC)Mbp/Tle4^em1(IMPC)Mbp (C57BL/6NCrl-Tle4^em1(IMPC)Mbp/Mmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
Tle4^tm1.2Dasw/Tle4^tm1.2Dasw (B6.129S6(Cg)-Tle4^tm1.2Dasw)	abnormal lymphopoiesis	J:219243
	abnormal thymus morphology	J:219243
	decreased B cell number	J:219243
	decreased DN2 thymocyte number	J:219243
	decreased double-positive T cell number	J:219243
	decreased follicular B cell number	J:219243
	decreased leukocyte cell number	J:219243
	decreased lymphocyte cell number	J:219243
	decreased pre-pro B cell number	J:219243
	decreased spleen B cell follicle number	J:219243
	immune system phenotype	J:219243
	increased NK T cell number	J:219243
	increased thymocyte apoptosis	J:219243
	spleen hypoplasia	J:219243
	thymus atrophy	J:219243
	thymus hypoplasia	J:219243
Tlf2^NOD/Smrf/? (involves: NOD/Smrf * NON/Lt)	increased CD8-positive, alpha-beta T cell number	J:49676
Tlf^NOD/Smrf/? (involves: NOD/Smrf * NON/Lt)	increased CD4-positive, alpha-beta T cell number	J:49676
Tll1^b2b2476Clo/Tll1^b2b2476Clo (C57BL/6J-Tll1^b2b2476Clo)	thymus hypoplasia	J:175213
Tln1^tm4.1Crit/Tln1^tm4.1Crit Tg(Mx1-cre)1Cgn/0 (involves: 129/Sv * 129P2/OlaHsd * C57BL/6 * CBA)	immune system phenotype	J:134784
Tlr1^tm1Aki/Tlr1^tm1Aki (involves: 129P2/OlaHsd * C57BL/6)	abnormal cytokine secretion	J:103395
	decreased interleukin-6 secretion	J:103395
	decreased tumor necrosis factor secretion	J:103395
Tlr1^tm1Flv/Tlr1^tm1Flv (involves: 129S1/Sv)	abnormal macrophage physiology	J:95726
	decreased immunoglobulin level	J:95726
	increased susceptibility to bacterial infection	J:95726
Tlr2^lngd/Tlr2^lngd (C57BL/6J-Tlr2^lngd)	abnormal macrophage physiology	J:94077
Tlr2^lngd/Tlr2^lngd (C57BL/6J-Tlr2^lngd)	increased susceptibility to bacterial infection	J:94077
Tlr2^tm1Aki/Tlr2^tm1Aki (involves: 129P2/OlaHsd * C57BL/6)	abnormal chemokine level	J:88174
	abnormal macrophage physiology	J:76115, J:95726
	abnormal tumor necrosis factor level	J:124334
	decreased immunoglobulin level	J:95726
	decreased interleukin-6 secretion	J:76115, J:88174
	decreased microglial cell activation	J:122551
	decreased susceptibility to Herpesvirales infection	J:88174
	decreased susceptibility to Herpesvirales infection induced morbidity/mortality	J:88174
	decreased tumor necrosis factor secretion	J:76115
	immune system phenotype	J:76115
	increased susceptibility to bacterial infection	J:95726
Tlr2^tm1Aki/Tlr2^tm1Aki (B6.129P2-Tlr2^tm1Aki)	abnormal dendritic cell physiology	J:118954
	abnormal interleukin level	J:118954
	decreased interleukin-6 secretion	J:118954
	decreased interleukin-12b secretion	J:118954
	decreased susceptibility to parasitic infection	J:116763
	increased T cell number	J:118954
Tlr2^tm1Aki/Tlr2^tm1Aki (involves: 129P2/OlaHsd)	abnormal cytokine secretion	J:70578
	abnormal leukocyte migration	J:171379
	abnormal macrophage physiology	J:103464, J:130138, J:70578
	abnormal osteoclast physiology	J:130138
	decreased circulating interleukin-1 beta level	J:119941
	decreased circulating tumor necrosis factor level	J:119941
	decreased inflammatory response	J:146111
	decreased interleukin-6 secretion	J:70578
	decreased interleukin-12 secretion	J:70578
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:146111
	decreased tumor necrosis factor secretion	J:103395, J:70578
	increased B cell apoptosis	J:135830
Tlr2^tm1Aki/Tlr2^tm1Aki (NOD.129P2-Tlr2^tm1Aki)	insulitis	J:124334
Tlr2^tm1Aki/Tlr2^tm1Aki (C.129P2-Tlr2^tm1Aki)	immune system phenotype	J:178054
Tlr2^tm1Aki/Tlr2^tm1Aki Tlr4^tm1Aki/Tlr4^tm1Aki (B6.129P2-Tlr2^tm1Aki Tlr4^tm1Aki)	abnormal chemokine secretion	J:102879
Tlr2^tm1Aki/Tlr2^tm1Aki Tlr4^tm1Aki/Tlr4^tm1Aki (involves: 129P2/OlaHsd * C57BL/6)	abnormal cytokine secretion	J:117688
	abnormal macrophage physiology	J:117688
	decreased IgG3 level	J:117688
Tlr2^tm1Aki/Tlr2^tm1Aki Tlr6^tm1Aki/Tlr6^tm1Aki (involves: 129P2/OlaHsd * C57BL/6)	decreased interleukin-6 secretion	J:70578
Tlr2^tm1Kir/Tlr2^tm1Kir (either: (involves: 129/Sv * C57BL/6) or (involves: 129/Sv * C57BL/6 * C57BL/6J))	abnormal innate immunity	J:85323
	abnormal macrophage physiology	J:85323
	decreased interleukin-6 secretion	J:85323
	decreased interleukin-10 secretion	J:85323
	decreased macrophage cytokine production	J:85323
	decreased macrophage nitric oxide production	J:85323
	increased susceptibility to bacterial infection	J:85323
Tlr2^tm1Kir/Tlr2^tm1Kir (Not Specified)	abnormal macrophage physiology	J:96018
Tlr2^tm1Kir/Tlr2^tm1Kir (Not Specified)	increased susceptibility to bacterial infection	J:96018
Tlr2^tm1Kir/Tlr2^tm1Kir (B6.129-Tlr2^tm1Kir)	abnormal cellular extravasation	J:171028
	abnormal cytokine secretion	J:121930
	decreased circulating tumor necrosis factor level	J:162168
	decreased interleukin-1 beta secretion	J:129871
	decreased interleukin-6 secretion	J:129871
	decreased splenocyte proliferation	J:121930
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:121930
	decreased tumor necrosis factor secretion	J:129871
	increased susceptibility to induced colitis	J:165105
Tlr2^tm1Kir/Tlr2^tm1Kir (involves: 129)	abnormal interleukin secretion	J:94463
	decreased interleukin-1 secretion	J:94463
	decreased interleukin-6 secretion	J:94463
	decreased tumor necrosis factor secretion	J:94463
	increased susceptibility to bacterial infection induced morbidity/mortality	J:147177
Tlr2^tm1Kir/Tlr2^tm1Kir Tlr4^Lps-d/Tlr4^Lps-d (C3.Cg-Tlr2^tm1Kir Tlr4^Lps-d)	abnormal macrophage physiology	J:121930
Tlr3^M1Btlr/Tlr3⁺ (C57BL/6J-Tlr3^M1Btlr)	decreased macrophage cytokine production	J:224670
Tlr3^M1Btlr/Tlr3⁺ (C57BL/6J-Tlr3^M1Btlr)	decreased tumor necrosis factor secretion	J:224670
Tlr3^M1Btlr/Tlr3^M1Btlr (C57BL/6J-Tlr3^M1Btlr)	decreased macrophage cytokine production	J:224670
Tlr3^M1Btlr/Tlr3^M1Btlr (C57BL/6J-Tlr3^M1Btlr)	decreased tumor necrosis factor secretion	J:224670
Tlr3^M2Btlr/Tlr3⁺ (C57BL/6J-Tlr3^M2Btlr)	decreased tumor necrosis factor secretion	J:254925
Tlr3^M2Btlr/Tlr3^M2Btlr (C57BL/6J-Tlr3^M2Btlr)	decreased tumor necrosis factor secretion	J:254925
Tlr3^tm1Aki/Tlr3^tm1Aki (involves: 129P2/OlaHsd)	abnormal dendritic cell physiology	J:114555
Tlr3^tm1Aki/Tlr3^tm1Aki (involves: 129P2/OlaHsd)	immune system phenotype	J:144400
Tlr3^tm1Aki/Tlr3^tm1Aki Tlr7^tm1Aki/Tlr7^tm1Aki (involves: 129P2/OlaHsd)	decreased interferon-alpha secretion	J:144400
Tlr3^tm1Flv/Tlr3^tm1Flv (involves: 129S1/Sv * C57BL/6)	abnormal B cell physiology	J:72167
	abnormal macrophage physiology	J:72167
	decreased inflammatory response	J:72167
	immune system phenotype	J:72167
Tlr3^tm1Flv/Tlr3^tm1Flv (involves: C57BL/6)	abnormal macrophage physiology	J:86617
Tlr3^tm1Flv/Tlr3^tm1Flv (involves: C57BL/6)	immune system phenotype	J:86617
Tlr3^tm1Flv/Tlr3^tm1Flv (Not Specified)	abnormal cytokine secretion	J:88906
	abnormal NK cell physiology	J:88906
	abnormal NK T cell physiology	J:88906
	increased susceptibility to Herpesvirales infection	J:88906
Tlr3^tm1Flv/Tlr3^tm1Flv (involves: 129S1/Sv)	abnormal cytokine level	J:119967
	abnormal interferon level	J:119967
	abnormal interleukin level	J:119967
	abnormal tumor necrosis factor level	J:119967
	decreased susceptibility to Riboviria infection	J:136330
	decreased susceptibility to Riboviria infection induced morbidity/mortality	J:136330
	heart inflammation	J:119967
	increased susceptibility to Picornaviridae infection induced morbidity/mortality	J:119967
Tlr3^tm1Flv/Tlr3^tm1Flv (B6.129S1-Tlr3^tm1Flv/Apb)	abnormal cytokine level	J:129533
	abnormal interleukin level	J:126415
	decreased interferon-beta secretion	J:251008
Tlr3^tm1Flv/Tlr3^tm1Flv (B6N.129S1-Tlr3^tm1Flv/J)	increased susceptibility to Coronaviridae infection	J:288471
Tlr4^Lps-2Btlr/? (C57BL/6J-Tlr4^Lps-2Btlr)	decreased tumor necrosis factor secretion	J:147339
Tlr4^Lps-2Btlr/Tlr4⁺ (C57BL/6J-Tlr4^Lps-2Btlr)	decreased interleukin-1 beta secretion	J:147339
Tlr4^lps-2J/Tlr4^lps-2J (BXD29-Tlr4^lps-2J/J)	abnormal inflammatory response	J:107391
Tlr4^Lps-3Btlr/Tlr4⁺ (C57BL/6J-Tlr4^Lps-3Btlr)	decreased interferon-beta secretion	J:217295
Tlr4^Lps-3Btlr/Tlr4⁺ (C57BL/6J-Tlr4^Lps-3Btlr)	decreased tumor necrosis factor secretion	J:217295
Tlr4^Lps-3Btlr/Tlr4^Lps-3Btlr (C57BL/6J-Tlr4^Lps-3Btlr)	decreased interferon-beta secretion	J:217295
Tlr4^Lps-3Btlr/Tlr4^Lps-3Btlr (C57BL/6J-Tlr4^Lps-3Btlr)	decreased tumor necrosis factor secretion	J:217295
Tlr4^lps-4Btlr/Tlr4⁺ (C57BL/6J-Tlr4^lps-4Btlr)	decreased macrophage cytokine production	J:224664
Tlr4^lps-4Btlr/Tlr4⁺ (C57BL/6J-Tlr4^lps-4Btlr)	decreased tumor necrosis factor secretion	J:224664
Tlr4^lps-4Btlr/Tlr4^lps-4Btlr (C57BL/6J-Tlr4^lps-4Btlr)	decreased macrophage apoptosis	J:224664
	decreased macrophage cytokine production	J:224664
	decreased tumor necrosis factor secretion	J:224664
Tlr4^lps-5Btlr/Tlr4^lps-5Btlr (C57BL/6J-Tlr4^lps-5Btlr)	decreased B cell number	J:224666
	decreased macrophage cytokine production	J:224666
	decreased memory B cell number	J:224666
	decreased tumor necrosis factor secretion	J:224666
Tlr4^Lps-6Btlr/Tlr4⁺ (C57BL/6J-Tlr4^Lps-6Btlr)	decreased macrophage cytokine production	J:224667
Tlr4^Lps-6Btlr/Tlr4⁺ (C57BL/6J-Tlr4^Lps-6Btlr)	decreased tumor necrosis factor secretion	J:224667
Tlr4^Lps-6Btlr/Tlr4^Lps-6Btlr (C57BL/6J-Tlr4^Lps-6Btlr)	decreased macrophage cytokine production	J:224667
Tlr4^Lps-6Btlr/Tlr4^Lps-6Btlr (C57BL/6J-Tlr4^Lps-6Btlr)	decreased tumor necrosis factor secretion	J:224667
Tlr4^lps-7Btlr/Tlr4⁺ (C57BL/6J-Tlr4^Lps-7Btlr)	decreased interleukin-1 beta secretion	J:234239
	decreased macrophage cytokine production	J:234239
	decreased tumor necrosis factor secretion	J:234239
Tlr4^lps-7Btlr/Tlr4^lps-7Btlr (C57BL/6J-Tlr4^Lps-7Btlr)	decreased interleukin-1 beta secretion	J:234239
	decreased macrophage cytokine production	J:234239
	decreased tumor necrosis factor secretion	J:234239
Tlr4^Lps-8Btlr/Tlr4⁺ (C57BL/6J-Tlr4^Lps-8Btlr)	decreased interleukin-1 beta secretion	J:234241
	decreased macrophage cytokine production	J:234241
	decreased tumor necrosis factor secretion	J:234241
Tlr4^Lps-8Btlr/Tlr4^Lps-8Btlr (C57BL/6J-Tlr4^Lps-8Btlr)	decreased interleukin-1 beta secretion	J:234241
	decreased macrophage cytokine production	J:234241
	decreased tumor necrosis factor secretion	J:234241
Tlr4^lps-Btlr/Tlr4^lps-Btlr (C57BL/6J-Tlr4^lps-Btlr)	abnormal macrophage physiology	J:128416
Tlr4^Lps-d/Tlr4^Lps-d (involves: C3H/HeJ)	abnormal osteoclast differentiation	J:131353
	abnormal T-helper 2 physiology	J:96356
	abnormal tumor necrosis factor level	J:124334, J:114368
	increased susceptibility to bacterial infection	J:5721, J:51522, J:87807
	increased susceptibility to induced arthritis	J:96356
Tlr4^Lps-d/Tlr4^Lps-d (C3H/HeJ-Tlr4^Lps-d)	abnormal cytokine level	J:96680
	abnormal interleukin level	J:96680
	abnormal macrophage chemotaxis	J:122597
	abnormal microglial cell physiology	J:99051
	abnormal phagocyte morphology	J:125179
	abnormal spleen weight	J:37271
	abnormal susceptibility to infection	J:162716
	abnormal tumor necrosis factor level	J:96680
	immune system phenotype	J:209808
	increased circulating interleukin-6 level	J:37271
	increased susceptibility to Poxviridae infection induced morbidity/mortality	J:162716
	liver inflammation	J:135830
	lung inflammation	J:96680
Tlr4^Lps-d/Tlr4^Lps-d Tg(IghelMD4)4Ccg/0 Tg(KLK4mHEL)6Ccg/0 (involves: 129P2/OlaHsd * C3H/HeJ * C57BL/6)	decreased B cell number	J:115059
	increased B-1 B cell number	J:115059
Tlr4^lps-del/Tlr4^lps-del (C57BL/10ScCr)	abnormal cytokine secretion	J:88996
	abnormal macrophage physiology	J:88996
	increased susceptibility to bacterial infection	J:51522, J:88996
Tlr4^lps-del/Tlr4^lps-del (C57BL/10ScN)	increased spleen weight	J:37271
Tlr4^lps-del/Tlr4^lps-del (involves: C57BL/10ScN)	abnormal tumor necrosis factor level	J:114368
	decreased interleukin-6 secretion	J:147023
	decreased interleukin-10 secretion	J:147023
Tlr4^lps-hypo/Tlr4^lps-hypo (B6.Cg-Tlr4^lps-hypo Cln8^mnd)	decreased susceptibility to bacterial infection	J:103167
Tlr4^lps-n/Tlr4^lps-n (C3H/HeN)	decreased acute inflammation	J:37271
	immune system phenotype	J:5557
	increased spleen weight	J:37271
Tlr4^tm1.1Djh/Tlr4^tm1.1Djh (involves: FVB/N)	decreased susceptibility to endotoxin shock	J:192520
Tlr4^tm1Aki/Tlr4^lps-2J (involves: 129P2/OlaHsd * C57BL/6 * DBA/2J)	abnormal inflammatory response	J:107391
Tlr4^tm1Aki/Tlr4^tm1Aki (involves: 129P2/OlaHsd)	decreased circulating interleukin-6 level	J:145306
	decreased susceptibility to Orthomyxoviridae infection	J:145306
	increased susceptibility to bacterial infection	J:53519
Tlr4^tm1Aki/Tlr4^tm1Aki (involves: 129P2/OlaHsd * C57BL/6J)	abnormal acute inflammation	J:98224
	enlarged mesenteric lymph nodes	J:98224
	impaired neutrophil chemotaxis	J:98224
	increased susceptibility to bacterial infection	J:98224
Tlr4^tm1Aki/Tlr4^tm1Aki (involves: 129P2/OlaHsd * C57BL/6)	abnormal level of surface class II molecules	J:76115
	abnormal macrophage physiology	J:76115
	decreased B cell proliferation	J:76115
	decreased interleukin-6 secretion	J:76115
	decreased susceptibility to endotoxin shock	J:76115
	decreased tumor necrosis factor secretion	J:76115
	increased susceptibility to bacterial infection	J:111778
Tlr4^tm1Aki/Tlr4^tm1Aki (C.129P2-Tlr4^tm1Aki)	decreased susceptibility to induced arthritis	J:178054
Tlr4^tm1Aki/Tlr4^tm1Aki Tlr5^tm1Flv/Tlr5^tm1Flv (involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6)	increased susceptibility to bacterial infection	J:111778
Tlr5^tm1.1Gewr/Tlr5^tm1.1Gewr Tg(Itgax-cre,-EGFP)4097Ach/? (involves: C57BL/6J * C57BL/6NTac)	immune system phenotype	J:229155
Tlr5^tm1Aki/Tlr5^tm1Aki (B6.129P2-Tlr5^tm1Aki)	decreased interleukin-6 secretion	J:112391
	decreased interleukin-12b secretion	J:112391
	decreased susceptibility to bacterial infection	J:112391
	immune system phenotype	J:116763
Tlr5^tm1Aki/Tlr5^tm1Aki (involves: 129P2/OlaHsd * C57BL/6)	abnormal macrophage physiology	J:112671
Tlr5^tm1Aki/Tlr5^tm1Aki (involves: 129P2/OlaHsd)	enlarged spleen	J:229155
	increased interleukin-1 beta secretion	J:229155
	increased susceptibility to colitis induced morbidity/mortality	J:229155
Tlr5^tm1Flv/Tlr5^tm1Flv (involves: 129S1/Sv * C57BL/6)	abnormal cytokine secretion	J:111778
	abnormal dendritic cell physiology	J:111778
	abnormal response to transplant	J:111778
	decreased neutrophil cell number	J:111778
	increased susceptibility to autoimmune diabetes	J:158055
	increased susceptibility to bacterial infection	J:111778
	increased susceptibility to induced colitis	J:158055
	increased susceptibility to induced pancreatitis	J:158055
	lung inflammation	J:111778
Tlr5^tm1Flv/Tlr5^tm1Flv (involves: 129S1/Sv)	abnormal leukocyte migration	J:171379
Tlr6^int/Tlr6^int (C57BL/6-Tlr6^int)	abnormal adaptive immunity	J:110094
	abnormal cell-mediated immunity	J:110094
	abnormal innate immunity	J:110094
	abnormal macrophage physiology	J:110094
Tlr6^m2Btlr/Tlr6^m2Btlr (C57BL/6J-Tlr6^m2Btlr)	abnormal macrophage physiology	J:144166
Tlr6^m2Btlr/Tlr6^m2Btlr (C57BL/6J-Tlr6^m2Btlr)	decreased tumor necrosis factor secretion	J:144166
Tlr6^m3Btlr/Tlr6^m3Btlr (C57BL/6J-Tlr6^m3Btlr)	abnormal macrophage physiology	J:144167
Tlr6^m3Btlr/Tlr6^m3Btlr (C57BL/6J-Tlr6^m3Btlr)	decreased tumor necrosis factor secretion	J:144167
Tlr6^m4Btlr/Tlr6^m4Btlr (C57BL/6J-Tlr6^m4Btlr)	abnormal macrophage physiology	J:144168
Tlr6^m4Btlr/Tlr6^m4Btlr (C57BL/6J-Tlr6^m4Btlr)	decreased tumor necrosis factor secretion	J:144168
Tlr6^tm1Aki/Tlr6^tm1Aki (involves: 129P2/OlaHsd * C57BL/6)	abnormal cytokine secretion	J:70578
	abnormal macrophage physiology	J:70578
	decreased interleukin-6 secretion	J:70578
	decreased interleukin-12 secretion	J:70578
	decreased tumor necrosis factor secretion	J:70578
Tlr7^em2Anu/Y (C57BL/6NCrl-Tlr7^em2Anu)	abnormal B cell physiology	J:324448
	abnormal macrophage physiology	J:324448
	abnormal Peyer's patch morphology	J:324448
	decreased B cell apoptosis	J:324448
	decreased B cell proliferation	J:324448
	enlarged spleen	J:324448
	increased anti-double stranded DNA antibody level	J:324448
	increased anti-nuclear antigen antibody level	J:324448
	increased anti-single stranded DNA antibody level	J:324448
	increased autoantibody level	J:324448
	increased CD4-positive, alpha-beta T cell number	J:324448
	increased circulating interferon-gamma level	J:324448
	increased circulating interleukin-6 level	J:324448
	increased circulating interleukin-10 level	J:324448
	increased circulating tumor necrosis factor level	J:324448
	increased effector memory CD4-positive, alpha-beta T cell number	J:324448
	increased susceptibility to systemic lupus erythematosus	J:324448
	increased T follicular helper cell number	J:324448
	liver inflammation	J:324448
	lung inflammation	J:324448
	lymph node inflammation	J:324448
Tlr7^em2Anu/Tlr7⁺ (C57BL/6NCrl-Tlr7^em2Anu)	abnormal mature B cell morphology	J:324448
	abnormal plasmacytoid dendritic cell physiology	J:324448
	decreased marginal zone B cell number	J:324448
	enlarged spleen	J:324448
	increased anti-double stranded DNA antibody level	J:324448
	increased anti-nuclear antigen antibody level	J:324448
	increased anti-single stranded DNA antibody level	J:324448
	increased autoantibody level	J:324448
	increased B cell number	J:324448
	increased CD4-positive, alpha-beta T cell number	J:324448
	increased circulating interferon-gamma level	J:324448
	increased circulating interleukin-6 level	J:324448
	increased circulating interleukin-10 level	J:324448
	increased circulating tumor necrosis factor level	J:324448
	increased germinal center B cell number	J:324448
	increased plasma cell number	J:324448
	increased spleen germinal center number	J:324448
	increased T follicular helper cell number	J:324448
	spleen hyperplasia	J:324448
Tlr7^em2Anu/Tlr7^em2Anu (C57BL/6NCrl-Tlr7^em2Anu)	abnormal mature B cell morphology	J:324448
	abnormal Peyer's patch morphology	J:324448
	abnormal plasmacytoid dendritic cell physiology	J:324448
	decreased leukocyte cell number	J:324448
	decreased marginal zone B cell number	J:324448
	enlarged spleen	J:324448
	glomerulonephritis	J:324448
	increased anti-nuclear antigen antibody level	J:324448
	increased anti-single stranded DNA antibody level	J:324448
	increased B cell number	J:324448
	increased CD4-positive, alpha-beta T cell number	J:324448
	increased effector memory CD4-positive, alpha-beta T cell number	J:324448
	increased germinal center B cell number	J:324448
	increased inflammatory response	J:324448
	increased plasma cell number	J:324448
	increased spleen germinal center number	J:324448
	increased susceptibility to systemic lupus erythematosus	J:324448
	increased T follicular helper cell number	J:324448
	liver inflammation	J:324448
	lung inflammation	J:324448
	lymph node inflammation	J:324448
	pancreas inflammation	J:324448
	salivary gland inflammation	J:324448
	spleen hyperplasia	J:324448
Tlr7^rsq1/Y (C57BL/6J-Tlr7^rsq1)	abnormal macrophage physiology	J:128404
Tlr7^rsq1/Y (C57BL/6J-Tlr7^rsq1)	decreased tumor necrosis factor secretion	J:128404
Tlr7^rsq1/Tlr7^rsq1 (C57BL/6J-Tlr7^rsq1)	abnormal macrophage physiology	J:128404
Tlr7^rsq1/Tlr7^rsq1 (C57BL/6J-Tlr7^rsq1)	decreased tumor necrosis factor secretion	J:128404
Tlr7^rsq2/Y (C57BL/6J-Tlr7^rsq2)	abnormal macrophage physiology	J:140020
Tlr7^rsq2/Y (C57BL/6J-Tlr7^rsq2)	decreased tumor necrosis factor secretion	J:140020
Tlr7^tm1Aki/Tlr7^tm1Aki (B6.129P2-Tlr7^tm1Aki)	abnormal dendritic cell physiology	J:118954
Tlr7^tm1Aki/Tlr7^tm1Aki (B6.129P2-Tlr7^tm1Aki)	decreased interleukin-12b secretion	J:118954
Tlr7^tm1Aki/Tlr7^tm1Aki (involves: 129P2/OlaHsd)	decreased interferon-alpha secretion	J:144400
Tlr7^tm1Flv/Y (B6.129S1-Tlr7^tm1Flv)	decreased splenocyte proliferation	J:127600
Tlr7^tm1Flv/Y (B6.129S1-Tlr7^tm1Flv)	increased marginal zone B cell number	J:127600
Tlr7^tm1Flv/Tlr7^tm1Flv (involves: 129S1/Sv)	decreased circulating interferon-alpha level	J:89257
Tlr7^tm1Flv/Tlr7^tm1Flv (B6.129S1-Tlr7^tm1Flv)	decreased anti-insulin autoantibody level	J:165267
	decreased IgG1 level	J:165267
	decreased IgG2a level	J:165267
	decreased IgG level	J:165267
	decreased IgM level	J:165267
Tlr8/Tlr7^tm1Vlcg/Tlr8/Tlr7^tm1Vlcg (B6.Cg-Tlr8/Tlr7^tm1Vlcg)	decreased anti-insulin autoantibody level	J:165267
	decreased follicular B cell number	J:165267
	increased marginal zone B cell number	J:165267
Tlr8/Tlr7^tm1Vlcg/Tlr7⁺ Tlr8/Tlr7^tm1Vlcg/Tlr8^tm1Vlcg (B6.Cg-Tlr8/Tlr7^tm1Vlcg Tlr8^tm1Vlcg)	abnormal spleen marginal zone morphology	J:165267
	decreased anti-insulin autoantibody level	J:165267
	decreased IgG level	J:165267
	decreased IgM level	J:165267
	decreased marginal zone B cell number	J:165267
	increased IgG level	J:165267
	increased IgM level	J:165267
	increased marginal zone B cell number	J:165267
Tlr8/Tlr7^tm1Vlcg/Tlr8/Tlr7^tm1Vlcg (B6.Cg-Tlr8/Tlr7^tm1Vlcg Tlr8^tm1Vlcg)	decreased anti-insulin autoantibody level	J:165267
	decreased follicular B cell number	J:165267
	increased marginal zone B cell number	J:165267
Tlr8^tm1Vlcg/Tlr8^tm1Vlcg (B6.129S1-Tlr8^tm1Vlcg)	abnormal spleen marginal zone morphology	J:165267
	decreased B-1a cell number	J:165267
	decreased B-1b cell number	J:165267
	decreased dendritic cell number	J:165267
	decreased IgG1 level	J:165267
	decreased marginal zone B cell number	J:165267
	enlarged spleen	J:165267
	glomerulonephritis	J:165267
	increased anti-double stranded DNA antibody level	J:165267
	increased anti-nuclear antigen antibody level	J:165267
	increased B-2 B cell number	J:165267
	increased circulating interleukin-12 level	J:165267
	increased IgG2a level	J:165267
	increased IgG level	J:165267
	increased IgM level	J:165267
	increased interleukin-6 secretion	J:165267
	increased spleen weight	J:165267
Tlr9^M1Btlr/Tlr9^M1Btlr (involves: C57BL/6)	abnormal cytokine secretion	J:88906
	abnormal macrophage physiology	J:88906
	abnormal NK cell physiology	J:88906
	abnormal NK T cell physiology	J:88906
	increased susceptibility to Herpesvirales infection	J:88906
	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:88906
Tlr9^M2Btlr/Tlr9⁺ (C57BL/6J-Tlr9^M2Btlr)	abnormal macrophage physiology	J:128405
Tlr9^M2Btlr/Tlr9^M2Btlr (C57BL/6J-Tlr9^M2Btlr)	abnormal macrophage physiology	J:128405
Tlr9^M2Btlr/Tlr9^M2Btlr (C57BL/6J-Tlr9^M2Btlr)	increased susceptibility to Herpesvirales infection	J:128405
Tlr9^m3Btlr/Tlr9^m3Btlr (C57BL/6J-Tlr9^m3Btlr)	abnormal macrophage physiology	J:128406
Tlr9^m3Btlr/Tlr9^m3Btlr (C57BL/6J-Tlr9^m3Btlr)	decreased B cell proliferation	J:128406
Tlr9^m4Btlr/Tlr9⁺ (C57BL/6J-Tlr9^m4Btlr)	abnormal macrophage physiology	J:132489
	abnormal plasmacytoid dendritic cell physiology	J:132489
	decreased B cell proliferation	J:132489
Tlr9^M5Btlr/? (C57BL/6J-Tlr9^M5Btlr)	abnormal macrophage physiology	J:147856
Tlr9^M5Btlr/? (C57BL/6J-Tlr9^M5Btlr)	decreased tumor necrosis factor secretion	J:147856
Tlr9^M5Btlr/Tlr9⁺ (C57BL/6J-Tlr9^M5Btlr)	decreased interferon-alpha secretion	J:147856
Tlr9^M5Btlr/Tlr9⁺ (C57BL/6J-Tlr9^M5Btlr)	decreased interferon-beta secretion	J:147856
Tlr9^m6Btlr/Tlr9^m6Btlr (C57BL/6J-Tlr9^m6Btlr)	increased susceptibility to induced colitis	J:155728
Tlr9^M7Btlr/Tlr9⁺ (C57BL/6J-Tlr9^M7Btlr)	decreased tumor necrosis factor secretion	J:165701
Tlr9^M7Btlr/Tlr9^M7Btlr (C57BL/6J-Tlr9^M7Btlr)	decreased tumor necrosis factor secretion	J:165701
Tlr9^M8Btlr/Tlr9^M8Btlr (involves: C57BL/6J)	decreased interferon-gamma secretion	J:168138
Tlr9^M9Btlr/Tlr9⁺ (C57BL/6J-Tlr9^M9Btlr)	decreased tumor necrosis factor secretion	J:220063
Tlr9^M9Btlr/Tlr9^M9Btlr (C57BL/6J-Tlr9^M9Btlr)	decreased tumor necrosis factor secretion	J:220063
Tlr9^tm1Aki/Tlr9^tm1Aki (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell physiology	J:66049
	abnormal dendritic cell physiology	J:66049
	abnormal macrophage physiology	J:117688, J:66049
	abnormal T-helper 1 physiology	J:66049
	decreased inflammatory response	J:66049
	immune system phenotype	J:66049
Tlr9^tm1Aki/Tlr9^tm1Aki (involves: 129P2/OlaHsd * BALB/c * C57BL/6)	abnormal dendritic cell physiology	J:88244
Tlr9^tm1Aki/Tlr9^tm1Aki (B6.129P2-Tlr9^tm1Aki)	abnormal immune system physiology	J:121070
	abnormal response to infection	J:121070
	decreased interferon-alpha secretion	J:125611
	decreased interferon-beta secretion	J:125611
	decreased interleukin-12b secretion	J:125611, J:118954
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:105435
	decreased susceptibility to parasitic infection	J:116763
	decreased tumor necrosis factor secretion	J:121070
	impaired natural killer cell mediated cytotoxicity	J:125611
Tlr9^tm1Aki/Tlr9^tm1Aki (involves: 129P2/OlaHsd)	abnormal leukocyte migration	J:171379
Tlr9^tm1Aki/Tlr9^tm1Aki Tg(IghelMD4)4Ccg/0 Tg(KLK4mHEL)6Ccg/0 (involves: 129P2/OlaHsd * C57BL/6)	decreased mature B cell number	J:115059
	increased B-1 B cell number	J:115059
Tlr12^tm1Gho/Tlr12^tm1Gho (Not Specified)	abnormal macrophage physiology	J:89754
Tlr12^tm1Gho/Tlr12^tm1Gho (Not Specified)	increased susceptibility to bacterial infection	J:89754
Tlr13^m1Btlr/Tlr13^m1Btlr (C57BL/6J-Tlr13^m1Btlr)	immune system phenotype	J:156849
Tlsm1^AKR/JMs/Tlsm1^AKR/JMs (involves: AKR/JMs * SL/Kh)	increased T cell derived lymphoma incidence	J:21741, J:41197, J:33016
Tlsm1^AKR/JMs/Tlsm1^SL/Kh (involves: AKR/JMs * SL/Kh)	increased T cell derived lymphoma incidence	J:21741, J:41197, J:33016
tlss/tlss (Not Specified)	enlarged mesenteric lymph nodes	J:169366
	enlarged spleen	J:169366
	enlarged thymus	J:169366
Tlx1^{tm1.1(cre/ERT2)Rygo}/Tlx1^{tm1.1(cre/ERT2)Rygo} (involves: C57BL/6 * C57BL/6JJcl * C57BL/6NSlc)	absent spleen	J:217489
Tlx1^tm1Sjk/Tlx1^tm1Sjk (involves: 129S2/SvPas)	abnormal spleen development	J:17695
	abnormal spleen mesenchyme morphology	J:17695
	absent spleen	J:17695
	increased leukocyte cell number	J:17695
	increased lymphocyte cell number	J:17695
	increased neutrophil cell number	J:17695
Tlx1^tm1Thr/Tlx1^tm1Thr (involves: 129P2/OlaHsd * MF1)	abnormal spleen development	J:28700
	absent spleen	J:28700
	increased splenocyte apoptosis	J:28700
Tlx3^tm1Sjk/Tlx3^tm1Sjk (involves: 129X1/SvJ)	immune system phenotype	J:60751
Tm4sf19^em1Sjkm/Tm4sf19^em1Sjkm (C57BL/6J-Tm4sf19^em1Sjkm)	abnormal osteoclast differentiation	J:343322
Tm4sf19^em1Sjkm/Tm4sf19^em1Sjkm (C57BL/6J-Tm4sf19^em1Sjkm)	abnormal osteoclast physiology	J:343322
Tm4sf19^em2Sjkm/Tm4sf19^em2Sjkm (C57BL/6J-Tm4sf19^em2Sjkm)	abnormal osteoclast differentiation	J:343322
Tm4sf19^em2Sjkm/Tm4sf19^em2Sjkm (C57BL/6J-Tm4sf19^em2Sjkm)	abnormal osteoclast physiology	J:343322
Tm4sf20^em1(IMPC)Bay/Tm4sf20^em1(IMPC)Bay (C57BL/6N-Tm4sf20^em1(IMPC)Bay/BayMmucd)	decreased spleen weight	J:211773
Tm7sf2^{tm1b(KOMP)Wtsi}/Tm7sf2^{tm1b(KOMP)Wtsi} (C57BL/6N-Tm7sf2^{tm1b(KOMP)Wtsi}/Orl)	decreased lymphocyte cell number	J:211773
	increased eosinophil cell number	J:211773
Tm9sf2^em1(IMPC)Tcp/Tm9sf2⁺ (C57BL/6N-Tm9sf2^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Tmc6^tm1.1Les/Tmc6^tm1.1Les (B6.129S6(Cg)-Tmc6^tm1.1Les)	decreased CD4-positive, alpha-beta T cell number	J:300461
Tmc6^tm1.1Les/Tmc6^tm1.1Les (B6.129S6(Cg)-Tmc6^tm1.1Les)	decreased CD8-positive, alpha-beta T cell number	J:300461
Tmc7^em1(IMPC)Mbp/Tmc7^em1(IMPC)Mbp (C57BL/6NCrl-Tmc7^em1(IMPC)Mbp/Mmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Tmc8^tm1.1Les/Tmc8^tm1.1Les (B6.129S6(Cg)-Tmc8^tm1.1Les)	decreased CD4-positive, alpha-beta T cell number	J:300461
Tmc8^tm1.1Les/Tmc8^tm1.1Les (B6.129S6(Cg)-Tmc8^tm1.1Les)	decreased CD8-positive, alpha-beta T cell number	J:300461
Tmcc2^em1(IMPC)Mbp/Tmcc2⁺ (C57BL/6N-Tmcc2^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Tmco1^em1(IMPC)J/Tmco1⁺ (C57BL/6NJ-Tmco1^em1(IMPC)J/J)	increased leukocyte cell number	J:211773
Tmem8b^em1(IMPC)Tcp/Tmem8b⁺ (C57BL/6N-Tmem8b^em1(IMPC)Tcp/Tcp)	increased basophil cell number	J:211773
Tmem30a^tm1.1Xjz/Tmem30a^tm1.1Xjz Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺ (involves: 129S/SvEv * 129S4/SvJaeSor * C57BL/6J * DBA)	liver inflammation	J:249038
Tmem35a^{tm1.1(KOMP)Vlcg}/Y (B6(FVB)-Tmem35a^{tm1.1(KOMP)Vlcg})	spleen hyperplasia	J:244268
Tmem41b^em1Cya/Tmem41b⁺ (involves: C57BL/6)	decreased susceptibility to Coronaviridae infection	J:316472
Tmem45a^em1(IMPC)Mbp/Tmem45a^em1(IMPC)Mbp (C57BL/6N-Tmem45a^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	small spleen	J:211773
Tmem60^{em1(IMPC)Ccpcz}/Tmem60^{em1(IMPC)Ccpcz} (C57BL/6N-Tmem60^{em1(IMPC)Ccpcz}/Ccpcz)	decreased effector memory T-helper cell number	J:211773
Tmem64^{Gt(SYA242)Byg}/Tmem64^{Gt(SYA242)Byg} (involves: 129P2/OlaHsd * C57BL/6)	abnormal osteoclast differentiation	J:198051
	decreased osteoclast cell number	J:198051
Tmem74^em1(IMPC)Tcp/Tmem74^em1(IMPC)Tcp (C57BL/6NCrl-Tmem74^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	small thymus	J:211773
Tmem79^ma/Tmem79^ma (involves: C57BL/6JJcl * CBA/CaGr)	dermatitis	J:202316
Tmem79^ma/Tmem79^ma (B6.CBACaGr-Tmem79^ma/J)	blepharitis	J:202453
	dermatitis	J:202453
	increased IgE level	J:202453
	skin inflammation	J:202453
Tmem86a^{tm1b(KOMP)Mbp}/Tmem86a^{tm1b(KOMP)Mbp} (C57BL/6N-Tmem86a^{tm1b(KOMP)Mbp}/Kmpc)	abnormal lymph node morphology	J:211773
Tmem100^{tm1e.1(KOMP)Wtsi}/Tmem100⁺ (C57BL/6N-Tmem100^{tm1e.1(KOMP)Wtsi}/Tcp)	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
Tmem102^tm1.1Jyen/Tmem102^tm1.1Jyen (B6.Cg-Tmem102^tm1.1Jyen)	abnormal leukocyte adhesion	J:200103
	impaired leukocyte migration	J:200103
Tmem106a^em1Cheyy/Tmem106a^em1Cheyy (B6.Cg-Tmem106a^em1Cheyy)	abnormal macrophage activation involved in immune response	J:345342
	immune system phenotype	J:345342
	increased circulating interferon-beta level	J:345342
	increased circulating interleukin-6 level	J:345342
	increased circulating tumor necrosis factor level	J:345342
	increased interleukin-6 secretion	J:345342
	increased susceptibility to endotoxin shock	J:345342
	increased tumor necrosis factor secretion	J:345342
Tmem109^tm1Yamt/Tmem109^tm1Yamt (B6.Cg-Tmem109^tm1Yamt)	decreased thymocyte apoptosis	J:157864
Tmem115^{tm1(KOMP)Vlcg}/Tmem115⁺ (C57BL/6N-Tmem115^{tm1(KOMP)Vlcg}/MbpMmucd)	decreased neutrophil cell number	J:211773
Tmem116^{tm1b(EUCOMM)Hmgu}/Tmem116^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Tmem116^{tm1b(EUCOMM)Hmgu}/Ieg)	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Tmem121b^em1(IMPC)Tcp/Tmem121b^em1(IMPC)Tcp (C57BL/6NCrl-Tmem121b^em1(IMPC)Tcp/Tcp)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Tmem126a^{tm1a(EUCOMM)Wtsi}/Tmem126a^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Tmem126a^{tm1a(EUCOMM)Wtsi}/Wtsi)	decreased alpha-beta T cell number	J:211773
	decreased CD4-positive, alpha-beta T cell number	J:211773
	decreased T-helper cell number	J:211773
Tmem127^{tm1(KOMP)Wtsi}/Tmem127^{tm1(KOMP)Wtsi} (C57BL/6N-Tmem127^{tm1(KOMP)Wtsi}/Wtsi)	decreased B cell number	J:211773
	decreased B-2 B cell number	J:211773
	decreased CD4-positive, alpha-beta T cell number	J:211773
	decreased effector memory CD8-positive, alpha-beta T cell number	J:211773
	decreased KLRG1-positive NK cell number	J:211773
	decreased KLRG1-positive T-helper cell number	J:211773
	decreased Ly6C high monocyte number	J:211773
	decreased memory-marker NK cell number	J:211773
	decreased monocyte cell number	J:211773
	decreased neutrophil cell number	J:211773
	decreased NK cell number	J:211773
	decreased plasmacytoid dendritic cell number	J:211773
	increased alpha-beta T cell number	J:211773
	increased CD4-positive, alpha-beta T cell number	J:211773
	increased CD8-positive, alpha-beta T cell number	J:211773
	increased CD8-positive, naive alpha-beta T cell number	J:211773
	increased KLRG1-positive NK cell number	J:211773
	increased Ly6C low monocyte number	J:211773
	increased memory-marker NK cell number	J:211773
	increased T cell number	J:211773
Tmem138^{tm1b(EUCOMM)Wtsi}/Tmem138^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Tmem138^{tm1b(EUCOMM)Wtsi}/BayMmucd)	increased spleen weight	J:211773
Tmem150b^{em1(IMPC)Ccpcz}/Tmem150b^{em1(IMPC)Ccpcz} (C57BL/6N-Tmem150b^{em1(IMPC)Ccpcz}/Ccpcz)	decreased eosinophil cell number	J:211773
	decreased memory-marker CD4-positive NK T cell number	J:211773
Tmem160^em1.1Bros/Tmem160^em1.1Bros (involves: C57BL/6JRj * FVB/N)	abnormal cytokine level	J:328221
Tmem178^tm1Lex/Tmem178^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6)	abnormal osteoclast differentiation	J:228311
	abnormal osteoclast physiology	J:228311
	increased osteoclast cell number	J:228311
	increased susceptibility to induced arthritis	J:228311
Tmem184b^{tm1.1(KOMP)Vlcg}/Tmem184b^{tm1.1(KOMP)Vlcg} (C57BL/6N-Tmem184b^{tm1.1(KOMP)Vlcg}/Ucd)	abnormal lymph node morphology	J:211773
Tmem204^tm1.1Ali/Tmem204^tm1.1Ali (involves: BALB/c * C57BL/6)	abnormal lymphatic vessel smooth muscle morphology	J:159519
	enlarged lymphatic vessel	J:159519
Tmem204^tm1Ali/Tmem204^tm1Ali Tg(Tie1-cre)9Ref/0 (involves: 129S1/Sv * 129X1/SvJ)	enlarged lymphatic vessel	J:159519
Tmem209^em1(IMPC)Tcp/Tmem209⁺ (C57BL/6NCrl-Tmem209^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Tmem219^{tm1(KOMP)Vlcg}/Tmem219^{tm1(KOMP)Vlcg} (B6J.B6N-Tmem219^{tm1(KOMP)Vlcg})	immune system phenotype	J:236976
	increased eosinophil cell number	J:236976
	increased IgE level	J:236976
	increased interleukin-4 secretion	J:236976
	increased interleukin-13 secretion	J:236976
Tmem219^{tm1(KOMP)Vlcg}/Tmem219^{tm1(KOMP)Vlcg} Tg(Scgb1a1-rtTA,tetO-Il13)1Eli/0 (involves: C57BL/6 * C57BL/6J * C57BL/6N * CBA)	lung inflammation	J:236976
Tmem225^em1(IMPC)Mbp/Tmem225^em1(IMPC)Mbp (C57BL/6N-Tmem225^em1(IMPC)Mbp/MbpMmucd)	small spleen	J:211773
Tmem234^tm1Lex/Tmem234^tm1Lex (B6;129S5-Tmem234^tm1Lex/Mmucd)	increased IgG2a level	J:171883
Tmem237^{tm1b(EUCOMM)Hmgu}/Tmem237⁺ (C57BL/6N-Tmem237^{tm1b(EUCOMM)Hmgu}/Ccpcz)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
Tmem241^em1Blsg/Tmem241^em1Blsg (involves: C57BL/6J)	lung inflammation	J:344360
Tmem248^{tm1.1(KOMP)Vlcg}/Tmem248^{tm1.1(KOMP)Vlcg} (C57BL/6N-Tmem248^{tm1.1(KOMP)Vlcg}/Ucd)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	decreased thymus weight	J:211773
	increased monocyte cell number	J:211773
	small spleen	J:211773
	small thymus	J:211773
Tmem256^{tm1.1(KOMP)Vlcg}/Tmem256^{tm1.1(KOMP)Vlcg} (C57BL/6N-Tmem256^{tm1.1(KOMP)Vlcg}/Ucd)	increased monocyte cell number	J:211773
Tmem258^{tm1.1(KOMP)Vlcg}/Tmem258⁺ (involves: C57BL/6NTac)	increased susceptibility to colitis induced morbidity/mortality	J:240635
Tmem258^{tm1.1(KOMP)Vlcg}/Tmem258⁺ (involves: C57BL/6NTac)	increased susceptibility to induced colitis	J:240635
Tmem263^em1Gww/Tmem263^em1Gww (C57BL/6J-Tmem263^em1Gww)	decreased spleen weight	J:345905
Tmem268^em1Cheyy/Tmem268^em1Cheyy (involves: C57BL/6)	abnormal leukocyte adhesion	J:350812
	abnormal leukocyte physiology	J:350812
	abnormal macrophage physiology	J:350812
	abnormal monocyte cell number	J:350812
	abnormal neutrophil cell number	J:350812
	decreased macrophage cell number	J:350812
	immune system phenotype	J:350812
	impaired leukocyte migration	J:350812
	impaired macrophage phagocytosis	J:350812
	impaired neutrophil phagocytosis	J:350812
	increased chemokine level	J:350812
	increased circulating interferon-beta level	J:350812
	increased circulating tumor necrosis factor level	J:350812
	increased susceptibility to bacterial infection	J:350812
	increased susceptibility to bacterial infection induced morbidity/mortality	J:350812
Tmem278^em1(IMPC)Mbp/Tmem278^em1(IMPC)Mbp (C57BL/6N-Tmem278^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
Tmevp2^C57BL/10SnSg/Tmevp2^C57BL/10SnSg (involves: A/WySn * C57BL/10SnSg * SJL/J * Swiss)	decreased susceptibility to Picornaviridae infection	J:54593
Tmevp3^C57BL/10SnSg/Tmevp3^C57BL/10SnSg (involves: A/WySn * C57BL/10SnSg * SJL/J * Swiss)	decreased susceptibility to Picornaviridae infection	J:54593
Tmevp3^C57BL/10SnSg/Tmevp3^SJL/J (involves: A/WySn * C57BL/10SnSg * SJL/J * Swiss)	decreased susceptibility to Picornaviridae infection	J:54593
Tmprss2^{em1(IMPC)Ccpcz}/Tmprss2^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Tmprss2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Tmprss2^{tm1(KOMP)Vlcg}/Tmprss2^{tm1(KOMP)Vlcg} (involves: C57BL/6NTac)	abnormal cytokine secretion	J:283077
	decreased susceptibility to Coronaviridae infection	J:283077
	decreased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:214427
	lung inflammation	J:214427
Tmprss2^tm1Psn/Tmprss2^tm1Psn (B6JRj.129S1-Tmprss2^tm1Psn)	decreased susceptibility to Orthomyxoviridae infection	J:287633
Tmprss2^tm1Psn/Tmprss2^tm1Psn (B6JRj.129S1-Tmprss2^tm1Psn)	decreased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:287633
Tmprss2^tm1Psn/Tmprss2^tm1Psn (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	decreased susceptibility to Orthomyxoviridae infection	J:244166
Tmprss2^{tm2.1(ETV1)Sho}/Tmprss2^{tm2.1(ETV1)Sho} (involves: C57BL/6 * DBA/2)	prostate gland inflammation	J:212219
Tmprss6^msk/Tmprss6^msk (C57BL/6J-Tmprss6^msk)	decreased spleen iron level	J:134446
Tmprss6^{tm1b(EUCOMM)Wtsi}/Tmprss6^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Tmprss6^{tm1b(EUCOMM)Wtsi}/Ics)	decreased CD8-positive, alpha-beta T cell number	J:211773
	decreased NK cell number	J:211773
	immune system phenotype	J:211773
	increased CD11b-high dendritic cell number	J:211773
	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
	increased Ly6C-positive mature NK cell number	J:211773
Tmprss6^tm1Dgen/Tmprss6⁺ (B6.129P2-Tmprss6^tm1Dgen/Crl)	decreased spleen iron level	J:160248
Tmprss6^tm1Dgen/Tmprss6^tm1Dgen (B6.129P2-Tmprss6^tm1Dgen/Crl)	decreased spleen iron level	J:160248
	increased spleen weight	J:160248
Tmprss15^{tm1a(KOMP)Wtsi}/Tmprss15^{tm1a(KOMP)Wtsi} (C57BL/6N-Tmprss15^{tm1a(KOMP)Wtsi}/Wtsi)	increased leukocyte cell number	J:175295
Tmub1^tm1Lex/Tmub1^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6J)	increased monocyte cell number	J:171883
Tmub2^{tm1b(KOMP)Wtsi}/Tmub2^{tm1b(KOMP)Wtsi} (C57BL/6N-Tmub2^{tm1b(KOMP)Wtsi}/Tcp)	decreased lymphocyte cell number	J:211773
	increased eosinophil cell number	J:211773
Tnbs1^SJL/J/? (involves: C57BL/6J * SJL/J)	increased susceptibility to induced colitis	J:82095
Tnbs2^SJL/J/? (involves: C57BL/6J * SJL/J)	increased interleukin-12b secretion	J:82095
Tnbs2^SJL/J/? (involves: C57BL/6J * SJL/J)	increased susceptibility to induced colitis	J:82095
Tnf^Bpsm1/Tnf⁺ (involves: C57BL/6)	aortic valve inflammation	J:226052
	increased circulating tumor necrosis factor level	J:226052
	increased synovial pannus formation	J:226052
	mitral valve inflammation	J:226052
	rheumatoid arthritis	J:226052
Tnf^Bpsm1/Tnf⁺ (C.Cg-Tnf^Bpsm1)	aortic valve inflammation	J:226052
	cardiovalvulitis	J:226052
	mitral valve inflammation	J:226052
Tnf^Bpsm1/Tnf⁺ Tnfrsf1a^tm1Mak/Tnfrsf1a^tm1Mak (involves: 129S2/SvPas * C57BL/6)	increased circulating tumor necrosis factor level	J:226052
Tnf^Bpsm1/Tnf^Bpsm1 (involves: C57BL/6)	accelerated temporomandibular joint osteoarthritis	J:226052
	aortic valve inflammation	J:226052
	increased circulating tumor necrosis factor level	J:226052
	mitral valve inflammation	J:226052
	rheumatoid arthritis	J:226052
Tnf^Bpsm1/Tnf^Bpsm1 Tnfrsf1a^tm1Mak/Tnfrsf1a^tm1Mak (involves: 129S2/SvPas * C57BL/6)	increased circulating tumor necrosis factor level	J:226052
Tnf^em4Boui/Tnf⁺ (C57BL/6-Tnf^em4Boui)	autoimmune arthritis	J:306876
	cardiovalvulitis	J:306876
	colitis	J:306876
	esophageal inflammation	J:306876
	ileum inflammation	J:306876
Tnf^em5Boui/Tnf⁺ Tnfrsf1a^tm1Mak/Tnfrsf1a⁺ (involves: 129S2/SvPas * C57BL/6)	autoimmune arthritis	J:306876
	cardiovalvulitis	J:306876
	colitis	J:306876
	increased synovial pannus formation	J:306876
Tnf^M1Btlr/Tnf⁺ (C57BL/6J-Tnf^M1Btlr)	decreased follicular dendritic cell number	J:124642
Tnf^M1Btlr/Tnf⁺ (C57BL/6J-Tnf^M1Btlr)	immune system phenotype	J:124642
Tnf^M1Btlr/Tnf^M1Btlr (C57BL/6J-Tnf^M1Btlr)	decreased follicular dendritic cell number	J:124642
	immune system phenotype	J:124642
	increased susceptibility to bacterial infection	J:124642
Tnf^M2Btlr/Tnf⁺ (C57BL/6J-Tnf^M2Btlr)	decreased macrophage cytokine production	J:213047
Tnf^M2Btlr/Tnf⁺ (C57BL/6J-Tnf^M2Btlr)	decreased tumor necrosis factor secretion	J:213047
Tnf^R8H/Tnf^R8H (involves: I/St)	increased susceptibility to bacterial infection	J:114302
Tnf^tm1.1Sned/Tnf^tm1.1Sned Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129 * 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:95684
Tnf^tm1.1Sned/Tnf^tm1.1Sned Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129 * 129P2/OlaHsd * C57BL/6)	abnormal chemokine secretion	J:95684
	decreased circulating tumor necrosis factor level	J:95684
	decreased susceptibility to autoimmune disorder	J:95684
	decreased susceptibility to endotoxin shock	J:95684
	increased susceptibility to bacterial infection	J:95684
Tnf^tm1.1Sned/Tnf^tm1.1Sned Tg(Cd4-cre)1Cwi/0 (involves: 129 * C57BL/6 * DBA/2)	decreased circulating tumor necrosis factor level	J:95684
	decreased susceptibility to autoimmune disorder	J:95684
	decreased susceptibility to endotoxin shock	J:95684
	increased susceptibility to bacterial infection	J:95684
Tnf^tm1.2Sned/Tnf^tm1.2Sned (involves: 129/Sv * C57BL/6)	absent Peyer's patches	J:97783
	decreased susceptibility to bacterial infection	J:97783
	increased leukocyte cell number	J:97783
	increased susceptibility to parasitic infection	J:97783
Tnf^tm1Gkl/Tnf^tm1Gkl (involves: 129S/SvEv * C57BL/6)	abnormal inflammatory response	J:114740
	abnormal lymph node B cell domain morphology	J:40970
	abnormal lymphocyte physiology	J:114740
	abnormal macrophage physiology	J:114740
	abnormal mesenteric lymph node morphology	J:114740
	abnormal Peyer's patch follicle morphology	J:40970
	abnormal Peyer's patch morphology	J:40970
	abnormal spleen follicular dendritic cell network	J:42579
	abnormal spleen primary B follicle morphology	J:47673
	absent follicular dendritic cells	J:40970
	absent spleen germinal center	J:47673, J:114740
	decreased inflammatory response	J:56068
	decreased Peyer's patch number	J:40970
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:114740
	decreased susceptibility to type IV hypersensitivity reaction	J:47673
	immune system phenotype	J:114740
	increased susceptibility to bacterial infection	J:47673, J:114740
Tnf^tm1Gkl/Tnf^tm1Gkl (involves: 129S/SvEv)	abnormal chemokine secretion	J:95684
	decreased circulating tumor necrosis factor level	J:95684
	decreased susceptibility to autoimmune disorder	J:95684
	decreased susceptibility to endotoxin shock	J:95684
	increased susceptibility to bacterial infection	J:95684
Tnf^tm1Gkl/Tnf^tm1Gkl (either: B6.129-Tnf^tm1Gkl or (involves: 129 * C57BL/6))	decreased Peyer's patch number	J:97783
	decreased susceptibility to bacterial infection	J:97783
	increased leukocyte cell number	J:97783
	increased lymphocyte cell number	J:97783
	increased neutrophil cell number	J:97783
	increased susceptibility to parasitic infection	J:97783
	small Peyer's patches	J:97783
Tnf^tm1Gkl/Tnf^tm1Gkl (involves: 129S/SvEv * C57BL/6J)	abnormal metallophilic macrophage morphology	J:124642
	abnormal Peyer's patch follicle morphology	J:124642
	abnormal Peyer's patch germinal center morphology	J:124642
	abnormal Peyer's patch morphology	J:124642
	abnormal Peyer's patch T cell area morphology	J:124642
	abnormal spleen follicular dendritic cell network	J:124642
	abnormal spleen marginal sinus morphology	J:124642
	abnormal spleen primary B follicle morphology	J:124642
	absent spleen germinal center	J:124642
	decreased Peyer's patch number	J:124642
	increased susceptibility to bacterial infection	J:124642
Tnf^tm1Gkl/Tnf^tm1Gkl Tnfaip3^tm1Ama/Tnfaip3^tm1Ama (involves: 129S/SvEv * C57BL/6J)	abnormal cytokine secretion	J:92694
	abnormal inflammatory response	J:92694
Tnf^tm1Gkl/Tnf^tm1Gkl Tnfrsf1a^tm1.1Gkl/Tnfrsf1a^tm1.1Gkl (involves: 129S/SvEv * C57BL/6)	immune system phenotype	J:92470
Tnf^tm1Gkl/Tnf^tm2Gkl (involves: 129S/SvEv * C57BL/6)	increased circulating tumor necrosis factor level	J:54056
	increased susceptibility to endotoxin shock	J:54056
	increased synovial pannus formation	J:54056
	increased tumor necrosis factor secretion	J:54056
	rheumatoid arthritis	J:54056
Tnf^tm1Jods/Tnf^tm1Jods (involves: C57BL/6)	abnormal immune system physiology	J:98591
	abnormal lymph node primary follicle morphology	J:98591
	abnormal metallophilic macrophage morphology	J:98591
	abnormal Peyer's patch follicle morphology	J:43602
	abnormal Peyer's patch morphology	J:43602, J:98591
	abnormal spleen marginal sinus morphology	J:43602
	abnormal spleen primary B follicle morphology	J:43602, J:98591
	abnormal spleen white pulp morphology	J:43602, J:98591
	absent spleen germinal center	J:98591
	decreased follicular dendritic cell number	J:43602
	decreased Peyer's patch number	J:43602
	decreased susceptibility to endotoxin shock	J:98591
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:44545, J:98591
	increased leukocyte cell number	J:43602
	increased susceptibility to bacterial infection	J:115034, J:98170
	small Peyer's patches	J:43602
Tnf^tm1Jods/Tnf^tm1Jods (C57BL/6-Tnf^tm1Jods)	abnormal cytokine level	J:118417
Tnf^tm1Jods/Tnf^tm1Jods (C57BL/6-Tnf^tm1Jods)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:118417
Tnf^tm1Jods/Tnf^tm1Jods (C57BL/6-Lta^tm1Jods)	abnormal spleen B cell follicle morphology	J:78229
Tnf^tm1Jods/Tnf^tm1Jods (C57BL/6-Lta^tm1Jods)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:47428
Tnf^tm1Ljo/Tnf⁺ (involves: 129S1/Sv)	increased susceptibility to bacterial infection	J:41992
Tnf^tm1Ljo/Tnf⁺ (involves: 129S1/Sv)	increased susceptibility to fungal infection	J:41992
Tnf^tm1Ljo/Tnf^tm1Ljo (involves: 129S1/Sv)	abnormal chemokine secretion	J:95684
	abnormal cytokine secretion	J:41992
	abnormal follicular dendritic cell physiology	J:41992
	abnormal susceptibility to infection	J:41992
	absent spleen germinal center	J:80616, J:41992
	decreased circulating tumor necrosis factor level	J:95684
	decreased IgG level	J:41992
	decreased spleen B cell follicle number	J:95684
	decreased spleen white pulp amount	J:80616
	decreased susceptibility to autoimmune disorder	J:95684
	decreased susceptibility to endotoxin shock	J:95684, J:41992
	increased susceptibility to bacterial infection	J:80616, J:95684, J:41992
	increased susceptibility to fungal infection	J:41992
Tnf^tm1Ljo/Tnf^tm1Ljo (either: B6.129-Tnf^tm1Ljo or (involves: 129 * C57BL/6))	abnormal Peyer's patch follicle morphology	J:97783
	abnormal Peyer's patch germinal center morphology	J:97783
	abnormal Peyer's patch T cell area morphology	J:97783
	absent follicular dendritic cells	J:97783
	decreased Peyer's patch number	J:97783
	decreased susceptibility to bacterial infection	J:97783
	increased leukocyte cell number	J:97783
	increased lymphocyte cell number	J:97783
	increased neutrophil cell number	J:97783
	increased susceptibility to parasitic infection	J:97783
	small Peyer's patches	J:97783
Tnf^tm1Ljo/Tnf^tm1Ljo (B6.129S1-Tnf^tm1Ljo)	lung inflammation	J:127028
Tnf^tm1Ljo/Tnf^tm1Ljo (involves: 129S1/Sv * C57BL/6)	abnormal lymph node cell ratio	J:127028
	abnormal neutrophil physiology	J:127028
	decreased immunoglobulin level	J:127028
	increased interferon-gamma secretion	J:127028
	increased neutrophil cell number	J:127028
	increased susceptibility to parasitic infection	J:127028
	lymph node hypoplasia	J:127028
	skin inflammation	J:127028
Tnf^tm1Sek/Tnf^tm1Sek (B6.Cg-Tnf^tm1Sek)	abnormal cytokine secretion	J:44841
	abnormal macrophage physiology	J:44841
	abnormal mesenteric lymph node morphology	J:44841
	abnormal Peyer's patch germinal center morphology	J:44841
	absent lymph node germinal center	J:44841
	absent spleen germinal center	J:44841
	decreased circulating interferon-gamma level	J:44841
	decreased circulating interleukin-1 alpha level	J:44841
	decreased circulating interleukin-1 beta level	J:44841
	decreased circulating interleukin-6 level	J:44841
	decreased susceptibility to endotoxin shock	J:44841
	immune system phenotype	J:44841
Tnf^tm2.1Gkl/Tnf^tm2.1Gkl Tg(Fabp1-cre)1Jig/0 (involves: 129S/SvEv * FVB/N)	ileum inflammation	J:204557
	increased circulating tumor necrosis factor level	J:204557
	large intestinal inflammation	J:204557
	small intestinal inflammation	J:204557
Tnf^tm2.1Gkl/Tnf^tm2.1Gkl Tg(Lck-cre)I57Jxm/0 (involves: 129S/SvEv * ICR)	small intestinal inflammation	J:108572
Tnf^tm2Gkl/Tnf⁺ (involves: 129S/SvEv * C57BL/6)	abnormal alpha-beta intraepithelial T cell morphology	J:136667
	abnormal CD4-positive, alpha-beta T cell physiology	J:136667
	abnormal CD8-positive, alpha beta T cell morphology	J:136667
	abnormal circulating chemokine level	J:204922
	abnormal T cell physiology	J:136667
	abnormal T cell subpopulation ratio	J:136667
	abnormal T-helper 17 cell physiology	J:204922
	autoimmune arthritis	J:92307, J:136667
	decreased inflammatory response	J:204922
	ileum inflammation	J:204922
	increased circulating tumor necrosis factor level	J:54056, J:204922
	increased dendritic cell number	J:204922
	intestinal inflammation	J:136667
	rheumatoid arthritis	J:54056
	small intestinal inflammation	J:92307, J:54056, J:204922
Tnf^tm2Gkl/Tnf⁺ (involves: 129S/SvEv * C57BL/6 * SPRET/Ei)	autoimmune arthritis	J:92307
Tnf^tm2Gkl/Tnf⁺ (involves: 129S/SvEv * C57BL/6 * SPRET/Ei)	small intestinal inflammation	J:92307
Tnf^tm2Gkl/Tnf⁺ (involves: 129S/SvEv * C57BL/6J)	abnormal cytotoxic T cell physiology	J:108572
	abnormal myelopoiesis	J:108572
	abnormal response to transplant	J:108572
	enlarged spleen	J:108572
	increased CD8-positive, alpha-beta T cell number	J:108572
	increased circulating tumor necrosis factor level	J:264147
	increased tumor necrosis factor secretion	J:264147
	small intestinal inflammation	J:108572
Tnf^tm2Gkl/Tnf⁺ (involves: 129S/SvEv * C57BL/6 * CBA)	autoimmune arthritis	J:131930
Tnf^tm2Gkl/Tnf⁺ (B6.129S-Tnf^tm2Gkl/Jarn)	abnormal CD4-positive, alpha-beta T cell physiology	J:145626
	abnormal CD8-positive, alpha beta T cell morphology	J:131978
	ileum inflammation	J:131978, J:145626
	increased CD4-positive, alpha-beta memory T cell number	J:145626
	increased CD4-positive, alpha-beta T cell number	J:145626
	increased interferon-gamma secretion	J:131978
	increased interleukin-2 secretion	J:145626
	increased tumor necrosis factor secretion	J:145626
Tnf^tm2Gkl/Tnf⁺ Tnfrsf1a^tm2Gkl/Tnfrsf1a^tm2Gkl Tg(Col6a1-cre)1Gkl/? (involves: 129S/SvEv * C57BL/6 * CBA)	autoimmune arthritis	J:131930
	small intestinal inflammation	J:131930
Tnf^tm2Gkl/Tnf⁺ Tnfrsf1b^tm1.1Gkl/Tnfrsf1b^tm1.1Gkl Tg(Col6a1-cre)1Gkl/0 (involves: 129S/SvEv * C57BL/6 * C57BL/6J * CBA)	increased circulating tumor necrosis factor level	J:264147
	increased tumor necrosis factor secretion	J:264147
	joint inflammation	J:264147
Tnf^tm2Gkl/Tnf⁺ Tnfrsf1b^tm1.2Gkl/Tnfrsf1b^tm1.2Gkl (involves: 129S/SvEv * C57BL/6 * C57BL/6J)	aortic valve inflammation	J:264147
	autoimmune arthritis	J:264147
	increased circulating tumor necrosis factor level	J:264147
	increased tumor necrosis factor secretion	J:264147
Tnf^tm2Gkl/Tnf⁺ Tnfrsf1b^tm1Mwm/Tnfrsf1b^tm1Mwm (involves: 129S/SvEv * 129S2/SvPas * C57BL/6)	rheumatoid arthritis	J:54056
	small intestinal inflammation	J:54056
Tnf^tm2Gkl/Tnf^tm2Gkl (involves: 129S/SvEv * C57BL/6)	cardiovalvulitis	J:226052
	increased circulating tumor necrosis factor level	J:54056
	rheumatoid arthritis	J:54056
	small intestinal inflammation	J:54056
	thymus hypoplasia	J:54056
Tnf^tm2Gkl/Tnf^tm2Gkl Tnfrsf1a^tm1Blt/Tnfrsf1a^tm1Blt (involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6)	increased circulating tumor necrosis factor level	J:54056
	increased tumor necrosis factor secretion	J:54056
Tnf^tm2Jods/Tnf^tm2Jods (involves: C57BL/6)	abnormal lymph node cell ratio	J:127028
	decreased immunoglobulin level	J:127028
	immune system phenotype	J:127028
	increased susceptibility to bacterial infection	J:98170
Tnf^tm2Jods/Tnf^tm2Jods (C57BL/6-Tnf^tm2Jods)	abnormal immune system physiology	J:98591
	abnormal lymph node primary follicle morphology	J:98591
	abnormal metallophilic macrophage morphology	J:98591
	abnormal Peyer's patch follicle morphology	J:98591
	abnormal spleen follicular dendritic cell network	J:98591
	abnormal spleen primary B follicle morphology	J:98591
	abnormal spleen white pulp morphology	J:98591
	decreased spleen germinal center number	J:98591
	decreased spleen germinal center size	J:98591
	decreased susceptibility to endotoxin shock	J:98591
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:98591
Tnf^tm3Gkl/Tnf^tm3Gkl (involves: 129S/SvEv * C57BL/6)	abnormal lymph node B cell domain morphology	J:114740
	abnormal lymphocyte physiology	J:114740
	abnormal mesenteric lymph node morphology	J:114740
	abnormal spleen primary B follicle morphology	J:114740
	absent follicular dendritic cells	J:114740
	absent spleen germinal center	J:114740
	autoimmune response	J:114740
	decreased circulating tumor necrosis factor level	J:114740
	decreased IgG1 level	J:114740
	decreased susceptibility to bacterial infection	J:114740
	decreased susceptibility to endotoxin shock	J:114740
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:114740
	decreased tumor necrosis factor secretion	J:114740
Tnf^tm3Gkl/Tnf^tm3Gkl Zfp36^tm1Pjb/Zfp36^tm1Pjb (involves: 129S/SvEv * C57BL/6)	immune system phenotype	J:114740
	myeloid hyperplasia	J:114740
Tnfaip3^m1Apb/Tnfaip3^m1Apb (C57BL/6-Tnfaip3^m1Apb)	CNS inflammation	J:324062
	enlarged lymph nodes	J:324062
	increased effector memory T-helper cell number	J:324062
	increased macrophage cell number	J:324062
	increased microglial cell activation	J:324062
	uterus inflammation	J:324062
Tnfaip3^tm1.1Gho/Tnfaip3^tm1.1Gho (involves: C57BL/6J)	enlarged spleen	J:217021
Tnfaip3^tm1.1Gho/Tnfaip3^tm1.1Gho (involves: C57BL/6J)	immune system phenotype	J:217021
Tnfaip3^tm1.1Gvl/Tnfaip3^tm1.1Gvl Tg(Vil1-cre)997Gum/0 (B6.Cg-Tnfaip3^tm1.1Gvl Tg(Vil1-cre)997Gum)	increased circulating interleukin-6 level	J:163410
	increased susceptibility to induced colitis	J:163410
Tnfaip3^tm1.1Gvl/Tnfaip3^tm1.1Gvl Tnfrsf1a^tm1Mak/Tnfrsf1a^tm1Mak Tg(Vil1-cre)997Gum/0 (involves: 129S2/SvPas * C57BL/6 * SJL)	decreased susceptibility to induced colitis	J:163410
	increased susceptibility to induced colitis	J:163410
Tnfaip3^tm1Ama/Tnfaip3^tm1Ama (involves: C57BL/6J)	abnormal cytokine secretion	J:92694
Tnfaip3^tm1Ama/Tnfaip3^tm1Ama (involves: C57BL/6J)	abnormal inflammatory response	J:92694
Tnfaip3^tm1Ama/Tnfaip3^tm1Ama (Not Specified)	increased granulocyte number	J:92931
	increased inflammatory response	J:92931
	increased lymphocyte cell number	J:92931
	increased macrophage cell number	J:92931
	intestinal inflammation	J:92931
	joint inflammation	J:92931
	kidney inflammation	J:92931
	liver inflammation	J:92931
Tnfaip3^tm1Ama/Tnfaip3^tm1Ama Tnfrsf1a^tm1Imx/Tnfrsf1a⁺ (involves: C57BL/6J)	abnormal inflammatory response	J:92694
Tnfaip3^tm1Ama/Tnfaip3^tm1Ama Tnfrsf1a^tm1Imx/Tnfrsf1a^tm1Imx (involves: C57BL/6J)	abnormal inflammatory response	J:92694
Tnfaip3^tm1Homy/Tnfaip3^tm1Homy Tg(Mx1-cre)1Cgn/? (involves: 129S6/SvEvTac * C57BL/6J * CBA/J)	abnormal B cell number	J:212681
	abnormal circulating cytokine level	J:212681
	abnormal circulating interleukin level	J:212681
	abnormal myelopoiesis	J:212681
	abnormal spleen morphology	J:212681
	enlarged lymph nodes	J:212681
	increased circulating interferon-gamma level	J:212681
	increased circulating interleukin-1 beta level	J:212681
	increased circulating interleukin-6 level	J:212681
	increased circulating tumor necrosis factor level	J:212681
	liver inflammation	J:212681
	lung inflammation	J:212681
Tnfaip3^tm2Ama/Tnfaip3^tm2Ama Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell activation	J:163917
	abnormal B cell morphology	J:163917
	abnormal B-1a B cell morphology	J:163917
	decreased B cell apoptosis	J:163917
	decreased B cell number	J:163917
	increased autoantibody level	J:163917
	increased B cell number	J:163917
	increased B cell proliferation	J:163917
	increased germinal center B cell number	J:163917
	increased IgG level	J:163917
	increased IgM level	J:163917
	increased immature B cell number	J:163917
	increased immunoglobulin level	J:163917
	increased interleukin-6 secretion	J:163917
	increased plasma cell number	J:163917
	increased susceptibility to autoimmune disorder	J:163917
	increased T cell number	J:163917
Tnfaip3^tm3.1Ama/Tnfaip3^tm3.1Ama (C57BL/6J-Tnfaip3^tm3.1Ama)	abnormal chemokine secretion	J:203160
	decreased interleukin-6 secretion	J:203160
	enlarged spleen	J:203160
	increased B cell number	J:203160
	increased CD4-positive, alpha-beta T cell number	J:203160
	increased CD8-positive, alpha-beta T cell number	J:203160
	increased susceptibility to induced colitis	J:203160
	myeloid hyperplasia	J:203160
Tnfaip3^tm4.1Ama/Tnfaip3^tm4.1Ama (C57BL/6J-Tnfaip3^tm4.1Ama)	abnormal chemokine secretion	J:203160
	decreased interleukin-6 secretion	J:203160
	enlarged spleen	J:203160
	increased B cell number	J:203160
	increased CD4-positive, alpha-beta T cell number	J:203160
	increased CD8-positive, alpha-beta T cell number	J:203160
	increased susceptibility to induced colitis	J:203160
	myeloid hyperplasia	J:203160
Tnfaip6^tm1Cful/Tnfaip6^tm1Cful (involves: 129S6/SvEvTac * BALB/c)	decreased inflammatory response	J:193758
Tnfaip8^{Gt(IST13629C1)Tigm}/Tnfaip8^{Gt(IST13629C1)Tigm} (involves: C57BL/6N)	immune system phenotype	J:223320
	increased circulating interleukin-6 level	J:223320
	increased circulating interleukin-17 level	J:223320
	increased interleukin-1 beta secretion	J:223320
	increased interleukin-6 secretion	J:223320
	increased interleukin-17 secretion	J:223320
	increased neutrophil cell number	J:223320
	increased susceptibility to induced colitis	J:223320
	small spleen	J:223320
Tnfaip8^{Gt(IST13629C1)Tigm}/Tnfaip8^{Gt(IST13629C1)Tigm} Tnfaip8l1^em1Huwa/Tnfaip8l1^em1Huwa (involves: C57BL/6 * C57BL/6N)	colitis	J:342074
	decreased spleen weight	J:342074
	increased leukocyte cell number	J:342074
	increased T-helper 17 cell number	J:342074
Tnfaip8l1^em1(IMPC)Mbp/Tnfaip8l1^em1(IMPC)Mbp (C57BL/6N-Tnfaip8l1^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	small spleen	J:211773
Tnfaip8l1^em1Huwa/Tnfaip8l1^em1Huwa (C57BL/6-Tnfaip8l1^em1Huwa)	increased susceptibility to colitis induced morbidity/mortality	J:342074
	increased susceptibility to induced colitis	J:342074
Tnfaip8l2^tm1Yhcn/Tnfaip8l2^tm1Yhcn (129S6/SvEvTac-Tnfaip8l2^tm1Yhcn)	abnormal B cell activation	J:139785
	abnormal B cell physiology	J:139785
	abnormal CD4-positive, alpha-beta T cell physiology	J:139785
	abnormal cytotoxic T cell physiology	J:139785
	abnormal inflammatory response	J:139785
	abnormal leukocyte morphology	J:139785
	abnormal macrophage activation involved in immune response	J:139785
	abnormal myeloid dendritic cell morphology	J:139785
	abnormal spleen morphology	J:139785
	abnormal T cell apoptosis	J:139785
	chronic inflammation	J:139785
	decreased IgG2a level	J:139785
	decreased IgG2b level	J:139785
	enlarged spleen	J:139785
	increased B cell number	J:139785
	increased circulating interleukin-1 beta level	J:139785
	increased circulating interleukin-6 level	J:139785
	increased circulating interleukin-10 level	J:139785
	increased circulating interleukin-12 level	J:139785
	increased circulating tumor necrosis factor level	J:139785
	increased interferon-gamma secretion	J:139785
	increased interleukin-1 beta secretion	J:139785
	increased interleukin-2 secretion	J:139785
	increased interleukin-4 secretion	J:139785
	increased interleukin-6 secretion	J:139785
	increased interleukin-12 secretion	J:139785
	increased interleukin-17 secretion	J:139785
	increased spleen white pulp amount	J:139785
	increased susceptibility to endotoxin shock	J:139785
	increased T cell number	J:139785
	increased tumor necrosis factor secretion	J:139785
	intestinal inflammation	J:139785
	liver inflammation	J:139785
	lung inflammation	J:139785
	lymph node inflammation	J:139785
	spleen hyperplasia	J:139785
Tnfrsf1a^{em1(IMPC)Ccpcz}/Tnfrsf1a^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Tnfrsf1a^{em1(IMPC)Ccpcz}/Ccpcz)	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
	increased neutrophil cell number	J:211773
	increased NK cell number	J:211773
Tnfrsf1a^tm1.1Gkl/Tnfrsf1a⁺ (involves: 129/Sv * C57BL/6)	liver inflammation	J:92470
Tnfrsf1a^tm1.1Gkl/Tnfrsf1a^tm1.1Gkl (involves: 129/Sv * C57BL/6)	abnormal cytokine secretion	J:92470
	decreased susceptibility to bacterial infection	J:92470
	increased susceptibility to experimental autoimmune encephalomyelitis	J:92470
	liver inflammation	J:92470
Tnfrsf1a^tm1.1Gkl/Tnfrsf1a^tm1.1Gkl Tnfrsf1b^tm1Mwm/Tnfrsf1b^tm1Mwm (involves: 129/Sv * C57BL/6)	liver inflammation	J:92470
Tnfrsf1a^tm1Blt/Tnfrsf1a⁺ (involves: 129P2/OlaHsd)	decreased circulating interleukin-6 level	J:210950
Tnfrsf1a^tm1Blt/Tnfrsf1a^tm1Blt (involves: 129P2/OlaHsd * C57BL/6)	abnormal immune system physiology	J:14424
	abnormal lymph node B cell domain morphology	J:40970
	abnormal Peyer's patch follicle morphology	J:40970
	abnormal Peyer's patch morphology	J:40970
	absent follicular dendritic cells	J:40970
	decreased IgG1 level	J:115225
	decreased interleukin-6 secretion	J:14424
	decreased Peyer's patch number	J:40970
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:115225
	increased susceptibility to bacterial infection	J:14424
	increased susceptibility to parasitic infection	J:114203
	increased susceptibility to type I hypersensitivity reaction	J:92307
Tnfrsf1a^tm1Blt/Tnfrsf1a^tm1Blt (involves: 129/Sv * 129P2/OlaHsd * C57BL/6)	decreased susceptibility to bacterial infection	J:50903
Tnfrsf1a^tm1Blt/Tnfrsf1a^tm1Blt (involves: 129P2/OlaHsd)	impaired humoral immune response	J:210950
Tnfrsf1a^tm1Blt/Tnfrsf1a^tm1Blt (involves: 129P2/OlaHsd)	increased susceptibility to bacterial infection induced morbidity/mortality	J:210950
Tnfrsf1a^tm1Blt/Tnfrsf1a^tm1Blt Tnfrsf1b^tm1Mwm/Tnfrsf1b^tm1Mwm (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)	abnormal lymph node cortex morphology	J:119206
	abnormal lymph node primary follicle morphology	J:119206
	abnormal lymph node secondary follicle morphology	J:119206
	absent lymph node germinal center	J:119206
	absent spleen germinal center	J:119206
	decreased IgG1 level	J:115225
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:115225
	immune system phenotype	J:119206
	increased susceptibility to parasitic infection	J:114203
	small Peyer's patches	J:119206
Tnfrsf1a^tm1Blt/Tnfrsf1a^tm2Gkl Tg(Cr2-cre)3Cgn/0 (involves: 129P2/OlaHsd * 129S/SvEv)	immune system phenotype	J:113314
Tnfrsf1a^tm1Imx/Tnfrsf1a⁺ (involves: C57BL/6)	decreased circulating interleukin-6 level	J:210950
Tnfrsf1a^tm1Imx/Tnfrsf1a^tm1Imx (involves: 129S7/SvEvBrd * C57BL/6)	abnormal immune system physiology	J:45147
Tnfrsf1a^tm1Imx/Tnfrsf1a^tm1Imx (C57BL/6-Tnfrsf1a^tm1Imx)	decreased inflammatory response	J:45147
	decreased microglial cell number	J:112713
	decreased susceptibility to endotoxin shock	J:45147
	increased circulating tumor necrosis factor level	J:45147
	increased susceptibility to bacterial infection	J:45147
	lung inflammation	J:120174
Tnfrsf1a^tm1Imx/Tnfrsf1a^tm1Imx (C57BL/6-Tnfrsf1a^tm1Imx/J)	abnormal chemokine secretion	J:160543
	abnormal follicular dendritic cell morphology	J:160543
	abnormal macrophage physiology	J:160543
	decreased circulating interleukin-6 level	J:160543
	decreased interleukin-6 secretion	J:160543
	decreased susceptibility to endotoxin shock	J:160543
	increased circulating tumor necrosis factor level	J:160543
Tnfrsf1a^tm1Imx/Tnfrsf1a^tm1Imx (involves: C57BL/6)	impaired humoral immune response	J:210950
Tnfrsf1a^tm1Imx/Tnfrsf1a^tm1Imx (involves: C57BL/6)	increased susceptibility to bacterial infection induced morbidity/mortality	J:210950
Tnfrsf1a^tm1Imx/Tnfrsf1a^tm1Imx Tg(Ins2-Cxcl13)1Cys/0 (involves: C57BL/6 * DBA/2)	abnormal lymph organ development	J:110548
Tnfrsf1a^tm1Imx/Tnfrsf1a^tm1Imx Tg(Thy1-APP)3Somm/0 (involves: C57BL/6 * C57BL/6J * DBA/2)	microgliosis	J:134832
Tnfrsf1a^tm1Imx/Tnfrsf1a^tm1Imx Tnfrsf1b^tm1Imx/Tnfrsf1b^tm1Imx (involves: 129S7/SvEvBrd * C57BL/6)	decreased inflammatory response	J:45147
	decreased microglial cell activation	J:33864
	decreased susceptibility to endotoxin shock	J:45147
	decreased susceptibility to experimental autoimmune uveoretinitis	J:115094
	decreased susceptibility to induced arthritis	J:120707
	increased circulating tumor necrosis factor level	J:45147
	increased susceptibility to bacterial infection	J:58851
	osteomyelitis	J:58851
Tnfrsf1a^tm1Imx/Tnfrsf1a^tm1Imx Tnfrsf1b^tm1Imx/Tnfrsf1b^tm1Imx (B6.129S-Tnfrsf1b^tm1Imx Tnfrsf1a^tm1Imx/J)	decreased susceptibility to Coronaviridae infection	J:288523
Tnfrsf1a^tm1Mak/Tnfrsf1a⁺ (involves: 129S2/SvPas)	decreased circulating interleukin-6 level	J:210950
Tnfrsf1a^tm1Mak/Tnfrsf1a^tm1Mak (involves: 129S2/SvPas * C57BL/6J * DBA/2J)	granulomatous inflammation	J:55889
Tnfrsf1a^tm1Mak/Tnfrsf1a^tm1Mak (involves: 129S2/SvPas * C57BL/6J * NOD)	decreased susceptibility to autoimmune diabetes	J:64051
Tnfrsf1a^tm1Mak/Tnfrsf1a^tm1Mak (involves: 129S2/SvPas)	abnormal spleen germinal center morphology	J:139030
	decreased circulating interleukin-6 level	J:138824
	decreased IgG level	J:139030
	decreased susceptibility to bacterial infection	J:4753, J:121930
	impaired humoral immune response	J:210950
	increased circulating tumor necrosis factor level	J:139030
	increased susceptibility to bacterial infection induced morbidity/mortality	J:4753, J:139030, J:210950
Tnfrsf1a^tm1Mak/Tnfrsf1a^tm1Mak Tnip1^{Gt(E059E05)Wrst}/Tnip1^{Gt(E059E05)Wrst} (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)	glomerulonephritis	J:180054
	increased neutrophil cell number	J:180054
	increased susceptibility to systemic lupus erythematosus	J:180054
	spleen hyperplasia	J:180054
Tnfrsf1a^tm1Rsie/Tnfrsf1a⁺ (B6.Cg-Tnfrsf1a^tm1Rsie)	increased circulating tumor necrosis factor level	J:160543
	increased interleukin-6 secretion	J:160543
	increased susceptibility to endotoxin shock	J:160543
Tnfrsf1a^tm1Rsie/Tnfrsf1a^tm1Rsie (B6.Cg-Tnfrsf1a^tm1Rsie)	abnormal chemokine secretion	J:160543
	abnormal follicular dendritic cell morphology	J:160543
	abnormal macrophage physiology	J:160543
	decreased circulating interleukin-1 beta level	J:160543
	decreased circulating interleukin-6 level	J:160543
	decreased interleukin-6 secretion	J:160543
	decreased susceptibility to endotoxin shock	J:160543
	increased circulating tumor necrosis factor level	J:160543
Tnfrsf1a^tm2.1Rsie/Tnfrsf1a⁺ (B6.Cg-Tnfrsf1a^tm2.1Rsie)	abnormal macrophage physiology	J:160543
	decreased circulating interleukin-1 beta level	J:160543
	decreased circulating interleukin-6 level	J:160543
	decreased interleukin-6 secretion	J:160543
	increased interleukin-6 secretion	J:160543
	increased susceptibility to endotoxin shock	J:160543
Tnfrsf1a^tm2.1Rsie/Tnfrsf1a⁺ (involves: 129S6/SvEvTac)	increased susceptibility to endotoxin shock	J:160543
Tnfrsf1a^tm2.1Rsie/Tnfrsf1a^tm2.1Rsie (B6.Cg-Tnfrsf1a^tm2.1Rsie)	abnormal chemokine secretion	J:160543
	abnormal macrophage physiology	J:160543
	decreased circulating interleukin-6 level	J:160543
	decreased interleukin-6 secretion	J:160543
	decreased susceptibility to endotoxin shock	J:160543
	increased circulating tumor necrosis factor level	J:160543
Tnfrsf1a^{tm2b(EUCOMM)Wtsi}/Tnfrsf1a^{tm2b(EUCOMM)Wtsi} (C57BL/6N-Tnfrsf1a^{tm2b(EUCOMM)Wtsi}/H)	decreased monocyte cell number	J:211773
	decreased neutrophil cell number	J:211773
	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
	increased large unstained cell number	J:211773
	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
Tnfrsf1b^{tm1a(EUCOMM)Wtsi}/Tnfrsf1b^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Tnfrsf1b^{tm1a(EUCOMM)Wtsi}/Ics)	decreased T cell number	J:165965
Tnfrsf1b^tm1Imx/Tnfrsf1b^tm1Imx (involves: 129S7/SvEvBrd * C57BL/6)	increased circulating tumor necrosis factor level	J:45147
	increased inflammatory response	J:45147
	lung inflammation	J:120174
	microgliosis	J:112713
Tnfrsf1b^tm1Mwm/Tnfrsf1b^tm1Mwm (B6.129S2-Tnfrsf1b^tm1Mwm/J)	decreased interferon-gamma secretion	J:107039
	decreased interleukin-2 secretion	J:107039
	decreased T cell proliferation	J:107039
	immune system phenotype	J:288523
Tnfrsf1b^tm1Mwm/Tnfrsf1b^tm1Mwm (involves: 129S2/SvPas * C57BL/6J)	abnormal immune system physiology	J:21815
	increased susceptibility to bacterial infection	J:21815
Tnfrsf1b^tm1Mwm/Tnfrsf1b^tm1Mwm (involves: 129S2/SvPas * C57BL/6J * NOD)	decreased susceptibility to autoimmune diabetes	J:64051
	periinsulitis	J:64051
Tnfrsf1b^tm1Mwm/Tnfrsf1b^tm1Mwm (involves: 129S2/SvPas * C57BL/6)	decreased susceptibility to bacterial infection	J:50903
	increased susceptibility to experimental autoimmune encephalomyelitis	J:115225
	increased susceptibility to parasitic infection	J:114203
Tnfrsf4^tm1Mfb/Tnfrsf4^tm1Mfb (involves: 129P2/OlaHsd * C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:59204
Tnfrsf4^tm1Nik/Tnfrsf4^tm1Nik (involves: 129S4/SvJae * C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:64552
	abnormal T-helper 2 physiology	J:68588
	decreased susceptibility to type I hypersensitivity reaction	J:68588
	decreased T cell proliferation	J:58979, J:64552
	immune system phenotype	J:58979
Tnfrsf8^tm1Mak/Tnfrsf8^tm1Mak (involves: 129P2/OlaHsd * C57BL/6)	enlarged thymus	J:62854
	immune system phenotype	J:62854
	increased thymocyte number	J:62854
Tnfrsf8^tm1Mak/Tnfrsf8^tm1Mak (involves: C57BL/6)	decreased susceptibility to graft versus host disease	J:92723
Tnfrsf9^em1Ygch/Tnfrsf9^em1Ygch (NOD/ShiLtDvs-Tnfrsf9^em1Ygch)	abnormal T cell physiology	J:208927
	immune system phenotype	J:208927
	insulitis	J:208927
Tnfrsf9^em2Ygch/Tnfrsf9^em2Ygch (NOD/ShiLtDvs-Tnfrsf9^em2Ygch)	abnormal T cell physiology	J:208927
	immune system phenotype	J:208927
	insulitis	J:208927
Tnfrsf9^m1Btlr/Tnfrsf9^m1Btlr (C57BL/6J-Tnfrsf9^m1Btlr)	decreased CD8-positive, alpha-beta T cell number	J:265260
	decreased CD8-positive, naive alpha-beta T cell number	J:265260
	decreased single-positive T cell number	J:265260
	increased B cell number	J:265260
	increased effector memory CD4-positive, alpha-beta T cell number	J:265260
	increased effector memory CD8-positive, alpha-beta T cell number	J:265260
Tnfrsf9^tm1Byk/Tnfrsf9^tm1Byk (B6.Cg-Tnfrsf9^tm1Byk)	abnormal cytotoxic T cell physiology	J:83996
	decreased IgG2a level	J:83996
	decreased IgG3 level	J:83996
	decreased interferon-gamma secretion	J:83996
	decreased interleukin-2 secretion	J:83996
	decreased interleukin-4 secretion	J:83996
	increased T cell proliferation	J:83996
Tnfrsf9^tm1Byk/Tnfrsf9^tm1Byk (C.Cg-Tnfrsf9^tm1Byk)	abnormal cytotoxic T cell physiology	J:83722
	abnormal immunoglobulin level	J:83996
	decreased IgG2a level	J:83996
	decreased IgG3 level	J:83996
	decreased interferon-gamma secretion	J:83996
	decreased interleukin-2 secretion	J:83996
	decreased interleukin-4 secretion	J:83996
	decreased interleukin-12 secretion	J:83722
	increased IgA level	J:83722
	increased IgG2a level	J:83722
	increased IgG2b level	J:83722
	increased splenocyte proliferation	J:83722
	increased T cell proliferation	J:83996
Tnfrsf9^tm1Lpc/Tnfrsf9^tm1Lpc (B6.129-Tnfrsf9^tm1Lpc)	abnormal memory T cell physiology	J:145439
Tnfrsf9^tm1Lpc/Tnfrsf9^tm1Lpc (B6.129-Tnfrsf9^tm1Lpc)	immune system phenotype	J:145439
Tnfrsf10b^tm1Wnt/Tnfrsf10b^tm1Wnt (involves: 129S6/SvEvTac * C57BL/6)	abnormal innate immunity	J:94681
	abnormal interferon level	J:94681
	decreased susceptibility to Herpesvirales infection	J:94681
	decreased susceptibility to Herpesvirales infection induced morbidity/mortality	J:94681
	increased circulating interferon-gamma level	J:94681
	increased circulating interleukin-12b level	J:94681
	increased interleukin-12 secretion	J:94681
	increased NK cell number	J:94681
	increased tumor necrosis factor secretion	J:94681
Tnfrsf10b^tm1Wsed/Tnfrsf10b^tm1Wsed (involves: 129P2/OlaHsd)	enlarged thymus	J:96816
Tnfrsf11a^del8/Tnfrsf11a^del8 (involves: 129)	abnormal mesenteric lymph node morphology	J:111512
	decreased osteoclast cell number	J:111512
	enlarged spleen	J:111512
Tnfrsf11a^tm1.1Pngr/Tnfrsf11a^tm1.2Pngr Tg(Gfap-cre)2Brn/0 (involves: 129 * C57BL/6 * C57BL/6NTac * FVB/N)	decreased susceptibility to endotoxin shock	J:155398
Tnfrsf11a^tm1.1Pngr/Tnfrsf11a^tm1.2Pngr Tg(Nes-cre)1Kln/0 (involves: 129 * C57BL/6 * C57BL/6NTac * SJL)	decreased susceptibility to endotoxin shock	J:155398
Tnfrsf11a^tm1.1Sral/Tnfrsf11a⁺ (B6.129P2(Cg)-Tnfrsf11a^tm1.1Sral)	abnormal osteoclast differentiation	J:312215
	abnormal osteoclast physiology	J:312215
	increased osteoclast cell number	J:312215
Tnfrsf11a^tm1.1Sral/Tnfrsf11a^tm1.1Sral (B6.129P2(Cg)-Tnfrsf11a^tm1.1Sral)	abnormal osteoclast differentiation	J:312215
	decreased osteoclast cell number	J:312215
Tnfrsf11a^tm1.2Pngr/Tnfrsf11a^tm1.2Pngr (B6.Cg-Tnfrsf11a^tm1.2Pngr)	absent lymph nodes	J:155398
	decreased osteoclast cell number	J:155398
Tnfrsf11a^tm1Imx/Tnfrsf11a^tm1Imx (involves: 129 * C57BL/6)	abnormal osteoclast differentiation	J:57899
	absent lymph nodes	J:57899
	decreased B cell number	J:57899
	decreased mature B cell number	J:57899
	decreased osteoclast cell number	J:57899
	decreased Peyer's patch number	J:57899
	decreased spleen germinal center size	J:57899
	increased granulocyte number	J:57899
	increased neutrophil cell number	J:57899
	small Peyer's patches	J:57899
	spleen hyperplasia	J:57899
Tnfrsf11a^tm1Imx/Tnfrsf11a^tm1Imx (involves: 129)	abnormal negative T cell selection	J:125864
Tnfrsf11a^tm1Imx/Tnfrsf11a^tm1Imx (involves: 129)	abnormal thymus epithelium morphology	J:125864
Tnfrsf11b^em1(IMPC)Mbp/Tnfrsf11b^em1(IMPC)Mbp (C57BL/6N-Tnfrsf11b^em1(IMPC)Mbp/MbpMmucd)	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	small spleen	J:211773
Tnfrsf11b^tm1Eac/Tnfrsf11b^tm1Eac (involves: 129S4/SvJaeSor)	abnormal dendritic cell antigen presentation	J:67105
	abnormal immune system morphology	J:67105
	abnormal immune system physiology	J:67105
	abnormal immunoglobulin level	J:67105
	abnormal pro-B cell differentiation	J:67105
	increased B cell number	J:67105
	increased immature B cell number	J:67105
	increased pro-B cell number	J:67105
Tnfrsf11b^tm1Khs/Tnfrsf11b^tm1Khs (involves: 129P2/OlaHsd * C57BL/6)	abnormal osteoclast differentiation	J:111153, J:48325
	abnormal osteoclast physiology	J:111153
	increased osteoclast cell number	J:80503
Tnfrsf11b^tm1Wss/Tnfrsf11b^tm1Wss (either: (involves: 129X1/SvJ * C57BL/6) or (involves: 129X1/SvJ * Black Swiss))	abnormal osteoclast morphology	J:47602
Tnfrsf12a^tm1Biib/Tnfrsf12a^tm1Biib (B6.129S4-Tnfrsf12a^tm1Biib)	abnormal chemokine secretion	J:126416
Tnfrsf13b^tm1Cmac/Tnfrsf13b^tm1Cmac (Not Specified)	enlarged spleen	J:91914
	immune system phenotype	J:92334
	increased B cell number	J:91914
Tnfrsf13b^tm1Rjb/Tnfrsf13b^tm1Rjb (involves: 129X1/SvJ * C57BL/6)	abnormal B cell activation	J:69474
	decreased IgA level	J:69474
	decreased IgM level	J:69474
	increased B cell number	J:69474
	increased B cell proliferation	J:69474
	increased spleen weight	J:69474
Tnfrsf13b^tm1Rjb/Tnfrsf13b^tm1Rjb (involves: 129X1/SvJ)	abnormal class switch recombination	J:95288
	decreased IgA level	J:95288
	decreased IgE level	J:95288
	decreased IgG1 level	J:95288
Tnfrsf13b^tm1Vmd/Tnfrsf13b^tm1Vmd (involves: C57BL/6)	abnormal immunoglobulin level	J:70172
	abnormal lymph node primary follicle morphology	J:70172, J:82331
	abnormal Peyer's patch follicle morphology	J:70172
	abnormal spleen morphology	J:70172
	abnormal spleen periarteriolar lymphoid sheath morphology	J:70172, J:82331
	abnormal spleen primary B follicle morphology	J:70172
	enlarged lymph nodes	J:70172, J:82331
	enlarged spleen	J:70172, J:82331
	glomerulonephritis	J:82331
	increased anti-double stranded DNA antibody level	J:82331
	increased anti-nuclear antigen antibody level	J:82331
	increased B cell number	J:70172, J:82331
	increased B cell proliferation	J:70172
	increased follicular B cell number	J:70172
	increased IgG1 level	J:70172
	increased marginal zone B cell number	J:70172
	increased mature B cell number	J:70172
	increased spleen germinal center size	J:70172
	increased spleen white pulp amount	J:70172
	increased transitional stage B cell number	J:70172
	kidney inflammation	J:82331
	liver inflammation	J:82331
Tnfrsf13c^Bcmd1/Tnfrsf13c^Bcmd1 (A/WySnJ)	abnormal lymphocyte physiology	J:92334
	decreased B cell proliferation	J:122315
	decreased IgG level	J:122315
	decreased interferon-gamma secretion	J:92334
	decreased T cell proliferation	J:92334
	increased length of allograft survival	J:92334
Tnfrsf13c^m1Btlr/Tnfrsf13c^m1Btlr (C57BL/6J-Tnfrsf13c^m1Btlr)	decreased B cell number	J:265247
Tnfrsf13c^M2Btlr/Tnfrsf13c^M2Btlr (C57BL/6J-Tnfrsf13c^M2Btlr)	decreased B cell number	J:265247
Tnfrsf13c^tm1Mass/Tnfrsf13c^tm1Mass (C57BL/6-Tnfrsf13c^tm1Mass)	abnormal B cell physiology	J:113556
	absent marginal zone B cells	J:92732
	arrested B cell differentiation	J:92732
	decreased B-2 B cell number	J:92732
	decreased IgG1 level	J:92732
	decreased IgG2a level	J:92732
	decreased IgG2b level	J:92732
	decreased IgG3 level	J:92732
	decreased IgG level	J:92732
	decreased IgM level	J:92732
	decreased mature B cell number	J:92732
Tnfrsf13c^tm1Mass/Tnfrsf13c^tm1Mass (involves: C57BL/6)	decreased lymphocyte cell number	J:139293
Tnfrsf13c^tm1Mass/Tnfrsf13c^tm1Mass (involves: C57BL/6)	decreased mature B cell number	J:139293
Tnfrsf13c^tm1Mass/Tnfrsf13c^tm1Mass Tg(BCL2)22Wehi/0 (involves: C57BL/6 * SJL)	immune system phenotype	J:92732
Tnfrsf13c^tm1Mass/Tnfrsf13c^tm1Mass Traf2^tm1Rbr/Traf2^tm1Rbr (involves: C57BL/6)	decreased germinal center B cell number	J:172843
	decreased spleen germinal center size	J:172843
	immune system phenotype	J:172843
Tnfrsf13c^tm1Mass/Tnfrsf13c^tm1Mass Traf3^tm1Rbr/Traf3^tm1Rbr (involves: C57BL/6)	immune system phenotype	J:172843
Tnfrsf13c^tm1Msc/Tnfrsf13c^tm1Msc (involves: 129P2/OlaHsd * C57BL/6)	abnormal humoral immune response	J:92676
	absent marginal zone B cells	J:92676
	absent transitional stage B cells	J:92676
	decreased B cell number	J:92676
	decreased B-2 B cell number	J:92676
	decreased IgD level	J:92676
	decreased IgG1 level	J:92676
	decreased IgG level	J:92676
	decreased IgM level	J:92676
Tnfrsf14^tm1Csj/Tnfrsf14^tm1Csj (B6.Cg-Tnfrsf14^tm1Csj)	decreased interferon-gamma secretion	J:169369
	decreased interleukin-6 secretion	J:169369
	decreased interleukin-10 secretion	J:169369
	decreased susceptibility to induced colitis	J:169369
	decreased tumor necrosis factor secretion	J:169369
Tnfrsf14^tm1Kpf/Tnfrsf14^tm1Kpf (B6.129P2-Tnfrsf14^tm1Kpf)	abnormal T cell physiology	J:99456
Tnfrsf14^tm1Kpf/Tnfrsf14^tm1Kpf (B6.129P2-Tnfrsf14^tm1Kpf)	increased T cell proliferation	J:99456
Tnfrsf14^tm1Kro/Tnfrsf14^tm1Kro (C57BL/6-Tnfrsf14^tm1Kro)	decreased susceptibility to Herpesvirales infection	J:243038
Tnfrsf14^tm1Wwhk/Tnfrsf14^tm1Wwhk (B6.Cg-Tnfrsf14^tm1Wwhk)	decreased length of allograft survival	J:119356
Tnfrsf17^tm1Kplm/Tnfrsf17^tm1Kplm (involves: 129P2/OlaHsd * C57BL/6)	decreased plasma cell number	J:124543
Tnfrsf18^tm1Ppp/Tnfrsf18^tm1Ppp (involves: 129/Sv * C57BL/6)	abnormal T cell activation	J:77393
	immune system phenotype	J:77393
	increased interleukin-2 secretion	J:77393
	increased T cell apoptosis	J:77393
	increased T cell proliferation	J:77393
Tnfrsf21^tm1Ddy/Tnfrsf21^tm1Ddy (involves: 129S1/Sv * 129X1/SvJ)	abnormal T-helper 1 physiology	J:70594
	abnormal T-helper 2 physiology	J:70594
	increased B cell proliferation	J:109341
	increased IgG1 level	J:109341
	increased IgG2a level	J:109341
	increased IgG2b level	J:109341
	increased IgG3 level	J:109341
	increased IgM level	J:109341
	increased interleukin-4 secretion	J:70594
	increased interleukin-5 secretion	J:70594
	increased interleukin-10 secretion	J:70594
	increased interleukin-13 secretion	J:70594
	increased spleen germinal center size	J:109341
	increased T cell proliferation	J:70594
Tnfrsf21^tm1Vmd/Tnfrsf21^tm1Vmd (involves: C57BL/6)	abnormal cell-mediated immunity	J:72761
	abnormal T-helper 2 physiology	J:72761
	immune system phenotype	J:72761
	increased CD4-positive, alpha-beta T cell number	J:72761
	increased CD8-positive, alpha-beta T cell number	J:72761
	increased IgE level	J:72761
	increased IgG1 level	J:72761
	increased IgG2a level	J:72761
	increased IgM level	J:72761
	increased interferon-gamma secretion	J:72761
	increased interleukin-2 secretion	J:72761
	increased interleukin-4 secretion	J:72761
	increased T cell number	J:72761
	increased T cell proliferation	J:72761
Tnfrsf25^tm1Mjo/Tnfrsf25^tm1Mjo (involves: 129P2/OlaHsd)	abnormal negative T cell selection	J:84536
	decreased T cell apoptosis	J:84536
	enlarged thymus	J:84536
	increased thymocyte number	J:84536
Tnfsf4^tm1Shr/Tnfsf4^tm1Shr (involves: 129S4/SvJae)	abnormal cell-mediated immunity	J:59203
	abnormal dendritic cell antigen presentation	J:59203
	decreased interferon-gamma secretion	J:59203
	decreased interleukin-2 secretion	J:59203
	decreased interleukin-4 secretion	J:59203
	decreased susceptibility to type IV hypersensitivity reaction	J:59203
	decreased T cell proliferation	J:59203
	immune system phenotype	J:59203
Tnfsf4^tm1Shr/Tnfsf4^tm1Shr (NOD.129S4-Tnfsf4^tm1Shr)	decreased susceptibility to autoimmune diabetes	J:86926
Tnfsf4^tm1Shr/Tnfsf4^tm1Shr (C.129S4-Tnfsf4^tm1Shr)	abnormal cytokine secretion	J:59203
Tnfsf4^tm1Shr/Tnfsf4^tm1Shr (C.129S4-Tnfsf4^tm1Shr)	abnormal dendritic cell antigen presentation	J:59203
Tnfsf4^tm1Sug/Tnfsf4^tm1Sug (B6.129S4-Tnfsf4^tm1Sug)	abnormal cytokine secretion	J:80214
	decreased susceptibility to type IV hypersensitivity reaction	J:80214
	decreased T cell proliferation	J:80214
Tnfsf8^tm1Pod/Tnfsf8^tm1Pod (B6.129X1-Tnfsf8^tm1Pod)	decreased susceptibility to graft versus host disease	J:92723
Tnfsf9^tm1Thw/Tnfsf9^tm1Thw (involves: 129 * C57BL/6)	abnormal cytotoxic T cell physiology	J:76373
Tnfsf9^tm1Thw/Tnfsf9^tm1Thw (involves: 129 * C57BL/6)	immune system phenotype	J:76373
Tnfsf10^tm1Mjs/Tnfsf10^tm1Mjs (C.129-Tnfsf10^tm1Mjs)	abnormal negative T cell selection	J:82145
	decreased susceptibility to bacterial infection	J:87620
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:87620
	immune system phenotype	J:84838
	impaired natural killer cell mediated cytotoxicity	J:73948
	liver inflammation	J:87620
	thymus hyperplasia	J:84838, J:82145
Tnfsf10^tm1Mjs/Tnfsf10^tm1Mjs (B6.129-Tnfsf10^tm1Mjs)	abnormal negative T cell selection	J:82145
	immune system phenotype	J:84838
	increased IgG1 level	J:82145
	increased IgG2a level	J:82145
	increased interferon-gamma secretion	J:82145
	increased interleukin-2 secretion	J:82145
	increased susceptibility to autoimmune diabetes	J:82145
	increased susceptibility to experimental autoimmune encephalomyelitis	J:101672
	increased susceptibility to induced arthritis	J:82145
	increased synovial pannus formation	J:101672
	thymus hyperplasia	J:82145
Tnfsf10^tm1Sdg/Tnfsf10^tm1Sdg (B6.129-Tnfsf10^tm1Sdg)	immune system phenotype	J:79085
Tnfsf10^tm1Sdg/Tnfsf10^tm1Sdg (involves: 129 * C57BL/6)	immune system phenotype	J:79085
Tnfsf11^tles/Tnfsf11^tles (involves: 129S6/SvEvTac * C57BL/6J)	absent lymph nodes	J:179743
	decreased osteoclast cell number	J:179743
	enlarged spleen	J:179743
	thymus hypoplasia	J:179743
Tnfsf11^tles/Tnfsf11^tm1Pngr (involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J)	decreased osteoclast cell number	J:179743
Tnfsf11^{tm1(TNFSF11)Kost}/Tnfsf11^{tm1(TNFSF11)Kost} (involves: 129/Sv * Black Swiss)	abnormal osteoclast morphology	J:166279
Tnfsf11^tm1.1Caob/Tnfsf11^tm1.1Caob Tg(Dmp1-cre)1Jqfe/0 (involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6 * FVB)	abnormal osteoclast cell number	J:177558
	decreased osteoclast cell number	J:177558
Tnfsf11^tm1.1Caob/Tnfsf11^tm1.1Caob Tg(Prrx1-cre)1Cjt/0 (involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6)	decreased osteoclast cell number	J:177558
Tnfsf11^tm1.1Htaka/Tnfsf11^tm1.2Htaka Tg(Dmp1-cre)1Jqfe/0 (involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J * FVB/N)	decreased osteoclast cell number	J:177557
Tnfsf11^tm1.2Htaka/Tnfsf11⁺ (B6.Cg-Tnfsf11^tm1.2Htaka)	decreased osteoclast cell number	J:177557
Tnfsf11^tm1.2Htaka/Tnfsf11^tm1.2Htaka (B6.Cg-Tnfsf11^tm1.2Htaka)	decreased osteoclast cell number	J:177557
	increased spleen weight	J:177557
Tnfsf11^tm1Pngr/Tnfsf11^tm1Pngr (involves: 129P2/OlaHsd * C57BL/6)	abnormal immune system morphology	J:52369
	abnormal immune system physiology	J:52369
	abnormal pro-B cell differentiation	J:52369
	absent mesenteric lymph nodes	J:52369
	absent peripheral lymph nodes	J:52369
	arrested T cell differentiation	J:52369
	decreased immature B cell number	J:52369
	decreased interferon-gamma secretion	J:52369
	decreased interleukin-2 secretion	J:52369
	decreased interleukin-4 secretion	J:52369
	decreased interleukin-5 secretion	J:52369
	decreased interleukin-6 secretion	J:52369
	decreased mature B cell number	J:52369
	decreased osteoclast cell number	J:52369
	decreased thymus weight	J:52369
	immune system phenotype	J:52369
	increased spleen weight	J:52369
	small Peyer's patches	J:52369
	thymus hypoplasia	J:52369
Tnfsf11^tm1Pngr/Tnfsf11^tm1Pngr (involves: 129P2/OlaHsd)	abnormal thymus epithelium morphology	J:173115
Tnfsf11^tm1Ywc/Tnfsf11⁺ (involves: 129P2/OlaHsd)	absent peripheral lymph nodes	J:65888
Tnfsf11^tm1Ywc/Tnfsf11^tm1Ywc (involves: 129P2/OlaHsd)	abnormal cervical lymph node morphology	J:65888
	abnormal spleen B cell follicle morphology	J:65888
	abnormal spleen marginal zone morphology	J:65888
	abnormal spleen morphology	J:65888
	abnormal splenic cell ratio	J:233265
	abnormal thymus cell ratio	J:233265
	absent cervical lymph nodes	J:65888
	absent mesenteric lymph nodes	J:65888
	absent peripheral lymph nodes	J:65888
	decreased Langerhans cell number	J:137471
	decreased osteoclast cell number	J:65888, J:64737
	decreased Peyer's patch number	J:233265
	decreased spleen white pulp amount	J:233265
	increased spleen red pulp amount	J:233265
	small Peyer's patches	J:233265
	small thymus medulla	J:233265
Tnfsf12^tm1Ash/Tnfsf12^tm1Ash (B6.129-Tnfsf12^tm1Ash)	abnormal cytokine secretion	J:104801
	abnormal immune system organ morphology	J:104801
	abnormal leukocyte morphology	J:104801
	decreased interleukin-10 secretion	J:104801
	enlarged lymph nodes	J:104801
	enlarged spleen	J:104801
	increased double-positive T cell number	J:104801
	increased interferon-gamma secretion	J:104801
	increased interleukin-12 secretion	J:104801
	increased memory T cell number	J:104801
	increased NK cell number	J:104801
	increased susceptibility to bacterial infection	J:104801
	increased T-helper 1 cell number	J:104801
Tnfsf13^tm1Geha/Tnfsf13^tm1Geha (involves: 129S4/SvJae)	abnormal class switch recombination	J:88910
	decreased IgA level	J:88910
	decreased IgM level	J:88910
	immune system phenotype	J:88910
	increased IgG level	J:88910
	increased memory T cell number	J:88910
	increased spleen germinal center number	J:88910
	increased spleen germinal center size	J:88910
Tnfsf13^tm1Pod/Tnfsf13⁺ (B6.Cg-Tnfsf13^tm1Pod)	decreased IgA level	J:141374
Tnfsf13^tm1Pod/Tnfsf13^tm1Pod (B6.Cg-Tnfsf13^tm1Pod)	abnormal interleukin secretion	J:141374
	decreased IgA level	J:141374
	decreased IgG2a level	J:141374
	decreased interleukin-10 secretion	J:141374
	decreased interleukin-17 secretion	J:141374
	decreased susceptibility to induced arthritis	J:141374
	increased IgG1 level	J:141374
	increased interferon-gamma secretion	J:141374
	increased interleukin-4 secretion	J:141374
	increased interleukin-5 secretion	J:141374
	increased interleukin-13 secretion	J:141374
	increased interleukin-17 secretion	J:141374
	increased T cell proliferation	J:141374
Tnfsf13b^m1Anu/Tnfsf13b^m1Anu (C57BL/6JAnu-Tnfsf13b^m1Anu/AnuApb)	abnormal B cell differentiation	J:104190
	decreased mature B cell number	J:104190
	increased immature B cell number	J:104190
Tnfsf13b^M1Btlr/Tnfsf13b⁺ (C57BL/6J-Tnfsf13b^M1Btlr)	decreased B cell number	J:220069
	decreased IgG level	J:220069
	decreased IgM level	J:220069
	impaired humoral immune response	J:220069
	increased single-positive T cell number	J:220069
	increased T cell number	J:220069
Tnfsf13b^M1Btlr/Tnfsf13b^M1Btlr (C57BL/6J-Tnfsf13b^M1Btlr)	decreased B cell number	J:220069
	decreased IgG level	J:220069
	decreased IgM level	J:220069
	impaired humoral immune response	J:220069
	increased single-positive T cell number	J:220069
	increased T cell number	J:220069
Tnfsf13b^m2Btlr/Tnfsf13b^m2Btlr (C57BL/6J-Tnfsf13b^m2Btlr)	decreased B cell number	J:220070
	decreased IgG level	J:220070
	impaired humoral immune response	J:220070
Tnfsf13b^m3Btlr/Tnfsf13b^m3Btlr (C57BL/6J-Tnfsf13b^m3Btlr)	abnormal lymphocyte morphology	J:272850
Tnfsf13b^m3Btlr/Tnfsf13b^m3Btlr (C57BL/6J-Tnfsf13b^m3Btlr)	decreased B cell number	J:272850
Tnfsf13b^tm1Cleg/Tnfsf13b^tm1Cleg (involves: 129S5/SvEvBrd)	abnormal B cell differentiation	J:71301
	abnormal B cell physiology	J:71301
	abnormal leukocyte morphology	J:71301
	abnormal lymph organ size	J:71301
	decreased follicular B cell number	J:71301
	decreased IgG level	J:71301
	decreased IgM level	J:71301
	decreased mature B cell number	J:71301
	decreased memory T cell number	J:71301
	increased T cell number	J:71301
	lymph node hypoplasia	J:71301
	spleen hypoplasia	J:71301
Tnfsf13b^tm1Msc/Tnfsf13b⁺ (involves: 129S2/SvPas * C57BL/6)	decreased immunoglobulin level	J:71681
Tnfsf13b^tm1Msc/Tnfsf13b^tm1Msc (involves: 129S2/SvPas * C57BL/6)	abnormal B cell differentiation	J:71681
	abnormal humoral immune response	J:71681
	abnormal lymph node B cell domain morphology	J:71681
	arrested B cell differentiation	J:71681
	decreased B cell number	J:71681
	decreased follicular B cell number	J:71681
	decreased immunoglobulin level	J:71681
	decreased marginal zone B cell number	J:71681
	decreased spleen weight	J:71681
Tnfsf13b^tm1Msc/Tnfsf13b^tm1Msc (involves: 129S2/SvPas)	decreased B cell number	J:138560
	decreased follicular B cell number	J:138560
	decreased T cell proliferation	J:92334
	decreased transitional stage B cell number	J:138560
	increased length of allograft survival	J:92334
Tnfsf13b^tm1Msc/Tnfsf13b^tm1Msc Traf2^tm1Rbr/Traf2^tm1Rbr (involves: 129S2/SvPas * C57BL/6)	absent follicular B cells	J:132877
	absent marginal zone B cells	J:132877
	decreased mature B cell number	J:132877
Tnfsf14^tm1Ddy/Tnfsf14^tm1Ddy (involves: 129S1/Sv * 129X1/SvJ)	abnormal cytotoxic T cell physiology	J:84366
	abnormal T cell activation	J:84366
	decreased T cell proliferation	J:84366
	immune system phenotype	J:84366
Tnfsf14^tm1Kpf/Tnfsf14^tm1Kpf (involves: 129P2/OlaHsd * C57BL/6)	abnormal T cell subpopulation ratio	J:77250
	decreased cytotoxic T cell cytolysis	J:77250
	decreased interferon-gamma secretion	J:77250
	decreased interleukin-2 secretion	J:77250
	decreased interleukin-4 secretion	J:77250
	decreased interleukin-10 secretion	J:77250
	decreased splenocyte proliferation	J:77250
	decreased T cell proliferation	J:77250
Tnfsf14^tm1Kpf/Tnfsf14^tm1Kpf (involves: 129P2/OlaHsd)	abnormal gamma-delta T cell morphology	J:169863
Tnfsf14^tm1Kpf/Tnfsf14^tm1Kpf (B6.129P2-Tnfsf14^tm1Kpf)	abnormal osteoclast differentiation	J:294030
Tnfsf14^tm1Lpc/Tnfsf14^tm1Lpc (involves: 129X1/SvJ * C57BL/6)	abnormal cytotoxic T cell physiology	J:76414
	decreased cytotoxic T cell cytolysis	J:76414
	decreased inflammatory response	J:107803
	decreased interferon-gamma secretion	J:76414
	decreased tumor necrosis factor secretion	J:76414
Tnfsf14^tm1Lpc/Tnfsf14^tm1Lpc (B6.129X1-Tnfsf14^tm1Lpc)	immune system phenotype	J:158663
Tnfsf14^tm1Wwh/Tnfsf14^tm1Wwh (involves: 129 * C57BL/6)	increased length of allograft survival	J:75705
Tnfsf15^tm1Cdon/Tnfsf15^tm1Cdon (B6.129-Tnfsf15^tm1Cdon)	abnormal dendritic cell differentiation	J:136280
Tnfsf15^tm1Cdon/Tnfsf15^tm1Cdon (B6.129-Tnfsf15^tm1Cdon)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:136280
Tnfsf15^tm1Hluo/Tnfsf15^tm1Hluo (D1LacJ.129(B6)-Tnfsf15^tm1Hluo)	decreased B cell number	J:207029
	decreased germinal center B cell number	J:207029
	decreased IgG2a level	J:207029
	decreased IgG2b level	J:207029
	decreased IgG level	J:207029
	decreased plasma cell number	J:207029
	decreased susceptibility to induced arthritis	J:207029
	decreased T cell number	J:207029
	decreased T follicular helper cell number	J:207029
	immune system phenotype	J:207029
	lymph node hypoplasia	J:207029
Tnfsf15^tm1Lex/Tnfsf15^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6)	increased NK cell number	J:82809
Tnik^m1Anu/Tnik^m1Anu (C57BL/6NCrl-Tnik^m1Anu/Anu)	immune system phenotype	J:104190
Tnip1^{Gt(E059E05)Wrst}/Tnip1^{Gt(E059E05)Wrst} (involves: 129P2/OlaHsd * C57BL/6)	decreased interleukin-12 secretion	J:180054
	decreased interleukin-12b secretion	J:180054
	enlarged lymph nodes	J:180054
	enlarged spleen	J:180054
	glomerulonephritis	J:180054
	increased anti-double stranded DNA antibody level	J:180054
	increased anti-nuclear antigen antibody level	J:180054
	increased IgA level	J:180054
	increased IgG1 level	J:180054
	increased IgG2b level	J:180054
	increased IgM level	J:180054
	increased neutrophil cell number	J:180054
	increased susceptibility to systemic lupus erythematosus	J:180054
	lymph node hyperplasia	J:180054
	spleen hyperplasia	J:180054
Tnip1^m1Btlr/Tnip1^m1Btlr (C57BL/6J-Tnip1^m1Btlr)	decreased B cell number	J:265175
	decreased B-2 B cell number	J:265175
	increased anti-double stranded DNA antibody level	J:265175
	increased B-1a cell number	J:265175
	increased B-1b cell number	J:265175
	increased dendritic cell number	J:265175
	increased IgA level	J:265175
	increased IgE level	J:265175
	increased macrophage cell number	J:265175
	increased susceptibility to induced colitis	J:265175
Tnip1^tm1.1Pcoh/Tnip1⁺ (involves: 129P2/OlaHsd * C57BL/6)	increased anti-double stranded DNA antibody level	J:176826
Tnip1^tm1.1Pcoh/Tnip1^tm1.1Pcoh (involves: 129P2/OlaHsd * C57BL/6)	abnormal complement pathway	J:176826
	abnormal effector T cell morphology	J:176826
	abnormal immune system morphology	J:176826
	abnormal Peyer's patch morphology	J:176826
	abnormal plasma cell morphology	J:176826
	abnormal spleen germinal center morphology	J:176826
	enlarged lymph nodes	J:176826
	enlarged spleen	J:176826
	glomerulonephritis	J:176826
	immune system phenotype	J:176826
	increased anti-double stranded DNA antibody level	J:176826
	increased anti-nuclear antigen antibody level	J:176826
	increased B cell number	J:176826
	increased B cell proliferation	J:176826
	increased germinal center B cell number	J:176826
	increased granulocyte number	J:176826
	increased IgA level	J:176826
	increased IgE level	J:176826
	increased IgG1 level	J:176826
	increased IgG2a level	J:176826
	increased IgG2b level	J:176826
	increased IgG3 level	J:176826
	increased IgG level	J:176826
	increased IgM level	J:176826
	increased immunoglobulin level	J:176826
	increased interleukin-6 secretion	J:176826
	increased interleukin-12b secretion	J:176826
	increased monocyte cell number	J:176826
	increased plasma cell number	J:176826
	increased spleen red pulp amount	J:176826
	increased spleen weight	J:176826
	increased spleen white pulp amount	J:176826
	increased T follicular helper cell number	J:176826
	increased tumor necrosis factor secretion	J:176826
Tnip1^tm1.2Ama/Tnip1^tm1.2Ama Tg(Itgax-cre)1-1Reiz/0 (involves: C57BL/6 * C57BL/6J * CBA)	abnormal leukocyte morphology	J:205446
	enlarged lymph nodes	J:205446
	enlarged spleen	J:205446
	increased interleukin-6 secretion	J:205446
	increased interleukin-12 secretion	J:205446
	increased interleukin-23 secretion	J:205446
	increased memory T cell number	J:205446
	increased plasmacytoid dendritic cell number	J:205446
	increased tumor necrosis factor secretion	J:205446
Tnip1^tm1.2Pcoh/Tnip1^tm1.2Pcoh (involves: 129P2/OlaHsd * C57BL/6)	abnormal immune system morphology	J:176826
Tnip1^{tm1b(EUCOMM)Hmgu}/Tnip1^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Tnip1^{tm1b(EUCOMM)Hmgu}/H)	decreased eosinophil cell number	J:211773
	decreased lymphocyte cell number	J:211773
	increased basophil cell number	J:211773
	increased large unstained cell number	J:211773
	increased monocyte cell number	J:211773
	increased spleen weight	J:211773
Tnip2^tm1.1Sley/Tnip2^tm1.1Sley (involves: 129S4/SvJae * 129S8/SvEv * C57BL/6)	abnormal macrophage physiology	J:112395
	immune system phenotype	J:112395
Tnip3^tm1Rds/Tnip3^tm1Rds (involves: 129S6/SvEvTac)	immune system phenotype	J:122758
Tnk2^em1(IMPC)Tcp/Tnk2^em1(IMPC)Tcp (C57BL/6N-Tnk2^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Tnk2^tm1.2Npma/Tnk2^tm1.2Npma (B6(Cg)-Tnk2^tm1.2Npma)	abnormal regulatory T cell number	J:341740
	abnormal T cell physiology	J:341740
	increased activated T cell number	J:341740
	increased circulating interferon-gamma level	J:341740
	increased circulating interleukin-2 level	J:341740
	increased effector memory CD8-positive, alpha-beta T cell number	J:341740
	increased interferon level	J:341740
	increased interleukin level	J:341740
Tnr^{em1(IMPC)Rbrc}/Tnr^{em1(IMPC)Rbrc} (C57BL/6NJcl-Tnr^{em1(IMPC)Rbrc}/Rbrc)	increased spleen weight	J:211773
Tns1^tm1Efu/Tns1^tm1Efu (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	tubulointerstitial nephritis	J:39202
Tns2^nph/Tns2^nph (involves: ICR)	enlarged lymph nodes	J:24698
Tns2^nph/Tns2^nph (involves: ICR)	glomerulonephritis	J:108691
Tns3^Gt(XK294)Byg/Tns3^Gt(XK294)Byg (involves: 129P2/OlaHsd * C57BL/6)	small spleen	J:96666
Tnxb^{tm1b(EUCOMM)Hmgu}/Tnxb^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Tnxb^{tm1b(EUCOMM)Hmgu}/H)	enlarged spleen	J:211773
Tob2^tm1Tya/Tob2^tm1Tya (involves: 129S4/SvJae * C57BL/6)	abnormal osteoclast differentiation	J:134287
	abnormal osteoclast physiology	J:134287
	increased osteoclast cell number	J:134287
Tollip^tm1Kbns/Tollip^tm1Kbns (involves: C57BL/6)	decreased circulating interleukin-6 level	J:105514
	decreased interleukin-6 secretion	J:105514
	decreased tumor necrosis factor secretion	J:105514
Tom1l2^Gt(XG909)Byg/Tom1l2⁺ (involves: 129P2/OlaHsd * C57BL/6J)	enlarged spleen	J:133892
	increased susceptibility to infection	J:133892
Tom1l2^Gt(XG909)Byg/Tom1l2^Gt(XG909)Byg (involves: 129P2/OlaHsd * C57BL/6J)	abnormal humoral immune response	J:133892
	abnormal immune system physiology	J:133892
	abnormal inflammatory response	J:133892
	abnormal lymph node cell ratio	J:133892
	abnormal spleen B cell follicle morphology	J:133892
	abnormal spleen morphology	J:133892
	abnormal spleen periarteriolar lymphoid sheath morphology	J:133892
	abnormal splenic cell ratio	J:133892
	conjunctivitis	J:133892
	dark spleen	J:133892
	dermatitis	J:133892
	enlarged spleen	J:133892
	increased B cell number	J:133892
	increased CD4-positive, alpha-beta T cell number	J:133892
	increased CD8-positive, alpha-beta T cell number	J:133892
	increased inflammatory response	J:133892
	increased leukocyte cell number	J:133892
	increased spleen white pulp amount	J:133892
	increased susceptibility to bacterial infection	J:133892
	increased susceptibility to infection	J:133892
	increased T cell number	J:133892
	lymphoid hyperplasia	J:133892
Tomm5^{Gt(OST44663)Lex}/Tomm5^{Gt(OST44663)Lex} (involves: 129S5/SvEvBrd * C57BL/6)	increased eosinophil cell number	J:186382
	lung inflammation	J:186382
	thymus atrophy	J:186382
Tomm6^{tm1a(KOMP)Wtsi}/Tomm6⁺ (C57BL/6N-Tomm6^{tm1a(KOMP)Wtsi}/Wtsi)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
Tomm20^em1(IMPC)J/Tomm20⁺ (C57BL/6NJ-Tomm20^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
Top2a^em2(IMPC)Tcp/Top2a⁺ (C57BL/6NCrl-Top2a^em2(IMPC)Tcp/Tcp)	small spleen	J:211773
	small thymus	J:211773
Top2b^em1(IMPC)Mbp/Top2b⁺ (C57BL/6NCrl-Top2b^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	small spleen	J:211773
Top3b^tm1Jcw/Top3b^tm1Jcw (involves: 129S6/SvEvTac * C57BL/6)	dermatitis	J:69405
	enlarged axillary lymph nodes	J:69405
	enlarged spleen	J:69405
	enlarged submandibular lymph nodes	J:69405
	glomerulonephritis	J:69405
	increased inflammatory response	J:69405
	pancreas inflammation	J:69405
	stomach inflammation	J:69405
Tor1b^em1(IMPC)Mbp/Tor1b^em1(IMPC)Mbp (C57BL/6NCrl-Tor1b^em1(IMPC)Mbp/MbpMmucd)	increased basophil cell number	J:211773
Tox2^em1Cdon/Tox2^em1Cdon (C57BL/6J-Tox2^em1Cdon)	abnormal T follicular helper cell differentiation	J:290926
Tox2^em1Cdon/Tox2^em1Cdon (C57BL/6J-Tox2^em1Cdon)	decreased germinal center B cell number	J:290926
Tox^tm1.1Kay/Tox^tm1.1Kay (involves: 129S6/SvEvTac)	abnormal CD4-positive T cell differentiation	J:131287
	abnormal CD4-positive, CD25-positive, alpha-beta regulatory T cell morphology	J:131287
	abnormal CD8-positive, alpha beta T cell morphology	J:131287
	decreased CD4-positive, alpha-beta T cell number	J:131287
	decreased cytotoxic T cell cytolysis	J:131287
	decreased NK T cell number	J:131287
Tox^tm1.1Kay/Tox^tm1.1Kay (involves: 129S6/SvEvTac * C57BL/6)	abnormal positive T cell selection	J:164687
	abnormal spleen morphology	J:164687
	absent axillary lymph nodes	J:164687
	absent inguinal lymph nodes	J:164687
	absent mesenteric lymph nodes	J:164687
	absent popliteal lymph nodes	J:164687
	decreased NK cell number	J:164687
	decreased Peyer's patch number	J:164687
	small Peyer's patches	J:164687
Tox^{tm1b(KOMP)Wtsi}/Tox^{tm1b(KOMP)Wtsi} (C57BL/6N-Tox^{tm1b(KOMP)Wtsi}/Tcp)	increased spleen weight	J:211773
Tox^tm1Kay/Tox^tm1Kay Tg(Lck-cre)1Cwi/0 (involves: 129S6/SvEvTac * C57BL/6)	abnormal CD4-positive T cell differentiation	J:164687
Tpcn1^tm1.1Dren/Tpcn1^tm1.1Dren Tpcn2^tm1.1Dren/Tpcn2^tm1.1Dren (Not Specified)	abnormal macrophage physiology	J:189070
Tpcn2^{tm1b(EUCOMM)Hmgu}/Tpcn2^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Tpcn2^{tm1b(EUCOMM)Hmgu}/H)	increased eosinophil cell number	J:211773
Tph2^em1(IMPC)Mbp/Tph2^em1(IMPC)Mbp (C57BL/6N-Tph2^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	increased eosinophil cell number	J:211773
Tpi1^a-m6Neu/Tpi1^a-m6Neu (involves: 101/El * C3H/El)	increased spleen weight	J:163223
Tpi1^rbc19/Tpi1^rbc19 (SJL-Tpi1^rbc19)	abnormal spleen red pulp morphology	J:263104
Tpi1^rbc19/Tpi1^rbc19 (SJL-Tpi1^rbc19)	enlarged spleen	J:263104
Tpm4^Plt53/Tpm4⁺ (BALB/c-Tpm4^Plt53)	abnormal thrombopoiesis	J:242938
Tpm4^Plt53/Tpm4^Plt53 (BALB/c-Tpm4^Plt53)	abnormal thrombopoiesis	J:242938
Tpm4^Plt53/Tpm4^Plt53 (BALB/c-Tpm4^Plt53)	increased lymphocyte cell number	J:242938
Tpo^R479C/Tpo^R479C (involves: ICR)	small spleen	J:112930
Tpp2^{Gt(OST432061)Lex}/Tpp2^{Gt(OST432061)Lex} (B6.129S5-Tpp2^{Gt(OST432061)Lex})	abnormal level of surface class I molecules	J:157195
Tpp2^{Gt(OST432061)Lex}/Tpp2^{Gt(OST432061)Lex} (involves: 129S5/SvEvBrd * C57BL/6)	abnormal antigen presentation	J:157195
Tpp2^tm1.1Gnie/Tpp2^tm1.1Gnie (involves: 129S6/SvEvTac * C57BL/6)	abnormal cytotoxic T cell physiology	J:133572
	abnormal immune system cell morphology	J:133572
	abnormal immune system organ morphology	J:133572
	abnormal spleen morphology	J:133572
	abnormal splenic cell ratio	J:133572
	decreased CD8-positive, alpha-beta T cell number	J:133572
	decreased double-positive T cell number	J:133572
	decreased T cell number	J:133572
	enlarged spleen	J:133572
	increased double-negative T cell number	J:133572
	increased single-positive T cell number	J:133572
	increased spleen red pulp amount	J:133572
	increased T cell apoptosis	J:133572
	increased T cell number	J:133572
	thymus atrophy	J:133572
Tpp2^tm1.1Gnie/Tpp2^tm1.1Gnie (involves: 129S6/SvEvTac)	abnormal CD4-positive T cell differentiation	J:221205
	abnormal CD8-positive, alpha-beta T cell differentiation	J:221205
	abnormal lymphocyte physiology	J:221205
	decreased leukocyte cell number	J:221205
	enlarged lymph nodes	J:221205
	enlarged spleen	J:221205
	increased anti-nuclear antigen antibody level	J:221205
	increased autoantibody level	J:221205
	increased B cell number	J:221205
	increased memory T cell number	J:221205
Tppp3^{em1(IMPC)Ccpcz}/Tppp3⁺ (C57BL/6NCrl-Tppp3^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
	increased CD4-positive NK T cell number	J:211773
	increased memory-marker CD4-positive NK T cell number	J:211773
	increased NK T cell number	J:211773
Tpsab1^m1/Tpsab1^m1 (involves: C57BL/6J)	abnormal mast cell differentiation	J:142880
Tpsab1^m1/Tpsab1^m1 Tpsb2^tm1(cre)Adch/Tpsb2^tm1(cre)Adch (B6.Cg-Tpsb2^tm1(cre)Adch Tpsab1^m1)	abnormal mast cell differentiation	J:142880
	decreased susceptibility to induced arthritis	J:142880
Tpsb2^tm1(cre)Adch/Tpsb2^tm1(cre)Adch (B6.Cg-Tpsb2^tm1(cre)Adch)	increased susceptibility to bacterial infection	J:124554
Tpsb2^tm1.1Mfg/Tpsb2^tm1.1Mfg (B6.129-Tpsb2^tm1.1Mfg)	abnormal mast cell differentiation	J:142880
	decreased susceptibility to induced arthritis	J:142880
	impaired eosinophil recruitment	J:133373
	impaired neutrophil chemotaxis	J:142880
	increased susceptibility to parasitic infection	J:133373
Tpsg1^tm1.2Rls/Tpsg1^tm1.2Rls (involves: C57BL/6 * C57BL/6NTac)	decreased susceptibility to colitis induced morbidity/mortality	J:243813
	immune system phenotype	J:243813
Tpx2^{Gt(D028B03)Wrst}/Tpx2⁺ (involves: 129S2/SvPas * C57BL/6J)	abnormal splenocyte morphology	J:184948
	granulomatous inflammation	J:184948
Tra2a^{tm2b(EUCOMM)Hmgu}/Tra2a⁺ (C57BL/6N-Tra2a^{tm2b(EUCOMM)Hmgu}/Bay)	increased basophil cell number	J:211773
Trabd2b^{em2(IMPC)Ccpcz}/Trabd2b^{em2(IMPC)Ccpcz} (C57BL/6N-Trabd2b^{em2(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Tradd^tm1.1Mak/Tradd⁺ (either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129P2/OlaHsd * FVB/N))	decreased acute inflammation	J:138824
Tradd^tm1.1Mak/Tradd^tm1.1Mak (either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129P2/OlaHsd * FVB/N))	abnormal spleen follicular dendritic cell network	J:138824
	absent spleen germinal center	J:138824
	decreased acute inflammation	J:138824
	decreased circulating interleukin-6 level	J:138824
	decreased inflammatory response	J:138824
	decreased interleukin-6 secretion	J:138824
Tradd^tm1.1Mpa/Tradd^tm1.1Mpa (involves: C57BL/6)	decreased interferon-beta secretion	J:136289
Tradd^tm1.1Mpa/Tradd^tm1.1Mpa (involves: BALB/cJ * C57BL/6)	abnormal interleukin level	J:139030
	abnormal spleen germinal center morphology	J:139030
	decreased circulating tumor necrosis factor level	J:139030
	decreased IgG level	J:139030
	increased susceptibility to bacterial infection	J:139030
Traf1^tm1Tsi/Traf1^tm1Tsi (involves: 129S4/SvJae * C57BL/6)	abnormal lymph node cell ratio	J:72327
	immune system phenotype	J:72327
	increased lymphocyte cell number	J:72327
	increased T cell proliferation	J:72327
Traf2^{tm1a(EUCOMM)Wtsi}/Traf2⁺ (C57BL/6N-Traf2^{tm1a(EUCOMM)Wtsi}/Wtsi)	decreased alpha-beta T cell number	J:211773
	decreased CD8-positive, alpha-beta T cell number	J:211773
Traf2^tm1Mak/Traf2^tm1Mak (either: (involves: 129P2/OlaHsd * C57BL/6J) or (involves: 129P2/OlaHsd * BALB/c * C57BL/6J))	absent lymph node germinal center	J:44360
	absent spleen germinal center	J:44360
	decreased double-positive T cell number	J:44360
	decreased immature B cell number	J:44360
	decreased lymphocyte cell number	J:44360
	decreased thymocyte number	J:44360
	increased circulating tumor necrosis factor level	J:44360
	increased granulocyte number	J:44360
	increased thymocyte apoptosis	J:44360
	lymphoid hypoplasia	J:44360
	spleen atrophy	J:44360
	thymus atrophy	J:44360
Traf3^m1Btlr/Traf3^m1Btlr (C57BL/6J-Traf3^m1Btlr)	decreased mature B cell number	J:212064
Traf3^m1Btlr/Traf3^m1Btlr (C57BL/6J-Traf3^m1Btlr)	impaired humoral immune response	J:212064
Traf3^m2Btlr/Traf3^m2Btlr (C57BL/6J-Traf3^m2Btlr)	decreased IgG level	J:217797
Traf3^m2Btlr/Traf3^m2Btlr (C57BL/6J-Traf3^m2Btlr)	decreased response to antigen	J:217797
Traf3^tm1Bal/Traf3^tm1Bal (involves: 129S4/SvJae * C57BL/6J)	abnormal B cell differentiation	J:37065
	abnormal T cell physiology	J:37065
	decreased double-positive T cell number	J:37065
	decreased leukocyte cell number	J:37065
	decreased thymocyte number	J:37065
	spleen hypoplasia	J:37065
Traf3^tm1Bshp/Traf3^tm1Bshp Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * SJL)	abnormal adaptive immunity	J:124329
	abnormal immune system organ morphology	J:124329
	abnormal immune system physiology	J:124329
	abnormal leukocyte morphology	J:124329
	abnormal lymph node B cell domain morphology	J:124329
	abnormal spleen germinal center morphology	J:124329
	autoimmune response	J:124329
	decreased B cell apoptosis	J:124329
	decreased T cell number	J:124329
	enlarged lymph nodes	J:124329
	enlarged spleen	J:124329
	increased anti-double stranded DNA antibody level	J:124329
	increased B cell number	J:124329
	increased follicular B cell number	J:124329
	increased IgA level	J:124329
	increased IgG2a level	J:124329
	increased IgG2b level	J:124329
	increased IgG3 level	J:124329
	increased IgG level	J:124329
	increased IgM level	J:124329
	increased marginal zone B cell number	J:124329
	increased spleen white pulp amount	J:124329
	increased transitional stage B cell number	J:124329
Traf3ip2^adjm/Traf3ip2^adjm (KOR-Traf3ip2^adjm)	dermatitis	J:162859
Traf3ip2^adjm/Traf3ip2^adjm (KOR-Traf3ip2^adjm)	increased IgE level	J:162859
Traf3ip2^adjm/Traf3ip2^adjm (A.KOR-Traf3ip2^adjm)	dermatitis	J:162859
Traf3ip2^adjm/Traf3ip2^adjm (A.KOR-Traf3ip2^adjm)	increased IgE level	J:162859
Traf3ip2^adjm/Traf3ip2^adjm (B6.KOR-Traf3ip2^adjm)	dermatitis	J:162859
Traf3ip2^adjm/Traf3ip2^adjm (B6.KOR-Traf3ip2^adjm)	increased IgE level	J:162859
Traf3ip2^adjm/Traf3ip2^adjm (C.KOR-Traf3ip2^adjm)	dermatitis	J:162859
Traf3ip2^adjm/Traf3ip2^adjm (C.KOR-Traf3ip2^adjm)	increased IgE level	J:162859
Traf3ip2^adjm/Traf3ip2^adjm (AK.KOR-Traf3ip2^adjm)	dermatitis	J:162859
Traf3ip2^adjm/Traf3ip2^adjm (AK.KOR-Traf3ip2^adjm)	increased IgE level	J:162859
Traf3ip2^{Gt(IST11484G7)Tigm}/Traf3ip2^{Gt(IST11484G7)Tigm} (involves: C57BL/6N)	immune system phenotype	J:177650
Traf3ip2^tm1.1Lix/Traf3ip2^tm1.1Lix (involves: 129/Sv * BALB/c)	abnormal immune system morphology	J:93923
	abnormal immune system physiology	J:93923
	abnormal spleen B cell corona morphology	J:93923
	enlarged lymph nodes	J:93923
	enlarged spleen	J:93923
	increased anti-double stranded DNA antibody level	J:93923
	increased anti-histone antibody level	J:93923
	increased anti-single stranded DNA antibody level	J:93923
	increased autoantibody level	J:93923
	increased B cell number	J:93923
	increased dendritic cell number	J:93923
	increased IgE level	J:93923
	increased IgG level	J:93923
	increased immunoglobulin level	J:93923
	increased inflammatory response	J:93923
	lymphoid hyperplasia	J:93923
	respiratory system inflammation	J:93923
Traf3ip2^tm1.1Lix/Traf3ip2^tm1.1Lix (C.129-Traf3ip2^tm1.1Lix)	blepharitis	J:138560
	enlarged submandibular lymph nodes	J:138560
	glomerulonephritis	J:138560
	increased autoantibody level	J:138560
	increased follicular B cell number	J:138560
	increased inflammatory response	J:138560
	increased marginal zone B cell number	J:138560
	increased transitional stage B cell number	J:138560
	kidney inflammation	J:138560
	lacrimal gland inflammation	J:138560
	parotid gland inflammation	J:138560
	stomatitis	J:138560
	submandibular gland inflammation	J:138560
Traf3ip2^tm1.1Lix/Traf3ip2^tm1.1Lix (B6.129-Traf3ip2^tm1.1Lix)	abnormal transitional stage B cell morphology	J:187766
	enlarged cervical lymph nodes	J:187766
	enlarged spleen	J:187766
	immune system phenotype	J:187766
	increased anti-chromatin antibody level	J:187766
	increased anti-double stranded DNA antibody level	J:187766
	increased anti-histone antibody level	J:187766
	increased anti-nuclear antigen antibody level	J:187766
	increased autoantibody level	J:187766
	increased B cell number	J:187766
	increased IgG1 level	J:187766
	increased IgG2c level	J:187766
	increased IgG level	J:187766
	increased immature B cell number	J:187766
	increased marginal zone B cell number	J:187766
	increased spleen weight	J:187766
	lymph node hyperplasia	J:187766
	spleen hyperplasia	J:187766
Traf3ip2^tm1.1Lix/Traf3ip2^tm1.1Lix Tnfsf13b^tm1Msc/Tnfsf13b^tm1Msc (involves: 129 * 129S2/SvPas * BALB/c)	decreased B cell number	J:138560
	decreased follicular B cell number	J:138560
	decreased mature B cell number	J:138560
	decreased transitional stage B cell number	J:138560
	enlarged lymph nodes	J:93923
	enlarged spleen	J:93923
	increased autoantibody level	J:138560
Traf3ip2^tm1Lix/Traf3ip2^tm1.1Lix Tg(CD19-cre/ERT2)1Cgn/0 (involves: 129/Sv * BALB/c)	enlarged lymph nodes	J:93923
	enlarged spleen	J:93923
	increased B cell number	J:93923
	increased dendritic cell number	J:93923
	increased immunoglobulin level	J:93923
Traf3ip2^tm1Sbn/Traf3ip2^tm1Sbn (either: B6.129-Traf3ip2^tm1Sbn or (involves: 129) or (involves: 129 * BALB/c))	abnormal cytokine secretion	J:144320
	decreased interleukin-6 secretion	J:144320
	decreased susceptibility to autoimmune disorder	J:144320
	impaired eosinophil recruitment	J:144320
	impaired macrophage chemotaxis	J:144320
	impaired neutrophil recruitment	J:144320
Traf3ip2^tm1Sbn/Traf3ip2^tm1Sbn (involves: 129 * C57BL/6)	decreased inflammatory response	J:191090
Traf3ip3^{tm1a(KOMP)Wtsi}/Traf3ip3^{tm1a(KOMP)Wtsi} (C57BL/6N-Traf3ip3^{tm1a(KOMP)Wtsi}/Wtsi)	decreased leukocyte cell number	J:175295
Traf3ip3^{tm1b(KOMP)Wtsi}/Traf3ip3^{tm1b(KOMP)Wtsi} (involves: BALB/cJ * C57BL/6N)	abnormal T cell differentiation	J:226431
	decreased CD4-positive, alpha-beta memory T cell number	J:226431
	decreased CD8-positive, alpha-beta memory T cell number	J:226431
	decreased regulatory T cell number	J:226431
	decreased T cell number	J:226431
	decreased thymocyte number	J:226431
	immune system phenotype	J:226431
	increased double-positive T cell number	J:226431
	increased gamma-delta T cell number	J:226431
Traf4^tm1Lind/Traf4^tm1Lind (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	immune system phenotype	J:74252
	lung inflammation	J:74252
Traf4^tm1Mrio/Traf4^tm1Mrio (involves: 129X1/SvJ)	abnormal dendritic cell physiology	J:142780
Traf4^tm1Mrio/Traf4^tm1Mrio (involves: 129X1/SvJ)	immune system phenotype	J:142780
Traf4^tm2Lind/Traf4^tm2Lind (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	immune system phenotype	J:74252
	lung inflammation	J:74252
Traf5^tm1Hna/Traf5^tm1Hna (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	abnormal B cell proliferation	J:57114
	abnormal humoral immune response	J:57114
	abnormal T cell proliferation	J:57114
	decreased IgG1 level	J:57114
	decreased IgM level	J:57114
Traf6^tm1.1Mpa/Traf6^tm1.1Mpa Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6)	decreased circulating interleukin-6 level	J:145306
Traf6^tm1Jino/Traf6^tm1Jino (involves: 129P2/OlaHsd * C57BL/6)	abnormal osteoclast differentiation	J:77453
	decreased immature B cell number	J:77453
	decreased lymph node number	J:77453
Traf6^tm1Mak/Traf6^tm1Mak (involves: 129P3/J)	abnormal macrophage physiology	J:54467
	abnormal osteoclast morphology	J:54467
	abnormal osteoclast physiology	J:54467
	decreased B cell proliferation	J:54467
	decreased tumor necrosis factor secretion	J:54467
	enlarged spleen	J:54467
Traf6^tm1Ywc/Traf6^tm1Ywc (Not Specified)	abnormal dendritic cell differentiation	J:85808
	abnormal dendritic cell physiology	J:85808
	abnormal lymph node morphology	J:85808
	abnormal spleen morphology	J:85808
	absent spleen white pulp	J:85808
	decreased dendritic cell number	J:85808
	decreased interleukin-6 secretion	J:85808
	decreased interleukin-12 secretion	J:85808
	enlarged spleen	J:85808
	thymus atrophy	J:85808
Traf6^{tm2a(EUCOMM)Wtsi}/Traf6^{tm2a(EUCOMM)Wtsi} (C57BL/6N-Traf6^{tm2a(EUCOMM)Wtsi}/Wtsi)	blood in lymph vessels	J:239583
Traf6^tm2Ywc/Traf6^tm2Ywc Tg(Cd4-cre)1Cwi/? (involves: C57BL/6 * DBA/2)	abnormal lymphocyte anergy	J:130882
	increased activated T cell number	J:130882
	increased memory T cell number	J:130882
Traf7^em1(IMPC)Tcp/Traf7⁺ (C57BL/6NCrl-Traf7^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Trafd1^tm1Ayos/Trafd1^tm1Ayos (involves: 129 * C57BL/6J)	decreased susceptibility to Riboviria infection	J:144594
	increased circulating interleukin-6 level	J:144594
	increased interleukin-6 secretion	J:144594
	increased interleukin-12 secretion	J:144594
	increased susceptibility to endotoxin shock	J:144594
	increased tumor necrosis factor secretion	J:144594
Traj18^em1Hwata/Traj18^em1Hwata (C57BL/6-Traj18^em1Hwata)	abnormal cytokine secretion	J:256533
Traj18^em1Hwata/Traj18^em1Hwata (C57BL/6-Traj18^em1Hwata)	absent NK T cells	J:256533
Traj18^em1Hwata/Traj18^em1Hwata (C.B6-Traj18^em1Hwata)	abnormal cytokine secretion	J:256533
Traj18^em1Hwata/Traj18^em1Hwata (C.B6-Traj18^em1Hwata)	absent NK T cells	J:256533
Traj18^tm1.1Kro/Traj18^tm1.1Kro (involves: C57BL/6NTac)	abnormal circulating interleukin-4 level	J:232957
	abnormal interferon-gamma secretion	J:232957
	absent NK T cells	J:232957
	decreased inflammatory response	J:232957
Traj33^em#Dig/Traj33^em#Dig (involves: C57BL/6)	decreased T cell number	J:276912
Traj33^em#Dig/Traj33^em#Dig (involves: C57BL/6)	immune system phenotype	J:276912
Trak1^{em1(IMPC)Ccpcz}/Trak1⁺ (C57BL/6NCrl-Trak1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Trak2^em1(IMPC)Mbp/Trak2^em1(IMPC)Mbp (C57BL/6N-Trak2^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
Trap1^em1(IMPC)Mbp/Trap1^em1(IMPC)Mbp (C57BL/6N-Trap1^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	decreased monocyte cell number	J:211773
Trap1^{Gt(E150H04)Wrst}/Trap1^{Gt(E150H04)Wrst} (involves: 129P2/OlaHsd * C57BL/6)	decreased inflammatory response	J:226880
	spleen hyperplasia	J:226880
Trappc1^em1(IMPC)Mbp/Trappc1⁺ (C57BL/6NCrl-Trappc1^em1(IMPC)Mbp/Mmucd)	enlarged spleen	J:211773
Trappc2l^em1(IMPC)Mbp/Trappc2l^em1(IMPC)Mbp (C57BL/6N-Trappc2l^em1(IMPC)Mbp/Ucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Trappc8^em1(IMPC)Tcp/Trappc8⁺ (C57BL/6NCrl-Trappc8^em1(IMPC)Tcp/Tcp)	increased eosinophil cell number	J:211773
	increased monocyte cell number	J:211773
Trappc9^{tm1a(EUCOMM)Wtsi}/Trappc9^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Trappc9^{tm1a(EUCOMM)Wtsi}/Wtsi)	blood in lymph vessels	J:239583
	decreased CD11b-low dendritic cell number	J:211773
	decreased gamma-delta T cell number	J:211773
	decreased KLRG1-positive NK cell number	J:211773
	increased CD11b-high dendritic cell number	J:211773
	increased Ly6C high monocyte number	J:211773
	increased Ly6C low monocyte number	J:211773
	increased monocyte cell number	J:211773
Trappc10^b2b2416Clo/Trappc10^b2b2416Clo (Trappc10^b2b2416Clo)	thymus hypoplasia	J:175213
Trat1^tm1Lsmn/Trat1^tm1Lsmn (B6.129X1-Trat1^tm1Lsmn)	lymph node hypoplasia	J:108406
	spleen hypoplasia	J:108406
	thymus hypoplasia	J:108406
Trbv13-2^tm1(CD2)Zhu/Trbv13-2^tm1(CD2)Zhu (involves: 129 * C57BL/6)	abnormal T cell differentiation	J:121608
	immune system phenotype	J:121608
Trbv13-2^tm1(CD2)Zhu/Trbv13-2^tm1(CD2)Zhu (involves: 129 * C57BL/6 * SJL)	abnormal T cell differentiation	J:121608
Trbv14^tm1Che/Trbv14^tm1Che (involves: 129S4/SvJae)	decreased T cell number	J:92288
Trbv14^tm2Che/Trbv14^tm2Che (involves: 129S4/SvJae)	decreased T cell number	J:92288
Trbv15^tm1Krg/Trbv15^tm1Krg (involves: 129S/SvEv * C57BL/6)	immune system phenotype	J:95669
Trdmt1^{Gt(OST19279)Lex}/Trdmt1^{Gt(OST19279)Lex} (involves: 129S5/SvEvBrd * C57BL/6J)	decreased NK cell number	J:103485
Treh^em1(IMPC)H/Treh^em1(IMPC)H (C57BL/6N-Treh^em1(IMPC)H/H)	increased eosinophil cell number	J:211773
Trem1^{tm1(KOMP)Vlcg}/Trem1^{tm1(KOMP)Vlcg} (C57BL/6N-Trem1^{tm1(KOMP)Vlcg}/Wtsi)	increased anti-nuclear antigen antibody level	J:211773
Trem1^tm1.1Ahoru/Trem1^tm1.1Ahoru (C57BL/6-Trem1^tm1.1Ahoru)	decreased monocyte cell number	J:191035
	decreased neutrophil cell number	J:191035
Trem2^em2Bwef/Trem2⁺ (involves: C57BL/6J * DBA/2J * FVB/N)	decreased macrophage cell number	J:242126
Trem2^em2Bwef/Trem2^em2Bwef (involves: C57BL/6J * DBA/2J * FVB/N)	decreased macrophage cell number	J:242126
	decreased macrophage proliferation	J:242126
	decreased microglial cell activation	J:242126
	impaired macrophage phagocytosis	J:242126
	increased circulating interleukin-6 level	J:242126
	increased circulating tumor necrosis factor level	J:242126
	increased macrophage apoptosis	J:242126
	increased susceptibility to endotoxin shock	J:242126
Trem2^{tm1(KOMP)Vlcg}/Trem2^{tm1(KOMP)Vlcg} (C57BL/6N-Trem2^{tm1(KOMP)Vlcg})	abnormal microglial cell physiology	J:239381
	decreased microglial cell activation	J:239381
Trem2^tm1Cln/Trem2^tm1Cln (B6.129P2-Trem2^tm1Cln)	abnormal interferon level	J:138057
	abnormal interleukin level	J:138057
	abnormal tumor necrosis factor level	J:138057
Treml1^tm1Mcvic/Treml1^tm1Mcvic (C57BL/6-Treml1^tm1Mcvic)	increased susceptibility to endotoxin shock	J:150578
Treml1^tm1Mcvic/Treml1^tm1Mcvic (C57BL/6-Treml1^tm1Mcvic)	increased tumor necrosis factor secretion	J:150578
Treml4^tm1Ji/Treml4^tm1Ji (B6(Cg)-Treml4^tm1Ji)	immune system phenotype	J:180744
Trex1^{em1(IMPC)Ccpcz}/Trex1⁺ (C57BL/6NCrl-Trex1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Trex1^{em1(IMPC)Ccpcz}/Trex1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Trex1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	decreased lymphocyte cell number	J:211773
	decreased NK cell number	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
	increased effector memory T-helper cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
	increased spleen weight	J:211773
Trex1^em3Gpt/Trex1^em3Gpt (C57BL/6JGpt-Trex1^em3Gpt)	enlarged spleen	J:330879
	increased circulating tumor necrosis factor level	J:330879
	increased spleen weight	J:330879
	increased susceptibility to autoimmune disorder	J:330879
Trex1^tm1.1Fwpe/Trex1⁺ (involves: 129S1/SvImJ * 129S4/SvJae * 129S6/SvEvTac)	increased CD4-positive, alpha-beta T cell number	J:220965
Trex1^tm1.1Fwpe/Trex1^tm1.1Fwpe (involves: 129S1/SvImJ * 129S4/SvJae * 129S6/SvEvTac)	abnormal immune system organ morphology	J:220965
	abnormal T cell activation	J:220965
	bronchiolitis	J:220965
	enlarged lymph nodes	J:220965
	enlarged spleen	J:220965
	glomerulonephritis	J:220965
	heart inflammation	J:220965
	increased anti-double stranded DNA antibody level	J:220965
	increased B cell number	J:220965
	increased CD4-positive, alpha-beta T cell number	J:220965
	increased IgG level	J:220965
	increased inflammatory response	J:220965
	increased plasma cell number	J:220965
	increased regulatory T cell number	J:220965
	increased spleen weight	J:220965
	increased splenocyte number	J:220965
	increased susceptibility to systemic lupus erythematosus	J:220965
	lacrimal gland inflammation	J:220965
	lymphoid hyperplasia	J:220965
	pancreas inflammation	J:220965
	salivary gland inflammation	J:220965
	tubulointerstitial nephritis	J:220965
Trex1^tm1Tld/Trex1^tm1Tld (involves: 129P2/OlaHsd)	abnormal interferon secretion	J:234263
	abnormal spleen marginal zone morphology	J:92264
	enlarged lymph nodes	J:92264
	enlarged spleen	J:92264
	heart inflammation	J:202757
	increased autoantibody level	J:202757
	increased spleen B cell follicle size	J:92264
	myocarditis	J:92264
	skin inflammation	J:202757
	thymus cortex hypoplasia	J:92264
Trex1^tm1Tld/Trex1^tm1Tld (involves: 129P2/OlaHsd * C57BL/6)	dermatitis	J:181257
	folliculitis	J:181257
	glomerulonephritis	J:181257
	immune system phenotype	J:181257
	increased anti-nuclear antigen antibody level	J:181257
	increased IgG level	J:181257
	increased inflammatory response	J:181257
	increased susceptibility to systemic lupus erythematosus	J:181257
	kidney inflammation	J:181257
	myocarditis	J:181257
	myositis	J:181257
	skin inflammation	J:181257
	stomach inflammation	J:181257
Trex1^tm1Tld/Trex1^tm1Tld (involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6N)	heart inflammation	J:234263
	increased autoantibody level	J:234263
	increased inflammatory response	J:234263
	kidney inflammation	J:234263
	myositis	J:234263
	stomach inflammation	J:234263
Trex1^tm1Tld/Trex1^tm1Tld (involves: 129P2/OlaHsd * C57BL/6J)	dermatitis	J:243357
	increased susceptibility to autoimmune disorder	J:243357
Trf^{em1(IMPC)Rbrc}/Trf⁺ (C57BL/6NJcl-Trf^{em1(IMPC)Rbrc}/Rbrc)	increased large unstained cell number	J:211773
Trgc1^tm1.2Dhr/Trgc1^tm1.2Dhr (either: 129S4/SvJae or (involves: 129S4/SvJae * C57BL/6))	decreased gamma-delta T cell number	J:91304
Tria4^STS/A/? (involves: BALB/c * STS/A)	abnormal leukocyte physiology	J:56029
Tria5^STS/A/? (involves: BALB/cHeA * STS/A)	abnormal leukocyte physiology	J:56029
Trib1^tm1Aki/Trib1^tm1Aki (involves: 129P2/OlaHsd)	abnormal spleen red pulp morphology	J:196449
	decreased eosinophil cell number	J:196449
	decreased interleukin-12 secretion	J:126085
	decreased macrophage cell number	J:196449
	decreased spleen iron level	J:196449
	increased neutrophil cell number	J:196449
Trib2^{Tg(Thy1-Trh/APP)2.1Ingm}/Trib2⁺ Tg(Thy1-APP)2.2Ingm/0 (involves: C57BL/6 * DBA/1)	microgliosis	J:176575
Trib2^{Tg(Thy1-Trh/APP)2.1Ingm}/Trib2^{Tg(Thy1-Trh/APP)2.1Ingm} (involves: C57BL/6 * DBA/1)	microgliosis	J:176575
Trib2^tm1Lex/Trib2^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6J)	decreased B cell number	J:82809
	increased CD8-positive, alpha-beta T cell number	J:82809
Trib3^tm1Tord/Trib3^tm1Tord (involves: C57BL/6)	abnormal mast cell physiology	J:192615
Trib3^tm1Tord/Trib3^tm1Tord (involves: C57BL/6)	decreased mast cell degranulation	J:192615
Tril^tm1.1Kaf/Tril^tm1.1Kaf (involves: C57BL/6)	abnormal chemokine secretion	J:301765
	abnormal cytokine secretion	J:301765
	decreased interferon-beta secretion	J:301765
	decreased interleukin-6 secretion	J:301765
	decreased tumor necrosis factor secretion	J:301765
Trim6^em1Raj/Trim6^em1Raj (C57BL/6J-Trim6^em1Raj)	abnormal response to infection	J:326927
Trim7^em1Jiew/Trim7^em1Jiew (C57BL/6-Trim7^em1Jiew)	decreased susceptibility to Herpesvirales infection	J:292408
Trim7^em1Jiew/Trim7^em1Jiew (C57BL/6-Trim7^em1Jiew)	decreased susceptibility to viral infection	J:292408
Trim8^tm1Hbsh/Trim8^tm1Hbsh (involves: 129S6/SvEvTac)	abnormal chemokine secretion	J:251270
	abnormal circulating chemokine level	J:251270
	decreased interleukin-6 secretion	J:251270
	decreased tumor necrosis factor secretion	J:251270
	immune system phenotype	J:251270
	increased circulating interleukin-6 level	J:251270
	increased circulating tumor necrosis factor level	J:251270
	increased interferon-beta secretion	J:251270
	increased interleukin-6 secretion	J:251270
	increased macrophage cytokine production	J:251270
	increased susceptibility to bacterial infection	J:251270
	increased susceptibility to bacterial infection induced morbidity/mortality	J:251270
	increased susceptibility to endotoxin shock	J:251270
	increased tumor necrosis factor secretion	J:251270
Trim9^{em1(IMPC)Ccpcz}/Trim9^{em1(IMPC)Ccpcz} (C57BL/6N-Trim9^{em1(IMPC)Ccpcz}/Ccpcz)	decreased effector memory T-helper cell number	J:211773
	decreased spleen weight	J:211773
Trim13^em1(IMPC)Tcp/Trim13^em1(IMPC)Tcp (C57BL/6N-Trim13^em1(IMPC)Tcp/Tcp)	enlarged thymus	J:211773
Trim13^tm1.1Jskg/Trim13^tm1.1Jskg (B6.129S7(Cg)-Trim13^tm1.1Jskg)	abnormal circulating interferon level	J:243916
	decreased circulating interferon-beta level	J:243916
	decreased susceptibility to Picornaviridae infection induced morbidity/mortality	J:243916
	increased interferon-beta secretion	J:243916
Trim14^em1Rfw/Trim14^em1Rfw (involves: C57BL/6J)	decreased interferon-beta secretion	J:249057
	increased susceptibility to Herpesvirales infection	J:249057
	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:249057
Trim21^tm1Mwah/Trim21⁺ (C57BL/6-Trim21^tm1Mwah)	dermatitis	J:151775
Trim21^tm1Mwah/Trim21^tm1Mwah (C57BL/6-Trim21^tm1Mwah)	abnormal interleukin level	J:151775
	abnormal T cell activation	J:151775
	abnormal tumor necrosis factor level	J:151775
	autoimmune response	J:151775
	dermatitis	J:151775
	enlarged lymph nodes	J:151775
	enlarged spleen	J:151775
	increased autoantibody level	J:151775
	increased inflammatory response	J:151775
Trim25^tm1Mura/Trim25⁺ Usp15^L749R/Usp15⁺ (involves: 129S1/SvImJ * 129S4/SvJae * C57BL/6J)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:259382
	decreased susceptibility to parasitic infection induced morbidity/mortality	J:259382
Trim25^tm1Mura/Trim25^tm1Mura (involves: 129S4/SvJae)	decreased susceptibility to parasitic infection	J:259382
Trim25^tm1Mura/Trim25^tm1Mura (involves: 129S4/SvJae)	decreased susceptibility to parasitic infection induced morbidity/mortality	J:259382
Trim27^{Gt(345D11)Cmhd}/Trim27^{Gt(345D11)Cmhd} (B6.129-Trim27^{Gt(345D11)Cmhd})	abnormal T-helper 1 physiology	J:180433
	abnormal T-helper 2 physiology	J:180433
	immune system phenotype	J:180433
	increased interferon-gamma secretion	J:180433
	increased tumor necrosis factor secretion	J:180433
Trim29^{tm1a(EUCOMM)Wtsi}/Trim29^{tm1a(EUCOMM)Wtsi} (involves: C57BL/6N * C57BL/6NTac)	abnormal interferon secretion	J:349246
	abnormal tumor necrosis factor level	J:349246
	decreased interleukin level	J:349246
	decreased susceptibility to Picornaviridae infection	J:349246
	decreased susceptibility to Picornaviridae infection induced morbidity/mortality	J:349246
	increased interferon level	J:349246
	increased interferon-alpha secretion	J:349246
	increased interferon-beta secretion	J:349246
Trim29^{tm1c(EUCOMM)Wtsi}/Trim29^{tm1c(EUCOMM)Wtsi} Tg(Myh6-cre)2182Mds/0 (involves: C57BL/6J * C57BL/6N * C57BL/6NTac)	abnormal tumor necrosis factor level	J:349246
	decreased inflammatory response	J:349246
	decreased interleukin level	J:349246
	decreased susceptibility to Picornaviridae infection	J:349246
	decreased susceptibility to Picornaviridae infection induced morbidity/mortality	J:349246
	increased interferon level	J:349246
	increased interferon-gamma secretion	J:349246
	increased T cell proliferation	J:349246
Trim30a^tm1Yjk/Trim30a^tm1Yjk (B6.129P2-Trim30a^tm1Yjk)	abnormal CD4-positive, alpha-beta T cell physiology	J:215171
	abnormal T cell subpopulation ratio	J:215171
	increased CD4-positive, alpha-beta T cell number	J:215171
	increased T cell proliferation	J:215171
Trim31^em1Cya/Trim31^em1Cya (involves: C57BL/6)	abnormal circulating cytokine level	J:243237
	decreased susceptibility to induced colitis	J:243237
	increased circulating interleukin-1 beta level	J:243237
	increased Ly6C high monocyte number	J:243237
	increased neutrophil cell number	J:243237
Trim33^em1(IMPC)Tcp/Trim33⁺ (C57BL/6N-Trim33^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Trim33^tm1Los/Trim33^tm1Los Tg(Cd4-cre)1Cwi/0 (involves: 129S2/SvPas * C57BL/6 * DBA/2)	immune system phenotype	J:149449
Trim35^em1Smoc/Trim35^em1Smoc (C57BL/6J-Trim35^em1Smoc)	decreased circulating interferon-beta level	J:303214
	decreased macrophage cytokine production	J:303214
	increased susceptibility to Orthomyxoviridae infection	J:303214
	increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:303214
Trim37^{Gt(RRO307)Byg}/Trim37^{Gt(RRO307)Byg} (B6J.129P2-Trim37^{Gt(RRO307)Byg})	enlarged spleen	J:232482
Trim38^{tm1(KOMP)Vlcg}/Trim38^{tm1(KOMP)Vlcg} (involves: C57BL/6N)	increased circulating interferon-alpha level	J:239773
	increased circulating interferon-beta level	J:239773
	increased circulating interleukin-6 level	J:239773
	increased circulating tumor necrosis factor level	J:239773
	increased susceptibility to bacterial infection	J:239773
	increased susceptibility to bacterial infection induced morbidity/mortality	J:239773
	increased susceptibility to infection induced morbidity/mortality	J:239773
Trim39^{tm1b(EUCOMM)Hmgu}/Trim39^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Trim39^{tm1b(EUCOMM)Hmgu}/H)	decreased monocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
Trim40^em1Caox/Trim40^em1Caox (involves: C57BL/6J)	abnormal immune system physiology	J:255265
	abnormal macrophage physiology	J:255265
	decreased susceptibility to Riboviria infection induced morbidity/mortality	J:255265
Trim41^tm1Caox/Trim41^tm1Caox (B6.Cg-Trim41^tm1Caox)	abnormal innate immunity	J:340065
	abnormal tumor necrosis factor level	J:340065
	decreased circulating interferon-beta level	J:340065
	decreased circulating interleukin-6 level	J:340065
	decreased interferon level	J:340065
	decreased interleukin level	J:340065
	increased susceptibility to bacterial infection	J:340065
	increased susceptibility to bacterial infection induced morbidity/mortality	J:340065
	increased susceptibility to Herpesvirales infection	J:340065
	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:340065
	increased susceptibility to Riboviria infection	J:340065
	increased susceptibility to Riboviria infection induced morbidity/mortality	J:340065
Trim45^{tm1a(KOMP)Wtsi}/Trim45^{tm1a(KOMP)Wtsi} (B6Brd;B6Dnk;B6N-Trim45^{tm1a(KOMP)Wtsi} Tyr^c-Brd/Wtsi)	blood in lymph vessels	J:239583
Trim46^em1(IMPC)J/Trim46^em1(IMPC)J (C57BL/6NJ-Trim46^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
Trim50^{tm1b(KOMP)Wtsi}/Trim50^{tm1b(KOMP)Wtsi} (C57BL/6N-Trim50^{tm1b(KOMP)Wtsi}/BayMmucd)	decreased spleen weight	J:211773
Trim55^tm1Slbt/Trim55^tm1Slbt (involves: 129 * C57BL/6)	decreased susceptibility to Coronaviridae infection	J:268979
Trim56^{tm1a(EUCOMM)Wtsi}/Trim56^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Trim56^{tm1a(EUCOMM)Wtsi}/Wtsi)	decreased regulatory T cell number	J:211773
Trim58^em1(IMPC)Mbp/Trim58^em1(IMPC)Mbp (C57BL/6N-Trim58^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
Trim58^tm2313.1Arte/Trim58^tm2313.1Arte Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6N)	increased susceptibility to induced colitis	J:279270
Trim58^tm2313.2Arte/Trim58^tm2313.2Arte (involves: BALB/cJ * C57BL/6N)	increased susceptibility to induced colitis	J:279270
Trim65^em1Cya/Trim65^em1Cya (involves: C57BL/6)	decreased circulating interferon-alpha level	J:240099
	decreased circulating interferon-beta level	J:240099
	decreased interferon-alpha secretion	J:240099
	decreased interferon-beta secretion	J:240099
	increased susceptibility to Picornaviridae infection	J:240099
	increased susceptibility to Picornaviridae infection induced morbidity/mortality	J:240099
Trim65^em2Cya/Trim65^em2Cya (involves: C57BL/6)	decreased interferon-beta secretion	J:240099
Trim65^em3Cya/Trim65^em3Cya (involves: C57BL/6)	decreased interferon-beta secretion	J:240099
Trio^em1(IMPC)H/Trio⁺ (C57BL/6NTac-Trio^em1(IMPC)H/H)	increased neutrophil cell number	J:211773
Trip6^{tm1b(EUCOMM)Hmgu}/Trip6⁺ (C57BL/6N-Trip6^{tm1b(EUCOMM)Hmgu}/Bay)	enlarged spleen	J:211773
Trip10^tm1.1Geha/Trip10^tm1.1Geha (B6.129S1-Trip10^tm1.1Geha)	abnormal spleen germinal center morphology	J:164363
	abnormal T cell physiology	J:164363
	decreased IgE level	J:164363
	decreased IgG level	J:164363
	decreased spleen germinal center number	J:164363
	decreased spleen germinal center size	J:164363
	decreased susceptibility to type IV hypersensitivity reaction	J:164363
Trip13^{tm1.1(KOMP)Vlcg}/Trip13^{tm1.1(KOMP)Vlcg} (C57BL/6N-Trip13^{tm1.1(KOMP)Vlcg}/Ucd)	increased leukocyte cell number	J:211773
Trmq1^C57BL/6J/Trmq1^DBA/2J (involves: C57BL/6J * DBA/2J)	abnormal CD4-positive, alpha beta T cell morphology	J:77603
Trmq1^DBA/2J/Trmq1^DBA/2J (involves: C57BL/6J * DBA/2J)	abnormal CD4-positive, alpha beta T cell morphology	J:77603
Trmq2^C57BL/6J/Trmq2^C57BL/6J (involves: C57BL/6J * DBA/2J)	abnormal CD4-positive, alpha beta T cell morphology	J:77603
Trmq2^C57BL/6J/Trmq2^DBA/2J (involves: C57BL/6J * DBA/2J)	abnormal CD4-positive, alpha beta T cell morphology	J:77603
Trmq3^DBA/1J/Trmq3^FVB/N (involves: DBA/1J * FVB/N)	abnormal CD4-positive, alpha beta T cell morphology	J:116665
Trmq3^FVB/N/? (involves: DBA/1J * FVB/N)	abnormal CD4-positive, alpha beta T cell morphology	J:94347
Trmq3^FVB/N/? (involves: DBA/1J * FVB/N)	abnormal T cell proliferation	J:94347
Trmq3^FVB/N/Trmq3^FVB/N (involves: DBA/1J * FVB/N)	abnormal CD4-positive, alpha beta T cell morphology	J:116665
Trmq4^RIIIS/J/Trmq4^RIIIS/J Trmq5^RIIIS/J/Trmq5^RIIIS/J (involves: B10.RIII * RIIIS/J)	abnormal CD4-positive, alpha beta T cell morphology	J:95848
Trmt2a^{tm2b(EUCOMM)Wtsi}/Trmt2a^{tm2b(EUCOMM)Wtsi} (C57BL/6N-Trmt2a^{tm2b(EUCOMM)Wtsi}/Wtsi)	decreased leukocyte cell number	J:211773
Trp53^Bbl/Trp53⁺ (C57BL/6JSfdAnu-Trp53^Bbl/Anu)	increased T cell derived lymphoma incidence	J:104190
Trp53^bhy/Trp53⁺ (C57BL/6JSfdAnu-Trp53^bhy/Anu)	increased T cell derived lymphoma incidence	J:104190
Trp53^tm1.1Awbr/Trp53^tm1.1Awbr (involves: C57BL/6)	decreased thymocyte apoptosis	J:173271
	increased pro-B cell number	J:169434
	increased T cell derived lymphoma incidence	J:173271
Trp53^tm1.1Manf/Trp53^tm1.1Manf (Not Specified)	abnormal abdominal lymph node morphology	J:201153
	abnormal spleen morphology	J:201153
	abnormal spleen white pulp morphology	J:201153
	abnormal thymus morphology	J:201153
	decreased neutrophil cell number	J:201153
	small spleen	J:201153
	small thymus	J:201153
Trp53^tm1.1Manf/Trp53^tm1.1Manf (involves: C57BL/6J)	abnormal abdominal lymph node morphology	J:201153
	abnormal spleen morphology	J:201153
	abnormal spleen white pulp morphology	J:201153
	abnormal thymus morphology	J:201153
	decreased neutrophil cell number	J:201153
	small spleen	J:201153
	small thymus	J:201153
Trp53^tm1.1Thst/Trp53⁺ (involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)	spleen hyperplasia	J:198482
Trp53^tm1.1Thst/Trp53^tm1.1Thst (involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)	decreased thymocyte apoptosis	J:198482
	immune system phenotype	J:198482
	increased T cell derived lymphoma incidence	J:198482
	spleen hyperplasia	J:198482
Trp53^tm1.1Tldo/Trp53^tm1.1Tldo (involves: 129S2/SvPas * BALB/c * C57BL/6)	increased thymocyte apoptosis	J:199308
Trp53^tm1.1Umol/Trp53^tm1.1Umol (involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NTac)	increased T cell derived lymphoma incidence	J:228632
Trp53^tm1.1Wgu/Trp53^tm1.1Wgu (involves: 129S6/SvEvTac * C57BL/6)	decreased thymocyte apoptosis	J:186159
Trp53^tm1.2Awbr/Trp53⁺ (involves: C57BL/6)	abnormal lymphocyte morphology	J:173271
	abnormal Peyer's patch morphology	J:173271
	increased inflammatory response	J:173271
	liver inflammation	J:173271
Trp53^tm1.2Awbr/Trp53^tm1.2Awbr (involves: C57BL/6)	abnormal lymphocyte morphology	J:173271
	abnormal Peyer's patch morphology	J:173271
	adipose tissue inflammation	J:173271
	decreased thymocyte apoptosis	J:173271
	enlarged spleen	J:173271
	increased circulating interferon-gamma level	J:173271
	increased circulating interleukin-3 level	J:173271
	increased circulating interleukin-5 level	J:173271
	increased circulating interleukin-6 level	J:173271
	increased circulating tumor necrosis factor level	J:173271
	increased inflammatory response	J:173271
	increased splenocyte proliferation	J:173271
	increased T cell derived lymphoma incidence	J:173271
	liver inflammation	J:173271
	lung inflammation	J:173271
Trp53^tm1Brd/Trp53^tm1Brd (involves: 129S7/SvEvBrd)	abnormal thymus physiology	J:175018
Trp53^tm1Brd/Trp53^tm1Brd (involves: 129S7/SvEvBrd)	decreased thymocyte apoptosis	J:186159
Trp53^tm1Brd/Trp53^tm1Brd (involves: 129S7/SvEvBrd * C57BL/6)	increased T cell derived lymphoma incidence	J:126497
Trp53^tm1Brd/Trp53^tm1Brd Tg(Lck-cre)1Cwi/0 (involves: 129S7/SvEvBrd)	increased T cell derived lymphoma incidence	J:157041
Trp53^tm1Brd/Trp53^tm1Brd Tg(Nes-cre)1Kln/0 (involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * SJL)	increased T cell derived lymphoma incidence	J:109585
Trp53^tm1Brd/Trp53^tm1Brd Trp73^tm2Mak/Trp73^tm2Mak (involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J)	decreased thymocyte apoptosis	J:157905
Trp53^tm1Brd/Trp53^tm1Ldo (involves: 129S7/SvEvBrd * C57BL/6)	increased T cell derived lymphoma incidence	J:73757
Trp53^tm1Brd/Trp53^tm8Xu (involves: 129S7/SvEvBrd)	decreased leukocyte cell number	J:170216
Trp53^tm1Gev/Trp53^tm1Gev (involves: 129P2/OlaHsd * C57BL/6)	increased T cell derived lymphoma incidence	J:99305
Trp53^tm1Glo/Trp53^tm1Glo (involves: 129S7/SvEvBrd * C57BL/6)	increased T cell derived lymphoma incidence	J:61683
Trp53^tm1Glo/Trp53^tm1Glo (involves: 129S7/SvEvBrd * C57BL/6J)	decreased thymocyte apoptosis	J:172038
Trp53^tm1Glo/Trp53^tm4Glo (involves: 129S7/SvEvBrd * C57BL/6)	increased T cell derived lymphoma incidence	J:171821
Trp53^tm1Holl/Trp53^tm7.1Xu (involves: 129P2/OlaHsd)	decreased thymocyte apoptosis	J:160414
Trp53^tm1Ldo/Trp53⁺ (involves: 129S7/SvEvBrd * C57BL/6)	decreased spleen weight	J:73757
Trp53^tm1Ldo/Trp53⁺ (involves: 129S7/SvEvBrd * C57BL/6)	spleen hypoplasia	J:73757
Trp53^tm1Sia/Trp53^tm1Sia (involves: C57BL/6 * CBA)	increased T cell derived lymphoma incidence	J:36762
Trp53^tm1Sia/Trp53^tm1Sia (involves: C57BL/6NCrlj * CBA/JNCrlj)	increased leukocyte cell number	J:233347
	increased spleen weight	J:233347
	increased T cell derived lymphoma incidence	J:233347
	increased thymus weight	J:233347
Trp53^tm1Thst/Trp53⁺ (involves: 129S1/Sv * 129X1/SvJ)	spleen hyperplasia	J:198482
Trp53^tm1Thst/Trp53^tm1.1Thst (involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)	spleen hyperplasia	J:198482
Trp53^tm1Thst/Trp53^tm1Thst (involves: 129S1/Sv * 129X1/SvJ)	decreased thymocyte apoptosis	J:198482
	increased T cell derived lymphoma incidence	J:198482
Trp53^tm1Tyj/Trp53⁺ (involves: 129S2/SvPas)	decreased thymocyte apoptosis	J:158953
Trp53^tm1Tyj/Trp53⁺ (involves: 129S2/SvPas * C57BL/6 * CBA)	decreased thymocyte apoptosis	J:80311
Trp53^tm1Tyj/Trp53⁺ Trp63^tm1Fmc/Trp63⁺ (involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)	increased T cell derived lymphoma incidence	J:98958
Trp53^tm1Tyj/Trp53⁺ Trp73^tm1Fmc/Trp73⁺ (involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)	increased T cell derived lymphoma incidence	J:98958
Trp53^tm1Tyj/Trp53⁺ Xrcc2^tm1Pmc/Xrcc2^tm1Pmc (involves: 129S1/Sv * 129S2/SvPas * C57BL/6)	increased T cell derived lymphoma incidence	J:111068
Trp53^tm1Tyj/Trp53^tm1.1Umol (involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6 * C57BL/6NTac)	increased T cell derived lymphoma incidence	J:228632
Trp53^tm1Tyj/Trp53^tm1Tyj (involves: 129S2/SvPas * C57BL/6)	increased T cell derived lymphoma incidence	J:87501, J:17728
Trp53^tm1Tyj/Trp53^tm1Tyj (involves: 129S2/SvPas)	decreased splenocyte apoptosis	J:195018
	decreased T cell apoptosis	J:109354
	decreased thymocyte apoptosis	J:158953, J:195018, J:126920
	increased T cell derived lymphoma incidence	J:251434, J:221224, J:88120, J:95316
Trp53^tm1Tyj/Trp53^tm1Tyj (involves: 129S2/SvPas * C57BL/6 * CBA)	decreased thymocyte apoptosis	J:80311
Trp53^tm1Tyj/Trp53^tm1Tyj Commd10^{Tg(Vav1-icre)A2Kio}/Commd10⁺ (involves: 129S2/SvPas * C57BL/6N * C57BL/10 * CBA/Ca)	abnormal interleukin secretion	J:305794
Trp53^tm1Tyj/Trp53^tm1Tyj Riok2^{tm1c(KOMP)Wtsi}/Riok2⁺ Commd10^{Tg(Vav1-icre)A2Kio}/Commd10⁺ (involves: 129S2/SvPas * C57BL/6N * C57BL/10 * CBA/Ca)	immune system phenotype	J:305794
Trp53^tm1Tyj/Trp53^tm1Tyj Xrcc2^tm1Pmc/Xrcc2^tm1Pmc (involves: 129S1/Sv * 129S2/SvPas * C57BL/6)	increased T cell derived lymphoma incidence	J:111068
Trp53^tm1Tyj/Trp53^tm1Tyj Xrcc4^tm1Fwa/Xrcc4^tm1Fwa (involves: 129P2/OlaHsd * 129S2/SvPas)	abnormal lymphopoiesis	J:61973
Trp53^tm1Tyj/Trp53^tm2.1Tyj (involves: 129S2/SvPas * 129S4/SvJae)	increased T cell derived lymphoma incidence	J:95316
Trp53^tm1Tyj/Trp53^tm2.1Umol (involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6 * C57BL/6NTac)	increased T cell derived lymphoma incidence	J:228632
Trp53^tm1Tyj/Trp53^tm3.1Tyj (involves: 129S2/SvPas * 129S4/SvJae)	increased T cell derived lymphoma incidence	J:95316
Trp53^tm1Xu/Trp53^tm1Xu (involves: 129S4/SvJae)	abnormal thymocyte apoptosis	J:86185
Trp53^tm1Yjc/Trp53^tm1Yjc (B6.129S1-Trp53^tm1Yjc)	abnormal spleen marginal zone morphology	J:195018
	abnormal spleen white pulp morphology	J:195018
	decreased splenocyte apoptosis	J:195018
	enlarged spleen	J:195018
	immune system phenotype	J:195018
Trp53^tm2.1Snj/Trp53^tm2.1Snj (involves: 129S4/SvJae * C57BL/6)	abnormal thymus physiology	J:175018
Trp53^tm2.1Thst/Trp53^tm2.1Thst (involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)	increased T cell derived lymphoma incidence	J:282255
Trp53^tm2.1Umol/Trp53^tm2.1Umol (involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NTac)	increased T cell derived lymphoma incidence	J:228632
Trp53^tm2.1Wgu/Trp53^tm2.1Wgu (involves: 129S6/SvEvTac * C57BL/6)	decreased thymocyte apoptosis	J:186159
Trp53^tm2Thst/Trp53^tm2.1Thst (involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)	increased T cell derived lymphoma incidence	J:282255
Trp53^tm2Wahl/Trp53^tm2Wahl (involves: 129S4/SvJae * C57BL/6)	decreased leukocyte cell number	J:174375
	decreased spleen red pulp amount	J:174375
Trp53^tm2Xu/Trp53^tm2Xu (involves: 129S6/SvEvTac)	decreased T cell apoptosis	J:109354
Trp53^tm2Xu/Trp53^tm2Xu (involves: 129S6/SvEvTac)	decreased T cell proliferation	J:109354
Trp53^tm3.1Glo/Trp53⁺ (B6.129S7-Trp53^tm3.1Glo)	hepatosplenomegaly	J:317504
	increased leukocyte cell number	J:317504
	increased T cell derived lymphoma incidence	J:317504
Trp53^tm3.1Holl/Trp53^tm3.1Holl (Not Specified)	increased thymocyte apoptosis	J:191183
Trp53^tm4Glo/Trp53^tm4Glo (involves: 129S7/SvEvBrd * C57BL/6)	increased T cell derived lymphoma incidence	J:171821
Trp53^tm4Xu/Trp53^tm4Xu (Not Specified)	increased T cell derived lymphoma incidence	J:126497
Trp53^tm6Xu/Trp53^tm6Xu Tg(Lck-cre)1Cwi/0 (involves: 129S4/SvJae)	increased T cell derived lymphoma incidence	J:157041
Trp53^tm7.1Xu/Trp53⁺ (Not Specified)	abnormal thymus physiology	J:160414
Trp53^tm7.1Xu/Trp53^tm7.1Xu (Not Specified)	abnormal thymus physiology	J:160414
Trp53^tm7.1Xu/Trp53^tm7.1Xu (Not Specified)	decreased thymocyte apoptosis	J:160414
Trp53bp1^{Gt(OST94324)Lex}/Trp53bp1^{Gt(OST94324)Lex} (involves: 129S5/SvEvBrd)	abnormal T cell differentiation	J:83164
	decreased mature B cell number	J:83164
	decreased T cell number	J:83164
	small thymus	J:83164
	thymus hypoplasia	J:83164
Trp53bp1^m2Btlr/Trp53bp1^m2Btlr (C57BL/6J-Trp53bp1^m2Btlr)	decreased B cell number	J:254841
	decreased CD8-positive, naive alpha-beta T cell number	J:254841
	decreased IgD level	J:254841
	decreased IgG level	J:254841
	impaired humoral immune response	J:254841
	increased central memory CD4-positive, alpha-beta T cell number	J:254841
Trp53bp1^m3Btlr/Trp53bp1^m3Btlr (C57BL/6J-Trp53bp1^m3Btlr)	decreased IgD level	J:254848
Trp53bp1^m4Btlr/Trp53bp1^m4Btlr (C57BL/6J-Trp53bp1^m4Btlr)	decreased IgD level	J:254852
Trp53bp1^m5Btlr/Trp53bp1^m5Btlr (C57BL/6J-Trp53bp1^m5Btlr)	decreased IgD level	J:272848
Trp53bp1^tm1Jc/Trp53bp1^tm1Jc (involves: 129 * C57BL/6)	decreased CD4-positive, alpha-beta T cell number	J:82512
	increased double-negative T cell number	J:82512
	increased T cell derived lymphoma incidence	J:82512
	thymus hypoplasia	J:82512
Trp53bp1^tm1Jc/Trp53bp1^tm1Jc (involves: 129)	abnormal class switch recombination	J:194603, J:231089, J:307190
Trp53bp2^tm1Cdlo/Trp53bp2⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal T cell physiology	J:146764
Trp53bp2^tm1Cdlo/Trp53bp2⁺ Tg(EmuSR-tTa)83Bop/0 Tg(tetO-MYC)36aBop/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)	increased T cell derived lymphoma incidence	J:146764
Trp53bp2^tm1Xlu/Trp53bp2⁺ (involves: 129S6/SvEvTac * C57BL/6J)	increased T cell derived lymphoma incidence	J:108701
Trp53bp2^tm1Xlu/Trp53bp2^tm1Xlu (C.129S6-Trp53bp2^tm1Xlu)	small thymus	J:240594
Trp53inp1^tm1Acar/Trp53inp1^tm1Acar (involves: 129/Sv * C57BL/6)	increased susceptibility to induced colitis	J:118867
	large intestinal inflammation	J:118867
Trp53inp2^em1(IMPC)Mbp/Trp53inp2^em1(IMPC)Mbp (C57BL/6N-Trp53inp2^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
Trp63^tm1Fmc/Trp63⁺ Trp73^tm1Fmc/Trp73⁺ (involves: 129S4/SvJae * C57BL/6)	increased T cell derived lymphoma incidence	J:98958
Trp63^tm2Brd/Trp63⁺ (involves: 129S7/SvEvBrd)	enlarged lymph nodes	J:100483
	increased susceptibility to infection	J:100483
	kidney inflammation	J:100483
	uterine cervix inflammation	J:100483
Trp73^em1(IMPC)H/Trp73⁺ (C57BL/6NTac-Trp73^em1(IMPC)H/H)	decreased spleen weight	J:211773
Trp73^tm1Fmc/Trp73⁺ (involves: 129S4/SvJae * C57BL/6)	increased T cell derived lymphoma incidence	J:98958
Trp73^tm1Fmc/Trp73^tm1Fmc (involves: 129S4/SvJae)	chronic inflammation	J:60896
	conjunctivitis	J:60896
	increased susceptibility to bacterial infection	J:60896
	increased susceptibility to otitis media	J:60896
	rhinitis	J:60896
	sinus inflammation	J:60896
Trp73^tm1Mak/Trp73⁺ (involves: 129P2/OlaHsd * C57BL/6J)	increased T cell derived lymphoma incidence	J:142848
Trp73^tm1Mak/Trp73^tm1Mak (involves: 129P2/OlaHsd * C57BL/6J)	increased T cell derived lymphoma incidence	J:142848
Trp73^tm2Mak/Trp73^tm2Mak (either: B6.129P2-Trp73^tm2Mak or (involves: 129P2/OlaHsd * C57BL/6J))	increased thymocyte apoptosis	J:157905
Trpa1^tm1Jul/Trpa1⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal acute inflammation	J:115886
Trpc1^em1(IMPC)H/Trpc1^em1(IMPC)H (C57BL/6N-Trpc1^em1(IMPC)H/H)	increased spleen weight	J:211773
Trpc3^tm1.2Akon/Trpc3^tm1.2Akon (involves: 129S/SvEv)	immune system phenotype	J:190105
Trpm2^tm1.1Alp/Trpm2^tm1.1Alp (B6.129P2-Trpm2^tm1.1Alp)	decreased circulating interferon-gamma level	J:174397
	decreased circulating interleukin-12 level	J:174397
	decreased circulating interleukin-12b level	J:174397
	decreased interferon-gamma secretion	J:174397
	decreased interleukin-12 secretion	J:174397
	increased susceptibility to bacterial infection	J:174397
	increased susceptibility to bacterial infection induced morbidity/mortality	J:174397
Trpm2^tm1Lhj/Trpm2^tm1Lhj (Not Specified)	abnormal macrophage morphology	J:202791
Trpm2^tm1Lhj/Trpm2^tm1Lhj (Not Specified)	abnormal macrophage physiology	J:202791
Trpm2^tm1Yamo/Trpm2^tm1Yamo (involves: 129S4/SvJae * C57BL/6J)	abnormal interferon level	J:137676
	abnormal interleukin level	J:137676
	abnormal leukocyte physiology	J:137676
	abnormal macrophage physiology	J:137676
	decreased inflammatory response	J:137676
	impaired neutrophil recruitment	J:137676
Trpm4^tm1.1Knt/Trpm4^tm1.1Knt (Not Specified)	abnormal dendritic cell physiology	J:140991
Trpm4^tm1.1Knt/Trpm4^tm1.1Knt (Not Specified)	decreased dendritic cell number	J:140991
Trpm4^tm1.1Knt/Trpm4^tm1.1Knt Trpm5^tm1Csz/Trpm5^tm1Csz (involves: 129S1/Sv * 129X1/SvJ)	abnormal dendritic cell physiology	J:140991
	decreased dendritic cell number	J:140991
Trpm4^tm1.1Mfre/Trpm4^tm1.1Mfre (involves: 129S1/Sv * 129X1/SvJ * BALB/cJ)	increased susceptibility to type I hypersensitivity reaction	J:118679
Trpm7^tm1Agry/Trpm7⁺ (involves: 129)	increased susceptibility to type IV hypersensitivity reaction	J:205665
Trpm7^tm1Clph/Trpm7^tm1.1Clph Tg(Lck-cre)548Jxm/0 (involves: 129S4/SvJae * C57BL/6 * CBA)	abnormal T cell differentiation	J:140630
	abnormal T cell physiology	J:140630
	abnormal thymus cell ratio	J:140630
	abnormal thymus corticomedullary boundary morphology	J:140630
	abnormal thymus medulla morphology	J:140630
	abnormal thymus morphology	J:140630
	decreased T cell number	J:140630
	decreased thymocyte number	J:140630
Trps1^m1Anu/Trps1^m1Anu (C57BL/6NCrl-Trps1^m1Anu/Anu)	immune system phenotype	J:104190
Trpv1^tm1Jul/Trpv1^tm1Jul (involves: 129X1/SvJ * C57BL/6)	decreased susceptibility to endotoxin shock	J:104828
Trpv1^tm1Jul/Trpv1^tm1Jul (B6.129X1-Trpv1^tm1Jul)	abnormal chemokine secretion	J:154624
	increased interleukin-6 secretion	J:154624
	increased tumor necrosis factor secretion	J:154624
	kidney inflammation	J:154624
Trpv2^tm1Mijc/Trpv2^tm1Mijc (involves: 129S6/SvEvTac * C57BL/6)	impaired macrophage chemotaxis	J:158505
	impaired macrophage phagocytosis	J:158505
	increased susceptibility to bacterial infection	J:158505
	increased susceptibility to bacterial infection induced morbidity/mortality	J:158505
Trpv3^Nh/Trpv3⁺ (involves: DS)	dermatitis	J:42153
Trpv3^Nh/Trpv3⁺ (involves: DS)	increased susceptibility to bacterial infection	J:42153
Trpv3^tm1.2Clph/Trpv3^tm1.2Clph (involves: 129S4/SvJae * 129S4/SvJaeSor * C57BL/6 * C57BL/6J * CBA)	erythroderma	J:164741
Trpv5^Hcalc1/Trpv5⁺ (involves: C3H/HeH * C57BL/6J)	kidney inflammation	J:196612
Trpv5^Hcalc1/Trpv5^Hcalc1 (involves: C3H/HeH * C57BL/6J)	kidney inflammation	J:196612
Trpv5^m1Btlr/Trpv5^m1Btlr (C57BL/6J-Trpv5^m1Btlr)	increased susceptibility to induced colitis	J:192586
Trpv5^m1Btlr/Trpv5^m1Btlr (C57BL/6J-Trpv5^m1Btlr)	intestinal inflammation	J:192586
Trpv5^tm1Bind/Trpv5^tm1Bind (involves: 129 * C57BL/6)	increased osteoclast cell number	J:86949
Try10^em1(IMPC)J/Try10^em1(IMPC)J (C57BL/6NJ-Try10^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
Ts(16C-tel)1Cje/0 (involves: C57BL/6J * Rb(11.16)2H * Rb(16.17)32Lub)	abnormal spleen B cell follicle morphology	J:174270
	abnormal spleen B cell follicle shape	J:241597
	abnormal spleen red pulp morphology	J:174270
	increased spleen B cell follicle size	J:241597
Ts(17¹⁶)65Dn/0 (involves: C3H/HeJ * C57BL/6J * DBA/2J)	abnormal spleen B cell follicle morphology	J:174270
	abnormal spleen B cell follicle shape	J:174270
	abnormal spleen red pulp morphology	J:174270
	increased spleen B cell follicle size	J:174270
Tsc1^{em1(IMPC)Ccpcz}/Tsc1⁺ (C57BL/6NCrl-Tsc1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Tsc22d2^em1(IMPC)Tcp/Tsc22d2^em1(IMPC)Tcp (C57BL/6NCrl-Tsc22d2^em1(IMPC)Tcp/Cmmr)	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
Tsc22d3^tm1.2Efmd/Y (Not Specified)	abnormal susceptibility to autoimmune disorder	J:201728
	abnormal T cell subpopulation ratio	J:201728
	immune system phenotype	J:201728
	increased interferon-gamma secretion	J:201728
	increased interleukin-17 secretion	J:201728
	increased susceptibility to type IV hypersensitivity reaction	J:201728
Tsc22d3^tm1.2Hum/Y (involves: 129S1/SvImJ)	abnormal thymus cell ratio	J:223992
	decreased DN3 thymocyte number	J:223992
	decreased thymus weight	J:223992
	increased DN4 thymocyte number	J:223992
Tshr^hyt/Tshr^hyt (CBy.RF-Tshr^hyt/J)	decreased B cell number	J:111014
Tshr^hyt/Tshr^hyt (CBy.RF-Tshr^hyt/J)	increased pro-B cell number	J:111014
Tsil^{Tg(Myc)12ALvn}/Tsil^{Tg(Myc)12ALvn} (involves: C57BL/6 * SJL/J)	increased double-positive T cell number	J:33857
Tsiq1^BALB/cOla/Tsiq1^BALB/cOla (involves: BALB/cOla * C57BL/6Ola)	increased interleukin-4 secretion	J:99489
Tsiq1^BALB/cOla/Tsiq1^BALB/cOla Tsiq2^BALB/cOla/Tsiq2^BALB/cOla Tsiq3^BALB/cOla/Tsiq3^C57BL/6Ola (involves: BALB/cOla * C57BL/6Ola)	increased interleukin-4 secretion	J:99489
Tsiq2^BALB/cOla/Tsiq2^BALB/cOla (involves: BALB/cOla * C57BL/6Ola)	increased interleukin-4 secretion	J:99489
Tsiq3^BALB/cOla/Tsiq3^C57BL/6Ola (involves: BALB/cOla * C57BL/6Ola)	increased interleukin-4 secretion	J:99489
Tslp^{tm1(KOMP)Vlcg}/Tslp^{tm1(KOMP)Vlcg} (involves: C57BL/6 * C57BL/6NTac)	abnormal immune system physiology	J:187770
	abnormal immunoglobulin level	J:187770
	abnormal T-helper 2 cell differentiation	J:187770
	decreased acute inflammation	J:187770
	decreased circulating interleukin-4 level	J:187770
	increased interferon-gamma secretion	J:187770
	respiratory system inflammation	J:187770
Tslp^tm1.1Pcn/Tslp^tm1.1Pcn Tg(KRT14-cre)1Ipc/0 (involves: 129 * C57BL/6 * SJL)	decreased eosinophil cell number	J:146511
	decreased IgE level	J:146511
	decreased lymphocyte cell number	J:146511
Tslp^tm1Mak/Tslp^tm1Mak (B6.Cg-Tslp^tm1Mak)	colitis	J:175844
Tslp^tm1Mak/Tslp^tm1Mak (B6.Cg-Tslp^tm1Mak)	immune system phenotype	J:175844
Tslp^tm1Sfz/Tslp^tm1Sfz (C.129(Cg)-Tslp^tm1Sfz)	immune system phenotype	J:199558
Tslp^tm1Sfz/Tslp^tm1Sfz (involves: 129)	abnormal interleukin secretion	J:197193
	abnormal T-helper 2 physiology	J:197193
	increased interleukin-5 secretion	J:197193
	increased interleukin-13 secretion	J:197193
Tsn^{Gt(OST63223)Lex}/Tsn^{Gt(OST63223)Lex} (involves: 129S5/SvEvBrd * C57BL/6J)	immune system phenotype	J:85466
Tspan2^tm1Hbw/Tspan2^tm1Hbw (C57BL/6-Tspan2^tm1Hbw)	microgliosis	J:201143
Tspan9^em1Tshu/Tspan9^em1Tshu (C57BL/6-Tspan9^em1Tshu)	abnormal macrophage morphology	J:307067
	abnormal neutrophil morphology	J:307067
	decreased neutrophil cell number	J:307067
Tspan32^em1(IMPC)Mbp/Tspan32^em1(IMPC)Mbp (C57BL/6N-Tspan32^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Tspan32^{Gt(pMS-1)1Jmt}/Tspan32^{Gt(pMS-1)1Jmt} (involves: 129S1/Sv)	increased T cell proliferation	J:78033
Tspan33^tm1Stsa/Tspan33^tm1Stsa (involves: 129S1/Sv * 129X1/SvJ)	abnormal spleen morphology	J:143158
	abnormal splenic cell ratio	J:143158
	enlarged spleen	J:143158
	increased monocyte cell number	J:143158
Tspo^tm1.1Guwu/Tspo^tm1.1Guwu (involves: C57BL/6)	increased NK cell number	J:219189
Tssk5^{tm1.1(KOMP)Vlcg}/Tssk5^{tm1.1(KOMP)Vlcg} (C57BL/6N-Tssk5^{tm1.1(KOMP)Vlcg}/J)	decreased leukocyte cell number	J:211773
Tst^{tm1(KOMP)Vlcg}/Tst^{tm1(KOMP)Vlcg} (C57BL/6N-Tst^{tm1(KOMP)Vlcg}/Ucd)	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
Tstd1^em1(IMPC)J/Tstd1^em1(IMPC)J (C57BL/6NJ-Tstd1^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
Ttc7^fsn-Jic/Ttc7^fsn-Jic (C3.INT-Ttc7^fsn-Jic)	decreased spleen white pulp amount	J:115742
	decreased thymus weight	J:115742
	increased spleen red pulp amount	J:115742
	increased spleen weight	J:115742
	liver inflammation	J:115742
Ttc7^fsn/Ttc7^fsn (CByJ.A-Ttc7^fsn)	enlarged spleen	J:29200, J:30519
	small thymus	J:29200
	thymus cortex hypoplasia	J:29200
Ttc7^fsn/Ttc7^fsn (involves: A/J)	stomach inflammation	J:2777
Ttc7^fsn/Ttc7^fsn (involves: A/J * BALB/cByJ)	increased dendritic epidermal T cell number	J:14506
Ttc7^fsn/Ttc7^fsn (involves: A/J * BALB/cByJ)	increased Langerhans cell number	J:14506
Ttc7^hea/Ttc7^hea (CFO)	enlarged spleen	J:7515
Ttc7^hea/Ttc7^hea (CFO)	increased leukocyte cell number	J:7515
Ttc9^tm1Vcl/Ttc9⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	thymus hyperplasia	J:241703
Ttc9^tm1Vcl/Ttc9^tm1Vcl (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	increased spleen weight	J:241703
	increased thymus weight	J:241703
	thymus hyperplasia	J:241703
Ttc28^{tm1b(EUCOMM)Hmgu}/Ttc28^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Ttc28^{tm1b(EUCOMM)Hmgu}/Tcp)	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
Ttc39aos1^em1Bcgen/Ttc39aos1^em1Bcgen (involves: C57BL/6N)	increased cytokine level	J:307097
Ttc39aos1^em1Bcgen/Ttc39aos1^em1Bcgen (involves: C57BL/6N)	increased susceptibility to induced pancreatitis	J:307097
Ttc39aos1^tm1Kaf/Ttc39aos1^tm1Kaf (C57BL/6-Ttc39aos1^tm1Kaf)	increased susceptibility to endotoxin shock	J:234649
Tti1^em1(IMPC)J/Tti1⁺ (C57BL/6NJ-Tti1^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
Tti2^{tm1b(KOMP)Wtsi}/Tti2⁺ (C57BL/6N-Tti2^{tm1b(KOMP)Wtsi}/Ics)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Ttk^em1(IMPC)J/Ttk⁺ (C57BL/6NJ-Ttk^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
Ttll1^{Gt(OST372941)Lex}/Ttll1^{Gt(OST372941)Lex} (involves: 129S5/SvEvBrd * C57BL/6)	increased susceptibility to otitis media	J:186050
	rhinitis	J:186050
Ttll1^tm1Seto/Ttll1^tm1Seto (involves: 129S/SvEv * C57BL/6)	rhinosinusitis	J:161297
Ttll11^{em1(IMPC)Ccpcz}/Ttll11^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Ttll11^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
Ttn^mdm/Ttn^mdm (Not Specified)	myositis	J:14016
Ttn^tm1.1Isrd/Ttn^tm1.1Isrd (involves: 129S2/SvPas * C57BL/6)	myositis	J:165576
Tub^tub/Tub^tub (C57BL/6J-Tub^tub)	abnormal Langerhans cell physiology	J:13772
Tubal3^em1(IMPC)J/Tubal3^em1(IMPC)J (C57BL/6NJ-Tubal3^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
Tulp4^{tm1a(KOMP)Wtsi}/Tulp4⁺ (involves: C57BL/6N * C57BL/6NRj)	absent connection between subcutaneous lymph vessels and lymph sac	J:344151
	immune system phenotype	J:344151
Tulp4^{tm1a(KOMP)Wtsi}/Tulp4^{tm1a(KOMP)Wtsi} (involves: C57BL/6N * C57BL/6NRj)	abnormal thymus topology	J:344151
Tusc2^tm1Avi/Tusc2⁺ (involves: 129S1/Sv * C57BL/6J)	arteritis	J:119985
	glomerulonephritis	J:119985
	increased anti-nuclear antigen antibody level	J:119985
	increased susceptibility to autoimmune disorder	J:119985
Tusc2^tm1Avi/Tusc2^tm1Avi (involves: 129S1/Sv * C57BL/6J)	abnormal NK cell differentiation	J:119985
	arteritis	J:119985
	decreased interleukin-15 secretion	J:119985
	decreased NK cell number	J:119985
	glomerulonephritis	J:119985
	increased anti-nuclear antigen antibody level	J:119985
	increased leukocyte cell number	J:119985
	increased susceptibility to autoimmune disorder	J:119985
Tusc2^tm1Avi/Tusc2^tm1Avi (involves: 129S1/Sv)	arteritis	J:309768
	chronic inflammation	J:309768
	decreased T cell proliferation	J:309768
	decreased thymocyte number	J:309768
	increased macrophage cell number	J:309768
	increased monocyte cell number	J:309768
	increased susceptibility to autoimmune disorder	J:309768
Tvp23b^em3Eetr/Tvp23b^em3Eetr (C57BL/6J-Tvp23b^em3Eetr)	increased susceptibility to induced colitis	J:340685
Tvp23b^m1Btlr/Tvp23b^m1Btlr (C57BL/6J-Tvp23b^m1Btlr)	increased susceptibility to induced colitis	J:340685
Twist2^tm1(cre)Dor/Twist2^tm1(cre)Dor (involves: 129/Sv * 129X1/SvJ)	abnormal interleukin level	J:81485
	abnormal spleen morphology	J:81485
	abnormal spleen white pulp morphology	J:81485
	abnormal thymus cortex morphology	J:81485
	abnormal thymus medulla morphology	J:81485
	abnormal thymus morphology	J:81485
	abnormal tumor necrosis factor level	J:81485
	thymus atrophy	J:81485
Twsg1^tm1Nosa/Twsg1^tm1Nosa (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell differentiation	J:82738
	abnormal spleen development	J:82738
	abnormal thymus development	J:82738
	decreased double-positive T cell number	J:82738
	decreased immature B cell number	J:82738
	decreased lymphocyte cell number	J:82738
	decreased pre-B cell number	J:82738
	decreased pro-B cell number	J:82738
	decreased spleen white pulp amount	J:82738
	decreased splenocyte number	J:82738
	decreased thymocyte number	J:82738
	increased granulocyte number	J:82738
	increased monocyte cell number	J:82738
	increased single-positive T cell number	J:82738
	increased thymocyte apoptosis	J:82738
	thymus atrophy	J:82738
Txk^tm1Pls/Txk^tm1Pls (involves: 129S6/SvEvTac)	abnormal cytokine secretion	J:54449
Txk^tm1Pls/Txk^tm1Pls (involves: 129S6/SvEvTac)	increased susceptibility to parasitic infection	J:54449
Txlna^{tm1b(EUCOMM)Hmgu}/Txlna⁺ (C57BL/6N-Txlna^{tm1b(EUCOMM)Hmgu}/H)	increased large unstained cell number	J:211773
Txlna^{tm1b(EUCOMM)Hmgu}/Txlna^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Txlna^{tm1b(EUCOMM)Hmgu}/H)	increased large unstained cell number	J:211773
	increased lymphocyte cell number	J:211773
Txndc2^tm1Lex/Txndc2^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6J)	decreased circulating interleukin-6 level	J:103485
Txnip^tm1Yu/Txnip^tm1Yu (involves: 129)	abnormal mesenteric lymph node morphology	J:96677
	abnormal NK cell morphology	J:96677
	abnormal NK cell physiology	J:96677
	decreased CD8-positive, alpha-beta T cell number	J:96677
	decreased NK cell number	J:96677
	decreased NK T cell number	J:96677
	increased lymphocyte cell number	J:96677
	increased regulatory T cell number	J:96677
	increased T cell proliferation	J:96677
Txnl1^em1(IMPC)Tcp/Txnl1^em1(IMPC)Tcp (C57BL/6NCrl-Txnl1^em1(IMPC)Tcp/Tcp)	increased monocyte cell number	J:211773
Tyk2^E775K/Tyk2^E775K (B10.D1-H2^q/SgJ)	abnormal T-helper 1 physiology	J:69051
	decreased IgG1 level	J:69051
	decreased IgG2a level	J:69051
	decreased IgG level	J:69051
	decreased interferon-gamma secretion	J:69051, J:120304
	decreased susceptibility to induced arthritis	J:69051
	increased circulating interleukin-12 level	J:120304
	increased susceptibility to parasitic infection	J:120304
Tyk2^tm1Biat/Tyk2^tm1Biat (involves: 129P2/OlaHsd * C57BL/6)	abnormal response to infection	J:116703
	decreased interferon-gamma secretion	J:65408
	decreased macrophage nitric oxide production	J:65408
	increased susceptibility to Herpesvirales infection	J:116703
	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:116703
	increased susceptibility to Riboviria infection	J:65408
	increased susceptibility to viral infection induced morbidity/mortality	J:65408
Tyk2^tm1Biat/Tyk2^tm1Biat (B6NCrl.129P2-Tyk2^tm1Biat)	increased susceptibility to Picornaviridae infection induced morbidity/mortality	J:187818
Tyk2^tm1Biat/Tyk2^tm1Biat (B6NCrl.129P2-Tyk2^tm1Biat)	increased susceptibility to Riboviria infection induced morbidity/mortality	J:187818
Tyk2^tm1Shmd/Tyk2^tm1Shmd (involves: 129P2/OlaHsd)	abnormal splenocyte physiology	J:65409
	abnormal T cell differentiation	J:65409
	abnormal T cell physiology	J:65409
	decreased interferon-gamma secretion	J:65409
Tyk2^{tm2b(EUCOMM)Hmgu}/Tyk2^{tm2b(EUCOMM)Hmgu} (C57BL/6N-Tyk2^{tm2b(EUCOMM)Hmgu}/Ieg)	decreased plasmacytoid dendritic cell number	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Tyk2^tm3.1Biat/Tyk2^tm3.1Biat (B6NCrl.129P2(C)-Tyk2^tm3.1Biat)	increased susceptibility to Picornaviridae infection induced morbidity/mortality	J:187818
	increased susceptibility to Riboviria infection induced morbidity/mortality	J:187818
Tymp^tm1Akiy/Tymp^tm1Akiy Upp1^tm1Akiy/Upp1^tm1Akiy (involves: 129X1/SvJ)	brain inflammation	J:78036
Tyro3^{em1(IMPC)Ccpcz}/Tyro3^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Tyro3^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
	increased eosinophil cell number	J:211773
Tyrobp^tm1.1Viv/Tyrobp^tm1.1Viv (involves: 129P2/OlaHsd * C57BL/6)	decreased uterine NK cell number	J:100668
Tyrobp^tm1.1Viv/Tyrobp^tm1.1Viv (involves: 129P2/OlaHsd * BALB/cJ * C57BL/6)	decreased susceptibility to type IV hypersensitivity reaction	J:64764
	impaired natural killer cell mediated cytotoxicity	J:64764
	increased dendritic cell number	J:64764
Tyrobp^tm1.1Viv/Tyrobp^tm1.1Viv (B6.129P2-Tyrobp^tm1.1Viv)	abnormal microglial cell morphology	J:95232
	abnormal myelopoiesis	J:95232
	abnormal osteoclast physiology	J:129304, J:95232
Tyrobp^tm1Lll/Tyrobp^tm1Lll (involves: 129P2/OlaHsd * C57BL/6)	abnormal osteoclast differentiation	J:89583
	decreased interferon-gamma secretion	J:64763
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:64763
	decreased T cell proliferation	J:64763
	immune system phenotype	J:64763
	impaired natural killer cell mediated cytotoxicity	J:64763
	increased dendritic cell number	J:64763
	increased natural killer cell mediated cytotoxicity	J:64763
Tyrobp^tm1Lll/Tyrobp^tm1Lll (B6.129P2-Tyrobp^tm1Lll)	abnormal NK T cell physiology	J:147867
Tyrobp^tm1Lll/Tyrobp^tm1Lll (B6.129P2-Tyrobp^tm1Lll)	decreased interferon-gamma secretion	J:147867
Tyrobp^tm1Lll/Tyrobp^tm1Lll (involves: 129P2/OlaHsd)	decreased susceptibility to induced arthritis	J:158811
Tyrobp^tm1Ttk/Tyrobp^tm1Ttk (involves: 129P2/OlaHsd * C57BL/6)	abnormal dendritic cell physiology	J:110786
	abnormal osteoclast morphology	J:81823
	abnormal osteoclast physiology	J:81823
Tyrobp^tm1Ttk/Tyrobp^tm1Ttk (B6.129P2-Tyrobp^tm1Ttk)	increased anti-double stranded DNA antibody level	J:177613
	increased autoantibody level	J:177613
	increased B cell proliferation	J:177613
	increased germinal center B cell number	J:177613
	increased IgG2a level	J:177613
	increased IgG3 level	J:177613
	increased interleukin-6 secretion	J:177613
	increased spleen germinal center number	J:177613
	increased spleen germinal center size	J:177613
Tyrobp^tm1Viv/Tyrobp^tm1Viv (B6.129P2-Tyrobp^tm1Viv)	increased susceptibility to Herpesvirales infection	J:124749
U2af2^em1(IMPC)J/U2af2⁺ (C57BL/6NJ-U2af2^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
U90926^em1Dnkv/U90926^em1Dnkv (C57BL6/J-U90926^em1Dnkv)	increased circulating interleukin-6 level	J:340649
	increased susceptibility to bacterial infection induced morbidity/mortality	J:340649
	increased susceptibility to endotoxin shock	J:340649
Uaca^tm1Kiy/Uaca^tm1Kiy (B6.129P2-Uaca^tm1Kiy)	abnormal Kupffer cell morphology	J:157049
	decreased dendritic cell number	J:157049
	increased tumor necrosis factor secretion	J:157049
	liver inflammation	J:157049
	lung inflammation	J:157049
Ubash3b^tm1Jni/Ubash3b^tm1Jni Ubash3a^tm1Jni/Ubash3a^tm1Jni (Not Specified)	abnormal cytokine secretion	J:89761
	increased mature B cell number	J:89761
	increased splenocyte number	J:89761
	increased susceptibility to experimental autoimmune encephalomyelitis	J:89761
	increased T cell proliferation	J:89761
Ubd^{tm1b(EUCOMM)Wtsi}/Ubd^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Ubd^{tm1b(EUCOMM)Wtsi}/Ccpcz)	abnormal thymus morphology	J:211773
	decreased memory-marker CD4-positive NK T cell number	J:211773
	increased CD4-positive, CD25-positive NK T cell number	J:211773
	small thymus	J:211773
Ubd^tm1Smwe/Ubd^tm1Smwe (B6.129S6-Ubd^tm1Smwe)	abnormal lymphocyte physiology	J:110321
Ubd^tm1Smwe/Ubd^tm1Smwe (B6.129S6-Ubd^tm1Smwe)	increased susceptibility to bacterial infection	J:110321
Ube2b^{tm1b(EUCOMM)Wtsi}/Ube2b⁺ (C57BL/6N-Ube2b^{tm1b(EUCOMM)Wtsi}/Ics)	decreased basophil cell number	J:211773
	decreased neutrophil cell number	J:211773
	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
Ube2i^em1(IMPC)J/Ube2i⁺ (C57BL/6NJ-Ube2i^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
Ube2j1^tm1.2Hpl/Ube2j1^tm1.2Hpl (involves: BALB/cJ * C57BL/6 * C57BL/6N * SJL)	immune system phenotype	J:218292
Ube2j2^{em1(IMPC)Rbrc}/Ube2j2^{em1(IMPC)Rbrc} (C57BL/6NJcl-Ube2j2^{em1(IMPC)Rbrc}/Rbrc)	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
	increased eosinophil cell number	J:211773
Ube2n^{em1(IMPC)Ccpcz}/Ube2n⁺ (C57BL/6N-Ube2n^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Ube2n^{Gt(OST374154)Lex}/Ube2n⁺ (involves: 129S5/SvEvBrd * C57BL/6)	abnormal leukocyte physiology	J:120846
	abnormal macrophage physiology	J:120846
	decreased B cell proliferation	J:120846
	decreased susceptibility to endotoxin shock	J:120846
	decreased T cell proliferation	J:120846
Ube2n^tm1Aki/Ube2n^tm1Aki Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal macrophage physiology	J:112287
Ube2s^tm1.1Smoc/Ube2s^tm1.1Smoc (involves: C57BL/6)	abnormal macrophage physiology	J:306461
	decreased susceptibility to Herpesvirales infection	J:306461
	decreased susceptibility to Picornaviridae infection	J:306461
	decreased susceptibility to Picornaviridae infection induced morbidity/mortality	J:306461
	decreased susceptibility to Riboviria infection	J:306461
	increased circulating interferon-alpha level	J:306461
	increased circulating interferon-beta level	J:306461
	increased circulating interleukin-6 level	J:306461
	increased circulating tumor necrosis factor level	J:306461
	increased interferon level	J:306461
	increased interferon-beta secretion	J:306461
Ube2u^{tm1e.1(KOMP)Wtsi}/Ube2u^{tm1e.1(KOMP)Wtsi} (C57BL/6N-Ube2u^{tm1e.1(KOMP)Wtsi}/H)	increased basophil cell number	J:211773
Ube2w^{tm1d(EUCOMM)Wtsi}/Ube2w^{tm1d(EUCOMM)Wtsi} (involves: 129 * C57BL/6N)	increased neutrophil cell number	J:230053
Ube3b^{Gt(RRJ142)Byg}/Ube3b^{Gt(RRJ142)Byg} (involves: 129P2/OlaHsd * CBA/Ca)	eye inflammation	J:203652
	lymphangiectasis	J:203652
Ube3c^{tm1b(EUCOMM)Hmgu}/Ube3c^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Ube3c^{tm1b(EUCOMM)Hmgu}/Rbrc)	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
Ube3c^{tm1b(EUCOMM)Hmgu}/Ube3c^{tm1b(EUCOMM)Hmgu} (C57BL/6NCrl-Ube3c^{tm1b(EUCOMM)Hmgu}/Rbrc)	decreased CD4-negative NK T cell number	J:211773
	decreased CD5-positive Ly6C-positive T cell number	J:211773
	decreased Ly6C-positive immature NK cell number	J:211773
	decreased Ly6C-positive NK T cell number	J:211773
	immune system phenotype	J:211773
	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
Ube4a^em1(IMPC)Tcp/Ube4a^em1(IMPC)Tcp (C57BL/6N-Ube4a^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Ubl4b^{em1(IMPC)Ccpcz}/Ubl4b^{em1(IMPC)Ccpcz} (C57BL/6N-Ubl4b^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Ubl7^em1Fanm/Ubl7^em1Fanm (involves: C57BL/6J)	increased susceptibility to Orthomyxoviridae infection	J:349835
	increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:349835
	increased susceptibility to Riboviria infection	J:349835
	increased susceptibility to Riboviria infection induced morbidity/mortality	J:349835
Ubox5^{tm1b(EUCOMM)Hmgu}/Ubox5^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Ubox5^{tm1b(EUCOMM)Hmgu}/Tcp)	increased neutrophil cell number	J:211773
Ubqln4^em1(IMPC)Mbp/Ubqln4^em1(IMPC)Mbp (C57BL/6NCrl-Ubqln4^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	small spleen	J:211773
Ubr7^em1(IMPC)Tcp/Ubr7^em1(IMPC)Tcp (C57BL/6NCrl-Ubr7^em1(IMPC)Tcp/Tcp)	increased leukocyte cell number	J:211773
Ubtf^em1(IMPC)Mbp/Ubtf⁺ (C57BL/6NCrl-Ubtf^em1(IMPC)Mbp/Mmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Ubxn11^em1(IMPC)J/Ubxn11^em1(IMPC)J (C57BL/6NJ-Ubxn11^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
Uchl3^tm1Tilg/Uchl3^tm1Tilg (involves: 129S1/Sv * C57BL/6)	immune system phenotype	J:61093
Ucp2^tm1Rcq/Ucp2^tm1Rcq (involves: 129X1/SvJ * C57BL/6J)	abnormal macrophage physiology	J:66262
	decreased susceptibility to bacterial infection	J:66262
	decreased susceptibility to infection induced morbidity/mortality	J:66262
	decreased susceptibility to parasitic infection	J:66262
Uevld^{tm1a(EUCOMM)Wtsi}/Uevld^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Uevld^{tm1a(EUCOMM)Wtsi}/Wtsi)	decreased leukocyte cell number	J:211773
Ufl1^{tm1c(EUCOMM)Wtsi}/Ufl1^{tm1c(EUCOMM)Wtsi} Gt(ROSA)26Sor^{tm1(cre/ERT2)Tyj}/Gt(ROSA)26Sor⁺ (involves: 129S4/SvJae * C3H * C57BL/6 * C57BL/6N)	decreased granulocyte number	J:238253
	decreased leukocyte cell number	J:238253
	decreased lymphocyte cell number	J:238253
	decreased monocyte cell number	J:238253
Ugcg^em1(IMPC)H/Ugcg⁺ (C57BL/6NTac-Ugcg^em1(IMPC)H/H)	decreased lymphocyte cell number	J:211773
Ugcg^em1(IMPC)H/Ugcg⁺ (C57BL/6NTac-Ugcg^em1(IMPC)H/H)	increased neutrophil cell number	J:211773
Uggt1^{tm1a(KOMP)Wtsi}/Uggt1⁺ (involves: C57BL/6N)	abnormal susceptibility to Picornaviridae infection	J:244058
	decreased susceptibility to Picornaviridae infection	J:244058
	decreased susceptibility to Picornaviridae infection induced morbidity/mortality	J:244058
Ugt8a^tm1Pop/Ugt8a^tm1Pop (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:78426
Uhrf1^{tm1a(EUCOMM)Wtsi}/Uhrf1⁺ (Not Specified)	increased NK cell number	J:165965
Uhrf2^{tm1b(EUCOMM)Wtsi}/Uhrf2^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Uhrf2^{tm1b(EUCOMM)Wtsi}/Tcp)	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
Uimc1^tm1.2Amj/Uimc1^tm1.2Amj (involves: BALB/cJ * C57BL/6)	increased T cell derived lymphoma incidence	J:191827
Ulk1^tm1.1Thsn/Ulk1^tm1.1Thsn (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)	increased spleen weight	J:139213
Ulk1^tm1.1Thsn/Ulk1^tm1.1Thsn (involves: 129S1/Sv * 129X1/SvJ)	immune system phenotype	J:235399
Ulk3^em2(IMPC)Tcp/Ulk3^em2(IMPC)Tcp (C57BL/6NCrl-Ulk3^em2(IMPC)Tcp/Tcp)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
Ulk4^tm1Lex/Ulk4^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6J)	increased susceptibility to otitis media	J:185566
	maxillary sinus inflammation	J:185566
	nasal inflammation	J:185566
Umod^em1Duf/Umod⁺ (C57BL/6J-Umod^em1Duf)	kidney inflammation	J:252597
Umod^tm1.1Rvt/Umod⁺ (either: B6J.129-Umod^tm1.1Rvt or (involves: 129S1/Sv * 129X1/SvJ))	kidney inflammation	J:242593
Umod^tm1.1Rvt/Umod^tm1.1Rvt (either: B6J.129-Umod^tm1.1Rvt or (involves: 129S1/Sv * 129X1/SvJ))	kidney inflammation	J:242593
Umod^tm1Xrw/Umod^tm1Xrw (involves: 129S6/SvEvTac)	increased susceptibility to bacterial infection	J:95431
Unc13d^Jinx/Unc13d^Jinx (C57BL/6J-Unc13d^Jinx/Mmucd)	abnormal cytokine secretion	J:119974
	abnormal macrophage physiology	J:105543
	abnormal NK cell physiology	J:119974
	absent lymph node germinal center	J:119974
	decreased cytotoxic T cell cytolysis	J:119974
	enlarged spleen	J:119974
	hemophagocytosis	J:119974
	increased CD8-positive, alpha-beta T cell number	J:119974
	increased monocyte cell number	J:119974
	increased neutrophil cell number	J:119974
	increased susceptibility to Herpesvirales infection	J:105543, J:119974
	increased susceptibility to Riboviria infection	J:105543, J:119974
Unc80^em1(IMPC)Tcp/Unc80⁺ (C57BL/6N-Unc80^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Unc93b1^3d/Unc93b1^3d (C57BL/6J-Unc93b1^3d)	abnormal antigen presentation via MHC class I	J:105484
	abnormal antigen presentation via MHC class II	J:105484
	abnormal circulating interferon level	J:105484
	abnormal dendritic cell antigen presentation	J:105484
	abnormal macrophage physiology	J:105484
	abnormal tumor necrosis factor secretion	J:105484
	decreased interleukin-12b secretion	J:105484
	increased circulating tumor necrosis factor level	J:105484
	increased susceptibility to bacterial infection	J:105484
	increased susceptibility to Herpesvirales infection	J:105484
Unc93b1^3d/Unc93b1^3d (C57BL/6-Unc93b1^3d)	abnormal dendritic cell antigen presentation	J:159599
	abnormal dendritic cell morphology	J:159599
	decreased interleukin-6 secretion	J:159599
	decreased interleukin-12b secretion	J:159599
Unc93b1^{tm1(KOMP)Vlcg}/Unc93b1^{tm1(KOMP)Vlcg} (involves: C57BL/6NTac)	abnormal dendritic cell antigen presentation	J:211069
	abnormal dendritic cell morphology	J:211069
	abnormal dendritic cell physiology	J:211069
	abnormal tumor necrosis factor level	J:211069
	decreased circulating interleukin-6 level	J:211069
	decreased circulating interleukin-12b level	J:211069
Unc93b1^tm1.1Kmiy/Unc93b1^tm1.1Kmiy (involves: 129P2/OlaHsd * C57BL/6)	abnormal cytokine secretion	J:174308
	abnormal T-helper 1 cell differentiation	J:174308
	abnormal T-helper 17 cell differentiation	J:174308
	decreased B cell proliferation	J:174308
	decreased interferon-alpha secretion	J:174308
	decreased interleukin-12b secretion	J:174308
	decreased marginal zone B cell number	J:174308
	decreased tumor necrosis factor secretion	J:174308
	enlarged spleen	J:174308
	glomerulonephritis	J:174308
	increased anti-nuclear antigen antibody level	J:174308
	increased autoantibody level	J:174308
	increased B cell number	J:174308
	increased B cell proliferation	J:174308
	increased CD4-positive, alpha-beta memory T cell number	J:174308
	increased IgG2a level	J:174308
	increased IgG2b level	J:174308
	increased interferon-alpha secretion	J:174308
	increased interleukin-12b secretion	J:174308
	increased memory T cell number	J:174308
	increased spleen weight	J:174308
	increased T-helper 1 cell number	J:174308
	increased T-helper 17 cell number	J:174308
	increased tumor necrosis factor secretion	J:174308
	liver inflammation	J:174308
Ung^tm1Tld/Ung^tm1Tld (Not Specified)	abnormal class switch recombination	J:79590
	decreased IgG3 level	J:79590
	enlarged lymph nodes	J:85353
	enlarged spleen	J:85353
	enlarged thymus	J:85353
	increased IgM level	J:79590
	lymphoid hyperplasia	J:85353
	spleen hyperplasia	J:85353
Ung^tm1Tld/Ung^tm1Tld (involves: 129P2/OlaHsd)	abnormal class switch recombination	J:306598
Ung^tm1Tld/Ung^tm1Tld (involves: 129P2/OlaHsd)	abnormal somatic hypermutation frequency	J:155454
Uox^em1Cli/Uox^em1Cli (C57BL/6J-Uox^em1Cli)	abnormal cytokine level	J:271949
Uox^em1Cli/Uox^em1Cli (C57BL/6J-Uox^em1Cli)	kidney inflammation	J:271949
Uoxⁱⁿ/Uoxⁱⁿ (involves: C57BL/6J * DBA/2J)	chronic inflammation	J:70677
Uox^tm1Bay/Uox^tm1Bay (involves: 129S7/SvEvBrd * C57BL/6J)	tubulointerstitial nephritis	J:16490
Upf2^tm1Btp/Upf2^tm1Btp Lyz2^tm1(cre)Ifo/? (involves: 129P2/OlaHsd * C57BL/6 * CBA)	immune system phenotype	J:134765
Upf2^tm1Btp/Upf2^tm1Btp Tg(Mx1-cre)1Cgn/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA)	abnormal B cell number	J:134765
	decreased granulocyte number	J:134765
	decreased T cell proliferation	J:134765
Upf3b^em1(IMPC)Tcp/Y (C57BL/6NCrl-Upf3b^em1(IMPC)Tcp/Tcp)	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
	small thymus	J:211773
Upf3b^em1(IMPC)Tcp/Upf3b^em1(IMPC)Tcp (C57BL/6NCrl-Upf3b^em1(IMPC)Tcp/Tcp)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
	small thymus	J:211773
Upk1a^em2Mgef/Upk1a^em2Mgef (C57BL/6NJNcbs-Upk1a^em2Mgef)	epididymis inflammation	J:345207
	increased susceptibility to bacterial infection	J:345207
	liver inflammation	J:345207
	lung inflammation	J:345207
	tubulointerstitial nephritis	J:345207
	urinary bladder inflammation	J:345207
Uqcrb^{tm1b(EUCOMM)Wtsi}/Uqcrb⁺ (C57BL/6N-Uqcrb^{tm1b(EUCOMM)Wtsi}/Ieg)	increased leukocyte cell number	J:211773
Urah^plt2/Urah^plt2 (C57BL/6-Urah^plt2)	abnormal NK cell morphology	J:267227
	decreased CD8-positive, alpha-beta T cell number	J:267227
	increased T cell proliferation	J:267227
Uri1^tm1.1Ndj/Uri1^tm1.1Ndj Alb^{tm1(cre/ERT2)Mtz}/Alb⁺ (B6.Cg-Alb^{tm1(cre/ERT2)Mtz} Uri1^tm1.1Ndj)	liver inflammation	J:217463
Uros^tm1Cged/Uros^tm1Cged (involves: 129S2/SvPas)	enlarged spleen	J:105776
Uros^tm1Cged/Uros^tm1Cged (involves: 129S2/SvPas)	increased spleen red pulp amount	J:105776
Uros^tm2Rjde/Uros^tm3Rjde (involves: 129S6/SvEvTac * C57BL/6)	enlarged spleen	J:132542
	increased spleen iron level	J:132542
Usp4^tm1Xilu/Usp4^tm1Xilu (B6.129-Usp4^tm1Xilu)	increased splenocyte apoptosis	J:173192
Usp4^tm1Xilu/Usp4^tm1Xilu (B6.129-Usp4^tm1Xilu)	increased thymocyte apoptosis	J:173192
Usp5^{tm1a(EUCOMM)Hmgu}/Usp5⁺ (C57BL/6N-Usp5^{tm1a(EUCOMM)Hmgu}/Wtsi)	decreased leukocyte cell number	J:211773
Usp12^{tm1a(EUCOMM)Hmgu}/Usp12^{tm1a(EUCOMM)Hmgu} (Not Specified)	decreased CD8-positive, alpha-beta T cell number	J:165965
	decreased IgA level	J:165965
Usp13^em1Nmw/Usp13^em1Nmw (B6.Cg-Usp13^em1Nmw)	increased interleukin-1 beta secretion	J:285981
	increased interleukin-6 secretion	J:285981
	increased susceptibility to bacterial infection	J:285981
	increased tumor necrosis factor secretion	J:285981
	lung inflammation	J:285981
Usp15^em1Peih/Usp15^em1Peih (involves: C57BL/6)	abnormal macrophage physiology	J:306461
Usp15^L749R/Usp15⁺ (involves: 129S1/SvImJ * C57BL/6J)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:259382
Usp15^L749R/Usp15⁺ (involves: 129S1/SvImJ * C57BL/6J)	decreased susceptibility to parasitic infection induced morbidity/mortality	J:259382
Usp15^L749R/Usp15^L749R (involves: 129S1/SvImJ * C57BL/6J)	abnormal T-helper 1 physiology	J:259382
	decreased susceptibility to bacterial infection	J:259382
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:259382
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:259382
	decreased susceptibility to parasitic infection	J:259382
	decreased susceptibility to parasitic infection induced morbidity/mortality	J:259382
	immune system phenotype	J:259382
Usp15^L749R/Usp15^tm1Pgrs (involves: 129S1/SvImJ * C57BL/6J)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:259382
	decreased susceptibility to parasitic infection induced morbidity/mortality	J:259382
Usp15^{tm1b(EUCOMM)Wtsi}/Usp15^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Usp15^{tm1b(EUCOMM)Wtsi}/Wtsi)	increased leukocyte cell number	J:211773
Usp15^tm1Pgrs/Usp15^tm1Pgrs (Not Specified)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:259382
Usp15^tm1Pgrs/Usp15^tm1Pgrs (Not Specified)	decreased susceptibility to parasitic infection induced morbidity/mortality	J:259382
Usp16^{tm1b(EUCOMM)Hmgu}/Usp16⁺ (C57BL/6N-Usp16^{tm1b(EUCOMM)Hmgu}/Nju)	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
Usp17lc^tm1Khb/Usp17lc⁺ (either: 129-Usp17lc^tm1Khb or (involves: 129S/SvEv * C57BL/6J))	decreased regulatory T cell number	J:191761
	increased B cell number	J:191761
	increased CD4-positive, alpha-beta T cell number	J:191761
	increased CD8-positive, alpha-beta T cell number	J:191761
	increased thymus weight	J:191761
Usp18^ity9/Usp18^ity9 (involves: 129S1/SvImJ * C57BL/6)	abnormal lymphocyte morphology	J:163843
	decreased circulating interferon-gamma level	J:163843
	decreased interferon-gamma secretion	J:163843
	decreased leukocyte cell number	J:163843
	increased circulating interleukin-6 level	J:163843
	increased interleukin-6 secretion	J:163843
	increased susceptibility to bacterial infection	J:163843
	increased susceptibility to bacterial infection induced morbidity/mortality	J:163843
	increased susceptibility to endotoxin shock	J:163843
Usp18^ity9/Usp18^tm1Dez (involves: 129 * C57BL/6 * FVB/N)	increased susceptibility to bacterial infection	J:163843
Usp18^ity9/Usp18^tm1Dez (involves: 129 * C57BL/6 * FVB/N)	increased susceptibility to bacterial infection induced morbidity/mortality	J:163843
Usp18^tm1Dez/Usp18^tm1Dez (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal cytokine level	J:214425
	decreased circulating interferon-alpha level	J:214425
	decreased circulating interferon-beta level	J:214425
	decreased circulating interferon-gamma level	J:214425
	decreased susceptibility to Coronaviridae infection	J:214425
Usp20^em1Dalin/Usp20^em1Dalin (involves: C57BL/6)	abnormal circulating chemokine level	J:274572
	decreased circulating interferon-beta level	J:274572
	decreased circulating interleukin-6 level	J:274572
	decreased interferon-beta secretion	J:274572
	decreased tumor necrosis factor secretion	J:274572
	increased susceptibility to Herpesvirales infection	J:274572
	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:274572
Usp21^tm1.1Jhy/Usp21^tm1.1Jhy (B6.129S7(Cg)-Usp21^tm1.1Jhy)	abnormal interferon level	J:208320
	decreased susceptibility to Riboviria infection	J:208320
	decreased susceptibility to Riboviria infection induced morbidity/mortality	J:208320
	enlarged spleen	J:208320
	increased circulating interferon-alpha level	J:208320
	increased circulating interferon-beta level	J:208320
	increased macrophage cell number	J:208320
	increased neutrophil cell number	J:208320
	increased spleen weight	J:208320
	increased splenocyte number	J:208320
Usp21^{tm1a(EUCOMM)Wtsi}/Usp21^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Usp21^{tm1a(EUCOMM)Wtsi}/Wtsi)	increased leukocyte cell number	J:211773
Usp22^{tm1b(KOMP)Wtsi}/Usp22⁺ (C57BL/6N-Usp22^{tm1b(KOMP)Wtsi}/Wtsi)	increased monocyte cell number	J:211773
Usp25^{Gt(RRS805)Byg}/Usp25^{Gt(RRS805)Byg} (involves: 129P2/OlaHsd)	decreased interferon-gamma secretion	J:188557
	increased interleukin-6 secretion	J:188557
	increased neutrophil cell number	J:188557
	increased susceptibility to experimental autoimmune encephalomyelitis	J:188557
	lung inflammation	J:188557
Usp28^{Gt(EUCE0037g10)Hmgu}/Usp28^{Gt(EUCE0037g10)Hmgu} (involves: 129P2/OlaHsd * C57BL/6J)	decreased spleen weight	J:215354
	decreased splenocyte number	J:215354
	immune system phenotype	J:215354
Usp32^{em1(IMPC)Mhzh}/Usp32⁺ (C57BL/6N-Usp32^{em1(IMPC)Mhzh}/Mhzh)	decreased neutrophil cell number	J:211773
	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
Usp38^em1Cya/Usp38^em1Cya (C57BL/6-Usp38^em1Cya)	lung inflammation	J:321973
Usp42^{tm2a(EUCOMM)Wtsi}/Usp42^{tm2a(EUCOMM)Wtsi} (involves: C57BL/6 * C57BL/6N)	increased CD4-positive, alpha-beta T cell number	J:213427
	increased T cell number	J:213427
Usp45^em1(IMPC)H/Usp45^em1(IMPC)H (C57BL/6NTac-Usp45^em1(IMPC)H/H)	decreased neutrophil cell number	J:211773
Usp49^em1Gpt/Usp49^em1Gpt (involves: C57BL/6NGpt)	decreased susceptibility to Herpesvirales infection	J:285681
	decreased susceptibility to Herpesvirales infection induced morbidity/mortality	J:285681
	immune system phenotype	J:285681
	increased circulating interferon-beta level	J:285681
	increased circulating interleukin-6 level	J:285681
	increased interferon-beta secretion	J:285681
	increased interleukin-6 secretion	J:285681
Usp54^{tm1b(KOMP)Wtsi}/Usp54^{tm1b(KOMP)Wtsi} (C57BL/6N-Usp54^{tm1b(KOMP)Wtsi}/H)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Utp4^em1(IMPC)J/Utp4⁺ (C57BL/6NJ-Utp4^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
Uvrag^{Tn(pb-Act-RFP)1.100107015-HRAZhu}/Uvrag^{Tn(pb-Act-RFP)1.100107015-HRAZhu} (involves: FVB/NJ)	abnormal interleukin level	J:219546
	abnormal tumor necrosis factor level	J:219546
	heart inflammation	J:219546
Uxs1^tm1Lex/Uxs1⁺ (B6;129S5-Uxs1^tm1Lex/Mmucd)	abnormal humoral immune response	J:171883
Uxs1^tm1Lex/Uxs1⁺ (B6;129S5-Uxs1^tm1Lex/Mmucd)	increased IgG1 level	J:171883
Vamp2^tm1Sud/Vamp2^tm1Sud (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:131926
Vamp3^tm1Jpes/Vamp3^tm1Jpes (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	immune system phenotype	J:131926
Vamp4^{em1(IMPC)Ccpcz}/Vamp4^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Vamp4^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Vamp8^{Gt(OST20346)Lex}/Vamp8^{Gt(OST20346)Lex} (involves: 129S5/SvEvBrd * C57BL/6)	abnormal mast cell physiology	J:131926
Vamp8^tm1Hong/Vamp8^tm1Hong (involves: 129P2/OlaHsd * C57BL/6)	abnormal dendritic cell physiology	J:131528
	abnormal type I hypersensitivity reaction	J:133439
	decreased mast cell degranulation	J:133439
	immune system phenotype	J:133439
Varc/Varc⁺ (C3H/HeJ-Varc/J)	increased susceptibility to otitis media	J:241135
Varc/Varc⁺ (C3OuJ.C3-Varc/Kjn)	increased susceptibility to otitis media	J:241135
Vav1^m1Anu/Vav1^m1Anu (C57BL/6JAnu-Vav1^m1Anu)	increased T cell number	J:104190
Vav1^m1Btlr/Vav1^m1Btlr (C57BL/6J-Vav1^m1Btlr)	abnormal humoral immune response	J:265128
	decreased B-1 B cell number	J:265128
	decreased CD4-positive, alpha-beta T cell number	J:265128
	decreased CD8-positive, alpha-beta T cell number	J:265128
	decreased CD8-positive, naive alpha-beta T cell number	J:265128
	decreased IgD level	J:265128
	decreased IgG level	J:265128
	decreased single-positive T cell number	J:265128
	decreased T cell number	J:265128
	increased central memory CD4-positive, alpha-beta T cell number	J:265128
	increased central memory CD8 positive, alpha-beta T cell number	J:265128
	increased effector memory CD4-positive, alpha-beta T cell number	J:265128
	increased IgM level	J:265128
Vav1^m2Btlr/Vav1^m2Btlr (C57BL/6J-Vav1^m2Btlr)	decreased B-1 B cell number	J:265130
Vav1^M3Btlr/Vav1^M3Btlr (C57BL/6J-Vav1^M3Btlr)	decreased IgG level	J:272527
Vav1^M3Btlr/Vav1^M3Btlr (C57BL/6J-Vav1^M3Btlr)	impaired humoral immune response	J:272527
Vav1^M4Btlr/Vav1^M4Btlr (C57BL/6J-Vav1^M4Btlr)	abnormal CD4-positive T cell differentiation	J:272528
	abnormal CD8-positive, alpha-beta T cell differentiation	J:272528
	abnormal T cell differentiation	J:272528
	decreased B-1 B cell number	J:272528
	decreased CD4-positive, alpha-beta T cell number	J:272528
	decreased CD8-positive, naive alpha-beta T cell number	J:272528
	increased central memory CD4-positive, alpha-beta T cell number	J:272528
	increased central memory CD8 positive, alpha-beta T cell number	J:272528
	increased effector memory CD4-positive, alpha-beta T cell number	J:272528
	increased effector memory CD8-positive, alpha-beta T cell number	J:272528
Vav1^M5Btlr/Vav1^M5Btlr (C57BL/6J-Vav1^M5Btlr)	decreased CD8-positive, alpha-beta T cell number	J:272529
Vav1^tm1Tyb/Vav1^tm1Tyb (involves: 129S2/SvPas * 129S8/SvEv)	abnormal T cell physiology	J:113270
	decreased CD4-positive, alpha-beta T cell number	J:113270
	decreased double-negative T cell number	J:113270
	decreased T cell proliferation	J:113270
Vav1^tm1Tyb/Vav1^tm1Tyb (involves: 129S4/SvJae * 129S8/SvEv * C57BL/10 * C57BR/cd)	abnormal CD4-positive, alpha beta T cell morphology	J:113270
	abnormal negative T cell selection	J:113270
Vav1^tm1Tyb/Vav1^tm1Tyb (involves: 129S2/SvPas)	abnormal double-negative T cell morphology	J:79323
	abnormal T cell physiology	J:86654, J:79323
	decreased double-positive T cell number	J:79323
	decreased interferon-gamma secretion	J:86654
	decreased interleukin-2 secretion	J:86654
	decreased mature B cell number	J:86654
	decreased single-positive T cell number	J:79323
	decreased T cell proliferation	J:86654
	decreased thymocyte number	J:86654
	thymus hypoplasia	J:79323
Vav1^tm1Tyb/Vav1^tm1Tyb (C.129S2-Vav1^tm1Tyb)	abnormal negative T cell selection	J:79323
Vav1^tm1Tyb/Vav1^tm1Tyb (involves: 129S2/SvPas * C57BL/10 * C57BR/cd)	abnormal CD4-positive, alpha beta T cell morphology	J:79323
	abnormal T cell physiology	J:128985
	decreased interleukin-2 secretion	J:128985
	decreased T cell proliferation	J:128985
	decreased tumor necrosis factor secretion	J:128985
Vav1^tm1Tyb/Vav1^tm1Tyb (either: (involves: 129S4/SvJae * 129S8/SvEv) or (involves: 129S4/SvJae * 129S8/SvEv * C57BL/10 * C57BR/cd))	abnormal CD8-positive, alpha-beta T cell physiology	J:190087
	abnormal immune system physiology	J:190087
	abnormal interleukin-2 secretion	J:190087
	abnormal lymphocyte cell number	J:190087
	abnormal T cell number	J:190087
	decreased double-positive T cell number	J:190087
	increased DN2 thymocyte number	J:190087
	increased DN3 thymocyte number	J:190087
	increased double-negative T cell number	J:190087
Vav1^tm1Tyb/Vav1^tm1Tyb Vav2^tm1Kdf/Vav2^tm1Kdf (involves: 129S1/Sv * 129S2/SvPas)	decreased B cell proliferation	J:86654
	decreased double-negative T cell number	J:86654
	decreased double-positive T cell number	J:86654
	decreased interferon-gamma secretion	J:86654
	decreased interleukin-2 secretion	J:86654
	decreased mature B cell number	J:86654
	decreased single-positive T cell number	J:86654
	decreased T cell number	J:86654
	decreased T cell proliferation	J:86654
	decreased thymocyte number	J:86654
Vav1^tm1Tyb/Vav1^tm1Tyb Vav2^tm1Kdf/Vav2^tm1Kdf Vav3^tm1Swat/Vav3^tm1Swat (involves: 129S1/Sv * 129S2/SvPas * 129S6/SvEvTac * C57BL/6)	abnormal B cell calcium ion homeostasis	J:86654
	abnormal humoral immune response	J:86654
	abnormal T cell physiology	J:86654
	arrested B cell differentiation	J:86654
	arrested T cell differentiation	J:86654
	decreased B cell proliferation	J:86654
	decreased double-positive T cell number	J:86654
	decreased follicular B cell number	J:86654
	decreased IgG1 level	J:86654
	decreased IgG2b level	J:86654
	decreased IgG3 level	J:86654
	decreased IgM level	J:86654
	decreased immunoglobulin level	J:86654
	decreased interferon-gamma secretion	J:86654
	decreased interleukin-2 secretion	J:86654
	decreased marginal zone B cell number	J:86654
	decreased mature B cell number	J:86654
	decreased single-positive T cell number	J:86654
	decreased T cell number	J:86654
	decreased T cell proliferation	J:86654
	decreased thymocyte number	J:86654
	decreased transitional stage T2 B cell number	J:86654
	increased immature B cell number	J:86654
	increased transitional stage T1 B cell number	J:86654
Vav1^tm1Tyb/Vav1^tm1Tyb Vav2^tm1Kdf/Vav2^tm1Kdf Vav3^tm1Swat/Vav3^tm1Swat (involves: 129S1/Sv * 129S2/SvPas * 129S6/SvEvTac)	abnormal macrophage physiology	J:145345
	abnormal neutrophil physiology	J:145345
	abnormal NK cell physiology	J:187430
	decreased interleukin-10 secretion	J:145345
	decreased tumor necrosis factor secretion	J:145345
Vav1^tm1Tyb/Vav1^tm1Tyb Vav2^tm1Tnr/Vav2^tm1Tnr (involves: 129P2/OlaHsd * 129S2/SvPas)	abnormal B cell calcium ion homeostasis	J:69807
	decreased B cell number	J:69807
	decreased B cell proliferation	J:69807
	decreased CD4-positive, alpha-beta T cell number	J:69807
	decreased CD8-positive, alpha-beta T cell number	J:69807
	decreased follicular B cell number	J:69807
	decreased immature B cell number	J:69807
	decreased mature B cell number	J:69807
Vav1^tm1Tyb/Vav1^tm1Tyb Vav3^tm1Swat/Vav3^tm1Swat (involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6)	decreased B cell proliferation	J:86654
	decreased double-negative T cell number	J:86654
	decreased double-positive T cell number	J:86654
	decreased interferon-gamma secretion	J:86654
	decreased interleukin-2 secretion	J:86654
	decreased mature B cell number	J:86654
	decreased single-positive T cell number	J:86654
	decreased T cell number	J:86654
	decreased T cell proliferation	J:86654
Vav1^tm2Bbd/Vav1^tm2Bbd (involves: 129S1/Sv * 129X1/SvJ * CD-1)	abnormal T cell activation	J:47596
	abnormal T cell differentiation	J:47596
	decreased B-1 B cell number	J:47596
	decreased CD4-positive, alpha-beta T cell number	J:47596
	decreased CD8-positive, alpha-beta T cell number	J:47596
	decreased interleukin-2 secretion	J:47596
	decreased T cell proliferation	J:47596
	immune system phenotype	J:47596
	thymus hypoplasia	J:47596
Vav1^tm2Bbd/Vav1^tm2Bbd (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal B cell number	J:55647
	abnormal lymph node cell ratio	J:69806
	abnormal response to infection	J:55647
	abnormal splenic cell ratio	J:69806
	abnormal T cell differentiation	J:47596
	abnormal T cell number	J:47596
	decreased B cell proliferation	J:55647, J:69806
	decreased B-1 B cell number	J:55647
	decreased CD4-positive, alpha-beta T cell number	J:47596
	decreased CD8-positive, alpha-beta T cell number	J:47596
	decreased IgG1 level	J:55647
	decreased IgG2a level	J:55647
	decreased IgG3 level	J:69806
	decreased IgG level	J:55647
	increased double-negative T cell number	J:47596
	increased transitional stage B cell number	J:69806
Vav1^tm2Bbd/Vav1^tm2Bbd (B6.129-Vav1^tm2Bbd)	abnormal CD4-positive T cell differentiation	J:141390
	abnormal positive T cell selection	J:141390
	abnormal T cell physiology	J:141390
	decreased double-positive T cell number	J:141390
	decreased interleukin-4 secretion	J:71161
	decreased NK T cell number	J:71161
	decreased T cell number	J:141390
	immune system phenotype	J:71161
	impaired natural killer cell mediated cytotoxicity	J:71161
Vav1^tm2Bbd/Vav1^tm2Bbd Vav2^tm1Kdf/Vav2^tm1Kdf (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal B cell activation	J:69806
	abnormal B cell differentiation	J:69806
	abnormal lymph node cell ratio	J:69806
	abnormal splenic cell ratio	J:69806
	abnormal T cell differentiation	J:69806
	decreased B cell number	J:69806
	decreased B cell proliferation	J:69806
	decreased B-1 B cell number	J:69806
	decreased CD8-positive, alpha-beta T cell number	J:69806
	decreased IgG1 level	J:69806
	decreased IgG2b level	J:69806
	decreased IgG3 level	J:69806
	decreased IgM level	J:69806
	decreased immunoglobulin level	J:69806
	decreased mature B cell number	J:69806
	decreased T cell number	J:69806
	thymus hypoplasia	J:69806
Vav1^tm2Tyb/Vav1^tm2Tyb (involves: 129S4/SvJae * 129S8/SvEv)	abnormal T cell physiology	J:113270
	decreased CD4-positive, alpha-beta T cell number	J:113270
	decreased double-negative T cell number	J:113270
	decreased T cell proliferation	J:113270
Vav1^tm2Tyb/Vav1^tm2Tyb (involves: 129S4/SvJae * 129S8/SvEv * C57BL/10 * C57BR/cd)	abnormal CD4-positive, alpha beta T cell morphology	J:113270
	abnormal negative T cell selection	J:113270
Vav1^tm4Tyb/Vav1^tm4Tyb (either: 129S8.129S4-Vav1^tm4Tyb or (involves: 129S4/SvJae * 129S8/SvEv * C57BL/10 * C57BR/cd))	abnormal CD4-positive, alpha-beta T cell physiology	J:190087
	abnormal CD8-positive, alpha-beta T cell physiology	J:190087
	abnormal immune serum protein physiology	J:190087
	abnormal immune system physiology	J:190087
	abnormal interleukin-2 secretion	J:190087
	abnormal lymphocyte cell number	J:190087
	abnormal T cell number	J:190087
	abnormal T cell physiology	J:190087
	increased circulating interferon-gamma level	J:190087
	increased DN2 thymocyte number	J:190087
	increased DN3 thymocyte number	J:190087
Vav2^tm1Kdf/Vav2^tm1Kdf (involves: 129S1/Sv * C57BL/6)	decreased B cell proliferation	J:69806
	decreased IgG3 level	J:69806
	decreased mature B cell number	J:69806
Vav2^tm1Kdf/Vav2^tm1Kdf Vav3^tm1Swat/Vav3^tm1Swat (involves: 129S1/Sv * 129S6/SvEvTac * C57BL/6)	immune system phenotype	J:86654
Vav2^tm1Tnr/Vav2^tm1Tnr (involves: 129P2/OlaHsd)	abnormal class switch recombination	J:69807
	decreased B cell number	J:69807
	decreased B cell proliferation	J:69807
	decreased IgG1 level	J:69807
	decreased IgG2b level	J:69807
	decreased IgG3 level	J:69807
	decreased IgM level	J:69807
	decreased spleen germinal center number	J:69807
Vcam1^tm1Dmil/Vcam1^tm1Dmil (either: (involves: 129S4/SvJae * BALB/c) or (involves: 129S4/SvJae * C57BL/6))	increased monocyte cell number	J:69597
Vcam1^tm1Dmil/Vcam1^tm1Dmil (C.129S4-Vcam1^tm1Dmil)	increased B cell number	J:69597
	increased leukocyte cell number	J:69597
	increased monocyte cell number	J:69597
	increased T cell number	J:69597
Vcam1^tm2Flv/Vcam1^tm3Flv Tg(Tek-cre)12Flv/0 (involves: 129S1/Sv * C3H * C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:68147
	abnormal CD8-positive, alpha-beta T cell physiology	J:68147
	abnormal lymphocyte physiology	J:68147
	abnormal splenic cell ratio	J:107447
	decreased B cell number	J:68147
	decreased CD4-positive, alpha-beta T cell number	J:68147
	decreased CD8-positive, alpha-beta T cell number	J:68147
	decreased immature B cell number	J:68147
	impaired B cell migration	J:68147
	increased immature B cell number	J:68147
	increased leukocyte cell number	J:107447, J:68147
	spleen hyperplasia	J:107447
Vcam1^tm2Roml/Vcam1^tm2Roml Tg(Mx1-cre)1Cgn/? (involves: 129S1/Sv * C57BL/6 * CBA)	abnormal humoral immune response	J:68148
	decreased B cell number	J:68148
	decreased mature B cell number	J:68148
	decreased transitional stage B cell number	J:68148
	increased B cell number	J:68148
	increased immature B cell number	J:68148
	increased mature B cell number	J:68148
	increased transitional stage B cell number	J:68148
Vcan^em2(IMPC)Mbp/Vcan⁺ (C57BL/6NCrl-Vcan^em2(IMPC)Mbp/Mmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Vcp^tm1Itl/Vcp⁺ (B6.129S-Vcp^tm1Itl)	abnormal osteoclast differentiation	J:166230
Vcp^tm1Itl/Vcp⁺ (B6.129S-Vcp^tm1Itl)	increased osteoclast cell number	J:166230
Vdac2^tm1.1Ehyc/Vdac2^tm1.1Ehyc Bak1^tm1Thsn/Bak1^tm1Thsn Tg(Lck-cre)1Cwi/? (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)	immune system phenotype	J:220951
Vdac2^tm1.1Ehyc/Vdac2^tm1.1Ehyc Bax^tm2Sjk/Bax^tm2Sjk Tg(Lck-cre)1Cwi/? (involves: 129X1/SvJ * C57BL/6 * DBA/2)	decreased thymocyte number	J:220951
	small thymus	J:220951
Vdac2^tm1.1Ehyc/Vdac2^tm1.1Ehyc Tg(Lck-cre)1Cwi/? (involves: 129X1/SvJ * C57BL/6 * DBA/2)	abnormal thymocyte apoptosis	J:220951
	decreased thymocyte number	J:220951
	small thymus	J:220951
Vdr^tm1Gcm/Vdr^tm1Gcm Tg(Col2a1-cre)1Bhr/? (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)	decreased osteoclast cell number	J:117377
Vdr^tm1Mbd/Vdr^tm1Mbd (involves: 129S4/SvJae * C57BL/6)	abnormal interleukin level	J:107077
	abnormal tumor necrosis factor level	J:107077
	immune system phenotype	J:107077
	increased susceptibility to induced colitis	J:130511
	increased thymus weight	J:107077
	intestinal inflammation	J:107077
	thymus hyperplasia	J:107077
Vdr^tm1Rge/Vdr^tm1Rge (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal macrophage physiology	J:134827
	decreased susceptibility to parasitic infection	J:134827
Vdr^tm1Ska/Vdr^tm1Ska (involves: C57BL/6NCrlj * CBA/JNCrlj)	abnormal macrophage chemotaxis	J:112519
	decreased splenocyte proliferation	J:112519
	decreased susceptibility to autoimmune diabetes	J:112519
	dermatitis	J:111828
Vdr^tm1Ska/Vdr^tm1Ska (NOD.Cg-Vdr^tm1Ska/CmatJ)	abnormal chemokine secretion	J:127787
	abnormal dendritic cell differentiation	J:127787
	abnormal interleukin-1 secretion	J:127787
	abnormal T cell number	J:127787
	decreased interleukin-6 secretion	J:127787
	decreased regulatory T cell number	J:127787
	increased susceptibility to autoimmune diabetes	J:127787
Vdr^tm2Ska/Vdr^tm2Ska (involves: C57BL/6NCrlj * CBA/JNCrlj)	ear inflammation	J:111828
Vegfa^tm1.1Nagy/Vegfa^tm1.1Nagy (involves: 129S1/Sv * 129X1/SvJ)	abnormal lymphatic vessel morphology	J:64090
Vegfa^tm1Pec/Vegfa^tm1Pec (involves: 129S1/Sv * 129X1/SvJ)	abnormal thymus morphology	J:81698
	athymia	J:81698
	decreased lymphocyte cell number	J:81698
	ectopic thymus	J:81698
	thymus hypoplasia	J:81698
Vegfa^tm2Gne/Vegfa^tm2Gne Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129/Sv * 129P2/OlaHsd)	decreased inflammatory response	J:107682
Vegfa^tm2Gne/Vegfa^tm2Gne Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129/Sv * 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:148597
Vegfa^tm2Gne/Vegfa^tm2Gne Tg(SFTPC-cre)#Mliu/0 (involves: 129/Sv * ICR)	lung inflammation	J:158566
Vegfc^tm1Ali/Vegfc⁺ (involves: 129S1/Sv * 129X1/SvJ * ICR)	abnormal lymph circulation	J:87394
Vegfc^tm1Ali/Vegfc⁺ (involves: 129S1/Sv * 129X1/SvJ * ICR)	lymphatic vessel hypoplasia	J:87394
Vegfc^tm1Ali/Vegfc⁺ (involves: 129S1/Sv * 129X1/SvJ)	lymphatic vessel hypoplasia	J:137909
Vegfc^tm1Ali/Vegfc⁺ Tg(KRT14-FIGF)2Ali/0 (involves: 129S1/Sv * 129X1/SvJ * FVB/N)	lymphatic vessel hyperplasia	J:137909
Vegfc^tm1Ali/Vegfc^tm1Ali (involves: 129S1/Sv * 129X1/SvJ * ICR)	absent lymphatic vessels	J:87394
Vegfc^tm1Ali/Vegfc^tm1Ali (involves: 129S1/Sv * 129X1/SvJ)	abnormal lymphangiogenesis	J:137909
Vegfc^tm1Ali/Vegfc^tm1Ali (involves: 129S1/Sv * 129X1/SvJ)	abnormal lymphatic vessel morphology	J:137909
Vegfd^{em1(IMPC)Ccpcz}/Vegfd^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Vegfd^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Vegfd^tm1Hrl/Y (involves: 129S/SvEv * Swiss)	immune system phenotype	J:153734
Vegfd^tm1Mach/Vegfd^tm1Mach Vegfc^tm1Ali/Vegfc^tm1Ali (involves: 129S1/Sv * 129X1/SvJ)	abnormal lymphangiogenesis	J:137909
	abnormal lymphatic vessel morphology	J:137909
Vezf1^tm1Stmn/Vezf1⁺ (B6.129-Vezf1^tm1Stmn)	abnormal lymphatic vessel morphology	J:99326
Vhl^tm1Jae/Vhl^tm1Jae Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * 129S4/SvJae)	increased inflammatory response	J:107682
Vhl^tm1Jae/Vhl^tm1Jae Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0 (involves: 129S4/SvJae * CD-1)	decreased lymphocyte cell number	J:186085
	enlarged spleen	J:186085
Vhl^tm1Mcs/Vhl^tm1Mcs (involves: 129S4/SvJae * C57BL/6 * FVB/N)	dark spleen	J:130780
	decreased spleen white pulp amount	J:130780
	increased leukocyte cell number	J:130780
	increased spleen red pulp amount	J:130780
	increased spleen weight	J:130780
Vim^tm1Cba/Vim^tm1Cba (involves: 129S2/SvPas * C57BL/6)	abnormal cellular extravasation	J:129405
	abnormal leukocyte adhesion	J:129405
	abnormal leukocyte migration	J:129405
	abnormal leukocyte tethering or rolling	J:129405
	immune system phenotype	J:125280
Vip^tm1Clw/Vip^tm1Clw (involves: 129S/Sv * C57BL/6)	lung inflammation	J:132313
Vipr2^tm1Ajh/Vipr2^tm1Ajh (B6.129P2-Vipr2^tm1Ajh)	abnormal cytokine secretion	J:72933
	decreased IgE level	J:72933
	decreased interleukin-4 secretion	J:72933
	decreased susceptibility to type I hypersensitivity reaction	J:72933
	increased interferon-gamma secretion	J:72933
	increased interleukin-2 secretion	J:72933
	increased susceptibility to type IV hypersensitivity reaction	J:72933
Vkorc1l1^em1(IMPC)J/Vkorc1l1^em1(IMPC)J (C57BL/6NJ-Vkorc1l1^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
Vldlr^em1(IMPC)Mbp/Vldlr^em1(IMPC)Mbp (C57BL/6N-Vldlr^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
Vms1^A/J/Vms1^A/J (involves: A/J * C57BL/10SnSg)	myocarditis	J:121574
Vnn1^tm1Pna/Vnn1^tm1Pna (involves: 129P2/OlaHsd)	immune system phenotype	J:65449
Vnn3^{em1(IMPC)Ccpcz}/Vnn3^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Vnn3^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Vpreb1a^tm1Ilm/Vpreb1a⁺ Vpreb1b^tm1Ilm/Vpreb1b^tm3Ilm (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:104211
Vpreb1a^tm1Ilm/Vpreb1a^tm1Ilm (involves: 129P2/OlaHsd * C57BL/6)	abnormal pre-B cell morphology	J:53512
	arrested B cell differentiation	J:53512
	immune system phenotype	J:53512
Vpreb1a^tm1Ilm/Vpreb1a^tm1Ilm (B6.129P2-Vpreb1a^tm1Ilm)	decreased pre-B cell number	J:104211
Vpreb1a^tm1Ilm/Vpreb1a^tm1Ilm (B6.129P2-Vpreb1a^tm1Ilm)	increased pre-B cell number	J:104211
Vpreb1a^tm1Ilm/Vpreb1a^tm1Ilm Vpreb1b^tm1Ilm/Vpreb1b⁺ (involves: 129P2/OlaHsd * C57BL/6)	decreased mature B cell number	J:104211
	decreased pre-B cell number	J:104211
	increased pre-B cell number	J:104211
Vpreb1a^tm1Ilm/Vpreb1a^tm1Ilm Vpreb1b^tm1Ilm/Vpreb1b^tm1Ilm (B6.129P2-Vpreb1a^tm1Ilm Vpreb1b^tm1Ilm)	abnormal B cell differentiation	J:67609
	abnormal immature B cell morphology	J:67609
	abnormal splenic cell ratio	J:67609
	decreased B-1a cell number	J:67609
	decreased IgG level	J:67609
	decreased mature B cell number	J:67609
	decreased pre-B cell number	J:67609
	immune system phenotype	J:67609
	increased pre-B cell number	J:67609
Vpreb1b^tm3Ilm/Vpreb1b^tm3Ilm (B6.129P2-Vpreb1b^tm3Ilm)	immune system phenotype	J:104211
Vps4a^{tm1b(EUCOMM)Hmgu}/Vps4a⁺ (C57BL/6N-Vps4a^{tm1b(EUCOMM)Hmgu}/Bay)	enlarged spleen	J:211773
	increased spleen weight	J:211773
Vps13a^{tm1b(EUCOMM)Wtsi}/Vps13a^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Vps13a^{tm1b(EUCOMM)Wtsi}/Wtsi)	decreased plasmacytoid dendritic cell number	J:211773
	decreased T-helper cell number	J:211773
Vps13b^em1(IMPC)Tcp/Vps13b^em1(IMPC)Tcp (C57BL/6N-Vps13b^em1(IMPC)Tcp/Tcp)	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
	enlarged lymph nodes	J:211773
	small spleen	J:211773
Vps13b^tm1.2Ics/Vps13b^tm1.2Ics (involves: C57BL/6N)	eye inflammation	J:296007
Vps33a^em2(IMPC)Tcp/Vps33a⁺ (C57BL/6NCrl-Vps33a^em2(IMPC)Tcp/Tcp)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
	increased spleen weight	J:211773
Vps33b^tm1.1Arte/Vps33b^tm1.1Arte Gt(ROSA)26Sor^{tm1(cre/ERT2)Tyj}/Gt(ROSA)26Sor⁺ (involves: C57BL/6 * C57BL/6J)	decreased dendritic cell number	J:222766
	decreased lymphocyte cell number	J:222766
	enlarged spleen	J:222766
	increased macrophage cell number	J:222766
	increased monocyte cell number	J:222766
	increased neutrophil cell number	J:222766
Vps35^tm1.1Mjff/Vps35^tm1.1Mjff (B6.Cg-Vps35^tm1.1Mjff)	microgliosis	J:303283
Vps54^wr/Vps54^wr (involves: C57BL/6J * C57BL/Fa)	increased microglial cell activation	J:181019
Vrk3^em1(IMPC)Mbp/Vrk3^em1(IMPC)Mbp (C57BL/6NCrl-Vrk3^em1(IMPC)Mbp/Mmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Vsig4^tm1Gne/Vsig4^tm1Gne (involves: C57BL/6N)	increased susceptibility to bacterial infection	J:138691
Vsig4^tm1Gne/Vsig4^tm1Gne (C57BL/6-Vsig4^tm1Gne)	abnormal macrophage physiology	J:281762
	decreased susceptibility to induced colitis	J:281762
	increased circulating interleukin-1 beta level	J:281762
	increased interleukin-1 beta secretion	J:281762
	increased susceptibility to experimental autoimmune encephalomyelitis	J:281762
	increased T-helper 1 cell number	J:281762
	increased T-helper 17 cell number	J:281762
Vsig10^{em1(IMPC)Wtsi}/Vsig10^{em1(IMPC)Wtsi} (C57BL/6N-Vsig10^{em1(IMPC)Wtsi}/Wtsi)	increased leukocyte cell number	J:211773
Vsir^tm1Lex/Vsir^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6)	abnormal T cell activation	J:222944
	increased IgA level	J:222944
	increased IgM level	J:222944
	increased inflammatory response	J:222944
	increased interferon-gamma secretion	J:222944
	increased interleukin-17 secretion	J:222944
Vsir^tm1Lex/Vsir^tm1Lex Tg(Tcra2D2,Tcrb2D2)1Kuch/0 (involves: 129S5/SvEvBrd * C57BL/6)	increased susceptibility to experimental autoimmune encephalomyelitis	J:222944
Vstm5^em1Cdj/Vstm5^em1Cdj (Not Specified)	decreased interleukin-2 secretion	J:267548
Vstm5^em1Cdj/Vstm5^em1Cdj (Not Specified)	immune system phenotype	J:267548
Vtcn1^tm1Lpc/Vtcn1^tm1Lpc (B6.129S-Vtcn1^tm1Lpc)	abnormal myelopoiesis	J:145712
	decreased susceptibility to bacterial infection	J:145712
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:145712
	increased neutrophil cell number	J:145712
Vtcn1^tm1Mak/Vtcn1^tm1Mak (C.Cg-Vtcn1^tm1Mak)	decreased interleukin-4 secretion	J:112130
	decreased susceptibility to parasitic infection	J:112130
	increased interferon-gamma secretion	J:112130
Vtcn1^tm1Xxz/Vtcn1^tm1Xxz (involves: 129S4/SvJae * BALB/c * C57BL/6)	increased CD4-positive, alpha-beta T cell number	J:177612
	increased interleukin-17 secretion	J:177612
	increased susceptibility to autoimmune diabetes	J:177612
	increased susceptibility to experimental autoimmune encephalomyelitis	J:177612
	increased T-helper 1 cell number	J:177612
	increased T-helper 17 cell number	J:177612
Vwf^tm1.1Geno/Vwf⁺ (involves: C57BL/6)	increased acute inflammation	J:250145
Vwf^tm1.1Geno/Vwf^tm1.1Geno (involves: C57BL/6)	increased acute inflammation	J:250145
Vwf^tm1Wgr/Vwf^tm1Wgr (B6.129S2-Vwf^tm1Wgr)	increased susceptibility to bacterial infection	J:140334
Vwf^tm1Wgr/Vwf^tm1Wgr (B6.129S2-Vwf^tm1Wgr)	increased susceptibility to experimental autoimmune encephalomyelitis	J:140334
Wac^{tm2b(EUCOMM)Wtsi}/Wac⁺ (C57BL/6N-Wac^{tm2b(EUCOMM)Wtsi}/Wtsi)	decreased eosinophil cell number	J:211773
	increased Ly6C low monocyte number	J:211773
	increased monocyte cell number	J:211773
Was^tm1Itl/Y (Not Specified)	abnormal dendritic cell morphology	J:153247
	abnormal dendritic cell physiology	J:153247
	abnormal lymphocyte morphology	J:153247
	decreased NK cell number	J:153247
	decreased T cell number	J:153247
	decreased T cell proliferation	J:153247
	increased anti-double stranded DNA antibody level	J:153247
	increased B cell number	J:153247
	increased follicular B cell number	J:153247
	increased leukocyte cell number	J:153247
	increased splenocyte number	J:153247
	spleen hyperplasia	J:153247
Was^tm1Itl/Was^tm1Itl (Not Specified)	abnormal dendritic cell morphology	J:153247
	abnormal dendritic cell physiology	J:153247
	abnormal lymphocyte morphology	J:153247
	decreased NK cell number	J:153247
	decreased T cell number	J:153247
	decreased T cell proliferation	J:153247
	increased anti-double stranded DNA antibody level	J:153247
	increased B cell number	J:153247
	increased follicular B cell number	J:153247
	increased leukocyte cell number	J:153247
	increased splenocyte number	J:153247
	spleen hyperplasia	J:153247
Was^tm1Kas/Was^tm1Kas (involves: 129/Sv * C57BL/6)	decreased B cell number	J:87875
	decreased double-positive T cell number	J:87875
	decreased lymphocyte cell number	J:87875
	decreased T cell number	J:87875
	lymphoid hypoplasia	J:87875
	thymus hypoplasia	J:87875
Was^tm1Sbs/Y (involves: 129S6/SvEvTac)	abnormal dendritic cell morphology	J:153247
	abnormal dendritic cell physiology	J:153247
	abnormal lymphocyte morphology	J:153247
	decreased NK cell number	J:153247
	decreased T cell number	J:153247
	decreased T cell proliferation	J:153247
	increased anti-double stranded DNA antibody level	J:153247
	increased B cell number	J:153247
	increased follicular B cell number	J:153247
	increased leukocyte cell number	J:153247
	increased monocyte cell number	J:153247
	increased splenocyte number	J:153247
	spleen hyperplasia	J:153247
Was^tm1Sbs/Y (involves: 129S6/SvEvTac * C57BL/6)	abnormal B cell physiology	J:182528
	decreased marginal zone B cell number	J:182528
	decreased mature B cell number	J:182528
	increased anti-chromatin antibody level	J:182528
	increased anti-double stranded DNA antibody level	J:182528
	increased anti-single stranded DNA antibody level	J:182528
	increased autoantibody level	J:182528
	increased germinal center B cell number	J:182528
	increased IgA level	J:182528
	increased IgE level	J:182528
	increased IgM level	J:182528
	increased plasma cell number	J:182528
Was^tm1Sbs/Was^tm1Sbs (either: (involves: 129S6/SvEvTac) or (involves: 129S6/SvEvTac * C57BL/6))	colitis	J:48836
	decreased B cell number	J:48836
	decreased lymphocyte cell number	J:48836
	decreased T cell number	J:48836
	decreased T cell proliferation	J:48836
	immune system phenotype	J:48836
	increased neutrophil cell number	J:48836
Was^tm1Sbs/Was^tm1Sbs (involves: C57BL/6 * CBA)	abnormal B cell physiology	J:95909
Was^tm1Sbs/Was^tm1Sbs (involves: 129S/SvEv)	abnormal cytokine secretion	J:86835
	abnormal mast cell morphology	J:86835
	abnormal mast cell physiology	J:86835
	abnormal osteoclast differentiation	J:90542
	abnormal osteoclast physiology	J:90542
Was^tm1Sbs/Was^tm1Sbs (involves: BALB/c)	abnormal dendritic cell antigen presentation	J:84131
	decreased T cell proliferation	J:84131
	immune system phenotype	J:84131
Was^tm1Sbs/Was^tm1Sbs (involves: 129S6/SvEvTac)	abnormal dendritic cell morphology	J:153247
	abnormal dendritic cell physiology	J:153247
	abnormal double-negative T cell morphology	J:125309
	abnormal double-positive T cell morphology	J:125309
	abnormal lymphocyte morphology	J:153247
	abnormal thymocyte activation	J:125309
	decreased NK cell number	J:153247
	decreased T cell number	J:153247
	decreased T cell proliferation	J:153247
	increased anti-double stranded DNA antibody level	J:153247
	increased B cell number	J:153247
	increased follicular B cell number	J:153247
	increased leukocyte cell number	J:153247
	increased monocyte cell number	J:153247
	increased splenocyte number	J:153247
	spleen hyperplasia	J:153247
Was^tm1Sbs/Was^tm1Sbs (129S6/SvEvTac-Was^tm1Sbs/J)	glomerulonephritis	J:180407
	increased IgA level	J:180407
	increased IgM level	J:180407
Was^tm1Sbs/Was^tm1Sbs (involves: 129S6/SvEvTac * C57BL/6)	abnormal B cell physiology	J:182528
	decreased marginal zone B cell number	J:182528
	decreased mature B cell number	J:182528
	increased anti-chromatin antibody level	J:182528
	increased anti-double stranded DNA antibody level	J:182528
	increased anti-single stranded DNA antibody level	J:182528
	increased autoantibody level	J:182528
	increased germinal center B cell number	J:182528
	increased IgA level	J:182528
	increased IgE level	J:182528
	increased IgM level	J:182528
	increased plasma cell number	J:182528
Was^tm1Sbs/Was^tm1Sbs Wasl^tm2Sbs/Wasl^tm2Sbs Tg(Lck-cre)1Cwi/? (involves: 129S6/SvEvTac * C57BL/6)	abnormal double-negative T cell morphology	J:125309
	abnormal double-positive T cell morphology	J:125309
	abnormal thymocyte activation	J:125309
	colitis	J:125309
	decreased regulatory T cell number	J:125309
	decreased single-positive T cell number	J:125309
	decreased T cell number	J:125309
	decreased thymocyte number	J:125309
	increased single-positive T cell number	J:125309
Was^tm2Itl/Y (Not Specified)	abnormal dendritic cell morphology	J:153247
	abnormal dendritic cell physiology	J:153247
	abnormal lymphocyte morphology	J:153247
	decreased NK cell number	J:153247
	decreased T cell number	J:153247
	decreased T cell proliferation	J:153247
	increased anti-double stranded DNA antibody level	J:153247
	increased B cell number	J:153247
	increased follicular B cell number	J:153247
	increased leukocyte cell number	J:153247
	increased splenocyte number	J:153247
Was^tm2Itl/Was^tm2Itl (Not Specified)	abnormal dendritic cell morphology	J:153247
	abnormal dendritic cell physiology	J:153247
	abnormal lymphocyte morphology	J:153247
	decreased NK cell number	J:153247
	decreased T cell number	J:153247
	decreased T cell proliferation	J:153247
	increased anti-double stranded DNA antibody level	J:153247
	increased B cell number	J:153247
	increased follicular B cell number	J:153247
	increased leukocyte cell number	J:153247
	increased splenocyte number	J:153247
Wasl^tm1.1Ttha/Wasl^tm1.1Ttha Tg(KRT14-cre)1Amc/0 (involves: C57BL/6 * C57BL/6N * CBA)	abnormal circulating chemokine level	J:271857
	dermatitis	J:271857
	increased circulating interleukin-1 alpha level	J:271857
	increased circulating interleukin-6 level	J:271857
	increased circulating interleukin-17 level	J:271857
	increased circulating tumor necrosis factor level	J:271857
	increased susceptibility to bacterial infection	J:271857
	skin inflammation	J:271857
Wbcq1^C57BLKS/J/Wbcq1^C57BLKS/J (involves: C57BLKS/J * SM/J)	increased leukocyte cell number	J:102636
Wbcq1^C57BLKS/J/Wbcq1^SM/J (involves: C57BLKS/J * SM/J)	increased leukocyte cell number	J:102636
Wbcq2^C57BLKS/J/Wbcq2^SM/J (involves: C57BLKS/J * SM/J)	increased leukocyte cell number	J:102636
Wbcq2^C57BLKS/J/Wbcq2^SM/J Wbcq3^C57BLKS/J/Wbcq3^C57BLKS/J (involves: C57BLKS/J * SM/J)	increased leukocyte cell number	J:102636
Wbcq2^SM/J/Wbcq2^SM/J (involves: C57BLKS/J * SM/J)	increased leukocyte cell number	J:102636
Wbcq2^SM/J/Wbcq2^SM/J Wbcq3^C57BLKS/J/Wbcq3^C57BLKS/J (involves: C57BLKS/J * SM/J)	increased leukocyte cell number	J:102636
Wbcq3^C57BLKS/J/Wbcq3^SM/J (involves: C57BLKS/J * SM/J)	increased leukocyte cell number	J:102636
Wbcq3^SM/J/Wbcq3^SM/J (involves: C57BLKS/J * SM/J)	increased leukocyte cell number	J:102636
Wbcq4^NZW/LacJ/Wbcq4^NZW/LacJ (involves: NZW/LacJ * SM/J)	increased leukocyte cell number	J:102636
Wbcq4^NZW/LacJ/Wbcq4^SM/J (involves: NZW/LacJ * SM/J)	increased leukocyte cell number	J:102636
Wbcq5^NZW/LacJ/Wbcq5^NZW/LacJ (involves: NZW/LacJ * SM/J)	increased leukocyte cell number	J:102636
Wbcq6^NZW/LacJ/Wbcq6^NZW/LacJ (involves: NZW/LacJ * SM/J)	increased leukocyte cell number	J:102636
Wbcq6^SM/J/Wbcq6^SM/J (involves: NZW/LacJ * SM/J)	increased leukocyte cell number	J:102636
Wbp1^em1(IMPC)Tcp/Wbp1^em1(IMPC)Tcp (C57BL/6NCrl-Wbp1^em1(IMPC)Tcp/Cmmr)	increased monocyte cell number	J:211773
Wbp1l^{tm2a(EUCOMM)Hmgu}/Wbp1l^{tm2a(EUCOMM)Hmgu} (involves: C57BL/6N)	abnormal pre-B cell morphology	J:284781
	decreased B cell number	J:284781
	decreased B-1 B cell number	J:284781
	decreased pre-B cell number	J:284781
	decreased pro-B cell number	J:284781
	immune system phenotype	J:284781
	increased dendritic cell number	J:284781
	increased marginal zone B cell number	J:284781
Wbp2^{tm2a(EUCOMM)Wtsi}/Wbp2^{tm2a(EUCOMM)Wtsi} (C57BL/6N-Wbp2^{tm2a(EUCOMM)Wtsi}/Cnrm)	increased leukocyte cell number	J:165965
Wbp11^em1Gcha/Wbp11⁺ (involves: C57BL/6J * FVB/N)	ectopic thymus	J:300837
Wdfy3^em1(IMPC)Mbp/Wdfy3⁺ (C57BL/6N-Wdfy3^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Wdfy4^em1Jkln/Wdfy4^em1Jkln (C57BL/6J-Wdfy4^em1Jkln)	decreased dendritic cell number	J:326216
Wdfy4^em1Jkln/Wdfy4^em1Jkln (C57BL/6J-Wdfy4^em1Jkln)	immune system phenotype	J:326216
Wdr1^Gt(XN462)Byg/Wdr1^rede (involves: 129P2/OlaHsd * C57BL/6)	ear inflammation	J:134092
	skin inflammation	J:134092
Wdr1^rede/Wdr1^rede (Not Specified)	increased inflammatory response	J:85113
Wdr1^rede/Wdr1^rede (C57BL/6-Wdr1^rede)	abnormal myelopoiesis	J:134092
	abnormal osteoclast physiology	J:134092
	abnormal thrombopoiesis	J:134092
	ear inflammation	J:134092
	impaired neutrophil chemotaxis	J:134092
	increased neutrophil cell number	J:134092
	increased osteoclast cell number	J:134092
	skin inflammation	J:134092
Wdr27^{em1(IMPC)Ccpcz}/Wdr27^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Wdr27^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Wdr37^{tm1a(KOMP)Wtsi}/Wdr37^{tm1a(KOMP)Wtsi} (C57BL/6N-Wdr37^{tm1a(KOMP)Wtsi}/Wtsi)	decreased leukocyte cell number	J:211773
Wdr41^m1Btlr/Wdr41^m1Btlr (C57BL/6J-Wdr41^m1Btlr)	increased CD4-positive, alpha-beta T cell number	J:268243
	increased CD8-positive, alpha-beta T cell number	J:268243
	increased circulating interleukin-12b level	J:268243
	increased susceptibility to induced colitis	J:268243
	increased tumor necrosis factor secretion	J:268243
Wdr41^m2Btlr/Wdr41^m2Btlr (C57BL/6J-Wdr41^m2Btlr)	increased CD4-positive, alpha-beta T cell number	J:268243
	increased CD8-positive, alpha-beta T cell number	J:268243
	increased tumor necrosis factor secretion	J:268243
Wdr45^em1Wrst/Y (involves: C57BL/6N * FVB)	increased leukocyte cell number	J:307284
Wdr59^{tm1b(EUCOMM)Wtsi}/Wdr59⁺ (C57BL/6N-Wdr59^{tm1b(EUCOMM)Wtsi}/Wtsi)	decreased leukocyte cell number	J:211773
Wdr62^em1(IMPC)Tcp/Wdr62^em1(IMPC)Tcp (C57BL/6NCrl-Wdr62^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Wdr83^tm1Guwo/Wdr83⁺ (involves: C57BL/6)	kidney inflammation	J:153983
Wdr89^m1Anu/Wdr89^m1Anu (C57BL/6NCrl-Wdr89^m1Anu/Anu)	immune system phenotype	J:104190
Wfdc1^tm1Bcm/Wfdc1^tm1Bcm (involves: 129S7/SvEvBrd * C57BL/6)	decreased susceptibility to Orthomyxoviridae infection	J:216357
Wfdc2^em1(IMPC)H/Wfdc2⁺ (C57BL/6NTac-Wfdc2^em1(IMPC)H/H)	decreased eosinophil cell number	J:211773
Wfdc2^tm1.1Ohbo/Wfdc2^tm1.1Ohbo (involves: C57BL/6NCrlj * CBA/JNCrlj)	abnormal cytokine level	J:282576
	lung inflammation	J:282576
Wfdc15a^em1Ohbo/Wfdc15a^em1Ohbo (involves: Slc:ICR)	testis inflammation	J:360881
Whrn^wi/Whrn^wi (involves: C57BL/6J * STOCK a Tyrp1^b Myo5a^d Oca2^p Ednrb^s)	decreased leukocyte cell number	J:5538
	decreased thymus weight	J:5037
Why1^MOLF/EiJ/? (involves: C57BL/6J * MOLF/Ei)	increased interleukin-6 secretion	J:131437
Why2^MOLF/EiJ/? (involves: C57BL/6J * MOLF/Ei)	decreased interleukin-6 secretion	J:131437
Wipf1^tm1Geha/Wipf1^tm1Geha (involves: 129S6/SvEvTac)	abnormal T cell physiology	J:74719
	decreased T cell proliferation	J:74719
	decreased thymocyte number	J:74719
	increased B cell proliferation	J:74719
	increased IgE level	J:74719
	increased IgM level	J:74719
	thymus hypoplasia	J:74719
Wipf1^tm1Geha/Wipf1^tm1Geha (involves: 129S6/SvEvTac * C57BL/6)	abnormal alpha-beta T cell morphology	J:116168
	abnormal lymph node B cell domain morphology	J:116168
	abnormal lymphopoiesis	J:116168
	abnormal Peyer's patch T cell area morphology	J:116168
	abnormal spleen morphology	J:116168
	abnormal thymus morphology	J:116168
	colitis	J:116168
	decreased B cell number	J:116168
	decreased follicular B cell number	J:116168
	decreased lymphocyte cell number	J:116168
	decreased marginal zone B cell number	J:116168
	decreased spleen white pulp amount	J:116168
	decreased thymus weight	J:116168
	enlarged spleen	J:116168
	glomerulonephritis	J:116168
	increased autoantibody level	J:116168
	increased granulocyte number	J:116168
	increased IgA level	J:116168
	increased monocyte cell number	J:116168
	increased spleen red pulp amount	J:116168
	interstitial pneumonia	J:116168
	joint inflammation	J:116168
	lung inflammation	J:116168
Wls^tm1.1Arte/Wls^tm1.1Arte Krt14^tm1(cre)Wbm/Krt14⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal T cell differentiation	J:202499
	abnormal T cell physiology	J:202499
	abnormal T cell subpopulation ratio	J:202499
	cutaneous mastocytosis	J:202499
	decreased double-positive T cell number	J:202499
	decreased gamma-delta T cell number	J:202499
	decreased T cell number	J:202499
	decreased thymus weight	J:202499
	increased double-negative T cell number	J:202499
	increased macrophage cell number	J:202499
	increased neutrophil cell number	J:202499
	increased T cell proliferation	J:202499
	skin inflammation	J:202499
	small thymus medulla	J:202499
	thymus atrophy	J:202499
	thymus hypoplasia	J:202499
Wls^tm1.1Arte/Wls^tm1.1Arte Tg(Foxn1-cre)1Tbo/0 (involves: C57BL/6)	immune system phenotype	J:202499
Wnt1^tm1Brd/Wnt1^tm1Brd (involves: 129S7/SvEvBrd * C57BL/6J)	decreased thymocyte number	J:75999
Wnt1^tm1Brd/Wnt1^tm1Brd Wnt4^tm1Amc/Wnt4^tm1Amc (involves: 129S1/Sv * 129S7/SvEvBrd * C57BL/6J)	decreased thymocyte number	J:75999
Wnt2b^{tm1b(EUCOMM)Wtsi}/Wnt2b^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Wnt2b^{tm1b(EUCOMM)Wtsi}/Tcp)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	small spleen	J:211773
Wnt3a^{em1(IMPC)Ccpcz}/Wnt3a⁺ (C57BL/6NCrl-Wnt3a^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	increased eosinophil cell number	J:211773
Wnt4^{em1(IMPC)Hmgu}/Wnt4⁺ (C57BL/6NCrl-Wnt4^{em1(IMPC)Hmgu}/Ieg)	decreased lymphocyte cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Wnt4^tm1Amc/Wnt4^tm1Amc (involves: 129S1/Sv)	decreased thymocyte number	J:75999
Wnt5a^b2b3077.1Clo/Wnt5a^b2b3077.1Clo (C57BL/6J-Wnt5a^b2b3077.1Clo)	thymus hypoplasia	J:175213
Wrn^b2b3121.1Clo/Wrn^b2b3121.1Clo (C57BL/6J-Wrn^b2b3121.1Clo)	thymus hypoplasia	J:175213
Wrn^{em1(IMPC)Ccpcz}/Wrn^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Wrn^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
Wrn^tm1Led/Wrn^tm1Led (involves: 129S6/SvEvTac * Black Swiss)	heart inflammation	J:106446
	increased susceptibility to infection	J:106446
Wrn^tm1Lgu/Wrn^tm1Lgu (B6J.Cg-Wrn^tm1Lgu)	increased osteoclast cell number	J:213181
Wrnip1^{tm1a(EUCOMM)Wtsi}/Wrnip1^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Wrnip1^{tm1a(EUCOMM)Wtsi}/Cnrm)	decreased T cell number	J:165965
Wsb1^tm1.1Jszh/Wsb1^tm1.1Jszh Ubc^{em1(cre/ERT2)Smoc}/Ubc⁺ (involves: C57BL/6J * C57BL/6N)	decreased inflammatory response	J:358004
Wt1^tm1Jae/Wt1^tm1Jae (involves: 129S4/SvJae * C57BL/6 * MF1)	abnormal spleen development	J:56651
	absent spleen	J:56651
	increased splenocyte apoptosis	J:56651
Wt1^tm1Mlh/Wt1⁺ (involves: 129P2/OlaHsd * C57BL/6)	glomerulonephritis	J:135449
Wt1^tm1Mlh/Wt1⁺ (129P2/OlaHsd-Wt1^tm1Mlh)	glomerulonephritis	J:135449
Wt1^tm1Mlh/Wt1⁺ (involves: 129P2/OlaHsd * C57BL/6 * MF1)	glomerulonephritis	J:135449
Wwc1^tm1Arsc/Wwc1^tm1Arsc Wwc2^tm1.1Arte/Wwc2^tm1.1Arte Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺ (involves: 129 * C57BL/6 * C57BL/6J * DBA)	liver inflammation	J:305034
Wwox^em1Mald/Wwox^em1Mald (FVB/N-Wwox^em1Mald)	microgliosis	J:339564
Wwox^tm1.1Mald/Wwox^tm1.1Mald (involves: C57BL/6 * FVB/N)	abnormal thymus cortex morphology	J:155406
	decreased leukocyte cell number	J:155406
	decreased spleen weight	J:155406
	decreased thymus weight	J:155406
	small spleen	J:155406
	spleen atrophy	J:155406
Wwox^tm1Ria/Wwox⁺ (involves: 129X1/SvJ * C57BL/6)	enlarged spleen	J:120064
Wwox^tm1Ria/Wwox^tm1Ria (involves: 129X1/SvJ * C57BL/6J)	abnormal osteoclast physiology	J:138140
Wwp2^tm1.1Yyiw/Wwp2^tm1.1Yyiw (involves: 129S/SvEv * C57BL/6 * FVB/N)	immune system phenotype	J:228707
	increased circulating interferon-beta level	J:228707
	increased circulating interleukin-6 level	J:228707
	increased circulating tumor necrosis factor level	J:228707
Wwtr1^tm1Benj/Wwtr1^tm1Benj (129S6/SvEvTac-Wwtr1^tm1Benj)	intestinal inflammation	J:125326
Wwtr1^tm1Benj/Wwtr1^tm1Benj (129S6/SvEvTac-Wwtr1^tm1Benj)	lung inflammation	J:125326
Wwtr1^tm1Benj/Wwtr1^tm1Benj (129S-Wwtr1^tm1Benj/J)	intestinal inflammation	J:156586
Wwtr1^tm1Benj/Wwtr1^tm1Benj (129S-Wwtr1^tm1Benj/J)	lung inflammation	J:156586
Wwtr1^tm1Hku/Wwtr1^tm1Hku (involves: 129 * C57BL/6 * ICR)	alveolitis	J:164957
Wwtr1^tm1Hku/Wwtr1^tm1Hku (involves: 129 * C57BL/6 * ICR)	lung inflammation	J:164957
Wwtr1^tm1Whun/Wwtr1^tm1Whun (either: (involves: 129S6/SvEvTac) or (involves: 129S6/SvEvTac * C57BL/6))	tubular nephritis	J:119488
Xaf1^em2.1Cya/Xaf1^em2.1Cya (C57BL/6J-Xaf1^em2.1Cya)	abnormal tumor necrosis factor level	J:344340
	decreased circulating CXCL10 level	J:344340
	decreased circulating interferon-beta level	J:344340
	decreased macrophage cytokine production	J:344340
	immune system phenotype	J:344340
	increased susceptibility to Riboviria infection	J:344340
	increased susceptibility to Riboviria infection induced morbidity/mortality	J:344340
Xbp1^{tm1a(EUCOMM)Wtsi}/Xbp1⁺ (C57BL/6N-Xbp1^{tm1a(EUCOMM)Wtsi}/Ics)	decreased IgG1 level	J:165965
	decreased T cell number	J:165965
Xbp1^{tm1b(EUCOMM)Wtsi}/Xbp1⁺ (C57BL/6N-Xbp1^{tm1b(EUCOMM)Wtsi}/Ics)	decreased large unstained cell number	J:211773
	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
Xbp1^tm2Glm/Xbp1⁺ Tg(Vil1-cre)997Gum/0 (involves: 129S6/SvEvTac * C57BL/6J * FVB/N * SJL)	small intestinal inflammation	J:188627
Xbp1^tm2Glm/Xbp1^tm2Glm Tg(Defa6-icre)1Rsb/0 (involves: 129S6/SvEvTac * C57BL/6)	small intestinal inflammation	J:206084
Xbp1^tm2Glm/Xbp1^tm2Glm Tg(Nes-cre)1Kln/0 (involves: 129S6/SvEvTac * C57BL/6 * SJL)	decreased susceptibility to prion infection	J:131028
Xbp1^tm2Glm/Xbp1^tm2Glm Tg(Vil1-cre)997Gum/0 (involves: 129S6/SvEvTac * C57BL/6J * FVB/N * SJL)	increased susceptibility to bacterial infection	J:188627
	increased susceptibility to induced colitis	J:188627
	small intestinal inflammation	J:188627
Xbp1^tm2Glm/Xbp1^tm2Glm Tg(Vil1-cre)997Gum/0 (involves: 129S6/SvEvTac * C57BL/6 * SJL)	small intestinal inflammation	J:206084
Xbp1^tm2Glm/Xbp1^tm2Glm Tg(Vil1-cre/ERT2)23Syr/0 (involves: 129S6/SvEvTac * C57BL/6 * DBA/2)	small intestinal inflammation	J:206084
Xbp1^tm2Glm/Xbp1^tm2Glm Tnfrsf1a^tm1Imx/Tnfrsf1a^tm1Imx Tg(Vil1-cre)997Gum/0 (involves: 129S6/SvEvTac * C57BL/6 * SJL)	small intestinal inflammation	J:206084
Xbp1^tm3Glm/Xbp1^tm3Glm Tg(Vil1-cre/ERT2)23Syr/0 (involves: 129S6/SvEvTac * C57BL/6 * DBA/2)	small intestinal inflammation	J:188627
Xcl1^tm1.1Dnax/Xcl1^tm1.1Dnax (either: (involves: 129/Sv * BALB/c) or (involves: 129/Sv * C57BL/6))	abnormal immune system morphology	J:176844
	autoimmune response	J:176844
	decreased dendritic cell number	J:176844
	decreased regulatory T cell number	J:176844
	heart inflammation	J:176844
	increased dendritic cell number	J:176844
	increased inflammatory response	J:176844
	lacrimal gland inflammation	J:176844
	liver inflammation	J:176844
	salivary gland inflammation	J:176844
	stomach inflammation	J:176844
Xcl1^tm1Rakr/Xcl1^tm1Rakr (B6.129-Xcl1^tm1Rakr)	decreased cytotoxic T cell cytolysis	J:155297
Xcl1^tm1Rakr/Xcl1^tm1Rakr (B6.129-Xcl1^tm1Rakr)	immune system phenotype	J:155297
Xcl1^tm1Rakr/Xcl1^tm1Rakr Tg(TcraTcrb)1100Mjb/0 (involves: 129/Sv * C57BL/6)	abnormal CD8-positive, alpha-beta T cell physiology	J:155297
	decreased cytotoxic T cell cytolysis	J:155297
	decreased interferon-gamma secretion	J:155297
	decreased T cell number	J:155297
Xcr1^tm1Dgen/Xcr1^tm1Dgen (B6.129P2-Xcr1^tm1Dgen/J)	abnormal dendritic cell physiology	J:155297
Xcr1^tm1Dgen/Xcr1^tm1Dgen (B6.129P2-Xcr1^tm1Dgen/J)	immune system phenotype	J:155297
Xcr1^{tm2(HBEGF/Venus)Ksho}/Xcr1⁺ (involves: C57BL/6 * C57BL/6J)	abnormal antigen presentation	J:204851
	abnormal CD8-positive, alpha-beta T cell physiology	J:204851
	decreased dendritic cell number	J:204851
	decreased interferon-gamma secretion	J:204851
	decreased susceptibility to bacterial infection	J:204851
	immune system phenotype	J:204851
Xdh^tm1.1Takni/Xdh^tm1.1Takni (involves: C57BL/6)	abnormal peritoneal macrophage morphology	J:281671
Xdh^tm1Fink/Xdh^tm1Fink (involves: 129X1/SvJ * C57BL/6J)	tubulointerstitial nephritis	J:166326
Xiap^tm1Hs/Xiap^tm1Hs (B6.129P2-Xiap^tm1Hs)	immune system phenotype	J:138979
Xkrx^{tm1b(EUCOMM)Wtsi}/Xkrx^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Xkrx^{tm1b(EUCOMM)Wtsi}/Wtsi)	increased anti-nuclear antigen antibody level	J:211773
Xpa^tm1Tnka/Xpa^tm1Tnka (involves: C57BL/6 * CBA)	abnormal immune system physiology	J:35054
	abnormal Langerhans cell physiology	J:35054
	abnormal lymphocyte physiology	J:55739
	abnormal NK cell physiology	J:55739
	increased NK cell number	J:55739
Xpnpep1^{tm1a(KOMP)Wtsi}/Xpnpep1^{tm1a(KOMP)Wtsi} (C57BL/6N-Xpnpep1^{tm1a(KOMP)Wtsi}/Wtsi)	abnormal thymus morphology	J:239583
	blood in lymph vessels	J:239583
	increased gamma-delta T cell number	J:211773
	increased NK cell number	J:211773
Xpo5^em1(IMPC)Mbp/Xpo5⁺ (C57BL/6NCrl-Xpo5^em1(IMPC)Mbp/Mmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Xpr1^Sxv/Xpr1^Sxv (M. spretus)	increased susceptibility to Retroviridae infection	J:7951
Xrcc4^tm1Fwa/Xrcc4^tm1Fwa (involves: 129P2/OlaHsd * C57BL/6)	thymus hypoplasia	J:65218
Xrcc5^{em1(IMPC)Ccpcz}/Xrcc5^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Xrcc5^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	decreased CD4-positive NK T cell number	J:211773
	decreased CD4-positive, alpha-beta T cell number	J:211773
	decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	decreased CD8-positive, alpha-beta T cell number	J:211773
	decreased CD8-positive, naive alpha-beta T cell number	J:211773
	decreased effector memory T-helper cell number	J:211773
	decreased leukocyte cell number	J:211773
	decreased memory-marker CD4-positive NK T cell number	J:211773
	decreased NK T cell number	J:211773
	decreased T-helper cell number	J:211773
	immune system phenotype	J:211773
	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
	increased effector memory T-helper cell number	J:211773
	small spleen	J:211773
	small thymus	J:211773
Xrcc5^m1Btlr/Xrcc5^m1Btlr (C57BL/6J-Xrcc5^m1Btlr)	abnormal B cell differentiation	J:274736
	abnormal CD8-positive, alpha-beta T cell differentiation	J:274736
	abnormal T cell differentiation	J:274736
	decreased B-2 B cell number	J:274736
	decreased CD4-positive, alpha-beta T cell number	J:274736
	decreased CD8-positive, alpha-beta T cell number	J:274736
	decreased CD8-positive, naive alpha-beta T cell number	J:274736
	decreased T cell number	J:274736
	increased B-1a cell number	J:274736
	increased B-1b cell number	J:274736
	increased CD4-positive, alpha-beta T cell number	J:274736
	increased dendritic cell number	J:274736
	increased effector memory CD4-positive, alpha-beta T cell number	J:274736
	increased effector memory CD8-positive, alpha-beta T cell number	J:274736
	increased neutrophil cell number	J:274736
Xrcc5^tm1Dbr/Xrcc5^tm1Dbr (involves: 129S1/Sv * C57BL/6)	abnormal B cell differentiation	J:34834
	absent T cells	J:34834
	arrested B cell differentiation	J:34834
	arrested T cell differentiation	J:34834
	increased double-negative T cell number	J:34834
	lymph node hypoplasia	J:34834
	thymus hypoplasia	J:34834
Xrcc5^tm1Dbr/Xrcc5^tm1Dbr Lig4^tm1Fwa/Lig4^tm1Fwa (involves: 129S6/SvEvTac * C57BL/6)	abnormal lymphocyte morphology	J:80467
Xrcc5^tm1Nus/Xrcc5^tm1Nus (involves: 129S1/Sv * 129X1/SvJ)	abnormal class switch recombination	J:120658
	abnormal humoral immune response	J:120658
	spleen hypoplasia	J:108657
	thymus hypoplasia	J:108657
Xrcc6^avon/Xrcc6^avon (involves: C57BL/6JAnu)	decreased B cell number	J:104190
Xrcc6^avon/Xrcc6^avon (involves: C57BL/6JAnu)	decreased T cell number	J:104190
Xrcc6^tm1Fwa/Xrcc6^tm1Fwa (involves: 129S6/SvEvTac * C57BL/6J)	abnormal B cell differentiation	J:44361
	abnormal B cell morphology	J:44361
	abnormal T cell differentiation	J:44361
	abnormal T cell morphology	J:44361
	absent immature B cells	J:44361
	absent mature B cells	J:44361
	absent pre-B cells	J:44361
	arrested B cell differentiation	J:44361
	decreased IgM level	J:44361
	decreased single-positive T cell number	J:44361
	decreased thymocyte number	J:44361
	increased double-positive T cell number	J:44361
	increased T cell derived lymphoma incidence	J:44361
Xrcc6^tm1Gcl/Xrcc6^tm1Gcl (involves: 129S1/Sv * C57BL/6)	abnormal B cell differentiation	J:108657
	abnormal immune system organ morphology	J:108657
	absent mature B cells	J:108657
	decreased spleen white pulp amount	J:108657
	small lymph nodes	J:108657
	small spleen	J:108657
	small thymus	J:108657
	spleen hypoplasia	J:108657
	thymus hypoplasia	J:108657
Xylt1^npo/Xylt1^npo (involves: C57BL/6J * FVB/NJ)	abnormal osteoclast differentiation	J:205339
X/Yaa ((NZB x BXSB)F1)	abnormal immune cell physiology	J:6235
	abnormal lymph node morphology	J:6235
	enlarged lymph nodes	J:6235
	increased anti-erythrocyte antigen antibody level	J:6235
	increased anti-nuclear antigen antibody level	J:6235
	increased autoantibody level	J:6235
	increased spleen weight	J:6235
	increased susceptibility to autoimmune disorder	J:6235
X/Yaa ((SJL/J x BXSB)F1)	enlarged lymph nodes	J:6235
X/Yaa ((SJL/J x BXSB)F1)	increased susceptibility to autoimmune disorder	J:6235
X/Yaa ((C57BL/6J x BXSB)F1)	enlarged lymph nodes	J:6235
X/Yaa ((C57BL/6J x BXSB)F1)	increased susceptibility to autoimmune disorder	J:6235
X/Yaa (involves: BXSB * NZB)	enlarged lymph nodes	J:6235
X/Yaa (involves: BXSB * NZB)	increased susceptibility to autoimmune disorder	J:6235
X/Yaa (BXSB/MpJ)	abnormal B cell differentiation	J:108760
	abnormal lymph node morphology	J:6235
	abnormal spleen B cell follicle morphology	J:179430
	abnormal T cell subpopulation ratio	J:179430
	enlarged lymph nodes	J:6235
	glomerulonephritis	J:6235
	increased anti-erythrocyte antigen antibody level	J:6235
	increased anti-nuclear antigen antibody level	J:179430
	increased circulating interleukin-21 level	J:93740
	increased IgG1 level	J:179430, J:93740
	increased IgG2a level	J:179430
	increased IgG2b level	J:179430
	increased IgG3 level	J:93740
	increased monocyte cell number	J:7308
	increased plasma cell number	J:108760
	increased spleen weight	J:6235
	increased splenocyte number	J:179430
	increased susceptibility to autoimmune disorder	J:108760, J:6235
X/Yaa ((NZW x SB)F1)	abnormal immune serum protein physiology	J:7276
	glomerulonephritis	J:7276
	increased susceptibility to autoimmune disorder	J:7276
X/Yaa ((NZW x BXSB)F1)	abnormal immune serum protein physiology	J:7276
X/Yaa ((NZW x BXSB)F1)	increased susceptibility to autoimmune disorder	J:7276
X/Yaa (BXSB/MpJScr)	decreased CD4-positive, alpha-beta T cell number	J:10973
	glomerulonephritis	J:10973
	increased anti-nuclear antigen antibody level	J:10973
	increased IgG level	J:10973
	increased monocyte cell number	J:10973
	increased susceptibility to autoimmune disorder	J:10973
X/Yaa ((NZB x B6.SB/Le-Yaa)F1)	increased monocyte cell number	J:129409
X/Yaa (B6.SB-Yaa/J)	decreased marginal zone B cell number	J:127600
X/Yaa (B6.SB-Yaa/J)	increased splenocyte proliferation	J:127600
Yaa2^BXSB/J/? (involves: BXSB/J * C57BL/10Ola)	kidney inflammation	J:49868
Yaa3^BXSB/J/? (involves: BXSB/J * C57BL/10Ola)	kidney inflammation	J:49868
Yaa4^BXSB/J/? (involves: BXSB/J * C57BL/10Ola)	kidney inflammation	J:49868
Yaail^NZW/Ola/? (involves: C57BL/6Ola * NZW/Ola)	glomerulonephritis	J:52110
Yaail^NZW/Ola/? (involves: C57BL/6Ola * NZW/Ola)	increased anti-double stranded DNA antibody level	J:52110
Yap1^M1Btlr/Yap1^M1Btlr (C57BL/6J-Yap1^M1Btlr)	increased susceptibility to induced colitis	J:267549
Yap1^tm1.1Dupa/Yap1^tm1.1Dupa Tg(Vil1-cre)997Gum/0 (involves: 129P2/OlaHsd * C57BL/6J * SJL)	increased susceptibility to induced colitis	J:165471
Ydjc^{tm1(KOMP)Wtsi}/Ydjc^{tm1(KOMP)Wtsi} (C57BL/6N-Ydjc^{tm1(KOMP)Wtsi}/Wtsi)	increased effector memory T-helper cell number	J:211773
	increased germinal center B cell number	J:211773
Yeats4^em1Zfa/Yeats4^em1Zfa Commd10^{Tg(Vav1-icre)A2Kio}/Commd10⁺ (involves: C57BL/6 * C57BL/10 * CBA/Ca)	abnormal acute inflammation	J:282740
	abnormal gut-associated lymphoid tissue morphology	J:282740
	abnormal interleukin secretion	J:282740
	abnormal lymphocyte physiology	J:282740
	abnormal lymphopoiesis	J:282740
	decreased interferon-gamma secretion	J:282740
	decreased interleukin-5 secretion	J:282740
	decreased interleukin-12 secretion	J:282740
	decreased lymphocyte cell number	J:282740
	decreased Peyer's patch number	J:282740
	increased susceptibility to bacterial infection	J:282740
Yipf6^em1(IMPC)Mbp/Yipf6^em1(IMPC)Mbp (C57BL/6N-Yipf6^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	increased monocyte cell number	J:211773
Yipf6^M1Btlr/Y (C57BL/6J-Yipf6^M1Btlr/Mmucd)	colitis	J:187584
Yipf6^M1Btlr/Y (C57BL/6J-Yipf6^M1Btlr/Mmucd)	increased susceptibility to induced colitis	J:187584
Yipf6^M1Btlr/Yipf6^M1Btlr (C57BL/6J-Yipf6^M1Btlr/Mmucd)	colitis	J:187584
Yipf6^M1Btlr/Yipf6^M1Btlr (C57BL/6J-Yipf6^M1Btlr/Mmucd)	increased susceptibility to induced colitis	J:187584
Ykt6^em1(IMPC)J/Ykt6⁺ (C57BL/6NJ-Ykt6^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
Yod1^em1Smoc/Yod1^em1Smoc (C57BL/6JSmoc-Yod1^em1Smoc/Smoc)	abnormal macrophage physiology	J:350806
	decreased circulating fibrinogen level	J:350806
	increased circulating interleukin-1 beta level	J:350806
	increased inflammatory response	J:350806
	increased interleukin-1 beta secretion	J:350806
	increased macrophage cytokine production	J:350806
	increased susceptibility to bacterial infection	J:350806
	increased susceptibility to bacterial infection induced morbidity/mortality	J:350806
Yod1^tm1bNarl/Yod1^tm1bNarl (C57BL/6N-Yod1^tm1bNarl/Narl)	decreased lymphocyte cell number	J:211773
Yod1^tm1bNarl/Yod1^tm1bNarl (C57BL/6N-Yod1^tm1bNarl/Narl)	increased neutrophil cell number	J:211773
Ythdf3^em1(IMPC)Mbp/Ythdf3^em1(IMPC)Mbp (C57BL/6N-Ythdf3^em1(IMPC)Mbp/MbpMmucd)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Ythdf3^em1Caox/Ythdf3^em1Caox (involves: C57BL/6J)	abnormal macrophage physiology	J:276397
	decreased susceptibility to Riboviria infection	J:276397
	decreased susceptibility to Riboviria infection induced morbidity/mortality	J:276397
	immune system phenotype	J:276397
Ywhaz^{tm1b(EUCOMM)Hmgu}/Ywhaz⁺ (C57BL/6N-Ywhaz^{tm1b(EUCOMM)Hmgu}/Tcp)	enlarged lymph nodes	J:211773
	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
Yy1^tm3.1Yshi/Yy1⁺ (involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6J)	immune system phenotype	J:208226
Yy2^em1(IMPC)Mbp/Yy2^em1(IMPC)Mbp (C57BL/6NCrl-Yy2^em1(IMPC)Mbp/Mmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
Zap70^m1Btlr/Zap70^m1Btlr (involves: C57BL/6J)	abnormal class switch recombination	J:185495
	abnormal humoral immune response	J:167119
	absent CD4-positive, alpha-beta T cells	J:167119
	absent CD8-positive, alpha-beta T cells	J:167119
	decreased IgG level	J:185495
	decreased T cell number	J:185495
	immune system phenotype	J:167119, J:185495
Zap70^m1Saka/Zap70^m1Saka (involves: BALB/c)	abnormal lymph node cell ratio	J:154166
	abnormal positive T cell selection	J:154166, J:86607
	abnormal splenic cell ratio	J:154166
	abnormal T cell clonal deletion	J:154166
	abnormal T cell differentiation	J:86607
	abnormal T cell selection	J:86607
	abnormal thymocyte activation	J:154166
	abnormal thymus cell ratio	J:154166
	chronic joint inflammation	J:86607
	decreased CD4-positive, alpha-beta T cell number	J:154166, J:86607
	decreased CD8-positive, alpha-beta T cell number	J:154166, J:86607
	decreased interleukin-2 secretion	J:154166
	decreased regulatory T cell number	J:154166
	decreased T cell proliferation	J:154166, J:86607
	increased activated T cell number	J:154166
	increased autoantibody level	J:86607
	increased B cell number	J:86607
	increased immunoglobulin level	J:86607
	increased interleukin-17 secretion	J:154166
	increased memory T cell number	J:154166
	increased susceptibility to induced arthritis	J:154166
	lung inflammation	J:86607
	rheumatoid arthritis	J:86607
Zap70^m1Saka/Zap70^m1Saka Tg(DO11.10)10Dlo/0 (involves: BALB/c * C3H * C57BL/6)	decreased T cell number	J:86607
	decreased T cell proliferation	J:86607
Zap70^m1Saka/Zap70^m1Saka Tg(TcraH-Y,TcrbH-Y)71Vbo/0 (involves: BALB/c * C57BL/6J * DBA/2J)	abnormal positive T cell selection	J:86607
	autoimmune arthritis	J:86607
Zap70^m1Saka/Zap70^tm1Dlo (involves: 129P2/OlaHsd * BALB/c)	autoimmune arthritis	J:86607
Zap70^m1Saka/Zap70^tm2.1Weis (involves: 129S4/SvJae * BALB/c)	abnormal T cell clonal deletion	J:154166
	decreased susceptibility to induced arthritis	J:154166
Zap70^m2Btlr/Zap70^m2Btlr (involves: C57BL/6J)	decreased T cell number	J:174837
Zap70^m3Btlr/Zap70^m3Btlr (C57BL/6J-Zap70^m3Btlr)	decreased IgG level	J:225043
Zap70^m3Btlr/Zap70^m3Btlr (C57BL/6J-Zap70^m3Btlr)	impaired humoral immune response	J:225043
Zap70^m4Btlr/Zap70^m4Btlr (C57BL/6J-Zap70^m4Btlr)	decreased CD4-positive, alpha-beta T cell number	J:236698
	decreased CD8-positive, alpha-beta T cell number	J:236698
	decreased T cell number	J:236698
Zap70^m5Btlr/Zap70^m5Btlr (C57BL/6J-Zap70^m5Btlr)	abnormal humoral immune response	J:254830
	decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:254830
	decreased CD8-positive, alpha-beta T cell number	J:254830
	decreased CD8-positive, naive alpha-beta T cell number	J:254830
	decreased IgG level	J:254830
	increased B cell number	J:254830
	increased central memory CD4-positive, alpha-beta T cell number	J:254830
	increased central memory CD8 positive, alpha-beta T cell number	J:254830
	increased effector memory CD4-positive, alpha-beta T cell number	J:254830
Zap70^m6Btlr/Zap70^m6Btlr (C57BL/6J-Zap70^m6Btlr)	abnormal humoral immune response	J:254831
	decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:254831
	decreased CD8-positive, alpha-beta T cell number	J:254831
	decreased CD8-positive, naive alpha-beta T cell number	J:254831
	decreased IgG level	J:254831
	increased B cell number	J:254831
	increased central memory CD4-positive, alpha-beta T cell number	J:254831
	increased central memory CD8 positive, alpha-beta T cell number	J:254831
	increased effector memory CD4-positive, alpha-beta T cell number	J:254831
Zap70^m6Hefl/Zap70^m6Hefl (C3HeB/FeJ-Zap70^m6Hefl)	abnormal humoral immune response	J:137446
	abnormal T cell differentiation	J:137446
	decreased CD4-positive, alpha-beta T cell number	J:137446
	decreased CD8-positive, alpha-beta T cell number	J:137446
	decreased T cell number	J:137446
	immune system phenotype	J:137446
	increased IgE level	J:137446
	increased IgG1 level	J:137446
Zap70^m6Hefl/Zap70^tm1Weis (involves: 129X1/SvJ * C3HeB/FeJ * C57BL/10 * DBA/2)	decreased T cell number	J:137446
	increased IgE level	J:137446
Zap70^m7Btlr/Zap70^m7Btlr (C57BL/6J-Zap70^m7Btlr)	abnormal humoral immune response	J:254832
	decreased IgG level	J:254832
	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:254832
	increased central memory CD8 positive, alpha-beta T cell number	J:254832
Zap70^m8Btlr/Zap70^m8Btlr (C57BL/6J-Zap70^m8Btlr)	decreased CD8-positive, naive alpha-beta T cell number	J:272864
Zap70^m8Btlr/Zap70^m8Btlr (C57BL/6J-Zap70^m8Btlr)	increased central memory CD8 positive, alpha-beta T cell number	J:272864
Zap70^mrtle/Zap70^mrtle (C57BL/6JSfdAnu-Zap70^mrtle/Apb)	abnormal positive T cell selection	J:104190
	abnormal T cell subpopulation ratio	J:104190
	absent T cells	J:104190
	arrested T cell differentiation	J:104190
	decreased T cell number	J:104190
Zap70^mrtle/Zap70^mrtle (involves: C57BL/6JSfdAnu)	abnormal double-positive T cell morphology	J:211510
	abnormal regulatory T cell number	J:211510
	decreased CD4-positive, alpha-beta T cell number	J:211510
	decreased CD8-positive, alpha-beta T cell number	J:211510
	increased double-positive T cell number	J:211510
Zap70^mrtle/Zap70^rps (involves: C57BL/6 * C57BL/6JSfdAnu)	abnormal CD4-positive, alpha beta T cell morphology	J:211510
	abnormal double-positive T cell morphology	J:211510
	abnormal regulatory T cell number	J:211510
	decreased CD4-positive, alpha-beta T cell number	J:211510
	decreased CD8-positive, alpha-beta T cell number	J:211510
	increased double-positive T cell number	J:211510
Zap70^mur/Zap70^mur (C57BL/6Apb-Zap70^mur/ApbH)	abnormal T cell activation	J:104190
	abnormal T cell physiology	J:104190
	decreased T cell number	J:104190
	increased IgG2b level	J:104190
Zap70^st/Zap70^st (involves: C57BL/6)	abnormal T cell physiology	J:41170
	arrested T cell differentiation	J:41170
	decreased T cell number	J:41170
	thymus hypoplasia	J:41170
Zap70^st/Zap70^tm1Dlo (involves: C57BL/6)	arrested T cell differentiation	J:41170
Zap70^tm1.1Mmal/Zap70^tm1.1Mmal (B6.129P2-Zap70^tm1.1Mmal)	immune system phenotype	J:71099
Zap70^tm1.1Mmal/Zap70^tm1.1Mmal Tg(TcraH-Y,TcrbH-Y)71Vbo/0 (involves: 129P2/OlaHsd * BALB/cJ * C57BL/6J * DBA/2J)	immune system phenotype	J:71099
Zap70^tm1.1Mmal/Zap70^tm1.1Mmal Tg(TcrLCMV)327Sdz/0 (involves: 129P2/OlaHsd * BALB/cJ * C57BL/6 * DBA/2)	abnormal cytokine secretion	J:71099
	abnormal T cell proliferation	J:71099
	immune system phenotype	J:71099
Zap70^tm1Dlo/Zap70^tm1Dlo (involves: 129P2/OlaHsd)	increased double-positive T cell number	J:97610
Zap70^tm1Weis/Zap70^tm1Weis (involves: 129X1/SvJ * C57BL/6J)	abnormal lymph node cell ratio	J:74974
	abnormal splenic cell ratio	J:74974
	abnormal T cell differentiation	J:74974
	arrested T cell differentiation	J:74974
	small lymph nodes	J:74974
Zap70^tm2.1Mmal/Zap70^tm2.1Mmal (B6.129P2-Zap70^tm2.1Mmal)	immune system phenotype	J:71099
Zap70^tm2.1Mmal/Zap70^tm2.1Mmal Tg(TcraH-Y,TcrbH-Y)71Vbo/0 (involves: 129P2/OlaHsd * BALB/cJ * C57BL/6J * DBA/2J)	abnormal lymph node cell ratio	J:71099
	abnormal T cell morphology	J:71099
	abnormal thymus cell ratio	J:71099
	immune system phenotype	J:71099
Zap70^tm2.1Mmal/Zap70^tm2.1Mmal Tg(TcrLCMV)327Sdz/0 (involves: 129P2/OlaHsd * BALB/cJ * C57BL/6 * DBA/2)	abnormal T cell morphology	J:71099
	immune system phenotype	J:71099
Zap70^tm2.1Weis/Zap70^tm2.1Weis (B6.129S4-Zap70^tm2.1Weis)	abnormal CD8-positive, alpha-beta T cell differentiation	J:154166
	abnormal thymus cell ratio	J:154166
	decreased CD4-positive, alpha-beta T cell number	J:154166
	decreased CD8-positive, alpha-beta T cell number	J:154166
Zap70^tm2.1Weis/Zap70^tm2.1Weis (C.129S4-Zap70^tm2.1Weis)	abnormal lymph node cell ratio	J:154166
	abnormal positive T cell selection	J:154166
	abnormal regulatory T cell physiology	J:154166
	abnormal splenic cell ratio	J:154166
	abnormal T cell clonal deletion	J:154166
	abnormal thymocyte activation	J:154166
	abnormal thymus cell ratio	J:154166
	decreased CD4-positive, alpha-beta T cell number	J:154166
	decreased CD8-positive, alpha-beta T cell number	J:154166
	decreased interleukin-2 secretion	J:154166
	decreased regulatory T cell number	J:154166
	decreased T cell proliferation	J:154166
	immune system phenotype	J:154166
	increased activated T cell number	J:154166
	increased interleukin-17 secretion	J:154166
	increased memory T cell number	J:154166
Zap70^tm2.1Weis/Zap70^tm2.1Weis Tg(DO11.10)10Dlo/? (involves: 129S4/SvJae * BALB/c * C3H * C57BL/6)	abnormal positive T cell selection	J:154166
Zap70^tm2.1Weis/Zap70^tm2.1Weis Tg(TcraH-Y,TcrbH-Y)71Vbo/? (involves: 129S4/SvJae * C57BL/6J * DBA/2J)	abnormal positive T cell selection	J:154166
	abnormal T cell clonal deletion	J:154166
Zbp1^tm1.1Jreh/Zbp1^tm1.1Jreh (involves: C57BL/6 * C57BL/6N)	increased susceptibility to Herpesvirales infection	J:252669
Zbp1^tm1Aki/Zbp1^tm1Aki (involves: C57BL/6)	immune system phenotype	J:132662
Zbtb1^m1Btlr/Zbtb1^m1Btlr (involves: C3H/HeN * C57BL/6J)	abnormal B cell differentiation	J:178820
	abnormal immune system physiology	J:178820
	abnormal T cell differentiation	J:178820
	abnormal thymus morphology	J:178820
	decreased B cell number	J:178820
	decreased CD4-positive, alpha-beta T cell number	J:178820
	decreased CD8-positive, alpha-beta T cell number	J:178820
	decreased DN2 thymocyte number	J:178820
	decreased DN3 thymocyte number	J:178820
	decreased DN4 thymocyte number	J:178820
	decreased double-positive T cell number	J:178820
	decreased follicular B cell number	J:178820
	decreased NK cell number	J:178820
	decreased T cell number	J:178820
	decreased transitional stage B cell number	J:178820
	immune system phenotype	J:178820
	increased B cell number	J:178820
	thymus hypoplasia	J:178820
Zbtb1^m2Btlr/Zbtb1^m2Btlr (C57BL/6J-Zbtb1^m2Btlr)	abnormal CD8-positive, alpha-beta T cell differentiation	J:272845
Zbtb1^m2Btlr/Zbtb1^m2Btlr (C57BL/6J-Zbtb1^m2Btlr)	increased central memory CD8 positive, alpha-beta T cell number	J:272845
Zbtb7a^tm1Ppp/Zbtb7a^tm1Ppp (B6.129S1-Zbtb7a^tm1Ppp)	abnormal lymphopoiesis	J:121576
	abnormal response to transplant	J:121576
	decreased B cell number	J:121576
	decreased pro-B cell number	J:121576
Zbtb7a^tm1Ppp/Zbtb7a^tm2Ppp Tg(Mx1-cre)1Cgn/0 (involves: 129S1/Sv * C57BL/6 * CBA)	abnormal B cell differentiation	J:121576
	abnormal double-positive T cell morphology	J:121576
	abnormal response to transplant	J:121576
	decreased B cell number	J:121576
	decreased leukocyte cell number	J:121576
	immune system phenotype	J:121576
Zbtb7b^hd/Zbtb7b^hd (involves: 129/Sv * BALB/c * C3H * C57BL/6)	abnormal CD4-positive T cell differentiation	J:48734
	absent CD4-positive, alpha-beta T cells	J:48734
	increased CD8-positive, alpha-beta T cell number	J:48734
Zbtb7b^hpls/Zbtb7b^hpls (involves: C57BL/6JAnu)	abnormal humoral immune response	J:104190
Zbtb7b^hpls/Zbtb7b^hpls (involves: C57BL/6JAnu)	decreased CD4-positive, alpha-beta T cell number	J:104190
Zbtb7b^tm1.1Rbo/Zbtb7b^tm1.1Rbo (Not Specified)	abnormal CD8-positive, alpha-beta T cell number	J:141145
	abnormal T cell differentiation	J:141145
	decreased CD4-positive, alpha-beta T cell number	J:141145
Zbtb7b^tm1.1Skok/Zbtb7b^tm1.1Skok (involves: 129/Sv * C57BL/6)	decreased CD4-positive, alpha-beta T cell number	J:169841
Zbtb7b^tm1.1Tani/Zbtb7b^tm1.1Tani (involves: 129 * C57BL/6)	increased double-negative T cell number	J:141142
Zbtb7b^tm1Itan/Zbtb7b^tm1.1Tani (involves: 129 * C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:141142
	abnormal CD4-positive, alpha-beta T cell physiology	J:141142
	decreased CD4-positive, alpha-beta T cell number	J:141142
	increased CD8-positive, alpha-beta T cell number	J:141142
	increased double-negative T cell number	J:141142
Zbtb7b^tm1Itan/Zbtb7b^tm2Itan (involves: 129 * C57BL/6)	decreased CD4-positive, alpha-beta T cell number	J:141142
	increased CD8-positive, alpha-beta T cell number	J:141142
	increased double-negative T cell number	J:141142
Zbtb7b^tm1Litt/Zbtb7b^tm1.2Litt (involves: C57BL/6)	abnormal double-positive T cell morphology	J:141144
	decreased CD4-positive, alpha-beta T cell number	J:141144
	increased CD8-positive, alpha-beta T cell number	J:141144
	increased interferon-gamma secretion	J:141144
Zbtb7b^tm2Litt/Zbtb7b^tm1.2Litt (involves: 129P2/OlaHsd)	decreased CD4-positive, alpha-beta T cell number	J:141144
Zbtb7b^tm2Litt/Zbtb7b^tm1.2Litt Tg(Lck-cre)1Cwi/? (involves: 129P2/OlaHsd * C57BL/6)	abnormal T cell differentiation	J:141144
	decreased CD4-positive, alpha-beta T cell number	J:141144
Zbtb7b^tm2Litt/Zbtb7b^tm2Litt (involves: 129P2/OlaHsd * C57BL/6 * FVB/N)	absent CD4-positive, alpha-beta T cells	J:141519
Zbtb7b^tm4.1Itan/Zbtb7b^tm4.1Itan (Not Specified)	decreased CD4-positive, alpha-beta T cell number	J:193321
Zbtb7b^tm4.1Itan/Zbtb7b^tm4.1Itan (Not Specified)	increased CD8-positive, alpha-beta T cell number	J:193321
Zbtb7b^tm6.1Itan/Zbtb7b^tm6.1Itan Tg(Cd4-cre)1Cwi/? (involves: C57BL/6 * DBA/2)	decreased CD8-positive, alpha-beta T cell number	J:195348
Zbtb7b^tm6.1Itan/Zbtb7b^tm6.1Itan Tg(Cd8a-cre)1Itan/? (involves: C57BL/6)	immune system phenotype	J:195348
Zbtb7b^tm7Itan/Zbtb7b^tm7Itan (Not Specified)	decreased CD4-positive, alpha-beta T cell number	J:195348
Zbtb16^em1(IMPC)Mbp/Zbtb16^em1(IMPC)Mbp (C57BL/6NCrl-Zbtb16^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	small spleen	J:211773
Zbtb16^lu/Zbtb16^lu (B6.C3-Zbtb16^lu/J)	decreased NK T cell number	J:139690
Zbtb17^tm1Cksn/Zbtb17^tm1Cksn Commd10^{Tg(Vav1-icre)A2Kio}/Commd10⁺ (B6.Cg-Zbtb17^tm1Cksn Commd10^{Tg(Vav1-icre)A2Kio})	arrested T cell differentiation	J:170508
	decreased DN1 thymic pro-T cell number	J:170508
	decreased DN2 thymocyte number	J:170508
	decreased DN3 thymocyte number	J:170508
	decreased double-negative T cell number	J:170508
	decreased gamma-delta T cell number	J:170508
	decreased T cell number	J:170508
	decreased thymocyte number	J:170508
	increased T cell apoptosis	J:170508
	thymus hypoplasia	J:170508
Zbtb17^tm1Cksn/Zbtb17^tm1Cksn Tg(Lck-cre)548Jxm/0 (B6.Cg-Zbtb17^tm1Cksn Tg(Lck-cre)548Jxm)	immune system phenotype	J:170508
Zbtb32^tm1Iho/Zbtb32^tm1Iho (involves: BALB/c)	abnormal cytokine secretion	J:94944
Zbtb32^tm1Iho/Zbtb32^tm1Iho (involves: BALB/c)	increased T cell proliferation	J:94944
Zbtb32^tm1Iho/Zbtb32^tm1Iho (involves: C57BL/6)	increased T cell proliferation	J:94944
Zbtb32^tm2Ppp/Zbtb32^tm2Ppp (involves: 129S1/Sv)	abnormal cytokine secretion	J:95119
Zbtb32^tm2Ppp/Zbtb32^tm2Ppp (involves: 129S1/Sv)	increased T cell proliferation	J:95119
Zbtb38^em1Dbhat/Zbtb38^em1Dbhat Commd10^{Tg(Vav1-icre)A2Kio}/Commd10⁺ (involves: C57BL/6J * C57BL/6N * C57BL/10 * CBA/Ca)	immune system phenotype	J:296556
Zbtb42^em1(IMPC)Mbp/Zbtb42^em1(IMPC)Mbp (C57BL/6NCrl-Zbtb42^em1(IMPC)Mbp/Mmucd)	enlarged lymph nodes	J:211773
Zbtb46^{tm1(HBEGF)Mnz}/Zbtb46⁺ (C57BL/6-Zbtb46^{tm1(HBEGF)Mnz})	abnormal memory T cell physiology	J:189122
	abnormal response to infection	J:189122
	abnormal T-helper 1 physiology	J:189122
	decreased dendritic cell number	J:189122
	immune system phenotype	J:189122
	increased monocyte cell number	J:189122
	increased neutrophil cell number	J:189122
	increased susceptibility to parasitic infection	J:189122
Zbtb46^tm1Kmm/Zbtb46^tm1Kmm (129S/SvEv-Zbtb46^tm1Kmm)	abnormal dendritic cell physiology	J:184205
Zbtb46^tm1Kmm/Zbtb46^tm1Kmm (129S/SvEv-Zbtb46^tm1Kmm)	immune system phenotype	J:184205
Zbtb46^tm2.1Mnz/Zbtb46^tm2.1Mnz (involves: C57BL/6)	abnormal dendritic cell morphology	J:191314
	abnormal lymphangiogenesis	J:191314
	decreased dendritic cell number	J:191314
	enlarged lymph nodes	J:191314
	increased dendritic cell number	J:191314
	lymph node hyperplasia	J:191314
Zc2hc1b^{em1(IMPC)Ccpcz}/Zc2hc1b^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Zc2hc1b^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Zc2hc1c^{em1(IMPC)Ccpcz}/Zc2hc1c^{em1(IMPC)Ccpcz} (C57BL/6N-Zc2hc1c^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
Zc3h7ait^em1Caox/Zc3h7ait^em1Caox (C57BL/6J-Zc3h7ait^em1Caox)	abnormal interferon secretion	J:282488
	abnormal macrophage activation involved in immune response	J:282488
	decreased circulating interferon-alpha level	J:282488
	decreased circulating interferon-beta level	J:282488
	decreased circulating interleukin-6 level	J:282488
	decreased interferon-alpha secretion	J:282488
	decreased interferon-beta secretion	J:282488
	decreased interleukin-6 secretion	J:282488
	immune system phenotype	J:282488
	increased susceptibility to Riboviria infection	J:282488
	increased susceptibility to Riboviria infection induced morbidity/mortality	J:282488
Zc3h7b^em1(IMPC)J/Zc3h7b^em1(IMPC)J (C57BL/6NJ-Zc3h7b^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
Zc3h8^{em1(IMPC)Ccpcz}/Zc3h8⁺ (C57BL/6N-Zc3h8^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	decreased CD8-positive, naive alpha-beta T cell number	J:211773
	enlarged spleen	J:211773
Zc3h11a^em1(IMPC)Mbp/Zc3h11a⁺ (C57BL/6NCrl-Zc3h11a^em1(IMPC)Mbp/Mmucd)	abnormal thymus morphology	J:211773
Zc3h12a^tm1Aki/Zc3h12a^tm1Aki (involves: 129X1/SvJ * C57BL/6)	abnormal acute inflammation	J:147868
	abnormal class switch recombination	J:147868
	enlarged lymph nodes	J:147868
	enlarged spleen	J:147868
	granulomatous inflammation	J:147868
	increased anti-double stranded DNA antibody level	J:147868
	increased anti-nuclear antigen antibody level	J:147868
	increased IgA level	J:147868
	increased IgG1 level	J:147868
	increased IgG2a level	J:147868
	increased IgG2b level	J:147868
	increased IgG3 level	J:147868
	increased IgM level	J:147868
	increased immunoglobulin level	J:147868
	increased interferon-gamma secretion	J:147868
	increased interleukin-6 secretion	J:147868
	increased interleukin-12b secretion	J:147868
	increased leukocyte cell number	J:147868
	increased memory T cell number	J:147868
	increased plasma cell number	J:147868
Zc3h12a^{tm1c(EUCOMM)Hmgu}/Zc3h12a^{tm1c(EUCOMM)Hmgu} Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6N)	increased inflammatory response	J:304105
Zc3h12a^{tm1c(EUCOMM)Hmgu}/Zc3h12a^{tm1c(EUCOMM)Hmgu} Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺ (involves: C57BL/6 * C57BL/6N * DBA)	bile duct inflammation	J:304105
	enlarged spleen	J:304105
	granulomatous inflammation	J:304105
	increased anti-nuclear antigen antibody level	J:304105
	increased autoantibody level	J:304105
	increased IgG level	J:304105
	increased IgM level	J:304105
	liver inflammation	J:304105
Zc3h12a^tm1Fum/Zc3h12a^tm1Fum (C57BL/6-Zc3h12a^tm1Fum)	abnormal chemokine secretion	J:176866
	abnormal circulating chemokine level	J:176866
	enlarged lymph nodes	J:176866
	enlarged spleen	J:176866
	increased circulating tumor necrosis factor level	J:176866
	increased interleukin-1 beta secretion	J:176866
	increased interleukin-6 secretion	J:176866
	increased tumor necrosis factor secretion	J:176866
Zc3h12b^em1(IMPC)Tcp/Zc3h12b^em1(IMPC)Tcp (C57BL/6NCrl-Zc3h12b^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Zc3h12c^em1(IMPC)Tcp/Zc3h12c^em1(IMPC)Tcp (C57BL/6NCrl-Zc3h12c^em1(IMPC)Tcp/Tcp)	decreased lymphocyte cell number	J:211773
	enlarged lymph nodes	J:211773
	increased neutrophil cell number	J:211773
Zc3h12c^{tm2c(EUCOMM)Hmgu}/Zc3h12c^{tm2c(EUCOMM)Hmgu} Cd19^tm1(cre)Cgn/Cd19⁺ (involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6N)	immune system phenotype	J:277714
Zc3h12c^{tm2c(EUCOMM)Hmgu}/Zc3h12c^{tm2c(EUCOMM)Hmgu} Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6N)	enlarged lymph nodes	J:277714
	increased B cell number	J:277714
	increased CD4-positive, alpha-beta T cell number	J:277714
	increased effector memory CD8-positive, alpha-beta T cell number	J:277714
	increased immature B cell number	J:277714
	increased marginal zone B cell number	J:277714
Zc3h12c^{tm2c(EUCOMM)Hmgu}/Zc3h12c^{tm2c(EUCOMM)Hmgu} Tg(Cd4-cre)1Cwi/0 (involves: 129S4/SvJaeSor * C57BL/6N * DBA/2)	immune system phenotype	J:277714
Zc3h12c^{tm2d(EUCOMM)Hmgu}/Zc3h12c^{tm2d(EUCOMM)Hmgu} (involves: 129S4/SvJaeSor * C57BL/6N)	abnormal lymph node cortex morphology	J:277714
	abnormal lymph node primary follicle morphology	J:277714
	decreased CD8-positive, alpha-beta T cell number	J:277714
	decreased germinal center B cell number	J:277714
	decreased macrophage cell number	J:277714
	enlarged lymph nodes	J:277714
	immune system phenotype	J:277714
	increased B cell number	J:277714
	increased CD4-positive, alpha-beta T cell number	J:277714
	increased circulating interferon-gamma level	J:277714
	increased effector memory CD4-positive, alpha-beta T cell number	J:277714
	increased IgA level	J:277714
	increased IgG level	J:277714
	increased IgM level	J:277714
	increased immature B cell number	J:277714
	increased marginal zone B cell number	J:277714
	increased splenocyte number	J:277714
	increased T cell number	J:277714
Zc3h12d^{tm1b(EUCOMM)Hmgu}/Zc3h12d^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Zc3h12d^{tm1b(EUCOMM)Hmgu}/Orl)	decreased lymphocyte cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Zc3h12d^tm1Tom/Zc3h12d^tm1Tom (B6.Cg-Zc3h12d^tm1Tom)	immune system phenotype	J:209383
	increased interleukin-6 secretion	J:209383
	increased interleukin-10 secretion	J:209383
	increased susceptibility to experimental autoimmune encephalomyelitis	J:209383
	increased T cell proliferation	J:209383
	increased T-helper 17 cell number	J:209383
Zc3hav1l^{tm1b(EUCOMM)Wtsi}/Zc3hav1l^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Zc3hav1l^{tm1b(EUCOMM)Wtsi}/Tcp)	increased eosinophil cell number	J:211773
Zcchc3^em1Hbsh/Zcchc3^em1Hbsh (involves: C57BL/6)	abnormal innate immunity	J:271802
	decreased circulating CXCL10 level	J:271802
	decreased circulating interferon-beta level	J:271802
	decreased circulating interleukin-6 level	J:271802
	increased susceptibility to Herpesvirales infection	J:271802
	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:271802
	increased susceptibility to Poxviridae infection induced morbidity/mortality	J:271802
Zcchc4^em1(IMPC)Bay/Zcchc4^em1(IMPC)Bay (C57BL/6N-Zcchc4^em1(IMPC)Bay/Bay)	abnormal lymph node morphology	J:211773
Zcchc17^{em1(IMPC)Hmgu}/Zcchc17^{em1(IMPC)Hmgu} (C57BL/6NCrl-Zcchc17^{em1(IMPC)Hmgu}/Ieg)	increased spleen weight	J:211773
Zcrb1^{em1(IMPC)Ccpcz}/Zcrb1⁺ (C57BL/6NCrl-Zcrb1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
Zcwpw1^em1(IMPC)Tcp/Zcwpw1^em1(IMPC)Tcp (C57BL/6N-Zcwpw1^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Zdbf2^em1(IMPC)J/Zdbf2^em1(IMPC)J (C57BL/6NJ-Zdbf2^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
Zdhhc1^tm1Yyiw/Zdhhc1^tm1Yyiw (involves: 129S6/SvEvTac)	abnormal circulating cytokine level	J:284987
	decreased circulating interferon-alpha level	J:284987
	decreased circulating interferon-beta level	J:284987
	decreased circulating interleukin-6 level	J:284987
	decreased circulating tumor necrosis factor level	J:284987
	immune system phenotype	J:284987
	increased susceptibility to Herpesvirales infection	J:284987
	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:284987
Zdhhc2^em1Eko/Zdhhc2^em1Eko (C57BL/6-Zdhhc2^em1Eko)	abnormal cytokine level	J:303593
	abnormal interferon level	J:303593
	abnormal interleukin level	J:303593
	abnormal plasmacytoid dendritic cell physiology	J:303593
	abnormal T cell activation	J:303593
	abnormal tumor necrosis factor level	J:303593
	decreased dendritic epidermal T cell number	J:303593
	decreased leukocyte cell number	J:303593
	decreased plasmacytoid dendritic cell number	J:303593
	decreased susceptibility to chemically induced skin inflammation	J:303593
	increased alpha-beta T cell number	J:303593
	increased gamma-delta T cell number	J:303593
Zdhhc9^tm1Lex/Y (involves: 129S5/SvEvBrd * C57BL/6)	abnormal leukocyte physiology	J:231488
Zdhhc11^{tm1.1(KOMP)Vlcg}/Zdhhc11^{tm1.1(KOMP)Vlcg} (involves: C57BL/6NTac)	decreased circulating interleukin-6 level	J:310891
	decreased susceptibility to endotoxin shock	J:310891
	decreased susceptibility to viral infection	J:310891
Zdhhc13^skc4/Zdhhc13^skc4 (involves: 129S6/SvEvTac * C3H * C57BL/6)	abnormal Kupffer cell morphology	J:161519
	decreased leukocyte cell number	J:161519
	enlarged spleen	J:161519
	increased neutrophil cell number	J:161519
Zeb1^m1Btlr/Zeb1^m1Btlr (involves: C57BL/6J)	abnormal B cell differentiation	J:185495
	abnormal class switch recombination	J:185495
	abnormal memory B cell physiology	J:185495
	absent marginal zone B cells	J:185495
	decreased B cell proliferation	J:185495
	decreased B-1 B cell number	J:185495
	decreased B-1a cell number	J:185495
	decreased B-1b cell number	J:185495
	decreased double-positive T cell number	J:185495
	decreased germinal center B cell number	J:185495
	decreased IgG1 level	J:185495
	decreased IgG level	J:185495
	decreased IgM level	J:185495
	decreased NK cell number	J:185495
	immune system phenotype	J:185495
	increased single-positive T cell number	J:185495
	increased thymocyte number	J:185495
Zeb1^m2Btlr/Zeb1^m2Btlr (C57BL/6J-Zeb1^m2Btlr)	impaired humoral immune response	J:221490
Zeb1^tm1Yhi/Zeb1^tm1Yhi (B6.129P2-Zeb1^tm1Yhi)	abnormal T cell differentiation	J:39865
	abnormal T cell subpopulation ratio	J:39865
	abnormal thymus development	J:39865
	decreased CD8-positive, alpha-beta T cell number	J:39865
	decreased double-positive T cell number	J:39865
	decreased lymphocyte cell number	J:39865
	decreased splenocyte number	J:39865
	decreased T cell number	J:39865
	decreased thymocyte number	J:39865
	lymph node hypoplasia	J:39865
	small thymus	J:39865
	thymus hypoplasia	J:39865
Zeb1^tm1Yhi/Zeb1^tm1Yhi (either: (involves: 129 * C3H * C57BL/6) or (involves: 129 * C57BL/6 * ICR))	increased T cell derived lymphoma incidence	J:139194
Zeb1^tm2Yhi/Zeb1^tm2Yhi (B6.129-Zeb1^tm2Yhi)	decreased thymocyte number	J:45575
Zeb1^tm2Yhi/Zeb1^tm2Yhi (B6.129-Zeb1^tm2Yhi)	thymus hypoplasia	J:45575
Zeb1^Tw/Zeb1⁺ (B6.Cg-Zeb1^Tw)	decreased leukocyte cell number	J:177274
	decreased lymphocyte cell number	J:177274
	decreased neutrophil cell number	J:177274
	small spleen	J:177274
	small thymus	J:177274
Zfand2b^tm1Otin/Zfand2b⁺ (involves: 129S7/SvEvBrd * C57BL/6)	increased granulocyte number	J:233169
Zfand2b^tm1Otin/Zfand2b^tm1Otin (involves: 129S7/SvEvBrd * C57BL/6)	abnormal myeloid leukocyte morphology	J:233169
	decreased lymphocyte cell number	J:233169
	enlarged spleen	J:233169
	increased granulocyte number	J:233169
	increased leukocyte cell number	J:233169
	increased lymphocyte cell number	J:233169
	increased spleen weight	J:233169
Zfand3^em1(IMPC)J/Zfand3^em1(IMPC)J (C57BL/6NJ-Zfand3^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
Zfand6^em1(IMPC)Mbp/Zfand6^em1(IMPC)Mbp (C57BL/6N-Zfand6^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Zfat^{em1(IMPC)Ccpcz}/Zfat⁺ (C57BL/6NCrl-Zfat^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
Zfat^tm2.1Sawa/Zfat^tm2.1Sawa Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * C57BL/6JJcl * C57BL/6NCrSlc * DBA/2)	abnormal CD4-positive, alpha-beta T cell physiology	J:187164
	abnormal CD8-positive, alpha-beta T cell differentiation	J:187164
	decreased CD4-positive, alpha-beta T cell number	J:187164
	decreased CD8-positive, alpha-beta T cell number	J:187164
	decreased interleukin-2 secretion	J:187164
	decreased T cell proliferation	J:187164
	immune system phenotype	J:187164
	increased T cell apoptosis	J:187164
Zfp14^tm1Xch/Zfp14⁺ (involves: C57BL/6)	chronic pancreas inflammation	J:331393
	increased inflammatory response	J:331393
	lymph node hyperplasia	J:331393
	spleen hyperplasia	J:331393
	thymus hyperplasia	J:331393
Zfp14^tm1Xch/Zfp14^tm1Xch (involves: C57BL/6)	chronic pancreas inflammation	J:331393
	increased inflammatory response	J:331393
	lymph node hyperplasia	J:331393
	spleen hyperplasia	J:331393
	thymus hyperplasia	J:331393
Zfp30^em1Snpk/Zfp30^em1Snpk (C57BL/6J-Zfp30^em1Snpk/Mmnc)	immune system phenotype	J:300801
Zfp35^tm1Naka/Zfp35^tm1Naka (either: B6.Cg-Zfp35^tm1Naka or C.Cg-Zfp35^tm1Naka)	abnormal T-helper 2 cell differentiation	J:153828
	increased circulating interleukin-4 level	J:153828
	increased circulating interleukin-5 level	J:153828
	increased circulating interleukin-13 level	J:153828
	increased eosinophil cell number	J:153828
Zfp36^{tm1(KOMP)Vlcg}/Zfp36⁺ (C57BL/6N-Zfp36^{tm1(KOMP)Vlcg}/Nju)	increased leukocyte cell number	J:211773
Zfp36^tm1Pjb/Zfp36^tm1Pjb (Not Specified)	abnormal thymus cortex morphology	J:33986
	abnormal thymus medulla morphology	J:33986
	autoimmune arthritis	J:33986
	conjunctivitis	J:33986
	dermatitis	J:33986
	enlarged lymph nodes	J:33986
	enlarged spleen	J:33986
	heart inflammation	J:33986
	increased leukocyte cell number	J:33986
	liver inflammation	J:33986
	spleen hyperplasia	J:33986
	thymus hypoplasia	J:33986
Zfp36^tm1Pjb/Zfp36^tm1Pjb (B6.Cg-Zfp36^tm1Pjb)	abnormal macrophage physiology	J:88443
	autoimmune arthritis	J:88443
	blood vessel inflammation	J:214114
	decreased lymphocyte cell number	J:214114
	increased granulocyte number	J:214114
	increased monocyte cell number	J:214114
	increased neutrophil cell number	J:214114
	increased synovial pannus formation	J:88443
Zfp36^tm2.1Pjb/Zfp36^tm2.1Pjb (involves: C57BL/6)	decreased inflammatory response	J:229078
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:229078
	decreased susceptibility to induced arthritis	J:229078
Zfp36^tm4.1Pjb/Zfp36^tm4.1Pjb Lyz2^tm1(cre)Ifo/Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N)	alveolitis	J:188677
	autoimmune arthritis	J:188677
	enlarged lymph nodes	J:188677
	enlarged spleen	J:188677
	increased circulating tumor necrosis factor level	J:188677
	increased inflammatory response	J:188677
	increased spleen weight	J:188677
	increased susceptibility to endotoxin shock	J:188677
Zfp36l1^tm1.1Tnr/Zfp36l1^tm1.1Tnr Zfp36l2^tm1.1Tnr/Zfp36l2^tm1.1Tnr Tg(CD2-icre)4Kio/0 (involves: C57BL/6 * C57BL/10 * CBA/Ca * SJL)	abnormal thymus development	J:162388
	enlarged lymph nodes	J:162388
	enlarged spleen	J:162388
	increased T cell derived lymphoma incidence	J:162388
	thymus atrophy	J:162388
Zfp36l2^tm2Pjb/Zfp36l2^tm2Pjb (involves: 129S7/SvEvBrd * C57BL/6)	decreased leukocyte cell number	J:152911
	decreased neutrophil cell number	J:152911
	decreased splenocyte number	J:152911
Zfp91^em1(IMPC)Tcp/Zfp91⁺ (C57BL/6N-Zfp91^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
Zfp106^{tm1a(KOMP)Wtsi}/Zfp106^{tm1a(KOMP)Wtsi} (involves: C57BL/6Brd * C57BL/6Dnk * C57BL/6N)	microgliosis	J:229162
Zfp119a^{tm1b(EUCOMM)Hmgu}/Zfp119a^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Zfp119a^{tm1b(EUCOMM)Hmgu}/Ieg)	increased leukocyte cell number	J:211773
Zfp131^tm1.1Mytk/Zfp131^tm1.1Mytk Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * C57BL/6N * DBA/2)	abnormal T cell subpopulation ratio	J:271921
	abnormal thymocyte activation	J:271921
	decreased CD4-positive, alpha-beta T cell number	J:271921
	decreased CD8-positive, alpha-beta T cell number	J:271921
	decreased T cell number	J:271921
	decreased T cell proliferation	J:271921
	immune system phenotype	J:271921
Zfp131^tm1.1Mytk/Zfp131^tm1.2Mytk Tg(Lck-cre)1Jtak/0 (involves: C57BL/6N * FVB/N)	abnormal double-negative T cell morphology	J:271921
	abnormal T cell differentiation	J:271921
	arrested T cell differentiation	J:271921
	decreased CD4-positive, alpha-beta T cell number	J:271921
	decreased CD8-positive, alpha-beta T cell number	J:271921
	decreased DN2 thymocyte number	J:271921
	decreased DN3 thymocyte number	J:271921
	decreased DN4 thymocyte number	J:271921
	decreased double-negative T cell number	J:271921
	decreased double-positive T cell number	J:271921
	decreased T cell proliferation	J:271921
	decreased thymocyte number	J:271921
Zfp148^tm1.1Jmer/Zfp148^tm1.1Jmer Tg(Vil1-cre)997Gum/0 (involves: C57BL/6 * C57BL/6J * SJL)	increased inflammatory response	J:198847
	increased susceptibility to bacterial infection	J:198847
	increased susceptibility to bacterial infection induced morbidity/mortality	J:198847
Zfp148^tm1Djl/Zfp148^tm1Djl (involves: 129)	increased susceptibility to induced colitis	J:107441
Zfp160^{tm1b(EUCOMM)Wtsi}/Zfp160^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Zfp160^{tm1b(EUCOMM)Wtsi}/BayMmucd)	decreased spleen weight	J:211773
Zfp207^{tm1b(EUCOMM)Hmgu}/Zfp207⁺ (C57BL/6N-Zfp207^{tm1b(EUCOMM)Hmgu}/H)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Zfp236^em1(IMPC)Mbp/Zfp236⁺ (C57BL/6NCrl-Zfp236^em1(IMPC)Mbp/Mmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
Zfp260^{tm1b(NCOM)Mfgc}/Zfp260⁺ (C57BL/6N-Zfp260^{tm1b(NCOM)Mfgc}/Tcp)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Zfp281^em1(IMPC)Mbp/Zfp281⁺ (C57BL/6N-Zfp281^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	small spleen	J:211773
Zfp292^em1Zfa/Zfp292^em1Zfa (involves: C57BL/6)	increased susceptibility to bacterial infection	J:259392
Zfp292^em1Zfa/Zfp292^em1Zfa (involves: C57BL/6)	increased susceptibility to bacterial infection induced morbidity/mortality	J:259392
Zfp318^m1Anu/Zfp318⁺ (C57BL/6JAnu-Zfp318^m1Anu)	decreased IgD level	J:207375
Zfp318^m1Anu/Zfp318⁺ (C57BL/6JAnu-Zfp318^m1Anu)	increased IgM level	J:207375
Zfp318^m1Anu/Zfp318^m1Anu (C57BL/6JAnu-Zfp318^m1Anu)	abnormal B cell number	J:104190
	abnormal follicular B cell physiology	J:207375
	abnormal marginal zone B cell physiology	J:207375
	decreased IgD level	J:207375, J:104190
	increased IgM level	J:207375, J:104190
	increased mature B cell number	J:207375
Zfp318^M1Btlr/Zfp318⁺ (C57BL/6J-Zfp318^M1Btlr)	decreased IgD level	J:218965
Zfp318^M1Btlr/Zfp318^M1Btlr (C57BL/6J-Zfp318^M1Btlr)	decreased IgD level	J:218965
Zfp318^tm1.1Jhws/Zfp318^tm1.1Jhws Commd10^{Tg(Vav1-icre)A2Kio}/Commd10⁺ (B6.Cg-Zfp318^tm1.1Jhws Tg^Vav1-creA2Kio)	decreased IgD level	J:215815
	decreased transitional stage T2 B cell number	J:215815
	increased IgM level	J:215815
Zfp318^tm1Hhag/Zfp318^tm1Hhag (involves: 129 * C57BL/6)	decreased IgD level	J:207375
Zfp318^tm1Hhag/Zfp318^tm1Hhag (involves: 129 * C57BL/6)	increased IgM level	J:207375
Zfp335^blt/Zfp335^blt (involves: C57BL/6)	abnormal CD4-positive T cell differentiation	J:214793
	abnormal CD8-positive, alpha-beta T cell differentiation	J:214793
	abnormal T cell differentiation	J:214793
	decreased B cell number	J:214793
	decreased CD4-positive, alpha-beta memory T cell number	J:214793
	decreased CD4-positive, alpha-beta T cell number	J:214793
	decreased CD8-positive, alpha-beta memory T cell number	J:214793
	decreased CD8-positive, alpha-beta T cell number	J:214793
	decreased NK T cell number	J:214793
	decreased regulatory T cell number	J:214793
	decreased single-positive T cell number	J:214793
Zfp354a^em1(IMPC)Mbp/Zfp354a^em1(IMPC)Mbp (C57BL/6NCrl-Zfp354a^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Zfp366^b2b2834Clo/Zfp366^b2b2834Clo (C57BL/6J-Zfp366^b2b2834Clo)	thymus hypoplasia	J:175213
Zfp398^em1(IMPC)Mbp/Zfp398^em1(IMPC)Mbp (C57BL/6NCrl-Zfp398^em1(IMPC)Mbp/Mmucd)	increased basophil cell number	J:211773
Zfp420^{tm1b(EUCOMM)Hmgu}/Zfp420^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Zfp420^{tm1b(EUCOMM)Hmgu}/Bay)	increased lymphocyte cell number	J:211773
Zfp467^{tm1.1(KOMP)Vlcg}/Zfp467^{tm1.1(KOMP)Vlcg} (B6(Cg)-Zfp467^{tm1.1(KOMP)Vlcg})	abnormal osteoclast physiology	J:302865
	increased osteoclast cell number	J:302865
Zfp469^em1(IMPC)Mbp/Zfp469^em1(IMPC)Mbp (C57BL/6N-Zfp469^em1(IMPC)Mbp/MbpMmucd)	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
Zfp474^{em1(IMPC)Ccpcz}/Zfp474^{em1(IMPC)Ccpcz} (C57BL/6N-Zfp474^{em1(IMPC)Ccpcz}/Ccpcz)	decreased lymphocyte cell number	J:211773
	increased eosinophil cell number	J:211773
	increased neutrophil cell number	J:211773
Zfp488^em1(IMPC)Bay/Zfp488^em1(IMPC)Bay (C57BL/6N-Zfp488^em1(IMPC)Bay/Bay)	abnormal spleen morphology	J:211773
Zfp503^em1(IMPC)Mbp/Zfp503⁺ (C57BL/6N-Zfp503^em1(IMPC)Mbp/Ucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
	increased basophil cell number	J:211773
Zfp513^em1(IMPC)J/Zfp513^em1(IMPC)J (C57BL/6NJ-Zfp513^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
Zfp521^tm1Nohk/Zfp521^tm1Nohk (B6J.Cg-Zfp521^tm1Nohk)	decreased spleen weight	J:214267
Zfp521^tm1Nohk/Zfp521^tm1Nohk (B6J.Cg-Zfp521^tm1Nohk)	decreased thymus weight	J:214267
Zfp574^em1Btlr/Zfp574^em1Btlr (C57BL/6J-Zfp574^em1Btlr)	abnormal B cell physiology	J:354285
	abnormal class switch recombination	J:354285
	abnormal humoral immune response	J:354285
	decreased B cell number	J:354285
	decreased B cell proliferation	J:354285
	decreased B-1 B cell number	J:354285
	decreased IgA level	J:354285
	decreased IgG1 level	J:354285
	decreased IgG2a level	J:354285
	decreased IgG2b level	J:354285
	decreased IgG level	J:354285
	decreased IgM level	J:354285
	decreased immunoglobulin level	J:354285
	decreased leukocyte cell number	J:354285
	decreased lymphocyte cell number	J:354285
	decreased monocyte cell number	J:354285
	decreased neutrophil cell number	J:354285
	decreased T cell number	J:354285
	increased B cell apoptosis	J:354285
Zfp574^em1Btlr/Zfp574^em1Btlr Tg(IghMyc)22Bri/0 (B6.Cg-Zfp574^em1Btlr Tg(IghMyc)22Bri)	decreased pre-B cell number	J:354285
Zfp574^em3Btlr/Zfp574^em3Btlr Ndor1^{Tg(UBC-cre/ERT2)1Ejb}/Ndor1⁺ (B6.Cg-Ndor1^{Tg(UBC-cre/ERT2)1Ejb} Zfp574^em3Btlr)	decreased B cell number	J:354285
Zfp574^em3Btlr/Zfp574^em3Btlr Ndor1^{Tg(UBC-cre/ERT2)1Ejb}/Ndor1⁺ Tg(IghMyc)22Bri/0 (B6.Cg-Ndor1^{Tg(UBC-cre/ERT2)1Ejb} Zfp574^em3Btlr Tg(IghMyc)22Bri)	decreased B cell number	J:354285
Zfp574^m1Btlr/Zfp574^m1Btlr (C57BL/6J-Zfp574^m1Btlr)	abnormal humoral immune response	J:354285
	abnormal T cell physiology	J:354285
	decreased B cell number	J:354285
Zfp593^em1(IMPC)J/Zfp593^em1(IMPC)J (C57BL/6NJ-Zfp593^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
Zfp595^{tm1b(KOMP)Wtsi}/Zfp595^{tm1b(KOMP)Wtsi} (C57BL/6N-Zfp595^{tm1b(KOMP)Wtsi}/Bay)	decreased eosinophil cell number	J:211773
	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
Zfp616^{tm1b(KOMP)Wtsi}/Zfp616^{tm1b(KOMP)Wtsi} (C57BL/6N-Zfp616^{tm1b(KOMP)Wtsi}/Wtsi)	increased KLRG1-positive T-helper cell number	J:211773
Zfp629^em1(IMPC)Tcp/Zfp629^em1(IMPC)Tcp (C57BL/6N-Zfp629^em1(IMPC)Tcp/Tcp)	small spleen	J:211773
Zfp638^em1(IMPC)J/Zfp638⁺ (C57BL/6NJ-Zfp638^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
Zfp639^tm1.2Jaty/Zfp639^tm1.2Jaty (involves: 129 * BALB/cJ * C57BL/6 * SJL)	decreased susceptibility to Retroviridae infection	J:305874
	immune system phenotype	J:305874
Zfp644^m1Anu/Zfp644^m1Anu (C57BL/6NCrl-Zfp644^m1Anu/Anu)	immune system phenotype	J:104190
Zfp683^{Gt(OST314703)Lex}/Zfp683^{Gt(OST314703)Lex} (B6.129S5-Zfp683^{Gt(OST314703)Lex})	abnormal NK T cell morphology	J:187727
	abnormal susceptibility to infection	J:187727
	decreased NK T cell number	J:187727
	immune system phenotype	J:187727
	increased interferon-gamma secretion	J:187727
Zfp760^{tm1a(EUCOMM)Hmgu}/Zfp760⁺ (C57BL/6N-Zfp760^{tm1a(EUCOMM)Hmgu}/Ieg)	decreased IgE level	J:165965
Zfp871^{tm1a(EUCOMM)Wtsi}/Zfp871⁺ (C57BL/6N-Zfp871^{tm1a(EUCOMM)Wtsi}/BayMmucd)	liver inflammation	J:317166
	spleen hyperplasia	J:317166
	thymus hyperplasia	J:317166
Zfp950^{Gt(ROSA)76Sor}/Zfp950^{Gt(ROSA)76Sor} (involves: 129S4/SvJaeSor)	kidney inflammation	J:117491
Zfpm1^tm1.1Esv/Zfpm1^tm1.1Esv (involves: 129S6/SvEvTac * C57BL/6)	abnormal spleen morphology	J:156475
	increased granulocyte number	J:156475
	increased neutrophil cell number	J:156475
	increased spleen red pulp amount	J:156475
	increased spleen weight	J:156475
Zfpm1^tm1.1Geab/Zfpm1^tm1.1Geab (Not Specified)	abnormal circulating chemokine level	J:162629
	decreased spleen white pulp amount	J:156393
	enlarged spleen	J:156393
	increased monocyte cell number	J:156393
	increased neutrophil cell number	J:156393
	increased spleen weight	J:156393
	spleen hypoplasia	J:156393
Zftraf1^em1(IMPC)H/Zftraf1^em1(IMPC)H (C57BL/6NTac-Zftraf1^em1(IMPC)H/H)	decreased eosinophil cell number	J:211773
Zfx^tm1.1Reiz/Y Tg(Mx1-cre)1Cgn/0 (involves: 129S6/SvEvTac * C57BL/6 * CBA)	decreased lymphocyte cell number	J:149654
Zfx^tm1.1Reiz/Y Tg(Tek-cre)12Flv/0 (involves: 129S6/SvEvTac * C3H * C57BL/6)	decreased mature B cell number	J:149654
	decreased T cell number	J:149654
Zfyve1^em1Hbsh/Zfyve1^em1Hbsh (C57BL/6J-Zfyve1^em1Hbsh)	decreased susceptibility to viral infection	J:292942
Zfyve1^em1Hbsh/Zfyve1^em1Hbsh (C57BL/6J-Zfyve1^em1Hbsh)	decreased susceptibility to viral infection induced morbidity/mortality	J:292942
Zfyve16^{tm2a(KOMP)Wtsi}/Zfyve16^{tm2a(KOMP)Wtsi} (C57BL/6N-Zfyve16^{tm2a(KOMP)Wtsi})	decreased B cell number	J:302014
	decreased B cell proliferation	J:302014
	increased T cell number	J:302014
Zg16^tm1Lex/Zg16^tm1Lex (B6.129S-Zg16^tm1Lex)	increased circulating interferon-gamma level	J:239095
	increased circulating interleukin-6 level	J:239095
	increased susceptibility to bacterial infection	J:239095
Zic2^iso/Zic2^iso (involves: C3H/HeH * C57BL/6)	abnormal spleen morphology	J:268103
	abnormal spleen size	J:268103
	absent spleen	J:268103
Zic3^tm1Bca/Y (involves: 129S7/SvEvBrd * C57BL/6)	spleen hypoplasia	J:75951
Zic3^tm1Bca/Zic3⁺ (involves: 129S7/SvEvBrd * C57BL/6)	spleen hypoplasia	J:75951
Zic3^tm1Bca/Zic3^tm1Bca (involves: 129S7/SvEvBrd * C57BL/6)	spleen hypoplasia	J:75951
Zkscan3^tm1.2Itl/Zkscan3^tm1.2Itl (B6.Cg-Zkscan3^tm1.2Itl)	abnormal response to infection	J:318724
Zkscan7^em1(IMPC)Mbp/Zkscan7^em1(IMPC)Mbp (C57BL/6N-Zkscan7^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
Zmpste24^tm1Otin/Zmpste24^tm1Otin (involves: 129P2/Ola * C57BL/6)	abnormal thymus corticomedullary boundary morphology	J:76209
	thymus hypoplasia	J:76209
Zmym2^em1(IMPC)J/Zmym2⁺ (C57BL/6NJ-Zmym2^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
Zmynd10^{tm1(KOMP)Wtsi}/Zmynd10^{tm1(KOMP)Wtsi} (involves: C57BL/6J * C57BL/6N)	lung inflammation	J:261915
Zmynd11^{em1(IMPC)Wtsi}/Zmynd11^{em1(IMPC)Wtsi} (C57BL/6N-Zmynd11^{em1(IMPC)Wtsi}/WtsiIeg)	blood in lymph vessels	J:239583
Zmynd12^em1(IMPC)J/Zmynd12^em1(IMPC)J (C57BL/6NJ-Zmynd12^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
Znfx1^em1Xua/Znfx1^em1Xua (involves: C57BL/6J)	abnormal macrophage physiology	J:345967
	abnormal response to infection	J:282875
	decreased circulating interferon-gamma level	J:345967
	decreased circulating interleukin-12 level	J:345967
	decreased circulating tumor necrosis factor level	J:345967
	decreased interferon-alpha secretion	J:282875
	decreased interferon-beta secretion	J:282875
	decreased macrophage cytokine production	J:282875
	impaired macrophage phagocytosis	J:345967
	increased susceptibility to bacterial infection	J:345967
	increased susceptibility to Riboviria infection	J:282875
Znhit2^em1(IMPC)J/Znhit2⁺ (C57BL/6NJ-Znhit2^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
Znhit6^em1(IMPC)Mbp/Znhit6⁺ (C57BL/6N-Znhit6^em1(IMPC)Mbp/Ucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
Zp3r^{em1(IMPC)Ccpcz}/Zp3r^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Zp3r^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
Zranb1^em1Shios/Zranb1^em1Shios (involves: C57BL/6)	increased susceptibility to colitis induced morbidity/mortality	J:333468
Zranb1^{tm1c(EUCOMM)Hmgu}/Zranb1^{tm1c(EUCOMM)Hmgu} Tg(Cd4-cre)1Cwi/0 (involves: 129S4/SvJaeSor * C57BL/6 * C57BL/6N * DBA/2)	immune system phenotype	J:235701
Zranb1^{tm1c(EUCOMM)Hmgu}/Zranb1^{tm1c(EUCOMM)Hmgu} Tg(Itgax-cre)1-1Reiz/0 (involves: 129S4/SvJaeSor * C57BL/6N * CBA)	abnormal dendritic cell physiology	J:235701
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:235701
	decreased T helper 1 cell number	J:235701
	decreased T-helper 17 cell number	J:235701
	immune system phenotype	J:235701
Zranb1^{tm1d(EUCOMM)Hmgu}/Zranb1^{tm1d(EUCOMM)Hmgu} (involves: 129S4/SvJaeSor * BALB/cJ * C57BL/6N)	decreased CD4-positive, alpha-beta T cell number	J:235701
	decreased circulating interferon-gamma level	J:235701
	decreased circulating interleukin-17 level	J:235701
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:235701
	decreased T helper 1 cell number	J:235701
	decreased T-helper 17 cell number	J:235701
	immune system phenotype	J:235701
Zrsr2^em1(IMPC)Mbp/Y (C57BL/6N-Zrsr2^em1(IMPC)Mbp/MbpMmucd)	decreased lymphocyte cell number	J:211773
Zrsr2^em1(IMPC)Mbp/Y (C57BL/6N-Zrsr2^em1(IMPC)Mbp/MbpMmucd)	increased neutrophil cell number	J:211773
Zscan10^{Gt(285B6)1.1Cmhd}/Zscan10^{Gt(285B6)1.1Cmhd} (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)	abnormal IgG level	J:221010
	abnormal T cell subpopulation ratio	J:221010
	decreased spleen weight	J:221010
	decreased T cell number	J:221010
	increased B cell number	J:221010
	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:221010
	increased IgG1 level	J:221010
	increased IgG2b level	J:221010
	increased mature NK cell number	J:221010
Zswim1^{tm1b(KOMP)Mbp}/Zswim1^{tm1b(KOMP)Mbp} (C57BL/6N-Zswim1^{tm1b(KOMP)Mbp}/Nju)	decreased lymphocyte cell number	J:211773
	decreased monocyte cell number	J:211773
	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
Zup1^em1Lisi/Zup1^em1Lisi (involves: C57BL/6J)	abnormal macrophage physiology	J:350802
	increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:350802
	increased susceptibility to Riboviria infection induced morbidity/mortality	J:350802

Contributing Projects: Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support.	last database update 03/18/2025 MGI 6.24